term,estimate,std.error,statistic,p.value,c2,path,gs_subcat,gs_cat,n_ctrl,n_case
Cohort,0.0024761042181043313,0.03144043455115818,0.07875540696091042,0.9372504801140051,LGP Offspring,Genes down-regulated in AtT20 cells (pituitary cancer) after  treatment with LIF [GeneID=3976].,CGP,C2,29,62
Cohort,-0.05200498097039498,0.08943319127580088,-0.5814953064798735,0.5610638066008691,LGP Proband,Genes down-regulated in AtT20 cells (pituitary cancer) after  treatment with LIF [GeneID=3976].,CGP,C2,29,93
Cohort,0.04766993260454654,0.02672245510630145,1.7838904552338624,0.07482232554669414,LonGen OPEL,Genes down-regulated in AtT20 cells (pituitary cancer) after  treatment with LIF [GeneID=3976].,CGP,C2,38,68
Cohort,0.062003683959694134,0.03607250116874371,1.7188628997375819,0.08609715929045339,LGP Offspring,Genes up-regulated in AtT20 cells (pituitary cancer) after  treatment with LIF [GeneID=3976].,CGP,C2,32,92
Cohort,0.012157720561484566,0.09408474545356968,0.12922095396946506,0.897213972730091,LGP Proband,Genes up-regulated in AtT20 cells (pituitary cancer) after  treatment with LIF [GeneID=3976].,CGP,C2,32,120
Cohort,0.02572354088558414,0.031875745611804514,0.8069941703907302,0.41991089723838404,LonGen OPEL,Genes up-regulated in AtT20 cells (pituitary cancer) after  treatment with LIF [GeneID=3976].,CGP,C2,61,89
Cohort,-0.01425036774738487,0.010069981514050464,-1.415133456551195,0.15748985741565455,LGP Offspring,Genes down-regulated in GH3 cells (pituitary cancer) after treatment with LIF [GeneID=3976].,CGP,C2,5,5
Cohort,0.013288237243787583,0.03411273561921417,0.38953889222249644,0.696976994121208,LGP Proband,Genes down-regulated in GH3 cells (pituitary cancer) after treatment with LIF [GeneID=3976].,CGP,C2,5,14
Cohort,-0.013925604521530556,0.009484260412203429,-1.468285761493056,0.14242165488613973,LonGen OPEL,Genes down-regulated in GH3 cells (pituitary cancer) after treatment with LIF [GeneID=3976].,CGP,C2,9,5
Cohort,-0.005598810320769079,0.020893419111092083,-0.2679700383646989,0.7888041260184189,LGP Offspring,Genes up-regulated in GH3 cells (pituitary cancer) after treatment with LIF [GeneID=3976].,CGP,C2,16,27
Cohort,-0.19000801112733862,0.05823972527714115,-3.26251558061377,0.0011491749424242313,LGP Proband,Genes up-regulated in GH3 cells (pituitary cancer) after treatment with LIF [GeneID=3976].,CGP,C2,16,38
Cohort,-0.0016288535909771702,0.01736835357749399,-0.09378284382049015,0.9253052604148981,LonGen OPEL,Genes up-regulated in GH3 cells (pituitary cancer) after treatment with LIF [GeneID=3976].,CGP,C2,22,24
Cohort,0.003809238786693127,0.012721368986481166,0.29943623133179736,0.7646992603084082,LGP Offspring,Major ELAVL4 [GeneID=1996] associated mRNAs encoding proteins with functions in neuronal physiology.,CGP,C2,6,11
Cohort,-0.009275927403265563,0.041253307685584786,-0.22485293722294336,0.8221487614753558,LGP Proband,Major ELAVL4 [GeneID=1996] associated mRNAs encoding proteins with functions in neuronal physiology.,CGP,C2,6,21
Cohort,-0.02876141882432922,0.014525961329264946,-1.9800010596465376,0.04804741144447436,LonGen OPEL,Major ELAVL4 [GeneID=1996] associated mRNAs encoding proteins with functions in neuronal physiology.,CGP,C2,22,11
Cohort,-0.004877514307287971,0.009548383435537518,-0.5108209510245119,0.6096432132118501,LGP Offspring,"Genes down-regulated in the RCC4 cells (renal cell carcinoma, RCC) expressing VHL [GeneID=7428] mutants Type 1 and 2B (associated with RCC) but not those of Type 2A and 2C (not associated with RCC).",CGP,C2,4,5
Cohort,0.011630945845823241,0.041087660619609376,0.2830763706287111,0.7771885411049706,LGP Proband,"Genes down-regulated in the RCC4 cells (renal cell carcinoma, RCC) expressing VHL [GeneID=7428] mutants Type 1 and 2B (associated with RCC) but not those of Type 2A and 2C (not associated with RCC).",CGP,C2,4,20
Cohort,-2.8973406316918634e-4,0.011758249447470304,-0.02464091823052116,0.9803475568858264,LonGen OPEL,"Genes down-regulated in the RCC4 cells (renal cell carcinoma, RCC) expressing VHL [GeneID=7428] mutants Type 1 and 2B (associated with RCC) but not those of Type 2A and 2C (not associated with RCC).",CGP,C2,10,11
Cohort,-0.04660780430316411,0.0284437149412758,-1.6385976444845354,0.10176238873315295,LGP Offspring,"Genes prefentially expressed in human inner ear tissue (cochlea and vestibule), at least 10-fold higher from a mixture of 29 other tissues.",CGP,C2,32,52
Cohort,-0.06756774974720997,0.07600510109881968,-0.8889896700401766,0.3742649652454457,LGP Proband,"Genes prefentially expressed in human inner ear tissue (cochlea and vestibule), at least 10-fold higher from a mixture of 29 other tissues.",CGP,C2,32,63
Cohort,-0.01421299120897924,0.024261939027638634,-0.5858143156978564,0.5581663561580861,LonGen OPEL,"Genes prefentially expressed in human inner ear tissue (cochlea and vestibule), at least 10-fold higher from a mixture of 29 other tissues.",CGP,C2,40,43
Cohort,0.008975229804676486,0.018165309654797363,0.49408625425254865,0.6214057705277749,LGP Offspring,Genes most profoundly induced in HUVEC cells (endothelium) by VEGFA [GeneID=7422].,CGP,C2,8,21
Cohort,0.021215560745482344,0.05021492086143218,0.42249515445870317,0.6727725371465901,LGP Proband,Genes most profoundly induced in HUVEC cells (endothelium) by VEGFA [GeneID=7422].,CGP,C2,8,33
Cohort,-0.0057625187789231425,0.013766580267089825,-0.41858752624999623,0.6756305204490864,LonGen OPEL,Genes most profoundly induced in HUVEC cells (endothelium) by VEGFA [GeneID=7422].,CGP,C2,13,14
Cohort,0.020797267302198517,0.023316475337827314,0.891955881018527,0.3727339579783431,LGP Offspring,Genes up-regulated in HUVEC cells (endothelium) at 2 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,15,39
Cohort,0.054788667828292864,0.060668924799980414,0.9030762949718626,0.3667461582740542,LGP Proband,Genes up-regulated in HUVEC cells (endothelium) at 2 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,15,44
Cohort,-0.020054069811346664,0.017698000144212155,-1.1331263220666785,0.2575023858906019,LonGen OPEL,Genes up-regulated in HUVEC cells (endothelium) at 2 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,25,20
Cohort,0.05110937632734596,0.031442766882985154,1.6254732453269924,0.10452784195998528,LGP Offspring,Genes up-regulated in HUVEC cells (endothelium) at 30 min after VEGFA [GeneID=7422] stimulation.,CGP,C2,25,73
Cohort,0.0915459027503748,0.08205894417720616,1.1156115115578573,0.2649098038443468,LGP Proband,Genes up-regulated in HUVEC cells (endothelium) at 30 min after VEGFA [GeneID=7422] stimulation.,CGP,C2,25,83
Cohort,-0.009370102947800392,0.026674802617420137,-0.35127168819915433,0.7254774876354775,LonGen OPEL,Genes up-regulated in HUVEC cells (endothelium) at 30 min after VEGFA [GeneID=7422] stimulation.,CGP,C2,54,57
Cohort,0.014029939565381322,0.018481920763691914,0.7591169632619249,0.44804720296353717,LGP Offspring,Genes down-regulated in immunoglobulin light chain amyloidosis plasma cells (ALPC) compared to multiple myeloma (MM) cells.,CGP,C2,9,26
Cohort,0.10308836047711703,0.053165457700314854,1.9390101192810105,0.052837108446275545,LGP Proband,Genes down-regulated in immunoglobulin light chain amyloidosis plasma cells (ALPC) compared to multiple myeloma (MM) cells.,CGP,C2,9,34
Cohort,0.02713904961599564,0.018695284247475765,1.4516521523153598,0.14699235108693434,LonGen OPEL,Genes down-regulated in immunoglobulin light chain amyloidosis plasma cells (ALPC) compared to multiple myeloma (MM) cells.,CGP,C2,18,33
Cohort,0.009025481884355613,0.03016740164563508,0.2991799555816737,0.7648946970744221,LGP Offspring,Genes up-regulated in immunoglobulin light chain amyloidosis plasma cells (ALPC) compared to multiple myeloma (MM) cells.,CGP,C2,24,57
Cohort,0.07409008150076281,0.0802979928014822,0.9226890849430448,0.35643610540746107,LGP Proband,Genes up-regulated in immunoglobulin light chain amyloidosis plasma cells (ALPC) compared to multiple myeloma (MM) cells.,CGP,C2,24,81
Cohort,0.027218644671097247,0.024529283833032527,1.1096387834382295,0.2674898229226409,LonGen OPEL,Genes up-regulated in immunoglobulin light chain amyloidosis plasma cells (ALPC) compared to multiple myeloma (MM) cells.,CGP,C2,37,54
Cohort,-0.05971529946516788,0.041459726211645107,-1.4403206417797134,0.1502396685223718,LGP Offspring,"Proteins interacting with AIRE [GeneID=326], based on massspectroscopy analysis of co-immunoprecipitates in 293T cells (embryonic kidney).",CGP,C2,64,103
Cohort,0.12957980328398475,0.12142797590232803,1.067133025326995,0.2862205728800599,LGP Proband,"Proteins interacting with AIRE [GeneID=326], based on massspectroscopy analysis of co-immunoprecipitates in 293T cells (embryonic kidney).",CGP,C2,64,169
Cohort,0.011915592175615851,0.035762664251097885,0.33318524850256515,0.7390821912675154,LonGen OPEL,"Proteins interacting with AIRE [GeneID=326], based on massspectroscopy analysis of co-immunoprecipitates in 293T cells (embryonic kidney).",CGP,C2,86,108
Cohort,0.07731526557673606,0.13334912484473718,0.5797958229328973,0.5622454954074223,LGP Offspring,Genes down-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.,CGP,C2,569,1246
Cohort,0.09977256823778573,0.37352260206838495,0.26711253264272145,0.7894485538841602,LGP Proband,Genes down-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.,CGP,C2,569,1747
Cohort,0.013599950695658601,0.11825642153283528,0.1150039086197312,0.9084710271094529,LonGen OPEL,Genes down-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.,CGP,C2,980,1189
Cohort,-0.24931903161890678,0.1484688211732707,-1.6792686144381703,0.09356179706584287,LGP Offspring,Genes up-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.,CGP,C2,735,1413
Cohort,-0.3543187859890629,0.4002835321668726,-0.8851695298855121,0.3763203328584511,LGP Proband,Genes up-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.,CGP,C2,735,2046
Cohort,0.014156384806851992,0.13164552016851522,0.10753411729264206,0.9143923578854973,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.,CGP,C2,1166,1404
Cohort,0.01234890343674465,0.07391373959349196,0.16707182595090833,0.8673634971766538,LGP Offspring,Genes whose promoters display lower levels of histone H3 trimethylation mark at K27 (H3K27me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,178,378
Cohort,0.23781024944927381,0.2073500054530187,1.1469025473604666,0.2517508212391483,LGP Proband,Genes whose promoters display lower levels of histone H3 trimethylation mark at K27 (H3K27me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,178,535
Cohort,-0.048177625137642226,0.06459665612179807,-0.7458222767259424,0.4559949647678968,LonGen OPEL,Genes whose promoters display lower levels of histone H3 trimethylation mark at K27 (H3K27me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,292,343
Cohort,8.651522677342782e-4,0.09825627412267196,0.008805058765551647,0.9929772681097884,LGP Offspring,Genes whose promoters display higher levels of histone H3 trimethylation mark at K27 (H3K27me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,282,604
Cohort,-0.4828279030403047,0.26116695142960095,-1.8487327757105352,0.06485017297211318,LGP Proband,Genes whose promoters display higher levels of histone H3 trimethylation mark at K27 (H3K27me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,282,848
Cohort,0.038959648099070716,0.0833454192477515,0.4674479827530746,0.6403073374492612,LonGen OPEL,Genes whose promoters display higher levels of histone H3 trimethylation mark at K27 (H3K27me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,463,572
Cohort,0.0769430923063847,0.06267777296181411,1.2275977379295466,0.22002530895384168,LGP Offspring,Genes whose promoters display lower histone H3 trimethylation mark at K9 (H3K9me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,109,269
Cohort,-0.1998263112961343,0.1694551868229972,-1.1792280604833947,0.23864366579782131,LGP Proband,Genes whose promoters display lower histone H3 trimethylation mark at K9 (H3K9me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,109,374
Cohort,0.074767849633637945,0.052176423355511106,1.4329815043893888,0.15225574377324688,LonGen OPEL,Genes whose promoters display lower histone H3 trimethylation mark at K9 (H3K9me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,176,234
Cohort,-0.09271765739069601,0.07787442997696882,-1.1906046364399334,0.23422674455826326,LGP Offspring,Genes whose promoters display higher histone H3 trimethylation mark at K9 (H3K9me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,185,361
Cohort,0.19495609099528863,0.2154407648703128,0.9049173730544673,0.3657704919158514,LGP Proband,Genes whose promoters display higher histone H3 trimethylation mark at K9 (H3K9me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,185,540
Cohort,0.04432248056387095,0.06681739601702362,0.6633374421322636,0.5073065146262498,LonGen OPEL,Genes whose promoters display higher histone H3 trimethylation mark at K9 (H3K9me3) in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,292,362
Cohort,0.06021579060265284,0.1000692510118111,0.6017411941610876,0.5475481740461858,LGP Offspring,Genes down-regulated in liver tumor compared to the normal adjacent tissue.,CGP,C2,332,746
Cohort,0.26086048123708677,0.27281851492680315,0.9561685404932114,0.33926416411161087,LGP Proband,Genes down-regulated in liver tumor compared to the normal adjacent tissue.,CGP,C2,332,1010
Cohort,-0.07772619149948105,0.09212468079711313,-0.8437064945783425,0.39908690805166114,LonGen OPEL,Genes down-regulated in liver tumor compared to the normal adjacent tissue.,CGP,C2,578,659
Cohort,-0.22607333390198642,0.14481752678348037,-1.5610909737465222,0.1189702905544859,LGP Offspring,Genes up-regulated in liver tumor compared to the normal adjacent tissue.,CGP,C2,662,1264
Cohort,-0.030641864581044627,0.3926119971130054,-0.07804617486567786,0.9378100431393319,LGP Proband,Genes up-regulated in liver tumor compared to the normal adjacent tissue.,CGP,C2,662,1734
Cohort,-0.03343727485053691,0.12447159882715625,-0.26863376999735156,0.7882811284744986,LonGen OPEL,Genes up-regulated in liver tumor compared to the normal adjacent tissue.,CGP,C2,1055,1243
Cohort,-0.4154417440229013,0.1703889804361813,-2.43819607910914,0.015017277143269893,LGP Offspring,Genes whose DNA is hypo-methylated in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,902,1697
Cohort,-1.006578851238796,0.46437747895807086,-2.167587570132102,0.030472365100130162,LGP Proband,Genes whose DNA is hypo-methylated in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,902,2430
Cohort,-0.14364200687379663,0.13875328109576554,-1.0352332264824569,0.30087440031664575,LonGen OPEL,Genes whose DNA is hypo-methylated in hepatocellular carcinoma (HCC) compared to normal liver.,CGP,C2,1365,1570
Cohort,0.02834361984047382,0.10806732030743511,0.26227743743289395,0.7931874588668142,LGP Offspring,"Genes down-regulated in normal tissue adjacent to liver tumor, compared to the normal liver samples.",CGP,C2,361,793
Cohort,-0.06085525863721693,0.2981955566594207,-0.2040783548854881,0.8383420562633677,LGP Proband,"Genes down-regulated in normal tissue adjacent to liver tumor, compared to the normal liver samples.",CGP,C2,361,1064
Cohort,0.03238126266778897,0.09262058410543987,0.34961194620545616,0.7267224178904236,LonGen OPEL,"Genes down-regulated in normal tissue adjacent to liver tumor, compared to the normal liver samples.",CGP,C2,618,770
Cohort,-0.08615802911777021,0.061125996985275405,-1.4095153186380707,0.15914271501660804,LGP Offspring,"Genes up-regulated in normal tissue adjacent to liver tumor, compared to the normal liver samples.",CGP,C2,142,276
Cohort,0.04492402596183482,0.1798116271626676,0.24983938286256677,0.8027730867356475,LGP Proband,"Genes up-regulated in normal tissue adjacent to liver tumor, compared to the normal liver samples.",CGP,C2,142,399
Cohort,-0.044103559321320845,0.05790789789672345,-0.7616156158867634,0.4465150355033285,LonGen OPEL,"Genes up-regulated in normal tissue adjacent to liver tumor, compared to the normal liver samples.",CGP,C2,234,263
Cohort,-0.13845085325763068,0.05625455789581416,-2.4611490772720597,0.014098058933064343,LGP Offspring,Genes down-regulated in K562 cells (lymphoblast) by MYC [GeneID=4609] in the presence of CKN1B [GeneID=1027].,CGP,C2,127,191
Cohort,-0.3760911650752829,0.15285961247685323,-2.460369740452093,0.014081129773404944,LGP Proband,Genes down-regulated in K562 cells (lymphoblast) by MYC [GeneID=4609] in the presence of CKN1B [GeneID=1027].,CGP,C2,127,268
Cohort,0.07814744377985837,0.04609027937566619,1.6955298348900238,0.09036601336802458,LonGen OPEL,Genes down-regulated in K562 cells (lymphoblast) by MYC [GeneID=4609] in the presence of CKN1B [GeneID=1027].,CGP,C2,139,196
Cohort,-0.047501140621722095,0.05980185457625378,-0.7943088213284931,0.4272944223247789,LGP Offspring,Genes up-regulated in K562 cells (lymphoblast) by MYC [GeneID=4609] in the presence of CKN1B [GeneID=1027].,CGP,C2,117,212
Cohort,-0.262098713784749,0.15748446794222098,-1.66428294300686,0.09643153074172742,LGP Proband,Genes up-regulated in K562 cells (lymphoblast) by MYC [GeneID=4609] in the presence of CKN1B [GeneID=1027].,CGP,C2,117,291
Cohort,-0.01644960505972391,0.049192335659378444,-0.3343936578581183,0.7381706098308447,LonGen OPEL,Genes up-regulated in K562 cells (lymphoblast) by MYC [GeneID=4609] in the presence of CKN1B [GeneID=1027].,CGP,C2,181,207
Cohort,0.054360823747647675,0.03989166049814784,1.3627114807660523,0.1734272376141415,LGP Offspring,Selected genes changed in K562 (immortalized erythroleukemia) cells induced by hemin [PubChem=26945] treatment to express erythroid properties.,CGP,C2,45,120
Cohort,-0.020010203442364673,0.1065348141918688,-0.18782783444223566,0.8510573035357689,LGP Proband,Selected genes changed in K562 (immortalized erythroleukemia) cells induced by hemin [PubChem=26945] treatment to express erythroid properties.,CGP,C2,45,154
Cohort,0.07220801390048713,0.03259391427367222,2.2153833164743046,0.027016068878961418,LonGen OPEL,Selected genes changed in K562 (immortalized erythroleukemia) cells induced by hemin [PubChem=26945] treatment to express erythroid properties.,CGP,C2,58,103
Cohort,-0.11685073423810677,0.0816042408621798,-1.4319198733244056,0.15262894644619568,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblast) expressing ~25% of YY1 [GeneID=7528].,CGP,C2,223,409
Cohort,-0.17709686027582383,0.2374495430510365,-0.7458294423323414,0.4559806079976484,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblast) expressing ~25% of YY1 [GeneID=7528].,CGP,C2,223,655
Cohort,0.04303434799521831,0.07280734234212803,0.5910715404635452,0.5546402832831251,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblast) expressing ~25% of YY1 [GeneID=7528].,CGP,C2,356,447
Cohort,-0.03874707279524661,0.07398794826135252,-0.5236943813927339,0.600662761717214,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) expressing ~25% of YY1 [GeneID=7528].,CGP,C2,194,386
Cohort,0.07798093967452045,0.21424222840153784,0.36398491677544886,0.7159615273741855,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) expressing ~25% of YY1 [GeneID=7528].,CGP,C2,194,558
Cohort,-0.02771738755091306,0.06383785065650292,-0.4341842224615937,0.6642723297734598,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) expressing ~25% of YY1 [GeneID=7528].,CGP,C2,297,346
Cohort,0.034562495369597705,0.0193245915411491,1.7885239797178405,0.07413921154587652,LGP Offspring,Angiogenic and metastatic genes changed in RKO cells (colorectal cancer) upon perturbation of key components of AKT pathway.,CGP,C2,6,31
Cohort,-0.038193145805639185,0.04538112671053786,-0.8416085843186091,0.40024833353509437,LGP Proband,Angiogenic and metastatic genes changed in RKO cells (colorectal cancer) upon perturbation of key components of AKT pathway.,CGP,C2,6,26
Cohort,-0.015553112692095413,0.016435464917857294,-0.9463141304385496,0.34427555865317416,LonGen OPEL,Angiogenic and metastatic genes changed in RKO cells (colorectal cancer) upon perturbation of key components of AKT pathway.,CGP,C2,23,19
Cohort,-0.15574103092311828,0.08555333531265641,-1.8203969530113526,0.06914060419204907,LGP Offspring,Down-regulated genes whose expression correlates with copy number losses in pancreatic adenocarcinoma cell lines and primary tumor specimens.,CGP,C2,237,445
Cohort,0.1876718094941875,0.23221547324649242,0.8081796052194048,0.4192176558189421,LGP Proband,Down-regulated genes whose expression correlates with copy number losses in pancreatic adenocarcinoma cell lines and primary tumor specimens.,CGP,C2,237,657
Cohort,0.09156148424273831,0.07029986621808983,1.3024417992303001,0.19314210563709902,LonGen OPEL,Down-regulated genes whose expression correlates with copy number losses in pancreatic adenocarcinoma cell lines and primary tumor specimens.,CGP,C2,338,443
Cohort,-0.012858641726372343,0.08008952478447813,-0.16055335277584806,0.8724931624548758,LGP Offspring,Up-regulated genes whose expression correlates with copy number gains in pancreatic adenocarcinoma cell lines and primary tumor specimens.,CGP,C2,208,454
Cohort,0.07468462831533017,0.22947083755206252,0.3254645736776276,0.7449111245734631,LGP Proband,Up-regulated genes whose expression correlates with copy number gains in pancreatic adenocarcinoma cell lines and primary tumor specimens.,CGP,C2,208,639
Cohort,-0.049556265463873685,0.07139596839691882,-0.6941045352640997,0.48781916890036237,LonGen OPEL,Up-regulated genes whose expression correlates with copy number gains in pancreatic adenocarcinoma cell lines and primary tumor specimens.,CGP,C2,386,452
Cohort,-0.09767913270147649,0.03524786996713247,-2.7712066797953807,0.005738455544312676,LGP Offspring,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of ZEB1 [GeneID=6935] by RNAi.,CGP,C2,59,78
Cohort,-0.2409061663917748,0.09512875391856938,-2.5324221801327442,0.011510148396653845,LGP Proband,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of ZEB1 [GeneID=6935] by RNAi.,CGP,C2,59,106
Cohort,0.06223249352885306,0.03413670561387808,1.8230374727065872,0.06867267301194621,LonGen OPEL,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of ZEB1 [GeneID=6935] by RNAi.,CGP,C2,70,110
Cohort,-0.04937990395025898,0.03423931793687796,-1.4421988207035406,0.14970942279881636,LGP Offspring,Genes down-regulated in T47D cells (breast cancer) after COBRA1 [GeneID=25920] knockdown by RNAi.,CGP,C2,49,79
Cohort,-0.14033995327377205,0.09366316139641803,-1.4983473884657825,0.13442140628580795,LGP Proband,Genes down-regulated in T47D cells (breast cancer) after COBRA1 [GeneID=25920] knockdown by RNAi.,CGP,C2,49,102
Cohort,-0.031737382455611994,0.02816418920291195,-1.1268700911983152,0.2601369956472577,LonGen OPEL,Genes down-regulated in T47D cells (breast cancer) after COBRA1 [GeneID=25920] knockdown by RNAi.,CGP,C2,67,62
Cohort,-0.0026531107173061483,0.024183543330985855,-0.10970727825094077,0.9126740869735612,LGP Offspring,Genes up-regulated in T47D cells (breast cancer) after COBRA1 [GeneID=25920] knockdown by RNAi.,CGP,C2,18,40
Cohort,-0.0811447310881303,0.06948969202062702,-1.1677232799368813,0.24325212681414998,LGP Proband,Genes up-regulated in T47D cells (breast cancer) after COBRA1 [GeneID=25920] knockdown by RNAi.,CGP,C2,18,61
Cohort,0.015987903503422912,0.021350368570078992,0.7488350119551945,0.4541778681441142,LonGen OPEL,Genes up-regulated in T47D cells (breast cancer) after COBRA1 [GeneID=25920] knockdown by RNAi.,CGP,C2,31,41
Cohort,-0.04928876524409227,0.046273656086769734,-1.065158222027427,0.2871846323098969,LGP Offspring,"Genes down-regulated in WE17/10 cells (CD4+ [GeneID=920] T lymphocytes) infected by HTLV1 (and thus displaying low CD7 [GeneID=924]) compared to the uninfected (i.e., CD7+) cells.",CGP,C2,76,135
Cohort,0.0028572985318611817,0.12773184994137554,0.022369507160293865,0.9821585547636125,LGP Proband,"Genes down-regulated in WE17/10 cells (CD4+ [GeneID=920] T lymphocytes) infected by HTLV1 (and thus displaying low CD7 [GeneID=924]) compared to the uninfected (i.e., CD7+) cells.",CGP,C2,76,182
Cohort,-0.05489129011780596,0.04133927304345468,-1.3278242716098512,0.18461680266860656,LonGen OPEL,"Genes down-regulated in WE17/10 cells (CD4+ [GeneID=920] T lymphocytes) infected by HTLV1 (and thus displaying low CD7 [GeneID=924]) compared to the uninfected (i.e., CD7+) cells.",CGP,C2,111,109
Cohort,-0.04315629184199726,0.02327155622705853,-1.8544652287507166,0.06410791831269684,LGP Offspring,"Genes up-regulated in WE17/10 cells (CD4+ [GeneID=920] T lymphocytes) infected by HTLV1 (and thus displaying low CD7 [GeneID=924]) compared to the uninfected (i.e., CD7+) cells.",CGP,C2,24,31
Cohort,-0.03562657553752518,0.07230225918608686,-0.4927449838853833,0.6223224866180834,LGP Proband,"Genes up-regulated in WE17/10 cells (CD4+ [GeneID=920] T lymphocytes) infected by HTLV1 (and thus displaying low CD7 [GeneID=924]) compared to the uninfected (i.e., CD7+) cells.",CGP,C2,24,55
Cohort,-0.018455930349747,0.02195936038648172,-0.8404584662269378,0.40090375719437454,LonGen OPEL,"Genes up-regulated in WE17/10 cells (CD4+ [GeneID=920] T lymphocytes) infected by HTLV1 (and thus displaying low CD7 [GeneID=924]) compared to the uninfected (i.e., CD7+) cells.",CGP,C2,34,38
Cohort,-0.007731373800885485,0.04888097670636835,-0.15816733465307825,0.8743721782153511,LGP Offspring,Genes able to induce cell death in an expression cDNA library screen.,CGP,C2,81,163
Cohort,-0.1620660981801013,0.13824979725318587,-1.1722700604276408,0.24142339342233965,LGP Proband,Genes able to induce cell death in an expression cDNA library screen.,CGP,C2,81,227
Cohort,0.004238500386882106,0.042137435379744265,0.10058752623847583,0.9199032280590084,LonGen OPEL,Genes able to induce cell death in an expression cDNA library screen.,CGP,C2,117,140
Cohort,-0.01034850990424547,0.07643347558658012,-0.1353923765055428,0.8923419558966108,LGP Offspring,Genes down-regulated in acute myeloid leukemia (AML) with respect to cellular localization of NPM1 [GeneID=4869]: cytoplasmic vs. nucleolar.,CGP,C2,196,409
Cohort,0.009916150192144443,0.21714588666902795,0.04566584402889731,0.9635875197216346,LGP Proband,Genes down-regulated in acute myeloid leukemia (AML) with respect to cellular localization of NPM1 [GeneID=4869]: cytoplasmic vs. nucleolar.,CGP,C2,196,508
Cohort,0.031225767859392715,0.06786056809163495,0.46014598370628523,0.6455371037639666,LonGen OPEL,Genes down-regulated in acute myeloid leukemia (AML) with respect to cellular localization of NPM1 [GeneID=4869]: cytoplasmic vs. nucleolar.,CGP,C2,305,376
Cohort,-0.03387593052109096,0.05452190115338242,-0.6213270228011734,0.5345939321032757,LGP Offspring,Genes up-regulated in acute myeloid leukemia (AML) with respect to cellular localization of NPM1 [GeneID=4869]: cytoplasmic vs. nucleolar.,CGP,C2,106,207
Cohort,-0.12287318514180481,0.1536122657338155,-0.7998917570470812,0.4240012842661899,LGP Proband,Genes up-regulated in acute myeloid leukemia (AML) with respect to cellular localization of NPM1 [GeneID=4869]: cytoplasmic vs. nucleolar.,CGP,C2,106,274
Cohort,0.09490673400775135,0.04762810712639347,1.9926623108470771,0.04663950409265971,LonGen OPEL,Genes up-regulated in acute myeloid leukemia (AML) with respect to cellular localization of NPM1 [GeneID=4869]: cytoplasmic vs. nucleolar.,CGP,C2,142,211
Cohort,-0.14331559952105236,0.09167773021403121,-1.5632542296418896,0.1184607993317961,LGP Offspring,Genes up-regulated hT-RPE cells (immortalized retinal pigment epithelium) by MYC [GeneID=4609].,CGP,C2,300,575
Cohort,-0.5753154679147969,0.2536862779930062,-2.2678225738747195,0.023595055655995234,LGP Proband,Genes up-regulated hT-RPE cells (immortalized retinal pigment epithelium) by MYC [GeneID=4609].,CGP,C2,300,782
Cohort,0.09085311882483661,0.08483712763420305,1.0709122451266035,0.28453348691328495,LonGen OPEL,Genes up-regulated hT-RPE cells (immortalized retinal pigment epithelium) by MYC [GeneID=4609].,CGP,C2,429,540
Cohort,0.004410377726528658,0.0175331776117011,0.25154468997024865,0.8014694636490672,LGP Offspring,Down-regulated genes in melanoma tumors that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,7,22
Cohort,0.021001408190640274,0.053127009004561354,0.39530567566559494,0.692718398898613,LGP Proband,Down-regulated genes in melanoma tumors that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,7,37
Cohort,0.03514722050975847,0.017116093079123942,2.053460468302,0.04035417888156357,LonGen OPEL,Down-regulated genes in melanoma tumors that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,15,32
Cohort,0.009965710843344161,0.00960561271734222,1.0374883036198004,0.2998793030275627,LGP Offspring,EMT (epithelial-mesenchymal transition) genes down-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,1,8
Cohort,-0.012796581544608556,0.025923808128980264,-0.49362275329847233,0.6217025919577668,LGP Proband,EMT (epithelial-mesenchymal transition) genes down-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,1,10
Cohort,0.014643814674082283,0.012034140706897147,1.2168558628942612,0.22401972458878835,LonGen OPEL,EMT (epithelial-mesenchymal transition) genes down-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,8,14
Cohort,-0.019939878718007505,0.02724358663794573,-0.7319109257895805,0.46447659338712377,LGP Offspring,EMT (epithelial-mesenchymal transition) genes up-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,26,46
Cohort,-0.05917550067168338,0.07731327688811429,-0.7653989463843395,0.4442505619290612,LGP Proband,EMT (epithelial-mesenchymal transition) genes up-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,26,65
Cohort,-0.003260559883169472,0.023447265222980875,-0.13905928269936435,0.8894384768271022,LonGen OPEL,EMT (epithelial-mesenchymal transition) genes up-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,37,42
Cohort,-0.041230782267529194,0.031513864694196286,-1.308337859149418,0.1912034046290406,LGP Offspring,Neural-related genes up-regulated in melanoma tumors that developed metastases compared to primary melanoma that did not.,CGP,C2,36,55
Cohort,-0.09099641106951276,0.08029178085086074,-1.1333216190401294,0.25740489996103694,LGP Proband,Neural-related genes up-regulated in melanoma tumors that developed metastases compared to primary melanoma that did not.,CGP,C2,36,72
Cohort,-0.012692714278241146,0.024976123501424728,-0.5081939267924067,0.6114581491756009,LonGen OPEL,Neural-related genes up-regulated in melanoma tumors that developed metastases compared to primary melanoma that did not.,CGP,C2,43,50
Cohort,-0.0708582668884949,0.06089110360619657,-1.1636883336317791,0.2449609032504949,LGP Offspring,Up-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,120,224
Cohort,0.09351494417832205,0.17320733361748356,0.5399017594996489,0.5894089097434814,LGP Proband,Up-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,120,318
Cohort,0.018487726455928836,0.04949537424608787,0.3735243290415187,0.7088576984392407,LonGen OPEL,Up-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.,CGP,C2,160,204
Cohort,-0.03878294532725814,0.0483596153609071,-0.8019696814753714,0.4228523184607371,LGP Offspring,Genes up-regulated in lung tissue upon LPS aspiration with mechanical ventilation (MV) compared to control (PBS aspiration without MV).,CGP,C2,75,139
Cohort,-0.15571914596896064,0.14369158151115718,-1.0837040300573875,0.27880923953939823,LGP Proband,Genes up-regulated in lung tissue upon LPS aspiration with mechanical ventilation (MV) compared to control (PBS aspiration without MV).,CGP,C2,75,244
Cohort,-0.04506911295326607,0.04372040876578598,-1.03084838924323,0.30292503215915423,LonGen OPEL,Genes up-regulated in lung tissue upon LPS aspiration with mechanical ventilation (MV) compared to control (PBS aspiration without MV).,CGP,C2,140,152
Cohort,-0.04207819510491913,0.0550957254890193,-0.7637288506765448,0.4452953105557651,LGP Offspring,Genes down-regulated by flavopiridol [PubChem=5287969] in the HCT116 cells (colon cancer) depending on their TP53 [GeneID=7157] status: wild-type vs loss of the gene's function (LOF).,CGP,C2,94,174
Cohort,-0.1769082520451376,0.15586575237325626,-1.1350039976805826,0.2566997326387075,LGP Proband,Genes down-regulated by flavopiridol [PubChem=5287969] in the HCT116 cells (colon cancer) depending on their TP53 [GeneID=7157] status: wild-type vs loss of the gene's function (LOF).,CGP,C2,94,274
Cohort,0.02468539539388903,0.04923640545093183,0.5013646948392705,0.616253105639017,LonGen OPEL,Genes down-regulated by flavopiridol [PubChem=5287969] in the HCT116 cells (colon cancer) depending on their TP53 [GeneID=7157] status: wild-type vs loss of the gene's function (LOF).,CGP,C2,156,199
Cohort,0.0012505249828166736,0.01927689999964917,0.06487168490988865,0.9482953439027346,LGP Offspring,Delayed early genes (DEG) which are coordinately down-regulated in multiple epithelial tumor types.,CGP,C2,12,24
Cohort,-0.09563835114029347,0.05087725107869321,-1.87978613452144,0.060485624521823815,LGP Proband,Delayed early genes (DEG) which are coordinately down-regulated in multiple epithelial tumor types.,CGP,C2,12,25
Cohort,-8.718807634728263e-4,0.012794368570919638,-0.06814566569971471,0.9456867924114432,LonGen OPEL,Delayed early genes (DEG) which are coordinately down-regulated in multiple epithelial tumor types.,CGP,C2,11,14
Cohort,-0.026832199836914632,0.03842452082946773,-0.6983092894248155,0.4852239326453244,LGP Offspring,Genes whose expression peaked at 120 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,49,88
Cohort,0.018889341876057016,0.10347237970976678,0.1825544355802039,0.8551920035623728,LGP Proband,Genes whose expression peaked at 120 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,49,120
Cohort,0.010453207126531193,0.031877073184027015,0.32792242456465837,0.743056550364984,LonGen OPEL,Genes whose expression peaked at 120 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,66,86
Cohort,0.022989891116239818,0.01933560367941685,1.1889926736920573,0.23486003578282738,LGP Offspring,Genes whose expression peaked at 120 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,8,29
Cohort,-0.043517300430937565,0.051714623405995974,-0.8414892648312705,0.4003151090928564,LGP Proband,Genes whose expression peaked at 120 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,8,37
Cohort,-0.006252568994823544,0.017077197177994656,-0.36613555079638493,0.7143612184239054,LonGen OPEL,Genes whose expression peaked at 120 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,23,24
Cohort,0.0077223861394249875,0.006416101448731247,1.2035947687441961,0.22916754824916605,LGP Offspring,Genes whose expression peaked at 20 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,0,4
Cohort,-0.009352320334596436,0.019295070488046517,-0.4846999828474474,0.628016451575359,LGP Proband,Genes whose expression peaked at 20 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,0,6
Cohort,-0.0031828380837226034,0.005197137385901603,-0.6124213865034168,0.5404339002929015,LonGen OPEL,Genes whose expression peaked at 20 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,2,2
Cohort,-0.0019064685008203246,0.019355034750831033,-0.09849987485754672,0.921564570769245,LGP Offspring,Genes whose expression peaked at 20 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,12,24
Cohort,-0.004307694683781408,0.04984250840787711,-0.08642612142491247,0.931148427242871,LGP Proband,Genes whose expression peaked at 20 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,12,30
Cohort,0.01892424758125837,0.013969192184438595,1.3547130951737931,0.17589335302110562,LonGen OPEL,Genes whose expression peaked at 20 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,10,20
Cohort,-0.10855021755489065,0.049171688796953925,-2.2075755421606567,0.0276089886378588,LGP Offspring,Genes whose expression peaked at 240 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,96,160
Cohort,-0.044950330348269264,0.13391963968477769,-0.3356515179855181,0.7372180868555938,LGP Proband,Genes whose expression peaked at 240 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,96,225
Cohort,-0.04201800869106059,0.04460921642299603,-0.9419131753545066,0.34652286100623886,LonGen OPEL,Genes whose expression peaked at 240 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,134,146
Cohort,-0.0011098694859903657,0.02578313714091484,-0.04304633217922624,0.9656773116404718,LGP Offspring,Genes whose expression peaked at 240 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,20,47
Cohort,0.09722039141637873,0.07081683061074924,1.3728430173719424,0.17017017342525995,LGP Proband,Genes whose expression peaked at 240 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,20,67
Cohort,-0.01812639581963224,0.024649481109615214,-0.735366222884162,0.46233309472565454,LonGen OPEL,Genes whose expression peaked at 240 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,45,43
Cohort,5.496144255389432e-4,0.025956638398781172,0.021174329938068986,0.9831128397040985,LGP Offspring,Genes whose expression peaked at 40 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,19,45
Cohort,0.04096774214095672,0.07483939262979278,0.5474088003841963,0.5842443643430134,LGP Proband,Genes whose expression peaked at 40 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,19,64
Cohort,0.010650125156944667,0.018098921713204555,0.5884397604291852,0.5564040796591219,LonGen OPEL,Genes whose expression peaked at 40 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,20,30
Cohort,0.017157943672427137,0.02435661227501974,0.7044470502995365,0.48139702111639837,LGP Offspring,Genes whose expression peaked at 40 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,16,41
Cohort,-0.044398509779286145,0.06686447244816456,-0.6640074789149839,0.5068690454827196,LGP Proband,Genes whose expression peaked at 40 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,16,55
Cohort,0.005623991333922514,0.018927435519492428,0.2971343544206316,0.7664414580745437,LonGen OPEL,Genes whose expression peaked at 40 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,23,32
Cohort,0.017539797349180614,0.06995532253111651,0.2507285609522966,0.8021001642543637,LGP Offspring,Genes whose expression peaked at 480 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,145,317
Cohort,-0.19658579704342016,0.18779513626353875,-1.046809842655058,0.29549057260215933,LGP Proband,Genes whose expression peaked at 480 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,145,410
Cohort,0.06662911660255132,0.06296753325624771,1.058150338070299,0.29030791035333775,LonGen OPEL,Genes whose expression peaked at 480 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,247,319
Cohort,-0.010378396666540156,0.03226179476361039,-0.32169309682195496,0.7477846530683324,LGP Offspring,Genes whose expression peaked at 480 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,31,64
Cohort,0.05071220455477322,0.08641283236939665,0.5868596499416803,0.5574567908176943,LGP Proband,Genes whose expression peaked at 480 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,31,81
Cohort,0.030394842044979484,0.02500395125849178,1.2156015555604183,0.22449713919668282,LonGen OPEL,Genes whose expression peaked at 480 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,39,56
Cohort,-0.03161471763436355,0.028910400261541958,-1.093541332819906,0.2745457092382625,LGP Offspring,Genes whose expression peaked at 60 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,33,55
Cohort,-0.06175606482806817,0.07497606182386622,-0.8236770954060715,0.41035853144030754,LGP Proband,Genes whose expression peaked at 60 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,33,57
Cohort,-0.012804206633038709,0.019987971119425307,-0.6405956140588447,0.5219698136213686,LonGen OPEL,Genes whose expression peaked at 60 min after stimulation of HeLa cells with EGF [GeneID=1950].,CGP,C2,30,30
Cohort,0.08040446461924508,0.032165689095987694,2.499696629514293,0.012665901507037742,LGP Offspring,Genes whose expression peaked at 60 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,18,79
Cohort,0.056701403467751904,0.0764268800633005,0.7419039403517323,0.45835441292856627,LGP Proband,Genes whose expression peaked at 60 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,18,73
Cohort,0.017929102724490737,0.024446257548727743,0.7334088945415623,0.463525014268815,LonGen OPEL,Genes whose expression peaked at 60 min after stimulation of MCF10A cells with EGF [GeneID=1950].,CGP,C2,40,53
Cohort,-0.04269017921898803,0.03188305819303422,-1.338961242692677,0.18103335409123975,LGP Offspring,Genes whose expression peaked at 120 min after stimulation of MCF10A cells with serum.,CGP,C2,41,64
Cohort,-0.12086399117507686,0.09166216813368867,-1.318580976600919,0.18767121193437522,LGP Proband,Genes whose expression peaked at 120 min after stimulation of MCF10A cells with serum.,CGP,C2,41,104
Cohort,0.0046997653065338815,0.029124544338251675,0.16136785701952736,0.8718446284438803,LonGen OPEL,Genes whose expression peaked at 120 min after stimulation of MCF10A cells with serum.,CGP,C2,53,63
Cohort,0.016664051350300666,0.021985295655063696,0.7579634866753575,0.44873698793444194,LGP Offspring,Genes whose expression peaked at 20 min after stimulation of MCF10A cells with serum.,CGP,C2,11,35
Cohort,0.029375442767248024,0.06220909598281401,0.47220494532444796,0.6369040382063489,LGP Proband,Genes whose expression peaked at 20 min after stimulation of MCF10A cells with serum.,CGP,C2,11,49
Cohort,-0.001109688712817202,0.017215983523181076,-0.06445688748034767,0.9486226177650068,LonGen OPEL,Genes whose expression peaked at 20 min after stimulation of MCF10A cells with serum.,CGP,C2,20,24
Cohort,0.050604516561204266,0.043598665560847114,1.160689574101291,0.2461778826003714,LGP Offspring,Genes whose expression peaked at 240 min after stimulation of MCF10A cells with serum.,CGP,C2,54,142
Cohort,0.11242778421415389,0.11924933767764256,0.9427958796557105,0.346058338837379,LGP Proband,Genes whose expression peaked at 240 min after stimulation of MCF10A cells with serum.,CGP,C2,54,176
Cohort,0.01179435522855372,0.03770946988694498,0.3127690541371659,0.7545380512011507,LonGen OPEL,Genes whose expression peaked at 240 min after stimulation of MCF10A cells with serum.,CGP,C2,90,111
Cohort,0.023131002029703283,0.022736236065357136,1.0173628547491924,0.30934481413051373,LGP Offspring,Genes whose expression peaked at 40 min after stimulation of MCF10A cells with serum.,CGP,C2,14,39
Cohort,-0.01847575836472951,0.05265067395128976,-0.35091209624063924,0.7257429169822658,LGP Proband,Genes whose expression peaked at 40 min after stimulation of MCF10A cells with serum.,CGP,C2,14,31
Cohort,0.006322808801009587,0.013702114493365038,0.46144766956014527,0.6446035262665973,LonGen OPEL,Genes whose expression peaked at 40 min after stimulation of MCF10A cells with serum.,CGP,C2,11,18
Cohort,-0.015666598742436002,0.02386866919563361,-0.6563666626751841,0.511811590550566,LGP Offspring,Genes whose expression peaked at 480 min after stimulation of MCF10A cells with serum.,CGP,C2,18,35
Cohort,-0.015146303459300256,0.05418895712925836,-0.27950904135636667,0.7799235023332931,LGP Proband,Genes whose expression peaked at 480 min after stimulation of MCF10A cells with serum.,CGP,C2,18,30
Cohort,7.533387685445596e-4,0.0185745224903794,0.0405576385037488,0.9676587260877083,LonGen OPEL,Genes whose expression peaked at 480 min after stimulation of MCF10A cells with serum.,CGP,C2,23,29
Cohort,0.0030873476779893845,0.043965257385568356,0.07022244066294969,0.9440373813190917,LGP Offspring,Genes whose expression peaked at 60 min after stimulation of MCF10A cells with serum.,CGP,C2,60,129
Cohort,-0.20670363542119027,0.11952335097704347,-1.7293996004252865,0.08410761774789532,LGP Proband,Genes whose expression peaked at 60 min after stimulation of MCF10A cells with serum.,CGP,C2,60,174
Cohort,-0.03533549431953076,0.035032279031744,-1.0086553115060541,0.3134464767530231,LonGen OPEL,Genes whose expression peaked at 60 min after stimulation of MCF10A cells with serum.,CGP,C2,97,100
Cohort,4.58012813693358e-4,0.012348296478890491,0.03709117403168401,0.9704232594824715,LGP Offspring,Genes discriminating TP53 [GeneID=7157] status across various genotoxic stress agents.,CGP,C2,4,11
Cohort,0.054074948174210984,0.03728822888213113,1.4501881638074852,0.14738201339394746,LGP Proband,Genes discriminating TP53 [GeneID=7157] status across various genotoxic stress agents.,CGP,C2,4,19
Cohort,0.006108938298784864,0.010846175351510084,0.5632343292268766,0.5734339439192703,LonGen OPEL,Genes discriminating TP53 [GeneID=7157] status across various genotoxic stress agents.,CGP,C2,7,11
Cohort,-0.12396589927598531,0.07545105448565007,-1.6429975713535219,0.1008484522726258,LGP Offspring,Genes discriminating responses to sodium arsenite [PubChem=26435] from other stresses.,CGP,C2,198,359
Cohort,0.08452882506353251,0.2018293900731114,0.4188132612049835,0.6754604468849915,LGP Proband,Genes discriminating responses to sodium arsenite [PubChem=26435] from other stresses.,CGP,C2,198,484
Cohort,5.773453686580926e-4,0.06525801225940593,0.008847118517234291,0.9929433295667158,LonGen OPEL,Genes discriminating responses to sodium arsenite [PubChem=26435] from other stresses.,CGP,C2,303,355
Cohort,0.002297654680286227,0.05012462160990703,0.04583884339651754,0.9634522363846829,LGP Offspring,Invasiveness signature resulting from cancer cell/microenvironment interaction.,CGP,C2,79,173
Cohort,0.10402613446963971,0.12707855508775515,0.8185970827084366,0.41325016438557616,LGP Proband,Invasiveness signature resulting from cancer cell/microenvironment interaction.,CGP,C2,79,216
Cohort,-0.08455482851632636,0.039908994254979305,-2.1186910393207103,0.03442576282312725,LonGen OPEL,Invasiveness signature resulting from cancer cell/microenvironment interaction.,CGP,C2,125,117
Cohort,0.06175612557969705,0.0424547384839394,1.4546344597802516,0.14623463990348134,LGP Offspring,Genes overexpressed in cholangiocarcinoma class 1 associated with good prognosis,CGP,C2,50,130
Cohort,-0.12671134990159297,0.12315143581349512,-1.028906801326207,0.30382177464610666,LGP Proband,Genes overexpressed in cholangiocarcinoma class 1 associated with good prognosis,CGP,C2,50,188
Cohort,0.04680813528938366,0.03812989725617935,1.2275966802349016,0.2199613110247057,LonGen OPEL,Genes overexpressed in cholangiocarcinoma class 1 associated with good prognosis,CGP,C2,87,128
Cohort,-0.06653852308127663,0.08277881039229701,-0.8038110570319138,0.4217886622905751,LGP Offspring,Genes overexpressed in cholangiocarcinoma class 2 associated with poor prognosis.,CGP,C2,243,476
Cohort,-0.37851987333324527,0.2239737951231723,-1.6900185717042557,0.09139810540561934,LGP Proband,Genes overexpressed in cholangiocarcinoma class 2 associated with poor prognosis.,CGP,C2,243,603
Cohort,-0.06337867472756235,0.07438103901187541,-0.8520810621836505,0.39442538547748585,LonGen OPEL,Genes overexpressed in cholangiocarcinoma class 2 associated with poor prognosis.,CGP,C2,363,417
Cohort,0.06983911573567475,0.050924270437944966,1.3714308547783505,0.17069572329139807,LGP Offspring,Genes under-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma.,CGP,C2,88,209
Cohort,-0.1684682877153855,0.1379176469264279,-1.2215136457864222,0.2222367718099279,LGP Proband,Genes under-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma.,CGP,C2,88,246
Cohort,-0.01829520413945057,0.04510226765166595,-0.40563823266599763,0.6851174393059645,LonGen OPEL,Genes under-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma.,CGP,C2,144,168
Cohort,-0.002010146103478624,0.02437230049958935,-0.08247666663688531,0.9342920870991842,LGP Offspring,Genes over-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma.,CGP,C2,22,40
Cohort,-0.11808796985933193,0.0659318795552934,-1.7910602678981438,0.073646154123193,LGP Proband,Genes over-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma.,CGP,C2,22,52
Cohort,0.006905451036318694,0.024391110529558457,0.28311343298413155,0.7771634943748548,LonGen OPEL,Genes over-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma.,CGP,C2,42,53
Cohort,-0.016172178647317226,0.0288992788287331,-0.5596049210486886,0.5759343114186146,LGP Offspring,Genes up-regulated by imatinib [PubChem=5291] during dendritic cell differentiation.,CGP,C2,27,52
Cohort,-0.06956746960747136,0.07627749154524534,-0.9120314289072575,0.36201571949951994,LGP Proband,Genes up-regulated by imatinib [PubChem=5291] during dendritic cell differentiation.,CGP,C2,27,79
Cohort,-8.823765313377947e-4,0.026951781178580447,-0.032739080415176834,0.9738908661682864,LonGen OPEL,Genes up-regulated by imatinib [PubChem=5291] during dendritic cell differentiation.,CGP,C2,48,57
Cohort,-0.06753477202972252,0.04093921672631665,-1.6496351769795743,0.09948212918648858,LGP Offspring,Genes down-regulated in A2780 cells (ovarian carcinoma) exposed to fenretinide [PubChem=1744].,CGP,C2,65,97
Cohort,-0.140972552861147,0.11138646847134287,-1.265616504372934,0.20600386230191522,LGP Proband,Genes down-regulated in A2780 cells (ovarian carcinoma) exposed to fenretinide [PubChem=1744].,CGP,C2,65,141
Cohort,-0.022655895293095443,0.03617868385948908,-0.6262222081125588,0.5313487304778672,LonGen OPEL,Genes down-regulated in A2780 cells (ovarian carcinoma) exposed to fenretinide [PubChem=1744].,CGP,C2,91,100
Cohort,-0.06901606400740086,0.03705712175638444,-1.8624237592200568,0.06297699977997943,LGP Offspring,Genes up-regulated in A2780 cells (ovarian carcinoma) exposed to fenretinide [PubChem=1744].,CGP,C2,56,85
Cohort,-0.2537548017341249,0.10490716921162473,-2.4188509102007725,0.015782733665308697,LGP Proband,Genes up-regulated in A2780 cells (ovarian carcinoma) exposed to fenretinide [PubChem=1744].,CGP,C2,56,125
Cohort,-0.03090291380983498,0.03254298254772281,-0.949602998573264,0.34260223046375127,LonGen OPEL,Genes up-regulated in A2780 cells (ovarian carcinoma) exposed to fenretinide [PubChem=1744].,CGP,C2,77,80
Cohort,-0.018696882256589314,0.032532775550722814,-0.5747091030532716,0.5656792549868843,LGP Offspring,Genes down-regulated in embryonic stem cells with BRCA1 [GeneID=672] loss of function (LOF).,CGP,C2,33,66
Cohort,0.10653888849624586,0.09499585589251389,1.1215109069262212,0.2623932541945433,LGP Proband,Genes down-regulated in embryonic stem cells with BRCA1 [GeneID=672] loss of function (LOF).,CGP,C2,33,111
Cohort,0.06272478740546557,0.03118936143837637,2.0110955951886536,0.04465205607049451,LonGen OPEL,Genes down-regulated in embryonic stem cells with BRCA1 [GeneID=672] loss of function (LOF).,CGP,C2,56,91
Cohort,0.019423370300089258,0.02818334057161802,0.689179135834931,0.4909470222506013,LGP Offspring,Down-regulated genes associated with poor survival prognosis of patients with metastatic neuroblastoma that lack MYCN [GeneID=4613] amplification.,CGP,C2,26,61
Cohort,-0.20863898128659444,0.09048256643746844,-2.3058472974546174,0.0213636546856401,LGP Proband,Down-regulated genes associated with poor survival prognosis of patients with metastatic neuroblastoma that lack MYCN [GeneID=4613] amplification.,CGP,C2,26,109
Cohort,-0.03431118323718679,0.02956493770789597,-1.1605362939094992,0.2461784624448375,LonGen OPEL,Down-regulated genes associated with poor survival prognosis of patients with metastatic neuroblastoma that lack MYCN [GeneID=4613] amplification.,CGP,C2,60,63
Cohort,-0.04523128336702373,0.043763886361124715,-1.03352986052908,0.30172560078630495,LGP Offspring,Integrin signaling signature in precursor B leukemia (PBL) cells:  fibronectin (FN1) [GeneID=2335] vs control treatment with poly-L-lysine.,CGP,C2,65,118
Cohort,0.0062474777712929995,0.12850548795988376,0.04861642775321244,0.9612366177455661,LGP Proband,Integrin signaling signature in precursor B leukemia (PBL) cells:  fibronectin (FN1) [GeneID=2335] vs control treatment with poly-L-lysine.,CGP,C2,65,201
Cohort,0.0418416817433842,0.03799004674151711,1.1013853714914719,0.2710618918590119,LonGen OPEL,Integrin signaling signature in precursor B leukemia (PBL) cells:  fibronectin (FN1) [GeneID=2335] vs control treatment with poly-L-lysine.,CGP,C2,96,136
Cohort,0.007158266820433417,0.07356269379534319,0.09730838351771402,0.9225103414493911,LGP Offspring,Genes down-regulated in the temporal cortex samples from patients with major depressive disorder.,CGP,C2,184,387
Cohort,0.05919230212638206,0.21627911113161385,0.2736847854454208,0.78439463511407,LGP Proband,Genes down-regulated in the temporal cortex samples from patients with major depressive disorder.,CGP,C2,184,560
Cohort,0.06556660223430888,0.06490977965268274,1.0101190080314653,0.3127452229260523,LonGen OPEL,Genes down-regulated in the temporal cortex samples from patients with major depressive disorder.,CGP,C2,303,376
Cohort,0.045247332785357294,0.05391049252855974,0.8393047561453267,0.4015950212036362,LGP Offspring,Genes up-regulated in the temporal cortex samples from patients with major depressive disorder.,CGP,C2,84,194
Cohort,0.08069397605771089,0.14791941615365545,0.5455265992524454,0.5855372607028555,LGP Proband,Genes up-regulated in the temporal cortex samples from patients with major depressive disorder.,CGP,C2,84,250
Cohort,-0.013196007946263928,0.04234606309016456,-0.3116230171897344,0.75540863868008,LonGen OPEL,Genes up-regulated in the temporal cortex samples from patients with major depressive disorder.,CGP,C2,126,148
Cohort,0.041302356448893504,0.018254818723756755,2.262545417399449,0.02398027948258525,LGP Offspring,Genes changed in HBE cells (bronchial epithelium) after treatment with IL22 and IL17A [GeneID=50616;3605].,CGP,C2,5,29
Cohort,0.060092905362818395,0.03328120190603258,1.80561103329402,0.07133959114563339,LGP Proband,Genes changed in HBE cells (bronchial epithelium) after treatment with IL22 and IL17A [GeneID=50616;3605].,CGP,C2,5,13
Cohort,0.0331785898447326,0.013357957079682639,2.48380719048701,0.013203351444882367,LonGen OPEL,Genes changed in HBE cells (bronchial epithelium) after treatment with IL22 and IL17A [GeneID=50616;3605].,CGP,C2,6,22
Cohort,0.03983029053348845,0.05393799843582449,0.7384458394554368,0.46049985537798654,LGP Offspring,Selected genes specifically expressed in gastric cancer.,CGP,C2,90,198
Cohort,-0.08596943129533581,0.1373422869463935,-0.6259501949963219,0.5315188720256216,LGP Proband,Selected genes specifically expressed in gastric cancer.,CGP,C2,90,227
Cohort,0.007811496865836109,0.043729083865427225,0.17863390163570242,0.8582706271336705,LonGen OPEL,Selected genes specifically expressed in gastric cancer.,CGP,C2,142,162
Cohort,-0.05096289381021096,0.01936891520520253,-2.6311692353592537,0.008703139830860192,LGP Offspring,Genes down-regulated in RWPE-1 cells (prostate cancer) upon expression of constitutively active form of STAT3 [GeneID=6774].,CGP,C2,19,20
Cohort,-0.049848927134510855,0.05771471164662014,-0.863712660295862,0.38799408129341484,LGP Proband,Genes down-regulated in RWPE-1 cells (prostate cancer) upon expression of constitutively active form of STAT3 [GeneID=6774].,CGP,C2,19,40
Cohort,0.04288704570040962,0.018754038105586863,2.286816602320622,0.02246824777277861,LonGen OPEL,Genes down-regulated in RWPE-1 cells (prostate cancer) upon expression of constitutively active form of STAT3 [GeneID=6774].,CGP,C2,15,40
Cohort,0.019270455534409967,0.05616039465233886,0.3431324807046638,0.7316054762126492,LGP Offspring,Genes up-regulated in RWPE-1 cells (prostate cancer) upon expression of constitutively active form of STAT3 [GeneID=6774].,CGP,C2,97,215
Cohort,-0.050810571008298874,0.15336355238945262,-0.33130799473965045,0.7404950813190626,LGP Proband,Genes up-regulated in RWPE-1 cells (prostate cancer) upon expression of constitutively active form of STAT3 [GeneID=6774].,CGP,C2,97,289
Cohort,-0.01904291488320689,0.04681205048022225,-0.4067951454348786,0.6842678069172979,LonGen OPEL,Genes up-regulated in RWPE-1 cells (prostate cancer) upon expression of constitutively active form of STAT3 [GeneID=6774].,CGP,C2,160,195
Cohort,0.03878924925744495,0.037759884696875426,1.0272607972411183,0.3046651033701583,LGP Offspring,Genes up-regulated in RPWE-1 cells by activated STAT3 [GeneID=6774].,CGP,C2,38,99
Cohort,-0.08036864308081776,0.09698907957615718,-0.8286360014140682,0.407547484647349,LGP Proband,Genes up-regulated in RPWE-1 cells by activated STAT3 [GeneID=6774].,CGP,C2,38,122
Cohort,-0.07122880088927777,0.028474738140492666,-2.5014734301625214,0.01256752944228927,LonGen OPEL,Genes up-regulated in RPWE-1 cells by activated STAT3 [GeneID=6774].,CGP,C2,71,58
Cohort,-0.029417307970762887,0.038085939252552894,-0.7723928711772823,0.44015172628094434,LGP Offspring,Genes down-regulated in D-341 MED (OBR) cells (medulloblastoma) resistant to both carmustine and O6-BG [PubChem=2578;4578].,CGP,C2,49,93
Cohort,-0.13055690982427084,0.09677280476843055,-1.3491074288554818,0.17766861626039235,LGP Proband,Genes down-regulated in D-341 MED (OBR) cells (medulloblastoma) resistant to both carmustine and O6-BG [PubChem=2578;4578].,CGP,C2,49,111
Cohort,-0.06724380285474299,0.02920290302211209,-2.3026410355102978,0.021556163261377777,LonGen OPEL,Genes down-regulated in D-341 MED (OBR) cells (medulloblastoma) resistant to both carmustine and O6-BG [PubChem=2578;4578].,CGP,C2,74,58
Cohort,-0.014064074392785373,0.025953957938081584,-0.5418855353907125,0.5880759233443169,LGP Offspring,Genes up-regulated in D-341 MED (OBR) cells (medulloblastoma) resistant to both carmustine and O6-BG [PubChem=2578;4578].,CGP,C2,25,38
Cohort,-0.20217348013042669,0.06748517095851059,-2.9958208189873523,0.0028180988698246374,LGP Proband,Genes up-regulated in D-341 MED (OBR) cells (medulloblastoma) resistant to both carmustine and O6-BG [PubChem=2578;4578].,CGP,C2,25,51
Cohort,-6.824667186957246e-4,0.021276000774003278,-0.03207683276312046,0.9744188197383488,LonGen OPEL,Genes up-regulated in D-341 MED (OBR) cells (medulloblastoma) resistant to both carmustine and O6-BG [PubChem=2578;4578].,CGP,C2,32,37
Cohort,-0.06078290780707764,0.028609669853789873,-2.1245581692382176,0.03398575819631068,LGP Offspring,"Genes concordantly down-regulated in DU-145 and MCF-7 cells (lprostate, breast cancer) upon expression of BRCA1.",CGP,C2,35,45
Cohort,0.012801193827609572,0.0901636001911397,0.1419774033032405,0.8871321436006226,LGP Proband,"Genes concordantly down-regulated in DU-145 and MCF-7 cells (lprostate, breast cancer) upon expression of BRCA1.",CGP,C2,35,91
Cohort,-0.028922962076017678,0.025316541534087557,-1.142453128405167,0.2536092349014938,LonGen OPEL,"Genes concordantly down-regulated in DU-145 and MCF-7 cells (lprostate, breast cancer) upon expression of BRCA1.",CGP,C2,51,48
Cohort,-0.030282460504484632,0.035826258174189156,-0.8452588142822427,0.39826541623684775,LGP Offspring,"Genes concordantly up-regulated in DU-145 and MCF-7 cells (lprostate, breast cancer) upon expression of BRCA1.",CGP,C2,47,87
Cohort,-0.09890587213462194,0.10755251121178469,-0.9196054189740265,0.35804489013804985,LGP Proband,"Genes concordantly up-regulated in DU-145 and MCF-7 cells (lprostate, breast cancer) upon expression of BRCA1.",CGP,C2,47,149
Cohort,-0.047084111848532735,0.031992772577495485,-1.4717108914046693,0.14149419395503446,LonGen OPEL,"Genes concordantly up-regulated in DU-145 and MCF-7 cells (lprostate, breast cancer) upon expression of BRCA1.",CGP,C2,83,77
Cohort,-0.13057124924114677,0.11887702127694229,-1.0983724847627279,0.272432921071305,LGP Offspring,Genes down-regulated in glomeruli of kidneys from patients with diabetic nephropathy (type 2 diabetes mellitus).,CGP,C2,424,819
Cohort,-0.5775387822479805,0.3231232926556037,-1.787363509146776,0.07424179078286325,LGP Proband,Genes down-regulated in glomeruli of kidneys from patients with diabetic nephropathy (type 2 diabetes mellitus).,CGP,C2,424,1086
Cohort,-0.041192044512522605,0.09789719481886985,-0.4207683845153729,0.674037794089637,LonGen OPEL,Genes down-regulated in glomeruli of kidneys from patients with diabetic nephropathy (type 2 diabetes mellitus).,CGP,C2,619,729
Cohort,6.307130418991442e-4,0.05673773839525834,0.011116288025182438,0.9911339478191165,LGP Offspring,Genes up-regulated in glomeruli of kidneys from patients with diabetic nephropathy (type 2 diabetes mellitus).,CGP,C2,99,216
Cohort,0.1518577937489233,0.15208238150731132,0.9985232493326177,0.3183153136287446,LGP Proband,Genes up-regulated in glomeruli of kidneys from patients with diabetic nephropathy (type 2 diabetes mellitus).,CGP,C2,99,285
Cohort,-0.015502688503724568,0.0490750462258343,-0.31589758331319867,0.7521630558502771,LonGen OPEL,Genes up-regulated in glomeruli of kidneys from patients with diabetic nephropathy (type 2 diabetes mellitus).,CGP,C2,183,208
Cohort,-2.5483972499773495e-4,0.007625627292430938,-0.033418853980797664,0.9733504395198476,LGP Offspring,Genes up-regulated in NIH3T3 cells (fibroblast) engineered to stably express MUC4 [GeneID=4585].,CGP,C2,2,4
Cohort,-0.01488386611862051,0.02216618661877692,-0.6714671483462304,0.5021089178610643,LGP Proband,Genes up-regulated in NIH3T3 cells (fibroblast) engineered to stably express MUC4 [GeneID=4585].,CGP,C2,2,4
Cohort,-0.0017798812688742597,0.00518732253359845,-0.3431213805090995,0.731597743809982,LonGen OPEL,Genes up-regulated in NIH3T3 cells (fibroblast) engineered to stably express MUC4 [GeneID=4585].,CGP,C2,2,2
Cohort,0.00839598345953248,0.01798650873352236,0.46679339408900766,0.6407981054139358,LGP Offspring,STAT1 [GeneID=6772] targets in hematopoetic signaling.,CGP,C2,9,25
Cohort,0.020123266698986623,0.04578412856813058,0.43952494736339764,0.6603950715201077,LGP Proband,STAT1 [GeneID=6772] targets in hematopoetic signaling.,CGP,C2,9,26
Cohort,-0.04451672424647885,0.01775268564931376,-2.5076050534472047,0.012353282858371862,LonGen OPEL,STAT1 [GeneID=6772] targets in hematopoetic signaling.,CGP,C2,31,19
Cohort,-0.008733996088329624,0.01454599958086485,-0.600439731884712,0.5484144545283596,LGP Offspring,STAT5 [GeneID=6777] targets in hematopoietic signaling.,CGP,C2,8,13
Cohort,0.01026184022700608,0.03417211702779514,0.3002986387603448,0.7640242079240811,LGP Proband,STAT5 [GeneID=6777] targets in hematopoietic signaling.,CGP,C2,8,11
Cohort,-0.006866774005481063,0.011492623616967644,-0.5974940304616777,0.5503475197117056,LonGen OPEL,STAT5 [GeneID=6777] targets in hematopoietic signaling.,CGP,C2,10,8
Cohort,0.036329044439905964,0.024226286236809995,1.499571336885583,0.1341923318395764,LGP Offspring,STAT3 [GeneID=6774] targets in hematopoietic signaling.,CGP,C2,14,48
Cohort,-0.03780014917529236,0.05607676618074077,-0.6740786202517255,0.5004481149419989,LGP Proband,STAT3 [GeneID=6774] targets in hematopoietic signaling.,CGP,C2,14,40
Cohort,-0.005947951629025064,0.019828704629280897,-0.2999667270368115,0.7642808508367781,LonGen OPEL,STAT3 [GeneID=6774] targets in hematopoietic signaling.,CGP,C2,30,31
Cohort,-0.03798389671599875,0.07122334077927354,-0.5333068668277395,0.5939964635342072,LGP Offspring,Genes down-regulated in I/11 erythroblast cells upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,169,329
Cohort,-0.34875700650815533,0.1868385371065508,-1.8666224426134594,0.06230505475645057,LGP Proband,Genes down-regulated in I/11 erythroblast cells upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,169,418
Cohort,0.016731440660011764,0.059780640312480725,0.2798805862994186,0.77964183483872,LonGen OPEL,Genes down-regulated in I/11 erythroblast cells upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,235,287
Cohort,-0.048519306913764396,0.029216948238702405,-1.6606562231401365,0.09724622313930276,LGP Offspring,Genes up-regulated in I/11 erythroblast cells upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,37,49
Cohort,-0.19437539028087739,0.0861683454205475,-2.2557632890851247,0.024343820881584405,LGP Proband,Genes up-regulated in I/11 erythroblast cells upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,37,90
Cohort,0.016242556914900164,0.02402775751262499,0.6759913781536117,0.4992424676594768,LonGen OPEL,Genes up-regulated in I/11 erythroblast cells upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,33,53
Cohort,0.005191464784319879,0.03812457605049697,0.13617108233396882,0.8917265756906793,LGP Offspring,Genes up-regulated in U87MG cells (glioblastoma multiforme) after knockdown of PRKCI [GeneID=5584] by RNAi.,CGP,C2,40,86
Cohort,-0.04641329963591725,0.09757363720836165,-0.47567458756103254,0.634430793314632,LGP Proband,Genes up-regulated in U87MG cells (glioblastoma multiforme) after knockdown of PRKCI [GeneID=5584] by RNAi.,CGP,C2,40,109
Cohort,-0.016251460245193125,0.03137830599041499,-0.5179202551647434,0.6046578215016243,LonGen OPEL,Genes up-regulated in U87MG cells (glioblastoma multiforme) after knockdown of PRKCI [GeneID=5584] by RNAi.,CGP,C2,68,72
Cohort,-0.006413168451912908,0.021115858836699714,-0.30371336072614363,0.76143973253722,LGP Offspring,Candidate genes in the pericentromeric microdeletion in 16p11.2-p12.2 associated with developmental disabilities.,CGP,C2,14,26
Cohort,-0.0891166231077482,0.0480638979217504,-1.854128087006863,0.06407370006575652,LGP Proband,Candidate genes in the pericentromeric microdeletion in 16p11.2-p12.2 associated with developmental disabilities.,CGP,C2,14,22
Cohort,-0.025659345350683056,0.021931103262611547,-1.1699979268451792,0.2423519897853664,LonGen OPEL,Candidate genes in the pericentromeric microdeletion in 16p11.2-p12.2 associated with developmental disabilities.,CGP,C2,33,21
Cohort,0.03343908439544208,0.03234302177001239,1.0338886895981356,0.30155792376577556,LGP Offspring,"Genes down-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,28,73
Cohort,0.04692078846528938,0.09092912745037537,0.5160149424165148,0.6059807462655635,LGP Proband,"Genes down-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,28,107
Cohort,-0.033678944266450114,0.03159889247317956,-1.065826730953816,0.2868251470924411,LonGen OPEL,"Genes down-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,66,62
Cohort,-0.04168624160146358,0.023139196280005755,-1.8015423309012706,0.07206290156122579,LGP Offspring,"Genes up-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,23,31
Cohort,0.07144884153937756,0.06265828451329958,1.1402936115209494,0.2544913545431002,LGP Proband,"Genes up-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,23,39
Cohort,0.003078919194828331,0.018931631012641826,0.16263359415638015,0.8708482112150594,LonGen OPEL,"Genes up-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,26,31
Cohort,-0.05405839736968099,0.0669111242658431,-0.8079134518036608,0.4194246075591981,LGP Offspring,"Genes down-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,144,292
Cohort,-0.3835278557653905,0.1791449530439849,-2.140880048522629,0.03257303713888139,LGP Proband,"Genes down-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,144,379
Cohort,-0.023088700150375535,0.05794970761470941,-0.39842651672870416,0.6904226598772698,LonGen OPEL,"Genes down-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,224,247
Cohort,0.014534706149375598,0.026925461794864543,0.5398126969970032,0.5895039792470893,LGP Offspring,"Genes up-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,19,52
Cohort,0.1209322979720845,0.07201364367355176,1.679297030438955,0.09346872326978492,LGP Proband,"Genes up-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,19,64
Cohort,-0.018807381723126845,0.024307959572701158,-0.7737128929673024,0.4393303104104246,LonGen OPEL,"Genes up-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,46,46
Cohort,-0.0094475933516817,0.023998808911515672,-0.393669260275177,0.6939493741192915,LGP Offspring,"Genes down-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,21,37
Cohort,0.10247270994666537,0.06871062913059207,1.4913662011725255,0.13624350366585994,LGP Proband,"Genes down-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,21,59
Cohort,0.013157570786622977,0.021362124726118283,0.6159298737983655,0.5381168819343476,LonGen OPEL,"Genes down-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,30,40
Cohort,-0.02110945676578966,0.025722006593534553,-0.8206769051639892,0.4121196268287364,LGP Offspring,"Genes up-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,24,43
Cohort,0.007245152414364802,0.06756826970596265,0.1072271414658624,0.9146345719932903,LGP Proband,"Genes up-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,24,47
Cohort,-0.024403949074834664,0.020219239425029595,-1.206966719263672,0.22780350838046118,LonGen OPEL,"Genes up-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.",CGP,C2,34,30
Cohort,-0.03711771493898619,0.022526410351085362,-1.6477421107263899,0.09987029157378316,LGP Offspring,"Genes down-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,21,28
Cohort,-0.03695816748679834,0.06219425995514943,-0.5942375954541502,0.5525143653397369,LGP Proband,"Genes down-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,21,42
Cohort,0.001054899006881394,0.021209743793031335,0.049736527568427835,0.9603448246689161,LonGen OPEL,"Genes down-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,28,36
Cohort,-0.022091624117386507,0.02376014105341864,-0.9297766401183858,0.35281863638968214,LGP Offspring,"Genes up-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,21,34
Cohort,0.05371585975123962,0.06744102820969258,0.7964863700509182,0.42597605875762223,LGP Proband,"Genes up-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,21,49
Cohort,-0.009502890233212389,0.02198395653849786,-0.4322647843927056,0.6656660524776696,LonGen OPEL,"Genes up-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.",CGP,C2,37,43
Cohort,0.01594691215107839,0.041588782016202905,0.3834426347197546,0.7015121530147859,LGP Offspring,Genes down-regulated in oncocytic follicular carcinoma (FTC) vs mitochondrial-rich papillary carcinoma (PTC) types of thyroid cancer.,CGP,C2,52,114
Cohort,0.1439810511938804,0.11352934496858613,1.2682276219749207,0.2050705808306576,LGP Proband,Genes down-regulated in oncocytic follicular carcinoma (FTC) vs mitochondrial-rich papillary carcinoma (PTC) types of thyroid cancer.,CGP,C2,52,148
Cohort,-0.0023546070072441865,0.0382510896236927,-0.061556599574244406,0.9509313921721475,LonGen OPEL,Genes down-regulated in oncocytic follicular carcinoma (FTC) vs mitochondrial-rich papillary carcinoma (PTC) types of thyroid cancer.,CGP,C2,93,112
Cohort,-0.008235089953004805,0.02309450523977555,-0.3565822202080151,0.721515859201902,LGP Offspring,Genes up-regulated in oncocytic follicular carcinoma (FTC) vs mitochondrial-rich papillary carcinoma (PTC) types of thyroid cancer.,CGP,C2,17,37
Cohort,0.05923373646543085,0.07285491578333289,0.8130369217856103,0.41642892277173293,LGP Proband,Genes up-regulated in oncocytic follicular carcinoma (FTC) vs mitochondrial-rich papillary carcinoma (PTC) types of thyroid cancer.,CGP,C2,17,63
Cohort,0.008928587894471296,0.021942442438594792,0.406909482363126,0.6841838600208263,LonGen OPEL,Genes up-regulated in oncocytic follicular carcinoma (FTC) vs mitochondrial-rich papillary carcinoma (PTC) types of thyroid cancer.,CGP,C2,30,41
Cohort,-0.016478923962978793,0.03799132649573689,-0.4337548983668138,0.6646048240664766,LGP Offspring,Down-regulated genes in non-neoplastic mucosa samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,47,91
Cohort,-0.026185915107229524,0.10221320829992994,-0.25618915150760874,0.7978679624418191,LGP Proband,Down-regulated genes in non-neoplastic mucosa samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,47,133
Cohort,-0.018929846519957858,0.03370377111581242,-0.5616536634702208,0.5745101067261135,LonGen OPEL,Down-regulated genes in non-neoplastic mucosa samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,81,94
Cohort,0.015762671295801667,0.02789143830747716,0.565143723390414,0.5721635124140885,LGP Offspring,Up-regulated genes in non-neoplastic mucosa samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,22,49
Cohort,-0.1427602363850522,0.07732576140728158,-1.8462183079339043,0.06521469375006002,LGP Proband,Up-regulated genes in non-neoplastic mucosa samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,22,81
Cohort,0.04374468570490925,0.023361874875424325,1.8724818079959307,0.061506370720847546,LonGen OPEL,Up-regulated genes in non-neoplastic mucosa samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,33,58
Cohort,-0.002360969772289239,0.02474964407380471,-0.09539408992099871,0.9240300806385728,LGP Offspring,Down-regulated genes in tumor samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,19,41
Cohort,-0.019708647209266995,0.07297292053145064,-0.27008165584893584,0.7871642499612457,LGP Proband,Down-regulated genes in tumor samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,19,64
Cohort,0.016515870664931216,0.021030708017715685,0.7853216663470723,0.43249867362692707,LonGen OPEL,Down-regulated genes in tumor samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,26,39
Cohort,0.0183721979406635,0.018047940552648228,1.0179664481423445,0.3090580816194103,LGP Offspring,Up-regulated genes in tumor samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,7,24
Cohort,0.07188292610190995,0.0450771870317405,1.5946630842624354,0.11116646006066166,LGP Proband,Up-regulated genes in tumor samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,7,23
Cohort,0.0038945549138880695,0.013554835139117198,0.28731850103060086,0.7739432370075684,LonGen OPEL,Up-regulated genes in tumor samples from colon cancer patients who developed recurrence of the disease.,CGP,C2,12,16
Cohort,0.0021599946333703797,0.025897910883557418,0.08340420364724323,0.9335548372390945,LGP Offspring,"Down-regulated genes from the 70-gene prognosis predictor for stage 2 colon cancer, based on non-neoplastic mucosa gene expression profiles.",CGP,C2,20,49
Cohort,-0.05133835995529456,0.07187807701493373,-0.7142422569906574,0.47527723972626634,LGP Proband,"Down-regulated genes from the 70-gene prognosis predictor for stage 2 colon cancer, based on non-neoplastic mucosa gene expression profiles.",CGP,C2,20,70
Cohort,-0.029392952843856866,0.021319420143459392,-1.3786938221616858,0.16837649029061139,LonGen OPEL,"Down-regulated genes from the 70-gene prognosis predictor for stage 2 colon cancer, based on non-neoplastic mucosa gene expression profiles.",CGP,C2,35,35
Cohort,0.0029998908368569304,0.03393990836546463,0.08838830100995361,0.9295942369880698,LGP Offspring,"Up-regulated genes from the 70-gene prognosis predictor for stage 2 colon cancer, based on non-neoplastic mucosa gene expression profiles.",CGP,C2,37,70
Cohort,-0.04227600859125007,0.09475850208134025,-0.4461447539025104,0.6556084914449465,LGP Proband,"Up-regulated genes from the 70-gene prognosis predictor for stage 2 colon cancer, based on non-neoplastic mucosa gene expression profiles.",CGP,C2,37,96
Cohort,0.026211805161221655,0.02940596967808886,0.8913770043350328,0.37299630471545364,LonGen OPEL,"Up-regulated genes from the 70-gene prognosis predictor for stage 2 colon cancer, based on non-neoplastic mucosa gene expression profiles.",CGP,C2,53,70
Cohort,-0.34899890332609673,0.10491316908199949,-3.3265500068282305,9.268706621294732e-4,LGP Offspring,Genes down-regulated in SKOC-3 cells (ovarian cancer) after YB-1 (YBX1) [GeneID=4904] knockdown by RNAi.,CGP,C2,450,784
Cohort,-0.5321800614627394,0.30699032878003735,-1.733540152804141,0.08336928508944277,LGP Proband,Genes down-regulated in SKOC-3 cells (ovarian cancer) after YB-1 (YBX1) [GeneID=4904] knockdown by RNAi.,CGP,C2,450,1128
Cohort,0.03937646637098023,0.09538116975365225,0.4128327055820414,0.6798403607080195,LonGen OPEL,Genes down-regulated in SKOC-3 cells (ovarian cancer) after YB-1 (YBX1) [GeneID=4904] knockdown by RNAi.,CGP,C2,624,762
Cohort,-0.02062967913732282,0.09019024061620685,-0.22873516021661155,0.8191439434672586,LGP Offspring,Genes up-regulated in SKOC-3 cells (ovarian cancer) after YB-1 (YBX1) [GeneID=4904] knockdown by RNAi.,CGP,C2,248,500
Cohort,-0.11300202379294795,0.2430048107500428,-0.4650196983514988,0.6420387368950278,LGP Proband,Genes up-regulated in SKOC-3 cells (ovarian cancer) after YB-1 (YBX1) [GeneID=4904] knockdown by RNAi.,CGP,C2,248,690
Cohort,0.0772344398663122,0.07137449333669746,1.0821014098407873,0.27953516721602517,LonGen OPEL,Genes up-regulated in SKOC-3 cells (ovarian cancer) after YB-1 (YBX1) [GeneID=4904] knockdown by RNAi.,CGP,C2,371,490
Cohort,-0.04713729647533133,0.06744610571365339,-0.6988883342717463,0.48486219261874897,LGP Offspring,Genes which comprise the top 1% of highly interconnected genes (major hubs) that account for most of gene interactions in the reconstructed regulatory networks from expression profiles in B lymphocytes.,CGP,C2,150,288
Cohort,-0.24467576671964272,0.17045135701992975,-1.43545801569086,0.15153154777432798,LGP Proband,Genes which comprise the top 1% of highly interconnected genes (major hubs) that account for most of gene interactions in the reconstructed regulatory networks from expression profiles in B lymphocytes.,CGP,C2,150,379
Cohort,-0.008272675078843697,0.057550456483470736,-0.14374647195404472,0.8857370552531352,LonGen OPEL,Genes which comprise the top 1% of highly interconnected genes (major hubs) that account for most of gene interactions in the reconstructed regulatory networks from expression profiles in B lymphocytes.,CGP,C2,214,255
Cohort,-0.08074614693113315,0.03756445846737859,-2.1495357640055968,0.03194619135186188,LGP Offspring,Gene down-regulated by CD40 [GeneID=958] signaling in Ramos cells (EBV negative Burkitt lymphoma).,CGP,C2,58,85
Cohort,-0.10349438096855162,0.11275944000059462,-0.9178334068349919,0.3589714371735888,LGP Proband,Gene down-regulated by CD40 [GeneID=958] signaling in Ramos cells (EBV negative Burkitt lymphoma).,CGP,C2,58,148
Cohort,0.011613716277315656,0.03409396678160282,0.3406384581679842,0.733465654480261,LonGen OPEL,Gene down-regulated by CD40 [GeneID=958] signaling in Ramos cells (EBV negative Burkitt lymphoma).,CGP,C2,77,96
Cohort,0.02598633688207951,0.04890588660437778,0.5313539675150958,0.5953480595196606,LGP Offspring,Gene up-regulated by CD40 [GeneID=958] signaling in Ramos cells (EBV negative Burkitt lymphoma).,CGP,C2,69,165
Cohort,-0.0038000579664209137,0.12189984123948627,-0.031173608823290115,0.9751385452076027,LGP Proband,Gene up-regulated by CD40 [GeneID=958] signaling in Ramos cells (EBV negative Burkitt lymphoma).,CGP,C2,69,191
Cohort,0.0014216779511747634,0.041935040134413355,0.033901909873411205,0.9729638692897615,LonGen OPEL,Gene up-regulated by CD40 [GeneID=958] signaling in Ramos cells (EBV negative Burkitt lymphoma).,CGP,C2,119,140
Cohort,0.0015100996459548497,0.0032272208876156674,0.4679257164422173,0.6399885312399896,LGP Offspring,Genes down-regulated in hairy cell leukemia (HCL) compared with normal and other neoplastic B cell populations.,CGP,C2,0,1
Cohort,-0,0,NA,NA,LGP Proband,Genes down-regulated in hairy cell leukemia (HCL) compared with normal and other neoplastic B cell populations.,CGP,C2,0,0
Cohort,0.0025130385468253185,0.0025939526809787066,0.9688066267566381,0.3329359485026081,LonGen OPEL,Genes down-regulated in hairy cell leukemia (HCL) compared with normal and other neoplastic B cell populations.,CGP,C2,0,1
Cohort,0.04971879755663225,0.05344653926577228,0.9302528889550139,0.35257223726623443,LGP Offspring,Genes up-regulated in hairy cell leukemia (HCL) compared with normal and other neoplastic B cell populations.,CGP,C2,80,182
Cohort,-0.1754278143786603,0.14179978347838845,-1.2371514968173212,0.21637906764842643,LGP Proband,Genes up-regulated in hairy cell leukemia (HCL) compared with normal and other neoplastic B cell populations.,CGP,C2,80,242
Cohort,-0.005572450441638514,0.04234380596497215,-0.13160013169926632,0.8953338358564944,LonGen OPEL,Genes up-regulated in hairy cell leukemia (HCL) compared with normal and other neoplastic B cell populations.,CGP,C2,128,156
Cohort,-0.02783247929019287,0.019122634361431714,-1.4554730673681642,0.14600255999203818,LGP Offspring,Genes down-regulated in pyloric atrium with knockout of TFF2 [GeneID=7032].,CGP,C2,16,23
Cohort,-0.02753877541340878,0.05177827902669643,-0.5318596123909415,0.594964871790777,LGP Proband,Genes down-regulated in pyloric atrium with knockout of TFF2 [GeneID=7032].,CGP,C2,16,30
Cohort,-0.0156708631681281,0.016378087721750357,-0.9568188566554657,0.33894919431185433,LonGen OPEL,Genes down-regulated in pyloric atrium with knockout of TFF2 [GeneID=7032].,CGP,C2,21,19
Cohort,-0.014045988405326388,0.03529837158016775,-0.3979217107346128,0.6908135256837249,LGP Offspring,Genes up-regulated in pyloric atrium with knockout of TFF2 [GeneID=7032].,CGP,C2,39,78
Cohort,-0.10680326140879225,0.09499873428081236,-1.1242598358530356,0.2612262904601118,LGP Proband,Genes up-regulated in pyloric atrium with knockout of TFF2 [GeneID=7032].,CGP,C2,39,113
Cohort,-0.009979389887147968,0.02870977477105367,-0.3475955477438849,0.7282358400710445,LonGen OPEL,Genes up-regulated in pyloric atrium with knockout of TFF2 [GeneID=7032].,CGP,C2,65,73
Cohort,-0.01961438879621881,0.042306661121666145,-0.4636241262294713,0.6430663058868675,LGP Offspring,Genes down-regulated in a breast cancer cell line resistant to tamoxifen [PubChem=5376] compared to the parental line sensitive to the drug.,CGP,C2,61,110
Cohort,0.0972569895217677,0.11954579383480263,0.8135542573431294,0.4161325522536108,LGP Proband,Genes down-regulated in a breast cancer cell line resistant to tamoxifen [PubChem=5376] compared to the parental line sensitive to the drug.,CGP,C2,61,164
Cohort,0.034587684889104776,0.036057649770224964,0.959232925870448,0.33773267990247413,LonGen OPEL,Genes down-regulated in a breast cancer cell line resistant to tamoxifen [PubChem=5376] compared to the parental line sensitive to the drug.,CGP,C2,77,105
Cohort,-0.020422482340969262,0.02814687087893048,-0.725568480731428,0.4683544524616524,LGP Offspring,Genes up-regulated in a breast cancer cell line resistant to tamoxifen [PubChem=5376] compared to the parental line sensitive to the drug.,CGP,C2,27,46
Cohort,0.07845659594279396,0.08650028025115394,0.9070097312401172,0.36466363365879784,LGP Proband,Genes up-regulated in a breast cancer cell line resistant to tamoxifen [PubChem=5376] compared to the parental line sensitive to the drug.,CGP,C2,27,87
Cohort,0.018982149464162105,0.02401384944335606,0.7904667474882465,0.4294906662900909,LonGen OPEL,Genes up-regulated in a breast cancer cell line resistant to tamoxifen [PubChem=5376] compared to the parental line sensitive to the drug.,CGP,C2,38,52
Cohort,0.010442725645996118,0.018255961971349734,0.5720172764593049,0.5675004316357617,LGP Offspring,Genes up-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] but down-regulated by PAX3 expression off adenoviral vectors.,CGP,C2,9,23
Cohort,-0.07291589509422962,0.04788381895389323,-1.5227669113952562,0.1281960916988113,LGP Proband,Genes up-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] but down-regulated by PAX3 expression off adenoviral vectors.,CGP,C2,9,29
Cohort,-0.027007952477075648,0.013657787109825171,-1.9774764579282835,0.04833237921929415,LonGen OPEL,Genes up-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] but down-regulated by PAX3 expression off adenoviral vectors.,CGP,C2,18,11
Cohort,-0.05148779439984358,0.048633302914098266,-1.0586941728137866,0.29011722744502794,LGP Offspring,Genes down-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] fusion protein off an adenoviral vector.,CGP,C2,79,146
Cohort,-0.016674235196885004,0.13525517730174283,-0.12327982950098981,0.9019152150536551,LGP Proband,Genes down-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] fusion protein off an adenoviral vector.,CGP,C2,79,208
Cohort,-0.0344110490801535,0.043758345289795594,-0.7863882615364371,0.4318740999581573,LonGen OPEL,Genes down-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] fusion protein off an adenoviral vector.,CGP,C2,138,156
Cohort,-0.0424759429667966,0.047456545252028644,-0.895049202195789,0.37107936332393554,LGP Offspring,Genes up-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] fusion protein off an adenoviral vector.,CGP,C2,87,164
Cohort,0.19906696542274546,0.13293335165342365,1.4974945184692374,0.134642988905966,LGP Proband,Genes up-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] fusion protein off an adenoviral vector.,CGP,C2,87,218
Cohort,-0.04664671449243106,0.038198549157594484,-1.2211645604649082,0.22238528858454687,LonGen OPEL,Genes up-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] fusion protein off an adenoviral vector.,CGP,C2,124,128
Cohort,-0.09239898170114275,0.04950531948850825,-1.8664455184980975,0.0624118188639519,LGP Offspring,Genes down-regulated in cancer stem cells derived from glyoblastoma tumors: CD133+ [GeneID=8842]  vs. CD133- cells.,CGP,C2,86,145
Cohort,0.034543012251784175,0.12699499200792097,0.2720029483495668,0.7856870734642997,LGP Proband,Genes down-regulated in cancer stem cells derived from glyoblastoma tumors: CD133+ [GeneID=8842]  vs. CD133- cells.,CGP,C2,86,181
Cohort,-0.017264534201611385,0.03758327355140741,-0.4593674943721039,0.6460957089805158,LonGen OPEL,Genes down-regulated in cancer stem cells derived from glyoblastoma tumors: CD133+ [GeneID=8842]  vs. CD133- cells.,CGP,C2,106,117
Cohort,-0.04575549190465245,0.04343934513853455,-1.053319099510625,0.29257110985355467,LGP Offspring,Genes up-regulated in cancer stem cells derived from glyoblastoma tumors: CD133+ [GeneID=8842]  vs. CD133- cells.,CGP,C2,67,124
Cohort,0.003609921949718079,0.11715772059793687,0.030812497301024214,0.975426445685655,LGP Proband,Genes up-regulated in cancer stem cells derived from glyoblastoma tumors: CD133+ [GeneID=8842]  vs. CD133- cells.,CGP,C2,67,179
Cohort,-0.011401161745832198,0.040036568246537195,-0.2847687063393176,0.7758954183983569,LonGen OPEL,Genes up-regulated in cancer stem cells derived from glyoblastoma tumors: CD133+ [GeneID=8842]  vs. CD133- cells.,CGP,C2,115,130
Cohort,-0.0332740784398664,0.03360976402284465,-0.9900122600459175,0.32252234857180284,LGP Offspring,"102 proteins were identified that were specifically and significantly accumulated after proteasome inhibition with carfilzomibin the PTEN-KO GBM spheres compared with placebo-treated and were not statistically present in the PTEN-WT drug vs placebo group at the proteomic level, this proteomic signature was then coorelated with the RNA-level transcriptomic response to carfilzomib using GSEA. The leading edge of the enrichment result was selected as the response signature.",CGP,C2,41,76
Cohort,0.027955752454094596,0.1008596539517047,0.27717478058650524,0.7817145883982206,LGP Proband,"102 proteins were identified that were specifically and significantly accumulated after proteasome inhibition with carfilzomibin the PTEN-KO GBM spheres compared with placebo-treated and were not statistically present in the PTEN-WT drug vs placebo group at the proteomic level, this proteomic signature was then coorelated with the RNA-level transcriptomic response to carfilzomib using GSEA. The leading edge of the enrichment result was selected as the response signature.",CGP,C2,41,111
Cohort,0.024628143352486868,0.029650673584840328,0.830609911171753,0.40644309009588964,LonGen OPEL,"102 proteins were identified that were specifically and significantly accumulated after proteasome inhibition with carfilzomibin the PTEN-KO GBM spheres compared with placebo-treated and were not statistically present in the PTEN-WT drug vs placebo group at the proteomic level, this proteomic signature was then coorelated with the RNA-level transcriptomic response to carfilzomib using GSEA. The leading edge of the enrichment result was selected as the response signature.",CGP,C2,48,72
Cohort,-0.007621112575449696,0.02293516826565777,-0.33228936832616374,0.7397737751862803,LGP Offspring,Genes significantly up-regulated in the blood mononuclear cells from patients with systemic lupus erythematosus compared to those from healthy persons.,CGP,C2,20,35
Cohort,-0.055421622439556215,0.05723631055504581,-0.9682948097476626,0.3331778682420635,LGP Proband,Genes significantly up-regulated in the blood mononuclear cells from patients with systemic lupus erythematosus compared to those from healthy persons.,CGP,C2,20,33
Cohort,-0.013587897332549673,0.020349542110099896,-0.6677249669320923,0.5045027110142377,LonGen OPEL,Genes significantly up-regulated in the blood mononuclear cells from patients with systemic lupus erythematosus compared to those from healthy persons.,CGP,C2,32,30
Cohort,-0.15862390158372217,0.13461622839105236,-1.1783415972918874,0.23907506905565257,LGP Offspring,Genes showing cell-cycle stage-specific expression [PMID=12058064].,CGP,C2,616,1201
Cohort,-0.4411984460847753,0.37932648345050396,-1.1631100525105957,0.24511753085162746,LGP Proband,Genes showing cell-cycle stage-specific expression [PMID=12058064].,CGP,C2,616,1681
Cohort,0.09700529862097375,0.11862073362785494,0.8177769235967246,0.41372929146834425,LonGen OPEL,Genes showing cell-cycle stage-specific expression [PMID=12058064].,CGP,C2,915,1140
Cohort,-0.14306509206515763,0.17143497455824142,-0.834515199910706,0.40428553091624686,LGP Offspring,Set 'Eed targets': genes identified by ChIP on chip as targets of the Polycomb protein EED [GeneID=8726] in human embryonic stem cells.,CGP,C2,946,1937
Cohort,0.3255722278110233,0.48030494252553885,0.6778448418604643,0.4980580813772426,LGP Proband,Set 'Eed targets': genes identified by ChIP on chip as targets of the Polycomb protein EED [GeneID=8726] in human embryonic stem cells.,CGP,C2,946,2822
Cohort,-0.09520306806660805,0.14790727138097873,-0.6436672597480655,0.5199766246152481,LonGen OPEL,Set 'Eed targets': genes identified by ChIP on chip as targets of the Polycomb protein EED [GeneID=8726] in human embryonic stem cells.,CGP,C2,1517,1782
Cohort,-0.39015807537829195,0.10700376931449064,-3.646208707205383,2.8658867968182585e-4,LGP Offspring,Set 'ES exp1': genes overexpressed in human embryonic stem cells according to 5 or more out of 20 profiling studies.,CGP,C2,401,671
Cohort,-0.29041400703440673,0.29181063160518345,-0.9952139352733853,0.31992088019747505,LGP Proband,Set 'ES exp1': genes overexpressed in human embryonic stem cells according to 5 or more out of 20 profiling studies.,CGP,C2,401,983
Cohort,0.11834295679997725,0.09400723033197218,1.2588707951725326,0.20844606374564512,LonGen OPEL,Set 'ES exp1': genes overexpressed in human embryonic stem cells according to 5 or more out of 20 profiling studies.,CGP,C2,537,693
Cohort,-0.033891238916865685,0.037192257539303226,-0.9112444675091539,0.3624914002561088,LGP Offspring,Set 'Set 'ES exp2': genes overexpressed in human embryonic stem cells according to a meta-analysis of 8 profiling studies.,CGP,C2,53,89
Cohort,-0.22154868111778162,0.11230434750777024,-1.9727524894123343,0.04885366770152756,LGP Proband,Set 'Set 'ES exp2': genes overexpressed in human embryonic stem cells according to a meta-analysis of 8 profiling studies.,CGP,C2,53,158
Cohort,0.03140743409327112,0.034357636867038,0.9141325468575155,0.3609240105966395,LonGen OPEL,Set 'Set 'ES exp2': genes overexpressed in human embryonic stem cells according to a meta-analysis of 8 profiling studies.,CGP,C2,82,103
Cohort,-0.0012872037427820993,0.012351365548160381,-0.10421550052607877,0.9170292446370516,LGP Offspring,"Set 'Core 9': 'embryonic stem cell' transcription regulators that are preferentially and coordinately overexpressed in the high-grade, ER-negative breast cancer tumors.",CGP,C2,5,10
Cohort,-0.029643913338867397,0.024241792993093248,-1.2228432668867881,0.22173433421621308,LGP Proband,"Set 'Core 9': 'embryonic stem cell' transcription regulators that are preferentially and coordinately overexpressed in the high-grade, ER-negative breast cancer tumors.",CGP,C2,5,5
Cohort,0.006476999959137645,0.011462122942498008,0.5650785628134324,0.5721795482103649,LonGen OPEL,"Set 'Core 9': 'embryonic stem cell' transcription regulators that are preferentially and coordinately overexpressed in the high-grade, ER-negative breast cancer tumors.",CGP,C2,8,12
Cohort,-0.09150932746660821,0.044585543060939314,-2.052443935504692,0.04051104391221112,LGP Offspring,"Breast cancer compendium: 100 transcription regulators showing most correlated expression with the 9 'embryonic stem cell' transcription factors that are preferentially and coordinately overexpressed in the high-grade, ER-negative breast cancer tumors.",CGP,C2,75,119
Cohort,0.0037582026958455804,0.1214350967604244,0.030948241456586673,0.9753182216566403,LGP Proband,"Breast cancer compendium: 100 transcription regulators showing most correlated expression with the 9 'embryonic stem cell' transcription factors that are preferentially and coordinately overexpressed in the high-grade, ER-negative breast cancer tumors.",CGP,C2,75,170
Cohort,0.07605558691094283,0.03968714288362734,1.9163784889720303,0.05567477142912542,LonGen OPEL,"Breast cancer compendium: 100 transcription regulators showing most correlated expression with the 9 'embryonic stem cell' transcription factors that are preferentially and coordinately overexpressed in the high-grade, ER-negative breast cancer tumors.",CGP,C2,87,135
Cohort,-0.38462538527995105,0.1765811185712163,-2.1781795720408756,0.029737543981152113,LGP Offspring,"Set 'H3K27 bound': genes posessing the trimethylated H3K27 (H3K27me3) mark in their promoters in human embryonic stem cells, as identified by ChIP on chip.",CGP,C2,1098,2156
Cohort,0.5825234089041385,0.5167395304258108,1.1273056822730778,0.2599374845029244,LGP Proband,"Set 'H3K27 bound': genes posessing the trimethylated H3K27 (H3K27me3) mark in their promoters in human embryonic stem cells, as identified by ChIP on chip.",CGP,C2,1098,3162
Cohort,-0.172557810218145,0.15202850018618524,-1.1350359308078293,0.25670192313069046,LonGen OPEL,"Set 'H3K27 bound': genes posessing the trimethylated H3K27 (H3K27me3) mark in their promoters in human embryonic stem cells, as identified by ChIP on chip.",CGP,C2,1711,1990
Cohort,-0.09973337581947511,0.13484933985928316,-0.7395911312843507,0.45980487344249876,LGP Offspring,Set 'Myc targets2': targets of c-Myc [GeneID=4609] and Max [GeneID=4149] identified by ChIP on chip in a Burkitt's lymphoma cell line; overlap set.,CGP,C2,550,1106
Cohort,-0.44077482514678334,0.37111565509404065,-1.1877020521677832,0.23528895561157964,LGP Proband,Set 'Myc targets2': targets of c-Myc [GeneID=4609] and Max [GeneID=4149] identified by ChIP on chip in a Burkitt's lymphoma cell line; overlap set.,CGP,C2,550,1632
Cohort,-0.1652421751023274,0.11716444294027234,-1.410344051109123,0.15882875783199532,LonGen OPEL,Set 'Myc targets2': targets of c-Myc [GeneID=4609] and Max [GeneID=4149] identified by ChIP on chip in a Burkitt's lymphoma cell line; overlap set.,CGP,C2,917,1024
Cohort,0.06822997212459621,0.0737739783117423,0.9248514677666003,0.35537319610448315,LGP Offspring,"Set 'Myc targets1': targets of c-Myc [GeneID=4609] identified by ChIP on chip in cultured cell lines, focusing on E-box-containing genes; high affinity bound subset",CGP,C2,182,410
Cohort,0.3517543600918082,0.21370418108206088,1.6459872629105794,0.10014314538768897,LGP Proband,"Set 'Myc targets1': targets of c-Myc [GeneID=4609] identified by ChIP on chip in cultured cell lines, focusing on E-box-containing genes; high affinity bound subset",CGP,C2,182,531
Cohort,-0.055063687275522286,0.07178577243502134,-0.7670557188106395,0.4432758307615815,LonGen OPEL,"Set 'Myc targets1': targets of c-Myc [GeneID=4609] identified by ChIP on chip in cultured cell lines, focusing on E-box-containing genes; high affinity bound subset",CGP,C2,348,394
Cohort,-0.4832965150516855,0.16885220198700954,-2.8622458538554767,0.004336639455215902,LGP Offspring,Set 'Nanog targets': genes upregulated and identified by ChIP on chip as Nanog [GeneID=79923] transcription factor targets in human embryonic stem cells.,CGP,C2,933,1734
Cohort,-0.28405683512050217,0.4803117964026243,-0.5914009134233085,0.5544120845889433,LGP Proband,Set 'Nanog targets': genes upregulated and identified by ChIP on chip as Nanog [GeneID=79923] transcription factor targets in human embryonic stem cells.,CGP,C2,933,2550
Cohort,-0.11468676530655192,0.13836055351936838,-0.8288978497798327,0.40741069003074437,LonGen OPEL,Set 'Nanog targets': genes upregulated and identified by ChIP on chip as Nanog [GeneID=79923] transcription factor targets in human embryonic stem cells.,CGP,C2,1400,1655
Cohort,-0.10190062245598078,0.07733955899341598,-1.3175743924872356,0.18809252707669477,LGP Offspring,"Set 'NOS targets': genes upregulated and identified by ChIP on chip as targets of the transcription factors NANOG , OCT4, and Sox2 [GeneID=79923;5460;6657] (NOS) in human embryonic stem cells.",CGP,C2,197,364
Cohort,-0.1351782918344697,0.1974031604111121,-0.6847828147885129,0.4936712396337922,LGP Proband,"Set 'NOS targets': genes upregulated and identified by ChIP on chip as targets of the transcription factors NANOG , OCT4, and Sox2 [GeneID=79923;5460;6657] (NOS) in human embryonic stem cells.",CGP,C2,197,480
Cohort,-0.019907804134502684,0.06118097512621761,-0.32539206989480757,0.7449698664237181,LonGen OPEL,"Set 'NOS targets': genes upregulated and identified by ChIP on chip as targets of the transcription factors NANOG , OCT4, and Sox2 [GeneID=79923;5460;6657] (NOS) in human embryonic stem cells.",CGP,C2,288,345
Cohort,-0.10796455718610169,0.09373191324211172,-1.1518441633344956,0.24979231357819412,LGP Offspring,Set 'Oct4 targets': genes upregulated and identified by ChIP on chip as OCT4 [GeneID=5460] transcription factor targets in human embryonic stem cells.,CGP,C2,283,548
Cohort,-0.08472011988236001,0.24839490466391911,-0.3410702807973747,0.7331365786616746,LGP Proband,Set 'Oct4 targets': genes upregulated and identified by ChIP on chip as OCT4 [GeneID=5460] transcription factor targets in human embryonic stem cells.,CGP,C2,283,719
Cohort,-0.03627020721394952,0.07602403896936957,-0.47708866439683567,0.6334299404232266,LonGen OPEL,Set 'Oct4 targets': genes upregulated and identified by ChIP on chip as OCT4 [GeneID=5460] transcription factor targets in human embryonic stem cells.,CGP,C2,438,517
Cohort,0.03474808030573434,0.14075097380944956,0.2468763047620312,0.8050789077096075,LGP Offspring,Set 'PRC2 targets': Polycomb Repression Complex 2 (PRC) targets; identified by ChIP on chip on human embryonic stem cells as genes that: posess the trimethylated H3K27 mark in their promoters and are bound by SUZ12 [GeneID=23512] and EED [GeneID=8726] Polycomb proteins.,CGP,C2,598,1281
Cohort,0.3668281055327789,0.37600737366554104,0.9755875315867419,0.3295517886270404,LGP Proband,Set 'PRC2 targets': Polycomb Repression Complex 2 (PRC) targets; identified by ChIP on chip on human embryonic stem cells as genes that: posess the trimethylated H3K27 mark in their promoters and are bound by SUZ12 [GeneID=23512] and EED [GeneID=8726] Polycomb proteins.,CGP,C2,598,1829
Cohort,-0.025928456006165133,0.11958849453283975,-0.21681396782735665,0.828408881483554,LonGen OPEL,Set 'PRC2 targets': Polycomb Repression Complex 2 (PRC) targets; identified by ChIP on chip on human embryonic stem cells as genes that: posess the trimethylated H3K27 mark in their promoters and are bound by SUZ12 [GeneID=23512] and EED [GeneID=8726] Polycomb proteins.,CGP,C2,976,1159
Cohort,-0.06708997989418844,0.054002209782672485,-1.2423561954998994,0.2145359689499461,LGP Offspring,Set 'Proliferation Cluster': genes defined in human breast tumor expression data.,CGP,C2,110,183
Cohort,-0.24288559585527067,0.1481982218178585,-1.6389238202452032,0.10160627388791481,LGP Proband,Set 'Proliferation Cluster': genes defined in human breast tumor expression data.,CGP,C2,110,270
Cohort,-0.016198595799193697,0.04637815535342594,-0.34927210182793766,0.7269774158375854,LonGen OPEL,Set 'Proliferation Cluster': genes defined in human breast tumor expression data.,CGP,C2,153,185
Cohort,-0.227584399032589,0.14324944400133457,-1.5887279746123744,0.11258938599386167,LGP Offspring,Set 'Sox2 targets': genes upregulated and identified by ChIP on chip as SOX2 [GeneID=6657] transcription factor targets in human embryonic stem cells.,CGP,C2,634,1248
Cohort,0.1082122959554948,0.3800631138026417,0.28472191071845776,0.7759278857563897,LGP Proband,Set 'Sox2 targets': genes upregulated and identified by ChIP on chip as SOX2 [GeneID=6657] transcription factor targets in human embryonic stem cells.,CGP,C2,634,1781
Cohort,-0.08845760844513695,0.11859127835621022,-0.7459031530079187,0.45594613171385323,LonGen OPEL,Set 'Sox2 targets': genes upregulated and identified by ChIP on chip as SOX2 [GeneID=6657] transcription factor targets in human embryonic stem cells.,CGP,C2,986,1166
Cohort,-0.06650495905131959,0.1715516384298521,-0.3876672916680632,0.6983842958084254,LGP Offspring,Set 'Suz12 targets': genes identified by ChIP on chip as targets of the Polycomb protein SUZ12 [GeneID=23512] in human embryonic stem cells.,CGP,C2,909,1903
Cohort,0.5915300661704692,0.4674702173175709,1.2653855673732035,0.2060865537366687,LGP Proband,Set 'Suz12 targets': genes identified by ChIP on chip as targets of the Polycomb protein SUZ12 [GeneID=23512] in human embryonic stem cells.,CGP,C2,909,2739
Cohort,-0.09516830206112974,0.1484511834482881,-0.6410747280723493,0.5216586579418646,LonGen OPEL,Set 'Suz12 targets': genes identified by ChIP on chip as targets of the Polycomb protein SUZ12 [GeneID=23512] in human embryonic stem cells.,CGP,C2,1479,1734
Cohort,0.03595768736161374,0.04400075425190909,0.817206158688828,0.414098536778564,LGP Offspring,"Genes down-regulated in NIH3T3 cells (fibroblasts) after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins; the changes did not depend on expression of constitutively active (Q63L) form of RHOA [GeneID=387].",CGP,C2,55,125
Cohort,-0.12775484302813722,0.11878452660803812,-1.0755175499389673,0.28245411508204515,LGP Proband,"Genes down-regulated in NIH3T3 cells (fibroblasts) after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins; the changes did not depend on expression of constitutively active (Q63L) form of RHOA [GeneID=387].",CGP,C2,55,170
Cohort,-0.019380474737122132,0.036858603964292594,-0.5258059897194506,0.5991694600107464,LonGen OPEL,"Genes down-regulated in NIH3T3 cells (fibroblasts) after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins; the changes did not depend on expression of constitutively active (Q63L) form of RHOA [GeneID=387].",CGP,C2,100,106
Cohort,-0.010396588833039873,0.03119756913216906,-0.3332499653737296,0.7390489368707329,LGP Offspring,"Genes up-regulated in NIH3T3 cells (fibroblasts) after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins; the changes did not depend on expression of constitutively active (Q63L) form of RHOA [GeneID=387].",CGP,C2,29,61
Cohort,0.0019792739421179975,0.08020998623366052,0.024676153619477687,0.9803191787474737,LGP Proband,"Genes up-regulated in NIH3T3 cells (fibroblasts) after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins; the changes did not depend on expression of constitutively active (Q63L) form of RHOA [GeneID=387].",CGP,C2,29,72
Cohort,-0.03743324642738761,0.025544129078613836,-1.4654344374859751,0.14319730080851995,LonGen OPEL,"Genes up-regulated in NIH3T3 cells (fibroblasts) after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins; the changes did not depend on expression of constitutively active (Q63L) form of RHOA [GeneID=387].",CGP,C2,55,46
Cohort,-0.08329743265196424,0.11628941696004244,-0.7162941807558086,0.47405709015890374,LGP Offspring,Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector.,CGP,C2,424,854
Cohort,-0.61565835041414,0.30757607722802416,-2.001645758547458,0.045646342316166225,LGP Proband,Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector.,CGP,C2,424,1188
Cohort,-0.03779048694205521,0.10032462803051646,-0.3766820538877075,0.7065102883175393,LonGen OPEL,Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector.,CGP,C2,701,835
Cohort,-0.016271256781497954,0.03362293591176173,-0.4839332539014258,0.6285899682478264,LGP Offspring,"Genes down-regulated in NIH3T3 cells (fibroblasts) transfrormed by expression of constitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression did NOT reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,38,74
Cohort,-0.01003766481279166,0.08738170053542584,-0.11487147482008825,0.9085746447557013,LGP Proband,"Genes down-regulated in NIH3T3 cells (fibroblasts) transfrormed by expression of constitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression did NOT reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,38,96
Cohort,0.025857017330347735,0.03130884002353556,0.825869540708325,0.4091255548404389,LonGen OPEL,"Genes down-regulated in NIH3T3 cells (fibroblasts) transfrormed by expression of constitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression did NOT reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,58,85
Cohort,-0.01737621032154024,0.017962412656446526,-0.9673650557907706,0.33370752836139783,LGP Offspring,"Genes up-regulated in NIH3T3 cells (fibroblasts) transfrormed by expression of constitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression did NOT reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,13,20
Cohort,-0.040214018867949244,0.05320862835486978,-0.7557800325117526,0.4499944940144638,LGP Proband,"Genes up-regulated in NIH3T3 cells (fibroblasts) transfrormed by expression of constitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression did NOT reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,13,36
Cohort,0.0139035169746786,0.01637599950989652,0.8490179159004174,0.39612657869450485,LonGen OPEL,"Genes up-regulated in NIH3T3 cells (fibroblasts) transfrormed by expression of constitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression did NOT reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,17,23
Cohort,-0.004656761913908984,0.026852181179960258,-0.17342210983532014,0.862371562388889,LGP Offspring,"Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,27,48
Cohort,-0.022284140251245105,0.08516130888481732,-0.26166977167277844,0.7936406564729904,LGP Proband,"Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,27,93
Cohort,-0.05395808733003198,0.02408241041020609,-2.240560077290462,0.025329680518718516,LonGen OPEL,"Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,52,41
Cohort,-0.004381464373807965,0.010984520968789593,-0.39887623559161617,0.6901103663332193,LGP Offspring,"Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,5,7
Cohort,-0.029353672125336752,0.03408531997186936,-0.8611822376777557,0.38938519876866873,LGP Proband,"Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,5,14
Cohort,0.012401321441129692,0.012268607132112795,1.0108173900743402,0.31241099469727013,LonGen OPEL,"Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.",CGP,C2,8,15
Cohort,-0.28419827432529704,0.1239220241118097,-2.2933637209546927,0.022133105057462812,LGP Offspring,Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector.,CGP,C2,487,903
Cohort,-0.4412737227979506,0.33149955443948725,-1.3311442410354786,0.18350531552851287,LGP Proband,Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector.,CGP,C2,487,1296
Cohort,-0.05026309283149369,0.10360117734507213,-0.4851594752063355,0.6276967182878473,LonGen OPEL,Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector.,CGP,C2,727,856
Cohort,0.012587270729487128,0.011494569572048415,1.095062381465406,0.27387930889769185,LGP Offspring,Genes strongly up-regulated in colon tissue upon MBD2 [GeneID=8932] knockout.,CGP,C2,3,10
Cohort,0.006709339263681899,0.0352501489592435,0.19033506131957884,0.8490928993229856,LGP Proband,Genes strongly up-regulated in colon tissue upon MBD2 [GeneID=8932] knockout.,CGP,C2,3,18
Cohort,-0.0038036492680885267,0.016605769825654693,-0.22905588286621728,0.8188843195654888,LonGen OPEL,Genes strongly up-regulated in colon tissue upon MBD2 [GeneID=8932] knockout.,CGP,C2,18,27
Cohort,-0.039384237356830935,0.04587662528724741,-0.8584815711756113,0.39093088913227103,LGP Offspring,"Genes down-regulated in ZR-75-1 cells (breast cancer, amplified 8p11-12 region) upon knockdown of PPAPDC1B [GeneID=84513] by RNAi.",CGP,C2,74,140
Cohort,0.25025671218927026,0.1294557785663871,1.9331443907769201,0.0535566067689859,LGP Proband,"Genes down-regulated in ZR-75-1 cells (breast cancer, amplified 8p11-12 region) upon knockdown of PPAPDC1B [GeneID=84513] by RNAi.",CGP,C2,74,222
Cohort,0.009821480288743769,0.044131703881450095,0.22254931092456726,0.8239433812063904,LonGen OPEL,"Genes down-regulated in ZR-75-1 cells (breast cancer, amplified 8p11-12 region) upon knockdown of PPAPDC1B [GeneID=84513] by RNAi.",CGP,C2,132,158
Cohort,-0.01491326140127229,0.039801653606406,-0.3746894927720297,0.7080089197690278,LGP Offspring,"Genes up-regulated in ZR-75-1 cells (breast cancer, amplified 8p11-12 region) upon knockdown of PPAPDC1B [GeneID=84513] by RNAi.",CGP,C2,51,102
Cohort,-0.021233183851664908,0.10737929341891099,-0.1977400220806952,0.8432966594799751,LGP Proband,"Genes up-regulated in ZR-75-1 cells (breast cancer, amplified 8p11-12 region) upon knockdown of PPAPDC1B [GeneID=84513] by RNAi.",CGP,C2,51,137
Cohort,-0.024614515674294676,0.03363087748417047,-0.7319022730192022,0.4644436418936543,LonGen OPEL,"Genes up-regulated in ZR-75-1 cells (breast cancer, amplified 8p11-12 region) upon knockdown of PPAPDC1B [GeneID=84513] by RNAi.",CGP,C2,84,91
Cohort,-0.0040507264142210925,0.03524287846929953,-0.11493744524158905,0.908528835417189,LGP Offspring,"Genes down-regulated in the invasive ductal carcinoma (IDC) compared to the invasive lobular carcinoma (ILC), the two major pathological types of breast cancer.",CGP,C2,41,86
Cohort,0.008777252222000768,0.1037625316729555,0.08458980405051601,0.9326078058206672,LGP Proband,"Genes down-regulated in the invasive ductal carcinoma (IDC) compared to the invasive lobular carcinoma (ILC), the two major pathological types of breast cancer.",CGP,C2,41,129
Cohort,-0.041579654683502804,0.033730238206605645,-1.232711563695982,0.21804734251904467,LonGen OPEL,"Genes down-regulated in the invasive ductal carcinoma (IDC) compared to the invasive lobular carcinoma (ILC), the two major pathological types of breast cancer.",CGP,C2,86,92
Cohort,-0.030431920398402583,0.02389295155254702,-1.273677734267138,0.20321540327989193,LGP Offspring,"Genes up-regulated in the invasive ductal carcinoma (IDC) compared to the invasive lobular carcinoma (ILC), the two major pathological types of breast cancer.",CGP,C2,24,35
Cohort,-0.06692847587163497,0.06794995653959045,-0.9849671623062729,0.32492585542616437,LGP Proband,"Genes up-regulated in the invasive ductal carcinoma (IDC) compared to the invasive lobular carcinoma (ILC), the two major pathological types of breast cancer.",CGP,C2,24,53
Cohort,0.002074189799284561,0.021946212740978344,0.09451242561827528,0.9247258977685244,LonGen OPEL,"Genes up-regulated in the invasive ductal carcinoma (IDC) compared to the invasive lobular carcinoma (ILC), the two major pathological types of breast cancer.",CGP,C2,31,38
Cohort,0.003794772154492228,0.07832162922179488,0.04845113913228252,0.9613710148437891,LGP Offspring,Genes down-regulated in medullary breast cancer (MBC) relative to ductal breast cancer (DBD).,CGP,C2,191,391
Cohort,-0.26519866641061274,0.2050193285606724,-1.2935300699325585,0.19618593095902082,LGP Proband,Genes down-regulated in medullary breast cancer (MBC) relative to ductal breast cancer (DBD).,CGP,C2,191,504
Cohort,-0.03750019248470567,0.06866111783325383,-0.5461634425436581,0.585106631515171,LonGen OPEL,Genes down-regulated in medullary breast cancer (MBC) relative to ductal breast cancer (DBD).,CGP,C2,310,353
Cohort,-0.03345741142133767,0.07507999292759496,-0.4456235292084146,0.6560118878990755,LGP Offspring,Genes up-regulated in medullary breast cancer (MBC) relative to ductal breast cancer (DBD).,CGP,C2,181,351
Cohort,-0.2851693487822015,0.20564899292238786,-1.3866800159328994,0.16590988882274613,LGP Proband,Genes up-regulated in medullary breast cancer (MBC) relative to ductal breast cancer (DBD).,CGP,C2,181,524
Cohort,0.060160488574357636,0.06689087324058336,0.8993826161901212,0.3687208830794594,LonGen OPEL,Genes up-regulated in medullary breast cancer (MBC) relative to ductal breast cancer (DBD).,CGP,C2,288,369
Cohort,-0.07159699706182882,0.04961464275447923,-1.4430618278585712,0.14946625973026875,LGP Offspring,Genes bound by ESR1 [GeneID=2099] and down-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer).,CGP,C2,95,168
Cohort,-0.21077763843230363,0.14207525612082017,-1.4835633183941561,0.13830260501312444,LGP Proband,Genes bound by ESR1 [GeneID=2099] and down-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer).,CGP,C2,95,221
Cohort,0.008918156820915233,0.04161314586945123,0.2143110460548519,0.8303593916852222,LonGen OPEL,Genes bound by ESR1 [GeneID=2099] and down-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer).,CGP,C2,124,154
Cohort,-0.1507911541947033,0.09900464049366985,-1.523071579703828,0.1282084389682774,LGP Offspring,Genes bound by ESR1 [GeneID=2099] and up-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer).,CGP,C2,297,574
Cohort,0.14802235781920212,0.27089807356149836,0.5464134752719036,0.5849278939095753,LGP Proband,Genes bound by ESR1 [GeneID=2099] and up-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer).,CGP,C2,297,829
Cohort,0.09257207543977795,0.08394823411132832,1.102728084988817,0.270478547070551,LonGen OPEL,Genes bound by ESR1 [GeneID=2099] and up-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer).,CGP,C2,453,592
Cohort,-0.07707877088253326,0.05331121507908988,-1.4458265632884753,0.14868929447617596,LGP Offspring,Genes bound by ESR1 [GeneID=2099] and down-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer) expressing constitutevly active form of AKT1 [GeneID=207].,CGP,C2,111,198
Cohort,-0.343519097556749,0.15180105101511218,-2.2629559891686837,0.02389477953414821,LGP Proband,Genes bound by ESR1 [GeneID=2099] and down-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer) expressing constitutevly active form of AKT1 [GeneID=207].,CGP,C2,111,273
Cohort,-0.08366961908980841,0.04969763944428865,-1.6835733049977666,0.09265624780400684,LonGen OPEL,Genes bound by ESR1 [GeneID=2099] and down-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer) expressing constitutevly active form of AKT1 [GeneID=207].,CGP,C2,186,193
Cohort,-0.06501888386289058,0.10836171888411408,-0.6000170958198264,0.5486959157744689,LGP Offspring,Genes bound by ESR1 [GeneID=2099] and up-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer) expressing constitutevly active form of AKT1 [GeneID=207].,CGP,C2,347,708
Cohort,0.24668733185287678,0.2966453822111833,0.8315899948082079,0.40587843859563855,LGP Proband,Genes bound by ESR1 [GeneID=2099] and up-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer) expressing constitutevly active form of AKT1 [GeneID=207].,CGP,C2,347,1020
Cohort,0.16794880939956064,0.09139354293235002,1.8376441487105628,0.06648741152458487,LonGen OPEL,Genes bound by ESR1 [GeneID=2099] and up-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer) expressing constitutevly active form of AKT1 [GeneID=207].,CGP,C2,552,734
Cohort,-0.009228866794385556,0.05604052990003782,-0.16468200445012793,0.8692435119294069,LGP Offspring,Down-regulated genes in MDA-MB-435 cells (breast cancer) undergoing G2/M arrest after treatment with 2-methoxyestradiol (2ME2) [PubChem=1573].,CGP,C2,108,225
Cohort,0.04246792143336851,0.15553240971286839,0.2730486945567771,0.7848833809142519,LGP Proband,Down-regulated genes in MDA-MB-435 cells (breast cancer) undergoing G2/M arrest after treatment with 2-methoxyestradiol (2ME2) [PubChem=1573].,CGP,C2,108,302
Cohort,0.08040114590079805,0.05121914097355127,1.5697480350620463,0.11687114224991457,LonGen OPEL,Down-regulated genes in MDA-MB-435 cells (breast cancer) undergoing G2/M arrest after treatment with 2-methoxyestradiol (2ME2) [PubChem=1573].,CGP,C2,155,230
Cohort,-0.06452934185403475,0.04557844216698513,-1.4157864724208753,0.15729858882054643,LGP Offspring,Up-regulated genes in MDA-MB-435 cells (breast cancer) undergoing G2/M arrest after treatment with 2-methoxyestradiol (2ME2)[PubChem=1573].,CGP,C2,77,125
Cohort,-0.2715726881669471,0.13763368286739244,-1.9731557167485116,0.04880763577999952,LGP Proband,Up-regulated genes in MDA-MB-435 cells (breast cancer) undergoing G2/M arrest after treatment with 2-methoxyestradiol (2ME2)[PubChem=1573].,CGP,C2,77,223
Cohort,-0.030687426896543846,0.04330059434782207,-0.7087068285954685,0.47871392266670254,LonGen OPEL,Up-regulated genes in MDA-MB-435 cells (breast cancer) undergoing G2/M arrest after treatment with 2-methoxyestradiol (2ME2)[PubChem=1573].,CGP,C2,124,133
Cohort,-0.007460073505477875,0.038699279636317606,-0.19277034548407762,0.8471967272793862,LGP Offspring,The 'stemnes' signature: genes up-regulated and common to 6 human embryonic stem cell lines tested.,CGP,C2,47,94
Cohort,-0.03867207789561325,0.09460217931839045,-0.40878633213574905,0.6828014155254098,LGP Proband,The 'stemnes' signature: genes up-regulated and common to 6 human embryonic stem cell lines tested.,CGP,C2,47,112
Cohort,0.009130239965204416,0.030018131349970664,0.30415750596725066,0.7610873904980402,LonGen OPEL,The 'stemnes' signature: genes up-regulated and common to 6 human embryonic stem cell lines tested.,CGP,C2,59,78
Cohort,0.051058045617270766,0.06402959576252805,0.7974132119564528,0.42549108548447434,LGP Offspring,Genes down-regulated in endometroid endometrial tumors from patients with lymph node metastases compared to those without the metastases.,CGP,C2,137,320
Cohort,0.05883139790511818,0.1856134145297124,0.316956606041535,0.7513558529505839,LGP Proband,Genes down-regulated in endometroid endometrial tumors from patients with lymph node metastases compared to those without the metastases.,CGP,C2,137,423
Cohort,0.07379774608023376,0.06079552843578932,1.2138679929096603,0.22515816656007098,LonGen OPEL,Genes down-regulated in endometroid endometrial tumors from patients with lymph node metastases compared to those without the metastases.,CGP,C2,228,307
Cohort,-0.10807439444636922,0.06706010879343266,-1.611604818287339,0.10751472343046409,LGP Offspring,Genes up-regulated in endometroid endometrial tumors from patients with lymph node metastases compared to those without the metastases.,CGP,C2,177,316
Cohort,-0.34547227673218245,0.18600045577872285,-1.8573732805428,0.063610379171858,LGP Proband,Genes up-regulated in endometroid endometrial tumors from patients with lymph node metastases compared to those without the metastases.,CGP,C2,177,465
Cohort,0.049399438877171235,0.06337720975424094,0.7794511476401126,0.4359456796692682,LonGen OPEL,Genes up-regulated in endometroid endometrial tumors from patients with lymph node metastases compared to those without the metastases.,CGP,C2,251,335
Cohort,0.0022389167438324944,0.0032219297680429497,0.6948993010460458,0.48735718328915956,LGP Offspring,Inflammatory genes down-regulated in mammary carcinoma cells after stimulation with TGFB1 [GeneID=7040] for 1 hr.,CGP,C2,0,1
Cohort,-0.0052803843150287825,0.01742715638675129,-0.30299747117912523,0.7619673490267519,LGP Proband,Inflammatory genes down-regulated in mammary carcinoma cells after stimulation with TGFB1 [GeneID=7040] for 1 hr.,CGP,C2,0,5
Cohort,0,0,NA,NA,LonGen OPEL,Inflammatory genes down-regulated in mammary carcinoma cells after stimulation with TGFB1 [GeneID=7040] for 1 hr.,CGP,C2,0,0
Cohort,-0.032286385114260144,0.030228713192386757,-1.0680701129676806,0.28587014591035764,LGP Offspring,Genes translationally regulated in MEF cells (embryonic fibroblasts) by rapamycin (sirolimus) [PubChem=6610346] but not in response to serum deprivation.,CGP,C2,30,52
Cohort,-0.11118658027479507,0.09082031850191957,-1.2242478567441386,0.22120445346473963,LGP Proband,Genes translationally regulated in MEF cells (embryonic fibroblasts) by rapamycin (sirolimus) [PubChem=6610346] but not in response to serum deprivation.,CGP,C2,30,97
Cohort,-0.02136264999594849,0.028151651098328435,-0.7588418143338294,0.44817182439954084,LonGen OPEL,Genes translationally regulated in MEF cells (embryonic fibroblasts) by rapamycin (sirolimus) [PubChem=6610346] but not in response to serum deprivation.,CGP,C2,60,61
Cohort,-0.06331129951766383,0.029898923736149566,-2.1175109872305113,0.03458100172423345,LGP Offspring,"Genes translationally repressed by rapamycin (sirolimus) [PubChem=6610346] in MEF cells (embryonic fibroblast) lacking either TSC1 or TSC2 [GeneID=7248, 7249] but not in the wild type cells.",CGP,C2,36,47
Cohort,0.029811042520599653,0.08933222027108763,0.3337098577661569,0.7386823954306712,LGP Proband,"Genes translationally repressed by rapamycin (sirolimus) [PubChem=6610346] in MEF cells (embryonic fibroblast) lacking either TSC1 or TSC2 [GeneID=7248, 7249] but not in the wild type cells.",CGP,C2,36,91
Cohort,0.0058418962225061585,0.03070597940239607,0.1902527239385271,0.849159605398845,LonGen OPEL,"Genes translationally repressed by rapamycin (sirolimus) [PubChem=6610346] in MEF cells (embryonic fibroblast) lacking either TSC1 or TSC2 [GeneID=7248, 7249] but not in the wild type cells.",CGP,C2,63,83
Cohort,0.007164072256303341,0.02435664757350944,0.29413211463859523,0.7687472416010446,LGP Offspring,Genes translationally regulated in MEF cells (embryonic fibroblasts) in response to serum starvation and by rapamycin (sirolimus) [PubChem=6610346].,CGP,C2,19,42
Cohort,-0.01621546914731483,0.07013479658342284,-0.23120433703728088,0.8172127696398687,LGP Proband,Genes translationally regulated in MEF cells (embryonic fibroblasts) in response to serum starvation and by rapamycin (sirolimus) [PubChem=6610346].,CGP,C2,19,59
Cohort,-0.023349319938896003,0.022625514156434823,-1.0319906888063062,0.3023899247684342,LonGen OPEL,Genes translationally regulated in MEF cells (embryonic fibroblasts) in response to serum starvation and by rapamycin (sirolimus) [PubChem=6610346].,CGP,C2,39,34
Cohort,0.013848671799275823,0.022727023070701124,0.6093482527911471,0.5424983659491436,LGP Offspring,Genes translationally repressed upon serum deprivation in MEF cells (embryonic fibroblast).,CGP,C2,13,39
Cohort,0.11173809439629769,0.05649988175174586,1.977669526588787,0.04829483005563622,LGP Proband,Genes translationally repressed upon serum deprivation in MEF cells (embryonic fibroblast).,CGP,C2,13,40
Cohort,-0.04167570227416222,0.016090654056119855,-2.590056446979012,0.009771471579949335,LonGen OPEL,Genes translationally repressed upon serum deprivation in MEF cells (embryonic fibroblast).,CGP,C2,25,14
Cohort,-0.024648371633746502,0.047741136602853625,-0.5162920991762311,0.6058192516985679,LGP Offspring,Genes translationally regulated in MEF cells (embryonic fibroblasts) in response to serum starvation but not by rapamycin (sirolimus) [PubChem=6610346].,CGP,C2,73,144
Cohort,0.13322836407164748,0.1310555855618049,1.0165790607132719,0.3096485322759749,LGP Proband,Genes translationally regulated in MEF cells (embryonic fibroblasts) in response to serum starvation but not by rapamycin (sirolimus) [PubChem=6610346].,CGP,C2,73,199
Cohort,-0.03510682811151639,0.0386824725859654,-0.9075642213278191,0.3643831712880494,LonGen OPEL,Genes translationally regulated in MEF cells (embryonic fibroblasts) in response to serum starvation but not by rapamycin (sirolimus) [PubChem=6610346].,CGP,C2,102,110
Cohort,-0.01648371567689298,0.024229056900159873,-0.6803284067067511,0.49652947173053097,LGP Offspring,Genes translationally up-regulated by serum in MEF cells (embryonic fibroblast) lacking TSC1 [GeneID=7248].,CGP,C2,20,37
Cohort,0.05305927017811599,0.06949897564536461,0.763453988859689,0.4454085998802294,LGP Proband,Genes translationally up-regulated by serum in MEF cells (embryonic fibroblast) lacking TSC1 [GeneID=7248].,CGP,C2,20,55
Cohort,-0.017507688577445973,0.01906790290271336,-0.9181758826218185,0.35880491500293854,LonGen OPEL,Genes translationally up-regulated by serum in MEF cells (embryonic fibroblast) lacking TSC1 [GeneID=7248].,CGP,C2,28,28
Cohort,0.03281481519105826,0.028199062596333032,1.1636846111092165,0.24496241132538768,LGP Offspring,Genes translationally up-regulated by serum in MEF cells (embryonic fibroblast) lacking TSC2 [GeneID=7249].,CGP,C2,20,56
Cohort,0.06334932175608529,0.07934348883673191,0.798418656462682,0.42485487214260387,LGP Proband,Genes translationally up-regulated by serum in MEF cells (embryonic fibroblast) lacking TSC2 [GeneID=7249].,CGP,C2,20,82
Cohort,-0.05345095253521087,0.027514588683778738,-1.942640435207485,0.05241193570133756,LonGen OPEL,Genes translationally up-regulated by serum in MEF cells (embryonic fibroblast) lacking TSC2 [GeneID=7249].,CGP,C2,51,48
Cohort,-0.04487997641573983,0.031865634630852485,-1.408413073696853,0.15946853384348172,LGP Offspring,Genes down-regulated in B-CLL (B-cell chronic leukemia) samples expressing high levels of LPL [GeneID=4023] compared with those expressing low levels of the gene.,CGP,C2,38,58
Cohort,-0.030451235191805443,0.08675651895252655,-0.3509965079219979,0.7256796121963671,LGP Proband,Genes down-regulated in B-CLL (B-cell chronic leukemia) samples expressing high levels of LPL [GeneID=4023] compared with those expressing low levels of the gene.,CGP,C2,38,85
Cohort,0.03114104213230592,0.026455749410329455,1.1770992251743633,0.23950775075308176,LonGen OPEL,Genes down-regulated in B-CLL (B-cell chronic leukemia) samples expressing high levels of LPL [GeneID=4023] compared with those expressing low levels of the gene.,CGP,C2,41,62
Cohort,-0.007268675008284293,0.04169569886340118,-0.17432673408586144,0.8616608837971296,LGP Offspring,Genes up-regulated in B-CLL (B-cell chronic leukemia) samples expressing high levels of LPL [GeneID=4023] compared with those expressing low levels of the gene.,CGP,C2,49,109
Cohort,0.004067091367053748,0.10964369576094561,0.0370937092080621,0.9704191645183566,LGP Proband,Genes up-regulated in B-CLL (B-cell chronic leukemia) samples expressing high levels of LPL [GeneID=4023] compared with those expressing low levels of the gene.,CGP,C2,49,138
Cohort,0.06450556150211857,0.036031576366442,1.790250885670265,0.07379354288004084,LonGen OPEL,Genes up-regulated in B-CLL (B-cell chronic leukemia) samples expressing high levels of LPL [GeneID=4023] compared with those expressing low levels of the gene.,CGP,C2,73,111
Cohort,-0.074967368037173715,0.04910902200090968,-1.5265498065871694,0.12734071689904106,LGP Offspring,Genes selected in supervised analyses to discriminate cells expressing activated beta-catenin (CTNNB1) [GeneID=1499] oncogene from control cells expressing GFP.,CGP,C2,91,146
Cohort,-0.1514251913847529,0.1467710327065321,-1.0317103354278823,0.3025069236755321,LGP Proband,Genes selected in supervised analyses to discriminate cells expressing activated beta-catenin (CTNNB1) [GeneID=1499] oncogene from control cells expressing GFP.,CGP,C2,91,248
Cohort,-0.07778740304656354,0.045306787879270644,-1.7169039494444904,0.08638572851403387,LonGen OPEL,Genes selected in supervised analyses to discriminate cells expressing activated beta-catenin (CTNNB1) [GeneID=1499] oncogene from control cells expressing GFP.,CGP,C2,151,146
Cohort,-0.29906563694995403,0.08842336965891816,-3.382201312883251,7.605161628520791e-4,LGP Offspring,Genes selected in supervised analyses to discriminate cells expressing E2F3 [GeneID=1871] from control cells expressing GFP.,CGP,C2,285,474
Cohort,0.36912738292471703,0.23196633717343346,1.5912972003723664,0.11192165049759042,LGP Proband,Genes selected in supervised analyses to discriminate cells expressing E2F3 [GeneID=1871] from control cells expressing GFP.,CGP,C2,285,683
Cohort,-0.21435301535169426,0.0724225513653576,-2.9597550943811033,0.0031701974626716337,LonGen OPEL,Genes selected in supervised analyses to discriminate cells expressing E2F3 [GeneID=1871] from control cells expressing GFP.,CGP,C2,442,439
Cohort,0.1639685758725902,0.08016365615739507,2.045422872812222,0.04119977206467486,LGP Offspring,Genes selected in supervised analyses to discriminate cells expressing activated HRAS [GeneID=3265] oncogene from control cells expressing GFP.,CGP,C2,164,432
Cohort,0.10883866090139607,0.20911964780224296,0.5204611907357501,0.6028803056550246,LGP Proband,Genes selected in supervised analyses to discriminate cells expressing activated HRAS [GeneID=3265] oncogene from control cells expressing GFP.,CGP,C2,164,559
Cohort,0.04093562385712306,0.06265345969985969,0.6533657367561895,0.5137091984300697,LonGen OPEL,Genes selected in supervised analyses to discriminate cells expressing activated HRAS [GeneID=3265] oncogene from control cells expressing GFP.,CGP,C2,282,355
Cohort,-0.05336446315532184,0.08766874590533325,-0.6087056750297994,0.5429240282550482,LGP Offspring,Genes selected in supervised analyses to discriminate cells expressing c-Myc [GeneID=4609] from control cells expressing GFP.,CGP,C2,254,511
Cohort,-0.14848607238500228,0.24220663300664477,-0.6130553508868135,0.5400068808016695,LGP Proband,Genes selected in supervised analyses to discriminate cells expressing c-Myc [GeneID=4609] from control cells expressing GFP.,CGP,C2,254,735
Cohort,0.016388184391835217,0.07841794111803546,0.20898513985680342,0.8345133070795975,LonGen OPEL,Genes selected in supervised analyses to discriminate cells expressing c-Myc [GeneID=4609] from control cells expressing GFP.,CGP,C2,393,478
Cohort,-0.11403843828847017,0.050015103819820744,-2.2800800074172254,0.022913517662182078,LGP Offspring,Genes selected in supervised analyses to discriminate cells expressing c-Src (CSK) [GeneID=1445] from control cells expressing GFP.,CGP,C2,100,156
Cohort,-0.1345089551300138,0.14212488734143652,-0.9464138030018173,0.3442116878700774,LGP Proband,Genes selected in supervised analyses to discriminate cells expressing c-Src (CSK) [GeneID=1445] from control cells expressing GFP.,CGP,C2,100,257
Cohort,0.017624770188528385,0.04594815074559938,0.3835795326369337,0.7013925381816126,LonGen OPEL,Genes selected in supervised analyses to discriminate cells expressing c-Src (CSK) [GeneID=1445] from control cells expressing GFP.,CGP,C2,140,166
Cohort,-0.3270748288006807,0.1712466798029968,-1.9099630379809378,0.05656088951551209,LGP Offspring,Genes down-regulated in brain from patients with Alzheimer's disease.,CGP,C2,954,1872
Cohort,-0.2913871899712103,0.48526648381016135,-0.6004684017806645,0.5483572451529886,LGP Proband,Genes down-regulated in brain from patients with Alzheimer's disease.,CGP,C2,954,2630
Cohort,0.0046840776820121065,0.1530373866158003,0.030607407677259044,0.9755903067973056,LonGen OPEL,Genes down-regulated in brain from patients with Alzheimer's disease.,CGP,C2,1519,1845
Cohort,-0.12263042639233204,0.06317193377889288,-1.9412169148018947,0.05264722388927162,LGP Offspring,Genes down-regulated in patients at the incipient stage of Alzheimer's disease.,CGP,C2,145,254
Cohort,0.05780695462876136,0.17908909570596532,0.3227832180451166,0.7469403279635896,LGP Proband,Genes down-regulated in patients at the incipient stage of Alzheimer's disease.,CGP,C2,145,364
Cohort,-0.01958522287638539,0.05911541699510616,-0.33130482489883717,0.7405014470386275,LonGen OPEL,Genes down-regulated in patients at the incipient stage of Alzheimer's disease.,CGP,C2,232,273
Cohort,-0.27260031771743437,0.11171213422831645,-2.4402032921535257,0.014934832410293574,LGP Offspring,Genes up-regulated in patients at the incipient stage of Alzheimer's disease.,CGP,C2,467,847
Cohort,-0.2555819503083002,0.3221136671940547,-0.7934526731966545,0.4277398107592585,LGP Proband,Genes up-regulated in patients at the incipient stage of Alzheimer's disease.,CGP,C2,467,1269
Cohort,-0.044128355978619124,0.09840110244094491,-0.44845387789331537,0.6539477094543937,LonGen OPEL,Genes up-regulated in patients at the incipient stage of Alzheimer's disease.,CGP,C2,706,835
Cohort,-0.8967062774402055,0.22611006660582847,-3.965795468113364,8.095341263358898e-5,LGP Offspring,Genes up-regulated in brain from patients with Alzheimer's disease.,CGP,C2,1823,3414
Cohort,-0.7162126220692323,0.6461186333328689,-1.1084847040779464,0.2679720981120228,LGP Proband,Genes up-regulated in brain from patients with Alzheimer's disease.,CGP,C2,1823,4926
Cohort,-0.1531877529984042,0.19657737562270097,-0.7792745859646827,0.436049597033904,LonGen OPEL,Genes up-regulated in brain from patients with Alzheimer's disease.,CGP,C2,2834,3353
Cohort,-0.10119828778695465,0.08198115564267817,-1.2344091394373113,0.21747941617370486,LGP Offspring,"Genes down-regulated on treatment of normal human bronchial epithelial cells with beta interferon (hIFNB treatment 100u/ml, 4-12hrs).",CGP,C2,226,454
Cohort,0.15085238670733195,0.2357216951585944,0.6399597058974055,0.5223745565624522,LGP Proband,"Genes down-regulated on treatment of normal human bronchial epithelial cells with beta interferon (hIFNB treatment 100u/ml, 4-12hrs).",CGP,C2,226,673
Cohort,0.07640972636725286,0.0757047557549962,1.0093121047049958,0.31313168041544587,LonGen OPEL,"Genes down-regulated on treatment of normal human bronchial epithelial cells with beta interferon (hIFNB treatment 100u/ml, 4-12hrs).",CGP,C2,378,482
Cohort,-0.16482431582527166,0.09697686723803306,-1.6996250809041367,0.08966150381906149,LGP Offspring,"Genes up-regulated on treatment of normal human bronchial epithelial cells with beta interferon (hIFNB treatment 100u/ml, 4-12hrs).",CGP,C2,321,605
Cohort,-0.33852906538621236,0.2723736724919369,-1.2428846822419441,0.21425964151490187,LGP Proband,"Genes up-regulated on treatment of normal human bronchial epithelial cells with beta interferon (hIFNB treatment 100u/ml, 4-12hrs).",CGP,C2,321,849
Cohort,-0.02624033106052424,0.0850023755858565,-0.30870114958164013,0.7576296429835431,LonGen OPEL,"Genes up-regulated on treatment of normal human bronchial epithelial cells with beta interferon (hIFNB treatment 100u/ml, 4-12hrs).",CGP,C2,493,582
Cohort,-0.2393238594617284,0.07433185326260099,-3.219667598172758,0.0013448109009665196,LGP Offspring,"Genes down-regulated on infection of normal human bronchial epithelial cells by mutant Influenza A lacking its antiviral antagonist (IAV_NS1) (MOI: 3, 12hpi)",CGP,C2,201,320
Cohort,0.20643789827138895,0.20965838225187514,0.9846393740813223,0.32508679975551347,LGP Proband,"Genes down-regulated on infection of normal human bronchial epithelial cells by mutant Influenza A lacking its antiviral antagonist (IAV_NS1) (MOI: 3, 12hpi)",CGP,C2,201,513
Cohort,-0.021545952412081723,0.06482768377583746,-0.3323572763540924,0.7397069965226503,LonGen OPEL,"Genes down-regulated on infection of normal human bronchial epithelial cells by mutant Influenza A lacking its antiviral antagonist (IAV_NS1) (MOI: 3, 12hpi)",CGP,C2,280,333
Cohort,-0.08765357177590237,0.12631655245049092,-0.6939199184545327,0.48797081089156147,LGP Offspring,"Genes up-regulated on infection of normal human bronchial epithelial cells by mutant Influenza A lacking its antiviral antagonist (IAV_NS1) (MOI: 3, 12hpi)",CGP,C2,530,1067
Cohort,0.0813502573248604,0.34900105792656005,0.2330945866129118,0.8157451533804234,LGP Proband,"Genes up-regulated on infection of normal human bronchial epithelial cells by mutant Influenza A lacking its antiviral antagonist (IAV_NS1) (MOI: 3, 12hpi)",CGP,C2,530,1472
Cohort,-0.08260161428612037,0.10961763752732437,-0.7535430989883383,0.45134644634944165,LonGen OPEL,"Genes up-regulated on infection of normal human bronchial epithelial cells by mutant Influenza A lacking its antiviral antagonist (IAV_NS1) (MOI: 3, 12hpi)",CGP,C2,860,999
Cohort,0.008290520486453488,0.0485626318879307,0.17071810493273398,0.8644965093965625,LGP Offspring,"Genes down-regulated oninfection of normal human bronchial epithelial cells by Influenza A (MOI: 3, 12hpi)",CGP,C2,77,165
Cohort,-0.20837459026534721,0.13127858504210743,-1.5872702329821071,0.11283048587266911,LGP Proband,"Genes down-regulated oninfection of normal human bronchial epithelial cells by Influenza A (MOI: 3, 12hpi)",CGP,C2,77,204
Cohort,-0.059740151850670394,0.040691505303581954,-1.4681234180199187,0.14246573025408338,LonGen OPEL,"Genes down-regulated oninfection of normal human bronchial epithelial cells by Influenza A (MOI: 3, 12hpi)",CGP,C2,127,123
Cohort,-0.030176301328600028,0.06477595262252432,-0.46585654254209957,0.6414682482056009,LGP Offspring,"Genes up-regulated oninfection of normal human bronchial epithelial cells by Influenza A (MOI: 3, 12hpi)",CGP,C2,139,277
Cohort,-0.18884364765733447,0.17618096829007487,-1.0718731398184338,0.2840870843546932,LGP Proband,"Genes up-regulated oninfection of normal human bronchial epithelial cells by Influenza A (MOI: 3, 12hpi)",CGP,C2,139,375
Cohort,-0.06733465203044905,0.05488595140780001,-1.2268103276584528,0.2202566288000385,LonGen OPEL,"Genes up-regulated oninfection of normal human bronchial epithelial cells by Influenza A (MOI: 3, 12hpi)",CGP,C2,216,227
Cohort,-0.02740775052675504,0.04576132132242626,-0.5989283030890832,0.5494213437702535,LGP Offspring,,CGP,C2,72,143
Cohort,0.10610695726752357,0.12213168335130145,0.8687914090426142,0.3852111737336541,LGP Proband,,CGP,C2,72,171
Cohort,-0.034274092952751474,0.0366395935535926,-0.9354386779050614,0.3498459660884543,LonGen OPEL,,CGP,C2,96,107
Cohort,-0.0753412440332496,0.05421762566756815,-1.389607956925291,0.16510543880528797,LGP Offspring,"Genes up-regulated on infection of normal human bronchial epithelial cells by SARS-CoV-2 (MOI: 2, 24hpi)",CGP,C2,107,184
Cohort,-0.10665410075429439,0.16086391755941593,-0.6630082269064543,0.5075084828963234,LGP Proband,"Genes up-regulated on infection of normal human bronchial epithelial cells by SARS-CoV-2 (MOI: 2, 24hpi)",CGP,C2,107,295
Cohort,-6.334178796586213e-4,0.04760449124572626,-0.013305842853965738,0.989387120784819,LonGen OPEL,"Genes up-regulated on infection of normal human bronchial epithelial cells by SARS-CoV-2 (MOI: 2, 24hpi)",CGP,C2,165,203
Cohort,-0.019464111127227943,0.0526432778465243,-0.36973592685420203,0.7116950571644405,LGP Offspring,"Genes down-regulated in SARS-CoV-2 infection (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,89,174
Cohort,0.003873993218512866,0.14386107668361706,0.02692871002927811,0.978523036539128,LGP Proband,"Genes down-regulated in SARS-CoV-2 infection (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,89,235
Cohort,-0.05266967466067673,0.04389049593779529,-1.2000245961067268,0.2304868190275847,LonGen OPEL,"Genes down-regulated in SARS-CoV-2 infection (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,141,146
Cohort,-0.09212429825501293,0.04621713902333677,-1.9932929688377274,0.04663085418744627,LGP Offspring,"Genes down-regulated in SARS-CoV-2 infection with Ruxolitinib (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,79,117
Cohort,-0.13616019804612947,0.12576183141809824,-1.0826830089127886,0.2792620722084381,LGP Proband,"Genes down-regulated in SARS-CoV-2 infection with Ruxolitinib (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,79,164
Cohort,0.034214287989576514,0.04183255715442966,0.8178866011769389,0.41366669332475003,LonGen OPEL,"Genes down-regulated in SARS-CoV-2 infection with Ruxolitinib (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,118,151
Cohort,-0.1387186287711782,0.0934748077166983,-1.484021547191667,0.13826930249339026,LGP Offspring,"Genes up-regulated in SARS-CoV-2 infection with Ruxolitinib (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,306,570
Cohort,0.033282445938624027,0.26870830548238506,0.12386087537888117,0.9014552756772892,LGP Proband,"Genes up-regulated in SARS-CoV-2 infection with Ruxolitinib (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,306,891
Cohort,-0.027331317962672786,0.08149622730492075,-0.3353691191177695,0.737435025105966,LonGen OPEL,"Genes up-regulated in SARS-CoV-2 infection with Ruxolitinib (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,464,558
Cohort,-0.08140277749698437,0.10126704007740106,-0.80384276497828,0.4217703602252437,LGP Offspring,"Genes up-regulated in SARS-CoV-2 infection (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,320,633
Cohort,0.21717623342848716,0.2783991676412642,0.7800893776677276,0.43555959827416757,LGP Proband,"Genes up-regulated in SARS-CoV-2 infection (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,320,945
Cohort,-0.1117761581947888,0.08666913754871892,-1.2896881330099377,0.19753354351581748,LonGen OPEL,"Genes up-regulated in SARS-CoV-2 infection (ACE2 expressing A549 cells, MOI: 2, 24hpi)",CGP,C2,509,572
Cohort,-0.023557903013052654,0.0533997143711518,-0.44116159216348494,0.6592370769337812,LGP Offspring,"Genes down-regulated in SARS-CoV-2 infection (A549 cells, MOI: 2, 24hpi)",CGP,C2,94,181
Cohort,-0.2919105266036132,0.1478223911488995,-1.9747382269684413,0.0486273307776957,LGP Proband,"Genes down-regulated in SARS-CoV-2 infection (A549 cells, MOI: 2, 24hpi)",CGP,C2,94,251
Cohort,-0.056957156219588835,0.0463290851926437,-1.2294038611544331,0.21928369624274824,LonGen OPEL,"Genes down-regulated in SARS-CoV-2 infection (A549 cells, MOI: 2, 24hpi)",CGP,C2,166,170
Cohort,0.05155002567767706,0.051895503520612084,0.9933428174023246,0.32089834121176025,LGP Offspring,"Genes up-regulated in SARS-CoV-2 infection (A549 cells, MOI: 2, 24hpi)",CGP,C2,68,164
Cohort,0.027080621933326877,0.13304325023091879,0.20354750719276576,0.838756770536055,LGP Proband,"Genes up-regulated in SARS-CoV-2 infection (A549 cells, MOI: 2, 24hpi)",CGP,C2,68,214
Cohort,0.07773373368589329,0.04280262607565594,1.8160973008640808,0.06973150968956454,LonGen OPEL,"Genes up-regulated in SARS-CoV-2 infection (A549 cells, MOI: 2, 24hpi)",CGP,C2,108,148
Cohort,-0.01979471043154856,0.030461306547384746,-0.6498312999396947,0.5160219515278095,LGP Offspring,"Genes down-regulated in SARS-CoV-2 infection (Calu-3 cells, MOI: 2, 24hpi)",CGP,C2,34,61
Cohort,-0.04206420954593728,0.08350417219124912,-0.5037378186277671,0.6145786581998514,LGP Proband,"Genes down-regulated in SARS-CoV-2 infection (Calu-3 cells, MOI: 2, 24hpi)",CGP,C2,34,89
Cohort,0.03243727671006851,0.02757739384706408,1.1762270535771393,0.23985580040126864,LonGen OPEL,"Genes down-regulated in SARS-CoV-2 infection (Calu-3 cells, MOI: 2, 24hpi)",CGP,C2,49,66
Cohort,0.09453965609719094,0.09415124402290556,1.0041254056525357,0.3156774563021075,LGP Offspring,"Genes up-regulated in SARS-CoV-2 infection (Calu-3 cells, MOI: 2, 24hpi)",CGP,C2,276,599
Cohort,0.07599656057935299,0.2576287063390987,0.2949848316954401,0.7680788819493115,LGP Proband,"Genes up-regulated in SARS-CoV-2 infection (Calu-3 cells, MOI: 2, 24hpi)",CGP,C2,276,794
Cohort,-0.010745765396368515,0.07934743590637204,-0.1354267503873502,0.8923087135437086,LonGen OPEL,"Genes up-regulated in SARS-CoV-2 infection (Calu-3 cells, MOI: 2, 24hpi)",CGP,C2,433,508
Cohort,0.005244616318478994,0.014493273451830154,0.3618655465178382,0.7175655908418254,LGP Offspring,"Genes down-regulated in SARS-CoV-2 low MOI infection (ACE2 expressing A549 cells, MOI: 0.2, 24hpi)",CGP,C2,6,15
Cohort,0.07205008095733866,0.05104046025536534,1.4116267877847906,0.15843284294048743,LGP Proband,"Genes down-regulated in SARS-CoV-2 low MOI infection (ACE2 expressing A549 cells, MOI: 0.2, 24hpi)",CGP,C2,6,36
Cohort,-0.016583969030588553,0.013643842472751863,-1.215491095247429,0.22453921748998593,LonGen OPEL,"Genes down-regulated in SARS-CoV-2 low MOI infection (ACE2 expressing A549 cells, MOI: 0.2, 24hpi)",CGP,C2,17,11
Cohort,0.043672822499529494,0.04394105471870244,0.9938956353940503,0.32062930163903025,LGP Offspring,"Genes up-regulated in SARS-CoV-2 low MOI infection (ACE2 expressing A549 cells, MOI: 0.2, 24hpi)",CGP,C2,70,155
Cohort,-0.2310506740546919,0.1271934747169686,-1.8165293036362655,0.06964807700727547,LGP Proband,"Genes up-regulated in SARS-CoV-2 low MOI infection (ACE2 expressing A549 cells, MOI: 0.2, 24hpi)",CGP,C2,70,214
Cohort,0.006554141899418459,0.040887660449107015,0.16029632968549076,0.8726883186191355,LonGen OPEL,"Genes up-regulated in SARS-CoV-2 low MOI infection (ACE2 expressing A549 cells, MOI: 0.2, 24hpi)",CGP,C2,106,133
Cohort,-0.15887921550739165,0.07465910854755614,-2.1280620489352513,0.03369308327133469,LGP Offspring,"Genes strongly down-regulated (og2(FC)<-3.58, padj<0.05) in post mortem lung tissue from COVID-19 patients vs uninfected biopsy.",CGP,C2,200,340
Cohort,-0.16511417988688679,0.21156026279079987,-0.7804593249638708,0.4353420106600675,LGP Proband,"Genes strongly down-regulated (og2(FC)<-3.58, padj<0.05) in post mortem lung tissue from COVID-19 patients vs uninfected biopsy.",CGP,C2,200,524
Cohort,0.09907530107189566,0.06670999570960255,1.485164254891929,0.13789622136749055,LonGen OPEL,"Genes strongly down-regulated (og2(FC)<-3.58, padj<0.05) in post mortem lung tissue from COVID-19 patients vs uninfected biopsy.",CGP,C2,241,336
Cohort,-0.09768613474855241,0.058383834238367495,-1.673170938889057,0.09475630043010455,LGP Offspring,"Genes strongly up-regulated (log2(FC)>3.58, padj<0.05) in post mortem lung tissue from COVID-19 patients vs uninfected biopsy.",CGP,C2,124,211
Cohort,-0.14496542113047706,0.1617579706746015,-0.8961871895765497,0.37041139292881464,LGP Proband,"Genes strongly up-regulated (log2(FC)>3.58, padj<0.05) in post mortem lung tissue from COVID-19 patients vs uninfected biopsy.",CGP,C2,124,306
Cohort,0.019763112513758202,0.053178390781818435,0.37163803235120013,0.710261270455826,LonGen OPEL,"Genes strongly up-regulated (log2(FC)>3.58, padj<0.05) in post mortem lung tissue from COVID-19 patients vs uninfected biopsy.",CGP,C2,180,218
Cohort,0.05918372700161246,0.061895575123888755,0.9561867206686694,0.33931972385728737,LGP Offspring,"Genes down-regulated in HPIV3 (A549 cells, MOI: 2, 24hpi)",CGP,C2,113,266
Cohort,0.05149826834495585,0.16426364179822128,0.3135098417470584,0.7539717360387568,LGP Proband,"Genes down-regulated in HPIV3 (A549 cells, MOI: 2, 24hpi)",CGP,C2,113,348
Cohort,-0.10255102565437926,0.05704742173710671,-1.7976452314877285,0.07261212286904534,LonGen OPEL,"Genes down-regulated in HPIV3 (A549 cells, MOI: 2, 24hpi)",CGP,C2,225,236
Cohort,0.04491606480821834,0.0823502419691191,0.5454272353572638,0.5856396296990265,LGP Offspring,"Genes up-regulated in HPIV3 (A549 cells, MOI: 2, 24hpi)",CGP,C2,181,405
Cohort,0.1384620610983458,0.2148202691579731,0.6445484015129155,0.5193971197703118,LGP Proband,"Genes up-regulated in HPIV3 (A549 cells, MOI: 2, 24hpi)",CGP,C2,181,531
Cohort,0.08413598478683762,0.06885122078059885,1.2219969934149049,0.2220705068439011,LonGen OPEL,"Genes up-regulated in HPIV3 (A549 cells, MOI: 2, 24hpi)",CGP,C2,293,383
Cohort,0.035255294102057994,0.05243864506339186,0.6723151229296388,0.5016128272683804,LGP Offspring,"Genes down-regulated in IAV (A549 cells, MOI: 5, 9hpi)",CGP,C2,86,192
Cohort,-0.08336453507479005,0.14673766630435345,-0.5681195372283004,0.5701067217020666,LGP Proband,"Genes down-regulated in IAV (A549 cells, MOI: 5, 9hpi)",CGP,C2,86,283
Cohort,-0.029450436826894435,0.04845910761907293,-0.6077379108669985,0.543534655397748,LonGen OPEL,"Genes down-regulated in IAV (A549 cells, MOI: 5, 9hpi)",CGP,C2,165,171
Cohort,0.014808792916403673,0.02854024230942926,0.5188741131153982,0.6040183443783558,LGP Offspring,"Genes up-regulated in IAV (A549 cells, MOI: 5, 9hpi)",CGP,C2,23,59
Cohort,0.013719060149851608,0.07806436469760858,0.17574036761836195,0.8605405802095685,LGP Proband,"Genes up-regulated in IAV (A549 cells, MOI: 5, 9hpi)",CGP,C2,23,76
Cohort,0.044782492211271945,0.025631471160558483,1.7471682343455537,0.08099380007137008,LonGen OPEL,"Genes up-regulated in IAV (A549 cells, MOI: 5, 9hpi)",CGP,C2,38,65
Cohort,0.05376405934588441,0.029666094203882817,1.8123066345163683,0.07038235732952908,LGP Offspring,"Genes down-regulated in MERS-CoV infection (MRC5 cells, MOI: 3, 24hpi)",CGP,C2,22,67
Cohort,-0.024057164898759052,0.07582180833782896,-0.3172855597372566,0.7511063462590228,LGP Proband,"Genes down-regulated in MERS-CoV infection (MRC5 cells, MOI: 3, 24hpi)",CGP,C2,22,72
Cohort,0.001224564007480162,0.021571958301777706,0.0567664738800857,0.9547454666589272,LonGen OPEL,"Genes down-regulated in MERS-CoV infection (MRC5 cells, MOI: 3, 24hpi)",CGP,C2,33,40
Cohort,4.359394874475377e-4,0.1006223472489798,0.004332432102471727,0.9965445082990141,LGP Offspring,"Genes up-regulated in MERS-CoV infection (MRC5 cells, MOI: 3, 24hpi)",CGP,C2,325,690
Cohort,-0.03593577089386797,0.27337412140943745,-0.13145271655046786,0.8954488920363526,LGP Proband,"Genes up-regulated in MERS-CoV infection (MRC5 cells, MOI: 3, 24hpi)",CGP,C2,325,973
Cohort,-0.028854805811804045,0.09009968775459395,-0.32025422652291946,0.7488596657376595,LonGen OPEL,"Genes up-regulated in MERS-CoV infection (MRC5 cells, MOI: 3, 24hpi)",CGP,C2,562,649
Cohort,-0.09053761767220007,0.06721591685961217,-1.3469669373297077,0.17844224388995414,LGP Offspring,"Genes down-regulated in RSV (A549 cells, MOI: 2, 24hpi)",CGP,C2,165,299
Cohort,-0.1492641837471257,0.1895085713390503,-0.7876381669305962,0.43113217023551254,LGP Proband,"Genes down-regulated in RSV (A549 cells, MOI: 2, 24hpi)",CGP,C2,165,417
Cohort,0.0027026734845473892,0.060464320698978516,0.04469864960532085,0.96435872060888,LonGen OPEL,"Genes down-regulated in RSV (A549 cells, MOI: 2, 24hpi)",CGP,C2,241,293
Cohort,0.09910829461782023,0.1028483900494806,0.9636348665267293,0.33557359857779834,LGP Offspring,"Genes up-regulated in RSV (A549 cells, MOI: 2, 24hpi)",CGP,C2,292,655
Cohort,-0.20023320259842464,0.2719981204546175,-0.736156567051842,0.4618424194920907,LGP Proband,"Genes up-regulated in RSV (A549 cells, MOI: 2, 24hpi)",CGP,C2,292,889
Cohort,0.048300489216883326,0.09045634606423257,0.5339646284472447,0.5935150876647469,LonGen OPEL,"Genes up-regulated in RSV (A549 cells, MOI: 2, 24hpi)",CGP,C2,521,632
Cohort,0.006491198170955666,0.014906240826904218,0.43546848909348945,0.663361411617494,LGP Offspring,"Genes down-regulated in SARS-CoV-1 infection (MRC5 cells, MOI: 3, 24hpi).",CGP,C2,5,15
Cohort,0.08467107869762062,0.03563419960321622,2.37611843791711,0.01772078612220435,LGP Proband,"Genes down-regulated in SARS-CoV-1 infection (MRC5 cells, MOI: 3, 24hpi).",CGP,C2,5,14
Cohort,0.02262647481072543,0.00986307074885954,2.294059871094579,0.02204667203406283,LonGen OPEL,"Genes down-regulated in SARS-CoV-1 infection (MRC5 cells, MOI: 3, 24hpi).",CGP,C2,5,11
Cohort,0.005826464061755581,0.024005581540860202,0.24271288957687956,0.808301443784418,LGP Offspring,"Genes up-regulated in SARS-CoV-1 infection (MRC5 cells, MOI: 3, 24hpi).",CGP,C2,18,39
Cohort,-0.03649278414350891,0.06743729652953763,-0.5411365226885247,0.5885579938362148,LGP Proband,"Genes up-regulated in SARS-CoV-1 infection (MRC5 cells, MOI: 3, 24hpi).",CGP,C2,18,58
Cohort,-0.004745113949425335,0.02157201797155969,-0.21996615966486033,0.8259539082426266,LonGen OPEL,"Genes up-regulated in SARS-CoV-1 infection (MRC5 cells, MOI: 3, 24hpi).",CGP,C2,33,36
Cohort,-0.29137516675683656,0.09865776921134256,-2.9533930179655585,0.003252115721835686,LGP Offspring,Selected genes down-regulated in response to the Ras inhibitor salirasib [PubChem=5469318] in a panel of cancer cell lines with constantly active HRAS [GeneID=3265].,CGP,C2,334,565
Cohort,-0.059383820181933965,0.26488903598082236,-0.22418376042651036,0.8226692269015359,LGP Proband,Selected genes down-regulated in response to the Ras inhibitor salirasib [PubChem=5469318] in a panel of cancer cell lines with constantly active HRAS [GeneID=3265].,CGP,C2,334,851
Cohort,0.04819697224472947,0.08204491269634051,0.5874462006329763,0.5570706667200966,LonGen OPEL,Selected genes down-regulated in response to the Ras inhibitor salirasib [PubChem=5469318] in a panel of cancer cell lines with constantly active HRAS [GeneID=3265].,CGP,C2,449,562
Cohort,-0.08025624378711613,0.07533011111645177,-1.0653939387272258,0.2870780731853407,LGP Offspring,Selected genes up-regulated in response to the Ras inhibitor salirasib [PubChem=5469318] in a panel of cancer cell lines with constantly active HRAS [GeneID=3265].,CGP,C2,190,375
Cohort,0.07509664982809686,0.2175889033334624,0.3451308806543718,0.7300830020248584,LGP Proband,Selected genes up-regulated in response to the Ras inhibitor salirasib [PubChem=5469318] in a panel of cancer cell lines with constantly active HRAS [GeneID=3265].,CGP,C2,190,567
Cohort,-0.006593224861017677,0.06532896612038813,-0.10092345329432723,0.9196366395154261,LonGen OPEL,Selected genes up-regulated in response to the Ras inhibitor salirasib [PubChem=5469318] in a panel of cancer cell lines with constantly active HRAS [GeneID=3265].,CGP,C2,300,373
Cohort,-0.07115923895973499,0.10700424026831254,-0.6650132628511131,0.506268815219465,LGP Offspring,"Direct targets of FOXA2 [GeneID=3170] in liver, according to a ChIP-chip analysis.",CGP,C2,410,818
Cohort,-0.2825417341536489,0.29760295725076324,-0.9493915543170373,0.3426965279775024,LGP Proband,"Direct targets of FOXA2 [GeneID=3170] in liver, according to a ChIP-chip analysis.",CGP,C2,410,1081
Cohort,-0.10070372554751408,0.09453999201803788,-1.065197102283446,0.28710973972393916,LonGen OPEL,"Direct targets of FOXA2 [GeneID=3170] in liver, according to a ChIP-chip analysis.",CGP,C2,637,710
Cohort,0.004583463062402808,0.02674116590864149,0.17140101811797398,0.8639597475341787,LGP Offspring,Genes down-regulated in ALL (acute lymphoblastic leukemia) patients who developed t-ML (treatment related myeloid leukemia).,CGP,C2,22,48
Cohort,-0.08322493790485413,0.06949286629042051,-1.1976040469685818,0.23141145810418765,LGP Proband,Genes down-regulated in ALL (acute lymphoblastic leukemia) patients who developed t-ML (treatment related myeloid leukemia).,CGP,C2,22,56
Cohort,0.005693933825737271,0.02356172190097665,0.24166034425103936,0.8091055995602212,LonGen OPEL,Genes down-regulated in ALL (acute lymphoblastic leukemia) patients who developed t-ML (treatment related myeloid leukemia).,CGP,C2,34,49
Cohort,0.04550225232733707,0.02510673262724446,1.8123526068844378,0.07037524973865107,LGP Offspring,Genes up-regulated in ALL (acute lymphoblastic leukemia) patients who developed t-ML (treatment related myeloid leukemia).,CGP,C2,14,44
Cohort,-0.05831642242564713,0.07194394192362832,-0.8105814175091016,0.4178373294680837,LGP Proband,Genes up-regulated in ALL (acute lymphoblastic leukemia) patients who developed t-ML (treatment related myeloid leukemia).,CGP,C2,14,66
Cohort,0.028955476333454865,0.023174641933107202,1.2494465466622457,0.21186905459608119,LonGen OPEL,Genes up-regulated in ALL (acute lymphoblastic leukemia) patients who developed t-ML (treatment related myeloid leukemia).,CGP,C2,27,43
Cohort,-0.05513650183305142,0.031397188951279964,-1.7560967613568372,0.07952470030615728,LGP Offspring,Genes down-regulated in B lymphocytes from patients with primary immunodefiency syndrom.,CGP,C2,37,54
Cohort,0.06702251898183577,0.08829410794491527,0.7590825768764732,0.44801764220777307,LGP Proband,Genes down-regulated in B lymphocytes from patients with primary immunodefiency syndrom.,CGP,C2,37,88
Cohort,-0.031175252560883784,0.02405950166056756,-1.2957563710464801,0.1954350373217039,LonGen OPEL,Genes down-regulated in B lymphocytes from patients with primary immunodefiency syndrom.,CGP,C2,50,42
Cohort,-0.04284522278969059,0.035476925815410246,-1.2076926567036357,0.22758785802001952,LGP Offspring,Genes up-regulated in B lymphocytes from patients with primary immunodefiency syndrom.,CGP,C2,46,79
Cohort,0.07606919155217717,0.1006590784391008,0.7557111860327569,0.45003575707573085,LGP Proband,Genes up-regulated in B lymphocytes from patients with primary immunodefiency syndrom.,CGP,C2,46,123
Cohort,0.06576033497238357,0.030642452105613525,2.146053284043043,0.03217046076226395,LonGen OPEL,Genes up-regulated in B lymphocytes from patients with primary immunodefiency syndrom.,CGP,C2,53,92
Cohort,-0.01893478115654548,0.0555735366878962,-0.3407157846167713,0.7334234134940081,LGP Offspring,Potential targets of MIR15A and MIR16-1 [GeneID=406948;406950] microRNAs in prostate cancer.,CGP,C2,96,196
Cohort,0.041258001660758464,0.14698691656508237,0.2806916603525756,0.7790165206204193,LGP Proband,Potential targets of MIR15A and MIR16-1 [GeneID=406948;406950] microRNAs in prostate cancer.,CGP,C2,96,260
Cohort,0.033648123014284465,0.04652430041524663,0.7232375922681801,0.4697463876497806,LonGen OPEL,Potential targets of MIR15A and MIR16-1 [GeneID=406948;406950] microRNAs in prostate cancer.,CGP,C2,152,193
Cohort,-0.044987158919756944,0.02844832302361798,-1.5813641768060744,0.11426253293712094,LGP Offspring,Top highly correlated genes negatively associated with poor survival of patients with suboptimally debulked ovarian tumors.,CGP,C2,29,44
Cohort,-0.005412425406369782,0.07586654449917284,-0.07134139879573391,0.9431431513636861,LGP Proband,Top highly correlated genes negatively associated with poor survival of patients with suboptimally debulked ovarian tumors.,CGP,C2,29,67
Cohort,0.0012881404543982414,0.022114564073409455,0.0582485121624939,0.9535652981716496,LonGen OPEL,Top highly correlated genes negatively associated with poor survival of patients with suboptimally debulked ovarian tumors.,CGP,C2,33,40
Cohort,0.028824969515710598,0.0354773560779982,0.8124892241783154,0.416796997008023,LGP Offspring,Top highly correlated genes positively associated with poor survival of patients with suboptimally debulked ovarian tumors.,CGP,C2,36,94
Cohort,0.20856779120796443,0.10420089123840122,2.0015931603769315,0.045652015498063254,LGP Proband,Top highly correlated genes positively associated with poor survival of patients with suboptimally debulked ovarian tumors.,CGP,C2,36,129
Cohort,-0.03411295991836256,0.02966418365308352,-1.1499713026762022,0.2505010641587529,LonGen OPEL,Top highly correlated genes positively associated with poor survival of patients with suboptimally debulked ovarian tumors.,CGP,C2,69,66
Cohort,-0.044191757158785365,0.0884920372316292,-0.499386821021114,0.6176693871188019,LGP Offspring,Genes whose expression in optimally debulked ovarian tumors is associated with survival prognosis.,CGP,C2,257,515
Cohort,-0.1543466696302601,0.2378437251192414,-0.6489415247464672,0.5165548270080744,LGP Proband,Genes whose expression in optimally debulked ovarian tumors is associated with survival prognosis.,CGP,C2,257,685
Cohort,-0.10135051414959571,0.08221002824565835,-1.2328242224506012,0.21800532148232024,LonGen OPEL,Genes whose expression in optimally debulked ovarian tumors is associated with survival prognosis.,CGP,C2,434,475
Cohort,-0.3251152815927389,0.13346726586045177,-2.4359177472974305,0.015111344508167906,LGP Offspring,Genes whose expression in suboptimally debulked ovarian tumors is associated with survival prognosis.,CGP,C2,605,1128
Cohort,0.27918058682641655,0.37131476741900266,0.7518704110988962,0.4523411213327011,LGP Proband,Genes whose expression in suboptimally debulked ovarian tumors is associated with survival prognosis.,CGP,C2,605,1584
Cohort,0.024896791567598473,0.11344572378407446,0.2194599385251883,0.8263480464680486,LonGen OPEL,Genes whose expression in suboptimally debulked ovarian tumors is associated with survival prognosis.,CGP,C2,901,1119
Cohort,-0.02731486010596462,0.028642797091541165,-0.9536380130288074,0.3406077741054264,LGP Offspring,"Genes down-regulated in cultured stromal stem cells from adipose tissue, compared to the freshly isolated cells.",CGP,C2,32,56
Cohort,-0.02755831262130124,0.0812612535056061,-0.3391322608554153,0.7345954685325725,LGP Proband,"Genes down-regulated in cultured stromal stem cells from adipose tissue, compared to the freshly isolated cells.",CGP,C2,32,83
Cohort,0.023005535173468514,0.02447546930502815,0.9399425558202614,0.34753216411106014,LonGen OPEL,"Genes down-regulated in cultured stromal stem cells from adipose tissue, compared to the freshly isolated cells.",CGP,C2,36,57
Cohort,-0.0667989202999607,0.1184672141899861,-0.5638599738897815,0.5730364376245298,LGP Offspring,"Genes up-regulated in cultured stromal stem cells from adipose tissue, compared to the freshly isolated cells.",CGP,C2,465,942
Cohort,-0.07042562923580893,0.32788912684622606,-0.21478488754168798,0.829987543201998,LGP Proband,"Genes up-regulated in cultured stromal stem cells from adipose tissue, compared to the freshly isolated cells.",CGP,C2,465,1279
Cohort,-0.15589379901693834,0.10387085466858738,-1.5008425560214798,0.133792826467075,LonGen OPEL,"Genes up-regulated in cultured stromal stem cells from adipose tissue, compared to the freshly isolated cells.",CGP,C2,763,863
Cohort,0.03082062502765286,0.07715964100691651,0.39943971518594973,0.6896953997707588,LGP Offspring,Genes down-regulated in freshly isolated CD31- [GeneID=5175] (stromal stem cells from adipose tissue) versus the CD31+ (non-stem) counterparts.,CGP,C2,200,445
Cohort,-0.057166767570422904,0.22332412224739132,-0.2559811586636189,0.7980285091202732,LGP Proband,Genes down-regulated in freshly isolated CD31- [GeneID=5175] (stromal stem cells from adipose tissue) versus the CD31+ (non-stem) counterparts.,CGP,C2,200,616
Cohort,0.029043035459127935,0.07034900495103877,0.4128421642827954,0.6798334331019283,LonGen OPEL,Genes down-regulated in freshly isolated CD31- [GeneID=5175] (stromal stem cells from adipose tissue) versus the CD31+ (non-stem) counterparts.,CGP,C2,321,400
Cohort,-0.13283803957980653,0.10895492575380923,-1.2192017814776246,0.22319285903479583,LGP Offspring,Genes up-regulated in freshly isolated CD31- [GeneID=5175] (stromal stem cells from adipose tissue) versus the CD31+ (non-stem) counterparts.,CGP,C2,387,754
Cohort,-0.300683374481988,0.2971493447714667,-1.0118931095514927,0.31188263799235655,LGP Proband,Genes up-regulated in freshly isolated CD31- [GeneID=5175] (stromal stem cells from adipose tissue) versus the CD31+ (non-stem) counterparts.,CGP,C2,387,1090
Cohort,-0.3320022721622435,0.09430755957846326,-3.5204205648648963,4.553529677002818e-4,LonGen OPEL,Genes up-regulated in freshly isolated CD31- [GeneID=5175] (stromal stem cells from adipose tissue) versus the CD31+ (non-stem) counterparts.,CGP,C2,651,658
Cohort,6.363440080776017e-4,0.05808541289097605,0.010955315222980225,0.9912623302126298,LGP Offspring,Genes down-regulated in biphasic (mixed) vs epithelial subtypes of malignant peritoneal mesothelioma.,CGP,C2,108,229
Cohort,-0.3857538827090766,0.16107487454260974,-2.394873091191089,0.016845857557640405,LGP Proband,Genes down-regulated in biphasic (mixed) vs epithelial subtypes of malignant peritoneal mesothelioma.,CGP,C2,108,313
Cohort,-0.1017566840597057,0.050534926914692725,-2.013591198647218,0.044388566458334305,LonGen OPEL,Genes down-regulated in biphasic (mixed) vs epithelial subtypes of malignant peritoneal mesothelioma.,CGP,C2,186,192
Cohort,-0.15351587069860334,0.07179117787241274,-2.138366791688969,0.03284482802533423,LGP Offspring,Genes up-regulated in biphasic (mixed) vs epithelial subtypes of malignant peritoneal mesothelioma.,CGP,C2,185,311
Cohort,-0.08969143330448683,0.20329089047171553,-0.44119750322489665,0.6591843727031657,LGP Proband,Genes up-regulated in biphasic (mixed) vs epithelial subtypes of malignant peritoneal mesothelioma.,CGP,C2,185,483
Cohort,-0.02315296753467463,0.06855080379231931,-0.3377490307016469,0.7356413716381841,LonGen OPEL,Genes up-regulated in biphasic (mixed) vs epithelial subtypes of malignant peritoneal mesothelioma.,CGP,C2,304,357
Cohort,-0.022014142278832187,0.029299709896402983,-0.7513433531140451,0.45270752561507477,LGP Offspring,Genes up-regulated in hepatocellular carcinoma (HCC) developed by transgenic mice overexpressing a secretable form of EGF [GeneID=1950] in liver.,CGP,C2,31,51
Cohort,-0.05636461588594185,0.08935804655679253,-0.6307726954406806,0.5283619678183795,LGP Proband,Genes up-regulated in hepatocellular carcinoma (HCC) developed by transgenic mice overexpressing a secretable form of EGF [GeneID=1950] in liver.,CGP,C2,31,90
Cohort,0.01642105622399593,0.02833363343243416,0.5795605517080761,0.5623749882281144,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma (HCC) developed by transgenic mice overexpressing a secretable form of EGF [GeneID=1950] in liver.,CGP,C2,53,67
Cohort,0.010045184113842793,0.05740281083231922,0.17499463821007008,0.8611362460354377,LGP Offspring,Genes representing a co-expression network in atopic CD4 [GeneID=920] T lymphocyte responses.,CGP,C2,104,221
Cohort,-0.23367154303211965,0.15329057896671117,-1.524369890225701,0.1277954289205974,LGP Proband,Genes representing a co-expression network in atopic CD4 [GeneID=920] T lymphocyte responses.,CGP,C2,104,298
Cohort,-0.016543237659822758,0.054468130596252926,-0.3037232502516037,0.7614181140765817,LonGen OPEL,Genes representing a co-expression network in atopic CD4 [GeneID=920] T lymphocyte responses.,CGP,C2,207,245
Cohort,0.08529239423511768,0.04421525463147465,1.9290264173759217,0.054145880772973144,LGP Offspring,Genes representing epithelial differentiation module in sputum during asthma exacerbations.,CGP,C2,47,144
Cohort,0.053316496093896805,0.11380304489502747,0.4684979751031813,0.6395509408382665,LGP Proband,Genes representing epithelial differentiation module in sputum during asthma exacerbations.,CGP,C2,47,178
Cohort,0.03183072611281236,0.04045918753093798,0.7867366611964789,0.431670198612499,LonGen OPEL,Genes representing epithelial differentiation module in sputum during asthma exacerbations.,CGP,C2,110,144
Cohort,-0.003941659178281759,0.04691052170910624,-0.0840250552471815,0.9330613871792135,LGP Offspring,Genes representing interferon-induced antiviral module in sputum during asthma exacerbations.,CGP,C2,67,135
Cohort,-0.04059918011936511,0.12360698910518284,-0.32845375826457035,0.742651050965563,LGP Proband,Genes representing interferon-induced antiviral module in sputum during asthma exacerbations.,CGP,C2,67,172
Cohort,-0.07575908532507471,0.039739306259571415,-1.9064018085828498,0.05695794893802678,LonGen OPEL,Genes representing interferon-induced antiviral module in sputum during asthma exacerbations.,CGP,C2,124,119
Cohort,0.03998604157988114,0.04861551048110598,0.822495561276095,0.4110849346033877,LGP Offspring,Genes representing Th1 / cytotoxic module in sputum during asthma exacerbations.,CGP,C2,71,165
Cohort,0.03209802829014747,0.14593679575975474,0.2199447241735261,0.8259680277441035,LGP Proband,Genes representing Th1 / cytotoxic module in sputum during asthma exacerbations.,CGP,C2,71,257
Cohort,0.08822902906700805,0.045599341281039076,1.9348750790769662,0.05335960554076995,LonGen OPEL,Genes representing Th1 / cytotoxic module in sputum during asthma exacerbations.,CGP,C2,128,196
Cohort,-0.028587269689345995,0.041969096553644336,-0.6811504663391105,0.4960095462990336,LGP Offspring,Transcripts bound to IGF2BP2 [GeneID=10644] complexes and differentially regulated in myoblasts with IGF2BP2 [GeneID=10644] knockdown by RNAi.,CGP,C2,59,109
Cohort,-0.12295917791713533,0.1103884487715116,-1.1138772152840317,0.26565277439605073,LGP Proband,Transcripts bound to IGF2BP2 [GeneID=10644] complexes and differentially regulated in myoblasts with IGF2BP2 [GeneID=10644] knockdown by RNAi.,CGP,C2,59,147
Cohort,-0.022298753165374472,0.037902285314904534,-0.5883221283389423,0.5564829796098459,LonGen OPEL,Transcripts bound to IGF2BP2 [GeneID=10644] complexes and differentially regulated in myoblasts with IGF2BP2 [GeneID=10644] knockdown by RNAi.,CGP,C2,95,101
Cohort,0.02153207022740422,0.018214349718235198,1.18214872122761,0.23756234634983547,LGP Offspring,Genes up-regulated by growing HMEC-E6 cells (mammary epithelial cells damaged by expression of HPV-16 E6 [GeneID=1489078]) in extracellular matrix (ECM).,CGP,C2,9,25
Cohort,-0.0482886034961887,0.0488803635816145,-0.987893705323248,0.3234912227754192,LGP Proband,Genes up-regulated by growing HMEC-E6 cells (mammary epithelial cells damaged by expression of HPV-16 E6 [GeneID=1489078]) in extracellular matrix (ECM).,CGP,C2,9,27
Cohort,0.012455521743487389,0.014829174253350131,0.8399336018776299,0.40119781692925327,LonGen OPEL,Genes up-regulated by growing HMEC-E6 cells (mammary epithelial cells damaged by expression of HPV-16 E6 [GeneID=1489078]) in extracellular matrix (ECM).,CGP,C2,14,20
Cohort,0.0011116299287549573,0.010091481791225295,0.11015527270945852,0.912318926987616,LGP Offspring,Genes up-regulated  by tamoxifen [PubChem=5376] in HMEC-E6 cells (mammary epithelial cells damaged by expression of HPV-16 E6 [GeneID=1489078]).,CGP,C2,3,7
Cohort,-0.041273248099557125,0.023615023860285505,-1.747753817389458,0.0808746667403564,LGP Proband,Genes up-regulated  by tamoxifen [PubChem=5376] in HMEC-E6 cells (mammary epithelial cells damaged by expression of HPV-16 E6 [GeneID=1489078]).,CGP,C2,3,6
Cohort,-4.212800468352093e-5,0.00893025960946755,-0.004717444567776987,0.9962372197541891,LonGen OPEL,Genes up-regulated  by tamoxifen [PubChem=5376] in HMEC-E6 cells (mammary epithelial cells damaged by expression of HPV-16 E6 [GeneID=1489078]).,CGP,C2,6,6
Cohort,-0.04315133639037675,0.040766914137972184,-1.0584891523634752,0.2902105700020067,LGP Offspring,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G1, defined by unsupervised clustering",CGP,C2,59,111
Cohort,0.05496290096756255,0.10970501484981321,0.5010062761744035,0.6164989056831411,LGP Proband,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G1, defined by unsupervised clustering",CGP,C2,59,139
Cohort,-0.037249060551267366,0.03406739731355258,-1.0933931996163695,0.27455197374611917,LonGen OPEL,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G1, defined by unsupervised clustering",CGP,C2,91,89
Cohort,0.04149847882712368,0.06298744804827261,0.6588372781084874,0.5102246068560491,LGP Offspring,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G1, defined by unsupervised clustering",CGP,C2,125,275
Cohort,0.3132352216674574,0.1757165354801384,1.7826166490908477,0.07501240171015514,LGP Proband,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G1, defined by unsupervised clustering",CGP,C2,125,354
Cohort,-0.08802163370637123,0.05668883504089071,-1.5527155151958862,0.12088859267738394,LonGen OPEL,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G1, defined by unsupervised clustering",CGP,C2,220,233
Cohort,-0.010252691768044104,0.03240924577205807,-0.3163508290243383,0.751833892432508,LGP Offspring,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G12, defined by unsupervised clustering",CGP,C2,34,72
Cohort,0.057438646872338524,0.08901529119893548,0.6452671905995565,0.5189315200169711,LGP Proband,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G12, defined by unsupervised clustering",CGP,C2,34,93
Cohort,-1.0652913047407205e-4,0.026123706748751852,-0.004077871930604253,0.9967473596925702,LonGen OPEL,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G12, defined by unsupervised clustering",CGP,C2,51,61
Cohort,0.020708285566668375,0.029622207241621464,0.6990797612667989,0.4847426368463641,LGP Offspring,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G12, defined by unsupervised clustering",CGP,C2,29,67
Cohort,0.1308523388678558,0.08652119862701059,1.5123731633903383,0.13081777865438685,LGP Proband,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G12, defined by unsupervised clustering",CGP,C2,29,104
Cohort,0.03191362701877211,0.03132778961122781,1.0187002471229036,0.30865481021471997,LonGen OPEL,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G12, defined by unsupervised clustering",CGP,C2,62,81
Cohort,-0.041697061924450496,0.04631916142187481,-0.9002119348550756,0.36832804932475016,LGP Offspring,"Down-regulated genes in hepatocellular  carcinoma (HCC) subclass G123, defined by unsupervised clustering.",CGP,C2,78,147
Cohort,0.014523581205263755,0.13166697842712602,0.11030541885870153,0.9121936970779715,LGP Proband,"Down-regulated genes in hepatocellular  carcinoma (HCC) subclass G123, defined by unsupervised clustering.",CGP,C2,78,195
Cohort,-0.07594334318027454,0.04293372088108929,-1.7688507220375758,0.07730169679934926,LonGen OPEL,"Down-regulated genes in hepatocellular  carcinoma (HCC) subclass G123, defined by unsupervised clustering.",CGP,C2,133,132
Cohort,0.0017334715783683728,0.025333509448425547,0.06842603398070086,0.9454667324719075,LGP Offspring,"Up-regulated genes in hepatocellular  carcinoma (HCC) subclass G123, defined by unsupervised clustering.",CGP,C2,21,46
Cohort,0.025336719577421903,0.06639608062221365,0.3815996266644869,0.7028555615678571,LGP Proband,"Up-regulated genes in hepatocellular  carcinoma (HCC) subclass G123, defined by unsupervised clustering.",CGP,C2,21,56
Cohort,0.016568559253049377,0.021731313429575544,0.7624278811652571,0.446030532218031,LonGen OPEL,"Up-regulated genes in hepatocellular  carcinoma (HCC) subclass G123, defined by unsupervised clustering.",CGP,C2,29,43
Cohort,0.027050092917342308,0.027748582977076563,0.9748279016513641,0.3299943326022019,LGP Offspring,"Genes in hepatocellular carcinoma (HCC) subclass G2, defined by unsupervised clustering.",CGP,C2,21,55
Cohort,-0.08629528361937673,0.07434121505688232,-1.1608000158908856,0.24605538545145786,LGP Proband,"Genes in hepatocellular carcinoma (HCC) subclass G2, defined by unsupervised clustering.",CGP,C2,21,69
Cohort,0.010471190779245212,0.026877017147649777,0.38959646160589106,0.6969391807449394,LonGen OPEL,"Genes in hepatocellular carcinoma (HCC) subclass G2, defined by unsupervised clustering.",CGP,C2,51,58
Cohort,-0.003348018274521416,0.021883917453380423,-0.1529898968799229,0.8784518967133089,LGP Offspring,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G23, defined by unsupervised clustering.",CGP,C2,14,31
Cohort,-0.01956756966211142,0.055263697815757136,-0.35407637265511016,0.7233711458749905,LGP Proband,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G23, defined by unsupervised clustering.",CGP,C2,14,33
Cohort,0.0012615765029478777,0.016075612010048427,0.07847766555695053,0.9374678187548942,LonGen OPEL,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G23, defined by unsupervised clustering.",CGP,C2,20,21
Cohort,-0.06861634887655534,0.044400993996271385,-1.5453786661243993,0.12272268672076793,LGP Offspring,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G23, defined by unsupervised clustering.",CGP,C2,75,119
Cohort,-0.2306249489294772,0.12237460144299693,-1.8845818185312266,0.05983384475833772,LGP Proband,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G23, defined by unsupervised clustering.",CGP,C2,75,174
Cohort,0.016500247984694363,0.03377216888421406,0.48857531304147256,0.62527696436468,LonGen OPEL,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G23, defined by unsupervised clustering.",CGP,C2,84,109
Cohort,0.07011062874733237,0.044552225059820816,1.5736728895850651,0.11603096922248851,LGP Offspring,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G3, defined by unsupervised clustering.",CGP,C2,50,139
Cohort,0.15523061964563858,0.12147518296768013,1.277879282445201,0.2016475568403495,LGP Proband,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G3, defined by unsupervised clustering.",CGP,C2,50,208
Cohort,-0.06525118244497949,0.03902105054209862,-1.6722046571909177,0.09487695601976967,LonGen OPEL,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G3, defined by unsupervised clustering.",CGP,C2,118,114
Cohort,-0.1971359555409676,0.06780232899633692,-2.9075100879147975,0.003762568660668611,LGP Offspring,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G3, defined by unsupervised clustering.",CGP,C2,172,266
Cohort,-0.13454421195217497,0.1862059712477662,-0.7225558399153057,0.4701553673533193,LGP Proband,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G3, defined by unsupervised clustering.",CGP,C2,172,393
Cohort,-0.07685950804202121,0.061137623848637856,-1.257155630259805,0.20906602254191464,LonGen OPEL,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G3, defined by unsupervised clustering.",CGP,C2,249,272
Cohort,-0.003825128355932246,0.013142822168124806,-0.29104314940890724,0.7711075924021455,LGP Offspring,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G5, defined by unsupervised clustering.",CGP,C2,6,11
Cohort,0.05214253107784146,0.043983848900258575,1.185492683827743,0.2361603672195163,LGP Proband,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G5, defined by unsupervised clustering.",CGP,C2,6,26
Cohort,-0.011160931271086999,0.013062628940401253,-0.854416926486175,0.3931310869979032,LonGen OPEL,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G5, defined by unsupervised clustering.",CGP,C2,14,12
Cohort,-0.0013342956933974836,0.019650394072248556,-0.06790172698276085,0.9458839424394465,LGP Offspring,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G56, defined by unsupervised clustering.",CGP,C2,13,23
Cohort,-0.03138140408189422,0.056280952940061565,-0.5575848034292344,0.5772775588866853,LGP Proband,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G56, defined by unsupervised clustering.",CGP,C2,13,43
Cohort,-0.009310408087380458,0.01717776514862024,-0.5420034566096215,0.5879678110556947,LonGen OPEL,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G56, defined by unsupervised clustering.",CGP,C2,23,23
Cohort,-0.012561875456012719,0.014961204620322037,-0.8396299479087217,0.40141273760195295,LGP Offspring,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G56, defined by unsupervised clustering.",CGP,C2,9,14
Cohort,0.06994458661009031,0.044069259106552044,1.5871514073103903,0.11285739156393883,LGP Proband,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G56, defined by unsupervised clustering.",CGP,C2,9,22
Cohort,-0.010709788487559916,0.012485867602462656,-0.8577528473429885,0.3912871351808205,LonGen OPEL,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G56, defined by unsupervised clustering.",CGP,C2,12,12
Cohort,-0.025815840562469727,0.024802474648639015,-1.04085745185456,0.2983138247151094,LGP Offspring,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G6, defined by unsupervised clustering.",CGP,C2,25,41
Cohort,-0.11080858096125781,0.06716743674088035,-1.6497366333739516,0.0993733622459992,LGP Proband,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G6, defined by unsupervised clustering.",CGP,C2,25,55
Cohort,-0.020466624159802556,0.01677215025715259,-1.2202743146231017,0.2227222861357653,LonGen OPEL,"Down-regulated genes in hepatocellular carcinoma (HCC) subclass G6, defined by unsupervised clustering.",CGP,C2,22,18
Cohort,-0.02128427517210584,0.044476523024877784,-0.47855078869813084,0.6324129703504564,LGP Offspring,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G6, defined by unsupervised clustering.",CGP,C2,77,143
Cohort,-0.04355300090533921,0.13179133790046169,-0.33046937377806707,0.7411283292289526,LGP Proband,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G6, defined by unsupervised clustering.",CGP,C2,77,237
Cohort,0.09329736893108692,0.044703984696549334,2.0870034195920004,0.037205421944933585,LonGen OPEL,"Up-regulated genes in hepatocellular carcinoma (HCC) subclass G6, defined by unsupervised clustering.",CGP,C2,117,178
Cohort,9.117557580489421e-4,0.012604261090941808,0.07233710500524188,0.9423550330705892,LGP Offspring,Embryonic genes targeted by LET7A1 [GeneID=406881] and which are up-regulated in many human cancers.,CGP,C2,4,10
Cohort,0.010490888557226201,0.030937395605875728,0.3391005723582543,0.7346193307820056,LGP Proband,Embryonic genes targeted by LET7A1 [GeneID=406881] and which are up-regulated in many human cancers.,CGP,C2,4,12
Cohort,0.011860616638753202,0.010907803166213733,1.087351546229836,0.2772106115300272,LonGen OPEL,Embryonic genes targeted by LET7A1 [GeneID=406881] and which are up-regulated in many human cancers.,CGP,C2,6,12
Cohort,0.012959914910532886,0.03234012174478984,0.4007379753485559,0.6887396705536988,LGP Offspring,Genes from cluster 2: down-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,36,70
Cohort,0.01595389679668823,0.08952592639047163,0.1782042078749852,0.8586058811740481,LGP Proband,Genes from cluster 2: down-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,36,96
Cohort,-0.012863952451929051,0.02495468662609586,-0.5154924461554581,0.6063520806845615,LonGen OPEL,Genes from cluster 2: down-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,45,50
Cohort,-0.04389749770011865,0.03840566472731568,-1.1429953891384401,0.25344513584782646,LGP Offspring,Genes from cluster 1: up-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,54,98
Cohort,-0.06322621123250098,0.10272093110200395,-0.6155143898541582,0.538382993434644,LGP Proband,Genes from cluster 1: up-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,54,135
Cohort,0.016883036917519578,0.033544562895096594,0.5033017413378629,0.6148913823336519,LonGen OPEL,Genes from cluster 1: up-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,75,94
Cohort,0.04372424517174598,0.09859752495384246,0.4434618941217347,0.6575735688461216,LGP Offspring,Genes down-regulated both in group C and D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,301,653
Cohort,0.6091714548625116,0.2799931095123868,2.1756658795046597,0.029860386155479066,LGP Proband,Genes down-regulated both in group C and D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,301,933
Cohort,0.12720248958464975,0.08619617385718324,1.4757324355882555,0.1404111777355271,LonGen OPEL,Genes down-regulated both in group C and D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,469,613
Cohort,-0.06827938514162112,0.057074334793629895,-1.196323801030824,0.23198964416118822,LGP Offspring,Genes up-regulated both in group C and D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,111,198
Cohort,-0.20122369543113494,0.15567684653139816,-1.292573044190939,0.1965167539700274,LGP Proband,Genes up-regulated both in group C and D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,111,277
Cohort,0.011843037034331868,0.04866230916807586,0.243371866991082,0.8077800395212262,LonGen OPEL,Genes up-regulated both in group C and D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,159,186
Cohort,0.03820780319564626,0.04692490235980934,0.8142329823656879,0.41579822028485836,LGP Offspring,Genes down-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,69,150
Cohort,-0.06278311439543174,0.12488377388859505,-0.502732360181865,0.6152851788126522,LGP Proband,Genes down-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,69,202
Cohort,0.004727845287183762,0.04175304524504307,0.11323354403102016,0.909873953433928,LonGen OPEL,Genes down-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,113,149
Cohort,0.0022754392531804113,0.04148164453911115,0.05485412351564325,0.956270888348119,LGP Offspring,Genes up-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,57,120
Cohort,-0.04575046785157623,0.11133684571375418,-0.41091938215314794,0.6812372074152442,LGP Proband,Genes up-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,57,154
Cohort,0.008064497679063254,0.03570636776290437,0.2258560078866808,0.8213713916595948,LonGen OPEL,Genes up-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,90,103
Cohort,-0.050377754120781666,0.038194321196520616,-1.3189854549731053,0.187620593897496,LGP Offspring,Genes from cluster 4: down-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,52,85
Cohort,-0.0962555252593612,0.1043644234104179,-0.9223020845027994,0.35663775725281044,LGP Proband,Genes from cluster 4: down-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,52,134
Cohort,0.014599603902181941,0.030188932231187227,0.4836078265497431,0.6287972227576488,LonGen OPEL,Genes from cluster 4: down-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,68,87
Cohort,0.035931731403246236,0.031053905944292633,1.1570760685533052,0.24764997748227702,LGP Offspring,Genes from cluster 3: up-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,29,72
Cohort,0.017642272314524133,0.08735460549512115,0.20196155903319227,0.8399960280038454,LGP Proband,Genes from cluster 3: up-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,29,101
Cohort,0.028468538981754127,0.025884984128511607,1.099809018248414,0.2717478433801089,LonGen OPEL,Genes from cluster 3: up-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,39,64
Cohort,-0.042187338057584275,0.05627977245490415,-0.7496003664795934,0.45375620925918536,LGP Offspring,Genes down-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,90,164
Cohort,-0.23881663573192896,0.14918437665767728,-1.6008153204938103,0.10979652541356667,LGP Proband,Genes down-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,90,220
Cohort,-0.03045071067922458,0.047656956499190474,-0.6389562598220436,0.5230351982129084,LonGen OPEL,Genes down-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,141,162
Cohort,-7.321678631680076e-5,0.05842860213984188,-0.001253098373662357,0.9990005421067616,LGP Offspring,Genes up-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,112,235
Cohort,-0.18606244083597415,0.15310815550442036,-1.2152353362430937,0.22462025476717143,LGP Proband,Genes up-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,112,293
Cohort,0.03459154700958978,0.05056652233628168,0.6840800081039033,0.49412374488044497,LonGen OPEL,Genes up-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.,CGP,C2,162,221
Cohort,-0.006591572989523986,0.011002231524613848,-0.5991123686842551,0.5492986734297016,LGP Offspring,Top down-regulated genes from principal component 1 (PCA1) which captures variation between normal plasma cells and tumors arising from aberrant expression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,5,7
Cohort,0.020215814721521185,0.03404398858442189,0.5938145194529789,0.5527971973297839,LGP Proband,Top down-regulated genes from principal component 1 (PCA1) which captures variation between normal plasma cells and tumors arising from aberrant expression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,5,14
Cohort,-0.010274622548516731,0.009618783140575885,-1.0681831993045203,0.28576171561121716,LonGen OPEL,Top down-regulated genes from principal component 1 (PCA1) which captures variation between normal plasma cells and tumors arising from aberrant expression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,8,6
Cohort,0.0112567884995272,0.06170623317959505,0.1824254685383969,0.8553035326211089,LGP Offspring,Top up-regulated genes from principal component 1 (PCA1) which captures variation between normal plasma cells and tumors arising from aberrant expression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,124,268
Cohort,0.5447708313305376,0.1731314654771508,3.14657321145609,0.001710621795754821,LGP Proband,Top up-regulated genes from principal component 1 (PCA1) which captures variation between normal plasma cells and tumors arising from aberrant expression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,124,382
Cohort,0.05438837578629788,0.053625684863663946,1.0142224929075119,0.31078477571982116,LonGen OPEL,Top up-regulated genes from principal component 1 (PCA1) which captures variation between normal plasma cells and tumors arising from aberrant expression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,196,250
Cohort,-0.07879355416588223,0.050447872070089335,-1.5618806291058431,0.11878411135602641,LGP Offspring,Top down-regulated genes from principal component 3 (PCA3) which captures variation among different plasma cell tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,88,148
Cohort,-0.2536202820943271,0.1355911646277227,-1.8704779385195456,0.06176752687566446,LGP Proband,Top down-regulated genes from principal component 3 (PCA3) which captures variation among different plasma cell tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,88,210
Cohort,-0.004075695901376435,0.04363119048577825,-0.09341243857888598,0.9255994153113746,LonGen OPEL,Top down-regulated genes from principal component 3 (PCA3) which captures variation among different plasma cell tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,123,140
Cohort,0.04020503896874354,0.0558344242741993,0.7200761804455824,0.4717269849279595,LGP Offspring,Top up-regulated genes from principal component 3 (PCA3) which captures variation among different plasma cell tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,94,213
Cohort,0.03623864354571806,0.15039717086757542,0.24095296032946095,0.8096507963466367,LGP Proband,Top up-regulated genes from principal component 3 (PCA3) which captures variation among different plasma cell tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,94,258
Cohort,-0.017826929395842985,0.04520048761372759,-0.3943968381090842,0.6933937192495736,LonGen OPEL,Top up-regulated genes from principal component 3 (PCA3) which captures variation among different plasma cell tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609].,CGP,C2,150,185
Cohort,-0.008825494730442888,0.03385975179709248,-0.26064853585845627,0.7944429343208567,LGP Offspring,Genes specifically down-regulated in FL5.12 cells (pro-B lymphocyte) by  camptothecin [PubChem=2538].,CGP,C2,33,65
Cohort,0.021461081378796043,0.08125388045808271,0.264123771785489,0.7917497984863495,LGP Proband,Genes specifically down-regulated in FL5.12 cells (pro-B lymphocyte) by  camptothecin [PubChem=2538].,CGP,C2,33,76
Cohort,-0.03836167967790095,0.026596642022432223,-1.4423504909208398,0.14959686523026622,LonGen OPEL,Genes specifically down-regulated in FL5.12 cells (pro-B lymphocyte) by  camptothecin [PubChem=2538].,CGP,C2,57,52
Cohort,0.005417848909811184,0.017005424765872336,0.3185953296905643,0.7501318033853414,LGP Offspring,Genes specifically up-regulated in FL5.12 cells (pro-B lymphocyte) by  camptothecin [PubChem=2538].,CGP,C2,10,20
Cohort,0.022202798368897717,0.04536186026399712,0.48945960857164567,0.624645050206065,LGP Proband,Genes specifically up-regulated in FL5.12 cells (pro-B lymphocyte) by  camptothecin [PubChem=2538].,CGP,C2,10,23
Cohort,-0.003100712591999047,0.01084126437031288,-0.28601023700610667,0.7749446959434274,LonGen OPEL,Genes specifically up-regulated in FL5.12 cells (pro-B lymphocyte) by  camptothecin [PubChem=2538].,CGP,C2,8,10
Cohort,-0.030234427575079256,0.02178315584301955,-1.3879727892948042,0.1656026022192624,LGP Offspring,Genes up-regulated in FL5.12 cells (pro-B lymphocyte) in response to cisplatin [PubChem=2767].,CGP,C2,21,26
Cohort,-0.01117817554258298,0.0573691958090713,-0.19484630009081408,0.8455607291970086,LGP Proband,Genes up-regulated in FL5.12 cells (pro-B lymphocyte) in response to cisplatin [PubChem=2767].,CGP,C2,21,35
Cohort,5.57572489697097e-4,0.015514940154417223,0.03593777895033335,0.971340982173351,LonGen OPEL,Genes up-regulated in FL5.12 cells (pro-B lymphocyte) in response to cisplatin [PubChem=2767].,CGP,C2,17,18
Cohort,-0.023708593720503702,0.024139394247791306,-0.9821536314099091,0.32637553994386925,LGP Offspring,Genes down-regulated in  FL5.12 cells (pro-B lymphocyte) in response to methotrexate [PubChem=4112].,CGP,C2,20,32
Cohort,-0.028244704657676166,0.06038276162745531,-0.4677610612104505,0.6400776720194591,LGP Proband,Genes down-regulated in  FL5.12 cells (pro-B lymphocyte) in response to methotrexate [PubChem=4112].,CGP,C2,20,43
Cohort,-0.0187732980541824,0.022151372276546316,-0.8475004536878922,0.39697098019155086,LonGen OPEL,Genes down-regulated in  FL5.12 cells (pro-B lymphocyte) in response to methotrexate [PubChem=4112].,CGP,C2,40,36
Cohort,-0.022009808918989446,0.021516570269134942,-1.0229236650490736,0.30670985531478173,LGP Offspring,Genes up-regulated in  FL5.12 cells (pro-B lymphocyte) in response to methotrexate [PubChem=4112].,CGP,C2,19,26
Cohort,0.036377438733952425,0.06070415118163566,0.5992578435880905,0.54916370243866,LGP Proband,Genes up-regulated in  FL5.12 cells (pro-B lymphocyte) in response to methotrexate [PubChem=4112].,CGP,C2,19,39
Cohort,0.008583315286027416,0.01605602232294472,0.5345854105945969,0.5930858562539141,LonGen OPEL,Genes up-regulated in  FL5.12 cells (pro-B lymphocyte) in response to methotrexate [PubChem=4112].,CGP,C2,16,22
Cohort,-0.017059376879143683,0.03688696269003467,-0.4624771365020091,0.6438880141587046,LGP Offspring,Genes down-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes are independent of ATM [GeneID=472] signaling.,CGP,C2,43,86
Cohort,0.07698203985717553,0.10356893357287397,0.7432927732427488,0.45751377391138315,LGP Proband,Genes down-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes are independent of ATM [GeneID=472] signaling.,CGP,C2,43,126
Cohort,0.022982650526206395,0.033407417559873955,0.6879505273047842,0.49168435382977815,LonGen OPEL,Genes down-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes are independent of ATM [GeneID=472] signaling.,CGP,C2,76,91
Cohort,-0.041630047603315276,0.04221921135019521,-0.986045126660633,0.3244637552369475,LGP Offspring,Genes up-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes are independent of ATM [GeneID=472] signaling.,CGP,C2,62,110
Cohort,-0.028460381420735297,0.10923835166256904,-0.2605347022138138,0.7945156629567526,LGP Proband,Genes up-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes are independent of ATM [GeneID=472] signaling.,CGP,C2,62,151
Cohort,-0.027387457291124385,0.035986713777262896,-0.7610435745991431,0.4468564290397232,LonGen OPEL,Genes up-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes are independent of ATM [GeneID=472] signaling.,CGP,C2,95,101
Cohort,-0.0868008068009991,0.04869123688573109,-1.7826782056225803,0.07508737377102202,LGP Offspring,Genes down-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes depend on ATM [GeneID=472] but not NFKB signaling.,CGP,C2,81,131
Cohort,-0.1943555003363351,0.12283466650142069,-1.5822528433704603,0.11397098869182407,LGP Proband,Genes down-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes depend on ATM [GeneID=472] but not NFKB signaling.,CGP,C2,81,152
Cohort,-0.028642539676725372,0.043250010775350546,-0.6622550876461191,0.5079994410722709,LonGen OPEL,Genes down-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes depend on ATM [GeneID=472] but not NFKB signaling.,CGP,C2,121,131
Cohort,-0.042402655775583435,0.043900131558771295,-0.9658890365468925,0.33444512040814434,LGP Offspring,Genes up-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes depend on ATM [GeneID=472] but not NFKB signaling.,CGP,C2,71,121
Cohort,-0.398653116133383,0.11919511078928342,-3.3445425193499214,8.609709817878159e-4,LGP Proband,Genes up-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes depend on ATM [GeneID=472] but not NFKB signaling.,CGP,C2,71,157
Cohort,-0.04777674648251752,0.038841054944040825,-1.2300579001098335,0.21903883031867788,LonGen OPEL,Genes up-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes depend on ATM [GeneID=472] but not NFKB signaling.,CGP,C2,109,115
Cohort,0.003806537373032048,0.022111441774031543,0.17215238209851064,0.8633692568390476,LGP Offspring,Growth factor signaling components up-regulated  in hepatocellular carcinoma (HCC).,CGP,C2,15,34
Cohort,0.02897941526877743,0.05363395324478963,0.5403184646209663,0.5891216810077831,LGP Proband,Growth factor signaling components up-regulated  in hepatocellular carcinoma (HCC).,CGP,C2,15,34
Cohort,5.8975434111645384e-5,0.018219271131958717,0.00323698097934311,0.9974180784011337,LonGen OPEL,Growth factor signaling components up-regulated  in hepatocellular carcinoma (HCC).,CGP,C2,22,28
Cohort,-0.028824324670919776,0.036802869701310484,-0.7832086167425524,0.43377891367572785,LGP Offspring,List of genomically imprinted genes.,CGP,C2,47,86
Cohort,0.05895422217948823,0.10621961263448829,0.5550220031620269,0.5790284339094993,LGP Proband,List of genomically imprinted genes.,CGP,C2,47,133
Cohort,0.031228955377380723,0.03438945311012466,0.9080968888157908,0.36410187470795996,LonGen OPEL,List of genomically imprinted genes.,CGP,C2,74,101
Cohort,-0.03316031962943127,0.05593537434092663,-0.592832711323586,0.5534913760773845,LGP Offspring,"Genes changed in INA-6 cells (multiple myeloma, MM) by re-addition of IL6 [GeneID=3569] after its initial withdrawal for 12h.",CGP,C2,102,200
Cohort,0.023010075442059977,0.1593662084506041,0.1443849086062181,0.8852314152948524,LGP Proband,"Genes changed in INA-6 cells (multiple myeloma, MM) by re-addition of IL6 [GeneID=3569] after its initial withdrawal for 12h.",CGP,C2,102,302
Cohort,-0.008072788644588201,0.04864263373003605,-0.16596117491071177,0.8682296470852507,LonGen OPEL,"Genes changed in INA-6 cells (multiple myeloma, MM) by re-addition of IL6 [GeneID=3569] after its initial withdrawal for 12h.",CGP,C2,175,206
Cohort,0.011608411413640064,0.061524651522008124,0.18867902745434637,0.8504010186306097,LGP Offspring,Genes defining proliferation and self renewal potential of the bipotential myeloid cell line FDB.,CGP,C2,120,254
Cohort,0.06962641314554138,0.17223829070542243,0.4042446825289436,0.6861364404653714,LGP Proband,Genes defining proliferation and self renewal potential of the bipotential myeloid cell line FDB.,CGP,C2,120,365
Cohort,-0.016654754445589823,0.05915535157954702,-0.28154265000342266,0.7783673941004728,LonGen OPEL,Genes defining proliferation and self renewal potential of the bipotential myeloid cell line FDB.,CGP,C2,221,255
Cohort,-0.009503928792978563,0.07008523627200001,-0.13560529005130156,0.8921736923304732,LGP Offspring,Genes defining differentiation potential of the bipotential myeloid cell line FDB.,CGP,C2,156,321
Cohort,0.06374674281620517,0.1890111424891596,0.3372644701084818,0.7360024004082129,LGP Proband,Genes defining differentiation potential of the bipotential myeloid cell line FDB.,CGP,C2,156,430
Cohort,-0.050724862799623814,0.059291911891410524,-0.855510662103851,0.39252593716964435,LonGen OPEL,Genes defining differentiation potential of the bipotential myeloid cell line FDB.,CGP,C2,248,276
Cohort,-0.026965973551588016,0.04764988538135406,-0.5659189594218857,0.5716366735116807,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 10 h time point that were not down-regulated at the previous time point, 8 h.",CGP,C2,82,151
Cohort,-0.04299335355859827,0.13182206273935718,-0.32614687302842554,0.7443950545708864,LGP Proband,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 10 h time point that were not down-regulated at the previous time point, 8 h.",CGP,C2,82,205
Cohort,-0.01066445347344338,0.04285646150428448,-0.2488412038492078,0.8035478068319809,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 10 h time point that were not down-regulated at the previous time point, 8 h.",CGP,C2,131,152
Cohort,0.03969513952358154,0.05125761401104241,0.774424254609862,0.43895071321698353,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 10 h time point that were not up-regulated at the previous time point, 8 h.",CGP,C2,77,175
Cohort,0.015574157254250778,0.1451130188423626,0.10732432815810349,0.914557496777261,LGP Proband,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 10 h time point that were not up-regulated at the previous time point, 8 h.",CGP,C2,77,248
Cohort,-0.030908442420202784,0.04540411144572515,-0.6807410482451551,0.4962333214671206,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 10 h time point that were not up-regulated at the previous time point, 8 h.",CGP,C2,144,161
Cohort,-0.04122988038046508,0.06669240460167948,-0.6182095341547605,0.5366454510957401,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 12 h time point that were not down-regulated at the previous time point, 10 h.",CGP,C2,145,287
Cohort,0.019253517107768885,0.1846556862111354,0.10426712278848757,0.9169824365353233,LGP Proband,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 12 h time point that were not down-regulated at the previous time point, 10 h.",CGP,C2,145,390
Cohort,0.052363621397548986,0.057597695618110054,0.909127020371361,0.36355825815627396,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 12 h time point that were not down-regulated at the previous time point, 10 h.",CGP,C2,215,279
Cohort,-0.091147582234843,0.06677446331437961,-1.3650065865106658,0.17270509633589476,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 12 h time point that were not up-regulated at the previous time point, 10 h.",CGP,C2,142,258
Cohort,0.13209620767307442,0.1778766038386177,0.7426283435955495,0.45791583464555596,LGP Proband,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 12 h time point that were not up-regulated at the previous time point, 10 h.",CGP,C2,142,377
Cohort,-0.017975660411070585,0.05350745949239672,-0.3359468115585806,0.7369995070443609,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 12 h time point that were not up-regulated at the previous time point, 10 h.",CGP,C2,218,246
Cohort,-0.08156381468071518,0.10874294867726796,-0.7500607227672648,0.45347909836097744,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 14 h time point that were not down-regulated at the previous time point, 12 h.",CGP,C2,358,717
Cohort,-0.0768628985239574,0.27731234037871355,-0.27717085514113454,0.7817176013854752,LGP Proband,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 14 h time point that were not down-regulated at the previous time point, 12 h.",CGP,C2,358,954
Cohort,-0.013257027554486517,0.08966734041528163,-0.14784678003260124,0.8825011314104931,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 14 h time point that were not down-regulated at the previous time point, 12 h.",CGP,C2,559,676
Cohort,-0.06048348550928787,0.0614075652836488,-0.9849516949565986,0.3250001885812557,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 14 h time point that were not up-regulated at the previous time point, 12 h.",CGP,C2,125,227
Cohort,-0.20571844701879516,0.1584429457082841,-1.2983755515221986,0.19451722596731907,LGP Proband,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 14 h time point that were not up-regulated at the previous time point, 12 h.",CGP,C2,125,294
Cohort,-0.03705538536289196,0.05275356482029339,-0.7024242909293855,0.48261995284026493,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 14 h time point that were not up-regulated at the previous time point, 12 h.",CGP,C2,184,203
Cohort,-0.04449061504409439,0.04584089037998903,-0.9705443039020011,0.33212237893199903,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 16 h time point that were not down-regulated at the previous time point, 14 h.",CGP,C2,83,147
Cohort,0.0685904099111547,0.13086639035104788,0.5241254819297878,0.600330525812968,LGP Proband,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 16 h time point that were not down-regulated at the previous time point, 14 h.",CGP,C2,83,203
Cohort,0.05058446546467582,0.0421324896648747,1.2006047083148619,0.230261732369906,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 16 h time point that were not down-regulated at the previous time point, 14 h.",CGP,C2,112,158
Cohort,-0.24555481805611998,0.07639190656861138,-3.2144088174520813,0.0013693054614567384,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 16 h time point that were not up-regulated at the previous time point, 14 h.",CGP,C2,220,340
Cohort,-0.42942525994152264,0.20832255099282188,-2.061347933264888,0.03957930776450375,LGP Proband,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 16 h time point that were not up-regulated at the previous time point, 14 h.",CGP,C2,220,505
Cohort,0.006919295525790842,0.06247551155648149,0.11075212276630016,0.9118408299975045,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 16 h time point that were not up-regulated at the previous time point, 14 h.",CGP,C2,271,338
Cohort,-0.008643457734145817,0.08457784946217976,-0.10219528859043486,0.9186319732633226,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 18 h time point that were not down-regulated at the previous time point, 16 h.",CGP,C2,212,430
Cohort,-0.5786245538703971,0.21939935710135794,-2.637311984478991,0.008512157442886975,LGP Proband,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 18 h time point that were not down-regulated at the previous time point, 16 h.",CGP,C2,212,553
Cohort,-0.04218134377821351,0.06622119317655467,-0.6369764988340264,0.5243232959060022,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 18 h time point that were not down-regulated at the previous time point, 16 h.",CGP,C2,328,370
Cohort,-0.012539906557923036,0.07215580107448562,-0.17378930551929195,0.8620830776178768,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 18 h time point that were not up-regulated at the previous time point, 16 h.",CGP,C2,168,347
Cohort,-0.14176035491362773,0.19516311254691043,-0.7263685901686645,0.467816645388587,LGP Proband,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 18 h time point that were not up-regulated at the previous time point, 16 h.",CGP,C2,168,464
Cohort,0.05531595438136657,0.06254255924048102,0.8844530037325848,0.37671878974883355,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 18 h time point that were not up-regulated at the previous time point, 16 h.",CGP,C2,274,341
Cohort,0.13930908022765343,0.08333283223203534,1.6717190151386614,0.09504252261568621,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 1 h time point that were not down-regulated at the previous time point, 30 min.",CGP,C2,177,438
Cohort,-0.13239560596380986,0.2140839744906623,-0.6184283820346608,0.5364618489181097,LGP Proband,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 1 h time point that were not down-regulated at the previous time point, 30 min.",CGP,C2,177,588
Cohort,-0.06632898483539691,0.06682838358936194,-0.9925271459948266,0.3212420530331521,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 1 h time point that were not down-regulated at the previous time point, 30 min.",CGP,C2,335,377
Cohort,0.03428257403430854,0.03861380413212795,0.8878320798697042,0.37494685987829124,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 1 h time point that were not up-regulated at the previous time point, 30 min.",CGP,C2,43,104
Cohort,-0.024454649513225044,0.10359704327666906,-0.23605547745137664,0.813447579065577,LGP Proband,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 1 h time point that were not up-regulated at the previous time point, 30 min.",CGP,C2,43,121
Cohort,0.03361977606536459,0.03525713145685457,0.9535595970564517,0.3405960862399424,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 1 h time point that were not up-regulated at the previous time point, 30 min.",CGP,C2,81,108
Cohort,-0.08835437387974678,0.05909005625536683,-1.495249445996627,0.13531601674407556,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 20 h time point that were not down-regulated at the previous time point, 18 h.",CGP,C2,133,239
Cohort,-0.09983614924085961,0.1713262566388261,-0.5827253288521023,0.5602357333866976,LGP Proband,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 20 h time point that were not down-regulated at the previous time point, 18 h.",CGP,C2,133,331
Cohort,-0.009403127799290298,0.05086923622931576,-0.18484900691061112,0.8533945535609906,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 20 h time point that were not down-regulated at the previous time point, 18 h.",CGP,C2,191,209
Cohort,-0.12063134496888771,0.07668476068121621,-1.573081064572405,0.11616793422763151,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 20 h time point that were not up-regulated at the previous time point, 18 h.",CGP,C2,193,348
Cohort,-0.4243945331530988,0.2133518734959041,-1.9891765007690276,0.047008019780128855,LGP Proband,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 20 h time point that were not up-regulated at the previous time point, 18 h.",CGP,C2,193,471
Cohort,0.12444309173211449,0.06268422643253609,1.9852377354619888,0.047460822653890504,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 20 h time point that were not up-regulated at the previous time point, 18 h.",CGP,C2,241,328
Cohort,-0.1028045285401917,0.0730942383041189,-1.4064655563200337,0.16004544730708345,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 24 h time point that were not down-regulated at the previous time point, 20 h.",CGP,C2,197,357
Cohort,-0.21086179232587146,0.2028719353041428,-1.0393837472381302,0.29892752971179204,LGP Proband,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 24 h time point that were not down-regulated at the previous time point, 20 h.",CGP,C2,197,474
Cohort,0.03404247098050513,0.06716774485804121,0.5068276603964265,0.6124161101356391,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 24 h time point that were not down-regulated at the previous time point, 20 h.",CGP,C2,278,351
Cohort,-0.0384112052904413,0.06046458333040148,-0.6352678406886204,0.5254687131951903,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 24 h time point that were not up-regulated at the previous time point, 20 h.",CGP,C2,121,239
Cohort,-0.3728971016562586,0.16624180654915366,-2.2431006339311046,0.02515217127411236,LGP Proband,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 24 h time point that were not up-regulated at the previous time point, 20 h.",CGP,C2,121,331
Cohort,-0.023028022706992765,0.05039446622948447,-0.45695538478626996,0.6478277875009362,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 24 h time point that were not up-regulated at the previous time point, 20 h.",CGP,C2,182,203
Cohort,2.099951104064738e-4,0.03725745616685026,0.005636324430365069,0.9955045504285793,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 2 h time point that were not down-regulated at the previous time point, 1 h.",CGP,C2,39,85
Cohort,-0.10832367157820007,0.1017580445266274,-1.0645219459760218,0.2874004194304591,LGP Proband,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 2 h time point that were not down-regulated at the previous time point, 1 h.",CGP,C2,39,121
Cohort,-0.02345436389223062,0.030645562210599046,-0.7653429142872346,0.44429423354033504,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 2 h time point that were not down-regulated at the previous time point, 1 h.",CGP,C2,75,78
Cohort,-0.04694871203111411,0.030498691840392108,-1.5393680580403055,0.12418240080009293,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 2 h time point that were not up-regulated at the previous time point, 1 h.",CGP,C2,37,58
Cohort,0.02914603247299545,0.08065476887794797,0.36136775144816446,0.7179160768270705,LGP Proband,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 2 h time point that were not up-regulated at the previous time point, 1 h.",CGP,C2,37,73
Cohort,-0.03274147355778688,0.025334433646147646,-1.2923704557636932,0.1966039194369754,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 2 h time point that were not up-regulated at the previous time point, 1 h.",CGP,C2,49,41
Cohort,0.08131273182850071,0.07195798072139979,1.130002968584121,0.2588757575239483,LGP Offspring,Genes down-regulated in primary fibroblast cell culture at 30 min time point after infection with HCMV (AD169 strain).,CGP,C2,153,373
Cohort,0.07315024829993914,0.21133082137375522,0.34614093592418854,0.7293241022257042,LGP Proband,Genes down-regulated in primary fibroblast cell culture at 30 min time point after infection with HCMV (AD169 strain).,CGP,C2,153,512
Cohort,0.05024136451170928,0.06733595978326318,0.7461297748398193,0.45580931327900076,LonGen OPEL,Genes down-regulated in primary fibroblast cell culture at 30 min time point after infection with HCMV (AD169 strain).,CGP,C2,285,362
Cohort,0.018995998214287973,0.03800101429297804,0.4998813470565211,0.6173212975103881,LGP Offspring,Genes up-regulated in primary fibroblast cell culture at 30 min time point after infection with HCMV (AD169 strain).,CGP,C2,44,97
Cohort,-0.11414608569416632,0.10499733298054609,-1.0871331914241604,0.27729203763513965,LGP Proband,Genes up-regulated in primary fibroblast cell culture at 30 min time point after infection with HCMV (AD169 strain).,CGP,C2,44,124
Cohort,-0.03445437128907558,0.03263808400404559,-1.055649323189586,0.29144874819509947,LonGen OPEL,Genes up-regulated in primary fibroblast cell culture at 30 min time point after infection with HCMV (AD169 strain).,CGP,C2,75,74
Cohort,-0.029879171786668168,0.13564824164961306,-0.22026951048763113,0.8257277676933585,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 48 h time point that were not down-regulated at the previous time point, 24 h.",CGP,C2,621,1301
Cohort,-0.43460151608111597,0.38870398086889096,-1.1180783770457605,0.26385547476583066,LGP Proband,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 48 h time point that were not down-regulated at the previous time point, 24 h.",CGP,C2,621,1802
Cohort,-0.06329839856368545,0.119183671718892,-0.5310995847902873,0.5954979270444828,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 48 h time point that were not down-regulated at the previous time point, 24 h.",CGP,C2,1009,1215
Cohort,-0.022755027878529257,0.08072729319276264,-0.2818752738828271,0.7781254188648561,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 48 h time point that were not up-regulated at the previous time point, 24 h.",CGP,C2,218,456
Cohort,-0.1903480322519087,0.22120274071642163,-0.8605138961453096,0.3897531310646435,LGP Proband,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 48 h time point that were not up-regulated at the previous time point, 24 h.",CGP,C2,218,577
Cohort,0.10334590672547161,0.07258472433480932,1.4237969169486837,0.15489712613258416,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 48 h time point that were not up-regulated at the previous time point, 24 h.",CGP,C2,328,426
Cohort,-0.1195856597931914,0.09283869641026109,-1.2881014535655853,0.19815138045879152,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 4 h time point that were not down-regulated at the previous time point, 2 h.",CGP,C2,301,591
Cohort,-0.2208605287926903,0.2608803214646267,-0.8465971199082459,0.39746257197344537,LGP Proband,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 4 h time point that were not down-regulated at the previous time point, 2 h.",CGP,C2,301,793
Cohort,-8.304164658256312e-4,0.08051753657112383,-0.01031348574719616,0.9917737590418385,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 4 h time point that were not down-regulated at the previous time point, 2 h.",CGP,C2,464,547
Cohort,-0.022249877438596726,0.03445935317801716,-0.6456847092762817,0.518702669059341,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 4 h time point that were not up-regulated at the previous time point, 2 h.",CGP,C2,39,72
Cohort,-0.23118294840424847,0.09042373653585307,-2.5566621913769763,0.010744219845061439,LGP Proband,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 4 h time point that were not up-regulated at the previous time point, 2 h.",CGP,C2,39,95
Cohort,0.020428049377301943,0.02898647030178428,0.7047442880979021,0.4811755281796857,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 4 h time point that were not up-regulated at the previous time point, 2 h.",CGP,C2,49,72
Cohort,0.02468387229095347,0.06563483804641568,0.37607881767754975,0.7069762957013774,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 6 h time point that were not down-regulated at the previous time point, 4 h.",CGP,C2,138,288
Cohort,-0.06360298831458161,0.1857245258739877,-0.3424587464432976,0.7320919717236269,LGP Proband,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 6 h time point that were not down-regulated at the previous time point, 4 h.",CGP,C2,138,423
Cohort,0.1282132191989939,0.059768246222882154,2.1451728518329474,0.03224100409973775,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 6 h time point that were not down-regulated at the previous time point, 4 h.",CGP,C2,206,296
Cohort,-0.09866922987775173,0.039458486040639486,-2.5005832655649614,0.012634536820996923,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 6 h time point that were not up-regulated at the previous time point, 4 h.",CGP,C2,65,99
Cohort,-0.14697480323040937,0.10712260277891394,-1.3720241986067572,0.17042483069921222,LGP Proband,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 6 h time point that were not up-regulated at the previous time point, 4 h.",CGP,C2,65,126
Cohort,0.03639586821049355,0.0317853788933613,1.145050632638367,0.25253234474941516,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 6 h time point that were not up-regulated at the previous time point, 4 h.",CGP,C2,65,96
Cohort,0.019647033841359927,0.024972399134966836,0.7867499528249079,0.4317039757358143,LGP Offspring,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 8 h time point that were not down-regulated at the previous time point, 6 h.",CGP,C2,19,44
Cohort,-0.053393060505851304,0.06655067145601963,-0.8022918377485702,0.42261271220202634,LGP Proband,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 8 h time point that were not down-regulated at the previous time point, 6 h.",CGP,C2,19,51
Cohort,0.02487711064791827,0.024343749901134595,1.0219095557976798,0.30713417874897797,LonGen OPEL,"Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 8 h time point that were not down-regulated at the previous time point, 6 h.",CGP,C2,36,60
Cohort,-0.07238371504165322,0.043549150340861265,-1.6621154368134041,0.09695322594106011,LGP Offspring,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 8 h time point that were not up-regulated at the previous time point, 6 h.",CGP,C2,74,115
Cohort,-0.20972016246334801,0.12423738585298902,-1.6880600072470244,0.09177357447353024,LGP Proband,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 8 h time point that were not up-regulated at the previous time point, 6 h.",CGP,C2,74,172
Cohort,-0.021367952209914377,0.038905356889790736,-0.5492290501394064,0.5830023073251503,LonGen OPEL,"Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 8 h time point that were not up-regulated at the previous time point, 6 h.",CGP,C2,107,119
Cohort,-0.06006723410687931,0.042464088494731794,-1.4145419396987977,0.15766326533488242,LGP Offspring,Genes up-regulated in primary fibroblast culture after treatment with interferon alpha for 6 h.,CGP,C2,66,108
Cohort,-0.06646121445785987,0.11384521384555728,-0.5837857579855867,0.5595223099935329,LGP Proband,Genes up-regulated in primary fibroblast culture after treatment with interferon alpha for 6 h.,CGP,C2,66,143
Cohort,0.004877438100177131,0.0342386201179792,0.14245428359468018,0.8867572362938996,LonGen OPEL,Genes up-regulated in primary fibroblast culture after treatment with interferon alpha for 6 h.,CGP,C2,82,99
Cohort,-0.004803530529074647,0.05028801763258721,-0.0955203795100864,0.9239298119298459,LGP Offspring,Genes down-regulated in A549 cells (lung cancer) expressing MIRLET7A3 [GeneID=406883] microRNA off a plasmid vector.,CGP,C2,82,174
Cohort,0.17473630753924474,0.13320045831757238,1.3118296269119727,0.18993860317586062,LGP Proband,Genes down-regulated in A549 cells (lung cancer) expressing MIRLET7A3 [GeneID=406883] microRNA off a plasmid vector.,CGP,C2,82,229
Cohort,0.07473241889345152,0.04432635293852051,1.6859591177533468,0.09219556204731476,LonGen OPEL,Genes down-regulated in A549 cells (lung cancer) expressing MIRLET7A3 [GeneID=406883] microRNA off a plasmid vector.,CGP,C2,125,175
Cohort,-0.01482259335989026,0.05768032416012732,-0.2569783297115496,0.7972736966584559,LGP Offspring,Genes up-regulated in A549 cells (lung cancer) expressing MIRLET7A3 [GeneID=406883] microRNA off a plasmid vector.,CGP,C2,116,237
Cohort,-0.25342406960204233,0.1640871572143703,-1.5444479257505725,0.12285919964257208,LGP Proband,Genes up-regulated in A549 cells (lung cancer) expressing MIRLET7A3 [GeneID=406883] microRNA off a plasmid vector.,CGP,C2,116,316
Cohort,-0.09000322035549659,0.05361434496463735,-1.6787152844049555,0.09360002515291165,LonGen OPEL,Genes up-regulated in A549 cells (lung cancer) expressing MIRLET7A3 [GeneID=406883] microRNA off a plasmid vector.,CGP,C2,203,210
Cohort,-0.1073609365761354,0.08692957517469113,-1.2350334895849426,0.21724711987048534,LGP Offspring,Early-late response genes: differentially expressed in the first 3 h and after 12 h following UV-C irradiation of MEF cells (embryonic fibroblast).,CGP,C2,268,521
Cohort,-0.2794854003025782,0.23848058560120547,-1.1719419406741236,0.24155503902494083,LGP Proband,Early-late response genes: differentially expressed in the first 3 h and after 12 h following UV-C irradiation of MEF cells (embryonic fibroblast).,CGP,C2,268,761
Cohort,0.07640215698170282,0.0804642366654333,0.9495169549595004,0.342645941731032,LonGen OPEL,Early-late response genes: differentially expressed in the first 3 h and after 12 h following UV-C irradiation of MEF cells (embryonic fibroblast).,CGP,C2,427,548
Cohort,-0.4916933166078887,0.1908331531306289,-2.57656129735128,0.010189850666597961,LGP Offspring,Late response genes: differentially expressed only 12 h after UV-C irradiation of MEF cells (embryonic fibroblast).,CGP,C2,1211,2373
Cohort,0.5668398907215909,0.5422087020998735,1.0454275051771125,0.29612833190904697,LGP Proband,Late response genes: differentially expressed only 12 h after UV-C irradiation of MEF cells (embryonic fibroblast).,CGP,C2,1211,3285
Cohort,-0.11568579151794822,0.16589016795493708,-0.6973637614820757,0.48577879972898796,LonGen OPEL,Late response genes: differentially expressed only 12 h after UV-C irradiation of MEF cells (embryonic fibroblast).,CGP,C2,1847,2174
Cohort,-0.0034381690788366777,0.0483770525493306,-0.07107024710384618,0.943362867599374,LGP Offspring,Middle response genes: differentially expressed in the period between 3 h and 12 h after UV-C irradiation of MEF cells (embryonic fibroblast).,CGP,C2,83,162
Cohort,-0.11248980950802911,0.14080135838505678,-0.7989255984334852,0.42456101125819,LGP Proband,Middle response genes: differentially expressed in the period between 3 h and 12 h after UV-C irradiation of MEF cells (embryonic fibroblast).,CGP,C2,83,236
Cohort,0.04049851728991271,0.0450960875462973,0.8980494648972696,0.3694307288895856,LonGen OPEL,Middle response genes: differentially expressed in the period between 3 h and 12 h after UV-C irradiation of MEF cells (embryonic fibroblast).,CGP,C2,134,179
Cohort,-0.32215714464727435,0.1763615840924993,-1.8266854786148168,0.06818790828305052,LGP Offspring,Category A genes: p53-dependent genes whose expression in the absence of S389 phosphorylation is similar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,977,1909
Cohort,-0.4993801457244884,0.4823549677677168,-1.0352959523472147,0.30083081164682596,LGP Proband,Category A genes: p53-dependent genes whose expression in the absence of S389 phosphorylation is similar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,977,2637
Cohort,-0.1370711796258857,0.14723152073593623,-0.9309907208778113,0.35214062869706575,LonGen OPEL,Category A genes: p53-dependent genes whose expression in the absence of S389 phosphorylation is similar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,1500,1741
Cohort,-0.08203894439622732,0.1358395734214753,-0.6039399442287819,0.546086182663206,LGP Offspring,Category B genes: p53-dependent genes whose expression in the absence of S389 phosphorylation is dissimilar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,543,1131
Cohort,-0.21134299358774278,0.35118803140742566,-0.6017944083708145,0.5474745507648304,LGP Proband,Category B genes: p53-dependent genes whose expression in the absence of S389 phosphorylation is dissimilar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,543,1512
Cohort,0.03626798244776029,0.10797904964490636,0.33587980786114596,0.737050016301546,LonGen OPEL,Category B genes: p53-dependent genes whose expression in the absence of S389 phosphorylation is dissimilar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,842,1004
Cohort,0.029318637904416977,0.0494304843531882,0.5931286793576799,0.5532934164863537,LGP Offspring,Category C genes: p53-independent genes whose expression in the absence of S389 phosphorylation is dissimilar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,74,159
Cohort,-0.11788957728414516,0.1374695713372725,-0.8575685232545818,0.3913771261964236,LGP Proband,Category C genes: p53-independent genes whose expression in the absence of S389 phosphorylation is dissimilar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,74,229
Cohort,0.11012071385831952,0.038361230383144033,2.8706251796007742,0.004205271663917813,LonGen OPEL,Category C genes: p53-independent genes whose expression in the absence of S389 phosphorylation is dissimilar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,79,137
Cohort,-0.09647680126869083,0.0973630932053945,-0.9908970441722309,0.32209039729410993,LGP Offspring,Category D genes: p53-independent genes whose expression in the absence of S389 phosphorylation is similar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,309,604
Cohort,-0.36236213480980217,0.27497818591676854,-1.3177850221162029,0.1879374819413922,LGP Proband,Category D genes: p53-independent genes whose expression in the absence of S389 phosphorylation is similar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,309,868
Cohort,-0.061708585352630865,0.08174836825450109,-0.7548601479177925,0.4505561739033449,LonGen OPEL,Category D genes: p53-independent genes whose expression in the absence of S389 phosphorylation is similar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.,CGP,C2,467,552
Cohort,-0.0045601344819222785,0.013456701529674688,-0.3388746099381249,0.7348094269775138,LGP Offspring,"Genes for which mutations result in developmental defects in the great vessels formation and valvulogenesis, a major class of congenital heart disease.",CGP,C2,6,12
Cohort,0.0420934669451279,0.03391765186828161,1.2410489708602728,0.21493662302090868,LGP Proband,"Genes for which mutations result in developmental defects in the great vessels formation and valvulogenesis, a major class of congenital heart disease.",CGP,C2,6,13
Cohort,0.008937723548352454,0.01278787278517864,0.6989218377830148,0.48480503613606096,LonGen OPEL,"Genes for which mutations result in developmental defects in the great vessels formation and valvulogenesis, a major class of congenital heart disease.",CGP,C2,9,16
Cohort,-0.018527636063285318,0.012680044687482555,-1.4611648870272018,0.14443484077022867,LGP Offspring,"Genes for which mutations result in atrial septation defects, a major class of congenital heart disease.",CGP,C2,8,8
Cohort,0.012978567450455338,0.04364813880826922,0.2973452661398823,0.7662769719399924,LGP Proband,"Genes for which mutations result in atrial septation defects, a major class of congenital heart disease.",CGP,C2,8,24
Cohort,0.011677057071598884,0.011435904747354547,1.0210872973824063,0.30752330600778566,LonGen OPEL,"Genes for which mutations result in atrial septation defects, a major class of congenital heart disease.",CGP,C2,7,13
Cohort,-0.006960356963853126,0.011908939532567532,-0.5844648841165535,0.559102581891314,LGP Offspring,"Genes for which mutations result in developmental defects in ventricular septation and atrioventricular cushion formation, a major class of congenital heart disease.",CGP,C2,6,8
Cohort,0.02351663902535785,0.03630343336259691,0.6477800264915666,0.5173055149578085,LGP Proband,"Genes for which mutations result in developmental defects in ventricular septation and atrioventricular cushion formation, a major class of congenital heart disease.",CGP,C2,6,16
Cohort,0.0035850516848176407,0.011182936686192885,0.3205823108382575,0.7486110844020051,LonGen OPEL,"Genes for which mutations result in developmental defects in ventricular septation and atrioventricular cushion formation, a major class of congenital heart disease.",CGP,C2,9,10
Cohort,-0.0022353728207610136,0.04607314912372368,-0.04851790822368576,0.9613178231642994,LGP Offspring,Genes that are rapidly down-regulated as multipotential cells of the FDCP-mix hematopoiesis model undergo differentiation and loose their self-renewal and proliferation properties.,CGP,C2,64,131
Cohort,-0.028900511504641933,0.13023753007130648,-0.22190617012483718,0.8244412520946313,LGP Proband,Genes that are rapidly down-regulated as multipotential cells of the FDCP-mix hematopoiesis model undergo differentiation and loose their self-renewal and proliferation properties.,CGP,C2,64,195
Cohort,-0.0054119185802709215,0.04151335166276152,-0.1303657344806862,0.8963100125552848,LonGen OPEL,Genes that are rapidly down-regulated as multipotential cells of the FDCP-mix hematopoiesis model undergo differentiation and loose their self-renewal and proliferation properties.,CGP,C2,114,133
Cohort,0.009005075157180307,0.02745510487140801,0.3279927430384093,0.7430187099997578,LGP Offspring,Genes  down-regulated in microdissected endothelial samples from ovarian cancer tumors with tumor-infiltrating lymphocytes (TIL) vs those without TILs.,CGP,C2,23,52
Cohort,0.029049849768044124,0.06945883828250175,0.41823114935918004,0.6758857896100714,LGP Proband,Genes  down-regulated in microdissected endothelial samples from ovarian cancer tumors with tumor-infiltrating lymphocytes (TIL) vs those without TILs.,CGP,C2,23,58
Cohort,-0.024206055447934968,0.024193371665927263,-1.0005242668191456,0.31736090699912706,LonGen OPEL,Genes  down-regulated in microdissected endothelial samples from ovarian cancer tumors with tumor-infiltrating lymphocytes (TIL) vs those without TILs.,CGP,C2,43,42
Cohort,-0.020607783808798127,0.027031461232894873,-0.762362923382044,0.4461093452014231,LGP Offspring,Genes up-regulated in microdissected endothelial samples from ovarian cancer tumors with tumor-infiltrating lymphocytes (TIL) vs those without TILs.,CGP,C2,28,50
Cohort,0.11678590181503568,0.07295824196506243,1.6007225320884382,0.10981708711871963,LGP Proband,Genes up-regulated in microdissected endothelial samples from ovarian cancer tumors with tumor-infiltrating lymphocytes (TIL) vs those without TILs.,CGP,C2,28,66
Cohort,-0.0115605093982974,0.02531539468804504,-0.45665925974113863,0.6480405597922659,LonGen OPEL,Genes up-regulated in microdissected endothelial samples from ovarian cancer tumors with tumor-infiltrating lymphocytes (TIL) vs those without TILs.,CGP,C2,48,47
Cohort,0.0035576785955059227,0.035028506055091314,0.10156523917721641,0.9191318890348117,LGP Offspring,"Common genes regulated by hypoxia across multiple head and neck and breast cancer clinical cohorts, and prognostic in multiple cancer types",CGP,C2,35,80
Cohort,-0.16590688603794623,0.09240305346006239,-1.7954697363940793,0.07294080831833699,LGP Proband,"Common genes regulated by hypoxia across multiple head and neck and breast cancer clinical cohorts, and prognostic in multiple cancer types",CGP,C2,35,94
Cohort,-0.009392257729575415,0.027416668144287705,-0.34257473155184626,0.7320088532750848,LonGen OPEL,"Common genes regulated by hypoxia across multiple head and neck and breast cancer clinical cohorts, and prognostic in multiple cancer types",CGP,C2,55,60
Cohort,0.026607457078527314,0.024773977954519803,1.0740082649372427,0.2832021892220189,LGP Offspring,Strongly up-regulated at 2 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,13,38
Cohort,-0.03440444638344298,0.05910404514498895,-0.5820996904534191,0.5606568502749492,LGP Proband,Strongly up-regulated at 2 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,13,43
Cohort,-0.009666485263821557,0.01815142183460109,-0.5325470011057123,0.594495820717389,LonGen OPEL,Strongly up-regulated at 2 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,25,26
Cohort,0.016046513592707694,0.02420965887420467,0.6628145268831199,0.5076752759425541,LGP Offspring,Strongly down-regulated at 8-48 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,16,40
Cohort,-0.04436933080209936,0.06372784051626272,-0.696231512674225,0.48647783691133484,LGP Proband,Strongly down-regulated at 8-48 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,16,50
Cohort,-0.017359616000421633,0.024571215597655603,-0.7065021236506489,0.48008267608108535,LonGen OPEL,Strongly down-regulated at 8-48 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,45,42
Cohort,-0.07561326014988534,0.03907229864539038,-1.9352140204529775,0.053380798538331525,LGP Offspring,Strongly down-regulated at 2-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,58,85
Cohort,-0.32935063384973007,0.10907044314283376,-3.0196139701974736,0.0026081156583353474,LGP Proband,Strongly down-regulated at 2-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,58,128
Cohort,0.023795585253036326,0.03405905482712078,0.6986566530932682,0.48497069590870046,LonGen OPEL,Strongly down-regulated at 2-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,70,100
Cohort,-0.0913518151563408,0.029846889473114237,-3.0606812558685403,0.0022958144798074284,LGP Offspring,Strongly down-regulated at 2 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,41,47
Cohort,-0.09447227115255735,0.08645697069467818,-1.0927085507793826,0.27483731669022476,LGP Proband,Strongly down-regulated at 2 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,41,75
Cohort,-0.0012895597676800122,0.026869459840944215,-0.0479935129069828,0.9617334513167497,LonGen OPEL,Strongly down-regulated at 2 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,51,54
Cohort,0.006630259874144318,0.044554507459621424,0.14881232566992572,0.8817461051836311,LGP Offspring,Strongly up-regulated at 8 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,66,135
Cohort,-0.10473416833364782,0.12529858143136374,-0.8358767285088481,0.40346366324178284,LGP Proband,Strongly up-regulated at 8 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,66,188
Cohort,0.036953373814344805,0.04144919687952135,0.891534133260908,0.3729120946885355,LonGen OPEL,Strongly up-regulated at 8 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,103,150
Cohort,-0.12648640336849715,0.056039156350448927,-2.2571075584631615,0.02431975781297317,LGP Offspring,Strongly up-regulated at 16-24 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,123,204
Cohort,-0.07324516181932988,0.16017618117049606,-0.45727873697629023,0.6475898007028908,LGP Proband,Strongly up-regulated at 16-24 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,123,282
Cohort,0.014138806681454463,0.047883940164546696,0.2952724156130085,0.7678627863600596,LonGen OPEL,Strongly up-regulated at 16-24 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,160,192
Cohort,0.08794052686676487,0.03564531739883499,2.467098998805354,0.013868052238413454,LGP Offspring,Progressively up-regulated from 8-48 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,32,102
Cohort,-0.07992238322049608,0.09574494202172817,-0.8347426144177793,0.404101685107802,LGP Proband,Progressively up-regulated from 8-48 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,32,126
Cohort,-0.03673222698940011,0.029712438736781387,-1.236257559159183,0.21672750339884111,LonGen OPEL,Progressively up-regulated from 8-48 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,66,68
Cohort,0.05487826379758274,0.05666526121178174,0.9684639693529296,0.3331590659748863,LGP Offspring,Up-regulated at 48-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,93,217
Cohort,-0.06461696049794219,0.15290967325694632,-0.42258255558077845,0.6727087819947832,LGP Proband,Up-regulated at 48-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,93,292
Cohort,0.08413303467807104,0.050493379815789705,1.6662191159515516,0.09606320389209991,LonGen OPEL,Up-regulated at 48-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,142,212
Cohort,-0.08433256883264509,0.07058215727808989,-1.1948142715499517,0.23257862750237707,LGP Offspring,Strongly up-regulated at 96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,177,344
Cohort,0.050514333062558196,0.1950937723369209,0.2589233498203187,0.7957582728839719,LGP Proband,Strongly up-regulated at 96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,177,481
Cohort,0.1008584968506041,0.06718711141695594,1.5011584026092029,0.13371114492944766,LonGen OPEL,Strongly up-regulated at 96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,292,385
Cohort,-0.011682349282074627,0.028718524091866822,-0.4067879409368083,0.6842925041487876,LGP Offspring,Down-regulated at 48-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,31,55
Cohort,0.01927775084505494,0.08105948456227394,0.23782227273163586,0.8120773562479301,LGP Proband,Down-regulated at 48-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,31,80
Cohort,-0.02765060371931905,0.02296048839092279,-1.2042689706134673,0.22884359673452734,LonGen OPEL,Down-regulated at 48-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,44,41
Cohort,-0.004130611875960606,0.04684339672608687,-0.08817917069750597,0.9297603874265865,LGP Offspring,Progressively down-regulated 8-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,72,150
Cohort,0.03351833180109912,0.13497608693926283,0.24832792653251134,0.8039418253580493,LGP Proband,Progressively down-regulated 8-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,72,216
Cohort,-0.010232493728224917,0.04521057110953708,-0.22632967195732664,0.8210031267091322,LonGen OPEL,Progressively down-regulated 8-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,137,159
Cohort,0.0587564934599746,0.04396735207896193,1.336366432858011,0.18187916477050242,LGP Offspring,Strongly down-regulated at 8-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,51,130
Cohort,-0.2513268263144785,0.11957907218906526,-2.1017626388429256,0.03587347085450708,LGP Proband,Strongly down-regulated at 8-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,51,163
Cohort,-0.03781621081866289,0.03789360377749476,-0.9979576247409375,0.31860317391127196,LonGen OPEL,Strongly down-regulated at 8-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.,CGP,C2,111,116
Cohort,0.025054134009584023,0.04329252081702664,0.57871737512061,0.5629726515783313,LGP Offspring,Cluster 1:  genes progressively down-regulated over 24 h (peak at 0 h timepoint) during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,54,131
Cohort,-0.05588628873498594,0.11636805262329007,-0.480254567083825,0.6311723278402923,LGP Proband,Cluster 1:  genes progressively down-regulated over 24 h (peak at 0 h timepoint) during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,54,173
Cohort,-0.004997624122540523,0.03521286952217942,-0.1419260682345892,0.8871743158772236,LonGen OPEL,Cluster 1:  genes progressively down-regulated over 24 h (peak at 0 h timepoint) during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,88,97
Cohort,0.004724122758111957,0.035661459447116156,0.13247138034598815,0.8946508788494067,LGP Offspring,Cluster 4: genes maximally expressed at 16 h time point during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,38,81
Cohort,-0.08880502922940743,0.10262195527241606,-0.8653609161282224,0.3870895749392297,LGP Proband,Cluster 4: genes maximally expressed at 16 h time point during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,38,122
Cohort,-0.017935822419711516,0.03262320903724428,-0.5497871898265768,0.5826195645186317,LonGen OPEL,Cluster 4: genes maximally expressed at 16 h time point during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,72,73
Cohort,-0.07173512032798393,0.03162006500838346,-2.2686582177792713,0.02360358962451819,LGP Offspring,Cluster 5: genes progressively up-regulated (peak at 24 h time point) during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,41,57
Cohort,-0.017328756835522888,0.08478120668879181,-0.20439384519651774,0.8380956069918265,LGP Proband,Cluster 5: genes progressively up-regulated (peak at 24 h time point) during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,41,74
Cohort,-0.010614050751179169,0.025142987725982602,-0.42214755330014647,0.6730313127404131,LonGen OPEL,Cluster 5: genes progressively up-regulated (peak at 24 h time point) during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,46,51
Cohort,7.590437789009779e-4,0.029522034113490813,0.025711093483023733,0.9794953632805818,LGP Offspring,Cluster 2: genes maximally expressed at 2 h time point during differentiation of 3T3-L1 fibroblasts into adipocytes (cluster 2) in response to adipogenic hormones.,CGP,C2,28,59
Cohort,0.0376662061484805,0.07532144660751451,0.5000727926104741,0.6171557394278349,LGP Proband,Cluster 2: genes maximally expressed at 2 h time point during differentiation of 3T3-L1 fibroblasts into adipocytes (cluster 2) in response to adipogenic hormones.,CGP,C2,28,69
Cohort,0.0064213798085251145,0.024775067247885807,0.2591871797673157,0.795557835117698,LonGen OPEL,Cluster 2: genes maximally expressed at 2 h time point during differentiation of 3T3-L1 fibroblasts into adipocytes (cluster 2) in response to adipogenic hormones.,CGP,C2,41,50
Cohort,0.035258949742173355,0.025079811626323358,1.4058697994831086,0.1602222439902821,LGP Offspring,Cluster 3: genes maximally expressed at 8 hr time point  during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,16,47
Cohort,0.02870347539060251,0.0649451693782262,0.4419647475771426,0.658629292972929,LGP Proband,Cluster 3: genes maximally expressed at 8 hr time point  during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,16,58
Cohort,0.035374786260406924,0.02378203571273041,1.4874582936342564,0.1372898166518255,LonGen OPEL,Cluster 3: genes maximally expressed at 8 hr time point  during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.,CGP,C2,34,56
Cohort,-0.4079897589745225,0.13700701065363638,-2.9778750519997117,0.003006411337809443,LGP Offspring,Genes down-regulated in T24 (bladder cancer) cells in response to the photodynamic therapy (PDT) stress.,CGP,C2,581,1053
Cohort,-0.3362686398159746,0.36247740955505725,-0.9276954396378686,0.35383396850572935,LGP Proband,Genes down-regulated in T24 (bladder cancer) cells in response to the photodynamic therapy (PDT) stress.,CGP,C2,581,1398
Cohort,0.08682107346820729,0.10951687354829448,0.7927643536127896,0.42815134301496527,LonGen OPEL,Genes down-regulated in T24 (bladder cancer) cells in response to the photodynamic therapy (PDT) stress.,CGP,C2,780,958
Cohort,-0.3756598275976054,0.15224281952733956,-2.4675044035830203,0.013852501985238597,LGP Offspring,Genes up-regulated in T24 (bladder cancer) cells in response to the photodynamic therapy (PDT) stress.,CGP,C2,729,1357
Cohort,-0.7142055949147563,0.4191990495417795,-1.70373858360472,0.08880245549119122,LGP Proband,Genes up-regulated in T24 (bladder cancer) cells in response to the photodynamic therapy (PDT) stress.,CGP,C2,729,1949
Cohort,-0.011415814009941492,0.1264644804046272,-0.09026893538340745,0.9280962139881329,LonGen OPEL,Genes up-regulated in T24 (bladder cancer) cells in response to the photodynamic therapy (PDT) stress.,CGP,C2,1113,1328
Cohort,-0.05700671257248432,0.03986795238806892,-1.4298881471912368,0.1532111219801786,LGP Offspring,Genes whose expression in bone marrow samples correlated inversely with increased levels of serum IL5 [GeneID=3567].,CGP,C2,58,97
Cohort,-0.03528501054930014,0.11262707863906928,-0.31329064888894403,0.754138186046715,LGP Proband,Genes whose expression in bone marrow samples correlated inversely with increased levels of serum IL5 [GeneID=3567].,CGP,C2,58,141
Cohort,-0.02491791520902751,0.031977121847516846,-0.7792419632964087,0.4360687990389741,LonGen OPEL,Genes whose expression in bone marrow samples correlated inversely with increased levels of serum IL5 [GeneID=3567].,CGP,C2,77,81
Cohort,0.06591573779171103,0.0318963668007684,2.0665594361713664,0.03915595954833217,LGP Offspring,Genes whose expression in bone marrow samples correlated directly with increased levels of serum IL5 [GeneID=3567].,CGP,C2,24,77
Cohort,-0.07969017839522649,0.08582407803881238,-0.9285293849493851,0.35340168289872564,LGP Proband,Genes whose expression in bone marrow samples correlated directly with increased levels of serum IL5 [GeneID=3567].,CGP,C2,24,100
Cohort,0.001404204545633917,0.02789549305994359,0.0503380435906429,0.9598656360489715,LonGen OPEL,Genes whose expression in bone marrow samples correlated directly with increased levels of serum IL5 [GeneID=3567].,CGP,C2,54,68
Cohort,-0.0651689503818717,0.05236133927427429,-1.244600525599809,0.21370994599248794,LGP Offspring,Genes associated with the same cis-regulatory QTL (quantitative trait loci) in both brain and hematopoietic stem cells (HSC).,CGP,C2,93,174
Cohort,0.008935232394583987,0.14932809969295743,0.059836242562225465,0.9523003945568166,LGP Proband,Genes associated with the same cis-regulatory QTL (quantitative trait loci) in both brain and hematopoietic stem cells (HSC).,CGP,C2,93,260
Cohort,-0.056247538323787524,0.045004951840023816,-1.249807766125981,0.2117371101188938,LonGen OPEL,Genes associated with the same cis-regulatory QTL (quantitative trait loci) in both brain and hematopoietic stem cells (HSC).,CGP,C2,167,170
Cohort,0.008479005588980822,0.06572878919924002,0.12899987497531537,0.8973961180707947,LGP Offspring,Genes trans-regulated by the same QTL (quantitative trait loci) in brain and hematopoietic stem cells (HSC).,CGP,C2,131,282
Cohort,0.1674110162339742,0.16446978945831303,1.0178830822690794,0.30902870654614273,LGP Proband,Genes trans-regulated by the same QTL (quantitative trait loci) in brain and hematopoietic stem cells (HSC).,CGP,C2,131,343
Cohort,0.02073141576239454,0.059404424261086206,0.34898773989086496,0.7271908065216184,LonGen OPEL,Genes trans-regulated by the same QTL (quantitative trait loci) in brain and hematopoietic stem cells (HSC).,CGP,C2,222,274
Cohort,-0.0024097969398804383,0.012343721436787837,-0.195224507634995,0.8452758553924544,LGP Offspring,Genes whose expression is coregulated with that of FGF3 [GeneID=2248] in hematopoietic stem cells (HSC).,CGP,C2,5,10
Cohort,0.041839809269565265,0.03674669558151109,1.1386005899974512,0.2551967341959955,LGP Proband,Genes whose expression is coregulated with that of FGF3 [GeneID=2248] in hematopoietic stem cells (HSC).,CGP,C2,5,15
Cohort,-0.0019479300913503288,0.011168240017615402,-0.17441692587891242,0.8615821633821354,LonGen OPEL,Genes whose expression is coregulated with that of FGF3 [GeneID=2248] in hematopoietic stem cells (HSC).,CGP,C2,10,9
Cohort,-0.01331360057399135,0.009498670396398151,-1.4016278087762473,0.16148537644675628,LGP Offspring,Genes whose expression is coregulated with that of FLI1 [GeneID=2313] in hematopoietic stem cells (HSC).,CGP,C2,6,3
Cohort,-0.06891816482025225,0.030315077437406017,-2.2733956382777887,0.02325584018836024,LGP Proband,Genes whose expression is coregulated with that of FLI1 [GeneID=2313] in hematopoietic stem cells (HSC).,CGP,C2,6,9
Cohort,-0.005987612019536111,0.00729725159425358,-0.8205297490703514,0.4121598242203358,LonGen OPEL,Genes whose expression is coregulated with that of FLI1 [GeneID=2313] in hematopoietic stem cells (HSC).,CGP,C2,5,3
Cohort,0.0033964556990826577,0.01195022506774792,0.2842168812576797,0.7763312142723281,LGP Offspring,Genes whose expression is coregulated with that of IL3RA [GeneID=3563] in hematopoietic stem cells (HSC).,CGP,C2,4,10
Cohort,-0.013305285006192597,0.029320228041646412,-0.45379200282118504,0.6500965988207685,LGP Proband,Genes whose expression is coregulated with that of IL3RA [GeneID=3563] in hematopoietic stem cells (HSC).,CGP,C2,4,10
Cohort,0.008331360762736039,0.00855163234351426,0.974242159633385,0.33023228069449184,LonGen OPEL,Genes whose expression is coregulated with that of IL3RA [GeneID=3563] in hematopoietic stem cells (HSC).,CGP,C2,3,8
Cohort,-0.04670883571906619,0.0633881547005374,-0.7368700972560447,0.4614570033019211,LGP Offspring,"Transcripts in hematopoietic stem cells (HSC) which are cis-regulated (i.e., modulated by a QTL (quantitative trait locus) in close proximity to the gene).",CGP,C2,138,277
Cohort,0.03313326809156919,0.17837281041060998,0.18575290715719056,0.8526837034815966,LGP Proband,"Transcripts in hematopoietic stem cells (HSC) which are cis-regulated (i.e., modulated by a QTL (quantitative trait locus) in close proximity to the gene).",CGP,C2,138,414
Cohort,-0.04248509495076886,0.05699577364205987,-0.7454078124736095,0.4562452643031598,LonGen OPEL,"Transcripts in hematopoietic stem cells (HSC) which are cis-regulated (i.e., modulated by a QTL (quantitative trait locus) in close proximity to the gene).",CGP,C2,257,278
Cohort,-0.024229058018385433,0.15188911772870106,-0.15951806410293667,0.8733083758755784,LGP Offspring,"Transcripts in hematopoietic stem cells (HSC) which are trans-regulated (i.e., modulated by a QTL (quantitative trait locus) not in a close proximity to the gene).",CGP,C2,662,1383
Cohort,-0.32290249653442055,0.4159210646672415,-0.7763552365224862,0.43775938071115783,LGP Proband,"Transcripts in hematopoietic stem cells (HSC) which are trans-regulated (i.e., modulated by a QTL (quantitative trait locus) not in a close proximity to the gene).",CGP,C2,662,1948
Cohort,-0.11732565491552757,0.13693714561382775,-0.8567847269607478,0.3918217273899657,LonGen OPEL,"Transcripts in hematopoietic stem cells (HSC) which are trans-regulated (i.e., modulated by a QTL (quantitative trait locus) not in a close proximity to the gene).",CGP,C2,1145,1350
Cohort,-0.0016180426054459582,0.009594235644096148,-0.1686473696778156,0.8661244654718052,LGP Offspring,Genes whose expression is coregulated with that of RUNX1 [GeneID=861] in hematopoietic stem cells (HSC).,CGP,C2,3,6
Cohort,0.06823096204327359,0.03725770610583513,1.8313248230971357,0.0674086553252822,LGP Proband,Genes whose expression is coregulated with that of RUNX1 [GeneID=861] in hematopoietic stem cells (HSC).,CGP,C2,3,20
Cohort,-3.3393292496958194e-4,0.014357717391144244,-0.023258078973998318,0.9814502397367291,LonGen OPEL,Genes whose expression is coregulated with that of RUNX1 [GeneID=861] in hematopoietic stem cells (HSC).,CGP,C2,12,21
Cohort,-0.007628235271915731,0.03315142841526367,-0.2301027628843745,0.818081529499749,LGP Offspring,Genes trans-regulated by the hematopoietic stem cell (HSC) proliferation QTL (quantitative trait locus) Scp2.,CGP,C2,38,71
Cohort,-0.03247148329266599,0.08904952424281233,-0.3646452192616508,0.7154686946107414,LGP Proband,Genes trans-regulated by the hematopoietic stem cell (HSC) proliferation QTL (quantitative trait locus) Scp2.,CGP,C2,38,98
Cohort,0.01085102491641024,0.025401563775343354,0.42717940566096374,0.6693641828757468,LonGen OPEL,Genes trans-regulated by the hematopoietic stem cell (HSC) proliferation QTL (quantitative trait locus) Scp2.,CGP,C2,46,59
Cohort,0.027940353389041116,0.017175058521827234,1.6267981476472184,0.10424598449610699,LGP Offspring,Genes that physically map to the hematopoietic stem cell (HSC) proliferation QTL (quantitative trait locus) Scp2.,CGP,C2,5,23
Cohort,0.07312289162959025,0.05022600475796324,1.4558771294265995,0.14580291083606953,LGP Proband,Genes that physically map to the hematopoietic stem cell (HSC) proliferation QTL (quantitative trait locus) Scp2.,CGP,C2,5,35
Cohort,-0.006660897616579906,0.0152419976779741,-0.4370094889992952,0.6622229917194227,LonGen OPEL,Genes that physically map to the hematopoietic stem cell (HSC) proliferation QTL (quantitative trait locus) Scp2.,CGP,C2,19,17
Cohort,-0.01415005582357642,0.04602107746352476,-0.30746902513943586,0.7585810963004176,LGP Offspring,Genes down-regulated in Paneth cell (part of intestiinal epithelium) of mice with hypomorphic (reduced function) form of ATG16L1 [GeneID=55054].,CGP,C2,60,122
Cohort,0.20141823723625665,0.11892065180046318,1.6937195868570925,0.09069197551017005,LGP Proband,Genes down-regulated in Paneth cell (part of intestiinal epithelium) of mice with hypomorphic (reduced function) form of ATG16L1 [GeneID=55054].,CGP,C2,60,183
Cohort,-0.019266021858927822,0.03798658889477002,-0.5071795709874957,0.6121693036206153,LonGen OPEL,Genes down-regulated in Paneth cell (part of intestiinal epithelium) of mice with hypomorphic (reduced function) form of ATG16L1 [GeneID=55054].,CGP,C2,105,116
Cohort,0.11551488116703462,0.05506543028049167,2.097774966592038,0.03629572405003661,LGP Offspring,Genes up-regulated in Paneth cell (part of intestiinal epithelium) of mice with hypomorphic (reduced function) form of ATG16L1 [GeneID=55054].,CGP,C2,79,206
Cohort,0.12512686954724392,0.15961752116857103,0.7839168822519067,0.43331145917759584,LGP Proband,Genes up-regulated in Paneth cell (part of intestiinal epithelium) of mice with hypomorphic (reduced function) form of ATG16L1 [GeneID=55054].,CGP,C2,79,293
Cohort,-0.029131991625092103,0.049515034218485146,-0.5883463898368151,0.5564667061286326,LonGen OPEL,Genes up-regulated in Paneth cell (part of intestiinal epithelium) of mice with hypomorphic (reduced function) form of ATG16L1 [GeneID=55054].,CGP,C2,158,185
Cohort,0.009853799163499731,0.017802235112619767,0.5535147188632794,0.5800940242375854,LGP Offspring,Genes down-regulated in EVSA-T cells (breast cancer) after treatment with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,9,23
Cohort,0.014576654388222806,0.04375868379448136,0.3331145529121501,0.7391315368136125,LGP Proband,Genes down-regulated in EVSA-T cells (breast cancer) after treatment with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,9,23
Cohort,0.003470109539313755,0.01612209653663884,0.2152393475270189,0.8296358496917631,LonGen OPEL,Genes down-regulated in EVSA-T cells (breast cancer) after treatment with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,17,21
Cohort,-0.0021152013469989397,0.012334001224186321,-0.17149352497639955,0.8638870430468277,LGP Offspring,Genes up-regulated in EVSA-T cells (breast cancer) after treatment with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,5,10
Cohort,-0.027259767250364005,0.034265311184843654,-0.7955499689850076,0.4265200161062246,LGP Proband,Genes up-regulated in EVSA-T cells (breast cancer) after treatment with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,5,14
Cohort,-2.0970998290814326e-4,0.013527522909343519,-0.01550246740024337,0.9876352006774627,LonGen OPEL,Genes up-regulated in EVSA-T cells (breast cancer) after treatment with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,12,16
Cohort,0.0070816430606227086,0.04277635430260562,0.1655504115784675,0.8685602707807487,LGP Offspring,Genes down-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,60,135
Cohort,-0.16979271338630864,0.10818941422409559,-1.569402280287908,0.11693353376158962,LGP Proband,Genes down-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,60,144
Cohort,-0.03248318547207956,0.03531975368907154,-0.9196889015149148,0.35801396714552036,LonGen OPEL,Genes down-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,87,91
Cohort,-0.03134756375933754,0.024907051956431562,-1.2585818592329587,0.20861588613021007,LGP Offspring,Genes up-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,25,36
Cohort,-0.011409008747417097,0.063115428495427,-0.1807641811105462,0.856596595774205,LGP Proband,Genes up-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,25,44
Cohort,0.03179009696260539,0.017182145992841128,1.850181984011229,0.064657728616361,LonGen OPEL,Genes up-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.,CGP,C2,14,30
Cohort,-0.0072195264606544655,0.01521947101935041,-0.4743611950425466,0.6353955483542214,LGP Offspring,Genes down-regulated in EVSA-T cells (breast cancer) treated with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,8,15
Cohort,0.0025898988132983043,0.04416748359956878,0.05863813380854667,0.9532543831926025,LGP Proband,Genes down-regulated in EVSA-T cells (breast cancer) treated with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,8,24
Cohort,-0.04201542985968855,0.01674377563733841,-2.5093163435608075,0.01229406970591612,LonGen OPEL,Genes down-regulated in EVSA-T cells (breast cancer) treated with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,26,12
Cohort,0.03090018753467633,0.012190527762395107,2.5347702853354797,0.01147653789433077,LGP Offspring,Genes up-regulated in EVSA-T cells (breast cancer) treated with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,1,14
Cohort,0.00251701821088122,0.03022663132226813,0.08327154237088003,0.933655609654898,LGP Proband,Genes up-regulated in EVSA-T cells (breast cancer) treated with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,1,14
Cohort,-0.0045415413532140375,0.00997387867979088,-0.4553435527961785,0.6489862719598389,LonGen OPEL,Genes up-regulated in EVSA-T cells (breast cancer) treated with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,8,7
Cohort,1.7766239513930557e-6,0.018301282899399588,9.707647060367235e-5,0.9999225728226061,LGP Offspring,Genes down-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,10,24
Cohort,0.030235233332311533,0.043114982567647175,0.7012697566297891,0.48333030532333,LGP Proband,Genes down-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,10,21
Cohort,0.022156790707876094,0.013006241007256992,1.7035506796708935,0.08885538188554673,LonGen OPEL,Genes down-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,7,17
Cohort,0.04027681392498419,0.02103093549049002,1.9151223179395402,0.05589859096494918,LGP Offspring,Genes up-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,9,33
Cohort,0.0016883446195353916,0.05113033625113249,0.03302040908244558,0.9736662131598778,LGP Proband,Genes up-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,9,36
Cohort,-0.021201159406745416,0.01894641180480014,-1.1190065762939887,0.26347489316746753,LonGen OPEL,Genes up-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.,CGP,C2,30,26
Cohort,-0.020053407799292978,0.022894846854339613,-0.875891764067072,0.3813999975074782,LGP Offspring,Genes down-regulated in EVSA-T cells (breast cancer) treated THC (delta-9-tetrahydrocannabinol) [PubChem=6610319].,CGP,C2,20,35
Cohort,0.05305996835053238,0.06399976807034188,0.8290650099265108,0.407304834965203,LGP Proband,Genes down-regulated in EVSA-T cells (breast cancer) treated THC (delta-9-tetrahydrocannabinol) [PubChem=6610319].,CGP,C2,20,51
Cohort,0.02736830367954445,0.020328040227344257,1.3463326210231512,0.17857852382517003,LonGen OPEL,Genes down-regulated in EVSA-T cells (breast cancer) treated THC (delta-9-tetrahydrocannabinol) [PubChem=6610319].,CGP,C2,24,42
Cohort,-0.01612737596362377,0.024451570944133614,-0.6595640010399015,0.5097582925603314,LGP Offspring,Genes up-regulated in EVSA-T cells (breast cancer) treated THC (delta-9-tetrahydrocannabinol) [PubChem=6610319].,CGP,C2,23,39
Cohort,-0.12699459657995424,0.06801777520265985,-1.8670795420986968,0.062241124712633114,LGP Proband,Genes up-regulated in EVSA-T cells (breast cancer) treated THC (delta-9-tetrahydrocannabinol) [PubChem=6610319].,CGP,C2,23,56
Cohort,-0.02188135250810007,0.022389150897224246,-0.9773194440711401,0.3287079509769847,LonGen OPEL,Genes up-regulated in EVSA-T cells (breast cancer) treated THC (delta-9-tetrahydrocannabinol) [PubChem=6610319].,CGP,C2,36,34
Cohort,0.012838884723721326,0.07675099481090353,0.1672797174206449,0.867199989370179,LGP Offspring,Genes down-regulated in robust Cluster 2 (rC2) of hepatoblastoma samples compared to those in the robust Cluster 1 (rC1).,CGP,C2,208,452
Cohort,-0.13826595575653597,0.23011793131725766,-0.6008482475271006,0.5481043179617111,LGP Proband,Genes down-regulated in robust Cluster 2 (rC2) of hepatoblastoma samples compared to those in the robust Cluster 1 (rC1).,CGP,C2,208,656
Cohort,-0.003353703268399047,0.07230002607865574,-0.04638592059082424,0.9630142927625498,LonGen OPEL,Genes down-regulated in robust Cluster 2 (rC2) of hepatoblastoma samples compared to those in the robust Cluster 1 (rC1).,CGP,C2,333,404
Cohort,-0.03680903972650087,0.1395190983517743,-0.263827964496251,0.7919928893587305,LGP Offspring,Genes up-regulated in robust Cluster 2 (rC2) of hepatoblastoma samples compared to those in the robust Cluster 1 (rC1).,CGP,C2,581,1173
Cohort,-0.36698951680815617,0.3689888855207283,-0.9945814933971506,0.3202283223254331,LGP Proband,Genes up-regulated in robust Cluster 2 (rC2) of hepatoblastoma samples compared to those in the robust Cluster 1 (rC1).,CGP,C2,581,1690
Cohort,-0.004406610025943478,0.11924560583459122,-0.036954066316338775,0.9705308957185348,LonGen OPEL,Genes up-regulated in robust Cluster 2 (rC2) of hepatoblastoma samples compared to those in the robust Cluster 1 (rC1).,CGP,C2,948,1125
Cohort,0.09677011662029988,0.09350349887263533,1.0349357808750466,0.30106898461377285,LGP Offspring,Genes down-regulated in hepatoblastoma samples compared to normal liver tissue.,CGP,C2,278,634
Cohort,0.1178952268524295,0.2506833132820333,0.47029547084288975,0.6382668909555663,LGP Proband,Genes down-regulated in hepatoblastoma samples compared to normal liver tissue.,CGP,C2,278,864
Cohort,0.03440375224996117,0.08774613661843421,0.39208281499123504,0.6951019763505865,LonGen OPEL,Genes down-regulated in hepatoblastoma samples compared to normal liver tissue.,CGP,C2,478,583
Cohort,-0.012066666940296737,0.02297436590236749,-0.5252230678128651,0.5996003477314551,LGP Offspring,Genes whose expression classifies hepatoblastoma tumors as belonging to either rC1 or rC2 subtypes and whose expression predicts poor survival.,CGP,C2,17,29
Cohort,-0.03934197748181131,0.05890972477049841,-0.6678350244391824,0.504423667089162,LGP Proband,Genes whose expression classifies hepatoblastoma tumors as belonging to either rC1 or rC2 subtypes and whose expression predicts poor survival.,CGP,C2,17,43
Cohort,-0.02042371267302451,0.023189536931517506,-0.8807296468807926,0.3787300022135195,LonGen OPEL,Genes whose expression classifies hepatoblastoma tumors as belonging to either rC1 or rC2 subtypes and whose expression predicts poor survival.,CGP,C2,44,40
Cohort,-0.05065587591306974,0.08568930655864795,-0.591157496162016,0.5546125065403398,LGP Offspring,Genes up-regulated in hepatoblastoma samples compared to normal liver tissue.,CGP,C2,241,483
Cohort,-0.22919002145114958,0.2417704878685477,-0.9479652519697184,0.34342173523054875,LGP Proband,Genes up-regulated in hepatoblastoma samples compared to normal liver tissue.,CGP,C2,241,689
Cohort,0.27483858580769277,0.08065885150423506,3.4074200249833972,6.887285625935415e-4,LonGen OPEL,Genes up-regulated in hepatoblastoma samples compared to normal liver tissue.,CGP,C2,374,544
Cohort,0.07602753542750965,0.10169650274003439,0.7475924282456199,0.45496600394427633,LGP Offspring,Genes down-regulated at early fetal liver stage (embryonic days  E11.5 - E12.5) compared to the late fetal liver stage (embryonic days E14.5 - E16.5).,CGP,C2,281,612
Cohort,-0.30408140890554314,0.2636749411279471,-1.153243488382876,0.2491408631430805,LGP Proband,Genes down-regulated at early fetal liver stage (embryonic days  E11.5 - E12.5) compared to the late fetal liver stage (embryonic days E14.5 - E16.5).,CGP,C2,281,880
Cohort,0.016225222210627957,0.0876787884282023,0.1850529928788231,0.8532346099648995,LonGen OPEL,Genes down-regulated at early fetal liver stage (embryonic days  E11.5 - E12.5) compared to the late fetal liver stage (embryonic days E14.5 - E16.5).,CGP,C2,507,617
Cohort,-0.05954575155464899,0.06835083114384181,-0.8711781635740046,0.3839661561488579,LGP Offspring,Genes up-regulated at early fetal liver stage (embryonic days  E11.5 - E12.5) compared to the late fetal liver stage (embryonic days E14.5 - E16.5).,CGP,C2,145,286
Cohort,0.10276921505004626,0.1888374990636546,0.5442203776242776,0.5864352945241142,LGP Proband,Genes up-regulated at early fetal liver stage (embryonic days  E11.5 - E12.5) compared to the late fetal liver stage (embryonic days E14.5 - E16.5).,CGP,C2,145,428
Cohort,0.09587309061475549,0.05849869916398523,1.6388926930836751,0.1016307614813279,LonGen OPEL,Genes up-regulated at early fetal liver stage (embryonic days  E11.5 - E12.5) compared to the late fetal liver stage (embryonic days E14.5 - E16.5).,CGP,C2,224,316
Cohort,0.0029614404365557183,0.015657524740365893,0.1891384804215557,0.8500410538430744,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblasts) after knockout of PML [GeneID=5371] and whose promoters were bound by MYC [GeneID=4609].,CGP,C2,7,16
Cohort,-0.0037263372130079365,0.03586270411758646,-0.10390563970831761,0.9172692123194611,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblasts) after knockout of PML [GeneID=5371] and whose promoters were bound by MYC [GeneID=4609].,CGP,C2,7,14
Cohort,0.007917694516550906,0.01065630234211109,0.7430058065509385,0.45769738537428617,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblasts) after knockout of PML [GeneID=5371] and whose promoters were bound by MYC [GeneID=4609].,CGP,C2,6,11
Cohort,-0.033237977773228886,0.019316867717569925,-1.7206711905469447,0.085768105940557,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblasts) after knockout of PML [GeneID=5371] and whose promoters were bound by MYC [GeneID=4609].,CGP,C2,16,20
Cohort,0.048468578924376775,0.05627946058982488,0.8612125705614833,0.3893685050729918,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblasts) after knockout of PML [GeneID=5371] and whose promoters were bound by MYC [GeneID=4609].,CGP,C2,16,34
Cohort,0.0018412160185255295,0.013734358468704692,0.13405912061498548,0.8933897113602745,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblasts) after knockout of PML [GeneID=5371] and whose promoters were bound by MYC [GeneID=4609].,CGP,C2,12,15
Cohort,-0.011718795840752937,0.018240969016313172,-0.6424437117497783,0.5208029419059548,LGP Offspring,Genes up-regulated in neuroblastoma xenografts: sensitive vs resistant to the topoisomerase inhibitor irinotecan [GeneID=3750].,CGP,C2,12,20
Cohort,0.008402599373618683,0.05004271362253639,0.16790854782572442,0.8666959327780346,LGP Proband,Genes up-regulated in neuroblastoma xenografts: sensitive vs resistant to the topoisomerase inhibitor irinotecan [GeneID=3750].,CGP,C2,12,29
Cohort,-0.0014747946087935524,0.01666170108000592,-0.08851404797816889,0.9294903832535908,LonGen OPEL,Genes up-regulated in neuroblastoma xenografts: sensitive vs resistant to the topoisomerase inhibitor irinotecan [GeneID=3750].,CGP,C2,21,21
Cohort,-0.011000091098211567,0.013483902224696726,-0.815794338679208,0.41490512139477065,LGP Offspring,Genes down-regulated in neuroblastoma xenografts: resistant vs those that reverted to be sensitive to the topoisomerase inhibitor irinotecan [PubChem=3750].,CGP,C2,7,11
Cohort,0.01064023844378085,0.0346530538731801,0.30705052670742866,0.758881563314918,LGP Proband,Genes down-regulated in neuroblastoma xenografts: resistant vs those that reverted to be sensitive to the topoisomerase inhibitor irinotecan [PubChem=3750].,CGP,C2,7,13
Cohort,0.01447268546437348,0.00993390824768628,1.4568974368919034,0.14553904158210484,LonGen OPEL,Genes down-regulated in neuroblastoma xenografts: resistant vs those that reverted to be sensitive to the topoisomerase inhibitor irinotecan [PubChem=3750].,CGP,C2,5,10
Cohort,-0.004923179755676935,0.003207977786945888,-1.534667657522648,0.12533335431748013,LGP Offspring,Genes up-regulated in neuroblastoma xenografts: resistant vs those that reverted to be sensitive to the topoisomerase inhibitor irinotecan [PubChem=3750].,CGP,C2,1,0
Cohort,0.002418702218584175,0.007830999563079543,0.3088625148170765,0.7575032498266601,LGP Proband,Genes up-regulated in neuroblastoma xenografts: resistant vs those that reverted to be sensitive to the topoisomerase inhibitor irinotecan [PubChem=3750].,CGP,C2,1,0
Cohort,0.002426130399992444,0.002603754867574031,0.9317814169860456,0.35173201923210995,LonGen OPEL,Genes up-regulated in neuroblastoma xenografts: resistant vs those that reverted to be sensitive to the topoisomerase inhibitor irinotecan [PubChem=3750].,CGP,C2,0,1
Cohort,-0.0068817368756154225,0.0451883624274264,-0.15229002570446445,0.8790036321098681,LGP Offspring,Genes from chromosomal copy number losses in a panel of 51 primary colon carcinoma samples.,CGP,C2,60,116
Cohort,-0.008836381019930726,0.12098353343576927,-0.07303788184217651,0.9417934851786949,LGP Proband,Genes from chromosomal copy number losses in a panel of 51 primary colon carcinoma samples.,CGP,C2,60,167
Cohort,-0.003373836318478817,0.03726370389582602,-0.09053947852072555,0.9278813007164769,LonGen OPEL,Genes from chromosomal copy number losses in a panel of 51 primary colon carcinoma samples.,CGP,C2,97,120
Cohort,-0.07958782662409578,0.046988824676306044,-1.6937607435886275,0.09077141388312972,LGP Offspring,Genes from chromosomal copy number gains in a panel of 51 primary colon carcinoma samples.,CGP,C2,83,141
Cohort,0.10988961901281864,0.12790265031835152,0.8591660824799315,0.3904957672170285,LGP Proband,Genes from chromosomal copy number gains in a panel of 51 primary colon carcinoma samples.,CGP,C2,83,192
Cohort,-0.04703552503282167,0.04287267208399984,-1.0970980521266696,0.2729303058206773,LonGen OPEL,Genes from chromosomal copy number gains in a panel of 51 primary colon carcinoma samples.,CGP,C2,132,132
Cohort,-0.06058442106108478,0.04071704969046087,-1.487937400220783,0.1372337097068107,LGP Offspring,Potential targets of MIR302A [GeneID=407028].,CGP,C2,66,116
Cohort,0.006932315727602529,0.1213357629856067,0.05713332621005455,0.9544526742910994,LGP Proband,Potential targets of MIR302A [GeneID=407028].,CGP,C2,66,191
Cohort,-0.014351231881015935,0.04037515645927013,-0.35544709022968735,0.7223488438001336,LonGen OPEL,Potential targets of MIR302A [GeneID=407028].,CGP,C2,107,120
Cohort,0.018156107131816104,0.01907733678367376,0.9517107832029239,0.3415838272123687,LGP Offspring,"Down-regulated synergystically by gamma-irradiation and 3-aminobenzamine [PubChem=1645], an inhibitor of PARP1 [GeneID=142].",CGP,C2,10,28
Cohort,0.03720898315517349,0.05481857978438088,0.678765909323598,0.4974745018527612,LGP Proband,"Down-regulated synergystically by gamma-irradiation and 3-aminobenzamine [PubChem=1645], an inhibitor of PARP1 [GeneID=142].",CGP,C2,10,39
Cohort,0.019146156842994786,0.01560011738322658,1.227308511382161,0.2200695008998429,LonGen OPEL,"Down-regulated synergystically by gamma-irradiation and 3-aminobenzamine [PubChem=1645], an inhibitor of PARP1 [GeneID=142].",CGP,C2,14,24
Cohort,-0.031048397832373904,0.1325622180433344,-0.23421754924336155,0.8148870086329063,LGP Offspring,Genes down-regulated in APL (acute promyeolocytic leukemia) blasts expressing PML-RARA fusion [GeneID=5371;5914] compared to normal promyeloblasts.,CGP,C2,580,1199
Cohort,-0.6572707567142045,0.3623050878005837,-1.8141361489131858,0.07001598605141375,LGP Proband,Genes down-regulated in APL (acute promyeolocytic leukemia) blasts expressing PML-RARA fusion [GeneID=5371;5914] compared to normal promyeloblasts.,CGP,C2,580,1548
Cohort,-0.0974695757931174,0.11607924383301954,-0.8396813467645238,0.4013391911641694,LonGen OPEL,Genes down-regulated in APL (acute promyeolocytic leukemia) blasts expressing PML-RARA fusion [GeneID=5371;5914] compared to normal promyeloblasts.,CGP,C2,945,1095
Cohort,0.06712000479837306,0.07066005664550162,0.9499002404584976,0.3425024163536027,LGP Offspring,Genes up-regulated in APL (acute promyeolocytic leukemia) blasts expressing PML-RARA fusion [GeneID=5371;5914] compared to normal promyeloblasts.,CGP,C2,145,333
Cohort,-0.07404444731884348,0.18649011212511574,-0.397042215670755,0.6914379127495611,LGP Proband,Genes up-regulated in APL (acute promyeolocytic leukemia) blasts expressing PML-RARA fusion [GeneID=5371;5914] compared to normal promyeloblasts.,CGP,C2,145,437
Cohort,0.0036826471706893275,0.05844231728060772,0.06301336671862771,0.9497716797723801,LonGen OPEL,Genes up-regulated in APL (acute promyeolocytic leukemia) blasts expressing PML-RARA fusion [GeneID=5371;5914] compared to normal promyeloblasts.,CGP,C2,240,289
Cohort,-0.011263835956519093,0.03516701441540105,-0.320295485521404,0.7488433219750179,LGP Offspring,Genes up-regulated in secondary APL (acute promyelocytic leukemia) compared to the de novo tumors.,CGP,C2,44,87
Cohort,-0.15015810744160313,0.09484850390332451,-1.583136277981291,0.11376951822493725,LGP Proband,Genes up-regulated in secondary APL (acute promyelocytic leukemia) compared to the de novo tumors.,CGP,C2,44,109
Cohort,-0.03281530271036565,0.02989310340334224,-1.0977549660065302,0.2726434515854914,LonGen OPEL,Genes up-regulated in secondary APL (acute promyelocytic leukemia) compared to the de novo tumors.,CGP,C2,68,67
Cohort,-0.017675897333324482,0.007155768233680185,-2.4701606810194066,0.013750995439140908,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblasts) isolated from HRAS and NRAS [GeneID=3265;4893] double knockout mice.,CGP,C2,4,1
Cohort,0.015331123073930534,0.02066856702717471,0.7417603288013829,0.4584413882521696,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblasts) isolated from HRAS and NRAS [GeneID=3265;4893] double knockout mice.,CGP,C2,4,3
Cohort,0.007478074105902565,0.007747072522322671,0.9652774108355117,0.3346990465551781,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblasts) isolated from HRAS and NRAS [GeneID=3265;4893] double knockout mice.,CGP,C2,3,6
Cohort,-0.010198964403089886,0.009558959962992926,-1.0669533550276085,0.28637379048227085,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblasts) isolated from HRAS and NRAS [GeneID=3265;4893] double knockout mice.,CGP,C2,4,5
Cohort,-0.010232522024152889,0.03404418576463664,-0.30056592026888507,0.7638204301857902,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblasts) isolated from HRAS and NRAS [GeneID=3265;4893] double knockout mice.,CGP,C2,4,15
Cohort,0.006012642127756683,0.007219781233291655,0.8328011519284483,0.40520668100258184,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblasts) isolated from HRAS and NRAS [GeneID=3265;4893] double knockout mice.,CGP,C2,3,5
Cohort,-0.006575579872675953,0.01350716005906551,-0.486821792584198,0.6265424265221055,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblast) isolated from HRAS [GeneID=3265] knockout mice.,CGP,C2,7,13
Cohort,-0.06700118663322353,0.03555259434019967,-1.8845653285410071,0.05983607586869158,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblast) isolated from HRAS [GeneID=3265] knockout mice.,CGP,C2,7,14
Cohort,-0.024563772933247463,0.013911457893766646,-1.7657224081635496,0.07782574921787203,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblast) isolated from HRAS [GeneID=3265] knockout mice.,CGP,C2,18,12
Cohort,0.007134217665437998,0.009047186232289122,0.7885565171606836,0.4306476987580835,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) isolated from HRAS [GeneID=3265] knockout mice.,CGP,C2,2,6
Cohort,-0.020052810890737936,0.027261665218433786,-0.7355680854439747,0.4622003973724924,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) isolated from HRAS [GeneID=3265] knockout mice.,CGP,C2,2,8
Cohort,0.009501751536101614,0.007726021610799154,1.229837556087134,0.21912130302760913,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) isolated from HRAS [GeneID=3265] knockout mice.,CGP,C2,2,7
Cohort,0.01615790741444948,0.014796553383175358,1.0920048065262327,0.2752200166616622,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblast) isolated from NRAS [GeneID=4893] knockout mice.,CGP,C2,5,16
Cohort,-0.011918347646889645,0.03674244341986467,-0.3243754779913748,0.7457351203202379,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblast) isolated from NRAS [GeneID=4893] knockout mice.,CGP,C2,5,18
Cohort,0.0077815242769614466,0.013568137262986824,0.5735145603360781,0.5664583360520509,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblast) isolated from NRAS [GeneID=4893] knockout mice.,CGP,C2,10,16
Cohort,0.010693339444809467,0.04561958588213117,0.23440237867213878,0.8147435879505589,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) isolated from NRAS [GeneID=4893] knockout mice.,CGP,C2,65,145
Cohort,-0.11461062312529102,0.12890374084825032,-0.889117898139313,0.37419609496187056,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) isolated from NRAS [GeneID=4893] knockout mice.,CGP,C2,65,203
Cohort,-0.04844080515366916,0.04314871329705114,-1.1226477327420026,0.2619256354006103,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) isolated from NRAS [GeneID=4893] knockout mice.,CGP,C2,130,144
Cohort,0.00793343106834644,0.02475010982813787,0.32054124702618864,0.7486571269964204,LGP Offspring,Genes identified by subtractive hybridization comparing malignant and benign components of a hepatocellular carcinoma (HCC) in a pre-existing liver adenoma in a morphologically normal liver.,CGP,C2,17,41
Cohort,-0.04458642203354519,0.0636398089639622,-0.7006058434083843,0.4837444358860594,LGP Proband,Genes identified by subtractive hybridization comparing malignant and benign components of a hepatocellular carcinoma (HCC) in a pre-existing liver adenoma in a morphologically normal liver.,CGP,C2,17,52
Cohort,-0.009715712896855019,0.022561259672449485,-0.4306369873805978,0.6668489194093422,LonGen OPEL,Genes identified by subtractive hybridization comparing malignant and benign components of a hepatocellular carcinoma (HCC) in a pre-existing liver adenoma in a morphologically normal liver.,CGP,C2,36,46
Cohort,-0.02875747880431496,0.026851312226073544,-1.0709896992069707,0.2845562828755889,LGP Offspring,"Genes down-regulated in K562 cells (chronic myelogenous leukemia, CML) expressing TP53 and MYC [GeneID=7157;4609].",CGP,C2,27,42
Cohort,0.025290995888676858,0.07212931031461813,0.3506341011491863,0.7259514134781981,LGP Proband,"Genes down-regulated in K562 cells (chronic myelogenous leukemia, CML) expressing TP53 and MYC [GeneID=7157;4609].",CGP,C2,27,60
Cohort,0.005477634197343938,0.02207464143921624,0.24814148000668146,0.8040889418091838,LonGen OPEL,"Genes down-regulated in K562 cells (chronic myelogenous leukemia, CML) expressing TP53 and MYC [GeneID=7157;4609].",CGP,C2,31,40
Cohort,0.015703838267775116,0.01659751712017807,0.9461558710298611,0.3444071602108588,LGP Offspring,"Genes up-regulated in K562 cells (chronic myelogenous leukemia, CML) expressing TP53 and MYC [GeneID=7157;4609].",CGP,C2,7,19
Cohort,0.004402828188286266,0.05219253868094487,0.08435742540137654,0.9327925006470738,LGP Proband,"Genes up-regulated in K562 cells (chronic myelogenous leukemia, CML) expressing TP53 and MYC [GeneID=7157;4609].",CGP,C2,7,28
Cohort,0.011259451887445664,0.01646296050605475,0.6839263134540511,0.49422074451205666,LonGen OPEL,"Genes up-regulated in K562 cells (chronic myelogenous leukemia, CML) expressing TP53 and MYC [GeneID=7157;4609].",CGP,C2,12,20
Cohort,-0.005384386352234354,0.02838559194888881,-0.18968730199213382,0.849611113048517,LGP Offspring,Transcriptionally inactive genes which where bound by NF-Y transcription factor.,CGP,C2,27,53
Cohort,0.06937088449879023,0.07374775375332195,0.940650812644791,0.34715619838859635,LGP Proband,Transcriptionally inactive genes which where bound by NF-Y transcription factor.,CGP,C2,27,64
Cohort,-0.038996903359338614,0.027215611692208177,-1.4328872633975527,0.15228267087038988,LonGen OPEL,Transcriptionally inactive genes which where bound by NF-Y transcription factor.,CGP,C2,49,44
Cohort,0.014101968194265863,0.02856603752723155,0.4936620341838689,0.6217052293607732,LGP Offspring,Transcriptionally inactive genes whose promoters (regions between -2 kb to +0.5 kb relative to trascription start sites) where bound by NF-Y transcription factor.,CGP,C2,23,57
Cohort,-0.041204982434858116,0.07560319299212115,-0.5450164312392496,0.5858879275959187,LGP Proband,Transcriptionally inactive genes whose promoters (regions between -2 kb to +0.5 kb relative to trascription start sites) where bound by NF-Y transcription factor.,CGP,C2,23,73
Cohort,-0.014736391451835988,0.02500949720760669,-0.5892318157981155,0.5558729628018222,LonGen OPEL,Transcriptionally inactive genes whose promoters (regions between -2 kb to +0.5 kb relative to trascription start sites) where bound by NF-Y transcription factor.,CGP,C2,48,48
Cohort,0.007206283296503083,0.034503179482869316,0.20885852853302905,0.8346215973415572,LGP Offspring,"Genes turned off in Hep3B cells (hepatocellular carcinoma, HCC) upon knockdown of SDHB [GeneID=6390] by RNAi.",CGP,C2,37,75
Cohort,-0.022148752221636685,0.08957392356605472,-0.24726785809827206,0.8047617890079216,LGP Proband,"Genes turned off in Hep3B cells (hepatocellular carcinoma, HCC) upon knockdown of SDHB [GeneID=6390] by RNAi.",CGP,C2,37,94
Cohort,-0.022362507435994185,0.030518162933618642,-0.7327606017647861,0.46392017143107633,LonGen OPEL,"Genes turned off in Hep3B cells (hepatocellular carcinoma, HCC) upon knockdown of SDHB [GeneID=6390] by RNAi.",CGP,C2,72,73
Cohort,-0.0820490612277677,0.06165930912061786,-1.3306840831976148,0.18374165376075874,LGP Offspring,"Genes turned on in Hep3B cells (hepatocellular carcinoma, HCC) upon knockdown of SDHB [GeneID=6390] by RNAi.",CGP,C2,131,242
Cohort,0.015871211322210456,0.16922666018903618,0.09378670774735716,0.9253011167677223,LGP Proband,"Genes turned on in Hep3B cells (hepatocellular carcinoma, HCC) upon knockdown of SDHB [GeneID=6390] by RNAi.",CGP,C2,131,362
Cohort,0.041336597652728554,0.057129178325004554,0.7235636650953926,0.4695462273667662,LonGen OPEL,"Genes turned on in Hep3B cells (hepatocellular carcinoma, HCC) upon knockdown of SDHB [GeneID=6390] by RNAi.",CGP,C2,218,280
Cohort,-0.12043794932501785,0.06854678063127073,-1.7570183196915101,0.07936736315879928,LGP Offspring,"Genes present but differentially expressed between Hep3B cells (hepatocellular carcinoma, HCC) with RNAi knockdown of SDHB [GeneID=6390] and control cells.",CGP,C2,164,289
Cohort,0.16370451824050247,0.19467393328909224,0.8409164774895673,0.4006357552574621,LGP Proband,"Genes present but differentially expressed between Hep3B cells (hepatocellular carcinoma, HCC) with RNAi knockdown of SDHB [GeneID=6390] and control cells.",CGP,C2,164,421
Cohort,-0.020644305990871942,0.056886493101581385,-0.36290347436266995,0.7167733331415481,LonGen OPEL,"Genes present but differentially expressed between Hep3B cells (hepatocellular carcinoma, HCC) with RNAi knockdown of SDHB [GeneID=6390] and control cells.",CGP,C2,255,296
Cohort,-0.11598810458727986,0.09659745956451694,-1.2007365940075474,0.2302739626885421,LGP Offspring,Genes down-regulated in metastatic tumors from the whole panel of patients with prostate cancer.,CGP,C2,326,631
Cohort,-0.0468497698416255,0.27495149481178904,-0.1703928537420584,0.8647425178993273,LGP Proband,Genes down-regulated in metastatic tumors from the whole panel of patients with prostate cancer.,CGP,C2,326,857
Cohort,0.041941226249429885,0.08461921317466078,0.49564661116453373,0.6202805686664798,LonGen OPEL,Genes down-regulated in metastatic tumors from the whole panel of patients with prostate cancer.,CGP,C2,477,585
Cohort,-0.0034661158335127246,0.03156481472412991,-0.10980947817390582,0.9125930636189941,LGP Offspring,Top 50 genes down-regulated in metastatic vs primary prostate cancer  tumors.,CGP,C2,32,73
Cohort,0.0678587985175578,0.08690891000667587,0.7808037002459846,0.4351395199191752,LGP Proband,Top 50 genes down-regulated in metastatic vs primary prostate cancer  tumors.,CGP,C2,32,97
Cohort,0.006362901504218535,0.02883621346184201,0.22065662374979808,0.8254163913355412,LonGen OPEL,Top 50 genes down-regulated in metastatic vs primary prostate cancer  tumors.,CGP,C2,54,67
Cohort,0.011312896707492186,0.025498559778564533,0.44366806618632704,0.6574245543229296,LGP Offspring,Top 50 genes up-regulated in metastatic vs primary prostate cancer  tumors.,CGP,C2,20,45
Cohort,0.08177993300759578,0.07657232036142736,1.0680090745792747,0.2858254552830461,LGP Proband,Top 50 genes up-regulated in metastatic vs primary prostate cancer  tumors.,CGP,C2,20,72
Cohort,-0.011684050051839987,0.025168543669790232,-0.4642322656858504,0.642608281728908,LonGen OPEL,Top 50 genes up-regulated in metastatic vs primary prostate cancer  tumors.,CGP,C2,43,47
Cohort,0.0648606861477694,0.08188901549267831,0.7920560011320271,0.4286058725908518,LGP Offspring,Genes up-regulated in metastatic tumors from the whole panel of patients with prostate cancer.,CGP,C2,206,451
Cohort,-0.2823248535820061,0.218937803785336,-1.2895208077396254,0.19757458018197366,LGP Proband,Genes up-regulated in metastatic tumors from the whole panel of patients with prostate cancer.,CGP,C2,206,619
Cohort,-0.016592856642645537,0.06828663832699311,-0.24298833635930392,0.808077032867625,LonGen OPEL,Genes up-regulated in metastatic tumors from the whole panel of patients with prostate cancer.,CGP,C2,329,386
Cohort,-0.02629346753610282,0.040295889761109926,-0.6525099133430472,0.5142940990693555,LGP Offspring,Genes down-regulated in normal keratinocytes immortalized by infection with the high risk HPV31 (human papilloma virus) strain.,CGP,C2,54,106
Cohort,-0.03587085828545826,0.11709767845219189,-0.30633278780247936,0.7594277337649227,LGP Proband,Genes down-regulated in normal keratinocytes immortalized by infection with the high risk HPV31 (human papilloma virus) strain.,CGP,C2,54,182
Cohort,0.09642577286309661,0.039281556154639796,2.4547340355737703,0.014311887446308636,LonGen OPEL,Genes down-regulated in normal keratinocytes immortalized by infection with the high risk HPV31 (human papilloma virus) strain.,CGP,C2,80,134
Cohort,-0.01274223532037797,0.04459584956279797,-0.28572693300606145,0.7751748040846725,LGP Offspring,Genes up-regulated in normal keratinocytes immortalized by infection with the high risk HPV31 (human papilloma virus) strain.,CGP,C2,64,139
Cohort,0.17934819450940942,0.1244974969443059,1.440576709663818,0.15007960295191444,LGP Proband,Genes up-regulated in normal keratinocytes immortalized by infection with the high risk HPV31 (human papilloma virus) strain.,CGP,C2,64,201
Cohort,-0.03588841313114045,0.039087697076032664,-0.9181511272288815,0.3588178653115577,LonGen OPEL,Genes up-regulated in normal keratinocytes immortalized by infection with the high risk HPV31 (human papilloma virus) strain.,CGP,C2,112,127
Cohort,-0.0012026587295111124,0.00787605850765571,-0.15269804412220916,0.8786819683042911,LGP Offspring,Genes down-regulated by POU5F1 [GeneID=5460] in bladder cancer cell lines.,CGP,C2,2,4
Cohort,0.018239363286760773,0.026034650850793536,0.7005802916771146,0.483760378197161,LGP Proband,Genes down-regulated by POU5F1 [GeneID=5460] in bladder cancer cell lines.,CGP,C2,2,9
Cohort,0.016342656919041954,0.010903949145464048,1.49878330328057,0.1343263211284437,LonGen OPEL,Genes down-regulated by POU5F1 [GeneID=5460] in bladder cancer cell lines.,CGP,C2,6,12
Cohort,-0.013069407682760766,0.02934082701573273,-0.4454341956943773,0.656148612501044,LGP Offspring,Genes up-regulated by POU5F1 [GeneID=5460] in bladder cancer cell lines.,CGP,C2,26,49
Cohort,-0.006808136678911498,0.08178222858408607,-0.08324714056809511,0.9336750062143191,LGP Proband,Genes up-regulated by POU5F1 [GeneID=5460] in bladder cancer cell lines.,CGP,C2,26,77
Cohort,-0.03850255746761052,0.02422950483415143,-1.5890773555281763,0.11244001254187144,LonGen OPEL,Genes up-regulated by POU5F1 [GeneID=5460] in bladder cancer cell lines.,CGP,C2,47,37
Cohort,-0.012011197628807944,0.03156444934838554,-0.38052929408769476,0.7036720969184653,LGP Offspring,Genes down-regulated in liver tissue upon knockout of H2AFY [GeneID=9555].,CGP,C2,30,68
Cohort,0.035595564744403806,0.08951963849322396,0.3976285577504667,0.6910057564301249,LGP Proband,Genes down-regulated in liver tissue upon knockout of H2AFY [GeneID=9555].,CGP,C2,30,101
Cohort,0.0038721331215400196,0.027921418366175312,0.13867967131035205,0.8897383585913342,LonGen OPEL,Genes down-regulated in liver tissue upon knockout of H2AFY [GeneID=9555].,CGP,C2,54,62
Cohort,-0.026255405799672126,0.04179278779826372,-0.6282281509050924,0.5300666730732592,LGP Offspring,Genes up-regulated in liver tissue upon knockout of H2AFY [GeneID=9555].,CGP,C2,57,104
Cohort,-0.009937997889037894,0.11954503692643026,-0.08313183168912217,0.9337666637266622,LGP Proband,Genes up-regulated in liver tissue upon knockout of H2AFY [GeneID=9555].,CGP,C2,57,167
Cohort,0.007222671585097498,0.03577788425614644,0.20187531306736461,0.8400657816789993,LonGen OPEL,Genes up-regulated in liver tissue upon knockout of H2AFY [GeneID=9555].,CGP,C2,87,114
Cohort,0.01409292216787338,0.05136772847232026,0.27435361825406424,0.7838967001071291,LGP Offspring,Genes down-regulated in basal-like breast cancer cell lines as compared to the mesenchymal-like ones.,CGP,C2,85,186
Cohort,0.005187278691002958,0.13522657472886002,0.03835990596821566,0.9694099078962379,LGP Proband,Genes down-regulated in basal-like breast cancer cell lines as compared to the mesenchymal-like ones.,CGP,C2,85,225
Cohort,-0.01926648007103411,0.04575990603641922,-0.42103408288689187,0.6738438488281326,LonGen OPEL,Genes down-regulated in basal-like breast cancer cell lines as compared to the mesenchymal-like ones.,CGP,C2,141,168
Cohort,0.026028314640494148,0.062361871291590355,0.41737545877658944,0.6765363229043787,LGP Offspring,Genes up-regulated in basal-like breast cancer cell lines as compared to the mesenchymal-like ones.,CGP,C2,130,285
Cohort,5.247910418076874e-4,0.16141209875590226,0.0032512497257179596,0.9974066601126573,LGP Proband,Genes up-regulated in basal-like breast cancer cell lines as compared to the mesenchymal-like ones.,CGP,C2,130,321
Cohort,0.04782677119638227,0.053418104637854985,0.8953288687537897,0.37088196824609165,LonGen OPEL,Genes up-regulated in basal-like breast cancer cell lines as compared to the mesenchymal-like ones.,CGP,C2,180,239
Cohort,-0.044953008835105626,0.11118677185815444,-0.4043017715493534,0.6861187032107032,LGP Offspring,Genes down-regulated in luminal-like breast cancer cell lines compared to the basal-like ones.,CGP,C2,397,803
Cohort,-0.20690564569741254,0.3146638649453523,-0.6575449829084946,0.5110119882403634,LGP Proband,Genes down-regulated in luminal-like breast cancer cell lines compared to the basal-like ones.,CGP,C2,397,1123
Cohort,-0.01592946943095149,0.09268575433681772,-0.1718653480778092,0.8635870725414132,LonGen OPEL,Genes down-regulated in luminal-like breast cancer cell lines compared to the basal-like ones.,CGP,C2,636,751
Cohort,0.06159504248577023,0.11044503622610226,0.5576986036717243,0.5772348407471896,LGP Offspring,Genes up-regulated in luminal-like breast cancer cell lines compared to the basal-like ones.,CGP,C2,388,851
Cohort,0.2604837552455111,0.309610993652189,0.8413259237756056,0.40040653160918005,LGP Proband,Genes up-regulated in luminal-like breast cancer cell lines compared to the basal-like ones.,CGP,C2,388,1141
Cohort,0.010238107351212713,0.10305662275581957,0.09934448730646542,0.9208897702355928,LonGen OPEL,Genes up-regulated in luminal-like breast cancer cell lines compared to the basal-like ones.,CGP,C2,663,787
Cohort,-0.07093260236968743,0.1110495426061151,-0.6387473618084171,0.5232036454094972,LGP Offspring,Genes down-regulated in luminal-like breast cancer cell lines compared to the mesenchymal-like ones.,CGP,C2,442,899
Cohort,-0.3112936001670701,0.31148977863118005,-0.9993701929322624,0.3179052566689642,LGP Proband,Genes down-regulated in luminal-like breast cancer cell lines compared to the mesenchymal-like ones.,CGP,C2,442,1183
Cohort,0.03440629243594795,0.09773034359179059,0.3520533252155485,0.7248914530053596,LonGen OPEL,Genes down-regulated in luminal-like breast cancer cell lines compared to the mesenchymal-like ones.,CGP,C2,681,809
Cohort,-0.1743207386279377,0.1316394572250839,-1.32422863404758,0.18587467470791338,LGP Offspring,Genes up-regulated in luminal-like breast cancer cell lines compared to the mesenchymal-like ones.,CGP,C2,536,1056
Cohort,-0.19103587573212677,0.35787332075929557,-0.5338086542098422,0.5936161672681451,LGP Proband,Genes up-regulated in luminal-like breast cancer cell lines compared to the mesenchymal-like ones.,CGP,C2,536,1432
Cohort,0.24082151667212942,0.11328131176689349,2.1258715397618624,0.03382119504903908,LonGen OPEL,Genes up-regulated in luminal-like breast cancer cell lines compared to the mesenchymal-like ones.,CGP,C2,811,1049
Cohort,0.017799852228563177,0.01630712180250083,1.0915385586825888,0.2754248542544016,LGP Offspring,List of the transcription factors up-regulated 1 hr after wounding HDF cells (dermal fibroblasts).,CGP,C2,6,21
Cohort,3.7872694402830097e-4,0.039043919905212505,0.00970002358748153,0.9922629420618265,LGP Proband,List of the transcription factors up-regulated 1 hr after wounding HDF cells (dermal fibroblasts).,CGP,C2,6,19
Cohort,0.0072591046298740415,0.008938177541202514,0.8121459432207054,0.4169506980079929,LonGen OPEL,List of the transcription factors up-regulated 1 hr after wounding HDF cells (dermal fibroblasts).,CGP,C2,4,8
Cohort,0.03857159254232968,0.05146534924504225,0.749467226165678,0.45383637074966043,LGP Offspring,Genes down-regulated by 2-methoxyestradiol (2ME2) [PubChem=1573] in the MM.1S cell line (multiple myeloma) sensitive to dexamethasone [PubChem=5743].,CGP,C2,79,196
Cohort,-0.040850436480536635,0.15492426802372677,-0.26368003542401997,0.7920916160244271,LGP Proband,Genes down-regulated by 2-methoxyestradiol (2ME2) [PubChem=1573] in the MM.1S cell line (multiple myeloma) sensitive to dexamethasone [PubChem=5743].,CGP,C2,79,261
Cohort,-0.051319079498006556,0.04679362321452723,-1.0967109612934265,0.27309943337968684,LonGen OPEL,Genes down-regulated by 2-methoxyestradiol (2ME2) [PubChem=1573] in the MM.1S cell line (multiple myeloma) sensitive to dexamethasone [PubChem=5743].,CGP,C2,150,166
Cohort,-0.031207815622308156,0.02527570335584382,-1.2346962291394679,0.21737257908614507,LGP Offspring,Genes up-regulated by 2-methoxyestradiol (2ME2) [PubChem=1573] in the MM.1S cell line (multiple myeloma) sensitive to dexamethasone [PubChem=5743].,CGP,C2,23,38
Cohort,0.00121944041596401,0.06301809226230055,0.019350639985868286,0.98456601495251,LGP Proband,Genes up-regulated by 2-methoxyestradiol (2ME2) [PubChem=1573] in the MM.1S cell line (multiple myeloma) sensitive to dexamethasone [PubChem=5743].,CGP,C2,23,45
Cohort,0.02548565789004618,0.02325341801894515,1.0959962044841052,0.2734119132984499,LonGen OPEL,Genes up-regulated by 2-methoxyestradiol (2ME2) [PubChem=1573] in the MM.1S cell line (multiple myeloma) sensitive to dexamethasone [PubChem=5743].,CGP,C2,31,52
Cohort,-0.03129212598484995,0.07020024002928231,-0.44575525627543733,0.6559167698156113,LGP Offspring,Genes down-regulated in follicular epithelial stem cells after transgenic expression of GR [GeneID=2908] under control of the keratin5 (K5) [GeneID=3852] promoter.,CGP,C2,151,306
Cohort,0.36338434648457524,0.1919445065347573,1.8931739857778822,0.058680681948484886,LGP Proband,Genes down-regulated in follicular epithelial stem cells after transgenic expression of GR [GeneID=2908] under control of the keratin5 (K5) [GeneID=3852] promoter.,CGP,C2,151,431
Cohort,0.012805998696105205,0.06128237244432423,0.20896708442121115,0.8345273972725178,LonGen OPEL,Genes down-regulated in follicular epithelial stem cells after transgenic expression of GR [GeneID=2908] under control of the keratin5 (K5) [GeneID=3852] promoter.,CGP,C2,239,286
Cohort,0.030200009732790526,0.04766746007121022,0.6335560923043698,0.52658485403486055,LGP Offspring,Genes up-regulated in follicular epithelial stem cells after transgenic expression of GR [GeneID=2908] under control of the keratin5 (K5) [GeneID=3852] promoter.,CGP,C2,65,158
Cohort,0.17967127538500158,0.12983306544834727,1.38386376971498,0.16677040572382007,LGP Proband,Genes up-regulated in follicular epithelial stem cells after transgenic expression of GR [GeneID=2908] under control of the keratin5 (K5) [GeneID=3852] promoter.,CGP,C2,65,208
Cohort,-0.03837251577585931,0.04232610706902645,-0.9065921350451737,0.3648968713926789,LonGen OPEL,Genes up-regulated in follicular epithelial stem cells after transgenic expression of GR [GeneID=2908] under control of the keratin5 (K5) [GeneID=3852] promoter.,CGP,C2,131,153
Cohort,0.0012496411425564709,0.008493433966819208,0.14713025937899435,0.8830730748724914,LGP Offspring,Genes down-regulated in type 2B (EDL) vs type 1 (soleus) myofibers.,CGP,C2,2,5
Cohort,0.011063442592735659,0.017666038566778074,0.6262548647177218,0.5313191460920381,LGP Proband,Genes down-regulated in type 2B (EDL) vs type 1 (soleus) myofibers.,CGP,C2,2,3
Cohort,0.0032528601206376836,0.003663324703550788,0.8879529891207162,0.37483426455564894,LonGen OPEL,Genes down-regulated in type 2B (EDL) vs type 1 (soleus) myofibers.,CGP,C2,0,2
Cohort,-0.0754112313206082,0.027280740229850053,-2.764266317014914,0.005860536402078437,LGP Offspring,Genes up-regulated in type 1 (soleus) vs type 2B (EDL) myofibers.,CGP,C2,35,35
Cohort,-0.014639337556394055,0.08392683014419688,-0.17442976854054687,0.8615700538831299,LGP Proband,Genes up-regulated in type 1 (soleus) vs type 2B (EDL) myofibers.,CGP,C2,35,79
Cohort,0.028311479851340384,0.02251067794372284,1.2576911242797604,0.20887232081850027,LonGen OPEL,Genes up-regulated in type 1 (soleus) vs type 2B (EDL) myofibers.,CGP,C2,30,45
Cohort,-0.30160122425567637,0.11760241286916649,-2.5645836415891385,0.010544783373917887,LGP Offspring,Genes down-regulated in CD4+ [GeneID=920] T lymphocytes after stimulation with prostaglandin E2 [PubChem=5280360].,CGP,C2,482,884
Cohort,-0.1884591760165432,0.32842780862465365,-0.573822225364373,0.5662428171742925,LGP Proband,Genes down-regulated in CD4+ [GeneID=920] T lymphocytes after stimulation with prostaglandin E2 [PubChem=5280360].,CGP,C2,482,1275
Cohort,-0.07392507268303099,0.09944221611020079,-0.7433972770790629,0.4574605466350492,LonGen OPEL,Genes down-regulated in CD4+ [GeneID=920] T lymphocytes after stimulation with prostaglandin E2 [PubChem=5280360].,CGP,C2,725,850
Cohort,0.07475254875701491,0.07316474049206391,1.0217018232316868,0.3072875369725603,LGP Offspring,Genes up-regulated in CD4+ [GeneID=920] T lymphocytes after stimulation with prostaglandin E2 [PubChem=5280360].,CGP,C2,148,349
Cohort,-0.06424558269600322,0.19583477165659166,-0.32806014045688375,0.7429485324127703,LGP Proband,Genes up-regulated in CD4+ [GeneID=920] T lymphocytes after stimulation with prostaglandin E2 [PubChem=5280360].,CGP,C2,148,470
Cohort,-0.07101303178260035,0.059412731344495213,-1.1952494048934168,0.23234557425478625,LonGen OPEL,Genes up-regulated in CD4+ [GeneID=920] T lymphocytes after stimulation with prostaglandin E2 [PubChem=5280360].,CGP,C2,265,297
Cohort,0.009539240101769406,0.026042489799702997,0.3662952419349012,0.7142593887074679,LGP Offspring,Genes down-regulated in Sertoli cells from both 4 and 10 week old ETV5 [GeneID=2119] knockout mice.,CGP,C2,22,46
Cohort,-0.10205234081557168,0.06538595277391158,-1.5607685823351596,0.11895772205736971,LGP Proband,Genes down-regulated in Sertoli cells from both 4 and 10 week old ETV5 [GeneID=2119] knockout mice.,CGP,C2,22,50
Cohort,0.014531774271532013,0.022238516622613825,0.653450700787974,0.5136544668673259,LonGen OPEL,Genes down-regulated in Sertoli cells from both 4 and 10 week old ETV5 [GeneID=2119] knockout mice.,CGP,C2,34,43
Cohort,-0.008039359738290362,0.01691208486551122,-0.47536183753932154,0.6346826479855168,LGP Offspring,Genes down-regulated in testis from 4 week old ETV5 [GeneID=2119] knockout mice.,CGP,C2,10,18
Cohort,-0.04602629394700374,0.0500428053236859,-0.9197384848690509,0.3579753737465151,LGP Proband,Genes down-regulated in testis from 4 week old ETV5 [GeneID=2119] knockout mice.,CGP,C2,10,32
Cohort,-0.002707824422065823,0.015029014159038399,-0.18017312336067942,0.8570625152728584,LonGen OPEL,Genes down-regulated in testis from 4 week old ETV5 [GeneID=2119] knockout mice.,CGP,C2,16,19
Cohort,-0.00538108182882568,0.003215454730535789,-1.6735057028556064,0.09469040568152691,LGP Offspring,Genes down-regulated 6 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,1,0
Cohort,0.011221200198592012,0.018179502127313094,0.6172446373948355,0.5372418543305337,LGP Proband,Genes down-regulated 6 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,1,5
Cohort,0.006498521325683612,0.007535414243534877,0.8623973567556843,0.3887286309080725,LonGen OPEL,Genes down-regulated 6 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,2,7
Cohort,0.021733877349773868,0.0165886405576405,1.310166271567295,0.19058459954484053,LGP Offspring,Genes up-regulated 6 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,5,21
Cohort,0.012899607408708541,0.04268904063831248,0.3021760905334431,0.7625931696243557,LGP Proband,Genes up-regulated 6 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,5,23
Cohort,0.010402194836075466,0.011711801574390097,0.8881805903219607,0.37471191791670455,LonGen OPEL,Genes up-regulated 6 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,8,13
Cohort,0.021623627873262632,0.029991527282144232,0.7209912209484738,0.4711641769461522,LGP Offspring,Genes down-regulated 9 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,29,71
Cohort,0.03131012327385053,0.07802427919061466,0.4012869275903127,0.688311681744106,LGP Proband,Genes down-regulated 9 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,29,69
Cohort,-0.00896092239856095,0.02465344912598023,-0.3634754047099144,0.7163462916795729,LonGen OPEL,Genes down-regulated 9 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,39,49
Cohort,-2.70373977941818e-4,0.07315324618201473,-0.003695994259353749,0.9970521203609746,LGP Offspring,Genes up-regulated 9 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,176,347
Cohort,-0.31852560631550525,0.1934074770114585,-1.646914644859537,0.09995230268399194,LGP Proband,Genes up-regulated 9 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,176,517
Cohort,0.004501004222735697,0.06340219081949754,0.07099130431548971,0.9434225078705234,LonGen OPEL,Genes up-regulated 9 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.,CGP,C2,282,340
Cohort,0.03548853256236422,0.04441703302482775,0.7989847620512434,0.4245798742759408,LGP Offspring,"Cis-regulated expression quantitative loci (cis-eQTL) in the liver that contribute to metabolic quantitative traits (weight, fat mass, and plasma glucose and cholesterol levels).",CGP,C2,61,141
Cohort,-0.17948865371483189,0.12139114257489385,-1.4785976135292904,0.13962545990636757,LGP Proband,"Cis-regulated expression quantitative loci (cis-eQTL) in the liver that contribute to metabolic quantitative traits (weight, fat mass, and plasma glucose and cholesterol levels).",CGP,C2,61,183
Cohort,0.01025342030063633,0.03536067894631086,0.28996672592753076,0.7719172105909262,LonGen OPEL,"Cis-regulated expression quantitative loci (cis-eQTL) in the liver that contribute to metabolic quantitative traits (weight, fat mass, and plasma glucose and cholesterol levels).",CGP,C2,86,101
Cohort,-0.0012404069133592607,0.016951499239746797,-0.07317387658849864,0.94168939948703,LGP Offspring,Protein profiles associated with survival in lung adenocarcinoma.,CGP,C2,9,20
Cohort,0.055876315282847436,0.053482027619101466,1.0447680794901433,0.29643289138221673,LGP Proband,Protein profiles associated with survival in lung adenocarcinoma.,CGP,C2,9,35
Cohort,0.002215819184006314,0.01820822624495666,0.12169330247750271,0.9031726314454562,LonGen OPEL,Protein profiles associated with survival in lung adenocarcinoma.,CGP,C2,21,27
Cohort,6.001166236427258e-4,0.03463046498010387,0.017329152929003663,0.9861791416495234,LGP Offspring,Down-regulated genesin the left ventricle myocardium of patients with heart failure following implantation of LVAD (left ventricular assist device).,CGP,C2,35,75
Cohort,-0.009403502752153063,0.09639931423888634,-0.09754740297063028,0.922315129042708,LGP Proband,Down-regulated genesin the left ventricle myocardium of patients with heart failure following implantation of LVAD (left ventricular assist device).,CGP,C2,35,117
Cohort,-0.01303346480415493,0.02820778718675016,-0.4620520113069006,0.6441702791312403,LonGen OPEL,Down-regulated genesin the left ventricle myocardium of patients with heart failure following implantation of LVAD (left ventricular assist device).,CGP,C2,56,64
Cohort,-0.08643513779068297,0.046531612442191145,-1.8575573304721866,0.06366654573382007,LGP Offspring,Up-regulated genesin the left ventricle myocardium of patients with heart failure following implantation of LVAD (left ventricular assist device).,CGP,C2,91,146
Cohort,-0.025546807370397513,0.13368347616400794,-0.19109921512704925,0.8484943732855027,LGP Proband,Up-regulated genesin the left ventricle myocardium of patients with heart failure following implantation of LVAD (left ventricular assist device).,CGP,C2,91,202
Cohort,-0.05065808343909232,0.041053880725019844,-1.233941409300663,0.21758893314524047,LonGen OPEL,Up-regulated genesin the left ventricle myocardium of patients with heart failure following implantation of LVAD (left ventricular assist device).,CGP,C2,123,131
Cohort,-0.14919098214138246,0.19675433445412321,-0.7582602058312926,0.44855949065208156,LGP Offspring,Genes forming the macrophage-enriched metabolic network (MEMN) claimed to have a causal relationship with the metabolic syndrom traits.,CGP,C2,1270,2595
Cohort,-0.580266263154932,0.5436799312813276,-1.067293879668096,0.2861479963210069,LGP Proband,Genes forming the macrophage-enriched metabolic network (MEMN) claimed to have a causal relationship with the metabolic syndrom traits.,CGP,C2,1270,3553
Cohort,0.10132695023356157,0.1858319320151334,0.5452612429671663,0.5857266009315949,LonGen OPEL,Genes forming the macrophage-enriched metabolic network (MEMN) claimed to have a causal relationship with the metabolic syndrom traits.,CGP,C2,2089,2527
Cohort,-0.029389682157610456,0.03917623824636168,-0.7501915312233913,0.453400375836718,LGP Offspring,"High-grade amplification (copy number, CN >= 5) detected in primary neuroblastoma samples.",CGP,C2,58,101
Cohort,-0.14712207734995658,0.109728041855713,-1.340788324131537,0.18035425771687214,LGP Proband,"High-grade amplification (copy number, CN >= 5) detected in primary neuroblastoma samples.",CGP,C2,58,150
Cohort,0.0636235300989192,0.03413961592048135,1.8636275887553144,0.06274203519413923,LonGen OPEL,"High-grade amplification (copy number, CN >= 5) detected in primary neuroblastoma samples.",CGP,C2,69,101
Cohort,0.009037253250192409,0.020125008180250384,0.44905587959268956,0.6535352694215629,LGP Offspring,Up-regulated PDGF targets identified by a gene-trap screen.,CGP,C2,9,26
Cohort,-0.024525134066753683,0.04984547968109772,-0.4920232330727082,0.6228323995800045,LGP Proband,Up-regulated PDGF targets identified by a gene-trap screen.,CGP,C2,9,33
Cohort,-0.003479038091228127,0.017732440260309155,-0.19619623921786566,0.8445066478428462,LonGen OPEL,Up-regulated PDGF targets identified by a gene-trap screen.,CGP,C2,23,24
Cohort,-0.05561350593065518,0.060647011386391766,-0.9170032398848589,0.3594679699385417,LGP Offspring,Genes whose CpG islands became hypermethylated in breast progenitor cells pre-exposed to estradiol [PubChem=5757].,CGP,C2,129,241
Cohort,-0.1920506269817612,0.16964070885304813,-1.1321022429122585,0.2579168411335478,LGP Proband,Genes whose CpG islands became hypermethylated in breast progenitor cells pre-exposed to estradiol [PubChem=5757].,CGP,C2,129,352
Cohort,0.03450567518121826,0.055301598428117986,0.623954391229204,0.532836305001358,LonGen OPEL,Genes whose CpG islands became hypermethylated in breast progenitor cells pre-exposed to estradiol [PubChem=5757].,CGP,C2,196,254
Cohort,-0.015563035144246215,0.03139077946080485,-0.49578364766884897,0.620208202021481,LGP Offspring,Genes down-regulated in HPL1D cells (lung epithelium) upon exposure to nickel acetate [PubChem=9756].,CGP,C2,32,63
Cohort,-0.04168332656002451,0.0898112461405002,-0.4641214586290825,0.6426818480118092,LGP Proband,Genes down-regulated in HPL1D cells (lung epithelium) upon exposure to nickel acetate [PubChem=9756].,CGP,C2,32,107
Cohort,0.0020168344636202055,0.02821749276294111,0.07147461613843224,0.9430379799650158,LonGen OPEL,Genes down-regulated in HPL1D cells (lung epithelium) upon exposure to nickel acetate [PubChem=9756].,CGP,C2,58,75
Cohort,-0.012014616226941575,0.01058794847423988,-1.1347444933428539,0.25688458734346975,LGP Offspring,Genes down-regulated in testis tissues upon knockout of TAF7L [GeneID=54457].,CGP,C2,5,6
Cohort,0.04703408257696208,0.03218706428723753,1.461272831757183,0.14431723001309926,LGP Proband,Genes down-regulated in testis tissues upon knockout of TAF7L [GeneID=54457].,CGP,C2,5,12
Cohort,-0.0050909940597990075,0.011157787085319398,-0.45627273767370646,0.6483183276442122,LonGen OPEL,Genes down-regulated in testis tissues upon knockout of TAF7L [GeneID=54457].,CGP,C2,9,10
Cohort,-0.009536680799444634,0.025929590562006503,-0.3677914148562884,0.7131438963546749,LGP Offspring,Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by high-dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,23,44
Cohort,0.06355669307982784,0.07449979200919582,0.8531123559644672,0.3938419393600743,LGP Proband,Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by high-dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,23,72
Cohort,-0.0049827522123725935,0.02482268535315004,-0.20073381028214474,0.8409579981017039,LonGen OPEL,Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by high-dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,40,48
Cohort,0.03616289367112382,0.028157821822223466,1.2842930074435792,0.19947941117165682,LGP Offspring,Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by high-dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,22,55
Cohort,-0.006158417261211353,0.08413879668302421,-0.07319355046652185,0.941669648662138,LGP Proband,Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by high-dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,22,86
Cohort,0.026798542752942602,0.026984901687644638,0.9930939553955328,0.3209659518509066,LonGen OPEL,Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by high-dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,41,54
Cohort,0.011793676350162582,0.028752575784589635,0.4101780806881162,0.6818052800222261,LGP Offspring,Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and high dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,25,59
Cohort,0.10757881608453987,0.07839606901206783,1.3722475812910953,0.1703553290613036,LGP Proband,Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and high dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,25,72
Cohort,0.011824842960720144,0.023551430643973213,0.5020859725880861,0.6157459000118269,LonGen OPEL,Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and high dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,38,45
Cohort,0.017532641798922704,0.01613510845668043,1.0866144374544724,0.27759454399277045,LGP Offspring,Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and high dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,5,21
Cohort,0.04109181861530017,0.03507860461337734,1.1714211288675282,0.24176409892395476,LGP Proband,Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and high dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,5,15
Cohort,-0.010913015727210422,0.012031300151005158,-0.9070520716997232,0.36465376087404766,LonGen OPEL,Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and high dose methotrexate (HDMTX) [PubChem=4112].,CGP,C2,12,10
Cohort,0.014641816942113542,0.0157666818051019,0.9286555740203772,0.35339907855253483,LGP Offspring,Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and low-dose methotrexate (LDMTX) [PubChem=4112].,CGP,C2,6,19
Cohort,0.057854972529268245,0.04264645702845834,1.3566184991794543,0.17526955788348983,LGP Proband,Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and low-dose methotrexate (LDMTX) [PubChem=4112].,CGP,C2,6,24
Cohort,-0.01034688392160905,0.014576421095027124,-0.7098370617969443,0.4780130655619771,LonGen OPEL,Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and low-dose methotrexate (LDMTX) [PubChem=4112].,CGP,C2,15,16
Cohort,0.01154452516339021,0.01009371434674171,1.1437340870575385,0.2531387786743842,LGP Offspring,Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and low-dose methotrexate (LDMTX) [PubChem=4112].,CGP,C2,2,8
Cohort,0.022530625898356114,0.0303796069011805,0.741636518591049,0.45851637875083306,LGP Proband,Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and low-dose methotrexate (LDMTX) [PubChem=4112].,CGP,C2,2,13
Cohort,-0.005966561979321556,0.008158249809429046,-0.7313531846531094,0.46477868802303146,LonGen OPEL,Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and low-dose methotrexate (LDMTX) [PubChem=4112].,CGP,C2,6,4
Cohort,0.009265416180100319,0.02092297305525184,0.44283458931160946,0.658027048417376,LGP Offspring,Genes specifically down-regulated in pediadric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490].,CGP,C2,13,33
Cohort,-0.030929206417753395,0.05482781382303686,-0.5641152594116009,0.5728273583149381,LGP Proband,Genes specifically down-regulated in pediadric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490].,CGP,C2,13,37
Cohort,0.004262981881274545,0.015666076129300707,0.2721154835511982,0.7856037899211146,LonGen OPEL,Genes specifically down-regulated in pediadric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490].,CGP,C2,16,20
Cohort,1.1389639379549857e-4,0.017452814185679844,0.006525961520231583,0.9947949983541566,LGP Offspring,Genes specifically up-regulated in pediadric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490].,CGP,C2,10,21
Cohort,0.05571438134348443,0.04611879454697542,1.208062393884454,0.22736570556952765,LGP Proband,Genes specifically up-regulated in pediadric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490].,CGP,C2,10,24
Cohort,-0.006599374597924084,0.013782461070013368,-0.4788241058255123,0.6321952650898014,LonGen OPEL,Genes specifically up-regulated in pediadric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490].,CGP,C2,15,14
Cohort,-0.008080660910386384,0.018895821996874673,-0.4276427303201156,0.6690474423479731,LGP Offspring,Cis-regulatory QTLs (quantitative trait loci) found at the D6Mit150 region.,CGP,C2,12,25
Cohort,-0.06372817264538182,0.05487808496787493,-1.1612681580031017,0.24586512054768625,LGP Proband,Cis-regulatory QTLs (quantitative trait loci) found at the D6Mit150 region.,CGP,C2,12,38
Cohort,0.006283524398621879,0.015035351817852562,0.41791668560498835,0.6761207425265439,LonGen OPEL,Cis-regulatory QTLs (quantitative trait loci) found at the D6Mit150 region.,CGP,C2,14,21
Cohort,-0.05524149840159702,0.02410108646291573,-2.292075026849804,0.02220778681312234,LGP Offspring,Neurologically relevant genes modulated in brain tissue by a trans-regulatory QTL (quantitative trait locus) near D6Mit150 marker.,CGP,C2,26,34
Cohort,-0.09158353500308597,0.07301826836187131,-1.2542550933857681,0.21010071560503615,LGP Proband,Neurologically relevant genes modulated in brain tissue by a trans-regulatory QTL (quantitative trait locus) near D6Mit150 marker.,CGP,C2,26,62
Cohort,-0.015456629465511086,0.019725676390578813,-0.7835791868152786,0.43352015601415594,LonGen OPEL,Neurologically relevant genes modulated in brain tissue by a trans-regulatory QTL (quantitative trait locus) near D6Mit150 marker.,CGP,C2,31,30
Cohort,0.06644791869813338,0.034808562528626893,1.9089532537715679,0.05669127884092995,LGP Offspring,Neurologically relevant transcripts with highest abundance fold range in brain tissue among mouse strains.,CGP,C2,26,86
Cohort,0.08592194467598713,0.09286801481141527,0.9252049249730023,0.3551269485084797,LGP Proband,Neurologically relevant transcripts with highest abundance fold range in brain tissue among mouse strains.,CGP,C2,26,109
Cohort,-0.019236904279525912,0.029615404807600706,-0.6495573639631229,0.5161655697792004,LonGen OPEL,Neurologically relevant transcripts with highest abundance fold range in brain tissue among mouse strains.,CGP,C2,68,69
Cohort,-0.059902366451436685,0.03251974804087401,-1.842030460265114,0.06590852111732405,LGP Offspring,Neurologically relevant transcripts with highest variance accounted for by mouse strain (genotype) differences.,CGP,C2,43,62
Cohort,-0.1213848893559019,0.08748142309046746,-1.387550465775731,0.16564459696997058,LGP Proband,Neurologically relevant transcripts with highest variance accounted for by mouse strain (genotype) differences.,CGP,C2,43,88
Cohort,0.006918387248240479,0.03267245211487455,0.21174986266460225,0.8323563893469034,LonGen OPEL,Neurologically relevant transcripts with highest variance accounted for by mouse strain (genotype) differences.,CGP,C2,69,79
Cohort,-0.03126145008261049,0.04309841675237096,-0.7253503130341955,0.46848816208252664,LGP Offspring,Best cis-regulated quantitative trait loci (QTLs) in the mouse genome which modulate transcription in brain tissue.,CGP,C2,72,134
Cohort,-0.022278739528980962,0.13104722781874492,-0.17000542399718144,0.8650471005318808,LGP Proband,Best cis-regulated quantitative trait loci (QTLs) in the mouse genome which modulate transcription in brain tissue.,CGP,C2,72,199
Cohort,-0.00553959492740883,0.039538717930761504,-0.14010557795802914,0.8886120167067373,LonGen OPEL,Best cis-regulated quantitative trait loci (QTLs) in the mouse genome which modulate transcription in brain tissue.,CGP,C2,115,130
Cohort,0.007003898309578947,0.00788404530932042,0.888363528466665,0.374661219587317,LGP Offspring,Best trans-regulated quantitative trait loci (QTLs) in the mouse genome which modulate transcription in brain tissue.,CGP,C2,1,5
Cohort,-0.0075160194871039376,0.027094668193267953,-0.2773984694513217,0.781542900768859,LGP Proband,Best trans-regulated quantitative trait loci (QTLs) in the mouse genome which modulate transcription in brain tissue.,CGP,C2,1,11
Cohort,-3.18593430814034e-4,0.006833783765294076,-0.046620355831572625,0.9628275015770502,LonGen OPEL,Best trans-regulated quantitative trait loci (QTLs) in the mouse genome which modulate transcription in brain tissue.,CGP,C2,3,4
Cohort,-0.04473347877804154,0.08289701640477501,-0.5396271267425834,0.589631903656034,LGP Offspring,Top 200 marker genes down-regulated in the 'CTNNB1' subclass of hepatocellular carcinoma (HCC); characterized by activated CTNNB1 [GeneID=1499].,CGP,C2,204,424
Cohort,0.10928254158769604,0.21844981115826062,0.5002638409631033,0.6170212857062175,LGP Proband,Top 200 marker genes down-regulated in the 'CTNNB1' subclass of hepatocellular carcinoma (HCC); characterized by activated CTNNB1 [GeneID=1499].,CGP,C2,204,484
Cohort,-0.01608072536976346,0.06900378425215863,-0.2330412098994471,0.8157893162624101,LonGen OPEL,Top 200 marker genes down-regulated in the 'CTNNB1' subclass of hepatocellular carcinoma (HCC); characterized by activated CTNNB1 [GeneID=1499].,CGP,C2,317,366
Cohort,-0.1694548239774464,0.07629480673576909,-2.2210531912652627,0.026677953783559173,LGP Offspring,Top 200 marker genes up-regulated in the 'CTNNB1' subclass of hepatocellular carcinoma (HCC); characterized by activated CTNNB1 [GeneID=1499].,CGP,C2,206,365
Cohort,-0.0984589724955579,0.22256410387206893,-0.4423847816544247,0.6583254898960307,LGP Proband,Top 200 marker genes up-regulated in the 'CTNNB1' subclass of hepatocellular carcinoma (HCC); characterized by activated CTNNB1 [GeneID=1499].,CGP,C2,206,553
Cohort,-0.044731330546356966,0.06602893576881805,-0.6774504242044924,0.4983170591076094,LonGen OPEL,Top 200 marker genes up-regulated in the 'CTNNB1' subclass of hepatocellular carcinoma (HCC); characterized by activated CTNNB1 [GeneID=1499].,CGP,C2,310,357
Cohort,-0.09914008011921299,0.04041464699531906,-2.453073019063996,0.01441565134052595,LGP Offspring,All marker genes down-regulated in the 'interferon' subclass of hepatocellular carcinoma (HCC).,CGP,C2,66,93
Cohort,0.12170582028389539,0.11636244966715861,1.0459200595382863,0.2959009798210562,LGP Proband,All marker genes down-regulated in the 'interferon' subclass of hepatocellular carcinoma (HCC).,CGP,C2,66,181
Cohort,-0.005998235209633287,0.037346452434705364,-0.16061057526468667,0.8724408754999315,LonGen OPEL,All marker genes down-regulated in the 'interferon' subclass of hepatocellular carcinoma (HCC).,CGP,C2,94,117
Cohort,-0.0037097705043047237,0.019736854448104826,-0.1879615880057799,0.8509631689698214,LGP Offspring,All marker genes up-regulated in the 'interferon' subclass of hepatocellular carcinoma (HCC).,CGP,C2,12,23
Cohort,0.013707788181280408,0.051828396202984475,0.2644841281137513,0.791472239487263,LGP Proband,All marker genes up-regulated in the 'interferon' subclass of hepatocellular carcinoma (HCC).,CGP,C2,12,31
Cohort,-0.006836077096069912,0.017085517832679732,-0.4001094472533014,0.6891832547774819,LonGen OPEL,All marker genes up-regulated in the 'interferon' subclass of hepatocellular carcinoma (HCC).,CGP,C2,20,19
Cohort,0.010105226558856087,0.02707321824606599,0.373255461061578,0.7090753370552514,LGP Offspring,Marker genes down-regulated in the 'chromosome 7 polysomy' subclass of hepatocellular carcinoma (HCC); characterized by polysomy of chromosome 7 and by a lack of gains of chromosome 8q.,CGP,C2,21,48
Cohort,-0.04196390618161593,0.07137253814268522,-0.5879559179711854,0.5567210479075975,LGP Proband,Marker genes down-regulated in the 'chromosome 7 polysomy' subclass of hepatocellular carcinoma (HCC); characterized by polysomy of chromosome 7 and by a lack of gains of chromosome 8q.,CGP,C2,21,68
Cohort,0.016698183690746705,0.02328246089243547,0.717200117628974,0.47346102410891966,LonGen OPEL,Marker genes down-regulated in the 'chromosome 7 polysomy' subclass of hepatocellular carcinoma (HCC); characterized by polysomy of chromosome 7 and by a lack of gains of chromosome 8q.,CGP,C2,40,49
Cohort,-0.008084517305170976,0.05656988979757195,-0.14291202146761073,0.8864022502041766,LGP Offspring,Marker genes up-regulated in the 'chromosome 7 polysomy' subclass of hepatocellular carcinoma (HCC); characterized by polysomy of chromosome 7 and by a lack of gains of chromosome 8q.,CGP,C2,110,225
Cohort,0.10892459135864539,0.15297811203965153,0.7120272953192965,0.47664700032442997,LGP Proband,Marker genes up-regulated in the 'chromosome 7 polysomy' subclass of hepatocellular carcinoma (HCC); characterized by polysomy of chromosome 7 and by a lack of gains of chromosome 8q.,CGP,C2,110,296
Cohort,0.03841197871933142,0.05063849307313947,0.7585529581982476,0.4483445587815217,LonGen OPEL,Marker genes up-regulated in the 'chromosome 7 polysomy' subclass of hepatocellular carcinoma (HCC); characterized by polysomy of chromosome 7 and by a lack of gains of chromosome 8q.,CGP,C2,172,214
Cohort,0.028119278165170403,0.0833926645530803,0.33719126635259616,0.7360773852540647,LGP Offspring,"Top 200 marker genes down-regulated in the 'proliferation' subclass of hepatocellular carcinoma (HCC); characterized by increased proliferation, high levels of serum AFP [GeneID=174], and chromosomal instability.",CGP,C2,226,499
Cohort,0.18864339511525852,0.2431223543967135,0.775919580012954,0.43801644239337434,LGP Proband,"Top 200 marker genes down-regulated in the 'proliferation' subclass of hepatocellular carcinoma (HCC); characterized by increased proliferation, high levels of serum AFP [GeneID=174], and chromosomal instability.",CGP,C2,226,753
Cohort,-0.03618878325712365,0.07658190648410343,-0.4725500437186893,0.6366637624181231,LonGen OPEL,"Top 200 marker genes down-regulated in the 'proliferation' subclass of hepatocellular carcinoma (HCC); characterized by increased proliferation, high levels of serum AFP [GeneID=174], and chromosomal instability.",CGP,C2,418,487
Cohort,-0.056857039038807004,0.07288395518009064,-0.7801036441877728,0.4356029223677602,LGP Offspring,"Top 200 marker genes up-regulated in the 'proliferation' subclass of hepatocellular carcinoma (HCC); characterized by increased proliferation, high levels of serum AFP [GeneID=174], and chromosomal instability.",CGP,C2,181,345
Cohort,-0.3132586487065018,0.20405205088285525,-1.5351899054733893,0.12511644547984607,LGP Proband,"Top 200 marker genes up-regulated in the 'proliferation' subclass of hepatocellular carcinoma (HCC); characterized by increased proliferation, high levels of serum AFP [GeneID=174], and chromosomal instability.",CGP,C2,181,466
Cohort,-0.05043978839614334,0.06387729886692753,-0.7896355871468845,0.42997576735361587,LonGen OPEL,"Top 200 marker genes up-regulated in the 'proliferation' subclass of hepatocellular carcinoma (HCC); characterized by increased proliferation, high levels of serum AFP [GeneID=174], and chromosomal instability.",CGP,C2,275,303
Cohort,-0.1384555103579619,0.06191750916670015,-2.2361285559016744,0.025668865436053807,LGP Offspring,Marker genes down-regulated in the 'unannotated' subclass of hepatocellular carcinoma (HCC) samples.,CGP,C2,135,219
Cohort,0.023330969054575695,0.1738251892132234,0.1342208753528619,0.8932603016278344,LGP Proband,Marker genes down-regulated in the 'unannotated' subclass of hepatocellular carcinoma (HCC) samples.,CGP,C2,135,332
Cohort,-0.03126713443704602,0.052967208118282164,-0.5903111670002077,0.5551495975465861,LonGen OPEL,Marker genes down-regulated in the 'unannotated' subclass of hepatocellular carcinoma (HCC) samples.,CGP,C2,189,220
Cohort,-0.014592798749206765,0.0580332157948642,-0.2514559730894353,0.8015380173572058,LGP Offspring,Marker genes up-regulated in the 'unannotated' subclass of hepatocellular carcinoma (HCC) samples.,CGP,C2,108,219
Cohort,-3.246668220605147e-4,0.15655588286633065,-0.002073807870495159,0.9983458378316841,LGP Proband,Marker genes up-regulated in the 'unannotated' subclass of hepatocellular carcinoma (HCC) samples.,CGP,C2,108,288
Cohort,0.043010716489587576,0.045125721805199435,0.9531308258127814,0.340813124411079,LonGen OPEL,Marker genes up-regulated in the 'unannotated' subclass of hepatocellular carcinoma (HCC) samples.,CGP,C2,127,175
Cohort,-0.032677550191735696,0.07095345071032579,-0.4605491327707923,0.6452702272535045,LGP Offspring,Genes down-regulated in reverted NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845] which then reverted to normal cells upon stable over-expression of a dominant negative form of CDC25 [GeneID=5923]) vs normal fibroblasts.,CGP,C2,154,325
Cohort,-0.16770223111897953,0.20743719443409228,-0.8084482224920493,0.4190631476256841,LGP Proband,Genes down-regulated in reverted NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845] which then reverted to normal cells upon stable over-expression of a dominant negative form of CDC25 [GeneID=5923]) vs normal fibroblasts.,CGP,C2,154,480
Cohort,0.022291820567584743,0.06685668290543127,0.3334269604598318,0.7388998228429117,LonGen OPEL,Genes down-regulated in reverted NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845] which then reverted to normal cells upon stable over-expression of a dominant negative form of CDC25 [GeneID=5923]) vs normal fibroblasts.,CGP,C2,267,331
Cohort,-0.07190029984634691,0.05915720766320915,-1.2154106437154049,0.22463381121995254,LGP Offspring,Genes up-regulated in reverted NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845] which then reverted to normal cells upon stable over-expression of a dominant negative form of CDC25 [GeneID=5923]) vs normal fibroblasts.,CGP,C2,126,224
Cohort,-0.3965882978178851,0.1661040573453427,-2.387589467446593,0.017181031402962597,LGP Proband,Genes up-regulated in reverted NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845] which then reverted to normal cells upon stable over-expression of a dominant negative form of CDC25 [GeneID=5923]) vs normal fibroblasts.,CGP,C2,126,328
Cohort,-0.07979543688592045,0.05343830509621467,-1.493225444599155,0.13577443346675636,LonGen OPEL,Genes up-regulated in reverted NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845] which then reverted to normal cells upon stable over-expression of a dominant negative form of CDC25 [GeneID=5923]) vs normal fibroblasts.,CGP,C2,213,230
Cohort,0.03594015271682588,0.03967412825632644,0.905883866801657,0.36532008498926205,LGP Offspring,Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by activated KRAS [GeneID=3845] vs those reverted to normal cells upon over-expression of a dominant negative form of CDC25 [GeneID=5923].,CGP,C2,48,111
Cohort,-0.27456510211246626,0.11505460906157716,-2.3863894228306766,0.017236813161656858,LGP Proband,Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by activated KRAS [GeneID=3845] vs those reverted to normal cells upon over-expression of a dominant negative form of CDC25 [GeneID=5923].,CGP,C2,48,158
Cohort,-0.011135502565887188,0.038555721199871704,-0.28881582860714955,0.7727975149117189,LonGen OPEL,Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by activated KRAS [GeneID=3845] vs those reverted to normal cells upon over-expression of a dominant negative form of CDC25 [GeneID=5923].,CGP,C2,95,112
Cohort,0.036849997835879396,0.035233061494462675,1.0458925870427367,0.29598445705064574,LGP Offspring,Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by activated KRAS [GeneID=3845] vs those reverted to normal cells upon over-expression of a dominant negative form of CDC25 [GeneID=5923].,CGP,C2,34,92
Cohort,0.01072392125639653,0.0903800099493653,0.11865368528289079,0.9055783032449674,LGP Proband,Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by activated KRAS [GeneID=3845] vs those reverted to normal cells upon over-expression of a dominant negative form of CDC25 [GeneID=5923].,CGP,C2,34,104
Cohort,0.056882121267717294,0.030843722876857285,1.8442041349812925,0.06552483407369893,LonGen OPEL,Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by activated KRAS [GeneID=3845] vs those reverted to normal cells upon over-expression of a dominant negative form of CDC25 [GeneID=5923].,CGP,C2,57,90
Cohort,0.004190071586227422,0.06711314319710185,0.06243295108264817,0.9502365097790204,LGP Offspring,Genes down-regulated in transformed NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845]) vs normal cells.,CGP,C2,135,283
Cohort,-0.128057692570652,0.18910815022542352,-0.6771664384533547,0.49848814452766355,LGP Proband,Genes down-regulated in transformed NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845]) vs normal cells.,CGP,C2,135,437
Cohort,0.015525757501456598,0.057996028788613783,0.2677038036180976,0.7889966718232753,LonGen OPEL,Genes down-regulated in transformed NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845]) vs normal cells.,CGP,C2,224,282
Cohort,-0.17294741193999955,0.05597092176726297,-3.0899511117423724,0.0020840468914630674,LGP Offspring,Genes up-regulated in transformed NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845]) vs normal cells.,CGP,C2,113,164
Cohort,-0.07193266748391132,0.15232970743378563,-0.4722169345410111,0.6368954850005135,LGP Proband,Genes up-regulated in transformed NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845]) vs normal cells.,CGP,C2,113,246
Cohort,0.051096098872641486,0.04655221269899747,1.0976083822916085,0.27270744229925714,LonGen OPEL,Genes up-regulated in transformed NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845]) vs normal cells.,CGP,C2,145,197
Cohort,0.011403779092768889,0.04628103814556068,0.2464028368789465,0.8054452117631431,LGP Offspring,Differentially expressed genes between high vs low ZAP70 [GeneID=7535] acute lymphoblastic leukemia (ALL) cases with no known molecular aberrations.,CGP,C2,62,144
Cohort,-0.04799327623621839,0.13004875959362192,-0.36904063050034785,0.7121911086108017,LGP Proband,Differentially expressed genes between high vs low ZAP70 [GeneID=7535] acute lymphoblastic leukemia (ALL) cases with no known molecular aberrations.,CGP,C2,62,213
Cohort,0.02858209339632527,0.04221170220079707,0.6771130256809583,0.4985309748283685,LonGen OPEL,Differentially expressed genes between high vs low ZAP70 [GeneID=7535] acute lymphoblastic leukemia (ALL) cases with no known molecular aberrations.,CGP,C2,124,151
Cohort,0.023682327162485223,0.020977092853926745,1.1289613545306914,0.2593146081306755,LGP Offspring,Genes down-regulated in T cell acute lymphocytic leukemia (T-ALL) patients refractory to chemotherapy treatment.,CGP,C2,10,36
Cohort,-0.0573988016415367,0.06122671577279234,-0.9374796756131631,0.34878326996605413,LGP Proband,Genes down-regulated in T cell acute lymphocytic leukemia (T-ALL) patients refractory to chemotherapy treatment.,CGP,C2,10,55
Cohort,0.04416009736931498,0.022478017588072427,1.9645903913140352,0.049809160932993805,LonGen OPEL,Genes down-regulated in T cell acute lymphocytic leukemia (T-ALL) patients refractory to chemotherapy treatment.,CGP,C2,26,48
Cohort,-0.042866753181725684,0.025028413664139573,-1.7127235372150127,0.08722196774732631,LGP Offspring,Genes whose expression predicted relapse in less than 2 years after chemotherapy for adult patients with T-ALL (T cell lymphoblastic leukemia).,CGP,C2,24,36
Cohort,0.034459698744696676,0.0662157150126334,0.5204157160897841,0.6029119796299536,LGP Proband,Genes whose expression predicted relapse in less than 2 years after chemotherapy for adult patients with T-ALL (T cell lymphoblastic leukemia).,CGP,C2,24,49
Cohort,-0.015646587856744706,0.024180612813384666,-0.647071601431204,0.5177721528055768,LonGen OPEL,Genes whose expression predicted relapse in less than 2 years after chemotherapy for adult patients with T-ALL (T cell lymphoblastic leukemia).,CGP,C2,41,43
Cohort,-0.016914531594632787,0.028301159726689444,-0.5976621367456372,0.5502655458212009,LGP Offspring,Genes up-regulated in more than one of several human hepatoma cell lines by TSA [PubChem=5562].,CGP,C2,29,52
Cohort,0.02980369435631674,0.08828457613969644,0.3375866505736754,0.7357596513203538,LGP Proband,Genes up-regulated in more than one of several human hepatoma cell lines by TSA [PubChem=5562].,CGP,C2,29,100
Cohort,-0.05660832476509625,0.027844577616371508,-2.033010719179048,0.04238279471685688,LonGen OPEL,Genes up-regulated in more than one of several human hepatoma cell lines by TSA [PubChem=5562].,CGP,C2,54,50
Cohort,-5.672367815643019e-4,0.02843423128756476,-0.019949080944993702,0.9840898785580248,LGP Offspring,Cancer related genes down-regulated in any of four hepatoma cell lines following 24 h treatment with TSA [PubChem=5562].,CGP,C2,26,57
Cohort,-0.046150347013450346,0.08197902950958222,-0.5629530782388197,0.5736181362418906,LGP Proband,Cancer related genes down-regulated in any of four hepatoma cell lines following 24 h treatment with TSA [PubChem=5562].,CGP,C2,26,87
Cohort,0.01724735130148847,0.030344022444738442,0.5683937036659787,0.5699279728389619,LonGen OPEL,Cancer related genes down-regulated in any of four hepatoma cell lines following 24 h treatment with TSA [PubChem=5562].,CGP,C2,59,75
Cohort,-0.025118557008663844,0.04356669062674788,-0.5765541666651688,0.5644325897647839,LGP Offspring,Cancer related genes up-regulated in any of four hepatoma cell lines following 24 h treatment with TSA [PubChem=5562].,CGP,C2,65,128
Cohort,-0.030224203325632772,0.1145565838731023,-0.2638364579648518,0.7919711165531266,LGP Proband,Cancer related genes up-regulated in any of four hepatoma cell lines following 24 h treatment with TSA [PubChem=5562].,CGP,C2,65,157
Cohort,0.0655552596256931,0.03361899978896617,1.9499467574049745,0.05153319896049066,LonGen OPEL,Cancer related genes up-regulated in any of four hepatoma cell lines following 24 h treatment with TSA [PubChem=5562].,CGP,C2,69,113
Cohort,-0.11211976355962473,0.12933107116518902,-0.8669205516470128,0.38629314747728327,LGP Offspring,Genes up-regulated in confluent IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,573,1138
Cohort,-0.49842580914055273,0.35277780507227474,-1.4128604520299644,0.15806983191344984,LGP Proband,Genes up-regulated in confluent IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,573,1616
Cohort,0.056831513282825735,0.12095175641760728,0.46986926826101566,0.6385771154286912,LonGen OPEL,Genes up-regulated in confluent IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,876,1064
Cohort,-0.07580209190057943,0.08743014070039812,-0.8670018290412549,0.38624864481370547,LGP Offspring,Genes up-regulated in growing IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,256,485
Cohort,-0.21343181033840944,0.24695565285883767,-0.8642515685211272,0.38769820506074704,LGP Proband,Genes up-regulated in growing IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,256,712
Cohort,0.09982798617784878,0.07101208057065429,1.405788780945853,0.16017705636457072,LonGen OPEL,Genes up-regulated in growing IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,341,435
Cohort,-0.12157554828110066,0.04382086318591579,-2.7743759351635857,0.005683476649850537,LGP Offspring,Genes up-regulated in IMR90 cells (fibroblast) grown under low serum conditions and after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,79,113
Cohort,-0.04598658710933489,0.12678435997549722,-0.36271498407392216,0.7169097056154047,LGP Proband,Genes up-regulated in IMR90 cells (fibroblast) grown under low serum conditions and after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,79,185
Cohort,-0.00863526954273269,0.035915496500982996,-0.2404329713915091,0.8100565278115994,LonGen OPEL,Genes up-regulated in IMR90 cells (fibroblast) grown under low serum conditions and after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,98,111
Cohort,0.01561045434074233,0.11669108002426995,0.13377590075861492,0.893619599327923,LGP Offspring,Genes up-regulated in senescent IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,449,921
Cohort,-0.3598243415909385,0.33102528297506456,-1.0869995740417306,0.2773510497542843,LGP Proband,Genes up-regulated in senescent IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,449,1281
Cohort,0.04495583924771422,0.10612851635961482,0.4235981128331434,0.6719733650560147,LonGen OPEL,Genes up-regulated in senescent IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.,CGP,C2,748,904
Cohort,0.014330704221692941,0.02237646289200017,0.6404365288142266,0.5221058601825481,LGP Offspring,Genes from common regions of losses observed in more than 15% of 148 primary breast cancer tumors.,CGP,C2,15,38
Cohort,0.009335288484631922,0.056224930353575925,0.1660346829409313,0.8681698970946427,LGP Proband,Genes from common regions of losses observed in more than 15% of 148 primary breast cancer tumors.,CGP,C2,15,39
Cohort,0.011210394205232805,0.021402531802815674,0.5237882278842351,0.6005716400494594,LonGen OPEL,Genes from common regions of losses observed in more than 15% of 148 primary breast cancer tumors.,CGP,C2,30,38
Cohort,-0.00857476423227152,0.026223750366218816,-0.3269846651422311,0.7437807050185932,LGP Offspring,Genes from common regions of gains observed in more than 15% of 148 primary breast cancer tumors.,CGP,C2,23,48
Cohort,0.13325093447874012,0.07385680587934745,1.804179491547725,0.07156385349413055,LGP Proband,Genes from common regions of gains observed in more than 15% of 148 primary breast cancer tumors.,CGP,C2,23,69
Cohort,-0.014711755535807048,0.024906760385852145,-0.5906731870341438,0.5549070803016731,LonGen OPEL,Genes from common regions of gains observed in more than 15% of 148 primary breast cancer tumors.,CGP,C2,43,44
Cohort,0.005222314158319393,0.018049904662985696,0.28932641229006645,0.7724203118721787,LGP Offspring,"Protein biosynthesis, transport or catabolism genes down-regulated in hyperploid multiple myeloma (MM) compared to the non-hyperploid MM samples.",CGP,C2,10,23
Cohort,0.007675849398785166,0.058154266079175,0.13199116619122603,0.8950231144111979,LGP Proband,"Protein biosynthesis, transport or catabolism genes down-regulated in hyperploid multiple myeloma (MM) compared to the non-hyperploid MM samples.",CGP,C2,10,44
Cohort,-0.018878959038530235,0.01767143070182457,-1.0683322339362704,0.28569454886202056,LonGen OPEL,"Protein biosynthesis, transport or catabolism genes down-regulated in hyperploid multiple myeloma (MM) compared to the non-hyperploid MM samples.",CGP,C2,26,21
Cohort,-0.011654394874509425,0.019611544987582812,-0.5942619452923514,0.5525357479737756,LGP Offspring,"Protein biosynthesis, transport or catabolism genes up-regulated in hyperploid multiple myeloma (MM) compared to the non-hyperploid MM samples.",CGP,C2,14,25
Cohort,0.0152183384203508,0.057472347934909546,0.26479409606836263,0.7912335125543075,LGP Proband,"Protein biosynthesis, transport or catabolism genes up-regulated in hyperploid multiple myeloma (MM) compared to the non-hyperploid MM samples.",CGP,C2,14,43
Cohort,-0.0035613818004935002,0.018023647306067526,-0.19759495622701115,0.8434124275199315,LonGen OPEL,"Protein biosynthesis, transport or catabolism genes up-regulated in hyperploid multiple myeloma (MM) compared to the non-hyperploid MM samples.",CGP,C2,24,28
Cohort,-0.001388226022796647,0.02447689460510078,-0.05671577400620715,0.9547883675851063,LGP Offspring,"Genes up-regulated in RKO cells (colon cancer) after treatment with the NR4A1 [GeneID=3164] agonist, DIM-C-pPhOCH3.",CGP,C2,19,37
Cohort,-0.05189058409714293,0.06536519517805064,-0.7938564851798617,0.42750479422849785,LGP Proband,"Genes up-regulated in RKO cells (colon cancer) after treatment with the NR4A1 [GeneID=3164] agonist, DIM-C-pPhOCH3.",CGP,C2,19,51
Cohort,0.02006545779047066,0.020490260413036577,0.9792680710736286,0.3277450677215086,LonGen OPEL,"Genes up-regulated in RKO cells (colon cancer) after treatment with the NR4A1 [GeneID=3164] agonist, DIM-C-pPhOCH3.",CGP,C2,25,38
Cohort,0.009640847780412345,0.019109817568626727,0.5044971123240899,0.6140764906072693,LGP Offspring,Acute stage-specific genes for adult T cell leukemia (ATL).,CGP,C2,10,27
Cohort,0.032369406527859,0.048147915652067386,0.6722909203748495,0.5015847130435669,LGP Proband,Acute stage-specific genes for adult T cell leukemia (ATL).,CGP,C2,10,29
Cohort,0.025065593527424445,0.013937721646679701,1.7983996353805551,0.07249246611620554,LonGen OPEL,Acute stage-specific genes for adult T cell leukemia (ATL).,CGP,C2,9,21
Cohort,-0.014630047258968522,0.012297058367996876,-1.1897192662794263,0.23457442935390763,LGP Offspring,"Genes down-regulated in adult T-cell leukemia (ATL), chronic vs acute clinical condition.",CGP,C2,7,8
Cohort,0.025548513687078195,0.040225894005398395,0.6351260629198081,0.5255204066563067,LGP Proband,"Genes down-regulated in adult T-cell leukemia (ATL), chronic vs acute clinical condition.",CGP,C2,7,20
Cohort,-0.007091306829456942,0.013289735066090517,-0.5335927912927924,0.5937722576458309,LonGen OPEL,"Genes down-regulated in adult T-cell leukemia (ATL), chronic vs acute clinical condition.",CGP,C2,13,14
Cohort,0.014159184045582297,0.03410058098753623,0.4152182641919644,0.6781138817839325,LGP Offspring,Genes used to predict the clinical stages of acute T-cell leukemia (ATL): chronic vs acute.,CGP,C2,38,78
Cohort,-0.16116602323893958,0.09065484109335631,-1.777798309446827,0.07580129650829426,LGP Proband,Genes used to predict the clinical stages of acute T-cell leukemia (ATL): chronic vs acute.,CGP,C2,38,101
Cohort,-0.036723836228714266,0.030830366152506783,-1.1911579657229692,0.2339466352041428,LonGen OPEL,Genes used to predict the clinical stages of acute T-cell leukemia (ATL): chronic vs acute.,CGP,C2,69,68
Cohort,0.05760048301384718,0.026703474033857453,2.157040800789263,0.031354285006522424,LGP Offspring,Genes down-regulated in C666-1 cells (nasopharyngeal carcinoma) by stable expression of RASSF1 [GeneID=11186].,CGP,C2,15,61
Cohort,0.14564599296883798,0.07103790189660407,2.0502575256350655,0.040651443127211535,LGP Proband,Genes down-regulated in C666-1 cells (nasopharyngeal carcinoma) by stable expression of RASSF1 [GeneID=11186].,CGP,C2,15,74
Cohort,-0.020571558148605548,0.026808291595513255,-0.7673580420189285,0.4430962136880653,LonGen OPEL,Genes down-regulated in C666-1 cells (nasopharyngeal carcinoma) by stable expression of RASSF1 [GeneID=11186].,CGP,C2,50,54
Cohort,0.024220298212382103,0.02801802684443265,0.8644541011707547,0.38764512060967715,LGP Offspring,Genes up-regulated in C666-1 cells (nasopharyngeal carcinoma) by stable expression of RASSF1 [GeneID=11186].,CGP,C2,23,52
Cohort,-0.010176531656272789,0.07530302664218685,-0.13514107081814972,0.8925329466004532,LGP Proband,Genes up-regulated in C666-1 cells (nasopharyngeal carcinoma) by stable expression of RASSF1 [GeneID=11186].,CGP,C2,23,66
Cohort,-0.017329738993524392,0.02172637486124347,-0.7976360117231521,0.4253196199657112,LonGen OPEL,Genes up-regulated in C666-1 cells (nasopharyngeal carcinoma) by stable expression of RASSF1 [GeneID=11186].,CGP,C2,35,35
Cohort,0.00574200758974529,0.019113009212157007,0.30042404762160807,0.7639460888196802,LGP Offspring,"Genes down-regulated in MCF7 cells (breast cancer) after treatment with the oxydants: hydrogen peroxyde, menadione, and t-butyl hydroperoxyde [PubChem=784;4055;6410].",CGP,C2,11,27
Cohort,-0.028796496820889687,0.05055248941878088,-0.5696355837659586,0.5690782834685337,LGP Proband,"Genes down-regulated in MCF7 cells (breast cancer) after treatment with the oxydants: hydrogen peroxyde, menadione, and t-butyl hydroperoxyde [PubChem=784;4055;6410].",CGP,C2,11,33
Cohort,9.977184791048386e-4,0.017934861193004772,0.05563011993056205,0.9556504291933784,LonGen OPEL,"Genes down-regulated in MCF7 cells (breast cancer) after treatment with the oxydants: hydrogen peroxyde, menadione, and t-butyl hydroperoxyde [PubChem=784;4055;6410].",CGP,C2,18,26
Cohort,0.024799165897773052,0.02635428811913386,0.940991681720602,0.34704525214540227,LGP Offspring,"Genes up-regulated in MCF7 cells (breast cancer) after treatment with the oxydants: hydrogen peroxyde, menadione, and t-butyl hydroperoxyde [PubChem=784;4055;6410].",CGP,C2,20,49
Cohort,-0.0731424702740591,0.06157701965559225,-1.1878208897272686,0.23524214880607425,LGP Proband,"Genes up-regulated in MCF7 cells (breast cancer) after treatment with the oxydants: hydrogen peroxyde, menadione, and t-butyl hydroperoxyde [PubChem=784;4055;6410].",CGP,C2,20,47
Cohort,-0.03552768717299014,0.02147962618398292,-1.654017945595472,0.09851811960540183,LonGen OPEL,"Genes up-regulated in MCF7 cells (breast cancer) after treatment with the oxydants: hydrogen peroxyde, menadione, and t-butyl hydroperoxyde [PubChem=784;4055;6410].",CGP,C2,33,26
Cohort,-0.019585088753364108,0.039617869718973464,-0.4943498702047722,0.6212197145052059,LGP Offspring,Genes down-regulated in blister cells from patients with adverse drug reactions (ADR).,CGP,C2,47,93
Cohort,0.029807143024529838,0.11007486883660002,0.2707897210286653,0.7866197678723335,LGP Proband,Genes down-regulated in blister cells from patients with adverse drug reactions (ADR).,CGP,C2,47,129
Cohort,-0.01767553717425297,0.03228765202656866,-0.5474395338412418,0.5842302549189384,LonGen OPEL,Genes down-regulated in blister cells from patients with adverse drug reactions (ADR).,CGP,C2,83,88
Cohort,-0.01123271291045911,0.05516461484704196,-0.20362170463085236,0.8387104100437124,LGP Offspring,Genes up-regulated in blister cells from patients with adverse drug reactions (ADR).,CGP,C2,103,215
Cohort,-0.11549337287574937,0.1475856245845391,-0.7825516421458322,0.43411257986402496,LGP Proband,Genes up-regulated in blister cells from patients with adverse drug reactions (ADR).,CGP,C2,103,274
Cohort,-0.038760430205535046,0.051025750228501594,-0.7596248958998064,0.4477037364797901,LonGen OPEL,Genes up-regulated in blister cells from patients with adverse drug reactions (ADR).,CGP,C2,189,192
Cohort,0.09378196845696198,0.09035474597091299,1.0379307412048093,0.29967341133981984,LGP Offspring,Genes down-regulated in immature bone marrow progenitor cells upon knock out of CBFA2T3 [GeneID=863].,CGP,C2,234,518
Cohort,-0.1733833069844382,0.23436661050526175,-0.7397952575695316,0.4596324233837279,LGP Proband,Genes down-regulated in immature bone marrow progenitor cells upon knock out of CBFA2T3 [GeneID=863].,CGP,C2,234,678
Cohort,-0.00903358006567326,0.07529644657109211,-0.11997352434346406,0.9045343945833144,LonGen OPEL,Genes down-regulated in immature bone marrow progenitor cells upon knock out of CBFA2T3 [GeneID=863].,CGP,C2,395,471
Cohort,-0.04787950258956102,0.11650994588389552,-0.410947771250996,0.6812410667852982,LGP Offspring,Genes up-regulated in immature bone marrow progenitor cells upon knock out of CBFA2T3 [GeneID=863].,CGP,C2,437,902
Cohort,-0.3664262227876407,0.3340991774933139,-1.0967588293298738,0.2730634071279431,LGP Proband,Genes up-regulated in immature bone marrow progenitor cells upon knock out of CBFA2T3 [GeneID=863].,CGP,C2,437,1295
Cohort,0.024383477549203204,0.09892621729744223,0.24648145067438706,0.8053731097842198,LonGen OPEL,Genes up-regulated in immature bone marrow progenitor cells upon knock out of CBFA2T3 [GeneID=863].,CGP,C2,688,850
Cohort,0.029639579942280687,0.042770914074931755,0.6929844868490335,0.4885572910207484,LGP Offspring,Selected genes down-regulated during invasion of lymphatic vessels during metastasis.,CGP,C2,60,132
Cohort,-0.13032945812004604,0.11872706321099209,-1.0977232536143433,0.27264217498909565,LGP Proband,Selected genes down-regulated during invasion of lymphatic vessels during metastasis.,CGP,C2,60,171
Cohort,-0.05993930209682294,0.03602902969362086,-1.6636390878835,0.096578182672787,LonGen OPEL,Selected genes down-regulated during invasion of lymphatic vessels during metastasis.,CGP,C2,110,101
Cohort,-0.010499234118843598,0.02658024838375248,-0.39500135466233605,0.6929664909673514,LGP Offspring,Selected genes up-regulated during invasion of lymphatic vessels during metastasis.,CGP,C2,25,49
Cohort,-0.0617480324702327,0.07428167513864825,-0.8312687127071212,0.4060597688467391,LGP Proband,Selected genes up-regulated during invasion of lymphatic vessels during metastasis.,CGP,C2,25,69
Cohort,-0.07880196685798316,0.024535505698448177,-3.2117522999726567,0.0013722973895025756,LonGen OPEL,Selected genes up-regulated during invasion of lymphatic vessels during metastasis.,CGP,C2,58,35
Cohort,-0.009138823908019296,0.015810722174013178,-0.5780143251799118,0.5634469360173584,LGP Offspring,Genes down-regulated in meningioma samples positive for PGR [GeneID=5241] compared to those without the receptor.,CGP,C2,8,13
Cohort,0.056078466324344954,0.04053156564515471,1.3835751329050565,0.16685878954924002,LGP Proband,Genes down-regulated in meningioma samples positive for PGR [GeneID=5241] compared to those without the receptor.,CGP,C2,8,17
Cohort,-0.0022333263776898667,0.01144481378396562,-0.1951387257011377,0.8453341434139324,LonGen OPEL,Genes down-regulated in meningioma samples positive for PGR [GeneID=5241] compared to those without the receptor.,CGP,C2,10,10
Cohort,0.009594119332545305,0.01836246321364783,0.5224854215318189,0.6015035738471606,LGP Offspring,Genes up-regulated in meningioma samples positive for PGR [GeneID=5241] compared to those without the receptor.,CGP,C2,9,24
Cohort,0.024714317244595843,0.04223793608844051,0.5851213277288789,0.5586244094209603,LGP Proband,Genes up-regulated in meningioma samples positive for PGR [GeneID=5241] compared to those without the receptor.,CGP,C2,9,21
Cohort,-0.017440143430454417,0.014353305504078581,-1.215061117837887,0.2247030650718081,LonGen OPEL,Genes up-regulated in meningioma samples positive for PGR [GeneID=5241] compared to those without the receptor.,CGP,C2,18,14
Cohort,-0.005795133762591171,0.016642444774347783,-0.34821409000699427,0.727787815800934,LGP Offspring,Genes from the most frequent genomic losses and homozygous deletions in a panel of patients with lymph node negative breast cancer (NNBC).,CGP,C2,8,18
Cohort,0.06496926463429391,0.05103720146984081,1.272978587446373,0.20338036787030542,LGP Proband,Genes from the most frequent genomic losses and homozygous deletions in a panel of patients with lymph node negative breast cancer (NNBC).,CGP,C2,8,35
Cohort,-0.013503248789145873,0.019105967886847836,-0.7067555472257041,0.4799252337177973,LonGen OPEL,Genes from the most frequent genomic losses and homozygous deletions in a panel of patients with lymph node negative breast cancer (NNBC).,CGP,C2,25,26
Cohort,-8.735831875938022e-4,0.023873344051231406,-0.036592409748677085,0.970820798369366,LGP Offspring,Genes from the most frequent genomic gains and amplifications in a panel of patients with lymph node negative breast cancer (NNBC).,CGP,C2,18,40
Cohort,0.0604786365698256,0.06943509398744085,0.8710096450760869,0.38399953259100794,LGP Proband,Genes from the most frequent genomic gains and amplifications in a panel of patients with lymph node negative breast cancer (NNBC).,CGP,C2,18,58
Cohort,-0.01756697424438272,0.021444589067549875,-0.819179802841977,0.4129290260934789,LonGen OPEL,Genes from the most frequent genomic gains and amplifications in a panel of patients with lymph node negative breast cancer (NNBC).,CGP,C2,36,34
Cohort,-0.06596230810031331,0.05181780918562623,-1.2729659770836208,0.20346771724958493,LGP Offspring,Down-regulated genes distinguishing between M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophage subtypes.,CGP,C2,89,161
Cohort,-0.0996029354815584,0.14522470063728166,-0.6858539562793123,0.4929958140448356,LGP Proband,Down-regulated genes distinguishing between M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophage subtypes.,CGP,C2,89,224
Cohort,0.0517090384241201,0.04139817374022398,1.249065689433486,0.2120082367231984,LonGen OPEL,Down-regulated genes distinguishing between M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophage subtypes.,CGP,C2,117,154
Cohort,-0.018744586725885443,0.04222568471151208,-0.44391433446134426,0.65724657743675,LGP Offspring,Up-regulated genes distinguishing between M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophage subtypes.,CGP,C2,66,118
Cohort,-0.06986071724225618,0.12128513604263634,-0.5760039483956012,0.5647679089107003,LGP Proband,Up-regulated genes distinguishing between M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophage subtypes.,CGP,C2,66,175
Cohort,0.027517760016924245,0.04147552904736979,0.6634697772147962,0.5072218274615785,LonGen OPEL,Up-regulated genes distinguishing between M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophage subtypes.,CGP,C2,110,147
Cohort,-0.036181115894841194,0.09393646615741755,-0.3851658187163368,0.7002357238939874,LGP Offspring,Genes down-regulated in NSCLC (non-small cell lung carcinoma) cell lines resistant to gefitinib [PubChem=123631] compared to the sensitive ones.,CGP,C2,281,556
Cohort,0.17158374962663994,0.25562430514539886,0.6712340969652446,0.5022572720731235,LGP Proband,Genes down-regulated in NSCLC (non-small cell lung carcinoma) cell lines resistant to gefitinib [PubChem=123631] compared to the sensitive ones.,CGP,C2,281,744
Cohort,0.011728173791377972,0.07754546881194416,0.15124254158318412,0.8798227130266867,LonGen OPEL,Genes down-regulated in NSCLC (non-small cell lung carcinoma) cell lines resistant to gefitinib [PubChem=123631] compared to the sensitive ones.,CGP,C2,404,504
Cohort,0.008094143810673188,0.049315541782310165,0.16412967430029562,0.8696781225113095,LGP Offspring,Genes up-regulated in NSCLC (non-small cell lung carcinoma) cell lines resistant to gefitinib [PubChem=123631] compared to the sensitive ones.,CGP,C2,78,159
Cohort,0.06291714143110028,0.1351178934221808,0.46564625777959223,0.6415902993747247,LGP Proband,Genes up-regulated in NSCLC (non-small cell lung carcinoma) cell lines resistant to gefitinib [PubChem=123631] compared to the sensitive ones.,CGP,C2,78,209
Cohort,-0.09036225769830135,0.0433265481487409,-2.085609437153542,0.03733197727988853,LonGen OPEL,Genes up-regulated in NSCLC (non-small cell lung carcinoma) cell lines resistant to gefitinib [PubChem=123631] compared to the sensitive ones.,CGP,C2,141,132
Cohort,-0.0036643998815478395,0.033696758237071404,-0.10874636235827752,0.9134359384704203,LGP Offspring,Genes down-regulated in pilocytic astrocytoma compared to glioblastoma samples.,CGP,C2,37,68
Cohort,-0.14759642030242348,0.09288690163713471,-1.5889906725386647,0.11244149408942145,LGP Proband,Genes down-regulated in pilocytic astrocytoma compared to glioblastoma samples.,CGP,C2,37,105
Cohort,-0.047827770618246807,0.02759395962730854,-1.7332695729145644,0.08343501759190032,LonGen OPEL,Genes down-regulated in pilocytic astrocytoma compared to glioblastoma samples.,CGP,C2,61,54
Cohort,-0.004692159893855108,0.028548401119044855,-0.16435806244591866,0.8694984065359213,LGP Offspring,Genes up-regulated in pilocytic astrocytoma compared to glioblastoma samples.,CGP,C2,23,51
Cohort,-0.09359554484226112,0.07043055165962524,-1.3289054627115091,0.18424261112273185,LGP Proband,Genes up-regulated in pilocytic astrocytoma compared to glioblastoma samples.,CGP,C2,23,54
Cohort,0.017890657591774294,0.022955990981784125,0.7793459060848543,0.4360076190507933,LonGen OPEL,Genes up-regulated in pilocytic astrocytoma compared to glioblastoma samples.,CGP,C2,29,46
Cohort,0.08742057328641188,0.10132972971949797,0.8627337063703855,0.3885898560072516,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) with double knockout of the translation repressors 4EBP1 [GeneID=1978] and 4EBP2 [GeneID=1979].,CGP,C2,296,673
Cohort,-0.17410216196773023,0.28387975068406124,-0.613295458898349,0.5398482114130514,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) with double knockout of the translation repressors 4EBP1 [GeneID=1978] and 4EBP2 [GeneID=1979].,CGP,C2,296,897
Cohort,-0.18351791916965413,0.08412657815111343,-2.181449943679009,0.029442055053455388,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) with double knockout of the translation repressors 4EBP1 [GeneID=1978] and 4EBP2 [GeneID=1979].,CGP,C2,506,551
Cohort,-0.012463381017016219,0.017041091332264204,-0.7313722327993792,0.46480526038593184,LGP Offspring,Genes down-regulated in 293T (transformed fetal renal cell) upon expression of MYC [GeneID=4609].,CGP,C2,11,19
Cohort,-0.014679397962346949,0.04834417284822044,-0.30364358510039746,0.7614751759585288,LGP Proband,Genes down-regulated in 293T (transformed fetal renal cell) upon expression of MYC [GeneID=4609].,CGP,C2,11,29
Cohort,-0.006234621006127349,0.012865424758380123,-0.4846028112726179,0.6280914361000284,LonGen OPEL,Genes down-regulated in 293T (transformed fetal renal cell) upon expression of MYC [GeneID=4609].,CGP,C2,12,11
Cohort,-0.0385893087088507,0.024286257666616178,-1.5889359834098877,0.11254240642251087,LGP Offspring,Genes up-regulated in 293T (transformed fetal renal cell) upon expression of MYC [GeneID=4609].,CGP,C2,22,29
Cohort,-0.08558553821951954,0.06452728065587479,-1.3263465831753989,0.18508801358163046,LGP Proband,Genes up-regulated in 293T (transformed fetal renal cell) upon expression of MYC [GeneID=4609].,CGP,C2,22,44
Cohort,0.007205702087683647,0.018407986070152194,0.391444347047144,0.6955735794215572,LonGen OPEL,Genes up-regulated in 293T (transformed fetal renal cell) upon expression of MYC [GeneID=4609].,CGP,C2,21,30
Cohort,-0.010053455809416753,0.007191283477567529,-1.3980057719567693,0.1625698583368081,LGP Offspring,Proteins that regulate activity of PRKDC [GeneID=5591].,CGP,C2,3,2
Cohort,0.01051665980155187,0.02481090038749424,0.423872557517208,0.6717680584692116,LGP Proband,Proteins that regulate activity of PRKDC [GeneID=5591].,CGP,C2,3,7
Cohort,-0.004786962187980279,0.0077522087608433085,-0.6174965530029843,0.5370838566015651,LonGen OPEL,Proteins that regulate activity of PRKDC [GeneID=5591].,CGP,C2,5,4
Cohort,-0.007234545947503348,0.02082023628979766,-0.3474766494868467,0.7283414155582849,LGP Offspring,Substrates of PRKDC [GeneID=5591].,CGP,C2,16,29
Cohort,-0.012299602203185683,0.06897524695125443,-0.17831907454971418,0.8585157042432792,LGP Proband,Substrates of PRKDC [GeneID=5591].,CGP,C2,16,59
Cohort,-0.0200514166502679,0.020956594597421618,-0.9568070116093631,0.33895517028594835,LonGen OPEL,Substrates of PRKDC [GeneID=5591].,CGP,C2,36,35
Cohort,3.75476496367387e-4,0.06840351295304935,0.0054891405449469495,0.9956219409369457,LGP Offspring,"Genes down-regulated in SH-SY5Y cells (neuroblastoma) after treatment with epoxomicin [PubChem=3035402], a protease inhibitor causing apoptosis.",CGP,C2,141,286
Cohort,-0.12907139758888106,0.18158297987573369,-0.7108122009959913,0.47739934926354644,LGP Proband,"Genes down-regulated in SH-SY5Y cells (neuroblastoma) after treatment with epoxomicin [PubChem=3035402], a protease inhibitor causing apoptosis.",CGP,C2,141,386
Cohort,-0.02019468711129612,0.05331227801704901,-0.3787999286925604,0.7049374525722698,LonGen OPEL,"Genes down-regulated in SH-SY5Y cells (neuroblastoma) after treatment with epoxomicin [PubChem=3035402], a protease inhibitor causing apoptosis.",CGP,C2,222,258
Cohort,-0.20725699696439678,0.08071882408056419,-2.567641430919965,0.010453139753548198,LGP Offspring,"Genes up-regulated in SH-SY5Y cells (neuroblastoma) after treatment with epoxomicin [PubChem=3035402], a protease inhibitor causing apoptosis.",CGP,C2,256,431
Cohort,0.13216202670047758,0.24471981426449246,0.5400544581879964,0.5893036492641952,LGP Proband,"Genes up-regulated in SH-SY5Y cells (neuroblastoma) after treatment with epoxomicin [PubChem=3035402], a protease inhibitor causing apoptosis.",CGP,C2,256,650
Cohort,-0.08645912779883719,0.07558260162258144,-1.1439025111965213,0.2530079460042066,LonGen OPEL,"Genes up-regulated in SH-SY5Y cells (neuroblastoma) after treatment with epoxomicin [PubChem=3035402], a protease inhibitor causing apoptosis.",CGP,C2,382,442
Cohort,-0.025437047701225835,0.018677035620350144,-1.3619424526614978,0.1736697128663484,LGP Offspring,Genes enriched in pluripotent adult germline stem cells.,CGP,C2,15,17
Cohort,-0.0964348734339964,0.05304540126127623,-1.8179685918295616,0.06942757633245314,LGP Proband,Genes enriched in pluripotent adult germline stem cells.,CGP,C2,15,29
Cohort,-0.022656920436765166,0.017589956230371045,-1.2880600804250686,0.1980993541104428,LonGen OPEL,Genes enriched in pluripotent adult germline stem cells.,CGP,C2,24,20
Cohort,0.003036065542914161,0.02819748778801901,0.10767149065684396,0.9142882330072205,LGP Offspring,"Supplementary Table 2. Genelist comparing microarray expression profiles of spermatogonial cells, haGSCs and hES (H1) cells. Examples of expression rates of different hES cell enriched and germ cell specific genes, surface markers for germ cell selection and signal transduction in all three cell types (spermatogonial cells = SC).",CGP,C2,24,54
Cohort,0.11391174836595436,0.08216129005259255,1.3864406010791446,0.16598291273652208,LGP Proband,"Supplementary Table 2. Genelist comparing microarray expression profiles of spermatogonial cells, haGSCs and hES (H1) cells. Examples of expression rates of different hES cell enriched and germ cell specific genes, surface markers for germ cell selection and signal transduction in all three cell types (spermatogonial cells = SC).",CGP,C2,24,90
Cohort,0.04003666486039985,0.024221982473359837,1.6529061939679603,0.0987442803772564,LonGen OPEL,"Supplementary Table 2. Genelist comparing microarray expression profiles of spermatogonial cells, haGSCs and hES (H1) cells. Examples of expression rates of different hES cell enriched and germ cell specific genes, surface markers for germ cell selection and signal transduction in all three cell types (spermatogonial cells = SC).",CGP,C2,33,56
Cohort,0.07868746242733234,0.04111871274124459,1.9136655109439744,0.05608494259104788,LGP Offspring,Genes down-regulated in multiple myeloma (MM) bone marrow mesenchymal stem cells.,CGP,C2,39,114
Cohort,-0.10416174204138066,0.10694746412845259,-0.9739524250549219,0.3303625590764614,LGP Proband,Genes down-regulated in multiple myeloma (MM) bone marrow mesenchymal stem cells.,CGP,C2,39,135
Cohort,-0.005889938730541177,0.03287649141284774,-0.17915350688058698,0.8578627595034609,LonGen OPEL,Genes down-regulated in multiple myeloma (MM) bone marrow mesenchymal stem cells.,CGP,C2,70,79
Cohort,-0.02194767515181134,0.04354968511576295,-0.5039686301627772,0.6144476228149535,LGP Offspring,Genes up-regulated in multiple myeloma (MM) bone marrow mesenchymal stem cells.,CGP,C2,63,123
Cohort,-0.26238384734489295,0.12368700005918207,-2.121353474652525,0.034186458548405296,LGP Proband,Genes up-regulated in multiple myeloma (MM) bone marrow mesenchymal stem cells.,CGP,C2,63,173
Cohort,0.020738182751749434,0.034447537293385025,0.6020222164250852,0.5473307842753103,LonGen OPEL,Genes up-regulated in multiple myeloma (MM) bone marrow mesenchymal stem cells.,CGP,C2,89,109
Cohort,-0.014907456230085273,0.06428436788444444,-0.23189862046839205,0.8166869369486872,LGP Offspring,'Early-TGFB1 signature': genes overexpressed in primary hepatocytes at an early phase of TGFB1 [GeneID=7040] treatment; is associated with a less invasive phenotype.,CGP,C2,127,260
Cohort,-0.24749130096947047,0.17559123036490817,-1.409474154575612,0.15906777833204558,LGP Proband,'Early-TGFB1 signature': genes overexpressed in primary hepatocytes at an early phase of TGFB1 [GeneID=7040] treatment; is associated with a less invasive phenotype.,CGP,C2,127,374
Cohort,0.061040760596937076,0.05478546871673232,1.1141779385432964,0.2655391602368299,LonGen OPEL,'Early-TGFB1 signature': genes overexpressed in primary hepatocytes at an early phase of TGFB1 [GeneID=7040] treatment; is associated with a less invasive phenotype.,CGP,C2,188,256
Cohort,0.03940852207558448,0.05477691834112051,0.7194366399031411,0.47212056335824726,LGP Offspring,'Late-TGFB1 signature': genes overexpressed in primary hepatocytes at a late phase of TGFB1 [GeneID=7040] treatment; is associated with a more invasive phenotype.,CGP,C2,89,203
Cohort,0.0024546281152835105,0.14616902947702184,0.016793079382588255,0.9866057074041458,LGP Proband,'Late-TGFB1 signature': genes overexpressed in primary hepatocytes at a late phase of TGFB1 [GeneID=7040] treatment; is associated with a more invasive phenotype.,CGP,C2,89,256
Cohort,0.04020047291797257,0.04612484654674653,0.8715578679970298,0.38371241409283874,LonGen OPEL,'Late-TGFB1 signature': genes overexpressed in primary hepatocytes at a late phase of TGFB1 [GeneID=7040] treatment; is associated with a more invasive phenotype.,CGP,C2,139,184
Cohort,0.038046364935880456,0.03810544328201208,0.9984496087423942,0.31841864549100557,LGP Offspring,"Genes down-regulated by MYCN [GeneID=4613] but not by its transactivation-defficient, trunkated form N-Myc-delta-73.",CGP,C2,39,109
Cohort,0.06356385295472158,0.10507924103628491,0.6049135141047731,0.5454010083018561,LGP Proband,"Genes down-regulated by MYCN [GeneID=4613] but not by its transactivation-defficient, trunkated form N-Myc-delta-73.",CGP,C2,39,134
Cohort,-0.03331715704214042,0.030312005317893104,-1.0991406438713371,0.27203904629619086,LonGen OPEL,"Genes down-regulated by MYCN [GeneID=4613] but not by its transactivation-defficient, trunkated form N-Myc-delta-73.",CGP,C2,73,71
Cohort,-0.006828452845600084,0.021673570918793208,-0.3150589661106152,0.7528141099510656,LGP Offspring,"Genes in the AKT1 [GeneID=207] pathway which depend on MTOR [GeneID=2475], sensitive to RAD001 (everolimus) [PubChem=6442177].",CGP,C2,15,32
Cohort,-0.11711372242838042,0.06276600367163811,-1.8658782713180808,0.062409251141019625,LGP Proband,"Genes in the AKT1 [GeneID=207] pathway which depend on MTOR [GeneID=2475], sensitive to RAD001 (everolimus) [PubChem=6442177].",CGP,C2,15,53
Cohort,-0.017727981988863814,0.019277628154653028,-0.9196142723909125,0.3580529545804938,LonGen OPEL,"Genes in the AKT1 [GeneID=207] pathway which depend on MTOR [GeneID=2475], sensitive to RAD001 (everolimus) [PubChem=6442177].",CGP,C2,29,23
Cohort,-0.014232056293935823,0.038003429044929656,-0.37449400360977786,0.7081542615067962,LGP Offspring,"Genes in the AKT1 [GeneID=207] pathway which are independent of MTOR [GeneID=2475], insensitive to RAD001 (everolimus) [PubChem=6442177].",CGP,C2,50,90
Cohort,-0.04665182217153176,0.10084221786992514,-0.4626219370909438,0.6437560556830195,LGP Proband,"Genes in the AKT1 [GeneID=207] pathway which are independent of MTOR [GeneID=2475], insensitive to RAD001 (everolimus) [PubChem=6442177].",CGP,C2,50,120
Cohort,0.018083186557006716,0.029954155527518386,0.6036954218386825,0.5462181509679651,LonGen OPEL,"Genes in the AKT1 [GeneID=207] pathway which are independent of MTOR [GeneID=2475], insensitive to RAD001 (everolimus) [PubChem=6442177].",CGP,C2,57,83
Cohort,-0.03348630386728332,0.12540713224042058,-0.26702072895731355,0.7895346380141824,LGP Offspring,The 'group 1 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].,CGP,C2,521,1053
Cohort,-0.18304916128622503,0.3509003943929387,-0.5216556156994407,0.6020486342575245,LGP Proband,The 'group 1 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].,CGP,C2,521,1460
Cohort,0.13001302189431346,0.10722972079655484,1.2124718867913962,0.22569152948985804,LonGen OPEL,The 'group 1 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].,CGP,C2,779,965
Cohort,-0.12696182122111485,0.13161501510832257,-0.9646454176723072,0.3350673949287307,LGP Offspring,The 'group 2 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].,CGP,C2,587,1223
Cohort,0.6792386309480022,0.37164723624110585,1.8276434336440126,0.06796024044321725,LGP Proband,The 'group 2 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].,CGP,C2,587,1737
Cohort,0.027006976494903835,0.11540716185804598,0.23401473582829432,0.8150337118153045,LonGen OPEL,The 'group 2 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].,CGP,C2,910,1108
Cohort,-0.2861883672834001,0.1630467039540392,-1.755253926286501,0.0796688194904126,LGP Offspring,The 'group 3 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].,CGP,C2,793,1564
Cohort,-0.2691821768731947,0.4353557836309664,-0.6183038953293649,0.5365438501357626,LGP Proband,The 'group 3 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].,CGP,C2,793,2199
Cohort,-0.07396102878020422,0.12643725110612933,-0.5849623282154605,0.5587388192780198,LonGen OPEL,The 'group 3 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].,CGP,C2,1206,1416
Cohort,0.09657502000128135,0.0956228437014762,1.0099576237533547,0.31287694959441564,LGP Offspring,The 'group 4 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 but not ERBB2 [GeneID=2099;2064].,CGP,C2,267,601
Cohort,0.3120308624989752,0.2697697876420378,1.1566560704455695,0.24774410003453265,LGP Proband,The 'group 4 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 but not ERBB2 [GeneID=2099;2064].,CGP,C2,267,748
Cohort,0.061469940078909824,0.08199755479727464,0.7496557699907523,0.4536835471867572,LonGen OPEL,The 'group 4 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 but not ERBB2 [GeneID=2099;2064].,CGP,C2,454,556
Cohort,-0.2874049876680126,0.12395037679337902,-2.3187100765906243,0.020708106412852877,LGP Offspring,The 'group 5 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 but not ERBB2 [GeneID=2099;2064].,CGP,C2,508,935
Cohort,-0.8004374983120114,0.34692537329473566,-2.3072325056835425,0.021285965127922617,LGP Proband,The 'group 5 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 but not ERBB2 [GeneID=2099;2064].,CGP,C2,508,1361
Cohort,0.001417085053464139,0.10396958168638723,0.01362980431852289,0.989128741567636,LonGen OPEL,The 'group 5 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 but not ERBB2 [GeneID=2099;2064].,CGP,C2,746,902
Cohort,-0.019541472670966478,0.04699183098351358,-0.41584829239410415,0.6776529948410273,LGP Offspring,Metastatic propensity markers of head and neck squamous cell carcinoma (HNSCC): down-regulated in metastatic vs non-metastatic tumors.,CGP,C2,68,143
Cohort,0.10334111687270918,0.12166548012747481,0.84938732633474745,0.3959095495805919,LGP Proband,Metastatic propensity markers of head and neck squamous cell carcinoma (HNSCC): down-regulated in metastatic vs non-metastatic tumors.,CGP,C2,68,167
Cohort,0.046243064665416944,0.04024599397896637,1.1490103757801287,0.25089683951593106,LonGen OPEL,Metastatic propensity markers of head and neck squamous cell carcinoma (HNSCC): down-regulated in metastatic vs non-metastatic tumors.,CGP,C2,96,147
Cohort,-0.050507779083255225,0.04058675608838797,-1.244439909739564,0.2137689839522919,LGP Offspring,Metastatic propensity markers of head and neck squamous cell carcinoma (HNSCC): up-regulated in metastatic vs non-metastatic tumors.,CGP,C2,65,108
Cohort,-0.05290517261890462,0.11789179384159709,-0.4487604344199697,0.6537210578061745,LGP Proband,Metastatic propensity markers of head and neck squamous cell carcinoma (HNSCC): up-regulated in metastatic vs non-metastatic tumors.,CGP,C2,65,161
Cohort,-0.03885148070774158,0.03838507084104045,-1.012150814274451,0.3117735061816419,LonGen OPEL,Metastatic propensity markers of head and neck squamous cell carcinoma (HNSCC): up-regulated in metastatic vs non-metastatic tumors.,CGP,C2,114,123
Cohort,-0.015900103148610588,0.04083361921748921,-0.38938755499293354,0.6971121105443262,LGP Offspring,Tumorigenesis markers of head and neck squamous cell carcinoma (HNSCC): down-regulated in the 'early' tumors vs normal samples.,CGP,C2,52,107
Cohort,-0.09757623250600503,0.11311499152047373,-0.8626286506713285,0.3885896513157375,LGP Proband,Tumorigenesis markers of head and neck squamous cell carcinoma (HNSCC): down-regulated in the 'early' tumors vs normal samples.,CGP,C2,52,164
Cohort,0.014002597743505681,0.03619281729574688,0.3868888577831482,0.6989418975160506,LonGen OPEL,Tumorigenesis markers of head and neck squamous cell carcinoma (HNSCC): down-regulated in the 'early' tumors vs normal samples.,CGP,C2,91,118
Cohort,0.020651421438830916,0.046892156781555436,0.4404024650654147,0.6597864259106176,LGP Offspring,Tumorigenesis markers of head and neck squamous cell carcinoma (HNSCC): up-regulated in the 'early' tumors vs normal samples.,CGP,C2,69,154
Cohort,-0.0404433684118295,0.13926401311112657,-0.2904078915172254,0.7715764015823348,LGP Proband,Tumorigenesis markers of head and neck squamous cell carcinoma (HNSCC): up-regulated in the 'early' tumors vs normal samples.,CGP,C2,69,239
Cohort,-0.11929523246712621,0.04203013412826062,-2.83832623762467,0.004650502182838233,LonGen OPEL,Tumorigenesis markers of head and neck squamous cell carcinoma (HNSCC): up-regulated in the 'early' tumors vs normal samples.,CGP,C2,140,117
Cohort,-0.03150583030237818,0.04634481599000272,-0.6798134727554956,0.4968552986517396,LGP Offspring,"Genes down-regulated in the ANBL-6 cell line (multiple myeloma, MM) after withdrawal of IL6 [GeneID=3569].",CGP,C2,80,142
Cohort,-0.08243792286673796,0.13910544382188206,-0.592629020128758,0.553590098296304,LGP Proband,"Genes down-regulated in the ANBL-6 cell line (multiple myeloma, MM) after withdrawal of IL6 [GeneID=3569].",CGP,C2,80,227
Cohort,0.009055776555420215,0.03982758306171791,0.2273744942390086,0.8201909367991287,LonGen OPEL,"Genes down-regulated in the ANBL-6 cell line (multiple myeloma, MM) after withdrawal of IL6 [GeneID=3569].",CGP,C2,113,141
Cohort,-0.03728810232489973,0.025698747213414887,-1.450969652926705,0.14725217541698032,LGP Offspring,"Genes up-regulated in the ANBL-6 cell line (multiple myeloma, MM) after withdrawal of IL6 [GeneID=3569].",CGP,C2,27,39
Cohort,-0.023159593144112704,0.07202471439366387,-0.32155064187453536,0.7478737111111602,LGP Proband,"Genes up-regulated in the ANBL-6 cell line (multiple myeloma, MM) after withdrawal of IL6 [GeneID=3569].",CGP,C2,27,59
Cohort,-0.03901238322699221,0.0243251467577546,-1.6037881956274516,0.10915742597509574,LonGen OPEL,"Genes up-regulated in the ANBL-6 cell line (multiple myeloma, MM) after withdrawal of IL6 [GeneID=3569].",CGP,C2,45,39
Cohort,-0.04986816068570369,0.04284337734881763,-1.1639642757314026,0.2448491312819685,LGP Offspring,"Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM)  expressing a constantly active form of NRAS [GeneID=4893] off a plasmid vector compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,67,112
Cohort,-0.01815570608659803,0.1274823173284671,-0.14241744633350667,0.8867846801977324,LGP Proband,"Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM)  expressing a constantly active form of NRAS [GeneID=4893] off a plasmid vector compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,67,205
Cohort,0.0093466852911647,0.0375747544207833,0.24874907195653884,0.8036190521109102,LonGen OPEL,"Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM)  expressing a constantly active form of NRAS [GeneID=4893] off a plasmid vector compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,99,125
Cohort,0.026862909075783113,0.029931767542184372,0.8974715254594918,0.3697868751000233,LGP Offspring,"Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM)  expressing a constantly active form of NRAS [GeneID=4893] off a plasmid vector compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,23,60
Cohort,0.0028104371038112407,0.07348238405152768,0.038246406129671735,0.9695003740560715,LGP Proband,"Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM)  expressing a constantly active form of NRAS [GeneID=4893] off a plasmid vector compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,23,71
Cohort,-0.001979406628542863,0.023835473173358893,-0.08304457034044797,0.9338369783601559,LonGen OPEL,"Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM)  expressing a constantly active form of NRAS [GeneID=4893] off a plasmid vector compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,40,50
Cohort,0.011874578675744577,0.051019917391516706,0.23274398083833456,0.8160306642701666,LGP Offspring,"Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM) expressing an activated form of NRAS [GeneID=4893] off a plasmid vector compared to those co-cultured with bone marrow stromal cells.",CGP,C2,87,180
Cohort,-0.14367199449578924,0.13414683530051302,-1.0710054707883205,0.2844768068966241,LGP Proband,"Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM) expressing an activated form of NRAS [GeneID=4893] off a plasmid vector compared to those co-cultured with bone marrow stromal cells.",CGP,C2,87,220
Cohort,0.009550632489361189,0.04008445053836424,0.23826277673983376,0.811738610299135,LonGen OPEL,"Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM) expressing an activated form of NRAS [GeneID=4893] off a plasmid vector compared to those co-cultured with bone marrow stromal cells.",CGP,C2,107,146
Cohort,-0.031008884907897414,0.03644602195162181,-0.850816721480835,0.3951724345765528,LGP Offspring,"Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM) expressing an activated form of NRAS [GeneID=4893] off a plasmid vector compared to those co-cultured with bone marrow stromal cells.",CGP,C2,45,81
Cohort,-0.060061186546863904,0.09050351578275487,-0.6636337387271795,0.5071081581681076,LGP Proband,"Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM) expressing an activated form of NRAS [GeneID=4893] off a plasmid vector compared to those co-cultured with bone marrow stromal cells.",CGP,C2,45,96
Cohort,-0.02830345836026784,0.029409866487211597,-0.9623796956907349,0.33615116284460556,LonGen OPEL,"Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM) expressing an activated form of NRAS [GeneID=4893] off a plasmid vector compared to those co-cultured with bone marrow stromal cells.",CGP,C2,70,71
Cohort,0.028612681162893797,0.01300811162893584,2.19960298459051,0.028172848902394198,LGP Offspring,"Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM) co-cultured with bone marrow stromal cells compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,1,16
Cohort,0.019900373742544247,0.030394622285189486,0.6547333786819646,0.5128199536129869,LGP Proband,"Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM) co-cultured with bone marrow stromal cells compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,1,14
Cohort,-0.007026880855363176,0.00888420507032091,-0.7909408663739181,0.4292140928040378,LonGen OPEL,"Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM) co-cultured with bone marrow stromal cells compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,8,5
Cohort,-0.06574520442480364,0.04159244343122304,-1.5807006994796884,0.11441424150772854,LGP Offspring,"Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM) co-cultured with bone marrow stromal cells compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,66,106
Cohort,-0.07755509276943266,0.10921352217950925,-0.7101235380171964,0.4778260369813979,LGP Proband,"Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM) co-cultured with bone marrow stromal cells compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,66,128
Cohort,-0.03192891802789294,0.032957251767810176,-0.9687979523547037,0.332940274614818,LonGen OPEL,"Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM) co-cultured with bone marrow stromal cells compared to those grown in the presence of IL6 [GeneID=3569].",CGP,C2,85,86
Cohort,0.006249513482834372,0.007818477010115506,0.7993261954660458,0.4243820566826899,LGP Offspring,Putative E2F4 [GeneID=1874] target genes identified as mitotic genes down-regulated in the LNCaP C4-2 cells (prostate cancer) at both 6 and 24 h following irradiation.,CGP,C2,1,5
Cohort,-0.007196295531784554,0.026106581630402477,-0.2756506245690969,0.7828847052047418,LGP Proband,Putative E2F4 [GeneID=1874] target genes identified as mitotic genes down-regulated in the LNCaP C4-2 cells (prostate cancer) at both 6 and 24 h following irradiation.,CGP,C2,1,10
Cohort,-0.009231270978254135,0.007206856713604518,-1.2809011397199133,0.20060145628250584,LonGen OPEL,Putative E2F4 [GeneID=1874] target genes identified as mitotic genes down-regulated in the LNCaP C4-2 cells (prostate cancer) at both 6 and 24 h following irradiation.,CGP,C2,5,3
Cohort,0.0035536265542803146,0.03288882838609816,0.10804965481173551,0.9139883652146017,LGP Offspring,Representative genes up-regulated in MiaPaCa2 cells (pancreatic cancer) under glucose-deprived conditions.,CGP,C2,31,70
Cohort,0.07614600517693397,0.0933565156969017,0.8156474629382626,0.4149346732816982,LGP Proband,Representative genes up-regulated in MiaPaCa2 cells (pancreatic cancer) under glucose-deprived conditions.,CGP,C2,31,101
Cohort,0.015142206879179042,0.027136908797620023,0.5579930636943826,0.5770060185432591,LonGen OPEL,Representative genes up-regulated in MiaPaCa2 cells (pancreatic cancer) under glucose-deprived conditions.,CGP,C2,43,56
Cohort,-0.11869062111821349,0.16979583745710142,-0.6990196161210397,0.4847801987857281,LGP Offspring,All significantly down-regulated genes in kidney glomeruli isolated from TCF21 [Gene ID=6943] knockout mice.,CGP,C2,924,1896
Cohort,0.2589674054570395,0.49334189917013926,0.5249248156150005,0.5997749629275932,LGP Proband,All significantly down-regulated genes in kidney glomeruli isolated from TCF21 [Gene ID=6943] knockout mice.,CGP,C2,924,2636
Cohort,-0.22790382071857435,0.14853716966744154,-1.53432182145941,0.12534784828638407,LonGen OPEL,All significantly down-regulated genes in kidney glomeruli isolated from TCF21 [Gene ID=6943] knockout mice.,CGP,C2,1590,1825
Cohort,-0.13230087732002938,0.12372696513319191,-1.0692970378575735,0.2853175093427746,LGP Offspring,All significantly up-regulated genes in kidney glomeruli isolated from TCF21 [Gene ID=6943] knockout mice.,CGP,C2,510,1008
Cohort,-0.05250572955264493,0.3458756972558301,-0.1518052004498269,0.8793772937407311,LGP Proband,All significantly up-regulated genes in kidney glomeruli isolated from TCF21 [Gene ID=6943] knockout mice.,CGP,C2,510,1412
Cohort,-0.04985036803964947,0.10439080565720885,-0.47753600258000295,0.6331115847837387,LonGen OPEL,All significantly up-regulated genes in kidney glomeruli isolated from TCF21 [Gene ID=6943] knockout mice.,CGP,C2,775,907
Cohort,0.001464146694610881,0.027538468809088414,0.05316732403537535,0.9576142980124329,LGP Offspring,Genes most strongly down-regulated in kidney glomeruli isolated from TCF21 [GeneID=6943] knockout mice.,CGP,C2,22,54
Cohort,0.030602106674302958,0.07022708125858503,0.43575934135183714,0.6631241065427431,LGP Proband,Genes most strongly down-regulated in kidney glomeruli isolated from TCF21 [GeneID=6943] knockout mice.,CGP,C2,22,64
Cohort,0.017329126688726392,0.023757945653814345,0.7294034148084767,0.46596949829336476,LonGen OPEL,Genes most strongly down-regulated in kidney glomeruli isolated from TCF21 [GeneID=6943] knockout mice.,CGP,C2,36,54
Cohort,-0.023284060881690563,0.04319809576403133,-0.5390066499430726,0.5900597276423708,LGP Offspring,Genes most strongly up-regulated in kidney glomeruli isolated from TCF21 [GeneID=6943] knockout mice.,CGP,C2,58,110
Cohort,0.1333546242306728,0.11235520863879508,1.1869020212439607,0.23560423740214884,LGP Proband,Genes most strongly up-regulated in kidney glomeruli isolated from TCF21 [GeneID=6943] knockout mice.,CGP,C2,58,147
Cohort,-0.05898390907232836,0.03228093229194196,-1.8272058730798197,0.06804310331757962,LonGen OPEL,Genes most strongly up-regulated in kidney glomeruli isolated from TCF21 [GeneID=6943] knockout mice.,CGP,C2,87,82
Cohort,-0.06123834446445487,0.041164370675964394,-1.4876540916052807,0.13730843219463532,LGP Offspring,Genes down-regulated in fibroblasts expressing different mutant forms of ERCC3 [GeneID=2071]: XP/CS (xeroderma pigmentosum (XP) and Cockraine's syndrome (CS)) vs TTD (trichothiodystrophy).,CGP,C2,55,101
Cohort,0.12401283616110235,0.1052208660668756,1.1785954706197066,0.23889544702166507,LGP Proband,Genes down-regulated in fibroblasts expressing different mutant forms of ERCC3 [GeneID=2071]: XP/CS (xeroderma pigmentosum (XP) and Cockraine's syndrome (CS)) vs TTD (trichothiodystrophy).,CGP,C2,55,124
Cohort,-0.01810280307613801,0.034333374142067614,-0.527265482303914,0.5981561589058542,LonGen OPEL,Genes down-regulated in fibroblasts expressing different mutant forms of ERCC3 [GeneID=2071]: XP/CS (xeroderma pigmentosum (XP) and Cockraine's syndrome (CS)) vs TTD (trichothiodystrophy).,CGP,C2,85,95
Cohort,-0.0176979370988679,0.015517598700383425,-1.1405074612756032,0.25447884692241035,LGP Offspring,Genes up-regulated in fibroblasts expressing different mutant forms of ERCC3 [GeneID=2071]: XP/CS (xeroderma pigmentosum (XP) and Cockraine's syndrome (CS)) vs TTD (trichothiodystrophy).,CGP,C2,10,14
Cohort,0.07701454804205048,0.04807276753653328,1.6020410720793776,0.10952518757787232,LGP Proband,Genes up-regulated in fibroblasts expressing different mutant forms of ERCC3 [GeneID=2071]: XP/CS (xeroderma pigmentosum (XP) and Cockraine's syndrome (CS)) vs TTD (trichothiodystrophy).,CGP,C2,10,27
Cohort,-0.004195336528501398,0.013522909144839964,-0.31023920101557756,0.756460270072374,LonGen OPEL,Genes up-regulated in fibroblasts expressing different mutant forms of ERCC3 [GeneID=2071]: XP/CS (xeroderma pigmentosum (XP) and Cockraine's syndrome (CS)) vs TTD (trichothiodystrophy).,CGP,C2,13,15
Cohort,0.005774123078339697,0.01614782195454033,0.3575790651268712,0.7207699585497113,LGP Offspring,"Genes down-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071], after low dose UVC irradiation.",CGP,C2,6,18
Cohort,0.011597708704679131,0.03989181399862732,0.29072903791936383,0.7713308412943687,LGP Proband,"Genes down-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071], after low dose UVC irradiation.",CGP,C2,6,18
Cohort,-0.006231920186456655,0.014358463608006307,-0.43402416557867124,0.664388504278623,LonGen OPEL,"Genes down-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071], after low dose UVC irradiation.",CGP,C2,16,16
Cohort,0.01423730417721256,0.021278127679337826,0.6691051201388234,0.5036568638082125,LGP Offspring,"Genes up-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071], after low dose UVC irradiation.",CGP,C2,11,29
Cohort,0.04757075795105963,0.05737499009376459,0.82912010744259,0.4072736777479574,LGP Proband,"Genes up-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071], after low dose UVC irradiation.",CGP,C2,11,46
Cohort,-0.005841574642347468,0.019251532709850052,-0.3034342631513503,0.7616382271480825,LonGen OPEL,"Genes up-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071], after low dose UVC irradiation.",CGP,C2,25,29
Cohort,-0.2646599828308596,0.13291258619540125,-1.9912334144320247,0.04685727703088558,LGP Offspring,"Common down-regulated transcripts in fibroblasts expressing either XP/CS or TDD mutant forms of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,597,1128
Cohort,-0.16809569956367784,0.3704066124865231,-0.45381398143855717,0.6500807847576497,LGP Proband,"Common down-regulated transcripts in fibroblasts expressing either XP/CS or TDD mutant forms of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,597,1505
Cohort,-0.14028141702180993,0.113841008008453,-1.2322573339423846,0.2182168266468071,LonGen OPEL,"Common down-regulated transcripts in fibroblasts expressing either XP/CS or TDD mutant forms of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,863,979
Cohort,-0.049961044588189035,0.042590471131845956,-1.1730568660188385,0.2411861729940517,LGP Offspring,"Common up-regulated transcripts in fibroblasts expressing either XP/CS or TDD mutant forms of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,66,114
Cohort,-0.1701530225126496,0.12911846853967734,-1.3178054575543745,0.18793064219943545,LGP Proband,"Common up-regulated transcripts in fibroblasts expressing either XP/CS or TDD mutant forms of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,66,187
Cohort,-0.013714835429183243,0.03934269988793424,-0.34859924377964097,0.7274823757645644,LonGen OPEL,"Common up-regulated transcripts in fibroblasts expressing either XP/CS or TDD mutant forms of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,108,129
Cohort,-0.29347773712287156,0.19540256094326905,-1.5019134637036642,0.13358641143814948,LGP Offspring,Genes down-regulated in fibroblasts expressing mutant forms of ERCC3 [GeneID=2071] after UV irradiation.,CGP,C2,1095,2167
Cohort,-0.20047800349821915,0.5094087848851616,-0.39355034590425025,0.6940136347223849,LGP Proband,Genes down-regulated in fibroblasts expressing mutant forms of ERCC3 [GeneID=2071] after UV irradiation.,CGP,C2,1095,2954
Cohort,-0.12304606505947972,0.15199953054867082,-0.809516086104489,0.418460265842008,LonGen OPEL,Genes down-regulated in fibroblasts expressing mutant forms of ERCC3 [GeneID=2071] after UV irradiation.,CGP,C2,1681,1956
Cohort,0.006318197643838553,0.05950884495849874,0.10617241265974565,0.9154770568173828,LGP Offspring,"Genes exclusively down-regulated in fibroblasts expressing the TTD mutant form of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,114,238
Cohort,-0.046277184157596546,0.17032417841504177,-0.27170061578004173,0.7859194693114808,LGP Proband,"Genes exclusively down-regulated in fibroblasts expressing the TTD mutant form of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,114,368
Cohort,0.02767244188723273,0.05332541710272735,0.5189353106028948,0.6039500910817149,LonGen OPEL,"Genes exclusively down-regulated in fibroblasts expressing the TTD mutant form of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,191,237
Cohort,0.023135439948395307,0.044117548756965136,0.5244044739621386,0.6001691520545878,LGP Offspring,"Genes exclusively up-regulated in fibroblasts expressing the TTD mutant form of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,50,109
Cohort,-0.03803877073745607,0.11279734978481194,-0.33723106801732633,0.7360275689547258,LGP Proband,"Genes exclusively up-regulated in fibroblasts expressing the TTD mutant form of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,50,142
Cohort,-0.009856344155948391,0.03846042327919931,-0.2562723786058546,0.7978067395877393,LonGen OPEL,"Genes exclusively up-regulated in fibroblasts expressing the TTD mutant form of ERCC3 [GeneID=2071], after UVC irradiation.",CGP,C2,93,107
Cohort,-0.12242098067793974,0.08857072508582312,-1.3821833405938189,0.16737192724772024,LGP Offspring,Genes up-regulated in fibroblasts expressing mutant forms of ERCC3 [GeneID=2071] after UV irradiation.,CGP,C2,270,502
Cohort,-0.46615369641393034,0.24351992432471295,-1.9142322654155983,0.05593242777592893,LGP Proband,Genes up-regulated in fibroblasts expressing mutant forms of ERCC3 [GeneID=2071] after UV irradiation.,CGP,C2,270,695
Cohort,-0.04334043480257907,0.07915461357925048,-0.5475414867534681,0.5841602634982145,LonGen OPEL,Genes up-regulated in fibroblasts expressing mutant forms of ERCC3 [GeneID=2071] after UV irradiation.,CGP,C2,412,486
Cohort,0.11121488615728146,0.05844658661743159,1.9028465577511045,0.057485164613032436,LGP Offspring,Genes exclusively down-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071] after high dose UVC irradiation.,CGP,C2,95,243
Cohort,0.17315320136155643,0.15793060863205977,1.0963878557890043,0.27322555613577026,LGP Proband,Genes exclusively down-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071] after high dose UVC irradiation.,CGP,C2,95,348
Cohort,-0.021479698487774326,0.04974552391928251,-0.43179158234673454,0.6660098271985682,LonGen OPEL,Genes exclusively down-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071] after high dose UVC irradiation.,CGP,C2,183,211
Cohort,0.010677647652818822,0.022593990783769436,0.4725879440691456,0.6366597199039783,LGP Offspring,Genes exclusively up-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071] after high dose UVC irradiation.,CGP,C2,13,34
Cohort,-0.021182772210188335,0.0629023860097242,-0.3367562592445007,0.7363853690508029,LGP Proband,Genes exclusively up-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071] after high dose UVC irradiation.,CGP,C2,13,48
Cohort,-0.012219631222898252,0.017773078231185544,-0.6875360060845885,0.4919452954122643,LonGen OPEL,Genes exclusively up-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071] after high dose UVC irradiation.,CGP,C2,24,23
Cohort,-0.08726102470755755,0.05008118510225878,-1.7423913697206392,0.08189474977743691,LGP Offspring,'Cancer prone response profile' (CPRP): genes changed in response to bisphenol A [PubChem=6623]  in epithelial cell cultures from patients at high risk of breast cancer.,CGP,C2,83,139
Cohort,0.00915412075413751,0.1223374696624643,0.07482679492549768,0.9403704661225711,LGP Proband,'Cancer prone response profile' (CPRP): genes changed in response to bisphenol A [PubChem=6623]  in epithelial cell cultures from patients at high risk of breast cancer.,CGP,C2,83,164
Cohort,0.035512158829674303,0.037003821611330555,0.9596889532836926,0.337503191408265,LonGen OPEL,'Cancer prone response profile' (CPRP): genes changed in response to bisphenol A [PubChem=6623]  in epithelial cell cultures from patients at high risk of breast cancer.,CGP,C2,86,118
Cohort,-0.051510280108032935,0.05123128156158493,-1.0054458631122203,0.3150419603950982,LGP Offspring,'Cancer prone response profile' (CPRP): genes common to estradiol and bisphenol A [PubChem=5757;6623]  response of epithelial cell cultures from patients at high risk of breast cancer.,CGP,C2,89,174
Cohort,-0.05734965342775458,0.14348508163277682,-0.3996907049509877,0.6894866776950205,LGP Proband,'Cancer prone response profile' (CPRP): genes common to estradiol and bisphenol A [PubChem=5757;6623]  response of epithelial cell cultures from patients at high risk of breast cancer.,CGP,C2,89,245
Cohort,0.049055064436753754,0.04667913199193689,1.05089924219729,0.29362380070780936,LonGen OPEL,'Cancer prone response profile' (CPRP): genes common to estradiol and bisphenol A [PubChem=5757;6623]  response of epithelial cell cultures from patients at high risk of breast cancer.,CGP,C2,136,189
Cohort,-0.02910290365282191,0.040716880254382685,-0.7147626112560362,0.4750024966553599,LGP Offspring,'Cancer prone response profile' (CPRP): genes changed in response to estradiol [PubChem=5757]  in epithelial cell cultures from patients at high risk of breast cancer.,CGP,C2,67,127
Cohort,-0.005362636124490896,0.1180547409013592,-0.045424995926014136,0.9637794317163563,LGP Proband,'Cancer prone response profile' (CPRP): genes changed in response to estradiol [PubChem=5757]  in epithelial cell cultures from patients at high risk of breast cancer.,CGP,C2,67,169
Cohort,-0.041465752058835875,0.03511937260927194,-1.1807087934107459,0.2380711074800795,LonGen OPEL,'Cancer prone response profile' (CPRP): genes changed in response to estradiol [PubChem=5757]  in epithelial cell cultures from patients at high risk of breast cancer.,CGP,C2,88,93
Cohort,0.04080863507337162,0.017788932521200552,2.2940463136130607,0.022093636549915998,LGP Offspring,Top genes up-regulated in HEK293 cells (fibroblast) in response to trichostatin A (TSA) [PubChem=5562].,CGP,C2,3,23
Cohort,0.06307518337097667,0.04307564161217415,1.4642888883435738,0.14349185337741394,LGP Proband,Top genes up-regulated in HEK293 cells (fibroblast) in response to trichostatin A (TSA) [PubChem=5562].,CGP,C2,3,26
Cohort,0.010419708055234697,0.013616793618730291,0.7652101035666787,0.44437325626018287,LonGen OPEL,Top genes up-regulated in HEK293 cells (fibroblast) in response to trichostatin A (TSA) [PubChem=5562].,CGP,C2,10,14
Cohort,0.05629331588196974,0.15605746640625714,0.36072170834443745,0.7184201850122793,LGP Offspring,"Genes whose promoters are bound by MYC [GeneID=4609], according to MYC Target Gene Database.",CGP,C2,765,1626
Cohort,0.05755084983515502,0.4447545811376861,0.12939911644741117,0.8970730468140702,LGP Proband,"Genes whose promoters are bound by MYC [GeneID=4609], according to MYC Target Gene Database.",CGP,C2,765,2313
Cohort,-0.15464122066366706,0.14375309696799637,-1.075741837395647,0.28236867254271675,LonGen OPEL,"Genes whose promoters are bound by MYC [GeneID=4609], according to MYC Target Gene Database.",CGP,C2,1335,1531
Cohort,0.02562737441242025,0.03271804392760843,0.7832795404616206,0.43373730146488754,LGP Offspring,"Genes down-regulated by MYC [GeneID=4609] and whose promoters are bound by MYC, according to MYC Target Gene Database.",CGP,C2,28,72
Cohort,0.14171098053871803,0.08006393717533518,1.7699726685733623,0.0770970117028315,LGP Proband,"Genes down-regulated by MYC [GeneID=4609] and whose promoters are bound by MYC, according to MYC Target Gene Database.",CGP,C2,28,86
Cohort,-0.015781007722519586,0.026919162549101292,-0.5862369490036918,0.5578824885890977,LonGen OPEL,"Genes down-regulated by MYC [GeneID=4609] and whose promoters are bound by MYC, according to MYC Target Gene Database.",CGP,C2,54,57
Cohort,0.03440219225969261,0.05000974871883271,0.687909720424918,0.4917456032385906,LGP Offspring,"Genes up-regulated by MYC [GeneID=4609] and whose promoters are bound by MYC, according to MYC Target Gene Database.",CGP,C2,79,180
Cohort,-0.04981368922169224,0.13504794659996802,-0.3688592864669594,0.7123262290827911,LGP Proband,"Genes up-regulated by MYC [GeneID=4609] and whose promoters are bound by MYC, according to MYC Target Gene Database.",CGP,C2,79,216
Cohort,-0.02534744514140626,0.045507718241132526,-0.5569922228817829,0.5776893133531054,LonGen OPEL,"Genes up-regulated by MYC [GeneID=4609] and whose promoters are bound by MYC, according to MYC Target Gene Database.",CGP,C2,137,147
Cohort,-0.06862331968828965,0.07965010003300835,-0.8615597426726518,0.3892353307627183,LGP Offspring,"Genes down-regulated by MYC [GeneID=4609], according to the MYC Target Gene Database.",CGP,C2,211,432
Cohort,0.026120195614517828,0.22357069314218433,0.11683193019357935,0.9070213680429626,LGP Proband,"Genes down-regulated by MYC [GeneID=4609], according to the MYC Target Gene Database.",CGP,C2,211,589
Cohort,-0.048972789011568235,0.06840667239581773,-0.7159066111007375,0.47425897142746964,LonGen OPEL,"Genes down-regulated by MYC [GeneID=4609], according to the MYC Target Gene Database.",CGP,C2,337,378
Cohort,-0.04953288263303222,0.040998125537866074,-1.2081743246354861,0.22740269247402387,LGP Offspring,"Genes up-regulated by MYC [GeneID=4609], according to the MYC Target Gene Database.",CGP,C2,67,112
Cohort,-0.3495322155646409,0.11667309754475036,-2.9958252838069774,0.0028180580553424576,LGP Proband,"Genes up-regulated by MYC [GeneID=4609], according to the MYC Target Gene Database.",CGP,C2,67,158
Cohort,-0.009688381251512137,0.03510909592771675,-0.27595074710720985,0.7826575207110738,LonGen OPEL,"Genes up-regulated by MYC [GeneID=4609], according to the MYC Target Gene Database.",CGP,C2,87,97
Cohort,-0.014919353576261974,0.043392207994417384,-0.3438256375011251,0.7310843334612724,LGP Offspring,Genes that classify progression risk of benign papilloma samples: low vs high risk.,CGP,C2,65,129
Cohort,0.18596114686070114,0.12402978426475837,1.499326536469191,0.13416736400049964,LGP Proband,Genes that classify progression risk of benign papilloma samples: low vs high risk.,CGP,C2,65,190
Cohort,0.0163878513656637,0.037864703046961844,0.43280020829263083,0.6652771593203402,LonGen OPEL,Genes that classify progression risk of benign papilloma samples: low vs high risk.,CGP,C2,95,120
Cohort,-0.014613637415232819,0.061930039837124716,-0.23597009550884376,0.8135273493482571,LGP Offspring,Genes down-regulated during skin tumor progression from normal skin to high risk papilloma.,CGP,C2,128,274
Cohort,-0.11378792546032136,0.17566251340290304,-0.6477644163005633,0.5173156078324417,LGP Proband,Genes down-regulated during skin tumor progression from normal skin to high risk papilloma.,CGP,C2,128,382
Cohort,0.06471260567799801,0.05861646290154921,1.1040005226294145,0.26992653008009593,LonGen OPEL,Genes down-regulated during skin tumor progression from normal skin to high risk papilloma.,CGP,C2,225,302
Cohort,0.046592272072244804,0.04728144376064961,0.9854240557480951,0.32476837929043845,LGP Offspring,Genes up-regulated during skin tumor progression from normal skin to high risk papilloma.,CGP,C2,74,175
Cohort,0.0625013104000525,0.1363583361141191,0.45836075872724624,0.6468126894883374,LGP Proband,Genes up-regulated during skin tumor progression from normal skin to high risk papilloma.,CGP,C2,74,256
Cohort,0.02879664995984451,0.04642244316363031,0.6203174154006023,0.5352263786709628,LonGen OPEL,Genes up-regulated during skin tumor progression from normal skin to high risk papilloma.,CGP,C2,141,188
Cohort,-0.03138893714622207,0.06011116419711337,-0.52218148767329,0.601715038651176,LGP Offspring,Genes down-regulated during skin tumor progression from low risk papilloma vs normal skin.,CGP,C2,120,244
Cohort,-0.04886896708079696,0.16699375221455828,-0.2926394935902077,0.7698705121633233,LGP Proband,Genes down-regulated during skin tumor progression from low risk papilloma vs normal skin.,CGP,C2,120,350
Cohort,0.029128514823192085,0.05392463720331132,0.5401708075173366,0.589230334424403,LonGen OPEL,Genes down-regulated during skin tumor progression from low risk papilloma vs normal skin.,CGP,C2,203,257
Cohort,0.06336757180323413,0.051056282055367344,1.2411317325165974,0.21498760254560167,LGP Offspring,Genes up-regulated during skin tumor progression from low risk papilloma vs normal skin.,CGP,C2,82,205
Cohort,-0.0024176479794718857,0.15008020270504888,-0.016109039939286765,0.987151254408164,LGP Proband,Genes up-regulated during skin tumor progression from low risk papilloma vs normal skin.,CGP,C2,82,288
Cohort,0.06438074081465066,0.05039419688880501,1.2775427487555167,0.20178316978156108,LonGen OPEL,Genes up-regulated during skin tumor progression from low risk papilloma vs normal skin.,CGP,C2,163,233
Cohort,0.007483668650453585,0.06182217528599452,0.12105152586161053,0.9036861949593656,LGP Offspring,"Genes down-regulated during skin tumor progression: epidermis treated with the carcinogen DMBA [PubChem=6001] followed by 20 weekly applications of the tumor promoter TPA [PubChem=4792], compared to the untreated skin.",CGP,C2,130,289
Cohort,-0.07314697691637204,0.17499239610379924,-0.41800088772419497,0.676054067875512,LGP Proband,"Genes down-regulated during skin tumor progression: epidermis treated with the carcinogen DMBA [PubChem=6001] followed by 20 weekly applications of the tumor promoter TPA [PubChem=4792], compared to the untreated skin.",CGP,C2,130,404
Cohort,0.023875244180161365,0.058589241383065684,0.40750219010451527,0.6837487529297461,LonGen OPEL,"Genes down-regulated during skin tumor progression: epidermis treated with the carcinogen DMBA [PubChem=6001] followed by 20 weekly applications of the tumor promoter TPA [PubChem=4792], compared to the untreated skin.",CGP,C2,242,302
Cohort,0.024494966006558497,0.048871939980717524,0.5012071551942282,0.616388505832881,LGP Offspring,"Genes up-regulated during skin tumor progression: epidermis treated with the carcinogen DMBA [PubChem=6001] followed by 20 weekly applications of the tumor promoter TPA [PubChem=4792], compared to the untreated skin.",CGP,C2,72,160
Cohort,0.021860361856103207,0.1340292837604863,0.1631013853298524,0.8704781212324468,LGP Proband,"Genes up-regulated during skin tumor progression: epidermis treated with the carcinogen DMBA [PubChem=6001] followed by 20 weekly applications of the tumor promoter TPA [PubChem=4792], compared to the untreated skin.",CGP,C2,72,234
Cohort,0.06963401145768125,0.04449774663309207,1.5648884882160718,0.11800650091359415,LonGen OPEL,"Genes up-regulated during skin tumor progression: epidermis treated with the carcinogen DMBA [PubChem=6001] followed by 20 weekly applications of the tumor promoter TPA [PubChem=4792], compared to the untreated skin.",CGP,C2,124,188
Cohort,0.023003123461033285,0.058792729562049034,0.39125796050608785,0.6957298586976983,LGP Offspring,Genes down-regulated in squamous cell carcinoma (SCC) compared to normal skin.,CGP,C2,118,269
Cohort,-0.07040298570695862,0.16951230260214784,-0.4153267027007311,0.6780095835171833,LGP Proband,Genes down-regulated in squamous cell carcinoma (SCC) compared to normal skin.,CGP,C2,118,383
Cohort,0.036824885466415984,0.05892405966788302,0.624954995870518,0.5321796982296585,LonGen OPEL,Genes down-regulated in squamous cell carcinoma (SCC) compared to normal skin.,CGP,C2,227,294
Cohort,0.008975511195978772,0.04949321521708508,0.18134831525110578,0.8561485441647094,LGP Offspring,Genes up-regulated in squamous cell carcinoma (SCC) compared to normal skin.,CGP,C2,84,180
Cohort,0.019116370646689838,0.14147558206838534,0.13512134297104017,0.892548539240557,LGP Proband,Genes up-regulated in squamous cell carcinoma (SCC) compared to normal skin.,CGP,C2,84,255
Cohort,0.05668437017142675,0.04527388075067124,1.252032501556349,0.21092578126810163,LonGen OPEL,Genes up-regulated in squamous cell carcinoma (SCC) compared to normal skin.,CGP,C2,139,196
Cohort,-0.009597137989112395,0.011004825199551035,-0.8720845461047333,0.3834718864463198,LGP Offspring,Genes down-regulated in normal fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,5,7
Cohort,0.07607511832581512,0.03548865921968009,2.1436458857151743,0.03234987247701052,LGP Proband,Genes down-regulated in normal fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,5,16
Cohort,-0.002038364379909715,0.010612305602511574,-0.19207554477391822,0.8477320188983073,LonGen OPEL,Genes down-regulated in normal fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,9,8
Cohort,-0.03711125226900508,0.01633207340018735,-2.2722927677130915,0.02338206540127191,LGP Offspring,Genes down-regulated in hypertrophic scar fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,14,13
Cohort,0.03472632533292666,0.05196213613324727,0.6683005726299902,0.5041266589943941,LGP Proband,Genes down-regulated in hypertrophic scar fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,14,30
Cohort,-0.0017420344790744855,0.016072968967913104,-0.10838286831463156,0.9137193038384976,LonGen OPEL,Genes down-regulated in hypertrophic scar fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,19,19
Cohort,-0.05330422586987951,0.03272970586516186,-1.6286191537889003,0.10385957442084932,LGP Offspring,Genes up-regulated in hypertrophic scar fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,42,64
Cohort,-0.20128663268803404,0.0987263281612479,-2.0388343862974043,0.04178142742843883,LGP Proband,Genes up-regulated in hypertrophic scar fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,42,122
Cohort,-0.0705581972011109,0.028454490893294902,-2.479685806564103,0.013355720967079265,LonGen OPEL,Genes up-regulated in hypertrophic scar fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,71,63
Cohort,0.02851554231928859,0.040202964047866274,0.7092895510225948,0.47838936506514895,LGP Offspring,Genes up-regulated in normal fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,50,118
Cohort,-0.12426499898181424,0.11088390871048527,-1.12067657450881,0.2627481539319495,LGP Proband,Genes up-regulated in normal fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,50,158
Cohort,-0.03405434381916534,0.03364559379285516,-1.0121486940853748,0.3117745191272549,LonGen OPEL,Genes up-regulated in normal fibroblasts in response to IL6 [GeneID=3569].,CGP,C2,88,97
Cohort,-0.028515127281267653,0.035478851356925106,-0.8037218283759853,0.4218401682471167,LGP Offspring,Top 50 genes down-regulated in A549 cells (lung cancer) expressing STAT3 [GeneID=6774] off an adenovirus vector.,CGP,C2,42,77
Cohort,0.053288264463043765,0.09324314117512167,0.571497954610539,0.5678161260151708,LGP Proband,Top 50 genes down-regulated in A549 cells (lung cancer) expressing STAT3 [GeneID=6774] off an adenovirus vector.,CGP,C2,42,95
Cohort,-0.010866370276196509,0.0296911756982471,-0.36597979098678923,0.7144773974211709,LonGen OPEL,Top 50 genes down-regulated in A549 cells (lung cancer) expressing STAT3 [GeneID=6774] off an adenovirus vector.,CGP,C2,58,70
Cohort,0.03244374686351209,0.03568014609030422,0.9092941150352635,0.36351896844637877,LGP Offspring,Top 50 genes up-regulated in A549 cells (lung cancer) expressing STAT3 [GeneID=6774] off an adenovirus vector.,CGP,C2,33,90
Cohort,0.13170808733050515,0.09511505017338705,1.3847239431657972,0.16650722004953483,LGP Proband,Top 50 genes up-regulated in A549 cells (lung cancer) expressing STAT3 [GeneID=6774] off an adenovirus vector.,CGP,C2,33,117
Cohort,0.07604697530255138,0.03246424691313896,2.3424838871519786,0.019401362469445026,LonGen OPEL,Top 50 genes up-regulated in A549 cells (lung cancer) expressing STAT3 [GeneID=6774] off an adenovirus vector.,CGP,C2,59,99
Cohort,-0.01430743915174256,0.07857316680874703,-0.18209065171788147,0.8555661739248648,LGP Offspring,Genes down-regulated in mARMS (molecular ARMS) compared to the mERMS (molecular ERMS) class of rhabdomyosarcoma tumors.,CGP,C2,192,411
Cohort,-0.05142912666460225,0.20809747868603473,-0.24713959529608476,0.8048610149835143,LGP Proband,Genes down-regulated in mARMS (molecular ARMS) compared to the mERMS (molecular ERMS) class of rhabdomyosarcoma tumors.,CGP,C2,192,567
Cohort,0.046464341627854865,0.06556152958027019,0.7087135081399573,0.47870977903294254,LonGen OPEL,Genes down-regulated in mARMS (molecular ARMS) compared to the mERMS (molecular ERMS) class of rhabdomyosarcoma tumors.,CGP,C2,284,355
Cohort,-0.246937853635953,0.10080603688963256,-2.4496335859955765,0.014552816707588992,LGP Offspring,Genes up-regulated in mARMS (molecular ARMS) compared to the mERMS (molecular ERMS) class of rhabdomyosarcoma tumors.,CGP,C2,350,625
Cohort,-0.4039344006606348,0.27691665135015586,-1.458685848941122,0.14502808628992006,LGP Proband,Genes up-regulated in mARMS (molecular ARMS) compared to the mERMS (molecular ERMS) class of rhabdomyosarcoma tumors.,CGP,C2,350,878
Cohort,0.16848793807323725,0.09051356981088551,1.8614660589043992,0.06304679399254054,LonGen OPEL,Genes up-regulated in mARMS (molecular ARMS) compared to the mERMS (molecular ERMS) class of rhabdomyosarcoma tumors.,CGP,C2,488,650
Cohort,-0.0031280396110611453,0.014181878882074537,-0.22056595159720987,0.8254970118139049,LGP Offspring,'PAX-FKHR signature':  genes down-regulated by PAX3- or PAX7-FOXO1 [GeneID=5081;5077;2308] fusion in primary alveolar rhabdomyosarcoma(ARMS) tumors.,CGP,C2,7,13
Cohort,0.01950497030033445,0.035055892700369753,0.5563963373304347,0.5780891943035967,LGP Proband,'PAX-FKHR signature':  genes down-regulated by PAX3- or PAX7-FOXO1 [GeneID=5081;5077;2308] fusion in primary alveolar rhabdomyosarcoma(ARMS) tumors.,CGP,C2,7,14
Cohort,0.008666533097766719,0.01119477521581252,0.7741587419750348,0.43906679203029575,LonGen OPEL,'PAX-FKHR signature':  genes down-regulated by PAX3- or PAX7-FOXO1 [GeneID=5081;5077;2308] fusion in primary alveolar rhabdomyosarcoma(ARMS) tumors.,CGP,C2,6,13
Cohort,0.04413042818240159,0.04216150538384042,1.046699537424862,0.2956122810142826,LGP Offspring,'PAX-FKHR signature':  genes up-regulated by PAX3- or PAX7-FOXO1 [GeneID=5081;5077;2308] fusion in primary alveolar rhabdomyosarcoma(ARMS) tumors.,CGP,C2,48,119
Cohort,0.0076206763076517945,0.12022830448497802,0.06338504348286773,0.9494750850051314,LGP Proband,'PAX-FKHR signature':  genes up-regulated by PAX3- or PAX7-FOXO1 [GeneID=5081;5077;2308] fusion in primary alveolar rhabdomyosarcoma(ARMS) tumors.,CGP,C2,48,179
Cohort,0.05334696379320864,0.03498733040423966,1.5247509077384258,0.1277184311387906,LonGen OPEL,'PAX-FKHR signature':  genes up-regulated by PAX3- or PAX7-FOXO1 [GeneID=5081;5077;2308] fusion in primary alveolar rhabdomyosarcoma(ARMS) tumors.,CGP,C2,75,105
Cohort,-0.01775244424174663,0.014280988336686399,-1.243082328982961,0.21426846432975633,LGP Offspring,Genes down-regulated in RMS cells (rhabdomyosarcoma) expressing PAX3 or PAX7 fusions with FOXO1 [GeneID=5077;5081;2308] compared to the fusion negative cell lines.,CGP,C2,9,12
Cohort,0.04070329773547768,0.04523982038622587,0.8997227970398967,0.36852749325775125,LGP Proband,Genes down-regulated in RMS cells (rhabdomyosarcoma) expressing PAX3 or PAX7 fusions with FOXO1 [GeneID=5077;5081;2308] compared to the fusion negative cell lines.,CGP,C2,9,24
Cohort,-0.00981477357412995,0.013913656135139587,-0.7054057882990427,0.48076411218014536,LonGen OPEL,Genes down-regulated in RMS cells (rhabdomyosarcoma) expressing PAX3 or PAX7 fusions with FOXO1 [GeneID=5077;5081;2308] compared to the fusion negative cell lines.,CGP,C2,14,17
Cohort,-0.010577476130352556,0.05146723189882644,-0.205518652161935,0.8372287991624503,LGP Offspring,Genes up-regulated in RMS cells (rhabdomyosarcoma) expressing PAX3 or PAX7 fusions with FOXO1 [GeneID=5077;5081;2308] compared to the fusion negative cell lines.,CGP,C2,85,172
Cohort,0.10841918531430637,0.14575839081882944,0.7438280891085449,0.45718998718858506,LGP Proband,Genes up-regulated in RMS cells (rhabdomyosarcoma) expressing PAX3 or PAX7 fusions with FOXO1 [GeneID=5077;5081;2308] compared to the fusion negative cell lines.,CGP,C2,85,235
Cohort,0.0791447128376758,0.042312871436279736,1.8704642382132413,0.06178614540213559,LonGen OPEL,Genes up-regulated in RMS cells (rhabdomyosarcoma) expressing PAX3 or PAX7 fusions with FOXO1 [GeneID=5077;5081;2308] compared to the fusion negative cell lines.,CGP,C2,105,155
Cohort,-0.006411595443208511,0.04982455175511758,-0.12868345458923194,0.8976464025587257,LGP Offspring,"Genes down-regulated in RD cells (embryonal rhabdomyosarcoma, ERMS) by expression of PAX3- or PAX7-FOXO1 [GeneID=5077;5081;2308] fusions off retroviral vectors.",CGP,C2,80,162
Cohort,0.11245879841646605,0.13749409343941416,0.8179173054151615,0.41363802062759036,LGP Proband,"Genes down-regulated in RD cells (embryonal rhabdomyosarcoma, ERMS) by expression of PAX3- or PAX7-FOXO1 [GeneID=5077;5081;2308] fusions off retroviral vectors.",CGP,C2,80,233
Cohort,0.03321441989371241,0.04193813315713439,0.7919861327461609,0.42860471148491874,LonGen OPEL,"Genes down-regulated in RD cells (embryonal rhabdomyosarcoma, ERMS) by expression of PAX3- or PAX7-FOXO1 [GeneID=5077;5081;2308] fusions off retroviral vectors.",CGP,C2,122,162
Cohort,-0.002581655739267802,0.09615299215652397,-0.02684945815378494,0.9785877295234697,LGP Offspring,"Genes up-regulated in RD cells (embryonal rhabdomyosarcoma, ERMS) by expression of PAX3- or PAX7-FOXO1 [GeneID=5077;5081;2308] fusions off retroviral vectors.",CGP,C2,263,546
Cohort,-0.1770836161973067,0.25847691996708794,-0.6851041718535446,0.493468550647829,LGP Proband,"Genes up-regulated in RD cells (embryonal rhabdomyosarcoma, ERMS) by expression of PAX3- or PAX7-FOXO1 [GeneID=5077;5081;2308] fusions off retroviral vectors.",CGP,C2,263,738
Cohort,-0.0663194232060857,0.07532051678284803,-0.8804961256079427,0.3788563615977114,LonGen OPEL,"Genes up-regulated in RD cells (embryonal rhabdomyosarcoma, ERMS) by expression of PAX3- or PAX7-FOXO1 [GeneID=5077;5081;2308] fusions off retroviral vectors.",CGP,C2,395,440
Cohort,-0.032916625387671795,0.030279394404188496,-1.0870965564330606,0.27738159667348256,LGP Offspring,Genes down-regulated in multiple myeloma (MM) compared to monoclonal gammopathy of uncertain significance (MGUS).,CGP,C2,34,57
Cohort,-0.026537394925731338,0.08374806847636232,-0.31687172502636823,0.7514202382193824,LGP Proband,Genes down-regulated in multiple myeloma (MM) compared to monoclonal gammopathy of uncertain significance (MGUS).,CGP,C2,34,80
Cohort,0.009042269151396436,0.02697628541229051,0.3351932637573867,0.7375676179408073,LonGen OPEL,Genes down-regulated in multiple myeloma (MM) compared to monoclonal gammopathy of uncertain significance (MGUS).,CGP,C2,49,57
Cohort,-0.014327469367511081,0.029375298537487236,-0.4877386811653031,0.6258930913689604,LGP Offspring,Genes up-regulated in multiple myeloma (MM) compared to monoclonal gammopathy of uncertain significance (MGUS).,CGP,C2,29,54
Cohort,-0.06003544451351637,0.08353932477421105,-0.7186489078739785,0.4725585565622148,LGP Proband,Genes up-regulated in multiple myeloma (MM) compared to monoclonal gammopathy of uncertain significance (MGUS).,CGP,C2,29,78
Cohort,-0.0176176748934903,0.022764077045525508,-0.7739244098610718,0.43920528232893596,LonGen OPEL,Genes up-regulated in multiple myeloma (MM) compared to monoclonal gammopathy of uncertain significance (MGUS).,CGP,C2,37,44
Cohort,-0.03268256204933977,0.04553913808568527,-0.7176807340500186,0.47320209382679956,LGP Offspring,Genes hypermethylated in at least one of the lymphoma tumors of transgenic mice overexpressing TCL1 [GeneID=8115] in germinal center B lymphocytes.,CGP,C2,69,138
Cohort,0.09927948196568649,0.13057309283956964,0.7603364506933105,0.44726838929963253,LGP Proband,Genes hypermethylated in at least one of the lymphoma tumors of transgenic mice overexpressing TCL1 [GeneID=8115] in germinal center B lymphocytes.,CGP,C2,69,186
Cohort,-0.009518623895400305,0.03818728111554475,-0.24926162893345122,0.8032227143118006,LonGen OPEL,Genes hypermethylated in at least one of the lymphoma tumors of transgenic mice overexpressing TCL1 [GeneID=8115] in germinal center B lymphocytes.,CGP,C2,104,107
Cohort,-0.20505482174516987,0.11462489432823846,-1.7889204866612778,0.07407525641184506,LGP Offspring,Genes down-regulated in NHEK cells (normal keratinocytes) by UV-B irradiation.,CGP,C2,416,764
Cohort,-0.4058462047280168,0.3022669019804047,-1.3426749739021275,0.17974256075784606,LGP Proband,Genes down-regulated in NHEK cells (normal keratinocytes) by UV-B irradiation.,CGP,C2,416,1134
Cohort,-0.22756851218538207,0.09781522684186503,-2.3265141791603194,0.02024129519940108,LonGen OPEL,Genes down-regulated in NHEK cells (normal keratinocytes) by UV-B irradiation.,CGP,C2,685,732
Cohort,0.015402893739431767,0.06873759288314471,0.22408253029193204,0.8227607923734318,LGP Offspring,Genes up-regulated in NHEK cells (normal keratinocytes) by UV-B irradiation.,CGP,C2,140,305
Cohort,-0.14163615560847687,0.1858344678480197,-0.7621630004844452,0.4461782119368519,LGP Proband,Genes up-regulated in NHEK cells (normal keratinocytes) by UV-B irradiation.,CGP,C2,140,406
Cohort,-0.05592340498794235,0.05285469634383243,-1.0580593373225955,0.29034936748505996,LonGen OPEL,Genes up-regulated in NHEK cells (normal keratinocytes) by UV-B irradiation.,CGP,C2,208,217
Cohort,-0.020795179230596622,0.04696193120105939,-0.44280928613360593,0.6580453427696271,LGP Offspring,Genes down-regulated in SCC12B2 cells (squamous cell carcinoma) by UV-B irradiation.,CGP,C2,75,145
Cohort,-0.08125199712407645,0.12528600396937659,-0.6485321149195302,0.5168193681155444,LGP Proband,Genes down-regulated in SCC12B2 cells (squamous cell carcinoma) by UV-B irradiation.,CGP,C2,75,205
Cohort,-0.011881100262132778,0.04331685054581355,-0.2742835666126482,0.7839378763416565,LonGen OPEL,Genes down-regulated in SCC12B2 cells (squamous cell carcinoma) by UV-B irradiation.,CGP,C2,125,148
Cohort,0.05677485002321713,0.03961603705478776,1.4331279513066706,0.1522835816793244,LGP Offspring,Genes up-regulated in SCC12B2 cells (squamous cell carcinoma) by UV-B irradiation.,CGP,C2,39,109
Cohort,0.10167609112134003,0.11367299513730725,0.8944612658312031,0.37133320001090797,LGP Proband,Genes up-regulated in SCC12B2 cells (squamous cell carcinoma) by UV-B irradiation.,CGP,C2,39,169
Cohort,-0.017678919822382497,0.03896826910003111,-0.45367475206560776,0.650186599056504,LonGen OPEL,Genes up-regulated in SCC12B2 cells (squamous cell carcinoma) by UV-B irradiation.,CGP,C2,105,118
Cohort,-0.03216544129866777,0.042813207395809565,-0.7512971640105626,0.45273529799799994,LGP Offspring,Cluster G1: genes most highly up-regulated in NHEK cells (normal keratinocyte) between 6 h and 12 h after UV-B irradiation.,CGP,C2,65,118
Cohort,-0.03741328513579333,0.11398472758021504,-0.3282306843209701,0.7428196370885434,LGP Proband,Cluster G1: genes most highly up-regulated in NHEK cells (normal keratinocyte) between 6 h and 12 h after UV-B irradiation.,CGP,C2,65,141
Cohort,-0.019850505767953355,0.032605182549484794,-0.6088144342644394,0.5428211448129553,LonGen OPEL,Cluster G1: genes most highly up-regulated in NHEK cells (normal keratinocyte) between 6 h and 12 h after UV-B irradiation.,CGP,C2,74,76
Cohort,-0.012122188693266658,0.01645774937771238,-0.7365641811074679,0.46164295396624455,LGP Offspring,Cluster G2: genes increasingly up-regulated in NHEK cells (normal keratinocyte) and reaching maximum levels at 12 h and 24 h after UV-B irradiation.,CGP,C2,10,15
Cohort,-0.01810415171101535,0.04838740933132143,-0.374150051866828,0.7083877843080661,LGP Proband,Cluster G2: genes increasingly up-regulated in NHEK cells (normal keratinocyte) and reaching maximum levels at 12 h and 24 h after UV-B irradiation.,CGP,C2,10,27
Cohort,0.009938749065786796,0.012471628293279956,0.7969086980520464,0.4257416846258427,LonGen OPEL,Cluster G2: genes increasingly up-regulated in NHEK cells (normal keratinocyte) and reaching maximum levels at 12 h and 24 h after UV-B irradiation.,CGP,C2,11,13
Cohort,0.023682793860481836,0.02061695974508128,1.1487044721097635,0.2510841526238895,LGP Offspring,Cluster G24: genes induced in NHEK (normal keratinocyte) but not in SCC12B2 cells (squamous cell carcinoma) by UV-B radiation.,CGP,C2,10,30
Cohort,6.531575636141392e-5,0.05550152272922857,0.0011768281868601222,0.9990613086004054,LGP Proband,Cluster G24: genes induced in NHEK (normal keratinocyte) but not in SCC12B2 cells (squamous cell carcinoma) by UV-B radiation.,CGP,C2,10,38
Cohort,-0.01978011187255566,0.02142672361829607,-0.9231514917971694,0.35620799853976204,LonGen OPEL,Cluster G24: genes induced in NHEK (normal keratinocyte) but not in SCC12B2 cells (squamous cell carcinoma) by UV-B radiation.,CGP,C2,34,39
Cohort,0.008733481774445448,0.0084608116320821,1.0322274214603036,0.30233473930105637,LGP Offspring,Cluster G28: genes differentially up-regulated in NHEK (normal keratinocyte) compared to SCC12B2 cells (squamous cell carcinoma) by UV-B radiation.,CGP,C2,1,6
Cohort,-0.008211033856950316,0.02369705775986331,-0.34650014107901966,0.7290542792701877,LGP Proband,Cluster G28: genes differentially up-regulated in NHEK (normal keratinocyte) compared to SCC12B2 cells (squamous cell carcinoma) by UV-B radiation.,CGP,C2,1,8
Cohort,0.005211110835894621,0.008169780343452171,0.6378520127620281,0.5237534569239366,LonGen OPEL,Cluster G28: genes differentially up-regulated in NHEK (normal keratinocyte) compared to SCC12B2 cells (squamous cell carcinoma) by UV-B radiation.,CGP,C2,4,6
Cohort,0.018056832898043187,0.02650208207689854,0.6813363888033179,0.49589199689338725,LGP Offspring,Cluster G3: genes increasingly up-regulated in NHEK cells (normal keratinocyte) after 6 h time point upon UV-B irradiation.,CGP,C2,21,51
Cohort,-0.007511578434365392,0.07226696025361354,-0.10394208374067862,0.9172402996442797,LGP Proband,Cluster G3: genes increasingly up-regulated in NHEK cells (normal keratinocyte) after 6 h time point upon UV-B irradiation.,CGP,C2,21,68
Cohort,0.025688027387189852,0.021060064590111616,1.219750645933499,0.22292068896039072,LonGen OPEL,Cluster G3: genes increasingly up-regulated in NHEK cells (normal keratinocyte) after 6 h time point upon UV-B irradiation.,CGP,C2,29,42
Cohort,0.02494873820961417,0.01755212025010128,1.4214088015645978,0.15565909911678372,LGP Offspring,Cluster G4: genes increasingly up-regulated in NHEK cells (normal keratinocyte) after 12 h time point after UV-B irradiation.,CGP,C2,6,25
Cohort,0.01684473229355864,0.055069297382189984,0.3058824625390338,0.7597704745827858,LGP Proband,Cluster G4: genes increasingly up-regulated in NHEK cells (normal keratinocyte) after 12 h time point after UV-B irradiation.,CGP,C2,6,41
Cohort,0.00803609582654099,0.0184390521700232,0.4358193551621628,0.6630859605512252,LonGen OPEL,Cluster G4: genes increasingly up-regulated in NHEK cells (normal keratinocyte) after 12 h time point after UV-B irradiation.,CGP,C2,21,34
Cohort,-0.013242782072777967,0.01893903942374955,-0.6992319819648045,0.484647578802896,LGP Offspring,Cluster G5: genes up-regulated in NHEK cells (normal keratinocyte) at 3 h and 24 h time points after UV-B irradiation.,CGP,C2,12,23
Cohort,-0.09666027128485247,0.0575749977969054,-1.6788584452199122,0.09355422203300286,LGP Proband,Cluster G5: genes up-regulated in NHEK cells (normal keratinocyte) at 3 h and 24 h time points after UV-B irradiation.,CGP,C2,12,43
Cohort,-0.021511849496224946,0.013264267957027153,-1.6217894244837223,0.10524443745248654,LonGen OPEL,Cluster G5: genes up-regulated in NHEK cells (normal keratinocyte) at 3 h and 24 h time points after UV-B irradiation.,CGP,C2,17,10
Cohort,-0.1556421549786336,0.07704797275338487,-2.020068139583801,0.04377027651881265,LGP Offspring,Cluster G6: genes increasingly down-regulated in NHEK cells (normal keratinocyte) after UV-B irradiation.,CGP,C2,211,375
Cohort,0.07291071617700919,0.2168849754619965,0.33617227759414303,0.7368255167320372,LGP Proband,Cluster G6: genes increasingly down-regulated in NHEK cells (normal keratinocyte) after UV-B irradiation.,CGP,C2,211,565
Cohort,-0.033027147547885397,0.06952370682075636,-0.47504871443398233,0.6348825662172515,LonGen OPEL,Cluster G6: genes increasingly down-regulated in NHEK cells (normal keratinocyte) after UV-B irradiation.,CGP,C2,318,371
Cohort,0.007445635463325513,0.05248767121441667,0.1418549402374788,0.8872368516007398,LGP Offspring,Genes down-regulated in SaOS-2 cells (osteosarcoma) upon knockdown of YY1 [GeneID=7528] by RNAi.,CGP,C2,85,190
Cohort,0.01520157718885087,0.14293122861237662,0.10635588412996083,0.915325570198365,LGP Proband,Genes down-regulated in SaOS-2 cells (osteosarcoma) upon knockdown of YY1 [GeneID=7528] by RNAi.,CGP,C2,85,263
Cohort,0.006084525749076357,0.04481909116195347,0.1357574549445897,0.8920473490601886,LonGen OPEL,Genes down-regulated in SaOS-2 cells (osteosarcoma) upon knockdown of YY1 [GeneID=7528] by RNAi.,CGP,C2,132,161
Cohort,0.012384989780340751,0.025650053665922677,0.48284459524522566,0.62936240905124885,LGP Offspring,Genes up-regulated in SaOS-2 cells (osteosarcoma) upon knockdown of YY1 [GeneID=7528] by RNAi.,CGP,C2,17,42
Cohort,0.01527808668420271,0.07215460550529035,0.2117409772697396,0.8323608500940421,LGP Proband,Genes up-regulated in SaOS-2 cells (osteosarcoma) upon knockdown of YY1 [GeneID=7528] by RNAi.,CGP,C2,17,61
Cohort,0.006522926073817378,0.021892230537217245,0.2979562115759867,0.7658143358795192,LonGen OPEL,Genes up-regulated in SaOS-2 cells (osteosarcoma) upon knockdown of YY1 [GeneID=7528] by RNAi.,CGP,C2,28,39
Cohort,-0.3142452486919083,0.12065486783240524,-2.604497061224321,0.009403132088414198,LGP Offspring,"Genes down-regulated in HEK293 cells (embryonic kidney) at 6 h, 12 h or 24 h after infection with reovirus strain T3A (known as a strong inducer of apoptosis).",CGP,C2,480,857
Cohort,-0.3728237500660167,0.3155856912156037,-1.1813708936863958,0.23779217703206051,LGP Proband,"Genes down-regulated in HEK293 cells (embryonic kidney) at 6 h, 12 h or 24 h after infection with reovirus strain T3A (known as a strong inducer of apoptosis).",CGP,C2,480,1199
Cohort,-0.06907863329263683,0.10133688457660368,-0.6816731497248483,0.49564392981941174,LonGen OPEL,"Genes down-regulated in HEK293 cells (embryonic kidney) at 6 h, 12 h or 24 h after infection with reovirus strain T3A (known as a strong inducer of apoptosis).",CGP,C2,744,863
Cohort,-0.07599947430920688,0.07571797731855835,-1.0037177035179403,0.31587384126106244,LGP Offspring,"Genes up-regulated in HEK293 cells (embryonic kidney) at 6 h, 12 h or 24 h after infection with reovirus strain T3A (known as a strong inducer of apoptosis).",CGP,C2,204,377
Cohort,-0.5572635172940282,0.2071499703396924,-2.690145291260271,0.007284883016654191,LGP Proband,"Genes up-regulated in HEK293 cells (embryonic kidney) at 6 h, 12 h or 24 h after infection with reovirus strain T3A (known as a strong inducer of apoptosis).",CGP,C2,204,529
Cohort,-0.09012919525455039,0.06841815711283468,-1.3173286019076784,0.18810755958424072,LonGen OPEL,"Genes up-regulated in HEK293 cells (embryonic kidney) at 6 h, 12 h or 24 h after infection with reovirus strain T3A (known as a strong inducer of apoptosis).",CGP,C2,303,334
Cohort,-0.0017576197700939764,0.013388850604750181,-0.13127488101707527,0.895596920031226,LGP Offspring,NF-kB-driven pro-inflammatory genes that are  negatively regulated by glucocorticoids.,CGP,C2,7,11
Cohort,-0.11166438639024058,0.04459292430109515,-2.504083061166236,0.012466851156945999,LGP Proband,NF-kB-driven pro-inflammatory genes that are  negatively regulated by glucocorticoids.,CGP,C2,7,22
Cohort,-0.006391352839854761,0.014041628281817086,-0.45517177292971855,0.6491097868769478,LonGen OPEL,NF-kB-driven pro-inflammatory genes that are  negatively regulated by glucocorticoids.,CGP,C2,13,13
Cohort,-0.1890334985432523,0.11280167935609929,-1.675803938578784,0.0942390153261385,LGP Offspring,"Genes with DNA sequences bound by RARA and RARG [GeneID=5914, 5916] in ES cells.",CGP,C2,418,806
Cohort,-0.5468604457440952,0.2973541926069145,-1.8390877254823643,0.06625762658734301,LGP Proband,"Genes with DNA sequences bound by RARA and RARG [GeneID=5914, 5916] in ES cells.",CGP,C2,418,1064
Cohort,0.323513845969382,0.0984078069287153,3.2874815125565102,0.0010552129671767617,LonGen OPEL,"Genes with DNA sequences bound by RARA and RARG [GeneID=5914, 5916] in ES cells.",CGP,C2,567,826
Cohort,0.006683904848354,0.02432492599057055,0.2747759582473133,0.7835723242444484,LGP Offspring,"Genes bound by RARG [GeneID=5916] and down-regulated by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] in MEF cells (embryonic fibroblast).",CGP,C2,17,41
Cohort,-0.006921287868844878,0.06208336217193358,-0.11148377965866398,0.9112595514956645,LGP Proband,"Genes bound by RARG [GeneID=5916] and down-regulated by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] in MEF cells (embryonic fibroblast).",CGP,C2,17,45
Cohort,7.871862648919729e-4,0.019299269666105776,0.04078839658240871,0.9674748179699947,LonGen OPEL,"Genes bound by RARG [GeneID=5916] and down-regulated by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] in MEF cells (embryonic fibroblast).",CGP,C2,26,34
Cohort,-0.07966872422575634,0.042943212503148115,-1.85521109348575,0.06400122108031898,LGP Offspring,"Genes bound by RARG [GeneID=5916] and up-regulated by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] in MEF cells (embryonic fibroblast).",CGP,C2,75,125
Cohort,-0.11128484201222333,0.12041143567971213,-0.9242049260855502,0.35564694917657835,LGP Proband,"Genes bound by RARG [GeneID=5916] and up-regulated by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] in MEF cells (embryonic fibroblast).",CGP,C2,75,166
Cohort,-0.024809616037228876,0.037489704135505,-0.6617714545720482,0.5083092251037469,LonGen OPEL,"Genes bound by RARG [GeneID=5916] and up-regulated by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] in MEF cells (embryonic fibroblast).",CGP,C2,103,110
Cohort,-0.19144367363034745,0.10197477252293553,-1.8773630859268564,0.06089873235854659,LGP Offspring,Genes with DNA sequences bound by RARG [GeneID=5916] in MEF cells (embryonic fibroblast).,CGP,C2,349,660
Cohort,-0.33815273672837415,0.2762113312898061,-1.2242536725387925,0.22120226135118745,LGP Proband,Genes with DNA sequences bound by RARG [GeneID=5916] in MEF cells (embryonic fibroblast).,CGP,C2,349,873
Cohort,-0.09197117006365213,0.08720876496374945,-1.0546092483006988,0.29192406605679894,LonGen OPEL,Genes with DNA sequences bound by RARG [GeneID=5916] in MEF cells (embryonic fibroblast).,CGP,C2,548,620
Cohort,-0.010408224299183682,0.04297862969101374,-0.2421720835217765,0.8087202750617846,LGP Offspring,Genes down-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MyoD [GeneID=4654] differentiation program.,CGP,C2,59,123
Cohort,0.022667156021775978,0.11625288108494644,0.1949814560312961,0.8454549535768494,LGP Proband,Genes down-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MyoD [GeneID=4654] differentiation program.,CGP,C2,59,156
Cohort,-0.04153059771206245,0.03762023654581391,-1.1039430244274648,0.26995145760184874,LonGen OPEL,Genes down-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MyoD [GeneID=4654] differentiation program.,CGP,C2,111,103
Cohort,-0.03430225452856062,0.05078993567802298,-0.6753750338652891,0.49966847031686024,LGP Offspring,Genes up-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MyoD [GeneID=4654] differentiation program.,CGP,C2,86,169
Cohort,-0.17739166543549384,0.14278521973353064,-1.2423671425274032,0.2144503459068496,LGP Proband,Genes up-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MyoD [GeneID=4654] differentiation program.,CGP,C2,86,244
Cohort,0.08708941425228081,0.04508221137272317,1.9317910901099664,0.05373992752958312,LonGen OPEL,Genes up-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MyoD [GeneID=4654] differentiation program.,CGP,C2,129,184
Cohort,3.448198136364883e-4,0.010048559124436187,0.034315349033271055,0.9726358150214531,LGP Offspring,Genes up-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MYOD [GeneID=4654] which were down-regulated by dominant negative form of SMARCA4 [GeneID=6597].,CGP,C2,3,7
Cohort,-0.010058094866479662,0.024491772808265835,-0.41067238967222136,0.6814182618126532,LGP Proband,Genes up-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MYOD [GeneID=4654] which were down-regulated by dominant negative form of SMARCA4 [GeneID=6597].,CGP,C2,3,7
Cohort,0.009960628285049823,0.00893656620296071,1.1145923455196738,0.26536156262429605,LonGen OPEL,Genes up-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MYOD [GeneID=4654] which were down-regulated by dominant negative form of SMARCA4 [GeneID=6597].,CGP,C2,4,8
Cohort,0.003808671504791267,0.020131541902144542,0.18918925948665374,0.8500012722025363,LGP Offspring,Genes up-regulated in HT-29 cells (colon cancer) by the combination of trichostatin A (TSA) and sodium butyrate [PubChem=5562;5222465].,CGP,C2,12,27
Cohort,-0.0475269500798616,0.05224806383898948,-0.9096404074670265,0.36327498362084154,LGP Proband,Genes up-regulated in HT-29 cells (colon cancer) by the combination of trichostatin A (TSA) and sodium butyrate [PubChem=5562;5222465].,CGP,C2,12,30
Cohort,-0.025155979674259196,0.015816749098070713,-1.5904646092747123,0.11212716779443346,LonGen OPEL,Genes up-regulated in HT-29 cells (colon cancer) by the combination of trichostatin A (TSA) and sodium butyrate [PubChem=5562;5222465].,CGP,C2,21,18
Cohort,0.02856030176997249,0.026824751134773877,1.0646995987578336,0.2873920362183501,LGP Offspring,Genes down-regulated in DL23 cells (colon cancer) upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,17,48
Cohort,0.05156826549055941,0.06896296332683881,0.7477675407618428,0.4548111725886832,LGP Proband,Genes down-regulated in DL23 cells (colon cancer) upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,17,63
Cohort,0.018515209799683272,0.023548942114155907,0.7862438027971235,0.43195866101415625,LonGen OPEL,Genes down-regulated in DL23 cells (colon cancer) upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,33,50
Cohort,-0.04254905079071146,0.04223856569300902,-1.007350749075124,0.31412668234727875,LGP Offspring,Genes up-regulated in DL23 cells (colon cancer) upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,76,136
Cohort,-0.2737841730951278,0.12217038714259047,-2.2410027462349134,0.025288318604508277,LGP Proband,Genes up-regulated in DL23 cells (colon cancer) upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,76,183
Cohort,-0.01566099669507208,0.038396540403380405,-0.40787520257146126,0.6834749781871271,LonGen OPEL,Genes up-regulated in DL23 cells (colon cancer) upon expression of an activated form of FOXO3 [GeneID=2309].,CGP,C2,101,115
Cohort,-0.04974480162676396,0.09320348899185026,-0.53372252653668,0.5937089683125806,LGP Offspring,Genes down-regulated in papillary thyroid carcinoma (PTC) compared to normal tissue.,CGP,C2,292,611
Cohort,0.11712406090261847,0.2713339197462185,0.4316602252020899,0.6660999438677844,LGP Proband,Genes down-regulated in papillary thyroid carcinoma (PTC) compared to normal tissue.,CGP,C2,292,832
Cohort,0.010986179085999305,0.08188356193046,0.13416830957267553,0.89330339923634,LonGen OPEL,Genes down-regulated in papillary thyroid carcinoma (PTC) compared to normal tissue.,CGP,C2,461,545
Cohort,-0.09568886458052907,0.11340310510967275,-0.8437940432758685,0.3990829901336198,LGP Offspring,Genes up-regulated in papillary thyroid carcinoma (PTC) compared to normal tissue.,CGP,C2,452,892
Cohort,-0.9085945902349336,0.3287106727794254,-2.7641164874638173,0.0058335920520444,LGP Proband,Genes up-regulated in papillary thyroid carcinoma (PTC) compared to normal tissue.,CGP,C2,452,1223
Cohort,0.11077264599084448,0.10529448028310583,1.0520270929018263,0.2931063750736778,LonGen OPEL,Genes up-regulated in papillary thyroid carcinoma (PTC) compared to normal tissue.,CGP,C2,724,914
Cohort,-0.01940204893015901,0.01712657365039398,-1.1328622599134233,0.2576737390801071,LGP Offspring,"Genes consistently underexpressed with age, based on meta-analysis of microarray data.",CGP,C2,13,18
Cohort,-0.023587389205954445,0.05218593678671245,-0.45198746364097564,0.6513955395885153,LGP Proband,"Genes consistently underexpressed with age, based on meta-analysis of microarray data.",CGP,C2,13,32
Cohort,-0.0013594530814426751,0.013811838927547549,-0.09842665329171064,0.9216182907715593,LonGen OPEL,"Genes consistently underexpressed with age, based on meta-analysis of microarray data.",CGP,C2,12,15
Cohort,0.04594356383908372,0.03731693506553766,1.2311719533878007,0.21868671719878513,LGP Offspring,"Genes consistently overexpressed with age, based on meta-analysis of microarray data.",CGP,C2,35,90
Cohort,0.0013712882687417856,0.0968333100607789,0.014161328037646092,0.9887046594996659,LGP Proband,"Genes consistently overexpressed with age, based on meta-analysis of microarray data.",CGP,C2,35,110
Cohort,0.04569662056249752,0.03372770574064933,1.3548689292382852,0.17584370980047256,LonGen OPEL,"Genes consistently overexpressed with age, based on meta-analysis of microarray data.",CGP,C2,64,96
Cohort,0.0026168644677817183,0.018530853737453376,0.14121661661452106,0.8877408904528348,LGP Offspring,Proteins shown to interact with LCA5 [GeneID=167691] in vivo.,CGP,C2,11,25
Cohort,0.06373161039638939,0.04875202399596947,1.3072608103749361,0.19148443578906138,LGP Proband,Proteins shown to interact with LCA5 [GeneID=167691] in vivo.,CGP,C2,11,29
Cohort,0.011609889744084865,0.017744206279898013,0.6542918607318847,0.5131127781783612,LonGen OPEL,Proteins shown to interact with LCA5 [GeneID=167691] in vivo.,CGP,C2,20,30
Cohort,-0.0016058253594188826,0.007205432898882975,-0.22286313424247226,0.8237093510710447,LGP Offspring,Genes down-regulated in HT1080 cells (fibrosarcoma) by treatment with interferon alpha for 6 h.,CGP,C2,2,3
Cohort,0.015176532282700463,0.023697909833029523,0.6404164919873149,0.5220777714427305,LGP Proband,Genes down-regulated in HT1080 cells (fibrosarcoma) by treatment with interferon alpha for 6 h.,CGP,C2,2,7
Cohort,-6.537026110264552e-4,0.00633055104958872,-0.10326156536861425,0.9177813881456924,LonGen OPEL,Genes down-regulated in HT1080 cells (fibrosarcoma) by treatment with interferon alpha for 6 h.,CGP,C2,3,3
Cohort,0.018377740719913722,0.03380188081841231,0.5436898857386402,0.5868341452312416,LGP Offspring,Genes up-regulated in HT1080 cells (fibrosarcoma) by treatment with interferon alpha for 6 h.,CGP,C2,38,81
Cohort,-0.11888296529244917,0.09184198276047154,-1.2944294288865894,0.1958754148433829,LGP Proband,Genes up-regulated in HT1080 cells (fibrosarcoma) by treatment with interferon alpha for 6 h.,CGP,C2,38,96
Cohort,1.876554916169372e-4,0.028775849957058244,0.006521284059270971,0.9947984389706002,LonGen OPEL,Genes up-regulated in HT1080 cells (fibrosarcoma) by treatment with interferon alpha for 6 h.,CGP,C2,60,73
Cohort,0.008618836941244292,0.00900229220399007,0.9574047082613226,0.338705291981773,LGP Offspring,Genes down-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon beta for 6 h.,CGP,C2,1,7
Cohort,0.0013795117665128121,0.02767244073020927,0.04985146702317572,0.9602526890529175,LGP Proband,Genes down-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon beta for 6 h.,CGP,C2,1,12
Cohort,0.008345954006812947,0.008597844214154847,0.9707030970708673,0.3319910106083658,LonGen OPEL,Genes down-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon beta for 6 h.,CGP,C2,3,8
Cohort,-0.021040222781828734,0.046590491793311505,-0.45159907036759916,0.651702687371831,LGP Offspring,Genes up-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon beta for 6 h.,CGP,C2,77,140
Cohort,-0.24502029472216053,0.12752688997255723,-1.921322591454139,0.05503160483260101,LGP Proband,Genes up-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon beta for 6 h.,CGP,C2,77,173
Cohort,-0.017142247540694405,0.04106687662423449,-0.4174227248287584,0.6764817962196377,LonGen OPEL,Genes up-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon beta for 6 h.,CGP,C2,122,138
Cohort,-0.02020160193668457,0.017276610883722288,-1.169303520965339,0.24269349765132286,LGP Offspring,Genes down-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon gamma for 6 h.,CGP,C2,12,18
Cohort,0.0463541178093736,0.057036478634121715,0.8127100220672204,0.41661626096840265,LGP Proband,Genes down-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon gamma for 6 h.,CGP,C2,12,39
Cohort,0.01926177420135717,0.01349376681469639,1.427457170845631,0.15384033028164984,LonGen OPEL,Genes down-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon gamma for 6 h.,CGP,C2,9,19
Cohort,-0.0064562798109288645,0.0347848101479733,-0.18560629721605748,0.8528091914695093,LGP Offspring,Genes up-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon gamma for 6 h.,CGP,C2,45,82
Cohort,-0.15986580609463333,0.08957451235136259,-1.784724269193317,0.07466944422041162,LGP Proband,Genes up-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon gamma for 6 h.,CGP,C2,45,86
Cohort,-0.01911223239788479,0.031013411312546472,-0.6162570187869961,0.5379010889941354,LonGen OPEL,Genes up-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon gamma for 6 h.,CGP,C2,70,76
Cohort,-0.041802899771562894,0.025624604657591945,-1.6313578425951527,0.1032805844938237,LGP Offspring,"Genes up-regulated in the extracellular matrix-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,30,41
Cohort,-0.15381749469097233,0.0712407411787815,-2.159122605209302,0.031125185242932608,LGP Proband,"Genes up-regulated in the extracellular matrix-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,30,54
Cohort,-0.00912479517650303,0.021720366310214578,-0.42010319007427854,0.6745234447779556,LonGen OPEL,"Genes up-regulated in the extracellular matrix-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,35,42
Cohort,0.004773575636920715,0.0796596154716222,0.05992466331476638,0.9522333473871567,LGP Offspring,"Genes up-regulated in the periportal-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,206,440
Cohort,0.009166224610895692,0.22138820983119664,0.04140340001793558,0.9669842119062751,LGP Proband,"Genes up-regulated in the periportal-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,206,589
Cohort,-0.09487267098057028,0.07117533256058917,-1.3329431358793915,0.18293184659537165,LonGen OPEL,"Genes up-regulated in the periportal-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,360,388
Cohort,0.010611793162822236,0.07090330970600056,0.14966569553415585,0.8810730149335418,LGP Offspring,"Genes up-regulated in the perivenous-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,177,364
Cohort,0.017351262593642384,0.2105430734749094,0.0824119374115157,0.934338918067612,LGP Proband,"Genes up-regulated in the perivenous-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,177,550
Cohort,0.08526469817158198,0.0626014775559895,1.3620237333108147,0.17357570098924036,LonGen OPEL,"Genes up-regulated in the perivenous-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,269,366
Cohort,-0.01697398871806626,0.08057351223305083,-0.210664624733879,0.8332124643311786,LGP Offspring,"Genes up-regulated in the stem cell-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,218,452
Cohort,-0.15701584916064,0.22417299272485355,-0.7004226836252251,0.4838587197878691,LGP Proband,"Genes up-regulated in the stem cell-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,218,614
Cohort,-0.0502140383901741,0.07601952113559332,-0.6605413667445905,0.5090975867926855,LonGen OPEL,"Genes up-regulated in the stem cell-type subclass of hepatocellular carcinomas. Sets created as part of a metaanalysis of nine public transcriptomic datasets merged into a metadataset including 1133 human hepatocellular carcinomas obtained after curative resection. For platform descriptions of each one of the 9 datasets, see Figure 1B in Désert et al., Hepatology (2017), 66: 1502-1518.",CGP,C2,400,450
Cohort,-0.20311543562840076,0.09076501271831072,-2.237816417861028,0.02555797288393472,LGP Offspring,Genes down-regulated in T-PLL cells (T-cell prolymphocytic leukemia) bearing the inv(14)/t(14:14) chromosomal aberration.,CGP,C2,279,492
Cohort,-0.5223150463784302,0.2544073925508003,-2.053065522748651,0.040377682146658996,LGP Proband,Genes down-regulated in T-PLL cells (T-cell prolymphocytic leukemia) bearing the inv(14)/t(14:14) chromosomal aberration.,CGP,C2,279,710
Cohort,0.0930792146958855,0.07930010290781526,1.1737590656608374,0.24084261315098682,LonGen OPEL,Genes down-regulated in T-PLL cells (T-cell prolymphocytic leukemia) bearing the inv(14)/t(14:14) chromosomal aberration.,CGP,C2,396,524
Cohort,0.0062696528388043815,0.10712277802020165,0.05852772822622304,0.953345572813822,LGP Offspring,Genes up-regulated in T-PLL cells (T-cell prolymphocytic leukemia) bearing the inv(14)/t(14:14) chromosomal aberration.,CGP,C2,373,796
Cohort,-0.4126972055581047,0.3127993260756181,-1.3193673104600507,0.1874084343338748,LGP Proband,Genes up-regulated in T-PLL cells (T-cell prolymphocytic leukemia) bearing the inv(14)/t(14:14) chromosomal aberration.,CGP,C2,373,1142
Cohort,0.056477703705009104,0.0956134961160244,0.5906875702617853,0.5548974460482572,LonGen OPEL,Genes up-regulated in T-PLL cells (T-cell prolymphocytic leukemia) bearing the inv(14)/t(14:14) chromosomal aberration.,CGP,C2,596,753
Cohort,-0.020681567906922594,0.06684155001479086,-0.30941185388947634,0.7571036000313213,LGP Offspring,"Genes down-regulated in CD34+ [GeneID=947] cells isolated from bone marrow of CML (chronic myelogenous leukemia) patients, compared to those from normal donors.",CGP,C2,148,294
Cohort,-0.014338440915608984,0.18290615111031105,-0.07839233852207322,0.9375347716738349,LGP Proband,"Genes down-regulated in CD34+ [GeneID=947] cells isolated from bone marrow of CML (chronic myelogenous leukemia) patients, compared to those from normal donors.",CGP,C2,148,369
Cohort,-0.030674271732786175,0.054888494715581694,-0.5588470205228345,0.5764233063377654,LonGen OPEL,"Genes down-regulated in CD34+ [GeneID=947] cells isolated from bone marrow of CML (chronic myelogenous leukemia) patients, compared to those from normal donors.",CGP,C2,214,245
Cohort,-0.39584149236459937,0.18695713569327502,-2.117284750307811,0.03460025787543413,LGP Offspring,"Genes up-regulated in CD34+ [GeneID=947] cells isolated from bone marrow of CML (chronic myelogenous leukemia) patients, compared to those from normal donors.",CGP,C2,1169,2265
Cohort,-0.2075867439028851,0.5338831392438669,-0.3888243112470044,0.6975053605894863,LGP Proband,"Genes up-regulated in CD34+ [GeneID=947] cells isolated from bone marrow of CML (chronic myelogenous leukemia) patients, compared to those from normal donors.",CGP,C2,1169,3304
Cohort,-0.21055177724416316,0.17178067619626727,-1.2257011784235738,0.22067365838857575,LonGen OPEL,"Genes up-regulated in CD34+ [GeneID=947] cells isolated from bone marrow of CML (chronic myelogenous leukemia) patients, compared to those from normal donors.",CGP,C2,1863,2190
Cohort,-0.0012015615210781143,0.016034254619139002,-0.07493716107288778,0.9402868792395549,LGP Offspring,"Genes involved in serotonin [PubChem=5202] function, orthologs computed from D. melanogaster genes using InsParanoid resource.",CGP,C2,8,18
Cohort,0.05750330655534558,0.047991662564210995,1.1981936753786842,0.23118200984315493,LGP Proband,"Genes involved in serotonin [PubChem=5202] function, orthologs computed from D. melanogaster genes using InsParanoid resource.",CGP,C2,8,31
Cohort,-0.008485815681654529,0.016703460984427997,-0.5080273896269482,0.6115748815178785,LonGen OPEL,"Genes involved in serotonin [PubChem=5202] function, orthologs computed from D. melanogaster genes using InsParanoid resource.",CGP,C2,18,21
Cohort,-0.04037850259950012,0.03319114110800313,-1.2165445733881068,0.22420212566118178,LGP Offspring,The lung adenocarcinoma TSP (tumor sequencing project) genes mutations in which show positive correlation with the  higher overall mutation rate.,CGP,C2,41,70
Cohort,-0.07317904417060006,0.10090384646031195,-0.7252354269704004,0.46851104687587164,LGP Proband,The lung adenocarcinoma TSP (tumor sequencing project) genes mutations in which show positive correlation with the  higher overall mutation rate.,CGP,C2,41,118
Cohort,-0.04812982048964255,0.030238586104363935,-1.5916690126823294,0.11185611643094957,LonGen OPEL,The lung adenocarcinoma TSP (tumor sequencing project) genes mutations in which show positive correlation with the  higher overall mutation rate.,CGP,C2,72,65
Cohort,-0.10511452029542895,0.05274734712563102,-1.992792548316646,0.04668578426097577,LGP Offspring,The lung adenocarcinoma TSP (tumor sequencing project) genes showing strong correlation between DNA copy number variation and gene expression.,CGP,C2,112,183
Cohort,0.029096254118814252,0.15793181143220397,0.18423301711640608,0.8538754446700302,LGP Proband,The lung adenocarcinoma TSP (tumor sequencing project) genes showing strong correlation between DNA copy number variation and gene expression.,CGP,C2,112,298
Cohort,-0.005151580112847959,0.04880921808951442,-0.10554522925157578,0.9159697732823804,LonGen OPEL,The lung adenocarcinoma TSP (tumor sequencing project) genes showing strong correlation between DNA copy number variation and gene expression.,CGP,C2,162,189
Cohort,-0.031050981361115698,0.023954045680787482,-1.2962729459107765,0.19532382013424854,LGP Offspring,"The lung adenocarcinoma TSP (tumor sequencing project) genes with significantly higher frequencies of nonsense, splice site, and frame-shift mutations.",CGP,C2,23,35
Cohort,0.11837618547297882,0.07007386324641122,1.6893058265778054,0.09153459968166412,LGP Proband,"The lung adenocarcinoma TSP (tumor sequencing project) genes with significantly higher frequencies of nonsense, splice site, and frame-shift mutations.",CGP,C2,23,62
Cohort,0.020854061366058763,0.022906486806375866,0.910399815665062,0.36288728711091045,LonGen OPEL,"The lung adenocarcinoma TSP (tumor sequencing project) genes with significantly higher frequencies of nonsense, splice site, and frame-shift mutations.",CGP,C2,36,49
Cohort,-0.009175070972107157,0.01034528892073066,-0.8868839761180055,0.3754567767289949,LGP Offspring,The lung adenocarcinoma TSP (tumor sequencing project) genes bearing recurrent somatic mutations.,CGP,C2,4,7
Cohort,0.08836886216323021,0.030655835681939907,2.882611424463318,0.004045285255826556,LGP Proband,The lung adenocarcinoma TSP (tumor sequencing project) genes bearing recurrent somatic mutations.,CGP,C2,4,10
Cohort,-0.002595789889034476,0.0063471889904000885,-0.40896685020101364,0.6826739965202966,LonGen OPEL,The lung adenocarcinoma TSP (tumor sequencing project) genes bearing recurrent somatic mutations.,CGP,C2,3,3
Cohort,-0.040638631077088094,0.034638149201714125,-1.1732333283868708,0.2411154695433535,LGP Offspring,The lung adenocarcinoma TSP (tumor sequencing project) genes that were found significantly mutated by at least one method.,CGP,C2,44,78
Cohort,0.05475660965847084,0.10029834550392457,0.5459373171447606,0.5852550223758191,LGP Proband,The lung adenocarcinoma TSP (tumor sequencing project) genes that were found significantly mutated by at least one method.,CGP,C2,44,130
Cohort,0.02349328395144069,0.03381940342325691,0.6946687869510094,0.48746559986181226,LonGen OPEL,The lung adenocarcinoma TSP (tumor sequencing project) genes that were found significantly mutated by at least one method.,CGP,C2,74,97
Cohort,0.016683717043305714,0.03297927224826213,0.5058849363840913,0.6131023481991456,LGP Offspring,"Clusters 1 and 2: genes up-regulated in B2264-19/3 cells (primary B lymphocytes) within 30-60 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).",CGP,C2,32,78
Cohort,-0.030829114402101458,0.08756174873005448,-0.3520842702347691,0.7248640098167204,LGP Proband,"Clusters 1 and 2: genes up-regulated in B2264-19/3 cells (primary B lymphocytes) within 30-60 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).",CGP,C2,32,102
Cohort,0.03507609074203187,0.028023653121178795,1.2516601811461625,0.2110614039523675,LonGen OPEL,"Clusters 1 and 2: genes up-regulated in B2264-19/3 cells (primary B lymphocytes) within 30-60 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).",CGP,C2,49,74
Cohort,0.020168075953563912,0.020228223760322808,0.9970265403689633,0.3191083747933477,LGP Offspring,"Cluster 4: genes down-regulated in B2264-19/3 cells (primary B lymphocytes) within 60-180 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).",CGP,C2,9,31
Cohort,0.037415760444693705,0.053486062604268775,0.6995422475108033,0.48440827914433193,LGP Proband,"Cluster 4: genes down-regulated in B2264-19/3 cells (primary B lymphocytes) within 60-180 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).",CGP,C2,9,37
Cohort,0.031340346807229476,0.015192755725899811,2.062848068688559,0.03945091584915325,LonGen OPEL,"Cluster 4: genes down-regulated in B2264-19/3 cells (primary B lymphocytes) within 60-180 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).",CGP,C2,11,25
Cohort,-0.049303060443120536,0.039516576199815814,-1.2476551661211563,0.21258938795108856,LGP Offspring,"Cluster 3: genes up-regulated in B2264-19/3 cells (primary B lymphocytes) within 60-180 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).",CGP,C2,58,100
Cohort,-0.04186566373342802,0.112382625791189,-0.372527901343184,0.7095944884786541,LGP Proband,"Cluster 3: genes up-regulated in B2264-19/3 cells (primary B lymphocytes) within 60-180 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).",CGP,C2,58,144
Cohort,-0.005669449043252655,0.031310875388442704,-0.1810696434678837,0.8563590045869286,LonGen OPEL,"Cluster 3: genes up-regulated in B2264-19/3 cells (primary B lymphocytes) within 60-180 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).",CGP,C2,72,85
Cohort,-0.007518594274840169,0.018256613552971444,-0.4118285274004961,0.6805956573353378,LGP Offspring,Genes that escape X inactivation.,CGP,C2,12,21
Cohort,-0.004187630110912463,0.050272484728389515,-0.0832986500177433,0.9336340623143679,LGP Proband,Genes that escape X inactivation.,CGP,C2,12,24
Cohort,0.0022477213216907767,0.017205419342234983,0.13064031029881296,0.8960928609231377,LonGen OPEL,Genes that escape X inactivation.,CGP,C2,13,18
Cohort,0.06876607666886864,0.054768236962540635,1.255583171609157,0.20970095143674353,LGP Offspring,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PTHLH [GeneID=5744] by RNAi.,CGP,C2,87,220
Cohort,-0.21735592247736707,0.15232869390857143,-1.426887586969172,0.15398655852545337,LGP Proband,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PTHLH [GeneID=5744] by RNAi.,CGP,C2,87,286
Cohort,-0.036346516766690415,0.048414252320628494,-0.7507400202316824,0.45303099823324666,LonGen OPEL,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PTHLH [GeneID=5744] by RNAi.,CGP,C2,158,189
Cohort,-0.05438038855611965,0.05959805037636559,-0.9124524747488204,0.3618558614075652,LGP Offspring,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PTHLH [GeneID=5744] by RNAi.,CGP,C2,125,245
Cohort,-0.14801683662254358,0.16592675527719347,-0.8920612976205676,0.3726173783136528,LGP Proband,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PTHLH [GeneID=5744] by RNAi.,CGP,C2,125,322
Cohort,0.008946832629816048,0.05337508123271346,0.16762190189103743,0.8669233153961151,LonGen OPEL,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PTHLH [GeneID=5744] by RNAi.,CGP,C2,181,225
Cohort,-0.04230517043983404,0.03206581081719862,-1.319323271786519,0.18750774034215825,LGP Offspring,Genes down-regulated in ER(-) / PR(-) breast tumors (do not express ESR1 and PGR [GeneID=2099;5241]) with molecular similarity to ER(+) (class A) relative to the rest of the ER(-) / PR(-) samples (class B).,CGP,C2,40,65
Cohort,0.08446329204453368,0.08962629078578198,0.9423941491276425,0.34626377838626676,LGP Proband,Genes down-regulated in ER(-) / PR(-) breast tumors (do not express ESR1 and PGR [GeneID=2099;5241]) with molecular similarity to ER(+) (class A) relative to the rest of the ER(-) / PR(-) samples (class B).,CGP,C2,40,108
Cohort,0.01792029073213399,0.028954981420150315,0.618901821144424,0.5361581117319282,LonGen OPEL,Genes down-regulated in ER(-) / PR(-) breast tumors (do not express ESR1 and PGR [GeneID=2099;5241]) with molecular similarity to ER(+) (class A) relative to the rest of the ER(-) / PR(-) samples (class B).,CGP,C2,52,68
Cohort,-0.019865327238863098,0.05157305882485415,-0.3851880747722797,0.7002192435112267,LGP Offspring,Genes up-regulated in ER(-) / PR(-) breast tumors (do not express ESR1 and PGR [GeneID=2099;5241]) with molecular similarity to ER(+) (class A) relative to the rest of the ER(-) / PR(-) samples (class B).,CGP,C2,91,183
Cohort,0.08105149607361838,0.14583802420185674,0.555763810687902,0.5785213828734669,LGP Proband,Genes up-regulated in ER(-) / PR(-) breast tumors (do not express ESR1 and PGR [GeneID=2099;5241]) with molecular similarity to ER(+) (class A) relative to the rest of the ER(-) / PR(-) samples (class B).,CGP,C2,91,259
Cohort,0.05881197956337905,0.046420077699919425,1.2669513382456303,0.20554325112094446,LonGen OPEL,Genes up-regulated in ER(-) / PR(-) breast tumors (do not express ESR1 and PGR [GeneID=2099;5241]) with molecular similarity to ER(+) (class A) relative to the rest of the ER(-) / PR(-) samples (class B).,CGP,C2,136,182
Cohort,0.025524789359130124,0.029969378251994496,0.8516956589658786,0.3946846409559823,LGP Offspring,Genes down-regulated in breast cancer samples positive for ESR1 [GeneID=2099] compared to the ESR1 negative tumors.,CGP,C2,25,71
Cohort,0.08692477735118624,0.08148228057561073,1.0667936235599738,0.286373749889,LGP Proband,Genes down-regulated in breast cancer samples positive for ESR1 [GeneID=2099] compared to the ESR1 negative tumors.,CGP,C2,25,86
Cohort,0.022647201671327562,0.027287494527567374,0.8299480059793718,0.40681701375849644,LonGen OPEL,Genes down-regulated in breast cancer samples positive for ESR1 [GeneID=2099] compared to the ESR1 negative tumors.,CGP,C2,47,66
Cohort,0.03365554021553521,0.0711106147134631,0.4732843380857927,0.6361631256919277,LGP Offspring,Genes up-regulated in breast cancer samples positive for ESR1 [GeneID=2099] compared to the ESR1 negative tumors.,CGP,C2,143,313
Cohort,0.18489405768594216,0.1790048771305388,1.0328995536312047,0.3019503301648243,LGP Proband,Genes up-regulated in breast cancer samples positive for ESR1 [GeneID=2099] compared to the ESR1 negative tumors.,CGP,C2,143,388
Cohort,0.04862622542893587,0.057548886222978185,0.8449551089577878,0.39838979405572106,LonGen OPEL,Genes up-regulated in breast cancer samples positive for ESR1 [GeneID=2099] compared to the ESR1 negative tumors.,CGP,C2,208,271
Cohort,-0.20002636760785314,0.08430329147223085,-2.372699382369204,0.017937453444044082,LGP Offspring,Genes down-regulated in MDA-MB-453 cells (class A ER(-) [GeneID=2099] breast cancer) after exposure to the androgen R1881 [PubChem=13766].,CGP,C2,250,437
Cohort,-0.2182229162115988,0.24088925291970617,-0.9059055709900742,0.36524747332140173,LGP Proband,Genes down-regulated in MDA-MB-453 cells (class A ER(-) [GeneID=2099] breast cancer) after exposure to the androgen R1881 [PubChem=13766].,CGP,C2,250,670
Cohort,-0.06344895644584066,0.07388482724913768,-0.8587548866006339,0.3907342805988391,LonGen OPEL,Genes down-regulated in MDA-MB-453 cells (class A ER(-) [GeneID=2099] breast cancer) after exposure to the androgen R1881 [PubChem=13766].,CGP,C2,381,438
Cohort,-0.09509121990623935,0.07913973959059221,-1.2015609401568386,0.22995446408523001,LGP Offspring,Genes up-regulated in MDA-MB-453 cells (class A ER(-) [GeneID=2099] breast cancer) after exposure to the androgen R1881 [PubChem=13766].,CGP,C2,203,406
Cohort,0.2076418788058333,0.22020753028999226,0.9429372307676708,0.3459860722982213,LGP Proband,Genes up-regulated in MDA-MB-453 cells (class A ER(-) [GeneID=2099] breast cancer) after exposure to the androgen R1881 [PubChem=13766].,CGP,C2,203,599
Cohort,0.08552248515306984,0.07313632836979564,1.1693571041828446,0.24260982048330773,LonGen OPEL,Genes up-regulated in MDA-MB-453 cells (class A ER(-) [GeneID=2099] breast cancer) after exposure to the androgen R1881 [PubChem=13766].,CGP,C2,342,443
Cohort,-0.3469278699110991,0.1963758903332288,-1.76665205347968,0.0777377413091645,LGP Offspring,Genes down-regulated in nasopharyngeal carcinoma (NPC) compared to the normal tissue.,CGP,C2,1188,2312
Cohort,-1.044075105179,0.526002465106897,-1.9849243576583195,0.04748012491196686,LGP Proband,Genes down-regulated in nasopharyngeal carcinoma (NPC) compared to the normal tissue.,CGP,C2,1188,3365
Cohort,-0.05052970610174876,0.1630278875160724,-0.30994516871702216,0.7566837782762478,LonGen OPEL,Genes down-regulated in nasopharyngeal carcinoma (NPC) compared to the normal tissue.,CGP,C2,1875,2243
Cohort,-0.8583556983767099,0.2668001784746485,-3.2172231041377333,0.001356146132279497,LGP Offspring,Genes up-regulated in nasopharyngeal carcinoma (NPC) compared to the normal tissue.,CGP,C2,2121,4117
Cohort,0.34403067674000015,0.7081877485445737,0.48579021233709846,0.6272435154503357,LGP Proband,Genes up-regulated in nasopharyngeal carcinoma (NPC) compared to the normal tissue.,CGP,C2,2121,5827
Cohort,-0.02930110937469757,0.2241656465951637,-0.13071186339097926,0.8960362735684757,LonGen OPEL,Genes up-regulated in nasopharyngeal carcinoma (NPC) compared to the normal tissue.,CGP,C2,3308,4015
Cohort,-5.583358181991046e-4,0.005558324490637529,-0.10045038197024451,0.920016556286256,LGP Offspring,Genes involved in cell cycle regulation which were up-regulated in MCF-7 cells (breast cancer) by tretinoin (retinoic acid) [PubChem=444795].,CGP,C2,1,2
Cohort,0.00661865340194438,0.015865688395716362,0.4171677419135104,0.6766630773257457,LGP Proband,Genes involved in cell cycle regulation which were up-regulated in MCF-7 cells (breast cancer) by tretinoin (retinoic acid) [PubChem=444795].,CGP,C2,1,3
Cohort,0.003479555698947437,0.0067713263091893384,0.5138661969702075,0.6074881553145991,LonGen OPEL,Genes involved in cell cycle regulation which were up-regulated in MCF-7 cells (breast cancer) by tretinoin (retinoic acid) [PubChem=444795].,CGP,C2,2,5
Cohort,0.006287156402324916,0.023387670845499146,0.26882353714734497,0.7881475009818033,LGP Offspring,Genes down-regulated in HeLa cells upon knockdown of ELAVL1 [GeneID=1994] by RNAi.,CGP,C2,17,40
Cohort,0.056991603167990866,0.05849809994791699,0.9742470818493691,0.3302163575285476,LGP Proband,Genes down-regulated in HeLa cells upon knockdown of ELAVL1 [GeneID=1994] by RNAi.,CGP,C2,17,39
Cohort,-0.0052147033777223345,0.019576466459487945,-0.2663761301618849,0.7900185315946389,LonGen OPEL,Genes down-regulated in HeLa cells upon knockdown of ELAVL1 [GeneID=1994] by RNAi.,CGP,C2,28,33
Cohort,-0.0157160213342499,0.022910949932452886,-0.6859611400044343,0.4929728007518982,LGP Offspring,Genes down-regulated in HeLa cells (cervical carcinoma) 12 h after infection with adenovirus Ad12.,CGP,C2,23,35
Cohort,0.04106424149499345,0.07660045117171944,0.5360835460738669,0.5920437555044856,LGP Proband,Genes down-regulated in HeLa cells (cervical carcinoma) 12 h after infection with adenovirus Ad12.,CGP,C2,23,74
Cohort,0.025580180005901006,0.024373842488058458,1.0494931202757043,0.2942697485384298,LonGen OPEL,Genes down-regulated in HeLa cells (cervical carcinoma) 12 h after infection with adenovirus Ad12.,CGP,C2,35,53
Cohort,0.002327482008270245,0.01909750865932641,0.12187359355554485,0.9030353482575362,LGP Offspring,Genes up-regulated in HeLa cells (cervical carcinoma) 12 h after infection with adenovirus Ad12.,CGP,C2,11,24
Cohort,0.03926649578121134,0.06559206594756656,0.5986470347282621,0.549570837299008,LGP Proband,Genes up-regulated in HeLa cells (cervical carcinoma) 12 h after infection with adenovirus Ad12.,CGP,C2,11,53
Cohort,-0.0034008949149973576,0.020429907937017124,-0.16646648264308853,0.867832132530415,LonGen OPEL,Genes up-regulated in HeLa cells (cervical carcinoma) 12 h after infection with adenovirus Ad12.,CGP,C2,30,34
Cohort,-0.020098851303591743,0.025070158932349117,-0.8017041837599729,0.42300581089564193,LGP Offspring,Genes down-regulated in HeLa cells (cervical carcinoma) 24 h after infection with adenovirus Ad12.,CGP,C2,25,40
Cohort,0.048046828537790166,0.08321338798313677,0.5773930097345259,0.5638298285982253,LGP Proband,Genes down-regulated in HeLa cells (cervical carcinoma) 24 h after infection with adenovirus Ad12.,CGP,C2,25,92
Cohort,0.0032807624012006,0.02754740928634904,0.11909513403230855,0.9052300346959532,LonGen OPEL,Genes down-regulated in HeLa cells (cervical carcinoma) 24 h after infection with adenovirus Ad12.,CGP,C2,50,59
Cohort,0.0023416302417255514,0.014470189565446254,0.16182443437487454,0.871492465158776,LGP Offspring,Genes up-regulated in HeLa cells (cervical carcinoma) 24 h after infection with adenovirus Ad12.,CGP,C2,7,14
Cohort,0.014586259699552354,0.043417743543109046,0.3359515835978395,0.7369918765971404,LGP Proband,Genes up-regulated in HeLa cells (cervical carcinoma) 24 h after infection with adenovirus Ad12.,CGP,C2,7,25
Cohort,0.013213497997797223,0.014358152799690523,0.9202784078243009,0.35770609379437845,LonGen OPEL,Genes up-regulated in HeLa cells (cervical carcinoma) 24 h after infection with adenovirus Ad12.,CGP,C2,12,20
Cohort,0.019671962887260273,0.02535152368797171,0.7759676747395596,0.43803946103016056,LGP Offspring,Genes down-regulated in HeLa cells (cervical carcinoma) 32 h after infection with adenovirus Ad12.,CGP,C2,20,46
Cohort,0.02030802567548762,0.08287461765711665,0.24504518089615246,0.806481728943329,LGP Proband,Genes down-regulated in HeLa cells (cervical carcinoma) 32 h after infection with adenovirus Ad12.,CGP,C2,20,91
Cohort,0.009177293218356114,0.028042394800987684,0.3272649601963695,0.7435535366986377,LonGen OPEL,Genes down-regulated in HeLa cells (cervical carcinoma) 32 h after infection with adenovirus Ad12.,CGP,C2,51,65
Cohort,-0.039482382255809884,0.01378976463310957,-2.8631657831934056,0.004324220713465685,LGP Offspring,Genes up-regulated in HeLa cells (cervical carcinoma) 32 h after infection with adenovirus Ad12.,CGP,C2,12,7
Cohort,0.046857117377032034,0.045040762508541415,1.040326912053191,0.2984895368030765,LGP Proband,Genes up-regulated in HeLa cells (cervical carcinoma) 32 h after infection with adenovirus Ad12.,CGP,C2,12,22
Cohort,0.0045897228731858666,0.012535562683848525,0.36613616707445495,0.7143607587641461,LonGen OPEL,Genes up-regulated in HeLa cells (cervical carcinoma) 32 h after infection with adenovirus Ad12.,CGP,C2,11,13
Cohort,0.021725161193943708,0.025541803230422735,0.850572725737193,0.39530791232535367,LGP Offspring,Genes down-regulated in HeLa cells (cervical carcinoma) 48 h after infection with adenovirus Ad12.,CGP,C2,20,47
Cohort,0.030738763430841396,0.08346839604022047,0.36826828942573037,0.7127666471161371,LGP Proband,Genes down-regulated in HeLa cells (cervical carcinoma) 48 h after infection with adenovirus Ad12.,CGP,C2,20,93
Cohort,0.009177293218356114,0.028042394800987684,0.3272649601963695,0.7435535366986377,LonGen OPEL,Genes down-regulated in HeLa cells (cervical carcinoma) 48 h after infection with adenovirus Ad12.,CGP,C2,51,65
Cohort,-0.039482382255809884,0.01378976463310957,-2.8631657831934056,0.004324220713465685,LGP Offspring,Genes up-regulated in HeLa cells (cervical carcinoma) 48 h after infection with adenovirus Ad12.,CGP,C2,12,7
Cohort,0.045306204070906846,0.046354753062995004,0.9773799034014224,0.3286645227195727,LGP Proband,Genes up-regulated in HeLa cells (cervical carcinoma) 48 h after infection with adenovirus Ad12.,CGP,C2,12,24
Cohort,0.0045897228731858666,0.012535562683848525,0.36613616707445495,0.7143607587641461,LonGen OPEL,Genes up-regulated in HeLa cells (cervical carcinoma) 48 h after infection with adenovirus Ad12.,CGP,C2,11,13
Cohort,-0.02303983844830125,0.02579553761482523,-0.8931714776535526,0.3720831987176886,LGP Offspring,HOXA9 [GeneID=3205] targets down-regulated in hematopoietic stem cells.,CGP,C2,27,42
Cohort,0.03164034176575913,0.07266799094281026,0.4354096123375709,0.6633777926304595,LGP Proband,HOXA9 [GeneID=3205] targets down-regulated in hematopoietic stem cells.,CGP,C2,27,62
Cohort,-0.023422773119868026,0.026421529665337118,-0.8865032954771269,0.37561412538104555,LonGen OPEL,HOXA9 [GeneID=3205] targets down-regulated in hematopoietic stem cells.,CGP,C2,51,46
Cohort,-0.03664519768650711,0.024526123866121418,-1.494129194100911,0.13560846616626598,LGP Offspring,HOXA9 [GeneID=3205] targets up-regulated in hematopoietic stem cells.,CGP,C2,25,37
Cohort,-0.025743455581926176,0.07570484046597402,-0.3400503247014532,0.7339042544970562,LGP Proband,HOXA9 [GeneID=3205] targets up-regulated in hematopoietic stem cells.,CGP,C2,25,62
Cohort,-0.0028904029332573193,0.021503982733578963,-0.13441244671127311,0.893110417316083,LonGen OPEL,HOXA9 [GeneID=3205] targets up-regulated in hematopoietic stem cells.,CGP,C2,33,36
Cohort,-0.0169947758519009,0.02720745090628831,-0.6246368287288903,0.5324202043183005,LGP Offspring,Genes up-regulated by expression of GAB2 [GeneID=9846] in K562 cells (chronic myeloid leukemia (CML) cell line with p210 BCR-ABL [GeneID=613;25]).,CGP,C2,27,46
Cohort,-0.1685651968608545,0.07867028032848773,-2.1426794992595752,0.03242769683445286,LGP Proband,Genes up-regulated by expression of GAB2 [GeneID=9846] in K562 cells (chronic myeloid leukemia (CML) cell line with p210 BCR-ABL [GeneID=613;25]).,CGP,C2,27,75
Cohort,0.00325841634623815,0.029985362104231385,0.10866690003314444,0.9134940823500866,LonGen OPEL,Genes up-regulated by expression of GAB2 [GeneID=9846] in K562 cells (chronic myeloid leukemia (CML) cell line with p210 BCR-ABL [GeneID=613;25]).,CGP,C2,55,77
Cohort,-0.004205565858534393,0.0970521761048799,-0.043333040301843706,0.9654488497368723,LGP Offspring,"Genes down-regulated in A4573 cells (Ewing's sarcoma, ESFT) after knockdown of BMI1 [GeneID=648] by RNAi.",CGP,C2,295,623
Cohort,-0.2659571997248043,0.2573142215800261,-1.033589197253484,0.30162786709385275,LGP Proband,"Genes down-regulated in A4573 cells (Ewing's sarcoma, ESFT) after knockdown of BMI1 [GeneID=648] by RNAi.",CGP,C2,295,855
Cohort,-0.02470193689080824,0.08610368456486217,-0.2868859447263281,0.7742743115613973,LonGen OPEL,"Genes down-regulated in A4573 cells (Ewing's sarcoma, ESFT) after knockdown of BMI1 [GeneID=648] by RNAi.",CGP,C2,498,589
Cohort,-0.050071665571444525,0.13827065132723979,-0.3621279359778371,0.7173696020788967,LGP Offspring,"Genes up-regulated in A4573 cells (Ewing's sarcoma, ESFT) after knockdown of BMI1 [GeneID=648] by RNAi.",CGP,C2,598,1229
Cohort,-0.7069781166750084,0.38266003084055034,-1.8475358273558427,0.06502348323799823,LGP Proband,"Genes up-regulated in A4573 cells (Ewing's sarcoma, ESFT) after knockdown of BMI1 [GeneID=648] by RNAi.",CGP,C2,598,1669
Cohort,-0.07172453156721227,0.12197112869185703,-0.5880451573783027,0.5566687752864286,LonGen OPEL,"Genes up-regulated in A4573 cells (Ewing's sarcoma, ESFT) after knockdown of BMI1 [GeneID=648] by RNAi.",CGP,C2,1010,1182
Cohort,-0.02575455559471182,0.05304571838779594,-0.4855161995626227,0.6274675406646244,LGP Offspring,Direct targets of PRDM5 [GeneID=11107].,CGP,C2,97,193
Cohort,-0.09410422571321253,0.14973582727063547,-0.6284683327199088,0.5298692549075119,LGP Proband,Direct targets of PRDM5 [GeneID=11107].,CGP,C2,97,252
Cohort,-0.049529466335752066,0.04377138151972596,-1.1315490764994742,0.2581648368954404,LonGen OPEL,Direct targets of PRDM5 [GeneID=11107].,CGP,C2,140,148
Cohort,-0.016065440016455892,0.02087684121091297,-0.7695340427295098,0.4418451450190606,LGP Offspring,Genes down-regulated in Kasumi-1 cells (acute myeloid leukaemia (AML) with the t(8;21) translocation) after knockdown of the AML1 MTG8 fusion [GeneID=861;862] by RNAi.,CGP,C2,16,27
Cohort,-0.10307202422503602,0.05927712915862186,-1.7388160608996732,0.08243612821990849,LGP Proband,Genes down-regulated in Kasumi-1 cells (acute myeloid leukaemia (AML) with the t(8;21) translocation) after knockdown of the AML1 MTG8 fusion [GeneID=861;862] by RNAi.,CGP,C2,16,39
Cohort,-0.02780853777606282,0.020907565222171364,-1.330070597917989,0.18387597683998316,LonGen OPEL,Genes down-regulated in Kasumi-1 cells (acute myeloid leukaemia (AML) with the t(8;21) translocation) after knockdown of the AML1 MTG8 fusion [GeneID=861;862] by RNAi.,CGP,C2,34,28
Cohort,-0.022421797279897477,0.027718729523622806,-0.8089042198268463,0.4188548382740379,LGP Offspring,Genes up-regulated in Kasumi-1 cells (acute myeloid leukaemia (AML) with the t(8;21) translocation) after knockdown of the AML1 MTG8 fusion [GeneID=861;862] by RNAi.,CGP,C2,29,42
Cohort,-0.15858863263620548,0.07264359446042545,-2.1831055279430163,0.02930618216745068,LGP Proband,Genes up-regulated in Kasumi-1 cells (acute myeloid leukaemia (AML) with the t(8;21) translocation) after knockdown of the AML1 MTG8 fusion [GeneID=861;862] by RNAi.,CGP,C2,29,62
Cohort,-0.0109487333193025,0.02495292250433084,-0.43877559101152314,0.6609432151426468,LonGen OPEL,Genes up-regulated in Kasumi-1 cells (acute myeloid leukaemia (AML) with the t(8;21) translocation) after knockdown of the AML1 MTG8 fusion [GeneID=861;862] by RNAi.,CGP,C2,42,47
Cohort,0.05196006038922827,0.07194220099853198,0.7222472994715375,0.4703922138858092,LGP Offspring,Genes up-regulated in the HSC non-supportive stromal cell lines.,CGP,C2,147,331
Cohort,0.46356761947516295,0.19873865656558398,2.3325488230931315,0.019908896850731946,LGP Proband,Genes up-regulated in the HSC non-supportive stromal cell lines.,CGP,C2,147,445
Cohort,-0.0343161719825122,0.06141450293192525,-0.5587633269709905,0.5764804037851348,LonGen OPEL,Genes up-regulated in the HSC non-supportive stromal cell lines.,CGP,C2,279,315
Cohort,0.028529696906388916,0.08306865134560094,0.34344721437324455,0.7313688315685832,LGP Offspring,Genes up-regulated in the HSC supportive stromal cell lines.,CGP,C2,216,481
Cohort,0.32320783778684403,0.23366255030277736,1.383224814451588,0.1669661083595582,LGP Proband,Genes up-regulated in the HSC supportive stromal cell lines.,CGP,C2,216,640
Cohort,0.067412570652419,0.07264021338853602,0.9280337640508358,0.3536713675488601,LonGen OPEL,Genes up-regulated in the HSC supportive stromal cell lines.,CGP,C2,345,444
Cohort,-0.12163971633860911,0.09691315283034191,-1.2551414620836245,0.20986112801485127,LGP Offspring,Genes down-regulated upon skin specific knockout of FOS [GeneID=2353] by cre-lox in the K5-SOS-F mice (express a constitutively active form of SOS1 [GeneID=6654] in the skin).,CGP,C2,322,622
Cohort,-0.09392686701348824,0.2733347862454937,-0.34363305272505085,0.731208874721603,LGP Proband,Genes down-regulated upon skin specific knockout of FOS [GeneID=2353] by cre-lox in the K5-SOS-F mice (express a constitutively active form of SOS1 [GeneID=6654] in the skin).,CGP,C2,322,887
Cohort,-0.01816993707145558,0.08565193447584162,-0.21213691415901956,0.8320545289241317,LonGen OPEL,Genes down-regulated upon skin specific knockout of FOS [GeneID=2353] by cre-lox in the K5-SOS-F mice (express a constitutively active form of SOS1 [GeneID=6654] in the skin).,CGP,C2,497,602
Cohort,0.00866099695361529,0.04922065930255025,0.17596263594068803,0.8603759942086601,LGP Offspring,Genes up-regulated upon skin specific knockout of FOS [GeneID=2353] by cre-lox in the K5-SOS-F mice (express a constitutively active form of SOS1 [GeneID=6654] in the skin).,CGP,C2,73,154
Cohort,-0.1550450006000699,0.14222536737690414,-1.0901360527984654,0.275968083875755,LGP Proband,Genes up-regulated upon skin specific knockout of FOS [GeneID=2353] by cre-lox in the K5-SOS-F mice (express a constitutively active form of SOS1 [GeneID=6654] in the skin).,CGP,C2,73,232
Cohort,-0.07923617270202205,0.042593901979094934,-1.8602703443537791,0.06321590637722382,LonGen OPEL,Genes up-regulated upon skin specific knockout of FOS [GeneID=2353] by cre-lox in the K5-SOS-F mice (express a constitutively active form of SOS1 [GeneID=6654] in the skin).,CGP,C2,147,140
Cohort,-0.054243214156480396,0.13080491641548722,-0.4146878851570294,0.6785019655940367,LGP Offspring,Genes down-regulated in MCF7 cells (breast cancer) at 24 h of estradiol [PubChem=5757] treatment.,CGP,C2,539,1126
Cohort,-0.33652222011267013,0.3546908962308815,-0.9487760291812375,0.34300937300718126,LGP Proband,Genes down-regulated in MCF7 cells (breast cancer) at 24 h of estradiol [PubChem=5757] treatment.,CGP,C2,539,1590
Cohort,0.006511463399785866,0.11238448000056023,0.05793916917846136,0.9538116241198604,LonGen OPEL,Genes down-regulated in MCF7 cells (breast cancer) at 24 h of estradiol [PubChem=5757] treatment.,CGP,C2,832,1017
Cohort,-0.08548908137027719,0.10411666515121754,-0.8210893159717908,0.4118848573960784,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) at 24 h of estradiol [PubChem=5757] treatment.,CGP,C2,357,688
Cohort,-0.17968119852158565,0.29448905307546475,-0.6101455950403059,0.541931576736246,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) at 24 h of estradiol [PubChem=5757] treatment.,CGP,C2,357,1016
Cohort,0.006009548967400184,0.0920973245046151,0.06525215580067192,0.9479896190276713,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) at 24 h of estradiol [PubChem=5757] treatment.,CGP,C2,564,663
Cohort,0.01842885096129082,0.05087220151121765,0.3622577835014107,0.7172726208735283,LGP Offspring,Genes down-regulated in MCF7 cells (breast cancer) at 6 h of estradiol [PubChem=5757] treatment.,CGP,C2,81,192
Cohort,0.05020465431164271,0.13746055983437686,0.3652295201775198,0.715032686507371,LGP Proband,Genes down-regulated in MCF7 cells (breast cancer) at 6 h of estradiol [PubChem=5757] treatment.,CGP,C2,81,236
Cohort,-0.03855638020393213,0.0457464279363909,-0.8428282150803921,0.3995777007215261,LonGen OPEL,Genes down-regulated in MCF7 cells (breast cancer) at 6 h of estradiol [PubChem=5757] treatment.,CGP,C2,146,171
Cohort,-0.26452845265212477,0.09832354827556061,-2.6903875754235385,0.007313183813540886,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) at 6 h of estradiol [PubChem=5757] treatment.,CGP,C2,336,584
Cohort,-0.2447853693608935,0.27044024679332596,-0.9051366143293078,0.3656544147777381,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) at 6 h of estradiol [PubChem=5757] treatment.,CGP,C2,336,831
Cohort,0.03600192239054446,0.08889056031826277,0.40501401118008,0.6855760310975902,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) at 6 h of estradiol [PubChem=5757] treatment.,CGP,C2,531,638
Cohort,0.004531074520748392,0.02509563904311195,0.18055226698807833,0.856773139071409,LGP Offspring,NF-kB target genes involved in the regulation of programmed cell death.,CGP,C2,20,45
Cohort,0.09468951698488177,0.06497642210868083,1.4572904126130897,0.14541264103133908,LGP Proband,NF-kB target genes involved in the regulation of programmed cell death.,CGP,C2,20,49
Cohort,-0.005295850684904617,0.021190170106923853,-0.24992015912011042,0.8027135762584161,LonGen OPEL,NF-kB target genes involved in the regulation of programmed cell death.,CGP,C2,35,34
Cohort,-0.06452259756596951,0.04578963469198705,-1.4091092449195852,0.1592626898658673,LGP Offspring,"Muscle development genes up-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) but not in the RD cells (embryonal rhabdomyosarcoma, ERMS) after knockdown of PAX3-FOXO1 [GeneID=5077;2308] fusion by RNAi for 72 hr.",CGP,C2,72,132
Cohort,0.014695620059285883,0.12448432197871723,0.11805197494507265,0.9060549010696486,LGP Proband,"Muscle development genes up-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) but not in the RD cells (embryonal rhabdomyosarcoma, ERMS) after knockdown of PAX3-FOXO1 [GeneID=5077;2308] fusion by RNAi for 72 hr.",CGP,C2,72,182
Cohort,-0.02073027058230326,0.038512964155700706,-0.5382673350847433,0.5905429734350781,LonGen OPEL,"Muscle development genes up-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) but not in the RD cells (embryonal rhabdomyosarcoma, ERMS) after knockdown of PAX3-FOXO1 [GeneID=5077;2308] fusion by RNAi for 72 hr.",CGP,C2,109,125
Cohort,-0.015528718714529224,0.04340498129371079,-0.3577635158842765,0.7206319703162395,LGP Offspring,"Genes down-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) after knockdown of the PAX3-FOXO1 [GeneiD=5077;2308] fusion protein by RNAi for 72 hr.",CGP,C2,54,108
Cohort,-0.03919715790882831,0.11950563900250744,-0.32799421212254165,0.7429983623148246,LGP Proband,"Genes down-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) after knockdown of the PAX3-FOXO1 [GeneiD=5077;2308] fusion protein by RNAi for 72 hr.",CGP,C2,54,154
Cohort,0.02965433897808045,0.033585282695512454,0.8829563605859645,0.37752642349260324,LonGen OPEL,"Genes down-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) after knockdown of the PAX3-FOXO1 [GeneiD=5077;2308] fusion protein by RNAi for 72 hr.",CGP,C2,76,99
Cohort,-0.07862817000156037,0.07409815714385726,-1.0611352971830104,0.2890073784585032,LGP Offspring,"Genes up-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) after knockdown of the PAX3-FOXO1 [GeneiD=5077;2308] fusion protein by RNAi for 72 hr.",CGP,C2,205,396
Cohort,0.016247539876765832,0.21226066966099089,0.07654522103748829,0.9390036965555253,LGP Proband,"Genes up-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) after knockdown of the PAX3-FOXO1 [GeneiD=5077;2308] fusion protein by RNAi for 72 hr.",CGP,C2,205,577
Cohort,0.03245609826262461,0.06815436923146083,0.4762144911414206,0.6340522566056777,LonGen OPEL,"Genes up-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) after knockdown of the PAX3-FOXO1 [GeneiD=5077;2308] fusion protein by RNAi for 72 hr.",CGP,C2,320,407
Cohort,-0.002742984020832208,0.024844414477652073,-0.1104064667452543,0.9121197936501103,LGP Offspring,RB1 [GeneID=5925] target genes involved in cell cycle regulation: genes down-regulated by doxorubicin [PubChem=31703] only in cells expressing RB1.,CGP,C2,20,37
Cohort,0.01908124464661161,0.07115039051414414,0.26818186813491074,0.7886256473528144,LGP Proband,RB1 [GeneID=5925] target genes involved in cell cycle regulation: genes down-regulated by doxorubicin [PubChem=31703] only in cells expressing RB1.,CGP,C2,20,62
Cohort,0.022919933981722946,0.021798279164924786,1.0514561176279913,0.2933682455137222,LonGen OPEL,RB1 [GeneID=5925] target genes involved in cell cycle regulation: genes down-regulated by doxorubicin [PubChem=31703] only in cells expressing RB1.,CGP,C2,31,45
Cohort,0.020647194017688327,0.02075905566555966,0.9946114288783897,0.3202811664475365,LGP Offspring,Down-regulated genes in the expression signature of aneuploidy in uveal melanoma tumors: low vs high aneuploidy.,CGP,C2,12,31
Cohort,6.068340358429391e-4,0.054890107178466874,0.011055435433381649,0.991181862375988,LGP Proband,Down-regulated genes in the expression signature of aneuploidy in uveal melanoma tumors: low vs high aneuploidy.,CGP,C2,12,37
Cohort,0.017220477786172785,0.017503442568125895,0.9838337640808789,0.32549619239304306,LonGen OPEL,Down-regulated genes in the expression signature of aneuploidy in uveal melanoma tumors: low vs high aneuploidy.,CGP,C2,18,28
Cohort,-0.02508037383997976,0.02878767649344904,-0.8712191081377159,0.3839438197818946,LGP Offspring,Up-regulated genes in the expression signature of aneuploidy in uveal melanoma tumors: low vs high aneuploidy.,CGP,C2,30,52
Cohort,0.02747940411115357,0.08078036594055847,0.3401742959591697,0.7338109325691371,LGP Proband,Up-regulated genes in the expression signature of aneuploidy in uveal melanoma tumors: low vs high aneuploidy.,CGP,C2,30,78
Cohort,0.04446889094222908,0.026670644680946654,1.6673346847891304,0.095841217042608,LonGen OPEL,Up-regulated genes in the expression signature of aneuploidy in uveal melanoma tumors: low vs high aneuploidy.,CGP,C2,40,69
Cohort,-0.001028520540498309,0.014126234801252533,-0.07280924853430251,0.9419794481782541,LGP Offspring,Down-regulated in B lymphocytes from patients with ICF syndrom caused by mutations in DNMT3B [GeneID=1789] compared to normals.,CGP,C2,7,11
Cohort,-0.09278440245412059,0.033972591502462755,-2.7311546853113757,0.0064445523071349755,LGP Proband,Down-regulated in B lymphocytes from patients with ICF syndrom caused by mutations in DNMT3B [GeneID=1789] compared to normals.,CGP,C2,7,10
Cohort,0.003517151786832317,0.009674910936204997,0.36353324697497696,0.7163031077205367,LonGen OPEL,Down-regulated in B lymphocytes from patients with ICF syndrom caused by mutations in DNMT3B [GeneID=1789] compared to normals.,CGP,C2,6,8
Cohort,0.004700642131927271,0.01615742265835258,0.2909277198054403,0.7711958362023571,LGP Offspring,Up-regulated in B lymphocytes from patients with ICF syndrom caused by mutations in DNMT3B [GeneID=1789] compared to normals.,CGP,C2,7,17
Cohort,-0.028259670166060687,0.04755497428136952,-0.5942526642713778,0.5525042929450614,LGP Proband,Up-regulated in B lymphocytes from patients with ICF syndrom caused by mutations in DNMT3B [GeneID=1789] compared to normals.,CGP,C2,7,31
Cohort,0.0011264952507893194,0.012558292700548973,0.08970130555565692,0.9285471431831812,LonGen OPEL,Up-regulated in B lymphocytes from patients with ICF syndrom caused by mutations in DNMT3B [GeneID=1789] compared to normals.,CGP,C2,11,13
Cohort,-0.001444763657399764,0.016395665553116008,-0.08811863432559379,0.9298084831065063,LGP Offspring,A gene expression signature found in a subset of cancer patients suggestive of a deregulated immune or inflammatory response.,CGP,C2,10,17
Cohort,0.004472246502581594,0.042666955314070706,0.10481756829521738,0.9165457717714671,LGP Proband,A gene expression signature found in a subset of cancer patients suggestive of a deregulated immune or inflammatory response.,CGP,C2,10,20
Cohort,-0.004838053178228126,0.013317574650903236,-0.3632833533919778,0.7164896801389213,LonGen OPEL,A gene expression signature found in a subset of cancer patients suggestive of a deregulated immune or inflammatory response.,CGP,C2,13,14
Cohort,0.04089857327097814,0.033119666470261315,1.234872739666676,0.2173069115321264,LGP Offspring,Genes down-regulated in transgenic mice expressing human MYC [GeneID=4609] in prostate.,CGP,C2,28,81
Cohort,0.19749254863097007,0.09335256313371182,2.1155557169661776,0.0346784925449129,LGP Proband,Genes down-regulated in transgenic mice expressing human MYC [GeneID=4609] in prostate.,CGP,C2,28,113
Cohort,-0.018277164904569203,0.02863277839952644,-0.6383301211478482,0.523442408600139,LonGen OPEL,Genes down-regulated in transgenic mice expressing human MYC [GeneID=4609] in prostate.,CGP,C2,58,65
Cohort,-0.017980498105478856,0.02763614366659666,-0.6506153073451988,0.5155159116045541,LGP Offspring,Genes up-regulated in transgenic mice expressing human MYC [GeneID=4609] in prostate.,CGP,C2,26,51
Cohort,0.14622085532928955,0.07268274078316088,2.0117685953192064,0.04456552699249724,LGP Proband,Genes up-regulated in transgenic mice expressing human MYC [GeneID=4609] in prostate.,CGP,C2,26,68
Cohort,-0.011856418637283792,0.02531655379343176,-0.46832672148133664,0.6396791739779328,LonGen OPEL,Genes up-regulated in transgenic mice expressing human MYC [GeneID=4609] in prostate.,CGP,C2,45,54
Cohort,-0.08152237397671266,0.06605485098931452,-1.2341618027402754,0.21757148998590756,LGP Offspring,Genes down-regulated in MCF7 cells (breast cancer) after knockdown of both HIF1A and HIF2A [GeneID=3091;2034] by RNAi.,CGP,C2,132,257
Cohort,0.016908891678774053,0.16359572958631163,0.10335778153581371,0.9177038658139739,LGP Proband,Genes down-regulated in MCF7 cells (breast cancer) after knockdown of both HIF1A and HIF2A [GeneID=3091;2034] by RNAi.,CGP,C2,132,301
Cohort,0.052763964725375596,0.05329646943883047,0.990008630607961,0.32247073781175795,LonGen OPEL,Genes down-regulated in MCF7 cells (breast cancer) after knockdown of both HIF1A and HIF2A [GeneID=3091;2034] by RNAi.,CGP,C2,179,224
Cohort,0.019405923241072865,0.03051520260075369,0.6359427953001223,0.5250289445368437,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) after knockdown of both HIF1A and HIF2A [GeneID=3091;2034] by RNAi.,CGP,C2,24,65
Cohort,0.08335884648008184,0.07351975929216328,1.1338291539940792,0.2571920255085701,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) after knockdown of both HIF1A and HIF2A [GeneID=3091;2034] by RNAi.,CGP,C2,24,68
Cohort,-0.006065235726304526,0.02483875542033661,-0.24418436526568651,0.8071509596446642,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) after knockdown of both HIF1A and HIF2A [GeneID=3091;2034] by RNAi.,CGP,C2,44,48
Cohort,-0.11223793127087535,0.06213746840125739,-1.8062842622761912,0.07131856624768705,LGP Offspring,Genes down-regulated in MCF7 cells (breast cancer) after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,124,223
Cohort,-0.09827964652775013,0.15786626568271087,-0.622550017907426,0.5337504388401397,LGP Proband,Genes down-regulated in MCF7 cells (breast cancer) after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,124,272
Cohort,0.05223144549459155,0.05018490759932061,1.0407799474617074,0.2982937002031631,LonGen OPEL,Genes down-regulated in MCF7 cells (breast cancer) after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,158,201
Cohort,0.04067894284811501,0.0425839567067367,0.955264517298358,0.339785419361309,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,48,130
Cohort,0.08979386000184914,0.10261140784356644,0.8750865219463906,0.38177876974786285,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,48,135
Cohort,-0.02161993509491209,0.03586603549273546,-0.6027969023588104,0.5468155008585456,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,89,98
Cohort,0.0031365576808989916,0.013725100780312917,0.2285271147442519,0.8193055915666865,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) after knockdown of HIF2A [GeneID=2034] by RNAi.,CGP,C2,5,14
Cohort,0.026915155563408594,0.0389234934561409,0.6914886916236506,0.4894509230024514,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) after knockdown of HIF2A [GeneID=2034] by RNAi.,CGP,C2,5,20
Cohort,-0.013327551988661446,0.014662416467560517,-0.9089601306952126,0.36364629390416825,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) after knockdown of HIF2A [GeneID=2034] by RNAi.,CGP,C2,16,13
Cohort,0.050544498630141106,0.037613452914032036,1.3437877863982284,0.17946787247204404,LGP Offspring,Genes down-regulated in MCF7 cells (breast cancer) treated with hypoxia mimetic DMOG [PubChem=3080614].,CGP,C2,32,97
Cohort,0.09056610610811214,0.09616862995709322,0.941742709119588,0.34659708135150935,LGP Proband,Genes down-regulated in MCF7 cells (breast cancer) treated with hypoxia mimetic DMOG [PubChem=3080614].,CGP,C2,32,117
Cohort,0.019998301151811494,0.02925244138524042,0.6836455422111132,0.49439797095577953,LonGen OPEL,Genes down-regulated in MCF7 cells (breast cancer) treated with hypoxia mimetic DMOG [PubChem=3080614].,CGP,C2,50,65
Cohort,-0.015758571341994657,0.06792276635036595,-0.23200720743185327,0.8166026311723852,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) treated with hypoxia mimetic DMOG [PubChem=3080614].,CGP,C2,155,320
Cohort,-0.09547134003438944,0.18456449082689294,-0.5172790259201814,0.6050985533361379,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) treated with hypoxia mimetic DMOG [PubChem=3080614].,CGP,C2,155,386
Cohort,0.0445950575332544,0.058612347742709604,0.7608474877855627,0.4469734876416057,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) treated with hypoxia mimetic DMOG [PubChem=3080614].,CGP,C2,216,267
Cohort,0.06572432865607775,0.06196601237434907,1.0606512528032936,0.28922721940768925,LGP Offspring,Genes down-regulated in MCF7 cells (breast cancer) under hypoxia conditions.,CGP,C2,109,274
Cohort,0.0555203527038381,0.1561268735743314,0.35561048160876085,0.7222222161114766,LGP Proband,Genes down-regulated in MCF7 cells (breast cancer) under hypoxia conditions.,CGP,C2,109,315
Cohort,0.047202415334702506,0.052070259957625355,0.9065139174092027,0.36493822528497544,LonGen OPEL,Genes down-regulated in MCF7 cells (breast cancer) under hypoxia conditions.,CGP,C2,164,211
Cohort,-0.07962763324188057,0.07709818087369581,-1.032808197800783,0.30206301444065375,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) under hypoxia conditions.,CGP,C2,205,404
Cohort,-0.1062134174877267,0.2045031916950716,-0.5193729085954719,0.6036385210914201,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) under hypoxia conditions.,CGP,C2,205,497
Cohort,0.07042181435901561,0.06360205497048418,1.1072254566569628,0.2685309380814527,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) under hypoxia conditions.,CGP,C2,275,349
Cohort,-0.0727051689984439,0.04958121988469504,-1.4663852395629915,0.14300837728618368,LGP Offspring,Down-regulated genes in the cancer progenitor (stem) cells corresponding to side population (SP) MCF7 cells (breast cancer) positive for MUC1 [GeneID=4582].,CGP,C2,89,145
Cohort,-0.2812390206967905,0.13589688345999787,-2.069503093347796,0.03880635463233352,LGP Proband,Down-regulated genes in the cancer progenitor (stem) cells corresponding to side population (SP) MCF7 cells (breast cancer) positive for MUC1 [GeneID=4582].,CGP,C2,89,209
Cohort,0.006033952465998119,0.043607077828551,0.13837094266489672,0.889982256742798,LonGen OPEL,Down-regulated genes in the cancer progenitor (stem) cells corresponding to side population (SP) MCF7 cells (breast cancer) positive for MUC1 [GeneID=4582].,CGP,C2,117,151
Cohort,-0.04641268677461603,0.03949539730690665,-1.175141660532169,0.2403517894558185,LGP Offspring,Up-regulated genes in the cancer progenitor (stem) cells corresponding to side population (SP) MCF7 cells (breast cancer) positive for MUC1 [GeneID=4582].,CGP,C2,52,86
Cohort,-0.1243673994186558,0.10579214978169757,-1.175582495254027,0.2400972377644038,LGP Proband,Up-regulated genes in the cancer progenitor (stem) cells corresponding to side population (SP) MCF7 cells (breast cancer) positive for MUC1 [GeneID=4582].,CGP,C2,52,132
Cohort,0.004595476442868532,0.03439750664404179,0.1335991149133056,0.8937533523856936,LonGen OPEL,Up-regulated genes in the cancer progenitor (stem) cells corresponding to side population (SP) MCF7 cells (breast cancer) positive for MUC1 [GeneID=4582].,CGP,C2,79,99
Cohort,-0.17832300141109383,0.12399041597760381,-1.4381998802496478,0.15084012391308105,LGP Offspring,Genes down-regulated in epidermis after to UVB irradiation.,CGP,C2,508,960
Cohort,-0.41051679691776155,0.3460927726524428,-1.186146690586964,0.23590217814786188,LGP Proband,Genes down-regulated in epidermis after to UVB irradiation.,CGP,C2,508,1424
Cohort,-0.06696209524497972,0.10607933449533236,-0.631245431200609,0.5280612764035655,LonGen OPEL,Genes down-regulated in epidermis after to UVB irradiation.,CGP,C2,775,912
Cohort,0.10304139498532086,0.09940449182028332,1.0365869096902867,0.30029906598553574,LGP Offspring,Genes up-regulated in epidermis after to UVB irradiation.,CGP,C2,285,654
Cohort,0.029179705080853203,0.2603990301582503,0.11205765652475759,0.9108046549875081,LGP Proband,Genes up-regulated in epidermis after to UVB irradiation.,CGP,C2,285,872
Cohort,0.04713057998132068,0.08719024133815202,0.540548796034788,0.5889698332349704,LonGen OPEL,Genes up-regulated in epidermis after to UVB irradiation.,CGP,C2,474,587
Cohort,-0.4253875567740197,0.11529481631345853,-3.689563593366544,2.4270825279147163e-4,LGP Offspring,Genes down-regulated in NHEK cells (normal epidermal keratinocytes) after UVB irradiation.,CGP,C2,510,893
Cohort,-0.029266020901840897,0.33829054929612556,-0.08651149422510952,0.9310805844238205,LGP Proband,Genes down-regulated in NHEK cells (normal epidermal keratinocytes) after UVB irradiation.,CGP,C2,510,1293
Cohort,-0.08984866021136434,0.10649900720541039,-0.8436572562415382,0.39911441337792586,LonGen OPEL,Genes down-regulated in NHEK cells (normal epidermal keratinocytes) after UVB irradiation.,CGP,C2,745,882
Cohort,0.007653443830135345,0.10352544182590688,0.07392814457151245,0.9410894306861326,LGP Offspring,Genes up-regulated in NHEK cells (normal epidermal keratinocytes) after UVB irradiation.,CGP,C2,331,696
Cohort,-0.22598500688496861,0.28554348766099896,-0.7914206299576373,0.42892359290699256,LGP Proband,Genes up-regulated in NHEK cells (normal epidermal keratinocytes) after UVB irradiation.,CGP,C2,331,1031
Cohort,0.07710317896831806,0.08832291211565772,0.8729691664531218,0.382943143955491,LonGen OPEL,Genes up-regulated in NHEK cells (normal epidermal keratinocytes) after UVB irradiation.,CGP,C2,533,674
Cohort,-0.013866301847186636,0.04238960044171869,-0.32711565343134963,0.743681678174354,LGP Offspring,Shared human hematopoietic stem cell (HSC) and acute myeloid leukemia (AML) stem cell (LSC) genes: HSC genes that are highly expressed in LSC versus other leukemic cells.,CGP,C2,59,113
Cohort,-0.10797728950470997,0.11476826407420743,-0.9408288116555765,0.3470650129241801,LGP Proband,Shared human hematopoietic stem cell (HSC) and acute myeloid leukemia (AML) stem cell (LSC) genes: HSC genes that are highly expressed in LSC versus other leukemic cells.,CGP,C2,59,147
Cohort,-0.012467684363782889,0.03378606478917524,-0.3690185418627809,0.712212037024873,LonGen OPEL,Shared human hematopoietic stem cell (HSC) and acute myeloid leukemia (AML) stem cell (LSC) genes: HSC genes that are highly expressed in LSC versus other leukemic cells.,CGP,C2,85,95
Cohort,-0.09053993952637697,0.06198877999867839,-1.46058592423189,0.14459371349658368,LGP Offspring,Genes up-regulated in human hematopoietic stem cell (HSC) enriched populations compared to committed progenitors and mature cells.,CGP,C2,134,237
Cohort,-0.2068821164995676,0.17010641621656952,-1.216192317144448,0.22425577136437508,LGP Proband,Genes up-regulated in human hematopoietic stem cell (HSC) enriched populations compared to committed progenitors and mature cells.,CGP,C2,134,343
Cohort,-0.05961099890119088,0.054744709644869056,-1.0888905848234398,0.2765316932549437,LonGen OPEL,Genes up-regulated in human hematopoietic stem cell (HSC) enriched populations compared to committed progenitors and mature cells.,CGP,C2,200,212
Cohort,-0.09718046335184345,0.034043625103372666,-2.8545862274289906,0.004441306853283415,LGP Offspring,Genes up-regulated in functionally defined leukemic stem cells (LSC) from acute myeloid leukemia (AML) patients.,CGP,C2,48,61
Cohort,0.02745737230005805,0.09203226808080386,0.2983450573656472,0.7655141316894102,LGP Proband,Genes up-regulated in functionally defined leukemic stem cells (LSC) from acute myeloid leukemia (AML) patients.,CGP,C2,48,93
Cohort,0.028046065687496968,0.029424615592059757,0.953149773520413,0.34080353146537956,LonGen OPEL,Genes up-regulated in functionally defined leukemic stem cells (LSC) from acute myeloid leukemia (AML) patients.,CGP,C2,50,71
Cohort,-0.0475558216067531,0.07564559335606046,-0.6286661191605696,0.5297800184809136,LGP Offspring,Genes up-regulated in human hematopoietic lineage committed progenitor cells versus hematopoietic stem cells (HSC) and mature cells.,CGP,C2,178,368
Cohort,0.15756399413758732,0.20761617414044412,0.7589196496367452,0.4481150518734678,LGP Proband,Genes up-regulated in human hematopoietic lineage committed progenitor cells versus hematopoietic stem cells (HSC) and mature cells.,CGP,C2,178,521
Cohort,-0.030294382643806284,0.06654288369428861,-0.4552610431340002,0.6490455976945633,LonGen OPEL,Genes up-regulated in human hematopoietic lineage committed progenitor cells versus hematopoietic stem cells (HSC) and mature cells.,CGP,C2,308,347
Cohort,-0.005284419200966023,0.03404969543234941,-0.1551972531285987,0.8767121415552798,LGP Offspring,Genes down-regulated in B-CLL (B-cell chronic lymphocytic leukemia) patients with mutated immunoglobulin variable heavy chain (VH) genes.,CGP,C2,39,78
Cohort,-0.07557348712348125,0.10001046656993252,-0.7556557799941502,0.45006896618379566,LGP Proband,Genes down-regulated in B-CLL (B-cell chronic lymphocytic leukemia) patients with mutated immunoglobulin variable heavy chain (VH) genes.,CGP,C2,39,126
Cohort,7.171448647853157e-4,0.03168756848057596,0.02263174169469379,0.9819496959866483,LonGen OPEL,Genes down-regulated in B-CLL (B-cell chronic lymphocytic leukemia) patients with mutated immunoglobulin variable heavy chain (VH) genes.,CGP,C2,74,85
Cohort,-0.012403832398306447,0.03595805841746045,-0.3449527851115403,0.7302371648189461,LGP Offspring,Genes up-regulated in B-CLL (B-cell chronic lymphocytic leukemia) patients with mutated immunoglobulin variable heavy chain (VH) genes.,CGP,C2,47,93
Cohort,0.05870379841295794,0.10134552989442303,0.5792440818466564,0.5625809067417482,LGP Proband,Genes up-regulated in B-CLL (B-cell chronic lymphocytic leukemia) patients with mutated immunoglobulin variable heavy chain (VH) genes.,CGP,C2,47,119
Cohort,0.01859784700859388,0.031327753315962686,0.5936540300551194,0.5529121881015538,LonGen OPEL,Genes up-regulated in B-CLL (B-cell chronic lymphocytic leukemia) patients with mutated immunoglobulin variable heavy chain (VH) genes.,CGP,C2,64,81
Cohort,-0.03180606846302502,0.02839165324038152,-1.1202612328959827,0.26300029768238775,LGP Offspring,Genes down-regulated in samples from B-CLL (B-cell chronic lymphocytic leukemia) with the immunoglobulin heavy chain VH3-21 gene.,CGP,C2,31,45
Cohort,-0.027461448489732043,0.07545114684537114,-0.3639633012605,0.7159776626431752,LGP Proband,Genes down-regulated in samples from B-CLL (B-cell chronic lymphocytic leukemia) with the immunoglobulin heavy chain VH3-21 gene.,CGP,C2,31,61
Cohort,0.022742789796567152,0.02424551676644473,0.9380204190179473,0.3485184385572263,LonGen OPEL,Genes down-regulated in samples from B-CLL (B-cell chronic lymphocytic leukemia) with the immunoglobulin heavy chain VH3-21 gene.,CGP,C2,32,50
Cohort,0.07015884164984776,0.03886035397041977,1.8054092276990625,0.07145544221327024,LGP Offspring,Genes up-regulated in samples from B-CLL (B-cell chronic lymphocytic leukemia) with the immunoglobulin heavy chain VH3-21 gene.,CGP,C2,37,104
Cohort,-0.020073488569966665,0.10237135539263886,-0.19608501316580276,0.8445913932721855,LGP Proband,Genes up-regulated in samples from B-CLL (B-cell chronic lymphocytic leukemia) with the immunoglobulin heavy chain VH3-21 gene.,CGP,C2,37,128
Cohort,-0.0011344468000288118,0.034913855348350356,-0.03249273930678679,0.9740872515973071,LonGen OPEL,Genes up-regulated in samples from B-CLL (B-cell chronic lymphocytic leukemia) with the immunoglobulin heavy chain VH3-21 gene.,CGP,C2,78,100
Cohort,-0.0019449492520974953,0.052124594007326434,-0.03731346572836847,0.9702460847805852,LGP Offspring,Genes that distinguish normal from cancer (lung adenocarcinoma) samples and smokers from non-smoking subjects.,CGP,C2,96,195
Cohort,-0.04921661313535362,0.1422808880698178,-0.3459116245549636,0.7294963708593657,LGP Proband,Genes that distinguish normal from cancer (lung adenocarcinoma) samples and smokers from non-smoking subjects.,CGP,C2,96,258
Cohort,-0.0032186437164916475,0.046202463267865486,-0.0696638986071174,0.9444786733332964,LonGen OPEL,Genes that distinguish normal from cancer (lung adenocarcinoma) samples and smokers from non-smoking subjects.,CGP,C2,153,172
Cohort,-0.05021703674284549,0.026304871636617322,-1.9090394143167604,0.05668014350605219,LGP Offspring,"Genes in the hypoxia signature, based on analysis of 11 neuroblastoma cell lines in hypoxia and normal oxygen conditions.",CGP,C2,27,39
Cohort,0.05753147507556253,0.06683656301618202,0.8607784793127886,0.3896074486393305,LGP Proband,"Genes in the hypoxia signature, based on analysis of 11 neuroblastoma cell lines in hypoxia and normal oxygen conditions.",CGP,C2,27,48
Cohort,-0.027325179937784612,0.0236233154813221,-1.1567038487628636,0.24774038957348474,LonGen OPEL,"Genes in the hypoxia signature, based on analysis of 11 neuroblastoma cell lines in hypoxia and normal oxygen conditions.",CGP,C2,41,42
Cohort,-0.0012990446134118754,0.004529092629308404,-0.2868222665629695,0.7743363009740881,LGP Offspring,"Genes in the hypoxia signature, based on analysis of nine neuroblastoma cell lines in hypoxia and normal oxygen conditions.",CGP,C2,1,1
Cohort,-4.36743308425765e-4,0.013758543345914042,-0.03174342642569551,0.9746842579266446,LGP Proband,"Genes in the hypoxia signature, based on analysis of nine neuroblastoma cell lines in hypoxia and normal oxygen conditions.",CGP,C2,1,2
Cohort,-0.0021713726246573384,0.0044702847249631405,-0.48573474806467554,0.6272889174081209,LonGen OPEL,"Genes in the hypoxia signature, based on analysis of nine neuroblastoma cell lines in hypoxia and normal oxygen conditions.",CGP,C2,2,1
Cohort,0.05484610008523767,0.09693649076369729,0.565794157114026,0.5717214716917127,LGP Offspring,Genes which best discriminate between two groups of breast cancer according the status of ESR1 and AR [GeneID=2099;367]: apocrine (ESR1- AR+) vs basal (ESR1- AR-).,CGP,C2,292,639
Cohort,0.13971433494648752,0.27847014660407715,0.5017210521497313,0.6159961705072412,LGP Proband,Genes which best discriminate between two groups of breast cancer according the status of ESR1 and AR [GeneID=2099;367]: apocrine (ESR1- AR+) vs basal (ESR1- AR-).,CGP,C2,292,854
Cohort,-0.1138651187145581,0.0839026127135177,-1.3571105241185544,0.1751307748865783,LonGen OPEL,Genes which best discriminate between two groups of breast cancer according the status of ESR1 and AR [GeneID=2099;367]: apocrine (ESR1- AR+) vs basal (ESR1- AR-).,CGP,C2,508,566
Cohort,-0.06771636685745747,0.09842284487855066,-0.6880147280950515,0.4916795170969016,LGP Offspring,Genes which best discriminate between two groups of breast cancer according to the status of ESR1 and AR [GeneID=2099;367]: apocrine (ESR1- AR+) and luminal (ESR1+ AR+).,CGP,C2,293,591
Cohort,-0.29540757871914614,0.2656366873623428,-1.1120737186283092,0.26642691366269033,LGP Proband,Genes which best discriminate between two groups of breast cancer according to the status of ESR1 and AR [GeneID=2099;367]: apocrine (ESR1- AR+) and luminal (ESR1+ AR+).,CGP,C2,293,856
Cohort,0.048255501010018464,0.0900918508734169,0.5356255925724027,0.592366956108962,LonGen OPEL,Genes which best discriminate between two groups of breast cancer according to the status of ESR1 and AR [GeneID=2099;367]: apocrine (ESR1- AR+) and luminal (ESR1+ AR+).,CGP,C2,471,597
Cohort,0.009927666057363681,0.10068743761628751,0.09859885495544432,0.9214860082692691,LGP Offspring,Genes which best discriminated between two groups of breast cancer according to the status of ESR1 and AR [GeneID=2099;367]: basal (ESR1- AR-) and luminal (ESR1+ AR+).,CGP,C2,333,694
Cohort,-0.40486739406096006,0.27349814544924433,-1.4803295773575735,0.13916296429408773,LGP Proband,Genes which best discriminated between two groups of breast cancer according to the status of ESR1 and AR [GeneID=2099;367]: basal (ESR1- AR-) and luminal (ESR1+ AR+).,CGP,C2,333,911
Cohort,0.044685033769905035,0.0864188893294139,0.5170748445929847,0.605247554223743,LonGen OPEL,Genes which best discriminated between two groups of breast cancer according to the status of ESR1 and AR [GeneID=2099;367]: basal (ESR1- AR-) and luminal (ESR1+ AR+).,CGP,C2,498,627
Cohort,-0.010996813309766625,0.02522505228592614,-0.43594808784210515,0.6630135722780353,LGP Offspring,"Cluster 1: interferon, T and B lymphocyte genes clustered together across breast cancer samples.",CGP,C2,21,36
Cohort,-0.01670433606582181,0.07257323797698882,-0.23017212034990558,0.8180144685818511,LGP Proband,"Cluster 1: interferon, T and B lymphocyte genes clustered together across breast cancer samples.",CGP,C2,21,62
Cohort,-0.013992836764715974,0.021877575916013046,-0.6395972213024786,0.5226185166254799,LonGen OPEL,"Cluster 1: interferon, T and B lymphocyte genes clustered together across breast cancer samples.",CGP,C2,35,38
Cohort,-0.00950110373918704,0.03167001696396856,-0.3000031149334901,0.76426700629431,LGP Offspring,Cluster 2: selected proliferation and 8q amplicon genes clustered together across breast cancer samples.,CGP,C2,39,69
Cohort,-0.16949927268314008,0.08256862913533014,-2.052828955235898,0.04040068533155918,LGP Proband,Cluster 2: selected proliferation and 8q amplicon genes clustered together across breast cancer samples.,CGP,C2,39,77
Cohort,-0.014259484996705669,0.02608304416335452,-0.5466955815203346,0.584741101963889,LonGen OPEL,Cluster 2: selected proliferation and 8q amplicon genes clustered together across breast cancer samples.,CGP,C2,48,59
Cohort,0.012706321539439135,0.02294609908346341,0.5537464774827985,0.5799354710859079,LGP Offspring,"Cluster 3: selected apocrine, basal and hypoxia genes clustered together across breast cancer samples.",CGP,C2,15,41
Cohort,0.013564371564345553,0.058627588616910656,0.2313649918808535,0.8170880099242881,LGP Proband,"Cluster 3: selected apocrine, basal and hypoxia genes clustered together across breast cancer samples.",CGP,C2,15,45
Cohort,-0.006073727266305167,0.018069902237245597,-0.33612396938075456,0.7368659660172376,LonGen OPEL,"Cluster 3: selected apocrine, basal and hypoxia genes clustered together across breast cancer samples.",CGP,C2,25,27
Cohort,0.01927118508250067,0.02843751677156835,0.6776676471895,0.49821430869964234,LGP Offspring,Cluster 4: selected stromal genes clustered together across breast cancer samples.,CGP,C2,22,55
Cohort,0.12096574167851075,0.07195053556427544,1.681234763992113,0.09309172863014359,LGP Proband,Cluster 4: selected stromal genes clustered together across breast cancer samples.,CGP,C2,22,61
Cohort,0.015303704839801239,0.02142918267450027,0.7141525214590632,0.47534222804465,LonGen OPEL,Cluster 4: selected stromal genes clustered together across breast cancer samples.,CGP,C2,29,39
Cohort,1.606215713257083e-4,0.011858703865339215,0.013544614415676174,0.9891972880155924,LGP Offspring,Cluster 5: selected 17q21_23 amplicon genes clustered together across breast cancer samples.,CGP,C2,4,10
Cohort,0.08120992205269885,0.04018447689158543,2.020927689858869,0.04360632701767926,LGP Proband,Cluster 5: selected 17q21_23 amplicon genes clustered together across breast cancer samples.,CGP,C2,4,23
Cohort,1.1799374640410852e-4,0.01270803261868688,0.009284973523801105,0.9925940958961932,LonGen OPEL,Cluster 5: selected 17q21_23 amplicon genes clustered together across breast cancer samples.,CGP,C2,11,14
Cohort,-0.005030097307532333,0.02098171945693508,-0.2397371348833728,0.8106067179739206,LGP Offspring,Cluster 6: selected luminal genes clustered together across breast cancer samples.,CGP,C2,15,29
Cohort,0.013759611559979198,0.058467788232623615,0.23533661826293725,0.81400524810636,LGP Proband,Cluster 6: selected luminal genes clustered together across breast cancer samples.,CGP,C2,15,38
Cohort,0.004066157921072039,0.01980132805492917,0.2053477377776106,0.8373529502931973,LonGen OPEL,Cluster 6: selected luminal genes clustered together across breast cancer samples.,CGP,C2,25,31
Cohort,0.03302263697041171,0.029512673101581403,1.1189307338155767,0.26356712502311547,LGP Offspring,Cluster 7: selected apocrine and luminal genes clustered together across breast cancer samples.,CGP,C2,24,63
Cohort,-0.1283475342990145,0.08014928762207903,-1.6013558960648593,0.10967679566499072,LGP Proband,Cluster 7: selected apocrine and luminal genes clustered together across breast cancer samples.,CGP,C2,24,86
Cohort,-0.018043953917855463,0.024673197387078592,-0.7313180223372721,0.46480014817001414,LonGen OPEL,Cluster 7: selected apocrine and luminal genes clustered together across breast cancer samples.,CGP,C2,47,46
Cohort,-0.021876759457814105,0.014323809517703899,-1.527300361735119,0.12715407606999368,LGP Offspring,Cluster 8: selected ERBB2 [GeneID=2064] amplicon genes clustered together across breast cancer samples.,CGP,C2,10,11
Cohort,-0.024130381290560495,0.04416647051630776,-0.5463506820553102,0.5849710290080246,LGP Proband,Cluster 8: selected ERBB2 [GeneID=2064] amplicon genes clustered together across breast cancer samples.,CGP,C2,10,21
Cohort,-0.0027517284789165906,0.013258113363928542,-0.20755053176745653,0.8356330194032168,LonGen OPEL,Cluster 8: selected ERBB2 [GeneID=2064] amplicon genes clustered together across breast cancer samples.,CGP,C2,13,14
Cohort,0.08493481727301805,0.0711716770495505,1.1933794564639175,0.23313944400721254,LGP Offspring,Genes identified by ChIP within the high-affinity group of MYC [GeneID=4609] targets.,CGP,C2,145,332
Cohort,0.12928998213084034,0.200301891262581,0.6454755934448503,0.5187965662739322,LGP Proband,Genes identified by ChIP within the high-affinity group of MYC [GeneID=4609] targets.,CGP,C2,145,454
Cohort,0.044344532193981566,0.06652639590320297,0.6665704881789118,0.505239674555896,LonGen OPEL,Genes identified by ChIP within the high-affinity group of MYC [GeneID=4609] targets.,CGP,C2,270,334
Cohort,-0.06959128282164066,0.028214265860362152,-2.4665282154092316,0.013889972160502166,LGP Offspring,"Nearest neighbors of HOX11 [GeneID=3195], based on the close agreement of their expression profiles with that of HOX11 in pediatric T cell acute lymphoblastic leukemia (T-ALL).",CGP,C2,33,39
Cohort,0.04103062159757078,0.0752433199502649,0.5453058374443289,0.5856889906074696,LGP Proband,"Nearest neighbors of HOX11 [GeneID=3195], based on the close agreement of their expression profiles with that of HOX11 in pediatric T cell acute lymphoblastic leukemia (T-ALL).",CGP,C2,33,58
Cohort,0.012313031045584457,0.022824142285481443,0.5394739873058381,0.5897107067760418,LonGen OPEL,"Nearest neighbors of HOX11 [GeneID=3195], based on the close agreement of their expression profiles with that of HOX11 in pediatric T cell acute lymphoblastic leukemia (T-ALL).",CGP,C2,30,41
Cohort,0.015289532893434044,0.020957693344862187,0.7295427336321006,0.4659224404149548,LGP Offspring,"Nearest neighbors of LYL1 [GeneID=4066], based on the close agreement of their expression profiles with that of LYL1 in pediatric T cell acute lymphoblastic leukemia (T-ALL).",CGP,C2,12,31
Cohort,0.03263351053337059,0.05557005458196555,0.5872499276608829,0.55719480776217,LGP Proband,"Nearest neighbors of LYL1 [GeneID=4066], based on the close agreement of their expression profiles with that of LYL1 in pediatric T cell acute lymphoblastic leukemia (T-ALL).",CGP,C2,12,39
Cohort,-0.031183394114234212,0.02057838885411441,-1.5153467229772681,0.13008160176883843,LonGen OPEL,"Nearest neighbors of LYL1 [GeneID=4066], based on the close agreement of their expression profiles with that of LYL1 in pediatric T cell acute lymphoblastic leukemia (T-ALL).",CGP,C2,34,25
Cohort,0.01656788668957358,0.05075020330600382,0.3264595136629448,0.7441777609558375,LGP Offspring,Top 100 genes negatively associated with T-cell acute lymphoblastic leukemia MLL T-ALL) expressing MLL-ENL fusion [GeneID=4297;4298].,CGP,C2,77,177
Cohort,0.18062584866128845,0.1273882321114553,1.4179162836898007,0.15658872204816754,LGP Proband,Top 100 genes negatively associated with T-cell acute lymphoblastic leukemia MLL T-ALL) expressing MLL-ENL fusion [GeneID=4297;4298].,CGP,C2,77,196
Cohort,0.018913026139703023,0.041472220808821784,0.4560408333782774,0.6484850054672522,LonGen OPEL,Top 100 genes negatively associated with T-cell acute lymphoblastic leukemia MLL T-ALL) expressing MLL-ENL fusion [GeneID=4297;4298].,CGP,C2,110,145
Cohort,-0.011479915003204806,0.0527396080738565,-0.21767160247244052,0.8277506763467642,LGP Offspring,Top 100 genes positively associated with T-cell acute lymphoblastic leukemia MLL T-ALL) expressing MLL-ENL fusion [GeneID=4297;4298].,CGP,C2,95,191
Cohort,0.030862663128718982,0.14708391254434558,0.20983031111178754,0.8338513616069316,LGP Proband,Top 100 genes positively associated with T-cell acute lymphoblastic leukemia MLL T-ALL) expressing MLL-ENL fusion [GeneID=4297;4298].,CGP,C2,95,259
Cohort,0.004721619023148545,0.05085294773349413,0.0928484824103651,0.9260472969649096,LonGen OPEL,Top 100 genes positively associated with T-cell acute lymphoblastic leukemia MLL T-ALL) expressing MLL-ENL fusion [GeneID=4297;4298].,CGP,C2,160,199
Cohort,-0.016617007447593268,0.01978926002225078,-0.8396982721389948,0.4013744453384017,LGP Offspring,"Nearest neighbors of TAL1 [GeneID=6886], based on the close agreement of their expression profiles with that of TAL1 in pediatric T cell acute lymphoblastic leukemia (T-ALL)",CGP,C2,14,24
Cohort,-0.011850239033848886,0.05948520641323924,-0.1992132119627554,0.8421445216457071,LGP Proband,"Nearest neighbors of TAL1 [GeneID=6886], based on the close agreement of their expression profiles with that of TAL1 in pediatric T cell acute lymphoblastic leukemia (T-ALL)",CGP,C2,14,43
Cohort,0.007227331613104094,0.01751113879287186,0.41272767571496116,0.6799172869981847,LonGen OPEL,"Nearest neighbors of TAL1 [GeneID=6886], based on the close agreement of their expression profiles with that of TAL1 in pediatric T cell acute lymphoblastic leukemia (T-ALL)",CGP,C2,19,28
Cohort,0.013923631320878817,0.0144478164232033,0.9637187318159278,0.3355315701438304,LGP Offspring,Genes down-regulated in HUVEC cells (umbilical vein endothelium) by fenretinide [PubChem=1744].,CGP,C2,5,16
Cohort,0.017451366466354163,0.04404473614479048,0.39621911705828833,0.6920447375074351,LGP Proband,Genes down-regulated in HUVEC cells (umbilical vein endothelium) by fenretinide [PubChem=1744].,CGP,C2,5,23
Cohort,-0.010740383393645482,0.015231848271374169,-0.7051267319823767,0.480937646132478,LonGen OPEL,Genes down-regulated in HUVEC cells (umbilical vein endothelium) by fenretinide [PubChem=1744].,CGP,C2,18,18
Cohort,0.010170998885571646,0.020847171942756884,0.4878838680613197,0.6257902974994194,LGP Offspring,Genes up-regulated in HUVEC cells (umbilical vein endothelium) by fenretinide [PubChem=1744].,CGP,C2,11,25
Cohort,0.03040662762284831,0.050507620870792955,0.602020588153095,0.5473240580123495,LGP Proband,Genes up-regulated in HUVEC cells (umbilical vein endothelium) by fenretinide [PubChem=1744].,CGP,C2,11,28
Cohort,-0.006908468025518506,0.015772759516248302,-0.43799995925898383,0.6615051418302476,LonGen OPEL,Genes up-regulated in HUVEC cells (umbilical vein endothelium) by fenretinide [PubChem=1744].,CGP,C2,20,19
Cohort,-0.03174110007842177,0.05362698769394245,-0.5918866869713652,0.5541243619835576,LGP Offspring,Genes down-regulated in genomically unstable Ewing's sarcoma tumors compared to the stable ones.,CGP,C2,96,190
Cohort,-0.26091421893525873,0.1541282708823428,-1.6928381629249143,0.09085974544739982,LGP Proband,Genes down-regulated in genomically unstable Ewing's sarcoma tumors compared to the stable ones.,CGP,C2,96,297
Cohort,-0.08005118263370893,0.04999084274059388,-1.6013169261638645,0.10970349823197267,LonGen OPEL,Genes down-regulated in genomically unstable Ewing's sarcoma tumors compared to the stable ones.,CGP,C2,176,177
Cohort,-0.09581107447899187,0.06535304973150916,-1.4660536099327246,0.14309867172829369,LGP Offspring,Genes up-regulated in genomically unstable Ewing's sarcoma tumors compared to the stable ones.,CGP,C2,150,260
Cohort,-0.36582066930025176,0.18168241958313142,-2.0135171588953065,0.044381040984889146,LGP Proband,Genes up-regulated in genomically unstable Ewing's sarcoma tumors compared to the stable ones.,CGP,C2,150,374
Cohort,-0.1055223054375478,0.057900611423240746,-1.8224730766002268,0.0687582834482089,LonGen OPEL,Genes up-regulated in genomically unstable Ewing's sarcoma tumors compared to the stable ones.,CGP,C2,238,246
Cohort,-0.012145209052787776,0.12224811016198649,-0.09934884912899353,0.9208907477733055,LGP Offspring,Genes down-regulated in intestinal crypt cells upon deletion of CTNNB1 [GeneID=1499].,CGP,C2,474,997
Cohort,0.01677077838275004,0.3445410984096222,0.048675697790953786,0.9611893972435561,LGP Proband,Genes down-regulated in intestinal crypt cells upon deletion of CTNNB1 [GeneID=1499].,CGP,C2,474,1453
Cohort,0.03884475876357163,0.11117385539685734,0.34940552007400916,0.7268773035230177,LonGen OPEL,Genes down-regulated in intestinal crypt cells upon deletion of CTNNB1 [GeneID=1499].,CGP,C2,833,1011
Cohort,-0.21341307291158432,0.15344808548531702,-1.390783548954771,0.16474870309922532,LGP Offspring,Genes up-regulated in intestinal crypt cells upon deletion of CTNNB1 [GeneID=1499].,CGP,C2,753,1488
Cohort,-1.0653056508476602,0.4233243628240005,-2.516523366954354,0.012038514799212599,LGP Proband,Genes up-regulated in intestinal crypt cells upon deletion of CTNNB1 [GeneID=1499].,CGP,C2,753,2008
Cohort,-0.14854353266557957,0.1359414564967531,-1.0927022300156646,0.27485514920608956,LonGen OPEL,Genes up-regulated in intestinal crypt cells upon deletion of CTNNB1 [GeneID=1499].,CGP,C2,1154,1357
Cohort,-0.10662355168916843,0.044004113614443105,-2.423036005755886,0.015653049828948613,LGP Offspring,Cluster 1 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,76,102
Cohort,-0.05491953346013459,0.12212643713114332,-0.44969406092769426,0.65304790388937906,LGP Proband,Cluster 1 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,76,165
Cohort,0.01632256347489542,0.03358708299831572,0.48597740612705015,0.6271169355395652,LonGen OPEL,Cluster 1 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,80,97
Cohort,0.05417886411708829,0.05534116312539362,0.9789975681271506,0.32793140378693364,LGP Offspring,Cluster 1 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,77,184
Cohort,0.11679968172227559,0.1507422971253053,0.774830183363766,0.43865962780942247,LGP Proband,Cluster 1 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,77,256
Cohort,0.024219338855928585,0.04379347327968517,0.5530353507531316,0.5803944817375566,LonGen OPEL,Cluster 1 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,138,170
Cohort,0.005179108340606322,0.021507542446333065,0.24080428312670077,0.8097798231704473,LGP Offspring,Cluster 2 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,14,33
Cohort,0.019214713926003428,0.058102561784691725,0.33070338614683814,0.7409516073406937,LGP Proband,Cluster 2 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,14,36
Cohort,-0.045958407370689736,0.01831596372979392,-2.5091995184468967,0.012298104000058627,LonGen OPEL,Cluster 2 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,29,18
Cohort,-0.01780312328017239,0.03738346401388677,-0.47622989869422194,0.6340644791304426,LGP Offspring,Cluster 2 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,45,85
Cohort,0.0961810261386544,0.09669218201207322,0.9947135759811998,0.32016409846590055,LGP Proband,Cluster 2 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,45,105
Cohort,-0.01139631508523637,0.03160178751016475,-0.3606224831924692,0.7184773552683867,LonGen OPEL,Cluster 2 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,73,77
Cohort,-0.04973739604157381,0.039360647255934175,-1.263632574895607,0.20679753030821035,LGP Offspring,Cluster 3 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,62,104
Cohort,0.014472415549375036,0.11196839230607132,0.12925447308213509,0.8971874589774014,LGP Proband,Cluster 3 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,62,160
Cohort,-0.027856443837114456,0.0353321606796031,-0.7884160861182685,0.4306880974987277,LonGen OPEL,Cluster 3 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,100,98
Cohort,0.05127157605563284,0.06498131679718293,0.7890202689437584,0.4303767911571592,LGP Offspring,Cluster 3 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,116,266
Cohort,0.12027632156585778,0.1734103842931569,0.6935935356819581,0.48813027166947265,LGP Proband,Cluster 3 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,116,359
Cohort,0.047416922046698194,0.054620239501690496,0.8681199950657602,0.38559029162383296,LonGen OPEL,Cluster 3 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,201,256
Cohort,-4.541698861034946e-4,0.02085678543661191,-0.02177564167228986,0.9826333505024734,LGP Offspring,Cluster 4 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,15,30
Cohort,-0.0010002386205375528,0.06624214411117738,-0.015099731960046527,0.9879562261361483,LGP Proband,Cluster 4 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,15,60
Cohort,-0.01999531057695935,0.019082887857904483,-1.0478136603772434,0.2950425130279657,LonGen OPEL,Cluster 4 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,29,27
Cohort,-0.026762168724061564,0.04968725814683634,-0.538612306699913,0.590331705097008,LGP Offspring,Cluster 4 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,80,155
Cohort,0.05826430433752379,0.13172192199805483,0.44232807609946806,0.6583665007037638,LGP Proband,Cluster 4 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,80,208
Cohort,0.004583289358994497,0.04314902429666248,0.10621999995835384,0.9154345655635028,LonGen OPEL,Cluster 4 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,123,149
Cohort,0.009910315308878639,0.0383526595774101,0.2583996890457073,0.7961771090951815,LGP Offspring,Cluster 5 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,46,94
Cohort,-0.07736443081230053,0.1084282526504891,-0.713508047221598,0.47573104453674386,LGP Proband,Cluster 5 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,46,138
Cohort,-0.008702802443800756,0.03289431267127492,-0.2645686058490138,0.7914102956966835,LonGen OPEL,Cluster 5 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,73,86
Cohort,-0.014064013718031372,0.013399177720256419,-1.0496176714463514,0.2942690217312556,LGP Offspring,Cluster 5 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,9,10
Cohort,0.03629432988079501,0.03823380722671738,0.9492732352176769,0.34275665031088687,LGP Proband,Cluster 5 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,9,17
Cohort,-0.014601976271584573,0.013476274505048775,-1.0835321190670362,0.27890039293371716,LonGen OPEL,Cluster 5 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,16,12
Cohort,-0.027848564099325065,0.03495142090004391,-0.7967791689776502,0.42585903799013103,LGP Offspring,Cluster 6 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,41,76
Cohort,-0.12204085306911434,0.09279741302619797,-1.3151320612209367,0.18882699156764593,LGP Proband,Cluster 6 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,41,98
Cohort,0.03707884019055997,0.031197697313808306,1.1885120820807706,0.23498618356067366,LonGen OPEL,Cluster 6 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,61,91
Cohort,0.02110498131258971,0.06079580913418948,0.3471453314488579,0.7285901836942037,LGP Offspring,Cluster 6 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,107,233
Cohort,0.054794385146327555,0.16259594777146616,0.336997236999675,0.7362037690685941,LGP Proband,Cluster 6 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,107,304
Cohort,0.05319570063539741,0.049413295344997214,1.0765463073043788,0.2820091672101156,LonGen OPEL,Cluster 6 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,169,224
Cohort,-0.005754864357709341,0.00224787340016311,-2.5601372200461805,0.010679323144526423,LGP Offspring,Cluster 7 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,1,0
Cohort,1.4813923376982247e-4,0.01984528403193165,0.007464707158207565,0.9940458658658967,LGP Proband,Cluster 7 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,1,6
Cohort,-0.008444208430364808,0.0076442356693899,-1.1046504576223715,0.26964487006874155,LonGen OPEL,Cluster 7 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,5,4
Cohort,0.025711035453027758,0.05279274142781484,0.4870183808920637,0.6264031793704452,LGP Offspring,Cluster 7 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,85,189
Cohort,0.03464906000564371,0.14010372271214638,0.24731005953947993,0.8047291420458739,LGP Proband,Cluster 7 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,85,237
Cohort,-0.004715610784420549,0.04719842251455157,-0.09991034727837983,0.9204406582817066,LonGen OPEL,Cluster 7 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.,CGP,C2,157,176
Cohort,0.02307564580700497,0.02484780651392916,0.9286793904350972,0.35338674109989665,LGP Offspring,Genes in the stroma-derived prognostic predictor of breast cancer disease outcome.,CGP,C2,13,39
Cohort,-0.07128556367891173,0.058456712773631285,-1.219458985915939,0.22301479260042914,LGP Proband,Genes in the stroma-derived prognostic predictor of breast cancer disease outcome.,CGP,C2,13,42
Cohort,0.0037830058356589954,0.021068572955023738,0.17955681401558568,0.8575462070536075,LonGen OPEL,Genes in the stroma-derived prognostic predictor of breast cancer disease outcome.,CGP,C2,24,32
Cohort,0.006463592689390885,0.01912098086746361,0.33803666946758876,0.7354405052380234,LGP Offspring,Genes in the green cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,10,26
Cohort,0.050367201897297306,0.05352612427969151,0.9409835398152909,0.3469857610755691,LGP Proband,Genes in the green cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,10,36
Cohort,0.013472309482183201,0.01433912945041705,0.9395486336021162,0.3477341458930925,LonGen OPEL,Genes in the green cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,12,18
Cohort,-0.04155116940134187,0.020797770407104687,-1.9978665303059433,0.04613134557026805,LGP Offspring,Genes in the red cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,20,23
Cohort,-0.06109582300185886,0.06281504491947967,-0.9726304117138718,0.33101902651514736,LGP Proband,Genes in the red cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,20,43
Cohort,-0.014447484251037486,0.0181995385487953,-0.7938379433248776,0.4275263605708104,LonGen OPEL,Genes in the red cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,27,23
Cohort,0.009578965035195898,0.027280318895946874,0.3511309773075665,0.725599493391149,LGP Offspring,Genes in the blue cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,23,49
Cohort,-0.025625949755245975,0.06798929423435858,-0.37691154238068014,0.7063352219956027,LGP Proband,Genes in the blue cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,23,53
Cohort,-0.026987700137486845,0.02322970609571867,-1.161775358942694,0.2456749594597305,LonGen OPEL,Genes in the blue cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,39,38
Cohort,0.031347878465616714,0.01699071727914416,1.8450002993161296,0.06547472351181013,LGP Offspring,Genes in the gray cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,5,22
Cohort,0.02975403506803823,0.04069524777564066,0.731142742564855,0.46489733126642663,LGP Proband,Genes in the gray cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,5,19
Cohort,0.014554048119865912,0.012779444604615857,1.1388638998136962,0.25510254561757023,LonGen OPEL,Genes in the gray cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.,CGP,C2,8,15
Cohort,0.0027224618240793974,0.03329750617008615,0.08176173345153415,0.9348603880620424,LGP Offspring,"Genes required for CTNNB1 [GeneID=1499] activity in DLD-1 cell (colon cancer with APC [GeneID=324] deletions), based on shRNA screen.",CGP,C2,33,77
Cohort,0.1786996846380562,0.10165529535276678,1.7578984352750933,0.07913160104078902,LGP Proband,"Genes required for CTNNB1 [GeneID=1499] activity in DLD-1 cell (colon cancer with APC [GeneID=324] deletions), based on shRNA screen.",CGP,C2,33,133
Cohort,0.007654693279802924,0.03245709840432831,0.23584034482830213,0.8136172261912694,LonGen OPEL,"Genes required for CTNNB1 [GeneID=1499] activity in DLD-1 cell (colon cancer with APC [GeneID=324] deletions), based on shRNA screen.",CGP,C2,78,87
Cohort,-0.010920116241383462,0.011344979735869488,-0.9625505285705594,0.3361173119664891,LGP Offspring,Genes required for both proliferation and CTNNB1 [GeneID=1499] activity in DLD-1 cell (colon cancer with APC [GeneID=324] deletions).,CGP,C2,6,7
Cohort,0.012303363340799425,0.03970179439397297,0.30989438962655974,0.7567186849004844,LGP Proband,Genes required for both proliferation and CTNNB1 [GeneID=1499] activity in DLD-1 cell (colon cancer with APC [GeneID=324] deletions).,CGP,C2,6,21
Cohort,-0.008446228247272147,0.011113170378021273,-0.7600196847495844,0.44746785657404575,LonGen OPEL,Genes required for both proliferation and CTNNB1 [GeneID=1499] activity in DLD-1 cell (colon cancer with APC [GeneID=324] deletions).,CGP,C2,10,9
Cohort,-0.03279882610764457,0.06828886580765742,-0.48029537055170635,0.6311727613162781,LGP Offspring,"Genes required for proliferation of DLD-1 cell (colon cancer with APC [GeneID=324] deletions), based on shRNA screen.",CGP,C2,155,302
Cohort,-0.05100878142818312,0.198108286083255,-0.2574792929496481,0.7968723124230559,LGP Proband,"Genes required for proliferation of DLD-1 cell (colon cancer with APC [GeneID=324] deletions), based on shRNA screen.",CGP,C2,155,484
Cohort,-0.007877913796969118,0.06341612520219264,-0.12422571974953675,0.9011679209520909,LonGen OPEL,"Genes required for proliferation of DLD-1 cell (colon cancer with APC [GeneID=324] deletions), based on shRNA screen.",CGP,C2,259,305
Cohort,-0.2263752858041342,0.10308934476775698,-2.1959135186485064,0.028437135628218153,LGP Offspring,Genes directly bound and regulated by TP53[GeneID=7157].,CGP,C2,385,687
Cohort,-0.30007690296100087,0.2928755599548957,-1.0245884054211085,0.3058545232416028,LGP Proband,Genes directly bound and regulated by TP53[GeneID=7157].,CGP,C2,385,974
Cohort,0.08695819437053665,0.09078836280361163,0.9578121213468713,0.33844832083019494,LonGen OPEL,Genes directly bound and regulated by TP53[GeneID=7157].,CGP,C2,525,665
Cohort,-0.33302417787218713,0.16368608453459327,-2.0345295619909955,0.04228801198791513,LGP Offspring,Target genes of the DREAM complex.,CGP,C2,850,1632
Cohort,-0.9672664470472687,0.4606885641162908,-2.099610284233371,0.03606307978108615,LGP Proband,Target genes of the DREAM complex.,CGP,C2,850,2355
Cohort,-0.09490082140771099,0.13839841997619784,-0.6857074049258098,0.493097289961944,LonGen OPEL,Target genes of the DREAM complex.,CGP,C2,1353,1561
Cohort,-0.09753479823325631,0.07368384507559374,-1.3236931125566724,0.18605244339157434,LGP Offspring,Cell cycle genes with peak expression in G1/S check point.,CGP,C2,184,354
Cohort,-0.16355553348020369,0.19330982936495558,-0.8460797571313466,0.39775093877804013,LGP Proband,Cell cycle genes with peak expression in G1/S check point.,CGP,C2,184,433
Cohort,-0.04402286905465464,0.0606963123433296,-0.7252972603284137,0.4684828509827942,LonGen OPEL,Cell cycle genes with peak expression in G1/S check point.,CGP,C2,264,301
Cohort,-0.07010915877343243,0.09048276476590733,-0.7748344002840263,0.43870845228504374,LGP Offspring,Cell cycle genes with peak expression in G2/M check point.,CGP,C2,272,507
Cohort,-0.7737824731727226,0.24582770882640798,-3.147661737835793,0.0017043404332549995,LGP Proband,Cell cycle genes with peak expression in G2/M check point.,CGP,C2,272,742
Cohort,0.05016859207358609,0.0762957000420211,0.6575546465391223,0.5110144393890754,LonGen OPEL,Cell cycle genes with peak expression in G2/M check point.,CGP,C2,393,478
Cohort,0.01674979896689813,0.027199441621415476,0.6158140744224021,0.5382245180468006,LGP Offspring,Genes down-regulated in kidney biopsies from patients with well functioning kidneys more than 1-year post transplant compared to the biopsies from normal living kidney donors.,CGP,C2,21,53
Cohort,0.07842053986889572,0.0793678329920525,0.9880645207580301,0.32340761456728584,LGP Proband,Genes down-regulated in kidney biopsies from patients with well functioning kidneys more than 1-year post transplant compared to the biopsies from normal living kidney donors.,CGP,C2,21,68
Cohort,0.008376168831430131,0.021529652430232873,0.38905267321770376,0.6973412321486321,LonGen OPEL,Genes down-regulated in kidney biopsies from patients with well functioning kidneys more than 1-year post transplant compared to the biopsies from normal living kidney donors.,CGP,C2,29,39
Cohort,-0.3266523015254994,0.12614061657027348,-2.589588590947786,0.009815950818732369,LGP Offspring,Genes up-regulated in kidney biopsies from patients with well functioning kidneys more than 1-year post transplant compared to the biopsies from normal living kidney donors.,CGP,C2,565,1034
Cohort,-0.4268481003111199,0.342539964635795,-1.2461264213796641,0.21306790375638518,LGP Proband,Genes up-regulated in kidney biopsies from patients with well functioning kidneys more than 1-year post transplant compared to the biopsies from normal living kidney donors.,CGP,C2,565,1398
Cohort,-0.0266646547773159,0.11053173373556517,-0.2412398130034593,0.809431381654811,LonGen OPEL,Genes up-regulated in kidney biopsies from patients with well functioning kidneys more than 1-year post transplant compared to the biopsies from normal living kidney donors.,CGP,C2,833,990
Cohort,-0.37330798728645237,0.14377469880032032,-2.59647900779063,0.009623183166994908,LGP Offspring,Genes down-regulated in kidney biopsies from patients with acute transplant rejection compared to the biopsies from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,672,1281
Cohort,0.3818406938721844,0.4016284472670128,0.9507311956374619,0.342016277583447,LGP Proband,Genes down-regulated in kidney biopsies from patients with acute transplant rejection compared to the biopsies from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,672,1806
Cohort,0.058271949493435206,0.12879220294320584,0.4524493576612839,0.6510685745410647,LonGen OPEL,Genes down-regulated in kidney biopsies from patients with acute transplant rejection compared to the biopsies from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,999,1232
Cohort,-0.03699279676569799,0.038966310056870915,-0.9493533442532126,0.3427801982484684,LGP Offspring,Genes up-regulated in kidney biopsies from patients with acute transplant rejection compared to the biopsies from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,54,103
Cohort,0.14509118642321014,0.10983701905790286,1.3209679911899497,0.18687435873317404,LGP Proband,Genes up-regulated in kidney biopsies from patients with acute transplant rejection compared to the biopsies from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,54,141
Cohort,-0.0555678333798838,0.035550143139998186,-1.5630832528874774,0.11843046819952528,LonGen OPEL,Genes up-regulated in kidney biopsies from patients with acute transplant rejection compared to the biopsies from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,86,85
Cohort,-0.06677914441648046,0.02626994765038257,-2.5420356867558493,0.011242963905856919,LGP Offspring,Genes downregulated in peripheral blood lymphocytes (PBL) from patients with well functioning kidneys more than 1-year post transplant compared to those from normal living kidney donors.,CGP,C2,33,38
Cohort,-0.127080452639076,0.07845546282216953,-1.6197782546656048,0.1056579554021023,LGP Proband,Genes downregulated in peripheral blood lymphocytes (PBL) from patients with well functioning kidneys more than 1-year post transplant compared to those from normal living kidney donors.,CGP,C2,33,66
Cohort,0.02482025605062877,0.02365222004995012,1.049383778698656,0.2943200181145302,LonGen OPEL,Genes downregulated in peripheral blood lymphocytes (PBL) from patients with well functioning kidneys more than 1-year post transplant compared to those from normal living kidney donors.,CGP,C2,32,52
Cohort,-0.06981950646213034,0.06337607662947424,-1.1016697494596794,0.2709973602541164,LGP Offspring,Genes upregulated in peripheral blood lymphocytes (PBL) from patients with well functioning kidneys more than 1-year post transplant compared to those from normal living kidney donors.,CGP,C2,146,283
Cohort,0.2809867830677341,0.18603312495446123,1.5104126382681389,0.1313169334098962,LGP Proband,Genes upregulated in peripheral blood lymphocytes (PBL) from patients with well functioning kidneys more than 1-year post transplant compared to those from normal living kidney donors.,CGP,C2,146,424
Cohort,0.035929815251334894,0.06012654063253095,0.5975699728165531,0.550296858391897,LonGen OPEL,Genes upregulated in peripheral blood lymphocytes (PBL) from patients with well functioning kidneys more than 1-year post transplant compared to those from normal living kidney donors.,CGP,C2,223,271
Cohort,0.014716328359906205,0.037869692614885105,0.3886043784290393,0.6976911870465942,LGP Offspring,Genes down-regulated in peripheral blood lymphocytes (PBL) from patients with acute transplant rejection compared to those from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,42,97
Cohort,0.07042616282996102,0.09715736506316408,0.72486694945026,0.4687369726961639,LGP Proband,Genes down-regulated in peripheral blood lymphocytes (PBL) from patients with acute transplant rejection compared to those from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,42,109
Cohort,-0.05541983841239787,0.031292602617422345,-1.7710204258159896,0.076939924441785,LonGen OPEL,Genes down-regulated in peripheral blood lymphocytes (PBL) from patients with acute transplant rejection compared to those from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,75,66
Cohort,-0.07850936782678627,0.04120831171733755,-1.9051828273215832,0.0571803563142563,LGP Offspring,Genes up-regulated in peripheral blood lymphocytes (PBL) from patients with acute transplant rejection compared to those from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,64,99
Cohort,-0.18508565284057,0.12022144353583795,-1.5395394315440576,0.124051963622025,LGP Proband,Genes up-regulated in peripheral blood lymphocytes (PBL) from patients with acute transplant rejection compared to those from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,64,142
Cohort,0.010052245841577373,0.03604682650581322,0.2788663196177966,0.7804198482895786,LonGen OPEL,Genes up-regulated in peripheral blood lymphocytes (PBL) from patients with acute transplant rejection compared to those from patients with well functioning kidneys more than 1-year post transplant.,CGP,C2,89,110
Cohort,-0.014718129536954602,0.030075559631793328,-0.48937175956639045,0.6247372748761653,LGP Offspring,"Human-specific genes up-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.",CGP,C2,30,61
Cohort,0.039568199953405554,0.08162997722401638,0.4847263382766715,0.6279977616343029,LGP Proband,"Human-specific genes up-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.",CGP,C2,30,89
Cohort,0.03819676341027565,0.024900227478455397,1.5339925485951849,0.12542882992151885,LonGen OPEL,"Human-specific genes up-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.",CGP,C2,38,63
Cohort,-0.18056394736550074,0.08066457938112608,-2.2384539627035998,0.02551619438838382,LGP Offspring,"Genes down-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.",CGP,C2,243,400
Cohort,-0.6582549537037051,0.2158700204549594,-3.0493115825735884,0.002366152653719216,LGP Proband,"Genes down-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.",CGP,C2,243,566
Cohort,-0.008724234629818894,0.06569067655086538,-0.13280780603718664,0.8943789455759119,LonGen OPEL,"Genes down-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.",CGP,C2,322,381
Cohort,-0.056769108382509884,0.1168298036009822,-0.48591289750342964,0.6271863871716818,LGP Offspring,"Genes up-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.",CGP,C2,393,798
Cohort,0.01736519383638722,0.32378303068040953,0.053632192520699326,0.9572410513957536,LGP Proband,"Genes up-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.",CGP,C2,393,1089
Cohort,0.07913149060336247,0.10322829672546903,0.7665678221331994,0.4435657891452992,LonGen OPEL,"Genes up-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.",CGP,C2,638,790
Cohort,-0.010694698279879813,0.03632178705485553,-0.29444306426134764,0.7685097562685564,LGP Offspring,Down-regulated genes significantly associated with positive minimal residual disease (MRD) on day 46 after chemotherapy treatment of children with acute lymphoblastic leukemia (ALL).,CGP,C2,41,89
Cohort,-0.041482056840903225,0.09598543812449618,-0.43217031303331316,0.665729346945364,LGP Proband,Down-regulated genes significantly associated with positive minimal residual disease (MRD) on day 46 after chemotherapy treatment of children with acute lymphoblastic leukemia (ALL).,CGP,C2,41,104
Cohort,0.03941778538631799,0.029988250596702258,1.3144409761152482,0.1890764603422796,LonGen OPEL,Down-regulated genes significantly associated with positive minimal residual disease (MRD) on day 46 after chemotherapy treatment of children with acute lymphoblastic leukemia (ALL).,CGP,C2,52,82
Cohort,0.027249393831678514,0.025434639459935755,1.0713497187409058,0.28439455207532627,LGP Offspring,Up-regulated genes significantly associated with positive minimal residual disease (MRD) on day 46 after chemotherapy treatment of children with acute lymphoblastic leukemia (ALL).,CGP,C2,16,49
Cohort,-0.07043560245790996,0.06706409606352963,-1.0502728970086543,0.2938968959340683,LGP Proband,Up-regulated genes significantly associated with positive minimal residual disease (MRD) on day 46 after chemotherapy treatment of children with acute lymphoblastic leukemia (ALL).,CGP,C2,16,57
Cohort,-0.004447693012506293,0.02388305281430316,-0.18622799384518565,0.8523134199760818,LonGen OPEL,Up-regulated genes significantly associated with positive minimal residual disease (MRD) on day 46 after chemotherapy treatment of children with acute lymphoblastic leukemia (ALL).,CGP,C2,40,47
Cohort,-0.008958994138774401,0.04470215072091589,-0.20041528191131389,0.8412160871671575,LGP Offspring,Genes down-regulated in follicular thyroid adenoma (FTA) compared to other thyroid tumors.,CGP,C2,65,138
Cohort,-0.17247639110305907,0.12554778197505181,-1.37379082600864,0.16987575643977823,LGP Proband,Genes down-regulated in follicular thyroid adenoma (FTA) compared to other thyroid tumors.,CGP,C2,65,195
Cohort,0.06291390549002764,0.04217171986572064,1.4918505977549026,0.13613450969708796,LonGen OPEL,Genes down-regulated in follicular thyroid adenoma (FTA) compared to other thyroid tumors.,CGP,C2,113,168
Cohort,-0.0552151052429364,0.04676571237685792,-1.1806749525804225,0.23814712778914435,LGP Offspring,Genes up-regulated in follicular thyroid adenoma (FTA) compared to other thyroid tumors.,CGP,C2,78,140
Cohort,0.15356927498757061,0.12954859152370066,1.1854183297660585,0.2361897334190003,LGP Proband,Genes up-regulated in follicular thyroid adenoma (FTA) compared to other thyroid tumors.,CGP,C2,78,191
Cohort,0.041223738372185376,0.04144493914544662,0.9946627796343248,0.3202025647032606,LonGen OPEL,Genes up-regulated in follicular thyroid adenoma (FTA) compared to other thyroid tumors.,CGP,C2,108,144
Cohort,-0.012700156420584495,0.04752326506109327,-0.26724082203227995,0.7893652555892285,LGP Offspring,Genes down-regulated in papillary thyroid carcinoma (PTC) compared to other thyroid tumors.,CGP,C2,80,160
Cohort,0.053104173470709296,0.14654937982458235,0.36236368611231434,0.7171720748072572,LGP Proband,Genes down-regulated in papillary thyroid carcinoma (PTC) compared to other thyroid tumors.,CGP,C2,80,246
Cohort,-0.01730632710046567,0.04587031065954855,-0.3772882034506804,0.706060003860323,LonGen OPEL,Genes down-regulated in papillary thyroid carcinoma (PTC) compared to other thyroid tumors.,CGP,C2,136,162
Cohort,-0.00184560781490296,0.039270499818637936,-0.04699730900870855,0.9625292527362572,LGP Offspring,Genes up-regulated in papillary thyroid carcinoma (PTC) compared to other thyroid tumors.,CGP,C2,50,111
Cohort,0.04764907231419223,0.1092508917633554,0.43614355494143925,0.6628454506759042,LGP Proband,Genes up-regulated in papillary thyroid carcinoma (PTC) compared to other thyroid tumors.,CGP,C2,50,132
Cohort,0.06143983330246314,0.03683192772973417,1.6681134301005693,0.09568649862653866,LonGen OPEL,Genes up-regulated in papillary thyroid carcinoma (PTC) compared to other thyroid tumors.,CGP,C2,83,119
Cohort,-0.01917105424040122,0.02834544028263861,-0.6763364424486771,0.4990583920929873,LGP Offspring,Genes down-regulated in thyroid tumors of uncertain malignancy (T-UM) compared to other thyroid tumors.,CGP,C2,24,51
Cohort,0.03695262623908913,0.07987769175371773,0.46261509850613897,0.643760956329779,LGP Proband,Genes down-regulated in thyroid tumors of uncertain malignancy (T-UM) compared to other thyroid tumors.,CGP,C2,24,83
Cohort,0.018207169340198285,0.026518664874473297,0.6865794121379163,0.49254775641895787,LonGen OPEL,Genes down-regulated in thyroid tumors of uncertain malignancy (T-UM) compared to other thyroid tumors.,CGP,C2,46,66
Cohort,-0.033466864597583995,0.024941046777063186,-1.341838812810435,0.1800988004352284,LGP Offspring,Genes up-regulated in thyroid tumors of uncertain malignancy (T-UM) compared to other thyroid tumors.,CGP,C2,25,38
Cohort,-0.01828010861011351,0.07095133761908569,-0.25764290320012545,0.796746071943689,LGP Proband,Genes up-regulated in thyroid tumors of uncertain malignancy (T-UM) compared to other thyroid tumors.,CGP,C2,25,64
Cohort,7.552141667875238e-4,0.024020988928682558,0.03143976166134239,0.97492671279211,LonGen OPEL,Genes up-regulated in thyroid tumors of uncertain malignancy (T-UM) compared to other thyroid tumors.,CGP,C2,39,45
Cohort,0.13425469355294714,0.15763697257925816,0.8516700832061802,0.394698829859329,LGP Offspring,Genes down-regulated in HeLa cells (cervical carcinoma) upon knockdown of PHF8 [GeneID=23133] by RNAi.,CGP,C2,727,1602
Cohort,-0.4822066591043725,0.43460506684276834,-1.1095283877093534,0.26752212447060925,LGP Proband,Genes down-regulated in HeLa cells (cervical carcinoma) upon knockdown of PHF8 [GeneID=23133] by RNAi.,CGP,C2,727,2050
Cohort,-0.22258808515678086,0.130903286705452,-1.700401042317834,0.08944613003530429,LonGen OPEL,Genes down-regulated in HeLa cells (cervical carcinoma) upon knockdown of PHF8 [GeneID=23133] by RNAi.,CGP,C2,1203,1367
Cohort,-0.013891960530112185,0.07778445957221093,-0.17859557817221358,0.85830877636906,LGP Offspring,Genes up-regulated in HeLa cells (cervical carcinoma) upon knockdown of PHF8 [GeneID=23133] by RNAi.,CGP,C2,196,416
Cohort,-0.1417049382759439,0.21293917350771563,-0.6654714392925423,0.5059330001971296,LGP Proband,Genes up-regulated in HeLa cells (cervical carcinoma) upon knockdown of PHF8 [GeneID=23133] by RNAi.,CGP,C2,196,538
Cohort,0.09785677953556808,0.06671131897318822,1.466869206631898,0.14280659551667454,LonGen OPEL,Genes up-regulated in HeLa cells (cervical carcinoma) upon knockdown of PHF8 [GeneID=23133] by RNAi.,CGP,C2,293,391
Cohort,-0.14446188498442333,0.08657072622747011,-1.6687151798269602,0.0956368813639754,LGP Offspring,Genes down-regulated in ES cells (embryonic stem) heterozygotic for KDM1A [GeneID=23028] loss of function mutant compared to the homozygotic loss of the gene.,CGP,C2,259,468
Cohort,-0.13199964016824997,0.24039200056755594,-0.5491016334012949,0.58308268428563,LGP Proband,Genes down-regulated in ES cells (embryonic stem) heterozygotic for KDM1A [GeneID=23028] loss of function mutant compared to the homozygotic loss of the gene.,CGP,C2,259,739
Cohort,0.09715038803028546,0.07873719425681307,1.233856361625168,0.2176206112264198,LonGen OPEL,Genes down-regulated in ES cells (embryonic stem) heterozygotic for KDM1A [GeneID=23028] loss of function mutant compared to the homozygotic loss of the gene.,CGP,C2,371,485
Cohort,-0.05464496197489525,0.09375494927287588,-0.582848824501519,0.560189442041245,LGP Offspring,Genes up-regulated in ES cells (embryonic stem) heterozygotic for KDM1A [GeneID=23028] loss of function mutant compared to the homozygotic loss of the gene.,CGP,C2,248,524
Cohort,0.3520099828407124,0.24497754393034113,1.4369071433780303,0.15111941153023295,LGP Proband,Genes up-regulated in ES cells (embryonic stem) heterozygotic for KDM1A [GeneID=23028] loss of function mutant compared to the homozygotic loss of the gene.,CGP,C2,248,727
Cohort,0.10516219898814731,0.07445699460129973,1.412388447200521,0.15822644945094266,LonGen OPEL,Genes up-regulated in ES cells (embryonic stem) heterozygotic for KDM1A [GeneID=23028] loss of function mutant compared to the homozygotic loss of the gene.,CGP,C2,392,520
Cohort,-0.1571842474760083,0.10973615839084587,-1.4323833618830282,0.15249637399564728,LGP Offspring,Class NT (non-tolerizeable) genes: induced during the first LPS stimulation and induced at equal or greater degree in tolerant macrophages.,CGP,C2,401,785
Cohort,0.14294846123050473,0.31659715269909267,0.45151530900332826,0.6517355804951914,LGP Proband,Class NT (non-tolerizeable) genes: induced during the first LPS stimulation and induced at equal or greater degree in tolerant macrophages.,CGP,C2,401,1151
Cohort,-0.16084566295713557,0.0959326664562272,-1.6766516443127046,0.09400326362064675,LonGen OPEL,Class NT (non-tolerizeable) genes: induced during the first LPS stimulation and induced at equal or greater degree in tolerant macrophages.,CGP,C2,671,757
Cohort,-0.12670800212915817,0.059604536779613596,-2.125811372339963,0.033880830375305496,LGP Offspring,Class T (tolerizeable) genes: induced during the first LPS stimulation and either not re-induced or induced to a much lesser degree in tolerant macrophages.,CGP,C2,130,227
Cohort,0.23199561392518103,0.170858418301858,1.3578237246426517,0.17488687035404282,LGP Proband,Class T (tolerizeable) genes: induced during the first LPS stimulation and either not re-induced or induced to a much lesser degree in tolerant macrophages.,CGP,C2,130,329
Cohort,0.09323200472840701,0.051016459638879026,1.8274887239991076,0.06800055609489856,LonGen OPEL,Class T (tolerizeable) genes: induced during the first LPS stimulation and either not re-induced or induced to a much lesser degree in tolerant macrophages.,CGP,C2,163,240
Cohort,-0.02337212884502964,0.014155861133184067,-1.6510566630412093,0.09919145533118263,LGP Offspring,Genes down-regulated early in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,9,11
Cohort,-0.004188849217833699,0.032831798499423484,-0.12758512811618447,0.8985080567054571,LGP Proband,Genes down-regulated early in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,9,9
Cohort,-0.010740813401909473,0.006835889457482854,-1.5712386030690013,0.1165246216021146,LonGen OPEL,Genes down-regulated early in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,6,1
Cohort,-0.010435384241378628,0.02643133569437212,-0.39481108189324604,0.6931068516887711,LGP Offspring,Genes up-regulated early in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,24,43
Cohort,-0.09693328856932462,0.06880412967799286,-1.408829513911124,0.15925829478273879,LGP Proband,Genes up-regulated early in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,24,55
Cohort,0.013518257518736428,0.019465571566278244,0.6944701044461072,0.48759008165209483,LonGen OPEL,Genes up-regulated early in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,24,35
Cohort,0.020332626701609128,0.10363614122976782,0.1961924330676344,0.8445185132292775,LGP Offspring,Genes identified by method 2 as coordinately down-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,315,665
Cohort,-0.3394467858792244,0.27330631161619545,-1.242001269095864,0.21458523786584333,LGP Proband,Genes identified by method 2 as coordinately down-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,315,883
Cohort,-0.0664262305846289,0.08851548203194196,-0.7504475947005309,0.4532069403329143,LonGen OPEL,Genes identified by method 2 as coordinately down-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,510,588
Cohort,-0.0010749911010501292,0.025527146316128766,-0.04211168329344043,0.9664221013418257,LGP Offspring,Genes down-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,23,46
Cohort,-5.161639703911591e-4,0.07779631153358589,-0.006634812887861952,0.9947078107439589,LGP Proband,Genes down-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,23,71
Cohort,0.022530401760474335,0.023883455398669626,0.9433476598921837,0.34578933039517046,LonGen OPEL,Genes down-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,34,52
Cohort,0.023227483018608358,0.01826242971323681,1.2718725483593687,0.20385577684008493,LGP Offspring,Genes up-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,7,25
Cohort,-0.0020938955050099264,0.044460150252646165,-0.04709600604386852,0.9624479854403667,LGP Proband,Genes up-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,7,26
Cohort,0.0038355147621345585,0.014055508212517387,0.27288339234285186,0.7850136305397288,LonGen OPEL,Genes up-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.,CGP,C2,13,15
Cohort,-0.03817126055015999,0.044419982497054,-0.8593263302769552,0.3904651209309008,LGP Offspring,Genes down-regulated in MCF-7 cells (breast cancer) by estradiol (E2) [PubChem=5757].,CGP,C2,66,124
Cohort,-0.09187507734974874,0.11665021741458283,-0.7876117111999753,0.43114764094745317,LGP Proband,Genes down-regulated in MCF-7 cells (breast cancer) by estradiol (E2) [PubChem=5757].,CGP,C2,66,157
Cohort,0.030075380813233077,0.037825213288033684,0.7951146391221453,0.4267838347729943,LonGen OPEL,Genes down-regulated in MCF-7 cells (breast cancer) by estradiol (E2) [PubChem=5757].,CGP,C2,94,127
Cohort,0.010783079353493848,0.032378563360849315,0.3330314329675373,0.7392138146140608,LGP Offspring,Genes up-regulated in MCF-7 cells (breast cancer) by estradiol (E2) [PubChem=5757].,CGP,C2,34,70
Cohort,0.13016424052136055,0.09718130097653035,1.339395945654151,0.18080669269445035,LGP Proband,Genes up-regulated in MCF-7 cells (breast cancer) by estradiol (E2) [PubChem=5757].,CGP,C2,34,120
Cohort,0.045854784573660136,0.029880683472129004,1.5345962422991717,0.12528038819947976,LonGen OPEL,Genes up-regulated in MCF-7 cells (breast cancer) by estradiol (E2) [PubChem=5757].,CGP,C2,47,76
Cohort,-8.257633013036544e-4,0.04346852061353427,-0.01899681170760954,0.9848492543095029,LGP Offspring,"Genes down-regulated in MCF-7 cells (breast cancer) by selective estrogen receptor modulators (SERM) 4-hydroxytamoxifen, raloxifene, or ICI 182780 but not by estradiol [PubChem=44959;5035;3478439;5757].",CGP,C2,62,131
Cohort,0.04242802391673841,0.11296013648536514,0.37560174090472426,0.7073085063612014,LGP Proband,"Genes down-regulated in MCF-7 cells (breast cancer) by selective estrogen receptor modulators (SERM) 4-hydroxytamoxifen, raloxifene, or ICI 182780 but not by estradiol [PubChem=44959;5035;3478439;5757].",CGP,C2,62,155
Cohort,0.0013079079167767215,0.032217203922280835,0.04059656821652968,0.9676277000097058,LonGen OPEL,"Genes down-regulated in MCF-7 cells (breast cancer) by selective estrogen receptor modulators (SERM) 4-hydroxytamoxifen, raloxifene, or ICI 182780 but not by estradiol [PubChem=44959;5035;3478439;5757].",CGP,C2,76,86
Cohort,0.01942730650512063,0.027040101357032036,0.7184627841666124,0.47272023019477294,LGP Offspring,"Genes up-regulated in MCF-7 cells (breast cancer) by selective estrogen receptor modulators (SERM) 4-hydroxytamoxifen, raloxifene, or ICI 182780 but not by estradiol [PubChem=44959;5035;3478439;5757].",CGP,C2,21,52
Cohort,0.0024813007791770043,0.07033600086245963,0.035277820017506095,0.9718666508974605,LGP Proband,"Genes up-regulated in MCF-7 cells (breast cancer) by selective estrogen receptor modulators (SERM) 4-hydroxytamoxifen, raloxifene, or ICI 182780 but not by estradiol [PubChem=44959;5035;3478439;5757].",CGP,C2,21,63
Cohort,-0.006651972363212129,0.02170046785128038,-0.3065358963133897,0.7592768160659651,LonGen OPEL,"Genes up-regulated in MCF-7 cells (breast cancer) by selective estrogen receptor modulators (SERM) 4-hydroxytamoxifen, raloxifene, or ICI 182780 but not by estradiol [PubChem=44959;5035;3478439;5757].",CGP,C2,36,38
Cohort,-0.01082364794930782,0.015383011905820507,-0.7036104512935111,0.4819176720252869,LGP Offspring,Genes preferentially down-regulated in MCF-7 cells (breast cancer) by tamoxifen [PubChem=5376] but not by estradiol or fulvestrant (ICI 182780) [PubChem=5757;3478439].,CGP,C2,9,13
Cohort,-0.04417314901186313,0.04776878347207308,-0.9247283644493051,0.3553747005906681,LGP Proband,Genes preferentially down-regulated in MCF-7 cells (breast cancer) by tamoxifen [PubChem=5376] but not by estradiol or fulvestrant (ICI 182780) [PubChem=5757;3478439].,CGP,C2,9,27
Cohort,0.0230815802045133,0.01729162055021281,1.3348419332639838,0.18230973936305506,LonGen OPEL,Genes preferentially down-regulated in MCF-7 cells (breast cancer) by tamoxifen [PubChem=5376] but not by estradiol or fulvestrant (ICI 182780) [PubChem=5757;3478439].,CGP,C2,14,29
Cohort,-0.09388812903174495,0.036394346602670366,-2.579744872376857,0.010097323245763944,LGP Offspring,Genes preferentially up-regulated in MCF-7 cells (breast cancer) by tamoxifen [PubChem=5376] but not by estradiol or fulvestrant (ICI 182780) [PubChem=5757;3478439].,CGP,C2,57,83
Cohort,-0.0027461152062886094,0.11138535590891485,-0.024654185317989553,0.9803366963268095,LGP Proband,Genes preferentially up-regulated in MCF-7 cells (breast cancer) by tamoxifen [PubChem=5376] but not by estradiol or fulvestrant (ICI 182780) [PubChem=5757;3478439].,CGP,C2,57,149
Cohort,0.06758907606140928,0.03351366974746741,2.0167614161835234,0.04405574670634001,LonGen OPEL,Genes preferentially up-regulated in MCF-7 cells (breast cancer) by tamoxifen [PubChem=5376] but not by estradiol or fulvestrant (ICI 182780) [PubChem=5757;3478439].,CGP,C2,69,103
Cohort,0.006088893655411451,0.01373904394521454,0.44318175847543456,0.6577760637207855,LGP Offspring,"Genes down-regulated in H1703 cells (non-small cell lung cancer, NSCLC) after knockdown of PRKCI [GeneID=5584] by RNAi.",CGP,C2,6,13
Cohort,0.0017660588149486837,0.04493571341698784,0.039301897770271724,0.9686590994161803,LGP Proband,"Genes down-regulated in H1703 cells (non-small cell lung cancer, NSCLC) after knockdown of PRKCI [GeneID=5584] by RNAi.",CGP,C2,6,28
Cohort,-1.518653507002384e-4,0.013030636140125179,-0.01165448479008635,0.9907041972835342,LonGen OPEL,"Genes down-regulated in H1703 cells (non-small cell lung cancer, NSCLC) after knockdown of PRKCI [GeneID=5584] by RNAi.",CGP,C2,12,14
Cohort,0.014471992469307917,0.02420708157957292,0.5978412730892794,0.5501460698260943,LGP Offspring,Genes down-regulated in immortalized cell lines.,CGP,C2,16,44
Cohort,0.16860074894776766,0.07374030288392164,2.2864124821018255,0.022480024054967438,LGP Proband,Genes down-regulated in immortalized cell lines.,CGP,C2,16,78
Cohort,-0.006959760250617065,0.024155707755499824,-0.2881207340750532,0.7733293244130315,LonGen OPEL,Genes down-regulated in immortalized cell lines.,CGP,C2,41,45
Cohort,0.014741382970893509,0.027674224500631405,0.5326755577399169,0.5944332368535423,LGP Offspring,Genes down-regulated in senescent cells.,CGP,C2,22,54
Cohort,2.638157953443505e-4,0.08274935538338372,0.0031881311234640193,0.9974570061155553,LGP Proband,Genes down-regulated in senescent cells.,CGP,C2,22,86
Cohort,0.005486527191801898,0.02213350962564961,0.2478832902958954,0.8042886379036867,LonGen OPEL,Genes down-regulated in senescent cells.,CGP,C2,33,40
Cohort,0.08054237856601906,0.04295751517185091,1.874931039279401,0.061233130873694634,LGP Offspring,Genes up-regulated in senescent cells.,CGP,C2,50,139
Cohort,-0.0024695915746360854,0.12006505771784634,-0.02056877847374747,0.9835945661826231,LGP Proband,Genes up-regulated in senescent cells.,CGP,C2,50,201
Cohort,-0.06288807326782744,0.03978221670219492,-1.580808674855911,0.11431903931923276,LonGen OPEL,Genes up-regulated in senescent cells.,CGP,C2,113,111
Cohort,-0.006816113204941751,0.015724828507131867,-0.4334618467762849,0.6648175603742406,LGP Offspring,Proteins identified by mass spectrometry in complexes containing ALKBH8 [GeneID=91801].,CGP,C2,9,16
Cohort,-0.03432079549998626,0.04277923402851117,-0.8022769990952247,0.4226212889311488,LGP Proband,Proteins identified by mass spectrometry in complexes containing ALKBH8 [GeneID=91801].,CGP,C2,9,22
Cohort,0.007248831281238528,0.01516467548862429,0.47800767557975143,0.6327759845898879,LonGen OPEL,Proteins identified by mass spectrometry in complexes containing ALKBH8 [GeneID=91801].,CGP,C2,14,19
Cohort,-0.16028310067341442,0.0737050962761712,-2.1746542474191686,0.030002070406554077,LGP Offspring,Genes down-regulated in MCF-7 cells (breast cancer) after knockdown of YBX1 [GeneID=4904] by RNAi.,CGP,C2,195,337
Cohort,0.01208269990400796,0.20917350356119233,0.05776400786093467,0.9539504444123594,LGP Proband,Genes down-regulated in MCF-7 cells (breast cancer) after knockdown of YBX1 [GeneID=4904] by RNAi.,CGP,C2,195,505
Cohort,0.028971715011162483,0.06732298619953293,0.43033912555951775,0.6670654558116162,LonGen OPEL,Genes down-regulated in MCF-7 cells (breast cancer) after knockdown of YBX1 [GeneID=4904] by RNAi.,CGP,C2,265,333
Cohort,-0.04781973273983985,0.03158785759570701,-1.5138643890283607,0.1305276217096005,LGP Offspring,Genes up-regulated in MCF-7 cells (breast cancer) after knockdown of YBX1 [GeneID=4904] by RNAi.,CGP,C2,39,60
Cohort,-0.16061050430712562,0.09240520722610097,-1.7381109693757522,0.0825603454191757,LGP Proband,Genes up-regulated in MCF-7 cells (breast cancer) after knockdown of YBX1 [GeneID=4904] by RNAi.,CGP,C2,39,88
Cohort,-0.04758031258778531,0.030350161009087412,-1.5677120320231206,0.11734577267762343,LonGen OPEL,Genes up-regulated in MCF-7 cells (breast cancer) after knockdown of YBX1 [GeneID=4904] by RNAi.,CGP,C2,66,57
Cohort,0.024678302514350384,0.017208942807458293,1.4340394288285332,0.15202340374241605,LGP Offspring,Genes commonly down-regulated in both non-tumorous and tumorous liver tissues of PARK2 [GeneID=5071] knockout mice.,CGP,C2,5,23
Cohort,0.059815366571751225,0.04784261405459653,1.250252891773258,0.21155786317744585,LGP Proband,Genes commonly down-regulated in both non-tumorous and tumorous liver tissues of PARK2 [GeneID=5071] knockout mice.,CGP,C2,5,31
Cohort,1.687008766715256e-4,0.01347480568671398,0.012519726116560104,0.9900141018736683,LonGen OPEL,Genes commonly down-regulated in both non-tumorous and tumorous liver tissues of PARK2 [GeneID=5071] knockout mice.,CGP,C2,12,16
Cohort,-0.023560659466857446,0.012610725784988253,-1.8683032101850903,0.06215217923771127,LGP Offspring,Genes commonly up-regulated in both non-tumorous and tumorous liver tissues of PARK2 [GeneID=5071] knockout mice.,CGP,C2,8,8
Cohort,0.019833171970290817,0.04648277395486483,0.4266778912452384,0.6697240700528695,LGP Proband,Genes commonly up-regulated in both non-tumorous and tumorous liver tissues of PARK2 [GeneID=5071] knockout mice.,CGP,C2,8,29
Cohort,0.016704055795789572,0.013867502868439768,1.2045467705512682,0.22873633774731292,LonGen OPEL,Genes commonly up-regulated in both non-tumorous and tumorous liver tissues of PARK2 [GeneID=5071] knockout mice.,CGP,C2,10,20
Cohort,-0.007667432675713263,0.008474759324136293,-0.9047375131794309,0.3659267816278502,LGP Offspring,"Genes down-regulated in tumorous  liver tissues from PARK2 [GeneID=5071] knockout mice compared to the normal, non-tumorous tissue from wild type mice.",CGP,C2,3,4
Cohort,9.883532691115835e-4,0.01930359903166407,0.05120046616645779,0.9591780403840874,LGP Proband,"Genes down-regulated in tumorous  liver tissues from PARK2 [GeneID=5071] knockout mice compared to the normal, non-tumorous tissue from wild type mice.",CGP,C2,3,3
Cohort,-0.004727844068058397,0.005808023358418318,-0.8140194651947674,0.4158772402892532,LonGen OPEL,"Genes down-regulated in tumorous  liver tissues from PARK2 [GeneID=5071] knockout mice compared to the normal, non-tumorous tissue from wild type mice.",CGP,C2,3,2
Cohort,1.0364168878892396e-4,0.020557118091929814,0.005041644861183678,0.995978853855501,LGP Offspring,"Genes up-regulated in tumorous  liver tissues from PARK2 [GeneID=5071] knockout mice compared to the normal, non-tumorous tissue from wild type mice.",CGP,C2,13,28
Cohort,0.10130510047745284,0.05896469990638331,1.7180635301848777,0.08615619558659732,LGP Proband,"Genes up-regulated in tumorous  liver tissues from PARK2 [GeneID=5071] knockout mice compared to the normal, non-tumorous tissue from wild type mice.",CGP,C2,13,42
Cohort,0.015341240675147113,0.01948143115159597,0.7874801679490738,0.43123524731351903,LonGen OPEL,"Genes up-regulated in tumorous  liver tissues from PARK2 [GeneID=5071] knockout mice compared to the normal, non-tumorous tissue from wild type mice.",CGP,C2,24,34
Cohort,-0.0036727723273313217,0.021067372113894957,-0.17433462073368655,0.8616546884888487,LGP Offspring,Genes up-regulated in RAW 264.7 cells (macrophage) upon stimulation with TNFSF11 [GeneID=8600].,CGP,C2,15,31
Cohort,-0.00483356079291021,0.057389708882485874,-0.084223476421664,0.932898965102875,LGP Proband,Genes up-regulated in RAW 264.7 cells (macrophage) upon stimulation with TNFSF11 [GeneID=8600].,CGP,C2,15,40
Cohort,-0.0022805902546191234,0.020083025280057627,-0.11355810306546502,0.909616735251074,LonGen OPEL,Genes up-regulated in RAW 264.7 cells (macrophage) upon stimulation with TNFSF11 [GeneID=8600].,CGP,C2,26,32
Cohort,-3.8432619072719255e-4,0.12216505421377759,-0.003145958500166972,0.9974908205526114,LGP Offspring,"Genes down-regulated in monocyte-derived dendritic cells (MDDC) after stimulation with galecin-1 (lectin, LGALS1) [GeneID=3956] compared to that with bacterial lipopolysaccharide (LPS).",CGP,C2,417,871
Cohort,-0.29215634570917076,0.31913059653304576,-0.9154758236379825,0.3602065051804998,LGP Proband,"Genes down-regulated in monocyte-derived dendritic cells (MDDC) after stimulation with galecin-1 (lectin, LGALS1) [GeneID=3956] compared to that with bacterial lipopolysaccharide (LPS).",CGP,C2,417,1134
Cohort,0.001777850055151797,0.09657529856916511,0.01840895220094546,0.9853172240196916,LonGen OPEL,"Genes down-regulated in monocyte-derived dendritic cells (MDDC) after stimulation with galecin-1 (lectin, LGALS1) [GeneID=3956] compared to that with bacterial lipopolysaccharide (LPS).",CGP,C2,664,796
Cohort,0.0784583397252529,0.1212789267432393,0.6469247529816763,0.5179002416234457,LGP Offspring,"Genes up-regulated in monocyte-derived dendritic cells (MDDC) after stimulation with galecin-1 (lectin, LGALS1) [GeneID=3956] compared to that with bacterial lipopolysaccharide (LPS).",CGP,C2,447,968
Cohort,-0.696144242798342,0.3359282213889046,-2.0723005644483043,0.03854418445841238,LGP Proband,"Genes up-regulated in monocyte-derived dendritic cells (MDDC) after stimulation with galecin-1 (lectin, LGALS1) [GeneID=3956] compared to that with bacterial lipopolysaccharide (LPS).",CGP,C2,447,1328
Cohort,-0.09673736641810458,0.10519976940301627,-0.9195587306613521,0.3580819721957572,LonGen OPEL,"Genes up-regulated in monocyte-derived dendritic cells (MDDC) after stimulation with galecin-1 (lectin, LGALS1) [GeneID=3956] compared to that with bacterial lipopolysaccharide (LPS).",CGP,C2,781,882
Cohort,0.006708358839846482,0.010599472584489048,0.6328955319591367,0.5270158948472872,LGP Offspring,"Genes up-regulated by IL2 [GeneID=3558] in both primary thymocytes and T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,3,8
Cohort,-8.080311652832015e-4,0.028261262198177945,-0.028591474776214938,0.9771972515535713,LGP Proband,"Genes up-regulated by IL2 [GeneID=3558] in both primary thymocytes and T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,3,10
Cohort,0.011593885459512154,0.008923622020866733,1.2992353813733208,0.19423934241374785,LonGen OPEL,"Genes up-regulated by IL2 [GeneID=3558] in both primary thymocytes and T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,3,9
Cohort,0.0027237481711557725,0.0032268126620873232,0.8440986373822724,0.3989128951261639,LGP Offspring,"Genes up-regulated by IL2 [GeneID=3558] in T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,0,1
Cohort,0.020704227954583647,0.01761929067515021,1.1750886194178267,0.24029463736406345,LGP Proband,"Genes up-regulated by IL2 [GeneID=3558] in T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,0,5
Cohort,-0.005641359955383666,0.0036661963163148875,-1.5387501019187464,0.12426271585152016,LonGen OPEL,"Genes up-regulated by IL2 [GeneID=3558] in T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,2,0
Cohort,0.0031349452918609812,0.010129295564277883,0.3094929229744982,0.7570419673239097,LGP Offspring,"Genes with putative STAT5 [GeneID=6777] binding sites; up-regulated by IL2 [Gene D=3558] in both primary thymocytes and T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,3,7
Cohort,-0.012710917969581252,0.024860166274642215,-0.5112965789994173,0.609278731671656,LGP Proband,"Genes with putative STAT5 [GeneID=6777] binding sites; up-regulated by IL2 [Gene D=3558] in both primary thymocytes and T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,3,7
Cohort,0.007850023811163422,0.008190673014781736,0.9584101083020232,0.33814700371986073,LonGen OPEL,"Genes with putative STAT5 [GeneID=6777] binding sites; up-regulated by IL2 [Gene D=3558] in both primary thymocytes and T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,3,7
Cohort,0.0027237481711557725,0.0032268126620873232,0.8440986373822724,0.3989128951261639,LGP Offspring,"Genes with putative STAT5 [GeneID=6777] binding sites; up-regulated by IL2 [GeneID=3558] only in T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,0,1
Cohort,0.021107683824015316,0.015782794830482623,1.3373856817328889,0.18146139002655,LGP Proband,"Genes with putative STAT5 [GeneID=6777] binding sites; up-regulated by IL2 [GeneID=3558] only in T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,0,4
Cohort,-0.005641359955383666,0.0036661963163148875,-1.5387501019187464,0.12426271585152016,LonGen OPEL,"Genes with putative STAT5 [GeneID=6777] binding sites; up-regulated by IL2 [GeneID=3558] only in T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).",CGP,C2,2,0
Cohort,-0.0379865026719947,0.052688601738566744,-0.7209624362490821,0.4711818757057097,LGP Offspring,"Genes down-regulated in PCI-35 cells (pancreatic cancer, lack endogenous DUSP6 [GeneID=1848]) upon expression of DUSP6 off an adenoviral vector.",CGP,C2,100,180
Cohort,-0.13039736486195447,0.14098120560174154,-0.9249272930060947,0.355271269250934,LGP Proband,"Genes down-regulated in PCI-35 cells (pancreatic cancer, lack endogenous DUSP6 [GeneID=1848]) upon expression of DUSP6 off an adenoviral vector.",CGP,C2,100,267
Cohort,0.012601475038439976,0.04446153686783733,0.2834241892244542,0.7769253839830598,LonGen OPEL,"Genes down-regulated in PCI-35 cells (pancreatic cancer, lack endogenous DUSP6 [GeneID=1848]) upon expression of DUSP6 off an adenoviral vector.",CGP,C2,135,170
Cohort,-0.0524235677379654,0.05782585881694787,-0.9065765526097272,0.36495379296260044,LGP Offspring,"Genes up-regulated in PCI-35 cells (pancreatic cancer, lack endogenous DUSP6 [GeneID=1848]) upon expression of DUSP6 off an adenoviral vector.",CGP,C2,106,202
Cohort,0.02781612848819558,0.15958386938305016,0.1743041360992968,0.8616687503876052,LGP Proband,"Genes up-regulated in PCI-35 cells (pancreatic cancer, lack endogenous DUSP6 [GeneID=1848]) upon expression of DUSP6 off an adenoviral vector.",CGP,C2,106,306
Cohort,-0.03943102774408565,0.04835246895691921,-0.8154915063224106,0.41503496403327234,LonGen OPEL,"Genes up-regulated in PCI-35 cells (pancreatic cancer, lack endogenous DUSP6 [GeneID=1848]) upon expression of DUSP6 off an adenoviral vector.",CGP,C2,168,176
Cohort,-0.015640819187068503,0.09922648369364756,-0.15762746602366826,0.8747974296646616,LGP Offspring,Genes significantly de-regulated (p < 0.05) by MIR21 [GeneID=406991] in A172 cells (glioma).,CGP,C2,294,605
Cohort,0.052050300365555816,0.27020052926480315,0.19263581943078004,0.8472910880155285,LGP Proband,Genes significantly de-regulated (p < 0.05) by MIR21 [GeneID=406991] in A172 cells (glioma).,CGP,C2,294,856
Cohort,-0.09421766983386518,0.08219624258534543,-1.146252758890259,0.252035041735872,LonGen OPEL,Genes significantly de-regulated (p < 0.05) by MIR21 [GeneID=406991] in A172 cells (glioma).,CGP,C2,499,550
Cohort,0.0317710409798295,0.03389296347694141,0.9373934209513569,0.34889099816536784,LGP Offspring,Genes down-regulated in HeLa cells (cervical carcinoma) by trabectedin [PubChem=3199].,CGP,C2,32,80
Cohort,-0.27103409027160763,0.08842210012946002,-3.0652301842501237,0.0022451020934774915,LGP Proband,Genes down-regulated in HeLa cells (cervical carcinoma) by trabectedin [PubChem=3199].,CGP,C2,32,93
Cohort,-0.029559848243867825,0.030212949944785655,-0.9783833852003403,0.3281819937550483,LonGen OPEL,Genes down-regulated in HeLa cells (cervical carcinoma) by trabectedin [PubChem=3199].,CGP,C2,62,62
Cohort,-0.04272486027564994,0.03970264880845419,-1.0761211545803009,0.28225697849326004,LGP Offspring,Genes up-regulated in HeLa cells (cervical carcinoma) by trabectedin [PubChem=3199].,CGP,C2,61,107
Cohort,-0.14791885300477775,0.11413199790489534,-1.296033152140529,0.19532260288020073,LGP Proband,Genes up-regulated in HeLa cells (cervical carcinoma) by trabectedin [PubChem=3199].,CGP,C2,61,155
Cohort,-6.722720320790755e-4,0.035925052402105466,-0.018713181669282007,0.9850746020996779,LonGen OPEL,Genes up-regulated in HeLa cells (cervical carcinoma) by trabectedin [PubChem=3199].,CGP,C2,88,107
Cohort,-0.056941827896184856,0.09299847337388471,-0.6122877702224188,0.5405532719903128,LGP Offspring,"Genes down-regulated in leukemic stem cells (LSC), defined as CD34+CD38- [GeneID=947;952] cells from AML (acute myeloid leukemia patients) compared to the CD34+CD38+ cells.",CGP,C2,280,562
Cohort,-0.11864980652276777,0.2588214269945518,-0.45842343078212516,0.6467676900432275,LGP Proband,"Genes down-regulated in leukemic stem cells (LSC), defined as CD34+CD38- [GeneID=947;952] cells from AML (acute myeloid leukemia patients) compared to the CD34+CD38+ cells.",CGP,C2,280,773
Cohort,0.021343452560521902,0.07916948913125575,0.26959189448774157,0.7875441066095211,LonGen OPEL,"Genes down-regulated in leukemic stem cells (LSC), defined as CD34+CD38- [GeneID=947;952] cells from AML (acute myeloid leukemia patients) compared to the CD34+CD38+ cells.",CGP,C2,429,525
Cohort,-0.07334127933191195,0.06660715382287147,-1.1011021357698088,0.2712441166287635,LGP Offspring,"Genes up-regulated in leukemic stem cells (LSC), defined as CD34+CD38- [GeneID=947;952] cells from AML (acute myeloid leukemia patients) compared to the CD34+CD38+ cells.",CGP,C2,178,334
Cohort,0.03970192191005341,0.19139110271437426,0.20743870194061864,0.8357178996209702,LGP Proband,"Genes up-regulated in leukemic stem cells (LSC), defined as CD34+CD38- [GeneID=947;952] cells from AML (acute myeloid leukemia patients) compared to the CD34+CD38+ cells.",CGP,C2,178,502
Cohort,-0.02951055214434211,0.0643819800413068,-0.4583666442909717,0.6468141630142661,LonGen OPEL,"Genes up-regulated in leukemic stem cells (LSC), defined as CD34+CD38- [GeneID=947;952] cells from AML (acute myeloid leukemia patients) compared to the CD34+CD38+ cells.",CGP,C2,280,339
Cohort,-0.003552267018533055,0.010951691114807496,-0.3243578531657204,0.7457674633588638,LGP Offspring,Genes down-regulated in acute promyelocytic leukemia (APL) patients with mutated FLT3 [GeneID=2322].,CGP,C2,5,7
Cohort,0.00266392291016659,0.03051248146775546,0.08730600665769292,0.9304492369272466,LGP Proband,Genes down-regulated in acute promyelocytic leukemia (APL) patients with mutated FLT3 [GeneID=2322].,CGP,C2,5,8
Cohort,-0.00847501010318435,0.01035292193889315,-0.8186104515427679,0.4132536988289126,LonGen OPEL,Genes down-regulated in acute promyelocytic leukemia (APL) patients with mutated FLT3 [GeneID=2322].,CGP,C2,9,7
Cohort,0.010074253476099379,0.03831417343818024,0.2629380349899534,0.7926784563482049,LGP Offspring,Genes up-regulated in acute promyelocytic leukemia (APL) patients with mutated FLT3 [GeneID=2322].,CGP,C2,45,110
Cohort,0.07619730035295783,0.11480752569610872,0.6636960416222998,0.507068293700869,LGP Proband,Genes up-regulated in acute promyelocytic leukemia (APL) patients with mutated FLT3 [GeneID=2322].,CGP,C2,45,157
Cohort,0.0230222967061751,0.0391244429422211,0.588437686900089,0.5564054704001744,LonGen OPEL,Genes up-regulated in acute promyelocytic leukemia (APL) patients with mutated FLT3 [GeneID=2322].,CGP,C2,89,122
Cohort,-0.005501400544033513,0.006438819742159826,-0.8544113306995814,0.39317980228680127,LGP Offspring,Apoptosis genes down-regulated by TP53 [GeneID=7157] in HCT116 cells (colon cancer) treated with thymoquinone [PubChem=10281].,CGP,C2,2,2
Cohort,-0.04161347531982317,0.029381991445648216,-1.416291860162071,0.15706344422363303,LGP Proband,Apoptosis genes down-regulated by TP53 [GeneID=7157] in HCT116 cells (colon cancer) treated with thymoquinone [PubChem=10281].,CGP,C2,2,12
Cohort,0.0013142663720345723,0.008929245924662937,0.14718671465913102,0.883021917470785,LonGen OPEL,Apoptosis genes down-regulated by TP53 [GeneID=7157] in HCT116 cells (colon cancer) treated with thymoquinone [PubChem=10281].,CGP,C2,5,7
Cohort,-0.011610578831368484,0.01987085364690844,-0.5843019649623804,0.5592121045558638,LGP Offspring,Apoptosis genes up-regulated by TP53 [GeneID=7157] in HCT116 cells (colon cancer) treated with thymoquinone [PubChem=10281].,CGP,C2,16,23
Cohort,-0.05344006606850582,0.05842111029544095,-0.914738966757983,0.360593070194546,LGP Proband,Apoptosis genes up-regulated by TP53 [GeneID=7157] in HCT116 cells (colon cancer) treated with thymoquinone [PubChem=10281].,CGP,C2,16,39
Cohort,-0.017342075184512407,0.01915638835818502,-0.9052893927733824,0.3655860173830128,LonGen OPEL,Apoptosis genes up-regulated by TP53 [GeneID=7157] in HCT116 cells (colon cancer) treated with thymoquinone [PubChem=10281].,CGP,C2,30,29
Cohort,-3.046765570607748e-4,0.013353083661925403,-0.022816943619511705,0.9818030257175643,LGP Offspring,Angiogenic genes up-regulated in A17 carcinomas (high vascularization) compared to the syngeneic BB1 and spontaneous tumors (little vascularization).,CGP,C2,6,12
Cohort,-0.007750128611210841,0.037551663141949104,-0.20638576198115557,0.8365399641398273,LGP Proband,Angiogenic genes up-regulated in A17 carcinomas (high vascularization) compared to the syngeneic BB1 and spontaneous tumors (little vascularization).,CGP,C2,6,17
Cohort,-0.00964518514074685,0.011203260009257754,-0.8609266528471716,0.3895376860972902,LonGen OPEL,Angiogenic genes up-regulated in A17 carcinomas (high vascularization) compared to the syngeneic BB1 and spontaneous tumors (little vascularization).,CGP,C2,11,8
Cohort,-0.04358041870719186,0.02347226442841594,-1.8566772217525223,0.06379191727478507,LGP Offspring,"Stemness-related genes changed in A17 carcinomas (MTC, mesenchymal tumor cells) compared with the mesenchymal stem cells (MSC).",CGP,C2,25,32
Cohort,-0.08068446956106748,0.06923978130025105,-1.165290647166948,0.2442345365161183,LGP Proband,"Stemness-related genes changed in A17 carcinomas (MTC, mesenchymal tumor cells) compared with the mesenchymal stem cells (MSC).",CGP,C2,25,58
Cohort,-0.036775150918264804,0.020116918102727723,-1.8280708173325184,0.06791306496818024,LonGen OPEL,"Stemness-related genes changed in A17 carcinomas (MTC, mesenchymal tumor cells) compared with the mesenchymal stem cells (MSC).",CGP,C2,37,29
Cohort,0.007654173900844355,0.03886692292338545,0.19693284996942714,0.8439392796870733,LGP Offspring,Genes up-regulated in macrophages by aerolysin-related cytotoxic enterotoxin (Act) from Aeromonas hydrophila.,CGP,C2,43,103
Cohort,0.03965310351939812,0.10395277621623034,0.3814530497667171,0.702964262133086,LGP Proband,Genes up-regulated in macrophages by aerolysin-related cytotoxic enterotoxin (Act) from Aeromonas hydrophila.,CGP,C2,43,133
Cohort,0.0012146280143229256,0.03745063991773621,0.03243277062797774,0.9741350594259952,LonGen OPEL,Genes up-regulated in macrophages by aerolysin-related cytotoxic enterotoxin (Act) from Aeromonas hydrophila.,CGP,C2,84,104
Cohort,0.004163277745848911,0.027692463150626068,0.15033974129364466,0.8805414263002038,LGP Offspring,Proteins that permeabilize mitochondria.,CGP,C2,25,49
Cohort,-0.01565883073569029,0.07619680359349645,-0.20550508679115773,0.8372276733466513,LGP Proband,Proteins that permeabilize mitochondria.,CGP,C2,25,71
Cohort,-0.04255922908324495,0.024110789331379265,-1.7651528740229068,0.07792146827134594,LonGen OPEL,Proteins that permeabilize mitochondria.,CGP,C2,49,41
Cohort,8.143122043546353e-4,0.014818764561989094,0.05495142330848475,0.9561934000989445,LGP Offspring,Proteins acting on mitochondria to prevent membrane permeabilization.,CGP,C2,8,14
Cohort,-0.04845782346602526,0.04130660764059782,-1.1731252270253956,0.24108052806782837,LGP Proband,Proteins acting on mitochondria to prevent membrane permeabilization.,CGP,C2,8,18
Cohort,0.023754055451544537,0.01588259648080411,1.4956027800778018,0.13515354196554996,LonGen OPEL,Proteins acting on mitochondria to prevent membrane permeabilization.,CGP,C2,12,25
Cohort,-0.04303811453204228,0.05711166192766929,-0.7535783950141242,0.45136480225700204,LGP Offspring,Genes down-regulated in the A673 cells (Ewing sarcoma) after double knockdown of both FLI1 and DAX1 [GeneID=2313;190] by RNAi.,CGP,C2,104,211
Cohort,0.2040947398288743,0.1539451673726947,1.3257625641132964,0.18528136408593285,LGP Proband,Genes down-regulated in the A673 cells (Ewing sarcoma) after double knockdown of both FLI1 and DAX1 [GeneID=2313;190] by RNAi.,CGP,C2,104,281
Cohort,-0.014232121268787071,0.047810011179772044,-0.297680776841327,0.766024490618028,LonGen OPEL,Genes down-regulated in the A673 cells (Ewing sarcoma) after double knockdown of both FLI1 and DAX1 [GeneID=2313;190] by RNAi.,CGP,C2,180,193
Cohort,-0.029236036404368008,0.05332354487784097,-0.548276309674177,0.583683200016674,LGP Offspring,Genes up-regulated in the A673 cells (Ewing sarcoma) after double knockdown of both FLI1 and DAX1 [GeneID=2313;190] by RNAi.,CGP,C2,86,169
Cohort,-0.1723884170001218,0.14619554221830086,-1.1791632931099187,0.238669435659257,LGP Proband,Genes up-regulated in the A673 cells (Ewing sarcoma) after double knockdown of both FLI1 and DAX1 [GeneID=2313;190] by RNAi.,CGP,C2,86,247
Cohort,0.01809864707447796,0.04122135993489963,0.4390599219205995,0.6607372721147249,LonGen OPEL,Genes up-regulated in the A673 cells (Ewing sarcoma) after double knockdown of both FLI1 and DAX1 [GeneID=2313;190] by RNAi.,CGP,C2,118,145
Cohort,0.0021749071893883603,0.01967302832985614,0.11055274017410334,0.9120038383641966,LGP Offspring,Genes from the black module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,11,27
Cohort,-0.0016634208081922805,0.05409137529872518,-0.03075205241142175,0.9754746364108544,LGP Proband,Genes from the black module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,11,35
Cohort,0.012899926709399464,0.01419959109501896,0.908471703380571,0.3639040202943309,LonGen OPEL,Genes from the black module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,9,20
Cohort,-0.00665751888446364,0.023641558151388103,-0.28160237332211313,0.7783346002077098,LGP Offspring,Genes from the black module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,18,38
Cohort,-0.13465522226091758,0.06497830300192331,-2.0723105412114546,0.038543252172931704,LGP Proband,Genes from the black module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,18,47
Cohort,1.653714046797097e-4,0.021656937240498223,0.007635955298908429,0.9939093616305381,LonGen OPEL,Genes from the black module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,29,35
Cohort,0.024000124300735635,0.03883284926462476,0.618036655955576,0.5367593327155095,LGP Offspring,Genes from the blue module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,40,95
Cohort,-0.03398468386732146,0.10050271703968669,-0.33814691650476997,0.7353375780544679,LGP Proband,Genes from the blue module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,40,110
Cohort,-0.040665237561083964,0.033350349520377985,-1.2193346740260211,0.2230783788957759,LonGen OPEL,Genes from the blue module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,82,80
Cohort,-0.01645488998732548,0.04837428874748311,-0.3401577658995889,0.7338433913437694,LGP Offspring,Genes from the blue module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,75,146
Cohort,-0.025472748294343317,0.13910921407300922,-0.1831133075122857,0.8547536194907954,LGP Proband,Genes from the blue module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,75,208
Cohort,0.003063498786324062,0.04150477306808065,0.07381075861561699,0.941179509869946,LonGen OPEL,Genes from the blue module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,120,140
Cohort,-0.025061041663852996,0.020173086945869605,-1.242300780792708,0.21455639340897711,LGP Offspring,Genes from the brown module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,15,22
Cohort,-0.10595433129104649,0.05601429378542178,-1.8915588170571929,0.058896032976597144,LGP Proband,Genes from the brown module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,15,34
Cohort,-0.005836128522131148,0.015957512804989447,-0.365729208144916,0.7146643174638618,LonGen OPEL,Genes from the brown module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,18,22
Cohort,-0.03321188123454996,0.023036569595337356,-1.4417025545883406,0.14984938889948152,LGP Offspring,Genes from the cyan module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,21,28
Cohort,-0.047337024889618995,0.06256260419648553,-0.7566345023130953,0.44948254728161363,LGP Proband,Genes from the cyan module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,21,40
Cohort,0.018475363940484733,0.018449567324938736,1.0013982233345455,0.3169386350425764,LonGen OPEL,Genes from the cyan module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,21,31
Cohort,-0.018665846848100888,0.03303174369239766,-0.5650881473870506,0.572201289921368,LGP Offspring,Genes from the green module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,36,73
Cohort,-0.1004354026083739,0.08640240485065225,-1.1624144348988652,0.24539968073388707,LGP Proband,Genes from the green module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,36,89
Cohort,0.0576191830564389,0.029229646252634942,1.971258309403753,0.04904033222673323,LonGen OPEL,Genes from the green module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,54,82
Cohort,-0.004990701958241717,0.018057598302232972,-0.27637684008202656,0.7823431186040597,LGP Offspring,Genes from the green module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,10,21
Cohort,-0.03084511778066197,0.05333134487895733,-0.5783675219642241,0.5631721565620738,LGP Proband,Genes from the green module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,10,38
Cohort,0.017541941409044855,0.017534504073787628,1.0004241542974885,0.31740930222091396,LonGen OPEL,Genes from the green module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,16,28
Cohort,-0.038272578449277055,0.04185454486198249,-0.9144186987454491,0.3608229184627024,LGP Offspring,Genes from the grey module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,58,114
Cohort,-0.05189028229776152,0.11152699631978236,-0.46527104656325585,0.6418588276757531,LGP Proband,Genes from the grey module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,58,151
Cohort,-7.316806450145671e-4,0.03687827526764169,-0.01984042474070282,0.9841756419878549,LonGen OPEL,Genes from the grey module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,95,112
Cohort,-0.011753187525400577,0.01876817111980622,-0.6262297722231087,0.5313756333573412,LGP Offspring,Genes from the grey module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,14,23
Cohort,0.0499510531403904,0.058619262092869794,0.8521269520802488,0.3943882583391385,LGP Proband,Genes from the grey module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,14,41
Cohort,0.03157833006807034,0.019741341032506226,1.5996041006572579,0.11008324602830613,LonGen OPEL,Genes from the grey module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,21,42
Cohort,-0.0026583065978816795,0.014852809857762633,-0.17897668005844355,0.8580096398446674,LGP Offspring,Genes from the lightgreen module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,8,14
Cohort,-0.02784402345010222,0.043274974738953156,-0.6434209059176861,0.5201278964207938,LGP Proband,Genes from the lightgreen module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,8,23
Cohort,-0.023745589105540053,0.013923804576786854,-1.7053951723171725,0.08851089250635888,LonGen OPEL,Genes from the lightgreen module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,18,12
Cohort,0.006792751223530052,0.011533066914948552,0.5889804744586755,0.5560711299170809,LGP Offspring,Genes from the lightyellow module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,3,10
Cohort,0.01713122115760794,0.030188665483918284,0.5674719595251357,0.570546288444505,LGP Proband,Genes from the lightyellow module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,3,12
Cohort,0.010175324475001609,0.011797772965913726,0.8624784104932587,0.388684071913056,LonGen OPEL,Genes from the lightyellow module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,7,12
Cohort,0.0013772709350085297,0.013164821512783427,0.10461751674119997,0.9167103464724979,LGP Offspring,Genes from the magenta module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,5,10
Cohort,-0.003299436650816156,0.036669800553589135,-0.08997694563389755,0.9283271386952093,LGP Proband,Genes from the magenta module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,5,15
Cohort,0.006288832057214907,0.010521701290996355,0.5977010640471607,0.5502094125440548,LonGen OPEL,Genes from the magenta module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,5,12
Cohort,0.029628946086682855,0.029098810077436112,1.0182184772448075,0.30893840920707155,LGP Offspring,Genes from the magenta module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,23,63
Cohort,0.06950478844238833,0.08222466033476343,0.8453034425367238,0.3981838766493224,LGP Proband,Genes from the magenta module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,23,80
Cohort,-0.027171782133158753,0.02375158707828369,-1.1439985902248269,0.25296812198847163,LonGen OPEL,Genes from the magenta module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,44,44
Cohort,-0.023139399459353227,0.02963647755107624,-0.7807742812712547,0.43520858323813916,LGP Offspring,Genes from the pink module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,31,51
Cohort,0.0961088055055693,0.08217447284413486,1.16957008885064,0.24250816008368722,LGP Proband,Genes from the pink module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,31,81
Cohort,0.006638404701622979,0.026082167221382263,0.254518907316137,0.7991604357828557,LonGen OPEL,Genes from the pink module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,42,52
Cohort,-0.022030141652185403,0.022182367412313258,-0.9931375331902872,0.3209982843741212,LGP Offspring,Genes from the purple module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,19,30
Cohort,0.054967701794252526,0.06785404326497425,0.8100873455631853,0.4181210542787812,LGP Proband,Genes from the purple module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,19,47
Cohort,-0.05030131125156383,0.02078038855244857,-2.4206145676538267,0.015717099522359106,LonGen OPEL,Genes from the purple module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,39,29
Cohort,0.030400183671953518,0.026820483033428235,1.1334689100887427,0.2574192089636911,LGP Offspring,Genes from the red module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,18,50
Cohort,0.045977301519338036,0.07860279276517364,0.5849321621013586,0.5587515424058974,LGP Proband,Genes from the red module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,18,73
Cohort,0.016688639503572696,0.025611387225136843,0.6516101356350301,0.5148407900111115,LonGen OPEL,Genes from the red module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,44,60
Cohort,-0.03812282099302041,0.013696921862718566,-2.7833130228176532,0.005530995040965413,LGP Offspring,Genes from the red module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,12,7
Cohort,-0.02826108821178458,0.04580240513406208,-0.6170219255749854,0.537388669725343,LGP Proband,Genes from the red module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,12,24
Cohort,-0.002961236729418934,0.009917670529851354,-0.29858188175397243,0.7653370181748668,LonGen OPEL,Genes from the red module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,8,7
Cohort,0.03484469285531259,0.02417507490784202,1.4413478753693336,0.14994948334157152,LGP Offspring,Genes from the salmon module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,13,48
Cohort,0.10749000266840122,0.06105343040863222,1.7605890766328411,0.07867446215317318,LGP Proband,Genes from the salmon module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,13,49
Cohort,-0.04296362231936945,0.021116736213332123,-2.034576834475217,0.042224437508538895,LonGen OPEL,Genes from the salmon module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,38,31
Cohort,0.007672613840112211,0.025005265663471284,0.3068399249731099,0.7590597086030215,LGP Offspring,Genes from the tan module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,17,41
Cohort,-0.09577669539355005,0.06041891926937197,-1.5852103372875443,0.11329762560825091,LGP Proband,Genes from the tan module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,17,41
Cohort,-0.021678030441163263,0.017644682658417253,-1.228587153468693,0.21958974015780894,LonGen OPEL,Genes from the tan module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,26,21
Cohort,-0.05400822801592436,0.04534459165299166,-1.1910621762620086,0.23404721218714794,LGP Offspring,Genes from the turquoise module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,71,135
Cohort,-0.14337590638189823,0.11539787186122144,-1.2424484444073929,0.21442037946195347,LGP Proband,Genes from the turquoise module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,71,144
Cohort,0.006499777083431669,0.03772062217847917,0.17231362337231013,0.863234774901134,LonGen OPEL,Genes from the turquoise module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,93,110
Cohort,-0.020257915473253695,0.03836222634419733,-0.5280693380903819,0.5976245084304607,LGP Offspring,Genes from the turquoise module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,51,100
Cohort,-0.03207692730901169,0.11720531854405795,-0.27368149933361463,0.7843971598070876,LGP Proband,Genes from the turquoise module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,51,161
Cohort,-0.005283751817828447,0.03411413150065689,-0.1548845474118755,0.876951599765699,LonGen OPEL,Genes from the turquoise module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,83,100
Cohort,0.01570207280202305,0.02756784719234356,0.5695792164135326,0.5691523451438221,LGP Offspring,Genes from the yellow module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,22,51
Cohort,-0.10138636774717064,0.07541941743190328,-1.344300595250727,0.1792167355319721,LGP Proband,Genes from the yellow module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,22,64
Cohort,0.01983350749594009,0.022428023000843237,0.884318136074428,0.3767915245960429,LonGen OPEL,Genes from the yellow module which are dn-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,33,45
Cohort,-0.023234577242422248,0.025580722497601332,-0.9082846367846303,0.36405154156526953,LGP Offspring,Genes from the yellow module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,25,40
Cohort,-0.04319913041494577,0.07473366193792644,-0.5780411302583679,0.5633923882410095,LGP Proband,Genes from the yellow module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,25,65
Cohort,-0.033196289286871225,0.020856399211150674,-1.591659660461579,0.11185821915440776,LonGen OPEL,Genes from the yellow module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).,CGP,C2,38,30
Cohort,-0.015764227077248144,0.1046498788106054,-0.15063779582371165,0.8803063817004023,LGP Offspring,Genes down-regulated in Daudi cells (B lymphocytes) stably expressing CD5 [GeneID=921] off a plasmid vector.,CGP,C2,386,804
Cohort,0.18311581472363872,0.30357384672374665,0.6032002318377406,0.5465394935311175,LGP Proband,Genes down-regulated in Daudi cells (B lymphocytes) stably expressing CD5 [GeneID=921] off a plasmid vector.,CGP,C2,386,1095
Cohort,0.19117887908097791,0.09090561080967446,2.1030481768748213,0.03577492037763216,LonGen OPEL,Genes down-regulated in Daudi cells (B lymphocytes) stably expressing CD5 [GeneID=921] off a plasmid vector.,CGP,C2,546,723
Cohort,-0.147566174442213,0.1088596540928167,-1.355563506718422,0.17569079458399695,LGP Offspring,Genes up-regulated in Daudi cells (B lymphocytes) stably expressing CD5 [GeneID=921] off a plasmid vector.,CGP,C2,391,768
Cohort,0.06220556662521816,0.31191908578202576,0.1994285359911847,0.8419761514437782,LGP Proband,Genes up-regulated in Daudi cells (B lymphocytes) stably expressing CD5 [GeneID=921] off a plasmid vector.,CGP,C2,391,1177
Cohort,0.0540466323566758,0.10055881166947359,0.5374629180615369,0.5910981063231335,LonGen OPEL,Genes up-regulated in Daudi cells (B lymphocytes) stably expressing CD5 [GeneID=921] off a plasmid vector.,CGP,C2,642,809
Cohort,0.02289575881795809,0.029450994178293617,0.7774188769095286,0.43718365080466626,LGP Offspring,"Inflammatory cytokines, chemokines and their cognate receptors up-regulated in THP-1 cells (monocyte) after treatment with PSMD4 [GeneID=5710].",CGP,C2,23,62
Cohort,0.0023284919532959533,0.07529981166377368,0.030922945248429853,0.9753383893970327,LGP Proband,"Inflammatory cytokines, chemokines and their cognate receptors up-regulated in THP-1 cells (monocyte) after treatment with PSMD4 [GeneID=5710].",CGP,C2,23,72
Cohort,0.02133449491163411,0.028594981914933697,0.7460922680455411,0.45583195566366186,LonGen OPEL,"Inflammatory cytokines, chemokines and their cognate receptors up-regulated in THP-1 cells (monocyte) after treatment with PSMD4 [GeneID=5710].",CGP,C2,49,66
Cohort,-0.08871819523065945,0.061421854082673435,-1.4444076388714235,0.14908766355980727,LGP Offspring,Down-regulated genes from the set A (Fig. 5a): specific to cells expressing MLL-AF4 [GeneID=4297;4299] fusion protein alone.,CGP,C2,138,246
Cohort,0.23155739386729668,0.17339890380808207,1.3354028703871417,0.18210887161782235,LGP Proband,Down-regulated genes from the set A (Fig. 5a): specific to cells expressing MLL-AF4 [GeneID=4297;4299] fusion protein alone.,CGP,C2,138,337
Cohort,0.051858806424991084,0.055859274177265966,0.9283831053805024,0.35349030352963373,LonGen OPEL,Down-regulated genes from the set A (Fig. 5a): specific to cells expressing MLL-AF4 [GeneID=4297;4299] fusion protein alone.,CGP,C2,199,253
Cohort,-0.07045520248556142,0.07628227989215719,-0.9236116511615318,0.3560180951506564,LGP Offspring,Up-regulated genes from the set A (Fig. 5a): specific to cells expressing MLL-AF4 [GeneID=4297;4299] fusion protein alone.,CGP,C2,199,388
Cohort,-0.24047537610420175,0.2137071321705715,-1.125256670948469,0.26080400772295637,LGP Proband,Up-regulated genes from the set A (Fig. 5a): specific to cells expressing MLL-AF4 [GeneID=4297;4299] fusion protein alone.,CGP,C2,199,507
Cohort,0.048251843786253974,0.06358721595618483,0.7588293190804613,0.44817929570861137,LonGen OPEL,Up-regulated genes from the set A (Fig. 5a): specific to cells expressing MLL-AF4 [GeneID=4297;4299] fusion protein alone.,CGP,C2,269,343
Cohort,-0.0020857620390039317,0.0141966161910108,-0.1469196610615297,0.8832392375758078,LGP Offspring,Down-regulated genes from the set B (Fig. 5a): specific signature shared by cells expressing either AF4-MLL or MLL-AF4 [GeneID=4299;4297] fusion proteins.,CGP,C2,5,11
Cohort,0.03448528722168704,0.03293992580069096,1.0469145386163459,0.2954423073289339,LGP Proband,Down-regulated genes from the set B (Fig. 5a): specific signature shared by cells expressing either AF4-MLL or MLL-AF4 [GeneID=4299;4297] fusion proteins.,CGP,C2,5,13
Cohort,-0.0037072019916096115,0.008512023789372483,-0.43552533255818254,0.6632992261064536,LonGen OPEL,Down-regulated genes from the set B (Fig. 5a): specific signature shared by cells expressing either AF4-MLL or MLL-AF4 [GeneID=4299;4297] fusion proteins.,CGP,C2,5,2
Cohort,-0.005530916275929223,0.01882994327975646,-0.29372984261059115,0.7690545059711466,LGP Offspring,Up-regulated genes from the set B (Fig. 5a): specific signature shared by cells expressing either AF4-MLL or MLL-AF4 [GeneID=4299;4297] fusion proteins.,CGP,C2,11,22
Cohort,-0.011379748559527633,0.05824530646431132,-0.19537623287295006,0.8451460096683084,LGP Proband,Up-regulated genes from the set B (Fig. 5a): specific signature shared by cells expressing either AF4-MLL or MLL-AF4 [GeneID=4299;4297] fusion proteins.,CGP,C2,11,41
Cohort,-9.414006813144023e-4,0.01598399395633357,-0.058896461290350866,0.9530493588178779,LonGen OPEL,Up-regulated genes from the set B (Fig. 5a): specific signature shared by cells expressing either AF4-MLL or MLL-AF4 [GeneID=4299;4297] fusion proteins.,CGP,C2,16,22
Cohort,-0.005900399156951799,0.018088519139341043,-0.3261958102539702,0.7443771672468324,LGP Offspring,Down-regulated genes from the set C (Fig. 5a): specific to cells expressing AF4-MLL [GeneID=4299;4297] fusion protein alone.,CGP,C2,11,22
Cohort,0.037714894228963736,0.05197477888414802,0.7256383776644896,0.4682640535485102,LGP Proband,Down-regulated genes from the set C (Fig. 5a): specific to cells expressing AF4-MLL [GeneID=4299;4297] fusion protein alone.,CGP,C2,11,35
Cohort,-0.013508258243168857,0.014592656887581991,-0.9256887451841664,0.3548883134880999,LonGen OPEL,Down-regulated genes from the set C (Fig. 5a): specific to cells expressing AF4-MLL [GeneID=4299;4297] fusion protein alone.,CGP,C2,17,14
Cohort,-0.06907041483772293,0.06846072094839387,-1.0089057474254275,0.3133808224581926,LGP Offspring,Up-regulated genes from the set C (Fig. 5a): specific to cells expressing AF4-MLL [GeneID=4299;4297] fusion protein alone.,CGP,C2,149,275
Cohort,-0.6025639495490314,0.18245028519640336,-3.3026199378114742,9.98631323619031e-4,LGP Proband,Up-regulated genes from the set C (Fig. 5a): specific to cells expressing AF4-MLL [GeneID=4299;4297] fusion protein alone.,CGP,C2,149,406
Cohort,-0.03768954453433791,0.055490165442355736,-0.6792112482254273,0.49720146447623437,LonGen OPEL,Up-regulated genes from the set C (Fig. 5a): specific to cells expressing AF4-MLL [GeneID=4299;4297] fusion protein alone.,CGP,C2,229,269
Cohort,0.003915485141944065,0.011795320972867422,0.33195240307158996,0.7400280941958368,LGP Offspring,Down-regulated genes from the set D (Fig. 5a): specific signature shared by cells expressing MLL-AF4 [GeneID=4297;4299] alone and those expressing both MLL-AF4 and AF4-MLL fusion proteins.,CGP,C2,4,10
Cohort,0.0409644711548606,0.04067221558279538,1.0071856319572825,0.31413769832607413,LGP Proband,Down-regulated genes from the set D (Fig. 5a): specific signature shared by cells expressing MLL-AF4 [GeneID=4297;4299] alone and those expressing both MLL-AF4 and AF4-MLL fusion proteins.,CGP,C2,4,19
Cohort,-0.008477787593738538,0.01370294234347333,-0.6186837382247676,0.5363017248856988,LonGen OPEL,Down-regulated genes from the set D (Fig. 5a): specific signature shared by cells expressing MLL-AF4 [GeneID=4297;4299] alone and those expressing both MLL-AF4 and AF4-MLL fusion proteins.,CGP,C2,15,12
Cohort,-0.012263374148030347,0.03104725913166708,-0.39499055604306627,0.6929744566274665,LGP Offspring,Up-regulated genes from the set D (Fig. 5a): specific signature shared by cells expressing MLL-AF4 [GeneID=4297;4299] alone and those expressing both MLL-AF4 and AF4-MLL fusion proteins.,CGP,C2,30,58
Cohort,0.05848263832740686,0.08116766294029379,0.7205164742814657,0.47140895502604574,LGP Proband,Up-regulated genes from the set D (Fig. 5a): specific signature shared by cells expressing MLL-AF4 [GeneID=4297;4299] alone and those expressing both MLL-AF4 and AF4-MLL fusion proteins.,CGP,C2,30,72
Cohort,0.03956665618062756,0.02495089919174036,1.585780771930077,0.11318620345219399,LonGen OPEL,Up-regulated genes from the set D (Fig. 5a): specific signature shared by cells expressing MLL-AF4 [GeneID=4297;4299] alone and those expressing both MLL-AF4 and AF4-MLL fusion proteins.,CGP,C2,37,55
Cohort,0.012925385129866898,0.03239704549526657,0.3989680210732607,0.6900427658455197,LGP Offspring,"Down-regulated genes from the set E (Fig. 5a): specific signature shared by cells expressing either MLL-AF4 [GeneID=4297;4299] or AF4-MLL fusion proteins alone, and those expressing both fusion proteins.",CGP,C2,28,67
Cohort,0.016957391626748405,0.07889615829790021,0.21493304607709549,0.8298720649119565,LGP Proband,"Down-regulated genes from the set E (Fig. 5a): specific signature shared by cells expressing either MLL-AF4 [GeneID=4297;4299] or AF4-MLL fusion proteins alone, and those expressing both fusion proteins.",CGP,C2,28,77
Cohort,-0.017084065235595945,0.024849463993529747,-0.6875023638354638,0.4919664765122781,LonGen OPEL,"Down-regulated genes from the set E (Fig. 5a): specific signature shared by cells expressing either MLL-AF4 [GeneID=4297;4299] or AF4-MLL fusion proteins alone, and those expressing both fusion proteins.",CGP,C2,49,48
Cohort,-0.055641225715959086,0.05812551957639447,-0.9572598425177039,0.33877833412836833,LGP Offspring,"Up-regulated genes from the set E (Fig. 5a): specific signature shared by cells expressing either MLL-AF4 [GeneID=4297;4299] or AF4-MLL fusion proteins alone, and those expressing both fusion proteins.",CGP,C2,114,205
Cohort,-0.07871785395344603,0.1588353062810881,-0.495594183664307,0.6203113168888765,LGP Proband,"Up-regulated genes from the set E (Fig. 5a): specific signature shared by cells expressing either MLL-AF4 [GeneID=4297;4299] or AF4-MLL fusion proteins alone, and those expressing both fusion proteins.",CGP,C2,114,289
Cohort,-0.01162227787264026,0.04729790433787537,-0.24572500696047406,0.8059584553545008,LonGen OPEL,"Up-regulated genes from the set E (Fig. 5a): specific signature shared by cells expressing either MLL-AF4 [GeneID=4297;4299] or AF4-MLL fusion proteins alone, and those expressing both fusion proteins.",CGP,C2,169,190
Cohort,-0.0044657519937561715,0.0359083625848053,-0.12436523618166494,0.9010630678704556,LGP Offspring,Down-regualted genes from the set F (Fig. 5a): specific signature shared by cells expressing AF4-MLL [GeneID=4299;4297] alone and those expressing both AF4-MLL and MLL-AF4 fusion proteins.,CGP,C2,47,94
Cohort,-0.03388372569897559,0.09296798530515485,-0.3644666020002137,0.715601998221721,LGP Proband,Down-regualted genes from the set F (Fig. 5a): specific signature shared by cells expressing AF4-MLL [GeneID=4299;4297] alone and those expressing both AF4-MLL and MLL-AF4 fusion proteins.,CGP,C2,47,107
Cohort,0.00809503673541887,0.028531739377686986,0.2837204079380287,0.7766984322079198,LonGen OPEL,Down-regualted genes from the set F (Fig. 5a): specific signature shared by cells expressing AF4-MLL [GeneID=4299;4297] alone and those expressing both AF4-MLL and MLL-AF4 fusion proteins.,CGP,C2,57,67
Cohort,-0.2122510192702339,0.08730551886978641,-2.4311294637261134,0.015310739088043654,LGP Offspring,Up-regualted genes from the set F (Fig. 5a): specific signature shared by cells expressing AF4-MLL [GeneID=4299;4297] alone and those expressing both AF4-MLL and MLL-AF4 fusion proteins.,CGP,C2,259,464
Cohort,0.0782566396978101,0.24262675258250752,0.32253920420914095,0.7471250809125172,LGP Proband,Up-regualted genes from the set F (Fig. 5a): specific signature shared by cells expressing AF4-MLL [GeneID=4299;4297] alone and those expressing both AF4-MLL and MLL-AF4 fusion proteins.,CGP,C2,259,674
Cohort,0.015248497292623387,0.07131191134276975,0.21382819511497245,0.8307357951206797,LonGen OPEL,Up-regualted genes from the set F (Fig. 5a): specific signature shared by cells expressing AF4-MLL [GeneID=4299;4297] alone and those expressing both AF4-MLL and MLL-AF4 fusion proteins.,CGP,C2,376,453
Cohort,-0.02031459939848142,0.031493378312190894,-0.6450435135000352,0.5191178367003509,LGP Offspring,Down-regulated genes from the set G (Fig. 5a): specific to cells expressing both MLL-AF4 [GeneID=4297;4299] and AF4-MLL fusion proteins.,CGP,C2,31,64
Cohort,0.08090315863579295,0.08814681801215458,0.917822792249145,0.35897699185767784,LGP Proband,Down-regulated genes from the set G (Fig. 5a): specific to cells expressing both MLL-AF4 [GeneID=4297;4299] and AF4-MLL fusion proteins.,CGP,C2,31,89
Cohort,0.01898982506823465,0.029724676998231236,0.6388572386964756,0.5230995859276135,LonGen OPEL,Down-regulated genes from the set G (Fig. 5a): specific to cells expressing both MLL-AF4 [GeneID=4297;4299] and AF4-MLL fusion proteins.,CGP,C2,57,72
Cohort,-0.0928987436674167,0.0926663937959102,-1.0025073800974518,0.31645731223540285,LGP Offspring,Up-regulated genes from the set G (Fig. 5a): specific to cells expressing both MLL-AF4 [GeneID=4297;4299] and AF4-MLL fusion proteins.,CGP,C2,272,511
Cohort,-0.24595472167848817,0.2548987791982181,-0.9649113363827659,0.33486892318759176,LGP Proband,Up-regulated genes from the set G (Fig. 5a): specific to cells expressing both MLL-AF4 [GeneID=4297;4299] and AF4-MLL fusion proteins.,CGP,C2,272,770
Cohort,-0.04176148865491147,0.07863759372854157,-0.531062646691262,0.5955235109217355,LonGen OPEL,Up-regulated genes from the set G (Fig. 5a): specific to cells expressing both MLL-AF4 [GeneID=4297;4299] and AF4-MLL fusion proteins.,CGP,C2,406,476
Cohort,0.00749216025707771,0.008466977605714257,0.8848683209013504,0.37654227844860655,LGP Offspring,"Genes down-regulated in A549 cells (lung cancer) after treatment with AZD0530 [PubChem=10302451], a SRC [GeneID=6714] kinase inhibitor.",CGP,C2,1,6
Cohort,-0.011486303386236782,0.030487698626303246,-0.37675206407108014,0.7064537011014742,LGP Proband,"Genes down-regulated in A549 cells (lung cancer) after treatment with AZD0530 [PubChem=10302451], a SRC [GeneID=6714] kinase inhibitor.",CGP,C2,1,12
Cohort,-0.014801860931569152,0.008535220095877715,-1.7342096355216496,0.0832680398324316,LonGen OPEL,"Genes down-regulated in A549 cells (lung cancer) after treatment with AZD0530 [PubChem=10302451], a SRC [GeneID=6714] kinase inhibitor.",CGP,C2,8,3
Cohort,-0.0015142266754895545,0.049326938095204984,-0.03069776341209289,0.9755196356095451,LGP Offspring,Cluster P2 of genes with similar expression profiles in peripheral T ymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,74,150
Cohort,-0.07932003699376025,0.13201872482648638,-0.6008241414088147,0.54812036774219,LGP Proband,Cluster P2 of genes with similar expression profiles in peripheral T ymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,74,213
Cohort,0.005899831360213871,0.040456000602159946,0.14583328239071855,0.8840899224056931,LonGen OPEL,Cluster P2 of genes with similar expression profiles in peripheral T ymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,113,143
Cohort,-0.08307676278375938,0.07880750573789432,-1.0541732288808146,0.2921802434325607,LGP Offspring,Cluster P3 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,193,373
Cohort,-0.05339753279645274,0.21845041067265722,-0.2444377771231004,0.8069519103574931,LGP Proband,Cluster P3 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,193,550
Cohort,0.09594313929620242,0.0696291061787561,1.3779171464572777,0.16861609590141963,LonGen OPEL,Cluster P3 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,300,393
Cohort,-0.10251836006874411,0.06583271834584944,-1.5572554596662433,0.11987786300996524,LGP Offspring,Cluster P4 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,146,265
Cohort,-0.06446153774297629,0.1765416663818963,-0.3651349795437673,0.7151032268628343,LGP Proband,Cluster P4 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,146,361
Cohort,0.0901898711997197,0.05818559015023029,1.550037921190746,0.12152988804617335,LonGen OPEL,Cluster P4 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,221,308
Cohort,0.01461240595960955,0.0488662666881284,0.299028490407668,0.7650102119914012,LGP Offspring,Cluster P6 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,82,167
Cohort,-0.3131340610915208,0.13746639377895264,-2.2778953639756025,0.02298505833641606,LGP Proband,Cluster P6 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,82,226
Cohort,-0.004858640965675847,0.042887357644211775,-0.1132884195380497,0.9098304630585922,LonGen OPEL,Cluster P6 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,122,154
Cohort,-0.031709352132064064,0.05206182992365475,-0.609071025328225,0.5426819890796737,LGP Offspring,Cluster P7 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,88,176
Cohort,0.0380354361673784,0.14257932981353275,0.2667668323109786,0.7897146377637824,LGP Proband,Cluster P7 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,88,248
Cohort,0.06251917827522555,0.048672729691934084,1.284480625412428,0.19934752616996027,LonGen OPEL,Cluster P7 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,141,187
Cohort,-0.09186083291243066,0.05214447553989143,-1.7616599258373118,0.07857875657354832,LGP Offspring,Cluster T4 of genes with similar expression profiles in thymic T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,93,163
Cohort,0.17280617224655676,0.1496244032070671,1.1549330760397962,0.24844863044384669,LGP Proband,Cluster T4 of genes with similar expression profiles in thymic T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,93,278
Cohort,0.05993627970236738,0.04816187177858182,1.2444757126117716,0.21369082607962558,LonGen OPEL,Cluster T4 of genes with similar expression profiles in thymic T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,143,198
Cohort,0.008432201751806666,0.045994904714533914,0.18332904055657664,0.8545948213273771,LGP Offspring,Cluster T7 of genes with similar expression profiles in thymic T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,66,140
Cohort,0.08110110413884448,0.1267052080882941,0.6400771157120033,0.5222982642353733,LGP Proband,Cluster T7 of genes with similar expression profiles in thymic T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,66,180
Cohort,0.02465225452039027,0.03785649840443974,0.6512027144459589,0.5151035830985722,LonGen OPEL,Cluster T7 of genes with similar expression profiles in thymic T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).,CGP,C2,103,131
Cohort,0.0018539349326357828,0.007816026337161457,0.23719660767021872,0.8125761321128396,LGP Offspring,FOXP3 [GeneID=50943] target genes down-regulated in T lymphocytes after stimulation with IL2 [GeneID=3558].,CGP,C2,1,5
Cohort,0.011376046215018207,0.028424395642046518,0.40022121695316887,0.6890960789323519,LGP Proband,FOXP3 [GeneID=50943] target genes down-regulated in T lymphocytes after stimulation with IL2 [GeneID=3558].,CGP,C2,1,12
Cohort,0.009826140840326437,0.0073341588680642476,1.3397774737486583,0.18070005220275703,LonGen OPEL,FOXP3 [GeneID=50943] target genes down-regulated in T lymphocytes after stimulation with IL2 [GeneID=3558].,CGP,C2,2,6
Cohort,-0.015025057494188794,0.020436690002902318,-0.7352001469932269,0.4624725902361223,LGP Offspring,FOXP3 [GeneID=50943] target genes up-regulated in T lymphocytes after stimulation with IL2 [GeneID=3558].,CGP,C2,15,28
Cohort,0.026814545595805886,0.053135687785650684,0.5046428627022904,0.6139430034669777,LGP Proband,FOXP3 [GeneID=50943] target genes up-regulated in T lymphocytes after stimulation with IL2 [GeneID=3558].,CGP,C2,15,33
Cohort,5.031270580418081e-4,0.018143312060115088,0.027730717322987868,0.9778838749073635,LonGen OPEL,FOXP3 [GeneID=50943] target genes up-regulated in T lymphocytes after stimulation with IL2 [GeneID=3558].,CGP,C2,24,28
Cohort,-0.013280736471986875,0.022106564779325093,-0.6007598468852804,0.5482013163996873,LGP Offspring,Genes changed in peripheral regulatory T lymphocytes that depend on PDE3B [GeneID=5140].,CGP,C2,18,29
Cohort,-0.05325918774604735,0.060566308742070654,-0.8793533707470664,0.37946299769184066,LGP Proband,Genes changed in peripheral regulatory T lymphocytes that depend on PDE3B [GeneID=5140].,CGP,C2,18,43
Cohort,-0.030503539883744622,0.01844049020796052,-1.654161008722894,0.09848904675998588,LonGen OPEL,Genes changed in peripheral regulatory T lymphocytes that depend on PDE3B [GeneID=5140].,CGP,C2,30,22
Cohort,0.13523957886148236,0.1207111411757875,1.1203570568895342,0.26295950674121854,LGP Offspring,Genes down-regulated in erythroid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,453,1001
Cohort,-0.288032924044749,0.3311713663984655,-0.8697398183216953,0.3846928490200977,LGP Proband,Genes down-regulated in erythroid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,453,1329
Cohort,0.14938841987864204,0.10514395568427397,1.42079893139293,0.15576681814177654,LonGen OPEL,Genes down-regulated in erythroid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,697,911
Cohort,0.012831607579220174,0.017019017216139312,0.7539570244427408,0.45113756079528655,LGP Offspring,Genes up-regulated in erythroid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,8,19
Cohort,-0.03494777025345045,0.04330144011603009,-0.8070810153150743,0.4198499120967506,LGP Proband,Genes up-regulated in erythroid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,8,21
Cohort,-0.03664911155294506,0.016414749105266753,-2.232693982583384,0.025846485694471243,LonGen OPEL,Genes up-regulated in erythroid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,25,15
Cohort,-0.025060313006202352,0.02812438462718214,-0.8910528474988082,0.3732178464213688,LGP Offspring,Genes down-regulated in myeloid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,26,43
Cohort,0.06628878981672394,0.08173953475411752,0.8109758639577371,0.41761089699052356,LGP Proband,Genes down-regulated in myeloid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,26,73
Cohort,0.0248475416015603,0.02558737374376985,0.9710860462031712,0.3318004127600821,LonGen OPEL,Genes down-regulated in myeloid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,40,57
Cohort,-0.008133195893873364,0.010086346050758036,-0.8063570150125987,0.42032060249407077,LGP Offspring,Genes up-regulated in myeloid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,5,5
Cohort,-0.0727670141624814,0.0389440848681519,-1.8684997839553692,0.062042836139140786,LGP Proband,Genes up-regulated in myeloid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,5,20
Cohort,-0.005750863347274383,0.010792722524410707,-0.5328464003653597,0.5942886306116681,LonGen OPEL,Genes up-regulated in myeloid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,10,8
Cohort,-0.012067886777284195,0.04202011499741549,-0.2871930925944979,0.7740524848050643,LGP Offspring,Genes down-regulated in common hematopoietic progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,64,134
Cohort,0.1180290900426767,0.12573845846376516,0.9386872678790624,0.34816309785085164,LGP Proband,Genes down-regulated in common hematopoietic progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,64,189
Cohort,-0.0022326270235264877,0.0415891638326654,-0.05368290241442446,0.9572012747729249,LonGen OPEL,Genes down-regulated in common hematopoietic progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,115,131
Cohort,0.011813206142073611,0.023605113346790593,0.500451150923186,0.6169203277461552,LGP Offspring,Genes up-regulated in common hematopoietic progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,16,40
Cohort,0.01022543710583155,0.06019328434556216,0.16987670995203696,0.8651482950998434,LGP Proband,Genes up-regulated in common hematopoietic progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,16,41
Cohort,0.06799922910903532,0.022317859219668192,3.0468526770304756,0.002388885185238974,LonGen OPEL,Genes up-regulated in common hematopoietic progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].,CGP,C2,21,52
Cohort,-0.017323080315234576,0.02441511829735799,-0.7095226860772222,0.4782448260102484,LGP Offspring,"Genes required for epigenetic silencing of FAS [GeneID=355] by activated KRAS [GeneID=3845] in NIH 3T3 cells, based on RNAi screen.",CGP,C2,18,33
Cohort,0.031436933611678014,0.06792832314495202,0.462795666906054,0.6436315631333731,LGP Proband,"Genes required for epigenetic silencing of FAS [GeneID=355] by activated KRAS [GeneID=3845] in NIH 3T3 cells, based on RNAi screen.",CGP,C2,18,53
Cohort,0.01506340609462081,0.019964199397625587,0.7545209199028715,0.45075964670961355,LonGen OPEL,"Genes required for epigenetic silencing of FAS [GeneID=355] by activated KRAS [GeneID=3845] in NIH 3T3 cells, based on RNAi screen.",CGP,C2,26,36
Cohort,0.04263137523865348,0.027790553154899596,1.5340239901319626,0.12549161112673024,LGP Offspring,Genes down-pregulated by dsRNA in GRE cells (glioma; no interferon system).,CGP,C2,17,56
Cohort,-0.04813016456034434,0.08683221952163177,-0.5542892353264572,0.5795295111806749,LGP Proband,Genes down-pregulated by dsRNA in GRE cells (glioma; no interferon system).,CGP,C2,17,109
Cohort,-0.0012312530028302131,0.025727329113431705,-0.047857785680030095,0.9618415875540649,LonGen OPEL,Genes down-pregulated by dsRNA in GRE cells (glioma; no interferon system).,CGP,C2,45,53
Cohort,-0.010904255396067817,0.03308149422278539,-0.3296179828708385,0.7417907404892372,LGP Offspring,Genes up-pregulated by dsRNA in GRE cells (glioma; no interferon system).,CGP,C2,36,72
Cohort,0.04131132233292402,0.08039974296097349,0.513824059773136,0.6075111082921401,LGP Proband,Genes up-pregulated by dsRNA in GRE cells (glioma; no interferon system).,CGP,C2,36,76
Cohort,0.03516836519490372,0.03063808164151105,1.147864465092836,0.2513693751946373,LonGen OPEL,Genes up-pregulated by dsRNA in GRE cells (glioma; no interferon system).,CGP,C2,52,75
Cohort,0.019401327086357355,0.028891586175161195,0.671521700772426,0.5021176455857318,LGP Offspring,Cluster d3: genes progressively down-regulated in WS1 cells (fibroblast) through 12 h irradiation with high dose UV-C.,CGP,C2,27,63
Cohort,-0.06617677552084898,0.08551155061016581,-0.7738928255732241,0.4392134836434263,LGP Proband,Cluster d3: genes progressively down-regulated in WS1 cells (fibroblast) through 12 h irradiation with high dose UV-C.,CGP,C2,27,90
Cohort,-0.002308354707086726,0.02451412114846468,-0.09416428568279708,0.9250023515513917,LonGen OPEL,Cluster d3: genes progressively down-regulated in WS1 cells (fibroblast) through 12 h irradiation with high dose UV-C.,CGP,C2,42,52
Cohort,-0.02716038935147241,0.08609419889368859,-0.31547293198013004,0.7524999644737627,LGP Offspring,Selected genes down-regulated in WS1 (fibroblast) in response to irradiation with high dose UV-C.,CGP,C2,247,512
Cohort,-0.28351665338502274,0.23893576122630367,-1.186581079072944,0.23573080067446733,LGP Proband,Selected genes down-regulated in WS1 (fibroblast) in response to irradiation with high dose UV-C.,CGP,C2,247,671
Cohort,-0.022506149644213096,0.07517170868652949,-0.2993965420962437,0.7647156555140475,LonGen OPEL,Selected genes down-regulated in WS1 (fibroblast) in response to irradiation with high dose UV-C.,CGP,C2,387,470
Cohort,0.014354760488470699,0.02603890557230424,0.5512812529163611,0.581623049281774,LGP Offspring,Selected genes up-regulated in WS1 (fibroblast) in response to irradiation with high dose UV-C.,CGP,C2,17,44
Cohort,-0.017816466847161025,0.07344611701715426,-0.2425787444011474,0.8083913910689091,LGP Proband,Selected genes up-regulated in WS1 (fibroblast) in response to irradiation with high dose UV-C.,CGP,C2,17,60
Cohort,-0.030358839746803788,0.02651546501978724,-1.1449484187491497,0.25257466080539837,LonGen OPEL,Selected genes up-regulated in WS1 (fibroblast) in response to irradiation with high dose UV-C.,CGP,C2,48,54
Cohort,-0.013568859779808337,0.05634008725649302,-0.2408384587342748,0.8097533452321451,LGP Offspring,Selected genes down-regulated in WS1 (fibroblast) in response to irradiation with low dose UV-C.,CGP,C2,96,201
Cohort,0.2451926025237802,0.14865011897688366,1.6494611925733453,0.0994297515465964,LGP Proband,Selected genes down-regulated in WS1 (fibroblast) in response to irradiation with low dose UV-C.,CGP,C2,96,245
Cohort,-0.04168947596335123,0.044896327095389175,-0.9285720828515772,0.3533923807610694,LonGen OPEL,Selected genes down-regulated in WS1 (fibroblast) in response to irradiation with low dose UV-C.,CGP,C2,152,160
Cohort,0.006587043091767224,0.025271254688296715,0.26065358340983863,0.7944390430957435,LGP Offspring,Selected genes up-regulated in WS1 (fibroblast) in response to irradiation with low dose UV-C.,CGP,C2,20,44
Cohort,-0.03807447888769863,0.05497153953692457,-0.6926216585606789,0.488739821316855,LGP Proband,Selected genes up-regulated in WS1 (fibroblast) in response to irradiation with low dose UV-C.,CGP,C2,20,28
Cohort,0.006945559430534317,0.021522368621663762,0.3227135243628867,0.7469969551588068,LonGen OPEL,Selected genes up-regulated in WS1 (fibroblast) in response to irradiation with low dose UV-C.,CGP,C2,31,38
Cohort,-8.580644833207421e-4,0.022675620050853555,-0.037840838812627876,0.969825754835502,LGP Offspring,Cluster d1: genes down-regulated in WS1 cells (fibroblast) at 6 h after irradiation with high dose UV-C.,CGP,C2,17,37
Cohort,0.016150389995223672,0.06562615088126345,0.24609686502023204,0.8056678030649109,LGP Proband,Cluster d1: genes down-regulated in WS1 cells (fibroblast) at 6 h after irradiation with high dose UV-C.,CGP,C2,17,59
Cohort,0.029056192698129008,0.021565619720377672,1.347338637835359,0.17825458350212658,LonGen OPEL,Cluster d1: genes down-regulated in WS1 cells (fibroblast) at 6 h after irradiation with high dose UV-C.,CGP,C2,25,44
Cohort,-0.07547766447977812,0.03727490291349271,-2.024892315747839,0.04327099482930231,LGP Offspring,Cluster d2: genes down-regulated consistently in WS1 cells (fibroblast) between 6 h and 24 h after irradiation with high dose UV-C.,CGP,C2,54,80
Cohort,-0.13949110840281792,0.10435548890871377,-1.3366916284091148,0.18168783625462384,LGP Proband,Cluster d2: genes down-regulated consistently in WS1 cells (fibroblast) between 6 h and 24 h after irradiation with high dose UV-C.,CGP,C2,54,125
Cohort,0.015039922692738007,0.03194039450155388,0.47087466912803233,0.6378592460145099,LonGen OPEL,Cluster d2: genes down-regulated consistently in WS1 cells (fibroblast) between 6 h and 24 h after irradiation with high dose UV-C.,CGP,C2,65,89
Cohort,0.0520534794300989,0.04408458859925904,1.1807636428975046,0.23811190729248302,LGP Offspring,Cluster d4: genes progressively down-regulated in WS1 cells (fibroblast) through 12 h after irradiation with high dose UV-C.,CGP,C2,57,139
Cohort,-0.10306643076341145,0.10664891790066733,-0.9664085936568751,0.3341199139996638,LGP Proband,Cluster d4: genes progressively down-regulated in WS1 cells (fibroblast) through 12 h after irradiation with high dose UV-C.,CGP,C2,57,136
Cohort,-0.03270339056874189,0.03849582468903952,-0.8495308473818243,0.3958414006236778,LonGen OPEL,Cluster d4: genes progressively down-regulated in WS1 cells (fibroblast) through 12 h after irradiation with high dose UV-C.,CGP,C2,102,105
Cohort,-0.004309538562414566,0.02814230840248823,-0.15313379772476426,0.8783384614599177,LGP Offspring,Cluster d5: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,27,58
Cohort,-0.04145951984532173,0.07522176197580409,-0.5511639019923202,0.5816689446638003,LGP Proband,Cluster d5: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,27,63
Cohort,0.015164622506515341,0.02137667342205549,0.7094004856185512,0.478283719616032,LonGen OPEL,Cluster d5: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,28,39
Cohort,-0.03839928996331619,0.02375609419785022,-1.6163974449466143,0.10647495369546996,LGP Offspring,Cluster d6: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,23,33
Cohort,-0.009137132842394922,0.07497965730111683,-0.12186149112018979,0.9030380695653206,LGP Proband,Cluster d6: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,23,73
Cohort,0.00190288327485552,0.0251341844425799,0.07570897234412904,0.9396696607744757,LonGen OPEL,Cluster d6: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,40,51
Cohort,0.005602242927808885,0.03127650871536763,0.1791198301188981,0.8578972830125162,LGP Offspring,Cluster d7: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,27,61
Cohort,0.02926516988222146,0.08003729777619267,0.3656441521058757,0.7147233426897079,LGP Proband,Cluster d7: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,27,68
Cohort,-0.021389758149618805,0.023135574140684668,-0.9245397594004038,0.3554855444237657,LonGen OPEL,Cluster d7: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,41,40
Cohort,-0.04977490211015815,0.03545142437615805,-1.4040310928559752,0.16076883128730984,LGP Offspring,Cluster d8: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,48,78
Cohort,-0.0466480880074362,0.10214837931847355,-0.4566698788435882,0.6480272537134615,LGP Proband,Cluster d8: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,48,128
Cohort,-0.03918216246162861,0.03377732429200373,-1.160013804613422,0.24639099679810356,LonGen OPEL,Cluster d8: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.,CGP,C2,81,82
Cohort,0.0035189418634206378,0.02430238477059983,0.1447982120535648,0.8849133531457474,LGP Offspring,Cluster d9: genes progressively down-regulated in WS1 cells (fibroblast) through 24 h after irradiation with high dose UV-C.,CGP,C2,19,44
Cohort,-0.027162093704382866,0.06749125531771412,-0.4024535264089799,0.6874534125416185,LGP Proband,Cluster d9: genes progressively down-regulated in WS1 cells (fibroblast) through 24 h after irradiation with high dose UV-C.,CGP,C2,19,54
Cohort,-0.0032628405275025407,0.023116172057000846,-0.14114969033181138,0.8877874017420436,LonGen OPEL,Cluster d9: genes progressively down-regulated in WS1 cells (fibroblast) through 24 h after irradiation with high dose UV-C.,CGP,C2,36,43
Cohort,-0.03460914900893609,0.018849879366525085,-1.8360408751685382,0.06679062911438086,LGP Offspring,Genes down-regulated in LSC (leukemic stem) cells compared to LPC (leukemia progenitor) cells from AML (acute myeloid leukemia) tumor samples.,CGP,C2,16,18
Cohort,0.010193688434062707,0.058936262745406136,0.17296122894825508,0.8627238694732852,LGP Proband,Genes down-regulated in LSC (leukemic stem) cells compared to LPC (leukemia progenitor) cells from AML (acute myeloid leukemia) tumor samples.,CGP,C2,16,42
Cohort,-6.096783560733323e-4,0.016510287467361447,-0.03692717993424294,0.9705523265655253,LonGen OPEL,Genes down-regulated in LSC (leukemic stem) cells compared to LPC (leukemia progenitor) cells from AML (acute myeloid leukemia) tumor samples.,CGP,C2,18,25
Cohort,0.05950242039464199,0.02999633829609942,1.9836561318679153,0.0476983024904219,LGP Offspring,Genes up-regulated in LSC (leukemic stem) cells compared to LPC (leukemia progenitor) cells from AML (acute myeloid leukemia) tumor samples.,CGP,C2,20,70
Cohort,0.03195609398960913,0.07932334921303731,0.4028586072908396,0.687155487960897,LGP Proband,Genes up-regulated in LSC (leukemic stem) cells compared to LPC (leukemia progenitor) cells from AML (acute myeloid leukemia) tumor samples.,CGP,C2,20,78
Cohort,0.022137367493690618,0.024726156003566896,0.8953016186785027,0.3708965220817755,LonGen OPEL,Genes up-regulated in LSC (leukemic stem) cells compared to LPC (leukemia progenitor) cells from AML (acute myeloid leukemia) tumor samples.,CGP,C2,41,53
Cohort,-0.10703190129518553,0.05289647387968202,-2.0234222329949554,0.04342262867386588,LGP Offspring,Experimentally validated direct targets of MIR192 [GeneID=406967] microRNA; MIR192 caused cell cycle arrest in HCT116 cells (colon cancer).,CGP,C2,100,161
Cohort,0.06815668779388097,0.14904752640448862,0.45728157613911535,0.6475877611037213,LGP Proband,Experimentally validated direct targets of MIR192 [GeneID=406967] microRNA; MIR192 caused cell cycle arrest in HCT116 cells (colon cancer).,CGP,C2,100,255
Cohort,0.017841553068281307,0.04774098937902844,0.3737156121049872,0.7087154220716448,LonGen OPEL,Experimentally validated direct targets of MIR192 [GeneID=406967] microRNA; MIR192 caused cell cycle arrest in HCT116 cells (colon cancer).,CGP,C2,149,171
Cohort,-0.23376754860419177,0.16839070222687386,-1.388244989258583,0.1655197631388402,LGP Offspring,Genes down-regulated in HCT116 cells (colon cancer) by expression of MIR192 or MIR215 [GeneID=406967;406997] at 24 h.,CGP,C2,851,1673
Cohort,0.09748073908554361,0.43736730185146167,0.22288071987295005,0.8236829164599511,LGP Proband,Genes down-regulated in HCT116 cells (colon cancer) by expression of MIR192 or MIR215 [GeneID=406967;406997] at 24 h.,CGP,C2,851,2390
Cohort,-0.251698938516412,0.14111547493741597,-1.7836381065084412,0.07486338313113837,LonGen OPEL,Genes down-regulated in HCT116 cells (colon cancer) by expression of MIR192 or MIR215 [GeneID=406967;406997] at 24 h.,CGP,C2,1365,1523
Cohort,0.01265074610105701,0.0460617286353165,0.2746476625142856,0.783670857079064,LGP Offspring,Selected genes down-regulated during differentiation of 3T3-L1 cells (fibroblast) into adipocytes in response to adipogenic hormones.,CGP,C2,70,153
Cohort,0.040329592727982366,0.12647453123007615,0.3188752101766385,0.7499009868528614,LGP Proband,Selected genes down-regulated during differentiation of 3T3-L1 cells (fibroblast) into adipocytes in response to adipogenic hormones.,CGP,C2,70,201
Cohort,0.050598234216775805,0.039966817967301255,1.2660060717911696,0.2058812956806028,LonGen OPEL,Selected genes down-regulated during differentiation of 3T3-L1 cells (fibroblast) into adipocytes in response to adipogenic hormones.,CGP,C2,104,144
Cohort,-0.010814949536217389,0.037802754773445246,-0.2860889266147982,0.7748976605029073,LGP Offspring,Selected genes up-regulated during differentiation of 3T3-L1 cells (fibroblast) into adipocytes in response to adipogenic hormones.,CGP,C2,48,85
Cohort,-0.1565772766838197,0.10094767346537624,-1.5510736533965166,0.12126340354762132,LGP Proband,Selected genes up-regulated during differentiation of 3T3-L1 cells (fibroblast) into adipocytes in response to adipogenic hormones.,CGP,C2,48,113
Cohort,-0.036806046817051,0.033249633941266926,-1.1069609633016178,0.2686452104789531,LonGen OPEL,Selected genes up-regulated during differentiation of 3T3-L1 cells (fibroblast) into adipocytes in response to adipogenic hormones.,CGP,C2,80,80
Cohort,0.01748767424019021,0.010477342342744441,1.6690944772173473,0.09556166694504474,LGP Offspring,"Genes down-regulated in 3T3-L1 cells (fibroblast) induced to differentiate to mature adipocytes and then treated with a TZD derivative AD-5075 [PubChem=128440], a PPARG [GeneID=5468] activator.",CGP,C2,2,9
Cohort,-0.04402152528347066,0.03126409310983496,-1.4080538056490917,0.1594877760295812,LGP Proband,"Genes down-regulated in 3T3-L1 cells (fibroblast) induced to differentiate to mature adipocytes and then treated with a TZD derivative AD-5075 [PubChem=128440], a PPARG [GeneID=5468] activator.",CGP,C2,2,14
Cohort,-0.010031068171024282,0.009288969736241853,-1.0798902844830096,0.28051812920306957,LonGen OPEL,"Genes down-regulated in 3T3-L1 cells (fibroblast) induced to differentiate to mature adipocytes and then treated with a TZD derivative AD-5075 [PubChem=128440], a PPARG [GeneID=5468] activator.",CGP,C2,8,5
Cohort,-0.030196590917750996,0.01782798633253022,-1.6937746279652535,0.0907687730451417,LGP Offspring,"Genes up-regulated in 3T3-L1 cells (fibroblast) induced to differentiate to mature adipocytes and then treated with a TZD derivative AD-5075 [PubChem=128440], a PPARG [GeneID=5468] activator.",CGP,C2,14,18
Cohort,0.039937349202065014,0.04758268263668105,0.8393252962849489,0.4015273088039307,LGP Proband,"Genes up-regulated in 3T3-L1 cells (fibroblast) induced to differentiate to mature adipocytes and then treated with a TZD derivative AD-5075 [PubChem=128440], a PPARG [GeneID=5468] activator.",CGP,C2,14,23
Cohort,0.0029571329190330896,0.013313233233370168,0.2221198162157119,0.8242775871432704,LonGen OPEL,"Genes up-regulated in 3T3-L1 cells (fibroblast) induced to differentiate to mature adipocytes and then treated with a TZD derivative AD-5075 [PubChem=128440], a PPARG [GeneID=5468] activator.",CGP,C2,11,14
Cohort,-0.10866486972476345,0.054820952435673545,-1.9821777057279317,0.047863871549670624,LGP Offspring,"Genes changed in NIH 3T3 cells (embryonic fibroblast) by expression of one or more of C/EBP proteins: CEBPA, CEBPB, CEBPG,  and CEBPD [GeneID=1050;1051;1054;1052].",CGP,C2,114,191
Cohort,-0.13487416798327437,0.15356086711737327,-0.8783107995879195,0.3800280379877694,LGP Proband,"Genes changed in NIH 3T3 cells (embryonic fibroblast) by expression of one or more of C/EBP proteins: CEBPA, CEBPB, CEBPG,  and CEBPD [GeneID=1050;1051;1054;1052].",CGP,C2,114,285
Cohort,-0.005138938156211589,0.04932040350130386,-0.10419497391329602,0.9170408693395755,LonGen OPEL,"Genes changed in NIH 3T3 cells (embryonic fibroblast) by expression of one or more of C/EBP proteins: CEBPA, CEBPB, CEBPG,  and CEBPD [GeneID=1050;1051;1054;1052].",CGP,C2,164,193
Cohort,0.004692634054005022,0.014124048811781196,0.3322442535097151,0.7398078232028727,LGP Offspring,"Genes down-regulated in MEF cells (embryonic fibroblasts) with TERT [GeneID=7015] knockout, after expression of the gene off a retroviral vector.",CGP,C2,6,14
Cohort,-0.036557973161825665,0.031454335888654456,-1.1622554452027736,0.2454642006702738,LGP Proband,"Genes down-regulated in MEF cells (embryonic fibroblasts) with TERT [GeneID=7015] knockout, after expression of the gene off a retroviral vector.",CGP,C2,6,10
Cohort,-0.005553524931338834,0.00858495825037412,-0.6468901501177154,0.5178895287485227,LonGen OPEL,"Genes down-regulated in MEF cells (embryonic fibroblasts) with TERT [GeneID=7015] knockout, after expression of the gene off a retroviral vector.",CGP,C2,6,5
Cohort,-0.0016047288472093078,0.027221981886297843,-0.058949743406340537,0.9530095589448733,LGP Offspring,Genes significantly (FDR < 10%) down-regulated in IMR-90 cells (fibroblast) in response to bystander irradiation.,CGP,C2,23,52
Cohort,0.02063910695207482,0.07733299241056259,0.26688618025410604,0.7896227734488559,LGP Proband,Genes significantly (FDR < 10%) down-regulated in IMR-90 cells (fibroblast) in response to bystander irradiation.,CGP,C2,23,76
Cohort,-0.02740216209469029,0.021679497203832877,-1.2639666795337698,0.20661199755587217,LonGen OPEL,Genes significantly (FDR < 10%) down-regulated in IMR-90 cells (fibroblast) in response to bystander irradiation.,CGP,C2,42,35
Cohort,-7.573276444561273e-4,0.04198744946301761,-0.018037000440409665,0.9856146582823864,LGP Offspring,Genes significantly (FDR < 10%) up-regulated in IMR-90 cells (fibroblast) in response to bystander irradiation.,CGP,C2,62,132
Cohort,-0.0089168934170489,0.1255194407390098,-0.07103993902896386,0.9433830000763743,LGP Proband,Genes significantly (FDR < 10%) up-regulated in IMR-90 cells (fibroblast) in response to bystander irradiation.,CGP,C2,62,180
Cohort,-0.030417336759701784,0.03760105567757748,-0.8089490098502862,0.4187861960048588,LonGen OPEL,Genes significantly (FDR < 10%) up-regulated in IMR-90 cells (fibroblast) in response to bystander irradiation.,CGP,C2,101,114
Cohort,0.019829836941344194,0.025486926388272754,0.7780395579777896,0.43681791440232454,LGP Offspring,Genes significantly (FDR < 10%) down-regulated in IMR-90 cells (fibroblast) in response to direct irradiation.,CGP,C2,16,41
Cohort,-0.004106657549324666,0.07397866487194923,-0.05551137691431632,0.9557443617487913,LGP Proband,Genes significantly (FDR < 10%) down-regulated in IMR-90 cells (fibroblast) in response to direct irradiation.,CGP,C2,16,60
Cohort,-7.179027402088486e-4,0.02208332495787577,-0.03250881565970059,0.9740744353306994,LonGen OPEL,Genes significantly (FDR < 10%) down-regulated in IMR-90 cells (fibroblast) in response to direct irradiation.,CGP,C2,31,39
Cohort,0.030841560827454727,0.05023565358260496,0.6139376842532849,0.5394630486130989,LGP Offspring,Genes significantly (FDR < 10%) up-regulated in IMR-90 cells (fibroblast) in response to direct irradiation.,CGP,C2,78,177
Cohort,-0.032776108721858946,0.1356096515016447,-0.24169451332497105,0.8090762946641837,LGP Proband,Genes significantly (FDR < 10%) up-regulated in IMR-90 cells (fibroblast) in response to direct irradiation.,CGP,C2,78,212
Cohort,-0.020194982510844898,0.04181803542612272,-0.48292518539093254,0.6292816470136848,LonGen OPEL,Genes significantly (FDR < 10%) up-regulated in IMR-90 cells (fibroblast) in response to direct irradiation.,CGP,C2,126,148
Cohort,0.0024092601603759025,0.018041484889614556,0.13354001486666847,0.8938060639789004,LGP Offspring,Genes down-regulated in HEP3B cells (liver cancer) overexpressing ATF5 [GeneID=22809] off a plasmid vector.,CGP,C2,10,22
Cohort,-0.027733351964237863,0.04801861976730839,-0.5775541258501361,0.5637210701027205,LGP Proband,Genes down-regulated in HEP3B cells (liver cancer) overexpressing ATF5 [GeneID=22809] off a plasmid vector.,CGP,C2,10,25
Cohort,0.0033957616646023664,0.016576469906586736,0.20485433169658426,0.8377383064586468,LonGen OPEL,Genes down-regulated in HEP3B cells (liver cancer) overexpressing ATF5 [GeneID=22809] off a plasmid vector.,CGP,C2,17,22
Cohort,-0.0011079978296959518,0.029361941873203217,-0.0377358498453793,0.9699094330832723,LGP Offspring,Genes up-regulated in HEP3B cells (liver cancer) overexpressing ATF5 [GeneID=22809] off a plasmid vector.,CGP,C2,30,62
Cohort,-0.024909810181851868,0.08639666299659673,-0.2883191238859896,0.7731741082176266,LGP Proband,Genes up-regulated in HEP3B cells (liver cancer) overexpressing ATF5 [GeneID=22809] off a plasmid vector.,CGP,C2,30,101
Cohort,0.015016020386577253,0.027773072554003388,0.540668316671817,0.5888874733820189,LonGen OPEL,Genes up-regulated in HEP3B cells (liver cancer) overexpressing ATF5 [GeneID=22809] off a plasmid vector.,CGP,C2,53,66
Cohort,-0.007354397981750926,0.02415847888667665,-0.3044230564452823,0.7608992938670995,LGP Offspring,Top genes down-regulated in metastatic (T24T) vs non-metastatic (T24) bladder cancer cell lines.,CGP,C2,20,36
Cohort,-0.09288356055356373,0.06745874418350031,-1.3768943029965572,0.16891440291448986,LGP Proband,Top genes down-regulated in metastatic (T24T) vs non-metastatic (T24) bladder cancer cell lines.,CGP,C2,20,56
Cohort,-0.03128806200211477,0.02173438441779827,-1.439565133323629,0.15038360372040396,LonGen OPEL,Top genes down-regulated in metastatic (T24T) vs non-metastatic (T24) bladder cancer cell lines.,CGP,C2,39,32
Cohort,0.002197649775072279,0.019474993966391397,0.11284469606844713,0.9101871837392825,LGP Offspring,Genes encoding the NF-kB core signaling proteins.,CGP,C2,9,23
Cohort,0.004368611094767392,0.046320838248790484,0.09431200427124102,0.9248839676033164,LGP Proband,Genes encoding the NF-kB core signaling proteins.,CGP,C2,9,21
Cohort,0.010020075455696746,0.0175374310387398,0.5713536625496984,0.5679212140754388,LonGen OPEL,Genes encoding the NF-kB core signaling proteins.,CGP,C2,17,23
Cohort,-0.10755453156691534,0.08793037383366198,-1.2231783725880252,0.2216885541081802,LGP Offspring,"Genes down-regulated in metastatic breast cancer tumors having  type 2 amplification in the 20q13 region; involves MYBL2, STK6 and ZNF217 [GeneID=4605;6790;7764]",CGP,C2,246,465
Cohort,-0.32343086395849746,0.25547598299039503,-1.2659932263404081,0.20586902157965295,LGP Proband,"Genes down-regulated in metastatic breast cancer tumors having  type 2 amplification in the 20q13 region; involves MYBL2, STK6 and ZNF217 [GeneID=4605;6790;7764]",CGP,C2,246,713
Cohort,0.0011471117118114517,0.07639229713979158,0.015016065163118897,0.9880231264170017,LonGen OPEL,"Genes down-regulated in metastatic breast cancer tumors having  type 2 amplification in the 20q13 region; involves MYBL2, STK6 and ZNF217 [GeneID=4605;6790;7764]",CGP,C2,369,448
Cohort,-0.06345587605894663,0.05587733668717484,-1.1356281423039127,0.2565146861795059,LGP Offspring,"Genes up-regulated in metastatic breast cancer tumors having  type 2 amplification in the 20q13 region; involves MYBL2, STK6 and ZNF217 [GeneID=4605;6790;7764]",CGP,C2,107,199
Cohort,-0.05884345325635043,0.14893280688404323,-0.3951006798801894,0.6928696164010016,LGP Proband,"Genes up-regulated in metastatic breast cancer tumors having  type 2 amplification in the 20q13 region; involves MYBL2, STK6 and ZNF217 [GeneID=4605;6790;7764]",CGP,C2,107,261
Cohort,-0.05239625794266201,0.048668359342101834,-1.0765979920209734,0.28198608073641546,LonGen OPEL,"Genes up-regulated in metastatic breast cancer tumors having  type 2 amplification in the 20q13 region; involves MYBL2, STK6 and ZNF217 [GeneID=4605;6790;7764]",CGP,C2,174,178
Cohort,-0.2539270629129056,0.10658968152168816,-2.3822855954517346,0.017481090025179398,LGP Offspring,Genes down-regulated in non-metastatic breast cancer tumors having type 1 amplification in the 20q13 region; involves ZNF217 [GeneID=7764] locus only.,CGP,C2,386,716
Cohort,0.0726529861274179,0.304415561230544,0.23866383779374337,0.8114248901058201,LGP Proband,Genes down-regulated in non-metastatic breast cancer tumors having type 1 amplification in the 20q13 region; involves ZNF217 [GeneID=7764] locus only.,CGP,C2,386,1060
Cohort,0.20872047248560463,0.09157062045733184,2.27933884736382,0.0229108196371018,LonGen OPEL,Genes down-regulated in non-metastatic breast cancer tumors having type 1 amplification in the 20q13 region; involves ZNF217 [GeneID=7764] locus only.,CGP,C2,543,756
Cohort,-0.020481069008192153,0.041399743860539476,-0.49471487256504165,0.6209621416107873,LGP Offspring,Genes up-regulated in non-metastatic breast cancer tumors having type 1 amplification in the 20q13 region; involves ZNF217 [GeneID=7764] locus only.,CGP,C2,58,117
Cohort,-0.20646976349500115,0.11667122787030429,-1.7696716428194275,0.0771472123934258,LGP Proband,Genes up-regulated in non-metastatic breast cancer tumors having type 1 amplification in the 20q13 region; involves ZNF217 [GeneID=7764] locus only.,CGP,C2,58,165
Cohort,-0.021041081748935504,0.03620232508862451,-0.5812080217893802,0.5612647923646894,LonGen OPEL,Genes up-regulated in non-metastatic breast cancer tumors having type 1 amplification in the 20q13 region; involves ZNF217 [GeneID=7764] locus only.,CGP,C2,99,102
Cohort,0.00973895992665539,0.013499821389755995,0.7214139835987429,0.47090427652301026,LGP Offspring,Genes whose over-expression is associated with the risk of death in multiple cancer types,CGP,C2,3,13
Cohort,0.0056169579383123745,0.03630445610757263,0.15471814043072116,0.8770809620582101,LGP Proband,Genes whose over-expression is associated with the risk of death in multiple cancer types,CGP,C2,3,19
Cohort,-0.015988334475968858,0.00997610221164021,-1.6026634588119515,0.10940568956246471,LonGen OPEL,Genes whose over-expression is associated with the risk of death in multiple cancer types,CGP,C2,9,6
Cohort,0.03258986625058772,0.023895801102358283,1.3638323365259102,0.17307428501544053,LGP Offspring,Top 50 most up-regulated genes in human platelet cells.,CGP,C2,15,41
Cohort,-0.10546798196796907,0.06719270498364308,-1.5696344118553265,0.11687948643595913,LGP Proband,Top 50 most up-regulated genes in human platelet cells.,CGP,C2,15,55
Cohort,0.008099245554373346,0.020399074773876247,0.39703984833398015,0.6914445062914842,LonGen OPEL,Top 50 most up-regulated genes in human platelet cells.,CGP,C2,20,28
Cohort,0.07017875444999708,0.047062760944419156,1.4911737654507302,0.13638234908018154,LGP Offspring,"Oligodendrocyte core differentiation genes: up-regulated in Oli-neo cells (oligodendroglial precursor) at 10 h after treatment with PD174265, dexamethasone or isotretinoin [PubChem=4709, 5743, 5282379].",CGP,C2,53,137
Cohort,-0.17113363188996134,0.12401696061290304,-1.3799211901678887,0.1679807189507602,LGP Proband,"Oligodendrocyte core differentiation genes: up-regulated in Oli-neo cells (oligodendroglial precursor) at 10 h after treatment with PD174265, dexamethasone or isotretinoin [PubChem=4709, 5743, 5282379].",CGP,C2,53,188
Cohort,0.0048305073375721165,0.03834163684374026,0.12598594466007407,0.89977486403698,LonGen OPEL,"Oligodendrocyte core differentiation genes: up-regulated in Oli-neo cells (oligodendroglial precursor) at 10 h after treatment with PD174265, dexamethasone or isotretinoin [PubChem=4709, 5743, 5282379].",CGP,C2,104,119
Cohort,-0.13025165939787955,0.2002521665928708,-0.6504382030617024,0.5156302015178751,LGP Offspring,Genes down-regulated during differentiation of Oli-Neu cells (oligodendroglial precursor) in response to PD174265 [PubChem=4709].,CGP,C2,1197,2454
Cohort,0.11674951794670131,0.5635851633989567,0.20715505930388628,0.8359393310136036,LGP Proband,Genes down-regulated during differentiation of Oli-Neu cells (oligodendroglial precursor) in response to PD174265 [PubChem=4709].,CGP,C2,1197,3416
Cohort,-0.05335913925060337,0.1653764914540117,-0.3226525050898278,0.7470431542526157,LonGen OPEL,Genes down-regulated during differentiation of Oli-Neu cells (oligodendroglial precursor) in response to PD174265 [PubChem=4709].,CGP,C2,1850,2194
Cohort,-0.02479280285150542,0.1304823713263835,-0.19000883107412017,0.849359251507513,LGP Offspring,Genes up-regulated during later stage of differentiation of Oli-Neu cells (oligodendroglial precursor) in response to PD174265 [PubChem=4709].,CGP,C2,538,1107
Cohort,-0.7153692926607488,0.3474529008762093,-2.0588957261738936,0.03981427489860233,LGP Proband,Genes up-regulated during later stage of differentiation of Oli-Neu cells (oligodendroglial precursor) in response to PD174265 [PubChem=4709].,CGP,C2,538,1519
Cohort,-0.1414809103159973,0.11421062630366081,-1.2387718629598512,0.21579516184018516,LonGen OPEL,Genes up-regulated during later stage of differentiation of Oli-Neu cells (oligodendroglial precursor) in response to PD174265 [PubChem=4709].,CGP,C2,902,1010
Cohort,-0.010839584945990032,0.004393464669571309,-2.4672065809619226,0.013863924166992744,LGP Offspring,Top scoring cis-regulated QTL (quantitative trait loci) influencing blood levels of high-density lipoprotein (HDL) cholesterol.,CGP,C2,2,0
Cohort,0.0012108497026152552,0.014698236255237742,0.08238061231215867,0.9343638196146189,LGP Proband,Top scoring cis-regulated QTL (quantitative trait loci) influencing blood levels of high-density lipoprotein (HDL) cholesterol.,CGP,C2,2,2
Cohort,0.0035444468262084724,0.008922625152749436,0.39724260131182126,0.6912950608882957,LonGen OPEL,Top scoring cis-regulated QTL (quantitative trait loci) influencing blood levels of high-density lipoprotein (HDL) cholesterol.,CGP,C2,3,7
Cohort,0.01471775210405399,0.02124942020558999,0.6926189967377206,0.4887865428733117,LGP Offspring,Top scoring trans-regulated expression quantitative trait loci (eQTL) influencing blood levels of high-density lipoprotein (HDL) cholesterol.,CGP,C2,14,34
Cohort,-0.018709447898788804,0.06374202941191956,-0.29351823390941795,0.7691990877858389,LGP Proband,Top scoring trans-regulated expression quantitative trait loci (eQTL) influencing blood levels of high-density lipoprotein (HDL) cholesterol.,CGP,C2,14,57
Cohort,-0.004587325917604253,0.018711497862414505,-0.24516080707887866,0.8063951111989851,LonGen OPEL,Top scoring trans-regulated expression quantitative trait loci (eQTL) influencing blood levels of high-density lipoprotein (HDL) cholesterol.,CGP,C2,27,24
Cohort,-0.1823026913407003,0.09331067940775906,-1.953717329010695,0.0511467110322856,LGP Offspring,Genes up-regulated at the peak of an antigen response of naive CD8+ [GeneID=925;926] T-cells.,CGP,C2,290,532
Cohort,-0.3930110854668729,0.25912723290627426,-1.516672258098878,0.1297283800227598,LGP Proband,Genes up-regulated at the peak of an antigen response of naive CD8+ [GeneID=925;926] T-cells.,CGP,C2,290,742
Cohort,0.013477516743618927,0.08236346936088396,0.16363464103929146,0.8700603095538152,LonGen OPEL,Genes up-regulated at the peak of an antigen response of naive CD8+ [GeneID=925;926] T-cells.,CGP,C2,448,539
Cohort,-0.0017286725218371647,0.05352217874027971,-0.032298246493769896,0.9742437411974808,LGP Offspring,Up-regulated in CD8+ [GeneID=925] T lymphocytes undergoing homeostatic proliferation (HP) versus the naive cells; these genes are not up-regulated versus effector or memory cell population.,CGP,C2,86,188
Cohort,0.2766022739039066,0.14760028749268037,1.8739954955550042,0.061280473956886274,LGP Proband,Up-regulated in CD8+ [GeneID=925] T lymphocytes undergoing homeostatic proliferation (HP) versus the naive cells; these genes are not up-regulated versus effector or memory cell population.,CGP,C2,86,266
Cohort,0.07389563093282613,0.04812157571853469,1.5356028939086506,0.125033168655755,LonGen OPEL,Up-regulated in CD8+ [GeneID=925] T lymphocytes undergoing homeostatic proliferation (HP) versus the naive cells; these genes are not up-regulated versus effector or memory cell population.,CGP,C2,157,202
Cohort,0.07497081218564812,0.04163396686173149,1.8007126833393026,0.07219378348759371,LGP Offspring,'Memory genes' expressed uniquely in CD8+ [GeneID=925] memory T lymphocytes (compared with effector or naive cells),CGP,C2,44,124
Cohort,7.447505883518302e-4,0.12004657371737956,0.006203847101085652,0.9950515615372753,LGP Proband,'Memory genes' expressed uniquely in CD8+ [GeneID=925] memory T lymphocytes (compared with effector or naive cells),CGP,C2,44,163
Cohort,-0.03335315348873247,0.03642712350069287,-0.9156131553483235,0.360147118695489,LonGen OPEL,'Memory genes' expressed uniquely in CD8+ [GeneID=925] memory T lymphocytes (compared with effector or naive cells),CGP,C2,94,99
Cohort,0.005218322907661389,0.016261511914903472,0.32090022963232967,0.7483851793156329,LGP Offspring,Down-regulated genes highly correlated with acute lymphoblastic leukemia (ALL) vs acute myeloid leukemia (AML).,CGP,C2,8,19
Cohort,-0.005055598151645256,0.05421352469708565,-0.0932534488375929,0.9257246100781867,LGP Proband,Down-regulated genes highly correlated with acute lymphoblastic leukemia (ALL) vs acute myeloid leukemia (AML).,CGP,C2,8,40
Cohort,5.000907479528938e-4,0.015063729056234383,0.03319833661943904,0.9735247470824543,LonGen OPEL,Down-regulated genes highly correlated with acute lymphoblastic leukemia (ALL) vs acute myeloid leukemia (AML).,CGP,C2,15,20
Cohort,0.004279998968259124,0.026788371904286793,0.15977077604982107,0.873109371396595,LGP Offspring,Up-regulated genes highly correlated with acute lymphoblastic leukemia (ALL) vs acute myeloid leukemia (AML).,CGP,C2,24,47
Cohort,-0.13262628199854262,0.07738329893032089,-1.7138876712656665,0.08692093126836793,LGP Proband,Up-regulated genes highly correlated with acute lymphoblastic leukemia (ALL) vs acute myeloid leukemia (AML).,CGP,C2,24,79
Cohort,0.01873164959562218,0.025139566781531668,0.745106300295638,0.4564273994593717,LonGen OPEL,Up-regulated genes highly correlated with acute lymphoblastic leukemia (ALL) vs acute myeloid leukemia (AML).,CGP,C2,43,59
Cohort,0.017141689706806677,0.040263437619807683,0.42573835519632297,0.670434018958028,LGP Offspring,Genes down-regulated in BJAB cell line (B lymphocyte) after expression of the viral microRNA miR-K12-11 which functions as an ortholog of cellular MIR155 [GeneID=406947].,CGP,C2,47,101
Cohort,0.022893777820044738,0.10475315461423525,0.21854976973584744,0.8270542520689342,LGP Proband,Genes down-regulated in BJAB cell line (B lymphocyte) after expression of the viral microRNA miR-K12-11 which functions as an ortholog of cellular MIR155 [GeneID=406947].,CGP,C2,47,135
Cohort,0.01684161341512728,0.038264798892142175,0.44013333148827216,0.6599600255177923,LonGen OPEL,Genes down-regulated in BJAB cell line (B lymphocyte) after expression of the viral microRNA miR-K12-11 which functions as an ortholog of cellular MIR155 [GeneID=406947].,CGP,C2,91,119
Cohort,-0.0058318518008493,0.07350771658786678,-0.0793365931028241,0.936788380188629,LGP Offspring,"Genes down-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic phenotype) during epithelial to mesenchymal transition (EMT).",CGP,C2,172,364
Cohort,0.18836951845411204,0.20559606636846203,0.916211685278661,0.35982072248390995,LGP Proband,"Genes down-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic phenotype) during epithelial to mesenchymal transition (EMT).",CGP,C2,172,515
Cohort,-0.10718452323998509,0.06695129888290112,-1.600932693291769,0.10978859550707605,LonGen OPEL,"Genes down-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic phenotype) during epithelial to mesenchymal transition (EMT).",CGP,C2,328,346
Cohort,0.009278794662640056,0.05398852634132264,0.1718660480558088,0.8635942753765243,LGP Offspring,"Genes up-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic phenotype) during epithelial to mesenchymal transition (EMT).",CGP,C2,83,172
Cohort,-0.1633117911942162,0.15550723106666056,-1.050187763450113,0.29393600451284235,LGP Proband,"Genes up-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic phenotype) during epithelial to mesenchymal transition (EMT).",CGP,C2,83,287
Cohort,-0.03795645526557224,0.04510215434837759,-0.8415663467511858,0.40028348363800736,LonGen OPEL,"Genes up-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic phenotype) during epithelial to mesenchymal transition (EMT).",CGP,C2,145,157
Cohort,0.024776233441449743,0.02557270418408222,0.9688546531137586,0.3329642182030409,LGP Offspring,Genes down-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs those expressing functionally inactive TATI [GeneID=6690].,CGP,C2,16,43
Cohort,-0.0020247917746878626,0.0640581447208011,-0.03160865466074555,0.9747917040256453,LGP Proband,Genes down-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs those expressing functionally inactive TATI [GeneID=6690].,CGP,C2,16,54
Cohort,-0.03425170996146738,0.0174953513333169,-1.9577606250319115,0.05060712392248035,LonGen OPEL,Genes down-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs those expressing functionally inactive TATI [GeneID=6690].,CGP,C2,29,19
Cohort,-0.005415357334189635,0.012175481863144549,-0.44477560683508066,0.6566242933173101,LGP Offspring,Genes up-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs those expressing functionally inactive TATI [GeneID=6690].,CGP,C2,6,9
Cohort,-0.03793163502328147,0.04396724897583263,-0.8627247759833976,0.38853681620433733,LGP Proband,Genes up-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs those expressing functionally inactive TATI [GeneID=6690].,CGP,C2,6,24
Cohort,0.004433634137629144,0.013057071374382681,0.3395580839304985,0.7342789182078027,LonGen OPEL,Genes up-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs those expressing functionally inactive TATI [GeneID=6690].,CGP,C2,10,16
Cohort,-0.01018263901146711,0.01540824411600719,-0.6608565476249597,0.5089294604844765,LGP Offspring,Genes up-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs the parental non-invasive cells.,CGP,C2,10,14
Cohort,-0.047873534299639094,0.03566138870988404,-1.3424472807019512,0.1798163022661064,LGP Proband,Genes up-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs the parental non-invasive cells.,CGP,C2,10,11
Cohort,0.0030514127813283,0.01148934932104185,0.2655862134629221,0.7906266722473734,LonGen OPEL,Genes up-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs the parental non-invasive cells.,CGP,C2,9,11
Cohort,-0.26429163683285,0.1548337105534167,-1.706938598114078,0.08829268876507992,LGP Offspring,Genes down-regulated in TMX2-28 cells (breast cancer) which do not express ESR1 [GeneID=2099]) compared to the parental MCF7 cells which do.,CGP,C2,816,1589
Cohort,-0.038240472908880406,0.4242084799978336,-0.0901454702392458,0.9281932605131417,LGP Proband,Genes down-regulated in TMX2-28 cells (breast cancer) which do not express ESR1 [GeneID=2099]) compared to the parental MCF7 cells which do.,CGP,C2,816,2168
Cohort,-1.604624131091143e-4,0.13874400094304468,-0.001156535864746939,0.9990775078683314,LonGen OPEL,Genes down-regulated in TMX2-28 cells (breast cancer) which do not express ESR1 [GeneID=2099]) compared to the parental MCF7 cells which do.,CGP,C2,1265,1515
Cohort,-0.10747276859260671,0.07118354334683312,-1.509797960870798,0.13156223520148155,LGP Offspring,Genes up-regulated in TMX2-28 cells (breast cancer) which do not express ESR1 [GeneID=2099]) compared to the parental MCF7 cells which do.,CGP,C2,178,329
Cohort,0.07224446092918094,0.19997242691096515,0.3612721115863976,0.7179875376510885,LGP Proband,Genes up-regulated in TMX2-28 cells (breast cancer) which do not express ESR1 [GeneID=2099]) compared to the parental MCF7 cells which do.,CGP,C2,178,479
Cohort,-0.03328649679707352,0.06264880792687716,-0.5313189172877011,0.5953460244398878,LonGen OPEL,Genes up-regulated in TMX2-28 cells (breast cancer) which do not express ESR1 [GeneID=2099]) compared to the parental MCF7 cells which do.,CGP,C2,279,318
Cohort,-0.05822797093627007,0.03198156570931711,-1.8206729296967055,0.06909856571718469,LGP Offspring,Genes down-regulated in Jurkat cells (transformed T lymphocytes) after knockdown of BCL11B [GeneID=64919] by RNAi.,CGP,C2,42,61
Cohort,-0.14447717682832062,0.087580470659746,-1.6496506097760177,0.09939097058229578,LGP Proband,Genes down-regulated in Jurkat cells (transformed T lymphocytes) after knockdown of BCL11B [GeneID=64919] by RNAi.,CGP,C2,42,93
Cohort,0.020612023402353234,0.02865095203135398,0.7194184465422512,0.4720942898829401,LonGen OPEL,Genes down-regulated in Jurkat cells (transformed T lymphocytes) after knockdown of BCL11B [GeneID=64919] by RNAi.,CGP,C2,53,73
Cohort,-0.03432479326256579,0.03178944276495522,-1.0797544806417791,0.2806366117811839,LGP Offspring,Genes up-regulated in Jurkat cells (transformed T lymphocytes) after knockdown of BCL11B [GeneID=64919] by RNAi.,CGP,C2,39,61
Cohort,-0.17293975130862824,0.09740295536565872,-1.7755082549538477,0.0761786121687212,LGP Proband,Genes up-regulated in Jurkat cells (transformed T lymphocytes) after knockdown of BCL11B [GeneID=64919] by RNAi.,CGP,C2,39,123
Cohort,-0.04296340563321624,0.030404536926845433,-1.4130590357810073,0.1580292623443008,LonGen OPEL,Genes up-regulated in Jurkat cells (transformed T lymphocytes) after knockdown of BCL11B [GeneID=64919] by RNAi.,CGP,C2,72,66
Cohort,-0.0202731328936718,0.05864957265264802,-0.345665483595923,0.7297016679053518,LGP Offspring,Down-regulated genes in both rectal and colon carcinoma compared to normal mucosa samples.,CGP,C2,120,242
Cohort,-0.08565085628374182,0.16542734048667987,-0.5177551427216373,0.6047664251237221,LGP Proband,Down-regulated genes in both rectal and colon carcinoma compared to normal mucosa samples.,CGP,C2,120,307
Cohort,-0.011207508487740662,0.055213160726134136,-0.20298617830143156,0.8391977096507315,LonGen OPEL,Down-regulated genes in both rectal and colon carcinoma compared to normal mucosa samples.,CGP,C2,197,233
Cohort,0.021410266994856403,0.08434108828589418,0.253853340406057,0.7996860529990867,LGP Offspring,Up-regulated genes in both rectal and colon carcinoma compared to normal mucosa samples.,CGP,C2,220,456
Cohort,-0.16555746657741868,0.2334981598174196,-0.7090311405746147,0.47850330230421423,LGP Proband,Up-regulated genes in both rectal and colon carcinoma compared to normal mucosa samples.,CGP,C2,220,619
Cohort,0.03245662995803091,0.0709757840234299,0.4572916017006113,0.6475862432643352,LonGen OPEL,Up-regulated genes in both rectal and colon carcinoma compared to normal mucosa samples.,CGP,C2,347,423
Cohort,-0.062488348710133694,0.04036200555183224,-1.5481973171498418,0.12204280291401803,LGP Offspring,Genes down-regulated in rectal but up-regulated in colon carcinoma compared to normal mucosa samples.,CGP,C2,59,99
Cohort,-0.03257180182650368,0.1172743355247161,-0.2777402377150031,0.7812806044068996,LGP Proband,Genes down-regulated in rectal but up-regulated in colon carcinoma compared to normal mucosa samples.,CGP,C2,59,176
Cohort,0.03556512321403833,0.040708339198131945,0.8736569438743002,0.3825685937972487,LonGen OPEL,Genes down-regulated in rectal but up-regulated in colon carcinoma compared to normal mucosa samples.,CGP,C2,103,134
Cohort,-0.017758934600841454,0.028148398717170987,-0.6309039025373835,0.5283166004620528,LGP Offspring,Genes up-regulated in rectal but down-regulated in colon carcinoma compared to normal mucosa samples.,CGP,C2,28,47
Cohort,-0.10216072101435741,0.07366785290004216,-1.3867747870020921,0.16588098939258264,LGP Proband,Genes up-regulated in rectal but down-regulated in colon carcinoma compared to normal mucosa samples.,CGP,C2,28,55
Cohort,-0.05672014797651641,0.02437282414585582,-2.3271881681450814,0.020205214215838933,LonGen OPEL,Genes up-regulated in rectal but down-regulated in colon carcinoma compared to normal mucosa samples.,CGP,C2,54,37
Cohort,-0.7948124267599115,0.23316727350826522,-3.408764938582761,6.913206650277003e-4,LGP Offspring,Genes down-regulated in ME-A cells (breast cancer) undergoing apoptosis in response to doxorubicin [PubChem=31703].,CGP,C2,1829,3472
Cohort,-1.0716447052093743,0.6573152542307781,-1.6303359739665018,0.10340808225364943,LGP Proband,Genes down-regulated in ME-A cells (breast cancer) undergoing apoptosis in response to doxorubicin [PubChem=31703].,CGP,C2,1829,4900
Cohort,0.06975743820972204,0.20816989457655335,0.3350985902722313,0.7376390038547576,LonGen OPEL,Genes down-regulated in ME-A cells (breast cancer) undergoing apoptosis in response to doxorubicin [PubChem=31703].,CGP,C2,2808,3378
Cohort,-0.21096976456886868,0.18505330980281331,-1.1400485881266922,0.25466982512239295,LGP Offspring,Genes up-regulated in ME-A cells (breast cancer) undergoing apoptosis in response to doxorubicin [PubChem=31703].,CGP,C2,1033,2076
Cohort,-0.5422346985178754,0.5017407915895256,-1.0807068263277226,0.28013995076067433,LGP Proband,Genes up-regulated in ME-A cells (breast cancer) undergoing apoptosis in response to doxorubicin [PubChem=31703].,CGP,C2,1033,2827
Cohort,0.11300557121144927,0.16622455428992058,0.6798368128835562,0.4968054503882624,LonGen OPEL,Genes up-regulated in ME-A cells (breast cancer) undergoing apoptosis in response to doxorubicin [PubChem=31703].,CGP,C2,1629,2033
Cohort,-0.18240688295707005,0.09032590788415179,-2.0194303852557725,0.04383664484741834,LGP Offspring,Genes down-regulated in ME-A cells (breast cancer) undergoing apoptosis upon serum starvation (5% to 0% FCS) for 22 hr.,CGP,C2,279,493
Cohort,0.12024454823167266,0.24922838722921764,0.4824673046617384,0.6296006209447778,LGP Proband,Genes down-regulated in ME-A cells (breast cancer) undergoing apoptosis upon serum starvation (5% to 0% FCS) for 22 hr.,CGP,C2,279,766
Cohort,-0.1241805151693994,0.07936401992762467,-1.564695378115231,0.11805179659304163,LonGen OPEL,Genes down-regulated in ME-A cells (breast cancer) undergoing apoptosis upon serum starvation (5% to 0% FCS) for 22 hr.,CGP,C2,485,516
Cohort,-0.16232435977770351,0.12516853936203143,-1.296846321008863,0.19512653559441342,LGP Offspring,Genes up-regulated in ME-A cells (breast cancer) undergoing apoptosis upon serum starvation (5% to 0% FCS) for 22 hr.,CGP,C2,523,1034
Cohort,0.01427970257466557,0.3361083740303343,0.04248541148628688,0.9661219102345537,LGP Proband,Genes up-regulated in ME-A cells (breast cancer) undergoing apoptosis upon serum starvation (5% to 0% FCS) for 22 hr.,CGP,C2,523,1428
Cohort,0.06959435816045682,0.10638374036466264,0.6541822831374512,0.5131833268717385,LonGen OPEL,Genes up-regulated in ME-A cells (breast cancer) undergoing apoptosis upon serum starvation (5% to 0% FCS) for 22 hr.,CGP,C2,810,1001
Cohort,-0.0680306876582137,0.14790552763658846,-0.459960413551065,0.6456925335546736,LGP Offspring,"Genes down-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) exposed to doxorubicin [PubChem=31703] in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,684,1394
Cohort,-0.5401023183310171,0.4145429857756938,-1.3028861586461928,0.19297324452771283,LGP Proband,"Genes down-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) exposed to doxorubicin [PubChem=31703] in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,684,1921
Cohort,-0.1787657827123693,0.12815261773326872,-1.3949444488480494,0.16342169522258745,LonGen OPEL,"Genes down-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) exposed to doxorubicin [PubChem=31703] in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,1141,1274
Cohort,-0.1709016626648887,0.1316714129015233,-1.2979405240582147,0.19475045321849424,LGP Offspring,"Genes up-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) exposed to doxorubicin [PubChem=31703] in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,585,1155
Cohort,-0.42165312551488054,0.3590233493709059,-1.1744448550594742,0.2405521185887999,LGP Proband,"Genes up-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) exposed to doxorubicin [PubChem=31703] in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,585,1557
Cohort,0.04290967880829839,0.12059452462487402,0.3558178030202855,0.7220712911756901,LonGen OPEL,"Genes up-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) exposed to doxorubicin [PubChem=31703] in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,915,1142
Cohort,-0.09564525994572744,0.04950719299776128,-1.9319467365086225,0.053783655088809994,LGP Offspring,"Genes down-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) upon serum deprivation for 22 hr in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,89,141
Cohort,-0.03054294874767985,0.14063544141086515,-0.21717817671897446,0.8281226086129121,LGP Proband,"Genes down-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) upon serum deprivation for 22 hr in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,89,253
Cohort,-0.07305131998758052,0.04265685637386873,-1.7125340730061678,0.0871877380551344,LonGen OPEL,"Genes down-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) upon serum deprivation for 22 hr in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,137,136
Cohort,-0.009637947555029797,0.08218889620410852,-0.11726581083525987,0.906684248305927,LGP Offspring,"Genes up-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) upon serum deprivation for 22 hr in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,219,458
Cohort,0.26005645263714616,0.221575118751724,1.1736717285867313,0.24086159699762766,LGP Proband,"Genes up-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) upon serum deprivation for 22 hr in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,219,595
Cohort,0.09734850338650118,0.07066869169940433,1.3775336863540908,0.1687344884037801,LonGen OPEL,"Genes up-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) upon serum deprivation for 22 hr in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).",CGP,C2,327,429
Cohort,0.0026369946773125807,0.0071944630234888444,0.366531132164164,0.7140834767814903,LGP Offspring,Genes down-regulated in dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,1,4
Cohort,-0.04671738857962509,0.025872891422650007,-1.8056500843476313,0.07133348158340932,LGP Proband,Genes down-regulated in dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,1,10
Cohort,0.0013918197631643061,0.00852915481897986,0.16318378464265892,0.8704151526156685,LonGen OPEL,Genes down-regulated in dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,5,6
Cohort,-5.350809669472845e-4,0.007854087638772655,-0.06812770515900439,0.9457041216325621,LGP Offspring,Genes up-regulated in dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,2,4
Cohort,0.0013721265287038496,0.019359352758772756,0.07087667370914896,0.9435129000786117,LGP Proband,Genes up-regulated in dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,2,4
Cohort,0.007065507999181288,0.005778508365164353,1.2227217739746803,0.221796693973734,LonGen OPEL,Genes up-regulated in dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,1,4
Cohort,-0.06679197229144734,0.038883464467374645,-1.7177474591413906,0.08630064440996724,LGP Offspring,Genes down-regulated in quiescent CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors compared to the dividing cells from CML (chronic myeloid leukemia) patients.,CGP,C2,66,96
Cohort,-0.09943132970903884,0.11673901340172688,-0.8517403634967502,0.39460271278009684,LGP Proband,Genes down-regulated in quiescent CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors compared to the dividing cells from CML (chronic myeloid leukemia) patients.,CGP,C2,66,160
Cohort,-0.01395799132230121,0.03860608518736347,-0.36154899556793013,0.7177850313476555,LonGen OPEL,Genes down-regulated in quiescent CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors compared to the dividing cells from CML (chronic myeloid leukemia) patients.,CGP,C2,106,126
Cohort,-0.064640754557183,0.07240138423238704,-0.8928110317574218,0.37227608667999723,LGP Offspring,Genes up-regulated in quiescent CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors compared to the dividing cells from CML (chronic myeloid leukemia) patients.,CGP,C2,178,347
Cohort,-0.18575073698357267,0.19724068950838844,-0.9417465404655914,0.3465951204824209,LGP Proband,Genes up-regulated in quiescent CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors compared to the dividing cells from CML (chronic myeloid leukemia) patients.,CGP,C2,178,452
Cohort,0.07791359290091866,0.06398714241305392,1.2176445136112788,0.22371992088902753,LonGen OPEL,Genes up-regulated in quiescent CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors compared to the dividing cells from CML (chronic myeloid leukemia) patients.,CGP,C2,261,345
Cohort,0.0061841462906225934,0.022103551878042933,0.2797806580925917,0.7797313770809781,LGP Offspring,Genes down-regulated in quiescent (G0) vs dividing (M) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients.,CGP,C2,15,34
Cohort,0.11527473244073902,0.06669266561371075,1.7284469196121128,0.08427824548711707,LGP Proband,Genes down-regulated in quiescent (G0) vs dividing (M) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients.,CGP,C2,15,58
Cohort,0.0021693911500181946,0.019918909004303615,0.10891114315294492,0.9133004165912011,LonGen OPEL,Genes down-regulated in quiescent (G0) vs dividing (M) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients.,CGP,C2,29,32
Cohort,0.02333577762872827,0.01971988426280309,1.1833628087131176,0.23708136890228398,LGP Offspring,Genes up-regulated in quiescent (G0) vs dividing (M) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients.,CGP,C2,11,29
Cohort,-0.026107922418233325,0.05915911451424707,-0.4413169911788631,0.6590979141525859,LGP Proband,Genes up-regulated in quiescent (G0) vs dividing (M) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients.,CGP,C2,11,47
Cohort,0.012297346950597438,0.019553122512846657,0.6289198537224896,0.5295819614651178,LonGen OPEL,Genes up-regulated in quiescent (G0) vs dividing (M) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients.,CGP,C2,22,30
Cohort,0.03795026412702596,0.017399058955547567,2.181167626593149,0.029514908368160925,LGP Offspring,Genes down-regulated in quescent CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloblastic leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,5,26
Cohort,0.0361985054134638,0.05468073792511173,0.6619973831194385,0.5081557695414576,LGP Proband,Genes down-regulated in quescent CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloblastic leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,5,43
Cohort,0.004851105442795031,0.014412842340536039,0.33658214862666774,0.7365206288230493,LonGen OPEL,Genes down-regulated in quescent CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloblastic leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,15,17
Cohort,0.025113187933221936,0.023997377693224683,1.0464971737437914,0.2957055842664363,LGP Offspring,Genes up-regulated in quescent CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloblastic leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,17,42
Cohort,-0.023694230507957492,0.07567306123855606,-0.3131131491200343,0.754272983668504,LGP Proband,Genes up-regulated in quescent CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloblastic leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,17,76
Cohort,0.008399269045676215,0.022553583765587994,0.3724139424126345,0.7096838050210907,LonGen OPEL,Genes up-regulated in quescent CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloblastic leukemia) patients compared to the dividing cells from normal donors.,CGP,C2,32,43
Cohort,-0.05160264951970203,0.02524096581576131,-2.0444007529806805,0.04130086069748766,LGP Offspring,Genes down-regulated in quiescent (G0) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the quiescent cells from normal donors.,CGP,C2,27,34
Cohort,-0.008560352027031592,0.07636923893299338,-0.11209162414912205,0.9107777306965694,LGP Proband,Genes down-regulated in quiescent (G0) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the quiescent cells from normal donors.,CGP,C2,27,62
Cohort,0.02013814548631116,0.02398217625717247,0.8397130131294211,0.40132144237457057,LonGen OPEL,Genes down-regulated in quiescent (G0) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the quiescent cells from normal donors.,CGP,C2,37,51
Cohort,-0.06383403422966731,0.051683996887173164,-1.2350831606351544,0.21722864689653396,LGP Offspring,Genes up-regulated in quiescent (G0) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the quiescent cells from normal donors.,CGP,C2,90,159
Cohort,0.006007451628971672,0.1347268445153933,0.04458986366510861,0.9644448959675875,LGP Proband,Genes up-regulated in quiescent (G0) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the quiescent cells from normal donors.,CGP,C2,90,212
Cohort,-0.00828596061809444,0.04467541342145427,-0.18547026168347244,0.852907452016845,LonGen OPEL,Genes up-regulated in quiescent (G0) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the quiescent cells from normal donors.,CGP,C2,139,161
Cohort,-0.06049165867684336,0.05017067206351692,-1.2057175275678966,0.22834827468587604,LGP Offspring,Genes down-regulated in quiescent vs dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors.,CGP,C2,90,153
Cohort,-0.2145062660928059,0.1302154504498637,-1.647318082084248,0.0998693714842188,LGP Proband,Genes down-regulated in quiescent vs dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors.,CGP,C2,90,189
Cohort,0.027699702240152776,0.04326292963816746,0.6402641354115677,0.5221851449719579,LonGen OPEL,Genes down-regulated in quiescent vs dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors.,CGP,C2,114,151
Cohort,-0.04392854276473515,0.032499066492614206,-1.3516862945807513,0.17692779755195748,LGP Offspring,Genes up-regulated in quiescent vs dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors.,CGP,C2,40,64
Cohort,-0.08347667964107107,0.08940958080253752,-0.9336435636067978,0.35075800733735685,LGP Proband,Genes up-regulated in quiescent vs dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors.,CGP,C2,40,100
Cohort,0.047219403738349604,0.0286216890076361,1.6497769829639244,0.09938307763257219,LonGen OPEL,Genes up-regulated in quiescent vs dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors.,CGP,C2,49,84
Cohort,0.006566992955283007,0.007145637064039717,0.919021340774677,0.35841220884273306,LGP Offspring,"Genes up-regulated in Jurkat cells (T lymphocyte) by IFN1@, and IFNB1 [GeneID=3438;3456] but not by overexpression of a constitutively active form of IRF3 [GeneID=3661].",CGP,C2,1,4
Cohort,-0.028823019603010185,0.017648794725783314,-1.6331437954175039,0.10281619691081019,LGP Proband,"Genes up-regulated in Jurkat cells (T lymphocyte) by IFN1@, and IFNB1 [GeneID=3438;3456] but not by overexpression of a constitutively active form of IRF3 [GeneID=3661].",CGP,C2,1,4
Cohort,-0.003032896250564379,0.009320788125877437,-0.32539053668048795,0.7449710262360845,LonGen OPEL,"Genes up-regulated in Jurkat cells (T lymphocyte) by IFN1@, and IFNB1 [GeneID=3438;3456] but not by overexpression of a constitutively active form of IRF3 [GeneID=3661].",CGP,C2,6,5
Cohort,8.211057789251644e-4,0.022172455602155524,0.03703269469374153,0.9704698699206078,LGP Offspring,Genes down-regulated in Jurkat cells (T lymphocyte) by expression of a constitutively active form of IRF3 [GeneID=3661].,CGP,C2,16,33
Cohort,0.0364614527745278,0.06419278856909469,0.567999203450744,0.5701883903602256,LGP Proband,Genes down-regulated in Jurkat cells (T lymphocyte) by expression of a constitutively active form of IRF3 [GeneID=3661].,CGP,C2,16,49
Cohort,0.0043225154476912876,0.021956205627322797,0.19686987456121524,0.8439796233225104,LonGen OPEL,Genes down-regulated in Jurkat cells (T lymphocyte) by expression of a constitutively active form of IRF3 [GeneID=3661].,CGP,C2,29,38
Cohort,0.008173833551370184,0.01761886369486511,0.4639251255319257,0.6428507411300339,LGP Offspring,Genes up-regulated in Jurkat cells (T lymphocyte) by expression of a constitutively active form of IRF3 [GeneID=3661].,CGP,C2,8,21
Cohort,0.00550414621773476,0.04590981944929222,0.11989039128794952,0.9045988503715787,LGP Proband,Genes up-regulated in Jurkat cells (T lymphocyte) by expression of a constitutively active form of IRF3 [GeneID=3661].,CGP,C2,8,25
Cohort,-0.014438963312029018,0.013959781510161036,-1.0343258812123381,0.3012979712102473,LonGen OPEL,Genes up-regulated in Jurkat cells (T lymphocyte) by expression of a constitutively active form of IRF3 [GeneID=3661].,CGP,C2,17,13
Cohort,-0.011189384771079735,0.023002188335207736,-0.48644870688033526,0.6268067267429909,LGP Offspring,Genes changed in retinoblastoma tumors with respect to chromosome 6p amplifications.,CGP,C2,20,33
Cohort,-0.07182207785653916,0.05567001182149219,-1.2901394396473118,0.19735984176475158,LGP Proband,Genes changed in retinoblastoma tumors with respect to chromosome 6p amplifications.,CGP,C2,20,34
Cohort,0.0058899995245558015,0.020431017288044227,0.2882871391823694,0.7732019999013563,LonGen OPEL,Genes changed in retinoblastoma tumors with respect to chromosome 6p amplifications.,CGP,C2,26,35
Cohort,0.00477940695994862,0.022139650825442718,0.21587544436139713,0.8291499585300833,LGP Offspring,Genes from 16q24 region up-regulated in retinoblastoma tumors with 16q24 LOH (loss of heterozygocity) compared to those without the LOH.,CGP,C2,14,35
Cohort,0.022473760601981443,0.0601314300341838,0.3737439902760578,0.7086897814570046,LGP Proband,Genes from 16q24 region up-regulated in retinoblastoma tumors with 16q24 LOH (loss of heterozygocity) compared to those without the LOH.,CGP,C2,14,46
Cohort,0.025045226437791144,0.021429941958355053,1.168702485823886,0.24287340125963575,LonGen OPEL,Genes from 16q24 region up-regulated in retinoblastoma tumors with 16q24 LOH (loss of heterozygocity) compared to those without the LOH.,CGP,C2,29,44
Cohort,0.024748685748276742,0.029997818772253278,0.8250161765484175,0.40965343377298824,LGP Offspring,Genes down-regulated in pre-B lymphocytes upon Cre-Lox knockout of E2A [GeneID=6929].,CGP,C2,24,69
Cohort,0.06546526634796938,0.07736871775801538,0.8461464561520047,0.3977137550966816,LGP Proband,Genes down-regulated in pre-B lymphocytes upon Cre-Lox knockout of E2A [GeneID=6929].,CGP,C2,24,73
Cohort,-0.031171285080659958,0.025325463217640048,-1.2308278357154825,0.21875082598119538,LonGen OPEL,Genes down-regulated in pre-B lymphocytes upon Cre-Lox knockout of E2A [GeneID=6929].,CGP,C2,55,53
Cohort,-0.061352593672335434,0.0286699956561263,-2.139958247926187,0.03271547156325047,LGP Offspring,Genes up-regulated in pre-B lymphocytes upon Cre-Lox knockout of E2A [GeneID=6929].,CGP,C2,36,43
Cohort,-0.0017023137951247146,0.08783549025926847,-0.019380705795572023,0.9845420375989392,LGP Proband,Genes up-regulated in pre-B lymphocytes upon Cre-Lox knockout of E2A [GeneID=6929].,CGP,C2,36,85
Cohort,-0.024400444347677998,0.02646484244850711,-0.9219946952321432,0.35681070296763673,LonGen OPEL,Genes up-regulated in pre-B lymphocytes upon Cre-Lox knockout of E2A [GeneID=6929].,CGP,C2,50,52
Cohort,-0.05289258669890003,0.0704514649735631,-0.7507663143519865,0.45305455419559715,LGP Offspring,"Genes identified as synthetic lethal with imatinib [PubChem=5291] in RNAi screen in K562 cells (CML, chronic myelogenous leukemia).",CGP,C2,159,299
Cohort,-0.31198809486440454,0.19224383195039169,-1.6228770083240576,0.10499360700925771,LGP Proband,"Genes identified as synthetic lethal with imatinib [PubChem=5291] in RNAi screen in K562 cells (CML, chronic myelogenous leukemia).",CGP,C2,159,438
Cohort,-0.012844045131935601,0.05979885304718938,-0.21478748299402853,0.8299880264650501,LonGen OPEL,"Genes identified as synthetic lethal with imatinib [PubChem=5291] in RNAi screen in K562 cells (CML, chronic myelogenous leukemia).",CGP,C2,242,288
Cohort,-0.20496247827805458,0.10558721094025782,-1.9411676513931615,0.052653209504556604,LGP Offspring,Genes from common genomic gains observed in a meta analyis of copy number alterations across a panel of different cancer cell lines and tumor samples.,CGP,C2,388,724
Cohort,0.17180504894117574,0.29942461834025275,0.5737839790646211,0.5662686892916318,LGP Proband,Genes from common genomic gains observed in a meta analyis of copy number alterations across a panel of different cancer cell lines and tumor samples.,CGP,C2,388,1049
Cohort,0.020273234181127184,0.09250744906895035,0.21915245080443788,0.8265874744429618,LonGen OPEL,Genes from common genomic gains observed in a meta analyis of copy number alterations across a panel of different cancer cell lines and tumor samples.,CGP,C2,587,702
Cohort,0.01430962281505681,0.02856708507377604,0.5009129485245497,0.6165954457211182,LGP Offspring,Genes down-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,22,55
Cohort,0.037385149073023725,0.0774200106582165,0.4828874183196212,0.6293024037493022,LGP Proband,Genes down-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,22,69
Cohort,0.04029416254499787,0.022420609771965774,1.7971929824754713,0.07268393215867681,LonGen OPEL,Genes down-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,27,46
Cohort,0.013174312479090356,0.02129496568604281,0.6186585446214216,0.5363497272815707,LGP Offspring,Genes up-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,11,31
Cohort,-0.005701008934068393,0.042712127665572405,-0.13347518013399326,0.8938497914978831,LGP Proband,Genes up-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,11,20
Cohort,0.006926804301664792,0.015149451460095638,0.45723136048261004,0.6476295188985732,LonGen OPEL,Genes up-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,15,22
Cohort,0.007301409541813786,0.021359024762415222,0.3418418969512989,0.7325761187677787,LGP Offspring,Genes down-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,12,33
Cohort,0.06822628625510123,0.05689958115308113,1.1990648238964543,0.23084330712699633,LGP Proband,Genes down-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,12,42
Cohort,0.008238572952819604,0.018140453817268212,0.45415473261077755,0.6498412675752077,LonGen OPEL,Genes down-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,21,29
Cohort,0.002220749009443173,0.019945811128452135,0.1113391175290604,0.9113804859545855,LGP Offspring,Genes up-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,12,27
Cohort,-0.03777696094679586,0.04909148096365851,-0.7695217215948614,0.44180154081627565,LGP Proband,Genes up-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,12,29
Cohort,0.02489875156694503,0.016487197733859708,1.5101869928939191,0.13139255527314664,LonGen OPEL,Genes up-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,15,25
Cohort,-0.11446289786144222,0.047959347241781164,-2.3866650495552317,0.017276017935389097,LGP Offspring,Genes down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] and HIF1A [GeneID=3091] by RNAi.,CGP,C2,93,144
Cohort,-0.14455562091491903,0.1437669216361335,-1.0054859578949717,0.3149545399411859,LGP Proband,Genes down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] and HIF1A [GeneID=3091] by RNAi.,CGP,C2,93,238
Cohort,-0.022824655007347344,0.042767076924943706,-0.5336968679763794,0.5937002709903911,LonGen OPEL,Genes down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] and HIF1A [GeneID=3091] by RNAi.,CGP,C2,140,150
Cohort,-0.060293750168445084,0.05808864637455448,-1.0379610118588776,0.2996593281158137,LGP Offspring,Genes up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] and HIF1A [GeneID=3091] by RNAi.,CGP,C2,120,215
Cohort,-0.4286908049821733,0.16824546971563473,-2.5480080129749605,0.01101229867821457,LGP Proband,Genes up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] and HIF1A [GeneID=3091] by RNAi.,CGP,C2,120,328
Cohort,-0.05502689375592922,0.048618735851203965,-1.1318042888720352,0.2580575662194734,LonGen OPEL,Genes up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] and HIF1A [GeneID=3091] by RNAi.,CGP,C2,173,189
Cohort,-0.04470487266692304,0.06657704661684237,-0.671475755363618,0.5021468868022092,LGP Offspring,Genes down-regulated in SEND cells (skin endothelium) at hypoxia with ELK3 [GeneID=2004] knockdown by RNAi.,CGP,C2,147,296
Cohort,-0.3054713530535725,0.18341078680614203,-1.6655037491139693,0.09618784492918275,LGP Proband,Genes down-regulated in SEND cells (skin endothelium) at hypoxia with ELK3 [GeneID=2004] knockdown by RNAi.,CGP,C2,147,439
Cohort,0.10590806686723954,0.05549822552074837,1.9083144708409663,0.056710054497631425,LonGen OPEL,Genes down-regulated in SEND cells (skin endothelium) at hypoxia with ELK3 [GeneID=2004] knockdown by RNAi.,CGP,C2,195,274
Cohort,0.00336869442882329,0.04096284118278506,0.08223781191815888,0.9344819491881606,LGP Offspring,Genes specifically down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,51,112
Cohort,0.07743761834851075,0.10906543205125427,0.7100106504150616,0.4778960007760048,LGP Proband,Genes specifically down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,51,149
Cohort,0.027598148611137026,0.03403625546698219,0.810845618370369,0.4176966967373047,LonGen OPEL,Genes specifically down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,83,104
Cohort,-0.03170867396815934,0.03173075840597851,-0.9993040053585667,0.3180050091201828,LGP Offspring,Genes specifically up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,34,60
Cohort,-0.1370382097250343,0.08126851335705902,-1.6862398986302005,0.09212361284250352,LGP Proband,Genes specifically up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,34,73
Cohort,0.016960645280950853,0.026059419261787523,0.6508450979113436,0.5153343089079255,LonGen OPEL,Genes specifically up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] by RNAi.,CGP,C2,41,57
Cohort,-0.08821010431395529,0.07721898032464804,-1.1423370775306512,0.2537183727011075,LGP Offspring,Genes up-regulated in SEND cells (skin endothelium) at hypoxia with ELK3 [GeneID=2004] knockdown by RNAi.,CGP,C2,208,395
Cohort,-0.045119594740981546,0.22560044028183854,-0.19999781332259128,0.8415310463231768,LGP Proband,Genes up-regulated in SEND cells (skin endothelium) at hypoxia with ELK3 [GeneID=2004] knockdown by RNAi.,CGP,C2,208,580
Cohort,0.09833869075312617,0.06694154178416144,1.4690233916362139,0.14222152441145067,LonGen OPEL,Genes up-regulated in SEND cells (skin endothelium) at hypoxia with ELK3 [GeneID=2004] knockdown by RNAi.,CGP,C2,312,428
Cohort,-0.046736746837048225,0.05400046769801154,-0.865487815742922,0.38707814335226864,LGP Offspring,Genes down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,94,181
Cohort,-0.024273001657006948,0.14858820236762377,-0.16335752953624702,0.8702765159399514,LGP Proband,Genes down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,94,249
Cohort,-0.032560120500836176,0.04568844884430959,-0.7126554156344811,0.47626785632008817,LonGen OPEL,Genes down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,148,177
Cohort,-0.017105922846014657,0.016127469007281726,-1.0606700182335584,0.2892186945116898,LGP Offspring,Genes uniquely up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,11,14
Cohort,0.040619973398112026,0.046579320930037034,0.872060231602001,0.38342649927681693,LGP Proband,Genes uniquely up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,11,25
Cohort,-0.003492221912945318,0.014008568253282522,-0.24929185123019348,0.8031993463187577,LonGen OPEL,Genes uniquely up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,13,15
Cohort,-0.026330325292592657,0.039550156328059895,-0.6657451635383782,0.5058010979458631,LGP Offspring,Genes up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,56,103
Cohort,-0.07504948114927514,0.1058888258485307,-0.7087573268271963,0.4786731438592281,LGP Proband,Genes up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,56,139
Cohort,-0.03212764101643742,0.035609252854278274,-0.902227326922908,0.36720904177172087,LonGen OPEL,Genes up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.,CGP,C2,88,94
Cohort,-0.015622321214829111,0.07298883710882906,-0.214037129972843,0.8305826448980405,LGP Offspring,Genes down-regulated in pancreatic ductal adenocarcinoma (PDAC) identified in a meta analysis across four independent studies.,CGP,C2,172,346
Cohort,-0.27271605003640426,0.19829511673519293,-1.3753039133111606,0.16940654046296566,LGP Proband,Genes down-regulated in pancreatic ductal adenocarcinoma (PDAC) identified in a meta analysis across four independent studies.,CGP,C2,172,464
Cohort,0.06395104788573867,0.06551352210634316,0.9761503553713958,0.3292865186975721,LonGen OPEL,Genes down-regulated in pancreatic ductal adenocarcinoma (PDAC) identified in a meta analysis across four independent studies.,CGP,C2,258,343
Cohort,0.05511241794877937,0.1004004203630933,0.5489261673354351,0.5832373772712611,LGP Offspring,Genes up-regulated in pancreatic ductal adenocarcinoma (PDAC) identified in a meta analysis across four independent studies.,CGP,C2,297,639
Cohort,0.033606199787883415,0.27029999705644286,0.1243292643501802,0.9010845364182059,LGP Proband,Genes up-regulated in pancreatic ductal adenocarcinoma (PDAC) identified in a meta analysis across four independent studies.,CGP,C2,297,828
Cohort,0.006062618476980161,0.0786225731267415,0.07711040526754413,0.9385550928160094,LonGen OPEL,Genes up-regulated in pancreatic ductal adenocarcinoma (PDAC) identified in a meta analysis across four independent studies.,CGP,C2,460,548
Cohort,0.11246679157758807,0.17836002815219626,0.6305605170773976,0.5285410262783833,LGP Offspring,"Expressed genes (FPKM>1) associated with high-confidence PAX3-FOXO1 sites with enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries",CGP,C2,988,2096
Cohort,-0.30834462995788536,0.49133410244269893,-0.6275661071049827,0.5304599978002533,LGP Proband,"Expressed genes (FPKM>1) associated with high-confidence PAX3-FOXO1 sites with enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries",CGP,C2,988,2929
Cohort,0.09842637539632602,0.15567464981940723,0.6322569250067821,0.527400561334765,LonGen OPEL,"Expressed genes (FPKM>1) associated with high-confidence PAX3-FOXO1 sites with enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries",CGP,C2,1664,2016
Cohort,-0.058077960315353346,0.11969693952191375,-0.48520839837112634,0.6276857273257501,LGP Offspring,"Expressed genes (FPKM>1) associated with high-confidence PAX3-FOXO1 sites with enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries, which are downregulated by delta log2(FPKM) < -0.2",CGP,C2,430,891
Cohort,0.13984807211479125,0.3192413882489198,0.43806372626643425,0.6614535227403255,LGP Proband,"Expressed genes (FPKM>1) associated with high-confidence PAX3-FOXO1 sites with enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries, which are downregulated by delta log2(FPKM) < -0.2",CGP,C2,430,1286
Cohort,0.03491128371216685,0.10362322383903955,0.33690597936226524,0.7362765844505088,LonGen OPEL,"Expressed genes (FPKM>1) associated with high-confidence PAX3-FOXO1 sites with enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries, which are downregulated by delta log2(FPKM) < -0.2",CGP,C2,721,865
Cohort,0.025827026535604904,0.12139777016734163,0.21274712459712772,0.8315883452150282,LGP Offspring,"Expressed genes (FPKM>1) associated with super-high-confidence PAX3-FOXO1 sites with highly-recurrent enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries",CGP,C2,465,972
Cohort,-0.16811644436187123,0.3314280746001968,-0.5072486528628296,0.6121144590103269,LGP Proband,"Expressed genes (FPKM>1) associated with super-high-confidence PAX3-FOXO1 sites with highly-recurrent enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries",CGP,C2,465,1395
Cohort,-0.07266369648551742,0.10948953904704893,-0.6636588035528488,0.5071008739201048,LonGen OPEL,"Expressed genes (FPKM>1) associated with super-high-confidence PAX3-FOXO1 sites with highly-recurrent enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries",CGP,C2,818,934
Cohort,0.03826397455732599,0.036021799047100116,1.062244961926919,0.2885038222131016,LGP Offspring,"Integrin, VEGF, Wnt and TGFbeta signaling pathway genes down-regulated in PC-3 cells (prostate cancer) after knockdown of PDEF [GeneID=25803] by RNAi.",CGP,C2,34,100
Cohort,0.1016902035803164,0.0995706519785817,1.0212869109483247,0.3074146770691642,LGP Proband,"Integrin, VEGF, Wnt and TGFbeta signaling pathway genes down-regulated in PC-3 cells (prostate cancer) after knockdown of PDEF [GeneID=25803] by RNAi.",CGP,C2,34,131
Cohort,-0.07091382936729329,0.03138921555107551,-2.2591781324354736,0.024142034745694454,LonGen OPEL,"Integrin, VEGF, Wnt and TGFbeta signaling pathway genes down-regulated in PC-3 cells (prostate cancer) after knockdown of PDEF [GeneID=25803] by RNAi.",CGP,C2,87,78
Cohort,0.002106445563467236,0.05934670830502325,0.03549389045540276,0.9716963960485374,LGP Offspring,"Integrin, VEGF, Wnt and TGFbeta signaling pathway genes up-regulated in PC-3 cells (prostate cancer) after knockdown of PDEF [GeneID=25803] by RNAi.",CGP,C2,111,219
Cohort,-0.1905787334991189,0.16760327666707184,-1.1370823845985163,0.2558304356186261,LGP Proband,"Integrin, VEGF, Wnt and TGFbeta signaling pathway genes up-regulated in PC-3 cells (prostate cancer) after knockdown of PDEF [GeneID=25803] by RNAi.",CGP,C2,111,318
Cohort,-0.036069103837157244,0.04759879487142355,-0.7577734674709531,0.44881087893354976,LonGen OPEL,"Integrin, VEGF, Wnt and TGFbeta signaling pathway genes up-regulated in PC-3 cells (prostate cancer) after knockdown of PDEF [GeneID=25803] by RNAi.",CGP,C2,181,203
Cohort,0.031950612562157726,0.03484568195552599,0.9169174132662039,0.3595129131453735,LGP Offspring,Genes down-regulated in glioblastoma cell lines displaying spherical growth (cluster-1) compared to those displaying semiadherent or adherent growth phenotype (cluster-2).,CGP,C2,35,82
Cohort,-0.19884575148587894,0.09072246183088215,-2.191802861969861,0.028669550500129093,LGP Proband,Genes down-regulated in glioblastoma cell lines displaying spherical growth (cluster-1) compared to those displaying semiadherent or adherent growth phenotype (cluster-2).,CGP,C2,35,108
Cohort,-0.015642539171833367,0.030734280960927996,-0.5089606355756128,0.6109208609175256,LonGen OPEL,Genes down-regulated in glioblastoma cell lines displaying spherical growth (cluster-1) compared to those displaying semiadherent or adherent growth phenotype (cluster-2).,CGP,C2,58,62
Cohort,-0.059990222906286014,0.03287347050882613,-1.824882556594667,0.06845993383226118,LGP Offspring,Genes up-regulated in glioblastoma cell lines displaying spherical growth (cluster-1) compared to those displaying semiadherent or adherent growth phenotype (cluster-2).,CGP,C2,41,65
Cohort,0.06897099772837836,0.08739704927762137,0.7891684936557563,0.4302378188652175,LGP Proband,Genes up-regulated in glioblastoma cell lines displaying spherical growth (cluster-1) compared to those displaying semiadherent or adherent growth phenotype (cluster-2).,CGP,C2,41,86
Cohort,-0.01726271539481763,0.026347843856843096,-0.6551851259105643,0.5125378614009712,LonGen OPEL,Genes up-regulated in glioblastoma cell lines displaying spherical growth (cluster-1) compared to those displaying semiadherent or adherent growth phenotype (cluster-2).,CGP,C2,50,54
Cohort,0.04818942505413087,0.03512566061119633,1.371915124601826,0.17054496848448533,LGP Offspring,Genes down-regulated in the liver tissue from 10 week old male mice with KLF10 [GeneID=7071] compared to wild-type littermates.,CGP,C2,39,99
Cohort,8.143743855308119e-4,0.10112506039739555,0.008053141153444354,0.9935765183345541,LGP Proband,Genes down-regulated in the liver tissue from 10 week old male mice with KLF10 [GeneID=7071] compared to wild-type littermates.,CGP,C2,39,137
Cohort,-0.027824727781679083,0.0337317808770586,-0.8248816711780261,0.40968589313235204,LonGen OPEL,Genes down-regulated in the liver tissue from 10 week old male mice with KLF10 [GeneID=7071] compared to wild-type littermates.,CGP,C2,84,88
Cohort,0.0035754103683838965,0.03600647850192351,0.09929908497419135,0.920930243555279,LGP Offspring,Genes up-regulated in the liver tissue from 10 week old male mice with KLF10 [GeneID=7071] compared to wild-type littermates.,CGP,C2,35,72
Cohort,-0.044712391002960566,0.10629938243493398,-0.4206270062794494,0.6741358293212641,LGP Proband,Genes up-regulated in the liver tissue from 10 week old male mice with KLF10 [GeneID=7071] compared to wild-type littermates.,CGP,C2,35,112
Cohort,4.0608291911732174e-4,0.03426328181689586,0.01185183956654948,0.9905467912881916,LonGen OPEL,Genes up-regulated in the liver tissue from 10 week old male mice with KLF10 [GeneID=7071] compared to wild-type littermates.,CGP,C2,62,82
Cohort,0.007699690553218141,0.03713100254808545,0.20736554428464127,0.8357868396490069,LGP Offspring,Genes down-regulated in day 6 embryoid bodies derived from embryonic stem cells (ES) with HEX [GeneID=3087] knockout.,CGP,C2,40,96
Cohort,-0.17776264507822553,0.1121758853955138,-1.5846778873325897,0.11341862166415534,LGP Proband,Genes down-regulated in day 6 embryoid bodies derived from embryonic stem cells (ES) with HEX [GeneID=3087] knockout.,CGP,C2,40,167
Cohort,0.01172997969518525,0.03464646895156189,0.3385620540893952,0.7350289554314671,LonGen OPEL,Genes down-regulated in day 6 embryoid bodies derived from embryonic stem cells (ES) with HEX [GeneID=3087] knockout.,CGP,C2,84,101
Cohort,-0.04751664754903853,0.050172354790190235,-0.9470683157635856,0.34394238054325843,LGP Offspring,Genes up-regulated in day 6 embryoid bodies derived from embryonic stem cells (ES) with HEX [GeneID=3087] knockout.,CGP,C2,81,142
Cohort,-0.042944574717089595,0.12965949747057365,-0.33121040536838353,0.740568762614309,LGP Proband,Genes up-regulated in day 6 embryoid bodies derived from embryonic stem cells (ES) with HEX [GeneID=3087] knockout.,CGP,C2,81,193
Cohort,-0.003839871081379967,0.04073662507921928,-0.09426090339866608,0.9249256276610119,LonGen OPEL,Genes up-regulated in day 6 embryoid bodies derived from embryonic stem cells (ES) with HEX [GeneID=3087] knockout.,CGP,C2,108,124
Cohort,-0.09495420498882197,0.04693316811365705,-2.023179103504656,0.04344774992852374,LGP Offspring,"Transcripts dependent upon IRS1 and IRS2 [GeneID=3667, 8660] for normal expression in liver.",CGP,C2,84,143
Cohort,0.1435329710074625,0.13687227183889072,1.0486636122794246,0.2946367593662989,LGP Proband,"Transcripts dependent upon IRS1 and IRS2 [GeneID=3667, 8660] for normal expression in liver.",CGP,C2,84,226
Cohort,0.047228495720981964,0.04346222297400169,1.0866562382056066,0.277517706546373,LonGen OPEL,"Transcripts dependent upon IRS1 and IRS2 [GeneID=3667, 8660] for normal expression in liver.",CGP,C2,127,174
Cohort,-0.012529492096016769,0.04357534592670051,-0.28753626229595586,0.7737898627043385,LGP Offspring,Genes exclusively down-regulated in B lymphocytes from CLL (chronic lymphocytic leukemia) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.,CGP,C2,65,133
Cohort,-0.12573428250864063,0.12106427668012998,-1.0385745981934003,0.2993036298424336,LGP Proband,Genes exclusively down-regulated in B lymphocytes from CLL (chronic lymphocytic leukemia) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.,CGP,C2,65,176
Cohort,0.04521206914829296,0.03522650837836303,1.2834672304923442,0.19970194498403102,LonGen OPEL,Genes exclusively down-regulated in B lymphocytes from CLL (chronic lymphocytic leukemia) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.,CGP,C2,80,117
Cohort,-2.145916270387229e-4,0.01798287147159964,-0.011933112427435607,0.9904825005657768,LGP Offspring,Genes exclusively up-regulated in B lymphocytes from CLL (chronic lymphocytic leukemia) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.,CGP,C2,10,19
Cohort,0.0019140921776301678,0.04252500773310885,0.04501097776732222,0.964109333556732,LGP Proband,Genes exclusively up-regulated in B lymphocytes from CLL (chronic lymphocytic leukemia) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.,CGP,C2,10,21
Cohort,-0.017478318943707424,0.01057648239044182,-1.6525644631624343,0.09881388117504326,LonGen OPEL,Genes exclusively up-regulated in B lymphocytes from CLL (chronic lymphocytic leukemia) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.,CGP,C2,11,6
Cohort,-0.0057654376121271155,0.020576750813592268,-0.2801918371057239,0.7794160483650867,LGP Offspring,Genes exclusively up-regulated in plasma cells from MM (multiple myeloma) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.,CGP,C2,15,29
Cohort,-0.007906893889791907,0.062367281778809285,-0.12677951746934168,0.8991454660915186,LGP Proband,Genes exclusively up-regulated in plasma cells from MM (multiple myeloma) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.,CGP,C2,15,54
Cohort,-0.019050528153899973,0.01918131658246396,-0.9931814676014703,0.3209233372167147,LonGen OPEL,Genes exclusively up-regulated in plasma cells from MM (multiple myeloma) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.,CGP,C2,30,30
Cohort,-0.001184975645559234,0.017476334896290628,-0.06780458560626154,0.945961242969199,LGP Offspring,Genes exclusively down-regulated in B lymphocytes from WM (Waldenstroem's macroblobulinemia) patients but with a similiar expression pattern in the normal cells and in the cells from CLL (chronic lymphocytic leukemia) patients.,CGP,C2,10,21
Cohort,-0.011052816663604637,0.034665448632679466,-0.31884245263120686,0.7499258192438366,LGP Proband,Genes exclusively down-regulated in B lymphocytes from WM (Waldenstroem's macroblobulinemia) patients but with a similiar expression pattern in the normal cells and in the cells from CLL (chronic lymphocytic leukemia) patients.,CGP,C2,10,10
Cohort,-0.0026214130589878866,0.012840307744455545,-0.20415500244687007,0.8382845579184913,LonGen OPEL,Genes exclusively down-regulated in B lymphocytes from WM (Waldenstroem's macroblobulinemia) patients but with a similiar expression pattern in the normal cells and in the cells from CLL (chronic lymphocytic leukemia) patients.,CGP,C2,12,13
Cohort,0.0024308056235370083,0.016025172914833293,0.15168670169461915,0.8794793029356313,LGP Offspring,Genes exclusively up-regulated in B lymphocytes from WM (Waldenstroem's macroblobulinemia) patients but with a similiar expression pattern in the normal cells and in the cells from CLL (chronic lymphocytic leukemia) patients.,CGP,C2,8,16
Cohort,0.009987044226551486,0.05616399759174312,0.17781932652208002,0.8589080485844248,LGP Proband,Genes exclusively up-regulated in B lymphocytes from WM (Waldenstroem's macroblobulinemia) patients but with a similiar expression pattern in the normal cells and in the cells from CLL (chronic lymphocytic leukemia) patients.,CGP,C2,8,38
Cohort,0.03166369755779862,0.01713800834269393,1.847571603692042,0.06503519844024491,LonGen OPEL,Genes exclusively up-regulated in B lymphocytes from WM (Waldenstroem's macroblobulinemia) patients but with a similiar expression pattern in the normal cells and in the cells from CLL (chronic lymphocytic leukemia) patients.,CGP,C2,14,30
Cohort,0.014160034466492947,0.021927779791315286,0.6457577831067589,0.5186553654248729,LGP Offspring,Genes exclusively up-regulated in B lymphocytes from WM (Waldenstroem's macroglobulinemia) but with a similar expression profile in MM (macroglobulinemia) and normal cells.,CGP,C2,12,36
Cohort,0.011535001315359577,0.056019805555738336,0.20590934225722243,0.8369119793624634,LGP Proband,Genes exclusively up-regulated in B lymphocytes from WM (Waldenstroem's macroglobulinemia) but with a similar expression profile in MM (macroglobulinemia) and normal cells.,CGP,C2,12,37
Cohort,0.023292437624009746,0.01900437000892823,1.2256358728580314,0.22069823033323954,LonGen OPEL,Genes exclusively up-regulated in B lymphocytes from WM (Waldenstroem's macroglobulinemia) but with a similar expression profile in MM (macroglobulinemia) and normal cells.,CGP,C2,20,31
Cohort,-0.05743335838163839,0.03789035056026316,-1.5157779627900994,0.1300429490029771,LGP Offspring,Genes associated with resistance to doxorubicin [PubChem=31703].,CGP,C2,48,81
Cohort,0.04073505818418506,0.10425944220763264,0.3907085758531223,0.6961124391666336,LGP Proband,Genes associated with resistance to doxorubicin [PubChem=31703].,CGP,C2,48,126
Cohort,-0.058580048811912595,0.034669169830550524,-1.6896870936982105,0.09147940501642687,LonGen OPEL,Genes associated with resistance to doxorubicin [PubChem=31703].,CGP,C2,92,86
Cohort,-0.0014884728716795133,0.0459008380993028,-0.032428010757871585,0.9741402968445521,LGP Offspring,Genes associated with resistance to mitoxantrone [PubChem=4212].,CGP,C2,62,130
Cohort,0.28518806198902225,0.12005138815156939,2.375549890593198,0.017747921403242644,LGP Proband,Genes associated with resistance to mitoxantrone [PubChem=4212].,CGP,C2,62,187
Cohort,-0.01913898933189129,0.03981773991718849,-0.4806648838355938,0.630886770279474,LonGen OPEL,Genes associated with resistance to mitoxantrone [PubChem=4212].,CGP,C2,105,113
Cohort,-0.018790863630369928,0.09772061354567987,-0.19229170743577112,0.8475714635427344,LGP Offspring,Genes up-regulated in hematopoietic progenitor cells (HPC) of B lymphocyte lineage CD34+CD45RA+CD10+ [GeneID=947;5788;4311].,CGP,C2,294,631
Cohort,0.19636674886691677,0.27051354267909195,0.7259035792520934,0.46810153456504233,LGP Proband,Genes up-regulated in hematopoietic progenitor cells (HPC) of B lymphocyte lineage CD34+CD45RA+CD10+ [GeneID=947;5788;4311].,CGP,C2,294,879
Cohort,-0.04720673182199101,0.08331219603107341,-0.5666245048250085,0.5711290494320256,LonGen OPEL,Genes up-regulated in hematopoietic progenitor cells (HPC) of B lymphocyte lineage CD34+CD45RA+CD10+ [GeneID=947;5788;4311].,CGP,C2,469,528
Cohort,0.0516023718184136,0.0488266180104935,1.0568491925310812,0.2909579467354105,LGP Offspring,Genes down-regulated in hematopoietic progenitor cells (HPC) of T lymphocyte and NK (natural killer) lineage.,CGP,C2,65,162
Cohort,0.034366643311269866,0.12134675427145311,0.2832102392651687,0.7770859617513883,LGP Proband,Genes down-regulated in hematopoietic progenitor cells (HPC) of T lymphocyte and NK (natural killer) lineage.,CGP,C2,65,186
Cohort,-0.11075893780014599,0.040729659687879206,-2.719368112793412,0.006683168801519659,LonGen OPEL,Genes down-regulated in hematopoietic progenitor cells (HPC) of T lymphocyte and NK (natural killer) lineage.,CGP,C2,130,112
Cohort,-0.03513039743199689,0.05301438486432426,-0.6626578337540553,0.5077755859088446,LGP Offspring,Genes up-regulated in hematopoietic progenitor cells (HPC) of T lymphocyte and NK (natural killer) lineage.,CGP,C2,89,173
Cohort,-0.02522585233481609,0.14324059560828573,-0.17610826196087742,0.8602516423297151,LGP Proband,Genes up-regulated in hematopoietic progenitor cells (HPC) of T lymphocyte and NK (natural killer) lineage.,CGP,C2,89,246
Cohort,-0.01642672241346697,0.04453080107667592,-0.3688845027778057,0.7123119084610352,LonGen OPEL,Genes up-regulated in hematopoietic progenitor cells (HPC) of T lymphocyte and NK (natural killer) lineage.,CGP,C2,138,152
Cohort,0.007635880117871342,0.020798562350728775,0.36713499659767507,0.7136332225137643,LGP Offspring,Genes with the highest differential expression in primary tissue cultures of high grade glioma: responders vs non-responders to imatinib [PubChem=5291] treatment.,CGP,C2,13,32
Cohort,0.035100388005416955,0.05319629116966824,0.6598277292201659,0.5095465556092507,LGP Proband,Genes with the highest differential expression in primary tissue cultures of high grade glioma: responders vs non-responders to imatinib [PubChem=5291] treatment.,CGP,C2,13,36
Cohort,0.023367428052535215,0.019159100255375233,1.2196516402684048,0.22295821356496434,LonGen OPEL,Genes with the highest differential expression in primary tissue cultures of high grade glioma: responders vs non-responders to imatinib [PubChem=5291] treatment.,CGP,C2,19,35
Cohort,0.013931438774032693,0.024747138157438696,0.5629515091968349,0.5736545586885462,LGP Offspring,Genes showing similar expression profiles in all subtypes of cutaneous T cell lymphoma (CTCL).,CGP,C2,16,42
Cohort,0.017787879430182573,0.06378742416209833,0.2788618550418266,0.7804199737576469,LGP Proband,Genes showing similar expression profiles in all subtypes of cutaneous T cell lymphoma (CTCL).,CGP,C2,16,53
Cohort,0.0022935263576219994,0.02215435471961368,0.10352485489417104,0.9175725003799731,LonGen OPEL,Genes showing similar expression profiles in all subtypes of cutaneous T cell lymphoma (CTCL).,CGP,C2,31,39
Cohort,-0.035747109928258726,0.02112003770265564,-1.6925684713036224,0.09099841771637356,LGP Offspring,Differentially expressed genes relevant to pathogenesis of cutaneous T cell lymphoma (CTCL).,CGP,C2,21,27
Cohort,0.03753892439614429,0.055326871458724884,0.6784935313783139,0.49764703991658077,LGP Proband,Differentially expressed genes relevant to pathogenesis of cutaneous T cell lymphoma (CTCL).,CGP,C2,21,33
Cohort,0.009240406755050981,0.016536788930369233,0.5587787806906876,0.5764698607413096,LonGen OPEL,Differentially expressed genes relevant to pathogenesis of cutaneous T cell lymphoma (CTCL).,CGP,C2,17,21
Cohort,-0.0457451201974145,0.053533729524468096,-0.8545102424912552,0.39312505800434105,LGP Offspring,Genes down-regulated in T helper cells (defines as CD4+) isolated from patients with mucosis fungoides compared to those from normal control donors.,CGP,C2,96,197
Cohort,0.34568774251443113,0.15189553852159018,2.2758255171878905,0.02310927374031497,LGP Proband,Genes down-regulated in T helper cells (defines as CD4+) isolated from patients with mucosis fungoides compared to those from normal control donors.,CGP,C2,96,274
Cohort,0.05786059793061033,0.04667297586523925,1.2397023514779422,0.2154508574677345,LonGen OPEL,Genes down-regulated in T helper cells (defines as CD4+) isolated from patients with mucosis fungoides compared to those from normal control donors.,CGP,C2,132,179
Cohort,0.004423284212734313,0.03359216791537106,0.13167605686771744,0.8952797039754409,LGP Offspring,Genes up-regulated in T helper cells (defines as CD4+) isolated from patients with mucosis fungoides compared to those from normal control donors.,CGP,C2,39,84
Cohort,-0.008678275025841734,0.10703904977011719,-0.08107578537439994,0.9354011344586108,LGP Proband,Genes up-regulated in T helper cells (defines as CD4+) isolated from patients with mucosis fungoides compared to those from normal control donors.,CGP,C2,39,142
Cohort,0.05901461530275236,0.03169443570794312,1.861986622716945,0.06297328672434722,LonGen OPEL,Genes up-regulated in T helper cells (defines as CD4+) isolated from patients with mucosis fungoides compared to those from normal control donors.,CGP,C2,55,91
Cohort,0.013232668495538055,0.023492223373648587,0.5632786767378197,0.573431916798901,LGP Offspring,Genes down-regulated in monocytes isolated from peripheral blood samples of patients with mucosis fungoides compared to those from normal healthy donors.,CGP,C2,15,34
Cohort,-0.07466724886258246,0.06717489031251231,-1.1115351065735135,0.2666584106763056,LGP Proband,Genes down-regulated in monocytes isolated from peripheral blood samples of patients with mucosis fungoides compared to those from normal healthy donors.,CGP,C2,15,54
Cohort,0.02187570957959599,0.021770354208852778,1.0048393962602762,0.31527954487298293,LonGen OPEL,Genes down-regulated in monocytes isolated from peripheral blood samples of patients with mucosis fungoides compared to those from normal healthy donors.,CGP,C2,23,37
Cohort,-0.055064067316369106,0.029815791085931714,-1.8468088657339212,0.06521170814296788,LGP Offspring,Genes down-regulated in lesional skin biopsies from mycosis fundoides patients compared to the normal skin samples.,CGP,C2,35,45
Cohort,-0.11088170561384969,0.08770322681905507,-1.264283078690084,0.20648165391571074,LGP Proband,Genes down-regulated in lesional skin biopsies from mycosis fundoides patients compared to the normal skin samples.,CGP,C2,35,87
Cohort,0.015328777287926221,0.02636971668428393,0.5813023124765694,0.5612012839835978,LonGen OPEL,Genes down-regulated in lesional skin biopsies from mycosis fundoides patients compared to the normal skin samples.,CGP,C2,43,56
Cohort,-0.042349210286130395,0.0678647548979296,-0.6240236238946819,0.5328225902574808,LGP Offspring,Genes up-regulated in lesional skin biopsies from mycosis fundoides patients compared to the normal skin samples.,CGP,C2,153,306
Cohort,-0.024939302670144277,0.18569953778642742,-0.13429921779787576,0.8931983734782305,LGP Proband,Genes up-regulated in lesional skin biopsies from mycosis fundoides patients compared to the normal skin samples.,CGP,C2,153,405
Cohort,-0.02765310718856402,0.0567710933771365,-0.4870983724914623,0.6263227236247824,LonGen OPEL,Genes up-regulated in lesional skin biopsies from mycosis fundoides patients compared to the normal skin samples.,CGP,C2,232,269
Cohort,0.029458254744399694,0.02073726653011637,1.42054666180897,0.1559096547382466,LGP Offspring,Genes up-regulated in monocytes isolated from peripheral blood samples of patients with mucosis fungoides compared to those from normal healthy donors.,CGP,C2,10,35
Cohort,-0.0936755292787229,0.056457386026615895,-1.6592254064784566,0.09744634417929683,LGP Proband,Genes up-regulated in monocytes isolated from peripheral blood samples of patients with mucosis fungoides compared to those from normal healthy donors.,CGP,C2,10,42
Cohort,-0.012422205900531093,0.019702532257881978,-0.6304877839020718,0.5285564537604392,LonGen OPEL,Genes up-regulated in monocytes isolated from peripheral blood samples of patients with mucosis fungoides compared to those from normal healthy donors.,CGP,C2,28,29
Cohort,-0.04074366510093504,0.032301321779173345,-1.2613621628079938,0.20761349110763935,LGP Offspring,Genes down-regulated in monocytes isolated from peripheral blood samples of Sezary syndrom patients compared to those from healthy normal donors.,CGP,C2,41,63
Cohort,-0.00391459591372457,0.08780962509870167,-0.04458048772357701,0.9644523672060327,LGP Proband,Genes down-regulated in monocytes isolated from peripheral blood samples of Sezary syndrom patients compared to those from healthy normal donors.,CGP,C2,41,85
Cohort,-0.01631284211063931,0.02600078561107315,-0.6273980469148609,0.5305782703881983,LonGen OPEL,Genes down-regulated in monocytes isolated from peripheral blood samples of Sezary syndrom patients compared to those from healthy normal donors.,CGP,C2,50,53
Cohort,0.011484451132844584,0.049113876336159545,0.23383312394728015,0.8151853281072423,LGP Offspring,Genes up-regulated in monocytes isolated from peripheral blood samples of Sezary syndrom patients compared to those from healthy normal donors.,CGP,C2,81,182
Cohort,-0.013167312858845145,0.1448032169483545,-0.09093246086888662,0.9275680917357533,LGP Proband,Genes up-regulated in monocytes isolated from peripheral blood samples of Sezary syndrom patients compared to those from healthy normal donors.,CGP,C2,81,258
Cohort,0.017665751580552027,0.04758272545199123,0.3712639705427541,0.7105397228236092,LonGen OPEL,Genes up-regulated in monocytes isolated from peripheral blood samples of Sezary syndrom patients compared to those from healthy normal donors.,CGP,C2,144,179
Cohort,0.035695651894558006,0.03400535038440582,1.0497069282052545,0.2942280002982409,LGP Offspring,Genes down-regulated in H358 cells (lung cancer) by inducible expression of CEBPA [GeneID=1050] off plasmid vector.,CGP,C2,30,75
Cohort,-0.053024769367984545,0.08808587051667698,-0.6019667973644599,0.5473598468147102,LGP Proband,Genes down-regulated in H358 cells (lung cancer) by inducible expression of CEBPA [GeneID=1050] off plasmid vector.,CGP,C2,30,98
Cohort,0.06468322812837761,0.027502455902978593,2.351907348076949,0.01892018046762322,LonGen OPEL,Genes down-regulated in H358 cells (lung cancer) by inducible expression of CEBPA [GeneID=1050] off plasmid vector.,CGP,C2,43,73
Cohort,0.018213276168656405,0.03019191803808776,0.6032500533977325,0.546544695546809,LGP Offspring,Genes up-regulated in H358 cells (lung cancer) by inducible expression of CEBPA [GeneID=1050] off plasmid vector.,CGP,C2,28,64
Cohort,0.03575867707858627,0.08320188789083317,0.42978203962756484,0.667465215922072,LGP Proband,Genes up-regulated in H358 cells (lung cancer) by inducible expression of CEBPA [GeneID=1050] off plasmid vector.,CGP,C2,28,83
Cohort,0.003066704792733032,0.02582981926000018,0.1187273035813341,0.9055213592391778,LonGen OPEL,Genes up-regulated in H358 cells (lung cancer) by inducible expression of CEBPA [GeneID=1050] off plasmid vector.,CGP,C2,44,53
Cohort,-0.0053938466015590845,0.07463230376596129,-0.07227227794647202,0.9424066032750983,LGP Offspring,"Genes down-regulated in T1 cells (primary melanoma, sensitive to TRAIL [GeneID=8743]) compared to G1 cells (metastatic melanoma, resistant to TRAIL).",CGP,C2,171,377
Cohort,0.032544589721228936,0.18919258119527071,0.17201831866567113,0.8634648586776721,LGP Proband,"Genes down-regulated in T1 cells (primary melanoma, sensitive to TRAIL [GeneID=8743]) compared to G1 cells (metastatic melanoma, resistant to TRAIL).",CGP,C2,171,481
Cohort,-0.13532891678351353,0.05880074117472918,-2.301483179971784,0.021621787067660145,LonGen OPEL,"Genes down-regulated in T1 cells (primary melanoma, sensitive to TRAIL [GeneID=8743]) compared to G1 cells (metastatic melanoma, resistant to TRAIL).",CGP,C2,297,307
Cohort,-0.32541942008614333,0.1454431145729103,-2.2374343470416496,0.025583038505393285,LGP Offspring,"Genes up-regulated in T1 cells (primary melanoma, sensitive to TRAIL [GeneID=8743]) compared to G1 cells (metastatic melanoma, resistant to TRAIL).",CGP,C2,769,1434
Cohort,-0.19635246465113537,0.443388580387989,-0.4428451099920443,0.6579926075996297,LGP Proband,"Genes up-regulated in T1 cells (primary melanoma, sensitive to TRAIL [GeneID=8743]) compared to G1 cells (metastatic melanoma, resistant to TRAIL).",CGP,C2,769,2162
Cohort,-0.21314111111548786,0.13565487795941045,-1.5712012300749127,0.11653330001625817,LonGen OPEL,"Genes up-regulated in T1 cells (primary melanoma, sensitive to TRAIL [GeneID=8743]) compared to G1 cells (metastatic melanoma, resistant to TRAIL).",CGP,C2,1218,1370
Cohort,0.04729399559344479,0.0380458583261949,1.243078686461976,0.21426980561776968,LGP Offspring,Genes down-regulated in 3T3 cells (fibroblast) upon activation of JNK pathway.,CGP,C2,43,109
Cohort,0.1303526860931463,0.10396983083764617,1.253754911813776,0.21028242601240973,LGP Proband,Genes down-regulated in 3T3 cells (fibroblast) upon activation of JNK pathway.,CGP,C2,43,133
Cohort,0.013873121698213885,0.0319738204537022,0.43389002319263154,0.6644858754197605,LonGen OPEL,Genes down-regulated in 3T3 cells (fibroblast) upon activation of JNK pathway.,CGP,C2,72,84
Cohort,-0.07099781076309702,0.034390083417292626,-2.0644849825341414,0.039352655497623165,LGP Offspring,Genes up-regulated in 3T3 cells (fibroblast) upon activation of JNK pathway.,CGP,C2,53,71
Cohort,-0.18725134522556386,0.09682607431378708,-1.9338938044594576,0.05346422840226925,LGP Proband,Genes up-regulated in 3T3 cells (fibroblast) upon activation of JNK pathway.,CGP,C2,53,108
Cohort,-0.026680501950766874,0.03091533476582349,-0.8630183743072978,0.38838730830933166,LonGen OPEL,Genes up-regulated in 3T3 cells (fibroblast) upon activation of JNK pathway.,CGP,C2,72,74
Cohort,-0.13808331382714314,0.10927887639388129,-1.2635865080588866,0.20681406299386496,LGP Offspring,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of SATB1 [GeneID=6304] by RNAi.,CGP,C2,427,818
Cohort,-0.6990875362998988,0.30012673718817984,-2.329307754615578,0.020080729269753673,LGP Proband,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of SATB1 [GeneID=6304] by RNAi.,CGP,C2,427,1131
Cohort,-0.08653358577826321,0.09439166305510355,-0.9167503037609055,0.35955115887070466,LonGen OPEL,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of SATB1 [GeneID=6304] by RNAi.,CGP,C2,625,723
Cohort,-0.22090406594775788,0.11540782219939223,-1.9141169267200782,0.05602714309352573,LGP Offspring,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of SATB1 [GeneID=6304] by RNAi.,CGP,C2,438,801
Cohort,-0.30726898290710447,0.3209551724304289,-0.9573579406130583,0.338664051217757,LGP Proband,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of SATB1 [GeneID=6304] by RNAi.,CGP,C2,438,1141
Cohort,-0.14748531037269472,0.09542888877199811,-1.545499609924952,0.12262291728401405,LonGen OPEL,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of SATB1 [GeneID=6304] by RNAi.,CGP,C2,695,760
Cohort,0.031173988056184605,0.04086578631374729,0.7628383268303256,0.4458259286250831,LGP Offspring,"Genes down-regulated in SCLC (small cell lung cancer) cells with acquired resistance to ABT-737 [PubChem=11228183], an inhibitor of the BCL2 [GeneID=596] family proteins.",CGP,C2,47,116
Cohort,-0.034052185588041246,0.11890674120134306,-0.2863772503056086,0.7746603194239354,LGP Proband,"Genes down-regulated in SCLC (small cell lung cancer) cells with acquired resistance to ABT-737 [PubChem=11228183], an inhibitor of the BCL2 [GeneID=596] family proteins.",CGP,C2,47,177
Cohort,-0.015512728190936263,0.04009410901255721,-0.38690791672357105,0.6989277929480042,LonGen OPEL,"Genes down-regulated in SCLC (small cell lung cancer) cells with acquired resistance to ABT-737 [PubChem=11228183], an inhibitor of the BCL2 [GeneID=596] family proteins.",CGP,C2,108,131
Cohort,-0.06773408308072072,0.02943596112943364,-2.301065787622337,0.021691306877568543,LGP Offspring,"Genes up-regulated in SCLC (small cell lung cancer) cells with acquired resistance to ABT-737 [PubChem=11228183], an inhibitor of the BCL2 [GeneID=596] family proteins.",CGP,C2,38,49
Cohort,-0.027816006607003056,0.07808468313598325,-0.3562287184871061,0.7217593813776597,LGP Proband,"Genes up-regulated in SCLC (small cell lung cancer) cells with acquired resistance to ABT-737 [PubChem=11228183], an inhibitor of the BCL2 [GeneID=596] family proteins.",CGP,C2,38,66
Cohort,-0.009072458022201068,0.027932542445021608,-0.3247988628338429,0.7454186459220331,LonGen OPEL,"Genes up-regulated in SCLC (small cell lung cancer) cells with acquired resistance to ABT-737 [PubChem=11228183], an inhibitor of the BCL2 [GeneID=596] family proteins.",CGP,C2,46,58
Cohort,0.02275723773550561,0.020639518247696505,1.1026050832385808,0.27059108283747824,LGP Offspring,Genes changed by expression of activated form of HRas[GeneID=3265] in MEF cells (embryonic fibroblast) with or without p65/c-Rel complex [GeneID=5970;5966].,CGP,C2,11,32
Cohort,-0.04134731122593675,0.058595025628196865,-0.7056454158463541,0.48060572018516734,LGP Proband,Genes changed by expression of activated form of HRas[GeneID=3265] in MEF cells (embryonic fibroblast) with or without p65/c-Rel complex [GeneID=5970;5966].,CGP,C2,11,47
Cohort,0.009629106952206007,0.016879808068530934,0.5704512108853639,0.5685326887605392,LonGen OPEL,Genes changed by expression of activated form of HRas[GeneID=3265] in MEF cells (embryonic fibroblast) with or without p65/c-Rel complex [GeneID=5970;5966].,CGP,C2,17,25
Cohort,0.03594467557530477,0.03744938130941221,0.9598202778925681,0.3374888407810448,LGP Offspring,"Genes from the brain cancer stem (cancer stem cell, CSC) signature.",CGP,C2,45,101
Cohort,0.16065125998999188,0.09953078247654998,1.6140861750769642,0.10688699319518308,LGP Proband,"Genes from the brain cancer stem (cancer stem cell, CSC) signature.",CGP,C2,45,119
Cohort,-0.0379686339939322,0.030518132596829367,-1.2441335941333742,0.21381662502576124,LonGen OPEL,"Genes from the brain cancer stem (cancer stem cell, CSC) signature.",CGP,C2,66,72
Cohort,0.0453701796891153,0.04297240720353328,1.0557979559819697,0.29143770713535005,LGP Offspring,Genes known to be induced by hypoxia,CGP,C2,49,121
Cohort,-0.1830412012070585,0.1145650930959264,-1.5977048179395832,0.11048746928035552,LGP Proband,Genes known to be induced by hypoxia,CGP,C2,49,153
Cohort,-0.01998300651080462,0.038480534381068375,-0.5193016893402562,0.6036947312328742,LonGen OPEL,Genes known to be induced by hypoxia,CGP,C2,101,109
Cohort,0.016945351001107695,0.018477590744326717,0.9170757830703944,0.3594299853755304,LGP Offspring,"Genes up-regulated in salivary, thyroid and mammary gland carcinomas developed in transgenic mice carrying RET [GeneID=5979] allele with the MEN2A mutation (C634R).",CGP,C2,9,26
Cohort,-0.06399397823329264,0.04191970232288727,-1.5265847486315114,0.12724343365033677,LGP Proband,"Genes up-regulated in salivary, thyroid and mammary gland carcinomas developed in transgenic mice carrying RET [GeneID=5979] allele with the MEN2A mutation (C634R).",CGP,C2,9,20
Cohort,0.0018104221786870102,0.015568014866392211,0.11629113886545023,0.9074511401439659,LonGen OPEL,"Genes up-regulated in salivary, thyroid and mammary gland carcinomas developed in transgenic mice carrying RET [GeneID=5979] allele with the MEN2A mutation (C634R).",CGP,C2,17,21
Cohort,0.017521537919567877,0.020206226390731163,0.86713558389137,0.3861754154478042,LGP Offspring,Genes down-regulated in SiHa cells (cervical carcinoma) by stable expression of NOL7 [GeneID=51406] off a plasmid vector.,CGP,C2,10,30
Cohort,0.05360776234177656,0.050714394012592076,1.0570522114188348,0.2907938422473976,LGP Proband,Genes down-regulated in SiHa cells (cervical carcinoma) by stable expression of NOL7 [GeneID=51406] off a plasmid vector.,CGP,C2,10,29
Cohort,0.015166224422873307,0.01414761047436347,1.0719990100346375,0.28404537753140696,LonGen OPEL,Genes down-regulated in SiHa cells (cervical carcinoma) by stable expression of NOL7 [GeneID=51406] off a plasmid vector.,CGP,C2,11,20
Cohort,0.026178021073570645,0.021733758359089174,1.204486616674969,0.22882308669265408,LGP Offspring,Genes up-regulated in SiHa cells (cervical carcinoma) by stable expression of NOL7 [GeneID=51406] off a plasmid vector.,CGP,C2,10,33
Cohort,-0.10532929933227213,0.050020291589317645,-2.1057314139041585,0.03552607927792191,LGP Proband,Genes up-regulated in SiHa cells (cervical carcinoma) by stable expression of NOL7 [GeneID=51406] off a plasmid vector.,CGP,C2,10,31
Cohort,0.005028391163397587,0.016491245208556507,0.30491276430651815,0.7605122996396652,LonGen OPEL,Genes up-regulated in SiHa cells (cervical carcinoma) by stable expression of NOL7 [GeneID=51406] off a plasmid vector.,CGP,C2,17,23
Cohort,-0.05587914271533732,0.02989113294046653,-1.86942203986147,0.06199623899892431,LGP Offspring,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 11q23 region.,CGP,C2,37,48
Cohort,-0.17472698680107734,0.08536715195710665,-2.046770716784252,0.04099357602134462,LGP Proband,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 11q23 region.,CGP,C2,37,86
Cohort,-0.022162141597915543,0.025894128265790343,-0.8558751764273423,0.3923243818673554,LonGen OPEL,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 11q23 region.,CGP,C2,53,55
Cohort,-0.031018993983786863,0.0188533865542039,-1.6452743858301835,0.10037810091028114,LGP Offspring,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 13q14 region.,CGP,C2,15,20
Cohort,-0.07483705898280656,0.0552372651398875,-1.3548291862981068,0.1758388609119497,LGP Proband,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 13q14 region.,CGP,C2,15,38
Cohort,0.03857007671579991,0.01832384690706207,2.1049115347571954,0.035611875777818866,LonGen OPEL,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 13q14 region.,CGP,C2,17,35
Cohort,0.013771948500454552,0.021544676648221232,0.6392274400456871,0.5228915230855653,LGP Offspring,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 17p13 region.,CGP,C2,14,35
Cohort,0.04582286479313885,0.06718629275578375,0.6820269866608197,0.49541124990614394,LGP Proband,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 17p13 region.,CGP,C2,14,54
Cohort,0.018827679619324106,0.021531182530129128,0.8744377877516972,0.3821436342665906,LonGen OPEL,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 17p13 region.,CGP,C2,28,42
Cohort,-0.02605119473058815,0.02232943921658825,-1.166674831279912,0.2437531113429006,LGP Offspring,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the  6q21 region.,CGP,C2,19,33
Cohort,-0.02791594432773843,0.05856257396632245,-0.47668574717689216,0.6337107814777028,LGP Proband,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the  6q21 region.,CGP,C2,19,40
Cohort,-0.05648821430871253,0.018366771901570295,-3.0755657342204477,0.0021728812225019854,LonGen OPEL,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the  6q21 region.,CGP,C2,33,19
Cohort,0.03988244376508591,0.021672028669761485,1.8402727484729209,0.06616638248570172,LGP Offspring,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with trisomy of chromosome 12.,CGP,C2,10,39
Cohort,-0.07566501730551822,0.059752904017703425,-1.2662985766030785,0.20575977419386507,LGP Proband,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with trisomy of chromosome 12.,CGP,C2,10,51
Cohort,-0.015587331859439113,0.019007931062352063,-0.8200435811929085,0.4124367454500474,LonGen OPEL,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with trisomy of chromosome 12.,CGP,C2,26,27
Cohort,-0.02292140553909731,0.017133967359188627,-1.3377757210915304,0.18141942585345427,LGP Offspring,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with mutations in the variable immunoglobulin veriable heavy chain (VH) genes.,CGP,C2,13,17
Cohort,0.008571197232623761,0.055974323277172264,0.15312730428523663,0.8783349243884963,LGP Proband,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with mutations in the variable immunoglobulin veriable heavy chain (VH) genes.,CGP,C2,13,38
Cohort,0.00827315662058493,0.01706479774812492,0.4848083606202707,0.6279456732856262,LonGen OPEL,Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with mutations in the variable immunoglobulin veriable heavy chain (VH) genes.,CGP,C2,21,26
Cohort,-0.07617548782797541,0.031299940530137745,-2.4337262799150814,0.015202315767757544,LGP Offspring,Genes with unmethylated DNA in lung cancer samples.,CGP,C2,44,61
Cohort,-0.030938346311869126,0.08442501290118876,-0.3664594798235855,0.7141151893260135,LGP Proband,Genes with unmethylated DNA in lung cancer samples.,CGP,C2,44,85
Cohort,0.004453543943309342,0.02569867551940912,0.17329857875149127,0.8624607984669967,LonGen OPEL,Genes with unmethylated DNA in lung cancer samples.,CGP,C2,47,52
Cohort,-0.06400725842074051,0.1104803925676423,-0.5793540096406851,0.5625433382516803,LGP Offspring,Genes with hypermethylated DNA in lung cancer samples.,CGP,C2,373,765
Cohort,0.10764292204412777,0.2957087147512482,0.3640167390219716,0.7159377733479704,LGP Proband,Genes with hypermethylated DNA in lung cancer samples.,CGP,C2,373,1023
Cohort,-0.09108670845756145,0.0906511305010729,-1.004804991996028,0.3152961038332964,LonGen OPEL,Genes with hypermethylated DNA in lung cancer samples.,CGP,C2,607,677
Cohort,-0.008917989646441806,0.013848484076669226,-0.6439686536857917,0.5198141828778177,LGP Offspring,Genes down-regulated in the intestine after the tissue specific knockout of PTEN [GeneID=5728] by Cre-lox.,CGP,C2,7,12
Cohort,0.031645189259750975,0.03965292018449787,0.7980544462428398,0.4250660686681219,LGP Proband,Genes down-regulated in the intestine after the tissue specific knockout of PTEN [GeneID=5728] by Cre-lox.,CGP,C2,7,19
Cohort,-0.0026552164805706256,0.013278913283253759,-0.19995736276997605,0.8415649986624806,LonGen OPEL,Genes down-regulated in the intestine after the tissue specific knockout of PTEN [GeneID=5728] by Cre-lox.,CGP,C2,14,13
Cohort,0.005684142644013095,0.017417912308245725,0.326338917283571,0.7442689509580956,LGP Offspring,Genes up-regulated in the intestine after the tissue specific knockout of PTEN [GeneID=5728] by Cre-lox.,CGP,C2,7,24
Cohort,0.13908615750950432,0.04752620830039131,2.926514916367926,0.003520933930666689,LGP Proband,Genes up-regulated in the intestine after the tissue specific knockout of PTEN [GeneID=5728] by Cre-lox.,CGP,C2,7,29
Cohort,-0.0016682436419200503,0.016418891141442002,-0.1016051344484117,0.9190956916248547,LonGen OPEL,Genes up-regulated in the intestine after the tissue specific knockout of PTEN [GeneID=5728] by Cre-lox.,CGP,C2,19,23
Cohort,2.996247034505996e-4,0.04903011279956483,0.0061110343489411455,0.9951259333075205,LGP Offspring,Genes transcriptionally modulated in the blood of multiple sclerosis patients in response to subcutaneous treatment with recombinant IFNB1 [GeneID = 3456].,CGP,C2,71,156
Cohort,0.07735441879623564,0.13441522210506338,0.5754885316171473,0.5651161785839887,LGP Proband,Genes transcriptionally modulated in the blood of multiple sclerosis patients in response to subcutaneous treatment with recombinant IFNB1 [GeneID = 3456].,CGP,C2,71,216
Cohort,-0.028090901623273948,0.04031694924914742,-0.6967516676343755,0.4861616348723625,LonGen OPEL,Genes transcriptionally modulated in the blood of multiple sclerosis patients in response to subcutaneous treatment with recombinant IFNB1 [GeneID = 3456].,CGP,C2,118,128
Cohort,0.056634084709460804,0.032654735781608206,1.7343299020461909,0.08331541901484701,LGP Offspring,Down-regulated genes distinguishing between two groups of non-BRCA1/BRCA2 [GeneID=672;675] breast tumors (BRACx): group A vs group B.,CGP,C2,27,84
Cohort,0.04251746173771193,0.08458592594076013,0.50265409126678,0.615340192215073,LGP Proband,Down-regulated genes distinguishing between two groups of non-BRCA1/BRCA2 [GeneID=672;675] breast tumors (BRACx): group A vs group B.,CGP,C2,27,93
Cohort,0.021312385113137162,0.02761294027314938,0.7718259954323361,0.4404465652106362,LonGen OPEL,Down-regulated genes distinguishing between two groups of non-BRCA1/BRCA2 [GeneID=672;675] breast tumors (BRACx): group A vs group B.,CGP,C2,46,65
Cohort,0.03903109183565948,0.0254415376954126,1.5341483012128325,0.12546103493385827,LGP Offspring,Up-regulated genes distinguishing between two groups of non-BRCA1/BRCA2 [GeneID=672;675] breast tumors (BRACx): group A vs group B.,CGP,C2,17,52
Cohort,0.02160612516870349,0.06535899406636266,0.33057615829836023,0.7410476858021078,LGP Proband,Up-regulated genes distinguishing between two groups of non-BRCA1/BRCA2 [GeneID=672;675] breast tumors (BRACx): group A vs group B.,CGP,C2,17,52
Cohort,-0.015626039793087777,0.021010140207530354,-0.7437380064454385,0.45725446230357114,LonGen OPEL,Up-regulated genes distinguishing between two groups of non-BRCA1/BRCA2 [GeneID=672;675] breast tumors (BRACx): group A vs group B.,CGP,C2,34,35
Cohort,0.019296188714071138,0.012137606168788652,1.589785370008996,0.11235072999030388,LGP Offspring,Genes up-regulated in HEL cells (erythroleukemia) upon expression of ELF4 [GeneID=2000].,CGP,C2,3,12
Cohort,-0.044819224224201766,0.03578399848983022,-1.2524934639973044,0.21074120193786214,LGP Proband,Genes up-regulated in HEL cells (erythroleukemia) upon expression of ELF4 [GeneID=2000].,CGP,C2,3,18
Cohort,0.021490657041950294,0.013706274628582732,1.567942976797955,0.11729185902306853,LonGen OPEL,Genes up-regulated in HEL cells (erythroleukemia) upon expression of ELF4 [GeneID=2000].,CGP,C2,8,19
Cohort,0.007667992939631296,0.01888812487301086,0.4059689879850408,0.6848938568751068,LGP Offspring,Down-regulated genes whose expression is associated with amplification of the 12p11-12 chromosome in pancreatic cancer cell lines.,CGP,C2,10,27
Cohort,0.061520432375774405,0.05523304859806705,1.1138337270401437,0.265671423166696,LGP Proband,Down-regulated genes whose expression is associated with amplification of the 12p11-12 chromosome in pancreatic cancer cell lines.,CGP,C2,10,44
Cohort,-0.029655932891410147,0.017109015536795023,-1.7333512163590856,0.08342050498396704,LonGen OPEL,Down-regulated genes whose expression is associated with amplification of the 12p11-12 chromosome in pancreatic cancer cell lines.,CGP,C2,26,18
Cohort,-0.07127664178305167,0.02939311623853581,-2.424943350838198,0.015571777040861295,LGP Offspring,Up-regulated genes whose expression is associated with amplification of the 12p11-12 chromosome in pancreatic cancer cell lines.,CGP,C2,38,47
Cohort,-0.14203483727637783,0.07902066709604366,-1.797439106705404,0.07262757852741863,LGP Proband,Up-regulated genes whose expression is associated with amplification of the 12p11-12 chromosome in pancreatic cancer cell lines.,CGP,C2,38,75
Cohort,0.005359400336432637,0.02764204195836446,0.1938858331994857,0.8463147426434761,LonGen OPEL,Up-regulated genes whose expression is associated with amplification of the 12p11-12 chromosome in pancreatic cancer cell lines.,CGP,C2,53,61
Cohort,0.020624246155490716,0.03512167551260108,0.5872227293965824,0.5572502013878615,LGP Offspring,Down-regulated genes whose expression is associated with amplification of the 8q24 chromosome region in pancreatic cancer cell lines.,CGP,C2,33,78
Cohort,-0.21329786324262778,0.09392750503799376,-2.270877557711648,0.02340857922441709,LGP Proband,Down-regulated genes whose expression is associated with amplification of the 8q24 chromosome region in pancreatic cancer cell lines.,CGP,C2,33,111
Cohort,0.009624106756580231,0.03098513742057091,0.310603972025337,0.7561830183139215,LonGen OPEL,Down-regulated genes whose expression is associated with amplification of the 8q24 chromosome region in pancreatic cancer cell lines.,CGP,C2,60,80
Cohort,0.04741525398244641,0.03407643885803179,1.3914380601795389,0.16455034262236684,LGP Offspring,Up-regulated genes whose expression is associated with amplification of the 8q24 chromosome region in pancreatic cancer cell lines.,CGP,C2,33,88
Cohort,0.10809298769910142,0.09396453701653427,1.1503593922894662,0.2503256105076675,LGP Proband,Up-regulated genes whose expression is associated with amplification of the 8q24 chromosome region in pancreatic cancer cell lines.,CGP,C2,33,108
Cohort,0.054768405729412724,0.028824303057198235,1.9000773625204972,0.05778408092927243,LonGen OPEL,Up-regulated genes whose expression is associated with amplification of the 8q24 chromosome region in pancreatic cancer cell lines.,CGP,C2,55,81
Cohort,-0.008720392547451768,0.00788578926504531,-1.1058363664504625,0.26919074338873844,LGP Offspring,Genes from selected recurrently amplified regions in bone tissue tumors with supernumerary  ring chromosomes.,CGP,C2,3,3
Cohort,-0.005804555073003432,0.019343560586818322,-0.30007686780059245,0.7641933004559123,LGP Proband,Genes from selected recurrently amplified regions in bone tissue tumors with supernumerary  ring chromosomes.,CGP,C2,3,3
Cohort,-0.008748887504086355,0.005801634076560601,-1.5080040189768367,0.13195027187296365,LonGen OPEL,Genes from selected recurrently amplified regions in bone tissue tumors with supernumerary  ring chromosomes.,CGP,C2,4,1
Cohort,-0.06060993229861724,0.03864635634014245,-1.5683220370159696,0.11727394088297209,LGP Offspring,Genes amplified and up-regulated more than twofold in at least two out of 10 pancreatic cancer cell lines studied.,CGP,C2,56,90
Cohort,-0.08157766996543768,0.11418669242005296,-0.7144236183437377,0.47516517946487147,LGP Proband,Genes amplified and up-regulated more than twofold in at least two out of 10 pancreatic cancer cell lines studied.,CGP,C2,56,154
Cohort,0.0015180949184244047,0.034883882931231895,0.04351851889358449,0.965299116548159,LonGen OPEL,Genes amplified and up-regulated more than twofold in at least two out of 10 pancreatic cancer cell lines studied.,CGP,C2,83,102
Cohort,0.019864079938554564,0.01141612243150265,1.74000235699469,0.08231369628256481,LGP Offspring,Genes from selected recurrently amplified regions in soft tissue tumors with supernumerary  ring chromosomes.,CGP,C2,1,12
Cohort,0.008694182734718992,0.025964856038700152,0.334844249541013,0.7378267749396153,LGP Proband,Genes from selected recurrently amplified regions in soft tissue tumors with supernumerary  ring chromosomes.,CGP,C2,1,10
Cohort,-0.001026007975116236,0.010619648252601746,-0.09661412042200838,0.9230571615519639,LonGen OPEL,Genes from selected recurrently amplified regions in soft tissue tumors with supernumerary  ring chromosomes.,CGP,C2,9,8
Cohort,-0.04405119842355953,0.04481318781120875,-0.9829963136999008,0.32596093221442846,LGP Offspring,Genes down-regulated in  tumor-conditioned vs quiescent endothelial cells and up-regulated upon treatment with decitabine and TSA [PubChem=451668;5562].,CGP,C2,71,125
Cohort,-0.016085504498333535,0.12821892517200018,-0.12545343424736655,0.9001948217572302,LGP Proband,Genes down-regulated in  tumor-conditioned vs quiescent endothelial cells and up-regulated upon treatment with decitabine and TSA [PubChem=451668;5562].,CGP,C2,71,195
Cohort,-0.029333010027047766,0.036991272675247266,-0.7929710957654066,0.42803094817523935,LonGen OPEL,Genes down-regulated in  tumor-conditioned vs quiescent endothelial cells and up-regulated upon treatment with decitabine and TSA [PubChem=451668;5562].,CGP,C2,99,108
Cohort,-0.06723851017673087,0.1035182586008561,-0.6495328561890511,0.5162146507730785,LGP Offspring,Genes down-regulated in at least one of three multiple myeloma (MM) cell lines by TSA [PubChem=5562].,CGP,C2,332,665
Cohort,-0.3566854584379098,0.2699263060438396,-1.321417922045654,0.18672443989366633,LGP Proband,Genes down-regulated in at least one of three multiple myeloma (MM) cell lines by TSA [PubChem=5562].,CGP,C2,332,839
Cohort,-0.02540424885871378,0.08412941636917876,-0.3019663032872383,0.7627566275356175,LonGen OPEL,Genes down-regulated in at least one of three multiple myeloma (MM) cell lines by TSA [PubChem=5562].,CGP,C2,491,565
Cohort,-0.06912742363503355,0.09350741761189395,-0.7392720855788095,0.45999841647819295,LGP Offspring,Genes down-regulated in multiple myeloma (MM) cell lines treated with both decitabine [PubChem=451668] TSA [PubChem=5562].,CGP,C2,279,560
Cohort,-0.37618451542776626,0.2434311587326626,-1.5453425000572507,0.12264278812962917,LGP Proband,Genes down-regulated in multiple myeloma (MM) cell lines treated with both decitabine [PubChem=451668] TSA [PubChem=5562].,CGP,C2,279,706
Cohort,-0.05001129455615155,0.07997651222766097,-0.6253247755264634,0.5319371490548507,LonGen OPEL,Genes down-regulated in multiple myeloma (MM) cell lines treated with both decitabine [PubChem=451668] TSA [PubChem=5562].,CGP,C2,417,479
Cohort,0.11634800918149327,0.12166661008927541,0.9562854516627075,0.3392698908737345,LGP Offspring,Genes up-regulated in multiple myeloma (MM) cell lines treated with both decitabine [PubChem=451668] TSA [PubChem=5562].,CGP,C2,432,999
Cohort,-0.17526476645171585,0.34002240404717143,-0.5154506419741721,0.606374752722319,LGP Proband,Genes up-regulated in multiple myeloma (MM) cell lines treated with both decitabine [PubChem=451668] TSA [PubChem=5562].,CGP,C2,432,1294
Cohort,0.04778183720252125,0.1102376779553339,0.4334437924380219,0.6648098257719954,LonGen OPEL,Genes up-regulated in multiple myeloma (MM) cell lines treated with both decitabine [PubChem=451668] TSA [PubChem=5562].,CGP,C2,748,914
Cohort,-0.11264675506318673,0.0998226697891386,-1.1284686664976724,0.25952236620458374,LGP Offspring,Genes up-regulated in at least one of three multiple myeloma (MM) cell lines by TSA [PubChem=5562].,CGP,C2,324,636
Cohort,-0.19602631953678612,0.27846117716233587,-0.7039628343684969,0.4816524175345701,LGP Proband,Genes up-regulated in at least one of three multiple myeloma (MM) cell lines by TSA [PubChem=5562].,CGP,C2,324,941
Cohort,-0.09789560345922864,0.08841365096499991,-1.1072453449296231,0.2685223468526139,LonGen OPEL,Genes up-regulated in at least one of three multiple myeloma (MM) cell lines by TSA [PubChem=5562].,CGP,C2,548,615
Cohort,-0.0882901010199716,0.058915118658186924,-1.498598373911663,0.13444466778552414,LGP Offspring,Genes down-regulated in at least one of three multiple myeloma (MM) cell lines treated with the DNA hypomethylating agent decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,123,231
Cohort,0.017162846456533994,0.163709942133329,0.10483692213730178,0.9165304189553607,LGP Proband,Genes down-regulated in at least one of three multiple myeloma (MM) cell lines treated with the DNA hypomethylating agent decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,123,310
Cohort,-0.0271636748222332,0.05158504845197562,-0.5265803878719219,0.598631711361608,LonGen OPEL,Genes down-regulated in at least one of three multiple myeloma (MM) cell lines treated with the DNA hypomethylating agent decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,175,202
Cohort,-0.020997316307471498,0.08221521282528112,-0.2553945381385042,0.7984960741624327,LGP Offspring,Genes up-regulated in at least one of three multiple myeloma (MM) cell lines treated with the DNA hypomethylating agent decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,208,445
Cohort,-0.16195271378328685,0.22871128484757725,-0.70810985077198485,0.47907489236862877,LGP Proband,Genes up-regulated in at least one of three multiple myeloma (MM) cell lines treated with the DNA hypomethylating agent decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,208,633
Cohort,-0.06515840059477725,0.07137242802185034,-0.9129351824044616,0.36155305087302625,LonGen OPEL,Genes up-regulated in at least one of three multiple myeloma (MM) cell lines treated with the DNA hypomethylating agent decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,368,431
Cohort,0.026789472502134874,0.03334236636658099,0.8034664428912858,0.4219876062663668,LGP Offspring,Genes down-regulated in ALAB cells (breast cancer) upon reintroduction of SMARCA4 [GeneID=6597] expressed off adenoviral vector.,CGP,C2,35,79
Cohort,-0.02632210926969848,0.09231880590275668,-0.28512185585919164,0.7756215752423377,LGP Proband,Genes down-regulated in ALAB cells (breast cancer) upon reintroduction of SMARCA4 [GeneID=6597] expressed off adenoviral vector.,CGP,C2,35,108
Cohort,-0.012463481816406335,0.028664769608171676,-0.4348013951192993,0.6638244414132575,LonGen OPEL,Genes down-regulated in ALAB cells (breast cancer) upon reintroduction of SMARCA4 [GeneID=6597] expressed off adenoviral vector.,CGP,C2,63,65
Cohort,0.005345363104143603,0.044512837154666966,0.12008587737443661,0.9044508001347757,LGP Offspring,Genes up-regulated in ALAB cells (breast cancer) upon reintroduction of SMARCA4 [GeneID=6597] expressed off adenoviral vector.,CGP,C2,62,135
Cohort,0.10702408315674562,0.13010814886225702,0.822577863820428,0.410983210243705,LGP Proband,Genes up-regulated in ALAB cells (breast cancer) upon reintroduction of SMARCA4 [GeneID=6597] expressed off adenoviral vector.,CGP,C2,62,194
Cohort,0.047256041257875386,0.041681480346842104,1.1337419128266548,0.25724415554491686,LonGen OPEL,Genes up-regulated in ALAB cells (breast cancer) upon reintroduction of SMARCA4 [GeneID=6597] expressed off adenoviral vector.,CGP,C2,104,144
Cohort,9.675248576977768e-4,0.02700244733967853,0.035831006187207894,0.9714276872488269,LGP Offspring,"Genes down-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment with 2 nM docetaxel [PubChem=148124].",CGP,C2,24,49
Cohort,-0.0041182453440166,0.06581038602078611,-0.06257743789431441,0.9501179900092643,LGP Proband,"Genes down-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment with 2 nM docetaxel [PubChem=148124].",CGP,C2,24,49
Cohort,-0.015675876335944073,0.018751077733880236,-0.8359986854313041,0.4034065173422511,LonGen OPEL,"Genes down-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment with 2 nM docetaxel [PubChem=148124].",CGP,C2,27,29
Cohort,0.040772953381260975,0.046917130137838436,0.8690419311981273,0.3851326340775202,LGP Offspring,"Genes up-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment with 2 nM docetaxel [PubChem=148124].",CGP,C2,61,165
Cohort,0.15031886050762522,0.12101434185783405,1.2421574021715351,0.2145276664861215,LGP Proband,"Genes up-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment with 2 nM docetaxel [PubChem=148124].",CGP,C2,61,194
Cohort,-0.12074239139632073,0.037527415355090715,-3.2174449067124904,0.0013457000963969692,LonGen OPEL,"Genes up-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment with 2 nM docetaxel [PubChem=148124].",CGP,C2,121,101
Cohort,0.00609483596761609,0.01812088719455962,0.33634313277144207,0.7367165049484203,LGP Offspring,"Genes down-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment wiht 4 nM docetaxel [PubChem=148124].",CGP,C2,9,20
Cohort,-0.13535359027347435,0.044683454095100425,-3.029165784395257,0.0025279253484768722,LGP Proband,"Genes down-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment wiht 4 nM docetaxel [PubChem=148124].",CGP,C2,9,18
Cohort,-0.0031029428422270884,0.01609511157105421,-0.19278790510576432,0.8471742522895962,LonGen OPEL,"Genes down-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment wiht 4 nM docetaxel [PubChem=148124].",CGP,C2,15,19
Cohort,0.007833487576356192,0.02374425725695232,0.3299108281882579,0.7415695476205588,LGP Offspring,"Genes up-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment wiht 4 nM docetaxel [PubChem=148124].",CGP,C2,17,40
Cohort,-0.041470271143214596,0.06168839610011947,-0.6722540018046325,0.5016081998483586,LGP Proband,"Genes up-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment wiht 4 nM docetaxel [PubChem=148124].",CGP,C2,17,48
Cohort,0.00789020196073797,0.019754896816312827,0.39940486827663646,0.6897020450718843,LonGen OPEL,"Genes up-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment wiht 4 nM docetaxel [PubChem=148124].",CGP,C2,26,34
Cohort,-0.05210469163081245,0.026517255549674674,-1.9649353053601242,0.04983085206962636,LGP Offspring,"Genes down-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,31,44
Cohort,-0.03786325940283961,0.07302735966367171,-0.5184804650917034,0.6042606143014675,LGP Proband,"Genes down-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,31,56
Cohort,0.00968464927245195,0.024541644870146154,0.39462103390767034,0.6932282962958412,LonGen OPEL,"Genes down-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,42,57
Cohort,0.013769866465490017,0.02501114241397285,0.5505492806996802,0.5821245661141712,LGP Offspring,"Genes up-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,16,39
Cohort,0.026878928559487456,0.07122538229828704,0.37737850878666174,0.7059883458420639,LGP Proband,"Genes up-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,16,60
Cohort,-0.05182064904427525,0.02263994330708541,-2.288903657636697,0.02234606195411041,LonGen OPEL,"Genes up-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,41,27
Cohort,0.002598825269152893,0.023527800826294843,0.11045763640809246,0.9120792297271487,LGP Offspring,"Genes down-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,18,39
Cohort,-0.02846069880480346,0.06484462649338983,-0.4389060488721406,0.6608432943656513,LGP Proband,"Genes down-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,18,55
Cohort,0.005887464887012983,0.019582736600071423,0.3006456659888644,0.763763210962056,LonGen OPEL,"Genes down-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,27,32
Cohort,0.0088982728941193,0.04947214015842959,0.17986432092129975,0.8573129873343099,LGP Offspring,"Genes up-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,77,159
Cohort,-0.21333413769725296,0.13113469025783886,-1.6268322079976885,0.10415047394043428,LGP Proband,"Genes up-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,77,210
Cohort,0.03569878514414669,0.04112873123115182,0.8679768151249857,0.38566862296943494,LonGen OPEL,"Genes up-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].",CGP,C2,113,142
Cohort,0.007456918587273316,0.04963432758244314,0.15023712318631285,0.8806223529675251,LGP Offspring,Genes down-regulated in hematopoietic precursor cells conditionally expressing HOXA9 and MEIS1 [GeneID=3205;4211].,CGP,C2,77,168
Cohort,-0.07995757399709641,0.13402198499348428,-0.5966004308993311,0.5509360873693321,LGP Proband,Genes down-regulated in hematopoietic precursor cells conditionally expressing HOXA9 and MEIS1 [GeneID=3205;4211].,CGP,C2,77,224
Cohort,-0.06594646345503392,0.04555310970339332,-1.4476830206417604,0.14809944768791242,LonGen OPEL,Genes down-regulated in hematopoietic precursor cells conditionally expressing HOXA9 and MEIS1 [GeneID=3205;4211].,CGP,C2,159,156
Cohort,0.06446143779099289,0.048056783377650104,1.3413598093827508,0.18025411751060713,LGP Offspring,Genes up-regulated in hematopoietic precursor cells conditionally expressing HOXA9 and MEIS1 [GeneID=3205;4211].,CGP,C2,57,154
Cohort,0.17742222230027166,0.13249034574290353,1.3391332123516235,0.18089215901267658,LGP Proband,Genes up-regulated in hematopoietic precursor cells conditionally expressing HOXA9 and MEIS1 [GeneID=3205;4211].,CGP,C2,57,214
Cohort,0.04667270758616129,0.040420207933179735,1.1546874687858562,0.24856495697347675,LonGen OPEL,Genes up-regulated in hematopoietic precursor cells conditionally expressing HOXA9 and MEIS1 [GeneID=3205;4211].,CGP,C2,104,142
Cohort,-9.877039741510094e-4,0.00557883468085696,-0.17704485446399518,0.8595261885300901,LGP Offspring,Genes in the tumor suppressor cluster of the 3p21.3 region.,CGP,C2,1,2
Cohort,-0.015195378566387542,0.020878386433321922,-0.7278042589601514,0.4669376896955071,LGP Proband,Genes in the tumor suppressor cluster of the 3p21.3 region.,CGP,C2,1,6
Cohort,6.139033490812738e-4,0.008928176988445285,0.06876021273724507,0.9451977573463706,LonGen OPEL,Genes in the tumor suppressor cluster of the 3p21.3 region.,CGP,C2,6,6
Cohort,-0.02092030675363346,0.033152916972500744,-0.6310246175618927,0.5282377165196241,LGP Offspring,Genes changed in Rat1a cells (fibroblasts) by overexpression of  HMGA1 isoform a [GeneID=3159] off a plasmid vector.,CGP,C2,36,65
Cohort,-0.18946895710861195,0.1015656371030631,-1.8654828789814955,0.06246467137261048,LGP Proband,Genes changed in Rat1a cells (fibroblasts) by overexpression of  HMGA1 isoform a [GeneID=3159] off a plasmid vector.,CGP,C2,36,123
Cohort,-0.01579069175593198,0.03486334843949835,-0.4529310138793769,0.6507218448575292,LonGen OPEL,Genes changed in Rat1a cells (fibroblasts) by overexpression of  HMGA1 isoform a [GeneID=3159] off a plasmid vector.,CGP,C2,79,93
Cohort,-0.027105973163334757,0.038562016465549,-0.7029189769562756,0.48234823731054,LGP Offspring,Genes changed in Rat1a cells (fibroblasts) by overexpression of  HMGA1 isoform b [GeneID=3159] off a plasmid vector.,CGP,C2,54,101
Cohort,-0.14041264724490704,0.11384738339934093,-1.2333410136654919,0.21779605304287966,LGP Proband,Genes changed in Rat1a cells (fibroblasts) by overexpression of  HMGA1 isoform b [GeneID=3159] off a plasmid vector.,CGP,C2,54,163
Cohort,-0.052068495938711164,0.04098747385031167,-1.2703514280696573,0.20433065807931203,LonGen OPEL,Genes changed in Rat1a cells (fibroblasts) by overexpression of  HMGA1 isoform b [GeneID=3159] off a plasmid vector.,CGP,C2,124,132
Cohort,-0.04040827061491707,0.04841568355837909,-0.8346111764836126,0.40423151063889795,LGP Offspring,Genes up-regulated in primary fibroblast cells by expression of p50 (NFKB1) and p65  (RELA) [GeneID=4790;5970] components of NFKB.,CGP,C2,81,157
Cohort,-0.026595454143743473,0.13486840079872445,-0.19719559204556836,0.8437225271341958,LGP Proband,Genes up-regulated in primary fibroblast cells by expression of p50 (NFKB1) and p65  (RELA) [GeneID=4790;5970] components of NFKB.,CGP,C2,81,236
Cohort,0.033116303535827354,0.04786690216949147,0.69184137754655906,0.4892386914927169,LonGen OPEL,Genes up-regulated in primary fibroblast cells by expression of p50 (NFKB1) and p65  (RELA) [GeneID=4790;5970] components of NFKB.,CGP,C2,144,187
Cohort,-0.01861029924089635,0.025545612707066477,-0.7285125416368788,0.4665521823320298,LGP Offspring,Genes down-regulated in primary keratinocytes by expression of p50 (NFKB1) and p65 (RELA) [GeneID=4790;5970] components of NFKB.,CGP,C2,23,44
Cohort,-0.010093946790707619,0.07361480502721819,-0.13711843408368063,0.8909702759097264,LGP Proband,Genes down-regulated in primary keratinocytes by expression of p50 (NFKB1) and p65 (RELA) [GeneID=4790;5970] components of NFKB.,CGP,C2,23,67
Cohort,-0.01760805034387742,0.027395508189256387,-0.6427349411529703,0.5205811896576265,LonGen OPEL,Genes down-regulated in primary keratinocytes by expression of p50 (NFKB1) and p65 (RELA) [GeneID=4790;5970] components of NFKB.,CGP,C2,53,52
Cohort,0.05797149697662901,0.05714845720562264,1.0144017846019018,0.3107539996216149,LGP Offspring,Genes up-regulated in primary keratinocytes by expression of p50 (NFKB1) and p65 (RELA) [GeneID=4790;5970] components of NFKB.,CGP,C2,90,219
Cohort,0.05925005723283417,0.14993040211361808,0.39518374123971306,0.6928083437546233,LGP Proband,Genes up-regulated in primary keratinocytes by expression of p50 (NFKB1) and p65 (RELA) [GeneID=4790;5970] components of NFKB.,CGP,C2,90,291
Cohort,-0.022963152607480608,0.05002476650436583,-0.4590356779671632,0.6463338647302694,LonGen OPEL,Genes up-regulated in primary keratinocytes by expression of p50 (NFKB1) and p65 (RELA) [GeneID=4790;5970] components of NFKB.,CGP,C2,182,206
Cohort,-0.02804465702710405,0.0501388800983638,-0.5593395179965186,0.5761152917977614,LGP Offspring,"Down-regulated genes in the cancer gene signature, representing a gene signature of cellular transformation.",CGP,C2,87,171
Cohort,0.045503962852258474,0.1395273648719149,0.32612930727983563,0.7444083393159595,LGP Proband,"Down-regulated genes in the cancer gene signature, representing a gene signature of cellular transformation.",CGP,C2,87,253
Cohort,-0.012513076427369135,0.04448418305312614,-0.2812927105444454,0.7785590051569216,LonGen OPEL,"Down-regulated genes in the cancer gene signature, representing a gene signature of cellular transformation.",CGP,C2,141,159
Cohort,0.10207849171259284,0.07784910163322012,1.3112353202677607,0.19022347763543007,LGP Offspring,"Up-regulated genes in the cancer gene signature, representing a gene signature of cellular transformation.",CGP,C2,171,405
Cohort,0.12967301862948505,0.2125706491542113,0.6100231576910347,0.5420126396284048,LGP Proband,"Up-regulated genes in the cancer gene signature, representing a gene signature of cellular transformation.",CGP,C2,171,559
Cohort,0.06386732605763502,0.07054251386406318,0.9053735479388872,0.36554147502451473,LonGen OPEL,"Up-regulated genes in the cancer gene signature, representing a gene signature of cellular transformation.",CGP,C2,296,384
Cohort,0.002272214889777138,0.024296136392344927,0.09352165517530817,0.9255168574341618,LGP Offspring,Gene expression signature of vascular invasion of hepatocellular carcinoma (HCC).,CGP,C2,19,40
Cohort,0.007032647217424464,0.06100139505495836,0.11528666206876906,0.9082456607886126,LGP Proband,Gene expression signature of vascular invasion of hepatocellular carcinoma (HCC).,CGP,C2,19,44
Cohort,0.024339710545176845,0.021854257962856064,1.1137285277104858,0.26573185172452013,LonGen OPEL,Gene expression signature of vascular invasion of hepatocellular carcinoma (HCC).,CGP,C2,24,37
Cohort,-0.021902627161631865,0.04214559859201682,-0.5196895498781845,0.6034500933087125,LGP Offspring,"Genes down-regulated in the common lymphoid progenitor (CLP, defined as CD34+CD38-CD7+ [GeneID=947;952;924]) compared to a multipotent cord blood cell (defined as CD34+CD38+CD7-).",CGP,C2,59,118
Cohort,0.09530208188740003,0.13082636460806807,0.7284623567497858,0.46653509117817127,LGP Proband,"Genes down-regulated in the common lymphoid progenitor (CLP, defined as CD34+CD38-CD7+ [GeneID=947;952;924]) compared to a multipotent cord blood cell (defined as CD34+CD38+CD7-).",CGP,C2,59,205
Cohort,-0.032498294024044624,0.03844544737423953,-0.8453092952124207,0.39819218216602714,LonGen OPEL,"Genes down-regulated in the common lymphoid progenitor (CLP, defined as CD34+CD38-CD7+ [GeneID=947;952;924]) compared to a multipotent cord blood cell (defined as CD34+CD38+CD7-).",CGP,C2,106,112
Cohort,0.041140496971562,0.06057966656185679,0.679113955332755,0.4972981045309067,LGP Offspring,"Genes up-regulated in the common lymphoid progenitor (CLP, defined as CD34+CD38-CD7+ [GeneID=947;952;924]) compared to a multipotent cord blood cell (defined as CD34+CD38+CD7-).",CGP,C2,111,240
Cohort,-0.18227746358104996,0.16803781676514096,-1.0847407273555043,0.2783499666057836,LGP Proband,"Genes up-regulated in the common lymphoid progenitor (CLP, defined as CD34+CD38-CD7+ [GeneID=947;952;924]) compared to a multipotent cord blood cell (defined as CD34+CD38+CD7-).",CGP,C2,111,328
Cohort,0.076019266037041,0.052095199876538156,1.4592374387122258,0.14489426436609215,LonGen OPEL,"Genes up-regulated in the common lymphoid progenitor (CLP, defined as CD34+CD38-CD7+ [GeneID=947;952;924]) compared to a multipotent cord blood cell (defined as CD34+CD38+CD7-).",CGP,C2,176,238
Cohort,-0.019288695830076686,0.02541364689054645,-0.7589896842885557,0.4481232868037057,LGP Offspring,Genes directly down-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,22,37
Cohort,0.1370416964422885,0.07019681092577847,1.9522496055723595,0.05124284262707994,LGP Proband,Genes directly down-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,22,61
Cohort,-0.003715714736908149,0.025204031642294407,-0.14742541152316593,0.8828335817818133,LonGen OPEL,Genes directly down-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,43,46
Cohort,0.04230176632588484,0.03790195625503951,1.1160839836666827,0.26478275060161693,LGP Offspring,Genes directly up-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,36,88
Cohort,0.027492774962041753,0.09854997832881578,0.2789729173791501,0.7803347689167407,LGP Proband,Genes directly up-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,36,113
Cohort,0.01669247559860222,0.02908786048490411,0.5738639872556185,0.5662219522788106,LonGen OPEL,Genes directly up-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,56,77
Cohort,0.03115090167074941,0.025312924601292454,1.230632262427664,0.21888846205446827,LGP Offspring,Genes temporally down-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,17,48
Cohort,-0.20971371473549336,0.06749721210774513,-3.1069981735057355,0.0019540040938561512,LGP Proband,Genes temporally down-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,17,55
Cohort,-0.017419647589451706,0.020626786744622694,-0.844515813593357,0.3986349732563398,LonGen OPEL,Genes temporally down-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,31,29
Cohort,-1.8646407007225844e-4,0.006402767497819715,-0.02912241778820699,0.9767755519341899,LGP Offspring,Genes temporally up-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,1,3
Cohort,0.025073049160286156,0.019248169067278362,1.3026199568721586,0.19306411421698863,LGP Proband,Genes temporally up-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,1,5
Cohort,-0.006869891439653433,0.005789146584205306,-1.186684658909269,0.23570607520921363,LonGen OPEL,Genes temporally up-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.,CGP,C2,3,2
Cohort,-0.0835962453932572,0.06001641132656696,-1.3928897704060548,0.16411102117141046,LGP Offspring,Genes down-regulated in SH-SY5Y cells (neuroblastoma) after knockdown of NF1 [GeneID=4763] by RNAi.,CGP,C2,126,225
Cohort,-0.19575735878887637,0.16351529501137185,-1.197180721077268,0.23157629123102086,LGP Proband,Genes down-regulated in SH-SY5Y cells (neuroblastoma) after knockdown of NF1 [GeneID=4763] by RNAi.,CGP,C2,126,304
Cohort,-0.12410732203171894,0.0483676165339436,-2.565917672305032,0.010472279859408417,LonGen OPEL,Genes down-regulated in SH-SY5Y cells (neuroblastoma) after knockdown of NF1 [GeneID=4763] by RNAi.,CGP,C2,200,185
Cohort,0.04525817173449479,0.06493378193945233,0.6969896159243564,0.48604890406622125,LGP Offspring,Genes up-regulated in SH-SY5Y cells (neuroblastoma) after knockdown of NF1 [GeneID=4763] by RNAi.,CGP,C2,115,258
Cohort,-0.005265256079817743,0.16625624308381565,-0.03166952399594006,0.9747431762032075,LGP Proband,Genes up-regulated in SH-SY5Y cells (neuroblastoma) after knockdown of NF1 [GeneID=4763] by RNAi.,CGP,C2,115,326
Cohort,0.062109265115998374,0.05656754251238974,1.0979664726003406,0.27255113711076445,LonGen OPEL,Genes up-regulated in SH-SY5Y cells (neuroblastoma) after knockdown of NF1 [GeneID=4763] by RNAi.,CGP,C2,205,259
Cohort,-0.010690067401251292,0.011943347234419003,-0.8950646072186581,0.37107113473967657,LGP Offspring,Genes down-regulated in MCF7 cells (breast cancer) upon knockdown of CLOCK [GeneID=9575] by RNAi that also belong to the highest confidence network (according to Ingenuity Pathway Analysis).,CGP,C2,6,6
Cohort,-0.05388992459640466,0.03366264936807603,-1.6008818559453957,0.1097817831814294,LGP Proband,Genes down-regulated in MCF7 cells (breast cancer) upon knockdown of CLOCK [GeneID=9575] by RNAi that also belong to the highest confidence network (according to Ingenuity Pathway Analysis).,CGP,C2,6,11
Cohort,-0.002781921079900022,0.007772012686863949,-0.3579408824952064,0.7204824487826813,LonGen OPEL,Genes down-regulated in MCF7 cells (breast cancer) upon knockdown of CLOCK [GeneID=9575] by RNAi that also belong to the highest confidence network (according to Ingenuity Pathway Analysis).,CGP,C2,5,4
Cohort,6.00855900823338e-4,0.014480344010848563,0.04149458744717538,0.9669138600280061,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) upon knockdown of CLOCK [GeneID=9575] by RNAi that also belong to the highest confidence network (according to Ingenuity Pathway Analysis).,CGP,C2,7,14
Cohort,-0.010416561477875869,0.03553953616838288,-0.2930978454114654,0.7695202749441273,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) upon knockdown of CLOCK [GeneID=9575] by RNAi that also belong to the highest confidence network (according to Ingenuity Pathway Analysis).,CGP,C2,7,15
Cohort,0.019786661707718388,0.012014789208301124,1.6468588307856127,0.09998176200350596,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) upon knockdown of CLOCK [GeneID=9575] by RNAi that also belong to the highest confidence network (according to Ingenuity Pathway Analysis).,CGP,C2,7,15
Cohort,0.012906027188633202,0.04268073604727382,0.3023853003457647,0.7624513737977582,LGP Offspring,Genes down-regulated during differentiation of immature to mature B lymphocyte.,CGP,C2,57,121
Cohort,-0.11860025046968331,0.12422225634259167,-0.9547423622913155,0.3399846440067559,LGP Proband,Genes down-regulated during differentiation of immature to mature B lymphocyte.,CGP,C2,57,190
Cohort,-0.04507132254743882,0.03914269425076778,-1.151461937154588,0.24988798357747136,LonGen OPEL,Genes down-regulated during differentiation of immature to mature B lymphocyte.,CGP,C2,110,115
Cohort,-0.004911890526501212,0.02711440135016548,-0.18115430479423933,0.8563007602255817,LGP Offspring,Genes up-regulated during differentiation of immature to mature B lymphocyte.,CGP,C2,25,53
Cohort,0.05518640607304446,0.07908035250743509,0.6978523024142548,0.48546407489633847,LGP Proband,Genes up-regulated during differentiation of immature to mature B lymphocyte.,CGP,C2,25,83
Cohort,0.015343085933377812,0.02590381733569884,0.5923098412307377,0.5538113334900712,LonGen OPEL,Genes up-regulated during differentiation of immature to mature B lymphocyte.,CGP,C2,46,60
Cohort,-0.006618957864907169,0.05423458967292472,-0.1220431076334209,0.9029011488293732,LGP Offspring,Genes down-regulated during differentiation from large pre-BII to small pre-BII lymphocyte.,CGP,C2,93,202
Cohort,-0.07137456367623624,0.150451163486769,-0.47440353415753456,0.6353363583152543,LGP Proband,Genes down-regulated during differentiation from large pre-BII to small pre-BII lymphocyte.,CGP,C2,93,284
Cohort,-0.07703356154848844,0.04805874752658853,-1.6029040604079325,0.10935254391073569,LonGen OPEL,Genes down-regulated during differentiation from large pre-BII to small pre-BII lymphocyte.,CGP,C2,180,177
Cohort,-0.11926484230871616,0.06563554414547006,-1.817077070990466,0.06964796119251158,LGP Offspring,Genes up-regulated during differentiation from large pre-BII to small pre-BII lymphocyte.,CGP,C2,172,306
Cohort,-0.17243345145389685,0.1781148239711045,-0.9681027530974663,0.33327370979724946,LGP Proband,Genes up-regulated during differentiation from large pre-BII to small pre-BII lymphocyte.,CGP,C2,172,395
Cohort,-0.031301882108986774,0.058300566682525826,-0.5369052805170889,0.5914830762802947,LonGen OPEL,Genes up-regulated during differentiation from large pre-BII to small pre-BII lymphocyte.,CGP,C2,239,278
Cohort,0.002269933111810152,0.05080420830566162,0.044680021350853145,0.9643755531232738,LGP Offspring,Genes down-regulated during differentiation from pre-BI to large pre-BII lymphocyte.,CGP,C2,86,183
Cohort,0.05444539265510061,0.14444310298495705,0.3769331420467393,0.7063191757901968,LGP Proband,Genes down-regulated during differentiation from pre-BI to large pre-BII lymphocyte.,CGP,C2,86,257
Cohort,0.11573170987118639,0.04465443311341866,2.5917182640576173,0.009724802227090537,LonGen OPEL,Genes down-regulated during differentiation from pre-BI to large pre-BII lymphocyte.,CGP,C2,107,171
Cohort,0.035060303556001794,0.02849409914406397,1.2304408494804344,0.2189600473579935,LGP Offspring,Genes up-regulated during differentiation from pre-BI to large pre-BII lymphocyte.,CGP,C2,22,60
Cohort,0.0037553116458942668,0.07700613318386995,0.04876639678722202,0.9611171375210275,LGP Proband,Genes up-regulated during differentiation from pre-BI to large pre-BII lymphocyte.,CGP,C2,22,77
Cohort,0.006517754726935289,0.024708021434437448,0.2637910422827705,0.7920092121760165,LonGen OPEL,Genes up-regulated during differentiation from pre-BI to large pre-BII lymphocyte.,CGP,C2,43,50
Cohort,0.004500244795073059,0.033348415582307354,0.13494628504811532,0.8926945135078808,LGP Offspring,Genes down-regulated during differentiation from small pre-BII to immature B lymphocyte.,CGP,C2,36,77
Cohort,-0.1766650087815438,0.10562472974357888,-1.6725724099879515,0.0947865548588811,LGP Proband,Genes down-regulated during differentiation from small pre-BII to immature B lymphocyte.,CGP,C2,36,136
Cohort,-0.07087686912625628,0.031184219868101697,-2.2728440674815835,0.02330135125542527,LonGen OPEL,Genes down-regulated during differentiation from small pre-BII to immature B lymphocyte.,CGP,C2,73,55
Cohort,-0.020531595303294466,0.04992415334392584,-0.41125575353983446,0.6810153537711916,LGP Offspring,Genes up-regulated during differentiation from small pre-BII to immature B lymphocyte.,CGP,C2,80,160
Cohort,0.0257902569481614,0.13722834365046563,0.1879368085492001,0.8509719033293696,LGP Proband,Genes up-regulated during differentiation from small pre-BII to immature B lymphocyte.,CGP,C2,80,218
Cohort,0.01642627820358892,0.042993470852863355,0.3820644827630829,0.7025155129489544,LonGen OPEL,Genes up-regulated during differentiation from small pre-BII to immature B lymphocyte.,CGP,C2,124,150
Cohort,-0.054891383747805035,0.02839708804837298,-1.9329933989816275,0.05365432544311783,LGP Offspring,Genes down-regulated in lymph nodes from patients with mantle cell lymphoma (MCL) compared to the non-malignant hyperplastic lymph nodes.,CGP,C2,31,44
Cohort,-0.06366977596620324,0.06866492264038788,-0.9272532978687642,0.3540632937599544,LGP Proband,Genes down-regulated in lymph nodes from patients with mantle cell lymphoma (MCL) compared to the non-malignant hyperplastic lymph nodes.,CGP,C2,31,45
Cohort,-0.015491962765267594,0.0195912629561128,-0.7907587581245671,0.42932031193485176,LonGen OPEL,Genes down-regulated in lymph nodes from patients with mantle cell lymphoma (MCL) compared to the non-malignant hyperplastic lymph nodes.,CGP,C2,30,26
Cohort,0.003535801535440899,0.02426474687796455,0.14571763526830164,0.8841877378710583,LGP Offspring,Genes up-regulated in lymph nodes from patients with mantle cell lymphoma (MCL) compared to the non-malignant hyperplastic lymph nodes.,CGP,C2,18,42
Cohort,0.04347791060473984,0.060241990981898565,0.7217210104792856,0.4706683096201161,LGP Proband,Genes up-regulated in lymph nodes from patients with mantle cell lymphoma (MCL) compared to the non-malignant hyperplastic lymph nodes.,CGP,C2,18,42
Cohort,-0.024802733777549123,0.021374767719705187,-1.1603744238438543,0.24624429299059677,LonGen OPEL,Genes up-regulated in lymph nodes from patients with mantle cell lymphoma (MCL) compared to the non-malignant hyperplastic lymph nodes.,CGP,C2,37,35
Cohort,-0.05316464612593849,0.019624365053673,-2.709114204741514,0.00691717044562906,LGP Offspring,"Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,19,17
Cohort,-0.030549162823989714,0.0528789696935756,-0.577718571315152,0.5636100746346704,LGP Proband,"Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,19,27
Cohort,-0.0045622131180280455,0.016955457285355444,-0.26907048516871696,0.7879451687526923,LonGen OPEL,"Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,23,22
Cohort,-0.028316578832926577,0.021191561690844424,-1.3362195408732163,0.18192713377229355,LGP Offspring,"Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,19,24
Cohort,-0.051413612507960345,0.055402729297727944,-0.9279978289818441,0.35367718267209414,LGP Proband,"Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,19,31
Cohort,0.009566152221601959,0.01753986432807528,0.5453948812072533,0.5856347487390483,LonGen OPEL,"Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,18,26
Cohort,0.016437731011700176,0.023760433351541172,0.6918110780430684,0.48929351194318793,LGP Offspring,"Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with low risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,16,43
Cohort,0.09337490776054948,0.06909400422887009,1.3514183872054981,0.17692789467913714,LGP Proband,"Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with low risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,16,60
Cohort,-0.013151248186184522,0.019101797638570013,-0.6884822274333884,0.49134975698905414,LonGen OPEL,"Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with low risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,28,26
Cohort,-0.029027768661070357,0.018248844879372113,-1.590663346252802,0.11215287313492238,LGP Offspring,"Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with low risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,17,18
Cohort,-0.06936800506162977,0.04572228583247966,-1.517159603869869,0.12960533228039192,LGP Proband,"Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with low risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,17,19
Cohort,0.004311992813904514,0.015803338934127817,0.27285327688521743,0.7850367727808898,LonGen OPEL,"Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with low risk of myelodysplastic syndrome (MDS) compared with healthy controls.",CGP,C2,16,23
Cohort,-0.0316174604784387,0.018315425145556594,-1.7262749964670756,0.08475484997854461,LGP Offspring,"Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrom (MDS) compared to the low risk patients.",CGP,C2,17,18
Cohort,-0.018698378202288937,0.0530733540294515,-0.3523119754578318,0.72469331636146594,LGP Proband,"Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrom (MDS) compared to the low risk patients.",CGP,C2,17,29
Cohort,-0.006459973045254309,0.019894003522196474,-0.3247196090041242,0.7454786104556397,LonGen OPEL,"Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrom (MDS) compared to the low risk patients.",CGP,C2,30,33
Cohort,0.004009741012019946,0.025805431903677595,0.15538360400193527,0.8765652940078669,LGP Offspring,"Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrom (MDS) compared to the low risk patients.",CGP,C2,20,47
Cohort,0.044558541664856004,0.0754234956680847,0.5907779965668027,0.5548292386978626,LGP Proband,"Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrom (MDS) compared to the low risk patients.",CGP,C2,20,74
Cohort,-0.026114304431161233,0.019757784151290723,-1.321722326309312,0.18664035792011968,LonGen OPEL,"Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrom (MDS) compared to the low risk patients.",CGP,C2,31,25
Cohort,0.008985785678331805,0.025602072444138084,0.35097883962082194,0.72571357561673,LGP Offspring,Genes distinguishing asparaginase resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,20,45
Cohort,0.038274488937897116,0.06942941834688965,0.5512719226116312,0.581594937939123,LGP Proband,Genes distinguishing asparaginase resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,20,62
Cohort,0.012431419199459025,0.02344553587670761,0.5302254239285374,0.5961035185428245,LonGen OPEL,Genes distinguishing asparaginase resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,35,47
Cohort,0.011201377710390282,0.02806879114518131,0.39906876118935636,0.6899685730757219,LGP Offspring,Genes distinguishing asparaginase resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,23,55
Cohort,0.027698738401856073,0.0803717571688002,0.3446327339052946,0.7304573795802594,LGP Proband,Genes distinguishing asparaginase resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,23,76
Cohort,0.019864889750957144,0.026472127271564956,0.7504077608562657,0.4532309099382458,LonGen OPEL,Genes distinguishing asparaginase resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,45,62
Cohort,3.800151635239829e-4,0.02137947322504474,0.01777476739131339,0.9858237790422402,LGP Offspring,Genes distinguishing asparaginase resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,15,30
Cohort,-0.036809827524266404,0.059088083679155655,-0.6229653295940567,0.5334776120215126,LGP Proband,Genes distinguishing asparaginase resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,15,43
Cohort,0.035697871617994315,0.020139268034212194,1.7725505990263137,0.07668561850460746,LonGen OPEL,Genes distinguishing asparaginase resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,22,39
Cohort,-0.02190686544548785,0.01941921929828746,-1.1281022737829511,0.25967694259406987,LGP Offspring,Genes distinguishing asparaginase resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,16,22
Cohort,0.025702170807429082,0.0547135555672784,0.4697587378656915,0.6386501952041264,LGP Proband,Genes distinguishing asparaginase resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,16,36
Cohort,-0.005587774075044742,0.016450169968326114,-0.33967880488795493,0.734188029323283,LonGen OPEL,Genes distinguishing asparaginase resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,21,21
Cohort,0.0067318419898621555,0.007778237473939097,0.8654713889126067,0.38708714926171417,LGP Offspring,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,1,5
Cohort,0.01569531881516214,0.020789473555807517,0.7549647071643942,0.4504832962523786,LGP Proband,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,1,6
Cohort,0.002226853427332105,0.009327626883234925,0.23873740397298218,0.811370659793839,LonGen OPEL,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,5,8
Cohort,0.02026461973243223,0.017486606530181352,1.158865197627459,0.24692033959520102,LGP Offspring,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,6,25
Cohort,-0.021667102261955142,0.048012808421658316,-0.45127754393515607,0.6519068439250832,LGP Proband,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,6,33
Cohort,0.013535731413416869,0.016267829135412623,0.8320551747099195,0.4056273460699482,LonGen OPEL,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,15,24
Cohort,-0.008004521847418341,0.010087074952541282,-0.7935424179039857,0.4277403110435547,LGP Offspring,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,4,6
Cohort,0.014288755934225138,0.024839408888556496,0.575245409354647,0.5652804933966975,LGP Proband,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,4,6
Cohort,-0.0014814339582738918,0.010312641053889886,-0.1436522371458959,0.8858114471196148,LonGen OPEL,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,7,9
Cohort,0.03755532000282661,0.022422237808509608,1.6749139993767148,0.09441360036698537,LGP Offspring,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,10,41
Cohort,0.07046078063962452,0.058370236785403526,1.2071354258621825,0.2277222445693577,LGP Proband,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,10,48
Cohort,0.010873954534752617,0.01891817043979714,0.5747889083332108,0.5655964815431305,LonGen OPEL,Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,23,32
Cohort,0.029403077479875483,0.02175189825752804,1.3517476558488164,0.17690817006351867,LGP Offspring,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,10,37
Cohort,0.04904808473583923,0.06604507568260813,0.7426455981600946,0.45790539102440897,LGP Proband,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,10,65
Cohort,-0.036231275159979315,0.02062655829540985,-1.7565351737833101,0.07938156279467035,LonGen OPEL,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,34,28
Cohort,0.00284846539297161,0.02050353518425186,0.13892557392538968,0.8895503375400567,LGP Offspring,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,14,30
Cohort,-0.05013027190607576,0.055419059907968055,-0.9045673454101324,0.36595586155308324,LGP Proband,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,14,34
Cohort,0.027189021998375508,0.0188966883238985,1.4388247047494431,0.15059327238453502,LonGen OPEL,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,17,33
Cohort,0.014981165939982074,0.016259398012308746,0.9213850308997282,0.357178142261654,LGP Offspring,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,5,20
Cohort,0.07568637780347015,0.042445596511029665,1.783138511996238,0.0749273629965924,LGP Proband,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,5,26
Cohort,-0.01319599452250151,0.012440414015648101,-1.060735961512455,0.2891316477398009,LonGen OPEL,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,13,11
Cohort,-0.004584392870438517,0.012550740000246339,-0.3652687307958365,0.7150250725233214,LGP Offspring,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,6,10
Cohort,-0.03576541856339987,0.038230334954553996,-0.9355245933867888,0.3497888131560739,LGP Proband,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,6,18
Cohort,0.0018874607131493892,0.013808382742470749,0.13668948408737863,0.891310805293066,LonGen OPEL,Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,11,19
Cohort,-0.021203067423101376,0.021429020577338753,-0.9894557404795101,0.32279423514603367,LGP Offspring,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,17,29
Cohort,0.03672350324514525,0.05782713729210561,0.6350565662561102,0.5255657074314206,LGP Proband,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,17,38
Cohort,0.03773907345091616,0.02214178796413908,1.704427551742366,0.08869147685277144,LonGen OPEL,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.,CGP,C2,24,45
Cohort,-0.07316725706860343,0.03364424958626332,-2.1747329177606933,0.029996145254814484,LGP Offspring,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,47,64
Cohort,-0.07631752109331322,0.09298678135294833,-0.8207351623843836,0.4120316611675351,LGP Proband,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,47,92
Cohort,-0.0048039585684288705,0.024447031129212166,-0.19650478387490333,0.844265246553397,LonGen OPEL,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.,CGP,C2,47,52
Cohort,-0.01602640519600264,0.01818570226651601,-0.8812640260536366,0.37848815041733874,LGP Offspring,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,12,20
Cohort,-0.010877012389656314,0.04941831326008675,-0.22010084262510138,0.8258464820131677,LGP Proband,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,12,29
Cohort,0.01832706290470706,0.01986086766412963,0.9227725200448947,0.35640537635974046,LonGen OPEL,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.,CGP,C2,20,34
Cohort,-0.01954313040751028,0.032023894885800264,-0.6102671295044724,0.5418899649503177,LGP Offspring,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,36,61
Cohort,-0.09540025400981406,0.08532367514912335,-1.1180982751045299,0.2638469822150622,LGP Proband,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,36,86
Cohort,-0.037393517984321556,0.025444482850338804,-1.4696120256900267,0.1420619741564569,LonGen OPEL,Genes distinguishing vincristine [PubChem=5978] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.,CGP,C2,54,49
Cohort,-0.006516072441626867,0.026855902996584788,-0.24263091963265965,0.8083649224815386,LGP Offspring,Genes that have high expression in mammary tumors of adenomyoepithelial histology.,CGP,C2,23,41
Cohort,-0.06658165584538883,0.07384832057615454,-0.9016001356012949,0.3675296115401909,LGP Proband,Genes that have high expression in mammary tumors of adenomyoepithelial histology.,CGP,C2,23,67
Cohort,-0.022336422191961757,0.022895619126945835,-0.9755762474959255,0.3295708795601584,LonGen OPEL,Genes that have high expression in mammary tumors of adenomyoepithelial histology.,CGP,C2,40,36
Cohort,0.015182468838384868,0.07728593166025673,0.19644543983924376,0.8443205746935191,LGP Offspring,Genes that that have low expression in mammary tumors of epithelial-mesenchymal transition (EMT) histology.,CGP,C2,189,400
Cohort,-0.03544239688121712,0.20780815964390278,-0.17055344189540356,0.8646162754569904,LGP Proband,Genes that that have low expression in mammary tumors of epithelial-mesenchymal transition (EMT) histology.,CGP,C2,189,545
Cohort,0.05044890267571805,0.06910904966959103,0.7299898192337072,0.46561117689396614,LonGen OPEL,Genes that that have low expression in mammary tumors of epithelial-mesenchymal transition (EMT) histology.,CGP,C2,296,379
Cohort,-0.17503582282946034,0.06646004798816216,-2.633699916386423,0.008639211185407007,LGP Offspring,Genes that are highly expressed in mammary tumors of epithelial-mesenchymal transition (EMT) histology.,CGP,C2,158,257
Cohort,-0.01258893618614554,0.18559424719438672,-0.06783042242123058,0.9459368839554675,LGP Proband,Genes that are highly expressed in mammary tumors of epithelial-mesenchymal transition (EMT) histology.,CGP,C2,158,396
Cohort,0.04289281451042879,0.05506104504981557,0.7790047295982527,0.43620845168237343,LonGen OPEL,Genes that are highly expressed in mammary tumors of epithelial-mesenchymal transition (EMT) histology.,CGP,C2,210,260
Cohort,-0.03716733156696888,0.025235930282613794,-1.4727941926743704,0.14127197345694292,LGP Offspring,Genes that have low expression in mammary tumors of microacinar histology.,CGP,C2,27,38
Cohort,-0.05823667249603424,0.076438192454722,-0.7618792468245584,0.4463474709693238,LGP Proband,Genes that have low expression in mammary tumors of microacinar histology.,CGP,C2,27,68
Cohort,-0.06165672379069713,0.023901793604979543,-2.579585649917585,0.010070153291067717,LonGen OPEL,Genes that have low expression in mammary tumors of microacinar histology.,CGP,C2,50,37
Cohort,-0.043388121602552746,0.03726104410632823,-1.1644365487649855,0.24465791755643612,LGP Offspring,Genes that have high expression in mammary tumors of microacinar histology.,CGP,C2,53,89
Cohort,-0.2816736699586111,0.1126679267106182,-2.500034199458338,0.012609146557954412,LGP Proband,Genes that have high expression in mammary tumors of microacinar histology.,CGP,C2,53,136
Cohort,-0.018688737671518532,0.03477700601502943,-0.5373877689023,0.5911499794727797,LonGen OPEL,Genes that have high expression in mammary tumors of microacinar histology.,CGP,C2,95,96
Cohort,0.025720112020909493,0.02254856971985529,1.1406538126567505,0.25441795801762274,LGP Offspring,Genes that have high expression in paplillary mammary tumors.,CGP,C2,13,36
Cohort,0.0053653809635648714,0.06770305643012528,0.07924872592867878,0.9368537993552012,LGP Proband,Genes that have high expression in paplillary mammary tumors.,CGP,C2,13,57
Cohort,0.006333774491258872,0.022620665247162254,0.27999947932802016,0.7795506500364844,LonGen OPEL,Genes that have high expression in paplillary mammary tumors.,CGP,C2,31,38
Cohort,-0.07483791478507586,0.03130092867849209,-2.3909167537415428,0.017078953958880254,LGP Offspring,Genes that have low expression in mammary tumors of solid nodular histology.,CGP,C2,43,63
Cohort,0.005576161530112129,0.08544379877334027,0.06526116125646762,0.9479817047731289,LGP Proband,Genes that have low expression in mammary tumors of solid nodular histology.,CGP,C2,43,87
Cohort,0.02289650803923618,0.02931841081899218,0.7809600656937397,0.43505817267830527,LonGen OPEL,Genes that have low expression in mammary tumors of solid nodular histology.,CGP,C2,55,76
Cohort,-0.009767846872631,0.014539379330112621,-0.6718200722915825,0.501927773803444,LGP Offspring,Genes that have high expression in mammary tumors of solid nodular histology.,CGP,C2,8,13
Cohort,3.5684665360119024e-5,0.03823278639181437,9.333524633652938e-4,0.9992555157880764,LGP Proband,Genes that have high expression in mammary tumors of solid nodular histology.,CGP,C2,8,16
Cohort,0.017994689103409012,0.012702940142463887,1.4165767059907381,0.15699794213728688,LonGen OPEL,Genes that have high expression in mammary tumors of solid nodular histology.,CGP,C2,8,17
Cohort,0.015519339057114803,0.07088886076178517,0.21892493249773004,0.8267746041087637,LGP Offspring,Genes that have high expression in mammary tumors of squamous epithelium histology.,CGP,C2,154,339
Cohort,0.16993302656121842,0.1967044886907433,0.8639000954796985,0.3878911583164386,LGP Proband,Genes that have high expression in mammary tumors of squamous epithelium histology.,CGP,C2,154,419
Cohort,-0.013936492789614355,0.06169161115951444,-0.2259058002809996,0.8213326771481337,LonGen OPEL,Genes that have high expression in mammary tumors of squamous epithelium histology.,CGP,C2,247,294
Cohort,-0.09793050558878472,0.0833536711671921,-1.174879333057259,0.2404566667946312,LGP Offspring,Genes down-regulated in DLBCL (diffuse large B-cell lymphoma) cell lines sensitive to stimulation of CD40 [GeneID=958] relative to the resistant ones.,CGP,C2,237,443
Cohort,0.06061134593722135,0.23202046606527713,0.26123275659729445,0.7939775135077813,LGP Proband,Genes down-regulated in DLBCL (diffuse large B-cell lymphoma) cell lines sensitive to stimulation of CD40 [GeneID=958] relative to the resistant ones.,CGP,C2,237,703
Cohort,0.06289261450400313,0.07392766131909205,0.8507318286796788,0.39517416893344914,LonGen OPEL,Genes down-regulated in DLBCL (diffuse large B-cell lymphoma) cell lines sensitive to stimulation of CD40 [GeneID=958] relative to the resistant ones.,CGP,C2,368,480
Cohort,-0.048931562037433554,0.07303744756394658,-0.6699516983338231,0.5031173598797156,LGP Offspring,Genes up-regulated in DLBCL (diffuse large B-cell lymphoma) cell lines sensitive to stimulation of CD40 [GeneID=958] relative to the resistant ones.,CGP,C2,187,368
Cohort,-0.13946953400725934,0.2063312674928361,-0.6759495819609685,0.4992600469055519,LGP Proband,Genes up-regulated in DLBCL (diffuse large B-cell lymphoma) cell lines sensitive to stimulation of CD40 [GeneID=958] relative to the resistant ones.,CGP,C2,187,514
Cohort,-0.021683996813914454,0.06564868123345671,-0.3303036162570099,0.7412574740023086,LonGen OPEL,Genes up-regulated in DLBCL (diffuse large B-cell lymphoma) cell lines sensitive to stimulation of CD40 [GeneID=958] relative to the resistant ones.,CGP,C2,294,361
Cohort,0.03323944154481346,0.022036583355953557,1.5083754594758112,0.1319256598007225,LGP Offspring,Genes up-regulated in MCF7-ADR cell line (breast cancer) resistant to docetaxel [PubChem=148124].,CGP,C2,9,40
Cohort,0.05902646381635722,0.062325287921913254,0.9470708565407816,0.34387699361311486,LGP Proband,Genes up-regulated in MCF7-ADR cell line (breast cancer) resistant to docetaxel [PubChem=148124].,CGP,C2,9,56
Cohort,0.004641169250503257,0.023421057127851308,0.1981622445634266,0.8429687224055771,LonGen OPEL,Genes up-regulated in MCF7-ADR cell line (breast cancer) resistant to docetaxel [PubChem=148124].,CGP,C2,38,48
Cohort,-0.010863693934662183,0.022823544770385843,-0.47598626961566964,0.6342379479090218,LGP Offspring,Genes distinguishing between breast cancer tumors bearing mutations in BRCA1 [GeneID=672] and those with mutated BRCA2 [GeneID=675].,CGP,C2,18,32
Cohort,0.13834290349426823,0.0611278178343987,2.2631742534806794,0.02388126651981224,LGP Proband,Genes distinguishing between breast cancer tumors bearing mutations in BRCA1 [GeneID=672] and those with mutated BRCA2 [GeneID=675].,CGP,C2,18,45
Cohort,-0.008808085432925746,0.01909611929518189,-0.46125002136680715,0.6447452447238917,LonGen OPEL,Genes distinguishing between breast cancer tumors bearing mutations in BRCA1 [GeneID=672] and those with mutated BRCA2 [GeneID=675].,CGP,C2,26,25
Cohort,-0.188741051445367,0.07424490179783498,-2.5421415730240855,0.011239591298288623,LGP Offspring,Genes down-regulated in PC-3 cells (prostate cancer) stably expressing ST7 [GeneID=7982] off a plasmid vector.,CGP,C2,205,354
Cohort,-0.24203013970769166,0.20825793985509625,-1.1621652450614548,0.2455008102745398,LGP Proband,Genes down-regulated in PC-3 cells (prostate cancer) stably expressing ST7 [GeneID=7982] off a plasmid vector.,CGP,C2,205,485
Cohort,-0.00783816840818603,0.06511948134811922,-0.12036595264456006,0.9042236351673686,LonGen OPEL,Genes down-regulated in PC-3 cells (prostate cancer) stably expressing ST7 [GeneID=7982] off a plasmid vector.,CGP,C2,272,326
Cohort,-0.001553238471761322,0.060018280626773605,-0.025879422994807295,0.9793611501487789,LGP Offspring,Genes up-regulated in PC-3 cells (prostate cancer) stably expressing ST7 [GeneID=7982] off a plasmid vector.,CGP,C2,116,245
Cohort,0.007451720674829687,0.15375530786677388,0.04846480279748433,0.9613574181284392,LGP Proband,Genes up-regulated in PC-3 cells (prostate cancer) stably expressing ST7 [GeneID=7982] off a plasmid vector.,CGP,C2,116,310
Cohort,-0.004280756746409629,0.053869893554991374,-0.07946473371141441,0.9366829539376966,LonGen OPEL,Genes up-regulated in PC-3 cells (prostate cancer) stably expressing ST7 [GeneID=7982] off a plasmid vector.,CGP,C2,183,223
Cohort,-0.04844761001623234,0.04007942473959082,-1.2087900545232961,0.22716614682377703,LGP Offspring,Genes whose DNA was methylated both in primary tumors and across a panel of cancer cell lines.,CGP,C2,55,90
Cohort,0.0803922249249052,0.10847929003677995,0.741083619718088,0.45885134766512614,LGP Proband,Genes whose DNA was methylated both in primary tumors and across a panel of cancer cell lines.,CGP,C2,55,131
Cohort,-0.015107046914561953,0.031064912392402964,-0.4863057949024326,0.6268842250719056,LonGen OPEL,Genes whose DNA was methylated both in primary tumors and across a panel of cancer cell lines.,CGP,C2,73,76
Cohort,-0.2380266829211745,0.0816906119436275,-2.913758108280916,0.003689010896373271,LGP Offspring,Genes down-regulated in primary endothelial cells (HUVEC) after knockdown of WTAP [GeneID=9589] by RNAi.,CGP,C2,246,410
Cohort,-0.7121729324346487,0.22630735540315447,-3.1469279076941654,0.0017085726753164779,LGP Proband,Genes down-regulated in primary endothelial cells (HUVEC) after knockdown of WTAP [GeneID=9589] by RNAi.,CGP,C2,246,621
Cohort,-0.05993777873549702,0.06954148563573065,-0.8618996011885716,0.3890023385228245,LonGen OPEL,Genes down-regulated in primary endothelial cells (HUVEC) after knockdown of WTAP [GeneID=9589] by RNAi.,CGP,C2,361,417
Cohort,-0.10734296992669443,0.09284535818226262,-1.1561479435080844,0.24802907827476992,LGP Offspring,Genes up-regulated in primary endothelial cells (HUVEC) after knockdown of WTAP [GeneID=9589] by RNAi.,CGP,C2,294,572
Cohort,0.017840007154288268,0.2605729147985728,0.06846454923405562,0.9454322501605996,LGP Proband,Genes up-regulated in primary endothelial cells (HUVEC) after knockdown of WTAP [GeneID=9589] by RNAi.,CGP,C2,294,838
Cohort,-0.14185603873706723,0.08296950039428554,-1.7097371692361965,0.0877042100641989,LonGen OPEL,Genes up-regulated in primary endothelial cells (HUVEC) after knockdown of WTAP [GeneID=9589] by RNAi.,CGP,C2,481,514
Cohort,-0.016901510492997766,0.028508248266485996,-0.5928638734659473,0.5534705314961414,LGP Offspring,"Genes up-regulated in liver from mice transgenic for SREBF1 or SREBF2 [GeneID = 6720, 6721] and down-regulated in mice lacking SCAP [GeneID=22937].",CGP,C2,30,56
Cohort,-0.16081018899279195,0.07806494758368912,-2.0599538457435873,0.03971274228540863,LGP Proband,"Genes up-regulated in liver from mice transgenic for SREBF1 or SREBF2 [GeneID = 6720, 6721] and down-regulated in mice lacking SCAP [GeneID=22937].",CGP,C2,30,68
Cohort,0.0029548955785767476,0.023904032119434464,0.12361494344606228,0.9016513659945881,LonGen OPEL,"Genes up-regulated in liver from mice transgenic for SREBF1 or SREBF2 [GeneID = 6720, 6721] and down-regulated in mice lacking SCAP [GeneID=22937].",CGP,C2,39,45
Cohort,0.032570815027859655,0.04201983664244914,0.7751295014544648,0.4385341923872075,LGP Offspring,Genes whose expression correlated with lower risk of late recurrence of hepatocellular carcinoma (HCC).,CGP,C2,53,124
Cohort,0.10127256382571544,0.11131238732038189,0.9098049755615285,0.36318822368970927,LGP Proband,Genes whose expression correlated with lower risk of late recurrence of hepatocellular carcinoma (HCC).,CGP,C2,53,164
Cohort,-0.006288091021109079,0.03605347805341984,-0.17441010855574376,0.8615875189279241,LonGen OPEL,Genes whose expression correlated with lower risk of late recurrence of hepatocellular carcinoma (HCC).,CGP,C2,94,101
Cohort,-0.002584780492684515,0.04161918858756478,-0.06210549941996732,0.9504971752016338,LGP Offspring,Genes whose expression correlated with higher risk of late recurrence of hepatocellular carcinoma (HCC).,CGP,C2,54,115
Cohort,-0.08024929695698353,0.11536331832217153,-0.6956223011275892,0.4868591791883279,LGP Proband,Genes whose expression correlated with higher risk of late recurrence of hepatocellular carcinoma (HCC).,CGP,C2,54,158
Cohort,-0.005922177987922113,0.03515863226899486,-0.16844164877098103,0.8662786345797069,LonGen OPEL,Genes whose expression correlated with higher risk of late recurrence of hepatocellular carcinoma (HCC).,CGP,C2,87,100
Cohort,-0.20919934787535205,0.08937622855811621,-2.3406598292444367,0.01953950906473313,LGP Offspring,Genes from 'subtype S1' signature of hepatocellular carcinoma (HCC): aberrant activation of the WNT signaling pathway.,CGP,C2,276,483
Cohort,-0.5008047705556261,0.23619579823230824,-2.1202950022974756,0.03427583852786609,LGP Proband,Genes from 'subtype S1' signature of hepatocellular carcinoma (HCC): aberrant activation of the WNT signaling pathway.,CGP,C2,276,652
Cohort,0.02626433005132812,0.07697535716122965,0.34120439345693265,0.7330397599058879,LonGen OPEL,Genes from 'subtype S1' signature of hepatocellular carcinoma (HCC): aberrant activation of the WNT signaling pathway.,CGP,C2,380,459
Cohort,-0.11742917071748502,0.061312766886774624,-1.9152482701415143,0.05588250373327199,LGP Offspring,"Genes from 'subtype S2' signature of hepatocellular carcinoma (HCC): proliferation, MYC and AKT1 [GeneID=4609;207] activation.",CGP,C2,142,252
Cohort,-0.17164050855031526,0.17378268668203029,-0.9876732361973747,0.3235991555954807,LGP Proband,"Genes from 'subtype S2' signature of hepatocellular carcinoma (HCC): proliferation, MYC and AKT1 [GeneID=4609;207] activation.",CGP,C2,142,328
Cohort,-0.06861398674905052,0.054843943410701215,-1.2510768278501008,0.21127402521896713,LonGen OPEL,"Genes from 'subtype S2' signature of hepatocellular carcinoma (HCC): proliferation, MYC and AKT1 [GeneID=4609;207] activation.",CGP,C2,214,233
Cohort,-0.023602127538742523,0.09012595540584266,-0.2618793601960801,0.7934942273291407,LGP Offspring,Genes from 'subtype S3' signature of hepatocellular carcinoma (HCC): hepatocyte differentiation.,CGP,C2,247,524
Cohort,-0.10270242445273627,0.2412760940921,-0.42566349077887783,0.6704628884720827,LGP Proband,Genes from 'subtype S3' signature of hepatocellular carcinoma (HCC): hepatocyte differentiation.,CGP,C2,247,726
Cohort,0.07007704210844844,0.07826082520665247,0.8954293789185809,0.3708282904223129,LonGen OPEL,Genes from 'subtype S3' signature of hepatocellular carcinoma (HCC): hepatocyte differentiation.,CGP,C2,405,514
Cohort,0.036720099156314044,0.0646251814050855,0.5682010999109468,0.5700871082760481,LGP Offspring,Survival signature genes defined in adjacent liver tissue: genes correlated with good survival of hepatocellular carcinoma (HCC) patients.,CGP,C2,121,273
Cohort,-0.022339456340973212,0.1750616845780887,-0.12760905617247378,0.8984891255240831,LGP Proband,Survival signature genes defined in adjacent liver tissue: genes correlated with good survival of hepatocellular carcinoma (HCC) patients.,CGP,C2,121,377
Cohort,0.016992186038517543,0.05100252973827624,0.33316359258480654,0.7390985310843892,LonGen OPEL,Survival signature genes defined in adjacent liver tissue: genes correlated with good survival of hepatocellular carcinoma (HCC) patients.,CGP,C2,198,246
Cohort,-0.018617236275046717,0.043312250635976414,-0.42983765566739446,0.66745071812133006,LGP Offspring,Survival signature genes defined in adjacent liver tissue: genes correlated with poor survival of hepatocellular carcinoma (HCC) patients.,CGP,C2,72,132
Cohort,-0.3387181761273158,0.12447216764033328,-2.721236261475368,0.00663936477343226,LGP Proband,Survival signature genes defined in adjacent liver tissue: genes correlated with poor survival of hepatocellular carcinoma (HCC) patients.,CGP,C2,72,184
Cohort,0.12463489026146803,0.044496345564966296,2.801014076077248,0.005217779534197256,LonGen OPEL,Survival signature genes defined in adjacent liver tissue: genes correlated with poor survival of hepatocellular carcinoma (HCC) patients.,CGP,C2,111,182
Cohort,-0.01864409487671404,0.03469793705505441,-0.5373257449609148,0.5912194451896868,LGP Offspring,Genes known to modulate ROS or whose expression changes in response to ROS,CGP,C2,41,78
Cohort,-0.013121543392630374,0.0908839989498284,-0.1443768269910085,0.8852377946394051,LGP Proband,Genes known to modulate ROS or whose expression changes in response to ROS,CGP,C2,41,97
Cohort,0.0038133740533606146,0.029327522804823456,0.13002714476564772,0.8965778010721687,LonGen OPEL,Genes known to modulate ROS or whose expression changes in response to ROS,CGP,C2,60,77
Cohort,0.03536914914246962,0.034520012250664554,1.0245983948568478,0.30591922235166413,LGP Offspring,Genes down-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs. heterozygotic animals.,CGP,C2,31,72
Cohort,-0.241529050316899,0.07781984406715203,-3.1036948635939128,0.001975695546852473,LGP Proband,Genes down-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs. heterozygotic animals.,CGP,C2,31,65
Cohort,0.08108907402348692,0.02451792482250258,3.307338390607319,9.84125298521519e-4,LonGen OPEL,Genes down-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs. heterozygotic animals.,CGP,C2,27,67
Cohort,-0.009812255230632979,0.03340028177243133,-0.2937776183293171,0.7690180119054201,LGP Offspring,Genes up-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs. heterozygotic animals.,CGP,C2,34,70
Cohort,0.01902615985218542,0.08226605459987689,0.23127594904999726,0.8171571573331322,LGP Proband,Genes up-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs. heterozygotic animals.,CGP,C2,34,77
Cohort,-0.02549438477617899,0.026621099807418554,-0.9576758646565917,0.33851700278802654,LonGen OPEL,Genes up-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs. heterozygotic animals.,CGP,C2,53,51
Cohort,-0.019123936173086827,0.02542526781178862,-0.752162624781473,0.4522150778012709,LGP Offspring,Genes down-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs wild type (WT) animals.,CGP,C2,24,39
Cohort,0.026306798864516423,0.06474339037248728,0.4063240851794426,0.684608728287762,LGP Proband,Genes down-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs wild type (WT) animals.,CGP,C2,24,51
Cohort,0.022059925556156303,0.022284533252522706,0.9899209153801336,0.3225135859054925,LonGen OPEL,Genes down-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs wild type (WT) animals.,CGP,C2,29,45
Cohort,0.0015811620293595368,0.02103039155931179,0.07518462149885333,0.9400900634382863,LGP Offspring,Genes up-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs wild type (WT) animals.,CGP,C2,15,31
Cohort,-0.028518237541008983,0.053195870537538825,-0.5360987094079881,0.5920332809932166,LGP Proband,Genes up-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs wild type (WT) animals.,CGP,C2,15,31
Cohort,-0.014881405505387659,0.018545879354318798,-0.8024103479311274,0.4225551266735982,LonGen OPEL,Genes up-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs wild type (WT) animals.,CGP,C2,27,25
Cohort,0.044220845586481684,0.041696524653325066,1.0605403197063648,0.28927761836667176,LGP Offspring,Genes up-regulated in pubertal mammary glands compared to mammary glands from other developmental stages.,CGP,C2,44,121
Cohort,0.09780205102753756,0.11713478954507492,0.8349530605499753,0.40398324812761777,LGP Proband,Genes up-regulated in pubertal mammary glands compared to mammary glands from other developmental stages.,CGP,C2,44,159
Cohort,0.0390668790806359,0.03684387643570125,1.0603357425979365,0.28931350626595875,LonGen OPEL,Genes up-regulated in pubertal mammary glands compared to mammary glands from other developmental stages.,CGP,C2,80,108
Cohort,-0.10191917400872162,0.0798498741519683,-1.2763849046869076,0.20225781236031654,LGP Offspring,Housekeeping genes identified as expressed across 19 normal tissues.,CGP,C2,213,397
Cohort,0.0792721398916587,0.22831452533484903,0.347205854622684,0.7285242686764688,LGP Proband,Housekeeping genes identified as expressed across 19 normal tissues.,CGP,C2,213,580
Cohort,-0.040189960870400485,0.07305096443043886,-0.5501633165797623,0.5823617028824741,LonGen OPEL,Housekeeping genes identified as expressed across 19 normal tissues.,CGP,C2,371,431
Cohort,-0.06332559001584723,0.08805982430260208,-0.71912010405835,0.4723154291440219,LGP Offspring,Liver selective genes,CGP,C2,264,531
Cohort,0.2746754380564958,0.24476992898103006,1.1221780355126199,0.2621097166458428,LGP Proband,Liver selective genes,CGP,C2,264,769
Cohort,-0.11785218807299759,0.08185414046299191,-1.439782855288563,0.15032199339436414,LonGen OPEL,Liver selective genes,CGP,C2,457,497
Cohort,0.03742549881737077,0.025111073406568842,1.4903982084485714,0.1365859945197257,LGP Offspring,Down-regulated genes that separate angiogenic from non-angiogenic non-small cell lung carcinoma (NSCLC) samples.,CGP,C2,17,49
Cohort,0.07847530915403297,0.06383038985415304,1.2294349029254297,0.21925552309258747,LGP Proband,Down-regulated genes that separate angiogenic from non-angiogenic non-small cell lung carcinoma (NSCLC) samples.,CGP,C2,17,47
Cohort,0.012829995106337838,0.02035717593959302,0.6302443494327993,0.5287156060771294,LonGen OPEL,Down-regulated genes that separate angiogenic from non-angiogenic non-small cell lung carcinoma (NSCLC) samples.,CGP,C2,27,35
Cohort,-0.008160329550882792,0.030440033899233932,-0.2680788588441144,0.7887203984248127,LGP Offspring,Up-regulated genes that separate angiogenic from non-angiogenic non-small cell lung carcinoma (NSCLC) samples.,CGP,C2,33,60
Cohort,-0.05012138297547654,0.08617793888135578,-0.5816034083210139,0.5609910067158195,LGP Proband,Up-regulated genes that separate angiogenic from non-angiogenic non-small cell lung carcinoma (NSCLC) samples.,CGP,C2,33,83
Cohort,-0.01645663962852642,0.0266730424169551,-0.6169764727725819,0.5374266724856306,LonGen OPEL,Up-regulated genes that separate angiogenic from non-angiogenic non-small cell lung carcinoma (NSCLC) samples.,CGP,C2,55,59
Cohort,-0.012801394507320967,0.016296053603628045,-0.7855518163287675,0.43240534124438934,LGP Offspring,"Genes most consistently regulated at 24 h by all six genotoxins tested: cisplatin, methyl methanesulfonate, mitomycin C, taxol, hydroxyurea and etoposide [PubChem=2767;4156;5746;4666;3657;36462].",CGP,C2,12,15
Cohort,-0.00592326616508739,0.047705176898995685,-0.12416401217059714,0.9012153343670652,LGP Proband,"Genes most consistently regulated at 24 h by all six genotoxins tested: cisplatin, methyl methanesulfonate, mitomycin C, taxol, hydroxyurea and etoposide [PubChem=2767;4156;5746;4666;3657;36462].",CGP,C2,12,27
Cohort,-0.007025738307581669,0.017423035711174224,-0.40324421209076255,0.6868768657884123,LonGen OPEL,"Genes most consistently regulated at 24 h by all six genotoxins tested: cisplatin, methyl methanesulfonate, mitomycin C, taxol, hydroxyurea and etoposide [PubChem=2767;4156;5746;4666;3657;36462].",CGP,C2,21,22
Cohort,0.00291739554702192,0.02387787181152674,0.12217988144209671,0.9027928709587768,LGP Offspring,"Genes most consistently regulated at 4 h by all six genotoxins tested: cisplatin, methyl methanesulfonate, mitomycin C, taxol, hydroxyurea and etoposide [PubChem=2767;4156;5746;4666;3657;36462].",CGP,C2,18,40
Cohort,0.013424033596108257,0.06175416571878916,0.2173785920327622,0.8279664818772592,LGP Proband,"Genes most consistently regulated at 4 h by all six genotoxins tested: cisplatin, methyl methanesulfonate, mitomycin C, taxol, hydroxyurea and etoposide [PubChem=2767;4156;5746;4666;3657;36462].",CGP,C2,18,48
Cohort,-0.01679015709051972,0.021578410763791873,-0.7780997995780699,0.43674139501448817,LonGen OPEL,"Genes most consistently regulated at 4 h by all six genotoxins tested: cisplatin, methyl methanesulfonate, mitomycin C, taxol, hydroxyurea and etoposide [PubChem=2767;4156;5746;4666;3657;36462].",CGP,C2,35,36
Cohort,-0.03190500944407507,0.03805277192791807,-0.8384411391767078,0.4020793563118443,LGP Offspring,"Genes discriminating between direct (cisplatin, MMS, mitomycin C [PubChem=2767;4156;5746]) and indirect (paclitaxel, hydroxyurea, etoposide [PubChem=4666;3657;36462]) acting genotoxins at 24 h time point.",CGP,C2,48,89
Cohort,0.06194215737095879,0.09995538637813618,0.6196980434513908,0.5356258652609005,LGP Proband,"Genes discriminating between direct (cisplatin, MMS, mitomycin C [PubChem=2767;4156;5746]) and indirect (paclitaxel, hydroxyurea, etoposide [PubChem=4666;3657;36462]) acting genotoxins at 24 h time point.",CGP,C2,48,105
Cohort,-0.0374661713948923,0.032793960315229985,-1.1424716940177693,0.25360152650061835,LonGen OPEL,"Genes discriminating between direct (cisplatin, MMS, mitomycin C [PubChem=2767;4156;5746]) and indirect (paclitaxel, hydroxyurea, etoposide [PubChem=4666;3657;36462]) acting genotoxins at 24 h time point.",CGP,C2,84,82
Cohort,-0.013414459300419117,0.02511299845251121,-0.5341639838741645,0.5934036998088548,LGP Offspring,"Genes discriminating between direct (cisplatin, MMS, mitomycin C [PubChem=2767;4156;5746]) and indirect (paclitaxel, hydroxyurea, etoposide [PubChem=4666;3657;36462]) acting genotoxins at 4 h time point.",CGP,C2,23,41
Cohort,0.013823491404472423,0.06866979552952882,0.20130380901641334,0.8405101096347447,LGP Proband,"Genes discriminating between direct (cisplatin, MMS, mitomycin C [PubChem=2767;4156;5746]) and indirect (paclitaxel, hydroxyurea, etoposide [PubChem=4666;3657;36462]) acting genotoxins at 4 h time point.",CGP,C2,23,54
Cohort,0.02052386503253688,0.023744954852931353,0.8643463489257036,0.3876580430918527,LonGen OPEL,"Genes discriminating between direct (cisplatin, MMS, mitomycin C [PubChem=2767;4156;5746]) and indirect (paclitaxel, hydroxyurea, etoposide [PubChem=4666;3657;36462]) acting genotoxins at 4 h time point.",CGP,C2,30,50
Cohort,1.0087897622340378e-4,0.04598526357264802,0.002193723997341759,0.9982503100919297,LGP Offspring,Genes whose expression negatively correlated with resistance of breast cancer cell lines to dasatinib [PubChem=3062316].,CGP,C2,65,132
Cohort,0.14437874862525701,0.12229491822469908,1.1805784796387215,0.23810680450812394,LGP Proband,Genes whose expression negatively correlated with resistance of breast cancer cell lines to dasatinib [PubChem=3062316].,CGP,C2,65,195
Cohort,0.03331664003501929,0.04181952774776369,0.7966766204527717,0.42587641222984707,LonGen OPEL,Genes whose expression negatively correlated with resistance of breast cancer cell lines to dasatinib [PubChem=3062316].,CGP,C2,112,151
Cohort,0.04309584792835687,0.04996053520719085,0.8625978034389443,0.38866454540450446,LGP Offspring,Genes whose expression positively correlated with sensitivity of breast cancer cell lines to dasatinib [PubChem=3062316].,CGP,C2,80,176
Cohort,-0.09009587528955329,0.1373868062324475,-0.6557825875733531,0.5121448832220894,LGP Proband,Genes whose expression positively correlated with sensitivity of breast cancer cell lines to dasatinib [PubChem=3062316].,CGP,C2,80,234
Cohort,-0.026587711480636784,0.04667519028128359,-0.5696326318202126,0.5690876064162698,LonGen OPEL,Genes whose expression positively correlated with sensitivity of breast cancer cell lines to dasatinib [PubChem=3062316].,CGP,C2,154,174
Cohort,-0.004142729418426948,0.036899026837762805,-0.11227205087661662,0.9106410311854134,LGP Offspring,Genes down-regulated in H358 cells (lung cancer) by inducible expression of FOXA2 [GeneID=3170] in a Tet-off system.,CGP,C2,47,90
Cohort,-0.2358223386970701,0.10481045611372194,-2.2499886694624913,0.024709616282469996,LGP Proband,Genes down-regulated in H358 cells (lung cancer) by inducible expression of FOXA2 [GeneID=3170] in a Tet-off system.,CGP,C2,47,138
Cohort,-0.09984159347958221,0.03452550281764762,-2.89182156178616,0.003934521143962985,LonGen OPEL,Genes down-regulated in H358 cells (lung cancer) by inducible expression of FOXA2 [GeneID=3170] in a Tet-off system.,CGP,C2,105,85
Cohort,-0.027927275799418762,0.03924133396228129,-0.7116800826970463,0.47690841897715397,LGP Offspring,Genes up-regulated in H358 cells (lung cancer) by inducible expression of FOXA2 [GeneID=3170] in a Tet-off system.,CGP,C2,51,104
Cohort,0.21177291874168874,0.11419776803356553,1.8544400857242977,0.06402903461573362,LGP Proband,Genes up-regulated in H358 cells (lung cancer) by inducible expression of FOXA2 [GeneID=3170] in a Tet-off system.,CGP,C2,51,151
Cohort,-0.028971741246972993,0.035342118429479756,-0.8197511222985131,0.41260338325696444,LonGen OPEL,Genes up-regulated in H358 cells (lung cancer) by inducible expression of FOXA2 [GeneID=3170] in a Tet-off system.,CGP,C2,94,99
Cohort,0.068792714780441,0.037152582048277545,1.8516267507611988,0.06451531429646733,LGP Offspring,Genes down-regulated in G1ME cells (megakaryocyte/erythroid progenitor lacking GATA1 [GeneID=2623]) upon knockdown of GATA2 [GeneID=2624] by RNAi.,CGP,C2,35,104
Cohort,0.034553733847267044,0.09750889652283436,0.3543649357079469,0.7231549865253349,LGP Proband,Genes down-regulated in G1ME cells (megakaryocyte/erythroid progenitor lacking GATA1 [GeneID=2623]) upon knockdown of GATA2 [GeneID=2624] by RNAi.,CGP,C2,35,119
Cohort,0.045235368213304844,0.029849794261526685,1.5154331657022033,0.13005972586023695,LonGen OPEL,Genes down-regulated in G1ME cells (megakaryocyte/erythroid progenitor lacking GATA1 [GeneID=2623]) upon knockdown of GATA2 [GeneID=2624] by RNAi.,CGP,C2,55,83
Cohort,0.11207916749681565,0.05911168812731049,1.8960576333977746,0.058378594562681074,LGP Offspring,Genes up-regulated in G1ME cells (megakaryocyte/erythroid progenitor lacking GATA1 [GeneID=2623]) upon knockdown of GATA2 [GeneID=2624] by RNAi.,CGP,C2,97,248
Cohort,-0.07994624425346648,0.15950787293358418,-0.5012056319424086,0.6163586713710798,LGP Proband,Genes up-regulated in G1ME cells (megakaryocyte/erythroid progenitor lacking GATA1 [GeneID=2623]) upon knockdown of GATA2 [GeneID=2624] by RNAi.,CGP,C2,97,319
Cohort,0.13101512475983831,0.051922802724849566,2.5232675796435045,0.01182065983425962,LonGen OPEL,Genes up-regulated in G1ME cells (megakaryocyte/erythroid progenitor lacking GATA1 [GeneID=2623]) upon knockdown of GATA2 [GeneID=2624] by RNAi.,CGP,C2,167,254
Cohort,0.011120597242600828,0.02275329386954416,0.48874669779068863,0.6251795552934233,LGP Offspring,Genes up-regulated in fetal liver (days E13.5 and E15.5) samples from embryo-specific Cre-lox knockout of MAPK14 [GeneID=1432].,CGP,C2,15,37
Cohort,-0.062446566379823674,0.06403239062356011,-0.975234030335376,0.32972696334819285,LGP Proband,Genes up-regulated in fetal liver (days E13.5 and E15.5) samples from embryo-specific Cre-lox knockout of MAPK14 [GeneID=1432].,CGP,C2,15,59
Cohort,-0.021992303035957266,0.021435385231818246,-1.025981236078386,0.30521210422716016,LonGen OPEL,Genes up-regulated in fetal liver (days E13.5 and E15.5) samples from embryo-specific Cre-lox knockout of MAPK14 [GeneID=1432].,CGP,C2,37,33
Cohort,-0.01353673565116868,0.02432356688029768,-0.5565275733524742,0.5780344287866924,LGP Offspring,Down-regulated genes constituting the molecular signature of Burkitt 's lymphoma.,CGP,C2,20,38
Cohort,0.07015107000665215,0.06205358977590165,1.13049172916496,0.25859408050460153,LGP Proband,Down-regulated genes constituting the molecular signature of Burkitt 's lymphoma.,CGP,C2,20,45
Cohort,0.012147429165524217,0.01663401054788884,0.7302766299535591,0.4654359775791552,LonGen OPEL,Down-regulated genes constituting the molecular signature of Burkitt 's lymphoma.,CGP,C2,18,25
Cohort,0.009705601566478842,0.03292015643846203,0.294822461874433,0.7682200238111496,LGP Offspring,Up-regulated genes constituting the molecular signature of Burkitt 's lymphoma.,CGP,C2,34,77
Cohort,0.10113049065344423,0.09085190337679833,1.1131356294652033,0.2659709072562883,LGP Proband,Up-regulated genes constituting the molecular signature of Burkitt 's lymphoma.,CGP,C2,34,102
Cohort,0.017463390087513634,0.030931292150941616,0.5645865036059288,0.5725141052289435,LonGen OPEL,Up-regulated genes constituting the molecular signature of Burkitt 's lymphoma.,CGP,C2,57,80
Cohort,0.013152516657025002,0.028483673215519176,0.4617563387105187,0.6444046201329097,LGP Offspring,Genes down-regulated in benign skin tumors (papilloma) induced by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,22,50
Cohort,-0.1204085994954645,0.06634630024557729,-1.8148502486164033,0.06990603782421971,LGP Proband,Genes down-regulated in benign skin tumors (papilloma) induced by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,22,54
Cohort,-0.03971193076922965,0.021337233580425965,-1.861156490579922,0.06309054089841214,LonGen OPEL,Genes down-regulated in benign skin tumors (papilloma) induced by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,37,30
Cohort,0.016194465510938283,0.018050649395786496,0.897168027357426,0.36994865991805614,LGP Offspring,Genes up-regulated in benign skin tumors (papilloma) induced by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,7,24
Cohort,0.009827690500126853,0.05642330618424393,0.1741778560092817,0.8617679578637659,LGP Proband,Genes up-regulated in benign skin tumors (papilloma) induced by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,7,43
Cohort,0.02572578221174963,0.018596640900579706,1.383356400184492,0.16694345785650003,LonGen OPEL,Genes up-regulated in benign skin tumors (papilloma) induced by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,18,32
Cohort,0.020480842404814837,0.02331801155381079,0.8783271402688587,0.38007828330842697,LGP Offspring,"Genes down-regulated in malignant skin tumors (squamous cell carcinoma, SCC) formed by treatment with DMBA and TPA [PubChem=6001;4792] in the two stage skin carcinogenesis model.",CGP,C2,14,37
Cohort,-0.08433413417095315,0.05527716663585752,-1.5256594956559655,0.1274738021981959,LGP Proband,"Genes down-regulated in malignant skin tumors (squamous cell carcinoma, SCC) formed by treatment with DMBA and TPA [PubChem=6001;4792] in the two stage skin carcinogenesis model.",CGP,C2,14,36
Cohort,-0.004913504907222303,0.015722580277313544,-0.3125126296421019,0.7547328170941532,LonGen OPEL,"Genes down-regulated in malignant skin tumors (squamous cell carcinoma, SCC) formed by treatment with DMBA and TPA [PubChem=6001;4792] in the two stage skin carcinogenesis model.",CGP,C2,18,20
Cohort,0.024959037917243007,0.02433142114022925,1.0257944973043955,0.30535537708597094,LGP Offspring,"Genes up-regulated in malignant skin tumors (squamous cell carcinoma, SCC) formed by treatment with DMBA and TPA [PubChem=6001;4792] in the two stage skin carcinogenesis model.",CGP,C2,15,42
Cohort,-0.07699141424421033,0.07660230787615468,-1.005079564556785,0.31515005434809346,LGP Proband,"Genes up-regulated in malignant skin tumors (squamous cell carcinoma, SCC) formed by treatment with DMBA and TPA [PubChem=6001;4792] in the two stage skin carcinogenesis model.",CGP,C2,15,76
Cohort,0.05627850715495084,0.022679136795668364,2.481510106050414,0.013288084708659548,LonGen OPEL,"Genes up-regulated in malignant skin tumors (squamous cell carcinoma, SCC) formed by treatment with DMBA and TPA [PubChem=6001;4792] in the two stage skin carcinogenesis model.",CGP,C2,23,48
Cohort,-0.04902627058298297,0.06524144031683989,-0.7514590472695081,0.4526379657705263,LGP Offspring,Selected genes down-regulated during progression through benign to malignant skin tumors formed by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,137,260
Cohort,-0.12218460122145632,0.16989362616788667,-0.7191829615827676,0.4722296559834682,LGP Proband,Selected genes down-regulated during progression through benign to malignant skin tumors formed by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,137,325
Cohort,0.014643926560881416,0.05431530598656968,0.2696095749603686,0.7875305079789652,LonGen OPEL,Selected genes down-regulated during progression through benign to malignant skin tumors formed by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,188,226
Cohort,0.032959681255058236,0.051651495029750825,0.6381166941261572,0.5236138188884784,LGP Offspring,Selected genes up-regulated during progression through benign to malignant skin tumors formed by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,90,200
Cohort,-0.0028946370494306933,0.1535363567217583,-0.01885310496637883,0.9849627989963429,LGP Proband,Selected genes up-regulated during progression through benign to malignant skin tumors formed by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,90,284
Cohort,0.016589488083239574,0.047079303237153376,0.352373271109665,0.7246516191808374,LonGen OPEL,Selected genes up-regulated during progression through benign to malignant skin tumors formed by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.,CGP,C2,156,191
Cohort,-0.02789428480383515,0.027137382899620983,-1.027891484857397,0.30436852109854867,LGP Offspring,Exercise regulated genes in hyppocampus.,CGP,C2,29,49
Cohort,-0.025882027101864102,0.08044882314113674,-0.32172039429908794,0.7477451420213361,LGP Proband,Exercise regulated genes in hyppocampus.,CGP,C2,29,75
Cohort,0.004579658340293634,0.02063800135136479,0.22190415933812221,0.8244454098881079,LonGen OPEL,Exercise regulated genes in hyppocampus.,CGP,C2,27,31
Cohort,0.0077518873180420665,0.03946540464997754,0.1964223447547111,0.8443386426047248,LGP Offspring,Genes down-regulated in basal mammary epithelial cells compared to the luminal ones.,CGP,C2,47,102
Cohort,0.05653176909942405,0.10495139758121194,0.5386471300268247,0.5902740978698708,LGP Proband,Genes down-regulated in basal mammary epithelial cells compared to the luminal ones.,CGP,C2,47,140
Cohort,0.01095153789674157,0.032351535608895796,0.33851678724425666,0.7350630486030052,LonGen OPEL,Genes down-regulated in basal mammary epithelial cells compared to the luminal ones.,CGP,C2,69,87
Cohort,-0.01553330512418213,0.03850771394504524,-0.4033816483198632,0.6867950402701276,LGP Offspring,Genes up-regulated in basal mammary epithelial cells compared to the luminal ones.,CGP,C2,50,110
Cohort,0.1248278577417693,0.10380044631027358,1.2025753470138456,0.2294819956421358,LGP Proband,Genes up-regulated in basal mammary epithelial cells compared to the luminal ones.,CGP,C2,50,141
Cohort,0.0244958784455277,0.03486551455886617,0.7025818708101783,0.4825217693223143,LonGen OPEL,Genes up-regulated in basal mammary epithelial cells compared to the luminal ones.,CGP,C2,79,108
Cohort,-0.05058165555367751,0.04107044101969757,-1.2315829657007658,0.21853316423940494,LGP Offspring,"Down-regulated genes in B-CLL (B-cell chronic leukemia) patients expressing high levels of ZAP70 and CD38 [GeneID=7535;952], which are associated with poor survival.",CGP,C2,58,94
Cohort,-0.03510448250180271,0.1171594044506094,-0.2996300866022379,0.7645339895566305,LGP Proband,"Down-regulated genes in B-CLL (B-cell chronic leukemia) patients expressing high levels of ZAP70 and CD38 [GeneID=7535;952], which are associated with poor survival.",CGP,C2,58,148
Cohort,0.029382773038391742,0.031529277744851834,0.9319202703014478,0.3516602948197267,LonGen OPEL,"Down-regulated genes in B-CLL (B-cell chronic leukemia) patients expressing high levels of ZAP70 and CD38 [GeneID=7535;952], which are associated with poor survival.",CGP,C2,62,89
Cohort,0.013537964022682755,0.09618372771402403,0.14075108487096885,0.8881085165291543,LGP Offspring,"Up-regulated genes in B-CLL (B-cell chronic leukemia) patients expressing high levels of ZAP70 and CD38 [GeneID=7535;952], which are associated with poor survival.",CGP,C2,279,594
Cohort,0.020387581319141607,0.26285270523610116,0.07756276010486159,0.9381944699782544,LGP Proband,"Up-regulated genes in B-CLL (B-cell chronic leukemia) patients expressing high levels of ZAP70 and CD38 [GeneID=7535;952], which are associated with poor survival.",CGP,C2,279,772
Cohort,-0.1093682685782742,0.08290141302964268,-1.3192569894938688,0.1874625643172685,LonGen OPEL,"Up-regulated genes in B-CLL (B-cell chronic leukemia) patients expressing high levels of ZAP70 and CD38 [GeneID=7535;952], which are associated with poor survival.",CGP,C2,466,531
Cohort,0.010271403346880766,0.024375524167590253,0.4213818450122867,0.6736102241260715,LGP Offspring,Proteins implicated in prostate carcinogenesis.,CGP,C2,17,39
Cohort,-0.14945887346243766,0.06294225821459641,-2.3745394223523095,0.017796238453709635,LGP Proband,Proteins implicated in prostate carcinogenesis.,CGP,C2,17,41
Cohort,-0.0023872921021760576,0.02320117873805931,-0.10289529377487763,0.9180719889355723,LonGen OPEL,Proteins implicated in prostate carcinogenesis.,CGP,C2,31,38
Cohort,0.07884589870080623,0.04367203167112419,1.8054094504822153,0.07145540733731139,LGP Offspring,"Hepatic graft versus host disease (GVHD), day 35: genes down-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,53,146
Cohort,0.08683560482624203,0.12119679112129031,0.716484355921102,0.47389290363616576,LGP Proband,"Hepatic graft versus host disease (GVHD), day 35: genes down-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,53,204
Cohort,0.044840515506287155,0.03987436920511104,1.1245448241608689,0.2611209550296562,LonGen OPEL,"Hepatic graft versus host disease (GVHD), day 35: genes down-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,95,123
Cohort,-0.061943006718501434,0.05305459513614352,-1.1675333033745585,0.24340670730670866,LGP Offspring,"Hepatic graft versus host disease (GVHD), day 35: genes up-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,93,170
Cohort,-0.18041308078137236,0.14844972764883554,-1.215314326531791,0.22459015384609046,LGP Proband,"Hepatic graft versus host disease (GVHD), day 35: genes up-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,93,246
Cohort,0.03925438449838142,0.050159738197827174,0.7825875076054892,0.43410212518583136,LonGen OPEL,"Hepatic graft versus host disease (GVHD), day 35: genes up-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,149,196
Cohort,0.0032072379064209348,0.04692775836038213,0.06834415319374353,0.9455318869792466,LGP Offspring,"Hepatic graft versus host disease (GVHD), day 7: down-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,68,140
Cohort,-0.10742157844184497,0.12554394582870348,-0.8556492129729194,0.39243759061949446,LGP Proband,"Hepatic graft versus host disease (GVHD), day 7: down-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,68,196
Cohort,-0.023189199801480417,0.03936318116439271,-0.5891088859062282,0.5559553778276372,LonGen OPEL,"Hepatic graft versus host disease (GVHD), day 7: down-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,107,122
Cohort,-0.025617248874630957,0.056834530877197253,-0.45073388447566,0.6523258904162388,LGP Offspring,"Hepatic graft versus host disease (GVHD), day 7: up-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,109,216
Cohort,-0.2121045839705544,0.15510149909310167,-1.367521172978708,0.17183041157737,LGP Proband,"Hepatic graft versus host disease (GVHD), day 7: up-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,109,303
Cohort,0.04848470096169195,0.04994003998058146,0.9708582728516957,0.33191376943463147,LonGen OPEL,"Hepatic graft versus host disease (GVHD), day 7: up-regulated in allogeneic vs syngeneic bone marrow transplant.",CGP,C2,162,215
Cohort,-0.08408771436568425,0.04909794511949248,-1.7126524167362842,0.08723506722107216,LGP Offspring,Genes down-regulated in A549 cells (lung cancer) after knockdown of ATF4 [GeneID=468] by RNAi.,CGP,C2,86,136
Cohort,-0.22987687047141703,0.14104254323309834,-1.6298406509268901,0.10351277675687506,LGP Proband,Genes down-regulated in A549 cells (lung cancer) after knockdown of ATF4 [GeneID=468] by RNAi.,CGP,C2,86,224
Cohort,0.02407345328052467,0.044684798803051914,0.5387392116640902,0.5902174405664765,LonGen OPEL,Genes down-regulated in A549 cells (lung cancer) after knockdown of ATF4 [GeneID=468] by RNAi.,CGP,C2,130,155
Cohort,0.002424406357119625,0.0032255178908060494,0.7516332071913486,0.4525332654347115,LGP Offspring,Genes up-regulated in A549 cells (lung cancer) after knockdown of ATF4 [GeneID=468] by RNAi.,CGP,C2,0,1
Cohort,0.013839714258528936,0.020486130670759918,0.675565067945335,0.4995040922224888,LGP Proband,Genes up-regulated in A549 cells (lung cancer) after knockdown of ATF4 [GeneID=468] by RNAi.,CGP,C2,0,7
Cohort,-0.012100404527110793,0.005148242929888261,-2.3503950166884264,0.01899669185332189,LonGen OPEL,Genes up-regulated in A549 cells (lung cancer) after knockdown of ATF4 [GeneID=468] by RNAi.,CGP,C2,4,0
Cohort,-0.0035106967988043775,0.018117247747208146,-0.19377649672784175,0.8464091023131469,LGP Offspring,Genes down-regulated in pancreatic cells from mice with double knockout of E2F1 [GeneID=1869] and E2F2 [GeneID=1870] compared to wild type.,CGP,C2,12,20
Cohort,-0.04397592208520769,0.051936170374114014,-0.8467301645160602,0.3973884362091037,LGP Proband,Genes down-regulated in pancreatic cells from mice with double knockout of E2F1 [GeneID=1869] and E2F2 [GeneID=1870] compared to wild type.,CGP,C2,12,35
Cohort,0.005173742479228108,0.02135488492793058,0.24227442557937845,0.8086299353655281,LonGen OPEL,Genes down-regulated in pancreatic cells from mice with double knockout of E2F1 [GeneID=1869] and E2F2 [GeneID=1870] compared to wild type.,CGP,C2,27,43
Cohort,0.11046399681643727,0.06976689717671801,1.5833296489685418,0.11381404570731286,LGP Offspring,Genes up-regulated in pancreatic cells from mice with double knockout of E2F1 [GeneID=1869] and E2F2 [GeneID=1870] compared to wild type.,CGP,C2,145,341
Cohort,-0.17136440688661939,0.19618361037737042,-0.8734899238371142,0.38264752927347023,LGP Proband,Genes up-regulated in pancreatic cells from mice with double knockout of E2F1 [GeneID=1869] and E2F2 [GeneID=1870] compared to wild type.,CGP,C2,145,455
Cohort,0.0934529416258468,0.06135623109169082,1.5231206344175643,0.1281256869615358,LonGen OPEL,Genes up-regulated in pancreatic cells from mice with double knockout of E2F1 [GeneID=1869] and E2F2 [GeneID=1870] compared to wild type.,CGP,C2,246,338
Cohort,-0.010089967579505671,0.009085055315105848,-1.110611573572804,0.2671304553674377,LGP Offspring,Genes down-regulated in hepatocellular carcinoma (HCC) tumors with higher risk of early intrahepatic recurrence. The single up-regulated gene (GenBank Accession=AC000063) has been excluded from the signature.,CGP,C2,4,4
Cohort,0.023652619217724775,0.029299776279565634,0.8072627924541758,0.4197452576647229,LGP Proband,Genes down-regulated in hepatocellular carcinoma (HCC) tumors with higher risk of early intrahepatic recurrence. The single up-regulated gene (GenBank Accession=AC000063) has been excluded from the signature.,CGP,C2,4,10
Cohort,0.0036605192506667878,0.00896180008983135,0.40845803454378043,0.6830472886369243,LonGen OPEL,Genes down-regulated in hepatocellular carcinoma (HCC) tumors with higher risk of early intrahepatic recurrence. The single up-regulated gene (GenBank Accession=AC000063) has been excluded from the signature.,CGP,C2,5,7
Cohort,0.007704839581692411,0.01568019367769221,0.49137400596357933,0.6233214402247875,LGP Offspring,"Genes down-regulated during transition from G1 (well differentiated tumor, infected with HCV) to G2 (moderately differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,7,16
Cohort,0.031133844947834603,0.04185193503342668,0.7439045511986088,0.4571437494871816,LGP Proband,"Genes down-regulated during transition from G1 (well differentiated tumor, infected with HCV) to G2 (moderately differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,7,21
Cohort,0.007507321298966772,0.013959895905709946,0.5377777420171228,0.5908808158410562,LonGen OPEL,"Genes down-regulated during transition from G1 (well differentiated tumor, infected with HCV) to G2 (moderately differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,12,16
Cohort,-0.0024968801706822153,0.012736774030049592,-0.19603709422742216,0.8446400466412917,LGP Offspring,"Genes up-regulated during transition from G1 (well differentiated tumor, infected with HCV) to G2 (moderately differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,5,11
Cohort,0.004109432322274078,0.0339979493813125,0.1208729466646271,0.903820784604169,LGP Proband,"Genes up-regulated during transition from G1 (well differentiated tumor, infected with HCV) to G2 (moderately differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,5,14
Cohort,0.009592658663762885,0.008948360800058557,1.0720017753084021,0.28404413626166836,LonGen OPEL,"Genes up-regulated during transition from G1 (well differentiated tumor, infected with HCV) to G2 (moderately differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,4,8
Cohort,-0.002731684105181597,0.01839824915616821,-0.14847522076663314,0.8820120182243463,LGP Offspring,"Genes down-regulated during transition from G2 (moderately differentiated tumor, infected with HCV) to G3 (poorly differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,11,21
Cohort,-0.0122091290334364,0.05469322682647277,-0.22322926881189067,0.8234117367657094,LGP Proband,"Genes down-regulated during transition from G2 (moderately differentiated tumor, infected with HCV) to G3 (poorly differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,11,35
Cohort,-0.0110567326186129,0.015912904977976584,-0.6948280426430867,0.4873658328108198,LonGen OPEL,"Genes down-regulated during transition from G2 (moderately differentiated tumor, infected with HCV) to G3 (poorly differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,18,19
Cohort,0.006329810220617644,0.025995533525227505,0.24349606883331884,0.8076950023909907,LGP Offspring,"Genes up-regulated during transition from G2 (moderately differentiated tumor, infected with HCV) to G3 (poorly differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,20,48
Cohort,0.033089770920268886,0.07742692760408539,0.4273677381268442,0.6692218165654231,LGP Proband,"Genes up-regulated during transition from G2 (moderately differentiated tumor, infected with HCV) to G3 (poorly differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,20,79
Cohort,0.024576717877817452,0.02507652474975176,0.9800687345267308,0.32734996461657795,LonGen OPEL,"Genes up-regulated during transition from G2 (moderately differentiated tumor, infected with HCV) to G3 (poorly differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,38,55
Cohort,-0.003229525250713483,0.010946126818145394,-0.29503817234785723,0.7680553078653336,LGP Offspring,"Genes down-regulated during transition from L0 (non-tumor, not infected with HCV) to L1 (non-tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,5,7
Cohort,-0.05275078761348435,0.02822133271545667,-1.869181308528106,0.06194787045956075,LGP Proband,"Genes down-regulated during transition from L0 (non-tumor, not infected with HCV) to L1 (non-tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,5,8
Cohort,0.0014478518061834878,0.009921822813322866,0.14592598894623832,0.8840167601170774,LonGen OPEL,"Genes down-regulated during transition from L0 (non-tumor, not infected with HCV) to L1 (non-tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,6,9
Cohort,0.025091602368208326,0.02065175593898801,1.2149863886798324,0.22479547748588402,LGP Offspring,"Genes up-regulated during transition from L0 (non-tumor, not infected with HCV) to L1 (non-tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,10,33
Cohort,-0.0822143347150846,0.0569562529698151,-1.4434645965677453,0.14926514180327996,LGP Proband,"Genes up-regulated during transition from L0 (non-tumor, not infected with HCV) to L1 (non-tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,10,41
Cohort,-0.01657500128916367,0.016232108989079248,-1.0211243221885165,0.30750577728574585,LonGen OPEL,"Genes up-regulated during transition from L0 (non-tumor, not infected with HCV) to L1 (non-tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,23,19
Cohort,-0.024274141475992085,0.018975604093334448,-1.2792289171188416,0.20125537158017826,LGP Offspring,"Genes down-regulated during transition from L1 (non-tumor, infected with HCV) to G1 (well differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,15,22
Cohort,0.12624701218720066,0.06311020393481231,2.0004215533450584,0.04577853813074698,LGP Proband,"Genes down-regulated during transition from L1 (non-tumor, infected with HCV) to G1 (well differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,15,47
Cohort,0.010609071292666755,0.017879773281551957,0.5933560300573281,0.5531114622862416,LonGen OPEL,"Genes down-regulated during transition from L1 (non-tumor, infected with HCV) to G1 (well differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,21,28
Cohort,2.2910244724734353e-4,0.011856422486029304,0.01932306709863791,0.9845890842531317,LGP Offspring,"Genes up-regulated during transition from L1 (non-tumor, infected with HCV) to G1 (well differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,6,9
Cohort,-0.017684079609047745,0.03891247837823052,-0.4544578075227677,0.6496176088458974,LGP Proband,"Genes up-regulated during transition from L1 (non-tumor, infected with HCV) to G1 (well differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,6,18
Cohort,-0.003813800581704489,0.01181581761712667,-0.3227707726443323,0.7469536119974676,LonGen OPEL,"Genes up-regulated during transition from L1 (non-tumor, infected with HCV) to G1 (well differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.",CGP,C2,10,11
Cohort,-0.006403270553932799,0.016783454228461853,-0.3815228061380805,0.7029352390820721,LGP Offspring,Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-1 microRNA.,CGP,C2,9,17
Cohort,0.004379928036434415,0.0419770123419051,0.10434110938529063,0.9169237419970158,LGP Proband,Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-1 microRNA.,CGP,C2,9,20
Cohort,-0.017696201983009908,0.011192898002498628,-1.58102057028122,0.11427057963415371,LonGen OPEL,Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-1 microRNA.,CGP,C2,12,8
Cohort,-0.02907384073763603,0.03193499378009158,-0.9104069641548135,0.36293242607947895,LGP Offspring,Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-1 microRNA.,CGP,C2,41,68
Cohort,-0.03698086705167442,0.09751369466274676,-0.3792376771239523,0.7046079091959634,LGP Proband,Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-1 microRNA.,CGP,C2,41,112
Cohort,0.0220073923047493,0.029662161059081055,0.7419348934460642,0.4583456374499739,LonGen OPEL,Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-1 microRNA.,CGP,C2,54,76
Cohort,-0.004678730133548572,0.006395533666392736,-0.7315621146886261,0.4646893949847949,LGP Offspring,Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-133 microRNA.,CGP,C2,2,2
Cohort,0.025779136024453638,0.02360486702952442,1.0921110460910326,0.27509967285507697,LGP Proband,Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-133 microRNA.,CGP,C2,2,7
Cohort,-0.0062438528750049455,0.00966587091784993,-0.6459689900756325,0.5184856148741139,LonGen OPEL,Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-133 microRNA.,CGP,C2,7,7
Cohort,-0.07595045289328256,0.03978623526450807,-1.9089630468514156,0.056690013097527074,LGP Offspring,Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-133 microRNA.,CGP,C2,58,84
Cohort,-0.21074292807859507,0.11354635986041162,-1.8560077869310139,0.06380499364291883,LGP Proband,Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-133 microRNA.,CGP,C2,58,133
Cohort,-0.019100598389875222,0.032468003453748534,-0.5882898964540426,0.5565045996145124,LonGen OPEL,Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-133 microRNA.,CGP,C2,71,82
Cohort,-0.027884825054034966,0.02918458845803934,-0.9554640489149562,0.33968462481560413,LGP Offspring,Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-30 microRNA.,CGP,C2,30,57
Cohort,0.06134408918355062,0.07605445034994723,0.8065811915185733,0.42013775450598567,LGP Proband,Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-30 microRNA.,CGP,C2,30,67
Cohort,0.003543373506242782,0.022243370461980137,0.1593002064277693,0.8734727679335769,LonGen OPEL,Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-30 microRNA.,CGP,C2,30,43
Cohort,0.011435566746140432,0.05932175705646023,0.19277188191267644,0.8471955244313227,LGP Offspring,Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-30 microRNA.,CGP,C2,105,218
Cohort,0.10999537344632579,0.16811623595160732,0.6542816809078942,0.5131107229734551,LGP Proband,Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-30 microRNA.,CGP,C2,105,312
Cohort,-0.007810443707477988,0.05175044488676386,-0.150925150973449,0.8800729980738705,LonGen OPEL,Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-30 microRNA.,CGP,C2,182,217
Cohort,0.007650294305623875,0.024250896760192122,0.3154643880296354,0.7525064477899281,LGP Offspring,Genes differentially expressed in liver tissue upon knockout of the 1a isoform of SREBF1 [GeneID=6720].,CGP,C2,16,43
Cohort,-0.019903492374913047,0.06569074955994389,-0.3029877495422819,0.7619747551573811,LGP Proband,Genes differentially expressed in liver tissue upon knockout of the 1a isoform of SREBF1 [GeneID=6720].,CGP,C2,16,60
Cohort,0.010690577673846834,0.020023244726389593,0.5339083560097135,0.5935540035222615,LonGen OPEL,Genes differentially expressed in liver tissue upon knockout of the 1a isoform of SREBF1 [GeneID=6720].,CGP,C2,25,37
Cohort,0.033728466184748965,0.021706815335996225,1.5538191882444101,0.12069557257981331,LGP Offspring,Down-regulated genes characteristic to the squamous cell carcinoma (SCC) type of non-small cell lung cancer (NSCLC).,CGP,C2,13,37
Cohort,0.04935347546830102,0.05929607191557428,0.8323228482751854,0.40546500055954815,LGP Proband,Down-regulated genes characteristic to the squamous cell carcinoma (SCC) type of non-small cell lung cancer (NSCLC).,CGP,C2,13,46
Cohort,0.012082514633255364,0.021873689013649143,0.5523766304675858,0.5808454013368929,LonGen OPEL,Down-regulated genes characteristic to the squamous cell carcinoma (SCC) type of non-small cell lung cancer (NSCLC).,CGP,C2,25,39
Cohort,-0.005981825002449523,0.016314170863038394,-0.3666643590206614,0.713984131396209,LGP Offspring,Up-regulated genes discriminating between two subtypes of squamous cell carcinoma (SCC) type of non-small cell lung cancer: SSC-A vs SSC-B.,CGP,C2,9,18
Cohort,-0.017082131737536598,0.04199776058219859,-0.4067391094366381,0.6843039693805799,LGP Proband,Up-regulated genes discriminating between two subtypes of squamous cell carcinoma (SCC) type of non-small cell lung cancer: SSC-A vs SSC-B.,CGP,C2,9,20
Cohort,-0.007941423641904798,0.01667599742964647,-0.4762188094240523,0.6340491818208287,LonGen OPEL,Up-regulated genes discriminating between two subtypes of squamous cell carcinoma (SCC) type of non-small cell lung cancer: SSC-A vs SSC-B.,CGP,C2,19,18
Cohort,-0.02280238631974727,0.019139199426967346,-1.1913970804660958,0.23391586231820177,LGP Offspring,Up-regulated genes characteristic to the squamous cell carcinoma (SCC) type of non-small cell lung cancer (NSCLC).,CGP,C2,16,22
Cohort,0.050948732455284015,0.061520273006755416,0.8281616768782778,0.4078158657965747,LGP Proband,Up-regulated genes characteristic to the squamous cell carcinoma (SCC) type of non-small cell lung cancer (NSCLC).,CGP,C2,16,49
Cohort,-0.0021985909715217617,0.019436964762107507,-0.11311390427624428,0.9099687722262472,LonGen OPEL,Up-regulated genes characteristic to the squamous cell carcinoma (SCC) type of non-small cell lung cancer (NSCLC).,CGP,C2,26,32
Cohort,4.1092803097995414e-4,0.007869381421348425,0.05221859368325564,0.9583699440649582,LGP Offspring,Genes whose promoters contain TP53 [GeneID=7157] response elements.,CGP,C2,2,4
Cohort,-0.043439968406661325,0.023578748152606507,-1.8423356543574287,0.0657808834992633,LGP Proband,Genes whose promoters contain TP53 [GeneID=7157] response elements.,CGP,C2,2,7
Cohort,-0.006146513440447186,0.007654347792601589,-0.8030094277122055,0.4222089866035553,LonGen OPEL,Genes whose promoters contain TP53 [GeneID=7157] response elements.,CGP,C2,6,3
Cohort,-0.05092024717377004,0.04156103026513533,-1.2251921294762984,0.22092955270297407,LGP Offspring,Genes down-regulated in 10T1/2 cells (multipotent mesoderma) by expression of SHH [GeneID=6469].,CGP,C2,62,111
Cohort,-0.02228583969310397,0.11603456241339807,-0.19206208244838183,0.8477403288469043,LGP Proband,Genes down-regulated in 10T1/2 cells (multipotent mesoderma) by expression of SHH [GeneID=6469].,CGP,C2,62,163
Cohort,-0.03635123776778596,0.03707772929276986,-0.9804062562934358,0.3271835007369224,LonGen OPEL,Genes down-regulated in 10T1/2 cells (multipotent mesoderma) by expression of SHH [GeneID=6469].,CGP,C2,99,95
Cohort,-0.06869913186799148,0.05706942946390403,-1.2037816483068775,0.22909533848588998,LGP Offspring,Genes up-regulated in 10T1/2 cells (multipotent mesoderma) by expression of SHH [GeneID=6469].,CGP,C2,106,195
Cohort,-0.062021614391287595,0.15641323335739593,-0.3965240859740525,0.6918198777892963,LGP Proband,Genes up-regulated in 10T1/2 cells (multipotent mesoderma) by expression of SHH [GeneID=6469].,CGP,C2,106,287
Cohort,0.05396524679432009,0.04746735584819528,1.1368917823631388,0.25592565412512247,LonGen OPEL,Genes up-regulated in 10T1/2 cells (multipotent mesoderma) by expression of SHH [GeneID=6469].,CGP,C2,151,206
Cohort,-0.06596008580885429,0.036857243347224684,-1.7896098519213055,0.07396417188863272,LGP Offspring,Genes down-regulated by overexpression of MAD1 [GeneID=4084] in primary thymocytes from RAG2 [GeneID=5897] knockout mice.,CGP,C2,51,81
Cohort,0.1242657099166836,0.10490483395602408,1.1845565664664754,0.23653027633993065,LGP Proband,Genes down-regulated by overexpression of MAD1 [GeneID=4084] in primary thymocytes from RAG2 [GeneID=5897] knockout mice.,CGP,C2,51,122
Cohort,0.02196469760095311,0.03452965067094688,0.6361112022321767,0.52488679738469,LonGen OPEL,Genes down-regulated by overexpression of MAD1 [GeneID=4084] in primary thymocytes from RAG2 [GeneID=5897] knockout mice.,CGP,C2,74,95
Cohort,-0.008107272705723331,0.023329080047180137,-0.3475178913753731,0.7283104513432277,LGP Offspring,Genes up-regulated by overexpression of MAD1 [GeneID=4084] in primary thymocytes from RAG2 [GeneID=5897] knockout mice.,CGP,C2,19,35
Cohort,-0.08668366101161816,0.06134513232000573,-1.41304872503061,0.15801448731908516,LGP Proband,Genes up-regulated by overexpression of MAD1 [GeneID=4084] in primary thymocytes from RAG2 [GeneID=5897] knockout mice.,CGP,C2,19,48
Cohort,0.03671791456899676,0.020282177000973244,1.8103537192893466,0.07061790878551859,LonGen OPEL,Genes up-regulated by overexpression of MAD1 [GeneID=4084] in primary thymocytes from RAG2 [GeneID=5897] knockout mice.,CGP,C2,21,41
Cohort,-0.1222175664975043,0.03602312544941418,-3.392752987775297,7.322924795038897e-4,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) after expression of E2F1 or E2F2 [GeneID=1869;1870].,CGP,C2,64,76
Cohort,-0.033136817049315787,0.10983146347393394,-0.3017060503539596,0.7629513693379874,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) after expression of E2F1 or E2F2 [GeneID=1869;1870].,CGP,C2,64,125
Cohort,0.00932714570122526,0.03336903744200719,0.27951497604433806,0.7799222580192298,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) after expression of E2F1 or E2F2 [GeneID=1869;1870].,CGP,C2,78,96
Cohort,7.433566154646929e-4,0.008510866300630146,0.08734206239494734,0.9304254862353454,LGP Offspring,Genes down-regulated in synovial sarcoma samples with SYT-SSX fusions resulting from translocation of SS18 [GeneID=SS18] to one of the SSX genes.,CGP,C2,2,5
Cohort,0.003418226608919297,0.024616022127629793,0.13886185961307584,0.8895928331758653,LGP Proband,Genes down-regulated in synovial sarcoma samples with SYT-SSX fusions resulting from translocation of SS18 [GeneID=SS18] to one of the SSX genes.,CGP,C2,2,8
Cohort,0.003654465459051798,0.006182078781164662,0.5911386102335178,0.5545953695190816,LonGen OPEL,Genes down-regulated in synovial sarcoma samples with SYT-SSX fusions resulting from translocation of SS18 [GeneID=SS18] to one of the SSX genes.,CGP,C2,3,3
Cohort,-0.023801420425204764,0.008459107183292566,-2.813703610732647,0.005039765885164636,LGP Offspring,Prmary innate immune response genes induced in 293T cells (embryonic kidney) by overexpression of STING (TMEM173) [GeneID=340061].,CGP,C2,6,1
Cohort,-0.013167558351301734,0.02721261011862834,-0.4838770810260463,0.6286001322080157,LGP Proband,Prmary innate immune response genes induced in 293T cells (embryonic kidney) by overexpression of STING (TMEM173) [GeneID=340061].,CGP,C2,6,6
Cohort,0.015185385890103101,0.009302398651852605,1.6324161604360914,0.10298733948101774,LonGen OPEL,Prmary innate immune response genes induced in 293T cells (embryonic kidney) by overexpression of STING (TMEM173) [GeneID=340061].,CGP,C2,2,11
Cohort,-0.05190418491028649,0.04621797768634062,-1.1230302040157503,0.2618233491319567,LGP Offspring,Genes down-regulated in HeLa cells upon knockdown of MLL2 [GeneID=8085] by RNAi.,CGP,C2,79,145
Cohort,-0.12964839200796602,0.12524455497282985,-1.0351619041330102,0.3008933613106066,LGP Proband,Genes down-regulated in HeLa cells upon knockdown of MLL2 [GeneID=8085] by RNAi.,CGP,C2,79,181
Cohort,0.011822210005347972,0.038530945126710466,0.30682377415010686,0.7590577555043483,LonGen OPEL,Genes down-regulated in HeLa cells upon knockdown of MLL2 [GeneID=8085] by RNAi.,CGP,C2,105,128
Cohort,0.0038812588927845753,0.012696316550219949,0.3056996001503552,0.7599274905796143,LGP Offspring,"Genes down-regulated in HSA/c and KYSE140 cells (esophageal squamous cell carcinoma, ESCC) after knockdown of PTTG1 [GeneID=9232] by RNAi.",CGP,C2,4,12
Cohort,0.021754056893129696,0.03473779909447315,0.6262359003795035,0.5313315770323552,LGP Proband,"Genes down-regulated in HSA/c and KYSE140 cells (esophageal squamous cell carcinoma, ESCC) after knockdown of PTTG1 [GeneID=9232] by RNAi.",CGP,C2,4,16
Cohort,0.0036737300718880624,0.013804448854011156,0.26612652998606223,0.7902106798200738,LonGen OPEL,"Genes down-regulated in HSA/c and KYSE140 cells (esophageal squamous cell carcinoma, ESCC) after knockdown of PTTG1 [GeneID=9232] by RNAi.",CGP,C2,13,14
Cohort,-0.01809902782054783,0.020843820324996213,-0.8683162461750457,0.38552938385995505,LGP Offspring,"Genes up-regulated in HSA/c and KYSE140 cells (esophageal squamous cell carcinoma, ESCC) after knockdown of PTTG1 [GeneID=9232] by RNAi.",CGP,C2,17,24
Cohort,-0.011842528230084894,0.05183280197764309,-0.22847555559880597,0.8193325653261119,LGP Proband,"Genes up-regulated in HSA/c and KYSE140 cells (esophageal squamous cell carcinoma, ESCC) after knockdown of PTTG1 [GeneID=9232] by RNAi.",CGP,C2,17,27
Cohort,0.019485505150033087,0.017998944096812897,1.082591570106794,0.279317583144706,LonGen OPEL,"Genes up-regulated in HSA/c and KYSE140 cells (esophageal squamous cell carcinoma, ESCC) after knockdown of PTTG1 [GeneID=9232] by RNAi.",CGP,C2,17,32
Cohort,-0.013744155332019182,0.026484473680126165,-0.518951424068991,0.603964458582008,LGP Offspring,"Genes mutated in colon cancer cell lines, identified using the GINI method described in the paper.",CGP,C2,24,46
Cohort,-0.1399785291407595,0.07780331669422681,-1.7991331872249894,0.07235901708006158,LGP Proband,"Genes mutated in colon cancer cell lines, identified using the GINI method described in the paper.",CGP,C2,24,71
Cohort,-0.005969350914828412,0.020658878083431254,-0.28894845551249587,0.772696055598472,LonGen OPEL,"Genes mutated in colon cancer cell lines, identified using the GINI method described in the paper.",CGP,C2,32,34
Cohort,0.185339335632983,0.11867606331737443,1.5617246684138109,0.11882086448110507,LGP Offspring,Genes in the expression cluster 'Early Progenitors Shared': up-regulated in hematopoietic progenitors from adult bone marrow and from fetal liver.,CGP,C2,419,947
Cohort,-0.35634036392318225,0.30385659311932983,-1.1727254632360111,0.24124076417909465,LGP Proband,Genes in the expression cluster 'Early Progenitors Shared': up-regulated in hematopoietic progenitors from adult bone marrow and from fetal liver.,CGP,C2,419,1313
Cohort,-0.11801997412425286,0.10990209792666494,-1.0738646154234905,0.28320878479530676,LonGen OPEL,Genes in the expression cluster 'Early Progenitors Shared': up-regulated in hematopoietic progenitors from adult bone marrow and from fetal liver.,CGP,C2,775,868
Cohort,-0.10502062366532501,0.05928160139532148,-1.7715551063641353,0.07691889833531312,LGP Offspring,Genes in the expression cluster 'Intermediate Progenitors Shared': up-regulated in hematopoietic intemediate progenitor cells from adult bone marrow and fetal liver.,CGP,C2,132,228
Cohort,-0.17328363410326583,0.16736060879766285,-1.0353907968437415,0.3007865604899069,LGP Proband,Genes in the expression cluster 'Intermediate Progenitors Shared': up-regulated in hematopoietic intemediate progenitor cells from adult bone marrow and fetal liver.,CGP,C2,132,335
Cohort,-0.008127885318401128,0.05066821385666254,-0.16041389067699222,0.872595747331261,LonGen OPEL,Genes in the expression cluster 'Intermediate Progenitors Shared': up-regulated in hematopoietic intemediate progenitor cells from adult bone marrow and fetal liver.,CGP,C2,181,215
Cohort,-0.029235923033781606,0.11978147234327015,-0.244077172052095,0.8072451099197622,LGP Offspring,Genes in the expression cluster 'Late Progenitors Shared': up-regulated in hematopoietic late progenitor cells from adult bone marrow and fetal liver.,CGP,C2,474,978
Cohort,-0.14083513947577544,0.34331749377884474,-0.4102183606364591,0.6817511294236975,LGP Proband,Genes in the expression cluster 'Late Progenitors Shared': up-regulated in hematopoietic late progenitor cells from adult bone marrow and fetal liver.,CGP,C2,474,1366
Cohort,0.16214729295701896,0.10574591255286589,1.5333670024924713,0.1255827897532395,LonGen OPEL,Genes in the expression cluster 'Late Progenitors Shared': up-regulated in hematopoietic late progenitor cells from adult bone marrow and fetal liver.,CGP,C2,751,961
Cohort,-0.02272847696598438,0.08676652604704825,-0.2619498325155959,0.7934399172297368,LGP Offspring,Genes in the expression cluster 'MBC Shared': up-regulated in mature blood cell populations from adult bone marrow and fetal liver.,CGP,C2,226,460
Cohort,-0.18660394753983134,0.22645721518123296,-0.8240141405540681,0.41016710640950815,LGP Proband,Genes in the expression cluster 'MBC Shared': up-regulated in mature blood cell populations from adult bone marrow and fetal liver.,CGP,C2,226,620
Cohort,-9.903089832211428e-4,0.07356645249826779,-0.013461420927486761,0.9892630375500058,LonGen OPEL,Genes in the expression cluster 'MBC Shared': up-regulated in mature blood cell populations from adult bone marrow and fetal liver.,CGP,C2,375,452
Cohort,-0.21958340543071114,0.08618956808004605,-2.5476796127668195,0.011064448213651705,LGP Offspring,Genes in the expression cluster 'HSC Shared': up-regulated in hematopoietic stem cells (HSC) from adult bone marrow and fetal liver.,CGP,C2,259,441
Cohort,-0.2739994029528024,0.24132048168850595,-1.1354171060642837,0.2565267843417563,LGP Proband,Genes in the expression cluster 'HSC Shared': up-regulated in hematopoietic stem cells (HSC) from adult bone marrow and fetal liver.,CGP,C2,259,660
Cohort,-0.06432468907036766,0.07459927751536166,-0.8622695984840036,0.38879887187556905,LonGen OPEL,Genes in the expression cluster 'HSC Shared': up-regulated in hematopoietic stem cells (HSC) from adult bone marrow and fetal liver.,CGP,C2,385,437
Cohort,0.007857624526383044,0.13891370350004809,0.05656479043034313,0.954908597210111,LGP Offspring,Genes in the expression cluster 'HSC and Progenitors Shared': up-regulated in hematopoietic stem cells (HSC) and progenitors from adult bone marrow and fetal liver.,CGP,C2,597,1258
Cohort,0.16586517154633101,0.3690379387919881,0.4494528993123999,0.653221756717387,LGP Proband,Genes in the expression cluster 'HSC and Progenitors Shared': up-regulated in hematopoietic stem cells (HSC) and progenitors from adult bone marrow and fetal liver.,CGP,C2,597,1764
Cohort,0.02744878260653621,0.12170899808935116,0.22552796455020543,0.8216264623387484,LonGen OPEL,Genes in the expression cluster 'HSC and Progenitors Shared': up-regulated in hematopoietic stem cells (HSC) and progenitors from adult bone marrow and fetal liver.,CGP,C2,1009,1221
Cohort,-0.14853412606541114,0.09252266721569648,-1.6053809356699167,0.10887701722254546,LGP Offspring,Genes in the expression cluster 'LT-HSC Shared': up-regulated in long term hematopoietic stem cells (LT-HSC) from adult bone marrow and fetal liver.,CGP,C2,283,523
Cohort,-0.24105765066210577,0.2530621590042908,-0.95256300511535,0.3410875129596658,LGP Proband,Genes in the expression cluster 'LT-HSC Shared': up-regulated in long term hematopoietic stem cells (LT-HSC) from adult bone marrow and fetal liver.,CGP,C2,283,702
Cohort,-0.0020852402911726493,0.0713089702705845,-0.029242327904331372,0.9766786527367537,LonGen OPEL,Genes in the expression cluster 'LT-HSC Shared': up-regulated in long term hematopoietic stem cells (LT-HSC) from adult bone marrow and fetal liver.,CGP,C2,396,474
Cohort,-0.003573618884630033,0.032136729219915686,-0.111200454164931,0.9114903988723719,LGP Offspring,Genes in the expression cluster 'ST-HSC Shared': up-regulated in short term hematopoietic stem cells (ST-HSC) from adult bone marrow and fetal liver.,CGP,C2,34,69
Cohort,-8.144771104029201e-4,0.08727354027814622,-0.00933246328505903,0.9925561115621893,LGP Proband,Genes in the expression cluster 'ST-HSC Shared': up-regulated in short term hematopoietic stem cells (ST-HSC) from adult bone marrow and fetal liver.,CGP,C2,34,92
Cohort,0.008032015005134476,0.02618601761458631,0.306729153067568,0.7591297552551581,LonGen OPEL,Genes in the expression cluster 'ST-HSC Shared': up-regulated in short term hematopoietic stem cells (ST-HSC) from adult bone marrow and fetal liver.,CGP,C2,50,64
Cohort,-0.05685147207925748,0.03842907085850896,-1.4793871100495117,0.1395027193644281,LGP Offspring,A consensus set of genes that were significantly down-regulated by MIR106B [GeneID=406900].,CGP,C2,52,85
Cohort,0.06524551232505428,0.11157169583288039,0.5847855214353236,0.5588501052281029,LGP Proband,A consensus set of genes that were significantly down-regulated by MIR106B [GeneID=406900].,CGP,C2,52,158
Cohort,-0.03480875755834901,0.03274819043635921,-1.0629215567191164,0.2881398798671726,LonGen OPEL,A consensus set of genes that were significantly down-regulated by MIR106B [GeneID=406900].,CGP,C2,74,78
Cohort,-0.041579241348823015,0.05902445503130912,-0.7044409190524096,0.4814008357341193,LGP Offspring,Cluster 4: genes down-regulated in lung tissue samples from mice with tumor-bearing genotypes (activated KRAS [GeneID=3845] alone or together with inactivated PTEN [GeneID=5728]).,CGP,C2,114,218
Cohort,-0.18458875889294682,0.16397387619493373,-1.1257205304673406,0.26060766730189155,LGP Proband,Cluster 4: genes down-regulated in lung tissue samples from mice with tumor-bearing genotypes (activated KRAS [GeneID=3845] alone or together with inactivated PTEN [GeneID=5728]).,CGP,C2,114,327
Cohort,0.02880421627281456,0.05172915170531507,0.5568275396608714,0.5778017825577783,LonGen OPEL,Cluster 4: genes down-regulated in lung tissue samples from mice with tumor-bearing genotypes (activated KRAS [GeneID=3845] alone or together with inactivated PTEN [GeneID=5728]).,CGP,C2,165,214
Cohort,-0.16377400303297543,0.09972615207748341,-1.6422372629571558,0.1010059105525144,LGP Offspring,Cluster 2: genes down-regulated in lung tissue samples from mice with oncogenic form of KRAS [GeneID=3845] and inactivated PTEN [GeneID=5728].,CGP,C2,370,676
Cohort,-0.7448391834645252,0.2854968137946705,-2.6089229282965447,0.009245414667535454,LGP Proband,Cluster 2: genes down-regulated in lung tissue samples from mice with oncogenic form of KRAS [GeneID=3845] and inactivated PTEN [GeneID=5728].,CGP,C2,370,994
Cohort,0.13401037326727835,0.08713758240002407,1.5379170453923603,0.12446629037059657,LonGen OPEL,Cluster 2: genes down-regulated in lung tissue samples from mice with oncogenic form of KRAS [GeneID=3845] and inactivated PTEN [GeneID=5728].,CGP,C2,510,650
Cohort,-0.08728173086751774,0.07194611943488013,-1.213154115233667,0.22549463892675647,LGP Offspring,Cluster 1: genes up-regulated in lung tissue samples from mice with oncogenic form of KRAS [GeneID=3845] and inactivated PTEN [GeneID=5728].,CGP,C2,173,336
Cohort,0.23265664173622624,0.19866274310492718,1.1711136074132662,0.2418876014821112,LGP Proband,Cluster 1: genes up-regulated in lung tissue samples from mice with oncogenic form of KRAS [GeneID=3845] and inactivated PTEN [GeneID=5728].,CGP,C2,173,496
Cohort,-0.03192362177087221,0.06307062185325428,-0.5061567625755863,0.6128867549878073,LonGen OPEL,Cluster 1: genes up-regulated in lung tissue samples from mice with oncogenic form of KRAS [GeneID=3845] and inactivated PTEN [GeneID=5728].,CGP,C2,276,309
Cohort,0.030390216969858802,0.07581225264734126,0.40086154821472103,0.68864872688127,LGP Offspring,Cluster 3: genes up-regulated in lung tissue samples from mice with tumor-bearing genotypes (activated KRAS [GeneID=3845] alone or together with inactivated PTEN [GeneID=5728]).,CGP,C2,169,362
Cohort,-0.2172277472244892,0.2007752179302943,-1.0819450202260865,0.2795896890394702,LGP Proband,Cluster 3: genes up-regulated in lung tissue samples from mice with tumor-bearing genotypes (activated KRAS [GeneID=3845] alone or together with inactivated PTEN [GeneID=5728]).,CGP,C2,169,483
Cohort,-0.01396472021836084,0.06098993433160821,-0.22896762181171235,0.8189528952664187,LonGen OPEL,Cluster 3: genes up-regulated in lung tissue samples from mice with tumor-bearing genotypes (activated KRAS [GeneID=3845] alone or together with inactivated PTEN [GeneID=5728]).,CGP,C2,275,326
Cohort,0.04638493371553213,0.025440068868953173,1.8233022070211404,0.06869911226126033,LGP Offspring,Genes up-regulated in REF52 cells (embryonic fibroblast) by expression of E2F1 [GeneID=1869] that were also induced at 16 hr after serum stimulation.,CGP,C2,17,50
Cohort,-0.00611161644095191,0.06093773132182098,-0.10029281216059027,0.9201359673121025,LGP Proband,Genes up-regulated in REF52 cells (embryonic fibroblast) by expression of E2F1 [GeneID=1869] that were also induced at 16 hr after serum stimulation.,CGP,C2,17,48
Cohort,0.01256781898374183,0.02074464660916134,0.6058343253816421,0.5447974792080384,LonGen OPEL,Genes up-regulated in REF52 cells (embryonic fibroblast) by expression of E2F1 [GeneID=1869] that were also induced at 16 hr after serum stimulation.,CGP,C2,24,36
Cohort,-0.001748543591713733,0.015281820353707462,-0.1144198499421259,0.9089389543577049,LGP Offspring,Genes up-regulated in REF52 cells (embryonic fibroblast) by expression of E2F1 [GeneID=1869] that were not induced at all at 16 hr after serum stimulation.,CGP,C2,8,15
Cohort,-0.01362827517253646,0.039867525150906184,-0.34183900608203893,0.7325581697502581,LGP Proband,Genes up-regulated in REF52 cells (embryonic fibroblast) by expression of E2F1 [GeneID=1869] that were not induced at all at 16 hr after serum stimulation.,CGP,C2,8,19
Cohort,-0.010957199992232563,0.01329766446772068,-0.8239943201176821,0.41018960504414426,LonGen OPEL,Genes up-regulated in REF52 cells (embryonic fibroblast) by expression of E2F1 [GeneID=1869] that were not induced at all at 16 hr after serum stimulation.,CGP,C2,13,14
Cohort,0.0026030713712027745,0.021780131967594204,0.11951586772182012,0.904902178277862,LGP Offspring,Genes up-regulated in MCF-7 cells (breast cancer) in response to growth medium from L3T3-L1 cells (differentiated to pre-adipocytes).,CGP,C2,16,33
Cohort,0.002615821628927459,0.06352094945112788,0.04118045544863959,0.9671618909014957,LGP Proband,Genes up-regulated in MCF-7 cells (breast cancer) in response to growth medium from L3T3-L1 cells (differentiated to pre-adipocytes).,CGP,C2,16,53
Cohort,0.019047725876707607,0.020614692613945225,0.9239878679453308,0.35577263761991706,LonGen OPEL,Genes up-regulated in MCF-7 cells (breast cancer) in response to growth medium from L3T3-L1 cells (differentiated to pre-adipocytes).,CGP,C2,28,41
Cohort,-0.02973174734940147,0.059560640330757204,-0.4991844812999425,0.617811835891172,LGP Offspring,Genes down-regulated in adipose tissue mesenchymal stem cells (ASC) vs bone marrow mesenchymal stem cells (rBMSC),CGP,C2,121,224
Cohort,-0.0507803271130942,0.17015052947256545,-0.29844354449265387,0.7654389983679294,LGP Proband,Genes down-regulated in adipose tissue mesenchymal stem cells (ASC) vs bone marrow mesenchymal stem cells (rBMSC),CGP,C2,121,346
Cohort,0.0995215558841768,0.05098585653394357,1.951944375356739,0.05129510584261997,LonGen OPEL,Genes down-regulated in adipose tissue mesenchymal stem cells (ASC) vs bone marrow mesenchymal stem cells (rBMSC),CGP,C2,167,236
Cohort,0.13715592690766626,0.05928554866057923,2.313479929028057,0.020995405674830343,LGP Offspring,Genes up-regulated in adipose tissue mesenchymal stem cells (ASC) vs bone marrow mesenchymal stem cells (rBMSC),CGP,C2,89,250
Cohort,0.160130831290355,0.15391959247631373,1.0403537893656851,0.29847706163915716,LGP Proband,Genes up-regulated in adipose tissue mesenchymal stem cells (ASC) vs bone marrow mesenchymal stem cells (rBMSC),CGP,C2,89,310
Cohort,0.025157867946366076,0.04620473712435201,0.5444867672043681,0.5862590452404025,LonGen OPEL,Genes up-regulated in adipose tissue mesenchymal stem cells (ASC) vs bone marrow mesenchymal stem cells (rBMSC),CGP,C2,150,192
Cohort,0.0281150810335944,0.07057283682935929,0.39838388672932207,0.6904730261334577,LGP Offspring,"Genes down-regulated in CD133+ [GeneID=8842] cells (hematopoietic stem cells, HSC) compared to the CD133- cells.",CGP,C2,157,345
Cohort,-0.14214689829421182,0.1957939901801352,-0.7260023566782271,0.4680410104732744,LGP Proband,"Genes down-regulated in CD133+ [GeneID=8842] cells (hematopoietic stem cells, HSC) compared to the CD133- cells.",CGP,C2,157,482
Cohort,-0.01568777244541106,0.06506279480504523,-0.24111740807350882,0.8095262139662187,LonGen OPEL,"Genes down-regulated in CD133+ [GeneID=8842] cells (hematopoietic stem cells, HSC) compared to the CD133- cells.",CGP,C2,267,304
Cohort,-0.026716484361228567,0.09644439672671196,-0.2770143758266567,0.7818537507481272,LGP Offspring,"Genes up-regulated in CD133+ [GeneID=8842] cells (hematopoietic stem cells, HSC) compared to the CD133- cells.",CGP,C2,333,667
Cohort,-0.12601416495666776,0.2681338458860314,-0.4699673946057123,0.6385011728960792,LGP Proband,"Genes up-regulated in CD133+ [GeneID=8842] cells (hematopoietic stem cells, HSC) compared to the CD133- cells.",CGP,C2,333,905
Cohort,-0.09226031500317862,0.08819520227602229,-1.0460922206905752,0.29583600590604975,LonGen OPEL,"Genes up-regulated in CD133+ [GeneID=8842] cells (hematopoietic stem cells, HSC) compared to the CD133- cells.",CGP,C2,528,607
Cohort,0.04154562539305176,0.02770073650284271,1.4998021943852742,0.13413251333554532,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblast) upon Cre-lox knockout of DNMT1 [GeneID=1786].,CGP,C2,20,63
Cohort,0.02753604570803075,0.07320126303183588,0.37616899719414787,0.706886931880401,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblast) upon Cre-lox knockout of DNMT1 [GeneID=1786].,CGP,C2,20,61
Cohort,0.006141934175818983,0.02329556940674876,0.2636524597694382,0.7921159679502757,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblast) upon Cre-lox knockout of DNMT1 [GeneID=1786].,CGP,C2,36,44
Cohort,-0.046392543673421764,0.04448651029251822,-1.0428451988787286,0.2973927861289573,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) upon Cre-lox knockout of DNMT1 [GeneID=1786].,CGP,C2,66,116
Cohort,-0.06019036678787187,0.11901516232601465,-0.5057369633542507,0.6131749533825295,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) upon Cre-lox knockout of DNMT1 [GeneID=1786].,CGP,C2,66,175
Cohort,0.07798102112375611,0.041121246625387305,1.896368119239178,0.058273227236963945,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) upon Cre-lox knockout of DNMT1 [GeneID=1786].,CGP,C2,102,150
Cohort,-0.037845276485245084,0.1049050159478518,-0.3607575495156298,0.7183934016852018,LGP Offspring,Genes down-regulated in metastases from malignant melanoma compared to the primary tumors.,CGP,C2,337,669
Cohort,-0.07972430188107431,0.27073428009539957,-0.2944743526862634,0.7684687373162844,LGP Proband,Genes down-regulated in metastases from malignant melanoma compared to the primary tumors.,CGP,C2,337,911
Cohort,-0.0013941476576569214,0.08612228126205394,-0.016188001957528175,0.9870884637369585,LonGen OPEL,Genes down-regulated in metastases from malignant melanoma compared to the primary tumors.,CGP,C2,507,617
Cohort,0.05837824129644562,0.036646585442958776,1.5930062948787589,0.11162622450855629,LGP Offspring,Genes up-regulated in metastases from malignant melanoma compared to the primary tumors.,CGP,C2,35,98
Cohort,-0.07730718525478475,0.09774860758208495,-0.7908776111195814,0.42924025545792577,LGP Proband,Genes up-regulated in metastases from malignant melanoma compared to the primary tumors.,CGP,C2,35,130
Cohort,-0.02102379764449892,0.02698877347496452,-0.778983071016589,0.43622120275189213,LonGen OPEL,Genes up-regulated in metastases from malignant melanoma compared to the primary tumors.,CGP,C2,51,56
Cohort,-0.0011339037241200284,0.038716560136959476,-0.029287305486563227,0.9766440953869906,LGP Offspring,Genes whose expression was increased due to copy number gain in laryngeal cancer tumors (both in primary cultures and cell lines).,CGP,C2,45,98
Cohort,0.06310218950523928,0.10214293549974549,0.6177831995576093,0.5368869085304347,LGP Proband,Genes whose expression was increased due to copy number gain in laryngeal cancer tumors (both in primary cultures and cell lines).,CGP,C2,45,131
Cohort,-0.03397647809992973,0.03501895221555994,-0.970231144860839,0.3322260037229444,LonGen OPEL,Genes whose expression was increased due to copy number gain in laryngeal cancer tumors (both in primary cultures and cell lines).,CGP,C2,84,93
Cohort,0.09551036348667925,0.040262245060520056,2.372206600578611,0.01796119303933841,LGP Offspring,Genes abnormally regulated in response to CD40L and IL4 [GeneID=959;3565] stimulation of B lymphocytes from patients with a hypomorphic mutation of IKBKG [GeneID=8517].,CGP,C2,42,129
Cohort,-0.134982995018167,0.11271910565375352,-1.1975165544056292,0.23144551880049485,LGP Proband,Genes abnormally regulated in response to CD40L and IL4 [GeneID=959;3565] stimulation of B lymphocytes from patients with a hypomorphic mutation of IKBKG [GeneID=8517].,CGP,C2,42,157
Cohort,0.023843737033688313,0.03654583552233828,0.6524337641456867,0.5143097498702053,LonGen OPEL,Genes abnormally regulated in response to CD40L and IL4 [GeneID=959;3565] stimulation of B lymphocytes from patients with a hypomorphic mutation of IKBKG [GeneID=8517].,CGP,C2,86,114
Cohort,0.018194342087867115,0.03615054118177999,0.5032937680345746,0.6149216957821766,LGP Offspring,Down-regulated genes distinguishing between breast cancer tumors with mutated BRCA1 [GeneID=672] from those with mutated BRCA2 [GeneID=675].,CGP,C2,37,87
Cohort,-0.006274763001617396,0.09996146311744003,-0.062771820318851,0.949963246346401,LGP Proband,Down-regulated genes distinguishing between breast cancer tumors with mutated BRCA1 [GeneID=672] from those with mutated BRCA2 [GeneID=675].,CGP,C2,37,121
Cohort,0.007721118490430472,0.03293984735853815,0.23440055463490558,0.8147343052806413,LonGen OPEL,Down-regulated genes distinguishing between breast cancer tumors with mutated BRCA1 [GeneID=672] from those with mutated BRCA2 [GeneID=675].,CGP,C2,74,95
Cohort,0.03447234728254606,0.03216721391643732,1.0716609580207015,0.2842547849781093,LGP Offspring,Up-regulated genes distinguishing between breast cancer tumors with mutated BRCA1 [GeneID=672] from those with mutated BRCA2 [GeneID=675].,CGP,C2,30,80
Cohort,0.09452333982681682,0.08715347419802966,1.084561925919802,0.2784291415756294,LGP Proband,Up-regulated genes distinguishing between breast cancer tumors with mutated BRCA1 [GeneID=672] from those with mutated BRCA2 [GeneID=675].,CGP,C2,30,106
Cohort,-0.02405280009708123,0.030562810881035178,-0.7869956788564387,0.4315186444291147,LonGen OPEL,Up-regulated genes distinguishing between breast cancer tumors with mutated BRCA1 [GeneID=672] from those with mutated BRCA2 [GeneID=675].,CGP,C2,71,67
Cohort,-0.032424395119412516,0.0286551680979883,-1.1315374248908638,0.2582302036573141,LGP Offspring,Genes down-regulated in PANC-1-puro cells (pancreatic cancer) stimulated by TGF1B [GeneID=7040] for 2 h.,CGP,C2,31,52
Cohort,0.011962464757748885,0.07923490358724644,0.15097468686355983,0.8800321921393236,LGP Proband,Genes down-regulated in PANC-1-puro cells (pancreatic cancer) stimulated by TGF1B [GeneID=7040] for 2 h.,CGP,C2,31,66
Cohort,-0.016623512467734653,0.025209094772915955,-0.6594252041764925,0.509813488887712,LonGen OPEL,Genes down-regulated in PANC-1-puro cells (pancreatic cancer) stimulated by TGF1B [GeneID=7040] for 2 h.,CGP,C2,48,49
Cohort,-0.13444877344572229,0.05858925471366142,-2.294768453751512,0.022051948153075814,LGP Offspring,Genes up-regulated in PANC-1-puro cells (pancreatic cancer) stimulated by TGF1B [GeneID=7040] for 2 h.,CGP,C2,125,204
Cohort,-0.1275964596202897,0.1637330331968791,-0.7792957665840262,0.4360265792619755,LGP Proband,Genes up-regulated in PANC-1-puro cells (pancreatic cancer) stimulated by TGF1B [GeneID=7040] for 2 h.,CGP,C2,125,315
Cohort,0.029136201810196275,0.049000320138281504,0.5946124786118206,0.5522715077102751,LonGen OPEL,Genes up-regulated in PANC-1-puro cells (pancreatic cancer) stimulated by TGF1B [GeneID=7040] for 2 h.,CGP,C2,153,201
Cohort,-0.04243552570871056,0.048119367593871816,-0.8818803702257069,0.3781549619562059,LGP Offspring,Genes down-regulated in PANC-1-S4KD cells (pancreatic cancer; SMAD4 [GeneID=4089] knocked down by RNAi) after stimulation by TGF1B [GeneID=7040] for 2 h.,CGP,C2,87,162
Cohort,-0.25110003063731534,0.13357816709544368,-1.879798443842252,0.06048394405011773,LGP Proband,Genes down-regulated in PANC-1-S4KD cells (pancreatic cancer; SMAD4 [GeneID=4089] knocked down by RNAi) after stimulation by TGF1B [GeneID=7040] for 2 h.,CGP,C2,87,208
Cohort,0.04179127064644878,0.04131929125630582,1.0114227368329056,0.3121214816533937,LonGen OPEL,Genes down-regulated in PANC-1-S4KD cells (pancreatic cancer; SMAD4 [GeneID=4089] knocked down by RNAi) after stimulation by TGF1B [GeneID=7040] for 2 h.,CGP,C2,106,151
Cohort,-0.08377671456286277,0.04784188505645531,-1.7511165052130144,0.08037937997732038,LGP Offspring,Genes up-regulated in PANC-1-S4KD cells (pancreatic cancer; SMAD4 [GeneID=4089] knocked down by RNAi) after stimulation by TGF1B [GeneID=7040] for 2 h.,CGP,C2,88,158
Cohort,0.2285018862314426,0.1382465004009202,1.6528583766589264,0.0987360519794099,LGP Proband,Genes up-regulated in PANC-1-S4KD cells (pancreatic cancer; SMAD4 [GeneID=4089] knocked down by RNAi) after stimulation by TGF1B [GeneID=7040] for 2 h.,CGP,C2,88,243
Cohort,0.010928854016080037,0.044451013092639935,0.24586287815990415,0.8058517607749786,LonGen OPEL,Genes up-regulated in PANC-1-S4KD cells (pancreatic cancer; SMAD4 [GeneID=4089] knocked down by RNAi) after stimulation by TGF1B [GeneID=7040] for 2 h.,CGP,C2,134,166
Cohort,0.07773289921031401,0.04308268273180555,1.8042724891160997,0.07163357696250676,LGP Offspring,Genes down-regulated during epithelial to mesenchymal transition (EMT) induced by TGFB1 [GeneID=7040] in the EpH4 cells (mammary epithelium cell line transformed by HRAS [GeneID=3265]).,CGP,C2,45,124
Cohort,-0.13795668788799043,0.11739967487021662,-1.1751028104677397,0.24028896367707364,LGP Proband,Genes down-regulated during epithelial to mesenchymal transition (EMT) induced by TGFB1 [GeneID=7040] in the EpH4 cells (mammary epithelium cell line transformed by HRAS [GeneID=3265]).,CGP,C2,45,174
Cohort,0.07048488227423169,0.034731831915514745,2.0294029536272755,0.04274950878646892,LonGen OPEL,Genes down-regulated during epithelial to mesenchymal transition (EMT) induced by TGFB1 [GeneID=7040] in the EpH4 cells (mammary epithelium cell line transformed by HRAS [GeneID=3265]).,CGP,C2,68,108
Cohort,0.03577379107530186,0.046435399488167155,0.7703991237206407,0.44133232277787915,LGP Offspring,Genes up-regulated during epithelial to mesenchymal transition (EMT) induced by TGFB1 [GeneID=7040] in the EpH4 cells (mammary epithelium cell line transformed by HRAS [GeneID=3265]).,CGP,C2,70,152
Cohort,-0.2866168576236968,0.13675288441662467,-2.095874312606847,0.03639422791597119,LGP Proband,Genes up-regulated during epithelial to mesenchymal transition (EMT) induced by TGFB1 [GeneID=7040] in the EpH4 cells (mammary epithelium cell line transformed by HRAS [GeneID=3265]).,CGP,C2,70,226
Cohort,-0.0070245681109321265,0.039461640539573385,-0.17801003746632546,0.8587603835755986,LonGen OPEL,Genes up-regulated during epithelial to mesenchymal transition (EMT) induced by TGFB1 [GeneID=7040] in the EpH4 cells (mammary epithelium cell line transformed by HRAS [GeneID=3265]).,CGP,C2,111,130
Cohort,-0.059022352598056715,0.02771105647840481,-2.1299206922714315,0.033538711775173105,LGP Offspring,Genes down-regulated in H1299 cells (lung cancer) upon knockdown of SMAD6 [GeneID=4091] by RNAi.,CGP,C2,31,41
Cohort,0.011435154133930767,0.07396979352522753,0.15459221378022078,0.8771802113918382,LGP Proband,Genes down-regulated in H1299 cells (lung cancer) upon knockdown of SMAD6 [GeneID=4091] by RNAi.,CGP,C2,31,54
Cohort,-0.028927686822715352,0.020221352994373137,-1.4305514982486518,0.1529512206739211,LonGen OPEL,Genes down-regulated in H1299 cells (lung cancer) upon knockdown of SMAD6 [GeneID=4091] by RNAi.,CGP,C2,35,31
Cohort,-0.010387728498278204,0.022673084287978824,-0.45815242277318813,0.6469901759264616,LGP Offspring,Genes up-regulated in H1299 cells (lung cancer) upon knockdown of SMAD6 [GeneID=4091] by RNAi.,CGP,C2,18,33
Cohort,-0.0279295633910101,0.05933160815572957,-0.47073666565218464,0.6379518871563734,LGP Proband,Genes up-regulated in H1299 cells (lung cancer) upon knockdown of SMAD6 [GeneID=4091] by RNAi.,CGP,C2,18,41
Cohort,0.0013149347247063277,0.019974048239732502,0.06583215925606165,0.9475279824078348,LonGen OPEL,Genes up-regulated in H1299 cells (lung cancer) upon knockdown of SMAD6 [GeneID=4091] by RNAi.,CGP,C2,29,30
Cohort,0.022780625775324158,0.030415357967412356,0.7489843058803316,0.454127195904362,LGP Offspring,Genes up-regulated in neural progenitor cells (NPC) isolated from E13 cortical tissue of SMRT [GeneID=9612] knockout mice.,CGP,C2,29,69
Cohort,0.14182579716151877,0.08709617210229718,1.6283815205442087,0.10382167806569034,LGP Proband,Genes up-regulated in neural progenitor cells (NPC) isolated from E13 cortical tissue of SMRT [GeneID=9612] knockout mice.,CGP,C2,29,94
Cohort,0.0396748061430514,0.024861409717900854,1.5958389565690845,0.11092166772405379,LonGen OPEL,Genes up-regulated in neural progenitor cells (NPC) isolated from E13 cortical tissue of SMRT [GeneID=9612] knockout mice.,CGP,C2,33,52
Cohort,-0.010484770028512712,0.02731044048867421,-0.38391068913226806,0.7011653632867223,LGP Offspring,Cluster B: genes down-regulated in primary lung tumors driven by KRAS [GeneID=3845] activation and loss of STK11 [GeneID=6794]; also up-regulated in human squamous cell carcinoma (SCC) vs adenocarcinoma subtype of NSCLC (non-small cell lung cancer).,CGP,C2,25,48
Cohort,-0.06659114716623753,0.07179683647529132,-0.9274941687598545,0.3539383498193901,LGP Proband,Cluster B: genes down-regulated in primary lung tumors driven by KRAS [GeneID=3845] activation and loss of STK11 [GeneID=6794]; also up-regulated in human squamous cell carcinoma (SCC) vs adenocarcinoma subtype of NSCLC (non-small cell lung cancer).,CGP,C2,25,62
Cohort,-0.04145121094283749,0.02081927927014729,-1.9910012448065038,0.04682220567915162,LonGen OPEL,Cluster B: genes down-regulated in primary lung tumors driven by KRAS [GeneID=3845] activation and loss of STK11 [GeneID=6794]; also up-regulated in human squamous cell carcinoma (SCC) vs adenocarcinoma subtype of NSCLC (non-small cell lung cancer).,CGP,C2,36,26
Cohort,0.003170313000317946,0.016543414826268508,0.19163594902329084,0.8480849272996729,LGP Offspring,Cluster A: genes up-regulated in primary lung tumors driven by KRAS [GeneID=3845] activation and loss of STK11 [GeneID=6794]; also up-regulated in human squamous cell carcinoma (SCC) vs adenocarcinoma subtype of NSCLC (non-small cell lung cancer).,CGP,C2,9,19
Cohort,0.031815715684581906,0.04952579409256064,0.642406977364569,0.5207855187958642,LGP Proband,Cluster A: genes up-regulated in primary lung tumors driven by KRAS [GeneID=3845] activation and loss of STK11 [GeneID=6794]; also up-regulated in human squamous cell carcinoma (SCC) vs adenocarcinoma subtype of NSCLC (non-small cell lung cancer).,CGP,C2,9,30
Cohort,0.02115801347719916,0.017504193753620254,1.208739675474811,0.2271218042974815,LonGen OPEL,Cluster A: genes up-regulated in primary lung tumors driven by KRAS [GeneID=3845] activation and loss of STK11 [GeneID=6794]; also up-regulated in human squamous cell carcinoma (SCC) vs adenocarcinoma subtype of NSCLC (non-small cell lung cancer).,CGP,C2,18,30
Cohort,-0.004905301917745906,0.02666636698521277,-0.18395088916559313,0.8541071463577977,LGP Offspring,Adenocarcinoma metastatic program genes up-regulated in A549 and H2126 cells (lung cancer) lacking functional STK11 [GeneID=6794] but down-regulated by the normal gene.,CGP,C2,23,45
Cohort,-0.004619835576019158,0.07629121292240919,-0.06055527758770451,0.9517278989834814,LGP Proband,Adenocarcinoma metastatic program genes up-regulated in A549 and H2126 cells (lung cancer) lacking functional STK11 [GeneID=6794] but down-regulated by the normal gene.,CGP,C2,23,69
Cohort,-0.026263558714421716,0.026264323819923826,-0.9999708690196117,0.3176284847364147,LonGen OPEL,Adenocarcinoma metastatic program genes up-regulated in A549 and H2126 cells (lung cancer) lacking functional STK11 [GeneID=6794] but down-regulated by the normal gene.,CGP,C2,50,49
Cohort,-0.03129807976589476,0.03870518075315673,-0.8086276606095462,0.4190138355664592,LGP Offspring,"Down-regulated in ovarian epithelial cells (MCV152) 72 hours following FSH treatment, compared to untreated",CGP,C2,51,97
Cohort,-0.05046821125960556,0.11056002272059616,-0.4564779385686927,0.6481651844069841,LGP Proband,"Down-regulated in ovarian epithelial cells (MCV152) 72 hours following FSH treatment, compared to untreated",CGP,C2,51,152
Cohort,-0.031237407007135364,0.0355641841464783,-0.8783389175603684,0.38002486517232126,LonGen OPEL,"Down-regulated in ovarian epithelial cells (MCV152) 72 hours following FSH treatment, compared to untreated",CGP,C2,94,102
Cohort,-0.03402622165758987,0.04833103610670006,-0.7040242543625681,0.4816601065353141,LGP Offspring,Genes up-regulated in MCV152 cells (ovarian cancer) treated with follicle stimulating hormone (FSH).,CGP,C2,78,138
Cohort,-0.31158388035346685,0.12714297878156458,-2.4506573885513347,0.014463945064237625,LGP Proband,Genes up-regulated in MCV152 cells (ovarian cancer) treated with follicle stimulating hormone (FSH).,CGP,C2,78,180
Cohort,0.03995194353175376,0.040324649860457466,0.9907573573485834,0.3221051430177102,LonGen OPEL,Genes up-regulated in MCV152 cells (ovarian cancer) treated with follicle stimulating hormone (FSH).,CGP,C2,95,141
Cohort,-0.018199564054083385,0.029692539840431187,-0.6129338935600834,0.5401261977891174,LGP Offspring,"Down-regulated in the cerebral cortex of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,30,55
Cohort,-0.007460737375345599,0.08570276913511508,-0.08705363257963508,0.9306497775048787,LGP Proband,"Down-regulated in the cerebral cortex of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,30,91
Cohort,0.003760212695000822,0.027045710655660936,0.13903175785894065,0.8894602201041188,LonGen OPEL,"Down-regulated in the cerebral cortex of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,47,59
Cohort,0.02070773082101926,0.029254241942635026,0.7078539536804708,0.47927993362100907,LGP Offspring,"Up-regulated in the cerebral cortex of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,26,61
Cohort,0.035998915835222724,0.08423231363593905,0.4273765527896317,0.6692153998749475,LGP Proband,"Up-regulated in the cerebral cortex of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,26,81
Cohort,-0.019378049788030448,0.02404130373347107,-0.8060315697876114,0.42046537463272404,LonGen OPEL,"Up-regulated in the cerebral cortex of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,43,43
Cohort,-0.027780031463073757,0.02130440393302558,-1.303957226421614,0.19269200475523787,LGP Offspring,"Down-regulated in the hypothalamus of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,17,23
Cohort,-0.06691527349891543,0.06173555505247519,-1.0839017069181203,0.27872162580875004,LGP Proband,"Down-regulated in the hypothalamus of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,17,44
Cohort,-0.01248245230274745,0.019272367288424883,-0.6476865097026506,0.5173744878570647,LonGen OPEL,"Down-regulated in the hypothalamus of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,29,28
Cohort,-0.01813744568830683,0.024806723024184258,-0.7311504091299967,0.4649406369663819,LGP Offspring,"Up-regulated in the hypothalamus of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,21,38
Cohort,0.04668249004719843,0.06939706754388458,0.6726867820124799,0.5013329109999699,LGP Proband,"Up-regulated in the hypothalamus of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,21,61
Cohort,0.027695747898314405,0.023873561861533856,1.1601012056327893,0.24635543548416353,LonGen OPEL,"Up-regulated in the hypothalamus of aged (22 months) BALB/c mice, compared to young (2 months) controls",CGP,C2,31,53
Cohort,-0.017013128513399155,0.014073393914304134,-1.208885974271429,0.22712931305923922,LGP Offspring,Genes mapped to core duplicons - elements shared by a majority of segmental duplication blocks.,CGP,C2,9,11
Cohort,-0.02743198758470942,0.04616801218754172,-0.5941773597112299,0.5525546293997772,LGP Proband,Genes mapped to core duplicons - elements shared by a majority of segmental duplication blocks.,CGP,C2,9,25
Cohort,0.0085845542820345,0.013293106376040871,0.6457899334580715,0.5186015243100351,LonGen OPEL,Genes mapped to core duplicons - elements shared by a majority of segmental duplication blocks.,CGP,C2,12,15
Cohort,0.049572245948396064,0.04071089584257793,1.2176653183974007,0.2237760438241866,LGP Offspring,"Genes up-regulated in 786-0 cells  (renal carcinoma, RCC) by hypoxia and in the absensce of VHL [GeneID=7428].",CGP,C2,43,105
Cohort,-0.18933681743416325,0.11550567359240731,-1.6391992838575957,0.10154889629456396,LGP Proband,"Genes up-regulated in 786-0 cells  (renal carcinoma, RCC) by hypoxia and in the absensce of VHL [GeneID=7428].",CGP,C2,43,161
Cohort,-9.562063793310719e-4,0.030848149780517992,-0.03099720359679269,0.9752795399627214,LonGen OPEL,"Genes up-regulated in 786-0 cells  (renal carcinoma, RCC) by hypoxia and in the absensce of VHL [GeneID=7428].",CGP,C2,70,81
Cohort,-0.0840411999335478,0.07147405145465378,-1.1758281253563352,0.24007749680372695,LGP Offspring,Genes up-regulated in RPTEC cells (normal kidney) by hypoxia.,CGP,C2,183,346
Cohort,-0.14808909051830452,0.2024898375477584,-0.7313408530113362,0.4647764097766838,LGP Proband,Genes up-regulated in RPTEC cells (normal kidney) by hypoxia.,CGP,C2,183,505
Cohort,0.11112536967771812,0.06207720276072836,1.790115609848627,0.07381530216117355,LonGen OPEL,Genes up-regulated in RPTEC cells (normal kidney) by hypoxia.,CGP,C2,252,342
Cohort,-3.9801204136206313e-4,0.01478872316468108,-0.026913211974419045,0.9785368985388949,LGP Offspring,"Genes up-regulated in 786-0 cells (renal carcinoma, RCC) by the loss of VHL [GeneID=7428] and in response to hypoxia.",CGP,C2,7,13
Cohort,-0.08722714632568992,0.03656783334124199,-2.3853517793003416,0.01728517424968558,LGP Proband,"Genes up-regulated in 786-0 cells (renal carcinoma, RCC) by the loss of VHL [GeneID=7428] and in response to hypoxia.",CGP,C2,7,15
Cohort,-0.01256883296343475,0.014190356488370389,-0.8857305997728424,0.3760302059017432,LonGen OPEL,"Genes up-regulated in 786-0 cells (renal carcinoma, RCC) by the loss of VHL [GeneID=7428] and in response to hypoxia.",CGP,C2,15,14
Cohort,-0.0031385192468797265,0.023141493107496264,-0.13562302277993724,0.892159678541729,LGP Offspring,Down-regulated genes in HepG2 cells (liver cancer) overexpressing an oncogenic variant of tumor suppressor TIP30 [GeneID=10553] compared to its wild type form.,CGP,C2,16,35
Cohort,0.08638521467678338,0.0646541448897533,1.3361125543317507,0.1818769293064237,LGP Proband,Down-regulated genes in HepG2 cells (liver cancer) overexpressing an oncogenic variant of tumor suppressor TIP30 [GeneID=10553] compared to its wild type form.,CGP,C2,16,50
Cohort,0.01615068524777626,0.01767588461907045,0.9137129821695793,0.36114435228234887,LonGen OPEL,Down-regulated genes in HepG2 cells (liver cancer) overexpressing an oncogenic variant of tumor suppressor TIP30 [GeneID=10553] compared to its wild type form.,CGP,C2,20,27
Cohort,-0.03314863043527721,0.03435169112263785,-0.9649781234040085,0.3349008444424836,LGP Offspring,Up-regulated genes in HepG2 cells (liver cancer) overexpressing an oncogenic variant of tumor suppressor TIP30 [GeneID=10553] compared to its wild type form.,CGP,C2,43,76
Cohort,-0.04592146867515137,0.09227686817012122,-0.4976487562461565,0.6188628139892196,LGP Proband,Up-regulated genes in HepG2 cells (liver cancer) overexpressing an oncogenic variant of tumor suppressor TIP30 [GeneID=10553] compared to its wild type form.,CGP,C2,43,97
Cohort,-0.025105509969552242,0.030340568605416212,-0.8274568053108458,0.40822618575831726,LonGen OPEL,Up-regulated genes in HepG2 cells (liver cancer) overexpressing an oncogenic variant of tumor suppressor TIP30 [GeneID=10553] compared to its wild type form.,CGP,C2,62,69
Cohort,-0.03368947167197278,0.03652036592271701,-0.922484504762771,0.35660502939558947,LGP Offspring,"Genes up-regulated in 786-0 cells (renal carcinoma, RCC) upon expression of VHL [GeneID=7428] off a retroviral vector under normoxia (normal oxygen) condition.",CGP,C2,46,86
Cohort,-0.11024483307699798,0.09315176666526374,-1.1834969644017308,0.23694947571011482,LGP Proband,"Genes up-regulated in 786-0 cells (renal carcinoma, RCC) upon expression of VHL [GeneID=7428] off a retroviral vector under normoxia (normal oxygen) condition.",CGP,C2,46,103
Cohort,0.017612980176620458,0.031097501813163658,0.5663792635961785,0.5712956344020508,LonGen OPEL,"Genes up-regulated in 786-0 cells (renal carcinoma, RCC) upon expression of VHL [GeneID=7428] off a retroviral vector under normoxia (normal oxygen) condition.",CGP,C2,57,81
Cohort,-0.32777625318979214,0.10721834263539652,-3.057091213435543,0.0023231060759015413,LGP Offspring,Genes Downregulated in PBSHMS (RT4 blebbishield-to-immune cell fusion),CGP,C2,389,682
Cohort,-0.09702106916226545,0.28356174083938207,-0.34215147951578245,0.7323231000777455,LGP Proband,Genes Downregulated in PBSHMS (RT4 blebbishield-to-immune cell fusion),CGP,C2,389,949
Cohort,-0.04531081993271592,0.08944064938849342,-0.5066020902409188,0.6125743331086856,LonGen OPEL,Genes Downregulated in PBSHMS (RT4 blebbishield-to-immune cell fusion),CGP,C2,558,649
Cohort,-0.14373034500094872,0.11764052783633921,-1.2217757574235428,0.22221831625334165,LGP Offspring,Genes Upregulated in PBSHMS (RT4 blebbishield-to-immune cell fusion),CGP,C2,454,870
Cohort,-0.019890103616274746,0.31908073857628827,-0.062335644906122305,0.9503104788304642,LGP Proband,Genes Upregulated in PBSHMS (RT4 blebbishield-to-immune cell fusion),CGP,C2,454,1213
Cohort,0.1344637502922165,0.10712830301656981,1.2551655025415518,0.20978704469835,LonGen OPEL,Genes Upregulated in PBSHMS (RT4 blebbishield-to-immune cell fusion),CGP,C2,697,882
Cohort,0.010026061713688222,0.10187858194118418,0.09841186952794845,0.9216344230185118,LGP Offspring,Genes Down-regulated in transformed spheres compared to blebbishields from RT4 cells,CGP,C2,337,728
Cohort,-0.14303323157039127,0.28523197016052143,-0.501462832128866,0.6161777678475471,LGP Proband,Genes Down-regulated in transformed spheres compared to blebbishields from RT4 cells,CGP,C2,337,969
Cohort,-0.020377836304696806,0.09476300305084563,-0.21504000135752305,0.8297912130304834,LonGen OPEL,Genes Down-regulated in transformed spheres compared to blebbishields from RT4 cells,CGP,C2,607,716
Cohort,-0.17278609043251542,0.05515767788996094,-3.1325845656015847,0.0018075779981303792,LGP Offspring,Genes up-regulated in transformed spheres compared to blebbishields from RT4 cells,CGP,C2,134,210
Cohort,-0.1969199315788521,0.15514746687019962,-1.269243614164841,0.20470827219991639,LGP Proband,Genes up-regulated in transformed spheres compared to blebbishields from RT4 cells,CGP,C2,134,298
Cohort,0.022759445935098585,0.052343022187769164,0.43481337117780555,0.6638157514573737,LonGen OPEL,Genes up-regulated in transformed spheres compared to blebbishields from RT4 cells,CGP,C2,181,226
Cohort,-0.09966861734796915,0.07779471634377483,-1.281174635402404,0.20057165181993836,LGP Offspring,Genes down-regulated in blebbishields compared to control RT4 live cells,CGP,C2,202,383
Cohort,-0.130154751362824,0.21302709888849874,-0.6109774392174807,0.5413809927408284,LGP Proband,Genes down-regulated in blebbishields compared to control RT4 live cells,CGP,C2,202,552
Cohort,0.06072033052421782,0.06941875281854194,0.8746963617012613,0.38200297422536145,LonGen OPEL,Genes down-regulated in blebbishields compared to control RT4 live cells,CGP,C2,306,383
Cohort,-0.28881641435823485,0.11276525065056853,-2.5612182183073853,0.01064647431614994,LGP Offspring,Genes up-regulated in blebbishields compared to control RT4 live cells,CGP,C2,452,822
Cohort,-0.4862389466715138,0.32103600969444773,-1.5145931670852164,0.13025434126713853,LGP Proband,Genes up-regulated in blebbishields compared to control RT4 live cells,CGP,C2,452,1163
Cohort,0.13477716401608156,0.10508376585340554,1.2825688432607092,0.200016527085402,LonGen OPEL,Genes up-regulated in blebbishields compared to control RT4 live cells,CGP,C2,704,911
Cohort,-0.12755858012433635,0.06964293008808767,-1.8316084628115765,0.06744966035112784,LGP Offspring,Genes down-regulated in peripheral blood mononuclear cells (PBMC) from sickle cell disease patients compared to those from healthy subjects.,CGP,C2,184,315
Cohort,-0.36909996952663054,0.1892459339719708,-1.9503719936265471,0.051466454884239406,LGP Proband,Genes down-regulated in peripheral blood mononuclear cells (PBMC) from sickle cell disease patients compared to those from healthy subjects.,CGP,C2,184,429
Cohort,-0.026344823750684157,0.06291492796264378,-0.4187372473243011,0.6755211293967592,LonGen OPEL,Genes down-regulated in peripheral blood mononuclear cells (PBMC) from sickle cell disease patients compared to those from healthy subjects.,CGP,C2,269,297
Cohort,0.08482236820328558,0.06637952712698275,1.277839295857321,0.20174472240466496,LGP Offspring,Genes up-regulated in peripheral blood mononuclear cells (PBMC) from sickle cell disease patients compared to those from healthy subjects.,CGP,C2,124,300
Cohort,-0.19808391386439667,0.17984354806487662,-1.1014235205865712,0.2710301411980275,LGP Proband,Genes up-regulated in peripheral blood mononuclear cells (PBMC) from sickle cell disease patients compared to those from healthy subjects.,CGP,C2,124,403
Cohort,0.041407837613618756,0.05513546958868287,0.7510199499981794,0.4528626105940071,LonGen OPEL,Genes up-regulated in peripheral blood mononuclear cells (PBMC) from sickle cell disease patients compared to those from healthy subjects.,CGP,C2,202,260
Cohort,0.014902565203467694,0.029060233641760674,0.5128164276715289,0.6082472647117095,LGP Offspring,Genes down-regulated in early vs late brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,23,56
Cohort,-0.13570974406736633,0.07904942979989439,-1.7167706890600194,0.086392372760996,LGP Proband,Genes down-regulated in early vs late brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,23,74
Cohort,0.05101195136936936,0.02406070194232359,2.120135625787276,0.034303396824490455,LonGen OPEL,Genes down-regulated in early vs late brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,36,62
Cohort,0.010306279302145095,0.024121333069609084,0.4272682306737917,0.6693200266144845,LGP Offspring,Genes up-regulated in early vs late brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,19,44
Cohort,0.044809230017256056,0.06031613920397114,0.7429061377042825,0.45774771127240244,LGP Proband,Genes up-regulated in early vs late brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,19,46
Cohort,-0.008454103573713853,0.02074011865482591,-0.40762079110606786,0.6836617004927893,LonGen OPEL,Genes up-regulated in early vs late brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,35,35
Cohort,0.028716766290179937,0.030228045905564774,0.9500040584791284,0.34244970094881977,LGP Offspring,Genes down-regulated in brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,24,63
Cohort,-0.061853778021860754,0.07731813453417455,-0.799990563591798,0.42394406681199315,LGP Proband,Genes down-regulated in brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,24,75
Cohort,-0.0016882432544302597,0.02361865187704053,-0.071479238663549,0.9430343023000949,LonGen OPEL,Genes down-regulated in brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,41,43
Cohort,0.010199464586363116,0.04813645802315907,0.21188647867394028,0.832259466702359,LGP Offspring,Genes up-regulated in brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,77,165
Cohort,0.0829058869461302,0.13498787230843204,0.6141728551487915,0.5392686048569575,LGP Proband,Genes up-regulated in brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,77,232
Cohort,-0.021374787421324235,0.042285783251929346,-0.5054840132433631,0.6133588593634949,LonGen OPEL,Genes up-regulated in brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].,CGP,C2,134,140
Cohort,-0.1220156176440786,0.053466664713452766,-2.282087695164913,0.022794051328257074,LGP Offspring,Genes down-regulated in MDA-MB-231 cells (breast cancer) upon overexpression of PARVB [GeneID=29780] under all three culture conditions.,CGP,C2,104,172
Cohort,-0.009272065112498137,0.1555236197568212,-0.05961837261115747,0.9524738674591706,LGP Proband,Genes down-regulated in MDA-MB-231 cells (breast cancer) upon overexpression of PARVB [GeneID=29780] under all three culture conditions.,CGP,C2,104,260
Cohort,-0.028322311105568255,0.04354736486633187,-0.6503794475854798,0.5156348161404729,LonGen OPEL,Genes down-regulated in MDA-MB-231 cells (breast cancer) upon overexpression of PARVB [GeneID=29780] under all three culture conditions.,CGP,C2,144,162
Cohort,-0.010550495982787718,0.011825848921194572,-0.892155485250523,0.3726270530963133,LGP Offspring,Genes up-regulated in MDA-MB-231 cells (breast cancer) upon overexpression of PARVB [GeneID=29780] under all three culture conditions.,CGP,C2,6,8
Cohort,0.011877625549179073,0.03814075170655897,0.3114156123760011,0.7555625124653762,LGP Proband,Genes up-regulated in MDA-MB-231 cells (breast cancer) upon overexpression of PARVB [GeneID=29780] under all three culture conditions.,CGP,C2,6,18
Cohort,-0.014830738661619549,0.013020043788983787,-1.139069798994669,0.2550167153047084,LonGen OPEL,Genes up-regulated in MDA-MB-231 cells (breast cancer) upon overexpression of PARVB [GeneID=29780] under all three culture conditions.,CGP,C2,15,11
Cohort,0.020913697976358912,0.09955309566791463,0.21007581769352524,0.8336717982844566,LGP Offspring,Genes down-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D collagen I and 3D Matrigel only.,CGP,C2,303,632
Cohort,-0.02789352952205192,0.2761741889079618,-0.1009997698638947,0.9195749179871013,LGP Proband,Genes down-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D collagen I and 3D Matrigel only.,CGP,C2,303,831
Cohort,-0.0213318107954005,0.08779507276004762,-0.24297275604181556,0.808089098332549,LonGen OPEL,Genes down-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D collagen I and 3D Matrigel only.,CGP,C2,496,603
Cohort,-0.027784297656967407,0.06210150348731585,-0.4474013686744688,0.6547286093962241,LGP Offspring,Genes up-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D collagen I and 3D Matrigel only.,CGP,C2,132,262
Cohort,-0.2722210336396685,0.17184526727940125,-1.5841055034531002,0.11354880617265177,LGP Proband,Genes up-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D collagen I and 3D Matrigel only.,CGP,C2,132,335
Cohort,-0.030257222961873824,0.05847657662817162,-0.5174246631136942,0.605003500135302,LonGen OPEL,Genes up-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D collagen I and 3D Matrigel only.,CGP,C2,222,241
Cohort,-0.2622441611952639,0.13916394245738117,-1.8844260701767337,0.05993618095536423,LGP Offspring,Genes down-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D Matrigel only.,CGP,C2,680,1295
Cohort,-0.6967869341288804,0.39770819598399476,-1.7520054682426551,0.08014037600412115,LGP Proband,Genes down-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D Matrigel only.,CGP,C2,680,1873
Cohort,-0.06891723804427749,0.12756851140397102,-0.5402370638788546,0.5891846681803478,LonGen OPEL,Genes down-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D Matrigel only.,CGP,C2,1063,1257
Cohort,-0.006531607277547921,0.12901499315801468,-0.050626730410690754,0.9596379173926876,LGP Offspring,Genes up-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D Matrigel only.,CGP,C2,531,1111
Cohort,-0.3692490583555743,0.3742377061472814,-0.986669841895237,0.3240906740322481,LGP Proband,Genes up-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D Matrigel only.,CGP,C2,531,1539
Cohort,0.17438346816139907,0.12089020339265005,1.4424946212970085,0.14955624064465595,LonGen OPEL,Genes up-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D Matrigel only.,CGP,C2,851,1087
Cohort,0,0,NA,NA,LGP Offspring,Genes up-regulated in E8.5 embryos with heterozygous knockout of TCOF1 [GeneID=6949] compared to wild type.,CGP,C2,0,0
Cohort,-0,0,NA,NA,LGP Proband,Genes up-regulated in E8.5 embryos with heterozygous knockout of TCOF1 [GeneID=6949] compared to wild type.,CGP,C2,0,0
Cohort,0,0,NA,NA,LonGen OPEL,Genes up-regulated in E8.5 embryos with heterozygous knockout of TCOF1 [GeneID=6949] compared to wild type.,CGP,C2,0,0
Cohort,0.08675014521221307,0.04909035560585661,1.767152511762688,0.07765383667328209,LGP Offspring,"Genes down-regulated in H460 cells (non-small cell lung carcinoma, NSCLC) after treatment with sodium butyrate [PubChem=5222465].",CGP,C2,66,179
Cohort,0.02378275931794535,0.13203887099532954,0.18011937801851238,0.857102605068502,LGP Proband,"Genes down-regulated in H460 cells (non-small cell lung carcinoma, NSCLC) after treatment with sodium butyrate [PubChem=5222465].",CGP,C2,66,235
Cohort,0.014601726643113957,0.04261617222473667,0.3426334623886832,0.7319646808240886,LonGen OPEL,"Genes down-regulated in H460 cells (non-small cell lung carcinoma, NSCLC) after treatment with sodium butyrate [PubChem=5222465].",CGP,C2,115,143
Cohort,-0.026579466944113474,0.021797964366491892,-1.2193554635299693,0.22313458700072147,LGP Offspring,"Genes up-regulated in H460 cells (non-small cell lung carcinoma, NSCLC) after treatment with sodium butyrate [PubChem=5222465].",CGP,C2,19,26
Cohort,-0.02018781855049031,0.05593376699123685,-0.3609236358719257,0.7182479349447186,LGP Proband,"Genes up-regulated in H460 cells (non-small cell lung carcinoma, NSCLC) after treatment with sodium butyrate [PubChem=5222465].",CGP,C2,19,30
Cohort,0.010083792753800171,0.016071349437762502,0.6274390829998694,0.5305513920471878,LonGen OPEL,"Genes up-regulated in H460 cells (non-small cell lung carcinoma, NSCLC) after treatment with sodium butyrate [PubChem=5222465].",CGP,C2,15,23
Cohort,0.01564649282840317,0.013166968654186444,1.1883139725883953,0.2351270400369355,LGP Offspring,"Cytokines, growth factors, and secreted proteins that show increased expression on a protein array of samples from aged TERC [GeneID=7012] knockout mice.",CGP,C2,1,13
Cohort,-0.026886467675301687,0.034112724678678055,-0.7881653526230025,0.43082395123773776,LGP Proband,"Cytokines, growth factors, and secreted proteins that show increased expression on a protein array of samples from aged TERC [GeneID=7012] knockout mice.",CGP,C2,1,16
Cohort,9.88741371547139e-4,0.011255629961870758,0.08784416109063378,0.9300226319154773,LonGen OPEL,"Cytokines, growth factors, and secreted proteins that show increased expression on a protein array of samples from aged TERC [GeneID=7012] knockout mice.",CGP,C2,7,6
Cohort,0.07817366985833113,0.05256062473387647,1.4873048076223967,0.13740059892852732,LGP Offspring,Genes down-regulated in atria of failing hearts (DCM and ICM) compared to healthy controls.,CGP,C2,78,200
Cohort,0.09630890816080838,0.14886540619093486,0.6469529128700493,0.5178404314882427,LGP Proband,Genes down-regulated in atria of failing hearts (DCM and ICM) compared to healthy controls.,CGP,C2,78,286
Cohort,-0.0873720824461387,0.04808214947665774,-1.8171417750064376,0.06957130495158365,LonGen OPEL,Genes down-regulated in atria of failing hearts (DCM and ICM) compared to healthy controls.,CGP,C2,182,184
Cohort,0.01637919415603956,0.028782581486189125,0.5690661959525368,0.5695002362555438,LGP Offspring,Genes up-regulated in atria of failing hearts (DCM and ICM) compared to healthy controls.,CGP,C2,26,60
Cohort,-0.04305325239239158,0.07899867467505377,-0.5449870212314707,0.5859081457084289,LGP Proband,Genes up-regulated in atria of failing hearts (DCM and ICM) compared to healthy controls.,CGP,C2,26,80
Cohort,0.0706353169979896,0.024864048409043927,2.8408614653556197,0.004614067100143815,LonGen OPEL,Genes up-regulated in atria of failing hearts (DCM and ICM) compared to healthy controls.,CGP,C2,30,62
Cohort,0.03215835065369343,0.03213729067324935,1.0006553128780582,0.3173515255043727,LGP Offspring,Genes down-regulated in the ventricles of failing hearts (DCM and ICM) compared to the healthy controls.,CGP,C2,28,72
Cohort,-0.15732469829700668,0.08715557973701471,-1.805101850870844,0.07141929239140764,LGP Proband,Genes down-regulated in the ventricles of failing hearts (DCM and ICM) compared to the healthy controls.,CGP,C2,28,104
Cohort,-0.009563138122696992,0.027525040453925446,-0.34743411689820636,0.7283570491373204,LonGen OPEL,Genes down-regulated in the ventricles of failing hearts (DCM and ICM) compared to the healthy controls.,CGP,C2,52,60
Cohort,0.13741600923828762,0.09002633739631798,1.5263978654751742,0.1273785261385079,LGP Offspring,"Genes down-regulated in the ventricles of healthy hearts, compared to atria.",CGP,C2,235,564
Cohort,0.05733627381807228,0.25680948154228184,0.22326385098297966,0.8233848321326982,LGP Proband,"Genes down-regulated in the ventricles of healthy hearts, compared to atria.",CGP,C2,235,795
Cohort,-0.08037833628954612,0.07802053679772815,-1.0302202418567137,0.30321955489100316,LonGen OPEL,"Genes down-regulated in the ventricles of healthy hearts, compared to atria.",CGP,C2,460,523
Cohort,-0.2442659153734265,0.09426716581629657,-2.5912088610942274,0.009770314287032148,LGP Offspring,"Genes up-regulated in the atria of healthy hearts, compared to venticles.",CGP,C2,319,570
Cohort,-0.27707357894240797,0.2719705994999346,-1.0187629819247233,0.30861093838845977,LGP Proband,"Genes up-regulated in the atria of healthy hearts, compared to venticles.",CGP,C2,319,826
Cohort,0.011771368431553183,0.08179160270451508,0.14391903376779505,0.8856008322464242,LonGen OPEL,"Genes up-regulated in the atria of healthy hearts, compared to venticles.",CGP,C2,463,545
Cohort,-0.044189410473668436,0.016353911751848266,-2.7020697643592393,0.007063816472889495,LGP Offspring,DNA replication genes up-regulated in a Rat-1a cell line (fibroblast) by expression of E2F1 [GeneID=1869].,CGP,C2,15,12
Cohort,0.10412434780120111,0.058331808356707406,1.7850354846615715,0.07461891131969833,LGP Proband,DNA replication genes up-regulated in a Rat-1a cell line (fibroblast) by expression of E2F1 [GeneID=1869].,CGP,C2,15,40
Cohort,0.002380263260108391,0.01683361880408493,0.1413993798844242,0.8875902209029563,LonGen OPEL,DNA replication genes up-regulated in a Rat-1a cell line (fibroblast) by expression of E2F1 [GeneID=1869].,CGP,C2,20,22
Cohort,0.01739863601702865,0.030476490175748005,0.5708871302665227,0.5682658788088735,LGP Offspring,Network of differentially expressed myeloid genes centered around CEBPA [GeneID=1050].,CGP,C2,29,64
Cohort,0.09287723519027014,0.0740453394372793,1.2543292514573796,0.2100737844962103,LGP Proband,Network of differentially expressed myeloid genes centered around CEBPA [GeneID=1050].,CGP,C2,29,59
Cohort,-0.059226769053359184,0.022939014108904258,-2.5819230404662017,0.010002781367333602,LonGen OPEL,Network of differentially expressed myeloid genes centered around CEBPA [GeneID=1050].,CGP,C2,46,37
Cohort,0.0041506693739118685,0.023392717807466733,0.1774342514655144,0.8592204566795532,LGP Offspring,Network of differentially expressed myeloid genes centered around MN1 [GeneID=4330].,CGP,C2,17,38
Cohort,0.016315840735166943,0.06736423176905015,0.24220332224827804,0.8086821658795645,LGP Proband,Network of differentially expressed myeloid genes centered around MN1 [GeneID=4330].,CGP,C2,17,58
Cohort,-0.001373821679057827,0.021802502664675042,-0.06301210921458696,0.9497726808085382,LonGen OPEL,Network of differentially expressed myeloid genes centered around MN1 [GeneID=4330].,CGP,C2,29,39
Cohort,-0.14868304187911735,0.03558322662853772,-4.178458671869675,3.3201396297161085e-5,LGP Offspring,Putative targets or partners of EZH2 [GeneID=2146] in hematopoietic stem cells.,CGP,C2,64,60
Cohort,-0.10824232977863436,0.11265888627255984,-0.9607970872067709,0.33693266970624747,LGP Proband,Putative targets or partners of EZH2 [GeneID=2146] in hematopoietic stem cells.,CGP,C2,64,129
Cohort,0.003543247085042732,0.029144737531687507,0.12157416347257717,0.9032669595227475,LonGen OPEL,Putative targets or partners of EZH2 [GeneID=2146] in hematopoietic stem cells.,CGP,C2,62,77
Cohort,-0.023118826729486,0.034951829472344494,-0.6614482583173132,0.5085502684326719,LGP Offspring,Genes down-regulated on serial passage of MEF cells (embryonic fibroblast).,CGP,C2,41,79
Cohort,0.05549060489709975,0.10538472284751962,0.5265526482181738,0.5986442878658265,LGP Proband,Genes down-regulated on serial passage of MEF cells (embryonic fibroblast).,CGP,C2,41,138
Cohort,-0.021749037606644546,0.031179935378236018,-0.6975331200277485,0.48567290300883204,LonGen OPEL,Genes down-regulated on serial passage of MEF cells (embryonic fibroblast).,CGP,C2,75,78
Cohort,-0.13262395981188727,0.05131451044700284,-2.5845313276224293,0.009959620598847762,LGP Offspring,"Genes changed in U373-MG cells (malignant glioma) upon treatment with arsenic trioxide [PubChem=14888], a chemical that can cause autophagic cell death.",CGP,C2,105,158
Cohort,-0.09513023390121578,0.14556013550541785,-0.653545928429525,0.5135845297042434,LGP Proband,"Genes changed in U373-MG cells (malignant glioma) upon treatment with arsenic trioxide [PubChem=14888], a chemical that can cause autophagic cell death.",CGP,C2,105,226
Cohort,-9.222219360614688e-4,0.043480653837934875,-0.021209937171112005,0.9830835027470807,LonGen OPEL,"Genes changed in U373-MG cells (malignant glioma) upon treatment with arsenic trioxide [PubChem=14888], a chemical that can cause autophagic cell death.",CGP,C2,129,152
Cohort,0.01474616292225365,0.020975292953248896,0.7030253620352699,0.48228198011223367,LGP Offspring,Genes down-regulated in osteoblasts from wild type male mice compared to those with AR [GeneID=367] knockout.,CGP,C2,11,30
Cohort,0.02554136371839988,0.04992248052425232,0.5116204854042037,0.60905207593831,LGP Proband,Genes down-regulated in osteoblasts from wild type male mice compared to those with AR [GeneID=367] knockout.,CGP,C2,11,32
Cohort,0.03223372708961973,0.015932639295957632,2.0231253900160753,0.04339400404391081,LonGen OPEL,Genes down-regulated in osteoblasts from wild type male mice compared to those with AR [GeneID=367] knockout.,CGP,C2,10,25
Cohort,-0.036438558963887945,0.02720054376116826,-1.3396261223243617,0.18081710003850823,LGP Offspring,Genes up-regulated in osteoblasts from wild type male mice compared to those with AR [GeneID=367] knockout.,CGP,C2,29,48
Cohort,-0.042741823272216914,0.07507396001627219,-0.5693295420003511,0.5692858210416044,LGP Proband,Genes up-regulated in osteoblasts from wild type male mice compared to those with AR [GeneID=367] knockout.,CGP,C2,29,66
Cohort,-0.03914763176177984,0.02636643389972496,-1.4847526180697577,0.13800525173152586,LonGen OPEL,Genes up-regulated in osteoblasts from wild type male mice compared to those with AR [GeneID=367] knockout.,CGP,C2,57,50
Cohort,-0.004328204707401499,0.018338759345279242,-0.23601404140327867,0.8134932624921611,LGP Offspring,Genes down-regulated in gastric cancer cell lines resistant to cisplatin [PubChem=2767].,CGP,C2,11,21
Cohort,-0.02307049011597585,0.04457643146229154,-0.5175490580822251,0.6049101750099747,LGP Proband,Genes down-regulated in gastric cancer cell lines resistant to cisplatin [PubChem=2767].,CGP,C2,11,22
Cohort,-0.008570251379074582,0.011752523922884716,-0.7292264568282598,0.4660776582880424,LonGen OPEL,Genes down-regulated in gastric cancer cell lines resistant to cisplatin [PubChem=2767].,CGP,C2,11,10
Cohort,0.03573090927778989,0.01981338714230706,1.8033720848009134,0.07177493519537455,LGP Offspring,Genes up-regulated in gastric cancer cell lines resistant to cisplatin [PubChem=2767].,CGP,C2,7,31
Cohort,-0.034306046324052826,0.046431061461482535,-0.7388598331423423,0.46019999591465854,LGP Proband,Genes up-regulated in gastric cancer cell lines resistant to cisplatin [PubChem=2767].,CGP,C2,7,27
Cohort,-0.017000427760799935,0.015925751182162044,-1.067480432561423,0.28607858176369355,LonGen OPEL,Genes up-regulated in gastric cancer cell lines resistant to cisplatin [PubChem=2767].,CGP,C2,20,17
Cohort,-0.007760328646337271,0.022303246375130866,-0.3479461472026059,0.7279889451643677,LGP Offspring,Genes down-regulated in gastric cancer cell lines: doxorubicin [PubChem=31703] resistant vs sensitive.,CGP,C2,17,33
Cohort,0.07432237114198206,0.070427754736829,1.0552994543089764,0.29159399678389386,LGP Proband,Genes down-regulated in gastric cancer cell lines: doxorubicin [PubChem=31703] resistant vs sensitive.,CGP,C2,17,58
Cohort,0.02374527021353497,0.02129130411570169,1.1152567303767718,0.2650770059635371,LonGen OPEL,Genes down-regulated in gastric cancer cell lines: doxorubicin [PubChem=31703] resistant vs sensitive.,CGP,C2,27,40
Cohort,-0.05588897055622505,0.04470099960206612,-1.2502845809658765,0.21162822996525532,LGP Offspring,Genes up-regulated in gastric cancer cell lines: doxorubicin [PubChem=31703] resistant vs sensitive.,CGP,C2,72,121
Cohort,-0.1097503509830726,0.11564274577668548,-0.9490465679101782,0.3428718472599669,LGP Proband,Genes up-regulated in gastric cancer cell lines: doxorubicin [PubChem=31703] resistant vs sensitive.,CGP,C2,72,151
Cohort,-0.07526513594457007,0.03692874954828436,-2.0381176418161915,0.04186825791438928,LonGen OPEL,Genes up-regulated in gastric cancer cell lines: doxorubicin [PubChem=31703] resistant vs sensitive.,CGP,C2,106,99
Cohort,-0.01296186495368448,0.02935524375541716,-0.44155194423458066,0.6589546669181356,LGP Offspring,Genes down-regulated in gastric cancer cell lines resistant to 5-fluorouracil [PubChem=3385].,CGP,C2,26,58
Cohort,0.059456192812658556,0.07916707152753501,0.7510217526737637,0.4528514154017933,LGP Proband,Genes down-regulated in gastric cancer cell lines resistant to 5-fluorouracil [PubChem=3385].,CGP,C2,26,78
Cohort,0.020902060262201184,0.02711497664369638,0.77086772143912,0.4410140862665206,LonGen OPEL,Genes down-regulated in gastric cancer cell lines resistant to 5-fluorouracil [PubChem=3385].,CGP,C2,43,60
Cohort,0.011820646786458867,0.01906296271648491,0.6200844518379524,0.53541115251278,LGP Offspring,Genes up-regulated in gastric cancer cell lines resistant to 5-fluorouracil [PubChem=3385].,CGP,C2,9,24
Cohort,-0.02590479245726103,0.04532880327853022,-0.5714863526858367,0.5678239846621641,LGP Proband,Genes up-regulated in gastric cancer cell lines resistant to 5-fluorouracil [PubChem=3385].,CGP,C2,9,26
Cohort,-0.014141291145545958,0.015979307867209108,-0.8849751981163767,0.3764372493842062,LonGen OPEL,Genes up-regulated in gastric cancer cell lines resistant to 5-fluorouracil [PubChem=3385].,CGP,C2,23,17
Cohort,-0.02078125970375688,0.029544329614886518,-0.7033924944191596,0.4820533661805968,LGP Offspring,Genes downregulated in the postnatal day 3 pancreata with impaired function of GLIS3 [GeneID=169792].,CGP,C2,27,44
Cohort,-0.04233167706873903,0.06853645289068087,-0.61765199807262,0.5369733675455319,LGP Proband,Genes downregulated in the postnatal day 3 pancreata with impaired function of GLIS3 [GeneID=169792].,CGP,C2,27,48
Cohort,-0.02100990643413691,0.02357903707912786,-0.8910417488055462,0.3731760174859753,LonGen OPEL,Genes downregulated in the postnatal day 3 pancreata with impaired function of GLIS3 [GeneID=169792].,CGP,C2,43,40
Cohort,-0.005572276131838941,0.056672766162998205,-0.09832370129618086,0.9217044051752545,LGP Offspring,Down-regulated genes in the signature of adipose stromal cells (ADSC) immortalized by forced expression of telomerase (TERT) [GeneID=7015].,CGP,C2,99,200
Cohort,-0.26027435913704955,0.15677308603947235,-1.6601979696407687,0.09725053445516338,LGP Proband,Down-regulated genes in the signature of adipose stromal cells (ADSC) immortalized by forced expression of telomerase (TERT) [GeneID=7015].,CGP,C2,99,295
Cohort,-0.04193017468997636,0.046491935235485234,-0.9018806052618975,0.36739310202644204,LonGen OPEL,Down-regulated genes in the signature of adipose stromal cells (ADSC) immortalized by forced expression of telomerase (TERT) [GeneID=7015].,CGP,C2,160,171
Cohort,-0.01314495921656571,0.053273678555150326,-0.24674397513131552,0.8051812817872422,LGP Offspring,Up-regulated genes in the signature of adipose stromal cells (ADSC) immortalized by forced expression of telomerase (TERT) [GeneID=7015].,CGP,C2,103,204
Cohort,-0.12276215583359204,0.15425834897307297,-0.795821792796584,0.42636207129872894,LGP Proband,Up-regulated genes in the signature of adipose stromal cells (ADSC) immortalized by forced expression of telomerase (TERT) [GeneID=7015].,CGP,C2,103,290
Cohort,-0.028424715509599286,0.04572736978128389,-0.6216127375258189,0.5343745248492406,LonGen OPEL,Up-regulated genes in the signature of adipose stromal cells (ADSC) immortalized by forced expression of telomerase (TERT) [GeneID=7015].,CGP,C2,161,182
Cohort,0.008451446456862839,0.02767470092420797,0.30538528600574977,0.7601667355128707,LGP Offspring,Primary down-regulated targets of TP53 [GeneID=7157] in the H1299 (lung cancer) cell line.,CGP,C2,27,55
Cohort,-0.057789280860768046,0.0889666160275641,-0.6495614134954112,0.5161544183133642,LGP Proband,Primary down-regulated targets of TP53 [GeneID=7157] in the H1299 (lung cancer) cell line.,CGP,C2,27,94
Cohort,-0.024701401809670353,0.026340452403312183,-0.9377743947391075,0.34864480546402854,LonGen OPEL,Primary down-regulated targets of TP53 [GeneID=7157] in the H1299 (lung cancer) cell line.,CGP,C2,47,45
Cohort,-0.05440960617842552,0.03143277039028887,-1.7309834768886716,0.08391100498677932,LGP Offspring,Primary up-regulated targets of TP53 [GeneID=7157] in the H1299 (lung cancer) cell line.,CGP,C2,35,48
Cohort,-0.19412976558684153,0.08291379542110411,-2.3413445808492024,0.019449034907737688,LGP Proband,Primary up-regulated targets of TP53 [GeneID=7157] in the H1299 (lung cancer) cell line.,CGP,C2,35,67
Cohort,0.0028337322010130736,0.023509684403576266,0.12053467636435007,0.9040900293273606,LonGen OPEL,Primary up-regulated targets of TP53 [GeneID=7157] in the H1299 (lung cancer) cell line.,CGP,C2,38,44
Cohort,-0.016379135344894664,0.009009033423252577,-1.8180790963234348,0.06949450610421104,LGP Offspring,Selected down-regulated MET [GeneID=4233] target genes from a classifier of hepatocellular carcinoma (HCC) cases; associated with poor survival.,CGP,C2,4,2
Cohort,-0.03109052097354507,0.0313603886782187,-0.9913946313790089,0.32178046041587277,LGP Proband,Selected down-regulated MET [GeneID=4233] target genes from a classifier of hepatocellular carcinoma (HCC) cases; associated with poor survival.,CGP,C2,4,10
Cohort,-0.005030905216328664,0.0093066445246647745,-0.5405713308374026,0.5889543044378224,LonGen OPEL,Selected down-regulated MET [GeneID=4233] target genes from a classifier of hepatocellular carcinoma (HCC) cases; associated with poor survival.,CGP,C2,7,6
Cohort,2.3598480155699066e-4,0.016862393172217223,0.013994739604684546,0.9888383069603461,LGP Offspring,Selected up-regulated MET [GeneID=4233] target genes from a classifier of hepatocellular carcinoma (HCC) cases; associated with poor survival.,CGP,C2,10,19
Cohort,0.01632136544687489,0.050754694125177004,0.3215735160696916,0.7478563859742948,LGP Proband,Selected up-regulated MET [GeneID=4233] target genes from a classifier of hepatocellular carcinoma (HCC) cases; associated with poor survival.,CGP,C2,10,32
Cohort,-0.004921973256639453,0.017922199153245232,-0.27462998343862366,0.7836717879562233,LonGen OPEL,Selected up-regulated MET [GeneID=4233] target genes from a classifier of hepatocellular carcinoma (HCC) cases; associated with poor survival.,CGP,C2,21,25
Cohort,0.010667564783318867,0.02143473496680896,0.4976765422962901,0.6188738903357094,LGP Offspring,Genes up-regulated by TGFB1 [GeneID=7040] in MCF10A cells (breast cancer): both wild-type and those lacking p21 [GeneID=1026].,CGP,C2,12,30
Cohort,-0.07356485463529816,0.05966365338159889,-1.2329927931967135,0.2179258765507625,LGP Proband,Genes up-regulated by TGFB1 [GeneID=7040] in MCF10A cells (breast cancer): both wild-type and those lacking p21 [GeneID=1026].,CGP,C2,12,45
Cohort,-0.006454355644689055,0.015969821670523136,-0.404159531512015,0.6862039729913552,LonGen OPEL,Genes up-regulated by TGFB1 [GeneID=7040] in MCF10A cells (breast cancer): both wild-type and those lacking p21 [GeneID=1026].,CGP,C2,20,20
Cohort,-0.10550930570888392,0.08340987679989643,-1.2649497848079176,0.2063252104706928,LGP Offspring,Genes down-regulated by TGFB1 [GeneID=7040] in MEF cells (embryonic fibroblast) via TGFB1R [GeneID=7046].,CGP,C2,225,417
Cohort,-0.19483079885522,0.2216916643539982,-0.8788368269188207,0.3797428832351789,LGP Proband,Genes down-regulated by TGFB1 [GeneID=7040] in MEF cells (embryonic fibroblast) via TGFB1R [GeneID=7046].,CGP,C2,225,577
Cohort,0.02848162964995516,0.06911311785203463,0.41210164633191537,0.680375874539402,LonGen OPEL,Genes down-regulated by TGFB1 [GeneID=7040] in MEF cells (embryonic fibroblast) via TGFB1R [GeneID=7046].,CGP,C2,321,403
Cohort,0.05921301652398727,0.058453120635116526,1.013000091023613,0.3114225496001477,LGP Offspring,Genes up-regulated by TGFB1 [GeneID=7040] in MEF cells (embryonic fibroblast) via TGFB1R [GeneID=7046].,CGP,C2,92,218
Cohort,-0.03731168692029424,0.15641286998757423,-0.23854614344240574,0.811516130760945,LGP Proband,Genes up-regulated by TGFB1 [GeneID=7040] in MEF cells (embryonic fibroblast) via TGFB1R [GeneID=7046].,CGP,C2,92,299
Cohort,-0.031478225257386284,0.05348792660295072,-0.588510852010662,0.5563563987025839,LonGen OPEL,Genes up-regulated by TGFB1 [GeneID=7040] in MEF cells (embryonic fibroblast) via TGFB1R [GeneID=7046].,CGP,C2,181,213
Cohort,-0.07494199218262575,0.023426716893597186,-3.1989967916976165,0.0014434876745662876,LGP Offspring,Genes down-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating form of HDAC7 [GeneID=51564] and up-regulated by its transcriptionally repressing form.,CGP,C2,29,27
Cohort,-0.009535205483315047,0.06385462931117174,-0.14932676904048378,0.881331894594687,LGP Proband,Genes down-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating form of HDAC7 [GeneID=51564] and up-regulated by its transcriptionally repressing form.,CGP,C2,29,36
Cohort,0.007411278278994998,0.019744157395430617,0.37536564010121737,0.7074885542122078,LonGen OPEL,Genes down-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating form of HDAC7 [GeneID=51564] and up-regulated by its transcriptionally repressing form.,CGP,C2,27,33
Cohort,-0.0548921504009194,0.0694025068752788,-0.7909246059305102,0.4292653838881183,LGP Offspring,Genes up-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating form of HDAC7 [GeneID=51564] and down-regulated by its transcriptionally repressing form.,CGP,C2,173,337
Cohort,-0.2755764598119801,0.21056318351185893,-1.3087589920317653,0.1909765162707552,LGP Proband,Genes up-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating form of HDAC7 [GeneID=51564] and down-regulated by its transcriptionally repressing form.,CGP,C2,173,536
Cohort,0.011093548443378266,0.06184679114685409,0.17937144737286104,0.8576916969582623,LonGen OPEL,Genes up-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating form of HDAC7 [GeneID=51564] and down-regulated by its transcriptionally repressing form.,CGP,C2,262,301
Cohort,0.015762042431073413,0.03500339559903643,0.4503003826150886,0.6526382381801328,LGP Offspring,Genes down-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating and by transcriptionally repressive forms of HDAC7 [GeneID=51564].,CGP,C2,37,89
Cohort,0.07141861629475801,0.10022517738469772,0.7125815903585733,0.47630401412069134,LGP Proband,Genes down-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating and by transcriptionally repressive forms of HDAC7 [GeneID=51564].,CGP,C2,37,119
Cohort,-0.021547888168450772,0.02748713488673122,-0.783926307970807,0.43331655403433156,LonGen OPEL,Genes down-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating and by transcriptionally repressive forms of HDAC7 [GeneID=51564].,CGP,C2,57,58
Cohort,0.009284481067405275,0.0105004735100503,0.8841964182395047,0.37690455265277323,LGP Offspring,Genes up-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating and by transcriptionally repressive forms of HDAC7 [GeneID=51564].,CGP,C2,2,9
Cohort,0.01835111511775529,0.03118172632468817,0.5885214605076491,0.5563416784743824,LGP Proband,Genes up-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating and by transcriptionally repressive forms of HDAC7 [GeneID=51564].,CGP,C2,2,14
Cohort,0.0021957891391361207,0.00772323171378063,0.2843096284704439,0.7762470501085618,LonGen OPEL,Genes up-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating and by transcriptionally repressive forms of HDAC7 [GeneID=51564].,CGP,C2,3,6
Cohort,0.041196088408504396,0.073408501898434,0.5611896080579628,0.5748542613954248,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblast) with ELAVL1 [GeneID=1994] knocked out.,CGP,C2,167,378
Cohort,-0.0966211340455151,0.19211858641985174,-0.5029244481029097,0.6151501738585976,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblast) with ELAVL1 [GeneID=1994] knocked out.,CGP,C2,167,488
Cohort,0.06426804523047505,0.061987998146411503,1.0367820731793633,0.3001522796359229,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblast) with ELAVL1 [GeneID=1994] knocked out.,CGP,C2,257,328
Cohort,-0.09959553306870929,0.0769947598673326,-1.2935365113199835,0.19626738055613674,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) with ELAVL1 [GeneID=1994] knocked out.,CGP,C2,216,423
Cohort,-0.24643086390829833,0.20156809293251177,-1.2225688119736655,0.22183797848570272,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) with ELAVL1 [GeneID=1994] knocked out.,CGP,C2,216,569
Cohort,0.0270665089584618,0.06782517344050618,0.3990628786552765,0.689953909003977,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) with ELAVL1 [GeneID=1994] knocked out.,CGP,C2,325,395
Cohort,-0.058178448103421904,0.09324220747484593,-0.6239497077449263,0.5328711045586376,LGP Offspring,"Genes involved in DNA repair, compiled manually by the authors.",CGP,C2,278,566
Cohort,0.03727737107411597,0.2668808852989729,0.1396779354668134,0.8889481837772213,LGP Proband,"Genes involved in DNA repair, compiled manually by the authors.",CGP,C2,278,836
Cohort,0.02362425669257797,0.08208550495227863,0.28780058923085394,0.7735742997424362,LonGen OPEL,"Genes involved in DNA repair, compiled manually by the authors.",CGP,C2,478,576
Cohort,-0.11958148717344044,0.07503664278102613,-1.593641223027611,0.11148384249179048,LGP Offspring,"Genes involved in DNA replication, compiled manually by the authors.",CGP,C2,193,337
Cohort,-0.23549059151516116,0.21685132336805432,-1.085954136030201,0.27781306331785355,LGP Proband,"Genes involved in DNA replication, compiled manually by the authors.",CGP,C2,193,513
Cohort,-9.581244976431321e-4,0.06155354018581293,-0.015565709051840432,0.9875847630789218,LonGen OPEL,"Genes involved in DNA replication, compiled manually by the authors.",CGP,C2,287,345
Cohort,-0.006966324098682669,0.011084542366482597,-0.6284719628793533,0.5299070859594981,LGP Offspring,DNA repair and replication genes down-regulated in melanoma patients who will relapse vs patients who will not.,CGP,C2,4,8
Cohort,0.018910513602328254,0.022030656954805706,0.8583726595680646,0.39093334034728633,LGP Proband,DNA repair and replication genes down-regulated in melanoma patients who will relapse vs patients who will not.,CGP,C2,4,4
Cohort,-0.015952094956920588,0.008503002395101005,-1.8760543882842335,0.06101354210507842,LonGen OPEL,DNA repair and replication genes down-regulated in melanoma patients who will relapse vs patients who will not.,CGP,C2,7,4
Cohort,-0.09710429696239761,0.04608424917809483,-2.107103808659946,0.03547636095713187,LGP Offspring,DNA repair and replication genes up-regulated in melanoma patients who will relapse vs patients who will not.,CGP,C2,89,139
Cohort,0.07694973415407892,0.1394918079616963,0.5516433923862317,0.5813404714788534,LGP Proband,DNA repair and replication genes up-regulated in melanoma patients who will relapse vs patients who will not.,CGP,C2,89,225
Cohort,0.0597765882018747,0.039080283503589275,1.5295843029486877,0.12651693595969388,LonGen OPEL,DNA repair and replication genes up-regulated in melanoma patients who will relapse vs patients who will not.,CGP,C2,101,140
Cohort,-0.1479839721514994,0.055175286851191004,-2.6820698286646976,0.007495529081338279,LGP Offspring,Downregulated in the vastus lateralis muscle of aged vs young adult rhesus monkeys,CGP,C2,125,209
Cohort,0.03708149455249946,0.15611298986221625,0.2375298467169658,0.8123041050290136,LGP Proband,Downregulated in the vastus lateralis muscle of aged vs young adult rhesus monkeys,CGP,C2,125,267
Cohort,-0.02273158354848268,0.049426377475653115,-0.4599079420635268,0.6457078893608728,LonGen OPEL,Downregulated in the vastus lateralis muscle of aged vs young adult rhesus monkeys,CGP,C2,157,186
Cohort,-0.17270334074003652,0.07664837560917763,-2.2531898343238677,0.024566916291187697,LGP Offspring,Upregulated in the vastus lateralis muscle of aged vs young adult rhesus monkeys,CGP,C2,199,347
Cohort,-0.28006280788946153,0.22113133737351648,-1.266499860290733,0.20568778254376727,LGP Proband,Upregulated in the vastus lateralis muscle of aged vs young adult rhesus monkeys,CGP,C2,199,546
Cohort,0.03656712380509477,0.06914673766049476,0.5288336809848727,0.5970682545438932,LonGen OPEL,Upregulated in the vastus lateralis muscle of aged vs young adult rhesus monkeys,CGP,C2,309,386
Cohort,-0.09171651430626845,0.04497476863809677,-2.0392881849886417,0.04180966452815704,LGP Offspring,Downregulated in the vastus lateralis muscle of middle aged rhesus monkeys subjected to caloric restriction since young adulthood vs age matched controls,CGP,C2,77,124
Cohort,0.14440876692855942,0.1290955557580718,1.1186191970789834,0.26362471836155393,LGP Proband,Downregulated in the vastus lateralis muscle of middle aged rhesus monkeys subjected to caloric restriction since young adulthood vs age matched controls,CGP,C2,77,195
Cohort,0.016069989276461073,0.042078668808980486,0.3819034615712794,0.7026349022656688,LonGen OPEL,Downregulated in the vastus lateralis muscle of middle aged rhesus monkeys subjected to caloric restriction since young adulthood vs age matched controls,CGP,C2,117,149
Cohort,0.018259385874751326,0.0560398136389421,0.3258288115016654,0.7446547116205848,LGP Offspring,Upregulated in the vastus lateralis muscle of middle aged rhesus monkeys subjected to caloric restriction since young adulthood vs age matched controls,CGP,C2,94,203
Cohort,-0.13117323819944146,0.15752918455874537,-0.8326916600683899,0.4052570314073525,LGP Proband,Upregulated in the vastus lateralis muscle of middle aged rhesus monkeys subjected to caloric restriction since young adulthood vs age matched controls,CGP,C2,94,282
Cohort,-0.06365693107847142,0.050873410551017545,-1.2512809813416017,0.21119959748217276,LonGen OPEL,Upregulated in the vastus lateralis muscle of middle aged rhesus monkeys subjected to caloric restriction since young adulthood vs age matched controls,CGP,C2,163,172
Cohort,-0.0219619582321505,0.03581127556408748,-0.6132693651988914,0.5399045247008105,LGP Offspring,Genes down-regulated in HC11 cells (mammary epithelium) by expression of constantly active CTNNB1 [GeneID=1499].,CGP,C2,46,88
Cohort,-0.10257304446343439,0.10421090435027582,-0.9842832197162764,0.3252617307808555,LGP Proband,Genes down-regulated in HC11 cells (mammary epithelium) by expression of constantly active CTNNB1 [GeneID=1499].,CGP,C2,46,132
Cohort,0.0015004228813438223,0.02937253210444252,0.051082517367199924,0.9592725824368813,LonGen OPEL,Genes down-regulated in HC11 cells (mammary epithelium) by expression of constantly active CTNNB1 [GeneID=1499].,CGP,C2,61,75
Cohort,-0.10418778497132294,0.04760709332607916,-2.1884928839847673,0.028975184189724213,LGP Offspring,Genes up-regulated in HC11 cells (mammary epithelium) by expression of constantly active CTNNB1 [GeneID=1499].,CGP,C2,87,139
Cohort,-0.09025211111242355,0.12549747806548894,-0.719154779073145,0.47224700921403884,LGP Proband,Genes up-regulated in HC11 cells (mammary epithelium) by expression of constantly active CTNNB1 [GeneID=1499].,CGP,C2,87,197
Cohort,-0.017581081799189095,0.037964613765774084,-0.4630912856813736,0.6434255159438425,LonGen OPEL,Genes up-regulated in HC11 cells (mammary epithelium) by expression of constantly active CTNNB1 [GeneID=1499].,CGP,C2,110,128
Cohort,0.022949023310321538,0.013082042058197471,1.754238612613328,0.07984271384661241,LGP Offspring,Genes genes down-regulated in NT2/D1 cells (embryonal carcinoma) in response to treatment with cisplatin [PubChem=2767].,CGP,C2,3,14
Cohort,-0.003259824973513103,0.030432624911970768,-0.10711612892224887,0.9147226129709336,LGP Proband,Genes genes down-regulated in NT2/D1 cells (embryonal carcinoma) in response to treatment with cisplatin [PubChem=2767].,CGP,C2,3,12
Cohort,0.013710800367238879,0.009914685068632438,1.3828780513277614,0.1670900531358132,LonGen OPEL,Genes genes down-regulated in NT2/D1 cells (embryonal carcinoma) in response to treatment with cisplatin [PubChem=2767].,CGP,C2,4,11
Cohort,-0.04040106996610681,0.03120847040673966,-1.294554633391515,0.1959159278115234,LGP Offspring,Genes genes up-regulated in NT2/D1 cells (embryonal carcinoma) in response to treatment with cisplatin [PubChem=2767].,CGP,C2,36,55
Cohort,-0.0620294538115198,0.08143973380580785,-0.7616608123919996,0.44647779203020765,LGP Proband,Genes genes up-regulated in NT2/D1 cells (embryonal carcinoma) in response to treatment with cisplatin [PubChem=2767].,CGP,C2,36,72
Cohort,-0.03617669905008349,0.025564608923740795,-1.415108643280973,0.15742772956164697,LonGen OPEL,Genes genes up-regulated in NT2/D1 cells (embryonal carcinoma) in response to treatment with cisplatin [PubChem=2767].,CGP,C2,47,44
Cohort,0.010057787470538504,0.03763263305380027,0.2672623904939024,0.7893486571558961,LGP Offspring,Genes up-regulated in multiple drug resistant neuroblastoma cell lines.,CGP,C2,46,93
Cohort,-0.13562598746232105,0.10360234433583175,-1.3091015298136806,0.19086052739972542,LGP Proband,Genes up-regulated in multiple drug resistant neuroblastoma cell lines.,CGP,C2,46,141
Cohort,-0.09830685573114252,0.035065797938443596,-2.803496897567131,0.005178170339985133,LonGen OPEL,Genes up-regulated in multiple drug resistant neuroblastoma cell lines.,CGP,C2,97,89
Cohort,0.009302096983761068,0.010066090706848264,0.9241022413430641,0.35576282295787165,LGP Offspring,Retinoic acid-responsive genes down-regulated in hepatocellular carcinoma (HCC) samples of TRIM24 [GeneID=8805] knockout mice.,CGP,C2,1,7
Cohort,-0.003801037608155527,0.03640497270090694,-0.10440984640707707,0.9168692124219708,LGP Proband,Retinoic acid-responsive genes down-regulated in hepatocellular carcinoma (HCC) samples of TRIM24 [GeneID=8805] knockout mice.,CGP,C2,1,19
Cohort,0.0015987467685449732,0.011450402912980252,0.139623625534838,0.8889926919945793,LonGen OPEL,Retinoic acid-responsive genes down-regulated in hepatocellular carcinoma (HCC) samples of TRIM24 [GeneID=8805] knockout mice.,CGP,C2,9,11
Cohort,0.008997540390699374,0.03150640253047831,0.2855781577092286,0.7752887153010442,LGP Offspring,Retinoic acid-responsive genes up-regulated in hepatocellular carcinoma (HCC) samples of TRIM24 [GeneID=8805] knockout mice.,CGP,C2,31,67
Cohort,0.20663218912407388,0.08863286049813271,2.331327094293963,0.01997351791026287,LGP Proband,Retinoic acid-responsive genes up-regulated in hepatocellular carcinoma (HCC) samples of TRIM24 [GeneID=8805] knockout mice.,CGP,C2,31,93
Cohort,0.003913703338430078,0.02825625437482901,0.13850750656875632,0.8898743688553233,LonGen OPEL,Retinoic acid-responsive genes up-regulated in hepatocellular carcinoma (HCC) samples of TRIM24 [GeneID=8805] knockout mice.,CGP,C2,57,66
Cohort,0.005953552393393467,0.03344305939536584,0.17802056692870757,0.8587601558379138,LGP Offspring,Genes whose expression significantly and negatively correlated with the density of CALB1-positive [GeneID=793]  GABAergic interneurons in the BA9 brain region across all subjects with psychiatric disorders.,CGP,C2,33,71
Cohort,0.012393141061400846,0.10098468802451642,0.12272297220339105,0.9023560383953351,LGP Proband,Genes whose expression significantly and negatively correlated with the density of CALB1-positive [GeneID=793]  GABAergic interneurons in the BA9 brain region across all subjects with psychiatric disorders.,CGP,C2,33,124
Cohort,0.0035770916956945,0.0308583127292274,0.11591987310137225,0.9077452825628541,LonGen OPEL,Genes whose expression significantly and negatively correlated with the density of CALB1-positive [GeneID=793]  GABAergic interneurons in the BA9 brain region across all subjects with psychiatric disorders.,CGP,C2,59,77
Cohort,-0.006825439851614291,0.10542987962336411,-0.06473914108597463,0.948400837387051,LGP Offspring,Genes whose expression significantly and positively correlated with the density of CALB1-positive [GeneID=793]  GABAergic interneurons in the BA9 brain region across all subjects with psychiatric disorders.,CGP,C2,361,728
Cohort,-0.2621876969239486,0.29227060945577443,-0.8970717151894197,0.36993952457570456,LGP Proband,Genes whose expression significantly and positively correlated with the density of CALB1-positive [GeneID=793]  GABAergic interneurons in the BA9 brain region across all subjects with psychiatric disorders.,CGP,C2,361,1091
Cohort,-0.030074916672784266,0.09192117427089089,-0.3271815978346159,0.7436165591035104,LonGen OPEL,Genes whose expression significantly and positively correlated with the density of CALB1-positive [GeneID=793]  GABAergic interneurons in the BA9 brain region across all subjects with psychiatric disorders.,CGP,C2,583,695
Cohort,0.010537804169739314,0.060820707618699406,0.17326013758017264,0.862498820630136,LGP Offspring,Genes whose expression in brain significantly and negatively correlated with the duration of all psychiatric disorders studied.,CGP,C2,121,248
Cohort,0.08161907524086626,0.16904184399298422,0.4828335595076312,0.6293406319821359,LGP Proband,Genes whose expression in brain significantly and negatively correlated with the duration of all psychiatric disorders studied.,CGP,C2,121,332
Cohort,0.10711695598687891,0.0540573152102779,1.981544136444882,0.04787393204779248,LonGen OPEL,Genes whose expression in brain significantly and negatively correlated with the duration of all psychiatric disorders studied.,CGP,C2,188,263
Cohort,-0.0014351404842777274,0.015527378113091005,-0.09242645305763322,0.9263866063170643,LGP Offspring,Genes whose expression in brain significantly and positively correlated with the duration of all psychiatric disorders studied.,CGP,C2,8,17
Cohort,-0.037191979388789015,0.04560596420859026,-0.815506919636261,0.4150150380106721,LGP Proband,Genes whose expression in brain significantly and positively correlated with the duration of all psychiatric disorders studied.,CGP,C2,8,27
Cohort,0.022778016788310356,0.01653170904239173,1.3778379918193224,0.16864052961273238,LonGen OPEL,Genes whose expression in brain significantly and positively correlated with the duration of all psychiatric disorders studied.,CGP,C2,17,26
Cohort,-0.019847213702240712,0.0274274737764554,-0.7236252913412018,0.46954613090272745,LGP Offspring,Genes whose expression was significantly and negatively correlated with the number of perineuronal oligodendrocytes in the layer III of BA9 brain region.,CGP,C2,28,55
Cohort,-0.05228404953512066,0.0830865720199669,-0.6292719541077715,0.5293433564656808,LGP Proband,Genes whose expression was significantly and negatively correlated with the number of perineuronal oligodendrocytes in the layer III of BA9 brain region.,CGP,C2,28,94
Cohort,0.047184608203701676,0.02837534297638779,1.6628735815798172,0.0967314041773604,LonGen OPEL,Genes whose expression was significantly and negatively correlated with the number of perineuronal oligodendrocytes in the layer III of BA9 brain region.,CGP,C2,52,77
Cohort,-0.2108819232637799,0.13301472631962988,-1.5854028279322832,0.11334248837830344,LGP Offspring,Genes whose expression was significantly and positively correlated with the number of perineuronal oligodendrocytes in the layer III of BA9 brain region.,CGP,C2,601,1169
Cohort,-0.11427327022675784,0.3640159572958593,-0.3139237935491948,0.7536574218112451,LGP Proband,Genes whose expression was significantly and positively correlated with the number of perineuronal oligodendrocytes in the layer III of BA9 brain region.,CGP,C2,601,1630
Cohort,0.15510499927715873,0.11962949939809174,1.296544749059051,0.19516360843733532,LonGen OPEL,Genes whose expression was significantly and positively correlated with the number of perineuronal oligodendrocytes in the layer III of BA9 brain region.,CGP,C2,912,1160
Cohort,-0.15690678124939844,0.04775705519954427,-3.285520444964449,0.0010705120331380245,LGP Offspring,Genes whose expression significantly and negatively correlated with oligodendrocyte density in layer VI of BA9 brain region in patients with bipolar disorder.,CGP,C2,84,114
Cohort,0.03315630265293695,0.13021844515733053,0.2546206308397966,0.7990788917120217,LGP Proband,Genes whose expression significantly and negatively correlated with oligodendrocyte density in layer VI of BA9 brain region in patients with bipolar disorder.,CGP,C2,84,178
Cohort,0.032444561349402025,0.03880727293660441,0.8360433211167269,0.40338142212752903,LonGen OPEL,Genes whose expression significantly and negatively correlated with oligodendrocyte density in layer VI of BA9 brain region in patients with bipolar disorder.,CGP,C2,101,132
Cohort,-0.2740219484123012,0.12162469106592637,-2.2530124928643667,0.024578155694269514,LGP Offspring,Genes whose expression significantly and positively correlated with oligodendrocyte density in layer VI of BA9 brain region in patients with bipolar disorder.,CGP,C2,483,892
Cohort,-0.3028660408626536,0.34007649871458506,-0.8905820955209229,0.37341024317751015,LGP Proband,Genes whose expression significantly and positively correlated with oligodendrocyte density in layer VI of BA9 brain region in patients with bipolar disorder.,CGP,C2,483,1331
Cohort,-0.04907188630020226,0.10819040599248099,-0.45356966590561326,0.6502622154168163,LonGen OPEL,Genes whose expression significantly and positively correlated with oligodendrocyte density in layer VI of BA9 brain region in patients with bipolar disorder.,CGP,C2,751,899
Cohort,-0.07098688510796097,0.050570061297989063,-1.403733420247679,0.16085745225630926,LGP Offspring,Genes up-regulated in gastric cancer patients refractory to chemotherapy treatment with 5-fluorouracil and cisplatin [PubChem=3385;2767] compared to the sensitive state.,CGP,C2,93,165
Cohort,-0.10413745871487737,0.13553430674102418,-0.7683475956671311,0.4424982083242489,LGP Proband,Genes up-regulated in gastric cancer patients refractory to chemotherapy treatment with 5-fluorouracil and cisplatin [PubChem=3385;2767] compared to the sensitive state.,CGP,C2,93,210
Cohort,-0.018473802737411074,0.04270831096993638,-0.43255755888860414,0.6654533911093262,LonGen OPEL,Genes up-regulated in gastric cancer patients refractory to chemotherapy treatment with 5-fluorouracil and cisplatin [PubChem=3385;2767] compared to the sensitive state.,CGP,C2,137,146
Cohort,-0.026763969372336636,0.012590726271492226,-2.125689082204519,0.033891057210514636,LGP Offspring,Genes down-regulated in germinal center T helper cells compared to other CD4+ [GeneID=920] T lymphocyte types.,CGP,C2,9,7
Cohort,-0.037134581552031316,0.03638051911077339,-1.0207270940516795,0.3076797465271935,LGP Proband,Genes down-regulated in germinal center T helper cells compared to other CD4+ [GeneID=920] T lymphocyte types.,CGP,C2,9,13
Cohort,-0.0027819027034176585,0.009954829426822142,-0.2794525736344755,0.7799701235546643,LonGen OPEL,Genes down-regulated in germinal center T helper cells compared to other CD4+ [GeneID=920] T lymphocyte types.,CGP,C2,6,9
Cohort,0.01238119370735417,0.03952887566537756,0.3132189696505478,0.7542109203009337,LGP Offspring,Genes up-regulated in germinal center T helper cells compared to other CD4+ [GeneID=920] T lymphocyte types.,CGP,C2,44,103
Cohort,0.025406948367485936,0.09885206764006214,0.25701989825844745,0.7972268064780296,LGP Proband,Genes up-regulated in germinal center T helper cells compared to other CD4+ [GeneID=920] T lymphocyte types.,CGP,C2,44,120
Cohort,0.0350639177840514,0.03238042895975853,1.0828737885970514,0.2791923575983387,LonGen OPEL,Genes up-regulated in germinal center T helper cells compared to other CD4+ [GeneID=920] T lymphocyte types.,CGP,C2,64,92
Cohort,0.0066861122470977565,0.015133842623487038,0.44179871652168584,0.6587761584438618,LGP Offspring,Partial list of genes down-regulated in the kidney of GLIS2 [GeneID=84662] knockout mice compared to the wild type.,CGP,C2,7,16
Cohort,0.0033535462076539693,0.03761043805969274,0.08916530571463827,0.928971944612889,LGP Proband,Partial list of genes down-regulated in the kidney of GLIS2 [GeneID=84662] knockout mice compared to the wild type.,CGP,C2,7,16
Cohort,-0.00317003963288561,0.010562255070367661,-0.3001290549950016,0.7641570783708753,LonGen OPEL,Partial list of genes down-regulated in the kidney of GLIS2 [GeneID=84662] knockout mice compared to the wild type.,CGP,C2,9,8
Cohort,-0.004147378853089796,0.058252114103162826,-0.07119705296437666,0.943261984506234,LGP Offspring,Partial list of genes up-regulated in the kidney of GLIS2 [GeneID=84662] knockout mice compared to the wild type.,CGP,C2,113,238
Cohort,-0.08310305886417806,0.16415723650811095,-0.5062406058478693,0.6128215431870973,LGP Proband,Partial list of genes up-regulated in the kidney of GLIS2 [GeneID=84662] knockout mice compared to the wild type.,CGP,C2,113,322
Cohort,0.07986937815833933,0.05052962389941579,1.5806446198239517,0.11435656921624844,LonGen OPEL,Partial list of genes up-regulated in the kidney of GLIS2 [GeneID=84662] knockout mice compared to the wild type.,CGP,C2,174,233
Cohort,0.03671006120875746,0.025719567194542443,1.4273203328455364,0.15394932914734147,LGP Offspring,Genes up-regulated in normal fibroblasts under hypoxia conditions.,CGP,C2,16,50
Cohort,-0.06263230651696534,0.06359740339716631,-0.984824901196454,0.32499569938468653,LGP Proband,Genes up-regulated in normal fibroblasts under hypoxia conditions.,CGP,C2,16,49
Cohort,-0.020630421471374154,0.020586260892137734,-1.0021451481387418,0.3165780341076634,LonGen OPEL,Genes up-regulated in normal fibroblasts under hypoxia conditions.,CGP,C2,36,31
Cohort,-5.152115660213466e-4,0.045337039242988236,-0.011364032028205911,0.9909363622947129,LGP Offspring,Genes under-expressed in hepatocellular carcinoma (HCC) with poor survival,CGP,C2,57,131
Cohort,0.1739642569468876,0.12472411377315497,1.39479248786878,0.1634497892007503,LGP Proband,Genes under-expressed in hepatocellular carcinoma (HCC) with poor survival,CGP,C2,57,192
Cohort,-0.034442988849496176,0.03954818886398195,-0.8709119137656572,0.3840648265994284,LonGen OPEL,Genes under-expressed in hepatocellular carcinoma (HCC) with poor survival,CGP,C2,105,107
Cohort,-0.016050234210241723,0.019423589290905326,-0.8263268940595289,0.40891023032883866,LGP Offspring,Genes over-expressed in hepatocellular carcinoma (HCC) with poor survival,CGP,C2,15,24
Cohort,-0.11464908721424326,0.053878473377981836,-2.127920114030108,0.0336364030762962,LGP Proband,Genes over-expressed in hepatocellular carcinoma (HCC) with poor survival,CGP,C2,15,36
Cohort,-0.02850156244116803,0.021155026631192075,-1.3472714044776404,0.178276219166358,LonGen OPEL,Genes over-expressed in hepatocellular carcinoma (HCC) with poor survival,CGP,C2,34,30
Cohort,0.03328842819213912,0.03337535761527835,0.9973954009979076,0.31892950230265293,LGP Offspring,Immune response genes up-regulated in zenograft tumors formed by SNU-601 cells (gastric cancer) made to express LRRC3B [GeneID=116135].,CGP,C2,25,76
Cohort,-0.023623245792881536,0.07095074006701976,-0.3329527749896212,0.7392536092878723,LGP Proband,Immune response genes up-regulated in zenograft tumors formed by SNU-601 cells (gastric cancer) made to express LRRC3B [GeneID=116135].,CGP,C2,25,57
Cohort,0.023832940522229465,0.024620353066966753,0.9680178207601027,0.33332949181726934,LonGen OPEL,Immune response genes up-regulated in zenograft tumors formed by SNU-601 cells (gastric cancer) made to express LRRC3B [GeneID=116135].,CGP,C2,39,55
Cohort,0.0047288341000686395,0.06580778838077256,0.07185827417124217,0.9427359507596009,LGP Offspring,Genes negatively correlated with amplifications of MYC [GeneID=4609] in SCLC (small cell lung cancer) cell lines.,CGP,C2,134,281
Cohort,0.22891293112956088,0.186892080809737,1.2248401865812744,0.22098127013638147,LGP Proband,Genes negatively correlated with amplifications of MYC [GeneID=4609] in SCLC (small cell lung cancer) cell lines.,CGP,C2,134,415
Cohort,0.010842198165443117,0.05899831581239966,0.18377131645450148,0.8542396611985679,LonGen OPEL,Genes negatively correlated with amplifications of MYC [GeneID=4609] in SCLC (small cell lung cancer) cell lines.,CGP,C2,220,268
Cohort,-0.20026609471221463,0.07495892100080732,-2.6716779275685907,0.007729081169943579,LGP Offspring,Genes positively correlated with amplifications of MYC [GeneID=4609] in SCLC (small cell lung cancer) cell lines.,CGP,C2,213,339
Cohort,-0.18741321834695074,0.2056179514991823,-0.9114633084344099,0.36231467945385143,LGP Proband,Genes positively correlated with amplifications of MYC [GeneID=4609] in SCLC (small cell lung cancer) cell lines.,CGP,C2,213,516
Cohort,0.04466417801481389,0.06761646977426129,0.6605517585275598,0.50909092402568,LonGen OPEL,Genes positively correlated with amplifications of MYC [GeneID=4609] in SCLC (small cell lung cancer) cell lines.,CGP,C2,309,389
Cohort,-0.01785548233795251,0.02125945581379234,-0.8398842611186943,0.40127021908883,LGP Offspring,Genes negatively correlated with amplifications of MYCL1 [GeneID=4610] in SCLC (small cell lung cancer) cell lines.,CGP,C2,16,26
Cohort,0.00847506972688742,0.06114827340256339,0.13859867589543645,0.8898007476364685,LGP Proband,Genes negatively correlated with amplifications of MYCL1 [GeneID=4610] in SCLC (small cell lung cancer) cell lines.,CGP,C2,16,40
Cohort,-0.014003202365860305,0.017747192423993977,-0.7890376140244106,0.43032496737650316,LonGen OPEL,Genes negatively correlated with amplifications of MYCL1 [GeneID=4610] in SCLC (small cell lung cancer) cell lines.,CGP,C2,25,26
Cohort,0.0011697655086708514,0.015233084514991337,0.07679111262854545,0.9388124424323017,LGP Offspring,Genes positively correlated with amplifications of MYCL1 [GeneID=4610] in SCLC (small cell lung cancer) cell lines.,CGP,C2,6,13
Cohort,-0.004044253896023895,0.041739458690502794,-0.09689282091586171,0.9228347888092874,LGP Proband,Genes positively correlated with amplifications of MYCL1 [GeneID=4610] in SCLC (small cell lung cancer) cell lines.,CGP,C2,6,23
Cohort,-0.012610882486119537,0.0118782147615014,-1.061681636452036,0.2887022419056217,LonGen OPEL,Genes positively correlated with amplifications of MYCL1 [GeneID=4610] in SCLC (small cell lung cancer) cell lines.,CGP,C2,15,8
Cohort,-0.022486189350596927,0.0660088513475901,-0.3406541530648506,0.7334697949065767,LGP Offspring,Genes negatively  correlated with amplifications of MYCN  [GeneID=4613] in the SCLC (small cell lung cancer) cell lines.,CGP,C2,132,281
Cohort,0.032928448018377306,0.17935639185633098,0.18359227500937814,0.8543779488971537,LGP Proband,Genes negatively  correlated with amplifications of MYCN  [GeneID=4613] in the SCLC (small cell lung cancer) cell lines.,CGP,C2,132,419
Cohort,-0.14719424288885757,0.06145416491334988,-2.395187422958246,0.016842033616229143,LonGen OPEL,Genes negatively  correlated with amplifications of MYCN  [GeneID=4613] in the SCLC (small cell lung cancer) cell lines.,CGP,C2,268,264
Cohort,-0.05019408739083772,0.05255251639476534,-0.9551224343623907,0.3398572050887463,LGP Offspring,Genes positively  correlated with amplifications of MYCN  [GeneID=4613] in the SCLC (small cell lung cancer) cell lines.,CGP,C2,101,193
Cohort,0.2060061109105666,0.15450968717469118,1.3332892887010555,0.18280094444901443,LGP Proband,Genes positively  correlated with amplifications of MYCN  [GeneID=4613] in the SCLC (small cell lung cancer) cell lines.,CGP,C2,101,285
Cohort,-0.005650217456658502,0.049360008535479706,-0.11446953970028502,0.9088944581012808,LonGen OPEL,Genes positively  correlated with amplifications of MYCN  [GeneID=4613] in the SCLC (small cell lung cancer) cell lines.,CGP,C2,171,197
Cohort,-0.00606492260778317,0.011008768994671672,-0.5509174196241776,0.5818723073730785,LGP Offspring,Genes down-regulated in HCT116 cells (colorectal carcinoma) upon knockout of PTEN [GeneID=5728].,CGP,C2,4,8
Cohort,0.028351283000360255,0.03459944088491496,0.8194144840277218,0.4127840707039514,LGP Proband,Genes down-regulated in HCT116 cells (colorectal carcinoma) upon knockout of PTEN [GeneID=5728].,CGP,C2,4,14
Cohort,0.008260983206437051,0.010620280817112483,0.7778497902923724,0.43688870000505475,LonGen OPEL,Genes down-regulated in HCT116 cells (colorectal carcinoma) upon knockout of PTEN [GeneID=5728].,CGP,C2,6,11
Cohort,-0.011330130254311708,0.023275078919094343,-0.48679234531044824,0.6265632857223711,LGP Offspring,Genes up-regulated in HCT116 cells (colorectal carcinoma) upon knockout of PTEN [GeneID=5728].,CGP,C2,18,37
Cohort,0.06061235647886352,0.06302186059468788,0.9617671694696449,0.3364453306083739,LGP Proband,Genes up-regulated in HCT116 cells (colorectal carcinoma) upon knockout of PTEN [GeneID=5728].,CGP,C2,18,49
Cohort,-0.03240003400103288,0.019325252397049304,-1.676564597209603,0.09402030338789612,LonGen OPEL,Genes up-regulated in HCT116 cells (colorectal carcinoma) upon knockout of PTEN [GeneID=5728].,CGP,C2,29,23
Cohort,6.241727882305822e-4,0.015510674359938258,0.04024149909579217,0.9679124746006958,LGP Offspring,Genes down-regulated in glioma cell lines treated with both decitabine [PubChem=451668] and TSA [PubChem=5562].,CGP,C2,7,17
Cohort,0.026592922483767822,0.0433909124455809,0.6128684783275662,0.5401303870460139,LGP Proband,Genes down-regulated in glioma cell lines treated with both decitabine [PubChem=451668] and TSA [PubChem=5562].,CGP,C2,7,24
Cohort,-0.026575241635034743,0.012193244080218966,-2.179505426135741,0.029586589334986476,LonGen OPEL,Genes down-regulated in glioma cell lines treated with both decitabine [PubChem=451668] and TSA [PubChem=5562].,CGP,C2,16,7
Cohort,0.018277997603220797,0.05534863901491442,0.3302339123152703,0.741325539502912,LGP Offspring,Genes up-regulated in glioma cell lines treated with both decitabine [PubChem=451668] and TSA [PubChem=5562].,CGP,C2,90,192
Cohort,0.05034016647064812,0.1404803137357282,0.35834320932218394,0.7201771683814915,LGP Proband,Genes up-regulated in glioma cell lines treated with both decitabine [PubChem=451668] and TSA [PubChem=5562].,CGP,C2,90,224
Cohort,-0.08857094583289307,0.04285356446343997,-2.0668279743323654,0.03907319706849378,LonGen OPEL,Genes up-regulated in glioma cell lines treated with both decitabine [PubChem=451668] and TSA [PubChem=5562].,CGP,C2,157,156
Cohort,-0.008234448552136092,0.029461692569780668,-0.2794967917281948,0.7799490923098276,LGP Offspring,Top scoring genes whose transcripts bound TIAR1 [GeneID=7073] in extracts from RKO cells (colon cancer).,CGP,C2,31,59
Cohort,-0.13738415009773022,0.07847102841607705,-1.75076270657851,0.08035444644161586,LGP Proband,Top scoring genes whose transcripts bound TIAR1 [GeneID=7073] in extracts from RKO cells (colon cancer).,CGP,C2,31,72
Cohort,0.02022851634367912,0.027053439981820655,0.747724369147593,0.4548472631794198,LonGen OPEL,Top scoring genes whose transcripts bound TIAR1 [GeneID=7073] in extracts from RKO cells (colon cancer).,CGP,C2,47,66
Cohort,-0.012009677800403809,0.05890696860841627,-0.20387533230979973,0.838512280835063,LGP Offspring,Genes down-regulated in UB27 cells (osteosarcoma) at 12 hr after inducing the expression of a mutated form of WT1 [GeneID=7490].,CGP,C2,134,265
Cohort,-0.03565021075306502,0.17100604752912438,-0.20847339183717092,0.834910258611715,LGP Proband,Genes down-regulated in UB27 cells (osteosarcoma) at 12 hr after inducing the expression of a mutated form of WT1 [GeneID=7490].,CGP,C2,134,363
Cohort,-0.014378422967301735,0.05613606660694312,-0.25613520569543,0.7979126164517051,LonGen OPEL,Genes down-regulated in UB27 cells (osteosarcoma) at 12 hr after inducing the expression of a mutated form of WT1 [GeneID=7490].,CGP,C2,215,249
Cohort,-0.024064941073498065,0.0656174211409765,-0.36674621853540185,0.7139230923221256,LGP Offspring,Genes up-regulated in UB27 cells (osteosarcoma) at 12 hr after inducing the expression of a mutated form of WT1 [GeneID=7490].,CGP,C2,141,286
Cohort,-0.02371522741196301,0.18552094508512365,-0.12783045817862568,0.8983139614503699,LGP Proband,Genes up-regulated in UB27 cells (osteosarcoma) at 12 hr after inducing the expression of a mutated form of WT1 [GeneID=7490].,CGP,C2,141,383
Cohort,0.019090163617974526,0.052340544010287204,0.36472994270412007,0.7154098810881204,LonGen OPEL,Genes up-regulated in UB27 cells (osteosarcoma) at 12 hr after inducing the expression of a mutated form of WT1 [GeneID=7490].,CGP,C2,207,248
Cohort,0.012449619492023459,0.058145607071371494,0.21411109315174973,0.8305249909209733,LGP Offspring,Genes down-regulated in UB27 cells (osteosarcoma) at 8 hr after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,105,232
Cohort,-0.06672868002122301,0.1609135129144456,-0.4146866152670551,0.6784779748076639,LGP Proband,Genes down-regulated in UB27 cells (osteosarcoma) at 8 hr after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,105,324
Cohort,9.235267944642555e-4,0.05075452245640961,0.01819595081911024,0.9854870926759396,LonGen OPEL,Genes down-regulated in UB27 cells (osteosarcoma) at 8 hr after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,175,206
Cohort,0.004385891257493216,0.06446587919334983,0.06803430454021724,0.9457784442909286,LGP Offspring,Genes up-regulated in UB27 cells (osteosarcoma) at 8 hr after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,137,285
Cohort,0.10320794820715688,0.1781261489738278,0.5794093051566578,0.5624694953350559,LGP Proband,Genes up-regulated in UB27 cells (osteosarcoma) at 8 hr after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,137,384
Cohort,0.05040449944063662,0.05578415747936227,0.9035629777017625,0.3665005379627879,LonGen OPEL,Genes up-regulated in UB27 cells (osteosarcoma) at 8 hr after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,194,260
Cohort,0.10700468092165061,0.11663787728401373,0.9174093648934792,0.3592553500939232,LGP Offspring,Genes down-regulated in UB27 cells (osteosarcoma) at any time point after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,407,909
Cohort,0.06583443622697521,0.3051785033479179,0.21572435641681106,0.8292553611917806,LGP Proband,Genes down-regulated in UB27 cells (osteosarcoma) at any time point after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,407,1194
Cohort,-0.012940768717712613,0.09708259254776852,-0.13329648887719225,0.8939925947627574,LonGen OPEL,Genes down-regulated in UB27 cells (osteosarcoma) at any time point after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,652,780
Cohort,-0.06226013049168205,0.08033550218096297,-0.7750014476966297,0.43860980438649266,LGP Offspring,Genes up-regulated in UB27 cells (osteosarcoma) at any time point after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,208,402
Cohort,-0.13670382737172976,0.21885468003705297,-0.6246328721349951,0.5323828803233974,LGP Proband,Genes up-regulated in UB27 cells (osteosarcoma) at any time point after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,208,542
Cohort,0.028821900373580036,0.06480917766187638,0.44471942730009906,0.6566434211070276,LonGen OPEL,Genes up-regulated in UB27 cells (osteosarcoma) at any time point after inducing the expression of a mutant form of WT1 [GeneID=7490].,CGP,C2,299,371
Cohort,-0.0014296306649961565,0.024236656532235685,-0.058986298836008706,0.9529804534386535,LGP Offspring,Hypomethylated genes in prostate tissue from mice carrying hypomorphic alleles of DNMT1 [GeneID=1786].,CGP,C2,17,39
Cohort,0.1488750599933562,0.06158462897061095,2.4174061365929718,0.015845076743549107,LGP Proband,Hypomethylated genes in prostate tissue from mice carrying hypomorphic alleles of DNMT1 [GeneID=1786].,CGP,C2,17,45
Cohort,-0.04999614185010619,0.01959217212024136,-2.5518427228624345,0.01090127853273851,LonGen OPEL,Hypomethylated genes in prostate tissue from mice carrying hypomorphic alleles of DNMT1 [GeneID=1786].,CGP,C2,36,23
Cohort,-0.19943903531186352,0.10901553168900133,-1.829455236532916,0.06777174193760438,LGP Offspring,Genes down-regulated in TC71 and EWS502 cells (Ewing's sarcoma) by EWSR1-FLI1  [GeneID=2130;2314] as inferred from RNAi knockdown of this fusion protein.,CGP,C2,418,789
Cohort,-0.5242016072333615,0.3048690990347623,-1.7194317459297184,0.08590681830210746,LGP Proband,Genes down-regulated in TC71 and EWS502 cells (Ewing's sarcoma) by EWSR1-FLI1  [GeneID=2130;2314] as inferred from RNAi knockdown of this fusion protein.,CGP,C2,418,1110
Cohort,-0.0826259478622216,0.09543103284011925,-0.8658184387530344,0.38685061416994726,LonGen OPEL,Genes down-regulated in TC71 and EWS502 cells (Ewing's sarcoma) by EWSR1-FLI1  [GeneID=2130;2314] as inferred from RNAi knockdown of this fusion protein.,CGP,C2,661,759
Cohort,-0.5516037582795786,0.19715642686969803,-2.7977975003784032,0.005291709106049073,LGP Offspring,Genes up-regulated in TC71 and EWS502 cells (Ewing's sarcoma) by EWSR1-FLI1  [GeneID=2130;2314] as inferred from RNAi knockdown of this fusion protein.,CGP,C2,1179,2219
Cohort,-1.4456410213004365,0.5206254593574119,-2.7767390075098053,0.005613834217646008,LGP Proband,Genes up-regulated in TC71 and EWS502 cells (Ewing's sarcoma) by EWSR1-FLI1  [GeneID=2130;2314] as inferred from RNAi knockdown of this fusion protein.,CGP,C2,1179,3057
Cohort,-0.0779817643245092,0.16314153597822678,-0.47800067503910726,0.6327809649930982,LonGen OPEL,Genes up-regulated in TC71 and EWS502 cells (Ewing's sarcoma) by EWSR1-FLI1  [GeneID=2130;2314] as inferred from RNAi knockdown of this fusion protein.,CGP,C2,1745,2032
Cohort,-0.03930677541672611,0.03202052895874754,-1.2275492221682387,0.22004351920037366,LGP Offspring,Genes down-regulated in AIDS-related primary effusion lymphoma (PEL) samples compared to other tumor subtypes and normal B lymphocytes.,CGP,C2,38,65
Cohort,0.09892250961253336,0.0931305972979227,1.062191293545369,0.28845632523831444,LGP Proband,Genes down-regulated in AIDS-related primary effusion lymphoma (PEL) samples compared to other tumor subtypes and normal B lymphocytes.,CGP,C2,38,105
Cohort,-0.0612088394515509,0.03043305111468029,-2.011262006589441,0.0446344450596785,LonGen OPEL,Genes down-regulated in AIDS-related primary effusion lymphoma (PEL) samples compared to other tumor subtypes and normal B lymphocytes.,CGP,C2,73,62
Cohort,-0.06304870635978482,0.038601500773728446,-1.6333226712961053,0.10286678401975764,LGP Offspring,Genes up-regulated in AIDS-related primary effusion lymphoma (PEL) samples compared to other tumor subtypes and normal B lymphocytes.,CGP,C2,61,99
Cohort,-0.10747593095376001,0.10413490592489028,-1.0320836226738375,0.3023321393065851,LGP Proband,Genes up-regulated in AIDS-related primary effusion lymphoma (PEL) samples compared to other tumor subtypes and normal B lymphocytes.,CGP,C2,61,125
Cohort,-0.022860815647855817,0.038359246515475454,-0.5959662330341386,0.5513672053548041,LonGen OPEL,Genes up-regulated in AIDS-related primary effusion lymphoma (PEL) samples compared to other tumor subtypes and normal B lymphocytes.,CGP,C2,108,123
Cohort,0.008192215072015114,0.03747331359994129,0.2186146429289335,0.8270162274601087,LGP Offspring,"Genes changed in pre-B lymphoblastic leukemia cells with BCR-ABL1 fusion [GeneID=613, 25] vs normal pre-B lymphocytes.",CGP,C2,41,95
Cohort,0.03378607479266811,0.10460116332460716,0.32299903479868874,0.7467769363287,LGP Proband,"Genes changed in pre-B lymphoblastic leukemia cells with BCR-ABL1 fusion [GeneID=613, 25] vs normal pre-B lymphocytes.",CGP,C2,41,139
Cohort,-0.023878438304015277,0.03441525671859914,-0.6938329270433884,0.48798941232721804,LonGen OPEL,"Genes changed in pre-B lymphoblastic leukemia cells with BCR-ABL1 fusion [GeneID=613, 25] vs normal pre-B lymphocytes.",CGP,C2,86,90
Cohort,-0.17313397235332614,0.08564372007937689,-2.0215606257278522,0.04361529226527727,LGP Offspring,"Genes down-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 24h.",CGP,C2,251,450
Cohort,-0.3888085926065399,0.22850640242892567,-1.7015216574838614,0.08921779233609622,LGP Proband,"Genes down-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 24h.",CGP,C2,251,603
Cohort,0.04739553164467485,0.06769305747669566,0.7001535077801955,0.48403601980483724,LonGen OPEL,"Genes down-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 24h.",CGP,C2,325,415
Cohort,-0.11491393536500377,0.06041619259174772,-1.9020386826014575,0.05759088098683717,LGP Offspring,"Genes up-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 24h.",CGP,C2,133,227
Cohort,-0.13500612496339992,0.1567983402868989,-0.8610175638107835,0.3894758346062335,LGP Proband,"Genes up-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 24h.",CGP,C2,133,296
Cohort,-0.06437896082080727,0.050150677507401015,-1.2837106898766524,0.19961675686808722,LonGen OPEL,"Genes up-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 24h.",CGP,C2,180,184
Cohort,0.017965006722494313,0.018331944980747365,0.9799836701103773,0.3274447618374895,LGP Offspring,"Genes down-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 6h.",CGP,C2,8,26
Cohort,-0.08693712976172602,0.047526423242837144,-1.8292377972042864,0.06772090103127767,LGP Proband,"Genes down-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 6h.",CGP,C2,8,29
Cohort,-0.0012510533979735105,0.017504985878401744,-0.0714684037258838,0.9430429225407693,LonGen OPEL,"Genes down-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 6h.",CGP,C2,21,23
Cohort,-0.001354023801220732,0.0055377425672472995,-0.24450826032055692,0.8069114009055632,LGP Offspring,"Genes up-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 6h.",CGP,C2,1,2
Cohort,0.009723458087671664,0.013658586869538778,0.7118934177119602,0.47672986130803807,LGP Proband,"Genes up-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 6h.",CGP,C2,1,2
Cohort,-0.00238759357837404,0.0026029090803754403,-0.9172789001257227,0.359274342099668,LonGen OPEL,"Genes up-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 6h.",CGP,C2,1,0
Cohort,0.008962351472472528,0.022714747601079274,0.3945609094968191,0.6932914153290202,LGP Offspring,Genes up-regulated in MM-LH cells (malignant melanoma) after treatment with the HDAC inhibitor romidepsin (FK228) [PubChem=5352062].,CGP,C2,17,38
Cohort,-0.03960141755299798,0.06076047963412307,-0.6517627542024509,0.5147337963979268,LGP Proband,Genes up-regulated in MM-LH cells (malignant melanoma) after treatment with the HDAC inhibitor romidepsin (FK228) [PubChem=5352062].,CGP,C2,17,45
Cohort,-0.0023467294691743366,0.017841601266639737,-0.13153132580999086,0.8953882442464449,LonGen OPEL,Genes up-regulated in MM-LH cells (malignant melanoma) after treatment with the HDAC inhibitor romidepsin (FK228) [PubChem=5352062].,CGP,C2,22,26
Cohort,-0.044955014925676176,0.04585000662151981,-0.9804800094527454,0.3271999959062457,LGP Offspring,Genes down-regulated in E14 ES (embryonic stem) cells upon knockdown of CYCT1 [GeneID=904] by RNAi.,CGP,C2,70,120
Cohort,-0.2554343786711801,0.12807632787528092,-1.9943918045489155,0.04643438498763773,LGP Proband,Genes down-regulated in E14 ES (embryonic stem) cells upon knockdown of CYCT1 [GeneID=904] by RNAi.,CGP,C2,70,172
Cohort,-0.015320662491524778,0.042281129286075386,-0.3623522538356229,0.7171849952464404,LonGen OPEL,Genes down-regulated in E14 ES (embryonic stem) cells upon knockdown of CYCT1 [GeneID=904] by RNAi.,CGP,C2,118,129
Cohort,-0.0908691262265495,0.03785210461914286,-2.4006360317569886,0.016635878844988617,LGP Offspring,Genes down-regulated in E14 ES (embryonic stem) cells upon knockdown of CYCT2 [GeneID=905] by RNAi.,CGP,C2,58,84
Cohort,-0.013971711513573282,0.11228065482460593,-0.1244356076779081,0.90100036655069915,LGP Proband,Genes down-regulated in E14 ES (embryonic stem) cells upon knockdown of CYCT2 [GeneID=905] by RNAi.,CGP,C2,58,139
Cohort,0.012183888186600593,0.03496009849648532,0.34850840559918583,0.7275505562037015,LonGen OPEL,Genes down-regulated in E14 ES (embryonic stem) cells upon knockdown of CYCT2 [GeneID=905] by RNAi.,CGP,C2,87,106
Cohort,0.02322269171611688,0.015116028689436987,1.5362958216892506,0.12493373778050157,LGP Offspring,Genes down-regulated in colorectal carcinoma samples positive for MSI (microsatellite instability) compared to the MSI negative ones.,CGP,C2,4,19
Cohort,-0.03375795951258903,0.036665477043509496,-0.9207014945565762,0.35747253108292376,LGP Proband,Genes down-regulated in colorectal carcinoma samples positive for MSI (microsatellite instability) compared to the MSI negative ones.,CGP,C2,4,18
Cohort,-0.012549682241504566,0.012825201260282224,-0.9785173726956706,0.3281157960951415,LonGen OPEL,Genes down-regulated in colorectal carcinoma samples positive for MSI (microsatellite instability) compared to the MSI negative ones.,CGP,C2,14,11
Cohort,-0.019347540781940828,0.02103159715430966,-0.9199273188805945,0.35793888650962746,LGP Offspring,Genes up-regulated in colorectal carcinoma samples positive for MSI (microsatellite instability) compared to the MSI negative ones.,CGP,C2,17,27
Cohort,-0.0980558202572532,0.05914239699358753,-1.6579615511336958,0.09770127237936257,LGP Proband,Genes up-regulated in colorectal carcinoma samples positive for MSI (microsatellite instability) compared to the MSI negative ones.,CGP,C2,17,42
Cohort,-0.009555786452106306,0.015312861384991886,-0.624036632465825,0.5327823219951757,LonGen OPEL,Genes up-regulated in colorectal carcinoma samples positive for MSI (microsatellite instability) compared to the MSI negative ones.,CGP,C2,17,17
Cohort,-0.02778074120001214,0.17190226458655317,-0.16160776745337452,0.8716630281937274,LGP Offspring,"Genes with promoters occupied by SMAD2 or SMAD3 [GeneID=4087, 4088] in HaCaT cells (keratinocyte) according to a ChIP-chip analysis.",CGP,C2,889,1842
Cohort,-0.5371405490507534,0.4818996679239757,-1.1146314986369579,0.2653294638089844,LGP Proband,"Genes with promoters occupied by SMAD2 or SMAD3 [GeneID=4087, 4088] in HaCaT cells (keratinocyte) according to a ChIP-chip analysis.",CGP,C2,889,2567
Cohort,-0.17730708370548046,0.14511575799583507,-1.2218320474236113,0.22213285520688114,LonGen OPEL,"Genes with promoters occupied by SMAD2 or SMAD3 [GeneID=4087, 4088] in HaCaT cells (keratinocyte) according to a ChIP-chip analysis.",CGP,C2,1474,1706
Cohort,-0.0024125934503603174,0.04445130354231919,-0.054274976392164616,0.9567321218893305,LGP Offspring,Genes down-regulated in MEWO cells (melanoma) after 48h of methionine [PubChem=876] deprivation.,CGP,C2,61,123
Cohort,-0.12822344136842584,0.12101619860316534,-1.0595560168675797,0.28965339381670635,LGP Proband,Genes down-regulated in MEWO cells (melanoma) after 48h of methionine [PubChem=876] deprivation.,CGP,C2,61,181
Cohort,0.07323068592223045,0.037934686495420075,1.9304413107795613,0.05390709622893253,LonGen OPEL,Genes down-regulated in MEWO cells (melanoma) after 48h of methionine [PubChem=876] deprivation.,CGP,C2,85,132
Cohort,-0.1405689539775621,0.060660323581481095,-2.317312959742869,0.02078451375998375,LGP Offspring,Genes up-regulated in MEWO cells (melanoma) after 48h of methionine [PubChem=876] deprivation.,CGP,C2,142,234
Cohort,-0.020010572708787852,0.16823615669764416,-0.11894335380444448,0.9053488770978971,LGP Proband,Genes up-regulated in MEWO cells (melanoma) after 48h of methionine [PubChem=876] deprivation.,CGP,C2,142,281
Cohort,-0.03479990862052051,0.05216990079735327,-0.6670495455932707,0.5049337984678928,LonGen OPEL,Genes up-regulated in MEWO cells (melanoma) after 48h of methionine [PubChem=876] deprivation.,CGP,C2,186,212
Cohort,-0.05850118717572078,0.050802141187380474,-1.1515496356726946,0.2499133000297575,LGP Offspring,Genes down-regulated in MEWO cells (melanoma) after 96 h of methionine [PubChem=876] deprivation.,CGP,C2,90,147
Cohort,-0.2226209366205672,0.13776830573906168,-1.6159082121705088,0.10649234871731962,LGP Proband,Genes down-regulated in MEWO cells (melanoma) after 96 h of methionine [PubChem=876] deprivation.,CGP,C2,90,207
Cohort,0.07587873451985408,0.04184394627668628,1.8133742457778315,0.07015060760908405,LonGen OPEL,Genes down-regulated in MEWO cells (melanoma) after 96 h of methionine [PubChem=876] deprivation.,CGP,C2,103,158
Cohort,-0.0844803602522019,0.05487813310558209,-1.5394175324744919,0.12417033045000628,LGP Offspring,Genes up-regulated in MEWO cells (melanoma) after 96 h of methionine [PubChem=876] deprivation.,CGP,C2,113,210
Cohort,0.07438692254335345,0.1508399494688117,0.49315133560644686,0.6220354812079081,LGP Proband,Genes up-regulated in MEWO cells (melanoma) after 96 h of methionine [PubChem=876] deprivation.,CGP,C2,113,255
Cohort,-0.037447957218144055,0.04877153308292267,-0.767824073819333,0.44281941528746327,LonGen OPEL,Genes up-regulated in MEWO cells (melanoma) after 96 h of methionine [PubChem=876] deprivation.,CGP,C2,168,186
Cohort,-4.996823069760098e-4,0.014555495952700137,-0.03432945937395665,0.9726245673980753,LGP Offspring,"Genes changed in H1299 cells (non-small cell lung cancer, NSCLC) transiently transfected to express the TP63 [GeneID=8626] gamma splice variant.",CGP,C2,7,14
Cohort,0.038952538202351394,0.03531093773422486,1.103129531578453,0.2702891197915759,LGP Proband,"Genes changed in H1299 cells (non-small cell lung cancer, NSCLC) transiently transfected to express the TP63 [GeneID=8626] gamma splice variant.",CGP,C2,7,12
Cohort,0.0055160222680042375,0.014622261471549717,0.37723455285878094,0.7060998546002677,LonGen OPEL,"Genes changed in H1299 cells (non-small cell lung cancer, NSCLC) transiently transfected to express the TP63 [GeneID=8626] gamma splice variant.",CGP,C2,13,18
Cohort,-0.04896218486471545,0.028134307948378966,-1.7403017324809136,0.08226110138370779,LGP Offspring,"Genes with high levels of histone H3 monomethylation mark at K27 (H3K27me1) in SW48 cells (colon cancer) by ChIP-chip assay on a 12K CpG array (CpG promoters only, HCP=high-CpG-density promoters).",CGP,C2,31,45
Cohort,-0.07344080061771359,0.08575837231149946,-0.8563688726618451,0.3920397572155132,LGP Proband,"Genes with high levels of histone H3 monomethylation mark at K27 (H3K27me1) in SW48 cells (colon cancer) by ChIP-chip assay on a 12K CpG array (CpG promoters only, HCP=high-CpG-density promoters).",CGP,C2,31,81
Cohort,0.018513772900412354,0.024918107856657008,0.7429847003999663,0.457710156504174,LonGen OPEL,"Genes with high levels of histone H3 monomethylation mark at K27 (H3K27me1) in SW48 cells (colon cancer) by ChIP-chip assay on a 12K CpG array (CpG promoters only, HCP=high-CpG-density promoters).",CGP,C2,40,52
Cohort,-0.0046791127046569275,0.005521557472287636,-0.8474262430738269,0.3970575050225108,LGP Offspring,"Genes with high histone H3 tri-methylation mark at K27 (H3K27me3) in SW48 cells (colon cancer), by ChIP-chip assay on a 12K CpG array (high-CpG-density promoters, HCP).",CGP,C2,2,1
Cohort,-0.023079198223471247,0.017706715132340994,-1.3034150067347903,0.19279281222914618,LGP Proband,"Genes with high histone H3 tri-methylation mark at K27 (H3K27me3) in SW48 cells (colon cancer), by ChIP-chip assay on a 12K CpG array (high-CpG-density promoters, HCP).",CGP,C2,2,3
Cohort,-0.006161073199488807,0.006350026834557558,-0.9702436477842197,0.33221977691457283,LonGen OPEL,"Genes with high histone H3 tri-methylation mark at K27 (H3K27me3) in SW48 cells (colon cancer), by ChIP-chip assay on a 12K CpG array (high-CpG-density promoters, HCP).",CGP,C2,4,2
Cohort,-0.07524552844192237,0.07983713566708228,-0.9424878261626677,0.3462796338591,LGP Offspring,Genes up-regulated in PC3 cells (prostate cancer) after EZH2 [GeneID=2146] knockdown by RNAi.,CGP,C2,215,425
Cohort,0.1706807612010117,0.2158945469734807,0.7905746745052212,0.4294169727046703,LGP Proband,Genes up-regulated in PC3 cells (prostate cancer) after EZH2 [GeneID=2146] knockdown by RNAi.,CGP,C2,215,568
Cohort,0.04069138058549976,0.07417792141533182,0.5485645837615675,0.58345811651227375,LonGen OPEL,Genes up-regulated in PC3 cells (prostate cancer) after EZH2 [GeneID=2146] knockdown by RNAi.,CGP,C2,343,425
Cohort,-0.00462383647935705,0.0064076720366572195,-0.7216094164783802,0.47078415769006843,LGP Offspring,Genes up-regulated in HSC-2/8 cells (chondrosarcoma) under hypoxic conditions.,CGP,C2,2,2
Cohort,-0.019798097634099707,0.017589456178785032,-1.125566216082255,0.26067297344319196,LGP Proband,Genes up-regulated in HSC-2/8 cells (chondrosarcoma) under hypoxic conditions.,CGP,C2,2,3
Cohort,0.004426780666815964,0.005748538589412599,0.7700706184644931,0.441486476282141,LonGen OPEL,Genes up-regulated in HSC-2/8 cells (chondrosarcoma) under hypoxic conditions.,CGP,C2,2,3
Cohort,-0.07434088684577045,0.05397358962830281,-1.3773567286839745,0.16885784633793835,LGP Offspring,"Genes with high histone H3 trimethylation mark at K27 (H3K27me3) in PC3 cells (prostate cancer) by ChIP-chip assay on a 12K CpG array (high-CpG-density promoters, HCP).",CGP,C2,102,185
Cohort,-0.13633687535852074,0.1529666540361371,-0.8912849419214744,0.3730333811715417,LGP Proband,"Genes with high histone H3 trimethylation mark at K27 (H3K27me3) in PC3 cells (prostate cancer) by ChIP-chip assay on a 12K CpG array (high-CpG-density promoters, HCP).",CGP,C2,102,263
Cohort,9.819726909574133e-4,0.04548927921039269,0.021586903727704422,0.9827828903217342,LonGen OPEL,"Genes with high histone H3 trimethylation mark at K27 (H3K27me3) in PC3 cells (prostate cancer) by ChIP-chip assay on a 12K CpG array (high-CpG-density promoters, HCP).",CGP,C2,138,168
Cohort,-0.029588670334630016,0.07899729285477329,-0.37455296587219905,0.708110423285838,LGP Offspring,"Top 200 genes with high histone H3 trimethylation mark at K27 (H3K27me3) in PC3 cells (prostate cancer), by ChIP-chip assay on an 88K microarray (all promoters).",CGP,C2,187,392
Cohort,0.008325536928339055,0.2117147357662212,0.039324314853228945,0.9686412323614095,LGP Proband,"Top 200 genes with high histone H3 trimethylation mark at K27 (H3K27me3) in PC3 cells (prostate cancer), by ChIP-chip assay on an 88K microarray (all promoters).",CGP,C2,187,567
Cohort,0.0037583234451606952,0.0689723163180439,0.05449031793901747,0.9565581951991302,LonGen OPEL,"Top 200 genes with high histone H3 trimethylation mark at K27 (H3K27me3) in PC3 cells (prostate cancer), by ChIP-chip assay on an 88K microarray (all promoters).",CGP,C2,330,384
Cohort,0.008367277590725013,0.009098914840626363,0.9195907135393099,0.35811469772405946,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) at 16 h after serum stimulation and knockdown of E2F1 [GeneID=1869] by RNAi.,CGP,C2,1,7
Cohort,-0.025844546107184473,0.027191773915789468,-0.9504545818607775,0.34215666710172055,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) at 16 h after serum stimulation and knockdown of E2F1 [GeneID=1869] by RNAi.,CGP,C2,1,11
Cohort,-0.018690052760324375,0.008081311786259137,-2.312749867181657,0.020990566101783896,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) at 16 h after serum stimulation and knockdown of E2F1 [GeneID=1869] by RNAi.,CGP,C2,8,2
Cohort,-0.13634424752925198,0.0518720425501575,-2.6284726960079574,0.0087717242674648,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblasts) at 16 hr after serum stimulation and knockdown of E2F3 [GeneID=1871] by RNAi.,CGP,C2,111,163
Cohort,-0.3104298554977927,0.14133243552781113,-2.196451609557856,0.028334188309978588,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblasts) at 16 hr after serum stimulation and knockdown of E2F3 [GeneID=1871] by RNAi.,CGP,C2,111,230
Cohort,-0.047562477586486636,0.04338453176374319,-1.096300355285498,0.27327891364962015,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblasts) at 16 hr after serum stimulation and knockdown of E2F3 [GeneID=1871] by RNAi.,CGP,C2,143,150
Cohort,-0.01247637916853208,0.015311368890332666,-0.8148441369216471,0.41544850324693383,LGP Offspring,Genes predicting the choriocarcinoma (CC) of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,8,16
Cohort,0.030299092935893366,0.04025226282686896,0.7527301773372177,0.45182448028827604,LGP Proband,Genes predicting the choriocarcinoma (CC) of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,8,19
Cohort,-0.0046037187117258915,0.012772972120371621,-0.360426584223371,0.7186237678204782,LonGen OPEL,Genes predicting the choriocarcinoma (CC) of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,12,13
Cohort,0.013827291807546264,0.016375838034504445,0.8443715538961544,0.3987605270486557,LGP Offspring,Genes from the 12p region that were down-regulated in choriocarcinoma cells compared to normal testis.,CGP,C2,7,18
Cohort,-0.004076452900870196,0.04542437186591164,-0.08974153595130585,0.9285141546716058,LGP Proband,Genes from the 12p region that were down-regulated in choriocarcinoma cells compared to normal testis.,CGP,C2,7,26
Cohort,0.012944899634866305,0.011446680169272938,1.1308868111485402,0.2584433442477568,LonGen OPEL,Genes from the 12p region that were down-regulated in choriocarcinoma cells compared to normal testis.,CGP,C2,6,14
Cohort,0.021505360016011863,0.014721433487046158,1.4608196976833194,0.14452954775940183,LGP Offspring,Genes from the 12p region that were up-regulated in choriocarcinoma cells compared to normal testis.,CGP,C2,3,19
Cohort,0.08202323940079767,0.04222280472558785,1.942628869253917,0.052397277070535576,LGP Proband,Genes from the 12p region that were up-regulated in choriocarcinoma cells compared to normal testis.,CGP,C2,3,27
Cohort,0.019835898438238523,0.012962575381532254,1.5302436324882378,0.12635372413440227,LonGen OPEL,Genes from the 12p region that were up-regulated in choriocarcinoma cells compared to normal testis.,CGP,C2,9,17
Cohort,-0.06521253948584022,0.025581176293111203,-2.549239281987256,0.011015563492196678,LGP Offspring,Genes whose expression pattern in adult male germ cell tumors (GCT) correlates with POU5F1 [GeneID=5460].,CGP,C2,30,37
Cohort,-0.00922179534727493,0.0760958040576989,-0.12118664703618341,0.9035723910601525,LGP Proband,Genes whose expression pattern in adult male germ cell tumors (GCT) correlates with POU5F1 [GeneID=5460].,CGP,C2,30,68
Cohort,-0.027984955338455315,0.02187958390025919,-1.2790442206775148,0.20125422142653812,LonGen OPEL,Genes whose expression pattern in adult male germ cell tumors (GCT) correlates with POU5F1 [GeneID=5460].,CGP,C2,44,35
Cohort,-0.01121241678787251,0.015111724449359185,-0.7419680543703915,0.45836439698370146,LGP Offspring,Genes predicting the embryonic carcinoma (EC) subtype of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,10,11
Cohort,-0.03772515076891657,0.04454437833084169,-0.8469116010267985,0.3972873487374181,LGP Proband,Genes predicting the embryonic carcinoma (EC) subtype of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,10,21
Cohort,-0.020424228388656308,0.0139373774451645,-1.465428375532901,0.1431989532943265,LonGen OPEL,Genes predicting the embryonic carcinoma (EC) subtype of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,17,13
Cohort,0.011620844830447395,0.017757222135247445,0.6544292086868947,0.513057905103927,LGP Offspring,Genes from the 12p region that were down-regulated in embryonic carcinoma tumors compared to normal tissue.,CGP,C2,9,21
Cohort,-0.02569502036633971,0.047767914696937516,-0.5379137969358972,0.5907800729626043,LGP Proband,Genes from the 12p region that were down-regulated in embryonic carcinoma tumors compared to normal tissue.,CGP,C2,9,28
Cohort,0.01289819780047226,0.011998060100150294,1.0750236032165474,0.28268990338231603,LonGen OPEL,Genes from the 12p region that were down-regulated in embryonic carcinoma tumors compared to normal tissue.,CGP,C2,7,15
Cohort,0.013049973990157605,0.027924801240536475,0.4673255819351678,0.6404175547475266,LGP Offspring,Genes from the 12p region that were up-regulated in embryonic carcinoma tumors compared to normal testis.,CGP,C2,24,62
Cohort,0.06096377287519259,0.08324616335752497,0.7323313221459331,0.4641721159776093,LGP Proband,Genes from the 12p region that were up-regulated in embryonic carcinoma tumors compared to normal testis.,CGP,C2,24,88
Cohort,0.02564892648331198,0.024932590953386038,1.0287308900733663,0.3039186368977424,LonGen OPEL,Genes from the 12p region that were up-regulated in embryonic carcinoma tumors compared to normal testis.,CGP,C2,38,57
Cohort,0.010866227136230611,0.010580347955694453,1.027019827867031,0.3047784705056356,LGP Offspring,Top 25 most highly expressed genes in seminoma relative to embryonic carcinoma tumors.,CGP,C2,2,9
Cohort,-0.03121166862653272,0.03659864315858761,-0.852809446822597,0.39400982671114637,LGP Proband,Top 25 most highly expressed genes in seminoma relative to embryonic carcinoma tumors.,CGP,C2,2,18
Cohort,0.005473604432053296,0.012846891072204868,0.42606451641018545,0.6701760184526042,LonGen OPEL,Top 25 most highly expressed genes in seminoma relative to embryonic carcinoma tumors.,CGP,C2,9,14
Cohort,-0.0509847332402925,0.024766553427697128,-2.058612369667668,0.03991405079444707,LGP Offspring,Top 25 most highly expressed genes in embryonic carcinoma relative to seminoma tumors.,CGP,C2,27,35
Cohort,-0.09149027895294325,0.06680419114686668,-1.3695290277791863,0.17120260693629902,LGP Proband,Top 25 most highly expressed genes in embryonic carcinoma relative to seminoma tumors.,CGP,C2,27,49
Cohort,-0.021602388387041347,0.019959631589572924,-1.0823039638831116,0.2794452386876471,LonGen OPEL,Top 25 most highly expressed genes in embryonic carcinoma relative to seminoma tumors.,CGP,C2,28,25
Cohort,0.012506296108730892,0.017235405900248493,0.7256165698163559,0.46832498269166567,LGP Offspring,Genes from the 12p region that were down-regulated in seminoma tumors compared to normal testis.,CGP,C2,8,20
Cohort,-0.020072973094366533,0.04650788029705828,-0.4316036973982706,0.6661410183539214,LGP Proband,Genes from the 12p region that were down-regulated in seminoma tumors compared to normal testis.,CGP,C2,8,27
Cohort,0.010468931999665969,0.01172564250084615,0.8928237406957023,0.3722214018610387,LonGen OPEL,Genes from the 12p region that were down-regulated in seminoma tumors compared to normal testis.,CGP,C2,7,14
Cohort,0.02247387798111802,0.027352665651935754,0.8216339228907125,0.4115749557068761,LGP Offspring,Genes from the 12p region that were up-regulated in seminoma tumors compared to normal testis.,CGP,C2,20,60
Cohort,0.17612954998061753,0.07975828628623563,2.2082915541656174,0.02749530568307681,LGP Proband,Genes from the 12p region that were up-regulated in seminoma tumors compared to normal testis.,CGP,C2,20,88
Cohort,0.010274385092219956,0.02552728149955667,0.4024864571810512,0.6874341139360547,LonGen OPEL,Genes from the 12p region that were up-regulated in seminoma tumors compared to normal testis.,CGP,C2,44,60
Cohort,0.04612672255194267,0.032620533872391166,1.4140394737985158,0.15781068110241658,LGP Offspring,Genes predicting the teratoma (T) subtype of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,30,84
Cohort,0.02127605783888028,0.08529936570690876,0.24942808967636956,0.8030910769129096,LGP Proband,Genes predicting the teratoma (T) subtype of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,30,90
Cohort,-0.04130328699407651,0.028556202341991258,-1.4463858498908642,0.1484626435399592,LonGen OPEL,Genes predicting the teratoma (T) subtype of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,63,60
Cohort,-0.01812406046502957,0.01886653605728151,-0.9606458975830181,0.337073714867795,LGP Offspring,Genes from the 12p region that up-regulated in teratoma cells compared to normal testis.,CGP,C2,14,22
Cohort,-0.08619878315839374,0.05553655994379717,-1.5521087954606236,0.12101556487706779,LGP Proband,Genes from the 12p region that up-regulated in teratoma cells compared to normal testis.,CGP,C2,14,39
Cohort,0.0045317686153964675,0.017643984474897848,0.25684496729431094,0.7973648274661328,LonGen OPEL,Genes from the 12p region that up-regulated in teratoma cells compared to normal testis.,CGP,C2,21,28
Cohort,-0.011450656526811131,0.049843821596997004,-0.2297307100445326,0.8183705234600991,LGP Offspring,Genes predicting the yolk sac tumor (YS) subtype of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,76,158
Cohort,-0.0769483100698616,0.1360157689806245,-0.565730801998575,0.5717289634562778,LGP Proband,Genes predicting the yolk sac tumor (YS) subtype of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,76,223
Cohort,0.012724490986421085,0.0421531345396096,0.30186345868216263,0.7628350007954333,LonGen OPEL,Genes predicting the yolk sac tumor (YS) subtype of nonseminomatous male germ cell tumors (NSGCT).,CGP,C2,121,149
Cohort,-0.018116827724632717,0.022241829288637056,-0.8145385655795979,0.41562333659686024,LGP Offspring,Genes from the 12p region that were up-regulated in yolk sac tumor cells compared to normal testis.,CGP,C2,19,33
Cohort,0.08355348962714287,0.07018477591911551,1.1904788258273296,0.23419698678754713,LGP Proband,Genes from the 12p region that were up-regulated in yolk sac tumor cells compared to normal testis.,CGP,C2,19,64
Cohort,-0.018148889180956668,0.02126153667420305,-0.8536019507459682,0.3935823705685966,LonGen OPEL,Genes from the 12p region that were up-regulated in yolk sac tumor cells compared to normal testis.,CGP,C2,36,38
Cohort,-0.10493255023503589,0.10328644595974032,-1.015937272891907,0.31002272529823377,LGP Offspring,Genes down-regulated in NCI-H1299 cells (large cell neuroendocrine carcinoma) stably expressing SEMA3B [GeneID=7869].,CGP,C2,350,684
Cohort,-0.5637481216916346,0.2815150430833488,-2.002550611566162,0.045548838986931274,LGP Proband,Genes down-regulated in NCI-H1299 cells (large cell neuroendocrine carcinoma) stably expressing SEMA3B [GeneID=7869].,CGP,C2,350,939
Cohort,-0.06388066602070544,0.08856770755478159,-0.7212636273914335,0.4709591170741452,LonGen OPEL,Genes down-regulated in NCI-H1299 cells (large cell neuroendocrine carcinoma) stably expressing SEMA3B [GeneID=7869].,CGP,C2,571,653
Cohort,-0.10914094872704563,0.07899149515857855,-1.3816797429639844,0.1675265030712157,LGP Offspring,Genes up-regulated in NCI-H1299 cells (large cell neuroendocrine carcinoma) stably expressing SEMA3B [GeneID=7869].,CGP,C2,207,384
Cohort,-0.21269634566633186,0.21792370002865094,-0.9760129147879196,0.3293410734592843,LGP Proband,Genes up-regulated in NCI-H1299 cells (large cell neuroendocrine carcinoma) stably expressing SEMA3B [GeneID=7869].,CGP,C2,207,522
Cohort,-0.026098249331041833,0.07247217673670288,-0.36011405350578646,0.7188573709740177,LonGen OPEL,Genes up-regulated in NCI-H1299 cells (large cell neuroendocrine carcinoma) stably expressing SEMA3B [GeneID=7869].,CGP,C2,353,413
Cohort,-0.014310940348261244,0.040751811716651445,-0.3511731072906804,0.7255679028088247,LGP Offspring,Down-regulated in GHOST(3)CXCR4 cells (osteosarcoma) upon ectopic expression of ILF3 [GeneID=3609].,CGP,C2,50,100
Cohort,-0.14455242001462904,0.11100562672632489,-1.3022080436608043,0.19320478550591785,LGP Proband,Down-regulated in GHOST(3)CXCR4 cells (osteosarcoma) upon ectopic expression of ILF3 [GeneID=3609].,CGP,C2,50,140
Cohort,0.026964238396234533,0.0324811187754035,0.8301511589758831,0.4067022266472796,LonGen OPEL,Down-regulated in GHOST(3)CXCR4 cells (osteosarcoma) upon ectopic expression of ILF3 [GeneID=3609].,CGP,C2,68,93
Cohort,0.023662101836017607,0.023599519984078093,1.0026518273245277,0.31638764009754805,LGP Offspring,Up-regulated in GHOST(3)CXCR4 cells (osteosarcoma) upon ectopic expression of ILF3 [GeneID=3609].,CGP,C2,16,41
Cohort,-0.10982093613313663,0.05791838522007001,-1.896132561635735,0.05828791289104948,LGP Proband,Up-regulated in GHOST(3)CXCR4 cells (osteosarcoma) upon ectopic expression of ILF3 [GeneID=3609].,CGP,C2,16,39
Cohort,0.007233724101807336,0.020841478725896846,0.34708305475556206,0.7286206648444964,LonGen OPEL,Up-regulated in GHOST(3)CXCR4 cells (osteosarcoma) upon ectopic expression of ILF3 [GeneID=3609].,CGP,C2,31,35
Cohort,-0.05133017188441688,0.018003147314301644,-2.8511776851173325,0.004488617413266669,LGP Offspring,Genes down-regulated in ESFT cells (Ewing's sarcoma family of tumors) after knockdown of CD99 [GeneID=4267] by RNAi.,CGP,C2,18,15
Cohort,-0.019625060413436077,0.05184001316942515,-0.378569742050351,0.7051037405950179,LGP Proband,Genes down-regulated in ESFT cells (Ewing's sarcoma family of tumors) after knockdown of CD99 [GeneID=4267] by RNAi.,CGP,C2,18,28
Cohort,-0.016398465814307026,0.015348813072701726,-1.0683865740388836,0.28567006158952346,LonGen OPEL,Genes down-regulated in ESFT cells (Ewing's sarcoma family of tumors) after knockdown of CD99 [GeneID=4267] by RNAi.,CGP,C2,17,18
Cohort,-0.10516531479037919,0.13551111462957496,-0.7760641263844134,0.4379825511425617,LGP Offspring,Genes induced under hypoxia independently of KDM3A [GeneID=55818] in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].,CGP,C2,613,1233
Cohort,-1.1336220575895488,0.38360217701088695,-2.9552023568348407,0.003212605247704691,LGP Proband,Genes induced under hypoxia independently of KDM3A [GeneID=55818] in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].,CGP,C2,613,1696
Cohort,0.0684880346882166,0.12211876776432883,0.56083136066676,0.575070332580351,LonGen OPEL,Genes induced under hypoxia independently of KDM3A [GeneID=55818] in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].,CGP,C2,968,1202
Cohort,-0.04240969416926673,0.03822204441957219,-1.109561113574296,0.26758274679028293,LGP Offspring,Genes dependent on KDM3A [GeneID=55818] for hypoxic induction in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].,CGP,C2,53,88
Cohort,-0.0757970209990376,0.10886119785482941,-0.696272156587105,0.48645240119015676,LGP Proband,Genes dependent on KDM3A [GeneID=55818] for hypoxic induction in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].,CGP,C2,53,131
Cohort,-0.02023532260089393,0.03275610612586281,-0.6177572670921647,0.5369120458532639,LonGen OPEL,Genes dependent on KDM3A [GeneID=55818] for hypoxic induction in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].,CGP,C2,79,85
Cohort,0.010130492489971006,0.07374714745830285,0.1373679232230488,0.890780887521559,LGP Offspring,"Genes not induced under hypoxia, but dependent on KDM3A [GeneID=55818] for hypoxic expression in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].",CGP,C2,161,338
Cohort,0.08862992674830641,0.20431292282188177,0.43379501171138946,0.6645494910284618,LGP Proband,"Genes not induced under hypoxia, but dependent on KDM3A [GeneID=55818] for hypoxic expression in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].",CGP,C2,161,487
Cohort,0.0647747246141147,0.06830776984467529,0.9482775497048964,0.34327597186879755,LonGen OPEL,"Genes not induced under hypoxia, but dependent on KDM3A [GeneID=55818] for hypoxic expression in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].",CGP,C2,266,337
Cohort,-0.007160083230239169,0.01873532148011306,-0.38217028930298136,0.7024551708530085,LGP Offspring,"The 'amino acid deprivation response' (AADR): genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after amino acid deprivation or treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703].",CGP,C2,12,24
Cohort,-0.10496443409374606,0.05841367781892048,-1.7969153460792289,0.072710775177357,LGP Proband,"The 'amino acid deprivation response' (AADR): genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after amino acid deprivation or treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703].",CGP,C2,12,40
Cohort,0.011573165845114322,0.018109629609005792,0.6390614327837532,0.5229668147792297,LonGen OPEL,"The 'amino acid deprivation response' (AADR): genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after amino acid deprivation or treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703].",CGP,C2,20,27
Cohort,-0.38315740130079373,0.17508445865243297,-2.188414689972081,0.02898090025122388,LGP Offspring,"Genes down-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 24 h.",CGP,C2,944,1803
Cohort,-1.045888218232051,0.47951887316553937,-2.181120028347643,0.029453214335378303,LGP Proband,"Genes down-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 24 h.",CGP,C2,944,2636
Cohort,0.245121075696613,0.14944077903788244,1.6402556067676555,0.10134710841316649,LonGen OPEL,"Genes down-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 24 h.",CGP,C2,1392,1779
Cohort,-0.1299388077300265,0.1407145621656925,-0.9234211849163311,0.35611723295836395,LGP Offspring,"Genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 24 h.",CGP,C2,624,1280
Cohort,-0.39311195436999685,0.38513433518543033,-1.0207138612575934,0.3076860139972528,LGP Proband,"Genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 24 h.",CGP,C2,624,1725
Cohort,0.039764290486280766,0.12220622204961061,0.3253867914363487,0.7449738593587254,LonGen OPEL,"Genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 24 h.",CGP,C2,988,1220
Cohort,-0.4905051042219021,0.16484014216369128,-2.975641113769579,0.0030281065739027183,LGP Offspring,"Genes down-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 6 h.",CGP,C2,862,1598
Cohort,-0.7183605494196861,0.4446080277499832,-1.6157165516220557,0.10653380693646232,LGP Proband,"Genes down-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 6 h.",CGP,C2,862,2338
Cohort,0.2430488611144944,0.13825504939630984,1.757974570735509,0.07913614719741072,LonGen OPEL,"Genes down-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 6 h.",CGP,C2,1247,1593
Cohort,-0.05295850956683982,0.15420102862212445,-0.34343810829314686,0.7313756779663212,LGP Offspring,"Genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 6 h.",CGP,C2,784,1641
Cohort,-0.6987922703017919,0.42371827333632434,-1.6491907814113291,0.09948513603640666,LGP Proband,"Genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 6 h.",CGP,C2,784,2221
Cohort,0.05690907913807376,0.1400086357531612,0.4064683498409764,0.6845077638591645,LonGen OPEL,"Genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 6 h.",CGP,C2,1244,1544
Cohort,0.0033116345105124434,0.014960332105755255,0.22136102909362917,0.8248781817341285,LGP Offspring,Genes down-regulated in naive T lymphocytes lacking FURIN [GeneID=5045]: Cre-Lox knockout of FURIN in CD4+ [GeneID=920] cells.,CGP,C2,7,16
Cohort,-0.011018592041947372,0.039269052361798784,-0.2805922572418971,0.7790927439046579,LGP Proband,Genes down-regulated in naive T lymphocytes lacking FURIN [GeneID=5045]: Cre-Lox knockout of FURIN in CD4+ [GeneID=920] cells.,CGP,C2,7,17
Cohort,-0.016246507902009127,0.01226495867978038,-1.324628017605359,0.18567472095714976,LonGen OPEL,Genes down-regulated in naive T lymphocytes lacking FURIN [GeneID=5045]: Cre-Lox knockout of FURIN in CD4+ [GeneID=920] cells.,CGP,C2,14,9
Cohort,-0.009680125816581458,0.00936022066736261,-1.034177094812978,0.3014232001444424,LGP Offspring,Genes up-regulated in naive T lymphocytes lacking FURIN [GeneID=5045]: Cre-Lox knockout of FURIN in CD4+ [GeneID=920] cells.,CGP,C2,4,5
Cohort,0.002514716136845196,0.022802281417588235,0.11028353219540143,0.912211048885347,LGP Proband,Genes up-regulated in naive T lymphocytes lacking FURIN [GeneID=5045]: Cre-Lox knockout of FURIN in CD4+ [GeneID=920] cells.,CGP,C2,4,5
Cohort,0.0039160094548591285,0.005178950003792264,0.7561396522444989,0.44978918187663386,LonGen OPEL,Genes up-regulated in naive T lymphocytes lacking FURIN [GeneID=5045]: Cre-Lox knockout of FURIN in CD4+ [GeneID=920] cells.,CGP,C2,1,3
Cohort,0.014550747465551146,0.015145694387810998,0.9607184123074175,0.33703726980803983,LGP Offspring,"Genes down-regulated in response to nutlin-3a [PubChem=216345], an inhibitor of MDM2 [GeneID=4193],  in skin fibroblast cultures after knockdown of TP53 [GeneID=7157] by RNAi.",CGP,C2,5,18
Cohort,0.0031155114017798607,0.037667741382827406,0.08271033216767841,0.93410171563195,LGP Proband,"Genes down-regulated in response to nutlin-3a [PubChem=216345], an inhibitor of MDM2 [GeneID=4193],  in skin fibroblast cultures after knockdown of TP53 [GeneID=7157] by RNAi.",CGP,C2,5,19
Cohort,-0.004345532349830303,0.012004000121965702,-0.36200702313211114,0.7174428621157687,LonGen OPEL,"Genes down-regulated in response to nutlin-3a [PubChem=216345], an inhibitor of MDM2 [GeneID=4193],  in skin fibroblast cultures after knockdown of TP53 [GeneID=7157] by RNAi.",CGP,C2,11,11
Cohort,0.012238057519752847,0.014013540782088595,0.8733023088208313,0.3828084295619274,LGP Offspring,"Genes up-regulated in response to nutlin-3a [PubChem=216345], an inhibitor of MDM2 [GeneID=4193],  in skin fibroblast cultures after knockdown of TP53 [GeneID=7157] by RNAi.",CGP,C2,5,15
Cohort,-0.01216414573128747,0.03455527108608092,-0.3520199769518597,0.724912208128925,LGP Proband,"Genes up-regulated in response to nutlin-3a [PubChem=216345], an inhibitor of MDM2 [GeneID=4193],  in skin fibroblast cultures after knockdown of TP53 [GeneID=7157] by RNAi.",CGP,C2,5,15
Cohort,0.015035354656400627,0.012012282828172027,1.2516650557992761,0.21105962788672764,LonGen OPEL,"Genes up-regulated in response to nutlin-3a [PubChem=216345], an inhibitor of MDM2 [GeneID=4193],  in skin fibroblast cultures after knockdown of TP53 [GeneID=7157] by RNAi.",CGP,C2,8,14
Cohort,-0.0680816784213897,0.046038128294718664,-1.478810736734486,0.13965670792063586,LGP Offspring,Genes defining the Mycobacterium tuberculosis strain-independent regulatory axis of the host macrophage cells.,CGP,C2,81,142
Cohort,0.22174934061589643,0.1413451604684481,1.5688498982276553,0.11706222425075008,LGP Proband,Genes defining the Mycobacterium tuberculosis strain-independent regulatory axis of the host macrophage cells.,CGP,C2,81,223
Cohort,0.0030165909251830994,0.0415827630712138,0.07254426359347374,0.94218700475894,LonGen OPEL,Genes defining the Mycobacterium tuberculosis strain-independent regulatory axis of the host macrophage cells.,CGP,C2,119,141
Cohort,-0.11347788760141295,0.07896037772157262,-1.437149756318983,0.15113812530627896,LGP Offspring,Genes indentified by RNAi screen as regulating infection of THP-1 cells (macrophage) with Mycobacterium tuberculosis.,CGP,C2,228,426
Cohort,0.17504890293634603,0.23014076952384843,0.7606166577895557,0.4471010490497118,LGP Proband,Genes indentified by RNAi screen as regulating infection of THP-1 cells (macrophage) with Mycobacterium tuberculosis.,CGP,C2,228,610
Cohort,-0.09830899930135313,0.06858969965852679,-1.4332910012842104,0.15216733802229862,LonGen OPEL,Genes indentified by RNAi screen as regulating infection of THP-1 cells (macrophage) with Mycobacterium tuberculosis.,CGP,C2,348,390
Cohort,-0.07815008079630927,0.10556622261793107,-0.7402943750213811,0.4593784253224955,LGP Offspring,"Myeloid leukemia model in mice with germ-line MLL-AF9 fusion knock-in [GeneID=4297;4300]: genes changed in comparison among the leukemic, preleukemic and wild-type animals.",CGP,C2,367,754
Cohort,-0.239454422125103,0.3023812431847264,-0.7918957525378614,0.4286466358510257,LGP Proband,"Myeloid leukemia model in mice with germ-line MLL-AF9 fusion knock-in [GeneID=4297;4300]: genes changed in comparison among the leukemic, preleukemic and wild-type animals.",CGP,C2,367,1061
Cohort,0.046726475508744654,0.09510808932943456,0.4912986459742021,0.6233506682818732,LonGen OPEL,"Myeloid leukemia model in mice with germ-line MLL-AF9 fusion knock-in [GeneID=4297;4300]: genes changed in comparison among the leukemic, preleukemic and wild-type animals.",CGP,C2,620,743
Cohort,-0.038880409544297286,0.024811226260771414,-1.5670490904260708,0.11757117597795645,LGP Offspring,Genes down-regulated in C2AS12 cells (myoblast) by IGF1 [GeneID=3479] vs PDGFB [GeneID=5155].,CGP,C2,24,34
Cohort,-0.14000437592213805,0.07194290413028777,-1.9460484340275135,0.05198447745516228,LGP Proband,Genes down-regulated in C2AS12 cells (myoblast) by IGF1 [GeneID=3479] vs PDGFB [GeneID=5155].,CGP,C2,24,62
Cohort,-0.010062358880449505,0.020865450239033852,-0.4822497844606985,0.6297610907129814,LonGen OPEL,Genes down-regulated in C2AS12 cells (myoblast) by IGF1 [GeneID=3479] vs PDGFB [GeneID=5155].,CGP,C2,33,33
Cohort,-0.061345596043148445,0.05742781734945897,-1.0682209227951163,0.28580217847374767,LGP Offspring,Genes up-regulated in C2AS12 cells (myoblast) by IGF1 [GeneID=3479] vs PDGFB [GeneID=5155].,CGP,C2,113,220
Cohort,-0.03228778291785479,0.1551782007856592,-0.20806906353072416,0.8352258417548969,LGP Proband,Genes up-regulated in C2AS12 cells (myoblast) by IGF1 [GeneID=3479] vs PDGFB [GeneID=5155].,CGP,C2,113,292
Cohort,-0.011862821565266286,0.04849935236382252,-0.2445975252674757,0.8068311168400186,LonGen OPEL,Genes up-regulated in C2AS12 cells (myoblast) by IGF1 [GeneID=3479] vs PDGFB [GeneID=5155].,CGP,C2,163,190
Cohort,0.0037756837957238667,0.014517228234934242,0.26008296725941565,0.7948789711919543,LGP Offspring,Genes down-regulated in hepatocellular carcinoma (HCC) with early recurrence.,CGP,C2,5,15
Cohort,0.040604551403392995,0.039908666134580065,1.0174369463130204,0.3092406707508407,LGP Proband,Genes down-regulated in hepatocellular carcinoma (HCC) with early recurrence.,CGP,C2,5,15
Cohort,0.01940533376422442,0.012214288677540944,1.5887403905809128,0.1125161067432901,LonGen OPEL,Genes down-regulated in hepatocellular carcinoma (HCC) with early recurrence.,CGP,C2,7,16
Cohort,-0.0361265813382404,0.016592764896963305,-2.177249033694923,0.029807171916610985,LGP Offspring,Genes up-regulated in hepatocellular carcinoma (HCC) with early recurrence.,CGP,C2,13,15
Cohort,0.0462282980868141,0.05581705945045898,0.8282109187038869,0.4077879989998502,LGP Proband,Genes up-regulated in hepatocellular carcinoma (HCC) with early recurrence.,CGP,C2,13,38
Cohort,0.0030013840688686315,0.01788338551427941,0.1678308654964747,0.8667589698526722,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma (HCC) with early recurrence.,CGP,C2,22,24
Cohort,0.0107966477817396,0.015745373576876005,0.6857028656084597,0.4931355828729508,LGP Offspring,"Inflammatory cytokines and their receptors modulated in brain tumors after treatment with an oncocytic virus, a potential anticancer therapy.",CGP,C2,8,16
Cohort,-0.08161818125357961,0.04703265322088437,-1.7353514136289019,0.08304796347407394,LGP Proband,"Inflammatory cytokines and their receptors modulated in brain tumors after treatment with an oncocytic virus, a potential anticancer therapy.",CGP,C2,8,26
Cohort,0.021272398852141487,0.015084564481870299,1.4102096800811297,0.15886840626970858,LonGen OPEL,"Inflammatory cytokines and their receptors modulated in brain tumors after treatment with an oncocytic virus, a potential anticancer therapy.",CGP,C2,11,22
Cohort,0.0018987388275147525,0.013858928879531536,0.13700473131938998,0.8910678485282089,LGP Offspring,Inflammatory cytokines and their receptors moduated in brain tumors in response to treatment with cyclic RGD peptide prior to the oncocytic virus therapy.,CGP,C2,7,13
Cohort,-0.04833660504617037,0.04394496474897849,-1.0999350055752168,0.2716778294589143,LGP Proband,Inflammatory cytokines and their receptors moduated in brain tumors in response to treatment with cyclic RGD peptide prior to the oncocytic virus therapy.,CGP,C2,7,24
Cohort,0.01590365503310384,0.014223093798004868,1.1181572208526607,0.2638371905831111,LonGen OPEL,Inflammatory cytokines and their receptors moduated in brain tumors in response to treatment with cyclic RGD peptide prior to the oncocytic virus therapy.,CGP,C2,11,21
Cohort,-0.011271776201870776,0.029107956252583927,-0.38724038555163676,0.6987001371521986,LGP Offspring,List of genes in the 19q13 amplicon region based on a copy number alterations study of a panel of 16 pancreatic cancer cell lines and 31 primary tumors.,CGP,C2,30,57
Cohort,0.05629249772256672,0.08113888604395808,0.6937795238163549,0.4880136689914437,LGP Proband,List of genes in the 19q13 amplicon region based on a copy number alterations study of a panel of 16 pancreatic cancer cell lines and 31 primary tumors.,CGP,C2,30,89
Cohort,0.0011164235815679705,0.023439856535702026,0.047629283902293026,0.9620236404737863,LonGen OPEL,List of genes in the 19q13 amplicon region based on a copy number alterations study of a panel of 16 pancreatic cancer cell lines and 31 primary tumors.,CGP,C2,43,48
Cohort,9.001777139770249e-4,0.005516614855683556,0.16317574047236713,0.8704288347791777,LGP Offspring,Transcripts stabilized by NO [PubChem=145068] identified as up-regulated by NO [PubChem=145068] in the presence of actinomycin D [PubChemiD=2019] in IMR-90 and NIH 3T3 cells (fibroblast).,CGP,C2,1,2
Cohort,-0.01811307438522012,0.01759942396847507,-1.0291856379882163,0.3036908308236061,LGP Proband,Transcripts stabilized by NO [PubChem=145068] identified as up-regulated by NO [PubChem=145068] in the presence of actinomycin D [PubChemiD=2019] in IMR-90 and NIH 3T3 cells (fibroblast).,CGP,C2,1,4
Cohort,0.007797531128909295,0.005169858663668354,1.5082677566617333,0.1318827934651872,LonGen OPEL,Transcripts stabilized by NO [PubChem=145068] identified as up-regulated by NO [PubChem=145068] in the presence of actinomycin D [PubChemiD=2019] in IMR-90 and NIH 3T3 cells (fibroblast).,CGP,C2,1,3
Cohort,0.04637469095874079,0.035890604787261624,1.2921122737725557,0.19675979958115394,LGP Offspring,Genes specifically responding to 4NQO treatment of primary fibroblasts.,CGP,C2,36,96
Cohort,0.15995893380654064,0.10438225388232883,1.5324341816460867,0.12579455076008983,LGP Proband,Genes specifically responding to 4NQO treatment of primary fibroblasts.,CGP,C2,36,142
Cohort,0.05535530411006251,0.034713283333498136,1.5946432833290918,0.11118897421040472,LonGen OPEL,Genes specifically responding to 4NQO treatment of primary fibroblasts.,CGP,C2,79,112
Cohort,0.021923294996276963,0.02747710651384685,0.797874950378378,0.4252232431327665,LGP Offspring,Genes responding to 4NQO treatment and gamma irradiation.,CGP,C2,20,48
Cohort,-0.04023161108503335,0.07570505878769476,-0.5314256633477797,0.5952653479966885,LGP Proband,Genes responding to 4NQO treatment and gamma irradiation.,CGP,C2,20,68
Cohort,0.03569415717123061,0.023281920681336308,1.533127685631385,0.1256417295855272,LonGen OPEL,Genes responding to 4NQO treatment and gamma irradiation.,CGP,C2,30,51
Cohort,-0.013012965713440357,0.03848600612424013,-0.338122009112404,0.7353762251815814,LGP Offspring,4NQO treatment and UV irradiation responding genes.,CGP,C2,51,102
Cohort,-0.061359676125265335,0.10883555611569606,-0.5637833656129604,0.5730531345013419,LGP Proband,4NQO treatment and UV irradiation responding genes.,CGP,C2,51,154
Cohort,0.06396960058536186,0.038422439033112356,1.6649021299827693,0.09632580115076386,LonGen OPEL,4NQO treatment and UV irradiation responding genes.,CGP,C2,94,133
Cohort,-0.06455183628715534,0.04083676544970714,-1.5807284337113992,0.1144078967080419,LGP Offspring,Gamma and UV responding genes.,CGP,C2,68,110
Cohort,0.030199557888701448,0.11586845102111198,0.2606365893611445,0.7944371092209648,LGP Proband,Gamma and UV responding genes.,CGP,C2,68,166
Cohort,-0.04276257771131209,0.03948329724581924,-1.0830548787523078,0.2791120247077674,LonGen OPEL,Gamma and UV responding genes.,CGP,C2,112,121
Cohort,0.023293492361654785,0.05262521593506557,0.4426298675980105,0.6581750693530084,LGP Offspring,Genes specifically responding to gamma radiation.,CGP,C2,86,187
Cohort,0.2723115767977768,0.14890345091378002,1.828779488498585,0.0677896292361875,LGP Proband,Genes specifically responding to gamma radiation.,CGP,C2,86,279
Cohort,-0.06561220396125743,0.046410299843921726,-1.413742298194838,0.15782854033671487,LonGen OPEL,Genes specifically responding to gamma radiation.,CGP,C2,151,165
Cohort,-0.006798283131745294,0.028863607256433246,-0.23553130665017843,0.8138677175555383,LGP Offspring,UV only responding genes in primary fibroblasts from young donors.,CGP,C2,28,54
Cohort,0.05399275688799216,0.08413746958870205,0.6417207119720925,0.521230865970403,LGP Proband,UV only responding genes in primary fibroblasts from young donors.,CGP,C2,28,91
Cohort,-0.05975741338690548,0.027391745504071766,-2.1815847178494914,0.029432059996150506,LonGen OPEL,UV only responding genes in primary fibroblasts from young donors.,CGP,C2,61,51
Cohort,0.05837119140437904,0.06495379453287743,0.8986571427298755,0.369155284090981,LGP Offspring,Genes with GO annotation and down-regulated after DNA damage in cell lines from young donors.,CGP,C2,137,308
Cohort,0.027996942612919858,0.19314559498611486,0.1449525297997738,0.8847833736333692,LGP Proband,Genes with GO annotation and down-regulated after DNA damage in cell lines from young donors.,CGP,C2,137,460
Cohort,0.02784338550252111,0.05882060962132108,0.47336104949902696,0.6360853995405884,LonGen OPEL,Genes with GO annotation and down-regulated after DNA damage in cell lines from young donors.,CGP,C2,260,313
Cohort,-0.09644351644962028,0.07932463179043593,-1.2158079309389036,0.2244824967955817,LGP Offspring,Genes with GO annotation and up-regulated after DNA damage in cell lines from young donors.,CGP,C2,215,404
Cohort,0.15396936798792213,0.2295937030623303,0.6706166847534246,0.5026504122575124,LGP Proband,Genes with GO annotation and up-regulated after DNA damage in cell lines from young donors.,CGP,C2,215,635
Cohort,-0.0984271854841013,0.07605923464238833,-1.2940859311414523,0.19601106529241982,LonGen OPEL,Genes with GO annotation and up-regulated after DNA damage in cell lines from young donors.,CGP,C2,384,434
Cohort,-0.010693540585752241,0.022453886815034078,-0.47624452166528,0.634054067923344,LGP Offspring,"All common down-regulated stress response genes (Human Environmental Stress Response, H-ESR).",CGP,C2,18,33
Cohort,-0.09615499656946533,0.07075954936202068,-1.3588978086550016,0.17454635013451367,LGP Proband,"All common down-regulated stress response genes (Human Environmental Stress Response, H-ESR).",CGP,C2,18,65
Cohort,1.045844000947879e-4,0.023450353061980945,0.004459821982993771,0.9964427061225136,LonGen OPEL,"All common down-regulated stress response genes (Human Environmental Stress Response, H-ESR).",CGP,C2,37,44
Cohort,-0.013999260873065921,0.015941045310843848,-0.8781896419015236,0.3801528304456262,LGP Offspring,Human environmental etress response genes not changed in primary fibroblasts from old donors in response to 4NQO treatment.,CGP,C2,10,16
Cohort,-0.016132948973966454,0.043933004764928264,-0.3672170628958526,0.7135502707190622,LGP Proband,Human environmental etress response genes not changed in primary fibroblasts from old donors in response to 4NQO treatment.,CGP,C2,10,22
Cohort,-0.0025425671503685773,0.014630233957007948,-0.17378855032941398,0.8620758287648591,LonGen OPEL,Human environmental etress response genes not changed in primary fibroblasts from old donors in response to 4NQO treatment.,CGP,C2,16,17
Cohort,-0.003676025035956004,0.031713456369376156,-0.11591373053571442,0.9077553380105456,LGP Offspring,Human environmental stress response genes not changed in primary fibroblasts from Wilmor syndrom (WS) patients in response to 4NQO treatment.,CGP,C2,33,70
Cohort,-0.14131686809073002,0.09368406807264774,-1.5084407733142544,0.13182046618551072,LGP Proband,Human environmental stress response genes not changed in primary fibroblasts from Wilmor syndrom (WS) patients in response to 4NQO treatment.,CGP,C2,33,107
Cohort,0.010575747349373032,0.030027712546729167,0.3521995667473851,0.7247818259070958,LonGen OPEL,Human environmental stress response genes not changed in primary fibroblasts from Wilmor syndrom (WS) patients in response to 4NQO treatment.,CGP,C2,62,79
Cohort,-0.0038323440166613395,0.025949316380472518,-0.1476857409448085,0.8826348230072674,LGP Offspring,Human environmental stress response (H-ESR) genes not changed in primary fibroblasts from old donors in response to gamma radiation.,CGP,C2,22,46
Cohort,-0.09801082582261428,0.0776560692354568,-1.2621141758468473,0.20726053382868295,LGP Proband,Human environmental stress response (H-ESR) genes not changed in primary fibroblasts from old donors in response to gamma radiation.,CGP,C2,22,73
Cohort,0.007663991482606139,0.02331835265676011,0.3286677920785416,0.7424932465748803,LonGen OPEL,Human environmental stress response (H-ESR) genes not changed in primary fibroblasts from old donors in response to gamma radiation.,CGP,C2,38,48
Cohort,0.010986497811331397,0.025228349116291984,0.4354822331294174,0.6633514424461961,LGP Offspring,Human environmental stress response genes not changed in primary fibroblasts from Werner syndrom (WS) patients in response to gamma radiation.,CGP,C2,16,42
Cohort,-0.029185356413333766,0.07267466804993124,-0.4015891258461879,0.6880893152051488,LGP Proband,Human environmental stress response genes not changed in primary fibroblasts from Werner syndrom (WS) patients in response to gamma radiation.,CGP,C2,16,72
Cohort,0.008255010694388883,0.02333296831029271,0.3537917072791552,0.7235886751610033,LonGen OPEL,Human environmental stress response genes not changed in primary fibroblasts from Werner syndrom (WS) patients in response to gamma radiation.,CGP,C2,34,47
Cohort,-0.017444022464739164,0.019433045584271377,-0.8976473805453284,0.36969315272688763,LGP Offspring,Human environmental stress response genes not changed in primary fibroblasts from old donors in response to UV radiation.,CGP,C2,15,24
Cohort,0.033354456992012685,0.061736592410149,0.5402704569507384,0.5891547686937425,LGP Proband,Human environmental stress response genes not changed in primary fibroblasts from old donors in response to UV radiation.,CGP,C2,15,46
Cohort,-0.0015553909217296017,0.0202036650565147,-0.07698558243659182,0.9386543602976486,LonGen OPEL,Human environmental stress response genes not changed in primary fibroblasts from old donors in response to UV radiation.,CGP,C2,29,30
Cohort,0.002583015696213192,0.016796891371292914,0.1537793892403061,0.8778295805057421,LGP Offspring,Human environmental stress response genes not changed in primary fibroblasts from patients with Warner syndrom (WS) .,CGP,C2,8,21
Cohort,0.03146302959693888,0.047760148565756215,0.65877160230397,0.5102242731319506,LGP Proband,Human environmental stress response genes not changed in primary fibroblasts from patients with Warner syndrom (WS) .,CGP,C2,8,28
Cohort,-0.01616836212466821,0.015392649513584877,-1.0503950025236866,0.29385532991547697,LonGen OPEL,Human environmental stress response genes not changed in primary fibroblasts from patients with Warner syndrom (WS) .,CGP,C2,19,16
Cohort,-0.029119693519631742,0.037197049969597135,-0.7828495416553897,0.43398962492830095,LGP Offspring,"All common  up-regulated stress response genes (Human Environmental Stress Response, H-ESR).",CGP,C2,48,89
Cohort,-0.14529656180615264,0.1074370705620117,-1.3523875981176234,0.17661792464526457,LGP Proband,"All common  up-regulated stress response genes (Human Environmental Stress Response, H-ESR).",CGP,C2,48,134
Cohort,-0.0479000254141074,0.03222954072483865,-1.4862149548780828,0.13761822376424784,LonGen OPEL,"All common  up-regulated stress response genes (Human Environmental Stress Response, H-ESR).",CGP,C2,83,76
Cohort,-0.00054745675632333565,0.02166121716774655,-0.025273591603083883,0.9798441966684468,LGP Offspring,Genes distinctly down-regulated in primary fibroblast cultures from normal old donors compared to those from normal young donors.,CGP,C2,16,33
Cohort,-0.019725602931622715,0.05223663185479901,-0.3776201150651047,0.7058088977237726,LGP Proband,Genes distinctly down-regulated in primary fibroblast cultures from normal old donors compared to those from normal young donors.,CGP,C2,16,31
Cohort,-0.0034067579393838128,0.018374940075617168,-0.18540239725213842,0.852960659129891,LonGen OPEL,Genes distinctly down-regulated in primary fibroblast cultures from normal old donors compared to those from normal young donors.,CGP,C2,22,27
Cohort,-0.0355529083472009,0.018401142697345448,-1.93210329010327,0.05376429415065445,LGP Offspring,Genes distinctly up-regulated in primary fibroblast cultures from normal old donors compared to those from normal young donors.,CGP,C2,15,15
Cohort,-0.0497188596839994,0.05294925120533861,-0.9389907987780287,0.34800732676898183,LGP Proband,Genes distinctly up-regulated in primary fibroblast cultures from normal old donors compared to those from normal young donors.,CGP,C2,15,29
Cohort,2.1070777498222626e-4,0.017149327721147155,0.01228664927327726,0.9901999975724803,LonGen OPEL,Genes distinctly up-regulated in primary fibroblast cultures from normal old donors compared to those from normal young donors.,CGP,C2,17,25
Cohort,0.03266215813348169,0.03373666825845562,0.9681500817821682,0.3333156662030623,LGP Offspring,"Genes up-regulated in response to hydrogen peroxide [PubChem=784] in CS-B cells (Cockayne syndrome fibroblast, CS) expressing ERCC6 [GeneID=2074] off a plasmid vector.",CGP,C2,29,75
Cohort,0.06657635794376521,0.08212539897341581,0.8106670868693878,0.4177881447062215,LGP Proband,"Genes up-regulated in response to hydrogen peroxide [PubChem=784] in CS-B cells (Cockayne syndrome fibroblast, CS) expressing ERCC6 [GeneID=2074] off a plasmid vector.",CGP,C2,29,81
Cohort,0.05488450379885274,0.03071455142078239,1.78692187448703,0.07433054697155526,LonGen OPEL,"Genes up-regulated in response to hydrogen peroxide [PubChem=784] in CS-B cells (Cockayne syndrome fibroblast, CS) expressing ERCC6 [GeneID=2074] off a plasmid vector.",CGP,C2,52,81
Cohort,0.012540291688236348,0.015547683423451997,0.8065697857804769,0.420198050165851,LGP Offspring,"Genes down-regulated in CS-B cells (Cockayne syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074] in response to hydrogen peroxide [PubChem=784].",CGP,C2,6,18
Cohort,0.019746577786028386,0.04341765506251313,0.45480525739119454,0.6493677057406803,LGP Proband,"Genes down-regulated in CS-B cells (Cockayne syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074] in response to hydrogen peroxide [PubChem=784].",CGP,C2,6,25
Cohort,0.016418577838034982,0.01587562175236985,1.0342006186676802,0.3013564780589269,LonGen OPEL,"Genes down-regulated in CS-B cells (Cockayne syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074] in response to hydrogen peroxide [PubChem=784].",CGP,C2,14,23
Cohort,0.003978537228182269,0.026886166050191694,0.14797711286745188,0.8824049570591954,LGP Offspring,"Genes down-regulated in response to hydorgen peroxyde [PubChem=784] in CS-B cells (Cockaine syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074].",CGP,C2,23,51
Cohort,0.0025817958990078894,0.08256428274628473,0.031270130535035336,0.9750615926670507,LGP Proband,"Genes down-regulated in response to hydorgen peroxyde [PubChem=784] in CS-B cells (Cockaine syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074].",CGP,C2,23,87
Cohort,0.025122466629080013,0.025468048898449853,0.98643075208675,0.3242215184243541,LonGen OPEL,"Genes down-regulated in response to hydorgen peroxyde [PubChem=784] in CS-B cells (Cockaine syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074].",CGP,C2,39,57
Cohort,-0.05966436579981865,0.028598240771877396,-2.0862949674334756,0.03732616323687063,LGP Offspring,"Genes up-regulated in response to hydorgen peroxyde [PubChem=784] in CS-B cells (Cockaine syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074].",CGP,C2,34,45
Cohort,-0.013874853314928432,0.07437509551593885,-0.18655241003293907,0.8520569507033195,LGP Proband,"Genes up-regulated in response to hydorgen peroxyde [PubChem=784] in CS-B cells (Cockaine syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074].",CGP,C2,34,57
Cohort,0.013461370185941717,0.02219813231957168,0.606419044275769,0.5444094259250536,LonGen OPEL,"Genes up-regulated in response to hydorgen peroxyde [PubChem=784] in CS-B cells (Cockaine syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074].",CGP,C2,32,46
Cohort,0.0017461723924277056,0.07231138504050418,0.02414795943197067,0.9807417145968863,LGP Offspring,Genes down-regulated similarly  in primary fibroblast cultures from Werner syndrom patients and normal old donors compared to those from normal young donors.,CGP,C2,147,314
Cohort,-0.22394984183180155,0.17777584872911245,-1.2597315295231533,0.20811863101414269,LGP Proband,Genes down-regulated similarly  in primary fibroblast cultures from Werner syndrom patients and normal old donors compared to those from normal young donors.,CGP,C2,147,401
Cohort,-0.046642576317353315,0.05377946211002585,-0.8672934701713567,0.38604260368189947,LonGen OPEL,Genes down-regulated similarly  in primary fibroblast cultures from Werner syndrom patients and normal old donors compared to those from normal young donors.,CGP,C2,204,220
Cohort,0.006165164882070321,0.04669270509363967,0.132037003846884,0.8949943118608965,LGP Offspring,Genes up-regulated similarly  in primary fibroblast cultures from Werner syndrom patients and normal old donors compared to those from normal young donors.,CGP,C2,71,153
Cohort,-0.019337539186875075,0.1358331051713892,-0.14236249081161534,0.8868280725655483,LGP Proband,Genes up-regulated similarly  in primary fibroblast cultures from Werner syndrom patients and normal old donors compared to those from normal young donors.,CGP,C2,71,228
Cohort,-0.03923073446872609,0.0426783494318108,-0.9192186434343455,0.3582596821060675,LonGen OPEL,Genes up-regulated similarly  in primary fibroblast cultures from Werner syndrom patients and normal old donors compared to those from normal young donors.,CGP,C2,127,143
Cohort,0.005718809603235279,0.020184977760530534,0.2833200844252487,0.777018224170329,LGP Offspring,Genes distinctly down-regulated in primary fibroblast cultures from Werner syndrom patients compared to those from normal young donors.,CGP,C2,13,29
Cohort,-0.01678107846288208,0.050098265655394,-0.3349632615690218,0.7377370283776074,LGP Proband,Genes distinctly down-regulated in primary fibroblast cultures from Werner syndrom patients compared to those from normal young donors.,CGP,C2,13,30
Cohort,-0.005031012297775104,0.016768358512047363,-0.3000301009881517,0.7642325284966404,LonGen OPEL,Genes distinctly down-regulated in primary fibroblast cultures from Werner syndrom patients compared to those from normal young donors.,CGP,C2,19,21
Cohort,-0.04181917470675954,0.020084928353018755,-2.0821171961250307,0.03770730177281651,LGP Offspring,Genes distinctly up-regulated in primary fibroblast cultures from Werner syndrom patients compared to those from normal young donors.,CGP,C2,18,19
Cohort,-0.05266338415273999,0.0550633039810861,-0.9564152592592251,0.33913962579585566,LGP Proband,Genes distinctly up-regulated in primary fibroblast cultures from Werner syndrom patients compared to those from normal young donors.,CGP,C2,18,30
Cohort,0.0018349621333735378,0.018556103226932484,0.09888725617295868,0.9212526840846199,LonGen OPEL,Genes distinctly up-regulated in primary fibroblast cultures from Werner syndrom patients compared to those from normal young donors.,CGP,C2,20,31
Cohort,0.004244803668537723,0.028743893077433316,0.14767671369715385,0.8826419448429875,LGP Offspring,Genes up-regulated in cells expressing MEN1 [GeneID=4221].,CGP,C2,26,60
Cohort,-0.05475337724834601,0.07397681190684677,-0.7401424289180327,0.4594218757176577,LGP Proband,Genes up-regulated in cells expressing MEN1 [GeneID=4221].,CGP,C2,26,69
Cohort,0.03532227454556562,0.02359771621790144,1.4968513994913553,0.13482832013221024,LonGen OPEL,Genes up-regulated in cells expressing MEN1 [GeneID=4221].,CGP,C2,40,54
Cohort,-0.08384967189518798,0.05558483752032294,-1.5084990014503656,0.1318940660723518,LGP Offspring,Genes down-regulated in serrated vs conventional colorectal carcinoma (CRC) samples.,CGP,C2,111,202
Cohort,0.21713368326976998,0.1619935835320114,1.3403844679246966,0.18048539862030857,LGP Proband,Genes down-regulated in serrated vs conventional colorectal carcinoma (CRC) samples.,CGP,C2,111,310
Cohort,-0.059931131461075836,0.04787271662955716,-1.251884908158182,0.21097953657852878,LonGen OPEL,Genes down-regulated in serrated vs conventional colorectal carcinoma (CRC) samples.,CGP,C2,155,154
Cohort,0.055081057433968655,0.059195465265566315,0.9304945435745905,0.35244725301426727,LGP Offspring,Genes up-regulated in serrated vs conventional colorectal carcinoma (CRC) samples.,CGP,C2,110,251
Cohort,-0.16526316997046975,0.16269449071162256,-1.01578836042703,0.3100247672543657,LGP Proband,Genes up-regulated in serrated vs conventional colorectal carcinoma (CRC) samples.,CGP,C2,110,301
Cohort,0.03147222950682129,0.050937098190977,0.6178645942653302,0.5368413252244528,LonGen OPEL,Genes up-regulated in serrated vs conventional colorectal carcinoma (CRC) samples.,CGP,C2,176,225
Cohort,-0.012817627920446682,0.01680701756968753,-0.7626354805247569,0.4459468449272448,LGP Offspring,The cyclin D1 signature: genes whose expression correlated with the levels of CCND1 [GeneID=595].,CGP,C2,12,18
Cohort,0.017878773255168467,0.05524366503279617,0.32363481395657734,0.7462956637354896,LGP Proband,The cyclin D1 signature: genes whose expression correlated with the levels of CCND1 [GeneID=595].,CGP,C2,12,37
Cohort,0.005077657832158734,0.015957091766876354,0.3182069706899166,0.7504114103647145,LonGen OPEL,The cyclin D1 signature: genes whose expression correlated with the levels of CCND1 [GeneID=595].,CGP,C2,18,22
Cohort,-0.025999244928954463,0.023414070542949052,-1.1104111470606257,0.2672167113300076,LGP Offspring,Genes associated with metastasis of breast cancer in the lung compared to the non-lung metastasis.,CGP,C2,21,34
Cohort,0.013749644503150166,0.06258036997154644,0.21971178037780456,0.826149393471969,LGP Proband,Genes associated with metastasis of breast cancer in the lung compared to the non-lung metastasis.,CGP,C2,21,45
Cohort,-0.012493986514548566,0.018823414833714226,-0.6637470737865717,0.5070443970583303,LonGen OPEL,Genes associated with metastasis of breast cancer in the lung compared to the non-lung metastasis.,CGP,C2,29,28
Cohort,0.056291220812051,0.04951200684116198,1.1369206057964327,0.25597432048283847,LGP Offspring,Genes down-regulated in preneoplastic mammary tissues and whose expression is maintained in tumors.,CGP,C2,70,167
Cohort,-0.06734513094654603,0.13539805221632997,-0.4973862610589587,0.6190477943729084,LGP Proband,Genes down-regulated in preneoplastic mammary tissues and whose expression is maintained in tumors.,CGP,C2,70,251
Cohort,-0.015725360053014573,0.045730425341933265,-0.3438708460600069,0.7310342308211027,LonGen OPEL,Genes down-regulated in preneoplastic mammary tissues and whose expression is maintained in tumors.,CGP,C2,143,167
Cohort,0.03937383366802012,0.03448394885798583,1.141801764936265,0.2539407094147764,LGP Offspring,Genes up-regulated in preneoplastic mammary tissues and whose expression is maintained in tumors.,CGP,C2,31,80
Cohort,-0.14040543556229365,0.08761074737064439,-1.602605157199459,0.10940049773244662,LGP Proband,Genes up-regulated in preneoplastic mammary tissues and whose expression is maintained in tumors.,CGP,C2,31,99
Cohort,0.007567031792780226,0.029509719971536702,0.2564250626599957,0.7976888948350016,LonGen OPEL,Genes up-regulated in preneoplastic mammary tissues and whose expression is maintained in tumors.,CGP,C2,55,74
Cohort,0.039090906601408834,0.04799486988346275,0.8144809371569546,0.41565631371258527,LGP Offspring,Down-regulated genes from top 82 genes out of the 324-gene signature identified in the pre-neoplastic tissue adjacent to the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,68,157
Cohort,0.03136938170935221,0.125641757669706,0.24967321606418286,0.8029015541960363,LGP Proband,Down-regulated genes from top 82 genes out of the 324-gene signature identified in the pre-neoplastic tissue adjacent to the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,68,208
Cohort,0.07390475074745144,0.04160554744616358,1.7763196324500268,0.07606215434058904,LonGen OPEL,Down-regulated genes from top 82 genes out of the 324-gene signature identified in the pre-neoplastic tissue adjacent to the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,111,154
Cohort,0.010762411062227226,0.024616903452537017,0.4371959732050723,0.6621088578265961,LGP Offspring,Up-regulated genes from top 82 genes out of the 324-gene signature identified in the pre-neoplastic tissue adjacent to the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,14,38
Cohort,0.01683515066045262,0.06252308633594371,0.2692629498485635,0.7877939416517716,LGP Proband,Up-regulated genes from top 82 genes out of the 324-gene signature identified in the pre-neoplastic tissue adjacent to the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,14,47
Cohort,0.017947289592263268,0.0209683008944426,0.8559248401962787,0.3922969255484692,LonGen OPEL,Up-regulated genes from top 82 genes out of the 324-gene signature identified in the pre-neoplastic tissue adjacent to the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,25,39
Cohort,0.057842617571198914,0.07475135658524185,0.7738002387319721,0.43931944866205463,LGP Offspring,Down-regulated genes from the 324 genes identified by two analytical methods as changed in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,163,361
Cohort,-0.017456116278982737,0.20769267723406334,-0.0840478177249852,0.93303858282651575,LGP Proband,Down-regulated genes from the 324 genes identified by two analytical methods as changed in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,163,532
Cohort,0.02355347823438326,0.0637333393752194,0.36956290797373864,0.7118064850865489,LonGen OPEL,Down-regulated genes from the 324 genes identified by two analytical methods as changed in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,275,339
Cohort,-0.0735493960882032,0.06969107724798072,-1.0553631683220146,0.2916362900298757,LGP Offspring,Up-regulated genes from the 324 genes identified by two analytical methods as changed in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,155,300
Cohort,-0.3626597755239877,0.19430378620602698,-1.8664575848225988,0.06232812515508081,LGP Proband,Up-regulated genes from the 324 genes identified by two analytical methods as changed in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,155,408
Cohort,-0.04762930504924969,0.05688615767531257,-0.8372740750237001,0.4026898329105334,LonGen OPEL,Up-regulated genes from the 324 genes identified by two analytical methods as changed in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,244,280
Cohort,-0.01906058326041148,0.03586233182776457,-0.5314931374778815,0.5952516938595274,LGP Offspring,Down-regulated genes from the 65 most significantly changed (p<0.01) genes identified by two analytical methods in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,47,90
Cohort,0.00295768591576837,0.10890156668571208,0.027159259556882198,0.9783392070813691,LGP Proband,Down-regulated genes from the 65 most significantly changed (p<0.01) genes identified by two analytical methods in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,47,145
Cohort,-0.018987469742931282,0.030940634312094883,-0.6136742237216826,0.5396059483655562,LonGen OPEL,Down-regulated genes from the 65 most significantly changed (p<0.01) genes identified by two analytical methods in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,69,81
Cohort,-0.008845177387515314,0.027119452975844314,-0.32615618741992475,0.7444071305829127,LGP Offspring,Up-regulated genes from the 65 most significantly changed (p<0.01) genes identified by two analytical methods in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,24,49
Cohort,0.06878864046553239,0.07307237372371432,0.9413768427124227,0.3467843630615959,LGP Proband,Up-regulated genes from the 65 most significantly changed (p<0.01) genes identified by two analytical methods in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,24,66
Cohort,0.012595182272129317,0.021152896988167264,0.595435333475833,0.5517217571316168,LonGen OPEL,Up-regulated genes from the 65 most significantly changed (p<0.01) genes identified by two analytical methods in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].,CGP,C2,30,41
Cohort,-0.09518610661223305,0.034018767817413954,-2.798046864105054,0.005287672917953056,LGP Offspring,Myb family target genes.,CGP,C2,48,66
Cohort,-0.019958301249002258,0.09217481207017095,-0.21652662805331654,0.8286302224275202,LGP Proband,Myb family target genes.,CGP,C2,48,85
Cohort,0.005800255157341542,0.028647011019332556,0.20247331051142528,0.8395984596139026,LonGen OPEL,Myb family target genes.,CGP,C2,56,68
Cohort,-0.08322649515422902,0.043553303578995985,-1.9109111896247941,0.05643868636862706,LGP Offspring,Genes co-amplified within MYCN [GeneID=4613] in primary neuroblastoma tumors.,CGP,C2,76,114
Cohort,0.0525385620197241,0.12344949097847426,0.4255875144020253,0.6705182372209235,LGP Proband,Genes co-amplified within MYCN [GeneID=4613] in primary neuroblastoma tumors.,CGP,C2,76,162
Cohort,0.01953737339516414,0.036405670605160166,0.5366574237035178,0.591654223443894,LonGen OPEL,Genes co-amplified within MYCN [GeneID=4613] in primary neuroblastoma tumors.,CGP,C2,94,122
Cohort,-0.25919758624350947,0.1504535324972918,-1.7227750119338348,0.08538655775732196,LGP Offspring,Genes with copy number losses in primary neuroblastoma tumors.,CGP,C2,760,1499
Cohort,-0.4733300654193053,0.4323670977315104,-1.0947411768904578,0.2739460999469275,LGP Proband,Genes with copy number losses in primary neuroblastoma tumors.,CGP,C2,760,2093
Cohort,-0.03146006237132774,0.13946361907167779,-0.22557899028246745,0.8215867859484238,LonGen OPEL,Genes with copy number losses in primary neuroblastoma tumors.,CGP,C2,1214,1460
Cohort,-0.07466186257748193,0.06469692780315485,-1.1540248526892363,0.24889780311078458,LGP Offspring,Genes with copy number gains in primary neuroblastoma tumors.,CGP,C2,141,270
Cohort,0.12967769785701977,0.18224233756515418,0.7115673536104539,0.476931705504246,LGP Proband,Genes with copy number gains in primary neuroblastoma tumors.,CGP,C2,141,407
Cohort,0.10580162234276488,0.05984145884885865,1.768032136549138,0.07743854647895804,LonGen OPEL,Genes with copy number gains in primary neuroblastoma tumors.,CGP,C2,219,318
Cohort,4.929672240999369e-4,0.0055413147866855365,0.08896214040834137,0.9291383472698465,LGP Offspring,Genes down-regulated by UV-irradiation in cervical cancer cells after knockdown of CDKN2A [GeneID=1029].,CGP,C2,1,2
Cohort,0.003964069040788637,0.007753741909845184,0.5112459360757581,0.6093141728026132,LGP Proband,Genes down-regulated by UV-irradiation in cervical cancer cells after knockdown of CDKN2A [GeneID=1029].,CGP,C2,1,0
Cohort,0,0,NA,NA,LonGen OPEL,Genes down-regulated by UV-irradiation in cervical cancer cells after knockdown of CDKN2A [GeneID=1029].,CGP,C2,0,0
Cohort,-0.06971711708445107,0.036212434749388914,-1.9252258945562213,0.05462033707245734,LGP Offspring,Genes up-regulated by UV-irradiation in cervical cancer cells after knockdown of CDKN2A [GeneID=1029].,CGP,C2,51,78
Cohort,0.21852324445740148,0.102288215320803,2.1363481978061167,0.03294154999400161,LGP Proband,Genes up-regulated by UV-irradiation in cervical cancer cells after knockdown of CDKN2A [GeneID=1029].,CGP,C2,51,121
Cohort,-0.029894996247542657,0.02993173019170427,-0.9987727423731825,0.31820830787507925,LonGen OPEL,Genes up-regulated by UV-irradiation in cervical cancer cells after knockdown of CDKN2A [GeneID=1029].,CGP,C2,71,70
Cohort,0.04461329703208398,0.06360816882135213,0.7013768492122994,0.4833092394618479,LGP Offspring,Genes down-regulated in P14 nerves of transgenic mice having hypomorhic (reduced function) allele of EGR2 [GeneID=1959].,CGP,C2,120,279
Cohort,-0.07223395399125147,0.17031048572162016,-0.424130984567333,0.6715796644716073,LGP Proband,Genes down-regulated in P14 nerves of transgenic mice having hypomorhic (reduced function) allele of EGR2 [GeneID=1959].,CGP,C2,120,355
Cohort,-0.09096606232116407,0.05319805865706526,-1.7099507880083669,0.0876646765336646,LonGen OPEL,Genes down-regulated in P14 nerves of transgenic mice having hypomorhic (reduced function) allele of EGR2 [GeneID=1959].,CGP,C2,205,206
Cohort,-0.047768375296160855,0.050882175612944634,-0.9388037111370762,0.34816683929788794,LGP Offspring,Genes up-regulated in P14 nerves of transgenic mice having hypomorhic (reduced function) allele of EGR2 [GeneID=1959].,CGP,C2,101,184
Cohort,-0.14482197736102742,0.14509591575067776,-0.998112018603466,0.31851454058185724,LGP Proband,Genes up-regulated in P14 nerves of transgenic mice having hypomorhic (reduced function) allele of EGR2 [GeneID=1959].,CGP,C2,101,275
Cohort,-0.03190484594541858,0.044853116432180734,-0.7113183761413695,0.47709535485778776,LonGen OPEL,Genes up-regulated in P14 nerves of transgenic mice having hypomorhic (reduced function) allele of EGR2 [GeneID=1959].,CGP,C2,153,168
Cohort,0.010542068068872219,0.02715479539405194,0.3882212300219129,0.697974549210013,LGP Offspring,"Genes down-regulated during neuronal differentiation of SH-SY5Y cells (neuroblastoma) in response to stimulation by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] and BDNF [GeneID=627].",CGP,C2,22,48
Cohort,-0.005384663732894235,0.06958002641637018,-0.07738806680917527,0.9383333952143491,LGP Proband,"Genes down-regulated during neuronal differentiation of SH-SY5Y cells (neuroblastoma) in response to stimulation by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] and BDNF [GeneID=627].",CGP,C2,22,56
Cohort,0.02487735241890081,0.02166691966430914,1.1481720892647265,0.25124246011800894,LonGen OPEL,"Genes down-regulated during neuronal differentiation of SH-SY5Y cells (neuroblastoma) in response to stimulation by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] and BDNF [GeneID=627].",CGP,C2,29,45
Cohort,1.9736918826433658e-4,0.024067771150502387,0.008200559454805051,0.9934593929751432,LGP Offspring,"Genes up-regulated during neuronal differentiation of SH-SY5Y cells (neuroblastoma) in response to stimulation by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] and BDNF [GeneID=627].",CGP,C2,21,42
Cohort,0.06258329187149173,0.07992129455636778,0.7830615384658501,0.43381327326011643,LGP Proband,"Genes up-regulated during neuronal differentiation of SH-SY5Y cells (neuroblastoma) in response to stimulation by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] and BDNF [GeneID=627].",CGP,C2,21,77
Cohort,-0.0018955178375411282,0.023444620275292014,-0.0808508653705426,0.9355808789818226,LonGen OPEL,"Genes up-regulated during neuronal differentiation of SH-SY5Y cells (neuroblastoma) in response to stimulation by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] and BDNF [GeneID=627].",CGP,C2,36,36
Cohort,0.010302478831463397,0.013388443352913063,0.76950535322852,0.4418621580841935,LGP Offspring,Selected genes implicated in metastasis and epithelial-to-mesenchymal transition (EMT) which were down-regulated in MDA-MB-231 cells (breast cancer) upon knockdown of SKI [GeneID=6497] by RNAi.,CGP,C2,5,13
Cohort,-0.0562463584616412,0.03929335053523679,-1.4314472473199147,0.15267669406493636,LGP Proband,Selected genes implicated in metastasis and epithelial-to-mesenchymal transition (EMT) which were down-regulated in MDA-MB-231 cells (breast cancer) upon knockdown of SKI [GeneID=6497] by RNAi.,CGP,C2,5,21
Cohort,0.014622030214513273,0.012036351660211313,1.2148224501324154,0.22479404893552976,LonGen OPEL,Selected genes implicated in metastasis and epithelial-to-mesenchymal transition (EMT) which were down-regulated in MDA-MB-231 cells (breast cancer) upon knockdown of SKI [GeneID=6497] by RNAi.,CGP,C2,7,13
Cohort,-0.038021125080409196,0.02759782398514368,-1.3776856139410316,0.16875628193980088,LGP Offspring,Selected genes implicated in metastasis and epithelial-to-mesenchymal transition (EMT) which were up-regulated in MDA-MB-231 cells (breast cancer) upon knockdown of SKI [GeneID=6497] by RNAi.,CGP,C2,30,46
Cohort,0.03437832123504487,0.07424258917915014,0.4630539103652312,0.6434465277091854,LGP Proband,Selected genes implicated in metastasis and epithelial-to-mesenchymal transition (EMT) which were up-regulated in MDA-MB-231 cells (breast cancer) upon knockdown of SKI [GeneID=6497] by RNAi.,CGP,C2,30,58
Cohort,3.2967082957198723e-4,0.025124924294533765,0.013121266584023544,0.989534332226527,LonGen OPEL,Selected genes implicated in metastasis and epithelial-to-mesenchymal transition (EMT) which were up-regulated in MDA-MB-231 cells (breast cancer) upon knockdown of SKI [GeneID=6497] by RNAi.,CGP,C2,42,55
Cohort,-0.10278848240527225,0.05021321291478678,-2.0470405385074075,0.04104021270065769,LGP Offspring,Downregulated in the cerebellum of aged adult mice (30-month) vs young adult (5-month),CGP,C2,97,158
Cohort,-0.16504491816754352,0.14313582293211333,-1.153065073345205,0.24921403946574058,LGP Proband,Downregulated in the cerebellum of aged adult mice (30-month) vs young adult (5-month),CGP,C2,97,257
Cohort,-0.035851710717399086,0.04184999014814279,-0.856671903398049,0.3918840569843737,LonGen OPEL,Downregulated in the cerebellum of aged adult mice (30-month) vs young adult (5-month),CGP,C2,137,147
Cohort,-0.002942452609433867,0.04238096467364611,-0.06942863693859196,0.9446689670124131,LGP Offspring,Upregulated in the cerebellum of aged adult mice (30-month) vs young adult (5-month),CGP,C2,55,121
Cohort,-0.031825712122643644,0.11225028033500783,-0.2835245669557412,0.7768451175689831,LGP Proband,Upregulated in the cerebellum of aged adult mice (30-month) vs young adult (5-month),CGP,C2,55,162
Cohort,0.05648704335117381,0.03941429815935198,1.4331612127862008,0.1522044064847997,LonGen OPEL,Upregulated in the cerebellum of aged adult mice (30-month) vs young adult (5-month),CGP,C2,93,137
Cohort,0.05286609315465799,0.037544311232572604,1.40809862850254,0.15956157512966274,LGP Offspring,Downregulated in the gastrocnemius muscle of aged adult mice (30-month) vs young adult (5-month),CGP,C2,36,97
Cohort,-0.01610103721554714,0.09837949821098745,-0.1636625263224702,0.8700364709066626,LGP Proband,Downregulated in the gastrocnemius muscle of aged adult mice (30-month) vs young adult (5-month),CGP,C2,36,121
Cohort,0.02827816007024714,0.030358680906461523,0.9314686681340109,0.3518936030458808,LonGen OPEL,Downregulated in the gastrocnemius muscle of aged adult mice (30-month) vs young adult (5-month),CGP,C2,56,79
Cohort,0.0267710248301378,0.026618804143897813,1.0057185396239854,0.3149108345379966,LGP Offspring,Upregulated in the gastrocnemius muscle of aged adult mice (30-month) vs young adult (5-month),CGP,C2,21,54
Cohort,0.10155172597675327,0.07690564450927816,1.3204716848124423,0.18703983338248734,LGP Proband,Upregulated in the gastrocnemius muscle of aged adult mice (30-month) vs young adult (5-month),CGP,C2,21,83
Cohort,0.021444027498717703,0.02122989543467714,1.0100863456769926,0.3127608600876321,LonGen OPEL,Upregulated in the gastrocnemius muscle of aged adult mice (30-month) vs young adult (5-month),CGP,C2,28,43
Cohort,-0.06571536667266822,0.04652933221463925,-1.412342785611537,0.15830923664809787,LGP Offspring,Downregulated in the neocortex of aged adult mice (30-month) vs young adult (5-month),CGP,C2,76,136
Cohort,-0.017590026006630278,0.1186939809209488,-0.14819644492626283,0.882223559507901,LGP Proband,Downregulated in the neocortex of aged adult mice (30-month) vs young adult (5-month),CGP,C2,76,171
Cohort,-0.016307185637998475,0.03825796261810026,-0.42624291839010187,0.6700460844441984,LonGen OPEL,Downregulated in the neocortex of aged adult mice (30-month) vs young adult (5-month),CGP,C2,112,127
Cohort,0.09548509133421107,0.04701415395059223,2.030986060805381,0.04264721966139398,LGP Offspring,Upregulated in the neocortex of aged adult mice (30-month) vs young adult (5-month),CGP,C2,58,163
Cohort,0.1543921453359729,0.12983684969668266,1.1891242408965936,0.23472922837598736,LGP Proband,Upregulated in the neocortex of aged adult mice (30-month) vs young adult (5-month),CGP,C2,58,223
Cohort,0.04833653160155607,0.04049170933257398,1.1937389751701897,0.23293572564108378,LonGen OPEL,Upregulated in the neocortex of aged adult mice (30-month) vs young adult (5-month),CGP,C2,107,142
Cohort,-0.375406774395114,0.15671576180347632,-2.395462779716307,0.016870437572634192,LGP Offspring,Genes down-regulated in uterus upon knockout of BMP2 [GeneID=650].,CGP,C2,845,1594
Cohort,-0.5154097550399668,0.4509700265451829,-1.1428913779224916,0.2534116665073051,LGP Proband,Genes down-regulated in uterus upon knockout of BMP2 [GeneID=650].,CGP,C2,845,2298
Cohort,0.01719583036278666,0.1472628279492299,0.11676966008499488,0.9070720412955677,LonGen OPEL,Genes down-regulated in uterus upon knockout of BMP2 [GeneID=650].,CGP,C2,1332,1620
Cohort,-0.11006452077179357,0.14993113492637727,-0.734100497710766,0.46314202817284655,LGP Offspring,Genes up-regulated in uterus upon knockout of BMP2 [GeneID=650].,CGP,C2,847,1753
Cohort,-0.2597587562240582,0.4322907779501083,-0.6008889605644967,0.5480772118730883,LGP Proband,Genes up-regulated in uterus upon knockout of BMP2 [GeneID=650].,CGP,C2,847,2418
Cohort,-0.03154607868984369,0.1355312378672178,-0.23275872917762253,0.8160085965001754,LonGen OPEL,Genes up-regulated in uterus upon knockout of BMP2 [GeneID=650].,CGP,C2,1377,1617
Cohort,-0.016647974965225944,0.03145550749334438,-0.5292546931168878,0.5968025277990701,LGP Offspring,Down-regulated in the gastrocnemius muscle of aged (30-month) mice subjected to caloric restriction diet since young adulthood.,CGP,C2,33,61
Cohort,0.10486112583292632,0.08612623859920046,1.2175282183274143,0.22374767791580608,LGP Proband,Down-regulated in the gastrocnemius muscle of aged (30-month) mice subjected to caloric restriction diet since young adulthood.,CGP,C2,33,83
Cohort,0.052368534910375714,0.027441448368675608,1.908373574412142,0.056702408610682986,LonGen OPEL,Down-regulated in the gastrocnemius muscle of aged (30-month) mice subjected to caloric restriction diet since young adulthood.,CGP,C2,41,70
Cohort,0.019213377893018184,0.031523014640851395,0.609503187176747,0.542395757831988,LGP Offspring,Up-regulated in the gastrocnemius muscle of aged (30-month) mice subjected to caloric restriction diet since young adulthood.,CGP,C2,31,76
Cohort,-0.035669565747300076,0.0888749422142491,-0.40134558581554003,0.6882685171510459,LGP Proband,Up-regulated in the gastrocnemius muscle of aged (30-month) mice subjected to caloric restriction diet since young adulthood.,CGP,C2,31,96
Cohort,0.016893847223957283,0.02863780805953123,0.589914115942078,0.5554156417235687,LonGen OPEL,Up-regulated in the gastrocnemius muscle of aged (30-month) mice subjected to caloric restriction diet since young adulthood.,CGP,C2,57,74
Cohort,-0.0016497444597302353,0.043227185170693856,-0.03816451275316187,0.9695677825124358,LGP Offspring,Down-regulated in the neocortex of aged (30-month) mice subjected to caloric restriction since young adulthood.,CGP,C2,61,130
Cohort,-0.24593327092958178,0.1151713844674223,-2.13536784390351,0.03302173736467108,LGP Proband,Down-regulated in the neocortex of aged (30-month) mice subjected to caloric restriction since young adulthood.,CGP,C2,61,156
Cohort,0.03561783802133769,0.038717334943915174,0.9199454991654945,0.3578799368947,LonGen OPEL,Down-regulated in the neocortex of aged (30-month) mice subjected to caloric restriction since young adulthood.,CGP,C2,100,130
Cohort,-0.034596385642740445,0.043726769539812894,-0.7911946390469274,0.4291079228801209,LGP Offspring,Up-regulated in the neocortex of aged (30-month) mice subjected to caloric restriction since young adulthood.,CGP,C2,64,125
Cohort,0.11807721337376323,0.1226139927866956,0.9629994969593336,0.3358269031106961,LGP Proband,Up-regulated in the neocortex of aged (30-month) mice subjected to caloric restriction since young adulthood.,CGP,C2,64,173
Cohort,0.023957083041443217,0.03613173227092706,0.6630482829277461,0.507491586479105,LonGen OPEL,Up-regulated in the neocortex of aged (30-month) mice subjected to caloric restriction since young adulthood.,CGP,C2,92,112
Cohort,0.03841278421420579,0.06943859704739742,0.5531906727318523,0.5803157482323416,LGP Offspring,Genes enriched at every T lymphocyte differentiation stage compared to the early passage fetal thymic stromal cultures (TSC).,CGP,C2,160,343
Cohort,-0.03710317732499364,0.18947068526664598,-0.19582542424849297,0.8447945111267656,LGP Proband,Genes enriched at every T lymphocyte differentiation stage compared to the early passage fetal thymic stromal cultures (TSC).,CGP,C2,160,484
Cohort,-0.021617022397115656,0.05779007919326557,-0.3740611312336589,0.7084584507068642,LonGen OPEL,Genes enriched at every T lymphocyte differentiation stage compared to the early passage fetal thymic stromal cultures (TSC).,CGP,C2,253,302
Cohort,-0.056189383830794665,0.027921990887578386,-2.0123702517140907,0.04457706940776848,LGP Offspring,Genes enriched in the double polar (DP) thymocyte compared to all other T lymphocyte differentiation stages.,CGP,C2,33,44
Cohort,0.04588741249130573,0.07926102849135731,0.5789404120123085,0.562785701582956,LGP Proband,Genes enriched in the double polar (DP) thymocyte compared to all other T lymphocyte differentiation stages.,CGP,C2,33,66
Cohort,0.022147593977178543,0.025013223087972568,0.8854354314629712,0.3761892230960826,LonGen OPEL,Genes enriched in the double polar (DP) thymocyte compared to all other T lymphocyte differentiation stages.,CGP,C2,40,56
Cohort,-0.0320130897513051,0.040662970202929,-0.7872786860267075,0.4313946759814583,LGP Offspring,Genes down-regulated at early stages of progenitor T lymphocyte maturation compared to the late stages.,CGP,C2,60,110
Cohort,-0.10286666228017213,0.117395995625327,-0.8762365507634035,0.3811537543801815,LGP Proband,Genes down-regulated at early stages of progenitor T lymphocyte maturation compared to the late stages.,CGP,C2,60,157
Cohort,-0.013735775811670976,0.037994491802404703,-0.3615201877973698,0.7178065540731733,LonGen OPEL,Genes down-regulated at early stages of progenitor T lymphocyte maturation compared to the late stages.,CGP,C2,92,112
Cohort,-0.019537007792249612,0.05231592684881987,-0.37344283030111936,0.7089359674631008,LGP Offspring,Genes up-regulated at early stages of progenitor T lymphocyte maturation compared to the late stages.,CGP,C2,89,178
Cohort,-0.2283544207395036,0.14199704657149384,-1.6081631713694118,0.10817791343501973,LGP Proband,Genes up-regulated at early stages of progenitor T lymphocyte maturation compared to the late stages.,CGP,C2,89,214
Cohort,0.06569298640722854,0.04424187880597363,1.4848597794711766,0.1379768614530357,LonGen OPEL,Genes up-regulated at early stages of progenitor T lymphocyte maturation compared to the late stages.,CGP,C2,118,165
Cohort,-0.014852245186607988,0.017545773782872857,-0.8464856192951643,0.3975814437590921,LGP Offspring,Genes enriched in the intrathymic T progenitor (ITTP) cells compared to all other T lymphocyte differentiation stages.,CGP,C2,11,21
Cohort,0.006853891402934629,0.047255560355575536,0.14503883461252745,0.8847152536980873,LGP Proband,Genes enriched in the intrathymic T progenitor (ITTP) cells compared to all other T lymphocyte differentiation stages.,CGP,C2,11,27
Cohort,0.007259375945330656,0.019340174478179817,0.3753521434628684,0.7074985864713171,LonGen OPEL,Genes enriched in the intrathymic T progenitor (ITTP) cells compared to all other T lymphocyte differentiation stages.,CGP,C2,25,32
Cohort,0.024572621523805047,0.048103723699920435,0.5108257663604885,0.6096398428955363,LGP Offspring,Genes down-regulated in hepatocellular carcinoma of ACOX1 [GeneID=51] knockout mice.,CGP,C2,64,147
Cohort,-0.10435703950016684,0.13264192766052071,-0.786757561057577,0.4316473018746959,LGP Proband,Genes down-regulated in hepatocellular carcinoma of ACOX1 [GeneID=51] knockout mice.,CGP,C2,64,184
Cohort,0.04622878103257083,0.042364833955647656,1.0912064728252775,0.2755122240623393,LonGen OPEL,Genes down-regulated in hepatocellular carcinoma of ACOX1 [GeneID=51] knockout mice.,CGP,C2,100,143
Cohort,0.006084859158609201,0.03871519851868988,0.15716977805684545,0.8751579762646546,LGP Offspring,Genes up-regulated in hepatocellular carcinoma of ACOX1 [GeneID=51] knockout mice.,CGP,C2,51,109
Cohort,0.005765614835047472,0.10776431646714255,0.053502077719811955,0.9573446878967764,LGP Proband,Genes up-regulated in hepatocellular carcinoma of ACOX1 [GeneID=51] knockout mice.,CGP,C2,51,133
Cohort,0.02293824485844252,0.03325121187949037,0.6898468826211721,0.49049154573689846,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma of ACOX1 [GeneID=51] knockout mice.,CGP,C2,75,90
Cohort,0.00249984415644749,0.03908258949249066,0.06396311475031129,0.9490185057395053,LGP Offspring,Genes down-regulated in hepatocellular carcinoma (HCC) induced by ciprofibrate [PubChem=2763].,CGP,C2,45,104
Cohort,0.03270480733654632,0.10995056809693661,0.2974500987363023,0.7661969740485896,LGP Proband,Genes down-regulated in hepatocellular carcinoma (HCC) induced by ciprofibrate [PubChem=2763].,CGP,C2,45,145
Cohort,0.01600546317277255,0.03601529394298929,0.44440740086998964,0.6568688607113018,LonGen OPEL,Genes down-regulated in hepatocellular carcinoma (HCC) induced by ciprofibrate [PubChem=2763].,CGP,C2,84,110
Cohort,-0.05286488016140089,0.04651377659403778,-1.1365424188793392,0.2561323544504964,LGP Offspring,Genes up-regulated in hepatocellular carcinoma (HCC) induced by ciprofibrate [PubChem=2763].,CGP,C2,82,136
Cohort,-0.0011898457776495308,0.1331886158139204,-0.008933539630082801,0.992874297901043,LGP Proband,Genes up-regulated in hepatocellular carcinoma (HCC) induced by ciprofibrate [PubChem=2763].,CGP,C2,82,204
Cohort,-0.013675674744121341,0.04024664563815442,-0.33979663465808435,0.7340993207657267,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma (HCC) induced by ciprofibrate [PubChem=2763].,CGP,C2,131,145
Cohort,0.021998044420733255,0.0525461257313013,0.4186425566981277,0.675610355036134,LGP Offspring,Genes down-regulated in hepatocellular carcinoma (HCC) induced by diethylnitrosamine (DENA) [PubChem=5921].,CGP,C2,78,171
Cohort,-0.03928392539992892,0.15049712212126382,-0.2610277515358447,0.7941355474073652,LGP Proband,Genes down-regulated in hepatocellular carcinoma (HCC) induced by diethylnitrosamine (DENA) [PubChem=5921].,CGP,C2,78,249
Cohort,-0.037755071123439926,0.048856162810841625,-0.7727801151641351,0.43988192152537053,LonGen OPEL,Genes down-regulated in hepatocellular carcinoma (HCC) induced by diethylnitrosamine (DENA) [PubChem=5921].,CGP,C2,147,170
Cohort,-0.0841916568738454,0.04813048414407787,-1.749237689399071,0.08070374683341369,LGP Offspring,Genes up-regulated in hepatocellular carcinoma (HCC) induced by diethylnitrosamine (DENA) [PubChem=5921].,CGP,C2,87,134
Cohort,-0.1704407351801532,0.12850466594519677,-1.3263388837012413,0.18509056166439092,LGP Proband,Genes up-regulated in hepatocellular carcinoma (HCC) induced by diethylnitrosamine (DENA) [PubChem=5921].,CGP,C2,87,183
Cohort,0.07380175454822019,0.04163876626207182,1.7724289447894903,0.07670581158094096,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma (HCC) induced by diethylnitrosamine (DENA) [PubChem=5921].,CGP,C2,109,154
Cohort,-0.03725067971106354,0.04639260993931453,-0.8029442568501879,0.4222891666298122,LGP Offspring,Genes down-regulated in hepatocellular carcinoma (HCC) induced by overexpression of E2F1 [GeneID=1869].,CGP,C2,68,135
Cohort,0.08824518405840594,0.12338507255618765,0.7152014601946313,0.4746847282890524,LGP Proband,Genes down-regulated in hepatocellular carcinoma (HCC) induced by overexpression of E2F1 [GeneID=1869].,CGP,C2,68,171
Cohort,0.0051370777141950185,0.04206076271971423,0.12213467807104762,0.9028231851142935,LonGen OPEL,Genes down-regulated in hepatocellular carcinoma (HCC) induced by overexpression of E2F1 [GeneID=1869].,CGP,C2,108,131
Cohort,-0.06501499473942786,0.042122315786884405,-1.5434810153451137,0.1231820848662883,LGP Offspring,Genes up-regulated in hepatocellular carcinoma (HCC) induced by overexpression of E2F1 [GeneID=1869].,CGP,C2,69,110
Cohort,-0.1369011256209722,0.12065379214259307,-1.1346607776668756,0.2568434837565713,LGP Proband,Genes up-regulated in hepatocellular carcinoma (HCC) induced by overexpression of E2F1 [GeneID=1869].,CGP,C2,69,167
Cohort,-0.03743510425865697,0.037485680375794944,-0.9986507883375478,0.31826736541737544,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma (HCC) induced by overexpression of E2F1 [GeneID=1869].,CGP,C2,99,108
Cohort,-0.01835029632067828,0.02466066109482599,-0.7441121002440735,0.4570672287947243,LGP Offspring,"Fig.5, Supplementary Fig.2 Genes overexpressed in human hepatocellular carcinoma with hepatoblast property",CGP,C2,24,39
Cohort,-0.1455028689651526,0.07329779724877339,-1.9850919731095675,0.04746143964755072,LGP Proband,"Fig.5, Supplementary Fig.2 Genes overexpressed in human hepatocellular carcinoma with hepatoblast property",CGP,C2,24,73
Cohort,-0.058144097662572336,0.025316811586054172,-2.29665957203715,0.0218970532297048,LonGen OPEL,"Fig.5, Supplementary Fig.2 Genes overexpressed in human hepatocellular carcinoma with hepatoblast property",CGP,C2,52,39
Cohort,-0.033569887700479195,0.03925391699110373,-0.8551984177295548,0.39274430476414124,LGP Offspring,Genes down-regulated in hepatocellular carcinoma (HCC) induced by overexpression of MYC [GeneID=4609].,CGP,C2,54,99
Cohort,0.029065940509803292,0.1067658593736961,0.2722400276671614,0.7855048496204672,LGP Proband,Genes down-regulated in hepatocellular carcinoma (HCC) induced by overexpression of MYC [GeneID=4609].,CGP,C2,54,132
Cohort,0.02586511581331998,0.03433134541175444,0.7533965098980427,0.45143445316585395,LonGen OPEL,Genes down-regulated in hepatocellular carcinoma (HCC) induced by overexpression of MYC [GeneID=4609].,CGP,C2,85,107
Cohort,-0.0011348278687040322,0.041423281296254846,-0.027395895090682593,0.9781520576591223,LGP Offspring,Genes down-regulated in hepatocellular carcinoma (HCC) from MYC and E2F1 [GeneID=4609;1869] double transgenic mice.,CGP,C2,54,117
Cohort,0.02667848603717111,0.10835945589764219,0.24620358063048942,0.8055852248300304,LGP Proband,Genes down-regulated in hepatocellular carcinoma (HCC) from MYC and E2F1 [GeneID=4609;1869] double transgenic mice.,CGP,C2,54,141
Cohort,0.04215536648532091,0.03873007502148187,1.0884400936982224,0.27673030138001953,LonGen OPEL,Genes down-regulated in hepatocellular carcinoma (HCC) from MYC and E2F1 [GeneID=4609;1869] double transgenic mice.,CGP,C2,93,127
Cohort,-0.07389485079097197,0.04603233662888782,-1.6052813348736004,0.10889892873892214,LGP Offspring,Genes up-regulated in hepatocellular carcinoma (HCC) from MYC and E2F1 [GeneID=4609;1869] double transgenic mice.,CGP,C2,78,128
Cohort,-0.05466619223850306,0.12180090823646142,-0.4488159655786425,0.653681011390769,LGP Proband,Genes up-regulated in hepatocellular carcinoma (HCC) from MYC and E2F1 [GeneID=4609;1869] double transgenic mice.,CGP,C2,78,185
Cohort,-0.00293658637217116,0.04154585631300841,-0.07068301469217006,0.9436677932027211,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma (HCC) from MYC and E2F1 [GeneID=4609;1869] double transgenic mice.,CGP,C2,124,152
Cohort,-0.060512080208617335,0.04511087608655971,-1.3414077814074252,0.1802385580678235,LGP Offspring,Genes down-regulated in hepatocellular carcinoma (HCC) tissue of MYC and TGFA [GeneID=4609;7039] double transgenic mice.,CGP,C2,77,134
Cohort,-0.07275830018369711,0.12588916041065942,-0.5779552421062651,0.5634503478880066,LGP Proband,Genes down-regulated in hepatocellular carcinoma (HCC) tissue of MYC and TGFA [GeneID=4609;7039] double transgenic mice.,CGP,C2,77,186
Cohort,0.029875731263440435,0.04242835195242033,0.704145456720625,0.4815481332360779,LonGen OPEL,Genes down-regulated in hepatocellular carcinoma (HCC) tissue of MYC and TGFA [GeneID=4609;7039] double transgenic mice.,CGP,C2,114,144
Cohort,-0.07320562617830037,0.043999370214756924,-1.6637880456240708,0.09661825160971901,LGP Offspring,Genes up-regulated in hepatocellular carcinoma (HCC) tissue of MYC and TGFA [GeneID=4609;7039] double transgenic mice.,CGP,C2,74,121
Cohort,-0.05329426426269455,0.12442473191992665,-0.4283253292198531,0.6685248735211566,LGP Proband,Genes up-regulated in hepatocellular carcinoma (HCC) tissue of MYC and TGFA [GeneID=4609;7039] double transgenic mice.,CGP,C2,74,198
Cohort,0.062022027748332764,0.03976796682823962,1.5595976534633982,0.11925246156988994,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma (HCC) tissue of MYC and TGFA [GeneID=4609;7039] double transgenic mice.,CGP,C2,104,144
Cohort,-0.005925499003597552,0.038525409613009765,-0.1538075535891655,0.8778073813940295,LGP Offspring,Genes up-regulated in hepatocellular carcinoma (HCC) induced by overexpression of MYC [GeneID=4609].,CGP,C2,49,100
Cohort,0.07799798197836681,0.10760056308439311,0.7248845149368925,0.46872620134138976,LGP Proband,Genes up-regulated in hepatocellular carcinoma (HCC) induced by overexpression of MYC [GeneID=4609].,CGP,C2,49,142
Cohort,-0.01567462838493639,0.0380054920589282,-0.4124306129396404,0.6801348806775243,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma (HCC) induced by overexpression of MYC [GeneID=4609].,CGP,C2,103,114
Cohort,-3.5549665252491085e-4,0.054897612022439236,-0.0064756305316086,0.9948351409747224,LGP Offspring,Genes highly expressed in hepatocellular carcinoma with poor survival.,CGP,C2,101,206
Cohort,-0.29622816052383677,0.15854320966864693,-1.8684380185247254,0.062051448680571594,LGP Proband,Genes highly expressed in hepatocellular carcinoma with poor survival.,CGP,C2,101,291
Cohort,0.03127499081368281,0.04935145191915051,0.6337197711005288,0.5264457675517409,LonGen OPEL,Genes highly expressed in hepatocellular carcinoma with poor survival.,CGP,C2,161,204
Cohort,-0.024788712505086862,0.08066636612464607,-0.30729923381925023,0.7587102624940435,LGP Offspring,Genes highly expressed in hepatocellular carcinoma with good survival.,CGP,C2,217,448
Cohort,-0.014219144645479074,0.22454586172511307,-0.06332401112288596,0.9495236694688155,LGP Proband,Genes highly expressed in hepatocellular carcinoma with good survival.,CGP,C2,217,649
Cohort,-0.011303776699191788,0.07048889380555563,-0.1603625208018355,0.8726361974003889,LonGen OPEL,Genes highly expressed in hepatocellular carcinoma with good survival.,CGP,C2,348,408
Cohort,5.372713084040852e-4,0.039098441463653634,0.013741501919035287,0.9890402672383212,LGP Offspring,Down-regulated genes displaying alternative splicing in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].,CGP,C2,46,105
Cohort,0.05837472520669769,0.10916347178973415,0.5347459571379014,0.5929680688389555,LGP Proband,Down-regulated genes displaying alternative splicing in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].,CGP,C2,46,137
Cohort,0.0347645460512148,0.03601690443654906,0.9652285946022778,0.33472347597965857,LonGen OPEL,Down-regulated genes displaying alternative splicing in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].,CGP,C2,75,96
Cohort,-0.021954319186499476,0.05812121515924553,-0.3777333134957198,0.7057472864509216,LGP Offspring,Up-regulated genes displaying alternative splicing in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].,CGP,C2,114,224
Cohort,0.09397833843160709,0.1564060585984154,0.6008612407586059,0.5480956672040539,LGP Proband,Up-regulated genes displaying alternative splicing in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].,CGP,C2,114,316
Cohort,-0.0194832914430579,0.05070519109394493,-0.38424648488080615,0.7008983913730346,LonGen OPEL,Up-regulated genes displaying alternative splicing in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].,CGP,C2,174,202
Cohort,-0.020550680435734263,0.0200506190718662,-1.0249399463465803,0.30575814372178517,LGP Offspring,Components of RNA post-transcriptional modification machinery up-regulated in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].,CGP,C2,16,26
Cohort,0.06276134761253777,0.05985685004804466,1.0485240630297414,0.29470097555111047,LGP Proband,Components of RNA post-transcriptional modification machinery up-regulated in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].,CGP,C2,16,45
Cohort,-0.01458168655890506,0.017610001879673536,-0.8280343556201474,0.407899229656828,LonGen OPEL,Components of RNA post-transcriptional modification machinery up-regulated in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].,CGP,C2,24,25
Cohort,0.02145602727541806,0.015463877158310714,1.3874933857636729,0.1657485759301125,LGP Offspring,Genes enriched in the naive circulating T lymphocytes compared to the earlier differentiation stages.,CGP,C2,5,19
Cohort,0.02810812271848753,0.04898052306585775,0.5738632615395753,0.5662150584478964,LGP Proband,Genes enriched in the naive circulating T lymphocytes compared to the earlier differentiation stages.,CGP,C2,5,33
Cohort,0.004334443023206128,0.016736415752132514,0.2589827527828857,0.7957155047936204,LonGen OPEL,Genes enriched in the naive circulating T lymphocytes compared to the earlier differentiation stages.,CGP,C2,19,25
Cohort,-0.09239118445242113,0.0585412324051655,-1.5782241107084862,0.11498193407553292,LGP Offspring,"Genes down-regulated in the neural crest stem cells (NCS), defined as p75+/HNK1+ [GeneID=4804;27087].",CGP,C2,118,222
Cohort,0.0963331997731599,0.16356650033494802,0.5889543370793581,0.5560513875509889,LGP Proband,"Genes down-regulated in the neural crest stem cells (NCS), defined as p75+/HNK1+ [GeneID=4804;27087].",CGP,C2,118,352
Cohort,-0.01076100686032493,0.05071191688088964,-0.21219877934411358,0.8320062827310784,LonGen OPEL,"Genes down-regulated in the neural crest stem cells (NCS), defined as p75+/HNK1+ [GeneID=4804;27087].",CGP,C2,186,215
Cohort,-0.014949282115624057,0.06578626561032787,-0.22724016900690513,0.8203056992087681,LGP Offspring,"Genes up-regulated in the neural crest stem cells (NCS), defined as p75+/HNK1+ [GeneID=4804;27087].",CGP,C2,137,264
Cohort,-0.23041095933699549,0.1734275122311098,-1.3285721300663613,0.1843525750240425,LGP Proband,"Genes up-regulated in the neural crest stem cells (NCS), defined as p75+/HNK1+ [GeneID=4804;27087].",CGP,C2,137,356
Cohort,-0.056346194345824316,0.05331985696090035,-1.0567581677337055,0.2909425767389262,LonGen OPEL,"Genes up-regulated in the neural crest stem cells (NCS), defined as p75+/HNK1+ [GeneID=4804;27087].",CGP,C2,211,226
Cohort,-0.10399010502357109,0.08391387601911973,-1.2392480237699544,0.2156837339933884,LGP Offspring,Candidate genes specific for recent thymic emigrants (RTEs).,CGP,C2,246,459
Cohort,-0.18732357733441393,0.23540767131977244,-0.7957411765054921,0.4264089102988482,LGP Proband,Candidate genes specific for recent thymic emigrants (RTEs).,CGP,C2,246,626
Cohort,0.00366126989892819,0.06975115479973308,0.052490455669734676,0.9581510698145737,LonGen OPEL,Candidate genes specific for recent thymic emigrants (RTEs).,CGP,C2,362,418
Cohort,-0.005295024925797816,0.0129842171321332,-0.4078047118215349,0.6835461738840252,LGP Offspring,Genes enriched in the single positive 4 (SP4) thymocytes compared to all other T lymphocyte differentiation stages.,CGP,C2,5,10
Cohort,0.02098994042832345,0.02870440460429992,0.7312445848529866,0.4648351671800969,LGP Proband,Genes enriched in the single positive 4 (SP4) thymocytes compared to all other T lymphocyte differentiation stages.,CGP,C2,5,9
Cohort,0.01463643208033145,0.009621102798457404,1.5212842422469675,0.1285856436790294,LonGen OPEL,Genes enriched in the single positive 4 (SP4) thymocytes compared to all other T lymphocyte differentiation stages.,CGP,C2,4,10
Cohort,0.021569811548028187,0.041339756197035706,0.5217692006992258,0.6020019448416356,LGP Offspring,Genes down-regulated in medulloblastoma tumors from animals with  inactivating mutations of one copy of PTCH1 or SUFU [GeneID=5727;51684] in conjunction with TP53 [GeneID=7157] loss.,CGP,C2,49,112
Cohort,-0.12895397835987507,0.11649249471829665,-1.1069724163064145,0.2686250296519045,LGP Proband,Genes down-regulated in medulloblastoma tumors from animals with  inactivating mutations of one copy of PTCH1 or SUFU [GeneID=5727;51684] in conjunction with TP53 [GeneID=7157] loss.,CGP,C2,49,179
Cohort,0.014409568549546744,0.03777285265317514,0.3814794895649877,0.7029492918623317,LonGen OPEL,Genes down-regulated in medulloblastoma tumors from animals with  inactivating mutations of one copy of PTCH1 or SUFU [GeneID=5727;51684] in conjunction with TP53 [GeneID=7157] loss.,CGP,C2,94,125
Cohort,-0.03423227954514115,0.04392481268772917,-0.7793380882123665,0.436053326824723,LGP Offspring,Genes up-regulated in medulloblastoma tumors from animals with  inactivating mutations of one copy of PTCH1 or SUFU [GeneID=5727;51684] in conjunction with TP53 [GeneID=7157] loss.,CGP,C2,69,124
Cohort,-0.05231977101477579,0.120294565335188,-0.4349304631426393,0.6637254201802929,LGP Proband,Genes up-regulated in medulloblastoma tumors from animals with  inactivating mutations of one copy of PTCH1 or SUFU [GeneID=5727;51684] in conjunction with TP53 [GeneID=7157] loss.,CGP,C2,69,160
Cohort,0.005642146675264376,0.03598950700080101,0.1567719912122942,0.8754643009980407,LonGen OPEL,Genes up-regulated in medulloblastoma tumors from animals with  inactivating mutations of one copy of PTCH1 or SUFU [GeneID=5727;51684] in conjunction with TP53 [GeneID=7157] loss.,CGP,C2,89,106
Cohort,0.034069827740924555,0.020177319614456842,1.688520992476814,0.09177245616945931,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblasts) by overexpression of HOXC8 [GeneID=3224].,CGP,C2,8,32
Cohort,0.03280413292614275,0.05634377247462501,0.5822139960705759,0.5605798997574293,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblasts) by overexpression of HOXC8 [GeneID=3224].,CGP,C2,8,42
Cohort,0.005093008379427702,0.017716011145015503,0.2874805359817494,0.7738192275719908,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblasts) by overexpression of HOXC8 [GeneID=3224].,CGP,C2,24,26
Cohort,-0.0012521667993320774,0.019477277049794513,-0.06428859620011863,0.9487594391339699,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblasts) by overexpression of HOXC8 [GeneID=3224].,CGP,C2,12,22
Cohort,-0.07914768264083932,0.0489189844899069,-1.6179338853031444,0.10605495691214811,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblasts) by overexpression of HOXC8 [GeneID=3224].,CGP,C2,12,26
Cohort,-0.0035378784839114265,0.013951697582766848,-0.2535805025104198,0.7998851418179712,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblasts) by overexpression of HOXC8 [GeneID=3224].,CGP,C2,15,15
Cohort,-0.055197702521462014,0.0898280533739982,-0.6144817843446627,0.5391037625523873,LGP Offspring,"Myb-regulated genes in MCF7 (breast cancer) and lung epithelial cell lines overexpressing MYBL2, MYBL1 or MYB [GeneID=4605;4603;4602].",CGP,C2,272,547
Cohort,-0.061991919260737424,0.23893637979617408,-0.2594494790354652,0.7953524860442251,LGP Proband,"Myb-regulated genes in MCF7 (breast cancer) and lung epithelial cell lines overexpressing MYBL2, MYBL1 or MYB [GeneID=4605;4603;4602].",CGP,C2,272,739
Cohort,0.05979052242695166,0.07224054777989636,0.8276587631799577,0.4081118379260349,LonGen OPEL,"Myb-regulated genes in MCF7 (breast cancer) and lung epithelial cell lines overexpressing MYBL2, MYBL1 or MYB [GeneID=4605;4603;4602].",CGP,C2,392,502
Cohort,-0.02327333771034061,0.04315041661252338,-0.5393537197874024,0.5898204023954395,LGP Offspring,Genes enriched in astrocytes in the adult mouse brain identified through correlation-based searches seeded with the astrocyte cell-type specific gene expression patterns.,CGP,C2,64,121
Cohort,-0.1641630494631567,0.11831732797987833,-1.387481041585685,0.16566574402654802,LGP Proband,Genes enriched in astrocytes in the adult mouse brain identified through correlation-based searches seeded with the astrocyte cell-type specific gene expression patterns.,CGP,C2,64,165
Cohort,0.0027102106515644246,0.0363768637635455,0.07450369193950193,0.9406283222572298,LonGen OPEL,Genes enriched in astrocytes in the adult mouse brain identified through correlation-based searches seeded with the astrocyte cell-type specific gene expression patterns.,CGP,C2,98,108
Cohort,-0.08588853645494945,0.05039198353931756,-1.704408725803307,0.08876426282272323,LGP Offspring,Top 100 ranked genes most specific to the cerebellum region of adult mouse brain.,CGP,C2,97,169
Cohort,-0.36912463330572515,0.14564272907909884,-2.534452874096124,0.011444169022945677,LGP Proband,Top 100 ranked genes most specific to the cerebellum region of adult mouse brain.,CGP,C2,97,267
Cohort,-0.06002179923110616,0.04773258009514776,-1.257459770904101,0.20895599119221658,LonGen OPEL,Top 100 ranked genes most specific to the cerebellum region of adult mouse brain.,CGP,C2,171,174
Cohort,0.08386734206554206,0.06911347852052119,1.2134730281393686,0.2253728359744915,LGP Offspring,Genes enriched in choroid plexus cells in the brain identified through correlation-based searches seeded with the choroid plexus cell-type specific gene expression patterns.,CGP,C2,143,338
Cohort,0.05083266989968714,0.19014690008683077,0.26733367662830343,0.7892783533220199,LGP Proband,Genes enriched in choroid plexus cells in the brain identified through correlation-based searches seeded with the choroid plexus cell-type specific gene expression patterns.,CGP,C2,143,441
Cohort,0.0028851490505367775,0.06115925203243573,0.047174367812847715,0.962386089075282,LonGen OPEL,Genes enriched in choroid plexus cells in the brain identified through correlation-based searches seeded with the choroid plexus cell-type specific gene expression patterns.,CGP,C2,261,307
Cohort,1.0627749424634255e-5,0.016084681160039294,6.607373387691256e-4,0.9994730028484347,LGP Offspring,Transcripts showing subcellular localization to both distal and proximal dendrites in the adult mouse brain.,CGP,C2,8,18
Cohort,-5.628497514077182e-4,0.04513409420567482,-0.012470611437172693,0.9900531319954041,LGP Proband,Transcripts showing subcellular localization to both distal and proximal dendrites in the adult mouse brain.,CGP,C2,8,26
Cohort,-0.017979912270981255,0.013367161114587599,-1.3450808377973207,0.17898221409259643,LonGen OPEL,Transcripts showing subcellular localization to both distal and proximal dendrites in the adult mouse brain.,CGP,C2,14,11
Cohort,-0.012533430681586117,0.035853207453850955,-0.34957627424878873,0.7267655927100283,LGP Offspring,Transcripts showing subcellular localization only to proximal dendrites in the adult mouse brain.,CGP,C2,43,89
Cohort,0.0944565648980103,0.09698799183080249,0.973899584010273,0.3303887819576713,LGP Proband,Transcripts showing subcellular localization only to proximal dendrites in the adult mouse brain.,CGP,C2,43,122
Cohort,0.028499696099226278,0.032570867989682006,0.8750057292994028,0.3818347250711287,LonGen OPEL,Transcripts showing subcellular localization only to proximal dendrites in the adult mouse brain.,CGP,C2,71,95
Cohort,-0.017919332437916706,0.05583109979413994,-0.3209561069724356,0.7483428521936486,LGP Offspring,Top 100 ranked genes most specific to  medulla (myelencephalon) hindbrain region of adult mouse brain.,CGP,C2,99,199
Cohort,-0.33865329858272764,0.14888131618699862,-2.2746527721273684,0.023179911233495925,LGP Proband,Top 100 ranked genes most specific to  medulla (myelencephalon) hindbrain region of adult mouse brain.,CGP,C2,99,277
Cohort,7.127581781172593e-4,0.04732115747887499,0.015062145900286723,0.9879863750154858,LonGen OPEL,Top 100 ranked genes most specific to  medulla (myelencephalon) hindbrain region of adult mouse brain.,CGP,C2,159,192
Cohort,-0.02576746911227792,0.058474040084151795,-0.44066510668999714,0.6595963421772695,LGP Offspring,Top 100 ranked genes most specific to midbrain region of adult mouse brain.,CGP,C2,123,238
Cohort,-0.2524781595669333,0.17083849116345537,-1.4778763137480915,0.13981842166131478,LGP Proband,Top 100 ranked genes most specific to midbrain region of adult mouse brain.,CGP,C2,123,352
Cohort,-0.021574259784297157,0.05301335395831209,-0.4069589673813588,0.6841475290193527,LonGen OPEL,Top 100 ranked genes most specific to midbrain region of adult mouse brain.,CGP,C2,190,226
Cohort,-0.021692967487742507,0.03793667992089932,-0.5718204000185015,0.5676337403041575,LGP Offspring,Genes enriched in neurons in the adult mouse brain identified through correlation-based searches seeded with neuron cell-type specific gene expression patterns.,CGP,C2,50,93
Cohort,0.08820533087492152,0.10945669608361698,0.805846823729624,0.4205608785544208,LGP Proband,Genes enriched in neurons in the adult mouse brain identified through correlation-based searches seeded with neuron cell-type specific gene expression patterns.,CGP,C2,50,151
Cohort,0.0514840854064712,0.03176317637738554,1.620873328119866,0.10544084179389258,LonGen OPEL,Genes enriched in neurons in the adult mouse brain identified through correlation-based searches seeded with neuron cell-type specific gene expression patterns.,CGP,C2,56,95
Cohort,-0.047496528023198224,0.04560913262687735,-1.0413819620680231,0.29807060345484804,LGP Offspring,Genes enriched in oligodendrocytes in the adult mouse brain identified through correlation-based searches seeded with the oligodendrocyte cell-type specific gene expression patterns.,CGP,C2,82,151
Cohort,-0.04659615182282296,0.12913196864938303,-0.3608413339483738,0.7183094395646964,LGP Proband,Genes enriched in oligodendrocytes in the adult mouse brain identified through correlation-based searches seeded with the oligodendrocyte cell-type specific gene expression patterns.,CGP,C2,82,222
Cohort,-0.03240737752592779,0.0386147565218136,-0.8392485268583982,0.4015818312035888,LonGen OPEL,Genes enriched in oligodendrocytes in the adult mouse brain identified through correlation-based searches seeded with the oligodendrocyte cell-type specific gene expression patterns.,CGP,C2,116,124
Cohort,0.004311555546361812,0.05557477136485244,0.07758116570657815,0.9381841814316725,LGP Offspring,Top 100 ranked genes most specific to  pons region (P) of the adult mouse brain.,CGP,C2,98,199
Cohort,-0.5587236077311009,0.1520673206991402,-3.6741859142538305,2.538428672627278e-4,LGP Proband,Top 100 ranked genes most specific to  pons region (P) of the adult mouse brain.,CGP,C2,98,281
Cohort,-0.012827625040268869,0.05007858305620597,-0.2561499199342704,0.7979012590931323,LonGen OPEL,Top 100 ranked genes most specific to  pons region (P) of the adult mouse brain.,CGP,C2,161,198
Cohort,0.008987042448645245,0.06075783975578555,0.14791576666926295,0.8824533528062135,LGP Offspring,Genes down-regulated during in vitro maturation of CD14+ [GeneID=929] monocytes (day 0) into immature (day 7) and mature dendritic cells (day 14).,CGP,C2,115,255
Cohort,0.18363522013966466,0.17081564426613738,1.0750491907729123,0.2826636174081834,LGP Proband,Genes down-regulated during in vitro maturation of CD14+ [GeneID=929] monocytes (day 0) into immature (day 7) and mature dendritic cells (day 14).,CGP,C2,115,334
Cohort,0.021582177891969485,0.05581981970059336,0.38664005021392195,0.6991260370967747,LonGen OPEL,Genes down-regulated during in vitro maturation of CD14+ [GeneID=929] monocytes (day 0) into immature (day 7) and mature dendritic cells (day 14).,CGP,C2,195,235
Cohort,-0.04518321874957309,0.058750841401847734,-0.7690650494777775,0.4421233082810241,LGP Offspring,Genes up-regulated during in vitro maturation of CD14+ [GeneID=929] monocytes (day 0) into immature (day 7) and mature dendritic cells (day 14).,CGP,C2,112,213
Cohort,-0.1724282687427226,0.1548198403003159,-1.1137349606371527,0.2657137798524283,LGP Proband,Genes up-regulated during in vitro maturation of CD14+ [GeneID=929] monocytes (day 0) into immature (day 7) and mature dendritic cells (day 14).,CGP,C2,112,273
Cohort,0.03867686955674549,0.0466288982218486,0.8294613647684886,0.4070920583631308,LonGen OPEL,Genes up-regulated during in vitro maturation of CD14+ [GeneID=929] monocytes (day 0) into immature (day 7) and mature dendritic cells (day 14).,CGP,C2,157,197
Cohort,-0.008200177889494792,0.027014747583226202,-0.30354449414091084,0.7615683429124763,LGP Offspring,Genes up-regulated in HK-2 cells kidney tubular epithelium) under hypoxia and down-regulated on re-oxygenation.,CGP,C2,22,42
Cohort,-0.10820078587917506,0.0744423111326173,-1.4534850440956595,0.1464653007608291,LGP Proband,Genes up-regulated in HK-2 cells kidney tubular epithelium) under hypoxia and down-regulated on re-oxygenation.,CGP,C2,22,60
Cohort,-0.038131608476448996,0.023016965821809978,-1.6566739843840308,0.09797948597256542,LonGen OPEL,Genes up-regulated in HK-2 cells kidney tubular epithelium) under hypoxia and down-regulated on re-oxygenation.,CGP,C2,46,37
Cohort,-0.01632682230945726,0.02563095584290698,-0.6369962325839473,0.5243429518926072,LGP Offspring,"Adipocyte genes induced in 3T3-L1 cells (adipocyte) by constitutively active PPARG [GeneID=5468] or its agonist, TZD [PubChem=5437].",CGP,C2,21,38
Cohort,-0.10072370499492028,0.07185967538262912,-1.401672140301215,0.16138521223362967,LGP Proband,"Adipocyte genes induced in 3T3-L1 cells (adipocyte) by constitutively active PPARG [GeneID=5468] or its agonist, TZD [PubChem=5437].",CGP,C2,21,57
Cohort,0.0036200872311771414,0.02335501085064858,0.15500259256255539,0.876858567804131,LonGen OPEL,"Adipocyte genes induced in 3T3-L1 cells (adipocyte) by constitutively active PPARG [GeneID=5468] or its agonist, TZD [PubChem=5437].",CGP,C2,38,43
Cohort,0.018269985839490202,0.061946676624230215,0.29493084754677484,0.7681372594873681,LGP Offspring,Genes with increased copy number that correlates with increased expression across six different lung adenocarcinoma cell lines.,CGP,C2,131,280
Cohort,-0.2628021374266316,0.17012844548977188,-1.544727788877794,0.12279146427997392,LGP Proband,Genes with increased copy number that correlates with increased expression across six different lung adenocarcinoma cell lines.,CGP,C2,131,396
Cohort,0.11258715354371512,0.058596595271251425,1.9213941189336041,0.05503884244723713,LonGen OPEL,Genes with increased copy number that correlates with increased expression across six different lung adenocarcinoma cell lines.,CGP,C2,210,303
Cohort,-0.012184114769467881,0.038030397919469654,-0.32037831408622275,0.7487805673708776,LGP Offspring,"Genes consistently down-regulated in ACRP cells (ovarian cancer, resistant to cisplatin [PubChem=2767]) compared to the parental sensitive A2780 cells, regardless of cisplatin exposure.",CGP,C2,51,93
Cohort,-0.1189917391170293,0.10027452532526211,-1.1866597097423683,0.2356997882806196,LGP Proband,"Genes consistently down-regulated in ACRP cells (ovarian cancer, resistant to cisplatin [PubChem=2767]) compared to the parental sensitive A2780 cells, regardless of cisplatin exposure.",CGP,C2,51,114
Cohort,0.002975086981067417,0.03325769526656957,0.08945559688430835,0.928742343046997,LonGen OPEL,"Genes consistently down-regulated in ACRP cells (ovarian cancer, resistant to cisplatin [PubChem=2767]) compared to the parental sensitive A2780 cells, regardless of cisplatin exposure.",CGP,C2,67,87
Cohort,-0.02906955738423011,0.029180119403918084,-0.996211049785042,0.3195040661740404,LGP Offspring,"Genes consistently up-regulated in ACRP cells (ovarian cancer, resistant to cisplatin [PubChem=2767]) compared to the parental sensitive A2780 cells, regardless of cisplatin exposure.",CGP,C2,33,56
Cohort,-0.12082606690041062,0.07644153911271369,-1.5806336228035855,0.11434098830205403,LGP Proband,"Genes consistently up-regulated in ACRP cells (ovarian cancer, resistant to cisplatin [PubChem=2767]) compared to the parental sensitive A2780 cells, regardless of cisplatin exposure.",CGP,C2,33,60
Cohort,0.0270086153157317,0.026627014889177177,1.0143313258411715,0.3107328914290955,LonGen OPEL,"Genes consistently up-regulated in ACRP cells (ovarian cancer, resistant to cisplatin [PubChem=2767]) compared to the parental sensitive A2780 cells, regardless of cisplatin exposure.",CGP,C2,42,65
Cohort,-0.0013007971114741479,0.014470801749364062,-0.08989115696587531,0.9284003346704524,LGP Offspring,The 'cytidine analog pathway': genes involved in transport and metabolism of the anti-cancer analogs of cytidine: gemcitabine and cytarabine [PubChem=596;3461;6253].,CGP,C2,6,15
Cohort,-0.038640473379967406,0.043818887798991644,-0.8818223218540155,0.37812697077604274,LGP Proband,The 'cytidine analog pathway': genes involved in transport and metabolism of the anti-cancer analogs of cytidine: gemcitabine and cytarabine [PubChem=596;3461;6253].,CGP,C2,6,24
Cohort,-0.01670332814414097,0.01561690418616794,-1.0695671782974303,0.28513839694487225,LonGen OPEL,The 'cytidine analog pathway': genes involved in transport and metabolism of the anti-cancer analogs of cytidine: gemcitabine and cytarabine [PubChem=596;3461;6253].,CGP,C2,20,18
Cohort,-0.005678187025588633,0.021708591580807672,-0.2615640450211729,0.7937372399703616,LGP Offspring,"Genes whose expression in a panel of lymphoblastoid cell lines was associated with cytotoxicity of the anti-cancer analogs of cytidine, gemcitabine and cytarabine [PubChem=596;3461;6253].",CGP,C2,15,27
Cohort,-0.02461071505911463,0.05785333100569396,-0.42539841062379674,0.670656006997569,LGP Proband,"Genes whose expression in a panel of lymphoblastoid cell lines was associated with cytotoxicity of the anti-cancer analogs of cytidine, gemcitabine and cytarabine [PubChem=596;3461;6253].",CGP,C2,15,38
Cohort,0.02412252882149015,0.019107894251895085,1.262437843934463,0.20716100590298298,LonGen OPEL,"Genes whose expression in a panel of lymphoblastoid cell lines was associated with cytotoxicity of the anti-cancer analogs of cytidine, gemcitabine and cytarabine [PubChem=596;3461;6253].",CGP,C2,21,35
Cohort,0.018991783579308478,0.04510883373542396,0.42102138332151634,0.6738732887022902,LGP Offspring,Genes encoding mRNA transcripts specifically bound by DCP2 [GeneID=167227].,CGP,C2,66,153
Cohort,0.20814657946141638,0.12674220595015878,1.6422830729588986,0.10090832240482396,LGP Proband,Genes encoding mRNA transcripts specifically bound by DCP2 [GeneID=167227].,CGP,C2,66,217
Cohort,-0.0040724279887416155,0.03972745383266261,-0.1025091616969774,0.9183783589559382,LonGen OPEL,Genes encoding mRNA transcripts specifically bound by DCP2 [GeneID=167227].,CGP,C2,113,133
Cohort,-0.09369461336143381,0.0575673989838184,-1.627563777682059,0.10408338171454275,LGP Offspring,"Genes down-regulated in ITNK cells (T-lymphocyte progenitors (DN3 cells) reprogrammed to natural killer (NK) cells by ablation of BCL11B [GeneID=64919] gene), compared to the parental DN3 cells.",CGP,C2,116,203
Cohort,-0.16197266103414149,0.16660952798567844,-0.9721692570191092,0.33124821917629343,LGP Proband,"Genes down-regulated in ITNK cells (T-lymphocyte progenitors (DN3 cells) reprogrammed to natural killer (NK) cells by ablation of BCL11B [GeneID=64919] gene), compared to the parental DN3 cells.",CGP,C2,116,310
Cohort,0.018767724814778643,0.05190985337887795,0.36154455451448464,0.7177883493119053,LonGen OPEL,"Genes down-regulated in ITNK cells (T-lymphocyte progenitors (DN3 cells) reprogrammed to natural killer (NK) cells by ablation of BCL11B [GeneID=64919] gene), compared to the parental DN3 cells.",CGP,C2,171,208
Cohort,-0.0553908219000621,0.09200441204939769,-0.6020452787668754,0.5473458667730582,LGP Offspring,"Genes up-regulated in ITNK cells (T-lymphocyte progenitors (DN3 cells) reprogrammed to natural killer (NK) cells by ablation of BCL11B [GeneID=64919] gene), compared to the parental DN3 cells.",CGP,C2,260,524
Cohort,0.014005491239861998,0.25020710935030255,0.0559755926849129,0.9553746577000948,LGP Proband,"Genes up-regulated in ITNK cells (T-lymphocyte progenitors (DN3 cells) reprogrammed to natural killer (NK) cells by ablation of BCL11B [GeneID=64919] gene), compared to the parental DN3 cells.",CGP,C2,260,715
Cohort,0.11019206492108877,0.08318824469478145,1.324611011151691,0.18568036185709777,LonGen OPEL,"Genes up-regulated in ITNK cells (T-lymphocyte progenitors (DN3 cells) reprogrammed to natural killer (NK) cells by ablation of BCL11B [GeneID=64919] gene), compared to the parental DN3 cells.",CGP,C2,431,546
Cohort,-0.004524509987629131,0.028989475433442543,-0.15607422762847276,0.8760211084246584,LGP Offspring,Proteins showing significant overexpression in lung cancer cell lines  relative to normal bronchial epithelial cell lines.,CGP,C2,27,62
Cohort,0.14229589178511418,0.0873860689492843,1.6283589992782206,0.10382645161457311,LGP Proband,Proteins showing significant overexpression in lung cancer cell lines  relative to normal bronchial epithelial cell lines.,CGP,C2,27,102
Cohort,-1.2047784495727853e-4,0.02627532946373798,-0.004585207775360056,0.9963426951744854,LonGen OPEL,Proteins showing significant overexpression in lung cancer cell lines  relative to normal bronchial epithelial cell lines.,CGP,C2,51,56
Cohort,0.012320035136474354,0.03633636233519652,0.339055269837531,0.7346733900507576,LGP Offspring,Genes affected by epigenetic aberrations in prostate cancer.,CGP,C2,41,94
Cohort,0.05109722689869351,0.0952255151059774,0.53659176158645,0.5916927373983538,LGP Proband,Genes affected by epigenetic aberrations in prostate cancer.,CGP,C2,41,119
Cohort,-0.004518926445078012,0.0317319687069073,-0.142409268293976,0.8867927792148018,LonGen OPEL,Genes affected by epigenetic aberrations in prostate cancer.,CGP,C2,73,85
Cohort,-0.043885619046183794,0.023333612870202258,-1.880789712690703,0.060430156727454956,LGP Offspring,"'Wilm's tumor signature': genes highly expressed in Wilm's tumor samples compared to normal fetal kidney and a heterologous tumor, Burkit lymphoma.",CGP,C2,25,31
Cohort,-0.08489715240546065,0.06694280509063187,-1.2682042870853847,0.20507890766870612,LGP Proband,"'Wilm's tumor signature': genes highly expressed in Wilm's tumor samples compared to normal fetal kidney and a heterologous tumor, Burkit lymphoma.",CGP,C2,25,50
Cohort,-0.012776808072669519,0.022391950475465265,-0.5705982641694833,0.5684330282828611,LonGen OPEL,"'Wilm's tumor signature': genes highly expressed in Wilm's tumor samples compared to normal fetal kidney and a heterologous tumor, Burkit lymphoma.",CGP,C2,36,37
Cohort,0.001198562459087168,0.016751374896076685,0.0715500946353891,0.9429811195232689,LGP Offspring,Selected down-regulated genes distinguishing between Wilms tumors of different histological types: anaplastic vs favorable histology.,CGP,C2,8,18
Cohort,0.029979276378873963,0.043190045304867995,0.6941246800566557,0.4877973179732904,LGP Proband,Selected down-regulated genes distinguishing between Wilms tumors of different histological types: anaplastic vs favorable histology.,CGP,C2,8,23
Cohort,0.0350670274945431,0.01438759780538729,2.4373094083442206,0.015015007846530063,LonGen OPEL,Selected down-regulated genes distinguishing between Wilms tumors of different histological types: anaplastic vs favorable histology.,CGP,C2,8,22
Cohort,-0.04604295874499641,0.01906304868237343,-2.4152988072453403,0.01598658359001899,LGP Offspring,Selected up-regulated genes distinguishing between Wilms tumors of different histological types: anaplastic vs favorable histology.,CGP,C2,17,19
Cohort,0.09664901974506933,0.057387222846007,1.6841557223359198,0.0925257546531971,LGP Proband,Selected up-regulated genes distinguishing between Wilms tumors of different histological types: anaplastic vs favorable histology.,CGP,C2,17,34
Cohort,-0.003371825067218893,0.015264904412347478,-0.22088740133161205,0.8252367523927826,LonGen OPEL,Selected up-regulated genes distinguishing between Wilms tumors of different histological types: anaplastic vs favorable histology.,CGP,C2,16,18
Cohort,-0.23311259228734899,0.07519752743362806,-3.1000034208984095,0.0020155649374556067,LGP Offspring,Genes down-regulated in Wilm's tumor samples compared to fetal  kidney.,CGP,C2,202,312
Cohort,-0.10273935112885844,0.2009567490360207,-0.5112510608461467,0.6093105863237804,LGP Proband,Genes down-regulated in Wilm's tumor samples compared to fetal  kidney.,CGP,C2,202,473
Cohort,0.049385027832514666,0.057762343126157044,0.8549692612824634,0.39282541651840963,LonGen OPEL,Genes down-regulated in Wilm's tumor samples compared to fetal  kidney.,CGP,C2,234,308
Cohort,-0.0775098015193621,0.07629576355238687,-1.0159122592192373,0.31003462889474537,LGP Offspring,Genes up-regulated in Wilm's tumor samples compared to fetal  kidney.,CGP,C2,179,338
Cohort,-0.38132172392458935,0.19592549763963132,-1.9462587999952923,0.05195917194229956,LGP Proband,Genes up-regulated in Wilm's tumor samples compared to fetal  kidney.,CGP,C2,179,487
Cohort,0.06615022490298915,0.06833981654198346,0.9679602353388063,0.3333582335433424,LonGen OPEL,Genes up-regulated in Wilm's tumor samples compared to fetal  kidney.,CGP,C2,275,363
Cohort,-0.011804517092564087,0.03133270067791874,-0.3767475141676232,0.7064794754518826,LGP Offspring,Genes down-regulated in Wilm's tumor vs fetal kidney.,CGP,C2,35,66
Cohort,-0.12078389225139478,0.08903048844117106,-1.3566576390424445,0.1752571202276334,LGP Proband,Genes down-regulated in Wilm's tumor vs fetal kidney.,CGP,C2,35,97
Cohort,0.011286480129929869,0.026220403668179976,0.4304464672916796,0.6669874184635116,LonGen OPEL,Genes down-regulated in Wilm's tumor vs fetal kidney.,CGP,C2,51,59
Cohort,-0.030588310592184424,0.030074310918030554,-1.0170909875725767,0.3094740201204462,LGP Offspring,Genes up-regulated in Wilm's tumor vs fetal kidney.,CGP,C2,30,49
Cohort,-0.09950143932606492,0.07934600806664305,-1.2540194743318813,0.21018629919993295,LGP Proband,Genes up-regulated in Wilm's tumor vs fetal kidney.,CGP,C2,30,69
Cohort,0.002179969572380194,0.022071491264762773,0.09876856738994,0.9213468925262973,LonGen OPEL,Genes up-regulated in Wilm's tumor vs fetal kidney.,CGP,C2,37,39
Cohort,0.02845456396468529,0.040728741309104644,0.6986359767107376,0.4850198270512538,LGP Offspring,"Genes up-regulated at 3 months of age in lungs from LIPA [GeneID=3988] knockout mice, which display pulmonary pathology.",CGP,C2,51,116
Cohort,-0.16162689856402285,0.11566192044429723,-1.3974080487610643,0.1626625242323488,LGP Proband,"Genes up-regulated at 3 months of age in lungs from LIPA [GeneID=3988] knockout mice, which display pulmonary pathology.",CGP,C2,51,179
Cohort,0.010596304289707016,0.038036799209394866,0.2785803356211369,0.7806392578627595,LonGen OPEL,"Genes up-regulated at 3 months of age in lungs from LIPA [GeneID=3988] knockout mice, which display pulmonary pathology.",CGP,C2,95,117
Cohort,0.029463733188964763,0.0448047005550862,0.6576036180119065,0.511016717802476,LGP Offspring,"Genes up-regulated at 6 months of age in lungs from LIPA [GeneID=3988] knockout mice, which display pulmonary pathology.",CGP,C2,62,141
Cohort,-0.1450443933936995,0.12730746915106073,-1.1393235162156312,0.2548953681616653,LGP Proband,"Genes up-regulated at 6 months of age in lungs from LIPA [GeneID=3988] knockout mice, which display pulmonary pathology.",CGP,C2,62,208
Cohort,0.004748082720643924,0.04227747465866715,0.11230762383463547,0.9106078118028043,LonGen OPEL,"Genes up-regulated at 6 months of age in lungs from LIPA [GeneID=3988] knockout mice, which display pulmonary pathology.",CGP,C2,118,140
Cohort,0.06667016430320957,0.032164444253689646,2.072790805193586,0.03857013704326878,LGP Offspring,Granule constituents expressed during mouse promyelocytic cell line differentiation to neutrophils.,CGP,C2,25,82
Cohort,-0.03753311107574237,0.08626196780801665,-0.4351061311199798,0.6635979628759947,LGP Proband,Granule constituents expressed during mouse promyelocytic cell line differentiation to neutrophils.,CGP,C2,25,97
Cohort,-0.01836035616854696,0.027290134986528415,-0.6727836332656625,0.5012802101957203,LonGen OPEL,Granule constituents expressed during mouse promyelocytic cell line differentiation to neutrophils.,CGP,C2,59,61
Cohort,0.010747636758919472,0.02558661172198031,0.42004923808206535,0.6745829585160743,LGP Offspring,"Genes down-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic B.D. chr3 (BD, large HSC size) vs parental B6 strain (tiny HSC size).",CGP,C2,17,45
Cohort,-0.024314434553122072,0.06773806201512828,-0.358947891773045,0.7197249221213737,LGP Proband,"Genes down-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic B.D. chr3 (BD, large HSC size) vs parental B6 strain (tiny HSC size).",CGP,C2,17,62
Cohort,0.02861538459004711,0.019685305074730524,1.4536419162118996,0.14643974433343554,LonGen OPEL,"Genes down-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic B.D. chr3 (BD, large HSC size) vs parental B6 strain (tiny HSC size).",CGP,C2,21,37
Cohort,0.03760109381553058,0.03028272932824611,1.2416679292001034,0.2147897461458514,LGP Offspring,"Genes up-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic B.D. chr3 (BD, large HSC size) vs parental B6 strain (tiny HSC size).",CGP,C2,21,67
Cohort,-0.006989059850405437,0.08400002914370978,-0.08320306458999369,0.9337100415260668,LGP Proband,"Genes up-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic B.D. chr3 (BD, large HSC size) vs parental B6 strain (tiny HSC size).",CGP,C2,21,88
Cohort,-0.04724544474971937,0.02862008365681666,-1.6507794077836864,0.09917808395372879,LonGen OPEL,"Genes up-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic B.D. chr3 (BD, large HSC size) vs parental B6 strain (tiny HSC size).",CGP,C2,64,63
Cohort,0.0016420882503550985,0.011872006422774115,0.13831598399450612,0.890031884309932,LGP Offspring,"Genes changed in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of reciprocal congenic strains D.B. Chr3 (DB), B.D. Chr3 (BD) and the parental strains B6 and D2.",CGP,C2,5,9
Cohort,-0.034570863673132037,0.03401392977820498,-1.0163737003797757,0.3097462188004296,LGP Proband,"Genes changed in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of reciprocal congenic strains D.B. Chr3 (DB), B.D. Chr3 (BD) and the parental strains B6 and D2.",CGP,C2,5,14
Cohort,0.01877550990833591,0.013266275463370772,1.4152811736931414,0.1573771735934065,LonGen OPEL,"Genes changed in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of reciprocal congenic strains D.B. Chr3 (DB), B.D. Chr3 (BD) and the parental strains B6 and D2.",CGP,C2,8,19
Cohort,-0.03054118430659043,0.03740352926208172,-0.8165321537599374,0.4144834854049715,LGP Offspring,"Genes down-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic D.B. Chr 3 (DB, small HSC population) vs parental D2 strain (huge HSC population).",CGP,C2,49,84
Cohort,-0.02387707636862474,0.09860834391967882,-0.24214052705391495,0.8087308050745082,LGP Proband,"Genes down-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic D.B. Chr 3 (DB, small HSC population) vs parental D2 strain (huge HSC population).",CGP,C2,49,111
Cohort,-0.0066235876172861625,0.02868369716770114,-0.2309181964431195,0.8174376925519514,LonGen OPEL,"Genes down-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic D.B. Chr 3 (DB, small HSC population) vs parental D2 strain (huge HSC population).",CGP,C2,64,69
Cohort,-0.012454875981911058,0.022856855489679757,-0.5449076749658166,0.5859967350971081,LGP Offspring,"Genes up-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic D.B. Chr 3 (DB, small HSC population) vs parental D2 strain (huge HSC population).",CGP,C2,21,35
Cohort,0.022847259413943256,0.07471294731596273,0.3058005370517868,0.7598328328380086,LGP Proband,"Genes up-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic D.B. Chr 3 (DB, small HSC population) vs parental D2 strain (huge HSC population).",CGP,C2,21,71
Cohort,0.03599057644116582,0.024592097672165473,1.4635016874506683,0.14372491072962754,LonGen OPEL,"Genes up-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic D.B. Chr 3 (DB, small HSC population) vs parental D2 strain (huge HSC population).",CGP,C2,34,55
Cohort,0.01311225761546073,0.02857421429205827,0.45888427522240094,0.6464647763581762,LGP Offspring,Genes up-regulated in T24 cells (bladder carcinoma) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,28,61
Cohort,-0.03183656132580791,0.08480929145400151,-0.3753900165888696,0.7074658790450352,LGP Proband,Genes up-regulated in T24 cells (bladder carcinoma) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,28,99
Cohort,-0.010811462610546156,0.027938454182438496,-0.3869742592037181,0.6988786970104337,LonGen OPEL,Genes up-regulated in T24 cells (bladder carcinoma) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,57,57
Cohort,0.002588058790110523,0.012363484126267622,0.20933086205140983,0.8342530267590582,LGP Offspring,Genes down-regulated in LD419 cells (fibroblast) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,4,9
Cohort,-0.027085538698813593,0.035947994800561336,-0.7534645214311271,0.45138347130155043,LGP Proband,Genes down-regulated in LD419 cells (fibroblast) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,4,15
Cohort,-0.0020036090178863547,0.009299999395060245,-0.21544184389416032,0.8294780380337612,LonGen OPEL,Genes down-regulated in LD419 cells (fibroblast) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,6,7
Cohort,0.01633693903329917,0.0275126835572708,0.5937966392588336,0.5528467762558807,LGP Offspring,Genes up-regulated in LD419 cells (fibroblast) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,21,56
Cohort,-0.007876487909443335,0.08512132437400609,-0.09253248780335725,0.9262972025554668,LGP Proband,Genes up-regulated in LD419 cells (fibroblast) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,21,100
Cohort,0.019399450142357732,0.02676785980765082,0.7247292193607858,0.46883113653111175,LonGen OPEL,Genes up-regulated in LD419 cells (fibroblast) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].,CGP,C2,49,65
Cohort,0.012500530026642781,0.04609011862460099,0.2712193068639775,0.7863051629710486,LGP Offspring,Genes up-regulated in the samples with intrahepatic metastatic hepatocellular carcinoma (HCC) vs primary HCC that also have putative binding sites for SOX4 [GeneID=6659].,CGP,C2,64,137
Cohort,-0.24236569403287436,0.12472777874655945,-1.9431573019940427,0.05233330745299933,LGP Proband,Genes up-regulated in the samples with intrahepatic metastatic hepatocellular carcinoma (HCC) vs primary HCC that also have putative binding sites for SOX4 [GeneID=6659].,CGP,C2,64,182
Cohort,-0.0036461039952713093,0.03903147044347051,-0.0934144666814944,0.9255978046791893,LonGen OPEL,Genes up-regulated in the samples with intrahepatic metastatic hepatocellular carcinoma (HCC) vs primary HCC that also have putative binding sites for SOX4 [GeneID=6659].,CGP,C2,113,128
Cohort,0.1117742638596473,0.13520473937169253,0.8267037411489526,0.4086966993345382,LGP Offspring,Genes up-regulated in the samples with intrahepatic metastatic hepatocellular carcinoma (HCC) vs primary HCC.,CGP,C2,538,1168
Cohort,-0.7010488569436949,0.3637277569738407,-1.927399939933961,0.05426915472835477,LGP Proband,Genes up-regulated in the samples with intrahepatic metastatic hepatocellular carcinoma (HCC) vs primary HCC.,CGP,C2,538,1558
Cohort,0.02715741133602093,0.11503239149605841,0.2360849060236349,0.8134275180181108,LonGen OPEL,Genes up-regulated in the samples with intrahepatic metastatic hepatocellular carcinoma (HCC) vs primary HCC.,CGP,C2,925,1114
Cohort,-0.029989121563384104,0.027927134610889935,-1.073834533374939,0.2832800043328974,LGP Offspring,Genes up-regulated in metaplastic carcinoma of the breast (MCB) subclass 2 compared to the MCB subclass 1.,CGP,C2,34,46
Cohort,-0.1960664486014694,0.07790246481831256,-2.5168195776442235,0.012028477141658549,LGP Proband,Genes up-regulated in metaplastic carcinoma of the breast (MCB) subclass 2 compared to the MCB subclass 1.,CGP,C2,34,69
Cohort,0.004031415275586427,0.020863282879738976,0.19323014977194541,0.8468280204401335,LonGen OPEL,Genes up-regulated in metaplastic carcinoma of the breast (MCB) subclass 2 compared to the MCB subclass 1.,CGP,C2,26,41
Cohort,-0.07557693482665369,0.05383494932422714,-1.4038637683390942,0.16081864139946747,LGP Offspring,Genes down-regulated between two breast carcinoma subtypes: metaplastic (MCB) and ductal (DCB).,CGP,C2,112,207
Cohort,-0.18051174501190034,0.14888713797882813,-1.212406574955919,0.22570011834806278,LGP Proband,Genes down-regulated between two breast carcinoma subtypes: metaplastic (MCB) and ductal (DCB).,CGP,C2,112,267
Cohort,0.019929712957944972,0.04905083890510367,0.4063072804218913,0.6846260444076604,LonGen OPEL,Genes down-regulated between two breast carcinoma subtypes: metaplastic (MCB) and ductal (DCB).,CGP,C2,166,211
Cohort,-0.020626625664697255,0.047807119796570124,-0.4314551002542741,0.6662750534828695,LGP Offspring,Genes up-regulated between two breast carcinoma subtypes: metaplastic (MCB) and ductal (DCB).,CGP,C2,74,148
Cohort,-0.16140903150917416,0.13406297251374416,-1.2039792082979994,0.2289392108034527,LGP Proband,Genes up-regulated between two breast carcinoma subtypes: metaplastic (MCB) and ductal (DCB).,CGP,C2,74,203
Cohort,-0.07721051312355301,0.04396633837601957,-1.7561278918252086,0.07945111634751548,LonGen OPEL,Genes up-regulated between two breast carcinoma subtypes: metaplastic (MCB) and ductal (DCB).,CGP,C2,141,139
Cohort,0.045773579823369215,0.05468557549660061,0.8370320584120874,0.4028703528038483,LGP Offspring,Genes consistently down-regulated in mature mammary luminal cells both in mouse and human species.,CGP,C2,103,233
Cohort,-0.004396866350664608,0.15697447573567166,-0.028010071892633447,0.9776608189926762,LGP Proband,Genes consistently down-regulated in mature mammary luminal cells both in mouse and human species.,CGP,C2,103,323
Cohort,-0.10104919421262856,0.05085957387629186,-1.986827385900151,0.047283955254004716,LonGen OPEL,Genes consistently down-regulated in mature mammary luminal cells both in mouse and human species.,CGP,C2,206,206
Cohort,-0.09671385906046372,0.06815725051477942,-1.418981228409324,0.15636538589180768,LGP Offspring,Genes consistently up-regulated in mature mammary luminal cells both in mouse and human species.,CGP,C2,154,293
Cohort,0.2137478610825105,0.17956713630487942,1.1903506704010531,0.23424730471745117,LGP Proband,Genes consistently up-regulated in mature mammary luminal cells both in mouse and human species.,CGP,C2,154,374
Cohort,-0.004292643850130456,0.05390771811347268,-0.0796294853567106,0.9365519580537467,LonGen OPEL,Genes consistently up-regulated in mature mammary luminal cells both in mouse and human species.,CGP,C2,223,259
Cohort,0.0018933323841319287,0.014910519526395695,0.12697963882346372,0.8989942739083919,LGP Offspring,Genes consistently down-regulated in mammary luminal progenitor cells both in mouse and human species.,CGP,C2,6,14
Cohort,0.029193501221532574,0.04081875213663444,0.7151982775909429,0.47468669354978255,LGP Proband,Genes consistently down-regulated in mammary luminal progenitor cells both in mouse and human species.,CGP,C2,6,22
Cohort,0.004215875212577703,0.015062171112214624,0.2798982418383795,0.7796282937616217,LonGen OPEL,Genes consistently down-regulated in mammary luminal progenitor cells both in mouse and human species.,CGP,C2,16,17
Cohort,-0.025001862625873474,0.04440520778266773,-0.5630389739023407,0.5735950337650302,LGP Offspring,Genes consistently up-regulated in mammary luminal progenitor cells both in mouse and human species.,CGP,C2,69,127
Cohort,0.029498024936382317,0.12737366872486436,0.23158652201578667,0.8169159839049612,LGP Proband,Genes consistently up-regulated in mammary luminal progenitor cells both in mouse and human species.,CGP,C2,69,181
Cohort,0.013730451999170933,0.0393386939156056,0.3490317199810257,0.727157801627099,LonGen OPEL,Genes consistently up-regulated in mammary luminal progenitor cells both in mouse and human species.,CGP,C2,96,121
Cohort,-0.023092580363140755,0.11959562152996077,-0.19308884445536048,0.8469473866044197,LGP Offspring,Genes consistently down-regulated in mammary stem cells both in mouse and human species.,CGP,C2,490,1027
Cohort,0.09505019195860998,0.3337573452378653,0.2847883149683753,0.7758770255626195,LGP Proband,Genes consistently down-regulated in mammary stem cells both in mouse and human species.,CGP,C2,490,1370
Cohort,-0.17139291654172004,0.10639974283382347,-1.610839575142618,0.10761112798899772,LonGen OPEL,Genes consistently down-regulated in mammary stem cells both in mouse and human species.,CGP,C2,807,901
Cohort,-0.13659215159851407,0.14018724224986542,-0.9743550797229924,0.33022879018122675,LGP Offspring,Genes consistently up-regulated in mammary stem cells both in mouse and human species.,CGP,C2,591,1200
Cohort,0.006414078154249346,0.37573532138012344,0.017070735140602762,0.9863842683428585,LGP Proband,Genes consistently up-regulated in mammary stem cells both in mouse and human species.,CGP,C2,591,1559
Cohort,-0.17290525461217324,0.11124867751896506,-1.5542230116191476,0.12052870976869595,LonGen OPEL,Genes consistently up-regulated in mammary stem cells both in mouse and human species.,CGP,C2,956,1068
Cohort,0.054912118646877166,0.043514865033620204,1.2619163268563807,0.20741411512827393,LGP Offspring,Genes up-regulated by forced expression of APC [GeneID=324] in the APC-deficient SW480  cell line (colon cancer).,CGP,C2,52,138
Cohort,-0.0036478321936463365,0.12122430152638726,-0.030091591765965358,0.9760012057968008,LGP Proband,Genes up-regulated by forced expression of APC [GeneID=324] in the APC-deficient SW480  cell line (colon cancer).,CGP,C2,52,179
Cohort,-0.05639454917846456,0.038868252710939855,-1.4509154707279073,0.1471973505938284,LonGen OPEL,Genes up-regulated by forced expression of APC [GeneID=324] in the APC-deficient SW480  cell line (colon cancer).,CGP,C2,113,115
Cohort,-0.006383142838866249,0.02966160962414865,-0.21519880140521733,0.829677232806574,LGP Offspring,Candidate genes in significant regions of chromosomal copy number losses in a panel of melanoma samples.,CGP,C2,31,57
Cohort,-0.02864516944800117,0.08107742281831658,-0.35330636387137115,0.72394805900092,LGP Proband,Candidate genes in significant regions of chromosomal copy number losses in a panel of melanoma samples.,CGP,C2,31,79
Cohort,-0.03664496532004962,0.02403967608174942,-1.5243535393503058,0.1278176039761553,LonGen OPEL,Candidate genes in significant regions of chromosomal copy number losses in a panel of melanoma samples.,CGP,C2,47,45
Cohort,0.033683549237145484,0.04793189183697272,0.7027377377824123,0.4824611254602409,LGP Offspring,Candidate genes in significant regions of chromosomal copy number gains in a panel of melanoma samples.,CGP,C2,77,163
Cohort,-0.048602566630286004,0.12591489349286367,-0.38599537578166315,0.699598536883741,LGP Proband,Candidate genes in significant regions of chromosomal copy number gains in a panel of melanoma samples.,CGP,C2,77,202
Cohort,0.04684887180944277,0.04256156633322654,1.1007318537727138,0.27134612629980825,LonGen OPEL,Candidate genes in significant regions of chromosomal copy number gains in a panel of melanoma samples.,CGP,C2,122,155
Cohort,2.0298150288693877e-4,0.03502630157400993,0.0057951166342253575,0.9953779014997627,LGP Offspring,Genes down-regulated in neurons after NPAS4 [GeneID=266743] knockdown by RNAi.,CGP,C2,39,81
Cohort,0.02739500341628534,0.09547808524074611,0.2869245162092367,0.7742413859756497,LGP Proband,Genes down-regulated in neurons after NPAS4 [GeneID=266743] knockdown by RNAi.,CGP,C2,39,110
Cohort,-0.045983345887032165,0.030239528840326914,-1.5206369824687733,0.12874806735967825,LonGen OPEL,Genes down-regulated in neurons after NPAS4 [GeneID=266743] knockdown by RNAi.,CGP,C2,69,61
Cohort,-0.06791097565339885,0.055628032796189185,-1.220804911477134,0.2225855325896761,LGP Offspring,Genes up-regulated in neurons after NPAS4 [GeneID=266743] knockdown by RNAi.,CGP,C2,109,189
Cohort,-0.15733787077205583,0.1594751910968095,-0.9865977879690628,0.3241259887965552,LGP Proband,Genes up-regulated in neurons after NPAS4 [GeneID=266743] knockdown by RNAi.,CGP,C2,109,282
Cohort,-0.02824950204780958,0.052559382010010175,-0.5374778197055158,0.5910878204264711,LonGen OPEL,Genes up-regulated in neurons after NPAS4 [GeneID=266743] knockdown by RNAi.,CGP,C2,195,230
Cohort,0.024301730148724103,0.05684058589708384,0.42754186581969916,0.6691208535411567,LGP Offspring,Genes downregulated in MCF10A cells (breast cancer) co-cultured with cancer-associated fibroblasts (CAF).,CGP,C2,103,233
Cohort,-0.16768417017999904,0.1587194641063978,-1.056481453765442,0.29105423731144975,LGP Proband,Genes downregulated in MCF10A cells (breast cancer) co-cultured with cancer-associated fibroblasts (CAF).,CGP,C2,103,318
Cohort,-0.005337456380609379,0.05017992010689807,-0.10636637860799736,0.9153184675064393,LonGen OPEL,Genes downregulated in MCF10A cells (breast cancer) co-cultured with cancer-associated fibroblasts (CAF).,CGP,C2,177,205
Cohort,-0.05983637802015292,0.026721344854406432,-2.2392726992663214,0.025462629209638155,LGP Offspring,Genes up-regulated in highly immune-resistant cancer cell line developed from a susceptible cancer using an in vivo selection strategy.,CGP,C2,32,42
Cohort,0.04615671883396281,0.07492530315704501,0.6160364641730892,0.5380385448081237,LGP Proband,Genes up-regulated in highly immune-resistant cancer cell line developed from a susceptible cancer using an in vivo selection strategy.,CGP,C2,32,62
Cohort,-0.008894000927049568,0.024494457484206315,-0.3631025889340189,0.7166246508053202,LonGen OPEL,Genes up-regulated in highly immune-resistant cancer cell line developed from a susceptible cancer using an in vivo selection strategy.,CGP,C2,42,50
Cohort,-0.2006076050839156,0.10220537726225497,-1.9627891453222113,0.05008037056318581,LGP Offspring,Down-regulated genes whose expression profile is specific to Custer I of urothelial cell carcinoma (UCC) tumors.,CGP,C2,390,713
Cohort,-0.43378749481200685,0.2818939469597422,-1.5388322434392565,0.12422455382831661,LGP Proband,Down-regulated genes whose expression profile is specific to Custer I of urothelial cell carcinoma (UCC) tumors.,CGP,C2,390,1008
Cohort,0.04043900028760057,0.09103232144838318,0.4442268377230185,0.6569993321749918,LonGen OPEL,Down-regulated genes whose expression profile is specific to Custer I of urothelial cell carcinoma (UCC) tumors.,CGP,C2,555,674
Cohort,-0.09243800030095148,0.049871613072089545,-1.8535193591458956,0.06424343823667016,LGP Offspring,Up-regulated genes whose expression profile is specific to Custer I of urothelial cell carcinoma (UCC) tumors.,CGP,C2,98,164
Cohort,0.09788860403366709,0.1445400097553633,0.6772422680705875,0.4984400637185592,LGP Proband,Up-regulated genes whose expression profile is specific to Custer I of urothelial cell carcinoma (UCC) tumors.,CGP,C2,98,241
Cohort,-0.01752640135491108,0.04497840713279718,-0.38966256193032783,0.6968903151024726,LonGen OPEL,Up-regulated genes whose expression profile is specific to Custer I of urothelial cell carcinoma (UCC) tumors.,CGP,C2,138,158
Cohort,-0.042173055267758185,0.05938812312070701,-0.7101260833254655,0.4778708429279155,LGP Offspring,Genes whose expression profile is specific to Cluster IIa of urothelial cell carcinoma (UCC) tumors.,CGP,C2,108,207
Cohort,-0.02173569441455127,0.15775737246383442,-0.137779262389364,0.8904481307598879,LGP Proband,Genes whose expression profile is specific to Cluster IIa of urothelial cell carcinoma (UCC) tumors.,CGP,C2,108,277
Cohort,0.029926641675085085,0.04922783153333284,0.6079211848854513,0.5434131499088488,LonGen OPEL,Genes whose expression profile is specific to Cluster IIa of urothelial cell carcinoma (UCC) tumors.,CGP,C2,158,210
Cohort,0.0031107469466966245,0.013516280934712705,0.23014814220882018,0.8180462825700636,LGP Offspring,Genes whose expression profile is specific to Cluster IIa of urothelial cell carcinoma (UCC) tumors.,CGP,C2,5,11
Cohort,0.03413240333169278,0.03741408603544635,0.9122875084895972,0.3618810143232565,LGP Proband,Genes whose expression profile is specific to Cluster IIa of urothelial cell carcinoma (UCC) tumors.,CGP,C2,5,18
Cohort,-0.009558705686464586,0.013471380855143848,-0.7095564878796174,0.4781869968621957,LonGen OPEL,Genes whose expression profile is specific to Cluster IIa of urothelial cell carcinoma (UCC) tumors.,CGP,C2,15,13
Cohort,0.07398808576651894,0.1044588891236962,0.7082986080668069,0.4790039966842591,LGP Offspring,Genes specifically up-regulated in Cluster IIb of urothelial cell carcinom (UCC) tumors.,CGP,C2,339,743
Cohort,-0.09355232539396334,0.2797919958464687,-0.33436383736044634,0.7381890885015634,LGP Proband,Genes specifically up-regulated in Cluster IIb of urothelial cell carcinom (UCC) tumors.,CGP,C2,339,1015
Cohort,0.05297147022252983,0.08908923237650915,0.5945889173077804,0.5522872530196847,LonGen OPEL,Genes specifically up-regulated in Cluster IIb of urothelial cell carcinom (UCC) tumors.,CGP,C2,565,701
Cohort,-0.15521583681130138,0.09099370121203706,-1.705786606587322,0.08850717103854797,LGP Offspring,Genes whose expression profile is specific to Cluster III of urothelial cell carcinoma (UCC) tumors.,CGP,C2,300,568
Cohort,-0.10131238031605654,0.25278460010317866,-0.400785412856258,0.6886807708896041,LGP Proband,Genes whose expression profile is specific to Cluster III of urothelial cell carcinoma (UCC) tumors.,CGP,C2,300,803
Cohort,-0.046561034306894906,0.08546454390198906,-0.5447994241950348,0.5860440696322664,LonGen OPEL,Genes whose expression profile is specific to Cluster III of urothelial cell carcinoma (UCC) tumors.,CGP,C2,477,557
Cohort,-0.3069255670099951,0.0947283807230927,-3.2400592585572765,0.0012536112787187755,LGP Offspring,Genes whose expression profile is specific to Cluster III of urothelial cell carcinoma (UCC) tumors.,CGP,C2,303,478
Cohort,-0.13042677498371322,0.2512416771076797,-0.5191287388509733,0.6038086951867532,LGP Proband,Genes whose expression profile is specific to Cluster III of urothelial cell carcinoma (UCC) tumors.,CGP,C2,303,707
Cohort,-0.028399925643290944,0.0792940458809404,-0.35815962381252797,0.7203188185741604,LonGen OPEL,Genes whose expression profile is specific to Cluster III of urothelial cell carcinoma (UCC) tumors.,CGP,C2,399,488
Cohort,-0.00438049481198034,0.048922884804915544,-0.08953876758183746,0.9286802662661526,LGP Offspring,Genes up-regulated among the high recurrence rate urothelial cell carcinoma (UCC) tumors.,CGP,C2,82,166
Cohort,0.1047073384061987,0.13678924531506287,0.7654646983761713,0.4442114429543734,LGP Proband,Genes up-regulated among the high recurrence rate urothelial cell carcinoma (UCC) tumors.,CGP,C2,82,238
Cohort,-0.014091574140463262,0.04394429786538198,-0.3206690020086585,0.7485454050264039,LonGen OPEL,Genes up-regulated among the high recurrence rate urothelial cell carcinoma (UCC) tumors.,CGP,C2,135,149
Cohort,-0.04938649079612166,0.06216120118760607,-0.7944906123527182,0.4271886972788296,LGP Offspring,Genes down-regulated in urothelial cell carcinoma (UCC) tumors with LOH on 9q as compared to the tumors showing retention.,CGP,C2,136,258
Cohort,-0.16603824341046694,0.1669123789500434,-0.9947629076700292,0.32014011358079,LGP Proband,Genes down-regulated in urothelial cell carcinoma (UCC) tumors with LOH on 9q as compared to the tumors showing retention.,CGP,C2,136,338
Cohort,-0.004468810994403011,0.053943341034199316,-0.0828426810191428,0.9339974584813298,LonGen OPEL,Genes down-regulated in urothelial cell carcinoma (UCC) tumors with LOH on 9q as compared to the tumors showing retention.,CGP,C2,202,239
Cohort,-0.013341757183840544,0.03583842780236491,-0.3722751806361368,0.7098046514087633,LGP Offspring,Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated only at 8 hr after the stimulation (cluster A).,CGP,C2,43,84
Cohort,-0.08489242544987421,0.09956191121145655,-0.852659660877479,0.39409286158385115,LGP Proband,Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated only at 8 hr after the stimulation (cluster A).,CGP,C2,43,130
Cohort,-0.012648279020498789,0.031256667813587845,-0.4046585866392434,0.6858371998660927,LonGen OPEL,Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated only at 8 hr after the stimulation (cluster A).,CGP,C2,69,77
Cohort,3.0069370464897317e-4,0.028715165559287593,0.010471599198275115,0.9916481148771946,LGP Offspring,Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated both at 8 hr and 48 hr after the stimulation (cluster B).,CGP,C2,26,58
Cohort,0.04126387164314322,0.0761555675086058,0.5418365720730829,0.5880758194114395,LGP Proband,Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated both at 8 hr and 48 hr after the stimulation (cluster B).,CGP,C2,26,66
Cohort,-0.012063548504698996,0.0236933167436494,-0.509154063790264,0.6107853449222085,LonGen OPEL,Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated both at 8 hr and 48 hr after the stimulation (cluster B).,CGP,C2,42,49
Cohort,-0.1071275233804202,0.04108973394272456,-2.6071603074808527,0.009331042377195748,LGP Offspring,Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated only at 48 hr after the stimulation (cluster C).,CGP,C2,68,99
Cohort,-0.08252186543071893,0.10786179648144852,-0.7650703782308329,0.4444460722014618,LGP Proband,Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated only at 48 hr after the stimulation (cluster C).,CGP,C2,68,145
Cohort,0.03222771972558247,0.034660618168797064,0.9298079904009101,0.35275239222825194,LonGen OPEL,Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated only at 48 hr after the stimulation (cluster C).,CGP,C2,81,112
Cohort,-0.0021815182943094947,0.042843404237178515,-0.05091841633855098,0.9594055718610881,LGP Offspring,Genes down-regulated during the course of maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli (cluster D).,CGP,C2,56,119
Cohort,-0.08476329595173582,0.11564844912294732,-0.7329393225292878,0.46380138681779004,LGP Proband,Genes down-regulated during the course of maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli (cluster D).,CGP,C2,56,166
Cohort,0.00458355372453103,0.04032757597513946,0.11365805193341229,0.9095375260981924,LonGen OPEL,Genes down-regulated during the course of maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli (cluster D).,CGP,C2,113,135
Cohort,0.0027503176518300395,0.05350570885299701,0.0514023215613559,0.9590201196354272,LGP Offspring,Genes down-regulated in BJ cells (foreskin fibroblasts) immortalized by expression of TERT [GeneID=7015].,CGP,C2,99,207
Cohort,-0.13073374643440092,0.15404125882610037,-0.8486930542549533,0.3962956362518013,LGP Proband,Genes down-regulated in BJ cells (foreskin fibroblasts) immortalized by expression of TERT [GeneID=7015].,CGP,C2,99,307
Cohort,0.003703760941189787,0.047794055213262535,0.07749417630839615,0.9382498983601759,LonGen OPEL,Genes down-regulated in BJ cells (foreskin fibroblasts) immortalized by expression of TERT [GeneID=7015].,CGP,C2,150,184
Cohort,0.038028630355916554,0.044019376642855386,0.8639066078662618,0.38794561805432626,LGP Offspring,Genes up-regulated in BJ cells (foreskin fibroblasts) immortalized by expression of TERT [GeneID=7015].,CGP,C2,55,132
Cohort,-0.004565380552082169,0.1205409294188258,-0.03787411109316666,0.9697971182212275,LGP Proband,Genes up-regulated in BJ cells (foreskin fibroblasts) immortalized by expression of TERT [GeneID=7015].,CGP,C2,55,174
Cohort,0.13625185041361318,0.03738036264065579,3.645011465603663,2.8474244830426474e-4,LonGen OPEL,Genes up-regulated in BJ cells (foreskin fibroblasts) immortalized by expression of TERT [GeneID=7015].,CGP,C2,76,147
Cohort,-0.18388065698585712,0.07673321635913997,-2.396363214142195,0.01682940333614524,LGP Offspring,Transcripts down-regulated by overexpression of MIR16 family of microRNA molecules in DLD-1 and HCT116 (colon cancer) cells hypomorphic for DICER1 [GeneID=23405].,CGP,C2,182,318
Cohort,0.5064395075756463,0.20770110685392387,2.4383091416639635,0.014963912635322691,LGP Proband,Transcripts down-regulated by overexpression of MIR16 family of microRNA molecules in DLD-1 and HCT116 (colon cancer) cells hypomorphic for DICER1 [GeneID=23405].,CGP,C2,182,449
Cohort,-0.07165719572068423,0.06559014020777718,-1.0924995051647666,0.27494414185166766,LonGen OPEL,Transcripts down-regulated by overexpression of MIR16 family of microRNA molecules in DLD-1 and HCT116 (colon cancer) cells hypomorphic for DICER1 [GeneID=23405].,CGP,C2,302,324
Cohort,-0.013600038882029432,0.030436665405665322,-0.44683077797011206,0.6551403615108506,LGP Offspring,Low abundance transcripts specific for breast cancer.,CGP,C2,28,55
Cohort,-0.042987638667434984,0.08437178155772232,-0.5095025596683094,0.610534788924368,LGP Proband,Low abundance transcripts specific for breast cancer.,CGP,C2,28,89
Cohort,-0.03324719180469591,0.02396302808293546,-1.3874370004336756,0.16569684735700807,LonGen OPEL,Low abundance transcripts specific for breast cancer.,CGP,C2,48,47
Cohort,0.005082234959138436,0.007845716974083015,0.6477718959180825,0.51735242895849,LGP Offspring,Genes down-regulated in HET1A cells (esophagus epithelium) engineered to stably express CDX2 [GeneID=1045].,CGP,C2,1,5
Cohort,0.006653583684610576,0.030948019979578766,0.21499222531848508,0.8298259402309942,LGP Proband,Genes down-regulated in HET1A cells (esophagus epithelium) engineered to stably express CDX2 [GeneID=1045].,CGP,C2,1,15
Cohort,-0.002447182353954917,0.008940182980821991,-0.27372844148766123,0.7843643297294773,LonGen OPEL,Genes down-regulated in HET1A cells (esophagus epithelium) engineered to stably express CDX2 [GeneID=1045].,CGP,C2,6,6
Cohort,-0.013803638699233279,0.029616367700885302,-0.46608141952602294,0.641307363876763,LGP Offspring,Genes up-regulated in HET1A cells (esophagus epithelium) engineered to stably express CDX2 [GeneID=1045].,CGP,C2,30,55
Cohort,-0.02928743175215055,0.07926996220537029,-0.3694644344130445,0.7118753652045031,LGP Proband,Genes up-regulated in HET1A cells (esophagus epithelium) engineered to stably express CDX2 [GeneID=1045].,CGP,C2,30,70
Cohort,-0.028350780270509145,0.022471301306943497,-1.2616439022936747,0.2074465302159362,LonGen OPEL,Genes up-regulated in HET1A cells (esophagus epithelium) engineered to stably express CDX2 [GeneID=1045].,CGP,C2,39,40
Cohort,0.006732523668691161,0.012724129756707121,0.529114666183149,0.5968996021615944,LGP Offspring,Genes down-regulated in MCF-7 cells (breast cancer) by overexpression of CMYB [GeneID=4602] off adenovirus vector.,CGP,C2,4,12
Cohort,-0.009915493014425531,0.02476201783366901,-0.40043154322195007,0.6889412455023991,LGP Proband,Genes down-regulated in MCF-7 cells (breast cancer) by overexpression of CMYB [GeneID=4602] off adenovirus vector.,CGP,C2,4,6
Cohort,-0.013733009496426895,0.007625816118459446,-1.8008576764897413,0.07210371526555619,LonGen OPEL,Genes down-regulated in MCF-7 cells (breast cancer) by overexpression of CMYB [GeneID=4602] off adenovirus vector.,CGP,C2,8,2
Cohort,-0.083122139306013,0.06911057317650322,-1.2027412808995996,0.22949754004910092,LGP Offspring,Genes up-regulated in MCF-7 cells (breast cancer) by overexpression of CMYB [GeneID=4602] off adenovirus vector.,CGP,C2,152,293
Cohort,0.11851498749564289,0.19167838816167743,0.618301252594411,0.5365455910124908,LGP Proband,Genes up-regulated in MCF-7 cells (breast cancer) by overexpression of CMYB [GeneID=4602] off adenovirus vector.,CGP,C2,152,395
Cohort,-0.0437509437227377,0.0552044094516079,-0.792526252111975,0.42829002421310736,LonGen OPEL,Genes up-regulated in MCF-7 cells (breast cancer) by overexpression of CMYB [GeneID=4602] off adenovirus vector.,CGP,C2,225,256
Cohort,0.025069943961909938,0.03587262472218863,0.6988600403806859,0.4848798649326609,LGP Offspring,"Low abundance transcripts common to nasopharyngeal carcinoma (NPC), breast and liver tumors.",CGP,C2,41,99
Cohort,0.05729436231484383,0.09845497620056572,0.5819346520192915,0.5607679631545899,LGP Proband,"Low abundance transcripts common to nasopharyngeal carcinoma (NPC), breast and liver tumors.",CGP,C2,41,117
Cohort,0.004936115491882479,0.03212552255934061,0.15365090117257207,0.8779239440700651,LonGen OPEL,"Low abundance transcripts common to nasopharyngeal carcinoma (NPC), breast and liver tumors.",CGP,C2,70,93
Cohort,0.00997749629145874,0.013323490104323215,0.7488650656348095,0.45419902119520783,LGP Offspring,Genes down-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3 and then rested for the next 3 days (repeated-stimulation or memory model),CGP,C2,5,13
Cohort,0.012342831780541939,0.035442245222052485,0.3482519717137479,0.7277388447349129,LGP Proband,Genes down-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3 and then rested for the next 3 days (repeated-stimulation or memory model),CGP,C2,5,16
Cohort,-0.0014557703007438954,0.006311132830244478,-0.23066703552292409,0.8176327556806163,LonGen OPEL,Genes down-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3 and then rested for the next 3 days (repeated-stimulation or memory model),CGP,C2,3,3
Cohort,0.0012933222527047544,0.022313116782645314,0.057962420279656944,0.9537956912246126,LGP Offspring,Genes up-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3 and then rested for the next 3 days (repeated-stimulation or memory model),CGP,C2,15,34
Cohort,-0.031466872759436555,0.06417232864505991,-0.49034955445486905,0.6240155415123501,LGP Proband,Genes up-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3 and then rested for the next 3 days (repeated-stimulation or memory model),CGP,C2,15,48
Cohort,-8.938559976928514e-4,0.019390930903622615,-0.046096600629207604,0.9632448173009728,LonGen OPEL,Genes up-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3 and then rested for the next 3 days (repeated-stimulation or memory model),CGP,C2,28,30
Cohort,0.0016781397668717331,0.02462929687818589,0.06813591858393885,0.9456975859000567,LGP Offspring,"Genes up-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3, rested on days 4 and 5, and then restimulated on day 6 for 1 h before lysis (priming model).",CGP,C2,21,41
Cohort,-0.024915973623120174,0.06639956645994927,-0.3752430166565761,0.707575150071051,LGP Proband,"Genes up-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3, rested on days 4 and 5, and then restimulated on day 6 for 1 h before lysis (priming model).",CGP,C2,21,49
Cohort,0.014638241577365114,0.020171442998034708,0.7256913438860725,0.4682413090705302,LonGen OPEL,"Genes up-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3, rested on days 4 and 5, and then restimulated on day 6 for 1 h before lysis (priming model).",CGP,C2,25,39
Cohort,0.03345074128401481,0.035409120700598616,0.9446927972839863,0.3451532564210126,LGP Offspring,Low abundance transcripts specific to hepatocellular carcinoma (HCC).,CGP,C2,37,88
Cohort,-0.10983063191007236,0.08888684042813107,-1.2356230841490565,0.2169466303191582,LGP Proband,Low abundance transcripts specific to hepatocellular carcinoma (HCC).,CGP,C2,37,100
Cohort,0.022518241601524016,0.029062761636386308,0.7748142410985261,0.43867952549326006,LonGen OPEL,Low abundance transcripts specific to hepatocellular carcinoma (HCC).,CGP,C2,53,65
Cohort,-0.027534243001072677,0.03596276876152497,-0.7656319006930965,0.44416258960380384,LGP Offspring,Low abundance transcripts specific to nasopharyngeal carcinoma (NPC).,CGP,C2,43,83
Cohort,0.0667927892930013,0.10097513535096815,0.6614775911004598,0.5084887834974492,LGP Proband,Low abundance transcripts specific to nasopharyngeal carcinoma (NPC).,CGP,C2,43,116
Cohort,-0.014826116767051947,0.03113584799556156,-0.47617513963857416,0.6340802766947751,LonGen OPEL,Low abundance transcripts specific to nasopharyngeal carcinoma (NPC).,CGP,C2,64,70
Cohort,-0.22886481458152588,0.13845676967210546,-1.6529694801021686,0.09880138368516854,LGP Offspring,Genes down-regulated in prostate cancer samples.,CGP,C2,597,1155
Cohort,-0.009087405324016242,0.37665228993576083,-0.024126775720827626,0.9807572569095743,LGP Proband,Genes down-regulated in prostate cancer samples.,CGP,C2,597,1627
Cohort,0.08682936261558603,0.11646621947831895,0.7455325930945149,0.4561698997667305,LonGen OPEL,Genes down-regulated in prostate cancer samples.,CGP,C2,893,1111
Cohort,0.04354622218394869,0.05922349457785548,0.7352862659379653,0.4624201861119587,LGP Offspring,Genes up-regulated in prostate cancer samples.,CGP,C2,98,225
Cohort,0.38042497425456473,0.16461643817435723,2.310978043709274,0.021077129408652667,LGP Proband,Genes up-regulated in prostate cancer samples.,CGP,C2,98,300
Cohort,-0.016385002960476125,0.04855000832186646,-0.3374871298033635,0.7358386864056572,LonGen OPEL,Genes up-regulated in prostate cancer samples.,CGP,C2,169,183
Cohort,0.016492223489595222,0.03420656999039854,0.48213613625173274,0.6298653035440515,LGP Offspring,Genes up-regulated in SW-13 cells (kidney cancer) by transient expression of SMARCA4 [GeneID=6597] at 24 h off a plasmid vector.,CGP,C2,37,84
Cohort,-0.06208646264483699,0.0941323741803791,-0.6595654596564744,0.5097148101308777,LGP Proband,Genes up-regulated in SW-13 cells (kidney cancer) by transient expression of SMARCA4 [GeneID=6597] at 24 h off a plasmid vector.,CGP,C2,37,111
Cohort,0.03825492947747488,0.028527817523741512,1.3409693694807967,0.18031291486055456,LonGen OPEL,Genes up-regulated in SW-13 cells (kidney cancer) by transient expression of SMARCA4 [GeneID=6597] at 24 h off a plasmid vector.,CGP,C2,49,71
Cohort,-0.009819800123087101,0.10541415658021046,-0.09315447224220913,0.925808443900075,LGP Offspring,Genes down-regulated in LNCaP cells (prostate cancer) by overexpression of SOX4 [GeneID=6659] and up-regulated by its RNAi knockdown.,CGP,C2,310,661
Cohort,-0.16985387582305356,0.2711355959301558,-0.626453620891621,0.531188872230882,LGP Proband,Genes down-regulated in LNCaP cells (prostate cancer) by overexpression of SOX4 [GeneID=6659] and up-regulated by its RNAi knockdown.,CGP,C2,310,913
Cohort,0.11963093863439228,0.09301054020573848,1.286208405733046,0.19874432449875298,LonGen OPEL,Genes down-regulated in LNCaP cells (prostate cancer) by overexpression of SOX4 [GeneID=6659] and up-regulated by its RNAi knockdown.,CGP,C2,507,667
Cohort,-0.04337424416222434,0.048313647785625496,-0.8977638027805727,0.3696311133695085,LGP Offspring,Genes up-regulated in LNCaP cells (prostate cancer) by overexpression of SOX4 [GeneID=6659] and down-regulated by its RNAi knockdown.,CGP,C2,83,161
Cohort,0.2800524157266224,0.14513598406117,1.9295863637000563,0.05399701975208889,LGP Proband,Genes up-regulated in LNCaP cells (prostate cancer) by overexpression of SOX4 [GeneID=6659] and down-regulated by its RNAi knockdown.,CGP,C2,83,264
Cohort,0.05560310050938741,0.04685917341422711,1.1866001138745124,0.23573941851874672,LonGen OPEL,Genes up-regulated in LNCaP cells (prostate cancer) by overexpression of SOX4 [GeneID=6659] and down-regulated by its RNAi knockdown.,CGP,C2,149,203
Cohort,-0.027856762677296344,0.027391321804264276,-1.0169922750117013,0.3095209425114989,LGP Offspring,Gene regulated in the opposite directions by v-MYB (DN) and c-MYB  (UP) variants of CMYB [GeneID=4602] overexpressed in primary monocyte cultures off adenoviral vectors.,CGP,C2,26,48
Cohort,-0.001458422853285946,0.07601748815613313,-0.01918535969368622,0.984697825521548,LGP Proband,Gene regulated in the opposite directions by v-MYB (DN) and c-MYB  (UP) variants of CMYB [GeneID=4602] overexpressed in primary monocyte cultures off adenoviral vectors.,CGP,C2,26,69
Cohort,-0.021580453137064182,0.02338538039733202,-0.9228181355359198,0.3563816150333535,LonGen OPEL,Gene regulated in the opposite directions by v-MYB (DN) and c-MYB  (UP) variants of CMYB [GeneID=4602] overexpressed in primary monocyte cultures off adenoviral vectors.,CGP,C2,43,40
Cohort,-0.016129514913091114,0.024389377488371295,-0.6613336039749915,0.5086237319571599,LGP Offspring,Genes regulated in the opposite directions by v-MYB (UP) and c-MYB  (DN) variants of CMYB [GeneID=4602] overexpressed in primary monocyte cultures off adenoviral vectors.,CGP,C2,23,39
Cohort,0.050693829647593794,0.06957690518318624,0.7286013874018117,0.4664500623564438,LGP Proband,Genes regulated in the opposite directions by v-MYB (UP) and c-MYB  (DN) variants of CMYB [GeneID=4602] overexpressed in primary monocyte cultures off adenoviral vectors.,CGP,C2,23,60
Cohort,-0.0016904222430441022,0.018590574052741213,-0.09092899650373339,0.9275718858137207,LonGen OPEL,Genes regulated in the opposite directions by v-MYB (UP) and c-MYB  (DN) variants of CMYB [GeneID=4602] overexpressed in primary monocyte cultures off adenoviral vectors.,CGP,C2,26,28
Cohort,-0.009489444698052237,0.01601664838942664,-0.592473810208425,0.5537314753965763,LGP Offspring,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of TOPBP1 [GeneID=11073].,CGP,C2,10,16
Cohort,-0.016237106186312956,0.043804944421145575,-0.3706683435140934,0.7109786960855016,LGP Proband,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of TOPBP1 [GeneID=11073].,CGP,C2,10,20
Cohort,-0.018103231312936882,0.017081651426559052,-1.059805686280979,0.2895544813981678,LonGen OPEL,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of TOPBP1 [GeneID=11073].,CGP,C2,24,22
Cohort,0.012984983171557756,0.016950627268407084,0.7660473542332812,0.4439155254665468,LGP Offspring,Selected genes down-regulated in prostate tumors developed by transgenic mice overexpressing VAV3 [GeneID=10451] in prostate epithelium.,CGP,C2,8,21
Cohort,-0.04014061609630622,0.05365532249993658,-0.7481199296929706,0.45459872550273395,LGP Proband,Selected genes down-regulated in prostate tumors developed by transgenic mice overexpressing VAV3 [GeneID=10451] in prostate epithelium.,CGP,C2,8,41
Cohort,-0.005556815771782658,0.017868273624637762,-0.3109878373543941,0.7558912874818946,LonGen OPEL,Selected genes down-regulated in prostate tumors developed by transgenic mice overexpressing VAV3 [GeneID=10451] in prostate epithelium.,CGP,C2,25,23
Cohort,0.022690891287113702,0.05693543296291634,0.39853725713990656,0.6903600472091163,LGP Offspring,Selected genes up-regulated in prostate tumors developed by transgenic mice overexpressing VAV3 [GeneID=10451] in prostate epithelium.,CGP,C2,106,227
Cohort,-0.141192520125357,0.1511194201593001,-0.9343108911913582,0.35041397403828467,LGP Proband,Selected genes up-regulated in prostate tumors developed by transgenic mice overexpressing VAV3 [GeneID=10451] in prostate epithelium.,CGP,C2,106,301
Cohort,-7.631799716808813e-5,0.0494584006069632,-0.0015430745076973514,0.9987691917843264,LonGen OPEL,Selected genes up-regulated in prostate tumors developed by transgenic mice overexpressing VAV3 [GeneID=10451] in prostate epithelium.,CGP,C2,164,194
Cohort,-0.05171394704773251,0.05865963337360556,-0.8815934241928227,0.3783100591004186,LGP Offspring,Genes up-regulated in MCF-7 cells (breast cancer) by overexpression of v-MYB oncogenic varian of CMYB [GeneID=4602] off adenovirus vector.,CGP,C2,109,221
Cohort,0.15743726962451818,0.154122809061022,1.0215053215269643,0.30731130224282194,LGP Proband,Genes up-regulated in MCF-7 cells (breast cancer) by overexpression of v-MYB oncogenic varian of CMYB [GeneID=4602] off adenovirus vector.,CGP,C2,109,276
Cohort,-0.049644279123272,0.04769057374462372,-1.040966279607163,0.2982072641205876,LonGen OPEL,Genes up-regulated in MCF-7 cells (breast cancer) by overexpression of v-MYB oncogenic varian of CMYB [GeneID=4602] off adenovirus vector.,CGP,C2,169,193
Cohort,-0.04690154207682253,0.06501687765299925,-0.7213748763381126,0.4709283150381771,LGP Offspring,Overexpressed genes with amplified copy number across 27 non-small cell lung cancer (NSCLC) cell lines.,CGP,C2,148,306
Cohort,0.12403097360829352,0.19218604599769307,0.6453692980903637,0.5188653968264065,LGP Proband,Overexpressed genes with amplified copy number across 27 non-small cell lung cancer (NSCLC) cell lines.,CGP,C2,148,463
Cohort,0.007441636516668991,0.05743690740270999,0.12956192896134028,0.896945756627648,LonGen OPEL,Overexpressed genes with amplified copy number across 27 non-small cell lung cancer (NSCLC) cell lines.,CGP,C2,220,269
Cohort,-0.03250167010284397,0.026363052520087252,-1.2328492718390414,0.2180605641763095,LGP Offspring,Genes un-methylated aberrantly in HCT116 and Colo320 (colon cancer) cells.,CGP,C2,27,40
Cohort,0.023324006880965538,0.07668940371853834,0.3041359790274045,0.7611001629805773,LGP Proband,Genes un-methylated aberrantly in HCT116 and Colo320 (colon cancer) cells.,CGP,C2,27,73
Cohort,-0.006739943184800685,0.02358079236622643,-0.28582343969297497,0.775087717483729,LonGen OPEL,Genes un-methylated aberrantly in HCT116 and Colo320 (colon cancer) cells.,CGP,C2,41,44
Cohort,0.02494114192293914,0.027964299939442157,0.891892233202698,0.3727680507495581,LGP Offspring,Genes methylated aberrantly in HCT116 and Colo320 (colon cancer) cells.,CGP,C2,22,57
Cohort,0.06362912914928077,0.06637648891613816,0.9586094442216057,0.3380333413969768,LGP Proband,Genes methylated aberrantly in HCT116 and Colo320 (colon cancer) cells.,CGP,C2,22,54
Cohort,0.015986904655393562,0.022093784579201588,0.7235928547272586,0.46952831157237684,LonGen OPEL,Genes methylated aberrantly in HCT116 and Colo320 (colon cancer) cells.,CGP,C2,31,40
Cohort,-0.01233626692279374,0.029346916393612154,-0.4203599028032442,0.6743561404807299,LGP Offspring,Top 20 genes expressed higher in epithelioid than in sarcomatoid mesothelioma samples.,CGP,C2,33,59
Cohort,0.005432002358106722,0.07836549995401305,0.06931624708952747,0.9447545093637248,LGP Proband,Top 20 genes expressed higher in epithelioid than in sarcomatoid mesothelioma samples.,CGP,C2,33,76
Cohort,0.04335384661616743,0.02299992085734217,1.8849563389835648,0.05979978238160442,LonGen OPEL,Top 20 genes expressed higher in epithelioid than in sarcomatoid mesothelioma samples.,CGP,C2,29,55
Cohort,-0.011364005390344264,0.1612083383363114,-0.07049266500493775,0.9438223867888009,LGP Offspring,"Genes up-regulated in HeLa cells (cervical cancer) after simultaneus knockdown of all three MBD (methyl-CpG binding domain) proteins MeCP2, MBD1 and MBD2 [GeneID=4204;4152;8932] by RNAi.",CGP,C2,811,1678
Cohort,-0.4199922005891779,0.4537057959022912,-0.9256928264580209,0.3548734137025832,LGP Proband,"Genes up-regulated in HeLa cells (cervical cancer) after simultaneus knockdown of all three MBD (methyl-CpG binding domain) proteins MeCP2, MBD1 and MBD2 [GeneID=4204;4152;8932] by RNAi.",CGP,C2,811,2320
Cohort,-0.14437951967732995,0.1411683104493652,-1.0227473801857008,0.3067380211740508,LonGen OPEL,"Genes up-regulated in HeLa cells (cervical cancer) after simultaneus knockdown of all three MBD (methyl-CpG binding domain) proteins MeCP2, MBD1 and MBD2 [GeneID=4204;4152;8932] by RNAi.",CGP,C2,1346,1584
Cohort,0.002645061025943546,0.025614163893488306,0.10326556185642194,0.917782833726969,LGP Offspring,X chromosome and imprinted genes up-regulated in HeLa cells (cervical cancer) after knockdown of the MBD (methyl-CpG binding domain) proteins by RNAi.,CGP,C2,17,37
Cohort,0.039635778967279295,0.06150181490772343,0.6444651922345435,0.5194510330042637,LGP Proband,X chromosome and imprinted genes up-regulated in HeLa cells (cervical cancer) after knockdown of the MBD (methyl-CpG binding domain) proteins by RNAi.,CGP,C2,17,40
Cohort,-0.05599593848709715,0.024629377242361816,-2.2735426046739726,0.023259072109321207,LonGen OPEL,X chromosome and imprinted genes up-regulated in HeLa cells (cervical cancer) after knockdown of the MBD (methyl-CpG binding domain) proteins by RNAi.,CGP,C2,42,28
Cohort,0.005967191533019465,0.012969483248951627,0.46009477929676307,0.6455961388072371,LGP Offspring,Top genes higher expressed in long term mesothelioma survivors.,CGP,C2,5,13
Cohort,0.08006512574714844,0.03849850721197497,2.0796942932437696,0.0378585170373099,LGP Proband,Top genes higher expressed in long term mesothelioma survivors.,CGP,C2,5,21
Cohort,-0.010361646769679229,0.013481584939009467,-0.7685777908573211,0.44237195668650475,LonGen OPEL,Top genes higher expressed in long term mesothelioma survivors.,CGP,C2,15,13
Cohort,0.008324716907161066,0.02754802927737206,0.3021891992106668,0.7626007870631242,LGP Offspring,Top genes higher expressed in short term mesothelioma survivors.,CGP,C2,21,49
Cohort,0.011333222228347671,0.06839086762822082,0.16571250842957766,0.8684233629065267,LGP Proband,Top genes higher expressed in short term mesothelioma survivors.,CGP,C2,21,50
Cohort,0.008136876297420626,0.024006853475063997,0.3389397242696727,0.7347445297981336,LonGen OPEL,Top genes higher expressed in short term mesothelioma survivors.,CGP,C2,34,42
Cohort,-0.02774480495092257,0.026189702390294535,-1.0593783975645454,0.28980585736800285,LGP Offspring,Top genes associated with unfavorable survival after surgery of patients with epithelioid mesothelioma.,CGP,C2,24,38
Cohort,-0.028161305221057267,0.07103221145632876,-0.396458235548123,0.6918684283299879,LGP Proband,Top genes associated with unfavorable survival after surgery of patients with epithelioid mesothelioma.,CGP,C2,24,54
Cohort,-0.008227716865312994,0.023051523644254793,-0.3569272466448705,0.7212408699520383,LonGen OPEL,Top genes associated with unfavorable survival after surgery of patients with epithelioid mesothelioma.,CGP,C2,35,34
Cohort,0.021271585849861413,0.024313400773843214,0.8748914250097732,0.3819437142422697,LGP Offspring,Top genes associated with unfavorable overall survival of mesothelioma patients after surgery.,CGP,C2,14,41
Cohort,0.07014816093912718,0.0674402431889148,1.0401528467598629,0.29857033803720484,LGP Proband,Top genes associated with unfavorable overall survival of mesothelioma patients after surgery.,CGP,C2,14,55
Cohort,0.00243226317952249,0.02228722798933572,0.10913260189586207,0.91312482152585694,LonGen OPEL,Top genes associated with unfavorable overall survival of mesothelioma patients after surgery.,CGP,C2,28,34
Cohort,-0.006486579639518566,0.01343877717698192,-0.4826763294080691,0.6294818357540273,LGP Offspring,Top genes associated with favorable overall survival of mesothelioma patients after surgery.,CGP,C2,8,12
Cohort,0.07410661210150143,0.038378615497753094,1.930935004829449,0.05382972972727994,LGP Proband,Top genes associated with favorable overall survival of mesothelioma patients after surgery.,CGP,C2,8,18
Cohort,-0.018372867522500818,0.011968452975180595,-1.5351079676380301,0.1251546679602893,LonGen OPEL,Top genes associated with favorable overall survival of mesothelioma patients after surgery.,CGP,C2,14,8
Cohort,0.006947088834493435,0.020648937460089906,0.33643807812972026,0.7366449488239187,LGP Offspring,Top genes associated with favorable survival after surgery of patients with epithelioid mesothelioma.,CGP,C2,13,31
Cohort,0.07195824867921746,0.05634053341145779,1.2772021193640943,0.20188634715896212,LGP Proband,Top genes associated with favorable survival after surgery of patients with epithelioid mesothelioma.,CGP,C2,13,41
Cohort,0.02030912820600767,0.013973409276094619,1.453412535532903,0.14650336770945502,LonGen OPEL,Top genes associated with favorable survival after surgery of patients with epithelioid mesothelioma.,CGP,C2,10,19
Cohort,-0.014630898773470109,0.015008957950618228,-0.9748110975863886,0.33000266335971074,LGP Offspring,Genes higher expressed in the best 25 mesothelioma survivors compared to the 25 worst ones.,CGP,C2,9,15
Cohort,0.07271393773755754,0.044185618897812855,1.645647148356607,0.10021320928009521,LGP Proband,Genes higher expressed in the best 25 mesothelioma survivors compared to the 25 worst ones.,CGP,C2,9,25
Cohort,-0.017787501027162964,0.015063817875413011,-1.180809617739439,0.23803106612105687,LonGen OPEL,Genes higher expressed in the best 25 mesothelioma survivors compared to the 25 worst ones.,CGP,C2,19,14
Cohort,0.012783418376938511,0.02466588123246092,0.5182631934558742,0.6044442319629126,LGP Offspring,Genes higher expressed in the worst 25 mesothelioma survivors compared to the 25 best ones.,CGP,C2,15,42
Cohort,0.08209981677652273,0.06717215521187545,1.2222299034110522,0.22196601079024506,LGP Proband,Genes higher expressed in the worst 25 mesothelioma survivors compared to the 25 best ones.,CGP,C2,15,53
Cohort,0.018962567775281724,0.02173549138176217,0.8724241583603142,0.38324010452814694,LonGen OPEL,Genes higher expressed in the worst 25 mesothelioma survivors compared to the 25 best ones.,CGP,C2,24,36
Cohort,0.011502455340177702,0.02265010129212204,0.5078324017993856,0.6117365363516989,LGP Offspring,Genes translationally up-regulated in HUVEC cells (endothelium) grown on FN1 [GeneID=2335] compared to those grown on laminin 1.,CGP,C2,15,32
Cohort,-0.052058073926188914,0.0652487847026444,-0.7978397477199158,0.4251905958238821,LGP Proband,Genes translationally up-regulated in HUVEC cells (endothelium) grown on FN1 [GeneID=2335] compared to those grown on laminin 1.,CGP,C2,15,55
Cohort,0.05770315453332938,0.020297084693898272,2.8429282039048767,0.004584556757992068,LonGen OPEL,Genes translationally up-regulated in HUVEC cells (endothelium) grown on FN1 [GeneID=2335] compared to those grown on laminin 1.,CGP,C2,18,44
Cohort,-0.04413546381634712,0.05475776136680672,-0.806012932499124,0.4205188326658732,LGP Offspring,Age down-regulated genes in the human frontal cortex.,CGP,C2,100,191
Cohort,-0.07285543725050256,0.1502293094297076,-0.4849615399756042,0.6278309790369428,LGP Proband,Age down-regulated genes in the human frontal cortex.,CGP,C2,100,275
Cohort,0.010428491013435017,0.048149999525379655,0.21658340843675822,0.8285885107507631,LonGen OPEL,Age down-regulated genes in the human frontal cortex.,CGP,C2,145,181
Cohort,-0.09098738994152215,0.09199669836378928,-0.9890288625546545,0.3230028870370807,LGP Offspring,Age up-regulated genes in the human frontal cortex.,CGP,C2,317,610
Cohort,-0.5245125996994574,0.25936349978230167,-2.022306917279071,0.04346340973146435,LGP Proband,Age up-regulated genes in the human frontal cortex.,CGP,C2,317,777
Cohort,0.05583927092748515,0.07948080092310456,0.7025504307827506,0.4825413578359169,LonGen OPEL,Age up-regulated genes in the human frontal cortex.,CGP,C2,449,563
Cohort,0.0757592424066725,0.10826952139259616,0.6997282469917077,0.48433774394218476,LGP Offspring,Genes down-regulated in SKOV3ip1 cells (ovarian cancer) upon knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,346,762
Cohort,-0.08845707951038355,0.28604092312462764,-0.3092462384196786,0.7572114641463622,LGP Proband,Genes down-regulated in SKOV3ip1 cells (ovarian cancer) upon knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,346,970
Cohort,-0.012476385343909482,0.08673947347956946,-0.1438374576581694,0.88566522928702,LonGen OPEL,Genes down-regulated in SKOV3ip1 cells (ovarian cancer) upon knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,578,698
Cohort,-0.11462787600076299,0.07752450504272193,-1.4786018425734453,0.13971255013290707,LGP Offspring,Genes up-regulated in SKOV3ip1 cells (ovarian cancer) upon knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,195,363
Cohort,-0.03803399866400064,0.21624201708175528,-0.1758862554894732,0.8604260001484902,LGP Proband,Genes up-regulated in SKOV3ip1 cells (ovarian cancer) upon knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,195,556
Cohort,-0.01132887194841905,0.07066662011084572,-0.1603143313016654,0.8726741434570415,LonGen OPEL,Genes up-regulated in SKOV3ip1 cells (ovarian cancer) upon knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,322,394
Cohort,-0.06183349937922656,0.05590051182332744,-1.106134762677133,0.2690616794710722,LGP Offspring,Genes up-regulated in peripheral B lymphocytes after incubation with IL4 [GeneID=3565] for 4 h.,CGP,C2,107,198
Cohort,0.05903551759242915,0.147117946004475,0.4012801918172064,0.6883166384355647,LGP Proband,Genes up-regulated in peripheral B lymphocytes after incubation with IL4 [GeneID=3565] for 4 h.,CGP,C2,107,246
Cohort,0.05869366557410251,0.044033224473917804,1.3329404393009765,0.1829327312009321,LonGen OPEL,Genes up-regulated in peripheral B lymphocytes after incubation with IL4 [GeneID=3565] for 4 h.,CGP,C2,122,177
Cohort,-0.03713596264673391,0.03194481785634343,-1.1625035025629253,0.24544123383217797,LGP Offspring,Up-regulated genes of putative pathways stimulated in tumor endothelial cells by papillary serous ovarian epithelial tumor cells.,CGP,C2,39,68
Cohort,-0.004415675758504839,0.09001033691741264,-0.04905742951008352,0.9608852744528433,LGP Proband,Up-regulated genes of putative pathways stimulated in tumor endothelial cells by papillary serous ovarian epithelial tumor cells.,CGP,C2,39,94
Cohort,-0.0369453124061889,0.0307035880995438,-1.2032897355973142,0.2292219669791559,LonGen OPEL,Up-regulated genes of putative pathways stimulated in tumor endothelial cells by papillary serous ovarian epithelial tumor cells.,CGP,C2,71,69
Cohort,0.04851566947897885,0.025953311728293967,1.869344073962156,0.06200709520164237,LGP Offspring,Genes specifically down-regulated in tumor endothelium.,CGP,C2,14,48
Cohort,0.018174906660533445,0.062300062725533234,0.2917317554013407,0.7705642746333697,LGP Proband,Genes specifically down-regulated in tumor endothelium.,CGP,C2,14,48
Cohort,0.06211130731130247,0.02103911229900124,2.952182888165438,0.0032481127527040072,LonGen OPEL,Genes specifically down-regulated in tumor endothelium.,CGP,C2,20,48
Cohort,0.0019036364634647275,0.026597662523860865,0.07157156993615389,0.9429640349135165,LGP Offspring,Genes specifically up-regulated in tumor endothelium.,CGP,C2,22,50
Cohort,-0.03890502058815078,0.07422162811431908,-0.5241736347824077,0.6002970514176431,LGP Proband,Genes specifically up-regulated in tumor endothelium.,CGP,C2,22,71
Cohort,-0.026998852129644167,0.025229343852298226,-1.0701369123075608,0.28488206709269215,LonGen OPEL,Genes specifically up-regulated in tumor endothelium.,CGP,C2,47,46
Cohort,0.06398442945892688,0.028933693811684473,2.2114158626054046,0.02734088049283808,LGP Offspring,Genes down-regulated in endothelial cells derived from invasive ovarian cancer tissue.,CGP,C2,18,64
Cohort,0.05643579457581531,0.07096971537740773,0.795209537979645,0.4267178737232358,LGP Proband,Genes down-regulated in endothelial cells derived from invasive ovarian cancer tissue.,CGP,C2,18,64
Cohort,0.04926880170832197,0.023067087833896136,2.135891711303214,0.03299275596532716,LonGen OPEL,Genes down-regulated in endothelial cells derived from invasive ovarian cancer tissue.,CGP,C2,29,53
Cohort,-0.019107709100997818,0.02971288093055422,-0.6430783048488934,0.5203913593689424,LGP Offspring,Genes up-regulated in endothelial cells derived from invasive ovarian cancer tissue.,CGP,C2,31,61
Cohort,-0.06346986972486145,0.08329676845810834,-0.7619727739711986,0.4462916779893241,LGP Proband,Genes up-regulated in endothelial cells derived from invasive ovarian cancer tissue.,CGP,C2,31,87
Cohort,0.004128716917928211,0.028636718659526873,0.144175628744904,0.8853982784046569,LonGen OPEL,Genes up-regulated in endothelial cells derived from invasive ovarian cancer tissue.,CGP,C2,55,69
Cohort,0.0017496237909068104,0.01850915378892198,0.09452748682405933,0.9247181601922431,LGP Offspring,Genes down-regulated in Tet-On HEK293 cells (embryonic kidney) by expression of HNF4A [GeneID=3172].,CGP,C2,11,24
Cohort,-0.07052893251910207,0.048957013721604485,-1.440629792498516,0.15006460160619545,LGP Proband,Genes down-regulated in Tet-On HEK293 cells (embryonic kidney) by expression of HNF4A [GeneID=3172].,CGP,C2,11,30
Cohort,-0.02405122940369497,0.01505112775041321,-1.597968590960546,0.11044682272807083,LonGen OPEL,Genes down-regulated in Tet-On HEK293 cells (embryonic kidney) by expression of HNF4A [GeneID=3172].,CGP,C2,22,13
Cohort,-0.016157606741309907,0.05109065415999455,-0.31625366726977194,0.7519076012283419,LGP Offspring,Genes up-regulated in Tet-On HEK293 cells (embryonic kidney) by expression of HNF4A [GeneID=3172].,CGP,C2,84,171
Cohort,0.08384444994992835,0.1378401328890117,0.6082731363690685,0.5431719495091467,LGP Proband,Genes up-regulated in Tet-On HEK293 cells (embryonic kidney) by expression of HNF4A [GeneID=3172].,CGP,C2,84,230
Cohort,-0.04478346772442967,0.04611802533169113,-0.9710621259764912,0.3318123160356875,LonGen OPEL,Genes up-regulated in Tet-On HEK293 cells (embryonic kidney) by expression of HNF4A [GeneID=3172].,CGP,C2,152,167
Cohort,-0.015818434137058243,0.011827488686612707,-1.337429656978899,0.1815322389656788,LGP Offspring,Genes changed in liver in response to nifedipine [PubChem=4485] treatment of iron overload.,CGP,C2,7,7
Cohort,-0.027541029823438857,0.03491484619623445,-0.7888057037011706,0.4304497424228245,LGP Proband,Genes changed in liver in response to nifedipine [PubChem=4485] treatment of iron overload.,CGP,C2,7,13
Cohort,0.001016493831785323,0.012832912149846434,0.07920991119677281,0.9368855695623463,LonGen OPEL,Genes changed in liver in response to nifedipine [PubChem=4485] treatment of iron overload.,CGP,C2,11,14
Cohort,0.0036820656911662605,0.023375001917805838,0.15752151397093397,0.874880891752162,LGP Offspring,Genes down-regulated in follicular thyroid carcinoma (FTC) samples that bear PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,16,38
Cohort,0.10797459961257311,0.06828384452333289,1.5812612831967554,0.11419745265780519,LGP Proband,Genes down-regulated in follicular thyroid carcinoma (FTC) samples that bear PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,16,55
Cohort,0.02335845675687532,0.01943354625147765,1.201965737730407,0.22973426038516506,LonGen OPEL,Genes down-regulated in follicular thyroid carcinoma (FTC) samples that bear PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,21,35
Cohort,-0.04277573606803022,0.041724753184648,-1.0251884745424669,0.3056409711147046,LGP Offspring,Cluster 1: genes with similar expression profiles across follicular thyrorid carcinoma (FTC) samples.,CGP,C2,63,106
Cohort,-0.2592398950446099,0.11872445866075604,-2.1835424475201317,0.029273912030784412,LGP Proband,Cluster 1: genes with similar expression profiles across follicular thyrorid carcinoma (FTC) samples.,CGP,C2,63,156
Cohort,-0.04325748126788754,0.03558564148287629,-1.215588070505991,0.22450227583478052,LonGen OPEL,Cluster 1: genes with similar expression profiles across follicular thyrorid carcinoma (FTC) samples.,CGP,C2,94,99
Cohort,-0.05324882244311924,0.055066359751977136,-0.9669936905754399,0.3338930068183289,LGP Offspring,Cluster 2: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.,CGP,C2,97,191
Cohort,0.06811217664024992,0.14676494603946322,0.46409022371006375,0.6427042160534553,LGP Proband,Cluster 2: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.,CGP,C2,97,256
Cohort,0.05580565856664336,0.043155706336325365,1.2931235126064933,0.19634350737829526,LonGen OPEL,Cluster 2: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.,CGP,C2,122,175
Cohort,0.00485944155030636,0.022259656334158957,0.21830712376494407,0.8272557096842922,LGP Offspring,Cluster 3: genes with similar expression profiles across follicular thyrorid carcinoma (FTC) samples; genes in this cluster correlated well with the presence of PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,15,35
Cohort,0.08591758930377906,0.06816458258521325,1.2604432690007688,0.20786203203367531,LGP Proband,Cluster 3: genes with similar expression profiles across follicular thyrorid carcinoma (FTC) samples; genes in this cluster correlated well with the presence of PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,15,51
Cohort,0.014340555565143128,0.01857537354007756,0.7720197676887874,0.44033185799256036,LonGen OPEL,Cluster 3: genes with similar expression profiles across follicular thyrorid carcinoma (FTC) samples; genes in this cluster correlated well with the presence of PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,20,28
Cohort,0.024838271306257997,0.02244604587622485,1.1065766969926325,0.26887060992483236,LGP Offspring,Cluster 4: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.,CGP,C2,12,39
Cohort,-0.05068935324174995,0.06002498330441453,-0.8444709261255556,0.39864847325760866,LGP Proband,Cluster 4: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.,CGP,C2,12,45
Cohort,0.01216480533144301,0.020345476264962394,0.5979120455583739,0.5500686894043236,LonGen OPEL,Cluster 4: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.,CGP,C2,26,32
Cohort,0.04090033345469309,0.02969372342767077,1.377406695200077,0.16884241301378017,LGP Offspring,Cluster 5: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.,CGP,C2,19,62
Cohort,0.074352931848659,0.0750905047643099,0.990177547507958,0.32237452843068404,LGP Proband,Cluster 5: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.,CGP,C2,19,73
Cohort,0.048358150703459266,0.02604153541857002,1.8569623459673363,0.06368572127678905,LonGen OPEL,Cluster 5: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.,CGP,C2,34,60
Cohort,-0.009947355731654369,0.02932404670187543,-0.3392217940717637,0.7345480046712617,LGP Offspring,Top down-regulated genes distinguishing between follicular thyroid carcinoma (FTC) samples by the presence or absence of the PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,26,55
Cohort,0.14885352352271863,0.08232716470810579,1.8080729981469017,0.07095525459568557,LGP Proband,Top down-regulated genes distinguishing between follicular thyroid carcinoma (FTC) samples by the presence or absence of the PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,26,75
Cohort,0.03603890655690579,0.025711813930797918,1.4016477660387063,0.1614102470926575,LonGen OPEL,Top down-regulated genes distinguishing between follicular thyroid carcinoma (FTC) samples by the presence or absence of the PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,36,52
Cohort,-0.045537346003953955,0.04163140698831492,-1.0938219315224045,0.2744226901938106,LGP Offspring,Top up-regulated genes distinguishing between follicular thyroid carcinoma (FTC) samples by the presence or absence of the PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,66,115
Cohort,-0.032817637052581096,0.12351331174463262,-0.2657012154320056,0.7905349923905488,LGP Proband,Top up-regulated genes distinguishing between follicular thyroid carcinoma (FTC) samples by the presence or absence of the PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,66,169
Cohort,-0.010398853074458985,0.03766098276672579,-0.2761174114565745,0.782529558750096,LonGen OPEL,Top up-regulated genes distinguishing between follicular thyroid carcinoma (FTC) samples by the presence or absence of the PAX8-PPARG [GeneID=7849;5468] fusion protein.,CGP,C2,92,110
Cohort,-0.007960957907825774,0.009066025106100115,-0.8781089633724054,0.3801965759089748,LGP Offspring,Genes up-regulated in FE-8 cells (fibroblasts) upon treatment with azacitidine [PubChem=9444].,CGP,C2,3,5
Cohort,0.020360907644624174,0.029243742637693335,0.6962483529170528,0.48646729788488474,LGP Proband,Genes up-regulated in FE-8 cells (fibroblasts) upon treatment with azacitidine [PubChem=9444].,CGP,C2,3,11
Cohort,0.01659552621593201,0.011223473853002553,1.4786443514092833,0.13963098369588658,LonGen OPEL,Genes up-regulated in FE-8 cells (fibroblasts) upon treatment with azacitidine [PubChem=9444].,CGP,C2,5,14
Cohort,0.012818221330909471,0.01748845475101773,0.7329533405553468,0.4638409642196305,LGP Offspring,"Genes down-regulated in fibroblasts from middle-age individuals, compared to those from the young donors.",CGP,C2,8,21
Cohort,0.01686378107260899,0.04265031556902761,0.3953963961958434,0.6926514817694516,LGP Proband,"Genes down-regulated in fibroblasts from middle-age individuals, compared to those from the young donors.",CGP,C2,8,23
Cohort,-0.004937179905026688,0.013072411994341534,-0.37767933776595886,0.7057695004053435,LonGen OPEL,"Genes down-regulated in fibroblasts from middle-age individuals, compared to those from the young donors.",CGP,C2,13,13
Cohort,0.0274425667791958,0.02116394602021268,1.2966658841875096,0.19518860375329616,LGP Offspring,"Genes up-regulated in fibroblasts from middle-age individuals, compared to those from the young donors.",CGP,C2,11,36
Cohort,0.04870987740683016,0.06699091355257125,0.7271117055092103,0.46736157524544186,LGP Proband,"Genes up-regulated in fibroblasts from middle-age individuals, compared to those from the young donors.",CGP,C2,11,59
Cohort,0.010806334237229794,0.020488599567513893,0.5274315700114512,0.5980408964237829,LonGen OPEL,"Genes up-regulated in fibroblasts from middle-age individuals, compared to those from the young donors.",CGP,C2,26,37
Cohort,0.036316540425803,0.04368987283324022,0.831234747796578,0.4061345302648761,LGP Offspring,"Genes down-regulated in fibroblasts from old individuals, compared to those from young donors.",CGP,C2,51,123
Cohort,-0.1196398098536819,0.1066856490295915,-1.1214236492154375,0.26243035544333154,LGP Proband,"Genes down-regulated in fibroblasts from old individuals, compared to those from young donors.",CGP,C2,51,146
Cohort,-0.025517386087944006,0.03274684499181771,-0.77923189529617,0.43607472525589985,LonGen OPEL,"Genes down-regulated in fibroblasts from old individuals, compared to those from young donors.",CGP,C2,78,87
Cohort,0.015272538750211392,0.010583732618321202,1.443020085727934,0.14947801414254058,LGP Offspring,"Genes up-regulated in fibroblasts from old individuals, compared to those from young donors.",CGP,C2,2,9
Cohort,0.020972087789472477,0.04104813020922024,0.5109145698617406,0.60954609347814,LGP Proband,"Genes up-regulated in fibroblasts from old individuals, compared to those from young donors.",CGP,C2,2,24
Cohort,-0.011878450937581636,0.010540644249990737,-1.1269188728755433,0.26011638077704224,LonGen OPEL,"Genes up-regulated in fibroblasts from old individuals, compared to those from young donors.",CGP,C2,9,8
Cohort,0.038159184732413635,0.029932709026951672,1.274832314644651,0.2028065967115611,LGP Offspring,"Genes down-regulated in fibroblasts from patients with Hutchinson-Gilford progeria (premature aging), compared to those from normal young individuals.",CGP,C2,24,66
Cohort,0.016037064224326672,0.08044143207366149,0.19936323621938107,0.8420272111014468,LGP Proband,"Genes down-regulated in fibroblasts from patients with Hutchinson-Gilford progeria (premature aging), compared to those from normal young individuals.",CGP,C2,24,87
Cohort,-0.03527049349676049,0.025384247394237454,-1.3894638256940144,0.16508027279262688,LonGen OPEL,"Genes down-regulated in fibroblasts from patients with Hutchinson-Gilford progeria (premature aging), compared to those from normal young individuals.",CGP,C2,51,45
Cohort,1.130179342452962e-4,0.027218096667808646,0.004152308503590724,0.9966881717024368,LGP Offspring,Genes down-regulated during myeloid differentiation induced by tretinoin (ATRA) [PubChem=444795] and IL3 [GeneID=3652] in the EML cell line (myeloid progenitor).,CGP,C2,24,54
Cohort,0.02762648368448851,0.07681645002037919,0.3596428066795495,0.7192053117192313,LGP Proband,Genes down-regulated during myeloid differentiation induced by tretinoin (ATRA) [PubChem=444795] and IL3 [GeneID=3652] in the EML cell line (myeloid progenitor).,CGP,C2,24,71
Cohort,0.07584844258799299,0.02590612355300789,2.927819070761223,0.003510816783957832,LonGen OPEL,Genes down-regulated during myeloid differentiation induced by tretinoin (ATRA) [PubChem=444795] and IL3 [GeneID=3652] in the EML cell line (myeloid progenitor).,CGP,C2,31,71
Cohort,0.005979970642022591,0.02238510708110627,0.2671405868355159,0.7894423948109874,LGP Offspring,Genes up-regulated during myeloid differentiation induced by tretinoin (ATRA) [PubChem=444795] and IL3 [GeneID=3652] in the EML cell line (myeloid progenitor).,CGP,C2,15,38
Cohort,-0.05653488084942917,0.06452436170191324,-0.8761788471555362,0.38118510001868156,LGP Proband,Genes up-regulated during myeloid differentiation induced by tretinoin (ATRA) [PubChem=444795] and IL3 [GeneID=3652] in the EML cell line (myeloid progenitor).,CGP,C2,15,56
Cohort,0.04265218070868249,0.022012249767049644,1.9376565848588982,0.05301852052025973,LonGen OPEL,Genes up-regulated during myeloid differentiation induced by tretinoin (ATRA) [PubChem=444795] and IL3 [GeneID=3652] in the EML cell line (myeloid progenitor).,CGP,C2,25,53
Cohort,-0.035290688446360755,0.058167282612454525,-0.606710282161341,0.5442468968052734,LGP Offspring,Genes up-regulated in human peripheral blood mononuclear cells (PBMC)  at 8 h after exposure to 0.1 and 1.0 Gy dose of ionizing radiation.,CGP,C2,105,209
Cohort,-0.031541149201998755,0.14935057059421059,-0.21118867558729912,0.8327916390905479,LGP Proband,Genes up-regulated in human peripheral blood mononuclear cells (PBMC)  at 8 h after exposure to 0.1 and 1.0 Gy dose of ionizing radiation.,CGP,C2,105,260
Cohort,-0.02103749048114451,0.045093418564989086,-0.4665312844007395,0.6409629115403057,LonGen OPEL,Genes up-regulated in human peripheral blood mononuclear cells (PBMC)  at 8 h after exposure to 0.1 and 1.0 Gy dose of ionizing radiation.,CGP,C2,149,170
Cohort,0.014630982353455517,0.023118472089075814,0.6328697803679294,0.5270327023966883,LGP Offspring,Genes down-regulated in SW480 cells (colon cancer with mutated p53 [GeneID=7157]) upon expression of BRCA1 [GeneID=672] off an adenovirus vector.,CGP,C2,15,37
Cohort,0.055279952212176395,0.06697582382334072,0.8253717394799946,0.4093965956906118,LGP Proband,Genes down-regulated in SW480 cells (colon cancer with mutated p53 [GeneID=7157]) upon expression of BRCA1 [GeneID=672] off an adenovirus vector.,CGP,C2,15,57
Cohort,0.008586377591520235,0.01938737721615715,0.44288495012953466,0.6579692823880317,LonGen OPEL,Genes down-regulated in SW480 cells (colon cancer with mutated p53 [GeneID=7157]) upon expression of BRCA1 [GeneID=672] off an adenovirus vector.,CGP,C2,24,36
Cohort,-0.022013692251518082,0.025493850559696156,-0.8634902836655072,0.3881742171512008,LGP Offspring,Genes up-regulated in SW480 cells (colon cancer with mutated p53 [GeneID=7157]) upon expression of BRCA1 [GeneID=672] off an adenovirus vector.,CGP,C2,23,41
Cohort,0.047377528782973063,0.0677265915526909,0.6995410177421024,0.48440904699055565,LGP Proband,Genes up-regulated in SW480 cells (colon cancer with mutated p53 [GeneID=7157]) upon expression of BRCA1 [GeneID=672] off an adenovirus vector.,CGP,C2,23,51
Cohort,-0.006263856837489193,0.020871994505203415,-0.30010820652178716,0.7641729746596703,LonGen OPEL,Genes up-regulated in SW480 cells (colon cancer with mutated p53 [GeneID=7157]) upon expression of BRCA1 [GeneID=672] off an adenovirus vector.,CGP,C2,30,33
Cohort,-0.024370141456544325,0.03140261972847484,-0.7760544077934459,0.43798828526245526,LGP Offspring,Genes differentially expressed in ES cells with DPPA4 [GeneID=55211] knockout.,CGP,C2,34,67
Cohort,0.01165469707615962,0.096050124637612,0.12133973922607269,0.9034511733674244,LGP Proband,Genes differentially expressed in ES cells with DPPA4 [GeneID=55211] knockout.,CGP,C2,34,107
Cohort,0.0013557475692926129,0.02821897067523647,0.04804383493981755,0.9616933590589442,LonGen OPEL,Genes differentially expressed in ES cells with DPPA4 [GeneID=55211] knockout.,CGP,C2,54,68
Cohort,-0.01973727783090881,0.03274500778865225,-0.6027568525345945,0.5468726021310977,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblast) upon knockout of ATF2 [GeneID=1386].,CGP,C2,38,74
Cohort,-0.06252529860597138,0.09039424083660474,-0.6916955994905821,0.4893210165587947,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblast) upon knockout of ATF2 [GeneID=1386].,CGP,C2,38,86
Cohort,-0.04699390077614878,0.027300726392195697,-1.7213425057284433,0.08557723574336946,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblast) upon knockout of ATF2 [GeneID=1386].,CGP,C2,62,53
Cohort,-0.031942105640709,0.020460777197716502,-1.5611384324283564,0.1189590946207447,LGP Offspring,Down-regulated genes discriminating multiple myeloma samples by type of immunoglobulin they produce: IgG vs IgA.,CGP,C2,19,26
Cohort,0.09426128385989013,0.06224295126567638,1.5144089723115384,0.13030101804799313,LGP Proband,Down-regulated genes discriminating multiple myeloma samples by type of immunoglobulin they produce: IgG vs IgA.,CGP,C2,19,46
Cohort,-0.015400256632179976,0.017988168770079204,-0.856132540728445,0.3921821121975879,LonGen OPEL,Down-regulated genes discriminating multiple myeloma samples by type of immunoglobulin they produce: IgG vs IgA.,CGP,C2,23,24
Cohort,0.007773240491442747,0.027090978888961077,0.2869309567329867,0.7742531105102377,LGP Offspring,Up-regulated genes discriminating multiple myeloma samples by type of immunoglobulin they produce: IgG vs IgA.,CGP,C2,23,49
Cohort,-0.09726471424390684,0.07334161759443142,-1.3261871967668712,0.18514076660995496,LGP Proband,Up-regulated genes discriminating multiple myeloma samples by type of immunoglobulin they produce: IgG vs IgA.,CGP,C2,23,65
Cohort,0.011797926514022505,0.022919832958589383,0.5147474911941338,0.6068723775226911,LonGen OPEL,Up-regulated genes discriminating multiple myeloma samples by type of immunoglobulin they produce: IgG vs IgA.,CGP,C2,31,47
Cohort,-0.01733656745782073,0.021018951627871332,-0.8248064777328035,0.4097724119200288,LGP Offspring,Down-regulated genes discriminating multiple myeloma samples by the ype of immunoglobulin light chain they produce: Ig lambda (IGLL) vs Ig kappa (IGLK).,CGP,C2,18,24
Cohort,-0.08562627171646592,0.05540988431491514,-1.5453248599080214,0.12264705267203056,LGP Proband,Down-regulated genes discriminating multiple myeloma samples by the ype of immunoglobulin light chain they produce: Ig lambda (IGLL) vs Ig kappa (IGLK).,CGP,C2,18,30
Cohort,-0.018039400895946404,0.015650424511248155,-1.1526461076491097,0.24940169715118649,LonGen OPEL,Down-regulated genes discriminating multiple myeloma samples by the ype of immunoglobulin light chain they produce: Ig lambda (IGLL) vs Ig kappa (IGLK).,CGP,C2,21,18
Cohort,0.0023464610172430557,0.03762527810824323,0.062363951450208024,0.9502914359723648,LGP Offspring,Up-regulated genes discriminating multiple myeloma samples by the ype of immunoglobulin light chain they produce: Ig lambda (IGLL) vs Ig kappa (IGLK).,CGP,C2,45,100
Cohort,-0.042842418112165784,0.10023541586667459,-0.4274179713999637,0.669185249255107,LGP Proband,Up-regulated genes discriminating multiple myeloma samples by the ype of immunoglobulin light chain they produce: Ig lambda (IGLL) vs Ig kappa (IGLK).,CGP,C2,45,133
Cohort,0.03091224294928468,0.035746156311085645,0.8647711009896226,0.38742496457695286,LonGen OPEL,Up-regulated genes discriminating multiple myeloma samples by the ype of immunoglobulin light chain they produce: Ig lambda (IGLL) vs Ig kappa (IGLK).,CGP,C2,81,112
Cohort,-0.013755217945498749,0.02373942527660448,-0.5794250612736905,0.562495434540651,LGP Offspring,Genes up-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] that may correlate with the morphological switch in these cells.,CGP,C2,19,35
Cohort,-0.03269533248184446,0.0649314486371075,-0.5035361626470705,0.6147203301526335,LGP Proband,Genes up-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] that may correlate with the morphological switch in these cells.,CGP,C2,19,41
Cohort,0.01240645695397374,0.02160996211610897,0.5741082232034755,0.5660567572968704,LonGen OPEL,Genes up-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] that may correlate with the morphological switch in these cells.,CGP,C2,30,41
Cohort,-0.00946563899886863,0.019642163284821827,-0.48190409893308717,0.6300300509584201,LGP Offspring,Top genes down-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] compared to the parental cell line sensitive to the drug.,CGP,C2,14,26
Cohort,0.023486809641998844,0.054421154168078856,0.4315750005863568,0.6661618705438813,LGP Proband,Top genes down-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] compared to the parental cell line sensitive to the drug.,CGP,C2,14,37
Cohort,0.012430704954444809,0.017826595996739737,0.6973123167607674,0.4858109696261159,LonGen OPEL,Top genes down-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] compared to the parental cell line sensitive to the drug.,CGP,C2,19,29
Cohort,-0.02909224396223882,0.01623052568462231,-1.7924400310584154,0.07350954544569759,LGP Offspring,Top genes up-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] compared to the parental cell line sensitive to the drug.,CGP,C2,13,14
Cohort,-0.03351062649339178,0.04716262802528875,-0.7105334858656154,0.4775720128121804,LGP Proband,Top genes up-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] compared to the parental cell line sensitive to the drug.,CGP,C2,13,25
Cohort,-0.011819232197726227,0.017057556572472335,-0.6929030044549422,0.4885725288321653,LonGen OPEL,Top genes up-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] compared to the parental cell line sensitive to the drug.,CGP,C2,22,24
Cohort,-0.030482070162968656,0.04432440603357837,-0.6877039737402612,0.4918751029123407,LGP Offspring,Genes down-regulated in corneal fibroblasts after treatment with IL1A [GeneID=3552].,CGP,C2,71,129
Cohort,0.04248522601282084,0.12763087917873286,0.33287576083625503,0.7393117240310749,LGP Proband,Genes down-regulated in corneal fibroblasts after treatment with IL1A [GeneID=3552].,CGP,C2,71,211
Cohort,0.043884501766204606,0.04117393282453308,1.06583216019764,0.28682269390027776,LonGen OPEL,Genes down-regulated in corneal fibroblasts after treatment with IL1A [GeneID=3552].,CGP,C2,115,159
Cohort,-0.10785950612722821,0.04675194310875282,-2.3070593210709767,0.021352853454143363,LGP Offspring,Genes up-regulated in corneal fibroblasts after treatment with IL1A [GeneID=3552].,CGP,C2,86,133
Cohort,-0.07013582902928213,0.12822107206860167,-0.5469914414048699,0.58453093610915,LGP Proband,Genes up-regulated in corneal fibroblasts after treatment with IL1A [GeneID=3552].,CGP,C2,86,204
Cohort,0.028561090027869118,0.04289960023019335,0.665765878344186,0.505753634417484,LonGen OPEL,Genes up-regulated in corneal fibroblasts after treatment with IL1A [GeneID=3552].,CGP,C2,116,148
Cohort,0.010190466973153895,0.015146156855089323,0.6728087574063221,0.501298886123207,LGP Offspring,Genes up-regulated by hypoxia in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.,CGP,C2,5,16
Cohort,-0.03086108853375837,0.04106037587364081,-0.7516026796425409,0.45250207176184465,LGP Proband,Genes up-regulated by hypoxia in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.,CGP,C2,5,22
Cohort,-0.023458076631897,0.012258519193167493,-1.9136142189973306,0.056027865444071075,LonGen OPEL,Genes up-regulated by hypoxia in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.,CGP,C2,16,7
Cohort,-0.0075267366687646305,0.020264168964341432,-0.37143080883352886,0.7104330654200273,LGP Offspring,Genes down-regulated in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.,CGP,C2,13,27
Cohort,-0.018153015874160548,0.06094122663433944,-0.2978774284128308,0.7658709040591171,LGP Proband,Genes down-regulated in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.,CGP,C2,13,44
Cohort,0.012064604342071033,0.016493893808006824,0.7314588345545411,0.4647142114507189,LonGen OPEL,Genes down-regulated in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.,CGP,C2,19,24
Cohort,8.346379041984683e-4,0.012196091985507513,0.06843486464272815,0.9454597057240265,LGP Offspring,Genes up-regulated in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.,CGP,C2,5,10
Cohort,-0.011917338556150302,0.036534696027607436,-0.3261923555391009,0.7443606570991594,LGP Proband,Genes up-regulated in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.,CGP,C2,5,17
Cohort,0.012245407555362353,0.011678738371161531,1.0485214383772914,0.2947166795091376,LonGen OPEL,Genes up-regulated in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.,CGP,C2,8,13
Cohort,-0.02382061076962602,0.018996286338716716,-1.2539614504060592,0.21028946948715624,LGP Offspring,Genes consistently and robustly repressed by estradiol [PubChem=5757] in MCF7 cells (breast cancer); this reperession was prevented by fulvestrant [PubChem=3478439].,CGP,C2,13,21
Cohort,-0.048626339985389816,0.05042336605607262,-0.9643612433829893,0.3351443815437335,LGP Proband,Genes consistently and robustly repressed by estradiol [PubChem=5757] in MCF7 cells (breast cancer); this reperession was prevented by fulvestrant [PubChem=3478439].,CGP,C2,13,24
Cohort,-0.01334491012352421,0.01688508988157261,-0.7903369314064509,0.42956641155888564,LonGen OPEL,Genes consistently and robustly repressed by estradiol [PubChem=5757] in MCF7 cells (breast cancer); this reperession was prevented by fulvestrant [PubChem=3478439].,CGP,C2,25,20
Cohort,-0.05146713499663051,0.036405459468041974,-1.413720242751234,0.15790439292969832,LGP Offspring,"Down-regulated genes in A2780 cells (ovarian cancer) treated with 17AAG [PubChem=6440175], a chemical with anticancer properties.",CGP,C2,47,77
Cohort,0.04843346824424812,0.09151710907702833,0.5292285642838929,0.5967877332076521,LGP Proband,"Down-regulated genes in A2780 cells (ovarian cancer) treated with 17AAG [PubChem=6440175], a chemical with anticancer properties.",CGP,C2,47,95
Cohort,-0.0340301866374884,0.027789499346980568,-1.224569979206405,0.22109956255585203,LonGen OPEL,"Down-regulated genes in A2780 cells (ovarian cancer) treated with 17AAG [PubChem=6440175], a chemical with anticancer properties.",CGP,C2,55,60
Cohort,7.873999283798928e-4,0.03333741297757521,0.023619107124765386,0.9811634011953323,LGP Offspring,"Up-regulated genes in A2780 cells (ovarian cancer) treated with 17AAG [PubChem=6440175], a chemical with anticancer properties.",CGP,C2,43,79
Cohort,-0.06782970507052236,0.09814299867786805,-0.6911313693721327,0.4896753104309075,LGP Proband,"Up-regulated genes in A2780 cells (ovarian cancer) treated with 17AAG [PubChem=6440175], a chemical with anticancer properties.",CGP,C2,43,108
Cohort,0.003922162181698738,0.030752543508740453,0.12753944013066712,0.8985456713400821,LonGen OPEL,"Up-regulated genes in A2780 cells (ovarian cancer) treated with 17AAG [PubChem=6440175], a chemical with anticancer properties.",CGP,C2,64,73
Cohort,0.005695773381153423,0.02477460202617787,0.22990372863043507,0.8182361273027663,LGP Offspring,Literature curated collection of genes marking normal and cancer stem cells.,CGP,C2,19,45
Cohort,-0.12314958066855208,0.0636248435544521,-1.9355580900274731,0.053259552739019035,LGP Proband,Literature curated collection of genes marking normal and cancer stem cells.,CGP,C2,19,48
Cohort,-0.007694686322197322,0.02431977461785309,-0.31639628422167493,0.751784687943987,LonGen OPEL,Literature curated collection of genes marking normal and cancer stem cells.,CGP,C2,39,43
Cohort,-0.007501578168898256,0.09908985776041045,-0.07570480307920449,0.9396763528748928,LGP Offspring,Genes down-regulated in response to both hypoxia and overexpression of an active form of HIF1A [GeneID=3091].,CGP,C2,317,646
Cohort,-0.1738279663950443,0.2630915195407107,-0.6607129211101243,0.5089788911409441,LGP Proband,Genes down-regulated in response to both hypoxia and overexpression of an active form of HIF1A [GeneID=3091].,CGP,C2,317,856
Cohort,-0.047553209215394535,0.08668013159035202,-0.5486056417187934,0.5834299468424592,LonGen OPEL,Genes down-regulated in response to both hypoxia and overexpression of an active form of HIF1A [GeneID=3091].,CGP,C2,502,583
Cohort,-0.05657355363080938,0.08334545058456609,-0.6787839436227809,0.49750708040987357,LGP Offspring,Genes up-regulated in response to both hypoxia and overexpression of an active form of HIF1A [GeneID=3091].,CGP,C2,229,458
Cohort,-0.13178278862039086,0.23021450277523067,-0.5724347816134617,0.5671817316949529,LGP Proband,Genes up-regulated in response to both hypoxia and overexpression of an active form of HIF1A [GeneID=3091].,CGP,C2,229,638
Cohort,0.03159597633753684,0.07221907940005846,0.43750178761640734,0.6618661561101395,LonGen OPEL,Genes up-regulated in response to both hypoxia and overexpression of an active form of HIF1A [GeneID=3091].,CGP,C2,351,424
Cohort,-0.0017580607676858154,0.007787222129523519,-0.22576224723583,0.8214545788713066,LGP Offspring,Genes down-regulated in HCT116 cells (colon cancer) after treatment with amifostine [PubChem=2141] depending on the presence of TP53 [GeneID=7157]: TP53-positive vs TP53-null cells.,CGP,C2,2,4
Cohort,0.009304641792788724,0.020829537602730475,0.44670419335516165,0.655204622991947,LGP Proband,Genes down-regulated in HCT116 cells (colon cancer) after treatment with amifostine [PubChem=2141] depending on the presence of TP53 [GeneID=7157]: TP53-positive vs TP53-null cells.,CGP,C2,2,5
Cohort,-0.004868508513425783,0.00448979981549831,-1.08434868223305,0.27853854244378834,LonGen OPEL,Genes down-regulated in HCT116 cells (colon cancer) after treatment with amifostine [PubChem=2141] depending on the presence of TP53 [GeneID=7157]: TP53-positive vs TP53-null cells.,CGP,C2,2,1
Cohort,-0.04822922163993035,0.022519512232159533,-2.1416636889255285,0.0325773357885671,LGP Offspring,Genes up-regulated in HCT116 cells (colon cancer) after treatment with amifostine [PubChem=2141] depending on the presence of TP53 [GeneID=7157]: TP53-positive vs TP53-null cells.,CGP,C2,22,24
Cohort,-0.014421920476781754,0.06279300952340654,-0.22967398100907843,0.8184014302180513,LGP Proband,Genes up-regulated in HCT116 cells (colon cancer) after treatment with amifostine [PubChem=2141] depending on the presence of TP53 [GeneID=7157]: TP53-positive vs TP53-null cells.,CGP,C2,22,40
Cohort,0.013330542724901315,0.017562192332362652,0.7590477585384665,0.4480486940266728,LonGen OPEL,Genes up-regulated in HCT116 cells (colon cancer) after treatment with amifostine [PubChem=2141] depending on the presence of TP53 [GeneID=7157]: TP53-positive vs TP53-null cells.,CGP,C2,16,26
Cohort,-0.10607131803015683,0.08863526545679651,-1.1967168765558578,0.2318364495204663,LGP Offspring,"Strongly downregulated genes from differential gene expression analysis of platelets from 10 combined ICU and Non-ICU COVID-19 patients and, for comparison, 5 healthy donors",CGP,C2,266,497
Cohort,-0.36528943150183407,0.2406476269983557,-1.5179432104033588,0.12940767335708414,LGP Proband,"Strongly downregulated genes from differential gene expression analysis of platelets from 10 combined ICU and Non-ICU COVID-19 patients and, for comparison, 5 healthy donors",CGP,C2,266,680
Cohort,0.07520541356582337,0.07923577413437202,0.9491345845663884,0.3428402340345582,LonGen OPEL,"Strongly downregulated genes from differential gene expression analysis of platelets from 10 combined ICU and Non-ICU COVID-19 patients and, for comparison, 5 healthy donors",CGP,C2,390,497
Cohort,0.09372109275381253,0.07255209987714897,1.2917764325568604,0.19687604606321493,LGP Offspring,"Strongly upregulated genes from differential gene expression analysis of platelets from 10 combined ICU and Non-ICU COVID-19 patients and, for comparison, 5 healthy donors",CGP,C2,165,394
Cohort,0.18371411990341063,0.193278372480907,0.9505156606260166,0.3421256646800014,LGP Proband,"Strongly upregulated genes from differential gene expression analysis of platelets from 10 combined ICU and Non-ICU COVID-19 patients and, for comparison, 5 healthy donors",CGP,C2,165,488
Cohort,-0.10178725782979944,0.06570577052101022,-1.5491372678941757,0.12174619649050608,LonGen OPEL,"Strongly upregulated genes from differential gene expression analysis of platelets from 10 combined ICU and Non-ICU COVID-19 patients and, for comparison, 5 healthy donors",CGP,C2,292,325
Cohort,-0.05445156066917076,0.07109377858863018,-0.7659117541668974,0.44399615619373833,LGP Offspring,Strongly downregualted genes from differential gene expression analysis of platelets from 4 ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,165,317
Cohort,-0.23739544486893285,0.19502579436938078,-1.2172515211977732,0.2238528484593057,LGP Proband,Strongly downregualted genes from differential gene expression analysis of platelets from 4 ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,165,443
Cohort,0.049898815491794965,0.06567000963773101,0.7598417567937339,0.44757415686556457,LonGen OPEL,Strongly downregualted genes from differential gene expression analysis of platelets from 4 ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,260,329
Cohort,0.15089495224419341,0.06584636261926669,2.2916216817729196,0.022234111012872003,LGP Offspring,Strongly upregulated genes from differential gene expression analysis of platelets from 4 ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,133,344
Cohort,0.11797906204893013,0.17720907331312571,0.6657619716822453,0.5057473443961457,LGP Proband,Strongly upregulated genes from differential gene expression analysis of platelets from 4 ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,133,426
Cohort,-0.0352286327823038,0.06123217924440272,-0.5753287440855549,0.5652315755266868,LonGen OPEL,Strongly upregulated genes from differential gene expression analysis of platelets from 4 ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,236,276
Cohort,-0.06378954996522306,0.07889459843567104,-0.8085414113266028,0.41906342861745915,LGP Offspring,Strongly downregulated genes from differential gene expression analysis of platelets from 6 Non-ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,217,416
Cohort,-0.3446480362205988,0.22362841684005216,-1.5411638694697045,0.12365622716822093,LGP Proband,Strongly downregulated genes from differential gene expression analysis of platelets from 6 Non-ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,217,585
Cohort,0.04554455109871057,0.06932126236176517,0.6570069491958808,0.5113663565077826,LonGen OPEL,Strongly downregulated genes from differential gene expression analysis of platelets from 6 Non-ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,315,401
Cohort,0.023169104432091393,0.056442945038485536,0.4104871639191324,0.6815786884966395,LGP Offspring,Strongly upregulated genes from differential gene expression analysis of platelets from 6 Non-ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,110,252
Cohort,0.15380919856736405,0.15529814582803086,0.9904123307285614,0.32225987316367777,LGP Proband,Strongly upregulated genes from differential gene expression analysis of platelets from 6 Non-ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,110,297
Cohort,-0.09300129120276751,0.05350673017952478,-1.7381232396509994,0.08257580205208268,LonGen OPEL,Strongly upregulated genes from differential gene expression analysis of platelets from 6 Non-ICU patients with SARS-CoV-2 infection as well as 5 healthy donors.,CGP,C2,189,206
Cohort,0.014281663636552047,0.03962946018043153,0.36037996913226017,0.7186755766962813,LGP Offspring,Genes down-regulated in chondrosarcoma and ovarian carcinoma cell lines which developed resistance to trabectedin [PubChem=3199].,CGP,C2,49,121
Cohort,0.07056569121217698,0.1107024264563371,0.6374358130262779,0.5240159559739314,LGP Proband,Genes down-regulated in chondrosarcoma and ovarian carcinoma cell lines which developed resistance to trabectedin [PubChem=3199].,CGP,C2,49,155
Cohort,0.007093122619278555,0.036783474373540716,0.1928344926650218,0.8471377776535096,LonGen OPEL,Genes down-regulated in chondrosarcoma and ovarian carcinoma cell lines which developed resistance to trabectedin [PubChem=3199].,CGP,C2,87,103
Cohort,-0.00698989736782189,0.01998030967008219,-0.34983929094393945,0.7265682733271055,LGP Offspring,Genes up-regulated in chondrosarcoma and ovarian carcinoma cell lines which developed resistance to trabectedin [PubChem=3199].,CGP,C2,14,25
Cohort,-0.04201298049846114,0.053291731319260245,-0.7883583336178303,0.43071115696890594,LGP Proband,Genes up-regulated in chondrosarcoma and ovarian carcinoma cell lines which developed resistance to trabectedin [PubChem=3199].,CGP,C2,14,33
Cohort,0.026204541052197085,0.017296733184403734,1.5149994379184515,0.13016951742767535,LonGen OPEL,Genes up-regulated in chondrosarcoma and ovarian carcinoma cell lines which developed resistance to trabectedin [PubChem=3199].,CGP,C2,16,31
Cohort,0.006278792315373598,0.030316669216631717,0.2071069308606321,0.8359887186849833,LGP Offspring,Endoplasmic retuculum (ER) stress response (caused by  tunicamycin [PubChem=5282055]) genes dependent on CHOP [GeneID=13198].,CGP,C2,29,68
Cohort,0.06683688911280798,0.07396321402766369,0.9036504158379283,0.36644173269869895,LGP Proband,Endoplasmic retuculum (ER) stress response (caused by  tunicamycin [PubChem=5282055]) genes dependent on CHOP [GeneID=13198].,CGP,C2,29,66
Cohort,0.015239268478657236,0.02212800601725905,0.6886869276323928,0.4912209726110285,LonGen OPEL,Endoplasmic retuculum (ER) stress response (caused by  tunicamycin [PubChem=5282055]) genes dependent on CHOP [GeneID=13198].,CGP,C2,32,43
Cohort,0.014780038333380272,0.04363953840768962,0.3386845707510031,0.7349525355091754,LGP Offspring,Cluster 10: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and TSA [PubChem=5222465;5562] with the same kinetics with which each alters the level of histone H4 acetylation.,CGP,C2,58,122
Cohort,0.04093539870427291,0.11624254156226317,0.35215505574907463,0.7248109457803358,LGP Proband,Cluster 10: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and TSA [PubChem=5222465;5562] with the same kinetics with which each alters the level of histone H4 acetylation.,CGP,C2,58,167
Cohort,0.028923802063874446,0.036821233330603186,0.7855196430868882,0.43238270340642393,LonGen OPEL,Cluster 10: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and TSA [PubChem=5222465;5562] with the same kinetics with which each alters the level of histone H4 acetylation.,CGP,C2,90,118
Cohort,0.006435635327241093,0.04937705063113208,0.13033656820286962,0.8963389239742021,LGP Offspring,Cluster 9: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate and TSA [PubChem=5222465;5562] with the same kinetics with which each alters the level of histone H4 acetylation.,CGP,C2,75,162
Cohort,0.14862800718359134,0.13340722127001028,1.114092668812694,0.26556039623074695,LGP Proband,Cluster 9: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate and TSA [PubChem=5222465;5562] with the same kinetics with which each alters the level of histone H4 acetylation.,CGP,C2,75,237
Cohort,-0.018574376145623968,0.04391190309663888,-0.4229918276314855,0.6724154726592748,LonGen OPEL,Cluster 9: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate and TSA [PubChem=5222465;5562] with the same kinetics with which each alters the level of histone H4 acetylation.,CGP,C2,137,168
Cohort,0.0054012902802284875,0.01494619188577231,0.3613823722797326,0.7179265409739995,LGP Offspring,"Cluster 1: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].",CGP,C2,6,12
Cohort,0.0037187190130658645,0.04677598819063186,0.07950059756964444,0.9366535277347596,LGP Proband,"Cluster 1: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].",CGP,C2,6,26
Cohort,-0.011067119877524284,0.00929441904178953,-1.1907274492105793,0.2341155592080198,LonGen OPEL,"Cluster 1: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].",CGP,C2,8,5
Cohort,-0.011776217506604422,0.009532644758705765,-1.2353567981068103,0.21712689971246474,LGP Offspring,"Cluster 2: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].",CGP,C2,5,4
Cohort,-0.03251946873149011,0.03127007173787339,-1.039955040848323,0.2986621774416669,LGP Proband,"Cluster 2: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].",CGP,C2,5,11
Cohort,0.0025322502883335313,0.008137097737144532,0.31119821466248576,0.7557314192511443,LonGen OPEL,"Cluster 2: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].",CGP,C2,4,6
Cohort,0.016728444180168004,0.014878390401292279,1.1243450218052509,0.26126576627053333,LGP Offspring,"Cluster 8: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].",CGP,C2,4,16
Cohort,-0.003902240657658014,0.04493054887434121,-0.08685050050404554,0.930811192785225,LGP Proband,"Cluster 8: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].",CGP,C2,4,28
Cohort,0.01238761092665816,0.012602137436377695,0.9829769742789602,0.3259174440998971,LonGen OPEL,"Cluster 8: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].",CGP,C2,8,14
Cohort,-0.007897396952586955,0.023143681152703606,-0.34123339759476395,0.7330339174115146,LGP Offspring,Cluster 4: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and sulindac [PubChem=5222465;5352].,CGP,C2,18,36
Cohort,0.005341380352023306,0.0620814180437473,0.08603831098476782,0.9314566131224082,LGP Proband,Cluster 4: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and sulindac [PubChem=5222465;5352].,CGP,C2,18,42
Cohort,0.008224680810697113,0.01953654394155298,0.42098954837164126,0.6738763550708509,LonGen OPEL,Cluster 4: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and sulindac [PubChem=5222465;5352].,CGP,C2,23,34
Cohort,0.006102411268653692,0.038507473298933746,0.15847342725607147,0.874131086957947,LGP Offspring,Cluster 6: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and sulindac [PubChem=5222465;5352].,CGP,C2,47,106
Cohort,0.05035976356021137,0.10643768151152064,0.4731384867187333,0.6362381872057752,LGP Proband,Cluster 6: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and sulindac [PubChem=5222465;5352].,CGP,C2,47,145
Cohort,-0.032612232554563796,0.03254186918344527,-1.0021622412259688,0.31656978505177386,LonGen OPEL,Cluster 6: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and sulindac [PubChem=5222465;5352].,CGP,C2,78,74
Cohort,0.027429443995902705,0.026219059379195997,1.0461643035778434,0.2958591027568844,LGP Offspring,Cluster 5: genes up-regulated in SW260 cells (colon cancer) by curcumin and sulindac [PubChem=969516;5352].,CGP,C2,17,48
Cohort,-0.06071240716755087,0.06974606603968928,-0.8704778723003852,0.3842897834823089,LGP Proband,Cluster 5: genes up-regulated in SW260 cells (colon cancer) by curcumin and sulindac [PubChem=969516;5352].,CGP,C2,17,66
Cohort,0.011729234667020031,0.02113395771487058,0.5549947068724822,0.5790541986253028,LonGen OPEL,Cluster 5: genes up-regulated in SW260 cells (colon cancer) by curcumin and sulindac [PubChem=969516;5352].,CGP,C2,28,38
Cohort,-8.510789710216365e-4,0.011523653165552629,-0.07385496237996347,0.9411476406722663,LGP Offspring,Cluster 7: genes up-regulated in SW260 cells (colon cancer) by curcumin and sulindac [PubChem=969516;5352].,CGP,C2,4,9
Cohort,0.08675261100382613,0.03589623926434397,2.4167604401388703,0.015873009115435013,LGP Proband,Cluster 7: genes up-regulated in SW260 cells (colon cancer) by curcumin and sulindac [PubChem=969516;5352].,CGP,C2,4,15
Cohort,0.0014859429034579852,0.006817448862273872,0.21796172343599626,0.827514796818175,LonGen OPEL,Cluster 7: genes up-regulated in SW260 cells (colon cancer) by curcumin and sulindac [PubChem=969516;5352].,CGP,C2,3,4
Cohort,-0.05710411959195428,0.07873936234369157,-0.7252296423572617,0.46856212727094537,LGP Offspring,Genes down-regulated in adult fibroblasts with inactivated RB1 [GeneID=5925] by Cre-lox: acute loss of function (LOF) of RB1.,CGP,C2,202,407
Cohort,-0.24580241163559002,0.2087271535064073,-1.177625467057618,0.2392818890686229,LGP Proband,Genes down-regulated in adult fibroblasts with inactivated RB1 [GeneID=5925] by Cre-lox: acute loss of function (LOF) of RB1.,CGP,C2,202,575
Cohort,-0.019577677561653867,0.07105165396244928,-0.27554147538916757,0.7829717773429741,LonGen OPEL,Genes down-regulated in adult fibroblasts with inactivated RB1 [GeneID=5925] by Cre-lox: acute loss of function (LOF) of RB1.,CGP,C2,305,367
Cohort,-0.09291648168221145,0.0790619524461956,-1.1752363660060676,0.24031393457279818,LGP Offspring,Genes up-regulated in adult fibroblasts with inactivated RB1 [GeneID=5925] by Cre-lox: acute loss of function (LOF) of RB1.,CGP,C2,224,417
Cohort,-0.2503513572496468,0.21850032740096606,-1.1457710852315177,0.2522185369889302,LGP Proband,Genes up-regulated in adult fibroblasts with inactivated RB1 [GeneID=5925] by Cre-lox: acute loss of function (LOF) of RB1.,CGP,C2,224,574
Cohort,-0.15930889333113374,0.06523133630908419,-2.4422141618605506,0.014814071417019063,LonGen OPEL,Genes up-regulated in adult fibroblasts with inactivated RB1 [GeneID=5925] by Cre-lox: acute loss of function (LOF) of RB1.,CGP,C2,362,362
Cohort,-0.08660159778658934,0.04580183144161568,-1.8907889719864535,0.059079897039747885,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblasts) isolated from RB1 [GeneID=5925] knockout mice: chronic loss of function (LOF) of RB1.,CGP,C2,73,123
Cohort,-0.22221126725523205,0.12448525234563573,-1.7850409029838983,0.07461803177993029,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblasts) isolated from RB1 [GeneID=5925] knockout mice: chronic loss of function (LOF) of RB1.,CGP,C2,73,177
Cohort,0.0014833578676579295,0.04389844367663974,0.03379067099928393,0.9730525463274704,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblasts) isolated from RB1 [GeneID=5925] knockout mice: chronic loss of function (LOF) of RB1.,CGP,C2,123,141
Cohort,-0.02790213439580559,0.05904731752453311,-0.4725385600152411,0.6366949415796658,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblasts) isolated from RB1 [GeneID=5925] knockout mice: chronic loss of function (LOF) of RB1.,CGP,C2,111,224
Cohort,-0.2744307811182758,0.15669864880338572,-1.7513283184886421,0.0802569600010314,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblasts) isolated from RB1 [GeneID=5925] knockout mice: chronic loss of function (LOF) of RB1.,CGP,C2,111,296
Cohort,0.004409893037969342,0.05192572425565251,0.08492694326722446,0.9323408264963163,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblasts) isolated from RB1 [GeneID=5925] knockout mice: chronic loss of function (LOF) of RB1.,CGP,C2,168,203
Cohort,0.003276451149970983,0.018612951466206843,0.1760307147375104,0.8603225309498898,LGP Offspring,Non-histone proteins that are acetylated.,CGP,C2,9,22
Cohort,0.015616377409169236,0.04746460341677005,0.3290110163156173,0.7422299622565263,LGP Proband,Non-histone proteins that are acetylated.,CGP,C2,9,22
Cohort,0.01109625351703611,0.014421092848039033,0.7694460908033727,0.44185679513153164,LonGen OPEL,Non-histone proteins that are acetylated.,CGP,C2,12,20
Cohort,0.016379907324257106,0.022616054928207632,0.724260149537727,0.46915661371867723,LGP Offspring,Genes whose transcription is down-regulated by histone deacetylase inhibitors.,CGP,C2,13,34
Cohort,-0.018789318211189364,0.04619021813927624,-0.40678132661193306,0.6842729715225233,LGP Proband,Genes whose transcription is down-regulated by histone deacetylase inhibitors.,CGP,C2,13,23
Cohort,0.01880948899807406,0.014184736428440807,1.3260372579331463,0.18520772861094306,LonGen OPEL,Genes whose transcription is down-regulated by histone deacetylase inhibitors.,CGP,C2,12,19
Cohort,-0.016450278064898627,0.02798768255013431,-0.5877684954955188,0.5568839783353468,LGP Offspring,Genes whose transcription is up-regulated by histone deacetylase inhibitors.,CGP,C2,29,50
Cohort,-0.12157448877853275,0.08047760647126943,-1.5106623334024594,0.13125327830202693,LGP Proband,Genes whose transcription is up-regulated by histone deacetylase inhibitors.,CGP,C2,29,71
Cohort,0.008017419851290506,0.024138961261394195,0.33213607513894505,0.7398739487827716,LonGen OPEL,Genes whose transcription is up-regulated by histone deacetylase inhibitors.,CGP,C2,42,50
Cohort,0.02349955018706981,0.02171210445694986,1.0823248494250775,0.2794941267538651,LGP Offspring,Genes down-regulated in the influenza-specific CD8+ [GeneID=925] T lymphocytes from bronchoalveolar lavage (BAL) compared to those from spleen.,CGP,C2,11,31
Cohort,-0.03858330202417065,0.0570212716497149,-0.6766475195641057,0.4988172384621703,LGP Proband,Genes down-regulated in the influenza-specific CD8+ [GeneID=925] T lymphocytes from bronchoalveolar lavage (BAL) compared to those from spleen.,CGP,C2,11,39
Cohort,1.7858182386457703e-5,0.017906033571027373,9.973276502370076e-4,0.9992044976807631,LonGen OPEL,Genes down-regulated in the influenza-specific CD8+ [GeneID=925] T lymphocytes from bronchoalveolar lavage (BAL) compared to those from spleen.,CGP,C2,22,26
Cohort,-0.014530593036484879,0.013341311819303746,-1.089142749475381,0.2764790541364811,LGP Offspring,Genes up-regulated in the influenza-specific CD8+ [GeneID=925] T lymphocytes from bronchoalveolar lavage (BAL) compared to those from spleen.,CGP,C2,8,10
Cohort,-0.04088784399051431,0.033927108150682936,-1.2051673785138466,0.2284805359821932,LGP Proband,Genes up-regulated in the influenza-specific CD8+ [GeneID=925] T lymphocytes from bronchoalveolar lavage (BAL) compared to those from spleen.,CGP,C2,8,11
Cohort,0.024547783381749823,0.012521544950408447,1.9604436576294113,0.050292378391868495,LonGen OPEL,Genes up-regulated in the influenza-specific CD8+ [GeneID=925] T lymphocytes from bronchoalveolar lavage (BAL) compared to those from spleen.,CGP,C2,5,17
Cohort,-0.17793695968867076,0.13797499547173392,-1.289631929903731,0.19761952263817134,LGP Offspring,Genes with promoters bound by E2F4 [GeneID=1874] in unstimulated hybridoma cells.,CGP,C2,644,1269
Cohort,-1.032227293382523,0.3842129909448828,-2.686601748795633,0.007361926649246931,LGP Proband,Genes with promoters bound by E2F4 [GeneID=1874] in unstimulated hybridoma cells.,CGP,C2,644,1830
Cohort,0.15636319666477522,0.12609135147647677,1.2400786797336047,0.21531171912586206,LonGen OPEL,Genes with promoters bound by E2F4 [GeneID=1874] in unstimulated hybridoma cells.,CGP,C2,1003,1248
Cohort,-0.20899159231799053,0.16316707514848525,-1.2808441416738277,0.20068766641123859,LGP Offspring,Genes with promoters bound by FOXP3 [GeneID=50943] in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].,CGP,C2,827,1644
Cohort,-0.7328584181634079,0.4369463515898643,-1.6772274570936314,0.09387272202936162,LGP Proband,Genes with promoters bound by FOXP3 [GeneID=50943] in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].,CGP,C2,827,2230
Cohort,0.26917398385331265,0.1337166376267481,2.0130178908975815,0.04444898057322949,LonGen OPEL,Genes with promoters bound by FOXP3 [GeneID=50943] in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].,CGP,C2,1201,1548
Cohort,-0.4480023059047884,0.18585734131464776,-2.410463330293429,0.016198196153203476,LGP Offspring,Genes with promoters bound by FOXP3 [GeneID=50943] in unstimulated hybridoma cells.,CGP,C2,1058,2034
Cohort,-0.8402777626138314,0.49690392426089475,-1.691026618201251,0.09120533931616956,LGP Proband,Genes with promoters bound by FOXP3 [GeneID=50943] in unstimulated hybridoma cells.,CGP,C2,1058,2825
Cohort,-0.19962273702104055,0.1583829329590515,-1.2603803534352482,0.20790152851126076,LonGen OPEL,Genes with promoters bound by FOXP3 [GeneID=50943] in unstimulated hybridoma cells.,CGP,C2,1621,1854
Cohort,0.021111043402659107,0.022527629937202212,0.9371178176092217,0.34903262749060004,LGP Offspring,Direct FOXP3 [GeneID=50943] targets that exhibit consistent transcriptional behavior in hybridoma and in ex vivo T lymphocytes.,CGP,C2,13,39
Cohort,0.08144184640840665,0.06819642076081812,1.1942246455139272,0.23272964587830805,LGP Proband,Direct FOXP3 [GeneID=50943] targets that exhibit consistent transcriptional behavior in hybridoma and in ex vivo T lymphocytes.,CGP,C2,13,60
Cohort,-0.04587502017657227,0.022926060815697234,-2.0009987998096093,0.04573162351466104,LonGen OPEL,Direct FOXP3 [GeneID=50943] targets that exhibit consistent transcriptional behavior in hybridoma and in ex vivo T lymphocytes.,CGP,C2,39,31
Cohort,0.026069702208160114,0.03325904479598489,0.7838379715375142,0.4334097408010378,LGP Offspring,Genes down-regulated by FOXP3 [GeneID=50943] in both ex vivo and hybridoma cells.,CGP,C2,29,82
Cohort,0.21970516452998473,0.10429375339302997,2.106599459528779,0.03545048261346062,LGP Proband,Genes down-regulated by FOXP3 [GeneID=50943] in both ex vivo and hybridoma cells.,CGP,C2,29,139
Cohort,0.0021311986806412638,0.0312352800715554,0.06823049691755614,0.9456192854675058,LonGen OPEL,Genes down-regulated by FOXP3 [GeneID=50943] in both ex vivo and hybridoma cells.,CGP,C2,61,78
Cohort,9.78137999413316e-4,0.019466595493926785,0.05024699874811067,0.9599404018372919,LGP Offspring,"Genes with promoters bound by FOXP3 [GeneID=50943], dependent on it, and down-regulated in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].",CGP,C2,12,25
Cohort,-0.035582642839769675,0.05253933789264791,-0.6772571613383223,0.4984306207281133,LGP Proband,"Genes with promoters bound by FOXP3 [GeneID=50943], dependent on it, and down-regulated in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].",CGP,C2,12,32
Cohort,-0.018879655567135223,0.01590100780458712,-1.1873244639052891,0.2354538539749884,LonGen OPEL,"Genes with promoters bound by FOXP3 [GeneID=50943], dependent on it, and down-regulated in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].",CGP,C2,22,17
Cohort,0.004622847689708793,0.025884637823356475,0.17859425815637492,0.8583098125183887,LGP Offspring,"Genes with promoters bound by FOXP3 [GeneID=50943], dependent on it, and up-regulated in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].",CGP,C2,20,47
Cohort,-0.060830563603803386,0.07434959554309784,-0.8181693949974759,0.41349416228736513,LGP Proband,"Genes with promoters bound by FOXP3 [GeneID=50943], dependent on it, and up-regulated in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].",CGP,C2,20,68
Cohort,0.007605600909015093,0.022436294908801765,0.33898649219624105,0.7347093111330224,LonGen OPEL,"Genes with promoters bound by FOXP3 [GeneID=50943], dependent on it, and up-regulated in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].",CGP,C2,33,41
Cohort,-0.06422934305017358,0.04155234279526268,-1.545745407584967,0.12263405794781351,LGP Offspring,Genes up-regulated by FOXP3 [GeneID=50943] in both ex vivo and hybridoma cells.,CGP,C2,66,112
Cohort,-0.1321161335109078,0.10562244091321396,-1.2508339361278606,0.21134585982600207,LGP Proband,Genes up-regulated by FOXP3 [GeneID=50943] in both ex vivo and hybridoma cells.,CGP,C2,66,125
Cohort,0.01541701717776752,0.03514310763796628,0.43869248378911146,0.6610034151906484,LonGen OPEL,Genes up-regulated by FOXP3 [GeneID=50943] in both ex vivo and hybridoma cells.,CGP,C2,81,114
Cohort,-0.05840317097646813,0.11547446545217493,-0.5057669740905315,0.6131851217766129,LGP Offspring,"Genes with promoters occupied by PML-RARA fusion [GeneID=5371,5914] protein in acute promyelocytic leukemia(APL) cells NB4 and two APL primary blasts, based on  Chip-seq data.",CGP,C2,423,865
Cohort,-0.747735285583233,0.32118877217585606,-2.328024359375289,0.020149128861506587,LGP Proband,"Genes with promoters occupied by PML-RARA fusion [GeneID=5371,5914] protein in acute promyelocytic leukemia(APL) cells NB4 and two APL primary blasts, based on  Chip-seq data.",CGP,C2,423,1154
Cohort,-0.026766854908445784,0.0998362947543904,-0.26810745505224876,0.7886860686545875,LonGen OPEL,"Genes with promoters occupied by PML-RARA fusion [GeneID=5371,5914] protein in acute promyelocytic leukemia(APL) cells NB4 and two APL primary blasts, based on  Chip-seq data.",CGP,C2,701,837
Cohort,-0.11529849196393935,0.1399200654013181,-0.8240311468783318,0.41021249509352087,LGP Offspring,"Genes down-regulated in NB4 cells (acute promyelocytic leukemia, APL) in response to tretinoin [PubChem=444795]; based on Chip-seq data.",CGP,C2,567,1162
Cohort,-0.04786502124270587,0.3609328734484603,-0.13261474574313273,0.8945300584005893,LGP Proband,"Genes down-regulated in NB4 cells (acute promyelocytic leukemia, APL) in response to tretinoin [PubChem=444795]; based on Chip-seq data.",CGP,C2,567,1573
Cohort,0.06667858483484554,0.12224912736375278,0.5454319901723563,0.5856092442055525,LonGen OPEL,"Genes down-regulated in NB4 cells (acute promyelocytic leukemia, APL) in response to tretinoin [PubChem=444795]; based on Chip-seq data.",CGP,C2,898,1085
Cohort,-0.18215669878329838,0.15103583845257085,-1.206049508842236,0.2282203366114218,LGP Offspring,"Genes up-regulated in NB4 cells (acute promyelocytic leukemia, APL) in response to tretinoin [PubChem=444795]; based on Chip-seq data.",CGP,C2,755,1502
Cohort,0.19465293215669172,0.42820932568098435,0.45457424788013145,0.6495338547882219,LGP Proband,"Genes up-regulated in NB4 cells (acute promyelocytic leukemia, APL) in response to tretinoin [PubChem=444795]; based on Chip-seq data.",CGP,C2,755,2206
Cohort,-0.19790378874454825,0.1304236279148705,-1.5173921467184082,0.1295647366140533,LonGen OPEL,"Genes up-regulated in NB4 cells (acute promyelocytic leukemia, APL) in response to tretinoin [PubChem=444795]; based on Chip-seq data.",CGP,C2,1271,1460
Cohort,-0.018912120770185264,0.035541369733069074,-0.5321156981912458,0.594820700608369,LGP Offspring,Interaction partners of class IIa histone deacetylases (HDAC).,CGP,C2,44,85
Cohort,-0.036834552004232746,0.10302346952803176,-0.35753554188165243,0.7207813815541505,LGP Proband,Interaction partners of class IIa histone deacetylases (HDAC).,CGP,C2,44,138
Cohort,-0.009250581980383131,0.03091769665244432,-0.2992002309994781,0.7648653732404901,LonGen OPEL,Interaction partners of class IIa histone deacetylases (HDAC).,CGP,C2,66,77
Cohort,0.014887909328400112,0.0214209348448127,0.6950167878413286,0.4872836005441197,LGP Offspring,NF-kB-controlled genes down-regulated in endothelial cells in response to viral GPCR protein.,CGP,C2,13,34
Cohort,-4.048911416992332e-4,0.056132070726737794,-0.007213187335816002,0.9942464840911956,LGP Proband,NF-kB-controlled genes down-regulated in endothelial cells in response to viral GPCR protein.,CGP,C2,13,39
Cohort,-0.019558292542620037,0.021962004298544637,-0.8905513484448281,0.3734389919379191,LonGen OPEL,NF-kB-controlled genes down-regulated in endothelial cells in response to viral GPCR protein.,CGP,C2,35,37
Cohort,-0.008381387728196571,0.026772442859295534,-0.313060252747407,0.7543314460941652,LGP Offspring,NF-kB-controlled genes up-regulated in endothelial cells in response to viral GPCR protein.,CGP,C2,25,49
Cohort,-0.011799980794125921,0.08385551480909027,-0.14071800550017918,0.8881266995237536,LGP Proband,NF-kB-controlled genes up-regulated in endothelial cells in response to viral GPCR protein.,CGP,C2,25,84
Cohort,-0.0049014020584987475,0.02883658376321688,-0.16997166164845212,0.8650756116927563,LonGen OPEL,NF-kB-controlled genes up-regulated in endothelial cells in response to viral GPCR protein.,CGP,C2,55,64
Cohort,-0.04568482308592122,0.04905185959826399,-0.9313576174294127,0.3520010989474619,LGP Offspring,Down-regulated genes in the expression signature of direct and paracrine viral GPCR signaling in endothelial cells.,CGP,C2,81,147
Cohort,-0.009328553612852184,0.1325646499540572,-0.07036984306212231,0.9439161630928219,LGP Proband,Down-regulated genes in the expression signature of direct and paracrine viral GPCR signaling in endothelial cells.,CGP,C2,81,198
Cohort,-0.012704497592428247,0.03880239540781734,-0.32741529121856044,0.7434398899685062,LonGen OPEL,Down-regulated genes in the expression signature of direct and paracrine viral GPCR signaling in endothelial cells.,CGP,C2,109,133
Cohort,-0.007674628313561649,0.0463456516435721,-0.16559543433728113,0.8685248506705596,LGP Offspring,Up-regulated genes in the expression signature of direct and paracrine viral GPCR signaling in endothelial cells.,CGP,C2,67,147
Cohort,0.09458162737647643,0.12606956167190975,0.7502336497577486,0.4533255892527722,LGP Proband,Up-regulated genes in the expression signature of direct and paracrine viral GPCR signaling in endothelial cells.,CGP,C2,67,185
Cohort,-0.007381811634294435,0.04241536396819928,-0.17403626760880594,0.8618812102722151,LonGen OPEL,Up-regulated genes in the expression signature of direct and paracrine viral GPCR signaling in endothelial cells.,CGP,C2,124,134
Cohort,0.02209831542290852,0.023703095398674233,0.9322966073091251,0.3515161083987932,LGP Offspring,Neutrophil-specific genes down-regulated in comparison of immature with mature neutrophils.,CGP,C2,15,39
Cohort,-0.05326831686973102,0.06306108403715018,-0.8447098187901416,0.39851512265678735,LGP Proband,Neutrophil-specific genes down-regulated in comparison of immature with mature neutrophils.,CGP,C2,15,52
Cohort,0.021535886799659506,0.022235252301325406,0.9685469950064739,0.3330654482240891,LonGen OPEL,Neutrophil-specific genes down-regulated in comparison of immature with mature neutrophils.,CGP,C2,29,45
Cohort,0.03484602987031535,0.02279399144728174,1.5287375162400905,0.12679729374073673,LGP Offspring,Neutrophil-specific genes up-regulated in comparison of immature with mature neutrophils.,CGP,C2,9,36
Cohort,0.11554422240548963,0.05872043070255714,1.9677005264278136,0.04943349421619479,LGP Proband,Neutrophil-specific genes up-regulated in comparison of immature with mature neutrophils.,CGP,C2,9,44
Cohort,-0.0031896150982036646,0.016321555388333873,-0.19542347664264276,0.8451113113008742,LonGen OPEL,Neutrophil-specific genes up-regulated in comparison of immature with mature neutrophils.,CGP,C2,19,20
Cohort,-0.19469339333051883,0.1425980396475713,-1.3653300831603317,0.17260349152527987,LGP Offspring,Genes down-regulated in mice with skin specific double knockout of both RB1 and TP53 [GeneID=5925;7157] by Cre-lox.,CGP,C2,620,1213
Cohort,-0.01738965459981372,0.38749443179504484,-0.044877172864800106,0.9642159545555582,LGP Proband,Genes down-regulated in mice with skin specific double knockout of both RB1 and TP53 [GeneID=5925;7157] by Cre-lox.,CGP,C2,620,1673
Cohort,-0.04126114359973929,0.11726199163778181,-0.3518714207685771,0.7250278219942111,LonGen OPEL,Genes down-regulated in mice with skin specific double knockout of both RB1 and TP53 [GeneID=5925;7157] by Cre-lox.,CGP,C2,986,1165
Cohort,-0.03995570378440583,0.1316742675233893,-0.3034435242049742,0.7616452457166167,LGP Offspring,Genes up-regulated in mice with skin specific double knockout of both RB1 and TP53 [GeneID=5925;7157] by Cre-lox.,CGP,C2,540,1136
Cohort,0.22244857483941632,0.3590979055179985,0.6194649743738673,0.5357792757419105,LGP Proband,Genes up-regulated in mice with skin specific double knockout of both RB1 and TP53 [GeneID=5925;7157] by Cre-lox.,CGP,C2,540,1575
Cohort,-0.1490644189636177,0.11889235722706744,-1.253776293449426,0.21029142226286224,LonGen OPEL,Genes up-regulated in mice with skin specific double knockout of both RB1 and TP53 [GeneID=5925;7157] by Cre-lox.,CGP,C2,915,1058
Cohort,-0.17591760435195236,0.12493159415516528,-1.4081114192256472,0.15955778967589712,LGP Offspring,Genes down-regulated in mice with skin specific knockout of RB1 [GeneID=5925] by Cre-lox.,CGP,C2,504,989
Cohort,-0.00640037437060576,0.35267730884799076,-0.01814796191882143,0.9855251567462457,LGP Proband,Genes down-regulated in mice with skin specific knockout of RB1 [GeneID=5925] by Cre-lox.,CGP,C2,504,1409
Cohort,0.032426247470465144,0.10960652049744299,0.29584232145405637,0.7674276601311297,LonGen OPEL,Genes down-regulated in mice with skin specific knockout of RB1 [GeneID=5925] by Cre-lox.,CGP,C2,823,1012
Cohort,-0.056144737320577426,0.1429829905202803,-0.39266724745566167,0.6946890475217103,LGP Offspring,Genes up-regulated in mice with skin specific knockout of RB1 [GeneID=5925] by Cre-lox.,CGP,C2,672,1395
Cohort,0.2758663835526469,0.3943095173472881,0.6996188816555438,0.48436043141895835,LGP Proband,Genes up-regulated in mice with skin specific knockout of RB1 [GeneID=5925] by Cre-lox.,CGP,C2,672,1868
Cohort,-0.1987134954348276,0.1307250391901984,-1.5200874803006132,0.1288860850213567,LonGen OPEL,Genes up-regulated in mice with skin specific knockout of RB1 [GeneID=5925] by Cre-lox.,CGP,C2,1096,1242
Cohort,-0.0528392832459943,0.05022127951911688,-1.0521293712933153,0.2931161391398926,LGP Offspring,Genes down-regulated by trabectedin [PubChem=3199] and its synthetic analog phthalascidin Pt 650 in HCT116 cells (colon cancer).,CGP,C2,84,158
Cohort,0.02275815865397536,0.14439699864741112,0.1576082527140767,0.8748036496323383,LGP Proband,Genes down-regulated by trabectedin [PubChem=3199] and its synthetic analog phthalascidin Pt 650 in HCT116 cells (colon cancer).,CGP,C2,84,240
Cohort,-0.012724261068537952,0.043970436498410745,-0.28938218680175837,0.7723642792319548,LonGen OPEL,Genes down-regulated by trabectedin [PubChem=3199] and its synthetic analog phthalascidin Pt 650 in HCT116 cells (colon cancer).,CGP,C2,138,160
Cohort,-0.15769943665745484,0.0993327604093261,-1.5875873780977583,0.11284726949701246,LGP Offspring,Genes down-regulated in at least 8 of 11 sarcoma cell lines by trabectedin [PubChem=3199].,CGP,C2,317,591
Cohort,-0.13506059148799762,0.2791497627628846,-0.48382843012738214,0.6286346473633807,LGP Proband,Genes down-regulated in at least 8 of 11 sarcoma cell lines by trabectedin [PubChem=3199].,CGP,C2,317,806
Cohort,-0.10821967566469429,0.07572228839871606,-1.4291654142154697,0.15334900614403776,LonGen OPEL,Genes down-regulated in at least 8 of 11 sarcoma cell lines by trabectedin [PubChem=3199].,CGP,C2,451,491
Cohort,-0.022110112957912077,0.03122068885699651,-0.7081878641174579,0.47907271236954607,LGP Offspring,Genes up-regulated in at least 8 of 11 sarcoma cell lines by trabectedin [PubChem=3199].,CGP,C2,36,63
Cohort,0.11866783817930403,0.09508648761239116,1.247998965563219,0.21238170165293635,LGP Proband,Genes up-regulated in at least 8 of 11 sarcoma cell lines by trabectedin [PubChem=3199].,CGP,C2,36,106
Cohort,0.016976097737843525,0.02654147203161574,0.6396064889551677,0.5226124930857285,LonGen OPEL,Genes up-regulated in at least 8 of 11 sarcoma cell lines by trabectedin [PubChem=3199].,CGP,C2,44,62
Cohort,-0.26886545787574534,0.1430477937996049,-1.8795498394920926,0.060599356780968915,LGP Offspring,Genes down-regulated in mice with skin specific knockout of TP53 [GeneID=7157].,CGP,C2,646,1244
Cohort,0.10687480151645108,0.396057152763439,0.26984691671579614,0.7873447807347429,LGP Proband,Genes down-regulated in mice with skin specific knockout of TP53 [GeneID=7157].,CGP,C2,646,1735
Cohort,-0.015802950496917968,0.12257745979332392,-0.12892215684321648,0.8974518111679164,LonGen OPEL,Genes down-regulated in mice with skin specific knockout of TP53 [GeneID=7157].,CGP,C2,1018,1210
Cohort,0.024263987747004057,0.12957315031322852,0.18726092318006157,0.851512248817953,LGP Offspring,Genes up-regulated in mice with skin specific knockout of TP53 [GeneID=7157].,CGP,C2,518,1110
Cohort,0.09635252117187967,0.34528264915815077,0.27905404863754696,0.7802725282813061,LGP Proband,Genes up-regulated in mice with skin specific knockout of TP53 [GeneID=7157].,CGP,C2,518,1522
Cohort,-0.16648202420751937,0.11739619208317431,-1.418121160945051,0.15654675279136504,LonGen OPEL,Genes up-regulated in mice with skin specific knockout of TP53 [GeneID=7157].,CGP,C2,887,1018
Cohort,-0.31375401539609993,0.11739999871910635,-2.6725214550197247,0.007709882482493795,LGP Offspring,Genes down-regulated in non-apoptotic tissues (fetal liver) after MDM4 [GeneID=4194] knockout.,CGP,C2,478,855
Cohort,-0.36031252148571064,0.3276557633392609,-1.0996678886818063,0.271794170646697,LGP Proband,Genes down-regulated in non-apoptotic tissues (fetal liver) after MDM4 [GeneID=4194] knockout.,CGP,C2,478,1278
Cohort,0.06813211909437343,0.09873605418958588,0.6900429600270539,0.4903683019615722,LonGen OPEL,Genes down-regulated in non-apoptotic tissues (fetal liver) after MDM4 [GeneID=4194] knockout.,CGP,C2,676,857
Cohort,-0.11114910759991564,0.06904884776912619,-1.6097170509138277,0.10792648410463627,LGP Offspring,Genes up-regulated in non-apoptotic tissues (fetal liver) after MDM4 [GeneID=4194] knockout.,CGP,C2,167,307
Cohort,-0.21309301803400388,0.19287114125361196,-1.1048465656860587,0.2695447168152418,LGP Proband,Genes up-regulated in non-apoptotic tissues (fetal liver) after MDM4 [GeneID=4194] knockout.,CGP,C2,167,455
Cohort,-0.07023162838073324,0.059193976264120984,-1.1864657996172232,0.23579239694770748,LonGen OPEL,Genes up-regulated in non-apoptotic tissues (fetal liver) after MDM4 [GeneID=4194] knockout.,CGP,C2,277,313
Cohort,-0.08257774076279932,0.054443561916345924,-1.516758600212131,0.12979511487970596,LGP Offspring,Genes down-regulated in apoptotic tissues (neuroepithelium) after MDM4 [GeneID=4194] knockout.,CGP,C2,105,186
Cohort,0.0018019380538509982,0.15602556519917252,0.011548992317706116,0.990788204164285,LGP Proband,Genes down-regulated in apoptotic tissues (neuroepithelium) after MDM4 [GeneID=4194] knockout.,CGP,C2,105,293
Cohort,-0.09938810146783336,0.04868628846491643,-2.041398196526172,0.04154053487184979,LonGen OPEL,Genes down-regulated in apoptotic tissues (neuroepithelium) after MDM4 [GeneID=4194] knockout.,CGP,C2,183,177
Cohort,-0.10201170918984313,0.07395402037416919,-1.379393691833338,0.16822954219669933,LGP Offspring,Genes up-regulated in apoptotic tissues (neuroepithelium) after MDM4 [GeneID=4194] knockout.,CGP,C2,173,324
Cohort,-0.17550678279614662,0.19963820572325305,-0.8791242245456843,0.3795871432174167,LGP Proband,Genes up-regulated in apoptotic tissues (neuroepithelium) after MDM4 [GeneID=4194] knockout.,CGP,C2,173,453
Cohort,-0.05881786517411395,0.05917644281640122,-0.9939405340162168,0.3205538603117435,LonGen OPEL,Genes up-regulated in apoptotic tissues (neuroepithelium) after MDM4 [GeneID=4194] knockout.,CGP,C2,265,295
Cohort,0.0175568466854791,0.031889697686739535,0.5505491729004267,0.5821246399886308,LGP Offspring,Genes down-regulated by IL2 [GeneID=3558] in cells derived from  CD4+ [GeneID=920] cutaneous T-cell lymphoma (CTCL).,CGP,C2,32,72
Cohort,-0.042805670605488656,0.09513525694219732,-0.4499453933413635,0.6528667390391831,LGP Proband,Genes down-regulated by IL2 [GeneID=3558] in cells derived from  CD4+ [GeneID=920] cutaneous T-cell lymphoma (CTCL).,CGP,C2,32,101
Cohort,-0.05618439873738049,0.032581080809142286,-1.7244485861750507,0.08501510911925701,LonGen OPEL,Genes down-regulated by IL2 [GeneID=3558] in cells derived from  CD4+ [GeneID=920] cutaneous T-cell lymphoma (CTCL).,CGP,C2,88,76
Cohort,-0.04301497531535291,0.04613493597383494,-0.9323731442858945,0.35147659557315647,LGP Offspring,Genes up-regulated by IL2 [GeneID=3558] in cells derived from  CD4+ [GeneID=920] cutaneous T-cell lymphoma (CTCL).,CGP,C2,76,140
Cohort,0.08292711713095018,0.13008581565274216,0.6374800873933876,0.5239871395822513,LGP Proband,Genes up-regulated by IL2 [GeneID=3558] in cells derived from  CD4+ [GeneID=920] cutaneous T-cell lymphoma (CTCL).,CGP,C2,76,211
Cohort,-0.028657916695850327,0.03988265188752238,-0.7185559469985042,0.4726254253857086,LonGen OPEL,Genes up-regulated by IL2 [GeneID=3558] in cells derived from  CD4+ [GeneID=920] cutaneous T-cell lymphoma (CTCL).,CGP,C2,122,135
Cohort,0.03979121753879541,0.02807101650866791,1.4175196515063313,0.1567917956320521,LGP Offspring,Genes down-regulated in derivatives of MCF-7aro cells (breast cancer) that developed resistance to tamoxifen [PubChem=5376] or  inhibitors of aromatase (CYP19A1) [GeneID=1588].,CGP,C2,20,65
Cohort,-0.06897927376047558,0.07963694963456666,-0.8661717215062054,0.38664510589461254,LGP Proband,Genes down-regulated in derivatives of MCF-7aro cells (breast cancer) that developed resistance to tamoxifen [PubChem=5376] or  inhibitors of aromatase (CYP19A1) [GeneID=1588].,CGP,C2,20,86
Cohort,0.01624617099723475,0.024193897192693322,0.6714987200218895,0.5020976968026132,LonGen OPEL,Genes down-regulated in derivatives of MCF-7aro cells (breast cancer) that developed resistance to tamoxifen [PubChem=5376] or  inhibitors of aromatase (CYP19A1) [GeneID=1588].,CGP,C2,39,52
Cohort,0.013034589302108927,0.026221439280138738,0.4970966377113362,0.6192825347457982,LGP Offspring,Genes up-regulated in derivatives of MCF-7aro cells (breast cancer) that developed resistance to tamoxifen [PubChem=5376] or  inhibitors of aromatase (CYP19A1) [GeneID=1588].,CGP,C2,24,49
Cohort,0.08081197514505216,0.07948374862369399,1.0167106678328233,0.30958593966025044,LGP Proband,Genes up-regulated in derivatives of MCF-7aro cells (breast cancer) that developed resistance to tamoxifen [PubChem=5376] or  inhibitors of aromatase (CYP19A1) [GeneID=1588].,CGP,C2,24,80
Cohort,0.05656862952963355,0.025030739520963945,2.2599663698412003,0.024092838560652138,LonGen OPEL,Genes up-regulated in derivatives of MCF-7aro cells (breast cancer) that developed resistance to tamoxifen [PubChem=5376] or  inhibitors of aromatase (CYP19A1) [GeneID=1588].,CGP,C2,27,60
Cohort,-0.047807966052661785,0.04934060454243389,-0.9689375818560552,0.33292286820231587,LGP Offspring,Genes rapidly up-regulated in breast cancer cell cultures by estradiol [PubChem=5757].,CGP,C2,90,161
Cohort,0.11709380694209685,0.13699125450416802,0.854753884588554,0.39293287720930026,LGP Proband,Genes rapidly up-regulated in breast cancer cell cultures by estradiol [PubChem=5757].,CGP,C2,90,223
Cohort,0.041303130401866235,0.04467568228758282,0.9245103440389101,0.35550084256004433,LonGen OPEL,Genes rapidly up-regulated in breast cancer cell cultures by estradiol [PubChem=5757].,CGP,C2,133,170
Cohort,-0.014533127032974508,0.08847988404902214,-0.16425345929389387,0.8695807167016514,LGP Offspring,Genes down-regulated in breast cancer tumors (formed by MCF-7 xenografts) resistant to tamoxifen [PubChem=5376].,CGP,C2,276,583
Cohort,0.49110247818642194,0.24501726099971077,2.0043586977613046,0.045354533503037774,LGP Proband,Genes down-regulated in breast cancer tumors (formed by MCF-7 xenografts) resistant to tamoxifen [PubChem=5376].,CGP,C2,276,748
Cohort,-0.023425866421921,0.08242277806780829,-0.2842159287891122,0.776318825235706,LonGen OPEL,Genes down-regulated in breast cancer tumors (formed by MCF-7 xenografts) resistant to tamoxifen [PubChem=5376].,CGP,C2,471,533
Cohort,-0.06748828213800345,0.14373308551983915,-0.4695389505757754,0.6388358623237124,LGP Offspring,Genes up-regulated in breast cancer tumors (formed by MCF-7 xenografts) resistant to tamoxifen [PubChem=5376].,CGP,C2,626,1281
Cohort,-1.016195525845851,0.3926092347294711,-2.588312846349792,0.009812608664800937,LGP Proband,Genes up-regulated in breast cancer tumors (formed by MCF-7 xenografts) resistant to tamoxifen [PubChem=5376].,CGP,C2,626,1661
Cohort,0.0690859401934925,0.12167819487581208,0.5677758472995379,0.5703472870107714,LonGen OPEL,Genes up-regulated in breast cancer tumors (formed by MCF-7 xenografts) resistant to tamoxifen [PubChem=5376].,CGP,C2,931,1154
Cohort,0.02726984113854392,0.02075789247448547,1.313709528655792,0.18938963400609032,LGP Offspring,Genes identified with the Fanconi anemia (FA) and the FA pathway.,CGP,C2,10,32
Cohort,-0.01888696280612961,0.05558416260118171,-0.3397903633386406,0.7340999585754866,LGP Proband,Genes identified with the Fanconi anemia (FA) and the FA pathway.,CGP,C2,10,38
Cohort,0.03495939139218799,0.019079604738079143,1.8322911754254485,0.0672814975896698,LonGen OPEL,Genes identified with the Fanconi anemia (FA) and the FA pathway.,CGP,C2,21,36
Cohort,0.045756976433837984,0.1139694041307968,0.4014847386700826,0.6881901575020357,LGP Offspring,Genes changed between developmental stages of Valpha14i  natural killer T lymphocyte cells (NKT).,CGP,C2,463,975
Cohort,0.20388675061490993,0.3378295259718456,0.6035196302880337,0.5463271621492336,LGP Proband,Genes changed between developmental stages of Valpha14i  natural killer T lymphocyte cells (NKT).,CGP,C2,463,1332
Cohort,0.10615891984011201,0.10727861542008763,0.989562732744163,0.3226885934951177,LonGen OPEL,Genes changed between developmental stages of Valpha14i  natural killer T lymphocyte cells (NKT).,CGP,C2,717,907
Cohort,-0.02258764100134121,0.02528086928851418,-0.8934677341812538,0.3719247073674077,LGP Offspring,"Known targets of AP1 that were down-regulated by overexpression of TAM67, a dominant-negative form of JUN [GeneID=3725].",CGP,C2,23,38
Cohort,0.07976789132051106,0.06717384638114389,1.1874843502024381,0.23537471948339375,LGP Proband,"Known targets of AP1 that were down-regulated by overexpression of TAM67, a dominant-negative form of JUN [GeneID=3725].",CGP,C2,23,52
Cohort,0.014273043890637039,0.022039781579345094,0.6476036905925253,0.5174280382512493,LonGen OPEL,"Known targets of AP1 that were down-regulated by overexpression of TAM67, a dominant-negative form of JUN [GeneID=3725].",CGP,C2,32,48
Cohort,0.0025589654212272122,0.020359555728922316,0.12568866704650164,0.9000157432657158,LGP Offspring,"Genes up-regulated by skin tumor promoters but completely blocked by expression of TAM67, a dominan-negative form of JUN [GeneID=3725].",CGP,C2,13,27
Cohort,-0.00427376691020946,0.05625447131594506,-0.07597203938166033,0.9394595632364304,LGP Proband,"Genes up-regulated by skin tumor promoters but completely blocked by expression of TAM67, a dominan-negative form of JUN [GeneID=3725].",CGP,C2,13,38
Cohort,0.021980204362443443,0.020186660097016976,1.0888479945075957,0.2765504658891282,LonGen OPEL,"Genes up-regulated by skin tumor promoters but completely blocked by expression of TAM67, a dominan-negative form of JUN [GeneID=3725].",CGP,C2,24,35
Cohort,0.011301770286017717,0.024999056309560664,0.4520878766809872,0.6513507024617313,LGP Offspring,Genes distinguishing between MGUS (monoclonal gammopathy of undetermined significance) and multiple myeloma (MM) samples.,CGP,C2,20,44
Cohort,-0.06524017231216538,0.07591803388364066,-0.8593501303281746,0.3903943073548445,LGP Proband,Genes distinguishing between MGUS (monoclonal gammopathy of undetermined significance) and multiple myeloma (MM) samples.,CGP,C2,20,74
Cohort,-0.008067400923343276,0.023424661311559694,-0.3443977616599367,0.7306381371361534,LonGen OPEL,Genes distinguishing between MGUS (monoclonal gammopathy of undetermined significance) and multiple myeloma (MM) samples.,CGP,C2,39,44
Cohort,0.008911677094743064,0.049995256502271344,0.17825045250719326,0.8585796918408601,LGP Offspring,Genes changed in MGUS (monoclonal gammopathy of undetermined significance) compared to PCL (plasma cell leukemia) samples.,CGP,C2,78,167
Cohort,-0.07975941148884329,0.13599092552891065,-0.5865053949639238,0.5576946447643367,LGP Proband,Genes changed in MGUS (monoclonal gammopathy of undetermined significance) compared to PCL (plasma cell leukemia) samples.,CGP,C2,78,209
Cohort,-0.0124236015093149,0.043080159408256734,-0.28838336904885725,0.7731283726153519,LonGen OPEL,Genes changed in MGUS (monoclonal gammopathy of undetermined significance) compared to PCL (plasma cell leukemia) samples.,CGP,C2,133,156
Cohort,0.009101246173298983,0.024411115859361066,0.3728320419981489,0.709390321930309,LGP Offspring,"Genes differentially expressed in multiple myeloma (MM) patients: comparison of MGUS-like vs PCL-like samples; MGUS=monoclonal gammopathy of undetermined significance, PCL=plasma cell leukemia.",CGP,C2,14,35
Cohort,0.045243847464327226,0.06279267177671172,0.720527510363193,0.47140216623694164,LGP Proband,"Genes differentially expressed in multiple myeloma (MM) patients: comparison of MGUS-like vs PCL-like samples; MGUS=monoclonal gammopathy of undetermined significance, PCL=plasma cell leukemia.",CGP,C2,14,45
Cohort,-0.00201156717499061,0.017061199776272774,-0.11790303151998265,0.9061742352436344,LonGen OPEL,"Genes differentially expressed in multiple myeloma (MM) patients: comparison of MGUS-like vs PCL-like samples; MGUS=monoclonal gammopathy of undetermined significance, PCL=plasma cell leukemia.",CGP,C2,21,23
Cohort,-0.021298853465340283,0.03122541841545655,-0.682099857941291,0.4954094500847597,LGP Offspring,Genes expressed in multiple myeloma (MM) patients carrying specific translocations involving the immunoglobulin heavy chain (IGH) locus at 14q32.,CGP,C2,32,61
Cohort,0.07801892972687587,0.08188010486911548,0.9528435491330688,0.3409454144322659,LGP Proband,Genes expressed in multiple myeloma (MM) patients carrying specific translocations involving the immunoglobulin heavy chain (IGH) locus at 14q32.,CGP,C2,32,84
Cohort,-0.03280964781132756,0.02862855765312887,-1.1460461336843397,0.2521204710045593,LonGen OPEL,Genes expressed in multiple myeloma (MM) patients carrying specific translocations involving the immunoglobulin heavy chain (IGH) locus at 14q32.,CGP,C2,61,59
Cohort,0.05754336958678077,0.025163131828889733,2.2868127059094987,0.02251503038212323,LGP Offspring,"Genes central for female fertility pathways, based on mouse models with female fertility defects.",CGP,C2,11,51
Cohort,0.09519284062953486,0.06901275483698345,1.3793514090894061,0.16815617831727803,LGP Proband,"Genes central for female fertility pathways, based on mouse models with female fertility defects.",CGP,C2,11,65
Cohort,-0.027250629052858924,0.022707477249739125,-1.2000729430730572,0.230468054160917,LonGen OPEL,"Genes central for female fertility pathways, based on mouse models with female fertility defects.",CGP,C2,43,37
Cohort,-0.018647854287520263,0.009020868786613862,-2.0671905033351066,0.039096289143181084,LGP Offspring,"Genes important for cumulus expansion, based on mouse models with female fertility defects.",CGP,C2,6,2
Cohort,-0.030611981647715412,0.028108250103967305,-1.0890746145522137,0.27643557481286646,LGP Proband,"Genes important for cumulus expansion, based on mouse models with female fertility defects.",CGP,C2,6,7
Cohort,-0.005280721394719431,0.006866613361035448,-0.7690430663658522,0.44209586635762244,LonGen OPEL,"Genes important for cumulus expansion, based on mouse models with female fertility defects.",CGP,C2,4,3
Cohort,-7.927003347069479e-4,0.010640852938158201,-0.07449593931181182,0.9406378107321263,LGP Offspring,"Genes important for early anral follicle, based on mouse models with female fertility defects.",CGP,C2,4,7
Cohort,-0.027755978052926504,0.032247572803534276,-0.860715261332304,0.3896422541430621,LGP Proband,"Genes important for early anral follicle, based on mouse models with female fertility defects.",CGP,C2,4,13
Cohort,-0.011752587333759433,0.007305558106402414,-1.6087186170567518,0.10807439477271132,LonGen OPEL,"Genes important for early anral follicle, based on mouse models with female fertility defects.",CGP,C2,6,2
Cohort,-0.05731500607219642,0.024772233233476208,-2.313679414044237,0.020984384160889383,LGP Offspring,"Genes important for embryonic germ cell, based on mouse models with female fertility defects.",CGP,C2,28,33
Cohort,0.00611392313386854,0.06448613968830896,0.09480987950930121,0.9244886133629748,LGP Proband,"Genes important for embryonic germ cell, based on mouse models with female fertility defects.",CGP,C2,28,41
Cohort,0.06905015308617468,0.02149629381242637,3.212188746985717,0.0013702411317173683,LonGen OPEL,"Genes important for embryonic germ cell, based on mouse models with female fertility defects.",CGP,C2,17,49
Cohort,-0.00338017377724615,0.014798302004008557,-0.22841632616569998,0.8193916757117167,LGP Offspring,"Genes important for fertilization, based on mouse models with female fertility defects.",CGP,C2,7,15
Cohort,0.06873457325012705,0.04429648595075788,1.551693588663799,0.1211149279478977,LGP Proband,"Genes important for fertilization, based on mouse models with female fertility defects.",CGP,C2,7,26
Cohort,0.011325577769052103,0.011931316298216902,0.9492312068488769,0.34279113108952053,LonGen OPEL,"Genes important for fertilization, based on mouse models with female fertility defects.",CGP,C2,8,14
Cohort,-0.014254106471679524,0.015168241425853808,-0.9397336231333866,0.3476898703247856,LGP Offspring,"Genes important for implantation and uterine, based on mouse models with female fertility defects.",CGP,C2,9,14
Cohort,0.010736161206286746,0.04064197393280586,0.2641643642613679,0.7917185314246917,LGP Proband,"Genes important for implantation and uterine, based on mouse models with female fertility defects.",CGP,C2,9,19
Cohort,-0.0016437077638083713,0.012004200417415426,-0.1369277175199205,0.891122554395685,LonGen OPEL,"Genes important for implantation and uterine, based on mouse models with female fertility defects.",CGP,C2,10,12
Cohort,0.019507459028462616,0.01225008335363224,1.5924347994479982,0.11175450472964862,LGP Offspring,"Luteal genes, based on mouse models with female fertility defects.",CGP,C2,2,13
Cohort,0.051341892958325544,0.035035594299727475,1.4654209236212359,0.14318299757956124,LGP Proband,"Luteal genes, based on mouse models with female fertility defects.",CGP,C2,2,18
Cohort,-0.0059772401186022435,0.009616578319362802,-0.6215558091558596,0.5344119487335273,LonGen OPEL,"Luteal genes, based on mouse models with female fertility defects.",CGP,C2,7,7
Cohort,-0.05434555762781575,0.028405562840383647,-1.9132012251682515,0.0561444418744641,LGP Offspring,"Genes important for Sertoli, peritubular, Leydig and interstitial cells, based on mouse models with male reproductive defects.",CGP,C2,33,47
Cohort,0.07454132568165071,0.08075113437605566,0.9230994246410701,0.3562223709751461,LGP Proband,"Genes important for Sertoli, peritubular, Leydig and interstitial cells, based on mouse models with male reproductive defects.",CGP,C2,33,80
Cohort,0.033240222097194766,0.0245079053763587,1.3563061219119772,0.17538636443872802,LonGen OPEL,"Genes important for Sertoli, peritubular, Leydig and interstitial cells, based on mouse models with male reproductive defects.",CGP,C2,38,57
Cohort,-0.0012744993127417337,0.004466957655447814,-0.2853170795535479,0.7754886239791162,LGP Offspring,"Maternal effect genes, based on mouse models wih female fertility defects.",CGP,C2,1,1
Cohort,-0.005742071307314041,0.01577602122187612,-0.36397461860356073,0.7159692146039981,LGP Proband,"Maternal effect genes, based on mouse models wih female fertility defects.",CGP,C2,1,3
Cohort,-0.0054118552111687744,0.007310217038881793,-0.7403138897770125,0.459327854628493,LonGen OPEL,"Maternal effect genes, based on mouse models wih female fertility defects.",CGP,C2,5,3
Cohort,0.008808979444221661,0.04205442211909317,0.20946618691550842,0.8341474369858506,LGP Offspring,"Meitic and DNA repair genes important for female fertility, based on mouse models with female fertility defects.",CGP,C2,52,115
Cohort,0.06454709686483336,0.11711162176466738,0.5511587653916961,0.5816724639442465,LGP Proband,"Meitic and DNA repair genes important for female fertility, based on mouse models with female fertility defects.",CGP,C2,52,173
Cohort,0.012078670648310018,0.038905075735948806,0.3104651621883148,0.7562885198999729,LonGen OPEL,"Meitic and DNA repair genes important for female fertility, based on mouse models with female fertility defects.",CGP,C2,99,119
Cohort,0.0015756952646829026,0.01776894992745334,0.08867689261977298,0.9293649609668593,LGP Offspring,"Genes important for ovulation, based on mouse models with female fertility defects.",CGP,C2,11,21
Cohort,-1.9735549104203762e-4,0.05169907976592136,-0.003817388857511716,0.9969550846554209,LGP Proband,"Genes important for ovulation, based on mouse models with female fertility defects.",CGP,C2,11,32
Cohort,0.01812315930978926,0.01605169941276365,1.1290492578859577,0.25921719656258324,LonGen OPEL,"Genes important for ovulation, based on mouse models with female fertility defects.",CGP,C2,13,23
Cohort,0.012950652434163002,0.01872210506852725,0.6917305712557754,0.4893440455049799,LGP Offspring,"Genes important for post-implantation and post-partum,  based on mouse models with female fertility defects.",CGP,C2,10,26
Cohort,0.029182489949945982,0.05985322877507067,0.487567513853166,0.6259843468346981,LGP Proband,"Genes important for post-implantation and post-partum,  based on mouse models with female fertility defects.",CGP,C2,10,40
Cohort,0.01314640296862032,0.015763206317792343,0.8339929519149687,0.40453515374488325,LonGen OPEL,"Genes important for post-implantation and post-partum,  based on mouse models with female fertility defects.",CGP,C2,17,22
Cohort,0.010354657307829388,0.01566599569781999,0.6609638804682102,0.5088606662516545,LGP Offspring,"Genes important for preovulatory follicle,  based on mouse models with female fertility defects.",CGP,C2,6,19
Cohort,0.02359115677122451,0.03890799536563901,0.6063318490075351,0.5444594100044402,LGP Proband,"Genes important for preovulatory follicle,  based on mouse models with female fertility defects.",CGP,C2,6,19
Cohort,0.008468800635689621,0.00998697861081449,0.847984256872154,0.39670164676992703,LonGen OPEL,"Genes important for preovulatory follicle,  based on mouse models with female fertility defects.",CGP,C2,6,9
Cohort,0.029528022676976292,0.033204729703787385,0.8892715869211932,0.3741734730428131,LGP Offspring,"Genes important for spermatid differentiation, based on mouse models with male reproductive defects.",CGP,C2,30,70
Cohort,-0.09731832110562548,0.08234723989515791,-1.1818042866953198,0.23762022310708283,LGP Proband,"Genes important for spermatid differentiation, based on mouse models with male reproductive defects.",CGP,C2,30,77
Cohort,0.0026927031567916507,0.028080594243677964,0.09589195774935864,0.9236305175782846,LonGen OPEL,"Genes important for spermatid differentiation, based on mouse models with male reproductive defects.",CGP,C2,55,61
Cohort,-0.038228182827455964,0.042492897035632374,-0.8996370098136581,0.3686338061741288,LGP Offspring,"Genes important for spermatocyte, based on mouse models with male reproductive defects.",CGP,C2,68,122
Cohort,0.05016033050291324,0.12071138766385513,0.4155393411812534,0.6778540104499569,LGP Proband,"Genes important for spermatocyte, based on mouse models with male reproductive defects.",CGP,C2,68,184
Cohort,0.0030093213587374457,0.04017422013552532,0.07490677724634556,0.9403077047464092,LonGen OPEL,"Genes important for spermatocyte, based on mouse models with male reproductive defects.",CGP,C2,112,133
Cohort,-0.03282766662575857,0.020761985569798674,-1.5811429265951895,0.11431310564570671,LGP Offspring,"Genes important for spermatogonia, based on mouse models with male reproductive defects.",CGP,C2,18,22
Cohort,-0.04060487049789683,0.05537867220646775,-0.7332221752538612,0.46362897325933417,LGP Proband,"Genes important for spermatogonia, based on mouse models with male reproductive defects.",CGP,C2,18,32
Cohort,0.04376529334151541,0.019454275003163244,2.2496491560029463,0.024743704067477345,LonGen OPEL,"Genes important for spermatogonia, based on mouse models with male reproductive defects.",CGP,C2,17,39
Cohort,0.0032834026599111664,0.05745054889206516,0.05715180660988701,0.9544411565675563,LGP Offspring,"Spermatozoa genes, based on mouse models with male reproductive defects.",CGP,C2,100,203
Cohort,-0.13195687418020824,0.16370399824880508,-0.8060699530359298,0.42043229061627707,LGP Proband,"Spermatozoa genes, based on mouse models with male reproductive defects.",CGP,C2,100,312
Cohort,-0.03489284489568689,0.05187298735305307,-0.6726592524583649,0.5013593127768217,LonGen OPEL,"Spermatozoa genes, based on mouse models with male reproductive defects.",CGP,C2,175,196
Cohort,-0.006043682357307405,0.01058281354311693,-0.5710846489625834,0.5681320638640921,LGP Offspring,"Genes important for steroidogenesis, based on mouse models with female fertility defects.",CGP,C2,5,6
Cohort,0.02623398085723048,0.03633359525032289,0.722030965460192,0.4704778286054616,LGP Proband,"Genes important for steroidogenesis, based on mouse models with female fertility defects.",CGP,C2,5,17
Cohort,-0.0026850056071012706,0.013586712543003336,-0.1976199613116825,0.8433928687189028,LonGen OPEL,"Genes important for steroidogenesis, based on mouse models with female fertility defects.",CGP,C2,12,14
Cohort,-0.05037420117731906,0.03814748846559259,-1.3205116038701852,0.18711115650521526,LGP Offspring,"Genes down-regulated in H720 cells (lung cancer) after treatment with L663536 (MK886) [PubChem=105049], an inhibitor of leukotriene biosynthesis.",CGP,C2,49,81
Cohort,0.11017115517835241,0.10402304969267992,1.059103299738242,0.28985937638519416,LGP Proband,"Genes down-regulated in H720 cells (lung cancer) after treatment with L663536 (MK886) [PubChem=105049], an inhibitor of leukotriene biosynthesis.",CGP,C2,49,119
Cohort,-0.02239052738761577,0.030602047791385364,-0.7316676171559611,0.46458680917780426,LonGen OPEL,"Genes down-regulated in H720 cells (lung cancer) after treatment with L663536 (MK886) [PubChem=105049], an inhibitor of leukotriene biosynthesis.",CGP,C2,68,77
Cohort,-0.023579299454225076,0.028035963468280373,-0.8410376008979493,0.40062426340837476,LGP Offspring,"Genes up-regulated in H720 cells (lung cancer) after treatment with L663536 (MK886) [PubChem=105049], an inhibitor of leukotriene biosynthesis.",CGP,C2,30,50
Cohort,-0.00590225286424144,0.07804354270296192,-0.07562769013069721,0.9397334429599148,LGP Proband,"Genes up-regulated in H720 cells (lung cancer) after treatment with L663536 (MK886) [PubChem=105049], an inhibitor of leukotriene biosynthesis.",CGP,C2,30,73
Cohort,0.011078179492604144,0.026469352441336177,0.4185285422889218,0.6756736179205775,LonGen OPEL,"Genes up-regulated in H720 cells (lung cancer) after treatment with L663536 (MK886) [PubChem=105049], an inhibitor of leukotriene biosynthesis.",CGP,C2,45,54
Cohort,0.020637612065401215,0.020926800821909987,0.9861809380721971,0.3243971670457102,LGP Offspring,Genes down-regulated during pubertal mammary gland development between weeks 3 and 4.,CGP,C2,12,34
Cohort,-0.03347595079090118,0.05992314406549213,-0.5586481035493419,0.5765518587428209,LGP Proband,Genes down-regulated during pubertal mammary gland development between weeks 3 and 4.,CGP,C2,12,48
Cohort,-0.00792120172574166,0.020557962517706876,-0.38531064150540273,0.7001102172597958,LonGen OPEL,Genes down-regulated during pubertal mammary gland development between weeks 3 and 4.,CGP,C2,32,34
Cohort,-0.04894657164842709,0.08453661703020517,-0.5789984667938433,0.5627830783907306,LGP Offspring,Genes up-regulated during pubertal mammary gland development between weeks 3 and 4.,CGP,C2,223,453
Cohort,-0.010387109022036801,0.22814011816722407,-0.04552951539379484,0.963696148511509,LGP Proband,Genes up-regulated during pubertal mammary gland development between weeks 3 and 4.,CGP,C2,223,644
Cohort,0.09349747377880065,0.07350697882539141,1.2719537011702615,0.20376104132725362,LonGen OPEL,Genes up-regulated during pubertal mammary gland development between weeks 3 and 4.,CGP,C2,348,434
Cohort,0.09547429509296633,0.07098206895177481,1.3450480734484018,0.17906076597355577,LGP Offspring,Genes down-regulated during pubertal mammary gland development between week 4 and 5.,CGP,C2,154,362
Cohort,-0.09518835667449398,0.18783187151658107,-0.5067742545816625,0.6124471757553553,LGP Proband,Genes down-regulated during pubertal mammary gland development between week 4 and 5.,CGP,C2,154,470
Cohort,0.07428972020038178,0.06129876141267947,1.2119285690006647,0.22589934057910607,LonGen OPEL,Genes down-regulated during pubertal mammary gland development between week 4 and 5.,CGP,C2,256,335
Cohort,-0.14619964720678838,0.08989287805872616,-1.6263763088247942,0.10433566004128228,LGP Offspring,Genes up-regulated during pubertal mammary gland development between week 4 and 5.,CGP,C2,273,509
Cohort,-0.40595774764408354,0.25322689328095166,-1.6031383649037592,0.10928273666973781,LGP Proband,Genes up-regulated during pubertal mammary gland development between week 4 and 5.,CGP,C2,273,745
Cohort,0.040724061084603705,0.07815843396614588,0.5210449981923029,0.6024803406987969,LonGen OPEL,Genes up-regulated during pubertal mammary gland development between week 4 and 5.,CGP,C2,388,485
Cohort,0.050554085474405784,0.06460110307681294,0.7825576200192005,0.434160973098105,LGP Offspring,Genes down-regulated during pubertal mammary gland development between week 5 and 6.,CGP,C2,128,277
Cohort,-0.09762527965169529,0.18481800973364254,-0.528223844593888,0.5974845014691268,LGP Proband,Genes down-regulated during pubertal mammary gland development between week 5 and 6.,CGP,C2,128,429
Cohort,0.012644904091491778,0.054784701772421944,0.23081085928000966,0.8175210541470815,LonGen OPEL,Genes down-regulated during pubertal mammary gland development between week 5 and 6.,CGP,C2,218,258
Cohort,0.029267622429597073,0.05530588240971516,0.5291954698919307,0.5968435837131668,LGP Offspring,Genes up-regulated during pubertal mammary gland development between week 5 and 6.,CGP,C2,93,212
Cohort,0.037591259680180976,0.14437070395288884,0.2603801093360865,0.7946348561480518,LGP Proband,Genes up-regulated during pubertal mammary gland development between week 5 and 6.,CGP,C2,93,252
Cohort,0.012906522963955922,0.04665284638886549,0.2766502788785099,0.7821204720732158,LonGen OPEL,Genes up-regulated during pubertal mammary gland development between week 5 and 6.,CGP,C2,137,179
Cohort,-0.044598221139167143,0.05728490551785253,-0.7785335549740647,0.43652695287166754,LGP Offspring,Genes down-regulated during pubertal mammary gland development between week 6 and 7.,CGP,C2,114,217
Cohort,-0.24560898771419049,0.1614124797714121,-1.521623285027373,0.12848253731624684,LGP Proband,Genes down-regulated during pubertal mammary gland development between week 6 and 7.,CGP,C2,114,302
Cohort,-0.019256820034061078,0.050729010932984195,-0.3796017245339239,0.704342329568559,LonGen OPEL,Genes down-regulated during pubertal mammary gland development between week 6 and 7.,CGP,C2,180,203
Cohort,0.048851795452853355,0.07472492942094026,0.6537549895519011,0.5134919843358857,LGP Offspring,Genes up-regulated during pubertal mammary gland development between week 6 and 7.,CGP,C2,170,372
Cohort,-0.14361033557406822,0.20660384458403958,-0.695100015506499,0.4871862380540648,LGP Proband,Genes up-regulated during pubertal mammary gland development between week 6 and 7.,CGP,C2,170,517
Cohort,0.06397247355700779,0.06587398171511125,0.9711341548120317,0.3317764736056019,LonGen OPEL,Genes up-regulated during pubertal mammary gland development between week 6 and 7.,CGP,C2,273,349
Cohort,-0.051357525906675354,0.0426094825154519,-1.2053074309938183,0.22850638730045925,LGP Offspring,Pubertal genes down-regulated by TGFB1 [GeneID=7040].,CGP,C2,67,126
Cohort,0.0655777097205326,0.1268668482675048,0.5169018590440497,0.6053617144651784,LGP Proband,Pubertal genes down-regulated by TGFB1 [GeneID=7040].,CGP,C2,67,170
Cohort,0.004539292049143527,0.03717530959272058,0.12210502343825487,0.9028466627198782,LonGen OPEL,Pubertal genes down-regulated by TGFB1 [GeneID=7040].,CGP,C2,93,118
Cohort,-0.04157668341885865,0.07099775350567573,-0.5856056194163229,0.558336013272189,LGP Offspring,Pubertal genes up-regulated by TGFB1 [GeneID=7040].,CGP,C2,162,309
Cohort,-0.6556926612824935,0.19169822081035742,-3.4204420808430713,6.555696644270585e-4,LGP Proband,Pubertal genes up-regulated by TGFB1 [GeneID=7040].,CGP,C2,162,439
Cohort,-0.004376261713502682,0.05966741604959287,-0.07334424721635892,0.9415506081034779,LonGen OPEL,Pubertal genes up-regulated by TGFB1 [GeneID=7040].,CGP,C2,249,292
Cohort,-5.749713237458319e-4,0.018008055349047803,-0.03192856266827468,0.9745384449244108,LGP Offspring,The 'TEB profile genes': down-regulated during pubertal mammary gland development specifically in the TEB (terminal end bud) structures.,CGP,C2,12,21
Cohort,-0.11900192132182144,0.04993526874720602,-2.383123678061307,0.017389421603115417,LGP Proband,The 'TEB profile genes': down-regulated during pubertal mammary gland development specifically in the TEB (terminal end bud) structures.,CGP,C2,12,30
Cohort,0.001838011758906999,0.014138491729355164,0.13000055409664465,0.8965988319685646,LonGen OPEL,The 'TEB profile genes': down-regulated during pubertal mammary gland development specifically in the TEB (terminal end bud) structures.,CGP,C2,13,18
Cohort,-0.03454933200124425,0.02860769850524454,-1.2076935163068239,0.22758752747053798,LGP Offspring,The 'TEB profile genes': up-regulated during pubertal mammary gland development specifically in the TEB (terminal end bud) structures.,CGP,C2,33,52
Cohort,0.009536573755814673,0.07945196769737124,0.12002942195389077,0.904488749202859,LGP Proband,The 'TEB profile genes': up-regulated during pubertal mammary gland development specifically in the TEB (terminal end bud) structures.,CGP,C2,33,77
Cohort,-0.01015932185939354,0.022587872538763442,-0.4497688678718613,0.6529995578351973,LonGen OPEL,The 'TEB profile genes': up-regulated during pubertal mammary gland development specifically in the TEB (terminal end bud) structures.,CGP,C2,40,42
Cohort,-0.0067382518939374456,0.10755155826801532,-0.06265136463337816,0.9500626462870838,LGP Offspring,"Genes whose promoters where bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer), according to a ChIP-chip analysis.",CGP,C2,391,836
Cohort,-0.13702092721824102,0.31724146128034125,-0.4319136807189203,0.6659157892191517,LGP Proband,"Genes whose promoters where bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer), according to a ChIP-chip analysis.",CGP,C2,391,1193
Cohort,0.0049055490380045886,0.09828291807348896,0.049912529401462916,0.9602046139835976,LonGen OPEL,"Genes whose promoters where bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer), according to a ChIP-chip analysis.",CGP,C2,639,761
Cohort,0.011656125877065864,0.020147664778748076,0.578534832948027,0.5630957777767971,LGP Offspring,Genes whose promoters were bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and which were down-regulated in comparison of tumor vs normal prostate tissue samples.,CGP,C2,10,27
Cohort,0.06728862511615523,0.05789681546886723,1.1622163424918983,0.24548007084809487,LGP Proband,Genes whose promoters were bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and which were down-regulated in comparison of tumor vs normal prostate tissue samples.,CGP,C2,10,45
Cohort,-0.014443630525736599,0.018783132505317414,-0.768968143180999,0.4421403184311722,LonGen OPEL,Genes whose promoters were bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and which were down-regulated in comparison of tumor vs normal prostate tissue samples.,CGP,C2,26,31
Cohort,-0.0014493619300311323,0.03158308919117844,-0.045890442231849744,0.9634111250202952,LGP Offspring,Genes whose promoters were bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and which were up-regulated in comparison of tumor vs normal prostate tissue samples.,CGP,C2,31,66
Cohort,0.007486359654060935,0.09120499920630987,0.08208277747063457,0.9346005833927333,LGP Proband,Genes whose promoters were bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and which were up-regulated in comparison of tumor vs normal prostate tissue samples.,CGP,C2,31,105
Cohort,0.010927972071162929,0.02877710328687964,0.37974538167451083,0.7042357209826963,LonGen OPEL,Genes whose promoters were bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and which were up-regulated in comparison of tumor vs normal prostate tissue samples.,CGP,C2,46,68
Cohort,0.020991974952468087,0.02443599368929939,0.8590595995144878,0.3906121496582591,LGP Offspring,Genes with promoters bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and down-regulated upon loss of function (LOF) of HOXC6.,CGP,C2,17,43
Cohort,-0.015408901888101293,0.06932407755849887,-0.22227345001595655,0.8241554377935691,LGP Proband,Genes with promoters bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and down-regulated upon loss of function (LOF) of HOXC6.,CGP,C2,17,52
Cohort,-0.014964461593490606,0.023526605903701443,-0.6360654679532948,0.524916589262679,LonGen OPEL,Genes with promoters bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and down-regulated upon loss of function (LOF) of HOXC6.,CGP,C2,39,43
Cohort,0.00931386212382139,0.024023332147109493,0.38770067644184164,0.6983595986916304,LGP Offspring,Genes with promoters bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and up-regulated upon loss of function (LOF) of HOXC6.,CGP,C2,18,40
Cohort,-0.011126702760756202,0.06809008206786933,-0.16341150462508727,0.8702340344492049,LGP Proband,Genes with promoters bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and up-regulated upon loss of function (LOF) of HOXC6.,CGP,C2,18,49
Cohort,-0.025798085931003745,0.021268708522267952,-1.2129596822483892,0.22550507140036777,LonGen OPEL,Genes with promoters bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and up-regulated upon loss of function (LOF) of HOXC6.,CGP,C2,36,36
Cohort,0.025510348673730147,0.03841351764287055,0.6640982195616444,0.5068538893553318,LGP Offspring,Genes up-regulated in the nucleus accumbens (a major reward center in the brain) after 4 weeks of cocaine [PubChem=5760] treatment.,CGP,C2,43,102
Cohort,0.006831119244841501,0.11682828902347205,0.05847144815643972,0.9533871112320025,LGP Proband,Genes up-regulated in the nucleus accumbens (a major reward center in the brain) after 4 weeks of cocaine [PubChem=5760] treatment.,CGP,C2,43,184
Cohort,0.014591889046237202,0.03738693085493963,0.39029384634040626,0.6964236922681115,LonGen OPEL,Genes up-regulated in the nucleus accumbens (a major reward center in the brain) after 4 weeks of cocaine [PubChem=5760] treatment.,CGP,C2,95,122
Cohort,-0.0059954186520438145,0.043278396074210156,-0.13853144284190602,0.8898616775126444,LGP Offspring,Genes up-regulated in the nucleus accumbens (a major reward center in the brain) after 5 days of cocaine [PubChem=5760] treatment.,CGP,C2,53,118
Cohort,0.2797917764858727,0.10783394673350354,2.5946539560249873,0.009634877562018026,LGP Proband,Genes up-regulated in the nucleus accumbens (a major reward center in the brain) after 5 days of cocaine [PubChem=5760] treatment.,CGP,C2,53,145
Cohort,-0.016627841692259292,0.03195758494814,-0.520309707984585,0.60299241011,LonGen OPEL,Genes up-regulated in the nucleus accumbens (a major reward center in the brain) after 5 days of cocaine [PubChem=5760] treatment.,CGP,C2,75,79
Cohort,0.05326242111955475,0.038225841958944864,1.3933616210928566,0.16396841900066583,LGP Offspring,Genes down-regulated in the nucleus accumbens (a major reward center in the brain) 8 weeks after induction of CREB1 [GeneID=1385] expression in a transgenic Tet-Off system.,CGP,C2,40,108
Cohort,0.09250414952283055,0.10722742624328693,0.8626911300934247,0.38855530911097835,LGP Proband,Genes down-regulated in the nucleus accumbens (a major reward center in the brain) 8 weeks after induction of CREB1 [GeneID=1385] expression in a transgenic Tet-Off system.,CGP,C2,40,154
Cohort,-0.027134083607221426,0.03183925801889383,-0.8522209779863495,0.3943477857188319,LonGen OPEL,Genes down-regulated in the nucleus accumbens (a major reward center in the brain) 8 weeks after induction of CREB1 [GeneID=1385] expression in a transgenic Tet-Off system.,CGP,C2,75,81
Cohort,-0.01714032042696878,0.03724186621750344,-0.46024332741179713,0.6454895764915024,LGP Offspring,Genes up-regulated in the nucleus accumbens (a major reward center in the brain) 8 weeks after induction of CREB1 [GeneID=1385] expression in a transgenic Tet-Off system.,CGP,C2,43,91
Cohort,0.14504231584873967,0.10458016086618803,1.3869008676925216,0.16584254830691367,LGP Proband,Genes up-regulated in the nucleus accumbens (a major reward center in the brain) 8 weeks after induction of CREB1 [GeneID=1385] expression in a transgenic Tet-Off system.,CGP,C2,43,142
Cohort,-0.028547388415470665,0.031362827810941234,-0.9102300528369965,0.3629767349400559,LonGen OPEL,Genes up-regulated in the nucleus accumbens (a major reward center in the brain) 8 weeks after induction of CREB1 [GeneID=1385] expression in a transgenic Tet-Off system.,CGP,C2,67,72
Cohort,0.026162655378942797,0.03127353054381524,0.8365750500183554,0.40312709797401214,LGP Offspring,"Genes up-regulated in the nucleus accumbens (a major reward center in brain) 2 weeks after induction of deltaFosB, a FOSB [GeneID=2354] splice variant.",CGP,C2,23,57
Cohort,-0.00940779640356335,0.08270358521226345,-0.11375318711296138,0.9094608258808323,LGP Proband,"Genes up-regulated in the nucleus accumbens (a major reward center in brain) 2 weeks after induction of deltaFosB, a FOSB [GeneID=2354] splice variant.",CGP,C2,23,81
Cohort,-0.012112790702839386,0.02439172078311361,-0.4965943489819329,0.6196122473149381,LonGen OPEL,"Genes up-regulated in the nucleus accumbens (a major reward center in brain) 2 weeks after induction of deltaFosB, a FOSB [GeneID=2354] splice variant.",CGP,C2,46,47
Cohort,0.01573788613549457,0.030777864308167355,0.5113378231158908,0.6092814950858827,LGP Offspring,"Genes up-regulated in the nucleus accumbens (a major reward center in brain) 8 weeks after induction of deltaFosB, a FOSB [GeneID=2354] splice variant.",CGP,C2,26,68
Cohort,0.030178507387827687,0.08705374194706825,0.34666525197937254,0.7289302647334188,LGP Proband,"Genes up-regulated in the nucleus accumbens (a major reward center in brain) 8 weeks after induction of deltaFosB, a FOSB [GeneID=2354] splice variant.",CGP,C2,26,100
Cohort,-0.048827413157646195,0.028017278823418923,-1.7427607251005623,0.08176158236326328,LonGen OPEL,"Genes up-regulated in the nucleus accumbens (a major reward center in brain) 8 weeks after induction of deltaFosB, a FOSB [GeneID=2354] splice variant.",CGP,C2,72,61
Cohort,-0.010201825864658573,0.010587421902358505,-0.9635797986274605,0.3356011972725753,LGP Offspring,Genes down-regulated in A549GARS cells (lung cancer) resistant to the geldanamycin and 17-AAG [PubChem=5476289;6440175].,CGP,C2,5,6
Cohort,0.021682133633237486,0.03030456720880058,0.7154741225586914,0.47451637564532956,LGP Proband,Genes down-regulated in A549GARS cells (lung cancer) resistant to the geldanamycin and 17-AAG [PubChem=5476289;6440175].,CGP,C2,5,10
Cohort,-0.011022646510961789,0.008951029426252676,-1.231438976016906,0.21852241515994622,LonGen OPEL,Genes down-regulated in A549GARS cells (lung cancer) resistant to the geldanamycin and 17-AAG [PubChem=5476289;6440175].,CGP,C2,8,4
Cohort,-0.023120723717967036,0.02319566165875502,-0.9967693122149116,0.31923315201384483,LGP Offspring,Genes up-regulated in A549GARS cells (lung cancer) resistant to the geldanamycin and 17-AAG [PubChem=5476289;6440175].,CGP,C2,20,32
Cohort,-0.08535310477510095,0.06436278346983682,-1.3261251327811376,0.18516131129506302,LGP Proband,Genes up-regulated in A549GARS cells (lung cancer) resistant to the geldanamycin and 17-AAG [PubChem=5476289;6440175].,CGP,C2,20,49
Cohort,0.0028571565973884378,0.0199245311922719,0.1433989372104594,0.8860114149035982,LonGen OPEL,Genes up-regulated in A549GARS cells (lung cancer) resistant to the geldanamycin and 17-AAG [PubChem=5476289;6440175].,CGP,C2,29,33
Cohort,0.011784125457439102,0.04238720730963484,0.27801136723533343,0.7810886408535849,LGP Offspring,Genes down-regulated in the mouse model of acute lung injury induced by inhaling nickel sulfate [PubChem=24586].,CGP,C2,56,120
Cohort,0.07859705019668588,0.1102997897027811,0.7125766096968735,0.476307095446878,LGP Proband,Genes down-regulated in the mouse model of acute lung injury induced by inhaling nickel sulfate [PubChem=24586].,CGP,C2,56,160
Cohort,-0.004174675081973951,0.03562542288471541,-0.11718247094170038,0.9067450172023065,LonGen OPEL,Genes down-regulated in the mouse model of acute lung injury induced by inhaling nickel sulfate [PubChem=24586].,CGP,C2,89,107
Cohort,-0.02435939777485966,0.033525014377923046,-0.7266036488533426,0.46772031205458964,LGP Offspring,Genes up-regulated in the mouse model of acute lung injury induced by inhaling nickel sulfate [PubChem=24586].,CGP,C2,43,71
Cohort,-0.19513108945465138,0.09567610899960531,-2.039496500170762,0.04171521105364247,LGP Proband,Genes up-regulated in the mouse model of acute lung injury induced by inhaling nickel sulfate [PubChem=24586].,CGP,C2,43,105
Cohort,-0.06552179925576343,0.02689186222778145,-2.4364917052146042,0.015048740173650836,LonGen OPEL,Genes up-regulated in the mouse model of acute lung injury induced by inhaling nickel sulfate [PubChem=24586].,CGP,C2,65,49
Cohort,-0.016133027506980376,0.027833525123158807,-0.5796257367902327,0.5623601477919382,LGP Offspring,Genes silenced in HCT116 cells (colon cancer) by methylation of CpG islands in their promoters.,CGP,C2,27,53
Cohort,0.04348800678599692,0.0847615860751067,0.5130626832237717,0.6080433446492154,LGP Proband,Genes silenced in HCT116 cells (colon cancer) by methylation of CpG islands in their promoters.,CGP,C2,27,92
Cohort,0.007125151626484606,0.02728395446941904,0.2611480544167732,0.7940458848581404,LonGen OPEL,Genes silenced in HCT116 cells (colon cancer) by methylation of CpG islands in their promoters.,CGP,C2,56,65
Cohort,-0.012925776501322392,0.011496648594547488,-1.1243082186101345,0.26128136242581257,LGP Offspring,Genes down-regulated by hemizygotic cre-lox knockout of RSP6 [GeneID=81492] in keratinocytes.,CGP,C2,6,7
Cohort,-0.01860962888033795,0.033476599921635986,-0.5558996111881277,0.5784285811920877,LGP Proband,Genes down-regulated by hemizygotic cre-lox knockout of RSP6 [GeneID=81492] in keratinocytes.,CGP,C2,6,13
Cohort,0.009260357378828687,0.011499798282596061,0.8052625925485517,0.4209086304338665,LonGen OPEL,Genes down-regulated by hemizygotic cre-lox knockout of RSP6 [GeneID=81492] in keratinocytes.,CGP,C2,7,13
Cohort,5.701559089500771e-4,0.024090463410274432,0.023667286894402752,0.9811249842699725,LGP Offspring,Genes up-regulated by hemizygotic cre-lox knockout of RSP6 [GeneID=81492] in keratinocytes.,CGP,C2,18,36
Cohort,0.012529870409339939,0.06728098347377909,0.18623197465927518,0.8523081377847593,LGP Proband,Genes up-regulated by hemizygotic cre-lox knockout of RSP6 [GeneID=81492] in keratinocytes.,CGP,C2,18,54
Cohort,-0.017288635023369595,0.019806132160177115,-0.8728930456260771,0.3829846117030431,LonGen OPEL,Genes up-regulated by hemizygotic cre-lox knockout of RSP6 [GeneID=81492] in keratinocytes.,CGP,C2,32,29
Cohort,-0.06864724988696648,0.05417639526440487,-1.2671062655966203,0.20555364398537745,LGP Offspring,Genes down-regulated in pulpal tissue extracted from carious teeth.,CGP,C2,105,185
Cohort,-0.3729412063213516,0.1512597876652725,-2.465567432546215,0.013879963582706783,LGP Proband,Genes down-regulated in pulpal tissue extracted from carious teeth.,CGP,C2,105,264
Cohort,-0.01582545080723007,0.04703257649948141,-0.33647850033060733,0.7365987455760441,LonGen OPEL,Genes down-regulated in pulpal tissue extracted from carious teeth.,CGP,C2,150,173
Cohort,-0.049717371808475574,0.07295699485951636,-0.6814613445113762,0.4958130020684913,LGP Offspring,Genes up-regulated in pulpal tissue extracted from carious teeth.,CGP,C2,168,336
Cohort,-0.3342110073841112,0.19486486800149933,-1.7150911337262689,0.08669997717730275,LGP Proband,Genes up-regulated in pulpal tissue extracted from carious teeth.,CGP,C2,168,464
Cohort,-0.04719978715034338,0.06443331747796481,-0.7325369699687583,0.4640565264313965,LonGen OPEL,Genes up-regulated in pulpal tissue extracted from carious teeth.,CGP,C2,304,334
Cohort,-0.038222634757306057,0.052854906274944546,-0.723161527493337,0.46983078638010045,LGP Offspring,Down-regulated 'cooperation response genes': responded synergystically to the combination of mutant TP53 and HRAS [GeneID=7157;3265] in YAMC cells (colon).,CGP,C2,94,179
Cohort,-0.04963405488219499,0.14587818966079538,-0.34024315079318596,0.7337591023705712,LGP Proband,Down-regulated 'cooperation response genes': responded synergystically to the combination of mutant TP53 and HRAS [GeneID=7157;3265] in YAMC cells (colon).,CGP,C2,94,231
Cohort,-0.03749837259209637,0.04770385726094602,-0.7860658392250257,0.43206284782987103,LonGen OPEL,Down-regulated 'cooperation response genes': responded synergystically to the combination of mutant TP53 and HRAS [GeneID=7157;3265] in YAMC cells (colon).,CGP,C2,150,157
Cohort,-0.0014417524572549417,0.015548083249853987,-0.0927286298951661,0.9261466253516585,LGP Offspring,Up-regulated 'cooperation response genes': responded synergystically to the combination of mutant TP53 and HRAS [GeneID=7157;3265] in YAMC cells (colon).,CGP,C2,7,15
Cohort,-8.911462978626345e-4,0.044067972796763756,-0.020222085140437367,0.9838710469523373,LGP Proband,Up-regulated 'cooperation response genes': responded synergystically to the combination of mutant TP53 and HRAS [GeneID=7157;3265] in YAMC cells (colon).,CGP,C2,7,25
Cohort,0.008218003956712336,0.012284922410915706,0.6689504159513673,0.5037210652483852,LonGen OPEL,Up-regulated 'cooperation response genes': responded synergystically to the combination of mutant TP53 and HRAS [GeneID=7157;3265] in YAMC cells (colon).,CGP,C2,9,14
Cohort,-0.22515137925733267,0.126037425363024,-1.786385104335732,0.07448498490008514,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,505,970
Cohort,-0.2620015296085681,0.35453902750433597,-0.7389920693720069,0.46011973721700283,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,505,1446
Cohort,0.1688567436357359,0.10762126280296715,1.5689905436705254,0.1170475509305141,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,741,948
Cohort,-0.37123212530177313,0.13193828665829896,-2.8136800522748224,0.005040130859250302,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,559,999
Cohort,0.17889104155646043,0.35696126803721473,0.5011497256834326,0.6163979965122817,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,559,1416
Cohort,0.09296577321362931,0.10846340232738816,0.8571165132089394,0.3916384663610951,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,780,969
Cohort,-0.013754916618206001,0.050590555675273145,-0.27188704363112803,0.7857918890044406,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,88,181
Cohort,0.02913857726795319,0.1368901569824934,0.21286101141428057,0.8314873912437719,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,88,238
Cohort,-0.01009061596290493,0.04461378925336816,-0.2261770661442556,0.8211217705609133,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,131,154
Cohort,-0.027747610752951193,0.04435411756163693,-0.6255926682430686,0.5317932886019309,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,67,134
Cohort,-0.04044807833724657,0.11690014047283581,-0.34600538693660104,0.7294259308431494,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,67,167
Cohort,0.011892122809728416,0.03521840602375939,0.33766783203378464,0.7357025444217814,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,88,112
Cohort,-0.012889893471491174,0.02971878645713086,-0.4337287960961917,0.6646237715114578,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,31,62
Cohort,0.054151314995993016,0.07997193803085595,0.6771289570986708,0.49851191100719783,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,31,82
Cohort,0.027736657667177117,0.024483559313012583,1.1328686859853572,0.25761051351707753,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,37,52
Cohort,-0.019874187570411667,0.029366749788928052,-0.6767581606155373,0.4987909088432133,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,31,59
Cohort,0.04367693744778266,0.07894470062040652,0.5532599035088689,0.5802337272562614,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,31,79
Cohort,0.027753194502990117,0.024223157299041526,1.1457298551286816,0.2522512756633834,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,37,52
Cohort,-0.021231199322315004,0.016009206587741253,-1.3261868541675508,0.18522570648223988,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,11,15
Cohort,0.0336415227520857,0.05463489994920813,0.6157515211588357,0.5382265277356099,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,11,40
Cohort,-0.018289984758052907,0.018127443410191582,-1.0089665897271505,0.3132972572967365,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,26,26
Cohort,-0.027671692396143182,0.08359487339723856,-0.33102140444245565,0.7407308981697083,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,213,449
Cohort,0.21672781648097042,0.2170283820280828,0.9986150864495065,0.3182708329194134,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,213,599
Cohort,0.02428283614243707,0.07102829180578984,0.34187554740627546,0.732534789747936,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,323,381
Cohort,-0.035369648413644296,0.0642152900162473,-0.5507979237451909,0.5819541835668725,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,128,253
Cohort,-0.027864755373451268,0.1650414309106873,-0.16883491145038831,0.8659674351141098,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,128,335
Cohort,-0.04629272156171588,0.05191805494442295,-0.8916497663726259,0.37285013102897646,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,186,193
Cohort,-0.042390028423647794,0.058856473760893764,-0.7202271171708076,0.47163412369048763,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,112,227
Cohort,0.18598243413663015,0.14783107584474528,1.25807400828194,0.2087170984523256,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,112,278
Cohort,0.022513917018694492,0.04741043156217065,0.47487264462402856,0.6350080097370269,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,143,176
Cohort,-0.015577859989095541,0.04346205714429073,-0.35842435937577066,0.7201376659491284,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,63,122
Cohort,-0.008294341466761935,0.11338558358425581,-0.07315164066336956,0.9417029883440464,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,63,150
Cohort,0.009897260896206463,0.03243645342655886,0.30512771436665814,0.7603486503097856,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,70,83
Cohort,0.019937651950299302,0.031163042117295134,0.639785162028008,0.5225290411314374,LGP Offspring,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,28,72
Cohort,-0.06657569070351094,0.08823029045890313,-0.754567284741302,0.45072166732914687,LGP Proband,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,28,95
Cohort,-0.022587042884942437,0.02482142668979264,-0.9099816528366981,0.36310764151584785,LonGen OPEL,Transcriptome of human HepaRG hepatocellular carcinoma liver progenitors in responses to a WNT3A-enriched microenvironment and dissection of pathways dependent on _-catenin and/or blocked by the SFRP-like Wnt inhibitor FZD8_CRD.,CGP,C2,50,45
Cohort,-0.04888505580347417,0.029436463842488738,-1.6606972924823002,0.09723796708694551,LGP Offspring,Genes up-regulated in H1299 cells (lung cancer) by expression of SMARCA4 [GeneID=6597] off a plasmid vector.,CGP,C2,37,51
Cohort,-0.07215935035615775,0.079825648931892,-0.903961963625561,0.36627660167985665,LGP Proband,Genes up-regulated in H1299 cells (lung cancer) by expression of SMARCA4 [GeneID=6597] off a plasmid vector.,CGP,C2,37,64
Cohort,-0.0426038478956695,0.025527942116729797,-1.6689103924185478,0.09552836841067304,LonGen OPEL,Genes up-regulated in H1299 cells (lung cancer) by expression of SMARCA4 [GeneID=6597] off a plasmid vector.,CGP,C2,59,50
Cohort,-0.027069034162664023,0.023073040433006814,-1.1731888669488395,0.2411332825981253,LGP Offspring,Genes down-regulated in low grade (LMP and G1) serous ovarian carcinomas vs the higher grade invasive tumors (G2 and G3).,CGP,C2,23,30
Cohort,-0.05380402200877158,0.06334844984615824,-0.849334468948091,0.3959389357163504,LGP Proband,Genes down-regulated in low grade (LMP and G1) serous ovarian carcinomas vs the higher grade invasive tumors (G2 and G3).,CGP,C2,23,45
Cohort,0.007871760699094241,0.019479556268390506,0.40410369674938407,0.6862450125257384,LonGen OPEL,Genes down-regulated in low grade (LMP and G1) serous ovarian carcinomas vs the higher grade invasive tumors (G2 and G3).,CGP,C2,26,32
Cohort,-6.893341260725185e-4,0.017336594983766686,-0.03976179444221799,0.9682947755701077,LGP Offspring,Genes up-regulated in low grade (LMP and G1) serous ovarian carcinomas vs the higher grade invasive tumors (G2 and G3).,CGP,C2,9,17
Cohort,-0.01013933069357359,0.04648614637023253,-0.21811510493514094,0.827392785082796,LGP Proband,Genes up-regulated in low grade (LMP and G1) serous ovarian carcinomas vs the higher grade invasive tumors (G2 and G3).,CGP,C2,9,25
Cohort,-0.030773092594538157,0.018103091364923163,-1.6998805327892554,0.08954406158736787,LonGen OPEL,Genes up-regulated in low grade (LMP and G1) serous ovarian carcinomas vs the higher grade invasive tumors (G2 and G3).,CGP,C2,28,22
Cohort,-0.0316309001735439,0.03333903480688339,-0.9487647244968586,0.34307933376368294,LGP Offspring,Genes with high-CpG-density promoters (HCP) that have no histone H3 methylation marks in brain.,CGP,C2,36,64
Cohort,0.05946089194790524,0.08874940887464579,0.6699863435923371,0.503051953084438,LGP Proband,Genes with high-CpG-density promoters (HCP) that have no histone H3 methylation marks in brain.,CGP,C2,36,96
Cohort,-0.039496611743004714,0.02981041840524786,-1.3249264470589144,0.18557575503614052,LonGen OPEL,Genes with high-CpG-density promoters (HCP) that have no histone H3 methylation marks in brain.,CGP,C2,69,65
Cohort,-0.1281986322299989,0.0769635910780946,-1.6657049188351454,0.09623549996716516,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing the H3K27 tri-methylation (H3K27me3) mark in brain.,CGP,C2,208,386
Cohort,0.19913630256979956,0.22935909306340718,0.868229377392714,0.3855185370022214,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing the H3K27 tri-methylation (H3K27me3) mark in brain.,CGP,C2,208,583
Cohort,-0.11133635789863267,0.06881587224606228,-1.6178877672367722,0.10608294689363018,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing the H3K27 tri-methylation (H3K27me3) mark in brain.,CGP,C2,348,384
Cohort,0.04689690261282085,0.03612324813067195,1.2982471134150608,0.19464517275821214,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark (H3K4me2) in brain.,CGP,C2,36,95
Cohort,0.0304013611900706,0.09391837671029334,0.3236998152539262,0.7462464645859235,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark (H3K4me2) in brain.,CGP,C2,36,102
Cohort,-0.03219444904224929,0.029926364859849036,-1.0757888301175946,0.2823476636542903,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark (H3K4me2) in brain.,CGP,C2,62,64
Cohort,-0.07500034403323344,0.04827503618134019,-1.5536051335415344,0.12074665433420732,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing bivalent histone H3 dimethylation mark at K4 (H3K4me2) and trimethlation mark at K27 (H3K27me3) in brain.,CGP,C2,84,149
Cohort,-0.11073456384284905,0.11896970726236092,-0.9307794932927664,0.3522369818825897,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing bivalent histone H3 dimethylation mark at K4 (H3K4me2) and trimethlation mark at K27 (H3K27me3) in brain.,CGP,C2,84,168
Cohort,-0.060766107011786884,0.03868268237585437,-1.5708865900601796,0.11660638300671781,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing bivalent histone H3 dimethylation mark at K4 (H3K4me2) and trimethlation mark at K27 (H3K27me3) in brain.,CGP,C2,124,121
Cohort,-0.4061458819130121,0.2002699252938906,-2.0279923773727093,0.042952703814980085,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation at K4 (H3K4me2) and trimethylation at K27 (H3K27me3) in brain.,CGP,C2,1251,2476
Cohort,-0.4648730608603366,0.5277372705217933,-0.8808797233530605,0.37863669751249895,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation at K4 (H3K4me2) and trimethylation at K27 (H3K27me3) in brain.,CGP,C2,1251,3452
Cohort,-0.04241775598361583,0.1723422479521488,-0.24612511724573308,0.8056488314388265,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation at K4 (H3K4me2) and trimethylation at K27 (H3K27me3) in brain.,CGP,C2,1955,2311
Cohort,0.01899088916082951,0.031956244418435496,0.5942778792201784,0.55252509865327,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in brain.,CGP,C2,30,69
Cohort,0.083257956312322,0.08389062216047008,0.9924584437228527,0.32126179215932094,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in brain.,CGP,C2,30,82
Cohort,-0.05300760513959694,0.0273181650519844,-1.940379415627934,0.052686400296406984,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in brain.,CGP,C2,59,55
Cohort,0.003147116719323115,0.03376260139827492,0.09321309937580564,0.9257618863845447,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in ES cells (embryonic stem).,CGP,C2,38,76
Cohort,0.010002181888812736,0.09064324539329711,0.11034668767003765,0.912160979163974,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in ES cells (embryonic stem).,CGP,C2,38,93
Cohort,-0.04002839441038307,0.029408058563076114,-1.3611369252590355,0.17385561635149518,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in ES cells (embryonic stem).,CGP,C2,64,62
Cohort,-0.02727357216622628,0.021755758919598377,-1.253625408657073,0.21041156777556325,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing histone trimethylation marks at K4 (H3K4me3) and K27 (H3K27me3)ES cells (embryonic stem).,CGP,C2,19,28
Cohort,0.023417467619895084,0.06030298135877693,0.38833018023721205,0.6978708106890001,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing histone trimethylation marks at K4 (H3K4me3) and K27 (H3K27me3)ES cells (embryonic stem).,CGP,C2,19,42
Cohort,0.00643499822270149,0.018732638441528116,0.34351798561572805,0.7312995237138821,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing histone trimethylation marks at K4 (H3K4me3) and K27 (H3K27me3)ES cells (embryonic stem).,CGP,C2,24,30
Cohort,-0.2434774283820369,0.1331229013577223,-1.828967261822025,0.0678449096053287,LGP Offspring,Genes with high-CpG-density promoters (HCP) that have no histone H3 methylation marks in neural precursor cells (NPC).,CGP,C2,576,1138
Cohort,0.016426552805114885,0.3715791651477875,0.044207410818046224,0.9647496568420757,LGP Proband,Genes with high-CpG-density promoters (HCP) that have no histone H3 methylation marks in neural precursor cells (NPC).,CGP,C2,576,1608
Cohort,-0.24399629185529478,0.1178081525020383,-2.071132486786712,0.03866813936521626,LonGen OPEL,Genes with high-CpG-density promoters (HCP) that have no histone H3 methylation marks in neural precursor cells (NPC).,CGP,C2,923,1026
Cohort,0.021427134237346084,0.04716710935021127,0.45428126786934653,0.6497722213157077,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing the H3K27 tri-methylation (H3K27me3) mark in neural precursor cells (NPC).,CGP,C2,72,163
Cohort,0.08788631888631375,0.1300745469801014,0.6756611568269267,0.49944310009396353,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing the H3K27 tri-methylation (H3K27me3) mark in neural precursor cells (NPC).,CGP,C2,72,212
Cohort,0.03348974536043733,0.0418968191284957,0.7993386146505717,0.42433254666223263,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing the H3K27 tri-methylation (H3K27me3) mark in neural precursor cells (NPC).,CGP,C2,107,143
Cohort,-0.07434723790199578,0.12738959706362035,-0.5836209519123104,0.5596700296482778,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark at K4 (H3K4me2) in neural precursor cells (NPC).,CGP,C2,533,1068
Cohort,0.1213892893953242,0.3595591229891091,0.33760592245910287,0.7357451316232132,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark at K4 (H3K4me2) in neural precursor cells (NPC).,CGP,C2,533,1524
Cohort,0.14374742410057098,0.11201441123256096,1.2832940201071708,0.19976256868626618,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark at K4 (H3K4me2) in neural precursor cells (NPC).,CGP,C2,817,1079
Cohort,-0.03539240925567156,0.10723508552145768,-0.3300450508671396,0.7414681732643789,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark at K4 (H3K4me2) and trimethylation mark at K27 (H3K27me3) in neural precursor cells (NPC).,CGP,C2,355,728
Cohort,-0.03254935694643419,0.2782016332499079,-0.11699915836653331,0.9068888888882789,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark at K4 (H3K4me2) and trimethylation mark at K27 (H3K27me3) in neural precursor cells (NPC).,CGP,C2,355,1013
Cohort,0.046452643612381994,0.09339372427036761,0.4973850649525998,0.6190548947387031,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark at K4 (H3K4me2) and trimethylation mark at K27 (H3K27me3) in neural precursor cells (NPC).,CGP,C2,560,699
Cohort,-0.09293774478284876,0.06404060243878291,-1.4512315818966401,0.14717927116109067,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation marks at k4 (H3K4me3) and K27 ((H3K27me3) in neural precursor cells (NPC).,CGP,C2,156,284
Cohort,-0.23419860681300056,0.18164821490708796,-1.2892975960858841,0.19765210305387845,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation marks at k4 (H3K4me3) and K27 ((H3K27me3) in neural precursor cells (NPC).,CGP,C2,156,384
Cohort,-0.04811230894756073,0.05523812348034914,-0.8709982511385745,0.3840177121323155,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation marks at k4 (H3K4me3) and K27 ((H3K27me3) in neural precursor cells (NPC).,CGP,C2,220,233
Cohort,-0.013947320830863428,0.03245272472007779,-0.42977349209246907,0.6674973733073779,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) that have no histone H3 methylation marks in neural precursor cells (NPC).,CGP,C2,37,68
Cohort,0.03422554101816379,0.0873454965863404,0.39184093463058034,0.6952758490259052,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) that have no histone H3 methylation marks in neural precursor cells (NPC).,CGP,C2,37,81
Cohort,-5.100910024534075e-4,0.028734077218945206,-0.017752127502361197,0.9858410439928822,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) that have no histone H3 methylation marks in neural precursor cells (NPC).,CGP,C2,53,63
Cohort,-0.01732596256031289,0.02446159313552036,-0.7082924838265782,0.4790077965827093,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural precursor cells (NPC).,CGP,C2,21,36
Cohort,0.03477402514103905,0.06835588914609268,0.508720251838415,0.6110828708253422,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural precursor cells (NPC).,CGP,C2,21,54
Cohort,-0.017496827204115044,0.0236428823571516,-0.7400462828434508,0.45949011961892317,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural precursor cells (NPC).,CGP,C2,39,41
Cohort,-0.022355783651853995,0.03410522648863005,-0.6554943612324913,0.5123725237059935,LGP Offspring,Genes down-regulated in HEK293 cells (embryo kidney) after knockdown of TUT1 [GeneID=64852] by RNAi.,CGP,C2,42,72
Cohort,-0.21426466107207148,0.09471941300799347,-2.2620987004426376,0.023947919657567925,LGP Proband,Genes down-regulated in HEK293 cells (embryo kidney) after knockdown of TUT1 [GeneID=64852] by RNAi.,CGP,C2,42,90
Cohort,0.016756302489058312,0.02765294969665808,0.6059499139465526,0.5447207570352826,LonGen OPEL,Genes down-regulated in HEK293 cells (embryo kidney) after knockdown of TUT1 [GeneID=64852] by RNAi.,CGP,C2,45,66
Cohort,0.03745864000418117,0.023884302183657075,1.568337216475698,0.11727040002484279,LGP Offspring,Genes up-regulated in HEK293 cells (embryo kidney) after knockdown of TUT1 [GeneID=64852] by RNAi.,CGP,C2,12,39
Cohort,0.035158039387755385,0.060091700066791834,0.5850731357022231,0.5586567966121592,LGP Proband,Genes up-regulated in HEK293 cells (embryo kidney) after knockdown of TUT1 [GeneID=64852] by RNAi.,CGP,C2,12,43
Cohort,0.008376186706056266,0.016497091759936747,0.5077371713721002,0.611778330344092,LonGen OPEL,Genes up-regulated in HEK293 cells (embryo kidney) after knockdown of TUT1 [GeneID=64852] by RNAi.,CGP,C2,16,24
Cohort,-0.12857557905121567,0.0473312656487299,-2.7165041392605542,0.006766283350195476,LGP Offspring,Hypoxia response genes up-regulated in both astrocytes and HeLa cell line.,CGP,C2,90,130
Cohort,-0.3434398341643007,0.12885652728157398,-2.6652886074899778,0.007840959914112492,LGP Proband,Hypoxia response genes up-regulated in both astrocytes and HeLa cell line.,CGP,C2,90,190
Cohort,-0.06529042515680564,0.03992548781974646,-1.6353068859565472,0.10238007443339234,LonGen OPEL,Hypoxia response genes up-regulated in both astrocytes and HeLa cell line.,CGP,C2,122,116
Cohort,-0.022379655182371547,0.04300760499255307,-0.5203650653470862,0.6029795313085791,LGP Offspring,Candidate genes in genomic amplification regions in hepatocellular carcinoma (HCC) samples.,CGP,C2,60,118
Cohort,0.10371452146543529,0.11780108785256335,0.8804207444607097,0.378885051758189,LGP Proband,Candidate genes in genomic amplification regions in hepatocellular carcinoma (HCC) samples.,CGP,C2,60,181
Cohort,0.024986300653972334,0.039453717672980115,0.6333066217251361,0.5267153388294252,LonGen OPEL,Candidate genes in genomic amplification regions in hepatocellular carcinoma (HCC) samples.,CGP,C2,101,128
Cohort,-0.006558293031660882,0.00959312322336674,-0.6836452403411561,0.4944334686428774,LGP Offspring,"Proteins significantly repressed by oxidative stress (hydrogen peroxide [PubChem=784] in 786-O cells (renal clear cell carcinoma, RCC) expressing VHL [GeneID=7428].",CGP,C2,3,6
Cohort,0.020257478915619315,0.028258813187029386,0.7168552614558268,0.47366411017043064,LGP Proband,"Proteins significantly repressed by oxidative stress (hydrogen peroxide [PubChem=784] in 786-O cells (renal clear cell carcinoma, RCC) expressing VHL [GeneID=7428].",CGP,C2,3,10
Cohort,0.02600301268465342,0.011650243365989939,2.231971630786951,0.02589439925768685,LonGen OPEL,"Proteins significantly repressed by oxidative stress (hydrogen peroxide [PubChem=784] in 786-O cells (renal clear cell carcinoma, RCC) expressing VHL [GeneID=7428].",CGP,C2,5,16
Cohort,-0.007725568923484341,0.007760860661781893,-0.9954525999324604,0.31987236895754756,LGP Offspring,"Proteins significantly induced by oxidative stress (hydrogen peroxide [PubChem=784] in 786-O cells (renal clear cell carcinoma, RCC) expressing VHL [GeneID=7428].",CGP,C2,3,3
Cohort,0.03452457629790952,0.021443926127477447,1.6099932490287314,0.10777773443804824,LGP Proband,"Proteins significantly induced by oxidative stress (hydrogen peroxide [PubChem=784] in 786-O cells (renal clear cell carcinoma, RCC) expressing VHL [GeneID=7428].",CGP,C2,3,5
Cohort,0.013952399670991118,0.007688193290449538,1.8147826340842823,0.06993358861378665,LonGen OPEL,"Proteins significantly induced by oxidative stress (hydrogen peroxide [PubChem=784] in 786-O cells (renal clear cell carcinoma, RCC) expressing VHL [GeneID=7428].",CGP,C2,3,6
Cohort,0.01106281077207432,0.0134659145411707,0.8215417332592504,0.4116274053005523,LGP Offspring,Nuclear receptors whose expression correlated with that of aromatase (CYP19A1) [GeneID=1588] in a panel of breast cancer biopsies.,CGP,C2,5,13
Cohort,0.03271837392804776,0.0383133881574895,0.8539671248482882,0.3933684178284864,LGP Proband,Nuclear receptors whose expression correlated with that of aromatase (CYP19A1) [GeneID=1588] in a panel of breast cancer biopsies.,CGP,C2,5,20
Cohort,0.011561305632804456,0.01572264672361863,0.735328207523547,0.46235622793841347,LonGen OPEL,Nuclear receptors whose expression correlated with that of aromatase (CYP19A1) [GeneID=1588] in a panel of breast cancer biopsies.,CGP,C2,12,25
Cohort,0.03502161443649904,0.019772301294714287,1.7712462456690026,0.07697027137826892,LGP Offspring,"Genes down-regulated in partially reprogrammed and pluripotent cell populations (induced, iPS; and embryonic stem cells, ES) compared to parental lineage-commited cell lines.",CGP,C2,8,31
Cohort,0.06416305736294627,0.04760891176425504,1.3477110688995027,0.17811730524706496,LGP Proband,"Genes down-regulated in partially reprogrammed and pluripotent cell populations (induced, iPS; and embryonic stem cells, ES) compared to parental lineage-commited cell lines.",CGP,C2,8,30
Cohort,-0.02829034817970629,0.01509421468586773,-1.8742510801965546,0.06126189283145164,LonGen OPEL,"Genes down-regulated in partially reprogrammed and pluripotent cell populations (induced, iPS; and embryonic stem cells, ES) compared to parental lineage-commited cell lines.",CGP,C2,22,15
Cohort,-0.002692209042888634,0.017272888952248298,-0.1558632751204139,0.8761873248907915,LGP Offspring,"Genes up-regulated in partially reprogrammed and pluripotent cell populations (induced, iPS; and embryonic stem cells, ES) compared to parental lineage-commited cell lines.",CGP,C2,10,20
Cohort,-0.02318275958550189,0.050297135930355924,-0.4609160970438151,0.644978970217181,LGP Proband,"Genes up-regulated in partially reprogrammed and pluripotent cell populations (induced, iPS; and embryonic stem cells, ES) compared to parental lineage-commited cell lines.",CGP,C2,10,30
Cohort,0.009220872228875285,0.01581088207643713,0.5831978370528169,0.5599253152166863,LonGen OPEL,"Genes up-regulated in partially reprogrammed and pluripotent cell populations (induced, iPS; and embryonic stem cells, ES) compared to parental lineage-commited cell lines.",CGP,C2,16,23
Cohort,-0.057479752810280026,0.03887206119636067,-1.478690633870001,0.13968881207375608,LGP Offspring,Genes with high-CpG-density promoters (HCP) without H3 methylation marks at K4 and K27 in embryonic stem cells (ES).,CGP,C2,56,93
Cohort,-0.10827047451674386,0.10968479284157415,-0.9871056115602727,0.3238771499615182,LGP Proband,Genes with high-CpG-density promoters (HCP) without H3 methylation marks at K4 and K27 in embryonic stem cells (ES).,CGP,C2,56,143
Cohort,-0.012320556308237503,0.029806794681012685,-0.41334723978509025,0.6794635522821562,LonGen OPEL,Genes with high-CpG-density promoters (HCP) without H3 methylation marks at K4 and K27 in embryonic stem cells (ES).,CGP,C2,69,69
Cohort,-0.0212619424159122,0.02789165476769213,-0.7623048038204117,0.4461440008188303,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing histone H3 K27 trimethylation mark (H327me3) in embryonic stem cells (ES).,CGP,C2,22,44
Cohort,-1.2004926666346853e-4,0.07853999908588684,-0.0015285111797899251,0.9987807905292516,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing histone H3 K27 trimethylation mark (H327me3) in embryonic stem cells (ES).,CGP,C2,22,74
Cohort,-0.04129882599377266,0.024400099443432906,-1.6925679376642013,0.09092905904262807,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing histone H3 K27 trimethylation mark (H327me3) in embryonic stem cells (ES).,CGP,C2,49,46
Cohort,0.014837617678406877,0.0450823392681203,0.32912262139199167,0.7421649471794676,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 K27 trimethylation mark (H3K27me3) in embryonic stem cells (ES).,CGP,C2,69,151
Cohort,0.006287005969481865,0.12031249465592603,0.052255636353162396,0.9583375153891864,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 K27 trimethylation mark (H3K27me3) in embryonic stem cells (ES).,CGP,C2,69,189
Cohort,-0.030563857681962646,0.038326874831316755,-0.7974523833857966,0.42542615752893487,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 K27 trimethylation mark (H3K27me3) in embryonic stem cells (ES).,CGP,C2,107,107
Cohort,-0.30854519284895626,0.17171059459122737,-1.7968908300823025,0.07279922568131082,LGP Offspring,Genes with intermediate-CpG-density (ICP) promoters bearing histone H3 K4 trimethylation mark (H3K4me3) in embryonic stem cells (ES).,CGP,C2,895,1740
Cohort,-0.5580668803103921,0.45459117191706866,-1.2276236644828655,0.219934651996435,LGP Proband,Genes with intermediate-CpG-density (ICP) promoters bearing histone H3 K4 trimethylation mark (H3K4me3) in embryonic stem cells (ES).,CGP,C2,895,2357
Cohort,0.17082153162401018,0.1461183817505983,1.1690625749987869,0.24272838712241274,LonGen OPEL,Genes with intermediate-CpG-density (ICP) promoters bearing histone H3 K4 trimethylation mark (H3K4me3) in embryonic stem cells (ES).,CGP,C2,1341,1674
Cohort,-0.08957380988202568,0.06856897281394644,-1.3063315112663756,0.1918841336086323,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing bivalent histone H3 methylation mark (H3K4me3 and H3K27me3) in embryonic stem cells (ES).,CGP,C2,159,295
Cohort,-0.08921016901355451,0.18933871072442135,-0.47116708818936714,0.6376446376299526,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing bivalent histone H3 methylation mark (H3K4me3 and H3K27me3) in embryonic stem cells (ES).,CGP,C2,159,444
Cohort,0.10834453159362552,0.060655627214106805,1.786223909797896,0.07444354066922376,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing bivalent histone H3 methylation mark (H3K4me3 and H3K27me3) in embryonic stem cells (ES).,CGP,C2,221,303
Cohort,-0.022512264364099515,0.018188360574725282,-1.2377291659470822,0.21624621722549955,LGP Offspring,Genes with low-CpG-density promoters bearing H3 trimethylation mark at K27 (H3K27me3) in embryonic stem cells (ES).,CGP,C2,14,20
Cohort,0.005984338489950241,0.050968639261917026,0.11741216906337237,0.9065617104809437,LGP Proband,Genes with low-CpG-density promoters bearing H3 trimethylation mark at K27 (H3K27me3) in embryonic stem cells (ES).,CGP,C2,14,30
Cohort,0.0073471326387078,0.01464695991347395,0.501614852645911,0.6160771727804859,LonGen OPEL,Genes with low-CpG-density promoters bearing H3 trimethylation mark at K27 (H3K27me3) in embryonic stem cells (ES).,CGP,C2,13,20
Cohort,-0.016566049491746847,0.06453560209566979,-0.2566962878441696,0.7974913414781597,LGP Offspring,Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in embryonic stem cells (ES).,CGP,C2,132,274
Cohort,0.05797060206316531,0.17558592601574619,0.33015517461215327,0.7413656282448807,LGP Proband,Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in embryonic stem cells (ES).,CGP,C2,132,355
Cohort,0.06630318888123177,0.05353655757360254,1.2384656744146754,0.21590854614224791,LonGen OPEL,Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in embryonic stem cells (ES).,CGP,C2,180,243
Cohort,-1.64523893305075e-4,0.007171267906676681,-0.02294209272978046,0.9817032342574531,LGP Offspring,Genes with low-CpG-density promoters (LCP) bearing the bivalent histone H3 trimethylation mark at K4 and K27 (H3K4me3 and H3K27me3) in embryonic stem cells (ES).,CGP,C2,2,3
Cohort,-0.021614639431101125,0.027239917034020313,-0.7934913826685411,0.4277172787771226,LGP Proband,Genes with low-CpG-density promoters (LCP) bearing the bivalent histone H3 trimethylation mark at K4 and K27 (H3K4me3 and H3K27me3) in embryonic stem cells (ES).,CGP,C2,2,10
Cohort,-0.0015680099567764217,0.008184773831662466,-0.1915764551380319,0.8481228435438665,LonGen OPEL,Genes with low-CpG-density promoters (LCP) bearing the bivalent histone H3 trimethylation mark at K4 and K27 (H3K4me3 and H3K27me3) in embryonic stem cells (ES).,CGP,C2,5,5
Cohort,-0.09824089660831797,0.04848622960882636,-2.0261607759749243,0.04314051824787994,LGP Offspring,"Genes with high-CpG-density promoters (HCP) without H3 methylation marks at either H3K4 or H3K27 in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,88,155
Cohort,0.1797691791175202,0.13908538176343915,1.292509513496374,0.1965387296312187,LGP Proband,"Genes with high-CpG-density promoters (HCP) without H3 methylation marks at either H3K4 or H3K27 in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,88,223
Cohort,-0.0763308867531287,0.042035744833659065,-1.8158566490300099,0.06976846460369317,LonGen OPEL,"Genes with high-CpG-density promoters (HCP) without H3 methylation marks at either H3K4 or H3K27 in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,141,137
Cohort,0.07508701320401433,0.04516964676503568,1.6623334159464067,0.09690951846013598,LGP Offspring,"Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,51,139
Cohort,-0.11300462550069881,0.12037706716527759,-0.9387554304304787,0.3481281131830821,LGP Proband,"Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,51,183
Cohort,-0.03851807864884667,0.037061485153336,-1.039302081108845,0.29897984916940484,LonGen OPEL,"Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,103,110
Cohort,-0.052872135757558184,0.07041997272253266,-0.7508116477960578,0.45302728541425197,LGP Offspring,"Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,164,315
Cohort,-0.027839634287991265,0.19821335415828195,-0.1404528691127446,0.8883361022636951,LGP Proband,"Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,164,475
Cohort,0.10981461636703166,0.06218795036012753,1.7658503895224127,0.07780425317000689,LonGen OPEL,"Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,234,310
Cohort,-0.011192600442531633,0.01976370585304793,-0.5663209382771464,0.5713635857019279,LGP Offspring,"Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,14,24
Cohort,-0.04835205987331328,0.052070712070524335,-0.9285845718381087,0.3533730879151763,LGP Proband,"Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,14,30
Cohort,0.008998303415279513,0.014926946598156254,0.6028227779947284,0.5467982937977589,LonGen OPEL,"Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,13,19
Cohort,-0.062250540473971536,0.06894452048118617,-0.9029077298602532,0.36689648159463095,LGP Offspring,"Table 2S. Genes in MEF, MCV6, MCV8.1 and ES cells by  epigenetic mark of their promoter",CGP,C2,163,321
Cohort,-0.2941669888092768,0.18572571259773346,-1.5838786385298096,0.11360043754952813,LGP Proband,"Table 2S. Genes in MEF, MCV6, MCV8.1 and ES cells by  epigenetic mark of their promoter",CGP,C2,163,408
Cohort,0.05430469059936308,0.05924149901047867,0.916666382627449,0.35959511926113297,LonGen OPEL,"Table 2S. Genes in MEF, MCV6, MCV8.1 and ES cells by  epigenetic mark of their promoter",CGP,C2,224,284
Cohort,-0.013757015992486452,0.014506899014134393,-0.9483085240396784,0.3433112889860075,LGP Offspring,"Genes with low-CpG-density promoters (LCP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,8,13
Cohort,3.2283243653374026e-4,0.04050097861143577,0.007970978667724981,0.9936420527592004,LGP Proband,"Genes with low-CpG-density promoters (LCP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,8,19
Cohort,0.011419372013919087,0.012001236391363633,0.951516297282231,0.3416311728283977,LonGen OPEL,"Genes with low-CpG-density promoters (LCP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).",CGP,C2,9,13
Cohort,0.057469655963944336,0.05566432343867374,1.0324324884188985,0.30223877706264995,LGP Offspring,"Genes with high-CpG-density promoters (HCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 (induced pluripotent cells, iPS).",CGP,C2,78,194
Cohort,-0.04110516875709502,0.1532621507022578,-0.26820169604007443,0.7886103910273837,LGP Proband,"Genes with high-CpG-density promoters (HCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 (induced pluripotent cells, iPS).",CGP,C2,78,250
Cohort,0.012068031594412424,0.0451341422879962,0.2673814319414245,0.7892447556875821,LonGen OPEL,"Genes with high-CpG-density promoters (HCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 (induced pluripotent cells, iPS).",CGP,C2,133,165
Cohort,-0.08386175793813017,0.13179742894167154,-0.6362928215788196,0.5248009582577511,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,504,1048
Cohort,0.6270642980470501,0.35354289104378434,1.7736583422614816,0.07648452825867262,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,504,1456
Cohort,0.10535961428523281,0.11165645871641268,0.9436051930755505,0.3456577445940172,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,803,1034
Cohort,-0.03609394619048677,0.058721372002930254,-0.6146645583942699,0.538983098184384,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,114,227
Cohort,-0.1308594557202468,0.15962007079111307,-0.8198183039994771,0.41255392211107766,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,114,289
Cohort,-0.012024876059125215,0.046355679378401016,-0.25940459120372833,0.7953901600200014,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,146,164
Cohort,-0.006089622216493938,0.033808240463579324,-0.1801224237935162,0.8571104397838154,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent trimethylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,37,72
Cohort,-0.1537318060438465,0.08461182883444303,-1.8169067866934787,0.06959019050207678,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent trimethylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,37,79
Cohort,-0.014335103410725351,0.027071754393367217,-0.5295225127425639,0.5965906774274974,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent trimethylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,54,64
Cohort,-0.01113805054459804,0.027724032132695597,-0.4017471373315384,0.687997108041083,LGP Offspring,Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,27,53
Cohort,0.034715978908776764,0.07898046785494954,0.43955144672647295,0.6603758826956907,LGP Proband,Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,27,77
Cohort,-0.05160459655975064,0.024319997658805298,-2.1218997338622967,0.034154470441973055,LonGen OPEL,Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,50,36
Cohort,-0.08450642985905887,0.0701544202828604,-1.2045774096390738,0.22878804013704163,LGP Offspring,Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K4 (H3K4me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,184,345
Cohort,-0.16630083708594004,0.1994882327453119,-0.8336373268605649,0.4047240716125532,LGP Proband,Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K4 (H3K4me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,184,467
Cohort,-0.006923549829965725,0.06319112200050996,-0.10956523022189496,0.9127818019559131,LonGen OPEL,Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K4 (H3K4me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).,CGP,C2,271,333
Cohort,-0.02515090221464376,0.08383258289287156,-0.3000134475969055,0.764259128225083,LGP Offspring,Genes with high-CpG-density promoters (HCP) with unmethylated histone H3 in MEF cells (embryonic fibroblast).,CGP,C2,178,369
Cohort,-0.22279126605172742,0.22232133463224357,-1.0021137486434273,0.31657931647716536,LGP Proband,Genes with high-CpG-density promoters (HCP) with unmethylated histone H3 in MEF cells (embryonic fibroblast).,CGP,C2,178,557
Cohort,-0.022753555310554688,0.06708368328073247,-0.3391816638233083,0.734562342848138,LonGen OPEL,Genes with high-CpG-density promoters (HCP) with unmethylated histone H3 in MEF cells (embryonic fibroblast).,CGP,C2,300,338
Cohort,-0.11083901424085342,0.13568102518809072,-0.8169087319851871,0.4142683818009367,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in MEF cells (embryonic fibroblast).,CGP,C2,587,1172
Cohort,0.2244187425122973,0.370829930302456,0.6051796906718319,0.5452242384172019,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in MEF cells (embryonic fibroblast).,CGP,C2,587,1670
Cohort,-0.2640710888236532,0.11697163159924154,-2.257565233666156,0.024242972453449717,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in MEF cells (embryonic fibroblast).,CGP,C2,958,1066
Cohort,0.0032177363678220373,0.09025643599351861,0.035651046181937714,0.9715711296834413,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).,CGP,C2,273,579
Cohort,-0.19724355591907516,0.25106554193546426,-0.7856257549264809,0.4323099036887388,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).,CGP,C2,273,785
Cohort,-0.07145878091209354,0.0767978214446539,-0.930479270998487,0.3524050918739785,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).,CGP,C2,436,483
Cohort,-0.02499731945393668,0.030043062922145557,-0.8320496321801623,0.4056747557524494,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).,CGP,C2,32,56
Cohort,-0.08414429964359693,0.08851926079671397,-0.9505761671105205,0.34209495451194194,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).,CGP,C2,32,93
Cohort,0.05021814719123012,0.027499227022142195,1.8261657737068318,0.0681997466160257,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).,CGP,C2,42,72
Cohort,-0.0938897095464612,0.0459349583265878,-2.043970713523354,0.04134345489714252,LGP Offspring,Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).,CGP,C2,81,124
Cohort,-0.24259758375654156,0.12578680801344183,-1.9286409090738441,0.05411455617031918,LGP Proband,Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).,CGP,C2,81,185
Cohort,0.018881194510170025,0.03849823202100623,0.49044315852914133,0.6239555033165675,LonGen OPEL,Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).,CGP,C2,97,125
Cohort,-0.06244452164358901,0.06394142307595904,-0.9765894883103902,0.32912176817493255,LGP Offspring,Genes with low-CpG-density promoters (LCP) bearing tri-methylation mark at H3K4 (H3K4me3) in MEF cells (embryonic fibroblasts).,CGP,C2,154,292
Cohort,-0.10950884377373564,0.18375540382036828,-0.5959489707349612,0.5513710143422994,LGP Proband,Genes with low-CpG-density promoters (LCP) bearing tri-methylation mark at H3K4 (H3K4me3) in MEF cells (embryonic fibroblasts).,CGP,C2,154,387
Cohort,-0.011945059924949892,0.055881372145574024,-0.21375745559418904,0.8307909429423419,LonGen OPEL,Genes with low-CpG-density promoters (LCP) bearing tri-methylation mark at H3K4 (H3K4me3) in MEF cells (embryonic fibroblasts).,CGP,C2,220,249
Cohort,0.032644428153493874,0.10592962744799461,0.30817089552703675,0.7580472306386435,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in neural progenitor cells (NPC).,CGP,C2,339,722
Cohort,0.2850019959496532,0.28661674771820717,0.9943661639404913,0.3203330422495532,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in neural progenitor cells (NPC).,CGP,C2,339,980
Cohort,0.042662238352516105,0.08924423704995003,0.4780391402599815,0.6327535998398631,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in neural progenitor cells (NPC).,CGP,C2,525,663
Cohort,-0.06339294414007807,0.08066201773987049,-0.7859082368174324,0.4321966306427546,LGP Offspring,Genes with high-CpG-density promoters (HCP) bearing the bivalent histone H3 trimethylation mark at K4 and K27 (H3K4me3 and H3K27me3) in neural progenitor cells (NPC).,CGP,C2,224,434
Cohort,-0.3666754934122144,0.22019301735657412,-1.6652457821513516,0.09623929668400324,LGP Proband,Genes with high-CpG-density promoters (HCP) bearing the bivalent histone H3 trimethylation mark at K4 and K27 (H3K4me3 and H3K27me3) in neural progenitor cells (NPC).,CGP,C2,224,575
Cohort,-0.03567847223099552,0.06878133977710144,-0.518723135469855,0.6040979958224633,LonGen OPEL,Genes with high-CpG-density promoters (HCP) bearing the bivalent histone H3 trimethylation mark at K4 and K27 (H3K4me3 and H3K27me3) in neural progenitor cells (NPC).,CGP,C2,338,378
Cohort,0.012656155181780458,0.020945842224561282,0.6042323362361498,0.5458919117635308,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in neural progenitor cells (NPC).,CGP,C2,11,32
Cohort,-0.03190528221632266,0.05132978943744668,-0.6215743833355133,0.5343916310100372,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in neural progenitor cells (NPC).,CGP,C2,11,34
Cohort,-0.0054341985189481235,0.015005799393546586,-0.3621398884810603,0.7173436157560809,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in neural progenitor cells (NPC).,CGP,C2,17,18
Cohort,-0.23180150121462406,0.12349100083230977,-1.8770720105296637,0.06093867423197858,LGP Offspring,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural progenitor cells (NPC).,CGP,C2,480,928
Cohort,-0.2200001914979569,0.3307393949443268,-0.6651768578550779,0.5061212800944568,LGP Proband,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural progenitor cells (NPC).,CGP,C2,480,1297
Cohort,0.05398810237682402,0.10513637406344303,0.5135054623839859,0.6077402882875014,LonGen OPEL,Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural progenitor cells (NPC).,CGP,C2,742,904
Cohort,-0.002218575468624071,0.042086251013350964,-0.05271497021486365,0.9579745846846135,LGP Offspring,Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural progenitor cells (NPC).,CGP,C2,57,119
Cohort,-0.020909806365022404,0.11991174753812579,-0.17437662943219268,0.8616117995581073,LGP Proband,Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural progenitor cells (NPC).,CGP,C2,57,164
Cohort,0.027117222673429777,0.033736235080601626,0.8038010942430921,0.4217518280299365,LonGen OPEL,Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural progenitor cells (NPC).,CGP,C2,75,99
Cohort,-0.008683018952287635,0.018263102242672063,-0.47544052685636323,0.6346266007494927,LGP Offspring,Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K27 in neural progenitor cells (NPC).,CGP,C2,13,21
Cohort,-0.0470344259099034,0.044995839371208865,-1.0453061120135243,0.29618438226534316,LGP Proband,Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K27 in neural progenitor cells (NPC).,CGP,C2,13,21
Cohort,-0.027557346175985473,0.016481291876641338,-1.6720379920606856,0.09490982675119364,LonGen OPEL,Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K27 in neural progenitor cells (NPC).,CGP,C2,24,16
Cohort,0.003940612226544037,0.01583881943812585,0.24879456716695264,0.8035952607411516,LGP Offspring,"Genes up-regulated in cells that have been partially reprogrammed to pluripotency: comparison with the parental lineage-committed cell lines, fully reprogrammed stem cells, and embryonic stem cells.",CGP,C2,6,17
Cohort,0.006893629385996481,0.039753053650316825,0.17341131694273101,0.8623702089314599,LGP Proband,"Genes up-regulated in cells that have been partially reprogrammed to pluripotency: comparison with the parental lineage-committed cell lines, fully reprogrammed stem cells, and embryonic stem cells.",CGP,C2,6,18
Cohort,0.013613265467856333,0.009281115968462138,1.466770323107171,0.14283349638941495,LonGen OPEL,"Genes up-regulated in cells that have been partially reprogrammed to pluripotency: comparison with the parental lineage-committed cell lines, fully reprogrammed stem cells, and embryonic stem cells.",CGP,C2,4,9
Cohort,-0.00465908142876581,0.012249225040129057,-0.38035724002966986,0.7037997325666201,LGP Offspring,Genes down-regulated in the induced pluripotent cells (iPS) and embryonic stem cells (ES) compared to the parental lineage-committed and partially reprogrammed cell lines.,CGP,C2,5,10
Cohort,-0.0023649896950082754,0.0358969651757626,-0.06588271970704368,0.9474869875101797,LGP Proband,Genes down-regulated in the induced pluripotent cells (iPS) and embryonic stem cells (ES) compared to the parental lineage-committed and partially reprogrammed cell lines.,CGP,C2,5,16
Cohort,-0.0203237120547407,0.01307648956474553,-1.554217739716156,0.12052996685852142,LonGen OPEL,Genes down-regulated in the induced pluripotent cells (iPS) and embryonic stem cells (ES) compared to the parental lineage-committed and partially reprogrammed cell lines.,CGP,C2,15,9
Cohort,-0.001070148973160651,0.011922131446159315,-0.08976154792399951,0.9285032926606263,LGP Offspring,Genes up-regulated in the induced pluripotent cells (iPS) and embryonic stem cells (ES) compared to the parental lineage-committed and partially reprogrammed cell lines.,CGP,C2,5,9
Cohort,0.0018572747909047416,0.03236306783436131,0.05738871235602671,0.9542493007875232,LGP Proband,Genes up-regulated in the induced pluripotent cells (iPS) and embryonic stem cells (ES) compared to the parental lineage-committed and partially reprogrammed cell lines.,CGP,C2,5,12
Cohort,-0.015704061702041083,0.011127803804564615,-1.4112453793981605,0.15856299966430665,LonGen OPEL,Genes up-regulated in the induced pluripotent cells (iPS) and embryonic stem cells (ES) compared to the parental lineage-committed and partially reprogrammed cell lines.,CGP,C2,11,8
Cohort,-0.035526283995109244,0.037174754076441684,-0.9556561940411838,0.33958757976079956,LGP Offspring,"Transcripts significantly enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to both chemotactic (lysophosphatidic acid, LPA [PubChem=3988]) and haptotactic (fibronectin, FN1 [GeneID=2335) migratory stimuli.",CGP,C2,49,91
Cohort,0.09647398366792359,0.10601667047161388,0.9099888087294219,0.36309132261718613,LGP Proband,"Transcripts significantly enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to both chemotactic (lysophosphatidic acid, LPA [PubChem=3988]) and haptotactic (fibronectin, FN1 [GeneID=2335) migratory stimuli.",CGP,C2,49,137
Cohort,0.023715826360733036,0.03417265768040828,0.694000056493402,0.48788465216058974,LonGen OPEL,"Transcripts significantly enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to both chemotactic (lysophosphatidic acid, LPA [PubChem=3988]) and haptotactic (fibronectin, FN1 [GeneID=2335) migratory stimuli.",CGP,C2,76,91
Cohort,-0.3648846971851589,0.13495376707306253,-2.7037755603192184,0.007028052015817054,LGP Offspring,Transcripts depleted in pseudopodia of NIH/3T3 cells (fibroblast) in response to the chemotactic migration stimulus by lysophosphatidic acid (LPA) [PubChem=3988].,CGP,C2,603,1109
Cohort,-0.4606864363122504,0.3647595234847361,-1.2629867259148575,0.20694693389294452,LGP Proband,Transcripts depleted in pseudopodia of NIH/3T3 cells (fibroblast) in response to the chemotactic migration stimulus by lysophosphatidic acid (LPA) [PubChem=3988].,CGP,C2,603,1527
Cohort,0.09985917396430856,0.11644530066058545,0.8575629363985919,0.39139196825270783,LonGen OPEL,Transcripts depleted in pseudopodia of NIH/3T3 cells (fibroblast) in response to the chemotactic migration stimulus by lysophosphatidic acid (LPA) [PubChem=3988].,CGP,C2,833,1032
Cohort,-0.04785643306141507,0.04660640410487707,-1.0268209697904411,0.30487204697150216,LGP Offspring,Transcripts enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to the chemotactic migration stimulus by lysophosphatidic acid (LPA) [PubChem=3988].,CGP,C2,76,143
Cohort,0.28071845754572344,0.12714841688537126,2.2078014372668195,0.027529600748301724,LGP Proband,Transcripts enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to the chemotactic migration stimulus by lysophosphatidic acid (LPA) [PubChem=3988].,CGP,C2,76,196
Cohort,-0.012000648543842701,0.04008786714665866,-0.2993586189042976,0.7647445771564351,LonGen OPEL,Transcripts enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to the chemotactic migration stimulus by lysophosphatidic acid (LPA) [PubChem=3988].,CGP,C2,117,127
Cohort,-0.09922360350043809,0.15264976935062505,-0.65000821110007,0.5159077411350463,LGP Offspring,"Transcripts depleted from pseudopodia of NIH/3T3 cells (fibroblast) in response to haptotactic migratory stimulus by fibronectin, FN1 [GeneID=2335].",CGP,C2,730,1510
Cohort,0.0925870543468463,0.4431479247746786,0.20893035749614033,0.8345536234359621,LGP Proband,"Transcripts depleted from pseudopodia of NIH/3T3 cells (fibroblast) in response to haptotactic migratory stimulus by fibronectin, FN1 [GeneID=2335].",CGP,C2,730,2108
Cohort,-0.013423118292700313,0.13781914770781736,-0.0973966137213235,0.9224359516648003,LonGen OPEL,"Transcripts depleted from pseudopodia of NIH/3T3 cells (fibroblast) in response to haptotactic migratory stimulus by fibronectin, FN1 [GeneID=2335].",CGP,C2,1203,1443
Cohort,-0.08284901007470137,0.1044558814839529,-0.7931483502671804,0.42796968278949865,LGP Offspring,"Transcripts enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to haptotactic migratory stimulus by fibronectin, FN1 [GeneID=2335].",CGP,C2,370,708
Cohort,-0.6023623527595998,0.3017950425012669,-1.995931900561525,0.046266122050743576,LGP Proband,"Transcripts enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to haptotactic migratory stimulus by fibronectin, FN1 [GeneID=2335].",CGP,C2,370,1067
Cohort,-0.07723217435769786,0.09736136384919528,-0.7932527986904963,0.42786693223871997,LonGen OPEL,"Transcripts enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to haptotactic migratory stimulus by fibronectin, FN1 [GeneID=2335].",CGP,C2,622,706
Cohort,0,0,NA,NA,LGP Offspring,Top genes down-regulated in colon epithelium biopsies from FAP (familial adenomatous polyposis) patients with mutated APC [GeneID=324].,CGP,C2,0,0
Cohort,-1.2613021214720997e-4,0.013722732650597206,-0.009191333487191478,0.9926686782653338,LGP Proband,Top genes down-regulated in colon epithelium biopsies from FAP (familial adenomatous polyposis) patients with mutated APC [GeneID=324].,CGP,C2,0,3
Cohort,0.008411016864398173,0.004490640162150795,1.8730106534231215,0.06143321024980034,LonGen OPEL,Top genes down-regulated in colon epithelium biopsies from FAP (familial adenomatous polyposis) patients with mutated APC [GeneID=324].,CGP,C2,0,3
Cohort,-0.013459235431302079,0.017683772689127436,-0.7611065618128681,0.4468588326119417,LGP Offspring,Top genes up-regulated in colon epithelium biopsies from FAP (familial adenomatous polyposis) patients with mutated APC [GeneID=324].,CGP,C2,14,18
Cohort,-0.1388475190175821,0.04955269377970944,-2.8020175781934307,0.0051960874993413056,LGP Proband,Top genes up-regulated in colon epithelium biopsies from FAP (familial adenomatous polyposis) patients with mutated APC [GeneID=324].,CGP,C2,14,28
Cohort,-0.00746951524068269,0.013730010704572393,-0.5440283624975747,0.5865742997803309,LonGen OPEL,Top genes up-regulated in colon epithelium biopsies from FAP (familial adenomatous polyposis) patients with mutated APC [GeneID=324].,CGP,C2,14,15
Cohort,-0.015745093519520706,0.025505422750736036,-0.6173233697554115,0.5372293309564029,LGP Offspring,Genes under-expressed in hepatocellular carcinoma (HCC) with vascular invasion.,CGP,C2,23,45
Cohort,-0.0037779173322868387,0.07526802667453165,-0.05019285743497734,0.9599807214368032,LGP Proband,Genes under-expressed in hepatocellular carcinoma (HCC) with vascular invasion.,CGP,C2,23,73
Cohort,-0.0035026105755148465,0.02566877334317161,-0.136454147172818,0.8914967734024709,LonGen OPEL,Genes under-expressed in hepatocellular carcinoma (HCC) with vascular invasion.,CGP,C2,40,48
Cohort,0.016245825430302653,0.014313850858278443,1.134972383822684,0.2567891554238621,LGP Offspring,Genes over-expressed in hepatocellular carcinoma (HCC) with vascular invasion.,CGP,C2,6,16
Cohort,0.006513317274338196,0.04388506736609503,0.14841762050866283,0.8820490716368091,LGP Proband,Genes over-expressed in hepatocellular carcinoma (HCC) with vascular invasion.,CGP,C2,6,25
Cohort,0.011445270245235263,0.01402393614696266,0.8161239558776877,0.4146733978636227,LonGen OPEL,Genes over-expressed in hepatocellular carcinoma (HCC) with vascular invasion.,CGP,C2,10,18
Cohort,-0.026424025453854007,0.029417836723562706,-0.8982314268094787,0.36938199011190676,LGP Offspring,"Top genes down-regulated in mesenchyme stem cells (MSC) grown in a tumor conditioned medium, which leads to carcinoma-associated fibroblast phenotype.",CGP,C2,32,56
Cohort,0.012684403708988413,0.0847313143567873,0.14970148646080036,0.8810363290598335,LGP Proband,"Top genes down-regulated in mesenchyme stem cells (MSC) grown in a tumor conditioned medium, which leads to carcinoma-associated fibroblast phenotype.",CGP,C2,32,82
Cohort,-0.01045667507486447,0.02664750439757377,-0.3924072933380035,0.6948623463456504,LonGen OPEL,"Top genes down-regulated in mesenchyme stem cells (MSC) grown in a tumor conditioned medium, which leads to carcinoma-associated fibroblast phenotype.",CGP,C2,46,51
Cohort,0.05297394574798046,0.03259816830631468,1.6250589680438803,0.10461609897285562,LGP Offspring,"Top genes up-regulated in mesenchyme stem cells (MSC) grown in a tumor conditioned medium, which leads to carcinoma-associated fibroblast phenotype.",CGP,C2,29,83
Cohort,-0.03843465409882378,0.09550390930550037,-0.4024406370201875,0.6874628930906601,LGP Proband,"Top genes up-regulated in mesenchyme stem cells (MSC) grown in a tumor conditioned medium, which leads to carcinoma-associated fibroblast phenotype.",CGP,C2,29,116
Cohort,-0.07352658704065311,0.029384058022089383,-2.5022611575766596,0.012539821989989779,LonGen OPEL,"Top genes up-regulated in mesenchyme stem cells (MSC) grown in a tumor conditioned medium, which leads to carcinoma-associated fibroblast phenotype.",CGP,C2,73,56
Cohort,0.019209813920422543,0.06091020508877908,0.3153792355882477,0.7525710640783091,LGP Offspring,"Genes down-regulated in PaCa44 and CFPAC1 cells (pancreatic cancer) after treatment with decitabine [PubChem=451668], a DNA hypomethylating agent similar to azacitidine [PubChem=9444].",CGP,C2,111,247
Cohort,-0.06189409222722522,0.16012782199244383,-0.3865292830258186,0.699203314367046,LGP Proband,"Genes down-regulated in PaCa44 and CFPAC1 cells (pancreatic cancer) after treatment with decitabine [PubChem=451668], a DNA hypomethylating agent similar to azacitidine [PubChem=9444].",CGP,C2,111,315
Cohort,-0.05671537265356093,0.05215592251885414,-1.087419604802476,0.2771805647327578,LonGen OPEL,"Genes down-regulated in PaCa44 and CFPAC1 cells (pancreatic cancer) after treatment with decitabine [PubChem=451668], a DNA hypomethylating agent similar to azacitidine [PubChem=9444].",CGP,C2,191,217
Cohort,-0.04682974242662023,0.05535620028028596,-0.845971041897862,0.3978682462331511,LGP Offspring,"Genes up-regulated in PaCa44 and CFPAC1 cells (pancreatic cancer) after treatment with decitabine [PubChem=451668], a DNA hypomethylating agent similar to azacitidine [PubChem=9444].",CGP,C2,103,191
Cohort,-0.03172165881528713,0.15390776767697043,-0.20610823803166442,0.8367566659466341,LGP Proband,"Genes up-regulated in PaCa44 and CFPAC1 cells (pancreatic cancer) after treatment with decitabine [PubChem=451668], a DNA hypomethylating agent similar to azacitidine [PubChem=9444].",CGP,C2,103,275
Cohort,0.10642189208670567,0.04624235237061245,2.3013944280727814,0.02162682444316907,LonGen OPEL,"Genes up-regulated in PaCa44 and CFPAC1 cells (pancreatic cancer) after treatment with decitabine [PubChem=451668], a DNA hypomethylating agent similar to azacitidine [PubChem=9444].",CGP,C2,132,196
Cohort,-0.2540928174353665,0.08686448224538396,-2.925163552090005,0.003558105271782706,LGP Offspring,"Genes down-regulated in the MM1S cells (multiple myeloma) after treatment with aplidin [PubChem=44152164], a marine-derived compound with potential anti-cancer properties.",CGP,C2,285,489
Cohort,0.1052295046109536,0.25773560255523015,0.40828470559632507,0.6831694668653631,LGP Proband,"Genes down-regulated in the MM1S cells (multiple myeloma) after treatment with aplidin [PubChem=44152164], a marine-derived compound with potential anti-cancer properties.",CGP,C2,285,758
Cohort,0.081073832932129275,0.0790958944057329,1.0250068419006715,0.3056713467241248,LonGen OPEL,"Genes down-regulated in the MM1S cells (multiple myeloma) after treatment with aplidin [PubChem=44152164], a marine-derived compound with potential anti-cancer properties.",CGP,C2,409,520
Cohort,-0.07573084101210324,0.09814308430493943,-0.7716370597932369,0.440599065760476,LGP Offspring,"Genes up-regulated in the MM1S cells (multiple myeloma) after treatment with aplidin [PubChem=44152164], a marine-derived compound with potential anti-cancer properties.",CGP,C2,335,654
Cohort,-0.2913108403802553,0.2773861838105278,-1.0501995318528152,0.2939305981461773,LGP Proband,"Genes up-regulated in the MM1S cells (multiple myeloma) after treatment with aplidin [PubChem=44152164], a marine-derived compound with potential anti-cancer properties.",CGP,C2,335,924
Cohort,0.12666823814746203,0.08639920034563102,1.4660811401117013,0.14302109413304884,LonGen OPEL,"Genes up-regulated in the MM1S cells (multiple myeloma) after treatment with aplidin [PubChem=44152164], a marine-derived compound with potential anti-cancer properties.",CGP,C2,478,633
Cohort,-0.10274501940681446,0.08306317327519087,-1.2369503277513492,0.2165350568961024,LGP Offspring,"Genes commonly down-regulated in UET-13 cells (mesenchymal progenitor) by expression of EWSR1 [GeneID=2130] fusions with ETS transcription factors FLI1 and ERG [GeneID=2313 ,2078].",CGP,C2,236,452
Cohort,0.1005125163216689,0.22597009958611558,0.44480449628409485,0.6565764555231745,LGP Proband,"Genes commonly down-regulated in UET-13 cells (mesenchymal progenitor) by expression of EWSR1 [GeneID=2130] fusions with ETS transcription factors FLI1 and ERG [GeneID=2313 ,2078].",CGP,C2,236,630
Cohort,-0.0556224229803875,0.07508418200366468,-0.7408008117831356,0.4590326891962664,LonGen OPEL,"Genes commonly down-regulated in UET-13 cells (mesenchymal progenitor) by expression of EWSR1 [GeneID=2130] fusions with ETS transcription factors FLI1 and ERG [GeneID=2313 ,2078].",CGP,C2,396,437
Cohort,-0.13318779965352787,0.08516965295545179,-1.5637940866471782,0.11833391966266768,LGP Offspring,"Genes commonly up-regulated in UET-13 cells (mesenchymal progenitor) by expression of EWSR1 [GeneID=2130] fusions with ETS transcription factors FLI1 and ERG [GeneID=2313 ,2078].",CGP,C2,242,450
Cohort,0.0410048783079911,0.23469366636775624,0.1747165952222076,0.8613447317388553,LGP Proband,"Genes commonly up-regulated in UET-13 cells (mesenchymal progenitor) by expression of EWSR1 [GeneID=2130] fusions with ETS transcription factors FLI1 and ERG [GeneID=2313 ,2078].",CGP,C2,242,609
Cohort,-0.1485008015155475,0.07054041305658174,-2.105187580861376,0.03558777572133241,LonGen OPEL,"Genes commonly up-regulated in UET-13 cells (mesenchymal progenitor) by expression of EWSR1 [GeneID=2130] fusions with ETS transcription factors FLI1 and ERG [GeneID=2313 ,2078].",CGP,C2,391,393
Cohort,0.0047172048776026754,0.015170612814876966,0.310943594379838,0.7559393576522044,LGP Offspring,Genes down-regulated in DLD-1 cells (colon cancer) in response to hypoxia; might not be direct targets of HIF1A [GeneID=3091].,CGP,C2,6,17
Cohort,-0.022143216888863896,0.0480989348935127,-0.4603681336787864,0.6453720088967918,LGP Proband,Genes down-regulated in DLD-1 cells (colon cancer) in response to hypoxia; might not be direct targets of HIF1A [GeneID=3091].,CGP,C2,6,33
Cohort,0.025175697242648037,0.014293154353844578,1.7613814711149656,0.07855773734395487,LonGen OPEL,Genes down-regulated in DLD-1 cells (colon cancer) in response to hypoxia; might not be direct targets of HIF1A [GeneID=3091].,CGP,C2,10,22
Cohort,-0.016077453927452898,0.009974105525400854,-1.611919373271996,0.10744623390648653,LGP Offspring,Genes up-regulated in DLD-1 cells (colon cancer) in response to hypoxia; might not be direct targets of HIF1A [GeneID=3091].,CGP,C2,7,3
Cohort,-0.06822927877399433,0.03489550480573494,-1.9552455009271315,0.05088773719304391,LGP Proband,Genes up-regulated in DLD-1 cells (colon cancer) in response to hypoxia; might not be direct targets of HIF1A [GeneID=3091].,CGP,C2,7,13
Cohort,-0.010924629648723146,0.009611518681107229,-1.136618469066394,0.2560398733986723,LonGen OPEL,Genes up-regulated in DLD-1 cells (colon cancer) in response to hypoxia; might not be direct targets of HIF1A [GeneID=3091].,CGP,C2,9,5
Cohort,-0.011210879019158964,0.01791973830419031,-0.6256162243472851,0.5317778433663263,LGP Offspring,Key proteins in mammalian autophagosome formation.,CGP,C2,13,20
Cohort,-0.0755137737041616,0.0507298890186963,-1.4885460064052436,0.13698497125902748,LGP Proband,Key proteins in mammalian autophagosome formation.,CGP,C2,13,29
Cohort,0.03188329415448426,0.014818332571281758,2.1516114583819475,0.03172817225522029,LonGen OPEL,Key proteins in mammalian autophagosome formation.,CGP,C2,8,22
Cohort,0.006375285929682946,0.02303582972193419,0.27675521162637107,0.7820526728973722,LGP Offspring,Up-regulated at 4 hours following treatment of mouse lymphocytes (TK 3.7.2C) with a high dose of methyl methanesulfonate (MMS),CGP,C2,16,38
Cohort,0.02584416435820647,0.07146346801151549,0.3616416202197463,0.7177114594262644,LGP Proband,Up-regulated at 4 hours following treatment of mouse lymphocytes (TK 3.7.2C) with a high dose of methyl methanesulfonate (MMS),CGP,C2,16,70
Cohort,-0.030200090953029557,0.021865464569607553,-1.3811776492051728,0.16761194471397856,LonGen OPEL,Up-regulated at 4 hours following treatment of mouse lymphocytes (TK 3.7.2C) with a high dose of methyl methanesulfonate (MMS),CGP,C2,37,35
Cohort,-0.017429862387312728,0.03755209744731882,-0.46415150077208805,0.6426886392667992,LGP Offspring,Genes highly expressed in the neonatal hippocampus (clusters 4 and 8).,CGP,C2,45,79
Cohort,-0.41046421058923355,0.10218360664398045,-4.016928194943622,6.428488189447498e-5,LGP Proband,Genes highly expressed in the neonatal hippocampus (clusters 4 and 8).,CGP,C2,45,122
Cohort,-0.0423038959288766,0.03265561107991983,-1.2954556515676283,0.19553864437421284,LonGen OPEL,Genes highly expressed in the neonatal hippocampus (clusters 4 and 8).,CGP,C2,85,83
Cohort,-0.016006599159539336,0.04639402264065832,-0.3450142550370624,0.7301909732511053,LGP Offspring,Genes up-regulated in hyppocampus at late postnatal stages (clusters 11 and 15).,CGP,C2,61,128
Cohort,-0.08198124611078396,0.1115606375003857,-0.7348581717319473,0.46263244970610073,LGP Proband,Genes up-regulated in hyppocampus at late postnatal stages (clusters 11 and 15).,CGP,C2,61,144
Cohort,-0.015843289968271244,0.03564216777843292,-0.44450971856594035,0.6567949325599087,LonGen OPEL,Genes up-regulated in hyppocampus at late postnatal stages (clusters 11 and 15).,CGP,C2,85,99
Cohort,-0.06309109217514244,0.021967939147821514,-2.871962260574587,0.004207092828959298,LGP Offspring,Genes highly expressed in prenatal hippocampus (cluster 1).,CGP,C2,24,23
Cohort,0.14243017923419163,0.06562761143832979,2.1702782733153887,0.03026734062759102,LGP Proband,Genes highly expressed in prenatal hippocampus (cluster 1).,CGP,C2,24,45
Cohort,-0.007599845141233457,0.01909952788484151,-0.3979074868790413,0.6908050708218268,LonGen OPEL,Genes highly expressed in prenatal hippocampus (cluster 1).,CGP,C2,27,31
Cohort,0.0017625743399795671,0.06919791508820976,0.02547149488149654,0.9796864019586887,LGP Offspring,Down-regulated in MCF7 cells (breast cancer) by HOXA1 [GeneID=3198].,CGP,C2,157,330
Cohort,-0.15954815383338194,0.18555572960224948,-0.8598395434912388,0.3901245871713359,LGP Proband,Down-regulated in MCF7 cells (breast cancer) by HOXA1 [GeneID=3198].,CGP,C2,157,460
Cohort,-0.12119946557756622,0.06007707959609047,-2.0173994207510266,0.04398902264930846,LonGen OPEL,Down-regulated in MCF7 cells (breast cancer) by HOXA1 [GeneID=3198].,CGP,C2,276,293
Cohort,0.049355876807607675,0.09357725853661839,0.5274345239371794,0.5980649301680546,LGP Offspring,Up-regulated in MCF7 cells (breast cancer) by HOXA1 [GeneID=3198].,CGP,C2,332,711
Cohort,-0.3166567067551182,0.27467756810991717,-1.1528306040207925,0.24931022914912782,LGP Proband,Up-regulated in MCF7 cells (breast cancer) by HOXA1 [GeneID=3198].,CGP,C2,332,1027
Cohort,0.07763293382355804,0.0887472245949686,0.87476463830689,0.3819658381677079,LonGen OPEL,Up-regulated in MCF7 cells (breast cancer) by HOXA1 [GeneID=3198].,CGP,C2,530,678
Cohort,-0.06245357398214456,0.031413567971931726,-1.988108260670909,0.047202619829340896,LGP Offspring,Genes commonly down-regulated in SK-N-BE cells (neuroblastoma) after RNAi knockdown of CCND1 and CDK4 [GeneID=595;1019].,CGP,C2,42,60
Cohort,0.08407453794027725,0.08934404755054151,0.9410200259028636,0.34696707456280107,LGP Proband,Genes commonly down-regulated in SK-N-BE cells (neuroblastoma) after RNAi knockdown of CCND1 and CDK4 [GeneID=595;1019].,CGP,C2,42,96
Cohort,0.03512088347699804,0.031055205189221783,1.1309177724959072,0.2584303191953729,LonGen OPEL,Genes commonly down-regulated in SK-N-BE cells (neuroblastoma) after RNAi knockdown of CCND1 and CDK4 [GeneID=595;1019].,CGP,C2,48,75
Cohort,0.061005607697521044,0.0415377699460771,1.468677971319029,0.14238532207422003,LGP Offspring,Genes commonly up-regulated in SK-N-BE cells (neuroblastoma) after RNAi knockdown of CCND1 and CDK4 [GeneID=595;1019].,CGP,C2,55,141
Cohort,-0.077936324799677,0.11197290034962294,-0.6960284547093939,0.48660492517237364,LGP Proband,Genes commonly up-regulated in SK-N-BE cells (neuroblastoma) after RNAi knockdown of CCND1 and CDK4 [GeneID=595;1019].,CGP,C2,55,176
Cohort,-0.03852967273211605,0.03765557004043924,-1.0232131047475337,0.30651795431199547,LonGen OPEL,Genes commonly up-regulated in SK-N-BE cells (neuroblastoma) after RNAi knockdown of CCND1 and CDK4 [GeneID=595;1019].,CGP,C2,105,114
Cohort,0.015099235003123566,0.10121070591617866,0.1491861445530135,0.8814512472659244,LGP Offspring,The postradiation tumor escape signature: genes down-regulated in tumors from irradiated stroma vs those from non-irradiated stroma.,CGP,C2,314,673
Cohort,-0.10591191770875584,0.26657243719434476,-0.39731008510658855,0.691240470326439,LGP Proband,The postradiation tumor escape signature: genes down-regulated in tumors from irradiated stroma vs those from non-irradiated stroma.,CGP,C2,314,896
Cohort,-0.03344776327072176,0.08336347337563046,-0.4012280428864604,0.6883599196216288,LonGen OPEL,The postradiation tumor escape signature: genes down-regulated in tumors from irradiated stroma vs those from non-irradiated stroma.,CGP,C2,467,560
Cohort,-0.3168507885813718,0.10755859124929801,-2.9458436085963493,0.003331501463829294,LGP Offspring,The postradiation tumor escape signature: genes up-regulated in tumors from irradiated stroma vs those from non-irradiated stroma.,CGP,C2,450,811
Cohort,0.00763177389775507,0.3097417761609543,0.024639149398398532,0.9803486860127109,LGP Proband,The postradiation tumor escape signature: genes up-regulated in tumors from irradiated stroma vs those from non-irradiated stroma.,CGP,C2,450,1137
Cohort,-0.01165297011255071,0.10431300260935428,-0.11171157785755972,0.9110802615861702,LonGen OPEL,The postradiation tumor escape signature: genes up-regulated in tumors from irradiated stroma vs those from non-irradiated stroma.,CGP,C2,723,861
Cohort,-0.029946515921598915,0.017007759967500296,-1.760756030119367,0.0787318249150441,LGP Offspring,Down-regulated genes predicting poor survival of patients with thyroid carcinoma.,CGP,C2,12,15
Cohort,0.003763237898706904,0.04367835583197542,0.08615795688792771,0.9313615316062792,LGP Proband,Down-regulated genes predicting poor survival of patients with thyroid carcinoma.,CGP,C2,12,20
Cohort,-0.008476194316489634,0.018180602151464748,-0.4662218691038645,0.641184252351335,LonGen OPEL,Down-regulated genes predicting poor survival of patients with thyroid carcinoma.,CGP,C2,24,26
Cohort,-0.011819151701409921,0.021725368757496984,-0.5440253665352112,0.5866033971404674,LGP Offspring,Up-regulated genes predicting poor survival of patients with thyroid carcinoma.,CGP,C2,19,30
Cohort,-0.10402397907534819,0.05817841282287443,-1.7880167922774326,0.07413624519588316,LGP Proband,Up-regulated genes predicting poor survival of patients with thyroid carcinoma.,CGP,C2,19,39
Cohort,-0.007536474870532347,0.01903314891595256,-0.3959657387126142,0.6922364130539307,LonGen OPEL,Up-regulated genes predicting poor survival of patients with thyroid carcinoma.,CGP,C2,26,32
Cohort,0.018628833785165666,0.030454770299818933,0.6116885335784793,0.5409495062361644,LGP Offspring,Genes involved in free fatty acid oxidation; based on literature and sequence annotation resources and coverted to Affymetrix HG-U133A probe sets.,CGP,C2,28,63
Cohort,0.10837059976143215,0.0852670453143492,1.2709552601700738,0.20409894444944393,LGP Proband,Genes involved in free fatty acid oxidation; based on literature and sequence annotation resources and coverted to Affymetrix HG-U133A probe sets.,CGP,C2,28,91
Cohort,-0.04216084682864341,0.02922500098095595,-1.4426294410089813,0.14951824799693728,LonGen OPEL,Genes involved in free fatty acid oxidation; based on literature and sequence annotation resources and coverted to Affymetrix HG-U133A probe sets.,CGP,C2,66,66
Cohort,-0.00417086414309032,0.031012469499352335,-0.13448990713807632,0.8930552227637174,LGP Offspring,Genes involved in gluconeogenesis; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,29,65
Cohort,-0.05826588474588609,0.08294269060066307,-0.7024836585831747,0.48257360593258647,LGP Proband,Genes involved in gluconeogenesis; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,29,82
Cohort,-0.03390985896113853,0.02733459778306451,-1.2405472079837152,0.21513858270900663,LonGen OPEL,Genes involved in gluconeogenesis; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,53,53
Cohort,0.008169513589158692,0.03807528401392194,0.2145621182017072,0.8301734386494938,LGP Offspring,Genes involved in glycogen metabolism; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,42,96
Cohort,0.16489615276747255,0.10276569952017754,1.6045835676435598,0.10896406268945727,LGP Proband,Genes involved in glycogen metabolism; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,42,125
Cohort,0.03452919460249533,0.031216600769288387,1.1061164172771158,0.2690103142942037,LonGen OPEL,Genes involved in glycogen metabolism; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,63,83
Cohort,-0.005562197732377283,0.025817003273613835,-0.21544707080941902,0.8294837598378465,LGP Offspring,Genes involved in glycolysis; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,22,48
Cohort,0.026950076384961278,0.07069597485407915,0.3812109026092065,0.703143850367542,LGP Proband,Genes involved in glycolysis; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,22,59
Cohort,-3.5239217711255486e-4,0.025561797311617323,-0.013785892001905505,0.9890042524345293,LonGen OPEL,Genes involved in glycolysis; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,39,47
Cohort,0.07710879265997649,0.11084599314200366,0.6956389714619021,0.48689402313880625,LGP Offspring,Mitochondrial genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,399,862
Cohort,-0.10230651550399951,0.32301029375290913,-0.3167283442126467,0.7515290016032778,LGP Proband,Mitochondrial genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,399,1198
Cohort,-0.008317448369035208,0.10376648468078191,-0.08015544127395541,0.9361337761275439,LonGen OPEL,Mitochondrial genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,684,837
Cohort,0.17868211617121513,0.1050049909448006,1.7016535553547676,0.08928014473077453,LGP Offspring,Mitochondrial genes,CGP,C2,358,826
Cohort,0.31102731468871087,0.3079032634062624,1.0101462103645404,0.31271821843364045,LGP Proband,Mitochondrial genes,CGP,C2,358,1166
Cohort,-0.0326604584232724,0.09876047309487791,-0.3307037461424058,0.7409553001336712,LonGen OPEL,Mitochondrial genes,CGP,C2,657,802
Cohort,0.010144589729460297,0.10466431895703034,0.09692500587162978,0.9228146787336571,LGP Offspring,Genes up-regulated in differentiating C2C12 cells (myoblasts) upon expression of PPARGC1A [GeneID=10891] off an adenoviral vector.,CGP,C2,363,766
Cohort,-0.22365835507974655,0.3018903946458098,-0.7408594610708026,0.4589871913422785,LGP Proband,Genes up-regulated in differentiating C2C12 cells (myoblasts) upon expression of PPARGC1A [GeneID=10891] off an adenoviral vector.,CGP,C2,363,1097
Cohort,-0.03384255215876647,0.10015182570333192,-0.3379124835828187,0.7355182359464245,LonGen OPEL,Genes up-regulated in differentiating C2C12 cells (myoblasts) upon expression of PPARGC1A [GeneID=10891] off an adenoviral vector.,CGP,C2,621,743
Cohort,0.004367333245714939,0.017540872227872407,0.24898039213667242,0.8034515752033599,LGP Offspring,Genes involved in pyruvate metabolism; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,9,18
Cohort,0.05336522844739676,0.04629827605765881,1.1526396443128235,0.24938858846998269,LGP Proband,Genes involved in pyruvate metabolism; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,9,27
Cohort,-0.030823761499606053,0.015498834671060337,-1.9887792955918586,0.0470675421482833,LonGen OPEL,Genes involved in pyruvate metabolism; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,19,12
Cohort,0.004631340404630141,0.012390747901309843,0.3737740805896435,0.7086895996970691,LGP Offspring,Reactive oxidative species (ROS) genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,4,11
Cohort,0.018262819018280956,0.03132070420976051,0.5830909450812951,0.5599897084010602,LGP Proband,Reactive oxidative species (ROS) genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,4,12
Cohort,-0.009195570833956241,0.008143516337109784,-1.1291892167087911,0.25915819892099956,LonGen OPEL,Reactive oxidative species (ROS) genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,6,4
Cohort,0.036478009723762805,0.02227469163758691,1.6376437580939993,0.10196139551321433,LGP Offspring,Tricarboxylic acid related genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,9,36
Cohort,-0.026129472585813714,0.05751774558344531,-0.4542854091509155,0.6497416209330615,LGP Proband,Tricarboxylic acid related genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,9,44
Cohort,0.002917882855113138,0.01968643251734633,0.1482179593759357,0.8822082963498841,LonGen OPEL,Tricarboxylic acid related genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,26,34
Cohort,0.0649072872732012,0.038282523427074416,1.6954808999684972,0.09044470765552683,LGP Offspring,Genes involved in oxidative phosphorylation; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,39,109
Cohort,-0.04462433732660686,0.105099341496578,-0.4245919783242392,0.6712436501391799,LGP Proband,Genes involved in oxidative phosphorylation; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,39,138
Cohort,-0.02471693046937453,0.03674534758927366,-0.6726546921164422,0.5013622131477105,LonGen OPEL,Genes involved in oxidative phosphorylation; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.,CGP,C2,92,106
Cohort,-0.05270347458268165,0.05131450472769614,-1.027067782537436,0.3047559073791214,LGP Offspring,Genes down-regulated in normal bone marrow plasma cells (BMPC) compared to polyclonal plasmablasts (PPC) that also distinguished multiple myeloma (MM) samples by expression of levels of TACI [GeneID=23495].,CGP,C2,95,177
Cohort,0.19817475495888157,0.15628005672935022,1.2680745010355714,0.20512522510567466,LGP Proband,Genes down-regulated in normal bone marrow plasma cells (BMPC) compared to polyclonal plasmablasts (PPC) that also distinguished multiple myeloma (MM) samples by expression of levels of TACI [GeneID=23495].,CGP,C2,95,272
Cohort,-0.05522817826846581,0.04511119841186788,-1.2242675923665187,0.22121351317841892,LonGen OPEL,Genes down-regulated in normal bone marrow plasma cells (BMPC) compared to polyclonal plasmablasts (PPC) that also distinguished multiple myeloma (MM) samples by expression of levels of TACI [GeneID=23495].,CGP,C2,150,152
Cohort,-0.016147151133743057,0.0502279736306711,-0.3214772559306075,0.7479481181339231,LGP Offspring,Genes up-regulated in normal bone marrow plasma cells (BMPC) compared to polyclonal plasmablasts (PPC) that also distinguished multiple myeloma (MM) samples by expression of levels of TACI (TNFRSF13B) [GeneID=23495].,CGP,C2,79,163
Cohort,0.20979245826534426,0.14606253493454172,1.4363194392002252,0.1512864530967597,LGP Proband,Genes up-regulated in normal bone marrow plasma cells (BMPC) compared to polyclonal plasmablasts (PPC) that also distinguished multiple myeloma (MM) samples by expression of levels of TACI (TNFRSF13B) [GeneID=23495].,CGP,C2,79,258
Cohort,0.015705777137351145,0.04719283995836164,0.33279999998322607,0.7393728864902493,LonGen OPEL,Genes up-regulated in normal bone marrow plasma cells (BMPC) compared to polyclonal plasmablasts (PPC) that also distinguished multiple myeloma (MM) samples by expression of levels of TACI (TNFRSF13B) [GeneID=23495].,CGP,C2,141,180
Cohort,-0.02245704806159174,0.07322763490194673,-0.3066744964747554,0.7591855801069907,LGP Offspring,Down-regulated genes distinguishing in multiple myeloma (MM) samples with lower expression of TACI [GeneID=23495].,CGP,C2,183,381
Cohort,0.37939770494555464,0.21063315751611297,1.8012249800534446,0.0720285310021494,LGP Proband,Down-regulated genes distinguishing in multiple myeloma (MM) samples with lower expression of TACI [GeneID=23495].,CGP,C2,183,519
Cohort,-0.03616149078128217,0.06746031885447124,-0.5360409110916232,0.5920800292764801,LonGen OPEL,Down-regulated genes distinguishing in multiple myeloma (MM) samples with lower expression of TACI [GeneID=23495].,CGP,C2,292,337
Cohort,-0.30875718365240323,0.10361887054237663,-2.979738941722318,0.0029884187374003978,LGP Offspring,Up-regulated genes distinguishing in multiple myeloma (MM) samples with higher expression of TACI [GeneID=23495].,CGP,C2,374,665
Cohort,-0.02004153579693097,0.29192318264284545,-0.06865345744551868,0.9452819225250038,LGP Proband,Up-regulated genes distinguishing in multiple myeloma (MM) samples with higher expression of TACI [GeneID=23495].,CGP,C2,374,970
Cohort,0.04059696836663848,0.09446048950486952,0.42977723892215985,0.6674740057861108,LonGen OPEL,Up-regulated genes distinguishing in multiple myeloma (MM) samples with higher expression of TACI [GeneID=23495].,CGP,C2,579,705
Cohort,-0.012037951904466045,0.014986446245207525,-0.8032559358971196,0.4221091579941272,LGP Offspring,Down-regulated in CD4+ [GeneID=920] T lymphocytes after 4 h treatment with 100 nM TSA [PubChem=5562].,CGP,C2,8,12
Cohort,-0.011763718523277325,0.03892669060743005,-0.3022018656020029,0.7625735288988349,LGP Proband,Down-regulated in CD4+ [GeneID=920] T lymphocytes after 4 h treatment with 100 nM TSA [PubChem=5562].,CGP,C2,8,15
Cohort,0.009354466893556809,0.014659536714575082,0.6381147696336292,0.5235825004911545,LonGen OPEL,Down-regulated in CD4+ [GeneID=920] T lymphocytes after 4 h treatment with 100 nM TSA [PubChem=5562].,CGP,C2,13,20
Cohort,0.013541202319889284,0.0174229427688697,0.7772052344730143,0.4373095805023822,LGP Offspring,Up-regulated in CD4+ [GeneID=920] T lymphocytes after 4 h treatment with 100 nM TSA [PubChem=5562].,CGP,C2,8,21
Cohort,0.03216336338206386,0.05008541361552297,0.642170265957342,0.5209391088386902,LGP Proband,Up-regulated in CD4+ [GeneID=920] T lymphocytes after 4 h treatment with 100 nM TSA [PubChem=5562].,CGP,C2,8,30
Cohort,-0.03302684836685462,0.013202902119249502,-2.501483997120777,0.012567157401995552,LonGen OPEL,Up-regulated in CD4+ [GeneID=920] T lymphocytes after 4 h treatment with 100 nM TSA [PubChem=5562].,CGP,C2,19,8
Cohort,-1.9642547459076295e-4,0.02148653715195151,-0.009141792984213961,0.9927087032495088,LGP Offspring,Genes correlated with the late tumor onset in the Emu-myc transgenic mouse lymphoma model.,CGP,C2,13,32
Cohort,-0.07705528952894863,0.06316221068756142,-1.219958717248052,0.22282538407150243,LGP Proband,Genes correlated with the late tumor onset in the Emu-myc transgenic mouse lymphoma model.,CGP,C2,13,51
Cohort,0.024175918709087085,0.019161540932577242,1.2616896936500923,0.20743005455433858,LonGen OPEL,Genes correlated with the late tumor onset in the Emu-myc transgenic mouse lymphoma model.,CGP,C2,23,33
Cohort,-0.11650146683084046,0.052211336633674645,-2.2313442700813897,0.02598546269609217,LGP Offspring,Genes correlated with the early tumor onset in the Emu-myc transgenic mouse lymphoma model.,CGP,C2,109,180
Cohort,-0.02270326205279542,0.1472376320647961,-0.15419469692913973,0.8774935277523925,LGP Proband,Genes correlated with the early tumor onset in the Emu-myc transgenic mouse lymphoma model.,CGP,C2,109,268
Cohort,0.004830629592361677,0.045427537190065474,0.1063370345645347,0.9153417411547569,LonGen OPEL,Genes correlated with the early tumor onset in the Emu-myc transgenic mouse lymphoma model.,CGP,C2,144,182
Cohort,-0.0633777731906934,0.0555996340222902,-1.1398955101985906,0.25473355677221976,LGP Offspring,Down-regulated genes in the B lymphocyte developmental signature based on expression profiling of lymphomas from the Emu-myc transgenic mice: the immature B stage.,CGP,C2,104,181
Cohort,-0.3449496296397833,0.151189536237618,-2.281570790042249,0.022765920433271122,LGP Proband,Down-regulated genes in the B lymphocyte developmental signature based on expression profiling of lymphomas from the Emu-myc transgenic mice: the immature B stage.,CGP,C2,104,228
Cohort,-0.023523100411183582,0.043226247161429254,-0.5441855806574212,0.5864661686819798,LonGen OPEL,Down-regulated genes in the B lymphocyte developmental signature based on expression profiling of lymphomas from the Emu-myc transgenic mice: the immature B stage.,CGP,C2,129,149
Cohort,-0.028354512982082317,0.03357154498637369,-0.8445995855594698,0.3986332449170382,LGP Offspring,Up-regulated genes in the B lymphocyte developmental signature based on expression profiling of lymphomas from the Emu-myc transgenic mice: the immature B stage.,CGP,C2,38,69
Cohort,-0.08346585138469018,0.09102765664464384,-0.9169284859273744,0.35944518274115445,LGP Proband,Up-regulated genes in the B lymphocyte developmental signature based on expression profiling of lymphomas from the Emu-myc transgenic mice: the immature B stage.,CGP,C2,38,94
Cohort,-0.0012709268325477995,0.03276580921870355,-0.0387882021794329,0.9690689768349761,LonGen OPEL,Up-regulated genes in the B lymphocyte developmental signature based on expression profiling of lymphomas from the Emu-myc transgenic mice: the immature B stage.,CGP,C2,66,78
Cohort,0.039875591219956284,0.039198158190016236,1.0172822668518284,0.30938311013314485,LGP Offspring,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  Large Pre-BII stage.",CGP,C2,42,107
Cohort,0.1469553012983194,0.10660616094362295,1.3784878847296123,0.1684223561932095,LGP Proband,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  Large Pre-BII stage.",CGP,C2,42,139
Cohort,-0.01298372993773428,0.0336207851460007,-0.3861816397609839,0.6994653477562831,LonGen OPEL,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  Large Pre-BII stage.",CGP,C2,73,88
Cohort,-0.13749447492618147,0.04450171370705981,-3.089644498440274,0.002086168939241666,LGP Offspring,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  Large Pre-BII stage.",CGP,C2,85,113
Cohort,-0.08497505121095456,0.12933499901896103,-0.6570151301311478,0.5113524478593234,LGP Proband,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  Large Pre-BII stage.",CGP,C2,85,180
Cohort,-6.196099000757718e-4,0.038492852564922464,-0.016096751962737264,0.9871612383418393,LonGen OPEL,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  Large Pre-BII stage.",CGP,C2,100,119
Cohort,0.03962783697499154,0.042206021066193,0.9389143059195745,0.34811009136850213,LGP Offspring,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  mature B",CGP,C2,50,125
Cohort,-0.03806197484863057,0.11823189342992989,-0.32192645947252796,0.7475890793996416,LGP Proband,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  mature B",CGP,C2,50,170
Cohort,-0.016977385901225325,0.03855650451477556,-0.4403248197646983,0.6598214091161422,LonGen OPEL,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  mature B",CGP,C2,99,108
Cohort,0.0386727718083156,0.052962944233656,0.7301854601908719,0.46552979049452325,LGP Offspring,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  mature B",CGP,C2,72,180
Cohort,0.1417179743154078,0.13166845938349842,1.0763243906624524,0.28209345352619797,LGP Proband,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  mature B",CGP,C2,72,227
Cohort,-0.023947879331275315,0.04759008150389581,-0.5032115637228924,0.6149547468009909,LonGen OPEL,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  mature B",CGP,C2,144,160
Cohort,0.006074338409263417,0.03525157354554645,0.17231396497563797,0.8632422801831294,LGP Offspring,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: plasma cell.",CGP,C2,36,81
Cohort,0.04829276851614546,0.10347772633874958,0.4666972325817439,0.6408383958047377,LGP Proband,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: plasma cell.",CGP,C2,36,116
Cohort,0.002458149702984995,0.031806239252936165,0.07728514155467384,0.9384161324157737,LonGen OPEL,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: plasma cell.",CGP,C2,70,78
Cohort,-0.013512041447478283,0.03452165843116255,-0.3914076571501276,0.6956192748066076,LGP Offspring,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: plasma cell.",CGP,C2,41,80
Cohort,0.20820279141495587,0.10369605295116122,2.00781790135267,0.044984741280038015,LGP Proband,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: plasma cell.",CGP,C2,41,127
Cohort,0.0323635684601956,0.03130941310169696,1.0336689593980766,0.30160488651030803,LonGen OPEL,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: plasma cell.",CGP,C2,58,82
Cohort,-0.030974611499935908,0.035895789006008864,-0.8629037655294562,0.38849640740368163,LGP Offspring,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Pre-BI stage.",CGP,C2,43,78
Cohort,-0.05434615072382865,0.09735101234691496,-0.5582494666841631,0.5768238770753107,LGP Proband,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Pre-BI stage.",CGP,C2,43,106
Cohort,-0.0017135676621141194,0.03118681593988062,-0.05494525845207777,0.9561958626832665,LonGen OPEL,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Pre-BI stage.",CGP,C2,65,77
Cohort,-0.07611258119570066,0.04367053979999152,-1.7428816209804543,0.081808992141404,LGP Offspring,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Pre-BI stage.",CGP,C2,80,123
Cohort,-0.11138739598481562,0.12147732961503903,-0.9169397807623995,0.3594392672278113,LGP Proband,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Pre-BI stage.",CGP,C2,80,164
Cohort,0.05441716945316702,0.03726180880908271,1.460400640558883,0.14457456614360356,LonGen OPEL,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Pre-BI stage.",CGP,C2,86,130
Cohort,-0.005005936466095333,0.04772973673520063,-0.1048808731937434,0.916501447029638,LGP Offspring,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Small Pre-BII stage.",CGP,C2,64,142
Cohort,0.03495816060282802,0.13245451143813414,0.2639257826952615,0.7919023078415621,LGP Proband,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Small Pre-BII stage.",CGP,C2,64,193
Cohort,0.004415266197254489,0.040297148593010014,0.10956770767697359,0.9127798376940521,LonGen OPEL,"Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Small Pre-BII stage.",CGP,C2,100,128
Cohort,-0.021590335975512735,0.04594281985985287,-0.46993928629921666,0.6385499544250268,LGP Offspring,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Small Pre-BII stage.",CGP,C2,67,147
Cohort,-0.01681051868482205,0.12993720939817752,-0.12937417051422248,0.8970927787669136,LGP Proband,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Small Pre-BII stage.",CGP,C2,67,226
Cohort,-0.0607879099581957,0.04633455473425352,-1.3119346955385183,0.18992039013347403,LonGen OPEL,"Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Small Pre-BII stage.",CGP,C2,145,147
Cohort,-0.02435005790078007,0.014217133597207592,-1.7127262492323136,0.0872214682602541,LGP Offspring,Genes down-regulated in FSHD (facioscapulohumeral muscular dystrophy) mesoangioblasts.,CGP,C2,8,8
Cohort,0.010583347025895331,0.036321599124252736,0.2913788842195716,0.7708340152728754,LGP Proband,Genes down-regulated in FSHD (facioscapulohumeral muscular dystrophy) mesoangioblasts.,CGP,C2,8,12
Cohort,-0.015323572453853039,0.010838620090415491,-1.4137936680153185,0.1578134572480805,LonGen OPEL,Genes down-regulated in FSHD (facioscapulohumeral muscular dystrophy) mesoangioblasts.,CGP,C2,10,8
Cohort,0.030699346518476146,0.023534947432217845,1.3044153426257794,0.1925359319781703,LGP Offspring,Genes up-regulated in FSHD (facioscapulohumeral muscular dystrophy) mesoangioblasts.,CGP,C2,12,40
Cohort,-0.020088843608461738,0.064736668892444,-0.31031630067092447,0.7563979657445317,LGP Proband,Genes up-regulated in FSHD (facioscapulohumeral muscular dystrophy) mesoangioblasts.,CGP,C2,12,52
Cohort,0.010993856200548267,0.019447415942398794,0.5653119279759797,0.5720209129487209,LonGen OPEL,Genes up-regulated in FSHD (facioscapulohumeral muscular dystrophy) mesoangioblasts.,CGP,C2,24,32
Cohort,-0.04125238331794301,0.03356135577023527,-1.2291631959197762,0.21943830048276264,LGP Offspring,"Top 50 genes up-regulated in ovarian cancer progenitor cells (also known as side population, SP, cells) in response to interferon alpha (IFNA).",CGP,C2,38,63
Cohort,-0.01945637449887491,0.09409295233630638,-0.20677823381855498,0.8362335276373059,LGP Proband,"Top 50 genes up-regulated in ovarian cancer progenitor cells (also known as side population, SP, cells) in response to interferon alpha (IFNA).",CGP,C2,38,101
Cohort,-0.05969761139594215,0.028729403990961994,-2.0779272488465987,0.03803602439616519,LonGen OPEL,"Top 50 genes up-regulated in ovarian cancer progenitor cells (also known as side population, SP, cells) in response to interferon alpha (IFNA).",CGP,C2,69,56
Cohort,-0.020737486008734863,0.01272549145762718,-1.6296019747281034,0.1036514982588913,LGP Offspring,Genes down-regulated in ovarian epithelial cells in response to dihydrotestosterone (DHT) [PubChem=10635].,CGP,C2,8,8
Cohort,-0.05574495010042445,0.03563196446169267,-1.5644646862048515,0.11808781978006419,LGP Proband,Genes down-regulated in ovarian epithelial cells in response to dihydrotestosterone (DHT) [PubChem=10635].,CGP,C2,8,13
Cohort,-0.008763674243847282,0.01448152421600913,-0.6051624202761169,0.5452435642032382,LonGen OPEL,Genes down-regulated in ovarian epithelial cells in response to dihydrotestosterone (DHT) [PubChem=10635].,CGP,C2,17,15
Cohort,0.0011670367109608058,0.00907384265446618,0.12861548909340917,0.8977001637310906,LGP Offspring,Genes up-regulated in ovarian epithelial cells in response to dihydrotestosterone (DHT) [PubChem=10635].,CGP,C2,2,4
Cohort,-0.015458896898926945,0.027249386816947684,-0.5673117344905657,0.5706550719279889,LGP Proband,Genes up-regulated in ovarian epithelial cells in response to dihydrotestosterone (DHT) [PubChem=10635].,CGP,C2,2,10
Cohort,-0.00951946101421842,0.007335110660271211,-1.2977937832319553,0.19473414844292822,LonGen OPEL,Genes up-regulated in ovarian epithelial cells in response to dihydrotestosterone (DHT) [PubChem=10635].,CGP,C2,5,3
Cohort,0.025867250671741927,0.035157999963471784,0.7357429517781815,0.46214234431754586,LGP Offspring,"Down-regulated target genes shared by acute myeloid leukemia (AML) translocation products PML RARA [GeneID=5371;5914], AML1 ETO [GeneID=861;862], and PLZF RARA [GeneID=5914;7704].",CGP,C2,35,84
Cohort,0.09406437773384384,0.09306502531287297,1.0107382168286225,0.31243488336102326,LGP Proband,"Down-regulated target genes shared by acute myeloid leukemia (AML) translocation products PML RARA [GeneID=5371;5914], AML1 ETO [GeneID=861;862], and PLZF RARA [GeneID=5914;7704].",CGP,C2,35,112
Cohort,-0.02292759515996551,0.03155275749275154,-0.7266431520361589,0.46765821135089825,LonGen OPEL,"Down-regulated target genes shared by acute myeloid leukemia (AML) translocation products PML RARA [GeneID=5371;5914], AML1 ETO [GeneID=861;862], and PLZF RARA [GeneID=5914;7704].",CGP,C2,67,76
Cohort,0.030664355018509542,0.019751970235823837,1.5524706979810088,0.12101765777654705,LGP Offspring,"Up-regulated target genes shared by acute myeloid leukemia (AML) translocation products PML RARA [GeneID=5371;5914], AML1 ETO [GeneID=861;862], and PLZF RARA [GeneID=5914;7704].",CGP,C2,9,29
Cohort,-0.03836806372629101,0.04929500435590055,-0.7783357406620941,0.43659186927146876,LGP Proband,"Up-regulated target genes shared by acute myeloid leukemia (AML) translocation products PML RARA [GeneID=5371;5914], AML1 ETO [GeneID=861;862], and PLZF RARA [GeneID=5914;7704].",CGP,C2,9,32
Cohort,0.00813345767571802,0.01540207066254506,0.5280755980101467,0.5975940458373359,LonGen OPEL,"Up-regulated target genes shared by acute myeloid leukemia (AML) translocation products PML RARA [GeneID=5371;5914], AML1 ETO [GeneID=861;862], and PLZF RARA [GeneID=5914;7704].",CGP,C2,15,22
Cohort,0.046313150822097006,0.0362930512612312,1.2760886509305276,0.20236244351059515,LGP Offspring,Genes up-regulated in short-term cultured glioblastomas after azacitidine [PubChem=9444] treatment.,CGP,C2,30,83
Cohort,0.12586711487289703,0.09293427065262147,1.35436705952506,0.1759861193389223,LGP Proband,Genes up-regulated in short-term cultured glioblastomas after azacitidine [PubChem=9444] treatment.,CGP,C2,30,106
Cohort,0.007724754338697254,0.027964328962980265,0.2762359986868785,0.7824385131464815,LonGen OPEL,Genes up-regulated in short-term cultured glioblastomas after azacitidine [PubChem=9444] treatment.,CGP,C2,54,61
Cohort,-0.12311337096867826,0.09043926948337579,-1.3612822358246548,0.17387808227744925,LGP Offspring,"Genes constituting the PluriNet protein-protein network shared by the pluripotent cells (embryonic stem cells, embryonical carcinomas and induced pluripotent cells).",CGP,C2,279,522
Cohort,-0.0616217761377304,0.25088598109385046,-0.2456166576907267,0.806039421980935,LGP Proband,"Genes constituting the PluriNet protein-protein network shared by the pluripotent cells (embryonic stem cells, embryonical carcinomas and induced pluripotent cells).",CGP,C2,279,774
Cohort,-0.0356454775499349,0.08204165036229256,-0.43448025963063797,0.6640574776405557,LonGen OPEL,"Genes constituting the PluriNet protein-protein network shared by the pluripotent cells (embryonic stem cells, embryonical carcinomas and induced pluripotent cells).",CGP,C2,452,514
Cohort,-0.03309965072949522,0.018314226811516763,-1.8073190350946597,0.07115698148612104,LGP Offspring,Genes similarly down-regulated in 3T3-L1 cells (fibroblasts able to differentiate to adipocytes) upon stimulation of INSR or IGFR1 by NTF3 [GeneID=3643;3480;4908].,CGP,C2,15,19
Cohort,0.03766620460283659,0.05281511176726842,0.7131709721417233,0.4759394656388234,LGP Proband,Genes similarly down-regulated in 3T3-L1 cells (fibroblasts able to differentiate to adipocytes) upon stimulation of INSR or IGFR1 by NTF3 [GeneID=3643;3480;4908].,CGP,C2,15,30
Cohort,-0.011964415240654981,0.012746565056646286,-0.9386383851245103,0.34820115759491066,LonGen OPEL,Genes similarly down-regulated in 3T3-L1 cells (fibroblasts able to differentiate to adipocytes) upon stimulation of INSR or IGFR1 by NTF3 [GeneID=3643;3480;4908].,CGP,C2,14,11
Cohort,-0.021432638157997782,0.017439165830303548,-1.2289944580236107,0.21950151883511018,LGP Offspring,Genes similarly up-regulated in 3T3-L1 cells (fibroblasts able to differentiate to adipocytes) upon stimulation of INSR or IGFR1 by NTF3 [GeneID=3643;3480;4908].,CGP,C2,11,18
Cohort,0.08232611924685103,0.05901644271243992,1.3949691893153995,0.16339651287301205,LGP Proband,Genes similarly up-regulated in 3T3-L1 cells (fibroblasts able to differentiate to adipocytes) upon stimulation of INSR or IGFR1 by NTF3 [GeneID=3643;3480;4908].,CGP,C2,11,45
Cohort,0.00465019912592495,0.019485599234237417,0.2386479917822727,0.811439972604141,LonGen OPEL,Genes similarly up-regulated in 3T3-L1 cells (fibroblasts able to differentiate to adipocytes) upon stimulation of INSR or IGFR1 by NTF3 [GeneID=3643;3480;4908].,CGP,C2,24,32
Cohort,-0.05432419925144589,0.08898368688117511,-0.6104961612119761,0.5417383730224108,LGP Offspring,The 'MLL signature 1': genes down-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to all AML cases with the intact gene.,CGP,C2,266,538
Cohort,-0.0403268705137324,0.25223258445536617,-0.15987970230257242,0.8730145506200337,LGP Proband,The 'MLL signature 1': genes down-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to all AML cases with the intact gene.,CGP,C2,266,741
Cohort,-0.0439662798915242,0.0824132445104574,-0.5334856084442268,0.5938463969228436,LonGen OPEL,The 'MLL signature 1': genes down-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to all AML cases with the intact gene.,CGP,C2,442,514
Cohort,-0.18455254810737357,0.1044441883845546,-1.7669968139143062,0.07767993236467485,LGP Offspring,The 'MLL signature 1': genes up-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to all AML cases with the intact gene.,CGP,C2,366,689
Cohort,0.09845748383866323,0.29266701195215195,0.33641469594379847,0.7366427952169772,LGP Proband,The 'MLL signature 1': genes up-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to all AML cases with the intact gene.,CGP,C2,366,953
Cohort,-0.04781072982105576,0.09383833693616159,-0.5095010353133336,0.6105422898101378,LonGen OPEL,The 'MLL signature 1': genes up-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to all AML cases with the intact gene.,CGP,C2,579,666
Cohort,-0.045262666831184795,0.1060762030806681,-0.42669953784793513,0.6697340403266356,LGP Offspring,The 'MLL signature 2': genes down-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to the AML cases with intact MLL and NPM1 [GeneID=4869].,CGP,C2,325,664
Cohort,-0.0798020561512168,0.2853003556762309,-0.2797124313499947,0.7797674957739991,LGP Proband,The 'MLL signature 2': genes down-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to the AML cases with intact MLL and NPM1 [GeneID=4869].,CGP,C2,325,941
Cohort,-0.04049162888818578,0.08776007716980883,-0.4613900784275482,0.6446448191434769,LonGen OPEL,The 'MLL signature 2': genes down-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to the AML cases with intact MLL and NPM1 [GeneID=4869].,CGP,C2,543,630
Cohort,-0.28032087100858705,0.11694777658906175,-2.396974779551352,0.01680158341791414,LGP Offspring,The 'MLL signature 2': genes up-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to the AML cases with intact MLL and NPM1 [GeneID=4869].,CGP,C2,437,810
Cohort,0.1831802220268996,0.31442781620239046,0.5825827505954193,0.5603316892272414,LGP Proband,The 'MLL signature 2': genes up-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to the AML cases with intact MLL and NPM1 [GeneID=4869].,CGP,C2,437,1127
Cohort,-0.03317661190988908,0.10516270315127506,-0.3154788809694726,0.7524807743704963,LonGen OPEL,The 'MLL signature 2': genes up-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to the AML cases with intact MLL and NPM1 [GeneID=4869].,CGP,C2,685,783
Cohort,-0.04975485843955306,0.06451414154403337,-0.7712240641936383,0.44084361437640707,LGP Offspring,The 'NPM1-mutated signature 1': genes down-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to all AML cases with the intact gene.,CGP,C2,138,272
Cohort,-0.08680922179373954,0.17701551561839624,-0.4904045924475896,0.6239766190719489,LGP Proband,The 'NPM1-mutated signature 1': genes down-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to all AML cases with the intact gene.,CGP,C2,138,374
Cohort,-0.10117193107497766,0.05610934750834651,-1.8031207912358613,0.07174730700164758,LonGen OPEL,The 'NPM1-mutated signature 1': genes down-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to all AML cases with the intact gene.,CGP,C2,244,243
Cohort,-0.10153824237504765,0.09157334780571832,-1.1088187208189746,0.2679027132121162,LGP Offspring,The 'NPM1-mutated signature 1': genes up-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to all AML cases with the intact gene.,CGP,C2,274,537
Cohort,0.1850969062423048,0.24811497571008245,0.7460126327021346,0.45586999971538866,LGP Proband,The 'NPM1-mutated signature 1': genes up-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to all AML cases with the intact gene.,CGP,C2,274,761
Cohort,0.10644750901652769,0.08153943120837318,1.3054727932121843,0.19210909968759382,LonGen OPEL,The 'NPM1-mutated signature 1': genes up-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to all AML cases with the intact gene.,CGP,C2,405,541
Cohort,0.05445501481851283,0.04532453677574204,1.2014466929457397,0.2299987249437618,LGP Offspring,The 'NPM1-mutated signature 2': genes down-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to the AML cases with the intact gene and without recurring cytogenetic anomalities or M7 phenotype.,CGP,C2,57,144
Cohort,0.09590311473371044,0.12068905178560003,0.7946297805378323,0.4270549505922422,LGP Proband,The 'NPM1-mutated signature 2': genes down-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to the AML cases with the intact gene and without recurring cytogenetic anomalities or M7 phenotype.,CGP,C2,57,182
Cohort,-0.06382700718871248,0.03972201581881087,-1.6068420968325172,0.1084855880515271,LonGen OPEL,The 'NPM1-mutated signature 2': genes down-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to the AML cases with the intact gene and without recurring cytogenetic anomalities or M7 phenotype.,CGP,C2,123,123
Cohort,-0.10603207911944196,0.06610666976529002,-1.6039543286011237,0.10919119500354044,LGP Offspring,The 'NPM1-mutated signature 2': genes up-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to the AML cases with the intact gene and without recurring cytogenetic anomalities or M7 phenotype.,CGP,C2,146,277
Cohort,-0.06693825922500356,0.19099141522183732,-0.35047784292950807,0.726068616175559,LGP Proband,The 'NPM1-mutated signature 2': genes up-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to the AML cases with the intact gene and without recurring cytogenetic anomalities or M7 phenotype.,CGP,C2,146,408
Cohort,0.09308915782223293,0.05951667125384295,1.5640854211284914,0.11819495714085229,LonGen OPEL,The 'NPM1-mutated signature 2': genes up-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to the AML cases with the intact gene and without recurring cytogenetic anomalities or M7 phenotype.,CGP,C2,210,300
Cohort,-0.05212965487474702,0.07850407246249078,-0.6640375873449693,0.5068926698705597,LGP Offspring,The 'NPM1 signature 3': genes down-regulated in pediatric AML (acute myeloid leukemia) with mutated NPM1 [GeneID=4869] compared to the AML cases with intact NPM1 and MLL [GeneID=4297].,CGP,C2,204,410
Cohort,0.029207383780440615,0.21676620748640354,0.1347414069707919,0.8928488439465421,LGP Proband,The 'NPM1 signature 3': genes down-regulated in pediatric AML (acute myeloid leukemia) with mutated NPM1 [GeneID=4869] compared to the AML cases with intact NPM1 and MLL [GeneID=4297].,CGP,C2,204,549
Cohort,-0.12860107742519442,0.07033344094635711,-1.8284485401940973,0.06785634124034821,LonGen OPEL,The 'NPM1 signature 3': genes down-regulated in pediatric AML (acute myeloid leukemia) with mutated NPM1 [GeneID=4869] compared to the AML cases with intact NPM1 and MLL [GeneID=4297].,CGP,C2,365,371
Cohort,-0.15953580137342602,0.10249208159079388,-1.5565670917913716,0.12004132066757307,LGP Offspring,The 'NPM1 signature 3': genes up-regulated in pediatric AML (acute myeloid leukemia) with mutated NPM1 [GeneID=4869] compared to the AML cases with intact NPM1 and MLL [GeneID=4297].,CGP,C2,340,650
Cohort,0.11667638582515685,0.27885050246653564,0.4184191342425821,0.6757484197836332,LGP Proband,The 'NPM1 signature 3': genes up-regulated in pediatric AML (acute myeloid leukemia) with mutated NPM1 [GeneID=4869] compared to the AML cases with intact NPM1 and MLL [GeneID=4297].,CGP,C2,340,919
Cohort,0.11705199445444078,0.08652297802082125,1.352842876331336,0.17648995574014942,LonGen OPEL,The 'NPM1 signature 3': genes up-regulated in pediatric AML (acute myeloid leukemia) with mutated NPM1 [GeneID=4869] compared to the AML cases with intact NPM1 and MLL [GeneID=4297].,CGP,C2,491,648
Cohort,0.011169346326234378,0.008461693422327112,1.3199894830463634,0.18728532813864524,LGP Offspring,Genes down-regulated in multiple myeloma (MM) compared to normal plasma cells from the patient's identical twin.,CGP,C2,1,6
Cohort,0.02546048903421498,0.02604583290133057,0.9775263909074036,0.32859207663269896,LGP Proband,Genes down-regulated in multiple myeloma (MM) compared to normal plasma cells from the patient's identical twin.,CGP,C2,1,10
Cohort,-0.004042371577546652,0.00857135667941394,-0.4716139729962849,0.6373315903120407,LonGen OPEL,Genes down-regulated in multiple myeloma (MM) compared to normal plasma cells from the patient's identical twin.,CGP,C2,6,5
Cohort,-0.0857659000516823,0.04002775744396874,-2.142660631731325,0.032496818423642736,LGP Offspring,Genes up-regulated in multiple myeloma (MM) compared to normal plasma cells from the patient's identical twin.,CGP,C2,61,99
Cohort,-0.024187419184132752,0.11063576023454705,-0.2186220724009632,0.8269979432021131,LGP Proband,Genes up-regulated in multiple myeloma (MM) compared to normal plasma cells from the patient's identical twin.,CGP,C2,61,144
Cohort,0.01745050733336505,0.03315553899698294,0.5263225349753173,0.5988107422439445,LonGen OPEL,Genes up-regulated in multiple myeloma (MM) compared to normal plasma cells from the patient's identical twin.,CGP,C2,76,91
Cohort,0.028676626260652146,0.01689463078240211,1.6973810573310943,0.0900849170394599,LGP Offspring,Genes down-regulated in primary keratinocytes at 1 h after UVB irradiation.,CGP,C2,6,23
Cohort,-0.04741916993545054,0.0477434508613718,-0.9932078448442522,0.3208967456150015,LGP Proband,Genes down-regulated in primary keratinocytes at 1 h after UVB irradiation.,CGP,C2,6,32
Cohort,0.016196620115664414,0.011168398415935275,1.450218689597855,0.14739144829352654,LonGen OPEL,Genes down-regulated in primary keratinocytes at 1 h after UVB irradiation.,CGP,C2,5,14
Cohort,0.009976872459924627,0.022363733559607014,0.4461183743462532,0.65565459681272,LGP Offspring,Genes up-regulated in primary keratinocytes at 1 h after UVB irradiation.,CGP,C2,13,33
Cohort,0.11638546194121684,0.06854380806801234,1.6979719280512366,0.08988609036714999,LGP Proband,Genes up-regulated in primary keratinocytes at 1 h after UVB irradiation.,CGP,C2,13,66
Cohort,-0.0018848628397078197,0.022427370939204022,-0.08404296896044099,0.9330433994333956,LonGen OPEL,Genes up-regulated in primary keratinocytes at 1 h after UVB irradiation.,CGP,C2,35,42
Cohort,0.05737412557936667,0.02716544653058562,2.1120258603063657,0.035050461810929315,LGP Offspring,Genes down-regulated in primary keratinocytes at 24 h after UVB irradiation.,CGP,C2,16,60
Cohort,0.007257300287646192,0.0738618110766566,0.09825510885610819,0.9217533326962586,LGP Proband,Genes down-regulated in primary keratinocytes at 24 h after UVB irradiation.,CGP,C2,16,81
Cohort,0.02330492803405951,0.02527417762325721,0.9220845236370577,0.35676387828832545,LonGen OPEL,Genes down-regulated in primary keratinocytes at 24 h after UVB irradiation.,CGP,C2,39,56
Cohort,0.01257060502298646,0.023255797523008173,0.5405363978831388,0.5890052125679635,LGP Offspring,Genes down-regulated in primary keratinocytes at 6 h after UVB irradiation.,CGP,C2,16,39
Cohort,-0.01232776204916657,0.06596615926429643,-0.18688009407634038,0.8518000969861252,LGP Proband,Genes down-regulated in primary keratinocytes at 6 h after UVB irradiation.,CGP,C2,16,56
Cohort,-3.844571329454039e-4,0.01887527213571802,-0.02036829615917901,0.9837546789863483,LonGen OPEL,Genes down-regulated in primary keratinocytes at 6 h after UVB irradiation.,CGP,C2,24,31
Cohort,-0.015892409395531767,0.03444276343745421,-0.4614150494745096,0.6446492870299636,LGP Offspring,Genes up-regulated in primary keratinocytes at 6 h after UVB irradiation.,CGP,C2,42,83
Cohort,0.0075440021956024944,0.10458049632982501,0.0721358423449272,0.9425110975743574,LGP Proband,Genes up-regulated in primary keratinocytes at 6 h after UVB irradiation.,CGP,C2,42,145
Cohort,0.023416601373312952,0.03373316491997971,0.6941714905453062,0.48777720641309363,LonGen OPEL,Genes up-regulated in primary keratinocytes at 6 h after UVB irradiation.,CGP,C2,71,97
Cohort,0.006679634791922589,0.03396107209724171,0.1966850390587376,0.8441331345688534,LGP Offspring,Selected genes up-regulated in WT-A10 cells (gastric epithelium) expressing the H. pilori virulence gene CagA.,CGP,C2,35,75
Cohort,-0.009408610332301785,0.08607511457706281,-0.10930697424606135,0.9129853092906713,LGP Proband,Selected genes up-regulated in WT-A10 cells (gastric epithelium) expressing the H. pilori virulence gene CagA.,CGP,C2,35,76
Cohort,-0.032055610934704507,0.026720984233476467,-1.1996418490657517,0.23063541271610374,LonGen OPEL,Selected genes up-regulated in WT-A10 cells (gastric epithelium) expressing the H. pilori virulence gene CagA.,CGP,C2,59,53
Cohort,0.016016019558558123,0.01279699744326514,1.2515451088870149,0.21116857374023232,LGP Offspring,Amplification hot spot 1: colocolized fragile sites and cancer genes in the Xp22.3-p11.1 region.,CGP,C2,1,9
Cohort,0.015601936431062164,0.022109487422929147,0.7056670348169999,0.4805922795769566,LGP Proband,Amplification hot spot 1: colocolized fragile sites and cancer genes in the Xp22.3-p11.1 region.,CGP,C2,1,7
Cohort,0.012337219334903579,0.007793559057671552,1.5830019691400807,0.11381822479897792,LonGen OPEL,Amplification hot spot 1: colocolized fragile sites and cancer genes in the Xp22.3-p11.1 region.,CGP,C2,1,6
Cohort,-0.036790472390834245,0.027129037106261383,-1.3561289420899867,0.175510937058437,LGP Offspring,Amplification hot spot 12: colocolized fragile sites and cancer genes in the 17q11.1-q21; 17q25 region.,CGP,C2,25,38
Cohort,0.09327826262182701,0.07624901625500007,1.2233372599834722,0.22154787183455987,LGP Proband,Amplification hot spot 12: colocolized fragile sites and cancer genes in the 17q11.1-q21; 17q25 region.,CGP,C2,25,60
Cohort,0.06319579979628566,0.02127746063246567,2.9700818574120613,0.0030666889731438083,LonGen OPEL,Amplification hot spot 12: colocolized fragile sites and cancer genes in the 17q11.1-q21; 17q25 region.,CGP,C2,19,48
Cohort,-0.012728465141528722,0.011616613227838033,-1.0957122262645578,0.27359493758340603,LGP Offspring,Amplification hot spot 13: colocolized fragile sites and cancer genes in the Xq12-q28 region.,CGP,C2,5,4
Cohort,-0.04326647447568913,0.030566035967656134,-1.4155081974473935,0.1572928525653943,LGP Proband,Amplification hot spot 13: colocolized fragile sites and cancer genes in the Xq12-q28 region.,CGP,C2,5,6
Cohort,-0.014853381497954954,0.009319411130943717,-1.5938111635226084,0.1113753045941057,LonGen OPEL,Amplification hot spot 13: colocolized fragile sites and cancer genes in the Xq12-q28 region.,CGP,C2,7,2
Cohort,0.009989299342135298,0.010993139266296647,0.9086848715508431,0.3638403301782219,LGP Offspring,Amplification hot spot 15: colocalized fragile sites and cancer genes in the 6p25-p11.1 region.,CGP,C2,2,10
Cohort,0.009928001789649405,0.02483042705519031,0.3998320998500166,0.6893825651133121,LGP Proband,Amplification hot spot 15: colocalized fragile sites and cancer genes in the 6p25-p11.1 region.,CGP,C2,2,8
Cohort,0.006260756175870895,0.008085998124457877,0.7742712871690959,0.4390002867456373,LonGen OPEL,Amplification hot spot 15: colocalized fragile sites and cancer genes in the 6p25-p11.1 region.,CGP,C2,3,7
Cohort,0.013069595627597956,0.01377952456195395,0.9484794318436683,0.343224379116163,LGP Offspring,Amplification hot spot 16: colocolized fragile sites and cancer genes in the 8q11.1-q24.3 region.,CGP,C2,4,15
Cohort,0.020479496482011528,0.0358063321240112,0.5719518103971972,0.5675087444680207,LGP Proband,Amplification hot spot 16: colocolized fragile sites and cancer genes in the 8q11.1-q24.3 region.,CGP,C2,4,17
Cohort,2.9585959512648074e-4,0.010916465296589819,0.027102142230865146,0.9783850591371144,LonGen OPEL,Amplification hot spot 16: colocolized fragile sites and cancer genes in the 8q11.1-q24.3 region.,CGP,C2,9,9
Cohort,-0.0037548948455537767,0.021452054593881453,-0.17503660682575115,0.8611032817941717,LGP Offspring,Amplification hot spot 17: colocalized fragile sites and cancer genes in the 1q11-q44 region.,CGP,C2,14,31
Cohort,0.014517696051143584,0.05872836986483392,0.24720073253449293,0.804813717930814,LGP Proband,Amplification hot spot 17: colocalized fragile sites and cancer genes in the 1q11-q44 region.,CGP,C2,14,41
Cohort,0.003879347607395002,0.018396656593112015,0.21087242607156606,0.8330407914532041,LonGen OPEL,Amplification hot spot 17: colocalized fragile sites and cancer genes in the 1q11-q44 region.,CGP,C2,24,29
Cohort,0.006133872862118882,0.011448456302779724,0.535781654739736,0.5922856937319144,LGP Offspring,Amplification hot spot 18: colocolized fragile sites and cancer genes in the 18q11.2-q23 region.,CGP,C2,2,9
Cohort,0.008541764986586686,0.027125385484269664,0.314899303146868,0.7529168776962074,LGP Proband,Amplification hot spot 18: colocolized fragile sites and cancer genes in the 18q11.2-q23 region.,CGP,C2,2,8
Cohort,-0.002623853044329577,0.009649510101533379,-0.2719156741348587,0.785757369302476,LonGen OPEL,Amplification hot spot 18: colocolized fragile sites and cancer genes in the 18q11.2-q23 region.,CGP,C2,7,7
Cohort,-0.012170024877045047,0.010160797362350909,-1.1977430946648917,0.23143683743492321,LGP Offspring,Amplification hot spot 2: colocolized fragile sites and cancer genes in the 12p13-p11.1 region.,CGP,C2,5,5
Cohort,-0.05703776167393914,0.02724538720450781,-2.0934832471201625,0.03660752620050254,LGP Proband,Amplification hot spot 2: colocolized fragile sites and cancer genes in the 12p13-p11.1 region.,CGP,C2,5,7
Cohort,0.004555345663245527,0.00636017231058755,0.716229913403825,0.47405946108713204,LonGen OPEL,Amplification hot spot 2: colocolized fragile sites and cancer genes in the 12p13-p11.1 region.,CGP,C2,2,4
Cohort,-2.4234817876904577e-4,0.01059326797072859,-0.022877565208272308,0.9817546872090779,LGP Offspring,Amplification hot spot 21: colocolized fragile sites and cancer genes in the 12q13-q21 region.,CGP,C2,4,7
Cohort,-0.0166792020038986,0.024808168430698177,-0.6723270220650142,0.5015617464844953,LGP Proband,Amplification hot spot 21: colocolized fragile sites and cancer genes in the 12q13-q21 region.,CGP,C2,4,6
Cohort,-0.007098085803746814,0.008191615861053044,-0.8665061843896504,0.38647374402487733,LonGen OPEL,Amplification hot spot 21: colocolized fragile sites and cancer genes in the 12q13-q21 region.,CGP,C2,6,4
Cohort,0.03216852189165239,0.019261551028221875,1.6700899031713137,0.0953645003896904,LGP Offspring,Amplification hot spot 22: colocolized fragile sites and cancer genes in the 22q11.1-q13s region.,CGP,C2,7,31
Cohort,0.08112330810386476,0.05929825825739693,1.368055495858436,0.17166317423878724,LGP Proband,Amplification hot spot 22: colocolized fragile sites and cancer genes in the 22q11.1-q13s region.,CGP,C2,7,45
Cohort,0.008716784826096101,0.017539253259975653,0.4969872261316672,0.619335292292154,LonGen OPEL,Amplification hot spot 22: colocolized fragile sites and cancer genes in the 22q11.1-q13s region.,CGP,C2,19,27
Cohort,-0.009750485675945697,0.0239041831163116,-0.4078987191698768,0.6834771862357195,LGP Offspring,Amplification hot spot 23: colocolized fragile sites and cancer genes in the 11q12-q25 region.,CGP,C2,22,39
Cohort,-0.005829423200413516,0.08145477892539159,-0.07156637434069976,0.9429641587196339,LGP Proband,Amplification hot spot 23: colocolized fragile sites and cancer genes in the 11q12-q25 region.,CGP,C2,22,86
Cohort,0.005533347894864848,0.022589972615538294,0.2449470828954785,0.8065605363101069,LonGen OPEL,Amplification hot spot 23: colocolized fragile sites and cancer genes in the 11q12-q25 region.,CGP,C2,37,45
Cohort,-0.027015796596064238,0.012246093563295646,-2.2060746520046837,0.02771438778385175,LGP Offspring,Amplification hot spot 24: colocalized fragile sites and cancer genes in the 1q21-q24 region.,CGP,C2,8,7
Cohort,3.552627966503643e-4,0.03560929732485846,0.009976686521201284,0.9920422738324848,LGP Proband,Amplification hot spot 24: colocalized fragile sites and cancer genes in the 1q21-q24 region.,CGP,C2,8,13
Cohort,0.007943022120003258,0.011248353223998784,0.7061497769341492,0.4803016224789177,LonGen OPEL,Amplification hot spot 24: colocalized fragile sites and cancer genes in the 1q21-q24 region.,CGP,C2,7,12
Cohort,-0.001454993102854443,0.017997161527533966,-0.08084569895249538,0.9355885932038304,LGP Offspring,Amplification hot spot 25: colocalized fragile sites and cancer genes in the 2q13-q36 region.,CGP,C2,11,22
Cohort,-0.06690690898471334,0.058597625606721375,-1.1418023903179937,0.2538638837263973,LGP Proband,Amplification hot spot 25: colocalized fragile sites and cancer genes in the 2q13-q36 region.,CGP,C2,11,43
Cohort,-0.0018057581507800221,0.014908515367047391,-0.12112260049523964,0.9036244960461093,LonGen OPEL,Amplification hot spot 25: colocalized fragile sites and cancer genes in the 2q13-q36 region.,CGP,C2,19,16
Cohort,-0.012612597609174192,0.019976158628761072,-0.6313825317253415,0.5280038648283136,LGP Offspring,Amplification hot spot 27: colocalized fragile sites and cancer genes in the 5p15.3-p15.1; 5p12-q35 region.,CGP,C2,15,27
Cohort,0.09505177075192442,0.061687756918288414,1.5408530882040332,0.12373186149358341,LGP Proband,Amplification hot spot 27: colocalized fragile sites and cancer genes in the 5p15.3-p15.1; 5p12-q35 region.,CGP,C2,15,46
Cohort,0.014917380122212871,0.019334620657268754,0.7715372536468543,0.44061752331587667,LonGen OPEL,Amplification hot spot 27: colocalized fragile sites and cancer genes in the 5p15.3-p15.1; 5p12-q35 region.,CGP,C2,25,33
Cohort,-0.02292446617485892,0.022658994814725032,-1.0117159371942381,0.31203587174676023,LGP Offspring,Amplification hot spot 29: colocolized fragile sites and cancer genes in the 7p22-p13 region.,CGP,C2,18,30
Cohort,0.008275788635626133,0.05790801919536572,0.14291265269678624,0.8863936852211292,LGP Proband,Amplification hot spot 29: colocolized fragile sites and cancer genes in the 7p22-p13 region.,CGP,C2,18,34
Cohort,0.005307097708649948,0.015995193416162304,0.3317932813045827,0.7401326976835829,LonGen OPEL,Amplification hot spot 29: colocolized fragile sites and cancer genes in the 7p22-p13 region.,CGP,C2,15,23
Cohort,-0.005904570891910136,0.006444855098429926,-0.9161681374882404,0.3599054225159891,LGP Offspring,Amplification hot spot 30: colocolized fragile sites and cancer genes in the 12q21-q24.3 region.,CGP,C2,2,2
Cohort,-0.0015896394093793077,0.01753493743945162,-0.09065555066097922,0.9277880582839185,LGP Proband,Amplification hot spot 30: colocolized fragile sites and cancer genes in the 12q21-q24.3 region.,CGP,C2,2,3
Cohort,0.002470556798895814,0.00260670267095766,0.9477708472167913,0.3435337586813778,LonGen OPEL,Amplification hot spot 30: colocolized fragile sites and cancer genes in the 12q21-q24.3 region.,CGP,C2,0,1
Cohort,-0.012468099756512342,0.021003120842087723,-0.5936308156418246,0.5529576398746665,LGP Offspring,Amplification hot spot 5: colocolized fragile sites and cancer genes in the 17q22-q25 region.,CGP,C2,14,25
Cohort,0.14282960853094584,0.05665980780535056,2.5208276212588565,0.011893385855865203,LGP Proband,Amplification hot spot 5: colocolized fragile sites and cancer genes in the 17q22-q25 region.,CGP,C2,14,40
Cohort,0.012450407443845754,0.019144577280716567,0.6503359808516882,0.5156628720267669,LonGen OPEL,Amplification hot spot 5: colocolized fragile sites and cancer genes in the 17q22-q25 region.,CGP,C2,24,34
Cohort,0.0077014934653803855,0.010101468915185239,0.7624132222792824,0.44607935414147815,LGP Offspring,Amplification hot spot 6: colocolized fragile sites and cancer genes in the 17p13-p11.1 region.,CGP,C2,2,8
Cohort,0.06020288776552177,0.034910466138248296,1.7244939533924704,0.0849892328924274,LGP Proband,Amplification hot spot 6: colocolized fragile sites and cancer genes in the 17p13-p11.1 region.,CGP,C2,2,16
Cohort,-0.010087585390720778,0.008954624409159308,-1.1265224458105259,0.26028394149354717,LonGen OPEL,Amplification hot spot 6: colocolized fragile sites and cancer genes in the 17p13-p11.1 region.,CGP,C2,7,5
Cohort,0.0022157289214322228,0.006422395232005269,0.3450003996001978,0.7302013848317783,LGP Offspring,Amplification hot spot 7: colocalized fragile sites and cancer genes in the 3q26.3-q29 region.,CGP,C2,2,3
Cohort,-0.05737852974445895,0.019220543327773704,-2.985270955454569,0.0029160632228698072,LGP Proband,Amplification hot spot 7: colocalized fragile sites and cancer genes in the 3q26.3-q29 region.,CGP,C2,2,4
Cohort,0.004504250331780436,0.006859373601987747,0.6566562186487654,0.5115917812754714,LonGen OPEL,Amplification hot spot 7: colocalized fragile sites and cancer genes in the 3q26.3-q29 region.,CGP,C2,2,5
Cohort,-0.07052721278905426,0.026226442139200654,-2.6891643332603343,0.007339747630546273,LGP Offspring,Amplification hot spot 8: colocolized fragile sites and cancer genes in the 9q11-34 region.,CGP,C2,36,39
Cohort,-0.16064645985796566,0.07124678179572505,-2.254788999713174,0.024405205884445124,LGP Proband,Amplification hot spot 8: colocolized fragile sites and cancer genes in the 9q11-34 region.,CGP,C2,36,52
Cohort,0.037611248662297925,0.020148775798921603,1.8666766178573957,0.06231422172905653,LonGen OPEL,Amplification hot spot 8: colocolized fragile sites and cancer genes in the 9q11-34 region.,CGP,C2,22,39
Cohort,0.01609865959911595,0.019910381580904104,0.80855605572904,0.41905500789084493,LGP Offspring,Amplification hot spot 9: colocolized fragile sites and cancer genes in the 8p23-q12; 8q23 region.,CGP,C2,9,27
Cohort,-1.499396841149302e-4,0.04926891117794106,-0.0030432920178285164,0.9975725358036536,LGP Proband,Amplification hot spot 9: colocolized fragile sites and cancer genes in the 8p23-q12; 8q23 region.,CGP,C2,9,28
Cohort,-0.005455387094849523,0.013970884848332163,-0.39048257530379576,0.6962842129126946,LonGen OPEL,Amplification hot spot 9: colocolized fragile sites and cancer genes in the 8p23-q12; 8q23 region.,CGP,C2,13,15
Cohort,0.0031086226815115322,0.006313461795264925,0.4923800574580159,0.6226105638457466,LGP Offspring,Epithelial and mesenchymal markers down-regulated in MEF cells (embryonic fibroblasts) after knockout of PRKAR1A [GeneID=5573].,CGP,C2,1,3
Cohort,-0.01562347843702113,0.01577001137545678,-0.9907081272836809,0.32211546027589927,LGP Proband,Epithelial and mesenchymal markers down-regulated in MEF cells (embryonic fibroblasts) after knockout of PRKAR1A [GeneID=5573].,CGP,C2,1,3
Cohort,0.0029589862587346195,0.0036570574988751634,0.8091166900287303,0.4186898053289505,LonGen OPEL,Epithelial and mesenchymal markers down-regulated in MEF cells (embryonic fibroblasts) after knockout of PRKAR1A [GeneID=5573].,CGP,C2,0,2
Cohort,-0.022564160088652696,0.015575463663276234,-1.4486990934243829,0.14788531385788045,LGP Offspring,Epithelial and mesenchymal markers up-regulated in MEF cells (embryonic fibroblasts) after knockout of PRKAR1A [GeneID=5573].,CGP,C2,12,13
Cohort,0.006670823376551235,0.046809939181403346,0.14250869565755428,0.8867126313331011,LGP Proband,Epithelial and mesenchymal markers up-regulated in MEF cells (embryonic fibroblasts) after knockout of PRKAR1A [GeneID=5573].,CGP,C2,12,25
Cohort,-0.024552683971630712,0.016248522095877183,-1.5110718271331633,0.13116701575659642,LonGen OPEL,Epithelial and mesenchymal markers up-regulated in MEF cells (embryonic fibroblasts) after knockout of PRKAR1A [GeneID=5573].,CGP,C2,22,15
Cohort,0.014044660714860512,0.018795630529276373,0.7472300912163774,0.4551845079083522,LGP Offspring,Down-regulated genes in the breast cancer prognostic signature of 70 genes that significantly correlated with survival.,CGP,C2,9,23
Cohort,-0.040887555860952544,0.05719828141253834,-0.7148388876591255,0.47490864595431515,LGP Proband,Down-regulated genes in the breast cancer prognostic signature of 70 genes that significantly correlated with survival.,CGP,C2,9,41
Cohort,0.0464507793551026,0.019080157770128378,2.4345070892351464,0.015130888885755717,LonGen OPEL,Down-regulated genes in the breast cancer prognostic signature of 70 genes that significantly correlated with survival.,CGP,C2,17,39
Cohort,-0.019904119384822866,0.03280908172788282,-0.6066649335055098,0.5442769798691409,LGP Offspring,Up-regulated genes in the breast cancer prognostic signature of 70 genes that significantly correlated with survival.,CGP,C2,38,73
Cohort,-0.1278419353823417,0.08946251565789741,-1.429000005669484,0.1533786590526717,LGP Proband,Up-regulated genes in the breast cancer prognostic signature of 70 genes that significantly correlated with survival.,CGP,C2,38,98
Cohort,-0.005479172933599641,0.02956560456078164,-0.18532253999188258,0.8530232697264225,LonGen OPEL,Up-regulated genes in the breast cancer prognostic signature of 70 genes that significantly correlated with survival.,CGP,C2,59,63
Cohort,-0.056149162844389706,0.04407661861758609,-1.2738990559041388,0.20313699254920856,LGP Offspring,Genes correlated with the development of hyperglycemia in obese mice.,CGP,C2,74,123
Cohort,-0.05951891406335541,0.12581391908212816,-0.47307098052086716,0.6362863263232638,LGP Proband,Genes correlated with the development of hyperglycemia in obese mice.,CGP,C2,74,180
Cohort,-0.03759901578543547,0.04109226563625848,-0.9149900888467761,0.36047392041313875,LonGen OPEL,Genes correlated with the development of hyperglycemia in obese mice.,CGP,C2,127,132
Cohort,-0.0629040466577817,0.03556147143710844,-1.7688819982893411,0.07736444755965854,LGP Offspring,Genes down-regulated in adipose tissue from obese mouse strains compared to the lean ones.,CGP,C2,47,73
Cohort,-0.09321695618774423,0.09561492782109161,-0.9749205308418544,0.32988236605638677,LGP Proband,Genes down-regulated in adipose tissue from obese mouse strains compared to the lean ones.,CGP,C2,47,104
Cohort,0.024710072048839207,0.03156568235108531,0.7828144430398987,0.4339689077215927,LonGen OPEL,Genes down-regulated in adipose tissue from obese mouse strains compared to the lean ones.,CGP,C2,62,83
Cohort,0.003957690705063811,0.03877386026740781,0.10207110351585322,0.9187305059703645,LGP Offspring,Genes up-regulated in adipose tissue from obese mouse strains compared to the lean ones.,CGP,C2,49,102
Cohort,-0.13128656083571613,0.11113456602502242,-1.1813296756488563,0.23780853537113975,LGP Proband,Genes up-regulated in adipose tissue from obese mouse strains compared to the lean ones.,CGP,C2,49,135
Cohort,-0.041968778101584676,0.03753823648111361,-1.1180274311154754,0.2638925834467095,LonGen OPEL,Genes up-regulated in adipose tissue from obese mouse strains compared to the lean ones.,CGP,C2,95,100
Cohort,0.013572427090773742,0.030010664093211348,0.45225347391909043,0.6512314750752104,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) after stimulation with EGF [GeneID=1950].,CGP,C2,28,63
Cohort,-0.11452288675724555,0.07991734780859099,-1.4330166090038154,0.1522278300075014,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) after stimulation with EGF [GeneID=1950].,CGP,C2,28,79
Cohort,0.003363843021061529,0.02484009754911913,0.13541987966874214,0.892314143777169,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) after stimulation with EGF [GeneID=1950].,CGP,C2,42,53
Cohort,-0.05650054579337993,0.04235574202509448,-1.3339524487590158,0.1826686679389008,LGP Offspring,Genes down-regulated in MCF7 cells (breast cancer) after stimulation with NRG1 [GeneID=3084].,CGP,C2,68,123
Cohort,-0.19611872434532804,0.11916845117901849,-1.6457268883247673,0.10019677926512005,LGP Proband,Genes down-regulated in MCF7 cells (breast cancer) after stimulation with NRG1 [GeneID=3084].,CGP,C2,68,177
Cohort,-0.01561157827827142,0.03575171656748627,-0.43666653736198724,0.6624716207303099,LonGen OPEL,Genes down-regulated in MCF7 cells (breast cancer) after stimulation with NRG1 [GeneID=3084].,CGP,C2,97,114
Cohort,0.03452001276921728,0.05111382755567231,0.6753556604936047,0.4996807680977592,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) after stimulation with NRG1 [GeneID=3084].,CGP,C2,82,179
Cohort,-0.09271445770522134,0.14217626835301178,-0.6521092358045233,0.5145103821367008,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) after stimulation with NRG1 [GeneID=3084].,CGP,C2,82,250
Cohort,-0.038464759161974046,0.04626492454349467,-0.8314021808424756,0.4059957912303538,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) after stimulation with NRG1 [GeneID=3084].,CGP,C2,153,170
Cohort,-0.015454360341805183,0.01572357541915498,-0.9828782531852246,0.3260189984345281,LGP Offspring,Composition of the 2 MDa human PCAF complex.,CGP,C2,10,13
Cohort,-0.014208145587534643,0.042770326388687524,-0.33219633299998863,0.7398244836519323,LGP Proband,Composition of the 2 MDa human PCAF complex.,CGP,C2,10,18
Cohort,-0.01254487108553733,0.013310163328511775,-0.942503166633943,0.3462210460124586,LonGen OPEL,Composition of the 2 MDa human PCAF complex.,CGP,C2,15,12
Cohort,0.0027573847413963847,0.01612367554784,0.17101465067409996,0.8642634201620447,LGP Offspring,Composition of the 2 MDa human STAGA complex containing KAT2A [GeneID=2648].,CGP,C2,8,16
Cohort,-0.06474474680140241,0.05219066456174851,-1.2405426783711626,0.21512360715851692,LGP Proband,Composition of the 2 MDa human STAGA complex containing KAT2A [GeneID=2648].,CGP,C2,8,36
Cohort,-0.013203530903032763,0.015256937565343456,-0.8654116100615722,0.3870736534418343,LonGen OPEL,Composition of the 2 MDa human STAGA complex containing KAT2A [GeneID=2648].,CGP,C2,20,16
Cohort,0.005517899217255525,0.018018063904026195,0.3062426266577139,0.7595142120425915,LGP Offspring,Composition of the 2 MDa human TFTC complex containing KAT2A [GeneID=2648].,CGP,C2,10,21
Cohort,-0.08058850847614935,0.05901281812320253,-1.365610235862702,0.1724295140554354,LGP Proband,Composition of the 2 MDa human TFTC complex containing KAT2A [GeneID=2648].,CGP,C2,10,46
Cohort,0.004637637650573372,0.017347483782046327,0.26733777122034647,0.7892783568133677,LonGen OPEL,Composition of the 2 MDa human TFTC complex containing KAT2A [GeneID=2648].,CGP,C2,20,25
Cohort,-0.020557345200418076,0.021306016155932413,-0.964861053796494,0.33495944268629696,LGP Offspring,Genes regulated by CTNNB1 [GeneID=1499] and whose promoters contain binding sites for LEF1 [GeneID=51176].,CGP,C2,19,27
Cohort,-0.1371419229280647,0.06634015534555232,-2.0672535693309797,0.03901827244492505,LGP Proband,Genes regulated by CTNNB1 [GeneID=1499] and whose promoters contain binding sites for LEF1 [GeneID=51176].,CGP,C2,19,56
Cohort,-0.01880247010623578,0.020431304297240056,-0.9202775227999366,0.3577065558787047,LonGen OPEL,Genes regulated by CTNNB1 [GeneID=1499] and whose promoters contain binding sites for LEF1 [GeneID=51176].,CGP,C2,32,33
Cohort,0.013759353603551138,0.031111596419539176,0.4422580383856413,0.658443949179083,LGP Offspring,Top 30 increased eosinophil specific transcripts.,CGP,C2,32,72
Cohort,-0.01333991839104787,0.08710801810764165,-0.15314225579743285,0.8783231375643729,LGP Proband,Top 30 increased eosinophil specific transcripts.,CGP,C2,32,89
Cohort,-0.0048828131469572005,0.027879646637644702,-0.17513898975907913,0.8610149613228627,LonGen OPEL,Top 30 increased eosinophil specific transcripts.,CGP,C2,56,68
Cohort,-0.02440791946863843,0.027749152969360813,-0.8795915138594824,0.3793932033091991,LGP Offspring,Top 50 most-increased mast cell specific genes.,CGP,C2,28,45
Cohort,-0.02460160309881945,0.07918385707962539,-0.3106896279892083,0.7561142129580981,LGP Proband,Top 50 most-increased mast cell specific genes.,CGP,C2,28,66
Cohort,-0.03558612837125205,0.024052070802411417,-1.479545302506105,0.13939026886396222,LonGen OPEL,Top 50 most-increased mast cell specific genes.,CGP,C2,51,44
Cohort,-0.02531300247817791,0.03538175572475579,-0.7154252794885188,0.47459331787499615,LGP Offspring,"Genes down-regulated in mesenchymal stem cells during early phase of adipogenesis, defined as days 1 to 5 of culturing with adipogenic hormones.",CGP,C2,47,85
Cohort,-0.09913398593880929,0.09684659335616654,-1.0236187201157458,0.3063122111362932,LGP Proband,"Genes down-regulated in mesenchymal stem cells during early phase of adipogenesis, defined as days 1 to 5 of culturing with adipogenic hormones.",CGP,C2,47,112
Cohort,-0.02971552944446843,0.029660463133007544,-1.0018565560225392,0.31671732884740994,LonGen OPEL,"Genes down-regulated in mesenchymal stem cells during early phase of adipogenesis, defined as days 1 to 5 of culturing with adipogenic hormones.",CGP,C2,72,70
Cohort,0.007709353496183188,0.030462832533768018,0.25307408585978924,0.8002879032357366,LGP Offspring,"Genes up-regulated in mesenchymal stem cells during early phase of adipogenesis, defined as days 1 to 5 of culturing with adipogenic hormones.",CGP,C2,31,71
Cohort,-0.08279527245187605,0.08273127005816927,-1.0007736179278015,0.3172265369262231,LGP Proband,"Genes up-regulated in mesenchymal stem cells during early phase of adipogenesis, defined as days 1 to 5 of culturing with adipogenic hormones.",CGP,C2,31,83
Cohort,-0.005275462762496824,0.027963751257487457,-0.18865361495748137,0.85041239490435,LonGen OPEL,"Genes up-regulated in mesenchymal stem cells during early phase of adipogenesis, defined as days 1 to 5 of culturing with adipogenic hormones.",CGP,C2,59,62
Cohort,-0.02613122117221116,0.03530912085317927,-0.740070002900066,0.459514460811259,LGP Offspring,"Genes down-regulated in mesenchymal stem cells during late phase of adipogenesis, defined as days 7 to 14 of culturing with adipogenic hormones.",CGP,C2,47,84
Cohort,-0.08005804800587457,0.09620923776414625,-0.8321243351094229,0.4055769665218051,LGP Proband,"Genes down-regulated in mesenchymal stem cells during late phase of adipogenesis, defined as days 7 to 14 of culturing with adipogenic hormones.",CGP,C2,47,110
Cohort,-0.03500562035175053,0.029642683468323393,-1.1809194126826625,0.23798746759267222,LonGen OPEL,"Genes down-regulated in mesenchymal stem cells during late phase of adipogenesis, defined as days 7 to 14 of culturing with adipogenic hormones.",CGP,C2,73,69
Cohort,3.7483363509261525e-4,0.05537637297288429,0.0067688368697631585,0.9946012878025793,LGP Offspring,"Genes up-regulated in mesenchymal stem cells during late phase of adipogenesis, defined as days 7 to 14 of culturing with adipogenic hormones.",CGP,C2,102,220
Cohort,-0.1325924406460466,0.14926810110294522,-0.8882838306799524,0.3746442064888067,LGP Proband,"Genes up-regulated in mesenchymal stem cells during late phase of adipogenesis, defined as days 7 to 14 of culturing with adipogenic hormones.",CGP,C2,102,259
Cohort,-0.07626372491593633,0.04940257203644212,-1.5437197249503511,0.12305368846432592,LonGen OPEL,"Genes up-regulated in mesenchymal stem cells during late phase of adipogenesis, defined as days 7 to 14 of culturing with adipogenic hormones.",CGP,C2,180,179
Cohort,-0.00999560271378269,0.006391671217918979,-1.5638480724352857,0.1183212375523615,LGP Offspring,Differentiation markers for normal alveolar epithelium cells.,CGP,C2,3,1
Cohort,-0.03386861715020725,0.022293934380368745,-1.5191852892520743,0.1290948487875017,LGP Proband,Differentiation markers for normal alveolar epithelium cells.,CGP,C2,3,5
Cohort,0.00623037741784072,0.0051991298068108675,1.198350041131675,0.23113743428702568,LonGen OPEL,Differentiation markers for normal alveolar epithelium cells.,CGP,C2,1,3
Cohort,-0.02584253361811621,0.014500256851629922,-1.7822121278638827,0.07516339501739161,LGP Offspring,Differentiation markers for normal bronchiolar and bronchial epithelial cells.,CGP,C2,10,11
Cohort,0.0778658395576737,0.04593370960061146,1.6951785569837183,0.09041482426568992,LGP Proband,Differentiation markers for normal bronchiolar and bronchial epithelial cells.,CGP,C2,10,25
Cohort,0.0040723724575699675,0.014885080838647747,0.273587527116173,0.7844725920704224,LonGen OPEL,Differentiation markers for normal bronchiolar and bronchial epithelial cells.,CGP,C2,14,18
Cohort,-0.013158480755281424,0.034244273427670516,-0.3842534660013821,0.7009114334603215,LGP Offspring,Genes down-regulated in pancreatic cancer cells grown in orthotopic xenograft tumors compared to those grown in vitro.,CGP,C2,36,71
Cohort,-0.04053402658322654,0.09020012552329029,-0.4493788267817917,0.6532751592134555,LGP Proband,Genes down-regulated in pancreatic cancer cells grown in orthotopic xenograft tumors compared to those grown in vitro.,CGP,C2,36,93
Cohort,0.03943766133185252,0.02624862378681458,1.5024658683882375,0.13337343045751593,LonGen OPEL,Genes down-regulated in pancreatic cancer cells grown in orthotopic xenograft tumors compared to those grown in vitro.,CGP,C2,45,71
Cohort,-0.020274505944537384,0.023423156424679816,-0.8655753126071064,0.38703017588869437,LGP Offspring,Genes up-regulated in pancreatic cancer cells grown in orthotopic xenograft tumors compared to those grown in vitro.,CGP,C2,20,36
Cohort,0.020787625510560025,0.06802800292642673,0.30557453719525096,0.7600048625855929,LGP Proband,Genes up-regulated in pancreatic cancer cells grown in orthotopic xenograft tumors compared to those grown in vitro.,CGP,C2,20,54
Cohort,0.013893063681495012,0.020894623230408565,0.6649109451888093,0.5063000412331289,LonGen OPEL,Genes up-regulated in pancreatic cancer cells grown in orthotopic xenograft tumors compared to those grown in vitro.,CGP,C2,24,44
Cohort,-0.033776328732715626,0.022460986404144578,-1.503777622450415,0.13310566193759538,LGP Offspring,Genes up-regulated in lung adenocarcinoma cell lines and not expressed in non-cancerous lung epithelial cells.,CGP,C2,23,30
Cohort,0.0257857424573654,0.060763549543396814,0.4243620172147685,0.6714112585632901,LGP Proband,Genes up-regulated in lung adenocarcinoma cell lines and not expressed in non-cancerous lung epithelial cells.,CGP,C2,23,39
Cohort,0.002124125536505215,0.020007923837682497,0.106164215424725,0.9154788107155651,LonGen OPEL,Genes up-regulated in lung adenocarcinoma cell lines and not expressed in non-cancerous lung epithelial cells.,CGP,C2,28,34
Cohort,-0.003890983882071146,0.02030298403151505,-0.19164591155819338,0.8480771260761399,LGP Offspring,"14 candidate differentiation markers in lung adenocarcinoma cells, noncancerous lung cells and peripheral blood cells.",CGP,C2,14,28
Cohort,0.09882673333762543,0.0594970893807219,1.661034755922817,0.09708231350474322,LGP Proband,"14 candidate differentiation markers in lung adenocarcinoma cells, noncancerous lung cells and peripheral blood cells.",CGP,C2,14,44
Cohort,0.012390994976960558,0.01817986015457812,0.6815781239021363,0.49570399993711656,LonGen OPEL,"14 candidate differentiation markers in lung adenocarcinoma cells, noncancerous lung cells and peripheral blood cells.",CGP,C2,21,29
Cohort,-0.06088483907181327,0.038862706350922864,-1.56666492863453,0.11766099468189738,LGP Offspring,Genes up-regulated in highly metastatic pancreatic cancer cells.,CGP,C2,54,89
Cohort,0.05851144643841784,0.11030528064494126,0.5304500935613299,0.5959411079280204,LGP Proband,Genes up-regulated in highly metastatic pancreatic cancer cells.,CGP,C2,54,124
Cohort,0.04117755005169182,0.034592388659092525,1.1903644601561332,0.23425805437974867,LonGen OPEL,Genes up-regulated in highly metastatic pancreatic cancer cells.,CGP,C2,76,108
Cohort,-0.022315588314395493,0.04280942238930469,-0.5212774914704459,0.602344200938693,LGP Offspring,Bottom genes down-regulated in subcutaneous tumors from highly metastatic pancreatic cancer cells.,CGP,C2,62,122
Cohort,0.08685212425739341,0.1146509919080128,0.7575348700609318,0.44894345947035996,LGP Proband,Bottom genes down-regulated in subcutaneous tumors from highly metastatic pancreatic cancer cells.,CGP,C2,62,152
Cohort,-0.07179850371794703,0.03450704909077196,-2.080690919964748,0.03778145105885267,LonGen OPEL,Bottom genes down-regulated in subcutaneous tumors from highly metastatic pancreatic cancer cells.,CGP,C2,97,84
Cohort,-0.03901597332986877,0.04230056907234742,-0.9223510270781239,0.35667457511992673,LGP Offspring,Top genes up-regulated in orthotopic tumors from highly metastatic pancreatic cancer cells.,CGP,C2,66,118
Cohort,0.016166837438650737,0.1097815156094266,0.1472637478987632,0.8829594374303196,LGP Proband,Top genes up-regulated in orthotopic tumors from highly metastatic pancreatic cancer cells.,CGP,C2,66,132
Cohort,0.02096096988247947,0.03555444294262885,0.589545726150242,0.5556625371930228,LonGen OPEL,Top genes up-regulated in orthotopic tumors from highly metastatic pancreatic cancer cells.,CGP,C2,83,115
Cohort,-0.14418997250579238,0.1410733714080583,-1.0220920579598203,0.3071029572159311,LGP Offspring,Down-regulated genes in peripheral zone of human pancreatic cancer growing in the pancreas of nude mice compared to that of the tumor from the central zone.,CGP,C2,587,1153
Cohort,-0.030350551911820643,0.36179427963538524,-0.0838889767478021,0.9331648352023477,LGP Proband,Down-regulated genes in peripheral zone of human pancreatic cancer growing in the pancreas of nude mice compared to that of the tumor from the central zone.,CGP,C2,587,1559
Cohort,-0.0324599267104823,0.10966989818200851,-0.2959784521420062,0.7673237344673665,LonGen OPEL,Down-regulated genes in peripheral zone of human pancreatic cancer growing in the pancreas of nude mice compared to that of the tumor from the central zone.,CGP,C2,932,1097
Cohort,-0.08502710963477501,0.08908490498664838,-0.9544502477441994,0.3401969515363584,LGP Offspring,Up-regulated genes in peripheral zone of human pancreatic cancer growing in the pancreas of nude mice compared to that of the tumor from the central zone.,CGP,C2,245,487
Cohort,-0.062086460482686325,0.2475312775803815,-0.25082268830663157,0.8020129795605295,LGP Proband,Up-regulated genes in peripheral zone of human pancreatic cancer growing in the pancreas of nude mice compared to that of the tumor from the central zone.,CGP,C2,245,668
Cohort,0.03260412961933297,0.07671899241007539,0.4249812021130131,0.6709652317878085,LonGen OPEL,Up-regulated genes in peripheral zone of human pancreatic cancer growing in the pancreas of nude mice compared to that of the tumor from the central zone.,CGP,C2,387,463
Cohort,-0.06692256175812837,0.02662946744785681,-2.5131017692775686,0.012198993289012718,LGP Offspring,"Genes down-regulated in ST1 cells (adult T-cell leukemia, ATL) after knockdown of FRA2 [GeneID=2355] by RNAi.",CGP,C2,33,41
Cohort,-0.12598872890252857,0.07876437125548341,-1.5995649669298604,0.11007385732518574,LGP Proband,"Genes down-regulated in ST1 cells (adult T-cell leukemia, ATL) after knockdown of FRA2 [GeneID=2355] by RNAi.",CGP,C2,33,70
Cohort,0.005497098015774206,0.021336072507888222,0.25764338838564865,0.7967487312043533,LonGen OPEL,"Genes down-regulated in ST1 cells (adult T-cell leukemia, ATL) after knockdown of FRA2 [GeneID=2355] by RNAi.",CGP,C2,30,40
Cohort,-0.04567186818655582,0.04957138957728474,-0.9213352414773578,0.3572041092986413,LGP Offspring,Top 100 probe sets contrubuting to the negative side of the 1st principal component; predominantly associated with synovial sarcoma and myxoid/round cell liposarcoma samples.,CGP,C2,84,165
Cohort,-0.06566303575029238,0.14578522826171708,-0.4504093901229317,0.6525323358294717,LGP Proband,Top 100 probe sets contrubuting to the negative side of the 1st principal component; predominantly associated with synovial sarcoma and myxoid/round cell liposarcoma samples.,CGP,C2,84,255
Cohort,-0.005784107260400186,0.04296302664936212,-0.1346298832157828,0.8929385466566262,LonGen OPEL,Top 100 probe sets contrubuting to the negative side of the 1st principal component; predominantly associated with synovial sarcoma and myxoid/round cell liposarcoma samples.,CGP,C2,137,160
Cohort,-0.020770403287128696,0.04331524174655234,-0.4795171964792718,0.6317258306223087,LGP Offspring,Top 100 probe sets contrubuting to the positive side of the 1st principal component; predominantly associated with spindle cell and pleomorphic sarcoma samples.,CGP,C2,60,111
Cohort,-0.053539774892295625,0.1230747484442019,-0.43501835729177885,0.6636616466595355,LGP Proband,Top 100 probe sets contrubuting to the positive side of the 1st principal component; predominantly associated with spindle cell and pleomorphic sarcoma samples.,CGP,C2,60,154
Cohort,-0.06498089981134424,0.03472181663012537,-1.8714717753265666,0.0616462994556734,LonGen OPEL,Top 100 probe sets contrubuting to the positive side of the 1st principal component; predominantly associated with spindle cell and pleomorphic sarcoma samples.,CGP,C2,91,78
Cohort,-0.0420470441911644,0.050500340368367334,-0.8326091247001188,0.40535925908842896,LGP Offspring,Top 100 probe sets contrubuting to the negative side of the 2nd principal component; associated with adipocytic differentiation.,CGP,C2,91,175
Cohort,-0.0371778624304725,0.13846424688423603,-0.2685015321070955,0.7883796959436666,LGP Proband,Top 100 probe sets contrubuting to the negative side of the 2nd principal component; associated with adipocytic differentiation.,CGP,C2,91,244
Cohort,-0.025640919262317315,0.044784784480335287,-0.5725363995795509,0.5671203039883026,LonGen OPEL,Top 100 probe sets contrubuting to the negative side of the 2nd principal component; associated with adipocytic differentiation.,CGP,C2,148,173
Cohort,-0.1190721977391349,0.05746048050895527,-2.072245074953339,0.038621142151436944,LGP Offspring,Top 100 probe sets contrubuting to the positive side of the 2nd principal component; associated with adipocytic differentiation.,CGP,C2,123,197
Cohort,-0.25948810411822465,0.16270166356601598,-1.5948706265866648,0.1111200267970488,LGP Proband,Top 100 probe sets contrubuting to the positive side of the 2nd principal component; associated with adipocytic differentiation.,CGP,C2,123,281
Cohort,-0.040321746711318385,0.05048614368165254,-0.7986695709138099,0.42472026041662336,LonGen OPEL,Top 100 probe sets contrubuting to the positive side of the 2nd principal component; associated with adipocytic differentiation.,CGP,C2,176,196
Cohort,-0.021527450358554835,0.021296700747585613,-1.0108349933496334,0.3124570786735705,LGP Offspring,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of FXYD5 [GeneID=53827] by RNAi.,CGP,C2,18,25
Cohort,-0.0858312259158994,0.04783720927212331,-1.7942356425444064,0.07313765565680284,LGP Proband,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of FXYD5 [GeneID=53827] by RNAi.,CGP,C2,18,17
Cohort,-0.014325028595404795,0.016724199341577494,-0.8565449563729967,0.3919541963182268,LonGen OPEL,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of FXYD5 [GeneID=53827] by RNAi.,CGP,C2,19,16
Cohort,0.04543452779948974,0.03430093209163368,1.324585806534734,0.18575617972960012,LGP Offspring,Genes down-regulated in T98 cells (glioma) 48 h after treatment with interferon beta.,CGP,C2,32,91
Cohort,-0.04602808846063308,0.08749033010039241,-0.5260934369297418,0.5989631530153245,LGP Proband,Genes down-regulated in T98 cells (glioma) 48 h after treatment with interferon beta.,CGP,C2,32,91
Cohort,-0.0014164606002785107,0.02631824371131031,-0.05382048345687233,0.9570916940706449,LonGen OPEL,Genes down-regulated in T98 cells (glioma) 48 h after treatment with interferon beta.,CGP,C2,51,63
Cohort,-0.11618183519099734,0.039584068794867464,-2.9350655131758883,0.0034479056847527482,LGP Offspring,Genes up-regulated in T98 cells (glioma) 48 h after treatment with interferon beta.,CGP,C2,68,96
Cohort,0.032928508659068885,0.11381368855699245,0.28931940504309256,0.7724088685773349,LGP Proband,Genes up-regulated in T98 cells (glioma) 48 h after treatment with interferon beta.,CGP,C2,68,148
Cohort,-0.09787931843163891,0.034025710748394354,-2.8766281814188925,0.004126923362100298,LonGen OPEL,Genes up-regulated in T98 cells (glioma) 48 h after treatment with interferon beta.,CGP,C2,92,71
Cohort,-0.004228201972205866,0.016118077975740622,-0.2623266855123637,0.7931495092702033,LGP Offspring,Genes down-regulated in acute myeloid leukemia (AML) samples with constitutively activated FLT3 [GeneID=2322] or with activating point mutations within NRAS [GeneID=4893].,CGP,C2,10,17
Cohort,-0.010143516452158535,0.04302828868796944,-0.23574064322466595,0.8136918062166066,LGP Proband,Genes down-regulated in acute myeloid leukemia (AML) samples with constitutively activated FLT3 [GeneID=2322] or with activating point mutations within NRAS [GeneID=4893].,CGP,C2,10,22
Cohort,0.017873544301113535,0.011770609248045093,1.51848930879105,0.12928815006597974,LonGen OPEL,Genes down-regulated in acute myeloid leukemia (AML) samples with constitutively activated FLT3 [GeneID=2322] or with activating point mutations within NRAS [GeneID=4893].,CGP,C2,7,14
Cohort,-0.010138702658886625,0.01276046263284969,-0.7945403666467563,0.42715976410687984,LGP Offspring,Genes up-regulated in acute myeloid leukemia (AML) samples with constitutively activated FLT3 [GeneID=2322] or with activating point mutations within NRAS [GeneID=4893].,CGP,C2,6,10
Cohort,-0.04631536318273364,0.04095481890292352,-1.13088921947174,0.2584268166500143,LGP Proband,Genes up-regulated in acute myeloid leukemia (AML) samples with constitutively activated FLT3 [GeneID=2322] or with activating point mutations within NRAS [GeneID=4893].,CGP,C2,6,20
Cohort,-0.003968785725584443,0.011922306638337913,-0.33288740559836255,0.7393069299588944,LonGen OPEL,Genes up-regulated in acute myeloid leukemia (AML) samples with constitutively activated FLT3 [GeneID=2322] or with activating point mutations within NRAS [GeneID=4893].,CGP,C2,10,12
Cohort,0.03400366083688649,0.026169727812315555,1.2993509554533562,0.19426646834178332,LGP Offspring,Genes down-regulated in LNCaP cells (prostate cancer) in response to synthetic androgen R1881 [PubChem=13766].,CGP,C2,16,53
Cohort,-0.023086154837765133,0.06749084135399105,-0.3420635211328557,0.7323892674742429,LGP Proband,Genes down-regulated in LNCaP cells (prostate cancer) in response to synthetic androgen R1881 [PubChem=13766].,CGP,C2,16,60
Cohort,-0.024144600301509268,0.021061854465690907,-1.1463663060078615,0.25198810424785495,LonGen OPEL,Genes down-regulated in LNCaP cells (prostate cancer) in response to synthetic androgen R1881 [PubChem=13766].,CGP,C2,34,34
Cohort,-0.04865106168997458,0.05305198164407681,-0.9170451353989415,0.35944603258975993,LGP Offspring,Genes up-regulated in LNCaP cells (prostate cancer) in response to synthetic androgen R1881 [PubChem=13766].,CGP,C2,96,184
Cohort,0.07819964260071047,0.141520071020695,0.5525692718828205,0.5807064471122447,LGP Proband,Genes up-regulated in LNCaP cells (prostate cancer) in response to synthetic androgen R1881 [PubChem=13766].,CGP,C2,96,231
Cohort,-0.020449667354294,0.04011690996396518,-0.5097518072220123,0.6103666497315177,LonGen OPEL,Genes up-regulated in LNCaP cells (prostate cancer) in response to synthetic androgen R1881 [PubChem=13766].,CGP,C2,124,136
Cohort,-0.01895299284619848,0.02358726199763068,-0.8035266173794268,0.42195286387062536,LGP Offspring,Genes down-regulated in RAW 264.7 cells (macrophage) 3 hr after stimulation with bacterial lipopolysaccharide (LPS).,CGP,C2,21,35
Cohort,0.00450461873792221,0.06598185383648364,0.06827056949757072,0.9455866155932782,LGP Proband,Genes down-regulated in RAW 264.7 cells (macrophage) 3 hr after stimulation with bacterial lipopolysaccharide (LPS).,CGP,C2,21,54
Cohort,0.005836753204873186,0.021966110306160937,0.2657162840175725,0.7905265248021269,LonGen OPEL,Genes down-regulated in RAW 264.7 cells (macrophage) 3 hr after stimulation with bacterial lipopolysaccharide (LPS).,CGP,C2,25,41
Cohort,-0.07148694249225361,0.04567139934219747,-1.5652452852742835,0.1179933817767324,LGP Offspring,Genes up-regulated in RAW 264.7 cells (macrophage) 3 hr after stimulation with bacterial lipopolysaccharide (LPS).,CGP,C2,75,135
Cohort,-0.10206520109561464,0.12333089563685579,-0.8275720416086382,0.408149638849453,LGP Proband,Genes up-regulated in RAW 264.7 cells (macrophage) 3 hr after stimulation with bacterial lipopolysaccharide (LPS).,CGP,C2,75,167
Cohort,-0.031953992228961454,0.04112985059596956,-0.7769051374111415,0.4374455463994136,LonGen OPEL,Genes up-regulated in RAW 264.7 cells (macrophage) 3 hr after stimulation with bacterial lipopolysaccharide (LPS).,CGP,C2,116,132
Cohort,-0.017820799637110682,0.03412607083625544,-0.5222048480945517,0.6016987842289996,LGP Offspring,Genes down-regulated in Cockayne syndrome fibroblasts rescued by expression of ERCC6 [GeneID=2074] off a plasmid vector.,CGP,C2,39,75
Cohort,-0.006184620821848204,0.09657081859236198,-0.06404233610107724,0.948951862910989,LGP Proband,Genes down-regulated in Cockayne syndrome fibroblasts rescued by expression of ERCC6 [GeneID=2074] off a plasmid vector.,CGP,C2,39,107
Cohort,-0.04865962848175348,0.028240799866688066,-1.7230258601545774,0.08527221622449872,LonGen OPEL,Genes down-regulated in Cockayne syndrome fibroblasts rescued by expression of ERCC6 [GeneID=2074] off a plasmid vector.,CGP,C2,59,54
Cohort,0.011373556059676397,0.024515295632004056,0.46393713665147596,0.6428421398280433,LGP Offspring,Genes up-regulated in Cockayne syndrome fibroblasts rescued by expression of ERCC6 [GeneID=2074] off a plasmid vector.,CGP,C2,19,42
Cohort,-0.16281856969607175,0.0679844407646568,-2.394938722224756,0.01684286370895011,LGP Proband,Genes up-regulated in Cockayne syndrome fibroblasts rescued by expression of ERCC6 [GeneID=2074] off a plasmid vector.,CGP,C2,19,58
Cohort,0.0016023225536407257,0.021656818087855217,0.07398697939561498,0.9410393339402819,LonGen OPEL,Genes up-regulated in Cockayne syndrome fibroblasts rescued by expression of ERCC6 [GeneID=2074] off a plasmid vector.,CGP,C2,31,38
Cohort,-0.010469083729213796,0.01055046144583895,-0.992286809724588,0.321412678558987,LGP Offspring,Proteins with reduced expression in mulignant glioma cell line (A172) which bears loss of heterozygosity (LOH) in the 1p region.,CGP,C2,4,7
Cohort,0.024231003659788457,0.03123494100435292,0.7757659493069512,0.43810711383270307,LGP Proband,Proteins with reduced expression in mulignant glioma cell line (A172) which bears loss of heterozygosity (LOH) in the 1p region.,CGP,C2,4,10
Cohort,0.006527443234344383,0.010785499616236871,0.6052054579388924,0.5452149855942269,LonGen OPEL,Proteins with reduced expression in mulignant glioma cell line (A172) which bears loss of heterozygosity (LOH) in the 1p region.,CGP,C2,7,11
Cohort,-0.011559220552359016,0.058887035302600095,-0.196294829463908,0.8444384027536868,LGP Offspring,Genes down-regulated in primary keratinocytes by expression of constantly active NOTCH1 [GeneID=4851].,CGP,C2,116,243
Cohort,-0.04964744598457416,0.1655828478938525,-0.2998344732927944,0.7643781306008139,LGP Proband,Genes down-regulated in primary keratinocytes by expression of constantly active NOTCH1 [GeneID=4851].,CGP,C2,116,318
Cohort,-0.014125807368860115,0.050569528152687775,-0.27933437160436164,0.7800607922709345,LonGen OPEL,Genes down-regulated in primary keratinocytes by expression of constantly active NOTCH1 [GeneID=4851].,CGP,C2,184,219
Cohort,-0.0666706088504719,0.027637925061464303,-2.4122870549146636,0.01611809734938003,LGP Offspring,Genes up-regulated in primary keratinocytes by expression of constantly active NOTCH1 [GeneID=4851].,CGP,C2,36,45
Cohort,0.04290092369732838,0.08698559830012659,0.49319570751594116,0.6220041449019165,LGP Proband,Genes up-regulated in primary keratinocytes by expression of constantly active NOTCH1 [GeneID=4851].,CGP,C2,36,89
Cohort,-0.00597907030599873,0.026439203603355114,-0.2261441152198696,0.821147388895234,LonGen OPEL,Genes up-regulated in primary keratinocytes by expression of constantly active NOTCH1 [GeneID=4851].,CGP,C2,45,55
Cohort,0.02234265019319967,0.028662066232493438,0.7795198717345224,0.4359463526052674,LGP Offspring,Genes down-regulated in neutrophils upon treatment with activated protein C (PROC) [GeneID=5624] of pulmonary inflammation induced by bacterial lipopolysaccharide (LPS).,CGP,C2,25,60
Cohort,-0.03524687571416263,0.08132027243848383,-0.43343282870609856,0.6648124362891432,LGP Proband,Genes down-regulated in neutrophils upon treatment with activated protein C (PROC) [GeneID=5624] of pulmonary inflammation induced by bacterial lipopolysaccharide (LPS).,CGP,C2,25,88
Cohort,0.03979837935410253,0.02513303599658563,1.5835086282257826,0.11370278126369394,LonGen OPEL,Genes down-regulated in neutrophils upon treatment with activated protein C (PROC) [GeneID=5624] of pulmonary inflammation induced by bacterial lipopolysaccharide (LPS).,CGP,C2,39,62
Cohort,-0.002109859459029977,0.009618005252355876,-0.21936559646951523,0.8264314860978756,LGP Offspring,Genes up-regulated in neutrophils upon treatment with activated protein C (PROC) [GeneID=5624] of pulmonary inflammation induced by bacterial lipopolysaccharide (LPS).,CGP,C2,3,6
Cohort,-0.015589361660366336,0.029208299651870998,-0.5337305439266721,0.5936701913094278,LGP Proband,Genes up-regulated in neutrophils upon treatment with activated protein C (PROC) [GeneID=5624] of pulmonary inflammation induced by bacterial lipopolysaccharide (LPS).,CGP,C2,3,11
Cohort,-0.0019478672182931232,0.006369035149667364,-0.3058339564030911,0.7598110381457712,LonGen OPEL,Genes up-regulated in neutrophils upon treatment with activated protein C (PROC) [GeneID=5624] of pulmonary inflammation induced by bacterial lipopolysaccharide (LPS).,CGP,C2,3,3
Cohort,0.006301774065709985,0.015130221802500194,0.41650242461539116,0.6771746029028587,LGP Offspring,Genes within amplicon 10q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,6,17
Cohort,0.013779164459268045,0.03908143613829953,0.3525756937515549,0.7244956437508366,LGP Proband,Genes within amplicon 10q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,6,19
Cohort,0.01341088501729485,0.008939699992752594,1.5001493370210457,0.13397223640811942,LonGen OPEL,Genes within amplicon 10q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,3,9
Cohort,-0.08535390744397263,0.06643129630023366,-1.2848448276279145,0.19928658506963529,LGP Offspring,Genes within amplicon  11q12-q14 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,153,287
Cohort,0.10688578480104126,0.18700312078378392,0.5715721981165457,0.5677658378779786,LGP Proband,Genes within amplicon  11q12-q14 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,153,410
Cohort,-0.007540224090702228,0.05874469763381927,-0.1283558243452653,0.897899810444907,LonGen OPEL,Genes within amplicon  11q12-q14 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,236,279
Cohort,-0.0480688417503707,0.03537446021333027,-1.3588572506968395,0.1746450323139747,LGP Offspring,Genes within amplicon 12q13-q21 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,39,66
Cohort,-0.1941828641307737,0.10486559915323808,-1.8517308411790794,0.06441774806672702,LGP Proband,Genes within amplicon 12q13-q21 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,39,117
Cohort,0.00769611362336111,0.03681062039684819,0.20907318432536035,0.8344445992508928,LonGen OPEL,Genes within amplicon 12q13-q21 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,66,84
Cohort,0.05651092271512505,0.03196745615145953,1.7677641426136732,0.07755139373031422,LGP Offspring,Genes within amplicon  12q24 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,25,78
Cohort,0.08874656794515888,0.08794491349255011,1.0091154157844124,0.3132119625457866,LGP Proband,Genes within amplicon  12q24 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,25,105
Cohort,0.01963215238600471,0.029827340563663117,0.6581931883636116,0.5106043112177834,LonGen OPEL,Genes within amplicon  12q24 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,56,76
Cohort,-0.005503195010831673,0.010552837405336508,-0.5214896050657181,0.6021965476803894,LGP Offspring,Genes within amplicon 14q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,4,7
Cohort,6.687630655422988e-4,0.03040294077846439,0.02199665717916374,0.9824558835898214,LGP Proband,Genes within amplicon 14q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,4,11
Cohort,0.005122801477214707,0.009310109378497066,0.5502407403554782,0.5823086300051771,LonGen OPEL,Genes within amplicon 14q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,5,8
Cohort,-0.028935140234642068,0.026192705267039543,-1.1047022420801091,0.269681669369717,LGP Offspring,Genes within amplicon 15q26 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,24,39
Cohort,0.04958266890531645,0.06996930608355363,0.7086345667928657,0.47874930032552787,LGP Proband,Genes within amplicon 15q26 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,24,57
Cohort,0.0026009128687427465,0.020807300060279272,0.12500001735966879,0.9005550974316038,LonGen OPEL,Genes within amplicon 15q26 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,29,36
Cohort,-0.11692468428291312,0.05909012060451787,-1.9787518300305074,0.04824939693391781,LGP Offspring,Genes within amplicon 16p13 identified in a study of 191 breast tumor samples.,CGP,C2,135,231
Cohort,-0.21178689769643108,0.1713477373524065,-1.2360063865964825,0.21680419360783768,LGP Proband,Genes within amplicon 16p13 identified in a study of 191 breast tumor samples.,CGP,C2,135,373
Cohort,-0.09990305634271417,0.05652013799202735,-1.7675656835233904,0.07751661567532782,LonGen OPEL,Genes within amplicon 16p13 identified in a study of 191 breast tumor samples.,CGP,C2,224,232
Cohort,0.08110088162040406,0.05073956503432667,1.5983755786147784,0.11042669151696377,LGP Offspring,Genes within amplicon 16q24 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,72,193
Cohort,0.018032140017521035,0.13887834387431877,0.12984126620806802,0.8967233219146159,LGP Proband,Genes within amplicon 16q24 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,72,239
Cohort,0.04482357547811393,0.048714519344561606,0.92012763507063,0.3577848199120385,LonGen OPEL,Genes within amplicon 16q24 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,149,194
Cohort,-0.04831797234145326,0.038522530519499616,-1.2542782545657356,0.21017440810161248,LGP Offspring,Genes within amplicon 17p11 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,44,75
Cohort,-0.008969631104626747,0.09731561600983005,-0.09217052177649172,0.9265846930362076,LGP Proband,Genes within amplicon 17p11 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,44,91
Cohort,0.006752353464152093,0.029911150462168936,0.2257470327894055,0.8214561233427509,LonGen OPEL,Genes within amplicon 17p11 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,49,65
Cohort,-0.05316956567495764,0.05379892564167573,-0.9883016257441664,0.3233585530236709,LGP Offspring,Genes within amplicon 17q11-q21 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,101,195
Cohort,0.28586599536028423,0.16077847468209083,1.7780116145866567,0.07576622967903048,LGP Proband,Genes within amplicon 17q11-q21 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,101,299
Cohort,-0.06556853786322496,0.04701136870541275,-1.3947379042311439,0.1634839718617244,LonGen OPEL,Genes within amplicon 17q11-q21 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,172,182
Cohort,-0.2804229445846865,0.1008403192904947,-2.780861331635226,0.005572452363181528,LGP Offspring,Genes within amplicon 17q21-q25 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,355,630
Cohort,0.18143318037610517,0.28491201043510167,0.6368042544048269,0.5244271004812676,LGP Proband,Genes within amplicon 17q21-q25 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,355,865
Cohort,-0.010123884900860115,0.08977410481058824,-0.1127706583342736,0.9102408140596151,LonGen OPEL,Genes within amplicon 17q21-q25 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,523,615
Cohort,0.010685487158173482,0.010990796178454356,0.9722213918515401,0.3312881630332444,LGP Offspring,Genes within amplicon 19p13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,3,10
Cohort,-0.020393447277385703,0.03595262162017846,-0.5672311602984704,0.5707097808600021,LGP Proband,Genes within amplicon 19p13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,3,17
Cohort,0.004286393820131207,0.011177281798769494,0.3834916124780084,0.7014576879228159,LonGen OPEL,Genes within amplicon 19p13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,7,12
Cohort,0.0022139479520218905,0.01772654448118052,0.12489450238721597,0.900644201207907,LGP Offspring,Genes within amplicon 19q13.1 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,10,20
Cohort,-0.04354856019065375,0.0493775467348733,-0.8819506652382391,0.37805759959593,LGP Proband,Genes within amplicon 19q13.1 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,10,29
Cohort,0.00508539077707455,0.01690404032460786,0.3008387746018064,0.7636159994830487,LonGen OPEL,Genes within amplicon 19q13.1 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,21,24
Cohort,0.011296044422061668,0.009026796337150941,1.2513901942787105,0.2112250249036612,LGP Offspring,Genes within amplicon 19q13.4 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,1,7
Cohort,0.029413986832798823,0.022770580808163094,1.2917539117954389,0.19680023521570583,LGP Proband,Genes within amplicon 19q13.4 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,1,8
Cohort,-1.5204393985777825e-4,0.007749293811976786,-0.01962036071245478,0.9843511383348573,LonGen OPEL,Genes within amplicon 19q13.4 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,4,5
Cohort,0.03607736607257557,0.03767222510449343,0.9576648571329642,0.33857414884722914,LGP Offspring,Genes within amplicon 1q21 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,35,93
Cohort,-0.12781182175071226,0.08751434663916573,-1.4604670737896135,0.14453835032280946,LGP Proband,Genes within amplicon 1q21 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,35,92
Cohort,0.00871008900902305,0.030459005166995977,0.2859610470292351,0.7749823575541732,LonGen OPEL,Genes within amplicon 1q21 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,64,78
Cohort,-0.007756800631525482,0.014521360088321363,-0.5341648843047284,0.593403077233198,LGP Offspring,Genes within amplicon 1q32 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,7,14
Cohort,-0.015262530098343654,0.032825838835168396,-0.46495476246571776,0.6420852199175471,LGP Proband,Genes within amplicon 1q32 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,7,12
Cohort,8.903453664620219e-4,0.010911650506494409,0.0815958471114984,0.9349886155534453,LonGen OPEL,Genes within amplicon 1q32 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,8,11
Cohort,0.013187366786450336,0.020286288533212953,0.6500630593348715,0.5158723348541344,LGP Offspring,Genes within amplicon 20p13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,11,29
Cohort,0.0407384132472658,0.05349631641860545,0.7615181002088101,0.44656294784733097,LGP Proband,Genes within amplicon 20p13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,11,33
Cohort,0.003640087447961458,0.013540459291528075,0.26883042661920403,0.7881298380161456,LonGen OPEL,Genes within amplicon 20p13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,13,15
Cohort,-0.025261381529295888,0.0306040420746177,-0.8254263102796838,0.40942079311920354,LGP Offspring,Genes within amplicon 20q11 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,34,57
Cohort,-0.026815529133751525,0.08865169516640492,-0.3024818542208026,0.7623601861025251,LGP Proband,Genes within amplicon 20q11 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,34,97
Cohort,-0.007722094873814035,0.0265531329824918,-0.2908167137529764,0.771267256216658,LonGen OPEL,Genes within amplicon 20q11 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,52,58
Cohort,-0.07861302744698452,0.06142977368321459,-1.2797219122502672,0.2010819735689018,LGP Offspring,Genes within amplicon 20q12-q13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,128,235
Cohort,-0.18268805959082868,0.16809861574994187,-1.0867909814474,0.2774431918089987,LGP Proband,Genes within amplicon 20q12-q13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,128,326
Cohort,-0.058354647968528836,0.05217850721749731,-1.1183656083775513,0.26374826983786637,LonGen OPEL,Genes within amplicon 20q12-q13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,194,205
Cohort,0.07025567908873348,0.02829056004534753,2.4833611980858343,0.013256256307979062,LGP Offspring,Genes within amplicon 21q22 identified in a copy alterations study of 191 breast tumor samples.,CGP,C2,19,65
Cohort,0.02846597658169924,0.07906732738670437,0.3600219904041674,0.7189218385552277,LGP Proband,Genes within amplicon 21q22 identified in a copy alterations study of 191 breast tumor samples.,CGP,C2,19,90
Cohort,-0.027112347189954332,0.025513649762735558,-1.0626604755527287,0.288258230877149,LonGen OPEL,Genes within amplicon 21q22 identified in a copy alterations study of 191 breast tumor samples.,CGP,C2,50,45
Cohort,-0.04287283894748898,0.020247112787990507,-2.1174791387006464,0.03458371195622669,LGP Offspring,Genes within amplicon 22q13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,18,20
Cohort,0.081058896985365,0.06605618276716325,1.2271205145335713,0.22012357756591186,LGP Proband,Genes within amplicon 22q13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,18,53
Cohort,-0.0037422987721473606,0.01898191556570461,-0.19715074377997563,0.8437599034817047,LonGen OPEL,Genes within amplicon 22q13 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,23,30
Cohort,0.022373666312222134,0.024716842941361995,0.9051991941406599,0.36568236566995094,LGP Offspring,Genes within amplicon 5p15 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,16,44
Cohort,0.058552081851238426,0.06481848536790662,0.9033238206493042,0.36661488928607755,LGP Proband,Genes within amplicon 5p15 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,16,54
Cohort,-0.016618376958651426,0.023609798663354192,-0.7038762674603211,0.48171567950087935,LonGen OPEL,Genes within amplicon 5p15 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,39,44
Cohort,-0.004984817957584099,0.023855459766513456,-0.20895920709025362,0.8345430329445851,LGP Offspring,Genes within amplicon 6p24-p22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,21,38
Cohort,-0.15131390162014338,0.06742230101623448,-2.2442708026786096,0.025076506948544408,LGP Proband,Genes within amplicon 6p24-p22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,21,54
Cohort,0.0013768027431794272,0.025453866990491188,0.054090120911441865,0.9568769352881025,LonGen OPEL,Genes within amplicon 6p24-p22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,44,61
Cohort,0.017458453461656594,0.010812914190208116,1.6145928058382724,0.10686553202675145,LGP Offspring,Genes within amplicon 7p15 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,1,11
Cohort,0.0025667365751953224,0.034701095427347506,0.07396701872334868,0.9410543651068601,LGP Proband,Genes within amplicon 7p15 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,1,20
Cohort,-0.0181577729554626,0.012462130922007847,-1.4570359651250635,0.14550080954429964,LonGen OPEL,Genes within amplicon 7p15 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,13,11
Cohort,9.909183835833378e-4,0.03136639713595003,0.03159171833757134,0.9748069727704567,LGP Offspring,Genes within amplicon 7p22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,26,62
Cohort,0.050901119892613346,0.08775973420756625,0.5800054017053402,0.5620676313731131,LGP Proband,Genes within amplicon 7p22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,26,93
Cohort,0.04043771960977762,0.031994776339505024,1.263885053631327,0.20664128283337427,LonGen OPEL,Genes within amplicon 7p22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,58,83
Cohort,8.079685888879436e-4,0.0454413333854685,0.017780477127159314,0.9858192257372975,LGP Offspring,Genes within amplicon 7q21-q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,68,148
Cohort,-0.13017009387930586,0.1277355030747392,-1.0190596251313324,0.30847017932581045,LGP Proband,Genes within amplicon 7q21-q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,68,210
Cohort,-0.03544100329714942,0.038441663931804246,-0.9219424882341718,0.35683791859105807,LonGen OPEL,Genes within amplicon 7q21-q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,116,123
Cohort,0.12316418986129012,0.044898738165435693,2.7431548166782416,0.006246445225235705,LGP Offspring,Genes within amplicon 8p12-p11 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,43,144
Cohort,0.07240056661664895,0.11454188080510976,0.6320881594378284,0.5275025028675155,LGP Proband,Genes within amplicon 8p12-p11 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,43,159
Cohort,-0.008854851962719904,0.03676078748403136,-0.2408776462301411,0.8097119757945941,LonGen OPEL,Genes within amplicon 8p12-p11 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,94,108
Cohort,-0.011074973059759533,0.057878421660318834,-0.19134891280825098,0.8483096991556716,LGP Offspring,Genes within amplicon 8q12-q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,105,223
Cohort,-0.1427693434496923,0.15653641737383703,-0.9120519419371501,0.36200492790023897,LGP Proband,Genes within amplicon 8q12-q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,105,290
Cohort,-0.029916206604271568,0.0485510888367445,-0.6161799317182428,0.5379519336146769,LonGen OPEL,Genes within amplicon 8q12-q22 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,161,178
Cohort,-0.07587123595655139,0.07164735699755984,-1.0589537302699863,0.2899990841077736,LGP Offspring,Genes within amplicon 8q23-q24 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,181,357
Cohort,-0.2111212203198124,0.19202096407867839,-1.099469640373787,0.2718805386194591,LGP Proband,Genes within amplicon 8q23-q24 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,181,447
Cohort,-0.13614911522902629,0.0632031679351989,-2.154150174380778,0.03152789968253749,LonGen OPEL,Genes within amplicon 8q23-q24 identified in a copy number alterations study of 191 breast tumor samples.,CGP,C2,318,328
Cohort,-0.07926516707598519,0.07528868728897184,-1.0528164313949437,0.29280130510132785,LGP Offspring,Genes both mutated and amplified in a panel of 191 breast tumor samples.,CGP,C2,192,369
Cohort,-0.27374006652173055,0.21249047030006127,-1.2882463205770016,0.19801751776101278,LGP Proband,Genes both mutated and amplified in a panel of 191 breast tumor samples.,CGP,C2,192,567
Cohort,-0.11050618317550247,0.0677657651583163,-1.6307081151866993,0.103347501306019,LonGen OPEL,Genes both mutated and amplified in a panel of 191 breast tumor samples.,CGP,C2,321,336
Cohort,0.020831148937724857,0.027378271068911414,0.7608642958239629,0.4470034398652759,LGP Offspring,Overconnected mutated transcription factors regulating genes within the breast cancer amplicome.,CGP,C2,22,58
Cohort,0.06046578265914059,0.07101890609349018,0.8514040272535693,0.39478934793078124,LGP Proband,Overconnected mutated transcription factors regulating genes within the breast cancer amplicome.,CGP,C2,22,63
Cohort,-0.004823114931006345,0.022631066162937644,-0.21311920950967148,0.8312885509124643,LonGen OPEL,Overconnected mutated transcription factors regulating genes within the breast cancer amplicome.,CGP,C2,34,43
Cohort,0.00440923624958885,0.028150819830843794,0.15662905293997215,0.8755839693710317,LGP Offspring,"Cellular proliferation, growth, apoptosis and Wnt signaling genes down-regulated in SNU638 cells (gastric cancer) by overexpression of SFRP2 [GeneID=6423] off a plasmid vector.",CGP,C2,24,54
Cohort,0.03361921995718015,0.07349411612247526,0.45744097256921834,0.6474732580707376,LGP Proband,"Cellular proliferation, growth, apoptosis and Wnt signaling genes down-regulated in SNU638 cells (gastric cancer) by overexpression of SFRP2 [GeneID=6423] off a plasmid vector.",CGP,C2,24,64
Cohort,0.019204416250632024,0.02249897573016662,0.8535684682251001,0.3936009178538249,LonGen OPEL,"Cellular proliferation, growth, apoptosis and Wnt signaling genes down-regulated in SNU638 cells (gastric cancer) by overexpression of SFRP2 [GeneID=6423] off a plasmid vector.",CGP,C2,32,47
Cohort,-0.01836342130690443,0.028726673528573634,-0.6392463536942012,0.5228792283606059,LGP Offspring,"Cellular proliferation, growth, apoptosis and Wnt signaling genes up-regulated in SNU638 cells (gastric cancer) by overexpression of SFRP2 [GeneID=6423] off a plasmid vector.",CGP,C2,29,56
Cohort,0.058319693059513844,0.08138002928229589,0.7166339650384128,0.47380060977383154,LGP Proband,"Cellular proliferation, growth, apoptosis and Wnt signaling genes up-regulated in SNU638 cells (gastric cancer) by overexpression of SFRP2 [GeneID=6423] off a plasmid vector.",CGP,C2,29,72
Cohort,-0.040596988256023724,0.02619565927605278,-1.5497601273633976,0.12159657320125743,LonGen OPEL,"Cellular proliferation, growth, apoptosis and Wnt signaling genes up-regulated in SNU638 cells (gastric cancer) by overexpression of SFRP2 [GeneID=6423] off a plasmid vector.",CGP,C2,52,45
Cohort,-0.02177922246314803,0.020806730585583688,-1.0467392930169506,0.29559395333756144,LGP Offspring,Genes with significantl germline mutation differences in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.,CGP,C2,18,27
Cohort,0.03813329128603909,0.06391818815893026,0.5965953101051933,0.5509395054477703,LGP Proband,Genes with significantl germline mutation differences in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.,CGP,C2,18,47
Cohort,-0.022309856383245764,0.017886455841313646,-1.247304473349889,0.21265272403027174,LonGen OPEL,Genes with significantl germline mutation differences in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.,CGP,C2,24,25
Cohort,-0.006479295116663238,0.039028308693963454,-0.1660152677245119,0.8681945739031215,LGP Offspring,Top 50 most differentially hypermethylated and down-regulated genes in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.,CGP,C2,48,99
Cohort,0.15299947848247833,0.10697128801655358,1.4302854655615813,0.1530096327400556,LGP Proband,Top 50 most differentially hypermethylated and down-regulated genes in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.,CGP,C2,48,139
Cohort,-0.05451442696300874,0.035829931624295416,-1.5214772814705517,0.12853723322322994,LonGen OPEL,Top 50 most differentially hypermethylated and down-regulated genes in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.,CGP,C2,95,95
Cohort,6.656800635009959e-4,0.012289050372120556,0.05416855195021293,0.9568168800405692,LGP Offspring,Genes showing significantly elevated somatic mutation frequencies in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.,CGP,C2,5,10
Cohort,-0.01621077410287714,0.03873337961356983,-0.4185220671319336,0.6756732062264146,LGP Proband,Genes showing significantly elevated somatic mutation frequencies in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.,CGP,C2,5,20
Cohort,-0.011291065609781966,0.01307290642302595,-0.8636997194361048,0.38801303903425,LonGen OPEL,Genes showing significantly elevated somatic mutation frequencies in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.,CGP,C2,12,12
Cohort,0.004019344203667028,0.039500396109312774,0.10175452905697345,0.9189816926832625,LGP Offspring,"Genes whose CpG islands are hyper-methylated in the NB4 cell line (APL, acute promyelocytic leukemia) compared to PBMC (normal peripheral peripheral blood mononuclear cells).",CGP,C2,42,95
Cohort,0.1476810241288864,0.10915268741039051,1.3529765288658233,0.17642977277184188,LGP Proband,"Genes whose CpG islands are hyper-methylated in the NB4 cell line (APL, acute promyelocytic leukemia) compared to PBMC (normal peripheral peripheral blood mononuclear cells).",CGP,C2,42,150
Cohort,-0.07377023536111889,0.03213903250209945,-2.2953471096648577,0.021972477478616678,LonGen OPEL,"Genes whose CpG islands are hyper-methylated in the NB4 cell line (APL, acute promyelocytic leukemia) compared to PBMC (normal peripheral peripheral blood mononuclear cells).",CGP,C2,84,72
Cohort,-0.07831455809018864,0.06543899481615452,-1.1967567397727756,0.23182091751674763,LGP Offspring,"Genes whose CpG islands showed greatly increased histone H4 acetylation in NB4 cells (acute promyelocytic leukemia, APL) upon treatment with tretinoin [PubChem=444795].",CGP,C2,144,265
Cohort,-0.13474259514248765,0.1699845914263168,-0.792675347876425,0.42819242226687737,LGP Proband,"Genes whose CpG islands showed greatly increased histone H4 acetylation in NB4 cells (acute promyelocytic leukemia, APL) upon treatment with tretinoin [PubChem=444795].",CGP,C2,144,331
Cohort,-0.030307299557556264,0.0551002940913044,-0.5500387984742023,0.5824470629867311,LonGen OPEL,"Genes whose CpG islands showed greatly increased histone H4 acetylation in NB4 cells (acute promyelocytic leukemia, APL) upon treatment with tretinoin [PubChem=444795].",CGP,C2,216,242
Cohort,-0.07405742731341415,0.028181720127691292,-2.627853338187313,0.008787545353787783,LGP Offspring,Target genes for STAT3 [GeneID=20848] in CSF3 [GeneID=12985] signaling during myeloblast differentiation to neutrophils.,CGP,C2,37,46
Cohort,-0.09688811314964654,0.08403238878909541,-1.1529853494087434,0.2492467428328263,LGP Proband,Target genes for STAT3 [GeneID=20848] in CSF3 [GeneID=12985] signaling during myeloblast differentiation to neutrophils.,CGP,C2,37,82
Cohort,0.004720067781371186,0.026687645446181022,0.17686340261413447,0.8596606762288455,LonGen OPEL,Target genes for STAT3 [GeneID=20848] in CSF3 [GeneID=12985] signaling during myeloblast differentiation to neutrophils.,CGP,C2,48,61
Cohort,-0.015596582402958562,0.011025502641830073,-1.4145915074915583,0.15764872857492931,LGP Offspring,Genes down-regulated in K562 cells (bone marrow) after treatment with dasatinib [PubChem=3062316] or imatinib [PubChem=5291].,CGP,C2,6,6
Cohort,0.01581618485218362,0.03678031870688849,0.4300176129039754,0.6672939147200563,LGP Proband,Genes down-regulated in K562 cells (bone marrow) after treatment with dasatinib [PubChem=3062316] or imatinib [PubChem=5291].,CGP,C2,6,14
Cohort,0.0044607108402948455,0.008572796664669848,0.5203332138598711,0.60297603715722,LonGen OPEL,Genes down-regulated in K562 cells (bone marrow) after treatment with dasatinib [PubChem=3062316] or imatinib [PubChem=5291].,CGP,C2,4,7
Cohort,0.008024655396414886,0.02579608066363152,0.31108041182893365,0.7558353926775285,LGP Offspring,Genes up-regulated in K562 cells (bone marrow) after treatment with dasatinib [PubChem=3062316] or imatinib [PubChem=5291].,CGP,C2,22,49
Cohort,0.05276557264180819,0.06465426533753223,0.816118973223835,0.4146651240845991,LGP Proband,Genes up-regulated in K562 cells (bone marrow) after treatment with dasatinib [PubChem=3062316] or imatinib [PubChem=5291].,CGP,C2,22,49
Cohort,-0.02600608927500814,0.02040718735876923,-1.274359313599039,0.20290800876891246,LonGen OPEL,Genes up-regulated in K562 cells (bone marrow) after treatment with dasatinib [PubChem=3062316] or imatinib [PubChem=5291].,CGP,C2,32,28
Cohort,0.05152092584515263,0.03974453361980697,1.296302186811341,0.19531375550008204,LGP Offspring,"Top 50 marker genes for anaplastic oligodendroglioma (AO), a class of high grade glioma.",CGP,C2,47,114
Cohort,-0.08231561913686669,0.1065564913750166,-0.7725068465999297,0.4400331527000372,LGP Proband,"Top 50 marker genes for anaplastic oligodendroglioma (AO), a class of high grade glioma.",CGP,C2,47,138
Cohort,0.05967885423441273,0.034458463316681225,1.7319070118115918,0.08367752348481222,LonGen OPEL,"Top 50 marker genes for anaplastic oligodendroglioma (AO), a class of high grade glioma.",CGP,C2,70,104
Cohort,-0.016553770081222573,0.032742267090187446,-0.5055780052012215,0.6133177306461564,LGP Offspring,"Top 50 marker genes for glioblastoma multiforme (GBM), a class of high grade glioma.",CGP,C2,41,72
Cohort,-0.20366072376879443,0.08916334539216596,-2.2841305793657267,0.022614375923045726,LGP Proband,"Top 50 marker genes for glioblastoma multiforme (GBM), a class of high grade glioma.",CGP,C2,41,91
Cohort,0.01568636478361171,0.030542719147303422,0.513587696889674,0.6076828069269411,LonGen OPEL,"Top 50 marker genes for glioblastoma multiforme (GBM), a class of high grade glioma.",CGP,C2,58,74
Cohort,-0.6582890967988136,0.17650429877770166,-3.729592431218323,2.07875758691844e-4,LGP Offspring,Genes down-regulated in PC3 cells (prostate cancer) after knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,967,1726
Cohort,-1.8282478181523942,0.4835616738648535,-3.7807955364621297,1.6747321237640898e-4,LGP Proband,Genes down-regulated in PC3 cells (prostate cancer) after knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,967,2494
Cohort,0.04131872189866785,0.14729619636701588,0.28051452052240755,0.7791556751976823,LonGen OPEL,Genes down-regulated in PC3 cells (prostate cancer) after knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,1340,1652
Cohort,-0.5389931026979295,0.1687601341982661,-3.1938413965984354,0.0014691191369755447,LGP Offspring,Genes up-regulated in PC3 cells (prostate cancer) after knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,993,1829
Cohort,-0.4502154244854344,0.4633235019356683,-0.9717085850480903,0.3314772745452337,LGP Proband,Genes up-regulated in PC3 cells (prostate cancer) after knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,993,2544
Cohort,-0.06978617539351836,0.15161484362971944,-0.4602859042215766,0.6454367249873174,LonGen OPEL,Genes up-regulated in PC3 cells (prostate cancer) after knockdown of EZH2 [GeneID=2146] by RNAi.,CGP,C2,1454,1732
Cohort,-0.3667423300205653,0.14630521015250053,-2.506693573238391,0.012420252649893836,LGP Offspring,Genes down-regulated in PC3 cells (prostate cancer) after knockdown of NIPP1 [GeneID=5511] by RNAi.,CGP,C2,728,1394
Cohort,-0.3818846401180863,0.40757631072943873,-0.9369647598866282,0.34904792419586006,LGP Proband,Genes down-regulated in PC3 cells (prostate cancer) after knockdown of NIPP1 [GeneID=5511] by RNAi.,CGP,C2,728,1935
Cohort,0.09920964577303736,0.13556424954678092,0.731827499541476,0.46448925971443733,LonGen OPEL,Genes down-regulated in PC3 cells (prostate cancer) after knockdown of NIPP1 [GeneID=5511] by RNAi.,CGP,C2,1110,1376
Cohort,-0.12293227903389665,0.1491161295002457,-0.824406316378364,0.4099995111392365,LGP Offspring,Genes up-regulated in PC3 cells (prostate cancer) after knockdown of NIPP1 [GeneID=5511] by RNAi.,CGP,C2,702,1415
Cohort,0.31991553718458815,0.4162814956679999,0.7685077057562337,0.44240316996588025,LGP Proband,Genes up-regulated in PC3 cells (prostate cancer) after knockdown of NIPP1 [GeneID=5511] by RNAi.,CGP,C2,702,1943
Cohort,-0.15649555540893142,0.1329546086799262,-1.1770600279504226,0.23952338517388697,LonGen OPEL,Genes up-regulated in PC3 cells (prostate cancer) after knockdown of NIPP1 [GeneID=5511] by RNAi.,CGP,C2,1161,1329
Cohort,0.004987810575487804,0.02269852592937223,0.21974160749502694,0.8261387356301086,LGP Offspring,Down-regulated genes in the signature set for lymph node metastasis in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,16,34
Cohort,-0.02219939564491646,0.07513187650034647,-0.29547239705658207,0.7677065807165602,LGP Proband,Down-regulated genes in the signature set for lymph node metastasis in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,16,70
Cohort,-0.010464384743065342,0.022136814726692072,-0.47271411322097856,0.6365467395298717,LonGen OPEL,Down-regulated genes in the signature set for lymph node metastasis in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,33,38
Cohort,-0.05747409179206761,0.05801703652531298,-0.9906416327726687,0.3222150501779404,LGP Offspring,Up-regulated genes in the signature set for lymph node metastasis in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,113,221
Cohort,0.23528194281223613,0.16599327007442177,1.4174185658656482,0.15673405933141585,LGP Proband,Up-regulated genes in the signature set for lymph node metastasis in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,113,334
Cohort,-0.020963181909422382,0.04849511513043446,-0.43227409303058556,0.6656592905870917,LonGen OPEL,Up-regulated genes in the signature set for lymph node metastasis in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,174,202
Cohort,-0.04818434737644021,0.031749485604585,-1.517641828171283,0.1295722135041654,LGP Offspring,"Genes up-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) by MYC [GeneID=4609] and down-regulated by RNAi knockdown of TFRC [GeneID=7037].",CGP,C2,43,61
Cohort,-0.18299987266724177,0.09915629878711067,-1.8455698216423335,0.06530897850118211,LGP Proband,"Genes up-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) by MYC [GeneID=4609] and down-regulated by RNAi knockdown of TFRC [GeneID=7037].",CGP,C2,43,119
Cohort,-0.009887808050194118,0.028600995174191117,-0.34571552458134913,0.7296478618615156,LonGen OPEL,"Genes up-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) by MYC [GeneID=4609] and down-regulated by RNAi knockdown of TFRC [GeneID=7037].",CGP,C2,58,65
Cohort,-0.06291802919934902,0.03611731318472408,-1.7420462280112348,0.08195516782102068,LGP Offspring,"Genes down-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) by MYC [GeneID=4609] and up-regulated by RNAi knockdown of TFRC [GeneID=7037].",CGP,C2,51,75
Cohort,-0.005915067254111992,0.11148807226687749,-0.053055606163434646,0.9577003081854618,LGP Proband,"Genes down-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) by MYC [GeneID=4609] and up-regulated by RNAi knockdown of TFRC [GeneID=7037].",CGP,C2,51,139
Cohort,-0.003749990440812397,0.03283339047784323,-0.11421270804618798,0.9090979793259166,LonGen OPEL,"Genes down-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) by MYC [GeneID=4609] and up-regulated by RNAi knockdown of TFRC [GeneID=7037].",CGP,C2,70,83
Cohort,-0.08411249278719167,0.05354311428509886,-1.57093015432986,0.11666678807819636,LGP Offspring,"Genes down-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) upon knockdown of TFRC [GeneID=7037] by RNAi.",CGP,C2,111,181
Cohort,-0.33734430537751153,0.15326081992976293,-2.2011124926260424,0.028001355346030325,LGP Proband,"Genes down-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) upon knockdown of TFRC [GeneID=7037] by RNAi.",CGP,C2,111,281
Cohort,-0.009645262343907248,0.04603227055507655,-0.20953262195413355,0.834086085506641,LonGen OPEL,"Genes down-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) upon knockdown of TFRC [GeneID=7037] by RNAi.",CGP,C2,151,174
Cohort,-0.05498531835226595,0.1062762337339819,-0.5173811342420988,0.6050593759637175,LGP Offspring,"Genes up-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) upon knockdown of TFRC [GeneID=7037] by RNAi.",CGP,C2,368,750
Cohort,0.14416730702601954,0.3024394175283579,0.47668160520941966,0.6337137301216895,LGP Proband,"Genes up-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) upon knockdown of TFRC [GeneID=7037] by RNAi.",CGP,C2,368,1077
Cohort,-0.0645743198777935,0.0965689043334698,-0.6686864713180005,0.503889366712295,LonGen OPEL,"Genes up-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) upon knockdown of TFRC [GeneID=7037] by RNAi.",CGP,C2,606,711
Cohort,0.007391180769246809,0.013462793213418863,0.5490079697487849,0.5831812695254707,LGP Offspring,Candidate substrate proteins of AURKA [GeneID=6790].,CGP,C2,4,14
Cohort,0.08620492902246095,0.04124966787835495,2.089833287304975,0.03693518298318781,LGP Proband,Candidate substrate proteins of AURKA [GeneID=6790].,CGP,C2,4,22
Cohort,0.00690347272663746,0.007742476227546744,0.8916362832443429,0.37285735582733204,LonGen OPEL,Candidate substrate proteins of AURKA [GeneID=6790].,CGP,C2,3,6
Cohort,0.01000474200025405,0.013628116337484406,0.7341250802750934,0.4631270570327092,LGP Offspring,Candidate substrate proteins of AURKB [GeneID=9212].,CGP,C2,5,14
Cohort,0.005847775752881619,0.037351030379172596,0.1565626354485367,0.8756274423880339,LGP Proband,Candidate substrate proteins of AURKB [GeneID=9212].,CGP,C2,5,19
Cohort,0.0018374381515572425,0.007729712865394748,0.23771104872255905,0.8121663848534416,LonGen OPEL,Candidate substrate proteins of AURKB [GeneID=9212].,CGP,C2,5,5
Cohort,0.011262891435617994,0.07910926928174167,0.14237132434514166,0.8868291331602816,LGP Offspring,Genes down-regulated in liver samples of liver-specific knockout of HNF4A [GeneID=3172].,CGP,C2,216,460
Cohort,0.004989335714260731,0.21951050972614683,0.022729370545789548,0.9818715844386221,LGP Proband,Genes down-regulated in liver samples of liver-specific knockout of HNF4A [GeneID=3172].,CGP,C2,216,599
Cohort,0.025675454863057133,0.06953052247808633,0.3692688325641328,0.7120255606909243,LonGen OPEL,Genes down-regulated in liver samples of liver-specific knockout of HNF4A [GeneID=3172].,CGP,C2,326,405
Cohort,-0.01681053586854483,0.03519771799270959,-0.47760300460463806,0.633087177262659,LGP Offspring,Genes up-regulated in liver samples of liver-specific knockout of HNF4A [GeneID=3172].,CGP,C2,42,79
Cohort,0.10124592361357594,0.10052756037196905,1.007145933303751,0.314156761056132,LGP Proband,Genes up-regulated in liver samples of liver-specific knockout of HNF4A [GeneID=3172].,CGP,C2,42,119
Cohort,-0.0208529526699559,0.027891131493593596,-0.747655313831412,0.45488890185643405,LonGen OPEL,Genes up-regulated in liver samples of liver-specific knockout of HNF4A [GeneID=3172].,CGP,C2,61,65
Cohort,-2.8698744877475395e-4,0.013800049323734501,-0.020796117611055816,0.9834144313851916,LGP Offspring,Genes with low to medium basal transcription state in undifferentiated embryonic carcinoma cells.,CGP,C2,8,10
Cohort,-0.043196194725604084,0.03667516807262079,-1.1778049562055437,0.23921034867281335,LGP Proband,Genes with low to medium basal transcription state in undifferentiated embryonic carcinoma cells.,CGP,C2,8,13
Cohort,-0.0017992734086258292,0.01061536240959177,-0.1694971249403649,0.8654486983907443,LonGen OPEL,Genes with low to medium basal transcription state in undifferentiated embryonic carcinoma cells.,CGP,C2,8,9
Cohort,-0.011871942114302949,0.01313071612886856,-0.9041351589500796,0.36624582420531504,LGP Offspring,Genes with a high basal transcription state in undifferentiated embryonic carcinoma cells.,CGP,C2,7,10
Cohort,0.03890854799582609,0.042533838898613036,0.9147669009743402,0.3605784107751663,LGP Proband,Genes with a high basal transcription state in undifferentiated embryonic carcinoma cells.,CGP,C2,7,23
Cohort,-0.018885444753566426,0.013996835876671183,-1.3492652853809044,0.17763542077422764,LonGen OPEL,Genes with a high basal transcription state in undifferentiated embryonic carcinoma cells.,CGP,C2,17,13
Cohort,-0.017456160991890228,0.030298854869058072,-0.5761326976656429,0.5647172494370254,LGP Offspring,Genes showing frequent DNA methylation and which are silenced in adult cancers but remain unmethylated in embryonic carcinoma and embryonic stem (ES) cells.,CGP,C2,30,51
Cohort,0.034752888469073255,0.08015388859578987,0.4335770737752912,0.6647077092571959,LGP Proband,Genes showing frequent DNA methylation and which are silenced in adult cancers but remain unmethylated in embryonic carcinoma and embryonic stem (ES) cells.,CGP,C2,30,68
Cohort,-0.03544737863327651,0.02566707099773507,-1.3810449441778723,0.16765272641079906,LonGen OPEL,Genes showing frequent DNA methylation and which are silenced in adult cancers but remain unmethylated in embryonic carcinoma and embryonic stem (ES) cells.,CGP,C2,50,42
Cohort,-0.014242833779396594,0.08813262705639542,-0.1616068220714981,0.8716637724238187,LGP Offspring,Genes under-expressed in stem cell-like cholangiocellular carcinoma,CGP,C2,253,539
Cohort,0.289012045630663,0.23385218064399405,1.2358749225034675,0.2168530385895418,LGP Proband,Genes under-expressed in stem cell-like cholangiocellular carcinoma,CGP,C2,253,708
Cohort,-0.07240007382996905,0.08422208744097186,-0.8596328591441239,0.39025026826125986,LonGen OPEL,Genes under-expressed in stem cell-like cholangiocellular carcinoma,CGP,C2,440,499
Cohort,-0.04111693847115275,0.10140460908616175,-0.40547405923350477,0.6852573774640396,LGP Offspring,Genes over-expressed in stem cell-like cholangiocellular carcinoma.,CGP,C2,327,662
Cohort,0.48257604165262097,0.2849519447750929,1.6935348240332557,0.0907271225100196,LGP Proband,Genes over-expressed in stem cell-like cholangiocellular carcinoma.,CGP,C2,327,920
Cohort,-0.012703935622005027,0.09115820872678948,-0.1393614003548493,0.8891998241435761,LonGen OPEL,Genes over-expressed in stem cell-like cholangiocellular carcinoma.,CGP,C2,545,624
Cohort,0.013695926945735895,0.02979470525464651,0.45967653744787434,0.6458962074906174,LGP Offspring,Genes in the smallest region of deletion (SRD) in 1p36.3 area in neuroblastoma samples.,CGP,C2,30,65
Cohort,0.01737183504986591,0.0880524585420239,0.19728960823478917,0.8436489818970305,LGP Proband,Genes in the smallest region of deletion (SRD) in 1p36.3 area in neuroblastoma samples.,CGP,C2,30,103
Cohort,0.0368027714513297,0.02856867760439907,1.2882210356723942,0.19804336315180818,LonGen OPEL,Genes in the smallest region of deletion (SRD) in 1p36.3 area in neuroblastoma samples.,CGP,C2,49,70
Cohort,-0.07241717688019968,0.0678758578769828,-1.0669062483371847,0.2863950482355324,LGP Offspring,Genes up-regulated in mast cells (MC) after stimulation with a bacterial lipopolysaccharide (LPS).,CGP,C2,155,300
Cohort,-0.04994811037966856,0.1963686329497437,-0.2543589046243027,0.7992809967945771,LGP Proband,Genes up-regulated in mast cells (MC) after stimulation with a bacterial lipopolysaccharide (LPS).,CGP,C2,155,445
Cohort,0.02111727523639498,0.06266403148178507,0.33699196711487145,0.7362117870891034,LonGen OPEL,Genes up-regulated in mast cells (MC) after stimulation with a bacterial lipopolysaccharide (LPS).,CGP,C2,238,302
Cohort,-0.034379848770638925,0.0223838976804038,-1.5359187779319192,0.12502619068249088,LGP Offspring,Genes down-regulated in the 5637 cell line (bladder cancer) after knockdown of E2F3 [GeneID=1871] by RNAi.,CGP,C2,20,25
Cohort,-0.06724240520855933,0.057092058132254965,-1.1777891252893855,0.23921665791728358,LGP Proband,Genes down-regulated in the 5637 cell line (bladder cancer) after knockdown of E2F3 [GeneID=1871] by RNAi.,CGP,C2,20,33
Cohort,-0.036906026402028565,0.019903704015219178,-1.8542290607722423,0.06407609004916097,LonGen OPEL,Genes down-regulated in the 5637 cell line (bladder cancer) after knockdown of E2F3 [GeneID=1871] by RNAi.,CGP,C2,32,25
Cohort,-0.0123330000828547,0.03406868442720908,-0.3620040013345776,0.7174621712999547,LGP Offspring,Genes up-regulated in the 5637 cell line (bladder cancer) after knockdown of E2F3 [GeneID=1871] by RNAi.,CGP,C2,42,71
Cohort,-0.21960552301029426,0.08721037551781327,-2.5181123427847005,0.011984756306193965,LGP Proband,Genes up-regulated in the 5637 cell line (bladder cancer) after knockdown of E2F3 [GeneID=1871] by RNAi.,CGP,C2,42,76
Cohort,0.02583047042014696,0.02839980372672503,0.909529892132309,0.3633457948665503,LonGen OPEL,Genes up-regulated in the 5637 cell line (bladder cancer) after knockdown of E2F3 [GeneID=1871] by RNAi.,CGP,C2,45,71
Cohort,-0.1194585228169629,0.05667936459471079,-2.107619301506964,0.03543154949904031,LGP Offspring,"Genes changed in HMLE cells (mmortalized nontransformed mammary epithelium) after RNAi knockdown of both CDH1 and CTNNB1 [GeneID=999;1499], compared to the knockdown of CDH1 alone.",CGP,C2,117,200
Cohort,0.050867414913007496,0.16172402995244925,0.3145321998713719,0.7531955321944901,LGP Proband,"Genes changed in HMLE cells (mmortalized nontransformed mammary epithelium) after RNAi knockdown of both CDH1 and CTNNB1 [GeneID=999;1499], compared to the knockdown of CDH1 alone.",CGP,C2,117,317
Cohort,-0.07082288301529559,0.05256940715873479,-1.347226207087402,0.17829076476666098,LonGen OPEL,"Genes changed in HMLE cells (mmortalized nontransformed mammary epithelium) after RNAi knockdown of both CDH1 and CTNNB1 [GeneID=999;1499], compared to the knockdown of CDH1 alone.",CGP,C2,193,199
Cohort,0.029518508498071035,0.06813496869602571,0.4332358121387504,0.6649816652369535,LGP Offspring,Genes down-regulated in HMLE cells (mmortalized nontransformed mammary epithelial) by expression of a dominant-negative form of E-cadhedrin (CDH1) [GeneID=999].,CGP,C2,139,303
Cohort,-0.30441878404897116,0.18986535613873307,-1.6033403367517707,0.10923815660472345,LGP Proband,Genes down-regulated in HMLE cells (mmortalized nontransformed mammary epithelial) by expression of a dominant-negative form of E-cadhedrin (CDH1) [GeneID=999].,CGP,C2,139,410
Cohort,0.05076172604454756,0.0586937146024713,0.864857956058045,0.3873773142571246,LonGen OPEL,Genes down-regulated in HMLE cells (mmortalized nontransformed mammary epithelial) by expression of a dominant-negative form of E-cadhedrin (CDH1) [GeneID=999].,CGP,C2,229,303
Cohort,-0.018115945891919144,0.06260486643192016,-0.2893696117316915,0.7723872709807087,LGP Offspring,Genes up-regulated in HMLE cells (mmortalized nontransformed mammary epithelial) by expression of a dominant-negative form of E-cadhedrin (CDH1) [GeneID=999].,CGP,C2,125,251
Cohort,0.08162975347844822,0.17732776964407412,0.46033260127442255,0.6453974987168865,LGP Proband,Genes up-regulated in HMLE cells (mmortalized nontransformed mammary epithelial) by expression of a dominant-negative form of E-cadhedrin (CDH1) [GeneID=999].,CGP,C2,125,355
Cohort,0.011325778331416212,0.0514760101248866,0.22002051642966497,0.8259115892724866,LonGen OPEL,Genes up-regulated in HMLE cells (mmortalized nontransformed mammary epithelial) by expression of a dominant-negative form of E-cadhedrin (CDH1) [GeneID=999].,CGP,C2,181,226
Cohort,-0.167621959277251,0.1283597352478764,-1.3058764802962162,0.19203876818079763,LGP Offspring,Genes down-regulated in HMLE cells (immortalized nontransformed mammary epithelium) after E-cadhedrin (CDH1) [GeneID=999] knockdown by RNAi.,CGP,C2,563,1122
Cohort,-0.05170116532163821,0.33816291872636234,-0.15288833416852016,0.8785233169401991,LGP Proband,Genes down-regulated in HMLE cells (immortalized nontransformed mammary epithelium) after E-cadhedrin (CDH1) [GeneID=999] knockdown by RNAi.,CGP,C2,563,1538
Cohort,9.140021426809678e-4,0.11725008745836552,0.007795321628271893,0.9937822494149625,LonGen OPEL,Genes down-regulated in HMLE cells (immortalized nontransformed mammary epithelium) after E-cadhedrin (CDH1) [GeneID=999] knockdown by RNAi.,CGP,C2,877,1047
Cohort,-0.13373203724970087,0.09328822270846217,-1.4335361245720253,0.15216702813993516,LGP Offspring,Genes up-regulated in HMLE cells (immortalized nontransformed mammary epithelium) after E-cadhedrin (CDH1) [GeneID=999] knockdown by RNAi.,CGP,C2,286,555
Cohort,0.43483463549069934,0.2638545330373071,1.6480089634435686,0.09972748050000911,LGP Proband,Genes up-regulated in HMLE cells (immortalized nontransformed mammary epithelium) after E-cadhedrin (CDH1) [GeneID=999] knockdown by RNAi.,CGP,C2,286,808
Cohort,-0.1960271816211242,0.07738962919514891,-2.5329903200183823,0.011500383771283304,LonGen OPEL,Genes up-regulated in HMLE cells (immortalized nontransformed mammary epithelium) after E-cadhedrin (CDH1) [GeneID=999] knockdown by RNAi.,CGP,C2,475,482
Cohort,0.05663845866397402,0.034699811782349224,1.632241091658726,0.10309440503863995,LGP Offspring,"Genes down-regulated in HMLE cells (immortalized nontransformed mammary epithelial) cells after loss of function of E-cadhedrin (CDH1) [GeneID=999], which was achieved either by RNAi knockdown or by expression of a dominan-negative form of CDH1.",CGP,C2,32,90
Cohort,-0.035076036883053476,0.0926671903803814,-0.37851624441264414,0.7051434591810358,LGP Proband,"Genes down-regulated in HMLE cells (immortalized nontransformed mammary epithelial) cells after loss of function of E-cadhedrin (CDH1) [GeneID=999], which was achieved either by RNAi knockdown or by expression of a dominan-negative form of CDH1.",CGP,C2,32,111
Cohort,0.00900131701719746,0.033321835295764914,0.2701326903906009,0.7871281921516947,LonGen OPEL,"Genes down-regulated in HMLE cells (immortalized nontransformed mammary epithelial) cells after loss of function of E-cadhedrin (CDH1) [GeneID=999], which was achieved either by RNAi knockdown or by expression of a dominan-negative form of CDH1.",CGP,C2,71,91
Cohort,-0.012875192963513148,0.013008423398820934,-0.9897581412271789,0.3226464792574364,LGP Offspring,"Genes up-regulated in HMLE cells (immortalized nontransformed mammary epithelial) cells after loss of function of E-cadhedrin (CDH1) [GeneID=999], which was achieved either by RNAi knockdown or by expression of a dominan-negative form of CDH1.",CGP,C2,8,9
Cohort,0.011973970243121763,0.042307347485510766,0.28302342157523713,0.7772291153844578,LGP Proband,"Genes up-regulated in HMLE cells (immortalized nontransformed mammary epithelial) cells after loss of function of E-cadhedrin (CDH1) [GeneID=999], which was achieved either by RNAi knockdown or by expression of a dominan-negative form of CDH1.",CGP,C2,8,22
Cohort,-0.00868576530462907,0.011188380136526394,-0.7763201820675446,0.43779056624969426,LonGen OPEL,"Genes up-regulated in HMLE cells (immortalized nontransformed mammary epithelial) cells after loss of function of E-cadhedrin (CDH1) [GeneID=999], which was achieved either by RNAi knockdown or by expression of a dominan-negative form of CDH1.",CGP,C2,10,9
Cohort,-0.004305724283786717,0.012479201251972475,-0.34503204146228106,0.7301776078270683,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of BRCA1.,CGP,C2,6,10
Cohort,-0.049337859286476306,0.042943653976456525,-1.1488975603595666,0.25092761391204255,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of BRCA1.,CGP,C2,6,24
Cohort,-0.016278076536510446,0.013746240716706735,-1.1841838704837024,0.2366937627325643,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of BRCA1.,CGP,C2,16,13
Cohort,-0.020498338646795133,0.02414602502032462,-0.8489322209159027,0.3962195269525449,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of BRCA1.,CGP,C2,22,34
Cohort,-0.12273688711227354,0.06622883401948439,-1.8532243384530158,0.06420322535520334,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of BRCA1.,CGP,C2,22,54
Cohort,0.0013422043540478777,0.019422046759099268,0.06910725582611689,0.9449216017084894,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of BRCA1.,CGP,C2,28,32
Cohort,0.04916522470474718,0.036284398676864414,1.3549962655463768,0.17587136491164715,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of TP53; most genes are further up-regulated by simultaneous expression of BRCA1.,CGP,C2,34,90
Cohort,0.005166376509454501,0.09859872896216913,0.05239800313690415,0.9582241127220665,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of TP53; most genes are further up-regulated by simultaneous expression of BRCA1.,CGP,C2,34,114
Cohort,0.025849714057728658,0.02710870689770634,0.9535576209987278,0.3405970862899651,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of TP53; most genes are further up-regulated by simultaneous expression of BRCA1.,CGP,C2,51,67
Cohort,-0.05551431428795987,0.11382953217658472,-0.4876969379250373,0.6259226473768321,LGP Offspring,Genes down-regulated in uveal melanoma: class 2 vs class 1 tumors.,CGP,C2,431,848
Cohort,-0.5898017017396585,0.30501615155352746,-1.9336736718224374,0.053491349768339254,LGP Proband,Genes down-regulated in uveal melanoma: class 2 vs class 1 tumors.,CGP,C2,431,1168
Cohort,-0.031169636028742776,0.10192112633760388,-0.30582114963581125,0.7598207859987782,LonGen OPEL,Genes down-regulated in uveal melanoma: class 2 vs class 1 tumors.,CGP,C2,681,810
Cohort,-0.3855145890761535,0.1721412462892514,-2.239524793659085,0.025446155783861755,LGP Offspring,Genes up-regulated in uveal melanoma: class 2 vs class 1 tumors.,CGP,C2,957,1843
Cohort,-1.2486783585512593,0.4793429502157618,-2.6049790822817034,0.009351626996162989,LGP Proband,Genes up-regulated in uveal melanoma: class 2 vs class 1 tumors.,CGP,C2,957,2523
Cohort,0.07365389917156992,0.14412876456116727,0.5110284501211533,0.6094728404981747,LonGen OPEL,Genes up-regulated in uveal melanoma: class 2 vs class 1 tumors.,CGP,C2,1427,1736
Cohort,3.112777519388947e-4,0.021118399901282385,0.014739646630140421,0.9882442383290309,LGP Offspring,Genes down-regulated in CD4+ [GeneID=920] T lymphocytes by expression of AML1 [GeneID=861] off a viral vector.,CGP,C2,16,27
Cohort,-0.11674015888051305,0.06820893541225474,-1.7115082968959365,0.08735912132858359,LGP Proband,Genes down-regulated in CD4+ [GeneID=920] T lymphocytes by expression of AML1 [GeneID=861] off a viral vector.,CGP,C2,16,57
Cohort,-0.04091534843450055,0.026532224087573834,-1.5421002136667068,0.12344667371396416,LonGen OPEL,Genes down-regulated in CD4+ [GeneID=920] T lymphocytes by expression of AML1 [GeneID=861] off a viral vector.,CGP,C2,50,46
Cohort,-0.02605618772798366,0.016378417439757025,-1.590885555568683,0.11210284072035126,LGP Offspring,Genes up-regulated in CD4+ [GeneID=920] T lymphocytes by expression of AML1 [GeneID=861] off a viral vector.,CGP,C2,13,12
Cohort,-0.01795826477422903,0.04434298444601786,-0.40498547850542205,0.6855920387990093,LGP Proband,Genes up-regulated in CD4+ [GeneID=920] T lymphocytes by expression of AML1 [GeneID=861] off a viral vector.,CGP,C2,13,16
Cohort,0.021637107879824004,0.013943442943752672,1.5517765567017623,0.12111317458904883,LonGen OPEL,Genes up-regulated in CD4+ [GeneID=920] T lymphocytes by expression of AML1 [GeneID=861] off a viral vector.,CGP,C2,11,19
Cohort,-0.0176114417896994,0.024155913776087886,-0.7290737147411536,0.4662090863963081,LGP Offspring,Genes down-regulated in CD4+ [GeneID=920] T lymphocytes transduced with FOXP3 [GeneID=50943].,CGP,C2,23,33
Cohort,-0.12239780999621262,0.07318619970436412,-1.6724165278514114,0.09481727923225072,LGP Proband,Genes down-regulated in CD4+ [GeneID=920] T lymphocytes transduced with FOXP3 [GeneID=50943].,CGP,C2,23,61
Cohort,-0.02710633561827111,0.02778269938627342,-0.9756552177094613,0.3295317554433582,LonGen OPEL,Genes down-regulated in CD4+ [GeneID=920] T lymphocytes transduced with FOXP3 [GeneID=50943].,CGP,C2,55,51
Cohort,-0.013547558480197081,0.010575526530845529,-1.2810292178534144,0.20062269230295326,LGP Offspring,Genes up-regulated in CD4+ [GeneID=920] T lymphocytes transduced with FOXP3 [GeneID=50943].,CGP,C2,7,5
Cohort,-0.009369754899548584,0.03508474642281532,-0.2670606418707222,0.7894884923931353,LGP Proband,Genes up-regulated in CD4+ [GeneID=920] T lymphocytes transduced with FOXP3 [GeneID=50943].,CGP,C2,7,12
Cohort,0.010134114322331961,0.011438630701263467,0.8859551975231253,0.375909235320804,LonGen OPEL,Genes up-regulated in CD4+ [GeneID=920] T lymphocytes transduced with FOXP3 [GeneID=50943].,CGP,C2,6,14
Cohort,-0.017526186078292372,0.0240106244451696,-0.7299346219968156,0.465683008842375,LGP Offspring,Genes down-regulated in A549 cells (lung cancer) upon expression of ASCL1 [GeneID=429] off a viral vector.,CGP,C2,21,33
Cohort,0.03233005939608541,0.06516897499355902,0.4960958707618273,0.6199574838762305,LGP Proband,Genes down-regulated in A549 cells (lung cancer) upon expression of ASCL1 [GeneID=429] off a viral vector.,CGP,C2,21,47
Cohort,-0.018327827314240965,0.019022309241243585,-0.9634911872057643,0.33559368761986397,LonGen OPEL,Genes down-regulated in A549 cells (lung cancer) upon expression of ASCL1 [GeneID=429] off a viral vector.,CGP,C2,29,25
Cohort,-0.005349039833550467,0.03347318110167171,-0.15980076160981685,0.8730857590350658,LGP Offspring,Genes up-regulated in A549 cells (lung cancer) upon expression of ASCL1 [GeneID=429] off a viral vector.,CGP,C2,37,73
Cohort,-0.02827075625066036,0.09649926011246082,-0.29296345088774206,0.769622964028115,LGP Proband,Genes up-regulated in A549 cells (lung cancer) upon expression of ASCL1 [GeneID=429] off a viral vector.,CGP,C2,37,105
Cohort,0.0320543646011757,0.029816666708235053,1.0750485597480492,0.28267873739260907,LonGen OPEL,Genes up-regulated in A549 cells (lung cancer) upon expression of ASCL1 [GeneID=429] off a viral vector.,CGP,C2,58,77
Cohort,0.0010754690105089443,0.024363794295606898,0.04414209861814771,0.9648041711384558,LGP Offspring,Genes up-regulated in Hc cells (normal hepatocyte) by  TNF [GeneID=7124].,CGP,C2,17,37
Cohort,0.04654033128518009,0.059447996956629695,0.7828746748041587,0.43392294742506166,LGP Proband,Genes up-regulated in Hc cells (normal hepatocyte) by  TNF [GeneID=7124].,CGP,C2,17,37
Cohort,0.0021013665488865906,0.017998839702068305,0.11675011187777375,0.907087527556148,LonGen OPEL,Genes up-regulated in Hc cells (normal hepatocyte) by  TNF [GeneID=7124].,CGP,C2,20,24
Cohort,-0.23469367085196283,0.09563305256330147,-2.454106237972633,0.014374670146856432,LGP Offspring,Genes down-regulated in blood samples from bladder cancer patients.,CGP,C2,331,575
Cohort,-0.4020384020205497,0.26061115584612077,-1.5426753345046187,0.12328889977337544,LGP Proband,Genes down-regulated in blood samples from bladder cancer patients.,CGP,C2,331,831
Cohort,-0.0027800896876443407,0.08337985937859267,-0.033342460737684015,0.9734098524714461,LonGen OPEL,Genes down-regulated in blood samples from bladder cancer patients.,CGP,C2,454,553
Cohort,-0.054598132523311096,0.10630085451528459,-0.5136189428793411,0.6076862628155744,LGP Offspring,Genes up-regulated in blood samples from bladder cancer patients.,CGP,C2,352,710
Cohort,-0.44134059163358724,0.28528494630661233,-1.5470167541166115,0.12223856174183335,LGP Proband,Genes up-regulated in blood samples from bladder cancer patients.,CGP,C2,352,918
Cohort,-0.012434420330963338,0.08926494184025302,-0.13929791556035245,0.8892499720388634,LonGen OPEL,Genes up-regulated in blood samples from bladder cancer patients.,CGP,C2,552,655
Cohort,0.16532068032085945,0.08273493115677528,1.9981968681111435,0.0460954427443129,LGP Offspring,"Genes down-regulated in hematopoietic stem cells (HSC, CD34+ [GeneID=947]) cultured in a three-dimentional collagen gel compared to the cells grown in suspension.",CGP,C2,190,472
Cohort,0.117456572708384,0.2279565709261406,0.5152585522373061,0.6065089000004148,LGP Proband,"Genes down-regulated in hematopoietic stem cells (HSC, CD34+ [GeneID=947]) cultured in a three-dimentional collagen gel compared to the cells grown in suspension.",CGP,C2,190,634
Cohort,0.006523975745703333,0.07233269701191423,0.09019400651725651,0.9281557366931407,LonGen OPEL,"Genes down-regulated in hematopoietic stem cells (HSC, CD34+ [GeneID=947]) cultured in a three-dimentional collagen gel compared to the cells grown in suspension.",CGP,C2,365,434
Cohort,-0.1362190447587822,0.07377079428949704,-1.8465172575507445,0.06525405685604267,LGP Offspring,"Genes up-regulated in hematopoietic stem cells (HSC, CD34+ [GeneID=947]) cultured in a three-dimentional collagen gel compared to the cells grown in suspension.",CGP,C2,205,382
Cohort,0.0877309076605836,0.2035019854774546,0.4311059052065271,0.6665027696465391,LGP Proband,"Genes up-regulated in hematopoietic stem cells (HSC, CD34+ [GeneID=947]) cultured in a three-dimentional collagen gel compared to the cells grown in suspension.",CGP,C2,205,525
Cohort,-0.015543789416279518,0.06446668767293201,-0.24111351113834217,0.809529233133863,LonGen OPEL,"Genes up-regulated in hematopoietic stem cells (HSC, CD34+ [GeneID=947]) cultured in a three-dimentional collagen gel compared to the cells grown in suspension.",CGP,C2,289,332
Cohort,0.02156026172202833,0.041781437473179056,0.5160248910983162,0.6060057618978612,LGP Offspring,Genes down-regulated in pirmary cultures of epithelial ovarian cancer (EOC): invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,49,119
Cohort,-0.03598156201817638,0.11132800293002645,-0.3232031570780269,0.7466224088967992,LGP Proband,Genes down-regulated in pirmary cultures of epithelial ovarian cancer (EOC): invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,49,148
Cohort,-0.011868037474300397,0.036900154721964534,-0.32162568324506347,0.747820721136632,LonGen OPEL,Genes down-regulated in pirmary cultures of epithelial ovarian cancer (EOC): invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,94,101
Cohort,0.018421163901261712,0.052650424852576934,0.3498768329570298,0.7265401101833736,LGP Offspring,Genes up-regulated in pirmary cultures of epithelial ovarian cancer (EOC): invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,79,174
Cohort,-0.14893011473736664,0.13442180045921268,-1.1079312598744442,0.2682109212579341,LGP Proband,Genes up-regulated in pirmary cultures of epithelial ovarian cancer (EOC): invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,79,200
Cohort,-0.027394749333124732,0.0429158869779834,-0.6383358532745395,0.5234386799624606,LonGen OPEL,Genes up-regulated in pirmary cultures of epithelial ovarian cancer (EOC): invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,128,146
Cohort,0.0011985312692980616,0.01272773873482444,0.09416686610786197,0.925004508328046,LGP Offspring,Genes down-regulated in epithelial ovarian cancer (EOC) biopsies: invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,6,11
Cohort,0.018924746623666583,0.03137851718483064,0.6031115655399867,0.5465984448401432,LGP Proband,Genes down-regulated in epithelial ovarian cancer (EOC) biopsies: invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,6,11
Cohort,0.005234408343202883,0.010303738844364873,0.5080105796805581,0.6115866648089768,LonGen OPEL,Genes down-regulated in epithelial ovarian cancer (EOC) biopsies: invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,6,10
Cohort,-0.0610677223945258,0.0520601178760769,-1.1730231295267226,0.2411996919124053,LGP Offspring,Genes up-regulated in epithelial ovarian cancer (EOC) biopsies: invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,99,171
Cohort,-0.1633680682394398,0.15229042486640973,-1.0727402486580984,0.2836979752984166,LGP Proband,Genes up-regulated in epithelial ovarian cancer (EOC) biopsies: invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,99,246
Cohort,-0.09960268095635963,0.04537410388343468,-2.1951437589211076,0.028441333809078262,LonGen OPEL,Genes up-regulated in epithelial ovarian cancer (EOC) biopsies: invasive (TOV) vs low malignant potential (LMP) tumors.,CGP,C2,168,164
Cohort,-0.09126372720261541,0.0423316111200486,-2.1559237833825833,0.03144178003752806,LGP Offspring,Genes down-regulated in chronic lymphocytic leukemia (CLL) samples bearing deletions in the 13q14 region.,CGP,C2,67,96
Cohort,-0.11721998700837645,0.11249636296151179,-1.0419891267816432,0.29771867237049643,LGP Proband,Genes down-regulated in chronic lymphocytic leukemia (CLL) samples bearing deletions in the 13q14 region.,CGP,C2,67,146
Cohort,0.00432058873920213,0.03279253425136101,0.1317552558178028,0.8952111729699256,LonGen OPEL,Genes down-regulated in chronic lymphocytic leukemia (CLL) samples bearing deletions in the 13q14 region.,CGP,C2,72,99
Cohort,-0.035024611413931935,0.04976803906564117,-0.7037571114211773,0.4818263770488821,LGP Offspring,Genes up-regulated in chronic lymphocytic leukemia (CLL) samples bearing deletions in the 13q14 region.,CGP,C2,86,170
Cohort,0.04318002022430379,0.13490729065744494,0.32007180645222505,0.7489940657332756,LGP Proband,Genes up-regulated in chronic lymphocytic leukemia (CLL) samples bearing deletions in the 13q14 region.,CGP,C2,86,212
Cohort,0.010033322057134458,0.040711727423099024,0.24644795719087445,0.8053990251496793,LonGen OPEL,Genes up-regulated in chronic lymphocytic leukemia (CLL) samples bearing deletions in the 13q14 region.,CGP,C2,102,124
Cohort,8.180470599694742e-4,0.031369249725401636,0.026077992528684882,0.9792028266796607,LGP Offspring,Mouse orthologs of human prostate cancer tumor markers which were deregulated in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].,CGP,C2,34,67
Cohort,-0.06998130410954692,0.08365886760739084,-0.8365079053898695,0.4031088421550004,LGP Proband,Mouse orthologs of human prostate cancer tumor markers which were deregulated in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].,CGP,C2,34,85
Cohort,0.023068778591596454,0.025200837421118095,0.9153973023239699,0.3602603136594874,LonGen OPEL,Mouse orthologs of human prostate cancer tumor markers which were deregulated in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].,CGP,C2,40,58
Cohort,-0.01261699667392795,0.030616520272569392,-0.4120976701990539,0.6803984788665477,LGP Offspring,Genes down-regulated during prostate cancer progression in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].,CGP,C2,32,61
Cohort,-0.053556623195126656,0.0817718503377252,-0.6549518321272285,0.5126793604322577,LGP Proband,Genes down-regulated during prostate cancer progression in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].,CGP,C2,32,77
Cohort,0.0022833086719197845,0.024777086518241207,0.09215404201130684,0.9265988385854605,LonGen OPEL,Genes down-regulated during prostate cancer progression in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].,CGP,C2,44,51
Cohort,-0.03202778612387136,0.02098659841588755,-1.5261065890328023,0.1274510322506833,LGP Offspring,Genes up-regulated during prostate cancer progression in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].,CGP,C2,19,25
Cohort,-0.0588005775504882,0.0690319597695465,-0.851787747976237,0.3945764231243003,LGP Proband,Genes up-regulated during prostate cancer progression in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].,CGP,C2,19,60
Cohort,4.7201309216030654e-4,0.019001161758604158,0.02484127539973014,0.9801877941601612,LonGen OPEL,Genes up-regulated during prostate cancer progression in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].,CGP,C2,25,32
Cohort,-0.005207215910913267,0.023830880585616606,-0.21850707078177128,0.8270999980234017,LGP Offspring,Cancer motility and invasion genes up-regulated by the AP-1 transcription factor.,CGP,C2,18,38
Cohort,0.05048140378273495,0.06134671852989662,0.8228867817621478,0.4108075991325202,LGP Proband,Cancer motility and invasion genes up-regulated by the AP-1 transcription factor.,CGP,C2,18,45
Cohort,-0.04499941440792388,0.02113018569635596,-2.1296270205369905,0.033508637983666024,LonGen OPEL,Cancer motility and invasion genes up-regulated by the AP-1 transcription factor.,CGP,C2,39,29
Cohort,0.008314673205313117,0.024211649834260097,0.3434162174916161,0.7313921366325358,LGP Offspring,Potential targets of MIR125B1 [GeneID=406911] microRNA which are up-regulated in prostate cancer.,CGP,C2,15,37
Cohort,-0.04360621670364347,0.05901490695333862,-0.7389017276282693,0.46017456786685085,LGP Proband,Potential targets of MIR125B1 [GeneID=406911] microRNA which are up-regulated in prostate cancer.,CGP,C2,15,38
Cohort,0.01205802098666751,0.02102449976680126,0.5735223724898193,0.566453050690874,LonGen OPEL,Potential targets of MIR125B1 [GeneID=406911] microRNA which are up-regulated in prostate cancer.,CGP,C2,26,41
Cohort,-0.06739070506008715,0.02918352286645373,-2.3092039082626425,0.02123287373734469,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) by IGF1 and IGF2 [GeneID=3479;3481].,CGP,C2,38,47
Cohort,0.006949531948867146,0.09129708392026235,0.07611997722661958,0.9393419024079509,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) by IGF1 and IGF2 [GeneID=3479;3481].,CGP,C2,38,101
Cohort,0.05234062138712277,0.029089621459373716,1.7992885008909854,0.0723516898594961,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) by IGF1 and IGF2 [GeneID=3479;3481].,CGP,C2,44,79
Cohort,-0.0468248094596735,0.01999724876735281,-2.3415625821547486,0.019492708325338802,LGP Offspring,Genes down-regulated in NIH-3T3 cells (fibroblast) after knockdown of PRMT5 [GeneID=10419] by RNAi.,CGP,C2,19,20
Cohort,0.011705483562674437,0.059660999476227355,0.1961999239945457,0.8445014834890852,LGP Proband,Genes down-regulated in NIH-3T3 cells (fibroblast) after knockdown of PRMT5 [GeneID=10419] by RNAi.,CGP,C2,19,37
Cohort,-0.011747487859024939,0.01633853199272063,-0.7190051018205823,0.4723487904069501,LonGen OPEL,Genes down-regulated in NIH-3T3 cells (fibroblast) after knockdown of PRMT5 [GeneID=10419] by RNAi.,CGP,C2,21,19
Cohort,-0.1022687201405586,0.07345116486425066,-1.3923362594666446,0.16427842194226644,LGP Offspring,Genes up-regulated in NIH-3T3 cells (fibroblast) after knockdown of PRMT5 [GeneID=10419] by RNAi.,CGP,C2,177,335
Cohort,0.050811672173482224,0.1989995612216317,0.2553355990413052,0.798526861759068,LGP Proband,Genes up-regulated in NIH-3T3 cells (fibroblast) after knockdown of PRMT5 [GeneID=10419] by RNAi.,CGP,C2,177,478
Cohort,-0.05495705612625237,0.06268130445581575,-0.8767695025394975,0.38087636962710714,LonGen OPEL,Genes up-regulated in NIH-3T3 cells (fibroblast) after knockdown of PRMT5 [GeneID=10419] by RNAi.,CGP,C2,289,331
Cohort,-0.007180895425196254,0.009885174333116396,-0.7264308330040758,0.4678261452761221,LGP Offspring,Down-regulated genes associated with sensitivity and resistance to gamma-secretase (GSI) in T-cell acute lymphoblastic leukemia (T-ALL) cell lines.,CGP,C2,5,5
Cohort,-0.06173354996455835,0.028398044027270145,-2.1738662671723694,0.02999579312893488,LGP Proband,Down-regulated genes associated with sensitivity and resistance to gamma-secretase (GSI) in T-cell acute lymphoblastic leukemia (T-ALL) cell lines.,CGP,C2,5,9
Cohort,-1.3954662436502333e-4,0.005169683910744187,-0.026993260472850708,0.9784718751281061,LonGen OPEL,Down-regulated genes associated with sensitivity and resistance to gamma-secretase (GSI) in T-cell acute lymphoblastic leukemia (T-ALL) cell lines.,CGP,C2,2,2
Cohort,-0.027217312672575097,0.014804774869108068,-1.838414492162746,0.06643989936338965,LGP Offspring,Up-regulated genes associated with sensitivity and resistance to gamma-secretase (GSI) in T-cell acute lymphoblastic leukemia (T-ALL) cell lines.,CGP,C2,12,11
Cohort,0.018994311455120663,0.039727604888782915,0.47811368211839284,0.6326945899621778,LGP Proband,Up-regulated genes associated with sensitivity and resistance to gamma-secretase (GSI) in T-cell acute lymphoblastic leukemia (T-ALL) cell lines.,CGP,C2,12,13
Cohort,0.016698278660467084,0.010877486472899392,1.535122907490609,0.12515099903106994,LonGen OPEL,Up-regulated genes associated with sensitivity and resistance to gamma-secretase (GSI) in T-cell acute lymphoblastic leukemia (T-ALL) cell lines.,CGP,C2,5,13
Cohort,-0.004279652900292523,0.06613504273669282,-0.06471082081751041,0.9484233780026521,LGP Offspring,"Genes down-regulated in ovarian tumors from mouse models for the BMP SMAD signaling (gonad specific double knockout of SMAD1 and SMAD5 [GeneID=4086, 4090]).",CGP,C2,145,308
Cohort,0.19808174615852864,0.1771258608844219,1.1183107038659976,0.26375632875870647,LGP Proband,"Genes down-regulated in ovarian tumors from mouse models for the BMP SMAD signaling (gonad specific double knockout of SMAD1 and SMAD5 [GeneID=4086, 4090]).",CGP,C2,145,402
Cohort,-0.04646093842270915,0.057178785826906754,-0.812555526508678,0.4167158824516515,LonGen OPEL,"Genes down-regulated in ovarian tumors from mouse models for the BMP SMAD signaling (gonad specific double knockout of SMAD1 and SMAD5 [GeneID=4086, 4090]).",CGP,C2,227,264
Cohort,-0.017969155715928324,0.0772079696679548,-0.23273705801625852,0.8160360380915515,LGP Offspring,"Genes up-regulated in ovarian tumors from mouse models for the BMP SMAD signaling (gonad specific double knockout of SMAD1 and SMAD5 [GeneID=4086, 4090]).",CGP,C2,182,381
Cohort,-0.19878715810204425,0.20280738505319207,-0.980177117563577,0.32728293956463184,LGP Proband,"Genes up-regulated in ovarian tumors from mouse models for the BMP SMAD signaling (gonad specific double knockout of SMAD1 and SMAD5 [GeneID=4086, 4090]).",CGP,C2,182,445
Cohort,0.019025241161229983,0.06050185309732334,0.31445716432232185,0.7532562467528228,LonGen OPEL,"Genes up-regulated in ovarian tumors from mouse models for the BMP SMAD signaling (gonad specific double knockout of SMAD1 and SMAD5 [GeneID=4086, 4090]).",CGP,C2,261,303
Cohort,-0.09536711014485143,0.0415867587190377,-2.2932085375817954,0.022142086557377472,LGP Offspring,Genes down-regulated in unstable ateroslerotic plaques compared to the stable ones.,CGP,C2,72,98
Cohort,-0.36166962189060115,0.12184510443409301,-2.968273724006951,0.003080464183386449,LGP Proband,Genes down-regulated in unstable ateroslerotic plaques compared to the stable ones.,CGP,C2,72,160
Cohort,-0.023769499558084405,0.03650045602862833,-0.6512110297866229,0.5150982188751345,LonGen OPEL,Genes down-regulated in unstable ateroslerotic plaques compared to the stable ones.,CGP,C2,96,102
Cohort,0.03925452606580134,0.03726509688181334,1.0533858583622497,0.29254054701664456,LGP Offspring,Genes up-regulated in unstable ateroslerotic plaques compared to the stable ones.,CGP,C2,38,95
Cohort,0.18931877895389962,0.09892606005326965,1.9137402101322478,0.05599539711682792,LGP Proband,Genes up-regulated in unstable ateroslerotic plaques compared to the stable ones.,CGP,C2,38,116
Cohort,0.02153290771637262,0.02999183795986005,0.7179589241976919,0.4729932707362271,LonGen OPEL,Genes up-regulated in unstable ateroslerotic plaques compared to the stable ones.,CGP,C2,61,81
Cohort,-0.10461006528870993,0.03879508159322814,-2.696477517061598,0.00718221743177224,LGP Offspring,Genes down-regulated in HepaRG cells (liver cancer) expressing constituvely active form of MTOR [GeneID=2475].,CGP,C2,63,84
Cohort,0.09386880554519725,0.11085859553554457,0.8467435934194215,0.39738095375432336,LGP Proband,Genes down-regulated in HepaRG cells (liver cancer) expressing constituvely active form of MTOR [GeneID=2475].,CGP,C2,63,130
Cohort,-0.02986779904399071,0.0352297775613347,-0.8477998191158365,0.39680431030734264,LonGen OPEL,Genes down-regulated in HepaRG cells (liver cancer) expressing constituvely active form of MTOR [GeneID=2475].,CGP,C2,101,103
Cohort,-0.07149402271881988,0.1511326692304639,-0.47305472127801734,0.6363268459045471,LGP Offspring,Genes up-regulated in HepaRG cells (liver cancer) expressing constituvely active form of MTOR [GeneID=2475].,CGP,C2,798,1655
Cohort,-0.3412396844121732,0.42034278555540777,-0.8118128730609377,0.4171306508681216,LGP Proband,Genes up-regulated in HepaRG cells (liver cancer) expressing constituvely active form of MTOR [GeneID=2475].,CGP,C2,798,2265
Cohort,0.016978865477213678,0.13438653427428793,0.12634350285839785,0.8994919271027126,LonGen OPEL,Genes up-regulated in HepaRG cells (liver cancer) expressing constituvely active form of MTOR [GeneID=2475].,CGP,C2,1263,1540
Cohort,0.0051003065307173075,0.035307559642031576,0.14445366891473554,0.8851852939698379,LGP Offspring,"Genes down-regulated in U937 cells (acute promyelocytic leukemia, APL) expressing RARA [GeneID=5914] fused with either PML or PLZF [GeneID=5371;7704].",CGP,C2,37,81
Cohort,0.022951073064838318,0.09052294747826074,0.25353872917527415,0.7999144237721242,LGP Proband,"Genes down-regulated in U937 cells (acute promyelocytic leukemia, APL) expressing RARA [GeneID=5914] fused with either PML or PLZF [GeneID=5371;7704].",CGP,C2,37,104
Cohort,0.04818505246758538,0.030169675057102864,1.5971352815827278,0.11063243395433882,LonGen OPEL,"Genes down-regulated in U937 cells (acute promyelocytic leukemia, APL) expressing RARA [GeneID=5914] fused with either PML or PLZF [GeneID=5371;7704].",CGP,C2,52,82
Cohort,0.076296605422542,0.02583941723138453,2.9527216012392192,0.003259105375812154,LGP Offspring,"Genes up-regulated in U937 cells (acute promyelocytic leukemia, APL) expressing RARA [GeneID=5914] fused with either PML or PLZF [GeneID=5371;7704].",CGP,C2,11,55
Cohort,0.07134121357364243,0.06948309923369249,1.0267419611451203,0.304839678300329,LGP Proband,"Genes up-regulated in U937 cells (acute promyelocytic leukemia, APL) expressing RARA [GeneID=5914] fused with either PML or PLZF [GeneID=5371;7704].",CGP,C2,11,67
Cohort,0.02191432706078433,0.020745145745850322,1.056359272152517,0.29112459852788064,LonGen OPEL,"Genes up-regulated in U937 cells (acute promyelocytic leukemia, APL) expressing RARA [GeneID=5914] fused with either PML or PLZF [GeneID=5371;7704].",CGP,C2,28,41
Cohort,0.027743587147528583,0.02751075829150459,1.0084631929646188,0.3135929760812311,LGP Offspring,Genes commonly expressed in long term hematopoietic stem cells (HSC) and multipotent progenitors (MPP).,CGP,C2,20,57
Cohort,0.01979231355928579,0.07003779797757755,0.2825947435643573,0.7775576290512951,LGP Proband,Genes commonly expressed in long term hematopoietic stem cells (HSC) and multipotent progenitors (MPP).,CGP,C2,20,63
Cohort,0.011589976881884295,0.020669214731734765,0.5607361978822284,0.5751351826415524,LonGen OPEL,Genes commonly expressed in long term hematopoietic stem cells (HSC) and multipotent progenitors (MPP).,CGP,C2,27,35
Cohort,0.02119279316133082,0.0406774007631795,0.5209967393126599,0.6025396589518988,LGP Offspring,Genes in a cCDNA library from hematopoietic stem cells (HSC) after subtraction of lineage-specific markers.,CGP,C2,43,103
Cohort,-0.026373822391720602,0.10764631300004074,-0.24500441916399515,0.8065132797483073,LGP Proband,Genes in a cCDNA library from hematopoietic stem cells (HSC) after subtraction of lineage-specific markers.,CGP,C2,43,136
Cohort,-0.02296800508190227,0.03493171031477032,-0.6575116097934264,0.5110420876037058,LonGen OPEL,Genes in a cCDNA library from hematopoietic stem cells (HSC) after subtraction of lineage-specific markers.,CGP,C2,92,101
Cohort,-0.019470825524699847,0.011472588695201263,-1.69716060097614,0.09012660067257737,LGP Offspring,Genes down-regulated in long term hematopoietic stem cells (LT-HSC) compared to multipotent progenitor (MPP) cells.,CGP,C2,8,5
Cohort,-0.07335163079901871,0.04341786644234617,-1.6894342539014684,0.09150999308817423,LGP Proband,Genes down-regulated in long term hematopoietic stem cells (LT-HSC) compared to multipotent progenitor (MPP) cells.,CGP,C2,8,25
Cohort,-0.011750771881967773,0.01446531739024418,-0.812341102857019,0.41683880254541583,LonGen OPEL,Genes down-regulated in long term hematopoietic stem cells (LT-HSC) compared to multipotent progenitor (MPP) cells.,CGP,C2,15,19
Cohort,-0.006250661433883633,0.022573653109497667,-0.2769007481227627,0.7819409642251478,LGP Offspring,Genes up-regulated in long term hematopoietic stem cells (LT-HSC) compared to multipotent progenitor (MPP) cells.,CGP,C2,16,32
Cohort,0.12768068934283644,0.06772428215282561,1.8853014795301055,0.05973654129950604,LGP Proband,Genes up-regulated in long term hematopoietic stem cells (LT-HSC) compared to multipotent progenitor (MPP) cells.,CGP,C2,16,60
Cohort,0.017253830064238196,0.020750686909876612,0.8314823571467395,0.40595054178429135,LonGen OPEL,Genes up-regulated in long term hematopoietic stem cells (LT-HSC) compared to multipotent progenitor (MPP) cells.,CGP,C2,24,40
Cohort,0.009390116883794356,0.0077466244485548405,1.2121559456191418,0.22587617600222273,LGP Offspring,Genes down-regulated in M2-10B4 cells (osteoblast) in response to phenylamil [PubChem=4755].,CGP,C2,1,5
Cohort,-0.027410504020889938,0.024761228249169143,-1.1069929062105266,0.2686161758104018,LGP Proband,Genes down-regulated in M2-10B4 cells (osteoblast) in response to phenylamil [PubChem=4755].,CGP,C2,1,9
Cohort,3.82173958849208e-5,0.007690764924634476,0.004969258098437742,0.9960363670776871,LonGen OPEL,Genes down-regulated in M2-10B4 cells (osteoblast) in response to phenylamil [PubChem=4755].,CGP,C2,4,5
Cohort,0.013299033927974416,0.0210206945288334,0.6326638689189154,0.5271671065482397,LGP Offspring,Genes up-regulated in M2-10B4 cells (osteoblast) in response to phenylamil [PubChem=4755].,CGP,C2,12,32
Cohort,-0.09618504046015487,0.0491679943253871,-1.956253082515739,0.050768772833439064,LGP Proband,Genes up-regulated in M2-10B4 cells (osteoblast) in response to phenylamil [PubChem=4755].,CGP,C2,12,27
Cohort,0.0408282348224596,0.01712993037274922,2.3834442951041015,0.01738505226808597,LonGen OPEL,Genes up-regulated in M2-10B4 cells (osteoblast) in response to phenylamil [PubChem=4755].,CGP,C2,13,31
Cohort,0.0011371959957334375,0.015176466400366554,0.07493153977568659,0.9402913501387966,LGP Offspring,"Genes up-regulated in U937 cells (acute promyelocytic leukemia, APL) by tretinoin (ATRA) [PubChem=444795].",CGP,C2,6,15
Cohort,-0.012328107066036596,0.03758867704532633,-0.32797395479417224,0.7430136734095452,LGP Proband,"Genes up-regulated in U937 cells (acute promyelocytic leukemia, APL) by tretinoin (ATRA) [PubChem=444795].",CGP,C2,6,17
Cohort,1.3725174524875593e-4,0.010925040111848144,0.012563042683926367,0.9899795538269033,LonGen OPEL,"Genes up-regulated in U937 cells (acute promyelocytic leukemia, APL) by tretinoin (ATRA) [PubChem=444795].",CGP,C2,9,9
Cohort,0.02833571218154666,0.020183913368159594,1.4038760306138967,0.16081499069911456,LGP Offspring,"Genes up-regulated by tretinoin (ATRA) [PubChem=444795] in U937 cells (acute promyelocytic leukemia, APL) made sensitive to the drug by expression of the PML-RARA fusion [GeneID=5371;5914].",CGP,C2,9,31
Cohort,-0.03559758333105833,0.055777764132307395,-0.6382038413483058,0.5235161928787931,LGP Proband,"Genes up-regulated by tretinoin (ATRA) [PubChem=444795] in U937 cells (acute promyelocytic leukemia, APL) made sensitive to the drug by expression of the PML-RARA fusion [GeneID=5371;5914].",CGP,C2,9,40
Cohort,-0.003983079955756002,0.01884040081829831,-0.21141163578046204,0.8326201918691696,LonGen OPEL,"Genes up-regulated by tretinoin (ATRA) [PubChem=444795] in U937 cells (acute promyelocytic leukemia, APL) made sensitive to the drug by expression of the PML-RARA fusion [GeneID=5371;5914].",CGP,C2,27,27
Cohort,-0.007260944730436391,0.029463378433934824,-0.24643965208258348,0.8054167277079426,LGP Offspring,"Genes up-regulated by tretinoin (ATRA) [PubChem=444795] in U937 cells (acute promyelocytic leukemia, APL) made resistant to the drug by expression of the PLZF-RARA fusion [GeneID=7704, 5914].",CGP,C2,24,54
Cohort,0.13577067018358857,0.08052814231802692,1.6860027597233562,0.09216929776086684,LGP Proband,"Genes up-regulated by tretinoin (ATRA) [PubChem=444795] in U937 cells (acute promyelocytic leukemia, APL) made resistant to the drug by expression of the PLZF-RARA fusion [GeneID=7704, 5914].",CGP,C2,24,75
Cohort,0.01803922374738863,0.0265548926924769,0.6793182693786298,0.49713370272631996,LonGen OPEL,"Genes up-regulated by tretinoin (ATRA) [PubChem=444795] in U937 cells (acute promyelocytic leukemia, APL) made resistant to the drug by expression of the PLZF-RARA fusion [GeneID=7704, 5914].",CGP,C2,43,57
Cohort,0.04034619204591639,0.1007393394108045,0.40050085976233013,0.6889141888211741,LGP Offspring,Genes down-regulated in ES (embryonic stem cells) with defficient SUZ12 [GeneID=23512].,CGP,C2,293,625
Cohort,-0.6055300421462133,0.25962031373952804,-2.3323677312620834,0.019918463806886926,LGP Proband,Genes down-regulated in ES (embryonic stem cells) with defficient SUZ12 [GeneID=23512].,CGP,C2,293,798
Cohort,-0.04111537256360488,0.08001604564401323,-0.5138390960548689,0.6075070956893147,LonGen OPEL,Genes down-regulated in ES (embryonic stem cells) with defficient SUZ12 [GeneID=23512].,CGP,C2,477,550
Cohort,0.033777924571343855,0.05356429303504,0.63060525319073,0.5285117854213051,LGP Offspring,Genes up-regulated in ES (embryonic stem cells) with defficient SUZ12 [GeneID=23512].,CGP,C2,97,205
Cohort,-0.2552743492323583,0.16130082121818184,-1.5825979514826163,0.11389225206676602,LGP Proband,Genes up-regulated in ES (embryonic stem cells) with defficient SUZ12 [GeneID=23512].,CGP,C2,97,318
Cohort,0.035941350023922965,0.04644255899858343,0.7738882352503278,0.4392266637661554,LonGen OPEL,Genes up-regulated in ES (embryonic stem cells) with defficient SUZ12 [GeneID=23512].,CGP,C2,144,181
Cohort,-0.049116081190287084,0.06386760591860785,-0.7690296275216587,0.44214432137580206,LGP Offspring,"Genes down-regulated in post-GC, BCL6 [GeneID=604] dependent B cell non-Hodgkin's lymphoma (B-NHL) vs MYC [GeneID=4609] driven pre-GC lymphoma.",CGP,C2,145,273
Cohort,-0.10548774297301199,0.18448395843288942,-0.571799000135753,0.5676122289015533,LGP Proband,"Genes down-regulated in post-GC, BCL6 [GeneID=604] dependent B cell non-Hodgkin's lymphoma (B-NHL) vs MYC [GeneID=4609] driven pre-GC lymphoma.",CGP,C2,145,407
Cohort,-0.044442242465609905,0.05466721144516366,-0.8129597484625614,0.41648421720812334,LonGen OPEL,"Genes down-regulated in post-GC, BCL6 [GeneID=604] dependent B cell non-Hodgkin's lymphoma (B-NHL) vs MYC [GeneID=4609] driven pre-GC lymphoma.",CGP,C2,216,246
Cohort,-0.02328736848236316,0.10161050547915451,-0.22918268512246093,0.8187962496842245,LGP Offspring,"Genes up-regulated in post-GC, BCL6 [GeneID=604] dependent B cell non-Hodgkin's lymphoma (B-NHL) vs MYC [GeneID=4609] driven pre-GC lymphoma.",CGP,C2,314,663
Cohort,-0.05530893307427628,0.2828441543970851,-0.1955456113002358,0.8450134650461463,LGP Proband,"Genes up-regulated in post-GC, BCL6 [GeneID=604] dependent B cell non-Hodgkin's lymphoma (B-NHL) vs MYC [GeneID=4609] driven pre-GC lymphoma.",CGP,C2,314,880
Cohort,0.13733825497247112,0.08845860610262149,1.5525708692848268,0.12092316807804716,LonGen OPEL,"Genes up-regulated in post-GC, BCL6 [GeneID=604] dependent B cell non-Hodgkin's lymphoma (B-NHL) vs MYC [GeneID=4609] driven pre-GC lymphoma.",CGP,C2,475,612
Cohort,-0.010508599462666246,0.008485157597876427,-1.2384683892372517,0.21597232635588806,LGP Offspring,"Genes down-regulated in K562 (chronic myelogenous leukemia, CML) cells engineered to stably express RIZ1 [GeneID=7799].",CGP,C2,4,3
Cohort,-0.031056052807707776,0.024848024436885642,-1.249839917317798,0.21170863713009117,LGP Proband,"Genes down-regulated in K562 (chronic myelogenous leukemia, CML) cells engineered to stably express RIZ1 [GeneID=7799].",CGP,C2,4,6
Cohort,-0.0012407134724756884,0.005139848386535059,-0.24139106432127547,0.8093142046910187,LonGen OPEL,"Genes down-regulated in K562 (chronic myelogenous leukemia, CML) cells engineered to stably express RIZ1 [GeneID=7799].",CGP,C2,2,2
Cohort,-0.005406621183084628,0.011938351656777646,-0.45287836533238474,0.6507816436981856,LGP Offspring,"Genes up-regulated in K562 (chronic myelogenous leukemia, CML) cells engineered to stably express RIZ1 [GeneID=7799].",CGP,C2,5,7
Cohort,0.02263633319154173,0.03972902502832421,0.5697681525132694,0.5689883952248673,LGP Proband,"Genes up-regulated in K562 (chronic myelogenous leukemia, CML) cells engineered to stably express RIZ1 [GeneID=7799].",CGP,C2,5,19
Cohort,0.00836880553965552,0.011664345362246635,0.7174689431558146,0.47329528204662186,LonGen OPEL,"Genes up-regulated in K562 (chronic myelogenous leukemia, CML) cells engineered to stably express RIZ1 [GeneID=7799].",CGP,C2,8,13
Cohort,-0.14021073122292788,0.14113501434692374,-0.9934510714561314,0.3208456456455772,LGP Offspring,Genes up-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.,CGP,C2,602,1186
Cohort,-0.48028034975900585,0.3887618113478965,-1.2354103097055769,0.21702572725274208,LGP Proband,Genes up-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.,CGP,C2,602,1629
Cohort,0.11000318556609068,0.11894619698276465,0.9248146502912589,0.35534260119885097,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.,CGP,C2,984,1190
Cohort,-0.009081333646344027,0.03984331011325911,-0.2279261843589127,0.8197725483367831,LGP Offspring,Cell proliferation genes down-regulated by histone deacetylase (HDAC) inhibitors SAHA and depsipeptide [PubChem=5311;5352062].,CGP,C2,55,106
Cohort,0.007129664166440652,0.1190597980078167,0.05988305276624578,0.9522631235261233,LGP Proband,Cell proliferation genes down-regulated by histone deacetylase (HDAC) inhibitors SAHA and depsipeptide [PubChem=5311;5352062].,CGP,C2,55,190
Cohort,0.07866708752435744,0.03785250015473538,2.078253410019896,0.038005904459535625,LonGen OPEL,Cell proliferation genes down-regulated by histone deacetylase (HDAC) inhibitors SAHA and depsipeptide [PubChem=5311;5352062].,CGP,C2,90,140
Cohort,-0.007577375390718757,0.033389137891840774,-0.2269413308982267,0.8205379734023328,LGP Offspring,Cell proliferation genes up-regulated by histone deacetylase (HDAC) inhibitors SAHA and depsipeptide [PubChem=5311;5352062].,CGP,C2,37,73
Cohort,-0.014152701679029756,0.0914228572637731,-0.15480484971276276,0.8770126230948927,LGP Proband,Cell proliferation genes up-regulated by histone deacetylase (HDAC) inhibitors SAHA and depsipeptide [PubChem=5311;5352062].,CGP,C2,37,101
Cohort,0.012814829649217136,0.028317042113707922,0.45254831340642176,0.6509973331292055,LonGen OPEL,Cell proliferation genes up-regulated by histone deacetylase (HDAC) inhibitors SAHA and depsipeptide [PubChem=5311;5352062].,CGP,C2,47,65
Cohort,-0.04880922497360967,0.06058813898025236,-0.8055904306537321,0.42076231642693895,LGP Offspring,The '3/3 signature': genes consistently down-regulated in all three pools of normal mammary stem cells (defined by their ability to retain the dye PKH26).,CGP,C2,124,226
Cohort,-0.41707230440127663,0.16544184582149285,-2.5209601738322363,0.011888941280287413,LGP Proband,The '3/3 signature': genes consistently down-regulated in all three pools of normal mammary stem cells (defined by their ability to retain the dye PKH26).,CGP,C2,124,309
Cohort,-0.034034713824475316,0.04924727820487224,-0.6910983726428178,0.489705212682917,LonGen OPEL,The '3/3 signature': genes consistently down-regulated in all three pools of normal mammary stem cells (defined by their ability to retain the dye PKH26).,CGP,C2,178,198
Cohort,0.017817934921073877,0.046049403897338644,0.3869308484599871,0.6989291771386813,LGP Offspring,The '3/3 signature': genes consistently up-regulated in all three pools of normal mammary stem cells (defined by their ability to retain the dye PKH26).,CGP,C2,60,148
Cohort,0.25534813723501876,0.1215809357076743,2.1002317160066153,0.0360082478522048,LGP Proband,The '3/3 signature': genes consistently up-regulated in all three pools of normal mammary stem cells (defined by their ability to retain the dye PKH26).,CGP,C2,60,201
Cohort,-0.04758565256281777,0.03846551074748715,-1.2370991997272887,0.2164150876416963,LonGen OPEL,The '3/3 signature': genes consistently up-regulated in all three pools of normal mammary stem cells (defined by their ability to retain the dye PKH26).,CGP,C2,109,114
Cohort,-0.008993424345550914,0.03784441010627515,-0.23764208030447473,0.812230715885055,LGP Offspring,Genes regulated in MCF7 cells (breast cancer) by expression of full-length and truncated (611-CTF) forms of ERBB2 [GeneID=2064] at both 15 h and 60 h time points.,CGP,C2,51,100
Cohort,-0.13671806336595008,0.10798045273884702,-1.2661371562925892,0.2058175214546393,LGP Proband,Genes regulated in MCF7 cells (breast cancer) by expression of full-length and truncated (611-CTF) forms of ERBB2 [GeneID=2064] at both 15 h and 60 h time points.,CGP,C2,51,138
Cohort,0.006245262419841991,0.03326592829805887,0.18773750619207621,0.851130272448513,LonGen OPEL,Genes regulated in MCF7 cells (breast cancer) by expression of full-length and truncated (611-CTF) forms of ERBB2 [GeneID=2064] at both 15 h and 60 h time points.,CGP,C2,78,98
Cohort,-0.006174364912655538,0.01773579873977481,-0.34813007315022865,0.7278508804363526,LGP Offspring,Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at both 15 h and 60 h time points.,CGP,C2,11,22
Cohort,0.09809151602644568,0.050611023087511,1.9381452901443357,0.052942678218316615,LGP Proband,Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at both 15 h and 60 h time points.,CGP,C2,11,32
Cohort,0.008528264528842417,0.018456751846674956,0.4620674645077818,0.6441592024583135,LonGen OPEL,Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at both 15 h and 60 h time points.,CGP,C2,21,28
Cohort,-0.015462854419576115,0.0644375854078877,-0.23996638486213873,0.8104290625092541,LGP Offspring,Genes regulated in MCF7 cells (breast cancer) by expression of the full-length and truncated (611-CTF) forms of ERBB2 [GeneID=2064] at 60 h time point.,CGP,C2,127,263
Cohort,-0.3653532836498978,0.16180270858471504,-2.2580171051871467,0.024202332965989504,LGP Proband,Genes regulated in MCF7 cells (breast cancer) by expression of the full-length and truncated (611-CTF) forms of ERBB2 [GeneID=2064] at 60 h time point.,CGP,C2,127,333
Cohort,-0.0553085438015727,0.05348774295483328,-1.03404145970932,0.30143082796639015,LonGen OPEL,Genes regulated in MCF7 cells (breast cancer) by expression of the full-length and truncated (611-CTF) forms of ERBB2 [GeneID=2064] at 60 h time point.,CGP,C2,209,215
Cohort,0.00982613110301057,0.008421164712600902,1.166837538316685,0.24368743041164687,LGP Offspring,Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at 15 h time point.,CGP,C2,1,6
Cohort,-0.04032229350178278,0.023485249174348362,-1.7169199782570153,0.08636507377650122,LGP Proband,Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at 15 h time point.,CGP,C2,1,8
Cohort,-3.555906442581996e-4,0.007324202810681428,-0.0485500816197519,0.9612900307611298,LonGen OPEL,Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at 15 h time point.,CGP,C2,4,4
Cohort,-0.0012760495394176247,0.023477706111638103,-0.054351542410060065,0.9566711437743667,LGP Offspring,Genes regulated in MCF7 cells (breast cancer) by expression of the full-length form of ERBB2 [GeneID=2064] at 60 h time point.,CGP,C2,20,34
Cohort,-0.13906356326749847,0.05898479070866182,-2.3576173043380355,0.018622725771138115,LGP Proband,Genes regulated in MCF7 cells (breast cancer) by expression of the full-length form of ERBB2 [GeneID=2064] at 60 h time point.,CGP,C2,20,39
Cohort,0.0035611892766536615,0.020002446528801475,0.1780376851164638,0.8587386779932975,LonGen OPEL,Genes regulated in MCF7 cells (breast cancer) by expression of the full-length form of ERBB2 [GeneID=2064] at 60 h time point.,CGP,C2,28,36
Cohort,-0.06882920238506207,0.11372127329726957,-0.6052447390836122,0.545219517203205,LGP Offspring,Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at 60 h time point.,CGP,C2,411,820
Cohort,0.09032096205908192,0.31258957502842827,0.28894425558135695,0.772695841184105,LGP Proband,Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at 60 h time point.,CGP,C2,411,1099
Cohort,-0.06776069950528225,0.09394608728616932,-0.7212721834691879,0.470953856811001,LonGen OPEL,Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at 60 h time point.,CGP,C2,647,734
Cohort,0.014665129397241825,0.05122682219171488,0.2862783356413952,0.7747526597357369,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) more than three-fold by the truncated form 611-CTF of ERBB2 [GeneID=2064] and less than two-fold by the full-length ERBB2 [GeneID=2064].,CGP,C2,79,166
Cohort,0.07738951083962217,0.13859940788809602,0.5583682644741585,0.5767428065406961,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) more than three-fold by the truncated form 611-CTF of ERBB2 [GeneID=2064] and less than two-fold by the full-length ERBB2 [GeneID=2064].,CGP,C2,79,207
Cohort,0.07031906467546171,0.042153129507349486,1.6681813544401594,0.09567301315919179,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) more than three-fold by the truncated form 611-CTF of ERBB2 [GeneID=2064] and less than two-fold by the full-length ERBB2 [GeneID=2064].,CGP,C2,113,163
Cohort,-0.041786331365942224,0.1290873199873655,-0.32370593308492335,0.7462607985661304,LGP Offspring,Genes down-regulated in primary LEC cells (lymphatic endothelum) upon overexpression of MIR31 [GeneID=407035].,CGP,C2,491,1010
Cohort,-0.4264279986744841,0.35313518607902694,-1.2075488806687624,0.2275631684830848,LGP Proband,Genes down-regulated in primary LEC cells (lymphatic endothelum) upon overexpression of MIR31 [GeneID=407035].,CGP,C2,491,1404
Cohort,-0.07775770114214654,0.11327350988478754,-0.6864597134955495,0.49262317027830194,LonGen OPEL,Genes down-regulated in primary LEC cells (lymphatic endothelum) upon overexpression of MIR31 [GeneID=407035].,CGP,C2,828,933
Cohort,-0.11738608716049251,0.09145600611247015,-1.2835251849521423,0.1997479435929543,LGP Offspring,Genes up-regulated in primary LEC cells (lymphatic endothelum) upon overexpression of MIR31 [GeneID=407035].,CGP,C2,256,488
Cohort,-0.02987840525713005,0.24710083418754508,-0.12091584132189889,0.9037868192931103,LGP Proband,Genes up-regulated in primary LEC cells (lymphatic endothelum) upon overexpression of MIR31 [GeneID=407035].,CGP,C2,256,651
Cohort,-0.11445086431412531,0.07671335845135993,-1.4919287412855589,0.13611402391045901,LonGen OPEL,Genes up-regulated in primary LEC cells (lymphatic endothelum) upon overexpression of MIR31 [GeneID=407035].,CGP,C2,422,476
Cohort,0.045445759558148044,0.0338321936123254,1.3432696702702631,0.17963543775530963,LGP Offspring,Antigen processing and presentation genes down-regulated in JY cells (B lymphocytes) treated with trichostatin A (TSA) [PubChem=5562].,CGP,C2,29,77
Cohort,-0.04320740793181269,0.08516894518296164,-0.5073141136008397,0.612068554754957,LGP Proband,Antigen processing and presentation genes down-regulated in JY cells (B lymphocytes) treated with trichostatin A (TSA) [PubChem=5562].,CGP,C2,29,89
Cohort,0.04069998705216392,0.028115700135189967,1.447589313318337,0.14812566206371194,LonGen OPEL,Antigen processing and presentation genes down-regulated in JY cells (B lymphocytes) treated with trichostatin A (TSA) [PubChem=5562].,CGP,C2,44,69
Cohort,0.050261083676389644,0.04159610571463712,1.208312240121638,0.22734969403811628,LGP Offspring,Antigen processing and presentation genes up-regulated in JY cells (B lymphocytes) treated with TSA [PubChem=5562].,CGP,C2,44,118
Cohort,-0.13082257191535154,0.11466714718923786,-1.1408897415006933,0.254243307007023,LGP Proband,Antigen processing and presentation genes up-regulated in JY cells (B lymphocytes) treated with TSA [PubChem=5562].,CGP,C2,44,156
Cohort,-0.003860503999038826,0.03532015974793908,-0.10930029837319988,0.912991857491346,LonGen OPEL,Antigen processing and presentation genes up-regulated in JY cells (B lymphocytes) treated with TSA [PubChem=5562].,CGP,C2,84,97
Cohort,-0.017079806716763048,0.024259284363192857,-0.7040523727351663,0.4816426074016519,LGP Offspring,Genes down-regulated in CD38+ [GeneID=952] CLL (chronic lymphocytic leukemia) cells.,CGP,C2,21,42
Cohort,0.08814590120138838,0.07082917992547512,1.2444856949372212,0.21367047197411665,LGP Proband,Genes down-regulated in CD38+ [GeneID=952] CLL (chronic lymphocytic leukemia) cells.,CGP,C2,21,63
Cohort,0.004286562649811256,0.022755518543371895,0.18837464159039446,0.8506309897898829,LonGen OPEL,Genes down-regulated in CD38+ [GeneID=952] CLL (chronic lymphocytic leukemia) cells.,CGP,C2,37,42
Cohort,-0.0280399098619022,0.03237227598770154,-0.8661704809558267,0.3867039895910842,LGP Offspring,Genes up-regulated in CD38+ [GeneID=952] CLL (chronic lymphocytic leukemia) cells.,CGP,C2,38,71
Cohort,0.11940559239193332,0.08121367731035804,1.4702645705307111,0.1418672620068627,LGP Proband,Genes up-regulated in CD38+ [GeneID=952] CLL (chronic lymphocytic leukemia) cells.,CGP,C2,38,82
Cohort,0.035095888120196914,0.02601892631497286,1.3488599681379096,0.1777655432971735,LonGen OPEL,Genes up-regulated in CD38+ [GeneID=952] CLL (chronic lymphocytic leukemia) cells.,CGP,C2,43,64
Cohort,-0.04167317081113462,0.08140484975236266,-0.5119249152588126,0.6088707515485392,LGP Offspring,Genes up-regulated in HMEC cells (primary mammary epithelium) upon expression of both of TP53 [GeneID=7157] and the transcriptionally active isoform of TP63 [GeneID=8626] off adenoviral vectors.,CGP,C2,212,415
Cohort,0.10717713627406006,0.21505485445954903,0.4983711553194427,0.6183538641827191,LGP Proband,Genes up-regulated in HMEC cells (primary mammary epithelium) upon expression of both of TP53 [GeneID=7157] and the transcriptionally active isoform of TP63 [GeneID=8626] off adenoviral vectors.,CGP,C2,212,555
Cohort,0.0013623435539071261,0.0686362801750936,0.019848738166342045,0.984169012224033,LonGen OPEL,Genes up-regulated in HMEC cells (primary mammary epithelium) upon expression of both of TP53 [GeneID=7157] and the transcriptionally active isoform of TP63 [GeneID=8626] off adenoviral vectors.,CGP,C2,304,358
Cohort,-0.45957862246682013,0.2062185902211838,-2.228599380753646,0.02616862723091508,LGP Offspring,Genes up-regulated in the HMEC cells (primary mammary epithelium) upon expression of TP53 [GeneID=7157] off adenoviral vector.,CGP,C2,1390,2684
Cohort,-0.7060414994994342,0.5445087652906416,-1.29665772987616,0.19510761796124945,LGP Proband,Genes up-regulated in the HMEC cells (primary mammary epithelium) upon expression of TP53 [GeneID=7157] off adenoviral vector.,CGP,C2,1390,3643
Cohort,0.03675030137868247,0.17590196096400834,0.20892491008785302,0.834560309701255,LonGen OPEL,Genes up-regulated in the HMEC cells (primary mammary epithelium) upon expression of TP53 [GeneID=7157] off adenoviral vector.,CGP,C2,2054,2481
Cohort,-0.06544457067338971,0.1045642762688351,-0.6258788661734864,0.5316056501491571,LGP Offspring,Genes up-regulated in the HMEC cells (primary mammary epithelium) upon expression of the transcriptionally active isoform of TP63 [GeneID=8626] off adenoviral vector.,CGP,C2,354,710
Cohort,-0.016017770774285442,0.2768769397938608,-0.05785158845735193,0.95388070291669,LGP Proband,Genes up-regulated in the HMEC cells (primary mammary epithelium) upon expression of the transcriptionally active isoform of TP63 [GeneID=8626] off adenoviral vector.,CGP,C2,354,956
Cohort,-0.024355814685105222,0.08803462105371122,-0.2766617768507844,0.7821116456508965,LonGen OPEL,Genes up-regulated in the HMEC cells (primary mammary epithelium) upon expression of the transcriptionally active isoform of TP63 [GeneID=8626] off adenoviral vector.,CGP,C2,539,636
Cohort,-0.00607471098273255,0.0064060592499031845,-0.9482758035408989,0.3433279295890357,LGP Offspring,Genes that are most strongly negatively correlated with systolic blood pressure (SBP).,CGP,C2,2,2
Cohort,-0.0013272361755722443,0.017550459835925215,-0.0756240114492861,0.9397363688543079,LGP Proband,Genes that are most strongly negatively correlated with systolic blood pressure (SBP).,CGP,C2,2,3
Cohort,-0.0022275827046446595,0.007231454707163433,-0.3080407462744709,0.7581319151170988,LonGen OPEL,Genes that are most strongly negatively correlated with systolic blood pressure (SBP).,CGP,C2,4,4
Cohort,-0.013515721963578179,0.022509755129201604,-0.6004384270730877,0.5484153233785372,LGP Offspring,Genes that are most strongly positively correlated with systolic blood pressure (SBP).,CGP,C2,15,26
Cohort,0.0076131078173064595,0.06491379045464178,0.11728028457413966,0.9066661848822043,LGP Proband,Genes that are most strongly positively correlated with systolic blood pressure (SBP).,CGP,C2,15,47
Cohort,-0.009817325989332916,0.01964437355457923,-0.49975256080611613,0.6173874288297836,LonGen OPEL,Genes that are most strongly positively correlated with systolic blood pressure (SBP).,CGP,C2,26,29
Cohort,0.04007849765377921,0.03649808635885205,1.098098603300027,0.272552397560765,LGP Offspring,Genes that correlated most highly with left ventricular mass (LVM) index.,CGP,C2,34,87
Cohort,-0.074610577860004,0.09466940730693292,-0.7881170906468752,0.4308521622650934,LGP Proband,Genes that correlated most highly with left ventricular mass (LVM) index.,CGP,C2,34,101
Cohort,-0.03309967305208657,0.02950679856825293,-1.121764293592301,0.2623009448887891,LonGen OPEL,Genes that correlated most highly with left ventricular mass (LVM) index.,CGP,C2,61,64
Cohort,-0.025553723580877076,0.027390117332991307,-0.9329541480312572,0.3511767397101264,LGP Offspring,Down-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that colocalize with previously mapped cardiac mass QTLs.,CGP,C2,28,46
Cohort,0.009940829071140297,0.07286315084036141,0.13643150147212313,0.891513097258547,LGP Proband,Down-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that colocalize with previously mapped cardiac mass QTLs.,CGP,C2,28,56
Cohort,4.6532194755778965e-4,0.02377701369394267,0.019570243494301098,0.9843911058487986,LonGen OPEL,Down-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that colocalize with previously mapped cardiac mass QTLs.,CGP,C2,39,43
Cohort,-0.0504031477190894,0.037764954398253406,-1.3346540071929889,0.18243895842015306,LGP Offspring,Up-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that colocalize with previously mapped cardiac mass QTLs.,CGP,C2,55,95
Cohort,0.025339951437486918,0.10858305781760039,0.23336929302592846,0.8155319212194885,LGP Proband,Up-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that colocalize with previously mapped cardiac mass QTLs.,CGP,C2,55,142
Cohort,0.038269661691055855,0.03339741002262509,1.1458871111601185,0.25218623269865065,LonGen OPEL,Up-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that colocalize with previously mapped cardiac mass QTLs.,CGP,C2,68,95
Cohort,-0.004790293858672696,0.013788073691603142,-0.3474229951055423,0.7283816996792964,LGP Offspring,Down-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that were identified as candidate genes for the regulation of left ventricle mass (LVM).,CGP,C2,7,6
Cohort,-0.20189201786443478,0.04323586559390405,-4.669549576287427,3.516848149519182e-6,LGP Proband,Down-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that were identified as candidate genes for the regulation of left ventricle mass (LVM).,CGP,C2,7,19
Cohort,0.0030960373679244806,0.012861283602864043,0.2407253788599322,0.8098299545437542,LonGen OPEL,Down-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that were identified as candidate genes for the regulation of left ventricle mass (LVM).,CGP,C2,9,12
Cohort,0.005036253276911335,0.013167790083018032,0.3824676156864308,0.702234761789313,LGP Offspring,Up-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that were identified as candidate genes for the regulation of left ventricle mass (LVM).,CGP,C2,5,12
Cohort,-0.04613405128770347,0.038190395751873434,-1.2080013935294283,0.22738915582881244,LGP Proband,Up-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that were identified as candidate genes for the regulation of left ventricle mass (LVM).,CGP,C2,5,17
Cohort,0.015788993102154446,0.013522949078524067,1.1675702548661597,0.2433297678004841,LonGen OPEL,Up-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that were identified as candidate genes for the regulation of left ventricle mass (LVM).,CGP,C2,8,18
Cohort,-0.06751415480280845,0.06659478434816402,-1.0138054423277036,0.31103831417328226,LGP Offspring,Genes down-regulated in BEC (blood endothelial cells) compared to LEC (lymphatic endothelial cells).,CGP,C2,148,291
Cohort,-0.06604877366616091,0.1764407143521865,-0.3743397543399394,0.7082467140438111,LGP Proband,Genes down-regulated in BEC (blood endothelial cells) compared to LEC (lymphatic endothelial cells).,CGP,C2,148,368
Cohort,0.04550108689557709,0.05828152582495437,0.7807120052456642,0.43520400368118217,LonGen OPEL,Genes down-regulated in BEC (blood endothelial cells) compared to LEC (lymphatic endothelial cells).,CGP,C2,250,296
Cohort,-0.0641981371656914,0.05383436015673335,-1.1925123095878718,0.2334788454867166,LGP Offspring,Genes up-regulated in LEC (lymphatic endothelial cells) compared to BEC (blood endothelial cells).,CGP,C2,108,194
Cohort,0.05497480303031241,0.17097925120770074,0.32152908988664697,0.74789003491216,LGP Proband,Genes up-regulated in LEC (lymphatic endothelial cells) compared to BEC (blood endothelial cells).,CGP,C2,108,335
Cohort,0.08019127675249507,0.05160554531051958,1.5539275143779638,0.12059918720622015,LonGen OPEL,Genes up-regulated in LEC (lymphatic endothelial cells) compared to BEC (blood endothelial cells).,CGP,C2,155,219
Cohort,-0.052522129679682394,0.03613417364308704,-1.4535306715041094,0.14654053819861362,LGP Offspring,Genes specific to BEC (blood endothelium cells) repressed in BEC by expression of PROX1 [GeneID=5629] off adenovirus vector.,CGP,C2,46,79
Cohort,-0.01339031780020233,0.09874431473159957,-0.1356059620910736,0.8921655144950174,LGP Proband,Genes specific to BEC (blood endothelium cells) repressed in BEC by expression of PROX1 [GeneID=5629] off adenovirus vector.,CGP,C2,46,107
Cohort,-0.0031758030459745844,0.035129967840557434,-0.0904015358166121,0.9279908785835234,LonGen OPEL,Genes specific to BEC (blood endothelium cells) repressed in BEC by expression of PROX1 [GeneID=5629] off adenovirus vector.,CGP,C2,87,97
Cohort,-0.050991896268926196,0.02618316855054429,-1.947506703418681,0.051887669221219616,LGP Offspring,Genes specific to LEC (lymphatic endothelium cells) induced in BEC (blood endothelium cells) by expression of PROX1 [GeneID=5629] off adenovirus vector.,CGP,C2,29,39
Cohort,0.046169543065908876,0.07809445233407117,0.5912013169438152,0.5545457333498459,LGP Proband,Genes specific to LEC (lymphatic endothelium cells) induced in BEC (blood endothelium cells) by expression of PROX1 [GeneID=5629] off adenovirus vector.,CGP,C2,29,69
Cohort,0.03640942259864879,0.026317320183022585,1.3834775860703576,0.16690633448549583,LonGen OPEL,Genes specific to LEC (lymphatic endothelium cells) induced in BEC (blood endothelium cells) by expression of PROX1 [GeneID=5629] off adenovirus vector.,CGP,C2,38,59
Cohort,0.026309591823076527,0.022829642969666653,1.1524311553200206,0.24955131058861976,LGP Offspring,"Genes down-regulated in small intestine upon loss of both APC and MBD2 [GeneID=324, 8932].",CGP,C2,13,38
Cohort,0.06512073837237409,0.05830491347940151,1.1168996656753556,0.2643588893197921,LGP Proband,"Genes down-regulated in small intestine upon loss of both APC and MBD2 [GeneID=324, 8932].",CGP,C2,13,41
Cohort,0.01806105315639884,0.018854262977297066,0.9579294177739351,0.3383892032194499,LonGen OPEL,"Genes down-regulated in small intestine upon loss of both APC and MBD2 [GeneID=324, 8932].",CGP,C2,20,34
Cohort,-0.005919258770111507,0.023449131940783494,-0.25242976094209013,0.8007856315782124,LGP Offspring,"Genes up-regulated in small intestine upon loss of both APC and MBD2 [GeneID=324, 8932].",CGP,C2,18,35
Cohort,-0.0743940414933306,0.06385694463981664,-1.1650109774739172,0.24434765870477673,LGP Proband,"Genes up-regulated in small intestine upon loss of both APC and MBD2 [GeneID=324, 8932].",CGP,C2,18,50
Cohort,-0.010807861728112652,0.01936228942559568,-0.5581913114998356,0.5768707159399971,LonGen OPEL,"Genes up-regulated in small intestine upon loss of both APC and MBD2 [GeneID=324, 8932].",CGP,C2,27,28
Cohort,0.15669136586764357,0.09669776713166855,1.6204238268944173,0.10560761118648798,LGP Offspring,Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were not affected by p38 inhibitor LY479754.,CGP,C2,275,649
Cohort,0.20231490701261304,0.2707404041087521,0.7472652915570975,0.45511406376064156,LGP Proband,Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were not affected by p38 inhibitor LY479754.,CGP,C2,275,894
Cohort,-0.06312251479783913,0.0823363539830798,-0.7666420936104467,0.44352164239166125,LonGen OPEL,Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were not affected by p38 inhibitor LY479754.,CGP,C2,511,585
Cohort,-0.0394603045833308,0.08327268155023684,-0.4738685466676745,0.6357466565741221,LGP Offspring,Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were blocked completely by p38 inhibitor LY479754.,CGP,C2,221,441
Cohort,-0.09938487579989667,0.22751840612531288,-0.43682125544232825,0.6623540535796733,LGP Proband,Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were blocked completely by p38 inhibitor LY479754.,CGP,C2,221,592
Cohort,-0.0575499733336518,0.06784908863561848,-0.8482055469119449,0.39657849135153267,LonGen OPEL,Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were blocked completely by p38 inhibitor LY479754.,CGP,C2,353,394
Cohort,0.022652711850968264,0.06807779872827657,0.3327474194837517,0.7394281142997401,LGP Offspring,Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were blocked partially by p38 inhibitor LY479754.,CGP,C2,131,288
Cohort,-0.36779353935630765,0.17301026028525898,-2.1258481361156867,0.03380913791943605,LGP Proband,Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were blocked partially by p38 inhibitor LY479754.,CGP,C2,131,376
Cohort,-0.09264139948802885,0.05578409978354367,-1.6607133546566275,0.09716483954863551,LonGen OPEL,Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were blocked partially by p38 inhibitor LY479754.,CGP,C2,224,240
Cohort,0.009070753307163493,0.005542757516085631,1.6365055265072066,0.102199267871738,LGP Offspring,Genes down-regulated in Calu-6 cells (lung cancer) at 1 h time point after TNF [GeneID=7124] treatment.,CGP,C2,0,3
Cohort,-0.029189043263307863,0.022313217657436588,-1.3081503399210417,0.1911827439969808,LGP Proband,Genes down-regulated in Calu-6 cells (lung cancer) at 1 h time point after TNF [GeneID=7124] treatment.,CGP,C2,0,6
Cohort,7.526324651641912e-4,0.0025843297788815094,0.2912292662161438,0.7709518504944973,LonGen OPEL,Genes down-regulated in Calu-6 cells (lung cancer) at 1 h time point after TNF [GeneID=7124] treatment.,CGP,C2,0,1
Cohort,0.0617062264013259,0.028419499213337456,2.1712636784383155,0.030258395102837257,LGP Offspring,Genes up-regulated in Calu-6 cells (lung cancer) at 1 h time point after TNF [GeneID=7124] treatment.,CGP,C2,14,59
Cohort,-0.07125723020201058,0.07476241834365391,-0.9531156399257802,0.34080763383776747,LGP Proband,Genes up-regulated in Calu-6 cells (lung cancer) at 1 h time point after TNF [GeneID=7124] treatment.,CGP,C2,14,78
Cohort,0.04101294945955508,0.024106430138104592,1.7013282026660042,0.08927190300936759,LonGen OPEL,Genes up-regulated in Calu-6 cells (lung cancer) at 1 h time point after TNF [GeneID=7124] treatment.,CGP,C2,29,55
Cohort,-0.05870824349792297,0.050350087408222347,-1.1660008258165546,0.24402532394215481,LGP Offspring,Down-regulated genes in angioimmunoblastic lymphoma (AILT) compared to normal T lymphocytes.,CGP,C2,95,161
Cohort,-0.2615426401168367,0.14555591802244416,-1.7968533582846684,0.0727206267854835,LGP Proband,Down-regulated genes in angioimmunoblastic lymphoma (AILT) compared to normal T lymphocytes.,CGP,C2,95,236
Cohort,0.05380828628704249,0.04250047422112555,1.2660631974853638,0.20586085500678394,LonGen OPEL,Down-regulated genes in angioimmunoblastic lymphoma (AILT) compared to normal T lymphocytes.,CGP,C2,116,164
Cohort,-0.03024610798871416,0.0861375796142618,-0.35113719382598385,0.7255948319917795,LGP Offspring,Up-regulated genes in angioimmunoblastic lymphoma (AILT) compared to normal T lymphocytes.,CGP,C2,255,497
Cohort,-0.7240509581715363,0.24312869165980353,-2.9780564080222196,0.0029848385395462697,LGP Proband,Up-regulated genes in angioimmunoblastic lymphoma (AILT) compared to normal T lymphocytes.,CGP,C2,255,699
Cohort,-0.01993281229868384,0.07436388994833211,-0.2680442391130039,0.7887347100634567,LonGen OPEL,Up-regulated genes in angioimmunoblastic lymphoma (AILT) compared to normal T lymphocytes.,CGP,C2,397,478
Cohort,-0.009573108368362808,0.019531861037981373,-0.4901278147405964,0.6242024872914282,LGP Offspring,"Down-regulated genes in U87 cells (glioblastoma multiforme, GBM) engineered to stably express LGI1 [GeneID=9211].",CGP,C2,14,25
Cohort,-0.058221684234264263,0.05619422666505344,-1.0360794638441333,0.30046538263072037,LGP Proband,"Down-regulated genes in U87 cells (glioblastoma multiforme, GBM) engineered to stably express LGI1 [GeneID=9211].",CGP,C2,14,38
Cohort,-0.0160712386832377,0.018879782095124933,-0.85124068711511,0.394891666954988,LonGen OPEL,"Down-regulated genes in U87 cells (glioblastoma multiforme, GBM) engineered to stably express LGI1 [GeneID=9211].",CGP,C2,26,26
Cohort,-0.007530159103509207,0.018323918813772926,-0.4109469802850941,0.6812416465025355,LGP Offspring,"Up-regulated genes in U87 cells (glioblastoma multiforme, GBM) engineered to stably express LGI1 [GeneID=9211].",CGP,C2,11,24
Cohort,0.012386543301009917,0.05299714318527044,0.23372096223580072,0.815258969097877,LGP Proband,"Up-regulated genes in U87 cells (glioblastoma multiforme, GBM) engineered to stably express LGI1 [GeneID=9211].",CGP,C2,11,36
Cohort,9.705748138195195e-4,0.015379679011479325,0.06310761187506493,0.9496966561367536,LonGen OPEL,"Up-regulated genes in U87 cells (glioblastoma multiforme, GBM) engineered to stably express LGI1 [GeneID=9211].",CGP,C2,15,20
Cohort,-0.2986440020696073,0.1353544583548356,-2.2063846710294794,0.027692588424410285,LGP Offspring,Genes up-regulated in erythroid progenitor cells from fetal livers of E13.5 embryos with KLF1 [GeneID=10661] knockout compared to those from the wild type embryos.,CGP,C2,615,1139
Cohort,-0.8604690263158362,0.37813766757106965,-2.2755443324199223,0.02312619314287547,LGP Proband,Genes up-regulated in erythroid progenitor cells from fetal livers of E13.5 embryos with KLF1 [GeneID=10661] knockout compared to those from the wild type embryos.,CGP,C2,615,1535
Cohort,0.0021969617567923535,0.1194992358854767,0.018384734768495375,0.9853365373947789,LonGen OPEL,Genes up-regulated in erythroid progenitor cells from fetal livers of E13.5 embryos with KLF1 [GeneID=10661] knockout compared to those from the wild type embryos.,CGP,C2,923,1105
Cohort,0.04792395316863333,0.020413752051662078,2.3476308053193673,0.019180657614880574,LGP Offspring,Genes down-regulated during later stages of renal maturation (days P14-P16) in kidney specific knockout of PKD1 [GeneID=5310].,CGP,C2,8,35
Cohort,0.10327959549628103,0.05396020273552015,1.9139956905368634,0.055962695378135786,LGP Proband,Genes down-regulated during later stages of renal maturation (days P14-P16) in kidney specific knockout of PKD1 [GeneID=5310].,CGP,C2,8,40
Cohort,0.04323616693155044,0.022190332172405732,1.9484236015770762,0.05171536369855171,LonGen OPEL,Genes down-regulated during later stages of renal maturation (days P14-P16) in kidney specific knockout of PKD1 [GeneID=5310].,CGP,C2,24,45
Cohort,-0.03462985800026295,0.041830337235539826,-0.8278646620816813,0.40803931077305067,LGP Offspring,Genes up-regulated during later stages of renal maturation (days P14-P16) in kidney specific knockout of PKD1 [GeneID=5310].,CGP,C2,59,103
Cohort,-0.057861739010589476,0.11275017346680465,-0.5131853657646465,0.6079575699780659,LGP Proband,Genes up-regulated during later stages of renal maturation (days P14-P16) in kidney specific knockout of PKD1 [GeneID=5310].,CGP,C2,59,139
Cohort,-0.06185636623449024,0.03589382296457363,-1.7233150755644235,0.08521989988771533,LonGen OPEL,Genes up-regulated during later stages of renal maturation (days P14-P16) in kidney specific knockout of PKD1 [GeneID=5310].,CGP,C2,96,91
Cohort,-0.003596492492311468,0.02170108888330485,-0.16572866512142315,0.8684200374734377,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblast) upon knockout of NFIC [GeneID=4782].,CGP,C2,17,31
Cohort,-0.034025584896275066,0.06350934522636151,-0.5357571358199376,0.59226925347941,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblast) upon knockout of NFIC [GeneID=4782].,CGP,C2,17,49
Cohort,-0.0024940543734192585,0.020191106647808998,-0.12352242088176461,0.9017246031589764,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblast) upon knockout of NFIC [GeneID=4782].,CGP,C2,29,34
Cohort,-0.008051719772422803,0.021766313989989433,-0.36991654977162775,0.711560529428281,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) upon knockout of NFIC [GeneID=4782].,CGP,C2,16,29
Cohort,-0.06546462915050603,0.064524804529018,-1.0145653230311666,0.3106073144654752,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) upon knockout of NFIC [GeneID=4782].,CGP,C2,16,48
Cohort,-0.03208236437774025,0.018259976542668043,-1.756977305133633,0.07930611399868506,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) upon knockout of NFIC [GeneID=4782].,CGP,C2,31,22
Cohort,0.005380091573682969,0.024250413249522956,0.22185566564680312,0.824493247880248,LGP Offspring,Genes down-regulated after 10 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,21,38
Cohort,-0.03756828112355331,0.06604132917138124,-0.5688601606739524,0.5696041951753993,LGP Proband,Genes down-regulated after 10 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,21,48
Cohort,-0.023953492946830905,0.018009225724206747,-1.3300678948475997,0.18387686697000366,LonGen OPEL,Genes down-regulated after 10 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,26,23
Cohort,-0.019518729003318178,0.04649922759025992,-0.41976458566822983,0.6747908108401814,LGP Offspring,Genes up-regulated after 10 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,73,147
Cohort,-0.11126570114933891,0.1267484776780682,-0.8778464498165066,0.38027986741842323,LGP Proband,Genes up-regulated after 10 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,73,206
Cohort,-0.08070650281585867,0.039125461571402634,-2.062761679336921,0.03945914907425069,LonGen OPEL,Genes up-regulated after 10 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,132,120
Cohort,-0.06725058923433885,0.05760866042891457,-1.167369432540821,0.2434728044138912,LGP Offspring,Genes down-regulated after 1 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,118,215
Cohort,-0.05274234382052156,0.16270530920174725,-0.3241587141764589,0.7458991558320516,LGP Proband,Genes down-regulated after 1 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,118,306
Cohort,-0.1353325415566132,0.048411633459455025,-2.7954549740602093,0.0053074617978964705,LonGen OPEL,Genes down-regulated after 1 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,201,180
Cohort,-0.021112052567127317,0.033873744169670525,-0.6232571298105977,0.5333257815819809,LGP Offspring,Genes up-regulated after 1 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,42,71
Cohort,-0.14181684489033944,0.09419338736567064,-1.5055923654150851,0.13255047670298797,LGP Proband,Genes up-regulated after 1 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,42,110
Cohort,0.013685834028282428,0.027772664556074782,0.49278073411536927,0.6223034249301469,LonGen OPEL,Genes up-regulated after 1 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.,CGP,C2,51,72
Cohort,-0.08871017933034585,0.08312490641215789,-1.0671913287997525,0.2862664168054327,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 10 h.,CGP,C2,220,447
Cohort,0.24003859029833552,0.2301948845655825,1.042762486887273,0.29736047554582934,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 10 h.,CGP,C2,220,632
Cohort,0.01925582417742389,0.07225971007294862,0.26648078380032914,0.7899379705087364,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 10 h.,CGP,C2,338,408
Cohort,-0.11044176897485272,0.07071099411358235,-1.5618754955905616,0.11878532095924331,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 10 h.,CGP,C2,170,317
Cohort,-0.008354491501872093,0.19338385056459956,-0.04320159867269417,0.9655511714985487,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 10 h.,CGP,C2,170,471
Cohort,-0.06660368951896285,0.06418137734107932,-1.037741667104005,0.2997054682478874,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 10 h.,CGP,C2,285,317
Cohort,-0.008873513468227397,0.013397280401678953,-0.6623369222842693,0.5079810557794188,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 1 h.,CGP,C2,7,11
Cohort,-0.006209218822530388,0.04142094058356749,-0.14990530719608305,0.880875568522367,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 1 h.,CGP,C2,7,19
Cohort,-0.0050986691706411446,0.010306431617667408,-0.49470751466501217,0.6209431063998769,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 1 h.,CGP,C2,8,6
Cohort,0.021220917544517152,0.020673248922972263,1.0264916570968348,0.3050270533713785,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 1 h.,CGP,C2,10,32
Cohort,-0.017750038571921013,0.05644071599466576,-0.31448996099905213,0.7532275962248657,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 1 h.,CGP,C2,10,38
Cohort,0.004160685031319267,0.013750434203776361,0.3025857198150582,0.7622846495465406,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 1 h.,CGP,C2,12,17
Cohort,-0.013719464683910113,0.020041720456854043,-0.6845452571522227,0.49386554099593305,LGP Offspring,"Down-regulated genes in MM1.S cells (multiple myeloma) treated with adaphostin [PubChem=387042], a tyrosine kinase inhibitor with anticancer properties.",CGP,C2,17,25
Cohort,-0.06818425949821365,0.060016811865734425,-1.136085996216375,0.2562469246236992,LGP Proband,"Down-regulated genes in MM1.S cells (multiple myeloma) treated with adaphostin [PubChem=387042], a tyrosine kinase inhibitor with anticancer properties.",CGP,C2,17,44
Cohort,0.024421560182227388,0.018136979845227705,1.3465064410188068,0.17852252194698545,LonGen OPEL,"Down-regulated genes in MM1.S cells (multiple myeloma) treated with adaphostin [PubChem=387042], a tyrosine kinase inhibitor with anticancer properties.",CGP,C2,18,30
Cohort,-0.009599862153121275,0.05408920660885935,-0.1774820293176365,0.8591829457482713,LGP Offspring,"Up-regulated genes in MM1.S cells (multiple myeloma) treated with adaphostin [PubChem=387042], a tyrosine kinase inhibitor with anticancer properties.",CGP,C2,86,179
Cohort,0.015420008068248376,0.13931173639335448,0.11068707107855666,0.9118911288888065,LGP Proband,"Up-regulated genes in MM1.S cells (multiple myeloma) treated with adaphostin [PubChem=387042], a tyrosine kinase inhibitor with anticancer properties.",CGP,C2,86,205
Cohort,0.07167054899643595,0.042702371607652716,1.6783739707700878,0.09366662225260665,LonGen OPEL,"Up-regulated genes in MM1.S cells (multiple myeloma) treated with adaphostin [PubChem=387042], a tyrosine kinase inhibitor with anticancer properties.",CGP,C2,115,170
Cohort,-0.04415850317876178,0.04276657885876254,-1.0325470111742185,0.30218519433381597,LGP Offspring,Top down-regulated marker genes for medulloblastoma classification: desmoplastic vs classic morphology.,CGP,C2,66,116
Cohort,-0.01822242680072194,0.10936686620909418,-0.16661743572210622,0.8677114598601426,LGP Proband,Top down-regulated marker genes for medulloblastoma classification: desmoplastic vs classic morphology.,CGP,C2,66,134
Cohort,-0.06650025887814333,0.03130313350661235,-2.124396232220524,0.033944661873673364,LonGen OPEL,Top down-regulated marker genes for medulloblastoma classification: desmoplastic vs classic morphology.,CGP,C2,81,72
Cohort,-0.05917920707048454,0.044681551181708,-1.3244662619213559,0.18579583342729217,LGP Offspring,Top up-regulated marker genes for medulloblastoma classification: desmoplastic vs classic morphology.,CGP,C2,66,121
Cohort,-0.05586516936084732,0.11436282440969871,-0.4884906406360981,0.625330767786562,LGP Proband,Top up-regulated marker genes for medulloblastoma classification: desmoplastic vs classic morphology.,CGP,C2,66,139
Cohort,-0.0229990898109988,0.03470025375329988,-0.6627931304050381,0.5076549223769118,LonGen OPEL,Top up-regulated marker genes for medulloblastoma classification: desmoplastic vs classic morphology.,CGP,C2,86,96
Cohort,0.03208910746386785,0.03185650634335685,1.0073015263508174,0.3141503112743252,LGP Offspring,Top marker genes in medulloblastoma associated with poor response to treatment (poor outcome).,CGP,C2,26,73
Cohort,0.0035208397914278057,0.0914891170129828,0.03848370064527106,0.9693112365840297,LGP Proband,Top marker genes in medulloblastoma associated with poor response to treatment (poor outcome).,CGP,C2,26,112
Cohort,-0.009564001235322177,0.025038849687475086,-0.3819664782806007,0.7025881775907472,LonGen OPEL,Top marker genes in medulloblastoma associated with poor response to treatment (poor outcome).,CGP,C2,44,47
Cohort,0.018041829631517195,0.03793852506986679,0.47555432369317846,0.6345455515520424,LGP Offspring,Top marker genes in medulloblastoma associated with good response to treatment (good outcome).,CGP,C2,42,99
Cohort,0.025767073604349298,0.1057153915641218,0.24374003844766776,0.8074921048030327,LGP Proband,Top marker genes in medulloblastoma associated with good response to treatment (good outcome).,CGP,C2,42,126
Cohort,-0.00999157670738751,0.0325370565088481,-0.30708299334546163,0.758860519301386,LonGen OPEL,Top marker genes in medulloblastoma associated with good response to treatment (good outcome).,CGP,C2,72,86
Cohort,-0.09543411248352636,0.06103404133747493,-1.563621061168856,0.11837457326747111,LGP Offspring,Genes down-regulated in atypical ductal hyperplastic tissues from patients with (ADHC) breast cancer vs those without the cancer (ADH).,CGP,C2,139,247
Cohort,0.10131006548254745,0.161954909902769,0.6255448849520512,0.531784631710025,LGP Proband,Genes down-regulated in atypical ductal hyperplastic tissues from patients with (ADHC) breast cancer vs those without the cancer (ADH).,CGP,C2,139,334
Cohort,-0.033264299152893535,0.05302427918134295,-0.627340902440742,0.5306157007620804,LonGen OPEL,Genes down-regulated in atypical ductal hyperplastic tissues from patients with (ADHC) breast cancer vs those without the cancer (ADH).,CGP,C2,197,226
Cohort,-0.1275727550432499,0.0925680117585187,-1.3781516165222145,0.1686124524541117,LGP Offspring,Genes up-regulated in atypical ductal hyperplastic tissues from patients with (ADHC) breast cancer vs those without the cancer (ADH).,CGP,C2,276,496
Cohort,-0.7510058813262859,0.24647577282858935,-3.04697647443252,0.0023844047561554504,LGP Proband,Genes up-regulated in atypical ductal hyperplastic tissues from patients with (ADHC) breast cancer vs those without the cancer (ADH).,CGP,C2,276,668
Cohort,-0.20606461949852228,0.07704650885984642,-2.6745484324717403,0.007636526514300345,LonGen OPEL,Genes up-regulated in atypical ductal hyperplastic tissues from patients with (ADHC) breast cancer vs those without the cancer (ADH).,CGP,C2,427,432
Cohort,-0.03195944906302822,0.027510315691500552,-1.1617260020357474,0.24575679215389373,LGP Offspring,Genes corresponding to the histamine [PubChem=774] response network.,CGP,C2,29,47
Cohort,0.002710869630136367,0.07801682604501038,0.03474724322381918,0.9722896034090917,LGP Proband,Genes corresponding to the histamine [PubChem=774] response network.,CGP,C2,29,74
Cohort,0.01583631107058716,0.026097143223186986,0.6068216331248393,0.5441423247037522,LonGen OPEL,Genes corresponding to the histamine [PubChem=774] response network.,CGP,C2,46,58
Cohort,-0.002434578189274794,0.018728610745352193,-0.12999246032592,0.8966110622212596,LGP Offspring,Genes gradually down-regulated by histamine [PubChem=774] in B16-F10 melanoma tumors.,CGP,C2,12,24
Cohort,0.03675202016943254,0.05633162299267517,0.6524225331517862,0.5143084088462884,LGP Proband,Genes gradually down-regulated by histamine [PubChem=774] in B16-F10 melanoma tumors.,CGP,C2,12,42
Cohort,-0.011177560428184607,0.01763121050951445,-0.6339644360863813,0.5262861620876831,LonGen OPEL,Genes gradually down-regulated by histamine [PubChem=774] in B16-F10 melanoma tumors.,CGP,C2,24,25
Cohort,-0.0030006810601880445,0.021277285822918324,-0.1410274357905148,0.8878902818704549,LGP Offspring,Genes gradually up-regulated by histamine [PubChem=774] in B16-F10 melanoma tumors.,CGP,C2,13,31
Cohort,0.0849299792504974,0.05640079710419152,1.5058294139638266,0.13248960479177568,LGP Proband,Genes gradually up-regulated by histamine [PubChem=774] in B16-F10 melanoma tumors.,CGP,C2,13,37
Cohort,0.001462081705736933,0.01760862414435106,0.08303213776108548,0.9338468608350099,LonGen OPEL,Genes gradually up-regulated by histamine [PubChem=774] in B16-F10 melanoma tumors.,CGP,C2,19,21
Cohort,-0.018395428135794575,0.03425169773549361,-0.53706617049619,0.5913986286285318,LGP Offspring,Genes down-regulated in ACC3 cells (adenoid cystic carcinoma) after knockdown of SOX4 [GeneID=6659] by RNAi.,CGP,C2,39,76
Cohort,-0.16816584982540642,0.09223361510696694,-1.8232598779780873,0.06862187625461888,LGP Proband,Genes down-regulated in ACC3 cells (adenoid cystic carcinoma) after knockdown of SOX4 [GeneID=6659] by RNAi.,CGP,C2,39,94
Cohort,-0.058403928989718655,0.02738563986145423,-2.1326479602152077,0.033259014225685064,LonGen OPEL,Genes down-regulated in ACC3 cells (adenoid cystic carcinoma) after knockdown of SOX4 [GeneID=6659] by RNAi.,CGP,C2,64,55
Cohort,-0.010640013261300277,0.03191924729275215,-0.33334160933413637,0.7389797971591451,LGP Offspring,Genes up-regulated in ACC3 cells (adenoid cystic carcinoma) after knockdown of SOX4 [GeneID=6659] by RNAi.,CGP,C2,36,69
Cohort,-0.002136012187050676,0.09228556071164945,-0.023145681410819463,0.9815396034339234,LGP Proband,Genes up-regulated in ACC3 cells (adenoid cystic carcinoma) after knockdown of SOX4 [GeneID=6659] by RNAi.,CGP,C2,36,109
Cohort,-0.00920048557381913,0.02971767263029501,-0.30959643738856935,0.7569488922997336,LonGen OPEL,Genes up-regulated in ACC3 cells (adenoid cystic carcinoma) after knockdown of SOX4 [GeneID=6659] by RNAi.,CGP,C2,66,72
Cohort,0.06508635565121168,0.06036917005208551,1.0781389837736093,0.2813562970356271,LGP Offspring,"Genes down-regulated in polysomal and total RNA samples from SW480 cells (primary colorectal carcinoma, CRC) compared to the SW620 cells (lymph node metastasis from the same individual).",CGP,C2,93,233
Cohort,-0.10212311796582095,0.15884658166789736,-0.6429040958484779,0.5204630398732525,LGP Proband,"Genes down-regulated in polysomal and total RNA samples from SW480 cells (primary colorectal carcinoma, CRC) compared to the SW620 cells (lymph node metastasis from the same individual).",CGP,C2,93,291
Cohort,0.07819450608989924,0.049628474212755055,1.5755976247563621,0.11551589436980064,LonGen OPEL,"Genes down-regulated in polysomal and total RNA samples from SW480 cells (primary colorectal carcinoma, CRC) compared to the SW620 cells (lymph node metastasis from the same individual).",CGP,C2,142,202
Cohort,0.014947607413488946,0.07112658555741798,0.2101549975490145,0.8336100260139339,LGP Offspring,"Genes up-regulated in polysomal and total RNA samples from SW480 cells (primary colorectal carcinoma, CRC) compared to the SW620 cells (lymph node metastasis from the same individual).",CGP,C2,145,309
Cohort,-0.2082956207579506,0.19426350036585752,-1.072232407866976,0.2839258214295167,LGP Proband,"Genes up-regulated in polysomal and total RNA samples from SW480 cells (primary colorectal carcinoma, CRC) compared to the SW620 cells (lymph node metastasis from the same individual).",CGP,C2,145,421
Cohort,0.02262383579360847,0.05921405714013832,0.3820686655546336,0.702512411712124,LonGen OPEL,"Genes up-regulated in polysomal and total RNA samples from SW480 cells (primary colorectal carcinoma, CRC) compared to the SW620 cells (lymph node metastasis from the same individual).",CGP,C2,237,299
Cohort,0.11419816228783894,0.055297306582604476,2.065166810923185,0.03928791320732365,LGP Offspring,Genes down-regulated in OV-90 cells (ovarian cancer) exposed to ascites which inhibited invasion.,CGP,C2,80,211
Cohort,-0.20025463069275976,0.14817422037862749,-1.3514809133535641,0.17690788551547104,LGP Proband,Genes down-regulated in OV-90 cells (ovarian cancer) exposed to ascites which inhibited invasion.,CGP,C2,80,267
Cohort,0.028167314683573103,0.04470563363275492,0.6300618600993383,0.5288349297775856,LonGen OPEL,Genes down-regulated in OV-90 cells (ovarian cancer) exposed to ascites which inhibited invasion.,CGP,C2,130,168
Cohort,-0.058076948570777484,0.040516677125731856,-1.4334084799341362,0.15220346964471104,LGP Offspring,Genes up-regulated in OV-90 cells (ovarian cancer) exposed to ascites which inhibited invasion.,CGP,C2,67,105
Cohort,-0.06016367462261487,0.10921650716091244,-0.55086612991545,0.5818729761031431,LGP Proband,Genes up-regulated in OV-90 cells (ovarian cancer) exposed to ascites which inhibited invasion.,CGP,C2,67,143
Cohort,-0.00376460008729019,0.03744847583215521,-0.10052745815779528,0.9199508984728137,LonGen OPEL,Genes up-regulated in OV-90 cells (ovarian cancer) exposed to ascites which inhibited invasion.,CGP,C2,95,112
Cohort,-0.35648168985695833,0.1804739350296859,-1.9752530458114141,0.04864582205361296,LGP Offspring,"Genes constituting the ATM-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of ATM [GeneID=472] across a compendium of normal tissues.",CGP,C2,1233,2390
Cohort,-0.38903897078898536,0.5274563036207404,-0.7375757349346573,0.46097976704173504,LGP Proband,"Genes constituting the ATM-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of ATM [GeneID=472] across a compendium of normal tissues.",CGP,C2,1233,3398
Cohort,-0.007329979220497547,0.17376883174630506,-0.0421823588662839,0.9663639039102666,LonGen OPEL,"Genes constituting the ATM-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of ATM [GeneID=472] across a compendium of normal tissues.",CGP,C2,1950,2325
Cohort,-0.0020341036213418315,0.05524158982807382,-0.03682196018746909,0.9706378348289337,LGP Offspring,Genes constituting the BRCA-centered network (BCN).,CGP,C2,101,216
Cohort,0.09564618959282889,0.1569262902882727,0.6094975508382144,0.5423607004052314,LGP Proband,Genes constituting the BRCA-centered network (BCN).,CGP,C2,101,304
Cohort,0.061206577090996986,0.05108045811762574,1.1982386091771786,0.23118077531465317,LonGen OPEL,Genes constituting the BRCA-centered network (BCN).,CGP,C2,175,220
Cohort,-0.16820220698502322,0.20778485712880682,-0.8095017572948248,0.41851142814386166,LGP Offspring,"Genes constituting the BRCA1-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of BRCA1 [GeneID=672] across a compendium of normal tissues.",CGP,C2,1296,2610
Cohort,-0.8233039986447785,0.5639244270594449,-1.4599544888272622,0.14467915187012492,LGP Proband,"Genes constituting the BRCA1-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of BRCA1 [GeneID=672] across a compendium of normal tissues.",CGP,C2,1296,3642
Cohort,-0.043862516238951495,0.1799761608729977,-0.24371292301264053,0.8075159604098078,LonGen OPEL,"Genes constituting the BRCA1-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of BRCA1 [GeneID=672] across a compendium of normal tissues.",CGP,C2,2055,2436
Cohort,-0.02409645349315635,0.11018671264688007,-0.2186874706969365,0.8269595147993908,LGP Offspring,"Genes constituting the BRCA2-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of BRCA2 [GeneID=675] across a compendium of normal tissues.",CGP,C2,365,754
Cohort,-0.1861978045621671,0.30018372571300883,-0.6202794775762822,0.5352432509692611,LGP Proband,"Genes constituting the BRCA2-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of BRCA2 [GeneID=675] across a compendium of normal tissues.",CGP,C2,365,1083
Cohort,-0.014755537445573745,0.08841722433721817,-0.1668853275612564,0.8675026617533088,LonGen OPEL,"Genes constituting the BRCA2-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of BRCA2 [GeneID=675] across a compendium of normal tissues.",CGP,C2,609,716
Cohort,0.045222837231130956,0.059222866179388496,0.763604333065359,0.4453694825910256,LGP Offspring,"Genes constituting the LIT-Int network of proteins interacting with breast cancer reference proteins BRCA1, BRCA2, ATM, and CHEK2 [GeneID=672;675;472;11200]; the interactions were manually curated from the literature.",CGP,C2,107,240
Cohort,0.06006781995346606,0.16682023533159848,0.3600751421676494,0.7188821060346728,LGP Proband,"Genes constituting the LIT-Int network of proteins interacting with breast cancer reference proteins BRCA1, BRCA2, ATM, and CHEK2 [GeneID=672;675;472;11200]; the interactions were manually curated from the literature.",CGP,C2,107,321
Cohort,0.018538325501890225,0.055042047265070886,0.3368029792317419,0.7363542042183424,LonGen OPEL,"Genes constituting the LIT-Int network of proteins interacting with breast cancer reference proteins BRCA1, BRCA2, ATM, and CHEK2 [GeneID=672;675;472;11200]; the interactions were manually curated from the literature.",CGP,C2,201,235
Cohort,-6.668234438659421e-4,0.008499580265636393,-0.07845369100894241,0.937490382219452,LGP Offspring,The XPRSS-Int network genes down-regulated in breast tumors from patients with germline mutations in BRCA1 [GeneID=672] compared to those with the wild type allele.,CGP,C2,2,5
Cohort,0.0018148921921319423,0.01758377014360022,0.10321405348855117,0.9178178992253623,LGP Proband,The XPRSS-Int network genes down-regulated in breast tumors from patients with germline mutations in BRCA1 [GeneID=672] compared to those with the wild type allele.,CGP,C2,2,3
Cohort,-0.0021276779596832844,0.0072994710398775866,-0.2914838552080845,0.7707572303573142,LonGen OPEL,The XPRSS-Int network genes down-regulated in breast tumors from patients with germline mutations in BRCA1 [GeneID=672] compared to those with the wild type allele.,CGP,C2,4,4
Cohort,-0.04506958046722076,0.04050366933689405,-1.1127283331381461,0.2662206539005052,LGP Offspring,The XPRSS-Int network genes up-regulated in breast tumors from patients with germline mutations in BRCA1 [GeneID=672] compared to those with the wild type allele.,CGP,C2,57,101
Cohort,-0.0684014782393977,0.11639122128349909,-0.5876858880343672,0.5569022302020802,LGP Proband,The XPRSS-Int network genes up-regulated in breast tumors from patients with germline mutations in BRCA1 [GeneID=672] compared to those with the wild type allele.,CGP,C2,57,153
Cohort,-0.0061514443719422,0.032675153119754274,-0.1882606134819686,0.8507203419944491,LonGen OPEL,The XPRSS-Int network genes up-regulated in breast tumors from patients with germline mutations in BRCA1 [GeneID=672] compared to those with the wild type allele.,CGP,C2,75,85
Cohort,-0.14231536292837682,0.13185989510531979,-1.0792922504200841,0.2808424019429289,LGP Offspring,"Genes constituting the CHEK2-PCC network of transcripts whose expression positively correlates (Pearson correlation coefficient, PCC >= 0.4) with that of CHEK2 [GeneID=11200].",CGP,C2,573,1116
Cohort,-0.2677743758599053,0.3641711601422388,-0.7352981377089756,0.4623646605397387,LGP Proband,"Genes constituting the CHEK2-PCC network of transcripts whose expression positively correlates (Pearson correlation coefficient, PCC >= 0.4) with that of CHEK2 [GeneID=11200].",CGP,C2,573,1642
Cohort,0.0724767428060925,0.1199153318158997,0.6043993016452858,0.5457504270375055,LonGen OPEL,"Genes constituting the CHEK2-PCC network of transcripts whose expression positively correlates (Pearson correlation coefficient, PCC >= 0.4) with that of CHEK2 [GeneID=11200].",CGP,C2,928,1138
Cohort,0.018612992508776745,0.06572160658476671,0.28320963950827943,0.7771028449007668,LGP Offspring,"Genes constituting the XPRSS-Int network: intersection of genes whose expression correlates with BRCA1, BRCA2, ATM, and CHEK2 [GeneID=672;675;472;11200] in a compendium of normal tissues.",CGP,C2,135,298
Cohort,0.056576920471673106,0.1805539204779967,0.3133519356538585,0.7540916451362412,LGP Proband,"Genes constituting the XPRSS-Int network: intersection of genes whose expression correlates with BRCA1, BRCA2, ATM, and CHEK2 [GeneID=672;675;472;11200] in a compendium of normal tissues.",CGP,C2,135,413
Cohort,0.0652587281321632,0.057789139760602015,1.1292559190620381,0.25913008477660976,LonGen OPEL,"Genes constituting the XPRSS-Int network: intersection of genes whose expression correlates with BRCA1, BRCA2, ATM, and CHEK2 [GeneID=672;675;472;11200] in a compendium of normal tissues.",CGP,C2,229,283
Cohort,0.16226024753334806,0.07552000523075976,2.148573044156232,0.03202280936157766,LGP Offspring,"Genes down-regulated in HEK-293 cells (fibroblast) upon knockdown of both CTBP1 and SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,161,415
Cohort,0.14573035306566406,0.19600427300087858,0.7435060003258747,0.45738478769128366,LGP Proband,"Genes down-regulated in HEK-293 cells (fibroblast) upon knockdown of both CTBP1 and SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,161,488
Cohort,-0.030931439920213473,0.06292009834162454,-0.4915987217990551,0.6231385730263532,LonGen OPEL,"Genes down-regulated in HEK-293 cells (fibroblast) upon knockdown of both CTBP1 and SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,274,306
Cohort,-0.04041224102757052,0.04407669503791031,-0.9168618698115182,0.3595420004244372,LGP Offspring,"Genes up-regulated in HEK-293 cells (fibroblast) upon knockdown of both CTBP1 and SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,72,126
Cohort,-0.21727240562295635,0.13733724297429642,-1.5820355856686328,0.11402057818640075,LGP Proband,"Genes up-regulated in HEK-293 cells (fibroblast) upon knockdown of both CTBP1 and SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,72,214
Cohort,-0.029646935161887652,0.0429280174652766,-0.6906197144060593,0.4900058817205041,LonGen OPEL,"Genes up-regulated in HEK-293 cells (fibroblast) upon knockdown of both CTBP1 and SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,117,128
Cohort,-0.053022620231520684,0.10765998731318493,-0.49250071038255727,0.6225253340998915,LGP Offspring,"Genes down-regulated in HEK-293 cells (fibroblast) upon knockdown of CTBP1 but not of SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,354,721
Cohort,-0.45804837929579,0.2978196663825021,-1.5380058169412476,0.12442648206510695,LGP Proband,"Genes down-regulated in HEK-293 cells (fibroblast) upon knockdown of CTBP1 but not of SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,354,1050
Cohort,-0.18322057770169603,0.0906697162734753,-2.02074722666024,0.04364030046733616,LonGen OPEL,"Genes down-regulated in HEK-293 cells (fibroblast) upon knockdown of CTBP1 but not of SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,629,679
Cohort,-0.014988530748626275,0.10091141053293132,-0.14853157506637898,0.8819675642395048,LGP Offspring,"Genes up-regulated in HEK-293 cells (fibroblast) upon knockdown of CTBP1 but not of SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,280,579
Cohort,0.3331874812049218,0.2714241564536903,1.2275527924935061,0.21996125635403446,LGP Proband,"Genes up-regulated in HEK-293 cells (fibroblast) upon knockdown of CTBP1 but not of SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,280,818
Cohort,0.16770957011429333,0.08495600263937972,1.974075579169903,0.04871850534193553,LonGen OPEL,"Genes up-regulated in HEK-293 cells (fibroblast) upon knockdown of CTBP1 but not of SATB1 [GeneID=1487, 6304] by RNAi.",CGP,C2,475,626
Cohort,-0.02340555923717217,0.03502408989607712,-0.6682703049992376,0.5041891710164947,LGP Offspring,Down-regulated genes in head and neck cancer compared to cervical carcinoma samples.,CGP,C2,41,82
Cohort,-0.05728083727680711,0.101138532556482,-0.5663601777573543,0.5713013274809882,LGP Proband,Down-regulated genes in head and neck cancer compared to cervical carcinoma samples.,CGP,C2,41,119
Cohort,0.01944726429132196,0.030451594165934192,0.6386287754050448,0.5232481579528441,LonGen OPEL,Down-regulated genes in head and neck cancer compared to cervical carcinoma samples.,CGP,C2,63,78
Cohort,-0.09700984969498591,0.07147553149972097,-1.3572455868392477,0.17515615152056432,LGP Offspring,Up-regulated genes in head and neck cancer compared to cervical carcinoma samples.,CGP,C2,184,334
Cohort,-0.09916898347934547,0.21249618999956615,-0.46668593671984393,0.6408464752925662,LGP Proband,Up-regulated genes in head and neck cancer compared to cervical carcinoma samples.,CGP,C2,184,507
Cohort,-0.0523008972576664,0.06295193377516155,-0.8308068413666803,0.4063318799189143,LonGen OPEL,Up-regulated genes in head and neck cancer compared to cervical carcinoma samples.,CGP,C2,295,334
Cohort,-0.0043068979434267305,0.009568255034100187,-0.4501236566205049,0.652765590722692,LGP Offspring,Down-regulated genes in cervical carcinoma and head and neck tumors positive for human papilloma virus (HPV) compared to those negative for HPV.,CGP,C2,3,6
Cohort,0.005230300249820445,0.02931404025779493,0.17842304246783755,0.858434085056141,LGP Proband,Down-regulated genes in cervical carcinoma and head and neck tumors positive for human papilloma virus (HPV) compared to those negative for HPV.,CGP,C2,3,11
Cohort,-0.008824057883233491,0.011463645791748094,-0.7697427191605428,0.4416808846816128,LonGen OPEL,Down-regulated genes in cervical carcinoma and head and neck tumors positive for human papilloma virus (HPV) compared to those negative for HPV.,CGP,C2,10,8
Cohort,-0.05672093808937273,0.0522998108313684,-1.0845342877483721,0.2785146052699729,LGP Offspring,Up-regulated genes in cervical carcinoma and head and neck tumors positive for human papilloma virus (HPV) compared to those negative for HPV.,CGP,C2,98,186
Cohort,-0.04978466728405277,0.1485626024860937,-0.3351090143208342,0.7376271216065665,LGP Proband,Up-regulated genes in cervical carcinoma and head and neck tumors positive for human papilloma virus (HPV) compared to those negative for HPV.,CGP,C2,98,274
Cohort,-0.045921549489605244,0.04942317224523693,-0.9291501820592031,0.35309293283443677,LonGen OPEL,Up-regulated genes in cervical carcinoma and head and neck tumors positive for human papilloma virus (HPV) compared to those negative for HPV.,CGP,C2,175,189
Cohort,-0.11295637258682367,0.05974753316093378,-1.8905612769412337,0.0591103624476388,LGP Offspring,Genes up-regulated by hypoxia in TRAMP-C cells (prostatic cancer).,CGP,C2,144,250
Cohort,-0.33382061759519516,0.17155050677020459,-1.9459028357307897,0.05200199793023514,LGP Proband,Genes up-regulated by hypoxia in TRAMP-C cells (prostatic cancer).,CGP,C2,144,381
Cohort,-0.061342543396975424,0.055178307621231416,-1.1117148394267196,0.26659643443905756,LonGen OPEL,Genes up-regulated by hypoxia in TRAMP-C cells (prostatic cancer).,CGP,C2,224,238
Cohort,0.03705029651293477,0.037937572012627756,0.9766122223267832,0.3291105171674149,LGP Offspring,"Genes up-regulated by hypoxia in TRAMP-C cells (prostatic cancer) expressing HIF1A and FOXA2 [GeneID=3091,3170] off plasmid vectors.",CGP,C2,41,94
Cohort,-0.012703777069715141,0.10576019354453668,-0.12011870103438732,0.9044180482807838,LGP Proband,"Genes up-regulated by hypoxia in TRAMP-C cells (prostatic cancer) expressing HIF1A and FOXA2 [GeneID=3091,3170] off plasmid vectors.",CGP,C2,41,132
Cohort,0.05553824928552877,0.03339129732435593,1.663255211261847,0.09665499396379816,LonGen OPEL,"Genes up-regulated by hypoxia in TRAMP-C cells (prostatic cancer) expressing HIF1A and FOXA2 [GeneID=3091,3170] off plasmid vectors.",CGP,C2,65,98
Cohort,-0.04638926038332605,0.06187779109173381,-0.7496916028329774,0.4537012820440983,LGP Offspring,Down-regulated genes that best disciminate plasmablastic plasmacytoma from plasmacytic plasmacytoma tumors.,CGP,C2,118,231
Cohort,-0.15344118438911433,0.16716602501407507,-0.9178969493124866,0.358938186100047,LGP Proband,Down-regulated genes that best disciminate plasmablastic plasmacytoma from plasmacytic plasmacytoma tumors.,CGP,C2,118,326
Cohort,0.062351930425436956,0.050016639936486966,1.2466237337136963,0.2129022086741743,LonGen OPEL,Down-regulated genes that best disciminate plasmablastic plasmacytoma from plasmacytic plasmacytoma tumors.,CGP,C2,159,217
Cohort,-0.24452158222258447,0.07812764801176916,-3.129770170295536,0.0018247317620000989,LGP Offspring,Up-regulated genes that best disciminate plasmablastic plasmacytoma from plasmacytic plasmacytoma tumors.,CGP,C2,238,407
Cohort,-0.20365091885807857,0.22540462298505845,-0.903490426066275,0.36652655084161856,LGP Proband,Up-regulated genes that best disciminate plasmablastic plasmacytoma from plasmacytic plasmacytoma tumors.,CGP,C2,238,572
Cohort,-0.10899253255007806,0.07085910861979383,-1.5381583916740382,0.12440728563841265,LonGen OPEL,Up-regulated genes that best disciminate plasmablastic plasmacytoma from plasmacytic plasmacytoma tumors.,CGP,C2,364,384
Cohort,0.022821980460396865,0.045422452416664996,0.5024383151100783,0.6155228607463115,LGP Offspring,"Genes up-regulated in the mouse embryonic brain or immature neurons at 2 h or 6 h, respectively after exposure to 1 Gy dose of ionizing radiation.",CGP,C2,72,153
Cohort,-0.07981724761895644,0.12886208882038183,-0.6194005416923827,0.5358216904645507,LGP Proband,"Genes up-regulated in the mouse embryonic brain or immature neurons at 2 h or 6 h, respectively after exposure to 1 Gy dose of ionizing radiation.",CGP,C2,72,196
Cohort,0.03180972835166961,0.042449741965401855,0.7493503347463394,0.4538674672603048,LonGen OPEL,"Genes up-regulated in the mouse embryonic brain or immature neurons at 2 h or 6 h, respectively after exposure to 1 Gy dose of ionizing radiation.",CGP,C2,115,156
Cohort,-0.013522798746333059,0.02396911392257428,-0.564175997077522,0.5728214891289909,LGP Offspring,Genes down-regulated in primary hepatocytes and Hep3B (hepatocyte) cells in response to IFNA [GeneID=3439].,CGP,C2,22,35
Cohort,-0.0892832803784342,0.06674819481697625,-1.3376134084711837,0.18138713619741414,LGP Proband,Genes down-regulated in primary hepatocytes and Hep3B (hepatocyte) cells in response to IFNA [GeneID=3439].,CGP,C2,22,53
Cohort,0.02256297773172105,0.018427665164553516,1.2244078417010746,0.2211606567632396,LonGen OPEL,Genes down-regulated in primary hepatocytes and Hep3B (hepatocyte) cells in response to IFNA [GeneID=3439].,CGP,C2,19,36
Cohort,-0.021520983776618794,0.027413617126857782,-0.7850472149307932,0.43270092274310556,LGP Offspring,Genes up-regulated in primary hepatocytes and Hep3B (hepatocyte) cells in response to IFNA [GeneID=3439].,CGP,C2,25,44
Cohort,0.07380836134857645,0.0748215124136168,0.9864590940177792,0.32419397195435284,LGP Proband,Genes up-regulated in primary hepatocytes and Hep3B (hepatocyte) cells in response to IFNA [GeneID=3439].,CGP,C2,25,65
Cohort,-0.04146931198060376,0.025540862640097296,-1.6236457070756865,0.10484735599711825,LonGen OPEL,Genes up-regulated in primary hepatocytes and Hep3B (hepatocyte) cells in response to IFNA [GeneID=3439].,CGP,C2,51,42
Cohort,-0.05867817767801968,0.04461759113304108,-1.3151354922557927,0.18891029194094394,LGP Offspring,The 'Bullinger validation signature' [PMID=15084693] used to validate prediction of prognostic outcome of acute myeloid leukemia (AML) patients with a normal karyotype.,CGP,C2,74,126
Cohort,-0.03385273727226893,0.132223347073073,-0.25602692732895554,0.7979931802125754,LGP Proband,The 'Bullinger validation signature' [PMID=15084693] used to validate prediction of prognostic outcome of acute myeloid leukemia (AML) patients with a normal karyotype.,CGP,C2,74,204
Cohort,-0.035315407370257526,0.03730163918839532,-0.946752157241505,0.3440523958327335,LonGen OPEL,The 'Bullinger validation signature' [PMID=15084693] used to validate prediction of prognostic outcome of acute myeloid leukemia (AML) patients with a normal karyotype.,CGP,C2,102,110
Cohort,0.007046361145374113,0.004515593499833875,1.5604507238380387,0.11912141224112685,LGP Offspring,Genes down-regulated in hearts of E18.5 embryos upon knockout of VEGFA [GeneID=7422].,CGP,C2,0,2
Cohort,0.012808412396143965,0.01567372941278091,0.8171898377739975,0.4140533262831343,LGP Proband,Genes down-regulated in hearts of E18.5 embryos upon knockout of VEGFA [GeneID=7422].,CGP,C2,0,4
Cohort,-0.0027089561129798566,0.0026070654953121632,-1.0390824925000564,0.2990818905244787,LonGen OPEL,Genes down-regulated in hearts of E18.5 embryos upon knockout of VEGFA [GeneID=7422].,CGP,C2,1,0
Cohort,0.013605994435889003,0.016098688750150605,0.8451616555268651,0.39831961485656064,LGP Offspring,Genes up-regulated in hearts of E18.5 embryos upon knockout of VEGFA [GeneID=7422].,CGP,C2,7,21
Cohort,-0.037336336573551634,0.036746650325481696,-1.0160473469784816,0.30990150168259817,LGP Proband,Genes up-regulated in hearts of E18.5 embryos upon knockout of VEGFA [GeneID=7422].,CGP,C2,7,16
Cohort,0.021301133748133434,0.010575889693174379,2.014122155782418,0.0443326771063153,LonGen OPEL,Genes up-regulated in hearts of E18.5 embryos upon knockout of VEGFA [GeneID=7422].,CGP,C2,4,13
Cohort,-0.011241671344592351,0.02770492542902415,-0.4057643603261745,0.6850441451350349,LGP Offspring,Genes in this set correspond to the most abuntant transcripts that are also specific to platelets.,CGP,C2,26,53
Cohort,0.0717237909564165,0.09057655319827095,0.7918582505498306,0.42866849261094253,LGP Proband,Genes in this set correspond to the most abuntant transcripts that are also specific to platelets.,CGP,C2,26,101
Cohort,0.0356023586974311,0.024432437757271795,1.457175868045947,0.14546220593030815,LonGen OPEL,Genes in this set correspond to the most abuntant transcripts that are also specific to platelets.,CGP,C2,30,53
Cohort,-0.0022794842973980632,0.01882279215506019,-0.12110234648610635,0.9036459574143432,LGP Offspring,Proteins phosporylated in HCT116 cells (colon cancer) upon p53 [GeneID=7157] activation.,CGP,C2,11,23
Cohort,0.029580153107237703,0.05374658614912848,0.5503633854095002,0.5822175292990615,LGP Proband,Proteins phosporylated in HCT116 cells (colon cancer) upon p53 [GeneID=7157] activation.,CGP,C2,11,36
Cohort,0.004818562999821181,0.016083216259395947,0.2996019528747017,0.7645590072973487,LonGen OPEL,Proteins phosporylated in HCT116 cells (colon cancer) upon p53 [GeneID=7157] activation.,CGP,C2,15,23
Cohort,-0.027671251454950672,0.04784119592397487,-0.5783979877702776,0.5631880895127062,LGP Offspring,"Genes depleted in embryonic, neural and hematopoietic stem cells.",CGP,C2,72,148
Cohort,-0.03870845586246537,0.1321792747478988,-0.2928481483673801,0.7697110683900563,LGP Proband,"Genes depleted in embryonic, neural and hematopoietic stem cells.",CGP,C2,72,209
Cohort,-0.04161752365041086,0.04115511636275201,-1.0112357181445697,0.3122109062654898,LonGen OPEL,"Genes depleted in embryonic, neural and hematopoietic stem cells.",CGP,C2,120,132
Cohort,0.04904451720073339,0.0719648267011782,0.6815067783652489,0.4957842812451986,LGP Offspring,"Genes enriched in embryonic, neural and hematopoietic stem cells.",CGP,C2,166,373
Cohort,-0.040374799621159516,0.21194923759688852,-0.19049278062490294,0.8489693579977318,LGP Proband,"Genes enriched in embryonic, neural and hematopoietic stem cells.",CGP,C2,166,522
Cohort,0.013766175865582559,0.06585227290268193,0.20904632837694978,0.8344655568660451,LonGen OPEL,"Genes enriched in embryonic, neural and hematopoietic stem cells.",CGP,C2,288,367
Cohort,-0.0760806124182887,0.04325785279844584,-1.7587699688372447,0.07906900442996978,LGP Offspring,Down-regulated genes in metastatic vs primary solid tumors.,CGP,C2,74,120
Cohort,-0.27815520735028704,0.1308655029863502,-2.1255044377837278,0.033837864415812755,LGP Proband,Down-regulated genes in metastatic vs primary solid tumors.,CGP,C2,74,192
Cohort,-0.07243977441586696,0.039755565749740006,-1.82212912958837,0.06881049813443511,LonGen OPEL,Down-regulated genes in metastatic vs primary solid tumors.,CGP,C2,121,111
Cohort,-0.042240928207551216,0.04291250884349366,-0.9843500029701884,0.32529562290093883,LGP Offspring,Up-regulated genes in metastatic vs primary solid tumors.,CGP,C2,69,116
Cohort,-0.10709862032417831,0.12926823522490927,-0.828499129255081,0.40762491848887983,LGP Proband,Up-regulated genes in metastatic vs primary solid tumors.,CGP,C2,69,210
Cohort,-0.02922195404622395,0.03711850509282504,-0.7872610702706482,0.43136339294494275,LonGen OPEL,Up-regulated genes in metastatic vs primary solid tumors.,CGP,C2,113,120
Cohort,0.012709033962743485,0.011410069396732,1.1138437042620903,0.26574211861369196,LGP Offspring,Apoptotic genes dependent on MAPK1 [GeneID=5594] and down-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,2,11
Cohort,-0.08856369501544144,0.038284426038551846,-2.3133086787368606,0.020948087362439798,LGP Proband,Apoptotic genes dependent on MAPK1 [GeneID=5594] and down-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,2,18
Cohort,0.006469083896340236,0.00683680750420924,0.9462141346465281,0.3443265167808953,LonGen OPEL,Apoptotic genes dependent on MAPK1 [GeneID=5594] and down-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,2,5
Cohort,0.002805431129995721,0.0072164632623256545,0.38875430082791174,0.6975803215702796,LGP Offspring,Apoptotic genes dependent on MAPK1 [GeneID=5594] and up-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,1,4
Cohort,0.0038588606411274467,0.019383216494122765,0.19908257446835523,0.8422466756896803,LGP Proband,Apoptotic genes dependent on MAPK1 [GeneID=5594] and up-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,1,5
Cohort,-0.004849215554629565,0.006340378967051354,-0.7648147815499952,0.4446085214299169,LonGen OPEL,Apoptotic genes dependent on MAPK1 [GeneID=5594] and up-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,4,2
Cohort,0.018022454618894197,0.021782897010286326,0.8273672051235255,0.4083209257522936,LGP Offspring,Apoptotic genes dependent on SMAD4 [GeneID=4089] and down-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,13,34
Cohort,-0.004272059125428843,0.06927404976676722,-0.06166896752553181,0.9508412286004011,LGP Proband,Apoptotic genes dependent on SMAD4 [GeneID=4089] and down-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,13,60
Cohort,-0.05255912383267861,0.022070549605471362,-2.381414363131629,0.017480462513445243,LonGen OPEL,Apoptotic genes dependent on SMAD4 [GeneID=4089] and down-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,44,29
Cohort,0.0015900722055680087,0.015061706294694981,0.10557052265240774,0.9159544311267435,LGP Offspring,Apoptotic genes dependent on SMAD4 [GeneID=4089] and up-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,7,16
Cohort,-0.06170127251111842,0.048581479943939944,-1.2700574906799447,0.20441837576361635,LGP Proband,Apoptotic genes dependent on SMAD4 [GeneID=4089] and up-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,7,28
Cohort,-0.0157311962485622,0.014213394350294877,-1.1067867295355691,0.26872050516515417,LonGen OPEL,Apoptotic genes dependent on SMAD4 [GeneID=4089] and up-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].,CGP,C2,18,13
Cohort,-0.015849503347102185,0.009020943526879578,-1.7569673615487829,0.0793760565836503,LGP Offspring,Genes down-regulated in the brain cortex of mice that were exposed to an enriched learning environment for one day.,CGP,C2,5,3
Cohort,-0.00959298369096166,0.02935034523221105,-0.32684398139322984,0.7438679022131363,LGP Proband,Genes down-regulated in the brain cortex of mice that were exposed to an enriched learning environment for one day.,CGP,C2,5,9
Cohort,-0.002474346603119336,0.007322276581268413,-0.3379203961578181,0.7355122752551682,LonGen OPEL,Genes down-regulated in the brain cortex of mice that were exposed to an enriched learning environment for one day.,CGP,C2,4,4
Cohort,-0.004047964546862648,0.01700670837533069,-0.23802163578782112,0.8119364402218572,LGP Offspring,Genes up-regulated in the brain cortex of mice that were exposed to an enriched learning environment for one day.,CGP,C2,10,20
Cohort,-0.005315402205725496,0.04915197359529805,-0.10814219281388072,0.9139089101476062,LGP Proband,Genes up-regulated in the brain cortex of mice that were exposed to an enriched learning environment for one day.,CGP,C2,10,31
Cohort,-0.008291202489412864,0.013833905923657356,-0.5993392274870166,0.549117236137279,LonGen OPEL,Genes up-regulated in the brain cortex of mice that were exposed to an enriched learning environment for one day.,CGP,C2,15,12
Cohort,-0.013155108915984518,0.02845394368906237,-0.4623298991429899,0.6439935272538304,LGP Offspring,Genes up-regulated in the brain cortex of mice that were exposed to an enriched learning environment for 2 or 14 days.,CGP,C2,27,54
Cohort,3.268901049608067e-4,0.08260203963682748,0.0039574096039035975,0.9968433985929812,LGP Proband,Genes up-regulated in the brain cortex of mice that were exposed to an enriched learning environment for 2 or 14 days.,CGP,C2,27,81
Cohort,0.015251476211029999,0.02696930677069538,0.5655123559795064,0.5718846841864751,LonGen OPEL,Genes up-regulated in the brain cortex of mice that were exposed to an enriched learning environment for 2 or 14 days.,CGP,C2,44,64
Cohort,-0.0036726538290645476,0.003216758484999906,-1.1417250770272407,0.25397257209476515,LGP Offspring,Angiogenic genes down-regulated in hepatocytes after knockout of VHL and HIF2A [GeneID=7428;2034].,CGP,C2,1,0
Cohort,-0.015341033692980352,0.01919450941473335,-0.7992407287682414,0.4243783985176135,LGP Proband,Angiogenic genes down-regulated in hepatocytes after knockout of VHL and HIF2A [GeneID=7428;2034].,CGP,C2,1,5
Cohort,0.00758030163568353,0.006333306239948361,1.1968948521499785,0.23170387992393612,LonGen OPEL,Angiogenic genes down-regulated in hepatocytes after knockout of VHL and HIF2A [GeneID=7428;2034].,CGP,C2,2,4
Cohort,-0.004065005696159438,0.011103067505149973,-0.36611555268613405,0.7143933997306962,LGP Offspring,Angiogenic genes up-regulated in hepatocytes after knockout of VHL and HIF2A [GeneID=7428;2034].,CGP,C2,4,8
Cohort,0.005338742206452243,0.02587498012292391,0.20632835971620284,0.8365847851069093,LGP Proband,Angiogenic genes up-regulated in hepatocytes after knockout of VHL and HIF2A [GeneID=7428;2034].,CGP,C2,4,7
Cohort,0.010718335369590826,0.007297781439071916,1.468711478834575,0.14230612476531543,LonGen OPEL,Angiogenic genes up-regulated in hepatocytes after knockout of VHL and HIF2A [GeneID=7428;2034].,CGP,C2,3,6
Cohort,-0.11497448307374425,0.07760390141253753,-1.4815554499321757,0.13892458122720286,LGP Offspring,Loci bound by both isoforms (a and b) of SALL4 [GeneID=57167] in ES cells (embryonic stem).,CGP,C2,209,380
Cohort,-0.2633607419380286,0.21486394237738624,-1.2257093443601754,0.22065407392716946,LGP Proband,Loci bound by both isoforms (a and b) of SALL4 [GeneID=57167] in ES cells (embryonic stem).,CGP,C2,209,566
Cohort,0.07143102267483648,0.06961186752081427,1.0261328307774285,0.3051406972559646,LonGen OPEL,Loci bound by both isoforms (a and b) of SALL4 [GeneID=57167] in ES cells (embryonic stem).,CGP,C2,289,392
Cohort,-0.1326099407000287,0.0868350321588696,-1.5271479425194583,0.127191960940212,LGP Offspring,Loci bound exclusively by SALL4 [GeneID=57167] isoform a in ES cells (embryonic stem).,CGP,C2,247,465
Cohort,-0.06593835312432929,0.24421973637129443,-0.26999600484410186,0.7872301202335588,LGP Proband,Loci bound exclusively by SALL4 [GeneID=57167] isoform a in ES cells (embryonic stem).,CGP,C2,247,686
Cohort,-0.053601064747090456,0.07352465454252145,-0.7290216469645756,0.46620285930621774,LonGen OPEL,Loci bound exclusively by SALL4 [GeneID=57167] isoform a in ES cells (embryonic stem).,CGP,C2,388,435
Cohort,-0.015040361630346014,0.11750512209767422,-0.12799749799709972,0.898189020482768,LGP Offspring,Loci bound exclusively by SALL4 [GeneID=57167] isoform b in ES cells (embryonic stem).,CGP,C2,458,981
Cohort,0.15971333407476737,0.32277773649006336,0.49480901567597463,0.6208652618177755,LGP Proband,Loci bound exclusively by SALL4 [GeneID=57167] isoform b in ES cells (embryonic stem).,CGP,C2,458,1400
Cohort,0.025037663841911702,0.11103372232814111,0.22549603234877763,0.8216512922882279,LonGen OPEL,Loci bound exclusively by SALL4 [GeneID=57167] isoform b in ES cells (embryonic stem).,CGP,C2,784,951
Cohort,-0.008604352564909386,0.010138650273623451,-0.848668445275633,0.39636622346907113,LGP Offspring,"Known and putative targets of NFKB1 [GeneID=4790] identified among the ATM [GeneID=472] dependent, late responders to ionizing radiation.",CGP,C2,4,6
Cohort,0.03999998251935109,0.03317580723246587,1.2056973396025488,0.22827616422223593,LGP Proband,"Known and putative targets of NFKB1 [GeneID=4790] identified among the ATM [GeneID=472] dependent, late responders to ionizing radiation.",CGP,C2,4,14
Cohort,0.003679060859344554,0.010340744993581783,0.35578295970242435,0.7220973768039289,LonGen OPEL,"Known and putative targets of NFKB1 [GeneID=4790] identified among the ATM [GeneID=472] dependent, late responders to ionizing radiation.",CGP,C2,6,10
Cohort,0.015924164470547758,0.033675348315506164,0.4728730441435497,0.6364563970315371,LGP Offspring,Cluster 1: ATM [GeneID=472] dependent genes induced at 30 min after ionizing radiation treatment.,CGP,C2,30,70
Cohort,-0.057898112614494214,0.08058118840938337,-0.7185065616102554,0.47264624279385714,LGP Proband,Cluster 1: ATM [GeneID=472] dependent genes induced at 30 min after ionizing radiation treatment.,CGP,C2,30,77
Cohort,0.043802161574672094,0.026422730436168957,1.6577454658021704,0.09776286235053454,LonGen OPEL,Cluster 1: ATM [GeneID=472] dependent genes induced at 30 min after ionizing radiation treatment.,CGP,C2,34,57
Cohort,-0.11433041295318458,0.05082703866912695,-2.2494014199302637,0.02480798839454354,LGP Offspring,Cluster 2: late ATM [GeneID=472] dependent genes induced by ionizing radiation treatment.,CGP,C2,97,161
Cohort,-0.12349761237460812,0.14337567043020022,-0.8613568257714312,0.3892891202212653,LGP Proband,Cluster 2: late ATM [GeneID=472] dependent genes induced by ionizing radiation treatment.,CGP,C2,97,236
Cohort,-0.02978471622554787,0.04293516990180555,-0.6937137152051968,0.4880641441803154,LonGen OPEL,Cluster 2: late ATM [GeneID=472] dependent genes induced by ionizing radiation treatment.,CGP,C2,136,152
Cohort,0.01880490907995631,0.037504192927087024,0.5014081789872261,0.6162471267356835,LGP Offspring,Cluster 3: genes activated by ionizing radiation regardless of ATM [GeneID=472] status.,CGP,C2,41,102
Cohort,0.07351697658163787,0.10747487412898026,0.6840387316333154,0.49414072522951136,LGP Proband,Cluster 3: genes activated by ionizing radiation regardless of ATM [GeneID=472] status.,CGP,C2,41,151
Cohort,-0.014309778231718178,0.032069009667963624,-0.4462182767687209,0.6555609366986588,LonGen OPEL,Cluster 3: genes activated by ionizing radiation regardless of ATM [GeneID=472] status.,CGP,C2,75,86
Cohort,-0.033407253989447105,0.031394177375467715,-1.0641226106963537,0.2876531122805029,LGP Offspring,Cluster 4: genes repressed by ionizing radiation regardless of ATM [GeneID=472] status.,CGP,C2,36,65
Cohort,0.09962088963911006,0.09288661947280284,1.0724998950820792,0.28380579605557327,LGP Proband,Cluster 4: genes repressed by ionizing radiation regardless of ATM [GeneID=472] status.,CGP,C2,36,105
Cohort,-0.0218837181466662,0.028303701893192614,-0.7731751213762431,0.4396482805219074,LonGen OPEL,Cluster 4: genes repressed by ionizing radiation regardless of ATM [GeneID=472] status.,CGP,C2,64,66
Cohort,0.013138294170797666,0.06611436339032362,0.1987207241674895,0.8425409619269901,LGP Offspring,Cluster 5: early responding genes activated in ATM [GeneID=472] deficient but not in the wild type tissues.,CGP,C2,153,314
Cohort,-0.10105802377241815,0.18538797556367678,-0.545116388833465,0.5858192134835837,LGP Proband,Cluster 5: early responding genes activated in ATM [GeneID=472] deficient but not in the wild type tissues.,CGP,C2,153,421
Cohort,0.03644423994850702,0.05771882467903184,0.6314099455622929,0.527953785663855,LonGen OPEL,Cluster 5: early responding genes activated in ATM [GeneID=472] deficient but not in the wild type tissues.,CGP,C2,236,293
Cohort,-0.014521656295691578,0.03611322414004428,-0.40211464474558467,0.6877267632175788,LGP Offspring,Cluster 6: late responding genes activated in ATM [GeneID=472] deficient but not in the wild type tissues.,CGP,C2,42,85
Cohort,0.05650791298882307,0.0980603188066405,0.5762566721840643,0.5645971799923558,LGP Proband,Cluster 6: late responding genes activated in ATM [GeneID=472] deficient but not in the wild type tissues.,CGP,C2,42,111
Cohort,-0.025846961673089502,0.02995661013257052,-0.8628133009277718,0.3885000001581125,LonGen OPEL,Cluster 6: late responding genes activated in ATM [GeneID=472] deficient but not in the wild type tissues.,CGP,C2,72,71
Cohort,-0.19785807256670893,0.10685219777581485,-1.8516986705489415,0.06450496554214118,LGP Offspring,Transcripts bound by CELF1 [GeneID=10658] in HeLa cells (cervical carcinoma).,CGP,C2,414,785
Cohort,-0.44072750249074194,0.31725963392252743,-1.3891698009030815,0.1651519140796225,LGP Proband,Transcripts bound by CELF1 [GeneID=10658] in HeLa cells (cervical carcinoma).,CGP,C2,414,1162
Cohort,-0.020715656644277252,0.09877884795539726,-0.20971753642673813,0.8339418006305118,LonGen OPEL,Transcripts bound by CELF1 [GeneID=10658] in HeLa cells (cervical carcinoma).,CGP,C2,645,767
Cohort,0.024465042542273274,0.01526101633011499,1.6031070285925664,0.10937813339167916,LGP Offspring,A biomarker of plasma signaling proteins that predicts clinical Alzheimer's diagnosis.,CGP,C2,3,18
Cohort,-0.04460642382250925,0.03504745044654199,-1.2727437589375465,0.20346367149493588,LGP Proband,A biomarker of plasma signaling proteins that predicts clinical Alzheimer's diagnosis.,CGP,C2,3,15
Cohort,0.002365693768312393,0.010931071994642994,0.2164191919577286,0.8287164576040693,LonGen OPEL,A biomarker of plasma signaling proteins that predicts clinical Alzheimer's diagnosis.,CGP,C2,8,10
Cohort,-0.020750670413751195,0.009589218638287534,-2.163958420021686,0.030817083160115343,LGP Offspring,"Genes down-regulated in HL-60 cells (acute myeloid leukemia, AML) by expression of p210 BCR-ABL [GeneID=613;25] fusion protein.",CGP,C2,6,3
Cohort,-0.022592156801598432,0.03231308152494401,-0.6991644168680868,0.4846442211284854,LGP Proband,"Genes down-regulated in HL-60 cells (acute myeloid leukemia, AML) by expression of p210 BCR-ABL [GeneID=613;25] fusion protein.",CGP,C2,6,11
Cohort,-0.006250117395328654,0.00925248640612641,-0.6755067903899025,0.4995500225051339,LonGen OPEL,"Genes down-regulated in HL-60 cells (acute myeloid leukemia, AML) by expression of p210 BCR-ABL [GeneID=613;25] fusion protein.",CGP,C2,7,6
Cohort,-0.004772571188841177,0.022832329217348613,-0.20902690844238747,0.8344902032025551,LGP Offspring,"Genes up-regulated in HL-60 cells (acute myeloid leukemia, AML) by expression of p210 BCR-ABL [GeneID=613;25] fusion protein.",CGP,C2,19,34
Cohort,-0.10527575086948239,0.062247599331307045,-1.6912419434709767,0.09116420570240245,LGP Proband,"Genes up-regulated in HL-60 cells (acute myeloid leukemia, AML) by expression of p210 BCR-ABL [GeneID=613;25] fusion protein.",CGP,C2,19,45
Cohort,0.037470242334123605,0.019913600268232613,1.8816407796383467,0.06024948519490365,LonGen OPEL,"Genes up-regulated in HL-60 cells (acute myeloid leukemia, AML) by expression of p210 BCR-ABL [GeneID=613;25] fusion protein.",CGP,C2,21,40
Cohort,-0.13806059901178194,0.0888461408451563,-1.5539290474349141,0.12066936249881235,LGP Offspring,Down-regulated genes in breast tumors from transgenic mice overexpressing ERBB2 and CDC25A [GeneID=2064;993] compared to those from mice overexpressing ERBB2 only.,CGP,C2,257,480
Cohort,0.2629821011789138,0.2487391168399676,1.057260733735377,0.29069874789789923,LGP Proband,Down-regulated genes in breast tumors from transgenic mice overexpressing ERBB2 and CDC25A [GeneID=2064;993] compared to those from mice overexpressing ERBB2 only.,CGP,C2,257,715
Cohort,0.06878811137264372,0.08005046525236809,0.8593093263828195,0.3904285842440893,LonGen OPEL,Down-regulated genes in breast tumors from transgenic mice overexpressing ERBB2 and CDC25A [GeneID=2064;993] compared to those from mice overexpressing ERBB2 only.,CGP,C2,410,524
Cohort,-0.07816422761387234,0.07148309119869295,-1.0934645704759556,0.27457936967575103,LGP Offspring,Up-regulated genes in breast tumors from transgenic mice overexpressing ERBB2 and CDC25A [GeneID=2064;993] compared to those from mice overexpressing ERBB2 only.,CGP,C2,190,364
Cohort,0.07001401109187626,0.20377963891748185,0.3435770691507977,0.7312509671720356,LGP Proband,Up-regulated genes in breast tumors from transgenic mice overexpressing ERBB2 and CDC25A [GeneID=2064;993] compared to those from mice overexpressing ERBB2 only.,CGP,C2,190,545
Cohort,0.0477840827446317,0.06619194716792777,0.721901753749657,0.4705668871329105,LonGen OPEL,Up-regulated genes in breast tumors from transgenic mice overexpressing ERBB2 and CDC25A [GeneID=2064;993] compared to those from mice overexpressing ERBB2 only.,CGP,C2,277,350
Cohort,-0.023007717537491458,0.014811856421338199,-1.5533311208948912,0.12081206912385457,LGP Offspring,"G1 to S phase regulators significantly changed in DanG cells (pancreatic cancer) treated with Ly294002 [PubChem=3973], a phosphoinositide 3-kinase (PI3K) inhibitor.",CGP,C2,10,10
Cohort,-0.057509844091771053,0.03816648635775371,-1.506815260715967,0.13223668095922506,LGP Proband,"G1 to S phase regulators significantly changed in DanG cells (pancreatic cancer) treated with Ly294002 [PubChem=3973], a phosphoinositide 3-kinase (PI3K) inhibitor.",CGP,C2,10,12
Cohort,0.011458915209158822,0.011654548896524189,0.9832139631398593,0.3258008899722702,LonGen OPEL,"G1 to S phase regulators significantly changed in DanG cells (pancreatic cancer) treated with Ly294002 [PubChem=3973], a phosphoinositide 3-kinase (PI3K) inhibitor.",CGP,C2,7,14
Cohort,-0.0016696013490732822,0.03003887986000381,-0.05558134513851578,0.955691748878334,LGP Offspring,Genes with known mitosis function that were down-regulated in MEF cells (embryonic fibroblast) upon knockout of LIN9 [GeneID=286826].,CGP,C2,32,58
Cohort,0.011630963703258602,0.08845825079500651,0.13148534589737979,0.8954230896067783,LGP Proband,Genes with known mitosis function that were down-regulated in MEF cells (embryonic fibroblast) upon knockout of LIN9 [GeneID=286826].,CGP,C2,32,87
Cohort,0.03024824350047757,0.02316633533573309,1.3056982497279548,0.1920324238384736,LonGen OPEL,Genes with known mitosis function that were down-regulated in MEF cells (embryonic fibroblast) upon knockout of LIN9 [GeneID=286826].,CGP,C2,34,50
Cohort,-0.1283572818132287,0.10853504047517679,-1.1826344860725921,0.23736982108869656,LGP Offspring,Genes commonly down-regulated in human alveolar rhabdomyosarcoma (ARMS) and its mouse model overexpressing PAX3-FOXO1 [GeneID=5077;2308] fusion.,CGP,C2,389,743
Cohort,-0.7456219574392512,0.300282860419438,-2.4830653218027803,0.013221300470404115,LGP Proband,Genes commonly down-regulated in human alveolar rhabdomyosarcoma (ARMS) and its mouse model overexpressing PAX3-FOXO1 [GeneID=5077;2308] fusion.,CGP,C2,389,1011
Cohort,-0.11727339707044138,0.09219099472311465,-1.2720699827858342,0.20371974769567763,LonGen OPEL,Genes commonly down-regulated in human alveolar rhabdomyosarcoma (ARMS) and its mouse model overexpressing PAX3-FOXO1 [GeneID=5077;2308] fusion.,CGP,C2,593,673
Cohort,3.26801838515418e-4,0.057696377624094505,0.005664165619627093,0.9954823449422339,LGP Offspring,Genes commonly up-regulated in human alveolar rhabdomyosarcoma (ARMS) and its mouse model overexpressing PAX3-FOXO1 [GeneID=5077;2308] fusion.,CGP,C2,109,224
Cohort,-0.2457777904228134,0.15143599870130292,-1.6229812761204365,0.1049713107136145,LGP Proband,Genes commonly up-regulated in human alveolar rhabdomyosarcoma (ARMS) and its mouse model overexpressing PAX3-FOXO1 [GeneID=5077;2308] fusion.,CGP,C2,109,252
Cohort,0.0331137198748746,0.04662512258919273,0.7102119637654327,0.47778071321308113,LonGen OPEL,Genes commonly up-regulated in human alveolar rhabdomyosarcoma (ARMS) and its mouse model overexpressing PAX3-FOXO1 [GeneID=5077;2308] fusion.,CGP,C2,135,172
Cohort,-0.07320072922303308,0.04080223883216121,-1.7940370753708417,0.0732540164168262,LGP Offspring,"Genes whose promoters were bound by E2F1 and E2F4 [GeneID=1869;1874] in the primary fibroblasts WI-38, by ChIP on chip assay.",CGP,C2,63,103
Cohort,0.22069687658291018,0.11985589085502432,1.8413519352992123,0.06592497748572859,LGP Proband,"Genes whose promoters were bound by E2F1 and E2F4 [GeneID=1869;1874] in the primary fibroblasts WI-38, by ChIP on chip assay.",CGP,C2,63,168
Cohort,-0.029399113272020775,0.03325850797691547,-0.8839576715956867,0.37698596760168956,LonGen OPEL,"Genes whose promoters were bound by E2F1 and E2F4 [GeneID=1869;1874] in the primary fibroblasts WI-38, by ChIP on chip assay.",CGP,C2,85,85
Cohort,0.0010190764029509682,0.009565015558989623,0.10654205386976033,0.9151839000811394,LGP Offspring,Genes down-regulated in SK-N-DZ cells (neuroblastoma) after knockdown of MIF [GeneID=4282] by antisense RNA.,CGP,C2,3,6
Cohort,-0.03593703015625781,0.02353840390127279,-1.5267403137013291,0.12720473310426936,LGP Proband,Genes down-regulated in SK-N-DZ cells (neuroblastoma) after knockdown of MIF [GeneID=4282] by antisense RNA.,CGP,C2,3,6
Cohort,0.014472783564631764,0.010323482354593107,1.4019284450263585,0.16132643484148673,LonGen OPEL,Genes down-regulated in SK-N-DZ cells (neuroblastoma) after knockdown of MIF [GeneID=4282] by antisense RNA.,CGP,C2,4,10
Cohort,-0.15001915754674217,0.09188974493823053,-1.6325995642667959,0.10301891919241633,LGP Offspring,Genes down-regulated in ALL (acute lymphoblastic leukemia) blasts after 1 week of treatment with glucocorticoids.,CGP,C2,310,579
Cohort,0.03769287108887266,0.2603071888474611,0.14480149878211976,0.8849025836747662,LGP Proband,Genes down-regulated in ALL (acute lymphoblastic leukemia) blasts after 1 week of treatment with glucocorticoids.,CGP,C2,310,789
Cohort,-0.03007903918408072,0.08707110535675645,-0.3454537422126189,0.729844550738723,LonGen OPEL,Genes down-regulated in ALL (acute lymphoblastic leukemia) blasts after 1 week of treatment with glucocorticoids.,CGP,C2,480,563
Cohort,-0.04090373998995674,0.03654538301128669,-1.1192587577293696,0.2634272998765843,LGP Offspring,Genes up-regulated in ALL (acute lymphoblastic leukemia) blasts after 1 week of treatment with glucocorticoids.,CGP,C2,50,91
Cohort,0.10977382433243284,0.10656338969223049,1.0301269943596438,0.3032490402066156,LGP Proband,Genes up-regulated in ALL (acute lymphoblastic leukemia) blasts after 1 week of treatment with glucocorticoids.,CGP,C2,50,142
Cohort,0.05527842398188994,0.03635525799356279,1.5205069921846728,0.12878070643604395,LonGen OPEL,Genes up-regulated in ALL (acute lymphoblastic leukemia) blasts after 1 week of treatment with glucocorticoids.,CGP,C2,75,105
Cohort,-0.0722800649241756,0.03882735044307185,-1.8615760307969427,0.06309667120526642,LGP Offspring,"Genes commonly up-regulated in cancer relative to normal tissue, according to the meta-analysis of the OncoMine gene expression database.",CGP,C2,54,81
Cohort,0.03768087366503532,0.1163815646424384,0.3237701244248012,0.7461932491007164,LGP Proband,"Genes commonly up-regulated in cancer relative to normal tissue, according to the meta-analysis of the OncoMine gene expression database.",CGP,C2,54,157
Cohort,-0.028179455594673244,0.0369206826601861,-0.7632430812299397,0.44554458012274334,LonGen OPEL,"Genes commonly up-regulated in cancer relative to normal tissue, according to the meta-analysis of the OncoMine gene expression database.",CGP,C2,97,101
Cohort,-0.025189570318296592,0.036423621632816545,-0.691572369497754,0.48944335587534216,LGP Offspring,"Genes commonly up-regulated in undifferentiated cancer relative to well-differentiated cancer, based on the meta-analysis of the OncoMine gene expression database.",CGP,C2,46,81
Cohort,-0.09374799955544157,0.09546472988301657,-0.9820171247571883,0.3263761969426945,LGP Proband,"Genes commonly up-regulated in undifferentiated cancer relative to well-differentiated cancer, based on the meta-analysis of the OncoMine gene expression database.",CGP,C2,46,107
Cohort,0.00561552774330408,0.028773332058658695,0.1951643185382908,0.8453141152082071,LonGen OPEL,"Genes commonly up-regulated in undifferentiated cancer relative to well-differentiated cancer, based on the meta-analysis of the OncoMine gene expression database.",CGP,C2,63,73
Cohort,0.10069210297342947,0.053978346896884105,1.8654165746458218,0.06255601535541445,LGP Offspring,Cluster a: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,74,204
Cohort,-0.10890846614788345,0.1564261830760224,-0.6962291350863841,0.4864793248725916,LGP Proband,Cluster a: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,74,305
Cohort,-0.040022877387577586,0.045978410256274437,-0.8704711007731258,0.3843054343162392,LonGen OPEL,Cluster a: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,165,172
Cohort,-0.017714046664672065,0.03139954413399874,-0.5641498038658365,0.572839303425515,LGP Offspring,Cluster b: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,31,55
Cohort,0.030838903441505233,0.08347275413661273,0.36944873522483557,0.7118870605689889,LGP Proband,Cluster b: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,31,71
Cohort,0.002637839339620586,0.0257051879370231,0.10261894782030807,0.9182912497605694,LonGen OPEL,Cluster b: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,42,53
Cohort,-0.01999918082350899,0.04901335929402528,-0.40803530122341325,0.6833769596984928,LGP Offspring,Cluster c: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,86,162
Cohort,-0.28175027055640073,0.14298018520287759,-1.97055466221854,0.04910521117926647,LGP Proband,Cluster c: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,86,237
Cohort,0.015155504924441008,0.042426034455004945,0.3572218124820085,0.721020441972049,LonGen OPEL,Cluster c: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,125,160
Cohort,0.006973271603889108,0.028438923161861095,0.24520167533069012,0.8063746964959836,LGP Offspring,Cluster d: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,24,58
Cohort,0.13170373245641664,0.07959699500080847,1.654631967639971,0.09837542851227753,LGP Proband,Cluster d: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,24,86
Cohort,-0.012481061384865202,0.023719650244928392,-0.5261907851079649,0.5989022274131119,LonGen OPEL,Cluster d: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,40,45
Cohort,0.02540595111715755,0.05431548733162689,0.4677478259937133,0.6401156888011134,LGP Offspring,Cluster e: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,79,184
Cohort,0.10023969944139763,0.15245277251171485,0.6575131287539882,0.5110324529383248,LGP Proband,Cluster e: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,79,262
Cohort,0.07208222602749166,0.0462609600848483,1.558165370871767,0.11959152609022947,LonGen OPEL,Cluster e: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,145,206
Cohort,-0.09466399727661676,0.04852298630924792,-1.9509103721131626,0.05148048786295612,LGP Offspring,Cluster f: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,90,148
Cohort,-0.16004991473939723,0.13945035726674104,-1.1477196464491897,0.25141343168803665,LGP Proband,Cluster f: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,90,236
Cohort,-0.018505939211195952,0.04492641655083092,-0.4119166546536791,0.6805114098335427,LonGen OPEL,Cluster f: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).,CGP,C2,135,159
Cohort,-0.038630308470875584,0.08555309108148132,-0.45153609276471174,0.6517480426207207,LGP Offspring,Genes down-regulated in metastatic vs non-metastatic HNSCC (head and neck squamous cell carcinoma) samples.,CGP,C2,226,472
Cohort,0.22899432898664457,0.22346820138939194,1.0247289214433841,0.3057882378970949,LGP Proband,Genes down-regulated in metastatic vs non-metastatic HNSCC (head and neck squamous cell carcinoma) samples.,CGP,C2,226,594
Cohort,0.0094580835410699,0.07275697661481673,0.12999555480626981,0.8966027859786756,LonGen OPEL,Genes down-regulated in metastatic vs non-metastatic HNSCC (head and neck squamous cell carcinoma) samples.,CGP,C2,332,406
Cohort,0.03413699080750499,0.10029375170482774,0.34037006520578467,0.7336836005395129,LGP Offspring,Genes up-regulated in metastatic vs non-metastatic HNSCC (head and neck squamous cell carcinoma) samples.,CGP,C2,294,642
Cohort,-0.3535911086543381,0.26624736451100833,-1.3280548684631899,0.184523312042891,LGP Proband,Genes up-regulated in metastatic vs non-metastatic HNSCC (head and neck squamous cell carcinoma) samples.,CGP,C2,294,830
Cohort,-0.061798821333892064,0.08665684737925937,-0.7131441219344788,0.4759655909985405,LonGen OPEL,Genes up-regulated in metastatic vs non-metastatic HNSCC (head and neck squamous cell carcinoma) samples.,CGP,C2,471,529
Cohort,0.012319485483395795,0.02182493888473237,0.5644682694627791,0.5726227292845603,LGP Offspring,Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: moderately vs poorly differentiated tumors.,CGP,C2,14,34
Cohort,0.014711634052906613,0.05838402197366797,0.25198048294003744,0.8011182307142963,LGP Proband,Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: moderately vs poorly differentiated tumors.,CGP,C2,14,47
Cohort,0.01945256597796057,0.0206135464237071,0.9436787624078448,0.3456201604383663,LonGen OPEL,Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: moderately vs poorly differentiated tumors.,CGP,C2,25,37
Cohort,-0.13121372326135441,0.07589114769076037,-1.7289727096501597,0.0842705332203422,LGP Offspring,Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: moderately vs poorly differentiated tumors.,CGP,C2,201,345
Cohort,-0.13268601388249016,0.19253199011154012,-0.6891634673574026,0.4909120859298174,LGP Proband,Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: moderately vs poorly differentiated tumors.,CGP,C2,201,434
Cohort,0.013549566631499567,0.05729129736146597,0.23650305117043802,0.8131031847249629,LonGen OPEL,Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: moderately vs poorly differentiated tumors.,CGP,C2,223,270
Cohort,-0.016406847753438716,0.046214554681442435,-0.3550147321884057,0.7226892868848753,LGP Offspring,Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs moderately differentiated tumors.,CGP,C2,73,146
Cohort,0.10428292700498842,0.1322367448115733,0.7886077894127173,0.43056537953101714,LGP Proband,Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs moderately differentiated tumors.,CGP,C2,73,210
Cohort,0.011128559044611365,0.040455399523042175,0.2750821689023952,0.7833244950990463,LonGen OPEL,Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs moderately differentiated tumors.,CGP,C2,115,150
Cohort,-0.04234911376333116,0.054223608496078476,-0.781008769757437,0.43507075115817784,LGP Offspring,Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs moderately differentiated tumors.,CGP,C2,115,215
Cohort,-0.128505429222996,0.15632312936326082,-0.8220500046693502,0.4112833865614529,LGP Proband,Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs moderately differentiated tumors.,CGP,C2,115,323
Cohort,-0.09045280168979575,0.0535209236636381,-1.6900456026929336,0.09141077097041446,LonGen OPEL,Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs moderately differentiated tumors.,CGP,C2,208,214
Cohort,-0.012274956781469577,0.09926986719749194,-0.12365239450808597,0.9016272616443584,LGP Offspring,Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs poorly differentiated tumors.,CGP,C2,325,679
Cohort,0.0376156821237149,0.27937932384447284,0.13464017882960838,0.8929288581448368,LGP Proband,Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs poorly differentiated tumors.,CGP,C2,325,978
Cohort,0.12720869414050986,0.08908630212459127,1.4279265286216807,0.1537052145289613,LonGen OPEL,Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs poorly differentiated tumors.,CGP,C2,521,685
Cohort,-0.12961544560413768,0.08258590813596649,-1.569462012704921,0.11700825680212974,LGP Offspring,Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs poorly differentiated tumors.,CGP,C2,228,414
Cohort,-0.24206966761280743,0.23579826153064196,-1.0265964899039364,0.3049081598036378,LGP Proband,Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs poorly differentiated tumors.,CGP,C2,228,681
Cohort,-0.18504566071837542,0.07187044251871225,-2.574711581471017,0.0102119451196821,LonGen OPEL,Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs poorly differentiated tumors.,CGP,C2,396,392
Cohort,-0.16679473174316714,0.06603223976062009,-2.5259590216511056,0.011765594335474062,LGP Offspring,"Genes directly up-regulated by DeltaNp63, the p63 isoform that lacks the canonical transactivation domain and is predominantly expressed in stratifying epithelia, identified through a meta-analysis of both cell lines and primary cells.",CGP,C2,162,265
Cohort,-0.11917036603498107,0.181197361251016,-0.6576826793293762,0.510923530125035,LGP Proband,"Genes directly up-regulated by DeltaNp63, the p63 isoform that lacks the canonical transactivation domain and is predominantly expressed in stratifying epithelia, identified through a meta-analysis of both cell lines and primary cells.",CGP,C2,162,381
Cohort,-0.024984977052215696,0.05669386700556367,-0.4406998211951883,0.6595499833152426,LonGen OPEL,"Genes directly up-regulated by DeltaNp63, the p63 isoform that lacks the canonical transactivation domain and is predominantly expressed in stratifying epithelia, identified through a meta-analysis of both cell lines and primary cells.",CGP,C2,222,261
Cohort,-0.24459802078471987,0.07754068585940091,-3.1544474758481287,0.00167929739390229,LGP Offspring,Genes down-regulated in mesenchymal stem cells (MSC) engineered to express EWS-FLI1 [GeneID=2130;2321] fusion protein.,CGP,C2,227,368
Cohort,-0.23739516579155573,0.21643212698967368,-1.0968573339524692,0.2730203627738579,LGP Proband,Genes down-regulated in mesenchymal stem cells (MSC) engineered to express EWS-FLI1 [GeneID=2130;2321] fusion protein.,CGP,C2,227,515
Cohort,-0.054448887866883226,0.06269545782748018,-0.8684662295107703,0.3854009128125665,LonGen OPEL,Genes down-regulated in mesenchymal stem cells (MSC) engineered to express EWS-FLI1 [GeneID=2130;2321] fusion protein.,CGP,C2,307,348
Cohort,-0.22531601644337765,0.1147972239944538,-1.9627305313085215,0.05008719988958817,LGP Offspring,Genes up-regulated in mesenchymal stem cells (MSC) engineered to express EWS-FLI1 [GeneID=2130;2321] fusion protein.,CGP,C2,445,830
Cohort,-0.3476213936212249,0.31361760440226005,-1.1084243637527122,0.26799812915526605,LGP Proband,Genes up-regulated in mesenchymal stem cells (MSC) engineered to express EWS-FLI1 [GeneID=2130;2321] fusion protein.,CGP,C2,445,1142
Cohort,-0.09876787400761995,0.10123745341287178,-0.9756060694733177,0.3295561045399442,LonGen OPEL,Genes up-regulated in mesenchymal stem cells (MSC) engineered to express EWS-FLI1 [GeneID=2130;2321] fusion protein.,CGP,C2,718,815
Cohort,-0.03696935079593491,0.08511351725217865,-0.43435346099492333,0.6641703908410521,LGP Offspring,Genes down-regulated SUM44/LCCTam cells (breast cancer) resistant to 4-hydroxytamoxifen [PubChem=63062] relative to the parental SUM44 cells sensitive to the drug.,CGP,C2,249,511
Cohort,0.00940422401096653,0.2434768587643196,0.03862471389968777,0.9691988416718205,LGP Proband,Genes down-regulated SUM44/LCCTam cells (breast cancer) resistant to 4-hydroxytamoxifen [PubChem=63062] relative to the parental SUM44 cells sensitive to the drug.,CGP,C2,249,729
Cohort,0.041965127056406044,0.07628481162530697,0.550111171048424,0.5823974491644185,LonGen OPEL,Genes down-regulated SUM44/LCCTam cells (breast cancer) resistant to 4-hydroxytamoxifen [PubChem=63062] relative to the parental SUM44 cells sensitive to the drug.,CGP,C2,395,490
Cohort,0.007299139157009461,0.04790761663210082,0.15235863668739938,0.878949540822044,LGP Offspring,Genes up-regulated SUM44/LCCTam cells (breast cancer) resistant to 4-hydroxytamoxifen [PubChem=63062] relative to the parental SUM44 cells sensitive to the drug.,CGP,C2,71,145
Cohort,-0.1367353412590518,0.12789298307974845,-1.0691387280707154,0.28531650191026847,LGP Proband,Genes up-regulated SUM44/LCCTam cells (breast cancer) resistant to 4-hydroxytamoxifen [PubChem=63062] relative to the parental SUM44 cells sensitive to the drug.,CGP,C2,71,211
Cohort,0.09034822909383898,0.04205620047485154,2.148273692671423,0.03199314206973381,LonGen OPEL,Genes up-regulated SUM44/LCCTam cells (breast cancer) resistant to 4-hydroxytamoxifen [PubChem=63062] relative to the parental SUM44 cells sensitive to the drug.,CGP,C2,106,160
Cohort,0.016422177228093804,0.04250954029683817,0.38631745046923677,0.6993831381810817,LGP Offspring,Selected gradually up-regulated genes in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,60,130
Cohort,0.14176199466474382,0.12536465015788115,1.130797194314444,0.2584655341356923,LGP Proband,Selected gradually up-regulated genes in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,60,189
Cohort,0.008595881640285519,0.03505383926986883,0.24521940590040492,0.806349756515633,LonGen OPEL,Selected gradually up-regulated genes in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,87,102
Cohort,0.035606822901953154,0.030355828287135227,1.1729814309512119,0.24121640214308016,LGP Offspring,Selected genes down-regulated in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts) at 12 h time point.,CGP,C2,25,67
Cohort,-0.03197945495081807,0.08306135705647164,-0.38501002251956856,0.7003281543932622,LGP Proband,Selected genes down-regulated in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts) at 12 h time point.,CGP,C2,25,89
Cohort,0.05591398455328222,0.024948399311997996,2.2411852501652274,0.025288993474814645,LonGen OPEL,Selected genes down-regulated in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts) at 12 h time point.,CGP,C2,31,60
Cohort,-0.005018053968113388,0.023253691795919254,-0.2157960126139625,0.8292118517580753,LGP Offspring,Selected genes down-regulated in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts) at 6 h time point.,CGP,C2,17,32
Cohort,0.05654332840323871,0.06691026671506285,0.8450620686363168,0.39831854484245466,LGP Proband,Selected genes down-regulated in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts) at 6 h time point.,CGP,C2,17,55
Cohort,-0.0593351952287312,0.02319012778493139,-2.558640287755825,0.010692175499648461,LonGen OPEL,Selected genes down-regulated in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts) at 6 h time point.,CGP,C2,48,35
Cohort,-0.016236736098891407,0.015196828116681363,-1.06842927841426,0.28570829413125326,LGP Offspring,Selected genes whose expression profile follows that of APOBEC2 [GeneID=10930] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,10,11
Cohort,-0.03687739048058156,0.04599978073422102,-0.8016862231072992,0.42296283993757033,LGP Proband,Selected genes whose expression profile follows that of APOBEC2 [GeneID=10930] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,10,23
Cohort,0.00917817343387585,0.014852941017529958,0.6179364358239523,0.5367939895998926,LonGen OPEL,Selected genes whose expression profile follows that of APOBEC2 [GeneID=10930] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,13,19
Cohort,0.02738694555158689,0.028050233195134302,0.9763535782774716,0.3292385342028822,LGP Offspring,Selected gradually up-regulated genes whose expression profile follows that of CCNE1 [GeneID=898] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,20,54
Cohort,0.06030807666005077,0.07186653148979509,0.8391677657160121,0.4016156394914021,LGP Proband,Selected gradually up-regulated genes whose expression profile follows that of CCNE1 [GeneID=898] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,20,65
Cohort,-0.021764357619896205,0.02188947591909519,-0.994284088862546,0.3203867259909117,LonGen OPEL,Selected gradually up-regulated genes whose expression profile follows that of CCNE1 [GeneID=898] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,36,33
Cohort,-0.049160118844455654,0.04087374624202969,-1.2027309303472957,0.2295015440560926,LGP Offspring,Selected gradually up-regulated genes whose expression profile follows that of HBZ [GeneID=3050] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,55,99
Cohort,-0.009274360100348164,0.10366491552959611,-0.08946479194979283,0.9287340128342401,LGP Proband,Selected gradually up-regulated genes whose expression profile follows that of HBZ [GeneID=3050] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,55,128
Cohort,-0.0394456656697448,0.030757282821989525,-1.2824821327046363,0.20004690910066067,LonGen OPEL,Selected gradually up-regulated genes whose expression profile follows that of HBZ [GeneID=3050] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,73,68
Cohort,-0.01843580404226554,0.02971998915463621,-0.6203166477060985,0.5352583928261436,LGP Offspring,Selected gradually up-regulated genes whose expression profile follows that of HEMGN [GeneID=55363] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,29,54
Cohort,-0.06808168110794818,0.07754379626238683,-0.8779771482631382,0.3802089757326519,LGP Proband,Selected gradually up-regulated genes whose expression profile follows that of HEMGN [GeneID=55363] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,29,70
Cohort,-0.015650510975435288,0.02130263721709344,-0.7346748111955438,0.4627539356067818,LonGen OPEL,Selected gradually up-regulated genes whose expression profile follows that of HEMGN [GeneID=55363] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).,CGP,C2,35,35
Cohort,0.02178348297794948,0.048750275574946225,0.446838150575388,0.6551350405892032,LGP Offspring,Genes down-regulated in monolayer (2D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,70,160
Cohort,-0.011774834018082202,0.12581225228625356,-0.09359051923887017,0.9254569195269444,LGP Proband,Genes down-regulated in monolayer (2D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,70,176
Cohort,0.0020867327154049393,0.03849596545796574,0.05420653023194003,0.9567842194490066,LonGen OPEL,Genes down-regulated in monolayer (2D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,104,133
Cohort,-0.01614524765212602,0.054533280521683165,-0.29606228522610983,0.7672734413213234,LGP Offspring,Genes up-regulated in monolayer (2D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,90,185
Cohort,0.04483925447831207,0.14725863914053153,0.30449320148559283,0.7608281333568722,LGP Proband,Genes up-regulated in monolayer (2D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,90,241
Cohort,-0.016406976548635568,0.043339892489764956,-0.3785652341548886,0.7051116859314512,LonGen OPEL,Genes up-regulated in monolayer (2D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,125,147
Cohort,-0.18042039938203275,0.09352271495177168,-1.9291612682017727,0.054129109551687205,LGP Offspring,Genes down-regulated in three-dimentional (3D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,292,533
Cohort,0.07159612455928434,0.26589382820192176,0.26926583833647205,0.7877917197833111,LGP Proband,Genes down-regulated in three-dimentional (3D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,292,794
Cohort,-0.046780973826609604,0.07931692008877526,-0.5897981637997305,0.5554933472586421,LonGen OPEL,Genes down-regulated in three-dimentional (3D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,466,534
Cohort,-8.605127131328537e-4,0.0691848752383886,-0.01243787330927181,0.9900799385033803,LGP Offspring,Genes up-regulated in three-dimentional (3D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,178,372
Cohort,-0.44890549655704204,0.20081081617780372,-2.2354647279535387,0.025650795054792133,LGP Proband,Genes up-regulated in three-dimentional (3D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,178,508
Cohort,-0.01635846910591719,0.06848160250279858,-0.23887392391626175,0.8112648316585256,LonGen OPEL,Genes up-regulated in three-dimentional (3D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.,CGP,C2,310,356
Cohort,0.04760205329584812,0.06891565165388594,0.6907292052452644,0.48997283145226456,LGP Offspring,Genes down-regulated in HCT8/S1 cells (colon cancer) which normally lack DCC [GeneID=9423] compared to those stably expressing wild type DCC off a plasmid vector.,CGP,C2,134,306
Cohort,0.1697203414457154,0.17966444427111525,0.9446518042802386,0.34511025420789165,LGP Proband,Genes down-regulated in HCT8/S1 cells (colon cancer) which normally lack DCC [GeneID=9423] compared to those stably expressing wild type DCC off a plasmid vector.,CGP,C2,134,397
Cohort,-0.05988332253763825,0.054728554154043076,-1.094187914577209,0.2742035611643763,LonGen OPEL,Genes down-regulated in HCT8/S1 cells (colon cancer) which normally lack DCC [GeneID=9423] compared to those stably expressing wild type DCC off a plasmid vector.,CGP,C2,233,260
Cohort,-0.006952524583839107,0.005553239258633076,-1.2519764159325029,0.21101146227277218,LGP Offspring,Genes up-regulated in HCT8/S1 cells (colon cancer) which normally lack DCC [GeneID=9423] compared to those stably expressing wild type DCC off a plasmid vector.,CGP,C2,2,1
Cohort,-0.028224256606420556,0.01365172772063723,-2.067449423544694,0.03899978282390221,LGP Proband,Genes up-regulated in HCT8/S1 cells (colon cancer) which normally lack DCC [GeneID=9423] compared to those stably expressing wild type DCC off a plasmid vector.,CGP,C2,2,1
Cohort,0.002109098740701787,0.0026009139980775775,0.810906759031899,0.4176616025862441,LonGen OPEL,Genes up-regulated in HCT8/S1 cells (colon cancer) which normally lack DCC [GeneID=9423] compared to those stably expressing wild type DCC off a plasmid vector.,CGP,C2,0,1
Cohort,0.008307174612569168,0.023509252608290614,0.35335766521304107,0.7239304848218242,LGP Offspring,Genes down-regulated in HCT8/S11 cells (colon cancer) which lack DCC [GeneID=9423] and stably express NTN1 [GeneID=1630].,CGP,C2,18,40
Cohort,0.015413809419669421,0.06955720870553189,0.2215990219636798,0.8246802902684142,LGP Proband,Genes down-regulated in HCT8/S11 cells (colon cancer) which lack DCC [GeneID=9423] and stably express NTN1 [GeneID=1630].,CGP,C2,18,68
Cohort,-0.009835328025404388,0.02340258319385364,-0.42026676901152943,0.6744040051023256,LonGen OPEL,Genes down-regulated in HCT8/S11 cells (colon cancer) which lack DCC [GeneID=9423] and stably express NTN1 [GeneID=1630].,CGP,C2,37,44
Cohort,0.10118622276502938,0.07992768874653071,1.2659720849168357,0.2059591797097354,LGP Offspring,Genes down-regulated in HCT8/S11 cells (colon cancer) engineered to stably express NTN1 [GeneID=1630] off a plasmid vector.,CGP,C2,180,419
Cohort,-0.19849380826824364,0.209930447529228,-0.9455217697309388,0.34466641087733696,LGP Proband,Genes down-regulated in HCT8/S11 cells (colon cancer) engineered to stably express NTN1 [GeneID=1630] off a plasmid vector.,CGP,C2,180,532
Cohort,-0.09632273977827291,0.06797603419968015,-1.4170102877041058,0.15687117814589,LonGen OPEL,Genes down-regulated in HCT8/S11 cells (colon cancer) engineered to stably express NTN1 [GeneID=1630] off a plasmid vector.,CGP,C2,302,343
Cohort,0.010147627958944421,0.019069207068593424,0.5321473474194608,0.5947987939449267,LGP Offspring,Genes up-regulated in HCT8/S11 cells (colon cancer) engineered to stably express NTN1 [GeneID=1630] off a plasmid vector.,CGP,C2,10,26
Cohort,-0.05517452290425339,0.05245882386672717,-1.0517682028942454,0.29321055361717335,LGP Proband,Genes up-regulated in HCT8/S11 cells (colon cancer) engineered to stably express NTN1 [GeneID=1630] off a plasmid vector.,CGP,C2,10,35
Cohort,-0.01145021891919251,0.017344689303607205,-0.6601570497322883,0.5093440265732734,LonGen OPEL,Genes up-regulated in HCT8/S11 cells (colon cancer) engineered to stably express NTN1 [GeneID=1630] off a plasmid vector.,CGP,C2,25,20
Cohort,-0.1702958042734526,0.13635119613561503,-1.248949837624279,0.21211573875494655,LGP Offspring,Genes down-regulated in anaplastic thyroid carcinoma (ATC) compared to normal thyroid tissue.,CGP,C2,594,1169
Cohort,-0.42651385000206266,0.3711620820049181,-1.1491309879989602,0.25083141720030355,LGP Proband,Genes down-regulated in anaplastic thyroid carcinoma (ATC) compared to normal thyroid tissue.,CGP,C2,594,1655
Cohort,0.050570482193763026,0.11991498533209641,0.421719454442758,0.6733436654137422,LonGen OPEL,Genes down-regulated in anaplastic thyroid carcinoma (ATC) compared to normal thyroid tissue.,CGP,C2,877,1088
Cohort,-0.3106299574935729,0.14158879856399834,-2.193887939187278,0.028583141669436454,LGP Offspring,Genes up-regulated in anaplastic thyroid carcinoma (ATC) compared to normal thyroid tissue.,CGP,C2,657,1209
Cohort,-0.9275118429815752,0.39996115132985954,-2.3190048330884747,0.020635603053269728,LGP Proband,Genes up-regulated in anaplastic thyroid carcinoma (ATC) compared to normal thyroid tissue.,CGP,C2,657,1791
Cohort,-0.2156163190700563,0.1209495653460374,-1.7826961052168875,0.07501681129554663,LonGen OPEL,Genes up-regulated in anaplastic thyroid carcinoma (ATC) compared to normal thyroid tissue.,CGP,C2,1053,1185
Cohort,-0.021131752866923356,0.04812548188509255,-0.43909696150947364,0.6607315949505175,LGP Offspring,Genes down-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to anaplastic thyroid carcinoma (ATC).,CGP,C2,75,148
Cohort,5.180650119817379e-4,0.1322941201780922,0.003916009353131698,0.996876421057311,LGP Proband,Genes down-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to anaplastic thyroid carcinoma (ATC).,CGP,C2,75,216
Cohort,-0.0681107880291457,0.04333520314072727,-1.5717195972974187,0.11641297492507763,LonGen OPEL,Genes down-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to anaplastic thyroid carcinoma (ATC).,CGP,C2,134,141
Cohort,-0.2826124188059226,0.16612868361430194,-1.7011657027395635,0.08937174264555957,LGP Offspring,Genes down-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to normal thyroid tissue.,CGP,C2,929,1830
Cohort,-0.455093702265031,0.47278096544815185,-0.9625888847569085,0.33603288201119264,LGP Proband,Genes down-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to normal thyroid tissue.,CGP,C2,929,2534
Cohort,0.23409066578903182,0.14135621640607307,1.6560337545860813,0.09810910581792161,LonGen OPEL,Genes down-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to normal thyroid tissue.,CGP,C2,1320,1712
Cohort,-0.05282208539744729,0.13207211191450424,-0.39994882062339715,0.6893205566881393,LGP Offspring,Genes up-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to normal thyroid tissue.,CGP,C2,533,1099
Cohort,0.4861812909524586,0.37030190744354863,1.3129321809571706,0.1895669436346961,LGP Proband,Genes up-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to normal thyroid tissue.,CGP,C2,533,1509
Cohort,-0.06312879075089521,0.10937359015487311,-0.5771849553580968,0.5639777214840846,LonGen OPEL,Genes up-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to normal thyroid tissue.,CGP,C2,866,1014
Cohort,0.007173500640799612,0.017540817208576517,0.40896045808470977,0.6826982091183668,LGP Offspring,Genes up-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to anaplastic thyroid carcinoma (ATC).,CGP,C2,9,22
Cohort,-0.06738058691480536,0.0436963139913414,-1.542019927084859,0.12344807677709861,LGP Proband,Genes up-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to anaplastic thyroid carcinoma (ATC).,CGP,C2,9,23
Cohort,0.006567235789507492,0.016801690971409423,0.3908675502175716,0.6959997307097794,LonGen OPEL,Genes up-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to anaplastic thyroid carcinoma (ATC).,CGP,C2,17,23
Cohort,0.10903645871000932,0.07018257080771596,1.5536116368370723,0.12074510214593942,LGP Offspring,Genes whose expression decreases with age in normal kidney.,CGP,C2,144,363
Cohort,0.4730791706572992,0.19487088290803004,2.4276544735550387,0.015407503546018489,LGP Proband,Genes whose expression decreases with age in normal kidney.,CGP,C2,144,495
Cohort,0.014980560993207253,0.05965849354382978,0.2511052509598045,0.8017975421636422,LonGen OPEL,Genes whose expression decreases with age in normal kidney.,CGP,C2,261,307
Cohort,0.06298927337122225,0.06528539277285318,0.9648295077335324,0.3349752339448807,LGP Offspring,"Genes whose expression decreases with age in normal kidney, excluding those with higher expression in blood.",CGP,C2,130,308
Cohort,0.230639860632601,0.17698533850137838,1.3031580049824565,0.19288048052385942,LGP Proband,"Genes whose expression decreases with age in normal kidney, excluding those with higher expression in blood.",CGP,C2,130,419
Cohort,-0.029856497978331686,0.0596862839055965,-0.5002237704319901,0.6170557834820732,LonGen OPEL,"Genes whose expression decreases with age in normal kidney, excluding those with higher expression in blood.",CGP,C2,244,272
Cohort,0.0764271879979479,0.08558230365423226,0.8930255991557243,0.3721612562290739,LGP Offspring,"Genes whose expression increases with age in normal kidney, excluding those with higher expression in blood.",CGP,C2,219,486
Cohort,-0.40302718584175784,0.21757128228861738,-1.8523914627074978,0.06432278482969349,LGP Proband,"Genes whose expression increases with age in normal kidney, excluding those with higher expression in blood.",CGP,C2,219,616
Cohort,-0.05701249033970374,0.07239817871215463,-0.7874851460887945,0.4312323359611051,LonGen OPEL,"Genes whose expression increases with age in normal kidney, excluding those with higher expression in blood.",CGP,C2,351,400
Cohort,-0.16975875662614084,0.11421330493973623,-1.4863308326093245,0.13765785753774962,LGP Offspring,Genes whose expression increases with age in normal kidney.,CGP,C2,440,831
Cohort,-0.5482179314168353,0.30705272121661553,-1.7854195502474823,0.07455658813328819,LGP Proband,Genes whose expression increases with age in normal kidney.,CGP,C2,440,1134
Cohort,-0.09374578875459655,0.10015196323553661,-0.9360354577785552,0.34953881742227366,LonGen OPEL,Genes whose expression increases with age in normal kidney.,CGP,C2,677,771
Cohort,0.008820487072686858,0.0421507628411355,0.20926043749032283,0.8343079780340008,LGP Offspring,Genes down-regulated in liver samples containing tumor thrombi in the major branches of the portal vein at surgery (PT) compared to those from metastasis-free HCC patients (PN) at the time of surgery and at follow-up.,CGP,C2,49,118
Cohort,0.20904885883930494,0.11737420514817885,1.781046002189251,0.07526881862303567,LGP Proband,Genes down-regulated in liver samples containing tumor thrombi in the major branches of the portal vein at surgery (PT) compared to those from metastasis-free HCC patients (PN) at the time of surgery and at follow-up.,CGP,C2,49,165
Cohort,-0.046764503219973996,0.03789861822183361,-1.233936893061518,0.21759061524514584,LonGen OPEL,Genes down-regulated in liver samples containing tumor thrombi in the major branches of the portal vein at surgery (PT) compared to those from metastasis-free HCC patients (PN) at the time of surgery and at follow-up.,CGP,C2,110,110
Cohort,-0.046693639934969736,0.06325632145519533,-0.7381655913716545,0.4606700041518279,LGP Offspring,Genes up-regulated in liver samples containing tumor thrombi in the major branches of the portal vein at surgery (PT) compared to those from metastasis-free HCC patients (PN) at the time of surgery and at follow-up.,CGP,C2,133,263
Cohort,-0.1097477381895777,0.1662993434850069,-0.6599408986811319,0.5094739626882203,LGP Proband,Genes up-regulated in liver samples containing tumor thrombi in the major branches of the portal vein at surgery (PT) compared to those from metastasis-free HCC patients (PN) at the time of surgery and at follow-up.,CGP,C2,133,322
Cohort,-0.02082108958519671,0.05354379844527564,-0.38886089873651525,0.6974830414428341,LonGen OPEL,Genes up-regulated in liver samples containing tumor thrombi in the major branches of the portal vein at surgery (PT) compared to those from metastasis-free HCC patients (PN) at the time of surgery and at follow-up.,CGP,C2,200,216
Cohort,-0.01849881304194991,0.011009475059116744,-1.6802629501059985,0.0933681648185174,LGP Offspring,Genes down-regulated in T lymphocytes overexpressing TERT [GeneID=7015] off a retrovirus vector.,CGP,C2,8,5
Cohort,-0.03582243439109199,0.034133901437629934,-1.0494679155427742,0.2942668273761028,LGP Proband,Genes down-regulated in T lymphocytes overexpressing TERT [GeneID=7015] off a retrovirus vector.,CGP,C2,8,12
Cohort,0.008904049854636128,0.009281731144319296,0.9593091758627031,0.3376943013231002,LonGen OPEL,Genes down-regulated in T lymphocytes overexpressing TERT [GeneID=7015] off a retrovirus vector.,CGP,C2,4,9
Cohort,-0.008588532413417631,0.023549243110746403,-0.3647052422461239,0.715445505936936,LGP Offspring,Genes up-regulated in T lymphocytes overexpressing TERT [GeneID=7015] off a retrovirus vector.,CGP,C2,17,35
Cohort,0.03202556913652337,0.06308010687443784,0.5076968116155999,0.6118002188205642,LGP Proband,Genes up-regulated in T lymphocytes overexpressing TERT [GeneID=7015] off a retrovirus vector.,CGP,C2,17,43
Cohort,-0.0015896847157282547,0.017768789970215474,-0.08946499555641815,0.9287348763225232,LonGen OPEL,Genes up-regulated in T lymphocytes overexpressing TERT [GeneID=7015] off a retrovirus vector.,CGP,C2,23,27
Cohort,-0.016813539051451828,0.059731024050150586,-0.28148754050047864,0.7784226256672863,LGP Offspring,Genes up-regulated genes in cell lines with HDAC2 [GeneID=3066] loss of function (LOS).,CGP,C2,107,218
Cohort,0.009305582562448296,0.1592927418064616,0.0584181203545008,0.9534295752360693,LGP Proband,Genes up-regulated genes in cell lines with HDAC2 [GeneID=3066] loss of function (LOS).,CGP,C2,107,287
Cohort,0.030223973135029062,0.05116007380376743,0.5907726648510693,0.5548404491939216,LonGen OPEL,Genes up-regulated genes in cell lines with HDAC2 [GeneID=3066] loss of function (LOS).,CGP,C2,184,229
Cohort,-0.02855149709609712,0.0245074218567749,-1.165014307215031,0.244424137827802,LGP Offspring,Neuroblastoma markers down-regulated in neuroblastoma cell lines expressing ESWR1-FLI1 [GeneID=2130;2313] fusion protein.,CGP,C2,23,40
Cohort,0.0032826136870418203,0.07457820723750243,0.044015722670672136,0.9649024071515736,LGP Proband,Neuroblastoma markers down-regulated in neuroblastoma cell lines expressing ESWR1-FLI1 [GeneID=2130;2313] fusion protein.,CGP,C2,23,67
Cohort,-0.008754973480274372,0.022393323184246673,-0.3909635657128973,0.6959287854896772,LonGen OPEL,Neuroblastoma markers down-regulated in neuroblastoma cell lines expressing ESWR1-FLI1 [GeneID=2130;2313] fusion protein.,CGP,C2,38,40
Cohort,-0.044706588178135484,0.02578064936159512,-1.734114123778974,0.08335371874460636,LGP Offspring,ES/PNET (Ewing sarcoma; primitive neuroectodermal tumors) markers up-regulated in neuroblastoma cell lines expressing ESWR1-FLI1 [GeneID=2130;2313] fusion protein.,CGP,C2,29,39
Cohort,-0.0060258522861034915,0.07482724705844498,-0.08053018817325867,0.9358349074728671,LGP Proband,ES/PNET (Ewing sarcoma; primitive neuroectodermal tumors) markers up-regulated in neuroblastoma cell lines expressing ESWR1-FLI1 [GeneID=2130;2313] fusion protein.,CGP,C2,29,61
Cohort,-0.022687459118433482,0.020781465134648625,-1.0917160542548572,0.2752882482795018,LonGen OPEL,ES/PNET (Ewing sarcoma; primitive neuroectodermal tumors) markers up-regulated in neuroblastoma cell lines expressing ESWR1-FLI1 [GeneID=2130;2313] fusion protein.,CGP,C2,32,31
Cohort,-0.01845158648135524,0.05843293504004936,-0.3157737407629568,0.7522717160624098,LGP Offspring,Top 100 probe sets for core-binding factor (CBF) acute myeloid leukemia (AML): contains CBFB MYH11 [GeneID=865;4629] or AML1 ETO [GeneID=861;862] fusions.,CGP,C2,112,217
Cohort,-0.31527260437764626,0.1619557491903771,-1.946658923525135,0.051911068450510786,LGP Proband,Top 100 probe sets for core-binding factor (CBF) acute myeloid leukemia (AML): contains CBFB MYH11 [GeneID=865;4629] or AML1 ETO [GeneID=861;862] fusions.,CGP,C2,112,288
Cohort,0.030146453378959784,0.04945217719031528,0.6096082132631295,0.5422953344608631,LonGen OPEL,Top 100 probe sets for core-binding factor (CBF) acute myeloid leukemia (AML): contains CBFB MYH11 [GeneID=865;4629] or AML1 ETO [GeneID=861;862] fusions.,CGP,C2,162,200
Cohort,-0.03823565973254764,0.04172150791299011,-0.9164496118473909,0.35975794008393713,LGP Offspring,"Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype FAB M7 (also known as acute megakaryoblastic leukemia, AMKL).",CGP,C2,61,120
Cohort,0.06308534749740896,0.12539737535570594,0.5030834761769071,0.6150384141991081,LGP Proband,"Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype FAB M7 (also known as acute megakaryoblastic leukemia, AMKL).",CGP,C2,61,188
Cohort,-6.818166670494379e-5,0.04106159418410024,-0.0016604729567792794,0.9986755509091443,LonGen OPEL,"Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype FAB M7 (also known as acute megakaryoblastic leukemia, AMKL).",CGP,C2,109,132
Cohort,-0.08677754165466316,0.048201564158224915,-1.8003055122819245,0.07225808852092969,LGP Offspring,Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype t(8;21) ; has AML1 ETO fusion [GeneID=861;862].,CGP,C2,95,162
Cohort,0.06687823850323148,0.14836079771418778,0.45078106571029775,0.6522645191015563,LGP Proband,Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype t(8;21) ; has AML1 ETO fusion [GeneID=861;862].,CGP,C2,95,244
Cohort,-0.07108189770238622,0.047010496931306815,-1.5120431040380893,0.13091978885538164,LonGen OPEL,Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype t(8;21) ; has AML1 ETO fusion [GeneID=861;862].,CGP,C2,158,162
Cohort,-0.05672251883853047,0.03592855135502184,-1.5787588616651027,0.11485916893797968,LGP Offspring,Top 63 probe sets for pediatric acute myeloid leukemia (AML) subtype inv(16); has a CBFB-MYH11 fusion [GeneID=865;4629].,CGP,C2,50,82
Cohort,0.0768684824124574,0.10269832260745068,0.7484881978674173,0.45437676506417446,LGP Proband,Top 63 probe sets for pediatric acute myeloid leukemia (AML) subtype inv(16); has a CBFB-MYH11 fusion [GeneID=865;4629].,CGP,C2,50,138
Cohort,-0.06044800379420585,0.030757279631777962,-1.965323478470179,0.049724141578126234,LonGen OPEL,Top 63 probe sets for pediatric acute myeloid leukemia (AML) subtype inv(16); has a CBFB-MYH11 fusion [GeneID=865;4629].,CGP,C2,80,71
Cohort,-0.037788316438475716,0.047415141568871146,-0.7969672806647148,0.42574985221448236,LGP Offspring,Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtypes with chimeric MLL fusions [GeneID=4297].,CGP,C2,74,144
Cohort,0.07698254710505051,0.12686942927021627,0.6067856342372847,0.5441583239277643,LGP Proband,Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtypes with chimeric MLL fusions [GeneID=4297].,CGP,C2,74,196
Cohort,-0.003048129844223655,0.04088685033339843,-0.0745503705804844,0.9405911931712124,LonGen OPEL,Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtypes with chimeric MLL fusions [GeneID=4297].,CGP,C2,117,139
Cohort,0.023728997444718694,0.058374367777619195,0.40649686408794683,0.6845062173504994,LGP Offspring,Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype t(15;17): has PML RARA fusion [GeneID=5371;5914].,CGP,C2,113,262
Cohort,-0.028635520029256383,0.1694066910643768,-0.16903417361699427,0.8658107490897093,LGP Proband,Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype t(15;17): has PML RARA fusion [GeneID=5371;5914].,CGP,C2,113,375
Cohort,0.07923139617692915,0.051342628463471846,1.5431893252854985,0.12318228555005513,LonGen OPEL,Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype t(15;17): has PML RARA fusion [GeneID=5371;5914].,CGP,C2,179,234
Cohort,-0.015039133016812301,0.0544742692499183,-0.2760777376896131,0.7825727372216847,LGP Offspring,Top 100 probe sets associated with MLL fusions [GeneID=4297] irrespective of the lineage of the pediatric acute leukemia.,CGP,C2,108,215
Cohort,-0.19862874329516658,0.14449000431626477,-1.3746884722932187,0.16959727420285356,LGP Proband,Top 100 probe sets associated with MLL fusions [GeneID=4297] irrespective of the lineage of the pediatric acute leukemia.,CGP,C2,108,277
Cohort,0.03631381518470163,0.047534394135956955,0.7639482072883386,0.44512448859444154,LonGen OPEL,Top 100 probe sets associated with MLL fusions [GeneID=4297] irrespective of the lineage of the pediatric acute leukemia.,CGP,C2,158,196
Cohort,-0.09073387845955164,0.06183358815341398,-1.4673882135779308,0.14273555923737546,LGP Offspring,The 'Cervical Cancer Proliferation Cluster' (CCPC): genes whose expression in cervical carcinoma positively correlates with that of the HPV E6 and E7 oncogenes; they are also differentially expressed according to disease outcome.,CGP,C2,136,236
Cohort,-0.23652446527419865,0.16566257974168802,-1.4277482919981275,0.15373864878496296,LGP Proband,The 'Cervical Cancer Proliferation Cluster' (CCPC): genes whose expression in cervical carcinoma positively correlates with that of the HPV E6 and E7 oncogenes; they are also differentially expressed according to disease outcome.,CGP,C2,136,315
Cohort,0.009255426623860225,0.047948826717523985,0.19302717620987417,0.8469869240797417,LonGen OPEL,The 'Cervical Cancer Proliferation Cluster' (CCPC): genes whose expression in cervical carcinoma positively correlates with that of the HPV E6 and E7 oncogenes; they are also differentially expressed according to disease outcome.,CGP,C2,169,214
Cohort,-0.05620784263212167,0.043818663017018665,-1.2827375086796051,0.20002369439556728,LGP Offspring,Genes in the most frequently homozygous deleted loci in a panel of glioma cell lines.,CGP,C2,69,118
Cohort,-0.2138333544528443,0.12440429681856686,-1.718858270343364,0.08601127137765725,LGP Proband,Genes in the most frequently homozygous deleted loci in a panel of glioma cell lines.,CGP,C2,69,179
Cohort,0.021279308195992025,0.03626515372738483,0.5867701087372871,0.5575244848006127,LonGen OPEL,Genes in the most frequently homozygous deleted loci in a panel of glioma cell lines.,CGP,C2,92,123
Cohort,0.062151965334200254,0.054752104237158455,1.1351520859360826,0.25671392036733715,LGP Offspring,Genes in the most frequently gained loci in a panel of glioma cell lines.,CGP,C2,97,226
Cohort,0.049611679094876154,0.15075185061993485,0.329094992140121,0.742166513125055,LGP Proband,Genes in the most frequently gained loci in a panel of glioma cell lines.,CGP,C2,97,305
Cohort,-0.03163314838142543,0.04827295953440509,-0.6552974726747356,0.5124655774264135,LonGen OPEL,Genes in the most frequently gained loci in a panel of glioma cell lines.,CGP,C2,163,184
Cohort,0.07850734799849199,0.03829408433625098,2.0501168616316345,0.040738225341274595,LGP Offspring,Genes in the most frequently heterozygous deleted loci of a panel of glioma cell lines.,CGP,C2,34,111
Cohort,-0.09326846020646316,0.09954652271600962,-0.9369333821186625,0.3490640557388547,LGP Proband,Genes in the most frequently heterozygous deleted loci of a panel of glioma cell lines.,CGP,C2,34,130
Cohort,-0.03954643535797739,0.03134559391142941,-1.2616266091406787,0.20745275251396667,LonGen OPEL,Genes in the most frequently heterozygous deleted loci of a panel of glioma cell lines.,CGP,C2,73,72
Cohort,0.05335083023901017,0.025836205738266744,2.064963825550852,0.03930717798560438,LGP Offspring,Genes down-regulated in blood vessel cells from wound site.,CGP,C2,14,53
Cohort,0.012053505263029582,0.06858899970221352,0.17573525369025886,0.8605445967325038,LGP Proband,Genes down-regulated in blood vessel cells from wound site.,CGP,C2,14,66
Cohort,0.03675631785898082,0.022330919971363033,1.645983143825547,0.10016197779910214,LonGen OPEL,Genes down-regulated in blood vessel cells from wound site.,CGP,C2,29,48
Cohort,-0.028042148944495554,0.03799505911295158,-0.7380472513842379,0.4607418632276893,LGP Offspring,Genes up-regulated in blood vessel cells from wound site.,CGP,C2,48,91
Cohort,-0.0912477773180852,0.09945679886787157,-0.9174614340776033,0.3591661253023255,LGP Proband,Genes up-regulated in blood vessel cells from wound site.,CGP,C2,48,118
Cohort,0.00841278229538287,0.03321988472221277,0.2532453789569471,0.8001439910437556,LonGen OPEL,Genes up-regulated in blood vessel cells from wound site.,CGP,C2,74,82
Cohort,0.03502432500983894,0.022933724311720593,1.5271974378770776,0.1271796575552565,LGP Offspring,Genes in discrete regions of loss within 16q region detected in individual invasive breast cancer tumors.,CGP,C2,12,43
Cohort,0.031282832105890196,0.06182498804537622,0.5059901035958192,0.6129973114675338,LGP Proband,Genes in discrete regions of loss within 16q region detected in individual invasive breast cancer tumors.,CGP,C2,12,55
Cohort,0.008365949462725484,0.021353757025398445,0.3917788074845523,0.6953265161604317,LonGen OPEL,Genes in discrete regions of loss within 16q region detected in individual invasive breast cancer tumors.,CGP,C2,28,39
Cohort,0.008581470964969874,0.04335720818694235,0.19792489700834354,0.8431633266783296,LGP Offspring,Genes in discrete regions of gain within 16q region detected in individual invasive breast cancer tumors.,CGP,C2,68,137
Cohort,-0.24540116560746564,0.11245550963632693,-2.1822066913490983,0.029372665140649887,LGP Proband,Genes in discrete regions of gain within 16q region detected in individual invasive breast cancer tumors.,CGP,C2,68,149
Cohort,0.04668996478186154,0.03518801551462643,1.3268712116616566,0.18493178432625543,LonGen OPEL,Genes in discrete regions of gain within 16q region detected in individual invasive breast cancer tumors.,CGP,C2,84,117
Cohort,0.009360745546234884,0.01628762415803044,0.5747152227613054,0.5656751178570526,LGP Offspring,Genes whose expression most uniformly correlated with that of MMP14 [GeneID=4323] both in HT1080 cells (fibrosarcoma) and in 190 human tumors.,CGP,C2,7,20
Cohort,0.04045640719177514,0.04917054000390412,0.8227773619846949,0.41086979607400254,LGP Proband,Genes whose expression most uniformly correlated with that of MMP14 [GeneID=4323] both in HT1080 cells (fibrosarcoma) and in 190 human tumors.,CGP,C2,7,34
Cohort,-0.032907851829761955,0.015455990994191109,-2.129132440755811,0.03354965826905066,LonGen OPEL,Genes whose expression most uniformly correlated with that of MMP14 [GeneID=4323] both in HT1080 cells (fibrosarcoma) and in 190 human tumors.,CGP,C2,23,14
Cohort,0.013753885454754772,0.030993432643863228,0.4437677366297816,0.6573525206316778,LGP Offspring,Genes down-regulated in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.,CGP,C2,30,69
Cohort,0.023039254788047362,0.09211362813936723,0.2501177649108462,0.8025578749929128,LGP Proband,Genes down-regulated in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.,CGP,C2,30,103
Cohort,-0.025445044348533858,0.0311284376990996,-0.81742118234446,0.41393236835607017,LonGen OPEL,Genes down-regulated in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.,CGP,C2,72,75
Cohort,0.066650994320331,0.044330786859269875,1.5034922464137093,0.13317917067740734,LGP Offspring,Genes linked to the ECM maintenance and angiogenesis that were changed in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.,CGP,C2,59,142
Cohort,-0.24905736786319763,0.12273531891092374,-2.0292232918215927,0.04275269060824166,LGP Proband,Genes linked to the ECM maintenance and angiogenesis that were changed in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.,CGP,C2,59,192
Cohort,0.06233548366169609,0.037975699640401185,1.6414571489653156,0.10109756465920892,LonGen OPEL,Genes linked to the ECM maintenance and angiogenesis that were changed in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.,CGP,C2,93,126
Cohort,-0.01653240879288318,0.08889274531685813,-0.18598153014572136,0.8525150381817821,LGP Offspring,Genes up-regulated in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.,CGP,C2,268,551
Cohort,0.024769638583348273,0.24570962593475568,0.10080858040915931,0.9197266440735725,LGP Proband,Genes up-regulated in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.,CGP,C2,268,741
Cohort,-0.03863715675449517,0.07847149490496337,-0.4923718708467136,0.6225922513143054,LonGen OPEL,Genes up-regulated in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.,CGP,C2,417,471
Cohort,0.010865915645043864,0.05662702186999848,0.1918856984919549,0.8478893639613392,LGP Offspring,Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to TNF [GeneID=7124].,CGP,C2,98,209
Cohort,-0.07801591869426946,0.15275103108189197,-0.5107390643565871,0.609668944358946,LGP Proband,Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to TNF [GeneID=7124].,CGP,C2,98,297
Cohort,0.08406616894221783,0.050884769074330316,1.6520890331528777,0.0989107779402225,LonGen OPEL,Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to TNF [GeneID=7124].,CGP,C2,157,230
Cohort,0.02252273317443971,0.032395321019003095,0.6952464882576059,0.4871397550475969,LGP Offspring,Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591] and TNF [GeneID=7124].,CGP,C2,30,68
Cohort,0.056885653017468105,0.08830203087288585,0.6442168142129956,0.5196119801294625,LGP Proband,Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591] and TNF [GeneID=7124].,CGP,C2,30,97
Cohort,0.05166964428799752,0.032063420309638685,1.611482611306597,0.10747098554351286,LonGen OPEL,Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591] and TNF [GeneID=7124].,CGP,C2,60,85
Cohort,-0.0029569582908980517,0.028482103210510704,-0.10381811585483092,0.9173444819935702,LGP Offspring,Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591] and TNF [GeneID=7124].,CGP,C2,27,58
Cohort,0.071060660897596,0.07928680941341153,0.8962482085396658,0.37037882908953135,LGP Proband,Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591] and TNF [GeneID=7124].,CGP,C2,27,72
Cohort,0.014176039598548896,0.02436388925718352,0.5818463320411453,0.5608349340635943,LonGen OPEL,Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591] and TNF [GeneID=7124].,CGP,C2,41,55
Cohort,-0.002922343407823476,0.019423866907717025,-0.15045116514170723,0.8804535566675904,LGP Offspring,Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to TNF [GeneID=7124].,CGP,C2,12,27
Cohort,0.028464433952982184,0.05326669162479688,0.5343758563697117,0.5932239363310601,LGP Proband,Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to TNF [GeneID=7124].,CGP,C2,12,34
Cohort,0.020071775838914927,0.015792917042440003,1.270935305046967,0.20412295240097456,LonGen OPEL,Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to TNF [GeneID=7124].,CGP,C2,16,23
Cohort,0.030899328016793626,0.02043809450259739,1.5118497476791077,0.13103940954147963,LGP Offspring,Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591].,CGP,C2,9,32
Cohort,0.04202049094227518,0.055484257781360485,0.7573407777726757,0.44905963955049377,LGP Proband,Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591].,CGP,C2,9,41
Cohort,0.022452628702455204,0.019444848239658426,1.1546826401381889,0.24856693387973874,LonGen OPEL,Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591].,CGP,C2,22,34
Cohort,-0.0057293015573669165,0.03284546286217744,-0.17443205417465385,0.8615781509450706,LGP Offspring,Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591].,CGP,C2,39,76
Cohort,-0.09630950746304567,0.09300786081892211,-1.0354985763036908,0.30073627960126387,LGP Proband,Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591].,CGP,C2,39,111
Cohort,0.026028961369402772,0.026256065413998712,0.9913504159509422,0.32181575163076104,LonGen OPEL,Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591].,CGP,C2,43,72
Cohort,-0.0699329491962062,0.06777505060901746,-1.0318391291160707,0.3025164985365683,LGP Offspring,Genes down-regulated in T98G cells (glioblastoma) by TNC [GeneID=3371].,CGP,C2,159,305
Cohort,-0.28672917310323776,0.18200700204743442,-1.5753744080049776,0.11554928098966542,LGP Proband,Genes down-regulated in T98G cells (glioblastoma) by TNC [GeneID=3371].,CGP,C2,159,364
Cohort,-0.04070964574882179,0.05810213540891586,-0.7006566189402883,0.48372208366564884,LonGen OPEL,Genes down-regulated in T98G cells (glioblastoma) by TNC [GeneID=3371].,CGP,C2,230,254
Cohort,-0.17146142479571544,0.06855940583785829,-2.500917601316711,0.012622727621092369,LGP Offspring,Genes up-regulated in T98G cells (glioblastoma) by TNC [GeneID=3371].,CGP,C2,192,319
Cohort,-0.39974517634210266,0.19075507758441157,-2.0955938966563568,0.0364191877599197,LGP Proband,Genes up-regulated in T98G cells (glioblastoma) by TNC [GeneID=3371].,CGP,C2,192,450
Cohort,-0.12710861731453288,0.06058616519009389,-2.097980899033955,0.036221538686312955,LonGen OPEL,Genes up-regulated in T98G cells (glioblastoma) by TNC [GeneID=3371].,CGP,C2,292,284
Cohort,-0.08012568294819203,0.09397191928412857,-0.8526555971037285,0.39415231071175294,LGP Offspring,Genes down-regulated in peripheral blood monocytes by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,298,589
Cohort,-0.020210257245328118,0.24352343414648372,-0.0829910161055436,0.9338785973761927,LGP Proband,Genes down-regulated in peripheral blood monocytes by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,298,816
Cohort,-7.443483166488815e-4,0.08624234115747398,-0.008630891817857086,0.9931157927413885,LonGen OPEL,Genes down-regulated in peripheral blood monocytes by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,479,579
Cohort,-0.019929773039392584,0.09521107328143344,-0.20932200796101072,0.8342599354342266,LGP Offspring,Genes up-regulated in peripheral blood monocytes by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,287,609
Cohort,0.005888482613751826,0.26134064200789725,0.022531828836533915,0.9820291122865337,LGP Proband,Genes up-regulated in peripheral blood monocytes by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,287,860
Cohort,-0.008207540168133876,0.08490245489848017,-0.0966702338342021,0.9230126123721616,LonGen OPEL,Genes up-regulated in peripheral blood monocytes by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,480,566
Cohort,-0.06749116267469248,0.07840009858834467,-0.8608555842393549,0.3896228083027238,LGP Offspring,Genes down-regulated in peripheral blood monocytes by HGF [GeneID=3082].,CGP,C2,207,401
Cohort,-0.14712401163099006,0.21395684699712064,-0.6876340425458317,0.4918744498571429,LGP Proband,Genes down-regulated in peripheral blood monocytes by HGF [GeneID=3082].,CGP,C2,207,540
Cohort,-0.044074594384770925,0.06694017575312895,-0.6584176675501299,0.5104601717478108,LonGen OPEL,Genes down-regulated in peripheral blood monocytes by HGF [GeneID=3082].,CGP,C2,318,357
Cohort,-0.03256429331289199,0.10820215843370036,-0.3009578901593298,0.7635391477595632,LGP Offspring,Genes up-regulated in peripheral blood monocytes by HGF [GeneID=3082].,CGP,C2,378,797
Cohort,0.13280223699941404,0.29919328367394793,0.44386770775288537,0.6572533683310373,LGP Proband,Genes up-regulated in peripheral blood monocytes by HGF [GeneID=3082].,CGP,C2,378,1136
Cohort,0.03512270589998822,0.10260578956584612,0.342307252335392,0.7322100401476137,LonGen OPEL,Genes up-regulated in peripheral blood monocytes by HGF [GeneID=3082].,CGP,C2,641,788
Cohort,-0.07451105996012194,0.07926442143748529,-0.9400315880547713,0.3475371267830567,LGP Offspring,Genes down-regulated in peripheral blood mononucleocytes by HGF [GeneID=3082] compared to those regulated by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,214,403
Cohort,-0.3101541517963991,0.2273130257454273,-1.36443633522237,0.172798321749895,LGP Proband,Genes down-regulated in peripheral blood mononucleocytes by HGF [GeneID=3082] compared to those regulated by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,214,584
Cohort,6.867734574623871e-5,0.07138483421105224,9.620719373416386e-4,0.9992326188228425,LonGen OPEL,Genes down-regulated in peripheral blood mononucleocytes by HGF [GeneID=3082] compared to those regulated by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,324,382
Cohort,-0.025544396027462484,0.10794272923179955,-0.23664767612654725,0.8130018198867788,LGP Offspring,Genes up-regulated in peripheral blood mononucleocytes by HGF [GeneID=3082] compared to those regulated by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,371,795
Cohort,0.29583237716482247,0.2793546441844692,1.0589849974696406,0.289913219221532,LGP Proband,Genes up-regulated in peripheral blood mononucleocytes by HGF [GeneID=3082] compared to those regulated by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,371,1092
Cohort,-0.009020565830529155,0.09664169042693474,-0.09334031504083727,0.9256566929332921,LonGen OPEL,Genes up-regulated in peripheral blood mononucleocytes by HGF [GeneID=3082] compared to those regulated by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].,CGP,C2,635,763
Cohort,-0.015569103577320376,0.06330066179289506,-0.24595483106099011,0.8057918561946774,LGP Offspring,Genes upregulated by rapid Notch activation and linked to Notch TF binding peaks in mantle cell lymphoma cell lines.,CGP,C2,116,247
Cohort,0.21641163005745084,0.1695503153925369,1.2763858890879813,0.20217445163117562,LGP Proband,Genes upregulated by rapid Notch activation and linked to Notch TF binding peaks in mantle cell lymphoma cell lines.,CGP,C2,116,360
Cohort,-0.016921722805873153,0.04915746709789625,-0.34423504311509445,0.7307604484593833,LonGen OPEL,Genes upregulated by rapid Notch activation and linked to Notch TF binding peaks in mantle cell lymphoma cell lines.,CGP,C2,178,201
Cohort,-0.008231249204458231,0.10063328976112688,-0.08179449587702774,0.934834344454154,LGP Offspring,Genes down-regulated in colorectal adenoma compared to normal mucosa samples.,CGP,C2,316,636
Cohort,-0.026857961741980022,0.26690019084829536,-0.10062923393429098,0.9198689743482139,LGP Proband,Genes down-regulated in colorectal adenoma compared to normal mucosa samples.,CGP,C2,316,927
Cohort,-0.20517405490040141,0.0860866743136725,-2.3833427941798786,0.017389812094905213,LonGen OPEL,Genes down-regulated in colorectal adenoma compared to normal mucosa samples.,CGP,C2,519,533
Cohort,-0.005612619950562912,0.015947059297032894,-0.3519532878144621,0.7249829799139333,LGP Offspring,A selection of genes whose expression displayed significant negative correlation with size of colorectal adenoma.,CGP,C2,9,17
Cohort,-0.036908174613887706,0.049306778670608196,-0.7485415922311853,0.45434458860583316,LGP Proband,A selection of genes whose expression displayed significant negative correlation with size of colorectal adenoma.,CGP,C2,9,30
Cohort,0.010225760882857218,0.011226363068219527,0.9108703166571468,0.3626394529693485,LonGen OPEL,A selection of genes whose expression displayed significant negative correlation with size of colorectal adenoma.,CGP,C2,6,11
Cohort,-0.0082949578976253,0.026003916550126703,-0.31898879084754195,0.7498335523185757,LGP Offspring,A selection of genes whose expression displayed significant positive correlation with size of colorectal adenoma.,CGP,C2,23,47
Cohort,0.015421442377346835,0.0693814059936494,0.22227053713437842,0.8241577044830878,LGP Proband,A selection of genes whose expression displayed significant positive correlation with size of colorectal adenoma.,CGP,C2,23,54
Cohort,-0.0033700919019395577,0.02232651529379611,-0.1509457189172736,0.8800567784247444,LonGen OPEL,A selection of genes whose expression displayed significant positive correlation with size of colorectal adenoma.,CGP,C2,34,38
Cohort,-0.01944072895860358,0.060029876947267635,-0.32385088804498136,0.7461510960613955,LGP Offspring,Genes up-regulated in colorectal adenoma compared to normal mucosa samples.,CGP,C2,116,239
Cohort,-0.15075959718257476,0.16016439772060248,-0.9412803302614489,0.3468337771415606,LGP Proband,Genes up-regulated in colorectal adenoma compared to normal mucosa samples.,CGP,C2,116,288
Cohort,-0.04453005791990626,0.05161779269610065,-0.8626881467418924,0.3885687846426168,LonGen OPEL,Genes up-regulated in colorectal adenoma compared to normal mucosa samples.,CGP,C2,191,210
Cohort,-0.020897055952340437,0.029512406675198163,-0.7080769854632711,0.4791415170412754,LGP Offspring,Detoxification pathway genes down-regulated in enterocytes of transgenic mice expressing SV40 T antigen.,CGP,C2,29,53
Cohort,-0.04758592172408814,0.07685890881101086,-0.6191334545367752,0.53599752656634,LGP Proband,Detoxification pathway genes down-regulated in enterocytes of transgenic mice expressing SV40 T antigen.,CGP,C2,29,65
Cohort,-0.043081446302931356,0.02628312100548591,-1.6391297781545517,0.10158137328130988,LonGen OPEL,Detoxification pathway genes down-regulated in enterocytes of transgenic mice expressing SV40 T antigen.,CGP,C2,58,51
Cohort,-0.08375300841053643,0.04969588976510344,-1.685310572089766,0.09239017932805128,LGP Offspring,"Genes up-regulated in anergic mouse T helper cells (A.E7), versus non-anergic stimulated controls",CGP,C2,89,151
Cohort,-0.1616534718450097,0.1284143234597395,-1.2588429973365967,0.2084392907760955,LGP Proband,"Genes up-regulated in anergic mouse T helper cells (A.E7), versus non-anergic stimulated controls",CGP,C2,89,191
Cohort,-0.027389966711589026,0.044835158178795534,-0.6109037599992881,0.5414376930327056,LonGen OPEL,"Genes up-regulated in anergic mouse T helper cells (A.E7), versus non-anergic stimulated controls",CGP,C2,139,155
Cohort,-0.02758699700120612,0.027725439678570427,-0.9950066552967486,0.32008904926320764,LGP Offspring,Genes down-regulated in HT29 cells (colon cancer) after knockdown of CD24 [GeneID=100133941] by both RNAi and monoclonal antibodies.,CGP,C2,28,46
Cohort,-0.23553729449813596,0.07406031192868805,-3.180344348602427,0.0015253593779409956,LGP Proband,Genes down-regulated in HT29 cells (colon cancer) after knockdown of CD24 [GeneID=100133941] by both RNAi and monoclonal antibodies.,CGP,C2,28,61
Cohort,0.025354087272769676,0.026543299498437492,0.9551972720747163,0.3397679341116494,LonGen OPEL,Genes down-regulated in HT29 cells (colon cancer) after knockdown of CD24 [GeneID=100133941] by both RNAi and monoclonal antibodies.,CGP,C2,42,59
Cohort,0.014735848397901631,0.03336879614872394,0.4416056345642288,0.6589158271112938,LGP Offspring,Genes up-regulated in HT29 cells (colon cancer) after knockdown of CD24 [GeneID=100133941] by both RNAi and monoclonal antibodies.,CGP,C2,33,71
Cohort,-0.18537135443624841,0.08734605862901006,-2.1222635267790024,0.03410977115275502,LGP Proband,Genes up-regulated in HT29 cells (colon cancer) after knockdown of CD24 [GeneID=100133941] by both RNAi and monoclonal antibodies.,CGP,C2,33,97
Cohort,-0.007075326457522446,0.02747653900922467,-0.25750428229505373,0.7968560623667146,LonGen OPEL,Genes up-regulated in HT29 cells (colon cancer) after knockdown of CD24 [GeneID=100133941] by both RNAi and monoclonal antibodies.,CGP,C2,56,68
Cohort,-0.006781456534991014,0.025090211660923806,-0.27028295443009925,0.787025072399928,LGP Offspring,Selected genes down-regulated in peripheral blood monocytes (PBMC) of patients with hepatocellular carcinoma (HCC) compared to those with chronic hepatitis.,CGP,C2,22,41
Cohort,0.003034031118862881,0.06964551082706492,0.043563915072668644,0.965262443637888,LGP Proband,Selected genes down-regulated in peripheral blood monocytes (PBMC) of patients with hepatocellular carcinoma (HCC) compared to those with chronic hepatitis.,CGP,C2,22,60
Cohort,-0.032924555642048166,0.021467860391085915,-1.5336673074192064,0.12550886009778442,LonGen OPEL,Selected genes down-regulated in peripheral blood monocytes (PBMC) of patients with hepatocellular carcinoma (HCC) compared to those with chronic hepatitis.,CGP,C2,39,31
Cohort,-0.034485811282710485,0.04514126830337714,-0.7639530872492235,0.445161756221479,LGP Offspring,Selected genes up-regulated in peripheral blood monocytes (PBMC) of patients with hepatocellular carcinoma (HCC) compared to those with chronic hepatitis.,CGP,C2,68,131
Cohort,-0.15854024788311716,0.118887188186113,-1.33353517987934,0.18272032940087266,LGP Proband,Selected genes up-regulated in peripheral blood monocytes (PBMC) of patients with hepatocellular carcinoma (HCC) compared to those with chronic hepatitis.,CGP,C2,68,174
Cohort,0.04118521744899467,0.03890911444013575,1.0584979391489584,0.29014959077080954,LonGen OPEL,Selected genes up-regulated in peripheral blood monocytes (PBMC) of patients with hepatocellular carcinoma (HCC) compared to those with chronic hepatitis.,CGP,C2,94,130
Cohort,-0.04849228463540497,0.04650680102940075,-1.0426923280478704,0.2974635523638245,LGP Offspring,Selected genes down-regulated in inflammatory monocytes infiltrating hepatocellular carcinoma (HCC).,CGP,C2,72,125
Cohort,0.07017450281804127,0.12955810013974986,0.5416450437475269,0.5882077205829284,LGP Proband,Selected genes down-regulated in inflammatory monocytes infiltrating hepatocellular carcinoma (HCC).,CGP,C2,72,190
Cohort,-0.03313129946549212,0.03717246839467149,-0.8912859677147872,0.3730450993240657,LonGen OPEL,Selected genes down-regulated in inflammatory monocytes infiltrating hepatocellular carcinoma (HCC).,CGP,C2,114,122
Cohort,0.0026172222178486517,0.03333358004496776,0.07851608541050674,0.9374407703605081,LGP Offspring,Selected genes up-regulated in inflammatory monocytes infiltrating hepatocellular carcinoma (HCC).,CGP,C2,35,76
Cohort,0.028889502618691658,0.08986184345252762,0.3214879809799746,0.7479211717326912,LGP Proband,Selected genes up-regulated in inflammatory monocytes infiltrating hepatocellular carcinoma (HCC).,CGP,C2,35,102
Cohort,0.04541797285910204,0.02803701614669634,1.6199289047545002,0.10564362414557657,LonGen OPEL,Selected genes up-regulated in inflammatory monocytes infiltrating hepatocellular carcinoma (HCC).,CGP,C2,45,74
Cohort,0.022698882949228817,0.03236201860355195,0.7014050398802212,0.4832916626430829,LGP Offspring,Genes upregulated in anti-TNF therapy non-responders vs. responders after two weeks of anti-TNF therapy,CGP,C2,29,72
Cohort,0.04983754022452708,0.09067774943392283,0.5496115699347375,0.5827329599566657,LGP Proband,Genes upregulated in anti-TNF therapy non-responders vs. responders after two weeks of anti-TNF therapy,CGP,C2,29,105
Cohort,-0.025405538499185646,0.028698610058249616,-0.885253273507671,0.3762873785202775,LonGen OPEL,Genes upregulated in anti-TNF therapy non-responders vs. responders after two weeks of anti-TNF therapy,CGP,C2,63,59
Cohort,0.06921510306847342,0.029848887656993898,2.318850332509983,0.0207004494869524,LGP Offspring,Genes upregulated in anti-TNF therapy non-responders vs. responders prior to the initiation of anti-TNF therapy,CGP,C2,21,72
Cohort,-0.010912119536976095,0.07726001727139623,-0.1412388959045193,0.8877153269617613,LGP Proband,Genes upregulated in anti-TNF therapy non-responders vs. responders prior to the initiation of anti-TNF therapy,CGP,C2,21,79
Cohort,-0.02344390528069886,0.024586908348822493,-0.9535117204689799,0.34062031631668654,LonGen OPEL,Genes upregulated in anti-TNF therapy non-responders vs. responders prior to the initiation of anti-TNF therapy,CGP,C2,46,43
Cohort,0.016010790528300588,0.03758962931634797,0.42593637712030835,0.6702897865568567,LGP Offspring,Genes down-regulated in 293 cells (embryonic kidney) upon expression of KHSV (Kaposi sarcoma-associated herpesvirus) microRNAs.,CGP,C2,44,93
Cohort,-0.14537020619245053,0.09752466289242759,-1.4905994225563015,0.1364447923135093,LGP Proband,Genes down-regulated in 293 cells (embryonic kidney) upon expression of KHSV (Kaposi sarcoma-associated herpesvirus) microRNAs.,CGP,C2,44,124
Cohort,-0.034335796386648326,0.032349612650068776,-1.061397450351707,0.28883123796958776,LonGen OPEL,Genes down-regulated in 293 cells (embryonic kidney) upon expression of KHSV (Kaposi sarcoma-associated herpesvirus) microRNAs.,CGP,C2,75,80
Cohort,-0.007398101459931927,0.01742604653092843,-0.4245427353129975,0.6713051261228424,LGP Offspring,Genes up-regulated in 293 cells (embryonic kidney) upon expression of KHSV (Kaposi sarcoma-associated herpesvirus) microRNAs.,CGP,C2,10,19
Cohort,-0.02745916532286872,0.03838769530105167,-0.7153116410746453,0.4746166942532304,LGP Proband,Genes up-regulated in 293 cells (embryonic kidney) upon expression of KHSV (Kaposi sarcoma-associated herpesvirus) microRNAs.,CGP,C2,10,13
Cohort,-0.008534894603361876,0.012277253835788352,-0.6951794527928182,0.48714572808521317,LonGen OPEL,Genes up-regulated in 293 cells (embryonic kidney) upon expression of KHSV (Kaposi sarcoma-associated herpesvirus) microRNAs.,CGP,C2,12,11
Cohort,0.06410962432755324,0.05297289417345753,1.2102345044170884,0.22661192102771624,LGP Offspring,"Genes down-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by IFNG [GeneID=3458].",CGP,C2,78,193
Cohort,0.13748885102790073,0.13500660165530992,1.0183861332864916,0.3087898167839068,LGP Proband,"Genes down-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by IFNG [GeneID=3458].",CGP,C2,78,236
Cohort,-0.01826038725364185,0.04725128345872161,-0.3864527250269085,0.6992646859858699,LonGen OPEL,"Genes down-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by IFNG [GeneID=3458].",CGP,C2,154,182
Cohort,0.017201591755558583,0.04273994999351126,0.40247103139264584,0.6874646372236796,LGP Offspring,"Genes up-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by IFNG [GeneID=3458].",CGP,C2,54,123
Cohort,0.10379248900242304,0.1241652428225653,0.8359222487950565,0.403438067384125,LGP Proband,"Genes up-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by IFNG [GeneID=3458].",CGP,C2,54,187
Cohort,0.034523071286050276,0.03906635648425326,0.8837033804257053,0.3771231755180049,LonGen OPEL,"Genes up-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by IFNG [GeneID=3458].",CGP,C2,100,131
Cohort,0.01446739925653389,0.052302331460316424,0.2766109818165717,0.7821633830482831,LGP Offspring,"Genes down-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by TNF [GeneID=7124].",CGP,C2,85,178
Cohort,-0.35796821669103857,0.1420954788050897,-2.5192090536677694,0.011947776665357835,LGP Proband,"Genes down-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by TNF [GeneID=7124].",CGP,C2,85,240
Cohort,0.006675858541010639,0.04792671841863298,0.13929304490864525,0.8892538194813602,LonGen OPEL,"Genes down-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by TNF [GeneID=7124].",CGP,C2,148,186
Cohort,0.003286861182881756,0.05287264816493901,0.062165624324853556,0.9504493128265358,LGP Offspring,"Genes up-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by TNF [GeneID=7124].",CGP,C2,91,195
Cohort,-0.05506362683206635,0.14287085480734651,-0.38540839491943,0.7000331410144888,LGP Proband,"Genes up-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by TNF [GeneID=7124].",CGP,C2,91,251
Cohort,-0.03821053194148585,0.0465588489392362,-0.8206932261438482,0.4120667324992071,LonGen OPEL,"Genes up-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by TNF [GeneID=7124].",CGP,C2,160,174
Cohort,0.0017599012513142968,0.006399621263961723,0.27500084438197203,0.7833996170856121,LGP Offspring,"Genes up-regulated in BJ cells (forskin fibroblasts) upon overexpression of the most abundant alternative splicing forms of MDM2 [GeneID=4193], HDM2-A and HDM2-B, off a retroviral vector.",CGP,C2,1,3
Cohort,-0.02520292543598859,0.01576482995884757,-1.5986804489346336,0.11027038053501464,LGP Proband,"Genes up-regulated in BJ cells (forskin fibroblasts) upon overexpression of the most abundant alternative splicing forms of MDM2 [GeneID=4193], HDM2-A and HDM2-B, off a retroviral vector.",CGP,C2,1,3
Cohort,5.584755010501731e-4,0.003677964707952596,0.15184362695015047,0.8793487474881422,LonGen OPEL,"Genes up-regulated in BJ cells (forskin fibroblasts) upon overexpression of the most abundant alternative splicing forms of MDM2 [GeneID=4193], HDM2-A and HDM2-B, off a retroviral vector.",CGP,C2,1,1
Cohort,0.046448904026495506,0.03279736328581211,1.4162389708501033,0.15716615538460554,LGP Offspring,Hepatic genes regulated by fasting or in response to WY14643 [PubChem=5694] and which require intact PPARA [GeneID=5465].,CGP,C2,32,82
Cohort,-0.016576104406632583,0.09133558084276074,-0.181485728274606,0.856030431574206,LGP Proband,Hepatic genes regulated by fasting or in response to WY14643 [PubChem=5694] and which require intact PPARA [GeneID=5465].,CGP,C2,32,105
Cohort,-8.323956194221529e-4,0.028997900725950307,-0.028705375167976888,0.9771067645350039,LonGen OPEL,Hepatic genes regulated by fasting or in response to WY14643 [PubChem=5694] and which require intact PPARA [GeneID=5465].,CGP,C2,50,67
Cohort,-0.1382453859834518,0.08950188222289122,-1.544608700397742,0.12290892406793853,LGP Offspring,Genes down-regulated after double Cre-lox knockout  of both APC and MYC [GeneID=324;4609] in small intestine.,CGP,C2,259,488
Cohort,-0.345959515256981,0.2341400242439323,-1.477575294416783,0.1398990109746207,LGP Proband,Genes down-regulated after double Cre-lox knockout  of both APC and MYC [GeneID=324;4609] in small intestine.,CGP,C2,259,656
Cohort,0.06378677993440221,0.0760021152026311,0.8392763775631601,0.40156621536644566,LonGen OPEL,Genes down-regulated after double Cre-lox knockout  of both APC and MYC [GeneID=324;4609] in small intestine.,CGP,C2,377,481
Cohort,0.01611185678060199,0.08470236397164199,0.1902173212780245,0.8491959442993403,LGP Offspring,Genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine.,CGP,C2,211,447
Cohort,-0.11126145860248646,0.22268946510939647,-0.4996260534723954,0.6174701903268525,LGP Proband,Genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine.,CGP,C2,211,636
Cohort,0.04019257769524661,0.0734957372637505,0.5468695082411311,0.5846216536962041,LonGen OPEL,Genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine.,CGP,C2,356,439
Cohort,-0.01854390269609677,0.11019654300909017,-0.16828025807095487,0.8664131383120203,LGP Offspring,Top genes down-regulated at day 5 of Cre-Lox induced APC [GeneID=324] knockout in the intestine.,CGP,C2,326,701
Cohort,-0.17547725761669994,0.2832655425567621,-0.6194797151564488,0.5357695724229214,LGP Proband,Top genes down-regulated at day 5 of Cre-Lox induced APC [GeneID=324] knockout in the intestine.,CGP,C2,326,979
Cohort,-0.08605574180691411,0.0901415998033927,-0.9546728923672285,0.34003296559415297,LonGen OPEL,Top genes down-regulated at day 5 of Cre-Lox induced APC [GeneID=324] knockout in the intestine.,CGP,C2,550,630
Cohort,-0.04411322973418271,0.08526159119519859,-0.517386892688755,0.6050553591378067,LGP Offspring,Genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine that require functional MYC [GeneID=4609].,CGP,C2,228,468
Cohort,-0.2773593924191662,0.22909712576042476,-1.2106629077014743,0.22636760032133416,LGP Proband,Genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine that require functional MYC [GeneID=4609].,CGP,C2,228,626
Cohort,0.04440401345398645,0.0716381746819613,0.6198373095227329,0.535542288941419,LonGen OPEL,Genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine that require functional MYC [GeneID=4609].,CGP,C2,355,444
Cohort,-0.016526637675893723,0.05679180400417323,-0.29100392152852367,0.7711375810593389,LGP Offspring,Top genes up-regulated at day 5 of Cre-Lox induced APC [GeneID=324] knockout in the intestine.,CGP,C2,109,215
Cohort,-0.06827941980672046,0.1601693235958311,-0.42629523727661944,0.6700027309089074,LGP Proband,Top genes up-regulated at day 5 of Cre-Lox induced APC [GeneID=324] knockout in the intestine.,CGP,C2,109,304
Cohort,0.033303919114290564,0.048260868266550475,0.6900812254423001,0.49034425231288203,LonGen OPEL,Top genes up-regulated at day 5 of Cre-Lox induced APC [GeneID=324] knockout in the intestine.,CGP,C2,165,207
Cohort,0.008651855093601434,0.03849072456628319,0.2247776624392314,0.8222201705381882,LGP Offspring,Wnt target genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine that require functional MYC [GeneID=4609].,CGP,C2,51,107
Cohort,-0.058480211205101246,0.11452519391428408,-0.5106318462020726,0.6097440006748132,LGP Proband,Wnt target genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine that require functional MYC [GeneID=4609].,CGP,C2,51,162
Cohort,-0.05378794596151752,0.03256515266277948,-1.651702558207097,0.09898960086943069,LonGen OPEL,Wnt target genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine that require functional MYC [GeneID=4609].,CGP,C2,90,79
Cohort,-0.06744901770391326,0.06348073300957553,-1.0625116394566387,0.28838289465853617,LGP Offspring,"Genes down-regulated in MCF10A cells (breast cancer) grown at low (mesenchymal phenotype) compared to those grown at high (epithelial, basal-like phenotype) confluency.",CGP,C2,136,257
Cohort,0.054868690309629854,0.17263181186204898,0.31783649674879,0.7506885267879887,LGP Proband,"Genes down-regulated in MCF10A cells (breast cancer) grown at low (mesenchymal phenotype) compared to those grown at high (epithelial, basal-like phenotype) confluency.",CGP,C2,136,402
Cohort,0.007795868276394502,0.05386309507926744,0.14473487394145731,0.8849568411263087,LonGen OPEL,"Genes down-regulated in MCF10A cells (breast cancer) grown at low (mesenchymal phenotype) compared to those grown at high (epithelial, basal-like phenotype) confluency.",CGP,C2,208,242
Cohort,-0.13964448368385485,0.06601141953899856,-2.115459486541643,0.034755951217360866,LGP Offspring,"Genes up-regulated in MCF10A cells (breast cancer) grown at low (mesenchymal phenotype) compared to those grown at high (epithelial, basal-like phenotype) confluency.",CGP,C2,163,280
Cohort,-0.14860879723471201,0.18995373528528894,-0.7823420635109832,0.43423563613726723,LGP Proband,"Genes up-regulated in MCF10A cells (breast cancer) grown at low (mesenchymal phenotype) compared to those grown at high (epithelial, basal-like phenotype) confluency.",CGP,C2,163,402
Cohort,-0.08097264591763728,0.05450021105004075,-1.4857308688821442,0.13774625097597676,LonGen OPEL,"Genes up-regulated in MCF10A cells (breast cancer) grown at low (mesenchymal phenotype) compared to those grown at high (epithelial, basal-like phenotype) confluency.",CGP,C2,245,256
Cohort,0.01656307343675675,0.023646106096229358,0.7004566996930595,0.48388314154546885,LGP Offspring,Genes down-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] but displayed blunted response to insulin the insulin resistant cells.,CGP,C2,16,43
Cohort,-0.09394774524292168,0.061909837365910485,-1.5174930066066088,0.12952120523429245,LGP Proband,Genes down-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] but displayed blunted response to insulin the insulin resistant cells.,CGP,C2,16,49
Cohort,1.9703000805187056e-4,0.01759701652104781,0.01119678485362577,0.9910692504566067,LonGen OPEL,Genes down-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] but displayed blunted response to insulin the insulin resistant cells.,CGP,C2,19,23
Cohort,-0.036213422512503674,0.02116712196466147,-1.7108335546496125,0.0875706191691949,LGP Offspring,Genes up-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] but displayed blunted response to insulin the insulin resistant cells.,CGP,C2,19,21
Cohort,-0.09043676543063736,0.053823577123734354,-1.6802444256488824,0.09328425031418144,LGP Proband,Genes up-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] but displayed blunted response to insulin the insulin resistant cells.,CGP,C2,19,27
Cohort,-0.030316227302579393,0.018654348674222162,-1.6251560336959072,0.10452515870620535,LonGen OPEL,Genes up-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] but displayed blunted response to insulin the insulin resistant cells.,CGP,C2,30,26
Cohort,0.014847187262480632,0.024396493659257345,0.6085787355285299,0.5430081364135404,LGP Offspring,Genes down-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] which continued to respond normally to insulin in the insulin resistant cells.,CGP,C2,18,43
Cohort,0.08133611474151568,0.07181878486966674,1.1325186702771501,0.2577419293694137,LGP Proband,Genes down-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] which continued to respond normally to insulin in the insulin resistant cells.,CGP,C2,18,67
Cohort,0.09877252372481207,0.025764879810820377,3.8336108862161646,1.3624131518493102e-4,LonGen OPEL,Genes down-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] which continued to respond normally to insulin in the insulin resistant cells.,CGP,C2,27,71
Cohort,0.00828960848835498,0.01770631498788321,0.468172428539068,0.6398121969356696,LGP Offspring,Genes up-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] which continued to respond normally to insulin in the insulin resistant cells.,CGP,C2,8,24
Cohort,0.036155137420304295,0.057006103794404586,0.6342327402465469,0.5261028634056992,LGP Proband,Genes up-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] which continued to respond normally to insulin in the insulin resistant cells.,CGP,C2,8,45
Cohort,0.004142830954607987,0.016609893490575123,0.24941947743125117,0.8031006672061427,LonGen OPEL,Genes up-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] which continued to respond normally to insulin in the insulin resistant cells.,CGP,C2,17,24
Cohort,-0.02418037824867119,0.0371351690430526,-0.6511449623573198,0.5151741903652761,LGP Offspring,Genes down-regulated in MEF and REF cells (mouse and rat fibroblasts) but not in TIG3/T cells (human lung fibroblasts expressing TERT [GeneID=7015]) by co-expression of the SV40 early region and the activated HRAS (H-RasV12) [GeneID=3265].,CGP,C2,46,81
Cohort,-0.14428320943374812,0.10837894206140804,-1.3312845345177529,0.18345918576855447,LGP Proband,Genes down-regulated in MEF and REF cells (mouse and rat fibroblasts) but not in TIG3/T cells (human lung fibroblasts expressing TERT [GeneID=7015]) by co-expression of the SV40 early region and the activated HRAS (H-RasV12) [GeneID=3265].,CGP,C2,46,136
Cohort,0.013657348499475086,0.03140983746022084,0.4348111803116304,0.6638173411698702,LonGen OPEL,Genes down-regulated in MEF and REF cells (mouse and rat fibroblasts) but not in TIG3/T cells (human lung fibroblasts expressing TERT [GeneID=7015]) by co-expression of the SV40 early region and the activated HRAS (H-RasV12) [GeneID=3265].,CGP,C2,66,85
Cohort,-3.733465628572901e-4,0.007145549866335815,-0.05224882197186869,0.9583458672143168,LGP Offspring,Down-regulated genes in medulloblastoma tumors from heterozygotic CXCR6 [GeneID=10663] knockout mice compared to those from PTCH1 [GeneID=5727] heterozygotic knockout mice.,CGP,C2,2,3
Cohort,0.012383694461448089,0.01925282069132136,0.6432145533371282,0.5202616995545,LGP Proband,Down-regulated genes in medulloblastoma tumors from heterozygotic CXCR6 [GeneID=10663] knockout mice compared to those from PTCH1 [GeneID=5727] heterozygotic knockout mice.,CGP,C2,2,4
Cohort,0.0076025695316745195,0.005180906699165208,1.46742066073097,0.14265664604495945,LonGen OPEL,Down-regulated genes in medulloblastoma tumors from heterozygotic CXCR6 [GeneID=10663] knockout mice compared to those from PTCH1 [GeneID=5727] heterozygotic knockout mice.,CGP,C2,0,4
Cohort,-0.029874322648042698,0.015364932813376954,-1.9443184692635713,0.05227152408988205,LGP Offspring,Up-regulated genes in medulloblastoma tumors from heterozygotic CXCR6 [GeneID=10663] knockout mice compared to those from PTCH1 [GeneID=5727] heterozygotic knockout mice.,CGP,C2,12,13
Cohort,0.08183309328829794,0.05564224011386892,1.4707009121277435,0.14174919184524026,LGP Proband,Up-regulated genes in medulloblastoma tumors from heterozygotic CXCR6 [GeneID=10663] knockout mice compared to those from PTCH1 [GeneID=5727] heterozygotic knockout mice.,CGP,C2,12,37
Cohort,-0.020925230079567883,0.014578717264037496,-1.4353272445433758,0.15158667438821308,LonGen OPEL,Up-regulated genes in medulloblastoma tumors from heterozygotic CXCR6 [GeneID=10663] knockout mice compared to those from PTCH1 [GeneID=5727] heterozygotic knockout mice.,CGP,C2,19,12
Cohort,0.004238091372092658,0.06340532208506534,0.06684125610791447,0.9467278426720724,LGP Offspring,Genes up-regulated in adult T-cell leukemia (ATL) cells compared to T lymphocytes from healthy controls.,CGP,C2,122,256
Cohort,-0.04349303144549238,0.17799988988301463,-0.2443430244483687,0.8070252631730445,LGP Proband,Genes up-regulated in adult T-cell leukemia (ATL) cells compared to T lymphocytes from healthy controls.,CGP,C2,122,360
Cohort,0.036735220160602974,0.054825106141387275,0.6700437581619507,0.503024224075571,LonGen OPEL,Genes up-regulated in adult T-cell leukemia (ATL) cells compared to T lymphocytes from healthy controls.,CGP,C2,192,251
Cohort,0.018087642532819307,0.021254410000408525,0.8510065691059714,0.39506704183425956,LGP Offspring,Genes up-regulated in DLD1 cells (colon cancer) by p73 beta [GeneID=7161] or by and p63 gamma [GeneID=8626] but not by p53 [GeneID=7157].,CGP,C2,13,32
Cohort,0.04579154715225752,0.054192683905689355,0.8449765512988396,0.39836626357554317,LGP Proband,Genes up-regulated in DLD1 cells (colon cancer) by p73 beta [GeneID=7161] or by and p63 gamma [GeneID=8626] but not by p53 [GeneID=7157].,CGP,C2,13,37
Cohort,-0.019742034146042618,0.019925570663294687,-0.9907888953168018,0.3220897493350199,LonGen OPEL,Genes up-regulated in DLD1 cells (colon cancer) by p73 beta [GeneID=7161] or by and p63 gamma [GeneID=8626] but not by p53 [GeneID=7157].,CGP,C2,32,30
Cohort,-9.669585738312936e-4,0.004565398162458334,-0.21180158650403771,0.8323256712589733,LGP Offspring,Genes up-regulated in rFSH-17 cells (primary granulosa) after stimulation with FSH.,CGP,C2,1,1
Cohort,0.005140508777700615,0.01368674944838425,0.3755828801489066,0.7073225248746433,LGP Proband,Genes up-regulated in rFSH-17 cells (primary granulosa) after stimulation with FSH.,CGP,C2,1,2
Cohort,-0.003211380191258885,0.0036446142147093935,-0.8811303479797647,0.3785132416601845,LonGen OPEL,Genes up-regulated in rFSH-17 cells (primary granulosa) after stimulation with FSH.,CGP,C2,2,0
Cohort,-0.07645424229882176,0.05369661074933188,-1.423818770531491,0.15496033705511666,LGP Offspring,Genes down-regulated in primary granulosa cells in response to forskolin [PubChem=47936].,CGP,C2,106,182
Cohort,-0.027114844319914153,0.14612362123361228,-0.1855609934314783,0.8528341639305402,LGP Proband,Genes down-regulated in primary granulosa cells in response to forskolin [PubChem=47936].,CGP,C2,106,243
Cohort,-0.03183268999513511,0.04579438333281609,-0.6951221455213683,0.4871816186571457,LonGen OPEL,Genes down-regulated in primary granulosa cells in response to forskolin [PubChem=47936].,CGP,C2,158,184
Cohort,-0.07346299194801145,0.04297305623577251,-1.7095128525407948,0.0878149216860628,LGP Offspring,Genes up-regulated in primary granulosa cells in response to forskolin [PubChem=47936].,CGP,C2,72,119
Cohort,0.14429433889960216,0.13074825090473954,1.1036043534129725,0.27008312441125853,LGP Proband,Genes up-regulated in primary granulosa cells in response to forskolin [PubChem=47936].,CGP,C2,72,203
Cohort,0.01196045165303696,0.0412537678442261,0.2899238609719124,0.7719499920952173,LonGen OPEL,Genes up-regulated in primary granulosa cells in response to forskolin [PubChem=47936].,CGP,C2,109,129
Cohort,-0.047819610079283426,0.05330794804477817,-0.8970446590650124,0.3700144360799338,LGP Offspring,Genes down-regulated in primary granulosa cells after stimulation with LH or FSH gonadotrophic hormones for 24 h.,CGP,C2,104,191
Cohort,0.0322548167107114,0.14485508259056123,0.222669554522163,0.8238472185868058,LGP Proband,Genes down-regulated in primary granulosa cells after stimulation with LH or FSH gonadotrophic hormones for 24 h.,CGP,C2,104,241
Cohort,-0.03058705861716168,0.04638372696122652,-0.6594351213461194,0.509807125732457,LonGen OPEL,Genes down-regulated in primary granulosa cells after stimulation with LH or FSH gonadotrophic hormones for 24 h.,CGP,C2,158,182
Cohort,-0.09787035228005847,0.04251273815745792,-2.302141817296454,0.0216302012752006,LGP Offspring,Genes up-regulated in primary granulosa cells after stimulation with LH or FSH gonadotrophic hormones for 24 h.,CGP,C2,73,110
Cohort,0.0873599145860478,0.13130048997222396,0.6653434012662741,0.5060148303699891,LGP Proband,Genes up-regulated in primary granulosa cells after stimulation with LH or FSH gonadotrophic hormones for 24 h.,CGP,C2,73,205
Cohort,0.010714820275063373,0.041537534290499875,0.2579551352308839,0.7965082082688361,LonGen OPEL,Genes up-regulated in primary granulosa cells after stimulation with LH or FSH gonadotrophic hormones for 24 h.,CGP,C2,109,131
Cohort,0.010424374470707095,0.028830688561780775,0.36157216461788233,0.7177847511129699,LGP Offspring,"50 most interesting genes up-regulated in pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by TSA [PubChem=5562].",CGP,C2,25,56
Cohort,-0.07699206148284161,0.07890953014783475,-0.9757004171561938,0.3294958618096614,LGP Proband,"50 most interesting genes up-regulated in pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by TSA [PubChem=5562].",CGP,C2,25,77
Cohort,0.004008475177403229,0.027442515052751068,0.1460680688230646,0.8839046352453551,LonGen OPEL,"50 most interesting genes up-regulated in pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by TSA [PubChem=5562].",CGP,C2,47,55
Cohort,0.006628334594350739,0.11468547504695469,0.057795763514402826,0.953928392128799,LGP Offspring,"Genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].",CGP,C2,397,851
Cohort,-0.1567771581167966,0.29930980073186036,-0.523795604866434,0.6005598690272581,LGP Proband,"Genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].",CGP,C2,397,1145
Cohort,-0.19825341461700938,0.10122660695713544,-1.958510915030078,0.05051894159893027,LonGen OPEL,"Genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].",CGP,C2,701,751
Cohort,-7.2149177659735e-4,0.02540663985652861,-0.028397764547835398,0.9773532884278764,LGP Offspring,"50 most interesting genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].",CGP,C2,22,45
Cohort,0.010542814375090182,0.07144928943790785,0.14755660214441024,0.8827283707915883,LGP Proband,"50 most interesting genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].",CGP,C2,22,56
Cohort,-0.015140192494802652,0.020702260076942026,-0.7313304169946957,0.4647925834411404,LonGen OPEL,"50 most interesting genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].",CGP,C2,31,29
Cohort,-0.008408931158550502,0.03257697335972188,-0.25812499723953153,0.7963890041613457,LGP Offspring,"50 genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by the combination of decitabine  and TSA [PubChem=451668;5562].",CGP,C2,30,60
Cohort,-0.09307623555771281,0.08998901631729513,-1.0343066228164153,0.3012926575861229,LGP Proband,"50 genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by the combination of decitabine  and TSA [PubChem=451668;5562].",CGP,C2,30,92
Cohort,0.03963170593376375,0.027216321588489023,1.4561742226960508,0.14573876469006508,LonGen OPEL,"50 genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by the combination of decitabine  and TSA [PubChem=451668;5562].",CGP,C2,40,63
Cohort,-0.03243077646069808,0.029719916114395097,-1.0912135934660312,0.2755676835171177,LGP Offspring,Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 12 h.,CGP,C2,32,55
Cohort,0.06065901873356779,0.08558436047643646,0.7087628907418051,0.4786696923385567,LGP Proband,Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 12 h.,CGP,C2,32,80
Cohort,0.0071232305742847,0.025337023184328462,0.2811392057568382,0.7786766931994653,LonGen OPEL,Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 12 h.,CGP,C2,46,57
Cohort,-0.03453022062863552,0.05048747191003647,-0.6839364167444323,0.49424969252747886,LGP Offspring,Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 12 h.,CGP,C2,89,171
Cohort,0.2255071438384253,0.14041823539124332,1.6059676523501465,0.10865955620349387,LGP Proband,Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 12 h.,CGP,C2,89,242
Cohort,-0.023174054910084216,0.04329192371946896,-0.5352974162167465,0.5925937251233127,LonGen OPEL,Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 12 h.,CGP,C2,134,147
Cohort,-0.07089921888087596,0.10838516769463019,-0.6541413404519608,0.5132432184735677,LGP Offspring,Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 48 h.,CGP,C2,359,743
Cohort,0.06071594906653351,0.289524857889127,0.20970893314378058,0.8339460688819711,LGP Proband,Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 48 h.,CGP,C2,359,1042
Cohort,-0.18006241306812767,0.09389080131820303,-1.9177854543799508,0.05549576717599268,LonGen OPEL,Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 48 h.,CGP,C2,608,660
Cohort,-0.1594077328541345,0.11343283966010571,-1.4053049657558572,0.1603900005442806,LGP Offspring,Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 48 h.,CGP,C2,455,914
Cohort,0.18526640313192277,0.30448658550517077,0.6084550582895107,0.5430513768867705,LGP Proband,Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 48 h.,CGP,C2,455,1250
Cohort,-0.11519943231715372,0.09888510498599083,-1.1649826567254407,0.24437501261048455,LonGen OPEL,Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 48 h.,CGP,C2,743,835
Cohort,-0.20797355953005525,0.11615129378607912,-1.7905401890149342,0.07381447350744552,LGP Offspring,Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 6 h.,CGP,C2,441,846
Cohort,0.056344700143894796,0.32545364224476253,0.17312665409201314,0.8625938820256507,LGP Proband,Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 6 h.,CGP,C2,441,1323
Cohort,-0.1171126019124841,0.10205646221745189,-1.1475275486519616,0.25150842665470335,LonGen OPEL,Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 6 h.,CGP,C2,714,791
Cohort,0.0702907998231583,0.07950661244017998,0.8840874697817673,0.3769633154057922,LGP Offspring,Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 6 h.,CGP,C2,190,420
Cohort,-0.12733602718130838,0.21759156053017215,-0.5852066452901395,0.5585670744561049,LGP Proband,Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 6 h.,CGP,C2,190,562
Cohort,-0.005405897609102718,0.06413891703038382,-0.0842842046513171,0.932851662784076,LonGen OPEL,Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 6 h.,CGP,C2,315,375
Cohort,0.016563228646241383,0.019798814500757645,0.8365767882520215,0.403126121256406,LGP Offspring,Early prostate development genes (down-regulated at 6 h dihydrotestosterone [PubChem=10635]) which are also down-regulated in normal epithelium vs high grade prostatic intraepithelial neoplasia (PIN).,CGP,C2,10,31
Cohort,0.013745635417407464,0.047950763656701124,0.28666144956142964,0.7744427559552095,LGP Proband,Early prostate development genes (down-regulated at 6 h dihydrotestosterone [PubChem=10635]) which are also down-regulated in normal epithelium vs high grade prostatic intraepithelial neoplasia (PIN).,CGP,C2,10,26
Cohort,-0.01885702691731144,0.016426311376206693,-1.147976955107865,0.25132296051509,LonGen OPEL,Early prostate development genes (down-regulated at 6 h dihydrotestosterone [PubChem=10635]) which are also down-regulated in normal epithelium vs high grade prostatic intraepithelial neoplasia (PIN).,CGP,C2,22,16
Cohort,-0.007048053281942253,0.020880735677758434,-0.33753855183606574,0.7358157375246939,LGP Offspring,Early prostate development genes (up-regulated at 6 h dihydrotestosterone [PubChem=10635]) which are also up-regulated in normal epithelium vs high grade prostatic intraepithelial neoplasia (PIN).,CGP,C2,14,29
Cohort,0.02036260192587582,0.05812677956257128,0.35031360896153296,0.7261918080710061,LGP Proband,Early prostate development genes (up-regulated at 6 h dihydrotestosterone [PubChem=10635]) which are also up-regulated in normal epithelium vs high grade prostatic intraepithelial neoplasia (PIN).,CGP,C2,14,38
Cohort,-0.012867060274358336,0.017202146867906415,-0.7479915369379891,0.45468618775768177,LonGen OPEL,Early prostate development genes (up-regulated at 6 h dihydrotestosterone [PubChem=10635]) which are also up-regulated in normal epithelium vs high grade prostatic intraepithelial neoplasia (PIN).,CGP,C2,21,21
Cohort,0.023345567692615136,0.0130129584338495,1.7940246110283655,0.07325600790346665,LGP Offspring,Early prostate development genes (down-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,3,14
Cohort,0.019279947787433447,0.029315400906748917,0.6576730043284131,0.5109297452197681,LGP Proband,Early prostate development genes (down-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,3,11
Cohort,-8.023620648363849e-4,0.010647302849951069,-0.07535824575893155,0.9399486143287399,LonGen OPEL,Early prostate development genes (down-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,8,9
Cohort,0.005979186933605473,0.010998314958472406,0.543645727202919,0.5868645211896388,LGP Offspring,Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,3,9
Cohort,-0.017792756407890357,0.026609524867464273,-0.6686611841628836,0.5038966614026085,LGP Proband,Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,3,9
Cohort,0.005668502396748849,0.0063448592687216565,0.8934008079096326,0.3719125914715353,LonGen OPEL,Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,2,4
Cohort,0.0010701321954450329,0.012243613122397693,0.08740330037768022,0.9303768298117332,LGP Offspring,Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in lower grade vs higher grade locally invasive prostate cancers.,CGP,C2,5,10
Cohort,0.005027136542844914,0.032856425595185625,0.15300314784032773,0.8784328025001935,LGP Proband,Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in lower grade vs higher grade locally invasive prostate cancers.,CGP,C2,5,11
Cohort,0.006654645700432711,0.011513640403029731,0.577979289563498,0.5634415662525171,LonGen OPEL,Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in lower grade vs higher grade locally invasive prostate cancers.,CGP,C2,7,13
Cohort,0.03248256295476274,0.03412921273550112,0.9517524827337861,0.3415626893514224,LGP Offspring,Early prostate development genes (down-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in localized vs metastatic prostate cancers.,CGP,C2,35,91
Cohort,0.12394820595359776,0.09954006474603873,1.2452092157045775,0.21340460227724967,LGP Proband,Early prostate development genes (down-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in localized vs metastatic prostate cancers.,CGP,C2,35,129
Cohort,-0.01311072207104348,0.026894368490930343,-0.48748949340323205,0.6260457140129513,LonGen OPEL,Early prostate development genes (down-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in localized vs metastatic prostate cancers.,CGP,C2,54,61
Cohort,-0.007062762577125522,0.02438138599279004,-0.2896784694362368,0.7721510546581672,LGP Offspring,Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in localized vs metastatic prostate cancers.,CGP,C2,19,40
Cohort,0.09428457115154669,0.05999545546964445,1.5715285501791265,0.11643920725865027,LGP Proband,Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in localized vs metastatic prostate cancers.,CGP,C2,19,42
Cohort,-3.4323458139620444e-4,0.019878250187059313,-0.01726684080169437,0.9862280657592841,LonGen OPEL,Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in localized vs metastatic prostate cancers.,CGP,C2,31,29
Cohort,0.009054573780361364,0.012712793544454527,0.7122410781469095,0.47656124435901936,LGP Offspring,Early prostate development genes (down-regulated at 12 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,4,10
Cohort,0.06067736266009892,0.03485718053237781,1.740742129264801,0.08209758290132407,LGP Proband,Early prostate development genes (down-regulated at 12 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,4,14
Cohort,-0.004338529618010347,0.011807646059809425,-0.367433914942431,0.7133930456233548,LonGen OPEL,Early prostate development genes (down-regulated at 12 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,9,10
Cohort,0.004086536505139211,0.024181970863546808,0.16899104412119997,0.8658542383215191,LGP Offspring,Early prostate development genes (up-regulated at 12 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,21,44
Cohort,0.03571848305666721,0.06634314062579064,0.5383899935961396,0.5904514905735196,LGP Proband,Early prostate development genes (up-regulated at 12 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,21,55
Cohort,-0.008638884653852527,0.01909314700607434,-0.45245996645310127,0.651060936779075,LonGen OPEL,Early prostate development genes (up-regulated at 12 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,25,29
Cohort,0.0090467320287863,0.015181253436335824,0.5959146961563297,0.5514316824609514,LGP Offspring,Early prostate development genes (down-regulated at 48 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,5,18
Cohort,0.067298159924783,0.03653690296408352,1.8419229454378876,0.0658413049085416,LGP Proband,Early prostate development genes (down-regulated at 48 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,5,17
Cohort,6.020159625788177e-4,0.012817642270357012,0.04696776129968009,0.9625507027600322,LonGen OPEL,Early prostate development genes (down-regulated at 48 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,11,14
Cohort,-8.899134265027053e-4,0.014306295683226729,-0.06220432222340234,0.9504185074948297,LGP Offspring,Early prostate development genes (up-regulated at 48 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,7,14
Cohort,0.030782224047726067,0.04577643907498992,0.672446889049175,0.5014854955465278,LGP Proband,Early prostate development genes (up-regulated at 48 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,7,28
Cohort,0.016520127836806578,0.01347839756816042,1.2256744730420728,0.22068370634755116,LonGen OPEL,Early prostate development genes (up-regulated at 48 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.,CGP,C2,10,18
Cohort,-0.014546686759815202,0.03427660804057313,-0.4243910815969984,0.6714156499624813,LGP Offspring,Predicted targets of SOX9 [GeneID=6662] that are down-regulated during early prostate development.,CGP,C2,40,78
Cohort,-0.011727593116007268,0.08598427362894197,-0.13639230316251466,0.8915440737121654,LGP Proband,Predicted targets of SOX9 [GeneID=6662] that are down-regulated during early prostate development.,CGP,C2,40,86
Cohort,0.03439289923421019,0.027719198016278417,1.2407609777892046,0.21505962121826905,LonGen OPEL,Predicted targets of SOX9 [GeneID=6662] that are down-regulated during early prostate development.,CGP,C2,53,72
Cohort,-0.020586499066736787,0.014765266446806934,-1.3942517827836913,0.16369965017140886,LGP Offspring,Predicted targets of SOX9 [GeneID=6662] that are up-regulated during early prostate development.,CGP,C2,10,12
Cohort,0.04093380800920732,0.05310952696381251,0.7707432234728541,0.44107743088230056,LGP Proband,Predicted targets of SOX9 [GeneID=6662] that are up-regulated during early prostate development.,CGP,C2,10,34
Cohort,-0.006152192551988557,0.015554862158991975,-0.3955157229363225,0.6925682956187099,LonGen OPEL,Predicted targets of SOX9 [GeneID=6662] that are up-regulated during early prostate development.,CGP,C2,15,16
Cohort,-0.005796223635590841,0.021623106812004755,-0.26805693030073197,0.7887372702743826,LGP Offspring,Genes up-regulated by TP53 [GeneID=7157]  and down-regulated by an isoform of TP63 [GeneID=8626] in primary HEK cells (epidermal keratinocytes).,CGP,C2,15,29
Cohort,-0.012541743378093329,0.056249539336444214,-0.22296615271953885,0.8236164456400352,LGP Proband,Genes up-regulated by TP53 [GeneID=7157]  and down-regulated by an isoform of TP63 [GeneID=8626] in primary HEK cells (epidermal keratinocytes).,CGP,C2,15,38
Cohort,-0.0031448733189226473,0.01938154974052357,-0.16226118968945216,0.8711413552799046,LonGen OPEL,Genes up-regulated by TP53 [GeneID=7157]  and down-regulated by an isoform of TP63 [GeneID=8626] in primary HEK cells (epidermal keratinocytes).,CGP,C2,26,29
Cohort,0.002732914967777882,0.03603003348913811,0.07585102491236284,0.9395600627300631,LGP Offspring,Genes encoding IkappaB kinase (IKK) interacting proteins.,CGP,C2,41,89
Cohort,0.08299122846962836,0.09826296178636408,0.8445830144023303,0.3985859018942295,LGP Proband,Genes encoding IkappaB kinase (IKK) interacting proteins.,CGP,C2,41,108
Cohort,-0.002072833758781421,0.033592791719958146,-0.06170471856168802,0.9508134718753096,LonGen OPEL,Genes encoding IkappaB kinase (IKK) interacting proteins.,CGP,C2,78,90
Cohort,-0.01872019527829697,0.027418214253314487,-0.6827649352121448,0.4949892962626654,LGP Offspring,Genes encoding substrates of IkappaB kinase (IKK) complex.,CGP,C2,24,49
Cohort,0.08510742261123101,0.07080703121858371,1.2019628721405011,0.22971908830668258,LGP Proband,Genes encoding substrates of IkappaB kinase (IKK) complex.,CGP,C2,24,61
Cohort,0.006069309989623316,0.024574119953449915,0.24697974947303278,0.8049875796366113,LonGen OPEL,Genes encoding substrates of IkappaB kinase (IKK) complex.,CGP,C2,39,52
Cohort,0.012116259528263807,0.015793561353868817,0.7671644955047322,0.4432515681199499,LGP Offspring,Genes bearing the H3K27me3 mark in normal cells; their DNA is methylated in cancer cells.,CGP,C2,6,17
Cohort,-0.035612857487703264,0.04915213694831003,-0.7245434216859156,0.4689353881131956,LGP Proband,Genes bearing the H3K27me3 mark in normal cells; their DNA is methylated in cancer cells.,CGP,C2,6,28
Cohort,-0.01529867886608562,0.01619560517344183,-0.9446191545329209,0.34513997486151304,LonGen OPEL,Genes bearing the H3K27me3 mark in normal cells; their DNA is methylated in cancer cells.,CGP,C2,19,22
Cohort,-0.07907262829069121,0.04660442656755726,-1.6966763484594838,0.09021821719750572,LGP Offspring,Genes bearing H3K27me3 mark or whose promoters are bound by the polycomb proteins SUZ12 or EED [GeneID=23512;8726]; their DNA is methylated de novo in cancer.,CGP,C2,81,122
Cohort,-0.09614938582996643,0.12853187557091159,-0.7480586850762977,0.45463564443449456,LGP Proband,Genes bearing H3K27me3 mark or whose promoters are bound by the polycomb proteins SUZ12 or EED [GeneID=23512;8726]; their DNA is methylated de novo in cancer.,CGP,C2,81,184
Cohort,-0.03074115736264826,0.04213590049416042,-0.7295716242473246,0.4658666985183231,LonGen OPEL,Genes bearing H3K27me3 mark or whose promoters are bound by the polycomb proteins SUZ12 or EED [GeneID=23512;8726]; their DNA is methylated de novo in cancer.,CGP,C2,122,130
Cohort,-0.01179968237957802,0.012829343433267807,-0.9197417187367696,0.3580358199689767,LGP Offspring,Genes expressed in normal colon; they undergo down-regulation in tumors through DNA methylation.,CGP,C2,6,8
Cohort,-0.01127436575943843,0.030384804702611207,-0.3710527637016385,0.7106924649874727,LGP Proband,Genes expressed in normal colon; they undergo down-regulation in tumors through DNA methylation.,CGP,C2,6,9
Cohort,0.011823227363278095,0.00932213432447682,1.2682961810831495,0.20506300746703002,LonGen OPEL,Genes expressed in normal colon; they undergo down-regulation in tumors through DNA methylation.,CGP,C2,4,9
Cohort,0.014512560401607201,0.025796711479275897,0.5625740479853816,0.5739114770951035,LGP Offspring,Down-regulated in murine dorsal skin cells at 6 h after treatment with the phorbol ester carcinogen TPA [PubChem=4792].,CGP,C2,17,43
Cohort,0.10340843143368804,0.0681220255201106,1.5179882078397742,0.12939633021240907,LGP Proband,Down-regulated in murine dorsal skin cells at 6 h after treatment with the phorbol ester carcinogen TPA [PubChem=4792].,CGP,C2,17,58
Cohort,0.016257677758487,0.020339404077324222,0.7993192768421464,0.42434375009613023,LonGen OPEL,Down-regulated in murine dorsal skin cells at 6 h after treatment with the phorbol ester carcinogen TPA [PubChem=4792].,CGP,C2,26,38
Cohort,-0.009874759838975075,0.026067437746203605,-0.37881589802255156,0.7049435260375845,LGP Offspring,Up-regulated in murine dorsal skin cells at 6 h after treatment with the phorbol ester carcinogen TPA [PubChem=4792].,CGP,C2,23,47
Cohort,0.06268798110132671,0.07191715626562746,0.8716693534125209,0.3836396390878408,LGP Proband,Up-regulated in murine dorsal skin cells at 6 h after treatment with the phorbol ester carcinogen TPA [PubChem=4792].,CGP,C2,23,59
Cohort,0.0053210588070936714,0.02421289617790257,0.21976135229745183,0.8261133637250894,LonGen OPEL,Up-regulated in murine dorsal skin cells at 6 h after treatment with the phorbol ester carcinogen TPA [PubChem=4792].,CGP,C2,39,53
Cohort,1.912871773365149e-4,0.02491565093675844,0.007677390320728327,0.993876654030189,LGP Offspring,Cluster 3: genes strongly up-regulated in B493-6 cells (B lymphocytes) by a combination of MYC [GeneID=4609] and serum but not by each of them alone.,CGP,C2,19,43
Cohort,0.03612205281035904,0.06623645888722457,0.5453499993389006,0.5856586366115637,LGP Proband,Cluster 3: genes strongly up-regulated in B493-6 cells (B lymphocytes) by a combination of MYC [GeneID=4609] and serum but not by each of them alone.,CGP,C2,19,57
Cohort,0.00408316644868497,0.021689195538893143,0.18825808644506992,0.850722322197417,LonGen OPEL,Cluster 3: genes strongly up-regulated in B493-6 cells (B lymphocytes) by a combination of MYC [GeneID=4609] and serum but not by each of them alone.,CGP,C2,29,38
Cohort,0.03120584421154334,0.03961681806477548,0.7876918373535254,0.4311530792580124,LGP Offspring,Cluster 6: genes down-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] in combination with serum but not affected by serum alone; they are also up-regulated by MYC alone.,CGP,C2,45,110
Cohort,0.12357135849942268,0.09794759724152083,1.2616068385497845,0.20744303276217943,LGP Proband,Cluster 6: genes down-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] in combination with serum but not affected by serum alone; they are also up-regulated by MYC alone.,CGP,C2,45,117
Cohort,0.02618914776775692,0.032974111236235955,0.7942336210407729,0.42729615398696186,LonGen OPEL,Cluster 6: genes down-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] in combination with serum but not affected by serum alone; they are also up-regulated by MYC alone.,CGP,C2,68,92
Cohort,0.0190145160208673,0.03504985324700402,0.5424991621753115,0.5876534805642828,LGP Offspring,Cluster 5: genes up-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] alone or in combination with serum but not by serum alone.,CGP,C2,35,88
Cohort,0.14163414205981611,0.09723431452856188,1.456627145946631,0.1455956982930773,LGP Proband,Cluster 5: genes up-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] alone or in combination with serum but not by serum alone.,CGP,C2,35,121
Cohort,-0.009112400656231617,0.03419577767657943,-0.2664773628608736,0.7899406038703692,LonGen OPEL,Cluster 5: genes up-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] alone or in combination with serum but not by serum alone.,CGP,C2,74,86
Cohort,0.07282838987025932,0.05699946283664589,1.2777030913252176,0.20179273315611973,LGP Offspring,Cluster 7: genes up-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] and down-regulated by the combination of MYC and serum.,CGP,C2,94,228
Cohort,-0.1987273744089113,0.15324244594282707,-1.2968167741400716,0.19505290136654216,LGP Proband,Cluster 7: genes up-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] and down-regulated by the combination of MYC and serum.,CGP,C2,94,295
Cohort,-0.006342735201797719,0.048397077187189275,-0.13105616228156527,0.8957639941698912,LonGen OPEL,Cluster 7: genes up-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] and down-regulated by the combination of MYC and serum.,CGP,C2,158,191
Cohort,-0.0707406145081856,0.05771975676276247,-1.2255875366720785,0.22078074006766626,LGP Offspring,Cluster 2: genes up-regulated in B493-6 cells (B lymphocytes) by serum alone or in combination with MYC [GeneID=4609] but not by MYC alone.,CGP,C2,105,197
Cohort,0.147212361482253,0.1627788503547138,0.9043703230576968,0.3660602276007593,LGP Proband,Cluster 2: genes up-regulated in B493-6 cells (B lymphocytes) by serum alone or in combination with MYC [GeneID=4609] but not by MYC alone.,CGP,C2,105,300
Cohort,0.04520844094603863,0.04469651586066514,1.0114533554912724,0.3121068426868131,LonGen OPEL,Cluster 2: genes up-regulated in B493-6 cells (B lymphocytes) by serum alone or in combination with MYC [GeneID=4609] but not by MYC alone.,CGP,C2,139,183
Cohort,-0.09972167918300198,0.1332667087314141,-0.7482865010494195,0.45454761519275133,LGP Offspring,Cluster 4: genes down-regulated in B493-6 cells (B lymphocytes) upon serum stimulation but not affected by MYC [GeneID=4609].,CGP,C2,574,1179
Cohort,0.288883944966283,0.36701911371376006,0.7871087204237133,0.43144183990998264,LGP Proband,Cluster 4: genes down-regulated in B493-6 cells (B lymphocytes) upon serum stimulation but not affected by MYC [GeneID=4609].,CGP,C2,574,1665
Cohort,-0.03200454112900393,0.11414434294609525,-0.280386572851167,0.7792537903903882,LonGen OPEL,Cluster 4: genes down-regulated in B493-6 cells (B lymphocytes) upon serum stimulation but not affected by MYC [GeneID=4609].,CGP,C2,918,1091
Cohort,-0.09014626463957551,0.06564045359762688,-1.3733339685945527,0.17010385318044868,LGP Offspring,Cluster 1: genes up-regulated in B493-6 cells (B lymphocytes) upon serum stimulation but not by affected by MYC [GeneID=4609].,CGP,C2,161,305
Cohort,-0.02593898945094988,0.1920732193491387,-0.13504740295834583,0.8926069808588663,LGP Proband,Cluster 1: genes up-regulated in B493-6 cells (B lymphocytes) upon serum stimulation but not by affected by MYC [GeneID=4609].,CGP,C2,161,443
Cohort,-0.05273330856768846,0.06297920305677211,-0.8373130495181469,0.4026679438746751,LonGen OPEL,Cluster 1: genes up-regulated in B493-6 cells (B lymphocytes) upon serum stimulation but not by affected by MYC [GeneID=4609].,CGP,C2,254,284
Cohort,-0.0034798680428422425,0.012714263527238675,-0.27369796413194303,0.7844003461303701,LGP Offspring,These genes form a a network that controls specific processes downstream of PDGF signaling.,CGP,C2,5,11
Cohort,-0.009566527981414287,0.03209641892101608,-0.29805592969595496,0.7657347125919679,LGP Proband,These genes form a a network that controls specific processes downstream of PDGF signaling.,CGP,C2,5,12
Cohort,-0.007665917631211156,0.012272997879269958,-0.6246165530721295,0.532401741824897,LonGen OPEL,These genes form a a network that controls specific processes downstream of PDGF signaling.,CGP,C2,13,10
Cohort,0.007564562398931436,0.019794768061188798,0.3821495849584174,0.7024705199885064,LGP Offspring,Genes down-regulated in E12.5 forelimb buds with POR [GeneID=5447] knockout.,CGP,C2,12,29
Cohort,-0.037407881468500666,0.05536087553072212,-0.675709715749373,0.4994122789711266,LGP Proband,Genes down-regulated in E12.5 forelimb buds with POR [GeneID=5447] knockout.,CGP,C2,12,38
Cohort,0.004302689949172132,0.018017819896610585,0.23880191798240422,0.8113206491073126,LonGen OPEL,Genes down-regulated in E12.5 forelimb buds with POR [GeneID=5447] knockout.,CGP,C2,23,26
Cohort,-0.017884164142597147,0.02435129533861603,-0.7344235242482821,0.4629453218679256,LGP Offspring,Genes up-regulated in E12.5 forelimb buds with POR [GeneID=5447] knockout.,CGP,C2,21,37
Cohort,-0.09901054936264156,0.07001258043183278,-1.4141822619870785,0.15768158432331966,LGP Proband,Genes up-regulated in E12.5 forelimb buds with POR [GeneID=5447] knockout.,CGP,C2,21,57
Cohort,0.007620801147204411,0.022345985309148768,0.341036702645837,0.7331659470405169,LonGen OPEL,Genes up-regulated in E12.5 forelimb buds with POR [GeneID=5447] knockout.,CGP,C2,33,44
Cohort,0.049338491774640586,0.028999626107064858,1.7013492378310628,0.08933727368646315,LGP Offspring,"Genes down-regulated in A375 cells (melanoma) treated with KINK-1, a small molecule inhibitor of NFKB.",CGP,C2,19,64
Cohort,-0.11473665390101931,0.07464479475014463,-1.537101874083417,0.1246476441867635,LGP Proband,"Genes down-regulated in A375 cells (melanoma) treated with KINK-1, a small molecule inhibitor of NFKB.",CGP,C2,19,77
Cohort,-0.04690321200756641,0.024965540698580712,-1.8787180527691456,0.06064823259964884,LonGen OPEL,"Genes down-regulated in A375 cells (melanoma) treated with KINK-1, a small molecule inhibitor of NFKB.",CGP,C2,54,42
Cohort,0.026015067289916444,0.03653345475343532,0.7120888912776635,0.47665541218760865,LGP Offspring,Genes down-regulated in fibroblasts from MLL [GeneID=4297] knockout mice.,CGP,C2,36,87
Cohort,0.08321855653088643,0.09739382838886355,0.8544541056402504,0.3930987966527959,LGP Proband,Genes down-regulated in fibroblasts from MLL [GeneID=4297] knockout mice.,CGP,C2,36,119
Cohort,-0.017963416099662996,0.029576776870781415,-0.6073486701456258,0.5437927559119589,LonGen OPEL,Genes down-regulated in fibroblasts from MLL [GeneID=4297] knockout mice.,CGP,C2,69,76
Cohort,-0.027723401054447077,0.03020257682111997,-0.9179150911077474,0.358990696480187,LGP Offspring,Genes up-regulated in fibroblasts from MLL [GeneID=4297] knockout mice.,CGP,C2,33,53
Cohort,-0.22894900953041145,0.08816170007562613,-2.5969214447318545,0.009572024798296264,LGP Proband,Genes up-regulated in fibroblasts from MLL [GeneID=4297] knockout mice.,CGP,C2,33,88
Cohort,-0.03985497114116068,0.02781641895861328,-1.432785837762186,0.15231165486409418,LonGen OPEL,Genes up-regulated in fibroblasts from MLL [GeneID=4297] knockout mice.,CGP,C2,61,58
Cohort,-0.046126681930477045,0.05801139718697236,-0.7951313736128343,0.4268161686236355,LGP Offspring,"Genes down-regulated in invasive ductal carcinoma (IDC) relative to ductal carcinoma in situ (DCIS, non-invasive).",CGP,C2,113,221
Cohort,0.1440180250780125,0.16705079788284954,0.8621211446054295,0.388868673794726,LGP Proband,"Genes down-regulated in invasive ductal carcinoma (IDC) relative to ductal carcinoma in situ (DCIS, non-invasive).",CGP,C2,113,309
Cohort,0.040921220128588794,0.048443208190837944,0.844725641773829,0.398517852754776,LonGen OPEL,"Genes down-regulated in invasive ductal carcinoma (IDC) relative to ductal carcinoma in situ (DCIS, non-invasive).",CGP,C2,144,189
Cohort,-0.043343474393660486,0.10543939813117473,-0.41107475158135737,0.6811480024054039,LGP Offspring,"Genes up-regulated in invasive ductal carcinoma (IDC) relative to ductal carcinoma in situ (DCIS, non-invasive).",CGP,C2,371,756
Cohort,-0.22186975295075478,0.28924691158317056,-0.7670600586065651,0.44326289146531717,LGP Proband,"Genes up-regulated in invasive ductal carcinoma (IDC) relative to ductal carcinoma in situ (DCIS, non-invasive).",CGP,C2,371,984
Cohort,-0.07993261766768377,0.08566345509591661,-0.9331005570366492,0.35105099478443036,LonGen OPEL,"Genes up-regulated in invasive ductal carcinoma (IDC) relative to ductal carcinoma in situ (DCIS, non-invasive).",CGP,C2,563,649
Cohort,0.0022759856112215485,0.012746315658477652,0.17856027358837429,0.8583364888638176,LGP Offspring,Genes down-regulated in P493-6 cells (Burkitt's lymphoma) induced to express MYC [GeneID=4609].,CGP,C2,5,11
Cohort,-0.01853578838241829,0.030163814827945147,-0.6145041165431728,0.5390498553564971,LGP Proband,Genes down-regulated in P493-6 cells (Burkitt's lymphoma) induced to express MYC [GeneID=4609].,CGP,C2,5,10
Cohort,-0.0027023560160502145,0.009637930415991102,-0.28038758316479523,0.7792530156292558,LonGen OPEL,Genes down-regulated in P493-6 cells (Burkitt's lymphoma) induced to express MYC [GeneID=4609].,CGP,C2,7,7
Cohort,-0.02730155226066075,0.05068423667023755,-0.5386596317567229,0.5902990620804998,LGP Offspring,Genes up-regulated in P493-6 cells (Burkitt's lymphoma) induced to express MYC [GeneID=4609].,CGP,C2,82,165
Cohort,-0.05739454626522832,0.13623578106377168,-0.4212883415580967,0.6736530931302728,LGP Proband,Genes up-regulated in P493-6 cells (Burkitt's lymphoma) induced to express MYC [GeneID=4609].,CGP,C2,82,218
Cohort,0.03731694741587375,0.04042533884112102,0.9231078448726474,0.35623072741433925,LonGen OPEL,Genes up-regulated in P493-6 cells (Burkitt's lymphoma) induced to express MYC [GeneID=4609].,CGP,C2,109,143
Cohort,0.035824238922480815,0.027019218088070042,1.3258799276022908,0.18532731299623484,LGP Offspring,Genes down-regulated in 293 cells (embryonic kidney) expressing  polymorphic variants S427G (SNP ID=rs2070235) or I624M (SNP ID=rs11556379) of BMYB [GeneID=4605].,CGP,C2,19,55
Cohort,0.08092610000809582,0.06623325042433734,1.2218349467922174,0.22211528372495695,LGP Proband,Genes down-regulated in 293 cells (embryonic kidney) expressing  polymorphic variants S427G (SNP ID=rs2070235) or I624M (SNP ID=rs11556379) of BMYB [GeneID=4605].,CGP,C2,19,54
Cohort,0.011685309669786204,0.02097714734256425,0.5570495110207768,0.5776501912568689,LonGen OPEL,Genes down-regulated in 293 cells (embryonic kidney) expressing  polymorphic variants S427G (SNP ID=rs2070235) or I624M (SNP ID=rs11556379) of BMYB [GeneID=4605].,CGP,C2,29,41
Cohort,0.016818797385086307,0.01608150901207144,1.0458469645144264,0.29600550813935605,LGP Offspring,Genes up-regulated in 293 cells (embryonic kidney) expressing  polymorphic variants S427G (SNP ID=rs2070235) or I624M (SNP ID=rs11556379) of BMYB [GeneID=4605].,CGP,C2,6,20
Cohort,0.007260271860711649,0.03581879719844255,0.20269446292371135,0.839423288445959,LGP Proband,Genes up-regulated in 293 cells (embryonic kidney) expressing  polymorphic variants S427G (SNP ID=rs2070235) or I624M (SNP ID=rs11556379) of BMYB [GeneID=4605].,CGP,C2,6,15
Cohort,0.0048078435329949555,0.010575827613542872,0.4546068363329101,0.6495160615308666,LonGen OPEL,Genes up-regulated in 293 cells (embryonic kidney) expressing  polymorphic variants S427G (SNP ID=rs2070235) or I624M (SNP ID=rs11556379) of BMYB [GeneID=4605].,CGP,C2,8,9
Cohort,0.01678967062016137,0.024253781523460458,0.6922496025587135,0.48901830255288503,LGP Offspring,Cell cycle genes down-regulated in H1299 cells (lung cancer) after overexpression of either P53 or P73 [GeneID=7157;7161].,CGP,C2,15,38
Cohort,0.11445759195174189,0.06011954564062208,1.9038332830380578,0.057275843295138754,LGP Proband,Cell cycle genes down-regulated in H1299 cells (lung cancer) after overexpression of either P53 or P73 [GeneID=7157;7161].,CGP,C2,15,43
Cohort,0.015374766209048684,0.01785726907710481,0.8609808220205968,0.3895078686719119,LonGen OPEL,Cell cycle genes down-regulated in H1299 cells (lung cancer) after overexpression of either P53 or P73 [GeneID=7157;7161].,CGP,C2,17,32
Cohort,-9.629594555594354e-4,0.018966312783007398,-0.050772096114653636,0.9595221243626484,LGP Offspring,Cell cycle genes up-regulated in H1299 cells (lung cancer) after overexpression of either P53 or P73 [GeneID=7157;7161].,CGP,C2,12,25
Cohort,0.08775979344831254,0.05259994472307274,1.6684388911499575,0.09560397962545537,LGP Proband,Cell cycle genes up-regulated in H1299 cells (lung cancer) after overexpression of either P53 or P73 [GeneID=7157;7161].,CGP,C2,12,31
Cohort,0.00696052981258956,0.014774653695015193,0.47111289078389473,0.6376892024440901,LonGen OPEL,Cell cycle genes up-regulated in H1299 cells (lung cancer) after overexpression of either P53 or P73 [GeneID=7157;7161].,CGP,C2,14,18
Cohort,-0.03924177748365293,0.02893365726982849,-1.3562674472049396,0.1754669014069946,LGP Offspring,Genes that were inversely correlated in H1299 cells (lung cancer): down-regulated by P53 [GeneID=7157] and up-regulated by P73 [GeneID=7161].,CGP,C2,36,54
Cohort,-0.10225630619347442,0.07988027689773078,-1.280119576004866,0.20085902500198696,LGP Proband,Genes that were inversely correlated in H1299 cells (lung cancer): down-regulated by P53 [GeneID=7157] and up-regulated by P73 [GeneID=7161].,CGP,C2,36,75
Cohort,0.04848143415676011,0.030392738233581823,1.5951650616064452,0.11107226210252376,LonGen OPEL,Genes that were inversely correlated in H1299 cells (lung cancer): down-regulated by P53 [GeneID=7157] and up-regulated by P73 [GeneID=7161].,CGP,C2,50,85
Cohort,-0.006997834968991373,0.01858231306586556,-0.3765857858592383,0.7065996229663545,LGP Offspring,Genes that were inversely correlated in H1299 cells (lung cancer): up-regulated by P53 [GeneID=7157] and down-regulated by P73 [GeneID=7161].,CGP,C2,13,23
Cohort,0.006895212428906805,0.05274946012897249,0.1307162653806883,0.896031287678,LGP Proband,Genes that were inversely correlated in H1299 cells (lung cancer): up-regulated by P53 [GeneID=7157] and down-regulated by P73 [GeneID=7161].,CGP,C2,13,33
Cohort,0.007222623234260995,0.016656216229834986,0.43362929098648895,0.664675151681906,LonGen OPEL,Genes that were inversely correlated in H1299 cells (lung cancer): up-regulated by P53 [GeneID=7157] and down-regulated by P73 [GeneID=7161].,CGP,C2,18,23
Cohort,-0.013158466534428469,0.03648967604732239,-0.36060792968848615,0.718505211622503,LGP Offspring,Genes down-regulated in HB2 cells (mammary epithelium) upon expression of KDM5B [GeneID=10765] off an adenoviral vector.,CGP,C2,45,90
Cohort,0.16949028652736361,0.10001482431705132,1.6946516447409044,0.09051483956398579,LGP Proband,Genes down-regulated in HB2 cells (mammary epithelium) upon expression of KDM5B [GeneID=10765] off an adenoviral vector.,CGP,C2,45,122
Cohort,-0.021842736517529167,0.031849131509755865,-0.6858189056376125,0.49302700456020265,LonGen OPEL,Genes down-regulated in HB2 cells (mammary epithelium) upon expression of KDM5B [GeneID=10765] off an adenoviral vector.,CGP,C2,74,77
Cohort,0.012019480029959149,0.020571029197298096,0.5842916226835091,0.559219057521851,LGP Offspring,Genes up-regulated in HB2 cells (mammary epithelium) upon expression of KDM5B [GeneID=10765] off an adenoviral vector.,CGP,C2,9,28
Cohort,0.048917113540425015,0.055984196517309785,0.8737664659579477,0.38249696710659653,LGP Proband,Genes up-regulated in HB2 cells (mammary epithelium) upon expression of KDM5B [GeneID=10765] off an adenoviral vector.,CGP,C2,9,36
Cohort,-0.006985587256295265,0.015839445550691906,-0.4410247337218264,0.6593148481337783,LonGen OPEL,Genes up-regulated in HB2 cells (mammary epithelium) upon expression of KDM5B [GeneID=10765] off an adenoviral vector.,CGP,C2,18,19
Cohort,-0.004953080984148939,0.018063992805438085,-0.27419635500839196,0.7840174948807501,LGP Offspring,Genes down-regulated both in vivo and in vitro upon activation of MET [GeneID=4233] signaling.,CGP,C2,11,22
Cohort,-0.0251172122540452,0.04370485153573193,-0.5747007796951338,0.565648666229904,LGP Proband,Genes down-regulated both in vivo and in vitro upon activation of MET [GeneID=4233] signaling.,CGP,C2,11,21
Cohort,0.01941494289649289,0.011735463699642387,1.6543822547961629,0.09844409933449978,LonGen OPEL,Genes down-regulated both in vivo and in vitro upon activation of MET [GeneID=4233] signaling.,CGP,C2,5,16
Cohort,0.020272933576815366,0.03452156213525954,0.5872542354075296,0.5572290568498401,LGP Offspring,Genes changed in xenograft tumors formed by DLD-1 or DKO-4 cells (colon cancer) overexpressing MET [GeneID=4233].,CGP,C2,34,78
Cohort,-0.11845832531611053,0.09486300819020639,-1.2487304332432092,0.21211408691429245,LGP Proband,Genes changed in xenograft tumors formed by DLD-1 or DKO-4 cells (colon cancer) overexpressing MET [GeneID=4233].,CGP,C2,34,119
Cohort,0.03836361213255111,0.03323660414123768,1.1542578769337086,0.24874088014507886,LonGen OPEL,Genes changed in xenograft tumors formed by DLD-1 or DKO-4 cells (colon cancer) overexpressing MET [GeneID=4233].,CGP,C2,64,91
Cohort,-0.01895866171502948,0.02834543664241291,-0.6688435233578968,0.5038236350310579,LGP Offspring,Genes down-regulated in CT60/4 cells (breast cancer reverted to normal by transfer of chromosome 8p region) vs parental MDA-MB-231 cells (deleted chromosome 8p).,CGP,C2,28,48
Cohort,0.007451704497285585,0.08262892612640486,0.09018275858851228,0.9281636384288179,LGP Proband,Genes down-regulated in CT60/4 cells (breast cancer reverted to normal by transfer of chromosome 8p region) vs parental MDA-MB-231 cells (deleted chromosome 8p).,CGP,C2,28,77
Cohort,0.010687319231709038,0.024610612152329712,0.4342565380153433,0.6642198434366333,LonGen OPEL,Genes down-regulated in CT60/4 cells (breast cancer reverted to normal by transfer of chromosome 8p region) vs parental MDA-MB-231 cells (deleted chromosome 8p).,CGP,C2,41,52
Cohort,-0.0317639078868072,0.045329314834099216,-0.7007365543260458,0.48370855554686387,LGP Offspring,Genes up-regulated in CT60/4 cells (breast cancer reverted to normal by transfer of chromosome 8p region) vs parental MDA-MB-231 cells (deleted chromosome 8p).,CGP,C2,67,131
Cohort,0.02108402566023721,0.12634921326009063,0.16687104823387872,0.8675119630624273,LGP Proband,Genes up-regulated in CT60/4 cells (breast cancer reverted to normal by transfer of chromosome 8p region) vs parental MDA-MB-231 cells (deleted chromosome 8p).,CGP,C2,67,179
Cohort,-0.0011620514291148841,0.03471108274057492,-0.033477821415133335,0.973301944509732,LonGen OPEL,Genes up-regulated in CT60/4 cells (breast cancer reverted to normal by transfer of chromosome 8p region) vs parental MDA-MB-231 cells (deleted chromosome 8p).,CGP,C2,86,99
Cohort,-9.092809022496444e-4,0.018540138492173563,-0.0490439110060307,0.9608987884489621,LGP Offspring,Genes down-regulated in hepatic stellar cells after stimulation with bacterial lipopolysacharide (LPS).,CGP,C2,11,24
Cohort,0.060113817891119775,0.05190008159010751,1.15826056625271,0.24708928435297284,LGP Proband,Genes down-regulated in hepatic stellar cells after stimulation with bacterial lipopolysacharide (LPS).,CGP,C2,11,35
Cohort,-0.010399105595568146,0.018461743281272473,-0.563278637186823,0.5734037915848069,LonGen OPEL,Genes down-regulated in hepatic stellar cells after stimulation with bacterial lipopolysacharide (LPS).,CGP,C2,24,25
Cohort,-0.019361210294060682,0.042867268683529275,-0.4516548613581197,0.6516625088606488,LGP Offspring,Genes up-regulated in hepatic stellar cells after stimulation with bacterial lipopolysacharide (LPS).,CGP,C2,62,124
Cohort,0.1526201365991996,0.11994466137152392,1.2724212553859706,0.20357811772593884,LGP Proband,Genes up-regulated in hepatic stellar cells after stimulation with bacterial lipopolysacharide (LPS).,CGP,C2,62,191
Cohort,0.09297960400120563,0.038751713980869386,2.3993675233850817,0.016652371295572087,LonGen OPEL,Genes up-regulated in hepatic stellar cells after stimulation with bacterial lipopolysacharide (LPS).,CGP,C2,82,137
Cohort,-0.025798847953881213,0.02274586995039289,-1.1342212019213442,0.2571038153823831,LGP Offspring,"Genes down-regulated in H1299 cells (non-small cell lung cancer, NSCLC) expressing the Y144F mutant form of FHIT [GeneID=2272].",CGP,C2,20,30
Cohort,-0.03823574821426413,0.06624744603912495,-0.5771656192101737,0.5639833416549678,LGP Proband,"Genes down-regulated in H1299 cells (non-small cell lung cancer, NSCLC) expressing the Y144F mutant form of FHIT [GeneID=2272].",CGP,C2,20,51
Cohort,-0.012606910215899046,0.019870801640110774,-0.6344439667925127,0.5259734155041539,LonGen OPEL,"Genes down-regulated in H1299 cells (non-small cell lung cancer, NSCLC) expressing the Y144F mutant form of FHIT [GeneID=2272].",CGP,C2,29,32
Cohort,0.0015442579195812118,0.009608752550605625,0.1607136734397307,0.8723669338759985,LGP Offspring,"Genes up-regulated in H1299 cells (non-small cell lung cancer, NSCLC) expressing the Y144F mutant form of FHIT [GeneID=2272].",CGP,C2,3,6
Cohort,2.005221455952703e-5,0.031088801352283375,6.449979956546075e-4,0.9994855203368469,LGP Proband,"Genes up-regulated in H1299 cells (non-small cell lung cancer, NSCLC) expressing the Y144F mutant form of FHIT [GeneID=2272].",CGP,C2,3,11
Cohort,-0.0017571244267945688,0.011410589643731223,-0.15399067722673754,0.8776561184211971,LonGen OPEL,"Genes up-regulated in H1299 cells (non-small cell lung cancer, NSCLC) expressing the Y144F mutant form of FHIT [GeneID=2272].",CGP,C2,8,12
Cohort,-0.020927871615704148,0.02514746852922118,-0.8322058974399793,0.4055866233052332,LGP Offspring,Genes that are transcriptionally regulated by HIF1A [GeneID=3091].,CGP,C2,24,41
Cohort,-0.08927780173096407,0.07066012882113808,-1.2634820119979244,0.2067690785615304,LGP Proband,Genes that are transcriptionally regulated by HIF1A [GeneID=3091].,CGP,C2,24,55
Cohort,-0.05495519343444773,0.024073241812754224,-2.282833108307497,0.022703075753999435,LonGen OPEL,Genes that are transcriptionally regulated by HIF1A [GeneID=3091].,CGP,C2,52,38
Cohort,-0.22729917494817847,0.07840438794767661,-2.8990619134718227,0.0038641535262890613,LGP Offspring,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of both HDAC1 and HDAC2 [GeneID=3065;3066] by RNAi.,CGP,C2,206,336
Cohort,0.13024640193968748,0.21290388355491766,0.6117615130589714,0.5408622834535062,LGP Proband,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of both HDAC1 and HDAC2 [GeneID=3065;3066] by RNAi.,CGP,C2,206,559
Cohort,-0.06939993474010715,0.07013068967522679,-0.9895800976932675,0.3226801075715865,LonGen OPEL,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of both HDAC1 and HDAC2 [GeneID=3065;3066] by RNAi.,CGP,C2,320,371
Cohort,-0.0033606624558089435,0.07860161075972341,-0.04275564359720469,0.9659089482356089,LGP Offspring,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of both HDAC1 and HDAC2 [GeneID=3065;3066] by RNAi.,CGP,C2,196,416
Cohort,-0.1548518258209711,0.22228279617007793,-0.6966433232308605,0.48622015148381903,LGP Proband,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of both HDAC1 and HDAC2 [GeneID=3065;3066] by RNAi.,CGP,C2,196,546
Cohort,-0.0036267341842943696,0.06881488532231939,-0.05270275707511898,0.9579819653551767,LonGen OPEL,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of both HDAC1 and HDAC2 [GeneID=3065;3066] by RNAi.,CGP,C2,339,403
Cohort,-0.17580476288819324,0.0963648374456278,-1.8243663098315095,0.06853798977785802,LGP Offspring,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC1 [GeneID=3065] by RNAi.,CGP,C2,315,586
Cohort,-0.2681936874933254,0.24481102193163815,-1.0955131242751672,0.27360815405558425,LGP Proband,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC1 [GeneID=3065] by RNAi.,CGP,C2,315,836
Cohort,0.016907538468003837,0.08496190746347848,0.19900139924791202,0.8423124683758161,LonGen OPEL,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC1 [GeneID=3065] by RNAi.,CGP,C2,462,576
Cohort,0.023502033426672033,0.1127666643397616,0.20841295221663483,0.8349693221630378,LGP Offspring,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC1 [GeneID=3065] by RNAi.,CGP,C2,374,765
Cohort,-0.5581399787196611,0.30828401968694835,-1.8104732748925254,0.07058218716954337,LGP Proband,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC1 [GeneID=3065] by RNAi.,CGP,C2,374,1071
Cohort,0.03985534963305104,0.09041363607910456,0.44081126875796545,0.6594693262921112,LonGen OPEL,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC1 [GeneID=3065] by RNAi.,CGP,C2,595,734
Cohort,-0.14210123528343988,0.05830478396844998,-2.4372139919141804,0.015057761811656061,LGP Offspring,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC2 [GeneID=3066] by RNAi.,CGP,C2,121,190
Cohort,0.1051575301611873,0.15658482130679902,0.6715691168759618,0.5020440147551679,LGP Proband,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC2 [GeneID=3066] by RNAi.,CGP,C2,121,288
Cohort,0.02333331099492538,0.05011199774239819,0.4656232448538726,0.6416125700530826,LonGen OPEL,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC2 [GeneID=3066] by RNAi.,CGP,C2,144,192
Cohort,-0.014568390471758414,0.05331902096141981,-0.27323064469431474,0.7847593765993116,LGP Offspring,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC2 [GeneID=3066] by RNAi.,CGP,C2,97,185
Cohort,-0.1994934599857272,0.1528369211389631,-1.3052700780614577,0.19216088122812203,LGP Proband,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC2 [GeneID=3066] by RNAi.,CGP,C2,97,289
Cohort,0.0032589441863093383,0.04530171107975359,0.07193865548636723,0.9426687979544237,LonGen OPEL,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC2 [GeneID=3066] by RNAi.,CGP,C2,160,190
Cohort,-0.20787127814781467,0.13713064195958466,-1.5158630863048013,0.130021421363685,LGP Offspring,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC3 [GeneID=8841] by RNAi.,CGP,C2,576,1139
Cohort,0.4655108997463394,0.3791446544412499,1.2277923328033427,0.2198713455616827,LGP Proband,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC3 [GeneID=8841] by RNAi.,CGP,C2,576,1576
Cohort,0.038134995993369614,0.11933962340650725,0.3195501620067139,0.7493932061709885,LonGen OPEL,Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC3 [GeneID=8841] by RNAi.,CGP,C2,900,1127
Cohort,-0.16709272926113078,0.11401991312103288,-1.4654697121524796,0.14325775901419008,LGP Offspring,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC3 [GeneID=8841] by RNAi.,CGP,C2,454,851
Cohort,-0.4491284497325003,0.33275303945773677,-1.3497350781961663,0.1774672100769169,LGP Proband,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC3 [GeneID=8841] by RNAi.,CGP,C2,454,1223
Cohort,0.09650719129454711,0.10090835463291947,0.9563845495808276,0.33916835195866923,LonGen OPEL,Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC3 [GeneID=8841] by RNAi.,CGP,C2,683,852
Cohort,-0.011886009648828463,0.06314865903505056,-0.18822267694126574,0.850758583692762,LGP Offspring,"Genes whose reduced expression in nasopharyngeal carinoma (NPC) correlated most with the increased expression of EBNA1 [GeneID=3783774], a latent gene of Epstein-Barr virus (EBV).",CGP,C2,123,252
Cohort,0.0659396313563713,0.1840982101804432,0.35817638472281077,0.7203019549464476,LGP Proband,"Genes whose reduced expression in nasopharyngeal carinoma (NPC) correlated most with the increased expression of EBNA1 [GeneID=3783774], a latent gene of Epstein-Barr virus (EBV).",CGP,C2,123,415
Cohort,-0.051892203574342384,0.05929123913670212,-0.8752086198552793,0.38172440804670693,LonGen OPEL,"Genes whose reduced expression in nasopharyngeal carinoma (NPC) correlated most with the increased expression of EBNA1 [GeneID=3783774], a latent gene of Epstein-Barr virus (EBV).",CGP,C2,229,263
Cohort,-0.028745584604635076,0.11717890829149818,-0.24531364068631356,0.8062880436800758,LGP Offspring,Genes down-regulated in nsopharyngeal carcinoma relative to the normal tissue.,CGP,C2,431,920
Cohort,0.4640453613003,0.31895848583352227,1.4548769884194417,0.14607957887017323,LGP Proband,Genes down-regulated in nsopharyngeal carcinoma relative to the normal tissue.,CGP,C2,431,1218
Cohort,0.16472081292095236,0.09901415835545005,1.6636086763432618,0.09658426604530648,LonGen OPEL,Genes down-regulated in nsopharyngeal carcinoma relative to the normal tissue.,CGP,C2,677,899
Cohort,-0.3234339092287697,0.09748573027338357,-3.3177564380114872,9.560587625103501e-4,LGP Offspring,Genes up-regulated in nsopharyngeal carcinoma relative to the normal tissue.,CGP,C2,354,590
Cohort,-0.2702021623062787,0.2694859653765464,-1.0026576409229013,0.31631688974573163,LGP Proband,Genes up-regulated in nsopharyngeal carcinoma relative to the normal tissue.,CGP,C2,354,862
Cohort,0.005796691678707578,0.08320817202263156,0.06966493239547375,0.9444778507495306,LonGen OPEL,Genes up-regulated in nsopharyngeal carcinoma relative to the normal tissue.,CGP,C2,469,563
Cohort,0.06240550391505029,0.07424394195874404,0.8405467472312805,0.4008991012398426,LGP Offspring,"Genes down-regulated in nasopharyngeal carcinoma (NPC) positive for LMP1 [GeneID=9260], a latent gene of Epstein-Barr virus (EBV).",CGP,C2,156,354
Cohort,0.1280517641212402,0.20221931016180844,0.6332321281225709,0.5267556663370336,LGP Proband,"Genes down-regulated in nasopharyngeal carcinoma (NPC) positive for LMP1 [GeneID=9260], a latent gene of Epstein-Barr virus (EBV).",CGP,C2,156,494
Cohort,0.017885068612924864,0.06169059332192595,0.2899156524495313,0.7719562697106355,LonGen OPEL,"Genes down-regulated in nasopharyngeal carcinoma (NPC) positive for LMP1 [GeneID=9260], a latent gene of Epstein-Barr virus (EBV).",CGP,C2,252,314
Cohort,-0.09787549578915994,0.11250982287720032,-0.8699284496784505,0.384648292260955,LGP Offspring,"Genes up-regulated in nasopharyngeal carcinoma (NPC) positive for LMP1 [GeneID=9260], a latent gene of Epstein-Barr virus (EBV).",CGP,C2,440,852
Cohort,-0.32703969650252185,0.32620548531362653,-1.0025573180907528,0.3163652845125165,LGP Proband,"Genes up-regulated in nasopharyngeal carcinoma (NPC) positive for LMP1 [GeneID=9260], a latent gene of Epstein-Barr virus (EBV).",CGP,C2,440,1285
Cohort,-0.09710340313032478,0.10500053477617298,-0.9247896054750357,0.35535562299514567,LonGen OPEL,"Genes up-regulated in nasopharyngeal carcinoma (NPC) positive for LMP1 [GeneID=9260], a latent gene of Epstein-Barr virus (EBV).",CGP,C2,741,847
Cohort,-0.06122273318965729,0.06631683752506778,-0.923185354948735,0.3562400067814312,LGP Offspring,Genes down-regulated in pancreatic islets upon knockout of HNF1A [GeneID=6927].,CGP,C2,151,287
Cohort,0.11207108148829827,0.1752007499823166,0.6396723843911047,0.5225612808767857,LGP Proband,Genes down-regulated in pancreatic islets upon knockout of HNF1A [GeneID=6927].,CGP,C2,151,352
Cohort,-0.010360688586647538,0.052753210794332484,-0.19639920358668733,0.844347849536856,LonGen OPEL,Genes down-regulated in pancreatic islets upon knockout of HNF1A [GeneID=6927].,CGP,C2,191,221
Cohort,0.022450842453152965,0.06542136543852094,0.34317294209108057,0.7315750523252453,LGP Offspring,Genes up-regulated in pancreatic islets upon knockout of HNF1A [GeneID=6927].,CGP,C2,136,287
Cohort,-0.01524261080196339,0.1814652479846197,-0.08399740981400083,0.9330786486182596,LGP Proband,Genes up-regulated in pancreatic islets upon knockout of HNF1A [GeneID=6927].,CGP,C2,136,401
Cohort,-0.008143388572714941,0.05619225479634394,-0.14492012470809015,0.8848106222811251,LonGen OPEL,Genes up-regulated in pancreatic islets upon knockout of HNF1A [GeneID=6927].,CGP,C2,213,243
Cohort,-0.04899948121659279,0.07978534626369918,-0.6141413619318542,0.5393285398907252,LGP Offspring,Genes down-regulated in liver tissue upon knockout of HNF1A [GeneID=6927].,CGP,C2,199,412
Cohort,-0.019076333397953706,0.22556056117527512,-0.08457300025570588,0.9326211613749473,LGP Proband,Genes down-regulated in liver tissue upon knockout of HNF1A [GeneID=6927].,CGP,C2,199,580
Cohort,-0.008595686046471662,0.06738978161553157,-0.1275517718029017,0.8985359149600605,LonGen OPEL,Genes down-regulated in liver tissue upon knockout of HNF1A [GeneID=6927].,CGP,C2,325,396
Cohort,-6.977539145145877e-4,0.0607881528784094,-0.011478452321297863,0.9908451078266829,LGP Offspring,Genes up-regulated in liver tissue upon knockout of HNF1A [GeneID=6927].,CGP,C2,117,239
Cohort,-0.06191856151761457,0.16038748515853343,-0.3860560657610647,0.6995536072808552,LGP Proband,Genes up-regulated in liver tissue upon knockout of HNF1A [GeneID=6927].,CGP,C2,117,332
Cohort,0.006569843284709638,0.05338765218322014,0.12305922841788788,0.9020912603897404,LonGen OPEL,Genes up-regulated in liver tissue upon knockout of HNF1A [GeneID=6927].,CGP,C2,186,228
Cohort,-0.05672048334246758,0.03616558293911736,-1.5683552906627602,0.11726618403375329,LGP Offspring,Cluster 0: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,54,82
Cohort,-0.12880908712363423,0.10179059886078387,-1.2654320592003077,0.2060699045022272,LGP Proband,Cluster 0: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,54,130
Cohort,0.07221842439803239,0.03427128032280733,2.1072578473227175,0.03540747613298581,LonGen OPEL,Cluster 0: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,70,116
Cohort,0.012155194176325058,0.02970941232215074,0.4091361365388702,0.6825693498922978,LGP Offspring,Cluster 1: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,26,61
Cohort,-0.024844038210327823,0.0824918862838739,-0.30116947653292436,0.7633603339651874,LGP Proband,Cluster 1: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,26,91
Cohort,0.01027019626890327,0.028448765290224047,0.36100674894430146,0.7181901897103381,LonGen OPEL,Cluster 1: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,55,69
Cohort,-0.00842943636916063,0.04794602679316666,-0.17581094686999185,0.8604951201248929,LGP Offspring,Cluster 2: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,73,148
Cohort,-0.05721571984836898,0.12104167128626181,-0.47269439722998063,0.6365548985965752,LGP Proband,Cluster 2: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,73,172
Cohort,0.014719879515712382,0.03764038556743318,0.39106611937705976,0.6958530122039482,LonGen OPEL,Cluster 2: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,96,120
Cohort,0.006003536703606748,0.013035080402167021,0.46056767725105,0.6452569265921677,LGP Offspring,Cluster 3: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,5,12
Cohort,-0.008251262417202853,0.037495777168914425,-0.2200584449825325,0.8258794902057094,LGP Proband,Cluster 3: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,5,18
Cohort,0.013174531274662766,0.011760110172410536,1.12027277648899,0.262935427015557,LonGen OPEL,Cluster 3: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,7,14
Cohort,8.799232300780545e-4,0.019928305398542873,0.044154443264523294,0.9647943347823591,LGP Offspring,Cluster 4: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,13,28
Cohort,0.05728756873497829,0.061285416193989126,0.934766740485921,0.35017908930220887,LGP Proband,Cluster 4: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,13,45
Cohort,0.03365996385245744,0.017779633602956736,1.8931753378123506,0.05869702204801793,LonGen OPEL,Cluster 4: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,15,31
Cohort,9.051431440806054e-4,0.038577598814590004,0.02346292075955441,0.9812879392423244,LGP Offspring,Cluster 5: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,49,108
Cohort,0.07009958814116411,0.10532931599716619,0.6655278018044861,0.5058969806561227,LGP Proband,Cluster 5: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,49,139
Cohort,-0.019676501378751852,0.037535871198074354,-0.5242052668744581,0.6002817101327562,LonGen OPEL,Cluster 5: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,93,107
Cohort,0.028539821617684962,0.0356508868741421,0.8005360909656681,0.42368150970868323,LGP Offspring,Cluster 6: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,43,98
Cohort,-0.019076636120969413,0.10021862594642504,-0.19035020626971494,0.849081036142185,LGP Proband,Cluster 6: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,43,141
Cohort,-0.08489952024806056,0.033433340122519174,-2.5393669892669837,0.01129454273559297,LonGen OPEL,Cluster 6: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,90,70
Cohort,-0.07607496036202686,0.05537577633090415,-1.3737949226649648,0.16996072822988162,LGP Offspring,Cluster 7: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,106,189
Cohort,-0.39633560553109354,0.1480212257683731,-2.677559272149849,0.007561857010229982,LGP Proband,Cluster 7: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,106,260
Cohort,0.029438597885337765,0.04433325270711565,0.6640297313581226,0.5068635700076201,LonGen OPEL,Cluster 7: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,126,163
Cohort,-0.053061128078520745,0.05499397969626846,-0.9648533961640375,0.3349632758828738,LGP Offspring,Cluster 8: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,103,199
Cohort,0.10591236802416377,0.14800514418994404,0.7155992354444111,0.4744391369456199,LGP Proband,Cluster 8: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,103,286
Cohort,-0.019585682257248386,0.04888836197747381,-0.4006205457706446,0.6888070181551325,LonGen OPEL,Cluster 8: genes changed in primary keratinocytes by UVB irradiation.,CGP,C2,164,193
Cohort,5.729767801643839e-4,0.019896109252901528,0.028798433547042594,0.9770338498738793,LGP Offspring,Genes down-regulated in prostate cancer samples bearing the fusion of TMPRSS2 with ERG [GeneID=7113;2078].,CGP,C2,12,24
Cohort,-0.07758713902135966,0.05895989219906918,-1.3159308154668667,0.18855885113781667,LGP Proband,Genes down-regulated in prostate cancer samples bearing the fusion of TMPRSS2 with ERG [GeneID=7113;2078].,CGP,C2,12,45
Cohort,0.007593906511741081,0.01659779368386628,0.45752505762995854,0.6474185462194844,LonGen OPEL,Genes down-regulated in prostate cancer samples bearing the fusion of TMPRSS2 with ERG [GeneID=7113;2078].,CGP,C2,20,23
Cohort,0.04726165587738824,0.05256858810379566,0.8990474650768823,0.3689475023919504,LGP Offspring,Genes up-regulated in prostate cancer samples bearing the fusion of TMPRSS2 with ERG [GeneID=7113;2078].,CGP,C2,75,171
Cohort,0.1133576103238697,0.1345276319160774,0.8426343994116078,0.3996745265660364,LGP Proband,Genes up-regulated in prostate cancer samples bearing the fusion of TMPRSS2 with ERG [GeneID=7113;2078].,CGP,C2,75,227
Cohort,0.002790427541211041,0.039513596478973206,0.07061942697865889,0.9437183863389643,LonGen OPEL,Genes up-regulated in prostate cancer samples bearing the fusion of TMPRSS2 with ERG [GeneID=7113;2078].,CGP,C2,111,133
Cohort,-0.04167487034645756,0.033523238524477694,-1.2431636136833195,0.21423853438717325,LGP Offspring,Direct targets of IRF4 [GeneID=3662] that constitute a multiple myeloma program.,CGP,C2,42,69
Cohort,-0.0777471115507587,0.0912853857725493,-0.8516928629132031,0.39462906791756147,LGP Proband,Direct targets of IRF4 [GeneID=3662] that constitute a multiple myeloma program.,CGP,C2,42,91
Cohort,0.10124873365055177,0.029224849394050505,3.464474094814793,5.596791088480299e-4,LonGen OPEL,Direct targets of IRF4 [GeneID=3662] that constitute a multiple myeloma program.,CGP,C2,40,90
Cohort,-0.04756758857026586,0.04506175591632395,-1.0556088550698077,0.2915240650091914,LGP Offspring,IRF4 [GeneID=3662] target genes induced after activation of primary B lymphocytes by anti-IgM crosslinking.,CGP,C2,68,125
Cohort,-0.19279176353843344,0.1094534437224314,-1.7614042736503015,0.07853638618543221,LGP Proband,IRF4 [GeneID=3662] target genes induced after activation of primary B lymphocytes by anti-IgM crosslinking.,CGP,C2,68,137
Cohort,0.03815235747811691,0.038133785231296034,1.0004870286730843,0.31737890766104704,LonGen OPEL,IRF4 [GeneID=3662] target genes induced after activation of primary B lymphocytes by anti-IgM crosslinking.,CGP,C2,91,131
Cohort,-0.0574402137839728,0.04222525639755027,-1.3603283599553284,0.17417946318485011,LGP Offspring,IRF4 [GeneID=3662] target genes up-regulated in plasmacytoid dendritic cells compared to monocytes.,CGP,C2,59,105
Cohort,-0.04177855163397323,0.10939105675361052,-0.38191926171875384,0.7026185432008273,LGP Proband,IRF4 [GeneID=3662] target genes up-regulated in plasmacytoid dendritic cells compared to monocytes.,CGP,C2,59,139
Cohort,0.05168756199466729,0.032796549461979255,1.5760060995010532,0.11542172225345389,LonGen OPEL,IRF4 [GeneID=3662] target genes up-regulated in plasmacytoid dendritic cells compared to monocytes.,CGP,C2,64,99
Cohort,-0.12527300756794799,0.05536580731782982,-2.2626421186060353,0.023974280015242374,LGP Offspring,IRF4 [GeneID=3662] target genes up-regulated in primary myeloma vs. mature B lymphocytes.,CGP,C2,111,190
Cohort,-0.1870676407462657,0.14924186872707976,-1.2534528168389418,0.2103922289332326,LGP Proband,IRF4 [GeneID=3662] target genes up-regulated in primary myeloma vs. mature B lymphocytes.,CGP,C2,111,238
Cohort,0.16597597606073705,0.04298770191113692,3.861010677049877,1.2208076427294349e-4,LonGen OPEL,IRF4 [GeneID=3662] target genes up-regulated in primary myeloma vs. mature B lymphocytes.,CGP,C2,98,193
Cohort,-0.060259737822028425,0.045314578023479456,-1.3298090912554725,0.18402970097963814,LGP Offspring,IRF4 [GeneID=3662] target genes up-regulated in plasma cells compared to mature B lymphocytes.,CGP,C2,74,135
Cohort,-0.19138210601339078,0.11753867122546913,-1.6282479971742332,0.10384998188425122,LGP Proband,IRF4 [GeneID=3662] target genes up-regulated in plasma cells compared to mature B lymphocytes.,CGP,C2,74,162
Cohort,0.12942283991998438,0.037112121606073,3.487346837611292,5.145869007472138e-4,LonGen OPEL,IRF4 [GeneID=3662] target genes up-regulated in plasma cells compared to mature B lymphocytes.,CGP,C2,70,138
Cohort,0.029408315270079338,0.018395449517735543,1.5986733698312725,0.11036046284741723,LGP Offspring,Genes down-regulated in preleukemic thymocytes from transgenic mice which overexpress TAL1 [GeneID=6886] in thymus.,CGP,C2,3,23
Cohort,0.03328474049624293,0.05368313594530262,0.6200222827920583,0.5354124816653946,LGP Proband,Genes down-regulated in preleukemic thymocytes from transgenic mice which overexpress TAL1 [GeneID=6886] in thymus.,CGP,C2,3,35
Cohort,-0.018663756994587874,0.01618823841971849,-1.1529208126718726,0.24928898270580602,LonGen OPEL,Genes down-regulated in preleukemic thymocytes from transgenic mice which overexpress TAL1 [GeneID=6886] in thymus.,CGP,C2,19,13
Cohort,2.865131305287009e-4,0.020804145565364078,0.013771924909317316,0.9890160044788374,LGP Offspring,Genes up-regulated in pilocytic astrocytoma (PA) samples from patients with type 1 neurofibromatosis syndrom (NF1) compared to the PA tumors from non-NF1 patients.,CGP,C2,10,26
Cohort,-0.04603644019788125,0.04959304093543589,-0.928284277986,0.35352870232430034,LGP Proband,Genes up-regulated in pilocytic astrocytoma (PA) samples from patients with type 1 neurofibromatosis syndrom (NF1) compared to the PA tumors from non-NF1 patients.,CGP,C2,10,30
Cohort,0.0018411170872993667,0.014002834809419202,0.13148174011600233,0.8954274545355043,LonGen OPEL,Genes up-regulated in pilocytic astrocytoma (PA) samples from patients with type 1 neurofibromatosis syndrom (NF1) compared to the PA tumors from non-NF1 patients.,CGP,C2,14,16
Cohort,-0.005018304595809499,0.0084681972000355335,-0.5926060148656483,0.5536430265699094,LGP Offspring,Genes down-regulated in pilocytic astrocytoma (PA) from supratentorial regions compared to the infratentorial PA tumors.,CGP,C2,3,4
Cohort,-0.016563626439530642,0.02616469143246606,-0.6330526191101157,0.5268728224743904,LGP Proband,Genes down-regulated in pilocytic astrocytoma (PA) from supratentorial regions compared to the infratentorial PA tumors.,CGP,C2,3,8
Cohort,-0.010229732587410518,0.008508728286347293,-1.202263398612066,0.22961901566202514,LonGen OPEL,Genes down-regulated in pilocytic astrocytoma (PA) from supratentorial regions compared to the infratentorial PA tumors.,CGP,C2,7,4
Cohort,-0.03713341927853959,0.02946954839550209,-1.2600606829864833,0.20808228256105438,LGP Offspring,Genes up-regulated in pilocytic astrocytoma (PA) from supratentorial regions compared to the infratentorial PA tumors.,CGP,C2,36,53
Cohort,-0.0825083023372824,0.07850965978632558,-1.050931854269139,0.29359430299296285,LGP Proband,Genes up-regulated in pilocytic astrocytoma (PA) from supratentorial regions compared to the infratentorial PA tumors.,CGP,C2,36,73
Cohort,-0.043679032027414036,0.02491367895424825,-1.7532148546839141,0.07995003862574655,LonGen OPEL,Genes up-regulated in pilocytic astrocytoma (PA) from supratentorial regions compared to the infratentorial PA tumors.,CGP,C2,49,46
Cohort,-0.20359734167531054,0.08372161421584409,-2.4318372690523242,0.015281119081262255,LGP Offspring,Cluster 12 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.,CGP,C2,244,428
Cohort,0.0036622728799326413,0.23341065559304272,0.015690255745298556,0.9874852534305791,LGP Proband,Cluster 12 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.,CGP,C2,244,655
Cohort,-0.1836000931586847,0.07274978166347197,-2.523720194900203,0.011805576192478403,LonGen OPEL,Cluster 12 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.,CGP,C2,404,405
Cohort,-0.08377694207886249,0.0931810639134102,-0.8990768999666432,0.3689318361680768,LGP Offspring,Cluster 4 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.,CGP,C2,286,550
Cohort,-0.034383351472162774,0.2502463423973574,-0.13739801806000687,0.8907493603634734,LGP Proband,Cluster 4 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.,CGP,C2,286,739
Cohort,-0.11187546912594272,0.08211523355498292,-1.3624203973192486,0.17345060576373011,LonGen OPEL,Cluster 4 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.,CGP,C2,478,523
Cohort,-0.0013275173699063031,0.05158325509038716,-0.025735432313841972,0.9794759573146006,LGP Offspring,Cluster 5 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.,CGP,C2,85,181
Cohort,-0.23739934895675552,0.1366621164440366,-1.7371262434236556,0.0827340806340166,LGP Proband,Cluster 5 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.,CGP,C2,85,227
Cohort,-0.019599442567569847,0.044256872146272136,-0.4428564789394127,0.6579898683408316,LonGen OPEL,Cluster 5 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.,CGP,C2,135,147
Cohort,-0.1740268763462448,0.10784042694994818,-1.6137443189743272,0.10704956301628256,LGP Offspring,Cluster 6 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts poor survival outcome.,CGP,C2,380,708
Cohort,-0.6029091170305251,0.29191363915866425,-2.0653680957429503,0.03919665246888719,LGP Proband,Cluster 6 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts poor survival outcome.,CGP,C2,380,981
Cohort,-0.019001668744821617,0.09401379145024892,-0.20211575824890643,0.8398778721724622,LonGen OPEL,Cluster 6 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts poor survival outcome.,CGP,C2,562,667
Cohort,-0.11433962803573865,0.09700731135644614,-1.1786702098732147,0.2389442302049091,LGP Offspring,Genes whose expression negatively correlated with that of SMARCA2 [GeneID=6595] in prostate cancer samples.,CGP,C2,308,569
Cohort,-0.48035839824165233,0.2642508816418865,-1.8178119038128142,0.06945155323258909,LGP Proband,Genes whose expression negatively correlated with that of SMARCA2 [GeneID=6595] in prostate cancer samples.,CGP,C2,308,786
Cohort,-0.16658621236440385,0.08494195462636481,-1.9611770543445652,0.050206630514333904,LonGen OPEL,Genes whose expression negatively correlated with that of SMARCA2 [GeneID=6595] in prostate cancer samples.,CGP,C2,494,509
Cohort,-0.16828323330260733,0.11228881200500278,-1.498664295202534,0.13442755963098557,LGP Offspring,Genes whose expression positively correlated with that of SMARCA2 [GeneID=6595] in prostate cancer samples.,CGP,C2,440,837
Cohort,0.2818039097241105,0.31449758316792104,0.8960447545749366,0.37048741279581354,LGP Proband,Genes whose expression positively correlated with that of SMARCA2 [GeneID=6595] in prostate cancer samples.,CGP,C2,440,1208
Cohort,0.06175112231577214,0.09993037703682191,0.6179414523075236,0.5367906843717694,LonGen OPEL,Genes whose expression positively correlated with that of SMARCA2 [GeneID=6595] in prostate cancer samples.,CGP,C2,645,805
Cohort,0.002697337645764695,0.08216804543465424,0.03282708784779122,0.9738221667635315,LGP Offspring,Human orthologs of genes down-regulated in zebra fish after knockdown of BMYB [GeneID=4605] by morpholino.,CGP,C2,217,448
Cohort,-0.3660232555592023,0.23111886910722512,-1.5837013090843297,0.11364080822132322,LGP Proband,Human orthologs of genes down-regulated in zebra fish after knockdown of BMYB [GeneID=4605] by morpholino.,CGP,C2,217,616
Cohort,-0.07403071394732154,0.06874646031362264,-1.0768658285763666,0.2818664643639158,LonGen OPEL,Human orthologs of genes down-regulated in zebra fish after knockdown of BMYB [GeneID=4605] by morpholino.,CGP,C2,342,365
Cohort,-0.0522296521855601,0.080851049752322,-0.6459984421421825,0.5184995929305874,LGP Offspring,Human orthologs of genes up-regulated in zebra fish after knockdown of BMYB [GeneID=4605] by morpholino.,CGP,C2,195,398
Cohort,-0.10256335504067679,0.21064947051855726,-0.48689111246373357,0.6264634298684781,LGP Proband,Human orthologs of genes up-regulated in zebra fish after knockdown of BMYB [GeneID=4605] by morpholino.,CGP,C2,195,537
Cohort,-0.03930233615541584,0.0681152324939481,-0.5769977539004623,0.564104113509107,LonGen OPEL,Human orthologs of genes up-regulated in zebra fish after knockdown of BMYB [GeneID=4605] by morpholino.,CGP,C2,292,326
Cohort,-0.06332182666459814,0.0508500933547841,-1.2452647082237986,0.21346593596516936,LGP Offspring,"Human orthologs of BMYB [GeneID=4605] target genes in zebra fish, identified as commonly changed in the BMYB loss of function mutant crb ('crush and burn') and after knockdown of BMYB by morpholino.",CGP,C2,90,155
Cohort,-0.3920310221837804,0.1409051755442689,-2.782232949708891,0.005520543717453378,LGP Proband,"Human orthologs of BMYB [GeneID=4605] target genes in zebra fish, identified as commonly changed in the BMYB loss of function mutant crb ('crush and burn') and after knockdown of BMYB by morpholino.",CGP,C2,90,228
Cohort,-0.08062593880995333,0.03877385582347244,-2.0793892456046374,0.03790117225932735,LonGen OPEL,"Human orthologs of BMYB [GeneID=4605] target genes in zebra fish, identified as commonly changed in the BMYB loss of function mutant crb ('crush and burn') and after knockdown of BMYB by morpholino.",CGP,C2,120,106
Cohort,-0.20585811256020461,0.07607884428312153,-2.7058522576147395,0.006984731105099333,LGP Offspring,Human orthologs of genes down-regulated in the crb ('crash and burn') zebrafish mutant that represents a loss-of-function mutation in BMYB [GeneID=4605].,CGP,C2,216,353
Cohort,-0.3323408859273414,0.2162285998410375,-1.5369885675237454,0.12467538785154164,LGP Proband,Human orthologs of genes down-regulated in the crb ('crash and burn') zebrafish mutant that represents a loss-of-function mutation in BMYB [GeneID=4605].,CGP,C2,216,559
Cohort,-0.08191165883474434,0.06651288701119842,-1.2315156132217402,0.2184937844821804,LonGen OPEL,Human orthologs of genes down-regulated in the crb ('crash and burn') zebrafish mutant that represents a loss-of-function mutation in BMYB [GeneID=4605].,CGP,C2,301,327
Cohort,0.0676345122748554,0.07910738917677654,0.8549708564356309,0.3928701849610404,LGP Offspring,Human orthologs of genes up-regulated in the crb ('crash and burn') zebrafish mutant that represents a loss-of-function mutation in BMYB [GeneID=4605].,CGP,C2,169,402
Cohort,0.1017814544941408,0.21295697881417297,0.47794373803056095,0.6328154945037581,LGP Proband,Human orthologs of genes up-regulated in the crb ('crash and burn') zebrafish mutant that represents a loss-of-function mutation in BMYB [GeneID=4605].,CGP,C2,169,571
Cohort,-0.20886018172537021,0.07083790057025299,-2.948424219860025,0.003287433765063238,LonGen OPEL,Human orthologs of genes up-regulated in the crb ('crash and burn') zebrafish mutant that represents a loss-of-function mutation in BMYB [GeneID=4605].,CGP,C2,350,342
Cohort,-0.07333686983112846,0.09548899617113722,-0.768013831663836,0.4427471578267963,LGP Offspring,Cluster PAM1: genes up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,296,572
Cohort,-0.3505949418780495,0.25493888264605274,-1.3752117301180846,0.1694350990520182,LGP Proband,Cluster PAM1: genes up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,296,759
Cohort,0.08785747070428584,0.08147442412458922,1.0783441754670864,0.2812068520146477,LonGen OPEL,Cluster PAM1: genes up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,435,545
Cohort,0.01883876071531888,0.06508511011901899,0.28944808852391984,0.7723272494302873,LGP Offspring,Cluster PAM2: genes up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,137,280
Cohort,-0.3714043838508292,0.1843726436461383,-2.014422402944203,0.04428578515043841,LGP Proband,Cluster PAM2: genes up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,137,380
Cohort,1.24695003525379e-4,0.05670929877940126,0.002198845801469731,0.9982461272247526,LonGen OPEL,Cluster PAM2: genes up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,217,262
Cohort,0.0016415641437131823,0.05415744892467522,0.03031095770401498,0.9758280040778101,LGP Offspring,Cluster PAM3: genes most highly up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,92,199
Cohort,-0.006096762497228959,0.14828621214318383,-0.041114830631333275,0.9672141918886425,LGP Proband,Cluster PAM3: genes most highly up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,92,273
Cohort,0.023651436863682276,0.05070562754464441,0.46644599443835044,0.6410239206823689,LonGen OPEL,Cluster PAM3: genes most highly up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,166,204
Cohort,0.06658554688658862,0.10146513056253599,0.6562406860113382,0.5118925799557623,LGP Offspring,Cluster PAM4: genes down-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,296,654
Cohort,-0.1385692486042917,0.26290494751685134,-0.5270697638560411,0.5982853077130373,LGP Proband,Cluster PAM4: genes down-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,296,792
Cohort,-0.11360434856466971,0.08027069432119804,-1.4152655527070588,0.15738175044739328,LonGen OPEL,Cluster PAM4: genes down-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].,CGP,C2,458,524
Cohort,-0.00410104243954369,0.04716383053685158,-0.08695312473271927,0.9307345213625229,LGP Offspring,Cluster PAM5: genes changed exclusively in hepatocellular carcinoma (HCC) samples from 27 month old mice deficient for TXNIP [GeneID=10628].,CGP,C2,74,151
Cohort,-0.11682223690346115,0.13153954512277743,-0.8881149527651222,0.3747349783708003,LGP Proband,Cluster PAM5: genes changed exclusively in hepatocellular carcinoma (HCC) samples from 27 month old mice deficient for TXNIP [GeneID=10628].,CGP,C2,74,226
Cohort,0.016527669249075356,0.04088809446831792,0.40421715572687783,0.6861616191501615,LonGen OPEL,Cluster PAM5: genes changed exclusively in hepatocellular carcinoma (HCC) samples from 27 month old mice deficient for TXNIP [GeneID=10628].,CGP,C2,119,141
Cohort,-0.033643158097291785,0.03185484555784313,-1.0561394195492606,0.2912818125368014,LGP Offspring,Cluster PAM6: genes changed exclusively in normal liver tissue adjacent to hepatocellular carcinoma (HCC) from mice deficient for TXNIP [GeneID=10628].,CGP,C2,38,66
Cohort,0.1463399312196014,0.09823807274443723,1.4896457873344013,0.1366954538001815,LGP Proband,Cluster PAM6: genes changed exclusively in normal liver tissue adjacent to hepatocellular carcinoma (HCC) from mice deficient for TXNIP [GeneID=10628].,CGP,C2,38,123
Cohort,-3.818252720777423e-4,0.029229938026222,-0.013062814971937647,0.989580951219688,LonGen OPEL,Cluster PAM6: genes changed exclusively in normal liver tissue adjacent to hepatocellular carcinoma (HCC) from mice deficient for TXNIP [GeneID=10628].,CGP,C2,60,69
Cohort,-0.03599869514444408,0.02312650160415706,-1.5565992539906341,0.12003367964005915,LGP Offspring,Genes down-regulated in glioma cell lines after knockdown of SPARC [GeneID=6678] by RNAi.,CGP,C2,23,27
Cohort,-0.04901060697347068,0.05712784589252233,-0.8579109925775418,0.3911880871665141,LGP Proband,Genes down-regulated in glioma cell lines after knockdown of SPARC [GeneID=6678] by RNAi.,CGP,C2,23,30
Cohort,-0.01914528902110115,0.01670648714083241,-1.1459793348362297,0.25214809333919824,LonGen OPEL,Genes down-regulated in glioma cell lines after knockdown of SPARC [GeneID=6678] by RNAi.,CGP,C2,24,20
Cohort,0.0288634558931912,0.03129270768080465,0.9223700354602556,0.3566646706814882,LGP Offspring,Genes up-regulated in glioma cell lines after knockdown of SPARC [GeneID=6678] by RNAi.,CGP,C2,27,67
Cohort,0.058802243107508236,0.08708372252707818,0.675238051396161,0.49971169467757237,LGP Proband,Genes up-regulated in glioma cell lines after knockdown of SPARC [GeneID=6678] by RNAi.,CGP,C2,27,89
Cohort,0.013560864628547057,0.027836708430439092,0.4871576200337832,0.6262807584256136,LonGen OPEL,Genes up-regulated in glioma cell lines after knockdown of SPARC [GeneID=6678] by RNAi.,CGP,C2,54,67
Cohort,-0.017853695597098724,0.013165816979181294,-1.3560643920031876,0.17553146262559002,LGP Offspring,Cluster 1 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,10,8
Cohort,-0.12060715768430355,0.05051798343021422,-2.387410373395265,0.01718934616012204,LGP Proband,Cluster 1 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,10,31
Cohort,0.0035783311722566093,0.012528902501254841,0.2856061152920792,0.7752541217387237,LonGen OPEL,Cluster 1 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,10,14
Cohort,-0.03561839603547132,0.03284221734306758,-1.0845307935028856,0.2785161525409231,LGP Offspring,Cluster 2 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,40,68
Cohort,-0.021073617158409618,0.0799857119301813,-0.2634672699644727,0.7922555270214553,LGP Proband,Cluster 2 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,40,69
Cohort,0.008907644522159777,0.022807656410745617,0.39055501195480224,0.6962306816393431,LonGen OPEL,Cluster 2 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,38,46
Cohort,0.028063337635503054,0.02247619958486506,1.248580193886525,0.21225089308697484,LGP Offspring,Cluster 3 of genes distinguishing  among different B lymphocyte neoplasms.,CGP,C2,12,41
Cohort,0.03766888852369945,0.06723201642143692,0.5602819984986904,0.5754375695707137,LGP Proband,Cluster 3 of genes distinguishing  among different B lymphocyte neoplasms.,CGP,C2,12,58
Cohort,-0.010594829640200426,0.02032667387528859,-0.5212279050278217,0.6023529915522786,LonGen OPEL,Cluster 3 of genes distinguishing  among different B lymphocyte neoplasms.,CGP,C2,29,30
Cohort,0.0169009088425978,0.011904139681162934,1.4197505485710769,0.15614129394976145,LGP Offspring,Cluster 5 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,2,12
Cohort,-0.0010296690695422515,0.029366751977481956,-0.035062409024048294,0.9720383661294096,LGP Proband,Cluster 5 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,2,12
Cohort,-0.014308627391748084,0.009267381926569304,-1.5439773071967264,0.12299127473503554,LonGen OPEL,Cluster 5 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,8,5
Cohort,-0.010510098243061969,0.01012717680728636,-1.0378112718936736,0.29972899797504937,LGP Offspring,Cluster 6 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,4,4
Cohort,0.0036407653661727317,0.027129348663963698,0.13420024974682906,0.8932766058689221,LGP Proband,Cluster 6 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,4,8
Cohort,0.01937777548176817,0.009645288557072553,2.0090405141439884,0.04487002601240787,LonGen OPEL,Cluster 6 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,2,12
Cohort,-0.08994284579820579,0.033769218561328126,-2.663456533199339,0.007918460815944127,LGP Offspring,Cluster 7 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,50,62
Cohort,-0.01814489291139066,0.09398677031562584,-0.1930579468839772,0.8469605904381469,LGP Proband,Cluster 7 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,50,103
Cohort,-0.01724187651203473,0.03072169350462893,-0.5612280621651552,0.5748000319069406,LonGen OPEL,Cluster 7 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,70,71
Cohort,4.3777126085745995e-5,0.021473345010126033,0.00203867287863639,0.9983739769649034,LGP Offspring,Cluster 8 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,16,30
Cohort,-0.07058156790669001,0.06401698118507508,-1.1025444592995803,0.27054309430537243,LGP Proband,Cluster 8 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,16,49
Cohort,-0.015337243483072333,0.02150390575406492,-0.7132305944083255,0.47591211866229766,LonGen OPEL,Cluster 8 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,32,32
Cohort,0.02065402053785071,0.020535083972415668,1.0057918713940885,0.31487557657487397,LGP Offspring,Cluster 9 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,10,31
Cohort,0.008176739208271593,0.05347549431099226,0.15290628564775713,0.8785091646174501,LGP Proband,Cluster 9 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,10,36
Cohort,-0.03606536151803591,0.016629631408863768,-2.1687408837463886,0.03039781705757375,LonGen OPEL,Cluster 9 of genes distinguishing among different B lymphocyte neoplasms.,CGP,C2,27,18
Cohort,-0.006882938475713819,0.03632754069433086,-0.18946888074886786,0.8497822164907951,LGP Offspring,Top 50 down-regulated markers for the diffused large B-cell lymphoma (DLBCL) that distinguished between cured and fatal/refractory clinical outcomes.,CGP,C2,40,77
Cohort,-0.0388975111705703,0.09537804517758335,-0.40782457952611045,0.6835071350112518,LGP Proband,Top 50 down-regulated markers for the diffused large B-cell lymphoma (DLBCL) that distinguished between cured and fatal/refractory clinical outcomes.,CGP,C2,40,104
Cohort,-0.019351423948684457,0.02776412320871968,-0.6969938795908706,0.4860101234483266,LonGen OPEL,Top 50 down-regulated markers for the diffused large B-cell lymphoma (DLBCL) that distinguished between cured and fatal/refractory clinical outcomes.,CGP,C2,61,65
Cohort,0.022392151994427758,0.034139547842444676,0.6559006609510003,0.5121112128418823,LGP Offspring,Top 50 up-regulated markers for the diffused large B-cell lymphoma (DLBCL) that distinguished between cured and fatal/refractory clinical outcomes.,CGP,C2,34,85
Cohort,-0.053523028733703695,0.09203089655208259,-0.5815767393226868,0.5610089662064549,LGP Proband,Top 50 up-regulated markers for the diffused large B-cell lymphoma (DLBCL) that distinguished between cured and fatal/refractory clinical outcomes.,CGP,C2,34,108
Cohort,0.03832650917518121,0.028384705630059417,1.3502521278428696,0.177318903276646,LonGen OPEL,Top 50 up-regulated markers for the diffused large B-cell lymphoma (DLBCL) that distinguished between cured and fatal/refractory clinical outcomes.,CGP,C2,52,75
Cohort,-0.014981858936051438,0.024042855022147307,-0.623131442678116,0.5334083161815681,LGP Offspring,Top 50 down-regulated markers distinguishing diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) samples.,CGP,C2,20,39
Cohort,0.05127380489908551,0.07082336411577739,0.7239673734682591,0.4692887862810353,LGP Proband,Top 50 down-regulated markers distinguishing diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) samples.,CGP,C2,20,61
Cohort,0.033993538755202224,0.022104159985199674,1.5378796922372686,0.12447542448481012,LonGen OPEL,Top 50 down-regulated markers distinguishing diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) samples.,CGP,C2,30,46
Cohort,-0.07299557531448553,0.035827321584964066,-2.037427641398685,0.041996141228767596,LGP Offspring,Top 50 up-regulated markers distinguishing diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) samples.,CGP,C2,49,69
Cohort,-0.19441489500463074,0.0939310087687357,-2.069762664673313,0.03878196471226044,LGP Proband,Top 50 up-regulated markers distinguishing diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) samples.,CGP,C2,49,78
Cohort,-0.015208154076616982,0.028908269365573405,-0.5260831730981528,0.5989769563194418,LonGen OPEL,Top 50 up-regulated markers distinguishing diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) samples.,CGP,C2,62,69
Cohort,0.013706779628682395,0.01708996718365795,0.8020366265998051,0.42281362057656724,LGP Offspring,Genes down-regulated in A375 and 397 cells (melanoma) by forced expression of PLZF [GeneID=7704] off adenovirus vector.,CGP,C2,9,20
Cohort,-0.02395107994890997,0.0389589000889159,-0.6147781352719512,0.5388689399025299,LGP Proband,Genes down-regulated in A375 and 397 cells (melanoma) by forced expression of PLZF [GeneID=7704] off adenovirus vector.,CGP,C2,9,17
Cohort,-0.022283564878072086,0.014178669095396385,-1.5716259917023698,0.11643469572327686,LonGen OPEL,Genes down-regulated in A375 and 397 cells (melanoma) by forced expression of PLZF [GeneID=7704] off adenovirus vector.,CGP,C2,18,11
Cohort,-0.004096217013070433,0.015565344645639849,-0.26316262866803025,0.7925054229598636,LGP Offspring,Genes up-regulated in A375 and 397 cells (melanoma) by forced expression of PLZF [GeneID=7704] off adenovirus vector.,CGP,C2,8,16
Cohort,-0.01570010977547588,0.03225904195804384,-0.4866886560331044,0.6266068568663923,LGP Proband,Genes up-regulated in A375 and 397 cells (melanoma) by forced expression of PLZF [GeneID=7704] off adenovirus vector.,CGP,C2,8,9
Cohort,0.014144686930677056,0.013013628718439715,1.086913361116157,0.2774041166517763,LonGen OPEL,Genes up-regulated in A375 and 397 cells (melanoma) by forced expression of PLZF [GeneID=7704] off adenovirus vector.,CGP,C2,11,15
Cohort,-0.012303280547345391,0.04122926031220217,-0.2984113819695214,0.7654809038807334,LGP Offspring,Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion but whose expression did not change in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.,CGP,C2,55,121
Cohort,0.059019848273287594,0.11728204674342947,0.5032300331729509,0.6149354267235667,LGP Proband,Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion but whose expression did not change in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.,CGP,C2,55,171
Cohort,0.022879328189831988,0.03677729150527353,0.6221047622974438,0.534051130140321,LonGen OPEL,Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion but whose expression did not change in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.,CGP,C2,90,120
Cohort,-0.03986536503301763,0.024289798708993303,-1.641239003691598,0.10121294595094452,LGP Offspring,Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion and down-regulated in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.,CGP,C2,25,37
Cohort,-0.09018910868282994,0.0723022029537085,-1.2473908815831454,0.2126043611540347,LGP Proband,Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion and down-regulated in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.,CGP,C2,25,62
Cohort,-0.023596542066165443,0.023678598504110884,-0.9965345737024429,0.3192933102845369,LonGen OPEL,Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion and down-regulated in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.,CGP,C2,41,39
Cohort,0.023019424231807625,0.01728456161372254,1.3317910367788601,0.1833777244930552,LGP Offspring,Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion and up-regulated in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.,CGP,C2,6,22
Cohort,-0.0042705128244124296,0.0539167491685355,-0.07920568079992102,0.9368880263868957,LGP Proband,Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion and up-regulated in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.,CGP,C2,6,43
Cohort,0.008324868842183595,0.016655759858823782,0.4998192164600223,0.6173405106983659,LonGen OPEL,Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion and up-regulated in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.,CGP,C2,21,24
Cohort,-0.017816882793343036,0.02523577116611109,-0.7060169739242675,0.480420819993297,LGP Offspring,Genes down-regulated in MEF cells (embryonic fibroblasts) from PARP1 [GeneID=142] knockout mice.,CGP,C2,23,39
Cohort,-0.076048689684338,0.06013027286610356,-1.2647321566905432,0.20632065084234252,LGP Proband,Genes down-regulated in MEF cells (embryonic fibroblasts) from PARP1 [GeneID=142] knockout mice.,CGP,C2,23,36
Cohort,-3.491859389174061e-4,0.018295265509741913,-0.019086136723813634,0.9847771736580988,LonGen OPEL,Genes down-regulated in MEF cells (embryonic fibroblasts) from PARP1 [GeneID=142] knockout mice.,CGP,C2,25,28
Cohort,-0.015031845651701896,0.026002324063165584,-0.5780962353667353,0.5633916686614718,LGP Offspring,Genes up-regulated in MEF cells (embryonic fibroblasts) from PARP1 [GeneID=142] knockout mice.,CGP,C2,21,43
Cohort,0.0763193403790067,0.0721641517064641,1.0575796787502512,0.2905533370165039,LGP Proband,Genes up-regulated in MEF cells (embryonic fibroblasts) from PARP1 [GeneID=142] knockout mice.,CGP,C2,21,63
Cohort,-0.01963547451115882,0.02317258828952891,-0.8473578465134851,0.39705039074706705,LonGen OPEL,Genes up-regulated in MEF cells (embryonic fibroblasts) from PARP1 [GeneID=142] knockout mice.,CGP,C2,40,40
Cohort,0.03033446191172421,0.03287880308996165,0.9226145437449255,0.3565372835709254,LGP Offspring,Genes down-regulated in response to UVB radiation in HFK cells (keratinocytes) immortalized by overexpression of HPV E6 and E7 viral oncogenes.,CGP,C2,30,74
Cohort,-0.05216983901434315,0.09960422493439355,-0.5237713465338034,0.6005767359184765,LGP Proband,Genes down-regulated in response to UVB radiation in HFK cells (keratinocytes) immortalized by overexpression of HPV E6 and E7 viral oncogenes.,CGP,C2,30,115
Cohort,-0.012892767595970644,0.027088131937875057,-0.47595632011610856,0.6342360958956248,LonGen OPEL,Genes down-regulated in response to UVB radiation in HFK cells (keratinocytes) immortalized by overexpression of HPV E6 and E7 viral oncogenes.,CGP,C2,54,63
Cohort,-0.04436168313101335,0.03953848762649842,-1.1219873544501096,0.26226618242734184,LGP Offspring,Genes down-regulated in HFK cells (primary keratinocytes) in response to UVB irradiation.,CGP,C2,59,102
Cohort,-0.04566696134372998,0.10554323316535638,-0.43268488158007035,0.6653555774715625,LGP Proband,Genes down-regulated in HFK cells (primary keratinocytes) in response to UVB irradiation.,CGP,C2,59,128
Cohort,0.01707382048998364,0.03333317682231735,0.5122170197276941,0.6086412180124117,LonGen OPEL,Genes down-regulated in HFK cells (primary keratinocytes) in response to UVB irradiation.,CGP,C2,69,94
Cohort,0.010323960837817054,0.00718793716252626,1.4362898011463157,0.15138249576967047,LGP Offspring,Genes up-regulated in HFK cells (primary keratinocytes) in response to UVB irradiation.,CGP,C2,0,5
Cohort,-0.015686154686478,0.019268324542291323,-0.8140902262700137,0.41582563865775435,LGP Proband,Genes up-regulated in HFK cells (primary keratinocytes) in response to UVB irradiation.,CGP,C2,0,6
Cohort,0.004770957636996757,0.007323426981214551,0.6514651746012929,0.5149342841634342,LonGen OPEL,Genes up-regulated in HFK cells (primary keratinocytes) in response to UVB irradiation.,CGP,C2,3,5
Cohort,-0.031190887803117958,0.02998304007241752,-1.0402843650204632,0.2985797233214867,LGP Offspring,Selected electrophile and drug detoxication genes down-regulated in A549 and H460 cells (lung cancer) upon knockdown of NFE2L2 [GeneID=4780] by RNAi.,CGP,C2,32,53
Cohort,-0.06616713932613162,0.07822356950948683,-0.8458721551706608,0.39786668712272766,LGP Proband,Selected electrophile and drug detoxication genes down-regulated in A549 and H460 cells (lung cancer) upon knockdown of NFE2L2 [GeneID=4780] by RNAi.,CGP,C2,32,60
Cohort,-0.029872099803133684,0.023294490532027052,-1.282367595121397,0.20008704644376196,LonGen OPEL,Selected electrophile and drug detoxication genes down-regulated in A549 and H460 cells (lung cancer) upon knockdown of NFE2L2 [GeneID=4780] by RNAi.,CGP,C2,47,41
Cohort,-0.026487894598121148,0.047766733052666654,-0.5545259829454134,0.5794023370782517,LGP Offspring,Genes up-regulated in head and neck squamous cell carcinoma (HNSCC) samples positive for HPV compared to the HPV-negative tumors.,CGP,C2,80,147
Cohort,-0.15921703862415101,0.13083343314398466,-1.2169445897588704,0.22396955226439277,LGP Proband,Genes up-regulated in head and neck squamous cell carcinoma (HNSCC) samples positive for HPV compared to the HPV-negative tumors.,CGP,C2,80,209
Cohort,-0.033647599155511035,0.042793978985458475,-0.7862694695191721,0.4319436359174038,LonGen OPEL,Genes up-regulated in head and neck squamous cell carcinoma (HNSCC) samples positive for HPV compared to the HPV-negative tumors.,CGP,C2,142,152
Cohort,-0.3626015096090296,0.15787259184851687,-2.296798357228187,0.021935131053908673,LGP Offspring,Genes down-regulated in basal subtype of breast cancer samles.,CGP,C2,817,1562
Cohort,0.2580022884418114,0.423899041383225,0.6086408867543651,0.5429282289079587,LGP Proband,Genes down-regulated in basal subtype of breast cancer samles.,CGP,C2,817,2210
Cohort,0.01985454039334644,0.1326215977913662,0.14970819778977953,0.8810327631639232,LonGen OPEL,Genes down-regulated in basal subtype of breast cancer samles.,CGP,C2,1225,1468
Cohort,-0.033141423471753854,0.1335563125431175,-0.24814569106237064,0.8040970436884366,LGP Offspring,Genes up-regulated in basal subtype of breast cancer samles.,CGP,C2,576,1166
Cohort,-0.6476616452221557,0.3593230012468399,-1.8024497262206691,0.07183560671558897,LGP Proband,Genes up-regulated in basal subtype of breast cancer samles.,CGP,C2,576,1532
Cohort,-0.09489495100650566,0.11732941179786423,-0.8087908185373947,0.4188771440139538,LonGen OPEL,Genes up-regulated in basal subtype of breast cancer samles.,CGP,C2,900,1042
Cohort,0.005542143123816712,0.010519158836889293,0.5268618156407291,0.5984623907563829,LGP Offspring,"Genes down-regulated in the erbb2 subype of breast cancer samples, characterized by higher expression of ERBB2 [GeneID=2064].",CGP,C2,2,9
Cohort,0.009119925661649599,0.02085791701926346,0.43724048059194187,0.6620501484869805,LGP Proband,"Genes down-regulated in the erbb2 subype of breast cancer samples, characterized by higher expression of ERBB2 [GeneID=2064].",CGP,C2,2,5
Cohort,-0.0036930242931142608,0.00581896178822743,-0.6346534704155926,0.5258368085826877,LonGen OPEL,"Genes down-regulated in the erbb2 subype of breast cancer samples, characterized by higher expression of ERBB2 [GeneID=2064].",CGP,C2,3,2
Cohort,0.030400324873511755,0.07051698200834006,0.4311064371687986,0.666528415303989,LGP Offspring,"Genes up-regulated in the erbb2 subype of breast cancer samples, characterized by higher expression of ERBB2 [GeneID=2064].",CGP,C2,143,314
Cohort,-0.008376611539192473,0.1929940488885244,-0.04340347066365192,0.9653903003063907,LGP Proband,"Genes up-regulated in the erbb2 subype of breast cancer samples, characterized by higher expression of ERBB2 [GeneID=2064].",CGP,C2,143,458
Cohort,0.09722729966786771,0.0575615322214745,1.6891020081566748,0.0915915046823088,LonGen OPEL,"Genes up-regulated in the erbb2 subype of breast cancer samples, characterized by higher expression of ERBB2 [GeneID=2064].",CGP,C2,206,292
Cohort,-0.019680790897267743,0.022827213668914794,-0.8621635203804253,0.38890327697231486,LGP Offspring,Genes down-regulated in the luminal A subtype of breast cancer.,CGP,C2,20,33
Cohort,0.03728389083438627,0.06121845172924053,0.6090302805972125,0.5426702239568659,LGP Proband,Genes down-regulated in the luminal A subtype of breast cancer.,CGP,C2,20,46
Cohort,-0.03700404293261164,0.02110167956784327,-1.7536065228192494,0.07988280869576571,LonGen OPEL,Genes down-regulated in the luminal A subtype of breast cancer.,CGP,C2,36,27
Cohort,-0.04213806492841656,0.06592425771174978,-0.6391890692598003,0.5229164662848389,LGP Offspring,Genes up-regulated in the luminal A subtype of breast cancer.,CGP,C2,141,277
Cohort,0.19841374164387263,0.17693760902715377,1.1213768668786692,0.26245024839623704,LGP Proband,Genes up-regulated in the luminal A subtype of breast cancer.,CGP,C2,141,351
Cohort,-0.059827134611785834,0.055287307786939834,-1.0821133639268725,0.27952985937716673,LonGen OPEL,Genes up-regulated in the luminal A subtype of breast cancer.,CGP,C2,197,217
Cohort,-0.06676704999368377,0.12231904556950356,-0.5458434513024851,0.5853536283025711,LGP Offspring,Genes down-regulated in the luminal B subtype of breast cancer.,CGP,C2,537,1078
Cohort,-0.37970825693181737,0.34993201072260277,-1.0850915186287966,0.27819467750942506,LGP Proband,Genes down-regulated in the luminal B subtype of breast cancer.,CGP,C2,537,1480
Cohort,-0.16711008361502036,0.1125586404802346,-1.4846490940370325,0.13803268264524618,LonGen OPEL,Genes down-regulated in the luminal B subtype of breast cancer.,CGP,C2,826,915
Cohort,-0.06779853355097305,0.06952597164004672,-0.9751540604420886,0.3298326636515675,LGP Offspring,Genes up-regulated in the luminal B subtype of breast cancer.,CGP,C2,162,312
Cohort,-0.13998541397517983,0.18660366562576075,-0.7501750488434926,0.4533608585743488,LGP Proband,Genes up-regulated in the luminal B subtype of breast cancer.,CGP,C2,162,449
Cohort,0.07442610136790744,0.06091892161582933,1.2217238814117215,0.22217374797638467,LonGen OPEL,Genes up-regulated in the luminal B subtype of breast cancer.,CGP,C2,242,317
Cohort,-0.002152982083601528,0.014576264356552227,-0.14770465401402613,0.8826199020148702,LGP Offspring,Genes down-regulated in the normal-like subtype of breast cancer.,CGP,C2,7,14
Cohort,-0.013430826351300431,0.03230713425806806,-0.41572323450342397,0.6777194793485835,LGP Proband,Genes down-regulated in the normal-like subtype of breast cancer.,CGP,C2,7,10
Cohort,-0.005117607211024113,0.013257831082830615,-0.3860063670332627,0.6995950987060696,LonGen OPEL,Genes down-regulated in the normal-like subtype of breast cancer.,CGP,C2,12,15
Cohort,-0.08395967680104863,0.1153885825128529,-0.7276255152167809,0.46709478822654116,LGP Offspring,Genes up-regulated in the normal-like subtype of breast cancer.,CGP,C2,431,881
Cohort,0.10228955690671666,0.3175796938916413,0.32209098652767776,0.7474644829433219,LGP Proband,Genes up-regulated in the normal-like subtype of breast cancer.,CGP,C2,431,1269
Cohort,-0.10234927531251958,0.10238835029150133,-0.9996183649910317,0.31779900396208943,LonGen OPEL,Genes up-regulated in the normal-like subtype of breast cancer.,CGP,C2,691,769
Cohort,-0.04707690171843745,0.08553989465441299,-0.5503502419383535,0.5822609741726696,LGP Offspring,Genes down-regulated in bone relapse of breast cancer.,CGP,C2,247,498
Cohort,0.09365831282735897,0.2500081428296373,0.37462104940790036,0.7080375503627472,LGP Proband,Genes down-regulated in bone relapse of breast cancer.,CGP,C2,247,704
Cohort,-0.06294849559857013,0.07581223106301838,-0.8303211067122487,0.406606216309939,LonGen OPEL,Genes down-regulated in bone relapse of breast cancer.,CGP,C2,395,451
Cohort,0.012930210462881746,0.0582782810194777,0.2218701416151967,0.824481983093277,LGP Offspring,Genes up-regulated in bone relapse of breast cancer.,CGP,C2,99,220
Cohort,0.2474329306502649,0.16028515904478707,1.5437045583311109,0.1230392590769349,LGP Proband,Genes up-regulated in bone relapse of breast cancer.,CGP,C2,99,316
Cohort,0.05106790794124735,0.050608857038679456,1.0090705645104185,0.3132474246713469,LonGen OPEL,Genes up-regulated in bone relapse of breast cancer.,CGP,C2,167,232
Cohort,-0.017265220749130908,0.05840341938783412,-0.2956200326984174,0.7676110532082077,LGP Offspring,Genes down-regulated in brain relapse of breast cancer.,CGP,C2,110,224
Cohort,0.023399602923069897,0.15007893639619446,0.1559153035393129,0.8761375125387973,LGP Proband,Genes down-regulated in brain relapse of breast cancer.,CGP,C2,110,301
Cohort,0.00427758889702579,0.04968686707361567,0.08609093607548546,0.9314157786097959,LonGen OPEL,Genes down-regulated in brain relapse of breast cancer.,CGP,C2,170,204
Cohort,-0.01185017984759736,0.03266604038966274,-0.3627675624667195,0.7168919186432752,LGP Offspring,Genes up-regulated in brain relapse of breast cancer.,CGP,C2,35,70
Cohort,0.017058560638812274,0.08792240230915088,0.1940183638162129,0.8462087487348736,LGP Proband,Genes up-regulated in brain relapse of breast cancer.,CGP,C2,35,97
Cohort,-0.0017733113939881558,0.027616180146544815,-0.06421276891221404,0.9488169319845833,LonGen OPEL,Genes up-regulated in brain relapse of breast cancer.,CGP,C2,51,61
Cohort,-0.007245168184524354,0.008402885620037524,-0.8622238254972224,0.38887012104510044,LGP Offspring,Genes down-regulated in liver relapse of breast cancer.,CGP,C2,3,4
Cohort,-0.003172131578168624,0.02923947779569852,-0.10848796959825605,0.9136347179678379,LGP Proband,Genes down-regulated in liver relapse of breast cancer.,CGP,C2,3,11
Cohort,-0.004373021894729165,0.00852106901898583,-0.5132010883828798,0.6079530647819867,LonGen OPEL,Genes down-regulated in liver relapse of breast cancer.,CGP,C2,6,5
Cohort,9.756636499255916e-4,0.006403521938549941,0.15236359917063513,0.878945628538746,LGP Offspring,Genes up-regulated in liver relapse of breast cancer.,CGP,C2,1,3
Cohort,-0.018696442310288875,0.02353175777062627,-0.7945195804125978,0.427119039642082,LGP Proband,Genes up-regulated in liver relapse of breast cancer.,CGP,C2,1,8
Cohort,-0.0037374656602238996,0.005155226757833917,-0.7249856962245981,0.4686738639307947,LonGen OPEL,Genes up-regulated in liver relapse of breast cancer.,CGP,C2,2,2
Cohort,-0.02608866512247316,0.03765117078158615,-0.6929044855952315,0.4886074664424125,LGP Offspring,Genes down-regulated in lung relapse of breast cancer.,CGP,C2,54,96
Cohort,0.1653106068644093,0.11476912080471854,1.4403753004755337,0.1501365321279511,LGP Proband,Genes down-regulated in lung relapse of breast cancer.,CGP,C2,54,148
Cohort,-0.02755146391932715,0.034831711790318014,-0.7909879389558306,0.4291866390483131,LonGen OPEL,Genes down-regulated in lung relapse of breast cancer.,CGP,C2,81,89
Cohort,-0.0860288947174323,0.0310546499234031,-2.770241974378209,0.005755286013676141,LGP Offspring,Genes up-regulated in lung relapse of breast cancer.,CGP,C2,44,54
Cohort,-1.3169615975707453e-4,0.08499933438826648,-0.001549378718137988,0.9987641456525401,LGP Proband,Genes up-regulated in lung relapse of breast cancer.,CGP,C2,44,77
Cohort,0.007187300678598184,0.0252406904031991,0.28475055807852384,0.7759093182256894,LonGen OPEL,Genes up-regulated in lung relapse of breast cancer.,CGP,C2,44,56
Cohort,-0.027250733809404095,0.019277137963800768,-1.4136296508629238,0.15793099431315494,LGP Offspring,Genes down-regulated in pleura relapse of breast cancer.,CGP,C2,15,21
Cohort,0.04676674526009356,0.05576135105479123,0.8386946222687548,0.40188101115740593,LGP Proband,Genes down-regulated in pleura relapse of breast cancer.,CGP,C2,15,38
Cohort,0.03433175669226931,0.02109125192664832,1.6277723490131903,0.10396888607918922,LonGen OPEL,Genes down-regulated in pleura relapse of breast cancer.,CGP,C2,21,35
Cohort,-0.01284887342151615,0.011866787381110213,-1.0827592177112098,0.27930137092963514,LGP Offspring,Genes up-regulated in pleura relapse of breast cancer.,CGP,C2,6,8
Cohort,3.0483285594985e-4,0.02409128816685967,0.012653240201957426,0.9899074705043971,LGP Proband,Genes up-regulated in pleura relapse of breast cancer.,CGP,C2,6,4
Cohort,0.01655192493460264,0.009523671554685233,1.7379772957898587,0.08260153242474406,LonGen OPEL,Genes up-regulated in pleura relapse of breast cancer.,CGP,C2,3,11
Cohort,0.0301084464751025,0.016565005086879563,1.8175935544354358,0.06956882959395508,LGP Offspring,Genes down-regulated in circulating endothelial cells (CEC) from cancer patients compared to those from healthy donors.,CGP,C2,4,22
Cohort,0.01359968230882352,0.03978959119249621,0.34178994810552965,0.7325950777071529,LGP Proband,Genes down-regulated in circulating endothelial cells (CEC) from cancer patients compared to those from healthy donors.,CGP,C2,4,18
Cohort,-0.020979667810445,0.01518445261023634,-1.3816545350012759,0.16746545414170652,LonGen OPEL,Genes down-regulated in circulating endothelial cells (CEC) from cancer patients compared to those from healthy donors.,CGP,C2,21,15
Cohort,0.007711267153030002,0.07184275314459417,0.10733535138206544,0.9145547871569191,LGP Offspring,Genes up-regulated in circulating endothelial cells (CEC) from cancer patients compared to those from healthy donors.,CGP,C2,149,312
Cohort,-0.28248511451370234,0.18906969294922127,-1.49407930011062,0.1355331258162386,LGP Proband,Genes up-regulated in circulating endothelial cells (CEC) from cancer patients compared to those from healthy donors.,CGP,C2,149,449
Cohort,0.12069793834097432,0.05701255401335454,2.1170414206089103,0.03456595317858007,LonGen OPEL,Genes up-regulated in circulating endothelial cells (CEC) from cancer patients compared to those from healthy donors.,CGP,C2,219,306
Cohort,-0.030248170160364057,0.03588256617804874,-0.8429767818241622,0.39953959096048464,LGP Offspring,Genes down-regulated in B lymphocytes at 2 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,47,89
Cohort,-0.10389713541086576,0.10726843934194248,-0.968571334198963,0.33303990623395074,LGP Proband,Genes down-regulated in B lymphocytes at 2 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,47,145
Cohort,0.01382860696639914,0.03647405183349759,0.37913547498166944,0.7046883754678435,LonGen OPEL,Genes down-regulated in B lymphocytes at 2 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,84,101
Cohort,0.04713484920998615,0.02872153932511651,1.6410975984413032,0.10124230026700809,LGP Offspring,Genes up-regulated in B lymphocytes at 2 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,21,64
Cohort,0.032533177585238986,0.07991725631082747,0.4070857670426716,0.6840494526575196,LGP Proband,Genes up-regulated in B lymphocytes at 2 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,21,85
Cohort,-0.013911539603566095,0.022974692996893954,-0.6055157997300271,0.5450089291567379,LonGen OPEL,Genes up-regulated in B lymphocytes at 2 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,41,42
Cohort,-0.022355482895484252,0.05134892118092974,-0.4353642176183978,0.6634370463832728,LGP Offspring,Genes down-regulated in B lymphocytes at 6 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,91,176
Cohort,-0.08418327868655033,0.14433198573197492,-0.5832614181784973,0.5598750141428435,LGP Proband,Genes down-regulated in B lymphocytes at 6 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,91,244
Cohort,0.02049071372391699,0.04139407927539875,0.49501556943905717,0.6207257380810043,LonGen OPEL,Genes down-regulated in B lymphocytes at 6 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,118,151
Cohort,-0.08181513343102059,0.05211253935487353,-1.5699701922771356,0.11688997261536867,LGP Offspring,Genes up-regulated in B lymphocytes at 6 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,94,162
Cohort,-0.036445210607421015,0.1503514912081106,-0.24240006078140586,0.8085297831564335,LGP Proband,Genes up-regulated in B lymphocytes at 6 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,94,242
Cohort,0.01925376633962098,0.04357043559142283,0.44189979003586616,0.6586817484712237,LonGen OPEL,Genes up-regulated in B lymphocytes at 6 h after exprosure to 10 Gy dose of ionizing radiation.,CGP,C2,132,173
Cohort,-0.026391571143323172,0.028551831590462227,-0.9243389888913224,0.35563967586218914,LGP Offspring,Potential marker genes specifically up-regulated in the majority of hepatocellular carcinoma (HCC) tumors.,CGP,C2,31,53
Cohort,0.09221094672832882,0.08781270655978916,1.0500866029626932,0.29398248007354677,LGP Proband,Potential marker genes specifically up-regulated in the majority of hepatocellular carcinoma (HCC) tumors.,CGP,C2,31,100
Cohort,-0.0015891550540130617,0.027357297178579768,-0.05808889100555369,0.9536924019485642,LonGen OPEL,Potential marker genes specifically up-regulated in the majority of hepatocellular carcinoma (HCC) tumors.,CGP,C2,54,57
Cohort,-0.12437177119596358,0.05538023827253501,-2.245778910952138,0.025040421089986085,LGP Offspring,Genes consistently down-regulated in HMEC cells (primary mammary epithelium) upon expression of TERT [GeneID=7015] off a retroviral vector.,CGP,C2,114,189
Cohort,-0.14711487652467212,0.1549780653702491,-0.9492625693397869,0.3427620703718509,LGP Proband,Genes consistently down-regulated in HMEC cells (primary mammary epithelium) upon expression of TERT [GeneID=7015] off a retroviral vector.,CGP,C2,114,260
Cohort,0.11096143081817306,0.04703721516606733,2.3590136113802225,0.018564266492293195,LonGen OPEL,Genes consistently down-regulated in HMEC cells (primary mammary epithelium) upon expression of TERT [GeneID=7015] off a retroviral vector.,CGP,C2,132,206
Cohort,0.03229261200822747,0.0603547153192706,0.535047043754621,0.5927932786526612,LGP Offspring,Genes consistently up-regulated in HMEC cells (primary mammary epithelium) upon expression of TERT [GeneID=7015] off a retroviral vector.,CGP,C2,110,251
Cohort,-0.00403682501908522,0.15610380484296232,-0.025859875889291714,0.9793752898853683,LGP Proband,Genes consistently up-regulated in HMEC cells (primary mammary epithelium) upon expression of TERT [GeneID=7015] off a retroviral vector.,CGP,C2,110,302
Cohort,0.0065968365647466705,0.05172863062199807,0.12752776335705485,0.8985549096017917,LonGen OPEL,Genes consistently up-regulated in HMEC cells (primary mammary epithelium) upon expression of TERT [GeneID=7015] off a retroviral vector.,CGP,C2,182,220
Cohort,-0.05520360393117013,0.03341629110846272,-1.6519967387161572,0.09899959654766446,LGP Offspring,Genes from the recurrent amplicons in 89 samples of oral squamous cell carcinoma (SCC).,CGP,C2,45,71
Cohort,0.09122635032189058,0.09474418086622989,0.9628702205013925,0.3358917443789662,LGP Proband,Genes from the recurrent amplicons in 89 samples of oral squamous cell carcinoma (SCC).,CGP,C2,45,108
Cohort,-0.020208303044587796,0.029105663884565352,-0.6943082667598659,0.48769149153077274,LonGen OPEL,Genes from the recurrent amplicons in 89 samples of oral squamous cell carcinoma (SCC).,CGP,C2,65,67
Cohort,-0.062336351899708854,0.03868738858416604,-1.6112835262605927,0.10758471561015547,LGP Offspring,Cellular genes up-regulated in forskin fibroblasts by expression of CMV EI86 protein off an adenovirus vector.,CGP,C2,59,94
Cohort,0.029088971942204216,0.1163552514706558,0.2500013671453437,0.8026478580157453,LGP Proband,Cellular genes up-regulated in forskin fibroblasts by expression of CMV EI86 protein off an adenovirus vector.,CGP,C2,59,159
Cohort,-0.009376804633128651,0.03480544092412429,-0.26940628775742403,0.7876868667403283,LonGen OPEL,Cellular genes up-regulated in forskin fibroblasts by expression of CMV EI86 protein off an adenovirus vector.,CGP,C2,85,96
Cohort,-0.0588145607427294,0.03622180708325028,-1.623733476564356,0.10489887816351712,LGP Offspring,Down-regulated genes whose expression correlated with histologic grade of invasive breast cancer tumors: comparison of grade 1 vs grade 3.,CGP,C2,46,82
Cohort,0.05315750289998638,0.10592105070049267,0.501859663857537,0.6158986993288154,LGP Proband,Down-regulated genes whose expression correlated with histologic grade of invasive breast cancer tumors: comparison of grade 1 vs grade 3.,CGP,C2,46,138
Cohort,0.021160178843204206,0.03291261540476614,0.6429200044715971,0.5204611558852896,LonGen OPEL,Down-regulated genes whose expression correlated with histologic grade of invasive breast cancer tumors: comparison of grade 1 vs grade 3.,CGP,C2,65,94
Cohort,-0.02522039657666322,0.06358369221097873,-0.39664882141443997,0.6917516271446307,LGP Offspring,Up-regulated genes whose expression correlated with histologic grade of invasive breast cancer tumors: comparison of grade 1 vs grade 3.,CGP,C2,132,248
Cohort,-0.3492961341859912,0.17296804917941502,-2.0194257600932755,0.04376241095576227,LGP Proband,Up-regulated genes whose expression correlated with histologic grade of invasive breast cancer tumors: comparison of grade 1 vs grade 3.,CGP,C2,132,325
Cohort,0.04473374526220485,0.05168372925401344,0.8655285891300327,0.3870095129303882,LonGen OPEL,Up-regulated genes whose expression correlated with histologic grade of invasive breast cancer tumors: comparison of grade 1 vs grade 3.,CGP,C2,178,236
Cohort,0.0026161742000722433,0.007308111652774349,0.357982242797163,0.7204683517916571,LGP Offspring,Chemokine genes up-regulated within 2 hr of c-Myc [GeneID=4609] activation in a mouse model of Myc-induced pancreatic beta-cell tumorigenesis.,CGP,C2,2,4
Cohort,-0.06002180282035811,0.024724290282789337,-2.4276451268710226,0.015407897717483915,LGP Proband,Chemokine genes up-regulated within 2 hr of c-Myc [GeneID=4609] activation in a mouse model of Myc-induced pancreatic beta-cell tumorigenesis.,CGP,C2,2,8
Cohort,-0.002740309912998932,0.002607162301459466,-1.0510699358704791,0.29354545193310566,LonGen OPEL,Chemokine genes up-regulated within 2 hr of c-Myc [GeneID=4609] activation in a mouse model of Myc-induced pancreatic beta-cell tumorigenesis.,CGP,C2,1,0
Cohort,-0.012362891209658528,0.019185480943995376,-0.6443878704811846,0.5195425365310475,LGP Offspring,Genes down-regulated more than two-fold in lymphoblastoid cell lines from European population compared to those from Asian population.,CGP,C2,13,20
Cohort,0.002085875927638241,0.05097241088137176,0.040921665104142434,0.9673681397688132,LGP Proband,Genes down-regulated more than two-fold in lymphoblastoid cell lines from European population compared to those from Asian population.,CGP,C2,13,27
Cohort,0.015296013540131098,0.012734593445649197,1.2011387411317018,0.23005466322521362,LonGen OPEL,Genes down-regulated more than two-fold in lymphoblastoid cell lines from European population compared to those from Asian population.,CGP,C2,6,15
Cohort,0.015936946796249876,0.011918953088240345,1.3371096167811771,0.18163661499488445,LGP Offspring,Genes up-regulated more than two-fold in lymphoblastoid cell lines from European population compared to those from Asian population.,CGP,C2,2,12
Cohort,0.00382509531387389,0.03653184162077503,0.10470578936536898,0.9166344432172543,LGP Proband,Genes up-regulated more than two-fold in lymphoblastoid cell lines from European population compared to those from Asian population.,CGP,C2,2,20
Cohort,-0.017882490012983546,0.011707577099342054,-1.5274287635473707,0.12705167058258943,LonGen OPEL,Genes up-regulated more than two-fold in lymphoblastoid cell lines from European population compared to those from Asian population.,CGP,C2,13,8
Cohort,-0.2609784716800013,0.1132305964918974,-2.304840562229808,0.02147760509791789,LGP Offspring,Genes down-regulated in lymphoblastoid cells from the European population compared to those from the Asian population.,CGP,C2,465,845
Cohort,-0.15204804747493772,0.3152551275765575,-0.48230158425579905,0.6297182740277274,LGP Proband,Genes down-regulated in lymphoblastoid cells from the European population compared to those from the Asian population.,CGP,C2,465,1247
Cohort,0.00856258996837453,0.10389440318511424,0.0824162775459435,0.9343364118350598,LonGen OPEL,Genes down-regulated in lymphoblastoid cells from the European population compared to those from the Asian population.,CGP,C2,698,875
Cohort,-0.050941440378627426,0.10630875511693846,-0.4791838670539637,0.6319628000695519,LGP Offspring,Genes up-regulated in lymphoblastoid cells from the European population compared to those from the Asian population.,CGP,C2,340,707
Cohort,0.030576237669787284,0.29426632922497653,0.10390668123776649,0.9172683860262068,LGP Proband,Genes up-regulated in lymphoblastoid cells from the European population compared to those from the Asian population.,CGP,C2,340,999
Cohort,-0.09695242707550915,0.09239468777496707,-1.0493290189111601,0.29434519598722375,LonGen OPEL,Genes up-regulated in lymphoblastoid cells from the European population compared to those from the Asian population.,CGP,C2,554,630
Cohort,0.0277106015145666,0.02496859578181493,1.1098181794728208,0.26747201445816926,LGP Offspring,Down-regulated genes that distinguished smokers with and without lung cancer.,CGP,C2,15,44
Cohort,-0.037565750911444505,0.064697312567119,-0.5806385060039801,0.561640970540249,LGP Proband,Down-regulated genes that distinguished smokers with and without lung cancer.,CGP,C2,15,56
Cohort,0.042203943573846596,0.023822552296000506,1.7715962189715535,0.07684415025333614,LonGen OPEL,Down-regulated genes that distinguished smokers with and without lung cancer.,CGP,C2,29,51
Cohort,0.05947594715560427,0.028277101655455623,2.1033254355518194,0.035806294236595496,LGP Offspring,Up-regulated genes that distinguished smokers with and without lung cancer.,CGP,C2,17,65
Cohort,-0.054114822263536165,0.08071289492157924,-0.67046067813717,0.5027497760052282,LGP Proband,Up-regulated genes that distinguished smokers with and without lung cancer.,CGP,C2,17,91
Cohort,0.02579546714248035,0.02723471178037267,0.9471540345461065,0.3438477316034505,LonGen OPEL,Up-regulated genes that distinguished smokers with and without lung cancer.,CGP,C2,47,68
Cohort,-0.010170733172453462,0.031224822676718705,-0.32572589051199907,0.7447325520269814,LGP Offspring,Genes up-regulated in Ewing family tumors (EFT) compared with normal bone marrow samples.,CGP,C2,31,65
Cohort,0.09451961261000508,0.0844834291535634,1.1187946980490004,0.26354986581482803,LGP Proband,Genes up-regulated in Ewing family tumors (EFT) compared with normal bone marrow samples.,CGP,C2,31,88
Cohort,0.013320585286524557,0.02789234967419932,0.4775712853925039,0.6330864780802169,LonGen OPEL,Genes up-regulated in Ewing family tumors (EFT) compared with normal bone marrow samples.,CGP,C2,49,61
Cohort,0.027166749478201593,0.016827662209635767,1.614410197908864,0.10690511720273503,LGP Offspring,Gene promoters preferentially bound by a mutated form of TP53 [GeneID=7157] in SKBR3 cells (breast cancer).,CGP,C2,5,24
Cohort,0.020811466717917625,0.052346489902498745,0.3975713893459014,0.691047887274563,LGP Proband,Gene promoters preferentially bound by a mutated form of TP53 [GeneID=7157] in SKBR3 cells (breast cancer).,CGP,C2,5,43
Cohort,-0.025415764429446104,0.015472396412785442,-1.6426520980579369,0.10084987681542187,LonGen OPEL,Gene promoters preferentially bound by a mutated form of TP53 [GeneID=7157] in SKBR3 cells (breast cancer).,CGP,C2,21,14
Cohort,-0.0017199434679790334,0.025318749966527696,-0.06793161077276172,0.9458601624302714,LGP Offspring,Genes repressed in SKBR3 cells (breast cancer) by 25-hydroxyvitamin D3 [PubChem=1593].,CGP,C2,18,41
Cohort,0.002626103926363611,0.0740905304452445,0.0354445286136046,0.9717337597589956,LGP Proband,Genes repressed in SKBR3 cells (breast cancer) by 25-hydroxyvitamin D3 [PubChem=1593].,CGP,C2,18,67
Cohort,-0.035601926660048334,0.022505040861368564,-1.581953433426618,0.11405742997293607,LonGen OPEL,Genes repressed in SKBR3 cells (breast cancer) by 25-hydroxyvitamin D3 [PubChem=1593].,CGP,C2,38,33
Cohort,-0.05806152820610151,0.045706748384339385,-1.2703053763062102,0.2044129096196632,LGP Offspring,Genes induced in SKBR3 cells (breast cancer) by 25-hydroxyvitamin D3 [PubChem=1593].,CGP,C2,82,141
Cohort,-0.15657181319649632,0.1264785248263815,-1.2379320000088887,0.21608964795947805,LGP Proband,Genes induced in SKBR3 cells (breast cancer) by 25-hydroxyvitamin D3 [PubChem=1593].,CGP,C2,82,198
Cohort,0.05831557929356886,0.04031343982260524,1.446554289343207,0.14841544357948233,LonGen OPEL,Genes induced in SKBR3 cells (breast cancer) by 25-hydroxyvitamin D3 [PubChem=1593].,CGP,C2,99,138
Cohort,-0.017311879347885695,0.03490027443790771,-0.4960384875679376,0.6200284908559426,LGP Offspring,Genes repressed in SKBR3 cells (breast cancer) by mutated TP53 [GeneID=7157].,CGP,C2,40,79
Cohort,8.317386829021807e-4,0.09925063494376041,0.008380185007113345,0.9933156621191968,LGP Proband,Genes repressed in SKBR3 cells (breast cancer) by mutated TP53 [GeneID=7157].,CGP,C2,40,130
Cohort,0.07850395702717675,0.032217319078586736,2.4367004850926426,0.015040121122755535,LonGen OPEL,Genes repressed in SKBR3 cells (breast cancer) by mutated TP53 [GeneID=7157].,CGP,C2,62,100
Cohort,-0.018156414942487674,0.03846676765102189,-0.47200261553573347,0.6370772406025831,LGP Offspring,Genes induced in SKBR3 cells (breast cancer) by mutated TP53 [GeneID=7157].,CGP,C2,45,78
Cohort,0.0030100516201548707,0.09843045602468438,0.03058049044698127,0.9756114176181815,LGP Proband,Genes induced in SKBR3 cells (breast cancer) by mutated TP53 [GeneID=7157].,CGP,C2,45,105
Cohort,-0.027469923871606315,0.0313950089663261,-0.8749774176229801,0.38185012044492805,LonGen OPEL,Genes induced in SKBR3 cells (breast cancer) by mutated TP53 [GeneID=7157].,CGP,C2,68,72
Cohort,9.046555962947499e-4,0.0299529999507548,0.030202503848765674,0.9759144660939822,LGP Offspring,Genes up-regulated by induction of E2F1 expression in Saos2 (osteosarcoma) cells.,CGP,C2,28,61
Cohort,0.06474225094289367,0.08998192266757314,0.7195028626147025,0.472032703293499,LGP Proband,Genes up-regulated by induction of E2F1 expression in Saos2 (osteosarcoma) cells.,CGP,C2,28,91
Cohort,0.012315499132333976,0.024647491278314042,0.4996654220614209,0.617448767127431,LonGen OPEL,Genes up-regulated by induction of E2F1 expression in Saos2 (osteosarcoma) cells.,CGP,C2,41,52
Cohort,-0.0015723088411913335,0.004529637148233926,-0.3471158482979957,0.7286123223274921,LGP Offspring,Selected genes up-regulated in Rat1Ras cells (fibroblasts) which were transformed by expression of an oncogenic activated form of HRAS [GeneID=3265] compared to the parental Rat1 cells.,CGP,C2,1,1
Cohort,-0.010041661990401931,0.013611147183567663,-0.7377528032703176,0.4608721979954028,LGP Proband,Selected genes up-regulated in Rat1Ras cells (fibroblasts) which were transformed by expression of an oncogenic activated form of HRAS [GeneID=3265] compared to the parental Rat1 cells.,CGP,C2,1,2
Cohort,0.009544718472769567,0.005771458206458875,1.6537793623954535,0.09856661901582459,LonGen OPEL,Selected genes up-regulated in Rat1Ras cells (fibroblasts) which were transformed by expression of an oncogenic activated form of HRAS [GeneID=3265] compared to the parental Rat1 cells.,CGP,C2,1,4
Cohort,-0.050525282701027165,0.028655125116230393,-1.7632197554918165,0.07831518131467818,LGP Offspring,Genes located outside the microdeletion region in 22q11 which were differentially expressed in the same manner both in hyppocampus and prefrontal cortex.,CGP,C2,35,55
Cohort,0.03497638374607806,0.07957932118955494,0.43951598509825984,0.6604015613618885,LGP Proband,Genes located outside the microdeletion region in 22q11 which were differentially expressed in the same manner both in hyppocampus and prefrontal cortex.,CGP,C2,35,76
Cohort,0.03147696506186436,0.027629830297151322,1.139238450737415,0.2549464268004828,LonGen OPEL,Genes located outside the microdeletion region in 22q11 which were differentially expressed in the same manner both in hyppocampus and prefrontal cortex.,CGP,C2,47,68
Cohort,0.0183444176482742,0.025434839068078807,0.7212319134071811,0.4710161975022059,LGP Offspring,Genes down-regulated in hyppocampus of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,18,44
Cohort,-0.12355212699131474,0.06637718066963116,-1.8613644891947363,0.0630443541962967,LGP Proband,Genes down-regulated in hyppocampus of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,18,58
Cohort,0.025003651885680427,0.022347312279978687,1.118866178286755,0.2635347570012753,LonGen OPEL,Genes down-regulated in hyppocampus of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,24,44
Cohort,-0.07168788239871583,0.04653368968560254,-1.5405587410554284,0.12389216268371765,LGP Offspring,Genes up-regulated in hyppocampus of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,78,143
Cohort,-0.0031862992732242293,0.1301213745092396,-0.02448713199688786,0.9804699053789883,LGP Proband,Genes up-regulated in hyppocampus of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,78,193
Cohort,-0.028980206672763836,0.044842962047588884,-0.6462598666432661,0.5182973491827125,LonGen OPEL,Genes up-regulated in hyppocampus of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,140,151
Cohort,-0.04919844071378186,0.10192245163866585,-0.48270464380310957,0.6294617389283366,LGP Offspring,Genes down-regulated in prefrontal cortex (PFC) of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,309,629
Cohort,-0.07502446578430383,0.28272069577585135,-0.2653660199102837,0.7907930874749476,LGP Proband,Genes down-regulated in prefrontal cortex (PFC) of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,309,888
Cohort,-0.11305207616864002,0.08846343095629308,-1.2779526516950874,0.20163866581956733,LonGen OPEL,Genes down-regulated in prefrontal cortex (PFC) of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,544,615
Cohort,-0.08389194826136137,0.08032745552151117,-1.044374525704921,0.2966854582715345,LGP Offspring,Genes up-regulated in prefrontal cortex (PFC) of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,215,429
Cohort,0.47508302790822,0.22543573964402772,2.1073988918456124,0.03538098304091084,LGP Proband,Genes up-regulated in prefrontal cortex (PFC) of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,215,576
Cohort,-0.01253971327144201,0.07377994239847578,-0.16996100652554952,0.8650839885533734,LonGen OPEL,Genes up-regulated in prefrontal cortex (PFC) of mice carrying a hemizygotic microdeletion in the 22q11.2 region.,CGP,C2,347,407
Cohort,-0.042593167294642305,0.04153697101341361,-1.0254278599392241,0.3055281372483069,LGP Offspring,Down-regulated genes classifying non-tumor lung tissues by age after incution of lung cancer by urethane injection [PubChem=5641]: early (24-26 weeks) vs late (46 weeks).,CGP,C2,62,113
Cohort,-0.10127014672407103,0.11965834603516971,-0.8463274821992436,0.39761284643127737,LGP Proband,Down-regulated genes classifying non-tumor lung tissues by age after incution of lung cancer by urethane injection [PubChem=5641]: early (24-26 weeks) vs late (46 weeks).,CGP,C2,62,166
Cohort,-0.010393726972403422,0.038835672619459735,-0.267633499598391,0.7890507730526608,LonGen OPEL,Down-regulated genes classifying non-tumor lung tissues by age after incution of lung cancer by urethane injection [PubChem=5641]: early (24-26 weeks) vs late (46 weeks).,CGP,C2,102,117
Cohort,-0.118120881932225,0.05225002253519673,-2.2606857605210844,0.024095909089474305,LGP Offspring,Up-regulated genes classifying non-tumor lung tissues by age after incution of lung cancer by urethane injection [PubChem=5641]: early (24-26 weeks) vs late (46 weeks).,CGP,C2,108,166
Cohort,-0.13693553151090132,0.1551166130141195,-0.8827908813251147,0.37760364647442424,LGP Proband,Up-regulated genes classifying non-tumor lung tissues by age after incution of lung cancer by urethane injection [PubChem=5641]: early (24-26 weeks) vs late (46 weeks).,CGP,C2,108,277
Cohort,0.006369110353193983,0.042767826374188224,0.14892293794565972,0.8816521610216992,LonGen OPEL,Up-regulated genes classifying non-tumor lung tissues by age after incution of lung cancer by urethane injection [PubChem=5641]: early (24-26 weeks) vs late (46 weeks).,CGP,C2,140,178
Cohort,-0.029504540852663495,0.0328326286317206,-0.8986347448330183,0.36916720945617043,LGP Offspring,Up-regulated genes in the 'Field Effect' signature of normal lung tissue adjacent to the tumor.,CGP,C2,37,71
Cohort,-0.03927864324435116,0.09399267603958199,-0.41789046657007856,0.6761347708758854,LGP Proband,Up-regulated genes in the 'Field Effect' signature of normal lung tissue adjacent to the tumor.,CGP,C2,37,111
Cohort,0.0358957707791411,0.031758537863229346,1.1302715173390248,0.25870228523443733,LonGen OPEL,Up-regulated genes in the 'Field Effect' signature of normal lung tissue adjacent to the tumor.,CGP,C2,62,87
Cohort,0.014638621967654008,0.020168351795963664,0.725821431307226,0.46819945178218925,LGP Offspring,Genes down-regulated during adipogenesis of 3T3-L1 cells (fibroblast).,CGP,C2,10,27
Cohort,0.04792967060909568,0.05549802259286043,0.8636284388132707,0.38804033377855207,LGP Proband,Genes down-regulated during adipogenesis of 3T3-L1 cells (fibroblast).,CGP,C2,10,34
Cohort,0.034396031494091796,0.016243502666657958,2.117525523894204,0.034524761827422985,LonGen OPEL,Genes down-regulated during adipogenesis of 3T3-L1 cells (fibroblast).,CGP,C2,9,26
Cohort,-0.029013835193424164,0.026161511005316763,-1.1090275017955855,0.2678127033560125,LGP Offspring,Genes up-regulated during adipogenesis of 3T3-L1 cells (fibroblast).,CGP,C2,26,46
Cohort,0.10167687213044331,0.07159397421580167,1.420187568076113,0.15592678963392256,LGP Proband,Genes up-regulated during adipogenesis of 3T3-L1 cells (fibroblast).,CGP,C2,26,62
Cohort,-0.005697040683856924,0.025655008228981594,-0.2220634908010347,0.8243214184293469,LonGen OPEL,Genes up-regulated during adipogenesis of 3T3-L1 cells (fibroblast).,CGP,C2,44,50
Cohort,0.013915288965546923,0.022219235256178492,0.6262721828681077,0.5313478368622282,LGP Offspring,Pre-mitotic cell cycle regulators (CDC) identified in an shRNA screen of the ubiquitin pathway components.,CGP,C2,13,32
Cohort,-0.1153552604210241,0.05357055123250785,-2.1533334596531812,0.0315785379098067,LGP Proband,Pre-mitotic cell cycle regulators (CDC) identified in an shRNA screen of the ubiquitin pathway components.,CGP,C2,13,37
Cohort,0.02807478814340553,0.01700789495660135,1.6506915297303584,0.09919604129293527,LonGen OPEL,Pre-mitotic cell cycle regulators (CDC) identified in an shRNA screen of the ubiquitin pathway components.,CGP,C2,14,29
Cohort,0.0017829782166698897,0.05041485575355948,0.03536612750387577,0.9717982344094548,LGP Offspring,Genes regulated by ESR1 [GeneID=2099] in MCF-7 cells (breast cancer).,CGP,C2,86,163
Cohort,-0.1892818726350526,0.13672423746942594,-1.3844061311907447,0.16660442392718627,LGP Proband,Genes regulated by ESR1 [GeneID=2099] in MCF-7 cells (breast cancer).,CGP,C2,86,203
Cohort,0.06958119545193289,0.042980354996065825,1.618906950822113,0.10586340256195895,LonGen OPEL,Genes regulated by ESR1 [GeneID=2099] in MCF-7 cells (breast cancer).,CGP,C2,114,170
Cohort,0.1872288721453204,0.13194963581438635,1.418941939397964,0.15637683677620628,LGP Offspring,Genes regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,491,1105
Cohort,-0.12356468409627669,0.34954136127898594,-0.35350518646533996,0.7237990802316098,LGP Proband,Genes regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,491,1514
Cohort,-0.03639088760912543,0.11409137924032532,-0.3189626407484358,0.7498385220685491,LonGen OPEL,Genes regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,878,1038
Cohort,0.05480338479670298,0.0551282709021125,0.9941067241890027,0.320526610181053,LGP Offspring,Genes down-regulated by ESRRA [GeneID=2101] only.,CGP,C2,92,210
Cohort,-0.0541833723728916,0.14726532481123708,-0.3679302812277309,0.7130185779968459,LGP Proband,Genes down-regulated by ESRRA [GeneID=2101] only.,CGP,C2,92,251
Cohort,0.008006667987602615,0.046999005589282605,0.17035824241839728,0.8647716993192561,LonGen OPEL,Genes down-regulated by ESRRA [GeneID=2101] only.,CGP,C2,143,172
Cohort,-0.014511315379265744,0.039867900827866815,-0.36398493720348185,0.7159830701755194,LGP Offspring,Genes down-regulated by estradiol [PubChem=5757] and down-regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,53,93
Cohort,-0.2787180141461015,0.10067235611078322,-2.7685655219928584,0.005755263154178757,LGP Proband,Genes down-regulated by estradiol [PubChem=5757] and down-regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,53,109
Cohort,-0.006958296976998007,0.03275681553941147,-0.2124228763515217,0.8318315237134011,LonGen OPEL,Genes down-regulated by estradiol [PubChem=5757] and down-regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,72,87
Cohort,0.032628422339886165,0.023860614726963474,1.3674594185125795,0.17193582116679038,LGP Offspring,Genes up-regulated by estradiol [PubChem=5757] and up-regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,15,40
Cohort,-0.06880575390421051,0.06668595882016452,-1.0317877274549287,0.30247068085794415,LGP Proband,Genes up-regulated by estradiol [PubChem=5757] and up-regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,15,58
Cohort,0.029094314783302145,0.022106315738927563,1.316108714220038,0.18851642642124025,LonGen OPEL,Genes up-regulated by estradiol [PubChem=5757] and up-regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,24,43
Cohort,0.07701070907242268,0.11447732668676196,0.6727158233100854,0.501357982282909,LGP Offspring,Genes up-regulated by ESRRA [GeneID=2101] only.,CGP,C2,383,839
Cohort,-0.026386629408700377,0.31241071050484637,-0.08446134694313256,0.9327099032335737,LGP Proband,Genes up-regulated by ESRRA [GeneID=2101] only.,CGP,C2,383,1183
Cohort,-0.0808290563887674,0.10338764449599139,-0.7818057639556858,0.4345612118446953,LonGen OPEL,Genes up-regulated by ESRRA [GeneID=2101] only.,CGP,C2,704,809
Cohort,0.0118504161012181,0.02362761894828726,0.5015493151110397,0.6161478748806373,LGP Offspring,Genes up-regulated by estradiol [PubChem=5757] and not modulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,17,35
Cohort,-0.01345047984592004,0.06364602568285622,-0.211332596208644,0.8326793777999713,LGP Proband,Genes up-regulated by estradiol [PubChem=5757] and not modulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,17,46
Cohort,0.0422753094126751,0.021672177087126345,1.9506720179850956,0.051446649302791664,LonGen OPEL,Genes up-regulated by estradiol [PubChem=5757] and not modulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).,CGP,C2,25,47
Cohort,0.002016077147917458,0.029449229138708247,0.06845942005549863,0.9454401664758136,LGP Offspring,Major erythrocyte membrane genes.,CGP,C2,29,61
Cohort,-0.041769942027147025,0.07940173442324247,-0.5260583075490115,0.5989875491785519,LGP Proband,Major erythrocyte membrane genes.,CGP,C2,29,77
Cohort,-0.015388281275558056,0.023864182143038547,-0.6448275152830658,0.5192247600666174,LonGen OPEL,Major erythrocyte membrane genes.,CGP,C2,42,43
Cohort,-0.003415931512678903,0.020942122206152297,-0.16311295861292335,0.8704782459995158,LGP Offspring,Genes down-regulated in esophagus by the carcinogen NMBA [PubChem=13643] and brought back to normal by a diet with PEITC [PubChem=16741] or black raspberries.,CGP,C2,14,29
Cohort,0.07933903932597094,0.05920072717083162,1.3401700134024963,0.1805550655092532,LGP Proband,Genes down-regulated in esophagus by the carcinogen NMBA [PubChem=13643] and brought back to normal by a diet with PEITC [PubChem=16741] or black raspberries.,CGP,C2,14,42
Cohort,-0.01992140309110135,0.01833577786333168,-1.0864771181014707,0.2775968556808905,LonGen OPEL,Genes down-regulated in esophagus by the carcinogen NMBA [PubChem=13643] and brought back to normal by a diet with PEITC [PubChem=16741] or black raspberries.,CGP,C2,28,23
Cohort,0.0023076018563315532,0.020320535065718005,0.11356009321942609,0.9096202401325935,LGP Offspring,Genes up-regulated in esophagus by the carcinogen NMBA [PubChem=13643] and brought back to normal by a diet with PEITC [PubChem=16741] or black raspberries.,CGP,C2,11,30
Cohort,0.17224142725414032,0.06557642527794363,2.626575427436009,0.008783112230810453,LGP Proband,Genes up-regulated in esophagus by the carcinogen NMBA [PubChem=13643] and brought back to normal by a diet with PEITC [PubChem=16741] or black raspberries.,CGP,C2,11,56
Cohort,0.009241820426859993,0.021031766482971198,0.43942197790864707,0.6604750694735984,LonGen OPEL,Genes up-regulated in esophagus by the carcinogen NMBA [PubChem=13643] and brought back to normal by a diet with PEITC [PubChem=16741] or black raspberries.,CGP,C2,28,37
Cohort,0.07969961010826553,0.04191109996990112,1.9016348930355589,0.057643780493413045,LGP Offspring,Genes up-regulated by estradiol (E2) [PubChem=5757] in U2OS cells (osteosarcoma) expressing ESR1 or ESR2 [GeneID=2099;2100].,CGP,C2,44,117
Cohort,0.02944203040093079,0.11916793702775376,0.24706335559097456,0.8049199966242498,LGP Proband,Genes up-regulated by estradiol (E2) [PubChem=5757] in U2OS cells (osteosarcoma) expressing ESR1 or ESR2 [GeneID=2099;2100].,CGP,C2,44,173
Cohort,0.018570621571385556,0.03797238806214162,0.4890559303511496,0.6249368222839313,LonGen OPEL,Genes up-regulated by estradiol (E2) [PubChem=5757] in U2OS cells (osteosarcoma) expressing ESR1 or ESR2 [GeneID=2099;2100].,CGP,C2,99,118
Cohort,0.03819668192834364,0.018954481431779264,2.0151794743538973,0.044281197845987,LGP Offspring,Genes down-regulated in MCF10A cells (breast cancer) by expression of LSM1 [GeneID=27257] off a letiviral vector.,CGP,C2,5,30
Cohort,-0.016296488766272137,0.0478646164287449,-0.34047047656868606,0.733587992442352,LGP Proband,Genes down-regulated in MCF10A cells (breast cancer) by expression of LSM1 [GeneID=27257] off a letiviral vector.,CGP,C2,5,31
Cohort,0.004201311571590761,0.014400087928431136,0.29175596652405206,0.7705492312940482,LonGen OPEL,Genes down-regulated in MCF10A cells (breast cancer) by expression of LSM1 [GeneID=27257] off a letiviral vector.,CGP,C2,11,19
Cohort,0.008439966383121089,0.026592959859670643,0.3173759682133262,0.7510563402742109,LGP Offspring,Genes up-regulated in MCF10A cells (breast cancer) by expression of LSM1 [GeneID=27257] off a letiviral vector.,CGP,C2,21,46
Cohort,-0.016421139059613784,0.07578719459386137,-0.21667432272184764,0.8285151489764674,LGP Proband,Genes up-regulated in MCF10A cells (breast cancer) by expression of LSM1 [GeneID=27257] off a letiviral vector.,CGP,C2,21,70
Cohort,-0.0031410574109468777,0.02083884168244516,-0.15073090236070724,0.8802261828300255,LonGen OPEL,Genes up-regulated in MCF10A cells (breast cancer) by expression of LSM1 [GeneID=27257] off a letiviral vector.,CGP,C2,33,38
Cohort,0.02546418012738147,0.03119216978540936,0.8163645011733922,0.41457927079929413,LGP Offspring,Genes up-regulated specifically in human kidney tissue.,CGP,C2,27,71
Cohort,0.11441722640262317,0.08671509152862446,1.319461519161913,0.18737696986818944,LGP Proband,Genes up-regulated specifically in human kidney tissue.,CGP,C2,27,97
Cohort,-0.007552275610836182,0.02549027617613389,-0.2962806506548269,0.7670930433454136,LonGen OPEL,Genes up-regulated specifically in human kidney tissue.,CGP,C2,45,53
Cohort,-0.03139526008906687,0.04665882380315259,-0.6728686565593537,0.5012607986190296,LGP Offspring,Genes up-regulated specifically in human liver tissue.,CGP,C2,77,152
Cohort,-0.04974444916712293,0.13430325645290841,-0.37038900232895794,0.7111867132095495,LGP Proband,Genes up-regulated specifically in human liver tissue.,CGP,C2,77,241
Cohort,-0.06823736798321854,0.046116374016980446,-1.4796776511113592,0.13935493512926583,LonGen OPEL,Genes up-regulated specifically in human liver tissue.,CGP,C2,154,162
Cohort,0.006666544571420528,0.03737654987004011,0.17836168920353518,0.8584923718448239,LGP Offspring,Genes up-regulated specifically in human pancreas.,CGP,C2,47,87
Cohort,-0.23715707123205215,0.09793740157682904,-2.4215168813316876,0.01566826216623217,LGP Proband,Genes up-regulated specifically in human pancreas.,CGP,C2,47,124
Cohort,0.030457018529218175,0.03345351600094976,0.9104280258120997,0.3628724245581616,LonGen OPEL,Genes up-regulated specifically in human pancreas.,CGP,C2,67,95
Cohort,0.03209891483484993,0.027344159656963195,1.1738855842540379,0.2408542561311036,LGP Offspring,Genes up-regulated specifically in human placenta.,CGP,C2,17,48
Cohort,0.04813575414852779,0.07544483803037605,0.6380258133650852,0.5236320155115399,LGP Proband,Genes up-regulated specifically in human placenta.,CGP,C2,17,69
Cohort,-0.03509205684809579,0.022980811286608095,-1.5270155787992323,0.12715437220817838,LonGen OPEL,Genes up-regulated specifically in human placenta.,CGP,C2,38,30
Cohort,-0.017098437103792826,0.013765863255971187,-1.2420897103111987,0.21463420151584905,LGP Offspring,Genes up-regulated specifically in human salivary gland tissue.,CGP,C2,8,9
Cohort,-0.04259793128814271,0.030991691242653385,-1.3744952140435573,0.16965720089267047,LGP Proband,Genes up-regulated specifically in human salivary gland tissue.,CGP,C2,8,8
Cohort,0.011339798739559263,0.011696246409005516,0.9695246101200633,0.3325780006926681,LonGen OPEL,Genes up-regulated specifically in human salivary gland tissue.,CGP,C2,7,14
Cohort,-0.07300446013410705,0.04646730478296372,-1.5710930615642815,0.11662894658858612,LGP Offspring,Genes up-regulated specifically in human testis tissue.,CGP,C2,81,131
Cohort,-0.2348679344501245,0.13114286579478387,-1.790931843884307,0.0736667804830422,LGP Proband,Genes up-regulated specifically in human testis tissue.,CGP,C2,81,202
Cohort,0.031039964685318142,0.042314534122929646,0.7335532655314767,0.4634370406770735,LonGen OPEL,Genes up-regulated specifically in human testis tissue.,CGP,C2,114,147
Cohort,0.008227558864478995,0.018076923793389717,0.4551415361659935,0.6491535557878421,LGP Offspring,Genes up-regulated specifically in human thymus.,CGP,C2,9,22
Cohort,-0.014967125503582942,0.04702236951215245,-0.31829798580683694,0.7503385991941842,LGP Proband,Genes up-regulated specifically in human thymus.,CGP,C2,9,28
Cohort,-0.015157262591638989,0.01607334864848589,-0.9430058989647314,0.3459640014806372,LonGen OPEL,Genes up-regulated specifically in human thymus.,CGP,C2,19,19
Cohort,0.006264897182566679,0.033765701009632415,0.1855402670532289,0.8528609560800314,LGP Offspring,Genes responding to progestin R5020 [PubChem=36709] treatment of T47D-MTVL cells (breast cancer).,CGP,C2,40,82
Cohort,-0.19778597731109993,0.08789258615970627,-2.2503146846960513,0.02468883840034329,LGP Proband,Genes responding to progestin R5020 [PubChem=36709] treatment of T47D-MTVL cells (breast cancer).,CGP,C2,40,94
Cohort,-0.021347653460554408,0.028315289419558,-0.7539267264493899,0.45111617625732003,LonGen OPEL,Genes responding to progestin R5020 [PubChem=36709] treatment of T47D-MTVL cells (breast cancer).,CGP,C2,59,62
Cohort,-0.006010490341747575,0.015499356216949435,-0.3877896770431509,0.6982937601136932,LGP Offspring,Genes whose expression positively correlates with that of both ID1 and ID2 [GeneID=3397;3398] genes in a cohort of 285 patients with primaly AML (acule myelogenous leukemia) [PMID=15084694].,CGP,C2,8,16
Cohort,-0.15240824692071733,0.053297378079588266,-2.859582448748757,0.00434784961260837,LGP Proband,Genes whose expression positively correlates with that of both ID1 and ID2 [GeneID=3397;3398] genes in a cohort of 285 patients with primaly AML (acule myelogenous leukemia) [PMID=15084694].,CGP,C2,8,34
Cohort,-0.008420247006153781,0.01946146873985588,-0.4326624633889855,0.6653771986318412,LonGen OPEL,Genes whose expression positively correlates with that of both ID1 and ID2 [GeneID=3397;3398] genes in a cohort of 285 patients with primaly AML (acule myelogenous leukemia) [PMID=15084694].,CGP,C2,18,22
Cohort,-0.04767824914170136,0.031364615768218126,-1.5201285899384074,0.12894622622684593,LGP Offspring,"Genes up-regulated in HepG2 cells (hepatocellular carcinoma, HCC) upon expression of HNF4A [GeneID=3172] and down-regulated upon knockdown of HNF4A [GeneID=3172] in these cells by RNAi.",CGP,C2,39,53
Cohort,-0.06077691230577128,0.08748538448370542,-0.6947093238995969,0.4874309695332416,LGP Proband,"Genes up-regulated in HepG2 cells (hepatocellular carcinoma, HCC) upon expression of HNF4A [GeneID=3172] and down-regulated upon knockdown of HNF4A [GeneID=3172] in these cells by RNAi.",CGP,C2,39,78
Cohort,0.03820614689300234,0.02596527504464883,1.4714323968186205,0.1415694309757292,LonGen OPEL,"Genes up-regulated in HepG2 cells (hepatocellular carcinoma, HCC) upon expression of HNF4A [GeneID=3172] and down-regulated upon knockdown of HNF4A [GeneID=3172] in these cells by RNAi.",CGP,C2,38,57
Cohort,0.028031984494833132,0.041667355489846056,0.6727565060293846,0.501332111963346,LGP Offspring,Genes down-regulated in metastatic vs non-metastatic stromal cells originated from either bone or prostate tissues.,CGP,C2,56,122
Cohort,0.133612283378354,0.11428326988127105,1.1691324855962197,0.24268429867214744,LGP Proband,Genes down-regulated in metastatic vs non-metastatic stromal cells originated from either bone or prostate tissues.,CGP,C2,56,173
Cohort,-0.02351855948197948,0.040189161168620216,-0.5851965753478533,0.5585813966498864,LonGen OPEL,Genes down-regulated in metastatic vs non-metastatic stromal cells originated from either bone or prostate tissues.,CGP,C2,112,126
Cohort,-0.15706120022888823,0.060782430648958254,-2.5839901193813164,0.009975106229030506,LGP Offspring,Genes up-regulated in metastatic vs non-metastatic stromal cells originated from either bone or prostate tissues.,CGP,C2,137,217
Cohort,-0.18243254206034465,0.15997791092722644,-1.1403608223346082,0.2544633799329071,LGP Proband,Genes up-regulated in metastatic vs non-metastatic stromal cells originated from either bone or prostate tissues.,CGP,C2,137,294
Cohort,-0.04801564060306001,0.04945978368111866,-0.9708016701534836,0.33194194296545265,LonGen OPEL,Genes up-regulated in metastatic vs non-metastatic stromal cells originated from either bone or prostate tissues.,CGP,C2,179,194
Cohort,-0.02544222398829466,0.01994076592235329,-1.27589000780428,0.20243262259308217,LGP Offspring,High-level amplifications detected in oral squamous cell carcinoma (OSCC) lines by array-CGH analysis.,CGP,C2,16,23
Cohort,0.055090574063169744,0.05357651235920797,1.0282598033595511,0.3041257545523215,LGP Proband,High-level amplifications detected in oral squamous cell carcinoma (OSCC) lines by array-CGH analysis.,CGP,C2,16,29
Cohort,-9.026548723728738e-4,0.015256914795187128,-0.05916365690510515,0.952836605971809,LonGen OPEL,High-level amplifications detected in oral squamous cell carcinoma (OSCC) lines by array-CGH analysis.,CGP,C2,16,20
Cohort,-0.0027511047952504353,0.016764997394777745,-0.1640981343729524,0.8697029414436706,LGP Offspring,Genes up-regulated in testis tissue upon knockout of CTCFL [GeneID=140690].,CGP,C2,9,19
Cohort,0.007753353404805472,0.04541341971933819,0.1707282440459752,0.8644788629638499,LGP Proband,Genes up-regulated in testis tissue upon knockout of CTCFL [GeneID=140690].,CGP,C2,9,25
Cohort,-0.024515685810471977,0.012923189493373271,-1.8970305916386263,0.05818561356168118,LonGen OPEL,Genes up-regulated in testis tissue upon knockout of CTCFL [GeneID=140690].,CGP,C2,16,10
Cohort,3.2545875156486285e-4,0.028424039230698805,0.011450123218706993,0.9908677013356045,LGP Offspring,"Genes up-regulated by TSA alone [PubChem=5562], with non-hypermethylated promoters, in RKO cells (colorectal cancer).",CGP,C2,25,55
Cohort,-0.05290282838731529,0.0746978729476985,-0.7082240269994899,0.47900403446025197,LGP Proband,"Genes up-regulated by TSA alone [PubChem=5562], with non-hypermethylated promoters, in RKO cells (colorectal cancer).",CGP,C2,25,68
Cohort,0.025020306664187583,0.024840562411449843,1.0072359171970635,0.3141274949695449,LonGen OPEL,"Genes up-regulated by TSA alone [PubChem=5562], with non-hypermethylated promoters, in RKO cells (colorectal cancer).",CGP,C2,36,55
Cohort,0.03385179660229801,0.024567780895468943,1.3778939476190672,0.16869196933863778,LGP Offspring,"Genes basally silent, with hypermethylated promoters, up-regulated by the combination of TSA and decitabine [PubChem=5562;451668] in RKO cells (colorectal cancer).",CGP,C2,13,46
Cohort,-0.023064612198384543,0.062287217444444126,-0.37029447043378644,0.7112571131978904,LGP Proband,"Genes basally silent, with hypermethylated promoters, up-regulated by the combination of TSA and decitabine [PubChem=5562;451668] in RKO cells (colorectal cancer).",CGP,C2,13,55
Cohort,-0.008529972377498155,0.02012304603274459,-0.42389071533295836,0.6717600378232802,LonGen OPEL,"Genes basally silent, with hypermethylated promoters, up-regulated by the combination of TSA and decitabine [PubChem=5562;451668] in RKO cells (colorectal cancer).",CGP,C2,32,32
Cohort,-0.007581633985328165,0.02001576063916968,-0.3787832059947474,0.704967793270928,LGP Offspring,"Genes with some basal expression and partially methylated promoters, up-regulated by the combination of TSA and decitabine [PubChem=5562;451668] in RKO cells (colorectal cancer).",CGP,C2,15,24
Cohort,-0.03361537017941676,0.052878323799074776,-0.6357117201208434,0.5251387307708233,LGP Proband,"Genes with some basal expression and partially methylated promoters, up-regulated by the combination of TSA and decitabine [PubChem=5562;451668] in RKO cells (colorectal cancer).",CGP,C2,15,31
Cohort,-0.004761004025491066,0.0149069043402981,-0.3193824765226781,0.7495202960424333,LonGen OPEL,"Genes with some basal expression and partially methylated promoters, up-regulated by the combination of TSA and decitabine [PubChem=5562;451668] in RKO cells (colorectal cancer).",CGP,C2,15,17
Cohort,0.012488998285072741,0.041848080647035706,0.2984365851903747,0.7654616787319831,LGP Offspring,Genes that contributed maximally to the GSEA score of the up-regulated gene set from the KrasLA mouse model in two human lung cancer expression data sets comparing mutant vs normal KRAS [GeneID=3845].,CGP,C2,51,123
Cohort,0.027434757654071693,0.12686741278594754,0.21624747483705684,0.8288477293300596,LGP Proband,Genes that contributed maximally to the GSEA score of the up-regulated gene set from the KrasLA mouse model in two human lung cancer expression data sets comparing mutant vs normal KRAS [GeneID=3845].,CGP,C2,51,198
Cohort,-0.12486395706154463,0.03917908151297282,-3.1870057244757044,0.0014936613041768765,LonGen OPEL,Genes that contributed maximally to the GSEA score of the up-regulated gene set from the KrasLA mouse model in two human lung cancer expression data sets comparing mutant vs normal KRAS [GeneID=3845].,CGP,C2,122,103
Cohort,-0.04407960857237819,0.03719601211399676,-1.185062754504028,0.23640907158502383,LGP Offspring,Genes upregulated in control vs KRAS [GeneID=3845] knockdown in a human cell line.,CGP,C2,50,84
Cohort,-0.03269909706772605,0.1147740251810531,-0.2848998021646802,0.7757916377053897,LGP Proband,Genes upregulated in control vs KRAS [GeneID=3845] knockdown in a human cell line.,CGP,C2,50,159
Cohort,-0.03797113986372569,0.03809350765594474,-0.9967876995386127,0.31917048035858286,LonGen OPEL,Genes upregulated in control vs KRAS [GeneID=3845] knockdown in a human cell line.,CGP,C2,101,110
Cohort,-0.08090467803401918,0.0474304481398942,-1.705754029466348,0.08851324248800256,LGP Offspring,Genes upregulated in KRAS [GeneID=3845] knockdown vs control in a human cell line.,CGP,C2,89,141
Cohort,-0.14774105244264046,0.13943403848552188,-1.0595766575173904,0.2896440048451271,LGP Proband,Genes upregulated in KRAS [GeneID=3845] knockdown vs control in a human cell line.,CGP,C2,89,246
Cohort,0.03537010817712008,0.04542192725801592,0.7787011761126466,0.4363871825351665,LonGen OPEL,Genes upregulated in KRAS [GeneID=3845] knockdown vs control in a human cell line.,CGP,C2,149,188
Cohort,-0.0647319529692442,0.11007502621751034,-0.5880712019212481,0.5566809052443583,LGP Offspring,Genes down-regulated in the Kras2LA mouse lung cancer model with mutated KRAS [GeneID=3845].,CGP,C2,421,848
Cohort,-0.4919449419187551,0.3153117594433577,-1.5601858388891696,0.11909533261386059,LGP Proband,Genes down-regulated in the Kras2LA mouse lung cancer model with mutated KRAS [GeneID=3845].,CGP,C2,421,1241
Cohort,0.03242524450702662,0.09880688787470587,0.3281678555461045,0.7428710532024052,LonGen OPEL,Genes down-regulated in the Kras2LA mouse lung cancer model with mutated KRAS [GeneID=3845].,CGP,C2,670,808
Cohort,-0.18726079103627857,0.11473814964029001,-1.6320708641663715,0.10313026635172652,LGP Offspring,Genes up-regulated in the Kras2LA mouse lung cancer model with mutated KRAS [GeneID=3845].,CGP,C2,412,808
Cohort,-0.3760517874761318,0.30019605172050035,-1.2526873199060509,0.2106706513555704,LGP Proband,Genes up-regulated in the Kras2LA mouse lung cancer model with mutated KRAS [GeneID=3845].,CGP,C2,412,1125
Cohort,0.1583365093740736,0.10152015891216339,1.5596558463927197,0.11923870151873403,LonGen OPEL,Genes up-regulated in the Kras2LA mouse lung cancer model with mutated KRAS [GeneID=3845].,CGP,C2,647,828
Cohort,-0.015887071140916812,0.025974609293984065,-0.6116385028588819,0.5409825947100972,LGP Offspring,Genes responsive to estradiol [PubChem=5757] both in normal and cancer ovarian cell lines.,CGP,C2,24,39
Cohort,-0.047495268162116806,0.07503999517606522,-0.6329327187545705,0.526951082583125,LGP Proband,Genes responsive to estradiol [PubChem=5757] both in normal and cancer ovarian cell lines.,CGP,C2,24,66
Cohort,-0.037134432672159996,0.025001068314482993,-1.4853138355951057,0.13785661836604032,LonGen OPEL,Genes responsive to estradiol [PubChem=5757] both in normal and cancer ovarian cell lines.,CGP,C2,47,38
Cohort,-0.05983435679173126,0.02723459912507501,-2.196997889226925,0.02835923793282441,LGP Offspring,Genes that cooperate with MYC and TBX2 [GeneID=4609;6909] to transform MEF cells (embryo fibroblasts).,CGP,C2,32,40
Cohort,0.03184871384190717,0.0682489800156131,0.46665479593425785,0.6408687492982232,LGP Proband,Genes that cooperate with MYC and TBX2 [GeneID=4609;6909] to transform MEF cells (embryo fibroblasts).,CGP,C2,32,48
Cohort,-0.022011710413161276,0.02121237433920292,-1.0376825366729971,0.299732988026989,LonGen OPEL,Genes that cooperate with MYC and TBX2 [GeneID=4609;6909] to transform MEF cells (embryo fibroblasts).,CGP,C2,34,37
Cohort,0.04962674024862979,0.035898514418896285,1.382417658556568,0.16730004158133027,LGP Offspring,Candidate genes in the regions of copy number loss in gastric cancer cell lines.,CGP,C2,37,92
Cohort,0.07895782251564473,0.08709693301780654,0.9065511239012538,0.36490605752499117,LGP Proband,Candidate genes in the regions of copy number loss in gastric cancer cell lines.,CGP,C2,37,96
Cohort,0.038410737759651356,0.02840258771933483,1.3523675426765271,0.17664182847678184,LonGen OPEL,Candidate genes in the regions of copy number loss in gastric cancer cell lines.,CGP,C2,49,74
Cohort,0.004084323664694752,0.015515012439612945,0.2632497834334089,0.7924382791954179,LGP Offspring,Candidate genes in the regions of copy number gain in gastric cancer cell lines.,CGP,C2,7,17
Cohort,0.03725177782924138,0.038791702595962985,0.96030272806634,0.3371811951507365,LGP Proband,Candidate genes in the regions of copy number gain in gastric cancer cell lines.,CGP,C2,7,18
Cohort,0.015516463837672283,0.010569820126011889,1.4679969623595495,0.14250006954502753,LonGen OPEL,Candidate genes in the regions of copy number gain in gastric cancer cell lines.,CGP,C2,5,12
Cohort,0.07298348427129187,0.05938098233495274,1.2290716893097344,0.21947258218766114,LGP Offspring,Genes down-regulated in primary tissue culture of epidermal kerationcytes after UVB irradiation.,CGP,C2,100,239
Cohort,-0.02058697493251182,0.1582144002488344,-0.13012074059082676,0.8965022778774809,LGP Proband,Genes down-regulated in primary tissue culture of epidermal kerationcytes after UVB irradiation.,CGP,C2,100,301
Cohort,0.041928553032467286,0.04996141457039933,0.8392186929252544,0.4015985594381768,LonGen OPEL,Genes down-regulated in primary tissue culture of epidermal kerationcytes after UVB irradiation.,CGP,C2,150,202
Cohort,0.023373226015088837,0.03650120625421298,0.6403411945431555,0.5221677860617453,LGP Offspring,Genes up-regulated in primary tissue culture of epidermal kerationcytes after UVB irradiation.,CGP,C2,35,94
Cohort,0.09720041053573884,0.09630755306776281,1.0092708976558444,0.3131374548009477,LGP Proband,Genes up-regulated in primary tissue culture of epidermal kerationcytes after UVB irradiation.,CGP,C2,35,114
Cohort,-0.018126755528462022,0.02976515311284321,-0.6089925175167537,0.542703157827171,LonGen OPEL,Genes up-regulated in primary tissue culture of epidermal kerationcytes after UVB irradiation.,CGP,C2,63,69
Cohort,0.01575332921908575,0.018324480206636233,0.8596876441483269,0.39026600936647393,LGP Offspring,"Genes whose promoters bound AR [GeneID=367] in LNCaP cells (prostate cancer) after exposure to the synthetic androgen R1881 [PubChem=13766], based on ChIP-chip analysis.",CGP,C2,8,26
Cohort,0.041553402240045244,0.0422801853864422,0.9828103131584184,0.3259858242027929,LGP Proband,"Genes whose promoters bound AR [GeneID=367] in LNCaP cells (prostate cancer) after exposure to the synthetic androgen R1881 [PubChem=13766], based on ChIP-chip analysis.",CGP,C2,8,22
Cohort,0.0027871998427270827,0.013198601086388475,0.21117388308685844,0.8328056401204527,LonGen OPEL,"Genes whose promoters bound AR [GeneID=367] in LNCaP cells (prostate cancer) after exposure to the synthetic androgen R1881 [PubChem=13766], based on ChIP-chip analysis.",CGP,C2,11,16
Cohort,0.14958803086439118,0.0695103952351576,2.1520238858997476,0.031748903434398686,LGP Offspring,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 10 days after transduction.,CGP,C2,132,345
Cohort,0.09212869509582652,0.18236532185570897,0.5051875771026278,0.6135605651145,LGP Proband,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 10 days after transduction.,CGP,C2,132,464
Cohort,0.010133662766997474,0.06031992743605521,0.16799859014651683,0.8666270620670979,LonGen OPEL,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 10 days after transduction.,CGP,C2,259,309
Cohort,-0.013998028038421945,0.07550931003254645,-0.18538148517564837,0.8529854363680871,LGP Offspring,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 10 days after transduction.,CGP,C2,177,371
Cohort,-0.006451424334145556,0.20954898873684405,-0.030787189062732187,0.9754466231018839,LGP Proband,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 10 days after transduction.,CGP,C2,177,519
Cohort,-0.06029156539923031,0.06579917989970989,-0.9162966087286467,0.3597888581353571,LonGen OPEL,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 10 days after transduction.,CGP,C2,290,323
Cohort,0.06691301013452228,0.07226840646018305,0.9258957463160423,0.3548305810258213,LGP Offspring,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 16 days after transduction.,CGP,C2,156,363
Cohort,0.2492335878440986,0.19928061035312827,1.2506665219584228,0.21140692778346407,LGP Proband,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 16 days after transduction.,CGP,C2,156,492
Cohort,-0.0070843534250671965,0.0648116067359526,-0.10930686310446507,0.912986652463492,LonGen OPEL,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 16 days after transduction.,CGP,C2,271,313
Cohort,-0.05960371635434254,0.06939047235355823,-0.8589610984437427,0.3906664544564862,LGP Offspring,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 16 days after transduction.,CGP,C2,158,320
Cohort,0.1892110999468229,0.19626952539067627,0.9640370789616802,0.33530677490956773,LGP Proband,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 16 days after transduction.,CGP,C2,158,466
Cohort,0.06698596330319995,0.06100406892079256,1.09805730155761,0.272511500349805,LonGen OPEL,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 16 days after transduction.,CGP,C2,243,328
Cohort,0.005748161517244793,0.02777919044704388,0.20692329131054585,0.836132078125627,LGP Offspring,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 3 days after transduction.,CGP,C2,25,50
Cohort,0.02193391975390024,0.07886377359838562,0.2781241469067775,0.7809859959368486,LGP Proband,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 3 days after transduction.,CGP,C2,25,81
Cohort,-0.026277139982280297,0.02357570104326374,-1.1145857310482157,0.2653643966680589,LonGen OPEL,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 3 days after transduction.,CGP,C2,46,39
Cohort,-0.06147929369045157,0.07805108027301036,-0.787680240624559,0.4311598595544732,LGP Offspring,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 3 days after transduction.,CGP,C2,199,391
Cohort,-0.21283338273446908,0.2232707065033321,-0.9532526056269399,0.340738291039007,LGP Proband,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 3 days after transduction.,CGP,C2,199,588
Cohort,-0.05246837861662564,0.06704022302556216,-0.782640275474914,0.43407114685427983,LonGen OPEL,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 3 days after transduction.,CGP,C2,332,378
Cohort,-0.03230006102242206,0.03442980349096476,-0.9381424738859868,0.3485062535236776,LGP Offspring,Genes down-rgulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 6h.,CGP,C2,42,74
Cohort,-0.1973591499446439,0.0908305448983675,-2.172827986064312,0.030074156059148795,LGP Proband,Genes down-rgulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 6h.,CGP,C2,42,90
Cohort,-0.029804463023554734,0.03003049432244716,-0.9924732741171206,0.3212683029013258,LonGen OPEL,Genes down-rgulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 6h.,CGP,C2,65,64
Cohort,-0.0845242243830969,0.061567444481565536,-1.3728720607918858,0.1702473650579008,LGP Offspring,Genes up-rgulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 6h.,CGP,C2,120,218
Cohort,-0.025810196891051292,0.16180832709702037,-0.15951093095212265,0.8733049680483456,LGP Proband,Genes up-rgulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 6h.,CGP,C2,120,310
Cohort,-0.012211287679778847,0.0522862026116978,-0.23354703669083937,0.8153966961385751,LonGen OPEL,Genes up-rgulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 6h.,CGP,C2,194,226
Cohort,0.07942211606728027,0.07690238369387907,1.032765335121878,0.30208306281487396,LGP Offspring,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 8 days after transduction.,CGP,C2,181,414
Cohort,-0.006483556495558205,0.20184345626698405,-0.03212170766131859,0.9743826776149707,LGP Proband,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 8 days after transduction.,CGP,C2,181,543
Cohort,-0.016187362753813155,0.06655881704261761,-0.24320388301745788,0.8079101173017531,LonGen OPEL,Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 8 days after transduction.,CGP,C2,304,347
Cohort,-0.014537036570486075,0.06937871475839019,-0.20953164988874437,0.8340963593439294,LGP Offspring,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 8 days after transduction.,CGP,C2,148,304
Cohort,0.1359553619200209,0.1811296619507432,0.7505968953720726,0.45310700225449085,LGP Proband,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 8 days after transduction.,CGP,C2,148,424
Cohort,-0.042650568839489277,0.0566189815670298,-0.7532909928624614,0.45149780781787763,LonGen OPEL,Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 8 days after transduction.,CGP,C2,233,272
Cohort,-0.14169025424751683,0.058634685437949446,-2.416492101717873,0.015934738276776057,LGP Offspring,Genes with hypermethylated DNA in all four esophageal squamous cell carcinoma (ESCC) lines analyzed.,CGP,C2,126,195
Cohort,-0.23226933905677613,0.16299613938821114,-1.4249990210110168,0.15453159064825117,LGP Proband,Genes with hypermethylated DNA in all four esophageal squamous cell carcinoma (ESCC) lines analyzed.,CGP,C2,126,292
Cohort,0.03234863067524256,0.04861226109609723,0.6654418030730034,0.5059607215344825,LonGen OPEL,Genes with hypermethylated DNA in all four esophageal squamous cell carcinoma (ESCC) lines analyzed.,CGP,C2,160,189
Cohort,-0.0859673202922243,0.037780922713732665,-2.2754161126132786,0.02319314609501089,LGP Offspring,Genes down-regulated in WI-38 cells (senescent primary fibroblasts) after inactivation of TP53 [GeneID=7157] by GSE56 polypeptide.,CGP,C2,60,84
Cohort,0.01249525127014342,0.10871669580468983,0.114934060289978,0.9085250525914764,LGP Proband,Genes down-regulated in WI-38 cells (senescent primary fibroblasts) after inactivation of TP53 [GeneID=7157] by GSE56 polypeptide.,CGP,C2,60,141
Cohort,-0.013428625301707835,0.03279381192113199,-0.40948656209907,0.6822927906540883,LonGen OPEL,Genes down-regulated in WI-38 cells (senescent primary fibroblasts) after inactivation of TP53 [GeneID=7157] by GSE56 polypeptide.,CGP,C2,76,90
Cohort,-0.02181893009209326,0.03815943234899946,-0.5717834031843336,0.5676587932197416,LGP Offspring,Genes up-regulated in WI-38 cells (senescent primary fibroblasts) after inactivation of TP53 [GeneID=7157] by GSE56 polypeptide.,CGP,C2,46,91
Cohort,0.00922078333658265,0.10110530958595208,0.09119979330802443,0.9273557386500976,LGP Proband,Genes up-regulated in WI-38 cells (senescent primary fibroblasts) after inactivation of TP53 [GeneID=7157] by GSE56 polypeptide.,CGP,C2,46,123
Cohort,-0.012489267653755059,0.03058711050858103,-0.40831799559004667,0.6831500417139791,LonGen OPEL,Genes up-regulated in WI-38 cells (senescent primary fibroblasts) after inactivation of TP53 [GeneID=7157] by GSE56 polypeptide.,CGP,C2,62,74
Cohort,0.017784226473564556,0.024128041828778823,0.7370770740438765,0.46133121656414466,LGP Offspring,Genes down-regulated in plasma cells compared with B lymphocytes.,CGP,C2,15,45
Cohort,-0.02988644160554073,0.05772947517545364,-0.517698134526751,0.6048061884222845,LGP Proband,Genes down-regulated in plasma cells compared with B lymphocytes.,CGP,C2,15,40
Cohort,-0.014035060917501256,0.021763833295163182,-0.6448800046920238,0.5191907593717799,LonGen OPEL,Genes down-regulated in plasma cells compared with B lymphocytes.,CGP,C2,30,35
Cohort,-0.03788288637013808,0.03815168386167875,-0.992954505166398,0.3210874092365078,LGP Offspring,Genes up-regulated in plasma cells compared with B lymphocytes.,CGP,C2,52,99
Cohort,0.06686164562856094,0.11919343735614885,0.5609507294330223,0.574981800378765,LGP Proband,Genes up-regulated in plasma cells compared with B lymphocytes.,CGP,C2,52,158
Cohort,0.024259494536841102,0.03747981896777762,0.6472681887203784,0.5176450013738586,LonGen OPEL,Genes up-regulated in plasma cells compared with B lymphocytes.,CGP,C2,87,113
Cohort,-0.03211512411607356,0.09291975977236015,-0.34562211734889253,0.7297342480273392,LGP Offspring,Genes down-regulated in mature plasma cells compared with plasmablastic B lymphocytes.,CGP,C2,246,499
Cohort,-0.347887145630799,0.23883638790898146,-1.456591889856314,0.14560543368865606,LGP Proband,Genes down-regulated in mature plasma cells compared with plasmablastic B lymphocytes.,CGP,C2,246,675
Cohort,-0.04429202703161046,0.08015341167840095,-0.5525906646285138,0.5806988686273399,LonGen OPEL,Genes down-regulated in mature plasma cells compared with plasmablastic B lymphocytes.,CGP,C2,399,459
Cohort,0.036348417004849365,0.1026820400936291,0.3539900158947523,0.7234567472086937,LGP Offspring,Genes up-regulated in mature plasma cells compared with plasmablastic B lymphocytes.,CGP,C2,358,758
Cohort,-0.3360421618732733,0.29544106876225923,-1.137425352816083,0.25568718443645444,LGP Proband,Genes up-regulated in mature plasma cells compared with plasmablastic B lymphocytes.,CGP,C2,358,1086
Cohort,0.05634909815870815,0.08972407945136862,0.6280264841195717,0.5301667244552137,LonGen OPEL,Genes up-regulated in mature plasma cells compared with plasmablastic B lymphocytes.,CGP,C2,583,699
Cohort,0.03211851841702535,0.057535169428763855,0.5582414849197989,0.5768643347078892,LGP Offspring,Putative metastasis genes: up-regulated in metastatic cell lines LM2 (lung) and BoM2 (bone) relative to the parental MDA-MB-231 line (breast adenocarcinoma).,CGP,C2,100,208
Cohort,-0.2043668071161234,0.14860338928754172,-1.3752499730721597,0.16942325084803048,LGP Proband,Putative metastasis genes: up-regulated in metastatic cell lines LM2 (lung) and BoM2 (bone) relative to the parental MDA-MB-231 line (breast adenocarcinoma).,CGP,C2,100,290
Cohort,-0.004129329339676126,0.04921283911678583,-0.08390756180266112,0.9331510241643448,LonGen OPEL,Putative metastasis genes: up-regulated in metastatic cell lines LM2 (lung) and BoM2 (bone) relative to the parental MDA-MB-231 line (breast adenocarcinoma).,CGP,C2,156,186
Cohort,-0.033347298088344794,0.028970366963999634,-1.1510830404662877,0.2501050525796317,LGP Offspring,"Genes down-regulated in KCL22 cells (chronic myelogenous leukemia, CML, with BCR-ABL1 [GeneID=613;25] fusion) by expression of CEBPA [GeneID=1050].",CGP,C2,33,55
Cohort,-0.03864823457605074,0.08478608187280583,-0.4558322984429207,0.6486292382749814,LGP Proband,"Genes down-regulated in KCL22 cells (chronic myelogenous leukemia, CML, with BCR-ABL1 [GeneID=613;25] fusion) by expression of CEBPA [GeneID=1050].",CGP,C2,33,81
Cohort,0.02547710929053924,0.02496592340930747,1.0204753444465504,0.3078131200016778,LonGen OPEL,"Genes down-regulated in KCL22 cells (chronic myelogenous leukemia, CML, with BCR-ABL1 [GeneID=613;25] fusion) by expression of CEBPA [GeneID=1050].",CGP,C2,38,57
Cohort,0.0034039384565367056,0.028880856117432182,0.11786141112631783,0.9062124800666336,LGP Offspring,"Genes up-regulated in KCL22 cells (chronic myelogenous leukemia, CML, with BCR-ABL1 [GeneID=613;25] fusion) by expression of CEBPA [GeneID=1050].",CGP,C2,26,57
Cohort,0.02922544114269417,0.07880491748546616,0.37085808951052024,0.7108374101456905,LGP Proband,"Genes up-regulated in KCL22 cells (chronic myelogenous leukemia, CML, with BCR-ABL1 [GeneID=613;25] fusion) by expression of CEBPA [GeneID=1050].",CGP,C2,26,75
Cohort,-0.04873036047967107,0.02343859753450096,-2.0790646884030215,0.0379310736371975,LonGen OPEL,"Genes up-regulated in KCL22 cells (chronic myelogenous leukemia, CML, with BCR-ABL1 [GeneID=613;25] fusion) by expression of CEBPA [GeneID=1050].",CGP,C2,54,40
Cohort,-0.00701721905111032,0.04809984042231204,-0.14588861396420033,0.8840528109973849,LGP Offspring,Genes whose DNA methylation differed between primary ALL cells (acute lymphoblastic leukemia) and normal peripheral blood samples.,CGP,C2,76,162
Cohort,0.01193610557892573,0.12774233125323883,0.09343892084812015,0.9255773130845331,LGP Proband,Genes whose DNA methylation differed between primary ALL cells (acute lymphoblastic leukemia) and normal peripheral blood samples.,CGP,C2,76,204
Cohort,0.00839428465976362,0.04225677298723999,0.1986494487475035,0.8425876950421598,LonGen OPEL,Genes whose DNA methylation differed between primary ALL cells (acute lymphoblastic leukemia) and normal peripheral blood samples.,CGP,C2,125,157
Cohort,0.01935861987937811,0.01933781079984216,1.0010760824868612,0.3171482243192844,LGP Offspring,Genes down-regulated and displaying decreased copy number in glioblastoma samples.,CGP,C2,10,27
Cohort,0.08134793006272659,0.05857842312411275,1.388701261049159,0.16529435363667505,LGP Proband,Genes down-regulated and displaying decreased copy number in glioblastoma samples.,CGP,C2,10,46
Cohort,0.03431925475302807,0.020545969299732757,1.6703643547970484,0.09524041892749993,LonGen OPEL,Genes down-regulated and displaying decreased copy number in glioblastoma samples.,CGP,C2,24,42
Cohort,-0.14724900542255995,0.05800796174645196,-2.538427501834546,0.01135842861816145,LGP Offspring,Genes up-regulated and displaying increased copy number in glioblastoma samples.,CGP,C2,103,160
Cohort,-0.3022848428454378,0.1515560452991708,-1.994541638037131,0.0464179923246889,LGP Proband,Genes up-regulated and displaying increased copy number in glioblastoma samples.,CGP,C2,103,237
Cohort,-0.011266547059912145,0.04400485235717022,-0.25602965255890364,0.7979940901396823,LonGen OPEL,Genes up-regulated and displaying increased copy number in glioblastoma samples.,CGP,C2,125,154
Cohort,7.014004572126934e-4,0.015152846886051901,0.04628836168458404,0.9630940860385391,LGP Offspring,Genes significantly mutated in 91 glioblastoma samples.,CGP,C2,6,17
Cohort,0.1486932483541543,0.04828282405347774,3.0796303088954082,0.0021405230607414623,LGP Proband,Genes significantly mutated in 91 glioblastoma samples.,CGP,C2,6,31
Cohort,0.010526685011961886,0.01566017155431544,0.672194744192382,0.5016547850906503,LonGen OPEL,Genes significantly mutated in 91 glioblastoma samples.,CGP,C2,15,23
Cohort,-0.07131836969176551,0.04037486032997753,-1.7664053598920575,0.07777912809209026,LGP Offspring,"Genes essential to the development of megakaryocytes, as expressed in normal cells and essential thrombocythemic cells (ET).",CGP,C2,64,104
Cohort,0.03879062353285026,0.11817479823105369,0.3282478507558556,0.7428066632710637,LGP Proband,"Genes essential to the development of megakaryocytes, as expressed in normal cells and essential thrombocythemic cells (ET).",CGP,C2,64,155
Cohort,0.004161343506372329,0.036040231732976484,0.11546383877894818,0.9081066018393313,LonGen OPEL,"Genes essential to the development of megakaryocytes, as expressed in normal cells and essential thrombocythemic cells (ET).",CGP,C2,87,105
Cohort,0.005263638463818522,0.014408687196462634,0.36531006552149714,0.7149942350223737,LGP Offspring,Cluster 1: genes whose up-regulation peaked one day after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,7,14
Cohort,-0.0727997777794642,0.0388322361042958,-1.874725359207701,0.06117981472598737,LGP Proband,Cluster 1: genes whose up-regulation peaked one day after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,7,18
Cohort,0.018220210197190386,0.013445098783324196,1.3551562908402508,0.17575219401107098,LonGen OPEL,Cluster 1: genes whose up-regulation peaked one day after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,9,19
Cohort,0.0027409292394400694,0.0031846529536988604,0.8606681102430889,0.3897260093137255,LGP Offspring,Cluster 3: genes whose up-regulation peaked 3 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,0,1
Cohort,-8.396440951698063e-4,0.013704227997257797,-0.06126898175787927,0.951159672515195,LGP Proband,Cluster 3: genes whose up-regulation peaked 3 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,0,3
Cohort,-0.0012109500510383514,0.0036722079497639604,-0.3297607509172208,0.7416675040949727,LonGen OPEL,Cluster 3: genes whose up-regulation peaked 3 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,1,1
Cohort,0.008378691905500552,0.022357488473609327,0.37475997876016887,0.7079565176571737,LGP Offspring,Cluster 4: genes whose up-regulation peaked 4 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,13,36
Cohort,0.00456441364019519,0.06971370495816706,0.06547369190798491,0.9478125428976905,LGP Proband,Cluster 4: genes whose up-regulation peaked 4 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,13,67
Cohort,-0.0025845748045620325,0.01951252611649113,-0.13245721179984293,0.8946561395321218,LonGen OPEL,Cluster 4: genes whose up-regulation peaked 4 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,28,31
Cohort,0.014572738690135822,0.0200254807049748,0.7277098065623769,0.46704321100899293,LGP Offspring,Cluster 5: genes whose up-regulation peaked 5 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,10,31
Cohort,-0.045454231604818957,0.05569152875101772,-0.8161785575690148,0.4146310687698491,LGP Proband,Cluster 5: genes whose up-regulation peaked 5 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,10,43
Cohort,0.019109534834204998,0.018450728736144426,1.0357062372701837,0.300653745031896,LonGen OPEL,Cluster 5: genes whose up-regulation peaked 5 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,23,29
Cohort,-0.0031175939334533035,0.025744978372894158,-0.12109522440833322,0.9036515963487055,LGP Offspring,Cluster 6:  genes exhibiting prolonged up-regulation (>72 h) after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,20,46
Cohort,0.0974901030905629,0.07067737198672838,1.3793679695514052,0.16815107671594123,LGP Proband,Cluster 6:  genes exhibiting prolonged up-regulation (>72 h) after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,20,66
Cohort,0.021963713169917933,0.02300495130124328,0.954738520517143,0.33999978861213764,LonGen OPEL,Cluster 6:  genes exhibiting prolonged up-regulation (>72 h) after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,29,48
Cohort,0.01783734235754719,0.020500697341739427,0.8700846639606914,0.384562984624481,LGP Offspring,Cluster 7: genes down-regulated early (within 24 h) after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,10,31
Cohort,0.034182146674402857,0.061264842757310346,0.5579406579040654,0.5770346409567779,LGP Proband,Cluster 7: genes down-regulated early (within 24 h) after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,10,49
Cohort,0.03324175210136193,0.01781123583956232,1.8663360813810206,0.06236188261836284,LonGen OPEL,Cluster 7: genes down-regulated early (within 24 h) after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,17,34
Cohort,-0.013848600747395974,0.015441952478630354,-0.8968166924850098,0.37013599997669255,LGP Offspring,Cluster 8: genes showing sustained pattern of down-regulation after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,9,13
Cohort,-0.015195179065228994,0.04368032803315916,-0.34787236610709144,0.7280238192785886,LGP Proband,Cluster 8: genes showing sustained pattern of down-regulation after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,9,23
Cohort,0.008588228523526153,0.01661055844707342,0.517034303867086,0.6052758406894765,LonGen OPEL,Cluster 8: genes showing sustained pattern of down-regulation after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].,CGP,C2,19,22
Cohort,0.03859705002155865,0.019705200244451077,1.958724069928062,0.05055586497996882,LGP Offspring,Genes down-regulated in Harderian gland tissue upon knockout of AOX4 [GeneID=71872].,CGP,C2,6,32
Cohort,0.07769527247033309,0.05332909380598036,1.456902169629972,0.14551977211591743,LGP Proband,Genes down-regulated in Harderian gland tissue upon knockout of AOX4 [GeneID=71872].,CGP,C2,6,40
Cohort,-0.012486604100249018,0.01753589294324543,-0.7120597816525035,0.47663639896878407,LonGen OPEL,Genes down-regulated in Harderian gland tissue upon knockout of AOX4 [GeneID=71872].,CGP,C2,23,23
Cohort,-0.04229092218339404,0.04039949836080485,-1.046818002681544,0.29555766974107417,LGP Offspring,Genes up-regulated in Harderian gland tissue upon knockout of AOX4 [GeneID=71872].,CGP,C2,60,103
Cohort,-0.24225846257931216,0.10607404565612885,-2.283861816345408,0.022630245842849055,LGP Proband,Genes up-regulated in Harderian gland tissue upon knockout of AOX4 [GeneID=71872].,CGP,C2,60,122
Cohort,-0.007078534962752745,0.031235298390460752,-0.2266197324023172,0.8207776296493801,LonGen OPEL,Genes up-regulated in Harderian gland tissue upon knockout of AOX4 [GeneID=71872].,CGP,C2,65,78
Cohort,0.012804528063844649,0.030528160891176163,0.41943332615053336,0.6750327268365368,LGP Offspring,Genes down-regulated in skin upon knockout of AOX4 [GeneID=71872].,CGP,C2,25,68
Cohort,0.1958315349311877,0.08400509565436476,2.3311863810848794,0.019980972438637678,LGP Proband,Genes down-regulated in skin upon knockout of AOX4 [GeneID=71872].,CGP,C2,25,90
Cohort,-0.021573670941747936,0.0257295465190302,-0.838478475545285,0.40201374211536045,LonGen OPEL,Genes down-regulated in skin upon knockout of AOX4 [GeneID=71872].,CGP,C2,52,53
Cohort,0.00446826490242143,0.029926913711146093,0.14930590389470239,0.8813567879154406,LGP Offspring,Genes up-regulated in skin upon knockout of AOX4 [GeneID=71872].,CGP,C2,30,64
Cohort,0.09179249630300813,0.08847732056595142,1.03746921488864,0.2998179334386671,LGP Proband,Genes up-regulated in skin upon knockout of AOX4 [GeneID=71872].,CGP,C2,30,98
Cohort,-0.016854485212375786,0.02718014777611073,-0.6201027805739007,0.5353675970232284,LonGen OPEL,Genes up-regulated in skin upon knockout of AOX4 [GeneID=71872].,CGP,C2,48,53
Cohort,0.010110185665125733,0.006422003517400705,1.574303975033918,0.11588505840677456,LGP Offspring,Genes down-regulated in mES cells (mouse embryonic stem cells) after tratment with the ALK [GeneID=238] inhibitor SB-431542 and JAK inhibitor I [PubChem=4521392;5494425].,CGP,C2,0,4
Cohort,0.02585042186781441,0.02358552436329315,1.096029135059053,0.27338241227352034,LGP Proband,Genes down-regulated in mES cells (mouse embryonic stem cells) after tratment with the ALK [GeneID=238] inhibitor SB-431542 and JAK inhibitor I [PubChem=4521392;5494425].,CGP,C2,0,9
Cohort,-0.001419178175981608,0.007739730524888,-0.18336273742581558,0.8545601062100573,LonGen OPEL,Genes down-regulated in mES cells (mouse embryonic stem cells) after tratment with the ALK [GeneID=238] inhibitor SB-431542 and JAK inhibitor I [PubChem=4521392;5494425].,CGP,C2,5,4
Cohort,-0.009403285257621678,0.006350357817364115,-1.4807488850328692,0.13913941689063497,LGP Offspring,Genes up-regulated in mES cells (mouse embryonic stem cells) after tratment with the ALK [GeneID=238] inhibitor SB-431542 and JAK inhibitor I [PubChem=4521392;5494425].,CGP,C2,3,1
Cohort,-0.004275121598901924,0.015457634289435716,-0.27657023829472344,0.7821786452705554,LGP Proband,Genes up-regulated in mES cells (mouse embryonic stem cells) after tratment with the ALK [GeneID=238] inhibitor SB-431542 and JAK inhibitor I [PubChem=4521392;5494425].,CGP,C2,3,1
Cohort,0.0049624722391530115,0.005794355035209734,0.8564322015130695,0.39201650075546157,LonGen OPEL,Genes up-regulated in mES cells (mouse embryonic stem cells) after tratment with the ALK [GeneID=238] inhibitor SB-431542 and JAK inhibitor I [PubChem=4521392;5494425].,CGP,C2,2,3
Cohort,-0.010968918898282517,0.005529994488712577,-1.9835316148454536,0.04771222852932521,LGP Offspring,Genes up-regulated in EpiSC cells (mouse epiblast embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,3,0
Cohort,-0.04178991445766814,0.013591608884213909,-3.0746848893073575,0.0021759231729417687,LGP Proband,Genes up-regulated in EpiSC cells (mouse epiblast embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,3,0
Cohort,0.005245639801322678,0.00518662596486826,1.0113780783218511,0.31214283397164894,LonGen OPEL,Genes up-regulated in EpiSC cells (mouse epiblast embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,1,3
Cohort,-0.016185831910346574,0.007759394192707634,-2.08596592831412,0.03735606181976439,LGP Offspring,Genes up-regulated in EpiSC cells (epiblast stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,5,1
Cohort,-0.041274989224331364,0.019031132865124915,-2.168814096189142,0.030378759303737724,LGP Proband,Genes up-regulated in EpiSC cells (epiblast stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,5,1
Cohort,0.004610128762772916,0.006855146756596315,0.6725062097812644,0.501456652562769,LonGen OPEL,Genes up-regulated in EpiSC cells (epiblast stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,3,4
Cohort,0.010110185665125733,0.006422003517400705,1.574303975033918,0.11588505840677456,LGP Offspring,Genes down-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=16079008].,CGP,C2,0,4
Cohort,0.043237652547054826,0.02482156902124577,1.7419387352204043,0.08188782476575655,LGP Proband,Genes down-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=16079008].,CGP,C2,0,10
Cohort,-0.001419178175981608,0.007739730524888,-0.18336273742581558,0.8545601062100573,LonGen OPEL,Genes down-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=16079008].,CGP,C2,5,4
Cohort,0.010110185665125733,0.006422003517400705,1.574303975033918,0.11588505840677456,LGP Offspring,Genes down-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,0,4
Cohort,0.043237652547054826,0.02482156902124577,1.7419387352204043,0.08188782476575655,LGP Proband,Genes down-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,0,10
Cohort,-0.001419178175981608,0.007739730524888,-0.18336273742581558,0.8545601062100573,LonGen OPEL,Genes down-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,5,4
Cohort,-0.005216913012064041,0.005546929557222984,-0.940504644640888,0.3472947151867193,LGP Offspring,Genes up-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,2,1
Cohort,5.149252333367377e-4,0.013547717026412177,0.038008266066737045,0.9696901872061048,LGP Proband,Genes up-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,2,1
Cohort,0.0020091706459669286,0.005169243890437462,0.3886778586097815,0.6976184019179719,LonGen OPEL,Genes up-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].,CGP,C2,2,2
Cohort,-0.012256284083838822,0.006293969319145933,-1.9473059785270692,0.05191176605016041,LGP Offspring,Genes down-regulated in mES cells (mouse embryonic stem cells) after tratment with JAK inhibitor I [PubChem=5494425].,CGP,C2,3,1
Cohort,-0.021575557969435,0.024781992199883543,-0.8706143475235373,0.3842152800925982,LGP Proband,Genes down-regulated in mES cells (mouse embryonic stem cells) after tratment with JAK inhibitor I [PubChem=5494425].,CGP,C2,3,8
Cohort,0.008204710585634123,0.00731623871313383,1.1214383383780717,0.26243951366048446,LonGen OPEL,Genes down-regulated in mES cells (mouse embryonic stem cells) after tratment with JAK inhibitor I [PubChem=5494425].,CGP,C2,3,5
Cohort,-0.05076906865200739,0.08343954771285042,-0.6084533059398225,0.543091250515525,LGP Offspring,Genes down-regulated in polymorphonuclear neutrophilic granulocytes (PMNs) attracted to skin wounds.,CGP,C2,212,429
Cohort,0.28116960280355047,0.22921151315209817,1.22668184916599,0.22028838525413727,LGP Proband,Genes down-regulated in polymorphonuclear neutrophilic granulocytes (PMNs) attracted to skin wounds.,CGP,C2,212,573
Cohort,0.005038134526995104,0.06980583597180856,0.0721735433270906,0.9424819297820134,LonGen OPEL,Genes down-regulated in polymorphonuclear neutrophilic granulocytes (PMNs) attracted to skin wounds.,CGP,C2,310,382
Cohort,-0.05290928516456804,0.04403320576934066,-1.2015769517605188,0.2299482614663803,LGP Offspring,Genes up-regulated in polymorphonuclear neutrophilic granulocytes (PMNs) attracted to skin wounds.,CGP,C2,65,118
Cohort,0.21573032633350453,0.11704017116414392,1.8432160871582444,0.0656521393948522,LGP Proband,Genes up-regulated in polymorphonuclear neutrophilic granulocytes (PMNs) attracted to skin wounds.,CGP,C2,65,153
Cohort,-0.04681411842656486,0.03851040621854677,-1.2156225556514382,0.22448914014791496,LonGen OPEL,Genes up-regulated in polymorphonuclear neutrophilic granulocytes (PMNs) attracted to skin wounds.,CGP,C2,110,118
Cohort,-0.016518228915308283,0.0330557553467442,-0.49970810656230347,0.6174432291496414,LGP Offspring,Candidate mammary tumorigenesis genes from the common insertion sites (CIS) of MMTV virus that induced breast tumors in mice.,CGP,C2,33,66
Cohort,-0.009724437933373888,0.08374192072138394,-0.11612389409753175,0.9075823071250777,LGP Proband,Candidate mammary tumorigenesis genes from the common insertion sites (CIS) of MMTV virus that induced breast tumors in mice.,CGP,C2,33,84
Cohort,-0.015354514232067077,0.028215877900395352,-0.5441799218961014,0.5864700604895469,LonGen OPEL,Candidate mammary tumorigenesis genes from the common insertion sites (CIS) of MMTV virus that induced breast tumors in mice.,CGP,C2,51,57
Cohort,-0.022177694417874982,0.020059044222793403,-1.1056206951612442,0.26928405318804316,LGP Offspring,Genes bound and repressed by ZNF217 [GeneID=7764] in MCF7 cells (breast cancer).,CGP,C2,17,21
Cohort,0.08577359138719749,0.05093428847808738,1.6840049002372626,0.09255491048343092,LGP Proband,Genes bound and repressed by ZNF217 [GeneID=7764] in MCF7 cells (breast cancer).,CGP,C2,17,24
Cohort,0.01904900013665137,0.014726328534718305,1.2935335573793616,0.1962018176698154,LonGen OPEL,Genes bound and repressed by ZNF217 [GeneID=7764] in MCF7 cells (breast cancer).,CGP,C2,10,19
Cohort,-0.08291145106426907,0.03531436849958606,-2.3478106670728356,0.019171475613112672,LGP Offspring,Genes bound and activated by ZNF217 [GeneID=7764] in MCF7 cells (breast cancer).,CGP,C2,49,68
Cohort,0.008645665019225937,0.10457780546487934,0.0826720830561838,0.9341321206059966,LGP Proband,Genes bound and activated by ZNF217 [GeneID=7764] in MCF7 cells (breast cancer).,CGP,C2,49,122
Cohort,0.01584777076289179,0.032908459387386915,0.4815713363040595,0.6302428549285265,LonGen OPEL,Genes bound and activated by ZNF217 [GeneID=7764] in MCF7 cells (breast cancer).,CGP,C2,71,96
Cohort,-1.048157547461637e-4,0.013833421852618513,-0.007576994026703757,0.9939567267315492,LGP Offspring,Genes down-regulated in a mouse model of heart disease whose expression reverted to normal by silencing of MIR21 [GeneID=406991] microRNA.,CGP,C2,6,13
Cohort,0.03815361617119418,0.04678157470200567,0.8155693008247201,0.41497936639141697,LGP Proband,Genes down-regulated in a mouse model of heart disease whose expression reverted to normal by silencing of MIR21 [GeneID=406991] microRNA.,CGP,C2,6,27
Cohort,0.020462473085790387,0.013536174348316445,1.5116880559635668,0.13101012006916388,LonGen OPEL,Genes down-regulated in a mouse model of heart disease whose expression reverted to normal by silencing of MIR21 [GeneID=406991] microRNA.,CGP,C2,6,16
Cohort,-0.0010936047108776313,0.022431767367449413,-0.04875249876496819,0.9611309376884463,LGP Offspring,Genes up-regulated in a mouse model of heart disease whose expression reverted to normal by silencing of MIR21 [GeneID=406991] microRNA.,CGP,C2,17,31
Cohort,0.043299989275005966,0.06102037380319999,0.709598886015596,0.47815124553345534,LGP Proband,Genes up-regulated in a mouse model of heart disease whose expression reverted to normal by silencing of MIR21 [GeneID=406991] microRNA.,CGP,C2,17,40
Cohort,0.013933174389616654,0.016638276760484412,0.8374169146355154,0.4026096141566494,LonGen OPEL,Genes up-regulated in a mouse model of heart disease whose expression reverted to normal by silencing of MIR21 [GeneID=406991] microRNA.,CGP,C2,15,26
Cohort,-0.056678132894134266,0.09318698103109715,-0.6082194343780745,0.5432462390773611,LGP Offspring,Genes down-regulated in samples with systolic heart failure compared to normal hearts.,CGP,C2,279,559
Cohort,0.14040306148014656,0.260476023676125,0.539024895645379,0.5900135303731632,LGP Proband,Genes down-regulated in samples with systolic heart failure compared to normal hearts.,CGP,C2,279,774
Cohort,-0.006412554200030977,0.08021151593117405,-0.07994555551765542,0.9363006519381849,LonGen OPEL,Genes down-regulated in samples with systolic heart failure compared to normal hearts.,CGP,C2,428,529
Cohort,-0.12602261634309175,0.09625353532028512,-1.3092777935246696,0.1908851098624274,LGP Offspring,Genes up-regulated in samples with systolic heart failure compared to normal hearts.,CGP,C2,315,590
Cohort,-0.1492529948316222,0.2749937188813061,-0.5427505596811226,0.5874465658073931,LGP Proband,Genes up-regulated in samples with systolic heart failure compared to normal hearts.,CGP,C2,315,853
Cohort,0.03228576176667768,0.0861900493298068,0.3745880414006494,0.7080666382296243,LonGen OPEL,Genes up-regulated in samples with systolic heart failure compared to normal hearts.,CGP,C2,489,592
Cohort,-0.01010454341888612,0.018636415469027893,-0.5421935047369488,0.5878638885673378,LGP Offspring,Genes up-regulated in both AGS and HGC-27 cells (gastric cancer) by BHLHA15 [GeneID=168620] transfection.,CGP,C2,10,21
Cohort,0.03580998294122527,0.04907488704876967,0.729700771509428,0.46577800098002653,LGP Proband,Genes up-regulated in both AGS and HGC-27 cells (gastric cancer) by BHLHA15 [GeneID=168620] transfection.,CGP,C2,10,27
Cohort,0.040894454629324666,0.014275770307886893,2.8646058144219246,0.0042851885311796165,LonGen OPEL,Genes up-regulated in both AGS and HGC-27 cells (gastric cancer) by BHLHA15 [GeneID=168620] transfection.,CGP,C2,7,25
Cohort,0.01868032848625927,0.022340918938523704,0.8361486175954798,0.4033667542918232,LGP Offspring,Genes modulated in HeLa cells (cervical carcinoma) by TNF [GeneID=7124] not via NFKB pathway.,CGP,C2,12,34
Cohort,-0.02573594469240537,0.053618357417074304,-0.4799838326306128,0.6313647454135718,LGP Proband,Genes modulated in HeLa cells (cervical carcinoma) by TNF [GeneID=7124] not via NFKB pathway.,CGP,C2,12,32
Cohort,0.005404106568068077,0.012522719164953323,0.4315441795734161,0.6661895898784871,LonGen OPEL,Genes modulated in HeLa cells (cervical carcinoma) by TNF [GeneID=7124] not via NFKB pathway.,CGP,C2,10,14
Cohort,0.011853598401062534,0.016730235249927866,0.7085135519008103,0.47887064124493417,LGP Offspring,Genes modulated in HeLa cells (cervical carcinoma) by TNF [GeneID=7124] via NFKB pathway.,CGP,C2,7,21
Cohort,0.04178200273833651,0.044778376864723524,0.9330843515065513,0.35104646805198236,LGP Proband,Genes modulated in HeLa cells (cervical carcinoma) by TNF [GeneID=7124] via NFKB pathway.,CGP,C2,7,27
Cohort,0.003877784170171102,0.01924815114070578,0.2014626829259672,0.8403882761531325,LonGen OPEL,Genes modulated in HeLa cells (cervical carcinoma) by TNF [GeneID=7124] via NFKB pathway.,CGP,C2,21,32
Cohort,-0.009551680352489177,0.07578233914385787,-0.12604098079312634,0.8997369617651991,LGP Offspring,Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 24h.,CGP,C2,157,345
Cohort,0.09843741848218976,0.1939128704839693,0.5076373643302214,0.6118418979841433,LGP Proband,Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 24h.,CGP,C2,157,452
Cohort,-0.10685441108047934,0.05916023720690311,-1.8061863191449652,0.07126683742187392,LonGen OPEL,Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 24h.,CGP,C2,272,290
Cohort,-0.10679987488187731,0.10693916548883725,-0.9986974780818307,0.3182986089293116,LGP Offspring,Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 24h.,CGP,C2,400,798
Cohort,-0.035286180471198955,0.3033850060451892,-0.11630825442290671,0.9074362438544736,LGP Proband,Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 24h.,CGP,C2,400,1134
Cohort,0.08839018854180658,0.09596120602887831,0.921103352069238,0.3572755418972988,LonGen OPEL,Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 24h.,CGP,C2,606,758
Cohort,0.006123052184045811,0.05854545085459366,0.10458630166250359,0.9167351072603374,LGP Offspring,Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 2h.,CGP,C2,109,230
Cohort,0.17862237235205963,0.16252622988838347,1.099037198332419,0.27206899969941856,LGP Proband,Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 2h.,CGP,C2,109,336
Cohort,-0.056658268208139365,0.051889862463716685,-1.0918947462571698,0.2752097374669387,LonGen OPEL,Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 2h.,CGP,C2,194,202
Cohort,-0.0031778549805930954,0.016888197035286844,-0.18817017435035627,0.8507997231077682,LGP Offspring,Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 2h.,CGP,C2,9,18
Cohort,0.056474897979188324,0.04775166940794761,1.1826790283857354,0.2372734268120048,LGP Proband,Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 2h.,CGP,C2,9,25
Cohort,-0.004504615239250355,0.014887067345891774,-0.3025858038113494,0.7622845855497281,LonGen OPEL,Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 2h.,CGP,C2,15,17
Cohort,0.01272187774443191,0.07621311548188847,0.16692504517093487,0.8674789445087585,LGP Offspring,Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 6h.,CGP,C2,186,409
Cohort,0.3403810162896741,0.2081698934016692,1.6351116423588694,0.1024029883823627,LGP Proband,Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 6h.,CGP,C2,186,517
Cohort,-0.07636469604624553,0.06542258946482055,-1.167252728315024,0.2434578610577277,LonGen OPEL,Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 6h.,CGP,C2,322,349
Cohort,-1.3705871581775984e-4,0.015678984557805937,-0.008741555635343987,0.9930279155900665,LGP Offspring,Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 6h.,CGP,C2,8,17
Cohort,0.015854423262117202,0.04035396455531758,0.39288390711608556,0.6945056263938656,LGP Proband,Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 6h.,CGP,C2,8,19
Cohort,0.0030415567247441366,0.012719271007192782,0.23912979942200524,0.8110664902570988,LonGen OPEL,Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 6h.,CGP,C2,12,13
Cohort,-0.006236140080582054,0.013454476322681708,-0.46349927942339153,0.6431557254682997,LGP Offspring,Genes down-regulated in SK-NEP-1 cells (Wilm's tumor ) stably expressing inactivated forms of STAT1 [GeneID=6772] under growth stress (hypoxia or nutritional deprivation).,CGP,C2,7,11
Cohort,-0.002800194033164916,0.04117574600507718,-0.06800590893531444,0.9457972308003264,LGP Proband,Genes down-regulated in SK-NEP-1 cells (Wilm's tumor ) stably expressing inactivated forms of STAT1 [GeneID=6772] under growth stress (hypoxia or nutritional deprivation).,CGP,C2,7,19
Cohort,0.011554067107482245,0.012554400150731972,0.9203201243198064,0.35768431342137397,LonGen OPEL,Genes down-regulated in SK-NEP-1 cells (Wilm's tumor ) stably expressing inactivated forms of STAT1 [GeneID=6772] under growth stress (hypoxia or nutritional deprivation).,CGP,C2,10,15
Cohort,0.03679945088795398,0.030790531768880584,1.1951547691406388,0.2324456804631182,LGP Offspring,Epigenetically silenced genes up-regulated in HCT116 cells (colon cancer) hypomorphic for DICER1 [GeneID=23405].,CGP,C2,27,73
Cohort,0.03964403000985173,0.08802488833810405,0.4503729656273894,0.6525585844914896,LGP Proband,Epigenetically silenced genes up-regulated in HCT116 cells (colon cancer) hypomorphic for DICER1 [GeneID=23405].,CGP,C2,27,102
Cohort,-0.0318973947008746,0.025701692439795584,-1.2410620341672833,0.21494845362777268,LonGen OPEL,Epigenetically silenced genes up-regulated in HCT116 cells (colon cancer) hypomorphic for DICER1 [GeneID=23405].,CGP,C2,50,53
Cohort,0.0037050120144038624,0.008422330213527084,0.4399034377034104,0.660147651634875,LGP Offspring,Metastatic signature genes that best distinguished between favorable and unfavorable prognosis for the non-small cell lung cancer (NSCLC) patients.,CGP,C2,3,5
Cohort,0.0216232654857122,0.019206476925161288,1.1258319560619061,0.26056051882873904,LGP Proband,Metastatic signature genes that best distinguished between favorable and unfavorable prognosis for the non-small cell lung cancer (NSCLC) patients.,CGP,C2,3,4
Cohort,-0.0027519754671827307,0.006344988469739596,-0.433724266057756,0.6646062028794468,LonGen OPEL,Metastatic signature genes that best distinguished between favorable and unfavorable prognosis for the non-small cell lung cancer (NSCLC) patients.,CGP,C2,3,3
Cohort,-0.013836998386561276,0.016372544620389503,-0.8451342602743258,0.3983348977104396,LGP Offspring,Down-regulated genes associated with the acquision of metastatic potential in LNM35 cells (large cell lung cancer).,CGP,C2,10,15
Cohort,0.026471800602925248,0.04607884173763882,0.5744892797794036,0.5657916725077909,LGP Proband,Down-regulated genes associated with the acquision of metastatic potential in LNM35 cells (large cell lung cancer).,CGP,C2,10,21
Cohort,0.001526060839988808,0.013504976481387617,0.11299988875152839,0.9100591348103484,LonGen OPEL,Down-regulated genes associated with the acquision of metastatic potential in LNM35 cells (large cell lung cancer).,CGP,C2,12,16
Cohort,0.01417045834088168,0.019304607935612762,0.7340453837832311,0.46317559434092637,LGP Offspring,Up-regulated genes associated with the acquision of metastatic potential in LNM35 cells (large cell lung cancer).,CGP,C2,11,25
Cohort,0.0610959786618075,0.05642094312361886,1.0828599324889978,0.2791835690403706,LGP Proband,Up-regulated genes associated with the acquision of metastatic potential in LNM35 cells (large cell lung cancer).,CGP,C2,11,36
Cohort,0.0029585039648381533,0.01740328492496066,0.1699968699929126,0.8650557934189125,LonGen OPEL,Up-regulated genes associated with the acquision of metastatic potential in LNM35 cells (large cell lung cancer).,CGP,C2,15,22
Cohort,0.010041510040610359,0.02399453199275699,0.4184915981541752,0.6757206465142764,LGP Offspring,Top genes down-regulated in hormone refractory metastatic prostate cancer compared to localized prostate cancer.,CGP,C2,16,39
Cohort,-0.062243531085685734,0.061266812010232645,-1.0159420580801555,0.3099516103965874,LGP Proband,Top genes down-regulated in hormone refractory metastatic prostate cancer compared to localized prostate cancer.,CGP,C2,16,50
Cohort,-4.2003261280911214e-4,0.022055130303094514,-0.01904466702471389,0.9848102452817218,LonGen OPEL,Top genes down-regulated in hormone refractory metastatic prostate cancer compared to localized prostate cancer.,CGP,C2,33,40
Cohort,0.011114026189786316,0.011928221239655637,0.9317421236988369,0.35180244921141024,LGP Offspring,Top genes up-regulated in hormone refractory metastatic prostate cancer compared to localized prostate cancer.,CGP,C2,2,10
Cohort,0.03366071675804925,0.039902002437950924,0.8435846499281057,0.3991434304082567,LGP Proband,Top genes up-regulated in hormone refractory metastatic prostate cancer compared to localized prostate cancer.,CGP,C2,2,20
Cohort,0.008875867374551986,0.01063670485151346,0.8344564880249609,0.40427415163471836,LonGen OPEL,Top genes up-regulated in hormone refractory metastatic prostate cancer compared to localized prostate cancer.,CGP,C2,5,12
Cohort,0.0662976660676322,0.04705857018847005,1.408832988382549,0.15934434930185454,LGP Offspring,"Genes down-regulated in prostate cancer vs benign prostate tissue, based on a meta-analysis of five gene expression profiling studies.",CGP,C2,64,151
Cohort,-0.27263013795230967,0.12226444636869148,-2.2298398761827025,0.026023555152151434,LGP Proband,"Genes down-regulated in prostate cancer vs benign prostate tissue, based on a meta-analysis of five gene expression profiling studies.",CGP,C2,64,184
Cohort,0.02782565038842956,0.03772755487953487,0.7375418438135637,0.46101025847847976,LonGen OPEL,"Genes down-regulated in prostate cancer vs benign prostate tissue, based on a meta-analysis of five gene expression profiling studies.",CGP,C2,90,124
Cohort,0.04435411285691446,0.04003537025592321,1.1078731774774155,0.2683106176040603,LGP Offspring,"Genes up-regulated in prostate cancer vs benign prostate tissue, based on a meta-analysis of five gene expression profiling studies.",CGP,C2,49,124
Cohort,0.02501607219812084,0.1113325246721553,0.22469689133329657,0.8222701222368467,LGP Proband,"Genes up-regulated in prostate cancer vs benign prostate tissue, based on a meta-analysis of five gene expression profiling studies.",CGP,C2,49,150
Cohort,-0.048533778906800704,0.034532805885491624,-1.4054397742174594,0.16028071410352351,LonGen OPEL,"Genes up-regulated in prostate cancer vs benign prostate tissue, based on a meta-analysis of five gene expression profiling studies.",CGP,C2,87,78
Cohort,-0.0064976214608972425,0.031526440207212826,-0.20610070208341105,0.8367743047796203,LGP Offspring,"Proteins that interact with PTTG1 [GeneID=9232], based on protein array.",CGP,C2,33,64
Cohort,0.0342937730579389,0.08656562709942395,0.3961592401860751,0.6920888891251491,LGP Proband,"Proteins that interact with PTTG1 [GeneID=9232], based on protein array.",CGP,C2,33,95
Cohort,0.007831997461364044,0.028744699236485233,0.2724675390383978,0.785333210086344,LonGen OPEL,"Proteins that interact with PTTG1 [GeneID=9232], based on protein array.",CGP,C2,59,70
Cohort,0.003350865934197988,0.012926880588087383,0.2592169016619477,0.795546806917054,LGP Offspring,Genes down-regulated in erythroid lineage cells by RUNX1-RUNX1T1 [GeneID=861;862] fusion .,CGP,C2,6,11
Cohort,-0.08618732754398278,0.04267630416578482,-2.019559313504996,0.043748512664176856,LGP Proband,Genes down-regulated in erythroid lineage cells by RUNX1-RUNX1T1 [GeneID=861;862] fusion .,CGP,C2,6,25
Cohort,0.009432458022136799,0.010556275845384806,0.893540312918278,0.371837960985296,LonGen OPEL,Genes down-regulated in erythroid lineage cells by RUNX1-RUNX1T1 [GeneID=861;862] fusion .,CGP,C2,6,11
Cohort,-0.007339602787597242,0.06917641051013679,-0.10609979230595856,0.9155346522541278,LGP Offspring,Genes up-regulated in erythroid lineage cells by RUNX1-RUNX1T1 [GeneID=861;862] fusion .,CGP,C2,154,314
Cohort,-0.13328766737348283,0.181349931266408,-0.7349750090485538,0.4625613271943032,LGP Proband,Genes up-regulated in erythroid lineage cells by RUNX1-RUNX1T1 [GeneID=861;862] fusion .,CGP,C2,154,413
Cohort,-0.0734572717044909,0.05867085837159033,-1.252023129425706,0.2109291944169212,LonGen OPEL,Genes up-regulated in erythroid lineage cells by RUNX1-RUNX1T1 [GeneID=861;862] fusion .,CGP,C2,263,271
Cohort,0.010052750460855369,0.01233125341417562,0.815225356515587,0.4152304486298707,LGP Offspring,Genes down-regulated in granulocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,4,11
Cohort,0.015551455388814833,0.04263947133657017,0.36471970456812325,0.7154131081482678,LGP Proband,Genes down-regulated in granulocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,4,26
Cohort,-1.1618602338219162e-4,0.014221412612407771,-0.008169794840269431,0.9934835663759443,LonGen OPEL,Genes down-regulated in granulocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,14,15
Cohort,-0.00627831078173426,0.038510059811332355,-0.163030408482688,0.870543216217416,LGP Offspring,Genes up-regulated in granulocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,42,93
Cohort,0.1372461430498441,0.10032556876955595,1.3680076249066009,0.17167815235482328,LGP Proband,Genes up-regulated in granulocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,42,135
Cohort,-0.08704413219098014,0.031786360053792054,-2.738411445779742,0.006311614012831523,LonGen OPEL,Genes up-regulated in granulocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,89,66
Cohort,-0.01131180128986253,0.0741569739057856,-0.15253860418082676,0.878807661367484,LGP Offspring,Genes down-regulated in normal hematopoietic progenitors by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,189,387
Cohort,-0.3924855174945624,0.2142106659623923,-1.8322407791004616,0.0672719918500093,LGP Proband,Genes down-regulated in normal hematopoietic progenitors by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,189,516
Cohort,-0.06385702844767914,0.061195687253675905,-1.043489031881791,0.29703865503110344,LonGen OPEL,Genes down-regulated in normal hematopoietic progenitors by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,282,307
Cohort,-0.03533959398561307,0.07126543389175741,-0.49588688450685864,0.6201353974459962,LGP Offspring,Genes up-regulated in normal hematopoietic progenitors by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,154,315
Cohort,-0.09035263094830656,0.1859393524393298,-0.48592527489729614,0.6271477891298192,LGP Proband,Genes up-regulated in normal hematopoietic progenitors by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,154,408
Cohort,-0.05228948241737949,0.06044815069758474,-0.8650303080234474,0.38728276933743966,LonGen OPEL,Genes up-regulated in normal hematopoietic progenitors by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,244,276
Cohort,0.022930744541542248,0.030304538905317008,0.756676899562362,0.44950708591199207,LGP Offspring,Genes down-regulated in monocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,28,68
Cohort,-0.0993036712006034,0.08889405342680447,-1.1171013962409784,0.26427268541357496,LGP Proband,Genes down-regulated in monocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,28,104
Cohort,-0.027784612449738066,0.028255690256603825,-0.9833280375532266,0.3257447964107697,LonGen OPEL,Genes down-regulated in monocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,59,61
Cohort,-0.11012686794327646,0.07745843750237168,-1.4217543174674099,0.15555877107072882,LGP Offspring,Genes up-regulated in monocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,224,420
Cohort,-0.38028302175352463,0.22420852563604757,-1.6961131191363754,0.09023765044395006,LGP Proband,Genes up-regulated in monocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,224,589
Cohort,0.14254905140903606,0.07282607394327846,1.9573903094111904,0.05065069508235781,LonGen OPEL,Genes up-regulated in monocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.,CGP,C2,328,436
Cohort,0.04482388546832431,0.0348755851438019,1.2852511372498197,0.19914469294519174,LGP Offspring,Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing erythroid lineage.,CGP,C2,34,89
Cohort,-0.039176824354273374,0.08969166089892527,-0.4367945019818761,0.6623734496151531,LGP Proband,Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing erythroid lineage.,CGP,C2,34,98
Cohort,-0.0031044761694884555,0.02797295896235494,-0.11098132927826312,0.9116591286153158,LonGen OPEL,Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing erythroid lineage.,CGP,C2,57,62
Cohort,0.010712944802455323,0.009541081305659288,1.1228229232362736,0.261911327114992,LGP Offspring,Genes down-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing granulocytes.,CGP,C2,2,7
Cohort,-0.04413145714602782,0.028361455017083766,-1.5560364275896585,0.12007880194897005,LGP Proband,Genes down-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing granulocytes.,CGP,C2,2,11
Cohort,0.0019864844696221543,0.010268552427783776,0.1934532139357144,0.8466533954971679,LonGen OPEL,Genes down-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing granulocytes.,CGP,C2,8,8
Cohort,0.001516046687232315,0.015068381979964325,0.10061111333971534,0.9198890057524249,LGP Offspring,Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing granulocytes.,CGP,C2,7,16
Cohort,-0.005128122008407785,0.04346297155483706,-0.11798829727823955,0.9061053403437869,LGP Proband,Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing granulocytes.,CGP,C2,7,22
Cohort,-0.005687990403240865,0.013051092044327849,-0.43582486307825324,0.6630819657153251,LonGen OPEL,Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing granulocytes.,CGP,C2,13,13
Cohort,0,0,NA,NA,LGP Offspring,Genes down-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing monocytes.,CGP,C2,0,0
Cohort,-0.00833122583776399,0.013694162212821877,-0.6083779137626574,0.5431025044320628,LGP Proband,Genes down-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing monocytes.,CGP,C2,0,3
Cohort,0.004532760126036865,0.005177848428596555,0.8754138303861978,0.3816128495202994,LonGen OPEL,Genes down-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing monocytes.,CGP,C2,1,3
Cohort,0.01715461335837931,0.01506588240080664,1.1386398023033046,0.2552567711755828,LGP Offspring,Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing monocytes.,CGP,C2,5,18
Cohort,0.024432223098183024,0.04449332843964662,0.5491210470199893,0.5830693682555396,LGP Proband,Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing monocytes.,CGP,C2,5,28
Cohort,0.016453182488072992,0.013172936311345019,1.2490140466179058,0.21202711439406802,LonGen OPEL,Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing monocytes.,CGP,C2,9,18
Cohort,0.029875602835796992,0.06092072653442728,0.4904012892708003,0.6240090968300979,LGP Offspring,"Down-regulated genes in Calu3 cells (non-small cell lung cancer, NSCLC) resistant to gemcitabine [PubChem=3461] which became up-regulated in response to bexarotene [PubChem=82146].",CGP,C2,104,239
Cohort,-0.05332522601671266,0.16869312719012533,-0.3161078753173658,0.7519997233374848,LGP Proband,"Down-regulated genes in Calu3 cells (non-small cell lung cancer, NSCLC) resistant to gemcitabine [PubChem=3461] which became up-regulated in response to bexarotene [PubChem=82146].",CGP,C2,104,335
Cohort,0.05864265884063773,0.05389527665557245,1.0880853106182995,0.2768867832254476,LonGen OPEL,"Down-regulated genes in Calu3 cells (non-small cell lung cancer, NSCLC) resistant to gemcitabine [PubChem=3461] which became up-regulated in response to bexarotene [PubChem=82146].",CGP,C2,175,233
Cohort,0.07076531188198326,0.046939608411026124,1.5075820672027693,0.13212869627197613,LGP Offspring,"Up-regulated genes in Calu3 cells (non-small cell lung cancer, NSCLC) resistant to gemcitabine [PubChem=3461] which became down-regulated in response to bexarotene [PubChem=82146].",CGP,C2,60,168
Cohort,0.23634521329199626,0.11710869348060518,2.018169670137583,0.043893309349050176,LGP Proband,"Up-regulated genes in Calu3 cells (non-small cell lung cancer, NSCLC) resistant to gemcitabine [PubChem=3461] which became down-regulated in response to bexarotene [PubChem=82146].",CGP,C2,60,176
Cohort,-0.014237778254412555,0.03528219316212839,-0.4035400574161378,0.6866593492586412,LonGen OPEL,"Up-regulated genes in Calu3 cells (non-small cell lung cancer, NSCLC) resistant to gemcitabine [PubChem=3461] which became down-regulated in response to bexarotene [PubChem=82146].",CGP,C2,98,105
Cohort,0.19341217088824858,0.09138973702970225,2.1163445390524362,0.03468038231417812,LGP Offspring,"Genes down-regulated in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,262,614
Cohort,-0.2465924607544426,0.2623135685230005,-0.9400675006745624,0.34745512489300956,LGP Proband,"Genes down-regulated in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,262,852
Cohort,0.11035296295036684,0.07799480276567225,1.4148758511757702,0.1574959633388762,LonGen OPEL,"Genes down-regulated in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,399,532
Cohort,0.04133768564910633,0.026033392409744123,1.5878716457112179,0.11278295431752923,LGP Offspring,"Top 20 down-regulated genes in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,13,45
Cohort,0.03809324557119657,0.06425010205063111,0.5928900399438726,0.5534154717502459,LGP Proband,"Top 20 down-regulated genes in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,13,52
Cohort,-0.013290577114903817,0.017240997438463943,-0.7708705463439776,0.4410124126491495,LonGen OPEL,"Top 20 down-regulated genes in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,24,23
Cohort,0.012796974044440863,0.0217109613731238,0.5894245687472115,0.5557734306630941,LGP Offspring,"Top 20 up-regulated genes in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,14,33
Cohort,0.007332010847194683,0.06309567243773076,0.11620465499326692,0.9075183222539382,LGP Proband,"Top 20 up-regulated genes in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,14,48
Cohort,0.00402194203401695,0.020040023468487093,0.20069547524939021,0.84098796492169825,LonGen OPEL,"Top 20 up-regulated genes in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,24,29
Cohort,0.0013835549340757713,0.08770639643069579,0.015774846423761518,0.9874186700760323,LGP Offspring,"Genes up-regulated in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,243,512
Cohort,0.20093204044282598,0.248297978785929,0.8092375194727632,0.4186093395806483,LGP Proband,"Genes up-regulated in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,243,744
Cohort,-0.0668036034405499,0.0755103395357633,-0.8846947828768575,0.37658841869053605,LonGen OPEL,"Genes up-regulated in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.",CGP,C2,394,439
Cohort,-0.24136223200090945,0.11545229839650584,-2.090579705671882,0.03693868474566967,LGP Offspring,Genes down-regulated in HCT116 cells (colon cancer) upon expression of MIR34B or MIR34C [GeneID=407041;407042] microRNAs.,CGP,C2,473,879
Cohort,-0.8602786948887685,0.33042879774187167,-2.6035221529353847,0.00939113879418897,LGP Proband,Genes down-regulated in HCT116 cells (colon cancer) upon expression of MIR34B or MIR34C [GeneID=407041;407042] microRNAs.,CGP,C2,473,1264
Cohort,0.12259852110953812,0.104763134686458,1.1702448716951726,0.24225268474121783,LonGen OPEL,Genes down-regulated in HCT116 cells (colon cancer) upon expression of MIR34B or MIR34C [GeneID=407041;407042] microRNAs.,CGP,C2,709,875
Cohort,-0.02855634005666288,0.018775894693634096,-1.5209043575614434,0.12875142652369842,LGP Offspring,Genes down-regulated in primary fibroblasts from Rett syndrom patients who carry mutations inactivating MECP2 [GeneID=4204].,CGP,C2,16,20
Cohort,-0.07704433056129707,0.055276021953463025,-1.393811056558318,0.16374593421451825,LGP Proband,Genes down-regulated in primary fibroblasts from Rett syndrom patients who carry mutations inactivating MECP2 [GeneID=4204].,CGP,C2,16,34
Cohort,0.022868332329515323,0.015037688892084003,1.5207345020652379,0.12872358553054877,LonGen OPEL,Genes down-regulated in primary fibroblasts from Rett syndrom patients who carry mutations inactivating MECP2 [GeneID=4204].,CGP,C2,11,22
Cohort,0.011359884318430116,0.04073059376687898,0.2789029883396315,0.7804045739387525,LGP Offspring,Genes up-regulated in primary fibroblasts from Rett syndrom patients who carry mutations inactivating MECP2 [GeneID=4204].,CGP,C2,56,121
Cohort,-0.018524911059619086,0.11379693805699645,-0.16278918726565983,0.8707238566457045,LGP Proband,Genes up-regulated in primary fibroblasts from Rett syndrom patients who carry mutations inactivating MECP2 [GeneID=4204].,CGP,C2,56,153
Cohort,-0.029790801989108863,0.03496784033728888,-0.8519485819471858,0.3944988698711175,LonGen OPEL,Genes up-regulated in primary fibroblasts from Rett syndrom patients who carry mutations inactivating MECP2 [GeneID=4204].,CGP,C2,81,92
Cohort,0.02171315297308692,0.008985570950533053,2.416446666841891,0.015936709578612956,LGP Offspring,Genes down-regulated in CL1-5 cells (lung cancer) overexpressing DNAJB4 [GeneID=11080] off a plasmid vector.,CGP,C2,0,8
Cohort,0.023535600435103502,0.025944773677909604,0.9071422525124061,0.3645936005298257,LGP Proband,Genes down-regulated in CL1-5 cells (lung cancer) overexpressing DNAJB4 [GeneID=11080] off a plasmid vector.,CGP,C2,0,11
Cohort,0.020250295062920025,0.008165258165371265,2.480055700969899,0.013341982471288118,LonGen OPEL,Genes down-regulated in CL1-5 cells (lung cancer) overexpressing DNAJB4 [GeneID=11080] off a plasmid vector.,CGP,C2,1,9
Cohort,-0.0033969126643079123,0.010106746294881223,-0.3361034862454548,0.7368971261291424,LGP Offspring,Genes up-regulated in CL1-5 cells (lung cancer) overexpressing DNAJB4 [GeneID=11080] off a plasmid vector.,CGP,C2,3,7
Cohort,0.01502961395819584,0.030459546717655987,0.49342868091611713,0.6218396258167497,LGP Proband,Genes up-regulated in CL1-5 cells (lung cancer) overexpressing DNAJB4 [GeneID=11080] off a plasmid vector.,CGP,C2,3,12
Cohort,3.790197589288931e-4,0.008192425624962058,0.04626465668165874,0.9631109131193303,LonGen OPEL,Genes up-regulated in CL1-5 cells (lung cancer) overexpressing DNAJB4 [GeneID=11080] off a plasmid vector.,CGP,C2,4,6
Cohort,-0.018813796884291575,0.05831552642561136,-0.32262071591329783,0.747082258950321,LGP Offspring,"Genes up-regulated in TK6, WTK1, and NH32 cell lines (lymphoblast) in response to ionizing radiation.",CGP,C2,104,202
Cohort,0.2704649482842699,0.1627839825471935,1.6614960762853808,0.09698967299475418,LGP Proband,"Genes up-regulated in TK6, WTK1, and NH32 cell lines (lymphoblast) in response to ionizing radiation.",CGP,C2,104,324
Cohort,0.08557442335467569,0.04851799467125195,1.7637667000565573,0.07815483770923717,LonGen OPEL,"Genes up-regulated in TK6, WTK1, and NH32 cell lines (lymphoblast) in response to ionizing radiation.",CGP,C2,156,212
Cohort,0.06476561395774288,0.03473996983083266,1.8642967818659892,0.06271325711324299,LGP Offspring,Genes up-regulated in response to both single dose and fractionated radiation that were common to all three cell lines studied.,CGP,C2,31,91
Cohort,-0.031526451876544806,0.09389203285646314,-0.33577345081814,0.7371261626821486,LGP Proband,Genes up-regulated in response to both single dose and fractionated radiation that were common to all three cell lines studied.,CGP,C2,31,108
Cohort,-0.05359023205827195,0.02942276854538175,-1.8213864536783562,0.06892335530558595,LonGen OPEL,Genes up-regulated in response to both single dose and fractionated radiation that were common to all three cell lines studied.,CGP,C2,72,58
Cohort,-0.03354180967143991,0.0292720963160295,-1.1458629170016874,0.2522573440541351,LGP Offspring,Genes showing decreasing expression in brown preadipocytes with increasing ability of the cells to differentiate.,CGP,C2,35,55
Cohort,-0.07103604771883736,0.0876250788231771,-0.8106816983546964,0.4177797562555473,LGP Proband,Genes showing decreasing expression in brown preadipocytes with increasing ability of the cells to differentiate.,CGP,C2,35,92
Cohort,0.0030365457216452937,0.02867872892868236,0.10588146110647056,0.9157030795573611,LonGen OPEL,Genes showing decreasing expression in brown preadipocytes with increasing ability of the cells to differentiate.,CGP,C2,52,70
Cohort,-0.006186364787100029,0.02987012577076138,-0.20710876260037725,0.8359872887526184,LGP Offspring,Genes showing increasing expression in brown preadipocytes with decreasing ability of the cells to differentiate.,CGP,C2,28,56
Cohort,-0.13966700141093866,0.0808362430380809,-1.7277769990515683,0.08439839806516368,LGP Proband,Genes showing increasing expression in brown preadipocytes with decreasing ability of the cells to differentiate.,CGP,C2,28,77
Cohort,0.032978669648347225,0.024389356916840046,1.3521746293186,0.17670349359913853,LonGen OPEL,Genes showing increasing expression in brown preadipocytes with decreasing ability of the cells to differentiate.,CGP,C2,37,54
Cohort,-0.0993893277521983,0.061814598970571115,-1.6078617253428413,0.10833238670834536,LGP Offspring,Down-regulated in brown preadipocytes with IRS1 [GeneID=3667] knockout vs wild type controls; the knockouts have severe defects in adipocyte differentiation.,CGP,C2,149,262
Cohort,-0.20319340872124084,0.18341816365890182,-1.1078150858554803,0.26826107145635436,LGP Proband,Down-regulated in brown preadipocytes with IRS1 [GeneID=3667] knockout vs wild type controls; the knockouts have severe defects in adipocyte differentiation.,CGP,C2,149,382
Cohort,0.055808233108063966,0.05821594515626042,0.958641708182633,0.33803035022251104,LonGen OPEL,Down-regulated in brown preadipocytes with IRS1 [GeneID=3667] knockout vs wild type controls; the knockouts have severe defects in adipocyte differentiation.,CGP,C2,220,281
Cohort,0.02231523905206214,0.05520721199526894,0.4042087663107218,0.6861870553252497,LGP Offspring,Up-regulated in brown preadipocytes with IRS1 [GeneID=3667] knockout vs wild type controls; the knockouts have severe defects in adipocyte differentiation.,CGP,C2,90,199
Cohort,-0.2984256626738002,0.15566768006049925,-1.9170688646340652,0.055570573289092436,LGP Proband,Up-regulated in brown preadipocytes with IRS1 [GeneID=3667] knockout vs wild type controls; the knockouts have severe defects in adipocyte differentiation.,CGP,C2,90,291
Cohort,0.05949799696792575,0.04573336375345332,1.3009757447249453,0.19364322237440357,LonGen OPEL,Up-regulated in brown preadipocytes with IRS1 [GeneID=3667] knockout vs wild type controls; the knockouts have severe defects in adipocyte differentiation.,CGP,C2,130,182
Cohort,-0.001329049286409673,0.020693278956919803,-0.064226132995962,0.9488091562331877,LGP Offspring,Protein kinase genes most significantly up-regulated in ASPS (alveolar soft part sarcoma) tumors compared to four other types of primitive sarcomas.,CGP,C2,13,31
Cohort,0.032321989719280665,0.05650059974720292,0.5720645420384369,0.5674324074251702,LGP Proband,Protein kinase genes most significantly up-regulated in ASPS (alveolar soft part sarcoma) tumors compared to four other types of primitive sarcomas.,CGP,C2,13,42
Cohort,0.0033297454670352185,0.015761424569183398,0.21125916965307237,0.832739115113415,LonGen OPEL,Protein kinase genes most significantly up-regulated in ASPS (alveolar soft part sarcoma) tumors compared to four other types of primitive sarcomas.,CGP,C2,16,23
Cohort,0.02934394532716847,0.04138541360428876,0.7090407651290831,0.47854363370915876,LGP Offspring,Genes down-regulated in bladder cancer cells resistant to cisplatin [PubChem=2767] compared to the parental cells sensitive to the drug.,CGP,C2,45,111
Cohort,-0.2005938732008661,0.11267990226726794,-1.7802098614274007,0.07540561542192815,LGP Proband,Genes down-regulated in bladder cancer cells resistant to cisplatin [PubChem=2767] compared to the parental cells sensitive to the drug.,CGP,C2,45,168
Cohort,-1.5682806891922923e-4,0.034536247740166545,-0.004540970116357897,0.996377980267939,LonGen OPEL,Genes down-regulated in bladder cancer cells resistant to cisplatin [PubChem=2767] compared to the parental cells sensitive to the drug.,CGP,C2,77,99
Cohort,-0.018327821588356094,0.020698403101683572,-0.8854703185708728,0.3762178783254675,LGP Offspring,Genes up-regulated in bladder cancer cells resistant to cisplatin [PubChem=2767] compared to the parental cells sensitive to the drug.,CGP,C2,18,26
Cohort,-0.013561382409242293,0.054104748449922746,-0.2506505029183193,0.8021460674451052,LGP Proband,Genes up-regulated in bladder cancer cells resistant to cisplatin [PubChem=2767] compared to the parental cells sensitive to the drug.,CGP,C2,18,34
Cohort,0.0020568897537927857,0.017694363783176657,0.11624547675166616,0.907487316144033,LonGen OPEL,Genes up-regulated in bladder cancer cells resistant to cisplatin [PubChem=2767] compared to the parental cells sensitive to the drug.,CGP,C2,22,25
Cohort,-0.004357567180406919,0.02036772734957882,-0.21394469326971957,0.8306547001920016,LGP Offspring,Genes differentially expressed in E18.5 whole embryos upon knockout of FBXW8 [GeneID=26259].,CGP,C2,16,27
Cohort,-0.031931660898439795,0.05144394596845314,-0.6207078461287006,0.5349614502164785,LGP Proband,Genes differentially expressed in E18.5 whole embryos upon knockout of FBXW8 [GeneID=26259].,CGP,C2,16,28
Cohort,0.001493376840699643,0.019127213206494534,0.07807602835694724,0.9377871970552222,LonGen OPEL,Genes differentially expressed in E18.5 whole embryos upon knockout of FBXW8 [GeneID=26259].,CGP,C2,22,29
Cohort,-0.021889295188580248,0.02409209825054058,-0.9085674050033851,0.3639023115124598,LGP Offspring,"Genes down-regulated in small intestine tissue from transgenic mice expressing a mutant form of COL13A1 [GeneID=1305], compared to normal controls.",CGP,C2,22,35
Cohort,-0.033323277427610466,0.06993016030310178,-0.47652225138875304,0.6338271776592872,LGP Proband,"Genes down-regulated in small intestine tissue from transgenic mice expressing a mutant form of COL13A1 [GeneID=1305], compared to normal controls.",CGP,C2,22,54
Cohort,0.028540427180140656,0.01923250620339384,1.483968177538105,0.13821321100986253,LonGen OPEL,"Genes down-regulated in small intestine tissue from transgenic mice expressing a mutant form of COL13A1 [GeneID=1305], compared to normal controls.",CGP,C2,20,37
Cohort,-0.027508224574157608,0.014472128994965609,-1.90077248369793,0.05775689825952244,LGP Offspring,"Genes up-regulated in small intestine tissue from transgenic mice expressing a mutant form of COL13A1 [GeneID=1305], compared to normal controls.",CGP,C2,10,11
Cohort,0.04075024747898865,0.04771147558813633,0.8540974047996408,0.3932962762012554,LGP Proband,"Genes up-regulated in small intestine tissue from transgenic mice expressing a mutant form of COL13A1 [GeneID=1305], compared to normal controls.",CGP,C2,10,24
Cohort,-0.01299320355039387,0.01353780287711683,-0.9597719562275865,0.3374614323081355,LonGen OPEL,"Genes up-regulated in small intestine tissue from transgenic mice expressing a mutant form of COL13A1 [GeneID=1305], compared to normal controls.",CGP,C2,15,13
Cohort,0.0023114452792836757,0.014679896481157606,0.15745651083102208,0.8749320976587258,LGP Offspring,Genes down-regulated in ductal vs lobular carcinoma breast tumor cells.,CGP,C2,8,14
Cohort,-0.0040811575854090764,0.03825791431905459,-0.10667485821035545,0.915072582919967,LGP Proband,Genes down-regulated in ductal vs lobular carcinoma breast tumor cells.,CGP,C2,8,16
Cohort,-0.003386772338103116,0.009294360685499487,-0.3643900266735891,0.7156635584602793,LonGen OPEL,Genes down-regulated in ductal vs lobular carcinoma breast tumor cells.,CGP,C2,6,7
Cohort,-0.0676134601618089,0.025908835088159807,-2.609668089350257,0.009263613019632418,LGP Offspring,Genes up-regulated in ductal vs lobular carcinoma breast tumor cells.,CGP,C2,28,35
Cohort,0.12131004952737909,0.0692066426384647,1.752867136773307,0.07999222300161746,LGP Proband,Genes up-regulated in ductal vs lobular carcinoma breast tumor cells.,CGP,C2,28,47
Cohort,-0.015007086453375796,0.02100246750827349,-0.7145392058082729,0.47510331023283625,LonGen OPEL,Genes up-regulated in ductal vs lobular carcinoma breast tumor cells.,CGP,C2,33,31
Cohort,0.013215810306254561,0.08643252462264059,0.15290320818411848,0.8785202335456092,LGP Offspring,Genes down-regulated in ductal carcinoma vs normal ductal breast cells.,CGP,C2,237,506
Cohort,0.21785061270664646,0.24438593625403904,0.8914204149627942,0.3729607684774643,LGP Proband,Genes down-regulated in ductal carcinoma vs normal ductal breast cells.,CGP,C2,237,707
Cohort,-0.15574665353278705,0.076390601910349007,-2.038819562065622,0.04179795324629156,LonGen OPEL,Genes down-regulated in ductal carcinoma vs normal ductal breast cells.,CGP,C2,399,415
Cohort,-0.06989902921302552,0.05353008824054737,-1.3057895383792621,0.19206832436648474,LGP Offspring,Genes up-regulated in ductal carcinoma vs normal ductal breast cells.,CGP,C2,87,158
Cohort,0.041610980969147615,0.14023425034652562,0.2967248077151257,0.7667504956598714,LGP Proband,Genes up-regulated in ductal carcinoma vs normal ductal breast cells.,CGP,C2,87,218
Cohort,-0.01086286772477906,0.040679584184287444,-0.26703487615723615,0.7895114745159664,LonGen OPEL,Genes up-regulated in ductal carcinoma vs normal ductal breast cells.,CGP,C2,119,129
Cohort,0.07734450439691504,0.04780266821251781,1.617995548973588,0.10613002340618853,LGP Offspring,Genes down-regulated in ductal carcinoma vs normal lobular breast cells.,CGP,C2,68,174
Cohort,0.1492803482445363,0.12723580401826898,1.1732573971325089,0.241027567242082,LGP Proband,Genes down-regulated in ductal carcinoma vs normal lobular breast cells.,CGP,C2,68,216
Cohort,-0.03655520686013385,0.038103869369376965,-0.9593568176966372,0.337670323389601,LonGen OPEL,Genes down-regulated in ductal carcinoma vs normal lobular breast cells.,CGP,C2,111,116
Cohort,-0.10130936590284582,0.04964363101104754,-2.0407323928481533,0.04166540058653769,LGP Offspring,Genes up-regulated in ductal carcinoma vs normal lobular breast cells.,CGP,C2,92,151
Cohort,-0.09192148722038625,0.13870501973033963,-0.6627120445899753,0.5076980962095694,LGP Proband,Genes up-regulated in ductal carcinoma vs normal lobular breast cells.,CGP,C2,92,210
Cohort,-0.03050725168953626,0.04144888235131909,-0.7360210929442681,0.4619346929726983,LonGen OPEL,Genes up-regulated in ductal carcinoma vs normal lobular breast cells.,CGP,C2,122,129
Cohort,0.031425028552422934,0.04516404952688739,0.6957974070441747,0.4867948463763506,LGP Offspring,Genes down-regulated in lobular carcinoma vs normal ductal breast cells.,CGP,C2,59,136
Cohort,0.21052110411247943,0.12251320572596172,1.718354383635788,0.08610313432654856,LGP Proband,Genes down-regulated in lobular carcinoma vs normal ductal breast cells.,CGP,C2,59,195
Cohort,-0.01696000029954647,0.0401279806147404,-0.42264773955050394,0.6726664347047839,LonGen OPEL,Genes down-regulated in lobular carcinoma vs normal ductal breast cells.,CGP,C2,109,121
Cohort,-0.02628231876753075,0.05253297456046258,-0.5003013628569849,0.6170257222037867,LGP Offspring,Genes up-regulated in lobular carcinoma vs normal ductal breast cells.,CGP,C2,90,183
Cohort,0.006919613313597622,0.13973230005044412,0.04952049963465572,0.9605163576241389,LGP Proband,Genes up-regulated in lobular carcinoma vs normal ductal breast cells.,CGP,C2,90,248
Cohort,-0.08645074646081609,0.04522140375948926,-1.911721867826256,0.05627066070619532,LonGen OPEL,Genes up-regulated in lobular carcinoma vs normal ductal breast cells.,CGP,C2,153,146
Cohort,-0.04000396830892902,0.05259246106148567,-0.7606407363625847,0.44713690495870195,LGP Offspring,Genes down-regulated in lobular carcinoma vs normal lobular breast cells.,CGP,C2,84,168
Cohort,-0.06006283300310334,0.13629774372315415,-0.44067371449010945,0.6595634271975096,LGP Proband,Genes down-regulated in lobular carcinoma vs normal lobular breast cells.,CGP,C2,84,213
Cohort,-0.018044974450137724,0.04188537822729465,-0.4308179898057766,0.6667173497807002,LonGen OPEL,Genes down-regulated in lobular carcinoma vs normal lobular breast cells.,CGP,C2,120,134
Cohort,-0.031226537839058238,0.06035378778045198,-0.5173915173750241,0.605052133179351,LGP Offspring,Genes up-regulated in lobular carcinoma vs normal lobular breast cells.,CGP,C2,112,222
Cohort,0.2923504730137561,0.1690287706532539,1.7295900093451233,0.08407354859978339,LGP Proband,Genes up-regulated in lobular carcinoma vs normal lobular breast cells.,CGP,C2,112,325
Cohort,-0.007791062427807528,0.05203924408129052,-0.14971513451727136,0.881027291931018,LonGen OPEL,Genes up-regulated in lobular carcinoma vs normal lobular breast cells.,CGP,C2,177,209
Cohort,0.01003981709112086,0.008416013472386803,1.1929421363287744,0.2333105673485903,LGP Offspring,Genes down-regulated in normal ductal and normal lobular breast cells.,CGP,C2,1,6
Cohort,0.007685605687524311,0.020900460808208392,0.3677242218748539,0.7131721775743667,LGP Proband,Genes down-regulated in normal ductal and normal lobular breast cells.,CGP,C2,1,6
Cohort,0.004666567526104083,0.008186490888653314,0.5700327026042459,0.5688163646326361,LonGen OPEL,Genes down-regulated in normal ductal and normal lobular breast cells.,CGP,C2,5,6
Cohort,0.05530942295771592,0.0490824354760939,1.1268679400527086,0.26019816229314296,LGP Offspring,Genes up-regulated in normal ductal and normal lobular breast cells.,CGP,C2,66,171
Cohort,-0.016557954666335792,0.12206940773480031,-0.13564376999607042,0.892135633605885,LGP Proband,Genes up-regulated in normal ductal and normal lobular breast cells.,CGP,C2,66,188
Cohort,-0.02547916160391187,0.0399280589092716,-0.6381267284194327,0.5235747204774486,LonGen OPEL,Genes up-regulated in normal ductal and normal lobular breast cells.,CGP,C2,119,136
Cohort,0.016318440462824154,0.012270610945513466,1.329880030854593,0.18400633519811302,LGP Offspring,Examples of transcription factors whose activities are regulated by MAPK1 and MAPK3 [GeneID=5594;5595] phosphorylation.,CGP,C2,2,13
Cohort,0.1345783441841904,0.04041582353153254,3.329842928455782,9.070964031443991e-4,LGP Proband,Examples of transcription factors whose activities are regulated by MAPK1 and MAPK3 [GeneID=5594;5595] phosphorylation.,CGP,C2,2,24
Cohort,-6.660066815346364e-4,0.009258291835538689,-0.0719362376305872,0.9426707215284792,LonGen OPEL,Examples of transcription factors whose activities are regulated by MAPK1 and MAPK3 [GeneID=5594;5595] phosphorylation.,CGP,C2,5,8
Cohort,0.002763660502463338,0.0032135183639928353,0.8600108010677295,0.3900879776065487,LGP Offspring,Examples of transcription factors whose activities are regulated by MAPK11 [GeneID=5600] phosphorylation.,CGP,C2,0,1
Cohort,-0.0032844433691897276,0.015822819976796267,-0.20757635958737278,0.8356104390796735,LGP Proband,Examples of transcription factors whose activities are regulated by MAPK11 [GeneID=5600] phosphorylation.,CGP,C2,0,4
Cohort,0,0,NA,NA,LonGen OPEL,Examples of transcription factors whose activities are regulated by MAPK11 [GeneID=5600] phosphorylation.,CGP,C2,0,0
Cohort,-0.004932148795520909,0.01605627793972414,-0.30717883771297294,0.7588018561109541,LGP Offspring,Examples of transcription factors whose activities are regulated by MAPK14 [GeneID=1432] phosphorylation.,CGP,C2,9,17
Cohort,0.07770289141066336,0.0481308071753595,1.6144107271577868,0.10681661191752048,LGP Proband,Examples of transcription factors whose activities are regulated by MAPK14 [GeneID=1432] phosphorylation.,CGP,C2,9,26
Cohort,0.025520976204119705,0.013724203986313011,1.8595596676915818,0.06331659668847703,LonGen OPEL,Examples of transcription factors whose activities are regulated by MAPK14 [GeneID=1432] phosphorylation.,CGP,C2,7,20
Cohort,0.005871036231787492,0.00776727064086355,0.7558686317559241,0.44999126558479474,LGP Offspring,Examples of transcription factors whose activities are regulated by MAPK7 [GeneID=5598] phosphorylation.,CGP,C2,1,5
Cohort,0.0050357584576191175,0.0209205374373915,0.24070884759483532,0.8098399397558294,LGP Proband,Examples of transcription factors whose activities are regulated by MAPK7 [GeneID=5598] phosphorylation.,CGP,C2,1,6
Cohort,1.0813118225900838e-4,0.0044962032643190335,0.024049442585729105,0.9808191980040608,LonGen OPEL,Examples of transcription factors whose activities are regulated by MAPK7 [GeneID=5598] phosphorylation.,CGP,C2,1,2
Cohort,0.013737587834151778,0.011004819955274135,1.248324633204739,0.21234437121953018,LGP Offspring,Examples of transcription factors whose activities are regulated by MAPK8 and MAPK9 [GeneID=5599;5601].,CGP,C2,2,10
Cohort,0.08712334667716204,0.03023345110973981,2.8816871206970798,0.0040570505046757,LGP Proband,Examples of transcription factors whose activities are regulated by MAPK8 and MAPK9 [GeneID=5599;5601].,CGP,C2,2,11
Cohort,0.0011740276620016382,0.005149602778069955,0.2279841208338127,0.8197171343113404,LonGen OPEL,Examples of transcription factors whose activities are regulated by MAPK8 and MAPK9 [GeneID=5599;5601].,CGP,C2,2,2
Cohort,-0.18995153810990967,0.07984497157429417,-2.3790043926957067,0.017636134078173746,LGP Offspring,Genes down-regulated in HeLa cells after knockdown of MED1 [GeneID=5469] by RNAi.,CGP,C2,236,401
Cohort,-0.2774377553510392,0.216356621829021,-1.2823169127233298,0.2000878049377599,LGP Proband,Genes down-regulated in HeLa cells after knockdown of MED1 [GeneID=5469] by RNAi.,CGP,C2,236,561
Cohort,0.006207769100801578,0.07034914020447929,0.08824228814677561,0.9297063021894139,LonGen OPEL,Genes down-regulated in HeLa cells after knockdown of MED1 [GeneID=5469] by RNAi.,CGP,C2,341,412
Cohort,-0.02301363470445433,0.04879874030166964,-0.4716030488120391,0.6373623218838893,LGP Offspring,Genes up-regulated in HeLa cells after knockdown of MED1 [GeneID=5469] by RNAi.,CGP,C2,89,177
Cohort,-0.08976665022108539,0.1440711759817137,-0.6230715450846258,0.5334078482139997,LGP Proband,Genes up-regulated in HeLa cells after knockdown of MED1 [GeneID=5469] by RNAi.,CGP,C2,89,266
Cohort,0.08606159368098562,0.04662883467988365,1.8456732678784664,0.0653108464990785,LonGen OPEL,Genes up-regulated in HeLa cells after knockdown of MED1 [GeneID=5469] by RNAi.,CGP,C2,139,196
Cohort,-0.020137327711626563,0.04711036418115909,-0.42745005396668345,0.6691876787929096,LGP Offspring,Molecular timetable composed of 96 time-indicating genes (103 probes) in the central (suprachiasmatic nucleus (SCN)) clock.,CGP,C2,72,148
Cohort,-0.2482775603482354,0.12882576560366715,-1.9272352792535465,0.05428969568949679,LGP Proband,Molecular timetable composed of 96 time-indicating genes (103 probes) in the central (suprachiasmatic nucleus (SCN)) clock.,CGP,C2,72,202
Cohort,0.05126746051417824,0.03803172920330641,1.348018130864298,0.1780360328169206,LonGen OPEL,Molecular timetable composed of 96 time-indicating genes (103 probes) in the central (suprachiasmatic nucleus (SCN)) clock.,CGP,C2,90,124
Cohort,-0.06582763669365037,0.07048110661102272,-0.9339756405492563,0.35064994178748843,LGP Offspring,Molecular timetable composed of 162 time-indicating genes (182 probes) in the peripheral (liver) clock.,CGP,C2,159,322
Cohort,0.1396326428711223,0.1859467561147744,0.7509280924746811,0.4529077527589861,LGP Proband,Molecular timetable composed of 162 time-indicating genes (182 probes) in the peripheral (liver) clock.,CGP,C2,159,447
Cohort,0.050919929789161794,0.06090860949346479,0.836005454936962,0.40340271130933314,LonGen OPEL,Molecular timetable composed of 162 time-indicating genes (182 probes) in the peripheral (liver) clock.,CGP,C2,264,334
Cohort,-0.08684789298391454,0.0438145279622098,-1.9821711432979763,0.04786460755448103,LGP Offspring,Genes whose splicing in neocortex was most affected by knock out of NOVA2 [GeneID=4858].,CGP,C2,77,125
Cohort,-0.17255807545464882,0.12683993928422577,-1.3604395936202465,0.17405842038245872,LGP Proband,Genes whose splicing in neocortex was most affected by knock out of NOVA2 [GeneID=4858].,CGP,C2,77,198
Cohort,-0.00667374846751925,0.039873939891264046,-0.1673711824243733,0.8671205086643942,LonGen OPEL,Genes whose splicing in neocortex was most affected by knock out of NOVA2 [GeneID=4858].,CGP,C2,117,133
Cohort,-0.011124177571384486,0.016097639311880376,-0.6910440317279704,0.48977509608737535,LGP Offspring,Interferon cluster genes up-regulated in skin tumors treated with imiquimod [PubChem=57469].,CGP,C2,11,15
Cohort,-7.941566934384899e-4,0.0450716066083404,-0.017619888732600293,0.9859463044661892,LGP Proband,Interferon cluster genes up-regulated in skin tumors treated with imiquimod [PubChem=57469].,CGP,C2,11,23
Cohort,-0.001162188629818176,0.016086858467740904,-0.07224459841856143,0.9424254015752902,LonGen OPEL,Interferon cluster genes up-regulated in skin tumors treated with imiquimod [PubChem=57469].,CGP,C2,17,21
Cohort,0.01141569850546442,0.03554078183682096,0.3211999825405509,0.7481581251897129,LGP Offspring,Genes down-regulated in primary adipocytes compared to preadipocytes.,CGP,C2,39,88
Cohort,-0.024844766416941118,0.09672413646496801,-0.2568621165818266,0.7973485691158525,LGP Proband,Genes down-regulated in primary adipocytes compared to preadipocytes.,CGP,C2,39,116
Cohort,-0.0942360439275137,0.030929317191071722,-3.046819409085324,0.0023891464930755483,LonGen OPEL,Genes down-regulated in primary adipocytes compared to preadipocytes.,CGP,C2,79,58
Cohort,-0.1253819645499806,0.05137081337600972,-2.4407237555739045,0.014913520131914236,LGP Offspring,Genes up-regulated in primary adipocytes compared to preadipocytes.,CGP,C2,101,163
Cohort,-0.13225846102428768,0.1445650457984232,-0.9148716433757064,0.3605234470141202,LGP Proband,Genes up-regulated in primary adipocytes compared to preadipocytes.,CGP,C2,101,221
Cohort,0.014139137936496265,0.03884678561443762,0.36397188886694853,0.7159756554384165,LonGen OPEL,Genes up-regulated in primary adipocytes compared to preadipocytes.,CGP,C2,114,140
Cohort,0.05482638895336132,0.027587058446343793,1.9873952512913766,0.047281710279176235,LGP Offspring,Genes up-regulated in HUVEC cells (primary endothelium) after stimulation with leukotriene LTD4 [PubChem=3908] or thrombin (F2) [GeneID=2147] for 1 h.,CGP,C2,12,52
Cohort,-0.05101174905799364,0.06119598656848124,-0.8335799767017245,0.4047563811041339,LGP Proband,Genes up-regulated in HUVEC cells (primary endothelium) after stimulation with leukotriene LTD4 [PubChem=3908] or thrombin (F2) [GeneID=2147] for 1 h.,CGP,C2,12,53
Cohort,0.01520707081397354,0.021620939854198534,0.7033492029728071,0.48204382204727647,LonGen OPEL,Genes up-regulated in HUVEC cells (primary endothelium) after stimulation with leukotriene LTD4 [PubChem=3908] or thrombin (F2) [GeneID=2147] for 1 h.,CGP,C2,31,39
Cohort,0.006505596670416347,0.02366814284433054,0.27486722186885465,0.7835022346825846,LGP Offspring,"Top 40 genes from cluster 1 of acute myeloid leukemia (AML) expression profile; 57% of the samples are FAB M1 subtype,  43% have 11q23 abnormalities, and 36% have up-regulated EVI1 [GeneID=2122] expression.",CGP,C2,18,41
Cohort,0.00795748301374989,0.06462201781638312,0.12313888180279772,0.9020267902163445,LGP Proband,"Top 40 genes from cluster 1 of acute myeloid leukemia (AML) expression profile; 57% of the samples are FAB M1 subtype,  43% have 11q23 abnormalities, and 36% have up-regulated EVI1 [GeneID=2122] expression.",CGP,C2,18,53
Cohort,0.029707002683467362,0.02258868295659904,1.3151277009175422,0.18884570643648627,LonGen OPEL,"Top 40 genes from cluster 1 of acute myeloid leukemia (AML) expression profile; 57% of the samples are FAB M1 subtype,  43% have 11q23 abnormalities, and 36% have up-regulated EVI1 [GeneID=2122] expression.",CGP,C2,30,48
Cohort,-0.09218456700805373,0.0370911317443312,-2.485353308803868,0.013182980343768844,LGP Offspring,"Top 40 genes from cluster 10 of acute myeloid leukemia (AML) expression profile; 41% of the samples are FAB M1 subtype, 45% have up-regulated EVI1 [GeneID=2122] expression; indicate poor survival.",CGP,C2,49,69
Cohort,0.06930137458444298,0.10131355585075003,0.6840286475240711,0.49414708952696984,LGP Proband,"Top 40 genes from cluster 10 of acute myeloid leukemia (AML) expression profile; 41% of the samples are FAB M1 subtype, 45% have up-regulated EVI1 [GeneID=2122] expression; indicate poor survival.",CGP,C2,49,98
Cohort,-0.0189491451328349,0.029428860063465564,-0.6438966746238092,0.5198279154219895,LonGen OPEL,"Top 40 genes from cluster 10 of acute myeloid leukemia (AML) expression profile; 41% of the samples are FAB M1 subtype, 45% have up-regulated EVI1 [GeneID=2122] expression; indicate poor survival.",CGP,C2,58,65
Cohort,-0.022316977273552443,0.03979008880528035,-0.5608677422853819,0.5750735526363415,LGP Offspring,Top 40 genes from cluster 11 of acute myeloid leukemia (AML) expression profile; 67% of the samples are FAB M4 or M5.,CGP,C2,52,107
Cohort,0.1584206690311253,0.11550474432652437,1.3715511856662825,0.17057207069914365,LGP Proband,Top 40 genes from cluster 11 of acute myeloid leukemia (AML) expression profile; 67% of the samples are FAB M4 or M5.,CGP,C2,52,159
Cohort,-0.03158990493110734,0.0370970135283048,-0.8515484651346511,0.39472085780837474,LonGen OPEL,Top 40 genes from cluster 11 of acute myeloid leukemia (AML) expression profile; 67% of the samples are FAB M4 or M5.,CGP,C2,103,113
Cohort,-0.03136595627492166,0.02964901990865604,-1.0579087056353036,0.2904749480359838,LGP Offspring,"Top 40 genes from cluster 12 of acute myeloid leukemia (AML) expression profile; 89% of the samples are FAB M3 subtype, 95% bear the t(15;17) translocation, all have the PML-RARA fusion [GeneID=5371;5914]; indicate good survival.",CGP,C2,32,51
Cohort,-0.04950423896621878,0.08438503740587328,-0.5866471176414177,0.5575994833594147,LGP Proband,"Top 40 genes from cluster 12 of acute myeloid leukemia (AML) expression profile; 89% of the samples are FAB M3 subtype, 95% bear the t(15;17) translocation, all have the PML-RARA fusion [GeneID=5371;5914]; indicate good survival.",CGP,C2,32,79
Cohort,-0.018525417490271326,0.02438894201318594,-0.7595826616937921,0.4477289749214717,LonGen OPEL,"Top 40 genes from cluster 12 of acute myeloid leukemia (AML) expression profile; 89% of the samples are FAB M3 subtype, 95% bear the t(15;17) translocation, all have the PML-RARA fusion [GeneID=5371;5914]; indicate good survival.",CGP,C2,45,48
Cohort,-0.08579267139615579,0.033836172470142,-2.53553121210331,0.011451874256600514,LGP Offspring,"Top 40 genes from cluster 13 of acute myeloid leukemia (AML) expression profile; 91% of the samples are FAB M2 subtype, all bear the t(8;21) translocation producing the AML1-ETO fusion [GeneID=861;862]; indicate good survival.",CGP,C2,50,66
Cohort,-0.10668061398019146,0.09912781736365278,-1.0761925039550813,0.2821523860959955,LGP Proband,"Top 40 genes from cluster 13 of acute myeloid leukemia (AML) expression profile; 91% of the samples are FAB M2 subtype, all bear the t(8;21) translocation producing the AML1-ETO fusion [GeneID=861;862]; indicate good survival.",CGP,C2,50,106
Cohort,0.010703355648938869,0.030257399971134243,0.35374340356904227,0.723624864099986,LonGen OPEL,"Top 40 genes from cluster 13 of acute myeloid leukemia (AML) expression profile; 91% of the samples are FAB M2 subtype, all bear the t(8;21) translocation producing the AML1-ETO fusion [GeneID=861;862]; indicate good survival.",CGP,C2,60,78
Cohort,-0.004608219241813469,0.030525523099340406,-0.15096282631477798,0.8800500760134338,LGP Offspring,"Top 40 genes from cluster 15 of acute myeloid leukemia (AML) expression profile; 88% of the samples are FAB M1 or M2 subtype, 63% have mutations in CEBPA [GeneID=1050].",CGP,C2,32,69
Cohort,-0.05604479680696567,0.07927058826134471,-0.7070061927911186,0.4797601193289899,LGP Proband,"Top 40 genes from cluster 15 of acute myeloid leukemia (AML) expression profile; 88% of the samples are FAB M1 or M2 subtype, 63% have mutations in CEBPA [GeneID=1050].",CGP,C2,32,72
Cohort,0.006401061760756032,0.022054591107842705,0.2902371542258967,0.7717104066162752,LonGen OPEL,"Top 40 genes from cluster 15 of acute myeloid leukemia (AML) expression profile; 88% of the samples are FAB M1 or M2 subtype, 63% have mutations in CEBPA [GeneID=1050].",CGP,C2,33,42
Cohort,-0.06466028795327441,0.025702011612560024,-2.515767595470088,0.012107984560794314,LGP Offspring,"Top 40 genes from cluster 16 of acute myeloid leukemia (AML) expression profile; 81% of the samples are FAB M5 subtype, 45% have 11q23 abnormalities.",CGP,C2,30,37
Cohort,0.012141577120633905,0.07442951506154166,0.16312852650718876,0.8704567586280001,LGP Proband,"Top 40 genes from cluster 16 of acute myeloid leukemia (AML) expression profile; 81% of the samples are FAB M5 subtype, 45% have 11q23 abnormalities.",CGP,C2,30,68
Cohort,-0.01134115058255689,0.02338256318180335,-0.48502597830603694,0.6277913682007212,LonGen OPEL,"Top 40 genes from cluster 16 of acute myeloid leukemia (AML) expression profile; 81% of the samples are FAB M5 subtype, 45% have 11q23 abnormalities.",CGP,C2,39,44
Cohort,0.008721403526720623,0.02809986606602702,0.3103717116027423,0.7563739684125343,LGP Offspring,"Top 40 genes from cluster 2 of acute myeloid leukemia (AML) expression profile; 71% of the samples are FAB M4 or M5 subtypes, and 82% bear internal tundem duplications in FLT3 [GeneID=2322].",CGP,C2,24,53
Cohort,0.041965787443889395,0.07121234509520466,0.5893049496935513,0.5558163178592181,LGP Proband,"Top 40 genes from cluster 2 of acute myeloid leukemia (AML) expression profile; 71% of the samples are FAB M4 or M5 subtypes, and 82% bear internal tundem duplications in FLT3 [GeneID=2322].",CGP,C2,24,62
Cohort,0.013632964081302486,0.019003097491665327,0.7174074693497648,0.4733331803715837,LonGen OPEL,"Top 40 genes from cluster 2 of acute myeloid leukemia (AML) expression profile; 71% of the samples are FAB M4 or M5 subtypes, and 82% bear internal tundem duplications in FLT3 [GeneID=2322].",CGP,C2,25,33
Cohort,0.06546930054174457,0.02892363076193356,2.26352289865036,0.023919695315569128,LGP Offspring,"Top 40 genes from cluster 3 of acute myeloid leukemia (AML) expression profile; 84% of the samples are FAB M1 or M2 subtypes, 52% bear intern tandem duplication in FLT3 [GeneID=2322].",CGP,C2,22,67
Cohort,-0.17744903099071818,0.07730804468975194,-2.2953501372702685,0.02196047139771001,LGP Proband,"Top 40 genes from cluster 3 of acute myeloid leukemia (AML) expression profile; 84% of the samples are FAB M1 or M2 subtypes, 52% bear intern tandem duplication in FLT3 [GeneID=2322].",CGP,C2,22,78
Cohort,0.01777372265616575,0.0246760908821618,0.7202811312797631,0.4715633701080745,LonGen OPEL,"Top 40 genes from cluster 3 of acute myeloid leukemia (AML) expression profile; 84% of the samples are FAB M1 or M2 subtypes, 52% bear intern tandem duplication in FLT3 [GeneID=2322].",CGP,C2,38,54
Cohort,0.0053660935603374845,0.021823673276257713,0.24588406783817346,0.8058466127270573,LGP Offspring,"Top 40 genes from cluster 4 of acute myeloid leukemia (AML) expression profile; 87% of the samples are FAB M1 subtype, 53% bear mutations in CEBPA [GeneID=1050].",CGP,C2,15,35
Cohort,-0.06001969728242322,0.06491127582140375,-0.9246420829496684,0.35541956789583995,LGP Proband,"Top 40 genes from cluster 4 of acute myeloid leukemia (AML) expression profile; 87% of the samples are FAB M1 subtype, 53% bear mutations in CEBPA [GeneID=1050].",CGP,C2,15,50
Cohort,0.004836249989923647,0.018607874037541817,0.2599034140152927,0.7950054866854408,LonGen OPEL,"Top 40 genes from cluster 4 of acute myeloid leukemia (AML) expression profile; 87% of the samples are FAB M1 subtype, 53% bear mutations in CEBPA [GeneID=1050].",CGP,C2,21,25
Cohort,-0.009672414946850562,0.029617938697504637,-0.3265728599696737,0.7440920564362452,LGP Offspring,Top 40 genes from cluster 5 of acute myeloid leukemia (AML) expression profile; 96% of the samples are FAB M4 or M5 subtype.,CGP,C2,28,56
Cohort,0.006045866825372324,0.08131163994235939,0.07435426009926929,0.9407463330366466,LGP Proband,Top 40 genes from cluster 5 of acute myeloid leukemia (AML) expression profile; 96% of the samples are FAB M4 or M5 subtype.,CGP,C2,28,84
Cohort,-0.08508085700945453,0.02654110485853056,-3.205626045447341,0.0014014628854847546,LonGen OPEL,Top 40 genes from cluster 5 of acute myeloid leukemia (AML) expression profile; 96% of the samples are FAB M4 or M5 subtype.,CGP,C2,60,41
Cohort,0.009018239717386812,0.031188322931965683,0.2891543651468286,0.7725519054298455,LGP Offspring,Top 40 genes from cluster 6 of acute myeloid leukemia (AML) expression profile; all samples are FAB M1 or M2 subtypes and all samples have internal tundem duplication of FLT3 [GeneID=2322].,CGP,C2,30,75
Cohort,0.03684402841344619,0.09166156208365464,0.40195723895497876,0.6878184830344176,LGP Proband,Top 40 genes from cluster 6 of acute myeloid leukemia (AML) expression profile; all samples are FAB M1 or M2 subtypes and all samples have internal tundem duplication of FLT3 [GeneID=2322].,CGP,C2,30,112
Cohort,0.028464127291373036,0.0326592062862069,0.8715498791345216,0.38371677135570326,LonGen OPEL,Top 40 genes from cluster 6 of acute myeloid leukemia (AML) expression profile; all samples are FAB M1 or M2 subtypes and all samples have internal tundem duplication of FLT3 [GeneID=2322].,CGP,C2,61,86
Cohort,9.899284526261876e-4,0.034920331515788126,0.028348197444191578,0.977392806697907,LGP Offspring,Top 40 genes from cluster 7 of acute myeloid leukemia (AML) expression profile; 61% of the samples are FAB M1 or M2 subtype.,CGP,C2,39,79
Cohort,-0.14491619694211946,0.0898728889555956,-1.6124573119455374,0.10724077918119669,LGP Proband,Top 40 genes from cluster 7 of acute myeloid leukemia (AML) expression profile; 61% of the samples are FAB M1 or M2 subtype.,CGP,C2,39,96
Cohort,0.006424589105127024,0.026080676538688955,0.24633521663429903,0.8054862589971115,LonGen OPEL,Top 40 genes from cluster 7 of acute myeloid leukemia (AML) expression profile; 61% of the samples are FAB M1 or M2 subtype.,CGP,C2,54,62
Cohort,-0.0038110722174606385,0.030541444390398822,-0.12478362741281183,0.9007319464992465,LGP Offspring,Top 40 genes from cluster 8 of aculte myeloid leukemia (AML) expression profile; 69% of the samples are FAB M2 subtype.,CGP,C2,31,62
Cohort,-0.08437547874890736,0.0817557365586983,-1.0320435274695146,0.302350909865749,LGP Proband,Top 40 genes from cluster 8 of aculte myeloid leukemia (AML) expression profile; 69% of the samples are FAB M2 subtype.,CGP,C2,31,84
Cohort,-0.02311840682405613,0.025615305815002005,-0.9025231629487895,0.3670520401317089,LonGen OPEL,Top 40 genes from cluster 8 of aculte myeloid leukemia (AML) expression profile; 69% of the samples are FAB M2 subtype.,CGP,C2,46,49
Cohort,-0.0324451630812363,0.034923479335023995,-0.9290358148449933,0.3532021376336457,LGP Offspring,"Top 40 genes from cluster 9 of acute myeloid leukemia (AML) expression profile; 87% of the samples are FAB M4 or M5 subtype, all have inv(16) inversion producing the CBFB-MYH11 fusion [GeneID=865;4629]; indicate good survival.",CGP,C2,47,82
Cohort,-0.172671118547786,0.0985172231695299,-1.7526998122008672,0.08002097488689562,LGP Proband,"Top 40 genes from cluster 9 of acute myeloid leukemia (AML) expression profile; 87% of the samples are FAB M4 or M5 subtype, all have inv(16) inversion producing the CBFB-MYH11 fusion [GeneID=865;4629]; indicate good survival.",CGP,C2,47,129
Cohort,-0.06876329412170634,0.0315561520875166,-2.179077282014642,0.029618494911452267,LonGen OPEL,"Top 40 genes from cluster 9 of acute myeloid leukemia (AML) expression profile; 87% of the samples are FAB M4 or M5 subtype, all have inv(16) inversion producing the CBFB-MYH11 fusion [GeneID=865;4629]; indicate good survival.",CGP,C2,81,67
Cohort,0.014397833026272526,0.024620807105647027,0.584783145592747,0.5588886602146439,LGP Offspring,Genes that best predicted acute myeloid leukemia (AML) with the 11q23 rearrangements.,CGP,C2,18,49
Cohort,-0.01721715746811597,0.0660586640158199,-0.26063435772774274,0.7944388297604668,LGP Proband,Genes that best predicted acute myeloid leukemia (AML) with the 11q23 rearrangements.,CGP,C2,18,59
Cohort,0.04358949411640447,0.022208620335688455,1.962728591760278,0.05002563114628529,LonGen OPEL,Genes that best predicted acute myeloid leukemia (AML) with the 11q23 rearrangements.,CGP,C2,25,49
Cohort,-0.036887504022454054,0.030188746466698033,-1.2218958499368495,0.22217292225616844,LGP Offspring,Genes that best predicted acute myeloid leukemia (AML) with mutations in CEBPA [GeneID=1050].,CGP,C2,35,60
Cohort,-0.041777433571235256,0.07729329248415814,-0.5405052913200439,0.5889929251113637,LGP Proband,Genes that best predicted acute myeloid leukemia (AML) with mutations in CEBPA [GeneID=1050].,CGP,C2,35,62
Cohort,0.02006034523141126,0.02456370812957165,0.8166659986999723,0.41436366501161614,LonGen OPEL,Genes that best predicted acute myeloid leukemia (AML) with mutations in CEBPA [GeneID=1050].,CGP,C2,35,49
Cohort,-0.02645620229312382,0.030441679953476235,-0.8690782615662674,0.3851127779517669,LGP Offspring,Genes that best predicted acute myeloid leukemia (AML) with the up-regulated expression of EVI1 [GeneID=2122].,CGP,C2,30,56
Cohort,-0.005599928389018698,0.0858314742159511,-0.06524329728893316,0.9479959235457978,LGP Proband,Genes that best predicted acute myeloid leukemia (AML) with the up-regulated expression of EVI1 [GeneID=2122].,CGP,C2,30,79
Cohort,-0.01899725883048153,0.025455206277485504,-0.7463015079663343,0.4557056482263291,LonGen OPEL,Genes that best predicted acute myeloid leukemia (AML) with the up-regulated expression of EVI1 [GeneID=2122].,CGP,C2,48,52
Cohort,0.03731587847220262,0.03250044493161228,1.148165157453168,0.2513065252896252,LGP Offspring,Genes that best predicted acute myeloid leukemia (AML) with internal tandem duplications (IDT) in FLT3 [GeneID=2322].,CGP,C2,28,79
Cohort,0.05478716304364455,0.08564561187112289,0.6396960900470503,0.5225458737603731,LGP Proband,Genes that best predicted acute myeloid leukemia (AML) with internal tandem duplications (IDT) in FLT3 [GeneID=2322].,CGP,C2,28,93
Cohort,0.007225073220908679,0.025285694144367443,0.28573758662338766,0.7751534535326405,LonGen OPEL,Genes that best predicted acute myeloid leukemia (AML) with internal tandem duplications (IDT) in FLT3 [GeneID=2322].,CGP,C2,43,59
Cohort,-0.031796298859358654,0.023248309077258764,-1.367682215239535,0.1718660735354563,LGP Offspring,Genes that best predicted acute myeloid leukemia (AML) with the t(8;21) translocation producing the AML1-ETO fusion [GeneID=861;862].,CGP,C2,22,33
Cohort,0.012049453959008142,0.06663124775092565,0.1808378856126216,0.8565387599148727,LGP Proband,Genes that best predicted acute myeloid leukemia (AML) with the t(8;21) translocation producing the AML1-ETO fusion [GeneID=861;862].,CGP,C2,22,54
Cohort,-0.03799952832988696,0.019969995907722027,-1.9028310524186562,0.05742316117217473,LonGen OPEL,Genes that best predicted acute myeloid leukemia (AML) with the t(8;21) translocation producing the AML1-ETO fusion [GeneID=861;862].,CGP,C2,38,26
Cohort,-0.02026048364168602,0.049439420514609825,-0.40980422971783925,0.6820793917594804,LGP Offspring,Genes down-regulated in primary B lymphocytes engineered to overexpress BCL2 [GeneID=12043].,CGP,C2,72,151
Cohort,0.15336265738614177,0.13375880393757758,1.1465612196839985,0.25189185296701705,LGP Proband,Genes down-regulated in primary B lymphocytes engineered to overexpress BCL2 [GeneID=12043].,CGP,C2,72,220
Cohort,-0.001608885279353484,0.04340594722177511,-0.03706601012836249,0.9704416667351765,LonGen OPEL,Genes down-regulated in primary B lymphocytes engineered to overexpress BCL2 [GeneID=12043].,CGP,C2,127,145
Cohort,-0.029556498978265965,0.03404904327929057,-0.8680566656697495,0.3856713636335799,LGP Offspring,Genes up-regulated in primary B lymphocytes engineered to overexpress BCL2 [GeneID=12043].,CGP,C2,42,79
Cohort,-0.004448493804863647,0.10601139257201396,-0.04196241268920005,0.9665387056715193,LGP Proband,Genes up-regulated in primary B lymphocytes engineered to overexpress BCL2 [GeneID=12043].,CGP,C2,42,132
Cohort,0.07904456155397326,0.034303971035916064,2.304239397567531,0.02146585832588257,LonGen OPEL,Genes up-regulated in primary B lymphocytes engineered to overexpress BCL2 [GeneID=12043].,CGP,C2,63,104
Cohort,0.00777253974430192,0.021024559854504667,0.36968858316606307,0.7117303201757579,LGP Offspring,Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 8.5 dpc and 9.5 dpc embryos.,CGP,C2,15,27
Cohort,-0.17942057480002116,0.05796395030443097,-3.0953821100475554,0.0020312653290495137,LGP Proband,Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 8.5 dpc and 9.5 dpc embryos.,CGP,C2,15,34
Cohort,0.01577654479223357,0.017015247934508194,0.9272004059510387,0.35410353513969706,LonGen OPEL,Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 8.5 dpc and 9.5 dpc embryos.,CGP,C2,17,26
Cohort,-0.035331013783491176,0.02474819750061707,-1.4276196794780804,0.15386313232582782,LGP Offspring,Genes down-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 9.5 dpc embryos.,CGP,C2,24,36
Cohort,0.02428679968683413,0.07737810122219423,0.3138717454062828,0.7536969397984071,LGP Proband,Genes down-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 9.5 dpc embryos.,CGP,C2,24,65
Cohort,-0.004775339984043772,0.02214835551249563,-0.21560697729227016,0.8293493495908704,LonGen OPEL,Genes down-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 9.5 dpc embryos.,CGP,C2,36,40
Cohort,0.03282105118729411,0.04700657023428919,0.6982226319365163,0.4852780817778948,LGP Offspring,Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 9.5 dpc embryos.,CGP,C2,74,167
Cohort,0.05842643080718901,0.13453258339849206,0.4342920453264997,0.664188711390499,LGP Proband,Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 9.5 dpc embryos.,CGP,C2,74,241
Cohort,-0.03154130236985033,0.04203551000641526,-0.750348987440301,0.45326627754489923,LonGen OPEL,Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 9.5 dpc embryos.,CGP,C2,129,142
Cohort,-0.0017148387055330738,0.0231479851690671,-0.07408155366474967,0.9409674082914832,LGP Offspring,Genes down-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout and in normal 8.5 dpc embryos compared to normal 9.5 dpc embryos.,CGP,C2,16,36
Cohort,0.07442841309445551,0.05922037115527226,1.2568042320996042,0.2091764104522688,LGP Proband,Genes down-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout and in normal 8.5 dpc embryos compared to normal 9.5 dpc embryos.,CGP,C2,16,45
Cohort,-0.03859560881079202,0.017964377294298815,-2.14845236094216,0.03197891043148677,LonGen OPEL,Genes down-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout and in normal 8.5 dpc embryos compared to normal 9.5 dpc embryos.,CGP,C2,27,20
Cohort,-0.004955116706384584,0.014121347115181919,-0.35089546811418,0.7257760953044305,LGP Offspring,Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout and in normal 8.5 dpc embryos compared to normal 9.5 dpc embryos.,CGP,C2,7,11
Cohort,0.004878432302956719,0.04053065692578626,0.12036400771616859,0.9042237915812077,LGP Proband,Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout and in normal 8.5 dpc embryos compared to normal 9.5 dpc embryos.,CGP,C2,7,19
Cohort,0.0022557082729474406,0.012754342344817295,0.17685806229468537,0.8596648696665432,LonGen OPEL,Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout and in normal 8.5 dpc embryos compared to normal 9.5 dpc embryos.,CGP,C2,12,13
Cohort,-0.01688290504767988,0.018848314653564895,-0.8957249153566479,0.37071853821525436,LGP Offspring,Genes down-regulated in normal 9.5 days post coitus (dpc) embryos compared to normal 8.5 dpc and 9.5 dpc embryos.,CGP,C2,14,19
Cohort,-0.0095127590680195,0.04899133177866386,-0.1941722897225339,0.8460882641778305,LGP Proband,Genes down-regulated in normal 9.5 days post coitus (dpc) embryos compared to normal 8.5 dpc and 9.5 dpc embryos.,CGP,C2,14,25
Cohort,-0.009128157682141485,0.015404169122655029,-0.5925770880246072,0.55363251151525406,LonGen OPEL,Genes down-regulated in normal 9.5 days post coitus (dpc) embryos compared to normal 8.5 dpc and 9.5 dpc embryos.,CGP,C2,19,18
Cohort,0.00374014928232887,0.011501068967795014,0.325200143812887,0.7451302214523139,LGP Offspring,Genes up-regulated in normal 9.5 days post coitus (dpc) embryos compared to normal 8.5 dpc and 9.5 dpc embryos.,CGP,C2,4,9
Cohort,-0.0701427320653889,0.03107481224399305,-2.2572214279089624,0.024252201462241416,LGP Proband,Genes up-regulated in normal 9.5 days post coitus (dpc) embryos compared to normal 8.5 dpc and 9.5 dpc embryos.,CGP,C2,4,12
Cohort,-0.012365830653246836,0.01170243613638517,-1.0566885825421461,0.29097432393919864,LonGen OPEL,Genes up-regulated in normal 9.5 days post coitus (dpc) embryos compared to normal 8.5 dpc and 9.5 dpc embryos.,CGP,C2,13,8
Cohort,-0.02433168208993209,0.04667761291150499,-0.5212709170895685,0.6023487776569121,LGP Offspring,Genes down-regulated in uterine fibroids vs normal myometrium samples.,CGP,C2,74,149
Cohort,0.22957612228800425,0.12982952254054644,1.7682890439368781,0.07737812494863819,LGP Proband,Genes down-regulated in uterine fibroids vs normal myometrium samples.,CGP,C2,74,214
Cohort,0.009670582980976821,0.04023031287170966,0.24038050640608533,0.8100971822341709,LonGen OPEL,Genes down-regulated in uterine fibroids vs normal myometrium samples.,CGP,C2,106,131
Cohort,-0.04621558650756109,0.041129972279791344,-1.1236474022684546,0.26156150752537627,LGP Offspring,Genes up-regulated in uterine fibroids vs normal myometrium samples.,CGP,C2,62,106
Cohort,-0.1605124396408791,0.11751808658402936,-1.3658530725490272,0.17235329504608152,LGP Proband,Genes up-regulated in uterine fibroids vs normal myometrium samples.,CGP,C2,62,161
Cohort,-0.031620699840613366,0.03409872389478263,-0.9273279533329275,0.3540373692352583,LonGen OPEL,Genes up-regulated in uterine fibroids vs normal myometrium samples.,CGP,C2,90,90
Cohort,-0.03155678431621603,0.033071947038952484,-0.9541858626904585,0.3403306406731498,LGP Offspring,Genes down-regulated in uterine fibroids with deletions in the 7q region vs those without the deletion.,CGP,C2,42,74
Cohort,0.08499402675850017,0.09890159967683532,0.8593796969535511,0.39037800968896075,LGP Proband,Genes down-regulated in uterine fibroids with deletions in the 7q region vs those without the deletion.,CGP,C2,42,110
Cohort,0.002326546788641044,0.0310566069555149,0.07491310277306085,0.940302673445308,LonGen OPEL,Genes down-regulated in uterine fibroids with deletions in the 7q region vs those without the deletion.,CGP,C2,64,79
Cohort,0.0011858803327141792,0.04358464913907737,0.027208669936290387,0.9783013307557928,LGP Offspring,Genes up-regulated in uterine fibroids with deletions in the 7q region vs those without the deletion.,CGP,C2,61,133
Cohort,-0.14238212917533236,0.12350644594697764,-1.1528315634348203,0.2493098355021131,LGP Proband,Genes up-regulated in uterine fibroids with deletions in the 7q region vs those without the deletion.,CGP,C2,61,180
Cohort,0.0159682090095564,0.04172073082260919,0.3827403953552739,0.7020144371505419,LonGen OPEL,Genes up-regulated in uterine fibroids with deletions in the 7q region vs those without the deletion.,CGP,C2,109,133
Cohort,-0.021520950798918057,0.04641652861374395,-0.46364843390174804,0.6430488964975954,LGP Offspring,Genes down-regulated in E12.5 hearts from mice with SP3 [GeneID=6670] knockout compared to the wild type organ.,CGP,C2,70,140
Cohort,-0.10131203585389352,0.12931729446855977,-0.7834376389503337,0.43359258074845575,LGP Proband,Genes down-regulated in E12.5 hearts from mice with SP3 [GeneID=6670] knockout compared to the wild type organ.,CGP,C2,70,213
Cohort,0.00548425217108319,0.04568066737981095,0.12005630577777009,0.9044688397057322,LonGen OPEL,Genes down-regulated in E12.5 hearts from mice with SP3 [GeneID=6670] knockout compared to the wild type organ.,CGP,C2,122,171
Cohort,-0.0014712694649862172,0.01104950349288834,-0.13315254082983483,0.8941123697987279,LGP Offspring,Genes up-regulated in E12.5 hearts from mice with SP3 [GeneID=6670] knockout compared to the wild type organ.,CGP,C2,4,8
Cohort,-0.05331422396862506,0.035778593223049104,-1.490115154507507,0.13657203694342648,LGP Proband,Genes up-regulated in E12.5 hearts from mice with SP3 [GeneID=6670] knockout compared to the wild type organ.,CGP,C2,4,15
Cohort,-0.002457011680338956,0.00966733899619149,-0.2541559452199733,0.7994407216123778,LonGen OPEL,Genes up-regulated in E12.5 hearts from mice with SP3 [GeneID=6670] knockout compared to the wild type organ.,CGP,C2,6,6
Cohort,0.011439073333961294,0.08336077004714473,0.13722370039878373,0.8908948374853243,LGP Offspring,Loci bound exclusively by SIN3A [GeneID=25942] in myotubules.,CGP,C2,215,450
Cohort,-0.09478090211576372,0.22895850128981168,-0.4139654198548046,0.6790058669044569,LGP Proband,Loci bound exclusively by SIN3A [GeneID=25942] in myotubules.,CGP,C2,215,600
Cohort,-0.05436639258547288,0.070839159590204,-0.767462416267724,0.4430342122598916,LonGen OPEL,Loci bound exclusively by SIN3A [GeneID=25942] in myotubules.,CGP,C2,337,386
Cohort,-0.05471419119932529,0.04014323205069577,-1.3629742400967682,0.17334444750675346,LGP Offspring,Down-regulated genes from the optimal set of 100 markers discriminating ER(-) breast cancer tumors by  BRCA1 [GeneID=672] mutation status.,CGP,C2,66,105
Cohort,-0.16215173865240987,0.11480523789553113,-1.4124071481822322,0.15820314511681977,LGP Proband,Down-regulated genes from the optimal set of 100 markers discriminating ER(-) breast cancer tumors by  BRCA1 [GeneID=672] mutation status.,CGP,C2,66,149
Cohort,0.010930657528022806,0.03746871749438409,0.2917275599214497,0.7705709442334319,LonGen OPEL,Down-regulated genes from the optimal set of 100 markers discriminating ER(-) breast cancer tumors by  BRCA1 [GeneID=672] mutation status.,CGP,C2,96,116
Cohort,0.009627113346164649,0.03469808916304414,0.27745370360100946,0.7815165762571188,LGP Offspring,Up-regulated genes from the optimal set of 100 markers discriminating ER(-) breast cancer tumors by  BRCA1 [GeneID=672] mutation status.,CGP,C2,36,83
Cohort,-0.041578340148496304,0.0863924137702532,-0.4812730462545849,0.6304486942449499,LGP Proband,Up-regulated genes from the optimal set of 100 markers discriminating ER(-) breast cancer tumors by  BRCA1 [GeneID=672] mutation status.,CGP,C2,36,85
Cohort,0.0334919271972243,0.028370914196572658,1.1805022201670992,0.23815316082909804,LonGen OPEL,Up-regulated genes from the optimal set of 100 markers discriminating ER(-) breast cancer tumors by  BRCA1 [GeneID=672] mutation status.,CGP,C2,43,67
Cohort,0.08753542977704658,0.08514851468667935,1.0280323749527558,0.30430229347643584,LGP Offspring,Down-regulated genes from the optimal set of 550 markers discriminating breast cancer samples by ESR1 [GeneID=2099] expression: ER(+) vs ER(-) tumors.,CGP,C2,221,491
Cohort,-0.1845860523653341,0.22729309637607287,-0.8121058461886723,0.4169626303837578,LGP Proband,Down-regulated genes from the optimal set of 550 markers discriminating breast cancer samples by ESR1 [GeneID=2099] expression: ER(+) vs ER(-) tumors.,CGP,C2,221,641
Cohort,-0.015536512434234357,0.070130947151521,-0.22153575654221577,0.8247321170853176,LonGen OPEL,Down-regulated genes from the optimal set of 550 markers discriminating breast cancer samples by ESR1 [GeneID=2099] expression: ER(+) vs ER(-) tumors.,CGP,C2,353,425
Cohort,-0.20081495502856334,0.07587639755596365,-2.646606342643634,0.008319674339624933,LGP Offspring,Up-regulated genes from the optimal set of 550 markers discriminating breast cancer samples by ESR1 [GeneID=2099] expression: ER(+) vs ER(-) tumors.,CGP,C2,221,358
Cohort,-0.40930722063655106,0.21748799318568698,-1.8819761709194336,0.060187249701375414,LGP Proband,Up-regulated genes from the optimal set of 550 markers discriminating breast cancer samples by ESR1 [GeneID=2099] expression: ER(+) vs ER(-) tumors.,CGP,C2,221,546
Cohort,-0.07403293070165903,0.07008416568368885,-1.0563431836485315,0.29113194155278577,LonGen OPEL,Up-regulated genes from the optimal set of 550 markers discriminating breast cancer samples by ESR1 [GeneID=2099] expression: ER(+) vs ER(-) tumors.,CGP,C2,320,363
Cohort,-0.02765429414622662,0.056228241028515376,-0.4918221456047705,0.6230047410827919,LGP Offspring,Genes whose expression is significantly and negatively correlated with poor breast cancer clinical outcome (defined as developing distant metastases in less than 5 years).,CGP,C2,110,200
Cohort,-0.5065593474547085,0.15183183365543484,-3.336318446922584,8.865013432758181e-4,LGP Proband,Genes whose expression is significantly and negatively correlated with poor breast cancer clinical outcome (defined as developing distant metastases in less than 5 years).,CGP,C2,110,254
Cohort,-0.0026438979058716794,0.047494515422748525,-0.055667436173173955,0.9556207105987339,LonGen OPEL,Genes whose expression is significantly and negatively correlated with poor breast cancer clinical outcome (defined as developing distant metastases in less than 5 years).,CGP,C2,163,191
Cohort,-0.03525239442497874,0.03655120796930218,-0.9644659201027156,0.3351572725358626,LGP Offspring,Genes whose expression is significantly and positively correlated with poor breast cancer clinical outcome (defined as developing distant metastases in less than 5 years).,CGP,C2,50,83
Cohort,-0.09412824323763624,0.09862088894172072,-0.9544452929567552,0.3401348417145671,LGP Proband,Genes whose expression is significantly and positively correlated with poor breast cancer clinical outcome (defined as developing distant metastases in less than 5 years).,CGP,C2,50,102
Cohort,0.013019499442165936,0.030627443874656317,0.4250925900133425,0.6708840669691077,LonGen OPEL,Genes whose expression is significantly and positively correlated with poor breast cancer clinical outcome (defined as developing distant metastases in less than 5 years).,CGP,C2,59,81
Cohort,-0.05354378204170484,0.03477067784526684,-1.5399119418948424,0.12404975904605159,LGP Offspring,The optimal set of 70 prognostic markers predicting poor breast cancer clinical outcome (defined as developing metastases with 5 years).,CGP,C2,48,72
Cohort,-0.1010701654690338,0.09192273451107558,-1.0995121718975416,0.2718620079398119,LGP Proband,The optimal set of 70 prognostic markers predicting poor breast cancer clinical outcome (defined as developing metastases with 5 years).,CGP,C2,48,93
Cohort,-0.023854230678520466,0.03182414531598533,-0.7495639063255043,0.4537388591370288,LonGen OPEL,The optimal set of 70 prognostic markers predicting poor breast cancer clinical outcome (defined as developing metastases with 5 years).,CGP,C2,71,77
Cohort,-0.04383971911644909,0.044263993068912905,-0.9904149191465109,0.3223257236137693,LGP Offspring,Top genes down-regulated in liver tissue from mice with knockout of ZMPSTE24 [GeneID=10269].,CGP,C2,63,108
Cohort,-0.1816794616408445,0.12316843633408062,-1.4750488603107639,0.1405768034572478,LGP Proband,Top genes down-regulated in liver tissue from mice with knockout of ZMPSTE24 [GeneID=10269].,CGP,C2,63,163
Cohort,-0.019152257572054167,0.037876701902733276,-0.5056474457896794,0.6132441551732042,LonGen OPEL,Top genes down-regulated in liver tissue from mice with knockout of ZMPSTE24 [GeneID=10269].,CGP,C2,100,116
Cohort,-0.02811226619387869,0.024229763898186176,-1.1602369016886358,0.24636195788016552,LGP Offspring,Top genes up-regulated in liver tissue from mice with knockout of ZMPSTE24 [GeneID=10269].,CGP,C2,22,36
Cohort,-0.02821375019743008,0.06319337185442638,-0.44646692160095347,0.655375901006056,LGP Proband,Top genes up-regulated in liver tissue from mice with knockout of ZMPSTE24 [GeneID=10269].,CGP,C2,22,47
Cohort,0.03465766049636776,0.01890589788739733,1.8331665971532911,0.06715110095354591,LonGen OPEL,Top genes up-regulated in liver tissue from mice with knockout of ZMPSTE24 [GeneID=10269].,CGP,C2,18,35
Cohort,-0.09787207212453213,0.0563351776457179,-1.7373171828805174,0.08278665585851597,LGP Offspring,Angiogenic markers down-regulated in lymph endothelial cells upon infection with KSHV (Kaposi's sarcoma herpes virus).,CGP,C2,117,211
Cohort,-0.1237403604849213,0.15946215434225694,-0.7759857565910893,0.43797738891341875,LGP Proband,Angiogenic markers down-regulated in lymph endothelial cells upon infection with KSHV (Kaposi's sarcoma herpes virus).,CGP,C2,117,330
Cohort,-0.03827090008884906,0.05224853178685887,-0.732478000433969,0.46409248564625327,LonGen OPEL,Angiogenic markers down-regulated in lymph endothelial cells upon infection with KSHV (Kaposi's sarcoma herpes virus).,CGP,C2,192,211
Cohort,0.041616030150998524,0.0700661036629903,0.593953823251921,0.5527416988614068,LGP Offspring,Angiogenic markers up-regulated in lymph endothelial cells upon infection with KSHV (Kaposi's sarcoma herpes virus).,CGP,C2,161,339
Cohort,-0.5164230086926571,0.18795770655271607,-2.7475490000609106,0.006133815342366709,LGP Proband,Angiogenic markers up-regulated in lymph endothelial cells upon infection with KSHV (Kaposi's sarcoma herpes virus).,CGP,C2,161,454
Cohort,0.04825379395256296,0.058655329551126005,0.8226668287747543,0.41094385422092916,LonGen OPEL,Angiogenic markers up-regulated in lymph endothelial cells upon infection with KSHV (Kaposi's sarcoma herpes virus).,CGP,C2,243,299
Cohort,0.008920387556776424,0.0659034078929827,0.13535548224246313,0.8923711135785959,LGP Offspring,Down-regulated genes distinguishing between two subtypes of gastric cancer: advanced (AGC) and early (EGC).,CGP,C2,138,299
Cohort,0.04827265356014472,0.17734009082554086,0.27220383916253416,0.7855326640583457,LGP Proband,Down-regulated genes distinguishing between two subtypes of gastric cancer: advanced (AGC) and early (EGC).,CGP,C2,138,435
Cohort,0.06975127760574866,0.055485804176020455,1.2571013188251379,0.2090856756408062,LonGen OPEL,Down-regulated genes distinguishing between two subtypes of gastric cancer: advanced (AGC) and early (EGC).,CGP,C2,225,306
Cohort,-0.10391705479630022,0.08272522755777659,-1.2561712776640346,0.2094878249852855,LGP Offspring,Up-regulated genes distinguishing between two subtypes of gastric cancer: advanced (AGC) and early (EGC).,CGP,C2,208,387
Cohort,-0.24142955073124037,0.21270919205437253,-1.1350217092147403,0.25669231602110604,LGP Proband,Up-regulated genes distinguishing between two subtypes of gastric cancer: advanced (AGC) and early (EGC).,CGP,C2,208,506
Cohort,0.04644517799265991,0.06448324136365646,0.7202674215883473,0.47157180484705274,LonGen OPEL,Up-regulated genes distinguishing between two subtypes of gastric cancer: advanced (AGC) and early (EGC).,CGP,C2,282,343
Cohort,-0.17294141948069985,0.10601387184629865,-1.6313093415872435,0.10329081574181265,LGP Offspring,Down-regulated genes distinguishing between early gastric cancer (EGC) and normal tissue samples.,CGP,C2,358,669
Cohort,0.1412592320620874,0.286041556328933,0.4938416427144823,0.6215480506412152,LGP Proband,Down-regulated genes distinguishing between early gastric cancer (EGC) and normal tissue samples.,CGP,C2,358,939
Cohort,-0.17319520458819673,0.08709037732425495,-1.9886835940939402,0.04707813331775434,LonGen OPEL,Down-regulated genes distinguishing between early gastric cancer (EGC) and normal tissue samples.,CGP,C2,530,578
Cohort,0.0051457251193441095,0.12098405922826065,0.04253225715989301,0.9660869567531158,LGP Offspring,Up-regulated genes distinguishing between early gastric cancer (EGC) and normal tissue samples.,CGP,C2,453,947
Cohort,-0.16948172345838391,0.33341773712878114,-0.5083164588599026,0.6113658521131506,LGP Proband,Up-regulated genes distinguishing between early gastric cancer (EGC) and normal tissue samples.,CGP,C2,453,1339
Cohort,0.15071450910284542,0.09818833578247599,1.5349532905490386,0.12519265849932126,LonGen OPEL,Up-regulated genes distinguishing between early gastric cancer (EGC) and normal tissue samples.,CGP,C2,700,904
Cohort,-0.1785943033585228,0.0888557178400114,-2.0099359692314867,0.0448348018381984,LGP Offspring,Genes down-regulated in acute myeloid leukemia (AML) patients with mutated NPM1 [GeneID=4869].,CGP,C2,262,493
Cohort,-0.06282290227803176,0.24492026845618836,-0.25650348447690685,0.7976253496067922,LGP Proband,Genes down-regulated in acute myeloid leukemia (AML) patients with mutated NPM1 [GeneID=4869].,CGP,C2,262,702
Cohort,-0.1204346582350985,0.0749668166262982,-1.6065062337574338,0.10855931487491534,LonGen OPEL,Genes down-regulated in acute myeloid leukemia (AML) patients with mutated NPM1 [GeneID=4869].,CGP,C2,431,463
Cohort,-0.03131809865777922,0.06339251036528559,-0.4940346813419357,0.6214421727206497,LGP Offspring,Genes up-regulated in acute myeloid leukemia (AML) patients with mutated NPM1 [GeneID=4869].,CGP,C2,146,301
Cohort,0.21415077474104566,0.18644505397789823,1.148599923527238,0.2510503089671912,LGP Proband,Genes up-regulated in acute myeloid leukemia (AML) patients with mutated NPM1 [GeneID=4869].,CGP,C2,146,399
Cohort,-0.0215850368808319,0.05706525840921524,-0.3782518029804666,0.7053443962398678,LonGen OPEL,Genes up-regulated in acute myeloid leukemia (AML) patients with mutated NPM1 [GeneID=4869].,CGP,C2,226,264
Cohort,-0.07455459658752549,0.07638180769732952,-0.9760779279138753,0.3293750041832316,LGP Offspring,Genes correlated with classical type of glioblastoma multiforme tumors.,CGP,C2,207,397
Cohort,-0.11679779054936819,0.2024398483588822,-0.5769505929598944,0.5641285260471052,LGP Proband,Genes correlated with classical type of glioblastoma multiforme tumors.,CGP,C2,207,545
Cohort,0.01979584106560676,0.06449342692851241,0.30694354461190926,0.7589666219089564,LonGen OPEL,Genes correlated with classical type of glioblastoma multiforme tumors.,CGP,C2,304,371
Cohort,-0.03545209057560903,0.08557680323900622,-0.41427220033675943,0.6788061862129136,LGP Offspring,Genes correlated with mesenchymal type of glioblastoma multiforme tumors.,CGP,C2,251,508
Cohort,-0.27359488524031933,0.23805394936822646,-1.149297820794048,0.25076268036434585,LGP Proband,Genes correlated with mesenchymal type of glioblastoma multiforme tumors.,CGP,C2,251,717
Cohort,-0.06300325085094774,0.07250687134654372,-0.8689280020072331,0.38514842713542075,LonGen OPEL,Genes correlated with mesenchymal type of glioblastoma multiforme tumors.,CGP,C2,384,447
Cohort,-0.048544560362839315,0.0511698581671575,-0.9486944482874649,0.34311505917665175,LGP Offspring,Genes correlated with neural type of glioblastoma multiforme tumors.,CGP,C2,85,166
Cohort,0.33159686245099845,0.1505590754391715,2.2024368938488164,0.027907398215995676,LGP Proband,Genes correlated with neural type of glioblastoma multiforme tumors.,CGP,C2,85,298
Cohort,-0.014933595603407367,0.044588573553048017,-0.3349197880403269,0.7377738308994257,LonGen OPEL,Genes correlated with neural type of glioblastoma multiforme tumors.,CGP,C2,151,170
Cohort,-0.12433237290765102,0.07241728989659527,-1.7168879570774516,0.08645770516741004,LGP Offspring,Genes correlated with proneural type of glioblastoma multiforme tumors.,CGP,C2,181,321
Cohort,-0.23022840936566508,0.19662706670006896,-1.1708886941636114,0.2419779562170753,LGP Proband,Genes correlated with proneural type of glioblastoma multiforme tumors.,CGP,C2,181,477
Cohort,-0.06314398669407599,0.06360396930984889,-0.9927680202860912,0.32112470064442034,LonGen OPEL,Genes correlated with proneural type of glioblastoma multiforme tumors.,CGP,C2,285,307
Cohort,-0.007822002294540628,0.026940727004970935,-0.29034117353616185,0.7716442858210446,LGP Offspring,"Cluster 2: genes down-regulated by RB1, CDNK2A [GeneID=1029;5925], and one of the E2Fs (E2F1, E2F2, or E2F3 [GeneID=1869;1870;1871]).",CGP,C2,24,52
Cohort,0.15034886231149794,0.07768830727248792,1.9352830250781072,0.053293335228246724,LGP Proband,"Cluster 2: genes down-regulated by RB1, CDNK2A [GeneID=1029;5925], and one of the E2Fs (E2F1, E2F2, or E2F3 [GeneID=1869;1870;1871]).",CGP,C2,24,71
Cohort,-0.008748468612373111,0.022794752962304,-0.3837930872442696,0.7012343011834137,LonGen OPEL,"Cluster 2: genes down-regulated by RB1, CDNK2A [GeneID=1029;5925], and one of the E2Fs (E2F1, E2F2, or E2F3 [GeneID=1869;1870;1871]).",CGP,C2,40,44
Cohort,0.001565218871342873,0.044783703683352064,0.034950634775763954,0.972129422002374,LGP Offspring,"Cluster 1: genes up-regulated by RB1, CDNK2A [GeneID=1029;5925], and one of the E2Fs (E2F1, E2F2, or E2F3 [GeneID=1869;1870;1871]).",CGP,C2,61,128
Cohort,0.04191109587373425,0.11807381600840203,0.354956732073027,0.7227117477343472,LGP Proband,"Cluster 1: genes up-regulated by RB1, CDNK2A [GeneID=1029;5925], and one of the E2Fs (E2F1, E2F2, or E2F3 [GeneID=1869;1870;1871]).",CGP,C2,61,157
Cohort,0.029106576530934635,0.037856176480964655,0.7688725919156254,0.4421970129034152,LonGen OPEL,"Cluster 1: genes up-regulated by RB1, CDNK2A [GeneID=1029;5925], and one of the E2Fs (E2F1, E2F2, or E2F3 [GeneID=1869;1870;1871]).",CGP,C2,87,110
Cohort,-0.016220788823654624,0.014346672756984691,-1.1306307112746763,0.25861152752903277,LGP Offspring,Genes up-regulated during adipogenic differentiation of 3T3-L1 cells (preadipocyte) and down-regulated by troglitazone [PubChem=5591].,CGP,C2,9,12
Cohort,0.012718492300076644,0.036427000569414066,0.3491501386681759,0.7270647301164945,LGP Proband,Genes up-regulated during adipogenic differentiation of 3T3-L1 cells (preadipocyte) and down-regulated by troglitazone [PubChem=5591].,CGP,C2,9,13
Cohort,0.037899374965529455,0.01370150780733817,2.76607330364265,0.005805043500411403,LonGen OPEL,Genes up-regulated during adipogenic differentiation of 3T3-L1 cells (preadipocyte) and down-regulated by troglitazone [PubChem=5591].,CGP,C2,7,22
Cohort,0.015130789139331413,0.04120899776034149,0.3671719760652104,0.7136056530759197,LGP Offspring,ECM related genes up-regulated later than 30 min following addition of TGFB1 [GeneID=7040] in dermal fibroblasts.,CGP,C2,54,117
Cohort,-0.25922927344569835,0.12119640194692918,-2.1389188893512907,0.032732074711486474,LGP Proband,ECM related genes up-regulated later than 30 min following addition of TGFB1 [GeneID=7040] in dermal fibroblasts.,CGP,C2,54,169
Cohort,-0.030658726828558813,0.03989903450906996,-0.7684077373248063,0.4424728895881278,LonGen OPEL,ECM related genes up-regulated later than 30 min following addition of TGFB1 [GeneID=7040] in dermal fibroblasts.,CGP,C2,108,121
Cohort,-0.031661726349233386,0.050400400055945954,-0.6282038696932548,0.5300825676788699,LGP Offspring,ECM related genes up-regulated early (within 30 min) in dermal fibroblasts after addition of TGFB1 [GeneID=7040].,CGP,C2,83,160
Cohort,-0.26712681758153317,0.1305862532349655,-2.045596768144412,0.04110931491855923,LGP Proband,ECM related genes up-regulated early (within 30 min) in dermal fibroblasts after addition of TGFB1 [GeneID=7040].,CGP,C2,83,201
Cohort,-0.05102757766978989,0.038994829098462386,-1.308572927475709,0.19105674601980535,LonGen OPEL,ECM related genes up-regulated early (within 30 min) in dermal fibroblasts after addition of TGFB1 [GeneID=7040].,CGP,C2,123,123
Cohort,-0.04507086965403921,0.026714327834372897,-1.6871421932633186,0.09203734486853601,LGP Offspring,"Cluster 1: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition, and which kept increasing with time.",CGP,C2,29,40
Cohort,-0.1300761772559109,0.066558751586267,-1.9543061454107766,0.050998856743625746,LGP Proband,"Cluster 1: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition, and which kept increasing with time.",CGP,C2,29,43
Cohort,-0.036222293345241914,0.02171501679841743,-1.6680757690172159,0.09569397638695466,LonGen OPEL,"Cluster 1: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition, and which kept increasing with time.",CGP,C2,38,30
Cohort,0.034224105318609546,0.033354701075530235,1.0260654185180849,0.30522776027382303,LGP Offspring,Cluster 2: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition; reached a plateau after that.,CGP,C2,25,69
Cohort,-0.13169285210491655,0.08774482375941842,-1.5008617769407828,0.13376979122672436,LGP Proband,Cluster 2: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition; reached a plateau after that.,CGP,C2,25,91
Cohort,-0.06975391323531185,0.024308807319890782,-2.8694913871087135,0.004220220269693549,LonGen OPEL,Cluster 2: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition; reached a plateau after that.,CGP,C2,58,40
Cohort,-0.020814962013803794,0.027636920703873368,-0.753157786167058,0.45161731452246323,LGP Offspring,Cluster 3: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition; returned rapidly to basal level after that.,CGP,C2,29,51
Cohort,-0.005357788220705817,0.07567528896059637,-0.07079970614311869,0.943574138878533,LGP Proband,Cluster 3: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition; returned rapidly to basal level after that.,CGP,C2,29,67
Cohort,0.05494862891076382,0.023124684685872105,2.3761893257007034,0.017728166757142203,LonGen OPEL,Cluster 3: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition; returned rapidly to basal level after that.,CGP,C2,27,53
Cohort,-0.00628601807053055,0.02621033174441867,-0.23982977902861224,0.8105349229457841,LGP Offspring,Cluster 4: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; kept increasing with time.,CGP,C2,26,45
Cohort,-0.16677634596640678,0.07977652972233613,-2.090544005196457,0.0368711864113069,LGP Proband,Cluster 4: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; kept increasing with time.,CGP,C2,26,80
Cohort,-0.046681102649287036,0.024994642543418533,-1.8676443389096946,0.06217894595133099,LonGen OPEL,Cluster 4: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; kept increasing with time.,CGP,C2,49,44
Cohort,0.02156233345288165,0.024301141427662997,0.8872971468054727,0.37523450916178536,LGP Offspring,Cluster 5: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; decreased slowly after the peak at 120 min time point.,CGP,C2,15,44
Cohort,-0.0771537393904116,0.06402770753954892,-1.2050054945783424,0.22854299017846325,LGP Proband,Cluster 5: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; decreased slowly after the peak at 120 min time point.,CGP,C2,15,51
Cohort,-0.006278073786783061,0.021880876088600384,-0.2869205858742487,0.7742477960344747,LonGen OPEL,Cluster 5: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; decreased slowly after the peak at 120 min time point.,CGP,C2,35,40
Cohort,-1.4552624301968946e-4,0.020096007139397645,-0.007241550125367414,0.9942242659226384,LGP Offspring,"Cluster 6: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; slowly increased up to 120 min time point, then reached a plateau.",CGP,C2,13,28
Cohort,-0.015299188088879834,0.0535736321218221,-0.2855730978644629,0.7752760194007694,LGP Proband,"Cluster 6: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; slowly increased up to 120 min time point, then reached a plateau.",CGP,C2,13,38
Cohort,0.022300449607511336,0.020282873750568704,1.0994718934680576,0.271894697972491,LonGen OPEL,"Cluster 6: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; slowly increased up to 120 min time point, then reached a plateau.",CGP,C2,24,37
Cohort,0.01322024121607262,0.019314624198032697,0.6844679492867988,0.49391430998275876,LGP Offspring,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PRKCA and ETS1 [GeneID=5578;2113] by RNAi.,CGP,C2,10,28
Cohort,-0.029758183485495044,0.049146333226111144,-0.605501601687849,0.5450104929298814,LGP Proband,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PRKCA and ETS1 [GeneID=5578;2113] by RNAi.,CGP,C2,10,29
Cohort,-0.0275451970094344,0.018516813034957242,-1.487577638626733,0.1372583255498284,LonGen OPEL,Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PRKCA and ETS1 [GeneID=5578;2113] by RNAi.,CGP,C2,29,21
Cohort,-0.03570586565706726,0.02804094228927205,-1.2733475675932497,0.20333241712412042,LGP Offspring,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PRKCA and ETS1 [GeneID=5578;2113] by RNAi.,CGP,C2,30,47
Cohort,-0.2062296709405563,0.07829551297576733,-2.6339909287571173,0.008595158910752725,LGP Proband,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PRKCA and ETS1 [GeneID=5578;2113] by RNAi.,CGP,C2,30,63
Cohort,-0.04594359750601793,0.025188350438019105,-1.824001838432064,0.06852659628387202,LonGen OPEL,Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PRKCA and ETS1 [GeneID=5578;2113] by RNAi.,CGP,C2,48,38
Cohort,-0.023398910589409582,0.030821019320034004,-0.7591867856946584,0.4480054681740383,LGP Offspring,The metastasis gene signature: genes up-regulated during metastasis of NSCLC (non-small cell lung carcinoma) tumors to bone.,CGP,C2,31,61
Cohort,0.09700615138190051,0.08480479418204634,1.1438757952016498,0.2530033574467841,LGP Proband,The metastasis gene signature: genes up-regulated during metastasis of NSCLC (non-small cell lung carcinoma) tumors to bone.,CGP,C2,31,78
Cohort,-0.004377757467446367,0.02578115416789095,-0.16980455719467477,0.8652069878729134,LonGen OPEL,The metastasis gene signature: genes up-regulated during metastasis of NSCLC (non-small cell lung carcinoma) tumors to bone.,CGP,C2,49,53
Cohort,-0.029287694488452573,0.018627265457010857,-1.5723024163715553,0.11634832931332648,LGP Offspring,Genes down-regulated in c-JunER cells (mammary gland epithelum) by overexpression of IFRD1 [GeneID=3475] off an adenovirus vector.,CGP,C2,15,19
Cohort,-0.08811542662394568,0.05409675954380921,-1.6288485182293981,0.10372273381918722,LGP Proband,Genes down-regulated in c-JunER cells (mammary gland epithelum) by overexpression of IFRD1 [GeneID=3475] off an adenovirus vector.,CGP,C2,15,32
Cohort,0.013438249638890001,0.016513032425826857,0.8137965997009848,0.41600484811107585,LonGen OPEL,Genes down-regulated in c-JunER cells (mammary gland epithelum) by overexpression of IFRD1 [GeneID=3475] off an adenovirus vector.,CGP,C2,16,25
Cohort,0.013248276328635171,0.02857502503637056,0.46363131132072993,0.6430611598347756,LGP Offspring,Genes down-regulated in bone marrow progenitors by constitutively active NOTCH1 [GeneID=4851].,CGP,C2,22,53
Cohort,0.07483413694673935,0.08473698017618643,0.883134338645808,0.3774181798100028,LGP Proband,Genes down-regulated in bone marrow progenitors by constitutively active NOTCH1 [GeneID=4851].,CGP,C2,22,93
Cohort,-0.033152100941616316,0.026571197728112072,-1.247670552183717,0.21251864709228643,LonGen OPEL,Genes down-regulated in bone marrow progenitors by constitutively active NOTCH1 [GeneID=4851].,CGP,C2,54,52
Cohort,0.04330332838126365,0.02872556759914594,1.5074838201822383,0.1321538554729253,LGP Offspring,Genes up-regulated in bone marrow progenitors by constitutively active NOTCH1 [GeneID=4851].,CGP,C2,15,53
Cohort,0.028103413774481684,0.07821640762516344,0.35930330512188313,0.719459151813727,LGP Proband,Genes up-regulated in bone marrow progenitors by constitutively active NOTCH1 [GeneID=4851].,CGP,C2,15,71
Cohort,-0.025232364257029145,0.025338717899887356,-0.9958027220130706,0.3196486174080809,LonGen OPEL,Genes up-regulated in bone marrow progenitors by constitutively active NOTCH1 [GeneID=4851].,CGP,C2,41,40
Cohort,0.03516648541741507,0.04958301732617134,0.709244562227422,0.47841725996875706,LGP Offspring,Genes under-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma (HCC).,CGP,C2,69,164
Cohort,0.032730376606989436,0.1275894276776567,0.25652890841143833,0.7976057274084665,LGP Proband,Genes under-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma (HCC).,CGP,C2,69,213
Cohort,0.031849816178129216,0.04123083418654127,0.7724756679438166,0.44006204677132077,LonGen OPEL,Genes under-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma (HCC).,CGP,C2,112,148
Cohort,-0.1683082706687308,0.07143914924296255,-2.35596689563476,0.0187591236867148,LGP Offspring,Genes over-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma (HCC).,CGP,C2,197,341
Cohort,0.3121258642400341,0.21116033538743884,1.4781462800167597,0.1397461763621605,LGP Proband,Genes over-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma (HCC).,CGP,C2,197,529
Cohort,-0.028579859815358332,0.06769270704971378,-0.42219998373486783,0.6729930619393263,LonGen OPEL,Genes over-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma (HCC).,CGP,C2,285,334
Cohort,-0.019618827199968433,0.02229857028491279,-0.8798244438677096,0.3792670771059031,LGP Offspring,Genes down-regulated in peripheral lymphocytes from old individuals compared to those from young donors.,CGP,C2,17,30
Cohort,-0.019280103155962566,0.05705973913115775,-0.33789329305633947,0.7355286339797444,LGP Proband,Genes down-regulated in peripheral lymphocytes from old individuals compared to those from young donors.,CGP,C2,17,39
Cohort,0.04657055945120868,0.020454357977779124,2.2768037746186534,0.02306257072485865,LonGen OPEL,Genes down-regulated in peripheral lymphocytes from old individuals compared to those from young donors.,CGP,C2,20,43
Cohort,-3.547507450306144e-4,0.014510643945988956,-0.024447622472927873,0.980502777137858,LGP Offspring,Genes up-regulated in peripheral lymphocytes from old individuals compared to those from young donors.,CGP,C2,7,14
Cohort,-0.003442657441853304,0.03753918595181939,-0.0917083669920778,0.9269517721037097,LGP Proband,Genes up-regulated in peripheral lymphocytes from old individuals compared to those from young donors.,CGP,C2,7,16
Cohort,-0.007297491876562843,0.012667576203499174,-0.5760764142509797,0.5647263696089498,LonGen OPEL,Genes up-regulated in peripheral lymphocytes from old individuals compared to those from young donors.,CGP,C2,13,12
Cohort,-0.0015509827303587125,0.01457104382436924,-0.10644280183721515,0.9152626142018605,LGP Offspring,"Genes down-regulated after heat shock in peripheral lympocytes from old donors, compared to those from the young ones.",CGP,C2,7,14
Cohort,0.010812961456607062,0.039732011853256886,0.27214734296724796,0.7855760875093735,LGP Proband,"Genes down-regulated after heat shock in peripheral lympocytes from old donors, compared to those from the young ones.",CGP,C2,7,19
Cohort,-0.0015328205329990117,0.012342833621225277,-0.12418708540015531,0.9011984999401171,LonGen OPEL,"Genes down-regulated after heat shock in peripheral lympocytes from old donors, compared to those from the young ones.",CGP,C2,11,12
Cohort,0.006672013090589978,0.01688305010187841,0.3951900308492036,0.6928273184446886,LGP Offspring,"Genes up-regulated after heat shock in peripheral lympocytes from old donors, compared to those from the young ones.",CGP,C2,9,20
Cohort,0.023134573722793116,0.04597538408692046,0.5031947896086131,0.6149601921327965,LGP Proband,"Genes up-regulated after heat shock in peripheral lympocytes from old donors, compared to those from the young ones.",CGP,C2,9,26
Cohort,-9.452276938322547e-5,0.017778183596506434,-0.005316784409955132,0.9957591719448553,LonGen OPEL,"Genes up-regulated after heat shock in peripheral lympocytes from old donors, compared to those from the young ones.",CGP,C2,22,28
Cohort,-0.005224880249578557,0.01721848315555006,-0.30344602380926994,0.7616433418879782,LGP Offspring,Genes down-regulated by VHL [GeneID=7428] and re-expressed under hypoxia conditions in renal carcinoma cells.,CGP,C2,11,19
Cohort,-0.05544223841409183,0.04710977609966093,-1.176873315992917,0.23958184421612774,LGP Proband,Genes down-regulated by VHL [GeneID=7428] and re-expressed under hypoxia conditions in renal carcinoma cells.,CGP,C2,11,24
Cohort,3.12533402521426e-4,0.014655257937886901,0.02132568419102757,0.9829911998914738,LonGen OPEL,Genes down-regulated by VHL [GeneID=7428] and re-expressed under hypoxia conditions in renal carcinoma cells.,CGP,C2,16,17
Cohort,-0.0011709727814847414,0.019445635485960715,-0.06021776878056548,0.9519999915754799,LGP Offspring,Subunits of the anaphase promoting complex (APC).,CGP,C2,13,26
Cohort,-0.02646326571375903,0.05532079736170307,-0.4783601642748331,0.6325192508661814,LGP Proband,Subunits of the anaphase promoting complex (APC).,CGP,C2,13,38
Cohort,-0.026362478297711666,0.016635767224189284,-1.5846866539091284,0.11343472230943683,LonGen OPEL,Subunits of the anaphase promoting complex (APC).,CGP,C2,24,19
Cohort,-0.010951916023922207,0.028856150019333233,-0.37953490041410826,0.7044098879813108,LGP Offspring,Genes whose expression most significantly correlated with cancer cell line sensitivity to the proapoptotic ligand APO2 [GeneID=8797].,CGP,C2,29,53
Cohort,-0.09342791392471816,0.0806339729623886,-1.158666880624836,0.24692365502246427,LGP Proband,Genes whose expression most significantly correlated with cancer cell line sensitivity to the proapoptotic ligand APO2 [GeneID=8797].,CGP,C2,29,79
Cohort,-1.037881232352987e-4,0.02416279699982026,-0.004295368753711367,0.9965738783523872,LonGen OPEL,Genes whose expression most significantly correlated with cancer cell line sensitivity to the proapoptotic ligand APO2 [GeneID=8797].,CGP,C2,41,52
Cohort,-0.008213632483635403,0.02943979900634107,-0.2789975733824222,0.7803320166647099,LGP Offspring,Genes up-regulated in placenta of mice with EHMT2 [GeneID=10919] knocked out.,CGP,C2,29,57
Cohort,0.07639749432968922,0.0822831775252433,0.9284703948902746,0.3534322501084627,LGP Proband,Genes up-regulated in placenta of mice with EHMT2 [GeneID=10919] knocked out.,CGP,C2,29,86
Cohort,-0.014783484471280448,0.026920024105346253,-0.5491631216015324,0.5830475254023728,LonGen OPEL,Genes up-regulated in placenta of mice with EHMT2 [GeneID=10919] knocked out.,CGP,C2,55,53
Cohort,0.06229448208197338,0.024723364252409043,2.519660408914754,0.011976170967055581,LGP Offspring,Genes with promoters bound by PPARG [GeneID=5468] at 36 h time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).,CGP,C2,12,51
Cohort,0.045269413203247226,0.06863761702090683,0.6595423204954549,0.5097296560594855,LGP Proband,Genes with promoters bound by PPARG [GeneID=5468] at 36 h time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).,CGP,C2,12,64
Cohort,0.02807935464516221,0.02474422615873955,1.1347841094333315,0.2568073815011156,LonGen OPEL,Genes with promoters bound by PPARG [GeneID=5468] at 36 h time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).,CGP,C2,37,56
Cohort,-0.33414842873471884,0.14525193525817623,-2.3004748827669035,0.02172492720875663,LGP Offspring,Genes with promoters bound by PPARG [GeneID=5468] at 8 day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).,CGP,C2,697,1319
Cohort,0.13721156552776814,0.39605373021352125,0.3464468456181296,0.7290943109232626,LGP Proband,Genes with promoters bound by PPARG [GeneID=5468] at 8 day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).,CGP,C2,697,1804
Cohort,-0.07767843000163031,0.11900804222442353,-0.652715804324766,0.5141279681363804,LonGen OPEL,Genes with promoters bound by PPARG [GeneID=5468] at 8 day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).,CGP,C2,1044,1215
Cohort,-0.11001072576102042,0.07298463157483998,-1.50731357255963,0.1321974614715081,LGP Offspring,"Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 36 h time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).",CGP,C2,168,296
Cohort,0.16951678959477973,0.19135683121244199,0.8858674577788356,0.37594430340029195,LGP Proband,"Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 36 h time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).",CGP,C2,168,463
Cohort,-0.10073315835158686,0.0649985852343889,-1.5497746295298105,0.12159309120812956,LonGen OPEL,"Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 36 h time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).",CGP,C2,280,306
Cohort,0.08478922810795464,0.16826792835480822,0.5038941700712499,0.6144999211608184,LGP Offspring,"Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 8 day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).",CGP,C2,834,1812
Cohort,0.29952938874771184,0.46624438239140686,0.6424300218083063,0.5207705676717589,LGP Proband,"Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 8 day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).",CGP,C2,834,2402
Cohort,0.045530946477890605,0.15548226769264598,0.2928369077295374,0.7697231344718645,LonGen OPEL,"Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 8 day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).",CGP,C2,1398,1688
Cohort,0.040718755926481075,0.06431834757270259,0.6330814994967713,0.5268945256882644,LGP Offspring,"Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 8 (but not 0) day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte) and that were newly modified by H4K20me1.",CGP,C2,119,279
Cohort,0.28239232896106203,0.17866572966731925,1.5805623691061779,0.1143572918420298,LGP Proband,"Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 8 (but not 0) day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte) and that were newly modified by H4K20me1.",CGP,C2,119,412
Cohort,0.02185551134717339,0.05954204717155921,0.3670601261693412,0.7136717275955159,LonGen OPEL,"Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 8 (but not 0) day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte) and that were newly modified by H4K20me1.",CGP,C2,253,309
Cohort,-0.007676667360754014,0.05831044240583613,-0.13165167410881584,0.8952989833280002,LGP Offspring,DNA repair genes whose promoters contain putative ZNF143 [GeneID=7702] binding sites.,CGP,C2,98,217
Cohort,0.15736233801386698,0.1567563965156125,1.0038654977514372,0.3157346133603979,LGP Proband,DNA repair genes whose promoters contain putative ZNF143 [GeneID=7702] binding sites.,CGP,C2,98,320
Cohort,0.06093633843475772,0.048277380300117724,1.262213029289187,0.20724182672024918,LonGen OPEL,DNA repair genes whose promoters contain putative ZNF143 [GeneID=7702] binding sites.,CGP,C2,163,214
Cohort,0.05471994425398464,0.021732205606691538,2.517919499028478,0.012034961071123482,LGP Offspring,Genes up-regulated more than 7-fold by expressing JAK2 [GeneID=3717] in the JAK2 null cell line.,CGP,C2,7,40
Cohort,0.09608823687010827,0.06406217086323049,1.4999216476015436,0.13401314283259885,LGP Proband,Genes up-regulated more than 7-fold by expressing JAK2 [GeneID=3717] in the JAK2 null cell line.,CGP,C2,7,55
Cohort,0.030027009308379825,0.020918244298169904,1.4354459619255344,0.15155287267885803,LonGen OPEL,Genes up-regulated more than 7-fold by expressing JAK2 [GeneID=3717] in the JAK2 null cell line.,CGP,C2,25,47
Cohort,0.01218429204478769,0.01887236318456031,0.6456155980908524,0.5187474095694886,LGP Offspring,Genes down-regulated in prostate tumor vs normal tissue samples.,CGP,C2,10,24
Cohort,-0.03285732813843146,0.04420345928469586,-0.7433202891839584,0.4574971277034068,LGP Proband,Genes down-regulated in prostate tumor vs normal tissue samples.,CGP,C2,10,25
Cohort,0.03179274442874905,0.014491601242504771,2.1938738098519397,0.028532888035423767,LonGen OPEL,Genes down-regulated in prostate tumor vs normal tissue samples.,CGP,C2,7,26
Cohort,-0.071208938129903,0.047822593200365054,-1.4890229359071945,0.1369476912049884,LGP Offspring,Genes down-regulated in prostate cancer samples from African-American patients compared to those from the European-American patients.,CGP,C2,83,145
Cohort,0.08079806621961005,0.13957262971511336,0.578896208981158,0.562815515098162,LGP Proband,Genes down-regulated in prostate cancer samples from African-American patients compared to those from the European-American patients.,CGP,C2,83,217
Cohort,-0.03950419319807324,0.042738289033498696,-0.9243279057593873,0.35559573308298065,LonGen OPEL,Genes down-regulated in prostate cancer samples from African-American patients compared to those from the European-American patients.,CGP,C2,130,141
Cohort,-0.0386688816186794,0.07637880865009977,-0.5062776220538613,0.6128268381755375,LGP Offspring,Genes up-regulated in prostate cancer samples from African-American patients compared to those from the European-American patients.,CGP,C2,187,374
Cohort,-0.12628558579122817,0.2191139144108798,-0.576346719608226,0.5645363539811914,LGP Proband,Genes up-regulated in prostate cancer samples from African-American patients compared to those from the European-American patients.,CGP,C2,187,531
Cohort,-0.03378949402041196,0.06662958596534196,-0.5071244782758803,0.6122079390478461,LonGen OPEL,Genes up-regulated in prostate cancer samples from African-American patients compared to those from the European-American patients.,CGP,C2,300,340
Cohort,-0.009595541168253091,0.02470804879064219,-0.3883568973640388,0.6978742099139001,LGP Offspring,Genes up-regulated in prostate tumor vs normal tissue samples.,CGP,C2,23,41
Cohort,-0.032438108139818206,0.06431537842375101,-0.5043600602968565,0.6141415976198431,LGP Proband,Genes up-regulated in prostate tumor vs normal tissue samples.,CGP,C2,23,45
Cohort,5.478834669996116e-4,0.02112549721610157,0.025934701625958522,0.9793159216409671,LonGen OPEL,Genes up-regulated in prostate tumor vs normal tissue samples.,CGP,C2,30,32
Cohort,-0.08940806225137096,0.04701858356595367,-1.9015473344907752,0.05765525666884242,LGP Offspring,Genes down-regulated in mucinous ovarian carcinoma tumors of grades 1 and 2 compared to the normal ovarian survace epithelium tissue.,CGP,C2,85,134
Cohort,-0.16249974251835914,0.13447815284835626,-1.2083728031392675,0.22724640223950138,LGP Proband,Genes down-regulated in mucinous ovarian carcinoma tumors of grades 1 and 2 compared to the normal ovarian survace epithelium tissue.,CGP,C2,85,213
Cohort,0.012394986073583579,0.04550002070225766,0.2724171523941428,0.7853719342355101,LonGen OPEL,Genes down-regulated in mucinous ovarian carcinoma tumors of grades 1 and 2 compared to the normal ovarian survace epithelium tissue.,CGP,C2,130,164
Cohort,-0.015645920433602117,0.06816794586885659,-0.22952019800775833,0.8185340507295018,LGP Offspring,Genes up-regulated in mucinous ovarian carcinoma tumors of grades 1 and 2 compared to the normal ovarian survace epithelium tissue.,CGP,C2,134,273
Cohort,-0.467143656483564,0.1742341052757211,-2.681126383059854,0.007482412453121156,LGP Proband,Genes up-regulated in mucinous ovarian carcinoma tumors of grades 1 and 2 compared to the normal ovarian survace epithelium tissue.,CGP,C2,134,336
Cohort,0.010461666999810335,0.050898772313108895,0.2055386903136748,0.8372038245205353,LonGen OPEL,Genes up-regulated in mucinous ovarian carcinoma tumors of grades 1 and 2 compared to the normal ovarian survace epithelium tissue.,CGP,C2,177,219
Cohort,-0.19954010807472197,0.07378329528527643,-2.7044076481433668,0.007014840827170268,LGP Offspring,Genes down-regulated in mucinous ovarian carcinoma tumors of low malignant potential (LMP) compared to normal ovarian surface epithelium tissue.,CGP,C2,219,360
Cohort,-0.22207639856725453,0.21449965552276065,-1.0353228681231608,0.30081825323649997,LGP Proband,Genes down-regulated in mucinous ovarian carcinoma tumors of low malignant potential (LMP) compared to normal ovarian surface epithelium tissue.,CGP,C2,219,555
Cohort,0.0024857799667392026,0.06941816839174761,0.03580878067411975,0.9714438093172676,LonGen OPEL,Genes down-regulated in mucinous ovarian carcinoma tumors of low malignant potential (LMP) compared to normal ovarian surface epithelium tissue.,CGP,C2,319,396
Cohort,0.016570576733215006,0.10118184616004987,0.16377025486373908,0.869960959144762,LGP Offspring,Genes up-regulated in mucinous ovarian carcinoma tumors of low malignant potential (LMP) compared to normal ovarian surface epithelium tissue.,CGP,C2,278,597
Cohort,0.08543826401038546,0.25755720225673784,0.3317253925022023,0.7401799672833804,LGP Proband,Genes up-regulated in mucinous ovarian carcinoma tumors of low malignant potential (LMP) compared to normal ovarian surface epithelium tissue.,CGP,C2,278,803
Cohort,0.09991933387694928,0.08089389163315369,1.235190097295284,0.21712421123326103,LonGen OPEL,Genes up-regulated in mucinous ovarian carcinoma tumors of low malignant potential (LMP) compared to normal ovarian surface epithelium tissue.,CGP,C2,425,553
Cohort,-0.0036142948007124474,0.029275243006068367,-0.12345908793868089,0.9017802668552504,LGP Offspring,Adipogenic genes (group 2) that are selectively repressed by  SIRT1 [GeneID=23411] in mature 3T3-L1 adipocytes.,CGP,C2,25,52
Cohort,-0.2461382460103583,0.0718662060469265,-3.4249511634110377,6.449349518024719e-4,LGP Proband,Adipogenic genes (group 2) that are selectively repressed by  SIRT1 [GeneID=23411] in mature 3T3-L1 adipocytes.,CGP,C2,25,52
Cohort,-0.010698617119221132,0.021204915064149864,-0.5045347782273729,0.6140252619484426,LonGen OPEL,Adipogenic genes (group 2) that are selectively repressed by  SIRT1 [GeneID=23411] in mature 3T3-L1 adipocytes.,CGP,C2,32,34
Cohort,-0.0013893137768189758,0.03677443752007637,-0.03777933451899852,0.9698747749127707,LGP Offspring,Genes down-regulated in esophageal adenocarcinoma (EAC) and Barret's esophagus (BE) relative to normal esophagi.,CGP,C2,44,92
Cohort,0.12114582547039948,0.10612814691801474,1.1415051424951956,0.2539874177171075,LGP Proband,Genes down-regulated in esophageal adenocarcinoma (EAC) and Barret's esophagus (BE) relative to normal esophagi.,CGP,C2,44,135
Cohort,-0.006911530143750264,0.03256236444283747,-0.21225516825976523,0.8319623078147809,LonGen OPEL,Genes down-regulated in esophageal adenocarcinoma (EAC) and Barret's esophagus (BE) relative to normal esophagi.,CGP,C2,74,80
Cohort,-0.02945267280139971,0.021118589006954035,-1.3946326050334796,0.16358476920690232,LGP Offspring,Genes up-regulated in esophageal adenocarcinoma (EAC) and Barret's esophagus (BE) relative to normal esophagi.,CGP,C2,18,26
Cohort,0.0257920782806923,0.05998743378730904,0.42995802041041603,0.6673372467965684,LGP Proband,Genes up-regulated in esophageal adenocarcinoma (EAC) and Barret's esophagus (BE) relative to normal esophagi.,CGP,C2,18,42
Cohort,0.002280494107787462,0.01731758415576593,0.13168661906159507,0.8952654465072685,LonGen OPEL,Genes up-regulated in esophageal adenocarcinoma (EAC) and Barret's esophagus (BE) relative to normal esophagi.,CGP,C2,21,24
Cohort,0.03310341293221826,0.025095400788462976,1.3191027794796877,0.18758139392084452,LGP Offspring,Genes down-regulated in Barrett's esophagus compared to the normal tissue.,CGP,C2,17,48
Cohort,-0.04008360756047181,0.07510449977477802,-0.5337044741749667,0.5936882226425212,LGP Proband,Genes down-regulated in Barrett's esophagus compared to the normal tissue.,CGP,C2,17,74
Cohort,0.008872732310661175,0.025303736831877113,0.3506490906704141,0.7259443972315678,LonGen OPEL,Genes down-regulated in Barrett's esophagus compared to the normal tissue.,CGP,C2,41,52
Cohort,-0.061074567237812565,0.03832577133097662,-1.5935639418807819,0.11150116503242462,LGP Offspring,Genes up-regulated in Barrett's esophagus compared to the normal tissue.,CGP,C2,58,85
Cohort,-0.18583390208454148,0.09779212347964544,-1.900295192211683,0.0577390051295887,LGP Proband,Genes up-regulated in Barrett's esophagus compared to the normal tissue.,CGP,C2,58,107
Cohort,0.003681979960269423,0.029801629255227977,0.12354961967804189,0.9017030735918019,LonGen OPEL,Genes up-regulated in Barrett's esophagus compared to the normal tissue.,CGP,C2,59,77
Cohort,-0.09933917525035613,0.06928333457804063,-1.4338105383547994,0.15208870777841826,LGP Offspring,Genes down-regulated in fibroblasts with defective XPC [GeneID=7508] in response to cisplatin [PubChem=2767].,CGP,C2,166,296
Cohort,-0.21670346080131608,0.19000723404980693,-1.140501107155274,0.2544049972285299,LGP Proband,Genes down-regulated in fibroblasts with defective XPC [GeneID=7508] in response to cisplatin [PubChem=2767].,CGP,C2,166,452
Cohort,0.05992884007115104,0.06019417078843898,0.9955920861802303,0.319750927133154,LonGen OPEL,Genes down-regulated in fibroblasts with defective XPC [GeneID=7508] in response to cisplatin [PubChem=2767].,CGP,C2,244,315
Cohort,0.009769776132113847,0.08161196776191634,0.11971009154704937,0.9047483732239474,LGP Offspring,Genes up-regulated in fibroblasts with defective XPC [GeneID=7508] in response to cisplatin [PubChem=2767].,CGP,C2,195,424
Cohort,0.11706622207500839,0.2299495198768831,0.5090953098649069,0.6108200793291546,LGP Proband,Genes up-regulated in fibroblasts with defective XPC [GeneID=7508] in response to cisplatin [PubChem=2767].,CGP,C2,195,646
Cohort,0.07084498531463285,0.0760026371516332,0.9321385147898184,0.3515475798101001,LonGen OPEL,Genes up-regulated in fibroblasts with defective XPC [GeneID=7508] in response to cisplatin [PubChem=2767].,CGP,C2,335,430
Cohort,-0.025225138290653204,0.02885124349863976,-0.8743171950922145,0.3822560419903336,LGP Offspring,Classic adipogenic genes (group 1) that are induced by PPARG  [GeneID=5468] during adipogenesis in 3T3-L1 preadipocytes.,CGP,C2,26,50
Cohort,-0.09213768291420599,0.08098272013516129,-1.1377449752296158,0.2555537346230912,LGP Proband,Classic adipogenic genes (group 1) that are induced by PPARG  [GeneID=5468] during adipogenesis in 3T3-L1 preadipocytes.,CGP,C2,26,73
Cohort,0.0192999771751409,0.02396466996719963,0.8053512609001802,0.42085750598670846,LonGen OPEL,Classic adipogenic genes (group 1) that are induced by PPARG  [GeneID=5468] during adipogenesis in 3T3-L1 preadipocytes.,CGP,C2,34,50
Cohort,-0.04740033483307691,0.07289409174887446,-0.6502630555625081,0.5157432416284308,LGP Offspring,Genes down-regulated in MCF7 cells (breast cancer) engineered to conditionally express a dominant negative form of CLIM2 [GeneID=8861] by a Tet Off system.,CGP,C2,174,346
Cohort,-0.10697383860519873,0.20864117669716226,-0.512716810260655,0.6082851941275979,LGP Proband,Genes down-regulated in MCF7 cells (breast cancer) engineered to conditionally express a dominant negative form of CLIM2 [GeneID=8861] by a Tet Off system.,CGP,C2,174,468
Cohort,-0.010424320568606172,0.06276245932290013,-0.1660916522562501,0.86812700020714,LonGen OPEL,Genes down-regulated in MCF7 cells (breast cancer) engineered to conditionally express a dominant negative form of CLIM2 [GeneID=8861] by a Tet Off system.,CGP,C2,276,329
Cohort,-0.06052391350509945,0.09422958937465419,-0.6423026345202256,0.5208944641891471,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) engineered to conditionally express a dominant negative form of CLIM2 [GeneID=8861] by a Tet Off system.,CGP,C2,291,598
Cohort,-0.1259705992575309,0.2686942688461073,-0.46882503225135647,0.6393172252836603,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) engineered to conditionally express a dominant negative form of CLIM2 [GeneID=8861] by a Tet Off system.,CGP,C2,291,845
Cohort,-0.05438884608803505,0.07485130711323597,-0.7266252011572081,0.467669204706078,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) engineered to conditionally express a dominant negative form of CLIM2 [GeneID=8861] by a Tet Off system.,CGP,C2,439,507
Cohort,-0.007735372703498792,0.008477527906536214,-0.9124561769398344,0.3618539147420826,LGP Offspring,Candidate progression biomarkers up-regulated in transition from non-tumor-risk associated to tumor-risk associated Barrett's esophagus and then to esophageal adenocarcinoma (EAC).,CGP,C2,3,4
Cohort,9.233297494959514e-4,0.02351939357842614,0.03925822944444039,0.9686939043631545,LGP Proband,Candidate progression biomarkers up-regulated in transition from non-tumor-risk associated to tumor-risk associated Barrett's esophagus and then to esophageal adenocarcinoma (EAC).,CGP,C2,3,6
Cohort,0.001663279091681811,0.002590298255159497,0.6421187553861032,0.5209809563992847,LonGen OPEL,Candidate progression biomarkers up-regulated in transition from non-tumor-risk associated to tumor-risk associated Barrett's esophagus and then to esophageal adenocarcinoma (EAC).,CGP,C2,0,1
Cohort,-0.0019589176446319742,0.04654654289180811,-0.0420851372181441,0.9664432554323217,LGP Offspring,Down-regulated genes specific to esophageal adenocarcinoma (EAC) relative to normal tissue.,CGP,C2,68,140
Cohort,0.13554012377375743,0.12586665485107543,1.0768548980198733,0.28185648483758885,LGP Proband,Down-regulated genes specific to esophageal adenocarcinoma (EAC) relative to normal tissue.,CGP,C2,68,184
Cohort,0.07119744267424727,0.04139132745987732,1.7201053226249507,0.0858019729821053,LonGen OPEL,Down-regulated genes specific to esophageal adenocarcinoma (EAC) relative to normal tissue.,CGP,C2,104,157
Cohort,-0.04386257700896701,0.05696603029263853,-0.7699777706756438,0.4415820592539411,LGP Offspring,Up-regulated genes specific to esophageal adenocarcinoma (EAC) relative to normal tissue.,CGP,C2,112,222
Cohort,-0.033454328011510534,0.16020973493227697,-0.20881582524090794,0.8346430060157599,LGP Proband,Up-regulated genes specific to esophageal adenocarcinoma (EAC) relative to normal tissue.,CGP,C2,112,291
Cohort,-0.08955945477272002,0.05060233375183754,-1.7698680699576987,0.07713189357439901,LonGen OPEL,Up-regulated genes specific to esophageal adenocarcinoma (EAC) relative to normal tissue.,CGP,C2,196,197
Cohort,-0.09066142949095594,0.0576646881894063,-1.5722174581637909,0.11636802553802122,LGP Offspring,Genes with the high-CpG-density promoters (HCP) that were up-regulated in 1542-CP3TX cells (prostate cancer) compared to 1542-NPTX (normal prostate).,CGP,C2,113,207
Cohort,-0.04693808932265067,0.15895052883121802,-0.2952999884164713,0.7678382245221892,LGP Proband,Genes with the high-CpG-density promoters (HCP) that were up-regulated in 1542-CP3TX cells (prostate cancer) compared to 1542-NPTX (normal prostate).,CGP,C2,113,303
Cohort,-0.10181184513022999,0.050769307040210945,-2.0053818156232013,0.04526030710089497,LonGen OPEL,Genes with the high-CpG-density promoters (HCP) that were up-regulated in 1542-CP3TX cells (prostate cancer) compared to 1542-NPTX (normal prostate).,CGP,C2,180,180
Cohort,0.012229364896759869,0.02967804554793017,0.41206773124629764,0.6804204115567403,LGP Offspring,Down-regulated genes in myeloid progenitors immortalized by HOXA9 [GeneID=3205] vs those immortalized by HOXA9 and MEIS1 [GeneID=4211].,CGP,C2,30,63
Cohort,-0.0684540023891711,0.08481615067963713,-0.8070868795700452,0.41984653563332075,LGP Proband,Down-regulated genes in myeloid progenitors immortalized by HOXA9 [GeneID=3205] vs those immortalized by HOXA9 and MEIS1 [GeneID=4211].,CGP,C2,30,85
Cohort,-0.03663656508831379,0.024283397611396695,-1.5087083642331622,0.13177012191418458,LonGen OPEL,Down-regulated genes in myeloid progenitors immortalized by HOXA9 [GeneID=3205] vs those immortalized by HOXA9 and MEIS1 [GeneID=4211].,CGP,C2,53,43
Cohort,-0.020264856438223337,0.03689550019687571,-0.5492500800934894,0.5830152223886499,LGP Offspring,Up-regulated genes in myeloid progenitors immortalized by HOXA9 [GeneID=3205] vs those immortalized by HOXA9 and MEIS1 [GeneID=4211].,CGP,C2,46,81
Cohort,-0.06948054630490366,0.10235064531069873,-0.6788481508249059,0.49742241216994887,LGP Proband,Up-regulated genes in myeloid progenitors immortalized by HOXA9 [GeneID=3205] vs those immortalized by HOXA9 and MEIS1 [GeneID=4211].,CGP,C2,46,126
Cohort,-0.025770352965784237,0.03449441967936138,-0.7470875928723942,0.45523130532131517,LonGen OPEL,Up-regulated genes in myeloid progenitors immortalized by HOXA9 [GeneID=3205] vs those immortalized by HOXA9 and MEIS1 [GeneID=4211].,CGP,C2,81,91
Cohort,-0.16269641288893985,0.09757923939539626,-1.6673261023247512,0.09591274012871039,LGP Offspring,Genes down-regulated in MCF7 cells (breast cancer) engineered to conditionally express LMO4 [GeneID=8543] by a Tet Off system.,CGP,C2,332,608
Cohort,-0.47600128914472795,0.2811985472272923,-1.692758706750988,0.09087488138732228,LGP Proband,Genes down-regulated in MCF7 cells (breast cancer) engineered to conditionally express LMO4 [GeneID=8543] by a Tet Off system.,CGP,C2,332,897
Cohort,-0.0776814809335846,0.08846328175871186,-0.8781211751273802,0.3801429337834905,LonGen OPEL,Genes down-regulated in MCF7 cells (breast cancer) engineered to conditionally express LMO4 [GeneID=8543] by a Tet Off system.,CGP,C2,533,617
Cohort,-0.09455658727359573,0.09195833841589708,-1.0282546303299613,0.30419783831257224,LGP Offspring,Genes up-regulated in MCF7 cells (breast cancer) engineered to conditionally express LMO4 [GeneID=8543] by a Tet Off system.,CGP,C2,262,508
Cohort,-0.4072486271674527,0.25822582872970745,-1.5771026049982466,0.11515112713245718,LGP Proband,Genes up-regulated in MCF7 cells (breast cancer) engineered to conditionally express LMO4 [GeneID=8543] by a Tet Off system.,CGP,C2,262,750
Cohort,-0.007606523949175345,0.07197071962035559,-0.10568914677107077,0.9158556190479681,LonGen OPEL,Genes up-regulated in MCF7 cells (breast cancer) engineered to conditionally express LMO4 [GeneID=8543] by a Tet Off system.,CGP,C2,407,489
Cohort,-2.2022634645191025e-4,0.026270627241894502,-0.00838298775374153,0.9933138950815775,LGP Offspring,Genes down-regulated after Cre-lox knockout of LSD1 [GeneID=23028] in pituitary.,CGP,C2,20,44
Cohort,0.06336583956868531,0.07086352844222607,0.8941953775325553,0.37147533624071727,LGP Proband,Genes down-regulated after Cre-lox knockout of LSD1 [GeneID=23028] in pituitary.,CGP,C2,20,66
Cohort,0.012405793572514976,0.02144455913720314,0.5785054145036145,0.5630865809833805,LonGen OPEL,Genes down-regulated after Cre-lox knockout of LSD1 [GeneID=23028] in pituitary.,CGP,C2,25,35
Cohort,-0.052689505270288026,0.028032529308566093,-1.8795844174570195,0.06059463274974025,LGP Offspring,Genes up-regulated after Cre-lox knockout of LSD1 [GeneID=23028] in pituitary.,CGP,C2,31,45
Cohort,-0.047204726455136174,0.07896160461776609,-0.5978187333406251,0.550123179912537,LGP Proband,Genes up-regulated after Cre-lox knockout of LSD1 [GeneID=23028] in pituitary.,CGP,C2,31,69
Cohort,-0.028846316376238076,0.023858256173308872,-1.2090706113093685,0.22699472057664855,LonGen OPEL,Genes up-regulated after Cre-lox knockout of LSD1 [GeneID=23028] in pituitary.,CGP,C2,46,39
Cohort,-0.025655859702735376,0.0181512787472215,-1.4134464056237712,0.1579848128077311,LGP Offspring,Genes whose expression in primary ER(-) [GeneID=2099] breast cancer tumors negatively correlates with developing distant metastases.,CGP,C2,14,18
Cohort,-0.057223583275996845,0.05246135048627675,-1.0907760235979025,0.2756864817092416,LGP Proband,Genes whose expression in primary ER(-) [GeneID=2099] breast cancer tumors negatively correlates with developing distant metastases.,CGP,C2,14,31
Cohort,-0.02569877787253605,0.018022705292798424,-1.4259112300307577,0.1542860056386643,LonGen OPEL,Genes whose expression in primary ER(-) [GeneID=2099] breast cancer tumors negatively correlates with developing distant metastases.,CGP,C2,26,21
Cohort,-0.012941633660527196,0.02836089287112134,-0.4563196835634571,0.6483066796717705,LGP Offspring,Genes whose expression in primary ER(+) [GeneID=2099] breast cancer tumors negatively correlates with developing distant metastases.,CGP,C2,29,53
Cohort,0.015095485838215057,0.08235868519454217,0.18328954381140872,0.8546153874919714,LGP Proband,Genes whose expression in primary ER(+) [GeneID=2099] breast cancer tumors negatively correlates with developing distant metastases.,CGP,C2,29,80
Cohort,0.043142259095981544,0.026628886842585152,1.620130024623788,0.10560041463312457,LonGen OPEL,Genes whose expression in primary ER(+) [GeneID=2099] breast cancer tumors negatively correlates with developing distant metastases.,CGP,C2,43,69
Cohort,-0.009595149904030056,0.02613762417650489,-0.3671010738862462,0.7136585133666243,LGP Offspring,Genes whose expression in primary ER(+) [GeneID=2099] breast cancer tumors positively correlates with developing distant metastases.,CGP,C2,27,45
Cohort,-0.016946395096920367,0.07465608895868531,-0.22699280572142622,0.8204849638867231,LGP Proband,Genes whose expression in primary ER(+) [GeneID=2099] breast cancer tumors positively correlates with developing distant metastases.,CGP,C2,27,68
Cohort,-0.005128833966898062,0.020757980452155846,-0.24707769518905198,0.8049118053333006,LonGen OPEL,Genes whose expression in primary ER(+) [GeneID=2099] breast cancer tumors positively correlates with developing distant metastases.,CGP,C2,32,38
Cohort,0.019080603577700014,0.024405693238113296,0.7818095307328815,0.4346002551123357,LGP Offspring,Genes up-regulated in MDA468 cells (breast cancer) vs DU99 cells (normal breast) after treatment with azacytidine [PubChem=9444].,CGP,C2,17,43
Cohort,-0.12114614551537073,0.06689882985167102,-1.8108858672711852,0.07051822186897407,LGP Proband,Genes up-regulated in MDA468 cells (breast cancer) vs DU99 cells (normal breast) after treatment with azacytidine [PubChem=9444].,CGP,C2,17,59
Cohort,-0.02284757866639973,0.024285622650234397,-0.9407862007680174,0.3470998406842034,LonGen OPEL,Genes up-regulated in MDA468 cells (breast cancer) vs DU99 cells (normal breast) after treatment with azacytidine [PubChem=9444].,CGP,C2,43,44
Cohort,-0.04533453615571807,0.0987488872147636,-0.45908908377997665,0.6463177751612712,LGP Offspring,Genes requiring MLL [GeneID=4297] for H3K4me3 and expression in MEF cells (embryonic fibroblast).,CGP,C2,309,633
Cohort,0.1420581899001555,0.2765516170682967,0.51367694539668185,0.6076139316062714,LGP Proband,Genes requiring MLL [GeneID=4297] for H3K4me3 and expression in MEF cells (embryonic fibroblast).,CGP,C2,309,903
Cohort,-0.15971114959014954,0.08144879080984953,-1.9608780928744716,0.05024156990188301,LonGen OPEL,Genes requiring MLL [GeneID=4297] for H3K4me3 and expression in MEF cells (embryonic fibroblast).,CGP,C2,516,561
Cohort,-0.004535728127376816,0.019308875919767463,-0.23490378964698633,0.8143545432492183,LGP Offspring,Selected genes changed in NMuMG cells (mammary epithelium) transformed by overexpression of CCND1 [GeneID=595] vs those transformed by overexpression of CCND1 and MYC [GeneID=4609].,CGP,C2,12,26
Cohort,-0.06466409618816708,0.054204210654940764,-1.1929718264843487,0.2332196806708592,LGP Proband,Selected genes changed in NMuMG cells (mammary epithelium) transformed by overexpression of CCND1 [GeneID=595] vs those transformed by overexpression of CCND1 and MYC [GeneID=4609].,CGP,C2,12,36
Cohort,0.019486891643103858,0.01783788228793711,1.0924442334885174,0.27496840856480514,LonGen OPEL,Selected genes changed in NMuMG cells (mammary epithelium) transformed by overexpression of CCND1 [GeneID=595] vs those transformed by overexpression of CCND1 and MYC [GeneID=4609].,CGP,C2,18,30
Cohort,-0.02349766747600185,0.02617682018040521,-0.8976517130064233,0.36969084391853635,LGP Offspring,Representative genes up-regulated in C2C12 cells (myoblast) lacking NFkB activity due to expression of a super repressor form of NFKBIA [GeneID=4792].,CGP,C2,25,41
Cohort,-0.0648942797973654,0.07221550957306215,-0.8986197034545648,0.3691146193535588,LGP Proband,Representative genes up-regulated in C2C12 cells (myoblast) lacking NFkB activity due to expression of a super repressor form of NFKBIA [GeneID=4792].,CGP,C2,25,60
Cohort,-0.034094441866595944,0.02462622358866113,-1.3844770694884112,0.1666003956309253,LonGen OPEL,Representative genes up-regulated in C2C12 cells (myoblast) lacking NFkB activity due to expression of a super repressor form of NFKBIA [GeneID=4792].,CGP,C2,44,44
Cohort,0.03309453604891295,0.040205831960022385,0.8231277512630415,0.41072562365549314,LGP Offspring,Genes changed in prostate cancer: androgen independent vs androgen dependent samples.,CGP,C2,45,103
Cohort,-0.13439143372745124,0.10360026080491584,-1.2972113456404963,0.1949172041349697,LGP Proband,Genes changed in prostate cancer: androgen independent vs androgen dependent samples.,CGP,C2,45,128
Cohort,-0.03182726022177164,0.03261712650286079,-0.9757836950774963,0.3294681104988254,LonGen OPEL,Genes changed in prostate cancer: androgen independent vs androgen dependent samples.,CGP,C2,79,79
Cohort,-0.005793315103013076,0.010517817215154022,-0.5508096389682542,0.581946156291075,LGP Offspring,Genes down-regulated in samples from patients with recurrent hepatocellular carcinoma (HCC).,CGP,C2,4,7
Cohort,-0.01042873683738399,0.030858635908147258,-0.3379519713193352,0.7354844298667538,LGP Proband,Genes down-regulated in samples from patients with recurrent hepatocellular carcinoma (HCC).,CGP,C2,4,12
Cohort,0.02211708897351562,0.013826589683206684,1.5996055050637903,0.11008293423387236,LonGen OPEL,Genes down-regulated in samples from patients with recurrent hepatocellular carcinoma (HCC).,CGP,C2,7,23
Cohort,-0.014826102115075481,0.025769581107897687,-0.5753334543157039,0.565257247470603,LGP Offspring,Genes up-regulated in samples from patients with recurrent hepatocellular carcinoma (HCC).,CGP,C2,21,43
Cohort,-0.01849958259038753,0.06215778170489119,-0.2976229537633548,0.7660650736052703,LGP Proband,Genes up-regulated in samples from patients with recurrent hepatocellular carcinoma (HCC).,CGP,C2,21,42
Cohort,-0.012712167779541185,0.018749852892495786,-0.6779876008856021,0.4979765819961467,LonGen OPEL,Genes up-regulated in samples from patients with recurrent hepatocellular carcinoma (HCC).,CGP,C2,29,27
Cohort,0.010109195089237685,0.03433658148499189,0.29441472190981777,0.7685314016154945,LGP Offspring,Genes up-regulated in LNCaP cells (prostate cancer) treated with synthetic androgen R1881 [PubChem=13766].,CGP,C2,39,82
Cohort,0.009312819840198824,0.09261299268128481,0.1005562996138959,0.9199268561316788,LGP Proband,Genes up-regulated in LNCaP cells (prostate cancer) treated with synthetic androgen R1881 [PubChem=13766].,CGP,C2,39,110
Cohort,-0.015202422307738184,0.027399885917287703,-0.5548352410528234,0.5791632255918506,LonGen OPEL,Genes up-regulated in LNCaP cells (prostate cancer) treated with synthetic androgen R1881 [PubChem=13766].,CGP,C2,55,59
Cohort,-0.018720500784462097,0.025505671449824005,-0.7339740426473372,0.4632190454227728,LGP Offspring,Genes down-regulated in the mouse lung cancer model and which reverted to normal levels upon treatment with bexarotene [PubChem=82146].,CGP,C2,23,39
Cohort,-0.037693979287019126,0.08233064550297026,-0.4578365571743177,0.647189124471208,LGP Proband,Genes down-regulated in the mouse lung cancer model and which reverted to normal levels upon treatment with bexarotene [PubChem=82146].,CGP,C2,23,82
Cohort,0.007323605931138436,0.024137229545475158,0.30341534919492624,0.7616526340326856,LonGen OPEL,Genes down-regulated in the mouse lung cancer model and which reverted to normal levels upon treatment with bexarotene [PubChem=82146].,CGP,C2,41,49
Cohort,-0.015916274624136594,0.030507794063835345,-0.5217117498181922,0.6020419292144814,LGP Offspring,Genes up-regulated in the mouse lung cancer model and which reverted to normal levels upon treatment with bexarotene [PubChem=82146].,CGP,C2,30,60
Cohort,0.07439183049412898,0.08301965268548454,0.8960749423507998,0.37047130028046604,LGP Proband,Genes up-regulated in the mouse lung cancer model and which reverted to normal levels upon treatment with bexarotene [PubChem=82146].,CGP,C2,30,80
Cohort,0.01808310595499204,0.025576000444675867,0.7070341586092825,0.4797521756939137,LonGen OPEL,Genes up-regulated in the mouse lung cancer model and which reverted to normal levels upon treatment with bexarotene [PubChem=82146].,CGP,C2,42,59
Cohort,0.011444335922692377,0.025870668293375414,0.44236723199079003,0.6583649837176031,LGP Offspring,"Genes down-regulated in LNCaP cells (prostate cancer) treated with forskolin [PubChem=47936], an activator of PKA pathway.",CGP,C2,20,45
Cohort,0.020418394529795374,0.06671947820691046,0.30603348645014644,0.7596555255968072,LGP Proband,"Genes down-regulated in LNCaP cells (prostate cancer) treated with forskolin [PubChem=47936], an activator of PKA pathway.",CGP,C2,20,53
Cohort,7.818640617420339e-4,0.018662373014113994,0.04189521135124269,0.9665927399831364,LonGen OPEL,"Genes down-regulated in LNCaP cells (prostate cancer) treated with forskolin [PubChem=47936], an activator of PKA pathway.",CGP,C2,24,27
Cohort,0.010697746817542387,0.02834513998554937,0.3774102658514371,0.7059871956448169,LGP Offspring,"Genes up-regulated in LNCaP cells (prostate cancer) treated with forskolin [PubChem=47936], an activator of PKA pathway.",CGP,C2,25,57
Cohort,0.018418775940090445,0.07272188031631657,0.25327694856038857,0.8001166264726847,LGP Proband,"Genes up-regulated in LNCaP cells (prostate cancer) treated with forskolin [PubChem=47936], an activator of PKA pathway.",CGP,C2,25,68
Cohort,-0.0023780837647974116,0.022691157962481997,-0.10480222158469751,0.9165591486350814,LonGen OPEL,"Genes up-regulated in LNCaP cells (prostate cancer) treated with forskolin [PubChem=47936], an activator of PKA pathway.",CGP,C2,38,44
Cohort,-0.15854661932116518,0.09102628307166716,-1.7417674760633437,0.0820039905918948,LGP Offspring,"Genes down-regulated in RS4;11 cells (MLL, mixed lineage leukemia) in response to SB216763 [PubChem=176158], an inhibitor of GSK3B [GeneID=2932].",CGP,C2,301,561
Cohort,-0.33386723099480653,0.2726082077482922,-1.224714522546866,0.22102860543363925,LGP Proband,"Genes down-regulated in RS4;11 cells (MLL, mixed lineage leukemia) in response to SB216763 [PubChem=176158], an inhibitor of GSK3B [GeneID=2932].",CGP,C2,301,791
Cohort,0.13970037747470576,0.07992921364812727,1.7478012243396932,0.08088401719429412,LonGen OPEL,"Genes down-regulated in RS4;11 cells (MLL, mixed lineage leukemia) in response to SB216763 [PubChem=176158], an inhibitor of GSK3B [GeneID=2932].",CGP,C2,421,552
Cohort,0.040885584451502206,0.1114274208231234,0.3669257005993415,0.7137892667880872,LGP Offspring,"Genes up-regulated in RS4;11 cells (MLL, mixed lineage leukemia) in response to SB216763 [PubChem=176158], an inhibitor of GSK3B [GeneID=2932].",CGP,C2,381,833
Cohort,-0.14405645847740917,0.3097476602277023,-0.46507682534715555,0.641997844868056,LGP Proband,"Genes up-regulated in RS4;11 cells (MLL, mixed lineage leukemia) in response to SB216763 [PubChem=176158], an inhibitor of GSK3B [GeneID=2932].",CGP,C2,381,1153
Cohort,0.020668310406901272,0.09824426645697826,0.21037675940052997,0.833427468417624,LonGen OPEL,"Genes up-regulated in RS4;11 cells (MLL, mixed lineage leukemia) in response to SB216763 [PubChem=176158], an inhibitor of GSK3B [GeneID=2932].",CGP,C2,639,761
Cohort,-0.038467098394916924,0.09521042069989284,-0.404021934911587,0.6863243706473094,LGP Offspring,Genes down-regulated in BT549 cells (breast cancer) by expression of SMARCE1 [GeneID=6605] off a retroviral vector.,CGP,C2,279,572
Cohort,-0.11278009075716872,0.25381555256094673,-0.44433877128190447,0.6569129478941951,LGP Proband,Genes down-regulated in BT549 cells (breast cancer) by expression of SMARCE1 [GeneID=6605] off a retroviral vector.,CGP,C2,279,732
Cohort,-0.053847043568992,0.08255078447736458,-0.6522899074781882,0.5144024818732923,LonGen OPEL,Genes down-regulated in BT549 cells (breast cancer) by expression of SMARCE1 [GeneID=6605] off a retroviral vector.,CGP,C2,434,509
Cohort,-0.24118508168718944,0.10940008154008346,-2.204615191249385,0.027817210881562415,LGP Offspring,Genes up-regulated in BT549 cells (breast cancer) by expression of SMARCE1 [GeneID=6605] off a retroviral vector.,CGP,C2,387,727
Cohort,-0.17102078863664408,0.30227697972324463,-0.5657751006815848,0.571698859262788,LGP Proband,Genes up-regulated in BT549 cells (breast cancer) by expression of SMARCE1 [GeneID=6605] off a retroviral vector.,CGP,C2,387,1040
Cohort,-0.06710935335977392,0.08781393513467192,-0.7642221391952729,0.44496134977858104,LonGen OPEL,Genes up-regulated in BT549 cells (breast cancer) by expression of SMARCE1 [GeneID=6605] off a retroviral vector.,CGP,C2,600,680
Cohort,0.010498863492247114,0.0356759253952421,0.2942842652554512,0.7686310350433491,LGP Offspring,Top 50 genes down-regulated in granulocyte/macrophage progenitors (GMP) upon expression of MLL-CBP fusion [GeneID=4297;1387].,CGP,C2,36,81
Cohort,-0.09881975902329618,0.08979228267532827,-1.1005373299241044,0.2714156160290041,LGP Proband,Top 50 genes down-regulated in granulocyte/macrophage progenitors (GMP) upon expression of MLL-CBP fusion [GeneID=4297;1387].,CGP,C2,36,96
Cohort,0.017308250915242223,0.03173800170813562,0.5453478474924109,0.5856670751728777,LonGen OPEL,Top 50 genes down-regulated in granulocyte/macrophage progenitors (GMP) upon expression of MLL-CBP fusion [GeneID=4297;1387].,CGP,C2,59,85
Cohort,0.0794621222658008,0.040800412038795905,1.947581367321551,0.05187870828536962,LGP Offspring,Top 50 genes up-regulated in granulocyte/macrophage progenitors (GMP) upon expression of MLL-CBP fusion [GeneID=4297;1387].,CGP,C2,42,125
Cohort,0.06867904316495099,0.11017071772107805,0.6233874534504481,0.5332003825250748,LGP Proband,Top 50 genes up-regulated in granulocyte/macrophage progenitors (GMP) upon expression of MLL-CBP fusion [GeneID=4297;1387].,CGP,C2,42,160
Cohort,-0.02250408003745783,0.03438846047838046,-0.6544078951020743,0.5130380779749597,LonGen OPEL,Top 50 genes up-regulated in granulocyte/macrophage progenitors (GMP) upon expression of MLL-CBP fusion [GeneID=4297;1387].,CGP,C2,83,92
Cohort,-0.04297934239779299,0.018545427141678426,-2.3175169851549295,0.02077334041732097,LGP Offspring,Genes down-regulated in testis tissue expressing hypomorphic allele of THOC1 [GeneID=9984].,CGP,C2,17,19
Cohort,0.06289310147977983,0.05532418529224989,1.1368102602423724,0.2559441364333826,LGP Proband,Genes down-regulated in testis tissue expressing hypomorphic allele of THOC1 [GeneID=9984].,CGP,C2,17,37
Cohort,0.018336088631644567,0.019169186470388736,0.9565397394390689,0.3390900304503488,LonGen OPEL,Genes down-regulated in testis tissue expressing hypomorphic allele of THOC1 [GeneID=9984].,CGP,C2,21,33
Cohort,-0.014792080764964724,0.011832008503443965,-1.2501749606298174,0.2116682376624563,LGP Offspring,Genes up-regulated in testis tissue expressing hypomorphic allele of THOC1 [GeneID=9984].,CGP,C2,6,8
Cohort,0.03096450868568462,0.036916774974048674,0.8387652688365029,0.4018413809696154,LGP Proband,Genes up-regulated in testis tissue expressing hypomorphic allele of THOC1 [GeneID=9984].,CGP,C2,6,17
Cohort,-0.01262704537517755,0.008931719988033163,-1.4137305459749558,0.1578319911502854,LonGen OPEL,Genes up-regulated in testis tissue expressing hypomorphic allele of THOC1 [GeneID=9984].,CGP,C2,8,4
Cohort,0.007023948200378293,0.019501358881319403,0.3601773724141153,0.718826998007031,LGP Offspring,Representative genes up-regulated in MEF cells (embryonic fibroblast) in response to TNF [GeneID=7124].,CGP,C2,11,28
Cohort,0.0070719903592178154,0.05470080175848806,0.1292849488832298,0.897163352596202,LGP Proband,Representative genes up-regulated in MEF cells (embryonic fibroblast) in response to TNF [GeneID=7124].,CGP,C2,11,36
Cohort,-0.0014877990007227618,0.020707576306768376,-0.0718480511037145,0.9427408803319215,LonGen OPEL,Representative genes up-regulated in MEF cells (embryonic fibroblast) in response to TNF [GeneID=7124].,CGP,C2,27,29
Cohort,-0.03208199232220332,0.06885136841595747,-0.46596012628803146,0.6413941389186542,LGP Offspring,Down-regulated genes in the subpopulation of invasive PyMT cells (breast cancer) compared to the general population of PyMT cells.,CGP,C2,148,299
Cohort,0.06723541211339674,0.1949230406137942,0.3449331177149648,0.7302316212152241,LGP Proband,Down-regulated genes in the subpopulation of invasive PyMT cells (breast cancer) compared to the general population of PyMT cells.,CGP,C2,148,440
Cohort,0.03614989243715961,0.05958359713152705,0.6067087953310538,0.5442171813761518,LonGen OPEL,Down-regulated genes in the subpopulation of invasive PyMT cells (breast cancer) compared to the general population of PyMT cells.,CGP,C2,238,291
Cohort,-0.12083403902721057,0.08908414565747581,-1.3564034109033447,0.17542368179643023,LGP Offspring,Up-regulated genes in the subpopulation of invasive PyMT cells (breast cancer) compared to the general population of PyMT cells.,CGP,C2,274,525
Cohort,-0.22332280966708204,0.2536616552828234,-0.8803964060633654,0.3788982241090598,LGP Proband,Up-regulated genes in the subpopulation of invasive PyMT cells (breast cancer) compared to the general population of PyMT cells.,CGP,C2,274,764
Cohort,-0.1346866787879398,0.07816200200119645,-1.7231733494477035,0.08524553355424258,LonGen OPEL,Up-regulated genes in the subpopulation of invasive PyMT cells (breast cancer) compared to the general population of PyMT cells.,CGP,C2,449,472
Cohort,-0.027403914534012457,0.03293036170895301,-0.832177756691994,0.4056024936318726,LGP Offspring,Genes up-regulated in the human skin cells at 4 h after exprosure to 5 Gy dose of ionizing radiation.,CGP,C2,37,73
Cohort,0.1324013851529724,0.08795927773840807,1.5052577574219705,0.1326364379204613,LGP Proband,Genes up-regulated in the human skin cells at 4 h after exprosure to 5 Gy dose of ionizing radiation.,CGP,C2,37,93
Cohort,0.025758885662085798,0.02919694019750951,0.8822460671506607,0.37791009306024625,LonGen OPEL,Genes up-regulated in the human skin cells at 4 h after exprosure to 5 Gy dose of ionizing radiation.,CGP,C2,58,78
Cohort,-0.04058530244843569,0.03397083597747892,-1.1947101471197779,0.23261929360515904,LGP Offspring,Genes displaying an ionizing radiation response in the human skin cell samples.,CGP,C2,43,74
Cohort,0.09411098854413542,0.10002096243449017,0.940912647244066,0.34702207085725234,LGP Proband,Genes displaying an ionizing radiation response in the human skin cell samples.,CGP,C2,43,116
Cohort,0.050335136566306234,0.033245576875567874,1.5140401008742144,0.13041261491993208,LonGen OPEL,Genes displaying an ionizing radiation response in the human skin cell samples.,CGP,C2,64,99
Cohort,0.04747677159199506,0.055555168620707474,0.8545878407126047,0.39308211329172293,LGP Offspring,Down-regulated genes discriminating between MSI (microsatellite instability) and MSS (microsatellite stability) colon cancers.,CGP,C2,97,226
Cohort,0.42053409572580003,0.14398688172309768,2.9206417327276557,0.003587292261652277,LGP Proband,Down-regulated genes discriminating between MSI (microsatellite instability) and MSS (microsatellite stability) colon cancers.,CGP,C2,97,264
Cohort,0.05134102944843798,0.04873440844533972,1.0534862551173023,0.2924378634766861,LonGen OPEL,Down-regulated genes discriminating between MSI (microsatellite instability) and MSS (microsatellite stability) colon cancers.,CGP,C2,145,193
Cohort,0.019701379900229698,0.029877567100870202,0.6594037537834158,0.5098610987589414,LGP Offspring,Up-regulated genes discriminating between MSI (microsatellite instability) and MSS (microsatellite stability) colon cancers.,CGP,C2,29,66
Cohort,-0.01412947109243919,0.08113901696963971,-0.17413904703486982,0.8617984471976936,LGP Proband,Up-regulated genes discriminating between MSI (microsatellite instability) and MSS (microsatellite stability) colon cancers.,CGP,C2,29,74
Cohort,0.01083206616874183,0.02336238963248294,0.46365403279127687,0.6430223906468233,LonGen OPEL,Up-regulated genes discriminating between MSI (microsatellite instability) and MSS (microsatellite stability) colon cancers.,CGP,C2,36,49
Cohort,0.026097988590519483,0.054297481916028977,0.48064823026010683,0.6309220425692401,LGP Offspring,Genes down-regulated in rectal cancer patients resistant to radiotherapy (non-responders) relative to the sensitive ones (responders).,CGP,C2,88,190
Cohort,0.12077761046188072,0.13924543882753823,0.8673721127158014,0.38598764599857616,LGP Proband,Genes down-regulated in rectal cancer patients resistant to radiotherapy (non-responders) relative to the sensitive ones (responders).,CGP,C2,88,232
Cohort,-0.01815035294238603,0.04586172006627719,-0.39576258622999744,0.6923862288461515,LonGen OPEL,Genes down-regulated in rectal cancer patients resistant to radiotherapy (non-responders) relative to the sensitive ones (responders).,CGP,C2,140,166
Cohort,-0.0351990049252097,0.058228705030526046,-0.6044957535421204,0.5457169216291435,LGP Offspring,Genes up-regulated in rectal cancer patients resistant to radiotherapy (non-responders) relative to the sensitive ones (responders).,CGP,C2,111,210
Cohort,-0.12474385983032779,0.16769651459134557,-0.7438667412635989,0.45716661335785747,LGP Proband,Genes up-regulated in rectal cancer patients resistant to radiotherapy (non-responders) relative to the sensitive ones (responders).,CGP,C2,111,308
Cohort,-0.07124513334791259,0.051297828038156905,-1.3888528242349416,0.16526596128960655,LonGen OPEL,Genes up-regulated in rectal cancer patients resistant to radiotherapy (non-responders) relative to the sensitive ones (responders).,CGP,C2,198,205
Cohort,-0.0017020703618237673,0.018420995418954943,-0.09239839232967623,0.9264088917564898,LGP Offspring,"Genes down-regulated in non-neoplastic rectal mucosa samples from patients having cancer associated with ulcerative collitis, compared to those who did not have the cancer.",CGP,C2,12,23
Cohort,0.04018980040452862,0.058592479987912865,0.6859207941500246,0.49295368479183876,LGP Proband,"Genes down-regulated in non-neoplastic rectal mucosa samples from patients having cancer associated with ulcerative collitis, compared to those who did not have the cancer.",CGP,C2,12,47
Cohort,-0.009808769501646534,0.01585247507204872,-0.6187531888280006,0.5362559877908593,LonGen OPEL,"Genes down-regulated in non-neoplastic rectal mucosa samples from patients having cancer associated with ulcerative collitis, compared to those who did not have the cancer.",CGP,C2,19,18
Cohort,0.005084431071318043,0.027628585011255764,0.1840279214171362,0.8540467389136163,LGP Offspring,"Genes up-regulated in non-neoplastic rectal mucosa samples from patients having cancer associated with ulcerative collitis, compared to those who did not have the cancer.",CGP,C2,22,49
Cohort,-0.0052106331933987424,0.07482003371595386,-0.06964221926416587,0.9444951267258843,LGP Proband,"Genes up-regulated in non-neoplastic rectal mucosa samples from patients having cancer associated with ulcerative collitis, compared to those who did not have the cancer.",CGP,C2,22,68
Cohort,0.017801507974196714,0.023034426837839583,0.7728218331420975,0.4398572425166617,LonGen OPEL,"Genes up-regulated in non-neoplastic rectal mucosa samples from patients having cancer associated with ulcerative collitis, compared to those who did not have the cancer.",CGP,C2,33,44
Cohort,0.016321867823590398,0.036320862018224355,0.44937996833337096,0.6533016195684684,LGP Offspring,Unmethylated germline-specific genes with high-CpG-density promoters (HCP) in primary fibroblasts.,CGP,C2,40,90
Cohort,0.01400936321291176,0.09804742963286317,0.14288353366701775,0.8864166756672155,LGP Proband,Unmethylated germline-specific genes with high-CpG-density promoters (HCP) in primary fibroblasts.,CGP,C2,40,116
Cohort,0.02416262117676812,0.03240750306908422,0.7455872525957895,0.45613688893327375,LonGen OPEL,Unmethylated germline-specific genes with high-CpG-density promoters (HCP) in primary fibroblasts.,CGP,C2,63,95
Cohort,0.004494938377407518,0.011021840351578714,0.40782103841339756,0.6835341923627791,LGP Offspring,Methylated germline-specific genes with high-CpG-density promoters (HCP) in primary fibroblasts.,CGP,C2,5,8
Cohort,0.0023562779155620025,0.025992142209038664,0.09065347121495111,0.9277897101347674,LGP Proband,Methylated germline-specific genes with high-CpG-density promoters (HCP) in primary fibroblasts.,CGP,C2,5,7
Cohort,0.006539031569339611,0.009962336887622976,0.6563752704913627,0.5117723923453019,LonGen OPEL,Methylated germline-specific genes with high-CpG-density promoters (HCP) in primary fibroblasts.,CGP,C2,5,10
Cohort,0.03693263642739025,0.028036690301348265,1.3172965863811033,0.1881855433217806,LGP Offspring,Unmethylated germline-specific genes with high-CpG-density promoters (HCP) in sperm.,CGP,C2,23,63
Cohort,0.05557005392401506,0.0725185473820885,0.7662874661736594,0.44372210598035833,LGP Proband,Unmethylated germline-specific genes with high-CpG-density promoters (HCP) in sperm.,CGP,C2,23,70
Cohort,0.050745949679303105,0.025121615520926958,2.0200113976360483,0.04371674641679279,LonGen OPEL,Unmethylated germline-specific genes with high-CpG-density promoters (HCP) in sperm.,CGP,C2,33,67
Cohort,-0.016115830226392368,0.024630365723753947,-0.6543073865464363,0.5131363230787336,LGP Offspring,Methylated germline-specific genes with high-CpG-density promoters (HCP) in sperm.,CGP,C2,22,35
Cohort,-0.03920441279554127,0.06778983544153938,-0.5783228789417905,0.5632022768319519,LGP Proband,Methylated germline-specific genes with high-CpG-density promoters (HCP) in sperm.,CGP,C2,22,53
Cohort,-0.0200442969331952,0.022121451719393375,-0.906102239014577,0.36515592919470474,LonGen OPEL,Methylated germline-specific genes with high-CpG-density promoters (HCP) in sperm.,CGP,C2,35,38
Cohort,0.02577502084309988,0.0202434363937658,1.2732532333807511,0.2033658589910025,LGP Offspring,Germline-specific genes with intermediate-CpG-density promoters (ICP) that are methylated in primary fibroblasts.,CGP,C2,10,31
Cohort,0.026935784044020285,0.05868536417160457,0.4589864001739194,0.6463635278858575,LGP Proband,Germline-specific genes with intermediate-CpG-density promoters (ICP) that are methylated in primary fibroblasts.,CGP,C2,10,46
Cohort,-0.007530213431140666,0.015472349384879661,-0.4866884300389157,0.62661312021144,LonGen OPEL,Germline-specific genes with intermediate-CpG-density promoters (ICP) that are methylated in primary fibroblasts.,CGP,C2,18,19
Cohort,0.02252918116954845,0.019812429007296573,1.137123628872126,0.2558895107052994,LGP Offspring,Unmethylated germline-specific genes with intermediate-CpG-density promoters (ICP) in sperm.,CGP,C2,10,29
Cohort,0.021851512414791167,0.05412330055565404,0.4037357698154723,0.686510528624393,LGP Proband,Unmethylated germline-specific genes with intermediate-CpG-density promoters (ICP) in sperm.,CGP,C2,10,39
Cohort,-0.010567233454119135,0.014851530631465172,-0.7115248735191565,0.47696750142779565,LonGen OPEL,Unmethylated germline-specific genes with intermediate-CpG-density promoters (ICP) in sperm.,CGP,C2,17,17
Cohort,0.0032458396735514177,0.0045407140695379765,0.7148302279869576,0.4749607363588749,LGP Offspring,Methylated germline-specific genes with intermediate-CpG-density promoters (ICP) in sperm.,CGP,C2,0,2
Cohort,0.005084271629229021,0.02086906021301882,0.24362724422335424,0.807579439569138,LGP Proband,Methylated germline-specific genes with intermediate-CpG-density promoters (ICP) in sperm.,CGP,C2,0,7
Cohort,0.003037020022978453,0.004495545117408595,0.6755621273197472,0.49951489654428927,LonGen OPEL,Methylated germline-specific genes with intermediate-CpG-density promoters (ICP) in sperm.,CGP,C2,1,2
Cohort,-0.02263647305194132,0.01641097687177482,-1.3793495188500149,0.16824314873124227,LGP Offspring,Genes identified as hypermethylated in SW48 cells (colon cancer).,CGP,C2,11,16
Cohort,0.08461739199555447,0.04852460114305796,1.7438039675192678,0.08156172897033465,LGP Proband,Genes identified as hypermethylated in SW48 cells (colon cancer).,CGP,C2,11,29
Cohort,-0.03339769909689084,0.016579638786785974,-2.0143803810435794,0.04430551743567024,LonGen OPEL,Genes identified as hypermethylated in SW48 cells (colon cancer).,CGP,C2,25,14
Cohort,-0.006902882868685335,0.013854908171880679,-0.4982265333735757,0.6184864343063282,LGP Offspring,Unmethylated germline-specific genes with low-CpG-density promoters (LCP) in primary fibroblasts.,CGP,C2,8,11
Cohort,-0.014456265443321297,0.03895367053694036,-0.37111433259189786,0.7106466258967423,LGP Proband,Unmethylated germline-specific genes with low-CpG-density promoters (LCP) in primary fibroblasts.,CGP,C2,8,17
Cohort,-0.012415586309174415,0.010858062005060879,-1.1434440421677075,0.25319803813360114,LonGen OPEL,Unmethylated germline-specific genes with low-CpG-density promoters (LCP) in primary fibroblasts.,CGP,C2,10,8
Cohort,0.006337408480813496,0.011432600339897863,0.5543278250265603,0.5795378431076532,LGP Offspring,Methylated germline-specific genes with low-CpG-density promoters (LCP) in primary fibroblasts.,CGP,C2,3,10
Cohort,0.025416221803471306,0.028153899305431784,0.9027602723068526,0.36691379556917136,LGP Proband,Methylated germline-specific genes with low-CpG-density promoters (LCP) in primary fibroblasts.,CGP,C2,3,10
Cohort,-0.006870478328537791,0.007286907310882665,-0.9428524386850707,0.34604245203578443,LonGen OPEL,Methylated germline-specific genes with low-CpG-density promoters (LCP) in primary fibroblasts.,CGP,C2,4,4
Cohort,-0.0010160548017328806,0.010097413845630013,-0.10062525090745009,0.9198777867947374,LGP Offspring,Unmethylated germline-specific genes with low-CpG-density promoters (LCP) in sperm.,CGP,C2,4,6
Cohort,-0.010102394158541432,0.028353288035067096,-0.35630414878326916,0.7217029184801474,LGP Proband,Unmethylated germline-specific genes with low-CpG-density promoters (LCP) in sperm.,CGP,C2,4,9
Cohort,1.3713298976365094e-4,0.005179720284648714,0.026474979772571103,0.978885125546207,LonGen OPEL,Unmethylated germline-specific genes with low-CpG-density promoters (LCP) in sperm.,CGP,C2,2,2
Cohort,4.5058041386103503e-4,0.014753286721073138,0.03054101925758956,0.9756445944297,LGP Offspring,Methylated germline-specific genes with low-CpG-density promoters (LCP) in sperm.,CGP,C2,7,15
Cohort,0.021062350518691403,0.038345348715225325,0.549280453155155,0.5829600350798314,LGP Proband,Methylated germline-specific genes with low-CpG-density promoters (LCP) in sperm.,CGP,C2,7,18
Cohort,-0.019423197627475852,0.011941100375053228,-1.626583565787108,0.10422134857025413,LonGen OPEL,Methylated germline-specific genes with low-CpG-density promoters (LCP) in sperm.,CGP,C2,12,10
Cohort,-0.056747561810434714,0.06502062980641293,-0.8727624137045462,0.3831024861458525,LGP Offspring,Potential direct target genes for MIR34A [GeneID=407040] microRNA in IMR32 cells (neuroblastoma).,CGP,C2,146,268
Cohort,-0.3027555164374124,0.17986994802974685,-1.6831912153960413,0.09271233362299444,LGP Proband,Potential direct target genes for MIR34A [GeneID=407040] microRNA in IMR32 cells (neuroblastoma).,CGP,C2,146,394
Cohort,0.13743473617473734,0.057604497203282125,2.3858334478598096,0.017273344412143576,LonGen OPEL,Potential direct target genes for MIR34A [GeneID=407040] microRNA in IMR32 cells (neuroblastoma).,CGP,C2,211,304
Cohort,-0.15043669021149256,0.1407714050626263,-1.068659435093131,0.2856046105911946,LGP Offspring,Genes whose promoters contain E-box motifs and whose expression changed in MYCN-3 cells (neuroblastoma) upon induction of MYCN [GeneID=4613].,CGP,C2,651,1298
Cohort,-0.6685400342164145,0.38803776929222455,-1.7228736146891632,0.0852820705690084,LGP Proband,Genes whose promoters contain E-box motifs and whose expression changed in MYCN-3 cells (neuroblastoma) upon induction of MYCN [GeneID=4613].,CGP,C2,651,1803
Cohort,0.11323081025356291,0.12967347841595278,0.8731994517055613,0.38281771004240317,LonGen OPEL,Genes whose promoters contain E-box motifs and whose expression changed in MYCN-3 cells (neuroblastoma) upon induction of MYCN [GeneID=4613].,CGP,C2,1033,1291
Cohort,-0.035683682805954346,0.031911010992413884,-1.1182247661923757,0.26386822843736435,LGP Offspring,Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE and H2O2 [PubChem=5283344;784].,CGP,C2,37,63
Cohort,0.0013369761622831508,0.08647759056950795,0.015460377115948111,0.987668592800441,LGP Proband,Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE and H2O2 [PubChem=5283344;784].,CGP,C2,37,81
Cohort,-0.0273911473236254,0.02613024922613491,-1.048254346392891,0.2948396098970618,LonGen OPEL,Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE and H2O2 [PubChem=5283344;784].,CGP,C2,53,53
Cohort,0.005036231631513091,0.039455348784620745,0.1276438248969721,0.8984688081024165,LGP Offspring,Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE and tBH [PubChem=5283344;6410].,CGP,C2,46,103
Cohort,-0.13313562200729104,0.10908130179983237,-1.2205173555005706,0.22261378516960048,LGP Proband,Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE and tBH [PubChem=5283344;6410].,CGP,C2,46,140
Cohort,0.009875019838484765,0.037128530748420284,0.2659685056054883,0.7903323374002422,LonGen OPEL,Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE and tBH [PubChem=5283344;6410].,CGP,C2,91,109
Cohort,-0.009256983620194328,0.03675795431380498,-0.25183620234050225,0.801244215685905,LGP Offspring,Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to tert-butyl hydroperoxide (tBH) and H2O2 [PubChem=6410;784].,CGP,C2,47,98
Cohort,0.07083745618292897,0.09271504528386017,0.7640341000325257,0.4450630183736385,LGP Proband,Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to tert-butyl hydroperoxide (tBH) and H2O2 [PubChem=6410;784].,CGP,C2,47,99
Cohort,0.02378120511114592,0.032179846108524486,0.7390092864628786,0.4601192119809481,LonGen OPEL,Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to tert-butyl hydroperoxide (tBH) and H2O2 [PubChem=6410;784].,CGP,C2,69,91
Cohort,0.06239986094334071,0.027388559741266486,2.2783184487544452,0.023018786822259944,LGP Offspring,"Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE, tBH and H2O2 [PubChem=5283344;6410;784].",CGP,C2,14,59
Cohort,0.08010309918999627,0.08646037569799671,0.9264717917696055,0.3544688668304433,LGP Proband,"Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE, tBH and H2O2 [PubChem=5283344;6410;784].",CGP,C2,14,91
Cohort,-0.01375913469382305,0.02733269672877576,-0.5033947008725812,0.6148260661275271,LonGen OPEL,"Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE, tBH and H2O2 [PubChem=5283344;6410;784].",CGP,C2,52,57
Cohort,-0.005272465773125019,0.032119151657494814,-0.1641533322345617,0.8696595060446182,LGP Offspring,Genes most down-regulated in hypoxia tolerant NCI H460 cells (lung cancer).,CGP,C2,32,65
Cohort,-0.056028061237873426,0.08931176249322248,-0.6273312682875918,0.5306138162222745,LGP Proband,Genes most down-regulated in hypoxia tolerant NCI H460 cells (lung cancer).,CGP,C2,32,97
Cohort,-4.970821771794362e-4,0.029329746400538103,-0.016948055751696386,0.9864823023029311,LonGen OPEL,Genes most down-regulated in hypoxia tolerant NCI H460 cells (lung cancer).,CGP,C2,61,67
Cohort,0.00661254548927399,0.028780918959602386,0.22975449458564973,0.818352047954703,LGP Offspring,Genes most up-regulated in hypoxia tolerant NCI H460 cells (lung cancer).,CGP,C2,24,55
Cohort,-0.024720677430734687,0.07932416750495642,-0.3116411833655873,0.7553911187265024,LGP Proband,Genes most up-regulated in hypoxia tolerant NCI H460 cells (lung cancer).,CGP,C2,24,71
Cohort,-9.442998182048748e-4,0.02256243273780157,-0.04185274829086915,0.9666265802456361,LonGen OPEL,Genes most up-regulated in hypoxia tolerant NCI H460 cells (lung cancer).,CGP,C2,36,43
Cohort,0.030066702043072987,0.02174534416176616,1.3826730825414062,0.16722170735134365,LGP Offspring,Genes up-regulated after GATA1 [GeneID=2623] activation in G1E-ER4 cells (erythroid precursors engineered to express GATA1 upon addition of estradiol [PubChem=5757]).,CGP,C2,12,35
Cohort,-0.09283212697813356,0.05106812519599061,-1.817809575383078,0.06945190958769383,LGP Proband,Genes up-regulated after GATA1 [GeneID=2623] activation in G1E-ER4 cells (erythroid precursors engineered to express GATA1 upon addition of estradiol [PubChem=5757]).,CGP,C2,12,32
Cohort,-0.004411372109106103,0.01605010766255211,-0.27485000112483077,0.7835028019586796,LonGen OPEL,Genes up-regulated after GATA1 [GeneID=2623] activation in G1E-ER4 cells (erythroid precursors engineered to express GATA1 upon addition of estradiol [PubChem=5757]).,CGP,C2,19,21
Cohort,0.011542169998335027,0.06885186074555937,0.16763773518030078,0.866918419745868,LGP Offspring,Down-regulated by induction of exogenous BRCA1 in EcR-293 cells,CGP,C2,150,324
Cohort,0.08682129221970117,0.2051253175140769,0.4232597578489695,0.6722148735887364,LGP Proband,Down-regulated by induction of exogenous BRCA1 in EcR-293 cells,CGP,C2,150,491
Cohort,-0.05323018325191947,0.062016719165122323,-0.8583198848393075,0.3909742254672661,LonGen OPEL,Down-regulated by induction of exogenous BRCA1 in EcR-293 cells,CGP,C2,278,309
Cohort,-0.013753268996181072,0.0655932367757746,-0.20967510786509222,0.8339844283674235,LGP Offspring,Up-regulated by induction of exogenous BRCA1 in EcR-293 cells,CGP,C2,143,286
Cohort,0.1576849363143788,0.17633157281188447,0.8942524234307238,0.3714448382973413,LGP Proband,Up-regulated by induction of exogenous BRCA1 in EcR-293 cells,CGP,C2,143,366
Cohort,0.07456423080384345,0.06149912642872852,1.2124437391847527,0.22570229217716467,LonGen OPEL,Up-regulated by induction of exogenous BRCA1 in EcR-293 cells,CGP,C2,218,281
Cohort,0.031887127139166936,0.030300152223497773,1.052375146631721,0.29300349046735097,LGP Offspring,Cohesin targets identified by ChIP-chip which were up-regulated after knockdown of CTCF and RAD21 [GeneID=10664;5885] by RNAi.,CGP,C2,25,62
Cohort,-0.11347275874275821,0.08132415200637252,-1.395314380085593,0.16329247404790348,LGP Proband,Cohesin targets identified by ChIP-chip which were up-regulated after knockdown of CTCF and RAD21 [GeneID=10664;5885] by RNAi.,CGP,C2,25,80
Cohort,-0.010022296587303445,0.028697123438273516,-0.34924394456681507,0.726998544643448,LonGen OPEL,Cohesin targets identified by ChIP-chip which were up-regulated after knockdown of CTCF and RAD21 [GeneID=10664;5885] by RNAi.,CGP,C2,60,63
Cohort,0.004531772202999685,0.024511626484057268,0.18488255791378094,0.8533766044263486,LGP Offspring,Genes up-regulated in liver from mice with liver specific knockout of POR [GeneID=5447] vs mice with reduced expression of POR in all tissues.,CGP,C2,19,39
Cohort,0.0752279587323546,0.06456843892110072,1.1650887026133505,0.24431621635660117,LGP Proband,Genes up-regulated in liver from mice with liver specific knockout of POR [GeneID=5447] vs mice with reduced expression of POR in all tissues.,CGP,C2,19,54
Cohort,0.02204786049112424,0.019937169559920653,1.1058671304800796,0.26911814812000234,LonGen OPEL,Genes up-regulated in liver from mice with liver specific knockout of POR [GeneID=5447] vs mice with reduced expression of POR in all tissues.,CGP,C2,24,38
Cohort,0.03350406541569915,0.025793034635346976,1.2989578732928508,0.19440126417926426,LGP Offspring,Genes down-regulated in liver from transgenic mice with reduced expression of POR [GeneID=5447] in all tissues.,CGP,C2,17,51
Cohort,0.15418113060319485,0.07759260999590413,1.987059471402413,0.04724257156512463,LGP Proband,Genes down-regulated in liver from transgenic mice with reduced expression of POR [GeneID=5447] in all tissues.,CGP,C2,17,80
Cohort,0.0500368136302522,0.024068162210005933,2.078962788835212,0.03794046576563219,LonGen OPEL,Genes down-regulated in liver from transgenic mice with reduced expression of POR [GeneID=5447] in all tissues.,CGP,C2,31,59
Cohort,-0.06666899921578709,0.028196993579151685,-2.364400978729905,0.018340921886927614,LGP Offspring,Genes up-regulated in liver from transgenic mice with reduced expression of POR [GeneID=5447] in all tissues.,CGP,C2,33,47
Cohort,0.05184419921970666,0.08096952158043239,0.6402927695232383,0.5221581483840534,LGP Proband,Genes up-regulated in liver from transgenic mice with reduced expression of POR [GeneID=5447] in all tissues.,CGP,C2,33,81
Cohort,0.03266616595821045,0.025173098098920408,1.2976617272075621,0.1947795208863761,LonGen OPEL,Genes up-regulated in liver from transgenic mice with reduced expression of POR [GeneID=5447] in all tissues.,CGP,C2,37,60
Cohort,0.017047319535210895,0.020554767055605275,0.8293608723024715,0.40719299161074607,LGP Offspring,Genes down-regulated in liver from mice with liver specific knockout of POR [GeneID=5447].,CGP,C2,11,31
Cohort,0.09494362731863486,0.06160070653057956,1.5412749733885496,0.12362919676459674,LGP Proband,Genes down-regulated in liver from mice with liver specific knockout of POR [GeneID=5447].,CGP,C2,11,51
Cohort,0.01930030939546883,0.018425100004025776,1.0475009303206944,0.29518655879857253,LonGen OPEL,Genes down-regulated in liver from mice with liver specific knockout of POR [GeneID=5447].,CGP,C2,22,34
Cohort,-0.04299437465565609,0.03290051184990621,-1.3067995674899706,0.1917251683984145,LGP Offspring,Genes up-regulated in liver from mice with liver specific knockout of POR [GeneID=5447].,CGP,C2,42,66
Cohort,-0.09997316029398727,0.09357016366770125,-1.0684298966177421,0.28563578659450706,LGP Proband,Genes up-regulated in liver from mice with liver specific knockout of POR [GeneID=5447].,CGP,C2,42,105
Cohort,0.01550407824441494,0.031104550800617234,0.49845047896037387,0.6183042625087276,LonGen OPEL,Genes up-regulated in liver from mice with liver specific knockout of POR [GeneID=5447].,CGP,C2,61,83
Cohort,0.02095889176515635,0.03314994231631337,0.63224519563771,0.5274404403290116,LGP Offspring,Down-regulated genes in pediatric adrenocortical carcinoma (ACC) compared to the adenoma (ACA) tumors.,CGP,C2,29,82
Cohort,0.09330193833967011,0.08822387315743566,1.0575588556758626,0.29056282901127073,LGP Proband,Down-regulated genes in pediatric adrenocortical carcinoma (ACC) compared to the adenoma (ACA) tumors.,CGP,C2,29,99
Cohort,0.039510984288086685,0.028775512221941687,1.3730766626617708,0.17011517308385307,LonGen OPEL,Down-regulated genes in pediatric adrenocortical carcinoma (ACC) compared to the adenoma (ACA) tumors.,CGP,C2,52,76
Cohort,-0.022819614666467498,0.032375418137339684,-0.7048438593028965,0.48115017742915234,LGP Offspring,Up-regulated genes in pediatric adrenocortical carcinoma (ACC) compared to the adenoma (ACA) tumors.,CGP,C2,36,66
Cohort,0.03470022439470475,0.08753542879548273,0.39641348505618396,0.6919014229269514,LGP Proband,Up-regulated genes in pediatric adrenocortical carcinoma (ACC) compared to the adenoma (ACA) tumors.,CGP,C2,36,89
Cohort,-0.010295214044446688,0.026152704265557686,-0.3936577242608586,0.6939391783523765,LonGen OPEL,Up-regulated genes in pediatric adrenocortical carcinoma (ACC) compared to the adenoma (ACA) tumors.,CGP,C2,46,53
Cohort,-0.038329172917566365,0.12616949163408364,-0.30379113382439954,0.7613805020373038,LGP Offspring,Down-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,495,1029
Cohort,-0.43473498280189693,0.33704628039294277,-1.2898376516574062,0.19746457649122567,LGP Proband,Down-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,495,1408
Cohort,-0.24798831543982433,0.10818425556145263,-2.2922773203255797,0.02214977615216745,LonGen OPEL,Down-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,828,880
Cohort,0.010679987539085787,0.01789055159970946,0.596962451356683,0.5507323275929485,LGP Offspring,Top down-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,8,22
Cohort,0.01919777374310254,0.041876548981000065,0.45843734047456536,0.6467577028576224,LGP Proband,Top down-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,8,19
Cohort,0.011422806198634915,0.010507954343100988,1.0870627931624555,0.27733811622656196,LonGen OPEL,Top down-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,6,9
Cohort,-0.08100249226455367,0.027617068841588252,-2.933058998012594,0.0034699815304563746,LGP Offspring,Top up-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,37,40
Cohort,-0.16426248668965585,0.08019880865482794,-2.048191107135197,0.04085391047300845,LGP Proband,Top up-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,37,64
Cohort,-0.004500055155532222,0.022543352559572044,-0.1996178316264442,0.8418304623697337,LonGen OPEL,Top up-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,34,42
Cohort,-0.24553863768974574,0.09093903473726507,-2.700035671140995,0.007106678194612398,LGP Offspring,Up-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,292,510
Cohort,-0.47078819976216935,0.24838158720319725,-1.8954231070961978,0.05838189734084691,LGP Proband,Up-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,292,716
Cohort,-0.0525941612444572,0.07581272751820457,-0.6937378849986369,0.4880489920522342,LonGen OPEL,Up-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.,CGP,C2,395,452
Cohort,-0.05056614428474355,0.04961080466977069,-1.019256684533379,0.30844575509512073,LGP Offspring,Genes up-regulated in MMEC cells (myometrial endothelium) by VEGFA [GeneID=7422] stimulation.,CGP,C2,92,183
Cohort,0.15227535676759632,0.13804827002561307,1.103058783274456,0.2703198222743509,LGP Proband,Genes up-regulated in MMEC cells (myometrial endothelium) by VEGFA [GeneID=7422] stimulation.,CGP,C2,92,245
Cohort,-0.004004258614665837,0.0466004973719767,-0.08592737933037181,0.9315457547834278,LonGen OPEL,Genes up-regulated in MMEC cells (myometrial endothelium) by VEGFA [GeneID=7422] stimulation.,CGP,C2,147,169
Cohort,-0.016246224613795213,0.018685109956903544,-0.8694743917090387,0.38489631630664034,LGP Offspring,Genes up-regulated in MMEC cells (myometrial endothelium) at 12 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,12,20
Cohort,-0.05431774586376107,0.0478421934822394,-1.1353523304470898,0.2565538973681148,LGP Proband,Genes up-regulated in MMEC cells (myometrial endothelium) at 12 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,12,22
Cohort,0.006405862694638289,0.016812717938956945,0.38101291640628726,0.7032953304907197,LonGen OPEL,Genes up-regulated in MMEC cells (myometrial endothelium) at 12 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,19,23
Cohort,-0.03619667342891351,0.03797739664875476,-0.9531109718680614,0.34087451811560165,LGP Offspring,Genes up-regulated in MMEC cells (myometrial endothelium) at 3 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,55,109
Cohort,0.10399595834760829,0.10758021379643244,0.9666829491935531,0.33398278391165903,LGP Proband,Genes up-regulated in MMEC cells (myometrial endothelium) at 3 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,55,150
Cohort,0.0041740107497089925,0.03619503422312725,0.11531998350873111,0.9082205833613557,LonGen OPEL,Genes up-regulated in MMEC cells (myometrial endothelium) at 3 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,90,109
Cohort,-0.028953903730085134,0.03927589199204123,-0.7371927730107896,0.4612609107868949,LGP Offspring,Genes up-regulated in MMEC cells (myometrial endothelium) at 6 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,54,106
Cohort,0.018745823620725018,0.10196651648528214,0.1838429345914822,0.8541813611888669,LGP Proband,Genes up-regulated in MMEC cells (myometrial endothelium) at 6 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,54,120
Cohort,0.017596616285666094,0.0333963171502846,0.5269028978998104,0.5984078223723213,LonGen OPEL,Genes up-regulated in MMEC cells (myometrial endothelium) at 6 h after VEGFA [GeneID=7422] stimulation.,CGP,C2,75,86
Cohort,0.00613906492038799,0.027718284677321327,0.22148069376785348,0.8247850529507531,LGP Offspring,Genes within the smallest region of consistend deletion (SRD) within 1p36.3 area across a large collection of neuroblastoma cell lines and biopsy samples.,CGP,C2,28,58
Cohort,0.031051113730431273,0.08249720904783961,0.37638986929151663,0.7067228081330208,LGP Proband,Genes within the smallest region of consistend deletion (SRD) within 1p36.3 area across a large collection of neuroblastoma cell lines and biopsy samples.,CGP,C2,28,92
Cohort,0.03350836713933182,0.02667534649619815,1.2561548973359178,0.2094283623773305,LonGen OPEL,Genes within the smallest region of consistend deletion (SRD) within 1p36.3 area across a large collection of neuroblastoma cell lines and biopsy samples.,CGP,C2,40,60
Cohort,-0.023297157256977005,0.05407696975627206,-0.43081476942917846,0.6667403898028432,LGP Offspring,Differentially expressed genes in a panel of xenografts representing 8 common pediatric tumors compared to the normal tissues.,CGP,C2,98,183
Cohort,-0.07324166516243466,0.14943167468918025,-0.4901348078630467,0.6241674186855319,LGP Proband,Differentially expressed genes in a panel of xenografts representing 8 common pediatric tumors compared to the normal tissues.,CGP,C2,98,237
Cohort,-0.028594155685702442,0.048860126590618315,-0.5852247564825761,0.5585624593533434,LonGen OPEL,Differentially expressed genes in a panel of xenografts representing 8 common pediatric tumors compared to the normal tissues.,CGP,C2,151,174
Cohort,0.05678768137167088,0.03652113641918906,1.5549264601151158,0.12043160513499122,LGP Offspring,"Genes that reduced viability of NCI-H1155 cells (non-small-cell lung cancer, NSCLC) in the presence of otherwise sublethal concentrations of paclitaxel [PubChem=4666], based on RNAi synthetic lethal screen.",CGP,C2,38,104
Cohort,0.1238660559457222,0.10805089193980807,1.1463677321120522,0.25197182377890853,LGP Proband,"Genes that reduced viability of NCI-H1155 cells (non-small-cell lung cancer, NSCLC) in the presence of otherwise sublethal concentrations of paclitaxel [PubChem=4666], based on RNAi synthetic lethal screen.",CGP,C2,38,151
Cohort,-0.036661465018579024,0.034737080505947905,-1.0553985678877538,0.29156329653250956,LonGen OPEL,"Genes that reduced viability of NCI-H1155 cells (non-small-cell lung cancer, NSCLC) in the presence of otherwise sublethal concentrations of paclitaxel [PubChem=4666], based on RNAi synthetic lethal screen.",CGP,C2,87,86
Cohort,0.007996990582217279,0.008450346742081553,0.9463505849284711,0.3443079434525561,LGP Offspring,Genes down-regulated in NCI-H2170 cells (lung cancer) upon induction of resistance to cisplatin [PubChem=2767].,CGP,C2,1,6
Cohort,-0.012173598628672655,0.02456510271741326,-0.49556473541807167,0.620332089069102,LGP Proband,Genes down-regulated in NCI-H2170 cells (lung cancer) upon induction of resistance to cisplatin [PubChem=2767].,CGP,C2,1,9
Cohort,-0.006301483522012772,0.005757762235548001,-1.0944327438718944,0.2740962860671887,LonGen OPEL,Genes down-regulated in NCI-H2170 cells (lung cancer) upon induction of resistance to cisplatin [PubChem=2767].,CGP,C2,4,1
Cohort,0.014494374387882075,0.022125931373547632,0.6550853902227426,0.5126356229564123,LGP Offspring,Genes up-regulated in NCI-H2170 cells (lung cancer) upon induction of resistance to cisplatin [PubChem=2767].,CGP,C2,13,36
Cohort,-0.01881381117720732,0.052716046701220355,-0.35688964470038287,0.7212647006886379,LGP Proband,Genes up-regulated in NCI-H2170 cells (lung cancer) upon induction of resistance to cisplatin [PubChem=2767].,CGP,C2,13,35
Cohort,-0.018624708253627345,0.02016795058191782,-0.9234804586602808,0.35603672048412816,LonGen OPEL,Genes up-regulated in NCI-H2170 cells (lung cancer) upon induction of resistance to cisplatin [PubChem=2767].,CGP,C2,32,29
Cohort,-0.047235803747067394,0.06081212189477863,-0.7767498037446888,0.4375781000719591,LGP Offspring,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G1/S phase of cell cycle.",CGP,C2,118,231
Cohort,0.09858376292006778,0.16259060751711352,0.606331229248229,0.5444598212708696,LGP Proband,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G1/S phase of cell cycle.",CGP,C2,118,308
Cohort,-0.00421153504512258,0.052259269105090135,-0.08058924507063896,0.9357888766453801,LonGen OPEL,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G1/S phase of cell cycle.",CGP,C2,182,219
Cohort,-0.16508526874055718,0.07157785955622771,-2.3063733641109385,0.021391354268588087,LGP Offspring,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G2 phase of cell cycle.",CGP,C2,196,332
Cohort,-0.17795371762175796,0.2089428450544861,-0.8516861038019891,0.39463281821723006,LGP Proband,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G2 phase of cell cycle.",CGP,C2,196,526
Cohort,0.04021936464492385,0.06518139293832415,0.6170375138036734,0.5373864309989516,LonGen OPEL,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G2 phase of cell cycle.",CGP,C2,270,340
Cohort,0.10524995834107478,0.07833247053169473,1.3436312888725852,0.1795184734632242,LGP Offspring,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G2/M phase of cell cycle.",CGP,C2,167,393
Cohort,-0.11433537708175502,0.21731187563388468,-0.5261349696064521,0.5989343105623981,LGP Proband,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G2/M phase of cell cycle.",CGP,C2,167,554
Cohort,-0.0031446001431461126,0.06397422875660119,-0.04915417042556588,0.9608087643355354,LonGen OPEL,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G2/M phase of cell cycle.",CGP,C2,266,332
Cohort,-0.02273496975690126,0.03885268011045974,-0.5851583389425086,0.5586365225610258,LGP Offspring,A list of known cell cycle regulated genes that was compiled from the literature by the authors.,CGP,C2,54,97
Cohort,0.07112001578761318,0.10938684656742398,0.6501697235030552,0.5157616455630867,LGP Proband,A list of known cell cycle regulated genes that was compiled from the literature by the authors.,CGP,C2,54,137
Cohort,0.041058579525971715,0.0340175126375054,1.2069835899966217,0.22779701468423963,LonGen OPEL,A list of known cell cycle regulated genes that was compiled from the literature by the authors.,CGP,C2,70,99
Cohort,0.09737726801429167,0.052432240759517336,1.857202107018782,0.06371712276374758,LGP Offspring,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the M/G1 phase of cell cycle.",CGP,C2,79,207
Cohort,-0.18526033030944994,0.13467124580273457,-1.3756487452475035,0.16929974271274748,LGP Proband,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the M/G1 phase of cell cycle.",CGP,C2,79,249
Cohort,0.05593517416477529,0.04871945744186703,1.1481074934284354,0.25126910640616335,LonGen OPEL,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the M/G1 phase of cell cycle.",CGP,C2,156,200
Cohort,-0.12629902415547345,0.07198450286173902,-1.7545307550162095,0.07979264650898636,LGP Offspring,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the S phase of cell cycle.",CGP,C2,170,302
Cohort,-0.23465996123946462,0.19420453085378875,-1.2083135249616481,0.22726918188144962,LGP Proband,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the S phase of cell cycle.",CGP,C2,170,441
Cohort,0.0020220783187801824,0.05985936683670019,0.033780482915840536,0.9730606680468282,LonGen OPEL,"Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the S phase of cell cycle.",CGP,C2,258,296
Cohort,-0.0888757759060087,0.05537737358395698,-1.6049113591720847,0.10898035155672259,LGP Offspring,"Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of both BMI1 and PCGF2 [GeneID=648, 7703] by RNAi.",CGP,C2,107,188
Cohort,-0.07697992475450696,0.14529517361242777,-0.5298174938683752,0.596379485681831,LGP Proband,"Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of both BMI1 and PCGF2 [GeneID=648, 7703] by RNAi.",CGP,C2,107,245
Cohort,0.058135329552543094,0.04595534402679664,1.2650395897078754,0.2062273455357471,LonGen OPEL,"Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of both BMI1 and PCGF2 [GeneID=648, 7703] by RNAi.",CGP,C2,135,180
Cohort,0.0018315500725427406,0.04591906415999211,0.039886485189707215,0.96819540248306,LGP Offspring,Genes induced in the liver during hepatitis B (HBV) viral clearance in chimpanzees.,CGP,C2,65,136
Cohort,-0.06458671949138445,0.12095841650034961,-0.5339580440952431,0.5935128498235356,LGP Proband,Genes induced in the liver during hepatitis B (HBV) viral clearance in chimpanzees.,CGP,C2,65,168
Cohort,0.01725058361758367,0.0403353200187169,0.4276793542131026,0.6690002579623862,LonGen OPEL,Genes induced in the liver during hepatitis B (HBV) viral clearance in chimpanzees.,CGP,C2,105,132
Cohort,-0.005185190733035514,0.0032142168865853873,-1.613204993936792,0.10716666967741129,LGP Offspring,Genes down-regulated by telomere shortening due to the knockout of TERC [GeneID=7012] in the presence of chronic liver damage.,CGP,C2,1,0
Cohort,-0.009621819943613183,0.013644881764572852,-0.7051596422473208,0.4809077818397278,LGP Proband,Genes down-regulated by telomere shortening due to the knockout of TERC [GeneID=7012] in the presence of chronic liver damage.,CGP,C2,1,2
Cohort,0,0,NA,NA,LonGen OPEL,Genes down-regulated by telomere shortening due to the knockout of TERC [GeneID=7012] in the presence of chronic liver damage.,CGP,C2,0,0
Cohort,0.011432752155727883,0.01718173284863211,0.6654015783185733,0.5060206358792599,LGP Offspring,Genes up-regulated by telomere shortening due to the knockout of TERC [GeneID=7012] in the presence of chronic liver damage.,CGP,C2,8,22
Cohort,-0.0063022698043422,0.04525058711349827,-0.1392748736836219,0.8892665684631782,LGP Proband,Genes up-regulated by telomere shortening due to the knockout of TERC [GeneID=7012] in the presence of chronic liver damage.,CGP,C2,8,26
Cohort,0.021549488854965416,0.016438293436994284,1.3109322410846138,0.190258719869684,LonGen OPEL,Genes up-regulated by telomere shortening due to the knockout of TERC [GeneID=7012] in the presence of chronic liver damage.,CGP,C2,16,24
Cohort,-0.07431790023144424,0.04213976622076196,-1.7636049484021188,0.07825020375517065,LGP Offspring,Proteins identified in complex with PML [GeneID=5371] in K562 cells (lymphoblast).,CGP,C2,68,117
Cohort,0.12126411605205525,0.11346761477081642,1.0687112467904285,0.2855090268148359,LGP Proband,Proteins identified in complex with PML [GeneID=5371] in K562 cells (lymphoblast).,CGP,C2,68,150
Cohort,0.03404209957090839,0.03675021178018019,0.9263102965101193,0.3545655021875378,LonGen OPEL,Proteins identified in complex with PML [GeneID=5371] in K562 cells (lymphoblast).,CGP,C2,87,118
Cohort,0.011106153973892504,0.07035618929194326,0.15785610456824883,0.874617327952082,LGP Offspring,Genes down-regulated in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,159,340
Cohort,-0.24899914882747953,0.19867270810620014,-1.2533133071019371,0.21044295077679956,LGP Proband,Genes down-regulated in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,159,470
Cohort,-0.009996551855060145,0.061391907924577306,-0.16283175084477508,0.8706922362874995,LonGen OPEL,Genes down-regulated in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,255,315
Cohort,0.037454613668507115,0.060602656609036715,0.618035838100901,0.5367598714972641,LGP Offspring,Genes up-regulated to their maximal levels in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,108,247
Cohort,0.1263015032840718,0.16827698025161011,0.7505572247328424,0.4531308715931459,LGP Proband,Genes up-regulated to their maximal levels in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,108,370
Cohort,0.0014859762856815784,0.0559153765638389,0.026575449849381427,0.9788050154187427,LonGen OPEL,Genes up-regulated to their maximal levels in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,210,257
Cohort,0.04823396995090585,0.036558280243373716,1.3193719625158895,0.18749147850301523,LGP Offspring,Genes up-regulated in a linear fashion in CD34+ [GeneID=947] cells upon increasing activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,38,99
Cohort,-0.012502264516563666,0.09336781250474649,-0.13390336756500634,0.8935112919109216,LGP Proband,Genes up-regulated in a linear fashion in CD34+ [GeneID=947] cells upon increasing activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,38,114
Cohort,0.008551887899661412,0.031979689409305984,0.26741622753762084,0.7892179774095713,LonGen OPEL,Genes up-regulated in a linear fashion in CD34+ [GeneID=947] cells upon increasing activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,65,78
Cohort,0.10521350038764392,0.07280263489073488,1.4451880834471522,0.14886844949417716,LGP Offspring,Genes up-regulated in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,157,378
Cohort,0.14172174820215255,0.2002085219905128,0.7078707079655093,0.4792233232677249,LGP Proband,Genes up-regulated in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,157,524
Cohort,0.02918271342863999,0.06400547429741932,0.45594089800872906,0.6485568379945452,LonGen OPEL,Genes up-regulated in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.,CGP,C2,288,357
Cohort,-0.02033293784378596,0.04018552329580926,-0.5059766845416787,0.6130379723741601,LGP Offspring,Genes negatively correlated with the asbestos exposure of lung cancer patients.,CGP,C2,54,110
Cohort,-0.048085718083128184,0.11309391030820212,-0.42518397278938874,0.6708122470851356,LGP Proband,Genes negatively correlated with the asbestos exposure of lung cancer patients.,CGP,C2,54,159
Cohort,0.040138678012194465,0.03592031598261564,1.1174366626290366,0.264144818620398,LonGen OPEL,Genes negatively correlated with the asbestos exposure of lung cancer patients.,CGP,C2,89,116
Cohort,0.039165363123987704,0.029302577937773047,1.3365842147799851,0.18180806327984259,LGP Offspring,Genes positively correlated with the asbestos exposure of lung cancer patients.,CGP,C2,20,60
Cohort,0.0264455299035501,0.07209322441088047,0.3668240686923539,0.7138433011265606,LGP Proband,Genes positively correlated with the asbestos exposure of lung cancer patients.,CGP,C2,20,58
Cohort,-0.002191631780705737,0.022249735707303247,-0.09850147478319737,0.9215588995699953,LonGen OPEL,Genes positively correlated with the asbestos exposure of lung cancer patients.,CGP,C2,33,36
Cohort,0.01524337914945651,0.049814931827858434,0.3060002009464123,0.7596987053006021,LGP Offspring,Genes down-regulated in primary cultures of ovarian surface epithlium cells exposed to progesterone [PubChem=5994] for 5 days.,CGP,C2,74,165
Cohort,0.09803436500092204,0.13556243459319192,0.723167633386878,0.4697796610469607,LGP Proband,Genes down-regulated in primary cultures of ovarian surface epithlium cells exposed to progesterone [PubChem=5994] for 5 days.,CGP,C2,74,245
Cohort,-0.040641149264399275,0.04158687662110413,-0.9772589952998556,0.3287378501377508,LonGen OPEL,Genes down-regulated in primary cultures of ovarian surface epithlium cells exposed to progesterone [PubChem=5994] for 5 days.,CGP,C2,123,143
Cohort,-0.05691398276135739,0.06311607023005973,-0.9017352087020695,0.3675187064027884,LGP Offspring,Genes up-regulated in primary cultures of ovarian surface epithlium cells exposed to progesterone [PubChem=5994] for 5 days.,CGP,C2,139,261
Cohort,-0.4806437617492726,0.17111459119128225,-2.8088999214098576,0.005087332908463603,LGP Proband,Genes up-regulated in primary cultures of ovarian surface epithlium cells exposed to progesterone [PubChem=5994] for 5 days.,CGP,C2,139,338
Cohort,-0.02036832687837444,0.05360249721243031,-0.37998839489983816,0.7040553930714482,LonGen OPEL,Genes up-regulated in primary cultures of ovarian surface epithlium cells exposed to progesterone [PubChem=5994] for 5 days.,CGP,C2,192,230
Cohort,-0.017531305489585022,0.029689076478210348,-0.590496828099444,0.5550549616036093,LGP Offspring,Atherosclerotic process genes whose coronary expression changed after darapladib [PubChem=9939609] treatment.,CGP,C2,29,57
Cohort,0.13757923690180413,0.07378822550257409,1.864514778133602,0.06260053755617276,LGP Proband,Atherosclerotic process genes whose coronary expression changed after darapladib [PubChem=9939609] treatment.,CGP,C2,29,70
Cohort,0.021698477057621225,0.02271142559138489,0.9553991655130665,0.3396659287153826,LonGen OPEL,Atherosclerotic process genes whose coronary expression changed after darapladib [PubChem=9939609] treatment.,CGP,C2,31,47
Cohort,-0.02470356027011568,0.01845907976513177,-1.3382877469753072,0.18125260668724455,LGP Offspring,Genes up-regulated in NCCIT cell line (embryonic teratocarcinoma) after stimulation with WNT3A [GeneID=89780].,CGP,C2,14,19
Cohort,-0.0708180831205772,0.05268862426570085,-1.3440867759889157,0.17928583221957095,LGP Proband,Genes up-regulated in NCCIT cell line (embryonic teratocarcinoma) after stimulation with WNT3A [GeneID=89780].,CGP,C2,14,31
Cohort,-0.003956150368465725,0.015243917133739437,-0.25952321399790074,0.7952986780761634,LonGen OPEL,Genes up-regulated in NCCIT cell line (embryonic teratocarcinoma) after stimulation with WNT3A [GeneID=89780].,CGP,C2,17,19
Cohort,0.006016942666859222,0.006948566767425842,0.8659257179575539,0.3868381133563943,LGP Offspring,"The 'ER-alpha profile': genes down-regulated in T47D cells (breast cancer, ESR2 [GeneID=2100] Tet-Off) upon activation of ESR1 [GeneID=2099] by estradiol (E2) [PubChem=5757].",CGP,C2,1,4
Cohort,0.0010086854316127694,0.02088922383059143,0.04828735810353997,0.9614987903581496,LGP Proband,"The 'ER-alpha profile': genes down-regulated in T47D cells (breast cancer, ESR2 [GeneID=2100] Tet-Off) upon activation of ESR1 [GeneID=2099] by estradiol (E2) [PubChem=5757].",CGP,C2,1,6
Cohort,-0.005540186010464337,0.005770274456521463,-0.9601252162629658,0.3372837430370902,LonGen OPEL,"The 'ER-alpha profile': genes down-regulated in T47D cells (breast cancer, ESR2 [GeneID=2100] Tet-Off) upon activation of ESR1 [GeneID=2099] by estradiol (E2) [PubChem=5757].",CGP,C2,3,2
Cohort,-0.01030396774499128,0.02895527158656505,-0.35585809354909365,0.7220578618208429,LGP Offspring,"The 'ER-alpha profile': genes up-regulated in T47D cells (breast cancer, ESR2 [GeneID=2100] Tet-Off) upon activation of ESR1 [GeneID=2099] by estradiol (E2) [PubChem=5757].",CGP,C2,31,56
Cohort,-0.0014623084414605006,0.07799300779471599,-0.0187492248703809,0.9850456438183834,LGP Proband,"The 'ER-alpha profile': genes up-regulated in T47D cells (breast cancer, ESR2 [GeneID=2100] Tet-Off) upon activation of ESR1 [GeneID=2099] by estradiol (E2) [PubChem=5757].",CGP,C2,31,64
Cohort,0.01234208310335778,0.024655601434030106,0.5005792755200452,0.6168056247316032,LonGen OPEL,"The 'ER-alpha profile': genes up-regulated in T47D cells (breast cancer, ESR2 [GeneID=2100] Tet-Off) upon activation of ESR1 [GeneID=2099] by estradiol (E2) [PubChem=5757].",CGP,C2,40,52
Cohort,-0.04356557537639291,0.021285343366287963,-2.046740549433311,0.0410697625979962,LGP Offspring,Genes uniquely down-regulated in T47D cells (breast cancer) by induction of ESR2 [GeneID=2100] expression in the Tet-Off system.,CGP,C2,20,25
Cohort,0.07382081627833817,0.05405223691404749,1.3657310130518037,0.17239160263301678,LGP Proband,Genes uniquely down-regulated in T47D cells (breast cancer) by induction of ESR2 [GeneID=2100] expression in the Tet-Off system.,CGP,C2,20,29
Cohort,0.012682873556331334,0.017250515931967948,0.7352170570636646,0.46242386923635403,LonGen OPEL,Genes uniquely down-regulated in T47D cells (breast cancer) by induction of ESR2 [GeneID=2100] expression in the Tet-Off system.,CGP,C2,20,27
Cohort,-0.006676674564048381,0.024331244066386832,-0.27440744689549534,0.7838553552270049,LGP Offspring,Genes uniquely up-regulated in T47D cells (breast cancer) by induction of ESR2 [GeneID=2100] expression in the Tet-Off system.,CGP,C2,22,39
Cohort,-0.03649887873549532,0.07090371871435974,-0.5147667766557271,0.6068523956438392,LGP Proband,Genes uniquely up-regulated in T47D cells (breast cancer) by induction of ESR2 [GeneID=2100] expression in the Tet-Off system.,CGP,C2,22,58
Cohort,-0.03598743118209506,0.021825440406227643,-1.6488753726053773,0.09956774416530213,LonGen OPEL,Genes uniquely up-regulated in T47D cells (breast cancer) by induction of ESR2 [GeneID=2100] expression in the Tet-Off system.,CGP,C2,41,34
Cohort,-0.0036561830844035427,0.02030571289192295,-0.18005686891484962,0.8571618834176559,LGP Offspring,Protease genes down-regulated at tumor-bone interface compared to the tumor alone area.,CGP,C2,14,29
Cohort,-0.08701716850380227,0.05313298260988905,-1.6377241447689166,0.10185646147868382,LGP Proband,Protease genes down-regulated at tumor-bone interface compared to the tumor alone area.,CGP,C2,14,34
Cohort,0.0302855749239137,0.018714043927655865,1.6183340725815691,0.10598676290725634,LonGen OPEL,Protease genes down-regulated at tumor-bone interface compared to the tumor alone area.,CGP,C2,17,35
Cohort,0.014147030825467012,0.02432633875286035,0.5815519946997191,0.5610623498100348,LGP Offspring,Protease genes up-regulated at tumor-bone interface compared to the tumor alone area.,CGP,C2,18,45
Cohort,-0.12457818788239433,0.06882069373846435,-1.8101850056295894,0.07062690661082237,LGP Proband,Protease genes up-regulated at tumor-bone interface compared to the tumor alone area.,CGP,C2,18,55
Cohort,-0.01590220427002908,0.022738871397266075,-0.6993400856271619,0.4845438208858711,LonGen OPEL,Protease genes up-regulated at tumor-bone interface compared to the tumor alone area.,CGP,C2,41,42
Cohort,-0.01072737039340255,0.027252606128450308,-0.3936273229371532,0.6939803258886577,LGP Offspring,Genes from the 254-gene classifier which were down-regulated in melanoma patients with a reported distant metastasis within 4 years.,CGP,C2,26,53
Cohort,0.024658526025967357,0.08170134537213682,0.30181297399267587,0.7628698824352478,LGP Proband,Genes from the 254-gene classifier which were down-regulated in melanoma patients with a reported distant metastasis within 4 years.,CGP,C2,26,81
Cohort,-0.03432639899080059,0.022138724255392064,-1.550513868586629,0.12141570220082505,LonGen OPEL,Genes from the 254-gene classifier which were down-regulated in melanoma patients with a reported distant metastasis within 4 years.,CGP,C2,37,38
Cohort,-0.1339493384999742,0.06010536915559371,-2.2285752567831656,0.02617024195162639,LGP Offspring,Genes from the 254-gene classifier which were up-regulated in melanoma patients with a reported distant metastasis within 4 years.,CGP,C2,145,232
Cohort,-0.1772299392219098,0.16394727126932068,-1.0810179263720059,0.2800016265156066,LGP Proband,Genes from the 254-gene classifier which were up-regulated in melanoma patients with a reported distant metastasis within 4 years.,CGP,C2,145,346
Cohort,-0.017155171951710974,0.052638118975091006,-0.3259077696113915,0.7445797940846324,LonGen OPEL,Genes from the 254-gene classifier which were up-regulated in melanoma patients with a reported distant metastasis within 4 years.,CGP,C2,203,238
Cohort,-0.03985089077535443,0.0422059480338786,-0.9442008207792473,0.3454043723161555,LGP Offspring,Genes down-regulated in head and neck tumor samples which clustered around known hypoxia genes.,CGP,C2,63,107
Cohort,0.06917726440920866,0.11794028683190694,0.5865448208363506,0.5576681709908538,LGP Proband,Genes down-regulated in head and neck tumor samples which clustered around known hypoxia genes.,CGP,C2,63,166
Cohort,-0.006793952236286307,0.03666230535642283,-0.18531164830571906,0.8530318092218642,LonGen OPEL,Genes down-regulated in head and neck tumor samples which clustered around known hypoxia genes.,CGP,C2,92,107
Cohort,-0.0018804516000334379,0.07573221573234867,-0.024830273112294687,0.9801976717547596,LGP Offspring,"Genes regulated by hypoxia, based on literature searches.",CGP,C2,180,392
Cohort,-0.26540090154425805,0.20774763165205667,-1.2775158948081833,0.20177567379339598,LGP Proband,"Genes regulated by hypoxia, based on literature searches.",CGP,C2,180,546
Cohort,0.03696365002809205,0.06759335939277666,0.5468532761228931,0.5846328010042712,LonGen OPEL,"Genes regulated by hypoxia, based on literature searches.",CGP,C2,301,368
Cohort,0.07368415297318731,0.04636310499990857,1.5892842589669658,0.11246378175265956,LGP Offspring,Genes up-regulated in head and neck tumor samples which clustered around known hypoxia genes.,CGP,C2,66,168
Cohort,-0.0636444601747391,0.1292821687349006,-0.4922910931765476,0.6226431367315353,LGP Proband,Genes up-regulated in head and neck tumor samples which clustered around known hypoxia genes.,CGP,C2,66,211
Cohort,0.016748194530575234,0.04192020327275718,0.39952560395763725,0.6896131354994544,LonGen OPEL,Genes up-regulated in head and neck tumor samples which clustered around known hypoxia genes.,CGP,C2,125,154
Cohort,0.0984320677508258,0.04343814713198475,2.2660282320915903,0.023765022194168976,LGP Offspring,Transcripts (mRNA molecules) rapidly degraded upon interaction with KHSRP [GeneID=8570].,CGP,C2,45,144
Cohort,-0.09126314608722938,0.11626331115506662,-0.7849694386005128,0.43269440606230514,LGP Proband,Transcripts (mRNA molecules) rapidly degraded upon interaction with KHSRP [GeneID=8570].,CGP,C2,45,184
Cohort,0.03273648389946367,0.03795275117354673,0.8625589156835927,0.3886398175641963,LonGen OPEL,Transcripts (mRNA molecules) rapidly degraded upon interaction with KHSRP [GeneID=8570].,CGP,C2,95,128
Cohort,0.04456905733678579,0.15505265331941703,0.28744466078223807,0.7738599612913032,LGP Offspring,The 'adult tissue stem' module: genes coordinately up-regulated in a compendium of adult tissue stem cells.,CGP,C2,713,1535
Cohort,-0.30691754583658704,0.44232804227056965,-0.6938686144814831,0.48795782016870615,LGP Proband,The 'adult tissue stem' module: genes coordinately up-regulated in a compendium of adult tissue stem cells.,CGP,C2,713,2079
Cohort,-0.029937824847973315,0.13367048945289733,-0.22396734664851192,0.8228401818658643,LonGen OPEL,The 'adult tissue stem' module: genes coordinately up-regulated in a compendium of adult tissue stem cells.,CGP,C2,1164,1384
Cohort,-0.16104113531203376,0.08631776880202201,-1.8656776877701378,0.06251939676548655,LGP Offspring,The 'core ESC-like gene module': genes coordinately up-regulated in a compendium of mouse embryonic stem cells (ESC) which are shared with the human ESC-like module.,CGP,C2,260,477
Cohort,0.0490029002986267,0.23820903335523785,0.2057138623519342,0.8370646316049593,LGP Proband,The 'core ESC-like gene module': genes coordinately up-regulated in a compendium of mouse embryonic stem cells (ESC) which are shared with the human ESC-like module.,CGP,C2,260,715
Cohort,0.004436088459401408,0.0771702891768258,0.05748440891852409,0.9541737520448732,LonGen OPEL,The 'core ESC-like gene module': genes coordinately up-regulated in a compendium of mouse embryonic stem cells (ESC) which are shared with the human ESC-like module.,CGP,C2,383,466
Cohort,-0.051774242226530334,0.044590492120940795,-1.1611049747131155,0.24600904860526787,LGP Offspring,Genes down-regulated in cancer endometrium samples compared to the normal endometrium.,CGP,C2,71,133
Cohort,-0.06266714760346605,0.12278368441611255,-0.5103866030855352,0.6099156945706503,LGP Proband,Genes down-regulated in cancer endometrium samples compared to the normal endometrium.,CGP,C2,71,174
Cohort,0.001961756474585549,0.03635357344456613,0.05396323631229651,0.956977994975826,LonGen OPEL,Genes down-regulated in cancer endometrium samples compared to the normal endometrium.,CGP,C2,98,114
Cohort,-0.011425870205095797,0.017784941781768763,-0.642446309091008,0.5208012569875531,LGP Offspring,Genes up-regulated in cancer endometrium samples compared to the normal endometrium.,CGP,C2,11,21
Cohort,-0.02627410119312634,0.06154524736517488,-0.4269070694806148,0.669557196935299,LGP Proband,Genes up-regulated in cancer endometrium samples compared to the normal endometrium.,CGP,C2,11,48
Cohort,0.014548496627323024,0.01802787995944089,0.8069998613289094,0.41990762042367,LonGen OPEL,Genes up-regulated in cancer endometrium samples compared to the normal endometrium.,CGP,C2,20,29
Cohort,0.0024864764629083046,0.0071415634466539665,0.34816976443348585,0.7278210871812304,LGP Offspring,Genes down-regulated in late stage (stage 3) endometrial cancers compared to the earlier stages (stage 1 and 2).,CGP,C2,1,4
Cohort,-0.0050635195864095935,0.019356071500466965,-0.2615985163253523,0.793695578413293,LGP Proband,Genes down-regulated in late stage (stage 3) endometrial cancers compared to the earlier stages (stage 1 and 2).,CGP,C2,1,5
Cohort,-0.003100996855697504,0.004503741997551612,-0.6885378552730844,0.4913147576842284,LonGen OPEL,Genes down-regulated in late stage (stage 3) endometrial cancers compared to the earlier stages (stage 1 and 2).,CGP,C2,2,1
Cohort,-0.07563139806129762,0.06710335485160017,-1.1270881795486576,0.26010510904287776,LGP Offspring,Genes that comprise the mitochondria gene module,CGP,C2,160,295
Cohort,-0.3073703285995015,0.1964992953901571,-1.5642311998585317,0.11814262398553818,LGP Proband,Genes that comprise the mitochondria gene module,CGP,C2,160,470
Cohort,-0.00673256775854359,0.06674065530642466,-0.1008765605856359,0.9196738525840719,LonGen OPEL,Genes that comprise the mitochondria gene module,CGP,C2,271,329
Cohort,0.006240087064857382,0.034685983298229923,0.17990226804888712,0.8572832075408693,LGP Offspring,Genes that comprise the proteasome gene module,CGP,C2,31,74
Cohort,-0.10701207244548493,0.08797257483645089,-1.2164253762542498,0.22416707077449718,LGP Proband,Genes that comprise the proteasome gene module,CGP,C2,31,86
Cohort,-0.02286064493089836,0.028098210260331994,-0.8135979024675521,0.4161186372502619,LonGen OPEL,Genes that comprise the proteasome gene module,CGP,C2,59,61
Cohort,-0.02372417530160967,0.05594971631237618,-0.42402673088016785,0.6716812145355218,LGP Offspring,Genes negatively correlated with recurrence free survival in patients with hepatitis B-related (HBV) hepatocellular carcinoma (HCC).,CGP,C2,96,197
Cohort,0.03191959041224681,0.15509071501524732,0.2058123879892405,0.8369876911660612,LGP Proband,Genes negatively correlated with recurrence free survival in patients with hepatitis B-related (HBV) hepatocellular carcinoma (HCC).,CGP,C2,96,304
Cohort,-0.003573418726005237,0.05134729468071062,-0.06959312556241926,0.9445349874743989,LonGen OPEL,Genes negatively correlated with recurrence free survival in patients with hepatitis B-related (HBV) hepatocellular carcinoma (HCC).,CGP,C2,166,206
Cohort,-0.025040149963718825,0.06459938179975662,-0.3876221299042395,0.6984177057205585,LGP Offspring,Genes positively correlated with recurrence free survival in patients with hepatitis B-related (HBV) hepatocellular carcinoma (HCC).,CGP,C2,146,290
Cohort,-0.23068050622647832,0.17932158220160932,-1.2864068194932985,0.19865810377571733,LGP Proband,Genes positively correlated with recurrence free survival in patients with hepatitis B-related (HBV) hepatocellular carcinoma (HCC).,CGP,C2,146,382
Cohort,0.050291136412318214,0.055354079329176235,0.9085353242576754,0.363870443252322,LonGen OPEL,Genes positively correlated with recurrence free survival in patients with hepatitis B-related (HBV) hepatocellular carcinoma (HCC).,CGP,C2,202,267
Cohort,0.007716686024538941,0.03100432882335091,0.2488906006804804,0.8035210038667484,LGP Offspring,Genes down-regulated in the Ad/AH cells (adenocarcinoma) engineered to stably express the Epstein-Barr virus (EBV) gene EBNA1.,CGP,C2,30,65
Cohort,0.10803149985052878,0.08140374370607018,1.3271072672112623,0.18483639909630747,LGP Proband,Genes down-regulated in the Ad/AH cells (adenocarcinoma) engineered to stably express the Epstein-Barr virus (EBV) gene EBNA1.,CGP,C2,30,84
Cohort,-0.028306997582404507,0.029098830891678577,-0.9727881401070133,0.33095412011485037,LonGen OPEL,Genes down-regulated in the Ad/AH cells (adenocarcinoma) engineered to stably express the Epstein-Barr virus (EBV) gene EBNA1.,CGP,C2,64,58
Cohort,-0.10348462986115486,0.06298459723061205,-1.6430148704810454,0.10084487194148878,LGP Offspring,Genes up-regulated in the Ad/AH cells (adenocarcinoma) engineered to stably express the Epstein-Barr virus (EBV) gene EBNA1.,CGP,C2,132,226
Cohort,-0.2660607489043362,0.18178765028806132,-1.4635798883077888,0.14368555205977127,LGP Proband,Genes up-regulated in the Ad/AH cells (adenocarcinoma) engineered to stably express the Epstein-Barr virus (EBV) gene EBNA1.,CGP,C2,132,361
Cohort,-0.014403111687587806,0.05251614538209919,-0.27426064085231383,0.7839554868835643,LonGen OPEL,Genes up-regulated in the Ad/AH cells (adenocarcinoma) engineered to stably express the Epstein-Barr virus (EBV) gene EBNA1.,CGP,C2,194,231
Cohort,-0.009463826640356618,0.008473774868410871,-1.1168371578570646,0.26446075237216876,LGP Offspring,Selected genes with immunologic function which were reciprocally changed in evasion and tolerogenic tumor models.,CGP,C2,3,4
Cohort,4.837420306981218e-4,0.024765625488216796,0.01953280085448602,0.9844207426602283,LGP Proband,Selected genes with immunologic function which were reciprocally changed in evasion and tolerogenic tumor models.,CGP,C2,3,7
Cohort,0.0022642437043923847,0.005791076939405635,0.3909883650457551,0.6959104618583827,LonGen OPEL,Selected genes with immunologic function which were reciprocally changed in evasion and tolerogenic tumor models.,CGP,C2,2,3
Cohort,-0.042326905969765155,0.023899556286886295,-1.771033129723415,0.07700573546038508,LGP Offspring,Selected genes with immunologic function which were reciprocally changed in evasion and tolerogenic tumor models.,CGP,C2,27,32
Cohort,-0.11069006925665967,0.0684946823420856,-1.6160388729717154,0.10646409273877418,LGP Proband,Selected genes with immunologic function which were reciprocally changed in evasion and tolerogenic tumor models.,CGP,C2,27,50
Cohort,0.03648018752056107,0.024279271804764534,1.5025239559862846,0.13335844196366525,LonGen OPEL,Selected genes with immunologic function which were reciprocally changed in evasion and tolerogenic tumor models.,CGP,C2,27,52
Cohort,0.0011793090988749028,0.020186863222400292,0.05841963091949253,0.9534316426077136,LGP Offspring,Down-regulated genes defining rejection of mammary carcinoma (MMC) tumors.,CGP,C2,13,27
Cohort,0.012375157231507552,0.055327416016607255,0.22367133913850207,0.823067825507485,LGP Proband,Down-regulated genes defining rejection of mammary carcinoma (MMC) tumors.,CGP,C2,13,40
Cohort,-0.006468219599798353,0.017051166377360996,-0.3793417679852255,0.704535259242074,LonGen OPEL,Down-regulated genes defining rejection of mammary carcinoma (MMC) tumors.,CGP,C2,20,26
Cohort,-0.05542879574582864,0.025666983080061823,-2.1595368482899677,0.031159527997935994,LGP Offspring,Up-regulated genes defining rejection of mammary carcinoma (MMC) tumors.,CGP,C2,31,37
Cohort,-0.16305157898494327,0.07147550632914028,-2.281223140051654,0.02278657001684051,LGP Proband,Up-regulated genes defining rejection of mammary carcinoma (MMC) tumors.,CGP,C2,31,53
Cohort,-0.011634313650235704,0.022849795008112763,-0.5091649026218822,0.6107777516214324,LonGen OPEL,Up-regulated genes defining rejection of mammary carcinoma (MMC) tumors.,CGP,C2,41,37
Cohort,-0.016374905694152356,0.026992309411592016,-0.6066507850239761,0.5442863657562127,LGP Offspring,"Common target genes down-regulated by all three Runx family members (RUNX1, RUNX2, and RUNX3 [GeneID=861;860;864]) in MEF cells (embryonic fibroblasts).",CGP,C2,26,46
Cohort,0.05505887606015205,0.078485461029554,0.7015168839923029,0.483176203418616,LGP Proband,"Common target genes down-regulated by all three Runx family members (RUNX1, RUNX2, and RUNX3 [GeneID=861;860;864]) in MEF cells (embryonic fibroblasts).",CGP,C2,26,77
Cohort,0.006763438871179336,0.02378068285193153,0.28440894289248686,0.7761709761096104,LonGen OPEL,"Common target genes down-regulated by all three Runx family members (RUNX1, RUNX2, and RUNX3 [GeneID=861;860;864]) in MEF cells (embryonic fibroblasts).",CGP,C2,40,51
Cohort,0.019616576795457953,0.022065112571202805,0.8890313490201524,0.3743024740099413,LGP Offspring,"Common target genes up-regulated by all three Runx family members (RUNX1, RUNX2, and RUNX3 [GeneID=861;860;864]) in MEF cells (embryonic fibroblasts).",CGP,C2,13,37
Cohort,-0.043954226274239394,0.054222775212316277,-0.8106229550614285,0.4178134813715011,LGP Proband,"Common target genes up-regulated by all three Runx family members (RUNX1, RUNX2, and RUNX3 [GeneID=861;860;864]) in MEF cells (embryonic fibroblasts).",CGP,C2,13,39
Cohort,0.024108279587975012,0.01884343385184311,1.2793994861831905,0.2011292145490234,LonGen OPEL,"Common target genes up-regulated by all three Runx family members (RUNX1, RUNX2, and RUNX3 [GeneID=861;860;864]) in MEF cells (embryonic fibroblasts).",CGP,C2,19,35
Cohort,-0.06653888576131131,0.022867032782075355,-2.90981722007539,0.0037352526754226944,LGP Offspring,Genes down-regulated in brain endothelial cells from patients with Alzheimer disease.,CGP,C2,28,28
Cohort,-0.08215888223160002,0.06424874155106981,-1.2787625134461795,0.20133641023253865,LGP Proband,Genes down-regulated in brain endothelial cells from patients with Alzheimer disease.,CGP,C2,28,45
Cohort,-0.009889721188953387,0.021410225079075758,-0.46191579735509763,0.6442679191165995,LonGen OPEL,Genes down-regulated in brain endothelial cells from patients with Alzheimer disease.,CGP,C2,32,39
Cohort,-0.03895920843770956,0.019491377549107684,-1.9987919447742222,0.04603082623379349,LGP Offspring,Genes up-regulated in brain endothelial cells from patients with Alzheimer disease.,CGP,C2,16,21
Cohort,0.05865341292618681,0.0546905557577104,1.0724596251322187,0.28382386356224604,LGP Proband,Genes up-regulated in brain endothelial cells from patients with Alzheimer disease.,CGP,C2,16,33
Cohort,0.003506134410944662,0.01705386033460752,0.2055918332947549,0.8371623231648415,LonGen OPEL,Genes up-regulated in brain endothelial cells from patients with Alzheimer disease.,CGP,C2,19,25
Cohort,0.008124759301435889,0.01375334598723086,0.5907478303082924,0.5548868429109252,LGP Offspring,Genes downstream of CDKN1A [GeneID=1026] in a TP53 [GeneID=7157] independent pathway in 2774qw1 cells (ovarian cancer).,CGP,C2,5,14
Cohort,0.024220675731491507,0.03742229210028646,0.6472258745291045,0.5176638681878536,LGP Proband,Genes downstream of CDKN1A [GeneID=1026] in a TP53 [GeneID=7157] independent pathway in 2774qw1 cells (ovarian cancer).,CGP,C2,5,18
Cohort,-0.0078667335976814,0.011677855064326267,-0.6736454215562965,0.5007323198421139,LonGen OPEL,Genes downstream of CDKN1A [GeneID=1026] in a TP53 [GeneID=7157] independent pathway in 2774qw1 cells (ovarian cancer).,CGP,C2,12,9
Cohort,0.014562242524854283,0.04533411672925251,0.321220387105453,0.7481426701196676,LGP Offspring,Genes downstream of both CDKN1A and TP53 [GeneID=1026;7157] in 2774qw1 cells (ovarian cancer).,CGP,C2,66,135
Cohort,-0.18634582224960042,0.12045818915871083,-1.54697512515383,0.12224859983994284,LGP Proband,Genes downstream of both CDKN1A and TP53 [GeneID=1026;7157] in 2774qw1 cells (ovarian cancer).,CGP,C2,66,176
Cohort,-0.062311033703707094,0.03932426267890872,-1.584544234496917,0.11346710322296753,LonGen OPEL,Genes downstream of both CDKN1A and TP53 [GeneID=1026;7157] in 2774qw1 cells (ovarian cancer).,CGP,C2,115,118
Cohort,-0.03167343336506392,0.06761907155201194,-0.46840976425860886,0.6396425835185474,LGP Offspring,Genes associated with migration rate of 40 human bladder cancer cells.,CGP,C2,156,314
Cohort,0.12623385441686172,0.18471558049680753,0.6833958135926895,0.49454657244743894,LGP Proband,Genes associated with migration rate of 40 human bladder cancer cells.,CGP,C2,156,434
Cohort,-0.08004807654000355,0.06058967568959833,-1.3211504374126517,0.18683084852524282,LonGen OPEL,Genes associated with migration rate of 40 human bladder cancer cells.,CGP,C2,273,300
Cohort,-7.091574736719694e-4,0.027617215457815102,-0.025678094692609295,0.979521674071008,LGP Offspring,Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in SK-Hep-1 cells (hepatocellular carcinoma).,CGP,C2,25,49
Cohort,-0.06550479101610904,0.08201313416790351,-0.7987109830725729,0.4246854035909019,LGP Proband,Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in SK-Hep-1 cells (hepatocellular carcinoma).,CGP,C2,25,82
Cohort,-0.005473420668835624,0.02666940533992662,-0.20523219768389048,0.8374431850135033,LonGen OPEL,Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in SK-Hep-1 cells (hepatocellular carcinoma).,CGP,C2,45,53
Cohort,-0.0053989200215319,0.015531187853355317,-0.34761797181955606,0.7282353132661828,LGP Offspring,Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in SK-Hep-1 cells (hepatocellular carcinoma).,CGP,C2,9,15
Cohort,-0.046390041556817245,0.05359050781834964,-0.8656391485234831,0.3869370177305733,LGP Proband,Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in SK-Hep-1 cells (hepatocellular carcinoma).,CGP,C2,9,38
Cohort,-0.02943683374874002,0.019866843487299293,-1.4817066318340275,0.13881411288517903,LonGen OPEL,Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in SK-Hep-1 cells (hepatocellular carcinoma).,CGP,C2,29,29
Cohort,0.024480561470498763,0.023612554466116445,1.036760402421851,0.3002182430471795,LGP Offspring,Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in primary hepatocytes.,CGP,C2,15,39
Cohort,-0.09099519284437771,0.06589768531542194,-1.380855676626964,0.1676932497867851,LGP Proband,Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in primary hepatocytes.,CGP,C2,15,55
Cohort,0.0026209788098739985,0.019405485591962833,0.1350638095322659,0.8925955687072885,LonGen OPEL,Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in primary hepatocytes.,CGP,C2,25,31
Cohort,-0.030588638965702644,0.020470360845927918,-1.4942891918677395,0.13556666773097797,LGP Offspring,Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in primary hepatocytes.,CGP,C2,19,25
Cohort,-0.020899639728548525,0.07141339931766719,-0.2926571193674868,0.7698570430296019,LGP Proband,Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in primary hepatocytes.,CGP,C2,19,65
Cohort,-0.0375312332274496,0.026550131612178497,-1.4135987638657916,0.1578706903559158,LonGen OPEL,Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in primary hepatocytes.,CGP,C2,49,51
Cohort,-0.007207689456369831,0.014948903845125767,-0.48215504835961376,0.6298518766857277,LGP Offspring,Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] both in SK-Hep-1 cells (hepatocellular carcinoma) and normal primary hepatocytes.,CGP,C2,7,13
Cohort,0.1004030569627093,0.04579121297275851,2.192627153651504,0.028609837250813536,LGP Proband,Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] both in SK-Hep-1 cells (hepatocellular carcinoma) and normal primary hepatocytes.,CGP,C2,7,22
Cohort,-0.011268494895270304,0.009964897895968116,-1.1308189018002517,0.25847191445957546,LonGen OPEL,Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] both in SK-Hep-1 cells (hepatocellular carcinoma) and normal primary hepatocytes.,CGP,C2,8,7
Cohort,-0.001438105356561662,0.015480512065197407,-0.09289778984732333,0.9260122858670176,LGP Offspring,Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] both in SK-Hep-1 cells (hepatocellular carcinoma) and normal primary hepatocytes.,CGP,C2,9,15
Cohort,-0.03094191815136909,0.05295186519547047,-0.5843404767168783,0.5591492886601326,LGP Proband,Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] both in SK-Hep-1 cells (hepatocellular carcinoma) and normal primary hepatocytes.,CGP,C2,9,39
Cohort,-0.008992673334332839,0.01779177099115442,-0.5054400339799646,0.6133897275756828,LonGen OPEL,Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] both in SK-Hep-1 cells (hepatocellular carcinoma) and normal primary hepatocytes.,CGP,C2,23,27
Cohort,0.026596043891238933,0.04576252527420105,0.5811751806064043,0.5613161103995661,LGP Offspring,Genes silenced by DNA methylation in bladder cancer cell lines.,CGP,C2,59,138
Cohort,-0.13052614120512754,0.12278544696896437,-1.0630424405110463,0.28807040845738874,LGP Proband,Genes silenced by DNA methylation in bladder cancer cell lines.,CGP,C2,59,178
Cohort,-0.04162269488642041,0.0380034109134173,-1.0952357666328656,0.27374463301002255,LonGen OPEL,Genes silenced by DNA methylation in bladder cancer cell lines.,CGP,C2,104,100
Cohort,0.011826642641036379,0.011927601480198185,0.991535696482699,0.32177884271326707,LGP Offspring,Genes down-regulated in gastric mucosal tissue of mice on 2% cholesterol [PubChem=5997] diet and infected with H. pylori vs those infected with H. pylori while on 0% cholesterol diet.,CGP,C2,3,11
Cohort,0.021995840519846377,0.024896109623880024,0.883505127995912,0.37721801702872004,LGP Proband,Genes down-regulated in gastric mucosal tissue of mice on 2% cholesterol [PubChem=5997] diet and infected with H. pylori vs those infected with H. pylori while on 0% cholesterol diet.,CGP,C2,3,7
Cohort,0.007777458870389854,0.011485407273786778,0.6771600418681191,0.49850116292787083,LonGen OPEL,Genes down-regulated in gastric mucosal tissue of mice on 2% cholesterol [PubChem=5997] diet and infected with H. pylori vs those infected with H. pylori while on 0% cholesterol diet.,CGP,C2,7,13
Cohort,0.009533806483323694,0.049775399586523786,0.19153651326798954,0.8481627918897172,LGP Offspring,Genes up-regulated in gastric mucosal tissue of mice on 2% cholesterol [PubChem=5997] diet and infected with H. pylori vs those infected with H. pylori while on 0% cholesterol diet.,CGP,C2,81,170
Cohort,-0.2210851444126913,0.13884768280320345,-1.5922854450948785,0.1116995026021341,LGP Proband,Genes up-regulated in gastric mucosal tissue of mice on 2% cholesterol [PubChem=5997] diet and infected with H. pylori vs those infected with H. pylori while on 0% cholesterol diet.,CGP,C2,81,242
Cohort,0.09710168321561509,0.046928000899142175,2.069163001942196,0.038853023501873696,LonGen OPEL,Genes up-regulated in gastric mucosal tissue of mice on 2% cholesterol [PubChem=5997] diet and infected with H. pylori vs those infected with H. pylori while on 0% cholesterol diet.,CGP,C2,124,197
Cohort,-0.03241892217374322,0.03609461857564148,-0.8981649745322752,0.36941738569450167,LGP Offspring,"Genes upregulated in long-term hematopoietic stem cells (CD34+,CD38_,CD45RA_,CD90+,CD49f+) upon overexpression of Sphingosine-1-Phosphate Receptor 3 (S1PR3)",CGP,C2,48,90
Cohort,-0.01096542694464831,0.09948515681839726,-0.1102217385520624,0.91226003928349,LGP Proband,"Genes upregulated in long-term hematopoietic stem cells (CD34+,CD38_,CD45RA_,CD90+,CD49f+) upon overexpression of Sphingosine-1-Phosphate Receptor 3 (S1PR3)",CGP,C2,48,127
Cohort,-0.019476325821998583,0.03501644065486751,-0.5562051841294512,0.5782269089307416,LonGen OPEL,"Genes upregulated in long-term hematopoietic stem cells (CD34+,CD38_,CD45RA_,CD90+,CD49f+) upon overexpression of Sphingosine-1-Phosphate Receptor 3 (S1PR3)",CGP,C2,88,92
Cohort,-0.026664871388578048,0.027315710085932282,-0.9761734659173507,0.32932770072388584,LGP Offspring,"Genes downregulated in short-term hematopoietic stem cells (CD34+,CD38_,CD45RA_,CD90_,CD49f_) upon overexpression of Sphingosine-1-Phosphate Receptor 3 (S1PR3)",CGP,C2,29,51
Cohort,-0.032997838573728455,0.07846589873239622,-0.4205373175711124,0.6742013072047357,LGP Proband,"Genes downregulated in short-term hematopoietic stem cells (CD34+,CD38_,CD45RA_,CD90_,CD49f_) upon overexpression of Sphingosine-1-Phosphate Receptor 3 (S1PR3)",CGP,C2,29,76
Cohort,0.041347466987379934,0.02059164692673048,2.007972802491376,0.044983626136421574,LonGen OPEL,"Genes downregulated in short-term hematopoietic stem cells (CD34+,CD38_,CD45RA_,CD90_,CD49f_) upon overexpression of Sphingosine-1-Phosphate Receptor 3 (S1PR3)",CGP,C2,24,43
Cohort,-0.08297976257999974,0.07905063713667335,-1.0497039060739408,0.2942293891739833,LGP Offspring,"Genes upregulated in short-term hematopoietic stem cells (CD34+,CD38_,CD45RA_,CD90_,CD49f_) upon overexpression of Sphingosine-1-Phosphate Receptor 3 (S1PR3)",CGP,C2,208,410
Cohort,-0.22028665606457634,0.21253305296552039,-1.036481869482738,0.30027781627079925,LGP Proband,"Genes upregulated in short-term hematopoietic stem cells (CD34+,CD38_,CD45RA_,CD90_,CD49f_) upon overexpression of Sphingosine-1-Phosphate Receptor 3 (S1PR3)",CGP,C2,208,543
Cohort,-0.006807513700885743,0.06842247943749363,-0.0994923562672798,0.9207724070979454,LonGen OPEL,"Genes upregulated in short-term hematopoietic stem cells (CD34+,CD38_,CD45RA_,CD90_,CD49f_) upon overexpression of Sphingosine-1-Phosphate Receptor 3 (S1PR3)",CGP,C2,303,349
Cohort,-0.014904470590575468,0.015395247052932057,-0.9681215598119863,0.3333298983293992,LGP Offspring,Genes up-regulated in DU-145 cells (prostate cancer) expressing a dominant negative form of AKT1 [GeneID=207] upon sham-treatment for 48 h (as a control for the HGF [GeneID=3082] experiments).,CGP,C2,10,14
Cohort,-0.014860222057069916,0.040390960099904616,-0.36790960205734274,0.7130339920189639,LGP Proband,Genes up-regulated in DU-145 cells (prostate cancer) expressing a dominant negative form of AKT1 [GeneID=207] upon sham-treatment for 48 h (as a control for the HGF [GeneID=3082] experiments).,CGP,C2,10,18
Cohort,0.01819975733354189,0.012796389773489892,1.4222571878238721,0.1553433268136189,LonGen OPEL,Genes up-regulated in DU-145 cells (prostate cancer) expressing a dominant negative form of AKT1 [GeneID=207] upon sham-treatment for 48 h (as a control for the HGF [GeneID=3082] experiments).,CGP,C2,7,18
Cohort,-0.0598546899620724,0.031742760833016304,-1.885617016016335,0.05977513001209709,LGP Offspring,Genes up-regulated in DU-145 cells (prostate cancer) expressing a dominant negative form of AKT1 [GeneID=207] upon sham-treatment for 6 h (as a control for the HGF [GeneID=3082] experiments).,CGP,C2,38,54
Cohort,0.014547057106677605,0.08530793463525017,0.17052408042553407,0.8646393569986686,LGP Proband,Genes up-regulated in DU-145 cells (prostate cancer) expressing a dominant negative form of AKT1 [GeneID=207] upon sham-treatment for 6 h (as a control for the HGF [GeneID=3082] experiments).,CGP,C2,38,84
Cohort,-0.011075714955756051,0.028713882644738044,-0.38572683091277205,0.6998020519762282,LonGen OPEL,Genes up-regulated in DU-145 cells (prostate cancer) expressing a dominant negative form of AKT1 [GeneID=207] upon sham-treatment for 6 h (as a control for the HGF [GeneID=3082] experiments).,CGP,C2,57,69
Cohort,-0.018348514681637323,0.03030452749954899,-0.6054710696911673,0.5450692544884748,LGP Offspring,Genes down-regulated in pro-B lymphocytes after knockout of CREBBP [GeneID=1387].,CGP,C2,34,62
Cohort,-0.08507563176797278,0.08212171902895109,-1.0359699330938301,0.30051644984050463,LGP Proband,Genes down-regulated in pro-B lymphocytes after knockout of CREBBP [GeneID=1387].,CGP,C2,34,76
Cohort,-0.021573879485486135,0.027670712166239054,-0.7796647717585077,0.43581996791351785,LonGen OPEL,Genes down-regulated in pro-B lymphocytes after knockout of CREBBP [GeneID=1387].,CGP,C2,54,56
Cohort,0.009917900114588221,0.01929257567797764,0.514078590652333,0.6073650481805948,LGP Offspring,Genes up-regulated in pro-B lymphocytes after knockout of CREBBP [GeneID=1387].,CGP,C2,10,27
Cohort,-0.09027501223145101,0.057032390776762865,-1.5828726623929719,0.11382960728295875,LGP Proband,Genes up-regulated in pro-B lymphocytes after knockout of CREBBP [GeneID=1387].,CGP,C2,10,46
Cohort,-0.037628096441504964,0.016745550418728772,-2.247050440302068,0.024910031204905207,LonGen OPEL,Genes up-regulated in pro-B lymphocytes after knockout of CREBBP [GeneID=1387].,CGP,C2,26,18
Cohort,-0.07924650501348347,0.06066526877417354,-1.306291171452295,0.19189783870299537,LGP Offspring,Genes down-regulated in MFCF-7 cells (breast cancer) upon stable autocrine expression of HG1 [GeneID=2688].,CGP,C2,131,242
Cohort,-0.11427348037409517,0.17151712833515625,-0.6662511288714964,0.5054348446962521,LGP Proband,Genes down-regulated in MFCF-7 cells (breast cancer) upon stable autocrine expression of HG1 [GeneID=2688].,CGP,C2,131,354
Cohort,-0.02511335586244099,0.052861458140883756,-0.4750787576746391,0.6348611625183884,LonGen OPEL,Genes down-regulated in MFCF-7 cells (breast cancer) upon stable autocrine expression of HG1 [GeneID=2688].,CGP,C2,215,235
Cohort,-0.03693080863035274,0.0672569887983427,-0.5490999417336799,0.5831181895486107,LGP Offspring,Genes up-regulated in MFCF-7 cells (breast cancer) upon stable autocrine expression of HG1 [GeneID=2688].,CGP,C2,145,281
Cohort,-0.15503784249431818,0.18924034790037145,-0.8192642013950444,0.4128697405457906,LGP Proband,Genes up-regulated in MFCF-7 cells (breast cancer) upon stable autocrine expression of HG1 [GeneID=2688].,CGP,C2,145,402
Cohort,-0.001225215595239771,0.05732052305047268,-0.021374815337273298,0.9829520201603101,LonGen OPEL,Genes up-regulated in MFCF-7 cells (breast cancer) upon stable autocrine expression of HG1 [GeneID=2688].,CGP,C2,204,257
Cohort,-0.05243342341663305,0.05489547030051167,-0.9551502725015241,0.33984313942979794,LGP Offspring,Genes down-regulated in MFCF-7 cells (breast cancer) by exogenous HG1 [GeneID=2688].,CGP,C2,103,200
Cohort,-0.021650536898939015,0.15927561649463662,-0.13593127043189354,0.8919084171342543,LGP Proband,Genes down-regulated in MFCF-7 cells (breast cancer) by exogenous HG1 [GeneID=2688].,CGP,C2,103,296
Cohort,-0.0588824518883159,0.048319825044238825,-1.2185982013470982,0.22335776290780276,LonGen OPEL,Genes down-regulated in MFCF-7 cells (breast cancer) by exogenous HG1 [GeneID=2688].,CGP,C2,171,183
Cohort,-0.002780284147643874,0.03446875399325401,-0.08066099947181184,0.9357354273275922,LGP Offspring,Genes up-regulated in MFCF-7 cells (breast cancer) by exogenous HG1 [GeneID=2688].,CGP,C2,34,79
Cohort,0.031199739556898816,0.09495312110318163,0.3285804531163894,0.7425553079779523,LGP Proband,Genes up-regulated in MFCF-7 cells (breast cancer) by exogenous HG1 [GeneID=2688].,CGP,C2,34,112
Cohort,-0.014196093228626394,0.027368528254238553,-0.5187013746867389,0.6041131659247614,LonGen OPEL,Genes up-regulated in MFCF-7 cells (breast cancer) by exogenous HG1 [GeneID=2688].,CGP,C2,56,62
Cohort,-0.013612782585841775,0.021732658601239796,-0.626374473349763,0.531280797374311,LGP Offspring,Genes down-regulated in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,17,30
Cohort,0.058621452163849695,0.05896959161298465,0.9940962886190601,0.3204643208125455,LGP Proband,Genes down-regulated in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,17,36
Cohort,0.004176224103520865,0.019771007164119232,0.2112297096882322,0.8327620942634335,LonGen OPEL,Genes down-regulated in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,26,30
Cohort,0.034233417120064946,0.03519782436933671,0.9726003732744366,0.33109983863403747,LGP Offspring,Genes up-regulated in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,32,80
Cohort,0.013349492828161653,0.08952485450692564,0.14911493463671519,0.8814989903625987,LGP Proband,Genes up-regulated in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,32,105
Cohort,0.006029146527011596,0.030564089642336527,0.197262427821838,0.8436725380894516,LonGen OPEL,Genes up-regulated in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,60,70
Cohort,-0.021968168055133803,0.023400147527579473,-0.9388046818611748,0.3481663411783865,LGP Offspring,Genes changed similarly in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 6 h.,CGP,C2,21,35
Cohort,-0.012296079060551286,0.06751272395545788,-0.18212980220830274,0.8555251196686136,LGP Proband,Genes changed similarly in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 6 h.,CGP,C2,21,53
Cohort,0.016597206912442566,0.021164064131149317,0.7842164344992113,0.43314642445507046,LonGen OPEL,Genes changed similarly in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 6 h.,CGP,C2,25,36
Cohort,0.010454019285629779,0.026258472925469633,0.39811984936450023,0.6906675430586364,LGP Offspring,Genes down-regulated in DU-145 cells (prostate cancer) in the absence but not in the presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,21,46
Cohort,-0.020436980025720003,0.0664935021582462,-0.3073530399569352,0.7586513989723404,LGP Proband,Genes down-regulated in DU-145 cells (prostate cancer) in the absence but not in the presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,21,53
Cohort,0.037779194139032024,0.021353226732394707,1.7692498942896389,0.07723503552684459,LonGen OPEL,Genes down-regulated in DU-145 cells (prostate cancer) in the absence but not in the presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,26,46
Cohort,0.017031672596555976,0.024498652107506992,0.6952085576715076,0.4871635067678943,LGP Offspring,Genes up-regulated in DU-145 cells (prostate cancer) in the absence but not in the presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,15,41
Cohort,0.02136306492138139,0.06622020227413532,0.32260645826697365,0.7470741586352756,LGP Proband,Genes up-regulated in DU-145 cells (prostate cancer) in the absence but not in the presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,15,55
Cohort,0.01021736708717431,0.021508516145588293,0.4750382136087077,0.6348900473898442,LonGen OPEL,Genes up-regulated in DU-145 cells (prostate cancer) in the absence but not in the presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,31,39
Cohort,-0.009064109418273679,0.019486853471919786,-0.465139712336571,0.6419812045121429,LGP Offspring,Genes changed in DU-145 cells (prostate cancer) in the absence but not presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 6 h.,CGP,C2,13,24
Cohort,0.025246928665046294,0.046371114392501855,0.5444537832614325,0.5862747800640714,LGP Proband,Genes changed in DU-145 cells (prostate cancer) in the absence but not presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 6 h.,CGP,C2,13,24
Cohort,-0.021947869693594566,0.01761453629901878,-1.2460089394926153,0.213127706843287,LonGen OPEL,Genes changed in DU-145 cells (prostate cancer) in the absence but not presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 6 h.,CGP,C2,28,21
Cohort,-0.012816291397129238,0.05171157062160627,-0.24784185131236952,0.8043320340978559,LGP Offspring,Genes down-regulated in DU-145 cells (prostate cancer) in the presence but not in the absence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,84,173
Cohort,0.05713697959247067,0.15135043611254587,0.37751446946596817,0.7058873618145216,LGP Proband,Genes down-regulated in DU-145 cells (prostate cancer) in the presence but not in the absence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,84,287
Cohort,-0.023621609630454968,0.044669926357134175,-0.5288034155597481,0.5970892420004431,LonGen OPEL,Genes down-regulated in DU-145 cells (prostate cancer) in the presence but not in the absence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,156,166
Cohort,4.377257402124726e-4,0.019275386364564263,0.022709051426184877,0.9818890570777395,LGP Offspring,Genes up-regulated in DU-145 cells (prostate cancer) in the presence but not in the absence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,11,25
Cohort,0.03513850704413006,0.04370234167499424,0.8040417446151572,0.4216019840150399,LGP Proband,Genes up-regulated in DU-145 cells (prostate cancer) in the presence but not in the absence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,11,19
Cohort,-0.006408612980802957,0.014222681844383606,-0.4505910383795623,0.6524070305181925,LonGen OPEL,Genes up-regulated in DU-145 cells (prostate cancer) in the presence but not in the absence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.,CGP,C2,12,15
Cohort,-0.010613483748302555,0.01876057720473053,-0.5657333264579053,0.5717628058641029,LGP Offspring,"Genes down-regulated synergistically in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin and NSC682994 [PubChem=444795;388304].",CGP,C2,12,24
Cohort,0.006036806020822019,0.041568558522101146,0.14522529131272074,0.8845680873193614,LGP Proband,"Genes down-regulated synergistically in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin and NSC682994 [PubChem=444795;388304].",CGP,C2,12,17
Cohort,0.005045294211722665,0.012018400467282699,0.41979747849618637,0.6747466868116458,LonGen OPEL,"Genes down-regulated synergistically in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin and NSC682994 [PubChem=444795;388304].",CGP,C2,9,13
Cohort,-0.0033146308819486784,0.020042073460409624,-0.16538363101483877,0.868691481967937,LGP Offspring,"Genes up-regulated synergistically in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin and NSC682994 [PubChem=444795;388304].",CGP,C2,13,28
Cohort,-0.03844511681194665,0.058263224122155316,-0.6598522033614582,0.5095308561315108,LGP Proband,"Genes up-regulated synergistically in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin and NSC682994 [PubChem=444795;388304].",CGP,C2,13,41
Cohort,0.01206872897672945,0.02103617663726405,0.5737130460936793,0.5663240566280838,LonGen OPEL,"Genes up-regulated synergistically in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin and NSC682994 [PubChem=444795;388304].",CGP,C2,24,38
Cohort,-0.008454800281573789,0.013481702183571762,-0.6271315125085951,0.5307847801184367,LGP Offspring,"Genes down-regulated in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin [PubChem=444795] alone.",CGP,C2,7,11
Cohort,-0.003992457583367423,0.03669110257057538,-0.10881269037058579,0.9133772320446676,LGP Proband,"Genes down-regulated in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin [PubChem=444795] alone.",CGP,C2,7,15
Cohort,0.020577595998198642,0.011100169453465888,1.8538091769196863,0.06413623304890416,LonGen OPEL,"Genes down-regulated in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin [PubChem=444795] alone.",CGP,C2,4,15
Cohort,-0.012650817294834383,0.022078136459242895,-0.5730020429119227,0.5668338537459044,LGP Offspring,"Genes up-regulated in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin [PubChem=444795] alone.",CGP,C2,17,31
Cohort,0.029248530619251947,0.07082658714163387,0.412959762705534,0.6797422392997094,LGP Proband,"Genes up-regulated in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin [PubChem=444795] alone.",CGP,C2,17,58
Cohort,0.017986900163616523,0.01931741291544156,0.9311236573111984,0.3520719098484234,LonGen OPEL,"Genes up-regulated in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin [PubChem=444795] alone.",CGP,C2,22,33
Cohort,-0.06269089566925867,0.07808998159724853,-0.8028033095537003,0.42237058482066914,LGP Offspring,"Genes specifically expressed in FAB subtypes M2, M4, M5 and M7 of pediatric AML (acute myeloid leukemia).",CGP,C2,192,393
Cohort,-0.02581513743039335,0.21198754923154306,-0.12177666812967779,0.9031052274767113,LGP Proband,"Genes specifically expressed in FAB subtypes M2, M4, M5 and M7 of pediatric AML (acute myeloid leukemia).",CGP,C2,192,537
Cohort,0.010832468273986063,0.07279816816075282,0.1488013853599423,0.8817480458545177,LonGen OPEL,"Genes specifically expressed in FAB subtypes M2, M4, M5 and M7 of pediatric AML (acute myeloid leukemia).",CGP,C2,334,404
Cohort,-0.03121363268611258,0.02828393509444957,-1.1035816827425098,0.27016732774051117,LGP Offspring,Genes associated with clinical prognosis of pediatric AML (acute myeloid leukemia): good prognosis=no relapse > 3 years; poor prognosis=relapse < 1 year or no response to therapy.,CGP,C2,27,44
Cohort,-0.029618251441383588,0.07340641271917642,-0.40348316099699866,0.6866962432093582,LGP Proband,Genes associated with clinical prognosis of pediatric AML (acute myeloid leukemia): good prognosis=no relapse > 3 years; poor prognosis=relapse < 1 year or no response to therapy.,CGP,C2,27,63
Cohort,-0.018158522638204697,0.024163599573006886,-0.7514825174677018,0.4525844375447383,LonGen OPEL,Genes associated with clinical prognosis of pediatric AML (acute myeloid leukemia): good prognosis=no relapse > 3 years; poor prognosis=relapse < 1 year or no response to therapy.,CGP,C2,42,47
Cohort,-0.10447273919131252,0.056204326333125255,-1.8588024447103677,0.06348952762901494,LGP Offspring,Genes differentially expressed in pediatric AML (acute myeloid leukemia) samples from patients with good survival (>3 years without relapse) compared to those with poor survival (relapsed within one year after treatment).,CGP,C2,115,197
Cohort,-0.029651032792128416,0.1536065609079233,-0.19303233284353133,0.84698064375170945,LGP Proband,Genes differentially expressed in pediatric AML (acute myeloid leukemia) samples from patients with good survival (>3 years without relapse) compared to those with poor survival (relapsed within one year after treatment).,CGP,C2,115,277
Cohort,0.019717393941081022,0.051007569303465526,0.3865581953880989,0.6991866207761654,LonGen OPEL,Genes differentially expressed in pediatric AML (acute myeloid leukemia) samples from patients with good survival (>3 years without relapse) compared to those with poor survival (relapsed within one year after treatment).,CGP,C2,165,214
Cohort,0.05752773845602939,0.10583641846876801,0.5435533372003291,0.5869280771727173,LGP Offspring,Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing 11q23 rearrangements.,CGP,C2,320,712
Cohort,0.04681225398728361,0.277131437077533,0.1689171552709372,0.8659027636061689,LGP Proband,Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing 11q23 rearrangements.,CGP,C2,320,933
Cohort,-0.02822567835032288,0.08720250646456959,-0.3236796681043908,0.74626558700456,LonGen OPEL,Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing 11q23 rearrangements.,CGP,C2,535,631
Cohort,-0.06109182601480662,0.1112167110955592,-0.5493043753318289,0.5829779879848125,LGP Offspring,Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing inv(16) translocation.,CGP,C2,403,802
Cohort,-0.31424150266320827,0.30796963687464046,-1.0203652082465544,0.3078511775945675,LGP Proband,Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing inv(16) translocation.,CGP,C2,403,1123
Cohort,-0.034794832901324235,0.09898952028748012,-0.35150016688913055,0.7253061683946497,LonGen OPEL,Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing inv(16) translocation.,CGP,C2,663,778
Cohort,-1.227011022496066e-5,0.11715603064486735,-1.0473306544632595e-4,0.9999164660026801,LGP Offspring,Genes specifically expressed in samples from patients with pediatric AML (acute myeloid leukemia ) bearing t(8;21) translocation.,CGP,C2,410,867
Cohort,0.12410220134764846,0.31953818556030456,0.38837987744731495,0.6978340523807061,LGP Proband,Genes specifically expressed in samples from patients with pediatric AML (acute myeloid leukemia ) bearing t(8;21) translocation.,CGP,C2,410,1160
Cohort,0.10283843166836114,0.10282530474503894,1.0001276623818889,0.3175526573029776,LonGen OPEL,Genes specifically expressed in samples from patients with pediatric AML (acute myeloid leukemia ) bearing t(8;21) translocation.,CGP,C2,676,850
Cohort,-0.08425119782022956,0.05812025988228983,-1.4496011888257616,0.1476335182175621,LGP Offspring,Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing t(9;11) translocation.,CGP,C2,124,219
Cohort,-0.11860697064173464,0.1640634325759883,-0.7229336164644742,0.4699233527104706,LGP Proband,Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing t(9;11) translocation.,CGP,C2,124,306
Cohort,0.04076183778653881,0.05130352109122332,0.7945232007382059,0.427127721436673,LonGen OPEL,Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing t(9;11) translocation.,CGP,C2,167,223
Cohort,-0.020630958600208877,0.03144435153608876,-0.6561101626322513,0.5119764994769258,LGP Offspring,Down-regulated genes common to all pretumorigenic cells with acquired drug resistance.,CGP,C2,36,65
Cohort,-0.1119544416727331,0.08401555518917385,-1.3325442106601637,0.18304537841389973,LGP Proband,Down-regulated genes common to all pretumorigenic cells with acquired drug resistance.,CGP,C2,36,86
Cohort,-0.011748951394835042,0.026325722947441094,-0.44629169038554595,0.6555079352294368,LonGen OPEL,Down-regulated genes common to all pretumorigenic cells with acquired drug resistance.,CGP,C2,51,57
Cohort,-0.00627720858983357,0.010605838762260776,-0.5918634754443032,0.5541398973030334,LGP Offspring,Up-regulated genes common to all pretumorigenic cells with acquired drug resistance.,CGP,C2,4,7
Cohort,-0.023518332960862542,0.03489715026678598,-0.67393276474058,0.5005407968321713,LGP Proband,Up-regulated genes common to all pretumorigenic cells with acquired drug resistance.,CGP,C2,4,16
Cohort,-0.008608346782178115,0.012941823637884153,-0.6651571697345031,0.5061426417561042,LonGen OPEL,Up-regulated genes common to all pretumorigenic cells with acquired drug resistance.,CGP,C2,12,14
Cohort,7.025874507293269e-4,0.009060688005816803,0.0775423952660414,0.9382150113190327,LGP Offspring,Genes whose expression most strongly and consistently associated with the short term survival of patients with high grade glioma tumors.,CGP,C2,3,5
Cohort,-0.02180532802653538,0.0273307309422784,-0.7978318645259621,0.42519516855647943,LGP Proband,Genes whose expression most strongly and consistently associated with the short term survival of patients with high grade glioma tumors.,CGP,C2,3,9
Cohort,7.416258605654866e-4,0.0068463599840204855,0.10832411124983982,0.9137658958175889,LonGen OPEL,Genes whose expression most strongly and consistently associated with the short term survival of patients with high grade glioma tumors.,CGP,C2,3,4
Cohort,-0.02398202214088254,0.014846918877781572,-1.6152861302941217,0.1067153413141381,LGP Offspring,Genes whose expression most strongly and consistently associated with the long term survival of patients with high grade glioma tumors.,CGP,C2,10,12
Cohort,-0.005929863580107788,0.04716010012962592,-0.12573899469697383,0.8999688373423811,LGP Proband,Genes whose expression most strongly and consistently associated with the long term survival of patients with high grade glioma tumors.,CGP,C2,10,25
Cohort,0.014635898214145166,0.018798675117545186,0.7785600912101079,0.4364702670470362,LonGen OPEL,Genes whose expression most strongly and consistently associated with the long term survival of patients with high grade glioma tumors.,CGP,C2,22,28
Cohort,0.0600598405672919,0.05047000311729621,1.1900106371641817,0.2344599676080777,LGP Offspring,Genes down-regulated in hepatocellular carcinoma (HCC) cells with hepatic stem cell properties.,CGP,C2,76,184
Cohort,0.14888409882096953,0.14310098884978367,1.040412788322913,0.29844967836608444,LGP Proband,Genes down-regulated in hepatocellular carcinoma (HCC) cells with hepatic stem cell properties.,CGP,C2,76,250
Cohort,0.02362757572878826,0.04264414544934992,0.5540637637316859,0.5796908218460535,LonGen OPEL,Genes down-regulated in hepatocellular carcinoma (HCC) cells with hepatic stem cell properties.,CGP,C2,117,147
Cohort,-0.033237446895408196,0.03814233979007583,-0.8714055581890698,0.38384211631462795,LGP Offspring,Genes up-regulated in hepatocellular carcinoma (HCC) cells with hepatic stem cell properties.,CGP,C2,58,100
Cohort,-0.07482391369705532,0.11062693300907082,-0.6763625426632786,0.49899801758058127,LGP Proband,Genes up-regulated in hepatocellular carcinoma (HCC) cells with hepatic stem cell properties.,CGP,C2,58,147
Cohort,-0.01107708244366903,0.03096379427662179,-0.35774305773735304,0.7206304433309545,LonGen OPEL,Genes up-regulated in hepatocellular carcinoma (HCC) cells with hepatic stem cell properties.,CGP,C2,70,76
Cohort,0.02879249251581402,0.02803476827717608,1.0270280186069818,0.30477461660624244,LGP Offspring,Down-regulated genes distinguishing hepatocellular carcinoma (HCC) samples positive for EPCAM [GeneID=4072] from the negative ones.,CGP,C2,20,58
Cohort,0.1511577662013621,0.07692204085949249,1.9650774279048346,0.049736827949174604,LGP Proband,Down-regulated genes distinguishing hepatocellular carcinoma (HCC) samples positive for EPCAM [GeneID=4072] from the negative ones.,CGP,C2,20,76
Cohort,0.02825317846485272,0.02421864214236393,1.1665880481148636,0.24372615310001614,LonGen OPEL,Down-regulated genes distinguishing hepatocellular carcinoma (HCC) samples positive for EPCAM [GeneID=4072] from the negative ones.,CGP,C2,33,56
Cohort,-0.010553251016781326,0.02870153226771849,-0.3676894640447784,0.7132198877043749,LGP Offspring,Up-regulated genes distinguishing hepatocellular carcinoma (HCC) samples positive for EPCAM [GeneID=4072] from the negative ones.,CGP,C2,25,48
Cohort,0.045197037186315764,0.07964796229514787,0.5674600565276376,0.5705543695474633,LGP Proband,Up-regulated genes distinguishing hepatocellular carcinoma (HCC) samples positive for EPCAM [GeneID=4072] from the negative ones.,CGP,C2,25,74
Cohort,-0.01246682794099049,0.02461434942327197,-0.5064861852169678,0.6126556400765,LonGen OPEL,Up-regulated genes distinguishing hepatocellular carcinoma (HCC) samples positive for EPCAM [GeneID=4072] from the negative ones.,CGP,C2,45,49
Cohort,-0.04504877210011026,0.03723070846224577,-1.2099896553349903,0.2267057998838775,LGP Offspring,Genes up-regulated in prostate cancer cell lines after treatment with 5-aza-2'-deoxycytidine (decitabine) [PubChem=451668].,CGP,C2,53,93
Cohort,0.07140806089917745,0.11581695862364022,0.6165596277763233,0.537693488697427,LGP Proband,Genes up-regulated in prostate cancer cell lines after treatment with 5-aza-2'-deoxycytidine (decitabine) [PubChem=451668].,CGP,C2,53,156
Cohort,-0.005247889634483583,0.03482911311479087,-0.15067537370783532,0.8802699736370808,LonGen OPEL,Genes up-regulated in prostate cancer cell lines after treatment with 5-aza-2'-deoxycytidine (decitabine) [PubChem=451668].,CGP,C2,87,98
Cohort,0.006334375539504011,0.023862686899674614,0.26545106031586013,0.7907429350113853,LGP Offspring,Genes silenced by DNA methylation in prostate cancer cell lines.,CGP,C2,17,43
Cohort,-0.017349202234764105,0.0600788080659137,-0.28877407514027137,0.7728260319018966,LGP Proband,Genes silenced by DNA methylation in prostate cancer cell lines.,CGP,C2,17,46
Cohort,0.03137991859194756,0.020474804667242663,1.5326113778341353,0.125768961308445,LonGen OPEL,Genes silenced by DNA methylation in prostate cancer cell lines.,CGP,C2,25,40
Cohort,-0.1626142257237692,0.07497787683685198,-2.168829427880566,0.030443583763910875,LGP Offspring,Genes down-regulated in embryonic stem cells from TCEB3 [GeneID=6924] knockout mice.,CGP,C2,189,321
Cohort,-0.3342752113013452,0.20566466098566175,-1.625341026986886,0.10446771520189206,LGP Proband,Genes down-regulated in embryonic stem cells from TCEB3 [GeneID=6924] knockout mice.,CGP,C2,189,464
Cohort,-0.06559490220788022,0.06086302520465838,-1.0777463326430194,0.2814734724318832,LonGen OPEL,Genes down-regulated in embryonic stem cells from TCEB3 [GeneID=6924] knockout mice.,CGP,C2,278,303
Cohort,-0.12175919787918808,0.07258241465666962,-1.6775302730714483,0.0939010889608397,LGP Offspring,Genes up-regulated in embryonic stem cells from TCEB3 [GeneID=6924] knockout mice.,CGP,C2,194,352
Cohort,-0.3404044085118704,0.19676493372172513,-1.7300054540881125,0.08399925348674105,LGP Proband,Genes up-regulated in embryonic stem cells from TCEB3 [GeneID=6924] knockout mice.,CGP,C2,194,467
Cohort,-0.004275627627889603,0.0622511359469591,-0.06868352782401656,0.9452587793955112,LonGen OPEL,Genes up-regulated in embryonic stem cells from TCEB3 [GeneID=6924] knockout mice.,CGP,C2,262,312
Cohort,-2.975619088510282e-4,0.021319461791555083,-0.01395728990536226,0.9888681735274325,LGP Offspring,Genes up-regulated in IEC-18 cells (intestinal epithelial cells) which avoided anoikis (a form of apoptosis) after detachment.,CGP,C2,14,28
Cohort,-0.077901691012412,0.057742124888991234,-1.34913100552114,0.17766104767150784,LGP Proband,Genes up-regulated in IEC-18 cells (intestinal epithelial cells) which avoided anoikis (a form of apoptosis) after detachment.,CGP,C2,14,40
Cohort,-0.00854081963798525,0.017679476956890337,-0.4830923255711239,0.629163024146351,LonGen OPEL,Genes up-regulated in IEC-18 cells (intestinal epithelial cells) which avoided anoikis (a form of apoptosis) after detachment.,CGP,C2,23,24
Cohort,0.019926876187012534,0.029795859750045384,0.6687800370312248,0.5038641127633872,LGP Offspring,Genes down-regulated in U2-OS Tet-On cells (osteosarcoma) after induction of ESX1 [GeneID=80712] expression.,CGP,C2,24,61
Cohort,0.08732223197090551,0.08668244187204488,1.0073808499742665,0.3140439684940272,LGP Proband,Genes down-regulated in U2-OS Tet-On cells (osteosarcoma) after induction of ESX1 [GeneID=80712] expression.,CGP,C2,24,97
Cohort,-0.03678035370447264,0.029261232504973023,-1.2569652935234947,0.2091349035488792,LonGen OPEL,Genes down-regulated in U2-OS Tet-On cells (osteosarcoma) after induction of ESX1 [GeneID=80712] expression.,CGP,C2,65,60
Cohort,-8.085664034971849e-4,0.0055657928582708285,-0.14527425365743651,0.884537645643948,LGP Offspring,Genes defining a 25-signal proteomic signature associated with a high risk of cancer recurrence and poor survival of NSCLC (non-small cell lung cancer) patients.,CGP,C2,1,2
Cohort,-0.009188556031062825,0.01117616777044918,-0.8221562363584248,0.4112229655813342,LGP Proband,Genes defining a 25-signal proteomic signature associated with a high risk of cancer recurrence and poor survival of NSCLC (non-small cell lung cancer) patients.,CGP,C2,1,1
Cohort,0,0,NA,NA,LonGen OPEL,Genes defining a 25-signal proteomic signature associated with a high risk of cancer recurrence and poor survival of NSCLC (non-small cell lung cancer) patients.,CGP,C2,0,0
Cohort,0.007820123325641287,0.01591203539896981,0.4914596485970351,0.6232609113956646,LGP Offspring,Genes down-regulated in neonatal cardiac myocytes upon knockdown of BCL3 [GeneID=602] by RNAi.,CGP,C2,6,18
Cohort,-0.04482591917447007,0.045221322656645975,-0.9912562601236123,0.32184796439834995,LGP Proband,Genes down-regulated in neonatal cardiac myocytes upon knockdown of BCL3 [GeneID=602] by RNAi.,CGP,C2,6,24
Cohort,-0.01557086297790109,0.015093765090549738,-1.031608938160172,0.3025686847743348,LonGen OPEL,Genes down-regulated in neonatal cardiac myocytes upon knockdown of BCL3 [GeneID=602] by RNAi.,CGP,C2,18,15
Cohort,0.026932806295052802,0.10687500195310838,0.2520028613133464,0.8011154478198227,LGP Offspring,Genes up-regulated in neonatal cardiac myocytes upon knockdown of BCL3 [GeneID=602] by RNAi.,CGP,C2,357,766
Cohort,0.411317743979749,0.28959602927820327,1.4203155513040981,0.15588955420453815,LGP Proband,Genes up-regulated in neonatal cardiac myocytes upon knockdown of BCL3 [GeneID=602] by RNAi.,CGP,C2,357,1013
Cohort,-0.028791438191242042,0.09118446575518867,-0.3157493763086913,0.7522755130600216,LonGen OPEL,Genes up-regulated in neonatal cardiac myocytes upon knockdown of BCL3 [GeneID=602] by RNAi.,CGP,C2,571,670
Cohort,0.03659491922679745,0.026272533188358108,1.392896488680178,0.16410899012539304,LGP Offspring,Genes down-regulated in bulk samples from early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative samples.,CGP,C2,18,49
Cohort,-0.020075315783171135,0.07233326605605622,-0.27753918601730687,0.7814349022264748,LGP Proband,Genes down-regulated in bulk samples from early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative samples.,CGP,C2,18,63
Cohort,0.014520853711377409,0.019891414333619004,0.7300060954858967,0.46560123350683635,LonGen OPEL,Genes down-regulated in bulk samples from early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative samples.,CGP,C2,25,36
Cohort,-0.012514556809110016,0.03302634120910438,-0.37892652806663685,0.704861407787375,LGP Offspring,Genes up-regulated in bulk samples from early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative samples.,CGP,C2,37,70
Cohort,0.04633494090279549,0.08886113006581206,0.5214309211291714,0.6022050482572308,LGP Proband,Genes up-regulated in bulk samples from early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative samples.,CGP,C2,37,96
Cohort,-0.024011517357498062,0.029462300856216355,-0.8149912484663189,0.4153210894838709,LonGen OPEL,Genes up-regulated in bulk samples from early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative samples.,CGP,C2,66,70
Cohort,0.03386844104363753,0.023403625188474015,1.4471450799134018,0.14831984595999978,LGP Offspring,Genes down-regulated in early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,11,42
Cohort,0.14345812527895974,0.059133796101433295,2.425992152319857,0.015477747503539705,LGP Proband,Genes down-regulated in early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,11,46
Cohort,2.4660941641997084e-5,0.01737431485710379,0.0014193907411499472,0.9988678460543781,LonGen OPEL,Genes down-regulated in early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,21,24
Cohort,-0.01493492903933159,0.03473191805605656,-0.4300058814841996,0.6673284023946937,LGP Offspring,Genes down-regulated in laser microdissected (LCM) samples of early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,41,73
Cohort,-0.12028278611314533,0.09845348203544575,-1.221722011516469,0.22215798058828717,LGP Proband,Genes down-regulated in laser microdissected (LCM) samples of early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,41,115
Cohort,-0.025613384355308626,0.030035963090841302,-0.8527572189992061,0.39405046276265754,LonGen OPEL,Genes down-regulated in laser microdissected (LCM) samples of early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,65,67
Cohort,0.037535068166167425,0.023699636064247888,1.5837824709380661,0.11371091662099532,LGP Offspring,Genes up-regulated in laser microdissected (LCM) samples of early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,10,43
Cohort,0.005168917442096539,0.05810959668302168,0.08895118426466005,0.9291420608312685,LGP Proband,Genes up-regulated in laser microdissected (LCM) samples of early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,10,41
Cohort,0.04162429469528447,0.020658004239482074,2.0149233300926097,0.04424845691333071,LonGen OPEL,Genes up-regulated in laser microdissected (LCM) samples of early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,21,43
Cohort,-0.04448305279328035,0.05007207854583621,-0.8883803925287496,0.37465215778455585,LGP Offspring,Genes up-regulated in early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,85,159
Cohort,-0.04477498736496443,0.1373875708027829,-0.32590275163419274,0.7445796872034601,LGP Proband,Genes up-regulated in early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,85,203
Cohort,0.04879692590640251,0.04033362474179418,1.2098323971323746,0.22670237786811115,LonGen OPEL,Genes up-regulated in early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.,CGP,C2,107,150
Cohort,-0.0076410015509582605,0.031435658144470566,-0.2430679680966784,0.8080264805101933,LGP Offspring,Genes down-regulated in the uteri of ovariectomized mice 6 h after progesterone [PubChem=5994] injection: HOXA10 [GeneID=3206] knockout vs wild type animals.,CGP,C2,30,62
Cohort,-0.01041024130460088,0.08061726190246221,-0.12913166558789974,0.8972846007593582,LGP Proband,Genes down-regulated in the uteri of ovariectomized mice 6 h after progesterone [PubChem=5994] injection: HOXA10 [GeneID=3206] knockout vs wild type animals.,CGP,C2,30,69
Cohort,-0.01530525949077726,0.025012650515325776,-0.6119007452408695,0.5407781591928171,LonGen OPEL,Genes down-regulated in the uteri of ovariectomized mice 6 h after progesterone [PubChem=5994] injection: HOXA10 [GeneID=3206] knockout vs wild type animals.,CGP,C2,43,48
Cohort,0.009637764439540102,0.043749073085270124,0.22029642595525165,0.8257068155146028,LGP Offspring,Genes up-regulated in the uteri of ovariectomized mice 6 h after progesterone [PubChem=5994] injection: HOXA10 [GeneID=3206] knockout vs wild type animals.,CGP,C2,68,149
Cohort,0.08524393392298875,0.12968976747667896,0.6572911308389651,0.5111750873839438,LGP Proband,Genes up-regulated in the uteri of ovariectomized mice 6 h after progesterone [PubChem=5994] injection: HOXA10 [GeneID=3206] knockout vs wild type animals.,CGP,C2,68,211
Cohort,-0.0060881368209556455,0.03812410122581487,-0.15969259930600546,0.8731637427351098,LonGen OPEL,Genes up-regulated in the uteri of ovariectomized mice 6 h after progesterone [PubChem=5994] injection: HOXA10 [GeneID=3206] knockout vs wild type animals.,CGP,C2,109,124
Cohort,0.07460665919944025,0.05351042070127727,1.394245424006906,0.16370156891261772,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 0.,CGP,C2,74,194
Cohort,0.09958053888173812,0.1498053321422072,0.664732940127981,0.5064050770929205,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 0.,CGP,C2,74,260
Cohort,-0.01889444971526983,0.04668674337804974,-0.4047069542261809,0.6858016567688849,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 0.,CGP,C2,158,177
Cohort,0.016894727992099238,0.041387100769550884,0.40821240623186983,0.6832470049653148,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 1.,CGP,C2,51,111
Cohort,-0.015162892508054481,0.11541788537810088,-0.13137385473994703,0.8955112543399699,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 1.,CGP,C2,51,160
Cohort,-0.07899506259641267,0.03460127389513991,-2.2830102393284517,0.0226925886183716,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 1.,CGP,C2,96,81
Cohort,-0.0020250033776839844,0.02558339385288032,-0.07915303924604195,0.9369343211907345,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 10.,CGP,C2,22,41
Cohort,-0.07932000608780634,0.07531894436540813,-1.0531215852281088,0.29259028367932144,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 10.,CGP,C2,22,71
Cohort,-0.015370877737874713,0.02568385640703124,-0.5984645566569499,0.5497002526916803,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 10.,CGP,C2,46,47
Cohort,0.0017098991766563802,0.054901139004450046,0.031145058329623786,0.9751630486304236,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 11.,CGP,C2,89,196
Cohort,0.08033642580118575,0.14579352444850713,0.551028765544109,0.5817615351036295,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 11.,CGP,C2,89,264
Cohort,0.039680820986690624,0.041938289116970846,0.9461716684726008,0.34434815911754046,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 11.,CGP,C2,123,164
Cohort,-0.040779445820622665,0.04406950764206635,-0.9253438035168069,0.35511730935864194,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 12.,CGP,C2,66,116
Cohort,-0.1835230023927408,0.12065900192548469,-1.5210054738069108,0.12863748851257636,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 12.,CGP,C2,66,161
Cohort,-0.060103603780833764,0.03697868495629222,-1.6253580637568523,0.10448211952399399,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 12.,CGP,C2,105,102
Cohort,0.012155837835297976,0.05694309418120657,0.21347343361102203,0.8310220737723797,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 13.,CGP,C2,93,203
Cohort,0.1335203489491968,0.15260162779129877,0.8749601880512183,0.38184746781873347,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 13.,CGP,C2,93,259
Cohort,0.04337160620114444,0.047451616064361074,0.9140174729205702,0.3609844352635344,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 13.,CGP,C2,149,199
Cohort,0.028188283127408106,0.04826618427094463,0.5840172276551172,0.5594035447289178,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 14.,CGP,C2,73,165
Cohort,0.20468485853328677,0.14181048297933055,1.4433690248634188,0.1492920413961822,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 14.,CGP,C2,73,257
Cohort,0.0435253775625603,0.04667534027745899,0.9325133422450933,0.3513540491433692,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 14.,CGP,C2,130,175
Cohort,-0.020305933902315478,0.03609105472360276,-0.5626306589769969,0.5738729414266371,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 15.,CGP,C2,45,82
Cohort,0.0991745111522345,0.10058754579362314,0.985952190897591,0.3244425181155305,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 15.,CGP,C2,45,125
Cohort,-0.044972107896901085,0.029002280412441604,-1.5506404068008608,0.12138535822178866,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 15.,CGP,C2,67,65
Cohort,-0.04113460209375918,0.047559417386829304,-0.8649097140780081,0.3873951611208045,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 16.,CGP,C2,82,155
Cohort,-0.098486502623785,0.13993973593256187,-0.7037779653324948,0.4817674962517622,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 16.,CGP,C2,82,229
Cohort,-0.05665218363161849,0.04456640209883694,-1.2711859374687318,0.20403384081960452,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 16.,CGP,C2,141,147
Cohort,0.004063401507059763,0.0599013343584888,0.06783490802962264,0.9459371137588195,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 17.,CGP,C2,107,226
Cohort,-0.007606163034855091,0.16117015562839124,-0.04719337153456972,0.9623704086656171,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 17.,CGP,C2,107,338
Cohort,0.016630981338985752,0.049647518780749154,0.3349811178365357,0.7377275838365612,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 17.,CGP,C2,168,213
Cohort,-0.01733527812692896,0.0424308151839823,-0.4085539731386791,0.682996399229468,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 2.,CGP,C2,61,116
Cohort,-0.0400732472719058,0.11388552168881551,-0.35187306233186727,0.7250223487205731,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 2.,CGP,C2,61,164
Cohort,0.04134140878321092,0.034941926137880226,1.183146247292678,0.2371044317551566,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 2.,CGP,C2,81,110
Cohort,-0.002257682030517287,0.019972651736661372,-0.11303867209445875,0.9100334555388081,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 3.,CGP,C2,12,25
Cohort,0.003005484509872411,0.051768620813108956,0.05805610546826381,0.9537178449084487,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 3.,CGP,C2,12,29
Cohort,-0.0018173780846341043,0.0165472352854565,-0.10982971192966676,0.9125721094113198,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 3.,CGP,C2,18,20
Cohort,-0.02433048071048292,0.025628407205557757,-0.949355943790632,0.3427788775388553,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 4.,CGP,C2,27,39
Cohort,-0.041281633335725605,0.07753231472572596,-0.5324442264075467,0.594560181459719,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 4.,CGP,C2,27,68
Cohort,0.010540241788783294,0.023214783579954663,0.45403144735256146,0.6499299604003936,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 4.,CGP,C2,33,48
Cohort,-0.02010002533438625,0.031603037049142066,-0.6360156241671054,0.5249815039629828,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 5.,CGP,C2,34,67
Cohort,6.460332912846793e-4,0.08910075005670742,0.007250593186628808,0.9942166482666713,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 5.,CGP,C2,34,100
Cohort,0.008114604371706389,0.025594590892116527,0.3170437224767595,0.7512935611329405,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 5.,CGP,C2,46,56
Cohort,-0.03559558602873266,0.047859302149676215,-0.7437548069006577,0.4572832510634325,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 6.,CGP,C2,79,154
Cohort,-0.0953719025894198,0.132111590899136,-0.7219041262036875,0.4705557717713754,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 6.,CGP,C2,79,231
Cohort,-0.013397253503944578,0.045377469013727356,-0.2952402105082527,0.7678873773234919,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 6.,CGP,C2,144,168
Cohort,-0.0256894307556603,0.0429487539454651,-0.5981414685110512,0.5499458815102818,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 7.,CGP,C2,58,117
Cohort,0.06751059691484813,0.11551081453224742,0.5844526089459879,0.5590738998945408,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 7.,CGP,C2,58,161
Cohort,0.06126332409524292,0.03560347134928516,1.7207121040031101,0.08569169007298308,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 7.,CGP,C2,83,124
Cohort,-0.018204026897741473,0.02758189553943263,-0.6599991241253151,0.5094791953657423,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 8.,CGP,C2,29,50
Cohort,0.022493565420229397,0.08774967649583394,0.25633787289571736,0.7977531717966189,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 8.,CGP,C2,29,97
Cohort,0.06762954368831599,0.02691866431299951,2.51236624900651,0.012189162824103294,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 8.,CGP,C2,37,77
Cohort,0.047347508642006285,0.0420351189841538,1.126379793521106,0.2604044910738443,LGP Offspring,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 9.,CGP,C2,48,120
Cohort,-0.1664702755763269,0.11289352234392386,-1.4745777447636406,0.14070347386917761,LGP Proband,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 9.,CGP,C2,48,155
Cohort,7.393657359941849e-4,0.03264033900814175,0.022651901250466757,0.9819336201657274,LonGen OPEL,Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 9.,CGP,C2,74,92
Cohort,0.04592113395799883,0.10935337952219029,0.41993337708123035,0.6746675568635563,LGP Offspring,"Genes down-regulated in mouse stroma of pancreatic adenocarcinoma zenografts after treatment with HhAntag, a hedgehog (Hh) pathway inhibitor.",CGP,C2,339,737
Cohort,-0.44880778017266104,0.29710101044909015,-1.5106235401025896,0.13126316635596755,LGP Proband,"Genes down-regulated in mouse stroma of pancreatic adenocarcinoma zenografts after treatment with HhAntag, a hedgehog (Hh) pathway inhibitor.",CGP,C2,339,973
Cohort,0.07875361576985332,0.09225523973307327,0.8536492452647148,0.3935561731779974,LonGen OPEL,"Genes down-regulated in mouse stroma of pancreatic adenocarcinoma zenografts after treatment with HhAntag, a hedgehog (Hh) pathway inhibitor.",CGP,C2,525,653
Cohort,-0.149604025378351,0.06462813179703131,-2.3148437254567686,0.020920156906793837,LGP Offspring,"Genes up-regulated in mouse stroma of pancreatic adenocarcinoma zenografts after treatment with HhAntag, a hedgehog (Hh) pathway inhibitor.",CGP,C2,151,257
Cohort,-0.13742601601659876,0.18792817500746384,-0.7312688265670685,0.4648203708265397,LGP Proband,"Genes up-regulated in mouse stroma of pancreatic adenocarcinoma zenografts after treatment with HhAntag, a hedgehog (Hh) pathway inhibitor.",CGP,C2,151,374
Cohort,-0.09412639600800067,0.0550243484098272,-1.7106317244674532,0.08753875459311931,LonGen OPEL,"Genes up-regulated in mouse stroma of pancreatic adenocarcinoma zenografts after treatment with HhAntag, a hedgehog (Hh) pathway inhibitor.",CGP,C2,223,227
Cohort,0.04252568083358581,0.056151360227791755,0.7573401723675074,0.44910998440620087,LGP Offspring,Genes expressed in at least one prostate cancer cell line but not in normal prostate epithelial cells or stromal cells,CGP,C2,88,207
Cohort,0.37075724385441955,0.14728151127379654,2.517337313066956,0.012010950547892852,LGP Proband,Genes expressed in at least one prostate cancer cell line but not in normal prostate epithelial cells or stromal cells,CGP,C2,88,289
Cohort,0.018296124433097808,0.03997848169974587,0.4576493067072657,0.6473293024095825,LonGen OPEL,Genes expressed in at least one prostate cancer cell line but not in normal prostate epithelial cells or stromal cells,CGP,C2,126,149
Cohort,0.019150977659164348,0.016617706880786082,1.1524440644278853,0.24954601228973822,LGP Offspring,Transcription factors down-regulated in LNCaP cells (prostate cancer) by expression of GR [GeneID=2908] off a lentiviral vector.,CGP,C2,6,22
Cohort,0.11584894550504553,0.04816240517690789,2.405381232094091,0.016372433708573365,LGP Proband,Transcription factors down-regulated in LNCaP cells (prostate cancer) by expression of GR [GeneID=2908] off a lentiviral vector.,CGP,C2,6,27
Cohort,0.01203189357996755,0.011973262554327228,1.0048968295294862,0.3152519032022221,LonGen OPEL,Transcription factors down-regulated in LNCaP cells (prostate cancer) by expression of GR [GeneID=2908] off a lentiviral vector.,CGP,C2,9,13
Cohort,-0.026990801686982323,0.02361891225159572,-1.1427622660801746,0.25354187171498455,LGP Offspring,Genes in cluster 1: strongly up-regulated in HFW cells (fibroblast) upon treatment with sodium arsenite [PubChem=26435] at all time points.,CGP,C2,21,34
Cohort,0.03790220468251427,0.06171221454791495,0.6141767065106053,0.5392660613421544,LGP Proband,Genes in cluster 1: strongly up-regulated in HFW cells (fibroblast) upon treatment with sodium arsenite [PubChem=26435] at all time points.,CGP,C2,21,40
Cohort,-0.010932057051013282,0.019460037968172878,-0.5617695643190825,0.5744311655641895,LonGen OPEL,Genes in cluster 1: strongly up-regulated in HFW cells (fibroblast) upon treatment with sodium arsenite [PubChem=26435] at all time points.,CGP,C2,29,27
Cohort,0.005810435835006319,0.012707931198695734,0.45722909135695256,0.6476532905917876,LGP Offspring,Genes in cluster 2: moderately up-regulated in HFW cells (fibroblast) upon treatment with sodium arsenite [PubChem=26435] at all time points.,CGP,C2,5,9
Cohort,-0.020826295543396118,0.03404883615141588,-0.6116595425106794,0.5409297286730859,LGP Proband,Genes in cluster 2: moderately up-regulated in HFW cells (fibroblast) upon treatment with sodium arsenite [PubChem=26435] at all time points.,CGP,C2,5,15
Cohort,1.8102882130798802e-4,0.012554516383831616,0.014419418141914787,0.9884989807596193,LonGen OPEL,Genes in cluster 2: moderately up-regulated in HFW cells (fibroblast) upon treatment with sodium arsenite [PubChem=26435] at all time points.,CGP,C2,11,13
Cohort,0.008396698449770347,0.014495235817755966,0.5792729801252903,0.5625979715584631,LGP Offspring,Genes in cluster 3: delayed up-regulation in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].,CGP,C2,6,15
Cohort,0.01530939604042906,0.03541230067991375,0.4323185940051819,0.6656216308899364,LGP Proband,Genes in cluster 3: delayed up-regulation in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].,CGP,C2,6,15
Cohort,-0.011910485665124206,0.013187635900110626,-0.9031554825550114,0.36671660556353836,LonGen OPEL,Genes in cluster 3: delayed up-regulation in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].,CGP,C2,12,13
Cohort,0.013619124632899991,0.023926266282938292,0.5692122820939983,0.5694011614864741,LGP Offspring,Genes in cluster 4: immediate down-regulation in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].,CGP,C2,15,41
Cohort,-0.0662241708984625,0.06190189834651021,-1.0698245557471817,0.28500780919170726,LGP Proband,Genes in cluster 4: immediate down-regulation in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].,CGP,C2,15,49
Cohort,-0.0017616080415629263,0.019558090646416556,-0.09007055307240275,0.9282538076925986,LonGen OPEL,Genes in cluster 4: immediate down-regulation in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].,CGP,C2,26,29
Cohort,-8.638570074819655e-4,0.014702580975723748,-0.058755466738005246,0.9531642434698357,LGP Offspring,Genes in cluster 5: slowly down-regulated in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].,CGP,C2,7,15
Cohort,-0.026641034593382136,0.04851483584076473,-0.5491317064500284,0.583062056887143,LGP Proband,Genes in cluster 5: slowly down-regulated in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].,CGP,C2,7,31
Cohort,-1.9293111010829933e-5,0.0114353527955378,-0.001687146112217746,0.9986542755230982,LonGen OPEL,Genes in cluster 5: slowly down-regulated in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].,CGP,C2,10,10
Cohort,-0.007314385252724061,0.037325937169617136,-0.19595985546152295,0.8447004777934648,LGP Offspring,Genes up-regulated in both colorectal cancer cells and normal testis relative to normal colon epithelium.,CGP,C2,45,89
Cohort,-0.026298953126191873,0.10096907840928107,-0.2604654171407637,0.7945690820872996,LGP Proband,Genes up-regulated in both colorectal cancer cells and normal testis relative to normal colon epithelium.,CGP,C2,45,124
Cohort,0.05248966887273178,0.030698207089704187,1.709861058639356,0.08768128061720831,LonGen OPEL,Genes up-regulated in both colorectal cancer cells and normal testis relative to normal colon epithelium.,CGP,C2,60,91
Cohort,-0.04985899078294841,0.0509786782836966,-0.9780361606372546,0.3284063115344905,LGP Offspring,Genes down-regulated in HUVEC cells (endothelium) by ETS1 [GeneID=2113] which were up-regulated by SP100 [GeneID=6672].,CGP,C2,86,150
Cohort,-0.36762437590190533,0.13790616927925478,-2.6657572886204957,0.007830131965850596,LGP Proband,Genes down-regulated in HUVEC cells (endothelium) by ETS1 [GeneID=2113] which were up-regulated by SP100 [GeneID=6672].,CGP,C2,86,215
Cohort,-0.02070081519582925,0.04414308385795347,-0.46894809756476685,0.6392351414709126,LonGen OPEL,Genes down-regulated in HUVEC cells (endothelium) by ETS1 [GeneID=2113] which were up-regulated by SP100 [GeneID=6672].,CGP,C2,139,160
Cohort,-0.002539999334571976,0.018433483899174024,-0.13779269011029377,0.8904452937895285,LGP Offspring,Genes up-regulated in HUVEC cells (endothelium) by ETS1 [GeneID=2113] which were down-regulated by SP100 [GeneID=6672].,CGP,C2,10,20
Cohort,-0.03174760648005197,0.04777173107798882,-0.6645688938553016,0.5065099732319185,LGP Proband,Genes up-regulated in HUVEC cells (endothelium) by ETS1 [GeneID=2113] which were down-regulated by SP100 [GeneID=6672].,CGP,C2,10,26
Cohort,0.003241144792467247,0.013855885313207493,0.23391827510132268,0.8151085723558068,LonGen OPEL,Genes up-regulated in HUVEC cells (endothelium) by ETS1 [GeneID=2113] which were down-regulated by SP100 [GeneID=6672].,CGP,C2,12,18
Cohort,-0.0028144422360388867,0.10245331436251638,-0.027470485006276964,0.9780925879378554,LGP Offspring,Genes down-regulated in vascular smooth muscle cells (VSMC) by MAPK8 (JNK1) [GeneID=5599].,CGP,C2,328,704
Cohort,0.29801805758252997,0.2869091083311492,1.0387194025173954,0.2992363001960241,LGP Proband,Genes down-regulated in vascular smooth muscle cells (VSMC) by MAPK8 (JNK1) [GeneID=5599].,CGP,C2,328,952
Cohort,-0.11462373101092922,0.09201818978588254,-1.2456638331795877,0.2132543628224194,LonGen OPEL,Genes down-regulated in vascular smooth muscle cells (VSMC) by MAPK8 (JNK1) [GeneID=5599].,CGP,C2,558,628
Cohort,-0.29196553199445924,0.19532963518239596,-1.4947323877496934,0.13545093759978682,LGP Offspring,Genes up-regulated in vascular smooth muscle cells (VSMC) by MAPK8 (JNK1) [GeneID=5599].,CGP,C2,1233,2423
Cohort,-0.28958120834220447,0.5549667092655419,-0.5217992422021929,0.6019486628347059,LGP Proband,Genes up-regulated in vascular smooth muscle cells (VSMC) by MAPK8 (JNK1) [GeneID=5599].,CGP,C2,1233,3523
Cohort,-0.15758405659736505,0.17696307106386516,-0.8904911948577886,0.3734712568744881,LonGen OPEL,Genes up-regulated in vascular smooth muscle cells (VSMC) by MAPK8 (JNK1) [GeneID=5599].,CGP,C2,1996,2333
Cohort,-0.010908306666109637,0.02627316846126779,-0.415188091310372,0.6781359572981706,LGP Offspring,Genes deregulated in U2OS cells (osteosarcoma) upon knockdown of BAP1 [GeneID=8314] by RNAi.,CGP,C2,25,47
Cohort,-0.031106146889003133,0.07759700077877182,-0.4008679018108755,0.6886200581406038,LGP Proband,Genes deregulated in U2OS cells (osteosarcoma) upon knockdown of BAP1 [GeneID=8314] by RNAi.,CGP,C2,25,75
Cohort,0.007762822556653431,0.024572100362719614,0.31592018761371565,0.7521459045157441,LonGen OPEL,Genes deregulated in U2OS cells (osteosarcoma) upon knockdown of BAP1 [GeneID=8314] by RNAi.,CGP,C2,43,55
Cohort,-0.0352733013255967,0.054442131448525805,-0.6479044884373615,0.5172667140210355,LGP Offspring,Genes down-regulated in B cell lymphoma tumors expressing an activated form of MYC [GeneID=4609].,CGP,C2,92,199
Cohort,0.06824292904938452,0.14646810158281584,0.46592348990608495,0.6413919221641424,LGP Proband,Genes down-regulated in B cell lymphoma tumors expressing an activated form of MYC [GeneID=4609].,CGP,C2,92,259
Cohort,-0.007660713490598123,0.04496022575150038,-0.17038867938385463,0.864747771999563,LonGen OPEL,Genes down-regulated in B cell lymphoma tumors expressing an activated form of MYC [GeneID=4609].,CGP,C2,162,176
Cohort,-0.0839666480160118,0.031495813246441344,-2.6659622140571027,0.00786030590608636,LGP Offspring,Genes up-regulated in B cell lymphoma tumors expressing an activated form of MYC [GeneID=4609].,CGP,C2,44,56
Cohort,-0.019478487216401368,0.09285045394884922,-0.20978343549221584,0.8338879368399589,LGP Proband,Genes up-regulated in B cell lymphoma tumors expressing an activated form of MYC [GeneID=4609].,CGP,C2,44,88
Cohort,0.019948555039658533,0.027148809741501467,0.7347856215281457,0.4626864743900376,LonGen OPEL,Genes up-regulated in B cell lymphoma tumors expressing an activated form of MYC [GeneID=4609].,CGP,C2,49,66
Cohort,0.025736028255253385,0.029319789586572106,0.8777698823268495,0.38038046612491216,LGP Offspring,"Proteins associated with ZNF143 [GeneID=7702] in HeLa cells, based on MudPIT analysis.",CGP,C2,25,58
Cohort,-0.027295161604180548,0.08107939339598613,-0.3366473336927038,0.7364674598026519,LGP Proband,"Proteins associated with ZNF143 [GeneID=7702] in HeLa cells, based on MudPIT analysis.",CGP,C2,25,79
Cohort,0.005438155553693022,0.025544969488111444,0.21288557640375824,0.8314707197025181,LonGen OPEL,"Proteins associated with ZNF143 [GeneID=7702] in HeLa cells, based on MudPIT analysis.",CGP,C2,39,50
Cohort,0.003133149492976767,0.01700312550466792,0.1842690328973114,0.8538576687398806,LGP Offspring,An assortment of osteoblast transcriptional regulators.,CGP,C2,8,19
Cohort,-0.041859631260213866,0.0519721420567974,-0.8054243986031565,0.42080438270245957,LGP Proband,An assortment of osteoblast transcriptional regulators.,CGP,C2,8,31
Cohort,0.019960176667407004,0.014649457683086677,1.3625198351507402,0.17341925681537534,LonGen OPEL,An assortment of osteoblast transcriptional regulators.,CGP,C2,10,19
Cohort,0.03465235482674204,0.044706399175195234,0.775109502578066,0.4385460006441029,LGP Offspring,Down-regulated in hepatocytes upon expression of NOS2 [GeneID=4843].,CGP,C2,57,139
Cohort,0.10253845819103134,0.1353904045442633,0.7573539538210654,0.44905175206919323,LGP Proband,Down-regulated in hepatocytes upon expression of NOS2 [GeneID=4843].,CGP,C2,57,213
Cohort,0.028253297276437352,0.0438237666185325,0.644702622720006,0.5193056654728799,LonGen OPEL,Down-regulated in hepatocytes upon expression of NOS2 [GeneID=4843].,CGP,C2,115,149
Cohort,0.007440880903860347,0.028278793521345272,0.2631258260096512,0.792533776078332,LGP Offspring,Up-regulated in hepatocytes upon expression of NOS2 [GeneID=4843].,CGP,C2,26,53
Cohort,-0.040336466784493354,0.08364613698295609,-0.4822274911836323,0.6297708793961213,LGP Proband,Up-regulated in hepatocytes upon expression of NOS2 [GeneID=4843].,CGP,C2,26,86
Cohort,0.032555859576150314,0.029367349837623485,1.1085732882318828,0.26794913693981637,LonGen OPEL,Up-regulated in hepatocytes upon expression of NOS2 [GeneID=4843].,CGP,C2,47,71
Cohort,0.0036519225539621432,0.01546118325934125,0.236199422302025,0.8133494747544852,LGP Offspring,Genes implicated in apoptosis that were down-regulated in duodenum of CD44 [GeneID=960] knockout mice.,CGP,C2,7,17
Cohort,0.028595811190575103,0.03486744513221103,0.8201292375207008,0.41237676410334334,LGP Proband,Genes implicated in apoptosis that were down-regulated in duodenum of CD44 [GeneID=960] knockout mice.,CGP,C2,7,13
Cohort,7.846671935229984e-4,0.009683364346783128,0.08103249711797424,0.9354364777195988,LonGen OPEL,Genes implicated in apoptosis that were down-regulated in duodenum of CD44 [GeneID=960] knockout mice.,CGP,C2,6,8
Cohort,-0.0020555953117139137,0.012411503554885761,-0.16562016863015222,0.8685053919271397,LGP Offspring,Genes implicated in apoptosis that were up-regulated in duodenum of CD44 [GeneID=960] knockout mice.,CGP,C2,5,10
Cohort,0.01572665814455659,0.03735515432102314,0.4210036989649316,0.6738608491356314,LGP Proband,Genes implicated in apoptosis that were up-regulated in duodenum of CD44 [GeneID=960] knockout mice.,CGP,C2,5,18
Cohort,-0.003788327466726438,0.01084869134800149,-0.34919672292311194,0.7270339795561457,LonGen OPEL,Genes implicated in apoptosis that were up-regulated in duodenum of CD44 [GeneID=960] knockout mice.,CGP,C2,9,9
Cohort,-0.008485850788864796,0.010041730186352389,-0.8450586334611766,0.3983770891036603,LGP Offspring,Selected genes down-regulated in DU145 and PC-3 cells (prostate cancer) after treatment with the NSAID (non-steroid anti-inflammatory drug) sulindac [PubChem=5352].,CGP,C2,5,5
Cohort,-0.002151706131001532,0.025909630510244402,-0.0830465772235065,0.93383443194654,LGP Proband,Selected genes down-regulated in DU145 and PC-3 cells (prostate cancer) after treatment with the NSAID (non-steroid anti-inflammatory drug) sulindac [PubChem=5352].,CGP,C2,5,7
Cohort,0.012986739351623375,0.0096027399860068,1.3523993537831671,0.17663166153934132,LonGen OPEL,Selected genes down-regulated in DU145 and PC-3 cells (prostate cancer) after treatment with the NSAID (non-steroid anti-inflammatory drug) sulindac [PubChem=5352].,CGP,C2,3,11
Cohort,0.008703774223179705,0.011922354750435243,0.7300381850206195,0.46561974651066107,LGP Offspring,Selected genes up-regulated in DU145 and PC-3 cells (prostate cancer) after treatment with the NSAID (non-steroid anti-inflammatory drug) sulindac [PubChem=5352].,CGP,C2,3,11
Cohort,0.0068486409357225156,0.034187783060872286,0.20032421884532034,0.841275860072811,LGP Proband,Selected genes up-regulated in DU145 and PC-3 cells (prostate cancer) after treatment with the NSAID (non-steroid anti-inflammatory drug) sulindac [PubChem=5352].,CGP,C2,3,16
Cohort,-0.012321614238980575,0.013297890720332061,-0.9265841100755332,0.35442335228069977,LonGen OPEL,Selected genes up-regulated in DU145 and PC-3 cells (prostate cancer) after treatment with the NSAID (non-steroid anti-inflammatory drug) sulindac [PubChem=5352].,CGP,C2,14,13
Cohort,-0.02453746712047839,0.03572367892635953,-0.6868684261511728,0.492401196002649,LGP Offspring,B lymphocyte early differentiation genes (EDG): top genes down-regulated in tonsil B lymphocytes (TBC) compared to the tonsil plasma cells (TPC).,CGP,C2,41,74
Cohort,-0.09227795415934405,0.09346019176304837,-0.987350361887747,0.323757264294936,LGP Proband,B lymphocyte early differentiation genes (EDG): top genes down-regulated in tonsil B lymphocytes (TBC) compared to the tonsil plasma cells (TPC).,CGP,C2,41,96
Cohort,-0.015573626094063826,0.029325882543419446,-0.5310539613259979,0.5955295266079528,LonGen OPEL,B lymphocyte early differentiation genes (EDG): top genes down-regulated in tonsil B lymphocytes (TBC) compared to the tonsil plasma cells (TPC).,CGP,C2,61,65
Cohort,0.029789024751832992,0.022884802745355204,1.3016946260495559,0.1934642028622533,LGP Offspring,B lymphocyte early differentiation genes (EDG): top genes up-regulated in tonsil B lymphocytes (TBC) compared to the tonsil plasma cells (TPC).,CGP,C2,10,35
Cohort,-0.04845380017962947,0.05756955161452769,-0.8416567234024129,0.40022139503863574,LGP Proband,B lymphocyte early differentiation genes (EDG): top genes up-regulated in tonsil B lymphocytes (TBC) compared to the tonsil plasma cells (TPC).,CGP,C2,10,43
Cohort,0.0208533909049333,0.018515456144817765,1.1262693579801377,0.26039095510249644,LonGen OPEL,B lymphocyte early differentiation genes (EDG): top genes up-regulated in tonsil B lymphocytes (TBC) compared to the tonsil plasma cells (TPC).,CGP,C2,18,32
Cohort,0.019532767625055323,0.011016318157770643,1.7730758448799324,0.07666636102581535,LGP Offspring,B lymphocyte late differentiation genes (LDG): top genes down-regulated in plasma cells from tonsils (TPC) compared to those from bone marrow (BPC).,CGP,C2,2,10
Cohort,-0.024050351582998314,0.037175081863647375,-0.6469481808059333,0.5178434926653229,LGP Proband,B lymphocyte late differentiation genes (LDG): top genes down-regulated in plasma cells from tonsils (TPC) compared to those from bone marrow (BPC).,CGP,C2,2,21
Cohort,0.00236492910847935,0.010537484123041563,0.22443014678504983,0.8224802097613896,LonGen OPEL,B lymphocyte late differentiation genes (LDG): top genes down-regulated in plasma cells from tonsils (TPC) compared to those from bone marrow (BPC).,CGP,C2,6,9
Cohort,0.013385497959602689,0.028730998501419098,0.4658904548319664,0.6414439851666935,LGP Offspring,B lymphocyte late differentiation genes (LDG): top genes up-regulated in plasma cells from tonsils (TPC) compared to those from bone marrow (BPC).,CGP,C2,24,58
Cohort,-0.11306609988218685,0.07002536783849138,-1.61464485474701,0.10676586263978374,LGP Proband,B lymphocyte late differentiation genes (LDG): top genes up-regulated in plasma cells from tonsils (TPC) compared to those from bone marrow (BPC).,CGP,C2,24,62
Cohort,0.031269649609707184,0.026322253587627357,1.187954880292063,0.2352055211162645,LonGen OPEL,B lymphocyte late differentiation genes (LDG): top genes up-regulated in plasma cells from tonsils (TPC) compared to those from bone marrow (BPC).,CGP,C2,42,63
Cohort,0.030421760046724252,0.03368782790906895,0.9030490220040143,0.36682154618859464,LGP Offspring,Genes commonly down-regulated in CD-1 and CD-2 clusters of multiple myeloma samples and which were higher expressed in the CD-1 group.,CGP,C2,35,80
Cohort,-0.04355717174811678,0.08986507273015007,-0.4846952261298642,0.6280198248250014,LGP Proband,Genes commonly down-regulated in CD-1 and CD-2 clusters of multiple myeloma samples and which were higher expressed in the CD-1 group.,CGP,C2,35,105
Cohort,0.0037054250329799027,0.030161572584280563,0.1228525144909412,0.9022548992486269,LonGen OPEL,Genes commonly down-regulated in CD-1 and CD-2 clusters of multiple myeloma samples and which were higher expressed in the CD-1 group.,CGP,C2,64,73
Cohort,-0.004708498895029308,0.04208456391465204,-0.1118818506609263,0.9109502994114593,LGP Offspring,Genes commonly up-regulated in CD-1 and CD-2 clusters of multiple myeloma samples and which were higher expressed in the CD-1 group.,CGP,C2,64,126
Cohort,-0.07178008707571612,0.12227764782745122,-0.58702541593707,0.5573455091739665,LGP Proband,Genes commonly up-regulated in CD-1 and CD-2 clusters of multiple myeloma samples and which were higher expressed in the CD-1 group.,CGP,C2,64,189
Cohort,-0.061441525663079914,0.04278604329830587,-1.4360179377818916,0.15139009793038755,LonGen OPEL,Genes commonly up-regulated in CD-1 and CD-2 clusters of multiple myeloma samples and which were higher expressed in the CD-1 group.,CGP,C2,138,138
Cohort,0.015590434080292422,0.029312385328573234,0.5318719000700063,0.5949894628649044,LGP Offspring,Top 50 down-regulated genes in cluster CD-1 of multiple myeloma samples with the characteristic expression spike of CCND1 [GeneID=595].,CGP,C2,28,66
Cohort,-0.026592214942470365,0.07955633268139395,-0.3342564199001792,0.7382701077483462,LGP Proband,Top 50 down-regulated genes in cluster CD-1 of multiple myeloma samples with the characteristic expression spike of CCND1 [GeneID=595].,CGP,C2,28,85
Cohort,4.13233982558758e-4,0.02319194561768378,0.017817995495973758,0.9857885137600971,LonGen OPEL,Top 50 down-regulated genes in cluster CD-1 of multiple myeloma samples with the characteristic expression spike of CCND1 [GeneID=595].,CGP,C2,42,43
Cohort,5.412977837299766e-4,0.032046076757894594,0.01689123407584135,0.9865283699441221,LGP Offspring,Top 50 up-regulated genes in cluster CD-1 of multiple myeloma samples with the characteristic expression spike of CCND1 [GeneID=595].,CGP,C2,31,68
Cohort,-0.08436069743887195,0.08989651835371158,-0.938420074367529,0.3483002574433225,LGP Proband,Top 50 up-regulated genes in cluster CD-1 of multiple myeloma samples with the characteristic expression spike of CCND1 [GeneID=595].,CGP,C2,31,99
Cohort,0.0097118607601769,0.027891276113005598,0.348204245686998,0.7277788653243829,LonGen OPEL,Top 50 up-regulated genes in cluster CD-1 of multiple myeloma samples with the characteristic expression spike of CCND1 [GeneID=595].,CGP,C2,52,65
Cohort,-0.054604957187525276,0.042149162861459664,-1.2955170039083963,0.1955841455050486,LGP Offspring,Genes down-regulated in CD-1 compared to CD-2 cluster of multiple myeloma samples.,CGP,C2,62,119
Cohort,-0.12360099491337949,0.1102789321963466,-1.1208033343423525,0.262694212758493,LGP Proband,Genes down-regulated in CD-1 compared to CD-2 cluster of multiple myeloma samples.,CGP,C2,62,135
Cohort,-0.0059181085814675105,0.033994179338812845,-0.17409182091095554,0.861837566104995,LonGen OPEL,Genes down-regulated in CD-1 compared to CD-2 cluster of multiple myeloma samples.,CGP,C2,90,102
Cohort,-0.04372876092992616,0.03593782882281718,-1.2167891706958787,0.22410908576397523,LGP Offspring,Genes up-regulated in CD-1 compared to CD-2 cluster of multiple myeloma samples.,CGP,C2,46,77
Cohort,-0.11699087014696305,0.10194235820680975,-1.1476178519396667,0.25145544656390195,LGP Proband,Genes up-regulated in CD-1 compared to CD-2 cluster of multiple myeloma samples.,CGP,C2,46,124
Cohort,0.009201481911543357,0.031366469302340674,0.2933540853084383,0.7693279800077106,LonGen OPEL,Genes up-regulated in CD-1 compared to CD-2 cluster of multiple myeloma samples.,CGP,C2,63,82
Cohort,-0.06015991664638218,0.046775114154422016,-1.2861522143542388,0.198830281327071,LGP Offspring,Top 50 down-regulated genes in cluster CD-2 of multiple myeloma samples with the charachteristic expression spike of CCND3 [GeneID=896].,CGP,C2,75,130
Cohort,-0.30358496051655237,0.1200245225812773,-2.529357784455864,0.011610354129125543,LGP Proband,Top 50 down-regulated genes in cluster CD-2 of multiple myeloma samples with the charachteristic expression spike of CCND3 [GeneID=896].,CGP,C2,75,157
Cohort,0.013502198141996363,0.03768744306292819,0.35826782197590895,0.720237885302458,LonGen OPEL,Top 50 down-regulated genes in cluster CD-2 of multiple myeloma samples with the charachteristic expression spike of CCND3 [GeneID=896].,CGP,C2,98,119
Cohort,-0.019519610048444002,0.03666119462357812,-0.5324324602311308,0.5946014639077508,LGP Offspring,Top 50 up-regulated genes in cluster CD-2 of multiple myeloma samples with the characteristic expression spike of CCND3 [GeneID=896].,CGP,C2,45,84
Cohort,-0.09974205205228785,0.10287910604154417,-0.96950737511279,0.33257317624476423,LGP Proband,Top 50 up-regulated genes in cluster CD-2 of multiple myeloma samples with the characteristic expression spike of CCND3 [GeneID=896].,CGP,C2,45,142
Cohort,0.018038194369562152,0.030950788798100013,0.5828024121527225,0.560191378371108,LonGen OPEL,Top 50 up-regulated genes in cluster CD-2 of multiple myeloma samples with the characteristic expression spike of CCND3 [GeneID=896].,CGP,C2,70,81
Cohort,0.003359050292276681,0.025702691883382145,0.13068865734053506,0.8960604863863724,LGP Offspring,"Genes most significantly down-regulated in multiple myeloma samples, compared to normal bone marrow plasma cells.",CGP,C2,20,45
Cohort,0.05573204135897237,0.07067113795385808,0.7886110648927204,0.4305634655907755,LGP Proband,"Genes most significantly down-regulated in multiple myeloma samples, compared to normal bone marrow plasma cells.",CGP,C2,20,64
Cohort,0.026950462174366054,0.021659328156578218,1.2442889262094148,0.213759501888744,LonGen OPEL,"Genes most significantly down-regulated in multiple myeloma samples, compared to normal bone marrow plasma cells.",CGP,C2,26,43
Cohort,-0.04374063828829671,0.04190767901217053,-1.043738028908589,0.29697970681919095,LGP Offspring,Top 50 down-regulated genes in cluster HP of multiple myeloma samples characterized by a hyperploid signature.,CGP,C2,61,108
Cohort,-0.1597678378588065,0.10469353828227596,-1.5260525193831787,0.12737590787031905,LGP Proband,Top 50 down-regulated genes in cluster HP of multiple myeloma samples characterized by a hyperploid signature.,CGP,C2,61,118
Cohort,-0.017022470561756122,0.03478322926048286,-0.48938729737481007,0.6247023540898664,LonGen OPEL,Top 50 down-regulated genes in cluster HP of multiple myeloma samples characterized by a hyperploid signature.,CGP,C2,83,85
Cohort,0.011752285537594387,0.027642745969017276,0.42514899029085823,0.6708633642338192,LGP Offspring,Top 50 up-regulated genes in cluster HP of multiple myeloma samples characterized by a hyperploid signature.,CGP,C2,25,55
Cohort,0.0717658748756888,0.08044334524697706,0.8921294192248383,0.37258088974328873,LGP Proband,Top 50 up-regulated genes in cluster HP of multiple myeloma samples characterized by a hyperploid signature.,CGP,C2,25,71
Cohort,-1.8061353321888223e-4,0.02283957072135587,-0.007907921537684668,0.9936924386697725,LonGen OPEL,Top 50 up-regulated genes in cluster HP of multiple myeloma samples characterized by a hyperploid signature.,CGP,C2,39,42
Cohort,0.03843344901191834,0.032197630777062294,1.1936732015480613,0.23302455167074562,LGP Offspring,Top 50 down-regulated genes in cluster LB of multiple myeloma samples belonging to the low bone disease group.,CGP,C2,29,72
Cohort,-0.06575158655596412,0.08547930465102692,-0.7692105922526852,0.44198608809698625,LGP Proband,Top 50 down-regulated genes in cluster LB of multiple myeloma samples belonging to the low bone disease group.,CGP,C2,29,87
Cohort,0.03453674773348717,0.023163469864216527,1.4910006115638295,0.136357492653927,LonGen OPEL,Top 50 down-regulated genes in cluster LB of multiple myeloma samples belonging to the low bone disease group.,CGP,C2,30,52
Cohort,0.012315936982887972,0.04296777387960211,0.2866319539243028,0.7744819707844086,LGP Offspring,Top 50 up-regulated genes in cluster LB of multiple myeloma samples belonging to the low bone disease group.,CGP,C2,50,121
Cohort,0.17806079403639102,0.11683841969721005,1.5239918042185132,0.12788984306790677,LGP Proband,Top 50 up-regulated genes in cluster LB of multiple myeloma samples belonging to the low bone disease group.,CGP,C2,50,167
Cohort,0.006776292668431363,0.03417542057542753,0.19827971548954645,0.8428768486448647,LonGen OPEL,Top 50 up-regulated genes in cluster LB of multiple myeloma samples belonging to the low bone disease group.,CGP,C2,83,104
Cohort,-0.06108869821996206,0.03649389092857538,-1.6739431358394428,0.09460435709202233,LGP Offspring,Top 50 down-regulated genes in cluster MF of multiple myeloma samples with characteristic expression spike of MAF family transcription factors.,CGP,C2,48,81
Cohort,0.02106281452432772,0.1015913079446659,0.20732890392355294,0.835803614129546,LGP Proband,Top 50 down-regulated genes in cluster MF of multiple myeloma samples with characteristic expression spike of MAF family transcription factors.,CGP,C2,48,116
Cohort,-0.00926608190614124,0.03342776990807063,-0.2771971307575647,0.7817007121848264,LonGen OPEL,Top 50 down-regulated genes in cluster MF of multiple myeloma samples with characteristic expression spike of MAF family transcription factors.,CGP,C2,75,91
Cohort,-0.07980529097693512,0.04518489589629204,-1.7661939768568569,0.07781460527229779,LGP Offspring,Top 50 up-regulated genes in cluster MF of multiple myeloma samples with characteristic expression spike of MAF family transcription factors.,CGP,C2,77,124
Cohort,-0.10417998196437785,0.12086721912290203,-0.8619374444152966,0.3889697006914946,LGP Proband,Top 50 up-regulated genes in cluster MF of multiple myeloma samples with characteristic expression spike of MAF family transcription factors.,CGP,C2,77,168
Cohort,0.02539582591891511,0.03882034349673363,0.6541885936957754,0.5131792638450194,LonGen OPEL,Top 50 up-regulated genes in cluster MF of multiple myeloma samples with characteristic expression spike of MAF family transcription factors.,CGP,C2,94,126
Cohort,-0.017677525368170927,0.03925922976956221,-0.4502769277933303,0.6526551396439407,LGP Offspring,Top 50 down-regulated genes in cluster MS of multiple myeloma samples with characteristic expression spike of WHSC1 [GeneID=7468].,CGP,C2,48,92
Cohort,-0.011492991175577697,0.10277258597266739,-0.11182934696840542,0.9109856262335565,LGP Proband,Top 50 down-regulated genes in cluster MS of multiple myeloma samples with characteristic expression spike of WHSC1 [GeneID=7468].,CGP,C2,48,135
Cohort,0.029803934920215686,0.03426180900967068,0.869887953429525,0.3846238739141694,LonGen OPEL,Top 50 down-regulated genes in cluster MS of multiple myeloma samples with characteristic expression spike of WHSC1 [GeneID=7468].,CGP,C2,77,103
Cohort,-0.03201450280067935,0.04129775729009931,-0.775211655581948,0.4384856867315292,LGP Offspring,Top 50 up-regulated genes in cluster MS of multiple myeloma samples with characteristic expression spike of WHSC1 [GeneID=7468].,CGP,C2,58,104
Cohort,0.03711958631085559,0.11226173843811313,0.3306521600974371,0.7409902911521662,LGP Proband,Top 50 up-regulated genes in cluster MS of multiple myeloma samples with characteristic expression spike of WHSC1 [GeneID=7468].,CGP,C2,58,138
Cohort,-0.046332224676212994,0.0354564936058862,-1.306734534757303,0.1916802820536195,LonGen OPEL,Top 50 up-regulated genes in cluster MS of multiple myeloma samples with characteristic expression spike of WHSC1 [GeneID=7468].,CGP,C2,94,93
Cohort,-0.040377506944278975,0.03940305189315265,-1.024730446102721,0.30585693916004975,LGP Offspring,Top 50 down-regulated genes in cluster PR of multiple myeloma samples characterized by increased expression of proliferation and cell cycle genes.,CGP,C2,54,100
Cohort,0.06963215369652408,0.11617431803169966,0.599376479038371,0.5490846432277954,LGP Proband,Top 50 down-regulated genes in cluster PR of multiple myeloma samples characterized by increased expression of proliferation and cell cycle genes.,CGP,C2,54,174
Cohort,0.02756147174165222,0.03890190673488701,0.7084863970674025,0.4788506776614002,LonGen OPEL,Top 50 down-regulated genes in cluster PR of multiple myeloma samples characterized by increased expression of proliferation and cell cycle genes.,CGP,C2,93,120
Cohort,-0.07749221949387634,0.036878297795670575,-2.1012959959061273,0.035984588183400404,LGP Offspring,Top 50 up-regulated genes in cluster PR of multiple myeloma samples characterized by increased expression of proliferation and cell cycle genes.,CGP,C2,56,80
Cohort,-0.1065937504747956,0.1053963583125834,-1.0113608494769903,0.3121370734170456,LGP Proband,Top 50 up-regulated genes in cluster PR of multiple myeloma samples characterized by increased expression of proliferation and cell cycle genes.,CGP,C2,56,112
Cohort,0.029491188989559606,0.030141494254463632,0.9784249161831875,0.32816147409213214,LonGen OPEL,Top 50 up-regulated genes in cluster PR of multiple myeloma samples characterized by increased expression of proliferation and cell cycle genes.,CGP,C2,65,91
Cohort,0.01311401301972082,0.017142524283817562,0.764998946631236,0.4445391492976871,LGP Offspring,'Spiked' genes: genes most highly up-regulated in multiple myeloma samples; were not differentially expressed as compared to the normal plasma cells.,CGP,C2,9,21
Cohort,0.024936750137127196,0.05467515793755292,0.45608922000021723,0.6484445595079809,LGP Proband,'Spiked' genes: genes most highly up-regulated in multiple myeloma samples; were not differentially expressed as compared to the normal plasma cells.,CGP,C2,9,37
Cohort,0.013961248160365591,0.014649333147864785,0.953029603426045,0.34086437475198883,LonGen OPEL,'Spiked' genes: genes most highly up-regulated in multiple myeloma samples; were not differentially expressed as compared to the normal plasma cells.,CGP,C2,12,19
Cohort,-0.004188717499832919,0.03314045522650466,-0.1263928775632182,0.8994585225883394,LGP Offspring,Top genes up-regulated in MM4 vs MM1 subgroup of multiple myeloma samples.,CGP,C2,34,66
Cohort,-0.0024543036064106467,0.08807931395609236,-0.02786469939620692,0.9777767294019735,LGP Proband,Top genes up-regulated in MM4 vs MM1 subgroup of multiple myeloma samples.,CGP,C2,34,87
Cohort,-0.006185750797610828,0.027258558932480317,-0.22692875338468868,0.8205374087289077,LonGen OPEL,Top genes up-regulated in MM4 vs MM1 subgroup of multiple myeloma samples.,CGP,C2,49,57
Cohort,-0.028616376669763063,0.059275763259957155,-0.48276690330016253,0.6294175497138101,LGP Offspring,"Genes most significantly up-regulated in multiple myeloma samples, compared to normal bone marrow plasma cells.",CGP,C2,113,220
Cohort,-0.19696584040000764,0.15006563495404618,-1.3125312831303682,0.1897020199720082,LGP Proband,"Genes most significantly up-regulated in multiple myeloma samples, compared to normal bone marrow plasma cells.",CGP,C2,113,256
Cohort,-0.003971091577118299,0.04678131075341555,-0.08488628285876675,0.9323731417817774,LonGen OPEL,"Genes most significantly up-regulated in multiple myeloma samples, compared to normal bone marrow plasma cells.",CGP,C2,148,169
Cohort,0.028787104103608883,0.017309656160453723,1.6630662005509365,0.09676270195732423,LGP Offspring,The v1LDG down-regulated set: most variable late differentiation genes (LDG) with similar expression patterns in tonsil plasma cells (TPC) and multiple myeloma (MM) samples.,CGP,C2,5,23
Cohort,-0.014608678185432999,0.05059130416055458,-0.28875867953653594,0.7728378100972285,LGP Proband,The v1LDG down-regulated set: most variable late differentiation genes (LDG) with similar expression patterns in tonsil plasma cells (TPC) and multiple myeloma (MM) samples.,CGP,C2,5,36
Cohort,-0.009071367934418406,0.014525778751396387,-0.6245013151908541,0.5324773571504584,LonGen OPEL,The v1LDG down-regulated set: most variable late differentiation genes (LDG) with similar expression patterns in tonsil plasma cells (TPC) and multiple myeloma (MM) samples.,CGP,C2,15,16
Cohort,-0.013068843472979211,0.0312252612881809,-0.41853431913237216,0.6756894335297713,LGP Offspring,The v1LDG up-regulated set: most variable late differentiation genes (LDG) with similar expression patterns in tonsil plasma cells (TPC) and multiple myeloma (MM) samples.,CGP,C2,31,64
Cohort,0.03181702725968257,0.08419141613335017,0.37791295978782224,0.7055914152704272,LGP Proband,The v1LDG up-regulated set: most variable late differentiation genes (LDG) with similar expression patterns in tonsil plasma cells (TPC) and multiple myeloma (MM) samples.,CGP,C2,31,90
Cohort,0.0088635443517721315,0.026762052411936004,0.3311982285715481,0.7405819275217317,LonGen OPEL,The v1LDG up-regulated set: most variable late differentiation genes (LDG) with similar expression patterns in tonsil plasma cells (TPC) and multiple myeloma (MM) samples.,CGP,C2,50,62
Cohort,-0.011503176912273129,0.0329690437689143,-0.34890841823926944,0.727266710704233,LGP Offspring,The v2LDG set: 50 most variable late differentiation genes (LDG) with similar expression patterns in bone marrow plasma cells (BPC) and multiple myeloma (MM) samples.,CGP,C2,31,65
Cohort,0.08890309586549804,0.09243257875164239,0.9618155964724544,0.3364210143021248,LGP Proband,The v2LDG set: 50 most variable late differentiation genes (LDG) with similar expression patterns in bone marrow plasma cells (BPC) and multiple myeloma (MM) samples.,CGP,C2,31,97
Cohort,9.787509814315123e-4,0.02220935187084006,0.044069317606542625,0.9648602023974713,LonGen OPEL,The v2LDG set: 50 most variable late differentiation genes (LDG) with similar expression patterns in bone marrow plasma cells (BPC) and multiple myeloma (MM) samples.,CGP,C2,35,44
Cohort,-0.04230383275024136,0.02652543687986191,-1.5948401883762524,0.11121536741449774,LGP Offspring,The vEDG down-regulated set: most variable early differentiation genes (EDG) with similar expression patterns in tonsil B lymphocytes (TBC) and multiple myeloma (MM) cells compared to the plasma cells from tonsil (TPC) and bone marrow (BPC).,CGP,C2,26,38
Cohort,-0.09951065659336208,0.07973846215394334,-1.247963077106334,0.21239483808758436,LGP Proband,The vEDG down-regulated set: most variable early differentiation genes (EDG) with similar expression patterns in tonsil B lymphocytes (TBC) and multiple myeloma (MM) cells compared to the plasma cells from tonsil (TPC) and bone marrow (BPC).,CGP,C2,26,66
Cohort,-0.02465708791554226,0.02037812538995989,-1.209978221435941,0.2266464470701336,LonGen OPEL,The vEDG down-regulated set: most variable early differentiation genes (EDG) with similar expression patterns in tonsil B lymphocytes (TBC) and multiple myeloma (MM) cells compared to the plasma cells from tonsil (TPC) and bone marrow (BPC).,CGP,C2,34,33
Cohort,-0.006369674773524771,0.02569930316943992,-0.24785398777268047,0.8043226473897038,LGP Offspring,The vEDG up-regulated set: most variable early differentiation genes (EDG) with similar expression patterns in tonsil B lymphocytes (TBC) and multiple myeloma (MM) cells compared to the plasma cells from tonsil (TPC) and bone marrow (BPC).,CGP,C2,24,44
Cohort,-0.06978903075875148,0.06929648463263431,-1.0071078082636995,0.31417506887678365,LGP Proband,The vEDG up-regulated set: most variable early differentiation genes (EDG) with similar expression patterns in tonsil B lymphocytes (TBC) and multiple myeloma (MM) cells compared to the plasma cells from tonsil (TPC) and bone marrow (BPC).,CGP,C2,24,55
Cohort,0.0015327195692129778,0.019730611688410633,0.07768231382878346,0.938100285051308,LonGen OPEL,The vEDG up-regulated set: most variable early differentiation genes (EDG) with similar expression patterns in tonsil B lymphocytes (TBC) and multiple myeloma (MM) cells compared to the plasma cells from tonsil (TPC) and bone marrow (BPC).,CGP,C2,29,33
Cohort,-0.02892131349916129,0.02493640005014904,-1.159803076666972,0.24653845973401026,LGP Offspring,Genes up-regulated in C3H10T1/2 cells (mesenchyme multipotent cells) upon their differentiation to brown adipocytes in response to BMP7 [GeneID=655].,CGP,C2,24,42
Cohort,-0.02114811375373485,0.0675935945839359,-0.3128715654776088,0.7544564601850772,LGP Proband,Genes up-regulated in C3H10T1/2 cells (mesenchyme multipotent cells) upon their differentiation to brown adipocytes in response to BMP7 [GeneID=655].,CGP,C2,24,54
Cohort,-0.005737946650853112,0.020764453462924007,-0.2763350675758699,0.7823624550809093,LonGen OPEL,Genes up-regulated in C3H10T1/2 cells (mesenchyme multipotent cells) upon their differentiation to brown adipocytes in response to BMP7 [GeneID=655].,CGP,C2,31,36
Cohort,-0.03180835585914371,0.03705688809510262,-0.8583655426627,0.3909948892687084,LGP Offspring,Genes up-regulated in A549 cells (lung carcinoma) upon infection with RSV (respiratory syncytial virus) and down-regulated by further treatment with ribavirin [PubChem=5064].,CGP,C2,53,93
Cohort,-0.050717133045273796,0.1031323361545813,-0.4917675186689821,0.6230131038942706,LGP Proband,Genes up-regulated in A549 cells (lung carcinoma) upon infection with RSV (respiratory syncytial virus) and down-regulated by further treatment with ribavirin [PubChem=5064].,CGP,C2,53,144
Cohort,0.016969627180680423,0.031533388718599,0.538147908304933,0.5906253753556484,LonGen OPEL,Genes up-regulated in A549 cells (lung carcinoma) upon infection with RSV (respiratory syncytial virus) and down-regulated by further treatment with ribavirin [PubChem=5064].,CGP,C2,66,90
Cohort,-0.02489813282915103,0.02597094601089005,-0.9586917942346354,0.3380567806664756,LGP Offspring,Genes up-regulated in A549 cells (lung carcinoma) upon infection with RSV (respiratory syncytial virus) and up-regulated by further treatment with ribavirin [PubChem=5064].,CGP,C2,27,44
Cohort,-0.09064390822216342,0.06927497521531246,-1.3084654009681636,0.19107597234281273,LGP Proband,Genes up-regulated in A549 cells (lung carcinoma) upon infection with RSV (respiratory syncytial virus) and up-regulated by further treatment with ribavirin [PubChem=5064].,CGP,C2,27,59
Cohort,-0.004877758662177086,0.023289643180139305,-0.20943896067659334,0.8341591695685965,LonGen OPEL,Genes up-regulated in A549 cells (lung carcinoma) upon infection with RSV (respiratory syncytial virus) and up-regulated by further treatment with ribavirin [PubChem=5064].,CGP,C2,41,43
Cohort,-0.14388823739096596,0.0724829713742265,-1.98513160626483,0.04753354531439582,LGP Offspring,Genes down-regulated in cancer stem cells isolated from mammary tumors compared to the non-tumorigenic cells.,CGP,C2,181,316
Cohort,-0.2049211451523129,0.19444896478947019,-1.0538556755711246,0.2922542115464546,LGP Proband,Genes down-regulated in cancer stem cells isolated from mammary tumors compared to the non-tumorigenic cells.,CGP,C2,181,437
Cohort,-0.08323252180599917,0.05798028486610254,-1.4355314396645893,0.15152853866144134,LonGen OPEL,Genes down-regulated in cancer stem cells isolated from mammary tumors compared to the non-tumorigenic cells.,CGP,C2,258,280
Cohort,-0.1033484171255614,0.09940729323443047,-1.039646224767801,0.2988759917285697,LGP Offspring,Genes up-regulated in cancer stem cells isolated from mammary tumors compared to the non-tumorigenic cells.,CGP,C2,384,740
Cohort,-0.9234661335024886,0.298058156652605,-3.0982749939596985,0.0020117657772653974,LGP Proband,Genes up-regulated in cancer stem cells isolated from mammary tumors compared to the non-tumorigenic cells.,CGP,C2,384,1048
Cohort,0.07936473345290598,0.09512193281866889,0.8343473592383696,0.40433558941862413,LonGen OPEL,Genes up-regulated in cancer stem cells isolated from mammary tumors compared to the non-tumorigenic cells.,CGP,C2,571,742
Cohort,-0.020783340462205594,0.04390104493272913,-0.4734133434421099,0.6360711507607756,LGP Offspring,Genes down-regulated after cre-lox knockout of GATA6 [GeneID=2627] in airway epithelium.,CGP,C2,66,131
Cohort,0.014023902897345324,0.12428441175797118,0.11283718286936237,0.9101867926960762,LGP Proband,Genes down-regulated after cre-lox knockout of GATA6 [GeneID=2627] in airway epithelium.,CGP,C2,66,195
Cohort,-0.010851460560757392,0.038304095939839786,-0.2832976551071885,0.7770223355394936,LonGen OPEL,Genes down-regulated after cre-lox knockout of GATA6 [GeneID=2627] in airway epithelium.,CGP,C2,104,118
Cohort,-0.023413199671486532,0.018387848551681265,-1.2732973955969298,0.2033502028038524,LGP Offspring,Genes up-regulated after cre-lox knockout of GATA6 [GeneID=2627] in airway epithelium.,CGP,C2,14,18
Cohort,-0.01889276849379937,0.046049800898158966,-0.4102681906395536,0.6817145939383504,LGP Proband,Genes up-regulated after cre-lox knockout of GATA6 [GeneID=2627] in airway epithelium.,CGP,C2,14,21
Cohort,7.352815156665345e-4,0.015494395505681312,0.04745467581467955,0.9621627563184519,LonGen OPEL,Genes up-regulated after cre-lox knockout of GATA6 [GeneID=2627] in airway epithelium.,CGP,C2,16,21
Cohort,-0.01840957986441167,0.013852594536606278,-1.328962586450018,0.1843086890326035,LGP Offspring,Interferon-inducible genes up-regulated in A549 cells (lung cancer) infected with a respiratory syncytial virus (RSV) that had its NS1 [GeneID=1494468] gene knocked down by RNAi.,CGP,C2,9,10
Cohort,-0.014498715928637199,0.03758294420612855,-0.3857791409080966,0.699758627014216,LGP Proband,Interferon-inducible genes up-regulated in A549 cells (lung cancer) infected with a respiratory syncytial virus (RSV) that had its NS1 [GeneID=1494468] gene knocked down by RNAi.,CGP,C2,9,14
Cohort,0.01908316515968256,0.015492242782833045,1.2317884135425903,0.21839189169075876,LonGen OPEL,Interferon-inducible genes up-regulated in A549 cells (lung cancer) infected with a respiratory syncytial virus (RSV) that had its NS1 [GeneID=1494468] gene knocked down by RNAi.,CGP,C2,11,24
Cohort,-0.014871995299739293,0.02939531302951083,-0.5059308361441449,0.6130701418932551,LGP Offspring,Genes up-regulated in HDMEC cells (microvascular endothelium): proliferating vs quiescent cells.,CGP,C2,30,56
Cohort,-0.11256108506991415,0.08180374684735965,-1.375989357552847,0.16919430149309247,LGP Proband,Genes up-regulated in HDMEC cells (microvascular endothelium): proliferating vs quiescent cells.,CGP,C2,30,79
Cohort,0.018592139710066687,0.027269435921379266,0.6817940702429576,0.49556749612406104,LonGen OPEL,Genes up-regulated in HDMEC cells (microvascular endothelium): proliferating vs quiescent cells.,CGP,C2,47,62
Cohort,-0.006173184543111691,0.04618304672950123,-0.13366776296221114,0.8937050800826163,LGP Offspring,Genes down-regulated in HL-60 cells (promyeloid leukemia) by cantharidin [PubChem=6708701].,CGP,C2,64,138
Cohort,0.12204269873122774,0.12495613844910698,0.976684300955204,0.32900867777491927,LGP Proband,Genes down-regulated in HL-60 cells (promyeloid leukemia) by cantharidin [PubChem=6708701].,CGP,C2,64,196
Cohort,-0.003526868652810587,0.04006777597763885,-0.088022570925296,0.9298808759615359,LonGen OPEL,Genes down-regulated in HL-60 cells (promyeloid leukemia) by cantharidin [PubChem=6708701].,CGP,C2,107,133
Cohort,-0.007676508863699592,0.013455658156824181,-0.5705041532885828,0.5685253810445537,LGP Offspring,Genes up-regulated in HL-60 cells (promyeloid leukemia) by cantharidin [PubChem=6708701].,CGP,C2,7,11
Cohort,-0.029027441963445734,0.03973314321844938,-0.7305599208161149,0.4652531721938269,LGP Proband,Genes up-regulated in HL-60 cells (promyeloid leukemia) by cantharidin [PubChem=6708701].,CGP,C2,7,20
Cohort,-6.572858222683192e-4,0.011631196078031177,-0.056510595974715826,0.9549492360664673,LonGen OPEL,Genes up-regulated in HL-60 cells (promyeloid leukemia) by cantharidin [PubChem=6708701].,CGP,C2,10,11
Cohort,-0.26414356931192035,0.06240533594612514,-4.232708073872992,2.6281027055017604e-5,LGP Offspring,"Genes down-regulated in BxPC3 cells (pancreatic cancer) after treatment with TNF [GeneID=7124] or IKI-1, an inhibitor of IkappaB kinase (IKK).",CGP,C2,167,243
Cohort,-0.17339875711944003,0.18553332366348013,-0.9345962962101096,0.3502669021371013,LGP Proband,"Genes down-regulated in BxPC3 cells (pancreatic cancer) after treatment with TNF [GeneID=7124] or IKI-1, an inhibitor of IkappaB kinase (IKK).",CGP,C2,167,404
Cohort,-0.062435735947752334,0.05569888641066424,-1.1209512428564143,0.2626466801432232,LonGen OPEL,"Genes down-regulated in BxPC3 cells (pancreatic cancer) after treatment with TNF [GeneID=7124] or IKI-1, an inhibitor of IkappaB kinase (IKK).",CGP,C2,216,239
Cohort,0.0049715873627040694,0.07395698475804602,0.06722268868814578,0.946424299765644,LGP Offspring,"Genes up-regulated in BxPC3 cells (pancreatic cancer) after treatment with TNF [GeneID=7124] or IKI-1, an inhibitor of IkappaB kinase (IKK).",CGP,C2,182,402
Cohort,-0.04455848732685676,0.20938747481751588,-0.21280397676933688,0.8315318646945754,LGP Proband,"Genes up-regulated in BxPC3 cells (pancreatic cancer) after treatment with TNF [GeneID=7124] or IKI-1, an inhibitor of IkappaB kinase (IKK).",CGP,C2,182,552
Cohort,0.036030163716380986,0.06758267014579729,0.5331272593795492,0.5940943007873808,LonGen OPEL,"Genes up-regulated in BxPC3 cells (pancreatic cancer) after treatment with TNF [GeneID=7124] or IKI-1, an inhibitor of IkappaB kinase (IKK).",CGP,C2,290,369
Cohort,-0.01903463016829424,0.041237628406741375,-0.4615840169213642,0.644528151105878,LGP Offspring,Genes up-regulated in RD-EF cells (rhabdomyosarcoma) engineered to express EWSR1-FLI1 fusion [GeneID=2130;2313] and which are also highly expressed in Ewing's famliy tumors.,CGP,C2,61,115
Cohort,-0.11350510837669817,0.11796782620719645,-0.9621700426804504,0.33624307323482694,LGP Proband,Genes up-regulated in RD-EF cells (rhabdomyosarcoma) engineered to express EWSR1-FLI1 fusion [GeneID=2130;2313] and which are also highly expressed in Ewing's famliy tumors.,CGP,C2,61,163
Cohort,0.015208487746599223,0.03707356029909355,0.4102246351282068,0.6817515576467039,LonGen OPEL,Genes up-regulated in RD-EF cells (rhabdomyosarcoma) engineered to express EWSR1-FLI1 fusion [GeneID=2130;2313] and which are also highly expressed in Ewing's famliy tumors.,CGP,C2,102,119
Cohort,-0.32099831377922383,0.12778269268479966,-2.5120640912696,0.012234582542513143,LGP Offspring,Genes whose promoters are bound by FOXP3 [GeneID=50943] based an a ChIP-chip analysis.,CGP,C2,523,957
Cohort,-0.9635089443376057,0.3357955560700538,-2.8693320293273867,0.004217331314798662,LGP Proband,Genes whose promoters are bound by FOXP3 [GeneID=50943] based an a ChIP-chip analysis.,CGP,C2,523,1366
Cohort,0.22479099999559507,0.1043381111776754,2.1544476649841084,0.03150450269843966,LonGen OPEL,Genes whose promoters are bound by FOXP3 [GeneID=50943] based an a ChIP-chip analysis.,CGP,C2,714,942
Cohort,-0.020903111334681708,0.014656780989275836,-1.4261734107902837,0.1542799256879344,LGP Offspring,Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated both in developing (located in the thymus) and mature (from peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,10,12
Cohort,-0.09343771978267926,0.042337523810203614,-2.206971768154286,0.027587739632507328,LGP Proband,Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated both in developing (located in the thymus) and mature (from peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,10,20
Cohort,-0.0038535195115201163,0.012788169480703566,-0.3013347232639356,0.7632379647751435,LonGen OPEL,Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated both in developing (located in the thymus) and mature (from peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,11,14
Cohort,-0.021008231193943055,0.03561636944642726,-0.5898476324360575,0.5554899018399067,LGP Offspring,Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated only in mature (peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,45,92
Cohort,0.1360204218284771,0.1051279597008779,1.2938558135770728,0.1960734217546911,LGP Proband,Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated only in mature (peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,45,132
Cohort,0.026533245990971684,0.029309712567161715,0.905271449870827,0.36559551479340335,LonGen OPEL,Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated only in mature (peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,58,81
Cohort,-0.005783636569561739,0.020392599895314487,-0.28361447776409415,0.7767926787204233,LGP Offspring,Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated only in mature (peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,13,32
Cohort,0.12097434594425462,0.06588765485241833,1.8360699924018373,0.06670313286025151,LGP Proband,Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated only in mature (peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,13,60
Cohort,-0.004320577857313746,0.02193652907770037,-0.1969581350819004,0.8439105771095164,LonGen OPEL,Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated only in mature (peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,33,41
Cohort,0.01333589566528878,0.01745190905653485,0.7641511093191931,0.4450438341648404,LGP Offspring,Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated only in developing (located in the thymus) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,9,22
Cohort,0.04661016485085103,0.04770916746045227,0.9769645401900539,0.3288699989636098,LGP Proband,Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated only in developing (located in the thymus) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,9,30
Cohort,0.016746886068654456,0.018842123439513272,0.8888003585378835,0.3743788879590618,LonGen OPEL,Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated only in developing (located in the thymus) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,20,36
Cohort,-0.0701474202945778,0.07614098451232028,-0.9212833370079071,0.3572311806798736,LGP Offspring,Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated only in developing (located in the thymus) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,209,398
Cohort,-0.5557191617198082,0.2186833725743545,-2.541204460027514,0.011227214247692472,LGP Proband,Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated only in developing (located in the thymus) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,209,591
Cohort,0.04466254500821178,0.07026500152299775,0.6356300297466545,0.5252002825596996,LonGen OPEL,Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated only in developing (located in the thymus) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,316,394
Cohort,-0.0786380988458759,0.02858301816843924,-2.751217467045045,0.006096436182250729,LGP Offspring,Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated both in developing (located in the thymus) and mature (from peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,38,45
Cohort,-0.15129084426388367,0.08183084602700831,-1.8488241489517296,0.06483695842689141,LGP Proband,Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated both in developing (located in the thymus) and mature (from peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,38,76
Cohort,0.05792097875023807,0.025259455100987753,2.293041497477636,0.022105524212812675,LonGen OPEL,Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated both in developing (located in the thymus) and mature (from peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.,CGP,C2,29,58
Cohort,0.015874261756366647,0.04958603552759591,0.32013573151118746,0.7489643634256389,LGP Offspring,The glioblastoma multiforme (GBM) plasticity signature: genes down-regulated in neural stem cells (NSC) with double knockout of TP53 and PTEN [GeneID=7157;5728] vs those with knockout of TP53 alone.,CGP,C2,77,169
Cohort,9.384325139921408e-4,0.13061535365172008,0.007184702929292896,0.9942692039582357,LGP Proband,The glioblastoma multiforme (GBM) plasticity signature: genes down-regulated in neural stem cells (NSC) with double knockout of TP53 and PTEN [GeneID=7157;5728] vs those with knockout of TP53 alone.,CGP,C2,77,200
Cohort,-0.05440508870022445,0.039738828810114535,-1.3690662339393602,0.1713647481694368,LonGen OPEL,The glioblastoma multiforme (GBM) plasticity signature: genes down-regulated in neural stem cells (NSC) with double knockout of TP53 and PTEN [GeneID=7157;5728] vs those with knockout of TP53 alone.,CGP,C2,125,123
Cohort,-0.12418813254719005,0.0817487093839418,-1.5191448707028123,0.1291935736913297,LGP Offspring,The glioblastoma multiforme (GBM) plasticity signature: genes up-regulated in neural stem cells (NSC) with double knockout of TP53 and PTEN [GeneID=7157;5728] vs those with knockout of TP53 alone.,CGP,C2,248,454
Cohort,-0.26424485173900275,0.22672276350048298,-1.1654976662210623,0.2441508241502168,LGP Proband,The glioblastoma multiforme (GBM) plasticity signature: genes up-regulated in neural stem cells (NSC) with double knockout of TP53 and PTEN [GeneID=7157;5728] vs those with knockout of TP53 alone.,CGP,C2,248,636
Cohort,-0.05684043611783901,0.06753887172268516,-0.8415958790550431,0.40026695717907845,LonGen OPEL,The glioblastoma multiforme (GBM) plasticity signature: genes up-regulated in neural stem cells (NSC) with double knockout of TP53 and PTEN [GeneID=7157;5728] vs those with knockout of TP53 alone.,CGP,C2,385,437
Cohort,-0.03384283141147167,0.035165855268203386,-0.9623776004695106,0.33620407481852,LGP Offspring,Genes down-regulated in ex-vivo colonic tissue after treatment with IL22 [GeneID=50616].,CGP,C2,46,75
Cohort,-0.19718940745881894,0.1034211092647262,-1.906664982233702,0.05690738712050353,LGP Proband,Genes down-regulated in ex-vivo colonic tissue after treatment with IL22 [GeneID=50616].,CGP,C2,46,113
Cohort,-0.04646011024658579,0.02966754660722894,-1.5660246821779693,0.1177402731539349,LonGen OPEL,Genes down-regulated in ex-vivo colonic tissue after treatment with IL22 [GeneID=50616].,CGP,C2,59,62
Cohort,0.028617048415149553,0.03741497299903664,0.7648555142853205,0.4446245060370134,LGP Offspring,Genes up-regulated in ex-vivo colonic tissue after treatment with IL22 [GeneID=50616].,CGP,C2,35,92
Cohort,0.008875598777842286,0.10519812156486541,0.08437031617878814,0.9327822549468164,LGP Proband,Genes up-regulated in ex-vivo colonic tissue after treatment with IL22 [GeneID=50616].,CGP,C2,35,152
Cohort,0.02862940334134242,0.033381185415307484,0.8576508888211605,0.39134341535893624,LonGen OPEL,Genes up-regulated in ex-vivo colonic tissue after treatment with IL22 [GeneID=50616].,CGP,C2,66,99
Cohort,0.018737581060187827,0.019922315040358442,0.9405323137511583,0.34728053985517726,LGP Offspring,Down-regulated in HEK293 cells (kidney epithelium) by treatment with sodium arsenite [PubChem=26435].,CGP,C2,11,28
Cohort,0.036959271186188074,0.054309398852242785,0.6805317673786365,0.4963566919244998,LGP Proband,Down-regulated in HEK293 cells (kidney epithelium) by treatment with sodium arsenite [PubChem=26435].,CGP,C2,11,36
Cohort,-0.014873429814653595,0.01746575319375189,-0.8515767771168518,0.3947051476111939,LonGen OPEL,Down-regulated in HEK293 cells (kidney epithelium) by treatment with sodium arsenite [PubChem=26435].,CGP,C2,23,21
Cohort,-0.003154553475566396,0.012344385052510416,-0.25554561544763793,0.7983794505996769,LGP Offspring,Up-regulated in HEK293 cells (kidney epithelium) by treatment with sodium arsenite [PubChem=26435].,CGP,C2,5,8
Cohort,-0.02165198453234517,0.03326661250121685,-0.6508623182343309,0.5153146411892315,LGP Proband,Up-regulated in HEK293 cells (kidney epithelium) by treatment with sodium arsenite [PubChem=26435].,CGP,C2,5,13
Cohort,-0.009644389096002669,0.01230630864543672,-0.7836947190154285,0.4334523850929747,LonGen OPEL,Up-regulated in HEK293 cells (kidney epithelium) by treatment with sodium arsenite [PubChem=26435].,CGP,C2,12,11
Cohort,-0.011904106369877205,0.04199757541948453,-0.28344746693054007,0.7769206294843505,LGP Offspring,Genes down-regulated in 3 out of 4 NSCLC cell lines (non-small cell lung cancer) after treatment with azacitidine [PubChem=9444] and TSA [PubChem=5562].,CGP,C2,57,112
Cohort,-0.08881853688749693,0.11740159983434263,-0.7565360013221514,0.44954154625182674,LGP Proband,Genes down-regulated in 3 out of 4 NSCLC cell lines (non-small cell lung cancer) after treatment with azacitidine [PubChem=9444] and TSA [PubChem=5562].,CGP,C2,57,171
Cohort,0.005294551808089347,0.0410842693656743,0.12887053584827574,0.8974926447797644,LonGen OPEL,Genes down-regulated in 3 out of 4 NSCLC cell lines (non-small cell lung cancer) after treatment with azacitidine [PubChem=9444] and TSA [PubChem=5562].,CGP,C2,103,126
Cohort,-0.09277868461097631,0.07446437366740716,-1.2459472905173348,0.21321537621686554,LGP Offspring,Genes up-regulated in 3 out of 4 NSCLC cell lines (non-small cell lung cancer) after treatment with azacitidine [PubChem=9444] and TSA [PubChem=5562].,CGP,C2,187,345
Cohort,-0.2566080806344632,0.20043745919513656,-1.2802401390682245,0.20081665358052458,LGP Proband,Genes up-regulated in 3 out of 4 NSCLC cell lines (non-small cell lung cancer) after treatment with azacitidine [PubChem=9444] and TSA [PubChem=5562].,CGP,C2,187,449
Cohort,-0.025639009395990644,0.06404906277326212,-0.40030264746815136,0.6890410246119827,LonGen OPEL,Genes up-regulated in 3 out of 4 NSCLC cell lines (non-small cell lung cancer) after treatment with azacitidine [PubChem=9444] and TSA [PubChem=5562].,CGP,C2,280,335
Cohort,0.062316435094957545,0.042088897221589386,1.4805908258150442,0.13918154738237193,LGP Offspring,"Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MEC stroma cells (endothelium).",CGP,C2,49,127
Cohort,-0.032639169859640424,0.11794165434062613,-0.27673996979367066,0.7820483486555633,LGP Proband,"Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MEC stroma cells (endothelium).",CGP,C2,49,185
Cohort,-0.002725971771027923,0.03817009906025198,-0.0714164185616847,0.9430842818589089,LonGen OPEL,"Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MEC stroma cells (endothelium).",CGP,C2,108,122
Cohort,-0.07511660973371227,0.061587954967767276,-1.2196639711941297,0.2230176422613833,LGP Offspring,"Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MLg stroma cells (fibroblasts).",CGP,C2,132,244
Cohort,-0.20275570784474442,0.1727784596061228,-1.173501073611605,0.2409299471071383,LGP Proband,"Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MLg stroma cells (fibroblasts).",CGP,C2,132,358
Cohort,-0.024555223387145813,0.05492821404596334,-0.4470420859960651,0.6549662816493909,LonGen OPEL,"Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MLg stroma cells (fibroblasts).",CGP,C2,214,246
Cohort,0.007559744876839425,0.04572702594607144,0.16532334479296937,0.8687389118083464,LGP Offspring,"Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MHS stroma cells (macrophages).",CGP,C2,63,134
Cohort,-0.012130311359719925,0.13018452869389424,-0.09317782597840174,0.9257846684967066,LGP Proband,"Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MHS stroma cells (macrophages).",CGP,C2,63,219
Cohort,0.030203489529905037,0.042225408580869185,0.7152918241645897,0.47463848485497395,LonGen OPEL,"Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MHS stroma cells (macrophages).",CGP,C2,116,158
Cohort,-0.22552657704564238,0.060651460712284,-3.718403059004406,2.1710667515117415e-4,LGP Offspring,Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 24 h after exposure to ionizing radiation.,CGP,C2,149,206
Cohort,-0.33925308077905386,0.17171872848580333,-1.9756323830868645,0.0485257021021001,LGP Proband,Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 24 h after exposure to ionizing radiation.,CGP,C2,149,312
Cohort,-9.225443496604524e-4,0.051725203544154066,-0.01783548998261443,0.9857745617824742,LonGen OPEL,Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 24 h after exposure to ionizing radiation.,CGP,C2,175,224
Cohort,0.010738437507653192,0.014041757826625301,0.7647502285854473,0.44468716763093363,LGP Offspring,Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 2 h after exposure to ionizing radiation.,CGP,C2,5,15
Cohort,0.02518155663684773,0.046431339077415326,0.5423396597471016,0.5877294197117586,LGP Proband,Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 2 h after exposure to ionizing radiation.,CGP,C2,5,29
Cohort,-5.161296104022251e-4,0.012788059795323286,-0.040360275027098214,0.9678160209538784,LonGen OPEL,Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 2 h after exposure to ionizing radiation.,CGP,C2,11,14
Cohort,-0.10752703676150768,0.04102052077173437,-2.621298675359586,0.008956552695606376,LGP Offspring,Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 6 h after exposure to ionizing radiation.,CGP,C2,69,100
Cohort,0.008633157328971113,0.11973161624375633,0.07210424113373069,0.9425362385893429,LGP Proband,Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 6 h after exposure to ionizing radiation.,CGP,C2,69,171
Cohort,0.04854505231787108,0.0351763915709151,1.380046393331873,0.16795983144091386,LonGen OPEL,Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 6 h after exposure to ionizing radiation.,CGP,C2,83,119
Cohort,-0.19567653541592483,0.0996281760727385,-1.9640682297853318,0.04993153460255009,LGP Offspring,Genes down-regulated in macrophages by P.gingivalis FimA pathogen.,CGP,C2,346,649
Cohort,-0.1576441036948931,0.2753888122538661,-0.5724419318442374,0.5671768910573549,LGP Proband,Genes down-regulated in macrophages by P.gingivalis FimA pathogen.,CGP,C2,346,959
Cohort,0.036131032030740945,0.08964470311881492,0.40304703762421906,0.6870218502460621,LonGen OPEL,Genes down-regulated in macrophages by P.gingivalis FimA pathogen.,CGP,C2,528,627
Cohort,0.024415112996166187,0.12149253179482179,0.20095978440385748,0.8407904682431313,LGP Offspring,Genes up-regulated in macrophages by P.gingivalis FimA pathogen.,CGP,C2,471,1008
Cohort,-0.018211771085638557,0.3450111646525098,-0.05278603405191593,0.9579150298982737,LGP Proband,Genes up-regulated in macrophages by P.gingivalis FimA pathogen.,CGP,C2,471,1323
Cohort,-0.1599677131535386,0.10454029423776372,-1.5302014818296974,0.12636415327995326,LonGen OPEL,Genes up-regulated in macrophages by P.gingivalis FimA pathogen.,CGP,C2,790,894
Cohort,-0.07380619129934979,0.10366568322394841,-0.7119635833577316,0.4767329559438246,LGP Offspring,Genes down-regulated in macrophage by live P.gingivalis.,CGP,C2,353,710
Cohort,-0.14680117466411224,0.2715575764904533,-0.5405895006183821,0.5889348945998771,LGP Proband,Genes down-regulated in macrophage by live P.gingivalis.,CGP,C2,353,969
Cohort,0.08941876415284657,0.0947436379981613,0.9437970299871948,0.34555974688577884,LonGen OPEL,Genes down-regulated in macrophage by live P.gingivalis.,CGP,C2,561,686
Cohort,0.12128358039010656,0.11700309284068822,1.0365843965787014,0.30030023684491025,LGP Offspring,Genes up-regulated in macrophage by live P.gingivalis.,CGP,C2,412,921
Cohort,-0.47883965304024506,0.3234503441296768,-1.4804116357602946,0.13914108115253204,LGP Proband,Genes up-regulated in macrophage by live P.gingivalis.,CGP,C2,412,1256
Cohort,-0.050847507317271855,0.09822424150306447,-0.5176675995577474,0.604834039316134,LonGen OPEL,Genes up-regulated in macrophage by live P.gingivalis.,CGP,C2,667,775
Cohort,-0.05558252819543067,0.10232658266556428,-0.5431875740157569,0.5871797205908649,LGP Offspring,Genes up-regulated in macrophages by P.gingivalis LPS (lipopolysaccharide).,CGP,C2,350,699
Cohort,-0.38639707320601546,0.2885289434803023,-1.3391969226560267,0.18087143149128018,LGP Proband,Genes up-regulated in macrophages by P.gingivalis LPS (lipopolysaccharide).,CGP,C2,350,949
Cohort,-0.01598116792481959,0.08975855430523728,-0.17804618232233618,0.8587320070391178,LonGen OPEL,Genes up-regulated in macrophages by P.gingivalis LPS (lipopolysaccharide).,CGP,C2,530,629
Cohort,-0.01585236769466862,0.012327944135795878,-1.2858889949573258,0.19892208849282422,LGP Offspring,Transcription factors expressed in adult pancreatic beta cells.,CGP,C2,6,7
Cohort,-0.03828475589389233,0.03331395099028067,-1.1492109088190077,0.25079848735257165,LGP Proband,Transcription factors expressed in adult pancreatic beta cells.,CGP,C2,6,12
Cohort,0.0031354017655966016,0.011150666748021912,0.2811851377544585,0.7786414778239077,LonGen OPEL,Transcription factors expressed in adult pancreatic beta cells.,CGP,C2,8,11
Cohort,-7.297935853610173e-4,0.018507486695149,-0.039432344184924015,0.9685573354253669,LGP Offspring,Transcription factors expressed in progenitors of endocrine pancreatic cells.,CGP,C2,9,19
Cohort,0.018161096579716728,0.0478784623083451,0.3793166217986765,0.7045493141259165,LGP Proband,Transcription factors expressed in progenitors of endocrine pancreatic cells.,CGP,C2,9,29
Cohort,-5.538370526241708e-4,0.01590131968514487,-0.03482962820636639,0.9722243270033333,LonGen OPEL,Transcription factors expressed in progenitors of endocrine pancreatic cells.,CGP,C2,17,20
Cohort,-0.003425801180336363,0.0045519709203830265,-0.7525973342659443,0.45195390588288664,LGP Offspring,Transcription factors expressed in progenitors of exocrine pancreatic cells.,CGP,C2,1,1
Cohort,0.010972707939874772,0.020867925779609543,0.5258168950646939,0.5991552141638601,LGP Proband,Transcription factors expressed in progenitors of exocrine pancreatic cells.,CGP,C2,1,6
Cohort,0.014481941352455145,0.006779292403729825,2.136202495777802,0.032967341937177826,LonGen OPEL,Transcription factors expressed in progenitors of exocrine pancreatic cells.,CGP,C2,0,7
Cohort,0.020065345742632305,0.031160617179334896,0.6439328729322873,0.5198373716828197,LGP Offspring,Genes up-regulated in HeLa cells (cervical carcinoma) at 30 min after stimulation with TNF [GeneID=7124].,CGP,C2,27,70
Cohort,0.1326658551496791,0.09825711619777086,1.350190808395503,0.17732107774258518,LGP Proband,Genes up-regulated in HeLa cells (cervical carcinoma) at 30 min after stimulation with TNF [GeneID=7124].,CGP,C2,27,125
Cohort,0.020453223835333705,0.028191572579197847,0.7255084397252051,0.46835340619707566,LonGen OPEL,Genes up-regulated in HeLa cells (cervical carcinoma) at 30 min after stimulation with TNF [GeneID=7124].,CGP,C2,50,71
Cohort,-0.016566621774045543,0.028147378941955757,-0.588567120519764,0.5563482923790339,LGP Offspring,Genes up-regulated in HeLa cells (cervical carcinoma) at 4 h after stimulation with TNF [GeneID=7124].,CGP,C2,29,48
Cohort,0.01640850171446033,0.08419911788701241,0.1948773588872873,0.8455364217428779,LGP Proband,Genes up-regulated in HeLa cells (cervical carcinoma) at 4 h after stimulation with TNF [GeneID=7124].,CGP,C2,29,91
Cohort,-0.0014772654612454856,0.02470263702331285,-0.05980193369037208,0.952328395710529,LonGen OPEL,Genes up-regulated in HeLa cells (cervical carcinoma) at 4 h after stimulation with TNF [GeneID=7124].,CGP,C2,42,53
Cohort,0.0014195163698512278,0.052908558028663996,0.026829617414297773,0.9786035485825769,LGP Offspring,Down-regulated at 24 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,87,181
Cohort,0.16056903672980244,0.14678154268846028,1.093932069310688,0.27430062056387305,LGP Proband,Down-regulated at 24 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,87,256
Cohort,-0.034649365927199305,0.04499690280197657,-0.7700389086707824,0.4415052745744974,LonGen OPEL,Down-regulated at 24 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,143,156
Cohort,0.029639429602842708,0.04578951317817344,0.6472973295765674,0.5176592745491664,LGP Offspring,Up-regulated at 24 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,59,144
Cohort,0.035369111004243364,0.11600466662776379,0.30489386360409015,0.7605230591007145,LGP Proband,Up-regulated at 24 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,59,176
Cohort,0.028703954446085762,0.03650601097339773,0.786280222920072,0.43193734105146087,LonGen OPEL,Up-regulated at 24 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,85,114
Cohort,0.0312333888415324,0.038763872933055166,0.8057344758990456,0.4206792952158035,LGP Offspring,Down-regulated at 8 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,39,104
Cohort,0.04711091061107263,0.10426324314405919,0.45184582016099467,0.6514975421406197,LGP Proband,Down-regulated at 8 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,39,132
Cohort,0.00815845504525722,0.030672654012836066,0.26598464684024486,0.7903199105794094,LonGen OPEL,Down-regulated at 8 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,68,79
Cohort,0.0010323117429121512,0.028019333978824428,0.03684283658178026,0.9706211953425039,LGP Offspring,Up-regulated at 8 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,25,55
Cohort,-0.005846622077111578,0.08115859935151286,-0.0720394649960478,0.942587772801196,LGP Proband,Up-regulated at 8 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,25,82
Cohort,0.02320185575480742,0.025417267032532363,0.9128383364391864,0.361603959375954,LonGen OPEL,Up-regulated at 8 h following infection of primary human foreskin fibroblasts with CMV,CGP,C2,37,55
Cohort,0.023568915041534293,0.06272829262802244,0.3757302176435361,0.7072353440781756,LGP Offspring,Down-regulated at any timepoint following infection of primary human foreskin fibroblasts with CMV,CGP,C2,120,267
Cohort,0.17909789556230543,0.1724053585896988,1.0388186134546662,0.29919017594546515,LGP Proband,Down-regulated at any timepoint following infection of primary human foreskin fibroblasts with CMV,CGP,C2,120,364
Cohort,-0.034760502059922184,0.05536066787574941,-0.627891667382664,0.5302549984729337,LonGen OPEL,Down-regulated at any timepoint following infection of primary human foreskin fibroblasts with CMV,CGP,C2,200,218
Cohort,-0.007819951779475368,0.050317202911416475,-0.15541308592296768,0.8765420621601012,LGP Offspring,Up-regulated at any timepoint following infection of primary human foreskin fibroblasts with CMV,CGP,C2,78,167
Cohort,-0.006019763722101926,0.13107635325823946,-0.04592562710561619,0.9633805223768266,LGP Proband,Up-regulated at any timepoint following infection of primary human foreskin fibroblasts with CMV,CGP,C2,78,220
Cohort,0.027215405868954413,0.041037119824458436,0.6631899603425342,0.5074009036149506,LonGen OPEL,Up-regulated at any timepoint following infection of primary human foreskin fibroblasts with CMV,CGP,C2,111,146
Cohort,0.009734559778653487,0.014465136293133224,0.6729670278512758,0.501198251535486,LGP Offspring,Genes down-regulated in A549 cells (lung adenocarcinoma) upon SKIL [GeneID=6498] knockdown by RNAi.,CGP,C2,6,15
Cohort,-0.027053164580839718,0.03863887225435853,-0.7001540935964577,0.4840263350546844,LGP Proband,Genes down-regulated in A549 cells (lung adenocarcinoma) upon SKIL [GeneID=6498] knockdown by RNAi.,CGP,C2,6,19
Cohort,0.011656734056757986,0.012571125254773654,0.9272625815522405,0.3540712802275644,LonGen OPEL,Genes down-regulated in A549 cells (lung adenocarcinoma) upon SKIL [GeneID=6498] knockdown by RNAi.,CGP,C2,9,15
Cohort,-0.021855155131325233,0.031091225480186713,-0.7029364328290216,0.482337365359216,LGP Offspring,Genes up-regulated in A549 cells (lung adenocarcinoma) upon SKIL [GeneID=6498] knockdown by RNAi.,CGP,C2,33,59
Cohort,-0.07177295908148593,0.08250179111158162,-0.8699563744551289,0.38457455669202645,LGP Proband,Genes up-regulated in A549 cells (lung adenocarcinoma) upon SKIL [GeneID=6498] knockdown by RNAi.,CGP,C2,33,76
Cohort,-0.05618806497092483,0.023841275749437358,-2.356755802895776,0.018676706294036175,LonGen OPEL,Genes up-regulated in A549 cells (lung adenocarcinoma) upon SKIL [GeneID=6498] knockdown by RNAi.,CGP,C2,52,38
Cohort,-0.0028273885593931456,0.015746519519751118,-0.17955641282168455,0.8575546321085247,LGP Offspring,Genes down-regulated in MS427 cells (Wilms tumor with normal WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,9,16
Cohort,-0.02048062381268698,0.04012261053674072,-0.5104509287583032,0.609870658298152,LGP Proband,Genes down-regulated in MS427 cells (Wilms tumor with normal WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,9,18
Cohort,-0.013029837017522307,0.011477512093135174,-1.1352492519102286,0.25661261156884985,LonGen OPEL,Genes down-regulated in MS427 cells (Wilms tumor with normal WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,12,8
Cohort,0.019654000611802006,0.02422862425914946,0.8111892941828945,0.4175424829636498,LGP Offspring,Genes up-regulated in MS427 cells (Wilms tumor with normal WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,14,39
Cohort,-0.022096588840759487,0.061089101761335245,-0.361710815901126,0.7176597640052933,LGP Proband,Genes up-regulated in MS427 cells (Wilms tumor with normal WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,14,45
Cohort,0.010257517312437599,0.019621489284754545,0.5227695596178552,0.6012800954810844,LonGen OPEL,Genes up-regulated in MS427 cells (Wilms tumor with normal WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,24,34
Cohort,-0.006006572286289573,0.005556978307248644,-1.0809061965303102,0.28012430128899796,LGP Offspring,Genes down-regulated in MZ128 cells (Wilms tumor with mutated WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,2,1
Cohort,-0.012453768186316001,0.022926929622879413,-0.5431938943053257,0.5871414554203404,LGP Proband,Genes down-regulated in MZ128 cells (Wilms tumor with mutated WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,2,7
Cohort,-0.004570927738515818,0.009320556611429026,-0.49041360179185733,0.6239764046592619,LonGen OPEL,Genes down-regulated in MZ128 cells (Wilms tumor with mutated WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,6,7
Cohort,0.0034420584338106276,0.029989011791081596,0.11477732103310781,0.9086557079417417,LGP Offspring,Genes up-regulated in MZ128 cells (Wilms tumor with mutated WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,28,58
Cohort,-0.024782222143544134,0.08013724765085055,-0.30924723359002343,0.7572107074580338,LGP Proband,Genes up-regulated in MZ128 cells (Wilms tumor with mutated WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,28,74
Cohort,0.01535388010903165,0.025204967586810626,0.6091608749802996,0.542591626324826,LonGen OPEL,Genes up-regulated in MZ128 cells (Wilms tumor with mutated WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.,CGP,C2,46,59
Cohort,0.02375965346816796,0.11704361344946332,0.20299829070491593,0.8391974528890132,LGP Offspring,Class I of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,431,919
Cohort,0.21393497671835962,0.32801015762992375,0.6522205844604696,0.5144385943069463,LGP Proband,Class I of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,431,1235
Cohort,-0.1025701323887271,0.10236083488140281,-1.0020447030113304,0.3166265113814422,LonGen OPEL,Class I of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,723,831
Cohort,-0.021992179268812685,0.030800723796414315,-0.7140150151722382,0.47546434884367295,LGP Offspring,Class II of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,37,60
Cohort,-0.028028656188581056,0.08582804651643666,-0.32656756533790354,0.7440769132709552,LGP Proband,Class II of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,37,92
Cohort,-0.0261589363434434,0.02460088583495425,-1.0633331059272422,0.2879533866828526,LonGen OPEL,Class II of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,47,45
Cohort,-0.043924174014112506,0.07989639154499431,-0.5497641778900145,0.5826627107264837,LGP Offspring,Class III of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,210,412
Cohort,-0.08197721888018739,0.21144761070827364,-0.38769517709655416,0.6983405502615085,LGP Proband,Class III of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,210,507
Cohort,0.019054440411832952,0.0645842937821924,0.29503210913930855,0.768046283649191,LonGen OPEL,Class III of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,295,363
Cohort,-0.23049433137943348,0.08173608644749987,-2.819982475274039,0.004943341403519219,LGP Offspring,Genes down-regulated by second pulse of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,257,439
Cohort,-0.5574783725725709,0.2328118960489839,-2.3945441879622718,0.01686086797472171,LGP Proband,Genes down-regulated by second pulse of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,257,643
Cohort,0.004621150796100476,0.07796078792323655,0.05927532185347658,0.9527476944481627,LonGen OPEL,Genes down-regulated by second pulse of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,347,428
Cohort,-0.15808013722689088,0.0808491919397942,-1.9552469657904321,0.05096558677196624,LGP Offspring,Genes repressed in the time interval between two pulses of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,215,378
Cohort,-0.2524272866973252,0.21693750594453892,-1.1635944904882396,0.2449211724073833,LGP Proband,Genes repressed in the time interval between two pulses of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,215,549
Cohort,-0.13499871757480902,0.06765744484175056,-1.995326868913959,0.046347683552657996,LonGen OPEL,Genes repressed in the time interval between two pulses of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,354,369
Cohort,-0.05429989914961642,0.05179837877233021,-1.0482934106544368,0.29487808900878987,LGP Offspring,Genes induced in the time interval between two pulses of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,90,166
Cohort,-0.166421890989928,0.14743026320383068,-1.1288177025082042,0.25929933546802364,LGP Proband,Genes induced in the time interval between two pulses of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,90,258
Cohort,0.04699937476955414,0.04389627222812231,1.070691709886103,0.2846326074295762,LonGen OPEL,Genes induced in the time interval between two pulses of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,122,172
Cohort,0.04820334754342762,0.05033503352462229,0.9576500534135551,0.33858161064432013,LGP Offspring,Genes persistently repressed by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,80,176
Cohort,-0.26633439065205533,0.13508863339021238,-1.9715529276451482,0.04899082407085195,LGP Proband,Genes persistently repressed by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,80,238
Cohort,0.051412096714272465,0.04414208776914336,1.164695629784214,0.24449114972794078,LonGen OPEL,Genes persistently repressed by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,130,173
Cohort,-9.726637215540488e-4,0.03182817585522279,-0.030559832457204464,0.975629596229588,LGP Offspring,Genes persistently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,34,74
Cohort,-0.027328625063691162,0.0900889259107543,-0.303351658235597,0.761697537386634,LGP Proband,Genes persistently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,34,108
Cohort,-0.0363176379400599,0.028356623364047845,-1.280746211345653,0.20065585918575285,LonGen OPEL,Genes persistently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,62,61
Cohort,-0.4113989619909681,0.231239323144731,-1.779104679931434,0.07567185744006157,LGP Offspring,Genes transiently induced only by the second pulse of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,1647,3283
Cohort,0.4814745644724578,0.6485818159765131,0.7423497739410772,0.45808446223679766,LGP Proband,Genes transiently induced only by the second pulse of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,1647,4581
Cohort,-0.2038613510068175,0.19464180389710295,-1.0473667368731767,0.29524838375915036,LonGen OPEL,Genes transiently induced only by the second pulse of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).,CGP,C2,2654,3139
Cohort,0.024443197758482367,0.06274433770566461,0.38956818499138635,0.6969785787816692,LGP Offspring,Genes encoding structural components of basement membranes,CP,C2,135,294
Cohort,-0.024595047740700933,0.17247638858835027,-0.1425995056019058,0.8866409303262058,LGP Proband,Genes encoding structural components of basement membranes,CP,C2,135,355
Cohort,0.06319970731480222,0.05358915984152948,1.1793375283675365,0.23861616461165427,LonGen OPEL,Genes encoding structural components of basement membranes,CP,C2,206,271
Cohort,-0.08678334437310552,0.06027128490603722,-1.4398787832116162,0.1503646219218571,LGP Offspring,Genes encoding collagen proteins,CP,C2,128,229
Cohort,-0.22404503062951048,0.15978758150528655,-1.4021429482747254,0.16124464780084927,LGP Proband,Genes encoding collagen proteins,CP,C2,128,296
Cohort,-0.0241647794204011,0.05056645438010753,-0.47788162560805025,0.6328656630295988,LonGen OPEL,Genes encoding collagen proteins,CP,C2,179,211
Cohort,-0.28458624301467944,0.12744164553494977,-2.2330710013991,0.025870809211905273,LGP Offspring,"Ensemble of genes encoding core extracellular matrix including ECM glycoproteins, collagens and proteoglycans",CP,C2,576,1081
Cohort,-0.34012098775235455,0.35193413914543226,-0.9664336303895881,0.3341073984765326,LGP Proband,"Ensemble of genes encoding core extracellular matrix including ECM glycoproteins, collagens and proteoglycans",CP,C2,576,1510
Cohort,-0.12423120718043483,0.10881099037460357,-1.1417156185486788,0.25391557955577154,LonGen OPEL,"Ensemble of genes encoding core extracellular matrix including ECM glycoproteins, collagens and proteoglycans",CP,C2,897,1000
Cohort,-0.020329175732410974,0.07623147846878096,-0.26667691799702364,0.7897992529916933,LGP Offspring,Genes encoding proteins affiliated structurally or functionally to extracellular matrix proteins,CP,C2,176,355
Cohort,0.07858009488424995,0.20878758904527572,0.37636382144922326,0.7067421628304624,LGP Proband,Genes encoding proteins affiliated structurally or functionally to extracellular matrix proteins,CP,C2,176,515
Cohort,0.05583906890260589,0.06475829694340356,0.8622689529869392,0.3887992267868303,LonGen OPEL,Genes encoding proteins affiliated structurally or functionally to extracellular matrix proteins,CP,C2,273,342
Cohort,-0.20861762909982923,0.10752157145036162,-1.9402397703621694,0.05276605567926802,LGP Offspring,Genes encoding structural ECM glycoproteins,CP,C2,402,760
Cohort,-0.06771786334495043,0.3022951515584752,-0.22401240309622122,0.822802516019341,LGP Proband,Genes encoding structural ECM glycoproteins,CP,C2,402,1091
Cohort,-0.08126887849723592,0.09032746318219043,-0.8997139478313108,0.3685445952039671,LonGen OPEL,Genes encoding structural ECM glycoproteins,CP,C2,634,703
Cohort,0.0564694720594497,0.09701921820095562,0.5820441878070451,0.560730972544268,LGP Offspring,Genes encoding enzymes and their regulators involved in the remodeling of the extracellular matrix,CP,C2,259,577
Cohort,-0.13188373257852795,0.2631547190504164,-0.5011642316521068,0.6163877927318786,LGP Proband,Genes encoding enzymes and their regulators involved in the remodeling of the extracellular matrix,CP,C2,259,831
Cohort,-0.12048792386527199,0.08005888160910163,-1.50499134441536,0.13272298049230408,LonGen OPEL,Genes encoding enzymes and their regulators involved in the remodeling of the extracellular matrix,CP,C2,490,541
Cohort,-0.47173611077091937,0.19753597307915896,-2.388102295584813,0.017209179944592607,LGP Offspring,Ensemble of genes encoding extracellular matrix and extracellular matrix-associated proteins ,CP,C2,1233,2389
Cohort,-0.7023523546225484,0.5210851245239512,-1.347864910295027,0.17806783038636345,LGP Proband,Ensemble of genes encoding extracellular matrix and extracellular matrix-associated proteins ,CP,C2,1233,3337
Cohort,-0.18165990953974723,0.1655982453514107,-1.0969917534708933,0.2729767426327064,LonGen OPEL,Ensemble of genes encoding extracellular matrix and extracellular matrix-associated proteins ,CP,C2,1938,2219
Cohort,-0.18714986775623993,0.15010333961064704,-1.2468068214983614,0.2129001655367018,LGP Offspring,"Ensemble of genes encoding ECM-associated proteins including ECM-affilaited proteins, ECM regulators and secreted factors",CP,C2,657,1308
Cohort,-0.362231366870194,0.3827893321886323,-0.9462943097162706,0.3442725785237616,LGP Proband,"Ensemble of genes encoding ECM-associated proteins including ECM-affilaited proteins, ECM regulators and secreted factors",CP,C2,657,1827
Cohort,-0.057428702359312585,0.12170838115386354,-0.4718549520982562,0.6371596385684362,LonGen OPEL,"Ensemble of genes encoding ECM-associated proteins including ECM-affilaited proteins, ECM regulators and secreted factors",CP,C2,1041,1219
Cohort,0.010814730458255276,0.0364482404339997,0.29671474752913074,0.7667754378837396,LGP Offspring,Genes encoding proteoglycans,CP,C2,46,92
Cohort,-0.04835809377789377,0.10463853386338401,-0.46214422156401824,0.6440984321070333,LGP Proband,Genes encoding proteoglycans,CP,C2,46,123
Cohort,-0.018797549262797954,0.03300119231632538,-0.5696021247541102,0.5691082922730284,LonGen OPEL,Genes encoding proteoglycans,CP,C2,84,86
Cohort,-0.2232901640832789,0.07911418824345531,-2.822378248970411,0.004906992469375846,LGP Offspring,Genes encoding secreted soluble factors,CP,C2,222,376
Cohort,-0.30892772917591643,0.20777471382278442,-1.4868398733033876,0.1374350485238729,LGP Proband,Genes encoding secreted soluble factors,CP,C2,222,481
Cohort,0.0072201526033536575,0.06725708770114451,0.10735154985354492,0.9145371407333972,LonGen OPEL,Genes encoding secreted soluble factors,CP,C2,278,336
Cohort,-0.02074980687668096,0.028505883585002074,-0.7279131276463273,0.46691881345051267,LGP Offspring,"Antigen binding to B cell receptors activates protein tyrosine kinases, such as the Src family, which ultimate activate MAP kinases.",CP,C2,30,51
Cohort,0.041340132579061724,0.08179444722942197,0.5054149025924515,0.6134009933800231,LGP Proband,"Antigen binding to B cell receptors activates protein tyrosine kinases, such as the Src family, which ultimate activate MAP kinases.",CP,C2,30,82
Cohort,-0.0037400902459076533,0.024464445631960152,-0.15287860195865752,0.8785327545295625,LonGen OPEL,"Antigen binding to B cell receptors activates protein tyrosine kinases, such as the Src family, which ultimate activate MAP kinases.",CP,C2,43,50
Cohort,-0.03224372089197541,0.024944249526613078,-1.2926314282405853,0.19658020105907772,LGP Offspring,"Apoptosis is mediated by caspases, cysteine proteases arranged in a proteolytic cascade.",CP,C2,25,34
Cohort,-0.10086259997972925,0.07279112761182824,-1.3856441476988401,0.16622601324588387,LGP Proband,"Apoptosis is mediated by caspases, cysteine proteases arranged in a proteolytic cascade.",CP,C2,25,59
Cohort,-0.025162782023760124,0.02308029692374577,-1.0902278296893062,0.2759427153271543,LonGen OPEL,"Apoptosis is mediated by caspases, cysteine proteases arranged in a proteolytic cascade.",CP,C2,45,45
Cohort,-0.005072649722060653,0.014773465255550637,-0.3433622128806086,0.7314327406946348,LGP Offspring,The TNF-type receptor Fas induces apoptosis on ligand binding.,CP,C2,8,14
Cohort,2.7734180298066803e-4,0.03316938856508346,0.008361378215835382,0.9933306627439884,LGP Proband,The TNF-type receptor Fas induces apoptosis on ligand binding.,CP,C2,8,10
Cohort,-0.009406100873676297,0.011729056256552635,-0.8019486536626866,0.4228220008917115,LonGen OPEL,The TNF-type receptor Fas induces apoptosis on ligand binding.,CP,C2,13,8
Cohort,0.008287134569016055,0.013470932507848934,0.6151864070425338,0.538638657121259,LGP Offspring,"Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition.",CP,C2,4,14
Cohort,0.0746823505064727,0.039366079562289394,1.8971244110885357,0.058156729497348895,LGP Proband,"Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition.",CP,C2,4,20
Cohort,-0.005846538775095873,0.011160405675549068,-0.5238643598686421,0.6005187075573393,LonGen OPEL,"Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition.",CP,C2,10,9
Cohort,-0.0039469597851747315,0.016214280675615613,-0.243424908211346,0.8077500996177293,LGP Offspring,Cdc25 activates the cdc2/cyclin B complex to induce the G2/M transition.,CP,C2,8,16
Cohort,-0.01779017168139973,0.049038132191769696,-0.3627824080213548,0.7168593534238827,LGP Proband,Cdc25 activates the cdc2/cyclin B complex to induce the G2/M transition.,CP,C2,8,30
Cohort,0.02580240455082376,0.012476688751064067,2.0680490685978854,0.03895792602524787,LonGen OPEL,Cdc25 activates the cdc2/cyclin B complex to induce the G2/M transition.,CP,C2,6,18
Cohort,-0.002454112480440948,0.015191298712601924,-0.16154724667517345,0.8717106720110209,LGP Offspring,"Cytokines can induce activation of matrix metalloproteinases, which degrade extracellular matrix.",CP,C2,8,15
Cohort,0.028532102389247548,0.04325679010007332,0.6595982347104203,0.5096937822668024,LGP Proband,"Cytokines can induce activation of matrix metalloproteinases, which degrade extracellular matrix.",CP,C2,8,23
Cohort,-0.009836785626794787,0.015566850623470399,-0.6319059561067351,0.5276297688871733,LonGen OPEL,"Cytokines can induce activation of matrix metalloproteinases, which degrade extracellular matrix.",CP,C2,19,19
Cohort,-0.0031031580498353238,0.015496958839847743,-0.20024303361096182,0.8413507374464977,LGP Offspring,"Programmed cell death, or apoptosis, eliminates damaged or unneeded cells.",CP,C2,7,15
Cohort,0.03341413786865342,0.04043145331298573,0.8264391984623888,0.4087913612477555,LGP Proband,"Programmed cell death, or apoptosis, eliminates damaged or unneeded cells.",CP,C2,7,18
Cohort,0.021545032949558264,0.01640636406930151,1.3132119254790822,0.18948996687668973,LonGen OPEL,"Programmed cell death, or apoptosis, eliminates damaged or unneeded cells.",CP,C2,15,23
Cohort,-0.01362321376030272,0.020178183070276506,-0.6751457112295909,0.49981404949959607,LGP Offspring,PTEN is a tumor suppressor that dephosphorylates the lipid messenger phosphatidylinositol triphosphate.,CP,C2,14,23
Cohort,0.018173583452035395,0.05332207515704226,0.3408266350945872,0.7333199357319269,LGP Proband,PTEN is a tumor suppressor that dephosphorylates the lipid messenger phosphatidylinositol triphosphate.,CP,C2,14,30
Cohort,0.004251992692716404,0.01654468370446475,0.25700054281297385,0.7972447687293288,LonGen OPEL,PTEN is a tumor suppressor that dephosphorylates the lipid messenger phosphatidylinositol triphosphate.,CP,C2,17,22
Cohort,-0.01666037902918455,0.018376043524707637,-0.906635805840562,0.3649224705524444,LGP Offspring,Expression of cyclins regulates progression through the cell cycle by activating cyclin-dependent kinases.,CP,C2,13,19
Cohort,-0.04079398284770115,0.046480531396634335,-0.8776574110048805,0.38038241769143855,LGP Proband,Expression of cyclins regulates progression through the cell cycle by activating cyclin-dependent kinases.,CP,C2,13,24
Cohort,-0.00413879168467675,0.016455086165708333,-0.25152051122660224,0.8014766251571597,LonGen OPEL,Expression of cyclins regulates progression through the cell cycle by activating cyclin-dependent kinases.,CP,C2,18,20
Cohort,-0.008321087116356356,0.015764487391675883,-0.5278374684577525,0.5977853579574902,LGP Offspring,The TrkA receptor binds nerve growth factor to activate MAP kinase pathways and promote cell growth.,CP,C2,9,16
Cohort,0.04884306890596625,0.043738609404256355,1.1167037446145502,0.2644426292853213,LGP Proband,The TrkA receptor binds nerve growth factor to activate MAP kinase pathways and promote cell growth.,CP,C2,9,23
Cohort,0.0014332010820745985,0.01124887627600648,0.12740837812676223,0.8986493638803659,LonGen OPEL,The TrkA receptor binds nerve growth factor to activate MAP kinase pathways and promote cell growth.,CP,C2,8,11
Cohort,-0.01486117344737762,0.028640619102704427,-0.5188845043497797,0.6040111015538123,LGP Offspring,Members of the BCR signaling pathway,CP,C2,30,52
Cohort,-0.13570347879592995,0.08056813593378521,-1.6843318667252973,0.09249171305549549,LGP Proband,Members of the BCR signaling pathway,CP,C2,30,83
Cohort,-0.019310302932891824,0.025676884932267365,-0.7520500630754142,0.4522432662088933,LonGen OPEL,Members of the BCR signaling pathway,CP,C2,48,49
Cohort,0.004475165701576162,0.02910820016945919,0.15374243943366794,0.8778587044525432,LGP Offspring,Genes related to CD40 signaling,CP,C2,23,53
Cohort,0.027705126828263423,0.07764227403856626,0.3568304402637899,0.7213090084269745,LGP Proband,Genes related to CD40 signaling,CP,C2,23,76
Cohort,-0.07208717275964802,0.024897100999235193,-2.8954042786693295,0.0038903571127014893,LonGen OPEL,Genes related to CD40 signaling,CP,C2,54,34
Cohort,0.00495206928506317,0.031098606261463324,0.15923765983042334,0.8735291967861596,LGP Offspring,Genes related to chemotaxis,CP,C2,30,70
Cohort,0.02999983198212597,0.08901802186749525,0.33700852201345477,0.7361952650839887,LGP Proband,Genes related to chemotaxis,CP,C2,30,96
Cohort,0.0321692944916613,0.026682923307353616,1.2056135724377577,0.22832477716454624,LonGen OPEL,Genes related to chemotaxis,CP,C2,45,62
Cohort,8.630662146363651e-4,0.022053945211180266,0.03913432296906374,0.9687948504228472,LGP Offspring,Genes related to IL4 rceptor signaling in B lymphocytes,CP,C2,16,35
Cohort,0.0030698025148935665,0.05656277430658512,0.054272488443626,0.9567310659695959,LGP Proband,Genes related to IL4 rceptor signaling in B lymphocytes,CP,C2,16,37
Cohort,-0.02710532510093837,0.017843601468470274,-1.519050128351813,0.12914694910702523,LonGen OPEL,Genes related to IL4 rceptor signaling in B lymphocytes,CP,C2,26,20
Cohort,0.036737258255234495,0.031164126351175558,1.178831642551363,0.23887997347252063,LGP Offspring,Genes related to the insulin receptor pathway,CP,C2,28,74
Cohort,0.08355837611098385,0.08356260913252571,0.9999493431142732,0.3176250545358529,LGP Proband,Genes related to the insulin receptor pathway,CP,C2,28,95
Cohort,-0.019873538577764163,0.026007766453021025,-0.7641386127356461,0.4450110899352351,LonGen OPEL,Genes related to the insulin receptor pathway,CP,C2,52,51
Cohort,-0.022969401140897207,0.02747399283904994,-0.83604160761991,0.40342690764454137,LGP Offspring,Genes related to PIP3 signaling in B lymphocytes,CP,C2,26,41
Cohort,-0.059631341458206366,0.06917256882873803,-0.862066314261735,0.38889882635848194,LGP Proband,Genes related to PIP3 signaling in B lymphocytes,CP,C2,26,55
Cohort,0.0049298862918348,0.020314710331066056,0.2426756872971909,0.8083191583921463,LonGen OPEL,Genes related to PIP3 signaling in B lymphocytes,CP,C2,29,35
Cohort,-0.03477287101063982,0.04422113047416405,-0.7863406167546004,0.43194351867037173,LGP Offspring,Genes related to PIP3 signaling in cardiac myocytes,CP,C2,65,118
Cohort,-9.513291320819786e-4,0.11529208299906422,-0.008251469722250574,0.9934183277227906,LGP Proband,Genes related to PIP3 signaling in cardiac myocytes,CP,C2,65,142
Cohort,-0.014022969520317105,0.035917221441466224,-0.3904246753377105,0.6963270025478667,LonGen OPEL,Genes related to PIP3 signaling in cardiac myocytes,CP,C2,85,99
Cohort,0.036303069020100644,0.03297839349669395,1.1008137501828277,0.27136954439537386,LGP Offspring,Genes related to regulation of the actin cytoskeleton,CP,C2,30,73
Cohort,-0.011562246096212217,0.08992117410153949,-0.1285820187707521,0.8977193949879827,LGP Proband,Genes related to regulation of the actin cytoskeleton,CP,C2,30,97
Cohort,0.004622239087601392,0.029769323397179595,0.1552685301554187,0.8766489873309881,LonGen OPEL,Genes related to regulation of the actin cytoskeleton,CP,C2,51,66
Cohort,-0.023297345349834395,0.04418933874620795,-0.5272164284611212,0.5982162746583553,LGP Offspring,Genes related to Wnt-mediated signal transduction,CP,C2,63,126
Cohort,-0.013931281130446942,0.12095307505224862,-0.11517922239206392,0.908330791785203,LGP Proband,Genes related to Wnt-mediated signal transduction,CP,C2,63,164
Cohort,-0.03599461322600035,0.035230943550324474,-1.0216761062497528,0.3072446236692233,LonGen OPEL,Genes related to Wnt-mediated signal transduction,CP,C2,94,100
Cohort,0.01431964027476473,0.021488009174174025,0.6664014408545207,0.5053819012915002,LGP Offspring,The 4-1BB-dependent immune response,CP:BIOCARTA,C2,12,34
Cohort,0.03897202105900682,0.058423355801975704,0.6670623507335213,0.5049168175415426,LGP Proband,The 4-1BB-dependent immune response,CP:BIOCARTA,C2,12,48
Cohort,0.01969730150459397,0.019350345536594857,1.0179302207985361,0.30902040398936614,LonGen OPEL,The 4-1BB-dependent immune response,CP:BIOCARTA,C2,23,37
Cohort,-0.04463385031448628,0.025953924072256607,-1.7197341793180918,0.08593848580829312,LGP Offspring,Angiotensin-converting enzyme 2 regulates heart function,CP:BIOCARTA,C2,28,39
Cohort,-0.03689104931137274,0.06992328051276181,-0.5275932284761682,0.5979220198398985,LGP Proband,Angiotensin-converting enzyme 2 regulates heart function,CP:BIOCARTA,C2,28,53
Cohort,-0.009972042810397059,0.023683185243090554,-0.4210600351279333,0.6738249062773733,LonGen OPEL,Angiotensin-converting enzyme 2 regulates heart function,CP:BIOCARTA,C2,42,45
Cohort,-0.0032598218374213605,0.009045280815631461,-0.36038923543290663,0.71866865130391,LGP Offspring,Mechanism of Acetaminophen Activity and Toxicity,CP:BIOCARTA,C2,3,5
Cohort,0.03645330667753304,0.03114233739118094,1.1705385571943643,0.24211866460429204,LGP Proband,Mechanism of Acetaminophen Activity and Toxicity,CP:BIOCARTA,C2,3,13
Cohort,0.006298396531241041,0.0063318392815388804,0.9947183197786865,0.3201755607813979,LonGen OPEL,Mechanism of Acetaminophen Activity and Toxicity,CP:BIOCARTA,C2,1,5
Cohort,-0.06327472580399697,0.02322499569362417,-2.724423575301994,0.006607881631225012,LGP Offspring,Role of nicotinic acetylcholine receptors in the regulation of apoptosis,CP:BIOCARTA,C2,26,30
Cohort,-0.016249730361228946,0.0748657259397126,-0.21705166359188754,0.8282211678661158,LGP Proband,Role of nicotinic acetylcholine receptors in the regulation of apoptosis,CP:BIOCARTA,C2,26,68
Cohort,0.011487474178687012,0.02531242070135848,0.4538275621371328,0.6500766486616893,LonGen OPEL,Role of nicotinic acetylcholine receptors in the regulation of apoptosis,CP:BIOCARTA,C2,43,49
Cohort,0.0028084714223417994,0.010608175091660444,0.2647459528217689,0.7912858758225463,LGP Offspring,Y branching of actin filaments,CP:BIOCARTA,C2,3,8
Cohort,0.029994969669335254,0.02480956245448462,1.2090084105418517,0.22700225110642613,LGP Proband,Y branching of actin filaments,CP:BIOCARTA,C2,3,7
Cohort,-0.009628457889462646,0.009511565929091479,-1.0122894548849888,0.3117072736950499,LonGen OPEL,Y branching of actin filaments,CP:BIOCARTA,C2,8,6
Cohort,0.009315075041188768,0.014773409773286216,0.6305297953646832,0.5285611073836642,LGP Offspring,Attenuation of GPCR Signaling,CP:BIOCARTA,C2,6,16
Cohort,0.0765131731294746,0.04528697424160783,1.6895183308399837,0.0914938868852619,LGP Proband,Attenuation of GPCR Signaling,CP:BIOCARTA,C2,6,26
Cohort,0.005835649633189481,0.015061260954985578,0.3874608939205561,0.6985186075494543,LonGen OPEL,Attenuation of GPCR Signaling,CP:BIOCARTA,C2,15,20
Cohort,0.024856914899331617,0.03712419091747209,0.6695611213343099,0.5033662271830032,LGP Offspring,Agrin in Postsynaptic Differentiation,CP:BIOCARTA,C2,40,99
Cohort,-0.034975823395823426,0.10677202379918331,-0.3275747911419747,0.7433153940036186,LGP Proband,Agrin in Postsynaptic Differentiation,CP:BIOCARTA,C2,40,150
Cohort,0.005985068219603726,0.0352825772706084,0.16963239883809436,0.8653423412942916,LonGen OPEL,Agrin in Postsynaptic Differentiation,CP:BIOCARTA,C2,80,97
Cohort,0.005265956665160797,0.009051488720942412,0.581777962444671,0.5609102014416594,LGP Offspring,Hemoglobin's Chaperone,CP:BIOCARTA,C2,2,6
Cohort,0.011052652671643284,0.025912405005975105,0.4265390522066427,0.6698251718183398,LGP Proband,Hemoglobin's Chaperone,CP:BIOCARTA,C2,2,9
Cohort,-0.005131624347834557,0.007750943809078555,-0.6620644497285567,0.5081215395270571,LonGen OPEL,Hemoglobin's Chaperone,CP:BIOCARTA,C2,6,3
Cohort,-0.01225627265407429,0.008895820972554914,-1.3777562174291647,0.1687344845795445,LGP Offspring,Rho-Selective Guanine Exchange Factor AKAP13 Mediates Stress Fiber Formation,CP:BIOCARTA,C2,5,3
Cohort,-0.09450631140621889,0.02910872277727674,-3.2466663731461876,0.0012142629829262315,LGP Proband,Rho-Selective Guanine Exchange Factor AKAP13 Mediates Stress Fiber Formation,CP:BIOCARTA,C2,5,9
Cohort,0.003792783990819281,0.010611360944833054,0.3574267250485043,0.7208671165557179,LonGen OPEL,Rho-Selective Guanine Exchange Factor AKAP13 Mediates Stress Fiber Formation,CP:BIOCARTA,C2,8,9
Cohort,-0.012193791318549594,0.012203927539848591,-0.9991694295737253,0.3180701374529224,LGP Offspring,AKAP95 role in mitosis and chromosome dynamics,CP:BIOCARTA,C2,7,6
Cohort,-0.07736250207451559,0.03948813265332119,-1.9591329565696476,0.05043003451700754,LGP Proband,AKAP95 role in mitosis and chromosome dynamics,CP:BIOCARTA,C2,7,17
Cohort,-0.0014250843043035998,0.012601316993986776,-0.11309010835801019,0.9099876314972729,LonGen OPEL,AKAP95 role in mitosis and chromosome dynamics,CP:BIOCARTA,C2,12,12
Cohort,-0.013197096522157002,0.02255483490487772,-0.5851116435927887,0.5586678997790331,LGP Offspring,Protein Kinase A at the Centrosome,CP:BIOCARTA,C2,18,31
Cohort,-0.08106107608047539,0.06669410648297727,-1.2154158793800631,0.22455145922716752,LGP Proband,Protein Kinase A at the Centrosome,CP:BIOCARTA,C2,18,56
Cohort,0.008176178596369571,0.02220051683149749,0.36828775917367074,0.7127565972604866,LonGen OPEL,Protein Kinase A at the Centrosome,CP:BIOCARTA,C2,31,38
Cohort,-1.2970925617011846e-5,0.02277483802669498,-5.695287756518087e-4,0.9995457498305096,LGP Offspring,AKT Signaling Pathway,CP:BIOCARTA,C2,15,35
Cohort,-0.0029333906572499182,0.05902313651431569,-0.04969899653737383,0.960374155692956,LGP Proband,AKT Signaling Pathway,CP:BIOCARTA,C2,15,39
Cohort,-0.021673775691604457,0.024240605138140237,-0.8941103395765841,0.3715331125889588,LonGen OPEL,AKT Signaling Pathway,CP:BIOCARTA,C2,42,36
Cohort,-0.018033496514678962,0.03002631802783941,-0.6005896726318192,0.5483146162674365,LGP Offspring,ALK in cardiac myocytes,CP:BIOCARTA,C2,29,54
Cohort,0.06910512544072474,0.0809855288631351,0.8533021443560842,0.3937367712807812,LGP Proband,ALK in cardiac myocytes,CP:BIOCARTA,C2,29,79
Cohort,-0.04335677801874252,0.026522986505308273,-1.6346868784955704,0.10251008057990962,LonGen OPEL,ALK in cardiac myocytes,CP:BIOCARTA,C2,59,51
Cohort,0.007296173086415503,0.02316727061965424,0.3149345128392338,0.7529085615878007,LGP Offspring,Alternative Complement Pathway,CP:BIOCARTA,C2,15,39
Cohort,-0.05072142625532791,0.060356909797731714,-0.8403582361208639,0.40094840729046355,LGP Proband,Alternative Complement Pathway,CP:BIOCARTA,C2,15,46
Cohort,-0.006430770771903169,0.018941479543302872,-0.33950731025005343,0.7343171460167962,LonGen OPEL,Alternative Complement Pathway,CP:BIOCARTA,C2,23,30
Cohort,-0.002530217356482121,0.015501039403752937,-0.16322888359793045,0.8703870099297841,LGP Offspring,Steps in the Glycosylation of Mammalian N-linked Oligosaccarides,CP:BIOCARTA,C2,9,17
Cohort,-0.0033684382394711947,0.044304234114198586,-0.0760297137918852,0.939413692335666,LGP Proband,Steps in the Glycosylation of Mammalian N-linked Oligosaccarides,CP:BIOCARTA,C2,9,24
Cohort,0.0013622246275960992,0.012308544823602267,0.11067308500871391,0.9119034875338458,LonGen OPEL,Steps in the Glycosylation of Mammalian N-linked Oligosaccarides,CP:BIOCARTA,C2,10,13
Cohort,-0.029589613356605333,0.02531413777263459,-1.168896749412207,0.24285725291548893,LGP Offspring,Acute Myocardial Infarction,CP:BIOCARTA,C2,26,37
Cohort,-0.07704886256630693,0.06510690378567456,-1.1834207754671318,0.2369796378068768,LGP Proband,Acute Myocardial Infarction,CP:BIOCARTA,C2,26,47
Cohort,-0.001986157945334901,0.020903836024921376,-0.09501404158389974,0.9243275865187435,LonGen OPEL,Acute Myocardial Infarction,CP:BIOCARTA,C2,34,37
Cohort,-0.006033466097148005,0.026454402248343514,-0.22807039979615493,0.8196604789685554,LGP Offspring,ADP-Ribosylation Factor,CP:BIOCARTA,C2,24,48
Cohort,-0.013210227029321436,0.06988769362502505,-0.18902078955702126,0.8501225107736118,LGP Proband,ADP-Ribosylation Factor,CP:BIOCARTA,C2,24,61
Cohort,-0.03581322932651573,0.020649984129947247,-1.7342981525384458,0.08325233105930818,LonGen OPEL,ADP-Ribosylation Factor,CP:BIOCARTA,C2,40,30
Cohort,0.027402045392275858,0.022606904475314472,1.2121095757359184,0.22589391149247373,LGP Offspring,Oxidative Stress Induced Gene Expression Via Nrf2,CP:BIOCARTA,C2,13,41
Cohort,0.030554136973593198,0.07053402995974446,0.43318291881282284,0.6649938952413161,LGP Proband,Oxidative Stress Induced Gene Expression Via Nrf2,CP:BIOCARTA,C2,13,63
Cohort,-0.039726770911398736,0.020518366482032865,-1.9361566110141333,0.05320222892776226,LonGen OPEL,Oxidative Stress Induced Gene Expression Via Nrf2,CP:BIOCARTA,C2,34,27
Cohort,-0.00571988605407126,0.014032140951748793,-0.40762746566897934,0.6836762538466041,LGP Offspring,Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,CP:BIOCARTA,C2,6,14
Cohort,0.14234103970071732,0.042706225391829326,3.333027875789519,8.969119517451714e-4,LGP Proband,Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,CP:BIOCARTA,C2,6,23
Cohort,0.01036911232681129,0.015211352810456012,0.6816693068668913,0.49564635898807996,LonGen OPEL,Tumor Suppressor Arf Inhibits Ribosomal Biogenesis,CP:BIOCARTA,C2,16,20
Cohort,0.02002796688227892,0.022391197145912815,0.8944571722434561,0.3713956817758981,LGP Offspring,Antigen Dependent B Cell Activation,CP:BIOCARTA,C2,13,38
Cohort,-0.030851102178940465,0.05860239845407084,-0.5264477733470204,0.598717103628722,LGP Proband,Antigen Dependent B Cell Activation,CP:BIOCARTA,C2,13,43
Cohort,0.010807857669828056,0.02194448145761543,0.4925091390608999,0.6224952767523277,LonGen OPEL,Antigen Dependent B Cell Activation,CP:BIOCARTA,C2,31,37
Cohort,-0.013283918818172563,0.022831741801880395,-0.581818020431473,0.5608832317283485,LGP Offspring,Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,CP:BIOCARTA,C2,18,34
Cohort,0.06893403634630796,0.06917919599047416,0.9964561651713911,0.3193175715663363,LGP Proband,Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,CP:BIOCARTA,C2,18,57
Cohort,-0.012342425738264804,0.021033003711494663,-0.5868123216048117,0.5574961446742757,LonGen OPEL,Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,CP:BIOCARTA,C2,34,35
Cohort,0.028332444744374328,0.029976775283166883,0.9451465168197758,0.3449217711869845,LGP Offspring,ATM Signaling Pathway,CP:BIOCARTA,C2,23,60
Cohort,0.13596776583708495,0.08292345424302486,1.639678026901803,0.10144923818459761,LGP Proband,ATM Signaling Pathway,CP:BIOCARTA,C2,23,83
Cohort,0.033468473230892436,0.025972847737894822,1.2885946727382291,0.19791343199898023,LonGen OPEL,ATM Signaling Pathway,CP:BIOCARTA,C2,47,66
Cohort,0.03190732578177389,0.03339784548152675,0.9553707828076122,0.33973173633520737,LGP Offspring,"Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility",CP:BIOCARTA,C2,31,78
Cohort,0.05751319323968985,0.09198099106103595,0.6252725979167342,0.5319632067725778,LGP Proband,"Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility",CP:BIOCARTA,C2,31,106
Cohort,0.0451581202033259,0.03000290795856775,1.5051247787609991,0.13268868232576483,LonGen OPEL,"Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility",CP:BIOCARTA,C2,58,85
Cohort,-0.01897727324503022,0.0186776868745229,-1.0160398004592297,0.30997393727159533,LGP Offspring,Regulation of BAD phosphorylation,CP:BIOCARTA,C2,15,21
Cohort,0.044764353266030975,0.055455704948592616,0.8072091646391925,0.419776131173649,LGP Proband,Regulation of BAD phosphorylation,CP:BIOCARTA,C2,15,36
Cohort,-0.02949442266016091,0.0212826304396959,-1.385844796945238,0.16618242311413384,LonGen OPEL,Regulation of BAD phosphorylation,CP:BIOCARTA,C2,38,31
Cohort,0.016985166714314784,0.018862314626986725,0.9004815713345029,0.36818470566366746,LGP Offspring,BRCA1-dependent Ub-ligase activity,CP:BIOCARTA,C2,8,26
Cohort,0.0338407931799668,0.04262986950781378,0.7938282141296258,0.4275212453835209,LGP Proband,BRCA1-dependent Ub-ligase activity,CP:BIOCARTA,C2,8,20
Cohort,0.016494922166266256,0.013009983962868439,1.2678664488245426,0.20521637600960863,LonGen OPEL,BRCA1-dependent Ub-ligase activity,CP:BIOCARTA,C2,8,18
Cohort,-0.0019122711781956734,0.01011181348869776,-0.1891125840417319,0.8500613418880104,LGP Offspring,Role of b-arrestins in the activation and targeting of MAP kinases,CP:BIOCARTA,C2,3,7
Cohort,0.018003517707298845,0.03325854414499962,0.5413200778966043,0.5884315484527867,LGP Proband,Role of b-arrestins in the activation and targeting of MAP kinases,CP:BIOCARTA,C2,3,15
Cohort,-0.02353604081671934,0.01106184188120078,-2.12767828988028,0.033670514430843096,LonGen OPEL,Role of b-arrestins in the activation and targeting of MAP kinases,CP:BIOCARTA,C2,13,6
Cohort,-0.0031956338875860336,0.010126112304027844,-0.315583492621834,0.752416070482308,LGP Offspring,b-arrestins in GPCR Desensitization,CP:BIOCARTA,C2,4,6
Cohort,-0.021003398849695435,0.032336069384001784,-0.6495346914392394,0.5161716757353392,LGP Proband,b-arrestins in GPCR Desensitization,CP:BIOCARTA,C2,4,13
Cohort,-0.017373753435972215,0.010895053020963316,-1.5946460657459074,0.11118835157834188,LonGen OPEL,b-arrestins in GPCR Desensitization,CP:BIOCARTA,C2,12,6
Cohort,-0.004363398577060085,0.014592857307266076,-0.29900919917084784,0.7650249248296013,LGP Offspring,Roles of b-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling,CP:BIOCARTA,C2,6,13
Cohort,0.053986731028526594,0.04477011153813701,1.2058654574165735,0.22821135930209088,LGP Proband,Roles of b-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling,CP:BIOCARTA,C2,6,25
Cohort,-0.016060361747616173,0.012159154199061288,-1.3208453059059047,0.186932543695541,LonGen OPEL,Roles of b-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling,CP:BIOCARTA,C2,14,9
Cohort,0.02002796688227892,0.022391197145912815,0.8944571722434561,0.3713956817758981,LGP Offspring,Bystander B Cell Activation,CP:BIOCARTA,C2,13,38
Cohort,-0.030851102178940465,0.05860239845407084,-0.5264477733470204,0.598717103628722,LGP Proband,Bystander B Cell Activation,CP:BIOCARTA,C2,13,43
Cohort,0.010807857669828056,0.02194448145761543,0.4925091390608999,0.6224952767523277,LonGen OPEL,Bystander B Cell Activation,CP:BIOCARTA,C2,31,37
Cohort,-0.005303717887583953,0.017046763915918917,-0.31112754970643663,0.755799574528013,LGP Offspring,B Cell Survival Pathway,CP:BIOCARTA,C2,10,18
Cohort,0.017847422666678953,0.04563601056044186,0.3910820084293133,0.6958365050341,LGP Proband,B Cell Survival Pathway,CP:BIOCARTA,C2,10,24
Cohort,-0.033428695333452906,0.015408467792387902,-2.169501587300417,0.030339867453412207,LonGen OPEL,B Cell Survival Pathway,CP:BIOCARTA,C2,23,14
Cohort,0.003114257731404774,0.026780895541750192,0.11628654189512776,0.9074599877875473,LGP Offspring,BCR Signaling Pathway,CP:BIOCARTA,C2,24,46
Cohort,-0.09304686492951086,0.07371072614053004,-1.2623246276548183,0.20718486454385432,LGP Proband,BCR Signaling Pathway,CP:BIOCARTA,C2,24,64
Cohort,-0.02373052463088471,0.023069714110993855,-1.0286440706075306,0.3039594218661342,LonGen OPEL,BCR Signaling Pathway,CP:BIOCARTA,C2,42,39
Cohort,-0.03297665627931029,0.02361561969666607,-1.3963917399959553,0.16305488906004356,LGP Offspring,Bioactive Peptide Induced Signaling Pathway,CP:BIOCARTA,C2,22,30
Cohort,0.005814179793771672,0.069200664991555,0.08401913181732015,0.9330613832665652,LGP Proband,Bioactive Peptide Induced Signaling Pathway,CP:BIOCARTA,C2,22,48
Cohort,-0.011717694870603427,0.020416028672009427,-0.5739458471014248,0.5661665817792418,LonGen OPEL,Bioactive Peptide Induced Signaling Pathway,CP:BIOCARTA,C2,30,30
Cohort,0.023378956442165325,0.022229765067059867,1.0516960647869524,0.29331481179805363,LGP Offspring,B Lymphocyte Cell Surface Molecules,CP:BIOCARTA,C2,12,38
Cohort,0.008973039701601808,0.05800968185943083,0.15468176025073357,0.8771096349687814,LGP Proband,B Lymphocyte Cell Surface Molecules,CP:BIOCARTA,C2,12,43
Cohort,0.013155776166307415,0.02150818841841659,0.6116636097088798,0.5409349945603275,LonGen OPEL,B Lymphocyte Cell Surface Molecules,CP:BIOCARTA,C2,28,36
Cohort,0.003518011361026198,0.004537395641203145,0.7753371403365995,0.4384116036593839,LGP Offspring,Blockade of Neurotransmitter Relase by Botulinum Toxin,CP:BIOCARTA,C2,0,2
Cohort,0.00898913195650405,0.017709453664282677,0.5075894562819737,0.6118754877742574,LGP Proband,Blockade of Neurotransmitter Relase by Botulinum Toxin,CP:BIOCARTA,C2,0,5
Cohort,5.838341471853993e-4,0.0025829690959292564,0.2260321844754234,0.8212344130474127,LonGen OPEL,Blockade of Neurotransmitter Relase by Botulinum Toxin,CP:BIOCARTA,C2,0,1
Cohort,8.561106245595875e-4,0.013501361232025156,0.06340920814183519,0.9494593995044456,LGP Offspring,BTG family proteins and cell cycle regulation,CP:BIOCARTA,C2,5,13
Cohort,0.07598472108700666,0.04262417415416533,1.7826672913868353,0.07500414597836179,LGP Proband,BTG family proteins and cell cycle regulation,CP:BIOCARTA,C2,5,23
Cohort,0.0029255024850775332,0.013246837401940027,0.22084535321986268,0.8252694822650402,LonGen OPEL,BTG family proteins and cell cycle regulation,CP:BIOCARTA,C2,12,15
Cohort,-0.01282339368490537,0.010586256133830773,-1.211324714119217,0.22619425544530655,LGP Offspring,Ca++/ Calmodulin-dependent Protein Kinase Activation,CP:BIOCARTA,C2,5,6
Cohort,0.031885131445906115,0.03122950061601285,1.0209939581793086,0.3075533692981296,LGP Proband,Ca++/ Calmodulin-dependent Protein Kinase Activation,CP:BIOCARTA,C2,5,11
Cohort,-0.021937554191056783,0.010810486436949446,-2.0292846505108075,0.04276157916852541,LonGen OPEL,Ca++/ Calmodulin-dependent Protein Kinase Activation,CP:BIOCARTA,C2,13,5
Cohort,-0.011212505123326779,0.02427066947520334,-0.4619775789366783,0.6442460358103291,LGP Offspring,Effects of calcineurin in Keratinocyte Differentiation,CP:BIOCARTA,C2,20,35
Cohort,-0.020823919023349787,0.06581891679222081,-0.3163819770703213,0.7517917633071448,LGP Proband,Effects of calcineurin in Keratinocyte Differentiation,CP:BIOCARTA,C2,20,46
Cohort,-0.009797484174437918,0.018415064199085316,-0.5320363843708219,0.5948492537018976,LonGen OPEL,Effects of calcineurin in Keratinocyte Differentiation,CP:BIOCARTA,C2,25,27
Cohort,0.0066708524856725435,0.02314028717690124,0.2882787250942773,0.77322175703303,LGP Offspring,Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,CP:BIOCARTA,C2,17,39
Cohort,0.012623053521288197,0.05413903259223738,0.23315993871486593,0.8156944246393835,LGP Proband,Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,CP:BIOCARTA,C2,17,33
Cohort,0.014323747680992809,0.017570638143541362,0.8152093033830959,0.41519635732724103,LonGen OPEL,Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,CP:BIOCARTA,C2,18,31
Cohort,2.5180399388926515e-4,0.035443099750059943,0.007104457444889235,0.9943336067933877,LGP Offspring,CARM1 and Regulation of the Estrogen Receptor,CP:BIOCARTA,C2,39,82
Cohort,0.07085050409354542,0.09548718365121558,0.7419896721673125,0.4583024956718029,LGP Proband,CARM1 and Regulation of the Estrogen Receptor,CP:BIOCARTA,C2,39,105
Cohort,0.004831751198447924,0.034460369354898386,0.14021182270819488,0.8885281016108668,LonGen OPEL,CARM1 and Regulation of the Estrogen Receptor,CP:BIOCARTA,C2,77,93
Cohort,0.014287268820952685,0.01720007589407479,0.8306514988038204,0.4064638027132971,LGP Offspring,Transcription Regulation by Methyltransferase of CARM1,CP:BIOCARTA,C2,8,20
Cohort,0.016748763086457112,0.0438104856202396,0.38230032946084275,0.702336008618959,LGP Proband,Transcription Regulation by Methyltransferase of CARM1,CP:BIOCARTA,C2,8,24
Cohort,-0.006329612488691226,0.018794196973465252,-0.3367854714743994,0.7363673981401815,LonGen OPEL,Transcription Regulation by Methyltransferase of CARM1,CP:BIOCARTA,C2,26,26
Cohort,-0.0378078959004136,0.023917139715951285,-1.5807866805744342,0.11439457239373697,LGP Offspring,Caspase Cascade in Apoptosis,CP:BIOCARTA,C2,25,29
Cohort,-0.07446832271966959,0.06709903950171829,-1.1098269553882747,0.26739349581118393,LGP Proband,Caspase Cascade in Apoptosis,CP:BIOCARTA,C2,25,46
Cohort,-0.035190080658449564,0.02252926920274314,-1.5619716885519241,0.11869211860444445,LonGen OPEL,Caspase Cascade in Apoptosis,CP:BIOCARTA,C2,42,40
Cohort,-0.04445532480667767,0.02018145716893365,-2.202780722648215,0.027946921793811197,LGP Offspring,"Metabolism of Anandamide, an Endogenous Cannabinoid",CP:BIOCARTA,C2,19,21
Cohort,-0.048366153491534065,0.05936555288446055,-0.8147174774176883,0.41546662393434186,LGP Proband,"Metabolism of Anandamide, an Endogenous Cannabinoid",CP:BIOCARTA,C2,19,33
Cohort,-0.022052126181026376,0.017289800734081675,-1.2754413148068966,0.20252518090370975,LonGen OPEL,"Metabolism of Anandamide, an Endogenous Cannabinoid",CP:BIOCARTA,C2,23,20
Cohort,0.018917658650132636,0.0250655010097562,0.7547289257361881,0.4506744909894306,LGP Offspring,CBL mediated ligand-induced downregulation of EGF receptors,CP:BIOCARTA,C2,17,45
Cohort,0.12228649063594281,0.06226263226388645,1.964043057441877,0.04985687115399656,LGP Proband,CBL mediated ligand-induced downregulation of EGF receptors,CP:BIOCARTA,C2,17,46
Cohort,-0.009794829522842418,0.015418089210558887,-0.635281673953122,0.5254272971908348,LonGen OPEL,CBL mediated ligand-induced downregulation of EGF receptors,CP:BIOCARTA,C2,18,19
Cohort,0.029613157097948224,0.020036938142621426,1.4779282586572853,0.13989273190545176,LGP Offspring,CCR3 signaling in Eosinophils,CP:BIOCARTA,C2,9,32
Cohort,0.0212910081191752,0.057821344317568475,0.368220565786917,0.7128022155294126,LGP Proband,CCR3 signaling in Eosinophils,CP:BIOCARTA,C2,9,45
Cohort,-0.017732683418727826,0.018379837444888802,-0.9647900027352558,0.33494301498995105,LonGen OPEL,CCR3 signaling in Eosinophils,CP:BIOCARTA,C2,29,25
Cohort,-0.023319774225718078,0.017271453698528696,-1.3501917460314659,0.17740635763414092,LGP Offspring,Pertussis toxin-insensitive CCR5 Signaling in Macrophage,CP:BIOCARTA,C2,14,15
Cohort,-0.015965549595016563,0.04639421709317572,-0.3441280098110544,0.7308367659035684,LGP Proband,Pertussis toxin-insensitive CCR5 Signaling in Macrophage,CP:BIOCARTA,C2,14,21
Cohort,0.015171368267055008,0.013989440654974228,1.0844871243412095,0.2784772251757004,LonGen OPEL,Pertussis toxin-insensitive CCR5 Signaling in Macrophage,CP:BIOCARTA,C2,11,19
Cohort,0.0011861372321115545,0.026239034042081593,0.04520506472186641,0.9639572073599323,LGP Offspring,CD40L Signaling Pathway,CP:BIOCARTA,C2,20,47
Cohort,0.03233368064780989,0.0720967750051854,0.44847610237052027,0.653926120129356,LGP Proband,CD40L Signaling Pathway,CP:BIOCARTA,C2,20,64
Cohort,6.732116515324501e-4,0.02442903685790613,0.027557846649798403,0.9780217096918356,LonGen OPEL,CD40L Signaling Pathway,CP:BIOCARTA,C2,38,45
Cohort,-9.30252604332714e-4,0.01732511572641473,-0.05369387535544163,0.957194926122698,LGP Offspring,cdc25 and chk1 Regulatory Pathway in response to DNA damage,CP:BIOCARTA,C2,10,20
Cohort,-0.04529201037338023,0.049971294920291724,-0.906360550504538,0.36500682595202494,LGP Proband,cdc25 and chk1 Regulatory Pathway in response to DNA damage,CP:BIOCARTA,C2,10,32
Cohort,0.018515792012145132,0.016788688965550837,1.1028730146909138,0.270415633645304,LonGen OPEL,cdc25 and chk1 Regulatory Pathway in response to DNA damage,CP:BIOCARTA,C2,17,25
Cohort,0.004308438081569122,0.004533501836964758,0.9503554286532904,0.3422713252144284,LGP Offspring,Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,CP:BIOCARTA,C2,0,2
Cohort,-0.008861785261060144,0.00786092205435603,-1.1273213498090213,0.25993086643072333,LGP Proband,Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,CP:BIOCARTA,C2,0,1
Cohort,-0.0019072632858719823,0.00563081042222115,-0.33871914393445984,0.7349106457207326,LonGen OPEL,Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration,CP:BIOCARTA,C2,3,2
Cohort,0.01776806151384843,0.013432254529384199,1.3227907105973375,0.18635228452681257,LGP Offspring,Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway,CP:BIOCARTA,C2,3,15
Cohort,0.03486825395584596,0.03734814503858201,0.933600689400391,0.35078011798834996,LGP Proband,Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway,CP:BIOCARTA,C2,3,20
Cohort,-0.01037758170750778,0.010825475574893753,-0.95862594079241,0.33803829120645523,LonGen OPEL,Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway,CP:BIOCARTA,C2,10,8
Cohort,-4.701255339700222e-5,0.017531442129455933,-0.002681613586027403,0.9978611756211495,LGP Offspring,Cadmium induces DNA synthesis and proliferation in macrophages,CP:BIOCARTA,C2,9,20
Cohort,0.021175481293176937,0.04500278339576443,0.47053714671279484,0.638094331368886,LGP Proband,Cadmium induces DNA synthesis and proliferation in macrophages,CP:BIOCARTA,C2,9,25
Cohort,0.009118334031374822,0.01702358143013862,0.5356295952643482,0.5923641905053817,LonGen OPEL,Cadmium induces DNA synthesis and proliferation in macrophages,CP:BIOCARTA,C2,18,26
Cohort,-0.0017426803985043007,0.024697488068110725,-0.07056103817920013,0.9437679887177228,LGP Offspring,Cell to Cell Adhesion Signaling,CP:BIOCARTA,C2,19,41
Cohort,-0.0716475849292315,0.06691966191306585,-1.0706507307569426,0.2846362463890357,LGP Proband,Cell to Cell Adhesion Signaling,CP:BIOCARTA,C2,19,55
Cohort,0.018417832686012044,0.023522947572921123,0.7829729938782873,0.43387584798160395,LonGen OPEL,Cell to Cell Adhesion Signaling,CP:BIOCARTA,C2,36,49
Cohort,-0.018250820314778374,0.020299323665265875,-0.8990851427236125,0.36892744917395925,LGP Offspring,Cyclins and Cell Cycle Regulation,CP:BIOCARTA,C2,15,25
Cohort,-0.016721570484286165,0.04624650814915472,-0.3615747686367062,0.7177614048240838,LGP Proband,Cyclins and Cell Cycle Regulation,CP:BIOCARTA,C2,15,21
Cohort,0.003702202265818969,0.017157640758900753,0.21577571869246667,0.8292178541709428,LonGen OPEL,Cyclins and Cell Cycle Regulation,CP:BIOCARTA,C2,19,25
Cohort,0.028429760481048817,0.024202672563457657,1.1746537662941166,0.24054687320290394,LGP Offspring,Ceramide Signaling Pathway,CP:BIOCARTA,C2,15,44
Cohort,-0.013979057112924053,0.06220501671663393,-0.22472555833565083,0.8222478268780786,LGP Proband,Ceramide Signaling Pathway,CP:BIOCARTA,C2,15,49
Cohort,-0.011022083362872297,0.02225906334919074,-0.4951728287018429,0.6206147862487625,LonGen OPEL,Ceramide Signaling Pathway,CP:BIOCARTA,C2,34,38
Cohort,-0.014105756428664311,0.026644490513910615,-0.5294061232396223,0.596697556224707,LGP Offspring,Cystic fibrosis transmembrane conductance regulator (CFTR) and beta 2 adrenergic receptor (b2AR) pathway,CP:BIOCARTA,C2,24,43
Cohort,0.07780914367961628,0.08160786495229366,0.9534515297649554,0.3406375961356559,LGP Proband,Cystic fibrosis transmembrane conductance regulator (CFTR) and beta 2 adrenergic receptor (b2AR) pathway,CP:BIOCARTA,C2,24,85
Cohort,-0.029386227190120923,0.025123218857598172,-1.1696840025430684,0.24247827098548153,LonGen OPEL,Cystic fibrosis transmembrane conductance regulator (CFTR) and beta 2 adrenergic receptor (b2AR) pathway,CP:BIOCARTA,C2,56,49
Cohort,-0.031001512224474243,0.022327101473469245,-1.3885148621424321,0.16543766311752944,LGP Offspring,Apoptotic Signaling in Response to DNA Damage,CP:BIOCARTA,C2,22,29
Cohort,0.032243316590674566,0.06491326162507924,0.4967138575920419,0.6195217474143981,LGP Proband,Apoptotic Signaling in Response to DNA Damage,CP:BIOCARTA,C2,22,47
Cohort,-0.04364811517750474,0.0220389503512379,-1.9804988205825818,0.04799139326781209,LonGen OPEL,Apoptotic Signaling in Response to DNA Damage,CP:BIOCARTA,C2,46,32
Cohort,-0.013518169487122733,0.015777788167295418,-0.8567848258441904,0.3918674315553031,LGP Offspring,ChREBP regulation by carbohydrates and cAMP,CP:BIOCARTA,C2,10,13
Cohort,0.03651722948993468,0.05816505236476901,0.6278207962562316,0.5302932031357853,LGP Proband,ChREBP regulation by carbohydrates and cAMP,CP:BIOCARTA,C2,10,46
Cohort,0.004271136099161293,0.018939686501431716,0.2255125024819404,0.8216384853638724,LonGen OPEL,ChREBP regulation by carbohydrates and cAMP,CP:BIOCARTA,C2,25,32
Cohort,0.005305393006851113,0.007050655650924946,0.7524680355301596,0.45203157917435,LGP Offspring,Circadian Rhythms,CP:BIOCARTA,C2,1,4
Cohort,-0.0037818733107078764,0.02493713974110454,-0.15165625849520006,0.8794947352950474,LGP Proband,Circadian Rhythms,CP:BIOCARTA,C2,1,9
Cohort,-0.010655346860586092,0.006296562188812094,-1.6922483318784347,0.09098998350484581,LonGen OPEL,Circadian Rhythms,CP:BIOCARTA,C2,4,2
Cohort,-0.004102039176032534,0.01148665088099419,-0.357113593729898,0.7211182197783517,LGP Offspring,Regulation of ck1/cdk5 by type 1 glutamate receptors,CP:BIOCARTA,C2,5,8
Cohort,0.06276055413638983,0.04981821039707569,1.2597914223766224,0.2080970293562784,LGP Proband,Regulation of ck1/cdk5 by type 1 glutamate receptors,CP:BIOCARTA,C2,5,28
Cohort,-0.009055628698827057,0.014395657227164899,-0.6290528147432477,0.5294949587456568,LonGen OPEL,Regulation of ck1/cdk5 by type 1 glutamate receptors,CP:BIOCARTA,C2,16,16
Cohort,0.01918300664536696,0.026651980838945207,0.7197591339003138,0.47192207527940877,LGP Offspring,Classical Complement Pathway,CP:BIOCARTA,C2,20,52
Cohort,-0.021722992716770664,0.07002110520741997,-0.31023493063158236,0.7564598165802818,LGP Proband,Classical Complement Pathway,CP:BIOCARTA,C2,20,63
Cohort,-0.018946945485288837,0.02285257849754589,-0.8290944274548068,0.4072995210184045,LonGen OPEL,Classical Complement Pathway,CP:BIOCARTA,C2,36,42
Cohort,0.02628859123070615,0.029815579584630474,0.8817065305098936,0.37824891934011273,LGP Offspring,Complement Pathway,CP:BIOCARTA,C2,24,65
Cohort,-0.06827105254431287,0.07697548303223563,-0.8869194431131074,0.3753779542462503,LGP Proband,Complement Pathway,CP:BIOCARTA,C2,24,78
Cohort,0.0035520444107112734,0.024734654876133175,0.14360598231506727,0.8858479624798701,LonGen OPEL,Complement Pathway,CP:BIOCARTA,C2,38,54
Cohort,-0.05530119847268665,0.02088478082516214,-2.647918545836945,0.008287787789752905,LGP Offspring,Polyadenylation of mRNA,CP:BIOCARTA,C2,20,21
Cohort,0.04917833114584703,0.05652990394151423,0.8699524980040099,0.3845766739813935,LGP Proband,Polyadenylation of mRNA,CP:BIOCARTA,C2,20,30
Cohort,-0.013290495923570615,0.01598653095254411,-0.8313558434299065,0.4060219442513555,LonGen OPEL,Polyadenylation of mRNA,CP:BIOCARTA,C2,18,20
Cohort,-0.00992197056757041,0.015550865147399714,-0.6380333488538725,0.5236680373286224,LGP Offspring,Transcription factor CREB and its extracellular signals,CP:BIOCARTA,C2,9,13
Cohort,0.07228003523586704,0.051355025573765284,1.4074578763872976,0.15966424257984027,LGP Proband,Transcription factor CREB and its extracellular signals,CP:BIOCARTA,C2,9,33
Cohort,-0.029942524181811103,0.017487256622797532,-1.7122482289632595,0.08724040850449066,LonGen OPEL,Transcription factor CREB and its extracellular signals,CP:BIOCARTA,C2,26,18
Cohort,0.0024307602203297108,0.009003761569798093,0.2699716336873434,0.787264470091991,LGP Offspring,Regulation of Spermatogenesis by CREM,CP:BIOCARTA,C2,2,4
Cohort,0.018353218793144544,0.020805582201272686,0.8821295465609162,0.3779609251394409,LGP Proband,Regulation of Spermatogenesis by CREM,CP:BIOCARTA,C2,2,5
Cohort,0.0022051467924609517,0.006355673575110885,0.34695721333084345,0.728715168128701,LonGen OPEL,Regulation of Spermatogenesis by CREM,CP:BIOCARTA,C2,2,4
Cohort,0.026648045072836815,0.025685934326123032,1.0374567159791925,0.29989400619080153,LGP Offspring,Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,CP:BIOCARTA,C2,15,47
Cohort,0.07034915824373916,0.06556334807896623,1.0729952070020703,0.2835836333311344,LGP Proband,Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,CP:BIOCARTA,C2,15,56
Cohort,0.005475885204663366,0.02579511641187063,0.2122837950110364,0.8319399834340877,LonGen OPEL,Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor,CP:BIOCARTA,C2,45,54
Cohort,0.00980488060112374,0.018580975392009924,0.5276838483592188,0.5978919361098471,LGP Offspring,SUMOylation as a mechanism to modulate CtBP-dependent gene responses,CP:BIOCARTA,C2,9,24
Cohort,0.08117385220502868,0.04773721345996378,1.700431305507757,0.0894226419901521,LGP Proband,SUMOylation as a mechanism to modulate CtBP-dependent gene responses,CP:BIOCARTA,C2,9,28
Cohort,-0.017702289464271364,0.01381976638308788,-1.2809398490219612,0.20058786524412478,LonGen OPEL,SUMOylation as a mechanism to modulate CtBP-dependent gene responses,CP:BIOCARTA,C2,17,13
Cohort,-0.015622558374530996,0.01734801923443137,-0.9005384513019344,0.3681544716835238,LGP Offspring,CTCF: First Multivalent Nuclear Factor,CP:BIOCARTA,C2,11,18
Cohort,0.11686504552346683,0.051478095446708824,2.270189767304968,0.023450449849465375,LGP Proband,CTCF: First Multivalent Nuclear Factor,CP:BIOCARTA,C2,11,32
Cohort,-0.016241718969885303,0.01504269748694572,-1.0797078771264337,0.28059932379627534,LonGen OPEL,CTCF: First Multivalent Nuclear Factor,CP:BIOCARTA,C2,21,15
Cohort,-0.0017328450510869916,0.009016721258193298,-0.1921812820278095,0.8476579229318588,LGP Offspring,CTL mediated immune response against target cells,CP:BIOCARTA,C2,3,5
Cohort,-0.041523115152158514,0.024619939806515976,-1.686564446480446,0.0920611180889269,LGP Proband,CTL mediated immune response against target cells,CP:BIOCARTA,C2,3,7
Cohort,0.010669269765984105,0.009247464497525153,1.1537508220593289,0.24894863760924602,LonGen OPEL,CTL mediated immune response against target cells,CP:BIOCARTA,C2,5,8
Cohort,-0.007540309530699701,0.022939163761256286,-0.3287089978160018,0.7424774541118848,LGP Offspring,The Co-Stimulatory Signal During T-cell Activation,CP:BIOCARTA,C2,17,36
Cohort,0.0014235015438622115,0.06330455076312623,0.022486559444812863,0.9820652120522777,LGP Proband,The Co-Stimulatory Signal During T-cell Activation,CP:BIOCARTA,C2,17,51
Cohort,0.020290406499966954,0.022331095806824512,0.9086166964438032,0.36382750047251045,LonGen OPEL,The Co-Stimulatory Signal During T-cell Activation,CP:BIOCARTA,C2,29,39
Cohort,-0.005612760684478611,0.031038250197279585,-0.18083366970766132,0.8565523347464364,LGP Offspring,CXCR4 Signaling Pathway,CP:BIOCARTA,C2,31,60
Cohort,-0.13247792835261735,0.07620589118193655,-1.7384210892086416,0.08250569235704541,LGP Proband,CXCR4 Signaling Pathway,CP:BIOCARTA,C2,31,59
Cohort,0.011684504661335368,0.026324108755122682,0.4438708550412579,0.6572565891105366,LonGen OPEL,CXCR4 Signaling Pathway,CP:BIOCARTA,C2,47,60
Cohort,-0.015902083798618096,0.010598126179676514,-1.5004618296687873,0.13396170622487266,LGP Offspring,Cytokine Network,CP:BIOCARTA,C2,6,5
Cohort,-0.001373539660615297,0.03414772921587176,-0.04022345532647834,0.9679246048453567,LGP Proband,Cytokine Network,CP:BIOCARTA,C2,6,13
Cohort,0.025438447496012973,0.012213207011026779,2.0828638598400646,0.03758231354295454,LonGen OPEL,Cytokine Network,CP:BIOCARTA,C2,5,18
Cohort,-0.02365456517152941,0.015896100884447404,-1.4880734177192356,0.13719784633786164,LGP Offspring,D4-GDI Signaling Pathway,CP:BIOCARTA,C2,12,12
Cohort,-0.05933920225143523,0.04855897337859967,-1.2220028168385144,0.2220518288335164,LGP Proband,D4-GDI Signaling Pathway,CP:BIOCARTA,C2,12,27
Cohort,-0.02584425350436164,0.017414276181275338,-1.4840842786305766,0.13818241675902496,LonGen OPEL,D4-GDI Signaling Pathway,CP:BIOCARTA,C2,27,21
Cohort,-0.016355762068091348,0.014058390597044092,-1.1634163921672727,0.24507108983992823,LGP Offspring,Dendritic cells in regulating TH1 and TH2 Development,CP:BIOCARTA,C2,9,11
Cohort,0.03942824239231805,0.044925338328160494,0.877639297990624,0.3803922445807324,LGP Proband,Dendritic cells in regulating TH1 and TH2 Development,CP:BIOCARTA,C2,9,23
Cohort,0.0034053552623503538,0.013977378150253144,0.24363333564733522,0.8075775828100387,LonGen OPEL,Dendritic cells in regulating TH1 and TH2 Development,CP:BIOCARTA,C2,11,17
Cohort,-0.03017302094634462,0.031131732973572152,-0.9692046688168183,0.3327897156564431,LGP Offspring,Induction of apoptosis through DR3 and DR4/5 Death Receptors,CP:BIOCARTA,C2,36,62
Cohort,7.328662026505181e-4,0.07679682709044294,0.0095429229359622891,0.9923882468702874,LGP Proband,Induction of apoptosis through DR3 and DR4/5 Death Receptors,CP:BIOCARTA,C2,36,61
Cohort,-0.004331711562300485,0.027884249422521778,-0.1553461775737027,0.8765877964776769,LonGen OPEL,Induction of apoptosis through DR3 and DR4/5 Death Receptors,CP:BIOCARTA,C2,52,64
Cohort,0.01179120633281871,0.00642462504776389,1.8353143172024764,0.06689829149697145,LGP Offspring,Dicer Pathway,CP:BIOCARTA,C2,0,4
Cohort,0.009636291080570432,0.020344800800672004,0.47364882925037727,0.6358743083682201,LGP Proband,Dicer Pathway,CP:BIOCARTA,C2,0,7
Cohort,-0.0036702870397792658,0.005795606463386704,-0.6332878298355867,0.5267276018208447,LonGen OPEL,Dicer Pathway,CP:BIOCARTA,C2,3,2
Cohort,-0.02598828868417199,0.02219963832494208,-1.170662706471809,0.2421468906392358,LGP Offspring,Apoptotic DNA fragmentation and tissue homeostasis,CP:BIOCARTA,C2,20,29
Cohort,0.02187932060840131,0.06094083208287728,0.359025629624588,0.7196667885596703,LGP Proband,Apoptotic DNA fragmentation and tissue homeostasis,CP:BIOCARTA,C2,20,44
Cohort,0.0010886169833776486,0.02007135029224091,0.05423735660666941,0.9567596674477286,LonGen OPEL,Apoptotic DNA fragmentation and tissue homeostasis,CP:BIOCARTA,C2,28,36
Cohort,-0.005209979886020564,0.011503840086645175,-0.4528904997618002,0.650772909926081,LGP Offspring,Repression of Pain Sensation by the Transcriptional Regulator DREAM,CP:BIOCARTA,C2,5,8
Cohort,0.04566430731095704,0.039812370847453274,1.146987891927519,0.25171556670453304,LGP Proband,Repression of Pain Sensation by the Transcriptional Regulator DREAM,CP:BIOCARTA,C2,5,21
Cohort,-0.020211199468743675,0.014131254193959466,-1.4302481005106495,0.1530382240033629,LonGen OPEL,Repression of Pain Sensation by the Transcriptional Regulator DREAM,CP:BIOCARTA,C2,18,13
Cohort,-0.008064026818147012,0.01109853667571619,-0.7265846889339255,0.4677319225471068,LGP Offspring,Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases,CP:BIOCARTA,C2,4,6
Cohort,-0.009340614641754785,0.02829809557430629,-0.3300792668972306,0.7414229612665537,LGP Proband,Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases,CP:BIOCARTA,C2,4,9
Cohort,-0.013771487432516829,0.008018846130841356,-1.7173901591090752,0.08629686401820677,LonGen OPEL,Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases,CP:BIOCARTA,C2,7,3
Cohort,-0.019725241465851178,0.020955084590319674,-0.9413105149173853,0.34688200596336016,LGP Offspring,Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,CP:BIOCARTA,C2,18,29
Cohort,-0.139932655783789,0.06072609029756168,-2.3043251277681494,0.021449310909643138,LGP Proband,Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,CP:BIOCARTA,C2,18,44
Cohort,-0.04454466165313298,0.02102315630120737,-2.118837962051148,0.03441330045430841,LonGen OPEL,Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia,CP:BIOCARTA,C2,38,29
Cohort,-0.006361873997043737,0.020453793077964494,-0.31103639177310255,0.7558688421964906,LGP Offspring,Phospholipids as signalling intermediaries,CP:BIOCARTA,C2,14,27
Cohort,-0.03825740134226036,0.06096830287613526,-0.6274965767045388,0.5305055375518444,LGP Proband,Phospholipids as signalling intermediaries,CP:BIOCARTA,C2,14,43
Cohort,-0.028711491288293877,0.01988612879006664,-1.4437948980113018,0.1491901258091983,LonGen OPEL,Phospholipids as signalling intermediaries,CP:BIOCARTA,C2,32,30
Cohort,0.011289286467302772,0.012652554934408715,0.8922535034091396,0.3725745630858366,LGP Offspring,The role of FYVE-finger proteins in vesicle transport,CP:BIOCARTA,C2,4,12
Cohort,-0.038321643325658766,0.033177571660244154,-1.1550466597764484,0.24840214300361071,LGP Proband,The role of FYVE-finger proteins in vesicle transport,CP:BIOCARTA,C2,4,14
Cohort,-0.0029091523465183144,0.010589765193711274,-0.2747135836633954,0.7836075770618114,LonGen OPEL,The role of FYVE-finger proteins in vesicle transport,CP:BIOCARTA,C2,7,10
Cohort,-0.019393851159046144,0.018005283229590344,-1.077120027035942,0.28181087557268014,LGP Offspring,Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,CP:BIOCARTA,C2,13,20
Cohort,0.05684641985715775,0.05227091431831984,1.0875344462309184,0.2771148749504211,LGP Proband,Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,CP:BIOCARTA,C2,13,30
Cohort,0.002050068833302345,0.01704463918966169,0.12027645821601202,0.9042945034744727,LonGen OPEL,Estrogen-responsive protein Efp controls cell cycle and breast tumors growth,CP:BIOCARTA,C2,15,22
Cohort,0.0018174851299602832,0.024556408618103244,0.07401266032934531,0.9410222062389504,LGP Offspring,EGF Signaling Pathway,CP:BIOCARTA,C2,20,41
Cohort,0.008609048641260643,0.06564982774293632,0.131135890789705,0.8956994352744331,LGP Proband,EGF Signaling Pathway,CP:BIOCARTA,C2,20,50
Cohort,-0.021843166618162612,0.019075895035462698,-1.1450664085514974,0.2525258140386466,LonGen OPEL,EGF Signaling Pathway,CP:BIOCARTA,C2,28,28
Cohort,-0.00584920040761648,0.02260620295614739,-0.25874316084673943,0.795912178881109,LGP Offspring,Map Kinase Inactivation of SMRT Corepressor,CP:BIOCARTA,C2,18,36
Cohort,-0.02035011506498807,0.06050635420456908,-0.33633021411578207,0.7367064712433156,LGP Proband,Map Kinase Inactivation of SMRT Corepressor,CP:BIOCARTA,C2,18,45
Cohort,-0.006724236571455981,0.019398382899539737,-0.34663902688587134,0.7289541354050642,LonGen OPEL,Map Kinase Inactivation of SMRT Corepressor,CP:BIOCARTA,C2,27,31
Cohort,-0.018991879369910813,0.018752113794658194,-1.0127860559016508,0.31152471911735924,LGP Offspring,Eicosanoid Metabolism,CP:BIOCARTA,C2,13,19
Cohort,-0.02030801868608872,0.06060620948628299,-0.3350814851848644,0.7376478799004488,LGP Proband,Eicosanoid Metabolism,CP:BIOCARTA,C2,13,44
Cohort,-0.011944893724539907,0.018054655870436177,-0.661596311237326,0.5084214350607132,LonGen OPEL,Eicosanoid Metabolism,CP:BIOCARTA,C2,23,24
Cohort,3.326200066290638e-4,0.014826925842867076,0.022433511177846775,0.9821087690394661,LGP Offspring,Eukaryotic protein translation,CP:BIOCARTA,C2,7,15
Cohort,0.023205134894841658,0.046979775546159126,0.493938819951191,0.6214794464784414,LGP Proband,Eukaryotic protein translation,CP:BIOCARTA,C2,7,30
Cohort,-0.0027675709241512317,0.01372115788160581,-0.20170097509491947,0.8402020336743747,LonGen OPEL,Eukaryotic protein translation,CP:BIOCARTA,C2,13,16
Cohort,-0.007010109408530626,0.010594307137471908,-0.6616864432536577,0.5083976718455367,LGP Offspring,Regulation of eIF2,CP:BIOCARTA,C2,4,7
Cohort,0.005452858678026632,0.02949958494336872,0.1848452677722299,0.8533953404414768,LGP Proband,Regulation of eIF2,CP:BIOCARTA,C2,4,10
Cohort,-0.010457577984269413,0.006840014623155436,-1.5288824016351477,0.1266908667654707,LonGen OPEL,Regulation of eIF2,CP:BIOCARTA,C2,5,2
Cohort,-0.0047702637410414455,0.019673296863334997,-0.24247403849894406,0.8084864170001259,LGP Offspring,Regulation of eIF4e and p70 S6 Kinase,CP:BIOCARTA,C2,11,25
Cohort,0.020326683049368466,0.05899321482464557,0.3445596770711434,0.7305122901767013,LGP Proband,Regulation of eIF4e and p70 S6 Kinase,CP:BIOCARTA,C2,11,46
Cohort,-0.01987238311440859,0.018747140253417727,-1.0600221071470206,0.2894560754110023,LonGen OPEL,Regulation of eIF4e and p70 S6 Kinase,CP:BIOCARTA,C2,24,25
Cohort,0.0213305863946354,0.021666676373661802,0.9844881617637047,0.3252277706355319,LGP Offspring,The Role of Eosinophils in the Chemokine Network of Allergy,CP:BIOCARTA,C2,10,37
Cohort,0.004814961815423127,0.051349010910041196,0.09376931960497745,0.9253149254146047,LGP Proband,The Role of Eosinophils in the Chemokine Network of Allergy,CP:BIOCARTA,C2,10,32
Cohort,0.012779006135403408,0.021359134986425516,0.5982923064779972,0.5498151029921324,LonGen OPEL,The Role of Eosinophils in the Chemokine Network of Allergy,CP:BIOCARTA,C2,26,34
Cohort,0.009853275284873831,0.01121901628316134,0.878265530255326,0.38011168513794025,LGP Offspring,Eph Kinases and ephrins support platelet aggregation,CP:BIOCARTA,C2,3,10
Cohort,0.0043735665392881165,0.02839572661367424,0.15402199770376654,0.8776296524861594,LGP Proband,Eph Kinases and ephrins support platelet aggregation,CP:BIOCARTA,C2,3,10
Cohort,-0.004467815499064048,0.006848809075135717,-0.6523492551842691,0.5143642244635295,LonGen OPEL,Eph Kinases and ephrins support platelet aggregation,CP:BIOCARTA,C2,4,3
Cohort,-1.5833104568869588e-4,0.020684513944055186,-0.007654569312913484,0.9938948552916917,LGP Offspring,EPO Signaling Pathway,CP:BIOCARTA,C2,14,28
Cohort,0.021432233476161123,0.057185617118211116,0.374783635400096,0.7079166657170103,LGP Proband,EPO Signaling Pathway,CP:BIOCARTA,C2,14,37
Cohort,-0.02379731716268138,0.01869474301747214,-1.2729416574723902,0.2034103951204219,LonGen OPEL,EPO Signaling Pathway,CP:BIOCARTA,C2,26,23
Cohort,0.027901309195236625,0.02215509617420647,1.2593630366506845,0.20833389038396344,LGP Offspring,Erythropoietin mediated neuroprotection through NF-kB,CP:BIOCARTA,C2,11,38
Cohort,-0.0298815590518643,0.0510936186762871,-0.5848393561862263,0.5588139198421455,LGP Proband,Erythropoietin mediated neuroprotection through NF-kB,CP:BIOCARTA,C2,11,33
Cohort,0.023454788378641504,0.01985919920995858,1.1810540863540904,0.23793399767287776,LonGen OPEL,Erythropoietin mediated neuroprotection through NF-kB,CP:BIOCARTA,C2,22,37
Cohort,0.005990252593977842,0.025740809106405704,0.2327142309014344,0.8160537576373825,LGP Offspring,ERbassociated degradation (ERAD) Pathway,CP:BIOCARTA,C2,21,47
Cohort,0.02211852802595099,0.06955969397373747,0.3179790876351745,0.7505804006733079,LGP Proband,ERbassociated degradation (ERAD) Pathway,CP:BIOCARTA,C2,21,60
Cohort,0.004827885792170791,0.020081419600535968,0.2404155626548402,0.8100700175542414,LonGen OPEL,ERbassociated degradation (ERAD) Pathway,CP:BIOCARTA,C2,26,32
Cohort,0.01842660624292827,0.013888724606624924,1.3267313424976959,0.18504555795085514,LGP Offspring,Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling,CP:BIOCARTA,C2,3,16
Cohort,0.006775852293941881,0.029392116501754516,0.23053298300370464,0.8177341731413161,LGP Proband,Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling,CP:BIOCARTA,C2,3,11
Cohort,-0.0068546137385655246,0.005800123543238294,-1.1818047818234048,0.23763610237350416,LonGen OPEL,Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling,CP:BIOCARTA,C2,3,2
Cohort,-0.02073082277622608,0.010419556712641371,-1.9896069811755732,0.047036738018861476,LGP Offspring,g-Secretase mediated ErbB4 Signaling Pathway,CP:BIOCARTA,C2,6,5
Cohort,0.011027883189516632,0.033108788043148686,0.33308024368468747,0.7391574249151823,LGP Proband,g-Secretase mediated ErbB4 Signaling Pathway,CP:BIOCARTA,C2,6,12
Cohort,0.023948143478485177,0.01198091782400258,1.9988571685641183,0.045963420934857994,LonGen OPEL,g-Secretase mediated ErbB4 Signaling Pathway,CP:BIOCARTA,C2,6,14
Cohort,-0.00890352504671573,0.02227979140781135,-0.3996233574967013,0.689560179190701,LGP Offspring,Erk1/Erk2 Mapk Signaling pathway,CP:BIOCARTA,C2,16,31
Cohort,0.06326654092118392,0.06359998246155311,0.9947572070389993,0.32014288514641837,LGP Proband,Erk1/Erk2 Mapk Signaling pathway,CP:BIOCARTA,C2,16,53
Cohort,-0.016101136362046454,0.020161627716478284,-0.7986029991460881,0.4247588503874121,LonGen OPEL,Erk1/Erk2 Mapk Signaling pathway,CP:BIOCARTA,C2,27,29
Cohort,-0.028770733392355346,0.01848914598541322,-1.556087740074834,0.12015524928759043,LGP Offspring,Role of Erk5 in Neuronal Survival,CP:BIOCARTA,C2,15,18
Cohort,0.03596672875285468,0.04789566356659354,0.7509391471912061,0.45290110305241926,LGP Proband,Role of Erk5 in Neuronal Survival,CP:BIOCARTA,C2,15,22
Cohort,-0.024840177971396194,0.015661179253308934,-1.586098822420917,0.11311404189091072,LonGen OPEL,Role of Erk5 in Neuronal Survival,CP:BIOCARTA,C2,21,15
Cohort,-0.0032287355925962775,0.019828232862939447,-0.1628352670111638,0.8706968037554361,LGP Offspring,Erythrocyte Differentiation Pathway,CP:BIOCARTA,C2,14,26
Cohort,-0.08749000587421595,0.05412171601222885,-1.6165416088146114,0.10635542940207605,LGP Proband,Erythrocyte Differentiation Pathway,CP:BIOCARTA,C2,14,33
Cohort,-0.0010293491816842425,0.015252857335932521,-0.06748566245744084,0.946212022768786,LonGen OPEL,Erythrocyte Differentiation Pathway,CP:BIOCARTA,C2,16,20
Cohort,0.006872490225677842,0.01105850301732107,0.6214665958777038,0.5345021763917286,LGP Offspring,Electron Transport Reaction in Mitochondria,CP:BIOCARTA,C2,2,10
Cohort,-0.0036605380146216356,0.03127303408976647,-0.11705093928892175,0.9068478682591438,LGP Proband,Electron Transport Reaction in Mitochondria,CP:BIOCARTA,C2,2,14
Cohort,5.064975745062717e-4,0.012749186567133437,0.03972783454373388,0.9683200721837918,LonGen OPEL,Electron Transport Reaction in Mitochondria,CP:BIOCARTA,C2,11,14
Cohort,-0.032056714629682445,0.023585755174074675,-1.3591557443502593,0.17455049135519984,LGP Offspring,METS affect on Macrophage Differentiation,CP:BIOCARTA,C2,23,37
Cohort,0.024588604446046308,0.06862731597790109,0.3582917981808318,0.7202156236631434,LGP Proband,METS affect on Macrophage Differentiation,CP:BIOCARTA,C2,23,58
Cohort,0.0033514583997587585,0.0249753169907679,0.1341908253255653,0.8932856010513656,LonGen OPEL,METS affect on Macrophage Differentiation,CP:BIOCARTA,C2,38,47
Cohort,0.0023664273936985524,0.020720251335291765,0.11420843094060039,0.9091064801483152,LGP Offspring,Extrinsic Prothrombin Activation Pathway,CP:BIOCARTA,C2,15,29
Cohort,-0.07333031271218558,0.05396814322692719,-1.358770347236955,0.17458673367532118,LGP Proband,Extrinsic Prothrombin Activation Pathway,CP:BIOCARTA,C2,15,33
Cohort,-0.0023626442972964814,0.016617274424505512,-0.14218001321638446,0.8869737966516165,LonGen OPEL,Extrinsic Prothrombin Activation Pathway,CP:BIOCARTA,C2,21,22
Cohort,-0.07840134433689872,0.03811201402422026,-2.0571293946070264,0.0400568887220309,LGP Offspring,FAS signaling pathway ( CD95 ),CP:BIOCARTA,C2,56,82
Cohort,-0.09476525589437075,0.10566270016880494,-0.8968657411080294,0.37004937224461665,LGP Proband,FAS signaling pathway ( CD95 ),CP:BIOCARTA,C2,56,113
Cohort,-0.06678913337081828,0.033692358350714983,-1.9823228957613457,0.04778658097998748,LonGen OPEL,FAS signaling pathway ( CD95 ),CP:BIOCARTA,C2,99,90
Cohort,-0.02861834018280581,0.014500130267257905,-1.9736609020284186,0.04882712321595455,LGP Offspring,Cyclin E Destruction Pathway,CP:BIOCARTA,C2,10,11
Cohort,0.009814842686335175,0.03647671663871062,0.26907144038066333,0.7879412574815474,LGP Proband,Cyclin E Destruction Pathway,CP:BIOCARTA,C2,10,12
Cohort,0.00851972475996072,0.013956983545140893,0.6104273700979501,0.5417529803904869,LonGen OPEL,Cyclin E Destruction Pathway,CP:BIOCARTA,C2,11,17
Cohort,-8.964900333532182e-4,0.027646564059882008,-0.03242681554971661,0.974141249628258,LGP Offspring,Fc Epsilon Receptor I Signaling in Mast Cells,CP:BIOCARTA,C2,26,50
Cohort,-0.07793033446714279,0.07669808610725871,-1.0160662204551079,0.30989252005197254,LGP Proband,Fc Epsilon Receptor I Signaling in Mast Cells,CP:BIOCARTA,C2,26,69
Cohort,-0.02620268637966795,0.024671075537418184,-1.0620812351665334,0.288520924252443,LonGen OPEL,Fc Epsilon Receptor I Signaling in Mast Cells,CP:BIOCARTA,C2,46,43
Cohort,-0.012257050691327362,0.024641317757111064,-0.497418636947295,0.6190556152827895,LGP Offspring,Feeder Pathways for Glycolysis,CP:BIOCARTA,C2,21,39
Cohort,0.10440127534585296,0.06556545412733004,1.5923213944816519,0.11169142810033322,LGP Proband,Feeder Pathways for Glycolysis,CP:BIOCARTA,C2,21,56
Cohort,0.010919819420320486,0.019389365386918666,0.5631860147257687,0.5734668236327739,LonGen OPEL,Feeder Pathways for Glycolysis,CP:BIOCARTA,C2,24,34
Cohort,-0.007669711373206475,0.014856164660256724,-0.5162645641458539,0.6058384698525409,LGP Offspring,Fibrinolysis Pathway,CP:BIOCARTA,C2,9,13
Cohort,-0.03763785319156004,0.04439973831678485,-0.8477043923777237,0.3968458267948467,LGP Proband,Fibrinolysis Pathway,CP:BIOCARTA,C2,9,24
Cohort,-0.005810249375106219,0.014702960634649398,-0.39517546972231066,0.6928192685510743,LonGen OPEL,Fibrinolysis Pathway,CP:BIOCARTA,C2,16,15
Cohort,0.018266726887724554,0.012154493919981782,1.5028784421615748,0.1333373844830006,LGP Offspring,Cardiac Protection Against ROS,CP:BIOCARTA,C2,2,13
Cohort,-0.026162399791380592,0.035740727942228184,-0.7320052303822648,0.46437101899217925,LGP Proband,Cardiac Protection Against ROS,CP:BIOCARTA,C2,2,19
Cohort,-0.011869764053990534,0.010198831717085665,-1.1638356611086764,0.24483934345134942,LonGen OPEL,Cardiac Protection Against ROS,CP:BIOCARTA,C2,9,7
Cohort,0.037353696625395706,0.03283641360518075,1.1375693178472526,0.2557033995984596,LGP Offspring,fMLP induced chemokine gene expression in HMC-1 cells,CP:BIOCARTA,C2,29,75
Cohort,-0.05071050861910779,0.09044214423986499,-0.5606955589710098,0.5751556899596478,LGP Proband,fMLP induced chemokine gene expression in HMC-1 cells,CP:BIOCARTA,C2,29,98
Cohort,-0.018752081419067618,0.031609898808128874,-0.593234465345561,0.5531927633845753,LonGen OPEL,fMLP induced chemokine gene expression in HMC-1 cells,CP:BIOCARTA,C2,69,76
Cohort,-0.0039199436428866115,0.013055152610146723,-0.3002602696379017,0.7640709477027454,LGP Offspring,FOSB gene expression and drug abuse,CP:BIOCARTA,C2,6,11
Cohort,-0.013687946272688123,0.0303566421972022,-0.4509044901530534,0.652175593597158,LGP Proband,FOSB gene expression and drug abuse,CP:BIOCARTA,C2,6,9
Cohort,-0.007359131130960039,0.007326443940681141,-1.0044615355749054,0.31546144266675136,LonGen OPEL,FOSB gene expression and drug abuse,CP:BIOCARTA,C2,5,3
Cohort,-0.018736883871890556,0.03077383329830703,-0.6088576515724914,0.5428233394942971,LGP Offspring,Free Radical Induced Apoptosis,CP:BIOCARTA,C2,31,58
Cohort,0.08709016995841395,0.07983893052659785,1.0908233537697551,0.27566566312563934,LGP Proband,Free Radical Induced Apoptosis,CP:BIOCARTA,C2,31,68
Cohort,0.02899444853647738,0.024537964550934436,1.181615878378683,0.2377110392624807,LonGen OPEL,Free Radical Induced Apoptosis,CP:BIOCARTA,C2,38,57
Cohort,0.01211589533368127,0.017212270347362425,0.7039103551808833,0.4817309938781471,LGP Offspring,FXR and LXR Regulation of Cholesterol Metabolism,CP:BIOCARTA,C2,7,21
Cohort,0.05934608540239274,0.05246824909598049,1.1310856837214176,0.25834417227687784,LGP Proband,FXR and LXR Regulation of Cholesterol Metabolism,CP:BIOCARTA,C2,7,33
Cohort,0.01800816197258817,0.013846647699592098,1.3005430890769805,0.19379129240849371,LonGen OPEL,FXR and LXR Regulation of Cholesterol Metabolism,CP:BIOCARTA,C2,11,17
Cohort,-0.01015017010207964,0.026133834374463386,-0.38839191970994713,0.6978483083161084,LGP Offspring,Cell Cycle: G1/S Check Point,CP:BIOCARTA,C2,23,45
Cohort,0.06452329795842833,0.07178333095151034,0.8988618541819109,0.3689856837355696,LGP Proband,Cell Cycle: G1/S Check Point,CP:BIOCARTA,C2,23,54
Cohort,-0.0024663589953091464,0.02604090200610368,-0.09471096641472176,0.9245682429588493,LonGen OPEL,Cell Cycle: G1/S Check Point,CP:BIOCARTA,C2,47,57
Cohort,-0.015284571112120537,0.026282468248567586,-0.5815500647643151,0.5610636493583544,LGP Offspring,Cell Cycle: G2/M Checkpoint,CP:BIOCARTA,C2,23,44
Cohort,0.08998533894899642,0.07862737681959237,1.1444530211845232,0.25276415372130306,LGP Proband,Cell Cycle: G2/M Checkpoint,CP:BIOCARTA,C2,23,75
Cohort,0.04101645250327636,0.025637008847297433,1.5998922786813399,0.11001928183047843,LonGen OPEL,Cell Cycle: G2/M Checkpoint,CP:BIOCARTA,C2,42,61
Cohort,0.008739361197960495,0.01002614907003719,0.8716568182770973,0.38370508686818683,LGP Offspring,Gamma-aminobutyric Acid Receptor Life Cycle,CP:BIOCARTA,C2,2,8
Cohort,-0.03279180771243951,0.031108946040004623,-1.054095746936293,0.292144361440791,LGP Proband,Gamma-aminobutyric Acid Receptor Life Cycle,CP:BIOCARTA,C2,2,14
Cohort,-0.0034949280004967173,0.009629493353499555,-0.3629399670572065,0.7167460826025349,LonGen OPEL,Gamma-aminobutyric Acid Receptor Life Cycle,CP:BIOCARTA,C2,7,7
Cohort,-0.009059250944186885,0.01715739038898039,-0.5280086737436093,0.5976665897927176,LGP Offspring,GATA3 participate in activating the Th2 cytokine genes expression,CP:BIOCARTA,C2,11,19
Cohort,0.10507751800551265,0.06220877747320153,1.6891108019407428,0.09157197646548695,LGP Proband,GATA3 participate in activating the Th2 cytokine genes expression,CP:BIOCARTA,C2,11,48
Cohort,-0.0046011451427736515,0.018998862567375808,-0.24218003190751952,0.8087030476076824,LonGen OPEL,GATA3 participate in activating the Th2 cytokine genes expression,CP:BIOCARTA,C2,26,29
Cohort,-0.010269948808980427,0.020958902173674875,-0.4900041387606574,0.6242899546164455,LGP Offspring,Corticosteroids and cardioprotection,CP:BIOCARTA,C2,16,30
Cohort,4.4057528238939953e-4,0.052709874652983935,0.008358496112729008,0.9933329615599107,LGP Proband,Corticosteroids and cardioprotection,CP:BIOCARTA,C2,16,32
Cohort,2.5517678679183825e-4,0.019137759447662554,0.013333681379457668,0.9893649178022901,LonGen OPEL,Corticosteroids and cardioprotection,CP:BIOCARTA,C2,26,30
Cohort,-0.025758528460577707,0.022914482752434927,-1.1241156407006643,0.2613629820276547,LGP Offspring,Growth Hormone Signaling Pathway,CP:BIOCARTA,C2,21,33
Cohort,0.049331808241625974,0.06553444700249868,0.7527614941153782,0.45180566807411326,LGP Proband,Growth Hormone Signaling Pathway,CP:BIOCARTA,C2,21,48
Cohort,-0.028547546342363724,0.02165908064102917,-1.318040539924193,0.18786924415255712,LonGen OPEL,Growth Hormone Signaling Pathway,CP:BIOCARTA,C2,36,31
Cohort,-0.008968367157092406,0.014182466699201297,-0.6323559467689405,0.5273681286315723,LGP Offspring,Ghrelin: Regulation of Food Intake and Energy Homeostasis,CP:BIOCARTA,C2,7,13
Cohort,0.012084948092295104,0.03881234453283053,0.31136866988472456,0.7555981819056002,LGP Proband,Ghrelin: Regulation of Food Intake and Energy Homeostasis,CP:BIOCARTA,C2,7,18
Cohort,-0.016685817917763055,0.012993673619309188,-1.2841493796617436,0.19946332343138873,LonGen OPEL,Ghrelin: Regulation of Food Intake and Energy Homeostasis,CP:BIOCARTA,C2,16,10
Cohort,-0.0034055600432999064,0.021483758137041207,-0.15851789158937757,0.8740960659744563,LGP Offspring,Inhibition of Cellular Proliferation by Gleevec,CP:BIOCARTA,C2,16,32
Cohort,0.04437228804049678,0.06394249258014828,0.6939405432917499,0.4879127322256901,LGP Proband,Inhibition of Cellular Proliferation by Gleevec,CP:BIOCARTA,C2,16,53
Cohort,-0.04559832157391574,0.021025513833003925,-2.168713779652779,0.030399883575611977,LonGen OPEL,Inhibition of Cellular Proliferation by Gleevec,CP:BIOCARTA,C2,39,26
Cohort,-0.005550288005224358,0.024315495419800985,-0.2282613580106025,0.8195120916134294,LGP Offspring,Signaling Pathway from G-Protein Families,CP:BIOCARTA,C2,19,34
Cohort,0.029917447705682183,0.0689667269511637,0.43379538261786943,0.6645492217711384,LGP Proband,Signaling Pathway from G-Protein Families,CP:BIOCARTA,C2,19,51
Cohort,-0.01949792433410318,0.02197730084522437,-0.8871846670989192,0.3752474574312269,LonGen OPEL,Signaling Pathway from G-Protein Families,CP:BIOCARTA,C2,37,37
Cohort,0.022091089961254293,0.01535161686816005,1.4390073795465947,0.15061127930527374,LGP Offspring,Adhesion and Diapedesis of Granulocytes,CP:BIOCARTA,C2,4,20
Cohort,0.0019534285638337333,0.04176379484375714,0.04677325351160545,0.9627051437817618,LGP Proband,Adhesion and Diapedesis of Granulocytes,CP:BIOCARTA,C2,4,23
Cohort,-0.011188564075237278,0.014871770488110836,-0.7523357144451578,0.4520716063753759,LonGen OPEL,Adhesion and Diapedesis of Granulocytes,CP:BIOCARTA,C2,18,16
Cohort,-0.009828989303075323,0.02598046816283564,-0.3783222550675753,0.7053099883335878,LGP Offspring,Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,CP:BIOCARTA,C2,22,43
Cohort,0.029502179861813964,0.06737892445850747,0.43785471642518814,0.6616049767679689,LGP Proband,Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,CP:BIOCARTA,C2,22,52
Cohort,-0.009599929508812163,0.02485296414758246,-0.3862689959960363,0.6994006829378132,LonGen OPEL,Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages,CP:BIOCARTA,C2,43,51
Cohort,-0.011284287462246557,0.012788178286587812,-0.8823999172799672,0.37787424156538785,LGP Offspring,Calcium Signaling by HBx of Hepatitis B virus,CP:BIOCARTA,C2,7,9
Cohort,-2.1694837908864322e-4,0.039039073625630014,-0.0055572112486350555,0.9955673387274049,LGP Proband,Calcium Signaling by HBx of Hepatitis B virus,CP:BIOCARTA,C2,7,18
Cohort,0.015340401024764746,0.012035069692189882,1.274641644553155,0.20280806506211407,LonGen OPEL,Calcium Signaling by HBx of Hepatitis B virus,CP:BIOCARTA,C2,8,14
Cohort,-0.00444663573702917,0.025040648846773535,-0.17757669796172695,0.8591086212676108,LGP Offspring,Human Cytomegalovirus and Map Kinase Pathways,CP:BIOCARTA,C2,19,43
Cohort,0.10026184920456252,0.06960125045190892,1.4405179296863149,0.15009621566162218,LGP Proband,Human Cytomegalovirus and Map Kinase Pathways,CP:BIOCARTA,C2,19,58
Cohort,0.005638840394116652,0.025225295225660076,0.2235391238704164,0.8231732925183111,LonGen OPEL,Human Cytomegalovirus and Map Kinase Pathways,CP:BIOCARTA,C2,42,52
Cohort,-0.002205758080362276,0.025528873840309524,-0.08640248270095773,0.9311720585418226,LGP Offspring,Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),CP:BIOCARTA,C2,23,45
Cohort,-0.017671644325971694,0.07108838652104232,-0.2485869379063885,0.8037415126978853,LGP Proband,Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),CP:BIOCARTA,C2,23,63
Cohort,-0.00802350751924554,0.023778146798728444,-0.3374319953174233,0.7358802266642681,LonGen OPEL,Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK),CP:BIOCARTA,C2,38,42
Cohort,0.01921791983916826,0.02279753380399038,0.8429824034652572,0.3995364490958623,LGP Offspring,Role of ERBB2 in Signal Transduction and Oncology,CP:BIOCARTA,C2,15,40
Cohort,-0.004545068799245287,0.05611209389905538,-0.08099980741089045,0.9354615390274439,LGP Proband,Role of ERBB2 in Signal Transduction and Oncology,CP:BIOCARTA,C2,15,39
Cohort,-0.0336984205737893,0.022691914839729207,-1.485040853176031,0.13792889983138928,LonGen OPEL,Role of ERBB2 in Signal Transduction and Oncology,CP:BIOCARTA,C2,42,33
Cohort,0.0077102361295854445,0.01420681202610012,0.5427140244708344,0.5875055948859935,LGP Offspring,Segmentation Clock,CP:BIOCARTA,C2,5,15
Cohort,-0.020635132161787254,0.04099442001618141,-0.5033644128552645,0.6148410030828959,LGP Proband,Segmentation Clock,CP:BIOCARTA,C2,5,23
Cohort,-0.03357172760697077,0.01770730920717253,-1.8959248530754853,0.05833191162058886,LonGen OPEL,Segmentation Clock,CP:BIOCARTA,C2,26,19
Cohort,-9.044335513141508e-4,0.015805918217334354,-0.057221196445408545,0.9543859025166936,LGP Offspring,Hypoxia-Inducible Factor in the Cardiovascular System,CP:BIOCARTA,C2,9,16
Cohort,-0.08542482500660266,0.038876253885183884,-2.197352277276872,0.02826960687813357,LGP Proband,Hypoxia-Inducible Factor in the Cardiovascular System,CP:BIOCARTA,C2,9,16
Cohort,0.028416770893652896,0.012592300073144774,2.2566783453847723,0.02429863132488693,LonGen OPEL,Hypoxia-Inducible Factor in the Cardiovascular System,CP:BIOCARTA,C2,6,18
Cohort,-0.05882041362852054,0.0449374266479997,-1.3089404092777266,0.19099931500737544,LGP Offspring,HIV-I Nef: negative effector of Fas and TNF,CP:BIOCARTA,C2,68,117
Cohort,-0.17501641575989194,0.11928640784060622,-1.4671949547994914,0.1427000127305451,LGP Proband,HIV-I Nef: negative effector of Fas and TNF,CP:BIOCARTA,C2,68,147
Cohort,-0.030392269588199447,0.036949740882693136,-0.822529978889104,0.4110216559746648,LonGen OPEL,HIV-I Nef: negative effector of Fas and TNF,CP:BIOCARTA,C2,105,115
Cohort,-0.03277345229608306,0.01370586167408258,-2.3911996980136454,0.017065910086765227,LGP Offspring,Stress Induction of HSP Regulation,CP:BIOCARTA,C2,10,7
Cohort,-0.032149080196839784,0.038153504007102775,-0.8426245775710355,0.39968001822690735,LGP Proband,Stress Induction of HSP Regulation,CP:BIOCARTA,C2,10,12
Cohort,0.012547467743506662,0.014897473708592198,0.842254733181361,0.3998983652036019,LonGen OPEL,Stress Induction of HSP Regulation,CP:BIOCARTA,C2,16,19
Cohort,0.002142952416132299,0.016433710695891394,0.13039978954163164,0.8962889266087694,LGP Offspring,Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes,CP:BIOCARTA,C2,8,19
Cohort,0.053788008616535085,0.052693114920774574,1.0207786861225934,0.3076553116980545,LGP Proband,Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes,CP:BIOCARTA,C2,8,40
Cohort,0.016586350595172078,0.01735931995593427,0.9554723708806373,0.3396289470221574,LonGen OPEL,Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes,CP:BIOCARTA,C2,18,28
Cohort,-0.04134591524596888,0.013038603454176605,-3.1710386308837935,0.0015876094103732489,LGP Offspring,IFN alpha signaling pathway,CP:BIOCARTA,C2,12,5
Cohort,-0.034952322279946074,0.04265791532165538,-0.8193631127164448,0.41281335415228726,LGP Proband,IFN alpha signaling pathway,CP:BIOCARTA,C2,12,18
Cohort,-8.321173900683337e-4,0.01422888295428328,-0.05848086548620064,0.9533802810481062,LonGen OPEL,IFN alpha signaling pathway,CP:BIOCARTA,C2,14,17
Cohort,0.0020919699274423225,0.011030529663287231,0.1896527176210766,0.8496382047433152,LGP Offspring,IFN gamma signaling pathway,CP:BIOCARTA,C2,3,9
Cohort,0.010522296835838425,0.030462753050212107,0.34541516383940746,0.7298693805114892,LGP Proband,IFN gamma signaling pathway,CP:BIOCARTA,C2,3,12
Cohort,-0.006201807789676458,0.011212808547206896,-0.5531003016386403,0.5803500292367861,LonGen OPEL,IFN gamma signaling pathway,CP:BIOCARTA,C2,9,8
Cohort,-0.005288516237472036,0.018437889951870724,-0.2868287125737758,0.7743313671838145,LGP Offspring,IGF-1 Signaling Pathway,CP:BIOCARTA,C2,12,23
Cohort,-0.005168558793223553,0.04919610609221527,-0.10506032293562802,0.9163532041348601,LGP Proband,IGF-1 Signaling Pathway,CP:BIOCARTA,C2,12,27
Cohort,-0.022985985086957678,0.017795203402574754,-1.291695552276288,0.19683752081861183,LonGen OPEL,IGF-1 Signaling Pathway,CP:BIOCARTA,C2,24,19
Cohort,-0.03763300112121671,0.017607681328366945,-2.1373058961822458,0.03293130314108589,LGP Offspring,Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,CP:BIOCARTA,C2,15,17
Cohort,-0.025529046089555474,0.04642552115798806,-0.5498925042258336,0.5825403316901192,LGP Proband,Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,CP:BIOCARTA,C2,15,22
Cohort,-0.016970582058844143,0.014208161497038107,-1.194424912919374,0.23266758582654998,LonGen OPEL,Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway,CP:BIOCARTA,C2,17,14
Cohort,-0.0051492046829390995,0.018882118842354696,-0.272702694328396,0.7851650436020685,LGP Offspring,Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,CP:BIOCARTA,C2,12,22
Cohort,0.074440584544774,0.05269293927907635,1.412724087197264,0.1581099268036788,LGP Proband,Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,CP:BIOCARTA,C2,12,35
Cohort,-0.038563900546462165,0.019241303053547244,-2.004224996568135,0.045384302441209695,LonGen OPEL,Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation,CP:BIOCARTA,C2,33,24
Cohort,0.029260017812816678,0.016338278590899015,1.790887433460433,0.07375866287287516,LGP Offspring,IL-10 Anti-inflammatory Signaling Pathway,CP:BIOCARTA,C2,5,22
Cohort,-0.023689169682519384,0.03809848834532439,-0.621787653825027,0.5342514352664911,LGP Proband,IL-10 Anti-inflammatory Signaling Pathway,CP:BIOCARTA,C2,5,19
Cohort,-0.005907829176853241,0.011728123763775918,-0.50373182410476125,0.6145892187241437,LonGen OPEL,IL-10 Anti-inflammatory Signaling Pathway,CP:BIOCARTA,C2,11,10
Cohort,-0.03457968845014912,0.01994390966183133,-1.7338470258079715,0.08340114729929085,LGP Offspring,IL12 and Stat4 Dependent Signaling Pathway in Th1 Development,CP:BIOCARTA,C2,18,20
Cohort,-0.001980601280120035,0.062393838454789186,-0.031743539573305564,0.9746841677204854,LGP Proband,IL12 and Stat4 Dependent Signaling Pathway in Th1 Development,CP:BIOCARTA,C2,18,39
Cohort,0.023648579353397804,0.019320578768015805,1.2240098827964085,0.22131066102312916,LonGen OPEL,IL12 and Stat4 Dependent Signaling Pathway in Th1 Development,CP:BIOCARTA,C2,21,34
Cohort,0.010554233497863849,0.015494922513616212,0.6811414183316685,0.4960152672784205,LGP Offspring,IL 17 Signaling Pathway,CP:BIOCARTA,C2,6,18
Cohort,0.009131086240523363,0.041770471732025805,0.21860146323227841,0.8270139934039815,LGP Proband,IL 17 Signaling Pathway,CP:BIOCARTA,C2,6,21
Cohort,-0.012342134452285382,0.016018988913643024,-0.770469005180087,0.44125034264070473,LonGen OPEL,IL 17 Signaling Pathway,CP:BIOCARTA,C2,20,18
Cohort,-0.017077294846112628,0.028522587590471313,-0.5987288071934164,0.5495543129065763,LGP Offspring,Signal transduction through IL1R,CP:BIOCARTA,C2,24,46
Cohort,0.0531175285007982,0.07720073665247866,0.6880443219072933,0.4916161892143057,LGP Proband,Signal transduction through IL1R,CP:BIOCARTA,C2,24,62
Cohort,0.0198788167690456,0.025511083547339313,0.7792227535987536,0.4360801062736145,LonGen OPEL,Signal transduction through IL1R,CP:BIOCARTA,C2,41,60
Cohort,0.005970224913119344,0.01641326223619509,0.3637439545658144,0.7161629472337665,LGP Offspring,IL 2 signaling pathway,CP:BIOCARTA,C2,8,19
Cohort,0.014179921188563115,0.04199544564165826,0.33765378535469204,0.7357090714843803,LGP Proband,IL 2 signaling pathway,CP:BIOCARTA,C2,8,21
Cohort,-0.014243216253963513,0.014186295539322113,-1.0040123733841315,0.3156777540112781,LonGen OPEL,IL 2 signaling pathway,CP:BIOCARTA,C2,15,12
Cohort,-0.017014008722343484,0.018564077727229376,-0.9165016960356568,0.3597306540157089,LGP Offspring,IL22 Soluble Receptor Signaling Pathway,CP:BIOCARTA,C2,13,20
Cohort,-0.007051886860375366,0.05262121914287347,-0.13401222881645092,0.8934252357576513,LGP Proband,IL22 Soluble Receptor Signaling Pathway,CP:BIOCARTA,C2,13,29
Cohort,-0.018331251719373345,0.016576570092903444,-1.1058531177822541,0.2691242104658139,LonGen OPEL,IL22 Soluble Receptor Signaling Pathway,CP:BIOCARTA,C2,23,18
Cohort,-0.002594289377773047,0.02707212249058199,-0.09582881352119929,0.9236849331809595,LGP Offspring,IL-2 Receptor Beta Chain in T cell Activation,CP:BIOCARTA,C2,24,48
Cohort,0.08643292831005418,0.06888459898345597,1.2547496767864292,0.20992115092950006,LGP Proband,IL-2 Receptor Beta Chain in T cell Activation,CP:BIOCARTA,C2,24,54
Cohort,-0.029372113951820697,0.02275150755277654,-1.290996382709426,0.1970797359876208,LonGen OPEL,IL-2 Receptor Beta Chain in T cell Activation,CP:BIOCARTA,C2,39,30
Cohort,-0.0014499623790367178,0.015536084186769147,-0.093328689623833,0.9256700935461784,LGP Offspring,IL 3 signaling pathway,CP:BIOCARTA,C2,8,16
Cohort,0.02329051881133363,0.04600547567561106,0.5062553635040592,0.6128111889745376,LGP Proband,IL 3 signaling pathway,CP:BIOCARTA,C2,8,27
Cohort,-0.029368641456702947,0.015833431426139764,-1.8548500742686518,0.06398722333560743,LonGen OPEL,IL 3 signaling pathway,CP:BIOCARTA,C2,21,14
Cohort,-0.007417624573744752,0.0154167981684387,-0.4811391115523668,0.6305733256264587,LGP Offspring,IL 4 signaling pathway,CP:BIOCARTA,C2,8,16
Cohort,0.01884408631448169,0.03478963252230636,0.5416581018037276,0.5881987273635899,LGP Proband,IL 4 signaling pathway,CP:BIOCARTA,C2,8,12
Cohort,-0.0047796325156386,0.009297164226806832,-0.5140957391994133,0.6073277426935876,LonGen OPEL,IL 4 signaling pathway,CP:BIOCARTA,C2,7,6
Cohort,0.023383784701318883,0.02188616020601649,1.0684279234550562,0.2857089046038274,LGP Offspring,IL 5 Signaling Pathway,CP:BIOCARTA,C2,10,38
Cohort,0.004814961815423127,0.051349010910041196,0.09376931960497745,0.9253149254146047,LGP Proband,IL 5 Signaling Pathway,CP:BIOCARTA,C2,10,32
Cohort,0.009373799141505736,0.02149946028843748,0.43600160263311416,0.6629537833981383,LonGen OPEL,IL 5 Signaling Pathway,CP:BIOCARTA,C2,27,34
Cohort,0.02304222560219073,0.019282291496586623,1.1949941533800428,0.23250838603533514,LGP Offspring,IL 6 signaling pathway,CP:BIOCARTA,C2,9,29
Cohort,0.013254271489147783,0.04728550372303441,0.28030306215583717,0.779314513645758,LGP Proband,IL 6 signaling pathway,CP:BIOCARTA,C2,9,28
Cohort,-0.021502664978911762,0.017545415433657795,-1.2255432229699548,0.22073309425553939,LonGen OPEL,IL 6 signaling pathway,CP:BIOCARTA,C2,24,18
Cohort,-0.013707991376646408,0.021047772348949247,-0.6512799145383545,0.51508714117025,LGP Offspring,IL-7 Signal Transduction,CP:BIOCARTA,C2,17,30
Cohort,-0.03028557045167691,0.052345451087656016,-0.5785712000257991,0.5630347465720995,LGP Proband,IL-7 Signal Transduction,CP:BIOCARTA,C2,17,30
Cohort,0.0010105634693482106,0.021734761363253408,0.04649526408220672,0.9629271707931996,LonGen OPEL,IL-7 Signal Transduction,CP:BIOCARTA,C2,34,36
Cohort,0.004575484722601123,0.025134191203132435,0.18204225016124204,0.8556041430218966,LGP Offspring,Cytokines and Inflammatory Response,CP:BIOCARTA,C2,18,45
Cohort,-0.028365908405867453,0.06461409939095628,-0.4390049334934736,0.6607716712920848,LGP Proband,Cytokines and Inflammatory Response,CP:BIOCARTA,C2,18,50
Cohort,0.03379540169094788,0.02557653738429634,1.3213439013718022,0.1867663914727282,LonGen OPEL,Cytokines and Inflammatory Response,CP:BIOCARTA,C2,35,56
Cohort,-0.010009197898453833,0.017048748757333965,-0.587092814899282,0.5573373946649722,LGP Offspring,Insulin Signaling Pathway,CP:BIOCARTA,C2,11,19
Cohort,-0.006021038588817807,0.04622371632968925,-0.13025864354724168,0.8963932095703772,LGP Proband,Insulin Signaling Pathway,CP:BIOCARTA,C2,11,25
Cohort,-0.010056795660794914,0.016315592937505206,-0.6163916750875181,0.5378122790086078,LonGen OPEL,Insulin Signaling Pathway,CP:BIOCARTA,C2,20,17
Cohort,0.03291415796884207,0.03761513243836988,0.8750243807534089,0.38187142103741867,LGP Offspring,Integrin Signaling Pathway,CP:BIOCARTA,C2,40,91
Cohort,-0.14932411023916,0.10226759997443043,-1.4601311683905258,0.14463060801786293,LGP Proband,Integrin Signaling Pathway,CP:BIOCARTA,C2,40,129
Cohort,-0.005255037297369884,0.031765815294796634,-0.1654305815418715,0.8686470892216096,LonGen OPEL,Integrin Signaling Pathway,CP:BIOCARTA,C2,68,78
Cohort,-0.0331483533223604,0.027679793030223197,-1.1975650716089588,0.23150612491654243,LGP Offspring,Intrinsic Prothrombin Activation Pathway,CP:BIOCARTA,C2,31,46
Cohort,-0.093693973133191,0.07205033694398977,-1.30039604403275,0.19382449201079235,LGP Proband,Intrinsic Prothrombin Activation Pathway,CP:BIOCARTA,C2,31,57
Cohort,0.002975514615606967,0.023686033626473216,0.1256231694394505,0.900061942259583,LonGen OPEL,Intrinsic Prothrombin Activation Pathway,CP:BIOCARTA,C2,40,48
Cohort,-0.026078014378045408,0.016942951157575565,-1.5391660009823822,0.12423170648136107,LGP Offspring,Ion Channel and Phorbal Esters Signaling Pathway,CP:BIOCARTA,C2,13,14
Cohort,-0.036922344748394315,0.04511459279763343,-0.8184124572289423,0.4133554836318758,LGP Proband,Ion Channel and Phorbal Esters Signaling Pathway,CP:BIOCARTA,C2,13,19
Cohort,0.02604002116698555,0.012999320443818107,2.0031832648120473,0.045496207330402466,LonGen OPEL,Ion Channel and Phorbal Esters Signaling Pathway,CP:BIOCARTA,C2,7,19
Cohort,0.006213881880848019,0.005576277108694707,1.1143423756970647,0.265528362342269,LGP Offspring,Internal Ribosome entry pathway,CP:BIOCARTA,C2,0,3
Cohort,0.013822138251501677,0.022360608766776095,0.6181467774723077,0.5366473549885491,LGP Proband,Internal Ribosome entry pathway,CP:BIOCARTA,C2,0,8
Cohort,0.006210031057352869,0.0057302036006188625,1.0837365458850687,0.27880977351426045,LonGen OPEL,Internal Ribosome entry pathway,CP:BIOCARTA,C2,1,4
Cohort,0.03080978889315042,0.03342896603746147,0.9216494718569541,0.35704024642906873,LGP Offspring,Keratinocyte Differentiation,CP:BIOCARTA,C2,31,82
Cohort,0.044215374804887526,0.0915639919651761,0.48289042292633605,0.6293002711507081,LGP Proband,Keratinocyte Differentiation,CP:BIOCARTA,C2,31,111
Cohort,-0.009812655266534706,0.02660508183231671,-0.3688263516113471,0.7123552379616787,LonGen OPEL,Keratinocyte Differentiation,CP:BIOCARTA,C2,54,63
Cohort,0.01569905719158236,0.013750613124437091,1.1416987045968565,0.2539835300898093,LGP Offspring,The Citric Acid Cycle,CP:BIOCARTA,C2,4,15
Cohort,-0.04787212214488863,0.03279344491482247,-1.4598076618431348,0.1447195030483101,LGP Proband,The Citric Acid Cycle,CP:BIOCARTA,C2,4,14
Cohort,-0.006014564775028677,0.011440578116175944,-0.5257221019735555,0.5992277255366192,LonGen OPEL,The Citric Acid Cycle,CP:BIOCARTA,C2,10,10
Cohort,0.048618883075794386,0.023390662735112616,2.07855945025494,0.038034486760581125,LGP Offspring,Cells and Molecules involved in local acute inflammatory response,CP:BIOCARTA,C2,10,43
Cohort,-0.0282567272001983,0.0628073064395336,-0.449895542446194,0.6529026708163949,LGP Proband,Cells and Molecules involved in local acute inflammatory response,CP:BIOCARTA,C2,10,50
Cohort,-0.011582831141523036,0.020029323328820608,-0.578293682286124,0.5632294272440435,LonGen OPEL,Cells and Molecules involved in local acute inflammatory response,CP:BIOCARTA,C2,29,33
Cohort,0.013016406344214373,0.007865089098544347,1.654959807972604,0.09839680951321744,LGP Offspring,Low-density lipoprotein (LDL) pathway during atherogenesis,CP:BIOCARTA,C2,0,6
Cohort,-0.0059533812952487965,0.013719334409008254,-0.4339409710240568,0.6644435360946944,LGP Proband,Low-density lipoprotein (LDL) pathway during atherogenesis,CP:BIOCARTA,C2,0,3
Cohort,0.009826633682340769,0.005163658263043208,1.9030371844455545,0.05739621964723986,LonGen OPEL,Low-density lipoprotein (LDL) pathway during atherogenesis,CP:BIOCARTA,C2,0,4
Cohort,0.028725938131972894,0.0288809776810008,0.9946317762944051,0.3202712738466969,LGP Offspring,Lectin Induced Complement Pathway,CP:BIOCARTA,C2,21,61
Cohort,-0.06545517927790465,0.07439119064237013,-0.8798780972948174,0.37917880857460917,LGP Proband,Lectin Induced Complement Pathway,CP:BIOCARTA,C2,21,72
Cohort,0.008087926361377848,0.02313844818050985,0.3495448916142324,0.7267727290572633,LonGen OPEL,Lectin Induced Complement Pathway,CP:BIOCARTA,C2,32,49
Cohort,0.004783871250696547,0.013081759700216617,0.3656901946163506,0.7147106640699286,LGP Offspring,Reversal of Insulin Resistance by Leptin,CP:BIOCARTA,C2,5,12
Cohort,-0.05447888397491056,0.03743230026427303,-1.4553977070681792,0.14593548279096716,LGP Proband,Reversal of Insulin Resistance by Leptin,CP:BIOCARTA,C2,5,18
Cohort,0.002001833740505626,0.015101957137990587,0.13255459025703362,0.8945791468988561,LonGen OPEL,Reversal of Insulin Resistance by Leptin,CP:BIOCARTA,C2,14,19
Cohort,0.0669399898408415,0.051295229035524297,1.3049944624378709,0.19233876851915482,LGP Offspring,Lissencephaly gene (LIS1) in neuronal migration and development,CP:BIOCARTA,C2,75,193
Cohort,0.07147897948025253,0.13740522020159365,0.5202057052518264,0.6030582659933793,LGP Proband,Lissencephaly gene (LIS1) in neuronal migration and development,CP:BIOCARTA,C2,75,252
Cohort,0.00875879912392394,0.043508133617729226,0.20131406235166102,0.8405044383608158,LonGen OPEL,Lissencephaly gene (LIS1) in neuronal migration and development,CP:BIOCARTA,C2,134,168
Cohort,-0.013198678034970093,0.016840631063876583,-0.7837401095545323,0.4334671336465278,LGP Offspring,The IGF-1 Receptor and Longevity,CP:BIOCARTA,C2,10,17
Cohort,0.03476791540632111,0.045938378699532656,0.7568381033585501,0.44936061065603516,LGP Proband,The IGF-1 Receptor and Longevity,CP:BIOCARTA,C2,10,24
Cohort,-0.027347931452366775,0.017193767873263426,-1.5905723314372082,0.11210290377465468,LonGen OPEL,The IGF-1 Receptor and Longevity,CP:BIOCARTA,C2,25,19
Cohort,0.029011412099973113,0.01658901129684853,1.748833102879646,0.0807737356144222,LGP Offspring,Adhesion and Diapedesis of Lymphocytes,CP:BIOCARTA,C2,5,23
Cohort,0.028867329515179247,0.04586699744462023,0.6293703779069828,0.5292789651624508,LGP Proband,Adhesion and Diapedesis of Lymphocytes,CP:BIOCARTA,C2,5,26
Cohort,-0.021169652761215327,0.018382492328699332,-1.151620377839875,0.24982288056943386,LonGen OPEL,Adhesion and Diapedesis of Lymphocytes,CP:BIOCARTA,C2,26,21
Cohort,0.01646257361083714,0.009988003468281693,1.648234671034742,0.09976917858138334,LGP Offspring,Adhesion Molecules on Lymphocyte,CP:BIOCARTA,C2,1,9
Cohort,0.03548738798892169,0.027112913677787086,1.3088740078125796,0.19093756425998695,LGP Proband,Adhesion Molecules on Lymphocyte,CP:BIOCARTA,C2,1,11
Cohort,0.006550822234842379,0.008919935968015916,0.7344023834175005,0.46291981272058,LonGen OPEL,Adhesion Molecules on Lymphocyte,CP:BIOCARTA,C2,5,7
Cohort,-0.006610475743824315,0.017835735049818686,-0.37063096784965505,0.7110285199175481,LGP Offspring,Role of MAL in Rho-Mediated Activation of SRF,CP:BIOCARTA,C2,11,21
Cohort,-0.008114307913739904,0.05347076767092825,-0.15175222401289007,0.8794190656495265,LGP Proband,Role of MAL in Rho-Mediated Activation of SRF,CP:BIOCARTA,C2,11,35
Cohort,-0.026789661262105472,0.016887612567151895,-1.5863498262752698,0.11305711799414597,LonGen OPEL,Role of MAL in Rho-Mediated Activation of SRF,CP:BIOCARTA,C2,25,20
Cohort,-4.884346113411838e-4,0.016739934677456308,-0.029177808680398216,0.9767313915319132,LGP Offspring,Shuttle for transfer of acetyl groups from mitochondria to the cytosol,CP:BIOCARTA,C2,9,15
Cohort,-0.05339708826520128,0.0433727950488886,-1.2311193734462715,0.2186252810807216,LGP Proband,Shuttle for transfer of acetyl groups from mitochondria to the cytosol,CP:BIOCARTA,C2,9,22
Cohort,-0.02457344356728642,0.015172234975085215,-1.6196324145809244,0.10570734907688469,LonGen OPEL,Shuttle for transfer of acetyl groups from mitochondria to the cytosol,CP:BIOCARTA,C2,17,12
Cohort,-0.012570062224223015,0.04474127911660299,-0.28094999679073557,0.7788347193526952,LGP Offspring,MAPKinase Signaling Pathway,CP:BIOCARTA,C2,65,136
Cohort,-0.023431377940254985,0.13410022559919632,-0.17473033945735145,0.8613339349777283,LGP Proband,MAPKinase Signaling Pathway,CP:BIOCARTA,C2,65,205
Cohort,-0.03980160473134354,0.03999825548521604,-0.9950835167312438,0.3199980371817013,LonGen OPEL,MAPKinase Signaling Pathway,CP:BIOCARTA,C2,115,127
Cohort,0.028626480451809915,0.020702794228256063,1.3827351098693366,0.1672026887842442,LGP Offspring,mCalpain and friends in Cell motility,CP:BIOCARTA,C2,10,33
Cohort,0.08137440594190616,0.05840948329703215,1.3931711316138433,0.16393924840955518,LGP Proband,mCalpain and friends in Cell motility,CP:BIOCARTA,C2,10,46
Cohort,-0.017815791372998328,0.017444189708262742,-1.0213023173303126,0.3074215179688609,LonGen OPEL,mCalpain and friends in Cell motility,CP:BIOCARTA,C2,26,22
Cohort,-0.03091845396016122,0.030723879467835155,-1.0063330053266797,0.3146154794189943,LGP Offspring,CDK Regulation of DNA Replication,CP:BIOCARTA,C2,32,49
Cohort,-0.0379049127575299,0.08410500683497205,-0.4506855677677503,0.6523333273697589,LGP Proband,CDK Regulation of DNA Replication,CP:BIOCARTA,C2,32,79
Cohort,0.01584969019765065,0.025694436571856764,0.616852996691544,0.5375080791072938,LonGen OPEL,CDK Regulation of DNA Replication,CP:BIOCARTA,C2,39,51
Cohort,0.008974261461936367,0.02144686896155036,0.4184415672994176,0.6757572009824792,LGP Offspring,Role of MEF2D in T-cell Apoptosis,CP:BIOCARTA,C2,14,34
Cohort,0.039730234641325954,0.06258085902202545,0.6348624046106944,0.5256922805565969,LGP Proband,Role of MEF2D in T-cell Apoptosis,CP:BIOCARTA,C2,14,52
Cohort,0.012407484234679727,0.01949611304257987,0.6364080987621252,0.5246934163862613,LonGen OPEL,Role of MEF2D in T-cell Apoptosis,CP:BIOCARTA,C2,24,33
Cohort,-1.669784314268165e-4,0.00841820548694431,-0.019835395047766567,0.9841805352756381,LGP Offspring,Melanocyte Development and Pigmentation Pathway,CP:BIOCARTA,C2,3,4
Cohort,-0.01718703271384286,0.02601737560012587,-0.6605982470330217,0.5090524117279618,LGP Proband,Melanocyte Development and Pigmentation Pathway,CP:BIOCARTA,C2,3,8
Cohort,0.011703556789760296,0.010227463219507954,1.1443264608800379,0.25283225507255913,LonGen OPEL,Melanocyte Development and Pigmentation Pathway,CP:BIOCARTA,C2,6,10
Cohort,-0.01370980490917629,0.025955593209246185,-0.5282023338342517,0.5975322572831033,LGP Offspring,Signaling of Hepatocyte Growth Factor Receptor,CP:BIOCARTA,C2,23,42
Cohort,0.11221142181907251,0.07376041284606069,1.521296010818971,0.12856460177023293,LGP Proband,Signaling of Hepatocyte Growth Factor Receptor,CP:BIOCARTA,C2,23,69
Cohort,0.008303594881613792,0.024167719418585757,0.34358206241123684,0.731251346132124,LonGen OPEL,Signaling of Hepatocyte Growth Factor Receptor,CP:BIOCARTA,C2,36,44
Cohort,0.04189835421228949,0.02614039819954259,1.6028200447620815,0.10944150761783278,LGP Offspring,Antigen Processing and Presentation,CP:BIOCARTA,C2,13,49
Cohort,0.008210506813803588,0.06391168747618783,0.1284664376427653,0.8978108285414622,LGP Proband,Antigen Processing and Presentation,CP:BIOCARTA,C2,13,48
Cohort,0.03800794804587082,0.023017660699794714,1.6512515559936896,0.09908164786530736,LonGen OPEL,Antigen Processing and Presentation,CP:BIOCARTA,C2,28,45
Cohort,-0.022469621780525795,0.023686131114433767,-0.9486404373922147,0.3431425176200239,LGP Offspring,Role of Mitochondria in Apoptotic Signaling,CP:BIOCARTA,C2,22,35
Cohort,0.007085456976778247,0.06153560844846001,0.11514401426147867,0.9083586895599735,LGP Proband,Role of Mitochondria in Apoptotic Signaling,CP:BIOCARTA,C2,22,41
Cohort,0.006090431802226814,0.022200903002146624,0.27433261618403204,0.7839001990309205,LonGen OPEL,Role of Mitochondria in Apoptotic Signaling,CP:BIOCARTA,C2,33,44
Cohort,0,0,NA,NA,LGP Offspring,Signal Dependent Regulation of Myogenesis by Corepressor MITR,CP:BIOCARTA,C2,0,0
Cohort,-0.0017678090307419506,0.01761476301685973,-0.10035951258895259,0.9200830314205117,LGP Proband,Signal Dependent Regulation of Myogenesis by Corepressor MITR,CP:BIOCARTA,C2,0,5
Cohort,0.0027984591292524734,0.0063133746623643796,0.443258839988508,0.6576989672963791,LonGen OPEL,Signal Dependent Regulation of Myogenesis by Corepressor MITR,CP:BIOCARTA,C2,2,4
Cohort,0.02164007625537543,0.013690340212130378,1.5806821393818364,0.11441848768276315,LGP Offspring,Monocyte and its Surface Molecules,CP:BIOCARTA,C2,3,16
Cohort,0.055990323931184846,0.034875618583839,1.6054288412573183,0.10877801743137831,LGP Proband,Monocyte and its Surface Molecules,CP:BIOCARTA,C2,3,17
Cohort,-0.009683608239965466,0.010854530890764892,-0.8921259092094294,0.37259505039927376,LonGen OPEL,Monocyte and its Surface Molecules,CP:BIOCARTA,C2,11,7
Cohort,0.005958653418222482,0.014233787042984999,0.4186274109783843,0.6756214203010396,LGP Offspring,How Progesterone Initiates the Oocyte Maturation,CP:BIOCARTA,C2,6,14
Cohort,0.06463393177852403,0.04511591237579275,1.432619410201794,0.15234134036916014,LGP Proband,How Progesterone Initiates the Oocyte Maturation,CP:BIOCARTA,C2,6,28
Cohort,-0.011909988613324077,0.018082867502154834,-0.6586338484150719,0.5103213808312888,LonGen OPEL,How Progesterone Initiates the Oocyte Maturation,CP:BIOCARTA,C2,25,27
Cohort,0.020122196613111886,0.021315147390146533,0.9440327221201333,0.34549020040840517,LGP Offspring,Multi-Drug Resistance Factors,CP:BIOCARTA,C2,12,35
Cohort,0.020374561408775506,0.06595726645908617,0.30890548536322393,0.7574705730489445,LGP Proband,Multi-Drug Resistance Factors,CP:BIOCARTA,C2,12,60
Cohort,0.007308077031594131,0.02176644603568516,0.3357496680722636,0.737148122558074,LonGen OPEL,Multi-Drug Resistance Factors,CP:BIOCARTA,C2,31,39
Cohort,0.0017454715121515956,0.013112530424432299,0.133114773095153,0.8941422267804007,LGP Offspring,Msp/Ron Receptor Signaling Pathway,CP:BIOCARTA,C2,6,12
Cohort,0.019507565351198422,0.04116738670670882,0.47385969603019235,0.6357239841447236,LGP Proband,Msp/Ron Receptor Signaling Pathway,CP:BIOCARTA,C2,6,21
Cohort,0.014051078025570679,0.012258974705301216,1.1461870477222287,0.2520622078497909,LonGen OPEL,Msp/Ron Receptor Signaling Pathway,CP:BIOCARTA,C2,8,15
Cohort,0.021555181221749348,0.028712016406397232,0.7507372842315145,0.4530720167585307,LGP Offspring,Downregulated of MTA-3 in ER-negative Breast Tumors,CP:BIOCARTA,C2,25,59
Cohort,0.07117822678057324,0.07853154491452503,0.906364784470301,0.3650045869925621,LGP Proband,Downregulated of MTA-3 in ER-negative Breast Tumors,CP:BIOCARTA,C2,25,73
Cohort,0.03960937063363911,0.027174249293183385,1.4576068029071572,0.1453433468311828,LonGen OPEL,Downregulated of MTA-3 in ER-negative Breast Tumors,CP:BIOCARTA,C2,40,65
Cohort,-0.0460149263115356,0.02567354007774649,-1.7923093649021458,0.07353048448263219,LGP Offspring,mTOR Signaling Pathway,CP:BIOCARTA,C2,30,38
Cohort,-0.16014176925371487,0.0667881842720467,-2.3977559953032,0.016714790294374074,LGP Proband,mTOR Signaling Pathway,CP:BIOCARTA,C2,30,47
Cohort,-0.005671395232811416,0.019785920420664405,-0.286637927992888,0.7744641598098901,LonGen OPEL,mTOR Signaling Pathway,CP:BIOCARTA,C2,25,29
Cohort,0.010150834623782716,0.01430037000175199,0.7098302087665633,0.47805420470825144,LGP Offspring,PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase,CP:BIOCARTA,C2,6,15
Cohort,-0.06844654288584617,0.04496176539987873,-1.5223277439642258,0.12830603166731422,LGP Proband,PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase,CP:BIOCARTA,C2,6,30
Cohort,0.004414266433500684,0.013236408095706642,0.3334942834629354,0.7388490311608336,LonGen OPEL,PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase,CP:BIOCARTA,C2,11,16
Cohort,0.0021343333068961586,0.01594255779463235,0.13387646664920735,0.8935401051239118,LGP Offspring,"Endocytotic role of NDK, Phosphins and Dynamin",CP:BIOCARTA,C2,6,15
Cohort,0.06780566641396873,0.04568216204248765,1.484291972672061,0.13810930949230635,LGP Proband,"Endocytotic role of NDK, Phosphins and Dynamin",CP:BIOCARTA,C2,6,22
Cohort,0.02861979727427803,0.02160806697816761,1.3244959534415985,0.18571852888239584,LonGen OPEL,"Endocytotic role of NDK, Phosphins and Dynamin",CP:BIOCARTA,C2,16,33
Cohort,0.011331347137838801,0.011075289042908634,1.0231197663499463,0.30661720664109854,LGP Offspring,Neutrophil and Its Surface Molecules,CP:BIOCARTA,C2,2,10
Cohort,0.022006492316665932,0.028329137679377506,0.7768147610326237,0.4374883298242971,LGP Proband,Neutrophil and Its Surface Molecules,CP:BIOCARTA,C2,2,11
Cohort,-0.0029865568107902826,0.009575055542379078,-0.3119101291446111,0.7551905046875316,LonGen OPEL,Neutrophil and Its Surface Molecules,CP:BIOCARTA,C2,8,6
Cohort,0.024260405786391496,0.026634462714753504,0.9108652217321824,0.36269106783396365,LGP Offspring,NFAT and Hypertrophy of the heart (Transcription in the broken heart),CP:BIOCARTA,C2,19,48
Cohort,0.032256197341617,0.07351506159998256,0.4387699151655836,0.6609419023970264,LGP Proband,NFAT and Hypertrophy of the heart (Transcription in the broken heart),CP:BIOCARTA,C2,19,69
Cohort,-0.04315591317196541,0.02706820231781451,-1.5943398333314152,0.11125689492757126,LonGen OPEL,NFAT and Hypertrophy of the heart (Transcription in the broken heart),CP:BIOCARTA,C2,59,50
Cohort,0.012727025376194087,0.022851680881476426,0.5569404474972611,0.5777524557169336,LGP Offspring,NF-kB Signaling Pathway,CP:BIOCARTA,C2,13,37
Cohort,0.011992527085994593,0.059285377321146304,0.20228473913612113,0.8397434632240095,LGP Proband,NF-kB Signaling Pathway,CP:BIOCARTA,C2,13,44
Cohort,0.009520255830339554,0.02235040386311341,0.4259545325734165,0.6702561269788929,LonGen OPEL,NF-kB Signaling Pathway,CP:BIOCARTA,C2,30,38
Cohort,-0.008760722167843203,0.01902073563127807,-0.46058797817666425,0.6452423662855729,LGP Offspring,Nerve growth factor pathway (NGF),CP:BIOCARTA,C2,13,22
Cohort,0.004636976508609072,0.04937721553176872,0.0939092344246446,0.9252038138779011,LGP Proband,Nerve growth factor pathway (NGF),CP:BIOCARTA,C2,13,26
Cohort,-0.010937575823872888,0.017033705347117588,-0.6421137151890282,0.5209842270127825,LonGen OPEL,Nerve growth factor pathway (NGF),CP:BIOCARTA,C2,21,20
Cohort,-0.006925247142837069,0.013075028288961359,-0.5296544672628919,0.596525422034867,LGP Offspring,Ras-Independent pathway in NK cell-mediated cytotoxicity,CP:BIOCARTA,C2,6,9
Cohort,-0.006433777302180284,0.04755900092443863,-0.13527990868441958,0.8924232120896092,LGP Proband,Ras-Independent pathway in NK cell-mediated cytotoxicity,CP:BIOCARTA,C2,6,23
Cohort,-0.0010132429178861873,0.016680180133453227,-0.06074532227946749,0.9515772842308367,LonGen OPEL,Ras-Independent pathway in NK cell-mediated cytotoxicity,CP:BIOCARTA,C2,18,19
Cohort,0.007745107581275703,0.01581734554313372,0.48965912517715976,0.6245339865143993,LGP Offspring,Selective expression of chemokine receptors during T-cell polarization,CP:BIOCARTA,C2,7,19
Cohort,-8.64614981538753e-4,0.03904266660928589,-0.02214538751134159,0.9823372784474756,LGP Proband,Selective expression of chemokine receptors during T-cell polarization,CP:BIOCARTA,C2,7,17
Cohort,-0.016574889617546697,0.01543520481420209,-1.0738367139965626,0.2832212842897861,LonGen OPEL,Selective expression of chemokine receptors during T-cell polarization,CP:BIOCARTA,C2,20,17
Cohort,-0.05794291657501961,0.024341256377651076,-2.3804406673198635,0.01756811890134692,LGP Offspring,Actions of Nitric Oxide in the Heart,CP:BIOCARTA,C2,28,31
Cohort,-0.11373056251855296,0.0724836961100382,-1.5690502640193387,0.11701553142229,LGP Proband,Actions of Nitric Oxide in the Heart,CP:BIOCARTA,C2,28,62
Cohort,-0.016088387259110597,0.02241587171073499,-0.7177230253064772,0.4731386592864377,LonGen OPEL,Actions of Nitric Oxide in the Heart,CP:BIOCARTA,C2,36,39
Cohort,-0.04375430324000837,0.0215641613376147,-2.029028746120864,0.042846740605590336,LGP Offspring,NO2-dependent IL 12 Pathway in NK cells,CP:BIOCARTA,C2,23,23
Cohort,-0.06509965217782794,0.0680244260655833,-0.9570040637324078,0.33884252874074505,LGP Proband,NO2-dependent IL 12 Pathway in NK cells,CP:BIOCARTA,C2,23,48
Cohort,0.012937960682784543,0.021085334047684662,0.6135999862997301,0.5396549912808908,LonGen OPEL,NO2-dependent IL 12 Pathway in NK cells,CP:BIOCARTA,C2,28,37
Cohort,-0.012780799397990882,0.01646890333962888,-0.776056494741616,0.43798705392691306,LGP Offspring,Nitric Oxide Signaling Pathway,CP:BIOCARTA,C2,10,17
Cohort,0.06799604763698955,0.05204247031771925,1.3065491938002505,0.19172603933956125,LGP Proband,Nitric Oxide Signaling Pathway,CP:BIOCARTA,C2,10,32
Cohort,-0.009873110863539508,0.016940529800150886,-0.5828100407728435,0.5601862448442396,LonGen OPEL,Nitric Oxide Signaling Pathway,CP:BIOCARTA,C2,21,22
Cohort,-0.016340679556814862,0.013669815647958833,-1.1953840474253097,0.2323561893775557,LGP Offspring,Proteolysis and Signaling Pathway of Notch,CP:BIOCARTA,C2,8,11
Cohort,-0.012188571174130067,0.04148880709433929,-0.2937797451349974,0.768999306786106,LGP Proband,Proteolysis and Signaling Pathway of Notch,CP:BIOCARTA,C2,8,21
Cohort,-5.240026955276591e-5,0.013732214672393547,-0.0038158644328586265,0.9969563441528045,LonGen OPEL,Proteolysis and Signaling Pathway of Notch,CP:BIOCARTA,C2,13,16
Cohort,-0.029725516308758224,0.022708437627824384,-1.3090075502303997,0.19097658366394474,LGP Offspring,Mechanism of Protein Import into the Nucleus,CP:BIOCARTA,C2,23,30
Cohort,-0.12129054344859501,0.0657634696480213,-1.8443452588156506,0.06548732730738058,LGP Proband,Mechanism of Protein Import into the Nucleus,CP:BIOCARTA,C2,23,46
Cohort,0.012249353717032053,0.021923416979250102,0.558733783544131,0.576500559551469,LonGen OPEL,Mechanism of Protein Import into the Nucleus,CP:BIOCARTA,C2,32,44
Cohort,-0.02346526028654581,0.018885148281653368,-1.2425245455627134,0.21447392799358972,LGP Offspring,Regulators of Bone Mineralization,CP:BIOCARTA,C2,15,20
Cohort,-0.03923664626051647,0.05128203570434076,-0.7651148344954506,0.4444196161934838,LGP Proband,Regulators of Bone Mineralization,CP:BIOCARTA,C2,15,28
Cohort,-0.0029968759264424475,0.01804956280903916,-0.16603592885594004,0.8681708376834246,LonGen OPEL,Regulators of Bone Mineralization,CP:BIOCARTA,C2,24,25
Cohort,0.038161886440331104,0.021384899703045083,1.7845249203996536,0.07478677723884666,LGP Offspring,NFkB activation by Nontypeable Hemophilus influenzae,CP:BIOCARTA,C2,9,37
Cohort,0.05428440132135712,0.05340774795127773,1.0164143481743348,0.30972688169622786,LGP Proband,NFkB activation by Nontypeable Hemophilus influenzae,CP:BIOCARTA,C2,9,39
Cohort,0.025696139061160445,0.023147127994255872,1.1101221312439766,0.2672816400953748,LonGen OPEL,NFkB activation by Nontypeable Hemophilus influenzae,CP:BIOCARTA,C2,31,48
Cohort,0.01277800760251417,0.03822716063930843,0.33426515045364713,0.7382831605206992,LGP Offspring,Nuclear Receptors in Lipid Metabolism and Toxicity,CP:BIOCARTA,C2,44,91
Cohort,0.04255056130882123,0.10947716444626653,0.38867065587642124,0.6976189937166293,LGP Proband,Nuclear Receptors in Lipid Metabolism and Toxicity,CP:BIOCARTA,C2,44,144
Cohort,0.01642712674621969,0.03322242221448382,0.4944590325222594,0.6211184634903362,LonGen OPEL,Nuclear Receptors in Lipid Metabolism and Toxicity,CP:BIOCARTA,C2,76,93
Cohort,-0.021716739857120484,0.01421101231470438,-1.5281627639327144,0.1269398856654106,LGP Offspring,Regulation of p27 Phosphorylation during Cell Cycle Progression,CP:BIOCARTA,C2,9,11
Cohort,3.7750362416819966e-4,0.03665335464720987,0.010299292596862918,0.9917849618133325,LGP Proband,Regulation of p27 Phosphorylation during Cell Cycle Progression,CP:BIOCARTA,C2,9,13
Cohort,0.00851972475996072,0.013956983545140893,0.6104273700979501,0.5417529803904869,LonGen OPEL,Regulation of p27 Phosphorylation during Cell Cycle Progression,CP:BIOCARTA,C2,11,17
Cohort,0.005209318071458611,0.01451565282762108,0.35887590681047915,0.7197999803532187,LGP Offspring,Deregulation of CDK5 in Alzheimers Disease,CP:BIOCARTA,C2,6,15
Cohort,0.05456663670384522,0.045197832094111746,1.207284380149596,0.22766492549584486,LGP Proband,Deregulation of CDK5 in Alzheimers Disease,CP:BIOCARTA,C2,6,26
Cohort,-0.010302607937629335,0.012245454890134996,-0.8413413817668114,0.40040938891363254,LonGen OPEL,Deregulation of CDK5 in Alzheimers Disease,CP:BIOCARTA,C2,12,11
Cohort,-0.015363104275123208,0.02675359563236279,-0.5742444674068056,0.5659934069408459,LGP Offspring,p38 MAPK Signaling Pathway,CP:BIOCARTA,C2,23,43
Cohort,-0.07135142757087756,0.07715258099373311,-0.9248093408135399,0.3553325952696631,LGP Proband,p38 MAPK Signaling Pathway,CP:BIOCARTA,C2,23,72
Cohort,8.769124833373434e-4,0.022874410642629083,0.038335959646676826,0.9694294324148295,LonGen OPEL,p38 MAPK Signaling Pathway,CP:BIOCARTA,C2,37,44
Cohort,-0.014672269065822134,0.021926044655905228,-0.6691708101520503,0.5036149901909225,LGP Offspring,p53 Signaling Pathway,CP:BIOCARTA,C2,17,31
Cohort,0.08413603553633393,0.05862393630208787,1.4351822965756302,0.15161006014008274,LGP Proband,p53 Signaling Pathway,CP:BIOCARTA,C2,17,38
Cohort,0.00977551062795169,0.021466348804595012,0.4553876729078016,0.6489545498265077,LonGen OPEL,p53 Signaling Pathway,CP:BIOCARTA,C2,32,38
Cohort,0.022013512493878475,0.02376788193077287,0.9261873884259342,0.35467913525907646,LGP Offspring,Hypoxia and p53 in the Cardiovascular system,CP:BIOCARTA,C2,13,40
Cohort,-0.006652146105975347,0.06618790067234667,-0.10050395976306611,0.9199683940935262,LGP Proband,Hypoxia and p53 in the Cardiovascular system,CP:BIOCARTA,C2,13,45
Cohort,0.02969630339640515,0.022018682031987112,1.3486866903870338,0.1778211938521813,LonGen OPEL,Hypoxia and p53 in the Cardiovascular system,CP:BIOCARTA,C2,27,40
Cohort,-0.007013653312739754,0.017105319380798675,-0.41002761518810504,0.6819155979612157,LGP Offspring,Thrombin signaling and protease-activated receptors,CP:BIOCARTA,C2,11,19
Cohort,-0.037681573456725195,0.052838073610780904,-0.7131519164437663,0.4759512497028484,LGP Proband,Thrombin signaling and protease-activated receptors,CP:BIOCARTA,C2,11,34
Cohort,0.026358546676558674,0.016747704962626557,1.5738602235577501,0.11591712121201307,LonGen OPEL,Thrombin signaling and protease-activated receptors,CP:BIOCARTA,C2,17,27
Cohort,0.010146496505942655,0.016724573692838755,0.6066819216018196,0.5442657103314315,LGP Offspring,Role of Parkin in the Ubiquitin-Proteasomal Pathway,CP:BIOCARTA,C2,9,20
Cohort,0.022866286787835203,0.04669261050502325,0.4897196053190305,0.6244611115059342,LGP Proband,Role of Parkin in the Ubiquitin-Proteasomal Pathway,CP:BIOCARTA,C2,9,25
Cohort,-0.00787453503147769,0.012591003310124664,-0.6254096546178832,0.5318814823218818,LonGen OPEL,Role of Parkin in the Ubiquitin-Proteasomal Pathway,CP:BIOCARTA,C2,12,10
Cohort,0.019523085038043744,0.022320374545229647,0.8746755122089228,0.38206113234675987,LGP Offspring,The information-processing pathway at the IFN-beta enhancer,CP:BIOCARTA,C2,14,38
Cohort,0.01508668470678783,0.053348233067036926,0.28279633343863575,0.7774031374375353,LGP Proband,The information-processing pathway at the IFN-beta enhancer,CP:BIOCARTA,C2,14,33
Cohort,-0.014203415348873592,0.021994909228049322,-0.6457592164445254,0.5186214098251622,LonGen OPEL,The information-processing pathway at the IFN-beta enhancer,CP:BIOCARTA,C2,35,37
Cohort,-0.019014589284915975,0.022786956642653768,-0.834450584301526,0.40432190215804575,LGP Offspring,PDGF Signaling Pathway,CP:BIOCARTA,C2,20,32
Cohort,0.009392905971691963,0.0645523047975424,0.14550845242708615,0.8843446017981653,LGP Proband,PDGF Signaling Pathway,CP:BIOCARTA,C2,20,46
Cohort,-0.014450739317858112,0.01980018871570385,-0.7298283630194391,0.4657098191261453,LonGen OPEL,PDGF Signaling Pathway,CP:BIOCARTA,C2,29,29
Cohort,-0.021260888109726265,0.03076180870908585,-0.6911455795980754,0.489711325357441,LGP Offspring,Synaptic Proteins at the Synaptic Junction,CP:BIOCARTA,C2,33,59
Cohort,-0.074372262455073,0.08390380439482381,-0.8863991685657244,0.3756579843813327,LGP Proband,Synaptic Proteins at the Synaptic Junction,CP:BIOCARTA,C2,33,83
Cohort,-0.008453631261402597,0.026527066538101676,-0.3186794608163845,0.750053190152796,LonGen OPEL,Synaptic Proteins at the Synaptic Junction,CP:BIOCARTA,C2,46,51
Cohort,0.006027913648018156,0.017380381729372098,0.3468228570510187,0.728832339150975,LGP Offspring,Pelp1 Modulation of Estrogen Receptor Activity,CP:BIOCARTA,C2,9,22
Cohort,0.03521233928721766,0.04033595851402333,0.8729763859454494,0.38292721928174756,LGP Proband,Pelp1 Modulation of Estrogen Receptor Activity,CP:BIOCARTA,C2,9,18
Cohort,-0.0159255814678729,0.017650348893002675,-0.9022813976321147,0.3671803430484317,LonGen OPEL,Pelp1 Modulation of Estrogen Receptor Activity,CP:BIOCARTA,C2,25,22
Cohort,0.005299285211815582,0.011014458914936028,0.48112079338092123,0.6305863371836378,LGP Offspring,Proepithelin Conversion to Epithelin and Wound Repair Control,CP:BIOCARTA,C2,3,9
Cohort,0.020530683057368403,0.03587444348610682,0.5722927260270774,0.5672779060733806,LGP Proband,Proepithelin Conversion to Epithelin and Wound Repair Control,CP:BIOCARTA,C2,3,16
Cohort,0.022368020773401418,0.011462635861696633,1.9513854442629597,0.051361630865614634,LonGen OPEL,Proepithelin Conversion to Epithelin and Wound Repair Control,CP:BIOCARTA,C2,5,15
Cohort,0.002912364270113145,0.019217195013232852,0.1515499149645777,0.8795871539695118,LGP Offspring,Regulation of PGC-1a,CP:BIOCARTA,C2,13,23
Cohort,-0.0049995796076263066,0.05529256302099117,-0.09042047129789,0.9279748003982754,LGP Proband,Regulation of PGC-1a,CP:BIOCARTA,C2,13,38
Cohort,-0.005921412196826904,0.018528601588405445,-0.3195822506395905,0.7493688867735524,LonGen OPEL,Regulation of PGC-1a,CP:BIOCARTA,C2,26,29
Cohort,-0.00819612595198495,0.023401055779497987,-0.350245990147406,0.7262631967921089,LGP Offspring,Multi-step Regulation of Transcription by Pitx2,CP:BIOCARTA,C2,19,34
Cohort,-0.016557283148561083,0.06247040727089539,-0.265042023445796,0.7910425813132316,LGP Proband,Multi-step Regulation of Transcription by Pitx2,CP:BIOCARTA,C2,19,47
Cohort,-0.03446030286652316,0.025163253415383075,-1.369469293086581,0.17123885209214232,LonGen OPEL,Multi-step Regulation of Transcription by Pitx2,CP:BIOCARTA,C2,47,41
Cohort,0.007192507258710027,0.015113788801722271,0.47589041722552156,0.6343062022498502,LGP Offspring,Activation of PKC through G protein coupled receptor,CP:BIOCARTA,C2,6,17
Cohort,0.018750677752812653,0.034780391156970736,0.539116356345366,0.5899504524518684,LGP Proband,Activation of PKC through G protein coupled receptor,CP:BIOCARTA,C2,6,14
Cohort,0.016292455482763715,0.013913480517776666,1.1709834546393718,0.24195584621607255,LonGen OPEL,Activation of PKC through G protein coupled receptor,CP:BIOCARTA,C2,10,20
Cohort,-0.01627409338320312,0.024249286438068993,-0.6711163821156566,0.5023756352730653,LGP Offspring,Platelet Amyloid Precursor Protein Pathway,CP:BIOCARTA,C2,21,38
Cohort,0.034116957178098074,0.06731022552655683,0.5068614302092547,0.612386029579792,LGP Proband,Platelet Amyloid Precursor Protein Pathway,CP:BIOCARTA,C2,21,52
Cohort,-0.025355939425743053,0.02136354930790894,-1.186878596823614,0.2356296015991573,LonGen OPEL,Platelet Amyloid Precursor Protein Pathway,CP:BIOCARTA,C2,38,34
Cohort,-0.027221331078692932,0.01532359075582167,-1.7764329204857632,0.07611127553853948,LGP Offspring,Phospholipase C Signaling Pathway,CP:BIOCARTA,C2,12,12
Cohort,-0.024653972588018942,0.040585920181120685,-0.6074513643647091,0.543716762741646,LGP Proband,Phospholipase C Signaling Pathway,CP:BIOCARTA,C2,12,14
Cohort,0.0024520218704307626,0.013084950802292978,0.18739251736438134,0.8514006433104611,LonGen OPEL,Phospholipase C Signaling Pathway,CP:BIOCARTA,C2,12,14
Cohort,-0.019248094795028245,0.014450642883940278,-1.331988822201095,0.18331275566884164,LGP Offspring,Phospholipase C d1 in phospholipid associated cell signaling,CP:BIOCARTA,C2,9,12
Cohort,-0.027366152136839496,0.03496024217701674,-0.7827792495908485,0.43397896065721786,LGP Proband,Phospholipase C d1 in phospholipid associated cell signaling,CP:BIOCARTA,C2,9,11
Cohort,0.003443119205693371,0.00818025178629272,0.42090626250195023,0.6739371479995643,LonGen OPEL,Phospholipase C d1 in phospholipid associated cell signaling,CP:BIOCARTA,C2,4,6
Cohort,-0.026910035734937422,0.013827647684319029,-1.9461036576347124,0.052056300008220535,LGP Offspring,Phospholipase C-epsilon pathway,CP:BIOCARTA,C2,10,9
Cohort,0.04868082763995271,0.050718172230043976,0.9598300865249951,0.3374189130296331,LGP Proband,Phospholipase C-epsilon pathway,CP:BIOCARTA,C2,10,31
Cohort,-0.002346862563057835,0.016449472309151225,-0.14267099387450993,0.8865861306389051,LonGen OPEL,Phospholipase C-epsilon pathway,CP:BIOCARTA,C2,20,22
Cohort,0.006753866454946139,0.01941667831388189,0.347838407052224,0.7280698248368593,LGP Offspring,Regulation of cell cycle progression by Plk3,CP:BIOCARTA,C2,10,26
Cohort,0.07002300097873795,0.05882356097686699,1.1903903778670466,0.23423171347265798,LGP Proband,Regulation of cell cycle progression by Plk3,CP:BIOCARTA,C2,10,45
Cohort,0.023677531949029492,0.021345484263510194,1.1092525077777646,0.2676562760572827,LonGen OPEL,Regulation of cell cycle progression by Plk3,CP:BIOCARTA,C2,30,40
Cohort,0.01831565127623381,0.023203323878461097,0.7893546360931349,0.43018152706527524,LGP Offspring,Regulation of transcriptional activity by PML,CP:BIOCARTA,C2,15,39
Cohort,-0.008882622137016485,0.06098741203758086,-0.14564681202643837,0.8842354045371659,LGP Proband,Regulation of transcriptional activity by PML,CP:BIOCARTA,C2,15,42
Cohort,0.0049147670420321326,0.021440863328021496,0.22922430719517364,0.8187534637027203,LonGen OPEL,Regulation of transcriptional activity by PML,CP:BIOCARTA,C2,33,36
Cohort,-0.05376838979906092,0.03872195058855842,-1.3885764787621113,0.165418922578416,LGP Offspring,Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),CP:BIOCARTA,C2,59,95
Cohort,0.06834216983822303,0.10436338775302127,0.6548481350562957,0.5127460957169806,LGP Proband,Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),CP:BIOCARTA,C2,59,141
Cohort,-0.07823770633431978,0.03889311042539596,-2.011608366587031,0.04459780924612398,LonGen OPEL,Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha),CP:BIOCARTA,C2,120,110
Cohort,0.023169951517613335,0.017207916009198805,1.3464705142230713,0.17860210676331728,LGP Offspring,Role of PPAR-gamma Coactivators in Obesity and Thermogenesis,CP:BIOCARTA,C2,6,22
Cohort,0.02917070885295392,0.04125511921227869,0.7070809492236758,0.4797136884789046,LGP Proband,Role of PPAR-gamma Coactivators in Obesity and Thermogenesis,CP:BIOCARTA,C2,6,22
Cohort,-0.027497978790695123,0.018728640250784793,-1.4682314584766967,0.14243639669144464,LonGen OPEL,Role of PPAR-gamma Coactivators in Obesity and Thermogenesis,CP:BIOCARTA,C2,28,19
Cohort,0.005012689816515043,0.010126803148849362,0.49499232312860747,0.6207663829400336,LGP Offspring,The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,CP:BIOCARTA,C2,2,8
Cohort,0.00741659370444233,0.03317685084895461,0.22354724799554096,0.8231643595213615,LGP Proband,The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,CP:BIOCARTA,C2,2,16
Cohort,-0.0022644204790462754,0.01108039577843689,-0.20436277948238749,0.8381222535113411,LonGen OPEL,The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails,CP:BIOCARTA,C2,7,12
Cohort,-2.6077079711453314e-4,0.019947374831410097,-0.013072938134391041,0.9895734587151354,LGP Offspring,Prion Pathway,CP:BIOCARTA,C2,13,28
Cohort,0.012349720493631217,0.0541107806986276,0.22823031444350314,0.8195231407307608,LGP Proband,Prion Pathway,CP:BIOCARTA,C2,13,37
Cohort,0.009995414247536812,0.018804283302909806,0.5315498648113913,0.5951860967924358,LonGen OPEL,Prion Pathway,CP:BIOCARTA,C2,25,31
Cohort,4.815384954007896e-4,0.015476865973401718,0.0311134370633146,0.9751882571867148,LGP Offspring,Proteasome Complex,CP:BIOCARTA,C2,7,16
Cohort,4.53732768991734e-4,0.039899498178542915,0.01137189162032473,0.9909294584370014,LGP Proband,Proteasome Complex,CP:BIOCARTA,C2,7,16
Cohort,-0.02329508809000279,0.01615216693721445,-1.4422268034099568,0.1496317345152113,LonGen OPEL,Proteasome Complex,CP:BIOCARTA,C2,18,12
Cohort,-0.01833695339878913,0.022634910719776677,-0.8101182118985645,0.4181573202950135,LGP Offspring,Presenilin action in Notch and Wnt signaling,CP:BIOCARTA,C2,18,31
Cohort,0.004645809760193662,0.06622846793916697,0.07014822937563635,0.9440924959569132,LGP Proband,Presenilin action in Notch and Wnt signaling,CP:BIOCARTA,C2,18,53
Cohort,-0.030504141329416302,0.022488470000686343,-1.35643471203178,0.17534548769440822,LonGen OPEL,Presenilin action in Notch and Wnt signaling,CP:BIOCARTA,C2,41,37
Cohort,-0.023835694010107777,0.018583832643542516,-1.2826037807863153,0.20007053769275734,LGP Offspring,Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,CP:BIOCARTA,C2,14,21
Cohort,-0.01422044792433276,0.05000952516475022,-0.28435478796259805,0.7762090889596894,LGP Proband,Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,CP:BIOCARTA,C2,14,28
Cohort,0.011017952314988763,0.013001603498488272,0.8474302662952187,0.3970100627186173,LonGen OPEL,Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle,CP:BIOCARTA,C2,10,16
Cohort,-0.013383143957558755,0.02827652029651557,-0.4732952929575256,0.6361553151499102,LGP Offspring,Phosphoinositides and their downstream targets.,CP:BIOCARTA,C2,28,51
Cohort,-0.07510087655647012,0.07546474751526276,-0.9951782657363419,0.31993821469609035,LGP Proband,Phosphoinositides and their downstream targets.,CP:BIOCARTA,C2,28,66
Cohort,-0.015385790296747418,0.021236130766939396,-0.7245100562622339,0.46896555136615015,LonGen OPEL,Phosphoinositides and their downstream targets.,CP:BIOCARTA,C2,35,38
Cohort,0.007659596763264301,0.026958502358115775,0.28412545554328256,0.7764012448284282,LGP Offspring,PTEN dependent cell cycle arrest and apoptosis,CP:BIOCARTA,C2,22,46
Cohort,-0.11561330712470523,0.06470409124097887,-1.7868005702162488,0.0743328388488132,LGP Proband,PTEN dependent cell cycle arrest and apoptosis,CP:BIOCARTA,C2,22,49
Cohort,-0.04841945029689794,0.023023560239007458,-2.103039225656496,0.03577570514988461,LonGen OPEL,PTEN dependent cell cycle arrest and apoptosis,CP:BIOCARTA,C2,43,31
Cohort,-0.025243306318765858,0.030943686372271788,-0.8157821280591196,0.414912101481663,LGP Offspring,Links between Pyk2 and Map Kinases,CP:BIOCARTA,C2,34,57
Cohort,-0.0635310454925346,0.08340156156270764,-0.76174887258876,0.44642525146556855,LGP Proband,Links between Pyk2 and Map Kinases,CP:BIOCARTA,C2,34,76
Cohort,0.004676834837230426,0.025369656955154425,0.18434757890095238,0.8537877444864995,LonGen OPEL,Links between Pyk2 and Map Kinases,CP:BIOCARTA,C2,45,55
Cohort,0,0,NA,NA,LGP Offspring,Rab GTPases Mark Targets In The Endocytotic Machinery,CP:BIOCARTA,C2,0,0
Cohort,-0.004086836548470844,0.01373686572793963,-0.29750866241333074,0.7661522851172096,LGP Proband,Rab GTPases Mark Targets In The Endocytotic Machinery,CP:BIOCARTA,C2,0,3
Cohort,-0.0036519233980563943,0.00448631771235106,-0.814013547904212,0.4158806280988745,LonGen OPEL,Rab GTPases Mark Targets In The Endocytotic Machinery,CP:BIOCARTA,C2,2,1
Cohort,0.012943064358996169,0.027151368236342864,0.47670026226050427,0.6337296278672956,LGP Offspring,Rac 1 cell motility signaling pathway,CP:BIOCARTA,C2,23,48
Cohort,-0.2041750536053565,0.0774183056119393,-2.6372968510675987,0.008512534030487769,LGP Proband,Rac 1 cell motility signaling pathway,CP:BIOCARTA,C2,23,71
Cohort,0.01700629704942509,0.025166657548542106,0.6757471474558312,0.49939746173062727,LonGen OPEL,Rac 1 cell motility signaling pathway,CP:BIOCARTA,C2,41,53
Cohort,-0.00727154231232648,0.012957134970538383,-0.5611998585227627,0.5748472782748368,LGP Offspring,Ion Channels and Their Functional Role in Vascular Endothelium,CP:BIOCARTA,C2,7,8
Cohort,-0.07851152549953162,0.04113682715382328,-1.9085459655396568,0.056663730255562726,LGP Proband,Ion Channels and Their Functional Role in Vascular Endothelium,CP:BIOCARTA,C2,7,19
Cohort,-0.005788417391305149,0.010265700406784374,-0.5638599571325608,0.5730082630682356,LonGen OPEL,Ion Channels and Their Functional Role in Vascular Endothelium,CP:BIOCARTA,C2,8,8
Cohort,-0.007912515437501506,0.02474719472465741,-0.31973383349255735,0.7492688984883937,LGP Offspring,Influence of Ras and Rho proteins on G1 to S Transition,CP:BIOCARTA,C2,18,40
Cohort,0.015498116856298727,0.06033390774562189,0.2568724194302389,0.7973406180925149,LGP Proband,Influence of Ras and Rho proteins on G1 to S Transition,CP:BIOCARTA,C2,18,39
Cohort,-0.007434859445487288,0.024548054422519817,-0.30286960088644416,0.7620683697293833,LonGen OPEL,Influence of Ras and Rho proteins on G1 to S Transition,CP:BIOCARTA,C2,38,42
Cohort,-6.888494705387272e-4,0.00557069721294866,-0.12365588080026127,0.9016245022224982,LGP Offspring,Cycling of Ran in nucleocytoplasmic transport,CP:BIOCARTA,C2,1,2
Cohort,0.005229441171880486,0.015819714018845268,0.3305648361058173,0.7410562361611202,LGP Proband,Cycling of Ran in nucleocytoplasmic transport,CP:BIOCARTA,C2,1,3
Cohort,-0.0016203954966487713,0.003673621007395577,-0.44108945734648736,0.6592680124738174,LonGen OPEL,Cycling of Ran in nucleocytoplasmic transport,CP:BIOCARTA,C2,1,1
Cohort,0.009553563855941234,0.01054205728970528,0.9062333464333051,0.36513525152847703,LGP Offspring,Sumoylation by RanBP2 Regulates Transcriptional Repression,CP:BIOCARTA,C2,3,9
Cohort,0.021987866632301577,0.0271344643617441,0.810329857231362,0.4179817757918437,LGP Proband,Sumoylation by RanBP2 Regulates Transcriptional Repression,CP:BIOCARTA,C2,3,10
Cohort,0.014843540677695069,0.011445215485720504,1.2969210318682465,0.19503415656513515,LonGen OPEL,Sumoylation by RanBP2 Regulates Transcriptional Repression,CP:BIOCARTA,C2,6,14
Cohort,-0.004847556553407662,0.017609649438634318,-0.2752784244967687,0.783186456962246,LGP Offspring,Bone Remodelling,CP:BIOCARTA,C2,9,18
Cohort,0.002101003338585552,0.044726606839246466,0.04697435122089286,0.9625449154456024,LGP Proband,Bone Remodelling,CP:BIOCARTA,C2,9,20
Cohort,0.02198087038787901,0.016542453466708795,1.328755159088999,0.18430953310008438,LonGen OPEL,Bone Remodelling,CP:BIOCARTA,C2,14,29
Cohort,-0.015532785806346372,0.017990275623575434,-0.8633989901739674,0.3882243564084905,LGP Offspring,Role of Ran in mitotic spindle regulation,CP:BIOCARTA,C2,14,20
Cohort,-0.03951556170062919,0.05022579135185155,-0.7867583692969025,0.4316468289118264,LGP Proband,Role of Ran in mitotic spindle regulation,CP:BIOCARTA,C2,14,29
Cohort,-0.013676887832818051,0.01439188625956849,-0.9503193386985622,0.3422384590808665,LonGen OPEL,Role of Ran in mitotic spindle regulation,CP:BIOCARTA,C2,16,16
Cohort,-0.034265534320228455,0.020573201635780903,-1.6655421419986403,0.09626795511222923,LGP Offspring,Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells,CP:BIOCARTA,C2,18,24
Cohort,0.0059411210655785675,0.05570850497417282,0.1066465716201314,0.9150950174591745,LGP Proband,Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells,CP:BIOCARTA,C2,18,33
Cohort,-0.011624520864487068,0.018736540170184918,-0.6204198191822489,0.5351590090340353,LonGen OPEL,Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells,CP:BIOCARTA,C2,28,28
Cohort,-0.01081226036756414,0.021471649536397852,-0.5035598382525591,0.6147347691628495,LGP Offspring,Ras Signaling Pathway,CP:BIOCARTA,C2,16,31
Cohort,-0.020123160346790833,0.05283400472473773,-0.380875166507468,0.7033928762173383,LGP Proband,Ras Signaling Pathway,CP:BIOCARTA,C2,16,32
Cohort,-0.02341657788463069,0.020892007834430924,-1.1208390342473051,0.2626944195894264,LonGen OPEL,Ras Signaling Pathway,CP:BIOCARTA,C2,34,31
Cohort,-0.0018743647907705472,0.020306723201864312,-0.09230267099905445,0.9264849127397112,LGP Offspring,RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,CP:BIOCARTA,C2,13,29
Cohort,0.05292632521390893,0.05915598739361967,0.8946909272554439,0.37121045683741805,LGP Proband,RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,CP:BIOCARTA,C2,13,45
Cohort,0.024686935274671938,0.020329317795046445,1.2143513876637462,0.22497370270164327,LonGen OPEL,RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage,CP:BIOCARTA,C2,25,37
Cohort,0.044054255449314156,0.019936456482411467,2.2097334843922805,0.02745805567966299,LGP Offspring,Inhibition of Matrix Metalloproteinases,CP:BIOCARTA,C2,6,34
Cohort,-0.007865315231237157,0.04883181380382171,-0.16106948766710763,0.8720776794827091,LGP Proband,Inhibition of Matrix Metalloproteinases,CP:BIOCARTA,C2,6,34
Cohort,-0.026702856358502336,0.018112630845652948,-1.4742671335849067,0.14080504671350955,LonGen OPEL,Inhibition of Matrix Metalloproteinases,CP:BIOCARTA,C2,29,23
Cohort,-0.020168446961984932,0.014864092484086431,-1.3568569344934693,0.17527957504023367,LGP Offspring,Reelin Signaling Pathway,CP:BIOCARTA,C2,9,13
Cohort,0.044275606474014545,0.04879113327043051,0.907451897635004,0.3644299961014469,LGP Proband,Reelin Signaling Pathway,CP:BIOCARTA,C2,9,31
Cohort,-0.010438544443135321,0.013031731697535005,-0.8010097725622917,0.4233650094817034,LonGen OPEL,Reelin Signaling Pathway,CP:BIOCARTA,C2,13,11
Cohort,0.02889241704930841,0.021391050604116155,1.350677794373915,0.17725061722519714,LGP Offspring,Acetylation and Deacetylation of RelA in The Nucleus,CP:BIOCARTA,C2,9,34
Cohort,0.0037735809191146263,0.04812655287893887,0.07840954095771152,0.9375210923861574,LGP Proband,Acetylation and Deacetylation of RelA in The Nucleus,CP:BIOCARTA,C2,9,27
Cohort,0.002779946095653451,0.021664111073776835,0.12832033985545876,0.8979278816600433,LonGen OPEL,Acetylation and Deacetylation of RelA in The Nucleus,CP:BIOCARTA,C2,29,34
Cohort,0.016706719583060126,0.026752516376412207,0.6244915187787906,0.5325155429866777,LGP Offspring,Rho cell motility signaling pathway,CP:BIOCARTA,C2,22,53
Cohort,-0.1340166739265028,0.07456443067803774,-1.7973271264575774,0.07264535944325916,LGP Proband,Rho cell motility signaling pathway,CP:BIOCARTA,C2,22,74
Cohort,-0.018786064918430385,0.024685880602650635,-0.7610044470689549,0.446879785736807,LonGen OPEL,Rho cell motility signaling pathway,CP:BIOCARTA,C2,43,45
Cohort,0.016505660847119033,0.02353443245595965,0.70134093431003,0.4833316328273507,LGP Offspring,Visual Signal Transduction,CP:BIOCARTA,C2,14,37
Cohort,0.033041692931494615,0.060904814863850194,0.5425136420717761,0.5876096466449532,LGP Proband,Visual Signal Transduction,CP:BIOCARTA,C2,14,44
Cohort,0.018244705605967537,0.019462949062920357,0.9374070469477955,0.3488335427646445,LonGen OPEL,Visual Signal Transduction,CP:BIOCARTA,C2,22,32
Cohort,0.01352577423289513,0.01631096037983283,0.8292445029551199,0.40725877733706684,LGP Offspring,Double Stranded RNA Induced Gene Expression,CP:BIOCARTA,C2,6,21
Cohort,0.09707515231936394,0.04096458510430973,2.3697335655219662,0.018027621590060734,LGP Proband,Double Stranded RNA Induced Gene Expression,CP:BIOCARTA,C2,6,20
Cohort,0.014596090646796137,0.01413719844904312,1.0324599105973558,0.3021703016436871,LonGen OPEL,Double Stranded RNA Induced Gene Expression,CP:BIOCARTA,C2,11,20
Cohort,0.0072001592492823684,0.013500415752247995,0.5333287049388422,0.5939813573964934,LGP Offspring,RNA polymerase III transcription,CP:BIOCARTA,C2,4,14
Cohort,-0.00543703850913492,0.032045281548931,-0.16966736587515782,0.8653128854699641,LGP Proband,RNA polymerase III transcription,CP:BIOCARTA,C2,4,11
Cohort,0.003046972631054886,0.009639020829146642,0.31610810735478406,0.7520033224870305,LonGen OPEL,RNA polymerase III transcription,CP:BIOCARTA,C2,6,8
Cohort,-0.0029197671218378156,0.012727409140040506,-0.22940781503222135,0.8186213538759384,LGP Offspring,SREBP control of lipid synthesis,CP:BIOCARTA,C2,5,11
Cohort,-0.025427487297069597,0.04713540455851761,-0.5394562226680776,0.5897160833045292,LGP Proband,SREBP control of lipid synthesis,CP:BIOCARTA,C2,5,30
Cohort,0.0048802042003230055,0.011769519682743599,0.4146476943726372,0.6785115491648883,LonGen OPEL,SREBP control of lipid synthesis,CP:BIOCARTA,C2,8,13
Cohort,0.0066787949814823165,0.005547810621983847,1.2038613854295626,0.2290645332153889,LGP Offspring,How does salmonella hijack a cell,CP:BIOCARTA,C2,0,3
Cohort,0.003430244777895926,0.01368151807282855,0.25072106469737304,0.8020915271744459,LGP Proband,How does salmonella hijack a cell,CP:BIOCARTA,C2,0,3
Cohort,0.0015946976194641486,0.0050083292958569255,0.31840909917471705,0.750258159270279,LonGen OPEL,How does salmonella hijack a cell,CP:BIOCARTA,C2,2,2
Cohort,-5.194772063090145e-4,0.005563045457297863,-0.09338000386596519,0.9256293440601004,LGP Offspring,Regulation of Splicing through Sam68,CP:BIOCARTA,C2,1,2
Cohort,0.03621826097323743,0.019297602827735447,1.8768269456340347,0.060890740150906474,LGP Proband,Regulation of Splicing through Sam68,CP:BIOCARTA,C2,1,5
Cohort,-0.01319911548713017,0.008058138676624185,-1.6379856461665794,0.10181988913721254,LonGen OPEL,Regulation of Splicing through Sam68,CP:BIOCARTA,C2,7,3
Cohort,0.010735478737064204,0.00906555728132937,1.1842050525866799,0.23674810786909445,LGP Offspring,SARS Coronavirus Protease,CP:BIOCARTA,C2,1,7
Cohort,0.013129056322728875,0.017659463766543232,0.7434572474166827,0.45741427770131504,LGP Proband,SARS Coronavirus Protease,CP:BIOCARTA,C2,1,4
Cohort,0.006283917579194447,0.006343887547070119,0.9905468110160041,0.3222079230100443,LonGen OPEL,SARS Coronavirus Protease,CP:BIOCARTA,C2,1,5
Cohort,0.022992144300596557,0.01797117172235854,1.2793903845452246,0.2011985676454487,LGP Offspring,Granzyme A mediated Apoptosis Pathway,CP:BIOCARTA,C2,8,25
Cohort,-0.02055521796220574,0.04184826304631824,-0.4911844952669825,0.6234251909238788,LGP Proband,Granzyme A mediated Apoptosis Pathway,CP:BIOCARTA,C2,8,21
Cohort,-0.007082548409817367,0.018538864785656074,-0.38203786972421794,0.7025352447049737,LonGen OPEL,Granzyme A mediated Apoptosis Pathway,CP:BIOCARTA,C2,24,26
Cohort,-0.041769353352709204,0.02408878454209078,-1.7339751318595937,0.08337839678994763,LGP Offspring,Sonic Hedgehog (Shh) Pathway,CP:BIOCARTA,C2,26,36
Cohort,0.08402562197894382,0.0746042944169852,1.1262839845290953,0.26036930876538256,LGP Proband,Sonic Hedgehog (Shh) Pathway,CP:BIOCARTA,C2,26,71
Cohort,-0.022273964417742716,0.023974961502846063,-0.9290511025470709,0.3531442433229366,LonGen OPEL,Sonic Hedgehog (Shh) Pathway,CP:BIOCARTA,C2,46,44
Cohort,-0.027996805804632312,0.014504317496402276,-1.930239448466071,0.05399517385750808,LGP Offspring,E2F1 Destruction Pathway,CP:BIOCARTA,C2,10,11
Cohort,0.008259421882634892,0.03632443038681102,0.22737925398091838,0.8201845773860368,LGP Proband,E2F1 Destruction Pathway,CP:BIOCARTA,C2,10,12
Cohort,0.00851972475996072,0.013956983545140893,0.6104273700979501,0.5417529803904869,LonGen OPEL,E2F1 Destruction Pathway,CP:BIOCARTA,C2,11,17
Cohort,0.002306921599374886,0.013017847708516973,0.1772122128810567,0.8593947858573592,LGP Offspring,Small Leucine-rich Proteoglycan (SLRP) molecules,CP:BIOCARTA,C2,6,11
Cohort,0.04746781982013355,0.03982387213998589,1.1919438585298345,0.2336223130659541,LGP Proband,Small Leucine-rich Proteoglycan (SLRP) molecules,CP:BIOCARTA,C2,6,18
Cohort,-0.010123217188786645,0.01055628174264688,-0.9589756540780192,0.33786219211944535,LonGen OPEL,Small Leucine-rich Proteoglycan (SLRP) molecules,CP:BIOCARTA,C2,9,8
Cohort,-0.0019798585570834095,0.0045419535280490355,-0.43590462668908986,0.663045090417991,LGP Offspring,Spliceosomal Assembly,CP:BIOCARTA,C2,1,1
Cohort,8.514909911152218e-4,0.013566307363974624,0.06276512600446892,0.9499685755145462,LGP Proband,Spliceosomal Assembly,CP:BIOCARTA,C2,1,2
Cohort,-0.003823092481011406,0.005205990374889684,-0.7343641085952677,0.46294312033614626,LonGen OPEL,Spliceosomal Assembly,CP:BIOCARTA,C2,3,1
Cohort,-0.0041863722455576366,0.00321047734819774,-1.3039718993525162,0.1926870044810775,LGP Offspring,SODD/TNFR1 Signaling Pathway,CP:BIOCARTA,C2,1,0
Cohort,0.016036375766897377,0.01577634898143252,1.016482063484453,0.3096946697173111,LGP Proband,SODD/TNFR1 Signaling Pathway,CP:BIOCARTA,C2,1,3
Cohort,0,0,NA,NA,LonGen OPEL,SODD/TNFR1 Signaling Pathway,CP:BIOCARTA,C2,0,0
Cohort,-0.010359472708167726,0.012217881773728014,-0.8478943322600808,0.3967969293491366,LGP Offspring,Aspirin Blocks Signaling Pathway Involved in Platelet Activation,CP:BIOCARTA,C2,6,9
Cohort,0.059555476713826355,0.041745904878906996,1.4266184165028848,0.1540641504158247,LGP Proband,Aspirin Blocks Signaling Pathway Involved in Platelet Activation,CP:BIOCARTA,C2,6,23
Cohort,-0.016064106455284333,0.012485618439637868,-1.2866087917828646,0.19860473293655298,LonGen OPEL,Aspirin Blocks Signaling Pathway Involved in Platelet Activation,CP:BIOCARTA,C2,12,10
Cohort,0.04190520578362008,0.023180203106622197,1.8078014929752044,0.07108174623967269,LGP Offspring,Sprouty regulation of tyrosine kinase signals,CP:BIOCARTA,C2,11,41
Cohort,0.08244203886483065,0.05674321449708182,1.4528968722607434,0.14662852356451764,LGP Proband,Sprouty regulation of tyrosine kinase signals,CP:BIOCARTA,C2,11,40
Cohort,-0.005949107590173144,0.017209105167870713,-0.3456953474420093,0.729663021220881,LonGen OPEL,Sprouty regulation of tyrosine kinase signals,CP:BIOCARTA,C2,20,22
Cohort,0.0029888987286403735,0.01653387606947753,0.18077423080230107,0.85659897290184706,LGP Offspring,Activation of Src by Protein-tyrosine phosphatase alpha,CP:BIOCARTA,C2,7,18
Cohort,0.015047871100576374,0.045528072308488376,0.3305185204990726,0.7410912133831205,LGP Proband,Activation of Src by Protein-tyrosine phosphatase alpha,CP:BIOCARTA,C2,7,27
Cohort,0.00586717750526267,0.011666224817879406,0.5029199759866413,0.6151596543920126,LonGen OPEL,Activation of Src by Protein-tyrosine phosphatase alpha,CP:BIOCARTA,C2,9,12
Cohort,-0.018016682365846942,0.019271383327090174,-0.934893051528923,0.3501772484239176,LGP Offspring,Stat3 Signaling Pathway,CP:BIOCARTA,C2,14,22
Cohort,-0.003430910207043998,0.05355384972310126,-0.0640646792860537,0.9489340775383359,LGP Proband,Stat3 Signaling Pathway,CP:BIOCARTA,C2,14,30
Cohort,-0.029930080124454583,0.01757490860820924,-1.703000612502431,0.0889583252558801,LonGen OPEL,Stat3 Signaling Pathway,CP:BIOCARTA,C2,28,19
Cohort,-0.01692227145477758,0.01626182708104926,-1.0406131715973028,0.29842714553426264,LGP Offspring,Stathmin and breast cancer resistance to antimicrotubule agents,CP:BIOCARTA,C2,11,16
Cohort,0.10096954012450798,0.050398249169975325,2.003433488016096,0.04545387329452925,LGP Proband,Stathmin and breast cancer resistance to antimicrotubule agents,CP:BIOCARTA,C2,11,33
Cohort,-0.012022462679622134,0.01663009909350896,-0.7229339171114577,0.46993284157180404,LonGen OPEL,Stathmin and breast cancer resistance to antimicrotubule agents,CP:BIOCARTA,C2,22,21
Cohort,0.011923484431325126,0.009601236927480916,1.241869617569525,0.21471535726044358,LGP Offspring,Regulation of hematopoiesis by cytokines,CP:BIOCARTA,C2,1,8
Cohort,-0.04363104501461581,0.024899690113590195,-1.7522726112483658,0.08009442027422346,LGP Proband,Regulation of hematopoiesis by cytokines,CP:BIOCARTA,C2,1,7
Cohort,0.006096319714531792,0.009669384075295493,0.6304765295348442,0.5285638110892642,LonGen OPEL,Regulation of hematopoiesis by cytokines,CP:BIOCARTA,C2,5,9
Cohort,0.005732538480743033,0.02501645791900496,0.2291506854928504,0.8188211098472907,LGP Offspring,TNF/Stress Related Signaling,CP:BIOCARTA,C2,17,43
Cohort,0.051391127175155524,0.06883845389568952,0.7465467956765587,0.455547564472373,LGP Proband,TNF/Stress Related Signaling,CP:BIOCARTA,C2,17,58
Cohort,0.01091133533404601,0.02390384565930659,0.4564677788487081,0.6481781583168602,LonGen OPEL,TNF/Stress Related Signaling,CP:BIOCARTA,C2,33,43
Cohort,0.018083319832192492,0.011065322840069315,1.6342333697404545,0.10267543616588493,LGP Offspring,Basic Mechanisms of SUMOylation,CP:BIOCARTA,C2,1,11
Cohort,0.0276788054808763,0.03003738379018342,0.9214785706444271,0.35706709997260033,LGP Proband,Basic Mechanisms of SUMOylation,CP:BIOCARTA,C2,1,14
Cohort,-0.0017434858870013568,0.007637898885494028,-0.22826773608021994,0.8194967306763061,LonGen OPEL,Basic Mechanisms of SUMOylation,CP:BIOCARTA,C2,4,5
Cohort,-0.0024026333895051572,0.02201970455731174,-0.10911288038636978,0.9131453392774468,LGP Offspring,TACI and BCMA stimulation of B cell immune responses.,CP:BIOCARTA,C2,13,31
Cohort,0.029426645379120948,0.053842556209867214,0.5465313582888215,0.5848469194890402,LGP Proband,TACI and BCMA stimulation of B cell immune responses.,CP:BIOCARTA,C2,13,30
Cohort,0.025155667039324998,0.01742359636524276,1.4437700754768668,0.1491971085896933,LonGen OPEL,TACI and BCMA stimulation of B cell immune responses.,CP:BIOCARTA,C2,18,30
Cohort,-0.008545260559336344,0.008310798233676458,-1.0282117696841457,0.3042179800207068,LGP Offspring,HIV Induced T Cell Apoptosis,CP:BIOCARTA,C2,5,3
Cohort,-0.05007966991298906,0.025709629783189004,-1.9478954125483021,0.0517626515833211,LGP Proband,HIV Induced T Cell Apoptosis,CP:BIOCARTA,C2,5,7
Cohort,-5.991162840092628e-4,0.00853512045585154,-0.07019423886378995,0.9440566902365098,LonGen OPEL,HIV Induced T Cell Apoptosis,CP:BIOCARTA,C2,6,5
Cohort,-0.008033451239604913,0.03224156127124484,-0.24916446111341625,0.8033092540157878,LGP Offspring,T Cell Receptor Signaling Pathway,CP:BIOCARTA,C2,34,66
Cohort,-0.05372228234030429,0.08696477491349683,-0.6177476155574647,0.5369103569439942,LGP Proband,T Cell Receptor Signaling Pathway,CP:BIOCARTA,C2,34,81
Cohort,-0.0016292654992793353,0.028691975809932064,-0.056784709079370756,0.954730945096997,LonGen OPEL,T Cell Receptor Signaling Pathway,CP:BIOCARTA,C2,55,65
Cohort,0.0072045821115188395,0.02064175496512403,0.3490295337625886,0.7271758243930155,LGP Offspring,Lck and Fyn tyrosine kinases in initiation of TCR Activation,CP:BIOCARTA,C2,11,31
Cohort,0.024083167727435652,0.05298699123129174,0.4545109500992616,0.6495793835208973,LGP Proband,Lck and Fyn tyrosine kinases in initiation of TCR Activation,CP:BIOCARTA,C2,11,34
Cohort,0.02745406076171279,0.019739509463756168,1.3908177815726046,0.1646693549118256,LonGen OPEL,Lck and Fyn tyrosine kinases in initiation of TCR Activation,CP:BIOCARTA,C2,19,32
Cohort,-0.008114647418922346,0.005540046208883552,-1.464725584041227,0.14346069928966346,LGP Offspring,T Cytotoxic Cell Surface Molecules,CP:BIOCARTA,C2,2,1
Cohort,0.008795327005927878,0.019197902026463678,0.458140008934508,0.6469712013481712,LGP Proband,T Cytotoxic Cell Surface Molecules,CP:BIOCARTA,C2,2,4
Cohort,0.007892581177746794,0.00578248960818713,1.3649105683773464,0.17266682654249466,LonGen OPEL,T Cytotoxic Cell Surface Molecules,CP:BIOCARTA,C2,1,4
Cohort,-0.031119728226352127,0.021938935814037476,-1.4184702708524441,0.15651435556464188,LGP Offspring,"Telomeres, Telomerase, Cellular Aging, and  Immortality",CP:BIOCARTA,C2,20,28
Cohort,0.10418025188972628,0.06104875936831826,1.7065089113635854,0.08828563533870215,LGP Proband,"Telomeres, Telomerase, Cellular Aging, and  Immortality",CP:BIOCARTA,C2,20,44
Cohort,0.0022494122925973445,0.02024727819760401,0.11109702107335749,0.9115674167515562,LonGen OPEL,"Telomeres, Telomerase, Cellular Aging, and  Immortality",CP:BIOCARTA,C2,30,34
Cohort,-0.003794264943581172,0.011497874263129721,-0.32999708091679664,0.7415044030101794,LGP Offspring,Overview of telomerase RNA component gene hTerc Transcriptional Regulation,CP:BIOCARTA,C2,4,9
Cohort,0.0012774698278825,0.03416141133148829,0.037395112733676544,0.970178918262608,LGP Proband,Overview of telomerase RNA component gene hTerc Transcriptional Regulation,CP:BIOCARTA,C2,4,13
Cohort,0.01609073654241573,0.015247226433940551,1.055322199885319,0.29159818846777324,LonGen OPEL,Overview of telomerase RNA component gene hTerc Transcriptional Regulation,CP:BIOCARTA,C2,13,21
Cohort,-0.0016861343423799323,0.007881221923173372,-0.21394326397815872,0.8306558143496446,LGP Offspring,Overview of telomerase protein component gene hTert Transcriptional Regulation,CP:BIOCARTA,C2,2,4
Cohort,0.09220745877287524,0.029125092989017973,3.165911223275523,0.0016021470533689726,LGP Proband,Overview of telomerase protein component gene hTert Transcriptional Regulation,CP:BIOCARTA,C2,2,10
Cohort,0.0017506307959627803,0.006763712720381591,0.25882690000825676,0.7958357159506544,LonGen OPEL,Overview of telomerase protein component gene hTert Transcriptional Regulation,CP:BIOCARTA,C2,2,5
Cohort,-0.01490726094530346,0.018922368157889488,-0.7878115900143308,0.4310830667125165,LGP Offspring,Trefoil Factors Initiate  Mucosal Healing,CP:BIOCARTA,C2,14,23
Cohort,0.0798008071258447,0.053737171707834236,1.4850206028653103,0.13791622899278314,LGP Proband,Trefoil Factors Initiate  Mucosal Healing,CP:BIOCARTA,C2,14,36
Cohort,-0.02419420621851216,0.021270135181881693,-1.1374730819351466,0.2556828434816071,LonGen OPEL,Trefoil Factors Initiate  Mucosal Healing,CP:BIOCARTA,C2,32,28
Cohort,-0.0021609155060603085,0.025263006256698826,-0.08553675220213797,0.931860005416507,LGP Offspring,TGF beta signaling pathway,CP:BIOCARTA,C2,20,43
Cohort,0.09321769491026013,0.062054084210555006,1.5022007994504316,0.1334237779378067,LGP Proband,TGF beta signaling pathway,CP:BIOCARTA,C2,20,46
Cohort,-0.02611965505764709,0.02488044919490072,-1.0498064103681999,0.2941257459684865,LonGen OPEL,TGF beta signaling pathway,CP:BIOCARTA,C2,47,45
Cohort,0.023419207458164597,0.022453677130639647,1.0430009891879766,0.2973206800275042,LGP Offspring,Th1/Th2 Differentiation,CP:BIOCARTA,C2,12,39
Cohort,0.02323423310488904,0.06107183626779858,0.38044104328233175,0.7037149260961111,LGP Proband,Th1/Th2 Differentiation,CP:BIOCARTA,C2,12,45
Cohort,0.015375313327214478,0.02163021609983156,0.7108256919973263,0.4774004775295977,LonGen OPEL,Th1/Th2 Differentiation,CP:BIOCARTA,C2,28,37
Cohort,-0.008114647418922346,0.005540046208883552,-1.464725584041227,0.14346069928966346,LGP Offspring,T Helper Cell Surface Molecules,CP:BIOCARTA,C2,2,1
Cohort,0.008795327005927878,0.019197902026463678,0.458140008934508,0.6469712013481712,LGP Proband,T Helper Cell Surface Molecules,CP:BIOCARTA,C2,2,4
Cohort,0.005787862440643515,0.005192128090004976,1.114737991881469,0.26529916411645155,LonGen OPEL,T Helper Cell Surface Molecules,CP:BIOCARTA,C2,1,3
Cohort,0.006316502807849068,0.02402590998199584,0.2629037906402892,0.7927048400731194,LGP Offspring,Chaperones modulate interferon Signaling Pathway,CP:BIOCARTA,C2,16,43
Cohort,0.10216848288630254,0.061746501871158425,1.6546440654968517,0.09837297228379768,LGP Proband,Chaperones modulate interferon Signaling Pathway,CP:BIOCARTA,C2,16,46
Cohort,-0.002293069916944578,0.022601339079956387,-0.10145725918417586,0.9192130348221882,LonGen OPEL,Chaperones modulate interferon Signaling Pathway,CP:BIOCARTA,C2,36,41
Cohort,-0.01908694200625578,0.027911943291150047,-0.6838270559365752,0.49431871135558236,LGP Offspring,TNFR1 Signaling Pathway,CP:BIOCARTA,C2,27,47
Cohort,-0.06582292186782104,0.08410905311911016,-0.7825902138573193,0.434089934282586,LGP Proband,TNFR1 Signaling Pathway,CP:BIOCARTA,C2,27,78
Cohort,-0.03178305048038372,0.02666533521059105,-1.1919239053015915,0.2336463134877602,LonGen OPEL,TNFR1 Signaling Pathway,CP:BIOCARTA,C2,59,59
Cohort,-0.004989244948531681,0.025097949701795463,-0.19879093741967133,0.8424860574268722,LGP Offspring,TNFR2 Signaling Pathway,CP:BIOCARTA,C2,18,42
Cohort,0.045701618198896024,0.06577823477249142,0.6947832874653018,0.4873846332268166,LGP Proband,TNFR2 Signaling Pathway,CP:BIOCARTA,C2,18,54
Cohort,0.012927937871485115,0.023325974695908844,0.5542292675878,0.5795776183954905,LonGen OPEL,TNFR2 Signaling Pathway,CP:BIOCARTA,C2,31,42
Cohort,-0.015912612282742412,0.012391270740584347,-1.2841792109847812,0.19951919279029232,LGP Offspring,Role of Tob in T-cell activation,CP:BIOCARTA,C2,6,7
Cohort,0.016503263429361485,0.03736765559440402,0.44164567369414864,0.658860111096623,LGP Proband,Role of Tob in T-cell activation,CP:BIOCARTA,C2,6,15
Cohort,-0.0018377879835786458,0.012009711774096436,-0.153025153155011,0.878417221351396,LonGen OPEL,Role of Tob in T-cell activation,CP:BIOCARTA,C2,10,12
Cohort,0.01394310717547435,0.029748642900924483,0.46869725190190265,0.6394371540059062,LGP Offspring,Toll-Like Receptor Pathway,CP:BIOCARTA,C2,25,59
Cohort,0.06292749857327515,0.07713720923733738,0.8157865600200611,0.4148551445966442,LGP Proband,Toll-Like Receptor Pathway,CP:BIOCARTA,C2,25,67
Cohort,2.3252729562629604e-4,0.025477285115670815,0.009126847486715564,0.9927202172497007,LonGen OPEL,Toll-Like Receptor Pathway,CP:BIOCARTA,C2,43,50
Cohort,-0.025470367388394574,0.024556285512117516,-1.0372239472385185,0.3000023683855785,LGP Offspring,TPO Signaling Pathway,CP:BIOCARTA,C2,23,37
Cohort,-0.0040363699729451695,0.07075508814241285,-0.05704706302988323,0.9545213695474959,LGP Proband,TPO Signaling Pathway,CP:BIOCARTA,C2,23,54
Cohort,-0.033809714426052746,0.021917908930877677,-1.5425611326645328,0.12333472883014177,LonGen OPEL,TPO Signaling Pathway,CP:BIOCARTA,C2,38,31
Cohort,-0.02078871528326471,0.016971322938155457,-1.2249319254026374,0.22102752056467115,LGP Offspring,Trka Receptor Signaling Pathway,CP:BIOCARTA,C2,13,16
Cohort,0.03168991319963379,0.045137982428553915,0.7020675602812724,0.4828329128050888,LGP Proband,Trka Receptor Signaling Pathway,CP:BIOCARTA,C2,13,21
Cohort,-0.00751104972513608,0.012838386024692077,-0.5850462597627204,0.5586824117305826,LonGen OPEL,Trka Receptor Signaling Pathway,CP:BIOCARTA,C2,12,13
Cohort,0.004919356486812508,0.011933644329745901,0.4122258340271193,0.680304591619826,LGP Offspring,TSP-1 Induced Apoptosis in Microvascular Endothelial Cell,CP:BIOCARTA,C2,4,10
Cohort,2.3519992044956272e-4,0.030986129342259347,0.007590490501464264,0.9939455382039347,LGP Proband,TSP-1 Induced Apoptosis in Microvascular Endothelial Cell,CP:BIOCARTA,C2,4,13
Cohort,0.008339798792763154,0.010305113056841368,0.8092874621328411,0.41859165071109206,LonGen OPEL,TSP-1 Induced Apoptosis in Microvascular Endothelial Cell,CP:BIOCARTA,C2,6,10
Cohort,-0.005761998081226109,0.005521656551419324,-1.0435270697423233,0.2970772750817403,LGP Offspring,G-Protein Signaling Through Tubby Proteins,CP:BIOCARTA,C2,2,1
Cohort,-0.02215834071048653,0.020770106117685663,-1.0668381078524578,0.28635367031540654,LGP Proband,G-Protein Signaling Through Tubby Proteins,CP:BIOCARTA,C2,2,5
Cohort,-0.002790481948354503,0.007346229422813955,-0.37985227356071544,0.7041563998287803,LonGen OPEL,G-Protein Signaling Through Tubby Proteins,CP:BIOCARTA,C2,4,4
Cohort,-0.021308116473388934,0.025695717282216726,-0.8292477785057074,0.4072569255213693,LGP Offspring,uCalpain and friends in Cell spread,CP:BIOCARTA,C2,23,41
Cohort,-0.0024045695801887847,0.07573311386998731,-0.03175057061983166,0.9746785622673056,LGP Proband,uCalpain and friends in Cell spread,CP:BIOCARTA,C2,23,68
Cohort,-0.007165703434032828,0.023179676273286785,-0.3091373386560571,0.7572979539957987,LonGen OPEL,uCalpain and friends in Cell spread,CP:BIOCARTA,C2,40,44
Cohort,-0.003956813161280323,0.028561749872600822,-0.1385353901259418,0.8898585593099719,LGP Offspring,Control of Gene Expression by Vitamin D Receptor,CP:BIOCARTA,C2,27,51
Cohort,-0.06679580213695725,0.0782511024986353,-0.8536084477291828,0.39356707429778826,LGP Proband,Control of Gene Expression by Vitamin D Receptor,CP:BIOCARTA,C2,27,70
Cohort,-0.07657587303614809,0.02934868418624974,-2.609175680592349,0.00924643628688841,LonGen OPEL,Control of Gene Expression by Vitamin D Receptor,CP:BIOCARTA,C2,67,49
Cohort,-0.05896969584321661,0.025100255965766156,-2.349366314178009,0.01909221986669848,LGP Offspring,"VEGF, Hypoxia, and Angiogenesis",CP:BIOCARTA,C2,31,37
Cohort,-0.1560474688284217,0.06755296640210155,-2.310001723678075,0.021131391931721238,LGP Proband,"VEGF, Hypoxia, and Angiogenesis",CP:BIOCARTA,C2,31,41
Cohort,0.002224325381314049,0.02161780609898361,0.102893206236068,0.9180736452255,LonGen OPEL,"VEGF, Hypoxia, and Angiogenesis",CP:BIOCARTA,C2,31,40
Cohort,0.005302421145105097,0.02772128511311843,0.19127616643558326,0.8483666672322101,LGP Offspring,Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,CP:BIOCARTA,C2,24,52
Cohort,0.06147628210659199,0.07957872130395884,0.772521612552396,0.44002441547318527,LGP Proband,Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,CP:BIOCARTA,C2,24,76
Cohort,0.006311632230509092,0.02606170055596733,0.24218036796773498,0.808702787310614,LonGen OPEL,Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells,CP:BIOCARTA,C2,45,59
Cohort,-0.029263264096248263,0.019294882178044984,-1.5166334692391112,0.12982671845821936,LGP Offspring,Vitamin C in the Brain,CP:BIOCARTA,C2,17,22
Cohort,-0.06530827957696,0.05184341545129496,-1.259721779679327,0.20812214766113465,LGP Proband,Vitamin C in the Brain,CP:BIOCARTA,C2,17,29
Cohort,-0.01285891053585426,0.017845059950609934,-0.7205865696973884,0.4713754740470013,LonGen OPEL,Vitamin C in the Brain,CP:BIOCARTA,C2,26,24
Cohort,0.004682893998945068,0.010568023948274061,0.4431191698529283,0.657821309084164,LGP Offspring,Visceral Fat Deposits and the Metabolic Syndrome,CP:BIOCARTA,C2,3,8
Cohort,0.02818632222069924,0.030426663218518602,0.9263691525511801,0.354522154657668,LGP Proband,Visceral Fat Deposits and the Metabolic Syndrome,CP:BIOCARTA,C2,3,12
Cohort,0.004770245163907863,0.00999252962108313,0.4773811381897908,0.633221788895662,LonGen OPEL,Visceral Fat Deposits and the Metabolic Syndrome,CP:BIOCARTA,C2,6,9
Cohort,-0.0027695640297340173,0.004541934177618849,-0.609776346689812,0.5422148765951366,LGP Offspring,Wnt/LRP6 Signalling,CP:BIOCARTA,C2,1,1
Cohort,-0.014076743344708879,0.017452833056766388,-0.8065592158547226,0.4201504126869542,LGP Proband,Wnt/LRP6 Signalling,CP:BIOCARTA,C2,1,4
Cohort,0.0028431977087675273,0.0045107834056196065,0.630311290323855,0.5286718390994704,LonGen OPEL,Wnt/LRP6 Signalling,CP:BIOCARTA,C2,1,2
Cohort,0.030759675887719284,0.02485889496166358,1.23737100684305,0.2163790094475901,LGP Offspring,WNT Signaling Pathway,CP:BIOCARTA,C2,15,46
Cohort,0.05783023634399535,0.06445245822106484,0.8972541612865099,0.3698422415280266,LGP Proband,WNT Signaling Pathway,CP:BIOCARTA,C2,15,56
Cohort,-0.040101913163952396,0.026171579800475422,-1.5322694873476428,0.12585326738390665,LonGen OPEL,WNT Signaling Pathway,CP:BIOCARTA,C2,48,43
Cohort,-0.023616294828446415,0.06310095909686719,-0.3742620582389675,0.7083267214244846,LGP Offspring,ABC transporters,CP:KEGG,C2,128,253
Cohort,-0.26033102743464387,0.17573639747620942,-1.4813722778736635,0.13888509676049954,LGP Proband,ABC transporters,CP:KEGG,C2,128,346
Cohort,0.03139618351099592,0.05938898826521478,0.5286532811569252,0.5971933571637191,LonGen OPEL,ABC transporters,CP:KEGG,C2,232,279
Cohort,-0.008764347811542285,0.04016391449185153,-0.21821448238867255,0.82732785781748,LGP Offspring,Acute myeloid leukemia,CP:KEGG,C2,54,107
Cohort,-0.03427228847390996,0.10143582356612305,-0.33787164405057407,0.7355449430531493,LGP Proband,Acute myeloid leukemia,CP:KEGG,C2,54,120
Cohort,0.013318620884071168,0.03282248289112421,0.4057773730357481,0.6850152340023399,LonGen OPEL,Acute myeloid leukemia,CP:KEGG,C2,66,80
Cohort,0.038252397998002854,0.04961047284612077,0.771054896345217,0.44094380686692214,LGP Offspring,Adherens junction,CP:KEGG,C2,76,183
Cohort,0.34114647973278794,0.13950289061309798,2.4454438057411663,0.014673208910808687,LGP Proband,Adherens junction,CP:KEGG,C2,76,243
Cohort,-0.0025052833849352313,0.04624854687861465,-0.05416999136233782,0.9568133212821279,LonGen OPEL,Adherens junction,CP:KEGG,C2,157,193
Cohort,0.01576890581898065,0.04921636695564993,0.3203996311468987,0.7487644168875092,LGP Offspring,Adipocytokine signaling pathway,CP:KEGG,C2,71,166
Cohort,0.11206062703948803,0.1278850976323751,0.8762602454401929,0.3811408834643629,LGP Proband,Adipocytokine signaling pathway,CP:KEGG,C2,71,201
Cohort,-0.042609165960002623,0.043406661070531295,-0.9816273564734034,0.32658172092912297,LonGen OPEL,Adipocytokine signaling pathway,CP:KEGG,C2,135,140
Cohort,0.020645344741290747,0.031732243541393215,0.6506109381884665,0.515518730974329,LGP Offspring,"Alanine, aspartate and glutamate metabolism",CP:KEGG,C2,28,68
Cohort,0.08462259665690236,0.08870514413717584,0.9539762037480022,0.3403720990909622,LGP Proband,"Alanine, aspartate and glutamate metabolism",CP:KEGG,C2,28,94
Cohort,-0.028451756628479048,0.028326636874613807,-1.0044170352597477,0.31548286915221574,LonGen OPEL,"Alanine, aspartate and glutamate metabolism",CP:KEGG,C2,61,61
Cohort,-0.031173455320110986,0.028927137564935652,-1.0776543392906677,0.2815724451419882,LGP Offspring,Aldosterone-regulated sodium reabsorption,CP:KEGG,C2,31,52
Cohort,-0.01870648203146108,0.0775544939914497,-0.2412043592667041,0.8094560190838354,LGP Proband,Aldosterone-regulated sodium reabsorption,CP:KEGG,C2,31,65
Cohort,-0.03611933515078869,0.02392327832139558,-1.5097987268110187,0.13149161725698436,LonGen OPEL,Aldosterone-regulated sodium reabsorption,CP:KEGG,C2,47,37
Cohort,0.014408146253707036,0.02490435512068845,0.5785392227136191,0.5630928166910025,LGP Offspring,Allograft rejection,CP:KEGG,C2,18,47
Cohort,-0.00826995108312884,0.07108921902945088,-0.11633200077360198,0.9074174305461657,LGP Proband,Allograft rejection,CP:KEGG,C2,18,63
Cohort,0.025622576492483194,0.025032368177611276,1.023577805770682,0.3063456968696379,LonGen OPEL,Allograft rejection,CP:KEGG,C2,39,53
Cohort,0.018282527856707725,0.028482372318815643,0.6418892236946909,0.5211627076615446,LGP Offspring,alpha-Linolenic acid metabolism,CP:KEGG,C2,19,46
Cohort,0.042574122237048345,0.08145994611699804,0.5226387232800356,0.6013644909350294,LGP Proband,alpha-Linolenic acid metabolism,CP:KEGG,C2,19,69
Cohort,-0.015902153644902044,0.02804770542406689,-0.5669680782962333,0.5708957092994822,LonGen OPEL,alpha-Linolenic acid metabolism,CP:KEGG,C2,44,46
Cohort,-0.019028845020744055,0.05787793941645759,-0.32877544039401657,0.7424272515741246,LGP Offspring,Alzheimer's disease,CP:KEGG,C2,112,229
Cohort,-0.05061561133572741,0.16449519331883763,-0.3077026769871641,0.7583854076365419,LGP Proband,Alzheimer's disease,CP:KEGG,C2,112,333
Cohort,-0.03075548765221028,0.051677591385332414,-0.5951416625222121,0.5519179282235824,LonGen OPEL,Alzheimer's disease,CP:KEGG,C2,181,206
Cohort,0.04213256886290192,0.040655209832945814,1.0363387382829075,0.3004147038320187,LGP Offspring,Amino sugar and nucleotide sugar metabolism,CP:KEGG,C2,49,120
Cohort,-0.019458596249993167,0.11093714941401175,-0.17540198529326442,0.8608063563730826,LGP Proband,Amino sugar and nucleotide sugar metabolism,CP:KEGG,C2,49,150
Cohort,0.023057765358178963,0.038161783925111895,0.6042108881342437,0.5458756071829464,LonGen OPEL,Amino sugar and nucleotide sugar metabolism,CP:KEGG,C2,87,119
Cohort,-0.030278579885202973,0.035161355766939274,-0.8611323205481352,0.38947050046695175,LGP Offspring,Aminoacyl-tRNA biosynthesis,CP:KEGG,C2,44,81
Cohort,-0.09363413247582533,0.09648629581709096,-0.9704397052751151,0.33210871739619086,LGP Proband,Aminoacyl-tRNA biosynthesis,CP:KEGG,C2,44,109
Cohort,0.041967736465031484,0.02810248879543291,1.4933814855519805,0.1357336125118748,LonGen OPEL,Aminoacyl-tRNA biosynthesis,CP:KEGG,C2,45,71
Cohort,0.01601117173965469,0.029628055569085213,0.540405755022318,0.589095235750051,LGP Offspring,Amyotrophic lateral sclerosis (ALS),CP:KEGG,C2,27,69
Cohort,0.2915536520944178,0.0887146375295479,3.2864210485818752,0.0010570902673612116,LGP Proband,Amyotrophic lateral sclerosis (ALS),CP:KEGG,C2,27,106
Cohort,-0.011123120802948472,0.02557841724538388,-0.43486352952334667,0.6637793565186176,LonGen OPEL,Amyotrophic lateral sclerosis (ALS),CP:KEGG,C2,46,52
Cohort,-0.032152936127353954,0.040792310277548566,-0.7882107168872564,0.4308497677316603,LGP Offspring,Antigen processing and presentation,CP:KEGG,C2,50,102
Cohort,-0.003602453518832151,0.10118957929567657,-0.03560103267457768,0.9716090038432195,LGP Proband,Antigen processing and presentation,CP:KEGG,C2,50,116
Cohort,0.06386054606086079,0.03693673783359605,1.7289167860074535,0.08421172247512798,LonGen OPEL,Antigen processing and presentation,CP:KEGG,C2,73,110
Cohort,-0.020286181416974466,0.04582753986096833,-0.44266354856749274,0.6581507159148294,LGP Offspring,Apoptosis,CP:KEGG,C2,69,139
Cohort,0.15241026940372823,0.12815028940104317,1.1893088194811956,0.234656653563019,LGP Proband,Apoptosis,CP:KEGG,C2,69,166
Cohort,-0.01772210554564729,0.04150064913763101,-0.4270320082674958,0.6694714919385012,LonGen OPEL,Apoptosis,CP:KEGG,C2,125,132
Cohort,-0.03622342800423724,0.043915125558037345,-0.82485083542264,0.4097472426990878,LGP Offspring,Arachidonic acid metabolism,CP:KEGG,C2,62,114
Cohort,-0.03291080957002212,0.1295602945008958,-0.25401925564312894,0.7995432939471208,LGP Proband,Arachidonic acid metabolism,CP:KEGG,C2,62,181
Cohort,0.00489112538009434,0.04250532690420663,0.11507088020090676,0.9084179610317455,LonGen OPEL,Arachidonic acid metabolism,CP:KEGG,C2,106,130
Cohort,-0.07513095705276765,0.04206862127126853,-1.7859144127473365,0.07456125451382688,LGP Offspring,Arginine and proline metabolism,CP:KEGG,C2,64,108
Cohort,0.2254105308288591,0.11574598968105855,1.9474586674664442,0.051815033800272144,LGP Proband,Arginine and proline metabolism,CP:KEGG,C2,64,156
Cohort,0.04159975351152187,0.03735317336312553,1.1136872657943566,0.26574954821003893,LonGen OPEL,Arginine and proline metabolism,CP:KEGG,C2,86,125
Cohort,0.01463547101368109,0.06177081475061438,0.2369318111274471,0.8127814707433768,LGP Offspring,Arrhythmogenic right ventricular cardiomyopathy (ARVC),CP:KEGG,C2,109,253
Cohort,0.05228984691704567,0.17055088806219573,0.30659381203560104,0.7592290908931815,LGP Proband,Arrhythmogenic right ventricular cardiomyopathy (ARVC),CP:KEGG,C2,109,345
Cohort,0.08310997881121494,0.054199587821748996,1.5334061042040785,0.12557316169251806,LonGen OPEL,Arrhythmogenic right ventricular cardiomyopathy (ARVC),CP:KEGG,C2,187,257
Cohort,-0.0455291344284504,0.038834788709932226,-1.1723801246485488,0.24145745964616558,LGP Offspring,Ascorbate and aldarate metabolism,CP:KEGG,C2,31,49
Cohort,0.03561094652162542,0.12034493061996117,0.2959073252040977,0.7673745181685165,LGP Proband,Ascorbate and aldarate metabolism,CP:KEGG,C2,31,63
Cohort,0.03859907907318215,0.0341399204778093,1.1306142056854311,0.25855804564243057,LonGen OPEL,Ascorbate and aldarate metabolism,CP:KEGG,C2,30,58
Cohort,0.01776104669371132,0.029097956773561588,0.6103881049768076,0.5418098908390987,LGP Offspring,Asthma,CP:KEGG,C2,23,58
Cohort,-0.058702582877011786,0.08152588718907378,-0.7200483785091417,0.4716969514675817,LGP Proband,Asthma,CP:KEGG,C2,23,86
Cohort,0.013264972244396005,0.027649997778672466,0.47974587016523385,0.631539895463188,LonGen OPEL,Asthma,CP:KEGG,C2,48,61
Cohort,-0.049592196843766055,0.03440616752691394,-1.441375207075097,0.14994176821149352,LGP Offspring,Autoimmune thyroid disease,CP:KEGG,C2,44,75
Cohort,0.03846317502212704,0.09904429415950786,0.38834316856439255,0.6978612038651903,LGP Proband,Autoimmune thyroid disease,CP:KEGG,C2,44,108
Cohort,4.1185201228724646e-4,0.03146111944934825,0.013090825103992872,0.9895586112983643,LonGen OPEL,Autoimmune thyroid disease,CP:KEGG,C2,66,76
Cohort,0.05053499637002419,0.06712412108313895,0.7528589656679793,0.45179675986972223,LGP Offspring,Axon guidance,CP:KEGG,C2,139,311
Cohort,0.13985658407378931,0.18814375976306338,0.7433495761428178,0.45747941046426555,LGP Proband,Axon guidance,CP:KEGG,C2,139,429
Cohort,0.002392638930713328,0.06281694968240611,0.03808906581440491,0.9696262194246265,LonGen OPEL,Axon guidance,CP:KEGG,C2,253,292
Cohort,-0.046978700200940054,0.042662374506976734,-1.1011740613091625,0.2712128402009303,LGP Offspring,B cell receptor signaling pathway,CP:KEGG,C2,62,111
Cohort,0.07938333200948249,0.11634557333655432,0.682306423295103,0.49523466625391654,LGP Proband,B cell receptor signaling pathway,CP:KEGG,C2,62,146
Cohort,-0.016258434271059618,0.03685414825384672,-0.44115615314383544,0.6592197510998095,LonGen OPEL,B cell receptor signaling pathway,CP:KEGG,C2,90,99
Cohort,-0.08623993426310068,0.04583128335709742,-1.8816827273012766,0.06030853421867843,LGP Offspring,Basal cell carcinoma,CP:KEGG,C2,71,116
Cohort,-0.014023224728363605,0.12351780239585192,-0.11353201284638906,0.9096361076519488,LGP Proband,Basal cell carcinoma,CP:KEGG,C2,71,174
Cohort,-0.03213636206358925,0.036981184569458286,-0.868992230447095,0.38511331665351667,LonGen OPEL,Basal cell carcinoma,CP:KEGG,C2,99,103
Cohort,-0.028415243342763716,0.027710472860667176,-1.0254333618065719,0.30552554427879675,LGP Offspring,Basal transcription factors,CP:KEGG,C2,26,44
Cohort,0.04359597934429153,0.07422979577503669,0.5873110506246706,0.5571537829830513,LGP Proband,Basal transcription factors,CP:KEGG,C2,26,67
Cohort,0.02598575575499951,0.022650366861721827,1.1472554026890553,0.2516207854191058,LonGen OPEL,Basal transcription factors,CP:KEGG,C2,29,43
Cohort,-0.07990678212831562,0.042807253873914285,-1.8666645228791212,0.062381163117760784,LGP Offspring,Base excision repair,CP:KEGG,C2,70,113
Cohort,-0.09481499256899951,0.12329781152052093,-0.7689916909289107,0.44211595654358804,LGP Proband,Base excision repair,CP:KEGG,C2,70,171
Cohort,0.01547184172114779,0.041025220702637144,0.37713000579063904,0.7061775126898464,LonGen OPEL,Base excision repair,CP:KEGG,C2,106,132
Cohort,0.03665056211841746,0.028581820888567616,1.2823032605692817,0.20017583565660202,LGP Offspring,beta-Alanine metabolism,CP:KEGG,C2,22,62
Cohort,0.06234028279048518,0.08540839626767867,0.7299081298178735,0.4656513017941435,LGP Proband,beta-Alanine metabolism,CP:KEGG,C2,22,90
Cohort,0.01037737257992599,0.030015034740281308,0.3457391493869959,0.7296301123580762,LonGen OPEL,beta-Alanine metabolism,CP:KEGG,C2,57,76
Cohort,1.8363696638835347e-4,0.02403409263010166,0.007640686470449737,0.993905927777346,LGP Offspring,Biosynthesis of unsaturated fatty acids,CP:KEGG,C2,21,41
Cohort,0.09092356269057837,0.07123807865798105,1.2763337305475164,0.20219287220958673,LGP Proband,Biosynthesis of unsaturated fatty acids,CP:KEGG,C2,21,67
Cohort,-0.03375032133413519,0.023010633906255167,-1.4667271432692068,0.14284524451614147,LonGen OPEL,Biosynthesis of unsaturated fatty acids,CP:KEGG,C2,40,39
Cohort,0.048024105303006374,0.03524088874274807,1.3627382003210364,0.1734188174747673,LGP Offspring,Bladder cancer,CP:KEGG,C2,34,104
Cohort,0.23787346153101394,0.10756338692329662,2.2114724009261755,0.02727362763797551,LGP Proband,Bladder cancer,CP:KEGG,C2,34,139
Cohort,-0.061266443022663424,0.03422080544417665,-1.7903273236103545,0.07378125006742091,LonGen OPEL,Bladder cancer,CP:KEGG,C2,91,78
Cohort,-0.048044019797152955,0.04479752642967129,-1.0724703711616401,0.28389152292075376,LGP Offspring,Butanoate metabolism,CP:KEGG,C2,67,115
Cohort,0.1415116805501885,0.12218334563885372,1.1581912396511467,0.24711755231908186,LGP Proband,Butanoate metabolism,CP:KEGG,C2,67,167
Cohort,-0.03151227709349403,0.03729410103638889,-0.8449667968332747,0.39838327207041435,LonGen OPEL,Butanoate metabolism,CP:KEGG,C2,102,109
Cohort,-0.14739873270905576,0.06990083050963512,-2.1086835683409846,0.03533918658500194,LGP Offspring,Calcium signaling pathway,CP:KEGG,C2,189,322
Cohort,-0.4895484750279479,0.2143393268143408,-2.283988115032158,0.02262278695030325,LGP Proband,Calcium signaling pathway,CP:KEGG,C2,189,517
Cohort,-0.016800477974275908,0.06523606743229601,-0.2575335797442413,0.7968334567871765,LonGen OPEL,Calcium signaling pathway,CP:KEGG,C2,274,323
Cohort,-0.07963894418230572,0.046993342418778436,-1.6946856742516396,0.09059562541693206,LGP Offspring,Cardiac muscle contraction,CP:KEGG,C2,82,140
Cohort,0.005491845855428287,0.13496747619601498,0.04069014261963681,0.967552658746959,LGP Proband,Cardiac muscle contraction,CP:KEGG,C2,82,214
Cohort,0.01877371347417837,0.03864464956311077,0.4858036930447235,0.6272400511672,LonGen OPEL,Cardiac muscle contraction,CP:KEGG,C2,101,119
Cohort,-0.053304251217468984,0.06238470982956655,-0.8544441636916297,0.3931616298391779,LGP Offspring,Cell adhesion molecules (CAMs),CP:KEGG,C2,119,232
Cohort,0.004273507455511606,0.1636563287297175,0.026112692913754714,0.9791736997022867,LGP Proband,Cell adhesion molecules (CAMs),CP:KEGG,C2,119,360
Cohort,-0.06042025481064093,0.05237480874824076,-1.1536128962508223,0.2490051714831621,LonGen OPEL,Cell adhesion molecules (CAMs),CP:KEGG,C2,220,227
Cohort,-0.0621698272255289,0.0567421839966218,-1.0956544645731339,0.2736202058370513,LGP Offspring,Cell cycle,CP:KEGG,C2,123,224
Cohort,-0.1442327919775082,0.15645972476309195,-0.9218525227236753,0.3568720979364972,LGP Proband,Cell cycle,CP:KEGG,C2,123,309
Cohort,0.05089884146123951,0.05369433070559475,0.9479369756989269,0.34344922653998355,LonGen OPEL,Cell cycle,CP:KEGG,C2,185,238
Cohort,0.043508661830286885,0.06933949421987372,0.6274730198106444,0.5305610993064358,LGP Offspring,Chemokine signaling pathway,CP:KEGG,C2,139,309
Cohort,0.09283729439913985,0.18741619607985655,0.49535363720423936,0.6204810022396939,LGP Proband,Chemokine signaling pathway,CP:KEGG,C2,139,422
Cohort,-0.03455609908729377,0.05990840686466968,-0.5768155238271383,0.5642271621502974,LonGen OPEL,Chemokine signaling pathway,CP:KEGG,C2,244,274
Cohort,0.013551099627675844,0.04350840464316095,0.3114593545503841,0.7555474644539144,LGP Offspring,Chronic myeloid leukemia,CP:KEGG,C2,55,129
Cohort,0.33295728211404546,0.11704702015832631,2.8446455250519254,0.004554937400851814,LGP Proband,Chronic myeloid leukemia,CP:KEGG,C2,55,156
Cohort,-0.04621230112460819,0.03721194497784213,-1.2418673937125653,0.21465127185002844,LonGen OPEL,Chronic myeloid leukemia,CP:KEGG,C2,99,98
Cohort,0.01639687354961108,0.010904331151471132,1.503702824303803,0.13312492581386032,LGP Offspring,Circadian rhythm - mammal,CP:KEGG,C2,2,10
Cohort,0.030790308415722483,0.03410749882786768,0.902743076269349,0.3669229187469728,LGP Proband,Circadian rhythm - mammal,CP:KEGG,C2,2,17
Cohort,-0.014234924474731623,0.010866456432738845,-1.3099877188891256,0.1905779041029635,LonGen OPEL,Circadian rhythm - mammal,CP:KEGG,C2,10,8
Cohort,0.025276684080454987,0.037917041675590873,0.6666312286891009,0.5052351678357123,LGP Offspring,Citrate cycle (TCA cycle),CP:KEGG,C2,39,96
Cohort,0.010354833704911345,0.09754497754542556,0.10615445269941469,0.915485335536681,LGP Proband,Citrate cycle (TCA cycle),CP:KEGG,C2,39,128
Cohort,-0.04423440491958999,0.03391131678834108,-1.3044142519053716,0.19246940215390695,LonGen OPEL,Citrate cycle (TCA cycle),CP:KEGG,C2,82,84
Cohort,-0.04868938452178491,0.043225588436944164,-1.1264018902324748,0.2603951488298776,LGP Offspring,Colorectal cancer,CP:KEGG,C2,62,117
Cohort,0.13115525475105705,0.11587135128689237,1.1319040754631609,0.25800010625530834,LGP Proband,Colorectal cancer,CP:KEGG,C2,62,152
Cohort,-0.06361229390544396,0.03526152041748383,-1.8040144937681948,0.0716069604685014,LonGen OPEL,Colorectal cancer,CP:KEGG,C2,104,89
Cohort,0.0271322123677584,0.042349433786931956,0.6406747373357036,0.5219511446218937,LGP Offspring,Complement and coagulation cascades,CP:KEGG,C2,58,132
Cohort,-0.11438747981080631,0.11324217319430972,-1.0101137816785923,0.3127337437416366,LGP Proband,Complement and coagulation cascades,CP:KEGG,C2,58,170
Cohort,-0.01748388913455937,0.037628740211313974,-0.4646418943704744,0.6423149882006389,LonGen OPEL,Complement and coagulation cascades,CP:KEGG,C2,97,117
Cohort,0.001292281012965907,0.027345583239164237,0.047257394426866974,0.9623220419023795,LGP Offspring,Cysteine and methionine metabolism,CP:KEGG,C2,25,49
Cohort,-0.10477503717122764,0.08971716536477266,-1.1678371328968384,0.24320621597080788,LGP Proband,Cysteine and methionine metabolism,CP:KEGG,C2,25,104
Cohort,-0.002984336893412229,0.024629637379218042,-0.12116852747212381,0.9035881312932216,LonGen OPEL,Cysteine and methionine metabolism,CP:KEGG,C2,41,47
Cohort,-0.13708690277789676,0.05706425583421059,-2.402325252013745,0.016559912519262275,LGP Offspring,Cytokine-cytokine receptor interaction,CP:KEGG,C2,124,207
Cohort,-0.22286293338689536,0.15505084063740007,-1.4373539186935451,0.15099252001489152,LGP Proband,Cytokine-cytokine receptor interaction,CP:KEGG,C2,124,280
Cohort,-0.03521559002196676,0.05062796040938978,-0.6955759176787903,0.48689746804415623,LonGen OPEL,Cytokine-cytokine receptor interaction,CP:KEGG,C2,183,202
Cohort,-0.07371848847532993,0.03840518690290655,-1.9194930273793518,0.055342598283414424,LGP Offspring,Cytosolic DNA-sensing pathway,CP:KEGG,C2,55,87
Cohort,-0.03478797269071681,0.09827968405764834,-0.3539691140064215,0.7234514977642776,LGP Proband,Cytosolic DNA-sensing pathway,CP:KEGG,C2,55,106
Cohort,0.02672691012621166,0.0313896768170783,0.8514554094316208,0.3947724966870917,LonGen OPEL,Cytosolic DNA-sensing pathway,CP:KEGG,C2,57,82
Cohort,0.009648684138243714,0.05755562808278514,0.16764101895240427,0.8669158372414207,LGP Offspring,Dilated cardiomyopathy,CP:KEGG,C2,105,238
Cohort,-0.02877926030562788,0.1667597171946624,-0.1725792103139225,0.8630240655551342,LGP Proband,Dilated cardiomyopathy,CP:KEGG,C2,105,339
Cohort,0.013139095333019584,0.05239411317473813,0.2507742671242427,0.8020533535556261,LonGen OPEL,Dilated cardiomyopathy,CP:KEGG,C2,176,215
Cohort,-0.01622419403780374,0.031143867867155686,-0.5209434520788527,0.6025767604452072,LGP Offspring,DNA replication,CP:KEGG,C2,35,66
Cohort,0.042165526512527016,0.09864560499894381,0.42744455278041504,0.6691658996576089,LGP Proband,DNA replication,CP:KEGG,C2,35,111
Cohort,0.016742477778696044,0.027750771824485748,0.6033157522459756,0.5464705217542101,LonGen OPEL,DNA replication,CP:KEGG,C2,57,70
Cohort,-0.019914776565972535,0.02692956151628122,-0.739513584502011,0.45985191152644944,LGP Offspring,Dorso-ventral axis formation,CP:KEGG,C2,24,45
Cohort,-0.03164182954923299,0.07000557910319252,-0.45199011213936235,0.6513936323720455,LGP Proband,Dorso-ventral axis formation,CP:KEGG,C2,24,55
Cohort,9.15736857380936e-4,0.02447167368696295,0.03742027901707377,0.9701592859752504,LonGen OPEL,Dorso-ventral axis formation,CP:KEGG,C2,38,47
Cohort,-0.11466103647080993,0.056757484131134496,-2.020192371562718,0.043757358136423306,LGP Offspring,Drug metabolism - cytochrome P450,CP:KEGG,C2,93,147
Cohort,0.034268026630848616,0.1694461622920556,0.20223548392783666,0.8397819550305361,LGP Proband,Drug metabolism - cytochrome P450,CP:KEGG,C2,93,201
Cohort,2.6032743997178614e-4,0.04678426895046349,0.00556442252517461,0.9955616502899334,LonGen OPEL,Drug metabolism - cytochrome P450,CP:KEGG,C2,106,134
Cohort,-0.060374299546491414,0.046105908235821905,-1.3094699108341978,0.1908201003384657,LGP Offspring,Drug metabolism - other enzymes,CP:KEGG,C2,50,84
Cohort,0.05521548261791721,0.13821582572220922,0.39948741274310456,0.6896363771265221,LGP Proband,Drug metabolism - other enzymes,CP:KEGG,C2,50,121
Cohort,-0.0028693769137491673,0.04007541321809032,-0.07159943424997327,0.9429386755365312,LonGen OPEL,Drug metabolism - other enzymes,CP:KEGG,C2,69,90
Cohort,0.010006087870617849,0.07972448984868719,0.12550833363259983,0.9001584436465504,LGP Offspring,ECM-receptor interaction,CP:KEGG,C2,192,419
Cohort,-0.24736438691139948,0.2181888480675572,-1.133716911300658,0.2572390927111843,LGP Proband,ECM-receptor interaction,CP:KEGG,C2,192,568
Cohort,0.022003346809410376,0.06599495291456707,0.33340953872479506,0.7389129668160375,LonGen OPEL,ECM-receptor interaction,CP:KEGG,C2,306,389
Cohort,-0.08271533427082599,0.0731231789544044,-1.131178040309253,0.2583812982431417,LGP Offspring,Endocytosis,CP:KEGG,C2,184,354
Cohort,0.04951820384633802,0.19766762222336856,0.2505124677949604,0.8022527635929144,LGP Proband,Endocytosis,CP:KEGG,C2,184,500
Cohort,-0.1665387554646671,0.0632708861315867,-2.632154623507415,0.008648881182826267,LonGen OPEL,Endocytosis,CP:KEGG,C2,305,323
Cohort,-0.007070989649946581,0.0391371260153013,-0.18067217422102128,0.8566790517700963,LGP Offspring,Endometrial cancer,CP:KEGG,C2,47,98
Cohort,0.20028559097808307,0.10369192023572343,1.9315448158619561,0.05375422912253914,LGP Proband,Endometrial cancer,CP:KEGG,C2,47,121
Cohort,-0.06420607084377444,0.03170305590339758,-2.025232868383945,0.04317672564638703,LonGen OPEL,Endometrial cancer,CP:KEGG,C2,84,71
Cohort,0.004507488013065021,0.047864281410030726,0.09417226959810587,0.9250002176557736,LGP Offspring,Epithelial cell signaling in Helicobacter pylori infection,CP:KEGG,C2,78,167
Cohort,0.07570003340156871,0.12398838195321543,0.6105413443505749,0.5416696018707097,LGP Proband,Epithelial cell signaling in Helicobacter pylori infection,CP:KEGG,C2,78,198
Cohort,-0.028790172080579456,0.04011781824185456,-0.7176405233957347,0.47318951244933116,LonGen OPEL,Epithelial cell signaling in Helicobacter pylori infection,CP:KEGG,C2,121,136
Cohort,0.01684854217771154,0.04450543111087465,0.378572721512065,0.7051240427272529,LGP Offspring,ErbB signaling pathway,CP:KEGG,C2,62,140
Cohort,0.19513292935873652,0.1193255969899514,1.6352981613422723,0.10236389189931071,LGP Proband,ErbB signaling pathway,CP:KEGG,C2,62,169
Cohort,-0.033457114655447595,0.03694788969578751,-0.9055216666207082,0.36546308575942554,LonGen OPEL,ErbB signaling pathway,CP:KEGG,C2,95,102
Cohort,0.026349689079515348,0.041309853357776295,0.6378548200427151,0.5237841850446735,LGP Offspring,Ether lipid metabolism,CP:KEGG,C2,46,110
Cohort,-0.06953351999352854,0.12162790859354787,-0.5716905009514992,0.5676857109836166,LGP Proband,Ether lipid metabolism,CP:KEGG,C2,46,159
Cohort,-0.03598376424860081,0.037843113303997186,-0.9508669109631637,0.34196055824370597,LonGen OPEL,Ether lipid metabolism,CP:KEGG,C2,88,91
Cohort,0.033843656971968776,0.04255835032697674,0.7952295310308604,0.42675911819171186,LGP Offspring,Fatty acid metabolism,CP:KEGG,C2,54,127
Cohort,0.22786579381936795,0.12599663662468522,1.8085069564049343,0.07088768614495097,LGP Proband,Fatty acid metabolism,CP:KEGG,C2,54,187
Cohort,-0.037163894115672835,0.04116016681545026,-0.9029092200307277,0.3668472207831076,LonGen OPEL,Fatty acid metabolism,CP:KEGG,C2,122,139
Cohort,-0.045869672079723166,0.0474620710397465,-0.966449020762499,0.33416516282054,LGP Offspring,Fc epsilon RI signaling pathway,CP:KEGG,C2,76,135
Cohort,0.26814489825738735,0.1390354917723489,1.9286075435791388,0.05411870798472485,LGP Proband,Fc epsilon RI signaling pathway,CP:KEGG,C2,76,200
Cohort,-0.05315365160617446,0.04111572253318915,-1.2927816497270146,0.19646169443891226,LonGen OPEL,Fc epsilon RI signaling pathway,CP:KEGG,C2,115,116
Cohort,-0.10906557999169851,0.0546369603581388,-1.9961868170701034,0.04631427083265111,LGP Offspring,Fc gamma R-mediated phagocytosis,CP:KEGG,C2,111,181
Cohort,0.02618203719783707,0.15364054531918572,0.17041098847601924,0.8647282615492426,LGP Proband,Fc gamma R-mediated phagocytosis,CP:KEGG,C2,111,255
Cohort,-0.051179107311766545,0.046117515954028486,-1.1097542062496086,0.2674400989936214,LonGen OPEL,Fc gamma R-mediated phagocytosis,CP:KEGG,C2,155,165
Cohort,-0.08137387174468154,0.1024037655898573,-0.7946374947831149,0.4271032853434854,LGP Offspring,Focal adhesion,CP:KEGG,C2,348,696
Cohort,-0.4749523728524792,0.2808431213603707,-1.6911661234637556,0.09117868790334234,LGP Proband,Focal adhesion,CP:KEGG,C2,348,911
Cohort,-0.10268876574797962,0.08828552626609366,-1.1631438367198992,0.2451197099944724,LonGen OPEL,Focal adhesion,CP:KEGG,C2,540,624
Cohort,-0.007835045977210148,0.026668528024649384,-0.29379371707236013,0.769005714799633,LGP Offspring,Folate biosynthesis,CP:KEGG,C2,24,48
Cohort,0.10286818624334367,0.07243290773749822,1.420185789256797,0.1559273072110936,LGP Proband,Folate biosynthesis,CP:KEGG,C2,24,56
Cohort,-0.019648690636441417,0.023708870508546795,-0.8287484901213777,0.4074951683289757,LonGen OPEL,Folate biosynthesis,CP:KEGG,C2,45,43
Cohort,2.8007943642055505e-4,0.04083962879797853,0.006858030904394957,0.9945301492272572,LGP Offspring,Fructose and mannose metabolism,CP:KEGG,C2,54,120
Cohort,0.033977075036270545,0.1082736770992543,0.3138073440059103,0.753745837994025,LGP Proband,Fructose and mannose metabolism,CP:KEGG,C2,54,145
Cohort,0.048586580065289924,0.03447500010090418,1.4093279165506265,0.15912877170140316,LonGen OPEL,Fructose and mannose metabolism,CP:KEGG,C2,74,106
Cohort,-0.00937413977755371,0.03696916242177518,-0.253566463600275,0.7999076058719199,LGP Offspring,Galactose metabolism,CP:KEGG,C2,44,92
Cohort,-0.02207555156969597,0.0982356550277075,-0.22472035803567994,0.8222518713277239,LGP Proband,Galactose metabolism,CP:KEGG,C2,44,118
Cohort,0.07853371259059683,0.0307589536419075,2.553198444422981,0.010859286181391205,LonGen OPEL,Galactose metabolism,CP:KEGG,C2,54,95
Cohort,0.023228828812685,0.0417789411713031,0.5559937174434736,0.5783991227035759,LGP Offspring,Gap junction,CP:KEGG,C2,57,128
Cohort,0.0022086682993722783,0.126107140944791,0.017514220708082034,0.9860305770623142,LGP Proband,Gap junction,CP:KEGG,C2,57,190
Cohort,-0.03839383372983552,0.03841874797224284,-0.9993515082161106,0.3179281324140056,LonGen OPEL,Gap junction,CP:KEGG,C2,101,108
Cohort,-0.026691110707423294,0.03961102121400136,-0.6738304110672297,0.5006494673521018,LGP Offspring,Glioma,CP:KEGG,C2,54,107
Cohort,0.2234622600986193,0.10692176408999704,2.0899604678288797,0.03692372405982321,LGP Proband,Glioma,CP:KEGG,C2,54,115
Cohort,-0.0384154071226606,0.03131976821057163,-1.2265546432011565,0.22035271345807556,LonGen OPEL,Glioma,CP:KEGG,C2,72,70
Cohort,-0.07996381941044994,0.04536176269624898,-1.7628022955347422,0.0783856516435505,LGP Offspring,Glutathione metabolism,CP:KEGG,C2,70,117
Cohort,0.033380476974588645,0.12325330996180055,0.27082823970353526,0.7865901510960461,LGP Proband,Glutathione metabolism,CP:KEGG,C2,70,145
Cohort,0.004848766096435911,0.036045004289549994,0.13451978136791745,0.8930255750075468,LonGen OPEL,Glutathione metabolism,CP:KEGG,C2,86,111
Cohort,0.01594063855756533,0.04308814774993574,0.3699541379703217,0.7115325349133472,LGP Offspring,Glycerolipid metabolism,CP:KEGG,C2,59,133
Cohort,-0.07463208491264774,0.12039182448547898,-0.6199099085972358,0.5354864308473979,LGP Proband,Glycerolipid metabolism,CP:KEGG,C2,59,186
Cohort,0.026419104973298954,0.04055354279215817,0.6514623175760519,0.5149361269208843,LonGen OPEL,Glycerolipid metabolism,CP:KEGG,C2,108,141
Cohort,-0.05814995560894954,0.05048309755717014,-1.1518698024244052,0.24978178346068078,LGP Offspring,Glycerophospholipid metabolism,CP:KEGG,C2,81,153
Cohort,0.07864440646129602,0.14920359313636455,0.527094588060081,0.5982680772861491,LGP Proband,Glycerophospholipid metabolism,CP:KEGG,C2,81,254
Cohort,-0.02752201239928953,0.044056037771959086,-0.6247046668551482,0.5323439281192834,LonGen OPEL,Glycerophospholipid metabolism,CP:KEGG,C2,139,160
Cohort,-0.027621161048036556,0.036147570831714604,-0.7641221916854983,0.4450610534899643,LGP Offspring,"Glycine, serine and threonine metabolism",CP:KEGG,C2,42,83
Cohort,-0.07264578185584808,0.0909201058238277,-0.7990067895060631,0.42451395799471414,LGP Proband,"Glycine, serine and threonine metabolism",CP:KEGG,C2,42,106
Cohort,0.05618420856284111,0.030259593436517532,1.8567403650254448,0.06371735106896682,LonGen OPEL,"Glycine, serine and threonine metabolism",CP:KEGG,C2,54,88
Cohort,0.044147861427654776,0.05357647656798956,0.8240157669127477,0.410221227715286,LGP Offspring,Glycolysis / Gluconeogenesis,CP:KEGG,C2,87,209
Cohort,0.0809529278541998,0.14108156282125875,0.5738023185691666,0.5662562832672922,LGP Proband,Glycolysis / Gluconeogenesis,CP:KEGG,C2,87,252
Cohort,0.02896122024030892,0.04649054438235758,0.6229486151446152,0.5334967188950184,LonGen OPEL,Glycolysis / Gluconeogenesis,CP:KEGG,C2,138,180
Cohort,-0.045414265248348795,0.025916010335207115,-1.75236329438614,0.08016471538086056,LGP Offspring,Glycosaminoglycan biosynthesis - chondroitin sulfate,CP:KEGG,C2,28,40
Cohort,-0.0073909525888224735,0.07691822891917202,-0.09608843953738337,0.9234734164686879,LGP Proband,Glycosaminoglycan biosynthesis - chondroitin sulfate,CP:KEGG,C2,28,65
Cohort,-0.02930987225368648,0.02324689199341294,-1.2608082087700798,0.20774737859500028,LonGen OPEL,Glycosaminoglycan biosynthesis - chondroitin sulfate,CP:KEGG,C2,37,38
Cohort,-0.006233622305357416,0.030139049716987217,-0.20682876082333712,0.836205876108675,LGP Offspring,Glycosaminoglycan biosynthesis - heparan sulfate,CP:KEGG,C2,30,57
Cohort,-0.145383012837394,0.08104635836005541,-1.793825358463578,0.07320319544257416,LGP Proband,Glycosaminoglycan biosynthesis - heparan sulfate,CP:KEGG,C2,30,69
Cohort,0.020111813708538435,0.023951176211750882,0.839700461085131,0.4013284776564964,LonGen OPEL,Glycosaminoglycan biosynthesis - heparan sulfate,CP:KEGG,C2,31,49
Cohort,-0.0055646402358943995,0.01585617122682827,-0.3509447619031232,0.725739130028565,LGP Offspring,Glycosaminoglycan biosynthesis - keratan sulfate,CP:KEGG,C2,8,17
Cohort,-0.0248336445924768,0.04475350558412561,-0.5548983094921054,0.5791130031339912,LGP Proband,Glycosaminoglycan biosynthesis - keratan sulfate,CP:KEGG,C2,8,24
Cohort,0.0043021463313271165,0.012534572433744971,0.34322242374579015,0.7315217623017858,LonGen OPEL,Glycosaminoglycan biosynthesis - keratan sulfate,CP:KEGG,C2,11,13
Cohort,0.01113916468256771,0.01844592286466905,0.6038822109520713,0.5461245458279568,LGP Offspring,Glycosaminoglycan degradation,CP:KEGG,C2,9,26
Cohort,0.0048865925817809155,0.052969279913983036,0.09225333230348358,0.9265189201636572,LGP Proband,Glycosaminoglycan degradation,CP:KEGG,C2,9,40
Cohort,0.008249539405582179,0.019587061488627468,0.4211728957083216,0.6737425317061774,LonGen OPEL,Glycosaminoglycan degradation,CP:KEGG,C2,24,33
Cohort,-2.0016226558132303e-4,0.01755449287223078,-0.011402338252559667,0.9909058116331827,LGP Offspring,Glycosphingolipid biosynthesis - ganglio series,CP:KEGG,C2,9,20
Cohort,-0.04514857860174176,0.04759066963710172,-0.9486855080211751,0.3430553964473769,LGP Proband,Glycosphingolipid biosynthesis - ganglio series,CP:KEGG,C2,9,29
Cohort,0.007177946565508287,0.01470865294709105,0.488008425470932,0.6256782643313413,LonGen OPEL,Glycosphingolipid biosynthesis - ganglio series,CP:KEGG,C2,13,18
Cohort,0.004371485458575722,0.020554726405543386,0.21267543884197748,0.8316442402260098,LGP Offspring,Glycosphingolipid biosynthesis - globo series,CP:KEGG,C2,13,29
Cohort,-0.07610704555878055,0.053610296605396186,-1.4196348533374825,0.15608767406047724,LGP Proband,Glycosphingolipid biosynthesis - globo series,CP:KEGG,C2,13,32
Cohort,0.02210617781465768,0.017879876060660146,1.2363719826501691,0.21668501047785121,LonGen OPEL,Glycosphingolipid biosynthesis - globo series,CP:KEGG,C2,17,29
Cohort,-0.007595332393236418,0.01515481035787107,-0.5011829388740303,0.6164055380206124,LGP Offspring,Glycosphingolipid biosynthesis - lacto and neolacto series,CP:KEGG,C2,7,16
Cohort,0.009978666119849367,0.04689536899530095,0.21278574694335506,0.8315460797347545,LGP Proband,Glycosphingolipid biosynthesis - lacto and neolacto series,CP:KEGG,C2,7,21
Cohort,-0.010591835815120127,0.014452550920649818,-0.7328696417174703,0.46385369461520454,LonGen OPEL,Glycosphingolipid biosynthesis - lacto and neolacto series,CP:KEGG,C2,17,13
Cohort,-0.058577358844949245,0.029626030494360595,-1.977226036275755,0.048421939292674285,LGP Offspring,Glycosylphosphatidylinositol(GPI)-anchor biosynthesis,CP:KEGG,C2,36,55
Cohort,-0.04644612932832803,0.08560562010231236,-0.5425593468374799,0.5875781844058587,LGP Proband,Glycosylphosphatidylinositol(GPI)-anchor biosynthesis,CP:KEGG,C2,36,86
Cohort,-0.04139043938180308,0.027948689870630195,-1.4809438143037292,0.13901725063076611,LonGen OPEL,Glycosylphosphatidylinositol(GPI)-anchor biosynthesis,CP:KEGG,C2,63,61
Cohort,0.024051237689386457,0.021663033899781234,1.1102432743563837,0.26728897213892217,LGP Offspring,Glyoxylate and dicarboxylate metabolism,CP:KEGG,C2,11,33
Cohort,0.037999039000183955,0.05865976641829479,0.6477870833855354,0.5173009523087772,LGP Proband,Glyoxylate and dicarboxylate metabolism,CP:KEGG,C2,11,41
Cohort,0.0017614346141179788,0.018423087807537354,0.09561017308929783,0.9238542493463748,LonGen OPEL,Glyoxylate and dicarboxylate metabolism,CP:KEGG,C2,23,26
Cohort,0.010215559837370216,0.05527516992746565,0.18481281651011644,0.8534312858374979,LGP Offspring,GnRH signaling pathway,CP:KEGG,C2,94,198
Cohort,0.08699954125892716,0.16004259653316613,0.543602410505118,0.5868603727544001,LGP Proband,GnRH signaling pathway,CP:KEGG,C2,94,304
Cohort,-0.0509934106843948,0.05147301867643063,-0.9906823418488289,0.322141760016874,LonGen OPEL,GnRH signaling pathway,CP:KEGG,C2,168,176
Cohort,0.013979408813793478,0.024686757524512798,0.5662715648222565,0.5713971246338871,LGP Offspring,Graft-versus-host disease,CP:KEGG,C2,17,46
Cohort,-0.00801568811117807,0.06940262764647591,-0.11549545576297912,0.9080802238538851,LGP Proband,Graft-versus-host disease,CP:KEGG,C2,17,62
Cohort,0.03652171557147891,0.02502421416409207,1.4594550435028213,0.14483441592518265,LonGen OPEL,Graft-versus-host disease,CP:KEGG,C2,36,53
Cohort,-0.09328253743632857,0.04300506265888407,-2.1691059533210115,0.03042249773530455,LGP Offspring,Hedgehog signaling pathway,CP:KEGG,C2,67,102
Cohort,-0.027088940686917817,0.11649561996973648,-0.2325318384841855,0.8161820114766623,LGP Proband,Hedgehog signaling pathway,CP:KEGG,C2,67,147
Cohort,0.004020484712411104,0.03230013000855859,0.1244727099038237,0.9009724323555458,LonGen OPEL,Hedgehog signaling pathway,CP:KEGG,C2,77,90
Cohort,-0.011290760746768784,0.04740875042244307,-0.23815773767839687,0.8118309246505353,LGP Offspring,Hematopoietic cell lineage,CP:KEGG,C2,71,141
Cohort,-0.09863735918661992,0.1271623191772172,-0.7756807191378442,0.4381574205630129,LGP Proband,Hematopoietic cell lineage,CP:KEGG,C2,71,188
Cohort,0.07529272932653111,0.04145847746865654,1.8160997200983553,0.06973113826949494,LonGen OPEL,Hematopoietic cell lineage,CP:KEGG,C2,102,152
Cohort,0.02713370511706215,0.04005639274722869,0.6773876341857917,0.49839179465751504,LGP Offspring,Histidine metabolism,CP:KEGG,C2,45,111
Cohort,0.031552720045421846,0.10082950086003886,0.3129314315382765,0.7544109921689229,LGP Proband,Histidine metabolism,CP:KEGG,C2,45,127
Cohort,-0.03466868135467238,0.03283866534063923,-1.0557274784175967,0.2914130520500705,LonGen OPEL,Histidine metabolism,CP:KEGG,C2,83,85
Cohort,0.049618464983961184,0.02919258581909556,1.699694069290175,0.0896485122442902,LGP Offspring,Homologous recombination,CP:KEGG,C2,23,68
Cohort,0.04236354524838526,0.08733347187427888,0.4850779928842152,0.6277484087952945,LGP Proband,Homologous recombination,CP:KEGG,C2,23,101
Cohort,-0.020794551363052298,0.0268971598433663,-0.7731132760539734,0.43968485650768774,LonGen OPEL,Homologous recombination,CP:KEGG,C2,51,52
Cohort,0.026817773858994913,0.07110122436191385,0.37717738477313967,0.7061601614042455,LGP Offspring,Huntington's disease,CP:KEGG,C2,149,338
Cohort,0.18313332847815614,0.1915771546267535,0.9559246708458097,0.3393872931322969,LGP Proband,Huntington's disease,CP:KEGG,C2,149,471
Cohort,0.01623213315054793,0.06695857006490114,0.24242054653817371,0.8085167612610706,LonGen OPEL,Huntington's disease,CP:KEGG,C2,288,360
Cohort,-0.009186733703341814,0.05893253158702995,-0.15588561115476768,0.8761697253305369,LGP Offspring,Hypertrophic cardiomyopathy (HCM),CP:KEGG,C2,107,232
Cohort,-0.08889287403099527,0.16891734643178277,-0.5262507131965553,0.5988539355162974,LGP Proband,Hypertrophic cardiomyopathy (HCM),CP:KEGG,C2,107,335
Cohort,0.03852479563739572,0.053400436288194755,0.7214322263114619,0.4708554687097558,LonGen OPEL,Hypertrophic cardiomyopathy (HCM),CP:KEGG,C2,173,221
Cohort,-0.04287294747141681,0.042558551594923805,-1.0073873725658113,0.31410910232939054,LGP Offspring,Inositol phosphate metabolism,CP:KEGG,C2,68,126
Cohort,0.00707960497058044,0.12008172919377606,0.05895655415784421,0.9530008358368727,LGP Proband,Inositol phosphate metabolism,CP:KEGG,C2,68,184
Cohort,0.044727558350530314,0.03671751641544719,1.2181531518758515,0.2235267158164474,LonGen OPEL,Inositol phosphate metabolism,CP:KEGG,C2,83,119
Cohort,0.0070120955829510254,0.06881050322429166,0.10190443688654201,0.9188627469687778,LGP Offspring,Insulin signaling pathway,CP:KEGG,C2,162,344
Cohort,0.052453626824707215,0.1864241204919069,0.2813671679732256,0.7784985911549438,LGP Proband,Insulin signaling pathway,CP:KEGG,C2,162,433
Cohort,-0.07759818929911047,0.058066222279547525,-1.3363739925344278,0.18180893424481054,LonGen OPEL,Insulin signaling pathway,CP:KEGG,C2,248,261
Cohort,0.018587707847071172,0.031560940173738145,0.5889465822231114,0.5560938528286914,LGP Offspring,Intestinal immune network for IgA production,CP:KEGG,C2,28,75
Cohort,0.04201985781722707,0.08104528168436063,0.518473832701055,0.6042652386035143,LGP Proband,Intestinal immune network for IgA production,CP:KEGG,C2,28,79
Cohort,0.017119479669282334,0.028693963999714103,0.5966230273883701,0.5509287323340013,LonGen OPEL,Intestinal immune network for IgA production,CP:KEGG,C2,56,69
Cohort,-0.10064459073263428,0.05181771718638661,-1.9422814473014902,0.05251801997374785,LGP Offspring,Jak-STAT signaling pathway,CP:KEGG,C2,99,166
Cohort,0.054688874241949285,0.13710489059809736,0.39888346800306057,0.6900811790899126,LGP Proband,Jak-STAT signaling pathway,CP:KEGG,C2,99,195
Cohort,-0.027767745825403922,0.043189768037612555,-0.6429241713273824,0.520458453388768,LonGen OPEL,Jak-STAT signaling pathway,CP:KEGG,C2,133,151
Cohort,0.02988829603075206,0.040825486840969816,0.7320989495404645,0.46436190698597457,LGP Offspring,Leishmania infection,CP:KEGG,C2,55,130
Cohort,-0.009358658855281704,0.11267216769440634,-0.08306096391670219,0.9338229960240425,LGP Proband,Leishmania infection,CP:KEGG,C2,55,173
Cohort,-0.0285102089577229,0.03950204807671072,-0.721740019716388,0.4706662812719872,LonGen OPEL,Leishmania infection,CP:KEGG,C2,112,118
Cohort,-0.16667001828720956,0.06006408171937292,-2.7748699974456152,0.0056749488995109535,LGP Offspring,Leukocyte transendothelial migration,CP:KEGG,C2,141,224
Cohort,-0.004250672277639566,0.1757313419145299,-0.02418846991851321,0.9807080611895829,LGP Proband,Leukocyte transendothelial migration,CP:KEGG,C2,141,352
Cohort,-0.043010411849745155,0.055226165766777316,-0.7788049605214336,0.43632607001123536,LonGen OPEL,Leukocyte transendothelial migration,CP:KEGG,C2,214,238
Cohort,0.011308535620419289,0.023259623758993583,0.4861873836650828,0.6269918811293314,LGP Offspring,Limonene and pinene degradation,CP:KEGG,C2,15,38
Cohort,0.03943570769026318,0.06664385185920817,0.5917381212234712,0.554186327874378,LGP Proband,Limonene and pinene degradation,CP:KEGG,C2,15,56
Cohort,0.021222970059589272,0.02124373282564153,0.9990226404077538,0.3180873145579526,LonGen OPEL,Limonene and pinene degradation,CP:KEGG,C2,28,43
Cohort,0.012081660910389801,0.03641414789700352,0.3317848036582503,0.7401545977187278,LGP Offspring,Linoleic acid metabolism,CP:KEGG,C2,37,81
Cohort,0.015107402902766819,0.10310318940187271,0.14652701813017255,0.8835407729648987,LGP Proband,Linoleic acid metabolism,CP:KEGG,C2,37,109
Cohort,-0.022420312856785692,0.03300527073455008,-0.6792949234413036,0.497148484071232,LonGen OPEL,Linoleic acid metabolism,CP:KEGG,C2,68,69
Cohort,-0.025674024892539365,0.04331543306648399,-0.5927223410910568,0.553565206620213,LGP Offspring,Long-term depression,CP:KEGG,C2,60,109
Cohort,-0.07661274630107971,0.12916387908421215,-0.5931437399083517,0.5532457682209709,LGP Proband,Long-term depression,CP:KEGG,C2,60,180
Cohort,-0.007924261831681106,0.03965893474377257,-0.19981025418050116,0.8416800138553185,LonGen OPEL,Long-term depression,CP:KEGG,C2,98,115
Cohort,-0.016420530873793297,0.03489326743664473,-0.47059309947421374,0.638083136244064,LGP Offspring,Long-term potentiation,CP:KEGG,C2,38,73
Cohort,-0.02181572956536023,0.10818640170353734,-0.20164946076256204,0.8402399480133427,LGP Proband,Long-term potentiation,CP:KEGG,C2,38,133
Cohort,-0.016874028748085135,0.03215998017797333,-0.5246902720307743,0.5999446092039413,LonGen OPEL,Long-term potentiation,CP:KEGG,C2,64,70
Cohort,-0.03525443817112881,0.0443264314670124,-0.7953367100477073,0.4266968293718879,LGP Offspring,Lysine degradation,CP:KEGG,C2,68,131
Cohort,-0.11256231201230311,0.12071239469907953,-0.932483464460352,0.3513565939578128,LGP Proband,Lysine degradation,CP:KEGG,C2,68,161
Cohort,0.04052356239364016,0.03646385459020194,1.111335124853451,0.2667596830052927,LonGen OPEL,Lysine degradation,CP:KEGG,C2,92,124
Cohort,0.010695758748661102,0.063094735805674207,0.1695190353376393,0.8654391157031079,LGP Offspring,Lysosome,CP:KEGG,C2,124,288
Cohort,-0.12241871231413863,0.1708811285535995,-0.7163969090696877,0.47394685418181437,LGP Proband,Lysosome,CP:KEGG,C2,124,374
Cohort,0.02101978313352929,0.05681566296446007,0.36996458435551133,0.7115072891405835,LonGen OPEL,Lysosome,CP:KEGG,C2,210,257
Cohort,-0.10117282748366893,0.08261307254528505,-1.224658814477699,0.221130381474702,LGP Offspring,MAPK signaling pathway,CP:KEGG,C2,241,466
Cohort,0.11703941737786061,0.24283240320006458,0.48197611124176976,0.6299493707543429,LGP Proband,MAPK signaling pathway,CP:KEGG,C2,241,665
Cohort,0.06442242053697389,0.0755677753979206,0.852511804108853,0.3941865180634353,LonGen OPEL,MAPK signaling pathway,CP:KEGG,C2,347,433
Cohort,-0.0173840623193824,0.024524054587716886,-0.7088575935599728,0.4786572332389679,LGP Offspring,Maturity onset diabetes of the young,CP:KEGG,C2,20,37
Cohort,-0.006213204543191689,0.0638208353969572,-0.09735385794539313,0.9224687771669655,LGP Proband,Maturity onset diabetes of the young,CP:KEGG,C2,20,46
Cohort,0.02433817822766214,0.018266251394170752,1.3324123106851087,0.1831060436640028,LonGen OPEL,Maturity onset diabetes of the young,CP:KEGG,C2,18,33
Cohort,0.013408321678504745,0.04842179787715619,0.27690672933130284,0.7819363733572358,LGP Offspring,Melanogenesis,CP:KEGG,C2,66,150
Cohort,-0.05777416281401088,0.13050336079394606,-0.44270249028476344,0.6580957344991238,LGP Proband,Melanogenesis,CP:KEGG,C2,66,207
Cohort,-0.07777814134499472,0.04082981847374828,-1.904934781794402,0.05714869739439917,LonGen OPEL,Melanogenesis,CP:KEGG,C2,136,131
Cohort,-0.014381742419693259,0.03771183031478488,-0.3813589077922562,0.7030567782859791,LGP Offspring,Melanoma,CP:KEGG,C2,50,106
Cohort,0.1908387626598947,0.10446776874120557,1.826771691971837,0.06809139720015125,LGP Proband,Melanoma,CP:KEGG,C2,50,119
Cohort,-0.009319658418267169,0.03208847478003032,-0.29043631653278484,0.7715581120996666,LonGen OPEL,Melanoma,CP:KEGG,C2,71,79
Cohort,-0.13881698911227194,0.05569904833918246,-2.492268597964873,0.012931392628018522,LGP Offspring,Metabolism of xenobiotics by cytochrome P450,CP:KEGG,C2,91,134
Cohort,0.10282283878432966,0.16478351172547737,0.6239874226957144,0.5328064788279568,LGP Proband,Metabolism of xenobiotics by cytochrome P450,CP:KEGG,C2,91,187
Cohort,0.0678655955165148,0.04727202712623419,1.4356396296542984,0.15149774313891415,LonGen OPEL,Metabolism of xenobiotics by cytochrome P450,CP:KEGG,C2,87,142
Cohort,-0.043531785900126935,0.034287439746541803,-1.2696131942752449,0.204659334810579,LGP Offspring,Mismatch repair,CP:KEGG,C2,42,76
Cohort,-0.019702141783155797,0.09735137483529194,-0.2023817518395575,0.8396676511620833,LGP Proband,Mismatch repair,CP:KEGG,C2,42,115
Cohort,0.012695811838371275,0.0291307134748959,0.4358222070088396,0.6630838921344411,LonGen OPEL,Mismatch repair,CP:KEGG,C2,61,72
Cohort,-0.025160804967153554,0.039970260898868605,-0.6294881344611326,0.5292422145377838,LGP Offspring,mTOR signaling pathway,CP:KEGG,C2,57,109
Cohort,-0.1156323692770398,0.10608010545794937,-1.0900476463315452,0.27600700024101943,LGP Proband,mTOR signaling pathway,CP:KEGG,C2,57,124
Cohort,0.0033670444566723905,0.031127002460398123,0.10817117584502947,0.913887168808102,LonGen OPEL,mTOR signaling pathway,CP:KEGG,C2,68,77
Cohort,-0.07391999075588232,0.03300177024351882,-2.239879564351533,0.025422988501495183,LGP Offspring,N-Glycan biosynthesis,CP:KEGG,C2,43,68
Cohort,0.06702173341598089,0.0933666174456315,0.7178340101590212,0.4730606602461426,LGP Proband,N-Glycan biosynthesis,CP:KEGG,C2,43,106
Cohort,-0.009850946635517515,0.02699380060283828,-0.3649336668242904,0.7152578580398434,LonGen OPEL,N-Glycan biosynthesis,CP:KEGG,C2,51,54
Cohort,-0.13772859902416432,0.04861717199586362,-2.8329208255034324,0.0047499014242413234,LGP Offspring,Natural killer cell mediated cytotoxicity,CP:KEGG,C2,96,138
Cohort,0.092863914949734,0.14250117278266788,0.6516712328491716,0.514792818569771,LGP Proband,Natural killer cell mediated cytotoxicity,CP:KEGG,C2,96,221
Cohort,-0.04511005587344987,0.04435482073838132,-1.0170271263077169,0.30944954123723417,LonGen OPEL,Natural killer cell mediated cytotoxicity,CP:KEGG,C2,134,147
Cohort,-0.06409435824489886,0.07952944413041982,-0.8059198570505652,0.4205724640311006,LGP Offspring,Neuroactive ligand-receptor interaction,CP:KEGG,C2,217,422
Cohort,-0.5782904734223347,0.21986233417126208,-2.6302389429372406,0.008689801783667113,LGP Proband,Neuroactive ligand-receptor interaction,CP:KEGG,C2,217,621
Cohort,-0.04563411483612474,0.07007783841732285,-0.65119181565458,0.5151106139492063,LonGen OPEL,Neuroactive ligand-receptor interaction,CP:KEGG,C2,352,406
Cohort,0.005324874618629766,0.050995400017843855,0.10441872437056153,0.9168680362525046,LGP Offspring,Neurotrophin signaling pathway,CP:KEGG,C2,78,172
Cohort,0.15053913877250924,0.1343618914015512,1.1204005630034715,0.2628656339210722,LGP Proband,Neurotrophin signaling pathway,CP:KEGG,C2,78,202
Cohort,-0.05083775216234661,0.04131305554847133,-1.2305493139499266,0.21885497916044303,LonGen OPEL,Neurotrophin signaling pathway,CP:KEGG,C2,131,138
Cohort,-0.023542316721613266,0.025395058836316656,-0.9270432044814229,0.3542349578405193,LGP Offspring,Nicotinate and nicotinamide metabolism,CP:KEGG,C2,24,41
Cohort,-0.06328037343164412,0.07387431389926488,-0.8565950746822952,0.3919147616431896,LGP Proband,Nicotinate and nicotinamide metabolism,CP:KEGG,C2,24,67
Cohort,-0.009313969199280833,0.024864176573687002,-0.37459391312147944,0.7080622724308153,LonGen OPEL,Nicotinate and nicotinamide metabolism,CP:KEGG,C2,43,48
Cohort,0.026104017419383573,0.024111672169155676,1.0826299078823973,0.2793587441515261,LGP Offspring,Nitrogen metabolism,CP:KEGG,C2,14,47
Cohort,0.027223831170774985,0.06243501732547681,0.43603465390032353,0.6629244278174435,LGP Proband,Nitrogen metabolism,CP:KEGG,C2,14,54
Cohort,3.184289807121135e-4,0.020351512905264307,0.015646452536201658,0.9875203671819932,LonGen OPEL,Nitrogen metabolism,CP:KEGG,C2,30,34
Cohort,0.01808358964113837,0.0402168407798297,0.4496521678601863,0.6531054052566067,LGP Offspring,NOD-like receptor signaling pathway,CP:KEGG,C2,47,113
Cohort,0.0822011870774685,0.10775581196313344,0.7628468996697091,0.44577041663680106,LGP Proband,NOD-like receptor signaling pathway,CP:KEGG,C2,47,151
Cohort,-2.8892422738040853e-4,0.03519057959005548,-0.00821027191783041,0.9934512815664828,LonGen OPEL,NOD-like receptor signaling pathway,CP:KEGG,C2,82,98
Cohort,0.03117884116711105,0.02307735561609031,1.3510577938735802,0.17712892826693316,LGP Offspring,Non-homologous end-joining,CP:KEGG,C2,12,37
Cohort,-0.040941316762279786,0.06148104378009822,-0.6659177243105416,0.5056478302562912,LGP Proband,Non-homologous end-joining,CP:KEGG,C2,12,49
Cohort,-0.00216306075282344,0.020352621772493702,-0.10627921930661473,0.915387596397055,LonGen OPEL,Non-homologous end-joining,CP:KEGG,C2,28,36
Cohort,-0.021911050145295076,0.03735879174457907,-0.5865031796290486,0.5577332173099944,LGP Offspring,Non-small cell lung cancer,CP:KEGG,C2,44,87
Cohort,0.20711543846536348,0.09878322099281457,2.096666178565173,0.03632382270649267,LGP Proband,Non-small cell lung cancer,CP:KEGG,C2,44,99
Cohort,-0.0393318136384016,0.029037426782621775,-1.3545213194283723,0.17595446036117368,LonGen OPEL,Non-small cell lung cancer,CP:KEGG,C2,66,61
Cohort,-0.016825993393666097,0.03892308766491743,-0.432288248520219,0.6656697870325763,LGP Offspring,Notch signaling pathway,CP:KEGG,C2,51,99
Cohort,-0.06876930854218902,0.10481274123470474,-0.6561159238092581,0.511930508942616,LGP Proband,Notch signaling pathway,CP:KEGG,C2,51,145
Cohort,-0.06985590211502857,0.038111965443052134,-1.8329126116418486,0.06718891136248321,LonGen OPEL,Notch signaling pathway,CP:KEGG,C2,111,106
Cohort,0.025873218087223197,0.03316671968341234,0.7800957807763896,0.43560754733154283,LGP Offspring,Nucleotide excision repair,CP:KEGG,C2,32,80
Cohort,0.007021252841737506,0.09728307772415846,0.07217342425828605,0.9424811985593948,LGP Proband,Nucleotide excision repair,CP:KEGG,C2,32,116
Cohort,0.029534487065485587,0.02803279326117078,1.0535691820049504,0.2923999015606019,LonGen OPEL,Nucleotide excision repair,CP:KEGG,C2,49,70
Cohort,-0.018633829543674877,0.03894708696745694,-0.4784396214085219,0.632492033448093,LGP Offspring,O-Glycan biosynthesis,CP:KEGG,C2,47,90
Cohort,-0.1395176665134509,0.10840362994155803,-1.287020246357681,0.19844431615900995,LGP Proband,O-Glycan biosynthesis,CP:KEGG,C2,47,129
Cohort,0.011374029308482607,0.031544256909114915,0.3605736962279181,0.7185138170955371,LonGen OPEL,O-Glycan biosynthesis,CP:KEGG,C2,63,79
Cohort,-0.12981191562587266,0.08275026658296691,-1.5687190022006865,0.11718136989752226,LGP Offspring,Olfactory transduction,CP:KEGG,C2,231,433
Cohort,-0.16501177296709754,0.2412284400223869,-0.6840477555290904,0.4941350300927383,LGP Proband,Olfactory transduction,CP:KEGG,C2,231,639
Cohort,0.0035267782087770776,0.07907834860588651,0.044598531342048636,0.9644384986822865,LonGen OPEL,Olfactory transduction,CP:KEGG,C2,368,456
Cohort,-0.0030327486048374575,0.03402666275764587,-0.08912859384530715,0.9290061118184711,LGP Offspring,One carbon pool by folate,CP:KEGG,C2,37,78
Cohort,-0.09344112916418353,0.08981762085975575,-1.0403429557557045,0.298482090041182,LGP Proband,One carbon pool by folate,CP:KEGG,C2,37,94
Cohort,-0.0019833097988925436,0.027244638256493453,-0.07279633446481323,0.9419864753200619,LonGen OPEL,One carbon pool by folate,CP:KEGG,C2,52,64
Cohort,0.04941782224303658,0.04291952664324117,1.1514065067355244,0.2499721095295118,LGP Offspring,Oocyte meiosis,CP:KEGG,C2,56,131
Cohort,-0.08178820966511967,0.12349446580180276,-0.6622823875879766,0.507973225046324,LGP Proband,Oocyte meiosis,CP:KEGG,C2,56,175
Cohort,-0.007342226026883847,0.04072738806886525,-0.18027736064166455,0.8569807131017395,LonGen OPEL,Oocyte meiosis,CP:KEGG,C2,105,128
Cohort,0.017888051729390262,0.0251010299329916,0.712642141662843,0.4763131294321953,LGP Offspring,Other glycan degradation,CP:KEGG,C2,19,46
Cohort,-0.12348948919790646,0.06793716358053238,-1.817701574360293,0.06946844028396346,LGP Proband,Other glycan degradation,CP:KEGG,C2,19,60
Cohort,-0.00317296502108508,0.0210218252128163,-0.15093670454222166,0.8800638870532995,LonGen OPEL,Other glycan degradation,CP:KEGG,C2,32,37
Cohort,0.07910171852358704,0.04367307459211266,1.8112239466161326,0.07054991776915094,LGP Offspring,Oxidative phosphorylation,CP:KEGG,C2,52,143
Cohort,0.01957704820653535,0.11224621466777622,0.1744116562369524,0.8615842827260705,LGP Proband,Oxidative phosphorylation,CP:KEGG,C2,52,179
Cohort,-0.007549763251212057,0.04103920397556167,-0.18396466110083048,0.85408803105204,LonGen OPEL,Oxidative phosphorylation,CP:KEGG,C2,120,144
Cohort,-0.020306363421794742,0.03906075231685493,-0.5198661627680027,0.6033270493369148,LGP Offspring,p53 signaling pathway,CP:KEGG,C2,53,100
Cohort,0.07499002826783796,0.10763549011513718,0.6967035518454134,0.4861824703626686,LGP Proband,p53 signaling pathway,CP:KEGG,C2,53,142
Cohort,-0.02150562848995326,0.035953845886514436,-0.5981454267183024,0.5499130465558018,LonGen OPEL,p53 signaling pathway,CP:KEGG,C2,96,106
Cohort,-0.0015215118508207148,0.039685216634380335,-0.03833951228837666,0.9694283069436134,LGP Offspring,Pancreatic cancer,CP:KEGG,C2,52,119
Cohort,0.14997173623572457,0.10754023833461432,1.3945639191265646,0.16351872322332828,LGP Proband,Pancreatic cancer,CP:KEGG,C2,52,133
Cohort,-0.03049594812934884,0.03666465200343898,-0.8317533772443404,0.40579760734600423,LonGen OPEL,Pancreatic cancer,CP:KEGG,C2,95,93
Cohort,0.0025649804581409953,0.023548654610457926,0.10892259029532375,0.9132962121162216,LGP Offspring,Pantothenate and CoA biosynthesis,CP:KEGG,C2,15,34
Cohort,0.039897136998626945,0.0622313340960157,0.6411101027831142,0.5216272816180195,LGP Proband,Pantothenate and CoA biosynthesis,CP:KEGG,C2,15,43
Cohort,0.020524974076915094,0.017668136030582173,1.1616943655735927,0.24570784957990502,LonGen OPEL,Pantothenate and CoA biosynthesis,CP:KEGG,C2,18,29
Cohort,0.04830944443719973,0.04540477251944718,1.063972832734895,0.2877209101520281,LGP Offspring,Parkinson's disease,CP:KEGG,C2,61,144
Cohort,0.056138484473659406,0.1326334846440738,0.4232602696393662,0.672214500374821,LGP Proband,Parkinson's disease,CP:KEGG,C2,61,204
Cohort,-4.664802195473513e-4,0.04516042675199213,-0.010329402379413382,0.9917610640717631,LonGen OPEL,Parkinson's disease,CP:KEGG,C2,125,162
Cohort,-0.010174016066653174,0.03111662002763984,-0.3269640487178858,0.7437962913746878,LGP Offspring,Pathogenic Escherichia coli infection,CP:KEGG,C2,29,64
Cohort,0.09995402836444309,0.08363628244615744,1.1951036732029612,0.2323862551119004,LGP Proband,Pathogenic Escherichia coli infection,CP:KEGG,C2,29,87
Cohort,-0.01777036823192303,0.02704195178348956,-0.6571407409568977,0.5112803783292609,LonGen OPEL,Pathogenic Escherichia coli infection,CP:KEGG,C2,52,53
Cohort,-0.14383692911421808,0.1067462223502806,-1.3474662236029937,0.1782815666483353,LGP Offspring,Pathways in cancer,CP:KEGG,C2,369,720
Cohort,-0.37069147845038086,0.2836113968238615,-1.3070401352051482,0.1915593340098504,LGP Proband,Pathways in cancer,CP:KEGG,C2,369,951
Cohort,-0.03177392117330651,0.09099210182109915,-0.34919427661730096,0.7270358152691502,LonGen OPEL,Pathways in cancer,CP:KEGG,C2,557,642
Cohort,-0.05383811999323884,0.035628784630038546,-1.5110849430392315,0.13123410399455504,LGP Offspring,Pentose and glucuronate interconversions,CP:KEGG,C2,23,30
Cohort,0.0765555197887978,0.11181142974058647,0.6846842041678042,0.49373344509071637,LGP Proband,Pentose and glucuronate interconversions,CP:KEGG,C2,23,37
Cohort,-7.467220605834941e-4,0.03127014101988864,-0.023879715160496365,0.9809545394526393,LonGen OPEL,Pentose and glucuronate interconversions,CP:KEGG,C2,24,32
Cohort,-0.03786605006600565,0.037898591269736194,-0.9991413611260921,0.31808372236158144,LGP Offspring,Pentose phosphate pathway,CP:KEGG,C2,53,96
Cohort,-0.09626679054859899,0.09910799211892561,-0.9713322658487794,0.3316644641326,LGP Proband,Pentose phosphate pathway,CP:KEGG,C2,53,125
Cohort,-0.05047000776348339,0.036846758672870246,-1.3697272048149993,0.1711583294214247,LonGen OPEL,Pentose phosphate pathway,CP:KEGG,C2,98,98
Cohort,0.016783953856399275,0.05190695119404681,0.3233469404445434,0.746532507845694,LGP Offspring,Peroxisome,CP:KEGG,C2,82,178
Cohort,0.014808704062649678,0.1397673500921668,0.10595252791788907,0.9156454956092186,LGP Proband,Peroxisome,CP:KEGG,C2,82,242
Cohort,-0.003737583479338775,0.045378205149791705,-0.08236516774960922,0.9343770404410617,LonGen OPEL,Peroxisome,CP:KEGG,C2,131,163
Cohort,-0.029823688747739784,0.02321152604435994,-1.284865488410509,0.19927936809046742,LGP Offspring,Phenylalanine metabolism,CP:KEGG,C2,19,28
Cohort,-0.008385025081173794,0.06508755673233048,-0.12882685266028368,0.8975257170629929,LGP Proband,Phenylalanine metabolism,CP:KEGG,C2,19,45
Cohort,0.009692965266499218,0.020232642527587243,0.479075595453379,0.6320164285333602,LonGen OPEL,Phenylalanine metabolism,CP:KEGG,C2,25,34
Cohort,-0.07502037027595164,0.050255437319893626,-1.4927811651189196,0.13596102667200152,LGP Offspring,Phosphatidylinositol signaling system,CP:KEGG,C2,94,171
Cohort,0.08961335496991742,0.14218809690648995,0.6302451254330499,0.528706858944582,LGP Proband,Phosphatidylinositol signaling system,CP:KEGG,C2,94,261
Cohort,0.04336974482831913,0.044264946022897586,0.9797762953530909,0.3274942385427677,LonGen OPEL,Phosphatidylinositol signaling system,CP:KEGG,C2,127,169
Cohort,0.0072754061322327515,0.04481519567467636,0.16234239352755636,0.8710847452236186,LGP Offspring,Porphyrin and chlorophyll metabolism,CP:KEGG,C2,35,82
Cohort,0.0365859652169547,0.12818179838120322,0.2854224677684014,0.7753913652106041,LGP Proband,Porphyrin and chlorophyll metabolism,CP:KEGG,C2,35,84
Cohort,-0.027403514453935685,0.03544668134460178,-0.7730911164158673,0.43969796238072834,LonGen OPEL,Porphyrin and chlorophyll metabolism,CP:KEGG,C2,58,58
Cohort,0.09412506723422721,0.049087676910767375,1.9174887295100513,0.05559698652295412,LGP Offspring,PPAR signaling pathway,CP:KEGG,C2,75,193
Cohort,0.07391976141899868,0.13673129902630138,0.5406206329158009,0.5889134413065981,LGP Proband,PPAR signaling pathway,CP:KEGG,C2,75,252
Cohort,-0.056135051775821385,0.046230900337343665,-1.2142322854672485,0.2250191421585562,LonGen OPEL,PPAR signaling pathway,CP:KEGG,C2,155,168
Cohort,-0.00894658515287578,0.01915616464988401,-0.4670342584954734,0.6406258591777053,LGP Offspring,Primary bile acid biosynthesis,CP:KEGG,C2,14,22
Cohort,-0.11398741853039608,0.05267342583626613,-2.1640403433170037,0.030744479856395567,LGP Proband,Primary bile acid biosynthesis,CP:KEGG,C2,14,29
Cohort,-0.026012766872164143,0.013704016392095038,-1.8981856214919028,0.05803312015955019,LonGen OPEL,Primary bile acid biosynthesis,CP:KEGG,C2,18,11
Cohort,0.033123789022129514,0.03783859695510973,0.8753968616073772,0.38166893352222186,LGP Offspring,Primary immunodeficiency,CP:KEGG,C2,37,96
Cohort,-0.18201901534759288,0.09619934840683421,-1.8921023724383341,0.05882348727636138,LGP Proband,Primary immunodeficiency,CP:KEGG,C2,37,99
Cohort,0.02249619911788689,0.03308781629525225,0.679893738442777,0.49676942199113217,LonGen OPEL,Primary immunodeficiency,CP:KEGG,C2,70,81
Cohort,0.02059714796208146,0.030568149010672774,0.6738107680281861,0.5006619493227163,LGP Offspring,Prion diseases,CP:KEGG,C2,27,73
Cohort,0.01514302806190582,0.08373489559489332,0.18084489094209055,0.8565332628790262,LGP Proband,Prion diseases,CP:KEGG,C2,27,83
Cohort,-0.019777519069719536,0.026273750520260947,-0.7527482250571019,0.45182377666077655,LonGen OPEL,Prion diseases,CP:KEGG,C2,51,58
Cohort,0.036802039282393256,0.03993087600076574,0.92164367447605,0.35704326918084917,LGP Offspring,Progesterone-mediated oocyte maturation,CP:KEGG,C2,46,112
Cohort,0.17017194021447568,0.11106459699357983,1.5321888776520982,0.12585505186406953,LGP Proband,Progesterone-mediated oocyte maturation,CP:KEGG,C2,46,148
Cohort,-0.041981889811367606,0.03461284157294501,-1.2128992565632803,0.2255281629231575,LonGen OPEL,Progesterone-mediated oocyte maturation,CP:KEGG,C2,89,94
Cohort,0.045206909727545735,0.0335496351455291,1.3474635277388438,0.17828243392493281,LGP Offspring,Propanoate metabolism,CP:KEGG,C2,32,86
Cohort,0.014479838468476605,0.09709681918734626,0.14912783538807858,0.8814888140506125,LGP Proband,Propanoate metabolism,CP:KEGG,C2,32,125
Cohort,0.049973756204774296,0.03229510187628925,1.5474097711846682,0.12216193048029331,LonGen OPEL,Propanoate metabolism,CP:KEGG,C2,62,103
Cohort,-0.03999537964978351,0.0489898802127648,-0.816400845972314,0.4145585047158892,LGP Offspring,Prostate cancer,CP:KEGG,C2,83,166
Cohort,0.0641200941762084,0.13483166425353277,0.4755566471065669,0.6345147972283818,LGP Proband,Prostate cancer,CP:KEGG,C2,83,200
Cohort,0.0027040642621880186,0.04322433137852132,0.06255884535282134,0.9501335066908198,LonGen OPEL,Prostate cancer,CP:KEGG,C2,128,148
Cohort,0.032701565921007286,0.02763263023740316,1.1834402168760207,0.23705072600056057,LGP Offspring,Proteasome,CP:KEGG,C2,21,56
Cohort,-0.005500071570837304,0.07817036998381381,-0.07036005550410168,0.9439239507674071,LGP Proband,Proteasome,CP:KEGG,C2,21,78
Cohort,-0.020253297263584453,0.02348041296401244,-0.8625613737980645,0.3886384663673159,LonGen OPEL,Proteasome,CP:KEGG,C2,41,41
Cohort,0.0030231839324321814,0.017217704294989616,0.17558577384279583,0.8606719610327327,LGP Offspring,Protein export,CP:KEGG,C2,8,20
Cohort,0.004221486661717643,0.04885771907204052,0.08640367872051247,0.93116626176902,LGP Proband,Protein export,CP:KEGG,C2,8,32
Cohort,0.004247462179679502,0.016112172434917367,0.2636182176448564,0.7921423466601636,LonGen OPEL,Protein export,CP:KEGG,C2,16,20
Cohort,-0.010391559085483178,0.026102484114528746,-0.39810613579491444,0.6906776464358346,LGP Offspring,Proximal tubule bicarbonate reclamation,CP:KEGG,C2,23,46
Cohort,-0.044040076865293334,0.07429753969706343,-0.5927528292977109,0.5535072645564966,LGP Proband,Proximal tubule bicarbonate reclamation,CP:KEGG,C2,23,68
Cohort,-0.011202453912057786,0.020692239065612305,-0.5413843265842962,0.5883941934105026,LonGen OPEL,Proximal tubule bicarbonate reclamation,CP:KEGG,C2,32,32
Cohort,3.192086407178028e-4,0.07374534092434276,0.004328526205408517,0.9965476235724016,LGP Offspring,Purine metabolism,CP:KEGG,C2,169,351
Cohort,-0.14394173072082841,0.1956004459042209,-0.7358967412135243,0.4620004544215115,LGP Proband,Purine metabolism,CP:KEGG,C2,169,478
Cohort,0.04083222913621698,0.06489701379347508,0.6291850233072259,0.5294084556148333,LonGen OPEL,Purine metabolism,CP:KEGG,C2,238,316
Cohort,0.030578211097199888,0.04921628968315031,0.6213026478440256,0.5346099570818628,LGP Offspring,Pyrimidine metabolism,CP:KEGG,C2,76,174
Cohort,-0.17911128278405167,0.13681922192882565,-1.309109058354583,0.1908579786967168,LGP Proband,Pyrimidine metabolism,CP:KEGG,C2,76,219
Cohort,-0.005201795219780079,0.047726199304156516,-0.10899244640515614,0.9132359505922772,LonGen OPEL,Pyrimidine metabolism,CP:KEGG,C2,128,158
Cohort,0.025720542304273307,0.041296475090268146,0.6228265789768233,0.5336085370103238,LGP Offspring,Pyruvate metabolism,CP:KEGG,C2,52,122
Cohort,0.008560628103327542,0.11230062939243753,0.07622956478197641,0.939254743939149,LGP Proband,Pyruvate metabolism,CP:KEGG,C2,52,165
Cohort,-0.004034989829778025,0.03471154376593948,-0.11624345655687424,0.9074889166562233,LonGen OPEL,Pyruvate metabolism,CP:KEGG,C2,85,105
Cohort,-0.08659230964486166,0.07799920763854419,-1.1101690935905237,0.2673209075405298,LGP Offspring,Regulation of actin cytoskeleton,CP:KEGG,C2,211,405
Cohort,-0.1959369767046328,0.22414556772895355,-0.8741505740660829,0.3822879014709253,LGP Proband,Regulation of actin cytoskeleton,CP:KEGG,C2,211,589
Cohort,-0.0454508927236563,0.06706706321451131,-0.6776932005846662,0.49816316550933626,LonGen OPEL,Regulation of actin cytoskeleton,CP:KEGG,C2,329,382
Cohort,-0.06215620967076807,0.026865148940414398,-2.313637263230051,0.02098671256522796,LGP Offspring,Regulation of autophagy,CP:KEGG,C2,33,46
Cohort,-0.04726237845289153,0.08222823100786784,-0.5747707067706385,0.5656013886623503,LGP Proband,Regulation of autophagy,CP:KEGG,C2,33,81
Cohort,-0.005649058971555415,0.021994907584030218,-0.25683485824950736,0.797372628854291,LonGen OPEL,Regulation of autophagy,CP:KEGG,C2,38,39
Cohort,0.029027529661997394,0.042962032057733676,0.6756554164614309,0.499490507778363,LGP Offspring,Renal cell carcinoma,CP:KEGG,C2,50,122
Cohort,0.04105691212490165,0.11005173205616293,0.37306920443513775,0.7091917363377849,LGP Proband,Renal cell carcinoma,CP:KEGG,C2,50,139
Cohort,0.016454901936086178,0.0367489055007199,0.44776576912648,0.6544440820356143,LonGen OPEL,Renal cell carcinoma,CP:KEGG,C2,88,108
Cohort,-0.040116673803513025,0.02573612366170324,-1.5587690800230662,0.11951905796603984,LGP Offspring,Renin-angiotensin system,CP:KEGG,C2,26,39
Cohort,-0.05158836368673825,0.07066867756971644,-0.7300032413348194,0.4655931935803378,LGP Proband,Renin-angiotensin system,CP:KEGG,C2,26,55
Cohort,0.010350221166189243,0.02262521163330783,0.45746405973732895,0.647462360752247,LonGen OPEL,Renin-angiotensin system,CP:KEGG,C2,31,44
Cohort,-0.030625443101524832,0.05843393123236465,-0.524103760531559,0.6003781658109393,LGP Offspring,Retinol metabolism,CP:KEGG,C2,86,176
Cohort,0.15885086095133777,0.16809679641604877,0.9449963612523179,0.3449344227565495,LGP Proband,Retinol metabolism,CP:KEGG,C2,86,239
Cohort,0.08199847318733183,0.04743295633935673,1.7287236452368229,0.08424632161880583,LonGen OPEL,Retinol metabolism,CP:KEGG,C2,109,168
Cohort,-0.013073900767798963,0.021881505350602754,-0.597486350153639,0.5503828001279546,LGP Offspring,Riboflavin metabolism,CP:KEGG,C2,18,33
Cohort,-0.053210786187550284,0.059437576643929055,-0.89523815054437,0.37091809351899696,LGP Proband,Riboflavin metabolism,CP:KEGG,C2,18,43
Cohort,-0.004512843528353323,0.01840867075404493,-0.2451477126539252,0.8064052461933028,LonGen OPEL,Riboflavin metabolism,CP:KEGG,C2,24,27
Cohort,-0.01263003123622433,0.019025808977990763,-0.6638367520053875,0.5070211358092003,LGP Offspring,Ribosome,CP:KEGG,C2,14,24
Cohort,-0.01115780078113486,0.05934382633533643,-0.18801957120333038,0.8509070455346429,LGP Proband,Ribosome,CP:KEGG,C2,14,38
Cohort,-0.007507115263678554,0.01678037177885872,-0.4473747877944295,0.6547261876719372,LonGen OPEL,Ribosome,CP:KEGG,C2,22,22
Cohort,-0.04530028173262727,0.043639416636976694,-1.0380588290046775,0.29961382235270406,LGP Offspring,RIG-I-like receptor signaling pathway,CP:KEGG,C2,68,127
Cohort,-0.06331417868971663,0.11818486774438199,-0.5357215343901447,0.5922938508368197,LGP Proband,RIG-I-like receptor signaling pathway,CP:KEGG,C2,68,180
Cohort,0.011522691050888705,0.03958737816711578,0.2910698203413812,0.7710737459898886,LonGen OPEL,RIG-I-like receptor signaling pathway,CP:KEGG,C2,99,131
Cohort,0.015682601653481277,0.038013108879198815,0.4125577232664326,0.6800614870815473,LGP Offspring,RNA degradation,CP:KEGG,C2,44,97
Cohort,0.004444211594663917,0.09991452683834,0.04448013452392739,0.9645323340568892,LGP Proband,RNA degradation,CP:KEGG,C2,44,114
Cohort,-0.007190445118238939,0.033735927519252216,-0.2131390967133048,0.8312730448485663,LonGen OPEL,RNA degradation,CP:KEGG,C2,80,94
Cohort,-0.004167064355455185,0.021117044321635286,-0.19733179946901258,0.8436272136261352,LGP Offspring,RNA polymerase,CP:KEGG,C2,15,27
Cohort,-0.019528920553943067,0.05467218315924538,-0.35720030599584013,0.7210322216621201,LGP Proband,RNA polymerase,CP:KEGG,C2,15,34
Cohort,0.013985327789713295,0.01761812759315877,0.793803298095303,0.4275465207233826,LonGen OPEL,RNA polymerase,CP:KEGG,C2,19,26
Cohort,0.03801960721732924,0.025377561490508526,1.4981584117744715,0.13455889171041158,LGP Offspring,Selenoamino acid metabolism,CP:KEGG,C2,15,45
Cohort,-0.0037868063700158628,0.06303553057296095,-0.06007415715542832,0.9521109642509336,LGP Proband,Selenoamino acid metabolism,CP:KEGG,C2,15,50
Cohort,-0.01252224112062341,0.020145937975175093,-0.621576475419213,0.5343983628786722,LonGen OPEL,Selenoamino acid metabolism,CP:KEGG,C2,30,30
Cohort,-0.029307636629838502,0.066221402810788,-0.4425704588828802,0.6582180264393386,LGP Offspring,Small cell lung cancer,CP:KEGG,C2,144,290
Cohort,-0.1393740530545362,0.17992332118729196,-0.7746302821381014,0.43877770954064044,LGP Proband,Small cell lung cancer,CP:KEGG,C2,144,355
Cohort,0.05827445218375653,0.05752362648499836,1.0130524750374348,0.31134292402290814,LonGen OPEL,Small cell lung cancer,CP:KEGG,C2,209,274
Cohort,-0.0068235196473666136,0.024103390618263013,-0.283093766990461,0.7771916270016472,LGP Offspring,SNARE interactions in vesicular transport,CP:KEGG,C2,21,38
Cohort,-0.07045924201087851,0.07021531053624161,-1.0034740496449275,0.3159232430373839,LGP Proband,SNARE interactions in vesicular transport,CP:KEGG,C2,21,62
Cohort,0.0073848263007578255,0.021378489943937318,0.34543255019992997,0.7298604740310743,LonGen OPEL,SNARE interactions in vesicular transport,CP:KEGG,C2,32,38
Cohort,0.034473906316519885,0.032974618900163274,1.0454679224920227,0.2961804440597703,LGP Offspring,Sphingolipid metabolism,CP:KEGG,C2,31,82
Cohort,-0.15469183088799546,0.09109998321381232,-1.6980445597331517,0.08987237585275444,LGP Proband,Sphingolipid metabolism,CP:KEGG,C2,31,107
Cohort,0.00417601929915895,0.03019498803817255,0.13830173715848537,0.8900369310902668,LonGen OPEL,Sphingolipid metabolism,CP:KEGG,C2,58,77
Cohort,-0.004232401208888627,0.04437148544077729,-0.09538561007919424,0.9240368133254866,LGP Offspring,Spliceosome,CP:KEGG,C2,64,133
Cohort,0.15887062182667255,0.12108502885857993,1.3120583388737839,0.18986146257199918,LGP Proband,Spliceosome,CP:KEGG,C2,64,185
Cohort,-0.041530780215138605,0.03875547706967626,-1.0716106046242906,0.2842197606088809,LonGen OPEL,Spliceosome,CP:KEGG,C2,103,109
Cohort,-0.07400778123317082,0.06105065773206442,-1.2122356086313089,0.22584570892676076,LGP Offspring,Starch and sucrose metabolism,CP:KEGG,C2,102,187
Cohort,0.24129032534349507,0.1706703304253581,1.4137801499659153,0.1577996176845703,LGP Proband,Starch and sucrose metabolism,CP:KEGG,C2,102,245
Cohort,0.07868086496322634,0.05001319213480984,1.5732022213487833,0.1160693631914121,LonGen OPEL,Starch and sucrose metabolism,CP:KEGG,C2,125,184
Cohort,0.0037840246010149305,0.02014898403086155,0.18780225321629426,0.8510880262031318,LGP Offspring,Steroid biosynthesis,CP:KEGG,C2,13,25
Cohort,-0.14418517796797573,0.059417553094242494,-2.4266428093947736,0.015450219422575967,LGP Proband,Steroid biosynthesis,CP:KEGG,C2,13,37
Cohort,0.002240256150553895,0.018900458222615057,0.11852919776692769,0.905678265846628,LonGen OPEL,Steroid biosynthesis,CP:KEGG,C2,23,32
Cohort,-0.1060242455791324,0.04807896339765188,-2.2052107218332937,0.027775214338351853,LGP Offspring,Steroid hormone biosynthesis,CP:KEGG,C2,61,80
Cohort,-0.044618023751692805,0.14451355581570902,-0.30874628680919014,0.7575916371195244,LGP Proband,Steroid hormone biosynthesis,CP:KEGG,C2,61,109
Cohort,0.02205425520570435,0.03730460412786727,0.5911939215360655,0.5545583312399693,LonGen OPEL,Steroid hormone biosynthesis,CP:KEGG,C2,53,80
Cohort,-0.0017694279571567992,0.016572451400769805,-0.1067692349409821,0.9150037320153896,LGP Offspring,Sulfur metabolism,CP:KEGG,C2,10,18
Cohort,-0.0085674071410318,0.04663961698884607,-0.18369377139354956,0.8542983460545425,LGP Proband,Sulfur metabolism,CP:KEGG,C2,10,27
Cohort,-0.011588374122283526,0.015963446712827102,-0.7259318323136271,0.46809394272376736,LonGen OPEL,Sulfur metabolism,CP:KEGG,C2,20,20
Cohort,0.038376118790183114,0.04198918759679553,0.9139524002867788,0.3610677174559138,LGP Offspring,Systemic lupus erythematosus,CP:KEGG,C2,47,124
Cohort,0.11529280101490151,0.11415828548199278,1.009938091905626,0.3128178644656778,LGP Proband,Systemic lupus erythematosus,CP:KEGG,C2,47,170
Cohort,0.006666259765203675,0.03700833922735683,0.1801285846481846,0.8570974683361242,LonGen OPEL,Systemic lupus erythematosus,CP:KEGG,C2,93,119
Cohort,-0.0032475344902214275,0.05180573763666092,-0.06268677251539166,0.9500344608150018,LGP Offspring,T cell receptor signaling pathway,CP:KEGG,C2,84,174
Cohort,0.20595396315803743,0.1463694454110162,1.40708303279898,0.15977531701771638,LGP Proband,T cell receptor signaling pathway,CP:KEGG,C2,84,233
Cohort,-0.04857583126674417,0.04385898681906003,-1.107545677403435,0.26839263384174744,LonGen OPEL,T cell receptor signaling pathway,CP:KEGG,C2,135,142
Cohort,-0.004855373449157598,0.03988253265522847,-0.12174185353600092,0.903139644965924,LGP Offspring,Taste transduction,CP:KEGG,C2,52,107
Cohort,-0.1476343789044144,0.11260580959493703,-1.3110724876050472,0.19019413824745823,LGP Proband,Taste transduction,CP:KEGG,C2,52,155
Cohort,-0.0108220655591721,0.040533440734058984,-0.2669910415495188,0.7895452125925111,LonGen OPEL,Taste transduction,CP:KEGG,C2,104,122
Cohort,0.01624404576282468,0.015231657183024763,1.0664660822939342,0.286593732814742,LGP Offspring,Taurine and hypotaurine metabolism,CP:KEGG,C2,5,18
Cohort,0.004932650609972311,0.0374380898983167,0.13175486846069284,0.8952099624917809,LGP Proband,Taurine and hypotaurine metabolism,CP:KEGG,C2,5,18
Cohort,-0.011704595233932507,0.014957873356904704,-0.782503966616989,0.43415117205035236,LonGen OPEL,Taurine and hypotaurine metabolism,CP:KEGG,C2,18,15
Cohort,7.304997444765271e-4,0.018738225237456264,0.03898446812435121,0.9689142818054108,LGP Offspring,Terpenoid backbone biosynthesis,CP:KEGG,C2,11,25
Cohort,0.0928216377181188,0.05870403794564251,1.5811797785370023,0.11421608340583592,LGP Proband,Terpenoid backbone biosynthesis,CP:KEGG,C2,11,44
Cohort,-0.015628205952818445,0.018385339964445375,-0.8500362779824124,0.3955605144395269,LonGen OPEL,Terpenoid backbone biosynthesis,CP:KEGG,C2,27,24
Cohort,-0.010029145504860651,0.03828074039590749,-0.26198932938958636,0.7934094790629481,LGP Offspring,TGF-beta signaling pathway,CP:KEGG,C2,49,99
Cohort,0.10401495030658413,0.10566207777967043,0.9844113658589893,0.32519878264847324,LGP Proband,TGF-beta signaling pathway,CP:KEGG,C2,49,126
Cohort,-0.05751757288688722,0.0327205890788843,-1.757840384481502,0.07915899964371442,LonGen OPEL,TGF-beta signaling pathway,CP:KEGG,C2,92,83
Cohort,-0.015095139237302994,0.023326335847332687,-0.6471286076003698,0.517768389715231,LGP Offspring,Thyroid cancer,CP:KEGG,C2,17,33
Cohort,0.14482423980908588,0.0644506746419756,2.2470554515307493,0.02489724208532206,LGP Proband,Thyroid cancer,CP:KEGG,C2,17,50
Cohort,-0.024761861529029483,0.018093082650286287,-1.3685816843730427,0.1715161897767397,LonGen OPEL,Thyroid cancer,CP:KEGG,C2,29,23
Cohort,-0.13142883664278615,0.06749651241507468,-1.9471944836876167,0.051925154950525805,LGP Offspring,Tight junction,CP:KEGG,C2,175,318
Cohort,-0.043980508105965106,0.20083519690726934,-0.21898804982013195,0.826712935935962,LGP Proband,Tight junction,CP:KEGG,C2,175,482
Cohort,-0.03075697638709244,0.06108512426719665,-0.5035100895032354,0.6147449948096761,LonGen OPEL,Tight junction,CP:KEGG,C2,257,304
Cohort,-0.12835325864006336,0.05342645916892533,-2.402428696130363,0.01655527044664141,LGP Offspring,Toll-like receptor signaling pathway,CP:KEGG,C2,106,168
Cohort,0.10231026460881167,0.14573625516813568,0.7020234223170925,0.4828604234390872,LGP Proband,Toll-like receptor signaling pathway,CP:KEGG,C2,106,219
Cohort,0.03884236843870238,0.04526097765134011,0.8581866865076946,0.39104771494876556,LonGen OPEL,Toll-like receptor signaling pathway,CP:KEGG,C2,126,165
Cohort,0.005059285592880209,0.0398133778703176,0.12707501507055247,0.8989188149749423,LGP Offspring,Tryptophan metabolism,CP:KEGG,C2,48,105
Cohort,0.053373999950982576,0.10719836708406975,0.49789937480227003,0.61868622563616,LGP Proband,Tryptophan metabolism,CP:KEGG,C2,48,133
Cohort,0.001639155083343548,0.03517670475398386,0.0465977440129013,0.9628455179280034,LonGen OPEL,Tryptophan metabolism,CP:KEGG,C2,79,97
Cohort,0.018651910644780435,0.02495877510047455,0.7473087348916333,0.4551370775428003,LGP Offspring,Type I diabetes mellitus,CP:KEGG,C2,16,46
Cohort,-0.025853168890006675,0.06972953070743738,-0.3707635578171067,0.7109077977343989,LGP Proband,Type I diabetes mellitus,CP:KEGG,C2,16,59
Cohort,0.038969760485157726,0.02650941021496716,1.4700349864123148,0.14194741499910177,LonGen OPEL,Type I diabetes mellitus,CP:KEGG,C2,41,58
Cohort,0.014249014962531545,0.037915555204881345,0.3758092130139002,0.7071766388037595,LGP Offspring,Type II diabetes mellitus,CP:KEGG,C2,47,107
Cohort,-0.026656261421292342,0.0981898701986664,-0.2714766947686054,0.786091604381679,LGP Proband,Type II diabetes mellitus,CP:KEGG,C2,47,124
Cohort,0.02517891487113333,0.032497521113952633,0.774794938446025,0.43869092662023457,LonGen OPEL,Type II diabetes mellitus,CP:KEGG,C2,66,89
Cohort,0.02384144045021118,0.03479924415856242,0.68511374389564,0.49350699547469423,LGP Offspring,Tyrosine metabolism,CP:KEGG,C2,38,88
Cohort,0.16397502993148036,0.10077382677946717,1.6271589079406732,0.10408107265911865,LGP Proband,Tyrosine metabolism,CP:KEGG,C2,38,130
Cohort,0.03807094399560014,0.030273420722314405,1.2575699437737544,0.2089161434612837,LonGen OPEL,Tyrosine metabolism,CP:KEGG,C2,59,79
Cohort,0.117715694352691,0.059230825900870296,1.987405925247471,0.04728052544929618,LGP Offspring,Ubiquitin mediated proteolysis,CP:KEGG,C2,103,261
Cohort,-0.10848051526584769,0.16360917233295608,-0.6630466600312742,0.507483881078603,LGP Proband,Ubiquitin mediated proteolysis,CP:KEGG,C2,103,339
Cohort,0.028405020507893886,0.049284257276146964,0.5763507878131624,0.564541028091887,LonGen OPEL,Ubiquitin mediated proteolysis,CP:KEGG,C2,173,231
Cohort,0.012153291174335395,0.02428771443801996,0.5003884249936111,0.6169644622445478,LGP Offspring,"Valine, leucine and isoleucine biosynthesis",CP:KEGG,C2,17,41
Cohort,0.020358302180037806,0.058557671275896984,0.34766242810645237,0.728181438469316,LGP Proband,"Valine, leucine and isoleucine biosynthesis",CP:KEGG,C2,17,40
Cohort,-0.011950610157537603,0.018930129110164534,-0.6313010380431437,0.5280249426378372,LonGen OPEL,"Valine, leucine and isoleucine biosynthesis",CP:KEGG,C2,25,25
Cohort,0.019491709930404166,0.04038163223982822,0.4826875202726348,0.6294738927347722,LGP Offspring,"Valine, leucine and isoleucine degradation",CP:KEGG,C2,51,116
Cohort,0.027518950917409843,0.11211803863832993,0.24544623908540178,0.8061713146901139,LGP Proband,"Valine, leucine and isoleucine degradation",CP:KEGG,C2,51,152
Cohort,0.06529694170617881,0.03629946056575658,1.7988405526824072,0.07242260670040204,LonGen OPEL,"Valine, leucine and isoleucine degradation",CP:KEGG,C2,71,120
Cohort,0.011663095633245527,0.061237844188524064,0.1904556861495654,0.8490092446646187,LGP Offspring,Vascular smooth muscle contraction,CP:KEGG,C2,114,244
Cohort,0.03870893029650575,0.18541835325159198,0.2087653655513921,0.834682386145037,LGP Proband,Vascular smooth muscle contraction,CP:KEGG,C2,114,382
Cohort,-0.027781472001788248,0.05113923826073771,-0.5432515803255041,0.5871086888312693,LonGen OPEL,Vascular smooth muscle contraction,CP:KEGG,C2,183,201
Cohort,-0.026212342444536654,0.02783794857976346,-0.9416046721054537,0.3467314376285895,LGP Offspring,Vasopressin-regulated water reabsorption,CP:KEGG,C2,31,52
Cohort,-0.10767734503387191,0.08540352149728271,-1.2608068513579722,0.2077310406956505,LGP Proband,Vasopressin-regulated water reabsorption,CP:KEGG,C2,31,94
Cohort,-0.02422212539166977,0.028816510619705638,-0.8405641373909414,0.40084456971073223,LonGen OPEL,Vasopressin-regulated water reabsorption,CP:KEGG,C2,65,63
Cohort,-0.0366292712705056,0.04677225397841649,-0.7831410324464699,0.43381856873962366,LGP Offspring,VEGF signaling pathway,CP:KEGG,C2,69,127
Cohort,-0.00998546959755322,0.13251861008941918,-0.07535145132306592,0.9399531558999576,LGP Proband,VEGF signaling pathway,CP:KEGG,C2,69,165
Cohort,-0.05756283911961116,0.039711879546700524,-1.4495118281147634,0.1475885542443779,LonGen OPEL,VEGF signaling pathway,CP:KEGG,C2,113,112
Cohort,0.0027659022506823696,0.04210008635888184,0.06569825598704142,0.9476374849843873,LGP Offspring,Vibrio cholerae infection,CP:KEGG,C2,53,109
Cohort,0.05012612342334737,0.11436787245224377,0.4382885013820501,0.6612906602701794,LGP Proband,Vibrio cholerae infection,CP:KEGG,C2,53,153
Cohort,-0.02073056005456785,0.036229997110602506,-0.5721932571863542,0.5673526127339368,LonGen OPEL,Vibrio cholerae infection,CP:KEGG,C2,98,104
Cohort,0.0277904367633981,0.04770696441143397,0.5825236861378995,0.5604082336165561,LGP Offspring,Viral myocarditis,CP:KEGG,C2,66,157
Cohort,-0.054930941007408,0.1364773001884758,-0.4024914101579392,0.6874255481430477,LGP Proband,Viral myocarditis,CP:KEGG,C2,66,229
Cohort,-0.0029596042874294056,0.04143658430548867,-0.07142490958255403,0.9430775264050186,LonGen OPEL,Viral myocarditis,CP:KEGG,C2,116,136
Cohort,-0.014362169649778697,0.05195738914202183,-0.27642208138135516,0.782308388859188,LGP Offspring,Wnt signaling pathway,CP:KEGG,C2,87,177
Cohort,-0.04776406544660393,0.14117070355501618,-0.33834261814803246,0.7351901661509666,LGP Proband,Wnt signaling pathway,CP:KEGG,C2,87,245
Cohort,-0.050521420801641244,0.04113559623179286,-1.2281679477054541,0.21974694788348859,LonGen OPEL,Wnt signaling pathway,CP:KEGG,C2,131,140
Cohort,0.11222388354725017,0.05416243690334312,2.0719873396302684,0.03864525060701817,LGP Offspring,a6b1 and a6b4 Integrin signaling,CP:PID,C2,81,222
Cohort,0.044493408992230594,0.14372838514263805,0.3095659145413393,0.7569684070102671,LGP Proband,a6b1 and a6b4 Integrin signaling,CP:PID,C2,81,264
Cohort,0.044930011122075945,0.045131856089128015,0.995527660846621,0.3197822239960858,LonGen OPEL,a6b1 and a6b4 Integrin signaling,CP:PID,C2,140,189
Cohort,0.04923889121796306,0.04590589821914395,1.072604896715193,0.2838311788188151,LGP Offspring,Posttranslational regulation of adherens junction stability and dissassembly,CP:PID,C2,62,152
Cohort,-0.07096563535216868,0.12034784960565348,-0.5896709877634156,0.5555709579635875,LGP Proband,Posttranslational regulation of adherens junction stability and dissassembly,CP:PID,C2,62,168
Cohort,0.03856335516693458,0.04098615406066753,0.9408873813789228,0.34704801400872753,LonGen OPEL,Posttranslational regulation of adherens junction stability and dissassembly,CP:PID,C2,111,153
Cohort,0.017532395194898236,0.017422330038727396,1.0063174762460694,0.3146229415306178,LGP Offspring,ALK1 signaling events,CP:PID,C2,8,23
Cohort,0.030273215228620313,0.04908235654427517,0.6167840617292305,0.5375454958902852,LGP Proband,ALK1 signaling events,CP:PID,C2,8,30
Cohort,-0.0015814536109981436,0.013467844671818953,-0.11742440231043696,0.9065533692650884,LonGen OPEL,ALK1 signaling events,CP:PID,C2,12,16
Cohort,0.005808264178441035,0.007164246216426996,0.8107292802309318,0.417806481038842,LGP Offspring,ALK2 signaling events,CP:PID,C2,1,4
Cohort,0.006518814709993682,0.020894055522809832,0.31199374879027947,0.7551232560175967,LGP Proband,ALK2 signaling events,CP:PID,C2,1,6
Cohort,-0.0046502341994608155,0.005183121785842628,-0.8971879094492125,0.36988992264046616,LonGen OPEL,ALK2 signaling events,CP:PID,C2,3,1
Cohort,-0.01427886755101791,0.02606755751543619,-0.5477639223606785,0.5840348259304484,LGP Offspring,Alpha-synuclein signaling,CP:PID,C2,20,39
Cohort,0.011986427610864098,0.07246230565903468,0.16541603944077118,0.8686566172667955,LGP Proband,Alpha-synuclein signaling,CP:PID,C2,20,60
Cohort,-0.006012605463120064,0.020799769984432066,-0.289070767014265,0.772602490998178,LonGen OPEL,Alpha-synuclein signaling,CP:PID,C2,32,33
Cohort,0.039071550276275464,0.03365074527381726,1.1610901915648204,0.24601505562074696,LGP Offspring,amb2 Integrin signaling,CP:PID,C2,31,83
Cohort,0.03711395947329168,0.0930218274824558,0.3989811905199507,0.6900091997180574,LGP Proband,amb2 Integrin signaling,CP:PID,C2,31,108
Cohort,-0.04257183440297824,0.03016909557433681,-1.4111074128185583,0.1586036574670929,LonGen OPEL,amb2 Integrin signaling,CP:PID,C2,70,62
Cohort,0.050829958914757355,0.04068701626764192,1.249291876808918,0.2119907331093064,LGP Offspring,Angiopoietin receptor Tie2-mediated signaling,CP:PID,C2,40,109
Cohort,-0.0237447356966547,0.10227830477258826,-0.2321580881639579,0.8164721833117292,LGP Proband,Angiopoietin receptor Tie2-mediated signaling,CP:PID,C2,40,130
Cohort,0.012846384824048294,0.034864287121012846,0.3684683062487093,0.7126220446221204,LonGen OPEL,Angiopoietin receptor Tie2-mediated signaling,CP:PID,C2,77,94
Cohort,0.004529727260652695,0.016507880495485856,0.2743978708769649,0.7838627103621283,LGP Offspring,Cellular roles of Anthrax toxin,CP:PID,C2,8,20
Cohort,0.10209473494383127,0.04907753125366128,2.080274462383737,0.03780515682271856,LGP Proband,Cellular roles of Anthrax toxin,CP:PID,C2,8,33
Cohort,0.009819415878085056,0.01496953306176185,0.6559600648578515,0.5120393735584434,LonGen OPEL,Cellular roles of Anthrax toxin,CP:PID,C2,14,21
Cohort,0.06773046344368291,0.041175707194823,1.644913179589509,0.10045260282961824,LGP Offspring,AP-1 transcription factor network,CP:PID,C2,44,130
Cohort,0.0919675248696369,0.10575556601407132,0.8696234944021778,0.38475639937881123,LGP Proband,AP-1 transcription factor network,CP:PID,C2,44,147
Cohort,0.037811987655572,0.032202358963739464,1.1741993093782073,0.24066637425987197,LonGen OPEL,AP-1 transcription factor network,CP:PID,C2,67,96
Cohort,-0.04210930189073395,0.02628704103942958,-1.6019034560630678,0.10964411144867041,LGP Offspring,Nongenotropic Androgen signaling,CP:PID,C2,24,34
Cohort,-0.03372430001173739,0.07457279333998777,-0.452233294493658,0.6512185234884083,LGP Proband,Nongenotropic Androgen signaling,CP:PID,C2,24,54
Cohort,4.461277609868785e-4,0.02229271050311413,0.02001227086874688,0.9840385989160919,LonGen OPEL,Nongenotropic Androgen signaling,CP:PID,C2,31,41
Cohort,-0.02597080940076203,0.041342981953905324,-0.6281793952288627,0.5300985890341654,LGP Offspring,Coregulation of Androgen receptor activity,CP:PID,C2,63,120
Cohort,-0.032921597170232714,0.11733649024350358,-0.2805742450785078,0.7791065560367345,LGP Proband,Coregulation of Androgen receptor activity,CP:PID,C2,63,167
Cohort,0.04691485568806667,0.03592040554362742,1.3060781184969041,0.191903284691591,LonGen OPEL,Coregulation of Androgen receptor activity,CP:PID,C2,82,114
Cohort,0.04600619383490609,0.0363366186153312,1.2661110358654861,0.20590946535678847,LGP Offspring,Regulation of Androgen receptor activity,CP:PID,C2,36,96
Cohort,-0.0630876711119541,0.10161852465435485,-0.6208284496014919,0.5348821251681993,LGP Proband,Regulation of Androgen receptor activity,CP:PID,C2,36,114
Cohort,-0.0010835208818923152,0.03235021602590585,-0.03349346665953138,0.9732894723339292,LonGen OPEL,Regulation of Androgen receptor activity,CP:PID,C2,67,75
Cohort,0.013888272155604012,0.018526508020499082,0.749643275475174,0.4537303761974453,LGP Offspring,Arf1 pathway,CP:PID,C2,9,26
Cohort,0.003935483704478833,0.047927446491650295,0.08211336076843684,0.9345762709357995,LGP Proband,Arf1 pathway,CP:PID,C2,9,30
Cohort,-0.01024440118458153,0.014324772119597226,-0.7151528205161826,0.4747243161946093,LonGen OPEL,Arf1 pathway,CP:PID,C2,17,15
Cohort,4.7878952397435953e-4,0.019362224608164075,0.024728022407739143,0.9802792007765867,LGP Offspring,Arf6 downstream pathway,CP:PID,C2,13,24
Cohort,-0.014731946770943673,0.05848499996950899,-0.251892737943475,0.8011860313015741,LGP Proband,Arf6 downstream pathway,CP:PID,C2,13,44
Cohort,-0.0092620538450502,0.022304867174661194,-0.4152481058292107,0.6780721887648942,LonGen OPEL,Arf6 downstream pathway,CP:PID,C2,33,39
Cohort,-0.02029819106327473,0.0395535692649273,-0.5131822852020947,0.607991481657419,LGP Offspring,Arf6 signaling events,CP:PID,C2,51,101
Cohort,0.15974993316782338,0.10830366610149193,1.475018703596985,0.1405849091609788,LGP Proband,Arf6 signaling events,CP:PID,C2,51,129
Cohort,-0.04720820956892616,0.03464426356959682,-1.3626558831042732,0.1733763729674856,LonGen OPEL,Arf6 signaling events,CP:PID,C2,97,95
Cohort,-0.045956666155629614,0.041075154716969244,-1.1188434096547344,0.263604356913181,LGP Offspring,Arf6 trafficking events,CP:PID,C2,58,102
Cohort,-0.14491499404603592,0.11356700921921269,-1.276030733241498,0.20229990453334346,LGP Proband,Arf6 trafficking events,CP:PID,C2,58,149
Cohort,-0.012259869813961497,0.03843394423204234,-0.3189854712788092,0.7498212159451987,LonGen OPEL,Arf6 trafficking events,CP:PID,C2,102,121
Cohort,-0.02071524539266002,0.0338213151998944,-0.6124908292367264,0.5404190359383566,LGP Offspring,ATF-2 transcription factor network,CP:PID,C2,41,79
Cohort,-0.0024877653376040856,0.09707341411965689,-0.025627669122027154,0.9795604471105214,LGP Proband,ATF-2 transcription factor network,CP:PID,C2,41,117
Cohort,0.0038709544141397175,0.03179231501667956,0.12175755090841466,0.90312176344247,LonGen OPEL,ATF-2 transcription factor network,CP:PID,C2,72,80
Cohort,0.00943849825782913,0.034508162952650606,0.2735149440084625,0.7845409506879788,LGP Offspring,ATM pathway,CP:PID,C2,40,84
Cohort,-0.0699416084772578,0.09873414691572022,-0.7083831750423709,0.4789052765523555,LGP Proband,ATM pathway,CP:PID,C2,40,124
Cohort,0.027602670624676286,0.03185357059040445,0.8665487137881898,0.3864504461821865,LonGen OPEL,ATM pathway,CP:PID,C2,65,89
Cohort,-0.03521917819751018,0.03676794069838798,-0.9578773662201402,0.33846704555590734,LGP Offspring,ATR signaling pathway,CP:PID,C2,48,88
Cohort,-0.04547101720795947,0.10138634048564579,-0.4484925384440444,0.6539142656017366,LGP Proband,ATR signaling pathway,CP:PID,C2,48,126
Cohort,0.029610046965454214,0.03403955154710208,0.8698718290833368,0.3846326812413934,LonGen OPEL,ATR signaling pathway,CP:PID,C2,65,94
Cohort,0.009899425709486069,0.02762666242586248,0.3583286883115783,0.7202092197026426,LGP Offspring,Aurora A signaling,CP:PID,C2,24,55
Cohort,0.09195215637103633,0.07515454640037772,1.223507569072018,0.22148361315184947,LGP Proband,Aurora A signaling,CP:PID,C2,24,73
Cohort,0.00356738822822221,0.02137877490382637,0.16686588657536777,0.8675179538648036,LonGen OPEL,Aurora A signaling,CP:PID,C2,29,36
Cohort,0.04529202331747309,0.03065740191094095,1.47736013146337,0.14004484357475738,LGP Offspring,Aurora B signaling,CP:PID,C2,26,75
Cohort,0.06060462994475789,0.08391604020622641,0.7222055496877597,0.47037055766877556,LGP Proband,Aurora B signaling,CP:PID,C2,26,96
Cohort,0.002123573415441771,0.022520526038145722,0.09429501832438636,0.9248985372495486,LonGen OPEL,Aurora B signaling,CP:PID,C2,38,46
Cohort,-0.1733338426317794,0.07017274681197917,-2.470102005500939,0.013753230525878983,LGP Offspring,Integrins in angiogenesis,CP:PID,C2,175,291
Cohort,-0.31221132620428815,0.18254471779376727,-1.7103279129501503,0.08757716478072357,LGP Proband,Integrins in angiogenesis,CP:PID,C2,175,382
Cohort,-0.015826408282204257,0.05566735298478019,-0.2843032304146256,0.7762519510384083,LonGen OPEL,Integrins in angiogenesis,CP:PID,C2,220,258
Cohort,0.0012436266981567547,0.04031260776742569,0.030849572057743635,0.9753986120259721,LGP Offspring,Osteopontin-mediated events,CP:PID,C2,52,109
Cohort,-0.22842110275949934,0.10463474582733127,-2.1830329968635933,0.029311542155996708,LGP Proband,Osteopontin-mediated events,CP:PID,C2,52,117
Cohort,0.019304493031257874,0.0341825636484391,0.564746788152017,0.572405115603933,LonGen OPEL,Osteopontin-mediated events,CP:PID,C2,77,101
Cohort,0.01660128709505305,0.03133027344865926,0.5298800574548922,0.5963690788066025,LGP Offspring,BARD1 signaling events,CP:PID,C2,29,68
Cohort,0.1541069275692738,0.0821017854330716,1.8770228534786242,0.060863850758734614,LGP Proband,BARD1 signaling events,CP:PID,C2,29,87
Cohort,0.013025541256573658,0.02627635827057844,0.4957133375349931,0.620233504583589,LonGen OPEL,BARD1 signaling events,CP:PID,C2,50,65
Cohort,-0.0036347322109753937,0.03426521299429986,-0.10607645169402695,0.9155531638630996,LGP Offspring,BCR signaling pathway,CP:PID,C2,36,80
Cohort,-0.035944940509884046,0.10193240067140948,-0.35263508239893804,0.7244511309505826,LGP Proband,BCR signaling pathway,CP:PID,C2,36,126
Cohort,4.255940873810095e-4,0.032929940977323276,0.012924228673051333,0.9896914830219332,LonGen OPEL,BCR signaling pathway,CP:PID,C2,68,83
Cohort,-0.01812900927291893,0.02526698318451811,-0.717497975145175,0.47331474056322176,LGP Offspring,Degradation of beta catenin,CP:PID,C2,25,40
Cohort,-0.04319031912917638,0.0723647347210488,-0.5968420846931339,0.5507747977833328,LGP Proband,Degradation of beta catenin,CP:PID,C2,25,61
Cohort,-0.04308083183767681,0.02156153667459355,-1.998040885853926,0.04605203110370937,LonGen OPEL,Degradation of beta catenin,CP:PID,C2,40,32
Cohort,-0.08115578024794791,0.044253806256052915,-1.8338711879014393,0.06711256112904931,LGP Offspring,Regulation of nuclear beta catenin signaling and target gene transcription,CP:PID,C2,73,127
Cohort,-0.011326283555227698,0.12679905611608464,-0.08932466772353949,0.9288453360434858,LGP Proband,Regulation of nuclear beta catenin signaling and target gene transcription,CP:PID,C2,73,183
Cohort,-0.0457501712773351,0.036626014704392265,-1.249116827112742,0.211989544900407,LonGen OPEL,Regulation of nuclear beta catenin signaling and target gene transcription,CP:PID,C2,110,102
Cohort,-0.016211137311932376,0.028072541697445583,-0.5774730869277677,0.5638121921579078,LGP Offspring,BMP receptor signaling,CP:PID,C2,27,53
Cohort,0.021070689599890554,0.07464621493299908,0.2822740525933321,0.7778034138441716,LGP Proband,BMP receptor signaling,CP:PID,C2,27,65
Cohort,0.004342934415039424,0.025397329206596292,0.17099965038494916,0.8642674975190825,LonGen OPEL,BMP receptor signaling,CP:PID,C2,44,51
Cohort,-0.05601205641392663,0.040153629908775676,-1.3949437831941827,0.16349094268960487,LGP Offspring,Caspase cascade in apoptosis,CP:PID,C2,59,94
Cohort,-0.21919011369876726,0.11898504059154982,-1.8421653058992518,0.06580581730222362,LGP Proband,Caspase cascade in apoptosis,CP:PID,C2,59,153
Cohort,-0.04242008087730318,0.036097239083510806,-1.175161368412817,0.2402815584632847,LonGen OPEL,Caspase cascade in apoptosis,CP:PID,C2,99,110
Cohort,-8.373907337593855e-4,0.028455245601284603,-0.029428343212809304,0.9765316537097535,LGP Offspring,CD40/CD40L signaling,CP:PID,C2,25,55
Cohort,0.0806705585102728,0.0762842502422159,1.0574995264963554,0.2905898747834667,LGP Proband,CD40/CD40L signaling,CP:PID,C2,25,66
Cohort,0.0037668240047480303,0.024774264466884268,0.15204584619588363,0.8791893040685393,LonGen OPEL,CD40/CD40L signaling,CP:PID,C2,40,51
Cohort,-0.04962933267327292,0.02983254160727339,-1.66359719954846,0.09665642550658927,LGP Offspring,Downstream signaling in na&#xef;ve CD8+ T cells,CP:PID,C2,37,62
Cohort,0.0023694548165133556,0.08912286949502687,0.026586383830982607,0.9787959936142352,LGP Proband,Downstream signaling in na&#xef;ve CD8+ T cells,CP:PID,C2,37,96
Cohort,0.020426471793565174,0.02674115334864575,0.7638590425494729,0.4451775975910496,LonGen OPEL,Downstream signaling in na&#xef;ve CD8+ T cells,CP:PID,C2,40,60
Cohort,-0.013665563902353807,0.031931627884402854,-0.42796327051740485,0.6688141678545085,LGP Offspring,TCR signaling in na&#xef;ve CD8+ T cells,CP:PID,C2,34,63
Cohort,-0.0658155472898512,0.08783953171045492,-0.7492702432294234,0.4539056182715222,LGP Proband,TCR signaling in na&#xef;ve CD8+ T cells,CP:PID,C2,34,85
Cohort,0.003043012005241247,0.025923731128718323,0.11738325745363856,0.9065859621197336,LonGen OPEL,TCR signaling in na&#xef;ve CD8+ T cells,CP:PID,C2,42,53
Cohort,-0.051852839239534786,0.04867206661723442,-1.0653510903351302,0.2870974414278119,LGP Offspring,CDC42 signaling events,CP:PID,C2,92,159
Cohort,-0.1413527876015172,0.13432578313399912,-1.0523131472124616,0.2929606934344601,LGP Proband,CDC42 signaling events,CP:PID,C2,92,215
Cohort,0.00581198529668464,0.04278597393806905,0.1358385648786972,0.8919832475453483,LonGen OPEL,CDC42 signaling events,CP:PID,C2,125,153
Cohort,-0.12173565490412828,0.04141120840883283,-2.939678883607816,0.0033976341129990455,LGP Offspring,Regulation of CDC42 activity,CP:PID,C2,72,93
Cohort,0.09016207871467932,0.11929337974831777,0.7558011928650278,0.4499818120116328,LGP Proband,Regulation of CDC42 activity,CP:PID,C2,72,160
Cohort,0.008639459902825311,0.03555012290480614,0.24302194189200155,0.8080510087541617,LonGen OPEL,Regulation of CDC42 activity,CP:PID,C2,89,110
Cohort,0.025691269104650048,0.034227903363996705,0.7505942982085755,0.45315803306536984,LGP Offspring,Ceramide signaling pathway,CP:PID,C2,34,83
Cohort,0.01342534522380123,0.09650665123479353,0.13911316009855484,0.8893943135377385,LGP Proband,Ceramide signaling pathway,CP:PID,C2,34,121
Cohort,-0.02293004144101026,0.0297601672207708,-0.7704943749444552,0.4412353078105379,LonGen OPEL,Ceramide signaling pathway,CP:PID,C2,67,77
Cohort,0.028826614312635036,0.01449467309150726,1.9887729878865064,0.047128985546735815,LGP Offspring,Circadian rhythm pathway,CP:PID,C2,3,18
Cohort,-0.021161325788685705,0.03827430934475917,-0.5528858952900553,0.580489703982592,LGP Proband,Circadian rhythm pathway,CP:PID,C2,3,21
Cohort,-0.009314183445710281,0.013434140537148021,-0.6933218704951571,0.48830982846680615,LonGen OPEL,Circadian rhythm pathway,CP:PID,C2,13,15
Cohort,0.06167707462811095,0.046179746698083425,1.3355871142244855,0.1821337662536295,LGP Offspring,C-MYB transcription factor network,CP:PID,C2,59,147
Cohort,-0.03556529548338839,0.12917219071057967,-0.27533244801177986,0.7831290361790245,LGP Proband,C-MYB transcription factor network,CP:PID,C2,59,209
Cohort,-0.025739432872085247,0.037959386793270176,-0.6780782053267677,0.4979191666764241,LonGen OPEL,C-MYB transcription factor network,CP:PID,C2,111,121
Cohort,-0.03062293475423646,0.03350818457796922,-0.913894176599775,0.3610982912605688,LGP Offspring,Visual signal transduction: Cones,CP:PID,C2,41,68
Cohort,-0.06391427716220137,0.09144825294008554,-0.6989119541089134,0.48480191003092654,LGP Proband,Visual signal transduction: Cones,CP:PID,C2,41,89
Cohort,0.04389562240592595,0.029628302930286593,1.4815435939483068,0.13885751049660078,LonGen OPEL,Visual signal transduction: Cones,CP:PID,C2,49,79
Cohort,-0.00891061891448796,0.02214518515585156,-0.4023727438618165,0.6875369249416537,LGP Offspring,CXCR3-mediated signaling events,CP:PID,C2,17,32
Cohort,0.036275372930611637,0.06401310180221309,0.566686692400797,0.5710795337585047,LGP Proband,CXCR3-mediated signaling events,CP:PID,C2,17,53
Cohort,-0.022509472026963996,0.021873655031365322,-1.0290677070058458,0.3037604457038761,LonGen OPEL,CXCR3-mediated signaling events,CP:PID,C2,37,32
Cohort,-0.003974486143425707,0.049261854339771254,-0.0806808066138292,0.9357196807552812,LGP Offspring,CXCR4-mediated signaling events,CP:PID,C2,77,161
Cohort,-0.14592977967273024,0.1363845494809099,-1.0699876212382577,0.28493444632519477,LGP Proband,CXCR4-mediated signaling events,CP:PID,C2,77,217
Cohort,0.001914557633960559,0.042279561361451466,0.04528328989964791,0.9638928639556952,LonGen OPEL,CXCR4-mediated signaling events,CP:PID,C2,130,152
Cohort,-0.02377908714597585,0.03797662746185191,-0.6261505756366149,0.5314275418210599,LGP Offspring,Validated transcriptional targets of deltaNp63 isoforms,CP:PID,C2,51,86
Cohort,-0.11214181829001507,0.0993994229545466,-1.128193856228877,0.25956249830435874,LGP Proband,Validated transcriptional targets of deltaNp63 isoforms,CP:PID,C2,51,112
Cohort,0.02767498869085487,0.035893047133299806,0.7710403797168666,0.4409118014173564,LonGen OPEL,Validated transcriptional targets of deltaNp63 isoforms,CP:PID,C2,78,107
Cohort,0.024986962402037106,0.02223364096262819,1.123835832558279,0.2614816035829848,LGP Offspring,DNA-PK pathway in nonhomologous end joining,CP:PID,C2,11,34
Cohort,-0.0860270679918925,0.062111797770522226,-1.3850358720854845,0.1664118570669179,LGP Proband,DNA-PK pathway in nonhomologous end joining,CP:PID,C2,11,49
Cohort,0.002001500936851025,0.021402058207422758,0.09351908669030978,0.9255147203657967,LonGen OPEL,DNA-PK pathway in nonhomologous end joining,CP:PID,C2,29,38
Cohort,-0.03955026097003995,0.04636356584071668,-0.8530461420054698,0.39393586012475734,LGP Offspring,E2F transcription factor network,CP:PID,C2,80,151
Cohort,-0.03391396753251934,0.1315763442803134,-0.2577512524612191,0.7966624733737637,LGP Proband,E2F transcription factor network,CP:PID,C2,80,194
Cohort,-0.004984130840735995,0.04215032607914398,-0.11824655475683611,0.9059021352004938,LonGen OPEL,E2F transcription factor network,CP:PID,C2,132,154
Cohort,-0.0118772757013436,0.025533303674137448,-0.4651679959994378,0.6419609617678123,LGP Offspring,E-cadherin signaling in keratinocytes,CP:PID,C2,22,43
Cohort,-0.039143081604287984,0.06832210495526075,-0.5729197253205237,0.5668534744015582,LGP Proband,E-cadherin signaling in keratinocytes,CP:PID,C2,22,54
Cohort,0.005206747680049967,0.020746598288313427,0.2509687423302996,0.8019030446252714,LonGen OPEL,E-cadherin signaling in keratinocytes,CP:PID,C2,27,38
Cohort,0.009249721229719416,0.032664570145131515,0.28317290534123374,0.7771309904869246,LGP Offspring,E-cadherin signaling in the nascent adherens junction,CP:PID,C2,31,69
Cohort,0.04602178896854716,0.09366426356089953,0.4913484312896377,0.6233093072877315,LGP Proband,E-cadherin signaling in the nascent adherens junction,CP:PID,C2,31,107
Cohort,0.03178552537514795,0.03230418783034081,0.9839444205216724,0.325441812614916,LonGen OPEL,E-cadherin signaling in the nascent adherens junction,CP:PID,C2,60,87
Cohort,0.0331778521559276,0.04145439303577335,0.800345867500618,0.42379160689680573,LGP Offspring,Stabilization and expansion of the E-cadherin adherens junction,CP:PID,C2,52,121
Cohort,-0.004041852576852488,0.1114462073496268,-0.036267295881792276,0.9710779054715231,LGP Proband,Stabilization and expansion of the E-cadherin adherens junction,CP:PID,C2,52,154
Cohort,0.03417407999864111,0.036588470874077426,0.9340122498219271,0.3505808103142133,LonGen OPEL,Stabilization and expansion of the E-cadherin adherens junction,CP:PID,C2,86,115
Cohort,-0.007670573585509575,0.038875674101343516,-0.19731036857427728,0.8436439766641254,LGP Offspring,Endothelins,CP:PID,C2,47,101
Cohort,-0.04223020856273479,0.10793725828865065,-0.39124774181127403,0.6957140554283336,LGP Proband,Endothelins,CP:PID,C2,47,142
Cohort,-0.03353985082897432,0.03416294634511728,-0.9817610720735738,0.3265158673062655,LonGen OPEL,Endothelins,CP:PID,C2,83,84
Cohort,-0.020721699642337235,0.03938164137264852,-0.5261766376433702,0.5989380632730583,LGP Offspring,EPHA forward signaling,CP:PID,C2,52,95
Cohort,0.18684027662337588,0.10344116082848061,1.8062469052641652,0.07124016201532912,LGP Proband,EPHA forward signaling,CP:PID,C2,52,119
Cohort,0.034726738756764644,0.028111283797628395,1.2353309442130267,0.21707183742219596,LonGen OPEL,EPHA forward signaling,CP:PID,C2,54,74
Cohort,-0.05034053279646773,0.033952651474300835,-1.4826686756576604,0.13862848441231934,LGP Offspring,EPHA2 forward signaling,CP:PID,C2,45,68
Cohort,-0.027496902026037936,0.09425520619626285,-0.29172820405042166,0.770566989207055,LGP Proband,EPHA2 forward signaling,CP:PID,C2,45,101
Cohort,0.009625776400003705,0.02766498902961363,0.34794072716601904,0.7279766876957668,LonGen OPEL,EPHA2 forward signaling,CP:PID,C2,57,70
Cohort,-0.01924639371601822,0.025424162850906137,-0.7570118956869514,0.44930649875670947,LGP Offspring,EPHB forward signaling,CP:PID,C2,25,43
Cohort,-0.04667371341132223,0.07663975743345457,-0.6090013196068436,0.5426894108508631,LGP Proband,EPHB forward signaling,CP:PID,C2,25,80
Cohort,-0.02184602112460842,0.02574173320611144,-0.8486616246734263,0.39632474153388253,LonGen OPEL,EPHB forward signaling,CP:PID,C2,49,47
Cohort,-0.0715681177875289,0.032752595653403806,-2.185112854714805,0.029223157192680413,LGP Offspring,Ephrin B reverse signaling,CP:PID,C2,44,57
Cohort,-0.10885323166330962,0.09007788230412697,-1.2084346221172482,0.22722264794629107,LGP Proband,Ephrin B reverse signaling,CP:PID,C2,44,91
Cohort,0.019889058984575346,0.029744400603833956,0.6686656507044123,0.5039026440182658,LonGen OPEL,Ephrin B reverse signaling,CP:PID,C2,61,76
Cohort,-0.00430290603375544,0.027518459875940822,-0.1563643479015131,0.8757925220079308,LGP Offspring,EPO signaling pathway,CP:PID,C2,28,51
Cohort,0.08723210643130368,0.0823408787256963,1.0594021800751194,0.28972337721244845,LGP Proband,EPO signaling pathway,CP:PID,C2,28,79
Cohort,-0.024741572432446405,0.023606639547897355,-1.048076850677806,0.29492132220169637,LonGen OPEL,EPO signaling pathway,CP:PID,C2,42,44
Cohort,-0.006157194843388908,0.035291730964392594,-0.17446565173017942,0.861551759134147,LGP Offspring,Plasma membrane estrogen receptor signaling,CP:PID,C2,40,85
Cohort,-0.035805003560735515,0.09272595613133651,-0.3861378739521598,0.6994930452511825,LGP Proband,Plasma membrane estrogen receptor signaling,CP:PID,C2,40,94
Cohort,-0.022494677358639067,0.03087225474215862,-0.7286373329875618,0.4664378423262906,LonGen OPEL,Plasma membrane estrogen receptor signaling,CP:PID,C2,70,71
Cohort,-0.07878535478394362,0.04830430441190748,-1.631021411924571,0.1033515708974369,LGP Offspring,Validated nuclear estrogen receptor alpha network,CP:PID,C2,89,146
Cohort,0.009419868927952916,0.1453633197079355,0.06480224135551767,0.9483469859755007,LGP Proband,Validated nuclear estrogen receptor alpha network,CP:PID,C2,89,236
Cohort,0.020813481020667025,0.04178681701986303,0.49808725586285985,0.6185601247832604,LonGen OPEL,Validated nuclear estrogen receptor alpha network,CP:PID,C2,123,150
Cohort,0.01201836633410681,0.020963858399514822,0.5732898069176502,0.5666391404109681,LGP Offspring,Validated nuclear estrogen receptor beta network,CP:PID,C2,11,30
Cohort,0.05040719609373541,0.05660257845545766,0.8905459339348367,0.37342963918664884,LGP Proband,Validated nuclear estrogen receptor beta network,CP:PID,C2,11,38
Cohort,-0.0034635850383323455,0.0158256686709962,-0.2188586852371097,0.8268162326334821,LonGen OPEL,Validated nuclear estrogen receptor beta network,CP:PID,C2,21,18
Cohort,0.003830505693436802,0.017556054871387165,0.21818715659631224,0.827349139137239,LGP Offspring,ErbB receptor signaling network,CP:PID,C2,9,22
Cohort,-0.0012264565356118308,0.042598825876742616,-0.02879085304276968,0.9770382839137767,LGP Proband,ErbB receptor signaling network,CP:PID,C2,9,21
Cohort,0.013422241727199339,0.01531537554821268,0.8763899837092619,0.3810824581207779,LonGen OPEL,ErbB receptor signaling network,CP:PID,C2,12,20
Cohort,0.0072483967283665076,0.04228858414036502,0.1714031546742615,0.863958068324256,LGP Offspring,ErbB1 downstream signaling,CP:PID,C2,62,129
Cohort,-0.05965377156647386,0.1158786001895319,-0.5147954106185586,0.6068323929926619,LGP Proband,ErbB1 downstream signaling,CP:PID,C2,62,161
Cohort,-0.057464976732687904,0.037617299047539944,-1.5276210197883928,0.12700390522746557,LonGen OPEL,ErbB1 downstream signaling,CP:PID,C2,105,103
Cohort,0.05222328241101671,0.030147312557471925,1.7322699100113756,0.08368164230696463,LGP Offspring,Internalization of ErbB1,CP:PID,C2,22,65
Cohort,0.08779266739848464,0.07826135835837443,1.1217881881945422,0.26227538060982114,LGP Proband,Internalization of ErbB1,CP:PID,C2,22,82
Cohort,-0.011241856462892687,0.026609326585746586,-0.42247805207195444,0.6727902104130778,LonGen OPEL,Internalization of ErbB1,CP:PID,C2,51,55
Cohort,0.001612587387140273,0.02973523716109318,0.0542315293603997,0.956766723750751,LGP Offspring,EGF receptor (ErbB1) signaling pathway,CP:PID,C2,29,59
Cohort,-0.1113629710882773,0.07398608283147541,-1.5051880951980996,0.13265433967200582,LGP Proband,EGF receptor (ErbB1) signaling pathway,CP:PID,C2,29,65
Cohort,-0.03431154293816215,0.02418955735217239,-1.4184444319763767,0.15645243881857826,LonGen OPEL,EGF receptor (ErbB1) signaling pathway,CP:PID,C2,45,41
Cohort,0.015349176577860835,0.029489334434506395,0.5204992541269525,0.6028860755221712,LGP Offspring,ErbB2/ErbB3 signaling events,CP:PID,C2,25,61
Cohort,-0.006265080406986073,0.07684184467852237,-0.08153214479944923,0.9350383240261674,LGP Proband,ErbB2/ErbB3 signaling events,CP:PID,C2,25,75
Cohort,-0.020808018808517428,0.025809765391888954,-0.8062072046209537,0.4203641733018312,LonGen OPEL,ErbB2/ErbB3 signaling events,CP:PID,C2,51,51
Cohort,-0.013619489067632433,0.036014485016879684,-0.3781669809036307,0.7054252723097421,LGP Offspring,ErbB4 signaling events,CP:PID,C2,45,84
Cohort,0.04762142646278477,0.0973776205548013,0.48903871537901067,0.6249428672349289,LGP Proband,ErbB4 signaling events,CP:PID,C2,45,113
Cohort,-0.049517493909847166,0.03261156320124937,-1.5184029543223527,0.1293099027257116,LonGen OPEL,ErbB4 signaling events,CP:PID,C2,83,77
Cohort,0.022733222352093387,0.04115683830689622,0.5523558972770807,0.580887114806303,LGP Offspring,Signaling events mediated by focal adhesion kinase,CP:PID,C2,50,113
Cohort,-0.007976169592066302,0.10747243290369829,-0.07421595823752707,0.9408563445633746,LGP Proband,Signaling events mediated by focal adhesion kinase,CP:PID,C2,50,140
Cohort,0.049734339012568,0.035455243407993824,1.4027357939772251,0.1610855396968386,LonGen OPEL,Signaling events mediated by focal adhesion kinase,CP:PID,C2,85,109
Cohort,-0.011352629864792128,0.043456698234343574,-0.2612400464382315,0.7939869658005443,LGP Offspring,Fanconi anemia pathway,CP:PID,C2,63,122
Cohort,-0.03607472337831489,0.12071111985657564,-0.2988517000022658,0.7651276504953635,LGP Proband,Fanconi anemia pathway,CP:PID,C2,63,166
Cohort,-0.004398800302146985,0.03729254397275534,-0.11795388121981162,0.9061339571974361,LonGen OPEL,Fanconi anemia pathway,CP:PID,C2,104,120
Cohort,-0.02753709325484744,0.03460758306600461,-0.795695359665189,0.42648843297606465,LGP Offspring,FAS (CD95) signaling pathway,CP:PID,C2,37,68
Cohort,-0.05940952803388941,0.08761596273690281,-0.6780673997989046,0.4979170373735575,LGP Proband,FAS (CD95) signaling pathway,CP:PID,C2,37,81
Cohort,-0.024142743886674447,0.027322898460202995,-0.8836084473921907,0.37717440645314626,LonGen OPEL,FAS (CD95) signaling pathway,CP:PID,C2,52,49
Cohort,-0.08632535854727817,0.04488018202280723,-1.923462754750177,0.05484162429841575,LGP Offspring,Fc-epsilon receptor I signaling in mast cells,CP:PID,C2,74,118
Cohort,0.1102077574548026,0.12143089601355622,0.9075759223789249,0.36436447914989945,LGP Proband,Fc-epsilon receptor I signaling in mast cells,CP:PID,C2,74,171
Cohort,-0.07519802879905871,0.041496927174602294,-1.812134871641358,0.07034204086889256,LonGen OPEL,Fc-epsilon receptor I signaling in mast cells,CP:PID,C2,123,112
Cohort,0.0056565390918214935,0.040740470086783435,0.13884324554361302,0.8896153706264456,LGP Offspring,FGF signaling pathway,CP:PID,C2,51,105
Cohort,0.013382006806776136,0.11542007007098465,0.11594176644101888,0.9077266045918477,LGP Proband,FGF signaling pathway,CP:PID,C2,51,163
Cohort,-0.0011398395785204333,0.0382105320983768,-0.029830507871123162,0.9762097052554719,LonGen OPEL,FGF signaling pathway,CP:PID,C2,100,112
Cohort,0.04225414129454814,0.03676945013067138,1.149164350959431,0.25089464202667305,LGP Offspring,FOXM1 transcription factor network,CP:PID,C2,38,98
Cohort,-0.011354586521098567,0.09675859177285427,-0.11734964630070308,0.9066112386826158,LGP Proband,FOXM1 transcription factor network,CP:PID,C2,38,130
Cohort,0.07450216370434531,0.03498051604199692,2.1298188858877745,0.03349273631025303,LonGen OPEL,FOXM1 transcription factor network,CP:PID,C2,69,110
Cohort,0.009783512445182297,0.03155394052676977,0.31005675620394063,0.7566133564145381,LGP Offspring,FoxO family signaling,CP:PID,C2,32,69
Cohort,0.015202980848226343,0.08395584486619583,0.18108305469924116,0.8563463814985982,LGP Proband,FoxO family signaling,CP:PID,C2,32,81
Cohort,-0.011373025098964065,0.028343634242147246,-0.4012550049792934,0.6883400789068292,LonGen OPEL,FoxO family signaling,CP:PID,C2,62,65
Cohort,0.012644106245743032,0.03279372628245417,0.38556479177872766,0.6999403098719663,LGP Offspring,Validated transcriptional targets of AP1 family members Fra1 and Fra2,CP:PID,C2,32,79
Cohort,-0.004078946244535328,0.08809485476937302,-0.04630175343626777,0.963080826132033,LGP Proband,Validated transcriptional targets of AP1 family members Fra1 and Fra2,CP:PID,C2,32,98
Cohort,7.992591398069584e-4,0.029929085452480884,0.02670509732333656,0.978701640919744,LonGen OPEL,Validated transcriptional targets of AP1 family members Fra1 and Fra2,CP:PID,C2,64,74
Cohort,-0.015749861005302047,0.029797598315727224,-0.5285614242604662,0.5972832102621941,LGP Offspring,Glypican 1 network,CP:PID,C2,27,52
Cohort,0.10030756275331801,0.08303411138361107,1.2080283763127777,0.22737878267180966,LGP Proband,Glypican 1 network,CP:PID,C2,27,78
Cohort,-0.01258272902392003,0.023084366904315166,-0.5450757682060554,0.5858540924859772,LonGen OPEL,Glypican 1 network,CP:PID,C2,41,42
Cohort,-0.005463966309974755,0.02108106588939912,-0.25918833225232596,0.7955688397634155,LGP Offspring,GMCSF-mediated signaling events,CP:PID,C2,16,30
Cohort,0.0454304006598191,0.060621259154920344,0.7494136758809261,0.4538192365804954,LGP Proband,GMCSF-mediated signaling events,CP:PID,C2,16,47
Cohort,-0.06048505278085335,0.02013061626247101,-3.0046299622537673,0.0027424452684436805,LonGen OPEL,GMCSF-mediated signaling events,CP:PID,C2,37,23
Cohort,-0.01486831690025167,0.042330952692919706,-0.3512398364409727,0.7255178678405149,LGP Offspring,Signaling events mediated by HDAC Class I,CP:PID,C2,60,123
Cohort,0.07621519188025465,0.11317148149581899,0.6734487423235715,0.5008484275786917,LGP Proband,Signaling events mediated by HDAC Class I,CP:PID,C2,60,161
Cohort,-0.03926547978022835,0.03836103060179974,-1.0235772909184089,0.3063459400019681,LonGen OPEL,Signaling events mediated by HDAC Class I,CP:PID,C2,114,121
Cohort,-0.03668810865377028,0.029158687497908356,-1.2582222247281203,0.20874580306438728,LGP Offspring,Signaling events mediated by HDAC Class II,CP:PID,C2,31,52
Cohort,-0.029337844784584705,0.07899245766062833,-0.37140058245342283,0.7104335217552715,LGP Proband,Signaling events mediated by HDAC Class II,CP:PID,C2,31,74
Cohort,0.01822113515219441,0.026912270590160013,0.6770567756871707,0.49856664292455477,LonGen OPEL,Signaling events mediated by HDAC Class II,CP:PID,C2,43,56
Cohort,0.012047347307223028,0.02657103316928626,0.45340153807600847,0.6504051330426694,LGP Offspring,Signaling events mediated by HDAC Class III,CP:PID,C2,21,50
Cohort,0.0940265370683525,0.071021728786227,1.3239122543942738,0.18589493217653918,LGP Proband,Signaling events mediated by HDAC Class III,CP:PID,C2,21,59
Cohort,-0.04611540719778811,0.024877448935754245,-1.853703220007834,0.06415141740002528,LonGen OPEL,Signaling events mediated by HDAC Class III,CP:PID,C2,50,39
Cohort,-0.08366904136497792,0.035541422304257414,-2.354127548659059,0.01885142979615672,LGP Offspring,Signaling events mediated by the Hedgehog family,CP:PID,C2,59,85
Cohort,-0.1122297646452957,0.10110539607720373,-1.11002744660233,0.2673071442762241,LGP Proband,Signaling events mediated by the Hedgehog family,CP:PID,C2,59,116
Cohort,0.011386811905156405,0.027760717706981523,0.4101771440258097,0.6817863781983112,LonGen OPEL,Signaling events mediated by the Hedgehog family,CP:PID,C2,52,67
Cohort,-0.043115980133450936,0.03662469633701679,-1.1772378871541216,0.23951488786320108,LGP Offspring,Hedgehog signaling events mediated by Gli proteins,CP:PID,C2,53,87
Cohort,0.009335565824346387,0.10063670537303417,0.0927650183870971,0.9261125208883649,LGP Proband,Hedgehog signaling events mediated by Gli proteins,CP:PID,C2,53,122
Cohort,-0.059618563728717155,0.033176022003090805,-1.7970377438007143,0.0727085947863486,LonGen OPEL,Hedgehog signaling events mediated by Gli proteins,CP:PID,C2,83,77
Cohort,-0.015367302877228987,0.03695096541486016,-0.41588366378781777,0.6776271230523803,LGP Offspring,Notch-mediated HES/HEY network,CP:PID,C2,44,85
Cohort,-0.21336161401316042,0.1066331882383584,-2.0008931322228753,0.04572757646819085,LGP Proband,Notch-mediated HES/HEY network,CP:PID,C2,44,146
Cohort,-0.03473768946082364,0.040465883141250415,-0.8584438733134301,0.39090582489064263,LonGen OPEL,Notch-mediated HES/HEY network,CP:PID,C2,110,119
Cohort,-0.03692191619347996,0.037038643155884926,-0.9968485086801453,0.31919473167930673,LGP Offspring,HIF-1-alpha transcription factor network,CP:PID,C2,48,84
Cohort,-0.23702628105213006,0.10193921863012574,-2.3251726297035056,0.02030184361866796,LGP Proband,HIF-1-alpha transcription factor network,CP:PID,C2,48,108
Cohort,0.01017408934616373,0.035826222966773145,0.28398442547515096,0.776496167871663,LonGen OPEL,HIF-1-alpha transcription factor network,CP:PID,C2,84,102
Cohort,0.009195152811101793,0.018893049076138698,0.48669501540198556,0.6266322322328495,LGP Offspring,Hypoxic and oxygen homeostasis regulation of HIF-1-alpha,CP:PID,C2,10,25
Cohort,0.03735633977933918,0.04730414830660867,0.7897053665824119,0.42992431620090166,LGP Proband,Hypoxic and oxygen homeostasis regulation of HIF-1-alpha,CP:PID,C2,10,26
Cohort,0.0057594675190625905,0.01400862135010009,0.4111373542851481,0.6810824825275434,LonGen OPEL,Hypoxic and oxygen homeostasis regulation of HIF-1-alpha,CP:PID,C2,13,17
Cohort,-0.02385113958310025,0.0285383430567694,-0.8357576869706411,0.4035865336153095,LGP Offspring,HIF-2-alpha transcription factor network,CP:PID,C2,28,52
Cohort,-0.11675011238221172,0.06780128643966463,-1.721945386480328,0.08545019358096603,LGP Proband,HIF-2-alpha transcription factor network,CP:PID,C2,28,46
Cohort,-0.04238872845730192,0.026774792990778343,-1.5831580274738728,0.11378265666800819,LonGen OPEL,HIF-2-alpha transcription factor network,CP:PID,C2,51,44
Cohort,-0.012808160627357904,0.0297671678544344,-0.43027810673798716,0.6671304882263751,LGP Offspring,HIV-1 Nef: Negative effector of Fas and TNF-alpha,CP:PID,C2,29,58
Cohort,0.04566270271103016,0.07396734921519095,0.6173359353217465,0.5371816750306883,LGP Proband,HIV-1 Nef: Negative effector of Fas and TNF-alpha,CP:PID,C2,29,64
Cohort,0.007037028216089952,0.024033652577846277,0.2927989490276871,0.7697521395416882,LonGen OPEL,HIV-1 Nef: Negative effector of Fas and TNF-alpha,CP:PID,C2,42,53
Cohort,-0.0023799709743279325,0.03751019342499587,-0.06344864574177264,0.9494280077922532,LGP Offspring,FOXA1 transcription factor network,CP:PID,C2,45,90
Cohort,-0.05296788851093924,0.11395149551738509,-0.46482837518229986,0.6421756956909198,LGP Proband,FOXA1 transcription factor network,CP:PID,C2,45,146
Cohort,0.06270265319526003,0.03156073544485348,1.9867297865989613,0.04729479830541518,LonGen OPEL,FOXA1 transcription factor network,CP:PID,C2,54,89
Cohort,0.04672294777725128,0.03945976808909343,1.1840654428520416,0.23680332601713527,LGP Offspring,FOXA2 and FOXA3 transcription factor networks,CP:PID,C2,40,105
Cohort,0.06415321629271199,0.10266321732080047,0.6248899846207526,0.5322141889516252,LGP Proband,FOXA2 and FOXA3 transcription factor networks,CP:PID,C2,40,141
Cohort,0.04258426529023411,0.034707169747892175,1.2269587407892955,0.22020086986555007,LonGen OPEL,FOXA2 and FOXA3 transcription factor networks,CP:PID,C2,70,107
Cohort,0.04277870300330898,0.028244444205634506,1.5145882387296197,0.1303441191162579,LGP Offspring,IFN-gamma pathway,CP:PID,C2,20,60
Cohort,0.05296657116397448,0.07961283120052043,0.6653019414743315,0.5060413291647868,LGP Proband,IFN-gamma pathway,CP:PID,C2,20,83
Cohort,-0.059437087004487237,0.026852016883566577,-2.2135054980120583,0.027145652948797824,LonGen OPEL,IFN-gamma pathway,CP:PID,C2,59,49
Cohort,-0.0037847192594729806,0.025051943084950547,-0.1510748785688634,0.8799617191289828,LGP Offspring,IGF1 pathway,CP:PID,C2,21,40
Cohort,-0.11937478002483437,0.0613719181123586,-1.9451042707559698,0.05209818074143215,LGP Proband,IGF1 pathway,CP:PID,C2,21,40
Cohort,-0.020452105182941778,0.020606481515689577,-0.9925083604093082,0.3212512064278041,LonGen OPEL,IGF1 pathway,CP:PID,C2,34,33
Cohort,-0.01575494607416647,0.026748612701808637,-0.5890004932144082,0.5560577086369329,LGP Offspring,IL1-mediated signaling events,CP:PID,C2,24,42
Cohort,-0.021266579664386102,0.0677831101649808,-0.31374452444900036,0.7537935360929549,LGP Proband,IL1-mediated signaling events,CP:PID,C2,24,50
Cohort,0.0092260635356415,0.02419549090338072,0.3813133435681764,0.7030725086302729,LonGen OPEL,IL1-mediated signaling events,CP:PID,C2,35,46
Cohort,-0.0693207664037599,0.03215341287933759,-2.1559380543490234,0.03144066088235847,LGP Offspring,IL12-mediated signaling events,CP:PID,C2,44,56
Cohort,-0.02585845391126621,0.09597181415333471,-0.26943800259888817,0.7876592915614532,LGP Proband,IL12-mediated signaling events,CP:PID,C2,44,97
Cohort,0.05954344410850272,0.029025002547149896,2.0514535360256008,0.04054954641696239,LonGen OPEL,IL12-mediated signaling events,CP:PID,C2,50,81
Cohort,0.012509402569664985,0.01862159957507433,0.6717684224296855,0.5019606389981692,LGP Offspring,IL12 signaling mediated by STAT4,CP:PID,C2,10,24
Cohort,0.031674430320498825,0.050163340144522874,0.6314258625770004,0.5279351285220268,LGP Proband,IL12 signaling mediated by STAT4,CP:PID,C2,10,29
Cohort,0.038216733656384894,0.018016879278607636,2.1211627754958418,0.034216617157123666,LonGen OPEL,IL12 signaling mediated by STAT4,CP:PID,C2,13,32
Cohort,-0.012038443821214967,0.024749094041914457,-0.48641957563484767,0.6268273658315846,LGP Offspring,IL2-mediated signaling events,CP:PID,C2,22,42
Cohort,0.07136872792367717,0.07184398562540319,0.9933848644728033,0.3208105558790294,LGP Proband,IL2-mediated signaling events,CP:PID,C2,22,63
Cohort,-0.01738795130380101,0.02140709529511099,-0.812251782135623,0.41689001269235537,LonGen OPEL,IL2-mediated signaling events,CP:PID,C2,35,36
Cohort,0.012548252012848309,0.028122125727267324,0.4462056721651548,0.6555915737038396,LGP Offspring,IL2 signaling events mediated by PI3K,CP:PID,C2,22,52
Cohort,0.08143556517792958,0.0720414043301506,1.1303994686823082,0.2586329144462396,LGP Proband,IL2 signaling events mediated by PI3K,CP:PID,C2,22,61
Cohort,-0.015584076465639555,0.024666450629525688,-0.6317924171459613,0.5277039287635596,LonGen OPEL,IL2 signaling events mediated by PI3K,CP:PID,C2,41,44
Cohort,0.0033817446660186655,0.021184722688937577,0.15963129259107905,0.8732192102156204,LGP Offspring,IL2 signaling events mediated by STAT5,CP:PID,C2,15,30
Cohort,-0.013499092053055715,0.05633241513218292,-0.23963275888989238,0.8106738472085144,LGP Proband,IL2 signaling events mediated by STAT5,CP:PID,C2,15,35
Cohort,-0.016600355555938737,0.017582475956555703,-0.9441420876648048,0.3453835227506392,LonGen OPEL,IL2 signaling events mediated by STAT5,CP:PID,C2,24,18
Cohort,-3.492381597037994e-4,0.031986872423534284,-0.010918171526105443,0.9912919538623743,LGP Offspring,IL23-mediated signaling events,CP:PID,C2,34,66
Cohort,-0.053435671532282195,0.09307075612459123,-0.5741402966657899,0.5660276764666632,LGP Proband,IL23-mediated signaling events,CP:PID,C2,34,97
Cohort,0.03754076779335873,0.028549235343409078,1.3149482759097941,0.1889059769065953,LonGen OPEL,IL23-mediated signaling events,CP:PID,C2,54,79
Cohort,-0.020954498345188248,0.022228427901666386,-0.9426891743260604,0.3461766808354001,LGP Offspring,IL27-mediated signaling events,CP:PID,C2,18,29
Cohort,0.04890382526989776,0.06511073715978438,0.7510869543664633,0.4528121984040314,LGP Proband,IL27-mediated signaling events,CP:PID,C2,18,44
Cohort,0.016919665189797786,0.020736915445680595,0.8159200549434692,0.4147899459521819,LonGen OPEL,IL27-mediated signaling events,CP:PID,C2,25,35
Cohort,-0.012801989563026509,0.015200910303514576,-0.8421857183162631,0.3999818549325135,LGP Offspring,IL3-mediated signaling events,CP:PID,C2,9,14
Cohort,0.05055086519555833,0.05245943059383912,0.9636182593544023,0.33551666188317975,LGP Proband,IL3-mediated signaling events,CP:PID,C2,9,33
Cohort,-0.02590556411785481,0.0165488426236651,-1.5654003549957902,0.11788650413091119,LonGen OPEL,IL3-mediated signaling events,CP:PID,C2,21,18
Cohort,0.01935089462911957,0.036405446247447154,0.5315384543727851,0.5952203165558654,LGP Offspring,IL4-mediated signaling events,CP:PID,C2,43,97
Cohort,0.03672204308387266,0.09819529042834058,0.3739694940937223,0.7085220635219864,LGP Proband,IL4-mediated signaling events,CP:PID,C2,43,127
Cohort,-0.02002343743633592,0.03172237110166935,-0.6312087256075952,0.5280852607055708,LonGen OPEL,IL4-mediated signaling events,CP:PID,C2,67,77
Cohort,-0.009211579211546531,0.014556422101588395,-0.6328189130034478,0.5270659033154685,LGP Offspring,IL5-mediated signaling events,CP:PID,C2,8,13
Cohort,0.039414237766214985,0.04526899646596405,0.8706673627247067,0.38418634087401216,LGP Proband,IL5-mediated signaling events,CP:PID,C2,8,26
Cohort,-0.03498442179637278,0.014993715600966231,-2.3332723340516277,0.019882044088852413,LonGen OPEL,IL5-mediated signaling events,CP:PID,C2,21,12
Cohort,-0.043663932111697445,0.02813757447019538,-1.5518015654813566,0.12117772922285619,LGP Offspring,IL6-mediated signaling events,CP:PID,C2,32,42
Cohort,-0.1435081538949582,0.08647791702151646,-1.6594774578029223,0.0973955674764313,LGP Proband,IL6-mediated signaling events,CP:PID,C2,32,77
Cohort,-0.02960107387140217,0.024261759673667248,-1.2200711848419636,0.22279923105885419,LonGen OPEL,IL6-mediated signaling events,CP:PID,C2,50,42
Cohort,-0.03308500893973285,0.03181554420214213,-1.0399007708158343,0.29875779045177697,LGP Offspring,IL8- and CXCR1-mediated signaling events,CP:PID,C2,35,62
Cohort,0.08039453891025972,0.09474264694918569,0.8485570278966194,0.39637130756579586,LGP Proband,IL8- and CXCR1-mediated signaling events,CP:PID,C2,35,101
Cohort,0.024633393135374056,0.02479071363935592,0.9936540550518032,0.3206932717105702,LonGen OPEL,IL8- and CXCR1-mediated signaling events,CP:PID,C2,42,59
Cohort,0.011235883029012328,0.03158536782134333,0.3557306374447174,0.7221532761089824,LGP Offspring,IL8- and CXCR2-mediated signaling events,CP:PID,C2,28,64
Cohort,0.2633814219636268,0.09039907892440414,2.913540990654102,0.0036690410873140003,LGP Proband,IL8- and CXCR2-mediated signaling events,CP:PID,C2,28,98
Cohort,0.032891365529749673,0.024962365776344277,1.3176381527474994,0.1880039125254174,LonGen OPEL,IL8- and CXCR2-mediated signaling events,CP:PID,C2,38,55
Cohort,-0.01234667520935693,0.0417125065831367,-0.29599456423816006,0.7673251360896476,LGP Offspring,Integrin-linked kinase signaling,CP:PID,C2,58,104
Cohort,-0.13695107540495455,0.10481730293505968,-1.3065693503848652,0.1917191928139881,LGP Proband,Integrin-linked kinase signaling,CP:PID,C2,58,124
Cohort,-0.04756108430725126,0.03423347082284039,-1.389315286007131,0.1651254007732567,LonGen OPEL,Integrin-linked kinase signaling,CP:PID,C2,85,81
Cohort,-0.01071340210954961,0.015557181085326489,-0.6886467445991533,0.4912818610676484,LGP Offspring,Insulin-mediated glucose transport,CP:PID,C2,8,14
Cohort,-0.022908545109173027,0.03889587501906195,-0.5889710695014855,0.556040168124565,LGP Proband,Insulin-mediated glucose transport,CP:PID,C2,8,17
Cohort,-0.009314622823640413,0.0161048872615008,-0.578372432690497,0.5631762958221653,LonGen OPEL,Insulin-mediated glucose transport,CP:PID,C2,20,18
Cohort,0.06678417828426488,0.032928648909027844,2.02814814749217,0.04293676298379697,LGP Offspring,Insulin Pathway,CP:PID,C2,24,79
Cohort,0.06319878252207153,0.08051655066039719,0.7849166662470607,0.4327253313129922,LGP Proband,Insulin Pathway,CP:PID,C2,24,89
Cohort,-0.02302038874555325,0.02581982857604206,-0.8915779079537972,0.37288863664057426,LonGen OPEL,Insulin Pathway,CP:PID,C2,45,46
Cohort,0.012199832241699595,0.03321510679656433,0.3672976972924112,0.713511926472449,LGP Offspring,Alpha4 beta1 integrin signaling events,CP:PID,C2,36,72
Cohort,-0.08750265373055288,0.09416821408809341,-0.929216451409974,0.3530457851528156,LGP Proband,Alpha4 beta1 integrin signaling events,CP:PID,C2,36,105
Cohort,7.690319747378569e-4,0.028516479133306523,0.026967984762173783,0.9784920285485943,LonGen OPEL,Alpha4 beta1 integrin signaling events,CP:PID,C2,59,70
Cohort,-4.8567361829112603e-4,0.0355412426410337,-0.013665071398781021,0.9891012216900337,LGP Offspring,Alpha9 beta1 integrin signaling events,CP:PID,C2,40,75
Cohort,-0.4016570616467493,0.09997878658785299,-4.0174228489341255,6.415270207254278e-5,LGP Proband,Alpha9 beta1 integrin signaling events,CP:PID,C2,40,116
Cohort,-0.07616359952065865,0.03041612851597672,-2.504053054636855,0.012476995712565388,LonGen OPEL,Alpha9 beta1 integrin signaling events,CP:PID,C2,78,57
Cohort,0.02930019108000141,0.03401672244911531,0.8613466839384886,0.389352545874298,LGP Offspring,Integrin family cell surface interactions,CP:PID,C2,31,84
Cohort,0.043134736081714545,0.08978552400945297,0.4804197175167475,0.6310549636985299,LGP Proband,Integrin family cell surface interactions,CP:PID,C2,31,104
Cohort,0.005414959066887582,0.030624440668620384,0.17681821932624125,0.8596961561234288,LonGen OPEL,Integrin family cell surface interactions,CP:PID,C2,65,86
Cohort,0.01189404819346164,0.0690423003595962,0.1722718989882046,0.8632753365530152,LGP Offspring,Beta1 integrin cell surface interactions,CP:PID,C2,153,305
Cohort,-0.6400893349757899,0.18969186806484906,-3.3743636008527558,7.7401439112765e-4,LGP Proband,Beta1 integrin cell surface interactions,CP:PID,C2,153,417
Cohort,-0.04663947923116325,0.05584913318550569,-0.8350976384225677,0.4039133071219353,LonGen OPEL,Beta1 integrin cell surface interactions,CP:PID,C2,247,282
Cohort,0.004479241540170724,0.02285087172180725,0.19602059801928928,0.8446529530997198,LGP Offspring,Beta2 integrin cell surface interactions,CP:PID,C2,18,37
Cohort,-0.04813545928285514,0.060547614222714964,-0.7950017502885639,0.42683866572966955,LGP Proband,Beta2 integrin cell surface interactions,CP:PID,C2,18,46
Cohort,-0.01851985325592474,0.020192988447850984,-0.9171427648637958,0.35934562094974265,LonGen OPEL,Beta2 integrin cell surface interactions,CP:PID,C2,32,27
Cohort,-0.06458262612851029,0.042765328427611396,-1.5101632210735596,0.13146904311744437,LGP Offspring,Beta3 integrin cell surface interactions,CP:PID,C2,66,99
Cohort,-0.47240933657376644,0.11595601696166949,-4.074039010238912,5.0614370446275225e-5,LGP Proband,Beta3 integrin cell surface interactions,CP:PID,C2,66,159
Cohort,-0.06837895089829643,0.03727705437500992,-1.8343442647157453,0.06697601273709201,LonGen OPEL,Beta3 integrin cell surface interactions,CP:PID,C2,102,99
Cohort,0.05537084100687087,0.03897502559757294,1.4206749106104226,0.1558723635809381,LGP Offspring,Alpha6 beta4 integrin-ligand interactions,CP:PID,C2,45,123
Cohort,-0.060260667320113426,0.10494756573912392,-0.5741978567650431,0.5659887475086995,LGP Proband,Alpha6 beta4 integrin-ligand interactions,CP:PID,C2,45,143
Cohort,0.014931619220522625,0.034703393083629436,0.4302639567416331,0.6671201056267122,LonGen OPEL,Alpha6 beta4 integrin-ligand interactions,CP:PID,C2,87,111
Cohort,0.047984016412568865,0.02705806425320972,1.7733721068711277,0.07661724201592143,LGP Offspring,Beta5 beta6 beta7 and beta8 integrin cell surface interactions,CP:PID,C2,14,54
Cohort,-0.05506366512127684,0.07296924743914641,-0.7546146774666663,0.4506932377606735,LGP Proband,Beta5 beta6 beta7 and beta8 integrin cell surface interactions,CP:PID,C2,14,67
Cohort,-9.319011482167591e-4,0.02075515033244786,-0.04489975419546146,0.9641984738366596,LonGen OPEL,Beta5 beta6 beta7 and beta8 integrin cell surface interactions,CP:PID,C2,29,36
Cohort,0.050968715931966696,0.03759646005482857,1.3556785893575294,0.17565417715344966,LGP Offspring,Signaling events mediated by Stem cell factor receptor (c-Kit),CP:PID,C2,41,106
Cohort,0.09177911633915133,0.11039494015526934,0.8313706788559779,0.4060022143372609,LGP Proband,Signaling events mediated by Stem cell factor receptor (c-Kit),CP:PID,C2,41,145
Cohort,-0.05099503896699539,0.03507175174250425,-1.4540202993394638,0.14633483839816597,LonGen OPEL,Signaling events mediated by Stem cell factor receptor (c-Kit),CP:PID,C2,95,89
Cohort,-0.039958863759138645,0.029592277429523577,-1.350313907211229,0.1773672049419691,LGP Offspring,Lissencephaly gene (LIS1) in neuronal migration and development,CP:PID,C2,33,53
Cohort,0.001912663286772339,0.08288606512503878,0.023075812368303014,0.9815953192569393,LGP Proband,Lissencephaly gene (LIS1) in neuronal migration and development,CP:PID,C2,33,83
Cohort,0.011482965307600564,0.02457037798684356,0.46734996562727793,0.640377420688893,LonGen OPEL,Lissencephaly gene (LIS1) in neuronal migration and development,CP:PID,C2,40,54
Cohort,-0.06249955457214885,0.03821981669777241,-1.6352656807951553,0.10245887940020601,LGP Offspring,LKB1 signaling events,CP:PID,C2,62,96
Cohort,-0.06752989535071435,0.10060654164448883,-0.6712276781100706,0.5022613584715498,LGP Proband,LKB1 signaling events,CP:PID,C2,62,112
Cohort,-0.018220255183839466,0.03444001514560092,-0.5290431815087855,0.596922986334449,LonGen OPEL,LKB1 signaling events,CP:PID,C2,79,85
Cohort,0.02214404669931569,0.017725338471544384,1.2492876643718223,0.21199227231134146,LGP Offspring,LPA4-mediated signaling events,CP:PID,C2,7,25
Cohort,0.008810165846573322,0.05477036662818566,0.16085643366936087,0.8722454311408852,LGP Proband,LPA4-mediated signaling events,CP:PID,C2,7,35
Cohort,-0.011818555027489365,0.014188298956196574,-0.8329789965644718,0.4051064309617858,LonGen OPEL,LPA4-mediated signaling events,CP:PID,C2,16,15
Cohort,0.028086276322137827,0.02668090735385022,1.0526732074606453,0.29286691634412776,LGP Offspring,VEGFR3 signaling in lymphatic endothelium,CP:PID,C2,16,47
Cohort,-0.041271628890716526,0.07321430999196055,-0.563709866216706,0.5731031393876705,LGP Proband,VEGFR3 signaling in lymphatic endothelium,CP:PID,C2,16,72
Cohort,-0.037253576293772246,0.024848863633514944,-1.499206436286544,0.13421656491638714,LonGen OPEL,VEGFR3 signaling in lymphatic endothelium,CP:PID,C2,44,36
Cohort,0.03292737776734941,0.043487641260294814,0.757166330780346,0.4492140440911533,LGP Offspring,LPA receptor mediated events,CP:PID,C2,52,129
Cohort,-0.11029557691185352,0.11507974745301636,-0.958427345844532,0.3381250649816995,LGP Proband,LPA receptor mediated events,CP:PID,C2,52,154
Cohort,-0.001388127766987279,0.03881569343090252,-0.03576202417865714,0.9714810799862168,LonGen OPEL,LPA receptor mediated events,CP:PID,C2,108,131
Cohort,0.027703146339891693,0.024515004409882774,1.1300485970430287,0.2588565452375974,LGP Offspring,Trk receptor signaling mediated by the MAPK pathway,CP:PID,C2,16,44
Cohort,0.1030928745773625,0.07674643512101575,1.3432920293275252,0.1795428322486046,LGP Proband,Trk receptor signaling mediated by the MAPK pathway,CP:PID,C2,16,78
Cohort,-0.01638494592846793,0.024509199555447926,-0.6685222783959042,0.5039940775664496,LonGen OPEL,Trk receptor signaling mediated by the MAPK pathway,CP:PID,C2,42,47
Cohort,-0.052057010183278754,0.05382540357631981,-0.9671457476294882,0.3338170538265687,LGP Offspring,Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met),CP:PID,C2,104,193
Cohort,-0.09578401034950515,0.1399228951583623,-0.6845485168177694,0.49381904612442784,LGP Proband,Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met),CP:PID,C2,104,246
Cohort,0.006724683864833684,0.04667638451045083,0.14407036738948856,0.88548136989569,LonGen OPEL,Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met),CP:PID,C2,146,176
Cohort,-0.13464806347475117,0.0461369174664043,-2.9184451599480696,0.0036346931930639494,LGP Offspring,mTOR signaling pathway,CP:PID,C2,84,114
Cohort,-0.2283038481066868,0.1246306704629554,-1.8318432153066746,0.0673312815169582,LGP Proband,mTOR signaling pathway,CP:PID,C2,84,163
Cohort,-0.030643434702456295,0.036536730427877216,-0.8387021592680777,0.4018882523113876,LonGen OPEL,mTOR signaling pathway,CP:PID,C2,94,101
Cohort,-0.054721192349759785,0.04271529465299074,-1.2810678890149818,0.20060911808434542,LGP Offspring,Validated targets of C-MYC transcriptional activation,CP:PID,C2,70,126
Cohort,-0.09475559030816746,0.11152495184228536,-0.8496357877129368,0.39577143482303756,LGP Proband,Validated targets of C-MYC transcriptional activation,CP:PID,C2,70,141
Cohort,0.020574207640070803,0.038102819796496074,0.539965486805331,0.5893718591602658,LonGen OPEL,Validated targets of C-MYC transcriptional activation,CP:PID,C2,92,116
Cohort,-0.01833473637120643,0.01636969610006395,-1.1200413409711867,0.26309391916424807,LGP Offspring,C-MYC pathway,CP:PID,C2,12,15
Cohort,-0.059437652269062724,0.04106086682388958,-1.4475498660072457,0.14811876405273974,LGP Proband,C-MYC pathway,CP:PID,C2,12,16
Cohort,0.004174259617370299,0.00922992035747805,0.4522530483145857,0.6512099133796587,LonGen OPEL,C-MYC pathway,CP:PID,C2,6,7
Cohort,0.04725753773867935,0.05031603879910566,0.9392141922650582,0.3479562446052754,LGP Offspring,Validated targets of C-MYC transcriptional repression,CP:PID,C2,69,170
Cohort,-0.006719167569475851,0.13178589604343954,-0.05098548305397616,0.9593492967337425,LGP Proband,Validated targets of C-MYC transcriptional repression,CP:PID,C2,69,236
Cohort,-0.032158237494531464,0.04224023422702565,-0.7613176887631072,0.4466928194813785,LonGen OPEL,Validated targets of C-MYC transcriptional repression,CP:PID,C2,132,152
Cohort,-0.0569506200705892,0.035542244002475486,-1.6023360839744007,0.10954844587887495,LGP Offspring,N-cadherin signaling events,CP:PID,C2,50,82
Cohort,-0.12686340973146937,0.09637892467143998,-1.316298248439193,0.18843559903974055,LGP Proband,N-cadherin signaling events,CP:PID,C2,50,111
Cohort,0.05080986201487923,0.031481889026624015,1.6139394294894338,0.10693688304277768,LonGen OPEL,N-cadherin signaling events,CP:PID,C2,56,92
Cohort,-0.013827728119046902,0.026998562997486333,-0.5121653371082866,0.6087025823964638,LGP Offspring,Nectin adhesion pathway,CP:PID,C2,22,43
Cohort,0.03780261859074398,0.07981154278668688,0.4736485133707967,0.6358745335659974,LGP Proband,Nectin adhesion pathway,CP:PID,C2,22,77
Cohort,-0.018946356111078883,0.025246119838554563,-0.7504660610120765,0.45319582866343044,LonGen OPEL,Nectin adhesion pathway,CP:PID,C2,49,53
Cohort,-0.004947969426333818,0.03209568575280332,-0.15416306928109955,0.8775271725656932,LGP Offspring,Nephrin/Neph1 signaling in the kidney podocyte,CP:PID,C2,34,67
Cohort,-0.02320285411059704,0.0790219302944547,-0.29362550401056553,0.7691171371397629,LGP Proband,Nephrin/Neph1 signaling in the kidney podocyte,CP:PID,C2,34,75
Cohort,-0.0026478506082618725,0.02531293353856631,-0.10460465217228407,0.9167158742028858,LonGen OPEL,Nephrin/Neph1 signaling in the kidney podocyte,CP:PID,C2,45,53
Cohort,-0.04671064405213879,0.03942112868130843,-1.1849139183649677,0.23646787951891943,LGP Offspring,Netrin-mediated signaling events,CP:PID,C2,58,103
Cohort,-0.21541700578030756,0.10877432441115743,-1.9804030679708027,0.047986487300537194,LGP Proband,Netrin-mediated signaling events,CP:PID,C2,58,144
Cohort,-0.04198977041945817,0.03551467174532996,-1.1823217942308495,0.2374310920785323,LonGen OPEL,Netrin-mediated signaling events,CP:PID,C2,105,109
Cohort,0.016381777981596554,0.03407039113123872,0.4808215414520529,0.630798914697217,LGP Offspring,Role of Calcineurin-dependent NFAT signaling in lymphocytes,CP:PID,C2,37,82
Cohort,-0.060896564274685275,0.09309420615663941,-0.6541391434416585,0.5132024958239587,LGP Proband,Role of Calcineurin-dependent NFAT signaling in lymphocytes,CP:PID,C2,37,110
Cohort,-0.005620062263348475,0.029907536710117776,-0.187914582127628,0.8509915032444363,LonGen OPEL,Role of Calcineurin-dependent NFAT signaling in lymphocytes,CP:PID,C2,66,77
Cohort,0.04047534589191129,0.025024523930842046,1.6174272087560686,0.10625259047292199,LGP Offspring,Calcineurin-regulated NFAT-dependent transcription in lymphocytes,CP:PID,C2,15,48
Cohort,0.0033864680315149266,0.07713673285288464,0.04390214501272185,0.9649929142559799,LGP Proband,Calcineurin-regulated NFAT-dependent transcription in lymphocytes,CP:PID,C2,15,77
Cohort,-0.02112816572081656,0.02274914731053373,-0.9287453913067505,0.3533025923389892,LonGen OPEL,Calcineurin-regulated NFAT-dependent transcription in lymphocytes,CP:PID,C2,42,39
Cohort,0.014548254727961335,0.020395381237255993,0.7133112423211887,0.4758993532878639,LGP Offspring,Atypical NF-kappaB pathway,CP:PID,C2,11,30
Cohort,-2.737693458650966e-4,0.04847346291475061,-0.0056478190210295,0.9954950669881284,LGP Proband,Atypical NF-kappaB pathway,CP:PID,C2,11,26
Cohort,0.03149415513068652,0.017635552062961034,1.7858332428862227,0.07450684719748159,LonGen OPEL,Atypical NF-kappaB pathway,CP:PID,C2,14,31
Cohort,0.016625355323321413,0.029748287008352782,0.5588676524014076,0.5764371269830432,LGP Offspring,Canonical NF-kappaB pathway,CP:PID,C2,24,62
Cohort,0.012048907905822004,0.08264179401551018,0.14579678538392654,0.884117043862079,LGP Proband,Canonical NF-kappaB pathway,CP:PID,C2,24,77
Cohort,0.004707336792834904,0.028841166514891856,0.16321589455836732,0.8703898798879309,LonGen OPEL,Canonical NF-kappaB pathway,CP:PID,C2,52,62
Cohort,-0.07562169605643243,0.037852196887091676,-1.997815246549689,0.046136921470739965,LGP Offspring,Notch signaling pathway,CP:PID,C2,61,93
Cohort,0.06199485872365359,0.10903592647131172,0.5685727698197252,0.5697991699729477,LGP Proband,Notch signaling pathway,CP:PID,C2,61,152
Cohort,-0.06669847663422074,0.03475809894645261,-1.9189333897971408,0.055350074746817246,LonGen OPEL,Notch signaling pathway,CP:PID,C2,98,89
Cohort,-0.016363169145597753,0.02580468966845176,-0.6341160988889163,0.526219569767746,LGP Offspring,Signaling mediated by p38-alpha and p38-beta,CP:PID,C2,23,41
Cohort,0.009972645114641602,0.07415551939482093,0.13448284357021303,0.8930532235027098,LGP Proband,Signaling mediated by p38-alpha and p38-beta,CP:PID,C2,23,73
Cohort,-0.010058359218064252,0.023166315232783997,-0.4341803656297521,0.6642751290927722,LonGen OPEL,Signaling mediated by p38-alpha and p38-beta,CP:PID,C2,40,37
Cohort,-0.0032274512313653896,0.02202166970797845,-0.14655797104231766,0.8835246240951136,LGP Offspring,Regulation of p38-alpha and p38-beta,CP:PID,C2,15,32
Cohort,0.0679457893991403,0.057170815665238836,1.1884698269304717,0.23498666698958387,LGP Proband,Regulation of p38-alpha and p38-beta,CP:PID,C2,15,37
Cohort,8.602333469679261e-4,0.01529645195780044,0.0562374431234852,0.9551667657025263,LonGen OPEL,Regulation of p38-alpha and p38-beta,CP:PID,C2,15,17
Cohort,3.734944171078176e-4,0.020546993368246346,0.018177570334208696,0.9855025596113709,LGP Offspring,Signaling mediated by p38-gamma and p38-delta,CP:PID,C2,14,30
Cohort,0.09548016844005006,0.06002241525786927,1.59074185918455,0.11204663898273036,LGP Proband,Signaling mediated by p38-gamma and p38-delta,CP:PID,C2,14,50
Cohort,-0.00415084599429417,0.01758100746766765,-0.2360983010744852,0.81341712768133,LonGen OPEL,Signaling mediated by p38-gamma and p38-delta,CP:PID,C2,22,27
Cohort,-0.005771279916790176,0.020663794900464726,-0.27929428958184155,0.7801044147000538,LGP Offspring,p38 signaling mediated by MAPKAP kinases,CP:PID,C2,15,29
Cohort,-0.0718187222808807,0.0561658557629721,-1.2786900743392198,0.20136191603064257,LGP Proband,p38 signaling mediated by MAPKAP kinases,CP:PID,C2,15,37
Cohort,0.03600436567280311,0.01929759521468844,1.865743646928517,0.062444870702508544,LonGen OPEL,p38 signaling mediated by MAPKAP kinases,CP:PID,C2,20,37
Cohort,0.009853063494551598,0.030981805565535956,0.31802741366087806,0.7505623605839111,LGP Offspring,p38 MAPK signaling pathway,CP:PID,C2,28,62
Cohort,0.05899892786141523,0.08837987079475439,0.667560693751512,0.5045987264793439,LGP Proband,p38 MAPK signaling pathway,CP:PID,C2,28,103
Cohort,0.04151157505386203,0.028193608984259738,1.4723753556005406,0.14131480921462777,LonGen OPEL,p38 MAPK signaling pathway,CP:PID,C2,50,72
Cohort,-0.0640421617691408,0.07107288689065612,-0.901077254223092,0.3678681531957745,LGP Offspring,Direct p53 effectors,CP:PID,C2,164,319
Cohort,-1.21499215167848e-4,0.18509265360831542,-6.564237575034127e-4,0.9994764066321394,LGP Proband,Direct p53 effectors,CP:PID,C2,164,379
Cohort,0.024146571816010473,0.056608845894739995,0.42655121181783595,0.6698215710089381,LonGen OPEL,Direct p53 effectors,CP:PID,C2,231,279
Cohort,0.020019433570565872,0.03729315224803737,0.5368125879361522,0.59157370002294,LGP Offspring,p53 pathway,CP:PID,C2,41,93
Cohort,0.1292506705809343,0.10018495287411636,1.2901205906972817,0.19736638205037418,LGP Proband,p53 pathway,CP:PID,C2,41,125
Cohort,-0.022425383867038278,0.03393204718255833,-0.6608909785603894,0.5088734557754473,LonGen OPEL,p53 pathway,CP:PID,C2,88,97
Cohort,0.032223429952416914,0.044428964395420135,0.7252797896801438,0.46853138864240995,LGP Offspring,p73 transcription factor network,CP:PID,C2,61,137
Cohort,0.05902854556491004,0.11163543904997161,0.5287617092497569,0.597111448846533,LGP Proband,p73 transcription factor network,CP:PID,C2,61,155
Cohort,0.026455319718133714,0.03985199148882415,0.6638393397617954,0.5069853671896267,LonGen OPEL,p73 transcription factor network,CP:PID,C2,107,137
Cohort,-0.025870437096072903,0.03651901774942296,-0.708409992666949,0.4789348889212631,LGP Offspring,p75(NTR)-mediated signaling,CP:PID,C2,41,84
Cohort,0.2376567741422717,0.09942200772588601,2.3903839761263863,0.017051748512129095,LGP Proband,p75(NTR)-mediated signaling,CP:PID,C2,41,123
Cohort,-0.02233927440128842,0.03123312534648228,-0.7152430041332525,0.47466862905273866,LonGen OPEL,p75(NTR)-mediated signaling,CP:PID,C2,72,74
Cohort,7.186474436882346e-4,0.020814128952352916,0.0345269045528324,0.9724671806298448,LGP Offspring,PDGFR-alpha signaling pathway,CP:PID,C2,15,30
Cohort,0.05979274511139773,0.05850887857784763,1.0219431061534,0.30710416600943896,LGP Proband,PDGFR-alpha signaling pathway,CP:PID,C2,15,42
Cohort,0.0074577039598043154,0.016609368379714273,0.44900587363169847,0.6535496338656939,LonGen OPEL,PDGFR-alpha signaling pathway,CP:PID,C2,16,25
Cohort,-0.036642386921020176,0.0514430089319663,-0.7122908959209591,0.4765304211090684,LGP Offspring,PDGFR-beta signaling pathway,CP:PID,C2,88,167
Cohort,0.02254762454103705,0.13997336846613004,0.16108510346018426,0.8720653843512776,LGP Proband,PDGFR-beta signaling pathway,CP:PID,C2,88,245
Cohort,-0.04063182966572318,0.04021204875506541,-1.010439182375777,0.3125919661912269,LonGen OPEL,PDGFR-beta signaling pathway,CP:PID,C2,128,136
Cohort,0.01897247197908715,0.027874083337265362,0.6806491804421964,0.4963265583477242,LGP Offspring,Trk receptor signaling mediated by PI3K and PLC-gamma,CP:PID,C2,22,53
Cohort,0.010192251457775012,0.07977084169836328,0.12776913519748073,0.8983624771500495,LGP Proband,Trk receptor signaling mediated by PI3K and PLC-gamma,CP:PID,C2,22,79
Cohort,-0.027901765364736052,0.021774531977338953,-1.281394493060691,0.20042828773816374,LonGen OPEL,Trk receptor signaling mediated by PI3K and PLC-gamma,CP:PID,C2,39,39
Cohort,-0.019699280621179534,0.023745753871020785,-0.829591712614374,0.40706251214602374,LGP Offspring,Class I PI3K signaling events mediated by Akt,CP:PID,C2,19,34
Cohort,0.09130759125717783,0.063325870468714393,1.4418687114974214,0.1497148052204847,LGP Proband,Class I PI3K signaling events mediated by Akt,CP:PID,C2,19,47
Cohort,-0.02491463491305743,0.019286673479044805,-1.2918057092700548,0.19679937876250675,LonGen OPEL,Class I PI3K signaling events mediated by Akt,CP:PID,C2,31,26
Cohort,-0.054270417957885064,0.03699284109896343,-1.4670519037102496,0.14282699392647571,LGP Offspring,Class I PI3K signaling events,CP:PID,C2,47,77
Cohort,0.023482235166107524,0.09364613444562016,0.2507549863656523,0.80206530798418,LGP Proband,Class I PI3K signaling events,CP:PID,C2,47,95
Cohort,-0.0011258527639448652,0.030342798975591553,-0.03710444658881098,0.9704110296087143,LonGen OPEL,Class I PI3K signaling events,CP:PID,C2,62,67
Cohort,-0.021110694277185413,0.03478625203923839,-0.6068688933022407,0.5441416850082103,LGP Offspring,PLK1 signaling events,CP:PID,C2,44,80
Cohort,-0.045599088730698456,0.09285359062329779,-0.4910858958130289,0.6234948937292802,LGP Proband,PLK1 signaling events,CP:PID,C2,44,108
Cohort,0.0015439422439465045,0.032721587654227204,0.04718420940516458,0.9623782478292324,LonGen OPEL,PLK1 signaling events,CP:PID,C2,60,76
Cohort,0.03290741558934742,0.026706291612022336,1.2321971192186614,0.2183038630344011,LGP Offspring,Signaling events mediated by PRL,CP:PID,C2,19,54
Cohort,-0.05415755054824526,0.06450440265070624,-0.8395946373073234,0.4013763107178715,LGP Proband,Signaling events mediated by PRL,CP:PID,C2,19,51
Cohort,-0.001260580413996596,0.021809346638117455,-0.057800008176008666,0.9539224377281692,LonGen OPEL,Signaling events mediated by PRL,CP:PID,C2,28,34
Cohort,0.02767374450150778,0.03335278386178372,0.8297281755007235,0.40698539004168843,LGP Offspring,Presenilin action in Notch and Wnt signaling,CP:PID,C2,33,81
Cohort,0.05268491005941932,0.09130087363433767,0.577047162444729,0.5640633206988777,LGP Proband,Presenilin action in Notch and Wnt signaling,CP:PID,C2,33,104
Cohort,-0.05996146863037376,0.0322388712763562,-1.85991215748143,0.06326663853644422,LonGen OPEL,Presenilin action in Notch and Wnt signaling,CP:PID,C2,79,73
Cohort,-0.02211917104196602,0.03865399441934992,-0.5722350658511328,0.5673529799287101,LGP Offspring,Signaling events mediated by PTP1B,CP:PID,C2,52,104
Cohort,-0.002374379901101738,0.10483801368634724,-0.022648081717814413,0.981936407393275,LGP Proband,Signaling events mediated by PTP1B,CP:PID,C2,52,118
Cohort,-0.038131559443022225,0.030236631007816758,-1.261104765050196,0.20764058252097956,LonGen OPEL,Signaling events mediated by PTP1B,CP:PID,C2,75,73
Cohort,-4.508019240588252e-4,0.04077822466093491,-0.011054966904694319,0.9911828538937806,LGP Offspring,RAC1 signaling pathway,CP:PID,C2,54,111
Cohort,-0.11044373953609661,0.11314354597965391,-0.9761382196378855,0.32927901990894026,LGP Proband,RAC1 signaling pathway,CP:PID,C2,54,133
Cohort,-0.0010364579493436993,0.03226837585052585,-0.03211992925038429,0.9743844622406344,LonGen OPEL,RAC1 signaling pathway,CP:PID,C2,74,91
Cohort,-0.002581955551810752,0.04516594796568266,-0.05716597720416577,0.9544298727250587,LGP Offspring,Regulation of RAC1 activity,CP:PID,C2,66,122
Cohort,0.14274241798445822,0.1262816176150973,1.1303499327949138,0.2586537665795744,LGP Proband,Regulation of RAC1 activity,CP:PID,C2,66,189
Cohort,0.04193151810191195,0.03472928037647815,1.207382290889961,0.22764358960271497,LonGen OPEL,Regulation of RAC1 activity,CP:PID,C2,83,115
Cohort,0.0038186931003944664,0.010581638538972805,0.36087918580189565,0.7183025081215746,LGP Offspring,Sumoylation by RanBP2 regulates transcriptional repression,CP:PID,C2,4,8
Cohort,0.004652679566828749,0.027245642624643327,0.1707678409692,0.864447736274326,LGP Proband,Sumoylation by RanBP2 regulates transcriptional repression,CP:PID,C2,4,9
Cohort,-0.00488681976464778,0.005668914115743815,-0.8620380667041703,0.3889261868126984,LonGen OPEL,Sumoylation by RanBP2 regulates transcriptional repression,CP:PID,C2,3,2
Cohort,-0.01444763462648543,0.029337797353299118,-0.4924580551327843,0.6225554653728322,LGP Offspring,Regulation of Ras family activation,CP:PID,C2,32,56
Cohort,-0.015179998771657129,0.0839432910735401,-0.1808363548476841,0.8565399610969546,LGP Proband,Regulation of Ras family activation,CP:PID,C2,32,88
Cohort,0.03262422670892888,0.023526788562281246,1.3866842311505652,0.16592628664039402,LonGen OPEL,Regulation of Ras family activation,CP:PID,C2,33,53
Cohort,0.04710070100725639,0.04439553867910578,1.0609332020431992,0.28909915133251973,LGP Offspring,Regulation of retinoblastoma protein,CP:PID,C2,53,140
Cohort,0.16264783029541655,0.10641381945243782,1.5284465037749424,0.1267808792964859,LGP Proband,Regulation of retinoblastoma protein,CP:PID,C2,53,142
Cohort,0.0035731639119848,0.04130239104448809,0.08651227741599837,0.9310809532052897,LonGen OPEL,Regulation of retinoblastoma protein,CP:PID,C2,105,123
Cohort,-0.012075691116197308,0.027113793622222045,-0.4453707690059372,0.6561944177964907,LGP Offspring,Reelin signaling pathway,CP:PID,C2,27,52
Cohort,0.008808553349747625,0.07935449663161862,0.1110025735610032,0.9116410128850382,LGP Proband,Reelin signaling pathway,CP:PID,C2,27,81
Cohort,-0.0026323658728470557,0.023043146879483174,-0.1142363882248576,0.9090792141807884,LonGen OPEL,Reelin signaling pathway,CP:PID,C2,37,47
Cohort,0.10925687633901454,0.041400500182580346,2.639023100136008,0.008506111161045965,LGP Offspring,Glucocorticoid receptor regulatory network,CP:PID,C2,42,140
Cohort,0.23015201148992084,0.11852547928750941,1.9417935525207786,0.05249853023174408,LGP Proband,Glucocorticoid receptor regulatory network,CP:PID,C2,42,182
Cohort,0.0035866182367007273,0.043759227976717406,0.08196255744294731,0.9346970926089504,LonGen OPEL,Glucocorticoid receptor regulatory network,CP:PID,C2,118,134
Cohort,0.01298087320304022,0.028489755085070612,0.45563302191539523,0.6488002105768043,LGP Offspring,Signaling events regulated by Ret tyrosine kinase,CP:PID,C2,25,57
Cohort,-0.13540686541377342,0.07062224895681034,-1.9173400368003388,0.05553608341992126,LGP Proband,Signaling events regulated by Ret tyrosine kinase,CP:PID,C2,25,62
Cohort,-0.01890026936058681,0.023472189060995605,-0.8052197139121514,0.4209333547318109,LonGen OPEL,Signaling events regulated by Ret tyrosine kinase,CP:PID,C2,40,38
Cohort,-0.02419817940707259,0.02873035585988433,-0.8422512942438025,0.39994518184934935,LGP Offspring,Retinoic acid receptors-mediated signaling,CP:PID,C2,33,56
Cohort,0.029163183893022613,0.07748822975892339,0.3763563057738358,0.7067477473445758,LGP Proband,Retinoic acid receptors-mediated signaling,CP:PID,C2,33,65
Cohort,-0.0415233957956015,0.0291152887076528,-1.4261715283862975,0.15421089614653016,LonGen OPEL,Retinoic acid receptors-mediated signaling,CP:PID,C2,62,57
Cohort,-0.006811687541584618,0.024832216152268834,-0.27430848297292454,0.783931368233745,LGP Offspring,RhoA signaling pathway,CP:PID,C2,20,39
Cohort,0.014372641025161977,0.06800097520669486,0.2113593368547302,0.8326585198768577,LGP Proband,RhoA signaling pathway,CP:PID,C2,20,61
Cohort,-0.04802435434689816,0.021284374992933206,-2.2563196881676397,0.024321171240154347,LonGen OPEL,RhoA signaling pathway,CP:PID,C2,40,29
Cohort,-0.030987779955442354,0.05239258273329578,-0.5914535672575165,0.554414281298231,LGP Offspring,Regulation of RhoA activity,CP:PID,C2,91,170
Cohort,-0.09510784495144849,0.1477631941493422,-0.6436504401449546,0.5199790827288582,LGP Proband,Regulation of RhoA activity,CP:PID,C2,91,260
Cohort,0.0425343222136331,0.0427663422526847,0.9945747046197986,0.32024539031558386,LonGen OPEL,Regulation of RhoA activity,CP:PID,C2,116,158
Cohort,0.01803199725589054,0.02761068289722228,0.6530804516140604,0.5139264604920816,LGP Offspring,Visual signal transduction: Rods,CP:PID,C2,23,53
Cohort,-0.03993944028569952,0.0793210718022407,-0.5035161449315072,0.6147343942398156,LGP Proband,Visual signal transduction: Rods,CP:PID,C2,23,73
Cohort,0.07157395683022906,0.028876277510189778,2.4786420896866725,0.013394553922859787,LonGen OPEL,Visual signal transduction: Rods,CP:PID,C2,37,77
Cohort,-0.009298305597917226,0.030847382661769156,-0.30142932059649663,0.7631798370402416,LGP Offspring,RXR and RAR heterodimerization with other nuclear receptor,CP:PID,C2,29,56
Cohort,-0.05588612596916632,0.08951584230655585,-0.6243154790163149,0.5325911591817556,LGP Proband,RXR and RAR heterodimerization with other nuclear receptor,CP:PID,C2,29,84
Cohort,-0.014933175673975254,0.026942604531254747,-0.5542588006535164,0.5795574190829773,LonGen OPEL,RXR and RAR heterodimerization with other nuclear receptor,CP:PID,C2,56,57
Cohort,-0.0017373562484557239,0.02088986692584117,-0.08316741579174831,0.9337430419131958,LGP Offspring,Sphingosine 1-phosphate (S1P) pathway,CP:PID,C2,14,29
Cohort,-0.07306202790903009,0.060318783133436506,-1.2112649512077047,0.22613697664843693,LGP Proband,Sphingosine 1-phosphate (S1P) pathway,CP:PID,C2,14,42
Cohort,-0.0217120753138949,0.02119782897785843,-1.0242593869671093,0.3060239413131352,LonGen OPEL,Sphingosine 1-phosphate (S1P) pathway,CP:PID,C2,34,30
Cohort,-0.05622624367145856,0.026780576842798495,-2.0995157797199666,0.03614161100623385,LGP Offspring,S1P1 pathway,CP:PID,C2,31,42
Cohort,-0.08311369595742442,0.07372708954154375,-1.1273155698163224,0.25993330792477976,LGP Proband,S1P1 pathway,CP:PID,C2,31,59
Cohort,-0.03543206911104987,0.024306738723437808,-1.4577055981962912,0.1453161079279524,LonGen OPEL,S1P1 pathway,CP:PID,C2,48,44
Cohort,-0.0029407619452889167,0.01269299689762464,-0.23168381502080485,0.8168537159002711,LGP Offspring,S1P2 pathway,CP:PID,C2,5,11
Cohort,0.020469098382934266,0.04001379314704078,0.511551062097897,0.6091006522096984,LGP Proband,S1P2 pathway,CP:PID,C2,5,17
Cohort,-0.024874092515053316,0.014501273609961628,-1.7153039921932165,0.08667867540981569,LonGen OPEL,S1P2 pathway,CP:PID,C2,19,12
Cohort,-0.0346725794848536,0.020022334745399686,-1.7316951257554984,0.08378405965453244,LGP Offspring,S1P3 pathway,CP:PID,C2,17,22
Cohort,0.027342414680939654,0.05929848600058815,0.4610980233233688,0.6448485015867652,LGP Proband,S1P3 pathway,CP:PID,C2,17,36
Cohort,-0.04178993238636133,0.019680149036791633,-2.1234560931543713,0.034023542286589825,LonGen OPEL,S1P3 pathway,CP:PID,C2,34,22
Cohort,-0.009024640345842055,0.01834619485860906,-0.4919080177330173,0.6229440634444421,LGP Offspring,S1P4 pathway,CP:PID,C2,12,18
Cohort,-0.0770348250463051,0.04525603521539258,-1.7022000420422125,0.08909053217936237,LGP Proband,S1P4 pathway,CP:PID,C2,12,16
Cohort,-0.018716090460794248,0.011893752273895582,-1.5736068845045932,0.11597571764530669,LonGen OPEL,S1P4 pathway,CP:PID,C2,13,9
Cohort,-0.03943960923911445,0.03298542484616623,-1.195667766083006,0.23224548324709607,LGP Offspring,SHP2 signaling,CP:PID,C2,40,71
Cohort,0.018300319782327764,0.09064549299882133,0.20188891004835424,0.8400528053526567,LGP Proband,SHP2 signaling,CP:PID,C2,40,91
Cohort,-0.03727422722697085,0.028065484655628237,-1.3281162853354074,0.184520373218414,LonGen OPEL,SHP2 signaling,CP:PID,C2,61,58
Cohort,-0.016552689449623882,0.0380033536134981,-0.4355586514276642,0.6632960138854145,LGP Offspring,Regulation of nuclear SMAD2/3 signaling,CP:PID,C2,50,96
Cohort,0.12082799983779506,0.10665349695322435,1.1329023734757362,0.2575808356993138,LGP Proband,Regulation of nuclear SMAD2/3 signaling,CP:PID,C2,50,137
Cohort,-0.0719007233907112,0.03860349549697803,-1.8625443749346418,0.06289460697477213,LonGen OPEL,Regulation of nuclear SMAD2/3 signaling,CP:PID,C2,109,104
Cohort,-0.02047251662471164,0.022848156237003193,-0.8960248876255432,0.3705584255554383,LGP Offspring,Regulation of cytoplasmic and nuclear SMAD2/3 signaling,CP:PID,C2,20,33
Cohort,-0.06341774969669194,0.06518402665819936,-0.9729032241170199,0.3308834878622555,LGP Proband,Regulation of cytoplasmic and nuclear SMAD2/3 signaling,CP:PID,C2,20,50
Cohort,0.006199125538751587,0.021236038042018283,0.2919153528773025,0.7704274056978319,LonGen OPEL,Regulation of cytoplasmic and nuclear SMAD2/3 signaling,CP:PID,C2,29,40
Cohort,-0.10621847663993944,0.061335881854741786,-1.73175103101135,0.08377409377009751,LGP Offspring,Syndecan-1-mediated signaling events,CP:PID,C2,145,264
Cohort,-0.04740466574233521,0.16744892072650439,-0.283099261175661,0.7771710005181528,LGP Proband,Syndecan-1-mediated signaling events,CP:PID,C2,145,331
Cohort,-0.026902622795928036,0.054004912781329885,-0.4981513979081655,0.6185149383574924,LonGen OPEL,Syndecan-1-mediated signaling events,CP:PID,C2,207,242
Cohort,0.04397448906355983,0.03411552805274308,1.2889874955350145,0.1978433431169919,LGP Offspring,Syndecan-2-mediated signaling events,CP:PID,C2,27,77
Cohort,0.0024646169879545023,0.09041576060391399,0.027258709891866042,0.9782599103703684,LGP Proband,Syndecan-2-mediated signaling events,CP:PID,C2,27,115
Cohort,-0.023052148786310945,0.0323677308278337,-0.712195393273844,0.47655247685989044,LonGen OPEL,Syndecan-2-mediated signaling events,CP:PID,C2,74,74
Cohort,-0.007873399348430886,0.019879908941240216,-0.39604805895754275,0.6921945454432084,LGP Offspring,Syndecan-3-mediated signaling events,CP:PID,C2,13,28
Cohort,0.06950083607894054,0.05715128798788178,1.216085210427407,0.22429654382465505,LGP Proband,Syndecan-3-mediated signaling events,CP:PID,C2,13,39
Cohort,-0.0213439914145773,0.022679491487787907,-0.9411141967654025,0.3469318526880347,LonGen OPEL,Syndecan-3-mediated signaling events,CP:PID,C2,38,29
Cohort,0.026971770616906882,0.037299763947884826,0.7231083460633102,0.4698634349312437,LGP Offspring,Syndecan-4-mediated signaling events,CP:PID,C2,40,94
Cohort,-0.047169654155996325,0.10660805430866295,-0.4424586346865101,0.6582720791684414,LGP Proband,Syndecan-4-mediated signaling events,CP:PID,C2,40,140
Cohort,-0.07946672475769485,0.03683313930561649,-2.1574790054774775,0.03126694385226308,LonGen OPEL,Syndecan-4-mediated signaling events,CP:PID,C2,104,86
Cohort,0.01698449449982714,0.042223811033873716,0.40224920688001053,0.6876277869814019,LGP Offspring,Validated transcriptional targets of TAp63 isoforms,CP:PID,C2,51,111
Cohort,-0.09848534430381413,0.10708646153757195,-0.9196806289958506,0.3580055978126584,LGP Proband,Validated transcriptional targets of TAp63 isoforms,CP:PID,C2,51,121
Cohort,0.04359130408449632,0.03285020598444301,1.3269720167094237,0.18489844992305732,LonGen OPEL,Validated transcriptional targets of TAp63 isoforms,CP:PID,C2,71,101
Cohort,-0.017574096213993855,0.03428736653291316,-0.5125531060288375,0.6084313912846786,LGP Offspring,Signaling events mediated by TCPTP,CP:PID,C2,43,84
Cohort,0.015498777305990493,0.0912294602579284,0.1698878548899839,0.8651395328978791,LGP Proband,Signaling events mediated by TCPTP,CP:PID,C2,43,91
Cohort,-0.029512886056298794,0.03010454033103016,-0.9803466763409929,0.3272128812388073,LonGen OPEL,Signaling events mediated by TCPTP,CP:PID,C2,66,70
Cohort,0.02323627126361394,0.02204132296771665,1.0542140005682734,0.29216159430104033,LGP Offspring,Calcium signaling in the CD4+ TCR pathway,CP:PID,C2,13,35
Cohort,-0.019575943651289954,0.06224840167856816,-0.31448106494965417,0.7532343493761358,LGP Proband,Calcium signaling in the CD4+ TCR pathway,CP:PID,C2,13,49
Cohort,0.0011543332819968634,0.01850812542022072,0.062369000414040705,0.9502846379742815,LonGen OPEL,Calcium signaling in the CD4+ TCR pathway,CP:PID,C2,25,28
Cohort,0.019578805868586135,0.019611210330203757,0.9983476562092797,0.31846802702839133,LGP Offspring,JNK signaling in the CD4+ TCR pathway,CP:PID,C2,9,28
Cohort,0.009402748090783723,0.05674281661229899,0.1657081662870024,0.8684267791125999,LGP Proband,JNK signaling in the CD4+ TCR pathway,CP:PID,C2,9,39
Cohort,-0.023460504529630017,0.019300014196726747,-1.2155692887318643,0.22450943020467634,LonGen OPEL,JNK signaling in the CD4+ TCR pathway,CP:PID,C2,29,26
Cohort,0.01483208876326484,0.04113675467853526,0.3605556364173782,0.7185442914733003,LGP Offspring,TCR signaling in na&#xef;ve CD4+ T cells,CP:PID,C2,47,100
Cohort,-0.08293324965257252,0.10925125491105972,-0.759105693752329,0.4480038222468955,LGP Proband,TCR signaling in na&#xef;ve CD4+ T cells,CP:PID,C2,47,135
Cohort,-0.005331904247008508,0.0337965548793678,-0.1577647267906452,0.8746822054886108,LonGen OPEL,TCR signaling in na&#xef;ve CD4+ T cells,CP:PID,C2,72,82
Cohort,-0.006654970252949374,0.008468521763918924,-0.7858479246405922,0.43223194377966256,LGP Offspring,Ras signaling in the CD4+ TCR pathway,CP:PID,C2,3,4
Cohort,0.016457173554373452,0.027234782812683284,0.6042704165318079,0.5458282118349276,LGP Proband,Ras signaling in the CD4+ TCR pathway,CP:PID,C2,3,9
Cohort,-0.013974524419922793,0.008482310107553865,-1.6474903938583751,0.09985194760816779,LonGen OPEL,Ras signaling in the CD4+ TCR pathway,CP:PID,C2,7,4
Cohort,0.04576867220162106,0.03931949431433322,1.1640198583361971,0.24482662156238735,LGP Offspring,Regulation of Telomerase,CP:PID,C2,44,106
Cohort,0.042856271471452816,0.10377168113831402,0.4129861923922292,0.6797228827682922,LGP Proband,Regulation of Telomerase,CP:PID,C2,44,125
Cohort,-0.0730095995640827,0.03278907380161965,-2.226644156093129,0.026250152755695397,LonGen OPEL,Regulation of Telomerase,CP:PID,C2,88,73
Cohort,-0.060206266280963074,0.035048957841798054,-1.7177762189882682,0.0862953929873135,LGP Offspring,TGF-beta receptor signaling,CP:PID,C2,48,72
Cohort,-0.024683909246964054,0.09028549649863095,-0.2733983884924236,0.7846146800987601,LGP Proband,TGF-beta receptor signaling,CP:PID,C2,48,89
Cohort,-0.007039574235005039,0.026074308402218995,-0.2699812446187816,0.7872446596994496,LonGen OPEL,TGF-beta receptor signaling,CP:PID,C2,47,57
Cohort,-0.047242637362602556,0.027941219307712675,-1.690786534486062,0.09133854395461802,LGP Offspring,PAR1-mediated thrombin signaling events,CP:PID,C2,31,45
Cohort,-0.044231692370039544,0.08404738805801029,-0.5262708739920676,0.5988399358911334,LGP Proband,PAR1-mediated thrombin signaling events,CP:PID,C2,31,75
Cohort,-0.03671661743299917,0.02450579338761287,-1.4982831550174824,0.1344561439334365,LonGen OPEL,PAR1-mediated thrombin signaling events,CP:PID,C2,48,44
Cohort,-0.00409516852502026,0.012998398513379477,-0.31505177509406496,0.7528195673465531,LGP Offspring,PAR4-mediated thrombin signaling events,CP:PID,C2,5,12
Cohort,0.04260146472523956,0.04336494075911393,0.9823941640295241,0.3261905967222998,LGP Proband,PAR4-mediated thrombin signaling events,CP:PID,C2,5,24
Cohort,6.632485700300286e-4,0.013911686510897112,0.04767564087290939,0.961986706587941,LonGen OPEL,PAR4-mediated thrombin signaling events,CP:PID,C2,14,16
Cohort,-0.00668796370267988,0.0370518693146699,-0.18050273377251502,0.8568120067682381,LGP Offspring,TNF receptor signaling pathway,CP:PID,C2,42,92
Cohort,0.15984785471865157,0.1060061634713977,1.507910950496584,0.1319560161888939,LGP Proband,TNF receptor signaling pathway,CP:PID,C2,42,141
Cohort,0.031044067323314488,0.03439310665385952,0.9026246926673251,0.36699816747143477,LonGen OPEL,TNF receptor signaling pathway,CP:PID,C2,69,97
Cohort,-0.06980651537358365,0.03278700513930442,-2.1290909333436177,0.03360755315517168,LGP Offspring,Endogenous TLR signaling,CP:PID,C2,47,67
Cohort,-0.03671470060217117,0.09206895081407346,-0.3987739653546594,0.6901618386777576,LGP Proband,Endogenous TLR signaling,CP:PID,C2,47,92
Cohort,0.006463860770373724,0.0292577976102679,0.2209277969748912,0.8252053090737761,LonGen OPEL,Endogenous TLR signaling,CP:PID,C2,59,61
Cohort,0.0012888362753564343,0.029988412939971232,0.04297780872686858,0.9657319146224072,LGP Offspring,TRAIL signaling pathway,CP:PID,C2,25,55
Cohort,-0.05680752342488225,0.07827990250395249,-0.7256974217873348,0.46822786783339854,LGP Proband,TRAIL signaling pathway,CP:PID,C2,25,66
Cohort,-0.03632169454427662,0.025086515206632593,-1.4478573147805547,0.14805069880856406,LonGen OPEL,TRAIL signaling pathway,CP:PID,C2,45,39
Cohort,0.00518511643153471,0.03327454842923527,0.15582830350235577,0.8762148807157052,LGP Offspring,Neurotrophic factor-mediated Trk receptor signaling,CP:PID,C2,32,68
Cohort,0.12596354335949644,0.09451391104985708,1.3327513586126951,0.18297739609663466,LGP Proband,Neurotrophic factor-mediated Trk receptor signaling,CP:PID,C2,32,116
Cohort,0.008460151089571663,0.02906901869735442,0.29103669365838014,0.7710990718677626,LonGen OPEL,Neurotrophic factor-mediated Trk receptor signaling,CP:PID,C2,56,73
Cohort,-0.03898927910064214,0.03682250676135465,-1.0588436945189599,0.29004916535821396,LGP Offspring,Thromboxane A2 receptor signaling,CP:PID,C2,46,84
Cohort,0.12245050376170732,0.1074030784598629,1.140102365012449,0.254570967247748,LGP Proband,Thromboxane A2 receptor signaling,CP:PID,C2,46,130
Cohort,-0.011794746830114061,0.02742039035996834,-0.4301451100905363,0.6672065140478699,LonGen OPEL,Thromboxane A2 receptor signaling,CP:PID,C2,59,62
Cohort,0.010774961203538377,0.042538187281883605,0.25330090189638327,0.8001127116317954,LGP Offspring,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,CP:PID,C2,58,126
Cohort,-0.2372615573686532,0.1158656392758891,-2.047730102310201,0.04089919626551412,LGP Proband,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,CP:PID,C2,58,165
Cohort,-0.05779716722858342,0.03749532384232743,-1.5414500077830453,0.12360472642958319,LonGen OPEL,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,CP:PID,C2,110,105
Cohort,-0.03504348505439071,0.02148184177392591,-1.631307288415352,0.10329124887456156,LGP Offspring,VEGF and VEGFR signaling network,CP:PID,C2,18,24
Cohort,-0.07599985705330116,0.05943040040493516,-1.27880439195207,0.20132166589415415,LGP Proband,VEGF and VEGFR signaling network,CP:PID,C2,18,39
Cohort,-0.028573338257325716,0.02015248324609207,-1.4178569414201896,0.15662387062872898,LonGen OPEL,VEGF and VEGFR signaling network,CP:PID,C2,32,26
Cohort,-0.06749998068884876,0.043115284696441325,-1.565569638797262,0.11791737452124734,LGP Offspring,Signaling events mediated by VEGFR1 and VEGFR2,CP:PID,C2,66,101
Cohort,-0.06566564506490158,0.11897044759437912,-0.5519492142181704,0.5811310147311239,LGP Proband,Signaling events mediated by VEGFR1 and VEGFR2,CP:PID,C2,66,148
Cohort,-0.02397357553807558,0.037028473836442574,-0.6474362309386172,0.5175363255502721,LonGen OPEL,Signaling events mediated by VEGFR1 and VEGFR2,CP:PID,C2,92,103
Cohort,-0.02856195307037123,0.03193942140881281,-0.8942539285476956,0.37150431244618787,LGP Offspring,VEGFR1 specific signals,CP:PID,C2,36,61
Cohort,-0.028129493628688,0.07942253271965681,-0.3541752279290641,0.7232970920063192,LGP Proband,VEGFR1 specific signals,CP:PID,C2,36,68
Cohort,-0.00784352561153594,0.02330966965107846,-0.3364923539863658,0.7365883043144403,LonGen OPEL,VEGFR1 specific signals,CP:PID,C2,41,50
Cohort,-0.03341317506508922,0.025073676936730762,-1.3325997279697666,0.18311219244385413,LGP Offspring,Canonical Wnt signaling pathway,CP:PID,C2,26,37
Cohort,-0.020848154925027094,0.07099629319601936,-0.29365131595625354,0.7690974180919321,LGP Proband,Canonical Wnt signaling pathway,CP:PID,C2,26,61
Cohort,-0.04178420068817278,0.021588092881718816,-1.9355207019493785,0.05328027216480618,LonGen OPEL,Canonical Wnt signaling pathway,CP:PID,C2,40,32
Cohort,-0.007264266931050012,0.03480800617857376,-0.2086952896348762,0.8347489841444561,LGP Offspring,Noncanonical Wnt signaling pathway,CP:PID,C2,41,74
Cohort,-0.13163008999456746,0.09194270588138988,-1.4316534273461132,0.1526176655776951,LGP Proband,Noncanonical Wnt signaling pathway,CP:PID,C2,41,92
Cohort,-0.014610991782787972,0.02501259491004835,-0.5841453809703797,0.5592880065755983,LonGen OPEL,Noncanonical Wnt signaling pathway,CP:PID,C2,44,46
Cohort,0.01467450163972231,0.01778921618749037,0.8249099614653976,0.40971369512488975,LGP Offspring,Wnt signaling network,CP:PID,C2,8,24
Cohort,0.019159295912018055,0.05244239254021021,0.3653398516730079,0.7149503670736593,LGP Proband,Wnt signaling network,CP:PID,C2,8,37
Cohort,9.266964532576574e-4,0.01113870699066457,0.08319605265084434,0.9337165681160355,LonGen OPEL,Wnt signaling network,CP:PID,C2,9,10
Cohort,-0.003320616853532271,0.004558696592033795,-0.7284136565120309,0.4666126543136979,LGP Offspring,2-LTR circle formation,CP:REACTOME,C2,1,1
Cohort,0.005287390241168551,0.013648599415733279,0.3873943457578195,0.698563128775403,LGP Proband,2-LTR circle formation,CP:REACTOME,C2,1,2
Cohort,9.965494884983958e-4,0.0025710925740095782,0.38759766901130777,0.6984174119000515,LonGen OPEL,2-LTR circle formation,CP:REACTOME,C2,0,1
Cohort,-0.0795381788523832,0.03349736625993949,-2.3744606735695912,0.017852828880185512,LGP Offspring,A tetrasaccharide linker sequence is required for GAG synthesis,CP:REACTOME,C2,45,63
Cohort,-0.08691415748959341,0.09672055264600088,-0.8986110512385195,0.3691192268333392,LGP Proband,A tetrasaccharide linker sequence is required for GAG synthesis,CP:REACTOME,C2,45,97
Cohort,-0.036754826951568224,0.02883476095496918,-1.274670770080865,0.20279775681966977,LonGen OPEL,A tetrasaccharide linker sequence is required for GAG synthesis,CP:REACTOME,C2,64,58
Cohort,-0.018350915837921252,0.0118085605545775,-1.5540349522794001,0.12064410006773701,LGP Offspring,Abacavir metabolism,CP:REACTOME,C2,7,7
Cohort,0.02331473538140969,0.03801682771563401,0.6132740889325112,0.5398623322740024,LGP Proband,Abacavir metabolism,CP:REACTOME,C2,7,17
Cohort,-4.2435823266577695e-4,0.009594545304530541,-0.044229113438590484,0.9647328681209754,LonGen OPEL,Abacavir metabolism,CP:REACTOME,C2,7,7
Cohort,-0.030290634759400033,0.020264171131952474,-1.49478774938087,0.13543648659359908,LGP Offspring,Abacavir transmembrane transport,CP:REACTOME,C2,17,25
Cohort,0.06776565989916447,0.06039276238496583,1.122082468544841,0.26215032072112454,LGP Proband,Abacavir transmembrane transport,CP:REACTOME,C2,17,46
Cohort,-0.017735367983973536,0.02157360613152579,-0.8220863900011883,0.4112739048913052,LonGen OPEL,Abacavir transmembrane transport,CP:REACTOME,C2,37,35
Cohort,-0.04864155059732125,0.02382572274923217,-2.0415561412041034,0.04158330452911177,LGP Offspring,Abacavir transport and metabolism,CP:REACTOME,C2,24,32
Cohort,0.09108039528057411,0.07123804956602182,1.2785357801825112,0.2014162508485809,LGP Proband,Abacavir transport and metabolism,CP:REACTOME,C2,24,63
Cohort,-0.01815972621663923,0.023217295223183956,-0.7821637293264712,0.4343509582963687,LonGen OPEL,Abacavir transport and metabolism,CP:REACTOME,C2,44,42
Cohort,0.04363208890596647,0.06324138683668315,0.6899293498835432,0.49047539598782175,LGP Offspring,ABC-family proteins mediated transport,CP:REACTOME,C2,130,277
Cohort,-0.35892009476470826,0.17674596677775023,-2.0307116553105478,0.04260104190122978,LGP Proband,ABC-family proteins mediated transport,CP:REACTOME,C2,130,389
Cohort,-0.05648743596891225,0.05719999206223729,-0.9875427239124486,0.32367672887392496,LonGen OPEL,ABC-family proteins mediated transport,CP:REACTOME,C2,249,265
Cohort,0.031574789300798205,0.04952403602174459,0.6375649449680275,0.5239728008864292,LGP Offspring,ABC transporter disorders,CP:REACTOME,C2,81,171
Cohort,-0.1232874466818468,0.13762966450825917,-0.89579123165303,0.37062274609547163,LGP Proband,ABC transporter disorders,CP:REACTOME,C2,81,261
Cohort,-1.9440549860868817e-4,0.04721486250019822,-0.004117464042342006,0.9967157799432487,LonGen OPEL,ABC transporter disorders,CP:REACTOME,C2,152,173
Cohort,-0.027139225626021158,0.025487525696663172,-1.064804247733401,0.28734470173260523,LGP Offspring,ABC transporters in lipid homeostasis,CP:REACTOME,C2,24,39
Cohort,-0.0393779971817863,0.07029532035227881,-0.5601794967922037,0.5755074440500908,LGP Proband,ABC transporters in lipid homeostasis,CP:REACTOME,C2,24,48
Cohort,0.011025924263285122,0.021462486990077502,0.513730038293447,0.6075833169963785,LonGen OPEL,ABC transporters in lipid homeostasis,CP:REACTOME,C2,28,41
Cohort,-0.002445871394972168,0.020738037963130247,-0.11794131148378814,0.9061491944184847,LGP Offspring,Aberrant regulation of mitotic exit in cancer due to RB1 defects,CP:REACTOME,C2,13,29
Cohort,0.04131595182896795,0.06124509784090877,0.6746001441011804,0.5001167943373763,LGP Proband,Aberrant regulation of mitotic exit in cancer due to RB1 defects,CP:REACTOME,C2,13,50
Cohort,0.005111083782771998,0.020868702252144558,0.2449162253128012,0.8065844211699779,LonGen OPEL,Aberrant regulation of mitotic exit in cancer due to RB1 defects,CP:REACTOME,C2,28,38
Cohort,-0.029146215904645938,0.022747207619404637,-1.281309617967464,0.20052428244024115,LGP Offspring,Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects,CP:REACTOME,C2,21,33
Cohort,-0.026491128393401845,0.05688761295719601,-0.4656748106716059,0.6415698667810039,LGP Proband,Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects,CP:REACTOME,C2,21,35
Cohort,9.343126485570739e-4,0.019311806932647304,0.04838038469500152,0.9614252277258655,LonGen OPEL,Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects,CP:REACTOME,C2,25,30
Cohort,-0.005721712632939813,0.015205027790961605,-0.37630399046958646,0.7068089854885414,LGP Offspring,Abortive elongation of HIV-1 transcript in the absence of Tat,CP:REACTOME,C2,9,14
Cohort,-0.03615736191071821,0.0459834811266027,-0.7863119760587284,0.43190809366562455,LGP Proband,Abortive elongation of HIV-1 transcript in the absence of Tat,CP:REACTOME,C2,9,26
Cohort,0.015453462120353426,0.014165112319791248,1.0909523180244831,0.27562397900080077,LonGen OPEL,Abortive elongation of HIV-1 transcript in the absence of Tat,CP:REACTOME,C2,11,18
Cohort,-0.0371816992300732,0.030126329472045344,-1.2341928101322346,0.2175599456025446,LGP Offspring,Acetylcholine binding and downstream events,CP:REACTOME,C2,34,58
Cohort,-0.14297869135781116,0.07996763544290204,-1.7879569724166704,0.07414590468648792,LGP Proband,Acetylcholine binding and downstream events,CP:REACTOME,C2,34,76
Cohort,-0.001260957097766964,0.025793301008046922,-0.048886999666059576,0.9610216126046535,LonGen OPEL,Acetylcholine binding and downstream events,CP:REACTOME,C2,46,56
Cohort,0.009478481443961472,0.016842578582046394,0.5627690200635433,0.5737787628216848,LGP Offspring,Acetylcholine inhibits contraction of outer hair cells,CP:REACTOME,C2,9,20
Cohort,0.002669519114704849,0.04307547160371688,0.06197306762567174,0.9505991281797671,LGP Proband,Acetylcholine inhibits contraction of outer hair cells,CP:REACTOME,C2,9,22
Cohort,-0.01366175029259095,0.013792967203493631,-0.9904866799893901,0.32223728042039446,LonGen OPEL,Acetylcholine inhibits contraction of outer hair cells,CP:REACTOME,C2,15,12
Cohort,-0.02606329076526273,0.028331428115549694,-0.9199427102285007,0.3579308488076093,LGP Offspring,Acetylcholine Neurotransmitter Release Cycle,CP:REACTOME,C2,29,51
Cohort,0.018599528143669653,0.07864603211618568,0.23649671373365821,0.8131053283111124,LGP Proband,Acetylcholine Neurotransmitter Release Cycle,CP:REACTOME,C2,29,76
Cohort,-0.021711204022033914,0.023003051848953102,-0.9438401549758719,0.3455377194176815,LonGen OPEL,Acetylcholine Neurotransmitter Release Cycle,CP:REACTOME,C2,42,41
Cohort,-0.01639996980035115,0.01657532781286781,-0.989420540305663,0.32281143715973093,LGP Offspring,Acetylcholine regulates insulin secretion,CP:REACTOME,C2,10,18
Cohort,0.08247914530280685,0.05401226697609035,1.5270446867064098,0.12712903955053395,LGP Proband,Acetylcholine regulates insulin secretion,CP:REACTOME,C2,10,35
Cohort,-0.0023914547786271713,0.01663533526270955,-0.14375753424025992,0.8857283224090755,LonGen OPEL,Acetylcholine regulates insulin secretion,CP:REACTOME,C2,19,22
Cohort,0.012602686456029973,0.011427036461671128,1.1028831927072467,0.2704703622224275,LGP Offspring,Acrosome Reaction and Sperm:Oocyte Membrane Binding,CP:REACTOME,C2,2,11
Cohort,0.07263790819815556,0.03474600263206549,2.0905399958475046,0.036871547167495904,LGP Proband,Acrosome Reaction and Sperm:Oocyte Membrane Binding,CP:REACTOME,C2,2,18
Cohort,0.022669611828387823,0.010441416073955628,2.171124267802467,0.03021657103643339,LonGen OPEL,Acrosome Reaction and Sperm:Oocyte Membrane Binding,CP:REACTOME,C2,4,13
Cohort,-0.04283043000230833,0.03007068051098594,-1.4243252654911078,0.1548137846837909,LGP Offspring,Activated NOTCH1 Transmits Signal to the Nucleus,CP:REACTOME,C2,35,53
Cohort,0.02033072416794278,0.07728617708395112,0.26305770236065357,0.7925710770319443,LGP Proband,Activated NOTCH1 Transmits Signal to the Nucleus,CP:REACTOME,C2,35,65
Cohort,-0.007500855359204859,0.02467868912552669,-0.30394059105215043,0.7612525846502131,LonGen OPEL,Activated NOTCH1 Transmits Signal to the Nucleus,CP:REACTOME,C2,46,50
Cohort,0.003427598617562391,0.007848970792195459,0.4366940212047403,0.6624727127162986,LGP Offspring,Activated NTRK2 signals through CDK5,CP:REACTOME,C2,2,4
Cohort,-0.017966762458292623,0.024286944150808454,-0.7397704028439722,0.45964749900890844,LGP Proband,Activated NTRK2 signals through CDK5,CP:REACTOME,C2,2,8
Cohort,0.012271638757310077,0.01058339349642071,1.1595183304353494,0.24659266112205647,LonGen OPEL,Activated NTRK2 signals through CDK5,CP:REACTOME,C2,5,12
Cohort,-7.008665747029807e-4,0.015254736625908422,-0.04594419372096134,0.9633682986330068,LGP Offspring,Activated NTRK2 signals through FRS2 and FRS3,CP:REACTOME,C2,7,15
Cohort,0.014574789364861996,0.045216480381012746,0.32233356603717933,0.7472807893653279,LGP Proband,Activated NTRK2 signals through FRS2 and FRS3,CP:REACTOME,C2,7,25
Cohort,0.007834268845406436,0.013158620802059023,0.5953715790776912,0.5517643419128055,LonGen OPEL,Activated NTRK2 signals through FRS2 and FRS3,CP:REACTOME,C2,12,15
Cohort,0.0012720737190812005,0.0077679189087228925,0.16375991227878814,0.8699690982445818,LGP Offspring,Activated NTRK2 signals through FYN,CP:REACTOME,C2,2,4
Cohort,-0.04508940799607742,0.015663850664232624,-2.878564726043777,0.004097025197985831,LGP Proband,Activated NTRK2 signals through FYN,CP:REACTOME,C2,2,2
Cohort,0.006828874944032796,0.005067059428805712,1.3476997931406416,0.17813839738985415,LonGen OPEL,Activated NTRK2 signals through FYN,CP:REACTOME,C2,0,4
Cohort,-0.00355842639568591,0.008456736397953711,-0.4207801010029055,0.6740493986298295,LGP Offspring,Activated NTRK2 signals through PI3K,CP:REACTOME,C2,3,4
Cohort,-0.01808246542860556,0.02607445533608878,-0.6934935052537118,0.4881929905822262,LGP Proband,Activated NTRK2 signals through PI3K,CP:REACTOME,C2,3,8
Cohort,-0.010090772645490107,0.007224131665122618,-1.3968146087656934,0.16285862624724107,LonGen OPEL,Activated NTRK2 signals through PI3K,CP:REACTOME,C2,5,3
Cohort,0.001037730364954064,0.010591691018090075,0.09797589102454678,0.9219804800660847,LGP Offspring,Activated NTRK2 signals through RAS,CP:REACTOME,C2,4,7
Cohort,-0.012072333607755871,0.02837243567216614,-0.42549514420431106,0.6705855312722405,LGP Proband,Activated NTRK2 signals through RAS,CP:REACTOME,C2,4,9
Cohort,-0.0036334906829021824,0.008116224692595946,-0.4476823671745863,0.6545042550862517,LonGen OPEL,Activated NTRK2 signals through RAS,CP:REACTOME,C2,5,5
Cohort,-0.0011211809971446688,0.010045408651652541,-0.11161128790516914,0.9111647522969508,LGP Offspring,Activated NTRK3 signals through PI3K,CP:REACTOME,C2,3,7
Cohort,0.011203840873763974,0.026109171575969026,0.42911514220834296,0.6679502560885909,LGP Proband,Activated NTRK3 signals through PI3K,CP:REACTOME,C2,3,8
Cohort,-0.0033448170127172144,0.008940591501063577,-0.37411585266134945,0.7084177560381031,LonGen OPEL,Activated NTRK3 signals through PI3K,CP:REACTOME,C2,5,7
Cohort,-4.975145849464263e-4,0.011924660930006374,-0.041721486914107195,0.9667330442030523,LGP Offspring,Activated NTRK3 signals through RAS,CP:REACTOME,C2,5,9
Cohort,0.026941468149089504,0.034172532991458934,0.7883954097234537,0.430689488550945,LGP Proband,Activated NTRK3 signals through RAS,CP:REACTOME,C2,5,14
Cohort,-0.0028427656722290707,0.010008960983516823,-0.2840220555271078,0.7764673406532892,LonGen OPEL,Activated NTRK3 signals through RAS,CP:REACTOME,C2,7,8
Cohort,-0.001080327639057881,0.010921034621796838,-0.09892173008056399,0.9212297411121102,LGP Offspring,Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,CP:REACTOME,C2,4,8
Cohort,-0.0773237507732046,0.032153612969303635,-2.404823086196376,0.01639728225374281,LGP Proband,Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,CP:REACTOME,C2,4,11
Cohort,-0.003478127640067882,0.008534915725934261,-0.4075175141447755,0.6837375049374455,LonGen OPEL,Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,CP:REACTOME,C2,7,4
Cohort,-0.003359178491189517,0.022507159446543742,-0.1492493310480973,0.881401409145286,LGP Offspring,activated TAK1 mediates p38 MAPK activation,CP:REACTOME,C2,15,34
Cohort,0.06825305186208981,0.06404701061389481,1.0656711563565546,0.286880730878999,LGP Proband,activated TAK1 mediates p38 MAPK activation,CP:REACTOME,C2,15,52
Cohort,-0.030995917427443422,0.021605493962967064,-1.434631278533693,0.15178494846941837,LonGen OPEL,activated TAK1 mediates p38 MAPK activation,CP:REACTOME,C2,35,28
Cohort,0.01583191378205543,0.02476088444361381,0.6393920951454022,0.5227844948315348,LGP Offspring,Activation of AMPK downstream of NMDARs,CP:REACTOME,C2,17,46
Cohort,-0.005421944700886779,0.07283950093372712,-0.07443687328143454,0.9406806193327933,LGP Proband,Activation of AMPK downstream of NMDARs,CP:REACTOME,C2,17,70
Cohort,-0.009892820936777503,0.023511924765970034,-0.42075759578373056,0.6740456697316053,LonGen OPEL,Activation of AMPK downstream of NMDARs,CP:REACTOME,C2,39,40
Cohort,0.020401294270533357,0.03927434870944471,0.519455953845703,0.6036128540829617,LGP Offspring,Activation of anterior HOX genes in hindbrain development during early embryogenesis,CP:REACTOME,C2,49,104
Cohort,-0.11451300805791681,0.10651439795635374,-1.0750941680658106,0.28264349398007754,LGP Proband,Activation of anterior HOX genes in hindbrain development during early embryogenesis,CP:REACTOME,C2,49,142
Cohort,-0.009572152635387299,0.03469558940342647,-0.2758896101774242,0.7827044620495431,LonGen OPEL,Activation of anterior HOX genes in hindbrain development during early embryogenesis,CP:REACTOME,C2,80,89
Cohort,-0.07319208998801441,0.03870186380648415,-1.8911773953313258,0.05902795646716133,LGP Offspring,Activation of ATR in response to replication stress,CP:REACTOME,C2,64,95
Cohort,-0.14465765652386928,0.11212880314058704,-1.2901025648378461,0.19737263688532292,LGP Proband,Activation of ATR in response to replication stress,CP:REACTOME,C2,64,147
Cohort,0.03969498680731646,0.03532114744399308,1.1238306136644838,0.26142369709868174,LonGen OPEL,Activation of ATR in response to replication stress,CP:REACTOME,C2,78,108
Cohort,-0.0013842721055015372,0.012557363639207723,-0.11023588591314176,0.9122550205041806,LGP Offspring,Activation of BAD and translocation to mitochondria ,CP:REACTOME,C2,5,11
Cohort,0.012772491568566122,0.034944175090630844,0.365511320139609,0.7148224393261604,LGP Proband,Activation of BAD and translocation to mitochondria ,CP:REACTOME,C2,5,15
Cohort,0.0072041484848367615,0.008942120392263237,0.8056420813870749,0.42068985018442906,LonGen OPEL,Activation of BAD and translocation to mitochondria ,CP:REACTOME,C2,5,7
Cohort,0.00514298476529474,0.01975987070276747,0.260274211438764,0.7947315203212688,LGP Offspring,Activation of BH3-only proteins,CP:REACTOME,C2,11,27
Cohort,0.016324431547659442,0.05491139389547727,0.29728678129593045,0.7663216028857872,LGP Proband,Activation of BH3-only proteins,CP:REACTOME,C2,11,36
Cohort,-0.0026906638476131345,0.015057105636188563,-0.17869728171039304,0.8582208744859792,LonGen OPEL,Activation of BH3-only proteins,CP:REACTOME,C2,16,17
Cohort,3.315265173312203e-4,0.015488534641651269,0.021404640593932614,0.9829291880201084,LGP Offspring,Activation of C3 and C5,CP:REACTOME,C2,7,15
Cohort,0.021382840369724446,0.041095751558679276,0.5203175403470256,0.6029803635015161,LGP Proband,Activation of C3 and C5,CP:REACTOME,C2,7,21
Cohort,1.8872396660734708e-4,0.0131788412516297,0.014320224593646229,0.9885780927284249,LonGen OPEL,Activation of C3 and C5,CP:REACTOME,C2,11,16
Cohort,-0.02231850884956324,0.011048105092614075,-2.0201209766264534,0.04376478181344796,LGP Offspring,Activation of caspases through apoptosome-mediated cleavage,CP:REACTOME,C2,7,5
Cohort,0.00520401146322877,0.027096055330951392,0.19205789919111624,0.847743604554332,LGP Proband,Activation of caspases through apoptosome-mediated cleavage,CP:REACTOME,C2,7,5
Cohort,-0.01463884578954602,0.011146717665900916,-1.3132875729263263,0.1894644964895784,LonGen OPEL,Activation of caspases through apoptosome-mediated cleavage,CP:REACTOME,C2,11,8
Cohort,-0.014381305373754786,0.035973237854894285,-0.3997778968844796,0.6894463955433585,LGP Offspring,Activation of gene expression by SREBF (SREBP),CP:REACTOME,C2,47,92
Cohort,-0.19309266997627533,0.10232896506971617,-1.8869796039149065,0.05951015725687185,LGP Proband,Activation of gene expression by SREBF (SREBP),CP:REACTOME,C2,47,121
Cohort,0.008243184774298718,0.03543018624561953,0.23265993345767066,0.8160852916867449,LonGen OPEL,Activation of gene expression by SREBF (SREBP),CP:REACTOME,C2,84,101
Cohort,-0.041771552644396213,0.01687825510096497,-2.4748738773362913,0.013572505642267634,LGP Offspring,Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon,CP:REACTOME,C2,15,14
Cohort,-0.06861721412956855,0.047937142364226394,-1.4313997611333393,0.1526902916288321,LGP Proband,Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon,CP:REACTOME,C2,15,22
Cohort,0.00884501509392372,0.01251265085925227,0.7068857905024516,0.4798443295331414,LonGen OPEL,Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon,CP:REACTOME,C2,9,15
Cohort,0.0050663472533468605,0.02127687274762246,0.2381152208523214,0.8118638862583716,LGP Offspring,Activation of kainate receptors upon glutamate binding,CP:REACTOME,C2,11,31
Cohort,-0.019820967792832097,0.05976458631645425,-0.3316507151556244,0.7402363416671485,LGP Proband,Activation of kainate receptors upon glutamate binding,CP:REACTOME,C2,11,46
Cohort,0.0038451172521724772,0.019018343185472388,0.20217940199489412,0.8398281356920726,LonGen OPEL,Activation of kainate receptors upon glutamate binding,CP:REACTOME,C2,25,32
Cohort,0.04183728468887957,0.035532932800088984,1.1774227847799492,0.23944116793539566,LGP Offspring,Activation of Matrix Metalloproteinases,CP:REACTOME,C2,34,88
Cohort,0.011054508977969975,0.10284946455746151,0.10748241641835553,0.9144321244717708,LGP Proband,Activation of Matrix Metalloproteinases,CP:REACTOME,C2,34,127
Cohort,-0.05390675535953414,0.03127217326874056,-1.7237930634459278,0.08513349339218218,LonGen OPEL,Activation of Matrix Metalloproteinases,CP:REACTOME,C2,77,74
Cohort,-0.01191659592656214,0.011013179159930109,-1.0820305157586998,0.2796247921425203,LGP Offspring,"Activation of NIMA Kinases NEK9, NEK6, NEK7",CP:REACTOME,C2,6,4
Cohort,-0.03212575225959145,0.03217883388077182,-0.9983504181233837,0.3183990343609384,LGP Proband,"Activation of NIMA Kinases NEK9, NEK6, NEK7",CP:REACTOME,C2,6,10
Cohort,0.006815893550204555,0.011214743098505215,0.6077618979174858,0.5435187518914981,LonGen OPEL,"Activation of NIMA Kinases NEK9, NEK6, NEK7",CP:REACTOME,C2,7,12
Cohort,-0.018827509796166906,0.04329591072747652,-0.4348565367910961,0.6638053488406518,LGP Offspring,Activation of NMDA receptors and postsynaptic events,CP:REACTOME,C2,57,122
Cohort,0.08899367415096826,0.12457085027692366,0.7144020768352581,0.4751784888560586,LGP Proband,Activation of NMDA receptors and postsynaptic events,CP:REACTOME,C2,57,194
Cohort,-0.009589701125092274,0.04115352357395807,-0.23302260152422602,0.8158037608707466,LonGen OPEL,Activation of NMDA receptors and postsynaptic events,CP:REACTOME,C2,114,130
Cohort,-0.003444298204329676,0.007893252965815776,-0.4363597897148738,0.662715034684868,LGP Offspring,Activation of NOXA and translocation to mitochondria,CP:REACTOME,C2,2,4
Cohort,0.07175260267117463,0.028343353669374453,2.5315494951010233,0.011538606594841301,LGP Proband,Activation of NOXA and translocation to mitochondria,CP:REACTOME,C2,2,9
Cohort,-0.0033270928395441658,0.004493791683044937,-0.7403754054949359,0.4592905587682182,LonGen OPEL,Activation of NOXA and translocation to mitochondria,CP:REACTOME,C2,2,1
Cohort,0.001310732484907347,0.014777250089988016,0.08869935048303766,0.9293471192198597,LGP Offspring,Activation of PPARGC1A (PGC-1alpha) by phosphorylation,CP:REACTOME,C2,8,14
Cohort,-0.04853082070354311,0.04365492628588893,-1.111691734071952,0.2665910774350349,LGP Proband,Activation of PPARGC1A (PGC-1alpha) by phosphorylation,CP:REACTOME,C2,8,24
Cohort,-0.012739827826422134,0.01380558624891172,-0.9228023784521575,0.3563898228601844,LonGen OPEL,Activation of PPARGC1A (PGC-1alpha) by phosphorylation,CP:REACTOME,C2,16,13
Cohort,0.004866143458894831,0.014467001913227693,0.33636156876744056,0.7367026103731931,LGP Offspring,Activation of PUMA and translocation to mitochondria,CP:REACTOME,C2,6,15
Cohort,0.010564097566741239,0.04198030808998066,0.25164411714411755,0.8013781488199395,LGP Proband,Activation of PUMA and translocation to mitochondria,CP:REACTOME,C2,6,19
Cohort,-0.008678873736910557,0.011419779286922746,-0.7599861187202706,0.4474879089759304,LonGen OPEL,Activation of PUMA and translocation to mitochondria,CP:REACTOME,C2,10,10
Cohort,0.01983546953331646,0.01668505380037203,1.1888166361725596,0.23492926910697526,LGP Offspring,Activation of RAC1,CP:REACTOME,C2,7,21
Cohort,0.001984347504606095,0.05082552668294077,0.03904234021980391,0.9688659753355502,LGP Proband,Activation of RAC1,CP:REACTOME,C2,7,30
Cohort,-0.0015366322648442852,0.01582453876735291,-0.09710439510657089,0.9226679341869914,LonGen OPEL,Activation of RAC1,CP:REACTOME,C2,17,20
Cohort,-0.017265547928869727,0.012333966178732734,-1.3998374633652266,0.16202074139454642,LGP Offspring,Activation of RAC1 downstream of NMDARs,CP:REACTOME,C2,7,8
Cohort,0.04413617071750621,0.03571628218995297,1.2357437003877678,0.2169018015752469,LGP Proband,Activation of RAC1 downstream of NMDARs,CP:REACTOME,C2,7,14
Cohort,-0.01096784491713169,0.011120208231893945,-0.9862985196333589,0.3242863429915688,LonGen OPEL,Activation of RAC1 downstream of NMDARs,CP:REACTOME,C2,12,7
Cohort,0,0,NA,NA,LGP Offspring,Activation of RAS in B cells,CP:REACTOME,C2,0,0
Cohort,-0.007087308970761873,0.0078020773937905186,-0.9083874220989513,0.3639359806849649,LGP Proband,Activation of RAS in B cells,CP:REACTOME,C2,0,1
Cohort,0.004410244388930118,0.00518080874029732,0.8512656247327555,0.39487782553045647,LonGen OPEL,Activation of RAS in B cells,CP:REACTOME,C2,1,3
Cohort,-0.002492835433983212,0.034372207208768414,-0.0725247412492988,0.9422057689959032,LGP Offspring,Activation of SMO,CP:REACTOME,C2,40,86
Cohort,-0.11276904826016482,0.0892734567310267,-1.2631867566182446,0.20687509024906175,LGP Proband,Activation of SMO,CP:REACTOME,C2,40,83
Cohort,0.032132625452672384,0.028771919735125728,1.1168050567527406,0.2644146739510216,LonGen OPEL,Activation of SMO,CP:REACTOME,C2,52,74
Cohort,0.00230009485137119,0.006423900866656716,0.3580526691048179,0.7204156721678323,LGP Offspring,Activation of the AP-1 family of transcription factors,CP:REACTOME,C2,1,3
Cohort,-0.0017457615355889187,0.01931816353712917,-0.09036891794779539,0.9280157538297545,LGP Proband,Activation of the AP-1 family of transcription factors,CP:REACTOME,C2,1,5
Cohort,-0.015854760318523634,0.006700080554096421,-2.3663536864239716,0.018202818069098754,LonGen OPEL,Activation of the AP-1 family of transcription factors,CP:REACTOME,C2,6,1
Cohort,0.003416195117126899,0.020195481776335997,0.1691564061190071,0.8657242217367191,LGP Offspring,"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S",CP:REACTOME,C2,11,27
Cohort,0.08404372985056642,0.05382869707766069,1.5613183007070255,0.11882802460219638,LGP Proband,"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S",CP:REACTOME,C2,11,37
Cohort,-0.0034218060080842432,0.01606997283380455,-0.21293166102223796,0.8314347858093931,LonGen OPEL,"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S",CP:REACTOME,C2,18,22
Cohort,0.021682688429694418,0.021772796279404455,0.9958614479943821,0.3196737980291828,LGP Offspring,Activation of the phototransduction cascade,CP:REACTOME,C2,13,34
Cohort,-0.06179145152231878,0.0650844403546296,-0.9494043612518122,0.342690020702887,LGP Proband,Activation of the phototransduction cascade,CP:REACTOME,C2,13,53
Cohort,0.04345217101389613,0.02178662024856277,1.9944429433364086,0.046444319282714974,LonGen OPEL,Activation of the phototransduction cascade,CP:REACTOME,C2,24,50
Cohort,-0.07268091084675156,0.03722360886736218,-1.9525487468378837,0.051285446507859773,LGP Offspring,Activation of the pre-replicative complex,CP:REACTOME,C2,57,83
Cohort,-0.09041427431009769,0.1087963615022136,-0.8310413423913823,0.4061881249642758,LGP Proband,Activation of the pre-replicative complex,CP:REACTOME,C2,57,139
Cohort,0.02580756336792861,0.031674662041951546,0.8147699676715651,0.415447689585271,LonGen OPEL,Activation of the pre-replicative complex,CP:REACTOME,C2,68,87
Cohort,0.02019399638271209,0.016720271896313126,1.2077552630687143,0.2275637844349877,LGP Offspring,Activation of the TFAP2 (AP-2) family of transcription factors,CP:REACTOME,C2,6,20
Cohort,-0.022655226745126676,0.03671484009010541,-0.6170591153202987,0.5373641522123831,LGP Proband,Activation of the TFAP2 (AP-2) family of transcription factors,CP:REACTOME,C2,6,16
Cohort,-0.005789478110448999,0.01586811688569379,-0.3648497267920061,0.7153204944151117,LonGen OPEL,Activation of the TFAP2 (AP-2) family of transcription factors,CP:REACTOME,C2,17,20
Cohort,-0.005936888938483949,0.006427192613598496,-0.9237141774657298,0.3559647373624022,LGP Offspring,Activation of TRKA receptors,CP:REACTOME,C2,2,2
Cohort,0.016651787068576927,0.015798616942118534,1.0540028364244893,0.292186871459111,LGP Proband,Activation of TRKA receptors,CP:REACTOME,C2,2,2
Cohort,-0.004953628666862014,0.005061369616545402,-0.978713084037335,0.3280191188419417,LonGen OPEL,Activation of TRKA receptors,CP:REACTOME,C2,2,2
Cohort,0.0011423064646889501,0.016538327261189183,0.06907025400142026,0.9449541239280715,LGP Offspring,Acyl chain remodeling of CL,CP:REACTOME,C2,8,18
Cohort,0.060701718848310035,0.0393799050080883,1.54143893531085,0.12358931501104449,LGP Proband,Acyl chain remodeling of CL,CP:REACTOME,C2,8,16
Cohort,-0.003353615142074396,0.010291159544336861,-0.3258733991661671,0.7446057896541511,LonGen OPEL,Acyl chain remodeling of CL,CP:REACTOME,C2,8,8
Cohort,0.0049969272355508704,0.01633014200351601,0.3059941079798934,0.7597033424079839,LGP Offspring,Acyl chain remodeling of DAG and TAG,CP:REACTOME,C2,8,20
Cohort,-0.08615546819273541,0.047681322183192355,-1.8069018275484225,0.0711378730424242,LGP Proband,Acyl chain remodeling of DAG and TAG,CP:REACTOME,C2,8,28
Cohort,0.013989810980392403,0.013981626974420012,1.0005853400314115,0.31733138608319333,LonGen OPEL,Acyl chain remodeling of DAG and TAG,CP:REACTOME,C2,11,19
Cohort,-0.004620298904053826,0.03294684251326795,-0.1402349527786523,0.8885161294254725,LGP Offspring,Acyl chain remodelling of PC,CP:REACTOME,C2,36,73
Cohort,-0.04339601635417671,0.0938081093735696,-0.4626041036746821,0.6437688354464617,LGP Proband,Acyl chain remodelling of PC,CP:REACTOME,C2,36,104
Cohort,-0.011322939104050724,0.02952288046436358,-0.3835309741445586,0.7014285202515386,LonGen OPEL,Acyl chain remodelling of PC,CP:REACTOME,C2,68,71
Cohort,0.019834155174963612,0.03074693654790925,0.6450774419122515,0.519095864095827,LGP Offspring,Acyl chain remodelling of PE,CP:REACTOME,C2,25,64
Cohort,0.04812339237785949,0.08670388575628626,0.55503155317777,0.579021904815975,LGP Proband,Acyl chain remodelling of PE,CP:REACTOME,C2,25,87
Cohort,-0.009389586704006516,0.026456166786123447,-0.3549110791413463,0.7227502199777027,LonGen OPEL,Acyl chain remodelling of PE,CP:REACTOME,C2,55,56
Cohort,2.5019191989268766e-4,0.025563927324973725,0.00978691250026642,0.9921941857588017,LGP Offspring,Acyl chain remodelling of PG,CP:REACTOME,C2,19,41
Cohort,0.031229842839402312,0.06952772417444021,0.4491710783032221,0.6534249447056186,LGP Proband,Acyl chain remodelling of PG,CP:REACTOME,C2,19,57
Cohort,-0.009108792566051445,0.021622774789474677,-0.421259188736745,0.6736795508781871,LonGen OPEL,Acyl chain remodelling of PG,CP:REACTOME,C2,35,36
Cohort,-0.008046201164199289,0.026134385486945803,-0.3078779552026731,0.7582700366241388,LGP Offspring,Acyl chain remodelling of PI,CP:REACTOME,C2,21,43
Cohort,0.053714318547632776,0.07063919388291963,0.7604039003709633,0.44722810495415677,LGP Proband,Acyl chain remodelling of PI,CP:REACTOME,C2,21,53
Cohort,0.0066394121115833,0.020822940591994365,0.3188508406029792,0.7499232712470656,LonGen OPEL,Acyl chain remodelling of PI,CP:REACTOME,C2,31,37
Cohort,0.009211780135770445,0.03138874430747077,0.29347399327401474,0.7692499483335712,LGP Offspring,Acyl chain remodelling of PS,CP:REACTOME,C2,27,65
Cohort,0.04403185670669682,0.08740105738208576,0.5037908925312596,0.6145413739063802,LGP Proband,Acyl chain remodelling of PS,CP:REACTOME,C2,27,86
Cohort,-0.0047619275618528785,0.025372489125811564,-0.18768074106724297,0.8511747585856302,LonGen OPEL,Acyl chain remodelling of PS,CP:REACTOME,C2,49,51
Cohort,-0.022146323611752915,0.1412512208530992,-0.15678677662393456,0.875459708038952,LGP Offspring,Adaptive Immune System,CP:REACTOME,C2,602,1275
Cohort,-0.31405432219163093,0.3851224497240356,-0.8154661521723041,0.4150383511709166,LGP Proband,Adaptive Immune System,CP:REACTOME,C2,602,1710
Cohort,-0.012842359998036587,0.12075458183096421,-0.1063509127629931,0.9153307339267797,LonGen OPEL,Adaptive Immune System,CP:REACTOME,C2,985,1162
Cohort,0.017412055402215906,0.015190798019214762,1.1462238771255786,0.2521081026425023,LGP Offspring,Adenylate cyclase activating pathway,CP:REACTOME,C2,5,18
Cohort,0.026275860375156015,0.0447323545260345,0.5874016839391565,0.5570929540302392,LGP Proband,Adenylate cyclase activating pathway,CP:REACTOME,C2,5,24
Cohort,-0.01681195966526726,0.013087006213780823,-1.2846299138731976,0.19929535383249544,LonGen OPEL,Adenylate cyclase activating pathway,CP:REACTOME,C2,15,11
Cohort,0.013684146955319786,0.015824812192667143,0.8647272895700278,0.38749523148387843,LGP Offspring,Adenylate cyclase inhibitory pathway,CP:REACTOME,C2,6,19
Cohort,0.025621889563557106,0.045989045169287236,0.5571302789445195,0.5775879023611635,LGP Proband,Adenylate cyclase inhibitory pathway,CP:REACTOME,C2,6,25
Cohort,-0.024127748182167428,0.013782829452149625,-1.7505656778191048,0.08040598096446226,LonGen OPEL,Adenylate cyclase inhibitory pathway,CP:REACTOME,C2,18,11
Cohort,-0.010371603400840238,0.03011569325017454,-0.3443919857558028,0.7306586226936564,LGP Offspring,Adherens junctions interactions,CP:REACTOME,C2,33,57
Cohort,-0.1156136777401842,0.08507059901756013,-1.3590321341962035,0.1745037993983615,LGP Proband,Adherens junctions interactions,CP:REACTOME,C2,33,96
Cohort,-0.004713883647224055,0.02717129728928014,-0.1734876180933701,0.8623122667462841,LonGen OPEL,Adherens junctions interactions,CP:REACTOME,C2,52,61
Cohort,0.010733995062972863,0.04483102068096595,0.23943231494459882,0.8108429509258787,LGP Offspring,ADORA2B mediated anti-inflammatory cytokines production,CP:REACTOME,C2,64,142
Cohort,0.03960443280383808,0.13269716968932296,0.29845725343322616,0.7654285403414944,LGP Proband,ADORA2B mediated anti-inflammatory cytokines production,CP:REACTOME,C2,64,216
Cohort,-0.061653955028195574,0.04105713410762693,-1.5016624118618767,0.13358088243538482,LonGen OPEL,ADORA2B mediated anti-inflammatory cytokines production,CP:REACTOME,C2,132,127
Cohort,-0.001973252779059897,0.009914067121482906,-0.19903564852652983,0.8422947072287444,LGP Offspring,ADP signalling through P2Y purinoceptor 1,CP:REACTOME,C2,3,7
Cohort,0.02257302014556826,0.03398649755275256,0.6641761220182005,0.5067611699005641,LGP Proband,ADP signalling through P2Y purinoceptor 1,CP:REACTOME,C2,3,14
Cohort,-0.006114971150434927,0.012965747487962082,-0.4716250379017724,0.6373236944694196,LonGen OPEL,ADP signalling through P2Y purinoceptor 1,CP:REACTOME,C2,13,13
Cohort,-0.004638632133655765,0.008983012897195095,-0.5163782114911754,0.6057591511248679,LGP Offspring,ADP signalling through P2Y purinoceptor 12,CP:REACTOME,C2,3,5
Cohort,-0.043025149091007714,0.023489279830632637,-1.8316929851079609,0.06735369692846122,LGP Proband,ADP signalling through P2Y purinoceptor 12,CP:REACTOME,C2,3,6
Cohort,-0.008011505646120796,0.010008141107264012,-0.8004988698956256,0.4236606654121262,LonGen OPEL,ADP signalling through P2Y purinoceptor 12,CP:REACTOME,C2,8,7
Cohort,0.0015260615131614918,0.025528605751714485,0.05977849037286349,0.9523497244577617,LGP Offspring,"Adrenaline,noradrenaline inhibits insulin secretion",CP:REACTOME,C2,19,43
Cohort,-0.015858847442703994,0.07278557174375225,-0.21788449362651716,0.8275724067449202,LGP Proband,"Adrenaline,noradrenaline inhibits insulin secretion",CP:REACTOME,C2,19,67
Cohort,0.016024469038586304,0.021642355770847714,0.7404216624223177,0.45926251515444083,LonGen OPEL,"Adrenaline,noradrenaline inhibits insulin secretion",CP:REACTOME,C2,31,41
Cohort,-0.01793542055948229,0.013891023094082126,-1.2911518783035618,0.19709236030556046,LGP Offspring,Adrenoceptors,CP:REACTOME,C2,8,9
Cohort,0.014567141385073982,0.03561871056630049,0.40897441691379527,0.682663434211232,LGP Proband,Adrenoceptors,CP:REACTOME,C2,8,13
Cohort,-0.004419875336177732,0.013539231212775655,-0.32644950564158515,0.7441700987088166,LonGen OPEL,Adrenoceptors,CP:REACTOME,C2,13,13
Cohort,0.001979293998053748,0.01787291910593871,0.1107426261105876,0.9118533129513093,LGP Offspring,Advanced glycosylation endproduct receptor signaling,CP:REACTOME,C2,9,21
Cohort,0.052551876639732424,0.05523705980141872,0.9513880142907728,0.3416830709737798,LGP Proband,Advanced glycosylation endproduct receptor signaling,CP:REACTOME,C2,9,36
Cohort,-0.019284588143616214,0.017855400870946544,-1.0800422954936384,0.2804504770840289,LonGen OPEL,Advanced glycosylation endproduct receptor signaling,CP:REACTOME,C2,24,22
Cohort,0.0032047625739265377,0.022399748519982797,0.14307136399623288,0.8862764548143635,LGP Offspring,Aflatoxin activation and detoxification,CP:REACTOME,C2,16,36
Cohort,0.07927429499215788,0.05761219666172194,1.3759984792391788,0.1691914784283417,LGP Proband,Aflatoxin activation and detoxification,CP:REACTOME,C2,16,41
Cohort,-0.04176934144733449,0.01934985065133663,-2.1586389579936727,0.031176449394042585,LonGen OPEL,Aflatoxin activation and detoxification,CP:REACTOME,C2,32,19
Cohort,0.07956256048051759,0.033486003524873374,2.3759945083150513,0.0177794186820871,LGP Offspring,Aggrephagy,CP:REACTOME,C2,26,91
Cohort,0.10402570921346661,0.09692230013986326,1.0732897286109886,0.2834515872279843,LGP Proband,Aggrephagy,CP:REACTOME,C2,26,136
Cohort,-0.0024891965835874197,0.03123516664666375,-0.07969211791777947,0.9365021586520621,LonGen OPEL,Aggrephagy,CP:REACTOME,C2,78,86
Cohort,-0.0331701062725253,0.019609501538219668,-1.6915323527156207,0.09119606187326368,LGP Offspring,AKT phosphorylates targets in the cytosol,CP:REACTOME,C2,17,21
Cohort,-0.07087037965815021,0.04275418644381612,-1.6576243299888767,0.09776938232901289,LGP Proband,AKT phosphorylates targets in the cytosol,CP:REACTOME,C2,17,14
Cohort,-0.03019143477258963,0.013191228931549752,-2.2887507243832386,0.0223549956763096,LonGen OPEL,AKT phosphorylates targets in the cytosol,CP:REACTOME,C2,17,10
Cohort,-0.005939839944538473,0.015761505344516858,-0.37685740128907397,0.7063978447941499,LGP Offspring,AKT phosphorylates targets in the nucleus,CP:REACTOME,C2,8,17
Cohort,0.023246864562938598,0.04184188910168833,0.555588312622352,0.5786413229737212,LGP Proband,AKT phosphorylates targets in the nucleus,CP:REACTOME,C2,8,21
Cohort,-0.015178031416051134,0.013562149564215465,-1.1191464409225562,0.26341526610696037,LonGen OPEL,AKT phosphorylates targets in the nucleus,CP:REACTOME,C2,15,13
Cohort,6.999416768818462e-4,0.011952056075532368,0.058562449210285306,0.953317927208864,LGP Offspring,Alpha-defensins,CP:REACTOME,C2,4,10
Cohort,-0.016587074963243985,0.03491092034664744,-0.47512568556036,0.634821792698854,LGP Proband,Alpha-defensins,CP:REACTOME,C2,4,16
Cohort,0.0016313586773535063,0.015197750355659899,0.10734211571951245,0.9145446224338653,LonGen OPEL,Alpha-defensins,CP:REACTOME,C2,14,23
Cohort,0.019433815541331525,0.021816822701030185,0.8907720343904094,0.37336839890689366,LGP Offspring,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,CP:REACTOME,C2,14,34
Cohort,-0.07080888712598135,0.056823219001567046,-1.2461259388354717,0.2130680807932503,LGP Proband,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,CP:REACTOME,C2,14,42
Cohort,-0.013318564166339308,0.017865828370403784,-0.7454770016935015,0.45620347478846734,LonGen OPEL,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,CP:REACTOME,C2,24,26
Cohort,-5.098625855381819e-4,0.012730633155811069,-0.04005005715724738,0.9680650435103066,LGP Offspring,Alpha-oxidation of phytanate,CP:REACTOME,C2,4,10
Cohort,0.03175225355160904,0.03432798579514952,0.9249669858607192,0.3552506335407608,LGP Proband,Alpha-oxidation of phytanate,CP:REACTOME,C2,4,13
Cohort,0.004679173222632429,0.01089120640799585,0.4296285505338677,0.6675821342268433,LonGen OPEL,Alpha-oxidation of phytanate,CP:REACTOME,C2,7,11
Cohort,0.003125276622598795,0.014265232856392534,0.21908346355512148,0.8266511618753579,LGP Offspring,Alpha-protein kinase 1 signaling pathway,CP:REACTOME,C2,5,13
Cohort,-0.0031116681966807517,0.0346741352315074,-0.08974032592032079,0.9285151159639845,LGP Proband,Alpha-protein kinase 1 signaling pathway,CP:REACTOME,C2,5,15
Cohort,0.025021648620705886,0.013703684463373222,1.8259066521549707,0.06823881758928788,LonGen OPEL,Alpha-protein kinase 1 signaling pathway,CP:REACTOME,C2,9,20
Cohort,-0.004402169090122966,0.004537650096717836,-0.97014291456874,0.33232223929695626,LGP Offspring,Alternative complement activation,CP:REACTOME,C2,1,1
Cohort,9.76534214779961e-4,0.013640582532141694,0.07159036005089413,0.94294507563471,LGP Proband,Alternative complement activation,CP:REACTOME,C2,1,2
Cohort,0.00456249416470101,0.007327887412517356,0.622620669213264,0.5337121447157178,LonGen OPEL,Alternative complement activation,CP:REACTOME,C2,3,5
Cohort,-0.03539691139393834,0.02894519819701234,-1.222894075660257,0.22179585858086756,LGP Offspring,Amine ligand-binding receptors,CP:REACTOME,C2,32,51
Cohort,0.018326640337477332,0.07694676067452959,0.23817299359742505,0.8118054261329866,LGP Proband,Amine ligand-binding receptors,CP:REACTOME,C2,32,69
Cohort,-0.013990913903932796,0.02253184071395866,-0.620939677390197,0.5348170695886878,LonGen OPEL,Amine ligand-binding receptors,CP:REACTOME,C2,40,39
Cohort,-0.01384549336234602,0.01346785746697746,-1.0280397900181604,0.30429880817309884,LGP Offspring,Amino Acid conjugation,CP:REACTOME,C2,8,10
Cohort,0.03081527384195034,0.047481313738863794,0.6489979197169479,0.5165183927773571,LGP Proband,Amino Acid conjugation,CP:REACTOME,C2,8,25
Cohort,0.001495591913525545,0.0122404809577618,0.12218408073068213,0.9027840731630833,LonGen OPEL,Amino Acid conjugation,CP:REACTOME,C2,9,14
Cohort,-0.058385546805374944,0.03383955135011511,-1.7253640924874831,0.0849188920343582,LGP Offspring,Amino acid transport across the plasma membrane,CP:REACTOME,C2,48,76
Cohort,-0.010483772724673397,0.10049493115996465,-0.10432140809157488,0.9169393712475944,LGP Proband,Amino acid transport across the plasma membrane,CP:REACTOME,C2,48,120
Cohort,0.01890345106957496,0.03419721356074889,0.5527775248703916,0.580570953989222,LonGen OPEL,Amino acid transport across the plasma membrane,CP:REACTOME,C2,67,91
Cohort,-0.003878081441830916,0.035416110355195096,-0.10950049011415648,0.9128380298841337,LGP Offspring,Amino acids regulate mTORC1,CP:REACTOME,C2,41,88
Cohort,0.10208574964129408,0.10240440701191664,0.9968882455362934,0.31910789983609983,LGP Proband,Amino acids regulate mTORC1,CP:REACTOME,C2,41,126
Cohort,-0.04975410894262715,0.030670124026190508,-1.62223370535248,0.1051492916902002,LonGen OPEL,Amino acids regulate mTORC1,CP:REACTOME,C2,76,74
Cohort,0.0075612210771808476,0.01232921793404857,0.6132766180002104,0.5398997326957611,LGP Offspring,AMPK inhibits chREBP transcriptional activation activity,CP:REACTOME,C2,4,11
Cohort,0.024120120998091864,0.036650432618303384,0.658112859111141,0.5106472282331247,LGP Proband,AMPK inhibits chREBP transcriptional activation activity,CP:REACTOME,C2,4,18
Cohort,-7.900864707513585e-4,0.012519296830994286,-0.06310949260307694,0.9496951589921774,LonGen OPEL,AMPK inhibits chREBP transcriptional activation activity,CP:REACTOME,C2,11,13
Cohort,-0.05607837880560979,0.03599851058742716,-1.557797194676041,0.1197493472186467,LGP Offspring,Amyloid fiber formation,CP:REACTOME,C2,52,81
Cohort,-0.05737603193401973,0.10270026874589179,-0.5586746036272168,0.576533778000353,LGP Proband,Amyloid fiber formation,CP:REACTOME,C2,52,124
Cohort,-0.039473565539485535,0.029605990903022888,-1.3332965503091851,0.18281593739506427,LonGen OPEL,Amyloid fiber formation,CP:REACTOME,C2,70,60
Cohort,-0.022572455692924986,0.030725781991481797,-0.7346421874366881,0.4628121938973535,LGP Offspring,Anchoring fibril formation,CP:REACTOME,C2,37,64
Cohort,-0.15284260527312313,0.08685647003422181,-1.759714678859301,0.07882278528227872,LGP Proband,Anchoring fibril formation,CP:REACTOME,C2,37,87
Cohort,0.004779956583160822,0.02876705652638462,0.16616078112742375,0.8680726172410288,LonGen OPEL,Anchoring fibril formation,CP:REACTOME,C2,58,71
Cohort,-0.01945726695266983,0.062417789828913224,-0.3117263044077991,0.7553446510637071,LGP Offspring,Anchoring of the basal body to the plasma membrane,CP:REACTOME,C2,128,257
Cohort,0.13948757791505714,0.18584356421098405,0.7505644788253201,0.453126506841256,LGP Proband,Anchoring of the basal body to the plasma membrane,CP:REACTOME,C2,128,406
Cohort,0.003180759265429745,0.05939794794629817,0.05354998573865678,0.9573071411648553,LonGen OPEL,Anchoring of the basal body to the plasma membrane,CP:REACTOME,C2,222,270
Cohort,-0.022844791210571373,0.019495853993988163,-1.1717768925442253,0.24169945990210848,LGP Offspring,Androgen biosynthesis,CP:REACTOME,C2,13,22
Cohort,0.08959452227090846,0.05972395930593489,1.5001437163929832,0.13395562961156843,LGP Proband,Androgen biosynthesis,CP:REACTOME,C2,13,42
Cohort,-0.025670824923407394,0.016740806572147625,-1.5334282020865715,0.12556772075963396,LonGen OPEL,Androgen biosynthesis,CP:REACTOME,C2,26,18
Cohort,-0.012332265765875173,0.05375216639214276,-0.22942825552195503,0.8186054747989713,LGP Offspring,Anti-inflammatory response favouring Leishmania parasite infection,CP:REACTOME,C2,97,198
Cohort,4.270743293641313e-4,0.15193401053984337,0.0028109198713749135,0.9977578855872244,LGP Proband,Anti-inflammatory response favouring Leishmania parasite infection,CP:REACTOME,C2,97,289
Cohort,-0.07310540189130414,0.0481118191268368,-1.519489456396919,0.1290364206623019,LonGen OPEL,Anti-inflammatory response favouring Leishmania parasite infection,CP:REACTOME,C2,174,171
Cohort,-0.048298116085291484,0.02402348129799796,-2.0104545001692364,0.04477979645973334,LGP Offspring,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,CP:REACTOME,C2,27,31
Cohort,-0.18543478566962596,0.06453075306999352,-2.873587814301399,0.004161483267261302,LGP Proband,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,CP:REACTOME,C2,27,47
Cohort,-6.430422178647937e-4,0.021653128122687833,-0.02969742820627489,0.9763158070549788,LonGen OPEL,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,CP:REACTOME,C2,33,35
Cohort,0.016977318665081134,0.03631055648187194,0.4675587572874866,0.6402508482856317,LGP Offspring,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",CP:REACTOME,C2,39,87
Cohort,-0.02091244492352447,0.09101011159344655,-0.22978155456992466,0.8183178618095545,LGP Proband,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",CP:REACTOME,C2,39,98
Cohort,0.022536863787586948,0.03131555897963901,0.719669854919088,0.47193953223334495,LonGen OPEL,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",CP:REACTOME,C2,59,80
Cohort,0.04516468012984023,0.05536502220198514,0.8157619799206155,0.41492361912889264,LGP Offspring,Antigen processing-Cross presentation,CP:REACTOME,C2,89,201
Cohort,-0.24402054531597586,0.14572476882861507,-1.674530330550499,0.09440132885240468,LGP Proband,Antigen processing-Cross presentation,CP:REACTOME,C2,89,242
Cohort,0.04572971334965821,0.049865922676648154,0.9170533882665546,0.35939242234395863,LonGen OPEL,Antigen processing-Cross presentation,CP:REACTOME,C2,146,184
Cohort,0.05304808067366494,0.08691957649180383,0.6103122313149693,0.541860111203791,LGP Offspring,Antigen processing: Ubiquitination & Proteasome degradation,CP:REACTOME,C2,234,521
Cohort,-0.2069061872327213,0.23763984435934157,-0.8706712790126765,0.38418420315687685,LGP Proband,Antigen processing: Ubiquitination & Proteasome degradation,CP:REACTOME,C2,234,700
Cohort,0.0010053714279628216,0.07306472841194801,0.013760010470365572,0.9890248944638838,LonGen OPEL,Antigen processing: Ubiquitination & Proteasome degradation,CP:REACTOME,C2,362,449
Cohort,0.00825925834402686,0.038235973813814814,0.21600753218014696,0.8290470380377358,LGP Offspring,Antimicrobial peptides,CP:REACTOME,C2,42,97
Cohort,-0.06541303033110615,0.10736357146585725,-0.6092665271656708,0.5425137213152468,LGP Proband,Antimicrobial peptides,CP:REACTOME,C2,42,143
Cohort,0.012045625246565089,0.03520267776734134,0.34217923210774054,0.7323063382272867,LonGen OPEL,Antimicrobial peptides,CP:REACTOME,C2,86,106
Cohort,-0.07034128293184137,0.05527919600466901,-1.2724729738453537,0.2036426181063193,LGP Offspring,Antiviral mechanism by IFN-stimulated genes,CP:REACTOME,C2,105,184
Cohort,-0.24102876650531974,0.14958342208119146,-1.6113334161755788,0.1074854285575738,LGP Proband,Antiviral mechanism by IFN-stimulated genes,CP:REACTOME,C2,105,229
Cohort,0.05311981297700605,0.04754006877122018,1.1173692918417428,0.2641735939040633,LonGen OPEL,Antiviral mechanism by IFN-stimulated genes,CP:REACTOME,C2,132,183
Cohort,0.008332335447873877,0.02195381153754692,0.3795393539578921,0.7044065830493573,LGP Offspring,APC/C:Cdc20 mediated degradation of Cyclin B,CP:REACTOME,C2,14,34
Cohort,-0.006723142280904439,0.06192680864538819,-0.10856594143908181,0.9135728897064574,LGP Proband,APC/C:Cdc20 mediated degradation of Cyclin B,CP:REACTOME,C2,14,52
Cohort,-0.02221084027420572,0.020590524469272672,-1.0786923037026594,0.28105167614743015,LonGen OPEL,APC/C:Cdc20 mediated degradation of Cyclin B,CP:REACTOME,C2,31,33
Cohort,0.04358725856046304,0.04133904847932252,1.0543846596339792,0.29208354286553123,LGP Offspring,APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1,CP:REACTOME,C2,42,108
Cohort,-0.044353362406121,0.10635248119143796,-0.4170411626437139,0.676755622264941,LGP Proband,APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1,CP:REACTOME,C2,42,154
Cohort,-0.02646920679108201,0.03527900953076654,-0.7502820272773936,0.45330657352636716,LonGen OPEL,APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1,CP:REACTOME,C2,87,96
Cohort,0.03458922725079171,0.042229833115822436,0.8190708960635701,0.41303462292467286,LGP Offspring,APC/C-mediated degradation of cell cycle proteins,CP:REACTOME,C2,45,111
Cohort,-0.04764162936697189,0.10758657875770637,-0.44282130649646056,0.6580098192186126,LGP Proband,APC/C-mediated degradation of cell cycle proteins,CP:REACTOME,C2,45,155
Cohort,-0.026666784667637278,0.03567008502763924,-0.7475952088977168,0.45492514542128615,LonGen OPEL,APC/C-mediated degradation of cell cycle proteins,CP:REACTOME,C2,88,98
Cohort,0.008332335447873877,0.02195381153754692,0.3795393539578921,0.7044065830493573,LGP Offspring,APC-Cdc20 mediated degradation of Nek2A,CP:REACTOME,C2,14,34
Cohort,-0.006723142280904439,0.06192680864538819,-0.10856594143908181,0.9135728897064574,LGP Proband,APC-Cdc20 mediated degradation of Nek2A,CP:REACTOME,C2,14,52
Cohort,-0.01939997590204802,0.0204486390265634,-0.948717216673778,0.34305238998776666,LonGen OPEL,APC-Cdc20 mediated degradation of Nek2A,CP:REACTOME,C2,30,33
Cohort,-0.057610703289686704,0.019417823921099628,-2.966898017191631,0.0031143996910858638,LGP Offspring,APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway,CP:REACTOME,C2,20,21
Cohort,-0.09869730607302328,0.05778250630677262,-1.708082815740637,0.08799309848002314,LGP Proband,APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway,CP:REACTOME,C2,20,34
Cohort,-3.6969231641309336e-5,0.017826036195409747,-0.0020738896317751792,0.9983457962874527,LonGen OPEL,APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway,CP:REACTOME,C2,21,24
Cohort,-0.0041527020624387715,0.005547498974183312,-0.7485719387717636,0.45437561572542706,LGP Offspring,APOBEC3G mediated resistance to HIV-1 infection,CP:REACTOME,C2,2,1
Cohort,-0.008525432848037622,0.013674723155722124,-0.6234446394967926,0.5331628312496683,LGP Proband,APOBEC3G mediated resistance to HIV-1 infection,CP:REACTOME,C2,2,1
Cohort,-0.006700855292097721,0.004427305287133758,-1.5135290786409406,0.13054225273612383,LonGen OPEL,APOBEC3G mediated resistance to HIV-1 infection,CP:REACTOME,C2,2,1
Cohort,-0.039263801329850335,0.06914501905651858,-0.5678471401932281,0.5703273140945853,LGP Offspring,Apoptosis,CP:REACTOME,C2,157,319
Cohort,-0.098872899619879,0.19022733105287842,-0.519761798016263,0.6033675292192375,LGP Proband,Apoptosis,CP:REACTOME,C2,157,427
Cohort,-0.06964749214796541,0.060667643130693796,-1.14801710687733,0.25130639488208134,LonGen OPEL,Apoptosis,CP:REACTOME,C2,277,294
Cohort,0.00870300752324659,0.011068195012886231,0.7863077505513814,0.43196275527617456,LGP Offspring,Apoptosis induced DNA fragmentation,CP:REACTOME,C2,3,9
Cohort,-0.005282599372550512,0.03130807805541171,-0.16872959634254509,0.8660502497833189,LGP Proband,Apoptosis induced DNA fragmentation,CP:REACTOME,C2,3,13
Cohort,0.0014087033683464318,0.01086761429023383,0.12962397548580296,0.8968966805623251,LonGen OPEL,Apoptosis induced DNA fragmentation,CP:REACTOME,C2,7,11
Cohort,0.0015222706154545472,0.027626412339071402,0.055102001547324864,0.9560734824286036,LGP Offspring,Apoptotic cleavage of cell adhesion  proteins,CP:REACTOME,C2,25,53
Cohort,-0.01032404278275782,0.07423853264066045,-0.1390658249231524,0.88943170633663,LGP Proband,Apoptotic cleavage of cell adhesion  proteins,CP:REACTOME,C2,25,67
Cohort,0.025781661578035693,0.024636006843251203,1.0465032641886252,0.2956464065838958,LonGen OPEL,Apoptotic cleavage of cell adhesion  proteins,CP:REACTOME,C2,39,53
Cohort,-0.028048442683588658,0.04471138670324766,-0.6273221376413121,0.530659918354391,LGP Offspring,Apoptotic cleavage of cellular proteins,CP:REACTOME,C2,69,136
Cohort,-0.08820410496979483,0.12131483956570728,-0.7270677295997345,0.4673884984363489,LGP Proband,Apoptotic cleavage of cellular proteins,CP:REACTOME,C2,69,172
Cohort,0.019393813680577677,0.04064113269781809,0.47719668210967153,0.6333530615949872,LonGen OPEL,Apoptotic cleavage of cellular proteins,CP:REACTOME,C2,114,138
Cohort,-0.013258193031468676,0.04612421578961957,-0.28744538643088396,0.7738594059772259,LGP Offspring,Apoptotic execution phase,CP:REACTOME,C2,72,147
Cohort,-0.089978098419588,0.1274206051134999,-0.7061502991564041,0.48029188559160085,LGP Proband,Apoptotic execution phase,CP:REACTOME,C2,72,187
Cohort,0.020716930651184313,0.041918298904835366,0.4942216452584761,0.6212860109239703,LonGen OPEL,Apoptotic execution phase,CP:REACTOME,C2,121,149
Cohort,-0.06329599520056713,0.021849234332409567,-2.8969434002855854,0.0038900161156777005,LGP Offspring,Apoptotic factor-mediated response,CP:REACTOME,C2,24,24
Cohort,0.031277130647446895,0.06007965017373333,0.5205944201905686,0.6027875130691523,LGP Proband,Apoptotic factor-mediated response,CP:REACTOME,C2,24,37
Cohort,-0.01969991689244972,0.021474914390764918,-0.9173455378672652,0.35923945459346873,LonGen OPEL,Apoptotic factor-mediated response,CP:REACTOME,C2,36,35
Cohort,0.04381144187181715,0.03181712890390384,1.3769765966042793,0.1689752937340353,LGP Offspring,Aquaporin-mediated transport,CP:REACTOME,C2,26,74
Cohort,0.07014606410714902,0.09674574131023136,0.7250558335401448,0.4686211540354088,LGP Proband,Aquaporin-mediated transport,CP:REACTOME,C2,26,115
Cohort,-0.03199582266125126,0.03249919145211122,-0.9845113441790794,0.3251633027906311,LonGen OPEL,Aquaporin-mediated transport,CP:REACTOME,C2,75,83
Cohort,-0.014576063384950492,0.013052166500221191,-1.1167543246328857,0.2644961521175059,LGP Offspring,Arachidonate production from DAG,CP:REACTOME,C2,7,10
Cohort,-0.01364863227737549,0.02877059907052145,-0.4743951366435039,0.635342342963168,LGP Proband,Arachidonate production from DAG,CP:REACTOME,C2,7,7
Cohort,0.004191672433405904,0.012311720843232055,0.3404619457165593,0.7335985057403241,LonGen OPEL,Arachidonate production from DAG,CP:REACTOME,C2,8,13
Cohort,-0.011886340711216378,0.04610097104457332,-0.25783276234515573,0.7966144483430051,LGP Offspring,Arachidonic acid metabolism,CP:REACTOME,C2,71,149
Cohort,-0.09228210222976439,0.13122911904653953,-0.703213607621927,0.4821188947079005,LGP Proband,Arachidonic acid metabolism,CP:REACTOME,C2,71,211
Cohort,-0.0576006257681053,0.042034975055452305,-1.3703023658779117,0.17097886058973585,LonGen OPEL,Arachidonic acid metabolism,CP:REACTOME,C2,134,132
Cohort,-0.00407470379947548,0.011957504917284714,-0.34076538773448023,0.7333860849026862,LGP Offspring,ARMS-mediated activation,CP:REACTOME,C2,5,9
Cohort,0.02032814601755042,0.028110607437610537,0.7231485859089767,0.4697913557181096,LGP Proband,ARMS-mediated activation,CP:REACTOME,C2,5,8
Cohort,-0.001532658123507297,0.009321681383982908,-0.16441863440439033,0.8694433360568605,LonGen OPEL,ARMS-mediated activation,CP:REACTOME,C2,6,7
Cohort,-0.012715663750649071,0.005515390677805142,-2.3054874066888926,0.021441170189970184,LGP Offspring,Aryl hydrocarbon receptor signalling,CP:REACTOME,C2,3,0
Cohort,-0.015906857939681676,0.02366812157814395,-0.6720794418417505,0.5017192590623356,LGP Proband,Aryl hydrocarbon receptor signalling,CP:REACTOME,C2,3,6
Cohort,0.02052918487691904,0.008527462814897082,2.40742004070138,0.016292297117126816,LonGen OPEL,Aryl hydrocarbon receptor signalling,CP:REACTOME,C2,1,10
Cohort,-0.09973268348142655,0.09729948800701081,-1.0250072793213507,0.3057263955621591,LGP Offspring,Asparagine N-linked glycosylation,CP:REACTOME,C2,347,681
Cohort,-0.45157864568913864,0.27686592889002576,-1.631037258717777,0.10325999865704817,LGP Proband,Asparagine N-linked glycosylation,CP:REACTOME,C2,347,915
Cohort,-0.06805951616655087,0.08596227188709199,-0.7917370571120355,0.4287498746652001,LonGen OPEL,Asparagine N-linked glycosylation,CP:REACTOME,C2,534,602
Cohort,3.0855880674128853e-4,0.021137997433902506,0.014597352833736353,0.9883577181453752,LGP Offspring,Aspartate and asparagine metabolism,CP:REACTOME,C2,14,31
Cohort,0.03391133905811963,0.0592471970294815,0.5723703526640306,0.5672253503695526,LGP Proband,Aspartate and asparagine metabolism,CP:REACTOME,C2,14,40
Cohort,-0.01007006733288632,0.018787704614614365,-0.5359924237393604,0.5921135239393243,LonGen OPEL,Aspartate and asparagine metabolism,CP:REACTOME,C2,26,31
Cohort,0.015428615427784018,0.035695505396660165,0.43222851886634417,0.6657131722386407,LGP Offspring,Assembly and cell surface presentation of NMDA receptors,CP:REACTOME,C2,34,90
Cohort,0.06816233200951184,0.10147665837600225,0.6717045387615093,0.5019578254186623,LGP Proband,Assembly and cell surface presentation of NMDA receptors,CP:REACTOME,C2,34,131
Cohort,0.0069190540589406145,0.032638945768390284,0.21198766982362172,0.8321709212441979,LonGen OPEL,Assembly and cell surface presentation of NMDA receptors,CP:REACTOME,C2,66,86
Cohort,0.014902772221964233,0.021270456052387598,0.7006324728186261,0.4837734823054788,LGP Offspring,Assembly of active LPL and LIPC lipase complexes,CP:REACTOME,C2,15,31
Cohort,-0.03864312655459486,0.0714331471939153,-0.5409691168960072,0.5886733253581207,LGP Proband,Assembly of active LPL and LIPC lipase complexes,CP:REACTOME,C2,15,63
Cohort,0.0024927093847114975,0.01885759918557797,0.13218593523919456,0.8948706305778092,LonGen OPEL,Assembly of active LPL and LIPC lipase complexes,CP:REACTOME,C2,26,26
Cohort,-0.04282595862286216,0.07416046688187118,-0.5774769283893375,0.5638095993340784,LGP Offspring,Assembly of collagen fibrils and other multimeric structures,CP:REACTOME,C2,160,332
Cohort,-0.11898275019430465,0.1859269251572733,-0.6399436235158442,0.5223850072625801,LGP Proband,Assembly of collagen fibrils and other multimeric structures,CP:REACTOME,C2,160,413
Cohort,-0.04329235594035174,0.059106824711092854,-0.7324425927455863,0.46411407775672653,LonGen OPEL,Assembly of collagen fibrils and other multimeric structures,CP:REACTOME,C2,254,290
Cohort,-0.047634053412681204,0.01790393872094368,-2.6605348775551723,0.00798675767739424,LGP Offspring,Assembly Of The HIV Virion,CP:REACTOME,C2,15,14
Cohort,0.02170195019496968,0.04348619986456921,0.4990537288279252,0.6178731410480149,LGP Proband,Assembly Of The HIV Virion,CP:REACTOME,C2,15,16
Cohort,-0.010720589065576124,0.017525978235911642,-0.6116970431704107,0.5409128811462873,LonGen OPEL,Assembly Of The HIV Virion,CP:REACTOME,C2,22,24
Cohort,-0.03345478635959408,0.015104344687435574,-2.214911474274231,0.027098798169874153,LGP Offspring,Assembly of the ORC complex at the origin of replication,CP:REACTOME,C2,13,10
Cohort,-0.07177020799525115,0.046181635927759486,-1.554085440098291,0.12054341023788047,LGP Proband,Assembly of the ORC complex at the origin of replication,CP:REACTOME,C2,13,23
Cohort,0.006346519888922072,0.012364476156238265,0.5132865969190337,0.6078932855974117,LonGen OPEL,Assembly of the ORC complex at the origin of replication,CP:REACTOME,C2,9,12
Cohort,0.00487351347429943,0.04440641817196939,0.10974795254654723,0.9126418405792157,LGP Offspring,Assembly of the pre-replicative complex,CP:REACTOME,C2,62,126
Cohort,-0.06719463149106629,0.11690375250723735,-0.5747859247452844,0.5655911000695447,LGP Proband,Assembly of the pre-replicative complex,CP:REACTOME,C2,62,180
Cohort,-7.183458471353275e-5,0.03733135878320034,-0.0019242424346434283,0.9984651597422212,LonGen OPEL,Assembly of the pre-replicative complex,CP:REACTOME,C2,92,107
Cohort,-0.05482587279753072,0.036992822910356625,-1.4820678305731974,0.13878823717206265,LGP Offspring,Association of TriC/CCT with target proteins during biosynthesis,CP:REACTOME,C2,51,86
Cohort,-0.0663067292931037,0.09959287698129644,-0.6657778277211142,0.5057372131153818,LGP Proband,Association of TriC/CCT with target proteins during biosynthesis,CP:REACTOME,C2,51,122
Cohort,0.037905756355236735,0.032312869174153436,1.173085440074661,0.24111245600017456,LonGen OPEL,Association of TriC/CCT with target proteins during biosynthesis,CP:REACTOME,C2,63,93
Cohort,0.03149246754897667,0.035999067801519756,0.8748134180198736,0.381986133590151,LGP Offspring,Asymmetric localization of PCP proteins,CP:REACTOME,C2,33,83
Cohort,-0.10871072597416558,0.09446862438716493,-1.1507601246381192,0.250160759761563,LGP Proband,Asymmetric localization of PCP proteins,CP:REACTOME,C2,33,116
Cohort,-0.0351021056391004,0.029015711999758668,-1.2097619951353376,0.2267293840293383,LonGen OPEL,Asymmetric localization of PCP proteins,CP:REACTOME,C2,64,63
Cohort,-0.017334336857996242,0.024848212249543405,-0.6976090144398523,0.4856616029747487,LGP Offspring,ATF4 activates genes in response to endoplasmic reticulum  stress,CP:REACTOME,C2,21,38
Cohort,-0.0562719082927052,0.06523643781666202,-0.8625840124939012,0.3886141881028433,LGP Proband,ATF4 activates genes in response to endoplasmic reticulum  stress,CP:REACTOME,C2,21,48
Cohort,0.05217872586768799,0.024009764844576415,2.1732293591986047,0.03005726248133378,LonGen OPEL,ATF4 activates genes in response to endoplasmic reticulum  stress,CP:REACTOME,C2,34,61
Cohort,-0.0016844718537874124,0.020253175760468548,-0.08317075177292803,0.9337403903694361,LGP Offspring,ATF6 (ATF6-alpha) activates chaperone genes,CP:REACTOME,C2,11,27
Cohort,-0.08793064473757344,0.06112741529987462,-1.4384813149093478,0.15067268261272113,LGP Proband,ATF6 (ATF6-alpha) activates chaperone genes,CP:REACTOME,C2,11,46
Cohort,0.03425277697986347,0.01864039483697996,1.8375564079742939,0.06650036479107918,LonGen OPEL,ATF6 (ATF6-alpha) activates chaperone genes,CP:REACTOME,C2,19,34
Cohort,-0.002236126837034875,0.020941489657843995,-0.10677974077155945,0.9149954003743437,LGP Offspring,ATF6 (ATF6-alpha) activates chaperones,CP:REACTOME,C2,12,29
Cohort,-0.08352261089356908,0.0645196519355395,-1.29452978105051,0.19584078926124893,LGP Proband,ATF6 (ATF6-alpha) activates chaperones,CP:REACTOME,C2,12,53
Cohort,0.03604900181704974,0.019118217819616243,1.8855838006020451,0.05971499186728148,LonGen OPEL,ATF6 (ATF6-alpha) activates chaperones,CP:REACTOME,C2,20,36
Cohort,-0.0048074594311565905,0.00774135565455425,-0.62101002016725,0.5348023600634351,LGP Offspring,Attachment and Entry,CP:REACTOME,C2,3,3
Cohort,0.0029144592391312806,0.020186503348616113,0.14437662574836577,0.885237953493408,LGP Proband,Attachment and Entry,CP:REACTOME,C2,3,4
Cohort,0.004580152983296653,0.0051873606228336365,0.8829447798820489,0.37753267695491766,LonGen OPEL,Attachment and Entry,CP:REACTOME,C2,1,3
Cohort,-0.014288848227526057,0.017434193054230857,-0.8195875876261735,0.412740115270135,LGP Offspring,Attachment of GPI anchor to uPAR,CP:REACTOME,C2,12,19
Cohort,-0.14373705391204092,0.046959407391607096,-3.060878786509784,0.002277614242333611,LGP Proband,Attachment of GPI anchor to uPAR,CP:REACTOME,C2,12,24
Cohort,-0.004860279426276437,0.014653638488584671,-0.3316773120930097,0.7402202406610339,LonGen OPEL,Attachment of GPI anchor to uPAR,CP:REACTOME,C2,17,16
Cohort,-0.005672513855595648,0.021994873919935577,-0.25790163090929247,0.7965613182572673,LGP Offspring,Attenuation phase,CP:REACTOME,C2,16,30
Cohort,0.009174930353184113,0.05271052387628488,0.17406259089206338,0.8618585137241834,LGP Proband,Attenuation phase,CP:REACTOME,C2,16,27
Cohort,-0.013178618625677718,0.02159184256610179,-0.6103517374829116,0.5418030444856373,LonGen OPEL,Attenuation phase,CP:REACTOME,C2,33,31
Cohort,0.03505561009483927,0.03374844512766478,1.0387325982642963,0.2993005019472405,LGP Offspring,AUF1 (hnRNP D0) binds and destabilizes mRNA,CP:REACTOME,C2,29,76
Cohort,0.01652798995028547,0.08834820490253557,0.18707782425821673,0.8516451146561067,LGP Proband,AUF1 (hnRNP D0) binds and destabilizes mRNA,CP:REACTOME,C2,29,108
Cohort,-0.01015136027992934,0.028734444346722354,-0.35328194126319595,0.7239706209384222,LonGen OPEL,AUF1 (hnRNP D0) binds and destabilizes mRNA,CP:REACTOME,C2,56,65
Cohort,-0.017077297594817433,0.05127795943261356,-0.33303387622628394,0.7392119711643268,LGP Offspring,AURKA Activation by TPX2,CP:REACTOME,C2,92,174
Cohort,0.033229397883454664,0.1587999987070091,0.20925313699003192,0.8343017333122752,LGP Proband,AURKA Activation by TPX2,CP:REACTOME,C2,92,294
Cohort,-0.021735162571591662,0.047071180728677796,-0.46175095323983795,0.6443860898109364,LonGen OPEL,AURKA Activation by TPX2,CP:REACTOME,C2,152,179
Cohort,-0.04637193597668437,0.06009636084187844,-0.7716263568553698,0.44060540234674006,LGP Offspring,Autophagy,CP:REACTOME,C2,113,213
Cohort,-0.139591884519468,0.1681135792109935,-0.8303427074398974,0.4065826733378364,LGP Proband,Autophagy,CP:REACTOME,C2,113,323
Cohort,-0.026997648439005782,0.05106270354624289,-0.5287156097122128,0.597150132570559,LonGen OPEL,Autophagy,CP:REACTOME,C2,202,219
Cohort,-0.021294756844532345,0.029856927523412253,-0.7132266649953884,0.4759516455420699,LGP Offspring,B-WICH complex positively regulates rRNA expression,CP:REACTOME,C2,32,58
Cohort,-0.002725916942754459,0.08655089206255324,-0.03149496068491526,0.9748823463217204,LGP Proband,B-WICH complex positively regulates rRNA expression,CP:REACTOME,C2,32,90
Cohort,0.006769814201640858,0.026281685505980586,0.25758675942227294,0.7967924243870084,LonGen OPEL,B-WICH complex positively regulates rRNA expression,CP:REACTOME,C2,51,63
Cohort,-0.08411804758857241,0.04317273832008975,-1.9484065839166245,0.0517797546794394,LGP Offspring,Base Excision Repair,CP:REACTOME,C2,73,121
Cohort,-0.013189928105769664,0.12711533553904847,-0.10376346842681196,0.9173820041811919,LGP Proband,Base Excision Repair,CP:REACTOME,C2,73,184
Cohort,0.023690130044309112,0.0407220713136895,0.5817515975997327,0.5608987211385711,LonGen OPEL,Base Excision Repair,CP:REACTOME,C2,106,132
Cohort,-0.09971972978633786,0.03485780225547506,-2.8607578026717118,0.004356796274174578,LGP Offspring,"Base-Excision Repair, AP Site Formation",CP:REACTOME,C2,52,73
Cohort,0.0029256637116876595,0.10050030516093364,0.02911099331492299,0.9767830326130482,LGP Proband,"Base-Excision Repair, AP Site Formation",CP:REACTOME,C2,52,110
Cohort,0.027346152895750202,0.02922527251426496,0.9357022379313126,0.3497102967457839,LonGen OPEL,"Base-Excision Repair, AP Site Formation",CP:REACTOME,C2,54,78
Cohort,-0.05007002905261185,0.032463403484926545,-1.5423530399657706,0.12345579107069776,LGP Offspring,Basigin interactions,CP:REACTOME,C2,42,66
Cohort,-0.02891334452371615,0.09763207279236245,-0.2961459661438017,0.767192336777796,LGP Proband,Basigin interactions,CP:REACTOME,C2,42,116
Cohort,0.0273897214740687,0.029181893974868825,0.9385861485774869,0.3482279701693186,LonGen OPEL,Basigin interactions,CP:REACTOME,C2,51,74
Cohort,0.00680070943419291,0.028852281262919603,0.23570785866880659,0.8137307620405679,LGP Offspring,BBSome-mediated cargo-targeting to cilium,CP:REACTOME,C2,26,58
Cohort,0.051329218391961,0.07927352097073011,0.6474951252753504,0.5174897358433037,LGP Proband,BBSome-mediated cargo-targeting to cilium,CP:REACTOME,C2,26,84
Cohort,0.006915713052109127,0.023816538533704953,0.29037439854335134,0.771605458318535,LonGen OPEL,BBSome-mediated cargo-targeting to cilium,CP:REACTOME,C2,35,45
Cohort,0.05209877941279834,0.05650369529284855,0.9220419857989762,0.3568356274113852,LGP Offspring,Beta-catenin independent WNT signaling,CP:REACTOME,C2,94,223
Cohort,-0.13352462398615023,0.1551918019156408,-0.8603845199164036,0.38982437913066803,LGP Proband,Beta-catenin independent WNT signaling,CP:REACTOME,C2,94,302
Cohort,-0.029747633631111832,0.04761611001197653,-0.6247388462356465,0.5323215030112204,LonGen OPEL,Beta-catenin independent WNT signaling,CP:REACTOME,C2,160,180
Cohort,-0.02036932254100146,0.01867145678171062,-1.0909337594350947,0.27569071722588523,LGP Offspring,Beta-catenin phosphorylation cascade,CP:REACTOME,C2,15,21
Cohort,-0.009068900168727355,0.05029158963653801,-0.18032637731813886,0.8569401559238962,LGP Proband,Beta-catenin phosphorylation cascade,CP:REACTOME,C2,15,29
Cohort,-0.0032056146940276854,0.015308522944552674,-0.20940065254096635,0.834189061888802,LonGen OPEL,Beta-catenin phosphorylation cascade,CP:REACTOME,C2,17,20
Cohort,9.375982195201533e-5,0.02691501287242175,0.003483551072274818,0.9972215617311058,LGP Offspring,Beta defensins,CP:REACTOME,C2,25,52
Cohort,-0.02161126934654844,0.07932225271709549,-0.27244901154819057,0.7853442302471292,LGP Proband,Beta defensins,CP:REACTOME,C2,25,76
Cohort,0.03921829228323165,0.024451436661199887,1.60392588896276,0.10912706356225478,LonGen OPEL,Beta defensins,CP:REACTOME,C2,38,56
Cohort,-0.007208897372760279,0.01786194260119045,-0.40358977372818483,0.6866420355629745,LGP Offspring,Beta oxidation of butanoyl-CoA to acetyl-CoA,CP:REACTOME,C2,12,19
Cohort,-0.034251480108685506,0.04642250353993568,-0.737820614935602,0.46083100611924954,LGP Proband,Beta oxidation of butanoyl-CoA to acetyl-CoA,CP:REACTOME,C2,12,22
Cohort,0.005507360621080431,0.01412190330669726,0.3899871356907384,0.6966503874358888,LonGen OPEL,Beta oxidation of butanoyl-CoA to acetyl-CoA,CP:REACTOME,C2,13,18
Cohort,-0.001670518126897044,0.017953578016997183,-0.09304652951715336,0.9258941650300421,LGP Offspring,Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA,CP:REACTOME,C2,11,22
Cohort,0.019713443629884576,0.04749658613595583,0.41504969585511153,0.6782122711530383,LGP Proband,Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA,CP:REACTOME,C2,11,27
Cohort,-0.007063101007018346,0.01589205465578518,-0.44444228012059905,0.6568436588419821,LonGen OPEL,Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA,CP:REACTOME,C2,15,20
Cohort,-0.003017522754520552,0.014545428369275788,-0.20745506271196834,0.8357169622215911,LGP Offspring,Beta oxidation of hexanoyl-CoA to butanoyl-CoA,CP:REACTOME,C2,7,14
Cohort,0.029814664967735324,0.033109809556687256,0.9004782983329964,0.3681257107056618,LGP Proband,Beta oxidation of hexanoyl-CoA to butanoyl-CoA,CP:REACTOME,C2,7,11
Cohort,-0.01400314859936808,0.010892867452320938,-1.2855337367007469,0.19897970528372505,LonGen OPEL,Beta oxidation of hexanoyl-CoA to butanoyl-CoA,CP:REACTOME,C2,9,7
Cohort,-7.845210702872624e-4,0.01786036265092147,-0.04392525984049862,0.9649769516423135,LGP Offspring,Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA,CP:REACTOME,C2,9,21
Cohort,0.03459239484726542,0.0419820958304225,0.8239797028474672,0.41018666289037364,LGP Proband,Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA,CP:REACTOME,C2,9,18
Cohort,-0.03420832228805021,0.016430443807455036,-2.08200841614082,0.03766060301770287,LonGen OPEL,Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA,CP:REACTOME,C2,25,16
Cohort,0.0043445520408499924,0.016391608309895202,0.26504733145845705,0.7910537984004674,LGP Offspring,Beta oxidation of octanoyl-CoA to hexanoyl-CoA,CP:REACTOME,C2,8,19
Cohort,0.035347094597134296,0.042305588678845304,0.8355183251429245,0.4036652259181903,LGP Proband,Beta oxidation of octanoyl-CoA to hexanoyl-CoA,CP:REACTOME,C2,8,22
Cohort,-0.006646298300390317,0.015045042355572908,-0.4417600258817769,0.6587828508334694,LonGen OPEL,Beta oxidation of octanoyl-CoA to hexanoyl-CoA,CP:REACTOME,C2,13,18
Cohort,0.040383777912239835,0.022076095446189194,1.8292989360675616,0.06779517078176928,LGP Offspring,Beta-oxidation of pristanoyl-CoA,CP:REACTOME,C2,10,39
Cohort,-0.08217424011599944,0.060196107527324384,-1.365108866527602,0.1725869584560089,LGP Proband,Beta-oxidation of pristanoyl-CoA,CP:REACTOME,C2,10,51
Cohort,-0.023806203225403985,0.015360928256296657,-1.5497893635201045,0.12158955363372331,LonGen OPEL,Beta-oxidation of pristanoyl-CoA,CP:REACTOME,C2,21,16
Cohort,0.03311741423166492,0.023065745149660588,1.4357834102815552,0.15152653614855255,LGP Offspring,Beta-oxidation of very long chain fatty acids,CP:REACTOME,C2,13,39
Cohort,0.018241830051740723,0.06102580213402726,0.2989199553932499,0.7650755878466757,LGP Proband,Beta-oxidation of very long chain fatty acids,CP:REACTOME,C2,13,51
Cohort,-0.0013829767388813191,0.020341517209743996,-0.06798788529986571,0.9458123518576642,LonGen OPEL,Beta-oxidation of very long chain fatty acids,CP:REACTOME,C2,26,33
Cohort,0.00873856313124565,0.008423176768566479,1.0374426859775905,0.29990053691866597,LGP Offspring,BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,CP:REACTOME,C2,1,6
Cohort,-0.0032503892034888176,0.02215065554684428,-0.1467400906765438,0.8833726361310682,LGP Proband,BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,CP:REACTOME,C2,1,7
Cohort,-0.008736196406422366,0.007733588852655424,-1.12964324492408,0.2589668739712036,LonGen OPEL,BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,CP:REACTOME,C2,7,2
Cohort,0.06159049785856736,0.024720844910066903,2.491439838833594,0.01296131780537612,LGP Offspring,Bicarbonate transporters,CP:REACTOME,C2,10,51
Cohort,-0.023797544587446658,0.061455314104068126,-0.38723330820745644,0.6986822876011769,LGP Proband,Bicarbonate transporters,CP:REACTOME,C2,10,54
Cohort,-0.04134216352090072,0.02153280292296824,-1.9199620072128452,0.05521979722289564,LonGen OPEL,Bicarbonate transporters,CP:REACTOME,C2,40,31
Cohort,-0.01726656689575725,0.048469077786769066,-0.3562388162555596,0.7217728766746134,LGP Offspring,Bile acid and bile salt metabolism,CP:REACTOME,C2,77,136
Cohort,-0.3040895611518384,0.13190541790104388,-2.305360659104753,0.021391006510376336,LGP Proband,Bile acid and bile salt metabolism,CP:REACTOME,C2,77,191
Cohort,-0.021326310937340835,0.03780694295136343,-0.5640845112702175,0.5728555117732197,LonGen OPEL,Bile acid and bile salt metabolism,CP:REACTOME,C2,92,109
Cohort,0.010004685664352789,0.042864097088881836,0.23340479197794234,0.8155177514110361,LGP Offspring,Binding and Uptake of Ligands by Scavenger Receptors,CP:REACTOME,C2,56,120
Cohort,-0.359596486847272,0.12477123273863876,-2.8820464377436044,0.0040524731492635555,LGP Proband,Binding and Uptake of Ligands by Scavenger Receptors,CP:REACTOME,C2,56,188
Cohort,0.017628017330727944,0.03684491092911939,0.4784383212281323,0.6324696419132954,LonGen OPEL,Binding and Uptake of Ligands by Scavenger Receptors,CP:REACTOME,C2,93,114
Cohort,0.006907589461791671,0.01274549798526786,0.5419630892238143,0.5880225247258092,LGP Offspring,Binding of TCF/LEF:CTNNB1 to target gene promoters,CP:REACTOME,C2,4,12
Cohort,-0.01083150963520469,0.028683768060204607,-0.37761808743085434,0.7058104036394344,LGP Proband,Binding of TCF/LEF:CTNNB1 to target gene promoters,CP:REACTOME,C2,4,10
Cohort,-0.006405566619532733,0.009965645609958964,-0.642764841359747,0.5205617951403396,LonGen OPEL,Binding of TCF/LEF:CTNNB1 to target gene promoters,CP:REACTOME,C2,8,7
Cohort,-0.2262680646537933,0.08741558053998681,-2.5884180286406804,0.00984903922923135,LGP Offspring,Biological oxidations,CP:REACTOME,C2,232,403
Cohort,0.27939902787221743,0.2504364880050373,1.115648243184905,0.26489408358467637,LGP Proband,Biological oxidations,CP:REACTOME,C2,232,611
Cohort,-0.050972496591123066,0.07364383118561675,-0.692148897884585,0.48904567445676106,LonGen OPEL,Biological oxidations,CP:REACTOME,C2,345,398
Cohort,0.020667757208858887,0.01761968800548338,1.172992234733494,0.2412120725715945,LGP Offspring,Biosynthesis of EPA-derived SPMs,CP:REACTOME,C2,8,24
Cohort,0.00879632126720684,0.04279469823416733,0.2055469866634986,0.8371949513869629,LGP Proband,Biosynthesis of EPA-derived SPMs,CP:REACTOME,C2,8,23
Cohort,-0.006600301175088077,0.014610561761699734,-0.45174862423087453,0.6515731463181793,LonGen OPEL,Biosynthesis of EPA-derived SPMs,CP:REACTOME,C2,17,16
Cohort,-0.045804944175437234,0.01897979187555165,-2.413353343164934,0.016071427309757,LGP Offspring,Biosynthesis of maresin-like SPMs,CP:REACTOME,C2,19,18
Cohort,-0.05036359127365727,0.0529610878851225,-0.9509546213042406,0.34190290952800995,LGP Proband,Biosynthesis of maresin-like SPMs,CP:REACTOME,C2,19,29
Cohort,-0.022527715430200983,0.017347606814985123,-1.298606526563722,0.194455073200916,LonGen OPEL,Biosynthesis of maresin-like SPMs,CP:REACTOME,C2,25,20
Cohort,-0.05266548751351768,0.020453284883807592,-2.574915853991344,0.010237969759751917,LGP Offspring,Biosynthesis of maresins,CP:REACTOME,C2,21,20
Cohort,-0.06283781153632362,0.05757320618836704,-1.091441934477853,0.27539367386803265,LGP Proband,Biosynthesis of maresins,CP:REACTOME,C2,21,34
Cohort,-0.022973638686498522,0.018844106784978314,-1.219141822355416,0.22315151376480558,LonGen OPEL,Biosynthesis of maresins,CP:REACTOME,C2,28,24
Cohort,-0.037047583608800096,0.03120902365282984,-1.1870792249356654,0.23561334783029098,LGP Offspring,Biosynthesis of specialized proresolving mediators (SPMs),CP:REACTOME,C2,37,58
Cohort,-0.05330651444556125,0.08079978938623025,-0.6597358093441471,0.5096055219068566,LGP Proband,Biosynthesis of specialized proresolving mediators (SPMs),CP:REACTOME,C2,37,70
Cohort,-0.040598336235982406,0.02521212284784788,-1.6102704433493549,0.10773528472870116,LonGen OPEL,Biosynthesis of specialized proresolving mediators (SPMs),CP:REACTOME,C2,53,45
Cohort,-0.012691198275570817,0.05008278952842174,-0.2534043809274766,0.8000327882787874,LGP Offspring,"Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein",CP:REACTOME,C2,89,184
Cohort,0.07398421882037844,0.14384891721314966,0.5143189135775804,0.6071652949942656,LGP Proband,"Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein",CP:REACTOME,C2,89,259
Cohort,-0.004697305036901814,0.04683370351668361,-0.10029753541119141,0.9201333692995878,LonGen OPEL,"Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein",CP:REACTOME,C2,143,173
Cohort,-0.003618291991203261,0.01873292722922284,-0.19315144648396582,0.8468983796731413,LGP Offspring,Biotin transport and metabolism,CP:REACTOME,C2,11,23
Cohort,-0.0517186093891584,0.04644906282295733,-1.113447855477433,0.2658369334268298,LGP Proband,Biotin transport and metabolism,CP:REACTOME,C2,11,26
Cohort,-0.001443371239729431,0.014456162953109995,-0.09984469906787502,0.9204927606771038,LonGen OPEL,Biotin transport and metabolism,CP:REACTOME,C2,15,17
Cohort,-0.012990217196485541,0.020103332594217836,-0.6461723266828812,0.5183870569561655,LGP Offspring,Blood group systems biosynthesis,CP:REACTOME,C2,11,22
Cohort,-0.00764872301057784,0.042947314114441616,-0.17809549137802436,0.8586912315646729,LGP Proband,Blood group systems biosynthesis,CP:REACTOME,C2,11,16
Cohort,-5.741089372502042e-4,0.01537034672498152,-0.03735172325794717,0.9702139301304382,LonGen OPEL,Blood group systems biosynthesis,CP:REACTOME,C2,15,17
Cohort,-0.004563523278293673,0.023725011400987817,-0.19235073067672648,0.8475252510794786,LGP Offspring,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",CP:REACTOME,C2,20,38
Cohort,-9.84991291035374e-5,0.06537578053814488,-0.0015066608504362864,0.9987982193243501,LGP Proband,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",CP:REACTOME,C2,20,44
Cohort,-0.03223403280613116,0.024475461103627357,-1.3169938931754772,0.1882196777958005,LonGen OPEL,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",CP:REACTOME,C2,45,36
Cohort,0.029556118681795942,0.027325129718655458,1.0816460520448083,0.2797955322018649,LGP Offspring,Branched-chain amino acid catabolism,CP:REACTOME,C2,22,57
Cohort,-0.060482343518159516,0.07451919217538566,-0.8116344494960502,0.4172329966135436,LGP Proband,Branched-chain amino acid catabolism,CP:REACTOME,C2,22,71
Cohort,0.053318424228633865,0.023502849146326246,2.2685940711561825,0.023560026703580577,LonGen OPEL,Branched-chain amino acid catabolism,CP:REACTOME,C2,27,57
Cohort,-0.06988322614598617,0.02362427643038866,-2.9581107532289606,0.003203387368114503,LGP Offspring,Budding and maturation of HIV virion,CP:REACTOME,C2,27,29
Cohort,-0.05582688267664552,0.0574838311622836,-0.9711753992012063,0.3317425133227184,LGP Proband,Budding and maturation of HIV virion,CP:REACTOME,C2,27,32
Cohort,-0.02874611570012913,0.022716026524863344,-1.2654552797191745,0.2060784554861334,LonGen OPEL,Budding and maturation of HIV virion,CP:REACTOME,C2,38,38
Cohort,-0.0482697949872748,0.02452339531385193,-1.9683161474793756,0.04943990570822075,LGP Offspring,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,CP:REACTOME,C2,26,34
Cohort,-0.05558685487114712,0.06647876465175746,-0.836159564070323,0.40330464182417625,LGP Proband,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,CP:REACTOME,C2,26,48
Cohort,0.026490128155527672,0.02121852283382675,1.2484435586296745,0.21223573327150327,LonGen OPEL,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,CP:REACTOME,C2,28,45
Cohort,-0.03297250570868196,0.020703560442496487,-1.5926007413199337,0.1117172447296898,LGP Offspring,Butyrophilin (BTN) family interactions,CP:REACTOME,C2,19,25
Cohort,0.04474348428062615,0.059272539910012474,0.7548771209831007,0.45053582366054656,LGP Proband,Butyrophilin (BTN) family interactions,CP:REACTOME,C2,19,39
Cohort,-0.00879649357611088,0.017730131929745065,-0.4961324377600027,0.619937936432379,LonGen OPEL,Butyrophilin (BTN) family interactions,CP:REACTOME,C2,24,26
Cohort,0.0831338019718626,0.06097707232224677,1.3633616506303174,0.17322243635242957,LGP Offspring,C-type lectin receptors (CLRs),CP:REACTOME,C2,87,228
Cohort,0.02873708002378143,0.16091777198618215,0.17858238819170982,0.8583089949052793,LGP Proband,C-type lectin receptors (CLRs),CP:REACTOME,C2,87,280
Cohort,0.04534450717704399,0.052172841915390455,0.8691208972396005,0.3850429868375451,LonGen OPEL,C-type lectin receptors (CLRs),CP:REACTOME,C2,163,212
Cohort,-0.016061734619426088,0.02579592660512208,-0.6226461590349247,0.5337270466754268,LGP Offspring,Ca-dependent events,CP:REACTOME,C2,22,40
Cohort,0.11714829478840061,0.07810687712692224,1.4998460967532574,0.13403271398051364,LGP Proband,Ca-dependent events,CP:REACTOME,C2,22,68
Cohort,-0.062493825307887996,0.024418030800578725,-2.5593310868625347,0.010671126820426976,LonGen OPEL,Ca-dependent events,CP:REACTOME,C2,52,36
Cohort,0.020466320949390236,0.019295224532541618,1.0606935884510464,0.28920798710240353,LGP Offspring,Ca2+ activated K+ channels,CP:REACTOME,C2,10,28
Cohort,-0.008834907962649307,0.04499002167191501,-0.1963748323367555,0.8443646336932978,LGP Proband,Ca2+ activated K+ channels,CP:REACTOME,C2,10,24
Cohort,0.022322362315039902,0.015081669884629301,1.48009885415872,0.13924253053071928,LonGen OPEL,Ca2+ activated K+ channels,CP:REACTOME,C2,10,23
Cohort,0.03475176273414283,0.037129568726599955,0.9359592348091659,0.3496284098094714,LGP Offspring,Ca2+ pathway,CP:REACTOME,C2,39,104
Cohort,-0.03498615695462106,0.10483442959136403,-0.33372773707067627,0.7386689073606085,LGP Proband,Ca2+ pathway,CP:REACTOME,C2,39,139
Cohort,0.02839337336976852,0.032502223602990765,0.8735824882810738,0.3826091299975102,LonGen OPEL,Ca2+ pathway,CP:REACTOME,C2,67,92
Cohort,0.004406401950045922,0.014898642485026675,0.2957586205907291,0.7675052516101906,LGP Offspring,Calcineurin activates NFAT,CP:REACTOME,C2,6,14
Cohort,-0.012940940848623057,0.04099639441601433,-0.3156604631447288,0.7523392121174786,LGP Proband,Calcineurin activates NFAT,CP:REACTOME,C2,6,20
Cohort,0.002245127940682784,0.011428918010922233,0.1964427374959896,0.8443137896494173,LonGen OPEL,Calcineurin activates NFAT,CP:REACTOME,C2,9,11
Cohort,-0.006743174566722264,0.007871177995408648,-0.8566919171000374,0.39191875320923475,LGP Offspring,Calcitonin-like ligand receptors,CP:REACTOME,C2,3,3
Cohort,-0.017698536882968557,0.020727994447917397,-0.8538470486104738,0.39343491633001215,LGP Proband,Calcitonin-like ligand receptors,CP:REACTOME,C2,3,4
Cohort,-0.0026971718109660135,0.006360433353168549,-0.42405472413642625,0.67164047577157,LonGen OPEL,Calcitonin-like ligand receptors,CP:REACTOME,C2,3,3
Cohort,-0.01345888203520504,0.02628231090942164,-0.5120889894952244,0.6087559834223801,LGP Offspring,Calnexin/calreticulin cycle,CP:REACTOME,C2,26,46
Cohort,-0.07987348229799834,0.08025175509285709,-0.9952864234006963,0.31988565468518093,LGP Proband,Calnexin/calreticulin cycle,CP:REACTOME,C2,26,73
Cohort,-0.009590843973208564,0.023542434048506106,-0.40738540260738904,0.6838344783807931,LonGen OPEL,Calnexin/calreticulin cycle,CP:REACTOME,C2,43,46
Cohort,-0.02429088435627137,0.015170547415722662,-1.6011870693009038,0.10980266918339944,LGP Offspring,CaMK IV-mediated phosphorylation of CREB,CP:REACTOME,C2,10,11
Cohort,0.030105978895949022,0.04292486386321311,0.7013645748973485,0.48327117606938585,LGP Proband,CaMK IV-mediated phosphorylation of CREB,CP:REACTOME,C2,10,19
Cohort,-0.01045343196365945,0.011698663603870951,-0.8935577872502062,0.3718286134613469,LonGen OPEL,CaMK IV-mediated phosphorylation of CREB,CP:REACTOME,C2,12,9
Cohort,0.0012914064126004494,0.036756546887795144,0.03513405153489147,0.9719832206395611,LGP Offspring,Carboxyterminal post-translational modifications of tubulin,CP:REACTOME,C2,43,99
Cohort,-0.09592082095099624,0.09978368408187561,-0.9612876276675677,0.3366861806608994,LGP Proband,Carboxyterminal post-translational modifications of tubulin,CP:REACTOME,C2,43,122
Cohort,0.012453594422020342,0.03214657456998513,0.3874003556711175,0.69856339963754,LonGen OPEL,Carboxyterminal post-translational modifications of tubulin,CP:REACTOME,C2,66,85
Cohort,-0.0651760247331176,0.06454505841835746,-1.0097755944486166,0.31296410752221,LGP Offspring,Cardiac conduction,CP:REACTOME,C2,147,275
Cohort,-0.05185334116733635,0.18730847789175942,-0.2768339252497744,0.7819762251496074,LGP Proband,Cardiac conduction,CP:REACTOME,C2,147,422
Cohort,-0.032255080369934706,0.05668366200412448,-0.5690366364753873,0.5694917967479747,LonGen OPEL,Cardiac conduction,CP:REACTOME,C2,224,244
Cohort,-0.011825486508677631,0.035547048943549694,-0.33267139917738414,0.7394854781435073,LGP Offspring,Cargo concentration in the ER,CP:REACTOME,C2,48,89
Cohort,-0.21201188595622644,0.1021108179444787,-2.0762921130599983,0.03817272097125079,LGP Proband,Cargo concentration in the ER,CP:REACTOME,C2,48,112
Cohort,0.0011649685716178324,0.030723770593574055,0.037917500004426154,0.969762967240462,LonGen OPEL,Cargo concentration in the ER,CP:REACTOME,C2,63,76
Cohort,-0.02744265306131472,0.05629291585916791,-0.48749745225438323,0.6260639001210533,LGP Offspring,Cargo recognition for clathrin-mediated endocytosis,CP:REACTOME,C2,122,237
Cohort,-0.027856583358867378,0.1726285034881675,-0.16136722960572242,0.8718432570026079,LGP Proband,Cargo recognition for clathrin-mediated endocytosis,CP:REACTOME,C2,122,359
Cohort,-0.011917029164881172,0.050574510387803716,-0.23563310991054143,0.8137779886325694,LonGen OPEL,Cargo recognition for clathrin-mediated endocytosis,CP:REACTOME,C2,179,208
Cohort,0.01736372596816073,0.047021062839464216,0.3692754888897909,0.7120380315040427,LGP Offspring,Cargo trafficking to the periciliary membrane,CP:REACTOME,C2,65,144
Cohort,-0.11446396968202101,0.12875759384054003,-0.8889881075579824,0.3742658044905298,LGP Proband,Cargo trafficking to the periciliary membrane,CP:REACTOME,C2,65,201
Cohort,0.01648266077967405,0.039443096436167877,0.4178845544327005,0.6761442260879492,LonGen OPEL,Cargo trafficking to the periciliary membrane,CP:REACTOME,C2,89,117
Cohort,0.04497721826673984,0.024315879931906478,1.8497055583714348,0.06479226917454017,LGP Offspring,Carnitine metabolism,CP:REACTOME,C2,13,46
Cohort,0.022050816924188612,0.06690881479116753,0.3295651999368473,0.7418112733629472,LGP Proband,Carnitine metabolism,CP:REACTOME,C2,13,65
Cohort,-0.0035055501898318443,0.02244791276702057,-0.1561637478822546,0.8759435466412012,LonGen OPEL,Carnitine metabolism,CP:REACTOME,C2,35,41
Cohort,-0.008808113693881287,0.01549564357244324,-0.5684251610914207,0.569935079808338,LGP Offspring,Caspase activation via Death Receptors in the presence of ligand,CP:REACTOME,C2,9,15
Cohort,-0.038611606717443764,0.03974229740651831,-0.9715494381839864,0.33155642940350294,LGP Proband,Caspase activation via Death Receptors in the presence of ligand,CP:REACTOME,C2,9,17
Cohort,-0.011094909423647416,0.011943825587788023,-0.9289242665257451,0.35320993502040066,LonGen OPEL,Caspase activation via Death Receptors in the presence of ligand,CP:REACTOME,C2,13,9
Cohort,-0.017592906658863185,0.023499601881477865,-0.7486470088980411,0.45433038596920206,LGP Offspring,Caspase activation via Dependence Receptors in the absence of ligand,CP:REACTOME,C2,20,37
Cohort,0.03424403739311911,0.06686684046599875,0.5121228572259509,0.6087006121733667,LGP Proband,Caspase activation via Dependence Receptors in the absence of ligand,CP:REACTOME,C2,20,56
Cohort,-0.05500999056642732,0.022092614456969622,-2.4899719620587124,0.012978310906929599,LonGen OPEL,Caspase activation via Dependence Receptors in the absence of ligand,CP:REACTOME,C2,46,34
Cohort,-0.026401020352744452,0.028193566522286075,-0.9364200280186377,0.34939137697324374,LGP Offspring,Caspase activation via extrinsic apoptotic signalling pathway,CP:REACTOME,C2,29,52
Cohort,-0.004367569324324729,0.07734907865411525,-0.05646569293805491,0.9549843495430497,LGP Proband,Caspase activation via extrinsic apoptotic signalling pathway,CP:REACTOME,C2,29,73
Cohort,-0.06610489999007473,0.024546757559792746,-2.6930196311692773,0.007229738108342285,LonGen OPEL,Caspase activation via extrinsic apoptotic signalling pathway,CP:REACTOME,C2,59,43
Cohort,-0.012634492184177604,0.026392270443274773,-0.4787194118570841,0.6322930522002757,LGP Offspring,Caspase-mediated cleavage of cytoskeletal proteins,CP:REACTOME,C2,24,46
Cohort,-0.1702689052284677,0.06792769601240074,-2.506619762245193,0.012378427527421569,LGP Proband,Caspase-mediated cleavage of cytoskeletal proteins,CP:REACTOME,C2,24,52
Cohort,-0.034263032258663714,0.02376654351085231,-1.4416497814677378,0.1497944873857648,LonGen OPEL,Caspase-mediated cleavage of cytoskeletal proteins,CP:REACTOME,C2,47,43
Cohort,-0.027786963787126338,0.01900888270596569,-1.4617883763576363,0.14426389953766056,LGP Offspring,Cation-coupled Chloride cotransporters,CP:REACTOME,C2,15,22
Cohort,0.08842822027334934,0.051776702518773456,1.7078766312181932,0.08803137674336202,LGP Proband,Cation-coupled Chloride cotransporters,CP:REACTOME,C2,15,29
Cohort,-0.0012131815707814974,0.016183919417911502,-0.07496216086189929,0.9402636528997096,LonGen OPEL,Cation-coupled Chloride cotransporters,CP:REACTOME,C2,18,23
Cohort,-0.006393738965226019,0.012198642851467429,-0.5241352700523475,0.600356263269038,LGP Offspring,CD163 mediating an anti-inflammatory response,CP:REACTOME,C2,6,9
Cohort,-0.01620162455856885,0.03618223623136196,-0.4477784196358113,0.6544294048330844,LGP Proband,CD163 mediating an anti-inflammatory response,CP:REACTOME,C2,6,16
Cohort,-0.0017445265267642571,0.009295485719785853,-0.18767459596554004,0.8511795744554748,LonGen OPEL,CD163 mediating an anti-inflammatory response,CP:REACTOME,C2,6,7
Cohort,0.030993259732965874,0.01984311754331976,1.561914838497736,0.11877605089072095,LGP Offspring,CD209 (DC-SIGN) signaling,CP:REACTOME,C2,8,31
Cohort,0.011542351007405798,0.04771820848747225,0.2418856736928018,0.8089282141211621,LGP Proband,CD209 (DC-SIGN) signaling,CP:REACTOME,C2,8,22
Cohort,0.010572992527143252,0.019975138244365722,0.5293076021701887,0.5967396593637662,LonGen OPEL,CD209 (DC-SIGN) signaling,CP:REACTOME,C2,25,35
Cohort,0.003266371167408138,0.003204273162621603,1.0193797474918551,0.3083873933272388,LGP Offspring,CD22 mediated BCR regulation,CP:REACTOME,C2,0,1
Cohort,-0.012098722159049143,0.017680113834814916,-0.6843124581712173,0.4939679873260161,LGP Proband,CD22 mediated BCR regulation,CP:REACTOME,C2,0,5
Cohort,-0.006216898671564751,0.005191734746341537,-1.1974607670289044,0.2314834751318534,LonGen OPEL,CD22 mediated BCR regulation,CP:REACTOME,C2,4,1
Cohort,-1.8312126946222096e-5,0.023034331600634894,-7.949927640061134e-4,0.9993659221540896,LGP Offspring,CD28 co-stimulation,CP:REACTOME,C2,16,35
Cohort,-0.10416945677982452,0.059928219255750016,-1.7382371455969738,0.08253810557529498,LGP Proband,CD28 co-stimulation,CP:REACTOME,C2,16,37
Cohort,-0.00292236963327618,0.017492010171806786,-0.1670688276860476,0.8673583245889198,LonGen OPEL,CD28 co-stimulation,CP:REACTOME,C2,23,23
Cohort,-0.007297467796054765,0.02047971445039806,-0.3563266379386909,0.7217071443608281,LGP Offspring,CD28 dependent PI3K/Akt signaling,CP:REACTOME,C2,13,27
Cohort,-0.07092409566592357,0.05298077088477494,-1.338676174043836,0.1810409037370387,LGP Proband,CD28 dependent PI3K/Akt signaling,CP:REACTOME,C2,13,28
Cohort,0.0069344569229110664,0.01628687604012031,0.42576961387985385,0.6703908240016275,LonGen OPEL,CD28 dependent PI3K/Akt signaling,CP:REACTOME,C2,17,22
Cohort,-0.001962439471748732,0.00835635081957527,-0.23484407418027442,0.8144008740659412,LGP Offspring,CD28 dependent Vav1 pathway,CP:REACTOME,C2,3,4
Cohort,-0.036638744550932884,0.024723107600200744,-1.4819635598979226,0.13872771729875133,LGP Proband,CD28 dependent Vav1 pathway,CP:REACTOME,C2,3,7
Cohort,-0.00985682655618727,0.006817531625685283,-1.4458057692099793,0.14862528114792292,LonGen OPEL,CD28 dependent Vav1 pathway,CP:REACTOME,C2,6,1
Cohort,-0.06428049351098916,0.07139126471702807,-0.9003971811646185,0.3682295652719184,LGP Offspring,CDC42 GTPase cycle,CP:REACTOME,C2,187,358
Cohort,-0.06010088595832042,0.2056928683006944,-0.2921875048699369,0.7702159332480605,LGP Proband,CDC42 GTPase cycle,CP:REACTOME,C2,187,538
Cohort,0.034175326518053946,0.06510139041194453,0.5249554011335463,0.5997603685518005,LonGen OPEL,CDC42 GTPase cycle,CP:REACTOME,C2,282,343
Cohort,-0.038948051081029375,0.02382118434517086,-1.6350174078949649,0.10251092844928225,LGP Offspring,CDC6 association with the ORC:origin complex,CP:REACTOME,C2,25,33
Cohort,-0.047093019880856624,0.0666135970815231,-0.7069580677834167,0.4797900108321904,LGP Proband,CDC6 association with the ORC:origin complex,CP:REACTOME,C2,25,49
Cohort,0.0030255401101162045,0.01870082839874232,0.1617864217351826,0.8715151020958298,LonGen OPEL,CDC6 association with the ORC:origin complex,CP:REACTOME,C2,23,28
Cohort,-0.20459592337799198,0.07440868100416183,-2.7496243800713054,0.006125815872511507,LGP Offspring,Cell-Cell communication,CP:REACTOME,C2,198,320
Cohort,-0.25669261136106997,0.203836806742787,-1.2593045165046146,0.2082726897340162,LGP Proband,Cell-Cell communication,CP:REACTOME,C2,198,498
Cohort,0.08232778151155049,0.07046840002929224,1.1682936107152788,0.24303813630760118,LonGen OPEL,Cell-Cell communication,CP:REACTOME,C2,277,381
Cohort,-0.08862679021595359,0.045877385088554205,-1.9318186955268466,0.053799494216558955,LGP Offspring,Cell-cell junction organization,CP:REACTOME,C2,78,124
Cohort,-0.14442259573165478,0.1270735004966844,-1.1365280343042337,0.2560620951078705,LGP Proband,Cell-cell junction organization,CP:REACTOME,C2,78,206
Cohort,0.014273504166481711,0.04155082634798033,0.343519140797437,0.7312986551551011,LonGen OPEL,Cell-cell junction organization,CP:REACTOME,C2,116,150
Cohort,-0.17648499498589698,0.13061590233628698,-1.3511754068927555,0.17709127716066753,LGP Offspring,Cell Cycle,CP:REACTOME,C2,612,1189
Cohort,-0.8753947001359131,0.39326704122854367,-2.2259549068776026,0.026283743898150067,LGP Proband,Cell Cycle,CP:REACTOME,C2,612,1712
Cohort,0.014307040554033574,0.11368677939017034,0.12584612415602126,0.8998855079173177,LonGen OPEL,Cell Cycle,CP:REACTOME,C2,929,1107
Cohort,-8.749589433885899e-4,0.08032550924301769,-0.010892665999059891,0.9913122955925253,LGP Offspring,Cell Cycle Checkpoints,CP:REACTOME,C2,220,452
Cohort,-0.12005558502803655,0.22651420228076544,-0.5300134994591954,0.5962436423619927,LGP Proband,Cell Cycle Checkpoints,CP:REACTOME,C2,220,616
Cohort,0.004620708721199163,0.068960606939771,0.06700504717475601,0.9465945110007219,LonGen OPEL,Cell Cycle Checkpoints,CP:REACTOME,C2,339,403
Cohort,-0.19062918642323884,0.11225558937868058,-1.6981709995764618,0.0899356833456776,LGP Offspring,"Cell Cycle, Mitotic",CP:REACTOME,C2,468,878
Cohort,-0.6871840207768372,0.3262785006227192,-2.106127187250497,0.03549159495660865,LGP Proband,"Cell Cycle, Mitotic",CP:REACTOME,C2,468,1272
Cohort,-0.019917069931326855,0.09943070354534787,-0.20031106309373717,0.8412884759177043,LonGen OPEL,"Cell Cycle, Mitotic",CP:REACTOME,C2,694,815
Cohort,-0.004816450011467755,0.05860768981667357,-0.08218119544608805,0.934526953333788,LGP Offspring,"Cell death signalling via NRAGE, NRIF and NADE",CP:REACTOME,C2,122,231
Cohort,-0.009736484576002695,0.16249679608581927,-0.05991800952715754,0.9522352904640203,LGP Proband,"Cell death signalling via NRAGE, NRIF and NADE",CP:REACTOME,C2,122,346
Cohort,0.03234154448425913,0.049508213162358816,0.6532561451611522,0.5137797989023472,LonGen OPEL,"Cell death signalling via NRAGE, NRIF and NADE",CP:REACTOME,C2,176,219
Cohort,-0.009842761240625924,0.034845197368532095,-0.28247110029328454,0.7776687672448761,LGP Offspring,Cell-extracellular matrix interactions,CP:REACTOME,C2,40,67
Cohort,-0.09839116973753896,0.09159411187034665,-1.0742084586923413,0.283039950979893,LGP Proband,Cell-extracellular matrix interactions,CP:REACTOME,C2,40,88
Cohort,0.013692577410047488,0.02786715782967135,0.4913517730706078,0.6233131154751208,LonGen OPEL,Cell-extracellular matrix interactions,CP:REACTOME,C2,48,67
Cohort,-0.10159411360471599,0.06269442394818123,-1.620464902727019,0.1055987918757666,LGP Offspring,Cell junction organization,CP:REACTOME,C2,143,247
Cohort,-0.20700994894357463,0.17296112373658204,-1.1968582561873764,0.2317019074980199,LGP Proband,Cell junction organization,CP:REACTOME,C2,143,368
Cohort,0.048298662303489656,0.059021840649046434,0.8183184694405151,0.41342026044374003,LonGen OPEL,Cell junction organization,CP:REACTOME,C2,208,280
Cohort,-0.050167760074566706,0.05697467577630303,-0.8805273464220842,0.378886628388163,LGP Offspring,Cell surface interactions at the vascular wall,CP:REACTOME,C2,117,212
Cohort,0.01608840522551668,0.1670473797993575,0.09631043147663043,0.9232971640316855,LGP Proband,Cell surface interactions at the vascular wall,CP:REACTOME,C2,117,352
Cohort,-0.018009419243545415,0.05050881768895252,-0.3565599051328518,0.7215157895545212,LonGen OPEL,Cell surface interactions at the vascular wall,CP:REACTOME,C2,181,213
Cohort,-0.008349209671280089,0.02579655681933667,-0.3236559719869925,0.7462986105232856,LGP Offspring,Cellular hexose transport,CP:REACTOME,C2,26,47
Cohort,-0.09191875687886804,0.07979682306913334,-1.1519099801659103,0.24968816117387227,LGP Proband,Cellular hexose transport,CP:REACTOME,C2,26,89
Cohort,-0.02268079057550599,0.025808608140117033,-0.8788071968999697,0.3797710219986302,LonGen OPEL,Cellular hexose transport,CP:REACTOME,C2,45,48
Cohort,0.017608504528012152,0.06381893938911273,0.2759134623132909,0.782698858250165,LGP Offspring,Cellular response to chemical stress,CP:REACTOME,C2,132,284
Cohort,-0.28228532612296336,0.18130157223039134,-1.5569932607327068,0.11985145563915575,LGP Proband,Cellular response to chemical stress,CP:REACTOME,C2,132,379
Cohort,-0.16269231710746987,0.05997525915734999,-2.712657175530218,0.00681872838379434,LonGen OPEL,Cellular response to chemical stress,CP:REACTOME,C2,264,245
Cohort,0.010866479843469746,0.05993325848672445,0.1813096787633653,0.8561788570206595,LGP Offspring,Cellular response to heat stress,CP:REACTOME,C2,105,222
Cohort,-0.07363746867891113,0.14892994952512822,-0.4944436556495753,0.6211231009322017,LGP Proband,Cellular response to heat stress,CP:REACTOME,C2,105,254
Cohort,-0.02428018059991129,0.055218830034739354,-0.43970834921051577,0.6602677076090135,LonGen OPEL,Cellular response to heat stress,CP:REACTOME,C2,199,226
Cohort,0.06902573347215224,0.039088871930791746,1.7658666025042826,0.07786957576096037,LGP Offspring,Cellular response to hypoxia,CP:REACTOME,C2,35,104
Cohort,-0.10008674389774219,0.09635640425350249,-1.0387139772715637,0.29923882258925105,LGP Proband,Cellular response to hypoxia,CP:REACTOME,C2,35,115
Cohort,-0.013497252699986544,0.032654291954679615,-0.41333778477632194,0.6794704757380341,LonGen OPEL,Cellular response to hypoxia,CP:REACTOME,C2,73,80
Cohort,-0.027259983892337927,0.04448007020566503,-0.6128583827834442,0.5401761001228855,LGP Offspring,Cellular response to starvation,CP:REACTOME,C2,67,135
Cohort,0.0540284080623644,0.12588623065774357,0.42918441341893476,0.6678998680773703,LGP Proband,Cellular response to starvation,CP:REACTOME,C2,67,198
Cohort,-0.029048474045918406,0.037750073259805006,-0.769494507891412,0.44182807944939617,LonGen OPEL,Cellular response to starvation,CP:REACTOME,C2,106,118
Cohort,-0.011145225827484869,0.12319383225867307,-0.09046902448884753,0.927941306657055,LGP Offspring,Cellular responses to external stimuli,CP:REACTOME,C2,466,987
Cohort,-0.0030210667215697976,0.32479482066356496,-0.009301462121217553,0.9925808384240964,LGP Proband,Cellular responses to external stimuli,CP:REACTOME,C2,466,1330
Cohort,-0.08444913071606464,0.10847639095288171,-0.7785024001466488,0.4365042437863438,LonGen OPEL,Cellular responses to external stimuli,CP:REACTOME,C2,799,921
Cohort,6.916571902225837e-4,0.05844256845535862,0.01183481849793967,0.9905608932317096,LGP Offspring,Cellular Senescence,CP:REACTOME,C2,110,240
Cohort,0.2825833233558221,0.16351666147283606,1.7281622607171796,0.08432928309329636,LGP Proband,Cellular Senescence,CP:REACTOME,C2,110,327
Cohort,0.08984984803241783,0.05126820413172701,1.7525452579060559,0.08006508177186894,LonGen OPEL,Cellular Senescence,CP:REACTOME,C2,161,237
Cohort,-0.03731758513161937,0.02751595770403596,-1.356216110411659,0.17548322221707893,LGP Offspring,cGMP effects,CP:REACTOME,C2,30,48
Cohort,-0.05448606345374867,0.07589530642022382,-0.7179108435515819,0.4730133063767338,LGP Proband,cGMP effects,CP:REACTOME,C2,30,67
Cohort,0.018528089512686974,0.022727364864969322,0.8152326335573169,0.4151830132734383,LonGen OPEL,cGMP effects,CP:REACTOME,C2,31,50
Cohort,0.005184013920457072,0.026315909096823572,0.19699163351657883,0.8438932965091892,LGP Offspring,Chaperone Mediated Autophagy,CP:REACTOME,C2,21,47
Cohort,0.07737541964684345,0.07490804298738746,1.0329387414362359,0.30193200060207526,LGP Proband,Chaperone Mediated Autophagy,CP:REACTOME,C2,21,74
Cohort,0.0157918995749971,0.025741982403862926,0.6134686648153141,0.5397417506908753,LonGen OPEL,Chaperone Mediated Autophagy,CP:REACTOME,C2,45,56
Cohort,0.01165063218145021,0.022261844036234026,0.5233453330500071,0.6009054645604651,LGP Offspring,Chemokine receptors bind chemokines,CP:REACTOME,C2,13,33
Cohort,-0.03247619998049321,0.06607655054835188,-0.4914935739075631,0.6232067161927768,LGP Proband,Chemokine receptors bind chemokines,CP:REACTOME,C2,13,55
Cohort,0.025849751025143964,0.022294503889353223,1.1594674253993404,0.24661338668429472,LonGen OPEL,Chemokine receptors bind chemokines,CP:REACTOME,C2,28,45
Cohort,-0.012967321607081275,0.013499257901668367,-0.9605951454174861,0.33709922382824453,LGP Offspring,Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex,CP:REACTOME,C2,7,11
Cohort,0.006167814955419999,0.04453096504784134,0.1385062045880586,0.8898738015350295,LGP Proband,Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex,CP:REACTOME,C2,7,26
Cohort,0.017888264532392905,0.01556805481855076,1.1490365842672523,0.25088603927311637,LonGen OPEL,Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex,CP:REACTOME,C2,16,22
Cohort,0.013581890734687274,0.02558121924945023,0.5309321108679823,0.5956402099139002,LGP Offspring,CHL1 interactions,CP:REACTOME,C2,20,49
Cohort,0.007412802912948138,0.06808435720307408,0.1088767408178371,0.9133264445959445,LGP Proband,CHL1 interactions,CP:REACTOME,C2,20,58
Cohort,-0.011401994233500343,0.020694774891223722,-0.5509600511931986,0.5818156610433313,LonGen OPEL,CHL1 interactions,CP:REACTOME,C2,32,34
Cohort,-0.015775445249952304,0.019980274626042765,-0.789550971906573,0.43006689468841375,LGP Offspring,Cholesterol biosynthesis,CP:REACTOME,C2,15,24
Cohort,-0.12309002171378525,0.05966529211810546,-2.0630087835677173,0.03942083796209371,LGP Proband,Cholesterol biosynthesis,CP:REACTOME,C2,15,42
Cohort,0.011213653957721528,0.020334359667754966,0.5514633428808423,0.581470853825474,LonGen OPEL,Cholesterol biosynthesis,CP:REACTOME,C2,26,36
Cohort,-0.012598158598802917,0.01754452583908934,-0.7180677730676608,0.4729635841817583,LGP Offspring,Choline catabolism,CP:REACTOME,C2,11,19
Cohort,-0.023665346419943913,0.04798576603678514,-0.4931742967654706,0.6220192655048761,LGP Proband,Choline catabolism,CP:REACTOME,C2,11,29
Cohort,0.009327019940908303,0.017538873511233403,0.5317912769559845,0.5950189435591742,LonGen OPEL,Choline catabolism,CP:REACTOME,C2,19,27
Cohort,-0.056350168490302666,0.027358948030878204,-2.059661373920665,0.03981327401535168,LGP Offspring,Chondroitin sulfate biosynthesis,CP:REACTOME,C2,32,41
Cohort,-0.06555527983468704,0.07823568159986632,-0.8379204794299261,0.402315431382529,LGP Proband,Chondroitin sulfate biosynthesis,CP:REACTOME,C2,32,70
Cohort,-0.055687702905510464,0.025921593454394334,-2.148313258731016,0.03198999000695003,LonGen OPEL,Chondroitin sulfate biosynthesis,CP:REACTOME,C2,59,44
Cohort,-0.09847890348575736,0.04057325375831336,-2.427187725006631,0.015476620056123859,LGP Offspring,Chondroitin sulfate/dermatan sulfate metabolism,CP:REACTOME,C2,65,96
Cohort,-0.07133190980738019,0.12272328707196309,-0.5812418450424346,0.5612345151156038,LGP Proband,Chondroitin sulfate/dermatan sulfate metabolism,CP:REACTOME,C2,65,161
Cohort,-0.04454619202249254,0.036622900541637256,-1.2163480053101514,0.2242129377130771,LonGen OPEL,Chondroitin sulfate/dermatan sulfate metabolism,CP:REACTOME,C2,98,97
Cohort,0.012915409908282013,0.02335193723767195,0.5530765938958819,0.5803938145373441,LGP Offspring,ChREBP activates metabolic gene expression,CP:REACTOME,C2,16,40
Cohort,-0.028607453789408488,0.0610997336715025,-0.46820914053756796,0.6397573722837668,LGP Proband,ChREBP activates metabolic gene expression,CP:REACTOME,C2,16,48
Cohort,0.015061169520993983,0.01958514031937577,0.7690100390086979,0.44211546123803014,LonGen OPEL,ChREBP activates metabolic gene expression,CP:REACTOME,C2,24,33
Cohort,-0.0583751199417999,0.08457785705524334,-0.690193887315817,0.4903091512874207,LGP Offspring,Chromatin modifying enzymes,CP:REACTOME,C2,229,453
Cohort,-0.016952919913036664,0.22938888766362733,-0.07390471302121744,0.9411039271514732,LGP Proband,Chromatin modifying enzymes,CP:REACTOME,C2,229,650
Cohort,-0.15138780881959774,0.07418376245891087,-2.0407135443345688,0.04160875043902278,LonGen OPEL,Chromatin modifying enzymes,CP:REACTOME,C2,375,378
Cohort,-0.07070841489154156,0.04842861145294462,-1.4600545580425113,0.14473964336016845,LGP Offspring,Chromosome Maintenance,CP:REACTOME,C2,79,139
Cohort,-0.17633792925608557,0.14133105860925912,-1.2476941090748543,0.21249330854249981,LGP Proband,Chromosome Maintenance,CP:REACTOME,C2,79,200
Cohort,-0.04436428393981681,0.04158511367825306,-1.0668308924935588,0.28637166029716066,LonGen OPEL,Chromosome Maintenance,CP:REACTOME,C2,119,120
Cohort,0.0013880925241487898,0.01386584760468064,0.1001087393806504,0.9202876781917675,LGP Offspring,Chylomicron assembly,CP:REACTOME,C2,6,13
Cohort,0.03011017786202221,0.044747636439481445,0.6728886765392506,0.5012045145506665,LGP Proband,Chylomicron assembly,CP:REACTOME,C2,6,28
Cohort,0.011955149908443406,0.014184833185212384,0.842812160872402,0.39958667538127324,LonGen OPEL,Chylomicron assembly,CP:REACTOME,C2,11,20
Cohort,0.021153936833060626,0.013390512557798917,1.5797705085411482,0.11462720341802275,LGP Offspring,Chylomicron clearance,CP:REACTOME,C2,4,14
Cohort,-0.053722982023168386,0.04256383659642373,-1.2621743319934242,0.20723890225374694,LGP Proband,Chylomicron clearance,CP:REACTOME,C2,4,26
Cohort,0.011594069571779771,0.012564159421159462,0.9227891164970456,0.35639673107304815,LonGen OPEL,Chylomicron clearance,CP:REACTOME,C2,9,15
Cohort,0.0023998778453496266,0.009596604386648562,0.2500757297746375,0.8026047621333743,LGP Offspring,Chylomicron remodeling,CP:REACTOME,C2,3,6
Cohort,0.004957878786997026,0.03650238582121933,0.13582341744124968,0.891993654141437,LGP Proband,Chylomicron remodeling,CP:REACTOME,C2,3,19
Cohort,0.02126577025477649,0.011436661681819298,1.85943860598608,0.06333376221952859,LonGen OPEL,Chylomicron remodeling,CP:REACTOME,C2,5,15
Cohort,-0.004647036567365009,0.09143568843888705,-0.05082300627583674,0.9594815713830638,LGP Offspring,Cilium Assembly,CP:REACTOME,C2,255,532
Cohort,-4.95911560947469e-4,0.2715084480609225,-0.001826505084792771,0.998543097390661,LGP Proband,Cilium Assembly,CP:REACTOME,C2,255,804
Cohort,-0.017775895402534776,0.0828688997940392,-0.2145062314899154,0.8302072471608459,LonGen OPEL,Cilium Assembly,CP:REACTOME,C2,439,521
Cohort,-0.012914768172155077,0.03797499361491552,-0.3400861183313673,0.7338973207534196,LGP Offspring,Circadian Clock,CP:REACTOME,C2,50,97
Cohort,-0.04414954562789732,0.113714746250656,-0.38824820072658456,0.6979314480012546,LGP Proband,Circadian Clock,CP:REACTOME,C2,50,135
Cohort,-0.050823283302050735,0.036490915131160255,-1.3927653806262537,0.164079623762519,LonGen OPEL,Circadian Clock,CP:REACTOME,C2,98,94
Cohort,0.024390453392021106,0.026214751453039052,0.930409484740453,0.35249124240785423,LGP Offspring,Citric acid cycle (TCA cycle),CP:REACTOME,C2,17,48
Cohort,-0.006855827366009102,0.06718046949879562,-0.10205089986952248,0.9187408040089196,LGP Proband,Citric acid cycle (TCA cycle),CP:REACTOME,C2,17,60
Cohort,0.003340285880096131,0.022916023639058022,0.14576201930613106,0.8841461625793193,LonGen OPEL,Citric acid cycle (TCA cycle),CP:REACTOME,C2,33,44
Cohort,0.07066050746802818,0.07871712466695317,0.8976510227855503,0.36969121174298414,LGP Offspring,Class A/1 (Rhodopsin-like receptors),CP:REACTOME,C2,177,390
Cohort,-0.6442128050927852,0.2073848761150949,-3.106363478189502,0.0019581547960375494,LGP Proband,Class A/1 (Rhodopsin-like receptors),CP:REACTOME,C2,177,543
Cohort,-0.03463327982521973,0.06267654636990884,-0.5525716050277979,0.5807119165649377,LonGen OPEL,Class A/1 (Rhodopsin-like receptors),CP:REACTOME,C2,303,338
Cohort,-0.028380817321173046,0.04052946699601397,-0.700251432469227,0.48401121831502436,LGP Offspring,Class B/2 (Secretin family receptors),CP:REACTOME,C2,51,99
Cohort,-0.14626828474871031,0.10621038840956246,-1.3771561043979885,0.16883349298546008,LGP Proband,Class B/2 (Secretin family receptors),CP:REACTOME,C2,51,131
Cohort,0.03338277658726085,0.031754670400231076,1.0512713930426412,0.29345300072508723,LonGen OPEL,Class B/2 (Secretin family receptors),CP:REACTOME,C2,57,89
Cohort,-0.032227424834584927,0.036406477151248805,-0.8852112963497615,0.37635743714046666,LGP Offspring,Class C/3 (Metabotropic glutamate/pheromone receptors),CP:REACTOME,C2,46,85
Cohort,0.053640191959297576,0.10087292975236328,0.5317600280965457,0.5950338200910991,LGP Proband,Class C/3 (Metabotropic glutamate/pheromone receptors),CP:REACTOME,C2,46,139
Cohort,0.009502456782552536,0.037683228159829864,0.25216673959695707,0.8009772806085145,LonGen OPEL,Class C/3 (Metabotropic glutamate/pheromone receptors),CP:REACTOME,C2,85,106
Cohort,0.06421090696238699,0.10405981103185738,0.6170576933176358,0.537404443327622,LGP Offspring,Class I MHC mediated antigen processing & presentation,CP:REACTOME,C2,330,720
Cohort,-0.41933553589066563,0.28704289107182096,-1.460881104997454,0.14442469725020735,LGP Proband,Class I MHC mediated antigen processing & presentation,CP:REACTOME,C2,330,940
Cohort,0.08146731880955652,0.0886324394168021,0.9191591627806728,0.35829076896463097,LonGen OPEL,Class I MHC mediated antigen processing & presentation,CP:REACTOME,C2,503,640
Cohort,-0.01732910507156592,0.021395118492616313,-0.8099560223303452,0.41825046913249564,LGP Offspring,Class I peroxisomal membrane protein import,CP:REACTOME,C2,18,30
Cohort,0.08056411755144259,0.05914001057841837,1.3622607903428816,0.17348338065192573,LGP Proband,Class I peroxisomal membrane protein import,CP:REACTOME,C2,18,43
Cohort,0.03647684645179025,0.020283670371611384,1.7983355962460577,0.07250261714144836,LonGen OPEL,Class I peroxisomal membrane protein import,CP:REACTOME,C2,22,42
Cohort,-0.058938952830535886,0.06481537494373202,-0.9093359851995362,0.36349688944858505,LGP Offspring,Clathrin-mediated endocytosis,CP:REACTOME,C2,159,305
Cohort,-0.032067230096876016,0.19144001220286272,-0.1675053701046332,0.867013029519081,LGP Proband,Clathrin-mediated endocytosis,CP:REACTOME,C2,159,463
Cohort,6.119520112479842e-4,0.060192567287511226,0.010166571037333911,0.9918909370592273,LonGen OPEL,Clathrin-mediated endocytosis,CP:REACTOME,C2,240,284
Cohort,0.0020173588884487624,0.019854499135135914,0.1016071407653242,0.9190986410192499,LGP Offspring,CLEC7A (Dectin-1) induces NFAT activation,CP:REACTOME,C2,12,24
Cohort,-0.06501199823275262,0.0544934492783387,-1.1930240991112133,0.23319921981399427,LGP Proband,CLEC7A (Dectin-1) induces NFAT activation,CP:REACTOME,C2,12,37
Cohort,0.01661006911932991,0.01634598753397968,1.0161557437139397,0.3098639832450632,LonGen OPEL,CLEC7A (Dectin-1) induces NFAT activation,CP:REACTOME,C2,17,25
Cohort,0.022968390478583227,0.04955153433993489,0.4635253132832336,0.6431370786938994,LGP Offspring,CLEC7A (Dectin-1) signaling,CP:REACTOME,C2,60,138
Cohort,-0.11066293574910732,0.12425324926003879,-0.8906240795161059,0.3733877249834978,LGP Proband,CLEC7A (Dectin-1) signaling,CP:REACTOME,C2,60,178
Cohort,0.01018282754282198,0.040888801210630675,0.24903707717834847,0.8033963440881448,LonGen OPEL,CLEC7A (Dectin-1) signaling,CP:REACTOME,C2,102,125
Cohort,0.015200507035923667,0.017741252786585452,0.8567888197510551,0.3918652254616145,LGP Offspring,CLEC7A/inflammasome pathway,CP:REACTOME,C2,7,25
Cohort,0.025278781558451178,0.04066353836015842,0.6216572039195434,0.5343371857628416,LGP Proband,CLEC7A/inflammasome pathway,CP:REACTOME,C2,7,19
Cohort,0.017650081743562702,0.016236561739673,1.0870578406040152,0.27734030347695354,LonGen OPEL,CLEC7A/inflammasome pathway,CP:REACTOME,C2,14,25
Cohort,-0.026981569291426293,0.02764762139946736,-0.9759092437494858,0.32945853506396006,LGP Offspring,"Cobalamin (Cbl, vitamin B12) transport and metabolism",CP:REACTOME,C2,28,50
Cohort,0.0964525338885151,0.08445260537408752,1.1420906846067476,0.2537441107885936,LGP Proband,"Cobalamin (Cbl, vitamin B12) transport and metabolism",CP:REACTOME,C2,28,90
Cohort,-0.008576680770983627,0.028830369151972936,-0.2974877194868212,0.766171802287337,LonGen OPEL,"Cobalamin (Cbl, vitamin B12) transport and metabolism",CP:REACTOME,C2,56,74
Cohort,0.005806876719701775,0.012738606277589,0.4558486692471059,0.6486451996415912,LGP Offspring,Coenzyme A biosynthesis,CP:REACTOME,C2,4,12
Cohort,-0.008493956516116494,0.03217523891893606,-0.26399047222358163,0.791852477156255,LGP Proband,Coenzyme A biosynthesis,CP:REACTOME,C2,4,13
Cohort,0.014901588231049069,0.006706842391412137,2.221848578122247,0.026573999131567643,LonGen OPEL,Coenzyme A biosynthesis,CP:REACTOME,C2,1,6
Cohort,-0.00909614675857444,0.015419921383352415,-0.5898957933984528,0.5554576298148917,LGP Offspring,Cohesin Loading onto Chromatin,CP:REACTOME,C2,9,15
Cohort,-0.060453491417968075,0.05276401281405899,-1.1457333927767568,0.25223412846506355,LGP Proband,Cohesin Loading onto Chromatin,CP:REACTOME,C2,9,34
Cohort,0.01738111844769576,0.017887528027771743,0.9716892362494278,0.3315003424015387,LonGen OPEL,Cohesin Loading onto Chromatin,CP:REACTOME,C2,20,27
Cohort,-0.07530831803115022,0.0652597391805322,-1.1539782257299558,0.24891690579631398,LGP Offspring,Collagen biosynthesis and modifying enzymes,CP:REACTOME,C2,152,282
Cohort,-0.21488294308580377,0.17987691485957996,-1.19461101083233,0.23257866848757588,LGP Proband,Collagen biosynthesis and modifying enzymes,CP:REACTOME,C2,152,373
Cohort,-0.1309390101721268,0.061113783986697666,-2.1425446377306248,0.03245237632960484,LonGen OPEL,Collagen biosynthesis and modifying enzymes,CP:REACTOME,C2,259,265
Cohort,-0.08678334437310552,0.06027128490603722,-1.4398787832116162,0.1503646219218571,LGP Offspring,Collagen chain trimerization,CP:REACTOME,C2,128,229
Cohort,-0.22404503062951048,0.15978758150528655,-1.4021429482747254,0.16124464780084927,LGP Proband,Collagen chain trimerization,CP:REACTOME,C2,128,296
Cohort,-0.0241647794204011,0.05056645438010753,-0.47788162560805025,0.6328656630295988,LonGen OPEL,Collagen chain trimerization,CP:REACTOME,C2,179,211
Cohort,-0.08838319403116635,0.0697656815233877,-1.2668577458322035,0.20564245450033702,LGP Offspring,Collagen degradation,CP:REACTOME,C2,162,304
Cohort,-0.17030834267763761,0.18048066559990222,-0.9436376030171837,0.34562814521600416,LGP Proband,Collagen degradation,CP:REACTOME,C2,162,385
Cohort,-0.018756200079411214,0.05779451904872174,-0.3245325056446863,0.745620181549757,LonGen OPEL,Collagen degradation,CP:REACTOME,C2,231,276
Cohort,-0.020552589740779337,0.08175110842109534,-0.2514044168663024,0.8015778568180159,LGP Offspring,Collagen formation,CP:REACTOME,C2,196,408
Cohort,-0.22823014259904467,0.209716018362555,-1.0882818793769136,0.2767850730689082,LGP Proband,Collagen formation,CP:REACTOME,C2,196,508
Cohort,-0.16745954941939328,0.06933599387869122,-2.415189284116659,0.01595140469358345,LonGen OPEL,Collagen formation,CP:REACTOME,C2,355,365
Cohort,-0.012023416689973391,0.02367275545999022,-0.5079010219276924,0.6116884357689991,LGP Offspring,Common Pathway of Fibrin Clot Formation,CP:REACTOME,C2,21,32
Cohort,-0.01879342401497996,0.060944230124409846,-0.3083708494900271,0.7578771656223181,LGP Proband,Common Pathway of Fibrin Clot Formation,CP:REACTOME,C2,21,38
Cohort,-0.004687169237507267,0.01768996748841332,-0.26496200406118875,0.7911073286292489,LonGen OPEL,Common Pathway of Fibrin Clot Formation,CP:REACTOME,C2,23,26
Cohort,0.011644481276648168,0.017531525073626243,0.664202414093779,0.5067872499261654,LGP Offspring,Competing endogenous RNAs (ceRNAs) regulate PTEN translation,CP:REACTOME,C2,8,23
Cohort,0.03163098215637244,0.04822966742825115,0.6558407686187814,0.5121074626099525,LGP Proband,Competing endogenous RNAs (ceRNAs) regulate PTEN translation,CP:REACTOME,C2,8,29
Cohort,0.0019752786208193157,0.013940203615763772,0.14169654011263105,0.8873555613661391,LonGen OPEL,Competing endogenous RNAs (ceRNAs) regulate PTEN translation,CP:REACTOME,C2,13,17
Cohort,-0.0020404730419213775,0.035614838324281174,-0.057292778457743034,0.9543289030996392,LGP Offspring,Complement cascade,CP:REACTOME,C2,42,91
Cohort,0.00979761046930335,0.09838034191141949,0.09958910773175604,0.9206944743575932,LGP Proband,Complement cascade,CP:REACTOME,C2,42,124
Cohort,-0.029315372883727608,0.03336644780148169,-0.8785883669170745,0.37988963156330524,LonGen OPEL,Complement cascade,CP:REACTOME,C2,74,86
Cohort,0.013640448173733956,0.027497742055527574,0.496057027016586,0.6200154178645352,LGP Offspring,Complex I biogenesis,CP:REACTOME,C2,23,55
Cohort,0.08380321333879032,0.07669115903503991,1.0927362996365844,0.27482513670527814,LGP Proband,Complex I biogenesis,CP:REACTOME,C2,23,80
Cohort,0.013291330357539781,0.025895406706225657,0.5132698052718492,0.6079050244635391,LonGen OPEL,Complex I biogenesis,CP:REACTOME,C2,41,60
Cohort,-0.006520424465144793,0.01388614250070409,-0.46956341293589476,0.6388183904878061,LGP Offspring,Condensation of Prometaphase Chromosomes,CP:REACTOME,C2,8,11
Cohort,-0.0015162565216195693,0.04450037381253852,-0.03407289403920346,0.9728271762061689,LGP Proband,Condensation of Prometaphase Chromosomes,CP:REACTOME,C2,8,26
Cohort,0.013867234032965097,0.012708895613295511,1.091143908559433,0.2755397314517074,LonGen OPEL,Condensation of Prometaphase Chromosomes,CP:REACTOME,C2,7,18
Cohort,-0.014680322574350445,0.02036258683235537,-0.7209458550238801,0.47119207111948613,LGP Offspring,Condensation of Prophase Chromosomes,CP:REACTOME,C2,14,24
Cohort,0.028854884366933963,0.057219707597185476,0.504282275786276,0.6141962257095439,LGP Proband,Condensation of Prophase Chromosomes,CP:REACTOME,C2,14,35
Cohort,-3.9527513766139725e-4,0.017792775941358766,-0.02221548447325705,0.9822816333328439,LonGen OPEL,Condensation of Prophase Chromosomes,CP:REACTOME,C2,21,27
Cohort,-0.0014110472665663386,0.00962382958130283,-0.1466201427036614,0.8834755673242345,LGP Offspring,Conjugation of benzoate with glycine,CP:REACTOME,C2,3,6
Cohort,0.023847275587794887,0.028300819053651463,0.8426355273529808,0.3996738959059405,LGP Proband,Conjugation of benzoate with glycine,CP:REACTOME,C2,3,10
Cohort,0.014418085305227561,0.008847238080631769,1.6296707711292862,0.10356672692583523,LonGen OPEL,Conjugation of benzoate with glycine,CP:REACTOME,C2,2,10
Cohort,8.350201378803849e-4,0.04365122860364398,0.019129361637502177,0.9847435531081264,LGP Offspring,Constitutive Signaling by Aberrant PI3K in Cancer,CP:REACTOME,C2,59,126
Cohort,0.070591357892154,0.1150494156433169,0.6135742410983256,0.5396640144855194,LGP Proband,Constitutive Signaling by Aberrant PI3K in Cancer,CP:REACTOME,C2,59,149
Cohort,0.05579884956058083,0.03418706475743564,1.632162630997581,0.10304073591506388,LonGen OPEL,Constitutive Signaling by Aberrant PI3K in Cancer,CP:REACTOME,C2,71,102
Cohort,-0.03065907219313227,0.024680922406444726,-1.242217437753725,0.21458711419005305,LGP Offspring,Constitutive Signaling by AKT1 E17K in Cancer,CP:REACTOME,C2,23,36
Cohort,-0.017140845664785048,0.06257612414077865,-0.2739198999641297,0.7842140044394944,LGP Proband,Constitutive Signaling by AKT1 E17K in Cancer,CP:REACTOME,C2,23,39
Cohort,-0.04723187880370795,0.01916883873043414,-2.4639927054484763,0.013950250379029949,LonGen OPEL,Constitutive Signaling by AKT1 E17K in Cancer,CP:REACTOME,C2,35,24
Cohort,0.01617951983698465,0.022286884882245273,0.7259659626040416,0.46811090003373323,LGP Offspring,Constitutive Signaling by EGFRvIII,CP:REACTOME,C2,15,35
Cohort,0.060016415455622044,0.05610942150915233,1.069631691815472,0.2850945948408861,LGP Proband,Constitutive Signaling by EGFRvIII,CP:REACTOME,C2,15,37
Cohort,-0.010397115599621462,0.01521500017015767,-0.6833464004827362,0.49458683054593733,LonGen OPEL,Constitutive Signaling by EGFRvIII,CP:REACTOME,C2,17,19
Cohort,0.01617951983698465,0.022286884882245273,0.7259659626040416,0.46811090003373323,LGP Offspring,Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,CP:REACTOME,C2,15,35
Cohort,0.0537528687938225,0.056641991545438516,0.9489932703143331,0.34289893778463487,LGP Proband,Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,CP:REACTOME,C2,15,38
Cohort,-0.011730026682037317,0.015593818837685975,-0.7522228393271484,0.4521394333359774,LonGen OPEL,Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,CP:REACTOME,C2,18,20
Cohort,0.0018917905752714181,0.011506393933348551,0.16441211610081524,0.8694558733319004,LGP Offspring,Constitutive Signaling by Overexpressed ERBB2,CP:REACTOME,C2,4,9
Cohort,-0.003953322586586727,0.03151582283372105,-0.1254392946503298,0.9002060116427737,LGP Proband,Constitutive Signaling by Overexpressed ERBB2,CP:REACTOME,C2,4,12
Cohort,-0.004344074596994273,0.010273146137863948,-0.42285727650492844,0.672513603720496,LonGen OPEL,Constitutive Signaling by Overexpressed ERBB2,CP:REACTOME,C2,8,8
Cohort,0.009814108275067472,0.022160880626145834,0.4428573232549522,0.6580106118125102,LGP Offspring,Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase,CP:REACTOME,C2,14,35
Cohort,-4.5959561910479936e-4,0.061570302432788424,-0.007464566535246512,0.9940459780300293,LGP Proband,Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase,CP:REACTOME,C2,14,51
Cohort,-0.013681612758176946,0.020294912998610373,-0.674140005385278,0.5004180270196357,LonGen OPEL,Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase,CP:REACTOME,C2,29,33
Cohort,-0.010101780671272147,0.024833024596007874,-0.4067881716227228,0.6842923347856055,LGP Offspring,Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,CP:REACTOME,C2,18,34
Cohort,-0.10028098564235535,0.06922355452040971,-1.4486540937852121,0.14781006367873686,LGP Proband,Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,CP:REACTOME,C2,18,51
Cohort,-4.682333486632942e-4,0.024007918955289812,-0.01950328762502447,0.9844445019231609,LonGen OPEL,Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,CP:REACTOME,C2,37,43
Cohort,0.018002933658930236,0.026456114083925487,0.6804829160405181,0.4964317274855061,LGP Offspring,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,CP:REACTOME,C2,18,50
Cohort,0.023580789349752287,0.07650700499849897,0.30821738937780835,0.7579938850104129,LGP Proband,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,CP:REACTOME,C2,18,72
Cohort,0.00547184333651637,0.023578795466928107,0.2320662793903633,0.8165461828974723,LonGen OPEL,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,CP:REACTOME,C2,36,45
Cohort,0.11260168759952417,0.050232764564714406,2.2415984582027226,0.025310999900178054,LGP Offspring,COPI-dependent Golgi-to-ER retrograde traffic,CP:REACTOME,C2,69,193
Cohort,0.048643116773897904,0.1457351700902492,0.33377747282124665,0.7386313873491008,LGP Proband,COPI-dependent Golgi-to-ER retrograde traffic,CP:REACTOME,C2,69,289
Cohort,-0.0602712501119041,0.0464636566286473,-1.2971697555707162,0.19494862325691587,LonGen OPEL,COPI-dependent Golgi-to-ER retrograde traffic,CP:REACTOME,C2,166,168
Cohort,0.06645483512672037,0.03359298058371846,1.978235749611605,0.0483076991801975,LGP Offspring,COPI-independent Golgi-to-ER retrograde traffic,CP:REACTOME,C2,21,81
Cohort,0.06269879472487912,0.08969044495899708,0.6990576839432843,0.4847108833959013,LGP Proband,COPI-independent Golgi-to-ER retrograde traffic,CP:REACTOME,C2,21,109
Cohort,-0.011453702719120423,0.029244097873021645,-0.39165860984505624,0.6954153014702158,LonGen OPEL,COPI-independent Golgi-to-ER retrograde traffic,CP:REACTOME,C2,60,61
Cohort,-0.02673062745637211,0.05987935103555585,-0.44640810219368765,0.6554454424004333,LGP Offspring,COPI-mediated anterograde transport,CP:REACTOME,C2,126,250
Cohort,-0.2560194682479414,0.16570847616208734,-1.5449992310442624,0.12272579496732142,LGP Proband,COPI-mediated anterograde transport,CP:REACTOME,C2,126,326
Cohort,-0.04813014357657593,0.05215662351186749,-0.9228002185690684,0.3563909479473657,LonGen OPEL,COPI-mediated anterograde transport,CP:REACTOME,C2,199,216
Cohort,-0.04662230454182091,0.04779646207701948,-0.9754342165889491,0.3296938381373943,LGP Offspring,COPII-mediated vesicle transport,CP:REACTOME,C2,83,149
Cohort,-0.24314831938888315,0.13491013305734448,-1.8022984180553085,0.07185941807480702,LGP Proband,COPII-mediated vesicle transport,CP:REACTOME,C2,83,203
Cohort,-0.008484414407505176,0.041470603494298576,-0.2045886409314401,0.8379458303459663,LonGen OPEL,COPII-mediated vesicle transport,CP:REACTOME,C2,124,141
Cohort,-0.0013437843563836587,0.03046234415587305,-0.044112966142974296,0.9648273842507433,LGP Offspring,Costimulation by the CD28 family,CP:REACTOME,C2,30,67
Cohort,-0.1310777870890122,0.08295664924943759,-1.5800757175579971,0.11446869147219996,LGP Proband,Costimulation by the CD28 family,CP:REACTOME,C2,30,75
Cohort,0.022730685171105533,0.02691537853878475,0.8445240752735793,0.39863036141380936,LonGen OPEL,Costimulation by the CD28 family,CP:REACTOME,C2,45,59
Cohort,-0.008965979652208028,0.018044823625832967,-0.4968726676481522,0.619440392485989,LGP Offspring,Creatine metabolism,CP:REACTOME,C2,11,22
Cohort,0.08523954212138446,0.04504743045359599,1.8922176306857492,0.05880811387231699,LGP Proband,Creatine metabolism,CP:REACTOME,C2,11,23
Cohort,-0.004783321218291511,0.011770909905220292,-0.40636800865922446,0.6845814480102508,LonGen OPEL,Creatine metabolism,CP:REACTOME,C2,10,11
Cohort,-0.005511613018136154,0.019439744245279902,-0.2835229182335776,0.7768628237891373,LGP Offspring,Creation of C4 and C2 activators,CP:REACTOME,C2,13,24
Cohort,-0.010857358671444665,0.05443139792653661,-0.19946867221926415,0.8419447681718351,LGP Proband,Creation of C4 and C2 activators,CP:REACTOME,C2,13,35
Cohort,0.008757562866027654,0.017501867182067053,0.500378775300096,0.616946705518254,LonGen OPEL,Creation of C4 and C2 activators,CP:REACTOME,C2,20,28
Cohort,0.0028912800248198168,0.004522964332469139,0.63924448929745,0.5228804402960098,LGP Offspring,CREB phosphorylation,CP:REACTOME,C2,0,2
Cohort,0.00214918837187829,0.013729719462441769,0.1565354906017917,0.8756488303404358,LGP Proband,CREB phosphorylation,CP:REACTOME,C2,0,3
Cohort,0.007001022642184851,0.004486859440152926,1.5603391939432438,0.11907721332844866,LonGen OPEL,CREB phosphorylation,CP:REACTOME,C2,0,3
Cohort,-0.013018948264728797,0.025453495878370088,-0.5114797718529523,0.6091821730744109,LGP Offspring,CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling,CP:REACTOME,C2,20,42
Cohort,0.041497370923879506,0.07263004622042232,0.5713526712889679,0.5679145384780344,LGP Proband,CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling,CP:REACTOME,C2,20,67
Cohort,-0.010585964247493156,0.024470642538518692,-0.4325985405095116,0.6654236256137097,LonGen OPEL,CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling,CP:REACTOME,C2,38,42
Cohort,-0.004002627863834489,0.010096264884089347,-0.3964463997118588,0.6919008528297819,LGP Offspring,CREB1 phosphorylation through the activation of Adenylate Cyclase,CP:REACTOME,C2,4,6
Cohort,0.054248771434398234,0.0382308736355963,1.418978073885496,0.15627901368239397,LGP Proband,CREB1 phosphorylation through the activation of Adenylate Cyclase,CP:REACTOME,C2,4,20
Cohort,-0.008787493493670752,0.013506424283022634,-0.6506158335864286,0.5154822531532391,LonGen OPEL,CREB1 phosphorylation through the activation of Adenylate Cyclase,CP:REACTOME,C2,15,13
Cohort,-0.02606277381375871,0.014845247195392054,-1.7556308406806835,0.07960434335923709,LGP Offspring,CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde,CP:REACTOME,C2,10,10
Cohort,0.03716284520901695,0.042214186518341884,0.880340195419136,0.3789286473361513,LGP Proband,CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde,CP:REACTOME,C2,10,18
Cohort,-0.004085999062329078,0.011159469539785225,-0.3661463520073121,0.7143531622022246,LonGen OPEL,CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde,CP:REACTOME,C2,10,9
Cohort,-0.01379048312739784,0.016051038437152772,-0.8591645444868847,0.3905542973189816,LGP Offspring,CREB3 factors activate genes,CP:REACTOME,C2,10,16
Cohort,-0.04302858100262181,0.04941912488084819,-0.8706868263322292,0.3841757166793819,LGP Proband,CREB3 factors activate genes,CP:REACTOME,C2,10,27
Cohort,0.01847727028734308,0.016313968476365508,1.1326042657316402,0.2577215212113999,LonGen OPEL,CREB3 factors activate genes,CP:REACTOME,C2,14,25
Cohort,0.015856707873976948,0.019522589377388502,0.812223602487001,0.41694926217461115,LGP Offspring,Cristae formation,CP:REACTOME,C2,10,29
Cohort,0.05235723897076683,0.05588051977916311,0.9369497488155066,0.34905564143956314,LGP Proband,Cristae formation,CP:REACTOME,C2,10,41
Cohort,-0.058982538768097316,0.021677821597104702,-2.72087019924433,0.006653161416233197,LonGen OPEL,Cristae formation,CP:REACTOME,C2,43,27
Cohort,0.05375125528538345,0.028286916869725533,1.9002161152073622,0.057829972320665786,LGP Offspring,CRMPs in Sema3A signaling,CP:REACTOME,C2,17,54
Cohort,0.03667360743955928,0.07479190218859937,0.49034195369280886,0.6240209167947928,LGP Proband,CRMPs in Sema3A signaling,CP:REACTOME,C2,17,74
Cohort,-0.004909463182667861,0.024809016830960436,-0.19789027578638635,0.8431814368213547,LonGen OPEL,CRMPs in Sema3A signaling,CP:REACTOME,C2,37,39
Cohort,0.013698427959668316,0.021605933028585395,0.6340123308511982,0.5262872463751905,LGP Offspring,Cross-presentation of particulate exogenous antigens (phagosomes),CP:REACTOME,C2,12,30
Cohort,-0.007592724088753547,0.05325316253544139,-0.14257790011439017,0.8866579893341107,LGP Proband,Cross-presentation of particulate exogenous antigens (phagosomes),CP:REACTOME,C2,12,34
Cohort,0.009919115739559484,0.017421472533416613,0.5693615003285946,0.5692714645373366,LonGen OPEL,Cross-presentation of particulate exogenous antigens (phagosomes),CP:REACTOME,C2,20,28
Cohort,0.06370180744238328,0.03652942983649105,1.7438489384454723,0.08163999742722622,LGP Offspring,Cross-presentation of soluble exogenous antigens (endosomes),CP:REACTOME,C2,28,85
Cohort,-0.06403262915904469,0.08979587536926556,-0.7130909843656487,0.4759889312405552,LGP Proband,Cross-presentation of soluble exogenous antigens (endosomes),CP:REACTOME,C2,28,107
Cohort,-0.017309907534134687,0.02862956451785461,-0.6046165153276954,0.5456061300354411,LonGen OPEL,Cross-presentation of soluble exogenous antigens (endosomes),CP:REACTOME,C2,58,60
Cohort,0.008750215252621422,0.029534352742127703,0.29627245699345034,0.7671130134607196,LGP Offspring,Crosslinking of collagen fibrils,CP:REACTOME,C2,26,57
Cohort,-0.009879054687136962,0.07898948597400447,-0.12506797031681116,0.9004998797961058,LGP Proband,Crosslinking of collagen fibrils,CP:REACTOME,C2,26,71
Cohort,-0.014389333420522055,0.025422751195031495,-0.5660022123543513,0.5715517991127648,LonGen OPEL,Crosslinking of collagen fibrils,CP:REACTOME,C2,49,52
Cohort,-0.03601342527748952,0.02496143410381715,-1.4427626685111925,0.14955051739437178,LGP Offspring,CS/DS degradation,CP:REACTOME,C2,25,35
Cohort,-0.027947843098019048,0.06982395381016304,-0.4002615373801873,0.6890663957040342,LGP Proband,CS/DS degradation,CP:REACTOME,C2,25,59
Cohort,-0.024716964107428227,0.024082923854959807,-1.0263273785312343,0.3050490740056196,LonGen OPEL,CS/DS degradation,CP:REACTOME,C2,47,40
Cohort,-0.004673524180755987,0.014073626659408495,-0.33207674850687074,0.7399342431963922,LGP Offspring,CTLA4 inhibitory signaling,CP:REACTOME,C2,7,13
Cohort,-0.028268516656836655,0.031173046868585935,-0.9068255912232863,0.36476095957312726,LGP Proband,CTLA4 inhibitory signaling,CP:REACTOME,C2,7,9
Cohort,0.007662102965470619,0.007774778040180982,0.9855076152492013,0.3246742460794474,LonGen OPEL,CTLA4 inhibitory signaling,CP:REACTOME,C2,2,7
Cohort,-0.015758850891233096,0.020476930337557594,-0.7695904919073309,0.4418116713779511,LGP Offspring,Cyclin A/B1/B2 associated events during G2/M transition,CP:REACTOME,C2,17,24
Cohort,-0.06540790961553726,0.05706114897536952,-1.1462774723265847,0.25200913533274705,LGP Proband,Cyclin A/B1/B2 associated events during G2/M transition,CP:REACTOME,C2,17,36
Cohort,0.03077667357208505,0.01731897052669553,1.7770498266421646,0.07594184777997896,LonGen OPEL,Cyclin A/B1/B2 associated events during G2/M transition,CP:REACTOME,C2,12,29
Cohort,-0.013236375304965419,0.03933267167553118,-0.33652367716479725,0.7365804385723773,LGP Offspring,Cyclin A:Cdk2-associated events at S phase entry,CP:REACTOME,C2,45,90
Cohort,-0.11804284663660973,0.10097281806660696,-1.169055681487888,0.24271522219518207,LGP Proband,Cyclin A:Cdk2-associated events at S phase entry,CP:REACTOME,C2,45,112
Cohort,0.012666446132925481,0.029265576623351424,0.4328104071190158,0.6652697525063782,LonGen OPEL,Cyclin A:Cdk2-associated events at S phase entry,CP:REACTOME,C2,61,76
Cohort,-0.015696931096741196,0.02738709315634245,-0.5731506811304659,0.5667332748072409,LGP Offspring,Cyclin D associated events in G1,CP:REACTOME,C2,27,50
Cohort,-0.04912265435184501,0.0695301275269214,-0.7064945240151499,0.48007798018642134,LGP Proband,Cyclin D associated events in G1,CP:REACTOME,C2,27,54
Cohort,-0.005797829037528776,0.02325558132091652,-0.24930914250309866,0.8031859767210525,LonGen OPEL,Cyclin D associated events in G1,CP:REACTOME,C2,38,44
Cohort,-0.02986698761184267,0.021222537823468012,-1.4073240373173266,0.1597909446900338,LGP Offspring,CYP2E1 reactions,CP:REACTOME,C2,18,24
Cohort,0.019684447352813283,0.0634593548123621,0.3101898437356738,0.7564940886167619,LGP Proband,CYP2E1 reactions,CP:REACTOME,C2,18,46
Cohort,-5.220803152394914e-4,0.019608882814311456,-0.026624684342468168,0.9787657582210639,LonGen OPEL,CYP2E1 reactions,CP:REACTOME,C2,27,32
Cohort,-0.05534271572798159,0.020790635080115118,-2.661905974239011,0.007954641247814693,LGP Offspring,Cytochrome c-mediated apoptotic response,CP:REACTOME,C2,21,22
Cohort,2.5251714768485914e-4,0.054572803599389104,0.004627160985507548,0.9963091794061849,LGP Proband,Cytochrome c-mediated apoptotic response,CP:REACTOME,C2,21,28
Cohort,-0.03119589945086741,0.020045745270270292,-1.5562354519756287,0.12004959225775827,LonGen OPEL,Cytochrome c-mediated apoptotic response,CP:REACTOME,C2,34,27
Cohort,-0.059162682049889934,0.046676997446376996,-1.2674911688108605,0.20541615089947113,LGP Offspring,Cytochrome P450 - arranged by substrate type,CP:REACTOME,C2,74,131
Cohort,0.12436546366947815,0.13507588510538174,0.9207081158302411,0.35746907527845717,LGP Proband,Cytochrome P450 - arranged by substrate type,CP:REACTOME,C2,74,222
Cohort,-0.01411743295467477,0.04224204369420209,-0.3342033604451872,0.7383141390651108,LonGen OPEL,Cytochrome P450 - arranged by substrate type,CP:REACTOME,C2,122,138
Cohort,-0.1459499775882785,0.12606947058410675,-1.1576948559556974,0.24739745432527577,LGP Offspring,Cytokine Signaling in Immune system,CP:REACTOME,C2,557,1106
Cohort,-0.43505805343045423,0.36113547518736655,-1.2046948675001665,0.22866286300623845,LGP Proband,Cytokine Signaling in Immune system,CP:REACTOME,C2,557,1442
Cohort,-0.1074992770467373,0.11128766744197999,-0.9659585784991156,0.3343582855074857,LonGen OPEL,Cytokine Signaling in Immune system,CP:REACTOME,C2,849,968
Cohort,0.052696471909999446,0.0547455255496694,0.9625713038810653,0.3361068893854454,LGP Offspring,Cytoprotection by HMOX1,CP:REACTOME,C2,91,215
Cohort,-0.160806547410493,0.15500724067269997,-1.037413134461495,0.2998440418034547,LGP Proband,Cytoprotection by HMOX1,CP:REACTOME,C2,91,286
Cohort,-0.13883660376035659,0.05216458832826695,-2.66151058044723,0.007935910611147838,LonGen OPEL,Cytoprotection by HMOX1,CP:REACTOME,C2,201,173
Cohort,-0.016214035635360027,0.021404212885106643,-0.7575160891172964,0.44900469650582253,LGP Offspring,Cytosolic iron-sulfur cluster assembly,CP:REACTOME,C2,16,29
Cohort,-0.0260652517802641,0.06640442922479842,-0.39252278928602186,0.6947722718531307,LGP Proband,Cytosolic iron-sulfur cluster assembly,CP:REACTOME,C2,16,54
Cohort,-0.011456971444821636,0.021186238150336878,-0.5407742216208148,0.5888145003436294,LonGen OPEL,Cytosolic iron-sulfur cluster assembly,CP:REACTOME,C2,28,33
Cohort,0.038639705041020524,0.038734824958353745,0.9975443307815257,0.3188573000625711,LGP Offspring,Cytosolic sensors of pathogen-associated DNA ,CP:REACTOME,C2,45,110
Cohort,-0.020305576639857714,0.09348359064214702,-0.21721006328893572,0.828097768009528,LGP Proband,Cytosolic sensors of pathogen-associated DNA ,CP:REACTOME,C2,45,103
Cohort,-0.022652279322553908,0.032163168572843515,-0.7042925286185895,0.48145660754147124,LonGen OPEL,Cytosolic sensors of pathogen-associated DNA ,CP:REACTOME,C2,72,76
Cohort,0.008219558469578765,0.025829147503269687,0.3182280200513106,0.7504102648927045,LGP Offspring,Cytosolic sulfonation of small molecules,CP:REACTOME,C2,21,44
Cohort,0.05468612364067269,0.07172678649049984,0.7624226082945432,0.44602338797935237,LGP Proband,Cytosolic sulfonation of small molecules,CP:REACTOME,C2,21,61
Cohort,-0.017568349161063788,0.019715457649622684,-0.8910951738114997,0.3731473755664466,LonGen OPEL,Cytosolic sulfonation of small molecules,CP:REACTOME,C2,29,31
Cohort,0.010013716791238674,0.020048105715440093,0.4994844367528743,0.6176006700198324,LGP Offspring,Cytosolic tRNA aminoacylation,CP:REACTOME,C2,11,28
Cohort,0.016354276441014507,0.050631974167468355,0.3230029385566073,0.746773980956954,LGP Proband,Cytosolic tRNA aminoacylation,CP:REACTOME,C2,11,31
Cohort,-0.007860097995121851,0.0132743164709084,-0.5921282660653608,0.5539328464521757,LonGen OPEL,Cytosolic tRNA aminoacylation,CP:REACTOME,C2,14,13
Cohort,-0.02392261930204636,0.032790270005800405,-0.7295645719847561,0.46590909605966835,LGP Offspring,DAG and IP3 signaling,CP:REACTOME,C2,37,66
Cohort,0.05446812472214328,0.09791196304485329,0.5562969327577625,0.5781571047175054,LGP Proband,DAG and IP3 signaling,CP:REACTOME,C2,37,100
Cohort,-0.040813139848082575,0.02895143932311512,-1.4097102182929107,0.15901584668747132,LonGen OPEL,DAG and IP3 signaling,CP:REACTOME,C2,65,61
Cohort,-0.0670431189453479,0.028575107691218814,-2.3462070439003235,0.019253477151389586,LGP Offspring,DAP12 interactions,CP:REACTOME,C2,39,46
Cohort,0.06749026465377467,0.08412077344260305,0.8023019985642946,0.4226068393180261,LGP Proband,DAP12 interactions,CP:REACTOME,C2,39,75
Cohort,-0.00622516562370724,0.025631434053802752,-0.24287231103183854,0.8081668844782082,LonGen OPEL,DAP12 interactions,CP:REACTOME,C2,45,54
Cohort,-0.0638350358589498,0.02766707298093425,-2.307256568229656,0.021341793733887223,LGP Offspring,DAP12 signaling,CP:REACTOME,C2,37,42
Cohort,0.02980878326267888,0.0801014601573495,0.3721378262533939,0.7098847710737299,LGP Proband,DAP12 signaling,CP:REACTOME,C2,37,68
Cohort,0.0041792659884509874,0.025145570602403657,0.16620286946487078,0.8680395070886954,LonGen OPEL,DAP12 signaling,CP:REACTOME,C2,41,53
Cohort,0.0015806417644616889,0.012297605728288866,0.1285324801742221,0.8977658249926899,LGP Offspring,DARPP-32 events,CP:REACTOME,C2,5,10
Cohort,0.07914331357524822,0.049973222467182166,1.583714430807865,0.11363782055306443,LGP Proband,DARPP-32 events,CP:REACTOME,C2,5,33
Cohort,-0.006653451158314833,0.015298493188903785,-0.4349089205164778,0.6637464214598221,LonGen OPEL,DARPP-32 events,CP:REACTOME,C2,17,17
Cohort,-0.004547642466690884,0.020846558181922763,-0.21814835940804864,0.8273793545953141,LGP Offspring,DCC mediated attractive signaling,CP:REACTOME,C2,15,28
Cohort,-0.014019364034938316,0.05547247023814643,-0.2527265141565248,0.8005418328239329,LGP Proband,DCC mediated attractive signaling,CP:REACTOME,C2,15,36
Cohort,0.013894275662852633,0.017233748779101977,0.8062248000099165,0.42035403557460105,LonGen OPEL,DCC mediated attractive signaling,CP:REACTOME,C2,20,27
Cohort,-0.048869108104657534,0.050008520912744846,-0.9772156267113885,0.3288119851647945,LGP Offspring,DDX58/IFIH1-mediated induction of interferon-alpha/beta,CP:REACTOME,C2,85,161
Cohort,-0.046379318412279526,0.1324149835775273,-0.35025732858340025,0.7262340256137776,LGP Proband,DDX58/IFIH1-mediated induction of interferon-alpha/beta,CP:REACTOME,C2,85,227
Cohort,0.023418623891469804,0.045823358582390304,0.5110630171152376,0.6094486473998537,LonGen OPEL,DDX58/IFIH1-mediated induction of interferon-alpha/beta,CP:REACTOME,C2,135,175
Cohort,-0.005594976189205564,0.03255878824422611,-0.1718422733437496,0.8636129594761446,LGP Offspring,Deactivation of the beta-catenin transactivating complex,CP:REACTOME,C2,35,76
Cohort,0.09086683571760583,0.09240997544501117,0.9833011563960041,0.32574440494020884,LGP Proband,Deactivation of the beta-catenin transactivating complex,CP:REACTOME,C2,35,110
Cohort,-0.0021273375624606488,0.028194251329053975,-0.07545288355532401,0.9398733425747829,LonGen OPEL,Deactivation of the beta-catenin transactivating complex,CP:REACTOME,C2,59,70
Cohort,0.027336143778183167,0.038587957703432325,0.7084112610539031,0.47893410199124864,LGP Offspring,Deadenylation-dependent mRNA decay,CP:REACTOME,C2,47,106
Cohort,-0.05532561899974392,0.10612537057537223,-0.5213232114035411,0.6022800334713798,LGP Proband,Deadenylation-dependent mRNA decay,CP:REACTOME,C2,47,133
Cohort,0.03013252735637109,0.03511570487496126,0.8580926244728936,0.39109961683396455,LonGen OPEL,Deadenylation-dependent mRNA decay,CP:REACTOME,C2,81,112
Cohort,0.0320716821119393,0.022524173977850136,1.4238782804411834,0.15494311261908333,LGP Offspring,Deadenylation of mRNA,CP:REACTOME,C2,13,42
Cohort,0.027530321594304727,0.06076357085248989,0.453072806750241,0.650614162122501,LGP Proband,Deadenylation of mRNA,CP:REACTOME,C2,13,47
Cohort,0.0039215929761288685,0.021643927058213188,0.18118675809530357,0.8562671116866541,LonGen OPEL,Deadenylation of mRNA,CP:REACTOME,C2,31,41
Cohort,0.01219619458130051,0.06890131389021051,0.17700960827444168,0.8595538628281487,LGP Offspring,Death Receptor Signalling,CP:REACTOME,C2,168,342
Cohort,0.0014880884359435528,0.19609627269573265,0.007588560534511046,0.9939470775888521,LGP Proband,Death Receptor Signalling,CP:REACTOME,C2,168,493
Cohort,0.052371002438979714,0.06039878240374681,0.867087056306799,0.38615561338231386,LonGen OPEL,Death Receptor Signalling,CP:REACTOME,C2,262,325
Cohort,0.03213901076695421,0.03511531525301988,0.9152419830316145,0.36039096265121295,LGP Offspring,Dectin-1 mediated noncanonical NF-kB signaling,CP:REACTOME,C2,31,79
Cohort,-0.04917069028287065,0.08800281477512581,-0.5587399722215346,0.5764891787969468,LGP Proband,Dectin-1 mediated noncanonical NF-kB signaling,CP:REACTOME,C2,31,95
Cohort,-7.975617442933894e-4,0.02854338535138093,-0.027942086563141445,0.9777153450020791,LonGen OPEL,Dectin-1 mediated noncanonical NF-kB signaling,CP:REACTOME,C2,54,65
Cohort,0.026083525978600444,0.032188268204139274,0.8103426320787961,0.41802845131772837,LGP Offspring,Dectin-2 family,CP:REACTOME,C2,28,77
Cohort,0.12613532521750723,0.08652853405675698,1.4577309854200329,0.14529114344521987,LGP Proband,Dectin-2 family,CP:REACTOME,C2,28,93
Cohort,0.039768442520084234,0.02796151657803205,1.4222562788789606,0.15534359050670948,LonGen OPEL,Dectin-2 family,CP:REACTOME,C2,48,74
Cohort,0.0038171096483038784,0.019860864957231886,0.1921925181266571,0.8476491253594993,LGP Offspring,Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),CP:REACTOME,C2,13,23
Cohort,-0.04605577883770989,0.05509292538799755,-0.8359653896277492,0.40341381038199176,LGP Proband,Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),CP:REACTOME,C2,13,36
Cohort,-0.009924228399544812,0.014951223326189884,-0.6637736714266489,0.5070273800654341,LonGen OPEL,Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),CP:REACTOME,C2,17,18
Cohort,-0.07225464967576072,0.028989683484195585,-2.4924263045214707,0.012925705037220918,LGP Offspring,"Defective B4GALT7 causes EDS, progeroid type",CP:REACTOME,C2,35,46
Cohort,-0.07305977286344663,0.08375913027887508,-0.8722604045695668,0.3833173761967267,LGP Proband,"Defective B4GALT7 causes EDS, progeroid type",CP:REACTOME,C2,35,79
Cohort,-0.02337095023563932,0.026314065659122043,-0.8881542874594728,0.3747260557115979,LonGen OPEL,"Defective B4GALT7 causes EDS, progeroid type",CP:REACTOME,C2,54,48
Cohort,0.03253777566124869,0.03332719719955989,0.9763129934514377,0.32925862477997625,LGP Offspring,Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS),CP:REACTOME,C2,27,80
Cohort,0.18128897056362436,0.09257463774122814,1.9583006208501454,0.05052774052474702,LGP Proband,Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS),CP:REACTOME,C2,27,101
Cohort,0.039154035575917685,0.02838121725149285,1.3795756266887456,0.16810476276960504,LonGen OPEL,Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS),CP:REACTOME,C2,49,75
Cohort,0.053897334064569244,0.03945329583938543,1.3661047301088753,0.1723603701638718,LGP Offspring,Defective CFTR causes cystic fibrosis,CP:REACTOME,C2,45,110
Cohort,-0.06798286094673042,0.10673729352287074,-0.636917601177171,0.5243532995712654,LGP Proband,Defective CFTR causes cystic fibrosis,CP:REACTOME,C2,45,162
Cohort,-0.05134972459120936,0.03600749701820105,-1.4260842558774114,0.15423607566088296,LonGen OPEL,Defective CFTR causes cystic fibrosis,CP:REACTOME,C2,99,94
Cohort,-0.05092304625138015,0.02340842870855544,-2.175414970624172,0.029944817861321985,LGP Offspring,"Defective CHST14 causes EDS, musculocontractural type",CP:REACTOME,C2,25,31
Cohort,-0.03226031971993343,0.06816186973413013,-0.4732898297210293,0.636130269099828,LGP Proband,"Defective CHST14 causes EDS, musculocontractural type",CP:REACTOME,C2,25,49
Cohort,-0.024742935742299906,0.022132224946070412,-1.1179597081898007,0.2639214900533559,LonGen OPEL,"Defective CHST14 causes EDS, musculocontractural type",CP:REACTOME,C2,41,35
Cohort,-0.04340435849595506,0.021816642153309765,-1.9895068265292264,0.04704780801873446,LGP Offspring,Defective CHST3 causes SEDCJD,CP:REACTOME,C2,22,26
Cohort,-0.04834100857003293,0.0611159036466021,-0.7909726549992782,0.4291848205983708,LGP Proband,Defective CHST3 causes SEDCJD,CP:REACTOME,C2,22,42
Cohort,-0.03215315486562857,0.02071239846235932,-1.552362703144233,0.12097294062737773,LonGen OPEL,Defective CHST3 causes SEDCJD,CP:REACTOME,C2,38,27
Cohort,0.002917606786321455,0.017696498900554258,0.16486915308598557,0.8690962597439665,LGP Offspring,Defective CHST6 causes MCDC1,CP:REACTOME,C2,12,20
Cohort,-0.05258482595058841,0.05222468040389105,-1.0068960794764485,0.3142767548122034,LGP Proband,Defective CHST6 causes MCDC1,CP:REACTOME,C2,12,32
Cohort,-0.003999076028956916,0.014570628575191978,-0.27446146254566955,0.7838012284250231,LonGen OPEL,Defective CHST6 causes MCDC1,CP:REACTOME,C2,15,18
Cohort,-0.046243812671702904,0.021660471356353576,-2.134940274886419,0.03312483200812782,LGP Offspring,Defective CHSY1 causes TPBS,CP:REACTOME,C2,22,25
Cohort,-0.0485461905063809,0.06064240602191074,-0.8005320647871499,0.4236305715789811,LGP Proband,Defective CHSY1 causes TPBS,CP:REACTOME,C2,22,41
Cohort,-0.03303663724247743,0.02100530082706633,-1.57277620132477,0.11616801538022685,LonGen OPEL,Defective CHSY1 causes TPBS,CP:REACTOME,C2,39,28
Cohort,-0.0010414971303145532,0.013871096457970538,-0.07508398009272681,0.9401701073871072,LGP Offspring,Defective CSF2RB causes SMDP5,CP:REACTOME,C2,6,13
Cohort,0.027610064334354048,0.038809332421422336,0.7114284789684655,0.4770176876183948,LGP Proband,Defective CSF2RB causes SMDP5,CP:REACTOME,C2,6,19
Cohort,2.9679514841189896e-4,0.011119360927194085,0.026691745178092148,0.9787122872450513,LonGen OPEL,Defective CSF2RB causes SMDP5,CP:REACTOME,C2,8,11
Cohort,-0.03455397091728602,0.021168642307046216,-1.6323187106706578,0.10307805657423612,LGP Offspring,Defective EXT2 causes exostoses 2,CP:REACTOME,C2,18,25
Cohort,-0.09001024712879359,0.06310380029928427,-1.4263839372890272,0.15413176635837858,LGP Proband,Defective EXT2 causes exostoses 2,CP:REACTOME,C2,18,42
Cohort,0.013852297904535356,0.0174786661177536,0.7925260320903531,0.4282901523758671,LonGen OPEL,Defective EXT2 causes exostoses 2,CP:REACTOME,C2,16,23
Cohort,-6.934805977334528e-4,0.00555618473996455,-0.12481237219226757,0.9007091980656208,LGP Offspring,Defective F9 activation,CP:REACTOME,C2,1,2
Cohort,-0.007084018056615815,0.011175706741144282,-0.6338765163312152,0.5263352176740546,LGP Proband,Defective F9 activation,CP:REACTOME,C2,1,1
Cohort,0,0,NA,NA,LonGen OPEL,Defective F9 activation,CP:REACTOME,C2,0,0
Cohort,-0.01765744359675232,0.010612415036672655,-1.6638478174604558,0.09660629826201765,LGP Offspring,Defective factor IX causes hemophilia B,CP:REACTOME,C2,6,5
Cohort,0.02196770002986228,0.02804800616279877,0.7832178837367394,0.4337215233081989,LGP Proband,Defective factor IX causes hemophilia B,CP:REACTOME,C2,6,7
Cohort,-2.2045794996992504e-4,0.008185811423752527,-0.026931716180295665,0.978520947086146,LonGen OPEL,Defective factor IX causes hemophilia B,CP:REACTOME,C2,5,5
Cohort,0.009665195990483898,0.014938298237213814,0.6470078342930836,0.5178465030430264,LGP Offspring,Defective factor VIII causes hemophilia A,CP:REACTOME,C2,5,17
Cohort,0.0035104589424641646,0.031168856228545067,0.11262713385193826,0.9103532748241696,LGP Proband,Defective factor VIII causes hemophilia A,CP:REACTOME,C2,5,12
Cohort,0.015273346762030788,0.0114341443766646,1.3357664779186653,0.18200739835066532,LonGen OPEL,Defective factor VIII causes hemophilia A,CP:REACTOME,C2,5,15
Cohort,0.03587945883912828,0.031387897470203784,1.1430985102837259,0.25340235330343464,LGP Offspring,Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC),CP:REACTOME,C2,25,76
Cohort,0.14641798960552554,0.08369293367657378,1.7494665699179444,0.08057820645578577,LGP Proband,Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC),CP:REACTOME,C2,25,91
Cohort,0.04004645217118813,0.02751954035438352,1.4552006194685307,0.14600796722903098,LonGen OPEL,Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC),CP:REACTOME,C2,46,71
Cohort,-0.020847133129801864,0.013483985521814438,-1.5460661164368132,0.1225565947536158,LGP Offspring,Defective LFNG causes SCDO3,CP:REACTOME,C2,8,10
Cohort,-0.0024105951970301402,0.03208653000325386,-0.07512794922933969,0.9401309268237629,LGP Proband,Defective LFNG causes SCDO3,CP:REACTOME,C2,8,9
Cohort,0.0054281402224445946,0.014004300355028391,0.38760524159249155,0.6984118093388765,LonGen OPEL,Defective LFNG causes SCDO3,CP:REACTOME,C2,11,17
Cohort,0,0,NA,NA,LGP Offspring,Defective RIPK1-mediated regulated necrosis,CP:REACTOME,C2,0,0
Cohort,0.0058622806225191865,0.007930755553893196,0.7391831185165456,0.46000379680468895,LGP Proband,Defective RIPK1-mediated regulated necrosis,CP:REACTOME,C2,0,1
Cohort,0,0,NA,NA,LonGen OPEL,Defective RIPK1-mediated regulated necrosis,CP:REACTOME,C2,0,0
Cohort,8.777698934496203e-4,0.018500397176403078,0.04744600264956473,0.9621717787594775,LGP Offspring,Defective ST3GAL3 causes MCT12 and EIEE15,CP:REACTOME,C2,13,22
Cohort,-0.03828604829842057,0.05278692900249648,-0.7252941025724359,0.46847507648764997,LGP Proband,Defective ST3GAL3 causes MCT12 and EIEE15,CP:REACTOME,C2,13,32
Cohort,-0.003517994986948891,0.014969519810269135,-0.2350105435269564,0.8142609916127741,LonGen OPEL,Defective ST3GAL3 causes MCT12 and EIEE15,CP:REACTOME,C2,16,19
Cohort,-0.0084609071300473,0.01483225309847528,-0.570439775661397,0.5685690083997804,LGP Offspring,Defects in biotin (Btn) metabolism,CP:REACTOME,C2,8,12
Cohort,-0.0705737408525658,0.033832474876270044,-2.0859763026696556,0.03728414003166049,LGP Proband,Defects in biotin (Btn) metabolism,CP:REACTOME,C2,8,11
Cohort,-4.257453003419655e-4,0.00967630984801928,-0.043998725446882485,0.9649164544735199,LonGen OPEL,Defects in biotin (Btn) metabolism,CP:REACTOME,C2,7,7
Cohort,-0.027577723172143805,0.02177709417617804,-1.2663637742041391,0.20581906215599186,LGP Offspring,Defects in cobalamin (B12) metabolism,CP:REACTOME,C2,20,31
Cohort,0.07688906727389397,0.061716343303204614,1.245846126951295,0.2131707567044327,LGP Proband,Defects in cobalamin (B12) metabolism,CP:REACTOME,C2,20,45
Cohort,0.007125323622748871,0.017859756902960947,0.39895972053055057,0.69002988827355,LonGen OPEL,Defects in cobalamin (B12) metabolism,CP:REACTOME,C2,21,30
Cohort,-0.03603863030219105,0.026977604574758153,-1.3358721380292946,0.18204061896621843,LGP Offspring,Defects in vitamin and cofactor metabolism,CP:REACTOME,C2,28,43
Cohort,0.006315326421328214,0.07102966128678721,0.08891111553847403,0.9291738951821826,LGP Proband,Defects in vitamin and cofactor metabolism,CP:REACTOME,C2,28,56
Cohort,0.006699578322406841,0.020388387205758432,0.32859775787045253,0.7425461683279162,LonGen OPEL,Defects in vitamin and cofactor metabolism,CP:REACTOME,C2,28,37
Cohort,-0.0058617596919934584,0.019011911491722096,-0.3083203755995658,0.7579335461129539,LGP Offspring,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),CP:REACTOME,C2,12,25
Cohort,0.0181917966475227,0.04805152850914541,0.3785893438137008,0.7050891877367261,LGP Proband,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),CP:REACTOME,C2,12,26
Cohort,0.020768646697814416,0.016665602565667285,1.2461983667245125,0.21305820910325302,LonGen OPEL,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),CP:REACTOME,C2,15,29
Cohort,7.937014988338497e-4,0.02920735023729894,0.027174717746913636,0.9783284006426604,LGP Offspring,Defensins,CP:REACTOME,C2,29,62
Cohort,-0.03819834430979248,0.08660271039262545,-0.44107562149746776,0.6592725680299019,LGP Proband,Defensins,CP:REACTOME,C2,29,92
Cohort,0.04084965096058518,0.028782316731828808,1.4192620886355463,0.15621408109156978,LonGen OPEL,Defensins,CP:REACTOME,C2,52,79
Cohort,-9.636118681609929e-4,0.03855222443155071,-0.024994974540882363,0.9800663484370569,LGP Offspring,Degradation of AXIN,CP:REACTOME,C2,41,83
Cohort,-0.11930576009130688,0.09517063417627496,-1.253598456329805,0.2103392879378809,LGP Proband,Degradation of AXIN,CP:REACTOME,C2,41,105
Cohort,-0.02324075408324219,0.030835066952322302,-0.753711808674761,0.45124517116127294,LonGen OPEL,Degradation of AXIN,CP:REACTOME,C2,69,73
Cohort,0.0013817115154920543,0.04217597225314832,0.032760632219661835,0.9738751425415177,LGP Offspring,Degradation of beta-catenin by the destruction complex,CP:REACTOME,C2,58,120
Cohort,-0.037059563791274966,0.11386477127211285,-0.3254699708895072,0.7449070418398103,LGP Proband,Degradation of beta-catenin by the destruction complex,CP:REACTOME,C2,58,171
Cohort,-0.04596533124999958,0.036937492999257054,-1.2444085268841638,0.21371552643807215,LonGen OPEL,Degradation of beta-catenin by the destruction complex,CP:REACTOME,C2,100,103
Cohort,0.0012117464277957841,0.020037173957723073,0.06047491678978671,0.9517952666761216,LGP Offspring,Degradation of cysteine and homocysteine,CP:REACTOME,C2,12,27
Cohort,-2.559516666381047e-4,0.05218193306616522,-0.004904986296953876,0.9960875758388655,LGP Proband,Degradation of cysteine and homocysteine,CP:REACTOME,C2,12,32
Cohort,0.00594199830083233,0.018719602443771913,0.31742118021364585,0.7510072798210217,LonGen OPEL,Degradation of cysteine and homocysteine,CP:REACTOME,C2,24,30
Cohort,0.031500320718380125,0.03585259787847248,0.878606365573702,0.37992692415428897,LGP Offspring,Degradation of DVL,CP:REACTOME,C2,35,82
Cohort,-0.1282090497623124,0.09254572570866539,-1.3853589539717417,0.1663131277754656,LGP Proband,Degradation of DVL,CP:REACTOME,C2,35,111
Cohort,-0.048698615151471926,0.03184827847836544,-1.5290815541114078,0.12664149793861357,LonGen OPEL,Degradation of DVL,CP:REACTOME,C2,71,67
Cohort,0.05366711896569692,0.03429098147160823,1.5650505369795693,0.11803903654647555,LGP Offspring,Degradation of GLI1 by the proteasome,CP:REACTOME,C2,27,78
Cohort,-0.024855593391222314,0.0869532415691217,-0.2858501068239517,0.7750639112615947,LGP Proband,Degradation of GLI1 by the proteasome,CP:REACTOME,C2,27,99
Cohort,-0.031700555288509694,0.02725813651953055,-1.1629758793597698,0.24518780988946026,LonGen OPEL,Degradation of GLI1 by the proteasome,CP:REACTOME,C2,56,54
Cohort,-0.1404831061800281,0.09515233445549962,-1.4764020975830978,0.14030163856632866,LGP Offspring,Degradation of the extracellular matrix,CP:REACTOME,C2,299,575
Cohort,-0.5424479799531889,0.25246008706627976,-2.1486484705630997,0.031949565756967654,LGP Proband,Degradation of the extracellular matrix,CP:REACTOME,C2,299,759
Cohort,-0.09815167958584108,0.07739083634545917,-1.268259709039829,0.20507602085008247,LonGen OPEL,Degradation of the extracellular matrix,CP:REACTOME,C2,457,519
Cohort,-0.025827868877993695,0.018628312396039626,-1.3864846331160248,0.16605604811469485,LGP Offspring,Depolymerisation of the Nuclear Lamina,CP:REACTOME,C2,16,20
Cohort,0.003446845693479832,0.04608020458758244,0.07480100673009334,0.9403909784045138,LGP Proband,Depolymerisation of the Nuclear Lamina,CP:REACTOME,C2,16,21
Cohort,-0.009324364530680074,0.010595676990173686,-0.8800159290744128,0.3791162797202463,LonGen OPEL,Depolymerisation of the Nuclear Lamina,CP:REACTOME,C2,10,7
Cohort,0.009290836018500215,0.0218062431676071,0.42606312087272485,0.6701974771317842,LGP Offspring,Deposition of new CENPA-containing nucleosomes at the centromere,CP:REACTOME,C2,13,33
Cohort,-0.04910023324262739,0.05129188743509022,-0.9572709388938676,0.3387079248605511,LGP Proband,Deposition of new CENPA-containing nucleosomes at the centromere,CP:REACTOME,C2,13,30
Cohort,-0.0073140403876356215,0.01631385206859237,-0.4483331316775087,0.6540347995861702,LonGen OPEL,Deposition of new CENPA-containing nucleosomes at the centromere,CP:REACTOME,C2,19,20
Cohort,0.01912035049267709,0.02456068154961348,0.7784942960175303,0.43655007208809216,LGP Offspring,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,CP:REACTOME,C2,16,43
Cohort,0.01997088322027513,0.0720752525033512,0.2770837773942806,0.7817844390125137,LGP Proband,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,CP:REACTOME,C2,16,63
Cohort,0.0017373613802039057,0.021723051142381745,0.0799777788495976,0.9362750316530914,LonGen OPEL,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,CP:REACTOME,C2,34,38
Cohort,-0.0653085688806908,0.024297451069003856,-2.687877370149523,0.007367788830665627,LGP Offspring,Dermatan sulfate biosynthesis,CP:REACTOME,C2,29,32
Cohort,-0.03655320090422329,0.07544054483815568,-0.48452991667334455,0.6281370596738873,LGP Proband,Dermatan sulfate biosynthesis,CP:REACTOME,C2,29,58
Cohort,-0.02384616265487146,0.022375878922898343,-1.065708423657428,0.2868786075146915,LonGen OPEL,Dermatan sulfate biosynthesis,CP:REACTOME,C2,42,36
Cohort,-0.03508796738198739,0.03373626775652492,-1.0400666616478653,0.2986807740422348,LGP Offspring,Detoxification of Reactive Oxygen Species,CP:REACTOME,C2,41,69
Cohort,-0.12147877871247052,0.08692075390655385,-1.397580822217316,0.16261062173844515,LGP Proband,Detoxification of Reactive Oxygen Species,CP:REACTOME,C2,41,93
Cohort,-0.023855713347113124,0.029275587446351715,-0.8148671103809393,0.4153921090765119,LonGen OPEL,Detoxification of Reactive Oxygen Species,CP:REACTOME,C2,63,72
Cohort,0.03704442982622208,0.08584301266363732,0.4315369262653327,0.6662155987803708,LGP Offspring,Deubiquitination,CP:REACTOME,C2,223,494
Cohort,-0.16299082014915403,0.23562789958182812,-0.6917297163808528,0.4892995981646152,LGP Proband,Deubiquitination,CP:REACTOME,C2,223,738
Cohort,-0.002227362905015991,0.0735510513610076,-0.03028322320076048,0.9758487673955634,LonGen OPEL,Deubiquitination,CP:REACTOME,C2,397,466
Cohort,-0.12952016860291682,0.17679838117369867,-0.7325868469104785,0.46406438425625074,LGP Offspring,Developmental Biology,CP:REACTOME,C2,925,1924
Cohort,-0.07530670428533678,0.49583941833593853,-0.1518772035875441,0.8793205198218117,LGP Proband,Developmental Biology,CP:REACTOME,C2,925,2793
Cohort,-0.23389403586524612,0.1522800463496634,-1.535946707871245,0.1249488201108399,LonGen OPEL,Developmental Biology,CP:REACTOME,C2,1577,1759
Cohort,0.012293087222789212,0.016638869393583243,0.738817460009033,0.4602742854006684,LGP Offspring,DEx/H-box helicases activate type I IFN and inflammatory cytokines production ,CP:REACTOME,C2,7,21
Cohort,-0.011165167808754477,0.038239722226130694,-0.29197826654517073,0.7703758538780116,LGP Proband,DEx/H-box helicases activate type I IFN and inflammatory cytokines production ,CP:REACTOME,C2,7,17
Cohort,0.005105973589176685,0.014820645102719892,0.34451763427218385,0.730548036381973,LonGen OPEL,DEx/H-box helicases activate type I IFN and inflammatory cytokines production ,CP:REACTOME,C2,14,20
Cohort,0.04023744021099092,0.044332425635414535,0.9076300165007805,0.3643971625196074,LGP Offspring,Digestion,CP:REACTOME,C2,54,119
Cohort,0.08543233196490814,0.11868779311520422,0.7198072330992228,0.47184535436195807,LGP Proband,Digestion,CP:REACTOME,C2,54,159
Cohort,-0.028427976725566958,0.03662099187070238,-0.7762754440386959,0.43781696020274585,LonGen OPEL,Digestion,CP:REACTOME,C2,95,109
Cohort,0.033699229736968435,0.04569765434921741,0.7374389389757715,0.4611113452375063,LGP Offspring,Digestion and absorption,CP:REACTOME,C2,58,126
Cohort,0.07349692423069823,0.124648670044482,0.5896326387154407,0.5555966613251528,LGP Proband,Digestion and absorption,CP:REACTOME,C2,58,172
Cohort,-0.03144338610821012,0.03735069280166383,-0.8418421118766888,0.40012917977298734,LonGen OPEL,Digestion and absorption,CP:REACTOME,C2,99,114
Cohort,0.01252230801691832,0.03116853360051972,0.40176121781711016,0.6879867494553417,LGP Offspring,Digestion of dietary carbohydrate,CP:REACTOME,C2,29,61
Cohort,0.055059827859577394,0.08859069641868024,0.6215080147848062,0.5344352629146125,LGP Proband,Digestion of dietary carbohydrate,CP:REACTOME,C2,29,90
Cohort,-0.012435714990554429,0.02710542849076428,-0.45879057011740987,0.6465098101658581,LonGen OPEL,Digestion of dietary carbohydrate,CP:REACTOME,C2,47,60
Cohort,0.0189720336465977,0.013810366887785417,1.3737530509328846,0.16997372554877235,LGP Offspring,Digestion of dietary lipid,CP:REACTOME,C2,4,15
Cohort,0.0012238569810200466,0.03363603695847558,0.03638529064916075,0.9709838496383931,LGP Proband,Digestion of dietary lipid,CP:REACTOME,C2,4,15
Cohort,-0.015260558611249007,0.013508263538111442,-1.1297202314859893,0.2589344419893629,LonGen OPEL,Digestion of dietary lipid,CP:REACTOME,C2,15,13
Cohort,-0.032467316123698325,0.02758684899123853,-1.1769128157409283,0.23964453491153148,LGP Offspring,Disassembly of the destruction complex and recruitment of AXIN to the membrane,CP:REACTOME,C2,30,44
Cohort,-0.08402720049980328,0.07357160094174951,-1.1421146124892947,0.2537341716320242,LGP Proband,Disassembly of the destruction complex and recruitment of AXIN to the membrane,CP:REACTOME,C2,30,60
Cohort,-0.03527647727071319,0.022098548612959918,-1.5963255274613348,0.11081303483709086,LonGen OPEL,Disassembly of the destruction complex and recruitment of AXIN to the membrane,CP:REACTOME,C2,40,36
Cohort,-0.08999721591712623,0.04154606318017624,-2.166203221875148,0.030644469081763024,LGP Offspring,Diseases associated with glycosaminoglycan metabolism,CP:REACTOME,C2,68,97
Cohort,-0.2004980614239751,0.1186216511686671,-1.6902315846108789,0.09135734419003654,LGP Proband,Diseases associated with glycosaminoglycan metabolism,CP:REACTOME,C2,68,153
Cohort,-0.029410501126989244,0.03462604154024601,-0.8493752048672754,0.39592792113777964,LonGen OPEL,Diseases associated with glycosaminoglycan metabolism,CP:REACTOME,C2,85,86
Cohort,-0.005231082395190799,0.014816344432027565,-0.3530616083602306,0.7241523179206767,LGP Offspring,Diseases associated with glycosylation precursor biosynthesis,CP:REACTOME,C2,8,14
Cohort,0.03512976760673854,0.04848112081438667,0.724607167009098,0.4688962902442445,LGP Proband,Diseases associated with glycosylation precursor biosynthesis,CP:REACTOME,C2,8,32
Cohort,-0.008553025836320697,0.01529060566574671,-0.5593647513571539,0.5760701592248921,LonGen OPEL,Diseases associated with glycosylation precursor biosynthesis,CP:REACTOME,C2,17,19
Cohort,4.1730839149054194e-4,0.021621049954213677,0.019301023418116365,0.9846066627789793,LGP Offspring,Diseases associated with N-glycosylation of proteins,CP:REACTOME,C2,12,30
Cohort,0.036519517500198585,0.06433923280602209,0.5676088431191302,0.5704533602826523,LGP Proband,Diseases associated with N-glycosylation of proteins,CP:REACTOME,C2,12,56
Cohort,0.0030618449031690398,0.01896088490535316,0.16148217335070683,0.8717546276181782,LonGen OPEL,Diseases associated with N-glycosylation of proteins,CP:REACTOME,C2,20,26
Cohort,-0.019039781674818818,0.05590398667673844,-0.3405800338518834,0.7335255753190519,LGP Offspring,Diseases associated with O-glycosylation of proteins,CP:REACTOME,C2,104,220
Cohort,0.1914478886860786,0.15729694605495936,1.2171112884746467,0.223906163405463,LGP Proband,Diseases associated with O-glycosylation of proteins,CP:REACTOME,C2,104,296
Cohort,0.028265367645370437,0.051564069053571644,0.5481601464772805,0.5837356329466679,LonGen OPEL,Diseases associated with O-glycosylation of proteins,CP:REACTOME,C2,171,219
Cohort,-0.04091143972618552,0.018036028875675847,-2.268317488743901,0.023624450180448127,LGP Offspring,Diseases associated with surfactant metabolism,CP:REACTOME,C2,16,17
Cohort,0.017917668738226304,0.05416189803640273,0.3308168544275104,0.74086592308509,LGP Proband,Diseases associated with surfactant metabolism,CP:REACTOME,C2,16,34
Cohort,-0.0015483656717818343,0.015465305779148984,-0.1001186587509579,0.9202753319486032,LonGen OPEL,Diseases associated with surfactant metabolism,CP:REACTOME,C2,15,18
Cohort,-0.0877899878302549,0.023335109192733985,-3.7621417198077944,1.8307952252240382e-4,LGP Offspring,Diseases of Base Excision Repair,CP:REACTOME,C2,27,24
Cohort,-0.07240063911553389,0.06875751737462668,-1.052985068106191,0.2926528109120978,LGP Proband,Diseases of Base Excision Repair,CP:REACTOME,C2,27,46
Cohort,0.02733069617825718,0.018350702424536753,1.48935422448534,0.13679020440510972,LonGen OPEL,Diseases of Base Excision Repair,CP:REACTOME,C2,17,32
Cohort,0.020403910834877297,0.03287546561539421,0.62064248986098,0.5350440611791976,LGP Offspring,Diseases of carbohydrate metabolism,CP:REACTOME,C2,32,79
Cohort,0.09656133455447852,0.09329890636347118,1.0349674858813207,0.30098409630286216,LGP Proband,Diseases of carbohydrate metabolism,CP:REACTOME,C2,32,110
Cohort,0.05284256647896256,0.03303235031875045,1.5997216658533393,0.11005714762011184,LonGen OPEL,Diseases of carbohydrate metabolism,CP:REACTOME,C2,60,95
Cohort,-0.11771903013401362,0.04009922524736676,-2.9356933808027628,0.0034410241965636417,LGP Offspring,Diseases of DNA repair,CP:REACTOME,C2,61,90
Cohort,-0.05913746063415902,0.11127233364095197,-0.5314659870887658,0.5952374239957958,LGP Proband,Diseases of DNA repair,CP:REACTOME,C2,61,127
Cohort,0.03502248196381399,0.029229855737476416,1.1981749851372234,0.23120552423298427,LonGen OPEL,Diseases of DNA repair,CP:REACTOME,C2,57,79
Cohort,-0.11475027445762752,0.07551971948189523,-1.519474320679081,0.12911069531796837,LGP Offspring,Diseases of glycosylation,CP:REACTOME,C2,191,358
Cohort,0.06873973744572627,0.21675436419361832,0.31713196503081115,0.7512228424127851,LGP Proband,Diseases of glycosylation,CP:REACTOME,C2,191,532
Cohort,-7.111620441824829e-4,0.06671697165399852,-0.01065938735754744,0.9914978713437801,LonGen OPEL,Diseases of glycosylation,CP:REACTOME,C2,291,350
Cohort,-0.03312826350642314,0.04259102666954493,-0.7778226095242682,0.4369457312254388,LGP Offspring,Diseases of Immune System,CP:REACTOME,C2,59,108
Cohort,-0.012080583294766285,0.111610764135291,-0.10823851434367555,0.9138325285958353,LGP Proband,Diseases of Immune System,CP:REACTOME,C2,59,138
Cohort,0.08963190896656051,0.036801250750135496,2.435566920676752,0.015086970450727025,LonGen OPEL,Diseases of Immune System,CP:REACTOME,C2,70,112
Cohort,-0.22216568027011124,0.09906956698313199,-2.2425219674972245,0.02525100872259844,LGP Offspring,Diseases of metabolism,CP:REACTOME,C2,322,599
Cohort,0.40483241461777314,0.27596885719096237,1.4669496360512917,0.1427667266918943,LGP Proband,Diseases of metabolism,CP:REACTOME,C2,322,880
Cohort,0.03950737899375983,0.08449009691505292,0.46759774738429866,0.6402002604256951,LonGen OPEL,Diseases of metabolism,CP:REACTOME,C2,485,604
Cohort,-0.021978823541955385,0.028764978596278128,-0.7640827358306883,0.44508454852964174,LGP Offspring,Diseases of Mismatch Repair (MMR),CP:REACTOME,C2,28,55
Cohort,-0.017508071446468265,0.07536017222824179,-0.23232525787549865,0.8163423931690308,LGP Proband,Diseases of Mismatch Repair (MMR),CP:REACTOME,C2,28,71
Cohort,5.214537637877819e-4,0.021817672234749837,0.023900522391992057,0.9809379476385909,LonGen OPEL,Diseases of Mismatch Repair (MMR),CP:REACTOME,C2,37,40
Cohort,-0.03450899462176009,0.02966934361616752,-1.1631195845854618,0.24519139157973552,LGP Offspring,Diseases of mitotic cell cycle,CP:REACTOME,C2,33,57
Cohort,0.003088877503372856,0.08440576334666858,0.03659557571544397,0.9708162284872085,LGP Proband,Diseases of mitotic cell cycle,CP:REACTOME,C2,33,82
Cohort,-0.0014652591791918669,0.027302447883459355,-0.05366768523636904,0.9572133950176995,LonGen OPEL,Diseases of mitotic cell cycle,CP:REACTOME,C2,47,59
Cohort,0.0017626795660003864,0.033882364750395536,0.05202351072558503,0.9585253286762883,LGP Offspring,Diseases of programmed cell death,CP:REACTOME,C2,36,71
Cohort,-0.031171135590867368,0.10712220606887725,-0.29098668459856963,0.7711338518092553,LGP Proband,Diseases of programmed cell death,CP:REACTOME,C2,36,154
Cohort,-0.010485443053110461,0.02958021587488671,-0.3544748658177471,0.7230769219540043,LonGen OPEL,Diseases of programmed cell death,CP:REACTOME,C2,67,74
Cohort,-0.2588918948094166,0.10312538627464592,-2.510457455353716,0.012289867249791893,LGP Offspring,Diseases of signal transduction by growth factor receptors and second messengers,CP:REACTOME,C2,383,667
Cohort,-0.31785241493590566,0.28233341062272693,-1.1258051756426435,0.2605718501188499,LGP Proband,Diseases of signal transduction by growth factor receptors and second messengers,CP:REACTOME,C2,383,941
Cohort,-0.10769122618671688,0.08684848944338683,-1.2399896287996652,0.21534463771206816,LonGen OPEL,Diseases of signal transduction by growth factor receptors and second messengers,CP:REACTOME,C2,545,603
Cohort,-0.011853477067530864,0.006424429124414031,-1.8450630924521272,0.06546557699332638,LGP Offspring,Disinhibition of SNARE formation,CP:REACTOME,C2,3,1
Cohort,-0.009117836793285936,0.022170402113267155,-0.41126167882312176,0.680986322020041,LGP Proband,Disinhibition of SNARE formation,CP:REACTOME,C2,3,5
Cohort,-0.0012298542256287757,0.008150654714269075,-0.15089023750149932,0.8801005305605094,LonGen OPEL,Disinhibition of SNARE formation,CP:REACTOME,C2,5,5
Cohort,-0.04860341131484629,0.08619215420319418,-0.5638960038087214,0.5730119293312335,LGP Offspring,Disorders of transmembrane transporters,CP:REACTOME,C2,240,481
Cohort,-0.37731683002140826,0.23975134866782685,-1.5737839729284568,0.11591665370098803,LGP Proband,Disorders of transmembrane transporters,CP:REACTOME,C2,240,695
Cohort,-0.035674113656331434,0.07825812183517235,-0.45585190162713635,0.6486208104465957,LonGen OPEL,Disorders of transmembrane transporters,CP:REACTOME,C2,392,457
Cohort,-0.03854687558260398,0.02677390980060003,-1.4397178398554293,0.1504101548973697,LGP Offspring,Displacement of DNA glycosylase by APEX1,CP:REACTOME,C2,30,46
Cohort,0.07741050258449894,0.07857498935072892,0.9851799309697371,0.32482141361849215,LGP Proband,Displacement of DNA glycosylase by APEX1,CP:REACTOME,C2,30,72
Cohort,0.04266603994778865,0.024062143302609095,1.7731604126537766,0.07658446252093112,LonGen OPEL,Displacement of DNA glycosylase by APEX1,CP:REACTOME,C2,32,58
Cohort,0.00418212827510734,0.010629890257428441,0.39343099259042313,0.6941252339155167,LGP Offspring,Dissolution of Fibrin Clot,CP:REACTOME,C2,3,8
Cohort,0.01391743105317003,0.031156875011841816,0.44668892653324255,0.655215643019138,LGP Proband,Dissolution of Fibrin Clot,CP:REACTOME,C2,3,13
Cohort,-0.012115566642417142,0.00965278908376053,-1.2551363691142792,0.20979761310161743,LonGen OPEL,Dissolution of Fibrin Clot,CP:REACTOME,C2,9,5
Cohort,-0.015118618677416831,0.04006789854951374,-0.37732497147895244,0.7060505438341118,LGP Offspring,DNA Damage Bypass,CP:REACTOME,C2,55,114
Cohort,0.0031420854617966528,0.1093059489555115,0.028745786407979583,0.9770742162187446,LGP Proband,DNA Damage Bypass,CP:REACTOME,C2,55,154
Cohort,0.007119155554059365,0.034300111609155484,0.2075548801467777,0.8356296249854656,LonGen OPEL,DNA Damage Bypass,CP:REACTOME,C2,85,101
Cohort,0.06471586054011984,0.02597171323378902,2.4917825003521505,0.012948937404855943,LGP Offspring,DNA Damage Recognition in GG-NER,CP:REACTOME,C2,15,52
Cohort,-0.02584219822683272,0.06537707087158774,-0.3952792298937867,0.692737906237797,LGP Proband,DNA Damage Recognition in GG-NER,CP:REACTOME,C2,15,54
Cohort,-0.021857416347417072,0.02551161156858451,-0.856763450190372,0.3918334813216111,LonGen OPEL,DNA Damage Recognition in GG-NER,CP:REACTOME,C2,50,45
Cohort,-0.007227869963487268,0.015506871437994594,-0.46610755705226914,0.6412886653329428,LGP Offspring,DNA Damage Reversal,CP:REACTOME,C2,10,13
Cohort,-0.05122160811401386,0.03569674931086998,-1.434909595491274,0.15168774363373067,LGP Proband,DNA Damage Reversal,CP:REACTOME,C2,10,10
Cohort,-0.01813971984873535,0.011992060772570675,-1.5126440895151365,0.13076699662877297,LonGen OPEL,DNA Damage Reversal,CP:REACTOME,C2,12,8
Cohort,0.011557358883723527,0.0322168735324914,0.3587362030045431,0.7199044507091623,LGP Offspring,DNA Damage/Telomere Stress Induced Senescence,CP:REACTOME,C2,36,79
Cohort,0.06197266744521657,0.08629818815486785,0.718122463173879,0.4728828947233311,LGP Proband,DNA Damage/Telomere Stress Induced Senescence,CP:REACTOME,C2,36,92
Cohort,0.02095970099341627,0.02941703644674843,0.7125021254727044,0.4763626881418588,LonGen OPEL,DNA Damage/Telomere Stress Induced Senescence,CP:REACTOME,C2,55,73
Cohort,-0.012206057592376161,0.06353973308624636,-0.19210117826286954,0.847720642641898,LGP Offspring,DNA Double-Strand Break Repair,CP:REACTOME,C2,154,311
Cohort,0.00626305517922167,0.1947020907998167,0.03216737505742062,0.9743462700623645,LGP Proband,DNA Double-Strand Break Repair,CP:REACTOME,C2,154,463
Cohort,-0.04020228807853589,0.06333862342877496,-0.6347199528853645,0.5257934624605187,LonGen OPEL,DNA Double-Strand Break Repair,CP:REACTOME,C2,258,295
Cohort,-0.00952450372456196,0.040341736000490354,-0.23609553452152354,0.8134300528783555,LGP Offspring,DNA Double Strand Break Response,CP:REACTOME,C2,56,110
Cohort,-0.008631384305561887,0.11841439782118472,-0.07289134146166898,0.9419100613407754,LGP Proband,DNA Double Strand Break Response,CP:REACTOME,C2,56,154
Cohort,-0.0022809961265174553,0.03272278221639278,-0.06970666832158207,0.9444446415884511,LonGen OPEL,DNA Double Strand Break Response,CP:REACTOME,C2,81,94
Cohort,0.010686171309235265,0.015395860772807699,0.6940937870852452,0.4878618438224419,LGP Offspring,DNA methylation,CP:REACTOME,C2,8,16
Cohort,-0.05935733031584312,0.06353522156408191,-0.9342429105401805,0.35044901089461244,LGP Proband,DNA methylation,CP:REACTOME,C2,8,61
Cohort,-0.01208888651475461,0.015405769525896099,-0.7846986477653048,0.4328637412895765,LonGen OPEL,DNA methylation,CP:REACTOME,C2,19,18
Cohort,-0.09853521743815824,0.09789085157005185,-1.006582493233755,0.31449561022578865,LGP Offspring,DNA Repair,CP:REACTOME,C2,344,678
Cohort,-0.29866230283375433,0.27955977855752956,-1.068330731891368,0.28568047344820646,LGP Proband,DNA Repair,CP:REACTOME,C2,344,934
Cohort,-0.03621349635825883,0.0858834097850298,-0.4216588098784493,0.6733879179181804,LonGen OPEL,DNA Repair,CP:REACTOME,C2,535,623
Cohort,-0.06914995964607193,0.059504417521751916,-1.162097916861283,0.2456058103113698,LGP Offspring,DNA Replication,CP:REACTOME,C2,120,216
Cohort,-0.13629826387777588,0.16653670855678587,-0.8184277512083815,0.413346758606171,LGP Proband,DNA Replication,CP:REACTOME,C2,120,329
Cohort,-0.002338051090302659,0.04868826485720639,-0.048020834120084725,0.9617116841173103,LonGen OPEL,DNA Replication,CP:REACTOME,C2,170,201
Cohort,-0.012080865486957226,0.016619700610577968,-0.7269003076546456,0.46753866784640885,LGP Offspring,DNA replication initiation,CP:REACTOME,C2,10,18
Cohort,0.016907801157858667,0.04736467525975014,0.3569706973632877,0.7212040435756094,LGP Proband,DNA replication initiation,CP:REACTOME,C2,10,27
Cohort,5.702216089686328e-4,0.012778349495011226,0.044624042345316355,0.9644181705022098,LonGen OPEL,DNA replication initiation,CP:REACTOME,C2,12,13
Cohort,-0.03656506473935258,0.050101600547104434,-0.7298182960237948,0.4657540732341948,LGP Offspring,DNA Replication Pre-Initiation,CP:REACTOME,C2,87,161
Cohort,-0.12822835478531755,0.13838296009665224,-0.9266195396872396,0.35439216854376754,LGP Proband,DNA Replication Pre-Initiation,CP:REACTOME,C2,87,236
Cohort,0.006960752333010875,0.04139953053486401,0.16813602094229013,0.8665189817895419,LonGen OPEL,DNA Replication Pre-Initiation,CP:REACTOME,C2,121,142
Cohort,-0.038490493073519164,0.03252027696694359,-1.1835844175818127,0.2369936499915948,LGP Offspring,DNA strand elongation,CP:REACTOME,C2,42,68
Cohort,0.04867176143618535,0.1002339798724903,0.4855814515007954,0.6273914881907693,LGP Proband,DNA strand elongation,CP:REACTOME,C2,42,115
Cohort,0.008963311658010753,0.029335579705513596,0.30554404405807967,0.7600317138801614,LonGen OPEL,DNA strand elongation,CP:REACTOME,C2,63,75
Cohort,-0.024408501721295238,0.0247961564128386,-0.9843663394806363,0.32528759926607853,LGP Offspring,Dopamine Neurotransmitter Release Cycle,CP:REACTOME,C2,22,39
Cohort,0.021145863994990247,0.06676580594709326,0.3167169735320309,0.7515376271928133,LGP Proband,Dopamine Neurotransmitter Release Cycle,CP:REACTOME,C2,22,50
Cohort,-0.017503062561726648,0.020098001146408497,-0.8708857380503452,0.38407911143669193,LonGen OPEL,Dopamine Neurotransmitter Release Cycle,CP:REACTOME,C2,34,27
Cohort,-6.483300621806345e-4,0.013466447367980488,-0.048144105454433754,0.9616156158187046,LGP Offspring,Dopamine receptors,CP:REACTOME,C2,6,10
Cohort,0.008544117216884676,0.0392636875047594,0.21760862924168772,0.8277872876052657,LGP Proband,Dopamine receptors,CP:REACTOME,C2,6,18
Cohort,0.006909597655887155,0.009976437609646652,0.6925916771339264,0.48876783353601416,LonGen OPEL,Dopamine receptors,CP:REACTOME,C2,6,9
Cohort,-0.009517607313858817,0.015702574727862663,-0.6061176258547438,0.5446401141868173,LGP Offspring,Downregulation of ERBB2:ERBB3 signaling,CP:REACTOME,C2,8,17
Cohort,0.009996456118832523,0.0420252699764336,0.23786774301362512,0.8120420997525593,LGP Proband,Downregulation of ERBB2:ERBB3 signaling,CP:REACTOME,C2,8,21
Cohort,0.03161118911785227,0.013445663367345399,2.351032318317911,0.01896441671173003,LonGen OPEL,Downregulation of ERBB2:ERBB3 signaling,CP:REACTOME,C2,6,20
Cohort,0.004387675170400863,0.022977425996351362,0.19095590476921098,0.8486174753055837,LGP Offspring,Downregulation of ERBB2 signaling,CP:REACTOME,C2,15,38
Cohort,0.019944230939685906,0.060781353970104694,0.32813074466053316,0.7428951695952177,LGP Proband,Downregulation of ERBB2 signaling,CP:REACTOME,C2,15,44
Cohort,0.01410584275516675,0.01905014675417892,0.740458482403682,0.4592401934478305,LonGen OPEL,Downregulation of ERBB2 signaling,CP:REACTOME,C2,20,31
Cohort,0.018645198634571446,0.015745153907826215,1.1841864959671018,0.2367554468184484,LGP Offspring,Downregulation of ERBB4 signaling,CP:REACTOME,C2,6,19
Cohort,0.0069343794504279094,0.037480958364615645,0.18501072952751377,0.8532656008064878,LGP Proband,Downregulation of ERBB4 signaling,CP:REACTOME,C2,6,15
Cohort,-0.007517001385223087,0.013139387577119594,-0.5720967846563026,0.5674179332380627,LonGen OPEL,Downregulation of ERBB4 signaling,CP:REACTOME,C2,13,14
Cohort,-0.052515333014707934,0.020892628012799282,-2.5135819669280424,0.01218255508410382,LGP Offspring,Downregulation of SMAD2/3:SMAD4 transcriptional activity,CP:REACTOME,C2,22,23
Cohort,-0.027380258604074482,0.06727029188084242,-0.4070185789081134,0.6840987795153881,LGP Proband,Downregulation of SMAD2/3:SMAD4 transcriptional activity,CP:REACTOME,C2,22,58
Cohort,-0.036139484704403146,0.023329974704794917,-1.5490580320678848,0.12176524085535273,LonGen OPEL,Downregulation of SMAD2/3:SMAD4 transcriptional activity,CP:REACTOME,C2,45,41
Cohort,-0.045279868742071114,0.016386794169452122,-2.7631926216831832,0.0058796308496500286,LGP Offspring,Downregulation of TGF-beta receptor signaling,CP:REACTOME,C2,15,13
Cohort,0.003839088256918528,0.039211789797894414,0.0979064785541791,0.9220300801236045,LGP Proband,Downregulation of TGF-beta receptor signaling,CP:REACTOME,C2,15,13
Cohort,-0.001794499405180015,0.013011958307086229,-0.13791155511178838,0.8903451959655888,LonGen OPEL,Downregulation of TGF-beta receptor signaling,CP:REACTOME,C2,11,15
Cohort,-0.04050336894075899,0.030471440813137893,-1.3292239506868277,0.18422251606784792,LGP Offspring,Downstream signal transduction,CP:REACTOME,C2,38,52
Cohort,-0.18591934940962812,0.07786296030555684,-2.387776533027086,0.01717235032774703,LGP Proband,Downstream signal transduction,CP:REACTOME,C2,38,62
Cohort,0.01260651708935062,0.022238611878050978,0.5668751790120936,0.5709587979596153,LonGen OPEL,Downstream signal transduction,CP:REACTOME,C2,34,45
Cohort,0.04965145420258277,0.04437041555309542,1.1190216179780386,0.2635283791378246,LGP Offspring,Downstream signaling events of B Cell Receptor (BCR),CP:REACTOME,C2,41,111
Cohort,-0.05489977462851167,0.11002516876873611,-0.49897469136272354,0.6179287971986865,LGP Proband,Downstream signaling events of B Cell Receptor (BCR),CP:REACTOME,C2,41,140
Cohort,-0.0014870542466907167,0.03614950567380967,-0.04113622631825054,0.967197610099788,LonGen OPEL,Downstream signaling events of B Cell Receptor (BCR),CP:REACTOME,C2,80,94
Cohort,0.0032856374531432192,0.027355637141846644,0.12010824080266412,0.9044330916562384,LGP Offspring,Downstream signaling of activated FGFR1,CP:REACTOME,C2,21,51
Cohort,0.14037544686056125,0.07637745196150562,1.8379173860278912,0.06643011076676647,LGP Proband,Downstream signaling of activated FGFR1,CP:REACTOME,C2,21,71
Cohort,0.020491749632605794,0.02142009574719227,0.9566600389866062,0.3390293254490747,LonGen OPEL,Downstream signaling of activated FGFR1,CP:REACTOME,C2,31,42
Cohort,-0.010574350315353715,0.020917233582801408,-0.5055329268803581,0.6133493662201214,LGP Offspring,Downstream signaling of activated FGFR2,CP:REACTOME,C2,15,27
Cohort,0.027854214071616864,0.05713235776149783,0.4875383261425305,0.6260050167062343,LGP Proband,Downstream signaling of activated FGFR2,CP:REACTOME,C2,15,39
Cohort,0.012074187145171436,0.017658827617237867,0.6837479478753776,0.49433332723018153,LonGen OPEL,Downstream signaling of activated FGFR2,CP:REACTOME,C2,19,28
Cohort,-0.007369296828843932,0.02146851555603911,-0.34326066045916914,0.7315090962318966,LGP Offspring,Downstream signaling of activated FGFR3,CP:REACTOME,C2,16,29
Cohort,0.037741684868588775,0.06259333046379875,0.602966555524904,0.5466948640352106,LGP Proband,Downstream signaling of activated FGFR3,CP:REACTOME,C2,16,47
Cohort,0.003427722936654577,0.018934353560486103,0.18103194945127965,0.8563885812606433,LonGen OPEL,Downstream signaling of activated FGFR3,CP:REACTOME,C2,26,31
Cohort,-0.007612071562447965,0.019830472332153962,-0.3838572997631242,0.701204917256139,LGP Offspring,Downstream signaling of activated FGFR4,CP:REACTOME,C2,13,24
Cohort,0.03510829846042217,0.05525093417659752,0.6354335720045234,0.5253199836420099,LGP Proband,Downstream signaling of activated FGFR4,CP:REACTOME,C2,13,37
Cohort,0.01625636823685926,0.016937529278162413,0.9597839194774781,0.33745541382543753,LonGen OPEL,Downstream signaling of activated FGFR4,CP:REACTOME,C2,18,27
Cohort,0.005420084395119723,0.021739562978331694,0.24931892147611437,0.8031898311000749,LGP Offspring,DSCAM interactions,CP:REACTOME,C2,15,31
Cohort,0.08990157336371973,0.055148893436274896,1.6301609653800564,0.10344506349962276,LGP Proband,DSCAM interactions,CP:REACTOME,C2,15,36
Cohort,-0.03007798903733117,0.015583882473671167,-1.9300703202907021,0.05395311911435411,LonGen OPEL,DSCAM interactions,CP:REACTOME,C2,23,15
Cohort,0.026602704678981754,0.03558907480615076,0.7474963826366198,0.45502391758478167,LGP Offspring,Dual Incision in GG-NER,CP:REACTOME,C2,40,92
Cohort,0.04381073698991015,0.10090611696978465,0.43417325238101123,0.6642749320258607,LGP Proband,Dual Incision in GG-NER,CP:REACTOME,C2,40,129
Cohort,-0.004367685415550226,0.03268001702987165,-0.133650034868644,0.8937130983367153,LonGen OPEL,Dual Incision in GG-NER,CP:REACTOME,C2,73,84
Cohort,0.018592709849527867,0.03972146470441077,0.46807714639644915,0.639880296207789,LGP Offspring,Dual incision in TC-NER,CP:REACTOME,C2,46,103
Cohort,-0.026915994170562254,0.11147570480470677,-0.24145166175639912,0.8092644271769901,LGP Proband,Dual incision in TC-NER,CP:REACTOME,C2,46,151
Cohort,0.04171293989845741,0.03239618320961532,1.2875880972940306,0.1982636081722341,LonGen OPEL,Dual incision in TC-NER,CP:REACTOME,C2,65,96
Cohort,-0.044238926737054006,0.017883515518442375,-2.4737265271714954,0.013615766100424758,LGP Offspring,E2F-enabled inhibition of pre-replication complex formation,CP:REACTOME,C2,18,15
Cohort,-0.06589936668085208,0.0534629568720723,-1.2326173211582363,0.21806592241404707,LGP Proband,E2F-enabled inhibition of pre-replication complex formation,CP:REACTOME,C2,18,31
Cohort,0.006217432546970565,0.015939053415498224,0.3900753943722335,0.6965851511289611,LonGen OPEL,E2F-enabled inhibition of pre-replication complex formation,CP:REACTOME,C2,15,20
Cohort,-0.07784593220266593,0.02411163814503272,-3.228562561134118,0.0013042997885706442,LGP Offspring,E2F mediated regulation of DNA replication,CP:REACTOME,C2,31,29
Cohort,-0.08295367163183383,0.0718325183754702,-1.1548205952940855,0.2484946724607798,LGP Proband,E2F mediated regulation of DNA replication,CP:REACTOME,C2,31,57
Cohort,-4.0999725556271956e-5,0.02302356882635311,-0.0017807719500611513,0.9985795964832096,LonGen OPEL,E2F mediated regulation of DNA replication,CP:REACTOME,C2,33,38
Cohort,-0.002540788045054655,0.025148327881703215,-0.10103208678550821,0.9195549464272414,LGP Offspring,E3 ubiquitin ligases ubiquitinate target proteins,CP:REACTOME,C2,18,35
Cohort,0.043305689838811064,0.06499351441590703,0.6663078651461888,0.5053986051320865,LGP Proband,E3 ubiquitin ligases ubiquitinate target proteins,CP:REACTOME,C2,18,48
Cohort,0.01918374990085052,0.015794423906090045,1.214590036009709,0.22488267417618737,LonGen OPEL,E3 ubiquitin ligases ubiquitinate target proteins,CP:REACTOME,C2,13,24
Cohort,-4.0024043405983983e-4,0.0071676297634577215,-0.055839998335343796,0.9554857701615773,LGP Offspring,Early Phase of HIV Life Cycle,CP:REACTOME,C2,3,3
Cohort,-0.037951955866329316,0.022152265401602155,-1.7132313638488845,0.08704162018010818,LGP Proband,Early Phase of HIV Life Cycle,CP:REACTOME,C2,3,6
Cohort,-0.0071708672964888726,0.0068597754159007126,-1.0453501553224411,0.29617849996769985,LonGen OPEL,Early Phase of HIV Life Cycle,CP:REACTOME,C2,4,3
Cohort,-0.07636659887117601,0.07928067472330147,-0.9632435538383609,0.3357697467759162,LGP Offspring,ECM proteoglycans,CP:REACTOME,C2,191,365
Cohort,-0.13646375961353321,0.20701848345101947,-0.6591863554339122,0.5099580693951307,LGP Proband,ECM proteoglycans,CP:REACTOME,C2,191,520
Cohort,-0.10029717139192218,0.06184323105459849,-1.621797077571424,0.10524279791260754,LonGen OPEL,ECM proteoglycans,CP:REACTOME,C2,299,317
Cohort,-0.033276043834661526,0.03501668904334248,-0.9502909824933351,0.3423040373360082,LGP Offspring,Effects of PIP2 hydrolysis,CP:REACTOME,C2,40,72
Cohort,-0.016803433341621342,0.09557561183540307,-0.17581298219214772,0.8604835484913698,LGP Proband,Effects of PIP2 hydrolysis,CP:REACTOME,C2,40,110
Cohort,0.01818929283793571,0.029506042679175025,0.6164599243521556,0.5377672693293412,LonGen OPEL,Effects of PIP2 hydrolysis,CP:REACTOME,C2,56,78
Cohort,0.02595995895901563,0.024496440016712903,1.0597441481825207,0.289639507796656,LGP Offspring,EGFR downregulation,CP:REACTOME,C2,16,41
Cohort,0.042975984126335916,0.06510488814369374,0.6601038009846992,0.5093694779977498,LGP Proband,EGFR downregulation,CP:REACTOME,C2,16,57
Cohort,-0.024461220472902175,0.020716234940131018,-1.180775393964878,0.23804465721168463,LonGen OPEL,EGFR downregulation,CP:REACTOME,C2,34,30
Cohort,-0.0019392013008995479,0.018356546423627367,-0.10564085728040502,0.9158986453693347,LGP Offspring,EGFR interacts with phospholipase C-gamma,CP:REACTOME,C2,12,22
Cohort,-0.0014539563883198593,0.04236574404345733,-0.03431915150194083,0.9726308650199076,LGP Proband,EGFR interacts with phospholipase C-gamma,CP:REACTOME,C2,12,18
Cohort,-0.0031351917214404077,0.012480701821531631,-0.2512031587864389,0.8017218750618046,LonGen OPEL,EGFR interacts with phospholipase C-gamma,CP:REACTOME,C2,10,14
Cohort,0.014098663715705687,0.01750604027552524,0.8053599496978583,0.4208951753513306,LGP Offspring,EGFR Transactivation by Gastrin,CP:REACTOME,C2,8,23
Cohort,0.039949541795478515,0.04794105593868659,0.8333054208603855,0.4049110796682982,LGP Proband,EGFR Transactivation by Gastrin,CP:REACTOME,C2,8,28
Cohort,-0.02864453897138768,0.013717802329880577,-2.088128862229862,0.03710351365091568,LonGen OPEL,EGFR Transactivation by Gastrin,CP:REACTOME,C2,18,11
Cohort,0.0314801024920886,0.04159284135915513,0.7568634761029477,0.44939536234839506,LGP Offspring,EGR2 and SOX10-mediated initiation of Schwann cell myelination,CP:REACTOME,C2,45,117
Cohort,-0.08855598143743865,0.11326589018500552,-0.7818415702449665,0.434529587625055,LGP Proband,EGR2 and SOX10-mediated initiation of Schwann cell myelination,CP:REACTOME,C2,45,156
Cohort,-0.04046443491852603,0.03461330374454684,-1.1690428402085429,0.24273633308353915,LonGen OPEL,EGR2 and SOX10-mediated initiation of Schwann cell myelination,CP:REACTOME,C2,87,86
Cohort,0.02353154023932431,0.017292306484635023,1.3608098063860434,0.17402729941906372,LGP Offspring,Eicosanoid ligand-binding receptors,CP:REACTOME,C2,8,23
Cohort,-0.033962818506864535,0.0452550931174048,-0.750475055233124,0.45318031423842153,LGP Proband,Eicosanoid ligand-binding receptors,CP:REACTOME,C2,8,29
Cohort,-0.004047407212598013,0.015338479473200401,-0.2638727795456973,0.7919462484532731,LonGen OPEL,Eicosanoid ligand-binding receptors,CP:REACTOME,C2,16,21
Cohort,-0.030593051959771994,0.017603929927453812,-1.7378535409903721,0.08269200713076595,LGP Offspring,Eicosanoids,CP:REACTOME,C2,14,18
Cohort,0.027052104909210388,0.05709798367698936,0.473783891603732,0.6357780224178,LGP Proband,Eicosanoids,CP:REACTOME,C2,14,41
Cohort,-0.009986009887784341,0.017772930025904073,-0.5618662692774752,0.5743653028410465,LonGen OPEL,Eicosanoids,CP:REACTOME,C2,23,23
Cohort,-0.0027805535267998328,0.04705473116645727,-0.059091901236531484,0.9528963729493127,LGP Offspring,Elastic fibre formation,CP:REACTOME,C2,68,148
Cohort,-0.03427710570550938,0.12595899520972592,-0.27212908175741524,0.7855901233718359,LGP Proband,Elastic fibre formation,CP:REACTOME,C2,68,187
Cohort,0.02591192354320508,0.04057640385779537,0.638595860639015,0.5232695645513492,LonGen OPEL,Elastic fibre formation,CP:REACTOME,C2,109,139
Cohort,-0.019622950131139932,0.01139489514720705,-1.722082553427411,0.08551198962708562,LGP Offspring,Electric Transmission Across Gap Junctions,CP:REACTOME,C2,7,6
Cohort,-0.031524385973636604,0.03770322623135,-0.8361190572976556,0.4033274140372788,LGP Proband,Electric Transmission Across Gap Junctions,CP:REACTOME,C2,7,17
Cohort,0.010027059176888202,0.014173767306399666,0.7074378293455429,0.47950149820953003,LonGen OPEL,Electric Transmission Across Gap Junctions,CP:REACTOME,C2,10,19
Cohort,0.015656234068015015,0.022282008053297366,0.7026401763506298,0.4825218993486049,LGP Offspring,Elevation of cytosolic Ca2+ levels,CP:REACTOME,C2,15,37
Cohort,-0.1011536629078766,0.06532869249022177,-1.5483803372157956,0.12191011410973701,LGP Proband,Elevation of cytosolic Ca2+ levels,CP:REACTOME,C2,15,56
Cohort,0.035147644158981944,0.020146037855544717,1.7446430117427976,0.08143296985936707,LonGen OPEL,Elevation of cytosolic Ca2+ levels,CP:REACTOME,C2,23,40
Cohort,-0.04009612580573063,0.026343544113349122,-1.5220475131670925,0.1284647913698079,LGP Offspring,Endogenous sterols,CP:REACTOME,C2,27,39
Cohort,0.004238516867836638,0.07916666205172512,0.053539163556843135,0.9573151489362008,LGP Proband,Endogenous sterols,CP:REACTOME,C2,27,77
Cohort,-0.01049512099147738,0.024799199410342837,-0.423204024364603,0.6722607243308423,LonGen OPEL,Endogenous sterols,CP:REACTOME,C2,47,47
Cohort,-0.05940743905629038,0.023352569633512104,-2.5439358489713157,0.011182578150948785,LGP Offspring,Endosomal Sorting Complex Required For Transport (ESCRT),CP:REACTOME,C2,25,29
Cohort,-0.05422915291634811,0.05824063113565836,-0.9311223429229945,0.3520597300120627,LGP Proband,Endosomal Sorting Complex Required For Transport (ESCRT),CP:REACTOME,C2,25,35
Cohort,-0.01737755147802524,0.02292778241619725,-0.7579255229563295,0.4487198920777873,LonGen OPEL,Endosomal Sorting Complex Required For Transport (ESCRT),CP:REACTOME,C2,36,42
Cohort,-0.005383731876254285,0.009549953847622089,-0.5637442821354387,0.5731151369093115,LGP Offspring,Endosomal/Vacuolar pathway,CP:REACTOME,C2,4,5
Cohort,-0.01172438187696956,0.02609537929243216,-0.4492895751996106,0.6533395073909025,LGP Proband,Endosomal/Vacuolar pathway,CP:REACTOME,C2,4,5
Cohort,0.0018762864975551499,0.008613840745303683,0.21782228776148577,0.8276234032227948,LonGen OPEL,Endosomal/Vacuolar pathway,CP:REACTOME,C2,4,7
Cohort,-0.054265737108840945,0.025949778643754483,-2.091183044519012,0.03688440016958306,LGP Offspring,Energy dependent regulation of mTOR by LKB1-AMPK,CP:REACTOME,C2,32,35
Cohort,-0.14845769392892366,0.07072693169532211,-2.0990263591307845,0.036114667287075713,LGP Proband,Energy dependent regulation of mTOR by LKB1-AMPK,CP:REACTOME,C2,32,51
Cohort,-0.016355666776292424,0.01996573686994034,-0.8191867338949508,0.41292507459163685,LonGen OPEL,Energy dependent regulation of mTOR by LKB1-AMPK,CP:REACTOME,C2,28,27
Cohort,-0.011682697561048942,0.016993403014340012,-0.6874842873549465,0.4920133966619209,LGP Offspring,eNOS activation,CP:REACTOME,C2,11,18
Cohort,-0.029907761500483958,0.044987558175272876,-0.6648007296586852,0.506361733762566,LGP Proband,eNOS activation,CP:REACTOME,C2,11,23
Cohort,0.003481600871144457,0.01373463123573867,0.2534906697811469,0.7999545264033183,LonGen OPEL,eNOS activation,CP:REACTOME,C2,12,17
Cohort,-0.004540885010519539,0.04695543046974366,-0.0967062800850163,0.9229883152482556,LGP Offspring,EPH-ephrin mediated repulsion of cells,CP:REACTOME,C2,67,139
Cohort,0.06153217049776838,0.13014849513500018,0.4727843409479488,0.6364907480408107,LGP Proband,EPH-ephrin mediated repulsion of cells,CP:REACTOME,C2,67,184
Cohort,0.004095045866162938,0.040567777128205605,0.1009433140302817,0.9196208785056954,LonGen OPEL,EPH-ephrin mediated repulsion of cells,CP:REACTOME,C2,109,125
Cohort,-0.021557259291944166,0.054677535964929,-0.3942617184829126,0.6935121662018231,LGP Offspring,EPH-Ephrin signaling,CP:REACTOME,C2,99,197
Cohort,0.034107864505939375,0.1563153816163469,0.21819902912467123,0.8273274193167254,LGP Proband,EPH-Ephrin signaling,CP:REACTOME,C2,99,282
Cohort,-0.025744348327328796,0.047766574584643444,-0.5389615761898361,0.5900640669528078,LonGen OPEL,EPH-Ephrin signaling,CP:REACTOME,C2,161,172
Cohort,-3.353414625948822e-5,0.03548865227225272,-9.449258879212874e-4,0.9992463371082149,LGP Offspring,EPHA-mediated growth cone collapse,CP:REACTOME,C2,40,81
Cohort,-0.0907426115725176,0.09347904724791832,-0.9707267483359844,0.33196580574792567,LGP Proband,EPHA-mediated growth cone collapse,CP:REACTOME,C2,40,105
Cohort,-0.009384412963472399,0.027685067599237414,-0.33897020225194946,0.7347215782393064,LonGen OPEL,EPHA-mediated growth cone collapse,CP:REACTOME,C2,58,58
Cohort,0.010653128455437281,0.021981492849150158,0.4846408079990413,0.6280881525931051,LGP Offspring,EPHB-mediated forward signaling,CP:REACTOME,C2,16,35
Cohort,-0.05101453213930705,0.06817411567493487,-0.7482976733068682,0.45449158927143773,LGP Proband,EPHB-mediated forward signaling,CP:REACTOME,C2,16,65
Cohort,0.01294536869262783,0.02331495005294371,0.5552389631215774,0.5788872190686443,LonGen OPEL,EPHB-mediated forward signaling,CP:REACTOME,C2,34,46
Cohort,-0.01031154924319433,0.015072244309560622,-0.6841415937408546,0.49412021697080977,LGP Offspring,Ephrin signaling,CP:REACTOME,C2,9,14
Cohort,-0.045834536036727366,0.04372289274148212,-1.0482960564327397,0.2948059172478708,LGP Proband,Ephrin signaling,CP:REACTOME,C2,9,23
Cohort,0.004242593710070849,0.01460428776269429,0.2905032945809436,0.7715068976153043,LonGen OPEL,Ephrin signaling,CP:REACTOME,C2,15,18
Cohort,-0.08612819835308086,0.05266966074564287,-1.6352525748935238,0.10246162645351349,LGP Offspring,Epigenetic regulation of gene expression,CP:REACTOME,C2,109,183
Cohort,-0.010502467304217012,0.17021226162819525,-0.06170217823177848,0.950814788644249,LGP Proband,Epigenetic regulation of gene expression,CP:REACTOME,C2,109,358
Cohort,-0.012428801476654974,0.049293420223404126,-0.2521391581336017,0.800998591308324,LonGen OPEL,Epigenetic regulation of gene expression,CP:REACTOME,C2,165,194
Cohort,-0.003797329784590198,0.023530513413857805,-0.1613789600678173,0.8718431548537122,LGP Offspring,ER Quality Control Compartment (ERQC),CP:REACTOME,C2,20,36
Cohort,-0.07493514872528279,0.0750125702399307,-0.9989678861236153,0.31809999463012495,LGP Proband,ER Quality Control Compartment (ERQC),CP:REACTOME,C2,20,65
Cohort,-0.0075266368996364805,0.02148797176273486,-0.3502720956051059,0.7262271698057199,LonGen OPEL,ER Quality Control Compartment (ERQC),CP:REACTOME,C2,35,37
Cohort,-0.04927494812099176,0.0743972935174597,-0.6623217833781523,0.5079907498411853,LGP Offspring,ER to Golgi Anterograde Transport,CP:REACTOME,C2,195,381
Cohort,-0.47658988403735275,0.20855110392188753,-2.2852426818889375,0.022548811444133766,LGP Proband,ER to Golgi Anterograde Transport,CP:REACTOME,C2,195,499
Cohort,-0.06729121690464482,0.06351003625647524,-1.0595367420812025,0.2896768010551588,LonGen OPEL,ER to Golgi Anterograde Transport,CP:REACTOME,C2,307,334
Cohort,0.0075856978369971345,0.01727456297593924,0.4391253108725716,0.6607110645807015,LGP Offspring,ERBB2 Activates PTK6 Signaling,CP:REACTOME,C2,8,22
Cohort,0.0037840113583560075,0.04192847752795114,0.09024919533110735,0.9281108609362869,LGP Proband,ERBB2 Activates PTK6 Signaling,CP:REACTOME,C2,8,21
Cohort,0.011215887933628928,0.015085991568986256,0.7434637545924739,0.45742033474579313,LonGen OPEL,ERBB2 Activates PTK6 Signaling,CP:REACTOME,C2,12,19
Cohort,5.332836653338122e-4,0.024460477274327087,0.021801850362647226,0.9826124516939689,LGP Offspring,ERBB2 Regulates Cell Motility,CP:REACTOME,C2,18,41
Cohort,-0.03931038459026122,0.05905917985922481,-0.6656100657672964,0.5058444107244063,LGP Proband,ERBB2 Regulates Cell Motility,CP:REACTOME,C2,18,40
Cohort,0.013052852574771049,0.02067946966991309,0.6311986130747765,0.5280918685712346,LonGen OPEL,ERBB2 Regulates Cell Motility,CP:REACTOME,C2,23,34
Cohort,-9.443283003329993e-4,0.023670157873458227,-0.03989531060085964,0.9681883690340518,LGP Offspring,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,CP:REACTOME,C2,17,38
Cohort,0.06944627196608237,0.06574689806404785,1.0562668964006598,0.29115216479185463,LGP Proband,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,CP:REACTOME,C2,17,54
Cohort,-0.006274365140717819,0.020124715842533485,-0.3117740985667475,0.7552938518067595,LonGen OPEL,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,CP:REACTOME,C2,28,32
Cohort,-0.011014288585129072,0.009611694187849318,-1.1459258242998256,0.25223133016485105,LGP Offspring,ERK/MAPK targets,CP:REACTOME,C2,5,4
Cohort,-0.03188762159442601,0.0323693690532362,-0.985117181060345,0.32485221340635484,LGP Proband,ERK/MAPK targets,CP:REACTOME,C2,5,12
Cohort,-0.024715123309444295,0.010454902230303115,-2.363974599189316,0.018319289724138058,LonGen OPEL,ERK/MAPK targets,CP:REACTOME,C2,12,5
Cohort,-0.013777949087592403,0.00904922317044276,-1.5225560059779448,0.1283374515805291,LGP Offspring,ERKs are inactivated,CP:REACTOME,C2,5,3
Cohort,-0.0369896904408426,0.0272345541853383,-1.3581896802539168,0.17477079455502123,LGP Proband,ERKs are inactivated,CP:REACTOME,C2,5,7
Cohort,-0.02911383024370052,0.009832449206553247,-2.9609947259423817,0.003157605907779598,LonGen OPEL,ERKs are inactivated,CP:REACTOME,C2,12,3
Cohort,0.013705696329407121,0.010550020238717105,1.2991156433149886,0.1943471533805114,LGP Offspring,Erythrocytes take up carbon dioxide and release oxygen,CP:REACTOME,C2,1,10
Cohort,-0.020902907170742824,0.029285539430626853,-0.7137620674619549,0.47557401124603693,LGP Proband,Erythrocytes take up carbon dioxide and release oxygen,CP:REACTOME,C2,1,13
Cohort,0.01126469346535766,0.008158371366579507,1.380752721248152,0.16774255601595905,LonGen OPEL,Erythrocytes take up carbon dioxide and release oxygen,CP:REACTOME,C2,2,8
Cohort,0.0073484435214758986,0.009062396627441885,0.8108719827185716,0.41772457475871316,LGP Offspring,Erythrocytes take up oxygen and release carbon dioxide,CP:REACTOME,C2,1,7
Cohort,-0.011292902413247721,0.0234707872926899,-0.48114714996224073,0.6305381248589393,LGP Proband,Erythrocytes take up oxygen and release carbon dioxide,CP:REACTOME,C2,1,8
Cohort,0.008575948115983391,0.0077538500433585525,1.1060244998326987,0.26905007150348675,LonGen OPEL,Erythrocytes take up oxygen and release carbon dioxide,CP:REACTOME,C2,2,7
Cohort,-0.0013827407015458999,0.012838531845872227,-0.1077024007219697,0.9142637222051444,LGP Offspring,Erythropoietin activates Phosphoinositide-3-kinase (PI3K),CP:REACTOME,C2,5,12
Cohort,0.09696172815198054,0.03986440872918496,2.432288129762083,0.015213182949115922,LGP Proband,Erythropoietin activates Phosphoinositide-3-kinase (PI3K),CP:REACTOME,C2,5,20
Cohort,-0.01189248889074832,0.014227332778168716,-0.8358902596976489,0.40346748069916394,LonGen OPEL,Erythropoietin activates Phosphoinositide-3-kinase (PI3K),CP:REACTOME,C2,16,13
Cohort,-0.01641594089726639,0.017504452776483343,-0.9378151437741983,0.3486743505877228,LGP Offspring,Erythropoietin activates Phospholipase C gamma (PLCG),CP:REACTOME,C2,12,17
Cohort,4.7220296310692957e-4,0.045765441230337434,0.01031789381709077,0.9917701254244379,LGP Proband,Erythropoietin activates Phospholipase C gamma (PLCG),CP:REACTOME,C2,12,19
Cohort,-0.008340854234403526,0.015068132281560927,-0.5535426739391145,0.5800473113732754,LonGen OPEL,Erythropoietin activates Phospholipase C gamma (PLCG),CP:REACTOME,C2,16,17
Cohort,0.012447621069120007,0.01443740782903134,0.8621783921688362,0.3888951002599291,LGP Offspring,Erythropoietin activates RAS,CP:REACTOME,C2,6,15
Cohort,-0.027248953527271406,0.04121731565482128,-0.6611045162540573,0.5087278711460428,LGP Proband,Erythropoietin activates RAS,CP:REACTOME,C2,6,22
Cohort,-0.0127229891484994,0.014626134205058377,-0.8698805145722796,0.3846279370992185,LonGen OPEL,Erythropoietin activates RAS,CP:REACTOME,C2,17,14
Cohort,0.004896832467632917,0.011021853196599617,0.4442839493764672,0.6569794950920311,LGP Offspring,Erythropoietin activates STAT5,CP:REACTOME,C2,3,9
Cohort,0.022011218794787527,0.03323271563041736,0.6623358451826614,0.5079389894590229,LGP Proband,Erythropoietin activates STAT5,CP:REACTOME,C2,3,15
Cohort,-0.01375448490838009,0.011757390137501007,-1.1698586801597417,0.2424079983283137,LonGen OPEL,Erythropoietin activates STAT5,CP:REACTOME,C2,11,8
Cohort,-0.008145541766902688,0.06395931455261007,-0.1273550510020324,0.8986972639247237,LGP Offspring,ESR-mediated signaling,CP:REACTOME,C2,142,281
Cohort,-0.14048972315565625,0.1787179998413808,-0.7860972217703106,0.43203381761388315,LGP Proband,ESR-mediated signaling,CP:REACTOME,C2,142,343
Cohort,-0.07657599538274652,0.05748523279149088,-1.33209855234476,0.18320906536756654,LonGen OPEL,ESR-mediated signaling,CP:REACTOME,C2,231,240
Cohort,0.019726319831087035,0.014760435893714912,1.3364320656334159,0.18185773479119458,LGP Offspring,Establishment of Sister Chromatid Cohesion,CP:REACTOME,C2,5,17
Cohort,-0.08706855306269995,0.04342560693552113,-2.0050048624992254,0.0452852635591798,LGP Proband,Establishment of Sister Chromatid Cohesion,CP:REACTOME,C2,5,27
Cohort,-0.0061158876500677795,0.017324666363746244,-0.3530161863818597,0.7241697669697823,LonGen OPEL,Establishment of Sister Chromatid Cohesion,CP:REACTOME,C2,22,21
Cohort,0.0061630637672032956,0.011482794912995111,0.5367215746602371,0.5916365406876347,LGP Offspring,Estrogen biosynthesis,CP:REACTOME,C2,3,8
Cohort,-0.01072927992495448,0.02917833028563699,-0.3677139788302404,0.7131798131897901,LGP Proband,Estrogen biosynthesis,CP:REACTOME,C2,3,11
Cohort,0.01400587402219059,0.007291356993069816,1.9208871593453305,0.05510284271678237,LonGen OPEL,Estrogen biosynthesis,CP:REACTOME,C2,1,7
Cohort,-0.03431620736140573,0.052955903224688156,-0.6480147683593365,0.5171954287604472,LGP Offspring,Estrogen-dependent gene expression,CP:REACTOME,C2,99,174
Cohort,-0.07555385986613276,0.14930868942341718,-0.506024533186232,0.6129731521594641,LGP Proband,Estrogen-dependent gene expression,CP:REACTOME,C2,99,240
Cohort,0.008078729489446908,0.04468877634727289,0.1807775945053351,0.8565881665783608,LonGen OPEL,Estrogen-dependent gene expression,CP:REACTOME,C2,138,160
Cohort,-0.0020553264992605245,0.022826639544419006,-0.0900406954453811,0.9282815467555282,LGP Offspring,Estrogen-dependent nuclear events downstream of ESR-membrane signaling,CP:REACTOME,C2,17,35
Cohort,0.021238213289926974,0.059216040891246095,0.358656420967627,0.7199429029311177,LGP Proband,Estrogen-dependent nuclear events downstream of ESR-membrane signaling,CP:REACTOME,C2,17,39
Cohort,-0.035656022216530005,0.018024461234452102,-1.9782018309860376,0.04825035651406054,LonGen OPEL,Estrogen-dependent nuclear events downstream of ESR-membrane signaling,CP:REACTOME,C2,28,21
Cohort,0,0,NA,NA,LGP Offspring,Estrogen-stimulated signaling through PRKCZ,CP:REACTOME,C2,0,0
Cohort,6.974963352640496e-4,0.007901741349581975,0.08827121825506845,0.9296823049006238,LGP Proband,Estrogen-stimulated signaling through PRKCZ,CP:REACTOME,C2,0,1
Cohort,8.223988290166164e-5,0.0036671446655759657,0.022426135427287528,0.9821136528716061,LonGen OPEL,Estrogen-stimulated signaling through PRKCZ,CP:REACTOME,C2,1,1
Cohort,-0.005232444053182676,0.015728659984334564,-0.33266941102383085,0.7394869783954421,LGP Offspring,Ethanol oxidation,CP:REACTOME,C2,9,16
Cohort,0.06934470615705188,0.05365993593995381,1.2922994584758642,0.19661140180247857,LGP Proband,Ethanol oxidation,CP:REACTOME,C2,9,38
Cohort,0.0018273671321417256,0.01504759996536973,0.12143910898397052,0.9033738903077577,LonGen OPEL,Ethanol oxidation,CP:REACTOME,C2,15,18
Cohort,-0.0038147444674241937,0.02123089998813953,-0.17967888641344784,0.857458513827567,LGP Offspring,Eukaryotic Translation Elongation,CP:REACTOME,C2,15,33
Cohort,0.011373756316063343,0.06224245976630829,0.18273307897481156,0.8550518692328064,LGP Proband,Eukaryotic Translation Elongation,CP:REACTOME,C2,15,43
Cohort,-0.018575629312227886,0.019450138295079744,-0.9550384182577725,0.3398482078395866,LonGen OPEL,Eukaryotic Translation Elongation,CP:REACTOME,C2,31,30
Cohort,-0.009682473257672991,0.026462246668493096,-0.36589762687086175,0.7145559391709391,LGP Offspring,Eukaryotic Translation Initiation,CP:REACTOME,C2,23,46
Cohort,0.1067932517948765,0.0770138021067777,1.3866767887502858,0.16591087298457477,LGP Proband,Eukaryotic Translation Initiation,CP:REACTOME,C2,23,71
Cohort,-0.0013017481985258424,0.023623973867549986,-0.05510284619447241,0.9560703557186863,LonGen OPEL,Eukaryotic Translation Initiation,CP:REACTOME,C2,38,45
Cohort,-0.03885974531739098,0.03757815861333954,-1.034104563697182,0.30145707804806887,LGP Offspring,Export of Viral Ribonucleoproteins from Nucleus,CP:REACTOME,C2,55,95
Cohort,-0.25386109669596246,0.10259866072034039,-2.474311993096358,0.013547254308426487,LGP Proband,Export of Viral Ribonucleoproteins from Nucleus,CP:REACTOME,C2,55,121
Cohort,0.002070257070900561,0.03557512415243127,0.05819395210063029,0.9536087433442365,LonGen OPEL,Export of Viral Ribonucleoproteins from Nucleus,CP:REACTOME,C2,80,95
Cohort,-0.0652362841078579,0.0404727165918999,-1.6118582986572763,0.10745952925723828,LGP Offspring,Extension of Telomeres,CP:REACTOME,C2,58,97
Cohort,-0.09499467795294392,0.11942378298275552,-0.7954418758168204,0.42658283376771045,LGP Proband,Extension of Telomeres,CP:REACTOME,C2,58,155
Cohort,-0.05392608955871126,0.035740450162672806,-1.5088251354772098,0.13174027386734471,LonGen OPEL,Extension of Telomeres,CP:REACTOME,C2,96,89
Cohort,0.022765574328786124,0.03896845258533689,0.5842052434320266,0.5592771306981718,LGP Offspring,Extra-nuclear estrogen signaling,CP:REACTOME,C2,49,117
Cohort,-0.08536908921567221,0.09979121315952658,-0.8554770155885458,0.39253281900251014,LGP Proband,Extra-nuclear estrogen signaling,CP:REACTOME,C2,49,112
Cohort,-0.08536854486002096,0.035888138678169146,-2.3787398289326966,0.017606872202344158,LonGen OPEL,Extra-nuclear estrogen signaling,CP:REACTOME,C2,97,82
Cohort,-0.18143684899111978,0.1285150520949646,-1.4117945410553876,0.15847058829991356,LGP Offspring,Extracellular matrix organization,CP:REACTOME,C2,526,1027
Cohort,-0.4939188925089096,0.34440529996087893,-1.4341210561074813,0.15191254321792305,LGP Proband,Extracellular matrix organization,CP:REACTOME,C2,526,1395
Cohort,-0.22105456170228585,0.10865395045057936,-2.0344825087867493,0.042233961004302004,LonGen OPEL,Extracellular matrix organization,CP:REACTOME,C2,861,955
Cohort,0.010907880368293878,0.01103106045795936,0.9888333410794968,0.32309848458997315,LGP Offspring,Extrinsic Pathway of Fibrin Clot Formation,CP:REACTOME,C2,2,10
Cohort,-0.028404201891470488,0.026017273627376932,-1.0917439812595078,0.2752609309178344,LGP Proband,Extrinsic Pathway of Fibrin Clot Formation,CP:REACTOME,C2,2,10
Cohort,-0.010132234936331511,0.009590339005610894,-1.0565043561446137,0.29105838574072224,LonGen OPEL,Extrinsic Pathway of Fibrin Clot Formation,CP:REACTOME,C2,9,5
Cohort,0.019175296738250868,0.06406612192251811,0.29930478329001353,0.7647995011607636,LGP Offspring,Factors involved in megakaryocyte development and platelet production,CP:REACTOME,C2,135,290
Cohort,0.3606737629573111,0.1873933582891758,1.9246880799304416,0.05460828043304873,LGP Proband,Factors involved in megakaryocyte development and platelet production,CP:REACTOME,C2,135,451
Cohort,-0.08632809505053972,0.05966679961135882,-1.4468363581227737,0.14833642822110707,LonGen OPEL,Factors involved in megakaryocyte development and platelet production,CP:REACTOME,C2,253,264
Cohort,-4.2230545788685554e-4,0.0339262143815267,-0.01244776246290558,0.9900720516293489,LGP Offspring,Fanconi Anemia Pathway,CP:REACTOME,C2,33,75
Cohort,-0.06938742708180706,0.08968725926340941,-0.7736598001954524,0.4393512335740183,LGP Proband,Fanconi Anemia Pathway,CP:REACTOME,C2,33,97
Cohort,0.0037951818647355227,0.029603939007341054,0.1281985435720027,0.8980242337347333,LonGen OPEL,Fanconi Anemia Pathway,CP:REACTOME,C2,66,81
Cohort,-6.053352352111943e-4,0.0063680858063859865,-0.09505764426166455,0.9242972104723408,LGP Offspring,FasL/ CD95L signaling,CP:REACTOME,C2,2,2
Cohort,-0.039225899488585805,0.019219837557864102,-2.0409069208046406,0.04157445503787831,LGP Proband,FasL/ CD95L signaling,CP:REACTOME,C2,2,4
Cohort,-0.0013868973652392562,0.006250288069503371,-0.2218933511250874,0.8244538209791151,LonGen OPEL,FasL/ CD95L signaling,CP:REACTOME,C2,4,2
Cohort,0.04903818870583006,0.07616375671639106,0.6438520212235886,0.5198897720597897,LGP Offspring,Fatty acid metabolism,CP:REACTOME,C2,182,405
Cohort,-0.12374673180638174,0.21980554388270815,-0.5629827602183457,0.5735979334119541,LGP Proband,Fatty acid metabolism,CP:REACTOME,C2,182,566
Cohort,-0.1453585718415666,0.06917108211068508,-2.101435562464803,0.03591653929212168,LonGen OPEL,Fatty acid metabolism,CP:REACTOME,C2,352,369
Cohort,-0.0458198669927417,0.02138576064957872,-2.1425409057706024,0.032506478968862336,LGP Offspring,Fatty acids,CP:REACTOME,C2,21,24
Cohort,-0.003081044123500826,0.06856368693639422,-0.04493696679933617,0.964168308321981,LGP Proband,Fatty acids,CP:REACTOME,C2,21,51
Cohort,0.0013795140421082614,0.022242958673968322,0.06202025829067213,0.9505622683953411,LonGen OPEL,Fatty acids,CP:REACTOME,C2,32,39
Cohort,-0.00976259414317784,0.012245553592964056,-0.7972358349554035,0.4255940034708302,LGP Offspring,Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion,CP:REACTOME,C2,5,10
Cohort,0.07967411964957784,0.04186658835907999,1.9030478186144866,0.05737839809243892,LGP Proband,Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion,CP:REACTOME,C2,5,22
Cohort,0.006211290445885213,0.013722646063797642,0.4526306673660782,0.6509380463094357,LonGen OPEL,Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion,CP:REACTOME,C2,12,17
Cohort,-0.02332711021118789,0.03088935387652981,-0.7551828472822858,0.45040230579832985,LGP Offspring,Fatty acyl-CoA biosynthesis,CP:REACTOME,C2,36,65
Cohort,-0.046818800383561954,0.08450000303388559,-0.5540686236991851,0.5796804085201556,LGP Proband,Fatty acyl-CoA biosynthesis,CP:REACTOME,C2,36,77
Cohort,-0.040174468706751364,0.029038510573672113,-1.3834893013822724,0.16690274601532865,LonGen OPEL,Fatty acyl-CoA biosynthesis,CP:REACTOME,C2,59,55
Cohort,-0.017587606044013725,0.007853763578741239,-2.2393857247779003,0.025455242271842853,LGP Offspring,FBXW7 Mutants and NOTCH1 in Cancer,CP:REACTOME,C2,4,2
Cohort,0.0047190665929424756,0.020862699048132368,0.22619636040644162,0.8211041245479792,LGP Proband,FBXW7 Mutants and NOTCH1 in Cancer,CP:REACTOME,C2,4,3
Cohort,0.007213257791092122,0.01000720655850806,0.7208063258132169,0.47124031262275723,LonGen OPEL,FBXW7 Mutants and NOTCH1 in Cancer,CP:REACTOME,C2,5,10
Cohort,-0.011953099789095827,0.05816963435283048,-0.20548693355357495,0.8372535682417661,LGP Offspring,Fc epsilon receptor (FCERI) signaling,CP:REACTOME,C2,99,194
Cohort,-0.19778588010310258,0.15887060202538233,-1.2449495223257405,0.21350000338176103,LGP Proband,Fc epsilon receptor (FCERI) signaling,CP:REACTOME,C2,99,272
Cohort,8.768366669815841e-5,0.04937368971725937,0.0017759188588149443,0.9985834674677045,LonGen OPEL,Fc epsilon receptor (FCERI) signaling,CP:REACTOME,C2,155,183
Cohort,-0.0655167325086487,0.036310474989467816,-1.8043479884978764,0.0716217343951621,LGP Offspring,FCERI mediated Ca+2 mobilization,CP:REACTOME,C2,52,70
Cohort,-0.05721824431410145,0.10529981202404923,-0.5433841069064157,0.5870105704300084,LGP Proband,FCERI mediated Ca+2 mobilization,CP:REACTOME,C2,52,118
Cohort,0.018220571207562136,0.030217182077082214,0.6029871071724211,0.5466890226704705,LonGen OPEL,FCERI mediated Ca+2 mobilization,CP:REACTOME,C2,60,76
Cohort,-0.052023403982655134,0.030102807559808153,-1.7281910957738813,0.08441062376589778,LGP Offspring,FCERI mediated MAPK activation,CP:REACTOME,C2,40,54
Cohort,0.020686825690771293,0.08693986136409537,0.23794408417718718,0.8119829076225997,LGP Proband,FCERI mediated MAPK activation,CP:REACTOME,C2,40,86
Cohort,-0.021591057713580594,0.026041569112643107,-0.8290997220708255,0.4072965270468747,LonGen OPEL,FCERI mediated MAPK activation,CP:REACTOME,C2,50,54
Cohort,0.05386030759789405,0.04090076181363917,1.3168534083375742,0.18833400051980645,LGP Offspring,FCERI mediated NF-kB activation,CP:REACTOME,C2,39,108
Cohort,-0.07455550195200744,0.10508974170801462,-0.709446048113386,0.47824600577575305,LGP Proband,FCERI mediated NF-kB activation,CP:REACTOME,C2,39,128
Cohort,0.002550312056126253,0.03441235353981332,0.07411036426717148,0.9409411877557663,LonGen OPEL,FCERI mediated NF-kB activation,CP:REACTOME,C2,73,89
Cohort,-0.04559093241420601,0.05031843096747552,-0.9060483710963635,0.3652330743482556,LGP Offspring,Fcgamma receptor (FCGR) dependent phagocytosis,CP:REACTOME,C2,86,161
Cohort,0.007691246466364253,0.14113960589688163,0.05449389218206812,0.9565547255631377,LGP Proband,Fcgamma receptor (FCGR) dependent phagocytosis,CP:REACTOME,C2,86,215
Cohort,0.014975383993874,0.04240924056619674,0.3531160613569316,0.724094922481451,LonGen OPEL,Fcgamma receptor (FCGR) dependent phagocytosis,CP:REACTOME,C2,120,154
Cohort,0.00659647894604775,0.013131360363515135,0.5023454359211522,0.6155881466755968,LGP Offspring,FCGR activation,CP:REACTOME,C2,4,11
Cohort,0.03696835416451822,0.03418411409908683,1.0814483609948449,0.279810319280159,LGP Proband,FCGR activation,CP:REACTOME,C2,4,13
Cohort,9.189667363943039e-4,0.006324269648883563,0.14530796240741115,0.8845045138493102,LonGen OPEL,FCGR activation,CP:REACTOME,C2,3,3
Cohort,-7.705814085596437e-4,0.030099103316292914,-0.025601473919740363,0.9795827658841254,LGP Offspring,FCGR3A-mediated IL10 synthesis,CP:REACTOME,C2,28,54
Cohort,0.0534582149369666,0.08173351175933881,0.6540550355204638,0.5132566527870212,LGP Proband,FCGR3A-mediated IL10 synthesis,CP:REACTOME,C2,28,77
Cohort,-0.005745022517411914,0.025173327343469977,-0.22821863947604795,0.8195348837034092,LonGen OPEL,FCGR3A-mediated IL10 synthesis,CP:REACTOME,C2,45,50
Cohort,-0.005253044690459291,0.018360799658010706,-0.2861010842829724,0.7748883530479629,LGP Offspring,Fertilization,CP:REACTOME,C2,10,22
Cohort,0.05027608930316004,0.05211016914786483,0.9648038017397236,0.3349227595255856,LGP Proband,Fertilization,CP:REACTOME,C2,10,36
Cohort,0.03055636589860794,0.016789744733280685,1.8199422554673517,0.06914325216574821,LonGen OPEL,Fertilization,CP:REACTOME,C2,14,29
Cohort,-0.004348484469668916,0.022911124454269783,-0.18979795070069205,0.8495244374897231,LGP Offspring,FGFR1 ligand binding and activation,CP:REACTOME,C2,13,33
Cohort,0.12268218630002395,0.06382283340186048,1.9222303329524018,0.05491715648208137,LGP Proband,FGFR1 ligand binding and activation,CP:REACTOME,C2,13,42
Cohort,-0.004010790423554144,0.015578741526543543,-0.2574527869738666,0.7968957959863368,LonGen OPEL,FGFR1 ligand binding and activation,CP:REACTOME,C2,15,19
Cohort,0.012723001369632957,0.0181278341767133,0.7018489492791535,0.4830149319834357,LGP Offspring,FGFR1 mutant receptor activation,CP:REACTOME,C2,9,24
Cohort,0.08743043474438225,0.05786692831862447,1.5108877779545586,0.1311958260178248,LGP Proband,FGFR1 mutant receptor activation,CP:REACTOME,C2,9,46
Cohort,-0.010919351590169876,0.015615524213348447,-0.6992625697980607,0.4845922273597142,LonGen OPEL,FGFR1 mutant receptor activation,CP:REACTOME,C2,20,16
Cohort,-3.074017824873108e-4,0.008404782579285938,-0.03657462636153371,0.9708349727105865,LGP Offspring,FGFR1b ligand binding and activation,CP:REACTOME,C2,2,5
Cohort,0.010180509126706294,0.024801925895894306,0.410472524167632,0.6815647838941328,LGP Proband,FGFR1b ligand binding and activation,CP:REACTOME,C2,2,8
Cohort,0.0016820274718062668,0.007334994296730709,0.2293154437156094,0.8186826580600282,LonGen OPEL,FGFR1b ligand binding and activation,CP:REACTOME,C2,3,5
Cohort,-0.014900970010703073,0.01629536973483971,-0.9144296970963849,0.3608171457700413,LGP Offspring,FGFR1c ligand binding and activation,CP:REACTOME,C2,7,11
Cohort,0.01786602663069426,0.04470441278839925,0.3996479433755246,0.6895181652669043,LGP Proband,FGFR1c ligand binding and activation,CP:REACTOME,C2,7,16
Cohort,-0.005978275119826725,0.01163095948558593,-0.5139967280631929,0.6073969330235852,LonGen OPEL,FGFR1c ligand binding and activation,CP:REACTOME,C2,8,9
Cohort,-8.144275359426156e-4,0.025944457340431812,-0.03139119563211726,0.9749668281803895,LGP Offspring,FGFR2 alternative splicing,CP:REACTOME,C2,21,40
Cohort,-0.07994018514708216,0.07154363808424773,-1.1173625955804332,0.26416109804137894,LGP Proband,FGFR2 alternative splicing,CP:REACTOME,C2,21,59
Cohort,0.01865949341149418,0.01965990913595418,0.9491139192179463,0.3428507366425806,LonGen OPEL,FGFR2 alternative splicing,CP:REACTOME,C2,20,30
Cohort,-0.013758129100010128,0.009995742177823024,-1.3763989562010208,0.1691538817975417,LGP Offspring,FGFR2 ligand binding and activation,CP:REACTOME,C2,6,4
Cohort,-0.05847165831465063,0.026758273385421916,-2.185180541077302,0.029153197767096,LGP Proband,FGFR2 ligand binding and activation,CP:REACTOME,C2,6,6
Cohort,0.004268632063316174,0.005778458493030563,0.73871467078367,0.4602980281968083,LonGen OPEL,FGFR2 ligand binding and activation,CP:REACTOME,C2,1,4
Cohort,-0.013180270895117623,0.015213700953417375,-0.8663421829753403,0.3866099183189249,LGP Offspring,FGFR2 mutant receptor activation,CP:REACTOME,C2,10,13
Cohort,-0.03814206924067558,0.04597122437391536,-0.8296944395137289,0.406948982206467,LGP Proband,FGFR2 mutant receptor activation,CP:REACTOME,C2,10,25
Cohort,0.017714722394532936,0.01372953624543421,1.2902637115965232,0.19733379169155182,LonGen OPEL,FGFR2 mutant receptor activation,CP:REACTOME,C2,9,18
Cohort,-0.013758129100010128,0.009995742177823024,-1.3763989562010208,0.1691538817975417,LGP Offspring,FGFR2b ligand binding and activation,CP:REACTOME,C2,6,4
Cohort,-0.05847165831465063,0.026758273385421916,-2.185180541077302,0.029153197767096,LGP Proband,FGFR2b ligand binding and activation,CP:REACTOME,C2,6,6
Cohort,0.004268632063316174,0.005778458493030563,0.73871467078367,0.4602980281968083,LonGen OPEL,FGFR2b ligand binding and activation,CP:REACTOME,C2,1,4
Cohort,-0.004084930316621268,0.0031934856592141367,-1.2791447191362997,0.20128499692131974,LGP Offspring,FGFR2c ligand binding and activation,CP:REACTOME,C2,1,0
Cohort,-0.0011422365415160512,0.007835557182872621,-0.14577604564137606,0.8841334117478574,LGP Proband,FGFR2c ligand binding and activation,CP:REACTOME,C2,1,0
Cohort,0,0,NA,NA,LonGen OPEL,FGFR2c ligand binding and activation,CP:REACTOME,C2,0,0
Cohort,2.4277473360401788e-4,0.008994326489537465,0.0269919858798124,0.9784740921464681,LGP Offspring,FGFR3 ligand binding and activation,CP:REACTOME,C2,3,5
Cohort,0.008849988722019687,0.030519909982566176,0.2899742734193858,0.7719079982180882,LGP Proband,FGFR3 ligand binding and activation,CP:REACTOME,C2,3,12
Cohort,-0.009785701346274298,0.009988034688831695,-0.979742426927728,0.32751095009305153,LonGen OPEL,FGFR3 ligand binding and activation,CP:REACTOME,C2,9,6
Cohort,2.4277473360401788e-4,0.008994326489537465,0.0269919858798124,0.9784740921464681,LGP Offspring,FGFR3b ligand binding and activation,CP:REACTOME,C2,3,5
Cohort,0.008849988722019687,0.030519909982566176,0.2899742734193858,0.7719079982180882,LGP Proband,FGFR3b ligand binding and activation,CP:REACTOME,C2,3,12
Cohort,-0.007239182439711374,0.00964437743083008,-0.7506116897260735,0.4531082054020438,LonGen OPEL,FGFR3b ligand binding and activation,CP:REACTOME,C2,8,6
Cohort,-8.955763394510255e-4,0.016812660220918325,-0.0532679735201422,0.9575341348004055,LGP Offspring,FGFRL1 modulation of FGFR1 signaling,CP:REACTOME,C2,9,20
Cohort,0.005759654044824177,0.046022214217254886,0.12514943365468795,0.9004354080837123,LGP Proband,FGFRL1 modulation of FGFR1 signaling,CP:REACTOME,C2,9,25
Cohort,0.021412101861162654,0.016745511679781104,1.2786770730342085,0.2013834689093218,LonGen OPEL,FGFRL1 modulation of FGFR1 signaling,CP:REACTOME,C2,14,28
Cohort,0.02116921257034725,0.017793215595822667,1.189735068197407,0.2345682207326405,LGP Offspring,Fibronectin matrix formation,CP:REACTOME,C2,6,22
Cohort,-0.044405554348464965,0.04675098446806585,-0.9498314282300734,0.3424730709180084,LGP Proband,Fibronectin matrix formation,CP:REACTOME,C2,6,31
Cohort,-0.024164162411639992,0.015238625276082498,-1.5857180010565919,0.11320044964808633,LonGen OPEL,Fibronectin matrix formation,CP:REACTOME,C2,22,14
Cohort,-0.007222750755884031,0.016017443007959625,-0.45093032341646505,0.6521843718888012,LGP Offspring,Ficolins bind to repetitive carbohydrate structures on the target cell surface,CP:REACTOME,C2,9,17
Cohort,-0.025101016076106833,0.044066495712841866,-0.5696167954828296,0.5690910234142295,LGP Proband,Ficolins bind to repetitive carbohydrate structures on the target cell surface,CP:REACTOME,C2,9,24
Cohort,0.018009205635617857,0.013994744056250945,1.286854948059861,0.19851894807312193,LonGen OPEL,Ficolins bind to repetitive carbohydrate structures on the target cell surface,CP:REACTOME,C2,10,20
Cohort,0.02701945904621902,0.029464913670357137,0.9170045209873349,0.3594672991145659,LGP Offspring,FLT3 Signaling,CP:REACTOME,C2,27,66
Cohort,0.0397957634335642,0.08241289821746708,0.48288270761396,0.6293057473027033,LGP Proband,FLT3 Signaling,CP:REACTOME,C2,27,87
Cohort,-9.292670646105408e-5,0.023138882728909776,-0.004016041204312395,0.996796677578243,LonGen OPEL,FLT3 Signaling,CP:REACTOME,C2,34,42
Cohort,0.007703410038300697,0.017926318305679468,0.4297262776964124,0.6675317050792677,LGP Offspring,FLT3 signaling by CBL mutants,CP:REACTOME,C2,11,22
Cohort,0.005977982778352682,0.04897640672779852,0.12205841909916267,0.9028821561236402,LGP Proband,FLT3 signaling by CBL mutants,CP:REACTOME,C2,11,29
Cohort,0.01620202797199738,0.011426228595820747,1.4179681279896175,0.1565914150525003,LonGen OPEL,FLT3 signaling by CBL mutants,CP:REACTOME,C2,6,14
Cohort,-0.03262038389865704,0.03147437210272325,-1.0364109502230432,0.30038105291828004,LGP Offspring,FLT3 signaling in disease,CP:REACTOME,C2,38,60
Cohort,-0.005021849396293971,0.08704190435544575,-0.057694617707198415,0.9540057008877978,LGP Proband,FLT3 signaling in disease,CP:REACTOME,C2,38,93
Cohort,-0.006107041150272977,0.025853983570212156,-0.23621277292483647,0.8133283349538399,LonGen OPEL,FLT3 signaling in disease,CP:REACTOME,C2,46,53
Cohort,-0.006520608318831493,0.01487690497602932,-0.4383040914315135,0.6613058883790381,LGP Offspring,FLT3 signaling through SRC family kinases,CP:REACTOME,C2,9,13
Cohort,-0.036595856121680634,0.03905702217637109,-0.9369853123062868,0.3490373583017279,LGP Proband,FLT3 signaling through SRC family kinases,CP:REACTOME,C2,9,16
Cohort,0.02066824637590069,0.009280341526311959,2.2270997589152657,0.02621956429367765,LonGen OPEL,FLT3 signaling through SRC family kinases,CP:REACTOME,C2,2,11
Cohort,-1.7448265704236008e-4,0.016441930988860896,-0.010612053849427348,0.9915360959504276,LGP Offspring,Folding of actin by CCT/TriC,CP:REACTOME,C2,8,17
Cohort,-0.0213281442382657,0.0415576396631893,-0.5132183735920312,0.6079344931627133,LGP Proband,Folding of actin by CCT/TriC,CP:REACTOME,C2,8,21
Cohort,0.0038432101512558617,0.013514105258241744,0.28438509822261687,0.7761892407268342,LonGen OPEL,Folding of actin by CCT/TriC,CP:REACTOME,C2,13,15
Cohort,-0.05141706458353433,0.019347996181024764,-2.657487840211628,0.00805854820251617,LGP Offspring,Formation of apoptosome,CP:REACTOME,C2,19,20
Cohort,0.007975805865941283,0.052479551498378914,0.151979306953255,0.879240013170938,LGP Proband,Formation of apoptosome,CP:REACTOME,C2,19,26
Cohort,-0.011775436403707148,0.01899836802809166,-0.6198130484837209,0.5355582552335725,LonGen OPEL,Formation of apoptosome,CP:REACTOME,C2,28,26
Cohort,-0.018462541441120462,0.03098934053295009,-0.5957707109478423,0.5515278237824701,LGP Offspring,Formation of Fibrin Clot (Clotting Cascade),CP:REACTOME,C2,36,61
Cohort,-0.04591828532393941,0.08365053652745788,-0.548929955863068,0.5832004461171951,LGP Proband,Formation of Fibrin Clot (Clotting Cascade),CP:REACTOME,C2,36,83
Cohort,0.013224948337057016,0.02668537831810642,0.495587815147582,0.6203220405277468,LonGen OPEL,Formation of Fibrin Clot (Clotting Cascade),CP:REACTOME,C2,47,65
Cohort,0.031313999141532205,0.0352303053434203,0.8888370065569268,0.37440685059113066,LGP Offspring,Formation of Incision Complex in GG-NER,CP:REACTOME,C2,38,88
Cohort,-0.07050618263974699,0.09471490862847173,-0.7444042723655493,0.45684162586937205,LGP Proband,Formation of Incision Complex in GG-NER,CP:REACTOME,C2,38,119
Cohort,-0.0303856011871092,0.031856767462964404,-0.9538193485084282,0.3404646467464123,LonGen OPEL,Formation of Incision Complex in GG-NER,CP:REACTOME,C2,75,76
Cohort,-0.032001025252085494,0.026692832304503443,-1.1988621097614467,0.23100164905756548,LGP Offspring,Formation of RNA Pol II elongation complex ,CP:REACTOME,C2,29,43
Cohort,0.010305141217087034,0.0807876503322378,0.127558372779841,0.8985292248170034,LGP Proband,Formation of RNA Pol II elongation complex ,CP:REACTOME,C2,29,84
Cohort,0.01980295551183669,0.023813929791820083,0.8315702483778578,0.4059009416989,LonGen OPEL,Formation of RNA Pol II elongation complex ,CP:REACTOME,C2,36,52
Cohort,0.013004000731810229,0.02344425523360908,0.5546774935792385,0.5792987398453707,LGP Offspring,Formation of Senescence-Associated Heterochromatin Foci (SAHF),CP:REACTOME,C2,15,39
Cohort,0.08801051247760454,0.06256205340766502,1.4067714802152196,0.15986768147330827,LGP Proband,Formation of Senescence-Associated Heterochromatin Foci (SAHF),CP:REACTOME,C2,15,47
Cohort,0.018391766758754147,0.020113632249877163,0.9143931106161329,0.36078721355025034,LonGen OPEL,Formation of Senescence-Associated Heterochromatin Foci (SAHF),CP:REACTOME,C2,25,38
Cohort,0.014578854873930448,0.03122346703303026,0.46691979652701493,0.6407077104610635,LGP Offspring,Formation of TC-NER Pre-Incision Complex,CP:REACTOME,C2,29,60
Cohort,-0.08942643563715537,0.08420219629749257,-1.0620439794848722,0.2885231540296584,LGP Proband,Formation of TC-NER Pre-Incision Complex,CP:REACTOME,C2,29,91
Cohort,0.027787545446750626,0.024430055866273472,1.1374327426370026,0.2556996881514584,LonGen OPEL,Formation of TC-NER Pre-Incision Complex,CP:REACTOME,C2,37,58
Cohort,0.02775944903345327,0.030174044957501634,0.9199777183520081,0.35791256721576326,LGP Offspring,Formation of the beta-catenin:TCF transactivating complex,CP:REACTOME,C2,27,68
Cohort,0.039705518348700675,0.08153398161096737,0.48698122628368945,0.6263995947345703,LGP Proband,Formation of the beta-catenin:TCF transactivating complex,CP:REACTOME,C2,27,86
Cohort,-0.011660085860944715,0.027532055393965672,-0.4235094581242311,0.67203800562738,LonGen OPEL,Formation of the beta-catenin:TCF transactivating complex,CP:REACTOME,C2,57,60
Cohort,0.011225039553314213,0.05683018248082402,0.19751897782664754,0.8434808075489267,LGP Offspring,Formation of the cornified envelope,CP:REACTOME,C2,95,207
Cohort,0.01779709999150567,0.1668209477018602,0.10668384418551781,0.9150654560160427,LGP Proband,Formation of the cornified envelope,CP:REACTOME,C2,95,318
Cohort,0.02880738861580607,0.05004189676888911,0.5756654019100957,0.5650040665633769,LonGen OPEL,Formation of the cornified envelope,CP:REACTOME,C2,156,201
Cohort,-0.014844004192268946,0.02323457658221403,-0.63887560592053,0.5231202582645311,LGP Offspring,Formation of the Early Elongation Complex,CP:REACTOME,C2,21,33
Cohort,-0.06134430980928212,0.06780912504322117,-0.9046615742377089,0.3659059535371696,LGP Proband,Formation of the Early Elongation Complex,CP:REACTOME,C2,21,58
Cohort,0.015309153348612986,0.019069764565467908,0.8027971869319904,0.42233159736333736,LonGen OPEL,Formation of the Early Elongation Complex,CP:REACTOME,C2,23,33
Cohort,0.032496590392686396,0.02577161971152348,1.2609448205599558,0.20776373357526257,LGP Offspring,Formation of tubulin folding intermediates by CCT/TriC,CP:REACTOME,C2,15,49
Cohort,-0.006455751986108894,0.07172899129739285,-0.09000199039943202,0.9283072426725631,LGP Proband,Formation of tubulin folding intermediates by CCT/TriC,CP:REACTOME,C2,15,66
Cohort,6.568066363013286e-4,0.02185358238067247,0.030054872691363182,0.9760308245527289,LonGen OPEL,Formation of tubulin folding intermediates by CCT/TriC,CP:REACTOME,C2,33,38
Cohort,-0.009849042678982206,0.016843754464372862,-0.5847296515639937,0.5589246138144757,LGP Offspring,Formation of xylulose-5-phosphate,CP:REACTOME,C2,10,19
Cohort,0.052057505764504255,0.04382564914634807,1.187831938111569,0.23523779749065854,LGP Proband,Formation of xylulose-5-phosphate,CP:REACTOME,C2,10,22
Cohort,0.0016551272740358788,0.012964757538118913,0.12766357328083322,0.8984474623125447,LonGen OPEL,Formation of xylulose-5-phosphate,CP:REACTOME,C2,13,13
Cohort,0.0019640177474324334,0.015215297137170571,0.1290817872123174,0.8973313282025559,LGP Offspring,Formyl peptide receptors bind formyl peptides and many other ligands,CP:REACTOME,C2,7,16
Cohort,0.050066645467522104,0.04663007418868787,1.0736986019993922,0.2832683417098636,LGP Proband,Formyl peptide receptors bind formyl peptides and many other ligands,CP:REACTOME,C2,7,29
Cohort,-0.00538728143357884,0.015000642457660477,-0.3591367135630702,0.719588059950721,LonGen OPEL,Formyl peptide receptors bind formyl peptides and many other ligands,CP:REACTOME,C2,16,17
Cohort,-0.02233515331634712,0.04061978220189458,-0.549859012176224,0.5825976947073483,LGP Offspring,FOXO-mediated transcription,CP:REACTOME,C2,60,120
Cohort,-0.08175940943665722,0.11845147283387567,-0.6902354819287231,0.49023814409084643,LGP Proband,FOXO-mediated transcription,CP:REACTOME,C2,60,165
Cohort,-0.04085829047779963,0.0386819748528408,-1.0562617506794383,0.2911691106467264,LonGen OPEL,FOXO-mediated transcription,CP:REACTOME,C2,114,114
Cohort,-0.013717729574200803,0.013021835248024312,-1.0534405721560693,0.29251550012395977,LGP Offspring,FOXO-mediated transcription of cell cycle genes,CP:REACTOME,C2,7,10
Cohort,0.024423107239305894,0.03788634259209114,0.6446414609681609,0.5193368278043242,LGP Proband,FOXO-mediated transcription of cell cycle genes,CP:REACTOME,C2,7,17
Cohort,-0.010881186910945287,0.01200305068611312,-0.9065351130720651,0.3649270187864848,LonGen OPEL,FOXO-mediated transcription of cell cycle genes,CP:REACTOME,C2,11,11
Cohort,0.028220315936489247,0.01752822304108486,1.6099929736370258,0.10786622175829061,LGP Offspring,FOXO-mediated transcription of cell death genes,CP:REACTOME,C2,6,25
Cohort,-0.056132631386957434,0.047901625556249855,-1.1718314511277301,0.2415993801537002,LGP Proband,FOXO-mediated transcription of cell death genes,CP:REACTOME,C2,6,26
Cohort,-0.018023873935650615,0.020697704310080917,-0.8708151235338695,0.3841176494247258,LonGen OPEL,FOXO-mediated transcription of cell death genes,CP:REACTOME,C2,34,31
Cohort,-0.03250357585710837,0.03345058324519995,-0.9716893609552392,0.3315526582719778,LGP Offspring,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",CP:REACTOME,C2,42,76
Cohort,-0.03301370500086181,0.09995086164467895,-0.3302993536786518,0.7412567339000316,LGP Proband,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",CP:REACTOME,C2,42,124
Cohort,-0.045775324140530774,0.0307604882377005,-1.488120857731636,0.13711505893962472,LonGen OPEL,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",CP:REACTOME,C2,76,69
Cohort,0.003858562010224513,0.00455409063236125,0.8472738734722737,0.3971423483760198,LGP Offspring,Free fatty acid receptors,CP:REACTOME,C2,0,2
Cohort,-0.008562343331318901,0.007827081304489858,-1.0939382124991182,0.27429792766657146,LGP Proband,Free fatty acid receptors,CP:REACTOME,C2,0,1
Cohort,0.002654053848969052,0.0026058062317282867,1.0185154278369983,0.3087425327330801,LonGen OPEL,Free fatty acid receptors,CP:REACTOME,C2,0,1
Cohort,-0.004843237656365339,0.01692853091507638,-0.2860991116513247,0.7748898632185922,LGP Offspring,Free fatty acids regulate insulin secretion,CP:REACTOME,C2,9,20
Cohort,0.08829439655646384,0.05155252245756228,1.7127075911590406,0.08713803436066571,LGP Proband,Free fatty acids regulate insulin secretion,CP:REACTOME,C2,9,35
Cohort,0.01741059146370092,0.01716521210386415,1.0142951545458347,0.3107501348570384,LonGen OPEL,Free fatty acids regulate insulin secretion,CP:REACTOME,C2,17,27
Cohort,0.009831296388758005,0.0231752274817163,0.4242157448730218,0.6715434426387834,LGP Offspring,FRS-mediated FGFR1 signaling,CP:REACTOME,C2,13,38
Cohort,0.146120387896746,0.06631313626765058,2.203490833354351,0.02783282315522705,LGP Proband,FRS-mediated FGFR1 signaling,CP:REACTOME,C2,13,55
Cohort,0.010192072467446415,0.017147525169751973,0.5943757111623961,0.5524297422977169,LonGen OPEL,FRS-mediated FGFR1 signaling,CP:REACTOME,C2,21,26
Cohort,-0.002253414558979315,0.016151758589596787,-0.13951512130887844,0.889084662264729,LGP Offspring,FRS-mediated FGFR2 signaling,CP:REACTOME,C2,8,17
Cohort,0.0301909914923214,0.04830578207330032,0.6249974681397122,0.5321436771074254,LGP Proband,FRS-mediated FGFR2 signaling,CP:REACTOME,C2,8,29
Cohort,0.009357123836978872,0.013866052981661568,0.6748224494276819,0.4999845269586154,LonGen OPEL,FRS-mediated FGFR2 signaling,CP:REACTOME,C2,13,17
Cohort,9.516389275304253e-4,0.016936311657602787,0.05618926639810801,0.9552076349414302,LGP Offspring,FRS-mediated FGFR3 signaling,CP:REACTOME,C2,9,19
Cohort,0.040078462289293404,0.05344350285633331,0.7499220699854242,0.4535131332631963,LGP Proband,FRS-mediated FGFR3 signaling,CP:REACTOME,C2,9,37
Cohort,7.106596284619036e-4,0.015983067209934285,0.04446328224285966,0.9645462709198178,LonGen OPEL,FRS-mediated FGFR3 signaling,CP:REACTOME,C2,20,20
Cohort,7.0886419392643e-4,0.01459813956767885,0.04855852971127208,0.9612854620902409,LGP Offspring,FRS-mediated FGFR4 signaling,CP:REACTOME,C2,6,14
Cohort,0.03744507588112661,0.04577344397866318,0.8180524038912441,0.4135609211586987,LGP Proband,FRS-mediated FGFR4 signaling,CP:REACTOME,C2,6,27
Cohort,0.013539304928666535,0.013430070416094437,1.00813357705416,0.3136966890625373,LonGen OPEL,FRS-mediated FGFR4 signaling,CP:REACTOME,C2,12,16
Cohort,-0.007917043619854092,0.011876585077786595,-0.6666094309097114,0.5052490860730148,LGP Offspring,Fructose catabolism,CP:REACTOME,C2,6,8
Cohort,-0.03769011895261968,0.038972023922365553,-0.9671070465239501,0.3337708805077161,LGP Proband,Fructose catabolism,CP:REACTOME,C2,6,19
Cohort,0.003670730422734361,0.013932161656484523,0.263471707638841,0.7922552145725409,LonGen OPEL,Fructose catabolism,CP:REACTOME,C2,11,15
Cohort,-0.010102868912920431,0.020229623140839027,-0.49940964508256347,0.6176533197023504,LGP Offspring,Fructose metabolism,CP:REACTOME,C2,14,26
Cohort,-0.017102341475313403,0.05623872242270036,-0.3041025958372441,0.7611255862333739,LGP Proband,Fructose metabolism,CP:REACTOME,C2,14,38
Cohort,0.011350711860763295,0.01850839583536962,0.6132736711342665,0.5398705889496165,LonGen OPEL,Fructose metabolism,CP:REACTOME,C2,21,27
Cohort,-0.027891469081119048,0.058860425230391866,-0.4738577570913916,0.6357543471739113,LGP Offspring,G alpha (12/13) signalling events,CP:REACTOME,C2,124,225
Cohort,-0.18230924256135267,0.1600281380470011,-1.1392324174127895,0.2549333308328865,LGP Proband,G alpha (12/13) signalling events,CP:REACTOME,C2,124,345
Cohort,0.05277181102870299,0.049199097598976824,1.0726174585324197,0.28376786138215077,LonGen OPEL,G alpha (12/13) signalling events,CP:REACTOME,C2,169,223
Cohort,-0.006238631667435316,0.07872436329062926,-0.07924651793503822,0.936859997378921,LGP Offspring,G alpha (i) signalling events,CP:REACTOME,C2,202,404
Cohort,-0.4592233926259998,0.22422433010765977,-2.048053359800459,0.0408674373170099,LGP Proband,G alpha (i) signalling events,CP:REACTOME,C2,202,614
Cohort,0.0184678441558428,0.07396112958140938,0.2496966211895825,0.8028863936671599,LonGen OPEL,G alpha (i) signalling events,CP:REACTOME,C2,352,422
Cohort,0.0118474083280949,0.07196796554747495,0.1646205813651846,0.8692918417977572,LGP Offspring,G alpha (q) signalling events,CP:REACTOME,C2,150,317
Cohort,-0.11568225535583024,0.20144203600156216,-0.5742706817902353,0.5659394964446256,LGP Proband,G alpha (q) signalling events,CP:REACTOME,C2,150,469
Cohort,-0.046976204259179935,0.06129361197678729,-0.7664127262881889,0.44365798578081617,LonGen OPEL,G alpha (q) signalling events,CP:REACTOME,C2,264,300
Cohort,-0.039678237857073036,0.05391975318769839,-0.7358757322005971,0.4620615799405978,LGP Offspring,G alpha (s) signalling events,CP:REACTOME,C2,98,190
Cohort,0.009886181903032086,0.15804591961404799,0.06255259184909287,0.9501377695468565,LGP Proband,G alpha (s) signalling events,CP:REACTOME,C2,98,295
Cohort,-0.03915917013109111,0.04710934430618496,-0.8312399738909108,0.40608734589385775,LonGen OPEL,G alpha (s) signalling events,CP:REACTOME,C2,163,176
Cohort,0.022280668682869195,0.02359574527430839,0.9442663676798088,0.3453709089627618,LGP Offspring,G alpha (z) signalling events,CP:REACTOME,C2,15,42
Cohort,-0.03272657775484713,0.07201675385037437,-0.45443005974472983,0.649637568121836,LGP Proband,G alpha (z) signalling events,CP:REACTOME,C2,15,61
Cohort,-0.019266638979022765,0.019548617558293947,-0.9855755232598764,0.32464092837870884,LonGen OPEL,G alpha (z) signalling events,CP:REACTOME,C2,29,30
Cohort,-0.012412416023265456,0.01231487756917969,-1.0079203754595072,0.3138533235416654,LGP Offspring,G beta:gamma signalling through CDC42,CP:REACTOME,C2,6,5
Cohort,-0.06425509061784826,0.03120287362329081,-2.0592683671893037,0.03977849272246532,LGP Proband,G beta:gamma signalling through CDC42,CP:REACTOME,C2,6,6
Cohort,-0.004677036741394877,0.009680537453565811,-0.48313812779806947,0.6291305190252845,LonGen OPEL,G beta:gamma signalling through CDC42,CP:REACTOME,C2,7,7
Cohort,-0.02058589987014273,0.01610517093920386,-1.2782167881268307,0.20161170373660267,LGP Offspring,G beta:gamma signalling through PI3Kgamma,CP:REACTOME,C2,10,15
Cohort,0.04282915500891566,0.04285524021948759,0.9993913180642943,0.31789503314104,LGP Proband,G beta:gamma signalling through PI3Kgamma,CP:REACTOME,C2,10,17
Cohort,0.006217061866017188,0.012611187952612343,0.49297987543904265,0.6221627699728447,LonGen OPEL,G beta:gamma signalling through PI3Kgamma,CP:REACTOME,C2,9,13
Cohort,-0.00836405789582986,0.015713709803608974,-0.5322777371075595,0.5947085459392759,LGP Offspring,G-protein activation,CP:REACTOME,C2,9,16
Cohort,-0.027493390985192562,0.050176684911047494,-0.5479315948020969,0.5838854897396502,LGP Proband,G-protein activation,CP:REACTOME,C2,9,29
Cohort,-0.027677230154718555,0.018791002904980966,-1.4728979764769288,0.1411738408409483,LonGen OPEL,G-protein activation,CP:REACTOME,C2,32,25
Cohort,-0.03886983310745179,0.021854607497792042,-1.7785646853359771,0.07576050140357025,LGP Offspring,G-protein beta:gamma signalling,CP:REACTOME,C2,18,24
Cohort,0.03887441470461254,0.05834468980286891,0.6662888231295561,0.5054107678219346,LGP Proband,G-protein beta:gamma signalling,CP:REACTOME,C2,18,32
Cohort,0.01386628672094247,0.016350871182049625,0.8480457442637802,0.39666742462974647,LonGen OPEL,G-protein beta:gamma signalling,CP:REACTOME,C2,15,24
Cohort,-0.029218305383353124,0.031884832057646036,-0.9163700574156396,0.35979961988537557,LGP Offspring,G-protein mediated events,CP:REACTOME,C2,36,64
Cohort,0.167467456668515,0.10095744503114815,1.6587925399344912,0.0975335962589921,LGP Proband,G-protein mediated events,CP:REACTOME,C2,36,120
Cohort,-0.056478266275595955,0.031512028092996,-1.7922764637338295,0.07346835407862669,LonGen OPEL,G-protein mediated events,CP:REACTOME,C2,78,67
Cohort,-0.05158278921401915,0.02312340244597674,-2.2307612097541503,0.02602427671023413,LGP Offspring,G0 and Early G1,CP:REACTOME,C2,24,26
Cohort,-0.0025972316479453707,0.06529647919992054,-0.03977598302036063,0.9682812433161125,LGP Proband,G0 and Early G1,CP:REACTOME,C2,24,42
Cohort,-0.009702910244843632,0.02104363770015024,-0.4610852164963075,0.6448634236255033,LonGen OPEL,G0 and Early G1,CP:REACTOME,C2,29,33
Cohort,0.029079151468059315,0.04074593188714029,0.7136700554205978,0.4756775423448262,LGP Offspring,G1/S DNA Damage Checkpoints,CP:REACTOME,C2,45,106
Cohort,-0.042811495202853656,0.10786073039452608,-0.39691456794572505,0.6915320073119571,LGP Proband,G1/S DNA Damage Checkpoints,CP:REACTOME,C2,45,148
Cohort,0.0037082413687125454,0.034711887335056334,0.10682914855417577,0.9149514402976344,LonGen OPEL,G1/S DNA Damage Checkpoints,CP:REACTOME,C2,87,101
Cohort,-0.03270779086929718,0.023966601425382376,-1.3647237790944047,0.17279395806561804,LGP Offspring,G1/S-Specific Transcription,CP:REACTOME,C2,23,36
Cohort,-0.040406045531671986,0.0660510309737362,-0.6117398159574314,0.5408766339679065,LGP Proband,G1/S-Specific Transcription,CP:REACTOME,C2,23,50
Cohort,-0.01778654451372341,0.021264599396099326,-0.8364392003070646,0.40315889069242994,LonGen OPEL,G1/S-Specific Transcription,CP:REACTOME,C2,32,33
Cohort,-0.019353262008573655,0.06166178638272938,-0.3138615201390636,0.7537230442750167,LGP Offspring,G2/M Checkpoints,CP:REACTOME,C2,138,267
Cohort,-0.05360125291883697,0.18325150410674151,-0.29250102573572856,0.7699763279044832,LGP Proband,G2/M Checkpoints,CP:REACTOME,C2,138,403
Cohort,0.04011901167541846,0.05410280130666775,0.7415329836252693,0.4585890571830801,LonGen OPEL,G2/M Checkpoints,CP:REACTOME,C2,203,260
Cohort,-0.02284054780993688,0.041281263940398424,-0.5532909031785919,0.5802471627118029,LGP Offspring,G2/M DNA damage checkpoint,CP:REACTOME,C2,62,120
Cohort,0.14459010387622892,0.12674463845891093,1.1407985823645177,0.254281227075707,LGP Proband,G2/M DNA damage checkpoint,CP:REACTOME,C2,62,193
Cohort,0.016719087732389632,0.0378418877131244,0.4418143159013467,0.6587435778667514,LonGen OPEL,G2/M DNA damage checkpoint,CP:REACTOME,C2,97,124
Cohort,-0.006619313685203884,0.011688328392456013,-0.5663182503903793,0.5713654115344267,LGP Offspring,G2/M DNA replication checkpoint,CP:REACTOME,C2,7,7
Cohort,-0.01494711096129061,0.03358131163735537,-0.44510205922581225,0.6563614989520505,LGP Proband,G2/M DNA replication checkpoint,CP:REACTOME,C2,7,13
Cohort,0.012667842751281915,0.010250991741193493,1.2357675307040132,0.21690955094908698,LonGen OPEL,G2/M DNA replication checkpoint,CP:REACTOME,C2,4,12
Cohort,-0.00743873909121067,0.011898481302037259,-0.6251839123314845,0.5320613374139618,LGP Offspring,G2 Phase,CP:REACTOME,C2,6,10
Cohort,0.007000583629530468,0.02707129729273165,0.2585980107946304,0.796009224294331,LGP Proband,G2 Phase,CP:REACTOME,C2,6,7
Cohort,0.0029933012274172407,0.006265130864199893,0.4777715409779408,0.6329439873267382,LonGen OPEL,G2 Phase,CP:REACTOME,C2,2,4
Cohort,0.007547627860003645,0.017371629217868664,0.43448013800801516,0.6640784639045192,LGP Offspring,GAB1 signalosome,CP:REACTOME,C2,8,20
Cohort,-0.03591780849969379,0.04261996792824155,-0.8427460236518229,0.39961211758159965,LGP Proband,GAB1 signalosome,CP:REACTOME,C2,8,22
Cohort,-0.015957238419333695,0.012473129692759955,-1.279329150934436,0.20115395882795825,LonGen OPEL,GAB1 signalosome,CP:REACTOME,C2,13,11
Cohort,-0.006785879260594842,0.02438590111743558,-0.27827059692877343,0.7808897378809424,LGP Offspring,GABA B receptor activation,CP:REACTOME,C2,20,38
Cohort,0.009987806313483267,0.07423864115935272,0.13453649147543678,0.8930108173214479,LGP Proband,GABA B receptor activation,CP:REACTOME,C2,20,67
Cohort,-0.01822243565241043,0.022646963974852493,-0.8046303986991316,0.4212732469510837,LonGen OPEL,GABA B receptor activation,CP:REACTOME,C2,39,38
Cohort,-0.006072077784889858,0.02609293875675528,-0.23270961701536358,0.8160573391774825,LGP Offspring,GABA receptor activation,CP:REACTOME,C2,23,43
Cohort,-0.04208173536264705,0.07992313712035173,-0.526527572350902,0.598661697946951,LGP Proband,GABA receptor activation,CP:REACTOME,C2,23,80
Cohort,-0.03578465048861928,0.024181874007067602,-1.4798129573481587,0.1393188189234857,LonGen OPEL,GABA receptor activation,CP:REACTOME,C2,47,41
Cohort,-0.013186250787556102,0.02575081832722826,-0.512071135759336,0.6087684714465209,LGP Offspring,"GABA synthesis, release, reuptake and degradation",CP:REACTOME,C2,24,44
Cohort,0.06174171483858478,0.07215128395123262,0.8557257952653523,0.39239524368423084,LGP Proband,"GABA synthesis, release, reuptake and degradation",CP:REACTOME,C2,24,64
Cohort,-0.03254673607008934,0.022534804746971906,-1.4442874671218429,0.14905161379548135,LonGen OPEL,"GABA synthesis, release, reuptake and degradation",CP:REACTOME,C2,42,32
Cohort,0.003184889131463346,0.009487820999896403,0.33568183163427323,0.7372149618555384,LGP Offspring,Galactose catabolism,CP:REACTOME,C2,2,7
Cohort,0.024684728654821086,0.02826968328401236,0.8731873083552122,0.38281232866077297,LGP Proband,Galactose catabolism,CP:REACTOME,C2,2,11
Cohort,0.01655577563341793,0.010407544796611526,1.5907474776191342,0.11206346160018853,LonGen OPEL,Galactose catabolism,CP:REACTOME,C2,5,12
Cohort,0.0024358214827485576,0.030240447375522422,0.08054846056014994,0.935824895640474,LGP Offspring,"Gamma carboxylation, hypusine formation and arylsulfatase activation",CP:REACTOME,C2,28,60
Cohort,0.0041457433038754234,0.0757039946438641,0.05476254355372304,0.9563407569151428,LGP Proband,"Gamma carboxylation, hypusine formation and arylsulfatase activation",CP:REACTOME,C2,28,63
Cohort,-0.0019346598607767513,0.025126583261159238,-0.0769965355284638,0.9386456496265918,LonGen OPEL,"Gamma carboxylation, hypusine formation and arylsulfatase activation",CP:REACTOME,C2,44,50
Cohort,3.739020811195879e-4,0.018817973293798168,0.01986941288958119,0.9841534083548786,LGP Offspring,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",CP:REACTOME,C2,12,24
Cohort,0.041511479962384266,0.04871521930961495,0.8521254866688268,0.39438907112158406,LGP Proband,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",CP:REACTOME,C2,12,24
Cohort,0.010229487207594763,0.01396107992091237,0.7327146084359824,0.4639482131144599,LonGen OPEL,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",CP:REACTOME,C2,13,17
Cohort,-1.9019692250065e-4,0.021001111082123464,-0.00905651714125493,0.9927767155500815,LGP Offspring,Gap-filling DNA repair synthesis and ligation in GG-NER,CP:REACTOME,C2,14,32
Cohort,0.023728213485120952,0.06506939900708342,0.3646600990203999,0.7154575901098779,LGP Proband,Gap-filling DNA repair synthesis and ligation in GG-NER,CP:REACTOME,C2,14,54
Cohort,0.01685264120824616,0.02002355890266244,0.8416406539002086,0.40024190168400253,LonGen OPEL,Gap-filling DNA repair synthesis and ligation in GG-NER,CP:REACTOME,C2,26,37
Cohort,0.03776871034228352,0.03642224100218669,1.0369683276769266,0.300121398597912,LGP Offspring,Gap junction assembly,CP:REACTOME,C2,32,87
Cohort,0.015728565695039633,0.09334285179147087,0.1685031621936884,0.8662283115528527,LGP Proband,Gap junction assembly,CP:REACTOME,C2,32,102
Cohort,0.002411108924570863,0.029302794613671187,0.08228255892855908,0.9344427088644727,LonGen OPEL,Gap junction assembly,CP:REACTOME,C2,61,72
Cohort,-0.005080366220167864,0.031106980154755475,-0.1633191712886731,0.8703159522952257,LGP Offspring,Gap junction degradation,CP:REACTOME,C2,29,61
Cohort,0.09925297948361861,0.08344183772004145,1.189486979141395,0.2345866177205508,LGP Proband,Gap junction degradation,CP:REACTOME,C2,29,82
Cohort,0.03154493133453473,0.02346442624891949,1.3443725834117652,0.17921092157538349,LonGen OPEL,Gap junction degradation,CP:REACTOME,C2,34,51
Cohort,0.0445303333094872,0.04819763448467741,0.9239111791605438,0.35586222591049543,LGP Offspring,Gap junction trafficking and regulation,CP:REACTOME,C2,63,156
Cohort,0.11466132592742877,0.12625565742222458,0.9081678260482062,0.3640519034353864,LGP Proband,Gap junction trafficking and regulation,CP:REACTOME,C2,63,195
Cohort,0.00932145755806196,0.03957392264239308,0.2355454535628081,0.8138459903905485,LonGen OPEL,Gap junction trafficking and regulation,CP:REACTOME,C2,105,122
Cohort,0.010828466269889495,0.01853451311561048,0.5842325720857131,0.5592587571987446,LGP Offspring,Gastrin-CREB signalling pathway via PKC and MAPK,CP:REACTOME,C2,10,25
Cohort,0.035708151050702026,0.05240563427789941,0.6813799993593613,0.4958202281255749,LGP Proband,Gastrin-CREB signalling pathway via PKC and MAPK,CP:REACTOME,C2,10,34
Cohort,-0.042096760496967645,0.01658509426153501,-2.5382285944916565,0.011331048409208452,LonGen OPEL,Gastrin-CREB signalling pathway via PKC and MAPK,CP:REACTOME,C2,25,14
Cohort,2.817914685184808e-4,0.008454080573039079,0.03333200648893061,0.9734196695447876,LGP Offspring,GDP-fucose biosynthesis,CP:REACTOME,C2,2,5
Cohort,0.04027596890698061,0.028146399434075663,1.430945688144402,0.15282036104056182,LGP Proband,GDP-fucose biosynthesis,CP:REACTOME,C2,2,11
Cohort,0.004689732566407978,0.010814246384841944,0.43366244854393715,0.6646510800542271,LonGen OPEL,GDP-fucose biosynthesis,CP:REACTOME,C2,7,11
Cohort,0.02629816843870587,0.025057660651028792,1.0495061292813122,0.2943202906955539,LGP Offspring,Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation,CP:REACTOME,C2,17,46
Cohort,-0.012540456068825192,0.06492708714117919,-0.19314675308868995,0.84689106454749,LGP Proband,Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation,CP:REACTOME,C2,17,50
Cohort,0.014305457490910391,0.022030055011965134,0.6493609518060985,0.5162924193941045,LonGen OPEL,Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation,CP:REACTOME,C2,26,42
Cohort,-0.08078409775753621,0.04934586689756452,-1.637099575638894,0.10207506585819316,LGP Offspring,Gene Silencing by RNA,CP:REACTOME,C2,94,155
Cohort,-0.23242982347320792,0.14315654101569905,-1.6236060317196324,0.10483779381305242,LGP Proband,Gene Silencing by RNA,CP:REACTOME,C2,94,238
Cohort,0.005442766311437228,0.04643806338903155,0.11720485124112182,0.9067272882342713,LonGen OPEL,Gene Silencing by RNA,CP:REACTOME,C2,141,171
Cohort,-0.03378625625154997,0.0314055786594303,-1.0758042899937084,0.28239859248502003,LGP Offspring,Generation of second messenger molecules,CP:REACTOME,C2,32,56
Cohort,-0.0042157758187506824,0.08204761613703175,-0.05138206345580727,0.9590333807758338,LGP Proband,Generation of second messenger molecules,CP:REACTOME,C2,32,71
Cohort,0.014361029063639421,0.028442377964452554,0.5049166100523633,0.6137571616366848,LonGen OPEL,Generation of second messenger molecules,CP:REACTOME,C2,47,63
Cohort,-0.07276283970839544,0.02614413200067252,-2.783142301550639,0.00553387282179629,LGP Offspring,GLI proteins bind promoters of Hh responsive genes to promote transcription,CP:REACTOME,C2,33,37
Cohort,-0.019332166103013457,0.08259631492946064,-0.2340560365135372,0.8149989182185515,LGP Proband,GLI proteins bind promoters of Hh responsive genes to promote transcription,CP:REACTOME,C2,33,71
Cohort,-0.009495284059774234,0.022952400650060205,-0.4136945936306374,0.6792092202646566,LonGen OPEL,GLI proteins bind promoters of Hh responsive genes to promote transcription,CP:REACTOME,C2,40,41
Cohort,0.06677665210690421,0.04356879472697805,1.532671549106584,0.12582464069003113,LGP Offspring,Global Genome Nucleotide Excision Repair (GG-NER),CP:REACTOME,C2,55,140
Cohort,-0.05058395629169183,0.12082082160241284,-0.4186691964250113,0.6755657037757843,LGP Proband,Global Genome Nucleotide Excision Repair (GG-NER),CP:REACTOME,C2,55,186
Cohort,-0.030583688748608586,0.04070221948647148,-0.7514010079665049,0.452633447690734,LonGen OPEL,Global Genome Nucleotide Excision Repair (GG-NER),CP:REACTOME,C2,116,122
Cohort,-0.03903485846885586,0.024918063211933933,-1.5665285916026177,0.11769288384685923,LGP Offspring,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,CP:REACTOME,C2,24,33
Cohort,-0.08574598514070637,0.08325281548465391,-1.029946971060841,0.3033334943366753,LGP Proband,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,CP:REACTOME,C2,24,77
Cohort,0.015982936410310112,0.024790403508091672,0.6447227212374025,0.5192926452125053,LonGen OPEL,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,CP:REACTOME,C2,37,51
Cohort,0.014708596339979804,0.019010179270938756,0.7737221269904135,0.4393656179990659,LGP Offspring,Glucagon signaling in metabolic regulation,CP:REACTOME,C2,10,27
Cohort,0.05031278608977014,0.05966544182690276,0.8432483620205831,0.39933133346159755,LGP Proband,Glucagon signaling in metabolic regulation,CP:REACTOME,C2,10,47
Cohort,-0.02549105537748515,0.020923972363603417,-1.2182703615985475,0.22348221092999315,LonGen OPEL,Glucagon signaling in metabolic regulation,CP:REACTOME,C2,32,29
Cohort,0.025173266862399447,0.013985901427047918,1.7999030662203737,0.07232169351405515,LGP Offspring,Glucagon-type ligand receptors,CP:REACTOME,C2,3,17
Cohort,-0.02669425307301956,0.04159524907612358,-0.6417620681671201,0.5212040225941941,LGP Proband,Glucagon-type ligand receptors,CP:REACTOME,C2,3,26
Cohort,0.0015786407588418438,0.01395631070236058,0.1131130420143793,0.9099694556043346,LonGen OPEL,Glucagon-type ligand receptors,CP:REACTOME,C2,12,16
Cohort,-0.024767362558344302,0.01955269119115887,-1.266698395438442,0.2056994143324156,LGP Offspring,Glucocorticoid biosynthesis,CP:REACTOME,C2,13,20
Cohort,0.03869639774002574,0.058946931707488825,0.6564616107933845,0.5117082412357739,LGP Proband,Glucocorticoid biosynthesis,CP:REACTOME,C2,13,38
Cohort,-0.03625460173740267,0.016323123066928544,-2.2210579181906853,0.02662772325760083,LonGen OPEL,Glucocorticoid biosynthesis,CP:REACTOME,C2,27,15
Cohort,0.019535279421937154,0.0379065792405998,0.5153532661953816,0.6064746671333057,LGP Offspring,Gluconeogenesis,CP:REACTOME,C2,38,92
Cohort,0.023482364438091857,0.09846819764626662,0.2384766350903365,0.8115700171988575,LGP Proband,Gluconeogenesis,CP:REACTOME,C2,38,106
Cohort,-0.008878691981502587,0.030169520390816544,-0.2942934414100006,0.7686104095810458,LonGen OPEL,Gluconeogenesis,CP:REACTOME,C2,66,75
Cohort,0.0265027676918137,0.06508330532926164,0.4072129950643115,0.6839804682356688,LGP Offspring,Glucose metabolism,CP:REACTOME,C2,125,276
Cohort,-0.3050020329483228,0.16924630387968062,-1.8021193134306357,0.07188761213260592,LGP Proband,Glucose metabolism,CP:REACTOME,C2,125,334
Cohort,0.04890073322257008,0.055389731294081083,0.8828483561861147,0.3775847472532171,LonGen OPEL,Glucose metabolism,CP:REACTOME,C2,190,244
Cohort,-0.045372929887984595,0.03617065616188126,-1.2544126842741998,0.2101255978339735,LGP Offspring,Glucuronidation,CP:REACTOME,C2,18,25
Cohort,0.01606130472602093,0.1089815368583829,0.14737638309222914,0.8828705652967187,LGP Proband,Glucuronidation,CP:REACTOME,C2,18,28
Cohort,0.019300439660870482,0.0269834721401363,0.7152689453986996,0.47465261134409054,LonGen OPEL,Glucuronidation,CP:REACTOME,C2,10,25
Cohort,0.022377764794722362,0.017276287339630558,1.2952878332481415,0.19566311582707577,LGP Offspring,Glutamate and glutamine metabolism,CP:REACTOME,C2,6,24
Cohort,0.11399029579733212,0.0581081098738118,1.9616934029496862,0.05013046340043868,LGP Proband,Glutamate and glutamine metabolism,CP:REACTOME,C2,6,43
Cohort,0.013383689125482028,0.018349031383940125,0.729394857169192,0.4659747285595822,LonGen OPEL,Glutamate and glutamine metabolism,CP:REACTOME,C2,21,31
Cohort,-0.029014741515362253,0.027027330411769735,-1.0735333854033564,0.283414924186766,LGP Offspring,Glutamate Neurotransmitter Release Cycle,CP:REACTOME,C2,27,46
Cohort,-0.024453415168745284,0.06766546582615815,-0.36138693305636077,0.717901744883912,LGP Proband,Glutamate Neurotransmitter Release Cycle,CP:REACTOME,C2,27,50
Cohort,-0.023929922507257666,0.021677108700205963,-1.1039259357974387,0.2699588664375227,LonGen OPEL,Glutamate Neurotransmitter Release Cycle,CP:REACTOME,C2,42,34
Cohort,-0.04377936286607714,0.03882770842895167,-1.127528886907817,0.2599189753730477,LGP Offspring,Glutathione conjugation,CP:REACTOME,C2,51,93
Cohort,0.05834222408330402,0.10796626253355365,0.5403745828950268,0.5890830044475059,LGP Proband,Glutathione conjugation,CP:REACTOME,C2,51,116
Cohort,0.01120709517994455,0.031099349815094206,0.36036429206970555,0.7186703264017975,LonGen OPEL,Glutathione conjugation,CP:REACTOME,C2,61,79
Cohort,-0.009168881566304198,0.02266992437387294,-0.40445135215675104,0.6860087776952246,LGP Offspring,Glutathione synthesis and recycling,CP:REACTOME,C2,17,33
Cohort,-0.006088534417506385,0.058308174464594076,-0.10441991150320558,0.9168612277415136,LGP Proband,Glutathione synthesis and recycling,CP:REACTOME,C2,17,37
Cohort,-0.012993243707717098,0.017903070327068688,-0.7257550504100887,0.4682022685210261,LonGen OPEL,Glutathione synthesis and recycling,CP:REACTOME,C2,25,23
Cohort,-0.03966434297977093,0.06761845200246139,-0.586590520858524,0.5576745764218511,LGP Offspring,Glycerophospholipid biosynthesis,CP:REACTOME,C2,149,295
Cohort,-3.547115333221469e-4,0.1922170230112089,-0.0018453700289670094,0.9985280498796821,LGP Proband,Glycerophospholipid biosynthesis,CP:REACTOME,C2,149,414
Cohort,-0.017395540361269644,0.060242182110384554,-0.2887601303916081,0.7728401250937247,LonGen OPEL,Glycerophospholipid biosynthesis,CP:REACTOME,C2,232,275
Cohort,-0.0017506734403237335,0.013734530468475588,-0.12746511024472196,0.8986101924751038,LGP Offspring,Glycerophospholipid catabolism,CP:REACTOME,C2,8,11
Cohort,0.0052609156500445405,0.042373608118312034,0.12415547987689537,0.9012220877943294,LGP Proband,Glycerophospholipid catabolism,CP:REACTOME,C2,8,22
Cohort,-0.009284464594590109,0.01300970012975135,-0.7136570791019117,0.4756484398585282,LonGen OPEL,Glycerophospholipid catabolism,CP:REACTOME,C2,14,12
Cohort,0.0020516210888359204,0.03422382559358058,0.05994715825166975,0.9522154379055126,LGP Offspring,Glycogen breakdown (glycogenolysis),CP:REACTOME,C2,39,81
Cohort,0.040492968192597734,0.09219493902456205,0.43921031480708317,0.660622921594703,LGP Proband,Glycogen breakdown (glycogenolysis),CP:REACTOME,C2,39,110
Cohort,0.003924122020091526,0.0277101927548526,0.14161294563367247,0.8874215727059616,LonGen OPEL,Glycogen breakdown (glycogenolysis),CP:REACTOME,C2,54,66
Cohort,-0.0017073422339445136,0.03829758094547478,-0.04458094197582086,0.9644544990155354,LGP Offspring,Glycogen metabolism,CP:REACTOME,C2,48,100
Cohort,0.020706949142339778,0.10485537229471088,0.19748105117723452,0.8434992276926224,LGP Proband,Glycogen metabolism,CP:REACTOME,C2,48,135
Cohort,0.028866107032884152,0.0318356521195368,0.9067226556094226,0.3648278713203037,LonGen OPEL,Glycogen metabolism,CP:REACTOME,C2,68,90
Cohort,0.014193120819800367,0.02136727367031988,0.6642457544555748,0.5067595322015346,LGP Offspring,Glycogen storage diseases,CP:REACTOME,C2,12,33
Cohort,0.002712556354308575,0.057439467346584186,0.047224608437631786,0.962345520475599,LGP Proband,Glycogen storage diseases,CP:REACTOME,C2,12,41
Cohort,0.041455502420505934,0.0178525811207421,2.3221013331422804,0.020478924795713997,LonGen OPEL,Glycogen storage diseases,CP:REACTOME,C2,18,33
Cohort,-5.740741913171058e-4,0.019453759672299273,-0.029509678385435455,0.9764668098305751,LGP Offspring,Glycogen synthesis,CP:REACTOME,C2,11,26
Cohort,0.003950896969252768,0.050336450883826885,0.07848978026621643,0.9374572867479352,LGP Proband,Glycogen synthesis,CP:REACTOME,C2,11,33
Cohort,0.044830640586700964,0.019001227059058268,2.359355027302265,0.018547315593896666,LonGen OPEL,Glycogen synthesis,CP:REACTOME,C2,18,36
Cohort,0.0051073445738409,0.0548850984501852,0.09305521385693472,0.9258872684572268,LGP Offspring,Glycolysis,CP:REACTOME,C2,96,205
Cohort,-0.34453053728477234,0.14294361773781214,-2.4102547755347277,0.016156868873236127,LGP Proband,Glycolysis,CP:REACTOME,C2,96,247
Cohort,0.03785490497000939,0.04964320800933609,0.7625394588297003,0.44596400136181114,LonGen OPEL,Glycolysis,CP:REACTOME,C2,146,188
Cohort,-0.11552251065246881,0.06641684221470268,-1.7393556634177894,0.0824274020051029,LGP Offspring,Glycosaminoglycan metabolism,CP:REACTOME,C2,166,281
Cohort,-0.5868879956409544,0.19106882817352644,-3.0716051448640784,0.0021982393129780097,LGP Proband,Glycosaminoglycan metabolism,CP:REACTOME,C2,166,403
Cohort,-0.10226459219880847,0.057980876583168535,-1.763764162001221,0.07815526552602864,LonGen OPEL,Glycosaminoglycan metabolism,CP:REACTOME,C2,246,254
Cohort,-0.029542104562594464,0.04176984442032277,-0.707259147659669,0.4796491853144954,LGP Offspring,Glycosphingolipid metabolism,CP:REACTOME,C2,58,109
Cohort,-0.13438878594460082,0.11399864392838725,-1.1788630225200085,0.2387889340388229,LGP Proband,Glycosphingolipid metabolism,CP:REACTOME,C2,58,154
Cohort,-0.004080077557379664,0.03655134505655252,-0.1116259210452293,0.9111481591799663,LonGen OPEL,Glycosphingolipid metabolism,CP:REACTOME,C2,94,114
Cohort,0.041415402156752844,0.03918288298116262,1.056976899241016,0.29089970058762676,LGP Offspring,Glyoxylate metabolism and glycine degradation,CP:REACTOME,C2,41,105
Cohort,0.07796232529744003,0.09924248041839381,0.785574130843573,0.4323401404302777,LGP Proband,Glyoxylate metabolism and glycine degradation,CP:REACTOME,C2,41,128
Cohort,0.04363744943616961,0.033850245630658166,1.2891324308928256,0.19772653792686984,LonGen OPEL,Glyoxylate metabolism and glycine degradation,CP:REACTOME,C2,72,106
Cohort,-0.08262118671423804,0.04910967635597598,-1.6823810060435098,0.09295677885451427,LGP Offspring,Golgi Associated Vesicle Biogenesis,CP:REACTOME,C2,88,145
Cohort,-0.08662794658290036,0.13048857773416342,-0.6638737894697749,0.5069545709214643,LGP Proband,Golgi Associated Vesicle Biogenesis,CP:REACTOME,C2,88,177
Cohort,0.006045187160210144,0.03720372906770492,0.16248874270664793,0.870962231214014,LonGen OPEL,Golgi Associated Vesicle Biogenesis,CP:REACTOME,C2,97,126
Cohort,-0.0281514511925905,0.015119987065331759,-1.861870057887699,0.06305514291175972,LGP Offspring,Golgi Cisternae Pericentriolar Stack Reorganization,CP:REACTOME,C2,12,9
Cohort,-0.038108831147080365,0.04438462083018264,-0.8586044092363952,0.390805499456386,LGP Proband,Golgi Cisternae Pericentriolar Stack Reorganization,CP:REACTOME,C2,12,20
Cohort,0.003630835858459408,0.015214934883091174,0.23863630612671682,0.8114490314964911,LonGen OPEL,Golgi Cisternae Pericentriolar Stack Reorganization,CP:REACTOME,C2,15,21
Cohort,0.1420121693968964,0.058088814007969815,2.44474210434753,0.014749876240738516,LGP Offspring,Golgi-to-ER retrograde transport,CP:REACTOME,C2,83,240
Cohort,0.0964695192466202,0.1587115333257597,0.6078292939720638,0.543466171523935,LGP Proband,Golgi-to-ER retrograde transport,CP:REACTOME,C2,83,353
Cohort,-0.06596378761237728,0.05185327967958051,-1.2721237310347682,0.2037006628166427,LonGen OPEL,Golgi-to-ER retrograde transport,CP:REACTOME,C2,204,205
Cohort,0.02274895359186021,0.018281137184006382,1.244394884349021,0.2137855361599891,LGP Offspring,GP1b-IX-V activation signalling,CP:REACTOME,C2,8,22
Cohort,-0.07778848658098207,0.05352019356630764,-1.45344180201082,0.14647729607103332,LGP Proband,GP1b-IX-V activation signalling,CP:REACTOME,C2,8,33
Cohort,0.02401155677653373,0.01837776836396473,1.3065545446538425,0.19174141062484806,LonGen OPEL,GP1b-IX-V activation signalling,CP:REACTOME,C2,13,29
Cohort,0.010052265312270181,0.09806010380442963,0.10251126525746238,0.9183812721644031,LGP Offspring,GPCR ligand binding,CP:REACTOME,C2,274,574
Cohort,-0.7368408978821984,0.25274773849277116,-2.9153214279037862,0.0036483855406020224,LGP Proband,GPCR ligand binding,CP:REACTOME,C2,274,813
Cohort,0.008251953544593927,0.08255417099145644,0.09995804506895144,0.9204028026412157,LonGen OPEL,GPCR ligand binding,CP:REACTOME,C2,445,533
Cohort,-0.06759684583783505,0.027192774966858693,-2.485838459672431,0.013165189443125705,LGP Offspring,GPVI-mediated activation cascade,CP:REACTOME,C2,36,42
Cohort,0.061347980013129785,0.08154721511395571,0.7523001236449447,0.45208286151706356,LGP Proband,GPVI-mediated activation cascade,CP:REACTOME,C2,36,74
Cohort,-0.0025501671942257742,0.024924567462571438,-0.10231540419127805,0.9185320971766882,LonGen OPEL,GPVI-mediated activation cascade,CP:REACTOME,C2,44,53
Cohort,-2.518656855768844e-5,0.01890512383445547,-0.001332261495784796,0.998937402481466,LGP Offspring,GRB2 events in ERBB2 signaling,CP:REACTOME,C2,11,23
Cohort,0.012461702780166216,0.04839055317478781,0.2575234619689974,0.7968382314041784,LGP Proband,GRB2 events in ERBB2 signaling,CP:REACTOME,C2,11,26
Cohort,0.0064120930651242,0.01664305512824964,0.3852713949279914,0.7001392797374794,LonGen OPEL,GRB2 events in ERBB2 signaling,CP:REACTOME,C2,17,22
Cohort,-0.004828687279235586,0.024740751949565213,-0.19517140340273464,0.8453174103441329,LGP Offspring,GRB2:SOS provides linkage to MAPK signaling for Integrins ,CP:REACTOME,C2,21,37
Cohort,-0.13148569810528155,0.06928114978718435,-1.8978567548196756,0.0580600264881343,LGP Proband,GRB2:SOS provides linkage to MAPK signaling for Integrins ,CP:REACTOME,C2,21,58
Cohort,-0.018430516626372018,0.022067900261441526,-0.8351730979396811,0.4038708506172938,LonGen OPEL,GRB2:SOS provides linkage to MAPK signaling for Integrins ,CP:REACTOME,C2,35,37
Cohort,-0.014143461117239842,0.016959888612594884,-0.8339359674058541,0.4046116429977318,LGP Offspring,GRB7 events in ERBB2 signaling,CP:REACTOME,C2,11,18
Cohort,-0.017770765363907405,0.04729854791030095,-0.37571481893289127,0.7072244616626775,LGP Proband,GRB7 events in ERBB2 signaling,CP:REACTOME,C2,11,24
Cohort,0.031846964872711894,0.013893949542374998,2.292146288251746,0.022157371699880576,LonGen OPEL,GRB7 events in ERBB2 signaling,CP:REACTOME,C2,8,20
Cohort,-0.003758701061069473,0.017226826094702823,-0.21818883179097384,0.8273478344924299,LGP Offspring,Growth hormone receptor signaling,CP:REACTOME,C2,10,20
Cohort,0.06804785135751523,0.05426673158234047,1.2539515348232142,0.2102109814714529,LGP Proband,Growth hormone receptor signaling,CP:REACTOME,C2,10,40
Cohort,-0.04864532193161682,0.016581729216355073,-2.933670023005588,0.0034460189555003836,LonGen OPEL,Growth hormone receptor signaling,CP:REACTOME,C2,26,14
Cohort,0.034380456695929394,0.042629355769328574,0.8064972147823499,0.4202398474569834,LGP Offspring,HATs acetylate histones,CP:REACTOME,C2,51,128
Cohort,0.09333744931205949,0.12176207265093258,0.7665560160070469,0.4435624541179293,LGP Proband,HATs acetylate histones,CP:REACTOME,C2,51,199
Cohort,-0.07086391049104088,0.04039235973486304,-1.7543889724738597,0.07974863886188553,LonGen OPEL,HATs acetylate histones,CP:REACTOME,C2,117,107
Cohort,-0.017452080138159947,0.048697341948302136,-0.3583784954153627,0.7201719679527604,LGP Offspring,HCMV Early Events,CP:REACTOME,C2,84,169
Cohort,-0.25350650508872535,0.13707533874042346,-1.8493954304120672,0.06475438923156897,LGP Proband,HCMV Early Events,CP:REACTOME,C2,84,235
Cohort,-0.053427753238360125,0.04673212396938691,-1.1432768019138047,0.25326740471007864,LonGen OPEL,HCMV Early Events,CP:REACTOME,C2,151,158
Cohort,-0.07674690572229151,0.05260857539869049,-1.4588288152771736,0.145076702193669,LGP Offspring,HCMV Infection,CP:REACTOME,C2,107,194
Cohort,-0.29584076633371414,0.14660215249976496,-2.0179837832475784,0.04391270891202823,LGP Proband,HCMV Infection,CP:REACTOME,C2,107,264
Cohort,-0.07075746294804434,0.050436486784999374,-1.4029022927324264,0.16103589401261256,LonGen OPEL,HCMV Infection,CP:REACTOME,C2,182,191
Cohort,-0.09342340006820431,0.04244286792817051,-2.2011566283954296,0.028062193418671343,LGP Offspring,HCMV Late Events,CP:REACTOME,C2,76,118
Cohort,-0.3003252346551916,0.11378540430970513,-2.639400338533366,0.00846033266652261,LGP Proband,HCMV Late Events,CP:REACTOME,C2,76,148
Cohort,-0.015259452638783602,0.04067701296890726,-0.3751370006064024,0.7076585123378663,LonGen OPEL,HCMV Late Events,CP:REACTOME,C2,111,128
Cohort,-0.06494379594240689,0.030147912715732604,-2.154172215992789,0.03157940146561512,LGP Offspring,HDACs deacetylate histones,CP:REACTOME,C2,36,50
Cohort,0.0335761154991555,0.08421357147751071,0.39870195397332153,0.6902148841415978,LGP Proband,HDACs deacetylate histones,CP:REACTOME,C2,36,83
Cohort,-0.06104596024700984,0.02530062884073643,-2.4128238326124136,0.016054522559167644,LonGen OPEL,HDACs deacetylate histones,CP:REACTOME,C2,55,43
Cohort,0.001041246085087811,0.02191535615934468,0.047512168066856854,0.9621190654509906,LGP Offspring,HDL assembly,CP:REACTOME,C2,15,33
Cohort,0.015080595709793448,0.06200578982896889,0.2432127024168289,0.8079004333017978,LGP Proband,HDL assembly,CP:REACTOME,C2,15,47
Cohort,0.02479838072727513,0.016885302454548265,1.4686370465691825,0.14232631880741647,LonGen OPEL,HDL assembly,CP:REACTOME,C2,18,27
Cohort,0.020137815950843012,0.01723985036716522,1.1680969104695489,0.24317947352781194,LGP Offspring,HDL clearance,CP:REACTOME,C2,7,23
Cohort,0.03751538982223984,0.04686470001225749,0.8005042134576273,0.423646692436636,LGP Proband,HDL clearance,CP:REACTOME,C2,7,30
Cohort,0.009190576255415197,0.014174278823316972,0.6483981562643254,0.5169144594848967,LonGen OPEL,HDL clearance,CP:REACTOME,C2,12,19
Cohort,5.215198943081412e-4,0.00947670734470635,0.05503176106830609,0.956129420497918,LGP Offspring,HDL remodeling,CP:REACTOME,C2,3,6
Cohort,-0.014793649874664392,0.02837028233150856,-0.5214488069522767,0.6021925969366431,LGP Proband,HDL remodeling,CP:REACTOME,C2,3,10
Cohort,-0.010725118500366233,0.008177762485340244,-1.3114979212947886,0.19006774740351606,LonGen OPEL,HDL remodeling,CP:REACTOME,C2,6,4
Cohort,-0.06613813477693255,0.02971570624916056,-2.225696210023643,0.026363569720235205,LGP Offspring,HDMs demethylate histones,CP:REACTOME,C2,36,43
Cohort,-0.17142264840758983,0.07514451167392072,-2.2812397684005834,0.022785581961303487,LGP Proband,HDMs demethylate histones,CP:REACTOME,C2,36,53
Cohort,-0.03421204217966599,0.019094590910170402,-1.791713807361201,0.07355856562249613,LonGen OPEL,HDMs demethylate histones,CP:REACTOME,C2,32,22
Cohort,-0.0253544475226971,0.04438522434549755,-0.5712362142260764,0.5680293916904597,LGP Offspring,HDR through Homologous Recombination (HRR),CP:REACTOME,C2,73,144
Cohort,0.12707018546481957,0.13730891116923827,0.9254329116935529,0.35500846245389983,LGP Proband,HDR through Homologous Recombination (HRR),CP:REACTOME,C2,73,232
Cohort,-0.014554734192464665,0.043281692842575194,-0.33627922654049963,0.7367489401879241,LonGen OPEL,HDR through Homologous Recombination (HRR),CP:REACTOME,C2,122,143
Cohort,0.03361113737005116,0.024356938017479353,1.3799409985742332,0.1680610248345734,LGP Offspring,HDR through MMEJ (alt-NHEJ),CP:REACTOME,C2,19,44
Cohort,0.05049692337569683,0.0667193813360303,0.7568553899109239,0.44935025860898703,LGP Proband,HDR through MMEJ (alt-NHEJ),CP:REACTOME,C2,19,54
Cohort,-0.02327969321513903,0.021657763570805028,-1.0748890641008004,0.2827501037009747,LonGen OPEL,HDR through MMEJ (alt-NHEJ),CP:REACTOME,C2,37,32
Cohort,-0.025272798894650603,0.03579098478630784,-0.7061219199623402,0.4803556016117634,LGP Offspring,HDR through Single Strand Annealing (SSA),CP:REACTOME,C2,48,90
Cohort,0.14003206252831138,0.10606282325272198,1.3202747035561078,0.18710553939909144,LGP Proband,HDR through Single Strand Annealing (SSA),CP:REACTOME,C2,48,137
Cohort,-0.016345348205070085,0.031432153507297174,-0.5200199916711213,0.6031942276684437,LonGen OPEL,HDR through Single Strand Annealing (SSA),CP:REACTOME,C2,71,78
Cohort,0.001462126867348039,0.039093814509083835,0.03740046566722977,0.9701767430125718,LGP Offspring,Hedgehog ligand biogenesis,CP:REACTOME,C2,51,97
Cohort,-0.2314609962215794,0.10591169521639753,-2.185414894442592,0.029135962954884114,LGP Proband,Hedgehog ligand biogenesis,CP:REACTOME,C2,51,141
Cohort,-0.07299058078474877,0.034232891320248225,-2.1321769202000174,0.03329783158196819,LonGen OPEL,Hedgehog ligand biogenesis,CP:REACTOME,C2,89,77
Cohort,0.024063629073862357,0.059889437500897896,0.40180088640006983,0.6879575667987134,LGP Offspring,Hedgehog 'off' state,CP:REACTOME,C2,113,241
Cohort,-0.09940478052306681,0.16703138785449964,-0.5951263519983316,0.5519204514207956,LGP Proband,Hedgehog 'off' state,CP:REACTOME,C2,113,352
Cohort,-0.07734951304298986,0.05350103334221896,-1.4457573659974805,0.14863885814795083,LonGen OPEL,Hedgehog 'off' state,CP:REACTOME,C2,209,217
Cohort,0.018200465024699696,0.052691553271392876,0.3454152306149804,0.729889684278565,LGP Offspring,Hedgehog 'on' state,CP:REACTOME,C2,88,192
Cohort,-0.14485333172616327,0.1441191123831933,-1.0050945313971804,0.31514285243711365,LGP Proband,Hedgehog 'on' state,CP:REACTOME,C2,88,241
Cohort,-0.004018157327044729,0.046597441475005226,-0.08623128652245983,0.9313042456055378,LonGen OPEL,Hedgehog 'on' state,CP:REACTOME,C2,146,170
Cohort,0.010223892217379371,0.018275342248656363,0.5594364296039955,0.5760492039105952,LGP Offspring,Heme biosynthesis,CP:REACTOME,C2,9,25
Cohort,0.018523330568281964,0.04432372941111265,0.4179100182765279,0.6761204809386245,LGP Proband,Heme biosynthesis,CP:REACTOME,C2,9,24
Cohort,-0.03518624945945772,0.016360651032357548,-2.1506631606448625,0.03180326082110485,LonGen OPEL,Heme biosynthesis,CP:REACTOME,C2,27,15
Cohort,0.0056531439788503,0.036330373998804226,0.15560379254659934,0.8763917873085173,LGP Offspring,Heme degradation,CP:REACTOME,C2,37,81
Cohort,-0.059234242887917815,0.09520908001314389,-0.6221490941803067,0.5340138808859788,LGP Proband,Heme degradation,CP:REACTOME,C2,37,102
Cohort,-0.019475823220012164,0.029289595330646585,-0.6649399897865446,0.5062814730808486,LonGen OPEL,Heme degradation,CP:REACTOME,C2,63,64
Cohort,-0.04659867966786156,0.036530753555642136,-1.2756013805432285,0.20253462404808503,LGP Offspring,Heme signaling,CP:REACTOME,C2,49,77
Cohort,0.030368211772994622,0.10554532449851368,0.28772673652087993,0.7736274033203281,LGP Proband,Heme signaling,CP:REACTOME,C2,49,117
Cohort,-0.02886411033717253,0.03330067569524813,-0.8667725124055462,0.3863278621976767,LonGen OPEL,Heme signaling,CP:REACTOME,C2,81,79
Cohort,-0.1390051737820697,0.13481375838358742,-1.0310904127941927,0.3028671774672335,LGP Offspring,Hemostasis,CP:REACTOME,C2,562,1100
Cohort,-0.09348698026146013,0.385929928875775,-0.24223822322821761,0.8086551329914851,LGP Proband,Hemostasis,CP:REACTOME,C2,562,1667
Cohort,-0.05247065379201286,0.11267866718841135,-0.46566626231277697,0.6415817869266199,LonGen OPEL,Hemostasis,CP:REACTOME,C2,897,1052
Cohort,-0.09400557549232874,0.045343876520704686,-2.0731702427207432,0.038534707828042476,LGP Offspring,Heparan sulfate/heparin (HS-GAG) metabolism,CP:REACTOME,C2,77,123
Cohort,-0.13558619875379674,0.12913156112466576,-1.0499849732545212,0.294029176176576,LGP Proband,Heparan sulfate/heparin (HS-GAG) metabolism,CP:REACTOME,C2,77,182
Cohort,-0.010837670377474285,0.03853376419415182,-0.2812512767470325,0.7785907708474666,LonGen OPEL,Heparan sulfate/heparin (HS-GAG) metabolism,CP:REACTOME,C2,107,122
Cohort,-0.007610974003335706,0.023101325069792268,-0.32946049546257244,0.7419097032276311,LGP Offspring,Highly calcium permeable nicotinic acetylcholine receptors,CP:REACTOME,C2,18,34
Cohort,-0.10537815939545266,0.059349301346853026,-1.7755585492000117,0.07617030909857479,LGP Proband,Highly calcium permeable nicotinic acetylcholine receptors,CP:REACTOME,C2,18,39
Cohort,0.0057078941844735925,0.019732536593557275,0.289263073574496,0.7724553889923473,LonGen OPEL,Highly calcium permeable nicotinic acetylcholine receptors,CP:REACTOME,C2,25,33
Cohort,-0.011946191242721178,0.023488767390817362,-0.5085916618762801,0.6112044120489326,LGP Offspring,Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,CP:REACTOME,C2,19,35
Cohort,-0.1016500933040596,0.0611014715940547,-1.663627579698921,0.09656255216141403,LGP Proband,Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,CP:REACTOME,C2,19,42
Cohort,0.007815839901176106,0.02046255222468746,0.3819582139781433,0.7025943052163882,LonGen OPEL,Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,CP:REACTOME,C2,27,36
Cohort,-0.016201168060053926,0.02373626650516074,-0.6825491303163228,0.49512560725172705,LGP Offspring,Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,CP:REACTOME,C2,20,37
Cohort,-0.06691933503319863,0.06533961118024856,-1.024177123561268,0.3060485912627936,LGP Proband,Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,CP:REACTOME,C2,20,51
Cohort,-0.005813329741535801,0.018546976773255883,-0.3134381313249083,0.7540299307619466,LonGen OPEL,Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,CP:REACTOME,C2,26,29
Cohort,0.019163089434691166,0.022198748514950545,0.8632508910033867,0.388305702296456,LGP Offspring,Histidine catabolism,CP:REACTOME,C2,12,35
Cohort,0.04940282055418232,0.056219698811656234,0.8787457350080903,0.3797922539150581,LGP Proband,Histidine catabolism,CP:REACTOME,C2,12,40
Cohort,-0.03655502612545111,0.017804367282339195,-2.053149406871166,0.040384407108512314,LonGen OPEL,Histidine catabolism,CP:REACTOME,C2,31,20
Cohort,-0.006403485316376634,0.01721735830476325,-0.37192031454703967,0.7100687323491128,LGP Offspring,HIV elongation arrest and recovery,CP:REACTOME,C2,11,19
Cohort,-0.025268329163559675,0.052275971959870104,-0.4833641196180346,0.6289640912153664,LGP Proband,HIV elongation arrest and recovery,CP:REACTOME,C2,11,35
Cohort,0.01717374346615948,0.015841017390298966,1.0841313435257431,0.27863482229849906,LonGen OPEL,HIV elongation arrest and recovery,CP:REACTOME,C2,12,21
Cohort,-0.11241477968821478,0.07106174369684215,-1.581931062201198,0.11413303652269216,LGP Offspring,HIV Infection,CP:REACTOME,C2,176,312
Cohort,-0.2690106837179277,0.18906469295912384,-1.4228499224658955,0.15515359595162523,LGP Proband,HIV Infection,CP:REACTOME,C2,176,442
Cohort,-0.05840721427056835,0.06427306118647573,-0.9087355291995698,0.36376479422262864,LonGen OPEL,HIV Infection,CP:REACTOME,C2,257,298
Cohort,-0.15688491980891978,0.0581908079915747,-2.6960429872641525,0.007191491772770636,LGP Offspring,HIV Life Cycle,CP:REACTOME,C2,133,205
Cohort,-0.30153595007911377,0.15658136058278538,-1.925746135790474,0.05447575750257611,LGP Proband,HIV Life Cycle,CP:REACTOME,C2,133,286
Cohort,0.007063356868093276,0.051593403016192765,0.13690426401756087,0.8911410869662706,LonGen OPEL,HIV Life Cycle,CP:REACTOME,C2,165,201
Cohort,-0.017694606979164938,0.024342966997512913,-0.7268878514674391,0.4675462939826259,LGP Offspring,HIV Transcription Elongation,CP:REACTOME,C2,23,37
Cohort,-0.06088601481747718,0.07109106687104466,-0.8564509930329377,0.39199437602788345,LGP Proband,HIV Transcription Elongation,CP:REACTOME,C2,23,65
Cohort,0.014675878811186613,0.02017794897539785,0.7273226247662888,0.4672421988000902,LonGen OPEL,HIV Transcription Elongation,CP:REACTOME,C2,24,35
Cohort,-0.025166295819616102,0.03249046831532787,-0.7745747329761794,0.43886182114745687,LGP Offspring,HIV Transcription Initiation,CP:REACTOME,C2,35,60
Cohort,0.061370428294099166,0.09040069946960977,0.6788711664197932,0.4974078351965161,LGP Proband,HIV Transcription Initiation,CP:REACTOME,C2,35,94
Cohort,0.037125600050530255,0.02524846022208625,1.4704104616270581,0.14184577689723288,LonGen OPEL,HIV Transcription Initiation,CP:REACTOME,C2,35,52
Cohort,-0.007860063000854478,0.03642237796821708,-0.21580312542232502,0.8292063094135548,LGP Offspring,Homologous DNA Pairing and Strand Exchange,CP:REACTOME,C2,49,96
Cohort,0.1333961601430887,0.110909864667147,1.2027438726341033,0.22941678898254536,LGP Proband,Homologous DNA Pairing and Strand Exchange,CP:REACTOME,C2,49,151
Cohort,-0.015053013391868394,0.0342452835744389,-0.4395645712539565,0.6603718141645882,LonGen OPEL,Homologous DNA Pairing and Strand Exchange,CP:REACTOME,C2,82,91
Cohort,0.04095985803228525,0.05642304450851552,0.7259420045315612,0.46812557807473165,LGP Offspring,Homology Directed Repair,CP:REACTOME,C2,107,238
Cohort,0.12215435306376078,0.17028813448102834,0.7173391935735246,0.47336568764653564,LGP Proband,Homology Directed Repair,CP:REACTOME,C2,107,352
Cohort,-0.00861472312641983,0.05365700947834264,-0.16055168206675693,0.8724872482052222,LonGen OPEL,Homology Directed Repair,CP:REACTOME,C2,183,222
Cohort,-0.0027469037116701466,0.011638159906774649,-0.23602560316009716,0.8134842946156172,LGP Offspring,Hormone ligand-binding receptors,CP:REACTOME,C2,5,9
Cohort,0.028569816181780956,0.03769636844196749,0.7578930640431157,0.4487290960018564,LGP Proband,Hormone ligand-binding receptors,CP:REACTOME,C2,5,19
Cohort,-0.0036965689332023742,0.012565645834253842,-0.294180576307949,0.7686966163035256,LonGen OPEL,Hormone ligand-binding receptors,CP:REACTOME,C2,12,12
Cohort,0.0014211963786969384,0.05637801684654541,0.025208342864653687,0.9798962217797734,LGP Offspring,Host Interactions of HIV factors,CP:REACTOME,C2,100,205
Cohort,-0.2227760469179057,0.15377491298972507,-1.4487151550707829,0.14779300763159,LGP Proband,Host Interactions of HIV factors,CP:REACTOME,C2,100,283
Cohort,-0.0701514386045876,0.0521865346068629,-1.3442440494096763,0.17925245073898965,LonGen OPEL,Host Interactions of HIV factors,CP:REACTOME,C2,175,194
Cohort,-0.021523029890108736,0.03282835232539074,-0.6556232148593695,0.5122896442052766,LGP Offspring,HS-GAG biosynthesis,CP:REACTOME,C2,36,69
Cohort,-0.1269927686429088,0.0927347118086058,-1.3694199956647066,0.1712366542387151,LGP Proband,HS-GAG biosynthesis,CP:REACTOME,C2,36,97
Cohort,0.04431632834179954,0.027395693477761524,1.6176384940856985,0.1061366983291584,LonGen OPEL,HS-GAG biosynthesis,CP:REACTOME,C2,41,67
Cohort,-0.03560021971158461,0.023446915652269487,-1.5183327410545266,0.12939805468315535,LGP Offspring,HS-GAG degradation,CP:REACTOME,C2,20,31
Cohort,0.013044309550101498,0.07195845675516895,0.18127556007049156,0.8561953330533938,LGP Proband,HS-GAG degradation,CP:REACTOME,C2,20,60
Cohort,5.621169095385256e-4,0.02237612830898737,0.025121276646985952,0.9799645254091083,LonGen OPEL,HS-GAG degradation,CP:REACTOME,C2,30,35
Cohort,-0.013466926763486254,0.020285236131995066,-0.6638782351784126,0.5069945993594258,LGP Offspring,HSF1 activation,CP:REACTOME,C2,15,25
Cohort,0.06284901245146722,0.05344249179495435,1.1760120147953312,0.2399256541515727,LGP Proband,HSF1 activation,CP:REACTOME,C2,15,34
Cohort,0.004157141593012705,0.021904060780298284,0.189788625712355,0.849523154582394,LonGen OPEL,HSF1 activation,CP:REACTOME,C2,32,35
Cohort,-0.010707502854716994,0.026175878092310537,-0.4090599297932414,0.6826252460025054,LGP Offspring,HSF1-dependent transactivation,CP:REACTOME,C2,23,41
Cohort,-0.007184261923364416,0.06347816959970967,-0.11317689165689608,0.9099175522792478,LGP Proband,HSF1-dependent transactivation,CP:REACTOME,C2,23,41
Cohort,-0.01630485743236922,0.022883225914754078,-0.7125244269802266,0.4763488908353417,LonGen OPEL,HSF1-dependent transactivation,CP:REACTOME,C2,38,36
Cohort,0.04786803549331874,0.03383169858597547,1.4148871470840625,0.15756204740821927,LGP Offspring,HSP90 chaperone cycle for steroid hormone receptors (SHR),CP:REACTOME,C2,27,81
Cohort,0.015434230441572636,0.09594342698588393,0.1608680336574121,0.8722362975464368,LGP Proband,HSP90 chaperone cycle for steroid hormone receptors (SHR),CP:REACTOME,C2,27,124
Cohort,0.014633250293291895,0.02978427811777137,0.49130787173789786,0.6233441469945333,LonGen OPEL,HSP90 chaperone cycle for steroid hormone receptors (SHR),CP:REACTOME,C2,57,71
Cohort,-0.027636345557690446,0.012557283614405574,-2.2008219616849574,0.02808599767466144,LGP Offspring,HuR (ELAVL1) binds and stabilizes mRNA,CP:REACTOME,C2,10,7
Cohort,-0.054069740342757695,0.040261101732086496,-1.3429771669578099,0.17964472624442365,LGP Proband,HuR (ELAVL1) binds and stabilizes mRNA,CP:REACTOME,C2,10,17
Cohort,0.010267036343509355,0.011157214462389792,0.9202150212419805,0.35773918981962105,LonGen OPEL,HuR (ELAVL1) binds and stabilizes mRNA,CP:REACTOME,C2,7,12
Cohort,0.003455445577434768,0.016453693920192965,0.21001032316482057,0.8337228947065072,LGP Offspring,Hyaluronan biosynthesis and export,CP:REACTOME,C2,11,17
Cohort,-0.14952889079488385,0.03822965477185847,-3.9113324901106545,9.925479105686912e-5,LGP Proband,Hyaluronan biosynthesis and export,CP:REACTOME,C2,11,14
Cohort,-0.01969248811981551,0.013223054989845528,-1.489254044162873,0.13681656852304203,LonGen OPEL,Hyaluronan biosynthesis and export,CP:REACTOME,C2,16,11
Cohort,0.01235498921638026,0.026567977078054198,0.46503311788031404,0.6420574970382256,LGP Offspring,Hyaluronan metabolism,CP:REACTOME,C2,26,44
Cohort,-0.3793849700575831,0.06828113503335334,-5.55621944292907,3.709271272644811e-8,LGP Proband,Hyaluronan metabolism,CP:REACTOME,C2,26,51
Cohort,-0.019652774956088966,0.0229852875824103,-0.8550154043375306,0.3927998867832341,LonGen OPEL,Hyaluronan metabolism,CP:REACTOME,C2,38,37
Cohort,0.00889954363894544,0.020408403196937937,0.43607251155645144,0.6629233431864572,LGP Offspring,Hyaluronan uptake and degradation,CP:REACTOME,C2,15,27
Cohort,-0.22985607926269916,0.056813065515094074,-4.04583130972982,5.6979389355251305e-5,LGP Proband,Hyaluronan uptake and degradation,CP:REACTOME,C2,15,37
Cohort,3.971316372653594e-5,0.01813662804365104,0.002189666327773538,0.9982534490675026,LonGen OPEL,Hyaluronan uptake and degradation,CP:REACTOME,C2,22,26
Cohort,-0.026600308312907966,0.023926813674041276,-1.1117363421343154,0.2666467537018745,LGP Offspring,Hydrolysis of LPC,CP:REACTOME,C2,21,35
Cohort,0.020236297233494044,0.06875029647141577,0.2943448722713169,0.7685676314874634,LGP Proband,Hydrolysis of LPC,CP:REACTOME,C2,21,53
Cohort,-0.011339088506515065,0.02206351294720207,-0.5139294242784218,0.6074439678369501,LonGen OPEL,Hydrolysis of LPC,CP:REACTOME,C2,39,37
Cohort,0.007656218712513944,0.018671175913734607,0.4100555180823931,0.6818951396685033,LGP Offspring,IkBA variant leads to EDA-ID,CP:REACTOME,C2,8,23
Cohort,0.014090173843029559,0.04360815164029917,0.32310871506896305,0.7466939034063862,LGP Proband,IkBA variant leads to EDA-ID,CP:REACTOME,C2,8,20
Cohort,0.007850857853044332,0.01739486234408307,0.4513319908918297,0.6518732241253564,LonGen OPEL,IkBA variant leads to EDA-ID,CP:REACTOME,C2,17,22
Cohort,-0.018147142307561995,0.017120688339460472,-1.0599540128147598,0.2895440869117056,LGP Offspring,IKK complex recruitment mediated by RIP1,CP:REACTOME,C2,10,14
Cohort,-0.005344396426330158,0.04946298627599485,-0.10804839797802253,0.9139832888338764,LGP Proband,IKK complex recruitment mediated by RIP1,CP:REACTOME,C2,10,25
Cohort,-0.00880272300956069,0.01651776172363915,-0.5329246877900413,0.5942344596478781,LonGen OPEL,IKK complex recruitment mediated by RIP1,CP:REACTOME,C2,18,16
Cohort,-0.005212272515700681,0.020281432175450427,-0.2569972608743999,0.7972590885080348,LGP Offspring,IL-6-type cytokine receptor ligand interactions,CP:REACTOME,C2,12,24
Cohort,-0.059953803265520154,0.053783796650949345,-1.11471868850415,0.2652921088867241,LGP Proband,IL-6-type cytokine receptor ligand interactions,CP:REACTOME,C2,12,31
Cohort,-0.013445538947750881,0.017943762633144875,-0.7493154709322176,0.45388846344041667,LonGen OPEL,IL-6-type cytokine receptor ligand interactions,CP:REACTOME,C2,26,23
Cohort,-0.05340387906627805,0.04924488620685509,-1.0844553248017053,0.27854957192377267,LGP Offspring,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,CP:REACTOME,C2,78,146
Cohort,0.22957447383465407,0.1348760809507503,1.7021140606723493,0.08910665356610349,LGP Proband,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,CP:REACTOME,C2,78,217
Cohort,-0.10948963290691754,0.045117480787032815,-2.42676743020603,0.01545504720071748,LonGen OPEL,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,CP:REACTOME,C2,153,137
Cohort,0.02496197613190168,0.014547870691628904,1.7158508390004616,0.08664753043735646,LGP Offspring,Inactivation of CDC42 and RAC1,CP:REACTOME,C2,3,18
Cohort,0.021975880334682316,0.034972638254789426,0.6283735351785411,0.5299313089686094,LGP Proband,Inactivation of CDC42 and RAC1,CP:REACTOME,C2,3,17
Cohort,-0.012087513410345412,0.011757722909262023,-1.0280488410577868,0.3042391394844848,LonGen OPEL,Inactivation of CDC42 and RAC1,CP:REACTOME,C2,12,9
Cohort,-0.031377869544418124,0.017766534175640034,-1.7661221504552531,0.07782666316328557,LGP Offspring,Inactivation of CSF3 (G-CSF) signaling,CP:REACTOME,C2,14,14
Cohort,-0.0018270915531386535,0.056770129881134765,-0.0321840298227997,0.9743329923480629,LGP Proband,Inactivation of CSF3 (G-CSF) signaling,CP:REACTOME,C2,14,34
Cohort,-0.011224430263363843,0.01765994018911941,-0.6355871052315005,0.5252282526602794,LonGen OPEL,Inactivation of CSF3 (G-CSF) signaling,CP:REACTOME,C2,23,22
Cohort,-0.005349514661811564,0.01270650381534855,-0.4210060249106235,0.6738844981430789,LGP Offspring,"Incretin synthesis, secretion, and inactivation",CP:REACTOME,C2,6,10
Cohort,0.0014956653949249263,0.038315394356275276,0.039035625759648925,0.9688713270094262,LGP Proband,"Incretin synthesis, secretion, and inactivation",CP:REACTOME,C2,6,18
Cohort,0.016907034994448553,0.013804273749909862,1.2247681624365752,0.22102490260551866,LonGen OPEL,"Incretin synthesis, secretion, and inactivation",CP:REACTOME,C2,10,19
Cohort,0.005279491782275984,0.02531266216872881,0.20857117860950453,0.8348458396223319,LGP Offspring,Infection with Mycobacterium tuberculosis,CP:REACTOME,C2,21,43
Cohort,-0.011082848332993105,0.0716891031960016,-0.15459599630772397,0.8771772301572691,LGP Proband,Infection with Mycobacterium tuberculosis,CP:REACTOME,C2,21,61
Cohort,-0.0046263149987302715,0.022554383945263233,-0.20511821603985192,0.8375322047119889,LonGen OPEL,Infection with Mycobacterium tuberculosis,CP:REACTOME,C2,36,40
Cohort,-0.25012358282910413,0.1331657727245389,-1.8782873234738722,0.06077205093502405,LGP Offspring,Infectious disease,CP:REACTOME,C2,550,1047
Cohort,-0.06705215205098804,0.3554901425161395,-0.18861887864568236,0.8504374223448415,LGP Proband,Infectious disease,CP:REACTOME,C2,550,1485
Cohort,-0.22857396721439538,0.110255623259696,-2.073127523627638,0.038481620721086005,LonGen OPEL,Infectious disease,CP:REACTOME,C2,878,960
Cohort,0.017217643323640293,0.02837809059867266,0.6067231078769485,0.5442383887249469,LGP Offspring,Inflammasomes,CP:REACTOME,C2,22,57
Cohort,0.11418556399699197,0.07463460989331788,1.529927793019993,0.12641378947593104,LGP Proband,Inflammasomes,CP:REACTOME,C2,22,63
Cohort,0.051384665403258506,0.024729765721748266,2.0778468337073224,0.0380434536005126,LonGen OPEL,Inflammasomes,CP:REACTOME,C2,32,57
Cohort,-0.13706236399473684,0.04850231526669608,-2.825893222644779,0.004854101344567798,LGP Offspring,Influenza Infection,CP:REACTOME,C2,100,142
Cohort,-0.2874775256448317,0.13664249592899694,-2.103866177870555,0.03568898584226098,LGP Proband,Influenza Infection,CP:REACTOME,C2,100,213
Cohort,0.009086974450807223,0.044332165689205644,0.20497474710602268,0.8376442569547209,LonGen OPEL,Influenza Infection,CP:REACTOME,C2,133,156
Cohort,-0.012381182665339873,0.017533807661985496,-0.7061319996216868,0.4803493378940853,LGP Offspring,Inhibition of DNA recombination at telomere,CP:REACTOME,C2,12,20
Cohort,-0.04363730085784232,0.044479166773172714,-0.9810728038224368,0.3268413471914857,LGP Proband,Inhibition of DNA recombination at telomere,CP:REACTOME,C2,12,21
Cohort,0.019375845180313166,0.014812428357551755,1.3080802629121149,0.19122369842044534,LonGen OPEL,Inhibition of DNA recombination at telomere,CP:REACTOME,C2,11,19
Cohort,-0.03360700546561193,0.016410492988890447,-2.0478973720267364,0.04095591122384196,LGP Offspring,Inhibition of replication initiation of damaged DNA by RB1/E2F1,CP:REACTOME,C2,13,14
Cohort,-0.01705430495098168,0.04979080055871426,-0.3425191955062245,0.7320465043765896,LGP Proband,Inhibition of replication initiation of damaged DNA by RB1/E2F1,CP:REACTOME,C2,13,26
Cohort,-0.006258432272526874,0.015179460753082357,-0.41229608708306914,0.680233427472682,LonGen OPEL,Inhibition of replication initiation of damaged DNA by RB1/E2F1,CP:REACTOME,C2,18,18
Cohort,0.008332335447873877,0.02195381153754692,0.3795393539578921,0.7044065830493573,LGP Offspring,Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components,CP:REACTOME,C2,14,34
Cohort,-4.5959561910479936e-4,0.061570302432788424,-0.007464566535246512,0.9940459780300293,LGP Proband,Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components,CP:REACTOME,C2,14,51
Cohort,-0.018067064819632103,0.020177333797982543,-0.8954138837430821,0.37083656536283316,LonGen OPEL,Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components,CP:REACTOME,C2,29,32
Cohort,-0.006439903768090105,0.023589456701926054,-0.27299924069740417,0.7849371758152814,LGP Offspring,Initial triggering of complement,CP:REACTOME,C2,18,34
Cohort,0.020695741797953977,0.06377227200846587,0.3245257091547026,0.7456214400109711,LGP Proband,Initial triggering of complement,CP:REACTOME,C2,18,48
Cohort,0.005339764268009601,0.021161285799771383,0.2523364751336277,0.8008461384384519,LonGen OPEL,Initial triggering of complement,CP:REACTOME,C2,30,40
Cohort,-0.021710760858760735,0.01831505454160245,-1.1854051981906455,0.23627380505839474,LGP Offspring,Initiation of Nuclear Envelope (NE) Reformation,CP:REACTOME,C2,14,18
Cohort,-0.06889832537929284,0.05115378906414806,-1.3468860594645826,0.17838280030504014,LGP Proband,Initiation of Nuclear Envelope (NE) Reformation,CP:REACTOME,C2,14,30
Cohort,-0.0035262727178388205,0.017536856400719596,-0.20107781219524187,0.840689099227361,LonGen OPEL,Initiation of Nuclear Envelope (NE) Reformation,CP:REACTOME,C2,20,24
Cohort,5.233971966772755e-4,0.012735515333526347,0.041097449374461366,0.9672303428255691,LGP Offspring,InlA-mediated entry of Listeria monocytogenes into host cells,CP:REACTOME,C2,5,9
Cohort,-0.05388782402690188,0.0388521909237872,-1.3869957586847215,0.16581362116144285,LGP Proband,InlA-mediated entry of Listeria monocytogenes into host cells,CP:REACTOME,C2,5,18
Cohort,0.013306282992904353,0.012002072539340781,1.1086654366809223,0.26790939212063114,LonGen OPEL,InlA-mediated entry of Listeria monocytogenes into host cells,CP:REACTOME,C2,7,15
Cohort,0.021533033968004663,0.020604252798253436,1.045077158528649,0.29636086248045607,LGP Offspring,InlB-mediated entry of Listeria monocytogenes into host cell,CP:REACTOME,C2,10,29
Cohort,0.07100490236492212,0.05321206595633296,1.3343759744865078,0.18244487565735082,LGP Proband,InlB-mediated entry of Listeria monocytogenes into host cell,CP:REACTOME,C2,10,36
Cohort,-2.6990361234569926e-4,0.015063781654062003,-0.01791738744918138,0.9857092480279693,LonGen OPEL,InlB-mediated entry of Listeria monocytogenes into host cell,CP:REACTOME,C2,15,20
Cohort,0.011010694469014702,0.17684362444474244,0.062262320757032245,0.9503723380966933,LGP Offspring,Innate Immune System,CP:REACTOME,C2,925,1966
Cohort,0.11651911604912513,0.4797838131050369,0.24285753888828282,0.8081754742007988,LGP Proband,Innate Immune System,CP:REACTOME,C2,925,2686
Cohort,-0.036583939876517174,0.1511559407386013,-0.24202780054660852,0.808820961326461,LonGen OPEL,Innate Immune System,CP:REACTOME,C2,1502,1815
Cohort,-0.038628206130031956,0.03696903836508733,-1.0448799275912868,0.2964519533472157,LGP Offspring,Inositol phosphate metabolism,CP:REACTOME,C2,55,93
Cohort,-0.07249577675157166,0.10350417275794546,-0.7004140492104609,0.48386410765697296,LGP Proband,Inositol phosphate metabolism,CP:REACTOME,C2,55,125
Cohort,0.03154385263525517,0.029000659305317686,1.0876943280207134,0.27705930131923057,LonGen OPEL,Inositol phosphate metabolism,CP:REACTOME,C2,53,79
Cohort,8.903729264920681e-4,0.02610802197562911,0.0341034233586596,0.9728047456989999,LGP Offspring,Insertion of tail-anchored proteins into the endoplasmic reticulum membrane,CP:REACTOME,C2,21,45
Cohort,0.03966895139866251,0.07104084355503709,0.5583964014719222,0.5767236059494525,LGP Proband,Insertion of tail-anchored proteins into the endoplasmic reticulum membrane,CP:REACTOME,C2,21,61
Cohort,0.02340050489019798,0.021731886522107155,1.0767820302389943,0.28190388517147363,LonGen OPEL,Insertion of tail-anchored proteins into the endoplasmic reticulum membrane,CP:REACTOME,C2,27,43
Cohort,0.014081331915494176,0.02093755249427816,0.6725395396306392,0.5014700900348048,LGP Offspring,Insulin processing,CP:REACTOME,C2,12,33
Cohort,-0.07366189056798188,0.057178050818592535,-1.2882896411017444,0.1980024501301268,LGP Proband,Insulin processing,CP:REACTOME,C2,12,40
Cohort,-0.006666551277764811,0.01678228569079107,-0.39723738473972836,0.6912989057743935,LonGen OPEL,Insulin processing,CP:REACTOME,C2,20,24
Cohort,0.015110256983605849,0.02370258406037471,0.6374940784986703,0.5240189175713705,LGP Offspring,Insulin receptor recycling,CP:REACTOME,C2,15,40
Cohort,-0.008231533525588433,0.06086080069393938,-0.13525181121069516,0.8924454195716542,LGP Proband,Insulin receptor recycling,CP:REACTOME,C2,15,47
Cohort,-0.0014939107811474488,0.021456368478107342,-0.06962551853412363,0.9445092123388581,LonGen OPEL,Insulin receptor recycling,CP:REACTOME,C2,34,39
Cohort,0.015851546605450635,0.032671611737309,0.4851779805937498,0.6277072909154036,LGP Offspring,Insulin receptor signalling cascade,CP:REACTOME,C2,32,74
Cohort,-0.012404256765507762,0.0957742163440016,-0.12951561744921183,0.896980896675241,LGP Proband,Insulin receptor signalling cascade,CP:REACTOME,C2,32,103
Cohort,0.005913649601760471,0.026284504508535124,0.22498615485942247,0.8220477887879659,LonGen OPEL,Insulin receptor signalling cascade,CP:REACTOME,C2,45,56
Cohort,-0.030164515316911434,0.05317746127241551,-0.56724248572879,0.5707377593621595,LGP Offspring,Integration of energy metabolism,CP:REACTOME,C2,93,185
Cohort,-0.04145340352427471,0.15614936991429446,-0.2654727556507413,0.7907109002003276,LGP Proband,Integration of energy metabolism,CP:REACTOME,C2,93,295
Cohort,0.06004852245778719,0.049747661872116336,1.20706220549924,0.22776675661582726,LonGen OPEL,Integration of energy metabolism,CP:REACTOME,C2,148,200
Cohort,-0.003320616853532271,0.004558696592033795,-0.7284136565120309,0.4666126543136979,LGP Offspring,Integration of provirus,CP:REACTOME,C2,1,1
Cohort,0.005287390241168551,0.013648599415733279,0.3873943457578195,0.698563128775403,LGP Proband,Integration of provirus,CP:REACTOME,C2,1,2
Cohort,-0.0028012684692635043,0.0036255511289676554,-0.7726462459408596,0.4399611196108463,LonGen OPEL,Integration of provirus,CP:REACTOME,C2,1,1
Cohort,-0.10259460092412866,0.07027311142860701,-1.459941061928903,0.1447708276148944,LGP Offspring,Integrin cell surface interactions,CP:REACTOME,C2,167,295
Cohort,-0.5409666663460201,0.1918312005649383,-2.820013974540566,0.004916054673505395,LGP Proband,Integrin cell surface interactions,CP:REACTOME,C2,167,425
Cohort,-0.02849863732141086,0.05880182655585548,-0.48465564746258666,0.6280539665719347,LonGen OPEL,Integrin cell surface interactions,CP:REACTOME,C2,244,297
Cohort,-0.0285519309988418,0.03502874757019834,-0.8150999672946667,0.41530216279941756,LGP Offspring,Integrin signaling,CP:REACTOME,C2,44,72
Cohort,-0.33692557844742077,0.09625103066605975,-3.500488006371325,4.890421067460843e-4,LGP Proband,Integrin signaling,CP:REACTOME,C2,44,100
Cohort,-0.007689274332187654,0.028313761847799664,-0.2715737447224876,0.7860202056610402,LonGen OPEL,Integrin signaling,CP:REACTOME,C2,55,68
Cohort,2.8867939749611563e-5,0.05464805960933017,5.28251871264664e-4,0.9995786718527158,LGP Offspring,Interaction between L1 and Ankyrins,CP:REACTOME,C2,95,195
Cohort,-0.2965411512673072,0.14619950236656656,-2.0283321520738724,0.04284370710590597,LGP Proband,Interaction between L1 and Ankyrins,CP:REACTOME,C2,95,257
Cohort,-0.04613202644406087,0.04379516177202998,-1.0533589688330216,0.2924961384990932,LonGen OPEL,Interaction between L1 and Ankyrins,CP:REACTOME,C2,158,169
Cohort,-0.008293726577901265,0.010129849479221442,-0.8187413440755985,0.41322252853531605,LGP Offspring,Interaction With Cumulus Cells And The Zona Pellucida,CP:REACTOME,C2,4,6
Cohort,-0.030699838927577168,0.03320122604743341,-0.9246597967110431,0.3554103562578803,LGP Proband,Interaction With Cumulus Cells And The Zona Pellucida,CP:REACTOME,C2,4,14
Cohort,0.0011873419681906181,0.01022343361968866,0.11613925539693355,0.9075714711989874,LonGen OPEL,Interaction With Cumulus Cells And The Zona Pellucida,CP:REACTOME,C2,7,9
Cohort,-0.03954859478792975,0.03810939355424743,-1.0377649996354223,0.2997505293651395,LGP Offspring,Interactions of Rev with host cellular proteins,CP:REACTOME,C2,56,97
Cohort,-0.24863165552408195,0.1033921258560096,-2.404744592159195,0.016400779453557654,LGP Proband,Interactions of Rev with host cellular proteins,CP:REACTOME,C2,56,124
Cohort,4.4986157425179734e-4,0.035679488106552915,0.012608408868096275,0.9899433710849799,LonGen OPEL,Interactions of Rev with host cellular proteins,CP:REACTOME,C2,81,96
Cohort,-0.037883766627633035,0.03738916709674306,-1.01322841799632,0.3113135822945834,LGP Offspring,Interactions of Vpr with host cellular proteins,CP:REACTOME,C2,54,93
Cohort,-0.2855037983686933,0.10739467960086883,-2.658453839890068,0.008000397722517847,LGP Proband,Interactions of Vpr with host cellular proteins,CP:REACTOME,C2,54,133
Cohort,-0.023719574959960046,0.037864529039365234,-0.6264325890677362,0.5312108381019578,LonGen OPEL,Interactions of Vpr with host cellular proteins,CP:REACTOME,C2,94,107
Cohort,-0.04862817733159782,0.02404793932777952,-2.0221348976635136,0.04355578202316515,LGP Offspring,Interconversion of nucleotide di- and triphosphates,CP:REACTOME,C2,26,33
Cohort,0.03549061965605237,0.06959162866630536,0.5099840359568435,0.6101975771206503,LGP Proband,Interconversion of nucleotide di- and triphosphates,CP:REACTOME,C2,26,56
Cohort,-0.0020819257604072572,0.022978652314835087,-0.09060260505630957,0.9278311552003112,LonGen OPEL,Interconversion of nucleotide di- and triphosphates,CP:REACTOME,C2,38,46
Cohort,-0.0775744952691101,0.03315163778717749,-2.3399898299780126,0.01957430690260095,LGP Offspring,Interferon alpha/beta signaling,CP:REACTOME,C2,48,67
Cohort,-0.04052625224735838,0.09373324565028555,-0.43235729186803123,0.6655935206579524,LGP Proband,Interferon alpha/beta signaling,CP:REACTOME,C2,48,90
Cohort,-0.019980426307152514,0.028323790476159003,-0.7054291099904388,0.48074961090131496,LonGen OPEL,Interferon alpha/beta signaling,CP:REACTOME,C2,56,64
Cohort,0.03968927258559143,0.0455146361135311,0.8720112028708972,0.3835118675480187,LGP Offspring,Interferon gamma signaling,CP:REACTOME,C2,58,141
Cohort,-5.50729822468977e-4,0.12361102693839512,-0.004455345417876416,0.9964462258922262,LGP Proband,Interferon gamma signaling,CP:REACTOME,C2,58,184
Cohort,0.004843631257232205,0.04080682707776933,0.11869659084253846,0.9055456845410319,LonGen OPEL,Interferon gamma signaling,CP:REACTOME,C2,104,130
Cohort,-0.0985097598121764,0.07592404427779495,-1.297477772018356,0.19490943803604263,LGP Offspring,Interferon Signaling,CP:REACTOME,C2,194,361
Cohort,-0.26476080143497077,0.21382516953493017,-1.238211581970568,0.21598604366040514,LGP Proband,Interferon Signaling,CP:REACTOME,C2,194,473
Cohort,0.06307447173211038,0.06495674949997446,0.9710225991547681,0.33183198613138587,LonGen OPEL,Interferon Signaling,CP:REACTOME,C2,269,357
Cohort,-0.026102442739809082,0.05925414196534747,-0.4405167617661918,0.6597037023348253,LGP Offspring,Interleukin-1 family signaling,CP:REACTOME,C2,112,222
Cohort,-0.0714782270944026,0.14941522264571463,-0.4783865112853189,0.632500509715159,LGP Proband,Interleukin-1 family signaling,CP:REACTOME,C2,112,288
Cohort,-0.07597842562431308,0.050526285510293124,-1.5037405749693373,0.13304481465143733,LonGen OPEL,Interleukin-1 family signaling,CP:REACTOME,C2,182,186
Cohort,0.012165876016256964,0.014799076084866514,0.8220699688609445,0.4113269292410854,LGP Offspring,Interleukin-1 processing,CP:REACTOME,C2,5,17
Cohort,0.018904324951743615,0.0346987698865512,0.5448125398552152,0.5860281008023529,LGP Proband,Interleukin-1 processing,CP:REACTOME,C2,5,15
Cohort,0.014958902857713893,0.014118149830342323,1.0595512186423073,0.28967021602116244,LonGen OPEL,Interleukin-1 processing,CP:REACTOME,C2,11,20
Cohort,0.029087370263643143,0.05071276846849017,0.5735709396681088,0.5664489451132995,LGP Offspring,Interleukin-1 signaling,CP:REACTOME,C2,67,151
Cohort,0.02777051617010195,0.12629550595762543,0.21988522837399688,0.8260143491882409,LGP Proband,Interleukin-1 signaling,CP:REACTOME,C2,67,206
Cohort,-0.06398205379769457,0.04222116968287928,-1.5154022088506789,0.1300675597274662,LonGen OPEL,Interleukin-1 signaling,CP:REACTOME,C2,125,128
Cohort,-0.004992992433323329,0.016837485544748305,-0.2965402654721606,0.7669086049641269,LGP Offspring,Interleukin-10 signaling,CP:REACTOME,C2,12,18
Cohort,-0.07888848329118182,0.05484697138564132,-1.4383380029591655,0.1507133108638369,LGP Proband,Interleukin-10 signaling,CP:REACTOME,C2,12,36
Cohort,0.0015328413790675036,0.017034754485553198,0.08998317999636994,0.9283232172289002,LonGen OPEL,Interleukin-10 signaling,CP:REACTOME,C2,20,23
Cohort,0.007452570693288205,0.03188034213777569,0.2337669608776719,0.8152366742962229,LGP Offspring,Interleukin-12 family signaling,CP:REACTOME,C2,31,67
Cohort,-0.022497867619326956,0.08570742778670744,-0.26249612431859964,0.7930037983043179,LGP Proband,Interleukin-12 family signaling,CP:REACTOME,C2,31,79
Cohort,-0.004649811338533784,0.027889689778762217,-0.1667215152057582,0.8676315166901118,LonGen OPEL,Interleukin-12 family signaling,CP:REACTOME,C2,52,63
Cohort,0.011204630924083922,0.030157799929022948,0.3715334324935595,0.7103566783963653,LGP Offspring,Interleukin-12 signaling,CP:REACTOME,C2,26,58
Cohort,-0.03677015238232108,0.08094131710169608,-0.4542816165954208,0.6497443491581637,LGP Proband,Interleukin-12 signaling,CP:REACTOME,C2,26,72
Cohort,-0.002106345112500749,0.026505985379771668,-0.07946677259198329,0.9366813327903509,LonGen OPEL,Interleukin-12 signaling,CP:REACTOME,C2,46,57
Cohort,0.007324792294479252,0.01652385764741275,0.4432858507242189,0.6577008181366584,LGP Offspring,Interleukin-15 signaling,CP:REACTOME,C2,8,20
Cohort,0.05214511263885385,0.04185941506178081,1.2457200503612451,0.213217031722803,LGP Proband,Interleukin-15 signaling,CP:REACTOME,C2,8,21
Cohort,-0.006766016247753197,0.01176908793825917,-0.5748972463497453,0.5655232405573263,LonGen OPEL,Interleukin-15 signaling,CP:REACTOME,C2,10,9
Cohort,-0.0061751261544380955,0.028839393393386033,-0.21412122197598948,0.8305170956175938,LGP Offspring,Interleukin-17 signaling,CP:REACTOME,C2,26,57
Cohort,0.04055361617790626,0.08619572348896591,0.4704829257926887,0.6381330440737855,LGP Proband,Interleukin-17 signaling,CP:REACTOME,C2,26,89
Cohort,-0.057215924489644354,0.02821902393948316,-2.0275656809514824,0.042937290378962864,LonGen OPEL,Interleukin-17 signaling,CP:REACTOME,C2,60,49
Cohort,0,0,NA,NA,LGP Offspring,Interleukin-18 signaling,CP:REACTOME,C2,0,0
Cohort,0.009904296327861486,0.01119213010091919,0.884933988307379,0.3764472903665309,LGP Proband,Interleukin-18 signaling,CP:REACTOME,C2,0,2
Cohort,-0.003401616314028655,0.002592851366391437,-1.3119210603895144,0.18992498903390156,LonGen OPEL,Interleukin-18 signaling,CP:REACTOME,C2,1,0
Cohort,-0.051199333373976634,0.03185180520567975,-1.607423285536321,0.10842848391114225,LGP Offspring,Interleukin-2 family signaling,CP:REACTOME,C2,36,56
Cohort,0.05870685119920461,0.08516966171246351,0.6892929949328847,0.4908306295376561,LGP Proband,Interleukin-2 family signaling,CP:REACTOME,C2,36,84
Cohort,0.024575003576185736,0.027799390468535738,0.8840123168887652,0.3769564866610784,LonGen OPEL,Interleukin-2 family signaling,CP:REACTOME,C2,47,64
Cohort,-0.014293667093171657,0.01408388327688903,-1.014895310629766,0.31051883418126497,LGP Offspring,Interleukin-2 signaling,CP:REACTOME,C2,8,12
Cohort,0.015378260404211733,0.03813929894974413,0.40321298051323784,0.6868948972161949,LGP Proband,Interleukin-2 signaling,CP:REACTOME,C2,8,16
Cohort,0.02039827026823666,0.012283221612505233,1.6606612590519172,0.09717531136967847,LonGen OPEL,Interleukin-2 signaling,CP:REACTOME,C2,7,16
Cohort,-0.054122953276984215,0.023738266276337256,-2.2799876219660984,0.022919028101541852,LGP Offspring,Interleukin-20 family signaling,CP:REACTOME,C2,24,29
Cohort,0.012180340049433074,0.06445050702892732,0.188987497708376,0.8501485952184173,LGP Proband,Interleukin-20 family signaling,CP:REACTOME,C2,24,42
Cohort,0.012377879058025159,0.02089491280400588,0.592387208031427,0.5537595623811746,LonGen OPEL,Interleukin-20 family signaling,CP:REACTOME,C2,29,37
Cohort,-0.013596185785185897,0.01567989467511875,-0.8671095097826561,0.3861896900799108,LGP Offspring,Interleukin-21 signaling,CP:REACTOME,C2,9,14
Cohort,0.0346304477245799,0.03879361233671781,0.8926842755450872,0.37228376981220224,LGP Proband,Interleukin-21 signaling,CP:REACTOME,C2,9,16
Cohort,0.02827889543353215,0.012819490146500669,2.2059298076882903,0.027673907042284864,LonGen OPEL,Interleukin-21 signaling,CP:REACTOME,C2,5,18
Cohort,-0.023949680034405802,0.019141239495465062,-1.2512084204411085,0.2112912775627057,LGP Offspring,Interleukin-23 signaling,CP:REACTOME,C2,14,19
Cohort,-0.01846979412181657,0.05455370091637821,-0.33856170730062296,0.7350251492413129,LGP Proband,Interleukin-23 signaling,CP:REACTOME,C2,14,30
Cohort,0.01564305076942234,0.018726108031842065,0.8353604893671839,0.40376542837597584,LonGen OPEL,Interleukin-23 signaling,CP:REACTOME,C2,21,30
Cohort,-0.02166516980309775,0.01874362791166636,-1.155868538641496,0.2481432832986192,LGP Offspring,Interleukin-27 signaling,CP:REACTOME,C2,14,20
Cohort,-0.002300124133043402,0.053185756129534405,-0.04324699506840569,0.9655149951225003,LGP Proband,Interleukin-27 signaling,CP:REACTOME,C2,14,27
Cohort,-0.019061371830364056,0.017336125920260417,-1.09951738456672,0.2718748784632997,LonGen OPEL,Interleukin-27 signaling,CP:REACTOME,C2,24,19
Cohort,-0.01399344838452222,0.031202424645697044,-0.44847310885027586,0.6539555001697923,LGP Offspring,"Interleukin-3, Interleukin-5 and GM-CSF signaling",CP:REACTOME,C2,31,57
Cohort,-0.020402249083337924,0.07754819952590424,-0.26309120273672826,0.7925452654987778,LGP Proband,"Interleukin-3, Interleukin-5 and GM-CSF signaling",CP:REACTOME,C2,31,73
Cohort,-0.02487873495144772,0.025336265123885086,-0.9819416883190868,0.32642692930006423,LonGen OPEL,"Interleukin-3, Interleukin-5 and GM-CSF signaling",CP:REACTOME,C2,47,45
Cohort,-0.03334088438056186,0.021772529762208,-1.5313279965488351,0.12615616440160146,LGP Offspring,Interleukin-35 Signalling,CP:REACTOME,C2,19,26
Cohort,0.01397392037062086,0.06039587628248317,0.23137209410228832,0.8170824946600402,LGP Proband,Interleukin-35 Signalling,CP:REACTOME,C2,19,35
Cohort,0.011204368913901292,0.019841517772780592,0.5646931369974078,0.5724415959956436,LonGen OPEL,Interleukin-35 Signalling,CP:REACTOME,C2,24,32
Cohort,5.981688935288842e-4,0.011012489450339698,0.05431731818916137,0.9566984003319179,LGP Offspring,Interleukin-36 pathway,CP:REACTOME,C2,4,8
Cohort,-0.03871433629076663,0.019780387993486862,-1.9572081348209243,0.05065622609817478,LGP Proband,Interleukin-36 pathway,CP:REACTOME,C2,4,3
Cohort,-9.13944778980583e-4,0.005784392089430612,-0.1580018720810033,0.8744953961462634,LonGen OPEL,Interleukin-36 pathway,CP:REACTOME,C2,3,2
Cohort,-0.04985111542461685,0.03192119512995681,-1.5616932643550525,0.11882826612703526,LGP Offspring,Interleukin-37 signaling,CP:REACTOME,C2,40,64
Cohort,-0.05860769228932859,0.08250077101453926,-0.7103896311344782,0.4776611439616325,LGP Proband,Interleukin-37 signaling,CP:REACTOME,C2,40,75
Cohort,-0.007226865572128888,0.027024941290204798,-0.2674146631633301,0.7892191813281101,LonGen OPEL,Interleukin-37 signaling,CP:REACTOME,C2,52,55
Cohort,0.025694852950054678,0.06198652533205244,0.4145232018154145,0.6786224834871905,LGP Offspring,Interleukin-4 and Interleukin-13 signaling,CP:REACTOME,C2,111,242
Cohort,-0.1601658047670391,0.16213369996134172,-0.987862515968168,0.32350649040224755,LGP Proband,Interleukin-4 and Interleukin-13 signaling,CP:REACTOME,C2,111,320
Cohort,-0.11789441006049502,0.05203347952729313,-2.2657414251656154,0.023735049697590334,LonGen OPEL,Interleukin-4 and Interleukin-13 signaling,CP:REACTOME,C2,215,194
Cohort,0.004771500802521632,0.0237624345831019,0.20080016573363968,0.8409152318569679,LGP Offspring,Interleukin-6 family signaling,CP:REACTOME,C2,17,36
Cohort,-0.014902808227428763,0.06384536966544986,-0.23342034521093027,0.8154922950837484,LGP Proband,Interleukin-6 family signaling,CP:REACTOME,C2,17,45
Cohort,-0.013845373564134532,0.019175327867233284,-0.7220410341871362,0.47048130122404985,LonGen OPEL,Interleukin-6 family signaling,CP:REACTOME,C2,30,27
Cohort,-0.002303865367994501,0.019882762171926638,-0.11587250041382237,0.907788002301237,LGP Offspring,Interleukin-6 signaling,CP:REACTOME,C2,14,25
Cohort,0.019476149170488143,0.05619643392628602,0.3465726881537607,0.7289997884018411,LGP Proband,Interleukin-6 signaling,CP:REACTOME,C2,14,35
Cohort,-0.01730762368998063,0.016528511426732943,-1.0471374731294654,0.29535402915331943,LonGen OPEL,Interleukin-6 signaling,CP:REACTOME,C2,23,18
Cohort,0.0060264984434337,0.028417143470340762,0.2120726331879069,0.8321142952145316,LGP Offspring,Interleukin-7 signaling,CP:REACTOME,C2,21,50
Cohort,-0.07640993562736081,0.07154508778390975,-1.0679969512113052,0.2858309206691907,LGP Proband,Interleukin-7 signaling,CP:REACTOME,C2,21,54
Cohort,-0.04175104354498171,0.02376014522153894,-1.7571880624337994,0.07927016927158548,LonGen OPEL,Interleukin-7 signaling,CP:REACTOME,C2,46,33
Cohort,-0.0019204712077216547,0.010936172530914893,-0.17560725219840628,0.8606550925826975,LGP Offspring,Interleukin-9 signaling,CP:REACTOME,C2,4,8
Cohort,0.018522959007227772,0.02735328939669046,0.6771748267127576,0.4984828257151772,LGP Proband,Interleukin-9 signaling,CP:REACTOME,C2,4,8
Cohort,-0.001423462645776349,0.007336362764086402,-0.19402838866483083,0.8462031569479915,LonGen OPEL,Interleukin-9 signaling,CP:REACTOME,C2,4,4
Cohort,-0.015548320037821322,0.02429132153349259,-0.6400771574483289,0.5223393152712563,LGP Offspring,Interleukin receptor SHC signaling,CP:REACTOME,C2,19,36
Cohort,-0.007632279889092535,0.061808411666316086,-0.12348286719122928,0.9017544924407184,LGP Proband,Interleukin receptor SHC signaling,CP:REACTOME,C2,19,45
Cohort,-0.03182055703682906,0.0214576049554285,-1.482950082403249,0.1384834740130578,LonGen OPEL,Interleukin receptor SHC signaling,CP:REACTOME,C2,38,30
Cohort,-0.006538210474022521,0.010586920597277978,-0.6175743374993831,0.5370639397645041,LGP Offspring,Intestinal absorption,CP:REACTOME,C2,4,7
Cohort,-0.011935407734209752,0.032138438324120715,-0.37137485069558984,0.7104526773232493,LGP Proband,Intestinal absorption,CP:REACTOME,C2,4,13
Cohort,-0.003015409382643131,0.007708479452337817,-0.3911808290192201,0.6957682608991385,LonGen OPEL,Intestinal absorption,CP:REACTOME,C2,4,5
Cohort,0.11225533171492216,0.07496308298893097,1.4974748534755136,0.1347365077417253,LGP Offspring,Intra-Golgi and retrograde Golgi-to-ER traffic,CP:REACTOME,C2,149,364
Cohort,0.13956354067162557,0.20805657136062658,0.6707961193387094,0.502536139627993,LGP Proband,Intra-Golgi and retrograde Golgi-to-ER traffic,CP:REACTOME,C2,149,533
Cohort,-0.12327607656770609,0.06419729464923812,-1.920269027554249,0.05518096182119443,LonGen OPEL,Intra-Golgi and retrograde Golgi-to-ER traffic,CP:REACTOME,C2,319,308
Cohort,-0.04818239486164084,0.036868118041649606,-1.3068851197451845,0.1916961229153902,LGP Offspring,Intra-Golgi traffic,CP:REACTOME,C2,52,85
Cohort,0.060286924744864134,0.10426422078773151,0.5782129697933535,0.5632764349219836,LGP Proband,Intra-Golgi traffic,CP:REACTOME,C2,52,121
Cohort,-0.06175189665829563,0.03085511055663202,-2.0013506853250482,0.04569363206204844,LonGen OPEL,Intra-Golgi traffic,CP:REACTOME,C2,83,63
Cohort,-0.03538462869791889,0.08314802577265146,-0.425561862342586,0.6705625805817195,LGP Offspring,Intracellular signaling by second messengers,CP:REACTOME,C2,216,438
Cohort,0.11507434200045237,0.22154429148145496,0.5194191248664379,0.6036063130936153,LGP Proband,Intracellular signaling by second messengers,CP:REACTOME,C2,216,602
Cohort,-0.05605978875746841,0.07070893906412466,-0.7928246343312944,0.4281162369230004,LonGen OPEL,Intracellular signaling by second messengers,CP:REACTOME,C2,323,364
Cohort,-0.005852275481719617,0.04154584657605297,-0.14086306969353873,0.8880200809526129,LGP Offspring,Intraflagellar transport,CP:REACTOME,C2,58,121
Cohort,0.009650840413029967,0.1219339135195548,0.07914812322891811,0.9369337930676234,LGP Proband,Intraflagellar transport,CP:REACTOME,C2,58,188
Cohort,-0.04033842220415208,0.04054397825351741,-0.9949300473653571,0.3200726313549423,LonGen OPEL,Intraflagellar transport,CP:REACTOME,C2,118,125
Cohort,-0.05672961872711436,0.029699372511923287,-1.9101285289559349,0.056539544216371626,LGP Offspring,Intrinsic Pathway for Apoptosis,CP:REACTOME,C2,35,52
Cohort,0.0614575016257577,0.08495942878843288,0.7233747036929827,0.46965253550129593,LGP Proband,Intrinsic Pathway for Apoptosis,CP:REACTOME,C2,35,80
Cohort,-0.02019393800035495,0.02628651903336403,-0.7682241218292881,0.4425818868208614,LonGen OPEL,Intrinsic Pathway for Apoptosis,CP:REACTOME,C2,52,53
Cohort,-0.019276699399925993,0.02141426205011101,-0.9001804197042627,0.36834480562460314,LGP Offspring,Intrinsic Pathway of Fibrin Clot Formation,CP:REACTOME,C2,18,28
Cohort,0.003841371681220406,0.05931288809833889,0.06476453607943579,0.9483769982955719,LGP Proband,Intrinsic Pathway of Fibrin Clot Formation,CP:REACTOME,C2,18,44
Cohort,0.03306443858426065,0.01819863623600156,1.816863536117653,0.0696139524959653,LonGen OPEL,Intrinsic Pathway of Fibrin Clot Formation,CP:REACTOME,C2,16,37
Cohort,-0.020530962684729655,0.02076031297715633,-0.9889524646049873,0.3230402385700645,LGP Offspring,Inwardly rectifying K+ channels,CP:REACTOME,C2,17,25
Cohort,0.011643660893489319,0.06448256968772892,0.18057067126630216,0.8567484464532158,LGP Proband,Inwardly rectifying K+ channels,CP:REACTOME,C2,17,51
Cohort,0.010092953444734345,0.021230781880387226,0.4753924514696329,0.6346376959901254,LonGen OPEL,Inwardly rectifying K+ channels,CP:REACTOME,C2,29,37
Cohort,-0.030120418164732824,0.09165724105674301,-0.3286201702938661,0.7425445719317617,LGP Offspring,Ion channel transport,CP:REACTOME,C2,277,554
Cohort,0.009406543917524693,0.25429025366199715,0.03699136629132425,0.9705007418229555,LGP Proband,Ion channel transport,CP:REACTOME,C2,277,832
Cohort,0.14340843370382733,0.07970392747062566,1.7992643305648839,0.07235551492589608,LonGen OPEL,Ion channel transport,CP:REACTOME,C2,399,529
Cohort,-0.07135887551200276,0.044345850618989005,-1.6091443622336723,0.10805164627775743,LGP Offspring,Ion homeostasis,CP:REACTOME,C2,73,115
Cohort,-0.10288626959858192,0.1252562729951796,-0.8214061231291899,0.41164971748491874,LGP Proband,Ion homeostasis,CP:REACTOME,C2,73,178
Cohort,0.025936617626038667,0.03795517774049375,0.6833486014311908,0.49458544086207834,LonGen OPEL,Ion homeostasis,CP:REACTOME,C2,89,111
Cohort,0.013104825103231387,0.05535762180627372,0.23673027625883683,0.8129377612414354,LGP Offspring,Ion transport by P-type ATPases,CP:REACTOME,C2,101,202
Cohort,-0.22327025432767067,0.14979260479399256,-1.4905292196148854,0.1364632329172069,LGP Proband,Ion transport by P-type ATPases,CP:REACTOME,C2,101,279
Cohort,0.06349673319279453,0.04611110215650886,1.3770378547291258,0.16888766801374072,LonGen OPEL,Ion transport by P-type ATPases,CP:REACTOME,C2,132,178
Cohort,0.01275931184090975,0.01617220766509414,0.7889653722694437,0.4304088547035956,LGP Offspring,Ionotropic activity of kainate receptors,CP:REACTOME,C2,5,19
Cohort,0.00462103845244044,0.046611818473486,0.09913877217789745,0.9210519114469353,LGP Proband,Ionotropic activity of kainate receptors,CP:REACTOME,C2,5,27
Cohort,-0.002414813962803013,0.014429087802152376,-0.16735735452679115,0.867131384679823,LonGen OPEL,Ionotropic activity of kainate receptors,CP:REACTOME,C2,16,16
Cohort,-0.01692914365240322,0.01613523370429321,-1.0492034985460899,0.2944594213659781,LGP Offspring,IRAK1 recruits IKK complex,CP:REACTOME,C2,9,13
Cohort,0.036541693551271764,0.04884348621480923,0.748138521287459,0.4545875186189692,LGP Proband,IRAK1 recruits IKK complex,CP:REACTOME,C2,9,25
Cohort,-0.02624448644495723,0.01538397621077411,-1.7059624953512995,0.08840515273407662,LonGen OPEL,IRAK1 recruits IKK complex,CP:REACTOME,C2,18,10
Cohort,-0.0036989990729327537,0.007193595833293266,-0.514207241921087,0.6072751567055613,LGP Offspring,IRAK2 mediated activation of TAK1 complex,CP:REACTOME,C2,2,3
Cohort,-0.011579387950836973,0.015711493549676204,-0.7370010950407456,0.46132895770988847,LGP Proband,IRAK2 mediated activation of TAK1 complex,CP:REACTOME,C2,2,2
Cohort,-0.0015534223593656382,0.008185760776813813,-0.18977128720469216,0.8495367372433557,LonGen OPEL,IRAK2 mediated activation of TAK1 complex,CP:REACTOME,C2,5,5
Cohort,-0.030665945606241352,0.030594676785497037,-1.0023294516638954,0.3165431474427133,LGP Offspring,IRAK4 deficiency (TLR2/4),CP:REACTOME,C2,38,62
Cohort,-0.11908319992753186,0.08838085187520414,-1.347386876239665,0.178221598041598,LGP Proband,IRAK4 deficiency (TLR2/4),CP:REACTOME,C2,38,86
Cohort,0.06397546131130462,0.028398300531263534,2.252791896503609,0.024543845663054793,LonGen OPEL,IRAK4 deficiency (TLR2/4),CP:REACTOME,C2,44,71
Cohort,-0.025449682346744808,0.04011504610896675,-0.6344173774003502,0.5260231038123284,LGP Offspring,IRE1alpha activates chaperones,CP:REACTOME,C2,56,108
Cohort,-0.17016108272692765,0.12480319052832566,-1.363435357754796,0.17311326816248884,LGP Proband,IRE1alpha activates chaperones,CP:REACTOME,C2,56,182
Cohort,0.0027599378930040106,0.037123221524757326,0.0743453229446539,0.9407542929551087,LonGen OPEL,IRE1alpha activates chaperones,CP:REACTOME,C2,91,111
Cohort,-0.028554106038201504,0.014835633325201348,-1.9246974775048218,0.054686578899335786,LGP Offspring,IRF3 mediated activation of type 1 IFN,CP:REACTOME,C2,11,11
Cohort,-0.008780138327854408,0.039522132821330894,-0.2221575026719102,0.8242456645766353,LGP Proband,IRF3 mediated activation of type 1 IFN,CP:REACTOME,C2,11,15
Cohort,-0.003630797730846218,0.011203381593044494,-0.32408051985842934,0.7459622104917042,LonGen OPEL,IRF3 mediated activation of type 1 IFN,CP:REACTOME,C2,9,10
Cohort,-0.0033603297351674816,0.017553483309005025,-0.1914337841677051,0.8482432369403334,LGP Offspring,IRF3-mediated induction of type I IFN,CP:REACTOME,C2,11,20
Cohort,-0.05383233035189951,0.04102595287580246,-1.312153078195787,0.18982951540482376,LGP Proband,IRF3-mediated induction of type I IFN,CP:REACTOME,C2,11,17
Cohort,0.007457986485954576,0.011655540520128698,0.6398662055247376,0.5224437040245126,LonGen OPEL,IRF3-mediated induction of type I IFN,CP:REACTOME,C2,8,11
Cohort,-0.00449067317281215,0.03966170018843223,-0.11322442435591563,0.9098862479289478,LGP Offspring,Iron uptake and transport,CP:REACTOME,C2,50,109
Cohort,-0.04436317594480007,0.10950828326118021,-0.40511251408254384,0.685498698360245,LGP Proband,Iron uptake and transport,CP:REACTOME,C2,50,143
Cohort,-0.026763293035006207,0.03479064447878888,-0.7692669519624226,0.4419630498609415,LonGen OPEL,Iron uptake and transport,CP:REACTOME,C2,95,94
Cohort,-0.002368599948187461,0.007813302564226647,-0.30314965134361244,0.7618690846477593,LGP Offspring,IRS activation,CP:REACTOME,C2,2,4
Cohort,-0.009184291358536805,0.017586086886458845,-0.5222475822980632,0.6016366433444666,LGP Proband,IRS activation,CP:REACTOME,C2,2,3
Cohort,0.0030620376692582487,0.00518229458264742,0.5908652278300205,0.5547784532245996,LonGen OPEL,IRS activation,CP:REACTOME,C2,1,3
Cohort,0.01676269716950954,0.03166911071736761,0.5293074794271609,0.5967659352981175,LGP Offspring,IRS-mediated signalling,CP:REACTOME,C2,30,70
Cohort,-0.010006019134719652,0.09432559926401775,-0.1060795713230802,0.9155447285724403,LGP Proband,IRS-mediated signalling,CP:REACTOME,C2,30,99
Cohort,0.017521732426713364,0.024634928474894492,0.711255664678296,0.477134186556195,LonGen OPEL,IRS-mediated signalling,CP:REACTOME,C2,39,53
Cohort,0.003041246042696419,0.021176154093842804,0.14361654289154865,0.8858460767611378,LGP Offspring,JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1,CP:REACTOME,C2,12,30
Cohort,0.01229612335260003,0.05809853795810914,0.21164256080705368,0.8324376101203781,LGP Proband,JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1,CP:REACTOME,C2,12,41
Cohort,-0.04067179866062873,0.019117174583111435,-2.127500509231064,0.033685315546683914,LonGen OPEL,JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1,CP:REACTOME,C2,30,18
Cohort,-1.5709104129611208e-4,0.01565488835270697,-0.010034631851523146,0.9919966171134598,LGP Offspring,Josephin domain DUBs,CP:REACTOME,C2,7,16
Cohort,-0.07139681420338542,0.043324048071908074,-1.647971908924183,0.0997350865473205,LGP Proband,Josephin domain DUBs,CP:REACTOME,C2,7,23
Cohort,-0.006161497885323188,0.014695073658707989,-0.4192900306880745,0.6751173074975363,LonGen OPEL,Josephin domain DUBs,CP:REACTOME,C2,13,16
Cohort,0.009099470741671436,0.03042816542381903,0.29904762955404507,0.7649956152319296,LGP Offspring,Keratan sulfate biosynthesis,CP:REACTOME,C2,28,60
Cohort,-0.09906963808501054,0.08181379269165673,-1.2109160915982513,0.2262705931674725,LGP Proband,Keratan sulfate biosynthesis,CP:REACTOME,C2,28,79
Cohort,-0.02723478258359009,0.023874116447729736,-1.140766094662319,0.2543103698301228,LonGen OPEL,Keratan sulfate biosynthesis,CP:REACTOME,C2,47,43
Cohort,-0.010292201675177875,0.023823174620012037,-0.4320247758471358,0.6658611713677912,LGP Offspring,Keratan sulfate degradation,CP:REACTOME,C2,21,35
Cohort,-0.03658761959247233,0.06880786415911434,-0.5317360165091813,0.5950504453290579,LGP Proband,Keratan sulfate degradation,CP:REACTOME,C2,21,57
Cohort,0.001079220673676702,0.02088024711512465,0.05168620216639899,0.958791698985715,LonGen OPEL,Keratan sulfate degradation,CP:REACTOME,C2,31,38
Cohort,-0.004110337719827952,0.03469505501772645,-0.11847041942224597,0.9057301257927015,LGP Offspring,Keratan sulfate/keratin metabolism,CP:REACTOME,C2,37,75
Cohort,-0.09574210391645907,0.09467512713533933,-1.0112698742890989,0.31218057584841485,LGP Proband,Keratan sulfate/keratin metabolism,CP:REACTOME,C2,37,105
Cohort,-0.02215648588095643,0.028772801175468793,-0.7700496641198312,0.4414988984463668,LonGen OPEL,Keratan sulfate/keratin metabolism,CP:REACTOME,C2,63,63
Cohort,-0.009194642431508741,0.06069339864356592,-0.15149328653526412,0.8796318039461807,LGP Offspring,Keratinization,CP:REACTOME,C2,109,232
Cohort,0.05567569580281713,0.17784761717017863,0.3130528071654861,0.7543188105180852,LGP Proband,Keratinization,CP:REACTOME,C2,109,353
Cohort,0.044206956054421286,0.053285924309444385,0.8296178892891243,0.40700358019477056,LonGen OPEL,Keratinization,CP:REACTOME,C2,171,228
Cohort,-0.007380840583839566,0.020310152718729386,-0.36340645420323137,0.7164148947105342,LGP Offspring,Ketone body metabolism,CP:REACTOME,C2,14,24
Cohort,0.061265915446433845,0.05395735707663865,1.1354506366836026,0.2565127502671007,LGP Proband,Ketone body metabolism,CP:REACTOME,C2,14,35
Cohort,0.013281509182687215,0.016065825752565245,0.8266932174691701,0.40865869927696663,LonGen OPEL,Ketone body metabolism,CP:REACTOME,C2,16,22
Cohort,-9.274152877241692e-4,0.01414190813963835,-0.06557921877067757,0.9477322232138956,LGP Offspring,Killing mechanisms,CP:REACTOME,C2,7,11
Cohort,-0.004432383366737351,0.04358673109268539,-0.10169111689775658,0.9190262962450673,LGP Proband,Killing mechanisms,CP:REACTOME,C2,7,23
Cohort,-0.036656968598824335,0.015119654459272651,-2.424458091788148,0.015552947543577264,LonGen OPEL,Killing mechanisms,CP:REACTOME,C2,22,11
Cohort,0.08223455243262197,0.04293927712540873,1.9151359300355058,0.055896852175129325,LGP Offspring,Kinesins,CP:REACTOME,C2,50,139
Cohort,0.05405473630420766,0.12303537623032242,0.43934304067975627,0.6605268005511343,LGP Proband,Kinesins,CP:REACTOME,C2,50,201
Cohort,-0.07064776201196901,0.03976007809179782,-1.7768516915097075,0.07597447707392571,LonGen OPEL,Kinesins,CP:REACTOME,C2,127,117
Cohort,-0.03286140333080692,0.02146954679427534,-1.5306053567730231,0.1263347586760155,LGP Offspring,KSRP (KHSRP) binds and destabilizes mRNA,CP:REACTOME,C2,18,26
Cohort,-0.0200744268885716,0.05367676631403846,-0.3739872624055856,0.7085088489833804,LGP Proband,KSRP (KHSRP) binds and destabilizes mRNA,CP:REACTOME,C2,18,28
Cohort,0.03371303107144235,0.018524795485232115,1.8198868159337158,0.06915170500780847,LonGen OPEL,KSRP (KHSRP) binds and destabilizes mRNA,CP:REACTOME,C2,19,36
Cohort,0.0032797958912146948,0.07325327761741506,0.0447733671159987,0.9643011760595139,LGP Offspring,L1CAM interactions,CP:REACTOME,C2,160,341
Cohort,-0.14762451969727378,0.208756641743593,-0.7071608283419062,0.47966407866798355,LGP Proband,L1CAM interactions,CP:REACTOME,C2,160,488
Cohort,-0.1146845591493325,0.06340176206608807,-1.8088544452406354,0.0708508074865905,LonGen OPEL,L1CAM interactions,CP:REACTOME,C2,300,304
Cohort,-0.038186029739271175,0.02220064477421096,-1.7200414730129547,0.08588257939560649,LGP Offspring,Lagging Strand Synthesis,CP:REACTOME,C2,21,28
Cohort,0.026616899680345533,0.0720335292709355,0.3695070885702816,0.7118435896422338,LGP Proband,Lagging Strand Synthesis,CP:REACTOME,C2,21,59
Cohort,-0.00843657027941253,0.02126998368863633,-0.3966420662522576,0.6917377389638277,LonGen OPEL,Lagging Strand Synthesis,CP:REACTOME,C2,33,34
Cohort,0.03488988399435794,0.05334211131408993,0.6540776721213514,0.5132842092790362,LGP Offspring,Laminin interactions,CP:REACTOME,C2,96,212
Cohort,-0.3337014216947003,0.1491583187263082,-2.2372297069599703,0.02553478724075541,LGP Proband,Laminin interactions,CP:REACTOME,C2,96,260
Cohort,0.05693569648481728,0.04521494093266866,1.259223064552986,0.20831889885547517,LonGen OPEL,Laminin interactions,CP:REACTOME,C2,146,202
Cohort,-0.0423981185872145,0.03358272923601262,-1.2624977049735628,0.20720509780821686,LGP Offspring,Late endosomal microautophagy,CP:REACTOME,C2,41,70
Cohort,0.027622778813369678,0.08881975491802603,0.31099814268642634,0.7558797467958603,LGP Proband,Late endosomal microautophagy,CP:REACTOME,C2,41,101
Cohort,0.007312993277163967,0.03136401029008584,0.2331651217279317,0.8156931322567342,LonGen OPEL,Late endosomal microautophagy,CP:REACTOME,C2,70,86
Cohort,-0.044965920641083144,0.025154684817411795,-1.7875763885524112,0.07429223779413097,LGP Offspring,LDL clearance,CP:REACTOME,C2,26,37
Cohort,-0.049729297614035474,0.07286967428057738,-0.6824416069510315,0.49514925209384686,LGP Proband,LDL clearance,CP:REACTOME,C2,26,65
Cohort,0.022024664807510242,0.019774296850326906,1.1138026790139004,0.265700051622097,LonGen OPEL,LDL clearance,CP:REACTOME,C2,21,33
Cohort,-0.008499417176894031,0.01785657315149477,-0.4759825474230226,0.6342405983408856,LGP Offspring,Lectin pathway of complement activation,CP:REACTOME,C2,11,20
Cohort,-0.00866035568020976,0.05020743084068962,-0.17249151241555155,0.8630929827021951,LGP Proband,Lectin pathway of complement activation,CP:REACTOME,C2,11,29
Cohort,0.013293444816694231,0.015453082891503819,0.8602454869379516,0.3899127526385844,LonGen OPEL,Lectin pathway of complement activation,CP:REACTOME,C2,14,23
Cohort,-0.006775011295796512,0.07412470337695579,-0.09140018087280141,0.9272016949083431,LGP Offspring,Leishmania infection,CP:REACTOME,C2,168,356
Cohort,0.1917418143777789,0.20150132364644074,0.9515660289865583,0.3415927992949003,LGP Proband,Leishmania infection,CP:REACTOME,C2,168,495
Cohort,-0.06412626388537868,0.06412706087832717,-0.99998757165949,0.3176204065434779,LonGen OPEL,Leishmania infection,CP:REACTOME,C2,297,323
Cohort,0.018399911382473516,0.013802092979339509,1.333124723186297,0.18293996430494572,LGP Offspring,Leukotriene receptors,CP:REACTOME,C2,4,15
Cohort,-0.014804324779356082,0.03032134671898663,-0.48824760049611865,0.6255028130121656,LGP Proband,Leukotriene receptors,CP:REACTOME,C2,4,12
Cohort,4.3120515950131476e-4,0.011392963358287676,0.03784837587383617,0.969818063399235,LonGen OPEL,Leukotriene receptors,CP:REACTOME,C2,8,12
Cohort,0.013168125749077412,0.01131213962796312,1.1640702981181716,0.2448061958315147,LGP Offspring,LGI-ADAM interactions,CP:REACTOME,C2,2,11
Cohort,0.029812442636899816,0.03392453882918626,0.8787869685424083,0.3797699053638339,LGP Proband,LGI-ADAM interactions,CP:REACTOME,C2,2,17
Cohort,-0.010794859741890938,0.010911841132982039,-0.9892794085191073,0.32282706930645366,LonGen OPEL,LGI-ADAM interactions,CP:REACTOME,C2,10,8
Cohort,-0.03951412534280034,0.022415377430097336,-1.7628132948475075,0.07838379421492844,LGP Offspring,Ligand-receptor interactions,CP:REACTOME,C2,23,30
Cohort,-0.07407382215123387,0.06246663568677778,-1.1858141764294339,0.23603342322093832,LGP Proband,Ligand-receptor interactions,CP:REACTOME,C2,23,39
Cohort,-0.004499385066134147,0.016071184549550487,-0.279965988335315,0.7795763355878913,LonGen OPEL,Ligand-receptor interactions,CP:REACTOME,C2,19,21
Cohort,-0.0018239332707245415,0.00999361684255031,-0.18250982596798107,0.8552373624169365,LGP Offspring,Linoleic acid (LA) metabolism,CP:REACTOME,C2,4,6
Cohort,-0.01725686619549074,0.029231770270221686,-0.5903462580598567,0.5551184549166699,LGP Proband,Linoleic acid (LA) metabolism,CP:REACTOME,C2,4,10
Cohort,-4.6370998000474394e-4,0.011629356406829055,-0.03987408793597912,0.9682035079826053,LonGen OPEL,Linoleic acid (LA) metabolism,CP:REACTOME,C2,10,12
Cohort,0.017468187393222707,0.013958002028476576,1.2514819354220459,0.21119159294471762,LGP Offspring,Lipid particle organization,CP:REACTOME,C2,2,13
Cohort,0.016669595498916525,0.027173435233888397,0.6134519009259316,0.5397448431817675,LGP Proband,Lipid particle organization,CP:REACTOME,C2,2,10
Cohort,-0.0209646602809743,0.010895855325950431,-1.9240949566431196,0.054698925321845136,LonGen OPEL,Lipid particle organization,CP:REACTOME,C2,12,6
Cohort,-0.00878627556898895,0.01145057384341127,-0.767321855580594,0.4431580890741841,LGP Offspring,Lipophagy,CP:REACTOME,C2,6,7
Cohort,-0.08076479490474264,0.03489751108660446,-2.314342553092404,0.020891065250277747,LGP Proband,Lipophagy,CP:REACTOME,C2,6,14
Cohort,0.0067227882743093334,0.011535231850770832,0.5828047811505487,0.5601897841991014,LonGen OPEL,Lipophagy,CP:REACTOME,C2,8,12
Cohort,0.022056431164681967,0.023939181983752732,0.9213527504678912,0.35719497757254703,LGP Offspring,Listeria monocytogenes entry into host cells,CP:REACTOME,C2,15,38
Cohort,0.023380624999819844,0.0650668977518364,0.3593320998488816,0.7194376212356635,LGP Proband,Listeria monocytogenes entry into host cells,CP:REACTOME,C2,15,53
Cohort,0.014369290462974594,0.01859316555457938,0.772826467918774,0.4398545007815672,LonGen OPEL,Listeria monocytogenes entry into host cells,CP:REACTOME,C2,21,34
Cohort,-0.012351358136901334,0.026303108035071333,-0.469577896286348,0.6388080460891141,LGP Offspring,Long-term potentiation,CP:REACTOME,C2,21,46
Cohort,0.0613628386979328,0.07584021787706681,0.8091068356026994,0.41868445653850295,LGP Proband,Long-term potentiation,CP:REACTOME,C2,21,73
Cohort,-0.00887994223918972,0.025156152606930323,-0.35299285935892144,0.7241872481967488,LonGen OPEL,Long-term potentiation,CP:REACTOME,C2,39,45
Cohort,-0.04906063935849372,0.018926246846138205,-2.5922011774090468,0.00974245836599151,LGP Offspring,Loss of function of MECP2 in Rett syndrome,CP:REACTOME,C2,18,17
Cohort,-0.02153702951654034,0.057456825052537644,-0.3748384895414463,0.7078758826648184,LGP Proband,Loss of function of MECP2 in Rett syndrome,CP:REACTOME,C2,18,34
Cohort,-0.010804900693895858,0.017974629250111143,-0.6011195303974933,0.5479315105888409,LonGen OPEL,Loss of function of MECP2 in Rett syndrome,CP:REACTOME,C2,23,26
Cohort,-0.0020245735381507852,0.007086858165046708,-0.2856799855451096,0.7752107493296906,LGP Offspring,Loss of Function of SMAD2/3 in Cancer,CP:REACTOME,C2,2,3
Cohort,0.02714973368335331,0.016719639148946246,1.6238229450702242,0.10479146872895355,LGP Proband,Loss of Function of SMAD2/3 in Cancer,CP:REACTOME,C2,2,3
Cohort,-0.00515270551493724,0.00581046415446346,-0.8867975738184453,0.3754557375666485,LonGen OPEL,Loss of Function of SMAD2/3 in Cancer,CP:REACTOME,C2,3,2
Cohort,-0.04776952092269842,0.018464816767093224,-2.5870563204196046,0.009887656082058455,LGP Offspring,Loss of MECP2 binding ability to the NCoR/SMRT complex,CP:REACTOME,C2,17,16
Cohort,-0.012314097829735218,0.05642504252483417,-0.2182381665785268,0.8272969368624531,LGP Proband,Loss of MECP2 binding ability to the NCoR/SMRT complex,CP:REACTOME,C2,17,33
Cohort,-0.009858927763679965,0.017502714126691642,-0.5632799400319919,0.5734029049874938,LonGen OPEL,Loss of MECP2 binding ability to the NCoR/SMRT complex,CP:REACTOME,C2,22,24
Cohort,0.01630693517223671,0.01144815185415777,1.424416393141598,0.15478742845026683,LGP Offspring,LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production,CP:REACTOME,C2,2,11
Cohort,-0.006709597518120392,0.022135336664953625,-0.30311703046032934,0.7618762682442362,LGP Proband,LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production,CP:REACTOME,C2,2,6
Cohort,-0.005070911757390907,0.01300418847151977,-0.3899444989202222,0.6966819031629916,LonGen OPEL,LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production,CP:REACTOME,C2,12,12
Cohort,0.0017705778783605843,0.015534488507327117,0.11397722413103334,0.9092896901894334,LGP Offspring,LTC4-CYSLTR mediated IL4 production,CP:REACTOME,C2,7,17
Cohort,0.0013582002888647558,0.03967817182414189,0.034230415022255864,0.9727016036542171,LGP Proband,LTC4-CYSLTR mediated IL4 production,CP:REACTOME,C2,7,19
Cohort,-0.02819581683973405,0.014639090456627146,-1.9260634342873226,0.05445228688582896,LonGen OPEL,LTC4-CYSLTR mediated IL4 production,CP:REACTOME,C2,19,10
Cohort,-0.031017797014165148,0.026704106484005077,-1.1615365986030588,0.2458337070767876,LGP Offspring,Lysine catabolism,CP:REACTOME,C2,25,41
Cohort,-0.04192179596729949,0.07060137623058571,-0.5937815692201515,0.5528192279886601,LGP Proband,Lysine catabolism,CP:REACTOME,C2,25,53
Cohort,-0.0020675581200268692,0.018882144188177605,-0.10949805802888628,0.9128350599471279,LonGen OPEL,Lysine catabolism,CP:REACTOME,C2,26,31
Cohort,-0.08074427669703164,0.03972725365902349,-2.0324656063581608,0.04249692366793583,LGP Offspring,Lysosome Vesicle Biogenesis,CP:REACTOME,C2,58,90
Cohort,0.023593758150601385,0.10588355940555781,0.22282739910765553,0.8237244031948419,LGP Proband,Lysosome Vesicle Biogenesis,CP:REACTOME,C2,58,128
Cohort,-0.01172146704095954,0.029807569734270088,-0.3932379306818577,0.6942490528546212,LonGen OPEL,Lysosome Vesicle Biogenesis,CP:REACTOME,C2,60,76
Cohort,-0.0044812079137281574,0.009601179361285798,-0.46673515253734726,0.6408397578501068,LGP Offspring,Lysosphingolipid and LPA receptors,CP:REACTOME,C2,4,5
Cohort,-0.046415911561583076,0.02353023661869782,-1.972607089071923,0.048870275373938656,LGP Proband,Lysosphingolipid and LPA receptors,CP:REACTOME,C2,4,5
Cohort,7.360540727370963e-4,0.005810823705965739,0.12666948955643229,0.8992339839478294,LonGen OPEL,Lysosphingolipid and LPA receptors,CP:REACTOME,C2,2,3
Cohort,-0.08775851244447427,0.09754785344506461,-0.8996457568786653,0.36862915312134936,LGP Offspring,M Phase,CP:REACTOME,C2,331,644
Cohort,-0.62163912591452275,0.27518621556383915,-2.2589762522836527,0.02414233751640555,LGP Proband,M Phase,CP:REACTOME,C2,331,929
Cohort,-0.013301622864903771,0.0893032731803054,-0.14894888385611,0.8816316942260324,LonGen OPEL,M Phase,CP:REACTOME,C2,517,609
Cohort,0.005947995332916039,0.03195272487372179,0.18614986222372928,0.8523830856668531,LGP Offspring,MAP2K and MAPK activation,CP:REACTOME,C2,33,66
Cohort,-0.13455934147327583,0.08724715150747643,-1.5422777609162988,0.12338543821336642,LGP Proband,MAP2K and MAPK activation,CP:REACTOME,C2,33,100
Cohort,-0.02373768250796961,0.029303680750351065,-0.8100580507342999,0.4181489085787484,LonGen OPEL,MAP2K and MAPK activation,CP:REACTOME,C2,65,69
Cohort,8.858445971767529e-4,0.013922532598343869,0.06362668508185983,0.9492862922444745,LGP Offspring,MAP3K8 (TPL2)-dependent MAPK1/3 activation,CP:REACTOME,C2,4,11
Cohort,-0.007079896573971673,0.03556257239869494,-0.19908280240805887,0.842246497446326,LGP Proband,MAP3K8 (TPL2)-dependent MAPK1/3 activation,CP:REACTOME,C2,4,13
Cohort,-0.016271140454220862,0.013845387566570586,-1.175202960262897,0.24026493186288084,LonGen OPEL,MAP3K8 (TPL2)-dependent MAPK1/3 activation,CP:REACTOME,C2,13,8
Cohort,-0.0034503278183872776,0.090418016844239,-0.03815973783555855,0.9695715881604875,LGP Offspring,MAPK family signaling cascades,CP:REACTOME,C2,258,546
Cohort,-0.28342283366986143,0.2501613606385932,-1.1329600740352581,0.2575566167924806,LGP Proband,MAPK family signaling cascades,CP:REACTOME,C2,258,777
Cohort,0.034119699569561616,0.0853256015427571,0.39987646090562934,0.6893547893441785,LonGen OPEL,MAPK family signaling cascades,CP:REACTOME,C2,426,519
Cohort,-0.005303436502629051,0.011113296953942349,-0.47721540462820994,0.633362984862577,LGP Offspring,MAPK targets/ Nuclear events mediated by MAP kinases,CP:REACTOME,C2,5,7
Cohort,-0.03812494543815403,0.03422520283606003,-1.1139435935785071,0.26562431158039096,LGP Proband,MAPK targets/ Nuclear events mediated by MAP kinases,CP:REACTOME,C2,5,14
Cohort,-0.02211280760151569,0.010753792869674084,-2.0562798511652813,0.0400810734513923,LonGen OPEL,MAPK targets/ Nuclear events mediated by MAP kinases,CP:REACTOME,C2,12,6
Cohort,-0.011365756187243005,0.01716832720388976,-0.6620188473963795,0.5081847526087035,LGP Offspring,MAPK1 (ERK2) activation,CP:REACTOME,C2,11,17
Cohort,-0.01511841972813079,0.04971016044830347,-0.30413138062294787,0.7611036649193116,LGP Proband,MAPK1 (ERK2) activation,CP:REACTOME,C2,11,26
Cohort,-0.018560809502216565,0.015619831947868278,-1.188284839693788,0.2350756179898182,LonGen OPEL,MAPK1 (ERK2) activation,CP:REACTOME,C2,21,15
Cohort,-0.00875081827432637,0.017338347701849974,-0.504708892958276,0.6139277932028979,LGP Offspring,MAPK3 (ERK1) activation,CP:REACTOME,C2,11,18
Cohort,-0.020309616450976103,0.048556650622507,-0.4182664205747787,0.6758600143690534,LGP Proband,MAPK3 (ERK1) activation,CP:REACTOME,C2,11,24
Cohort,-0.031706613707760414,0.01674522885620206,-1.8934715064235736,0.058657602423026624,LonGen OPEL,MAPK3 (ERK1) activation,CP:REACTOME,C2,26,16
Cohort,0.0667923814882935,0.04765385280958244,1.4016155578266822,0.1614890352795605,LGP Offspring,MAPK6/MAPK4 signaling,CP:REACTOME,C2,55,150
Cohort,-0.05700043720853383,0.12724548538454977,-0.4479564601940279,0.6543009574356466,LGP Proband,MAPK6/MAPK4 signaling,CP:REACTOME,C2,55,205
Cohort,-0.03490592812475838,0.04064475865765596,-0.8588051516990224,0.3907065603912453,LonGen OPEL,MAPK6/MAPK4 signaling,CP:REACTOME,C2,109,115
Cohort,-0.0025222006593244198,0.00846313586923682,-0.298021997790739,0.765777946561455,LGP Offspring,MASTL Facilitates Mitotic Progression,CP:REACTOME,C2,3,4
Cohort,-0.03885998138974411,0.017565687409221327,-2.2122664763659676,0.027218528909144165,LGP Proband,MASTL Facilitates Mitotic Progression,CP:REACTOME,C2,3,2
Cohort,-0.009414552007143182,0.0068504906145030004,-1.374288724257482,0.16973886686701625,LonGen OPEL,MASTL Facilitates Mitotic Progression,CP:REACTOME,C2,5,2
Cohort,-0.002211627547182957,0.011919617873651407,-0.1855451718860729,0.852857110894847,LGP Offspring,Maturation of nucleoprotein,CP:REACTOME,C2,5,9
Cohort,-0.0026078500465775913,0.03580452984410829,-0.07283575731707921,0.9419542801017549,LGP Proband,Maturation of nucleoprotein,CP:REACTOME,C2,5,16
Cohort,-0.03672145383895497,0.014254862507047614,-2.576065102052009,0.010172392259061254,LonGen OPEL,Maturation of nucleoprotein,CP:REACTOME,C2,18,7
Cohort,-0.012408030491335906,0.013803288780974376,-0.8989184163442548,0.3690161912990526,LGP Offspring,Maturation of protein 3a,CP:REACTOME,C2,7,12
Cohort,-0.021623340049981676,0.034248818091701695,-0.6313601827684937,0.5279780417679547,LGP Proband,Maturation of protein 3a,CP:REACTOME,C2,7,13
Cohort,0.0025414546313814314,0.011805235850511632,0.21528198704063045,0.8296026188324552,LonGen OPEL,Maturation of protein 3a,CP:REACTOME,C2,9,12
Cohort,-0.015836079349124538,0.011506642576800548,-1.3762554318887865,0.169198276955954,LGP Offspring,Maturation of SARS-CoV-1 spike protein,CP:REACTOME,C2,6,7
Cohort,-0.0038961267891464064,0.03025582856648113,-0.12877276788455644,0.8975685007576852,LGP Proband,Maturation of SARS-CoV-1 spike protein,CP:REACTOME,C2,6,7
Cohort,0.0010306068377264178,0.00856729224493735,0.1202955155796666,0.9042794123805161,LonGen OPEL,Maturation of SARS-CoV-1 spike protein,CP:REACTOME,C2,5,6
Cohort,-0.04661008113502581,0.023612836497438092,-1.9739297792572625,0.048796465695008846,LGP Offspring,Maturation of SARS-CoV-2 spike protein,CP:REACTOME,C2,23,33
Cohort,-0.02242591158752782,0.062154164143455905,-0.36081108798707906,0.718332042975298,LGP Proband,Maturation of SARS-CoV-2 spike protein,CP:REACTOME,C2,23,40
Cohort,-0.006172235543180206,0.018868791174871946,-0.32711345872542863,0.7436680739237435,LonGen OPEL,Maturation of SARS-CoV-2 spike protein,CP:REACTOME,C2,26,28
Cohort,0.0069687519891322896,0.019479238501718184,0.3577527934943455,0.720639991522741,LGP Offspring,MECP2 regulates neuronal receptors and channels,CP:REACTOME,C2,11,28
Cohort,-0.0021266954238973556,0.05494000264415838,-0.03870941611837511,0.9691313298840512,LGP Proband,MECP2 regulates neuronal receptors and channels,CP:REACTOME,C2,11,36
Cohort,0.027306061557449034,0.01943302339651067,1.4051370700429469,0.16037066075373688,LonGen OPEL,MECP2 regulates neuronal receptors and channels,CP:REACTOME,C2,19,39
Cohort,-0.001912926428429429,0.014185193077553818,-0.1348537462952394,0.8927676519408141,LGP Offspring,MECP2 regulates transcription factors,CP:REACTOME,C2,7,13
Cohort,0.02368338201711937,0.039769311829158646,0.5955190303231459,0.5516581431796449,LGP Proband,MECP2 regulates transcription factors,CP:REACTOME,C2,7,19
Cohort,-0.0026982834722379134,0.011793451273226105,-0.22879506683201792,0.8190869683574021,LonGen OPEL,MECP2 regulates transcription factors,CP:REACTOME,C2,10,12
Cohort,0.010552262188947184,0.010554106318638925,0.9998252689866802,0.3177528247693615,LGP Offspring,MECP2 regulates transcription of neuronal ligands,CP:REACTOME,C2,2,9
Cohort,-4.7554562099200176e-4,0.02924840715065761,-0.01625885534697604,0.987031770501495,LGP Proband,MECP2 regulates transcription of neuronal ligands,CP:REACTOME,C2,2,12
Cohort,0.0026415083851759123,0.010236642873784878,0.2580444016407545,0.7964393398654601,LonGen OPEL,MECP2 regulates transcription of neuronal ligands,CP:REACTOME,C2,6,10
Cohort,0.03871092792457974,0.048202912598046425,0.8030827565832322,0.42220917125362367,LGP Offspring,Meiosis,CP:REACTOME,C2,76,174
Cohort,-0.05606399453367688,0.13407200233524377,-0.41816332684798896,0.6759353535183974,LGP Proband,Meiosis,CP:REACTOME,C2,76,225
Cohort,0.03353579383025929,0.044048937794031885,0.7613303636757162,0.44668525507700163,LonGen OPEL,Meiosis,CP:REACTOME,C2,127,159
Cohort,0.06516696046515934,0.030833745105231347,2.113494816888232,0.034924205460646854,LGP Offspring,Meiotic recombination,CP:REACTOME,C2,26,76
Cohort,0.023955374614397805,0.08920747617102515,0.26853550445112334,0.7883535586569166,LGP Proband,Meiotic recombination,CP:REACTOME,C2,26,103
Cohort,0.011819173410827359,0.028197151839174855,0.4191619592730195,0.6752108584948455,LonGen OPEL,Meiotic recombination,CP:REACTOME,C2,55,66
Cohort,-0.03651674706240441,0.03880876380302251,-0.9409407433781852,0.34707133768848797,LGP Offspring,Meiotic synapsis,CP:REACTOME,C2,54,102
Cohort,-0.059598594188205484,0.10458498699189031,-0.5698580255388553,0.5689274606813717,LGP Proband,Meiotic synapsis,CP:REACTOME,C2,54,129
Cohort,0.031448195108914515,0.033895002527122915,0.927812148228918,0.35378626172993266,LonGen OPEL,Meiotic synapsis,CP:REACTOME,C2,74,100
Cohort,0.019367385822790382,0.020348892094184206,0.9517661076165251,0.341555782959731,LGP Offspring,Melanin biosynthesis,CP:REACTOME,C2,9,29
Cohort,0.03455780431623787,0.05660715449590954,0.6104847456823683,0.5417070647095652,LGP Proband,Melanin biosynthesis,CP:REACTOME,C2,9,46
Cohort,-0.01420894152380934,0.016863405640033642,-0.8425902707385146,0.3997107293490746,LonGen OPEL,Melanin biosynthesis,CP:REACTOME,C2,22,23
Cohort,-0.09950171992924291,0.14882036205415194,-0.6686028615696874,0.5039770857276127,LGP Offspring,Membrane Trafficking,CP:REACTOME,C2,721,1458
Cohort,-0.42842197913531704,0.41272339477769454,-1.0380365749949267,0.2995538831177676,LGP Proband,Membrane Trafficking,CP:REACTOME,C2,721,1994
Cohort,-0.20629295083128893,0.1266260446372626,-1.6291510283073514,0.10367670519481452,LonGen OPEL,Membrane Trafficking,CP:REACTOME,C2,1173,1310
Cohort,-0.0032202665904959697,0.01922262628451241,-0.1675247982680975,0.8670072392234441,LGP Offspring,MET activates PI3K/AKT signaling,CP:REACTOME,C2,12,24
Cohort,0.02112851361672806,0.05111745343928614,0.41333267201628265,0.6794691481420989,LGP Proband,MET activates PI3K/AKT signaling,CP:REACTOME,C2,12,32
Cohort,-6.157780425496423e-4,0.015481845995586397,-0.039774200229429346,0.9682831185802756,LonGen OPEL,MET activates PI3K/AKT signaling,CP:REACTOME,C2,17,20
Cohort,0.048511018939455676,0.05532522462668352,0.8768336552954304,0.3808884844799395,LGP Offspring,MET activates PTK2 signaling,CP:REACTOME,C2,86,203
Cohort,-0.18599469538293104,0.1431135187854407,-1.2996305098317011,0.19408674466717224,LGP Proband,MET activates PTK2 signaling,CP:REACTOME,C2,86,244
Cohort,0.015577191704839196,0.04424085866004639,0.35209966932461123,0.7248567114405722,LonGen OPEL,MET activates PTK2 signaling,CP:REACTOME,C2,128,171
Cohort,-0.005493880799934702,0.019696159184211776,-0.2789315799365867,0.7803826407937762,LGP Offspring,MET activates PTPN11,CP:REACTOME,C2,13,25
Cohort,0.031461462321540123,0.051646062288504116,0.6091744641787167,0.5425747061902404,LGP Proband,MET activates PTPN11,CP:REACTOME,C2,13,32
Cohort,0.0059759851410264775,0.015090761360555361,0.3960028919844077,0.6922090154965901,LonGen OPEL,MET activates PTPN11,CP:REACTOME,C2,15,20
Cohort,0.001800943677268584,0.019770578785176383,0.09109210695535623,0.9274463891664317,LGP Offspring,MET activates RAP1 and RAC1,CP:REACTOME,C2,12,25
Cohort,0.039088837716505356,0.05228954563681405,0.7475459432752302,0.45494479724636827,LGP Proband,MET activates RAP1 and RAC1,CP:REACTOME,C2,12,34
Cohort,0.006282306623947843,0.015690372311212494,0.40039245081892955,0.6889749169149635,LonGen OPEL,MET activates RAP1 and RAC1,CP:REACTOME,C2,16,22
Cohort,-0.00495250944353916,0.023347150262694835,-0.21212479415325092,0.8320736188258488,LGP Offspring,MET activates RAS signaling,CP:REACTOME,C2,18,33
Cohort,-0.012807807049408787,0.0618330541943994,-0.20713528089914196,0.8359547719135124,LGP Proband,MET activates RAS signaling,CP:REACTOME,C2,18,46
Cohort,0.008345611855359132,0.01816511129967215,0.4594308131494772,0.6460502671004429,LonGen OPEL,MET activates RAS signaling,CP:REACTOME,C2,22,30
Cohort,0.012231526139346902,0.020084857587417855,0.6089924255678733,0.5427340557095683,LGP Offspring,MET interacts with TNS proteins,CP:REACTOME,C2,11,31
Cohort,0.06997027313460054,0.05608970443719282,1.2474708832340287,0.2125750576483517,LGP Proband,MET interacts with TNS proteins,CP:REACTOME,C2,11,43
Cohort,-0.011338941681157429,0.017497646546656954,-0.6480266732398827,0.5171545700830025,LonGen OPEL,MET interacts with TNS proteins,CP:REACTOME,C2,24,24
Cohort,0.05772832238646024,0.05624166708642604,1.0264333434097832,0.3050545068929335,LGP Offspring,MET promotes cell motility,CP:REACTOME,C2,89,214
Cohort,-0.15409943490061803,0.14669241123012872,-1.0504935709241925,0.29379553922280216,LGP Proband,MET promotes cell motility,CP:REACTOME,C2,89,269
Cohort,-0.0045009392070001365,0.04580271150253015,-0.09826796404294762,0.9217442552957138,LonGen OPEL,MET promotes cell motility,CP:REACTOME,C2,142,180
Cohort,-0.015618788095336091,0.029630608233161087,-0.5271166886765534,0.5982854935772769,LGP Offspring,MET Receptor Activation,CP:REACTOME,C2,30,56
Cohort,0.0503587283622847,0.07545424702597578,0.6674074733652603,0.504696515386752,LGP Proband,MET Receptor Activation,CP:REACTOME,C2,30,62
Cohort,0.002581119399763759,0.021726724805534794,0.11879928626454686,0.9054643473972868,LonGen OPEL,MET Receptor Activation,CP:REACTOME,C2,33,40
Cohort,0.004909685370026081,0.0211817399088854,0.2317885778574095,0.8167723750432647,LGP Offspring,MET receptor recycling,CP:REACTOME,C2,14,31
Cohort,0.04063461971008331,0.055533486359497085,0.7317138248269579,0.46454880499732254,LGP Proband,MET receptor recycling,CP:REACTOME,C2,14,37
Cohort,0.0017469935816652018,0.01796477661226562,0.09724549430091024,0.9225559194618828,LonGen OPEL,MET receptor recycling,CP:REACTOME,C2,23,28
Cohort,-0.05757503713039925,0.038482359691146495,-1.4961410264985737,0.1350836127290366,LGP Offspring,Metabolic disorders of biological oxidation enzymes,CP:REACTOME,C2,49,84
Cohort,0.17027719686669845,0.1016945025695758,1.6743992306781854,0.09442708376291263,LGP Proband,Metabolic disorders of biological oxidation enzymes,CP:REACTOME,C2,49,120
Cohort,-0.002552520444580999,0.031605628541051034,-0.0807615783139909,0.9356518649481278,LonGen OPEL,Metabolic disorders of biological oxidation enzymes,CP:REACTOME,C2,65,79
Cohort,0.05102399404014825,0.02896546402530584,1.7615458877361967,0.0785980547299336,LGP Offspring,Metabolism of amine-derived hormones,CP:REACTOME,C2,17,61
Cohort,0.13051406673451846,0.06935601128729085,1.8817989142122784,0.06021135394425744,LGP Proband,Metabolism of amine-derived hormones,CP:REACTOME,C2,17,59
Cohort,0.01982526863098083,0.02407203186143804,0.823581023201441,0.4104243421613156,LonGen OPEL,Metabolism of amine-derived hormones,CP:REACTOME,C2,37,50
Cohort,0.07666292314436231,0.10097145779360994,0.7592534050668522,0.4479656500055903,LGP Offspring,Metabolism of amino acids and derivatives,CP:REACTOME,C2,308,694
Cohort,0.41675668809865474,0.26720661015744207,1.5596795597724755,0.11921498811961341,LGP Proband,Metabolism of amino acids and derivatives,CP:REACTOME,C2,308,930
Cohort,0.035169310218095086,0.08693445407617235,0.40454973338050276,0.6859171936263964,LonGen OPEL,Metabolism of amino acids and derivatives,CP:REACTOME,C2,526,650
Cohort,-0.007319403665522821,0.02217651570365458,-0.3300520137307512,0.7414629145453855,LGP Offspring,Metabolism of Angiotensinogen to Angiotensins,CP:REACTOME,C2,17,34
Cohort,-0.030721986247491704,0.061508939147087785,-0.49947189259800906,0.6175787174441358,LGP Proband,Metabolism of Angiotensinogen to Angiotensins,CP:REACTOME,C2,17,46
Cohort,0.03573441209683141,0.02190258113635626,1.6315160242696505,0.10317701914944442,LonGen OPEL,Metabolism of Angiotensinogen to Angiotensins,CP:REACTOME,C2,26,48
Cohort,-0.12815408189712393,0.10827020364665305,-1.1836505112280313,0.23696749275217907,LGP Offspring,Metabolism of carbohydrates,CP:REACTOME,C2,396,758
Cohort,-0.8925900850033258,0.294926944582751,-3.0264785954573292,0.0025502536088886727,LGP Proband,Metabolism of carbohydrates,CP:REACTOME,C2,396,1007
Cohort,-0.059197311694383636,0.09455253335754767,-0.6260785363680391,0.5314429093273054,LonGen OPEL,Metabolism of carbohydrates,CP:REACTOME,C2,597,682
Cohort,-0.01006257200382181,0.02335370491772149,-0.4308769010858757,0.6666952323268411,LGP Offspring,Metabolism of cofactors,CP:REACTOME,C2,17,33
Cohort,0.04448728717531427,0.059874843856877726,0.7430046461858805,0.45768810143255145,LGP Proband,Metabolism of cofactors,CP:REACTOME,C2,17,40
Cohort,-0.03107342410409006,0.019184376061109985,-1.619725551933962,0.1056873276816808,LonGen OPEL,Metabolism of cofactors,CP:REACTOME,C2,32,25
Cohort,-0.08570118424477573,0.044561279755948514,-1.9232208929846863,0.05487203811619026,LGP Offspring,Metabolism of fat-soluble vitamins,CP:REACTOME,C2,79,123
Cohort,-0.14275907753594522,0.12570906245468333,-1.1356307552401659,0.25643737167791586,LGP Proband,Metabolism of fat-soluble vitamins,CP:REACTOME,C2,79,186
Cohort,0.08890201466487616,0.03840522389795146,2.314841723123458,0.020875156582624635,LonGen OPEL,Metabolism of fat-soluble vitamins,CP:REACTOME,C2,76,129
Cohort,0.02480782124391472,0.02840469068261922,0.8733705823839363,0.38277125389884714,LGP Offspring,Metabolism of folate and pterines,CP:REACTOME,C2,23,54
Cohort,-0.043721999826821574,0.07793744203806885,-0.5609883861144095,0.5749561408007106,LGP Proband,Metabolism of folate and pterines,CP:REACTOME,C2,23,73
Cohort,-0.006033827302894579,0.02358401758749831,-0.2558439112635779,0.7981374643089729,LonGen OPEL,Metabolism of folate and pterines,CP:REACTOME,C2,39,46
Cohort,-0.023165873847868668,0.013500519343172703,-1.7159246440088836,0.08663401065901727,LGP Offspring,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",CP:REACTOME,C2,8,6
Cohort,0.010805570126262798,0.03560057029308859,0.30352238847029267,0.7615674893425107,LGP Proband,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",CP:REACTOME,C2,8,9
Cohort,0.006175033955933565,0.010578007521094624,0.5837615395545271,0.5595461319974744,LonGen OPEL,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",CP:REACTOME,C2,6,11
Cohort,-0.24031981125284899,0.15508664634884967,-1.5495841641470347,0.1217093679106673,LGP Offspring,Metabolism of lipids,CP:REACTOME,C2,846,1663
Cohort,-0.3887240971219184,0.45677764109086133,-0.8510138460227176,0.3950059290071637,LGP Proband,Metabolism of lipids,CP:REACTOME,C2,846,2352
Cohort,-0.2506499072347793,0.1395949132260881,-1.7955518682032947,0.0729450018522534,LonGen OPEL,Metabolism of lipids,CP:REACTOME,C2,1386,1562
Cohort,-0.013474309736406915,0.022375200556247716,-0.6021983893522934,0.5472440164392653,LGP Offspring,Metabolism of nitric oxide: NOS3 activation and regulation,CP:REACTOME,C2,19,31
Cohort,0.0030528408288811085,0.061031921531403736,0.05002039510275424,0.9601181124394047,LGP Proband,Metabolism of nitric oxide: NOS3 activation and regulation,CP:REACTOME,C2,19,41
Cohort,0.005085890741417167,0.016174208914928326,0.31444448183942014,0.753265874195412,LonGen OPEL,Metabolism of nitric oxide: NOS3 activation and regulation,CP:REACTOME,C2,18,23
Cohort,0.015673332410481005,0.057008647464521306,0.27492903458611484,0.7834547641249642,LGP Offspring,Metabolism of nucleotides,CP:REACTOME,C2,95,218
Cohort,0.06351367753801565,0.16307319630883918,0.3894795648558277,0.6970208556155013,LGP Proband,Metabolism of nucleotides,CP:REACTOME,C2,95,301
Cohort,-0.03823385976119717,0.04493588247157469,-0.8508536532109489,0.3951065246965152,LonGen OPEL,Metabolism of nucleotides,CP:REACTOME,C2,148,172
Cohort,0.014362262528804263,0.036147857854157105,0.39731987955553394,0.6912570075678317,LGP Offspring,Metabolism of polyamines,CP:REACTOME,C2,37,83
Cohort,-0.035236385711721406,0.0943345663093049,-0.37352570844697663,0.7088521415330801,LGP Proband,Metabolism of polyamines,CP:REACTOME,C2,37,109
Cohort,-0.02473892613686869,0.03030802100616142,-0.8162501316677665,0.4146012865422498,LonGen OPEL,Metabolism of polyamines,CP:REACTOME,C2,62,67
Cohort,0.03293440287613778,0.04006047600473553,0.822117112943057,0.41130011863401705,LGP Offspring,Metabolism of porphyrins,CP:REACTOME,C2,42,103
Cohort,-0.026862365510933066,0.10427648507499872,-0.25760712486245446,0.7967736777938317,LGP Proband,Metabolism of porphyrins,CP:REACTOME,C2,42,125
Cohort,-0.049318171664020964,0.03293390605617335,-1.4974892920354475,0.13466240540420907,LonGen OPEL,Metabolism of porphyrins,CP:REACTOME,C2,87,78
Cohort,-0.1915899921649466,0.11823313937217812,-1.620442400348124,0.10560362324447045,LGP Offspring,Metabolism of RNA,CP:REACTOME,C2,497,944
Cohort,-0.098522690333798,0.34490103543703743,-0.28565495667171914,0.7752133376598357,LGP Proband,Metabolism of RNA,CP:REACTOME,C2,497,1379
Cohort,-0.014265201937808364,0.10786139175100809,-0.1322549404029458,0.8948160693286527,LonGen OPEL,Metabolism of RNA,CP:REACTOME,C2,766,908
Cohort,-0.04637379819174146,0.030601065212336888,-1.5154308475851932,0.13013076274679838,LGP Offspring,Metabolism of steroid hormones,CP:REACTOME,C2,35,58
Cohort,0.09500163016809382,0.0861072802015946,1.103293820750995,0.2702178328278266,LGP Proband,Metabolism of steroid hormones,CP:REACTOME,C2,35,82
Cohort,-0.019433458652178544,0.024533615060873776,-0.7921155770953232,0.4285292816423638,LonGen OPEL,Metabolism of steroid hormones,CP:REACTOME,C2,48,46
Cohort,-0.05177476388879585,0.07529243108086346,-0.6876489860340699,0.4919097160046859,LGP Offspring,Metabolism of steroids,CP:REACTOME,C2,200,379
Cohort,-0.3757470235824186,0.21295265272820324,-1.7644627515487863,0.07802010912788224,LGP Proband,Metabolism of steroids,CP:REACTOME,C2,200,517
Cohort,-0.047077406576996654,0.06418226144430744,-0.7334956032648818,0.46347217651217165,LonGen OPEL,Metabolism of steroids,CP:REACTOME,C2,284,329
Cohort,-0.10646846506605892,0.08114137168997607,-1.3121353860377452,0.1899198295590293,LGP Offspring,Metabolism of vitamins and cofactors,CP:REACTOME,C2,216,399
Cohort,-0.2665881447020261,0.22440030798710098,-1.1880025793785904,0.23517059907743226,LGP Proband,Metabolism of vitamins and cofactors,CP:REACTOME,C2,216,595
Cohort,0.03656420637183798,0.07050299042010406,0.5186192267017886,0.6041704353227486,LonGen OPEL,Metabolism of vitamins and cofactors,CP:REACTOME,C2,321,405
Cohort,-0.019385323014781894,0.06390789442084946,-0.3033322125608567,0.761730027919975,LGP Offspring,Metabolism of water-soluble vitamins and cofactors,CP:REACTOME,C2,123,245
Cohort,-0.1767947370366908,0.18173053821031881,-0.972840001343551,0.3309148949971471,LGP Proband,Metabolism of water-soluble vitamins and cofactors,CP:REACTOME,C2,123,373
Cohort,-0.021012310059657615,0.05673093939524469,-0.37038537143312156,0.7111939059804426,LonGen OPEL,Metabolism of water-soluble vitamins and cofactors,CP:REACTOME,C2,217,256
Cohort,-0.008986058259749661,0.026870257626149623,-0.33442397109749333,0.7381633821449649,LGP Offspring,Metal ion SLC transporters,CP:REACTOME,C2,23,48
Cohort,-0.1279155287018431,0.07663300960936835,-1.6691962034883399,0.09545379556585729,LGP Proband,Metal ion SLC transporters,CP:REACTOME,C2,23,72
Cohort,0.003690875025330018,0.022006511540739404,0.16771740575498806,0.8668482028715478,LonGen OPEL,Metal ion SLC transporters,CP:REACTOME,C2,31,41
Cohort,-0.0014786815391315774,0.005543596113342361,-0.2667368814211911,0.7897531002401987,LGP Offspring,Metal sequestration by antimicrobial proteins,CP:REACTOME,C2,1,2
Cohort,0.009225581671154436,0.015631301436033498,0.5901992043917401,0.5552169811740565,LGP Proband,Metal sequestration by antimicrobial proteins,CP:REACTOME,C2,1,3
Cohort,0.001863056107978664,0.002592936004778945,0.7185121825393815,0.4726523847447497,LonGen OPEL,Metal sequestration by antimicrobial proteins,CP:REACTOME,C2,0,1
Cohort,-0.005079733277451021,0.02117773896762046,-0.23986192696102449,0.8105100101234763,LGP Offspring,Metalloprotease DUBs,CP:REACTOME,C2,15,32
Cohort,0.07324360514083919,0.058355963591469294,1.2551177400409892,0.20978759322204402,LGP Proband,Metalloprotease DUBs,CP:REACTOME,C2,15,44
Cohort,0.004798220459031467,0.01737456198938092,0.2761635350556791,0.7824941469019648,LonGen OPEL,Metalloprotease DUBs,CP:REACTOME,C2,19,26
Cohort,-0.007164902485121589,0.004504009602186108,-1.5907831283583331,0.1121259009304485,LGP Offspring,Metallothioneins bind metals,CP:REACTOME,C2,2,0
Cohort,-0.014764263614743365,0.017573467369952536,-0.8401451633834992,0.40106778079427796,LGP Proband,Metallothioneins bind metals,CP:REACTOME,C2,2,3
Cohort,-0.006728136611905019,0.007742312408335611,-0.8690086704149654,0.3851043300588146,LonGen OPEL,Metallothioneins bind metals,CP:REACTOME,C2,5,4
Cohort,0.012199245733607807,0.014201142022924869,0.859032725249462,0.390626965300506,LGP Offspring,Methionine salvage pathway,CP:REACTOME,C2,4,16
Cohort,0.012633392452421063,0.03601835878866215,0.35074869808887016,0.7258654632347128,LGP Proband,Methionine salvage pathway,CP:REACTOME,C2,4,15
Cohort,-0.0032154884597736617,0.009656388698435046,-0.332990785705921,0.7392289215091139,LonGen OPEL,Methionine salvage pathway,CP:REACTOME,C2,8,6
Cohort,-0.05337188081371951,0.016757698900970085,-3.184917041959136,0.0015144848684980772,LGP Offspring,Methylation,CP:REACTOME,C2,15,10
Cohort,0.05618352161111859,0.048103957576628185,1.1679604847817333,0.24315648160236228,LGP Proband,Methylation,CP:REACTOME,C2,15,21
Cohort,-0.005898068486813426,0.01501142384401568,-0.39290533317162296,0.6944945991376565,LonGen OPEL,Methylation,CP:REACTOME,C2,16,19
Cohort,0.0955476467202574,0.061737384434756425,1.547646496447082,0.12217543329488173,LGP Offspring,MHC class II antigen presentation,CP:REACTOME,C2,108,277
Cohort,0.1533045811733919,0.17285792971796826,0.8868819696239609,0.3753981194832242,LGP Proband,MHC class II antigen presentation,CP:REACTOME,C2,108,358
Cohort,-0.05172393285332956,0.05516822064865102,-0.9375675387963472,0.3487510766744196,LonGen OPEL,MHC class II antigen presentation,CP:REACTOME,C2,218,227
Cohort,-0.012136756745559562,0.021115781180169914,-0.5747718562719971,0.5656368323774251,LGP Offspring,MicroRNA (miRNA) biogenesis,CP:REACTOME,C2,17,27
Cohort,-0.02263602110328617,0.06312284705778254,-0.35860266382733336,0.7199831085062249,LGP Proband,MicroRNA (miRNA) biogenesis,CP:REACTOME,C2,17,52
Cohort,-6.354761057665022e-4,0.018335429240999117,-0.03465837081935009,0.9723608451921821,LonGen OPEL,MicroRNA (miRNA) biogenesis,CP:REACTOME,C2,23,30
Cohort,-0.02295330714299677,0.011369527373061041,-2.018844441799959,0.04389769649008706,LGP Offspring,Mineralocorticoid biosynthesis,CP:REACTOME,C2,7,6
Cohort,0.00632890031017474,0.038946947543807994,0.16250054777863956,0.8709510599017017,LGP Proband,Mineralocorticoid biosynthesis,CP:REACTOME,C2,7,18
Cohort,-0.014982549761038425,0.008918620954779327,-1.6799177627354538,0.09336570079590427,LonGen OPEL,Mineralocorticoid biosynthesis,CP:REACTOME,C2,8,4
Cohort,0.01264601975562295,0.01876899218677885,0.6737719121930792,0.5006866403574014,LGP Offspring,Miro GTPase Cycle,CP:REACTOME,C2,9,27
Cohort,0.09464515837687872,0.04774773331805338,1.9821916518305895,0.04778563375651883,LGP Proband,Miro GTPase Cycle,CP:REACTOME,C2,9,29
Cohort,0.00510583895283577,0.015172801688671468,0.33651260048089626,0.736573044968067,LonGen OPEL,Miro GTPase Cycle,CP:REACTOME,C2,15,21
Cohort,-0.04262788957196193,0.024255969222895624,-1.7574185216117746,0.07929911595281486,LGP Offspring,Miscellaneous substrates,CP:REACTOME,C2,23,30
Cohort,-0.018369392668465222,0.07419908248840767,-0.24756900021418893,0.8045288334567626,LGP Proband,Miscellaneous substrates,CP:REACTOME,C2,23,62
Cohort,-0.010742188836324341,0.02561837303431166,-0.41931580986571315,0.6750984774571429,LonGen OPEL,Miscellaneous substrates,CP:REACTOME,C2,42,47
Cohort,-0.07662187852969407,0.02500979876571857,-3.06367433210703,0.0022732863616294215,LGP Offspring,Miscellaneous transport and binding events,CP:REACTOME,C2,30,30
Cohort,-0.05313360844773245,0.06920474928129812,-0.7677740183951691,0.44283876909021236,LGP Proband,Miscellaneous transport and binding events,CP:REACTOME,C2,30,49
Cohort,0.006504445279296192,0.023177313107411845,0.28063845231551643,0.7790606428959236,LonGen OPEL,Miscellaneous transport and binding events,CP:REACTOME,C2,32,41
Cohort,-0.033620039345858076,0.032638912652818146,-1.0300600299855645,0.3033502243131911,LGP Offspring,Mismatch Repair,CP:REACTOME,C2,38,70
Cohort,-0.0408188993348166,0.08910312981379596,-0.45810847969222007,0.6469938425833455,LGP Proband,Mismatch Repair,CP:REACTOME,C2,38,98
Cohort,0.0132665411155125,0.027686203728259362,0.4791751605140186,0.6319456328739534,LonGen OPEL,Mismatch Repair,CP:REACTOME,C2,56,66
Cohort,0.01646679984182148,0.04387851898094946,0.3752815779623464,0.7075687829718903,LGP Offspring,Mitochondrial biogenesis,CP:REACTOME,C2,60,134
Cohort,-0.017308631263055697,0.12530162016341992,-0.1381357339233249,0.8901664890212512,LGP Proband,Mitochondrial biogenesis,CP:REACTOME,C2,60,187
Cohort,-0.1399125143989835,0.044931223724826316,-3.113926192080902,0.0019122605345029174,LonGen OPEL,Mitochondrial biogenesis,CP:REACTOME,C2,156,128
Cohort,0.015314538025566366,0.023124741639077268,0.6622576919816109,0.508031791265656,LGP Offspring,Mitochondrial calcium ion transport,CP:REACTOME,C2,15,35
Cohort,-0.12427678711278922,0.06475715305679239,-1.919120610564794,0.055310059249113835,LGP Proband,Mitochondrial calcium ion transport,CP:REACTOME,C2,15,56
Cohort,0.008171820046083671,0.021968641530265644,0.37197657555773583,0.7100092916104678,LonGen OPEL,Mitochondrial calcium ion transport,CP:REACTOME,C2,30,42
Cohort,-0.001968651749592199,0.033252276194091206,-0.0592035185231025,0.9528075039870055,LGP Offspring,Mitochondrial Fatty Acid Beta-Oxidation,CP:REACTOME,C2,38,78
Cohort,-0.05427844038469126,0.09915432270149323,-0.5474137577248949,0.5842409608710655,LGP Proband,Mitochondrial Fatty Acid Beta-Oxidation,CP:REACTOME,C2,38,119
Cohort,-0.026990478373521788,0.032929072858182674,-0.81965497448905,0.4126581752766546,LonGen OPEL,Mitochondrial Fatty Acid Beta-Oxidation,CP:REACTOME,C2,75,85
Cohort,0.0035635497092021086,0.026051795844161844,0.13678710406448594,0.8912398045239115,LGP Offspring,mitochondrial fatty acid beta-oxidation of saturated fatty acids,CP:REACTOME,C2,22,46
Cohort,-0.0018070389442623501,0.07144578258506765,-0.02529245084705708,0.9798277456805528,LGP Proband,mitochondrial fatty acid beta-oxidation of saturated fatty acids,CP:REACTOME,C2,22,59
Cohort,-0.028446197322869675,0.025486407625903137,-1.1161320865777236,0.26470241175867265,LonGen OPEL,mitochondrial fatty acid beta-oxidation of saturated fatty acids,CP:REACTOME,C2,47,48
Cohort,0.007027264189824043,0.018985926418297036,0.37013017089604633,0.7114014362828511,LGP Offspring,mitochondrial fatty acid beta-oxidation of unsaturated fatty acids,CP:REACTOME,C2,9,23
Cohort,0.0205579962016677,0.04975902595576778,0.4131510978519211,0.6796021143498878,LGP Proband,mitochondrial fatty acid beta-oxidation of unsaturated fatty acids,CP:REACTOME,C2,9,28
Cohort,-0.026645468771225558,0.018555322596355367,-1.4360013755007017,0.1513948094015594,LonGen OPEL,mitochondrial fatty acid beta-oxidation of unsaturated fatty acids,CP:REACTOME,C2,28,24
Cohort,-0.011134391751190135,0.013399244566934816,-0.830971604075827,0.4062830679383781,LGP Offspring,Mitochondrial iron-sulfur cluster biogenesis,CP:REACTOME,C2,8,10
Cohort,-0.0335438088842119,0.03540426761755085,-0.9474510035502989,0.3436834469155641,LGP Proband,Mitochondrial iron-sulfur cluster biogenesis,CP:REACTOME,C2,8,14
Cohort,0.0014562538333847382,0.01265496267665267,0.11507373594008323,0.9084156982470701,LonGen OPEL,Mitochondrial iron-sulfur cluster biogenesis,CP:REACTOME,C2,9,11
Cohort,0.005163415816031541,0.03547180444391108,0.14556394570217215,0.8843090239987221,LGP Offspring,Mitochondrial protein import,CP:REACTOME,C2,40,85
Cohort,-0.08290792846592045,0.10144148927240498,-0.8172980213577542,0.41399154947060124,LGP Proband,Mitochondrial protein import,CP:REACTOME,C2,40,132
Cohort,-0.008417444594829317,0.029477744817302982,-0.2855525294420897,0.7752951537574259,LonGen OPEL,Mitochondrial protein import,CP:REACTOME,C2,63,76
Cohort,0.04295275563228312,0.04027258061074236,1.0665508636619587,0.28655545648051484,LGP Offspring,Mitochondrial translation,CP:REACTOME,C2,48,116
Cohort,-0.176173167680755,0.1162275206197361,-1.5157612133630922,0.12995864928239106,LGP Proband,Mitochondrial translation,CP:REACTOME,C2,48,163
Cohort,0.043732381148757576,0.036320305210520584,1.2040752657576788,0.22891840770487476,LonGen OPEL,Mitochondrial translation,CP:REACTOME,C2,89,121
Cohort,0.005527107711502987,0.029344139456854396,0.18835473841819983,0.8506551061824699,LGP Offspring,Mitochondrial tRNA aminoacylation,CP:REACTOME,C2,27,58
Cohort,-0.08865162444265082,0.08103284329347596,-1.0940209036178328,0.2742616813629222,LGP Proband,Mitochondrial tRNA aminoacylation,CP:REACTOME,C2,27,78
Cohort,0.026337604474219335,0.023725757169778244,1.1100848873125975,0.26729767746629274,LonGen OPEL,Mitochondrial tRNA aminoacylation,CP:REACTOME,C2,34,50
Cohort,0.006691454966450862,0.014812758702000387,0.4517359055843673,0.6516041457525544,LGP Offspring,Mitochondrial Uncoupling,CP:REACTOME,C2,8,15
Cohort,-0.040140740329301206,0.03645601206227507,-1.1010732677159474,0.27118244910342415,LGP Proband,Mitochondrial Uncoupling,CP:REACTOME,C2,8,15
Cohort,0.009335723872290752,0.01534069246151677,0.6085594829379499,0.5429900821308777,LonGen OPEL,Mitochondrial Uncoupling,CP:REACTOME,C2,13,20
Cohort,0.012452697133038596,0.016125856122823298,0.7722192879678497,0.44025444127256486,LGP Offspring,Mitophagy,CP:REACTOME,C2,6,21
Cohort,-0.0227536600846156,0.0470455753150314,-0.48365143655381426,0.6287602214969106,LGP Proband,Mitophagy,CP:REACTOME,C2,6,30
Cohort,0.004493103301798494,0.015998853885416674,0.2808390734722605,0.7789068113366102,LonGen OPEL,Mitophagy,CP:REACTOME,C2,17,23
Cohort,-0.13094490712180895,0.058345146780703454,-2.244315326071242,0.025134864363292996,LGP Offspring,Mitotic G1 phase and G1/S transition,CP:REACTOME,C2,127,204
Cohort,-0.20232905630966902,0.16048932583853992,-1.260701017045968,0.20776916445828347,LGP Proband,Mitotic G1 phase and G1/S transition,CP:REACTOME,C2,127,282
Cohort,0.00530945953367515,0.04877507164456283,0.10885600686282167,0.9133441349218583,LonGen OPEL,Mitotic G1 phase and G1/S transition,CP:REACTOME,C2,163,190
Cohort,0.028424235463212162,0.07333534876517944,0.38759255859308533,0.6984395823956898,LGP Offspring,Mitotic G2-G2/M phases,CP:REACTOME,C2,175,363
Cohort,-0.19233713944812336,0.21534211670092718,-0.8931700978645355,0.3720237377278095,LGP Proband,Mitotic G2-G2/M phases,CP:REACTOME,C2,175,554
Cohort,-0.02096559599011162,0.06469192845814384,-0.3240836452058547,0.7459598452908939,LonGen OPEL,Mitotic G2-G2/M phases,CP:REACTOME,C2,273,325
Cohort,0.08982994469655005,0.07542690439764747,1.1909536181276956,0.23408980006937904,LGP Offspring,Mitotic Metaphase and Anaphase,CP:REACTOME,C2,157,373
Cohort,-0.29596991038912224,0.19434131305810162,-1.522938719162801,0.12815310178509612,LGP Proband,Mitotic Metaphase and Anaphase,CP:REACTOME,C2,157,474
Cohort,-0.04198779098484177,0.06434945383985861,-0.6524964623527879,0.5142693364613946,LonGen OPEL,Mitotic Metaphase and Anaphase,CP:REACTOME,C2,279,313
Cohort,-0.005585249421855942,0.07525783855089865,-0.07421485295619414,0.9408613824658405,LGP Offspring,Mitotic Prometaphase,CP:REACTOME,C2,182,374
Cohort,-0.29479847010309795,0.21244153718440842,-1.387668692338637,0.16560858907840986,LGP Proband,Mitotic Prometaphase,CP:REACTOME,C2,182,544
Cohort,-0.0011171613895768313,0.06571890969814455,-0.016999085875101978,0.9864416048113616,LonGen OPEL,Mitotic Prometaphase,CP:REACTOME,C2,294,343
Cohort,-0.10849248425838713,0.04971706241385801,-2.1821982030085953,0.029438455576867025,LGP Offspring,Mitotic Prophase,CP:REACTOME,C2,102,159
Cohort,-0.3648071685513261,0.1385865916238399,-2.632341009882888,0.008636663383376542,LGP Proband,Mitotic Prophase,CP:REACTOME,C2,102,215
Cohort,-0.003009031254490547,0.04355201790904508,-0.06909051288449294,0.9449349245641496,LonGen OPEL,Mitotic Prophase,CP:REACTOME,C2,131,158
Cohort,0.03402718777469791,0.049361460861113274,0.6893472596047977,0.49084130907439716,LGP Offspring,Mitotic Spindle Checkpoint,CP:REACTOME,C2,71,169
Cohort,-0.031455288864993027,0.12257586314107766,-0.2566189464951173,0.7975362370258339,LGP Proband,Mitotic Spindle Checkpoint,CP:REACTOME,C2,71,197
Cohort,-0.03862776435439843,0.04154767112140472,-0.9297215297946748,0.3527971401068313,LonGen OPEL,Mitotic Spindle Checkpoint,CP:REACTOME,C2,126,129
Cohort,-0.008645865785441203,0.016321964536449976,-0.5297074237683448,0.5964887193310049,LGP Offspring,Mitotic Telophase/Cytokinesis,CP:REACTOME,C2,10,17
Cohort,-0.04613860461401215,0.05544407656713632,-0.8321647229193848,0.40555418537458177,LGP Proband,Mitotic Telophase/Cytokinesis,CP:REACTOME,C2,10,38
Cohort,0.02118426716062453,0.01868009495226443,1.1340556466527245,0.25711261857409506,LonGen OPEL,Mitotic Telophase/Cytokinesis,CP:REACTOME,C2,22,30
Cohort,-0.001637243776189583,0.015346371365516698,-0.10668605217442283,0.9150697003762613,LGP Offspring,Modulation by Mtb of host immune system,CP:REACTOME,C2,8,16
Cohort,-0.02180087060788494,0.043902225752853546,-0.496577798369777,0.6196176699529677,LGP Proband,Modulation by Mtb of host immune system,CP:REACTOME,C2,8,24
Cohort,0.02277311512954869,0.013364074046429225,1.7040548451341069,0.0887611133638031,LonGen OPEL,Modulation by Mtb of host immune system,CP:REACTOME,C2,8,17
Cohort,-0.021603998552210596,0.04310548181790188,-0.5011891212230545,0.6164011897379362,LGP Offspring,Molecules associated with elastic fibres,CP:REACTOME,C2,60,124
Cohort,-0.03150129083438892,0.11968830998875447,-0.2631943824534633,0.7924657685183982,LGP Proband,Molecules associated with elastic fibres,CP:REACTOME,C2,60,163
Cohort,0.016935804902161653,0.035432203533986385,0.47797774941987214,0.6327972751112552,LonGen OPEL,Molecules associated with elastic fibres,CP:REACTOME,C2,89,115
Cohort,-0.0012398483010129361,0.01193010361162849,-0.10392602959495116,0.9172588748794167,LGP Offspring,Molybdenum cofactor biosynthesis,CP:REACTOME,C2,5,9
Cohort,-0.009371161908884677,0.03657018882386792,-0.25625139520112317,0.7978199190965616,LGP Proband,Molybdenum cofactor biosynthesis,CP:REACTOME,C2,5,17
Cohort,0.00889151161817394,0.009298298489068779,0.9562514720974958,0.3392355230119558,LonGen OPEL,Molybdenum cofactor biosynthesis,CP:REACTOME,C2,4,9
Cohort,-0.035167869006377035,0.02426149364334944,-1.4495343742373936,0.14765215644306479,LGP Offspring,mRNA Capping,CP:REACTOME,C2,26,34
Cohort,-0.09032610296399002,0.07101454189582102,-1.2719381207372884,0.20374965464575015,LGP Proband,mRNA Capping,CP:REACTOME,C2,26,63
Cohort,0.01649694092350248,0.018932336042154812,0.8713632003346196,0.38381859782023664,LonGen OPEL,mRNA Capping,CP:REACTOME,C2,22,33
Cohort,-0.004691382663598995,0.025624415616558427,-0.1830825230826898,0.8547881641920676,LGP Offspring,mRNA decay by 3' to 5' exoribonuclease,CP:REACTOME,C2,22,42
Cohort,-0.002078681018957366,0.06421908344346129,-0.032368587458702115,0.9741858575462149,LGP Proband,mRNA decay by 3' to 5' exoribonuclease,CP:REACTOME,C2,22,47
Cohort,0.03018617251668031,0.023620717438347545,1.2779532457246172,0.20163845645993847,LonGen OPEL,mRNA decay by 3' to 5' exoribonuclease,CP:REACTOME,C2,33,51
Cohort,-4.415567015710102e-5,0.018250710046376437,-0.002419394645189043,0.9980703180236531,LGP Offspring,mRNA decay by 5' to 3' exoribonuclease,CP:REACTOME,C2,12,22
Cohort,-0.08077725957509116,0.056761705261047145,-1.4230943063390442,0.15508276905114532,LGP Proband,mRNA decay by 5' to 3' exoribonuclease,CP:REACTOME,C2,12,39
Cohort,-0.0039752381364380265,0.015391237604991604,-0.2582793040079375,0.7962581219417316,LonGen OPEL,mRNA decay by 5' to 3' exoribonuclease,CP:REACTOME,C2,17,20
Cohort,0.0026033348493606457,0.014786903793571733,0.17605679226048565,0.8603020520657958,LGP Offspring,mRNA Editing,CP:REACTOME,C2,7,16
Cohort,-0.09262481568778082,0.04312736410996053,-2.147704076039012,0.03202480879582818,LGP Proband,mRNA Editing,CP:REACTOME,C2,7,24
Cohort,-0.006685459243764964,0.012599698688232876,-0.5306046921589208,0.5958407387593901,LonGen OPEL,mRNA Editing,CP:REACTOME,C2,12,12
Cohort,0.0026033348493606457,0.014786903793571733,0.17605679226048565,0.8603020520657958,LGP Offspring,mRNA Editing: C to U Conversion,CP:REACTOME,C2,7,16
Cohort,-0.09262481568778082,0.04312736410996053,-2.147704076039012,0.03202480879582818,LGP Proband,mRNA Editing: C to U Conversion,CP:REACTOME,C2,7,24
Cohort,-0.006685459243764964,0.012599698688232876,-0.5306046921589208,0.5958407387593901,LonGen OPEL,mRNA Editing: C to U Conversion,CP:REACTOME,C2,12,12
Cohort,-0.09050605105710104,0.058934781135902115,-1.535698433296908,0.12508024496643622,LGP Offspring,mRNA Splicing,CP:REACTOME,C2,116,207
Cohort,0.1287852333384888,0.16145003540208824,0.797678569829679,0.4252840945359515,LGP Proband,mRNA Splicing,CP:REACTOME,C2,116,311
Cohort,-0.0318288673329719,0.051693417485281924,-0.6157237977549882,0.538252837141081,LonGen OPEL,mRNA Splicing,CP:REACTOME,C2,173,197
Cohort,-0.005303944506221168,0.026883506689988002,-0.19729362569342457,0.8436570728325197,LGP Offspring,mRNA Splicing - Minor Pathway,CP:REACTOME,C2,25,46
Cohort,-0.005781064214593933,0.07642190349342594,-0.07564669224826674,0.9397183293538978,LGP Proband,mRNA Splicing - Minor Pathway,CP:REACTOME,C2,25,72
Cohort,0.006971004615088561,0.02327057793126068,0.29956302055240397,0.7645886967161872,LonGen OPEL,mRNA Splicing - Minor Pathway,CP:REACTOME,C2,39,42
Cohort,-0.06683725174337087,0.030943722008365947,-2.159961614355918,0.031126488937988493,LGP Offspring,MTOR signalling,CP:REACTOME,C2,41,51
Cohort,-0.1238897810994444,0.08657263427143484,-1.431050148145054,0.15279043094960704,LGP Proband,MTOR signalling,CP:REACTOME,C2,41,76
Cohort,-0.015179878409585588,0.024314807018477547,-0.624305938272508,0.5326055695326382,LonGen OPEL,MTOR signalling,CP:REACTOME,C2,39,43
Cohort,-0.02400576981032772,0.01628777329759462,-1.4738521571805578,0.14098690304117156,LGP Offspring,mTORC1-mediated signalling,CP:REACTOME,C2,12,15
Cohort,0.054420132225083816,0.053692133315340625,1.0135587629842824,0.31108729352506503,LGP Proband,mTORC1-mediated signalling,CP:REACTOME,C2,12,35
Cohort,-0.010559825959241797,0.013754120623614965,-0.7677572596761465,0.4428590932939652,LonGen OPEL,mTORC1-mediated signalling,CP:REACTOME,C2,14,15
Cohort,0.016136373255842967,0.014906826091561201,1.0824821566126552,0.27942430944985847,LGP Offspring,Mucopolysaccharidoses,CP:REACTOME,C2,4,18
Cohort,0.05353656548288479,0.03996888676801655,1.3394560072092179,0.18078715907821236,LGP Proband,Mucopolysaccharidoses,CP:REACTOME,C2,4,23
Cohort,0.009525960238904856,0.017270295657804285,0.5515806114529466,0.5813905263963617,LonGen OPEL,Mucopolysaccharidoses,CP:REACTOME,C2,17,28
Cohort,0.0049653098181243445,0.023118641710857212,0.21477515332539995,0.8300073998877808,LGP Offspring,Multifunctional anion exchangers,CP:REACTOME,C2,15,36
Cohort,0.02233927133359808,0.06648617999142922,0.33599871938014564,0.7369563444511339,LGP Proband,Multifunctional anion exchangers,CP:REACTOME,C2,15,56
Cohort,-0.028760318810963515,0.020675787556266728,-1.3910144284804478,0.1646097379330906,LonGen OPEL,Multifunctional anion exchangers,CP:REACTOME,C2,35,30
Cohort,0.0013382122973288248,0.003211064033568325,0.4167504239526871,0.676993265594438,LGP Offspring,Muscarinic acetylcholine receptors,CP:REACTOME,C2,0,1
Cohort,0.007122305680675858,0.011246515783245833,0.6332899733521118,0.5267179166220706,LGP Proband,Muscarinic acetylcholine receptors,CP:REACTOME,C2,0,2
Cohort,-0.008226291788775512,0.00519650864050599,-1.5830420687945799,0.11380908462431012,LonGen OPEL,Muscarinic acetylcholine receptors,CP:REACTOME,C2,3,1
Cohort,-0.09318132211897946,0.08493960901343911,-1.0970302689318518,0.27301878507336785,LGP Offspring,Muscle contraction,CP:REACTOME,C2,242,473
Cohort,-0.12676262826531456,0.24500405176816195,-0.5173899262093234,0.6050211845090803,LGP Proband,Muscle contraction,CP:REACTOME,C2,242,708
Cohort,0.016097104028460995,0.07433073081821032,0.21656055108390457,0.8286063194480424,LonGen OPEL,Muscle contraction,CP:REACTOME,C2,370,430
Cohort,-0.045488318993309476,0.03840262510537649,-1.184510664791532,0.23662726461642936,LGP Offspring,MyD88-independent TLR4 cascade ,CP:REACTOME,C2,54,99
Cohort,0.04085329054846638,0.11111709659644439,0.3676598093346297,0.7132201939901313,LGP Proband,MyD88-independent TLR4 cascade ,CP:REACTOME,C2,54,149
Cohort,-0.03432306678503371,0.03444345128713439,-0.9965048652907309,0.3193077283952676,LonGen OPEL,MyD88-independent TLR4 cascade ,CP:REACTOME,C2,92,98
Cohort,0.014015786002291405,0.008832426102114344,1.5868557336626057,0.11301293634343125,LGP Offspring,Myoclonic epilepsy of Lafora,CP:REACTOME,C2,1,7
Cohort,-0.05696803078488657,0.022139279429561762,-2.573165534412979,0.010249062581102189,LGP Proband,Myoclonic epilepsy of Lafora,CP:REACTOME,C2,1,7
Cohort,0.006266926964883438,0.008582980286994935,0.730157445937419,0.46550877708752425,LonGen OPEL,Myoclonic epilepsy of Lafora,CP:REACTOME,C2,4,7
Cohort,-0.028457361682366553,0.028533120506645943,-0.9973448812140353,0.3189539970968974,LGP Offspring,Myogenesis,CP:REACTOME,C2,34,50
Cohort,-0.15138438907715035,0.08383256851594832,-1.8057944753100457,0.07131089525620242,LGP Proband,Myogenesis,CP:REACTOME,C2,34,79
Cohort,-0.014765826146461401,0.028889000523873377,-0.5111227760980922,0.6094068236860422,LonGen OPEL,Myogenesis,CP:REACTOME,C2,59,66
Cohort,-0.0013330888925182185,0.02506378744077203,-0.05318784703502719,0.9575979522448563,LGP Offspring,N-Glycan antennae elongation,CP:REACTOME,C2,19,39
Cohort,-0.045208315610793366,0.06433079580516199,-0.7027476505609431,0.4824091289937954,LGP Proband,N-Glycan antennae elongation,CP:REACTOME,C2,19,50
Cohort,-0.016968462797929573,0.020042694445661955,-0.8466158501758845,0.3974637250177617,LonGen OPEL,N-Glycan antennae elongation,CP:REACTOME,C2,31,29
Cohort,-0.02119912271558795,0.029381655809704862,-0.7215087826529438,0.4708460081012873,LGP Offspring,N-glycan antennae elongation in the medial/trans-Golgi,CP:REACTOME,C2,30,54
Cohort,-0.042056407657498913,0.07614918573088546,-0.5522896568602597,0.5808978878792199,LGP Proband,N-glycan antennae elongation in the medial/trans-Golgi,CP:REACTOME,C2,30,70
Cohort,-0.013092563517681994,0.0222614390930528,-0.5881274549661901,0.5566135658446174,LonGen OPEL,N-glycan antennae elongation in the medial/trans-Golgi,CP:REACTOME,C2,37,37
Cohort,0.002416543630508325,0.011802617650856318,0.20474641321054715,0.8378318868951478,LGP Offspring,N-glycan trimming and elongation in the cis-Golgi,CP:REACTOME,C2,4,9
Cohort,0.05912004554919517,0.03494789208415527,1.6916627019115442,0.09108387129051865,LGP Proband,N-glycan trimming and elongation in the cis-Golgi,CP:REACTOME,C2,4,15
Cohort,0.010084550789376617,0.009683038899443492,1.0414654835225543,0.2979757751420593,LonGen OPEL,N-glycan trimming and elongation in the cis-Golgi,CP:REACTOME,C2,4,8
Cohort,-0.005194476691018055,0.0275902720452184,-0.18827203597357411,0.8507199078448532,LGP Offspring,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,CP:REACTOME,C2,27,51
Cohort,-0.0709565868883097,0.0825007937875327,-0.8600715657481647,0.3899967571927935,LGP Proband,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,CP:REACTOME,C2,27,77
Cohort,0.004807092086498177,0.02413714360620531,0.19915745478940364,0.8421904385065114,LonGen OPEL,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,CP:REACTOME,C2,43,52
Cohort,0.005805726935517726,0.030423802366607498,0.1908284462789558,0.848717296766279,LGP Offspring,Na+/Cl- dependent neurotransmitter transporters,CP:REACTOME,C2,31,63
Cohort,0.011230031940219494,0.08254876415847148,0.13604118795359366,0.8918215498003256,LGP Proband,Na+/Cl- dependent neurotransmitter transporters,CP:REACTOME,C2,31,80
Cohort,-0.07580705142115207,0.028970951020094723,-2.616657332669924,0.009047946677494319,LonGen OPEL,Na+/Cl- dependent neurotransmitter transporters,CP:REACTOME,C2,71,51
Cohort,0,0,NA,NA,LGP Offspring,"NADE modulates death signalling",CP:REACTOME,C2,0,0
Cohort,-0.00130346983509231,0.00795789424616909,-0.1637958227102348,0.8699315649248551,LGP Proband,"NADE modulates death signalling",CP:REACTOME,C2,0,1
Cohort,-1.708529716829856e-4,0.0036832374675408557,-0.04638662947709886,0.9630137279395006,LonGen OPEL,"NADE modulates death signalling",CP:REACTOME,C2,1,1
Cohort,-0.11868722874807065,0.06478633691507975,-1.8319793092121075,0.06739431642980184,LGP Offspring,NCAM signaling for neurite out-growth,CP:REACTOME,C2,147,259
Cohort,-0.18373328557925886,0.173014619769991,-1.0619523704038276,0.28856471761711655,LGP Proband,NCAM signaling for neurite out-growth,CP:REACTOME,C2,147,366
Cohort,-0.030565769262602432,0.05257249175194638,-0.5814023312195546,0.561133921345705,LonGen OPEL,NCAM signaling for neurite out-growth,CP:REACTOME,C2,211,227
Cohort,-0.08428389963779162,0.0551827865508171,-1.5273585280108262,0.12713962075245516,LGP Offspring,NCAM1 interactions,CP:REACTOME,C2,100,179
Cohort,-0.12156144386265776,0.14414937663717237,-0.8433019045835418,0.3993014126382518,LGP Proband,NCAM1 interactions,CP:REACTOME,C2,100,261
Cohort,-0.014261406811435923,0.04400924730406268,-0.3240547767814105,0.7459816924319422,LonGen OPEL,NCAM1 interactions,CP:REACTOME,C2,144,156
Cohort,0.005645193236330886,0.014912835977155207,0.37854592144503496,0.7051439381808353,LGP Offspring,Nectin/Necl  trans heterodimerization,CP:REACTOME,C2,6,16
Cohort,0.045958945793399424,0.048301586053381744,0.9514997238932632,0.34162642097951457,LGP Proband,Nectin/Necl  trans heterodimerization,CP:REACTOME,C2,6,34
Cohort,-0.004800826764163994,0.014424784766524512,-0.33281791318683906,0.739359368978212,LonGen OPEL,Nectin/Necl  trans heterodimerization,CP:REACTOME,C2,15,17
Cohort,0.09085836284830773,0.07433790299975636,1.2222346768189778,0.22204488431850491,LGP Offspring,Neddylation,CP:REACTOME,C2,145,345
Cohort,-0.35191383350071703,0.19754776743806626,-1.7814113419988231,0.07520911095916077,LGP Proband,Neddylation,CP:REACTOME,C2,145,429
Cohort,-0.014719982840876184,0.057609403112600606,-0.2555135454555084,0.7983924913538278,LonGen OPEL,Neddylation,CP:REACTOME,C2,235,282
Cohort,0.027663841102673593,0.014755128024086402,1.8748628312485593,0.061242531183684605,LGP Offspring,Nef and signal transduction,CP:REACTOME,C2,4,18
Cohort,0.09216219747736698,0.04060518568213575,2.2697149619959434,0.023479392558183113,LGP Proband,Nef and signal transduction,CP:REACTOME,C2,4,24
Cohort,0.005782200745573857,0.012011557563698858,0.48138642427596023,0.6303741877978859,LonGen OPEL,Nef and signal transduction,CP:REACTOME,C2,9,13
Cohort,0,0,NA,NA,LGP Offspring,Nef Mediated CD4 Down-regulation,CP:REACTOME,C2,0,0
Cohort,0.01397637244395749,0.013750189641583135,1.0164494314820456,0.30971019239055037,LGP Proband,Nef Mediated CD4 Down-regulation,CP:REACTOME,C2,0,3
Cohort,-9.091137650309003e-4,0.005153029698115276,-0.17642315652933444,0.8600063887983136,LonGen OPEL,Nef Mediated CD4 Down-regulation,CP:REACTOME,C2,1,3
Cohort,0,0,NA,NA,LGP Offspring,Nef Mediated CD8 Down-regulation,CP:REACTOME,C2,0,0
Cohort,0.01397637244395749,0.013750189641583135,1.0164494314820456,0.30971019239055037,LGP Proband,Nef Mediated CD8 Down-regulation,CP:REACTOME,C2,0,3
Cohort,-9.091137650309003e-4,0.005153029698115276,-0.17642315652933444,0.8600063887983136,LonGen OPEL,Nef Mediated CD8 Down-regulation,CP:REACTOME,C2,1,3
Cohort,-0.013384922866157853,0.018230380773900875,-0.7342097256311884,0.463075508844796,LGP Offspring,Nef mediated downregulation of MHC class I complex cell surface expression,CP:REACTOME,C2,12,22
Cohort,0.012038575773907444,0.049594891239701476,0.24273822309081663,0.8082678784458969,LGP Proband,Nef mediated downregulation of MHC class I complex cell surface expression,CP:REACTOME,C2,12,27
Cohort,-0.021358869771505275,0.016783148313650458,-1.2726378491294859,0.2035181761134966,LonGen OPEL,Nef mediated downregulation of MHC class I complex cell surface expression,CP:REACTOME,C2,20,20
Cohort,-0.013384922866157853,0.018230380773900875,-0.7342097256311884,0.463075508844796,LGP Offspring,Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,CP:REACTOME,C2,12,22
Cohort,0.02601494821786485,0.051297043440504474,0.5071432284014108,0.6121883909804895,LGP Proband,Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,CP:REACTOME,C2,12,30
Cohort,-0.022267983536536196,0.017450323024431984,-1.2760785863596371,0.20229995176924542,LonGen OPEL,Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,CP:REACTOME,C2,21,23
Cohort,-0.029469772569722174,0.0317665352760396,-0.9276986713735258,0.35389500198068213,LGP Offspring,Negative epigenetic regulation of rRNA expression,CP:REACTOME,C2,37,66
Cohort,0.032369671015429695,0.08989731977726903,0.36007381638995783,0.7188830970835854,LGP Proband,Negative epigenetic regulation of rRNA expression,CP:REACTOME,C2,37,95
Cohort,0.006984319337204438,0.027229164601385247,0.25650141822012124,0.7976299637459804,LonGen OPEL,Negative epigenetic regulation of rRNA expression,CP:REACTOME,C2,50,61
Cohort,-0.0036538923255346567,0.0071818193218576385,-0.5087697367175684,0.6110796387952222,LGP Offspring,Negative feedback regulation of MAPK pathway,CP:REACTOME,C2,2,3
Cohort,0.02979295775072625,0.02610895271744574,1.141101218158739,0.254155352843473,LGP Proband,Negative feedback regulation of MAPK pathway,CP:REACTOME,C2,2,9
Cohort,-0.018563716431503487,0.007169694443045855,-2.5891921307063654,0.009795823421256806,LonGen OPEL,Negative feedback regulation of MAPK pathway,CP:REACTOME,C2,7,1
Cohort,0.006751171302484427,0.013479611112622195,0.5008431805694072,0.616644523774659,LGP Offspring,Negative regulation of activity of TFAP2 (AP-2) family transcription factors,CP:REACTOME,C2,5,13
Cohort,-0.005926086965154763,0.035945450270635414,-0.16486333932491887,0.8690914984094147,LGP Proband,Negative regulation of activity of TFAP2 (AP-2) family transcription factors,CP:REACTOME,C2,5,16
Cohort,-0.0061782079021807735,0.009953469656908022,-0.6207089703531574,0.5349688047167159,LonGen OPEL,Negative regulation of activity of TFAP2 (AP-2) family transcription factors,CP:REACTOME,C2,7,8
Cohort,0.0012981831488156027,0.02895733436209996,0.04483089267065602,0.9642553403713979,LGP Offspring,Negative regulation of FGFR1 signaling,CP:REACTOME,C2,24,57
Cohort,0.10744041377836971,0.08197977352381901,1.3105722199531715,0.1903631180610186,LGP Proband,Negative regulation of FGFR1 signaling,CP:REACTOME,C2,24,78
Cohort,-0.027410449494778697,0.02171294339726296,-1.2624013701538934,0.20717411666182567,LonGen OPEL,Negative regulation of FGFR1 signaling,CP:REACTOME,C2,33,31
Cohort,0.0026843888655787157,0.01959784920964209,0.13697364628451186,0.8910924097430436,LGP Offspring,Negative regulation of FGFR2 signaling,CP:REACTOME,C2,13,27
Cohort,-0.01627925459660652,0.055218652089368984,-0.29481441470645203,0.7682090237244514,LGP Proband,Negative regulation of FGFR2 signaling,CP:REACTOME,C2,13,40
Cohort,-0.021992377302418938,0.014757464715836336,-1.4902544390852426,0.13655347412938912,LonGen OPEL,Negative regulation of FGFR2 signaling,CP:REACTOME,C2,19,15
Cohort,0.0058894423520884755,0.021180295233554622,0.2780623351632133,0.7810495328091962,LGP Offspring,Negative regulation of FGFR3 signaling,CP:REACTOME,C2,14,29
Cohort,-0.0063917837996345685,0.06056839677690896,-0.10553001465727035,0.9159806302749081,LGP Proband,Negative regulation of FGFR3 signaling,CP:REACTOME,C2,14,48
Cohort,-0.03063884151093587,0.017074961139885488,-1.7943725470253895,0.07313308348111892,LonGen OPEL,Negative regulation of FGFR3 signaling,CP:REACTOME,C2,26,18
Cohort,0.00564666761848448,0.018404350550388013,0.3068115662666202,0.7590812857673108,LGP Offspring,Negative regulation of FGFR4 signaling,CP:REACTOME,C2,11,24
Cohort,-0.009025170207801496,0.053243587046445086,-0.16950717839368562,0.8654388319253455,LGP Proband,Negative regulation of FGFR4 signaling,CP:REACTOME,C2,11,38
Cohort,-0.017810196210731273,0.014340338499180759,-1.2419648400732481,0.21461533378203773,LonGen OPEL,Negative regulation of FGFR4 signaling,CP:REACTOME,C2,18,14
Cohort,0.041593588173522524,0.02346567689626491,1.7725288027017485,0.07675712596875084,LGP Offspring,Negative regulation of FLT3,CP:REACTOME,C2,14,45
Cohort,0.005005585560253171,0.06287626317719035,0.07961009938117712,0.9365664604097191,LGP Proband,Negative regulation of FLT3,CP:REACTOME,C2,14,52
Cohort,0.01668441317941087,0.016769514202891835,0.994925254097922,0.3200749613181363,LonGen OPEL,Negative regulation of FLT3,CP:REACTOME,C2,15,25
Cohort,0.009377230713153347,0.026747196364978666,0.35058742550794547,0.7260071101001582,LGP Offspring,Negative regulation of MAPK pathway,CP:REACTOME,C2,19,44
Cohort,-0.04678492267900234,0.07686941939130562,-0.6086285423965878,0.5429364090455009,LGP Proband,Negative regulation of MAPK pathway,CP:REACTOME,C2,19,71
Cohort,-0.01666461170455149,0.02357644710257589,-0.7068330368883599,0.479877097989886,LonGen OPEL,Negative regulation of MAPK pathway,CP:REACTOME,C2,42,43
Cohort,0.025688446875537417,0.026058730132387332,0.9857904335718299,0.32458865503320466,LGP Offspring,Negative regulation of MET activity,CP:REACTOME,C2,19,47
Cohort,0.10168650621171711,0.07444728681666547,1.3658859920863358,0.1723429645536394,LGP Proband,Negative regulation of MET activity,CP:REACTOME,C2,19,66
Cohort,-0.008487298604842484,0.022438707843304248,-0.378243643266433,0.7053504548752951,LonGen OPEL,Negative regulation of MET activity,CP:REACTOME,C2,35,38
Cohort,-9.556830836823085e-4,0.02689057330403376,-0.03553970653124565,0.9716598767005691,LGP Offspring,Negative regulation of NMDA receptor-mediated neuronal transmission,CP:REACTOME,C2,20,48
Cohort,0.07238638296195397,0.07513249500892158,0.9634497423965287,0.3356011362621796,LGP Proband,Negative regulation of NMDA receptor-mediated neuronal transmission,CP:REACTOME,C2,20,72
Cohort,-0.005177396540193339,0.024735814072746467,-0.20930770764070844,0.8342615889616525,LonGen OPEL,Negative regulation of NMDA receptor-mediated neuronal transmission,CP:REACTOME,C2,38,45
Cohort,-1.3179620381740436e-4,0.030223736670102242,-0.004360685287063762,0.9965219740676985,LGP Offspring,Negative regulation of NOTCH4 signaling,CP:REACTOME,C2,25,51
Cohort,-0.10085375920566599,0.07321661508415823,-1.3774709345650638,0.16873623305881014,LGP Proband,Negative regulation of NOTCH4 signaling,CP:REACTOME,C2,25,65
Cohort,-0.010740167787715338,0.022843689080530052,-0.47015907762767223,0.6383701528820713,LonGen OPEL,Negative regulation of NOTCH4 signaling,CP:REACTOME,C2,36,37
Cohort,0.002719442111664069,0.012990759117262354,0.2093366590140545,0.8342485035083832,LGP Offspring,Negative regulation of TCF-dependent signaling by DVL-interacting proteins,CP:REACTOME,C2,6,11
Cohort,-0.0660238153059377,0.03632555659841038,-1.8175582561844885,0.0694903816405,LGP Proband,Negative regulation of TCF-dependent signaling by DVL-interacting proteins,CP:REACTOME,C2,6,16
Cohort,-0.024052287245975138,0.013047915043094572,-1.843381656497256,0.06564488540615776,LonGen OPEL,Negative regulation of TCF-dependent signaling by DVL-interacting proteins,CP:REACTOME,C2,16,10
Cohort,-0.006309007433960376,0.011048116327754208,-0.5710482444967911,0.5681567260220329,LGP Offspring,Negative regulation of TCF-dependent signaling by WNT ligand antagonists,CP:REACTOME,C2,5,7
Cohort,0.010193220726491047,0.03392489011067224,0.3004643697662095,0.763897851239389,LGP Proband,Negative regulation of TCF-dependent signaling by WNT ligand antagonists,CP:REACTOME,C2,5,14
Cohort,0.007388119457127073,0.008555496605339176,0.8635523801758527,0.3880939552096251,LonGen OPEL,Negative regulation of TCF-dependent signaling by WNT ligand antagonists,CP:REACTOME,C2,3,8
Cohort,-0.03214889832021578,0.04872683905735525,-0.6597780390058555,0.5096209940387117,LGP Offspring,Negative regulation of the PI3K/AKT network,CP:REACTOME,C2,79,153
Cohort,-0.0516345826448796,0.13085875916724551,-0.3945825481876031,0.6932518768571723,LGP Proband,Negative regulation of the PI3K/AKT network,CP:REACTOME,C2,79,189
Cohort,0.054802554433356604,0.03770968327832573,1.4532753836427814,0.14654141968355966,LonGen OPEL,Negative regulation of the PI3K/AKT network,CP:REACTOME,C2,89,123
Cohort,-0.03352534883324837,0.03217771954669794,-1.0418808201928258,0.2978394005705639,LGP Offspring,Negative regulators of DDX58/IFIH1 signaling,CP:REACTOME,C2,36,62
Cohort,0.006373466063999548,0.09347903363052391,0.06818070123821227,0.9456581317610754,LGP Proband,Negative regulators of DDX58/IFIH1 signaling,CP:REACTOME,C2,36,109
Cohort,-0.0016543254970825473,0.028904782935422747,-0.05723362464885267,0.9543734569033567,LonGen OPEL,Negative regulators of DDX58/IFIH1 signaling,CP:REACTOME,C2,54,65
Cohort,-0.06779153974428863,0.033922671012654726,-1.9984139727381505,0.046071859532982845,LGP Offspring,Nephrin family interactions,CP:REACTOME,C2,44,63
Cohort,-0.09158645137260654,0.09737334989535211,-0.940569996524051,0.3471976039711987,LGP Proband,Nephrin family interactions,CP:REACTOME,C2,44,103
Cohort,0.03399829581658461,0.030941641649768124,1.0987877179050516,0.2721928983334987,LonGen OPEL,Nephrin family interactions,CP:REACTOME,C2,56,85
Cohort,0.010784516344211958,0.13616780220582855,0.07920019394827492,0.9368968289698751,LGP Offspring,Nervous system development,CP:REACTOME,C2,579,1247
Cohort,-0.04519997515285477,0.39728929956619796,-0.11377093519057481,0.9094467606270977,LGP Proband,Nervous system development,CP:REACTOME,C2,579,1801
Cohort,-0.23605830625596178,0.12165299523834286,-1.9404232981972678,0.05268106197116542,LonGen OPEL,Nervous system development,CP:REACTOME,C2,1026,1095
Cohort,-0.06476231321766637,0.042636677848298964,-1.5189343186654993,0.129246563088574,LGP Offspring,Netrin-1 signaling,CP:REACTOME,C2,67,112
Cohort,0.027463119743006602,0.12137672588833433,0.22626347466541868,0.8210519452656058,LGP Proband,Netrin-1 signaling,CP:REACTOME,C2,67,168
Cohort,-0.05303946204198272,0.037501974961781336,-1.414311168839396,0.15766157086303886,LonGen OPEL,Netrin-1 signaling,CP:REACTOME,C2,112,114
Cohort,-0.018491276658887366,0.021901921507028625,-0.8442764555134243,0.3988136160664635,LGP Offspring,Netrin mediated repulsion signals,CP:REACTOME,C2,17,31
Cohort,-0.03384243692927135,0.05885198101573075,-0.575043292429281,0.5654171121545886,LGP Proband,Netrin mediated repulsion signals,CP:REACTOME,C2,17,38
Cohort,-0.03148018408269379,0.0206518227212923,-1.524329571657484,0.12782358760839627,LonGen OPEL,Netrin mediated repulsion signals,CP:REACTOME,C2,34,30
Cohort,0.030630796536396013,0.0335811969942671,0.9121412956668944,0.362019507372185,LGP Offspring,Neurexins and neuroligins,CP:REACTOME,C2,34,86
Cohort,0.2288745603123521,0.0922879447514385,2.4800049554552963,0.01333446307717429,LGP Proband,Neurexins and neuroligins,CP:REACTOME,C2,34,119
Cohort,-0.007977408237628752,0.029117808482368893,-0.27397007719379524,0.7841786944707558,LonGen OPEL,Neurexins and neuroligins,CP:REACTOME,C2,56,68
Cohort,0.017157610006947547,0.02069628250748848,0.8290189313341395,0.407386315199744,LGP Offspring,Neurofascin interactions,CP:REACTOME,C2,13,31
Cohort,-0.07729032795161365,0.05720041800609983,-1.3512196352021666,0.1769915090700562,LGP Proband,Neurofascin interactions,CP:REACTOME,C2,13,39
Cohort,-3.3168322270112554e-4,0.01765248127936965,-0.0187896090896163,0.9850136517199974,LonGen OPEL,Neurofascin interactions,CP:REACTOME,C2,23,26
Cohort,-0.134811513357431,0.10637544587145807,-1.2673179628345295,0.20547801432807408,LGP Offspring,Neuronal System,CP:REACTOME,C2,384,756
Cohort,0.3944940854149944,0.2939533095954238,1.3420297460094859,0.17995158501694658,LGP Proband,Neuronal System,CP:REACTOME,C2,384,1081
Cohort,-0.09665161630320565,0.09762435814065673,-0.9900358695721251,0.3224574325817944,LonGen OPEL,Neuronal System,CP:REACTOME,C2,624,713
Cohort,-0.017372980762317664,0.015190337054400933,-1.1436863250696847,0.2531585789883414,LGP Offspring,Neurotoxicity of clostridium toxins,CP:REACTOME,C2,9,15
Cohort,0.0033983691978760775,0.03671057406423627,0.09257194376556468,0.926265865352448,LGP Proband,Neurotoxicity of clostridium toxins,CP:REACTOME,C2,9,14
Cohort,0.012272296171989093,0.01255834056981289,0.9772227551694707,0.3287557760716996,LonGen OPEL,Neurotoxicity of clostridium toxins,CP:REACTOME,C2,8,16
Cohort,-0.018820059517756983,0.02442867350670805,-0.7704085738666508,0.44132672259435324,LGP Offspring,Neurotransmitter clearance,CP:REACTOME,C2,24,40
Cohort,0.09616598254103477,0.07181716695517218,1.3390389320294542,0.1809228354307603,LGP Proband,Neurotransmitter clearance,CP:REACTOME,C2,24,66
Cohort,-0.02398888169126564,0.02533765802405897,-0.9467679162962646,0.3440443687446705,LonGen OPEL,Neurotransmitter clearance,CP:REACTOME,C2,51,49
Cohort,-0.09667610832097105,0.06806799138122005,-1.4202873679572683,0.15598507084845134,LGP Offspring,Neurotransmitter receptors and postsynaptic signal transmission,CP:REACTOME,C2,153,289
Cohort,-0.13500431852810402,0.19334197754945506,-0.6982669787453228,0.4852048897543825,LGP Proband,Neurotransmitter receptors and postsynaptic signal transmission,CP:REACTOME,C2,153,448
Cohort,-0.044883853254741306,0.0642803426523454,-0.6982516178778276,0.4852237790042301,LonGen OPEL,Neurotransmitter receptors and postsynaptic signal transmission,CP:REACTOME,C2,262,301
Cohort,-0.08575667616893386,0.04485370205466898,-1.9119196909189604,0.05630894684385575,LGP Offspring,Neurotransmitter release cycle,CP:REACTOME,C2,77,127
Cohort,0.17186976764271134,0.12669835686316025,1.3565272028613455,0.1752985721024272,LGP Proband,Neurotransmitter release cycle,CP:REACTOME,C2,77,186
Cohort,-0.0721213477997429,0.039598412029740376,-1.8213191919306304,0.06893358393363487,LonGen OPEL,Neurotransmitter release cycle,CP:REACTOME,C2,126,112
Cohort,0.06995362684294927,0.12809731790041895,0.5460975139021274,0.5851790819994084,LGP Offspring,Neutrophil degranulation,CP:REACTOME,C2,474,1046
Cohort,0.3438234736710905,0.3448729691285816,0.9969568636818856,0.3190746104376675,LGP Proband,Neutrophil degranulation,CP:REACTOME,C2,474,1417
Cohort,-0.09488019674499398,0.10351296818031419,-0.9166020298028517,0.3596288314797135,LonGen OPEL,Neutrophil degranulation,CP:REACTOME,C2,781,916
Cohort,-0.014002191580949262,0.019129969705390326,-0.7319505360744931,0.464452431503683,LGP Offspring,NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,CP:REACTOME,C2,12,21
Cohort,-0.009963638746052429,0.05885167008389811,-0.1693008665998502,0.8656010483913494,LGP Proband,NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,CP:REACTOME,C2,12,44
Cohort,-0.021074368536178917,0.01745192085395675,-1.2075672765500123,0.22757242987456908,LonGen OPEL,NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,CP:REACTOME,C2,22,17
Cohort,0.0018611065223590184,0.015375206339236827,0.12104595420027367,0.9036906063719078,LGP Offspring,NF-kB is activated and signals survival,CP:REACTOME,C2,7,17
Cohort,-0.0017269154606311464,0.040661259805776714,-0.042470781005801615,0.9661335696339409,LGP Proband,NF-kB is activated and signals survival,CP:REACTOME,C2,7,21
Cohort,0.018194537229037366,0.01540783872231048,1.1808623880967652,0.23801011080855455,LonGen OPEL,NF-kB is activated and signals survival,CP:REACTOME,C2,13,24
Cohort,-0.005936888938483949,0.006427192613598496,-0.9237141774657298,0.3559647373624022,LGP Offspring,NGF-independant TRKA activation,CP:REACTOME,C2,2,2
Cohort,0.01795525690366925,0.013622233696774497,1.3180846330599023,0.18783722057581667,LGP Proband,NGF-independant TRKA activation,CP:REACTOME,C2,2,1
Cohort,-0.004953628666862014,0.005061369616545402,-0.978713084037335,0.3280191188419417,LonGen OPEL,NGF-independant TRKA activation,CP:REACTOME,C2,2,2
Cohort,0.034158392512765326,0.023672207065689035,1.4429745573776758,0.14949083554468717,LGP Offspring,NGF-stimulated transcription,CP:REACTOME,C2,13,42
Cohort,-0.07096284009637847,0.06443961157715233,-1.1012301030308973,0.2711142418061451,LGP Proband,NGF-stimulated transcription,CP:REACTOME,C2,13,46
Cohort,-0.02402656449806864,0.018936169107339498,-1.2688186486862407,0.2048766547820374,LonGen OPEL,NGF-stimulated transcription,CP:REACTOME,C2,27,22
Cohort,0.00754743703001986,0.020015906693759,0.377071953096842,0.706238472769122,LGP Offspring,Nicotinamide salvaging,CP:REACTOME,C2,12,27
Cohort,-0.001528629664611568,0.0632450233474465,-0.024169959685425367,0.980722821471789,LGP Proband,Nicotinamide salvaging,CP:REACTOME,C2,12,49
Cohort,-0.02716559959773296,0.02219976285438885,-1.2236887292857894,0.22143176797001593,LonGen OPEL,Nicotinamide salvaging,CP:REACTOME,C2,37,30
Cohort,0.007075571333002114,0.026006442178897075,0.27206994652823313,0.7856513120044686,LGP Offspring,Nicotinate metabolism,CP:REACTOME,C2,22,48
Cohort,-0.07872077251601034,0.08119903898545226,-0.9694791157579349,0.3325872607644451,LGP Proband,Nicotinate metabolism,CP:REACTOME,C2,22,81
Cohort,-0.012532492129873484,0.029123037192164372,-0.4303291599423354,0.6670727009899164,LonGen OPEL,Nicotinate metabolism,CP:REACTOME,C2,57,59
Cohort,-0.05439568611379481,0.03048156923871364,-1.784543495375843,0.07478375873333992,LGP Offspring,Nitric oxide stimulates guanylate cyclase,CP:REACTOME,C2,39,54
Cohort,-0.13199429429796283,0.08643954895814907,-1.5270127608124118,0.12713697745075453,LGP Proband,Nitric oxide stimulates guanylate cyclase,CP:REACTOME,C2,39,82
Cohort,0.010750476469045015,0.02479054386768985,0.43365230413748146,0.6646584446243073,LonGen OPEL,Nitric oxide stimulates guanylate cyclase,CP:REACTOME,C2,40,57
Cohort,-0.011025637084395013,0.03124902061623737,-0.3528314445370476,0.7243247939275277,LGP Offspring,NOD1/2 Signaling Pathway,CP:REACTOME,C2,32,61
Cohort,0.03931073599244824,0.08488860279820079,0.4630861469813405,0.643423431230814,LGP Proband,NOD1/2 Signaling Pathway,CP:REACTOME,C2,32,87
Cohort,-0.06570801633450384,0.0272700922730592,-2.4095267326769707,0.016199233422795518,LonGen OPEL,NOD1/2 Signaling Pathway,CP:REACTOME,C2,60,49
Cohort,0.01225139891120613,0.06172175236374356,0.19849402264221547,0.842718240448778,LGP Offspring,Non-integrin membrane-ECM interactions,CP:REACTOME,C2,119,260
Cohort,-0.28483991605263975,0.16778988302316467,-1.6975988714010573,0.08995655855072744,LGP Proband,Non-integrin membrane-ECM interactions,CP:REACTOME,C2,119,351
Cohort,0.0015931460827939465,0.05159295723606081,0.03087913870694777,0.9753736674186136,LonGen OPEL,Non-integrin membrane-ECM interactions,CP:REACTOME,C2,188,236
Cohort,-0.006411288552924426,0.011380714402356015,-0.5633467571769636,0.5733855923105283,LGP Offspring,Noncanonical activation of NOTCH3,CP:REACTOME,C2,5,8
Cohort,0.035263819922006084,0.026821605450310475,1.3147542561289107,0.1889539181697739,LGP Proband,Noncanonical activation of NOTCH3,CP:REACTOME,C2,5,7
Cohort,-0.019560915704992434,0.010257729462159606,-1.9069440052159639,0.05688758489297769,LonGen OPEL,Noncanonical activation of NOTCH3,CP:REACTOME,C2,11,3
Cohort,0.03417861583838176,0.03318917826060974,1.0298120540979565,0.3034665527959499,LGP Offspring,Nonhomologous End-Joining (NHEJ),CP:REACTOME,C2,33,80
Cohort,-0.10687781250456338,0.09279671099185868,-1.1517413856827325,0.24975741554866726,LGP Proband,Nonhomologous End-Joining (NHEJ),CP:REACTOME,C2,33,113
Cohort,0.019158697818267303,0.03045233916632641,0.6291371481719411,0.5294397791465391,LonGen OPEL,Nonhomologous End-Joining (NHEJ),CP:REACTOME,C2,55,81
Cohort,-0.025054144208871643,0.02570226671472059,-0.9747834495282961,0.33001637041563203,LGP Offspring,Nonsense-Mediated Decay (NMD),CP:REACTOME,C2,23,43
Cohort,0.12577121979284978,0.08212151662859914,1.5315257797984878,0.12601871016530491,LGP Proband,Nonsense-Mediated Decay (NMD),CP:REACTOME,C2,23,90
Cohort,-0.04019065189440383,0.02508985574664734,-1.6018685918421174,0.10958141042202045,LonGen OPEL,Nonsense-Mediated Decay (NMD),CP:REACTOME,C2,49,46
Cohort,-0.023694810775817306,0.030543800634907414,-0.7757649763054489,0.43815907417735045,LGP Offspring,Norepinephrine Neurotransmitter Release Cycle,CP:REACTOME,C2,32,60
Cohort,0.05498276360385354,0.08440880561592887,0.6513865846418005,0.5149764108726345,LGP Proband,Norepinephrine Neurotransmitter Release Cycle,CP:REACTOME,C2,32,84
Cohort,-0.039863077874436686,0.027978188846168702,-1.4247912219627286,0.15460950344867688,LonGen OPEL,Norepinephrine Neurotransmitter Release Cycle,CP:REACTOME,C2,66,55
Cohort,-0.012908144012558442,0.017143795935931915,-0.7529338345368477,0.45175179640926877,LGP Offspring,NOSTRIN mediated eNOS trafficking,CP:REACTOME,C2,13,17
Cohort,0.0022843500424906942,0.046826828609348656,0.04878293299654804,0.9611039631881215,LGP Proband,NOSTRIN mediated eNOS trafficking,CP:REACTOME,C2,13,24
Cohort,0.004720911454365555,0.011713936982051245,0.403016634082905,0.6870442073160845,LonGen OPEL,NOSTRIN mediated eNOS trafficking,CP:REACTOME,C2,9,12
Cohort,-0.08559279813240138,0.03453599334854287,-2.4783650282933785,0.013441620567660696,LGP Offspring,Notch-HLH transcription pathway,CP:REACTOME,C2,48,64
Cohort,-0.05416741673783345,0.10133325959372709,-0.5345472646888645,0.5931054276662936,LGP Proband,Notch-HLH transcription pathway,CP:REACTOME,C2,48,109
Cohort,-0.030455861625846643,0.03304375162160632,-0.9216829243424184,0.3569732492719655,LonGen OPEL,Notch-HLH transcription pathway,CP:REACTOME,C2,81,83
Cohort,-0.07753035188580304,0.03998709410666299,-1.93888437301785,0.05293125917979311,LGP Offspring,NOTCH1 Intracellular Domain Regulates Transcription,CP:REACTOME,C2,60,93
Cohort,-0.03328476528928105,0.11806067540329786,-0.28192931452898745,0.7780676537137662,LGP Proband,NOTCH1 Intracellular Domain Regulates Transcription,CP:REACTOME,C2,60,154
Cohort,-0.012165880958985806,0.03841303396794192,-0.316712316166929,0.7515449432036424,LonGen OPEL,NOTCH1 Intracellular Domain Regulates Transcription,CP:REACTOME,C2,101,112
Cohort,-0.03855268945758413,0.022953702346544435,-1.6795847953211804,0.09350019051150285,LGP Offspring,NOTCH2 Activation and Transmission of Signal to the Nucleus,CP:REACTOME,C2,21,28
Cohort,0.02977683389824955,0.0656963595063628,0.4532493751859358,0.6504870805126206,LGP Proband,NOTCH2 Activation and Transmission of Signal to the Nucleus,CP:REACTOME,C2,21,44
Cohort,-0.01669987694146247,0.019665961596330463,-0.8491767290229304,0.3960382689802536,LonGen OPEL,NOTCH2 Activation and Transmission of Signal to the Nucleus,CP:REACTOME,C2,30,28
Cohort,-0.02174729211737518,0.010542565781277083,-2.0628082924554256,0.0395122500388627,LGP Offspring,NOTCH2 intracellular domain regulates transcription,CP:REACTOME,C2,7,4
Cohort,-0.045477266523859396,0.04191229573933193,-1.0850578743454984,0.27820956867723134,LGP Proband,NOTCH2 intracellular domain regulates transcription,CP:REACTOME,C2,7,22
Cohort,-0.006982903807224023,0.012786435880051504,-0.5461180795594696,0.5851377965495006,LonGen OPEL,NOTCH2 intracellular domain regulates transcription,CP:REACTOME,C2,13,10
Cohort,-0.030416378535915778,0.026042411093579642,-1.1679555486094937,0.24323645342482142,LGP Offspring,NOTCH3 Activation and Transmission of Signal to the Nucleus,CP:REACTOME,C2,25,42
Cohort,0.06200621427875044,0.07005023639823639,0.8851678090883863,0.3763212602764697,LGP Proband,NOTCH3 Activation and Transmission of Signal to the Nucleus,CP:REACTOME,C2,25,49
Cohort,-0.024775991213851132,0.02069018557716689,-1.1974755432446784,0.2314777222924914,LonGen OPEL,NOTCH3 Activation and Transmission of Signal to the Nucleus,CP:REACTOME,C2,35,31
Cohort,-0.02142183325753341,0.023315676483016926,-0.9187738246898826,0.3585415905899063,LGP Offspring,NOTCH3 Intracellular Domain Regulates Transcription,CP:REACTOME,C2,21,36
Cohort,0.019044946327170322,0.06745672772042038,0.28232834545582425,0.7777618010029045,LGP Proband,NOTCH3 Intracellular Domain Regulates Transcription,CP:REACTOME,C2,21,52
Cohort,-0.03705506841979338,0.024034094783696863,-1.5417709197406129,0.12352669905255298,LonGen OPEL,NOTCH3 Intracellular Domain Regulates Transcription,CP:REACTOME,C2,48,40
Cohort,-0.0025959724855848486,0.016753180271752603,-0.1549540113265477,0.8769038264867792,LGP Offspring,NOTCH4 Activation and Transmission of Signal to the Nucleus,CP:REACTOME,C2,9,17
Cohort,0.015617131840022435,0.04139662623571614,0.3772561500808561,0.7060792315149785,LGP Proband,NOTCH4 Activation and Transmission of Signal to the Nucleus,CP:REACTOME,C2,9,17
Cohort,-0.003532799903421846,0.012082053196063595,-0.2924006248021531,0.7700565272030382,LonGen OPEL,NOTCH4 Activation and Transmission of Signal to the Nucleus,CP:REACTOME,C2,10,10
Cohort,-0.018663581461313455,0.02207992406852183,-0.8452738063497748,0.39825705352330754,LGP Offspring,NOTCH4 Intracellular Domain Regulates Transcription,CP:REACTOME,C2,19,32
Cohort,-0.033004883991965016,0.06308307879932026,-0.5231971016658853,0.6009760727132634,LGP Proband,NOTCH4 Intracellular Domain Regulates Transcription,CP:REACTOME,C2,19,46
Cohort,-0.01632796250110303,0.023332084169095785,-0.6998072860859136,0.4842521228366714,LonGen OPEL,NOTCH4 Intracellular Domain Regulates Transcription,CP:REACTOME,C2,41,41
Cohort,-0.05546065031011269,0.040743688537319245,-1.361208381006384,0.17390140305018534,LGP Offspring,NR1H2 and NR1H3-mediated signaling,CP:REACTOME,C2,61,105
Cohort,-0.0604699686469771,0.11663533103913894,-0.5184532689043031,0.604279576401672,LGP Proband,NR1H2 and NR1H3-mediated signaling,CP:REACTOME,C2,61,160
Cohort,-0.014475416984245489,0.03475797983295222,-0.4164631274261257,0.6771834134314207,LonGen OPEL,NR1H2 and NR1H3-mediated signaling,CP:REACTOME,C2,88,98
Cohort,-0.00977742848522538,0.013083547530083239,-0.7473071399590945,0.45513803942630704,LGP Offspring,NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis ,CP:REACTOME,C2,7,10
Cohort,0.024450846832246662,0.039797269910372295,0.614385029106584,0.5391284899895323,LGP Proband,NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis ,CP:REACTOME,C2,7,19
Cohort,-0.009259450512454798,0.011150068624856953,-0.8304388810498097,0.40653968878211344,LonGen OPEL,NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis ,CP:REACTOME,C2,11,8
Cohort,-0.00263867091958006,0.016539471214333107,-0.15953780416470556,0.873292830770179,LGP Offspring,NR1H2 & NR1H3 regulate gene expression linked to lipogenesis,CP:REACTOME,C2,10,18
Cohort,-0.09083973594634656,0.05024437924188589,-1.8079581699880694,0.07097314249274998,LGP Proband,NR1H2 & NR1H3 regulate gene expression linked to lipogenesis,CP:REACTOME,C2,10,33
Cohort,-0.007444054233205967,0.016955288184926576,-0.439040265904994,0.6607515082876316,LonGen OPEL,NR1H2 & NR1H3 regulate gene expression linked to lipogenesis,CP:REACTOME,C2,22,21
Cohort,-4.894655975684745e-4,0.0055305639801648135,-0.0885019320495933,0.9295039603694263,LGP Offspring,NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose,CP:REACTOME,C2,1,2
Cohort,0.006376493324147905,0.015748125373206568,0.4049049123647883,0.68565123792692,LGP Proband,NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose,CP:REACTOME,C2,1,3
Cohort,-0.003651112054216541,0.0036404906075740073,-1.0029175866078148,0.3162053994651017,LonGen OPEL,NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose,CP:REACTOME,C2,2,0
Cohort,-0.036996658060509995,0.022153081031995495,-1.6700457154052772,0.09537324584235965,LGP Offspring,NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis,CP:REACTOME,C2,19,28
Cohort,0.032687494902837906,0.06369367221244283,0.5131984664632394,0.607948410818798,LGP Proband,NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis,CP:REACTOME,C2,19,47
Cohort,-0.03065486016422659,0.0196366116628694,-1.5611074196772676,0.11889587190096372,LonGen OPEL,NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis,CP:REACTOME,C2,32,28
Cohort,0.0015904807214813345,0.003187402772808923,0.49898956449727605,0.6179490724916983,LGP Offspring,NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake ,CP:REACTOME,C2,0,1
Cohort,0.0033376232368308076,0.011208693343510809,0.2977709474729363,0.7659521494789541,LGP Proband,NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake ,CP:REACTOME,C2,0,2
Cohort,-0.003651112054216541,0.0036404906075740073,-1.0029175866078148,0.3162053994651017,LonGen OPEL,NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake ,CP:REACTOME,C2,2,0
Cohort,-0.03892267052290366,0.03279728400838824,-1.1867650538669237,0.2357371984833975,LGP Offspring,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,CP:REACTOME,C2,41,70
Cohort,-0.0054270699704013926,0.09253957035934098,-0.05864593869765662,0.9532481683665813,LGP Proband,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,CP:REACTOME,C2,41,104
Cohort,-0.0046868013255291574,0.027681217325577778,-0.16931341098205593,0.8655931446759,LonGen OPEL,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,CP:REACTOME,C2,57,64
Cohort,-0.005559433054227106,0.05780263674323699,-0.09617957531803373,0.9234064574306353,LGP Offspring,NRAGE signals death through JNK,CP:REACTOME,C2,119,224
Cohort,-0.02490076115808994,0.1595862075928024,-0.1560332909321733,0.8760445396188803,LGP Proband,NRAGE signals death through JNK,CP:REACTOME,C2,119,336
Cohort,0.048493082784173365,0.048328399747658415,1.003407583064509,0.31596916820878496,LonGen OPEL,NRAGE signals death through JNK,CP:REACTOME,C2,166,215
Cohort,0.01186722027375139,0.02714550857125316,0.43717067383731634,0.6621271949161573,LGP Offspring,NrCAM interactions,CP:REACTOME,C2,20,46
Cohort,0.051636944553963615,0.07161953913611672,0.7209896234577113,0.4711179482238276,LGP Proband,NrCAM interactions,CP:REACTOME,C2,20,62
Cohort,-0.019719749699238814,0.021369263342279687,-0.922809054452651,0.3563863453330962,LonGen OPEL,NrCAM interactions,CP:REACTOME,C2,39,36
Cohort,7.429830427593829e-4,0.010000048087866711,0.07429794699296109,0.9407952902688945,LGP Offspring,NRIF signals cell death from the nucleus,CP:REACTOME,C2,3,7
Cohort,0.013860806746995084,0.029317785640325035,0.47277809166904783,0.6364952051255889,LGP Proband,NRIF signals cell death from the nucleus,CP:REACTOME,C2,3,11
Cohort,-0.010603386821492262,0.01034385766953735,-1.0250901704418482,0.3056320551401825,LonGen OPEL,NRIF signals cell death from the nucleus,CP:REACTOME,C2,9,5
Cohort,-0.0748241603862575,0.038542510766517143,-1.9413411035811177,0.05263213720223898,LGP Offspring,NS1 Mediated Effects on Host Pathways,CP:REACTOME,C2,62,94
Cohort,-0.2608100569287226,0.10610580688331372,-2.4580186946369453,0.014172965882192712,LGP Proband,NS1 Mediated Effects on Host Pathways,CP:REACTOME,C2,62,126
Cohort,0.013648428660409806,0.03689185814117105,0.3699577453697909,0.7115123829109458,LonGen OPEL,NS1 Mediated Effects on Host Pathways,CP:REACTOME,C2,83,104
Cohort,-6.457504309931338e-4,0.007094146501360529,-0.09102580992220707,0.9274990478943729,LGP Offspring,NTRK2 activates RAC1,CP:REACTOME,C2,2,3
Cohort,-0.04508940799607742,0.015663850664232624,-2.878564726043777,0.004097025197985831,LGP Proband,NTRK2 activates RAC1,CP:REACTOME,C2,2,2
Cohort,0.006828874944032796,0.005067059428805712,1.3476997931406416,0.17813839738985415,LonGen OPEL,NTRK2 activates RAC1,CP:REACTOME,C2,0,4
Cohort,-0.0700964427922494,0.04300630959647714,-1.6299106677591175,0.10358621243804933,LGP Offspring,Nuclear Envelope Breakdown,CP:REACTOME,C2,76,121
Cohort,-0.29917461359651754,0.11780083233449139,-2.539664683752162,0.01127636858497432,LGP Proband,Nuclear Envelope Breakdown,CP:REACTOME,C2,76,159
Cohort,0.006633168723974039,0.03911522779570636,0.16958021460639827,0.8653833700833614,LonGen OPEL,Nuclear Envelope Breakdown,CP:REACTOME,C2,97,118
Cohort,0.007637500314490312,0.04738698392984808,0.16117295681440508,0.8720053348538328,LGP Offspring,Nuclear Envelope (NE) Reassembly,CP:REACTOME,C2,64,141
Cohort,-0.12756453899384523,0.12217612346924439,-1.0441036707631117,0.29673996456006946,LGP Proband,Nuclear Envelope (NE) Reassembly,CP:REACTOME,C2,64,177
Cohort,-0.016616043628633326,0.038010670732305976,-0.43714155284587075,0.6621272595835316,LonGen OPEL,Nuclear Envelope (NE) Reassembly,CP:REACTOME,C2,100,116
Cohort,0.02327172344999277,0.025853406892206023,0.9001414609309557,0.36836552028353353,LGP Offspring,Nuclear Events (kinase and transcription factor activation),CP:REACTOME,C2,18,47
Cohort,-0.10108052808549967,0.07073367861277019,-1.4290297078830378,0.15337012457675192,LGP Proband,Nuclear Events (kinase and transcription factor activation),CP:REACTOME,C2,18,57
Cohort,-0.04613937209958428,0.021507280760826936,-2.1452908255897185,0.03223154392735451,LonGen OPEL,Nuclear Events (kinase and transcription factor activation),CP:REACTOME,C2,39,28
Cohort,-0.034128574484072687,0.03732369034995507,-0.9143944278841594,0.3608356576891124,LGP Offspring,Nuclear import of Rev protein,CP:REACTOME,C2,53,93
Cohort,-0.257990973410203,0.1018862136555567,-2.5321480125111373,0.011519082253666216,LGP Proband,Nuclear import of Rev protein,CP:REACTOME,C2,53,119
Cohort,0.002070257070900561,0.03557512415243127,0.05819395210063029,0.9536087433442365,LonGen OPEL,Nuclear import of Rev protein,CP:REACTOME,C2,80,95
Cohort,-0.04243862426394352,0.03828985562978609,-1.1083516395117996,0.2681041571941816,LGP Offspring,Nuclear Pore Complex (NPC) Disassembly,CP:REACTOME,C2,58,97
Cohort,-0.2910322708130174,0.10592137126377997,-2.747625595671801,0.0061323958400196854,LGP Proband,Nuclear Pore Complex (NPC) Disassembly,CP:REACTOME,C2,58,128
Cohort,0.008231404902194657,0.03688569477092938,0.2231598171950946,0.8234683784399467,LonGen OPEL,Nuclear Pore Complex (NPC) Disassembly,CP:REACTOME,C2,85,105
Cohort,-0.0042517955062747964,0.033477963487414754,-0.12700281209976103,0.8989759397969389,LGP Offspring,Nuclear Receptor transcription pathway,CP:REACTOME,C2,38,75
Cohort,-0.07563332304535465,0.09942091273736339,-0.7607385706179589,0.4470282535980946,LGP Proband,Nuclear Receptor transcription pathway,CP:REACTOME,C2,38,114
Cohort,0.0056808305794200575,0.03086336271458023,0.18406388934205034,0.8540102136016304,LonGen OPEL,Nuclear Receptor transcription pathway,CP:REACTOME,C2,63,79
Cohort,-0.04409256663607903,0.02712670228922785,-1.6254304030751432,0.10453696626115525,LGP Offspring,Nuclear signaling by ERBB4,CP:REACTOME,C2,28,38
Cohort,0.021057465700892047,0.07207063939241085,0.2921781446427605,0.7702230870506962,LGP Proband,Nuclear signaling by ERBB4,CP:REACTOME,C2,28,54
Cohort,-0.008658178024154993,0.0230328783401632,-0.37590516896264065,0.7070875557885484,LonGen OPEL,Nuclear signaling by ERBB4,CP:REACTOME,C2,39,39
Cohort,0.016229319777640968,0.026813656202498676,0.6052632156941212,0.5452072496601172,LGP Offspring,Nucleobase biosynthesis,CP:REACTOME,C2,16,45
Cohort,0.018322490056827255,0.07123950672745462,0.25719563341341956,0.7970911946735703,LGP Proband,Nucleobase biosynthesis,CP:REACTOME,C2,16,60
Cohort,-0.0015838570987045232,0.017628173807386953,-0.08984805323628134,0.9284305635668901,LonGen OPEL,Nucleobase biosynthesis,CP:REACTOME,C2,21,26
Cohort,0.019470920795684764,0.03634274470523697,0.5357581259645207,0.5923019480155249,LGP Offspring,Nucleobase catabolism,CP:REACTOME,C2,36,85
Cohort,0.040077782149275154,0.09545288457584002,0.41986978525968194,0.674688721589028,LGP Proband,Nucleobase catabolism,CP:REACTOME,C2,36,120
Cohort,-0.026983097962514593,0.028833073871449708,-0.935838408447774,0.34964021514162946,LonGen OPEL,Nucleobase catabolism,CP:REACTOME,C2,61,69
Cohort,0.006192006239245391,0.042693089339484507,0.14503532855184462,0.8847262098535247,LGP Offspring,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",CP:REACTOME,C2,54,118
Cohort,0.15349629998943995,0.11198858398132727,1.3706423863260346,0.1708552306810717,LGP Proband,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",CP:REACTOME,C2,54,150
Cohort,-0.014323350931245362,0.036081203800696036,-0.3969754171829781,0.691491999801987,LonGen OPEL,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",CP:REACTOME,C2,92,106
Cohort,0.06936485852677275,0.051525663832154844,1.3462195994743356,0.17868294932560713,LGP Offspring,Nucleotide Excision Repair,CP:REACTOME,C2,71,172
Cohort,-0.09088389394452072,0.1404572992777652,-0.6470571085436491,0.5177730295779683,LGP Proband,Nucleotide Excision Repair,CP:REACTOME,C2,71,234
Cohort,-0.007710158355778795,0.043924715730279736,-0.17553120669290426,0.8607068936584467,LonGen OPEL,Nucleotide Excision Repair,CP:REACTOME,C2,137,158
Cohort,0.025169529444205228,0.015328508028960113,1.642007780317073,0.10105347447361995,LGP Offspring,Nucleotide-like (purinergic) receptors,CP:REACTOME,C2,5,19
Cohort,-0.0853973371155282,0.037243343808612384,-2.2929556904012576,0.022098625806076005,LGP Proband,Nucleotide-like (purinergic) receptors,CP:REACTOME,C2,5,19
Cohort,0.0046824382197857995,0.012008420219196361,0.38992957727283484,0.6966929328879108,LonGen OPEL,Nucleotide-like (purinergic) receptors,CP:REACTOME,C2,9,13
Cohort,0.023979512869312457,0.030507030829598193,0.7860323413069528,0.4321239719974449,LGP Offspring,Nucleotide salvage,CP:REACTOME,C2,20,60
Cohort,-0.006206589119160597,0.07950703959653221,-0.07806339099854127,0.9377963525885272,LGP Proband,Nucleotide salvage,CP:REACTOME,C2,20,80
Cohort,-0.020502362289529816,0.02155313633835017,-0.9512472787103992,0.34176760126807126,LonGen OPEL,Nucleotide salvage,CP:REACTOME,C2,37,37
Cohort,-1.1149534748024414e-4,0.042672888795770206,-0.0026127911802234422,0.9979160674594958,LGP Offspring,O-glycosylation of TSR domain-containing proteins,CP:REACTOME,C2,60,124
Cohort,0.056514192030836144,0.11865939272131834,0.4762723854786997,0.6340050801310981,LGP Proband,O-glycosylation of TSR domain-containing proteins,CP:REACTOME,C2,60,171
Cohort,-0.016484841676690443,0.037992657743891094,-0.4338954591651612,0.6644819294511504,LonGen OPEL,O-glycosylation of TSR domain-containing proteins,CP:REACTOME,C2,102,114
Cohort,-0.007944270994231265,0.07317617116249178,-0.10856363305194756,0.9135808224159319,LGP Offspring,O-linked glycosylation,CP:REACTOME,C2,161,342
Cohort,-0.012418093018449065,0.20241588172044944,-0.0613494006147172,0.9510956473689844,LGP Proband,O-linked glycosylation,CP:REACTOME,C2,161,448
Cohort,-0.0017160295719965532,0.06248255149539258,-0.027464140482852915,0.9780964246023155,LonGen OPEL,O-linked glycosylation,CP:REACTOME,C2,261,306
Cohort,0.011248865116214783,0.05428844558424927,0.20720551113879046,0.8359117635846882,LGP Offspring,O-linked glycosylation of mucins,CP:REACTOME,C2,85,191
Cohort,-0.09925288778280157,0.14629787917945786,-0.6784301203782452,0.4976872122531534,LGP Proband,O-linked glycosylation of mucins,CP:REACTOME,C2,85,242
Cohort,0.043578929223945836,0.04613687921722911,0.9445573684938784,0.3451715111286766,LonGen OPEL,O-linked glycosylation of mucins,CP:REACTOME,C2,132,172
Cohort,0.025572294839495982,0.019500903923272573,1.311338948189871,0.1901884992594765,LGP Offspring,OAS antiviral response,CP:REACTOME,C2,9,26
Cohort,-0.0678243444739229,0.05295749306043306,-1.2807317823093392,0.2006439351196284,LGP Proband,OAS antiviral response,CP:REACTOME,C2,9,30
Cohort,0.015662590913545337,0.016628359299177872,0.9419204042770303,0.3465191619748216,LonGen OPEL,OAS antiviral response,CP:REACTOME,C2,12,20
Cohort,-0.10154376098599732,0.08372809253670681,-1.212780058753638,0.22563756298039622,LGP Offspring,Olfactory Signaling Pathway,CP:REACTOME,C2,210,411
Cohort,-0.16016507583106224,0.2314100398352538,-0.6921267372197312,0.489050387880373,LGP Proband,Olfactory Signaling Pathway,CP:REACTOME,C2,210,584
Cohort,0.041056811285367985,0.07508061720192738,0.5468363582433899,0.5846444193601014,LonGen OPEL,Olfactory Signaling Pathway,CP:REACTOME,C2,336,431
Cohort,0.006294618339989513,0.02921983031231715,0.21542282322345035,0.8295026551952287,LGP Offspring,Oncogene Induced Senescence,CP:REACTOME,C2,23,54
Cohort,0.1077384733560394,0.0764155091464261,1.409903232465451,0.15894106488928864,LGP Proband,Oncogene Induced Senescence,CP:REACTOME,C2,23,67
Cohort,-0.01288752259831942,0.022159700095119944,-0.581574775064647,0.5610177895976466,LonGen OPEL,Oncogene Induced Senescence,CP:REACTOME,C2,37,40
Cohort,0.017161265772953117,0.04877569984045888,0.35184048263963696,0.7250675431336617,LGP Offspring,Oncogenic MAPK signaling,CP:REACTOME,C2,72,150
Cohort,-0.08680741499312715,0.12795993695328065,-0.6783952622985532,0.49770929639027184,LGP Proband,Oncogenic MAPK signaling,CP:REACTOME,C2,72,222
Cohort,-0.042739864996236665,0.04049925541696807,-1.0553247104471417,0.2915970413672691,LonGen OPEL,Oncogenic MAPK signaling,CP:REACTOME,C2,128,137
Cohort,-0.033897432523179435,0.036360542329924236,-0.9322587164846082,0.35153567088327775,LGP Offspring,Opioid Signalling,CP:REACTOME,C2,46,82
Cohort,0.09974304484714662,0.1139555869887109,0.87527998830832,0.3816735809886219,LGP Proband,Opioid Signalling,CP:REACTOME,C2,46,158
Cohort,-0.08337070247864678,0.03666968322421066,-2.2735593860707914,0.02325805723220694,LonGen OPEL,Opioid Signalling,CP:REACTOME,C2,107,90
Cohort,0.014737006011633774,0.01666078221417782,0.8845326601228259,0.3767232319696625,LGP Offspring,Opsins,CP:REACTOME,C2,8,20
Cohort,-0.06123553213450409,0.04517112252092921,-1.3556345009166362,0.17558246441471828,LGP Proband,Opsins,CP:REACTOME,C2,8,24
Cohort,0.01025107506525475,0.01149444108247634,0.891828927713837,0.3727541374779215,LonGen OPEL,Opsins,CP:REACTOME,C2,7,13
Cohort,-0.004190512164541596,0.04295763756103957,-0.0975498747710973,0.9223186438989482,LGP Offspring,Orc1 removal from chromatin,CP:REACTOME,C2,59,115
Cohort,-0.08870525625301189,0.11440544626458836,-0.7753586839551415,0.43834753044308805,LGP Proband,Orc1 removal from chromatin,CP:REACTOME,C2,59,171
Cohort,-0.0025862801333246845,0.03633318783173902,-0.07118230707698672,0.9432705425062182,LonGen OPEL,Orc1 removal from chromatin,CP:REACTOME,C2,87,102
Cohort,-0.0043960968283655154,0.013409599550464394,-0.3278320737186572,0.7431401412958716,LGP Offspring,Orexin and neuropeptides FF and QRFP bind to their respective receptors,CP:REACTOME,C2,7,11
Cohort,-0.08786581692681336,0.03399253335840873,-2.58485638597095,0.009910715146992771,LGP Proband,Orexin and neuropeptides FF and QRFP bind to their respective receptors,CP:REACTOME,C2,7,12
Cohort,-0.003239022195619411,0.009308905081868263,-0.34794878314188926,0.7279706398355679,LonGen OPEL,Orexin and neuropeptides FF and QRFP bind to their respective receptors,CP:REACTOME,C2,7,6
Cohort,0.01181976327445653,0.10113238092161604,0.11687417191945268,0.90699447904551,LGP Offspring,Organelle biogenesis and maintenance,CP:REACTOME,C2,315,666
Cohort,-0.01780454282400297,0.30397077850090287,-0.05857320533180819,0.9533060841254801,LGP Proband,Organelle biogenesis and maintenance,CP:REACTOME,C2,315,991
Cohort,-0.15768840980151816,0.0933054619901727,-1.6900233538110183,0.09141502915635778,LonGen OPEL,Organelle biogenesis and maintenance,CP:REACTOME,C2,595,649
Cohort,-0.020249411700322323,0.010077043675288564,-2.0094595550854817,0.04488538982969112,LGP Offspring,Organic anion transport,CP:REACTOME,C2,6,4
Cohort,0.003722012689579464,0.030279157974450945,0.12292325607997545,0.9021974847655703,LGP Proband,Organic anion transport,CP:REACTOME,C2,6,9
Cohort,-0.013020890682087234,0.008206351430972411,-1.5866845079219725,0.11298125241824103,LonGen OPEL,Organic anion transport,CP:REACTOME,C2,7,3
Cohort,-0.007889743926480446,0.011494416059016707,-0.6863979767194347,0.4926975421801222,LGP Offspring,Organic anion transporters,CP:REACTOME,C2,5,8
Cohort,0.040302269552745955,0.03553685055157263,1.1340979554239772,0.2570793322088768,LGP Proband,Organic anion transporters,CP:REACTOME,C2,5,14
Cohort,-0.007933270937245595,0.011469115534349072,-0.6917072997901269,0.48932285908874507,LonGen OPEL,Organic anion transporters,CP:REACTOME,C2,10,10
Cohort,-0.00972603522722768,0.025382408363470742,-0.3831801572156946,0.7017066544824682,LGP Offspring,Organic cation/anion/zwitterion transport,CP:REACTOME,C2,22,45
Cohort,0.10982545247880694,0.07472642100770814,1.4697004218558558,0.1420200277882119,LGP Proband,Organic cation/anion/zwitterion transport,CP:REACTOME,C2,22,75
Cohort,-0.013274250057529002,0.025811710127523084,-0.5142723977585135,0.6072043000433236,LonGen OPEL,Organic cation/anion/zwitterion transport,CP:REACTOME,C2,52,55
Cohort,0.010523376473094634,0.02322584267496329,0.4530891137241059,0.6506299640869777,LGP Offspring,Organic cation transport,CP:REACTOME,C2,16,41
Cohort,0.10610343978922747,0.06882340063647777,1.5416767960894764,0.12353147614059418,LGP Proband,Organic cation transport,CP:REACTOME,C2,16,66
Cohort,-2.533593754418334e-4,0.024827438953264194,-0.010204813147210374,0.9918604354361162,LonGen OPEL,Organic cation transport,CP:REACTOME,C2,45,52
Cohort,-0.06255520193924725,0.027677902271303338,-2.2601135492881976,0.024131585335164876,LGP Offspring,Other interleukin signaling,CP:REACTOME,C2,34,46
Cohort,0.026975304258105248,0.08088475109480425,0.333502964316324,0.7388384808140679,LGP Proband,Other interleukin signaling,CP:REACTOME,C2,34,78
Cohort,-0.04181794877130762,0.023955601824695975,-1.745643840523232,0.081258681374438535,LonGen OPEL,Other interleukin signaling,CP:REACTOME,C2,48,42
Cohort,-3.633564673255988e-4,0.020707669555449136,-0.01754695120822918,0.98600545446953,LGP Offspring,Other semaphorin interactions,CP:REACTOME,C2,14,28
Cohort,0.16959870141823596,0.0654279626366133,2.5921440097437642,0.009704880632277474,LGP Proband,Other semaphorin interactions,CP:REACTOME,C2,14,56
Cohort,0.02986703026391505,0.0181733690560511,1.6434503790572814,0.10068468001512587,LonGen OPEL,Other semaphorin interactions,CP:REACTOME,C2,18,30
Cohort,-0.030451942771627515,0.03575621827818114,-0.8516544600637939,0.39470749740823385,LGP Offspring,Ovarian tumor domain proteases,CP:REACTOME,C2,40,79
Cohort,0.17818202938282346,0.1047563368330048,1.7009188634275056,0.08933099529071668,LGP Proband,Ovarian tumor domain proteases,CP:REACTOME,C2,40,141
Cohort,-0.022813421996015364,0.030886580170338514,-0.7386192278394067,0.46035596539405255,LonGen OPEL,Ovarian tumor domain proteases,CP:REACTOME,C2,70,73
Cohort,-0.007379707706096725,0.03700271960710722,-0.19943690043472595,0.841980971210724,LGP Offspring,Oxidative Stress Induced Senescence,CP:REACTOME,C2,39,89
Cohort,0.3316161805798015,0.10565657727451905,3.13862316132189,0.0017571484610816857,LGP Proband,Oxidative Stress Induced Senescence,CP:REACTOME,C2,39,149
Cohort,0.019520690961545573,0.031527926463945526,0.6191555598770158,0.5359910427318617,LonGen OPEL,Oxidative Stress Induced Senescence,CP:REACTOME,C2,61,87
Cohort,-0.002708249730022451,0.028532406973279276,-0.09491837588601407,0.9244077887484661,LGP Offspring,p130Cas linkage to MAPK signaling for integrins,CP:REACTOME,C2,28,52
Cohort,-0.26722125723863566,0.07472825294198418,-3.575906658035948,3.690986148718094e-4,LGP Proband,p130Cas linkage to MAPK signaling for integrins,CP:REACTOME,C2,28,63
Cohort,-0.0077698409392458374,0.024050790740050135,-0.3230596874433427,0.7467348843793944,LonGen OPEL,p130Cas linkage to MAPK signaling for integrins,CP:REACTOME,C2,41,49
Cohort,0.023869320970501047,0.015024874467905432,1.5886536038279853,0.11260618667572934,LGP Offspring,P2Y receptors,CP:REACTOME,C2,5,18
Cohort,-0.07725927715160184,0.03638617754669741,-2.12331391645766,0.034021441100595816,LGP Proband,P2Y receptors,CP:REACTOME,C2,5,18
Cohort,0.008830448459620027,0.011442297382262094,0.7717373674721155,0.4404990359592955,LonGen OPEL,P2Y receptors,CP:REACTOME,C2,7,13
Cohort,0.021245235347123435,0.015698019334672613,1.3533704408299807,0.176389683459152,LGP Offspring,p38MAPK events,CP:REACTOME,C2,5,20
Cohort,0.04012434328007231,0.037040307050022,1.0832616270131183,0.27900538805725283,LGP Proband,p38MAPK events,CP:REACTOME,C2,5,18
Cohort,-0.01983981100593991,0.011504715903477096,-1.7244937791070252,0.0850069524088999,LonGen OPEL,p38MAPK events,CP:REACTOME,C2,12,8
Cohort,0.023115919793468553,0.06222553824990227,0.37148605610502466,0.7103919422344223,LGP Offspring,p75 NTR receptor-mediated signalling,CP:REACTOME,C2,137,278
Cohort,0.04432817571537367,0.17236064244182367,0.25718270184758457,0.7971011735319866,LGP Proband,p75 NTR receptor-mediated signalling,CP:REACTOME,C2,137,405
Cohort,0.059843122952705316,0.05434657648508595,1.1011387804552464,0.2711691176704904,LonGen OPEL,p75 NTR receptor-mediated signalling,CP:REACTOME,C2,208,269
Cohort,0.0033132917742564588,0.004549178774591434,0.7283274495085168,0.46666537670270003,LGP Offspring,p75NTR negatively regulates cell cycle via SC1,CP:REACTOME,C2,0,2
Cohort,0.0017343665055999124,0.011210257444449747,0.154712459922908,0.877085439119768,LGP Proband,p75NTR negatively regulates cell cycle via SC1,CP:REACTOME,C2,0,2
Cohort,0.005789415335657031,0.00506091010236741,1.1439474755635035,0.2529893080764307,LonGen OPEL,p75NTR negatively regulates cell cycle via SC1,CP:REACTOME,C2,0,4
Cohort,-0.008807868599291079,0.006324023183313407,-1.3927634899460135,0.16414920138636854,LGP Offspring,p75NTR recruits signalling complexes,CP:REACTOME,C2,2,2
Cohort,-0.01987352620765249,0.026796159157542444,-0.7416557757703344,0.4585047144341653,LGP Proband,p75NTR recruits signalling complexes,CP:REACTOME,C2,2,10
Cohort,0.00950223874147213,0.008151193866940245,1.1657480973445469,0.24406548903444455,LonGen OPEL,p75NTR recruits signalling complexes,CP:REACTOME,C2,3,7
Cohort,0.024195728071451168,0.015703259696280895,1.5408092675931226,0.12383116253202411,LGP Offspring,p75NTR regulates axonogenesis,CP:REACTOME,C2,4,19
Cohort,0.04824799168185238,0.047719259039953645,1.011080068143054,0.31227135006202367,LGP Proband,p75NTR regulates axonogenesis,CP:REACTOME,C2,4,32
Cohort,-2.3360378928995483e-4,0.014171128275328317,-0.016484487667552547,0.9868520082460495,LonGen OPEL,p75NTR regulates axonogenesis,CP:REACTOME,C2,15,16
Cohort,0.0033580074169658105,0.0159338985213462,0.21074612797785686,0.833148887369819,LGP Offspring,p75NTR signals via NF-kB,CP:REACTOME,C2,7,19
Cohort,-0.00451261269921912,0.0414214124379697,-0.10894395998632221,0.9132731449580171,LGP Proband,p75NTR signals via NF-kB,CP:REACTOME,C2,7,22
Cohort,0.02425392692001579,0.015769745050633374,1.5380037433795837,0.12444509178891046,LonGen OPEL,p75NTR signals via NF-kB,CP:REACTOME,C2,13,26
Cohort,-0.01014582893146956,0.04094057718282804,-0.2478184146296083,0.8043501608223391,LGP Offspring,Parasite infection,CP:REACTOME,C2,53,112
Cohort,0.16975905523666202,0.112415895569749,1.5100983217389765,0.13139709662001184,LGP Proband,Parasite infection,CP:REACTOME,C2,53,144
Cohort,0.007114900879322128,0.03341316143409409,0.21293707551007823,0.831430563954774,LonGen OPEL,Parasite infection,CP:REACTOME,C2,75,96
Cohort,0.0028345166652065366,0.01920973544695627,0.1475562572443265,0.8827369770513792,LGP Offspring,Passive transport by Aquaporins,CP:REACTOME,C2,12,26
Cohort,-0.029922704275206647,0.05673821769345241,-0.5273818158489623,0.5980687295045454,LGP Proband,Passive transport by Aquaporins,CP:REACTOME,C2,12,39
Cohort,-0.014882350148437619,0.020867995626541676,-0.7131662482001382,0.4759519083752862,LonGen OPEL,Passive transport by Aquaporins,CP:REACTOME,C2,31,35
Cohort,0.0014895955029186844,0.021097518612944503,0.07060524653381439,0.9437328164491007,LGP Offspring,PCNA-Dependent Long Patch Base Excision Repair,CP:REACTOME,C2,14,32
Cohort,0.008406326152247259,0.06399898818278674,0.1313509227401854,0.8955293886168428,LGP Proband,PCNA-Dependent Long Patch Base Excision Repair,CP:REACTOME,C2,14,50
Cohort,0.016376966946911722,0.02003740285217979,0.8173198426826127,0.41399022948370934,LonGen OPEL,PCNA-Dependent Long Patch Base Excision Repair,CP:REACTOME,C2,27,36
Cohort,0.016631190023435497,0.043553110347478635,0.38185998406881416,0.7026852279267484,LGP Offspring,PCP/CE pathway,CP:REACTOME,C2,59,129
Cohort,-0.0907257924794449,0.11647532866463689,-0.7789271214736669,0.43624359776069166,LGP Proband,PCP/CE pathway,CP:REACTOME,C2,59,180
Cohort,-0.05895909453047181,0.03488629607757349,-1.6900359499148265,0.09141261838403825,LonGen OPEL,PCP/CE pathway,CP:REACTOME,C2,98,94
Cohort,0.0033496543309162654,0.020886270665879423,0.16037589402632724,0.8726328885106753,LGP Offspring,PD-1 signaling,CP:REACTOME,C2,12,31
Cohort,0.013829198325336989,0.05432791332879859,0.25455051515859145,0.7991330337458844,LGP Proband,PD-1 signaling,CP:REACTOME,C2,12,36
Cohort,0.029173922132757338,0.02017807434646952,1.4458229081637706,0.14862047393463704,LonGen OPEL,PD-1 signaling,CP:REACTOME,C2,20,34
Cohort,-0.00768119153886097,0.015246483277681083,-0.5038008699425959,0.614565454908695,LGP Offspring,PECAM1 interactions,CP:REACTOME,C2,9,14
Cohort,0.01828451382741926,0.03798559342242168,0.481353907627161,0.6303912571118948,LGP Proband,PECAM1 interactions,CP:REACTOME,C2,9,15
Cohort,0.00326270428309069,0.009651132917497904,0.33806438176550985,0.735403810981666,LonGen OPEL,PECAM1 interactions,CP:REACTOME,C2,5,9
Cohort,-0.00935467885949234,0.027040720405867764,-0.3459478415916168,0.7294895504195578,LGP Offspring,Pentose phosphate pathway,CP:REACTOME,C2,26,45
Cohort,0.0021907883074091116,0.07330587696485333,0.02988557531969081,0.976165459908605,LGP Proband,Pentose phosphate pathway,CP:REACTOME,C2,26,62
Cohort,-0.024022199109113726,0.025568641906386764,-0.9395179922760484,0.3477498602249437,LonGen OPEL,Pentose phosphate pathway,CP:REACTOME,C2,50,51
Cohort,0.0035782102156036244,0.015423218095482364,0.2320015312920799,0.8166070380149286,LGP Offspring,Peptide hormone biosynthesis,CP:REACTOME,C2,7,17
Cohort,-0.002627933158588156,0.045514850004854696,-0.05773792857293512,0.9539712117353214,LGP Proband,Peptide hormone biosynthesis,CP:REACTOME,C2,7,23
Cohort,-0.010388269141112624,0.015541433006584691,-0.668424149607778,0.5040566627908791,LonGen OPEL,Peptide hormone biosynthesis,CP:REACTOME,C2,18,17
Cohort,-7.756983365966358e-4,0.03829733192387643,-0.020254631266180385,0.9838462241252092,LGP Offspring,Peptide hormone metabolism,CP:REACTOME,C2,49,106
Cohort,-0.050016457292426875,0.10971022104538733,-0.4558960579592212,0.6485834050331525,LGP Proband,Peptide hormone metabolism,CP:REACTOME,C2,49,143
Cohort,0.02966083261700447,0.036174045134070305,0.8199479075971129,0.41249125414105436,LonGen OPEL,Peptide hormone metabolism,CP:REACTOME,C2,86,121
Cohort,0.06368084046002151,0.060595369265227475,1.0509192572338135,0.2936712076364799,LGP Offspring,Peptide ligand-binding receptors,CP:REACTOME,C2,102,239
Cohort,-0.42701279603183484,0.16526341370383957,-2.5838313905161336,0.0099399759301654865,LGP Proband,Peptide ligand-binding receptors,CP:REACTOME,C2,102,353
Cohort,-0.023088559964212604,0.05122270617460075,-0.4507485388513362,0.6522935470929591,LonGen OPEL,Peptide ligand-binding receptors,CP:REACTOME,C2,198,221
Cohort,-0.041226715034574285,0.027616605269713407,-1.4928234166342964,0.1359499655474248,LGP Offspring,PERK regulates gene expression,CP:REACTOME,C2,27,42
Cohort,-0.048947612551160265,0.07190117146181466,-0.6807623791937161,0.49621081093425057,LGP Proband,PERK regulates gene expression,CP:REACTOME,C2,27,55
Cohort,0.05772665729506454,0.024840287867612033,2.323912573103927,0.02038109706691048,LonGen OPEL,PERK regulates gene expression,CP:REACTOME,C2,37,66
Cohort,0.04353696085970629,0.030228428018175234,1.4402654624821751,0.15025526836518724,LGP Offspring,Peroxisomal lipid metabolism,CP:REACTOME,C2,24,68
Cohort,0.04758179426744686,0.08355634530206739,0.5694575809345453,0.5691989889795612,LGP Proband,Peroxisomal lipid metabolism,CP:REACTOME,C2,24,94
Cohort,-0.018305327744661214,0.026684742010931878,-0.6859848124880545,0.49292243375081934,LonGen OPEL,Peroxisomal lipid metabolism,CP:REACTOME,C2,49,55
Cohort,0.017017344746785876,0.045021804269149264,0.3779800703910669,0.7055640538202926,LGP Offspring,Peroxisomal protein import,CP:REACTOME,C2,63,134
Cohort,-0.09773301487035817,0.12752008720996874,-0.7664127041368428,0.4436476483929981,LGP Proband,Peroxisomal protein import,CP:REACTOME,C2,63,191
Cohort,-0.03540532343116436,0.03994012399484839,-0.8864600279090533,0.3756374165321359,LonGen OPEL,Peroxisomal protein import,CP:REACTOME,C2,104,117
Cohort,0.006822874645811449,0.015508265041278198,0.4399508666927648,0.6601133162919742,LGP Offspring,Pexophagy,CP:REACTOME,C2,7,17
Cohort,-0.022790264381745667,0.04865704052407505,-0.46838574924155646,0.6396311458779376,LGP Proband,Pexophagy,CP:REACTOME,C2,7,33
Cohort,2.500229055784283e-4,0.01631145320098524,0.015328058297302811,0.9877742987604483,LonGen OPEL,Pexophagy,CP:REACTOME,C2,20,22
Cohort,0.01581515762714804,0.03984371590419029,0.39692978599631046,0.6915445193731509,LGP Offspring,Phase 0 - rapid depolarisation,CP:REACTOME,C2,46,108
Cohort,-0.00974865057604859,0.11203825762086794,-0.0870118009960272,0.9306830179931526,LGP Proband,Phase 0 - rapid depolarisation,CP:REACTOME,C2,46,152
Cohort,-0.017886213671241612,0.03309583304421593,-0.5404370286539,0.5890468552559411,LonGen OPEL,Phase 0 - rapid depolarisation,CP:REACTOME,C2,85,91
Cohort,-0.004516470392456902,0.0032233725686293675,-1.4011630043676215,0.16162423754190514,LGP Offspring,Phase 1 - inactivation of fast Na+ channels,CP:REACTOME,C2,1,0
Cohort,0.005416978321191279,0.015799668054185624,0.3428539322860154,0.731794745933672,LGP Proband,Phase 1 - inactivation of fast Na+ channels,CP:REACTOME,C2,1,3
Cohort,-0.0027924266657022414,0.002594943753669903,-1.0761029643717894,0.28220725191469165,LonGen OPEL,Phase 1 - inactivation of fast Na+ channels,CP:REACTOME,C2,1,0
Cohort,-0.02039446048945033,0.02432932508354787,-0.8382665947129624,0.40217728726941104,LGP Offspring,Phase 2 - plateau phase,CP:REACTOME,C2,20,33
Cohort,-6.048412716695328e-4,0.06898621697999809,-0.008767566887236344,0.9930066801082917,LGP Proband,Phase 2 - plateau phase,CP:REACTOME,C2,20,55
Cohort,0.004632833833304681,0.02010088807630596,0.23047906220450334,0.8177787518134709,LonGen OPEL,Phase 2 - plateau phase,CP:REACTOME,C2,26,30
Cohort,-0.00679321717603779,0.014728877974002784,-0.4612175610408452,0.644790882167361,LGP Offspring,Phase 3 - rapid repolarisation,CP:REACTOME,C2,9,14
Cohort,-0.07049663073521796,0.045931722668415005,-1.5348135589021799,0.1252088850058575,LGP Proband,Phase 3 - rapid repolarisation,CP:REACTOME,C2,9,26
Cohort,-0.01816214893695788,0.012752232180286961,-1.4242329248861887,0.1547709520030013,LonGen OPEL,Phase 3 - rapid repolarisation,CP:REACTOME,C2,15,10
Cohort,0.0015421242364849755,0.020772889439272933,0.07423734868436054,0.9408434895398974,LGP Offspring,Phase 4 - resting membrane potential,CP:REACTOME,C2,14,28
Cohort,0.034859719488559364,0.059277879468059146,0.5880729844147499,0.5566425086469343,LGP Proband,Phase 4 - resting membrane potential,CP:REACTOME,C2,14,42
Cohort,0.0052735021180200315,0.01677985483606006,0.3142757890066622,0.7533939348388544,LonGen OPEL,Phase 4 - resting membrane potential,CP:REACTOME,C2,19,25
Cohort,-0.0735782242351901,0.05773330076823118,-1.2744503303313273,0.2029417808053984,LGP Offspring,Phase I - Functionalization of compounds,CP:REACTOME,C2,113,208
Cohort,0.05437462813144508,0.17095198911197157,0.31806958441314376,0.750511779864107,LGP Proband,Phase I - Functionalization of compounds,CP:REACTOME,C2,113,348
Cohort,-0.029795860085593623,0.053752313212917346,-0.5543177270821772,0.57951711699735875,LonGen OPEL,Phase I - Functionalization of compounds,CP:REACTOME,C2,202,222
Cohort,-0.15559675779708584,0.06273031699047046,-2.4804076443727037,0.013365561276185439,LGP Offspring,Phase II - Conjugation of compounds,CP:REACTOME,C2,114,182
Cohort,0.21575014295028302,0.1812095866261049,1.1906110872348419,0.23414506476280528,LGP Proband,Phase II - Conjugation of compounds,CP:REACTOME,C2,114,251
Cohort,0.013081466784183217,0.050321354212814466,0.25995856011466373,0.7949629631571681,LonGen OPEL,Phase II - Conjugation of compounds,CP:REACTOME,C2,125,170
Cohort,-0.019403378185549727,0.019392198653299966,-1.0005764963761785,0.3173896164071232,LGP Offspring,Phenylalanine and tyrosine metabolism,CP:REACTOME,C2,14,23
Cohort,0.020401118286908965,0.05777765772693378,0.35309701170870983,0.7241049389522307,LGP Proband,Phenylalanine and tyrosine metabolism,CP:REACTOME,C2,14,39
Cohort,0.0053967792115447565,0.017451225771495018,0.3092492918382789,0.7572128292383781,LonGen OPEL,Phenylalanine and tyrosine metabolism,CP:REACTOME,C2,20,28
Cohort,0.013156364334570993,0.014311998628902764,0.9192541639853156,0.3582905342281747,LGP Offspring,Phenylalanine metabolism,CP:REACTOME,C2,4,17
Cohort,0.051050462809795985,0.04109105121878218,1.2423742225037426,0.21444773623168978,LGP Proband,Phenylalanine metabolism,CP:REACTOME,C2,4,24
Cohort,-0.010986207539150151,0.014145451087033075,-0.776660105892349,0.43759005242758375,LonGen OPEL,Phenylalanine metabolism,CP:REACTOME,C2,15,16
Cohort,0.03327585709323613,0.021724509828246502,1.531719581077517,0.1260594699769938,LGP Offspring,Phosphate bond hydrolysis by NTPDase proteins,CP:REACTOME,C2,9,32
Cohort,0.014600008309255964,0.05338961856108122,0.27346155868397143,0.7845661435884825,LGP Proband,Phosphate bond hydrolysis by NTPDase proteins,CP:REACTOME,C2,9,40
Cohort,0.010710149291692285,0.01567336967146125,0.6833341850663924,0.4945945434256098,LonGen OPEL,Phosphate bond hydrolysis by NTPDase proteins,CP:REACTOME,C2,13,23
Cohort,0.003853400864452307,0.0055839495525889,0.6900851857921505,0.49037745950253353,LGP Offspring,Phosphate bond hydrolysis by NUDT proteins,CP:REACTOME,C2,0,3
Cohort,0.012514546554582884,0.015800399637686237,0.7920398750379631,0.4285626449904105,LGP Proband,Phosphate bond hydrolysis by NUDT proteins,CP:REACTOME,C2,0,4
Cohort,-0.00247320102121196,0.0036583884190637592,-0.6760356577568908,0.49921436960946164,LonGen OPEL,Phosphate bond hydrolysis by NUDT proteins,CP:REACTOME,C2,1,1
Cohort,-0.013166111671028588,0.014466246525797255,-0.9101263169786182,0.36308028900085776,LGP Offspring,Phospholipase C-mediated cascade; FGFR2,CP:REACTOME,C2,9,12
Cohort,0.005360667585885461,0.03530089620586592,0.1518564161834136,0.8793369104658809,LGP Proband,Phospholipase C-mediated cascade; FGFR2,CP:REACTOME,C2,9,12
Cohort,0.005861740143435136,0.010915890536461866,0.5369914734721299,0.5914235646788764,LonGen OPEL,Phospholipase C-mediated cascade; FGFR2,CP:REACTOME,C2,5,11
Cohort,-0.010203832918122822,0.012704337728924618,-0.8031770829652325,0.4221546948407061,LGP Offspring,Phospholipase C-mediated cascade; FGFR4,CP:REACTOME,C2,7,9
Cohort,0.012614751974690619,0.03212336819793513,0.392697051472376,0.6946435938334266,LGP Proband,Phospholipase C-mediated cascade; FGFR4,CP:REACTOME,C2,7,10
Cohort,0.010043921235122797,0.009618130822074923,1.0442695593275386,0.2966777152709427,LonGen OPEL,Phospholipase C-mediated cascade; FGFR4,CP:REACTOME,C2,4,10
Cohort,-0.06827927763896066,0.08810092327077963,-0.7750120555388867,0.43860354048059935,LGP Offspring,Phospholipid metabolism,CP:REACTOME,C2,237,469
Cohort,0.048397303039083975,0.23710799680642125,0.20411501801264131,0.838313415578746,LGP Proband,Phospholipid metabolism,CP:REACTOME,C2,237,651
Cohort,-0.02533159327727909,0.07429964356336438,-0.3409382880238954,0.733240007290151,LonGen OPEL,Phospholipid metabolism,CP:REACTOME,C2,389,449
Cohort,0.007831195947465812,0.012786594476677493,0.6124536100483804,0.5404436391453428,LGP Offspring,Phosphorylation of Emi1,CP:REACTOME,C2,4,12
Cohort,-0.022944826449354264,0.02778439298555736,-0.8258170859187474,0.40914402554115403,LGP Proband,Phosphorylation of Emi1,CP:REACTOME,C2,4,9
Cohort,-0.005450416136220582,0.011190702435925293,-0.4870486162444297,0.6263579670495987,LonGen OPEL,Phosphorylation of Emi1,CP:REACTOME,C2,10,9
Cohort,-0.005230179965780937,0.01906736173727136,-0.2743001385219119,0.7839377776013585,LGP Offspring,Phosphorylation of the APC/C,CP:REACTOME,C2,12,23
Cohort,0.02447559120369217,0.058518224599167064,0.4182558744962428,0.6758677211153201,LGP Proband,Phosphorylation of the APC/C,CP:REACTOME,C2,12,45
Cohort,-0.010193720914238296,0.01878701696377023,-0.542593905881724,0.5875613139437221,LonGen OPEL,Phosphorylation of the APC/C,CP:REACTOME,C2,25,29
Cohort,0.006350584601560779,0.014866025849688304,0.42718778144018443,0.6693785882981935,LGP Offspring,Physiological factors,CP:REACTOME,C2,6,16
Cohort,0.07612910885281694,0.0471931529182598,1.6131388590348104,0.10709263554037123,LGP Proband,Physiological factors,CP:REACTOME,C2,6,29
Cohort,-0.02580519107292353,0.013908349470387642,-1.855374077841913,0.06391231803464531,LonGen OPEL,Physiological factors,CP:REACTOME,C2,18,10
Cohort,0.00690505609964041,0.019924409752381186,0.34656264278118354,0.72902776142896,LGP Offspring,PI-3K cascade:FGFR1,CP:REACTOME,C2,10,29
Cohort,0.11493429654703045,0.05727114057316281,2.006844902978736,0.04508849739704493,LGP Proband,PI-3K cascade:FGFR1,CP:REACTOME,C2,10,39
Cohort,-0.005262412224554212,0.013679720314101917,-0.38468712106119496,0.700571992301807,LonGen OPEL,PI-3K cascade:FGFR1,CP:REACTOME,C2,14,15
Cohort,-0.005179654848096808,0.01146377738287823,-0.4518279337692741,0.6515378752611822,LGP Offspring,PI-3K cascade:FGFR2,CP:REACTOME,C2,5,8
Cohort,-9.950998573941055e-4,0.03312415666170328,-0.03004151524692543,0.9760411310311164,LGP Proband,PI-3K cascade:FGFR2,CP:REACTOME,C2,5,13
Cohort,-0.0060973608550218585,0.008917728873884666,-0.6837347200449005,0.4943416770628224,LonGen OPEL,PI-3K cascade:FGFR2,CP:REACTOME,C2,6,6
Cohort,-0.001974601361587038,0.012604028471527261,-0.15666430507100962,0.8755561959970919,LGP Offspring,PI-3K cascade:FGFR3,CP:REACTOME,C2,6,10
Cohort,0.008892370939577848,0.04054626087201731,0.21931420427758477,0.826458960325975,LGP Proband,PI-3K cascade:FGFR3,CP:REACTOME,C2,6,21
Cohort,-0.014743825063538865,0.012005132352276793,-1.2281268236699343,0.21976237430032058,LonGen OPEL,PI-3K cascade:FGFR3,CP:REACTOME,C2,13,9
Cohort,-0.0022173760951910595,0.009044588544061928,-0.24516052713606748,0.8064065427215128,LGP Offspring,PI-3K cascade:FGFR4,CP:REACTOME,C2,3,5
Cohort,0.006258984531410984,0.029277780835579293,0.21377933548176803,0.8307713915147794,LGP Proband,PI-3K cascade:FGFR4,CP:REACTOME,C2,3,11
Cohort,-0.0019151797633342217,0.008132216603065725,-0.23550525727662336,0.8138771742055937,LonGen OPEL,PI-3K cascade:FGFR4,CP:REACTOME,C2,5,5
Cohort,-0.028614934659189767,0.05246056933571101,-0.5454560448262421,0.5856198312743393,LGP Offspring,PI Metabolism,CP:REACTOME,C2,88,174
Cohort,0.04875201457240638,0.14183966625080774,0.3437121354064717,0.7311494160936046,LGP Proband,PI Metabolism,CP:REACTOME,C2,88,237
Cohort,-0.007936052916009635,0.046335681291640625,-0.1712730382889907,0.8640526079415234,LonGen OPEL,PI Metabolism,CP:REACTOME,C2,157,174
Cohort,-0.010272856030451787,0.010077428091389663,-1.0193926403929492,0.30838127938056414,LGP Offspring,PI3K/AKT activation,CP:REACTOME,C2,5,5
Cohort,-0.04689541505573426,0.03048874619811714,-1.538122123848777,0.12439804825088721,LGP Proband,PI3K/AKT activation,CP:REACTOME,C2,5,8
Cohort,-0.005366222968853259,0.010303720986147584,-0.520804375047389,0.6026478934113663,LonGen OPEL,PI3K/AKT activation,CP:REACTOME,C2,8,8
Cohort,-0.02982405205525193,0.048299301229082686,-0.6174841311636582,0.5371233840261417,LGP Offspring,PI3K/AKT Signaling in Cancer,CP:REACTOME,C2,82,162
Cohort,0.053450512227368595,0.1304366559091633,0.40978137514190627,0.6820715603185036,LGP Proband,PI3K/AKT Signaling in Cancer,CP:REACTOME,C2,82,188
Cohort,0.008566970756872865,0.03902074139112838,0.21954915389743523,0.826278581172864,LonGen OPEL,PI3K/AKT Signaling in Cancer,CP:REACTOME,C2,106,126
Cohort,0.00543700220994063,0.01913789917873771,0.2840960838575826,0.7764237434312107,LGP Offspring,PI3K events in ERBB2 signaling,CP:REACTOME,C2,10,25
Cohort,0.0023552301321622007,0.04835428414802412,0.048707786159180304,0.961163832463414,LGP Proband,PI3K events in ERBB2 signaling,CP:REACTOME,C2,10,29
Cohort,0.0012406885109056455,0.016461288755442727,0.0753700715258656,0.9399392084778512,LonGen OPEL,PI3K events in ERBB2 signaling,CP:REACTOME,C2,17,21
Cohort,-0.01444989513333922,0.011472371206433511,-1.259538666708759,0.20827052817376002,LGP Offspring,PI3K events in ERBB4 signaling,CP:REACTOME,C2,6,7
Cohort,-0.014598295878435304,0.03330481697620837,-0.43832385834348653,0.6612650435842058,LGP Proband,PI3K events in ERBB4 signaling,CP:REACTOME,C2,6,12
Cohort,0.015672186602940494,0.01371386530562334,1.1427986387261766,0.2534658065688663,LonGen OPEL,PI3K events in ERBB4 signaling,CP:REACTOME,C2,10,17
Cohort,0.003934172735138495,0.007865742523416507,0.5001654609754091,0.6171213528522494,LGP Offspring,PI5P Regulates TP53 Acetylation,CP:REACTOME,C2,1,5
Cohort,0.0820931461640033,0.02712201452098599,3.026808576497248,0.0025475020477987065,LGP Proband,PI5P Regulates TP53 Acetylation,CP:REACTOME,C2,1,9
Cohort,0.008977033067391105,0.005775300032216942,1.5543838445299136,0.12049036396345639,LonGen OPEL,PI5P Regulates TP53 Acetylation,CP:REACTOME,C2,1,4
Cohort,8.39991216426228e-4,0.014229105327780588,0.059033312149727915,0.952943021436635,LGP Offspring,PINK1-PRKN Mediated Mitophagy,CP:REACTOME,C2,6,15
Cohort,-0.012577181538454866,0.04582046567977667,-0.274488295827293,0.7837773729049049,LGP Proband,PINK1-PRKN Mediated Mitophagy,CP:REACTOME,C2,6,28
Cohort,1.5349479083954197e-4,0.015212601082537934,0.010089976724344255,0.9919520281506597,LonGen OPEL,PINK1-PRKN Mediated Mitophagy,CP:REACTOME,C2,16,20
Cohort,-0.02901348948301163,0.018227122924019807,-1.5917755974958334,0.11190261665324902,LGP Offspring,PIWI-interacting RNA (piRNA) biogenesis,CP:REACTOME,C2,16,18
Cohort,-0.04148229635969329,0.0575182201927238,-0.7212027114312711,0.4709869225194341,LGP Proband,PIWI-interacting RNA (piRNA) biogenesis,CP:REACTOME,C2,16,38
Cohort,0.022798782454088826,0.018857141781054305,1.2090264112557434,0.2270116910395627,LonGen OPEL,PIWI-interacting RNA (piRNA) biogenesis,CP:REACTOME,C2,21,31
Cohort,0.015619320026739436,0.01746298180879928,0.8944245718030321,0.37141310488643153,LGP Offspring,PKA activation in glucagon signalling,CP:REACTOME,C2,8,23
Cohort,0.08001429217961456,0.05686518041099841,1.4070876343186425,0.15977395313094434,LGP Proband,PKA activation in glucagon signalling,CP:REACTOME,C2,8,43
Cohort,-0.019886310472202875,0.019473406328327423,-1.0212034883324348,0.30746829973589485,LonGen OPEL,PKA activation in glucagon signalling,CP:REACTOME,C2,27,24
Cohort,0.021898617230100628,0.01829555724105817,1.1969363349565878,0.23175095058442557,LGP Offspring,PKA-mediated phosphorylation of CREB,CP:REACTOME,C2,8,26
Cohort,0.06455179556007712,0.055366754368560145,1.1658945209317286,0.24399040431531877,LGP Proband,PKA-mediated phosphorylation of CREB,CP:REACTOME,C2,8,40
Cohort,-0.026505172885024804,0.019570947387893115,-1.354312203681121,0.17602111098663417,LonGen OPEL,PKA-mediated phosphorylation of CREB,CP:REACTOME,C2,30,24
Cohort,0.0020215474552396514,0.0071705822770168695,0.2819223568104238,0.7780893309017002,LGP Offspring,PKA-mediated phosphorylation of key metabolic factors,CP:REACTOME,C2,1,4
Cohort,0.06502382484384317,0.03681256499330661,1.7663486599118,0.07770314617258643,LGP Proband,PKA-mediated phosphorylation of key metabolic factors,CP:REACTOME,C2,1,17
Cohort,0.021161253118452947,0.012779768882517162,1.6558400478902033,0.09814835038016684,LonGen OPEL,PKA-mediated phosphorylation of key metabolic factors,CP:REACTOME,C2,5,14
Cohort,0.004169249137470565,0.04682314071326887,0.08904249210880193,0.9290745132970295,LGP Offspring,PKMTs methylate histone lysines,CP:REACTOME,C2,69,141
Cohort,-0.1428452335774657,0.1223643497167033,-1.1673762326051627,0.24339211019160034,LGP Proband,PKMTs methylate histone lysines,CP:REACTOME,C2,69,152
Cohort,0.034710977071351484,0.03609450651541147,0.9616692517054014,0.33650780286977733,LonGen OPEL,PKMTs methylate histone lysines,CP:REACTOME,C2,87,112
Cohort,0.002429338609236579,0.026199171844207062,0.0927257786498978,0.9261488897048706,LGP Offspring,Plasma lipoprotein assembly,CP:REACTOME,C2,21,46
Cohort,0.04519077357181573,0.08021777365197176,0.5633511317314518,0.5733472320611899,LGP Proband,Plasma lipoprotein assembly,CP:REACTOME,C2,21,75
Cohort,0.036753530635718526,0.02220031017110611,1.6555413123711018,0.09820889818384525,LonGen OPEL,Plasma lipoprotein assembly,CP:REACTOME,C2,29,47
Cohort,-0.020430131646535593,0.04584235736183561,-0.4456605816598768,0.6559851323302072,LGP Offspring,"Plasma lipoprotein assembly, remodeling, and clearance",CP:REACTOME,C2,73,140
Cohort,-0.0071082857551450235,0.137142381994659,-0.051831429874259115,0.9586754232674115,LGP Proband,"Plasma lipoprotein assembly, remodeling, and clearance",CP:REACTOME,C2,73,231
Cohort,0.019006499371730667,0.03707731455583318,0.5126180145304098,0.6083607628323491,LonGen OPEL,"Plasma lipoprotein assembly, remodeling, and clearance",CP:REACTOME,C2,102,121
Cohort,-0.0148604525097973,0.03207680997479475,-0.463277131406593,0.643314848336781,LGP Offspring,Plasma lipoprotein clearance,CP:REACTOME,C2,37,71
Cohort,-0.028921966993834546,0.09303404236416746,-0.31087509753283593,0.7559732564167944,LGP Proband,Plasma lipoprotein clearance,CP:REACTOME,C2,37,113
Cohort,0.022561175698214864,0.02549866076681795,0.8847984568497139,0.37653252462289954,LonGen OPEL,Plasma lipoprotein clearance,CP:REACTOME,C2,41,57
Cohort,0.011009183488625833,0.024836986382769426,0.44325762066944707,0.6577212245668251,LGP Offspring,Plasma lipoprotein remodeling,CP:REACTOME,C2,22,41
Cohort,-0.06942150737028786,0.08368275123297056,-0.8295796487022783,0.4070138662007292,LGP Proband,Plasma lipoprotein remodeling,CP:REACTOME,C2,22,87
Cohort,-0.013149470103145619,0.02402561904263659,-0.5473103556586897,0.5843189423025705,LonGen OPEL,Plasma lipoprotein remodeling,CP:REACTOME,C2,46,45
Cohort,-0.10111967103073133,0.08965587030539657,-1.1278644743092159,0.25977730132671856,LGP Offspring,"Platelet activation, signaling and aggregation",CP:REACTOME,C2,244,470
Cohort,-0.2411328333556962,0.2591540536426115,-0.930461360593774,0.3524015058103487,LGP Proband,"Platelet activation, signaling and aggregation",CP:REACTOME,C2,244,684
Cohort,0.0015327981576969628,0.0751220886755595,0.02040409398515099,0.9837261313631517,LonGen OPEL,"Platelet activation, signaling and aggregation",CP:REACTOME,C2,379,452
Cohort,0.02163545561019775,0.015230921479612225,1.42049551231411,0.15592452947031107,LGP Offspring,Platelet Adhesion to exposed collagen,CP:REACTOME,C2,4,17
Cohort,0.025245294889928216,0.04392941498140128,0.5746786043159579,0.565663659360238,LGP Proband,Platelet Adhesion to exposed collagen,CP:REACTOME,C2,4,30
Cohort,0.022803652602251402,0.01442396908057141,1.580955455108895,0.1142854695041195,LonGen OPEL,Platelet Adhesion to exposed collagen,CP:REACTOME,C2,7,26
Cohort,-0.035204441625177274,0.03714054350058865,-0.9478709331385877,0.3435338765014545,LGP Offspring,Platelet Aggregation (Plug Formation),CP:REACTOME,C2,50,82
Cohort,-0.378744854713174,0.1043903515262465,-3.6281595873153805,3.02811853067825e-4,LGP Proband,Platelet Aggregation (Plug Formation),CP:REACTOME,C2,50,119
Cohort,-0.008643924397989194,0.03041855423805561,-0.2841661812833654,0.77635693322471,LonGen OPEL,Platelet Aggregation (Plug Formation),CP:REACTOME,C2,63,80
Cohort,0.013495378878101323,0.02786239759670778,0.4843581329015252,0.6282886124288913,LGP Offspring,Platelet calcium homeostasis,CP:REACTOME,C2,28,59
Cohort,-0.15251765072973314,0.08026123849741248,-1.9002653533018943,0.057742924483804456,LGP Proband,Platelet calcium homeostasis,CP:REACTOME,C2,28,82
Cohort,0.02627515462214676,0.025232042192041896,1.0413407849497753,0.2980335886264409,LonGen OPEL,Platelet calcium homeostasis,CP:REACTOME,C2,42,58
Cohort,-0.004874697479079527,0.047724244203982656,-0.10214300007023948,0.9186734606201167,LGP Offspring,Platelet homeostasis,CP:REACTOME,C2,81,154
Cohort,-0.4010428528028397,0.1385506902633573,-2.894556873304182,0.003896001000084494,LGP Proband,Platelet homeostasis,CP:REACTOME,C2,81,234
Cohort,0.040327993606259244,0.039472125499979915,1.0216828482236093,0.3072414336737342,LonGen OPEL,Platelet homeostasis,CP:REACTOME,C2,108,149
Cohort,-0.008163724005555373,0.014114315257568205,-0.5784002876921657,0.5631865379925476,LGP Offspring,Platelet sensitization by LDL,CP:REACTOME,C2,8,12
Cohort,0.0014743184418328995,0.04651717135632493,0.03169406906837719,0.9747236077735404,LGP Proband,Platelet sensitization by LDL,CP:REACTOME,C2,8,28
Cohort,0.023040789468769616,0.012745559832683166,1.8077502888250239,0.07102273142233634,LonGen OPEL,Platelet sensitization by LDL,CP:REACTOME,C2,6,17
Cohort,0.01163186881918983,0.01565244700598599,0.7431342086474682,0.45765860603157105,LGP Offspring,POLB-Dependent Long Patch Base Excision Repair,CP:REACTOME,C2,8,17
Cohort,-0.04771523956186734,0.04328117958261882,-1.102447761868052,0.2705850855507172,LGP Proband,POLB-Dependent Long Patch Base Excision Repair,CP:REACTOME,C2,8,24
Cohort,-0.017335722866000325,0.018107814397325023,-0.9573614178727856,0.33867553799360983,LonGen OPEL,POLB-Dependent Long Patch Base Excision Repair,CP:REACTOME,C2,27,20
Cohort,-0.012654267843031326,0.01768439187929835,-0.7155613791755331,0.4745093042111558,LGP Offspring,Polo-like kinase mediated events,CP:REACTOME,C2,13,17
Cohort,-0.02590860673699571,0.05055201463471983,-0.5125138320244376,0.6084271453643064,LGP Proband,Polo-like kinase mediated events,CP:REACTOME,C2,13,28
Cohort,0.02733131283512936,0.01734353815194567,1.575878727609177,0.11545108081021913,LonGen OPEL,Polo-like kinase mediated events,CP:REACTOME,C2,15,28
Cohort,-0.03205314928178042,0.02157884309321861,-1.4853970225981892,0.13790485658320234,LGP Offspring,Polymerase switching,CP:REACTOME,C2,19,27
Cohort,0.037752709319225745,0.06592948451725267,0.5726225465837895,0.5670546231894891,LGP Proband,Polymerase switching,CP:REACTOME,C2,19,48
Cohort,-0.013568859063557218,0.01823667780452049,-0.7440422652087312,0.4570704807504039,LonGen OPEL,Polymerase switching,CP:REACTOME,C2,25,24
Cohort,-0.024887190320461067,0.027716404237023786,-0.8979227647147882,0.3695464158299161,LGP Offspring,Polymerase switching on the C-strand of the telomere,CP:REACTOME,C2,27,49
Cohort,-0.02717191385114052,0.08295866200267586,-0.32753558453322307,0.7433450317018655,LGP Proband,Polymerase switching on the C-strand of the telomere,CP:REACTOME,C2,27,78
Cohort,-0.03077758392659431,0.027002223059383386,-1.1398166683871966,0.2547055471546233,LonGen OPEL,Polymerase switching on the C-strand of the telomere,CP:REACTOME,C2,54,49
Cohort,-0.02373442841789031,0.03778915284546809,-0.6280751652451159,0.5301668223217256,LGP Offspring,Positive epigenetic regulation of rRNA expression,CP:REACTOME,C2,49,95
Cohort,0.04528736979431964,0.10832917893638702,0.4180532912643347,0.6760157692460432,LGP Proband,Positive epigenetic regulation of rRNA expression,CP:REACTOME,C2,49,141
Cohort,7.09682879120002e-4,0.03335843188316246,0.021274467625026813,0.9830320426885606,LonGen OPEL,Positive epigenetic regulation of rRNA expression,CP:REACTOME,C2,78,94
Cohort,0.03549899044450183,0.0223531918697563,1.5880949195685874,0.11273245920203122,LGP Offspring,Post-chaperonin tubulin folding pathway,CP:REACTOME,C2,10,40
Cohort,0.021436464823101388,0.06598786300186521,0.324854660356185,0.7453725411650134,LGP Proband,Post-chaperonin tubulin folding pathway,CP:REACTOME,C2,10,61
Cohort,-0.025868186102334646,0.01878634243404676,-1.37696766643907,0.1689093600573268,LonGen OPEL,Post-chaperonin tubulin folding pathway,CP:REACTOME,C2,29,25
Cohort,0.03152070649836776,0.05400710832308035,0.5836399592032433,0.5596572463406786,LGP Offspring,Post-translational modification: synthesis of GPI-anchored proteins,CP:REACTOME,C2,87,202
Cohort,0.26293017873476365,0.15502546786238303,1.6960450586620273,0.09025054385803234,LGP Proband,Post-translational modification: synthesis of GPI-anchored proteins,CP:REACTOME,C2,87,285
Cohort,-0.06800884570157763,0.04462249248949062,-1.5240933867061528,0.12788256381752586,LonGen OPEL,Post-translational modification: synthesis of GPI-anchored proteins,CP:REACTOME,C2,159,163
Cohort,-0.18814204739163598,0.20374018745116698,-0.9234410243032214,0.35610690573047565,LGP Offspring,Post-translational protein modification,CP:REACTOME,C2,1334,2716
Cohort,-1.4738526455680385,0.5474686881868773,-2.692122266296519,0.007242215354355958,LGP Proband,Post-translational protein modification,CP:REACTOME,C2,1334,3783
Cohort,-0.17892640456583198,0.16939500611567893,-1.0562672930490296,0.29116658079777047,LonGen OPEL,Post-translational protein modification,CP:REACTOME,C2,2125,2455
Cohort,0.018560969198821057,0.028747576142335408,0.6456533624581677,0.5187229618022958,LGP Offspring,Postmitotic nuclear pore complex (NPC) reformation,CP:REACTOME,C2,25,64
Cohort,-0.06374738109877942,0.07404621799181395,-0.8609133974381636,0.3895331739991311,LGP Proband,Postmitotic nuclear pore complex (NPC) reformation,CP:REACTOME,C2,25,64
Cohort,0.0031970448964850264,0.023300884532541775,0.13720701855846143,0.8909018599064777,LonGen OPEL,Postmitotic nuclear pore complex (NPC) reformation,CP:REACTOME,C2,36,43
Cohort,0.06706539160050229,0.05479261845890098,1.2239858850842638,0.2213839714999768,LGP Offspring,Potassium Channels,CP:REACTOME,C2,84,201
Cohort,0.09078028476260612,0.14409378612228615,0.6300083244780925,0.5288617014075665,LGP Proband,Potassium Channels,CP:REACTOME,C2,84,241
Cohort,0.02638081590568556,0.04456143335444927,0.592010039171048,0.5540119727819283,LonGen OPEL,Potassium Channels,CP:REACTOME,C2,128,172
Cohort,-0.054579708983295845,0.038985579991206665,-1.3999973578847997,0.16197287378850744,LGP Offspring,Potential therapeutics for SARS,CP:REACTOME,C2,60,102
Cohort,-0.03960289958288721,0.10995831076813374,-0.36016285905298073,0.7188165367245217,LGP Proband,Potential therapeutics for SARS,CP:REACTOME,C2,60,139
Cohort,-0.09321143864194849,0.03441599132329811,-2.708375817692877,0.006906499304518663,LonGen OPEL,Potential therapeutics for SARS,CP:REACTOME,C2,97,80
Cohort,-0.009452769194422037,0.01553383706886807,-0.6085276388901154,0.543041994095143,LGP Offspring,"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",CP:REACTOME,C2,9,15
Cohort,-0.031802300758762475,0.04453780539257649,-0.7140518145975654,0.4753949266505676,LGP Proband,"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",CP:REACTOME,C2,9,24
Cohort,0.00804347108607249,0.015490886096735247,0.5192389277052186,0.6037384715915625,LonGen OPEL,"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",CP:REACTOME,C2,14,21
Cohort,0.011965739500025328,0.009582353047071005,1.2487266375227994,0.2121973408530718,LGP Offspring,"POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation",CP:REACTOME,C2,1,8
Cohort,-0.005134829935543399,0.02365313940146718,-0.21708872756336486,0.8281922931323644,LGP Proband,"POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation",CP:REACTOME,C2,1,8
Cohort,-0.010666532287887082,0.0044671808761385335,-2.3877547347282064,0.017183970271047018,LonGen OPEL,"POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation",CP:REACTOME,C2,3,0
Cohort,0.0015736927823772724,0.008477014167727124,0.18564234425471232,0.8527809325172988,LGP Offspring,PP2A-mediated dephosphorylation of key metabolic factors,CP:REACTOME,C2,2,5
Cohort,0.023732176811623786,0.037695863271068775,0.6295697923394691,0.5291485155055957,LGP Proband,PP2A-mediated dephosphorylation of key metabolic factors,CP:REACTOME,C2,2,17
Cohort,0.019354293905637046,0.013290190483026695,1.4562841616420021,0.14570839036703326,LonGen OPEL,PP2A-mediated dephosphorylation of key metabolic factors,CP:REACTOME,C2,6,15
Cohort,0.008430832573105987,0.01983726243297377,0.4249998003299156,0.6709720644244307,LGP Offspring,PRC2 methylates histones and DNA,CP:REACTOME,C2,14,27
Cohort,-0.09111945920565245,0.0715713714390664,-1.273127192808212,0.20332766410451944,LGP Proband,PRC2 methylates histones and DNA,CP:REACTOME,C2,14,74
Cohort,-0.012037591216802073,0.020448212173889358,-0.5886867328270909,0.5562384444324555,LonGen OPEL,PRC2 methylates histones and DNA,CP:REACTOME,C2,32,34
Cohort,-0.013668585745248193,0.036013284455390905,-0.3795428812437049,0.7044039654884936,LGP Offspring,Pre-NOTCH Expression and Processing,CP:REACTOME,C2,50,99
Cohort,-0.05019522056942079,0.10273019483040056,-0.4886121422459008,0.6252447659056426,LGP Proband,Pre-NOTCH Expression and Processing,CP:REACTOME,C2,50,127
Cohort,-0.025346485515930807,0.03232787024109624,-0.7840443965810506,0.43324730245182075,LonGen OPEL,Pre-NOTCH Expression and Processing,CP:REACTOME,C2,73,77
Cohort,-0.020549329092118075,0.023357326507771094,-0.8797808724076882,0.37929066807638234,LGP Offspring,Pre-NOTCH Processing in Golgi,CP:REACTOME,C2,22,35
Cohort,-0.12414993003693137,0.062051285675815714,-2.0007632184375255,0.04574161095584426,LGP Proband,Pre-NOTCH Processing in Golgi,CP:REACTOME,C2,22,40
Cohort,6.458427702975482e-4,0.01758981603781869,0.03671685757878108,0.9707199729946994,LonGen OPEL,Pre-NOTCH Processing in Golgi,CP:REACTOME,C2,20,27
Cohort,-0.014044215232851962,0.010131940219312156,-1.3861328559837678,0.16616337235980239,LGP Offspring,Pre-NOTCH Processing in the Endoplasmic Reticulum,CP:REACTOME,C2,5,5
Cohort,-0.004945217575910865,0.023479617247096036,-0.2106174697767908,0.8332372260092817,LGP Proband,Pre-NOTCH Processing in the Endoplasmic Reticulum,CP:REACTOME,C2,5,4
Cohort,0.005358966643956458,0.011808215938218193,0.45383372661840926,0.6500722133344115,LonGen OPEL,Pre-NOTCH Processing in the Endoplasmic Reticulum,CP:REACTOME,C2,8,13
Cohort,-0.017948358561099303,0.020454516641469515,-0.8774765434794375,0.38053959363801004,LGP Offspring,Pregnenolone biosynthesis,CP:REACTOME,C2,16,28
Cohort,0.0360469377184481,0.050471573396914965,0.7142027738063629,0.475301637675822,LGP Proband,Pregnenolone biosynthesis,CP:REACTOME,C2,16,27
Cohort,-0.005656968548531616,0.01688453192517972,-0.33503851771546245,0.73768430107474,LonGen OPEL,Pregnenolone biosynthesis,CP:REACTOME,C2,20,20
Cohort,-0.024986072495713146,0.026724022380551445,-0.934966755375003,0.35013929031857305,LGP Offspring,Presynaptic depolarization and calcium channel opening,CP:REACTOME,C2,24,42
Cohort,0.003224560830353152,0.0752743268576594,0.04283745820073106,0.965841357510676,LGP Proband,Presynaptic depolarization and calcium channel opening,CP:REACTOME,C2,24,64
Cohort,-0.0016679964266375052,0.021474404432856496,-0.07767369902400738,0.9381071357871649,LonGen OPEL,Presynaptic depolarization and calcium channel opening,CP:REACTOME,C2,36,36
Cohort,-0.005665293265776275,0.014571382454356319,-0.3887958663855231,0.6975495855784598,LGP Offspring,Presynaptic function of Kainate receptors,CP:REACTOME,C2,6,13
Cohort,-0.01798956021171318,0.03981230435782472,-0.45185930585747436,0.6514878303252292,LGP Proband,Presynaptic function of Kainate receptors,CP:REACTOME,C2,6,20
Cohort,0.008613302333589461,0.01308946900008145,0.6580329831206954,0.5107071930256941,LonGen OPEL,Presynaptic function of Kainate receptors,CP:REACTOME,C2,9,17
Cohort,9.411387383198005e-4,0.0063878012297133606,0.14733375452292088,0.8829125214923601,LGP Offspring,Prevention of phagosomal-lysosomal fusion,CP:REACTOME,C2,1,3
Cohort,-0.005421971295539737,0.022286067741060626,-0.24328972515640832,0.8078407895387236,LGP Proband,Prevention of phagosomal-lysosomal fusion,CP:REACTOME,C2,1,7
Cohort,-4.512925248095229e-4,0.007270502215329654,-0.06207171271579905,0.9505213056182626,LonGen OPEL,Prevention of phagosomal-lysosomal fusion,CP:REACTOME,C2,3,5
Cohort,0.016212073451172003,0.011459395704598665,1.414740695677878,0.15760498225653255,LGP Offspring,Processing and activation of SUMO,CP:REACTOME,C2,2,11
Cohort,-0.007520726589129873,0.03179535970534086,-0.23653535166222922,0.8130753599926663,LGP Proband,Processing and activation of SUMO,CP:REACTOME,C2,2,15
Cohort,-0.0017434858870013568,0.007637898885494028,-0.22826773608021994,0.8194967306763061,LonGen OPEL,Processing and activation of SUMO,CP:REACTOME,C2,4,5
Cohort,-0.13037940487720118,0.07021399767967247,-1.8568862219184976,0.06376212670046676,LGP Offspring,Processing of Capped Intron-Containing Pre-mRNA,CP:REACTOME,C2,174,308
Cohort,-0.0704007618039848,0.19158987234595337,-0.36745554940849023,0.7133724673575108,LGP Proband,Processing of Capped Intron-Containing Pre-mRNA,CP:REACTOME,C2,174,441
Cohort,-0.030461023880726083,0.06267861529535165,-0.4859875052629812,0.6271097783015377,LonGen OPEL,Processing of Capped Intron-Containing Pre-mRNA,CP:REACTOME,C2,260,302
Cohort,-0.028971690074625515,0.020788477878132736,-1.3936417204022737,0.1638838119821935,LGP Offspring,Processing of Capped Intronless Pre-mRNA,CP:REACTOME,C2,17,26
Cohort,-0.022288869031545328,0.0622434681396639,-0.35809169536525254,0.7203653063383991,LGP Proband,Processing of Capped Intronless Pre-mRNA,CP:REACTOME,C2,17,46
Cohort,-0.0010432861709668115,0.017836964429645902,-0.05849011893710003,0.953372912809313,LonGen OPEL,Processing of Capped Intronless Pre-mRNA,CP:REACTOME,C2,20,26
Cohort,0.01890005803694049,0.04137070698999395,0.45684638750581946,0.6479282215994908,LGP Offspring,Processing of DNA double-strand break ends,CP:REACTOME,C2,58,128
Cohort,0.07761252724882642,0.12316499431462502,0.6301508612955821,0.5287684948246293,LGP Proband,Processing of DNA double-strand break ends,CP:REACTOME,C2,58,189
Cohort,-0.004835764403896553,0.037629246838154065,-0.12851079440137356,0.8977772176007024,LonGen OPEL,Processing of DNA double-strand break ends,CP:REACTOME,C2,93,116
Cohort,-0.031014499431962734,0.020550195154653176,-1.5092070512498335,0.13171310788321913,LGP Offspring,Processing of Intronless Pre-mRNAs,CP:REACTOME,C2,17,25
Cohort,-0.023201902707929156,0.06178675981920274,-0.37551577030129724,0.7073724059882894,LGP Proband,Processing of Intronless Pre-mRNAs,CP:REACTOME,C2,17,45
Cohort,-0.0010432861709668115,0.017836964429645902,-0.05849011893710003,0.953372912809313,LonGen OPEL,Processing of Intronless Pre-mRNAs,CP:REACTOME,C2,20,26
Cohort,0.0076047006172520705,0.017582824353419242,0.4325073415053039,0.6655106563479172,LGP Offspring,Processing of SMDT1,CP:REACTOME,C2,8,21
Cohort,-0.04059693452568506,0.05323390710697002,-0.7626142196196157,0.4459091351808747,LGP Proband,Processing of SMDT1,CP:REACTOME,C2,8,38
Cohort,0.012178670157858788,0.01742332278283568,0.6989866576917474,0.48476454808080593,LonGen OPEL,Processing of SMDT1,CP:REACTOME,C2,17,26
Cohort,0.00271549509004917,0.025353088382960715,0.1071070730725728,0.91473581443266,LGP Offspring,Processive synthesis on the C-strand of the telomere,CP:REACTOME,C2,20,43
Cohort,-0.04209776704436752,0.06686827030162383,-0.6295626738134008,0.529153171903969,LGP Proband,Processive synthesis on the C-strand of the telomere,CP:REACTOME,C2,20,50
Cohort,-0.005822921104227916,0.02071002058643244,-0.2811644285878997,0.7786573551757913,LonGen OPEL,Processive synthesis on the C-strand of the telomere,CP:REACTOME,C2,34,36
Cohort,-0.03233939441107166,0.020482347146189843,-1.5788910411611439,0.11482883984327104,LGP Offspring,Processive synthesis on the lagging strand,CP:REACTOME,C2,18,23
Cohort,-0.003802915622282535,0.0629024129428955,-0.06045738858595017,0.9518058367302311,LGP Proband,Processive synthesis on the lagging strand,CP:REACTOME,C2,18,46
Cohort,-0.0011958523517575025,0.01976299793969213,-0.060509663331783536,0.9517649082470565,LonGen OPEL,Processive synthesis on the lagging strand,CP:REACTOME,C2,29,32
Cohort,-0.09524094406623214,0.07402052503348311,-1.2866829034669776,0.19864527893352132,LGP Offspring,Programmed Cell Death,CP:REACTOME,C2,186,352
Cohort,-0.21001090771846162,0.20453071767275519,-1.026793970646867,0.30481519698155024,LGP Proband,Programmed Cell Death,CP:REACTOME,C2,186,486
Cohort,-0.07460895887222137,0.0658533581211121,-1.1329560253405253,0.2575738544129911,LonGen OPEL,Programmed Cell Death,CP:REACTOME,C2,309,334
Cohort,0.00878242064065673,0.014221879103286898,0.6175288495193982,0.5370939150649348,LGP Offspring,Prolactin receptor signaling,CP:REACTOME,C2,5,15
Cohort,0.05961593690176533,0.043291635185516854,1.3770775034552112,0.16885778160791673,LGP Proband,Prolactin receptor signaling,CP:REACTOME,C2,5,26
Cohort,-0.020108935501950795,0.013503478146386244,-1.4891671082040652,0.1368394503494989,LonGen OPEL,Prolactin receptor signaling,CP:REACTOME,C2,14,10
Cohort,-5.024521159414462e-4,0.014442693155398733,-0.03478936445822279,0.9722579712286296,LGP Offspring,Prolonged ERK activation events,CP:REACTOME,C2,7,14
Cohort,0.03551862702223433,0.03650300635154495,0.9730329244711934,0.3308190627509867,LGP Proband,Prolonged ERK activation events,CP:REACTOME,C2,7,15
Cohort,-0.01779579243514551,0.012256959912001472,-1.4518928480561204,0.1469254190935918,LonGen OPEL,Prolonged ERK activation events,CP:REACTOME,C2,13,10
Cohort,-0.006282328837808475,0.011919018138760687,-0.5270844263067542,0.5983078842827401,LGP Offspring,Propionyl-CoA catabolism,CP:REACTOME,C2,5,9
Cohort,-0.03049227226857578,0.03570968060251004,-0.8538937272497606,0.3934090647799737,LGP Proband,Propionyl-CoA catabolism,CP:REACTOME,C2,5,16
Cohort,0.006281703449738998,0.011565397720510965,0.543146340622471,0.5871811060924458,LonGen OPEL,Propionyl-CoA catabolism,CP:REACTOME,C2,7,11
Cohort,0.003365989834195108,0.008405172616882445,0.40046647316133105,0.6889394989109195,LGP Offspring,Prostacyclin signalling through prostacyclin receptor,CP:REACTOME,C2,2,5
Cohort,-0.030180738143014765,0.032386383750541294,-0.9318958972228671,0.35166001343794695,LGP Proband,Prostacyclin signalling through prostacyclin receptor,CP:REACTOME,C2,2,15
Cohort,-0.00281431543606197,0.010307127567750181,-0.2730455616817667,0.7848890146894418,LonGen OPEL,Prostacyclin signalling through prostacyclin receptor,CP:REACTOME,C2,7,9
Cohort,0.005131628856850802,0.010919650823497504,0.4699444093769264,0.638546296023754,LGP Offspring,Prostanoid ligand receptors,CP:REACTOME,C2,4,8
Cohort,-0.019158493727508316,0.03463915566724411,-0.5530877805322835,0.5803515241709134,LGP Proband,Prostanoid ligand receptors,CP:REACTOME,C2,4,17
Cohort,-0.004478612372099324,0.010589325596355241,-0.4229365063286774,0.6724558190112033,LonGen OPEL,Prostanoid ligand receptors,CP:REACTOME,C2,8,9
Cohort,-0.043747837101014896,0.04731065869363369,-0.9246930461127099,0.35545555901645964,LGP Offspring,Protein folding,CP:REACTOME,C2,74,144
Cohort,-0.09378656453823067,0.13885560315692438,-0.6754251352193544,0.49959292118533727,LGP Proband,Protein folding,CP:REACTOME,C2,74,219
Cohort,0.012541163453197952,0.04203962182921238,0.29831770381158335,0.7655385460842979,LonGen OPEL,Protein folding,CP:REACTOME,C2,119,153
Cohort,0.009447175256834596,0.0646203290534829,0.1461950967321082,0.8838109602875683,LGP Offspring,Protein localization,CP:REACTOME,C2,131,273
Cohort,-0.021876343068559293,0.1829618620628537,-0.119567776704437,0.9048543423962441,LGP Proband,Protein localization,CP:REACTOME,C2,131,406
Cohort,-0.007751473728250943,0.05629856929147844,-0.13768509263741158,0.8905241211630319,LonGen OPEL,Protein localization,CP:REACTOME,C2,209,260
Cohort,0.006292471447499151,0.02475692616835869,0.2541701423152211,0.7994414079591345,LGP Offspring,Protein methylation,CP:REACTOME,C2,19,41
Cohort,-0.06286425387818094,0.06669818540174942,-0.9425182034492363,0.3462003303837352,LGP Proband,Protein methylation,CP:REACTOME,C2,19,55
Cohort,0.05473334822636144,0.02096108194221034,2.61118907779957,0.009192641171870844,LonGen OPEL,Protein methylation,CP:REACTOME,C2,20,48
Cohort,-0.023460454444790807,0.0426233298034266,-0.5504134602572688,0.5822176468791785,LGP Offspring,Protein-protein interactions at synapses,CP:REACTOME,C2,64,129
Cohort,0.31947122098043934,0.12476181874461112,2.560648956508085,0.010622689989971831,LGP Proband,Protein-protein interactions at synapses,CP:REACTOME,C2,64,206
Cohort,-0.02742955374884128,0.03837431425625328,-0.7147894178818192,0.47494874873435033,LonGen OPEL,Protein-protein interactions at synapses,CP:REACTOME,C2,101,112
Cohort,0.0030281313546488384,0.010616300169553396,0.2852341499662236,0.77555212664565,LGP Offspring,Protein repair,CP:REACTOME,C2,3,8
Cohort,-0.02298960971000611,0.024898613892727132,-0.9233288973054584,0.3561028804003721,LGP Proband,Protein repair,CP:REACTOME,C2,3,7
Cohort,-0.012302895328959756,0.010528745029033214,-1.1685053911966041,0.2429528005105145,LonGen OPEL,Protein repair,CP:REACTOME,C2,10,7
Cohort,-0.010802464022673175,0.02985305880209723,-0.3618545119374596,0.717573833401993,LGP Offspring,Protein ubiquitination,CP:REACTOME,C2,27,53
Cohort,0.0503911571577736,0.07892825395044598,0.6384425682267214,0.5233609010224305,LGP Proband,Protein ubiquitination,CP:REACTOME,C2,27,69
Cohort,0.016956147540219284,0.023058822204035066,0.735343175387862,0.4623471195748472,LonGen OPEL,Protein ubiquitination,CP:REACTOME,C2,27,43
Cohort,-0.024531650267329588,0.014823897397403354,-1.6548718336128463,0.09841466401909311,LGP Offspring,Proton-coupled monocarboxylate transport,CP:REACTOME,C2,11,11
Cohort,-0.029849444000930835,0.04763857172366911,-0.6265814217536714,0.5311051142908948,LGP Proband,Proton-coupled monocarboxylate transport,CP:REACTOME,C2,11,27
Cohort,-0.008173557095781303,0.011742595701604876,-0.6960605051457415,0.4865941200663002,LonGen OPEL,Proton-coupled monocarboxylate transport,CP:REACTOME,C2,11,10
Cohort,0.03476424684186688,0.0564388200412313,0.6159633886121274,0.5381260231428877,LGP Offspring,PTEN Regulation,CP:REACTOME,C2,88,202
Cohort,0.15670542267490775,0.14977968684469758,1.0462394866494231,0.2957536019888667,LGP Proband,PTEN Regulation,CP:REACTOME,C2,88,291
Cohort,-0.019199968039843272,0.04584726129707475,-0.4187811331942812,0.6754890662637536,LonGen OPEL,PTEN Regulation,CP:REACTOME,C2,140,166
Cohort,0.008537716262494633,0.014501857263496419,0.5887326090283264,0.5562373207680839,LGP Offspring,PTK6 Expression,CP:REACTOME,C2,5,16
Cohort,-0.020825199017036868,0.038291380462559636,-0.543861275448119,0.5866822910999507,LGP Proband,PTK6 Expression,CP:REACTOME,C2,5,19
Cohort,0.016748109715122805,0.0123324842956359,1.358048331028442,0.17483314921504542,LonGen OPEL,PTK6 Expression,CP:REACTOME,C2,7,16
Cohort,0.0224499975817463,0.020658027082938412,1.0867445129979467,0.2775370798868568,LGP Offspring,PTK6 promotes HIF1A stabilization,CP:REACTOME,C2,11,31
Cohort,-0.02263189223638595,0.04886859357340929,-0.4631173230387496,0.6434010949362443,LGP Proband,PTK6 promotes HIF1A stabilization,CP:REACTOME,C2,11,29
Cohort,0.011172063356012441,0.017886569127998207,0.6246062772611091,0.532408484254546,LonGen OPEL,PTK6 promotes HIF1A stabilization,CP:REACTOME,C2,18,28
Cohort,-0.006166703379337895,0.011543361460440365,-0.534220764070455,0.5933644414348569,LGP Offspring,PTK6 Regulates Cell Cycle,CP:REACTOME,C2,5,8
Cohort,-0.008533742396298335,0.026025926254819615,-0.3278938975214384,0.7430741840873742,LGP Proband,PTK6 Regulates Cell Cycle,CP:REACTOME,C2,5,6
Cohort,-0.0029435758917712132,0.00994225785904539,-0.29606714425467956,0.7672560268856763,LonGen OPEL,PTK6 Regulates Cell Cycle,CP:REACTOME,C2,6,7
Cohort,0.007462494461121793,0.005567904857454221,1.3402697517596993,0.18060794085818316,LGP Offspring,PTK6 Regulates Proteins Involved in RNA Processing,CP:REACTOME,C2,0,3
Cohort,0.04545287108557168,0.02226508890657888,2.0414412570408054,0.04152123510575492,LGP Proband,PTK6 Regulates Proteins Involved in RNA Processing,CP:REACTOME,C2,0,8
Cohort,0.006203041448523879,0.00854852834967859,0.7256268207564759,0.4682808518920901,LonGen OPEL,PTK6 Regulates Proteins Involved in RNA Processing,CP:REACTOME,C2,4,7
Cohort,-0.0029800691112311316,0.02176076556817113,-0.1369468873645694,0.891113552849091,LGP Offspring,"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases",CP:REACTOME,C2,15,31
Cohort,-0.136676949797558,0.05550784802191959,-2.4622995606600604,0.014006141074753392,LGP Proband,"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases",CP:REACTOME,C2,15,36
Cohort,0.011555710440801411,0.01840380316302274,0.6278979588316482,0.5302508788515862,LonGen OPEL,"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases",CP:REACTOME,C2,24,30
Cohort,0.004725973411713511,0.012626845072264773,0.37427982878274535,0.7083135078409535,LGP Offspring,PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1,CP:REACTOME,C2,5,11
Cohort,0.06288885832340095,0.03719008115367995,1.6910115915995552,0.09120821040770923,LGP Proband,PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1,CP:REACTOME,C2,5,18
Cohort,0.002023814796378122,0.009296365280113397,0.2176995777809449,0.8277189847216536,LonGen OPEL,PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1,CP:REACTOME,C2,5,8
Cohort,-0.014882249294169958,0.019570485275142522,-0.7604435498118519,0.44725464426412065,LGP Offspring,Purine catabolism,CP:REACTOME,C2,14,26
Cohort,-0.009393086026801533,0.05848038244587178,-0.16061943567991502,0.8724320422669029,LGP Proband,Purine catabolism,CP:REACTOME,C2,14,43
Cohort,-0.017740148479457717,0.017314861672666236,-1.0245619523176932,0.30588118057294805,LonGen OPEL,Purine catabolism,CP:REACTOME,C2,24,23
Cohort,0.013877127231838572,0.023244569270292906,0.5970051357145972,0.5507038459449031,LGP Offspring,Purine ribonucleoside monophosphate biosynthesis,CP:REACTOME,C2,13,37
Cohort,-0.01843524917770086,0.06081183964457352,-0.3031523020097602,0.7618493988550071,LGP Proband,Purine ribonucleoside monophosphate biosynthesis,CP:REACTOME,C2,13,44
Cohort,-0.0026980386429003734,0.015993753605052445,-0.16869327298177583,0.8660807653744523,LonGen OPEL,Purine ribonucleoside monophosphate biosynthesis,CP:REACTOME,C2,18,22
Cohort,0.039920689781345026,0.024618232729976163,1.6215903968092709,0.10535736703970232,LGP Offspring,Purine salvage,CP:REACTOME,C2,12,46
Cohort,0.0014231658654850834,0.06499627561116787,0.02189611407888963,0.9825360619993071,LGP Proband,Purine salvage,CP:REACTOME,C2,12,58
Cohort,0.005395456387532165,0.017791922337817255,0.30325314404413534,0.7617761901576897,LonGen OPEL,Purine salvage,CP:REACTOME,C2,21,29
Cohort,0.025726298602255636,0.02519659459864523,1.0210228410643591,0.3076088687716975,LGP Offspring,Purinergic signaling in leishmaniasis infection,CP:REACTOME,C2,16,50
Cohort,0.05900477916523795,0.06994839344032168,0.843547310569462,0.39916429138630494,LGP Proband,Purinergic signaling in leishmaniasis infection,CP:REACTOME,C2,16,61
Cohort,0.03660670314892315,0.02324255200358906,1.574986393201161,0.11565692424219363,LonGen OPEL,Purinergic signaling in leishmaniasis infection,CP:REACTOME,C2,32,51
Cohort,-0.002236432813785606,0.024166942809675806,-0.09254099003744062,0.9262956432430208,LGP Offspring,Pyrimidine catabolism,CP:REACTOME,C2,17,36
Cohort,7.996349830873954e-4,0.06714357031403793,0.011909330697599394,0.9905008017003325,LGP Proband,Pyrimidine catabolism,CP:REACTOME,C2,17,52
Cohort,-0.0322471591690901,0.02142343101459729,-1.5052285111156025,0.13266202355503875,LonGen OPEL,Pyrimidine catabolism,CP:REACTOME,C2,38,35
Cohort,-0.010841063826617515,0.01799488283031395,-0.6024525932647251,0.5470749388081672,LGP Offspring,Pyrimidine salvage,CP:REACTOME,C2,8,16
Cohort,-0.0029678285730114144,0.048505939273423185,-0.06118484906110277,0.9512266547580368,LGP Proband,Pyrimidine salvage,CP:REACTOME,C2,8,25
Cohort,-0.03642691771199792,0.013428140043539087,-2.7127299532093154,0.006817245108593222,LonGen OPEL,Pyrimidine salvage,CP:REACTOME,C2,20,8
Cohort,-0.04335449716592472,0.024249331997998027,-1.7878635654583792,0.07424583437584541,LGP Offspring,Pyroptosis,CP:REACTOME,C2,26,34
Cohort,-0.04727096475096976,0.07107856785041722,-0.665052296079602,0.5062009040873541,LGP Proband,Pyroptosis,CP:REACTOME,C2,26,55
Cohort,0.004825370204371264,0.02071438962934289,0.23294773781487163,0.815861873883694,LonGen OPEL,Pyroptosis,CP:REACTOME,C2,26,36
Cohort,-0.018569911847566678,0.03370690730540269,-0.5509230401743268,0.5818684564170293,LGP Offspring,Pyruvate metabolism,CP:REACTOME,C2,40,71
Cohort,-0.03704782160371854,0.09238774835717932,-0.40100362074512674,0.6885201719330892,LGP Proband,Pyruvate metabolism,CP:REACTOME,C2,40,103
Cohort,-0.033043226781331016,0.02784983328279578,-1.1864784412100395,0.23578741028389238,LonGen OPEL,Pyruvate metabolism,CP:REACTOME,C2,63,63
Cohort,0.010421068547433137,0.0423166561123388,0.2462639892851679,0.8055526409726984,LGP Offspring,Pyruvate metabolism and Citric Acid (TCA) cycle,CP:REACTOME,C2,54,115
Cohort,-0.05279156601376887,0.11042742684800645,-0.47806570813636523,0.6327287194404435,LGP Proband,Pyruvate metabolism and Citric Acid (TCA) cycle,CP:REACTOME,C2,54,158
Cohort,-0.039423795533689514,0.034859875628956025,-1.130921864246197,0.258428597881205,LonGen OPEL,Pyruvate metabolism and Citric Acid (TCA) cycle,CP:REACTOME,C2,95,101
Cohort,0.001357952268241731,0.03277414910955349,0.04143363916794701,0.9669624299058335,LGP Offspring,RA biosynthesis pathway,CP:REACTOME,C2,36,74
Cohort,-0.04079455727804846,0.08617820903958888,-0.47337439165518164,0.6360699739177498,LGP Proband,RA biosynthesis pathway,CP:REACTOME,C2,36,95
Cohort,0.03758439634441772,0.028917412143069796,1.2997150698848068,0.19407490199009422,LonGen OPEL,RA biosynthesis pathway,CP:REACTOME,C2,51,79
Cohort,-0.0033312467291997682,0.05287314033472673,-0.06300451813738453,0.9497815309467893,LGP Offspring,RAB GEFs exchange GTP for GDP on RABs,CP:REACTOME,C2,88,191
Cohort,0.08364084942672811,0.14955136565319374,0.5592784061944935,0.576121882058482,LGP Proband,RAB GEFs exchange GTP for GDP on RABs,CP:REACTOME,C2,88,260
Cohort,-0.0019965025692622604,0.04627800723257939,-0.04314149827645856,0.9655995584873847,LonGen OPEL,RAB GEFs exchange GTP for GDP on RABs,CP:REACTOME,C2,151,174
Cohort,-0.02034065307951872,0.023792697151068666,-0.8549116121795005,0.39290296115648593,LGP Offspring,RAB geranylgeranylation,CP:REACTOME,C2,22,33
Cohort,-0.06703501422832,0.0719857713340315,-0.9312258934791603,0.35200620591974596,LGP Proband,RAB geranylgeranylation,CP:REACTOME,C2,22,59
Cohort,-0.007507863413254906,0.01859267262860175,-0.4038076484875714,0.6864626286997346,LonGen OPEL,RAB geranylgeranylation,CP:REACTOME,C2,28,28
Cohort,-0.03607629773709887,0.059788975788265863,-0.6033938073275905,0.5464491385407553,LGP Offspring,Rab regulation of trafficking,CP:REACTOME,C2,123,243
Cohort,-0.017834139250875722,0.17019189656810604,-0.10478841596162011,0.9165688974926519,LGP Proband,Rab regulation of trafficking,CP:REACTOME,C2,123,337
Cohort,-0.030588792910761248,0.05396988184940081,-0.5667752432017017,0.5710266688946577,LonGen OPEL,Rab regulation of trafficking,CP:REACTOME,C2,207,234
Cohort,0.08253230226188545,0.08522682258965147,0.9683841278380216,0.33319889482984566,LGP Offspring,RAC1 GTPase cycle,CP:REACTOME,C2,246,538
Cohort,0.023423543338461264,0.23480677798629399,0.09975667457022272,0.9205614785076462,LGP Proband,RAC1 GTPase cycle,CP:REACTOME,C2,246,742
Cohort,0.013028239125789003,0.07560158910875972,0.1723275830491698,0.863223804487753,LonGen OPEL,RAC1 GTPase cycle,CP:REACTOME,C2,382,461
Cohort,0.0022260555240609064,0.05888267612580575,0.03780493127222732,0.9698543738057902,LGP Offspring,RAC2 GTPase cycle,CP:REACTOME,C2,111,224
Cohort,-0.15744908593111573,0.16652224059715232,-0.94551385668665,0.34467044634911737,LGP Proband,RAC2 GTPase cycle,CP:REACTOME,C2,111,308
Cohort,0.028604885853189682,0.04910549556807066,0.5825190342196471,0.5603820880486736,LonGen OPEL,RAC2 GTPase cycle,CP:REACTOME,C2,171,215
Cohort,0.006886587007936671,0.05614022326142659,0.12266760992146568,0.90240677231816,LGP Offspring,RAC3 GTPase cycle,CP:REACTOME,C2,102,218
Cohort,-0.18609052376947172,0.158646261554398,-1.1729902863526562,0.2411346075332872,LGP Proband,RAC3 GTPase cycle,CP:REACTOME,C2,102,305
Cohort,-0.03232186404393859,0.04953457643836477,-0.6525111622617035,0.5142598615745565,LonGen OPEL,RAC3 GTPase cycle,CP:REACTOME,C2,176,199
Cohort,0.012938870609354636,0.022168285453743292,0.5836658246012347,0.5596398508577586,LGP Offspring,RAF activation,CP:REACTOME,C2,14,35
Cohort,-0.013225768141057564,0.06674063051522598,-0.19816666457833781,0.8429629604410611,LGP Proband,RAF activation,CP:REACTOME,C2,14,60
Cohort,-0.025962740835995958,0.02119393938517389,-1.2250077894512643,0.2209346540611869,LonGen OPEL,RAF activation,CP:REACTOME,C2,33,31
Cohort,-0.015003747720702206,0.02357653557716555,-0.6363847509145365,0.5247410893864222,LGP Offspring,RAF-independent MAPK1/3 activation,CP:REACTOME,C2,18,32
Cohort,-0.03716933906557904,0.06089026835853217,-0.6104315199716267,0.5417422961590617,LGP Proband,RAF-independent MAPK1/3 activation,CP:REACTOME,C2,18,42
Cohort,-0.021139784323578922,0.02053430418952979,-1.0294862746972386,0.30356393541152754,LonGen OPEL,RAF-independent MAPK1/3 activation,CP:REACTOME,C2,33,28
Cohort,-0.036904769320926935,0.018837112142558315,-1.9591521801024223,0.05050561072196783,LGP Offspring,Rap1 signalling,CP:REACTOME,C2,16,18
Cohort,-0.05344584248288423,0.059807992395985866,-0.8936237506355649,0.3717810259847967,LGP Proband,Rap1 signalling,CP:REACTOME,C2,16,37
Cohort,0.014552929073132813,0.017145245135139806,0.8488026247758951,0.39624631261815124,LonGen OPEL,Rap1 signalling,CP:REACTOME,C2,19,27
Cohort,-0.012499471058419791,0.024527008816491735,-0.5096206859931188,0.610483553029308,LGP Offspring,Ras activation upon Ca2+ influx through NMDA receptor,CP:REACTOME,C2,19,40
Cohort,0.030501440913445806,0.0709291148586137,0.43002709076866036,0.6672870230894437,LGP Proband,Ras activation upon Ca2+ influx through NMDA receptor,CP:REACTOME,C2,19,63
Cohort,0.0061608316979901165,0.023142056222227363,0.2662179902610725,0.7901402700141699,LonGen OPEL,Ras activation upon Ca2+ influx through NMDA receptor,CP:REACTOME,C2,31,40
Cohort,-0.003929016943358778,0.007117095906971502,-0.5520533929450264,0.5810942306613799,LGP Offspring,RAS processing,CP:REACTOME,C2,2,3
Cohort,-0.005469548578034478,0.023260819645607504,-0.2351399762074734,0.8141578134823879,LGP Proband,RAS processing,CP:REACTOME,C2,2,7
Cohort,0.0023504348225307724,0.007300306386989682,0.32196385986204973,0.7475646064711214,LonGen OPEL,RAS processing,CP:REACTOME,C2,3,5
Cohort,0.0016998700726805465,0.01574795097815954,0.10794230151199073,0.9140734904853215,LGP Offspring,RAS signaling downstream of NF1 loss-of-function variants,CP:REACTOME,C2,8,17
Cohort,0.03567039107396156,0.05085621817133568,0.7013968469654439,0.4832510519069768,LGP Proband,RAS signaling downstream of NF1 loss-of-function variants,CP:REACTOME,C2,8,33
Cohort,0.0293058053945295,0.016148487241336492,1.8147709414856665,0.06993538805465715,LonGen OPEL,RAS signaling downstream of NF1 loss-of-function variants,CP:REACTOME,C2,12,27
Cohort,-0.021891105305649965,0.015316718624375256,-1.4292294480628593,0.15340023005836348,LGP Offspring,Reactions specific to the complex N-glycan synthesis pathway,CP:REACTOME,C2,11,13
Cohort,0.0027673923234591094,0.041710113022130395,0.066348233628396,0.9471164841041748,LGP Proband,Reactions specific to the complex N-glycan synthesis pathway,CP:REACTOME,C2,11,18
Cohort,0.003875899280247526,0.010316578297382653,0.37569620163992296,0.7072428586178683,LonGen OPEL,Reactions specific to the complex N-glycan synthesis pathway,CP:REACTOME,C2,6,8
Cohort,0.011612705916612355,0.007836052553810985,1.4819586567173586,0.1388172795797277,LGP Offspring,Receptor Mediated Mitophagy,CP:REACTOME,C2,0,6
Cohort,-0.010176478546160779,0.011199306201219608,-0.9086704446970615,0.3637866097502229,LGP Proband,Receptor Mediated Mitophagy,CP:REACTOME,C2,0,2
Cohort,0.0069842901954756155,0.005783785376653133,1.20756386010941,0.22757374395669816,LonGen OPEL,Receptor Mediated Mitophagy,CP:REACTOME,C2,1,4
Cohort,-0.04716526974261075,0.024415163698710156,-1.931802314522367,0.053801520887008514,LGP Offspring,Receptor-type tyrosine-protein phosphatases,CP:REACTOME,C2,25,34
Cohort,0.07407974589035135,0.07743574059374457,0.9566609077712582,0.3390156569165962,LGP Proband,Receptor-type tyrosine-protein phosphatases,CP:REACTOME,C2,25,68
Cohort,-0.01253038582675701,0.023377202430788925,-0.5360087830806425,0.5921022229439636,LonGen OPEL,Receptor-type tyrosine-protein phosphatases,CP:REACTOME,C2,37,37
Cohort,-0.03564076120428444,0.020802857285347254,-1.7132627847900703,0.08712269706306208,LGP Offspring,Recognition and association of DNA glycosylase with site containing an affected purine,CP:REACTOME,C2,19,25
Cohort,-0.06460601827171615,0.05547685849083456,-1.16455798019619,0.24453096747741113,LGP Proband,Recognition and association of DNA glycosylase with site containing an affected purine,CP:REACTOME,C2,19,30
Cohort,0.030451435138046958,0.01594589698077353,1.9096721353940274,0.05653463805843174,LonGen OPEL,Recognition and association of DNA glycosylase with site containing an affected purine,CP:REACTOME,C2,13,27
Cohort,-0.0150427163871686,0.028293559910912994,-0.5316657371689214,0.5951321903161266,LGP Offspring,Recognition of DNA damage by PCNA-containing replication complex,CP:REACTOME,C2,28,55
Cohort,-0.03117735182287295,0.07664058579765598,-0.40679949792119796,0.6842596294470229,LGP Proband,Recognition of DNA damage by PCNA-containing replication complex,CP:REACTOME,C2,28,72
Cohort,0.005295515278206117,0.02434998108717593,0.2174751290051323,0.8278938194160295,LonGen OPEL,Recognition of DNA damage by PCNA-containing replication complex,CP:REACTOME,C2,41,50
Cohort,-0.05127864472173648,0.053100695309995366,-0.9656868789076682,0.3345462239795224,LGP Offspring,Recruitment of mitotic centrosome proteins and complexes,CP:REACTOME,C2,105,187
Cohort,-0.10548739493420213,0.16342240969117822,-0.6454891659812338,0.518787777846454,LGP Proband,Recruitment of mitotic centrosome proteins and complexes,CP:REACTOME,C2,105,318
Cohort,0.007911474293715935,0.04858988593035047,0.16282142141795455,0.8707003667571597,LonGen OPEL,Recruitment of mitotic centrosome proteins and complexes,CP:REACTOME,C2,158,197
Cohort,-0.023560955885678407,0.05619004697268493,-0.41930835005587097,0.67512400455606425,LGP Offspring,Recruitment of NuMA to mitotic centrosomes,CP:REACTOME,C2,113,219
Cohort,-0.1387933030219953,0.1725919828200411,-0.8041700474970084,0.4215279335189688,LGP Proband,Recruitment of NuMA to mitotic centrosomes,CP:REACTOME,C2,113,359
Cohort,-0.004247872219681331,0.05120915158001089,-0.08295142740344592,0.9339110165619857,LonGen OPEL,Recruitment of NuMA to mitotic centrosomes,CP:REACTOME,C2,180,217
Cohort,0.008859432442646779,0.030956685924183873,0.28618801328877536,0.7748218044048785,LGP Offspring,Recycling of bile acids and salts,CP:REACTOME,C2,33,65
Cohort,-0.0373600633923214,0.086844155179151,-0.4301966357465421,0.6671637467635894,LGP Proband,Recycling of bile acids and salts,CP:REACTOME,C2,33,105
Cohort,-0.026200577833220787,0.025235696143748307,-1.038234795821613,0.29947602792490957,LonGen OPEL,Recycling of bile acids and salts,CP:REACTOME,C2,50,51
Cohort,-0.0035957182469768256,0.007201850329341395,-0.49927700279014986,0.6177466982387945,LGP Offspring,Recycling of eIF2:GDP,CP:REACTOME,C2,2,3
Cohort,0.0017198592930455303,0.013641604544710655,0.1260745601742562,0.8997032907547801,LGP Proband,Recycling of eIF2:GDP,CP:REACTOME,C2,2,1
Cohort,-5.657582569006227e-4,0.006332614354674578,-0.08934039327422395,0.9288338664455122,LonGen OPEL,Recycling of eIF2:GDP,CP:REACTOME,C2,3,3
Cohort,0.022608710187947547,0.025696290066442362,0.8798433598581226,0.3792568356703283,LGP Offspring,Recycling pathway of L1,CP:REACTOME,C2,18,51
Cohort,0.05736852296800234,0.0788117961174288,0.7279179741383359,0.46686810939746504,LGP Proband,Recycling pathway of L1,CP:REACTOME,C2,18,77
Cohort,-0.01960413041861812,0.022706308204294506,-0.8633781521079829,0.38818965154361906,LonGen OPEL,Recycling pathway of L1,CP:REACTOME,C2,40,38
Cohort,-0.002160855189913686,0.018425560251920194,-0.1172748703632225,0.9066770721089468,LGP Offspring,Reduction of cytosolic Ca++ levels,CP:REACTOME,C2,13,22
Cohort,-0.051363987821856416,0.04688979546078212,-1.095419319216618,0.27364920512506535,LGP Proband,Reduction of cytosolic Ca++ levels,CP:REACTOME,C2,13,26
Cohort,-0.008872489536835183,0.015684900176847354,-0.5656707684969495,0.5717770238323787,LonGen OPEL,Reduction of cytosolic Ca++ levels,CP:REACTOME,C2,19,18
Cohort,-0.020168446961984932,0.014864092484086431,-1.3568569344934693,0.17527957504023367,LGP Offspring,Reelin signalling pathway,CP:REACTOME,C2,9,13
Cohort,0.04140061880672489,0.04819206118650942,0.8590754947479672,0.39054571131401083,LGP Proband,Reelin signalling pathway,CP:REACTOME,C2,9,30
Cohort,-0.006687717452424715,0.012251910426088121,-0.5458509913837183,0.5853213057046026,LonGen OPEL,Reelin signalling pathway,CP:REACTOME,C2,12,11
Cohort,-0.06338502474070995,0.031172331038579196,-2.033374554577391,0.04240481321742487,LGP Offspring,Regulated Necrosis,CP:REACTOME,C2,41,58
Cohort,-0.05866904934150849,0.0911344512340115,-0.6437636760533115,0.5199056767109138,LGP Proband,Regulated Necrosis,CP:REACTOME,C2,41,88
Cohort,-0.016242684730092608,0.02700395958188409,-0.6014927063136769,0.5476831270783372,LonGen OPEL,Regulated Necrosis,CP:REACTOME,C2,51,57
Cohort,0.006151992614105276,0.018194456602513003,0.3381245589525091,0.735374304603779,LGP Offspring,Regulated proteolysis of p75NTR,CP:REACTOME,C2,10,25
Cohort,0.021489962847217985,0.04455424336574661,0.48233257314699485,0.6296962727711499,LGP Proband,Regulated proteolysis of p75NTR,CP:REACTOME,C2,10,23
Cohort,0.004069717137331008,0.01728314539023569,0.23547317605915882,0.8139020626560308,LonGen OPEL,Regulated proteolysis of p75NTR,CP:REACTOME,C2,19,23
Cohort,-0.006036768421946412,0.01516529117997153,-0.3980647882263574,0.6907081093042327,LGP Offspring,Regulation by c-FLIP,CP:REACTOME,C2,8,15
Cohort,-0.021353443213327935,0.03905738573137593,-0.5467197256926004,0.5847175398361167,LGP Proband,Regulation by c-FLIP,CP:REACTOME,C2,8,17
Cohort,-0.008194956003447587,0.011686058811989171,-0.7012591785897971,0.4833462384119659,LonGen OPEL,Regulation by c-FLIP,CP:REACTOME,C2,12,9
Cohort,-0.004148271328554651,0.0032096511657664314,-1.2924368145670704,0.19664751244257037,LGP Offspring,Regulation of BACH1 activity,CP:REACTOME,C2,1,0
Cohort,-0.012278601231229317,0.013572269219280526,-0.9046829997880202,0.3658946061524667,LGP Proband,Regulation of BACH1 activity,CP:REACTOME,C2,1,2
Cohort,-0.0013329110824159165,0.0036629009560606657,-0.3638949287477924,0.716033103455527,LonGen OPEL,Regulation of BACH1 activity,CP:REACTOME,C2,1,1
Cohort,-0.03311667230201745,0.035167917984696165,-0.9416728143084461,0.3466965640700276,LGP Offspring,Regulation of beta-cell development,CP:REACTOME,C2,40,74
Cohort,-0.014348776196784692,0.09478574330271389,-0.1513811644749096,0.8797116554312411,LGP Proband,Regulation of beta-cell development,CP:REACTOME,C2,40,94
Cohort,0.008671485054836345,0.029701475521226834,0.2919546892085907,0.7703973401823222,LonGen OPEL,Regulation of beta-cell development,CP:REACTOME,C2,59,74
Cohort,0.001988339499253741,0.04252450796506694,0.04675749572192872,0.9627203149501934,LGP Offspring,Regulation of cholesterol biosynthesis by SREBP (SREBF),CP:REACTOME,C2,64,134
Cohort,-0.20437416184969187,0.11955057851757254,-1.7095204756340954,0.08772656978713726,LGP Proband,Regulation of cholesterol biosynthesis by SREBP (SREBF),CP:REACTOME,C2,64,172
Cohort,-0.010095648407174215,0.03965777141811938,-0.2545692318595991,0.7991215763147596,LonGen OPEL,Regulation of cholesterol biosynthesis by SREBP (SREBF),CP:REACTOME,C2,110,125
Cohort,-0.02501636638438323,0.020425168774165555,-1.2247813793355173,0.22108421600452605,LGP Offspring,Regulation of commissural axon pathfinding by SLIT and ROBO,CP:REACTOME,C2,17,24
Cohort,0.03895138075736112,0.0638392925124203,0.6101474377991094,0.5419303567352283,LGP Proband,Regulation of commissural axon pathfinding by SLIT and ROBO,CP:REACTOME,C2,17,49
Cohort,-4.269552702638477e-4,0.019858887435776768,-0.02149945567920722,0.9828526256545647,LonGen OPEL,Regulation of commissural axon pathfinding by SLIT and ROBO,CP:REACTOME,C2,27,35
Cohort,-0.015473904190595184,0.020066467424094882,-0.7711324501498873,0.4408978727041911,LGP Offspring,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,CP:REACTOME,C2,14,17
Cohort,-0.09041256858375837,0.0555074512359268,-1.6288366078902121,0.10372525636641634,LGP Proband,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,CP:REACTOME,C2,14,28
Cohort,0.0180916216960925,0.014787565951714494,1.223434725847828,0.22152758632581118,LonGen OPEL,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,CP:REACTOME,C2,12,22
Cohort,0.024714293724944672,0.04227542377311855,0.584601915703554,0.5590104702677922,LGP Offspring,Regulation of expression of SLITs and ROBOs,CP:REACTOME,C2,48,113
Cohort,0.11339642148687903,0.11867723853331381,0.9555026969644865,0.3396004142408737,LGP Proband,Regulation of expression of SLITs and ROBOs,CP:REACTOME,C2,48,190
Cohort,-0.04068861178672906,0.036854375276005845,-1.1040374848849903,0.2699105064589973,LonGen OPEL,Regulation of expression of SLITs and ROBOs,CP:REACTOME,C2,96,104
Cohort,0.029523343722040782,0.020929509242307926,1.410608504014077,0.15882007302273368,LGP Offspring,Regulation of FOXO transcriptional activity by acetylation,CP:REACTOME,C2,10,35
Cohort,0.030708127595760252,0.05367985538459099,0.5720605500098858,0.5674351105719176,LGP Proband,Regulation of FOXO transcriptional activity by acetylation,CP:REACTOME,C2,10,34
Cohort,-0.026350439379140903,0.02181926256895363,-1.207668650389433,0.22753344042832782,LonGen OPEL,Regulation of FOXO transcriptional activity by acetylation,CP:REACTOME,C2,36,32
Cohort,-0.01714781153687277,0.026736985493920454,-0.641351716362037,0.5215115782530516,LGP Offspring,Regulation of FZD by ubiquitination,CP:REACTOME,C2,26,46
Cohort,-0.10658193671604407,0.07763895839023699,-1.372789369227893,0.1701868495510888,LGP Proband,Regulation of FZD by ubiquitination,CP:REACTOME,C2,26,73
Cohort,5.852806872063585e-4,0.02015029517693257,0.029045762459915206,0.97683537336476,LonGen OPEL,Regulation of FZD by ubiquitination,CP:REACTOME,C2,29,34
Cohort,0.032294660337765006,0.01858594917288934,1.7375846687922765,0.08273944281719119,LGP Offspring,Regulation of gene expression by Hypoxia-inducible Factor,CP:REACTOME,C2,6,27
Cohort,-0.07298861476142303,0.03981203773251967,-1.8333302920037104,0.06710973069642162,LGP Proband,Regulation of gene expression by Hypoxia-inducible Factor,CP:REACTOME,C2,6,18
Cohort,0.011310141821967722,0.017569690458660515,0.6437302836142277,0.5199357696767957,LonGen OPEL,Regulation of gene expression by Hypoxia-inducible Factor,CP:REACTOME,C2,17,25
Cohort,-0.02130324912485842,0.02771823088939836,-0.7685645310432299,0.4424202801136716,LGP Offspring,Regulation of gene expression in beta cells,CP:REACTOME,C2,24,45
Cohort,-0.002825704576507453,0.06772508733183234,-0.041723158844555776,0.9667293782153517,LGP Proband,Regulation of gene expression in beta cells,CP:REACTOME,C2,24,47
Cohort,0.026405164995806203,0.01841010885470644,1.4342753323294921,0.15188643059581766,LonGen OPEL,Regulation of gene expression in beta cells,CP:REACTOME,C2,18,34
Cohort,-0.008627141219793608,0.005546655180077368,-1.555377239021603,0.12032427177061765,LGP Offspring,Regulation of gene expression in early pancreatic precursor cells,CP:REACTOME,C2,2,1
Cohort,-0.008219199899789309,0.024856862293127623,-0.33066119942506733,0.7409834649750244,LGP Proband,Regulation of gene expression in early pancreatic precursor cells,CP:REACTOME,C2,2,8
Cohort,0.001844347143688874,0.007327845271567728,0.2516902411743053,0.8013454659286499,LonGen OPEL,Regulation of gene expression in early pancreatic precursor cells,CP:REACTOME,C2,3,5
Cohort,0.0016611134119014358,0.003222168872091942,0.5155264909573111,0.6063537120491795,LGP Offspring,Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells,CP:REACTOME,C2,0,1
Cohort,7.730496574500071e-4,0.007859362740870056,0.09836034840713155,0.9216697939871987,LGP Proband,Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells,CP:REACTOME,C2,0,1
Cohort,0.0030991338660252814,0.002600465453107462,1.1917612142556744,0.23371008105529312,LonGen OPEL,Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells,CP:REACTOME,C2,0,1
Cohort,-0.011813423177159018,0.020978431429656677,-0.5631223295588573,0.5735383080239553,LGP Offspring,Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,CP:REACTOME,C2,16,29
Cohort,-3.923442239327234e-4,0.06166439107711182,-0.006362573554680752,0.994924956610363,LGP Proband,Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,CP:REACTOME,C2,16,45
Cohort,-0.02083281380699513,0.023426059153736953,-0.8893008282048948,0.374110096474089,LonGen OPEL,Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,CP:REACTOME,C2,41,39
Cohort,-0.02540483299973768,0.039556191955433126,-0.6422466810849894,0.520930765656825,LGP Offspring,Regulation of Glucokinase by Glucokinase Regulatory Protein,CP:REACTOME,C2,57,107
Cohort,-0.24553619197615273,0.10642296516536735,-2.3071730015661718,0.021289297348859697,LGP Proband,Regulation of Glucokinase by Glucokinase Regulatory Protein,CP:REACTOME,C2,57,134
Cohort,3.705445389716494e-4,0.03684611208842719,0.010056543770001501,0.9919786940574049,LonGen OPEL,Regulation of Glucokinase by Glucokinase Regulatory Protein,CP:REACTOME,C2,91,106
Cohort,-0.001964649905000307,0.01224796128030573,-0.16040627987283007,0.8726089632623519,LGP Offspring,"Regulation of glycolysis by fructose 2,6-bisphosphate metabolism",CP:REACTOME,C2,5,10
Cohort,0.019673493459087435,0.04524404418236996,0.4348305686332416,0.6637979037875333,LGP Proband,"Regulation of glycolysis by fructose 2,6-bisphosphate metabolism",CP:REACTOME,C2,5,25
Cohort,0.029165907329105522,0.01424163695872574,2.047932229534597,0.040894274224605655,LonGen OPEL,"Regulation of glycolysis by fructose 2,6-bisphosphate metabolism",CP:REACTOME,C2,6,19
Cohort,0.04540972167979993,0.0357242404849173,1.271117903793415,0.2041239160717766,LGP Offspring,Regulation of HMOX1 expression and activity,CP:REACTOME,C2,31,86
Cohort,-0.054249308744411064,0.09427808928901227,-0.5754179911104075,0.5651638511997672,LGP Proband,Regulation of HMOX1 expression and activity,CP:REACTOME,C2,31,118
Cohort,-0.044498634687642674,0.029291966619609647,-1.519141246660197,0.12912401903301052,LonGen OPEL,Regulation of HMOX1 expression and activity,CP:REACTOME,C2,64,59
Cohort,-0.018264011135034407,0.05543053915439525,-0.3294936584355089,0.7418846520883903,LGP Offspring,Regulation of HSF1-mediated heat shock response,CP:REACTOME,C2,96,192
Cohort,-0.09090622735273048,0.1390085300912902,-0.6539615036072262,0.5133168813454327,LGP Proband,Regulation of HSF1-mediated heat shock response,CP:REACTOME,C2,96,229
Cohort,-0.026401729458114285,0.0527159591439889,-0.5008299172931737,0.6166292820718624,LonGen OPEL,Regulation of HSF1-mediated heat shock response,CP:REACTOME,C2,177,199
Cohort,-0.09341343633192667,0.02127164742240101,-4.391452832823549,1.3065846723669817e-5,LGP Offspring,Regulation of IFNA signaling,CP:REACTOME,C2,27,17
Cohort,-0.025992036775872175,0.06603225249735976,-0.39362638396912847,0.6939575085977676,LGP Proband,Regulation of IFNA signaling,CP:REACTOME,C2,27,41
Cohort,-0.006390368693099985,0.01794410330525473,-0.35612638783842915,0.7218402817061573,LonGen OPEL,Regulation of IFNA signaling,CP:REACTOME,C2,23,28
Cohort,-1.816442819963941e-4,0.011918954333009107,-0.015239951166969147,0.9878452455623838,LGP Offspring,Regulation of IFNG signaling,CP:REACTOME,C2,4,10
Cohort,0.019317905126677273,0.035048861042280985,0.5511706957716325,0.5816642900025242,LGP Proband,Regulation of IFNG signaling,CP:REACTOME,C2,4,16
Cohort,-0.00373125099078067,0.01150510442603407,-0.32431265746162996,0.7457865398956814,LonGen OPEL,Regulation of IFNG signaling,CP:REACTOME,C2,9,9
Cohort,-0.026031223310224165,0.018284922593104488,-1.4236441624336391,0.15501088370474708,LGP Offspring,Regulation of innate immune responses to cytosolic DNA,CP:REACTOME,C2,15,19
Cohort,-0.07946582201012817,0.04792772705705281,-1.6580344383019174,0.09768655604992113,LGP Proband,Regulation of innate immune responses to cytosolic DNA,CP:REACTOME,C2,15,24
Cohort,0.00768946083301685,0.015191910066414098,0.5061549732325313,0.6128880104527167,LonGen OPEL,Regulation of innate immune responses to cytosolic DNA,CP:REACTOME,C2,15,21
Cohort,-0.11581430721277952,0.06597744097230877,-1.7553622193590026,0.0796502901911472,LGP Offspring,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),CP:REACTOME,C2,146,259
Cohort,-0.19594399390893738,0.18409097387652873,-1.0643867528255815,0.28746159742242083,LGP Proband,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),CP:REACTOME,C2,146,380
Cohort,-0.10254985714709851,0.05410895138720183,-1.895247542560106,0.05842167632836473,LonGen OPEL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),CP:REACTOME,C2,226,223
Cohort,-0.06047397182142459,0.04290031583915761,-1.4096393147349857,0.1591060939198129,LGP Offspring,Regulation of insulin secretion,CP:REACTOME,C2,63,111
Cohort,-0.016228452557841253,0.12682252499695282,-0.12796191022242442,0.8982099643994282,LGP Proband,Regulation of insulin secretion,CP:REACTOME,C2,63,199
Cohort,0.040419078347686085,0.03930721804884758,1.028286415422653,0.30412747507651533,LonGen OPEL,Regulation of insulin secretion,CP:REACTOME,C2,98,130
Cohort,0.02609500063219532,0.01834764623256268,1.4222533125738461,0.1554139638354332,LGP Offspring,Regulation of KIT signaling,CP:REACTOME,C2,8,24
Cohort,0.032368421376835425,0.04961305922791511,0.6524173651163023,0.5143117401868527,LGP Proband,Regulation of KIT signaling,CP:REACTOME,C2,8,32
Cohort,0.004028288219002662,0.013077174074336706,0.3080396571999431,0.758132743501235,LonGen OPEL,Regulation of KIT signaling,CP:REACTOME,C2,11,13
Cohort,-0.025482810181887767,0.06270251537307445,-0.4064081007000643,0.6845713938648965,LGP Offspring,Regulation of lipid metabolism by PPARalpha,CP:REACTOME,C2,135,270
Cohort,0.25777105739052414,0.18880761123943368,1.3652577652901685,0.1725401887194232,LGP Proband,Regulation of lipid metabolism by PPARalpha,CP:REACTOME,C2,135,419
Cohort,-0.020714613701683215,0.058127683995775045,-0.3563639952210867,0.7216624239225982,LonGen OPEL,Regulation of lipid metabolism by PPARalpha,CP:REACTOME,C2,234,276
Cohort,-0.004096788565705247,0.013809519577126861,-0.2966640905083249,0.7668140993003919,LGP Offspring,Regulation of localization of FOXO transcription factors,CP:REACTOME,C2,6,13
Cohort,0.023763982155203606,0.03745369038653844,0.6344897367909259,0.5259352648176769,LGP Proband,Regulation of localization of FOXO transcription factors,CP:REACTOME,C2,6,17
Cohort,-0.00681026344485828,0.012063466607475136,-0.5645361873541636,0.5725483211024077,LonGen OPEL,Regulation of localization of FOXO transcription factors,CP:REACTOME,C2,11,11
Cohort,-0.05584123579187765,0.030841675162448488,-1.8105772626730587,0.0706501571042618,LGP Offspring,Regulation of MECP2 expression and activity,CP:REACTOME,C2,36,54
Cohort,0.03053856720982802,0.08535960657446565,0.35776368279283144,0.7206106924229776,LGP Proband,Regulation of MECP2 expression and activity,CP:REACTOME,C2,36,85
Cohort,-0.0070330127351320194,0.024932949436625558,-0.2820770464003264,0.7779577551557817,LonGen OPEL,Regulation of MECP2 expression and activity,CP:REACTOME,C2,46,55
Cohort,-0.03310810959111761,0.042878126922341275,-0.7721444934169202,0.44029870395765214,LGP Offspring,Regulation of mRNA stability by proteins that bind AU-rich elements,CP:REACTOME,C2,66,122
Cohort,-0.1045681824452944,0.11844746254402155,-0.8828233226729626,0.3775861257678549,LGP Proband,Regulation of mRNA stability by proteins that bind AU-rich elements,CP:REACTOME,C2,66,175
Cohort,0.030150012683108827,0.036197092655816075,0.8329401747757326,0.405128313322602,LonGen OPEL,Regulation of mRNA stability by proteins that bind AU-rich elements,CP:REACTOME,C2,92,125
Cohort,-0.009377678306312113,0.05563081823343063,-0.16856984319307958,0.8661854257992143,LGP Offspring,Regulation of PLK1 Activity at G2/M Transition,CP:REACTOME,C2,104,199
Cohort,0.00856697581043287,0.1725985900681168,0.04963525951777401,0.9604249324924488,LGP Proband,Regulation of PLK1 Activity at G2/M Transition,CP:REACTOME,C2,104,342
Cohort,-0.02544268379336962,0.05088892105504912,-0.4999650860321244,0.6172378402794811,LonGen OPEL,Regulation of PLK1 Activity at G2/M Transition,CP:REACTOME,C2,174,206
Cohort,0.028623570883794285,0.031337299472411886,0.9134026021927428,0.3613564864622284,LGP Offspring,Regulation of PTEN gene transcription,CP:REACTOME,C2,26,71
Cohort,0.22467964520615857,0.09547237722615619,2.3533471327935467,0.018836526631426105,LGP Proband,Regulation of PTEN gene transcription,CP:REACTOME,C2,26,129
Cohort,-0.01057711986573531,0.02593430691721997,-0.40784278135893687,0.6834987722769865,LonGen OPEL,Regulation of PTEN gene transcription,CP:REACTOME,C2,45,55
Cohort,-0.007238004783817404,0.014767857153991776,-0.49011882416948754,0.6242088455113637,LGP Offspring,Regulation of PTEN localization,CP:REACTOME,C2,9,13
Cohort,-0.045134776267263706,0.03714680616073821,-1.2150378708726852,0.22469551575903807,LGP Proband,Regulation of PTEN localization,CP:REACTOME,C2,9,14
Cohort,6.970902384935748e-4,0.010632043272454601,0.06556503022326758,0.94774059368884,LonGen OPEL,Regulation of PTEN localization,CP:REACTOME,C2,7,10
Cohort,0.011644481276648168,0.017531525073626243,0.664202414093779,0.5067872499261654,LGP Offspring,Regulation of PTEN mRNA translation,CP:REACTOME,C2,8,23
Cohort,0.03163098215637244,0.04822966742825115,0.6558407686187814,0.5121074626099525,LGP Proband,Regulation of PTEN mRNA translation,CP:REACTOME,C2,8,29
Cohort,0.0019752786208193157,0.013940203615763772,0.14169654011263105,0.8873555613661391,LonGen OPEL,Regulation of PTEN mRNA translation,CP:REACTOME,C2,13,17
Cohort,0.0012230697344264847,0.041839676998133485,0.02923229389368965,0.9766879532520925,LGP Offspring,Regulation of PTEN stability and activity,CP:REACTOME,C2,50,104
Cohort,-0.05506070307318202,0.10253580735332402,-0.5369899988542594,0.5914177468301023,LGP Proband,Regulation of PTEN stability and activity,CP:REACTOME,C2,50,129
Cohort,-0.014903319931750597,0.03449229370596062,-0.4320768012356091,0.6658026112101729,LonGen OPEL,Regulation of PTEN stability and activity,CP:REACTOME,C2,81,92
Cohort,-0.005137975349296929,0.027079039444425256,-0.1897399411024781,0.8495698785008368,LGP Offspring,Regulation of pyruvate dehydrogenase (PDH) complex,CP:REACTOME,C2,23,44
Cohort,0.080522769089972,0.07188986168182573,1.1200851859522873,0.26299991370539,LGP Proband,Regulation of pyruvate dehydrogenase (PDH) complex,CP:REACTOME,C2,23,60
Cohort,-0.024016788262269294,0.022822071046816387,-1.0523492023577574,0.2929587130999362,LonGen OPEL,Regulation of pyruvate dehydrogenase (PDH) complex,CP:REACTOME,C2,42,39
Cohort,0.03748849630328159,0.04014727770752671,0.9337743041106207,0.35075373403953025,LGP Offspring,Regulation of RAS by GAPs,CP:REACTOME,C2,40,97
Cohort,-0.0380353028623615,0.10927977672863631,-0.3480543610261102,0.7278871887768844,LGP Proband,Regulation of RAS by GAPs,CP:REACTOME,C2,40,149
Cohort,0.017670715695623486,0.033987406819995444,0.5199195039860313,0.6032642349069162,LonGen OPEL,Regulation of RAS by GAPs,CP:REACTOME,C2,72,95
Cohort,0.002670224061640043,0.022717395401559072,0.11754094227971171,0.906466315696441,LGP Offspring,Regulation of RUNX1 Expression and Activity,CP:REACTOME,C2,16,35
Cohort,-0.023909908944637792,0.059434297892233055,-0.40229143428246616,0.6875726399586768,LGP Proband,Regulation of RUNX1 Expression and Activity,CP:REACTOME,C2,16,38
Cohort,0.004959295525129068,0.016709510100457018,0.29679478903414575,0.7667006099211283,LonGen OPEL,Regulation of RUNX1 Expression and Activity,CP:REACTOME,C2,17,22
Cohort,0.04647542722939193,0.03793142671389521,1.2252485934668742,0.2209082979078727,LGP Offspring,Regulation of RUNX2 expression and activity,CP:REACTOME,C2,39,98
Cohort,0.019256629473632113,0.10206982210548045,0.18866134060400372,0.8504041507520198,LGP Proband,Regulation of RUNX2 expression and activity,CP:REACTOME,C2,39,130
Cohort,-0.0070038528901343695,0.03299459472260273,-0.21227273585319797,0.8319486078283301,LonGen OPEL,Regulation of RUNX2 expression and activity,CP:REACTOME,C2,71,86
Cohort,0.02549866781295142,0.030291283582667198,0.8417823478283326,0.40020748287815855,LGP Offspring,Regulation of RUNX3 expression and activity,CP:REACTOME,C2,20,52
Cohort,-0.090169590984599493,0.07216393481521464,-1.2495104544325462,0.21182897740317064,LGP Proband,Regulation of RUNX3 expression and activity,CP:REACTOME,C2,20,66
Cohort,-0.009065486220859082,0.023762333835777007,-0.38150655922567334,0.7029292172705637,LonGen OPEL,Regulation of RUNX3 expression and activity,CP:REACTOME,C2,38,40
Cohort,0.008971961692179425,0.021205310447250564,0.4230997567565775,0.6723570439900766,LGP Offspring,Regulation of signaling by CBL,CP:REACTOME,C2,14,29
Cohort,-0.04767401263132606,0.052971669852939426,-0.8999907453112054,0.36838496462292714,LGP Proband,Regulation of signaling by CBL,CP:REACTOME,C2,14,35
Cohort,-0.00706738652246104,0.016910554093639653,-0.41792755478776444,0.676112798688608,LonGen OPEL,Regulation of signaling by CBL,CP:REACTOME,C2,21,22
Cohort,-5.257623156028195e-4,0.007840278174015346,-0.06705914049648494,0.9465544499754007,LGP Offspring,Regulation of signaling by NODAL,CP:REACTOME,C2,2,4
Cohort,0.007766512081333604,0.025903162916104016,0.2998287161489903,0.7643825206894095,LGP Proband,Regulation of signaling by NODAL,CP:REACTOME,C2,2,9
Cohort,-0.004753720626491138,0.01026983601705236,-0.46288184335153065,0.643575577340745,LonGen OPEL,Regulation of signaling by NODAL,CP:REACTOME,C2,9,7
Cohort,-0.041306716657231936,0.03200816935668582,-1.2905054393122875,0.19731643792649445,LGP Offspring,Regulation of TLR by endogenous ligand,CP:REACTOME,C2,43,67
Cohort,-0.1351749238972241,0.09691842840276278,-1.3947288057074063,0.16346899289119696,LGP Proband,Regulation of TLR by endogenous ligand,CP:REACTOME,C2,43,106
Cohort,0.08632946081802538,0.03141742575738816,2.7478209540361225,0.006134990868786706,LonGen OPEL,Regulation of TLR by endogenous ligand,CP:REACTOME,C2,48,88
Cohort,-0.01684227408762469,0.02874402579404433,-0.585939986566334,0.5581114172409083,LGP Offspring,Regulation of TNFR1 signaling,CP:REACTOME,C2,27,54
Cohort,0.022018586107731757,0.08171175297119831,0.2694665737435941,0.7876373153195658,LGP Proband,Regulation of TNFR1 signaling,CP:REACTOME,C2,27,76
Cohort,-0.00467291405769408,0.026125030207008196,-0.17886731692430896,0.8580874015379453,LonGen OPEL,Regulation of TNFR1 signaling,CP:REACTOME,C2,45,49
Cohort,-0.07031916063002532,0.0662870110755246,-1.0608286523872175,0.28914663581447003,LGP Offspring,Regulation of TP53 Activity,CP:REACTOME,C2,143,273
Cohort,0.23836722736022303,0.18101374478459126,1.316846008814873,0.1882519682762207,LGP Proband,Regulation of TP53 Activity,CP:REACTOME,C2,143,389
Cohort,0.04060402347835038,0.055863349625527955,0.7268454854664766,0.4675343096111939,LonGen OPEL,Regulation of TP53 Activity,CP:REACTOME,C2,195,247
Cohort,-0.006620345475070822,0.028288069911217996,-0.23403312759932904,0.8150301190866159,LGP Offspring,Regulation of TP53 Activity through Acetylation,CP:REACTOME,C2,25,54
Cohort,0.14567534226820872,0.07295318059816833,1.9968333261657172,0.04616787576439952,LGP Proband,Regulation of TP53 Activity through Acetylation,CP:REACTOME,C2,25,67
Cohort,0.003497707910151764,0.021495740362448616,0.16271632663846217,0.8707830894453126,LonGen OPEL,Regulation of TP53 Activity through Acetylation,CP:REACTOME,C2,29,37
Cohort,0.00858908749289641,0.021049342708986226,0.4080454013050784,0.6833695482863988,LGP Offspring,Regulation of TP53 Activity through Association with Co-factors,CP:REACTOME,C2,11,30
Cohort,0.045798869471379434,0.055795771124176545,0.8208304778054154,0.4119773901395416,LGP Proband,Regulation of TP53 Activity through Association with Co-factors,CP:REACTOME,C2,11,35
Cohort,-0.020948830631944918,0.016649615241903233,-1.2582171015713055,0.20868218839953212,LonGen OPEL,Regulation of TP53 Activity through Association with Co-factors,CP:REACTOME,C2,21,22
Cohort,-0.010120465569370136,0.03006799279672332,-0.3365860048520771,0.7365334675454933,LGP Offspring,Regulation of TP53 Activity through Methylation,CP:REACTOME,C2,29,58
Cohort,0.050050214851294926,0.08344003766607348,0.599834518910401,0.5487794561433619,LGP Proband,Regulation of TP53 Activity through Methylation,CP:REACTOME,C2,29,81
Cohort,0.0395488715820547,0.027495037359034736,1.4384003580580382,0.150713536101249,LonGen OPEL,Regulation of TP53 Activity through Methylation,CP:REACTOME,C2,46,63
Cohort,-0.02398218515543741,0.04757496025600793,-0.5040925946419231,0.6143605585560079,LGP Offspring,Regulation of TP53 Activity through Phosphorylation,CP:REACTOME,C2,78,155
Cohort,0.24139491486427994,0.13960895262760004,1.7290790477326259,0.08416499831555284,LGP Proband,Regulation of TP53 Activity through Phosphorylation,CP:REACTOME,C2,78,240
Cohort,0.007316097840739106,0.04201141608201418,0.17414547099428182,0.8617954175587736,LonGen OPEL,Regulation of TP53 Activity through Phosphorylation,CP:REACTOME,C2,122,142
Cohort,-0.028960178990609483,0.02936250240345513,-0.986298054323929,0.32433975223279765,LGP Offspring,Regulation of TP53 Expression and Degradation,CP:REACTOME,C2,30,52
Cohort,0.07081189700894677,0.08407074574169328,0.8422893883505659,0.3998674589782598,LGP Proband,Regulation of TP53 Expression and Degradation,CP:REACTOME,C2,30,81
Cohort,0.062357952718119315,0.026119043525437712,2.3874516177205343,0.01719804356531006,LonGen OPEL,Regulation of TP53 Expression and Degradation,CP:REACTOME,C2,36,63
Cohort,0.01026549446216129,0.015481315800353432,0.6630892744870519,0.5074994164184515,LGP Offspring,Relaxin receptors,CP:REACTOME,C2,8,17
Cohort,-0.1095111434798808,0.04692188032186203,-2.333903559036549,0.019837454484026507,LGP Proband,Relaxin receptors,CP:REACTOME,C2,8,27
Cohort,-0.02540470449653951,0.015623117544286733,-1.6260969953355973,0.10432482239050843,LonGen OPEL,Relaxin receptors,CP:REACTOME,C2,23,15
Cohort,0,0,NA,NA,LGP Offspring,Release of apoptotic factors from the mitochondria,CP:REACTOME,C2,0,0
Cohort,0.0030178943132869672,0.007876598656256003,0.38314689436283506,0.7017084885379287,LGP Proband,Release of apoptotic factors from the mitochondria,CP:REACTOME,C2,0,1
Cohort,-0.0026955185855357337,0.002605310153340544,-1.0346248342369233,0.3011583687238197,LonGen OPEL,Release of apoptotic factors from the mitochondria,CP:REACTOME,C2,1,0
Cohort,-0.040789472225132184,0.01965106964262444,-2.0756871237511256,0.03830040020242184,LGP Offspring,Release of Hh-Np from the secreting cell,CP:REACTOME,C2,20,20
Cohort,-0.0841912936540979,0.05226479727353084,-1.610860427018934,0.10758852103239169,LGP Proband,Release of Hh-Np from the secreting cell,CP:REACTOME,C2,20,25
Cohort,-0.02975680129915262,0.01624466158915815,-1.8317895473435166,0.0673563106109426,LonGen OPEL,Release of Hh-Np from the secreting cell,CP:REACTOME,C2,23,16
Cohort,0.01231250932749892,0.01694278135531416,0.7267112210969457,0.4676544410323058,LGP Offspring,Removal of aminoterminal propeptides from gamma-carboxylated proteins,CP:REACTOME,C2,8,21
Cohort,0.014760942020727145,0.04236243390036711,0.3484441440603635,0.7275945929933745,LGP Proband,Removal of aminoterminal propeptides from gamma-carboxylated proteins,CP:REACTOME,C2,8,18
Cohort,0.010449945157564696,0.011445605182930493,0.9130094032204882,0.3615140386589015,LonGen OPEL,Removal of aminoterminal propeptides from gamma-carboxylated proteins,CP:REACTOME,C2,8,12
Cohort,-0.012199810705140026,0.022050767872968415,-0.5532601302331754,0.5802682195658357,LGP Offspring,Repression of WNT target genes,CP:REACTOME,C2,18,33
Cohort,0.03256891064981806,0.06644999650260175,0.4901265968997135,0.6241732261169852,LGP Proband,Repression of WNT target genes,CP:REACTOME,C2,18,54
Cohort,-0.021134886491053096,0.02131587783495715,-0.9915090832615284,0.32173835649917626,LonGen OPEL,Repression of WNT target genes,CP:REACTOME,C2,35,34
Cohort,0.033457883234120474,0.05149789207638606,0.6496942279597171,0.5161104515591731,LGP Offspring,Reproduction,CP:REACTOME,C2,86,196
Cohort,-0.0057879052305168455,0.1437016244226182,-0.040277242889718144,0.9678817362229786,LGP Proband,Reproduction,CP:REACTOME,C2,86,261
Cohort,0.06409215972886714,0.04619891704275878,1.3873087040016006,0.1657359343774213,LonGen OPEL,Reproduction,CP:REACTOME,C2,141,188
Cohort,-0.06742634117305304,0.04053500118358703,-1.6634103664552142,0.09669380842008239,LGP Offspring,Resolution of Abasic Sites (AP sites),CP:REACTOME,C2,64,107
Cohort,0.03249203392680846,0.11998287390199568,0.2708055980835113,0.7866075600633611,LGP Proband,Resolution of Abasic Sites (AP sites),CP:REACTOME,C2,64,169
Cohort,0.018043558047461297,0.039553737053875306,0.4561783384180501,0.6483861735995727,LonGen OPEL,Resolution of Abasic Sites (AP sites),CP:REACTOME,C2,98,121
Cohort,0.013466861530372352,0.025938658498009495,0.5191811107504185,0.6038043795488595,LGP Offspring,Resolution of AP sites via the multiple-nucleotide patch replacement pathway,CP:REACTOME,C2,21,47
Cohort,-0.008333215758125923,0.07617101971370002,-0.10940139425003813,0.9129104451098877,LGP Proband,Resolution of AP sites via the multiple-nucleotide patch replacement pathway,CP:REACTOME,C2,21,70
Cohort,-0.0044696104526975415,0.026522073289341173,-0.16852417244823056,0.8662137396819883,LonGen OPEL,Resolution of AP sites via the multiple-nucleotide patch replacement pathway,CP:REACTOME,C2,50,51
Cohort,0.016772246864891774,0.03435204843522476,0.4882459017405619,0.6255340055502889,LGP Offspring,Resolution of D-Loop Structures,CP:REACTOME,C2,39,88
Cohort,0.09267514762468254,0.10577914387256385,0.8761192824204723,0.3812174583177712,LGP Proband,Resolution of D-Loop Structures,CP:REACTOME,C2,39,133
Cohort,-0.032787001000533916,0.031236459199503894,-1.0496388464238817,0.29420276019259606,LonGen OPEL,Resolution of D-Loop Structures,CP:REACTOME,C2,69,70
Cohort,0.019051907234722797,0.03150488286327197,0.6047287119716065,0.5455621887972568,LGP Offspring,Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA),CP:REACTOME,C2,33,75
Cohort,0.06484484089571711,0.09264764742626429,0.6999081217612713,0.4841798629686712,LGP Proband,Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA),CP:REACTOME,C2,33,103
Cohort,-0.022794461382764062,0.027703850294224227,-0.8227903753694594,0.4108736231660899,LonGen OPEL,Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA),CP:REACTOME,C2,56,55
Cohort,0.07510159754765428,0.05300870119928303,1.4167786768688093,0.1570083095424064,LGP Offspring,Resolution of Sister Chromatid Cohesion,CP:REACTOME,C2,76,196
Cohort,-0.13156988212801415,0.1315537866802649,-1.000122348798582,0.317541383083236,LGP Proband,Resolution of Sister Chromatid Cohesion,CP:REACTOME,C2,76,227
Cohort,-0.02803919911655079,0.044393386835553786,-0.6316075684969985,0.5278246771480672,LonGen OPEL,Resolution of Sister Chromatid Cohesion,CP:REACTOME,C2,146,153
Cohort,0.0472164435256778,0.04102558557415559,1.150902366532513,0.2501793302192977,LGP Offspring,Respiratory electron transport,CP:REACTOME,C2,44,114
Cohort,0.054930869675895305,0.11571244279390039,0.4747187800168964,0.6351117096305985,LGP Proband,Respiratory electron transport,CP:REACTOME,C2,44,168
Cohort,-0.020355456351772504,0.03905503486148301,-0.5211992877222479,0.602372915590528,LonGen OPEL,Respiratory electron transport,CP:REACTOME,C2,98,111
Cohort,0.0539078984921286,0.04363712582187771,1.2353677625830612,0.2171228234847475,LGP Offspring,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",CP:REACTOME,C2,52,129
Cohort,0.01479012934659406,0.12158231342207956,0.1216470466000209,0.9032078556077838,LGP Proband,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",CP:REACTOME,C2,52,183
Cohort,-0.011019732479481776,0.04254358726978937,-0.25902217435498204,0.7956850992210914,LonGen OPEL,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",CP:REACTOME,C2,111,131
Cohort,-0.002458200278472871,0.013496654645425848,-0.18213404306866365,0.8555321354200286,LGP Offspring,Response of EIF2AK1 (HRI) to heme deficiency,CP:REACTOME,C2,5,11
Cohort,-0.06141777063889442,0.037587385530613006,-1.6339995392569346,0.10263634485009485,LGP Proband,Response of EIF2AK1 (HRI) to heme deficiency,CP:REACTOME,C2,5,16
Cohort,0.00805980084122395,0.008884006270750085,0.9072259288875371,0.364561890914208,LonGen OPEL,Response of EIF2AK1 (HRI) to heme deficiency,CP:REACTOME,C2,4,8
Cohort,-0.023381902450507037,0.027738726359336153,-0.8429335272142833,0.3995637659170631,LGP Offspring,Response of EIF2AK4 (GCN2) to amino acid deficiency,CP:REACTOME,C2,26,47
Cohort,-0.048057341578929484,0.0798089373185695,-0.6021548863268447,0.5472347100294052,LGP Proband,Response of EIF2AK4 (GCN2) to amino acid deficiency,CP:REACTOME,C2,26,72
Cohort,0.0207056348967088,0.022577331451682038,0.917098415329603,0.35936884377577305,LonGen OPEL,Response of EIF2AK4 (GCN2) to amino acid deficiency,CP:REACTOME,C2,30,44
Cohort,0.009152120738563557,0.01970159365819056,0.4645370774236194,0.6424125763617814,LGP Offspring,Response of Mtb to phagocytosis,CP:REACTOME,C2,12,26
Cohort,4.0535375727186055e-5,0.05334770818331336,7.598334981495067e-4,0.9993939223465953,LGP Proband,Response of Mtb to phagocytosis,CP:REACTOME,C2,12,36
Cohort,-0.03059539731867357,0.018464310133553243,-1.6570019186948004,0.09791314605134446,LonGen OPEL,Response of Mtb to phagocytosis,CP:REACTOME,C2,29,23
Cohort,0.04713508169016012,0.06759024197761557,0.6973651863203899,0.48581404525432503,LGP Offspring,Response to elevated platelet cytosolic Ca2+,CP:REACTOME,C2,123,285
Cohort,-0.04692412386575063,0.18495864105484466,-0.2537006305741428,0.7997893757807113,LGP Proband,Response to elevated platelet cytosolic Ca2+,CP:REACTOME,C2,123,401
Cohort,0.008727752326049868,0.05812505190952937,0.1501547446294665,0.8806805680991119,LonGen OPEL,Response to elevated platelet cytosolic Ca2+,CP:REACTOME,C2,216,254
Cohort,-0.007134914521336977,0.00636487061937719,-1.1209834336012217,0.2626929747091175,LGP Offspring,Response to metal ions,CP:REACTOME,C2,3,1
Cohort,-0.047822317413154916,0.020673906091237922,-2.313172808375245,0.020955591223637608,LGP Proband,Response to metal ions,CP:REACTOME,C2,3,4
Cohort,-0.009873308779300928,0.008166797070837204,-1.2089572807627977,0.22703823527877776,LonGen OPEL,Response to metal ions,CP:REACTOME,C2,6,4
Cohort,-0.006056990971101698,0.030693208329709846,-0.19733977973357592,0.8436209715587386,LGP Offspring,RET signaling,CP:REACTOME,C2,32,65
Cohort,4.1185226692089076e-4,0.07800021880387328,0.005280142456477818,0.9957883381321146,LGP Proband,RET signaling,CP:REACTOME,C2,32,75
Cohort,0.002545900142486154,0.0271998626030925,0.09359974275004966,0.9254506676544902,LonGen OPEL,RET signaling,CP:REACTOME,C2,52,57
Cohort,0.025850464681766914,0.01901427950668602,1.359529014637503,0.17443232051993746,LGP Offspring,Retinoid cycle disease events,CP:REACTOME,C2,10,29
Cohort,-3.0194467781516474e-4,0.05493439138059343,-0.005496459871981619,0.9956157960439267,LGP Proband,Retinoid cycle disease events,CP:REACTOME,C2,10,43
Cohort,0.01441289341862609,0.020383009871800892,0.7071032938352138,0.47970923798661647,LonGen OPEL,Retinoid cycle disease events,CP:REACTOME,C2,26,39
Cohort,-0.021442284805495218,0.014794454450469367,-1.4493460963553775,0.14770468708778636,LGP Offspring,Retrograde neurotrophin signalling,CP:REACTOME,C2,10,12
Cohort,0.04025983602777972,0.043664206554495544,0.9220329236381071,0.3567780496374492,LGP Proband,Retrograde neurotrophin signalling,CP:REACTOME,C2,10,20
Cohort,-0.013055859919858689,0.012972696962993007,-1.0064106143158142,0.314523919070804,LonGen OPEL,Retrograde neurotrophin signalling,CP:REACTOME,C2,14,10
Cohort,-0.027723738352149408,0.032202085289456395,-0.8609299088226039,0.3895818985888635,LGP Offspring,Retrograde transport at the Trans-Golgi-Network,CP:REACTOME,C2,38,69
Cohort,0.0053125860674401474,0.08947007364446324,0.059378358047980785,0.9526649750056073,LGP Proband,Retrograde transport at the Trans-Golgi-Network,CP:REACTOME,C2,38,103
Cohort,-0.02028934912251024,0.027767328671248984,-0.7306914310240568,0.46518265986429896,LonGen OPEL,Retrograde transport at the Trans-Golgi-Network,CP:REACTOME,C2,62,62
Cohort,0.017180608780939986,0.014794504072234066,1.16128318306959,0.24593664315695096,LGP Offspring,Reversible hydration of carbon dioxide,CP:REACTOME,C2,4,18
Cohort,-0.01673237056868525,0.03883865696785836,-0.43081743486991403,0.66671243991961,LGP Proband,Reversible hydration of carbon dioxide,CP:REACTOME,C2,4,21
Cohort,0.022838475020845857,0.011454247525554215,1.9938869812175475,0.04650518720940808,LonGen OPEL,Reversible hydration of carbon dioxide,CP:REACTOME,C2,5,15
Cohort,-0.06553965736064528,0.1317670063332118,-0.49739050149556324,0.6190754414620647,LGP Offspring,RHO GTPase cycle,CP:REACTOME,C2,569,1154
Cohort,0.251991074486097,0.3603213116215124,0.6993510135497971,0.4845276902488729,LGP Proband,RHO GTPase cycle,CP:REACTOME,C2,569,1664
Cohort,-0.06639164071524528,0.1176776930896445,-0.5641820380067228,0.5727891759614127,LonGen OPEL,RHO GTPase cycle,CP:REACTOME,C2,931,1083
Cohort,0.16655414748238648,0.08431973020563989,1.9752689800618715,0.04864401045011265,LGP Offspring,RHO GTPase Effectors,CP:REACTOME,C2,202,493
Cohort,-0.25006230625819936,0.21747777454501177,-1.1498292493628746,0.25054381411242016,LGP Proband,RHO GTPase Effectors,CP:REACTOME,C2,202,608
Cohort,-0.17845048142910716,0.06842518440276726,-2.6079649326000243,0.009278921110289369,LonGen OPEL,RHO GTPase Effectors,CP:REACTOME,C2,384,361
Cohort,-0.0014346542249676856,0.031009364159295116,-0.04626519323640002,0.9631125451451804,LGP Offspring,RHO GTPases activate CIT,CP:REACTOME,C2,34,65
Cohort,-0.11158879817278171,0.08471501452609771,-1.3172257456015088,0.18812474325843018,LGP Proband,RHO GTPases activate CIT,CP:REACTOME,C2,34,91
Cohort,-0.02988200141408958,0.023344371101190205,-1.280051678606414,0.20089987606613843,LonGen OPEL,RHO GTPases activate CIT,CP:REACTOME,C2,47,41
Cohort,0.07467093824030027,0.055461595271938426,1.3463539567186067,0.17863965719084018,LGP Offspring,RHO GTPases Activate Formins,CP:REACTOME,C2,87,222
Cohort,-0.08370620659164113,0.14186698870264802,-0.5900330116056006,0.5553283409809713,LGP Proband,RHO GTPases Activate Formins,CP:REACTOME,C2,87,254
Cohort,-0.08832247090398967,0.047719863091511355,-1.8508534011217839,0.06456093283805636,LonGen OPEL,RHO GTPases Activate Formins,CP:REACTOME,C2,175,165
Cohort,0.01961257729583697,0.03202027363258276,0.6125049873365188,0.5404096770783295,LGP Offspring,RHO GTPases activate IQGAPs,CP:REACTOME,C2,30,74
Cohort,-0.034415253193122004,0.0821124272471469,-0.4191235644458166,0.6752337541197564,LGP Proband,RHO GTPases activate IQGAPs,CP:REACTOME,C2,30,83
Cohort,0.023557012828992505,0.024910935927072986,0.9456494488186191,0.34461437272238327,LonGen OPEL,RHO GTPases activate IQGAPs,CP:REACTOME,C2,43,58
Cohort,0.052046835633263414,0.0190802784584526,2.727781764118152,0.00654172727561193,LGP Offspring,RHO GTPases activate KTN1,CP:REACTOME,C2,5,33
Cohort,-0.01056470111183729,0.050442318107619295,-0.20944122927295636,0.8341549580226804,LGP Proband,RHO GTPases activate KTN1,CP:REACTOME,C2,5,36
Cohort,-0.009153455857840855,0.016785954115827936,-0.5453044726965988,0.5856968875546619,LonGen OPEL,RHO GTPases activate KTN1,CP:REACTOME,C2,23,21
Cohort,0.01386813488771333,0.024802180932454575,0.5591498153118608,0.5762446679983222,LGP Offspring,RHO GTPases Activate NADPH Oxidases,CP:REACTOME,C2,18,41
Cohort,0.04078102947401284,0.06280067836094216,0.649372435750247,0.5162764688261896,LGP Proband,RHO GTPases Activate NADPH Oxidases,CP:REACTOME,C2,18,51
Cohort,-0.059070597044064865,0.01946319404579206,-3.0349898842444065,0.002483742912072762,LonGen OPEL,RHO GTPases Activate NADPH Oxidases,CP:REACTOME,C2,39,23
Cohort,0.017668797615806066,0.03461540119166876,0.5104316866926446,0.609915691831063,LGP Offspring,RHO GTPases activate PAKs,CP:REACTOME,C2,36,77
Cohort,-0.10509740264101032,0.09417475359154526,-1.1159827728017084,0.26475094253368364,LGP Proband,RHO GTPases activate PAKs,CP:REACTOME,C2,36,109
Cohort,-0.02590533431873213,0.02862718753749607,-0.9049206906826303,0.36578120715952733,LonGen OPEL,RHO GTPases activate PAKs,CP:REACTOME,C2,58,52
Cohort,-0.004609092577881213,0.031192470327099528,-0.14776298669351962,0.8825738821709057,LGP Offspring,RHO GTPases activate PKNs,CP:REACTOME,C2,34,67
Cohort,-0.12975956715561832,0.08650832712080667,-1.4999662052696083,0.13400160138333025,LGP Proband,RHO GTPases activate PKNs,CP:REACTOME,C2,34,96
Cohort,-0.020170107041653063,0.023755605844913527,-0.8490672548337393,0.39609914198392193,LonGen OPEL,RHO GTPases activate PKNs,CP:REACTOME,C2,48,42
Cohort,0.002508720885422519,0.009534008910067027,0.2631338935265251,0.792527560762979,LGP Offspring,RHO GTPases Activate Rhotekin and Rhophilins,CP:REACTOME,C2,2,7
Cohort,-0.02227846087081325,0.027132156888211825,-0.821109098056728,0.4118187727215177,LGP Proband,RHO GTPases Activate Rhotekin and Rhophilins,CP:REACTOME,C2,2,10
Cohort,-0.0055118228478676385,0.009253488844688806,-0.5956480782954897,0.5515796658336712,LonGen OPEL,RHO GTPases Activate Rhotekin and Rhophilins,CP:REACTOME,C2,7,6
Cohort,7.786250708731372e-4,0.02949077451839176,0.026402326951011475,0.9789442301129839,LGP Offspring,RHO GTPases Activate ROCKs,CP:REACTOME,C2,29,58
Cohort,-0.05172483648947705,0.08215218021054468,-0.6296222006149252,0.5291142346404076,LGP Proband,RHO GTPases Activate ROCKs,CP:REACTOME,C2,29,86
Cohort,-0.02287343078346592,0.022269286077941045,-1.0271290558399766,0.30467171299659934,LonGen OPEL,RHO GTPases Activate ROCKs,CP:REACTOME,C2,42,37
Cohort,0.011068055861223986,0.023301877317678285,0.4749855863684878,0.6349506655703115,LGP Offspring,RHO GTPases Activate WASPs and WAVEs,CP:REACTOME,C2,15,38
Cohort,0.08086729810489535,0.06322475789567578,1.2790448045420861,0.201237038106836,LGP Proband,RHO GTPases Activate WASPs and WAVEs,CP:REACTOME,C2,15,43
Cohort,-0.015564004810481306,0.017671560491640217,-0.8807374322060624,0.37872578998761774,LonGen OPEL,RHO GTPases Activate WASPs and WAVEs,CP:REACTOME,C2,24,24
Cohort,-0.015762302946328858,0.07661091328023123,-0.20574487721707113,0.8370521445787629,LGP Offspring,RHOA GTPase cycle,CP:REACTOME,C2,201,390
Cohort,-0.07589750851727252,0.21175736140597828,-0.3584173320509168,0.7201217261921924,LGP Proband,RHOA GTPase cycle,CP:REACTOME,C2,201,563
Cohort,0.01935144951983392,0.06683938863052481,0.2895216415997606,0.7722576141904404,LonGen OPEL,RHOA GTPase cycle,CP:REACTOME,C2,305,365
Cohort,0.029859909310098364,0.04745032249445495,0.629287805443004,0.5293732542496468,LGP Offspring,RHOB GTPase cycle,CP:REACTOME,C2,67,149
Cohort,-0.19436030931340148,0.13041274634830657,-1.4903474909906709,0.1365109775530998,LGP Proband,RHOB GTPase cycle,CP:REACTOME,C2,67,219
Cohort,0.007278511264998068,0.04182980706368353,0.17400298437707218,0.8619073586759771,LonGen OPEL,RHOB GTPase cycle,CP:REACTOME,C2,120,143
Cohort,0.015544458583177947,0.03350116990368953,0.46399748509875216,0.6427989243313996,LGP Offspring,RHOBTB GTPase Cycle,CP:REACTOME,C2,32,72
Cohort,0.1197380194979136,0.09319326853017774,1.2848354970953741,0.19920650040407992,LGP Proband,RHOBTB GTPase Cycle,CP:REACTOME,C2,32,111
Cohort,0.010163126441690899,0.028995086412072085,0.35051202459805353,0.7260472020115061,LonGen OPEL,RHOBTB GTPase Cycle,CP:REACTOME,C2,59,70
Cohort,0.027511527185787796,0.030222718140569618,0.910292947769564,0.3629924926625554,LGP Offspring,RHOBTB1 GTPase cycle,CP:REACTOME,C2,24,61
Cohort,0.13493501710909384,0.07994095454708548,1.687933523856244,0.09179786475089079,LGP Proband,RHOBTB1 GTPase cycle,CP:REACTOME,C2,24,86
Cohort,0.02033469372883634,0.023948754334732626,0.8490919170415953,0.3960854280961428,LonGen OPEL,RHOBTB1 GTPase cycle,CP:REACTOME,C2,39,51
Cohort,-0.00459159137794757,0.03061338617895333,-0.14998639324336763,0.8808200888096145,LGP Offspring,RHOBTB2 GTPase cycle,CP:REACTOME,C2,31,62
Cohort,0.10200000431078698,0.08739130196401695,1.1671642602691181,0.24347763824612909,LGP Proband,RHOBTB2 GTPase cycle,CP:REACTOME,C2,31,93
Cohort,-0.006521097273651612,0.02714705543775477,-0.24021379735285747,0.8102263662787914,LonGen OPEL,RHOBTB2 GTPase cycle,CP:REACTOME,C2,55,60
Cohort,0.0014342282439286647,0.011888682633091554,0.1206381134219667,0.9040135260270787,LGP Offspring,RHOBTB3 ATPase cycle,CP:REACTOME,C2,4,10
Cohort,0.002240579339297145,0.028215503731793636,0.07940951048031186,0.9367259536829574,LGP Proband,RHOBTB3 ATPase cycle,CP:REACTOME,C2,4,9
Cohort,0.004405439778160574,0.011209676297389939,0.39300330012083723,0.694422269881128,LonGen OPEL,RHOBTB3 ATPase cycle,CP:REACTOME,C2,8,10
Cohort,0.016639134823114684,0.04710271279905406,0.3532521554352776,0.7240095398143302,LGP Offspring,RHOC GTPase cycle,CP:REACTOME,C2,73,157
Cohort,-0.10733683634018885,0.13294641818068498,-0.8073691477291955,0.4196840329361955,LGP Proband,RHOC GTPase cycle,CP:REACTOME,C2,73,226
Cohort,0.005118571235367636,0.043847228403277066,0.1167364830518018,0.9070983244521135,LonGen OPEL,RHOC GTPase cycle,CP:REACTOME,C2,130,156
Cohort,-0.05491927203873779,0.04086558190046556,-1.3439004043182883,0.1794314658305957,LGP Offspring,RHOD GTPase cycle,CP:REACTOME,C2,59,108
Cohort,-0.03395088309122406,0.11376892176706334,-0.29841966122116315,0.7654572181045987,LGP Proband,RHOD GTPase cycle,CP:REACTOME,C2,59,169
Cohort,-0.008092823046990607,0.03742318561189205,-0.21625158079591525,0.828847054069341,LonGen OPEL,RHOD GTPase cycle,CP:REACTOME,C2,97,112
Cohort,-0.06332757865966117,0.04020224417507373,-1.5752249646532333,0.11567237940552384,LGP Offspring,RHOF GTPase cycle,CP:REACTOME,C2,59,103
Cohort,-0.2056813641362803,0.11307688418560281,-1.8189514649048677,0.06927732924734822,LGP Proband,RHOF GTPase cycle,CP:REACTOME,C2,59,167
Cohort,-0.013367053446602913,0.03682474229220803,-0.36299109279663117,0.7167079055975729,LonGen OPEL,RHOF GTPase cycle,CP:REACTOME,C2,93,109
Cohort,-0.014918639490187636,0.056189479741161494,-0.26550591959403774,0.7907006970046714,LGP Offspring,RHOG GTPase cycle,CP:REACTOME,C2,106,210
Cohort,-0.03459915832996375,0.15655780730021884,-0.22099925213959856,0.8251471083025927,LGP Proband,RHOG GTPase cycle,CP:REACTOME,C2,106,308
Cohort,-0.017014009969726428,0.04874580330240284,-0.34903537980853727,0.7271550551294175,LonGen OPEL,RHOG GTPase cycle,CP:REACTOME,C2,171,203
Cohort,-0.04082920097575069,0.033201186756480726,-1.2297512518217744,0.21921808527951905,LGP Offspring,RHOH GTPase cycle,CP:REACTOME,C2,39,71
Cohort,3.4320776460315303e-4,0.09020059110152082,0.003804939196206292,0.9969650149985694,LGP Proband,RHOH GTPase cycle,CP:REACTOME,C2,39,98
Cohort,-0.0085668587877583,0.030209118541258136,-0.2835851955116831,0.7768020245787756,LonGen OPEL,RHOH GTPase cycle,CP:REACTOME,C2,60,71
Cohort,-0.015277417902493198,0.04323934447962789,-0.3533221441340563,0.7239570992639012,LGP Offspring,RHOJ GTPase cycle,CP:REACTOME,C2,66,128
Cohort,-0.3563299648300167,0.12207953746683349,-2.918834492855318,0.003607939529153037,LGP Proband,RHOJ GTPase cycle,CP:REACTOME,C2,66,179
Cohort,0.0629816070464022,0.04017322973416288,1.5677506504497773,0.11733675591655338,LonGen OPEL,RHOJ GTPase cycle,CP:REACTOME,C2,96,139
Cohort,0.03273041334276672,0.05652524893019262,0.5790405873875589,0.5627546741787907,LGP Offspring,RHOQ GTPase cycle,CP:REACTOME,C2,105,231
Cohort,-0.17576207948386763,0.15208628576578528,-1.1556734297170184,0.24814572884334235,LGP Proband,RHOQ GTPase cycle,CP:REACTOME,C2,105,306
Cohort,0.04025295095415897,0.051799078159913546,0.7770978245962312,0.43733192949169863,LonGen OPEL,RHOQ GTPase cycle,CP:REACTOME,C2,172,225
Cohort,0.013546247758461171,0.015534903489807636,0.8719878927699029,0.3835245749616314,LGP Offspring,RHOT1 GTPase cycle,CP:REACTOME,C2,6,18
Cohort,0.01935747193300204,0.03675586180185389,0.5266499269519425,0.5985767497814007,LGP Proband,RHOT1 GTPase cycle,CP:REACTOME,C2,6,16
Cohort,0.011740070219614929,0.013027868244722709,0.9011505181878519,0.36778086346014194,LonGen OPEL,RHOT1 GTPase cycle,CP:REACTOME,C2,9,17
Cohort,-0.060527958487249255,0.037738067777057294,-1.6038965970601966,0.10920392417351506,LGP Offspring,RHOU GTPase cycle,CP:REACTOME,C2,54,79
Cohort,-0.2179212001469948,0.10706389287988592,-2.035431313818177,0.04212316831084006,LGP Proband,RHOU GTPase cycle,CP:REACTOME,C2,54,134
Cohort,-0.005967062216335709,0.03275222901578297,-0.18218797302193512,0.8554815975433736,LonGen OPEL,RHOU GTPase cycle,CP:REACTOME,C2,76,87
Cohort,-0.05378139478878141,0.03141445470343852,-1.711995172174505,0.08735619849280386,LGP Offspring,RHOV GTPase cycle,CP:REACTOME,C2,38,58
Cohort,-0.10291268779552577,0.09173203005988931,-1.1218839017117241,0.2622347008474445,LGP Proband,RHOV GTPase cycle,CP:REACTOME,C2,38,101
Cohort,-0.01371374680768856,0.027011898808838298,-0.5076928099257287,0.6118094312535172,LonGen OPEL,RHOV GTPase cycle,CP:REACTOME,C2,55,59
Cohort,0.008319035648665379,0.027556713637739334,0.30188779975825325,0.7628304464465614,LGP Offspring,RIP-mediated NFkB activation via ZBP1,CP:REACTOME,C2,21,50
Cohort,0.09777607067055977,0.06728488085682914,1.4531655466346256,0.1465539468014626,LGP Proband,RIP-mediated NFkB activation via ZBP1,CP:REACTOME,C2,21,50
Cohort,-0.009841575462175036,0.0231255503341661,-0.42557151375701174,0.6705351343159793,LonGen OPEL,RIP-mediated NFkB activation via ZBP1,CP:REACTOME,C2,34,38
Cohort,-0.02003052757478524,0.019793136955228153,-1.0119935824267807,0.31190319860479643,LGP Offspring,RIPK1-mediated regulated necrosis,CP:REACTOME,C2,15,24
Cohort,-0.011398084590538609,0.055421789602217136,-0.20566070984619794,0.8371061399992433,LGP Proband,RIPK1-mediated regulated necrosis,CP:REACTOME,C2,15,33
Cohort,-0.021068054934463905,0.017464535900838827,-1.2063335123295202,0.22804733097146349,LonGen OPEL,RIPK1-mediated regulated necrosis,CP:REACTOME,C2,25,21
Cohort,0.043846876518601155,0.029289471548920146,1.4970183550552216,0.13485522556488075,LGP Offspring,RMTs methylate histone arginines,CP:REACTOME,C2,23,65
Cohort,-0.005611063530933961,0.09319669109925816,-0.060206681854809166,0.9520054477523371,LGP Proband,RMTs methylate histone arginines,CP:REACTOME,C2,23,116
Cohort,-0.02412236672350508,0.028527659183450002,-0.8455782007343736,0.3980421906556668,LonGen OPEL,RMTs methylate histone arginines,CP:REACTOME,C2,58,58
Cohort,-0.03707894407121804,0.02589523297256795,-1.4318830075982527,0.1526394949874146,LGP Offspring,RNA Polymerase I Promoter Escape,CP:REACTOME,C2,26,39
Cohort,-0.021505640641895293,0.07028393525170298,-0.3059823068369555,0.7596944793931819,LGP Proband,RNA Polymerase I Promoter Escape,CP:REACTOME,C2,26,55
Cohort,0.018992590899216965,0.021907339822012397,0.8669510334674817,0.38623009570168276,LonGen OPEL,RNA Polymerase I Promoter Escape,CP:REACTOME,C2,30,44
Cohort,-0.0420443824212082,0.03772028966263114,-1.1146357251561847,0.2654026731047059,LGP Offspring,RNA Polymerase I Transcription,CP:REACTOME,C2,50,91
Cohort,0.09756203117465831,0.10151935123354598,0.9610190568516949,0.3368211189742911,LGP Proband,RNA Polymerase I Transcription,CP:REACTOME,C2,50,119
Cohort,-0.01063004774178812,0.03181404571413103,-0.33413064900030964,0.7383689830962659,LonGen OPEL,RNA Polymerase I Transcription,CP:REACTOME,C2,71,82
Cohort,-0.046916138942774535,0.03677650209253193,-1.275709658975469,0.20249635383415468,LGP Offspring,RNA Polymerase I Transcription Initiation,CP:REACTOME,C2,49,87
Cohort,0.110731580532866,0.1001622400395074,1.1055222056654253,0.26925218658139893,LGP Proband,RNA Polymerase I Transcription Initiation,CP:REACTOME,C2,49,113
Cohort,0.010864361997542612,0.03098842907710423,0.3505941514657074,0.7259856031357936,LonGen OPEL,RNA Polymerase I Transcription Initiation,CP:REACTOME,C2,61,79
Cohort,-0.03868125821158029,0.025476496734518357,-1.5183115094145057,0.1294034038404844,LGP Offspring,RNA Polymerase I Transcription Termination,CP:REACTOME,C2,26,39
Cohort,-0.005714608057651789,0.07001876815760338,-0.08161537553458424,0.9349721561914819,LGP Proband,RNA Polymerase I Transcription Termination,CP:REACTOME,C2,26,52
Cohort,0.022408301568120157,0.02097746740534661,1.0682081461563309,0.2857504718489016,LonGen OPEL,RNA Polymerase I Transcription Termination,CP:REACTOME,C2,26,41
Cohort,-0.024935930233030545,0.03481863337948105,-0.7161662538922484,0.4741360171034886,LGP Offspring,RNA polymerase II transcribes snRNA genes,CP:REACTOME,C2,46,91
Cohort,0.08809388946261473,0.1083888765805391,0.8127576578133086,0.4165889589930142,LGP Proband,RNA polymerase II transcribes snRNA genes,CP:REACTOME,C2,46,149
Cohort,0.0980543727614412,0.03362218719240312,2.9163591351248095,0.003640961362644547,LonGen OPEL,RNA polymerase II transcribes snRNA genes,CP:REACTOME,C2,51,105
Cohort,-0.44112287405877876,0.18178573737646042,-2.4266088221500928,0.015501115168680576,LGP Offspring,RNA Polymerase II Transcription,CP:REACTOME,C2,999,1910
Cohort,0.12552159612100372,0.4738012879720584,0.2649245565757224,0.7911330421066828,LGP Proband,RNA Polymerase II Transcription,CP:REACTOME,C2,999,2704
Cohort,-0.0370147445476863,0.153525516311633,-0.24109832317744567,0.8095410001004117,LonGen OPEL,RNA Polymerase II Transcription,CP:REACTOME,C2,1545,1810
Cohort,-0.022737742915834476,0.036350110835479565,-0.6255205938365744,0.5318405476693904,LGP Offspring,RNA Polymerase II Transcription Termination,CP:REACTOME,C2,36,73
Cohort,0.15974816454532517,0.1005926024337042,1.588070699837074,0.11264936815556528,LGP Proband,RNA Polymerase II Transcription Termination,CP:REACTOME,C2,36,105
Cohort,-0.0018478823200521986,0.029468950384532865,-0.06270607863326147,0.9500162988266897,LonGen OPEL,RNA Polymerase II Transcription Termination,CP:REACTOME,C2,57,72
Cohort,0.009156150443194788,0.014808026733587514,0.618323467935592,0.5365704051251815,LGP Offspring,RNA Polymerase III Chain Elongation,CP:REACTOME,C2,6,16
Cohort,0.004751454706083219,0.03868320608277335,0.12282990959736316,0.902271381509445,LGP Proband,RNA Polymerase III Chain Elongation,CP:REACTOME,C2,6,19
Cohort,-0.008780921736090014,0.009541576789224394,-0.9202799422006003,0.3577052926746832,LonGen OPEL,RNA Polymerase III Chain Elongation,CP:REACTOME,C2,8,6
Cohort,0.035248743133895026,0.03071264668577865,1.147694742642183,0.25150060127418183,LGP Offspring,RNA Polymerase III Transcription,CP:REACTOME,C2,27,73
Cohort,0.11967689101220962,0.08672746622309915,1.3799191446957626,0.16798134859056588,LGP Proband,RNA Polymerase III Transcription,CP:REACTOME,C2,27,94
Cohort,-0.019822578853151245,0.025032003545480602,-0.7918894233590067,0.4286610710519616,LonGen OPEL,RNA Polymerase III Transcription,CP:REACTOME,C2,50,47
Cohort,0.04489976532555352,0.02481563081568,1.8093340305974879,0.07084319334116053,LGP Offspring,RNA Polymerase III Transcription Initiation From Type 1 Promoter,CP:REACTOME,C2,14,48
Cohort,0.05638554555846673,0.06905375206823033,0.8165457179322211,0.41442125555034104,LGP Proband,RNA Polymerase III Transcription Initiation From Type 1 Promoter,CP:REACTOME,C2,14,60
Cohort,-2.589754338175809e-4,0.01991183516645786,-0.013006105748295542,0.9896261805778853,LonGen OPEL,RNA Polymerase III Transcription Initiation From Type 1 Promoter,CP:REACTOME,C2,28,31
Cohort,0.019926324420996212,0.02677823767922457,0.7441238164995341,0.457060146030687,LGP Offspring,RNA Polymerase III Transcription Initiation From Type 3 Promoter,CP:REACTOME,C2,22,53
Cohort,0.11318543279171925,0.07735896262531657,1.4631198370630436,0.14381134540327176,LGP Proband,RNA Polymerase III Transcription Initiation From Type 3 Promoter,CP:REACTOME,C2,22,77
Cohort,-0.01755143286022953,0.022218901939857653,-0.7899325046637283,0.42980243688187914,LonGen OPEL,RNA Polymerase III Transcription Initiation From Type 3 Promoter,CP:REACTOME,C2,38,36
Cohort,0.010100997303523923,0.016054297690490982,0.6291771523276773,0.5294456420279239,LGP Offspring,RNA Polymerase III Transcription Termination,CP:REACTOME,C2,7,19
Cohort,0.009013191252254077,0.04290669640943662,0.21006490842934658,0.8336683198063786,LGP Proband,RNA Polymerase III Transcription Termination,CP:REACTOME,C2,7,24
Cohort,-0.009723929006916507,0.010503098248411266,-0.9258152953474829,0.3548225728399347,LonGen OPEL,RNA Polymerase III Transcription Termination,CP:REACTOME,C2,10,7
Cohort,-0.06936590446952141,0.054629335715973074,-1.2697555912113996,0.20460862209340325,LGP Offspring,RND1 GTPase cycle,CP:REACTOME,C2,105,183
Cohort,-0.32478855501132875,0.1508528681715888,-2.1530154444388514,0.03160360549295304,LGP Proband,RND1 GTPase cycle,CP:REACTOME,C2,105,250
Cohort,0.007623989663817528,0.047989308373647434,0.15886850471894112,0.8738127727620376,LonGen OPEL,RND1 GTPase cycle,CP:REACTOME,C2,162,191
Cohort,-0.05402590668136136,0.04734335338471178,-1.1411508230595158,0.254211254664505,LGP Offspring,RND2 GTPase cycle,CP:REACTOME,C2,79,138
Cohort,-0.19279466973818762,0.13169329490478035,-1.4639672420496888,0.14357970220652033,LGP Proband,RND2 GTPase cycle,CP:REACTOME,C2,79,205
Cohort,0.012233974678407557,0.04343482492953299,0.28166280624488516,0.7782752835397848,LonGen OPEL,RND2 GTPase cycle,CP:REACTOME,C2,125,154
Cohort,-0.047844603306539474,0.04844596653867771,-0.9875869287970935,0.32370833535534105,LGP Offspring,RND3 GTPase cycle,CP:REACTOME,C2,80,140
Cohort,-0.19222301464430067,0.13651664183070436,-1.4080555459507884,0.1594872609080351,LGP Proband,RND3 GTPase cycle,CP:REACTOME,C2,80,205
Cohort,0.007578672107486782,0.04414756151190311,0.1716668338622375,0.8637430927021417,LonGen OPEL,RND3 GTPase cycle,CP:REACTOME,C2,134,158
Cohort,-7.899799743959261e-4,0.005567480660239343,-0.1418918219218323,0.887207730147477,LGP Offspring,ROBO receptors bind AKAP5,CP:REACTOME,C2,1,2
Cohort,0.05041101762855117,0.03130144058895904,1.610501519419929,0.10766680068224224,LGP Proband,ROBO receptors bind AKAP5,CP:REACTOME,C2,1,15
Cohort,0.010067708354943538,0.009598081464955001,1.0489292460897797,0.29452905041453026,LonGen OPEL,ROBO receptors bind AKAP5,CP:REACTOME,C2,5,9
Cohort,0.01951914956705279,0.01799499021130027,1.084699093350737,0.2784416351091336,LGP Offspring,Role of ABL in ROBO-SLIT signaling,CP:REACTOME,C2,8,25
Cohort,-0.035980935080210545,0.05061223270412884,-0.7109138079434163,0.47733641244474245,LGP Proband,Role of ABL in ROBO-SLIT signaling,CP:REACTOME,C2,8,33
Cohort,0.004892255062441434,0.015412125878320443,0.31742895828038575,0.7510013809383358,LonGen OPEL,Role of ABL in ROBO-SLIT signaling,CP:REACTOME,C2,17,20
Cohort,3.930272403343308e-4,0.012328127697315368,0.03188052962980893,0.9745767360513936,LGP Offspring,Role of LAT2/NTAL/LAB on calcium mobilization,CP:REACTOME,C2,6,9
Cohort,-0.03451279121324713,0.03757048243137546,-0.9186145340637196,0.35856281660409206,LGP Proband,Role of LAT2/NTAL/LAB on calcium mobilization,CP:REACTOME,C2,6,17
Cohort,-0.00805895299983161,0.01203558696190793,-0.6695936829120025,0.5033110175226947,LonGen OPEL,Role of LAT2/NTAL/LAB on calcium mobilization,CP:REACTOME,C2,12,10
Cohort,-0.044609752124254644,0.028540932023808255,-1.56300964828486,0.11851831714536744,LGP Offspring,Role of phospholipids in phagocytosis,CP:REACTOME,C2,34,47
Cohort,-0.1729427401480571,0.08046087972687402,-2.149401556820091,0.03188967373125955,LGP Proband,Role of phospholipids in phagocytosis,CP:REACTOME,C2,34,70
Cohort,0.0038836388545334974,0.026801845382702662,0.14490191996406018,0.8848249911523212,LonGen OPEL,Role of phospholipids in phagocytosis,CP:REACTOME,C2,47,59
Cohort,-0.02103333278585618,0.02033676395168711,-1.0342517047364994,0.3013883539203982,LGP Offspring,Role of second messengers in netrin-1 signaling,CP:REACTOME,C2,16,24
Cohort,0.010861087364519692,0.051300712580949794,0.21171416181366828,0.8323817646792658,LGP Proband,Role of second messengers in netrin-1 signaling,CP:REACTOME,C2,16,28
Cohort,-0.0036778510154010327,0.01484432939778361,-0.24776134487760482,0.8043829606891424,LonGen OPEL,Role of second messengers in netrin-1 signaling,CP:REACTOME,C2,14,18
Cohort,5.961142966817939e-5,0.024816822024507867,0.0024020573467992833,0.9980841460312563,LGP Offspring,RORA activates gene expression,CP:REACTOME,C2,21,43
Cohort,-0.07239791410650426,0.0693118078101864,-1.044524971917762,0.29654522493441626,LGP Proband,RORA activates gene expression,CP:REACTOME,C2,21,51
Cohort,-0.014463368058492056,0.02571333757920721,-0.5624850532895306,0.5739439531988271,LonGen OPEL,RORA activates gene expression,CP:REACTOME,C2,47,48
Cohort,0.05656695789588399,0.03779982527022954,1.4964872850995716,0.13499343854167395,LGP Offspring,ROS and RNS production in phagocytes,CP:REACTOME,C2,36,98
Cohort,-0.04253904486143033,0.09942940671176151,-0.4278316271638618,0.6688841584369112,LGP Proband,ROS and RNS production in phagocytes,CP:REACTOME,C2,36,133
Cohort,-0.03001863175562863,0.03228330410131129,-0.929850044512926,0.35273062832984814,LonGen OPEL,ROS and RNS production in phagocytes,CP:REACTOME,C2,82,84
Cohort,-0.013178474386742894,0.015538297502528012,-0.8481285922475622,0.3966665604443125,LGP Offspring,rRNA modification in the mitochondrion,CP:REACTOME,C2,9,15
Cohort,0.057895498598514665,0.042599163688242146,1.3590759438898206,0.1744899233380331,LGP Proband,rRNA modification in the mitochondrion,CP:REACTOME,C2,9,21
Cohort,-0.011836092569191123,0.013024047654814184,-0.9087875661155196,0.36373733726046276,LonGen OPEL,rRNA modification in the mitochondrion,CP:REACTOME,C2,14,12
Cohort,0.018024234245835036,0.05112865772018344,0.3525270376640423,0.7245529263893055,LGP Offspring,rRNA modification in the nucleus and cytosol,CP:REACTOME,C2,84,176
Cohort,0.2148594764128184,0.14666250128001848,1.4649925818638085,0.14329980290169456,LGP Proband,rRNA modification in the nucleus and cytosol,CP:REACTOME,C2,84,256
Cohort,-0.04021136078043138,0.045703604403052385,-0.8798290923799831,0.37921743934940344,LonGen OPEL,rRNA modification in the nucleus and cytosol,CP:REACTOME,C2,147,153
Cohort,-0.07099072250801239,0.06672827724951895,-1.0638776457925738,0.2877640026933348,LGP Offspring,rRNA processing,CP:REACTOME,C2,156,294
Cohort,0.3653467241228303,0.19260988659449613,1.8968222793879688,0.0581966638044888,LGP Proband,rRNA processing,CP:REACTOME,C2,156,422
Cohort,0.008661053639048687,0.061001403900104105,0.14198121822297777,0.8871307679039702,LonGen OPEL,rRNA processing,CP:REACTOME,C2,243,286
Cohort,-0.029581477482475246,0.019567671275529944,-1.5117525772966105,0.13106413351270302,LGP Offspring,rRNA processing in the mitochondrion,CP:REACTOME,C2,16,23
Cohort,0.08125208146539087,0.05773158031166259,1.4074113514085949,0.1596780257780178,LGP Proband,rRNA processing in the mitochondrion,CP:REACTOME,C2,16,39
Cohort,-0.008460821278715865,0.017568359732701117,-0.48159426420254786,0.6302265713156772,LonGen OPEL,rRNA processing in the mitochondrion,CP:REACTOME,C2,22,22
Cohort,-5.194772063090145e-4,0.005563045457297863,-0.09338000386596519,0.9256293440601004,LGP Offspring,RSK activation,CP:REACTOME,C2,1,2
Cohort,0.010995930010433646,0.017655489989624108,0.6228051454191192,0.5335828319463579,LGP Proband,RSK activation,CP:REACTOME,C2,1,4
Cohort,-0.016746795945483017,0.00761325050589654,-2.1996906488907007,0.02811561162102956,LonGen OPEL,RSK activation,CP:REACTOME,C2,7,2
Cohort,-0.01211275998941278,0.005518616367668742,-2.1948907447845727,0.028510777636902122,LGP Offspring,RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),CP:REACTOME,C2,3,0
Cohort,-0.0014646224436368116,0.02075554122547095,-0.07056536988008988,0.9437605892300543,LGP Proband,RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),CP:REACTOME,C2,3,4
Cohort,0.002544547854647745,0.004491731023207717,0.566496043841598,0.5712163062147055,LonGen OPEL,RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),CP:REACTOME,C2,1,2
Cohort,0.014031912568604456,0.03136030769769571,0.4474418013964669,0.6546994361528042,LGP Offspring,RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,CP:REACTOME,C2,27,70
Cohort,0.17535193833889873,0.08726643977545065,2.009385724799877,0.04481798009165365,LGP Proband,RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,CP:REACTOME,C2,27,106
Cohort,0.037061600788435296,0.02554428479019989,1.4508764325495638,0.1472082200201963,LonGen OPEL,RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,CP:REACTOME,C2,40,62
Cohort,-0.009713334293669912,0.011802157669336144,-0.8230134324426691,0.41079058395017487,LGP Offspring,RUNX1 regulates estrogen receptor mediated transcription,CP:REACTOME,C2,6,8
Cohort,-0.016532054887949146,0.025861240047968775,-0.6392599448937727,0.5228293768245657,LGP Proband,RUNX1 regulates estrogen receptor mediated transcription,CP:REACTOME,C2,6,5
Cohort,0.006380491488107578,0.008194668921016208,0.7786149202128282,0.43643797731301315,LonGen OPEL,RUNX1 regulates estrogen receptor mediated transcription,CP:REACTOME,C2,4,6
Cohort,-0.024804021484118408,0.017173486586875848,-1.444320660143287,0.1491121097425715,LGP Offspring,RUNX1 regulates expression of components of tight junctions,CP:REACTOME,C2,14,17
Cohort,-0.0373047440495488,0.04605179522807178,-0.8100605821075344,0.41813642665412176,LGP Proband,RUNX1 regulates expression of components of tight junctions,CP:REACTOME,C2,14,22
Cohort,-0.015969746182837835,0.01227983961383655,-1.300484915523132,0.19381120780222896,LonGen OPEL,RUNX1 regulates expression of components of tight junctions,CP:REACTOME,C2,14,9
Cohort,0.0025341059956235806,0.03289010348750687,0.07704767473857743,0.9386084165331989,LGP Offspring,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,CP:REACTOME,C2,36,80
Cohort,-0.012454017347140101,0.0918439438506106,-0.13559976657140585,0.8921704110421642,LGP Proband,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,CP:REACTOME,C2,36,106
Cohort,-0.0476826991818642,0.030867461655126497,-1.5447560837560808,0.1228027231429188,LonGen OPEL,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,CP:REACTOME,C2,77,66
Cohort,0.0075308002174167285,0.016408166431729248,0.4589665913464934,0.6464056923557105,LGP Offspring,RUNX1 regulates transcription of genes involved in BCR signaling,CP:REACTOME,C2,7,18
Cohort,-0.04284894703435643,0.04263073910153179,-1.0051185585195919,0.3151312910252706,LGP Proband,RUNX1 regulates transcription of genes involved in BCR signaling,CP:REACTOME,C2,7,19
Cohort,0.009213708824559581,0.011809506870875406,0.7801942049995687,0.4355085017047342,LonGen OPEL,RUNX1 regulates transcription of genes involved in BCR signaling,CP:REACTOME,C2,8,13
Cohort,0.04065740401668834,0.037149676022063254,1.094421496234364,0.2741599577263219,LGP Offspring,RUNX1 regulates transcription of genes involved in differentiation of HSCs,CP:REACTOME,C2,37,90
Cohort,-0.0786529762287441,0.09786660657043245,-0.8036753187323328,0.42181351018734103,LGP Proband,RUNX1 regulates transcription of genes involved in differentiation of HSCs,CP:REACTOME,C2,37,127
Cohort,-0.026402355736868957,0.03423809732208967,-0.7711396894661765,0.4408529752935345,LonGen OPEL,RUNX1 regulates transcription of genes involved in differentiation of HSCs,CP:REACTOME,C2,78,85
Cohort,-0.0022226616793459527,0.008465117843732002,-0.2625671278742709,0.7929642361899476,LGP Offspring,RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,CP:REACTOME,C2,3,4
Cohort,-0.025448306999269282,0.019158081566529206,-1.328332740984339,0.18443157768307325,LGP Proband,RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,CP:REACTOME,C2,3,3
Cohort,1.6449127479848676e-4,0.005811354513939545,0.02830515233650362,0.9774258660419848,LonGen OPEL,RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,CP:REACTOME,C2,2,3
Cohort,0.01626282957924766,0.011425352738935036,1.4233984675000526,0.15508203026850587,LGP Offspring,RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,CP:REACTOME,C2,2,11
Cohort,0.0010287577416172801,0.022198187393648934,0.046344222768009216,0.9630469870332786,LGP Proband,RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,CP:REACTOME,C2,2,6
Cohort,-0.014924455031368399,0.013878736606545327,-1.0753468024121087,0.2825453215730767,LonGen OPEL,RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,CP:REACTOME,C2,14,12
Cohort,0.0057377378661633525,0.00901894877424536,0.6361869891697489,0.5248698858295633,LGP Offspring,RUNX1 regulates transcription of genes involved in interleukin signaling,CP:REACTOME,C2,2,6
Cohort,-0.006491987382264177,0.022866377819931682,-0.2839097400291085,0.7765500195318785,LGP Proband,RUNX1 regulates transcription of genes involved in interleukin signaling,CP:REACTOME,C2,2,7
Cohort,0.00911631967644635,0.007771550670334362,1.1730374108278356,0.2411317038348128,LonGen OPEL,RUNX1 regulates transcription of genes involved in interleukin signaling,CP:REACTOME,C2,3,6
Cohort,-0.009713334293669912,0.011802157669336144,-0.8230134324426691,0.41079058395017487,LGP Offspring,RUNX1 regulates transcription of genes involved in WNT signaling,CP:REACTOME,C2,6,8
Cohort,-0.016532054887949146,0.025861240047968775,-0.6392599448937727,0.5228293768245657,LGP Proband,RUNX1 regulates transcription of genes involved in WNT signaling,CP:REACTOME,C2,6,5
Cohort,0.006380491488107578,0.008194668921016208,0.7786149202128282,0.43643797731301315,LonGen OPEL,RUNX1 regulates transcription of genes involved in WNT signaling,CP:REACTOME,C2,4,6
Cohort,-0.013423204448913493,0.02763027949565957,-0.4858150078077255,0.6272557599298074,LGP Offspring,RUNX2 regulates bone development,CP:REACTOME,C2,26,50
Cohort,0.06082907811830842,0.07846955739272723,0.7751933378936864,0.4384451591020273,LGP Proband,RUNX2 regulates bone development,CP:REACTOME,C2,26,78
Cohort,0.0016378107800065524,0.0272556714507865,0.06009064142719152,0.9520985265161942,LonGen OPEL,RUNX2 regulates bone development,CP:REACTOME,C2,56,64
Cohort,-0.021995684223015947,0.01259098974168355,-1.7469384595078614,0.08110214452717146,LGP Offspring,RUNX2 regulates chondrocyte maturation,CP:REACTOME,C2,9,7
Cohort,0.01338201115874382,0.03919400931496454,0.34143001424542896,0.7328658869331164,LGP Proband,RUNX2 regulates chondrocyte maturation,CP:REACTOME,C2,9,17
Cohort,0.005089491517153642,0.00992494103077237,0.5127981618604712,0.6082347868331235,LonGen OPEL,RUNX2 regulates chondrocyte maturation,CP:REACTOME,C2,7,8
Cohort,0.002050422971932687,0.01265709448659708,0.16199791935692132,0.8713558998284492,LGP Offspring,RUNX2 regulates genes involved in cell migration,CP:REACTOME,C2,4,12
Cohort,0.008664011552637648,0.02865789753677089,0.30232544245511633,0.7624793648732965,LGP Proband,RUNX2 regulates genes involved in cell migration,CP:REACTOME,C2,4,10
Cohort,0.006803686451424194,0.01178125276190831,0.5775011018711174,0.5637643011977231,LonGen OPEL,RUNX2 regulates genes involved in cell migration,CP:REACTOME,C2,9,12
Cohort,-0.008415643900895062,0.022890982530009575,-0.36764013470642154,0.7132566574695393,LGP Offspring,RUNX2 regulates osteoblast differentiation,CP:REACTOME,C2,17,35
Cohort,0.014100808736171781,0.06560642445747616,0.21493030374352198,0.8298742023186039,LGP Proband,RUNX2 regulates osteoblast differentiation,CP:REACTOME,C2,17,51
Cohort,-0.002179023605165582,0.02533961047475403,-0.08599278222277937,0.9314937798335798,LonGen OPEL,RUNX2 regulates osteoblast differentiation,CP:REACTOME,C2,46,53
Cohort,0.00453070339801698,0.009602268934855399,0.47183675324598773,0.637195572839466,LGP Offspring,RUNX3 regulates BCL2L11 (BIM) transcription,CP:REACTOME,C2,2,7
Cohort,0.006588193456381345,0.03138705612368226,0.2099016049934801,0.8337957344388268,LGP Proband,RUNX3 regulates BCL2L11 (BIM) transcription,CP:REACTOME,C2,2,14
Cohort,-0.01242710615137356,0.010914099075858358,-1.13862867333337,0.25520062581613945,LonGen OPEL,RUNX3 regulates BCL2L11 (BIM) transcription,CP:REACTOME,C2,10,8
Cohort,-0.018360931928571248,0.02134371038971114,-0.8602502373449671,0.38995610066221065,LGP Offspring,RUNX3 regulates CDKN1A transcription,CP:REACTOME,C2,19,29
Cohort,-0.025347767039444802,0.06435842634338575,-0.39385312040106846,0.6937901571786702,LGP Proband,RUNX3 regulates CDKN1A transcription,CP:REACTOME,C2,19,49
Cohort,0.02495501517349817,0.0163731202906278,1.5241453510717053,0.12786958631479858,LonGen OPEL,RUNX3 regulates CDKN1A transcription,CP:REACTOME,C2,14,28
Cohort,0.0016612567558749718,0.005539683014759836,0.2998829989818457,0.7643585896822048,LGP Offspring,RUNX3 Regulates Immune Response and Cell Migration,CP:REACTOME,C2,1,2
Cohort,-3.127787648252261e-4,0.019219097761746688,-0.016274372954581395,0.9870193945922392,LGP Proband,RUNX3 Regulates Immune Response and Cell Migration,CP:REACTOME,C2,1,5
Cohort,0.009598670490071712,0.005769806656169249,1.6636034900421712,0.09658530351770836,LonGen OPEL,RUNX3 Regulates Immune Response and Cell Migration,CP:REACTOME,C2,1,4
Cohort,-0.012154776745474249,0.02328702283819931,-0.5219549458909762,0.6018726790561274,LGP Offspring,RUNX3 regulates NOTCH signaling,CP:REACTOME,C2,19,35
Cohort,-0.006751751739153403,0.06463449450888004,-0.10446050194181977,0.9168290272717355,LGP Proband,RUNX3 regulates NOTCH signaling,CP:REACTOME,C2,19,47
Cohort,-0.01984674989738844,0.023952661626760734,-0.8285822346863938,0.40758921523586633,LonGen OPEL,RUNX3 regulates NOTCH signaling,CP:REACTOME,C2,43,42
Cohort,0.0017595614894547371,0.010981126535953496,0.16023506183028913,0.8727437786772354,LGP Offspring,RUNX3 regulates p14-ARF,CP:REACTOME,C2,4,8
Cohort,-0.007826280147171938,0.03405609769612155,-0.2298055466308821,0.8182992238840471,LGP Proband,RUNX3 regulates p14-ARF,CP:REACTOME,C2,4,15
Cohort,0.0072451656925718025,0.009984086543500857,0.7256713632243147,0.4682535539658247,LonGen OPEL,RUNX3 regulates p14-ARF,CP:REACTOME,C2,6,9
Cohort,0.008787873771714121,0.013888222840217188,0.6327572557567556,0.5271061481799284,LGP Offspring,RUNX3 regulates WNT signaling,CP:REACTOME,C2,4,13
Cohort,-0.007849946343158175,0.029825446182566172,-0.2631962752579606,0.7924643101875938,LGP Proband,RUNX3 regulates WNT signaling,CP:REACTOME,C2,4,11
Cohort,-0.0012744948930554446,0.009287618022003006,-0.13722516258055387,0.8908875233900438,LonGen OPEL,RUNX3 regulates WNT signaling,CP:REACTOME,C2,6,7
Cohort,-0.002103693182719278,0.009648982331552822,-0.2180222857119408,0.8274775432332616,LGP Offspring,RUNX3 regulates YAP1-mediated transcription,CP:REACTOME,C2,3,6
Cohort,-0.00363916967372057,0.028429796301839217,-0.12800547830464548,0.8981754963063514,LGP Proband,RUNX3 regulates YAP1-mediated transcription,CP:REACTOME,C2,3,8
Cohort,0.010348611773654376,0.010666077307436048,0.9702359616725874,0.33222360480593516,LonGen OPEL,RUNX3 regulates YAP1-mediated transcription,CP:REACTOME,C2,5,10
Cohort,-0.030577844752116033,0.061372683881139686,-0.4982321583220324,0.6184824722087292,LGP Offspring,S Phase,CP:REACTOME,C2,123,241
Cohort,-0.15570389583796734,0.17422456075600926,-0.8936965899774661,0.3717420648985478,LGP Proband,S Phase,CP:REACTOME,C2,123,369
Cohort,0.0021597709392100098,0.051817828532234815,0.04168007422129741,0.966764190726427,LonGen OPEL,S Phase,CP:REACTOME,C2,198,234
Cohort,-0.002304010403076128,0.008505200815049357,-0.27089429787470076,0.7865550236362349,LGP Offspring,SARS-CoV-1 Genome Replication and Transcription,CP:REACTOME,C2,2,5
Cohort,0.022461830814157403,0.023751280831751313,0.9457102955108787,0.3445702759671371,LGP Proband,SARS-CoV-1 Genome Replication and Transcription,CP:REACTOME,C2,2,7
Cohort,-0.00210103897813925,0.011721444479115793,-0.1792474453027262,0.8577890259616587,LonGen OPEL,SARS-CoV-1 Genome Replication and Transcription,CP:REACTOME,C2,10,11
Cohort,-0.03654351465552567,0.03128029983900924,-1.1682597303607922,0.2431138560164673,LGP Offspring,SARS-CoV-1 Infection,CP:REACTOME,C2,33,56
Cohort,-0.08151652394087967,0.08288619251849808,-0.9834753107121825,0.325658775843212,LGP Proband,SARS-CoV-1 Infection,CP:REACTOME,C2,33,74
Cohort,-0.036262133859550356,0.028933327679410665,-1.2532998022676447,0.2104646233706564,LonGen OPEL,SARS-CoV-1 Infection,CP:REACTOME,C2,58,55
Cohort,-0.06600310807177863,0.03442445399344092,-1.9173320246228034,0.05561691681103799,LGP Offspring,SARS-CoV-2 Infection,CP:REACTOME,C2,46,71
Cohort,-0.08423855331606261,0.09346227571170575,-0.9013107446249792,0.36768332457251973,LGP Proband,SARS-CoV-2 Infection,CP:REACTOME,C2,46,96
Cohort,-0.04413052906330055,0.03104735818683262,-1.4213940135498093,0.15559389481527006,LonGen OPEL,SARS-CoV-2 Infection,CP:REACTOME,C2,71,67
Cohort,-0.10948919493338685,0.051145361533452185,-2.140745351106263,0.03265165614728639,LGP Offspring,SARS-CoV Infections,CP:REACTOME,C2,103,172
Cohort,-0.11802586827216664,0.14084753355230958,-0.8379690101448091,0.4022881894612458,LGP Proband,SARS-CoV Infections,CP:REACTOME,C2,103,233
Cohort,-0.13921786951378665,0.04628898094242478,-3.007581214348806,0.0027162557971535913,LonGen OPEL,SARS-CoV Infections,CP:REACTOME,C2,167,145
Cohort,-0.02086827086109928,0.031484396057840314,-0.6628131224992203,0.5076761749382361,LGP Offspring,Scavenging by Class A Receptors,CP:REACTOME,C2,33,59
Cohort,-0.20189811770654423,0.09294170422026252,-2.1723091845622493,0.03011337793294373,LGP Proband,Scavenging by Class A Receptors,CP:REACTOME,C2,33,97
Cohort,0.006942564501654172,0.027879729694654413,0.24901835769897446,0.8034108189588304,LonGen OPEL,Scavenging by Class A Receptors,CP:REACTOME,C2,48,62
Cohort,3.995221671648803e-4,0.01966840207986238,0.020312894028840994,0.9837997639278618,LGP Offspring,Scavenging by Class B Receptors,CP:REACTOME,C2,12,23
Cohort,-0.013466270291473027,0.05655669257464396,-0.2381021534047476,0.8118603499804659,LGP Proband,Scavenging by Class B Receptors,CP:REACTOME,C2,12,42
Cohort,0.015722779724677838,0.018329185849108108,0.8578002238677123,0.3912609854447947,LonGen OPEL,Scavenging by Class B Receptors,CP:REACTOME,C2,21,30
Cohort,-0.0076758467644377,0.011052769942417238,-0.6944726800998623,0.48762442931633243,LGP Offspring,Scavenging by Class F Receptors,CP:REACTOME,C2,5,7
Cohort,0.007124883899373905,0.03720017521060492,0.1915282349891396,0.848158380366749,LGP Proband,Scavenging by Class F Receptors,CP:REACTOME,C2,5,18
Cohort,0.02885974057595278,0.01277813094144136,2.2585259697375926,0.024182804053686235,LonGen OPEL,Scavenging by Class F Receptors,CP:REACTOME,C2,6,17
Cohort,0.004721477984544443,0.014892801991771787,0.3170308708296156,0.7513180630385965,LGP Offspring,Scavenging of heme from plasma,CP:REACTOME,C2,6,16
Cohort,-0.009697040162653043,0.042418385646789285,-0.22860464901702424,0.8192322519128641,LGP Proband,Scavenging of heme from plasma,CP:REACTOME,C2,6,24
Cohort,1.0155457950013146e-4,0.013554402909838599,0.007492368359982648,0.9940238881755095,LonGen OPEL,Scavenging of heme from plasma,CP:REACTOME,C2,13,13
Cohort,-0.0030221282598897553,0.0334718415847301,-0.09028867599769158,0.928084563579626,LGP Offspring,SCF(Skp2)-mediated degradation of p27/p21,CP:REACTOME,C2,31,61
Cohort,-0.13084870139242527,0.08152523033808194,-1.6050086684796943,0.10887046623631443,LGP Proband,SCF(Skp2)-mediated degradation of p27/p21,CP:REACTOME,C2,31,77
Cohort,-0.015909256732334353,0.025210852017981684,-0.6310479598621676,0.5281903153949616,LonGen OPEL,SCF(Skp2)-mediated degradation of p27/p21,CP:REACTOME,C2,46,48
Cohort,0.010787291974429902,0.028321068574469564,0.3808928305817621,0.703402440499362,LGP Offspring,Sealing of the nuclear envelope (NE) by ESCRT-III,CP:REACTOME,C2,25,59
Cohort,0.033584039037729094,0.08004964438136937,0.41954014033753023,0.6749294700219985,LGP Proband,Sealing of the nuclear envelope (NE) by ESCRT-III,CP:REACTOME,C2,25,85
Cohort,-0.016286815807279607,0.02469331514965242,-0.6595637608224856,0.5097245905366348,LonGen OPEL,Sealing of the nuclear envelope (NE) by ESCRT-III,CP:REACTOME,C2,44,49
Cohort,0.09005185669037861,0.04319429203962289,2.084809182837687,0.037461333263019425,LGP Offspring,Selective autophagy,CP:REACTOME,C2,45,136
Cohort,-0.003794841526026556,0.12494450017450491,-0.030372217430350713,0.9757774684112257,LGP Proband,Selective autophagy,CP:REACTOME,C2,45,210
Cohort,0.01164254006293079,0.04038439411478917,0.28829304780054077,0.7731974790472087,LonGen OPEL,Selective autophagy,CP:REACTOME,C2,121,141
Cohort,-0.024521524937946976,0.033742827273950705,-0.7267181477966274,0.4676501996984894,LGP Offspring,Selenoamino acid metabolism,CP:REACTOME,C2,41,71
Cohort,0.05385309868312422,0.09433335184133285,0.570880792762503,0.5682342374008251,LGP Proband,Selenoamino acid metabolism,CP:REACTOME,C2,41,98
Cohort,-6.572471046376139e-4,0.026998580970459707,-0.024343764783665327,0.9805845054101928,LonGen OPEL,Selenoamino acid metabolism,CP:REACTOME,C2,52,64
Cohort,0.04499335842847864,0.02568753021674615,1.751564204453828,0.08030224404883395,LGP Offspring,Sema3A PAK dependent Axon repulsion,CP:REACTOME,C2,14,43
Cohort,0.025127240644284128,0.06917066875933882,0.36326438785358234,0.716499446893529,LGP Proband,Sema3A PAK dependent Axon repulsion,CP:REACTOME,C2,14,61
Cohort,-0.0016383151119892339,0.021804189015589424,-0.07513763115967677,0.9401240859252789,LonGen OPEL,Sema3A PAK dependent Axon repulsion,CP:REACTOME,C2,29,30
Cohort,0.05500975488616843,0.028837207179047954,1.907596479250476,0.05686686824970652,LGP Offspring,SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,CP:REACTOME,C2,17,53
Cohort,0.006736420638147984,0.07669654997096527,0.0878321207498664,0.9300311922876444,LGP Proband,SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,CP:REACTOME,C2,17,77
Cohort,1.2274387636829323e-4,0.023852547609253066,0.005145944088617078,0.9958954381280176,LonGen OPEL,SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,CP:REACTOME,C2,35,41
Cohort,-0.013870166838720815,0.031269582869358555,-0.4435673765355009,0.6574973278526965,LGP Offspring,Sema4D in semaphorin signaling,CP:REACTOME,C2,32,64
Cohort,-0.0022378965927261365,0.09096572965190608,-0.02460153511976193,0.9803786797670873,LGP Proband,Sema4D in semaphorin signaling,CP:REACTOME,C2,32,101
Cohort,-0.025472540966733587,0.02518696427493488,-1.011338273587933,0.3121618663941018,LonGen OPEL,Sema4D in semaphorin signaling,CP:REACTOME,C2,51,48
Cohort,-0.0065423502901918685,0.025908545587545934,-0.25251708043915566,0.8007181742286165,LGP Offspring,Sema4D induced cell migration and growth-cone collapse,CP:REACTOME,C2,23,47
Cohort,-0.031403504062205004,0.07734577027626757,-0.4060144976258736,0.6848360968535411,LGP Proband,Sema4D induced cell migration and growth-cone collapse,CP:REACTOME,C2,23,79
Cohort,-0.03405427067065968,0.022207728597885237,-1.5334423113358178,0.12556424688150325,LonGen OPEL,Sema4D induced cell migration and growth-cone collapse,CP:REACTOME,C2,41,33
Cohort,-0.004607078653861574,0.018048157363442202,-0.2552658734676999,0.7985953999260901,LGP Offspring,Sema4D mediated inhibition of cell attachment and migration,CP:REACTOME,C2,10,21
Cohort,0.003027047046428859,0.04981279510747197,0.06076846400403657,0.9515581647758569,LGP Proband,Sema4D mediated inhibition of cell attachment and migration,CP:REACTOME,C2,10,32
Cohort,0.0062721081851148264,0.014579823717819788,0.4301909478815519,0.6671731867864032,LonGen OPEL,Sema4D mediated inhibition of cell attachment and migration,CP:REACTOME,C2,14,19
Cohort,0.03154646381163651,0.04660203319531208,0.6769332076011207,0.4986799041967095,LGP Offspring,Semaphorin interactions,CP:REACTOME,C2,58,135
Cohort,0.15233651681817725,0.12957313993131564,1.1756797504400067,0.24005837887022158,LGP Proband,Semaphorin interactions,CP:REACTOME,C2,58,217
Cohort,-0.014617743793232493,0.03995537161610589,-0.36585177917204315,0.7145728845527433,LonGen OPEL,Semaphorin interactions,CP:REACTOME,C2,105,115
Cohort,-0.00211630452637982,0.03420766686278621,-0.06186638027284178,0.950687527547948,LGP Offspring,Senescence-Associated Secretory Phenotype (SASP),CP:REACTOME,C2,38,81
Cohort,0.005399486883307814,0.09048865959226285,0.05967031567975058,0.9524325090271759,LGP Proband,Senescence-Associated Secretory Phenotype (SASP),CP:REACTOME,C2,38,93
Cohort,0.01897723318739725,0.03085334592340472,0.6150786120412797,0.5386785992023179,LonGen OPEL,Senescence-Associated Secretory Phenotype (SASP),CP:REACTOME,C2,57,79
Cohort,0.007646332600194112,0.016601386575680353,0.460583973834773,0.6452452382840074,LGP Offspring,Sensing of DNA Double Strand Breaks,CP:REACTOME,C2,9,19
Cohort,0.02902574628504715,0.04690797622062919,0.6187806130992751,0.536229863380556,LGP Proband,Sensing of DNA Double Strand Breaks,CP:REACTOME,C2,9,28
Cohort,0.0029569546003043556,0.013959984044570306,0.21181647420682076,0.8323044374178384,LonGen OPEL,Sensing of DNA Double Strand Breaks,CP:REACTOME,C2,14,16
Cohort,-0.3180554606560694,0.12303959431276613,-2.5849846338697584,0.009946666634988315,LGP Offspring,Sensory Perception,CP:REACTOME,C2,528,967
Cohort,-0.9213893933017795,0.36019632271342633,-2.5580199885461927,0.010702691321085565,LGP Proband,Sensory Perception,CP:REACTOME,C2,528,1336
Cohort,0.19157580571882415,0.10959794762813567,1.7479871645848537,0.08085179158340118,LonGen OPEL,Sensory Perception,CP:REACTOME,C2,739,991
Cohort,-0.20348321375124304,0.06989062254484926,-2.9114522999228765,0.0037160031776197386,LGP Offspring,Sensory processing of sound,CP:REACTOME,C2,185,289
Cohort,-0.4504594803640819,0.1886705957037561,-2.3875446975922916,0.01718310959098444,LGP Proband,Sensory processing of sound,CP:REACTOME,C2,185,389
Cohort,-0.015362078592530191,0.0581913918920621,-0.2639922863681447,0.7918541925887115,LonGen OPEL,Sensory processing of sound,CP:REACTOME,C2,230,277
Cohort,-0.13198666298985512,0.05967369822107156,-2.2118063221234863,0.0273137474629318,LGP Offspring,Sensory processing of sound by outer hair cells of the cochlea,CP:REACTOME,C2,128,201
Cohort,-0.35505056416968217,0.1572739980719202,-2.257528698464957,0.024232932937026833,LGP Proband,Sensory processing of sound by outer hair cells of the cochlea,CP:REACTOME,C2,128,266
Cohort,-0.09407566079668873,0.048226986639189874,-1.950685028291642,0.05144509781918744,LonGen OPEL,Sensory processing of sound by outer hair cells of the cochlea,CP:REACTOME,C2,171,171
Cohort,0.12229637477700464,0.06510848393038164,1.8783477573793936,0.060763775137122375,LGP Offspring,Separation of Sister Chromatids,CP:REACTOME,C2,111,293
Cohort,-0.19828660173346632,0.16308375305267392,-1.215857484402032,0.22438325024230443,LGP Proband,Separation of Sister Chromatids,CP:REACTOME,C2,111,361
Cohort,-0.04492958306135421,0.05465942639271242,-0.8219914848455954,0.4113278851095218,LonGen OPEL,Separation of Sister Chromatids,CP:REACTOME,C2,218,234
Cohort,0.0025277533133624044,0.01511646759300291,0.16721851833509352,0.8672481222029774,LGP Offspring,Serine biosynthesis,CP:REACTOME,C2,7,16
Cohort,0.00939170101655244,0.04218266977621417,0.22264358956834457,0.8238674217589146,LGP Proband,Serine biosynthesis,CP:REACTOME,C2,7,23
Cohort,0.01684490703239328,0.013067800792856726,1.2890391657639317,0.19775894229102653,LonGen OPEL,Serine biosynthesis,CP:REACTOME,C2,8,16
Cohort,8.682436835539e-4,0.006331662997394929,0.13712727350004672,0.8909710253105438,LGP Offspring,Serotonin and melatonin biosynthesis,CP:REACTOME,C2,1,3
Cohort,0.024818076739136493,0.0201180235755813,1.2336240011797177,0.21769059070911834,LGP Proband,Serotonin and melatonin biosynthesis,CP:REACTOME,C2,1,6
Cohort,-0.011868587634543862,0.006849739009343417,-1.7327065481406607,0.08353515438318432,LonGen OPEL,Serotonin and melatonin biosynthesis,CP:REACTOME,C2,5,2
Cohort,-0.021026168510089746,0.024027097635463672,-0.8751023044520951,0.3818290548043829,LGP Offspring,Serotonin Neurotransmitter Release Cycle,CP:REACTOME,C2,21,38
Cohort,0.018408390805525473,0.06406721829936707,0.2873293283861418,0.7739315435824645,LGP Proband,Serotonin Neurotransmitter Release Cycle,CP:REACTOME,C2,21,49
Cohort,-0.017503062561726648,0.020098001146408497,-0.8708857380503452,0.38407911143669193,LonGen OPEL,Serotonin Neurotransmitter Release Cycle,CP:REACTOME,C2,34,27
Cohort,-0.0077763292497687285,0.013461185161987911,-0.5776853342547991,0.5636689428329626,LGP Offspring,Serotonin receptors,CP:REACTOME,C2,7,11
Cohort,-0.007080050278165416,0.03288535358785033,-0.21529494153838682,0.8295900104565962,LGP Proband,Serotonin receptors,CP:REACTOME,C2,7,11
Cohort,6.112308974856313e-4,0.006370854558629889,0.09594174405655904,0.9235909888069909,LonGen OPEL,Serotonin receptors,CP:REACTOME,C2,3,3
Cohort,0.011569893328414987,0.020194609599616102,0.5729198809881886,0.5668894538882209,LGP Offspring,SHC-mediated cascade:FGFR1,CP:REACTOME,C2,10,30
Cohort,0.11947326492412816,0.05719181083262814,2.0889925180681326,0.03701101236503135,LGP Proband,SHC-mediated cascade:FGFR1,CP:REACTOME,C2,10,39
Cohort,-0.001275687060862005,0.013964026471906915,-0.09135524509556435,0.9272333064048659,LonGen OPEL,SHC-mediated cascade:FGFR1,CP:REACTOME,C2,14,16
Cohort,0.002690235867187472,0.012974282730989505,0.20735141379043284,0.8357978699278049,LGP Offspring,SHC-mediated cascade:FGFR3,CP:REACTOME,C2,6,11
Cohort,0.013431339316675553,0.0406684985902321,0.3302639581560933,0.7412834666499799,LGP Proband,SHC-mediated cascade:FGFR3,CP:REACTOME,C2,6,21
Cohort,-0.010757099899846481,0.012277712229850897,-0.8761485607793169,0.3812135926738971,LonGen OPEL,SHC-mediated cascade:FGFR3,CP:REACTOME,C2,13,10
Cohort,0.0024474611335834587,0.00960858890148318,0.25471597949264635,0.7990199405025378,LGP Offspring,SHC-mediated cascade:FGFR4,CP:REACTOME,C2,3,6
Cohort,0.010797952908508721,0.02941474095688597,0.3670932517928881,0.7136425841005183,LGP Proband,SHC-mediated cascade:FGFR4,CP:REACTOME,C2,3,11
Cohort,0.0020715454003579475,0.008590107268092187,0.24115477673400762,0.8094972625764998,LonGen OPEL,SHC-mediated cascade:FGFR4,CP:REACTOME,C2,5,6
Cohort,-0.007259737900099112,0.01411368746449185,-0.5143757021943162,0.6071574588034054,LGP Offspring,SHC-related events triggered by IGF1R,CP:REACTOME,C2,8,12
Cohort,0.0010697451466699175,0.038499922599178976,0.027785644085755387,0.9778397630728942,LGP Proband,SHC-related events triggered by IGF1R,CP:REACTOME,C2,8,15
Cohort,-0.010995013478173688,0.011483658143266543,-0.9574486928296997,0.33863153163408566,LonGen OPEL,SHC-related events triggered by IGF1R,CP:REACTOME,C2,11,9
Cohort,0.01071209275080677,0.017085430292969,0.626972371612731,0.5308890307705733,LGP Offspring,SHC1 events in EGFR signaling,CP:REACTOME,C2,8,19
Cohort,-0.00327075545450179,0.04039206019925709,-0.08097520746322188,0.9354810967416147,LGP Proband,SHC1 events in EGFR signaling,CP:REACTOME,C2,8,19
Cohort,-0.011107567556205303,0.012278736409293748,-0.9046181289304337,0.3659414311078585,LonGen OPEL,SHC1 events in EGFR signaling,CP:REACTOME,C2,11,10
Cohort,0.013217502044831348,0.02235880264394879,0.5911542874326746,0.5546146550360589,LGP Offspring,SHC1 events in ERBB2 signaling,CP:REACTOME,C2,14,36
Cohort,0.005028859077853239,0.059396139407203626,0.08466642997412276,0.932546904241958,LGP Proband,SHC1 events in ERBB2 signaling,CP:REACTOME,C2,14,42
Cohort,0.004713425908164669,0.01820106287996581,0.25896432198763564,0.7957297204388913,LonGen OPEL,SHC1 events in ERBB2 signaling,CP:REACTOME,C2,20,26
Cohort,-0.01200243399975575,0.015587844160713165,-0.7699867843178786,0.44157671600813353,LGP Offspring,SHC1 events in ERBB4 signaling,CP:REACTOME,C2,9,13
Cohort,-0.0011551600227193066,0.043411136385410186,-0.026609762353688074,0.9787773524456006,LGP Proband,SHC1 events in ERBB4 signaling,CP:REACTOME,C2,9,20
Cohort,0.016275475527485532,0.015457244289621867,1.0529351301262044,0.2926902393733014,LonGen OPEL,SHC1 events in ERBB4 signaling,CP:REACTOME,C2,13,20
Cohort,-0.001211824884652608,0.03171790678068456,-0.03820633224732787,0.9695344520661414,LGP Offspring,Sialic acid metabolism,CP:REACTOME,C2,37,76
Cohort,-0.1310336007779659,0.0893180352691207,-1.4670452656415207,0.1427407175572752,LGP Proband,Sialic acid metabolism,CP:REACTOME,C2,37,98
Cohort,0.0024347345844670915,0.02967135226218275,0.08205674493542554,0.9346222179896904,LonGen OPEL,Sialic acid metabolism,CP:REACTOME,C2,56,70
Cohort,-0.013465675248775455,0.013972379042656363,-0.9637353243614427,0.33552325532191374,LGP Offspring,Signal amplification,CP:REACTOME,C2,8,12
Cohort,-0.01899972971389791,0.041930495461718745,-0.4531243789199696,0.6505770430297355,LGP Proband,Signal amplification,CP:REACTOME,C2,8,20
Cohort,-0.0014565530886327467,0.01604140790234927,-0.09079957928252881,0.9276746875980899,LonGen OPEL,Signal amplification,CP:REACTOME,C2,17,19
Cohort,-4.4061602091301065e-4,0.013481525489119517,-0.032682949809249476,0.9739370680092747,LGP Offspring,Signal attenuation,CP:REACTOME,C2,6,12
Cohort,-1.1137845574183052e-4,0.03577298006969345,-0.003113479937227521,0.997516550996617,LGP Proband,Signal attenuation,CP:REACTOME,C2,6,15
Cohort,-0.018890508182091068,0.011721614733634811,-1.6115960651637304,0.10744627459701167,LonGen OPEL,Signal attenuation,CP:REACTOME,C2,12,7
Cohort,-0.03366382156182047,0.016613078932011797,-2.0263445264774815,0.04312164493118568,LGP Offspring,Signal regulatory protein family interactions,CP:REACTOME,C2,13,15
Cohort,0.07288496523593553,0.05398346806176393,1.3501349182039564,0.17733899440066284,LGP Proband,Signal regulatory protein family interactions,CP:REACTOME,C2,13,35
Cohort,0.006514140543666637,0.015616004804953393,0.4171451421172945,0.6766847241188279,LonGen OPEL,Signal regulatory protein family interactions,CP:REACTOME,C2,16,22
Cohort,-0.007019636718262877,0.018037266813974086,-0.38917408001219594,0.6972699352728322,LGP Offspring,Signal transduction by L1,CP:REACTOME,C2,10,21
Cohort,0.07643341249904886,0.0592042443980153,1.291012380551742,0.1970571192463966,LGP Proband,Signal transduction by L1,CP:REACTOME,C2,10,46
Cohort,-0.015014041745041113,0.02036895075560803,-0.7371043273256188,0.4612761099330007,LonGen OPEL,Signal transduction by L1,CP:REACTOME,C2,30,28
Cohort,-0.008282453840114608,0.005437761409668071,-1.5231366763147818,0.128192156954921,LGP Offspring,Signaling by Activin,CP:REACTOME,C2,2,1
Cohort,0.018446914763567017,0.01225809899292098,1.5048756560230148,0.13273465313828817,LGP Proband,Signaling by Activin,CP:REACTOME,C2,2,1
Cohort,-0.0036867596538479844,0.005152760476752542,-0.7154921464875688,0.4745148057594839,LonGen OPEL,Signaling by Activin,CP:REACTOME,C2,2,2
Cohort,0.015204199412979548,0.018921584890524448,0.8035373094245138,0.4219466908778552,LGP Offspring,Signaling by BMP,CP:REACTOME,C2,8,26
Cohort,0.13587590675947264,0.049724840701001166,2.7325558984995784,0.006417449728660888,LGP Proband,Signaling by BMP,CP:REACTOME,C2,8,34
Cohort,-0.009599555558321779,0.01737812905052578,-0.552392926212695,0.5808342442850603,LonGen OPEL,Signaling by BMP,CP:REACTOME,C2,18,18
Cohort,0.0108043094222461,0.04318421459138312,0.25019117574508276,0.8025155235712362,LGP Offspring,Signaling by BRAF and RAF fusions,CP:REACTOME,C2,61,124
Cohort,-0.13400806781592184,0.11583012306439261,-1.1569362465532709,0.2476296689036848,LGP Proband,Signaling by BRAF and RAF fusions,CP:REACTOME,C2,61,176
Cohort,-0.06379834793248078,0.03715474126011001,-1.7170984312835418,0.08635017420463302,LonGen OPEL,Signaling by BRAF and RAF fusions,CP:REACTOME,C2,110,106
Cohort,-0.03391728221916492,0.01984480680981054,-1.7091263494889488,0.08788652085393364,LGP Offspring,Signaling by CSF3 (G-CSF),CP:REACTOME,C2,17,19
Cohort,0.026125539249733373,0.06227263772644355,0.4195348102082945,0.6749333630306824,LGP Proband,Signaling by CSF3 (G-CSF),CP:REACTOME,C2,17,43
Cohort,-0.01691755119380445,0.01861313227888163,-0.9089040436788289,0.3636758832896486,LonGen OPEL,Signaling by CSF3 (G-CSF),CP:REACTOME,C2,27,24
Cohort,-0.02354444887949127,0.018165569739005506,-1.2961029693957862,0.19538233311050757,LGP Offspring,Signaling by CTNNB1 phospho-site mutants,CP:REACTOME,C2,15,19
Cohort,-0.009068900168727355,0.05029158963653801,-0.18032637731813886,0.8569401559238962,LGP Proband,Signaling by CTNNB1 phospho-site mutants,CP:REACTOME,C2,15,29
Cohort,-0.0032056146940276854,0.015308522944552674,-0.20940065254096635,0.834189061888802,LonGen OPEL,Signaling by CTNNB1 phospho-site mutants,CP:REACTOME,C2,17,20
Cohort,0.01415305471583581,0.017326286871061587,0.8168544605754094,0.4142993778537505,LGP Offspring,Signaling by cytosolic FGFR1 fusion mutants,CP:REACTOME,C2,8,22
Cohort,0.07735468008423974,0.05432491732471718,1.4239263287206936,0.1548418182050517,LGP Proband,Signaling by cytosolic FGFR1 fusion mutants,CP:REACTOME,C2,8,42
Cohort,-0.011194097293170571,0.014768516254082188,-0.7579703404582971,0.4486930762138064,LonGen OPEL,Signaling by cytosolic FGFR1 fusion mutants,CP:REACTOME,C2,18,14
Cohort,0.012383332373343759,0.0324515547953616,0.3815944244099438,0.70288213277291,LGP Offspring,Signaling by EGFR,CP:REACTOME,C2,36,73
Cohort,-0.03735629976068817,0.08522541567047683,-0.4383234680265557,0.6612653263729169,LGP Proband,Signaling by EGFR,CP:REACTOME,C2,36,94
Cohort,-0.014569940531400167,0.02868641092939104,-0.5079039189413669,0.6116614332800425,LonGen OPEL,Signaling by EGFR,CP:REACTOME,C2,55,60
Cohort,0.010584006861261454,0.023733780273429386,0.4459469473183983,0.6557783626593137,LGP Offspring,Signaling by EGFR in Cancer,CP:REACTOME,C2,18,37
Cohort,0.03228389994177929,0.059782289909623997,0.5400244786639078,0.5893243145001685,LGP Proband,Signaling by EGFR in Cancer,CP:REACTOME,C2,18,42
Cohort,-0.012465063039541736,0.017274946581855886,-0.721568832672048,0.47077149743518887,LonGen OPEL,Signaling by EGFR in Cancer,CP:REACTOME,C2,21,24
Cohort,-0.010970878931555347,0.03667750204405685,-0.2991173967730184,0.7649424069154511,LGP Offspring,Signaling by ERBB2,CP:REACTOME,C2,45,92
Cohort,-0.03906728155575768,0.09458546287330873,-0.41303684909895555,0.6796857834820675,LGP Proband,Signaling by ERBB2,CP:REACTOME,C2,45,109
Cohort,0.01913162834735002,0.028611821947352917,0.6686616595948733,0.5039051891700779,LonGen OPEL,Signaling by ERBB2,CP:REACTOME,C2,50,71
Cohort,0.005548102250095081,0.020232828080998327,0.2742128894628223,0.7840047944289239,LGP Offspring,Signaling by ERBB2 ECD mutants,CP:REACTOME,C2,13,29
Cohort,0.007326762795594252,0.049551187995362456,0.14786250525981276,0.8824870190627603,LGP Proband,Signaling by ERBB2 ECD mutants,CP:REACTOME,C2,13,28
Cohort,-0.00976750243573666,0.015369567753753722,-0.635509247379526,0.5252789876678581,LonGen OPEL,Signaling by ERBB2 ECD mutants,CP:REACTOME,C2,17,20
Cohort,-7.263445058542854e-4,0.02415823007756942,-0.03006613081844461,0.9760231863489783,LGP Offspring,Signaling by ERBB2 in Cancer,CP:REACTOME,C2,19,40
Cohort,-0.0025060886489352186,0.061016048182205296,-0.04107261488734194,0.9672478366297039,LGP Proband,Signaling by ERBB2 in Cancer,CP:REACTOME,C2,19,43
Cohort,0.01002589055188418,0.020528212594222075,0.4883956898763847,0.6254041076496355,LonGen OPEL,Signaling by ERBB2 in Cancer,CP:REACTOME,C2,25,36
Cohort,-0.006086947155225186,0.035351891649111296,-0.17218165340745506,0.8633462543068697,LGP Offspring,Signaling by ERBB4,CP:REACTOME,C2,40,77
Cohort,0.026419735632791336,0.09191406018125794,0.28743954494764606,0.7738471903033288,LGP Proband,Signaling by ERBB4,CP:REACTOME,C2,40,89
Cohort,-0.03126073176149119,0.028954023746571557,-1.0796679603190824,0.28061709401095825,LonGen OPEL,Signaling by ERBB4,CP:REACTOME,C2,61,59
Cohort,-0.021004816208436736,0.022023543977079466,-0.953743694942878,0.34055430292328615,LGP Offspring,Signaling by Erythropoietin,CP:REACTOME,C2,20,29
Cohort,0.06308589453780662,0.06459858379321423,0.9765832442975861,0.3290586958503452,LGP Proband,Signaling by Erythropoietin,CP:REACTOME,C2,20,43
Cohort,-0.012073288713776388,0.020596155638722004,-0.5861913711254874,0.5579130982230616,LonGen OPEL,Signaling by Erythropoietin,CP:REACTOME,C2,30,31
Cohort,-0.015706966550291166,0.04773771837419058,-0.3290263356780609,0.7422376905680417,LGP Offspring,Signaling by FGFR,CP:REACTOME,C2,71,142
Cohort,0.0074937662377107875,0.13212471531407557,0.056717369039526386,0.9547839228385872,LGP Proband,Signaling by FGFR,CP:REACTOME,C2,71,208
Cohort,0.032649865200155975,0.04013991185737657,0.8134015170777178,0.41623112053653166,LonGen OPEL,Signaling by FGFR,CP:REACTOME,C2,94,124
Cohort,-0.005500134369807851,0.029057791198869573,-0.1892826034905854,0.8499281450801184,LGP Offspring,Signaling by FGFR in disease,CP:REACTOME,C2,30,54
Cohort,0.07142544671170203,0.08569221194097804,0.8335115303231702,0.4047949439212254,LGP Proband,Signaling by FGFR in disease,CP:REACTOME,C2,30,96
Cohort,0.007256712728567541,0.024768819752683358,0.2929777357591444,0.7696155275314144,LonGen OPEL,Signaling by FGFR in disease,CP:REACTOME,C2,43,52
Cohort,-0.004339463400848174,0.03772899433618898,-0.11501667291157659,0.9084660611735726,LGP Offspring,Signaling by FGFR1,CP:REACTOME,C2,43,96
Cohort,0.12980153658861865,0.1069285906214115,1.2139086079249888,0.22512626434771837,LGP Proband,Signaling by FGFR1,CP:REACTOME,C2,43,133
Cohort,0.015325259979932207,0.0334339450582752,0.4583742646349498,0.6468086915500868,LonGen OPEL,Signaling by FGFR1,CP:REACTOME,C2,65,85
Cohort,0.007437361791705746,0.023023864821553174,0.3230283816096531,0.7467736406064034,LGP Offspring,Signaling by FGFR1 in disease,CP:REACTOME,C2,17,36
Cohort,0.09123064732404522,0.06639679343876224,1.3740218856831878,0.16980404059995544,LGP Proband,Signaling by FGFR1 in disease,CP:REACTOME,C2,17,58
Cohort,-0.003218827226253952,0.019149250771518057,-0.16809154909817808,0.8665539556950145,LonGen OPEL,Signaling by FGFR1 in disease,CP:REACTOME,C2,26,28
Cohort,-0.0102356541681039,0.03724574991984559,-0.2748140174417606,0.783543094944238,LGP Offspring,Signaling by FGFR2,CP:REACTOME,C2,47,87
Cohort,-0.13239699259440238,0.10156272074347623,-1.3035983245152158,0.19273029689666435,LGP Proband,Signaling by FGFR2,CP:REACTOME,C2,47,129
Cohort,0.014676741928972939,0.03067768309028375,0.4784175482150855,0.6324844174859732,LonGen OPEL,Signaling by FGFR2,CP:REACTOME,C2,54,70
Cohort,-0.014302922458833146,0.01383518495861664,-1.0338078241538213,0.3015957059025072,LGP Offspring,Signaling by FGFR2 IIIa TM,CP:REACTOME,C2,9,10
Cohort,-0.03824682370723943,0.04263608914812405,-0.8970528130374327,0.3699496044026098,LGP Proband,Signaling by FGFR2 IIIa TM,CP:REACTOME,C2,9,21
Cohort,0.01630744062572732,0.012766848879989611,1.2773269879685918,0.20185926277606633,LonGen OPEL,Signaling by FGFR2 IIIa TM,CP:REACTOME,C2,8,15
Cohort,-0.02061460610010127,0.02146897336378175,-0.9602045589603367,0.3372955812969186,LGP Offspring,Signaling by FGFR2 in disease,CP:REACTOME,C2,20,28
Cohort,-0.03589749606672431,0.06183887023978963,-0.5805005157359167,0.5617339513924966,LGP Proband,Signaling by FGFR2 in disease,CP:REACTOME,C2,20,44
Cohort,0.014342113425851469,0.018702635773000215,0.7668498493969631,0.44339816630331563,LonGen OPEL,Signaling by FGFR2 in disease,CP:REACTOME,C2,20,31
Cohort,4.947468848316203e-4,0.027756987092028763,0.017824228659662468,0.9857843355100129,LGP Offspring,Signaling by FGFR3,CP:REACTOME,C2,24,48
Cohort,0.013722603047834035,0.07819974524555003,0.17548142906021708,0.8607439573100764,LGP Proband,Signaling by FGFR3,CP:REACTOME,C2,24,76
Cohort,-0.01803708489211164,0.024272741999200497,-0.7431004248595297,0.45764013520441704,LonGen OPEL,Signaling by FGFR3,CP:REACTOME,C2,42,42
Cohort,0.003012272446743187,0.012981908991815113,0.2320361703846774,0.8165801449997082,LGP Offspring,Signaling by FGFR3 fusions in cancer,CP:REACTOME,C2,6,11
Cohort,0.0046964122351332415,0.04207507283136355,0.11161982425928084,0.9111517100181501,LGP Proband,Signaling by FGFR3 fusions in cancer,CP:REACTOME,C2,6,23
Cohort,-0.01506624978302231,0.013025502346451159,-1.1566732232117833,0.24775289905561326,LonGen OPEL,Signaling by FGFR3 fusions in cancer,CP:REACTOME,C2,15,11
Cohort,2.5197215122756643e-4,0.025883836074743757,0.009734729832933425,0.9922358041228752,LGP Offspring,Signaling by FGFR4,CP:REACTOME,C2,21,43
Cohort,0.011089216639667221,0.07216610169021385,0.15366240353774,0.8779131029078813,LGP Proband,Signaling by FGFR4,CP:REACTOME,C2,21,66
Cohort,-0.0026619206853441303,0.022457898862611778,-0.1185293736350257,0.9056781265514187,LonGen OPEL,Signaling by FGFR4,CP:REACTOME,C2,33,38
Cohort,-0.007434335204983652,0.015753004985772468,-0.4719312417978709,0.6371281601066343,LGP Offspring,Signaling by FGFR4 in disease,CP:REACTOME,C2,10,15
Cohort,0.011731453080264072,0.04254724702049578,0.2757276651674506,0.7828255481805062,LGP Proband,Signaling by FGFR4 in disease,CP:REACTOME,C2,10,20
Cohort,-0.0033726089686815187,0.012579028764454572,-0.2681136224293987,0.7886813232197509,LonGen OPEL,Signaling by FGFR4 in disease,CP:REACTOME,C2,11,13
Cohort,-0.03805017972751903,0.02604985745716287,-1.4606674831173196,0.1445713248686488,LGP Offspring,Signaling by FLT3 fusion proteins,CP:REACTOME,C2,26,37
Cohort,-0.012470995618398664,0.07331234585849179,-0.17010771476976472,0.8649666814366347,LGP Proband,Signaling by FLT3 fusion proteins,CP:REACTOME,C2,26,63
Cohort,-0.02477962592116608,0.022568464745170554,-1.0979757019789613,0.27254710933075516,LonGen OPEL,Signaling by FLT3 fusion proteins,CP:REACTOME,C2,40,38
Cohort,-0.018570135353833544,0.019526497100465723,-0.9510223599393376,0.3419329163121232,LGP Offspring,Signaling by FLT3 ITD and TKD mutants,CP:REACTOME,C2,16,21
Cohort,-0.001421135548062055,0.05706558269840359,-0.024903549229890038,0.9801378534709704,LGP Proband,Signaling by FLT3 ITD and TKD mutants,CP:REACTOME,C2,16,37
Cohort,0.004130240537657849,0.015182436696783791,0.272040688866023,0.7856612783325425,LonGen OPEL,Signaling by FLT3 ITD and TKD mutants,CP:REACTOME,C2,13,18
Cohort,-0.1045897147453749,0.13226996188849074,-0.7907291515933793,0.429379377706982,LGP Offspring,Signaling by GPCR,CP:REACTOME,C2,544,1075
Cohort,-0.6853418001101449,0.3617332106473099,-1.8946056926422317,0.058490340019254,LGP Proband,Signaling by GPCR,CP:REACTOME,C2,544,1582
Cohort,0.02996544484358509,0.11378144796182678,0.2633596722520035,0.7923415269807486,LonGen OPEL,Signaling by GPCR,CP:REACTOME,C2,848,1027
Cohort,5.503926336932228e-4,0.07370365288013726,0.007467643898034675,0.9940439407791087,LGP Offspring,Signaling by Hedgehog,CP:REACTOME,C2,171,347
Cohort,-0.378119064170286,0.19963684923414285,-1.8940344211043494,0.05856622748727538,LGP Proband,Signaling by Hedgehog,CP:REACTOME,C2,171,486
Cohort,-0.09282794876057887,0.06510572211893587,-1.4258032280327024,0.15431717795560704,LonGen OPEL,Signaling by Hedgehog,CP:REACTOME,C2,300,318
Cohort,0.01766229411157352,0.02701833173972049,0.6537151990627028,0.513517608439934,LGP Offspring,Signaling by Hippo,CP:REACTOME,C2,21,52
Cohort,0.011033672910198787,0.07768622821171843,0.14202868596128385,0.8870916490613293,LGP Proband,Signaling by Hippo,CP:REACTOME,C2,21,77
Cohort,0.002594866314222434,0.02551923784447216,0.10168275126541525,0.9190341011953747,LonGen OPEL,Signaling by Hippo,CP:REACTOME,C2,47,56
Cohort,0.03323637410855479,0.04019403517774634,0.8268981693820157,0.40858655745296646,LGP Offspring,Signaling by Insulin receptor,CP:REACTOME,C2,46,113
Cohort,-0.013745990352168953,0.11264897825296542,-0.12202498917745042,0.9029086232723919,LGP Proband,Signaling by Insulin receptor,CP:REACTOME,C2,46,149
Cohort,0.0014589387354117236,0.033551888108785254,0.043483059155461176,0.9653273736592425,LonGen OPEL,Signaling by Insulin receptor,CP:REACTOME,C2,79,94
Cohort,-0.07265430549863808,0.10411365512222513,-0.6978364693213865,0.4855194206988226,LGP Offspring,Signaling by Interleukins,CP:REACTOME,C2,337,675
Cohort,-0.17735795156591302,0.2869590324903726,-0.6180601810185687,0.5367044066125184,LGP Proband,Signaling by Interleukins,CP:REACTOME,C2,337,896
Cohort,-0.2383583159333212,0.08927184968213574,-2.670027749867709,0.007739164863352002,LonGen OPEL,Signaling by Interleukins,CP:REACTOME,C2,564,566
Cohort,0.011639050369595262,0.02050658843051641,0.5675761431031051,0.5705112520914222,LGP Offspring,Signaling by KIT in disease,CP:REACTOME,C2,13,30
Cohort,-0.04918893649283653,0.05476919437866033,-0.8981132012414987,0.36938440235656966,LGP Proband,Signaling by KIT in disease,CP:REACTOME,C2,13,38
Cohort,-0.012833666762307214,0.019718608547649442,-0.6508403841627585,0.5153373504669997,LonGen OPEL,Signaling by KIT in disease,CP:REACTOME,C2,28,27
Cohort,0.003498186131436578,0.015190896080583967,0.23028174986383695,0.8179425092650017,LGP Offspring,Signaling by Leptin,CP:REACTOME,C2,6,17
Cohort,0.034907856429036294,0.042431038376444616,0.8226962564370147,0.41091590211334694,LGP Proband,Signaling by Leptin,CP:REACTOME,C2,6,24
Cohort,-0.006927443328846903,0.015480150057010136,-0.4475049210333612,0.6546322868582184,LonGen OPEL,Signaling by Leptin,CP:REACTOME,C2,16,19
Cohort,0,0,NA,NA,LGP Offspring,Signaling by LRP5 mutants ,CP:REACTOME,C2,0,0
Cohort,-0.001436542448977974,0.017430082637061414,-0.08241742043858517,0.9343345594015007,LGP Proband,Signaling by LRP5 mutants ,CP:REACTOME,C2,0,5
Cohort,0.0028431977087675273,0.0045107834056196065,0.630311290323855,0.5286718390994704,LonGen OPEL,Signaling by LRP5 mutants ,CP:REACTOME,C2,1,2
Cohort,0.008501911252270478,0.009651226735640539,0.8809150883249058,0.37867686235980347,LGP Offspring,Signaling by MAPK mutants,CP:REACTOME,C2,1,6
Cohort,-0.009011430815266454,0.02085574424494909,-0.4320838762418594,0.6657921405919245,LGP Proband,Signaling by MAPK mutants,CP:REACTOME,C2,1,6
Cohort,0.0033129039365623067,0.004500069284575087,0.7361895399961876,0.46183224629417563,LonGen OPEL,Signaling by MAPK mutants,CP:REACTOME,C2,1,2
Cohort,-0.022531277910076256,0.027453155376517248,-0.8207172400061873,0.41209666226372665,LGP Offspring,Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,CP:REACTOME,C2,30,50
Cohort,-0.11915419662275686,0.07179475303336694,-1.6596504840316033,0.09736072294733161,LGP Proband,Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,CP:REACTOME,C2,30,53
Cohort,0.0027045526005601405,0.020521322838240773,0.13179231289711502,0.8951818708165455,LonGen OPEL,Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,CP:REACTOME,C2,27,36
Cohort,0.07621391361863701,0.06592425826659952,1.1560829901252108,0.24805562428201797,LGP Offspring,Signaling by MET,CP:REACTOME,C2,125,289
Cohort,-0.09389248460050051,0.1745817844632146,-0.5378137523865453,0.5908491158190426,LGP Proband,Signaling by MET,CP:REACTOME,C2,125,367
Cohort,-0.019645001147656656,0.055114640553360836,-0.3564388872070531,0.7216063676666424,LonGen OPEL,Signaling by MET,CP:REACTOME,C2,200,245
Cohort,0.020198145923264122,0.03413670142509006,0.5916841721683962,0.5542599109823306,LGP Offspring,Signaling by moderate kinase activity BRAF mutants,CP:REACTOME,C2,36,78
Cohort,-0.13898440670417425,0.09343188808141625,-1.487547876406647,0.1372481391005308,LGP Proband,Signaling by moderate kinase activity BRAF mutants,CP:REACTOME,C2,36,117
Cohort,-0.034565222703879586,0.030247862508829465,-1.142732736694696,0.253493159468554,LonGen OPEL,Signaling by moderate kinase activity BRAF mutants,CP:REACTOME,C2,71,73
Cohort,-0.0035888175314190097,0.007082390525484087,-0.5067240387981445,0.6125136967861449,LGP Offspring,Signaling by MRAS-complex mutants,CP:REACTOME,C2,2,3
Cohort,0.03352011330214538,0.030441114207448043,1.1011460708604417,0.27115078572833334,LGP Proband,Signaling by MRAS-complex mutants,CP:REACTOME,C2,2,11
Cohort,-0.0036549338344031624,0.006358104038435059,-0.5748464970546099,0.5655575486141673,LonGen OPEL,Signaling by MRAS-complex mutants,CP:REACTOME,C2,3,3
Cohort,0.006056274205802045,0.02195620042834487,0.27583434691111475,0.7827596004724688,LGP Offspring,Signaling by MST1,CP:REACTOME,C2,16,33
Cohort,0.005260040410403733,0.05877258973925558,0.0894981901212774,0.9287074795012831,LGP Proband,Signaling by MST1,CP:REACTOME,C2,16,42
Cohort,-7.587687522723667e-4,0.017039885420092844,-0.044528982065668875,0.9644939184240875,LonGen OPEL,Signaling by MST1,CP:REACTOME,C2,20,23
Cohort,-0.014527423284452792,0.014833130564181079,-0.9793902387358131,0.3277375642718272,LGP Offspring,Signaling by NODAL,CP:REACTOME,C2,9,13
Cohort,0.03850961084729704,0.04889893956423191,0.7875346825612074,0.43119268738693295,LGP Proband,Signaling by NODAL,CP:REACTOME,C2,9,30
Cohort,-0.019212665813566825,0.015616099650747004,-1.2303114249560887,0.21894396597146057,LonGen OPEL,Signaling by NODAL,CP:REACTOME,C2,21,17
Cohort,-0.10543522727408387,0.06477221460939467,-1.6277848134405362,0.10403647622224009,LGP Offspring,Signaling by NOTCH,CP:REACTOME,C2,156,281
Cohort,-0.09428673907780585,0.1815937948663637,-0.5192178463322065,0.6037465892283447,LGP Proband,Signaling by NOTCH,CP:REACTOME,C2,156,381
Cohort,-0.04626523541347425,0.055244544854146746,-0.8374625139119325,0.40258400761526425,LonGen OPEL,Signaling by NOTCH,CP:REACTOME,C2,216,234
Cohort,-0.1125960098074704,0.04961985404760054,-2.2691725312101196,0.023572131998461383,LGP Offspring,Signaling by NOTCH1,CP:REACTOME,C2,93,144
Cohort,-0.01386356729420213,0.14022270196066397,-0.09886820821703474,0.9212666692113346,LGP Proband,Signaling by NOTCH1,CP:REACTOME,C2,93,216
Cohort,-0.025547083026866913,0.044651730292720675,-0.57214094189384,0.5673880344034511,LonGen OPEL,Signaling by NOTCH1,CP:REACTOME,C2,141,151
Cohort,-0.04617482308665319,0.020975942744566215,-2.2013228987581357,0.028050373381108627,LGP Offspring,Signaling by NOTCH1 HD Domain Mutants in Cancer,CP:REACTOME,C2,20,24
Cohort,0.007451237457034442,0.06036543622388461,0.12343549426859328,0.9017919920137576,LGP Proband,Signaling by NOTCH1 HD Domain Mutants in Cancer,CP:REACTOME,C2,20,39
Cohort,0.005337686309939377,0.01968025697493029,0.2712203563570736,0.786291876034635,LonGen OPEL,Signaling by NOTCH1 HD Domain Mutants in Cancer,CP:REACTOME,C2,26,34
Cohort,-0.12755761218501216,0.04163132964308261,-3.0639812198793637,0.002270988005254234,LGP Offspring,Signaling by NOTCH1 PEST Domain Mutants in Cancer,CP:REACTOME,C2,69,91
Cohort,0.0033962724990607525,0.11973541510466534,0.02836481166488578,0.9773779749599338,LGP Proband,Signaling by NOTCH1 PEST Domain Mutants in Cancer,CP:REACTOME,C2,69,157
Cohort,-0.034568126410473014,0.03792446625670878,-0.9114993518032165,0.3623082776487473,LonGen OPEL,Signaling by NOTCH1 PEST Domain Mutants in Cancer,CP:REACTOME,C2,107,110
Cohort,-0.006783013382020191,0.017688004355625616,-0.38348098777253375,0.7014837342198552,LGP Offspring,Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,CP:REACTOME,C2,11,21
Cohort,-0.015770494112517963,0.046329837767946885,-0.34039605732072553,0.7336440069459125,LGP Proband,Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,CP:REACTOME,C2,11,25
Cohort,0.0059584496864606,0.015272449040097091,0.39014369410020444,0.6965346690035833,LonGen OPEL,Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,CP:REACTOME,C2,15,21
Cohort,-0.06029998157495937,0.024845854773609812,-2.426963456254578,0.015486105484122508,LGP Offspring,Signaling by NOTCH2,CP:REACTOME,C2,28,32
Cohort,-0.015700432625609922,0.07683515938133222,-0.204339169099511,0.8381383167817908,LGP Proband,Signaling by NOTCH2,CP:REACTOME,C2,28,66
Cohort,-0.02368278074868648,0.0232832336226875,-1.0171602936462252,0.3093862372874341,LonGen OPEL,Signaling by NOTCH2,CP:REACTOME,C2,43,38
Cohort,-0.04468394019776534,0.035093524628679075,-1.2732816287495043,0.20335579229362657,LGP Offspring,Signaling by NOTCH3,CP:REACTOME,C2,44,77
Cohort,0.07743074979232216,0.0980451600319661,0.7897457637590378,0.4299007319695497,LGP Proband,Signaling by NOTCH3,CP:REACTOME,C2,44,101
Cohort,-0.054229268921097945,0.03137411056655072,-1.7284719133652218,0.08429143404438742,LonGen OPEL,Signaling by NOTCH3,CP:REACTOME,C2,80,71
Cohort,-0.023141007037661452,0.04056462833539428,-0.5704725517593363,0.5685467965315836,LGP Offspring,Signaling by NOTCH4,CP:REACTOME,C2,51,96
Cohort,-0.08676410890926285,0.10277241237658595,-0.8442354023114264,0.3987799697032284,LGP Proband,Signaling by NOTCH4,CP:REACTOME,C2,51,124
Cohort,-0.03917042082275387,0.0344178052257869,-1.1380859577125553,0.2554270171045635,LonGen OPEL,Signaling by NOTCH4,CP:REACTOME,C2,87,84
Cohort,-0.0015026684571749496,0.022473405089248607,-0.06686429809845923,0.9467095057045201,LGP Offspring,Signaling by NTRK2 (TRKB),CP:REACTOME,C2,16,31
Cohort,-0.015156371373571287,0.061136919435568274,-0.24790865345357266,0.8042661075871465,LGP Proband,Signaling by NTRK2 (TRKB),CP:REACTOME,C2,16,47
Cohort,0.02988299230047568,0.02075260531079273,1.439963409554874,0.15027091530240944,LonGen OPEL,Signaling by NTRK2 (TRKB),CP:REACTOME,C2,23,40
Cohort,-0.010332915106760033,0.02137551554534802,-0.48339957391150723,0.6289685817273124,LGP Offspring,Signaling by NTRK3 (TRKC),CP:REACTOME,C2,17,28
Cohort,-0.031754360495613976,0.05582710622622041,-0.5687982530733404,0.5696461925011119,LGP Proband,Signaling by NTRK3 (TRKC),CP:REACTOME,C2,17,34
Cohort,0.0032884339012821825,0.01649725083330163,0.1993322362926127,0.8420537701109105,LonGen OPEL,Signaling by NTRK3 (TRKC),CP:REACTOME,C2,16,24
Cohort,2.0709401447426327e-4,0.047883682817120896,0.0043249391502571816,0.9965504845432496,LGP Offspring,Signaling by NTRKs,CP:REACTOME,C2,73,150
Cohort,-0.08178926872639308,0.13240556205232465,-0.6177177715092604,0.5369300233596466,LGP Proband,Signaling by NTRKs,CP:REACTOME,C2,73,198
Cohort,-0.0354974744328833,0.040353233038507165,-0.8796686599809674,0.37930431608567783,LonGen OPEL,Signaling by NTRKs,CP:REACTOME,C2,114,127
Cohort,-0.054402365256569205,0.08684830129635433,-0.6264067856771411,0.5312596213034724,LGP Offspring,Signaling by Nuclear Receptors,CP:REACTOME,C2,249,483
Cohort,-0.21930678942839288,0.22845126178263667,-0.9599718894836115,0.3373475810591169,LGP Proband,Signaling by Nuclear Receptors,CP:REACTOME,C2,249,626
Cohort,-0.08261751869858651,0.07189913000176473,-1.1490753601129624,0.25087006074989077,LonGen OPEL,Signaling by Nuclear Receptors,CP:REACTOME,C2,384,425
Cohort,-0.07030125560936852,0.05226241799899012,-1.3451588790003357,0.17902500575514319,LGP Offspring,Signaling by PDGF,CP:REACTOME,C2,105,180
Cohort,-0.3151361840951684,0.13383829937746936,-2.3546039180188445,0.018773379110333197,LGP Proband,Signaling by PDGF,CP:REACTOME,C2,105,217
Cohort,-0.00217252184037578,0.04146437688304965,-0.05239489903594552,0.9582271841657359,LonGen OPEL,Signaling by PDGF,CP:REACTOME,C2,129,148
Cohort,-0.06337006709794646,0.032047421579301294,-1.9773842629160454,0.04840402233952268,LGP Offspring,Signaling by PDGFR in disease,CP:REACTOME,C2,46,62
Cohort,-0.2149927255393377,0.08781496420913831,-2.448247032559456,0.014560362479815583,LGP Proband,Signaling by PDGFR in disease,CP:REACTOME,C2,46,74
Cohort,-0.004709297559844038,0.025418980339311222,-0.18526697361502603,0.8530668360559325,LonGen OPEL,Signaling by PDGFR in disease,CP:REACTOME,C2,44,50
Cohort,-0.008904512417376886,0.011882644987993607,-0.7493712406938129,0.4538941669150196,LGP Offspring,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",CP:REACTOME,C2,7,7
Cohort,-0.05787658670484339,0.035823716109412373,-1.6155941647169545,0.10656028723276045,LGP Proband,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",CP:REACTOME,C2,7,14
Cohort,-0.005944871166464924,0.01151404397163308,-0.5163147874987437,0.6057779672823854,LonGen OPEL,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",CP:REACTOME,C2,11,9
Cohort,0.03114413170530377,0.03924474038189938,0.7935874056557192,0.42771412995180846,LGP Offspring,Signaling by PTK6,CP:REACTOME,C2,46,110
Cohort,-0.03402110978523204,0.10523980419510658,-0.3232722641915933,0.7465700947992544,LGP Proband,Signaling by PTK6,CP:REACTOME,C2,46,133
Cohort,0.04766471486504897,0.03579261197122756,1.3316914368631432,0.18334280477105033,LonGen OPEL,Signaling by PTK6,CP:REACTOME,C2,72,106
Cohort,0.0018618339309340725,0.1266090865988027,0.014705373689598034,0.9882715711011416,LGP Offspring,Signaling by Receptor Tyrosine Kinases,CP:REACTOME,C2,527,1094
Cohort,-0.7455024105398244,0.3457484638498276,-2.1561987643815703,0.03135344933810054,LGP Proband,Signaling by Receptor Tyrosine Kinases,CP:REACTOME,C2,527,1414
Cohort,-0.009566146746305251,0.11053329456600318,-0.08654538692495935,0.9310546427396489,LonGen OPEL,Signaling by Receptor Tyrosine Kinases,CP:REACTOME,C2,799,949
Cohort,0.018096736845047298,0.04244471660060308,0.426360176116482,0.6699811467848783,LGP Offspring,Signaling by Retinoic Acid,CP:REACTOME,C2,59,128
Cohort,0.023473265236341412,0.11032977538373608,0.21275548830494267,0.8315696745832561,LGP Proband,Signaling by Retinoic Acid,CP:REACTOME,C2,59,164
Cohort,0.011491712623479896,0.036173629097306766,0.31768204933398536,0.7508094447431238,LonGen OPEL,Signaling by Retinoic Acid,CP:REACTOME,C2,86,112
Cohort,0.06059166645941941,0.15193665889585192,0.39879556981013514,0.6901697791494708,LGP Offspring,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",CP:REACTOME,C2,720,1526
Cohort,0.003218323245640257,0.41091796705430017,0.007832033407327202,0.9937528783462364,LGP Proband,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",CP:REACTOME,C2,720,2107
Cohort,-0.2012534485543676,0.13228714718878848,-1.5213378837715545,0.12857219001133088,LonGen OPEL,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",CP:REACTOME,C2,1222,1355
Cohort,0.0032202881729726796,0.014575791302362523,0.22093402040208396,0.8252105204855773,LGP Offspring,Signaling by RNF43 mutants,CP:REACTOME,C2,6,15
Cohort,-0.0025992186823328807,0.03959190736227255,-0.06565025166758441,0.947672013524494,LGP Proband,Signaling by RNF43 mutants,CP:REACTOME,C2,6,20
Cohort,-0.0014638397343548634,0.00856032714365958,-0.17100277942521072,0.8642650379599921,LonGen OPEL,Signaling by RNF43 mutants,CP:REACTOME,C2,5,6
Cohort,0.04890107928632447,0.053294150955282664,0.9175693469130548,0.3591716159771955,LGP Offspring,Signaling by ROBO receptors,CP:REACTOME,C2,83,203
Cohort,0.14405683263764557,0.1572417114032271,0.9161489744170329,0.35985358913297083,LGP Proband,Signaling by ROBO receptors,CP:REACTOME,C2,83,307
Cohort,-0.033535273127018934,0.05077574773369443,-0.6604584791720391,0.5091507323992372,LonGen OPEL,Signaling by ROBO receptors,CP:REACTOME,C2,164,188
Cohort,0.06035699300075168,0.03703511103847398,1.629723559841625,0.10362578018146182,LGP Offspring,Signaling by SCF-KIT,CP:REACTOME,C2,37,100
Cohort,0.0033176796849261015,0.10281456567791696,0.03226857656841408,0.9742655890748135,LGP Proband,Signaling by SCF-KIT,CP:REACTOME,C2,37,134
Cohort,-0.02941529422609742,0.03424225920639204,-0.8590348565729692,0.39057989793061354,LonGen OPEL,Signaling by SCF-KIT,CP:REACTOME,C2,87,81
Cohort,-0.07364905847490599,0.035493921842892184,-2.074976634053037,0.03836641955348405,LGP Offspring,Signaling by TGF-beta Receptor Complex,CP:REACTOME,C2,53,76
Cohort,0.012518444895108848,0.10234658422708806,0.12231424223531236,0.9026796193268669,LGP Proband,Signaling by TGF-beta Receptor Complex,CP:REACTOME,C2,53,132
Cohort,-0.04162586412618478,0.03173540479024027,-1.3116537949119265,0.19001514966253136,LonGen OPEL,Signaling by TGF-beta Receptor Complex,CP:REACTOME,C2,83,82
Cohort,-0.0020245735381507852,0.007086858165046708,-0.2856799855451096,0.7752107493296906,LGP Offspring,Signaling by TGF-beta Receptor Complex in Cancer,CP:REACTOME,C2,2,3
Cohort,0.02714973368335331,0.016719639148946246,1.6238229450702242,0.10479146872895355,LGP Proband,Signaling by TGF-beta Receptor Complex in Cancer,CP:REACTOME,C2,2,3
Cohort,-0.00515270551493724,0.00581046415446346,-0.8867975738184453,0.3754557375666485,LonGen OPEL,Signaling by TGF-beta Receptor Complex in Cancer,CP:REACTOME,C2,3,2
Cohort,-0.0617996144141325,0.03974436193739501,-1.5549278287944022,0.12043127912997494,LGP Offspring,Signaling by TGFB family members,CP:REACTOME,C2,61,100
Cohort,0.14872765644997316,0.11059983080941943,1.3447367447266159,0.1790758533070049,LGP Proband,Signaling by TGFB family members,CP:REACTOME,C2,61,161
Cohort,-0.06430925321468918,0.03550894709343851,-1.8110718136886832,0.07050658232261903,LonGen OPEL,Signaling by TGFB family members,CP:REACTOME,C2,101,95
Cohort,-0.0013154615090177854,0.05085995914774023,-0.0258643839094832,0.9793731411461941,LGP Offspring,Signaling by the B Cell Receptor (BCR),CP:REACTOME,C2,68,141
Cohort,-0.24033456029813782,0.13040121050584455,-1.8430393350326,0.0656779688323481,LGP Proband,Signaling by the B Cell Receptor (BCR),CP:REACTOME,C2,68,187
Cohort,-0.002130096464555378,0.04264529464552047,-0.04994915575707311,0.9601754359967947,LonGen OPEL,Signaling by the B Cell Receptor (BCR),CP:REACTOME,C2,113,129
Cohort,7.329824233926394e-4,0.03352465212878441,0.021863982975181943,0.9825629071993551,LGP Offspring,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),CP:REACTOME,C2,37,77
Cohort,-0.03410284222530313,0.10128110356046709,-0.33671475750600377,0.736416646103314,LGP Proband,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),CP:REACTOME,C2,37,109
Cohort,0.010898439756538286,0.027304029759573186,0.3991513286685141,0.6898887652237665,LonGen OPEL,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),CP:REACTOME,C2,47,61
Cohort,-0.08883177567685104,0.05458428214872837,-1.6274240894990046,0.10411303330595911,LGP Offspring,Signaling by VEGF,CP:REACTOME,C2,117,201
Cohort,-0.36422994145412374,0.1474029067464128,-2.4709820823325632,0.013673107873084959,LGP Proband,Signaling by VEGF,CP:REACTOME,C2,117,256
Cohort,0.04695747297985103,0.046119578557530225,1.0181678681490032,0.30890754298857603,LonGen OPEL,Signaling by VEGF,CP:REACTOME,C2,146,193
Cohort,-0.022562729320730255,0.07811274624090622,-0.28884824060781217,0.7727860668626534,LGP Offspring,Signaling by WNT,CP:REACTOME,C2,204,420
Cohort,-0.30052867781269793,0.2100325075900689,-1.4308674464776425,0.15284278192834896,LGP Proband,Signaling by WNT,CP:REACTOME,C2,204,567
Cohort,-0.011069313160274923,0.06872774760316798,-0.16106032201417128,0.8720867578667102,LonGen OPEL,Signaling by WNT,CP:REACTOME,C2,313,371
Cohort,-0.06845591031829594,0.03074790114267951,-2.226360427030122,0.026318858184033317,LGP Offspring,Signaling by WNT in cancer,CP:REACTOME,C2,41,54
Cohort,-0.0518962908777396,0.08420738294109649,-0.6162914588384885,0.5378703474349363,LGP Proband,Signaling by WNT in cancer,CP:REACTOME,C2,41,85
Cohort,-0.005515089516925134,0.026821152236631746,-0.20562463045091495,0.8371367108567384,LonGen OPEL,Signaling by WNT in cancer,CP:REACTOME,C2,50,59
Cohort,0.026568763198452763,0.026251369526184915,1.0120905567212888,0.31185686809214647,LGP Offspring,Signalling to ERKs,CP:REACTOME,C2,18,50
Cohort,0.10797461156097135,0.06893410665809169,1.566345265000935,0.11764713617874054,LGP Proband,Signalling to ERKs,CP:REACTOME,C2,18,57
Cohort,-0.042315989677942735,0.0204929010460174,-2.064909676913042,0.03925486999131685,LonGen OPEL,Signalling to ERKs,CP:REACTOME,C2,36,30
Cohort,-0.004330729312904073,0.007081462976382967,-0.6115585617473779,0.5410354669182444,LGP Offspring,Signalling to p38 via RIT and RIN,CP:REACTOME,C2,2,3
Cohort,0.06467429151931126,0.03289409724782994,1.9661366910921347,0.04961414759401256,LGP Proband,Signalling to p38 via RIT and RIN,CP:REACTOME,C2,2,14
Cohort,-0.004013677687173803,0.008539495947036495,-0.4700134190668116,0.6384741689972382,LonGen OPEL,Signalling to p38 via RIT and RIN,CP:REACTOME,C2,5,6
Cohort,0.021685901545087462,0.021063064137690306,1.029570123478979,0.3035800740004626,LGP Offspring,Signalling to RAS,CP:REACTOME,C2,11,33
Cohort,0.059359053659413824,0.053208824244694294,1.115586643794949,0.2649204470189229,LGP Proband,Signalling to RAS,CP:REACTOME,C2,11,35
Cohort,-0.029159288065523176,0.01486122860120707,-1.962104806271184,0.050098334773549295,LonGen OPEL,Signalling to RAS,CP:REACTOME,C2,20,14
Cohort,-0.001477763848235706,0.01422946952983944,-0.10385234988112593,0.9173173243079591,LGP Offspring,SIRT1 negatively regulates rRNA expression,CP:REACTOME,C2,6,14
Cohort,-0.004405254805585951,0.038350747417524825,-0.11486750851622042,0.9085777876312922,LGP Proband,SIRT1 negatively regulates rRNA expression,CP:REACTOME,C2,6,18
Cohort,0.0016101025518856446,0.01153351440045539,0.13960207582712789,0.8890097138619275,LonGen OPEL,SIRT1 negatively regulates rRNA expression,CP:REACTOME,C2,9,11
Cohort,0.0020428093573372137,0.0032249282697965204,0.6334433470875638,0.5266584118151574,LGP Offspring,SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs,CP:REACTOME,C2,0,1
Cohort,9.130336763839295e-4,0.007944917056559938,0.11492047933087712,0.9085358139911548,LGP Proband,SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs,CP:REACTOME,C2,0,1
Cohort,0,0,NA,NA,LonGen OPEL,SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs,CP:REACTOME,C2,0,0
Cohort,-0.13168114625898203,0.0909248764161161,-1.4482411354220113,0.14801326629546085,LGP Offspring,SLC-mediated transmembrane transport,CP:REACTOME,C2,306,595
Cohort,-0.09705458724795618,0.27126287390830334,-0.3577879488247409,0.7205925380257141,LGP Proband,SLC-mediated transmembrane transport,CP:REACTOME,C2,306,869
Cohort,-0.17868401403625672,0.08631237340298609,-2.0702016059967936,0.03875543165288416,LonGen OPEL,SLC-mediated transmembrane transport,CP:REACTOME,C2,509,559
Cohort,-0.08017820061564451,0.07019483499393175,-1.1422236496827125,0.25376547247506237,LGP Offspring,SLC transporter disorders,CP:REACTOME,C2,159,310
Cohort,-0.25402938333956143,0.1967035062575617,-1.2914329193854723,0.19691140443805827,LGP Proband,SLC transporter disorders,CP:REACTOME,C2,159,434
Cohort,-0.035479708157722833,0.061001521783849974,-0.5816200501266185,0.5609873011857923,LonGen OPEL,SLC transporter disorders,CP:REACTOME,C2,240,284
Cohort,-0.02231850884956324,0.011048105092614075,-2.0201209766264534,0.04376478181344796,LGP Offspring,"SMAC, XIAP-regulated apoptotic response",CP:REACTOME,C2,7,5
Cohort,0.00520401146322877,0.027096055330951392,0.19205789919111624,0.847743604554332,LGP Proband,"SMAC, XIAP-regulated apoptotic response",CP:REACTOME,C2,7,5
Cohort,-0.01733436437508177,0.011421045519561126,-1.5177563512370864,0.12947287231961568,LonGen OPEL,"SMAC, XIAP-regulated apoptotic response",CP:REACTOME,C2,12,8
Cohort,-0.014349657108196488,0.01635037153342595,-0.8776349258401074,0.3804536708751859,LGP Offspring,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,CP:REACTOME,C2,11,14
Cohort,0.022315137436833155,0.053258627374927744,0.4189957296447021,0.6753271405621801,LGP Proband,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,CP:REACTOME,C2,11,33
Cohort,-0.008157323220096954,0.013955230892799183,-0.5845351669749932,0.5590259428112015,LonGen OPEL,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,CP:REACTOME,C2,15,15
Cohort,-8.969444502932359e-4,0.01607932933348374,-0.05578245408690216,0.9555315953207878,LGP Offspring,Small interfering RNA (siRNA) biogenesis,CP:REACTOME,C2,9,17
Cohort,0.015260371319004432,0.051720534807700405,0.2950543991036302,0.7680257575203617,LGP Proband,Small interfering RNA (siRNA) biogenesis,CP:REACTOME,C2,9,36
Cohort,-0.012889478617013067,0.015134664617576395,-0.8516527417491684,0.39466299703556285,LonGen OPEL,Small interfering RNA (siRNA) biogenesis,CP:REACTOME,C2,18,19
Cohort,-0.0022803196519405725,0.03924220252191348,-0.05810885998733647,0.9536790892671758,LGP Offspring,Smooth Muscle Contraction,CP:REACTOME,C2,46,101
Cohort,-0.054790519668008776,0.10118358448365812,-0.5414961324764872,0.5883102818287911,LGP Proband,Smooth Muscle Contraction,CP:REACTOME,C2,46,136
Cohort,0.022606362548984998,0.03135384227599898,0.7210077268995487,0.47111645930679646,LonGen OPEL,Smooth Muscle Contraction,CP:REACTOME,C2,68,85
Cohort,-0.02515542906705631,0.044194000310749854,-0.5692046180516825,0.5694063589903194,LGP Offspring,snRNP Assembly,CP:REACTOME,C2,69,128
Cohort,-0.2814804650464517,0.12501822876479396,-2.251515381617042,0.024612445254635292,LGP Proband,snRNP Assembly,CP:REACTOME,C2,69,180
Cohort,-0.014761676338957716,0.04070427080734491,-0.3626566953827861,0.7169576222515852,LonGen OPEL,snRNP Assembly,CP:REACTOME,C2,110,122
Cohort,-0.0012103648654324605,0.02246031437744457,-0.053889043808218066,0.957039487184854,LGP Offspring,Sodium/Calcium exchangers,CP:REACTOME,C2,18,34
Cohort,-0.11965733608855596,0.055682362052984,-2.1489270870854438,0.0319273964783461,LGP Proband,Sodium/Calcium exchangers,CP:REACTOME,C2,18,35
Cohort,0.00928878176577554,0.02025104136910495,0.4586816843871809,0.6465879778162062,LonGen OPEL,Sodium/Calcium exchangers,CP:REACTOME,C2,26,31
Cohort,-0.015570263263249152,0.01977532183061672,-0.7873582739443878,0.4313481295815099,LGP Offspring,Sodium-coupled phosphate cotransporters,CP:REACTOME,C2,15,26
Cohort,0.007449070484571728,0.0469636966485769,0.1586133762065651,0.8740118881225246,LGP Proband,Sodium-coupled phosphate cotransporters,CP:REACTOME,C2,15,24
Cohort,-8.517023813642478e-4,0.012264529699027686,-0.06944435720448126,0.9446533634237833,LonGen OPEL,Sodium-coupled phosphate cotransporters,CP:REACTOME,C2,10,13
Cohort,-0.030614530739675298,0.01608964309424457,-1.9027476594944748,0.057498097480602604,LGP Offspring,"Sodium-coupled sulphate, di- and tri-carboxylate transporters",CP:REACTOME,C2,13,11
Cohort,0.005900967225668866,0.05703205822881081,0.10346754805857389,0.9176167785186817,LGP Proband,"Sodium-coupled sulphate, di- and tri-carboxylate transporters",CP:REACTOME,C2,13,36
Cohort,-0.002803673169298643,0.016065436407874886,-0.17451584246565194,0.8615044573082302,LonGen OPEL,"Sodium-coupled sulphate, di- and tri-carboxylate transporters",CP:REACTOME,C2,18,22
Cohort,-0.003752513050287411,0.015386527699254518,-0.24388303349749413,0.8073954056766385,LGP Offspring,Sodium/Proton exchangers,CP:REACTOME,C2,7,15
Cohort,0.03734986858552514,0.04404549190419017,0.8479839132406632,0.3966902265789808,LGP Proband,Sodium/Proton exchangers,CP:REACTOME,C2,7,23
Cohort,-0.005597596960093239,0.016441153994488075,-0.3404625345623454,0.7335980625350441,LonGen OPEL,Sodium/Proton exchangers,CP:REACTOME,C2,17,19
Cohort,4.705345431459103e-4,0.01103446625280663,0.04264225675856585,0.9659993018662286,LGP Offspring,SOS-mediated signalling,CP:REACTOME,C2,4,8
Cohort,0.002286859175046373,0.03039048319078345,0.07524918773716341,0.9400344947760993,LGP Proband,SOS-mediated signalling,CP:REACTOME,C2,4,11
Cohort,-0.004702557284447675,0.008602967002920495,-0.5466204023392479,0.5847927365544314,LonGen OPEL,SOS-mediated signalling,CP:REACTOME,C2,6,5
Cohort,-0.009562004568587988,0.009557914234735282,-1.000427952558712,0.31746141370320863,LGP Offspring,Sperm Motility And Taxes,CP:REACTOME,C2,4,5
Cohort,0.008338020032581637,0.022238034311423103,0.3749441122275188,0.7077973564912647,LGP Proband,Sperm Motility And Taxes,CP:REACTOME,C2,4,4
Cohort,0.006699412102029483,0.0081722406587255,0.8197766538943664,0.41258883422130865,LonGen OPEL,Sperm Motility And Taxes,CP:REACTOME,C2,3,7
Cohort,0.016345353436907004,0.03668093939442563,0.44560891042476936,0.6560224442419276,LGP Offspring,Sphingolipid de novo biosynthesis,CP:REACTOME,C2,38,90
Cohort,-0.18216373993312102,0.0957937589032458,-1.9016243022378019,0.057564650504518845,LGP Proband,Sphingolipid de novo biosynthesis,CP:REACTOME,C2,38,114
Cohort,0.005774452658279134,0.02984219296598095,0.19349960858646703,0.8466170765665274,LonGen OPEL,Sphingolipid de novo biosynthesis,CP:REACTOME,C2,54,66
Cohort,-0.013196751125687477,0.055130793500802154,-0.23937168844659318,0.8108899380236724,LGP Offspring,Sphingolipid metabolism,CP:REACTOME,C2,96,199
Cohort,-0.31655252587772165,0.14855375120569975,-2.1308955398870877,0.03338967330479919,LGP Proband,Sphingolipid metabolism,CP:REACTOME,C2,96,268
Cohort,0.0016943751008993062,0.04822486485875088,0.03513488541361552,0.9719809925983465,LonGen OPEL,Sphingolipid metabolism,CP:REACTOME,C2,148,180
Cohort,0.003441733877180322,0.018128582943614042,0.18985123591210995,0.8494826977027033,LGP Offspring,Spry regulation of FGF signaling,CP:REACTOME,C2,11,23
Cohort,-0.015241772521654241,0.05214039489635179,-0.2923217699434933,0.770113319749452,LGP Proband,Spry regulation of FGF signaling,CP:REACTOME,C2,11,36
Cohort,-0.02339965907122452,0.013887902743049104,-1.684895084892213,0.09240079201377932,LonGen OPEL,Spry regulation of FGF signaling,CP:REACTOME,C2,18,12
Cohort,-0.0173461448905433,0.02594386572629905,-0.668602939652115,0.5039770359367108,LGP Offspring,SRP-dependent cotranslational protein targeting to membrane,CP:REACTOME,C2,23,43
Cohort,0.026877886922362895,0.07831849862346263,0.34318695320738474,0.7315443067029201,LGP Proband,SRP-dependent cotranslational protein targeting to membrane,CP:REACTOME,C2,23,69
Cohort,-0.004847623525158406,0.023415967226679175,-0.20702213486339469,0.8360455176924027,LonGen OPEL,SRP-dependent cotranslational protein targeting to membrane,CP:REACTOME,C2,36,40
Cohort,0.053700202834273056,0.03650259224951656,1.4711339530957355,0.14172022271509876,LGP Offspring,Stabilization of p53,CP:REACTOME,C2,33,93
Cohort,0.022838589919680404,0.09842990241697012,0.232028980613343,0.8165724255401442,LGP Proband,Stabilization of p53,CP:REACTOME,C2,33,133
Cohort,-0.007104358132410144,0.032598351227277875,-0.2179361183907151,0.8275347403325425,LonGen OPEL,Stabilization of p53,CP:REACTOME,C2,76,82
Cohort,-0.008748010407931606,0.017218898018154762,-0.5080470538072839,0.6115860775346238,LGP Offspring,STAT5 Activation,CP:REACTOME,C2,12,18
Cohort,0.008346965610760988,0.049666204839919556,0.16806127300574528,0.8665758209943784,LGP Proband,STAT5 Activation,CP:REACTOME,C2,12,29
Cohort,0.00980306893071879,0.011800191735977425,0.8307550546683375,0.40636112307562433,LonGen OPEL,STAT5 Activation,CP:REACTOME,C2,7,12
Cohort,-0.021283394952725087,0.01879754445314038,-1.1322433632638338,0.25793358765265473,LGP Offspring,STAT5 activation downstream of FLT3 ITD mutants,CP:REACTOME,C2,15,19
Cohort,0.010165444973690712,0.0545487555982917,0.18635521309690634,0.8522115302453203,LGP Proband,STAT5 activation downstream of FLT3 ITD mutants,CP:REACTOME,C2,15,33
Cohort,0.006103314842925861,0.01288659242779749,0.4736174343312422,0.6359026067738522,LonGen OPEL,STAT5 activation downstream of FLT3 ITD mutants,CP:REACTOME,C2,9,14
Cohort,-0.06312646187779475,0.06724526700512891,-0.9387495163485631,0.3481946496512335,LGP Offspring,Stimuli-sensing channels,CP:REACTOME,C2,163,314
Cohort,0.21188519167536812,0.198313265908656,1.0684368022710262,0.2856326748586417,LGP Proband,Stimuli-sensing channels,CP:REACTOME,C2,163,510
Cohort,0.0924187813078834,0.05999418775422237,1.5404622475512888,0.12384513497776131,LonGen OPEL,Stimuli-sensing channels,CP:REACTOME,C2,233,316
Cohort,-0.011398336916834518,0.01832022521477395,-0.622172314106847,0.5340383573386098,LGP Offspring,STING mediated induction of host immune responses,CP:REACTOME,C2,13,21
Cohort,-0.04497989880508207,0.04382787166511492,-1.0262852631487491,0.30505470610560154,LGP Proband,STING mediated induction of host immune responses,CP:REACTOME,C2,13,19
Cohort,0.007457986485954576,0.011655540520128698,0.6398662055247376,0.5224437040245126,LonGen OPEL,STING mediated induction of host immune responses,CP:REACTOME,C2,8,11
Cohort,-0.028886019618110527,0.038011102260888274,-0.759936384371388,0.44755755188406043,LGP Offspring,Striated Muscle Contraction,CP:REACTOME,C2,50,98
Cohort,-0.008219346126187962,0.11133622195125854,-0.07382454678394133,0.9411676969740312,LGP Proband,Striated Muscle Contraction,CP:REACTOME,C2,50,156
Cohort,0.030005226850829635,0.03498744630631628,0.8575997970281356,0.3913716194163661,LonGen OPEL,Striated Muscle Contraction,CP:REACTOME,C2,78,103
Cohort,0.01076709073715225,0.015456490654206694,0.6966064275542289,0.48628859011253955,LGP Offspring,Sulfide oxidation to sulfate,CP:REACTOME,C2,6,18
Cohort,-0.02145485553708705,0.03578279904755257,-0.5995857257721848,0.5489452139524357,LGP Proband,Sulfide oxidation to sulfate,CP:REACTOME,C2,6,15
Cohort,-0.0021435980478293026,0.014186383127240713,-0.15110250643895007,0.8799331392064069,LonGen OPEL,Sulfide oxidation to sulfate,CP:REACTOME,C2,15,16
Cohort,-0.03774174770339797,0.028733795586833876,-1.3134967703567721,0.18946123032081416,LGP Offspring,Sulfur amino acid metabolism,CP:REACTOME,C2,30,50
Cohort,-0.05845310363968377,0.07967227159438679,-0.7336693490712772,0.4633564703700105,LGP Proband,Sulfur amino acid metabolism,CP:REACTOME,C2,30,65
Cohort,-0.002939377960842481,0.02493515779204319,-0.11788086465530355,0.9061917936923738,LonGen OPEL,Sulfur amino acid metabolism,CP:REACTOME,C2,46,50
Cohort,0.010289946575625689,0.009070848253556493,1.134397389085548,0.2570299888935144,LGP Offspring,SUMO is conjugated to E1 (UBA2:SAE1),CP:REACTOME,C2,1,7
Cohort,0.014588659365687168,0.024695540619846496,0.5907406357390305,0.5548542633315077,LGP Proband,SUMO is conjugated to E1 (UBA2:SAE1),CP:REACTOME,C2,1,9
Cohort,0.0037161556621213222,0.006714432559074903,0.5534578878298131,0.5801053252414874,LonGen OPEL,SUMO is conjugated to E1 (UBA2:SAE1),CP:REACTOME,C2,2,5
Cohort,-0.001871246381020477,0.003135546038069192,-0.5967848528777316,0.5508508400998073,LGP Offspring,SUMO is proteolytically processed,CP:REACTOME,C2,1,0
Cohort,-0.03519953207000617,0.010865985614943457,-3.2394237685717147,0.0012451276010238036,LGP Proband,SUMO is proteolytically processed,CP:REACTOME,C2,1,1
Cohort,0,0,NA,NA,LonGen OPEL,SUMO is proteolytically processed,CP:REACTOME,C2,0,0
Cohort,0.018083319832192492,0.011065322840069315,1.6342333697404545,0.10267543616588493,LGP Offspring,"SUMO is transferred from E1 to E2 (UBE2I, UBC9)",CP:REACTOME,C2,1,11
Cohort,0.0276788054808763,0.03003738379018342,0.9214785706444271,0.35706709997260033,LGP Proband,"SUMO is transferred from E1 to E2 (UBE2I, UBC9)",CP:REACTOME,C2,1,14
Cohort,-0.0017434858870013568,0.007637898885494028,-0.22826773608021994,0.8194967306763061,LonGen OPEL,"SUMO is transferred from E1 to E2 (UBE2I, UBC9)",CP:REACTOME,C2,4,5
Cohort,-0.034804151270165236,0.07165628468730884,-0.4857096822985222,0.627330406010935,LGP Offspring,SUMOylation,CP:REACTOME,C2,180,346
Cohort,-0.35527234980540634,0.20255489851413006,-1.7539558530134627,0.07980535093782629,LGP Proband,SUMOylation,CP:REACTOME,C2,180,527
Cohort,-0.019273635241618403,0.0644037504140111,-0.29926262240506735,0.7648177891407612,LonGen OPEL,SUMOylation,CP:REACTOME,C2,291,337
Cohort,-0.03237731646699759,0.04125182407112339,-0.7848699347494302,0.4328047963722512,LGP Offspring,SUMOylation of chromatin organization proteins,CP:REACTOME,C2,62,116
Cohort,-0.16646892313834105,0.11632048869899599,-1.431122968964778,0.15276956882403028,LGP Proband,SUMOylation of chromatin organization proteins,CP:REACTOME,C2,62,176
Cohort,0.00634325402260544,0.03864663643983733,0.16413469856504126,0.8696667737806772,LonGen OPEL,SUMOylation of chromatin organization proteins,CP:REACTOME,C2,94,115
Cohort,-0.039354371690690046,0.05490554638093697,-0.71676495881942,0.4737666968846973,LGP Offspring,SUMOylation of DNA damage response and repair proteins,CP:REACTOME,C2,107,195
Cohort,-0.388863415243091,0.15096979445660963,-2.5757696540737793,0.01017281698664592,LGP Proband,SUMOylation of DNA damage response and repair proteins,CP:REACTOME,C2,107,281
Cohort,0.008539406628019839,0.048343548447039114,0.17664004613510842,0.8598360682742738,LonGen OPEL,SUMOylation of DNA damage response and repair proteins,CP:REACTOME,C2,160,197
Cohort,0.015894444391573566,0.02174150199480481,0.7310646888780539,0.4649929569931731,LGP Offspring,SUMOylation of DNA methylation proteins,CP:REACTOME,C2,13,34
Cohort,0.03220123470083366,0.08313238799739453,0.3873488477420242,0.6985967940211313,LGP Proband,SUMOylation of DNA methylation proteins,CP:REACTOME,C2,13,106
Cohort,-0.010174341588878267,0.020046573303582168,-0.507535199896742,0.6119199341152343,LonGen OPEL,SUMOylation of DNA methylation proteins,CP:REACTOME,C2,30,33
Cohort,-0.03996877799308948,0.04297616879662974,-0.9300218961403534,0.3526917334839631,LGP Offspring,SUMOylation of DNA replication proteins,CP:REACTOME,C2,66,119
Cohort,-0.20801581383827786,0.1164328194642959,-1.786573706583356,0.07436955692910899,LGP Proband,SUMOylation of DNA replication proteins,CP:REACTOME,C2,66,155
Cohort,-0.0013524296095543044,0.03745447309876163,-0.03610862729234389,0.9712047962276296,LonGen OPEL,SUMOylation of DNA replication proteins,CP:REACTOME,C2,96,109
Cohort,0.00967375380113892,0.019970331178680016,0.48440627822268933,0.6282544680978772,LGP Offspring,SUMOylation of immune response proteins,CP:REACTOME,C2,9,28
Cohort,0.025533793424767855,0.04887574012108314,0.5224226448849937,0.6015148294753839,LGP Proband,SUMOylation of immune response proteins,CP:REACTOME,C2,9,27
Cohort,0.023447666234577814,0.01804425797607578,1.2994530595642235,0.19416470818440537,LonGen OPEL,SUMOylation of immune response proteins,CP:REACTOME,C2,15,26
Cohort,0.025216650069808253,0.025456557379646336,0.9905758148574363,0.32224717755585586,LGP Offspring,SUMOylation of intracellular receptors,CP:REACTOME,C2,18,43
Cohort,-0.03893703557743935,0.06564865282356641,-0.5931124844569822,0.5532666740586543,LGP Proband,SUMOylation of intracellular receptors,CP:REACTOME,C2,18,49
Cohort,-0.004837903794191763,0.018449360241470064,-0.26222610057324536,0.7932149773428053,LonGen OPEL,SUMOylation of intracellular receptors,CP:REACTOME,C2,26,26
Cohort,-0.023256923586209764,0.04030854584336863,-0.5769725277756672,0.5641500976252817,LGP Offspring,SUMOylation of RNA binding proteins,CP:REACTOME,C2,58,114
Cohort,-0.14684043608335726,0.11599142478322859,-1.2659594134461325,0.20588112166063932,LGP Proband,SUMOylation of RNA binding proteins,CP:REACTOME,C2,58,170
Cohort,0.001729580101009976,0.03824690829627165,0.045221435615452804,0.9639421504831898,LonGen OPEL,SUMOylation of RNA binding proteins,CP:REACTOME,C2,93,112
Cohort,-0.023591898321952937,0.03826718765040941,-0.616504628912821,0.53776907071665,LGP Offspring,SUMOylation of SUMOylation proteins,CP:REACTOME,C2,54,102
Cohort,-0.24672733461046029,0.10639230780328669,-2.319033581512726,0.020634036331519712,LGP Proband,SUMOylation of SUMOylation proteins,CP:REACTOME,C2,54,132
Cohort,0.01422005695016508,0.03632656550269195,0.3914506299559565,0.6955689379883434,LonGen OPEL,SUMOylation of SUMOylation proteins,CP:REACTOME,C2,82,103
Cohort,-0.005890277337363353,0.03067055455278052,-0.19204991312520478,0.8477607827676863,LGP Offspring,SUMOylation of transcription cofactors,CP:REACTOME,C2,29,65
Cohort,0.18163554917113844,0.08634219524036103,2.1036707332434386,0.03570609253550809,LGP Proband,SUMOylation of transcription cofactors,CP:REACTOME,C2,29,108
Cohort,-0.017614231977552557,0.030265404460728836,-0.5819922876103663,0.5607366654059756,LonGen OPEL,SUMOylation of transcription cofactors,CP:REACTOME,C2,62,68
Cohort,0.014977689095990277,0.01367599763994052,1.09518073125782,0.27382750409718354,LGP Offspring,SUMOylation of transcription factors,CP:REACTOME,C2,4,16
Cohort,0.06749382828749494,0.03650493696900385,1.8488958998834484,0.06482658325176376,LGP Proband,SUMOylation of transcription factors,CP:REACTOME,C2,4,17
Cohort,8.369960575440818e-4,0.008889549545930929,0.09415505850093445,0.9250096788703709,LonGen OPEL,SUMOylation of transcription factors,CP:REACTOME,C2,5,7
Cohort,-0.02623073823303455,0.03907826096466775,-0.6712360679701389,0.5022994466288713,LGP Offspring,SUMOylation of ubiquitinylation proteins,CP:REACTOME,C2,59,107
Cohort,-0.29763767301850014,0.1070603792622796,-2.7800917115129846,0.005556735274811423,LGP Proband,SUMOylation of ubiquitinylation proteins,CP:REACTOME,C2,59,130
Cohort,0.004753820358563807,0.03597903725115716,0.13212750317300148,0.8949168322420848,LonGen OPEL,SUMOylation of ubiquitinylation proteins,CP:REACTOME,C2,84,99
Cohort,0.020813348251839732,0.014547934394656101,1.4306737772673148,0.15298580531275546,LGP Offspring,Suppression of apoptosis,CP:REACTOME,C2,4,17
Cohort,0.06777737802243773,0.035028656888944756,1.9349122701826647,0.05333889838424597,LGP Proband,Suppression of apoptosis,CP:REACTOME,C2,4,16
Cohort,-0.01900421093329514,0.013693977436353505,-1.3877787532236265,0.16559276224824124,LonGen OPEL,Suppression of apoptosis,CP:REACTOME,C2,17,12
Cohort,-0.008233476051539238,0.01092405173555579,-0.7537016713991549,0.4512908085273154,LGP Offspring,Suppression of phagosomal maturation,CP:REACTOME,C2,6,6
Cohort,-0.058830824138768154,0.038204533015267404,-1.539891198650642,0.12396618422237166,LGP Proband,Suppression of phagosomal maturation,CP:REACTOME,C2,6,18
Cohort,-0.013387652761317616,0.011444975527478819,-1.1697406192939885,0.2424554925424933,LonGen OPEL,Suppression of phagosomal maturation,CP:REACTOME,C2,11,9
Cohort,-0.03894853921585086,0.026151915782472317,-1.489318776483487,0.13686982268003758,LGP Offspring,Surfactant metabolism,CP:REACTOME,C2,29,43
Cohort,-0.015459843801045136,0.07166259405281152,-0.21573101009505816,0.8292501761274875,LGP Proband,Surfactant metabolism,CP:REACTOME,C2,29,61
Cohort,-0.00637029075134479,0.020777086683701738,-0.3066017314324373,0.7592267171424967,LonGen OPEL,Surfactant metabolism,CP:REACTOME,C2,29,35
Cohort,-0.020618989941155005,0.05041829785748848,-0.40895846978881156,0.6826996675760515,LGP Offspring,Switching of origins to a post-replicative state,CP:REACTOME,C2,78,147
Cohort,-0.10009222206230824,0.13274830815134808,-0.7539999827959524,0.4510620548327551,LGP Proband,Switching of origins to a post-replicative state,CP:REACTOME,C2,78,227
Cohort,-0.0046862807741889665,0.04180202684353102,-0.11210654430059487,0.9107671919200152,LonGen OPEL,Switching of origins to a post-replicative state,CP:REACTOME,C2,118,142
Cohort,-0.05670932693046899,0.020383225039867794,-2.7821567401405094,0.005550512531710159,LGP Offspring,Synaptic adhesion-like molecules,CP:REACTOME,C2,20,21
Cohort,0.052068339716215994,0.06197638089229396,0.8401319819997765,0.4010751663359494,LGP Proband,Synaptic adhesion-like molecules,CP:REACTOME,C2,20,43
Cohort,-0.005798075583861586,0.015903779454897606,-0.36457218237367184,0.715527612798894,LonGen OPEL,Synaptic adhesion-like molecules,CP:REACTOME,C2,17,21
Cohort,-0.0027043411110619095,0.040142576630651315,-0.0673683987937381,0.94630834615455806,LGP Offspring,Syndecan interactions,CP:REACTOME,C2,47,98
Cohort,-0.14684386440476827,0.11439704503501046,-1.283633369724084,0.19962679440334938,LGP Proband,Syndecan interactions,CP:REACTOME,C2,47,161
Cohort,-0.016772490376167546,0.03513478746621459,-0.47737560366049964,0.6332257275109986,LonGen OPEL,Syndecan interactions,CP:REACTOME,C2,78,93
Cohort,0.0068555841166723095,0.022198290354878362,0.3088338789642738,0.7575430498481621,LGP Offspring,Synthesis of 12-eicosatetraenoic acid derivatives,CP:REACTOME,C2,15,32
Cohort,-0.062486176171744685,0.06126886658214829,-1.019868322322631,0.3080866635100199,LGP Proband,Synthesis of 12-eicosatetraenoic acid derivatives,CP:REACTOME,C2,15,41
Cohort,-0.01372667714568831,0.01850701354373266,-0.7417013616622551,0.4584870689098489,LonGen OPEL,Synthesis of 12-eicosatetraenoic acid derivatives,CP:REACTOME,C2,28,25
Cohort,0.009221031610856243,0.021745365996351317,0.4240458225629981,0.6716672981465508,LGP Offspring,Synthesis of 15-eicosatetraenoic acid derivatives,CP:REACTOME,C2,15,32
Cohort,-0.05645868382213771,0.05461217571185539,-1.0338112899955654,0.3015240700378497,LGP Proband,Synthesis of 15-eicosatetraenoic acid derivatives,CP:REACTOME,C2,15,37
Cohort,0.0024313291209748064,0.017310293031250226,0.14045568821888424,0.8883354944974216,LonGen OPEL,Synthesis of 15-eicosatetraenoic acid derivatives,CP:REACTOME,C2,23,25
Cohort,0.0066260303229140624,0.010920202738095004,0.6067680684900868,0.5442085641281968,LGP Offspring,Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE),CP:REACTOME,C2,3,9
Cohort,0.06804621075765793,0.035854934628861274,1.897819964309304,0.05806488132990042,LGP Proband,Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE),CP:REACTOME,C2,3,18
Cohort,-0.004502380290684394,0.007302278025785377,-0.6165720169494852,0.5376933495411205,LonGen OPEL,Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE),CP:REACTOME,C2,4,4
Cohort,0.031990034820367545,0.017484382210812107,1.8296348383750922,0.06774482854792897,LGP Offspring,Synthesis of 5-eicosatetraenoic acids,CP:REACTOME,C2,5,26
Cohort,-0.03905288739472657,0.04695169122838638,-0.8317674267527919,0.4057783175311437,LGP Proband,Synthesis of 5-eicosatetraenoic acids,CP:REACTOME,C2,5,32
Cohort,-0.016959787981295892,0.01824844807954549,-0.9293824826838814,0.35297264940731354,LonGen OPEL,Synthesis of 5-eicosatetraenoic acids,CP:REACTOME,C2,27,24
Cohort,-0.008261675977618553,0.01661328821665818,-0.49729324320844276,0.619143978496854,LGP Offspring,Synthesis of active ubiquitin: roles of E1 and E2 enzymes,CP:REACTOME,C2,9,18
Cohort,8.219206571628467e-4,0.047182462822275506,0.01742004566948562,0.9861056838785685,LGP Proband,Synthesis of active ubiquitin: roles of E1 and E2 enzymes,CP:REACTOME,C2,9,22
Cohort,-0.003560513443047105,0.017327947218711875,-0.20547808682163024,0.8372511526241658,LonGen OPEL,Synthesis of active ubiquitin: roles of E1 and E2 enzymes,CP:REACTOME,C2,15,20
Cohort,-0.02164749666936198,0.037997149064275225,-0.5697137075400974,0.5690611604113252,LGP Offspring,Synthesis of bile acids and bile salts,CP:REACTOME,C2,49,86
Cohort,-0.2255768075189346,0.10166465162393121,-2.218832248138401,0.026766623910936645,LGP Proband,Synthesis of bile acids and bile salts,CP:REACTOME,C2,49,102
Cohort,-0.0075913170358493185,0.02958743516114502,-0.2565723251949338,0.7975752389004416,LonGen OPEL,Synthesis of bile acids and bile salts,CP:REACTOME,C2,55,65
Cohort,-0.054996666710929225,0.026878308752001697,-2.0461356857816986,0.04112939856939508,LGP Offspring,Synthesis of bile acids and bile salts via 24-hydroxycholesterol,CP:REACTOME,C2,30,33
Cohort,-0.11306396400436378,0.07314541513564905,-1.5457423243095318,0.12254616091595295,LGP Proband,Synthesis of bile acids and bile salts via 24-hydroxycholesterol,CP:REACTOME,C2,30,48
Cohort,0.004161646074624347,0.022797403475136674,0.18254912578808047,0.8551982863466374,LonGen OPEL,Synthesis of bile acids and bile salts via 24-hydroxycholesterol,CP:REACTOME,C2,29,39
Cohort,-0.030659683273476446,0.02784265351944654,-1.1011767700970876,0.2712116623476864,LGP Offspring,Synthesis of bile acids and bile salts via 27-hydroxycholesterol,CP:REACTOME,C2,28,41
Cohort,-0.11933000716344387,0.07210949787648936,-1.65484451670756,0.0983322818057185,LGP Proband,Synthesis of bile acids and bile salts via 27-hydroxycholesterol,CP:REACTOME,C2,28,49
Cohort,6.809706849878977e-4,0.023278020917315234,0.029253805012322213,0.9766695021248,LonGen OPEL,Synthesis of bile acids and bile salts via 27-hydroxycholesterol,CP:REACTOME,C2,33,39
Cohort,-0.012128598919086115,0.03456897034930755,-0.35085218901606835,0.7258085507081058,LGP Offspring,Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol,CP:REACTOME,C2,38,71
Cohort,-0.22229231502083324,0.09231202474519151,-2.408053724684577,0.016253913571304963,LGP Proband,Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol,CP:REACTOME,C2,38,82
Cohort,-0.006617598388417271,0.02706669698452765,-0.24449227743599972,0.8069125901027213,LonGen OPEL,Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol,CP:REACTOME,C2,47,53
Cohort,0.010086331472000044,0.008494951866962792,1.187332386334782,0.23551358162654615,LGP Offspring,Synthesis of diphthamide-EEF2,CP:REACTOME,C2,0,5
Cohort,0.005484868167957682,0.0221356552315888,0.24778431496938355,0.8043622823333583,LGP Proband,Synthesis of diphthamide-EEF2,CP:REACTOME,C2,0,8
Cohort,0.003107486756558547,0.008180430974552672,0.37986834266130737,0.7041444757263022,LonGen OPEL,Synthesis of diphthamide-EEF2,CP:REACTOME,C2,4,6
Cohort,-0.002343189664060638,0.013366384394654146,-0.17530467438881908,0.8608927339010398,LGP Offspring,Synthesis of Dolichyl-phosphate,CP:REACTOME,C2,6,12
Cohort,0.0392834140366815,0.045116242891276005,0.8707155454267141,0.3841600407135001,LGP Proband,Synthesis of Dolichyl-phosphate,CP:REACTOME,C2,6,26
Cohort,-0.005684954111191072,0.01420906428784242,-0.40009348934083155,0.6891950031682385,LonGen OPEL,Synthesis of Dolichyl-phosphate,CP:REACTOME,C2,16,15
Cohort,-0.0017298651848823524,0.012996503305655344,-0.13310235408701146,0.8941520445611609,LGP Offspring,Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET),CP:REACTOME,C2,5,10
Cohort,0.028377177228492746,0.03910008590021503,0.7257574139584355,0.4681911026873947,LGP Proband,Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET),CP:REACTOME,C2,5,18
Cohort,0.002986267940449616,0.008560111417288583,0.348858536399228,0.7272877703204119,LonGen OPEL,Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET),CP:REACTOME,C2,4,7
Cohort,-0.01645380873331545,0.01347199767000647,-1.2213339948794355,0.22238535619488314,LGP Offspring,Synthesis of GDP-mannose,CP:REACTOME,C2,9,10
Cohort,0.04671390338945757,0.034718721255450315,1.3454960810840404,0.17883077420797103,LGP Proband,Synthesis of GDP-mannose,CP:REACTOME,C2,9,12
Cohort,0.005770660823950181,0.011467399704690873,0.5032231344992383,0.6149466162843938,LonGen OPEL,Synthesis of GDP-mannose,CP:REACTOME,C2,8,12
Cohort,-0.04195618943424235,0.022884382323977385,-1.833398377996956,0.06718288492040833,LGP Offspring,Synthesis of glycosylphosphatidylinositol (GPI),CP:REACTOME,C2,22,31
Cohort,0.062039272776756735,0.066816068220052,0.9285082829542833,0.3534126172454992,LGP Proband,Synthesis of glycosylphosphatidylinositol (GPI),CP:REACTOME,C2,22,53
Cohort,-0.036446731069615865,0.02217242948019152,-1.6437860858764606,0.1006152731884101,LonGen OPEL,Synthesis of glycosylphosphatidylinositol (GPI),CP:REACTOME,C2,39,37
Cohort,0.026629738392521977,0.018071528387980505,1.4735742224345338,0.14106175009627245,LGP Offspring,"Synthesis of IP2, IP, and Ins in the cytosol",CP:REACTOME,C2,9,25
Cohort,-0.08108849316593734,0.04254951625109335,-1.9057441849025416,0.05702698242870014,LGP Proband,"Synthesis of IP2, IP, and Ins in the cytosol",CP:REACTOME,C2,9,21
Cohort,-0.010251591477025994,0.012786522804580971,-0.801749751179672,0.42293700343383556,LonGen OPEL,"Synthesis of IP2, IP, and Ins in the cytosol",CP:REACTOME,C2,12,13
Cohort,-0.05832393799777807,0.030949698045324464,-1.8844751865548168,0.05992953185197708,LGP Offspring,Synthesis of IP3 and IP4 in the cytosol,CP:REACTOME,C2,38,56
Cohort,0.05973333063048771,0.09117412425797498,0.6551566150662845,0.5125475836508906,LGP Proband,Synthesis of IP3 and IP4 in the cytosol,CP:REACTOME,C2,38,92
Cohort,0.01307714090334762,0.022944658775716813,0.5699427056717725,0.5688773757610446,LonGen OPEL,Synthesis of IP3 and IP4 in the cytosol,CP:REACTOME,C2,35,50
Cohort,-0.007380840583839566,0.020310152718729386,-0.36340645420323137,0.7164148947105342,LGP Offspring,Synthesis of Ketone Bodies,CP:REACTOME,C2,14,24
Cohort,0.061265915446433845,0.05395735707663865,1.1354506366836026,0.2565127502671007,LGP Proband,Synthesis of Ketone Bodies,CP:REACTOME,C2,14,35
Cohort,0.013281509182687215,0.016065825752565245,0.8266932174691701,0.40865869927696663,LonGen OPEL,Synthesis of Ketone Bodies,CP:REACTOME,C2,16,22
Cohort,0.015624075664899205,0.031944452137216126,0.48910138129108016,0.6249285721809525,LGP Offspring,Synthesis of Leukotrienes (LT) and Eoxins (EX),CP:REACTOME,C2,30,74
Cohort,0.020685477006935783,0.08582480445522443,0.2410197976941221,0.8095990113669207,LGP Proband,Synthesis of Leukotrienes (LT) and Eoxins (EX),CP:REACTOME,C2,30,89
Cohort,-0.0348422720814238,0.029545623762059912,-1.179270147146645,0.2386429703532903,LonGen OPEL,Synthesis of Leukotrienes (LT) and Eoxins (EX),CP:REACTOME,C2,70,66
Cohort,0.001608323722105185,0.011924942486947445,0.13487056427027555,0.8927543597081875,LGP Offspring,Synthesis of Lipoxins (LX),CP:REACTOME,C2,4,10
Cohort,-0.003285113786164552,0.025874807994363716,-0.12696186139352783,0.8990011875388023,LGP Proband,Synthesis of Lipoxins (LX),CP:REACTOME,C2,4,7
Cohort,-0.005942148849442373,0.008931466327961088,-0.66530496015416,0.5060481788559683,LonGen OPEL,Synthesis of Lipoxins (LX),CP:REACTOME,C2,7,5
Cohort,0.007218953520619865,0.03610977272589429,0.19991689162427653,0.8416057025374613,LGP Offspring,Synthesis of PA,CP:REACTOME,C2,41,89
Cohort,-0.03273816305575404,0.10093478044770958,-0.32434967322997665,0.7457546474080041,LGP Proband,Synthesis of PA,CP:REACTOME,C2,41,113
Cohort,-0.0043119823689907405,0.03218790211319863,-0.13396282720838196,0.8934658308071581,LonGen OPEL,Synthesis of PA,CP:REACTOME,C2,70,78
Cohort,-0.004000479994300921,0.03323162298770268,-0.12038172182506082,0.9042165395901208,LGP Offspring,Synthesis of PC,CP:REACTOME,C2,40,76
Cohort,0.09000444255000682,0.09244438663424778,0.9736063575834573,0.330534322941745,LGP Proband,Synthesis of PC,CP:REACTOME,C2,40,109
Cohort,-0.012173496474710907,0.02705914024419076,-0.4498848213525334,0.6529159784136589,LonGen OPEL,Synthesis of PC,CP:REACTOME,C2,52,67
Cohort,-0.009205088005983837,0.01829801891668676,-0.503064733285925,0.6150826233450051,LGP Offspring,Synthesis of PE,CP:REACTOME,C2,13,21
Cohort,0.013326567410377408,0.0472225098078434,0.28220794414793976,0.7778540836176351,LGP Proband,Synthesis of PE,CP:REACTOME,C2,13,25
Cohort,-0.007793299722964914,0.011407530584051766,-0.6831714949649395,0.4946972729745147,LonGen OPEL,Synthesis of PE,CP:REACTOME,C2,11,9
Cohort,-0.02925236505475703,0.01604868706404376,-1.8227263662144313,0.06878643394013562,LGP Offspring,Synthesis of PG,CP:REACTOME,C2,12,12
Cohort,-0.05100030508927389,0.05216852639060413,-0.97760677975484,0.3285523243575962,LGP Proband,Synthesis of PG,CP:REACTOME,C2,12,32
Cohort,-0.018740681060994774,0.019026245759081406,-0.9849910118000904,0.3249277801866528,LonGen OPEL,Synthesis of PG,CP:REACTOME,C2,25,24
Cohort,-0.013014434781384743,0.010644198295514497,-1.2226787231941247,0.22187716561007048,LGP Offspring,Synthesis of PI,CP:REACTOME,C2,5,6
Cohort,0.011595502689899192,0.03503098863433326,0.3310070067087585,0.7407223390156139,LGP Proband,Synthesis of PI,CP:REACTOME,C2,5,15
Cohort,-0.0012334389546724486,0.011613889666504907,-0.10620377755350595,0.9154474322348356,LonGen OPEL,Synthesis of PI,CP:REACTOME,C2,8,13
Cohort,0.03368075760768353,0.02097535541402013,1.605730007567404,0.10880025130212621,LGP Offspring,Synthesis of PIPs at the early endosome membrane,CP:REACTOME,C2,11,33
Cohort,-0.07531699082062798,0.05420264797218569,-1.3895444897687876,0.16503807253318528,LGP Proband,Synthesis of PIPs at the early endosome membrane,CP:REACTOME,C2,11,38
Cohort,-0.006136554539118932,0.016995124153940628,-0.361077358631479,0.7181374267357704,LonGen OPEL,Synthesis of PIPs at the early endosome membrane,CP:REACTOME,C2,20,23
Cohort,0.015366324371005375,0.013790273103209993,1.1142871686441453,0.2655520210860273,LGP Offspring,Synthesis of PIPs at the ER membrane,CP:REACTOME,C2,4,15
Cohort,0.023378888919323066,0.03660034763190465,0.6387613897673367,0.523153544517402,LGP Proband,Synthesis of PIPs at the ER membrane,CP:REACTOME,C2,4,18
Cohort,0.011246341275154887,0.014650410781668377,0.7676468218370436,0.44292468197639556,LonGen OPEL,Synthesis of PIPs at the ER membrane,CP:REACTOME,C2,13,19
Cohort,0.025459370746362255,0.02397752785893835,1.061801320642466,0.28870507161952824,LGP Offspring,Synthesis of PIPs at the Golgi membrane,CP:REACTOME,C2,15,39
Cohort,-0.07552606004206805,0.06261209466206914,-1.206253527368767,0.22806181884695248,LGP Proband,Synthesis of PIPs at the Golgi membrane,CP:REACTOME,C2,15,53
Cohort,-0.012462383233175903,0.02092424647179934,-0.5955953180905265,0.5516149024546253,LonGen OPEL,Synthesis of PIPs at the Golgi membrane,CP:REACTOME,C2,33,32
Cohort,0.023878005923698018,0.018955380672835788,1.259695404477772,0.20821399357576537,LGP Offspring,Synthesis of PIPs at the late endosome membrane,CP:REACTOME,C2,9,26
Cohort,-0.12361485650945192,0.05274787768534595,-2.3435038893288733,0.01933757287491543,LGP Proband,Synthesis of PIPs at the late endosome membrane,CP:REACTOME,C2,9,37
Cohort,-0.005096638195644186,0.015984035448338842,-0.3188580388298538,0.7499178145994208,LonGen OPEL,Synthesis of PIPs at the late endosome membrane,CP:REACTOME,C2,18,22
Cohort,-0.06936453822440097,0.04454517948446319,-1.5571727182869355,0.119897501273404,LGP Offspring,Synthesis of PIPs at the plasma membrane,CP:REACTOME,C2,70,122
Cohort,0.059459395109023955,0.11809935783029737,0.5034692499722481,0.614767342350881,LGP Proband,Synthesis of PIPs at the plasma membrane,CP:REACTOME,C2,70,166
Cohort,-0.025940050815111276,0.03995864779414317,-0.6491723881335486,0.5164142154261966,LonGen OPEL,Synthesis of PIPs at the plasma membrane,CP:REACTOME,C2,117,121
Cohort,-0.022791015164960782,0.01921435268992174,-1.1861453535676518,0.23598162837795206,LGP Offspring,Synthesis of Prostaglandins (PG) and Thromboxanes (TX),CP:REACTOME,C2,16,22
Cohort,-0.061859692493422665,0.058507856659573004,-1.0572886450678285,0.290686020826816,LGP Proband,Synthesis of Prostaglandins (PG) and Thromboxanes (TX),CP:REACTOME,C2,16,39
Cohort,0.003248399508785368,0.01746069799080806,0.18604064456618183,0.852460286602995,LonGen OPEL,Synthesis of Prostaglandins (PG) and Thromboxanes (TX),CP:REACTOME,C2,17,24
Cohort,0.0022127793719296067,0.009560919036222028,0.231440028259457,0.8170430065531222,LGP Offspring,Synthesis of pyrophosphates in the cytosol,CP:REACTOME,C2,3,6
Cohort,-0.011861397448814252,0.019217175478159116,-0.6172289711510975,0.5372521811228143,LGP Proband,Synthesis of pyrophosphates in the cytosol,CP:REACTOME,C2,3,3
Cohort,-0.0029177647286041802,0.006349747774481173,-0.4595087603842006,0.6459943286571806,LonGen OPEL,Synthesis of pyrophosphates in the cytosol,CP:REACTOME,C2,3,3
Cohort,2.0429250542697538e-4,0.04479529785754641,0.004560579239290836,0.9963625423310756,LGP Offspring,Synthesis of substrates in N-glycan biosythesis,CP:REACTOME,C2,70,144
Cohort,0.04509520969329158,0.12551249152083818,0.35928861858187766,0.7194701334135447,LGP Proband,Synthesis of substrates in N-glycan biosythesis,CP:REACTOME,C2,70,200
Cohort,-0.007123073111299297,0.04232461162153687,-0.16829624273917076,0.8663929810462792,LonGen OPEL,Synthesis of substrates in N-glycan biosythesis,CP:REACTOME,C2,118,141
Cohort,0.014188867731373579,0.021254964208353305,0.6675554751485907,0.50464520770177,LGP Offspring,Synthesis of UDP-N-acetyl-glucosamine,CP:REACTOME,C2,12,30
Cohort,-0.016004196894447327,0.05313387970520504,-0.3012051253031226,0.7633331612126432,LGP Proband,Synthesis of UDP-N-acetyl-glucosamine,CP:REACTOME,C2,12,34
Cohort,-0.008381010129271305,0.018737551846976244,-0.44728415951648365,0.654791585949885,LonGen OPEL,Synthesis of UDP-N-acetyl-glucosamine,CP:REACTOME,C2,23,24
Cohort,-0.005987655852451638,0.025087907390462436,-0.23866701033534346,0.8114361317659877,LGP Offspring,Synthesis of very long-chain fatty acyl-CoAs,CP:REACTOME,C2,23,45
Cohort,-0.00439967181074439,0.06616252223002583,-0.06649794570176971,0.9469973304141953,LGP Proband,Synthesis of very long-chain fatty acyl-CoAs,CP:REACTOME,C2,23,50
Cohort,-0.021398791486694914,0.021301873113007724,-1.0045497582852472,0.3154189670884255,LonGen OPEL,Synthesis of very long-chain fatty acyl-CoAs,CP:REACTOME,C2,35,35
Cohort,-0.005030111427328776,0.00906998116610478,-0.5545889605732248,0.5793592743034044,LGP Offspring,Synthesis of wybutosine at G37 of tRNA(Phe),CP:REACTOME,C2,3,5
Cohort,-0.006439870141905442,0.033333320741280995,-0.1931961772392545,0.8468523711681517,LGP Proband,Synthesis of wybutosine at G37 of tRNA(Phe),CP:REACTOME,C2,3,15
Cohort,0.016609421562406423,0.012934897637354838,1.2840783149639998,0.19948817272131916,LonGen OPEL,Synthesis of wybutosine at G37 of tRNA(Phe),CP:REACTOME,C2,10,16
Cohort,0.0031258131487416256,0.018221235407970406,0.17154781653138182,0.8638443738870869,LGP Offspring,"Synthesis, secretion, and deacylation of Ghrelin",CP:REACTOME,C2,11,23
Cohort,0.014447404523577801,0.05305284111232967,0.272321033533116,0.7854425896109714,LGP Proband,"Synthesis, secretion, and deacylation of Ghrelin",CP:REACTOME,C2,11,34
Cohort,0.0036051043346111023,0.017865903342804152,0.20178684869372304,0.8401349194732555,LonGen OPEL,"Synthesis, secretion, and deacylation of Ghrelin",CP:REACTOME,C2,20,31
Cohort,-0.0026584945859699106,0.01190005598952185,-0.22340185527788683,0.8232902522556775,LGP Offspring,"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",CP:REACTOME,C2,5,9
Cohort,-7.802963295503481e-4,0.03428489282925407,-0.022759188235949485,0.9818478066528729,LGP Proband,"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",CP:REACTOME,C2,5,14
Cohort,0.009884346896389541,0.012833518167070072,0.7701977561969015,0.4414111107331079,LonGen OPEL,"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",CP:REACTOME,C2,9,16
Cohort,-0.007927531845378982,0.010070297666472855,-0.7872192171411372,0.4314294578204878,LGP Offspring,"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)",CP:REACTOME,C2,5,5
Cohort,-0.006326163182571762,0.034173677772373005,-0.18511800879933432,0.8531814845584904,LGP Proband,"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)",CP:REACTOME,C2,5,14
Cohort,0.009041455683217731,0.010258250845376978,0.8813837582546918,0.37837619806176426,LonGen OPEL,"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)",CP:REACTOME,C2,6,10
Cohort,9.873185647574277e-5,0.00452618760624368,0.021813469759748013,0.9826031863910722,LGP Offspring,Tachykinin receptors bind tachykinins,CP:REACTOME,C2,1,1
Cohort,0.006751783528957001,0.019281131393544905,0.3501756920352412,0.7262952650351971,LGP Proband,Tachykinin receptors bind tachykinins,CP:REACTOME,C2,1,5
Cohort,0.0048281435467901436,0.006854536848955394,0.7043719587744188,0.4814071805598561,LonGen OPEL,Tachykinin receptors bind tachykinins,CP:REACTOME,C2,3,4
Cohort,0.01612621744485709,0.02971138856307209,0.5427621603959689,0.5874724662003499,LGP Offspring,TAK1 activates NFkB by phosphorylation and activation of IKKs complex,CP:REACTOME,C2,24,62
Cohort,0.06521391381818867,0.07949643176304796,0.8203376223547912,0.412258059698956,LGP Proband,TAK1 activates NFkB by phosphorylation and activation of IKKs complex,CP:REACTOME,C2,24,83
Cohort,-0.029830903799444985,0.02736999575802878,-1.0899126204904257,0.27608146921152066,LonGen OPEL,TAK1 activates NFkB by phosphorylation and activation of IKKs complex,CP:REACTOME,C2,57,56
Cohort,0.006560660371928038,0.018074650082613112,0.3629757888502117,0.7167364357375727,LGP Offspring,Tandem pore domain potassium channels,CP:REACTOME,C2,10,21
Cohort,-0.03373308326753491,0.047493233265682035,-0.7102713575811647,0.47773443206156874,LGP Proband,Tandem pore domain potassium channels,CP:REACTOME,C2,10,26
Cohort,0.0088619483559136,0.01566149462518024,0.5658430799871129,0.5716599284181281,LonGen OPEL,Tandem pore domain potassium channels,CP:REACTOME,C2,16,22
Cohort,-0.03814030942266072,0.0308549011424141,-1.2361183478313555,0.2168439119894235,LGP Offspring,TBC/RABGAPs,CP:REACTOME,C2,39,57
Cohort,-0.12354991473890342,0.08896856521842214,-1.3886917748485927,0.16529723846768243,LGP Proband,TBC/RABGAPs,CP:REACTOME,C2,39,88
Cohort,-0.022829897787896236,0.030543956321581918,-0.7474440294352097,0.45501631456995706,LonGen OPEL,TBC/RABGAPs,CP:REACTOME,C2,63,69
Cohort,-0.016130004596839703,0.06426814797700063,-0.25097976376434683,0.8019060221343108,LGP Offspring,TCF dependent signaling in response to WNT,CP:REACTOME,C2,134,270
Cohort,-0.2301186649272928,0.16757869986987275,-1.373197578844944,0.17005999147955433,LGP Proband,TCF dependent signaling in response to WNT,CP:REACTOME,C2,134,359
Cohort,-0.05337654118223909,0.054670009488437615,-0.9763404411613997,0.32919240258245186,LonGen OPEL,TCF dependent signaling in response to WNT,CP:REACTOME,C2,214,237
Cohort,0.0181602956131947,0.051707735434258814,0.35121042259303137,0.7255399228387712,LGP Offspring,TCR signaling,CP:REACTOME,C2,70,164
Cohort,-0.07763382756873465,0.13860006981373543,-0.5601283438967001,0.5755423160149125,LGP Proband,TCR signaling,CP:REACTOME,C2,70,204
Cohort,0.005532798154299743,0.04438106409615544,0.12466573902582538,0.9008196572064057,LonGen OPEL,TCR signaling,CP:REACTOME,C2,127,154
Cohort,-0.024397909382380567,0.033141441591248266,-0.7361752600654335,0.4618794195702821,LGP Offspring,Telomere C-strand (Lagging Strand) Synthesis,CP:REACTOME,C2,36,67
Cohort,-0.05419721040641246,0.09755821255666798,-0.5555371401964883,0.5786762977906832,LGP Proband,Telomere C-strand (Lagging Strand) Synthesis,CP:REACTOME,C2,36,105
Cohort,-0.042815574802925464,0.03037012938929506,-1.4097923078989978,0.1589916068294836,LonGen OPEL,Telomere C-strand (Lagging Strand) Synthesis,CP:REACTOME,C2,70,62
Cohort,-0.02181445947422564,0.0179415517169386,-1.2158624749068183,0.22446172838488676,LGP Offspring,Telomere C-strand synthesis initiation,CP:REACTOME,C2,13,20
Cohort,-3.8320108896260525e-4,0.04702415403524349,-0.008149026746454707,0.9935000381428727,LGP Proband,Telomere C-strand synthesis initiation,CP:REACTOME,C2,13,24
Cohort,-0.007543212560439127,0.01434855492774551,-0.525712352109617,0.5992344976216187,LonGen OPEL,Telomere C-strand synthesis initiation,CP:REACTOME,C2,17,15
Cohort,-0.038456590588633294,0.026478467202262695,-1.452372234951237,0.14686210883325387,LGP Offspring,Telomere Extension By Telomerase,CP:REACTOME,C2,26,41
Cohort,-0.05219175034385943,0.06897913164985758,-0.756631014272375,0.44948463643227154,LGP Proband,Telomere Extension By Telomerase,CP:REACTOME,C2,26,56
Cohort,-0.00861051558200269,0.021832222984418212,-0.3943948166958567,0.6933952108166981,LonGen OPEL,Telomere Extension By Telomerase,CP:REACTOME,C2,33,35
Cohort,-0.07999925091004186,0.0424992969402585,-1.882366454732116,0.06021555271863087,LGP Offspring,Telomere Maintenance,CP:REACTOME,C2,66,106
Cohort,-0.1272376960134582,0.12828646696799798,-0.9918247732646546,0.3215706761808442,LGP Proband,Telomere Maintenance,CP:REACTOME,C2,66,170
Cohort,-0.037050243552181145,0.037577095133050305,-0.9859794489434662,0.32444279643885254,LonGen OPEL,Telomere Maintenance,CP:REACTOME,C2,100,100
Cohort,0.020969971417296625,0.024177892860108748,0.8673200571541578,0.3860744322266354,LGP Offspring,Terminal pathway of complement,CP:REACTOME,C2,15,45
Cohort,-0.019459981909490238,0.06300362533853206,-0.30887082774884084,0.7574969282575083,LGP Proband,Terminal pathway of complement,CP:REACTOME,C2,15,50
Cohort,-0.012740622723569196,0.020028003945680772,-0.6361404140983721,0.5248677688657127,LonGen OPEL,Terminal pathway of complement,CP:REACTOME,C2,27,33
Cohort,0.02347142834779241,0.03495345904253534,0.6715051668914858,0.5021281682043397,LGP Offspring,Termination of O-glycan biosynthesis,CP:REACTOME,C2,32,88
Cohort,0.12479464955554395,0.0886246046865576,1.408126445211355,0.159466276114835,LGP Proband,Termination of O-glycan biosynthesis,CP:REACTOME,C2,32,104
Cohort,0.04513442570913244,0.02982968017445792,1.5130710569193235,0.13065853030877164,LonGen OPEL,Termination of O-glycan biosynthesis,CP:REACTOME,C2,54,83
Cohort,-0.01357878076892742,0.029226326973668428,-0.4646078441933971,0.6423619145610584,LGP Offspring,Termination of translesion DNA synthesis,CP:REACTOME,C2,29,56
Cohort,0.0036802950974215544,0.08699234894978033,0.042305963016887216,0.9662649177522671,LGP Proband,Termination of translesion DNA synthesis,CP:REACTOME,C2,29,94
Cohort,0.028644549303871863,0.02619421982503333,1.0935446634870492,0.27448554681166654,LonGen OPEL,Termination of translesion DNA synthesis,CP:REACTOME,C2,46,64
Cohort,-0.02578903300428395,0.013419151245658003,-1.9218080586600763,0.0550499820726417,LGP Offspring,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",CP:REACTOME,C2,10,8
Cohort,-0.00853626964607807,0.035681924825897604,-0.2392323196612568,0.8109842198186221,LGP Proband,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",CP:REACTOME,C2,10,11
Cohort,-0.003531891648653374,0.011790984708555264,-0.29954170376378453,0.7646049528433896,LonGen OPEL,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",CP:REACTOME,C2,10,11
Cohort,-3.2443085974206414e-6,0.00556328227051134,-5.831644773117805e-4,0.9995348741393066,LGP Offspring,TFAP2 (AP-2) family regulates transcription of cell cycle factors,CP:REACTOME,C2,1,2
Cohort,0.012956702965621077,0.01584270562776039,0.8178339779865432,0.41368557908141346,LGP Proband,TFAP2 (AP-2) family regulates transcription of cell cycle factors,CP:REACTOME,C2,1,3
Cohort,-0.0025846231015249593,0.004508323016574844,-0.5733003362941377,0.5666032798944336,LonGen OPEL,TFAP2 (AP-2) family regulates transcription of cell cycle factors,CP:REACTOME,C2,2,1
Cohort,-0.002974921698976764,0.018774725079537768,-0.1584535425351755,0.8741467486352165,LGP Offspring,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,CP:REACTOME,C2,11,23
Cohort,-0.010163502720853848,0.03951422954864454,-0.25721120813811965,0.7970791762216469,LGP Proband,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,CP:REACTOME,C2,11,15
Cohort,0.008175298129057791,0.013747763338057033,0.5946638684437234,0.5522371662002667,LonGen OPEL,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,CP:REACTOME,C2,12,17
Cohort,-0.002996600292795375,0.004569806378039371,-0.6557390061854297,0.5122151724400861,LGP Offspring,TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation,CP:REACTOME,C2,1,1
Cohort,0.01175208785929281,0.01583270401756184,0.7422666302772566,0.45813479865774487,LGP Proband,TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation,CP:REACTOME,C2,1,3
Cohort,-0.0027130536402884837,0.0044756066509150025,-0.6061867925175732,0.544563545148923,LonGen OPEL,TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation,CP:REACTOME,C2,2,1
Cohort,-0.046297743835181204,0.02051302090631009,-2.2569929629886634,0.024326956545183236,LGP Offspring,TGF-beta receptor signaling activates SMADs,CP:REACTOME,C2,21,23
Cohort,0.042178483108920646,0.052599674531185046,0.8018772641628051,0.42285237382285523,LGP Proband,TGF-beta receptor signaling activates SMADs,CP:REACTOME,C2,21,27
Cohort,-0.0013743678973860956,0.014953495464680897,-0.09190947364997407,0.9267930892132257,LonGen OPEL,TGF-beta receptor signaling activates SMADs,CP:REACTOME,C2,15,20
Cohort,0.030027023201528134,0.01597040238433712,1.8801669788218338,0.06051508936588363,LGP Offspring,TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),CP:REACTOME,C2,4,22
Cohort,-9.642714046508196e-4,0.04386048168669069,-0.021984970697287724,0.9824652030022076,LGP Proband,TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),CP:REACTOME,C2,4,28
Cohort,0.0026217601215006237,0.015570197649032936,0.16838322676420625,0.8663245769727583,LonGen OPEL,TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),CP:REACTOME,C2,17,21
Cohort,2.775836487315364e-4,0.01887825161029251,0.014703885426561246,0.9882727579956567,LGP Offspring,The activation of arylsulfatases,CP:REACTOME,C2,10,20
Cohort,-0.00953569775133323,0.04682480283262949,-0.20364629799761494,0.8386795887703123,LGP Proband,The activation of arylsulfatases,CP:REACTOME,C2,10,23
Cohort,-0.019612206171710157,0.017388696459554077,-1.1278709831601201,0.259714250988075,LonGen OPEL,The activation of arylsulfatases,CP:REACTOME,C2,22,19
Cohort,0.06963601120443501,0.036036315963396716,1.9323843001922456,0.053729556341581365,LGP Offspring,The canonical retinoid cycle in rods (twilight vision),CP:REACTOME,C2,35,106
Cohort,0.029947387891959464,0.09540307996725818,0.3139037848907734,0.753672613475769,LGP Proband,The canonical retinoid cycle in rods (twilight vision),CP:REACTOME,C2,35,124
Cohort,0.031373240151447636,0.034135229152661296,0.9190868475245514,0.3583285659657831,LonGen OPEL,The canonical retinoid cycle in rods (twilight vision),CP:REACTOME,C2,73,99
Cohort,0.054476227936275295,0.05991992857961912,0.9091504150224334,0.3635947508101449,LGP Offspring,The citric acid (TCA) cycle and respiratory electron transport,CP:REACTOME,C2,105,235
Cohort,-0.07053547986138481,0.1631821021912717,-0.43225009920945623,0.6656713868483213,LGP Proband,The citric acid (TCA) cycle and respiratory electron transport,CP:REACTOME,C2,105,328
Cohort,-0.04656769901295203,0.054178438494388415,-0.859524569313221,0.3903099469807967,LonGen OPEL,The citric acid (TCA) cycle and respiratory electron transport,CP:REACTOME,C2,195,220
Cohort,0.00555623030506796,0.014470540961668275,0.3839683892804098,0.7011226165526274,LGP Offspring,The fatty acid cycling model,CP:REACTOME,C2,8,14
Cohort,-0.040349685263858084,0.03481923494905769,-1.1588331944366876,0.24685588160722752,LGP Proband,The fatty acid cycling model,CP:REACTOME,C2,8,13
Cohort,0.004548941669665294,0.014535840994448636,0.31294657608063914,0.7544032244908876,LonGen OPEL,The fatty acid cycling model,CP:REACTOME,C2,12,17
Cohort,0.0024437749702918604,0.022212293147018256,0.11001903108864332,0.9124269344431309,LGP Offspring,The NLRP3 inflammasome,CP:REACTOME,C2,14,35
Cohort,0.0964408475304022,0.061167934032304375,1.5766569372682964,0.11525369953019687,LGP Proband,The NLRP3 inflammasome,CP:REACTOME,C2,14,45
Cohort,0.03665756346651157,0.020361574132581904,1.800330525912207,0.0721869422225246,LonGen OPEL,The NLRP3 inflammasome,CP:REACTOME,C2,23,42
Cohort,0.0238119548194999,0.03460197130229574,0.6881675789933982,0.49158332955749706,LGP Offspring,The phototransduction cascade,CP:REACTOME,C2,37,86
Cohort,-0.15481520672346857,0.09553421221699795,-1.6205211005646731,0.10549839143571162,LGP Proband,The phototransduction cascade,CP:REACTOME,C2,37,111
Cohort,0.04666662977715989,0.032134040025407554,1.452249071086667,0.14682640445340195,LonGen OPEL,The phototransduction cascade,CP:REACTOME,C2,58,93
Cohort,-0.004657275773258484,0.005266304357293154,-0.884353705613075,0.37681972767135696,LGP Offspring,The retinoid cycle in cones (daylight vision),CP:REACTOME,C2,2,1
Cohort,-0.03255314086976445,0.013624158758324609,-2.3893688738670846,0.017098611150103173,LGP Proband,The retinoid cycle in cones (daylight vision),CP:REACTOME,C2,2,1
Cohort,0.0015720763918670346,0.0025999509522339477,0.6046561726544358,0.5455797873638991,LonGen OPEL,The retinoid cycle in cones (daylight vision),CP:REACTOME,C2,0,1
Cohort,0.07088755834533907,0.03922940604674759,1.8070005510882867,0.0712066822263593,LGP Offspring,The role of GTSE1 in G2/M progression after G2 checkpoint,CP:REACTOME,C2,38,109
Cohort,0.024045668533706644,0.10541902940880922,0.2280960910810406,0.8196274494089312,LGP Proband,The role of GTSE1 in G2/M progression after G2 checkpoint,CP:REACTOME,C2,38,148
Cohort,-0.01901804466048858,0.03285261081521511,-0.5788899021590305,0.5628272291252577,LonGen OPEL,The role of GTSE1 in G2/M progression after G2 checkpoint,CP:REACTOME,C2,76,85
Cohort,0.01427891823651573,0.023851789635803266,0.5986518602814624,0.5496056042477682,LGP Offspring,The role of Nef in HIV-1 replication and disease pathogenesis,CP:REACTOME,C2,16,40
Cohort,0.11817714569523181,0.0661850594770451,1.7855562362411879,0.07453441807145128,LGP Proband,The role of Nef in HIV-1 replication and disease pathogenesis,CP:REACTOME,C2,16,54
Cohort,-0.01648578279096228,0.020773894458375988,-0.793581714973778,0.42767547365843384,LonGen OPEL,The role of Nef in HIV-1 replication and disease pathogenesis,CP:REACTOME,C2,30,36
Cohort,-0.002552912118529865,0.017767360590145678,-0.14368550160150337,0.8857916414072499,LGP Offspring,Thrombin signalling through proteinase activated receptors (PARs),CP:REACTOME,C2,11,22
Cohort,-0.010987353305602606,0.05218880571061564,-0.2105308438466084,0.8333048059599365,LGP Proband,Thrombin signalling through proteinase activated receptors (PARs),CP:REACTOME,C2,11,28
Cohort,-0.014125522259438191,0.017503601794435737,-0.807006605002211,0.4199037374686483,LonGen OPEL,Thrombin signalling through proteinase activated receptors (PARs),CP:REACTOME,C2,23,21
Cohort,-0.01165559095195366,0.012940883529934014,-0.9006796889093934,0.3680794049388132,LGP Offspring,Thromboxane signalling through TP receptor,CP:REACTOME,C2,7,10
Cohort,-0.021545009711834432,0.0397794486553243,-0.5416115718072109,0.5882307733476572,LGP Proband,Thromboxane signalling through TP receptor,CP:REACTOME,C2,7,18
Cohort,0.0035217873668156757,0.015252312491041833,0.23090186284106973,0.817450377634738,LonGen OPEL,Thromboxane signalling through TP receptor,CP:REACTOME,C2,14,18
Cohort,0.04798091763328745,0.025170531249559952,1.906233808002216,0.05704367703062825,LGP Offspring,Thyroxine biosynthesis,CP:REACTOME,C2,13,50
Cohort,0.052200524176070996,0.0579326343338577,0.9010555928675131,0.36781888435725696,LGP Proband,Thyroxine biosynthesis,CP:REACTOME,C2,13,42
Cohort,0.021914779229065758,0.019940544036257026,1.0990060847496972,0.2720976980067622,LonGen OPEL,Thyroxine biosynthesis,CP:REACTOME,C2,25,37
Cohort,-0.033552963960230615,0.021486255953556077,-1.5616012409401387,0.11884995728003912,LGP Offspring,TICAM1-dependent activation of IRF3/IRF7,CP:REACTOME,C2,20,28
Cohort,-0.004766692659903861,0.057832759211077785,-0.08242201694901681,0.9343309054625974,LGP Proband,TICAM1-dependent activation of IRF3/IRF7,CP:REACTOME,C2,20,31
Cohort,0.006822853868763669,0.01501627386335901,0.45436397410225815,0.6496907482304932,LonGen OPEL,TICAM1-dependent activation of IRF3/IRF7,CP:REACTOME,C2,14,21
Cohort,-0.012202167832835129,0.022613654485656897,-0.5395929189850568,0.5896554864601424,LGP Offspring,"TICAM1, RIP1-mediated IKK complex recruitment",CP:REACTOME,C2,16,29
Cohort,0.05997728848708643,0.058865314740184145,1.0188901350788702,0.3085505982095224,LGP Proband,"TICAM1, RIP1-mediated IKK complex recruitment",CP:REACTOME,C2,16,35
Cohort,-0.008354327435824914,0.019022662097939267,-0.4391776184012616,0.6606520311937751,LonGen OPEL,"TICAM1, RIP1-mediated IKK complex recruitment",CP:REACTOME,C2,23,23
Cohort,0.008942208998094536,0.015800835391266775,0.5659326723343345,0.571627356501281,LGP Offspring,"TICAM1,TRAF6-dependent induction of TAK1 complex",CP:REACTOME,C2,7,18
Cohort,0.03754546419099255,0.0341766055778831,1.0985720657785147,0.2722718075007535,LGP Proband,"TICAM1,TRAF6-dependent induction of TAK1 complex",CP:REACTOME,C2,7,12
Cohort,0.0016706940387510578,0.01124119336393753,0.14862248025291974,0.8818891754740454,LonGen OPEL,"TICAM1,TRAF6-dependent induction of TAK1 complex",CP:REACTOME,C2,8,11
Cohort,-0.006512195210767768,0.020157949480887973,-0.3230584150903875,0.7467509057348823,LGP Offspring,Tie2 Signaling,CP:REACTOME,C2,16,26
Cohort,-0.06408204598106522,0.05482386849405219,-1.1688712916713901,0.2427894741210151,LGP Proband,Tie2 Signaling,CP:REACTOME,C2,16,33
Cohort,0.007137302999434156,0.01580393619326347,0.45161552869825417,0.6516690014802383,LonGen OPEL,Tie2 Signaling,CP:REACTOME,C2,18,21
Cohort,-0.059188924029926655,0.027862170433141903,-2.1243472102059124,0.03400344866317038,LGP Offspring,Tight junction interactions,CP:REACTOME,C2,32,44
Cohort,0.017937030095526378,0.0816763681763198,0.21961101474057473,0.8262278506121108,LGP Proband,Tight junction interactions,CP:REACTOME,C2,32,81
Cohort,0.032041049608786606,0.025102083861920053,1.2764298687326507,0.2021758772228954,LonGen OPEL,Tight junction interactions,CP:REACTOME,C2,38,62
Cohort,0.004278221367949828,0.017286738903091677,0.24748573990347492,0.8046074740914905,LGP Offspring,TLR3-mediated TICAM1-dependent programmed cell death,CP:REACTOME,C2,9,20
Cohort,0.06775140328667084,0.04326840036484573,1.565840260221795,0.11776534880775806,LGP Proband,TLR3-mediated TICAM1-dependent programmed cell death,CP:REACTOME,C2,9,20
Cohort,-0.008060346894199615,0.012578332938113519,-0.6408120164935383,0.5218292614418406,LonGen OPEL,TLR3-mediated TICAM1-dependent programmed cell death,CP:REACTOME,C2,11,11
Cohort,-0.0221305315371427,0.020492523984521983,-1.0799319573254083,0.28055762441497584,LGP Offspring,TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,CP:REACTOME,C2,15,24
Cohort,0.008615212424800714,0.055428887394832864,0.15542820413176528,0.876521360255286,LGP Proband,TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,CP:REACTOME,C2,15,33
Cohort,0.0010677762085879723,0.01586925316656318,0.06728585128617125,0.9463710370610166,LonGen OPEL,TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,CP:REACTOME,C2,19,21
Cohort,-0.011575017627460278,0.032007695768598694,-0.36163233089762137,0.7177398041853043,LGP Offspring,TNF signaling,CP:REACTOME,C2,32,67
Cohort,-0.003340361417296587,0.08909866853206472,-0.0374905873716223,0.9701028167832456,LGP Proband,TNF signaling,CP:REACTOME,C2,32,90
Cohort,0.004801538077196339,0.029068964576033324,0.16517747182350945,0.8688462351767081,LonGen OPEL,TNF signaling,CP:REACTOME,C2,53,62
Cohort,-0.005637072768320133,0.022059242051914778,-0.25554245041845514,0.7983818937858671,LGP Offspring,TNFR1-induced NFkappaB signaling pathway,CP:REACTOME,C2,15,31
Cohort,-0.02036002862599773,0.06329801658978289,-0.32165350073992843,0.7477958058137333,LGP Proband,TNFR1-induced NFkappaB signaling pathway,CP:REACTOME,C2,15,47
Cohort,0.014373386295014974,0.021577229144163393,0.6661367962949475,0.5055166692599367,LonGen OPEL,TNFR1-induced NFkappaB signaling pathway,CP:REACTOME,C2,28,36
Cohort,0.002261653506634706,0.0133998208517959,0.16878236893231227,0.8660183152823238,LGP Offspring,TNFR1-induced proapoptotic signaling,CP:REACTOME,C2,5,13
Cohort,0.002903518607149685,0.040635522314116136,0.07145272022604343,0.9430545826343225,LGP Proband,TNFR1-induced proapoptotic signaling,CP:REACTOME,C2,5,22
Cohort,0.005524776079258691,0.011807666373058521,0.46789737317312236,0.6399860598961707,LonGen OPEL,TNFR1-induced proapoptotic signaling,CP:REACTOME,C2,9,12
Cohort,0.006255543109772925,0.01106318312780867,0.5654379067493558,0.5719635625482169,LGP Offspring,TNFR1-mediated ceramide production,CP:REACTOME,C2,3,9
Cohort,-0.006522187014537765,0.030438156428169716,-0.21427667703624953,0.8303836825090559,LGP Proband,TNFR1-mediated ceramide production,CP:REACTOME,C2,3,12
Cohort,0.005430784469395542,0.010298552812347216,0.5273347205526223,0.5981081073281682,LonGen OPEL,TNFR1-mediated ceramide production,CP:REACTOME,C2,6,10
Cohort,0.005517101367521207,0.03895042304286052,0.14164419630180303,0.88740325608264,LGP Offspring,TNFR2 non-canonical NF-kB pathway,CP:REACTOME,C2,47,103
Cohort,-0.0860355737534697,0.10412110564747978,-0.8263029211844732,0.4088685988501324,LGP Proband,TNFR2 non-canonical NF-kB pathway,CP:REACTOME,C2,47,134
Cohort,-0.023426047736508405,0.03344286692717772,-0.7004796504892637,0.483832497520541,LonGen OPEL,TNFR2 non-canonical NF-kB pathway,CP:REACTOME,C2,83,86
Cohort,0.0016435242090782206,0.014227255935837903,0.11551940982085289,0.9080677423766613,LGP Offspring,TNFs bind their physiological receptors,CP:REACTOME,C2,6,14
Cohort,-0.03525597822324571,0.0350294196074167,-1.0064676668459855,0.3144825727384656,LGP Proband,TNFs bind their physiological receptors,CP:REACTOME,C2,6,14
Cohort,-2.0883224951226328e-4,0.014633899244580553,-0.014270444672468359,0.9886177948244882,LonGen OPEL,TNFs bind their physiological receptors,CP:REACTOME,C2,16,17
Cohort,0.015722107942788974,0.0381756655469626,0.4118358571495785,0.6805902871499236,LGP Offspring,Toll Like Receptor 9 (TLR9) Cascade,CP:REACTOME,C2,46,104
Cohort,0.04104474303887901,0.11055820088875014,0.37125009912363294,0.7105455490994951,LGP Proband,Toll Like Receptor 9 (TLR9) Cascade,CP:REACTOME,C2,46,154
Cohort,-0.07140491346969534,0.03563815689827098,-2.0036084827147618,0.04545050147267664,LonGen OPEL,Toll Like Receptor 9 (TLR9) Cascade,CP:REACTOME,C2,102,96
Cohort,-0.08029694475801981,0.060738303938625844,-1.3220149321119892,0.186610338429471,LGP Offspring,Toll-like Receptor Cascades,CP:REACTOME,C2,136,250
Cohort,-2.654775766712189e-4,0.17876718365283453,-0.0014850464791500869,0.9988154599093586,LGP Proband,Toll-like Receptor Cascades,CP:REACTOME,C2,136,378
Cohort,0.00410076661127515,0.058741155081127344,0.06981079288637729,0.9443617903818071,LonGen OPEL,Toll-like Receptor Cascades,CP:REACTOME,C2,215,250
Cohort,-0.025116239221355002,0.04812743087694003,-0.5218695193927191,0.6019321284229031,LGP Offspring,Toll Like Receptor TLR1:TLR2 Cascade,CP:REACTOME,C2,83,164
Cohort,-0.024827796016892723,0.14275714503747533,-0.17391631088149845,0.8619734384681103,LGP Proband,Toll Like Receptor TLR1:TLR2 Cascade,CP:REACTOME,C2,83,240
Cohort,0.010933773874151924,0.04644206957381187,0.23542822218063575,0.8139369379701725,LonGen OPEL,Toll Like Receptor TLR1:TLR2 Cascade,CP:REACTOME,C2,139,167
Cohort,-0.01955277982601507,0.014863525005618942,-1.3154873974123518,0.188792135979667,LGP Offspring,Toxicity of botulinum toxin type D (botD),CP:REACTOME,C2,9,14
Cohort,0.005998724245382158,0.03501144246685538,0.17133610679025946,0.8640010522316516,LGP Proband,Toxicity of botulinum toxin type D (botD),CP:REACTOME,C2,9,12
Cohort,0.0145716204368717,0.011780906769988274,1.2368844539193484,0.21649477009573448,LonGen OPEL,Toxicity of botulinum toxin type D (botD),CP:REACTOME,C2,7,14
Cohort,-0.0940809691505642,0.044324222674523336,-2.122563318062203,0.03415335681844,LGP Offspring,TP53 Regulates Metabolic Genes,CP:REACTOME,C2,76,113
Cohort,-0.19016877314390082,0.12103323150667603,-1.5712112349360132,0.11651287380935585,LGP Proband,TP53 Regulates Metabolic Genes,CP:REACTOME,C2,76,156
Cohort,-0.027056245125230034,0.03746456342656632,-0.7221823144492938,0.4703944952486462,LonGen OPEL,TP53 Regulates Metabolic Genes,CP:REACTOME,C2,87,89
Cohort,0.01028652601057855,0.022301005592410016,0.4612583933918878,0.6447616051540201,LGP Offspring,TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,CP:REACTOME,C2,12,34
Cohort,0.08726684809915934,0.05761615573891869,1.5146246218612627,0.13024637161480282,LGP Proband,TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,CP:REACTOME,C2,12,38
Cohort,-0.006038528947930373,0.019297737355084988,-0.3129138321669203,0.7544280927070628,LonGen OPEL,TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,CP:REACTOME,C2,28,30
Cohort,1.0279554924606633e-4,0.02017418880681769,0.005095399385343686,0.9959359803608447,LGP Offspring,TP53 Regulates Transcription of Caspase Activators and Caspases,CP:REACTOME,C2,14,28
Cohort,0.044162113848423286,0.056115076514734685,0.7869919563742769,0.43151015179261043,LGP Proband,TP53 Regulates Transcription of Caspase Activators and Caspases,CP:REACTOME,C2,14,33
Cohort,0.005887360372881566,0.018458278558901794,0.3189550073206742,0.7498443084293048,LonGen OPEL,TP53 Regulates Transcription of Caspase Activators and Caspases,CP:REACTOME,C2,25,30
Cohort,-0.0455677310123325,0.028732026222431633,-1.5859560568254292,0.11321691415538628,LGP Offspring,TP53 Regulates Transcription of Cell Cycle Genes,CP:REACTOME,C2,32,51
Cohort,0.016415153736165877,0.07481964761159042,0.21939629843462377,0.8263950366878445,LGP Proband,TP53 Regulates Transcription of Cell Cycle Genes,CP:REACTOME,C2,32,62
Cohort,0.016422493112911128,0.02534471422647332,0.647965211450573,0.5171943019096745,LonGen OPEL,TP53 Regulates Transcription of Cell Cycle Genes,CP:REACTOME,C2,42,57
Cohort,0.07851594266872926,0.03611475265874198,2.17406840386386,0.030046225639521407,LGP Offspring,TP53 Regulates Transcription of Cell Death Genes,CP:REACTOME,C2,34,104
Cohort,0.09426324483076241,0.09683473122228517,0.9734445858519514,0.3306146350517277,LGP Proband,TP53 Regulates Transcription of Cell Death Genes,CP:REACTOME,C2,34,119
Cohort,-0.0017093354892669284,0.03202013723010359,-0.053383140646252575,0.9574400321641068,LonGen OPEL,TP53 Regulates Transcription of Cell Death Genes,CP:REACTOME,C2,69,82
Cohort,0.0028283129705394933,0.01510960156578075,0.18718646936030886,0.8515705992090402,LGP Offspring,TP53 Regulates Transcription of Death Receptors and Ligands,CP:REACTOME,C2,7,16
Cohort,0.005086007709748434,0.04651943347791052,0.10933081788632475,0.9129664039590043,LGP Proband,TP53 Regulates Transcription of Death Receptors and Ligands,CP:REACTOME,C2,7,25
Cohort,-0.00928246856325458,0.01269175111491286,-0.7313780800781416,0.4647634942643797,LonGen OPEL,TP53 Regulates Transcription of Death Receptors and Ligands,CP:REACTOME,C2,12,13
Cohort,-0.02828874788145576,0.040852570367728464,-0.6924594371129824,0.48888664406878746,LGP Offspring,TP53 Regulates Transcription of DNA Repair Genes,CP:REACTOME,C2,59,112
Cohort,0.07320581699765533,0.10856577848541432,0.6742991946351717,0.5003079712869811,LGP Proband,TP53 Regulates Transcription of DNA Repair Genes,CP:REACTOME,C2,59,161
Cohort,0.03673853842359181,0.03381669204339277,1.086402489529425,0.27762983690895326,LonGen OPEL,TP53 Regulates Transcription of DNA Repair Genes,CP:REACTOME,C2,75,100
Cohort,0.06843565125230036,0.029974928996656155,2.2830963589583377,0.02273423631320098,LGP Offspring,TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,CP:REACTOME,C2,22,73
Cohort,0.08108886634114773,0.07999151574854242,1.0137183372803547,0.3110111677020502,LGP Proband,TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,CP:REACTOME,C2,22,83
Cohort,-0.009755045977011724,0.026409233804751808,-0.3693801209505934,0.7119426520432124,LonGen OPEL,TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,CP:REACTOME,C2,50,55
Cohort,-0.044197747587891516,0.01897590533521137,-2.329150931517292,0.020144833261458495,LGP Offspring,TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,CP:REACTOME,C2,18,19
Cohort,0.03205320326857968,0.05244254360043173,0.6112061137384611,0.541229685882045,LGP Proband,TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,CP:REACTOME,C2,18,27
Cohort,0.020427131293772383,0.015676564956981245,1.3030361785140672,0.19293921112348,LonGen OPEL,TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,CP:REACTOME,C2,12,24
Cohort,-0.012821873366549311,0.011065137145836965,-1.1587631673750454,0.2469619086819541,LGP Offspring,TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,CP:REACTOME,C2,5,7
Cohort,0.06204466210243383,0.03323449623145391,1.866875359576334,0.06226967500762489,LGP Proband,TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,CP:REACTOME,C2,5,11
Cohort,0.0068406326192832845,0.008553820164029188,0.7997166749015536,0.4241135508031607,LonGen OPEL,TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,CP:REACTOME,C2,4,7
Cohort,0.03368131520440733,0.02099086330627394,1.6045702700727107,0.10905545986818642,LGP Offspring,TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,CP:REACTOME,C2,9,35
Cohort,0.04890242337328401,0.055500531625372274,0.8811163053963988,0.3785087217930677,LGP Proband,TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,CP:REACTOME,C2,9,39
Cohort,0.005072072709481469,0.01648356414319254,0.3077048546916449,0.7583874179420698,LonGen OPEL,TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,CP:REACTOME,C2,17,24
Cohort,-0.041866027175922395,0.02384908765508012,-1.7554561323860314,0.07963422420752447,LGP Offspring,TRAF3-dependent IRF activation pathway,CP:REACTOME,C2,25,36
Cohort,-0.06455056725953845,0.07051042961242192,-0.9154754497222137,0.3602067012756166,LGP Proband,TRAF3-dependent IRF activation pathway,CP:REACTOME,C2,25,58
Cohort,0.006459118019152231,0.023473620476171013,0.27516496765844595,0.7832609076962559,LonGen OPEL,TRAF3-dependent IRF activation pathway,CP:REACTOME,C2,33,46
Cohort,-0.006470344344867633,0.007864195177023137,-0.822759888230149,0.4109346792199784,LGP Offspring,TRAF6-mediated induction of TAK1 complex within TLR4 complex,CP:REACTOME,C2,3,3
Cohort,-0.02883755145495275,0.017544953895302272,-1.6436379158952428,0.10062791207299576,LGP Proband,TRAF6-mediated induction of TAK1 complex within TLR4 complex,CP:REACTOME,C2,3,2
Cohort,-0.004453375779565503,0.008556741095003097,-0.5204523229253896,0.6028930751464756,LonGen OPEL,TRAF6-mediated induction of TAK1 complex within TLR4 complex,CP:REACTOME,C2,6,5
Cohort,-0.08324558835298224,0.027320983797606935,-3.046946953655226,0.0024018404881337345,LGP Offspring,TRAF6 mediated IRF7 activation,CP:REACTOME,C2,36,43
Cohort,-0.07788886274131095,0.07711905773163126,-1.0099820333951506,0.31279682376544937,LGP Proband,TRAF6 mediated IRF7 activation,CP:REACTOME,C2,36,69
Cohort,-0.004503692049762599,0.026866797930883826,-0.1676303987303798,0.8669166326956663,LonGen OPEL,TRAF6 mediated IRF7 activation,CP:REACTOME,C2,41,53
Cohort,-0.010161600962264856,0.00631413167777738,-1.6093425796026182,0.10800831247998358,LGP Offspring,TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,CP:REACTOME,C2,3,1
Cohort,-0.03846383437992951,0.024474825729671152,-1.5715672423889537,0.11643022714853654,LGP Proband,TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,CP:REACTOME,C2,3,7
Cohort,-0.005168860702463112,0.00851230232848648,-0.6072224062302725,0.543876493009412,LonGen OPEL,TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,CP:REACTOME,C2,6,5
Cohort,0.0077632694111828965,0.030761724798280845,0.25236781949290293,0.8008334844056091,LGP Offspring,TRAF6 mediated NF-kB activation,CP:REACTOME,C2,27,65
Cohort,0.026165101573708365,0.08398281291327758,0.3115530507501219,0.7554580823674194,LGP Proband,TRAF6 mediated NF-kB activation,CP:REACTOME,C2,27,101
Cohort,-0.013686559555423371,0.02848837354078152,-0.4804261477346491,0.6310564076516233,LonGen OPEL,TRAF6 mediated NF-kB activation,CP:REACTOME,C2,57,64
Cohort,-0.011958658149286061,0.020272047250913163,-0.5899087547138279,0.5554489447653141,LGP Offspring,Trafficking and processing of endosomal TLR,CP:REACTOME,C2,14,24
Cohort,-0.01167478189242152,0.05507630903672174,-0.21197466018714947,0.8321785952670867,LGP Proband,Trafficking and processing of endosomal TLR,CP:REACTOME,C2,14,33
Cohort,-0.0038507898634379577,0.015304579381023297,-0.25161030352867403,0.8014072372394698,LonGen OPEL,Trafficking and processing of endosomal TLR,CP:REACTOME,C2,16,18
Cohort,0.0193397335255882,0.028770375849124476,0.6722099713611053,0.5016797149298736,LGP Offspring,Trafficking of AMPA receptors,CP:REACTOME,C2,24,56
Cohort,-0.002897983591733574,0.08259926612128009,-0.035084858834925715,0.9720204701645562,LGP Proband,Trafficking of AMPA receptors,CP:REACTOME,C2,24,84
Cohort,0.008044230419103437,0.02481255497775459,0.32420000384141817,0.7458717890953266,LonGen OPEL,Trafficking of AMPA receptors,CP:REACTOME,C2,40,54
Cohort,0.00287769063981508,0.017436343683400895,0.16503979802569463,0.8689619969531865,LGP Offspring,Trafficking of GluR2-containing AMPA receptors,CP:REACTOME,C2,10,21
Cohort,-0.018456199481298462,0.05189268892806293,-0.3556608813793339,0.7221844811842927,LGP Proband,Trafficking of GluR2-containing AMPA receptors,CP:REACTOME,C2,10,33
Cohort,-0.0011548412784709722,0.0191925805500047,-0.060171235205298615,0.9520343584358151,LonGen OPEL,Trafficking of GluR2-containing AMPA receptors,CP:REACTOME,C2,23,32
Cohort,-9.523841061223022e-4,0.011090170355152067,-0.08587641809125691,0.9315900861090407,LGP Offspring,Trafficking of myristoylated proteins to the cilium,CP:REACTOME,C2,4,8
Cohort,-0.010137762448394351,0.03497514697688285,-0.2898561785914724,0.7719983149852064,LGP Proband,Trafficking of myristoylated proteins to the cilium,CP:REACTOME,C2,4,16
Cohort,-0.00624709265068259,0.011767443800585895,-0.5308793274518593,0.5956504879879982,LonGen OPEL,Trafficking of myristoylated proteins to the cilium,CP:REACTOME,C2,11,10
Cohort,-0.005172455254611513,0.015183320741272153,-0.34066692937279885,0.7334601798939815,LGP Offspring,TRAIL  signaling,CP:REACTOME,C2,8,15
Cohort,0.01647169046961957,0.0382667725715602,0.43044368162527774,0.6669841355658686,LGP Proband,TRAIL  signaling,CP:REACTOME,C2,8,16
Cohort,-0.00680805863820832,0.009975965602359901,-0.682446081870793,0.4951554691364677,LonGen OPEL,TRAIL  signaling,CP:REACTOME,C2,8,7
Cohort,-0.08568115700216905,0.05555776357588017,-1.5421995322966282,0.12349307686972007,LGP Offspring,trans-Golgi Network Vesicle Budding,CP:REACTOME,C2,114,198
Cohort,-0.05624303979458928,0.1478157002325429,-0.380494356865394,0.7036753730901184,LGP Proband,trans-Golgi Network Vesicle Budding,CP:REACTOME,C2,114,257
Cohort,3.430004831365992e-4,0.04506839916414656,0.007610664889323775,0.9939295335344183,LonGen OPEL,trans-Golgi Network Vesicle Budding,CP:REACTOME,C2,139,180
Cohort,0.01843678589348948,0.04033384614953063,0.4571045822195668,0.6477427315533372,LGP Offspring,Transcription-Coupled Nucleotide Excision Repair (TC-NER),CP:REACTOME,C2,47,106
Cohort,-0.03512686888222602,0.11242089023115026,-0.3124585547223576,0.7547701633030589,LGP Proband,Transcription-Coupled Nucleotide Excision Repair (TC-NER),CP:REACTOME,C2,47,159
Cohort,0.04192269779283407,0.03333737081718305,1.2575286162406634,0.20893109030972837,LonGen OPEL,Transcription-Coupled Nucleotide Excision Repair (TC-NER),CP:REACTOME,C2,70,103
Cohort,-0.02480531244404597,0.017474592169010938,-1.4195073741426236,0.15621210076870154,LGP Offspring,Transcription of E2F targets under negative control by DREAM complex,CP:REACTOME,C2,13,16
Cohort,0.03000275506151979,0.051177838504391386,0.5862450611106867,0.5578694697032707,LGP Proband,Transcription of E2F targets under negative control by DREAM complex,CP:REACTOME,C2,13,30
Cohort,-0.012220790721581705,0.016315687324443467,-0.7490208949562938,0.4540658890660402,LonGen OPEL,Transcription of E2F targets under negative control by DREAM complex,CP:REACTOME,C2,19,19
Cohort,-0.00732244938931077,0.011439341840658666,-0.6401110738106197,0.5223172802018218,LGP Offspring,Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1,CP:REACTOME,C2,5,8
Cohort,-0.016648932981488184,0.02855466325193449,-0.5830547828421779,0.5600140398137478,LGP Proband,Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1,CP:REACTOME,C2,5,9
Cohort,-0.005531284326208441,0.009543141281013988,-0.5796083452324962,0.5623427662058766,LonGen OPEL,Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1,CP:REACTOME,C2,7,7
Cohort,-0.038916505019516656,0.035007664126933256,-1.1116567183234634,0.2666809756883262,LGP Offspring,Transcription of the HIV genome,CP:REACTOME,C2,44,73
Cohort,0.03869646980659421,0.09890982305681939,0.3912297950868315,0.6957273147109221,LGP Proband,Transcription of the HIV genome,CP:REACTOME,C2,44,116
Cohort,0.041177374546138436,0.027081740072632404,1.5204848150710393,0.12878627549927493,LonGen OPEL,Transcription of the HIV genome,CP:REACTOME,C2,40,61
Cohort,-0.004055787797049061,0.038725023428325116,-0.10473299789103516,0.9166187438755993,LGP Offspring,Transcriptional activation of mitochondrial biogenesis,CP:REACTOME,C2,46,97
Cohort,0.0017082946895148393,0.11273377309113287,0.015153353273591496,0.9879134602396742,LGP Proband,Transcriptional activation of mitochondrial biogenesis,CP:REACTOME,C2,46,130
Cohort,-0.07922410537475878,0.03721032589390635,-2.129089264110227,0.03355324136750928,LonGen OPEL,Transcriptional activation of mitochondrial biogenesis,CP:REACTOME,C2,104,91
Cohort,-0.06440135384375002,0.026115047574042413,-2.4660630489435933,0.013907858719045046,LGP Offspring,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,CP:REACTOME,C2,31,35
Cohort,-0.026094899298604445,0.08281621335765173,-0.3150940889546652,0.7527690360965262,LGP Proband,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,CP:REACTOME,C2,31,83
Cohort,-0.05031329376227516,0.02531782365898632,-1.9872677225325779,0.04723506093556695,LonGen OPEL,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,CP:REACTOME,C2,57,48
Cohort,-0.05907533056255887,0.027976069643291385,-2.1116379575758253,0.035083867032234047,LGP Offspring,Transcriptional Regulation by E2F6,CP:REACTOME,C2,34,50
Cohort,-0.010045286375547462,0.07954334944471429,-0.12628694222298653,0.8995352300260497,LGP Proband,Transcriptional Regulation by E2F6,CP:REACTOME,C2,34,75
Cohort,0.024991553925830138,0.023632734876209514,1.0574973254994924,0.2906054911672816,LonGen OPEL,Transcriptional Regulation by E2F6,CP:REACTOME,C2,32,48
Cohort,-0.03566321493299825,0.04300209746691301,-0.8293366378335033,0.40720669127688036,LGP Offspring,Transcriptional Regulation by MECP2,CP:REACTOME,C2,57,110
Cohort,0.04061413807885643,0.120365873211844,0.3374223689415315,0.7358834271453123,LGP Proband,Transcriptional Regulation by MECP2,CP:REACTOME,C2,57,161
Cohort,-0.02427895839436606,0.03493692949075113,-0.6949368117994869,0.48729769981794013,LonGen OPEL,Transcriptional Regulation by MECP2,CP:REACTOME,C2,88,100
Cohort,0.028560251698500117,0.06909678987835094,0.4133368822022291,0.6794908943177801,LGP Offspring,Transcriptional regulation by RUNX1,CP:REACTOME,C2,141,309
Cohort,-0.044923994324150625,0.17915188230755352,-0.250759264962836,0.8020620009293843,LGP Proband,Transcriptional regulation by RUNX1,CP:REACTOME,C2,141,403
Cohort,-0.07580955648568362,0.0587660638498622,-1.2900227022072601,0.19741741482538405,LonGen OPEL,Transcriptional regulation by RUNX1,CP:REACTOME,C2,241,250
Cohort,0.034663362536510034,0.04905096277525601,0.7066805741475911,0.48000850915118165,LGP Offspring,Transcriptional regulation by RUNX2,CP:REACTOME,C2,71,165
Cohort,0.12326839472380291,0.13747609649193085,0.8966532936948652,0.37016269346037234,LGP Proband,Transcriptional regulation by RUNX2,CP:REACTOME,C2,71,234
Cohort,-0.004606304066838212,0.04531732486475132,-0.10164554241861447,0.9190636270665871,LonGen OPEL,Transcriptional regulation by RUNX2,CP:REACTOME,C2,144,170
Cohort,-0.0010411962947983748,0.04838411808535136,-0.021519381483024375,0.982837692992953,LGP Offspring,Transcriptional regulation by RUNX3,CP:REACTOME,C2,72,148
Cohort,-0.11483157844055553,0.13167788447007225,-0.8720642718607349,0.38342429656582167,LGP Proband,Transcriptional regulation by RUNX3,CP:REACTOME,C2,72,204
Cohort,-0.01777892105011666,0.04195664323813056,-0.4237450777272626,0.6718662142880215,LonGen OPEL,Transcriptional regulation by RUNX3,CP:REACTOME,C2,121,136
Cohort,-0.03010613606568837,0.04032097547776206,-0.7466618976590135,0.4555272709433362,LGP Offspring,Transcriptional regulation by small RNAs,CP:REACTOME,C2,61,109
Cohort,-0.29860262364082135,0.10918955474245008,-2.7347178431595194,0.006375834419467593,LGP Proband,Transcriptional regulation by small RNAs,CP:REACTOME,C2,61,139
Cohort,0.02017634654130504,0.037259847676368675,0.5415037312163112,0.5883119507110168,LonGen OPEL,Transcriptional regulation by small RNAs,CP:REACTOME,C2,85,109
Cohort,0.017824857996292923,0.027044318994828422,0.6590980530773025,0.5100572503834231,LGP Offspring,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,CP:REACTOME,C2,20,50
Cohort,-2.4905165722934156e-4,0.06052577937819129,-0.00411480297797008,0.9967178555125158,LGP Proband,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,CP:REACTOME,C2,20,41
Cohort,-0.00837149827232718,0.02158290872804888,-0.3878762764468204,0.6982112955086187,LonGen OPEL,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,CP:REACTOME,C2,35,39
Cohort,-0.16297789673777816,0.0964809804403051,-1.6892230571663411,0.0916378147509572,LGP Offspring,Transcriptional Regulation by TP53,CP:REACTOME,C2,312,583
Cohort,0.032628709772194134,0.2537468747777818,0.1285876320674635,0.8977149544735891,LGP Proband,Transcriptional Regulation by TP53,CP:REACTOME,C2,312,787
Cohort,0.031729933083346346,0.08279201561733643,0.3832487087885584,0.7016376934815751,LonGen OPEL,Transcriptional Regulation by TP53,CP:REACTOME,C2,419,505
Cohort,-9.798801513073167e-4,0.03793150753354248,-0.025832881818388522,0.9793982584796219,LGP Offspring,Transcriptional Regulation by VENTX,CP:REACTOME,C2,44,100
Cohort,0.17193731022375533,0.102213685104677,1.6821359101540503,0.09291682361140678,LGP Proband,Transcriptional Regulation by VENTX,CP:REACTOME,C2,44,123
Cohort,0.03992744782807279,0.03141228638042711,1.271077416795469,0.2040724215268203,LonGen OPEL,Transcriptional Regulation by VENTX,CP:REACTOME,C2,58,89
Cohort,-0.029928650479214988,0.020489228636759775,-1.460701669633376,0.14456194116269108,LGP Offspring,Transcriptional regulation of granulopoiesis,CP:REACTOME,C2,18,21
Cohort,-0.0971824221287649,0.059483219535053845,-1.6337787848133316,0.10268271689536734,LGP Proband,Transcriptional regulation of granulopoiesis,CP:REACTOME,C2,18,36
Cohort,0.0052981165706817235,0.016361725956640795,0.3238115944932666,0.7461657368423333,LonGen OPEL,Transcriptional regulation of granulopoiesis,CP:REACTOME,C2,18,22
Cohort,-0.005326138272747774,0.019978670456893492,-0.26659122709089134,0.7898652089984367,LGP Offspring,Transcriptional regulation of pluripotent stem cells,CP:REACTOME,C2,13,28
Cohort,-0.030977128059631435,0.05430958120218645,-0.5703805364344132,0.5685732564923942,LGP Proband,Transcriptional regulation of pluripotent stem cells,CP:REACTOME,C2,13,37
Cohort,-0.005370509731254964,0.01762487006297166,-0.3047120184186744,0.7606651445119935,LonGen OPEL,Transcriptional regulation of pluripotent stem cells,CP:REACTOME,C2,20,25
Cohort,-0.016744205606042825,0.014831519934172687,-1.128960867150453,0.2593148135934793,LGP Offspring,Transcriptional regulation of testis differentiation,CP:REACTOME,C2,10,12
Cohort,0.01729798507821973,0.043189555511446515,0.4005131535478584,0.6888811708976966,LGP Proband,Transcriptional regulation of testis differentiation,CP:REACTOME,C2,10,21
Cohort,0.01192214632394875,0.01256114966094859,0.9491285945755077,0.34284327826525507,LonGen OPEL,Transcriptional regulation of testis differentiation,CP:REACTOME,C2,9,15
Cohort,-0.048659882199803266,0.05119697499913292,-0.9504444784213789,0.3422261278845975,LGP Offspring,Transcriptional regulation of white adipocyte differentiation,CP:REACTOME,C2,95,187
Cohort,0.2430129794731924,0.14720130428947906,1.6508887651925601,0.09913777041738968,LGP Proband,Transcriptional regulation of white adipocyte differentiation,CP:REACTOME,C2,95,254
Cohort,-0.026619435467141236,0.04663276829730822,-0.5708311223864827,0.5682752334819994,LonGen OPEL,Transcriptional regulation of white adipocyte differentiation,CP:REACTOME,C2,158,174
Cohort,0.0306027873070985,0.029231833536120633,1.0468993424337831,0.29552017686678855,LGP Offspring,Transferrin endocytosis and recycling,CP:REACTOME,C2,22,62
Cohort,-0.028345629983489103,0.08270030150695384,-0.34275122904002553,0.7318719868636382,LGP Proband,Transferrin endocytosis and recycling,CP:REACTOME,C2,22,87
Cohort,-0.005214016532671002,0.027823127497394615,-0.18739865003167772,0.8513958369308022,LonGen OPEL,Transferrin endocytosis and recycling,CP:REACTOME,C2,57,62
Cohort,0.05173988204021042,0.0649591300286448,0.7964989989458736,0.4260216876004418,LGP Offspring,Translation,CP:REACTOME,C2,122,281
Cohort,-0.10881979226849281,0.176762201298705,-0.6156281799444304,0.5383079087784532,LGP Proband,Translation,CP:REACTOME,C2,122,387
Cohort,0.040370548443692165,0.05688467937093906,0.709691060758909,0.4781035691170493,LonGen OPEL,Translation,CP:REACTOME,C2,208,259
Cohort,-0.010069929555337212,0.018780533747043148,-0.5361897425797414,0.5920038087835551,LGP Offspring,Translation of Replicase and Assembly of the Replication Transcription Complex,CP:REACTOME,C2,13,21
Cohort,-0.07831753507344619,0.05155318457008004,-1.5191599845201298,0.12910121604930505,LGP Proband,Translation of Replicase and Assembly of the Replication Transcription Complex,CP:REACTOME,C2,13,28
Cohort,-0.00950622317064201,0.01599096327830403,-0.5944747045689058,0.5523635810796652,LonGen OPEL,Translation of Replicase and Assembly of the Replication Transcription Complex,CP:REACTOME,C2,17,17
Cohort,-0.03045573738764336,0.022072785305870965,-1.3797867811246585,0.16810849598425423,LGP Offspring,Translation of SARS-CoV-1 structural proteins,CP:REACTOME,C2,18,28
Cohort,-0.03439086354750532,0.058297151728646954,-0.5899235644921879,0.5554016835228006,LGP Proband,Translation of SARS-CoV-1 structural proteins,CP:REACTOME,C2,18,37
Cohort,-0.03448230345226306,0.021480995567749506,-1.6052469888329137,0.10883609110103558,LonGen OPEL,Translation of SARS-CoV-1 structural proteins,CP:REACTOME,C2,33,26
Cohort,-0.04882170868220869,0.026444537311048195,-1.8461925844250486,0.06530123415618438,LGP Offspring,Translation of SARS-CoV-2 structural proteins,CP:REACTOME,C2,28,42
Cohort,-0.03129730829590511,0.07256366976064134,-0.43130823453585615,0.6663557252247096,LGP Proband,Translation of SARS-CoV-2 structural proteins,CP:REACTOME,C2,28,57
Cohort,-0.04422660046455109,0.024492901300519575,-1.8056905518013457,0.07134436096761551,LonGen OPEL,Translation of SARS-CoV-2 structural proteins,CP:REACTOME,C2,45,36
Cohort,-0.011700204874838851,0.013092037437960726,-0.8936886202993723,0.37180656499179865,LGP Offspring,Translesion Synthesis by POLH,CP:REACTOME,C2,7,10
Cohort,0.022335570202725134,0.04635475728508247,0.48183986953833097,0.6300461176963406,LGP Proband,Translesion Synthesis by POLH,CP:REACTOME,C2,7,27
Cohort,0.004752882869182716,0.013740792847099231,0.3458958243582051,0.7295124048856652,LonGen OPEL,Translesion Synthesis by POLH,CP:REACTOME,C2,13,16
Cohort,-0.00279904269154759,0.023573181707631733,-0.11873843447452025,0.9055178602332208,LGP Offspring,Translesion synthesis by POLK,CP:REACTOME,C2,17,40
Cohort,0.0969120616915953,0.06679358068031159,1.450918796454965,0.14717847960412916,LGP Proband,Translesion synthesis by POLK,CP:REACTOME,C2,17,59
Cohort,-0.015991028487639326,0.02068612460728141,-0.7730316234298698,0.43973314942392494,LonGen OPEL,Translesion synthesis by POLK,CP:REACTOME,C2,33,31
Cohort,0.001759090420934318,0.03584356894162403,0.04907687690919474,0.9608725268600082,LGP Offspring,Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template,CP:REACTOME,C2,40,89
Cohort,0.06743791442661125,0.1015205792168584,0.6642782669960632,0.5066958369147079,LGP Proband,Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template,CP:REACTOME,C2,40,129
Cohort,0.013356841606740109,0.030900985449562362,0.4322464611538554,0.6656793627469518,LonGen OPEL,Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template,CP:REACTOME,C2,68,83
Cohort,0.052248005006911305,0.040007487314656094,1.3059556726465822,0.19201184940246202,LGP Offspring,Translocation of SLC2A4 (GLUT4) to the plasma membrane,CP:REACTOME,C2,44,123
Cohort,-0.07546190906227886,0.10992007859135978,-0.6865161490906221,0.4925785058976977,LGP Proband,Translocation of SLC2A4 (GLUT4) to the plasma membrane,CP:REACTOME,C2,44,156
Cohort,-0.002247991858537962,0.03515600332825125,-0.06394332818632666,0.949031405750439,LonGen OPEL,Translocation of SLC2A4 (GLUT4) to the plasma membrane,CP:REACTOME,C2,90,110
Cohort,-0.20676546111181535,0.0857541881645643,-2.411141257789387,0.01616838042429287,LGP Offspring,Transmission across Chemical Synapses,CP:REACTOME,C2,263,474
Cohort,0.06430570038429219,0.2395228419007489,0.2684741875722172,0.7884007341693066,LGP Proband,Transmission across Chemical Synapses,CP:REACTOME,C2,263,721
Cohort,-0.12420416657501154,0.08058167452509701,-1.5413450676844447,0.12363025020266964,LonGen OPEL,Transmission across Chemical Synapses,CP:REACTOME,C2,441,467
Cohort,-0.01641858184975879,0.019785396489960916,-0.8298333499704975,0.4069259565708394,LGP Offspring,Transport and synthesis of PAPS,CP:REACTOME,C2,15,21
Cohort,0.015855334920024642,0.054028389447602826,0.29346303086456565,0.7692412620090258,LGP Proband,Transport and synthesis of PAPS,CP:REACTOME,C2,15,34
Cohort,-0.03766977749558696,0.014864767817712529,-2.5341652125033858,0.011462209013303267,LonGen OPEL,Transport and synthesis of PAPS,CP:REACTOME,C2,21,11
Cohort,-0.0439237943647184,0.05714787962188399,-0.768598846629795,0.4423999160486014,LGP Offspring,"Transport of bile salts and organic acids, metal ions and amine compounds",CP:REACTOME,C2,113,221
Cohort,-0.035000376159530326,0.16393073334178968,-0.21350710416548802,0.830983630422853,LGP Proband,"Transport of bile salts and organic acids, metal ions and amine compounds",CP:REACTOME,C2,113,318
Cohort,-0.08703147490442499,0.05173699614316434,-1.682190335588779,0.092924137321523,LonGen OPEL,"Transport of bile salts and organic acids, metal ions and amine compounds",CP:REACTOME,C2,191,199
Cohort,0.03535522972995028,0.024333729430387783,1.4529309956820236,0.1467069348683579,LGP Offspring,Transport of connexons to the plasma membrane,CP:REACTOME,C2,13,46
Cohort,0.039442412935706786,0.06789127107477155,0.580964420186907,0.5614213920567939,LGP Proband,Transport of connexons to the plasma membrane,CP:REACTOME,C2,13,58
Cohort,0.029248115106186367,0.021151850332958102,1.3827686299677024,0.16712360013361854,LonGen OPEL,Transport of connexons to the plasma membrane,CP:REACTOME,C2,25,43
Cohort,6.434519414389459e-4,0.006463772970202262,0.09954742290690498,0.9207331498048401,LGP Offspring,Transport of fatty acids,CP:REACTOME,C2,1,3
Cohort,-0.0030343775318438133,0.020910881746573427,-0.14510997520901017,0.8846591034408882,LGP Proband,Transport of fatty acids,CP:REACTOME,C2,1,7
Cohort,0.015251455500272995,0.009939965758592432,1.534356945554781,0.12533921224828987,LonGen OPEL,Transport of fatty acids,CP:REACTOME,C2,4,11
Cohort,-0.05481535738092329,0.06571313621976117,-0.8341613341601444,0.4044847411517696,LGP Offspring,Transport of inorganic cations/anions and amino acids/oligopeptides,CP:REACTOME,C2,145,292
Cohort,0.03312120704999114,0.17400957045679663,0.19034129538417846,0.8490880161178515,LGP Proband,Transport of inorganic cations/anions and amino acids/oligopeptides,CP:REACTOME,C2,145,372
Cohort,-0.06814391843909282,0.057363176977952006,-1.1879383609677767,0.23521202601757307,LonGen OPEL,Transport of inorganic cations/anions and amino acids/oligopeptides,CP:REACTOME,C2,235,259
Cohort,-0.04559413750327637,0.0416240090784977,-1.0953807312815906,0.2737399741099977,LGP Offspring,Transport of Mature mRNAs Derived from Intronless Transcripts,CP:REACTOME,C2,63,113
Cohort,-0.22575033805765243,0.11189247026589598,-2.0175650561757195,0.043956434755499485,LGP Proband,Transport of Mature mRNAs Derived from Intronless Transcripts,CP:REACTOME,C2,63,147
Cohort,9.436235085553395e-4,0.03809638083513417,0.024769374094588223,0.9802451274228039,LonGen OPEL,Transport of Mature mRNAs Derived from Intronless Transcripts,CP:REACTOME,C2,94,111
Cohort,-0.044785341404509946,0.050105455705648415,-0.8938216562205874,0.3717354211200675,LGP Offspring,Transport of Mature Transcript to Cytoplasm,CP:REACTOME,C2,83,160
Cohort,-0.05175109912694322,0.13491572159698512,-0.38358093863613646,0.7013868302234907,LGP Proband,Transport of Mature Transcript to Cytoplasm,CP:REACTOME,C2,83,206
Cohort,1.390273594699153e-4,0.0441649708704722,0.003147910136240261,0.9974891239722263,LonGen OPEL,Transport of Mature Transcript to Cytoplasm,CP:REACTOME,C2,131,157
Cohort,6.867440013578341e-4,0.010083775677693764,0.06810385547121747,0.9457230997508792,LGP Offspring,Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,CP:REACTOME,C2,3,7
Cohort,-0.0608415210905949,0.03684216243591921,-1.6514101526048741,0.09903130221482367,LGP Proband,Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,CP:REACTOME,C2,3,21
Cohort,-0.017000825355568315,0.015482592806466461,-1.0980606134954185,0.2725100551311416,LonGen OPEL,Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,CP:REACTOME,C2,19,21
Cohort,-0.0023666358865249947,0.008990154498960684,-0.2632475211408872,0.7924400220391519,LGP Offspring,Transport of nucleotide sugars,CP:REACTOME,C2,3,5
Cohort,0.02267545445438917,0.024858204082212832,0.9121919821478367,0.36193126022784294,LGP Proband,Transport of nucleotide sugars,CP:REACTOME,C2,3,7
Cohort,0.00134678242692053,0.004513081596356309,0.29841747776239436,0.765462431744913,LonGen OPEL,Transport of nucleotide sugars,CP:REACTOME,C2,1,2
Cohort,-0.012623910935721828,0.024089925085629602,-0.5240328017147877,0.600427491227381,LGP Offspring,Transport of organic anions,CP:REACTOME,C2,23,38
Cohort,-0.0031440130797922767,0.07051949647453984,-0.04458360080502535,0.9644498865402806,LGP Proband,Transport of organic anions,CP:REACTOME,C2,23,63
Cohort,-0.02744216804046565,0.018131342197708504,-1.5135210477652272,0.13054429083448207,LonGen OPEL,Transport of organic anions,CP:REACTOME,C2,28,24
Cohort,-0.15546242939491112,0.1576265741353971,-0.9862704321758142,0.32435329305613525,LGP Offspring,Transport of small molecules,CP:REACTOME,C2,878,1755
Cohort,-0.5345998619062406,0.4696867774164001,-1.1382050498566452,0.2553617278897695,LGP Proband,Transport of small molecules,CP:REACTOME,C2,878,2613
Cohort,-0.11313641672151938,0.14090925881057612,-0.8029026458339995,0.42227067151000997,LonGen OPEL,Transport of small molecules,CP:REACTOME,C2,1434,1669
Cohort,-0.034128574484072687,0.03732369034995507,-0.9143944278841594,0.3608356576891124,LGP Offspring,Transport of the SLBP Dependant Mature mRNA,CP:REACTOME,C2,53,93
Cohort,-0.2471652584645594,0.10210499866231426,-2.4206969463071464,0.01570339038080052,LGP Proband,Transport of the SLBP Dependant Mature mRNA,CP:REACTOME,C2,53,120
Cohort,0.004662430479344233,0.035622049514646884,0.13088608159469206,0.8958984963125388,LonGen OPEL,Transport of the SLBP Dependant Mature mRNA,CP:REACTOME,C2,80,96
Cohort,-0.013660350879450053,0.028043236251385505,-0.48711749089854595,0.6263329829711699,LGP Offspring,"Transport of vitamins, nucleosides, and related molecules",CP:REACTOME,C2,30,53
Cohort,-0.04375103294490858,0.08887721450559437,-0.4922637729848596,0.6226624393110096,LGP Proband,"Transport of vitamins, nucleosides, and related molecules",CP:REACTOME,C2,30,103
Cohort,-0.02651558278998322,0.026378081603906988,-1.0052127060694158,0.315099905627016,LonGen OPEL,"Transport of vitamins, nucleosides, and related molecules",CP:REACTOME,C2,53,60
Cohort,-0.06805752720607132,0.08086716733806816,-0.841596527321828,0.4003114485970314,LGP Offspring,Transport to the Golgi and subsequent modification,CP:REACTOME,C2,229,444
Cohort,-0.4595262461456567,0.22474859743712666,-2.0446234209501974,0.04120548682347749,LGP Proband,Transport to the Golgi and subsequent modification,CP:REACTOME,C2,229,584
Cohort,-0.07029922963295013,0.06901534222189798,-1.0186029275479676,0.30870099986277283,LonGen OPEL,Transport to the Golgi and subsequent modification,CP:REACTOME,C2,348,379
Cohort,-0.0016667531067770223,0.008493633586275744,-0.19623557925434995,0.8444847573375979,LGP Offspring,TRIF-mediated programmed cell death,CP:REACTOME,C2,3,5
Cohort,0.0024297183732542027,0.028295683002036096,0.08586887169605927,0.931591266667509,LGP Proband,TRIF-mediated programmed cell death,CP:REACTOME,C2,3,10
Cohort,-0.008508742467935386,0.008182293503421706,-1.0398970000742658,0.2987035112985539,LonGen OPEL,TRIF-mediated programmed cell death,CP:REACTOME,C2,6,4
Cohort,-0.06019113926071104,0.030652076188750054,-1.9636888180123484,0.049975644633922095,LGP Offspring,Triglyceride biosynthesis,CP:REACTOME,C2,38,50
Cohort,-0.08279396122367925,0.08153840681601925,-1.0153983191073748,0.3102104700101449,LGP Proband,Triglyceride biosynthesis,CP:REACTOME,C2,38,70
Cohort,0.010171814935443413,0.02422314119375277,0.41992138237078674,0.6746562041085131,LonGen OPEL,Triglyceride biosynthesis,CP:REACTOME,C2,41,51
Cohort,-0.009793601494774646,0.023778100079321473,-0.4118748538404719,0.6805617162591547,LGP Offspring,Triglyceride catabolism,CP:REACTOME,C2,18,36
Cohort,-0.009245735991749422,0.06294018609217088,-0.14689718232179644,0.8832486775347306,LGP Proband,Triglyceride catabolism,CP:REACTOME,C2,18,41
Cohort,0.0027604675594224476,0.021885030509581946,0.1261349650946947,0.8996569421422597,LonGen OPEL,Triglyceride catabolism,CP:REACTOME,C2,25,33
Cohort,-0.06998474075548569,0.03776727250721032,-1.8530525534276956,0.06431040735759307,LGP Offspring,Triglyceride metabolism,CP:REACTOME,C2,56,86
Cohort,-0.09203969721542869,0.1028751603870808,-0.8946736692231408,0.3712196795632623,LGP Proband,Triglyceride metabolism,CP:REACTOME,C2,56,111
Cohort,0.012932282494865917,0.0319038114723145,0.40535227291222864,0.6853275086470483,LonGen OPEL,Triglyceride metabolism,CP:REACTOME,C2,66,84
Cohort,-0.04722279601569692,0.023566271012552854,-2.0038297951569484,0.04548684770189035,LGP Offspring,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",CP:REACTOME,C2,25,32
Cohort,-0.05955092391193567,0.06519293117742496,-0.9134567634313856,0.3612663527618081,LGP Proband,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",CP:REACTOME,C2,25,48
Cohort,0.028860413148114047,0.021369019133783175,1.3505726663180069,0.1772161851328234,LonGen OPEL,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",CP:REACTOME,C2,28,46
Cohort,0.015540824502741666,0.03505955855742625,0.44326925786262755,0.6577128124526348,LGP Offspring,tRNA Aminoacylation,CP:REACTOME,C2,38,86
Cohort,-0.07229734800163629,0.09722646550242806,-0.7435974107258974,0.4573294975942972,LGP Proband,tRNA Aminoacylation,CP:REACTOME,C2,38,109
Cohort,0.0184775064790975,0.02696007651121591,0.6853655059699293,0.49331284233845607,LonGen OPEL,tRNA Aminoacylation,CP:REACTOME,C2,48,63
Cohort,-0.0056742316232632085,0.013111923083506961,-0.4327535775740349,0.6653318292323571,LGP Offspring,tRNA modification in the mitochondrion,CP:REACTOME,C2,6,11
Cohort,-0.049035702499505424,0.04675805710106608,-1.0487112925482829,0.2946148205566079,LGP Proband,tRNA modification in the mitochondrion,CP:REACTOME,C2,6,31
Cohort,-4.5075753671500234e-5,0.014429366682291491,-0.003123889957472608,0.9975082831893739,LonGen OPEL,tRNA modification in the mitochondrion,CP:REACTOME,C2,14,18
Cohort,-0.011864279659853715,0.03243866178988192,-0.36574504018394355,0.7146697533058644,LGP Offspring,tRNA modification in the nucleus and cytosol,CP:REACTOME,C2,35,66
Cohort,-0.21390200074453838,0.09087367338252769,-2.353839046916589,0.018811788137993585,LGP Proband,tRNA modification in the nucleus and cytosol,CP:REACTOME,C2,35,103
Cohort,0.06519606575074191,0.02736712240757689,2.3822769811082387,0.017439861950886076,LonGen OPEL,tRNA modification in the nucleus and cytosol,CP:REACTOME,C2,40,71
Cohort,-0.07402902710119487,0.057321298052713104,-1.2914750645234379,0.19698040306063047,LGP Offspring,tRNA processing,CP:REACTOME,C2,125,224
Cohort,-0.45231487626663747,0.16461395908347473,-2.7477309870013595,0.006130443167659798,LGP Proband,tRNA processing,CP:REACTOME,C2,125,321
Cohort,0.0916454268719134,0.05109334769808362,1.79368608636601,0.07324274516623176,LonGen OPEL,tRNA processing,CP:REACTOME,C2,169,241
Cohort,-0.016403003095732317,0.01234218745037038,-1.3290191193166554,0.1842900473578047,LGP Offspring,tRNA processing in the mitochondrion,CP:REACTOME,C2,7,8
Cohort,0.02335658286687619,0.038694419105498486,0.6036163200485213,0.546262892297043,LGP Proband,tRNA processing in the mitochondrion,CP:REACTOME,C2,7,18
Cohort,0.005718051011084323,0.011191426560267559,0.5109313795066014,0.6095407815513718,LonGen OPEL,tRNA processing in the mitochondrion,CP:REACTOME,C2,8,11
Cohort,-0.04635707404135328,0.048298781285697014,-0.9597980074723181,0.3375000430241172,LGP Offspring,tRNA processing in the nucleus,CP:REACTOME,C2,84,152
Cohort,-0.1833125152361339,0.13367692771382686,-1.3713100560522007,0.17064716652740208,LGP Proband,tRNA processing in the nucleus,CP:REACTOME,C2,84,195
Cohort,0.02724822679024625,0.04267576187735531,0.6384942082241947,0.5233356785257077,LonGen OPEL,tRNA processing in the nucleus,CP:REACTOME,C2,116,154
Cohort,-0.02573635224042785,0.03209969587867756,-0.8017631175603566,0.4229717366211011,LGP Offspring,TRP channels,CP:REACTOME,C2,37,69
Cohort,0.10678575850462818,0.09957205952455403,1.0724470199222431,0.28382951917325133,LGP Proband,TRP channels,CP:REACTOME,C2,37,114
Cohort,-0.001856367344945212,0.027943297007852818,-0.06643336841831952,0.9470494863619121,LonGen OPEL,TRP channels,CP:REACTOME,C2,56,64
Cohort,0.013979791889120513,0.018555178041230722,0.7534172864338232,0.4514615142345617,LGP Offspring,Tryptophan catabolism,CP:REACTOME,C2,10,25
Cohort,0.021944445987080004,0.0547112055333597,0.4010960053457342,0.688452181972836,LGP Proband,Tryptophan catabolism,CP:REACTOME,C2,10,39
Cohort,0.004006807414022411,0.020632840971241625,0.19419562335633575,0.8460722574571586,LonGen OPEL,Tryptophan catabolism,CP:REACTOME,C2,29,31
Cohort,-0.0031245621481365126,0.02813742265540763,-0.11104649442851562,0.9116124386027021,LGP Offspring,Type I hemidesmosome assembly,CP:REACTOME,C2,25,56
Cohort,0.03580381652561895,0.07544557568248504,0.4745648263895604,0.6352214149732105,LGP Proband,Type I hemidesmosome assembly,CP:REACTOME,C2,25,74
Cohort,0.020332580726960654,0.02647477429856615,0.7679982649771578,0.4427159803297268,LonGen OPEL,Type I hemidesmosome assembly,CP:REACTOME,C2,44,63
Cohort,-0.03255974252012069,0.012672620051884345,-2.5692984076547964,0.010403776523483387,LGP Offspring,Tyrosine catabolism,CP:REACTOME,C2,10,6
Cohort,-0.03064934452288702,0.04043251754132492,-0.7580370055255947,0.448642969702419,LGP Proband,Tyrosine catabolism,CP:REACTOME,C2,10,15
Cohort,0.016382986750694883,0.01059535333038253,1.5462426065316879,0.12244344540899192,LonGen OPEL,Tyrosine catabolism,CP:REACTOME,C2,5,12
Cohort,-0.009807113661911677,0.016040958211449238,-0.6113795405882828,0.5411538790093853,LGP Offspring,TYSND1 cleaves peroxisomal proteins,CP:REACTOME,C2,11,15
Cohort,-0.013894289340839229,0.04512423403523856,-0.30791191557930614,0.7582262401054919,LGP Proband,TYSND1 cleaves peroxisomal proteins,CP:REACTOME,C2,11,24
Cohort,-0.017155580057643508,0.013679002233471677,-1.2541543428997226,0.21015407755594104,LonGen OPEL,TYSND1 cleaves peroxisomal proteins,CP:REACTOME,C2,14,13
Cohort,0.03476747262092082,0.07092767675807853,0.4901820306268649,0.6241641458802906,LGP Offspring,Ub-specific processing proteases,CP:REACTOME,C2,153,340
Cohort,-0.2360173481041772,0.19725997440591875,-1.1964786511555765,0.2318498448279586,LGP Proband,Ub-specific processing proteases,CP:REACTOME,C2,153,502
Cohort,-0.001933281188848643,0.06052041291601349,-0.03194428285761255,0.9745244918290019,LonGen OPEL,Ub-specific processing proteases,CP:REACTOME,C2,271,318
Cohort,0.009127299429390747,0.018172758845448344,0.5022517223177054,0.6156540222158862,LGP Offspring,Ubiquinol biosynthesis,CP:REACTOME,C2,7,22
Cohort,0.048726250332402535,0.04516257550014325,1.0789076971982694,0.2809408087708478,LGP Proband,Ubiquinol biosynthesis,CP:REACTOME,C2,7,27
Cohort,-0.019536497172229234,0.013159804157714464,-1.4845583519399612,0.138056730173243,LonGen OPEL,Ubiquinol biosynthesis,CP:REACTOME,C2,17,10
Cohort,0.04155765383209065,0.0432761738697,0.9602894645265169,0.33725289090342103,LGP Offspring,UCH proteinases,CP:REACTOME,C2,52,123
Cohort,-0.1245740531183012,0.11741676222079425,-1.060956295865561,0.2890169035714,LGP Proband,UCH proteinases,CP:REACTOME,C2,52,166
Cohort,-0.013210280014010525,0.03704328134623002,-0.3566174359808696,0.7214727308958793,LonGen OPEL,UCH proteinases,CP:REACTOME,C2,98,108
Cohort,-0.016903554831734304,0.025801953113275707,-0.6551269494027966,0.5126088838815821,LGP Offspring,"Unblocking of NMDA receptors, glutamate binding and activation",CP:REACTOME,C2,21,43
Cohort,0.05891852224500598,0.07553125697037417,0.7800548356836661,0.43557991764005244,LGP Proband,"Unblocking of NMDA receptors, glutamate binding and activation",CP:REACTOME,C2,21,72
Cohort,-0.009938121799338269,0.024385975764189573,-0.4075343096966514,0.6837251769222946,LonGen OPEL,"Unblocking of NMDA receptors, glutamate binding and activation",CP:REACTOME,C2,38,44
Cohort,-0.07104827099936842,0.05137326297594247,-1.3829814748702947,0.16712716543225986,LGP Offspring,Unfolded Protein Response (UPR),CP:REACTOME,C2,93,172
Cohort,-0.28946774843122125,0.15450604059939896,-1.8735044099780478,0.06134827937643123,LGP Proband,Unfolded Protein Response (UPR),CP:REACTOME,C2,93,278
Cohort,0.06869463428988683,0.04832002177221845,1.4216598372764548,0.15551669699732829,LonGen OPEL,Unfolded Protein Response (UPR),CP:REACTOME,C2,147,203
Cohort,-3.0446333424798404e-4,0.02429283770687862,-0.012533049367129883,0.990004033000534,LGP Offspring,Unwinding of DNA,CP:REACTOME,C2,21,40
Cohort,0.0220548617558398,0.06701256796968807,0.329115305144192,0.7421511656088584,LGP Proband,Unwinding of DNA,CP:REACTOME,C2,21,56
Cohort,0.017399881937423277,0.021059926083007198,0.8262081200495223,0.4089336114133114,LonGen OPEL,Unwinding of DNA,CP:REACTOME,C2,30,41
Cohort,-0.015682173006617745,0.02789864239739833,-0.5621124061606732,0.5742257671539135,LGP Offspring,Uptake and actions of bacterial toxins,CP:REACTOME,C2,26,50
Cohort,0.04248254393015868,0.07949462237677678,0.5344077707395883,0.5932018704798593,LGP Proband,Uptake and actions of bacterial toxins,CP:REACTOME,C2,26,71
Cohort,0.02808866474989654,0.024588004929161866,1.1423726662988758,0.25364264447735563,LonGen OPEL,Uptake and actions of bacterial toxins,CP:REACTOME,C2,34,51
Cohort,-0.013329353099355744,0.014993685488121149,-0.8889977790928065,0.3743205023076541,LGP Offspring,Uptake and function of anthrax toxins,CP:REACTOME,C2,9,14
Cohort,0.05771582301811677,0.04187424468354863,1.3783131720771529,0.1684762491723563,LGP Proband,Uptake and function of anthrax toxins,CP:REACTOME,C2,9,21
Cohort,0.007126491061847796,0.013023714575204052,0.5471934309291434,0.5843992224795946,LonGen OPEL,Uptake and function of anthrax toxins,CP:REACTOME,C2,10,14
Cohort,0.012602686456029973,0.011427036461671128,1.1028831927072467,0.2704703622224275,LGP Offspring,Uptake and function of diphtheria toxin,CP:REACTOME,C2,2,11
Cohort,0.06882005217639832,0.03478373910692519,1.9785121997622372,0.048199599465670984,LGP Proband,Uptake and function of diphtheria toxin,CP:REACTOME,C2,2,18
Cohort,0.013660413524679327,0.010164074539212453,1.3439899001112385,0.17933458713814832,LonGen OPEL,Uptake and function of diphtheria toxin,CP:REACTOME,C2,5,11
Cohort,-0.006785080722361359,0.020277250705204076,-0.3346154180862396,0.7380190063007939,LGP Offspring,Urea cycle,CP:REACTOME,C2,15,27
Cohort,-0.0018507377252922727,0.05728523739310649,-0.03230741128978867,0.9742346288988444,LGP Proband,Urea cycle,CP:REACTOME,C2,15,41
Cohort,-0.003225527925490716,0.01886929774841042,-0.17094053888478386,0.8643139619266891,LonGen OPEL,Urea cycle,CP:REACTOME,C2,25,29
Cohort,0.009946643419224533,0.013524564491559633,0.7354501821801362,0.4623204508330947,LGP Offspring,Vasopressin-like receptors,CP:REACTOME,C2,4,14
Cohort,-0.011153225361378203,0.03600846031374506,-0.3097390242237273,0.7568367977701216,LGP Proband,Vasopressin-like receptors,CP:REACTOME,C2,4,15
Cohort,-0.006575614828535101,0.00731240099590351,-0.8992415531121495,0.3687959528646876,LonGen OPEL,Vasopressin-like receptors,CP:REACTOME,C2,5,3
Cohort,0.0382766248882057,0.0248000144622383,1.5434113938315455,0.12319896494708893,LGP Offspring,Vasopressin regulates renal water homeostasis via Aquaporins,CP:REACTOME,C2,15,49
Cohort,0.07742616760148212,0.07592246273550683,1.0198057967536405,0.30811630430112014,LGP Proband,Vasopressin regulates renal water homeostasis via Aquaporins,CP:REACTOME,C2,15,78
Cohort,-0.0161016713540237,0.02604273452679229,-0.6182788269587665,0.536568420688477,LonGen OPEL,Vasopressin regulates renal water homeostasis via Aquaporins,CP:REACTOME,C2,47,54
Cohort,-0.02118463329536403,0.01741100600689745,-1.2167380383977604,0.22412853317453243,LGP Offspring,VEGF ligand-receptor interactions,CP:REACTOME,C2,11,16
Cohort,-0.0890595959777829,0.04729260135493655,-1.883161285829471,0.060026297765855566,LGP Proband,VEGF ligand-receptor interactions,CP:REACTOME,C2,11,25
Cohort,-0.01613944764182015,0.01620195630351549,-0.9961419065374361,0.31948391429937417,LonGen OPEL,VEGF ligand-receptor interactions,CP:REACTOME,C2,19,15
Cohort,-0.039763659973324615,0.021586890375339694,-1.8420281607002364,0.06590885792706133,LGP Offspring,VEGFR2 mediated cell proliferation,CP:REACTOME,C2,23,26
Cohort,-0.12593126012239714,0.06024138303503303,-2.0904443719222474,0.03688015218084077,LGP Proband,VEGFR2 mediated cell proliferation,CP:REACTOME,C2,23,38
Cohort,-0.003937196932792193,0.01884050060628522,-0.20897517614148417,0.8345210826079968,LonGen OPEL,VEGFR2 mediated cell proliferation,CP:REACTOME,C2,26,31
Cohort,-0.046259677222474524,0.029575523731820746,-1.5641203057615864,0.11825730194060337,LGP Offspring,VEGFR2 mediated vascular permeability,CP:REACTOME,C2,35,50
Cohort,-0.07613806924670612,0.08456018975994473,-0.9004008796911656,0.36816687008543914,LGP Proband,VEGFR2 mediated vascular permeability,CP:REACTOME,C2,35,82
Cohort,0.043690853109189756,0.02470845472865751,1.768255181839274,0.077401238575553,LonGen OPEL,VEGFR2 mediated vascular permeability,CP:REACTOME,C2,31,56
Cohort,-0.09581569309090773,0.15650157440388837,-0.6122346912858094,0.5405883635926836,LGP Offspring,Vesicle-mediated transport,CP:REACTOME,C2,772,1565
Cohort,-0.7623130223444611,0.4352552631141228,-1.751415978040878,0.08024185999579424,LGP Proband,Vesicle-mediated transport,CP:REACTOME,C2,772,2167
Cohort,-0.20674449374974183,0.1306109798155675,-1.5829028619315204,0.11384081743312074,LonGen OPEL,Vesicle-mediated transport,CP:REACTOME,C2,1261,1410
Cohort,-0.04434656662628457,0.03914741954389241,-1.132809445500305,0.2576959065171537,LGP Offspring,Viral Messenger RNA Synthesis,CP:REACTOME,C2,61,103
Cohort,-0.29509556057592645,0.10886739123891423,-2.7105964165920575,0.00685422982058608,LGP Proband,Viral Messenger RNA Synthesis,CP:REACTOME,C2,61,140
Cohort,0.018377697696627972,0.03738979871738074,0.49151635812591454,0.623196785009431,LonGen OPEL,Viral Messenger RNA Synthesis,CP:REACTOME,C2,88,110
Cohort,0.004976131470658018,0.06701896952659168,0.07424959687993406,0.940833747433677,LGP Offspring,Visual phototransduction,CP:REACTOME,C2,144,300
Cohort,-0.29796911554700484,0.18770674354477626,-1.58741827768125,0.1127969712045917,LGP Proband,Visual phototransduction,CP:REACTOME,C2,144,401
Cohort,0.15014687324388482,0.05812536489297271,2.583155796447093,0.009967411201639107,LonGen OPEL,Visual phototransduction,CP:REACTOME,C2,202,309
Cohort,-0.007018927263069745,0.007147945731878611,-0.981950273036704,0.3264756456252158,LGP Offspring,Vitamin B1 (thiamin) metabolism,CP:REACTOME,C2,3,2
Cohort,-0.015600991970231804,0.022275204324868927,-0.7003748088099122,0.4838885940517538,LGP Proband,Vitamin B1 (thiamin) metabolism,CP:REACTOME,C2,3,5
Cohort,0.006499780009183135,0.004511021641486135,1.4408665100178535,0.15001563073409835,LonGen OPEL,Vitamin B1 (thiamin) metabolism,CP:REACTOME,C2,0,3
Cohort,-0.008138992547510666,0.01229209393470073,-0.6621323096575265,0.5081120858540679,LGP Offspring,Vitamin B2 (riboflavin) metabolism,CP:REACTOME,C2,6,9
Cohort,-0.020197789152303414,0.03175429611841334,-0.6360647729990568,0.524908713031975,LGP Proband,Vitamin B2 (riboflavin) metabolism,CP:REACTOME,C2,6,11
Cohort,0.0027365186807965713,0.009940855779581549,0.27527999012090715,0.783172575688619,LonGen OPEL,Vitamin B2 (riboflavin) metabolism,CP:REACTOME,C2,6,9
Cohort,-0.004802150849283734,0.0241025174605026,-0.19923855909048252,0.842136049760291,LGP Offspring,Vitamin B5 (pantothenate) metabolism,CP:REACTOME,C2,20,40
Cohort,0.005227946510185668,0.06825099118780213,0.07659883643008558,0.9389610558235264,LGP Proband,Vitamin B5 (pantothenate) metabolism,CP:REACTOME,C2,20,58
Cohort,-0.011173890775516242,0.020584805192860326,-0.5428222745285837,0.5874041276005646,LonGen OPEL,Vitamin B5 (pantothenate) metabolism,CP:REACTOME,C2,34,32
Cohort,-0.006154917433139212,0.010147098297212357,-0.606569213469639,0.5443404806550509,LGP Offspring,Vitamin C (ascorbate) metabolism,CP:REACTOME,C2,4,6
Cohort,-0.031652196629338346,0.02490958276947152,-1.2706835326094013,0.2041955881869078,LGP Proband,Vitamin C (ascorbate) metabolism,CP:REACTOME,C2,4,6
Cohort,0.002765209431930782,0.006852556058918748,0.40352963305302747,0.6866670131979036,LonGen OPEL,Vitamin C (ascorbate) metabolism,CP:REACTOME,C2,3,4
Cohort,0.022226351056592764,0.028566902061406337,0.7780455510652096,0.4368143838358891,LGP Offspring,Vitamin D (calciferol) metabolism,CP:REACTOME,C2,25,60
Cohort,0.07883884871969005,0.07597289086216118,1.0377234277254057,0.29969960314690114,LGP Proband,Vitamin D (calciferol) metabolism,CP:REACTOME,C2,25,73
Cohort,0.0056267066779269286,0.022345956195169943,0.2517997721280388,0.8012608285964324,LonGen OPEL,Vitamin D (calciferol) metabolism,CP:REACTOME,C2,31,44
Cohort,0.029316097580939005,0.019178565475965723,1.5285865680453252,0.1268347308003572,LGP Offspring,Vitamins,CP:REACTOME,C2,8,30
Cohort,0.034017266743976524,0.05267286778470679,0.6458214290328275,0.5185726564082578,LGP Proband,Vitamins,CP:REACTOME,C2,8,37
Cohort,0.013734725626306735,0.016247550288028267,0.8453413211730101,0.3981743167710061,LonGen OPEL,Vitamins,CP:REACTOME,C2,15,24
Cohort,-0.007997205408731037,0.012349373698109635,-0.6475798371827715,0.5174765991237005,LGP Offspring,VLDL assembly,CP:REACTOME,C2,6,9
Cohort,0.01645713347930039,0.040616437831127034,0.40518406729130274,0.6854461261663596,LGP Proband,VLDL assembly,CP:REACTOME,C2,6,22
Cohort,0.013561408666565973,0.01324081941665291,1.0242121910906707,0.306046213940287,LonGen OPEL,VLDL assembly,CP:REACTOME,C2,9,18
Cohort,-0.014676357266982923,0.012286181221282633,-1.1945418191911354,0.23268504526669764,LGP Offspring,VLDL clearance,CP:REACTOME,C2,7,8
Cohort,0.018520954099601833,0.0408747815093956,0.45311444895049896,0.6505841900623162,LGP Proband,VLDL clearance,CP:REACTOME,C2,7,21
Cohort,0.01884776949262662,0.011700574622993183,1.6108413560807733,0.10761073965358275,LonGen OPEL,VLDL clearance,CP:REACTOME,C2,6,15
Cohort,-0.041436975760574354,0.016018143046391115,-2.5868776199941665,0.009892733892188794,LGP Offspring,VLDLR internalisation and degradation,CP:REACTOME,C2,13,13
Cohort,0.042549538668064234,0.04937068212387078,0.8618381767808608,0.38902430011534894,LGP Proband,VLDLR internalisation and degradation,CP:REACTOME,C2,13,28
Cohort,-0.0062158417522275465,0.012194251557915805,-0.5097354046458539,0.610378137372062,LonGen OPEL,VLDLR internalisation and degradation,CP:REACTOME,C2,11,12
Cohort,0.07851611764843765,0.03858801058937169,2.034728311960798,0.04226794073928419,LGP Offspring,Voltage gated Potassium channels,CP:REACTOME,C2,39,116
Cohort,0.08056194812379881,0.10152813688994927,0.7934938096138155,0.42771586612559187,LGP Proband,Voltage gated Potassium channels,CP:REACTOME,C2,39,125
Cohort,-0.012759514831920166,0.03176469945691725,-0.40168851114823273,0.6880211023100391,LonGen OPEL,Voltage gated Potassium channels,CP:REACTOME,C2,65,82
Cohort,0.0027911179535760576,0.03492507699756226,0.07991730279566385,0.9363266803986179,LGP Offspring,VxPx cargo-targeting to cilium,CP:REACTOME,C2,35,75
Cohort,-0.15211307148390518,0.09077575723176515,-1.6757014881796688,0.09417150209269469,LGP Proband,VxPx cargo-targeting to cilium,CP:REACTOME,C2,35,97
Cohort,0.00908769737110121,0.026873454760280094,0.33816632257245705,0.7353270222273682,LonGen OPEL,VxPx cargo-targeting to cilium,CP:REACTOME,C2,42,57
Cohort,2.5551010994004695e-4,0.009927428261300003,0.025737794644772154,0.9794740737689922,LGP Offspring,Wax and plasmalogen biosynthesis,CP:REACTOME,C2,3,7
Cohort,-0.025157436158788175,0.03502091819198639,-0.7183545565788388,0.4727398887976497,LGP Proband,Wax and plasmalogen biosynthesis,CP:REACTOME,C2,3,17
Cohort,0.00939236733983876,0.01053475626129348,0.8915600045107779,0.37289823065374683,LonGen OPEL,Wax and plasmalogen biosynthesis,CP:REACTOME,C2,6,11
Cohort,-0.01238028744045143,0.02098711478730153,-0.5898994485865323,0.5554551805590879,LGP Offspring,WNT ligand biogenesis and trafficking,CP:REACTOME,C2,14,27
Cohort,-0.03736068486286985,0.053193556547759285,-0.7023535797860394,0.4826546611452036,LGP Proband,WNT ligand biogenesis and trafficking,CP:REACTOME,C2,14,32
Cohort,0.005633805055303007,0.015791383199499017,0.35676450784132324,0.7213626597609573,LonGen OPEL,WNT ligand biogenesis and trafficking,CP:REACTOME,C2,17,22
Cohort,0.0026355691541412626,0.012949287963507873,0.20353004439846475,0.8387820158277689,LGP Offspring,WNT mediated activation of DVL,CP:REACTOME,C2,6,11
Cohort,-0.06993725834193344,0.03916390317289175,-1.7857581261293236,0.07450168200265901,LGP Proband,WNT mediated activation of DVL,CP:REACTOME,C2,6,20
Cohort,-0.023566863555427888,0.014178985219877156,-1.6620980408661479,0.09688683272090846,LonGen OPEL,WNT mediated activation of DVL,CP:REACTOME,C2,18,13
Cohort,-0.008033573147479425,0.020854890297468356,-0.38521291806817354,0.7002008474707146,LGP Offspring,"WNT5A-dependent internalization of FZD2, FZD5 and ROR2",CP:REACTOME,C2,15,30
Cohort,0.0422282482090338,0.05845562648732635,0.7223983514775815,0.47025210891940517,LGP Proband,"WNT5A-dependent internalization of FZD2, FZD5 and ROR2",CP:REACTOME,C2,15,46
Cohort,-0.010061720335858648,0.01417792613941684,-0.7096750425215929,0.4781134991206145,LonGen OPEL,"WNT5A-dependent internalization of FZD2, FZD5 and ROR2",CP:REACTOME,C2,15,14
Cohort,-0.03250698954847582,0.02195324167867031,-1.4807375614171594,0.13914243485928623,LGP Offspring,WNT5A-dependent internalization of FZD4,CP:REACTOME,C2,21,27
Cohort,0.021500255284340433,0.06423515531961681,0.3347116571503713,0.7379267666228959,LGP Proband,WNT5A-dependent internalization of FZD4,CP:REACTOME,C2,21,50
Cohort,7.524208900628359e-4,0.016984564893037117,0.044300274678881736,0.9646761631454861,LonGen OPEL,WNT5A-dependent internalization of FZD4,CP:REACTOME,C2,18,23
Cohort,-0.03989076878716687,0.029142378885679093,-1.3688233532221923,0.17150916723253123,LGP Offspring,Xenobiotics,CP:REACTOME,C2,31,45
Cohort,-0.009362463824922526,0.08316108768744924,-0.11258226756376971,0.9103888357738505,LGP Proband,Xenobiotics,CP:REACTOME,C2,31,80
Cohort,0.004939349455617652,0.025145080422685432,0.19643402894673032,0.8443206029863436,LonGen OPEL,Xenobiotics,CP:REACTOME,C2,41,51
Cohort,-0.0064740661594107594,0.01579389687970343,-0.40990935984459376,0.6820023049166176,LGP Offspring,YAP1- and WWTR1 (TAZ)-stimulated gene expression,CP:REACTOME,C2,9,16
Cohort,0.04808234612622256,0.04854498117610166,0.9904699715877765,0.3222317286005719,LGP Proband,YAP1- and WWTR1 (TAZ)-stimulated gene expression,CP:REACTOME,C2,9,26
Cohort,-0.0020619844499994056,0.01544203085665796,-0.1335306520975098,0.8938074751264883,LonGen OPEL,YAP1- and WWTR1 (TAZ)-stimulated gene expression,CP:REACTOME,C2,18,19
Cohort,-0.011883834204414662,0.02937616322717107,-0.40454003855149046,0.6859436059624571,LGP Offspring,ZBP1(DAI) mediated induction of type I IFNs,CP:REACTOME,C2,28,56
Cohort,0.05485024427132062,0.0720657918995771,0.7611134607075968,0.4468044450446548,LGP Proband,ZBP1(DAI) mediated induction of type I IFNs,CP:REACTOME,C2,28,57
Cohort,-0.006533137599815324,0.024177125618670078,-0.27021978141066944,0.7870612180112604,LonGen OPEL,ZBP1(DAI) mediated induction of type I IFNs,CP:REACTOME,C2,38,43
Cohort,-0.005150035367385447,0.009089684845019647,-0.5665801900939631,0.5711874937435066,LGP Offspring,Zinc efflux and compartmentalization by the SLC30 family,CP:REACTOME,C2,3,5
Cohort,-0.007141541917116658,0.02363724165473411,-0.30213093479485315,0.7626275788822834,LGP Proband,Zinc efflux and compartmentalization by the SLC30 family,CP:REACTOME,C2,3,6
Cohort,0.001720845740130526,0.00730742326016553,0.23549282405896177,0.8138868198122529,LonGen OPEL,Zinc efflux and compartmentalization by the SLC30 family,CP:REACTOME,C2,3,5
Cohort,-0.0063808141040343404,0.0201153038266441,-0.31721191780272856,0.7511807529602089,LGP Offspring,Zinc influx into cells by the SLC39 gene family,CP:REACTOME,C2,14,25
Cohort,-0.08018772686522752,0.05593158279921609,-1.4336752663175374,0.15203974293635178,LGP Proband,Zinc influx into cells by the SLC39 gene family,CP:REACTOME,C2,14,37
Cohort,0.016649225486670926,0.014186775932196548,1.1735735847414004,0.2409168923548829,LonGen OPEL,Zinc influx into cells by the SLC39 gene family,CP:REACTOME,C2,10,21
Cohort,-0.011530849471419783,0.022323898837723916,-0.5165248935788241,0.6056567831049066,LGP Offspring,Zinc transporters,CP:REACTOME,C2,17,30
Cohort,-0.08732926878234412,0.05996376456270234,-1.4563673481678503,0.14566744893850458,LGP Proband,Zinc transporters,CP:REACTOME,C2,17,43
Cohort,0.01837007122680147,0.01624346960708448,1.1309204050093762,0.2584292117508447,LonGen OPEL,Zinc transporters,CP:REACTOME,C2,13,26
Cohort,-0.02623074119833548,0.013536465731396219,-1.9377835927657543,0.05306574706288928,LGP Offspring,15q11.2 copy number variation syndrome,CP:WIKIPATHWAYS,C2,10,9
Cohort,-0.0893745984194023,0.04633376500494514,-1.9289301961509813,0.05407857007646892,LGP Proband,15q11.2 copy number variation syndrome,CP:WIKIPATHWAYS,C2,10,24
Cohort,0.02020439676257597,0.011912855978208223,1.6960162029604973,0.0902738258193311,LonGen OPEL,15q11.2 copy number variation syndrome,CP:WIKIPATHWAYS,C2,6,17
Cohort,0.031056778992932788,0.03158291471319519,0.9833411284221154,0.3257913790614213,LGP Offspring,15q13.3 copy number variation syndrome,CP:WIKIPATHWAYS,C2,26,71
Cohort,0.041560973828042205,0.0818611037580923,0.5077011171368885,0.6117972002198269,LGP Proband,15q13.3 copy number variation syndrome,CP:WIKIPATHWAYS,C2,26,78
Cohort,-0.0469109146571241,0.023869489262227903,-1.965308689338315,0.049725855533183434,LonGen OPEL,15q13.3 copy number variation syndrome,CP:WIKIPATHWAYS,C2,51,39
Cohort,-0.014505409293657694,0.02720580327900162,-0.5331733507333515,0.5940888248257201,LGP Offspring,16p11.2 distal deletion syndrome,CP:WIKIPATHWAYS,C2,26,45
Cohort,-0.10299417854593297,0.08048794614054018,-1.2796223967014217,0.20103382578612314,LGP Proband,16p11.2 distal deletion syndrome,CP:WIKIPATHWAYS,C2,26,82
Cohort,-0.011030477521076066,0.02585271149133523,-0.4266661748332677,0.6697378572242592,LonGen OPEL,16p11.2 distal deletion syndrome,CP:WIKIPATHWAYS,C2,49,50
Cohort,0.057820633785928124,0.0457575531832458,1.2636303683978285,0.2067983221647121,LGP Offspring,16p11.2 proximal deletion syndrome,CP:WIKIPATHWAYS,C2,62,156
Cohort,-0.16172778182947534,0.12321649961788302,-1.3125497180249632,0.18969580706073172,LGP Proband,16p11.2 proximal deletion syndrome,CP:WIKIPATHWAYS,C2,62,186
Cohort,-0.05108449382766992,0.04449351371354936,-1.1481335045048027,0.2512583763959623,LonGen OPEL,16p11.2 proximal deletion syndrome,CP:WIKIPATHWAYS,C2,136,134
Cohort,-0.007339645297986392,0.030094065684764273,-0.24389012022733225,0.8073899192354623,LGP Offspring,1q21.1 copy number variation syndrome,CP:WIKIPATHWAYS,C2,34,67
Cohort,-0.00961609673339905,0.08334708678864888,-0.11537411928725833,0.9081763638895602,LGP Proband,1q21.1 copy number variation syndrome,CP:WIKIPATHWAYS,C2,34,84
Cohort,-0.016502860715326657,0.02635394393418715,-0.6262007977454425,0.5313627647370444,LonGen OPEL,1q21.1 copy number variation syndrome,CP:WIKIPATHWAYS,C2,53,56
Cohort,0.009097004503153443,0.06618771007225291,0.13744250244075257,0.8907219636215361,LGP Offspring,22q11.2 copy number variation syndrome,CP:WIKIPATHWAYS,C2,126,273
Cohort,0.21347059595754192,0.1867002140321602,1.1433869910870609,0.2532060424507663,LGP Proband,22q11.2 copy number variation syndrome,CP:WIKIPATHWAYS,C2,126,402
Cohort,-0.007124361037037085,0.05765923475370916,-0.12355975703577617,0.9016950492506473,LonGen OPEL,22q11.2 copy number variation syndrome,CP:WIKIPATHWAYS,C2,224,263
Cohort,-0.05766723778930514,0.04732083810684405,-1.218643627128926,0.22340458769380286,LGP Offspring,3q29 copy number variation syndrome,CP:WIKIPATHWAYS,C2,81,135
Cohort,-0.26986573316311474,0.1306210285944465,-2.0660205792820436,0.039134844263198444,LGP Proband,3q29 copy number variation syndrome,CP:WIKIPATHWAYS,C2,81,184
Cohort,-0.01340493421983227,0.04034023340683161,-0.3322968928970586,0.7397525698934027,LonGen OPEL,3q29 copy number variation syndrome,CP:WIKIPATHWAYS,C2,102,118
Cohort,-0.06676283796873256,0.027107075412977966,-2.4629303217553575,0.01402884987951402,LGP Offspring,"4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression",CP:WIKIPATHWAYS,C2,35,44
Cohort,0.040573355380341083,0.08011613989141685,0.5064317306766282,0.612687452878678,LGP Proband,"4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression",CP:WIKIPATHWAYS,C2,35,73
Cohort,0.003879275673232742,0.021949963098785892,0.17673267402655973,0.8597633308129096,LonGen OPEL,"4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression",CP:WIKIPATHWAYS,C2,31,39
Cohort,-0.0028313386269480842,0.023607031974764568,-0.11993623891282593,0.9045692925615965,LGP Offspring,7-oxo-C and 7beta-HC pathways,CP:WIKIPATHWAYS,C2,17,38
Cohort,-0.13409370771279588,0.07484743612616845,-1.7915604682404547,0.07356586134411486,LGP Proband,7-oxo-C and 7beta-HC pathways,CP:WIKIPATHWAYS,C2,17,73
Cohort,-0.020038815811183358,0.019909988621893176,-1.0064704803069813,0.3144951520969872,LonGen OPEL,7-oxo-C and 7beta-HC pathways,CP:WIKIPATHWAYS,C2,30,29
Cohort,-0.08068597503142019,0.05548058478069587,-1.4543101041626798,0.14632447932502793,LGP Offspring,7q11.23 copy number variation syndrome,CP:WIKIPATHWAYS,C2,99,186
Cohort,0.08389094476283206,0.14410029833083116,0.5821705141111638,0.5606091711994634,LGP Proband,7q11.23 copy number variation syndrome,CP:WIKIPATHWAYS,C2,99,249
Cohort,6.561399540773472e-4,0.04684089641564084,0.014007843664115975,0.9888272333564294,LonGen OPEL,7q11.23 copy number variation syndrome,CP:WIKIPATHWAYS,C2,150,182
Cohort,-0.062185356042697044,0.02329869922167695,-2.669048406996053,0.00778920491408722,LGP Offspring,ACE Inhibitor Pathway,CP:WIKIPATHWAYS,C2,27,26
Cohort,-0.08009775977755433,0.06346629614292286,-1.2620519022754733,0.2072829285382468,LGP Proband,ACE Inhibitor Pathway,CP:WIKIPATHWAYS,C2,27,40
Cohort,0.007174725371557868,0.018958705771963586,0.37843961807603754,0.7052049476071167,LonGen OPEL,ACE Inhibitor Pathway,CP:WIKIPATHWAYS,C2,23,30
Cohort,-0.03114882195347798,0.025004345160045596,-1.2457363611845607,0.2132927806402264,LGP Offspring,Acetylcholine Synthesis,CP:WIKIPATHWAYS,C2,24,32
Cohort,0.03585274353537646,0.06726790803502915,0.5329843692583166,0.5941863876667539,LGP Proband,Acetylcholine Synthesis,CP:WIKIPATHWAYS,C2,24,54
Cohort,-0.03716355549508876,0.020685588381385657,-1.796591656466061,0.07277950247129804,LonGen OPEL,Acetylcholine Synthesis,CP:WIKIPATHWAYS,C2,32,28
Cohort,0.0023343936237467324,0.019281952206860763,0.1210662488270314,0.9036745379345589,LGP Offspring,Activation of NLRP3 Inflammasome by SARS-CoV-2,CP:WIKIPATHWAYS,C2,10,26
Cohort,0.036839047933749154,0.04537921266187972,0.8118044755037226,0.41713546746799246,LGP Proband,Activation of NLRP3 Inflammasome by SARS-CoV-2,CP:WIKIPATHWAYS,C2,10,25
Cohort,0.022335412217414707,0.015574418067690804,1.434108942005969,0.15193388709830896,LonGen OPEL,Activation of NLRP3 Inflammasome by SARS-CoV-2,CP:WIKIPATHWAYS,C2,13,25
Cohort,-0.06753850243676514,0.05325784395927405,-1.2681418813801668,0.20518385918154033,LGP Offspring,Adipogenesis,CP:WIKIPATHWAYS,C2,107,195
Cohort,-0.13055043186327325,0.14729489838703458,-0.8863201189781653,0.3757005429683452,LGP Proband,Adipogenesis,CP:WIKIPATHWAYS,C2,107,276
Cohort,-0.07454265826869871,0.04780783457807575,-1.5592142778807916,0.11934314408323946,LonGen OPEL,Adipogenesis,CP:WIKIPATHWAYS,C2,175,169
Cohort,-0.0014309897732282773,0.014206825262907093,-0.10072551374053142,0.9197982230382684,LGP Offspring,Aflatoxin B1 metabolism,CP:WIKIPATHWAYS,C2,7,13
Cohort,0.06565758937641006,0.038234915340222206,1.7172155029552234,0.08631105478902575,LGP Proband,Aflatoxin B1 metabolism,CP:WIKIPATHWAYS,C2,7,17
Cohort,-0.015885483551161962,0.01146044278171792,-1.3861142936382016,0.16610015916714696,LonGen OPEL,Aflatoxin B1 metabolism,CP:WIKIPATHWAYS,C2,12,6
Cohort,0.0029473777359281346,0.03834528763574874,0.07686414466168559,0.9387543647546303,LGP Offspring,AGE/RAGE pathway,CP:WIKIPATHWAYS,C2,44,95
Cohort,-0.056758692255041154,0.09678901003398008,-0.5864167040774017,0.557754201359514,LGP Proband,AGE/RAGE pathway,CP:WIKIPATHWAYS,C2,44,112
Cohort,-0.039544863724148754,0.03321605659002807,-1.1905345722472271,0.23419126742569835,LonGen OPEL,AGE/RAGE pathway,CP:WIKIPATHWAYS,C2,83,85
Cohort,0.00423351526314098,0.019687611070214935,0.2150344827537657,0.8298052897895374,LGP Offspring,Airway smooth muscle cell contraction,CP:WIKIPATHWAYS,C2,13,27
Cohort,-0.03214668002522415,0.04864767790232575,-0.660806053061112,0.5089191858829811,LGP Proband,Airway smooth muscle cell contraction,CP:WIKIPATHWAYS,C2,13,28
Cohort,0.013047963739362754,0.017738565900438444,0.7355703844717373,0.4622088688189083,LonGen OPEL,Airway smooth muscle cell contraction,CP:WIKIPATHWAYS,C2,19,28
Cohort,0.01721038816804685,0.01966049989079729,0.8753789712184636,0.38167865756048447,LGP Offspring,Alanine and aspartate metabolism,CP:WIKIPATHWAYS,C2,9,27
Cohort,-0.05409272411523896,0.048414830912852085,-1.117275906893225,0.2641981288397946,LGP Proband,Alanine and aspartate metabolism,CP:WIKIPATHWAYS,C2,9,29
Cohort,-0.009279374109293982,0.01667174370590995,-0.556592895919132,0.5779620486217607,LonGen OPEL,Alanine and aspartate metabolism,CP:WIKIPATHWAYS,C2,20,22
Cohort,0.037991718759698645,0.04646521867421679,0.81763779109857,0.41385212726654175,LGP Offspring,Allograft Rejection,CP:WIKIPATHWAYS,C2,52,130
Cohort,0.002035817678456728,0.11816929254391997,0.017227975514028535,0.9862588647429558,LGP Proband,Allograft Rejection,CP:WIKIPATHWAYS,C2,52,172
Cohort,-0.025800624936368113,0.039402920657105996,-0.6547896578756575,0.5127923481255339,LonGen OPEL,Allograft Rejection,CP:WIKIPATHWAYS,C2,112,129
Cohort,0.03720270721033533,0.04379749308217783,0.8494254942978445,0.39594528545541396,LGP Offspring,Alpha 6 Beta 4 signaling pathway,CP:WIKIPATHWAYS,C2,59,142
Cohort,-0.07989535739280126,0.11928815491884018,-0.6697677355070124,0.5031912507621435,LGP Proband,Alpha 6 Beta 4 signaling pathway,CP:WIKIPATHWAYS,C2,59,173
Cohort,-0.0055571135153840694,0.03905299869749648,-0.14229671730023416,0.8868816475759156,LonGen OPEL,Alpha 6 Beta 4 signaling pathway,CP:WIKIPATHWAYS,C2,109,129
Cohort,-0.057801027942698965,0.04814555660235277,-1.2005475068051108,0.23034729334677317,LGP Offspring,Alzheimers Disease,CP:WIKIPATHWAYS,C2,88,163
Cohort,-0.009845936780250392,0.14251331553241015,-0.06908783746604537,0.9449362630086455,LGP Proband,Alzheimers Disease,CP:WIKIPATHWAYS,C2,88,242
Cohort,-0.03675229018659664,0.04195179001157371,-0.876060119877063,0.38126163837860205,LonGen OPEL,Alzheimers Disease,CP:WIKIPATHWAYS,C2,125,130
Cohort,0.009281530552776947,0.05724231971255332,0.1621445566738885,0.8712404716603948,LGP Offspring,Amino Acid metabolism,CP:WIKIPATHWAYS,C2,99,209
Cohort,0.29659441608424525,0.15175249525231863,1.9544615433907575,0.050980460149455384,LGP Proband,Amino Acid metabolism,CP:WIKIPATHWAYS,C2,99,288
Cohort,0.05325687371023191,0.04870182475689559,1.0935293282351064,0.2744922718344321,LonGen OPEL,Amino Acid metabolism,CP:WIKIPATHWAYS,C2,146,201
Cohort,0.03142449901201853,0.02316959816725166,1.3562815714445362,0.1754624112782349,LGP Offspring,Amino Acid Metabolism Pathway Excerpt (Histidine catabolism extension),CP:WIKIPATHWAYS,C2,12,40
Cohort,0.07029071260012594,0.059030473478774444,1.1907529866823843,0.23408936820715742,LGP Proband,Amino Acid Metabolism Pathway Excerpt (Histidine catabolism extension),CP:WIKIPATHWAYS,C2,12,46
Cohort,-0.03439220432725867,0.018443165057546142,-1.8647669323539926,0.0625818884579452,LonGen OPEL,Amino Acid Metabolism Pathway Excerpt (Histidine catabolism extension),CP:WIKIPATHWAYS,C2,33,22
Cohort,-0.05365970392683884,0.049057377064522324,-1.0938151841314985,0.27442564791709206,LGP Offspring,AMP-activated Protein Kinase (AMPK) Signaling,CP:WIKIPATHWAYS,C2,83,153
Cohort,-0.054171075235594106,0.1300438422399736,-0.4165600946766144,0.6771073864305517,LGP Proband,AMP-activated Protein Kinase (AMPK) Signaling,CP:WIKIPATHWAYS,C2,83,203
Cohort,-0.04103643607176002,0.042686444387022744,-0.9613458478691106,0.33667023103623184,LonGen OPEL,AMP-activated Protein Kinase (AMPK) Signaling,CP:WIKIPATHWAYS,C2,133,141
Cohort,-0.023513967381218127,0.02567919519424221,-0.9156816326740033,0.3601604232353287,LGP Offspring,Amplification and Expansion of Oncogenic Pathways as Metastatic Traits,CP:WIKIPATHWAYS,C2,25,43
Cohort,-0.08512313416142527,0.0749808093190959,-1.1352656090862752,0.25659019931002075,LGP Proband,Amplification and Expansion of Oncogenic Pathways as Metastatic Traits,CP:WIKIPATHWAYS,C2,25,58
Cohort,-0.040275108990129475,0.02504339247108042,-1.6082129861854109,0.10818506950578091,LonGen OPEL,Amplification and Expansion of Oncogenic Pathways as Metastatic Traits,CP:WIKIPATHWAYS,C2,48,43
Cohort,-0.005315057389114403,0.02183391357618037,-0.24343127358133568,0.8077451710913351,LGP Offspring,Amyotrophic lateral sclerosis (ALS),CP:WIKIPATHWAYS,C2,16,35
Cohort,0.18203202532291826,0.0661924579207917,2.750041787853601,0.006087769799138027,LGP Proband,Amyotrophic lateral sclerosis (ALS),CP:WIKIPATHWAYS,C2,16,62
Cohort,0.009507451997777982,0.018888080125777675,0.503357246182083,0.6148523825681812,LonGen OPEL,Amyotrophic lateral sclerosis (ALS),CP:WIKIPATHWAYS,C2,23,29
Cohort,-0.0012921224548710002,0.048850197887814556,-0.026450710759419745,0.978905653186092,LGP Offspring,Androgen receptor signaling pathway,CP:WIKIPATHWAYS,C2,72,152
Cohort,-0.08994955970861179,0.13449167482209118,-0.668811358231647,0.5038008969309369,LGP Proband,Androgen receptor signaling pathway,CP:WIKIPATHWAYS,C2,72,205
Cohort,0.004851219632697366,0.04583767492156391,0.10583476672843095,0.9157401162228184,LonGen OPEL,Androgen receptor signaling pathway,CP:WIKIPATHWAYS,C2,131,159
Cohort,0.005359316718076554,0.032279915277179,0.16602635639088686,0.8681858509241568,LGP Offspring,Angiogenesis,CP:WIKIPATHWAYS,C2,32,67
Cohort,-0.13443236295638533,0.08184848378064806,-1.642453919081272,0.10087292824520105,LGP Proband,Angiogenesis,CP:WIKIPATHWAYS,C2,32,68
Cohort,-0.032184068665467996,0.02829189745653252,-1.1375719396309627,0.2556415662768154,LonGen OPEL,Angiogenesis,CP:WIKIPATHWAYS,C2,58,59
Cohort,-0.024316309158038184,0.06567549628050826,-0.3702493400914732,0.7113126911590365,LGP Offspring,Angiopoietin Like Protein 8 Regulatory Pathway,CP:WIKIPATHWAYS,C2,143,282
Cohort,-0.14947375255520046,0.1827641721713212,-0.8178504067804129,0.41367620222398405,LGP Proband,Angiopoietin Like Protein 8 Regulatory Pathway,CP:WIKIPATHWAYS,C2,143,383
Cohort,-0.08420690346023009,0.054932668779026306,-1.5329112044230573,0.12569506396990543,LonGen OPEL,Angiopoietin Like Protein 8 Regulatory Pathway,CP:WIKIPATHWAYS,C2,228,234
Cohort,-0.010794125158637024,0.02081443245069212,-0.5185884930664106,0.6042174405439036,LGP Offspring,ApoE and miR-146 in inflammation and atherosclerosis,CP:WIKIPATHWAYS,C2,16,29
Cohort,-0.022869105990217325,0.054912233641049385,-0.4164665043441546,0.6771758292975999,LGP Proband,ApoE and miR-146 in inflammation and atherosclerosis,CP:WIKIPATHWAYS,C2,16,36
Cohort,0.04269237515836153,0.01880430015546442,2.270351717713641,0.0234527465691703,LonGen OPEL,ApoE and miR-146 in inflammation and atherosclerosis,CP:WIKIPATHWAYS,C2,17,35
Cohort,-0.06820680723358502,0.04498080084961996,-1.5163537763948305,0.1298973804474421,LGP Offspring,Apoptosis,CP:WIKIPATHWAYS,C2,68,116
Cohort,0.045003542386832164,0.12042112366002325,0.3737180074310517,0.7087091070462763,LGP Proband,Apoptosis,CP:WIKIPATHWAYS,C2,68,153
Cohort,-0.035377774748219175,0.03607341277885178,-0.9807160460559355,0.3270307626049439,LonGen OPEL,Apoptosis,CP:WIKIPATHWAYS,C2,97,105
Cohort,-0.12095308589745755,0.04944454311522878,-2.4462373050061483,0.01468939153971682,LGP Offspring,Apoptosis Modulation and Signaling,CP:WIKIPATHWAYS,C2,101,156
Cohort,0.053920545623278415,0.1459289396860467,0.36949864597991144,0.7118498789789851,LGP Proband,Apoptosis Modulation and Signaling,CP:WIKIPATHWAYS,C2,101,231
Cohort,-0.027999669427369322,0.044251104116718336,-0.6327451028909101,0.5270818312292394,LonGen OPEL,Apoptosis Modulation and Signaling,CP:WIKIPATHWAYS,C2,139,160
Cohort,-0.008260141728837439,0.018299467868795993,-0.45138699048853337,0.6518554283372797,LGP Offspring,Apoptosis Modulation by HSP70,CP:WIKIPATHWAYS,C2,12,22
Cohort,-0.034312372410327995,0.05112312039740097,-0.6711713241211386,0.5022972355399833,LGP Proband,Apoptosis Modulation by HSP70,CP:WIKIPATHWAYS,C2,12,32
Cohort,-0.02348509120744051,0.018677186561639404,-1.2574212464995096,0.20896992614312754,LonGen OPEL,Apoptosis Modulation by HSP70,CP:WIKIPATHWAYS,C2,28,24
Cohort,-0.06218145614535089,0.034699397801321134,-1.7920038987818805,0.07357945399987158,LGP Offspring,Apoptosis-related network due to altered Notch3 in ovarian cancer,CP:WIKIPATHWAYS,C2,50,74
Cohort,-0.045007758205496046,0.09615863740191233,-0.4680573625162555,0.6398658599629011,LGP Proband,Apoptosis-related network due to altered Notch3 in ovarian cancer,CP:WIKIPATHWAYS,C2,50,103
Cohort,0.04363930098535482,0.03104133105149344,1.4058450300653351,0.16016035468657863,LonGen OPEL,Apoptosis-related network due to altered Notch3 in ovarian cancer,CP:WIKIPATHWAYS,C2,54,83
Cohort,-0.006860543338080415,0.006379071500374238,-1.0754767896359103,0.28254501057345527,LGP Offspring,Arachidonate Epoxygenase / Epoxide Hydrolase,CP:WIKIPATHWAYS,C2,2,2
Cohort,-0.012474220262666352,0.020892838610471327,-0.597057225934554,0.5506312233426562,LGP Proband,Arachidonate Epoxygenase / Epoxide Hydrolase,CP:WIKIPATHWAYS,C2,2,5
Cohort,0.0029556930577310917,0.006350065808633321,0.4654586498477918,0.6417303592982458,LonGen OPEL,Arachidonate Epoxygenase / Epoxide Hydrolase,CP:WIKIPATHWAYS,C2,2,4
Cohort,0.01463547101368109,0.06177081475061438,0.2369318111274471,0.8127814707433768,LGP Offspring,Arrhythmogenic Right Ventricular Cardiomyopathy,CP:WIKIPATHWAYS,C2,109,253
Cohort,0.05228984691704567,0.17055088806219573,0.30659381203560104,0.7592290908931815,LGP Proband,Arrhythmogenic Right Ventricular Cardiomyopathy,CP:WIKIPATHWAYS,C2,109,345
Cohort,0.08310997881121494,0.054199587821748996,1.5334061042040785,0.12557316169251806,LonGen OPEL,Arrhythmogenic Right Ventricular Cardiomyopathy,CP:WIKIPATHWAYS,C2,187,257
Cohort,-0.029737127138664696,0.03689277401476575,-0.8060420484174728,0.4205020564961828,LGP Offspring,Aryl Hydrocarbon Receptor Netpath,CP:WIKIPATHWAYS,C2,45,86
Cohort,0.06778644681530949,0.0992909412273706,0.6827052496167035,0.4949826953438299,LGP Proband,Aryl Hydrocarbon Receptor Netpath,CP:WIKIPATHWAYS,C2,45,111
Cohort,0.06954684990811068,0.032001993257885504,2.1732036922723204,0.030059200532355165,LonGen OPEL,Aryl Hydrocarbon Receptor Netpath,CP:WIKIPATHWAYS,C2,55,95
Cohort,-0.014247225749243305,0.03720244341743071,-0.3829647851186021,0.7018662644627517,LGP Offspring,Aryl Hydrocarbon Receptor Pathway,CP:WIKIPATHWAYS,C2,36,70
Cohort,-0.004580524090558957,0.10445849162268314,-0.043850184120065326,0.965034320701041,LGP Proband,Aryl Hydrocarbon Receptor Pathway,CP:WIKIPATHWAYS,C2,36,79
Cohort,0.004635483137365055,0.030827177391300007,0.15037001534474814,0.880510790805885,LonGen OPEL,Aryl Hydrocarbon Receptor Pathway,CP:WIKIPATHWAYS,C2,46,59
Cohort,-0.016587729177718648,0.011941978321602969,-1.3890269041697676,0.16528197545897466,LGP Offspring,Arylamine metabolism,CP:WIKIPATHWAYS,C2,6,6
Cohort,0.02408088904505768,0.03693599164411315,0.6519627055659594,0.5146048599086603,LGP Proband,Arylamine metabolism,CP:WIKIPATHWAYS,C2,6,12
Cohort,0.007671203407618809,0.008589687006196186,0.8930713542979124,0.3720888750019272,LonGen OPEL,Arylamine metabolism,CP:WIKIPATHWAYS,C2,2,7
Cohort,-0.0014736396357125918,0.01760872996928256,-0.08368801374564057,0.9333292630624658,LGP Offspring,aspirin and miRNAs,CP:WIKIPATHWAYS,C2,11,19
Cohort,-0.04383141179190283,0.05310438827227449,-0.8253821052823797,0.40939071585797404,LGP Proband,aspirin and miRNAs,CP:WIKIPATHWAYS,C2,11,32
Cohort,0.002474462419914658,0.016273812595081132,0.15205179520517403,0.8791846135389206,LonGen OPEL,aspirin and miRNAs,CP:WIKIPATHWAYS,C2,19,22
Cohort,0.0066523194273381955,0.038733586383716205,0.1717455068951442,0.863689007199075,LGP Offspring,Association Between Physico-Chemical Features and Toxicity Associated Pathways,CP:WIKIPATHWAYS,C2,45,95
Cohort,0.09646490336205554,0.10256917308394779,0.9404863124235563,0.3472404822609433,LGP Proband,Association Between Physico-Chemical Features and Toxicity Associated Pathways,CP:WIKIPATHWAYS,C2,45,129
Cohort,-0.08479378485718095,0.030884790624290503,-2.7454867960313027,0.006178383735504956,LonGen OPEL,Association Between Physico-Chemical Features and Toxicity Associated Pathways,CP:WIKIPATHWAYS,C2,83,65
Cohort,0.004858923576639075,0.03940674154380703,0.12330183583531229,0.9019047370829854,LGP Offspring,ATM Signaling Network in Development and Disease ,CP:WIKIPATHWAYS,C2,49,99
Cohort,-0.051300186982317565,0.11283420109148826,-0.45465104096161707,0.6494786209364155,LGP Proband,ATM Signaling Network in Development and Disease ,CP:WIKIPATHWAYS,C2,49,169
Cohort,0.011845386718129106,0.039299761902307745,0.301411157339188,0.7631797082618252,LonGen OPEL,ATM Signaling Network in Development and Disease ,CP:WIKIPATHWAYS,C2,100,119
Cohort,0.016966430239551692,0.03439167710550477,0.493329539804153,0.6219399825168443,LGP Offspring,ATM Signaling Pathway,CP:WIKIPATHWAYS,C2,33,79
Cohort,0.04603207915320512,0.09404263950606254,0.4894809354031117,0.624629961328665,LGP Proband,ATM Signaling Pathway,CP:WIKIPATHWAYS,C2,33,104
Cohort,0.03345604627521214,0.031082497961871014,1.0763628559150158,0.28209112144940846,LonGen OPEL,ATM Signaling Pathway,CP:WIKIPATHWAYS,C2,57,78
Cohort,-0.023666806146634255,0.014218288249699304,-1.6645327293272996,0.09646941218381443,LGP Offspring,ATR Signaling,CP:WIKIPATHWAYS,C2,9,9
Cohort,-0.05123789970162009,0.04502988339880383,-1.1378643654889227,0.2555038988476301,LGP Proband,ATR Signaling,CP:WIKIPATHWAYS,C2,9,23
Cohort,0.0020308880523056574,0.01588169810635874,0.12787600159031653,0.898279401413239,LonGen OPEL,ATR Signaling,CP:WIKIPATHWAYS,C2,15,22
Cohort,-0.03590521741317061,0.025418263586593416,-1.4125755400580717,0.15824077333484546,LGP Offspring,Autophagy,CP:WIKIPATHWAYS,C2,26,35
Cohort,-0.12806686868357697,0.07289243664896063,-1.756929450723789,0.07929676024497316,LGP Proband,Autophagy,CP:WIKIPATHWAYS,C2,26,55
Cohort,0.002508839075632754,0.022658492374007324,0.11072400732675257,0.9118631185752276,LonGen OPEL,Autophagy,CP:WIKIPATHWAYS,C2,36,39
Cohort,-0.0011594945522288033,0.02163295291672516,-0.05359853352855769,0.9572708602602045,LGP Offspring,Autosomal recessive Osteopetrosis pathways,CP:WIKIPATHWAYS,C2,15,31
Cohort,0.03567869728128913,0.057829070186771046,0.6169681989708176,0.5374240902338044,LGP Proband,Autosomal recessive Osteopetrosis pathways,CP:WIKIPATHWAYS,C2,15,43
Cohort,-0.008014944298033825,0.01916396733960601,-0.4182299080352431,0.6758918356366286,LonGen OPEL,Autosomal recessive Osteopetrosis pathways,CP:WIKIPATHWAYS,C2,26,28
Cohort,-0.060675138917998195,0.046521464940932795,-1.304239644968962,0.19259577831452,LGP Offspring,B Cell Receptor Signaling Pathway,CP:WIKIPATHWAYS,C2,74,130
Cohort,0.16323840313190116,0.1253369035624459,1.3023969676303022,0.19314025726660264,LGP Proband,B Cell Receptor Signaling Pathway,CP:WIKIPATHWAYS,C2,74,173
Cohort,-0.02377629938525586,0.03941305133257736,-0.6032595442719061,0.546507888764783,LonGen OPEL,B Cell Receptor Signaling Pathway,CP:WIKIPATHWAYS,C2,98,110
Cohort,-0.022696743173853638,0.03948896431601647,-0.5747616724566257,0.5656437167651589,LGP Offspring,Base Excision Repair,CP:WIKIPATHWAYS,C2,55,102
Cohort,-0.0698279993497859,0.11293542956297384,-0.6183002058786978,0.5365462805273828,LGP Proband,Base Excision Repair,CP:WIKIPATHWAYS,C2,55,147
Cohort,0.03956551193157255,0.03759081255809072,1.052531436250021,0.2928751952865369,LonGen OPEL,Base Excision Repair,CP:WIKIPATHWAYS,C2,86,118
Cohort,-0.07047773602584745,0.034191826910406155,-2.0612451101405704,0.039661536069438924,LGP Offspring,BDNF-TrkB Signaling,CP:WIKIPATHWAYS,C2,48,63
Cohort,-0.10260444567647109,0.09308704556561027,-1.1022419398212902,0.27067447949704576,LGP Proband,BDNF-TrkB Signaling,CP:WIKIPATHWAYS,C2,48,86
Cohort,-0.015562428875386013,0.028134056018519073,-0.5531526938434379,0.5803141730838798,LonGen OPEL,BDNF-TrkB Signaling,CP:WIKIPATHWAYS,C2,47,53
Cohort,0.037973175084267424,0.016837284579208276,2.255302801685674,0.024433345356522942,LGP Offspring,Benzene metabolism,CP:WIKIPATHWAYS,C2,4,25
Cohort,0.035168275168928814,0.04766966375525306,0.7377495958329131,0.4608741463891932,LGP Proband,Benzene metabolism,CP:WIKIPATHWAYS,C2,4,34
Cohort,0.0014481228143228863,0.01462596665380855,0.0990104003789589,0.9211549403504353,LonGen OPEL,Benzene metabolism,CP:WIKIPATHWAYS,C2,16,17
Cohort,-0.0488576769876858,0.024449331563145167,-1.9983236294825204,0.04608167192372952,LGP Offspring,Benzo(a)pyrene metabolism,CP:WIKIPATHWAYS,C2,25,25
Cohort,-0.09711908160422474,0.0623362084946684,-1.557988269570988,0.1196153970279354,LGP Proband,Benzo(a)pyrene metabolism,CP:WIKIPATHWAYS,C2,25,27
Cohort,0.023763323227145184,0.020972886477467752,1.1330497236360546,0.25753453029108675,LonGen OPEL,Benzo(a)pyrene metabolism,CP:WIKIPATHWAYS,C2,22,37
Cohort,0.021021918841123383,0.01849351538001348,1.1367183798837093,0.25605881671234587,LGP Offspring,Bile Acids synthesis and enterohepatic circulation ,CP:WIKIPATHWAYS,C2,9,26
Cohort,-0.018992531588510303,0.05154307490214839,-0.3684788232864754,0.7126097437650729,LGP Proband,Bile Acids synthesis and enterohepatic circulation ,CP:WIKIPATHWAYS,C2,9,37
Cohort,-0.013337669144223461,0.018093890503564653,-0.737136612029117,0.46125648960202037,LonGen OPEL,Bile Acids synthesis and enterohepatic circulation ,CP:WIKIPATHWAYS,C2,24,26
Cohort,-0.0032482710353300766,0.025761200444028166,-0.12609160207373313,0.8996969067911496,LGP Offspring,Biogenic Amine Synthesis,CP:WIKIPATHWAYS,C2,20,42
Cohort,0.11646464657064183,0.07599201889488696,1.532590504428328,0.12575600758163996,LGP Proband,Biogenic Amine Synthesis,CP:WIKIPATHWAYS,C2,20,72
Cohort,-0.015759226519746625,0.023656559408620225,-0.6661673089284537,0.5054971785240732,LonGen OPEL,Biogenic Amine Synthesis,CP:WIKIPATHWAYS,C2,40,46
Cohort,-0.005654139178883736,0.015565553921667242,-0.363246898076218,0.7165340157669011,LGP Offspring,Biomarkers for pyrimidine metabolism disorders,CP:WIKIPATHWAYS,C2,8,16
Cohort,0.02673175122041698,0.04910789325773309,0.5443473431067518,0.5863479770667974,LGP Proband,Biomarkers for pyrimidine metabolism disorders,CP:WIKIPATHWAYS,C2,8,30
Cohort,-0.027928829701598285,0.015835708185596292,-1.7636615536399913,0.07817256287930098,LonGen OPEL,Biomarkers for pyrimidine metabolism disorders,CP:WIKIPATHWAYS,C2,20,17
Cohort,0.007015735908883674,0.013428603169120288,0.5224471838602464,0.601530176214008,LGP Offspring,Biomarkers for urea cycle disorders,CP:WIKIPATHWAYS,C2,4,14
Cohort,0.015617154305840646,0.036817115315776146,0.42418191028531477,0.6715425419270259,LGP Proband,Biomarkers for urea cycle disorders,CP:WIKIPATHWAYS,C2,4,18
Cohort,0.002857895442592681,0.009908486025181218,0.2884290733548683,0.7730934041051633,LonGen OPEL,Biomarkers for urea cycle disorders,CP:WIKIPATHWAYS,C2,6,9
Cohort,-0.003618291991203261,0.01873292722922284,-0.19315144648396582,0.8468983796731413,LGP Offspring,Biotin Metabolism (including IEMs),CP:WIKIPATHWAYS,C2,11,23
Cohort,-0.05495499135478634,0.04512916921746741,-1.2177266346289355,0.22367228313606524,LGP Proband,Biotin Metabolism (including IEMs),CP:WIKIPATHWAYS,C2,11,24
Cohort,0.0020620521557330592,0.014232573082855658,0.1448825973862011,0.8848402423630927,LonGen OPEL,Biotin Metabolism (including IEMs),CP:WIKIPATHWAYS,C2,14,17
Cohort,0.016240390561883002,0.0324394250201502,0.50063743582986,0.6167892642752675,LGP Offspring,Bladder Cancer,CP:WIKIPATHWAYS,C2,33,82
Cohort,0.11585473115397171,0.10212967653391226,1.1343885057297918,0.2569575594474055,LGP Proband,Bladder Cancer,CP:WIKIPATHWAYS,C2,33,122
Cohort,-0.05738823825110277,0.032140096929607315,-1.7855651890781008,0.07455031008694947,LonGen OPEL,Bladder Cancer,CP:WIKIPATHWAYS,C2,85,75
Cohort,0.0072636956532007,0.024378689593797003,0.29795266990268826,0.7658308371330185,LGP Offspring,Blood Clotting Cascade,CP:WIKIPATHWAYS,C2,20,43
Cohort,-0.05728155257580361,0.06645324834917604,-0.8619827322032461,0.38894479294529805,LGP Proband,Blood Clotting Cascade,CP:WIKIPATHWAYS,C2,20,54
Cohort,-0.0022166966641880333,0.022639167937405825,-0.09791422857575392,0.9220250508926306,LonGen OPEL,Blood Clotting Cascade,CP:WIKIPATHWAYS,C2,36,43
Cohort,-5.388251686684997e-4,0.02096214960660252,-0.025704671456918904,0.9795004837266057,LGP Offspring,BMP Signaling Pathway in Eyelid Development,CP:WIKIPATHWAYS,C2,13,30
Cohort,0.04251073784291281,0.05298662547482417,0.8022918512353872,0.42261270440670407,LGP Proband,BMP Signaling Pathway in Eyelid Development,CP:WIKIPATHWAYS,C2,13,32
Cohort,0.004404218153446177,0.019137294481698226,0.2301379726198032,0.8180436872835644,LonGen OPEL,BMP Signaling Pathway in Eyelid Development,CP:WIKIPATHWAYS,C2,24,31
Cohort,0.015054707719336499,0.008472957156096405,1.7767949774777791,0.07605160695030191,LGP Offspring,BMP2-WNT4-FOXO1 Pathway in Human Primary Endometrial Stromal Cell Differentiation,CP:WIKIPATHWAYS,C2,0,7
Cohort,0.002956175500402914,0.02824685109666576,0.10465504598322675,0.9166746970235999,LGP Proband,BMP2-WNT4-FOXO1 Pathway in Human Primary Endometrial Stromal Cell Differentiation,CP:WIKIPATHWAYS,C2,0,13
Cohort,-0.008119823624346698,0.005778449568211153,-1.4051907053089274,0.16035472058445663,LonGen OPEL,BMP2-WNT4-FOXO1 Pathway in Human Primary Endometrial Stromal Cell Differentiation,CP:WIKIPATHWAYS,C2,4,1
Cohort,0.008913331385076523,0.010084659002654976,0.8838505479193616,0.37709112180618876,LGP Offspring,Bone Morphogenic Protein (BMP) Signalling and Regulation,CP:WIKIPATHWAYS,C2,2,8
Cohort,0.026544518711912074,0.026099811636793157,1.0170387082216337,0.30942995943069757,LGP Proband,Bone Morphogenic Protein (BMP) Signalling and Regulation,CP:WIKIPATHWAYS,C2,2,9
Cohort,-0.005816290989009875,0.006869202419573532,-0.8467199878164274,0.3974056987383271,LonGen OPEL,Bone Morphogenic Protein (BMP) Signalling and Regulation,CP:WIKIPATHWAYS,C2,4,3
Cohort,-0.056160605705429335,0.0614513884414307,-0.9139029585793003,0.36109367965646133,LGP Offspring,Brain-Derived Neurotrophic Factor (BDNF) signaling pathway,CP:WIKIPATHWAYS,C2,135,263
Cohort,0.00347203640043223,0.1726057813197784,0.02011541197452567,0.9839561169899751,LGP Proband,Brain-Derived Neurotrophic Factor (BDNF) signaling pathway,CP:WIKIPATHWAYS,C2,135,358
Cohort,-0.024623519086068246,0.055701224342654114,-0.44206423425440555,0.6585628010883594,LonGen OPEL,Brain-Derived Neurotrophic Factor (BDNF) signaling pathway,CP:WIKIPATHWAYS,C2,220,254
Cohort,0.03567278610933123,0.06188186169085666,0.5764659487386116,0.5644921663219928,LGP Offspring,Breast cancer pathway,CP:WIKIPATHWAYS,C2,117,264
Cohort,0.1867942210232091,0.16281940353084168,1.147247913777218,0.2516081769225617,LGP Proband,Breast cancer pathway,CP:WIKIPATHWAYS,C2,117,314
Cohort,-0.02801293581973851,0.05053231353367266,-0.5543568829689905,0.5794903374859623,LonGen OPEL,Breast cancer pathway,CP:WIKIPATHWAYS,C2,189,216
Cohort,-0.05534328741746048,0.06695224109095865,-0.8266084378306813,0.40875069429428534,LGP Offspring,Calcium Regulation in the Cardiac Cell,CP:WIKIPATHWAYS,C2,152,292
Cohort,0.023837969130351806,0.1857398118910427,0.12834065506826,0.8979103337674684,LGP Proband,Calcium Regulation in the Cardiac Cell,CP:WIKIPATHWAYS,C2,152,425
Cohort,0.05899637872937085,0.055640126483804724,1.0603207155997936,0.2893203360015949,LonGen OPEL,Calcium Regulation in the Cardiac Cell,CP:WIKIPATHWAYS,C2,222,279
Cohort,9.2519808680605e-4,0.019039429617729177,0.04859379221867666,0.9612573702950863,LGP Offspring,Caloric restriction and aging,CP:WIKIPATHWAYS,C2,10,22
Cohort,0.10749964997026844,0.05111979808734108,2.1028966074278928,0.03577391834462441,LGP Proband,Caloric restriction and aging,CP:WIKIPATHWAYS,C2,10,30
Cohort,-0.006888374617206244,0.013798184441522563,-0.4992232598715824,0.6177600530586014,LonGen OPEL,Caloric restriction and aging,CP:WIKIPATHWAYS,C2,14,13
Cohort,-0.04648558638504379,0.035487836696637166,-1.3099019470366524,0.19067396564454633,LGP Offspring,CAMKK2  Pathway,CP:WIKIPATHWAYS,C2,48,79
Cohort,0.022202018285220643,0.09246997274966821,0.24009976022514082,0.8103119212762603,LGP Proband,CAMKK2  Pathway,CP:WIKIPATHWAYS,C2,48,88
Cohort,0.026791687972364413,0.02886969892519706,0.9280210383136698,0.3536779644218121,LonGen OPEL,CAMKK2  Pathway,CP:WIKIPATHWAYS,C2,54,73
Cohort,0.017888235717763667,0.023296438084051106,0.7678528216727719,0.4428427544016327,LGP Offspring,Cancer immunotherapy by CTLA4 blockade,CP:WIKIPATHWAYS,C2,14,41
Cohort,-0.029079245394624358,0.058548079583722476,-0.49667291568533295,0.619550611013014,LGP Proband,Cancer immunotherapy by CTLA4 blockade,CP:WIKIPATHWAYS,C2,14,40
Cohort,0.008671880132371659,0.021667439050806023,0.4002263540253996,0.6890971890157281,LonGen OPEL,Cancer immunotherapy by CTLA4 blockade,CP:WIKIPATHWAYS,C2,30,35
Cohort,0.019956775099033205,0.02724553498180822,0.7324787387129046,0.46413030010609824,LGP Offspring,Cancer immunotherapy by PD-1 blockade,CP:WIKIPATHWAYS,C2,19,52
Cohort,-0.0010277123912373095,0.06841162309024192,-0.015022482215948187,0.9880178370443257,LGP Proband,Cancer immunotherapy by PD-1 blockade,CP:WIKIPATHWAYS,C2,19,59
Cohort,0.015625054852698505,0.023682744279290055,0.6597653831174544,0.5095952436022075,LonGen OPEL,Cancer immunotherapy by PD-1 blockade,CP:WIKIPATHWAYS,C2,35,47
Cohort,-0.010877698242960037,0.027334629860918502,-0.39794569373380656,0.6907958551130224,LGP Offspring,Cannabinoid receptor signaling,CP:WIKIPATHWAYS,C2,27,51
Cohort,0.10880458346464693,0.07247408142537518,1.501289582768709,0.13365916752787874,LGP Proband,Cannabinoid receptor signaling,CP:WIKIPATHWAYS,C2,27,58
Cohort,-0.06881393479287606,0.023694055276402545,-2.904270036940846,0.003783002072006812,LonGen OPEL,Cannabinoid receptor signaling,CP:WIKIPATHWAYS,C2,48,32
Cohort,-0.024083708261003745,0.027533647581336654,-0.8747009705073945,0.3820472864134091,LGP Offspring,Canonical  and Non-canonical Notch signaling,CP:WIKIPATHWAYS,C2,29,50
Cohort,-0.017996264882541607,0.078041492844418,-0.23059867548175444,0.8176831498616255,LGP Proband,Canonical  and Non-canonical Notch signaling,CP:WIKIPATHWAYS,C2,29,75
Cohort,-0.014994399651526965,0.024416701328658474,-0.6141042333973129,0.5393219182662765,LonGen OPEL,Canonical  and Non-canonical Notch signaling,CP:WIKIPATHWAYS,C2,48,46
Cohort,0.011913875053944352,0.01476913889215008,0.8066736416350363,0.42013823860898647,LGP Offspring,Canonical and Non-Canonical TGF-B signaling,CP:WIKIPATHWAYS,C2,6,16
Cohort,0.013812743573788146,0.03280503585570072,0.42105558532373394,0.6738229762672595,LGP Proband,Canonical and Non-Canonical TGF-B signaling,CP:WIKIPATHWAYS,C2,6,12
Cohort,0.0049292239665655584,0.014595697799058628,0.3377175955837806,0.7356650537691448,LonGen OPEL,Canonical and Non-Canonical TGF-B signaling,CP:WIKIPATHWAYS,C2,13,18
Cohort,0.007656218712513944,0.018671175913734607,0.4100555180823931,0.6818951396685033,LGP Offspring,Canonical NF-KB pathway,CP:WIKIPATHWAYS,C2,8,23
Cohort,0.014090173843029559,0.04360815164029917,0.32310871506896305,0.7466939034063862,LGP Proband,Canonical NF-KB pathway,CP:WIKIPATHWAYS,C2,8,20
Cohort,0.010020075455696746,0.0175374310387398,0.5713536625496984,0.5679212140754388,LonGen OPEL,Canonical NF-KB pathway,CP:WIKIPATHWAYS,C2,17,23
Cohort,-0.010852580045517549,0.0309474604781704,-0.350677563775312,0.7259395088341887,LGP Offspring,Cardiac Hypertrophic Response,CP:WIKIPATHWAYS,C2,31,63
Cohort,0.04363237605609829,0.09036303159396127,0.48285648773003464,0.6293243577283323,LGP Proband,Cardiac Hypertrophic Response,CP:WIKIPATHWAYS,C2,31,99
Cohort,-0.014537662692076818,0.02678576519797241,-0.542738375574847,0.587461873059306,LonGen OPEL,Cardiac Hypertrophic Response,CP:WIKIPATHWAYS,C2,51,56
Cohort,-0.04494103686616193,0.03286800891056641,-1.3673185068327727,0.17197994523133053,LGP Offspring,Cardiac Progenitor Differentiation,CP:WIKIPATHWAYS,C2,39,62
Cohort,-0.11984897235436168,0.09003125820658896,-1.3311929072384163,0.18348931266784935,LGP Proband,Cardiac Progenitor Differentiation,CP:WIKIPATHWAYS,C2,39,95
Cohort,0.005908865797021105,0.028036748941439555,0.2107543142524467,0.8331329285765454,LonGen OPEL,Cardiac Progenitor Differentiation,CP:WIKIPATHWAYS,C2,56,67
Cohort,0.004087208495250172,0.01765794678733709,0.23146567063964657,0.8170230957687578,LGP Offspring,Catalytic cycle of mammalian Flavin-containing MonoOxygenases (FMOs),CP:WIKIPATHWAYS,C2,11,21
Cohort,-0.07709857440311538,0.04318434709720185,-1.785336113327762,0.07457012400629744,LGP Proband,Catalytic cycle of mammalian Flavin-containing MonoOxygenases (FMOs),CP:WIKIPATHWAYS,C2,11,20
Cohort,-0.011593784792526669,0.015514309398172086,-0.7472962215058482,0.45510546047320277,LonGen OPEL,Catalytic cycle of mammalian Flavin-containing MonoOxygenases (FMOs),CP:WIKIPATHWAYS,C2,18,17
Cohort,-0.08340602556232332,0.055441897355573776,-1.5043862050283567,0.1329490050079288,LGP Offspring,Cell Cycle,CP:WIKIPATHWAYS,C2,122,213
Cohort,-0.14059379831272556,0.15496228362596717,-0.9072775324612351,0.3645221182162466,LGP Proband,Cell Cycle,CP:WIKIPATHWAYS,C2,122,304
Cohort,0.06237513951031309,0.05115481382812388,1.2193405633317056,0.2230761457730479,LonGen OPEL,Cell Cycle,CP:WIKIPATHWAYS,C2,173,228
Cohort,0.0074546256699243784,0.013876616345710224,0.5372077374055872,0.5913009023342326,LGP Offspring,Cell Differentiation - Index,CP:WIKIPATHWAYS,C2,5,12
Cohort,0.024699457687648058,0.040940819960124754,0.6032966049948354,0.5464754217630096,LGP Proband,Cell Differentiation - Index,CP:WIKIPATHWAYS,C2,5,23
Cohort,0.005441442960680336,0.011127649509550587,0.4890020085562615,0.6249749797875837,LonGen OPEL,Cell Differentiation - Index,CP:WIKIPATHWAYS,C2,8,11
Cohort,0.0074546256699243784,0.013876616345710224,0.5372077374055872,0.5913009023342326,LGP Offspring,Cell Differentiation - Index expanded,CP:WIKIPATHWAYS,C2,5,12
Cohort,0.014210759723733502,0.04179693279763223,0.33999527650838846,0.7339456944255004,LGP Proband,Cell Differentiation - Index expanded,CP:WIKIPATHWAYS,C2,5,24
Cohort,0.00767340673802933,0.011412707859925255,0.6723563620666958,0.5015519699696771,LonGen OPEL,Cell Differentiation - Index expanded,CP:WIKIPATHWAYS,C2,8,12
Cohort,0.007681613011452071,0.033715658552396235,0.22783517633251524,0.8198432722900111,LGP Offspring,Cell migration and invasion through p75NTR,CP:WIKIPATHWAYS,C2,30,65
Cohort,-0.20384866879186542,0.07604561817000614,-2.6806103191395616,0.007493859331504227,LGP Proband,Cell migration and invasion through p75NTR,CP:WIKIPATHWAYS,C2,30,59
Cohort,0.04648147790437633,0.02666838702870696,1.7429429779289516,0.08172971733017993,LonGen OPEL,Cell migration and invasion through p75NTR,CP:WIKIPATHWAYS,C2,43,66
Cohort,0.048618883075794386,0.023390662735112616,2.07855945025494,0.038034486760581125,LGP Offspring,Cells and Molecules involved in local acute inflammatory response ,CP:WIKIPATHWAYS,C2,10,43
Cohort,-0.0282567272001983,0.0628073064395336,-0.449895542446194,0.6529026708163949,LGP Proband,Cells and Molecules involved in local acute inflammatory response ,CP:WIKIPATHWAYS,C2,10,50
Cohort,-0.011582831141523036,0.020029323328820608,-0.578293682286124,0.5632294272440435,LonGen OPEL,Cells and Molecules involved in local acute inflammatory response ,CP:WIKIPATHWAYS,C2,29,33
Cohort,-0.03804977058689677,0.02674026040406029,-1.4229394183879833,0.15521502498016984,LGP Offspring,Cell-type Dependent Selectivity of CCK2R Signaling,CP:WIKIPATHWAYS,C2,27,44
Cohort,0.04082394066438665,0.07708462270397368,0.5295990203021672,0.5965309172608522,LGP Proband,Cell-type Dependent Selectivity of CCK2R Signaling,CP:WIKIPATHWAYS,C2,27,66
Cohort,0.024373403517659615,0.021439045876483025,1.1368697869337252,0.25593484483508133,LonGen OPEL,Cell-type Dependent Selectivity of CCK2R Signaling,CP:WIKIPATHWAYS,C2,28,44
Cohort,-0.014493656733756159,0.006404300220582023,-2.2631132574292363,0.023945068613980224,LGP Offspring,Cellular Proteostasis,CP:WIKIPATHWAYS,C2,3,1
Cohort,0.030036541335861176,0.023447231973620357,1.2810271749626658,0.20054021340921102,LGP Proband,Cellular Proteostasis,CP:WIKIPATHWAYS,C2,3,6
Cohort,0.004815036700215047,0.008042395228826037,0.5987067985612922,0.549538754443698,LonGen OPEL,Cellular Proteostasis,CP:WIKIPATHWAYS,C2,3,7
Cohort,-0.0024656582371683105,0.012200790072467976,-0.2020900468349389,0.8399071298795862,LGP Offspring,"Cerebral Organic Acidurias, including diseases",CP:WIKIPATHWAYS,C2,5,10
Cohort,-0.047902650403212996,0.03536400063423576,-1.3545597088593708,0.1759247197137233,LGP Proband,"Cerebral Organic Acidurias, including diseases",CP:WIKIPATHWAYS,C2,5,16
Cohort,-0.007966805651184107,0.011426652143842449,-0.6972125825565828,0.4858733396464482,LonGen OPEL,"Cerebral Organic Acidurias, including diseases",CP:WIKIPATHWAYS,C2,9,9
Cohort,0.04691878508554671,0.06523829057347177,0.719190902660248,0.47227184025660485,LGP Offspring,Chemokine signaling pathway,CP:WIKIPATHWAYS,C2,121,274
Cohort,0.15756129299283914,0.17405396055531838,0.9052439398111972,0.3655975997762231,LGP Proband,Chemokine signaling pathway,CP:WIKIPATHWAYS,C2,121,360
Cohort,-0.02223491651730428,0.055232778110566455,-0.40256741156118975,0.687374572476064,LonGen OPEL,Chemokine signaling pathway,CP:WIKIPATHWAYS,C2,211,238
Cohort,-0.010224510426226725,0.017911514553127447,-0.5708344984395232,0.5683015383621941,LGP Offspring,Cholesterol Biosynthesis Pathway,CP:WIKIPATHWAYS,C2,12,21
Cohort,-0.09662372582566779,0.05342830548410868,-1.8084744584386425,0.07089274433286341,LGP Proband,Cholesterol Biosynthesis Pathway,CP:WIKIPATHWAYS,C2,12,37
Cohort,0.023267803846910674,0.017528423793032297,1.3274327527475591,0.18474614956408392,LonGen OPEL,Cholesterol Biosynthesis Pathway,CP:WIKIPATHWAYS,C2,16,30
Cohort,-0.00545772483425523,0.007184173746282221,-0.7596871995307155,0.4477064218422152,LGP Offspring,Cholesterol Biosynthesis with Skeletal Dysplasias,CP:WIKIPATHWAYS,C2,2,3
Cohort,-0.02891797470040016,0.020812964159615407,-1.3894212510350339,0.16507550956805284,LGP Proband,Cholesterol Biosynthesis with Skeletal Dysplasias,CP:WIKIPATHWAYS,C2,2,5
Cohort,-7.842034323180184e-4,0.008469004261776764,-0.09259688719928635,0.9262471159615376,LonGen OPEL,Cholesterol Biosynthesis with Skeletal Dysplasias,CP:WIKIPATHWAYS,C2,5,6
Cohort,-0.03113734897992674,0.03464374157233324,-0.8987871276811874,0.369086080635988,LGP Offspring,Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways),CP:WIKIPATHWAYS,C2,44,78
Cohort,-0.13411225365515597,0.1009089271774673,-1.3290425079962884,0.18419741504151232,LGP Proband,Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways),CP:WIKIPATHWAYS,C2,44,135
Cohort,0.015428757168822896,0.03255929976873255,0.4738663693142286,0.6357251467275838,LonGen OPEL,Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways),CP:WIKIPATHWAYS,C2,70,92
Cohort,-0.052558524125018775,0.04579547311734785,-1.147679465835871,0.2515069056831895,LGP Offspring,Chromosomal and microsatellite instability in colorectal cancer ,CP:WIKIPATHWAYS,C2,66,126
Cohort,0.02071363903157153,0.1173894809841938,0.17645225839579756,0.8599814904087582,LGP Proband,Chromosomal and microsatellite instability in colorectal cancer ,CP:WIKIPATHWAYS,C2,66,160
Cohort,-0.05235887911379525,0.03413821624775889,-1.5337321298160245,0.1254929064529418,LonGen OPEL,Chromosomal and microsatellite instability in colorectal cancer ,CP:WIKIPATHWAYS,C2,99,90
Cohort,-0.07877300085122836,0.08688361668983909,-0.9066496521713138,0.3649151513553338,LGP Offspring,Ciliary landscape,CP:WIKIPATHWAYS,C2,244,476
Cohort,0.19532405360277694,0.2428247922876933,0.8043826652237447,0.4214052372174658,LGP Proband,Ciliary landscape,CP:WIKIPATHWAYS,C2,244,653
Cohort,-0.06691517587464928,0.07614069253866942,-0.8788359239136838,0.3797554531636629,LonGen OPEL,Ciliary landscape,CP:WIKIPATHWAYS,C2,396,451
Cohort,-0.19734413261489814,0.0974711589730273,-2.024641285628995,0.04329685590687618,LGP Offspring,Ciliopathies,CP:WIKIPATHWAYS,C2,326,602
Cohort,-0.16941558580204968,0.2793346394609035,-0.6064968746053481,0.5443499060782102,LGP Proband,Ciliopathies,CP:WIKIPATHWAYS,C2,326,877
Cohort,0.07453900575961113,0.08862487061835359,0.8410619416371213,0.4005658152813546,LonGen OPEL,Ciliopathies,CP:WIKIPATHWAYS,C2,492,625
Cohort,-0.10359323647365708,0.0687888373741643,-1.5059599846146636,0.13254455733046355,LGP Offspring,Circadian rhythm related genes,CP:WIKIPATHWAYS,C2,173,299
Cohort,-0.14803646384480734,0.20270462107216533,-0.7303063100475866,0.4654080612096242,LGP Proband,Circadian rhythm related genes,CP:WIKIPATHWAYS,C2,173,483
Cohort,-0.01213023319799335,0.05672047685369643,-0.213859859275898,0.8307111103286341,LonGen OPEL,Circadian rhythm related genes,CP:WIKIPATHWAYS,C2,239,286
Cohort,-0.02989677554691076,0.020650008874634515,-1.4477851185640183,0.14814076059659276,LGP Offspring,Classical pathway of steroidogenesis with Glucocorticoid and Mineralocorticoid Metabolism,CP:WIKIPATHWAYS,C2,16,26
Cohort,0.0731096124016741,0.06426277373665418,1.1376666170880494,0.2555864464869961,LGP Proband,Classical pathway of steroidogenesis with Glucocorticoid and Mineralocorticoid Metabolism,CP:WIKIPATHWAYS,C2,16,52
Cohort,-0.0056696999444933215,0.018968907568010653,-0.29889438409488367,0.765098646588421,LonGen OPEL,Classical pathway of steroidogenesis with Glucocorticoid and Mineralocorticoid Metabolism,CP:WIKIPATHWAYS,C2,26,29
Cohort,-0.08237043118826569,0.03240059385793966,-2.5422506621149807,0.011236117618597925,LGP Offspring,Codeine and Morphine Metabolism,CP:WIKIPATHWAYS,C2,38,43
Cohort,-0.07465304514408466,0.09966422138921772,-0.7490455863046663,0.4540409355962274,LGP Proband,Codeine and Morphine Metabolism,CP:WIKIPATHWAYS,C2,38,66
Cohort,-0.025130623538790486,0.0279351761158188,-0.899604979564092,0.3686025669163987,LonGen OPEL,Codeine and Morphine Metabolism,CP:WIKIPATHWAYS,C2,46,46
Cohort,-0.024605369349237537,0.01629858483118347,-1.5096629311129521,0.13159669953387912,LGP Offspring,Common Pathways Underlying Drug Addiction,CP:WIKIPATHWAYS,C2,13,14
Cohort,0.03742855703961444,0.06426607692030155,0.5823999041676499,0.5604547574117149,LGP Proband,Common Pathways Underlying Drug Addiction,CP:WIKIPATHWAYS,C2,13,48
Cohort,-0.018376395143453555,0.014553530549871718,-1.2626760963933616,0.20707537920804717,LonGen OPEL,Common Pathways Underlying Drug Addiction,CP:WIKIPATHWAYS,C2,18,15
Cohort,0.03453723850156269,0.03061980330613152,1.1279379608113524,0.259746284877086,LGP Offspring,Complement Activation,CP:WIKIPATHWAYS,C2,25,71
Cohort,-0.03603307398369535,0.0806132616134017,-0.44698692575546367,0.6550005522858213,LGP Proband,Complement Activation,CP:WIKIPATHWAYS,C2,25,84
Cohort,7.973910560091622e-4,0.0256030053961253,0.031144431822439,0.9751621624657865,LonGen OPEL,Complement Activation,CP:WIKIPATHWAYS,C2,42,58
Cohort,0.018770063367469992,0.039786324323004316,0.471771737823421,0.637241959754568,LGP Offspring,Complement and Coagulation Cascades,CP:WIKIPATHWAYS,C2,50,113
Cohort,-0.05303045533059456,0.10538706179238061,-0.5031970189572987,0.6149586255718493,LGP Proband,Complement and Coagulation Cascades,CP:WIKIPATHWAYS,C2,50,141
Cohort,-0.0377457757028816,0.03370477308194467,-1.1198940758661171,0.263096692746156,LonGen OPEL,Complement and Coagulation Cascades,CP:WIKIPATHWAYS,C2,84,91
Cohort,0.004231912188926852,0.010113143049194234,0.41845667250440305,0.6757461644575606,LGP Offspring,Composition of Lipid Particles,CP:WIKIPATHWAYS,C2,3,7
Cohort,-0.015601203367144077,0.03548915481413071,-0.43960481586144023,0.6603372375039689,LGP Proband,Composition of Lipid Particles,CP:WIKIPATHWAYS,C2,3,18
Cohort,0.018316906699375593,0.011162331348457616,1.6409570839255347,0.10120136163375915,LonGen OPEL,Composition of Lipid Particles,CP:WIKIPATHWAYS,C2,5,14
Cohort,-0.0070254459446680685,0.020109535188015136,-0.34935894236158616,0.7269286523185308,LGP Offspring,Computational Model of Aerobic Glycolysis,CP:WIKIPATHWAYS,C2,13,26
Cohort,-0.060269774338265296,0.045691790733434476,-1.3190503889392005,0.1875143106330463,LGP Proband,Computational Model of Aerobic Glycolysis,CP:WIKIPATHWAYS,C2,13,22
Cohort,-0.021529227940069718,0.016956554863419484,-1.2696699366989281,0.20457328342194944,LonGen OPEL,Computational Model of Aerobic Glycolysis,CP:WIKIPATHWAYS,C2,25,20
Cohort,-0.03950361793162937,0.03444301234370141,-1.1469269161892395,0.251817603500198,LGP Offspring,Constitutive Androstane Receptor Pathway,CP:WIKIPATHWAYS,C2,36,57
Cohort,0.04748063535718421,0.09815994079358785,0.4837068459222809,0.6287209082715995,LGP Proband,Constitutive Androstane Receptor Pathway,CP:WIKIPATHWAYS,C2,36,78
Cohort,-0.02209346123387774,0.02926095488810738,-0.7550492223634592,0.4504427875310303,LonGen OPEL,Constitutive Androstane Receptor Pathway,CP:WIKIPATHWAYS,C2,54,55
Cohort,0.00318314967043097,0.0032063224479245114,0.992772786308956,0.32117591263066275,LGP Offspring,Control of immune tolerance by vasoactive intestinal peptide,CP:WIKIPATHWAYS,C2,0,1
Cohort,0.0011146687792090517,0.01122136359714051,0.09933452111765613,0.9208965410423258,LGP Proband,Control of immune tolerance by vasoactive intestinal peptide,CP:WIKIPATHWAYS,C2,0,2
Cohort,-0.006165805672147528,0.00516475493861092,-1.1938234718656069,0.23290268319673152,LonGen OPEL,Control of immune tolerance by vasoactive intestinal peptide,CP:WIKIPATHWAYS,C2,3,1
Cohort,-0.03369506998924096,0.03455724736752993,-0.9750507507406659,0.32988386618509624,LGP Offspring,Copper homeostasis,CP:WIKIPATHWAYS,C2,41,75
Cohort,0.13802361098088603,0.09882902044566641,1.3965898919009094,0.16290847495681166,LGP Proband,Copper homeostasis,CP:WIKIPATHWAYS,C2,41,123
Cohort,-0.03653019109991129,0.03080610637150563,-1.1858100682824428,0.23605116241599916,LonGen OPEL,Copper homeostasis,CP:WIKIPATHWAYS,C2,71,73
Cohort,-0.027486449729852324,0.02640375283859689,-1.0410054168388045,0.29824519824726337,LGP Offspring,Cori Cycle,CP:WIKIPATHWAYS,C2,26,40
Cohort,-0.11041719231226933,0.07018949833112224,-1.5731298119751627,0.11606802423501286,LGP Proband,Cori Cycle,CP:WIKIPATHWAYS,C2,26,53
Cohort,-0.024075392020321315,0.02133410139014588,-1.1284933721858856,0.25945161426197744,LonGen OPEL,Cori Cycle,CP:WIKIPATHWAYS,C2,36,33
Cohort,-0.10506931207461777,0.04794105649275013,-2.1916353072132826,0.02874627342494119,LGP Offspring,Corticotropin-releasing hormone signaling pathway,CP:WIKIPATHWAYS,C2,88,132
Cohort,-0.06410444071129284,0.1370979035105474,-0.4675814806049246,0.6402060601659161,LGP Proband,Corticotropin-releasing hormone signaling pathway,CP:WIKIPATHWAYS,C2,88,209
Cohort,-0.04729716459264787,0.04118398124906469,-1.148435949079644,0.25113363639327707,LonGen OPEL,Corticotropin-releasing hormone signaling pathway,CP:WIKIPATHWAYS,C2,129,133
Cohort,0.009155848540701197,0.010091679053178954,0.9072671150611985,0.36458885271932684,LGP Offspring,COVID-19 Adverse Outcome Pathway,CP:WIKIPATHWAYS,C2,2,8
Cohort,-0.009153405736520211,0.029729702140833227,-0.3078875695814042,0.7582447595475351,LGP Proband,COVID-19 Adverse Outcome Pathway,CP:WIKIPATHWAYS,C2,2,13
Cohort,0.008702007169520437,0.008962774291978115,0.9709055350539095,0.33189024624554897,LonGen OPEL,COVID-19 Adverse Outcome Pathway,CP:WIKIPATHWAYS,C2,4,8
Cohort,-0.011851839648313815,0.010526777308370639,-1.1258754033762564,0.26061780483041325,LGP Offspring,"COVID-19, thrombosis and anticoagulation",CP:WIKIPATHWAYS,C2,6,5
Cohort,-0.039205946280931644,0.03418615892242689,-1.1468368344596813,0.251777968583487,LGP Proband,"COVID-19, thrombosis and anticoagulation",CP:WIKIPATHWAYS,C2,6,13
Cohort,0.013120723087459474,0.010949404965912301,1.1983046684552197,0.23115508111591626,LonGen OPEL,"COVID-19, thrombosis and anticoagulation",CP:WIKIPATHWAYS,C2,6,12
Cohort,-0.054615784486245274,0.02705561791179021,-2.018648572888257,0.04391812084464963,LGP Offspring,Cysteine and methionine catabolism,CP:WIKIPATHWAYS,C2,30,41
Cohort,-0.014252955232462934,0.07204118487234654,-0.19784454208684205,0.8432149063989174,LGP Proband,Cysteine and methionine catabolism,CP:WIKIPATHWAYS,C2,30,51
Cohort,0.013051034452626656,0.02344870109060995,0.5565781406055346,0.5779721274771146,LonGen OPEL,Cysteine and methionine catabolism,CP:WIKIPATHWAYS,C2,38,48
Cohort,0.004669671367105175,0.022132762673672056,0.2109845678081555,0.8329628976198691,LGP Offspring,Cytokines and Inflammatory Response,CP:WIKIPATHWAYS,C2,14,35
Cohort,-0.032059778016033325,0.056163003482597916,-0.5708344644703169,0.5682656295865778,LGP Proband,Cytokines and Inflammatory Response,CP:WIKIPATHWAYS,C2,14,35
Cohort,0.031067296988024556,0.020360389719944347,1.5258694659263858,0.12743958997339866,LonGen OPEL,Cytokines and Inflammatory Response,CP:WIKIPATHWAYS,C2,22,38
Cohort,-0.00562677332862008,0.018835033624670237,-0.29873975490280513,0.765230430638885,LGP Offspring,Cytoplasmic Ribosomal Proteins,CP:WIKIPATHWAYS,C2,12,25
Cohort,0.05687914271496057,0.06095663674459191,0.9331082840623897,0.35103411973734544,LGP Proband,Cytoplasmic Ribosomal Proteins,CP:WIKIPATHWAYS,C2,12,41
Cohort,-0.010989433970076918,0.017992276134328675,-0.6107862000355495,0.5415154887750679,LonGen OPEL,Cytoplasmic Ribosomal Proteins,CP:WIKIPATHWAYS,C2,24,25
Cohort,-0.005506959464764449,0.02414647659806526,-0.22806472167478442,0.819664891349241,LGP Offspring,Cytosine methylation,CP:WIKIPATHWAYS,C2,21,36
Cohort,-0.058751551522959904,0.08313866197031754,-0.7066694379076679,0.4799693065628844,LGP Proband,Cytosine methylation,CP:WIKIPATHWAYS,C2,21,98
Cohort,-0.015165283369879122,0.022459884517453094,-0.6752164445945618,0.499734345462315,LonGen OPEL,Cytosine methylation,CP:WIKIPATHWAYS,C2,37,41
Cohort,-0.05808525174446901,0.041317100976624804,-1.4058404479377875,0.16023095817217625,LGP Offspring,Cytosolic DNA-sensing pathway,CP:WIKIPATHWAYS,C2,61,105
Cohort,0.02030967738439033,0.10927313124381469,0.18586158512356113,0.8525985022872093,LGP Proband,Cytosolic DNA-sensing pathway,CP:WIKIPATHWAYS,C2,61,135
Cohort,0.02049946493698674,0.034852088892225686,0.5881846852961365,0.5565751743812825,LonGen OPEL,Cytosolic DNA-sensing pathway,CP:WIKIPATHWAYS,C2,73,99
Cohort,0.018683864890772,0.017653795077874356,1.0583483499357391,0.29027468684455116,LGP Offspring,DDX1 as a regulatory component of the Drosha microprocessor,CP:WIKIPATHWAYS,C2,9,23
Cohort,0.035094573220059794,0.04879791275784893,0.7191818509576516,0.47223033983832174,LGP Proband,DDX1 as a regulatory component of the Drosha microprocessor,CP:WIKIPATHWAYS,C2,9,31
Cohort,0.0026427505956983025,0.014869333046395828,0.1777316163039927,0.8589789720696734,LonGen OPEL,DDX1 as a regulatory component of the Drosha microprocessor,CP:WIKIPATHWAYS,C2,16,18
Cohort,0.010895821133963531,0.017354054373207913,0.6278545001440737,0.5303112936374208,LGP Offspring,"Degradation pathway of sphingolipids, including diseases",CP:WIKIPATHWAYS,C2,9,23
Cohort,-0.06871703028793376,0.048653631272078314,-1.4123720777110744,0.15821346262858674,LGP Proband,"Degradation pathway of sphingolipids, including diseases",CP:WIKIPATHWAYS,C2,9,32
Cohort,0.0012365653457714438,0.015110349553590563,0.08183565452181137,0.9347979753678088,LonGen OPEL,"Degradation pathway of sphingolipids, including diseases",CP:WIKIPATHWAYS,C2,15,18
Cohort,-0.008045008505645003,0.029397443278636203,-0.2736635437780229,0.784426788906266,LGP Offspring,Deregulation of Rab and Rab Effector Genes in Bladder Cancer,CP:WIKIPATHWAYS,C2,28,51
Cohort,-0.04105191035212617,0.07938639756392084,-0.5171151684905684,0.6052128754801737,LGP Proband,Deregulation of Rab and Rab Effector Genes in Bladder Cancer,CP:WIKIPATHWAYS,C2,28,70
Cohort,-0.003197906043991882,0.023363150742636805,-0.13687820102773351,0.891161681580688,LonGen OPEL,Deregulation of Rab and Rab Effector Genes in Bladder Cancer,CP:WIKIPATHWAYS,C2,41,42
Cohort,0.013567310501886597,0.010994171197275327,1.234045773750455,0.21761469273534212,LGP Offspring,Development and heterogeneity of the ILC family,CP:WIKIPATHWAYS,C2,2,10
Cohort,-0.012831746878548829,0.035817834753248894,-0.35825021157608955,0.720246730758374,LGP Proband,Development and heterogeneity of the ILC family,CP:WIKIPATHWAYS,C2,2,19
Cohort,0.009483211325678382,0.009254811785264926,1.0246790043615044,0.3058259632619005,LonGen OPEL,Development and heterogeneity of the ILC family,CP:WIKIPATHWAYS,C2,4,9
Cohort,0.004654840647785642,0.015168930794637249,0.306866760143127,0.7590392908183545,LGP Offspring,Development of pulmonary dendritic cells and macrophage subsets,CP:WIKIPATHWAYS,C2,7,16
Cohort,-0.01680199166219997,0.031924437260802324,-0.5263050222291593,0.5988162237473709,LGP Proband,Development of pulmonary dendritic cells and macrophage subsets,CP:WIKIPATHWAYS,C2,7,10
Cohort,-0.018962364971082033,0.011782741186551605,-1.6093339122754382,0.10793983735459471,LonGen OPEL,Development of pulmonary dendritic cells and macrophage subsets,CP:WIKIPATHWAYS,C2,13,8
Cohort,-0.020217522431926812,0.04559754359290198,-0.4433906048192036,0.6576250976303943,LGP Offspring,Development of ureteric collection system,CP:WIKIPATHWAYS,C2,66,134
Cohort,-0.06746805575115583,0.1250998530921907,-0.5393136289411637,0.5898144095838138,LGP Proband,Development of ureteric collection system,CP:WIKIPATHWAYS,C2,66,182
Cohort,-0.03507489265633035,0.038943229994750826,-0.9006672703075247,0.36803766487502965,LonGen OPEL,Development of ureteric collection system,CP:WIKIPATHWAYS,C2,109,114
Cohort,-0.005390271595785681,0.02946323592640369,-0.18294906945218295,0.8548928350934177,LGP Offspring,Differentiation of white and brown adipocyte   ,CP:WIKIPATHWAYS,C2,29,54
Cohort,0.018102914685600043,0.07084039983932185,0.2555450664685766,0.7983651501736342,LGP Proband,Differentiation of white and brown adipocyte   ,CP:WIKIPATHWAYS,C2,29,52
Cohort,0.020757418368663714,0.024069278080550427,0.8624030309175366,0.38872551145697376,LonGen OPEL,Differentiation of white and brown adipocyte   ,CP:WIKIPATHWAYS,C2,35,50
Cohort,-0.009254744477183342,0.02991934116669159,-0.3093231373519148,0.7571710484824338,LGP Offspring,Differentiation Pathway,CP:WIKIPATHWAYS,C2,30,58
Cohort,-0.07967269040378352,0.08322215211080129,-0.9573495563742206,0.33866827910267117,LGP Proband,Differentiation Pathway,CP:WIKIPATHWAYS,C2,30,77
Cohort,0.03799227388685177,0.02721574049249562,1.395966936755869,0.1631136619801714,LonGen OPEL,Differentiation Pathway,CP:WIKIPATHWAYS,C2,47,66
Cohort,0.0027702523740945643,0.026078069806658548,0.1062291954363598,0.9154320225239623,LGP Offspring,Disorders of Folate Metabolism and Transport,CP:WIKIPATHWAYS,C2,21,44
Cohort,-0.06591505179295652,0.06790537421438092,-0.9706897658035012,0.3319842162025701,LGP Proband,Disorders of Folate Metabolism and Transport,CP:WIKIPATHWAYS,C2,21,54
Cohort,-0.0176922640283689,0.021362100682620185,-0.8282080630189615,0.40780092302258775,LonGen OPEL,Disorders of Folate Metabolism and Transport,CP:WIKIPATHWAYS,C2,33,36
Cohort,0.030755420401410417,0.01579831418569074,1.9467533079742783,0.051978162101709455,LGP Offspring,Disorders of the Krebs cycle,CP:WIKIPATHWAYS,C2,4,19
Cohort,-0.016200116072662654,0.0470349502638561,-0.34442719683519246,0.7306118678098057,LGP Proband,Disorders of the Krebs cycle,CP:WIKIPATHWAYS,C2,4,34
Cohort,0.022226577912907216,0.0156205951532802,1.4229021170323215,0.1551563128587169,LonGen OPEL,Disorders of the Krebs cycle,CP:WIKIPATHWAYS,C2,13,25
Cohort,0.008209011429252526,0.03057183369423336,0.26851550716112127,0.7883844613349863,LGP Offspring,Disruption of postsynaptic signalling by CNV,CP:WIKIPATHWAYS,C2,27,63
Cohort,0.031201748496732608,0.08080079421761494,0.3861564579761332,0.6994792878955867,LGP Proband,Disruption of postsynaptic signalling by CNV,CP:WIKIPATHWAYS,C2,27,87
Cohort,-0.040349789407950115,0.023722575958305785,-1.7009025275698522,0.08935185956931062,LonGen OPEL,Disruption of postsynaptic signalling by CNV,CP:WIKIPATHWAYS,C2,47,39
Cohort,-0.04079295712228634,0.04247045878200734,-0.9605019180901413,0.3371460848174995,LGP Offspring,DNA Damage Response,CP:WIKIPATHWAYS,C2,65,115
Cohort,0.11721768419099479,0.11965556024573094,0.979625885752993,0.32755490138046794,LGP Proband,DNA Damage Response,CP:WIKIPATHWAYS,C2,65,156
Cohort,0.0564132443877227,0.03860640531946187,1.461240535629051,0.14434406352262794,LonGen OPEL,DNA Damage Response,CP:WIKIPATHWAYS,C2,92,133
Cohort,0.05094124594033452,0.058317183963476515,0.8735203327416928,0.38268972104205057,LGP Offspring,DNA Damage Response (only ATM dependent),CP:WIKIPATHWAYS,C2,87,205
Cohort,0.018581532940400054,0.15769272798893869,0.117833797267452,0.9062277218502589,LGP Proband,DNA Damage Response (only ATM dependent),CP:WIKIPATHWAYS,C2,87,267
Cohort,-0.052584975604956535,0.04697888787694252,-1.1193320655588679,0.26333614505669495,LonGen OPEL,DNA Damage Response (only ATM dependent),CP:WIKIPATHWAYS,C2,167,172
Cohort,-0.042303952004073324,0.05822367647768836,-0.7265764473029187,0.46773696952749255,LGP Offspring,DNA IR-damage and cellular response via ATR,CP:WIKIPATHWAYS,C2,117,230
Cohort,0.06337100055296088,0.16463047561460953,0.38492873398063154,0.7003883579210192,LGP Proband,DNA IR-damage and cellular response via ATR,CP:WIKIPATHWAYS,C2,117,338
Cohort,0.007944273993544004,0.05487488006846286,0.14477068530505377,0.8849285748305651,LonGen OPEL,DNA IR-damage and cellular response via ATR,CP:WIKIPATHWAYS,C2,199,232
Cohort,-0.014250485333132027,0.042985384365429265,-0.33151931856617045,0.7403549994665626,LGP Offspring,DNA IR-Double Strand Breaks (DSBs) and cellular response via ATM,CP:WIKIPATHWAYS,C2,63,121
Cohort,0.020261186407731564,0.12011973611787025,0.16867491606749627,0.8660932482683809,LGP Proband,DNA IR-Double Strand Breaks (DSBs) and cellular response via ATM,CP:WIKIPATHWAYS,C2,63,175
Cohort,0.018509751774412338,0.04019285008754823,0.46052349445471824,0.64526629291908,LonGen OPEL,DNA IR-Double Strand Breaks (DSBs) and cellular response via ATM,CP:WIKIPATHWAYS,C2,106,136
Cohort,-0.020454310997032654,0.03264505805070833,-0.6265668440613735,0.5311547324405435,LGP Offspring,DNA Mismatch Repair,CP:WIKIPATHWAYS,C2,36,70
Cohort,0.042126102785553204,0.09397149637640571,0.4482859634033687,0.6540632643283039,LGP Proband,DNA Mismatch Repair,CP:WIKIPATHWAYS,C2,36,108
Cohort,0.0107963192591129,0.027351829983969747,0.39472018016492366,0.6931551458644247,LonGen OPEL,DNA Mismatch Repair,CP:WIKIPATHWAYS,C2,54,65
Cohort,-0.0167998376508396,0.0715639373632072,-0.2347528415824255,0.8144716590070092,LGP Offspring,DNA Repair Pathways Full Network,CP:WIKIPATHWAYS,C2,175,363
Cohort,-0.19878376497667544,0.20330788535430597,-0.9777474426545418,0.3284827740869988,LGP Proband,DNA Repair Pathways Full Network,CP:WIKIPATHWAYS,C2,175,502
Cohort,0.041175491984582833,0.06386976826713989,0.6446789005459262,0.5193210334347689,LonGen OPEL,DNA Repair Pathways Full Network,CP:WIKIPATHWAYS,C2,281,347
Cohort,-0.06789897578236664,0.040529746278461634,-1.6752874620991545,0.09434030419257947,LGP Offspring,DNA Replication,CP:WIKIPATHWAYS,C2,62,97
Cohort,-0.07580703467543562,0.11922708050624703,-0.6358206068080617,0.5250677844145738,LGP Proband,DNA Replication,CP:WIKIPATHWAYS,C2,62,162
Cohort,0.019600139008387463,0.03310098214636227,0.5921316449681684,0.5539305851177608,LonGen OPEL,DNA Replication,CP:WIKIPATHWAYS,C2,78,96
Cohort,0.0021644432351637043,0.01743091274460288,0.12417268486607962,0.901215461797708,LGP Offspring,Dopamine metabolism,CP:WIKIPATHWAYS,C2,10,21
Cohort,-0.025169465720384036,0.04583149359541605,-0.549174023054344,0.5830330320914212,LGP Proband,Dopamine metabolism,CP:WIKIPATHWAYS,C2,10,26
Cohort,-0.004733146312932094,0.0125491951151233,-0.3771673218490387,0.7061497937816119,LonGen OPEL,Dopamine metabolism,CP:WIKIPATHWAYS,C2,12,12
Cohort,-0.014764360483272669,0.020331257685674342,-0.7261902195886201,0.46797352018282645,LGP Offspring,Dopaminergic Neurogenesis,CP:WIKIPATHWAYS,C2,15,25
Cohort,0.0942498214319802,0.05812415254815728,1.6215259457570916,0.10528285463191421,LGP Proband,Dopaminergic Neurogenesis,CP:WIKIPATHWAYS,C2,15,44
Cohort,-0.010584819302139574,0.017138908549043652,-0.617590045004949,0.537022242129563,LonGen OPEL,Dopaminergic Neurogenesis,CP:WIKIPATHWAYS,C2,24,22
Cohort,-0.007016396770587185,0.02290711391738397,-0.30629772025809476,0.7594722860678154,LGP Offspring,Drug Induction of Bile Acid Pathway,CP:WIKIPATHWAYS,C2,19,35
Cohort,0.03727612598048466,0.06646347263251456,0.560851314324025,0.5750495452730622,LGP Proband,Drug Induction of Bile Acid Pathway,CP:WIKIPATHWAYS,C2,19,57
Cohort,-0.020271897505705027,0.02172364856506178,-0.9331718585389193,0.3510142082566523,LonGen OPEL,Drug Induction of Bile Acid Pathway,CP:WIKIPATHWAYS,C2,36,34
Cohort,-0.0041527020624387715,0.005547498974183312,-0.7485719387717636,0.45437561572542706,LGP Offspring,Dual hijack model of Vif in HIV infection,CP:WIKIPATHWAYS,C2,2,1
Cohort,-0.009858081334419665,0.015805386528947283,-0.6237165612093551,0.5329842919136201,LGP Proband,Dual hijack model of Vif in HIV infection,CP:WIKIPATHWAYS,C2,2,2
Cohort,-0.003941486896914092,0.005124093138283328,-0.7692067241062225,0.4419987768092456,LonGen OPEL,Dual hijack model of Vif in HIV infection,CP:WIKIPATHWAYS,C2,2,2
Cohort,-0.11600810066089268,0.07290883363940673,-1.5911391647635835,0.11204575990191736,LGP Offspring,Ebola Virus Pathway on Host,CP:WIKIPATHWAYS,C2,195,351
Cohort,-0.15172201856743237,0.20077277580287461,-0.7556901973422835,0.45004833705146485,LGP Proband,Ebola Virus Pathway on Host,CP:WIKIPATHWAYS,C2,195,456
Cohort,0.06370470314362908,0.06531763890706094,0.9753062757561266,0.3297046540987443,LonGen OPEL,Ebola Virus Pathway on Host,CP:WIKIPATHWAYS,C2,275,367
Cohort,-0.025191434900008875,0.024246488572309495,-1.0389725021370124,0.2991889932595712,LGP Offspring,EBV LMP1 signaling,CP:WIKIPATHWAYS,C2,18,30
Cohort,0.016882751891171804,0.0624648231647049,0.2702761496123346,0.7870146793645736,LGP Proband,EBV LMP1 signaling,CP:WIKIPATHWAYS,C2,18,38
Cohort,0.020192873697982023,0.022243262585937628,0.9078197777851224,0.3642481974002244,LonGen OPEL,EBV LMP1 signaling,CP:WIKIPATHWAYS,C2,28,41
Cohort,-0.09747761625839668,0.06571653020132011,-1.4833043674061561,0.13845962121004599,LGP Offspring,Ectoderm Differentiation,CP:WIKIPATHWAYS,C2,148,281
Cohort,0.12534312061597488,0.18576389259359005,0.6747442620089668,0.5000252577611237,LGP Proband,Ectoderm Differentiation,CP:WIKIPATHWAYS,C2,148,403
Cohort,0.07987288992402225,0.05954136472634729,1.3414689147808228,0.18015084222709693,LonGen OPEL,Ectoderm Differentiation,CP:WIKIPATHWAYS,C2,222,293
Cohort,-0.02175372812027356,0.019029261561305875,-1.1431724794044356,0.2533716683547909,LGP Offspring,EDA Signalling in Hair Follicle Development,CP:WIKIPATHWAYS,C2,14,23
Cohort,-0.010429737062026262,0.053137354389764954,-0.19627881707327124,0.8444397562813908,LGP Proband,EDA Signalling in Hair Follicle Development,CP:WIKIPATHWAYS,C2,14,34
Cohort,0.013097585664691883,0.014596229923292707,0.8973266201973646,0.3698159682856831,LonGen OPEL,EDA Signalling in Hair Follicle Development,CP:WIKIPATHWAYS,C2,14,19
Cohort,-0.02328614917323623,0.01990087459204926,-1.1701068244779276,0.24237033790781556,LGP Offspring,Effects of Nitric Oxide,CP:WIKIPATHWAYS,C2,18,21
Cohort,-0.05284752866364741,0.05825426760459007,-0.9071872471620149,0.36456982425382123,LGP Proband,Effects of Nitric Oxide,CP:WIKIPATHWAYS,C2,18,39
Cohort,-0.016837736558301928,0.016339257485520127,-1.0305080615336133,0.3030845797190382,LonGen OPEL,Effects of Nitric Oxide,CP:WIKIPATHWAYS,C2,21,18
Cohort,-0.14188636427618448,0.06552970532583256,-2.16522207097811,0.030719812058703676,LGP Offspring,EGF/EGFR Signaling Pathway,CP:WIKIPATHWAYS,C2,173,294
Cohort,-0.019580894668536346,0.18445203028463744,-0.10615711108367881,0.9154832270169266,LGP Proband,EGF/EGFR Signaling Pathway,CP:WIKIPATHWAYS,C2,173,381
Cohort,-0.0310184566995569,0.056923892572694465,-0.5449110258920695,0.5859673437992668,LonGen OPEL,EGF/EGFR Signaling Pathway,CP:WIKIPATHWAYS,C2,226,270
Cohort,-0.0633506694322107,0.04783521600459528,-1.32435211385112,0.18583370291146759,LGP Offspring,EGFR Tyrosine Kinase Inhibitor Resistance,CP:WIKIPATHWAYS,C2,84,149
Cohort,0.02578474277106908,0.132516467214451,0.19457764995607457,0.8457709882021035,LGP Proband,EGFR Tyrosine Kinase Inhibitor Resistance,CP:WIKIPATHWAYS,C2,84,193
Cohort,-0.04653415133210519,0.03867458378287407,-1.2032230674635342,0.22924774333476078,LonGen OPEL,EGFR Tyrosine Kinase Inhibitor Resistance,CP:WIKIPATHWAYS,C2,121,129
Cohort,-0.0032520577578932595,0.025428441157792567,-0.12789056701168108,0.8982736112907981,LGP Offspring,Eicosanoid metabolism via Cyclo Oxygenases (COX),CP:WIKIPATHWAYS,C2,22,44
Cohort,0.06975351667207108,0.07720741318498146,0.9034562070477408,0.36654469355340935,LGP Proband,Eicosanoid metabolism via Cyclo Oxygenases (COX),CP:WIKIPATHWAYS,C2,22,80
Cohort,-0.018127034377413996,0.02639502610787937,-0.686759478976335,0.4924343204046151,LonGen OPEL,Eicosanoid metabolism via Cyclo Oxygenases (COX),CP:WIKIPATHWAYS,C2,47,50
Cohort,-0.02595882185640344,0.014122103611219934,-1.838169621966185,0.0664760113283991,LGP Offspring,Eicosanoid metabolism via Cytochrome P450 Mono-Oxygenases (CYP) pathway,CP:WIKIPATHWAYS,C2,10,10
Cohort,-0.015917637630129794,0.046715606541240864,-0.34073490228747416,0.7333889737697643,LGP Proband,Eicosanoid metabolism via Cytochrome P450 Mono-Oxygenases (CYP) pathway,CP:WIKIPATHWAYS,C2,10,27
Cohort,3.1161147112334644e-4,0.015452587990198212,0.020165649360547624,0.9839162837296465,LonGen OPEL,Eicosanoid metabolism via Cytochrome P450 Mono-Oxygenases (CYP) pathway,CP:WIKIPATHWAYS,C2,16,19
Cohort,0.01574063802843813,0.03347311136833314,0.47024723382390393,0.6383300640756338,LGP Offspring,Eicosanoid metabolism via Lipo Oxygenases (LOX),CP:WIKIPATHWAYS,C2,32,68
Cohort,-0.06424224711656429,0.08375072370622172,-0.7670649789476605,0.44325996777860455,LGP Proband,Eicosanoid metabolism via Lipo Oxygenases (LOX),CP:WIKIPATHWAYS,C2,32,88
Cohort,-0.030110322068284238,0.028492281408351656,-1.0567887364561233,0.2909286309555825,LonGen OPEL,Eicosanoid metabolism via Lipo Oxygenases (LOX),CP:WIKIPATHWAYS,C2,60,60
Cohort,0.0028874682411146736,0.02845537494430515,0.10147356155967821,0.9192046337611092,LGP Offspring,Eicosanoid Synthesis,CP:WIKIPATHWAYS,C2,26,56
Cohort,-0.031031352511939465,0.08141670874757219,-0.38114231082652067,0.7031947244217613,LGP Proband,Eicosanoid Synthesis,CP:WIKIPATHWAYS,C2,26,84
Cohort,-0.028915578779469948,0.02584465172255538,-1.1188225358918062,0.263553367450617,LonGen OPEL,Eicosanoid Synthesis,CP:WIKIPATHWAYS,C2,54,48
Cohort,0.03946611785178949,0.03515989425140637,1.1224754423205032,0.26205885738267215,LGP Offspring,Electron Transport Chain (OXPHOS system in mitochondria),CP:WIKIPATHWAYS,C2,37,91
Cohort,0.01283204679216611,0.10343831823080286,0.12405506017154926,0.9013015719038546,LGP Proband,Electron Transport Chain (OXPHOS system in mitochondria),CP:WIKIPATHWAYS,C2,37,136
Cohort,-0.03161749864956608,0.038652750404630315,-0.8179883273139222,0.41360863846432583,LonGen OPEL,Electron Transport Chain (OXPHOS system in mitochondria),CP:WIKIPATHWAYS,C2,96,113
Cohort,-0.07881216724562265,0.03873888729392452,-2.0344458179102856,0.042296471506844006,LGP Offspring,Endochondral Ossification,CP:WIKIPATHWAYS,C2,61,92
Cohort,-0.2127701517761068,0.10603858182065654,-2.0065352452182528,0.04512156026336562,LGP Proband,Endochondral Ossification,CP:WIKIPATHWAYS,C2,61,130
Cohort,-0.04066749317473694,0.0351821504585069,-1.1559126615270245,0.24806370439503886,LonGen OPEL,Endochondral Ossification,CP:WIKIPATHWAYS,C2,99,100
Cohort,-0.07881216724562265,0.03873888729392452,-2.0344458179102856,0.042296471506844006,LGP Offspring,Endochondral Ossification with Skeletal Dysplasias,CP:WIKIPATHWAYS,C2,61,92
Cohort,-0.2127701517761068,0.10603858182065654,-2.0065352452182528,0.04512156026336562,LGP Proband,Endochondral Ossification with Skeletal Dysplasias,CP:WIKIPATHWAYS,C2,61,130
Cohort,-0.04066749317473694,0.0351821504585069,-1.1559126615270245,0.24806370439503886,LonGen OPEL,Endochondral Ossification with Skeletal Dysplasias,CP:WIKIPATHWAYS,C2,99,100
Cohort,-0.1066374874763498,0.06674787299302322,-1.5976162639294291,0.11059570525079745,LGP Offspring,Endoderm Differentiation,CP:WIKIPATHWAYS,C2,139,252
Cohort,0.43710006201579066,0.17895874463147815,2.4424627190802637,0.014794061958715425,LGP Proband,Endoderm Differentiation,CP:WIKIPATHWAYS,C2,139,423
Cohort,0.011420031962419995,0.05465493920803867,0.20894784859152002,0.8345424086859647,LonGen OPEL,Endoderm Differentiation,CP:WIKIPATHWAYS,C2,214,261
Cohort,-0.012725279559954245,0.03915356512425891,-0.3250094728173264,0.7452744598721138,LGP Offspring,Endometrial cancer,CP:WIKIPATHWAYS,C2,49,99
Cohort,0.14863782231156278,0.10358912440415313,1.4348786435499936,0.15169656273386442,LGP Proband,Endometrial cancer,CP:WIKIPATHWAYS,C2,49,130
Cohort,-0.06057875578963554,0.03119091732057107,-1.942192182648074,0.05246625357484053,LonGen OPEL,Endometrial cancer,CP:WIKIPATHWAYS,C2,83,74
Cohort,0.02097087054508143,0.03641758008967769,0.5758447017468215,0.564911801344917,LGP Offspring,Endoplasmic reticulum stress response in Coronavirus infection,CP:WIKIPATHWAYS,C2,42,90
Cohort,-0.07604482033116329,0.10761536445948756,-0.7066353462919397,0.4799904865556558,LGP Proband,Endoplasmic reticulum stress response in Coronavirus infection,CP:WIKIPATHWAYS,C2,42,139
Cohort,0.03447907455118119,0.030237946352168074,1.140258473562277,0.25452160248970584,LonGen OPEL,Endoplasmic reticulum stress response in Coronavirus infection,CP:WIKIPATHWAYS,C2,58,80
Cohort,-0.011119029752841262,0.019258593174695294,-0.5773542050543464,0.5638924352324186,LGP Offspring,Endothelin Pathways,CP:WIKIPATHWAYS,C2,14,22
Cohort,-0.007364957795487591,0.06272097430333456,-0.11742416117244582,0.9065522108208135,LGP Proband,Endothelin Pathways,CP:WIKIPATHWAYS,C2,14,42
Cohort,0.0069761079142986494,0.01540577463303534,0.45282422211600104,0.6507987144748555,LonGen OPEL,Endothelin Pathways,CP:WIKIPATHWAYS,C2,14,21
Cohort,-0.011014208953830996,0.03265632159332596,-0.3372764725615022,0.7360131873565345,LGP Offspring,Energy Metabolism,CP:WIKIPATHWAYS,C2,36,65
Cohort,0.035643470752793525,0.10270144787462308,0.3470590871932665,0.7286344844195907,LGP Proband,Energy Metabolism,CP:WIKIPATHWAYS,C2,36,125
Cohort,-0.039724192541175575,0.03427552131072787,-1.1589668376172102,0.24681726197708417,LonGen OPEL,Energy Metabolism,CP:WIKIPATHWAYS,C2,86,90
Cohort,-0.026163282090469607,0.03980637364453493,-0.6572636413480885,0.5112351238175091,LGP Offspring,Envelope proteins and their potential roles in EDMD physiopathology,CP:WIKIPATHWAYS,C2,57,108
Cohort,-0.011128241289533786,0.10937290069112614,-0.10174587323929926,0.9189828457354987,LGP Proband,Envelope proteins and their potential roles in EDMD physiopathology,CP:WIKIPATHWAYS,C2,57,145
Cohort,-0.024882362575682913,0.03261920406782259,-0.7628132962394466,0.4458007432502651,LonGen OPEL,Envelope proteins and their potential roles in EDMD physiopathology,CP:WIKIPATHWAYS,C2,82,92
Cohort,-0.08814752928780435,0.07059843948331293,-1.2485761715546053,0.21225236413128884,LGP Offspring,Epithelial to mesenchymal transition in colorectal cancer,CP:WIKIPATHWAYS,C2,168,323
Cohort,0.0038172587590188304,0.1909331579210566,0.019992644549445507,0.9840540221520292,LGP Proband,Epithelial to mesenchymal transition in colorectal cancer,CP:WIKIPATHWAYS,C2,168,427
Cohort,-0.056661855338821086,0.060611601658626404,-0.9348351435744781,0.3501567655800205,LonGen OPEL,Epithelial to mesenchymal transition in colorectal cancer,CP:WIKIPATHWAYS,C2,260,286
Cohort,-0.01647911878663102,0.021305523987805917,-0.7734669560843818,0.4395164607687092,LGP Offspring,EPO Receptor Signaling,CP:WIKIPATHWAYS,C2,17,28
Cohort,0.05330872361801005,0.06486149421223493,0.821885531091486,0.41137694396474334,LGP Proband,EPO Receptor Signaling,CP:WIKIPATHWAYS,C2,17,55
Cohort,-0.037494563334192536,0.021151593578769456,-1.7726590289550124,0.07666762415733892,LonGen OPEL,EPO Receptor Signaling,CP:WIKIPATHWAYS,C2,36,27
Cohort,0.03888926942119319,0.0465564099353628,0.8353150398663818,0.40383547443236245,LGP Offspring,ErbB Signaling Pathway,CP:WIKIPATHWAYS,C2,59,144
Cohort,0.1862456417563698,0.1230753390099526,1.5132653158185398,0.1305911230001546,LGP Proband,ErbB Signaling Pathway,CP:WIKIPATHWAYS,C2,59,176
Cohort,-0.029159229520728545,0.03675560294247115,-0.7933274708176536,0.42782346202213584,LonGen OPEL,ErbB Signaling Pathway,CP:WIKIPATHWAYS,C2,91,100
Cohort,-0.011167208089156739,0.019496444820775772,-0.5727817656918022,0.566982924377132,LGP Offspring,ERK Pathway in Huntington's Disease,CP:WIKIPATHWAYS,C2,12,22
Cohort,0.013642774946169278,0.04712901864332166,0.2894771700938548,0.7722881946609349,LGP Proband,ERK Pathway in Huntington's Disease,CP:WIKIPATHWAYS,C2,12,23
Cohort,-0.021336379043735382,0.012318618722374348,-1.7320431392995423,0.08365327010580186,LonGen OPEL,ERK Pathway in Huntington's Disease,CP:WIKIPATHWAYS,C2,13,11
Cohort,-0.03268641534503086,0.04606962147374778,-0.7095004104528365,0.47825863541660274,LGP Offspring,ESC Pluripotency Pathways,CP:WIKIPATHWAYS,C2,75,142
Cohort,-0.02213333339365906,0.12908407306893321,-0.17146447944696833,0.863900151223672,LGP Proband,ESC Pluripotency Pathways,CP:WIKIPATHWAYS,C2,75,200
Cohort,-0.028616170237608856,0.03998943016818747,-0.7155933484737097,0.47445233034950507,LonGen OPEL,ESC Pluripotency Pathways,CP:WIKIPATHWAYS,C2,106,115
Cohort,-0.026389729240823973,0.02481150156792582,-1.0636087126197291,0.2878857763099856,LGP Offspring,Estrogen metabolism,CP:WIKIPATHWAYS,C2,20,29
Cohort,-0.012488890427181617,0.06966997513096332,-0.17925785682721163,0.8577787757063404,LGP Proband,Estrogen metabolism,CP:WIKIPATHWAYS,C2,20,35
Cohort,0.010401181029742607,0.02004934782763417,0.5187790206026841,0.6040590373856904,LonGen OPEL,Estrogen metabolism,CP:WIKIPATHWAYS,C2,18,28
Cohort,-0.004176121318231201,0.02264258508404518,-0.18443659603045295,0.8537262772513703,LGP Offspring,Estrogen Receptor Pathway,CP:WIKIPATHWAYS,C2,17,30
Cohort,0.05457057380467192,0.059279381274775,0.92056584652467,0.3575433337419681,LGP Proband,Estrogen Receptor Pathway,CP:WIKIPATHWAYS,C2,17,41
Cohort,-0.020545281744012392,0.016831684512492413,-1.2206313473118964,0.2225870894623786,LonGen OPEL,Estrogen Receptor Pathway,CP:WIKIPATHWAYS,C2,23,19
Cohort,-0.005748762218462061,0.019889705952616844,-0.28903203657999327,0.7726454747685112,LGP Offspring,Estrogen signaling pathway,CP:WIKIPATHWAYS,C2,12,24
Cohort,0.009301402057330405,0.0538148551956013,0.17284078947202444,0.8628185105131934,LGP Proband,Estrogen signaling pathway,CP:WIKIPATHWAYS,C2,12,33
Cohort,-0.013315741552773212,0.017272415865178827,-0.7709252519572397,0.4409800029794315,LonGen OPEL,Estrogen signaling pathway,CP:WIKIPATHWAYS,C2,21,17
Cohort,-0.10614021838882612,0.032581961861718835,-3.257637426478369,0.001179623895430042,LGP Offspring,Ethanol effects on histone modifications,CP:WIKIPATHWAYS,C2,46,52
Cohort,0.10216250671503364,0.09079002188429136,1.1252613954123296,0.2608020074561001,LGP Proband,Ethanol effects on histone modifications,CP:WIKIPATHWAYS,C2,46,87
Cohort,0.033864460071190323,0.028448839726569943,1.1903634874628097,0.23425843630343168,LonGen OPEL,Ethanol effects on histone modifications,CP:WIKIPATHWAYS,C2,47,68
Cohort,-0.002176539231856642,0.005550593544099257,-0.39212729495757875,0.6950877546236429,LGP Offspring,Ethanol metabolism resulting in production of ROS by CYP2E1,CP:WIKIPATHWAYS,C2,1,2
Cohort,0.016864931081867283,0.022278948710515438,0.7569895375676864,0.4492699289284364,LGP Proband,Ethanol metabolism resulting in production of ROS by CYP2E1,CP:WIKIPATHWAYS,C2,1,7
Cohort,-0.0013245249657542896,0.0051956925839523275,-0.25492750857610064,0.7988449375919826,LonGen OPEL,Ethanol metabolism resulting in production of ROS by CYP2E1,CP:WIKIPATHWAYS,C2,2,2
Cohort,-0.0301291807059579,0.026318431106201596,-1.1447939500792794,0.252699677695428,LGP Offspring,Eukaryotic Transcription Initiation,CP:WIKIPATHWAYS,C2,27,40
Cohort,-0.04168057933045048,0.07526015149290699,-0.5538200296391741,0.5798504678369897,LGP Proband,Eukaryotic Transcription Initiation,CP:WIKIPATHWAYS,C2,27,67
Cohort,0.025387658535551676,0.02130757562357842,1.191485084180968,0.23381833990527215,LonGen OPEL,Eukaryotic Transcription Initiation,CP:WIKIPATHWAYS,C2,26,41
Cohort,-0.003960263533618203,0.0031643940563724046,-1.2515077019700152,0.21118220388700248,LGP Offspring,EV release from cardiac cells and their functional effects,CP:WIKIPATHWAYS,C2,1,0
Cohort,-0.010570804240852372,0.013692103680112177,-0.7720365319908071,0.4403114967947621,LGP Proband,EV release from cardiac cells and their functional effects,CP:WIKIPATHWAYS,C2,1,2
Cohort,-0.0013815125290427923,0.00632800521563605,-0.21831722351131652,0.8272379128751096,LonGen OPEL,EV release from cardiac cells and their functional effects,CP:WIKIPATHWAYS,C2,3,3
Cohort,-0.0265508754225831,0.02338097530384857,-1.1355760432377153,0.2565364848964775,LGP Offspring,Exercise-induced Circadian Regulation,CP:WIKIPATHWAYS,C2,22,34
Cohort,-0.05017856142057546,0.06156904866267236,-0.8149965365795453,0.41530696004793877,LGP Proband,Exercise-induced Circadian Regulation,CP:WIKIPATHWAYS,C2,22,40
Cohort,0.019276984821317737,0.021049218386673233,0.9158052554351596,0.36004639876844,LonGen OPEL,Exercise-induced Circadian Regulation,CP:WIKIPATHWAYS,C2,25,40
Cohort,0.0051243333918355415,0.011461292236747566,0.4470990954585154,0.6549467239928743,LGP Offspring,exRNA mechanism of action and biogenesis,CP:WIKIPATHWAYS,C2,3,8
Cohort,-0.007198639286655042,0.031128287537270725,-0.2312571572732975,0.8171717505224686,LGP Proband,exRNA mechanism of action and biogenesis,CP:WIKIPATHWAYS,C2,3,13
Cohort,0.003947229151412692,0.0092958748247169,0.4246215903120127,0.6712272957135982,LonGen OPEL,exRNA mechanism of action and biogenesis,CP:WIKIPATHWAYS,C2,5,8
Cohort,-0.03579051568770921,0.0308812377292908,-1.1589728365635412,0.24687649074766457,LGP Offspring,Extracellular vesicle-mediated signaling in recipient cells,CP:WIKIPATHWAYS,C2,35,61
Cohort,0.19946665929629095,0.08432343608724183,2.365494915196777,0.018233882463773655,LGP Proband,Extracellular vesicle-mediated signaling in recipient cells,CP:WIKIPATHWAYS,C2,35,85
Cohort,-0.004791608846753962,0.024275444374175618,-0.197385010667459,0.8435766492725874,LonGen OPEL,Extracellular vesicle-mediated signaling in recipient cells,CP:WIKIPATHWAYS,C2,43,49
Cohort,0.03241928769290042,0.03085991440402723,1.0505307068729164,0.2938495819946162,LGP Offspring,Extracellular vesicles in the crosstalk of cardiac cells,CP:WIKIPATHWAYS,C2,22,62
Cohort,-0.10512545175188191,0.0714585070934719,-1.4711397708655134,0.14163051686271366,LGP Proband,Extracellular vesicles in the crosstalk of cardiac cells,CP:WIKIPATHWAYS,C2,22,62
Cohort,-0.021066837274416137,0.024454691189716275,-0.8614640483898319,0.3892419382391923,LonGen OPEL,Extracellular vesicles in the crosstalk of cardiac cells,CP:WIKIPATHWAYS,C2,46,45
Cohort,-0.07249522660360383,0.04120985499724032,-1.7591720865909035,0.07900064083277851,LGP Offspring,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling,CP:WIKIPATHWAYS,C2,65,107
Cohort,0.024927534188878917,0.11030267607340476,0.2259921071388152,0.8212629300909664,LGP Proband,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling,CP:WIKIPATHWAYS,C2,65,141
Cohort,-0.03745854973091437,0.03565964897089727,-1.0504463956301204,0.29383172638693394,LonGen OPEL,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling,CP:WIKIPATHWAYS,C2,98,96
Cohort,0.006157138772908599,0.021517680141768244,0.2861432427818693,0.7748560783329179,LGP Offspring,Farnesoid X Receptor  Pathway,CP:WIKIPATHWAYS,C2,15,32
Cohort,0.0468682988711575,0.06418777198760235,0.7301748825338563,0.46548833990762906,LGP Proband,Farnesoid X Receptor  Pathway,CP:WIKIPATHWAYS,C2,15,52
Cohort,-0.023137885835620556,0.01896452606197904,-1.2200613798627145,0.22280294563640193,LonGen OPEL,Farnesoid X Receptor  Pathway,CP:WIKIPATHWAYS,C2,31,22
Cohort,-0.04840736652011698,0.036861542401218,-1.3132214054753573,0.1895539243550747,LGP Offspring,Fas Ligand (FasL) pathway and Stress induction of Heat Shock Proteins (HSP) regulation,CP:WIKIPATHWAYS,C2,45,72
Cohort,-0.0671297555637959,0.09644351868925236,-0.6960525339198022,0.48658985373337516,LGP Proband,Fas Ligand (FasL) pathway and Stress induction of Heat Shock Proteins (HSP) regulation,CP:WIKIPATHWAYS,C2,45,93
Cohort,-0.023151086319637203,0.030408344370935612,-0.7613399150321739,0.4466795548632636,LonGen OPEL,Fas Ligand (FasL) pathway and Stress induction of Heat Shock Proteins (HSP) regulation,CP:WIKIPATHWAYS,C2,80,84
Cohort,0.03737908545892235,0.039565256148048636,0.9447451905544125,0.3451265205908224,LGP Offspring,Fatty Acid Beta Oxidation,CP:WIKIPATHWAYS,C2,45,109
Cohort,-0.007770916421214518,0.10596502476559516,-0.07333472943930824,0.9415573400827383,LGP Proband,Fatty Acid Beta Oxidation,CP:WIKIPATHWAYS,C2,45,141
Cohort,-0.0925143460243192,0.03516567969482976,-2.630813532602389,0.00868278141873297,LonGen OPEL,Fatty Acid Beta Oxidation,CP:WIKIPATHWAYS,C2,108,98
Cohort,-0.024432493369365586,0.0307364950184099,-0.7949017399261538,0.42694965226141535,LGP Offspring,Fatty Acid Biosynthesis,CP:WIKIPATHWAYS,C2,32,60
Cohort,-0.08135230672401539,0.08094541684134764,-1.0050267192207467,0.31517548392210526,LGP Proband,Fatty Acid Biosynthesis,CP:WIKIPATHWAYS,C2,32,79
Cohort,-0.00330043964698379,0.025398730578402955,-0.12994506307296394,0.8966427207553989,LonGen OPEL,Fatty Acid Biosynthesis,CP:WIKIPATHWAYS,C2,44,51
Cohort,-0.03299001603776917,0.02380675993563696,-1.3857415342095987,0.16628282276191206,LGP Offspring,Fatty Acid Omega Oxidation,CP:WIKIPATHWAYS,C2,25,36
Cohort,0.07710134200526088,0.07006756985236061,1.1003855587930498,0.2714816710833083,LGP Proband,Fatty Acid Omega Oxidation,CP:WIKIPATHWAYS,C2,25,64
Cohort,-0.016141509204237722,0.023113341644823975,-0.698363285252285,0.4851539973632123,LonGen OPEL,Fatty Acid Omega Oxidation,CP:WIKIPATHWAYS,C2,37,37
Cohort,-0.0010677262307866695,0.014178922784436656,-0.07530376228288992,0.9399953070127431,LGP Offspring,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma,CP:WIKIPATHWAYS,C2,6,14
Cohort,-0.04510768505139323,0.03636267793381946,-1.2404940343912456,0.2151415785533329,LGP Proband,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma,CP:WIKIPATHWAYS,C2,6,16
Cohort,-0.010148208040592048,0.01194847729524351,-0.8493306544284,0.39595268850122256,LonGen OPEL,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma,CP:WIKIPATHWAYS,C2,12,10
Cohort,0.031004977120577242,0.040631505980438805,0.7630772321238584,0.44568354163616597,LGP Offspring,Ferroptosis,CP:WIKIPATHWAYS,C2,46,116
Cohort,0.10209683062599073,0.10344021727067505,0.9870129174113291,0.3239225617532605,LGP Proband,Ferroptosis,CP:WIKIPATHWAYS,C2,46,130
Cohort,-0.008450624250606558,0.029917017622421337,-0.2824688061243521,0.7776574929179406,LonGen OPEL,Ferroptosis,CP:WIKIPATHWAYS,C2,67,75
Cohort,0.019888467996121185,0.029590388653488987,0.6721259470100318,0.501733166819208,LGP Offspring,FGF23 signalling in Hypophosphatemic rickets and related disorders,CP:WIKIPATHWAYS,C2,25,64
Cohort,0.1519736225211211,0.08939492814054097,1.70002510972656,0.08949905288587036,LGP Proband,FGF23 signalling in Hypophosphatemic rickets and related disorders,CP:WIKIPATHWAYS,C2,25,90
Cohort,-0.02418232410222577,0.025283962245141945,-0.9564293708306006,0.33914573029231243,LonGen OPEL,FGF23 signalling in Hypophosphatemic rickets and related disorders,CP:WIKIPATHWAYS,C2,46,47
Cohort,0.011677829626866818,0.022122574195811935,0.52786938461608,0.5977632163334907,LGP Offspring,FGFR3 signalling in chondrocyte proliferation and terminal differentiation,CP:WIKIPATHWAYS,C2,15,36
Cohort,0.10428164775595586,0.06205023480083692,1.6806003730794798,0.0932150173545193,LGP Proband,FGFR3 signalling in chondrocyte proliferation and terminal differentiation,CP:WIKIPATHWAYS,C2,15,50
Cohort,-0.036331869593191415,0.01846042223034067,-1.9680952656368869,0.04940378646712354,LonGen OPEL,FGFR3 signalling in chondrocyte proliferation and terminal differentiation,CP:WIKIPATHWAYS,C2,30,21
Cohort,-0.0552102961852776,0.03174412078214047,-1.7392290233579066,0.08244968359121942,LGP Offspring,Fibrin Complement Receptor 3 Signaling Pathway,CP:WIKIPATHWAYS,C2,39,51
Cohort,-0.03400698002007219,0.08233111976549755,-0.4130513482257225,0.6796751649471543,LGP Proband,Fibrin Complement Receptor 3 Signaling Pathway,CP:WIKIPATHWAYS,C2,39,68
Cohort,-0.03303386477789681,0.02827285858079203,-1.1683949354997059,0.24299730540153364,LonGen OPEL,Fibrin Complement Receptor 3 Signaling Pathway,CP:WIKIPATHWAYS,C2,54,49
Cohort,0.001628412192843417,0.016860818251486005,0.09657966585933035,0.9230888302398974,LGP Offspring,Fluoroacetic acid toxicity,CP:WIKIPATHWAYS,C2,8,19
Cohort,0.035875121262183465,0.051010675483697435,0.7032865360437903,0.48207347782658005,LGP Proband,Fluoroacetic acid toxicity,CP:WIKIPATHWAYS,C2,8,34
Cohort,0.035225094172403375,0.016155289670482034,2.180406225507954,0.029519557873843093,LonGen OPEL,Fluoroacetic acid toxicity,CP:WIKIPATHWAYS,C2,12,29
Cohort,-0.05592772550584147,0.034950506435306714,-1.6001978572002533,0.1100219097660353,LGP Offspring,Fluoropyrimidine Activity,CP:WIKIPATHWAYS,C2,46,73
Cohort,0.050512280589035514,0.10529913042337721,0.47970273245315803,0.6315645566443151,LGP Proband,Fluoropyrimidine Activity,CP:WIKIPATHWAYS,C2,46,125
Cohort,-0.017849808199402625,0.03210372540792412,-0.5560042634490258,0.578364187794941,LonGen OPEL,Fluoropyrimidine Activity,CP:WIKIPATHWAYS,C2,71,83
Cohort,-0.051240792701853596,0.10303755439977673,-0.4973021050465133,0.6191377335023391,LGP Offspring,Focal Adhesion,CP:WIKIPATHWAYS,C2,343,689
Cohort,-0.6309828473194738,0.2830591180672264,-2.229155702977976,0.026069213923251792,LGP Proband,Focal Adhesion,CP:WIKIPATHWAYS,C2,343,895
Cohort,-0.10906605456711577,0.08769170248309618,-1.2437442936877612,0.21395983815521205,LonGen OPEL,Focal Adhesion,CP:WIKIPATHWAYS,C2,538,612
Cohort,-0.14351639096343452,0.10526855588159499,-1.3633358010996208,0.1732305754054006,LGP Offspring,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,CP:WIKIPATHWAYS,C2,363,700
Cohort,-0.6523406277089074,0.29714685046386585,-2.1953476090712747,0.028413523180492457,LGP Proband,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,CP:WIKIPATHWAYS,C2,363,972
Cohort,-0.17480665355297006,0.09509157695464815,-1.8382979770788772,0.06639095163819074,LonGen OPEL,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway,CP:WIKIPATHWAYS,C2,587,641
Cohort,-0.010046679816029571,0.05042778784958782,-0.19922904105958497,0.8421434918447911,LGP Offspring,Folate Metabolism,CP:WIKIPATHWAYS,C2,74,147
Cohort,-0.06429681449824061,0.1393526727521728,-0.4613963494807679,0.6446345803678912,LGP Proband,Folate Metabolism,CP:WIKIPATHWAYS,C2,74,206
Cohort,0.03429216884681232,0.04112077604875932,0.8339377838139552,0.4045662238317328,LonGen OPEL,Folate Metabolism,CP:WIKIPATHWAYS,C2,114,144
Cohort,-0.01946044125850801,0.011407738556343848,-1.7058982516465586,0.08848636612474141,LGP Offspring,Folate-Alcohol and Cancer Pathway Hypotheses,CP:WIKIPATHWAYS,C2,7,6
Cohort,-0.034827019525270994,0.041607735391236286,-0.8370323257873464,0.4028141775735008,LGP Proband,Folate-Alcohol and Cancer Pathway Hypotheses,CP:WIKIPATHWAYS,C2,7,23
Cohort,-0.013898110728629951,0.013307228909303538,-1.0444030701924205,0.2966160052146071,LonGen OPEL,Folate-Alcohol and Cancer Pathway Hypotheses,CP:WIKIPATHWAYS,C2,14,13
Cohort,-0.004038099523323767,0.020237492680282698,-0.19953556436653194,0.841903830432148,LGP Offspring,Follicle Stimulating Hormone (FSH) signaling pathway,CP:WIKIPATHWAYS,C2,16,27
Cohort,-0.03919884244117356,0.05830572278786854,-0.6722983708441314,0.5015799732850907,LGP Proband,Follicle Stimulating Hormone (FSH) signaling pathway,CP:WIKIPATHWAYS,C2,16,36
Cohort,-0.022025028231255264,0.016145468366385498,-1.364161616835525,0.1729022788680436,LonGen OPEL,Follicle Stimulating Hormone (FSH) signaling pathway,CP:WIKIPATHWAYS,C2,22,19
Cohort,-0.11382827379646988,0.06719045520204331,-1.6941137465758422,0.09070429119080096,LGP Offspring,Fragile X Syndrome ,CP:WIKIPATHWAYS,C2,154,279
Cohort,0.10082236083178445,0.1908529563857889,0.5282724603331939,0.5974507781609808,LGP Proband,Fragile X Syndrome ,CP:WIKIPATHWAYS,C2,154,381
Cohort,-0.018326077370103135,0.05764313984298416,-0.3179229552731179,0.750626763701686,LonGen OPEL,Fragile X Syndrome ,CP:WIKIPATHWAYS,C2,218,256
Cohort,0.009439955752693676,0.024115169142159255,0.39145301851481973,0.6955857667441023,LGP Offspring,FTO Obesity Variant Mechanism,CP:WIKIPATHWAYS,C2,20,41
Cohort,-0.03618246481861517,0.05618896184489426,-0.6439425757410212,0.5197897145734789,LGP Proband,FTO Obesity Variant Mechanism,CP:WIKIPATHWAYS,C2,20,31
Cohort,-0.017042021550972692,0.017361141114175208,-0.981618744925588,0.32658596232834103,LonGen OPEL,FTO Obesity Variant Mechanism,CP:WIKIPATHWAYS,C2,27,21
Cohort,-0.020332257056284896,0.03685892724520681,-0.5516236791435359,0.581388502640632,LGP Offspring,G Protein Signaling Pathways,CP:WIKIPATHWAYS,C2,44,87
Cohort,0.15668864582947034,0.11775984499349361,1.3305778878880794,0.18369162506118386,LGP Proband,G Protein Signaling Pathways,CP:WIKIPATHWAYS,C2,44,165
Cohort,-0.0281752058830047,0.03537370717525534,-0.7965013602734251,0.42597817223409984,LonGen OPEL,G Protein Signaling Pathways,CP:WIKIPATHWAYS,C2,90,102
Cohort,-0.07997451762633821,0.044899349459739654,-1.7811954647149122,0.07532943996389943,LGP Offspring,G1 to S cell cycle control,CP:WIKIPATHWAYS,C2,77,122
Cohort,-0.03477632055193567,0.12375606430665832,-0.28100700152973945,0.7787747279938085,LGP Proband,G1 to S cell cycle control,CP:WIKIPATHWAYS,C2,77,172
Cohort,0.045231624368440616,0.03899116433746821,1.160048055425103,0.2463770605601869,LonGen OPEL,G1 to S cell cycle control,CP:WIKIPATHWAYS,C2,99,128
Cohort,-0.021511914766900658,0.02895258075512595,-0.743005086449575,0.4577367244810442,LGP Offspring,G13 Signaling Pathway,CP:WIKIPATHWAYS,C2,32,56
Cohort,-0.053911537787616134,0.07927948860959623,-0.6800187379247363,0.4966813075323977,LGP Proband,G13 Signaling Pathway,CP:WIKIPATHWAYS,C2,32,74
Cohort,0.024148501463549278,0.028680211852643706,0.8419917393784279,0.40004547097645893,LonGen OPEL,G13 Signaling Pathway,CP:WIKIPATHWAYS,C2,51,69
Cohort,0.033084005346721124,0.024159495784180543,1.3693996614111577,0.17132913052795182,LGP Offspring,GABA receptor Signaling,CP:WIKIPATHWAYS,C2,12,40
Cohort,-0.04855347322428381,0.06350477163059076,-0.7645641733304841,0.444747379187878,LGP Proband,GABA receptor Signaling,CP:WIKIPATHWAYS,C2,12,53
Cohort,0.01162970084546304,0.022526979259603015,0.5162565611412555,0.6058186096948909,LonGen OPEL,GABA receptor Signaling,CP:WIKIPATHWAYS,C2,31,41
Cohort,-0.006306834906308592,0.025514518781086785,-0.24718612020163502,0.8048392385146718,LGP Offspring,Galanin receptor pathway,CP:WIKIPATHWAYS,C2,22,40
Cohort,0.009361942864904165,0.06729120199104582,0.1391258082468184,0.8893843220739921,LGP Proband,Galanin receptor pathway,CP:WIKIPATHWAYS,C2,22,49
Cohort,-0.021202025493060016,0.022248610385771604,-0.952959538840192,0.34089985234900333,LonGen OPEL,Galanin receptor pathway,CP:WIKIPATHWAYS,C2,40,34
Cohort,0.010215659179770527,0.021350274465963718,0.4784790563726089,0.6324639864929563,LGP Offspring,"Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases",CP:WIKIPATHWAYS,C2,13,35
Cohort,0.002323779971106294,0.05591754100915315,0.04155726323383774,0.9668615892817379,LGP Proband,"Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases",CP:WIKIPATHWAYS,C2,13,36
Cohort,-0.016724769104589907,0.016785472284889965,-0.996383588184486,0.3193665911278573,LonGen OPEL,"Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases",CP:WIKIPATHWAYS,C2,23,19
Cohort,0.002459092030239425,0.019554484290779085,0.1257559132561225,0.8999625312178842,LGP Offspring,Ganglio Sphingolipid Metabolism,CP:WIKIPATHWAYS,C2,11,26
Cohort,-0.03434614731610634,0.0484501334735347,-0.7088968564940593,0.478586592090267,LGP Proband,Ganglio Sphingolipid Metabolism,CP:WIKIPATHWAYS,C2,11,29
Cohort,0.017874619228421842,0.017225177722841253,1.0377030365683486,0.29972344701927667,LonGen OPEL,Ganglio Sphingolipid Metabolism,CP:WIKIPATHWAYS,C2,19,28
Cohort,-3.0136342124528715e-4,0.008450844750107371,-0.035660745186622704,0.9715633987819033,LGP Offspring,Gastric acid production,CP:WIKIPATHWAYS,C2,2,5
Cohort,0.0011399208752408965,0.01111612592180868,0.10254659611263403,0.9183474801090659,LGP Proband,Gastric acid production,CP:WIKIPATHWAYS,C2,2,0
Cohort,0.0037363688498811666,0.003626112929853436,1.030406091084479,0.3031323949391715,LonGen OPEL,Gastric acid production,CP:WIKIPATHWAYS,C2,0,2
Cohort,-0.058322685400557565,0.028613799938072226,-2.038271237192654,0.041911502923446364,LGP Offspring,Gastric Cancer Network 1,CP:WIKIPATHWAYS,C2,34,43
Cohort,0.1263283898469217,0.08316784795776652,1.51895706031822,0.1291522853583647,LGP Proband,Gastric Cancer Network 1,CP:WIKIPATHWAYS,C2,34,81
Cohort,-0.003989873390020374,0.026621931682636817,-0.149871671131311,0.8809038276926182,LonGen OPEL,Gastric Cancer Network 1,CP:WIKIPATHWAYS,C2,50,59
Cohort,-0.05708501690130347,0.0351189201906677,-1.62547756569329,0.10452692186792106,LGP Offspring,Gastric Cancer Network 2,CP:WIKIPATHWAYS,C2,44,73
Cohort,0.08206545077979677,0.09439807856023101,0.869355097386168,0.3849030552078325,LGP Proband,Gastric Cancer Network 2,CP:WIKIPATHWAYS,C2,44,106
Cohort,-0.04514865413210891,0.030457582204173564,-1.4823453099281876,0.1386442096158032,LonGen OPEL,Gastric Cancer Network 2,CP:WIKIPATHWAYS,C2,76,68
Cohort,0.055654055774360625,0.05296854903820327,1.050700024541364,0.2937718432727015,LGP Offspring,Gastrin Signaling Pathway,CP:WIKIPATHWAYS,C2,79,188
Cohort,-0.12986681922674748,0.13608336316374328,-0.9543181194786045,0.34019915341173534,LGP Proband,Gastrin Signaling Pathway,CP:WIKIPATHWAYS,C2,79,212
Cohort,-0.009703491442919588,0.043575863335512874,-0.22268041755610074,0.8238413685891519,LonGen OPEL,Gastrin Signaling Pathway,CP:WIKIPATHWAYS,C2,131,152
Cohort,-0.018068848438785,0.02298879853463607,-0.7859848965817666,0.4321517483136811,LGP Offspring,GDNF/RET signalling axis,CP:WIKIPATHWAYS,C2,19,34
Cohort,-0.10183414593394224,0.06479956728219362,-1.5715250919881594,0.1164400098998686,LGP Proband,GDNF/RET signalling axis,CP:WIKIPATHWAYS,C2,19,53
Cohort,-0.02260232016036058,0.021366798296958957,-1.057824379967001,0.2904564252600557,LonGen OPEL,GDNF/RET signalling axis,CP:WIKIPATHWAYS,C2,37,33
Cohort,0.004376594960441591,0.017501906121091964,0.2500639033349203,0.8026139039968131,LGP Offspring,Gene regulatory network modelling somitogenesis ,CP:WIKIPATHWAYS,C2,8,23
Cohort,-0.041037283977917456,0.04379457799898075,-0.9370402879295363,0.34900909661437807,LGP Proband,Gene regulatory network modelling somitogenesis ,CP:WIKIPATHWAYS,C2,8,22
Cohort,6.900527147658104e-4,0.01716596931303403,0.04019887850095695,0.9679446517902048,LonGen OPEL,Gene regulatory network modelling somitogenesis ,CP:WIKIPATHWAYS,C2,21,23
Cohort,-0.0468737434786626,0.03324006123593737,-1.4101581566277388,0.15895292809555384,LGP Offspring,Genes controlling nephrogenesis,CP:WIKIPATHWAYS,C2,44,68
Cohort,-0.200150478157256,0.09150970666379485,-2.187204892838369,0.029004612462943863,LGP Proband,Genes controlling nephrogenesis,CP:WIKIPATHWAYS,C2,44,93
Cohort,-0.007217583940788084,0.029123765109245095,-0.24782454856762057,0.8043340733129631,LonGen OPEL,Genes controlling nephrogenesis,CP:WIKIPATHWAYS,C2,58,71
Cohort,-0.027241246020667347,0.06720261743024121,-0.40535989612227175,0.6853412395840257,LGP Offspring,Genes involved in male infertility,CP:WIKIPATHWAYS,C2,149,294
Cohort,-0.3076445523441955,0.182823561271598,-1.682740179681582,0.09279968797147753,LGP Proband,Genes involved in male infertility,CP:WIKIPATHWAYS,C2,149,440
Cohort,0.043099500590349615,0.0614869385094342,0.7009537575811597,0.4835367242410583,LonGen OPEL,Genes involved in male infertility,CP:WIKIPATHWAYS,C2,265,314
Cohort,-0.021343974378023805,0.06463336522433483,-0.33023151902955034,0.7413273469274866,LGP Offspring,Genes related to primary cilium development (based on CRISPR),CP:WIKIPATHWAYS,C2,130,273
Cohort,-0.054905415134121935,0.18362538595306702,-0.29900775891714265,0.7650086161802412,LGP Proband,Genes related to primary cilium development (based on CRISPR),CP:WIKIPATHWAYS,C2,130,408
Cohort,0.057284717541132645,0.059765843738078195,0.9584858835454745,0.3381088339792593,LonGen OPEL,Genes related to primary cilium development (based on CRISPR),CP:WIKIPATHWAYS,C2,229,299
Cohort,-0.012658431447940134,0.012307693643874618,-1.0284974434865035,0.3040837487226808,LGP Offspring,Genes targeted by miRNAs in adipocytes,CP:WIKIPATHWAYS,C2,6,9
Cohort,0.017036392186904777,0.03223702558416642,0.5284728314163201,0.597311795784657,LGP Proband,Genes targeted by miRNAs in adipocytes,CP:WIKIPATHWAYS,C2,6,11
Cohort,0.004981429506948072,0.010535931043818818,0.4728039208144361,0.6364826879381388,LonGen OPEL,Genes targeted by miRNAs in adipocytes,CP:WIKIPATHWAYS,C2,6,11
Cohort,-0.026858710005260217,0.032005527529679424,-0.8391897299725352,0.4016595101090271,LGP Offspring,Genotoxicity pathway,CP:WIKIPATHWAYS,C2,38,66
Cohort,-0.0437907502959744,0.09149498063109057,-0.47861368999617043,0.6323389228026974,LGP Proband,Genotoxicity pathway,CP:WIKIPATHWAYS,C2,38,95
Cohort,0.02073905477611787,0.02940671237616575,0.7052490095059709,0.48086160242898035,LonGen OPEL,Genotoxicity pathway,CP:WIKIPATHWAYS,C2,56,79
Cohort,-0.006469490800557852,0.011882014567899784,-0.5444776021429649,0.5862924102753844,LGP Offspring,Glial Cell Differentiation,CP:WIKIPATHWAYS,C2,5,9
Cohort,0.03498879381882019,0.038216345325745825,0.9155452600342902,0.36017009135637534,LGP Proband,Glial Cell Differentiation,CP:WIKIPATHWAYS,C2,5,19
Cohort,-0.009290767499258711,0.012468564058267035,-0.7451353223869152,0.45640986623675905,LonGen OPEL,Glial Cell Differentiation,CP:WIKIPATHWAYS,C2,14,10
Cohort,-0.013483841584337419,0.025498127617931767,-0.5288169306539511,0.5971060327151043,LGP Offspring,Globo Sphingolipid Metabolism,CP:WIKIPATHWAYS,C2,22,41
Cohort,-0.1341503631312701,0.06571457220369913,-2.0414096696153896,0.04152437960789659,LGP Proband,Globo Sphingolipid Metabolism,CP:WIKIPATHWAYS,C2,22,48
Cohort,0.01438723826227604,0.021029915937967224,0.6841319910509698,0.4940909397581853,LonGen OPEL,Globo Sphingolipid Metabolism,CP:WIKIPATHWAYS,C2,29,38
Cohort,-0.01577933156023836,0.030665459313294043,-0.5145636789271155,0.6070261374160766,LGP Offspring,Glucocorticoid Receptor Pathway,CP:WIKIPATHWAYS,C2,37,69
Cohort,0.15077742194723903,0.09033752627780721,1.6690452811776826,0.09548371014799505,LGP Proband,Glucocorticoid Receptor Pathway,CP:WIKIPATHWAYS,C2,37,104
Cohort,-0.013585675525173624,0.027312298204036748,-0.49741971267601587,0.6190304775859475,LonGen OPEL,Glucocorticoid Receptor Pathway,CP:WIKIPATHWAYS,C2,54,63
Cohort,-0.022197306371786348,0.039685313607152724,-0.5593330215686035,0.5761197220991054,LGP Offspring,Glucuronidation,CP:WIKIPATHWAYS,C2,24,48
Cohort,0.02750659140546162,0.11742201592973427,0.23425412336577203,0.8148451927717348,LGP Proband,Glucuronidation,CP:WIKIPATHWAYS,C2,24,55
Cohort,0.027100865075245343,0.031422077439541035,0.8624784636658699,0.3886840426826308,LonGen OPEL,Glucuronidation,CP:WIKIPATHWAYS,C2,27,48
Cohort,-0.038395469601826625,0.033257619411439725,-1.1544864088684477,0.24870876271996353,LGP Offspring,Glutathione metabolism,CP:WIKIPATHWAYS,C2,38,64
Cohort,-0.011941237950952213,0.08664116742964692,-0.13782406568619426,0.8904127317203432,LGP Proband,Glutathione metabolism,CP:WIKIPATHWAYS,C2,38,73
Cohort,-0.0015384230119529288,0.026085312978924666,-0.05897659779646425,0.9529855502707775,LonGen OPEL,Glutathione metabolism,CP:WIKIPATHWAYS,C2,49,56
Cohort,-0.03976752394301906,0.027187871980194196,-1.4626935117242306,0.14401601643825912,LGP Offspring,Glycerolipids and Glycerophospholipids,CP:WIKIPATHWAYS,C2,28,44
Cohort,-0.059398137924714225,0.07754262874371617,-0.7660062456875074,0.4438893257349249,LGP Proband,Glycerolipids and Glycerophospholipids,CP:WIKIPATHWAYS,C2,28,73
Cohort,0.014337194685202606,0.025108648648210823,0.5710062252284628,0.5681565900483717,LonGen OPEL,Glycerolipids and Glycerophospholipids,CP:WIKIPATHWAYS,C2,43,56
Cohort,-0.00645266930263284,0.022747984959291048,-0.2836589400854756,0.7767586161565974,LGP Offspring,Glycerophospholipid Biosynthetic Pathway,CP:WIKIPATHWAYS,C2,18,34
Cohort,0.04121359318369084,0.06604720043296332,0.6240021214150003,0.5327968303848365,LGP Proband,Glycerophospholipid Biosynthetic Pathway,CP:WIKIPATHWAYS,C2,18,54
Cohort,-3.2430629405970254e-4,0.021584534055655417,-0.015024938375944707,0.9880160496400519,LonGen OPEL,Glycerophospholipid Biosynthetic Pathway,CP:WIKIPATHWAYS,C2,29,33
Cohort,0.019443444345747646,0.04152979405903335,0.46818061072273504,0.639806349174201,LGP Offspring,Glycogen Synthesis and Degradation,CP:WIKIPATHWAYS,C2,56,128
Cohort,0.0327161036789648,0.11340867126393653,0.288479737169519,0.773051220202825,LGP Proband,Glycogen Synthesis and Degradation,CP:WIKIPATHWAYS,C2,56,168
Cohort,-0.010471207039184798,0.035120991194515755,-0.2981466833094365,0.765669017402583,LonGen OPEL,Glycogen Synthesis and Degradation,CP:WIKIPATHWAYS,C2,90,103
Cohort,0.028817320417589862,0.04509375875509574,0.6390534125597461,0.5230046557858188,LGP Offspring,Glycolysis and Gluconeogenesis,CP:WIKIPATHWAYS,C2,60,144
Cohort,-0.0383914965815032,0.11305412394917104,-0.33958510526129904,0.7342544931611494,LGP Proband,Glycolysis and Gluconeogenesis,CP:WIKIPATHWAYS,C2,60,163
Cohort,0.011798305874991246,0.03758901672008228,0.3138764166897692,0.7536971394543428,LonGen OPEL,Glycolysis and Gluconeogenesis,CP:WIKIPATHWAYS,C2,88,112
Cohort,-0.009913450227695896,0.017032983170054448,-0.5820149135780662,0.5607506792530572,LGP Offspring,Glycolysis in senescence,CP:WIKIPATHWAYS,C2,9,18
Cohort,0.14830472034114114,0.04755009997984971,3.118915005520245,0.0018775589060422739,LGP Proband,Glycolysis in senescence,CP:WIKIPATHWAYS,C2,9,23
Cohort,-0.00723833119298524,0.015855218805297114,-0.4565267298970965,0.6481357947012212,LonGen OPEL,Glycolysis in senescence,CP:WIKIPATHWAYS,C2,18,17
Cohort,0.01113916468256771,0.01844592286466905,0.6038822109520713,0.5461245458279568,LGP Offspring,Glycosaminoglycan degradation,CP:WIKIPATHWAYS,C2,9,26
Cohort,0.006391665401450202,0.052381094547840464,0.12202237193826858,0.9029106953984316,LGP Proband,Glycosaminoglycan degradation,CP:WIKIPATHWAYS,C2,9,39
Cohort,0.004163161348205907,0.01944797210272835,0.21406660428219446,0.8305499398745472,LonGen OPEL,Glycosaminoglycan degradation,CP:WIKIPATHWAYS,C2,24,32
Cohort,0.018726090922143758,0.023574183639179236,0.7943473762977664,0.42727199845676833,LGP Offspring,Glycosylation and related congenital defects,CP:WIKIPATHWAYS,C2,13,38
Cohort,0.029783663754267886,0.07194861094619506,0.4139574532792696,0.6790116990657948,LGP Proband,Glycosylation and related congenital defects,CP:WIKIPATHWAYS,C2,13,70
Cohort,0.016816803552634957,0.021490297154268798,0.7825300614465674,0.4341358514469489,LonGen OPEL,Glycosylation and related congenital defects,CP:WIKIPATHWAYS,C2,25,38
Cohort,-0.03876232553077739,0.07074942382433799,-0.5478818545154434,0.5839538862057145,LGP Offspring,"GPCRs, Class A Rhodopsin-like",CP:WIKIPATHWAYS,C2,162,308
Cohort,-0.531504715903044,0.19133601647358497,-2.7778602570437716,0.00559467978841447,LGP Proband,"GPCRs, Class A Rhodopsin-like",CP:WIKIPATHWAYS,C2,162,430
Cohort,-0.01106878846723736,0.05649696631883037,-0.19591828001476508,0.8447241320029582,LonGen OPEL,"GPCRs, Class A Rhodopsin-like",CP:WIKIPATHWAYS,C2,242,278
Cohort,-0.01052880587234132,0.03024555203805016,-0.3481108845061133,0.7278652840532087,LGP Offspring,"GPCRs, Class B Secretin-like",CP:WIKIPATHWAYS,C2,29,58
Cohort,-0.020560201104636605,0.07490644134954345,-0.2744784124598107,0.7837849645488255,LGP Proband,"GPCRs, Class B Secretin-like",CP:WIKIPATHWAYS,C2,29,62
Cohort,0.03786870961927086,0.023701999669390805,1.5977010441095905,0.11050638920245473,LonGen OPEL,"GPCRs, Class B Secretin-like",CP:WIKIPATHWAYS,C2,30,55
Cohort,-0.026575885275316232,0.028044738502746087,-0.9476246417028981,0.3436591971458668,LGP Offspring,"GPCRs, Class C Metabotropic glutamate, pheromone",CP:WIKIPATHWAYS,C2,26,49
Cohort,0.015712810368551426,0.06699315107740594,0.23454353341875742,0.8146206087281478,LGP Proband,"GPCRs, Class C Metabotropic glutamate, pheromone",CP:WIKIPATHWAYS,C2,26,53
Cohort,0.017472554898265404,0.020155498298733563,0.8668877662708673,0.3862647420508051,LonGen OPEL,"GPCRs, Class C Metabotropic glutamate, pheromone",CP:WIKIPATHWAYS,C2,26,36
Cohort,0.0483947143032898,0.053226321556434635,0.9092252270707456,0.36355529631501915,LGP Offspring,"GPCRs, Other",CP:WIKIPATHWAYS,C2,83,189
Cohort,-0.10954091602822741,0.14764456395028988,-0.7419231233268331,0.4583427958639156,LGP Proband,"GPCRs, Other",CP:WIKIPATHWAYS,C2,83,257
Cohort,0.038101805292625184,0.04577129283064283,0.8324389139193573,0.4054109185119632,LonGen OPEL,"GPCRs, Other",CP:WIKIPATHWAYS,C2,121,167
Cohort,-0.07906423884385667,0.03025426235688704,-2.6133256171046124,0.009166050453212338,LGP Offspring,GPR40 Pathway,CP:WIKIPATHWAYS,C2,40,51
Cohort,0.050648106527343674,0.08927066920661196,0.5673543950938854,0.5706261068916945,LGP Proband,GPR40 Pathway,CP:WIKIPATHWAYS,C2,40,89
Cohort,0.06398891909924086,0.022368975902037604,2.860610131615908,0.004338997066501063,LonGen OPEL,GPR40 Pathway,CP:WIKIPATHWAYS,C2,22,56
Cohort,0.012423185749022497,0.017188063869556295,0.7227798222827524,0.4700651464434986,LGP Offspring,H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity,CP:WIKIPATHWAYS,C2,7,23
Cohort,-0.0023830177624355247,0.04511447165526294,-0.05282158196698128,0.957886714816051,LGP Proband,H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity,CP:WIKIPATHWAYS,C2,7,27
Cohort,0.006830351143620027,0.01660752396815797,0.41128052301571466,0.6809775544829723,LonGen OPEL,H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity,CP:WIKIPATHWAYS,C2,18,23
Cohort,0.04517810972895397,0.04603745801168732,0.9813337156340127,0.3267792758512479,LGP Offspring,Hair Follicle Development: Cytodifferentiation - Part 3 of 3,CP:WIKIPATHWAYS,C2,59,147
Cohort,0.05963812070763344,0.12544773191963843,0.4754021439449978,0.6346248503216214,LGP Proband,Hair Follicle Development: Cytodifferentiation - Part 3 of 3,CP:WIKIPATHWAYS,C2,59,206
Cohort,0.015026572663065577,0.041888288793337614,0.35872968545460304,0.7198924422849202,LonGen OPEL,Hair Follicle Development: Cytodifferentiation - Part 3 of 3,CP:WIKIPATHWAYS,C2,120,141
Cohort,-0.008650223806533368,0.035806110999750757,-0.24158512513670033,0.809174911516728,LGP Offspring,Hair Follicle Development: Organogenesis - Part 2 of 3,CP:WIKIPATHWAYS,C2,41,85
Cohort,0.0920990502467258,0.09211083277818304,0.9998720831079053,0.3176624247871989,LGP Proband,Hair Follicle Development: Organogenesis - Part 2 of 3,CP:WIKIPATHWAYS,C2,41,101
Cohort,0.02953203668719543,0.027391843135900786,1.0781325134156317,0.28130122745489955,LonGen OPEL,Hair Follicle Development: Organogenesis - Part 2 of 3,CP:WIKIPATHWAYS,C2,52,71
Cohort,-0.13339867526834098,0.0524017400688674,-2.5456917097223455,0.011127035008979526,LGP Offspring,Head and Neck Squamous Cell Carcinoma,CP:WIKIPATHWAYS,C2,105,174
Cohort,0.13991313973102196,0.1444142165794564,0.96883217625629,0.3329098022616265,LGP Proband,Head and Neck Squamous Cell Carcinoma,CP:WIKIPATHWAYS,C2,105,239
Cohort,-0.028536904286044853,0.04340594812119708,-0.657442252070264,0.5110866469237201,LonGen OPEL,Head and Neck Squamous Cell Carcinoma,CP:WIKIPATHWAYS,C2,136,155
Cohort,0.017439907196737044,0.02909976403674884,0.5993143853232946,0.5491640552179085,LGP Offspring,Heart Development,CP:WIKIPATHWAYS,C2,22,54
Cohort,0.06270200793049167,0.07192541644224013,0.8717642668199866,0.38358787760033286,LGP Proband,Heart Development,CP:WIKIPATHWAYS,C2,22,59
Cohort,0.0017314288808840616,0.022476440162494893,0.07703305631882021,0.9386166057718481,LonGen OPEL,Heart Development,CP:WIKIPATHWAYS,C2,37,43
Cohort,-0.09637993593403461,0.043092604485650506,-2.2365771826608523,0.02563935002892572,LGP Offspring,Hedgehog Signaling Pathway,CP:WIKIPATHWAYS,C2,81,121
Cohort,-0.05974713122195795,0.12718929262352033,-0.4697496934652287,0.6386566550310444,LGP Proband,Hedgehog Signaling Pathway,CP:WIKIPATHWAYS,C2,81,184
Cohort,0.010062776484887844,0.03632370851258975,0.2770305372701716,0.7818285815033377,LonGen OPEL,Hedgehog Signaling Pathway,CP:WIKIPATHWAYS,C2,96,116
Cohort,-0.05176912756401773,0.027154936524063197,-1.9064352265431668,0.05701751382151818,LGP Offspring,Hedgehog Signaling Pathway Netpath,CP:WIKIPATHWAYS,C2,34,48
Cohort,0.020437883503483287,0.08567699528586499,0.23854575473020975,0.8115164321080801,LGP Proband,Hedgehog Signaling Pathway Netpath,CP:WIKIPATHWAYS,C2,34,83
Cohort,-0.02224827926849978,0.025080293616662957,-0.8870820895700507,0.37530264352225673,LonGen OPEL,Hedgehog Signaling Pathway Netpath,CP:WIKIPATHWAYS,C2,50,49
Cohort,-0.051726826137174976,0.033941534402547824,-1.5239978700931123,0.12797690613246632,LGP Offspring,Hematopoietic Stem Cell Differentiation,CP:WIKIPATHWAYS,C2,45,74
Cohort,0.06577787401715691,0.09195230376180054,0.7153477545005547,0.4745943962511717,LGP Proband,Hematopoietic Stem Cell Differentiation,CP:WIKIPATHWAYS,C2,45,96
Cohort,-0.022442720605988984,0.028834569610718726,-0.7783268801642287,0.43660762441341194,LonGen OPEL,Hematopoietic Stem Cell Differentiation,CP:WIKIPATHWAYS,C2,64,62
Cohort,0.053261746016373124,0.03191338140491092,1.6689471209771916,0.09559088194843449,LGP Offspring,Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex,CP:WIKIPATHWAYS,C2,29,73
Cohort,-0.16409620968650218,0.10063095157033301,-1.630673337832963,0.10333682325526812,LGP Proband,Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex,CP:WIKIPATHWAYS,C2,29,125
Cohort,-0.014386390159511426,0.030168469908166195,-0.4768684060976266,0.6335867158886602,LonGen OPEL,Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex,CP:WIKIPATHWAYS,C2,70,73
Cohort,0.007741689555863211,0.009619808494917722,0.8047654545257582,0.4212379812985404,LGP Offspring,Heme Biosynthesis,CP:WIKIPATHWAYS,C2,2,7
Cohort,0.004066101350117867,0.023472409032290833,0.17322897468786264,0.8625134826122827,LGP Proband,Heme Biosynthesis,CP:WIKIPATHWAYS,C2,2,7
Cohort,-0.005131624347834557,0.007750943809078555,-0.6620644497285567,0.5081215395270571,LonGen OPEL,Heme Biosynthesis,CP:WIKIPATHWAYS,C2,6,3
Cohort,-0.12067476810949607,0.06709461535465744,-1.7985760477441848,0.07253174908245238,LGP Offspring,Hepatitis B infection,CP:WIKIPATHWAYS,C2,152,277
Cohort,0.008800898902351811,0.18738758734959252,0.04696628537050722,0.9625513420326279,LGP Proband,Hepatitis B infection,CP:WIKIPATHWAYS,C2,152,373
Cohort,0.023189123584492002,0.0585499892319711,0.3960568377325957,0.6921692355533945,LonGen OPEL,Hepatitis B infection,CP:WIKIPATHWAYS,C2,227,273
Cohort,-0.0022576537473502204,0.04218705916340867,-0.05351531469888323,0.9573371394636571,LGP Offspring,Hepatitis C and Hepatocellular Carcinoma,CP:WIKIPATHWAYS,C2,52,102
Cohort,0.008734388022028479,0.1139961317319862,0.07662003867432719,0.9389441935648102,LGP Proband,Hepatitis C and Hepatocellular Carcinoma,CP:WIKIPATHWAYS,C2,52,154
Cohort,-5.061283621957937e-4,0.03520159423312341,-0.014377995463612991,0.9885320174674361,LonGen OPEL,Hepatitis C and Hepatocellular Carcinoma,CP:WIKIPATHWAYS,C2,86,100
Cohort,0.0107465018693773,0.03427533502477442,0.3135345536844399,0.7539712912140315,LGP Offspring,Hereditary leiomyomatosis and renal cell carcinoma pathway,CP:WIKIPATHWAYS,C2,31,74
Cohort,0.03413503436698928,0.08705365855788788,0.39211487411859414,0.6950735174632641,LGP Proband,Hereditary leiomyomatosis and renal cell carcinoma pathway,CP:WIKIPATHWAYS,C2,31,85
Cohort,-0.027931690441374724,0.026740865315815456,-1.0445320340795021,0.2965564049855722,LonGen OPEL,Hereditary leiomyomatosis and renal cell carcinoma pathway,CP:WIKIPATHWAYS,C2,52,51
Cohort,-0.005943196888818082,0.011471338947868283,-0.518090949611641,0.6045643319176505,LGP Offspring,Hfe effect on hepcidin production,CP:WIKIPATHWAYS,C2,6,8
Cohort,-0.013903427542680355,0.037555001230534193,-0.37021507354861,0.7113162437164191,LGP Proband,Hfe effect on hepcidin production,CP:WIKIPATHWAYS,C2,6,16
Cohort,0.004422765741167102,0.011792779000808528,0.37504016151442093,0.7077305016352315,LonGen OPEL,Hfe effect on hepcidin production,CP:WIKIPATHWAYS,C2,8,13
Cohort,0.009952279463349508,0.016721453304765262,0.5951802921647557,0.5519221425538854,LGP Offspring,HIF1A and PPARG regulation of glycolysis,CP:WIKIPATHWAYS,C2,7,21
Cohort,-0.05009050163260104,0.037413008801070124,-1.3388525338589794,0.18098349604024822,LGP Proband,HIF1A and PPARG regulation of glycolysis,CP:WIKIPATHWAYS,C2,7,16
Cohort,0.01654953064914412,0.012237095250025191,1.3524067853529254,0.1766292864474329,LonGen OPEL,HIF1A and PPARG regulation of glycolysis,CP:WIKIPATHWAYS,C2,7,16
Cohort,0.012685894518761924,0.00842203696175788,1.5062739069378381,0.13246399638427592,LGP Offspring,Hijack of Ubiquitination by SARS-CoV-2,CP:WIKIPATHWAYS,C2,0,7
Cohort,-0.0021013488721719916,0.01939452533641339,-0.10834752775447878,0.9137460835315194,LGP Proband,Hijack of Ubiquitination by SARS-CoV-2,CP:WIKIPATHWAYS,C2,0,6
Cohort,-2.1535342519170077e-4,0.004479813163676364,-0.0480719657993439,0.9616709468573486,LonGen OPEL,Hijack of Ubiquitination by SARS-CoV-2,CP:WIKIPATHWAYS,C2,2,1
Cohort,-0.0015474218820715963,0.06109049546106673,-0.025329993976849898,0.9797992251436662,LGP Offspring,Hippo-Merlin Signaling Dysregulation,CP:WIKIPATHWAYS,C2,132,263
Cohort,-0.07200490641083584,0.17627196775015225,-0.4084875623156119,0.683020618583988,LGP Proband,Hippo-Merlin Signaling Dysregulation,CP:WIKIPATHWAYS,C2,132,369
Cohort,-0.03474236025704343,0.05516683006070188,-0.6297690155264543,0.5290264397913031,LonGen OPEL,Hippo-Merlin Signaling Dysregulation,CP:WIKIPATHWAYS,C2,216,250
Cohort,0.004939931899126021,0.023424975699294207,0.2108831173419258,0.8330420306821011,LGP Offspring,Hippo-Yap signaling pathway,CP:WIKIPATHWAYS,C2,18,41
Cohort,0.08987602734831716,0.07176012746368698,1.2524507762865587,0.2107567397088705,LGP Proband,Hippo-Yap signaling pathway,CP:WIKIPATHWAYS,C2,18,65
Cohort,0.009391539229445465,0.021627097946509844,0.43424870283907235,0.6642255300962312,LonGen OPEL,Hippo-Yap signaling pathway,CP:WIKIPATHWAYS,C2,33,42
Cohort,-0.0370004436480864,0.043742059475298745,-0.8458779511508974,0.39792014420586774,LGP Offspring,Histone Modifications,CP:WIKIPATHWAYS,C2,68,124
Cohort,-0.03873175844872546,0.11708128503279228,-0.3308108416975217,0.7408704634475987,LGP Proband,Histone Modifications,CP:WIKIPATHWAYS,C2,68,155
Cohort,0.028075410343317512,0.037861298161195274,0.7415332201179649,0.45858891392813605,LonGen OPEL,Histone Modifications,CP:WIKIPATHWAYS,C2,92,114
Cohort,0.03329060111343255,0.02479250941083792,1.3427685177717321,0.17979762764904095,LGP Offspring,Homologous recombination,CP:WIKIPATHWAYS,C2,17,48
Cohort,-0.00751660289742726,0.069184720009637,-0.10864541905178259,0.9135098679730809,LGP Proband,Homologous recombination,CP:WIKIPATHWAYS,C2,17,60
Cohort,0.0035724312125435744,0.024005828943527825,0.14881515739146062,0.8817371819182434,LonGen OPEL,Homologous recombination,CP:WIKIPATHWAYS,C2,37,43
Cohort,0.0043318079606242885,0.01957181451379654,0.22132888892701877,0.8249031951727384,LGP Offspring,Host-pathogen interaction of human corona viruses - apoptosis,CP:WIKIPATHWAYS,C2,13,27
Cohort,1.5539897774343524e-4,0.04825801383817471,0.003220169364295432,0.9974314510907456,LGP Proband,Host-pathogen interaction of human corona viruses - apoptosis,CP:WIKIPATHWAYS,C2,13,27
Cohort,-0.0451890103292308,0.01682051620555413,-2.6865412319694086,0.007370137536877563,LonGen OPEL,Host-pathogen interaction of human corona viruses - apoptosis,CP:WIKIPATHWAYS,C2,29,14
Cohort,-0.007619197495469781,0.023187971291636005,-0.3285840490158816,0.7425718656264789,LGP Offspring,Host-pathogen interaction of human corona viruses - autophagy,CP:WIKIPATHWAYS,C2,19,36
Cohort,-0.047030792679177834,0.06659701361206848,-0.7061997247074016,0.4802611687692031,LGP Proband,Host-pathogen interaction of human corona viruses - autophagy,CP:WIKIPATHWAYS,C2,19,52
Cohort,0.013476178927176985,0.0176491298414104,0.7635605295144715,0.4453554265913352,LonGen OPEL,Host-pathogen interaction of human corona viruses - autophagy,CP:WIKIPATHWAYS,C2,21,28
Cohort,-0.06552434638088828,0.026707416201243263,-2.453413908974019,0.014402119014710566,LGP Offspring,Host-pathogen interaction of human corona viruses - Interferon induction,CP:WIKIPATHWAYS,C2,30,38
Cohort,-0.08936906656801111,0.08210987086133792,-1.088408319615215,0.2767293083338835,LGP Proband,Host-pathogen interaction of human corona viruses - Interferon induction,CP:WIKIPATHWAYS,C2,30,82
Cohort,-0.035281517401379275,0.024078187475952813,-1.4652895877904168,0.14323679078314835,LonGen OPEL,Host-pathogen interaction of human corona viruses - Interferon induction,CP:WIKIPATHWAYS,C2,46,39
Cohort,0.03263371692723607,0.026336845738611572,1.2390898003170085,0.21574228003821236,LGP Offspring,Host-pathogen interaction of human corona viruses - MAPK signaling,CP:WIKIPATHWAYS,C2,18,52
Cohort,0.12474596270506451,0.07665665226340979,1.6273338193325853,0.1040439311418782,LGP Proband,Host-pathogen interaction of human corona viruses - MAPK signaling,CP:WIKIPATHWAYS,C2,18,77
Cohort,-0.031176136057452154,0.022218553141430175,-1.4031577960546442,0.16095973195674596,LonGen OPEL,Host-pathogen interaction of human corona viruses - MAPK signaling,CP:WIKIPATHWAYS,C2,40,36
Cohort,-0.052417720361850724,0.054783849372575515,-0.9568097342953549,0.3390053459400517,LGP Offspring,Human Complement System,CP:WIKIPATHWAYS,C2,112,207
Cohort,-0.14119522737521412,0.16163842040868323,-0.8735251620141983,0.3826283419769174,LGP Proband,Human Complement System,CP:WIKIPATHWAYS,C2,112,294
Cohort,0.07432891972506649,0.04925971098406064,1.5089191195035168,0.13171625430354889,LonGen OPEL,Human Complement System,CP:WIKIPATHWAYS,C2,150,219
Cohort,-0.056303276028173664,0.03550585877941372,-1.5857460701899224,0.11326456486405269,LGP Offspring,Human Thyroid Stimulating Hormone (TSH) signaling pathway,CP:WIKIPATHWAYS,C2,46,78
Cohort,0.049900805983814044,0.09852616807771583,0.5064726149143759,0.6126587707981352,LGP Proband,Human Thyroid Stimulating Hormone (TSH) signaling pathway,CP:WIKIPATHWAYS,C2,46,109
Cohort,-0.030582144168845492,0.034605528944584435,-0.8837357815804003,0.37710569110842695,LonGen OPEL,Human Thyroid Stimulating Hormone (TSH) signaling pathway,CP:WIKIPATHWAYS,C2,83,84
Cohort,-0.018152203127231245,0.016577980937913416,-1.0949586198230945,0.27392473360552155,LGP Offspring,Hypertrophy Model,CP:WIKIPATHWAYS,C2,12,16
Cohort,-0.04921033242747457,0.04532245867875653,-1.085782498612335,0.27788896569970656,LGP Proband,Hypertrophy Model,CP:WIKIPATHWAYS,C2,12,23
Cohort,0.00775738574961511,0.014816919005968963,0.5235491768896128,0.6007378594165875,LonGen OPEL,Hypertrophy Model,CP:WIKIPATHWAYS,C2,14,18
Cohort,-8.836039155511018e-4,0.02877694744541346,-0.03070526911261857,0.9755136519661938,LGP Offspring,Hypothesized Pathways in Pathogenesis of Cardiovascular Disease,CP:WIKIPATHWAYS,C2,27,55
Cohort,0.004733963133515536,0.08380962197119052,0.05648472123096834,0.954969195926405,LGP Proband,Hypothesized Pathways in Pathogenesis of Cardiovascular Disease,CP:WIKIPATHWAYS,C2,27,88
Cohort,-0.006552353748821455,0.027649808748663154,-0.2369764582598878,0.812736026396314,LonGen OPEL,Hypothesized Pathways in Pathogenesis of Cardiovascular Disease,CP:WIKIPATHWAYS,C2,46,53
Cohort,0.004679425875463877,0.009574200823705532,0.48875367893659705,0.6251746148357646,LGP Offspring,Hypothetical Craniofacial Development Pathway,CP:WIKIPATHWAYS,C2,3,7
Cohort,0.04647495140312524,0.026102870076514104,1.7804536921378922,0.0753657025179646,LGP Proband,Hypothetical Craniofacial Development Pathway,CP:WIKIPATHWAYS,C2,3,9
Cohort,-0.004718255315722043,0.006845910096710268,-0.689207899179008,0.49089329232308365,LonGen OPEL,Hypothetical Craniofacial Development Pathway,CP:WIKIPATHWAYS,C2,4,3
Cohort,-0.01620553064184715,0.019313916561201624,-0.8390597831618113,0.4017323716950829,LGP Offspring,ID signaling pathway,CP:WIKIPATHWAYS,C2,13,25
Cohort,-0.07159483173239836,0.05685025790990492,-1.2593580814683432,0.2082533599037078,LGP Proband,ID signaling pathway,CP:WIKIPATHWAYS,C2,13,37
Cohort,0.005257506438486434,0.01907547575152375,0.27561600596338803,0.7829145468815288,LonGen OPEL,ID signaling pathway,CP:WIKIPATHWAYS,C2,22,31
Cohort,0.002027526572482476,0.03156824761001345,0.06422676980775278,0.9488086493668112,LGP Offspring,IL1 and megakaryocytes in obesity,CP:WIKIPATHWAYS,C2,30,67
Cohort,-0.056246085363523796,0.07811522603377923,-0.7200399745268791,0.4717021229147309,LGP Proband,IL1 and megakaryocytes in obesity,CP:WIKIPATHWAYS,C2,30,79
Cohort,0.014424048599099196,0.028047468622486464,0.5142727421588065,0.6072040593997416,LonGen OPEL,IL1 and megakaryocytes in obesity,CP:WIKIPATHWAYS,C2,55,64
Cohort,-0.05392754074013392,0.03835861734548367,-1.4058781174103852,0.16021977454569392,LGP Offspring,IL-1 signaling pathway,CP:WIKIPATHWAYS,C2,56,89
Cohort,-0.010616656228980635,0.10301016420222273,-0.10306416178639148,0.9179368246666251,LGP Proband,IL-1 signaling pathway,CP:WIKIPATHWAYS,C2,56,116
Cohort,-0.01941455838349944,0.034949885309610566,-0.5554970556129636,0.5787108053439927,LonGen OPEL,IL-1 signaling pathway,CP:WIKIPATHWAYS,C2,84,94
Cohort,0.03342146928496949,0.016008872207964642,2.0876841822962287,0.037200155296244757,LGP Offspring,IL-10 Anti-inflammatory Signaling Pathway ,CP:WIKIPATHWAYS,C2,4,22
Cohort,-0.030453750927709005,0.03641827186565786,-0.8362217471506838,0.40326968506389704,LGP Proband,IL-10 Anti-inflammatory Signaling Pathway ,CP:WIKIPATHWAYS,C2,4,18
Cohort,-0.005907829176853241,0.011728123763775918,-0.50373182410476125,0.6145892187241437,LonGen OPEL,IL-10 Anti-inflammatory Signaling Pathway ,CP:WIKIPATHWAYS,C2,11,10
Cohort,-0.021197974359707498,0.028675733066620062,-0.7392304256166676,0.46002369207772553,LGP Offspring,IL17 signaling pathway,CP:WIKIPATHWAYS,C2,25,52
Cohort,0.06440129766091518,0.0787174392293273,0.8181325293534393,0.4135151983145404,LGP Proband,IL17 signaling pathway,CP:WIKIPATHWAYS,C2,25,68
Cohort,-0.018215442231137146,0.028756819918967686,-0.6334303404363025,0.5266346075665028,LonGen OPEL,IL17 signaling pathway,CP:WIKIPATHWAYS,C2,56,58
Cohort,-0.07914166588893025,0.0796700972558315,-0.9933672559077669,0.3208864446180605,LGP Offspring,IL-18 signaling pathway,CP:WIKIPATHWAYS,C2,216,422
Cohort,0.028611856616274047,0.2303965216594181,0.12418528027332508,0.9011985004037972,LGP Proband,IL-18 signaling pathway,CP:WIKIPATHWAYS,C2,216,586
Cohort,-0.04158759178246663,0.06882642054850169,-0.6042387712602318,0.5458570809998736,LonGen OPEL,IL-18 signaling pathway,CP:WIKIPATHWAYS,C2,340,400
Cohort,-0.046405585827050184,0.027890813422492118,-1.6638304922877263,0.09660976287900766,LGP Offspring,IL-2 Signaling Pathway,CP:WIKIPATHWAYS,C2,31,45
Cohort,0.13248534113065485,0.07881395297609463,1.680988405325127,0.0931395908576297,LGP Proband,IL-2 Signaling Pathway,CP:WIKIPATHWAYS,C2,31,74
Cohort,-0.028960628233344984,0.025172340200960493,-1.15049407413618,0.2502859346664671,LonGen OPEL,IL-2 Signaling Pathway,CP:WIKIPATHWAYS,C2,47,43
Cohort,0.006149868457325464,0.026391707192477024,0.23302276023577925,0.815814269745736,LGP Offspring,IL-3 Signaling Pathway,CP:WIKIPATHWAYS,C2,24,47
Cohort,0.02523044335812263,0.0741015720063947,0.34048458993481723,0.733577369635854,LGP Proband,IL-3 Signaling Pathway,CP:WIKIPATHWAYS,C2,24,72
Cohort,-0.042527500013548235,0.025600354806437225,-1.6612074455645696,0.09706556647847792,LonGen OPEL,IL-3 Signaling Pathway,CP:WIKIPATHWAYS,C2,53,43
Cohort,0.030857853555513327,0.03826056790662576,0.8065184403645386,0.4202276223224223,LGP Offspring,IL-4 Signaling Pathway,CP:WIKIPATHWAYS,C2,42,94
Cohort,-0.023514705195400963,0.09965611702283458,-0.2359584729757527,0.8135228266570997,LGP Proband,IL-4 Signaling Pathway,CP:WIKIPATHWAYS,C2,42,119
Cohort,-0.008134945134545471,0.034058422338685675,-0.2388526706742166,0.8112813066139526,LonGen OPEL,IL-4 Signaling Pathway,CP:WIKIPATHWAYS,C2,75,82
Cohort,-0.012678239167171982,0.02617415641034453,-0.4843800490991678,0.6282730695132395,LGP Offspring,IL-5 Signaling Pathway,CP:WIKIPATHWAYS,C2,25,45
Cohort,0.008036046178197566,0.0742737209114117,0.10819501271226709,0.9138670246489319,LGP Proband,IL-5 Signaling Pathway,CP:WIKIPATHWAYS,C2,25,69
Cohort,-0.04573117204728405,0.02590204930267837,-1.7655426222416803,0.07785595466552148,LonGen OPEL,IL-5 Signaling Pathway,CP:WIKIPATHWAYS,C2,55,45
Cohort,-0.010700156835007569,0.030418270906104283,-0.351767425178013,0.7251223116889463,LGP Offspring,IL-6 signaling pathway,CP:WIKIPATHWAYS,C2,35,61
Cohort,-0.13299651195730167,0.0852155465779694,-1.560707139695622,0.11897222539151818,LGP Proband,IL-6 signaling pathway,CP:WIKIPATHWAYS,C2,35,81
Cohort,-0.03496990214707336,0.03016011168162744,-1.159475220656291,0.24661021283094195,LonGen OPEL,IL-6 signaling pathway,CP:WIKIPATHWAYS,C2,68,64
Cohort,-0.03512946859439655,0.0211610204114343,-1.6601027696856452,0.09735753709636183,LGP Offspring,IL-7 Signaling Pathway,CP:WIKIPATHWAYS,C2,20,25
Cohort,-0.07969812032397125,0.05909280502310332,-1.348694148006884,0.17780132687446176,LGP Proband,IL-7 Signaling Pathway,CP:WIKIPATHWAYS,C2,20,36
Cohort,-0.021193596906448925,0.018255191191105757,-1.1609627466829715,0.24600508857168202,LonGen OPEL,IL-7 Signaling Pathway,CP:WIKIPATHWAYS,C2,29,22
Cohort,-0.01781266941025939,0.016632681276254745,-1.070943951513652,0.2845768384786887,LGP Offspring,IL-9 Signaling Pathway,CP:WIKIPATHWAYS,C2,12,16
Cohort,-0.02855311713562186,0.047037219215517886,-0.6070324226607767,0.5439946148616268,LGP Proband,IL-9 Signaling Pathway,CP:WIKIPATHWAYS,C2,12,25
Cohort,-0.02652676563990628,0.013628102271268094,-1.9464753868065863,0.051949150714347865,LonGen OPEL,IL-9 Signaling Pathway,CP:WIKIPATHWAYS,C2,19,10
Cohort,-0.03557333591672691,0.021477003869136604,-1.6563453698421757,0.09811594982251264,LGP Offspring,Imatinib and Chronic Myeloid Leukemia,CP:WIKIPATHWAYS,C2,19,27
Cohort,0.05904302789577304,0.06641262845731324,0.8890331442569387,0.37424161471238726,LGP Proband,Imatinib and Chronic Myeloid Leukemia,CP:WIKIPATHWAYS,C2,19,53
Cohort,-0.026076628402760375,0.020420896185482998,-1.2769580808749215,0.2019894148821666,LonGen OPEL,Imatinib and Chronic Myeloid Leukemia,CP:WIKIPATHWAYS,C2,32,30
Cohort,0.011274070398961493,0.035781279030202215,0.31508293455483494,0.7527959199447589,LGP Offspring,Inflammatory Response Pathway,CP:WIKIPATHWAYS,C2,39,84
Cohort,-0.1871946991793351,0.09697758715945821,-1.9302882723977735,0.05390989844588105,LGP Proband,Inflammatory Response Pathway,CP:WIKIPATHWAYS,C2,39,113
Cohort,-0.02518258541243024,0.029869726674054815,-0.8430805439644052,0.3994366592165075,LonGen OPEL,Inflammatory Response Pathway,CP:WIKIPATHWAYS,C2,65,70
Cohort,-0.015382250406613876,0.011937892039135983,-1.2885231627314315,0.1980047271417655,LGP Offspring,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells,CP:WIKIPATHWAYS,C2,7,7
Cohort,0.02098095775318823,0.04736405697677522,0.44297214158567877,0.6579007578003628,LGP Proband,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells,CP:WIKIPATHWAYS,C2,7,28
Cohort,-0.015772648002035553,0.014317977577728035,-1.101597478862538,0.2709696839563567,LonGen OPEL,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells,CP:WIKIPATHWAYS,C2,18,14
Cohort,0.048800762029554204,0.02834759127867862,1.7215135335417104,0.085615173529037,LGP Offspring,Initiation of transcription and translation elongation at the HIV-1 LTR,CP:WIKIPATHWAYS,C2,19,57
Cohort,-0.045593939986247986,0.07718855726658012,-0.590682629664702,0.5548931174406593,LGP Proband,Initiation of transcription and translation elongation at the HIV-1 LTR,CP:WIKIPATHWAYS,C2,19,68
Cohort,0.030568083930074465,0.026265422509716366,1.163814666174375,0.24484784847258736,LonGen OPEL,Initiation of transcription and translation elongation at the HIV-1 LTR,CP:WIKIPATHWAYS,C2,39,61
Cohort,0.04656094485745592,0.07009810351058582,0.6642254572611161,0.5067725128900763,LGP Offspring,Insulin Signaling,CP:WIKIPATHWAYS,C2,161,358
Cohort,-0.20834652397817915,0.19397703374199196,-1.074078306895341,0.2830982407006702,LGP Proband,Insulin Signaling,CP:WIKIPATHWAYS,C2,161,456
Cohort,-0.12221794768217321,0.059756129671765155,-2.0452788417440186,0.04115567576151481,LonGen OPEL,Insulin Signaling,CP:WIKIPATHWAYS,C2,274,284
Cohort,-0.017825474416970306,0.014404794225817075,-1.2374681746596905,0.21634297738161268,LGP Offspring,Insulin signalling in human adipocytes (diabetic condition),CP:WIKIPATHWAYS,C2,8,11
Cohort,0.004516295561912879,0.03290884259805186,0.13723653599960503,0.8908769556877196,LGP Proband,Insulin signalling in human adipocytes (diabetic condition),CP:WIKIPATHWAYS,C2,8,10
Cohort,0.008873286216781252,0.010628562330784783,0.8348529124282864,0.40405101804763455,LonGen OPEL,Insulin signalling in human adipocytes (diabetic condition),CP:WIKIPATHWAYS,C2,6,11
Cohort,-0.017825474416970306,0.014404794225817075,-1.2374681746596905,0.21634297738161268,LGP Offspring,Insulin signalling in human adipocytes (normal condition),CP:WIKIPATHWAYS,C2,8,11
Cohort,0.004516295561912879,0.03290884259805186,0.13723653599960503,0.8908769556877196,LGP Proband,Insulin signalling in human adipocytes (normal condition),CP:WIKIPATHWAYS,C2,8,10
Cohort,0.008873286216781252,0.010628562330784783,0.8348529124282864,0.40405101804763455,LonGen OPEL,Insulin signalling in human adipocytes (normal condition),CP:WIKIPATHWAYS,C2,6,11
Cohort,-0.058283194214082686,0.0697537530854511,-0.8355563913913487,0.40369972904937024,LGP Offspring,Integrated Breast Cancer Pathway,CP:WIKIPATHWAYS,C2,158,316
Cohort,0.3153771367241243,0.1898758993954887,1.6609645443586898,0.0970964193228681,LGP Proband,Integrated Breast Cancer Pathway,CP:WIKIPATHWAYS,C2,158,430
Cohort,0.06978745050769661,0.06081249354012736,1.1475840973639255,0.2514850842332176,LonGen OPEL,Integrated Breast Cancer Pathway,CP:WIKIPATHWAYS,C2,229,287
Cohort,5.071601013843278e-4,0.03976230999664884,0.012754794714569428,0.9898271853889575,LGP Offspring,Integrated Cancer Pathway,CP:WIKIPATHWAYS,C2,50,107
Cohort,0.26342384113411926,0.114661213887245,2.297410189579571,0.02184221386924408,LGP Proband,Integrated Cancer Pathway,CP:WIKIPATHWAYS,C2,50,155
Cohort,0.029189832692491733,0.03370870431981558,0.8659434790358453,0.386782078021781,LonGen OPEL,Integrated Cancer Pathway,CP:WIKIPATHWAYS,C2,81,99
Cohort,0.03261460299289211,0.06223613987158902,0.5240460455964232,0.6004182849032534,LGP Offspring,Integrin-mediated Cell Adhesion,CP:WIKIPATHWAYS,C2,121,265
Cohort,-0.16954225388111552,0.17452311346660238,-0.9714601723144252,0.33160083291763676,LGP Proband,Integrin-mediated Cell Adhesion,CP:WIKIPATHWAYS,C2,121,362
Cohort,0.04951615970800774,0.053756994650373174,0.9211110113214636,0.3572715459407676,LonGen OPEL,Integrin-mediated Cell Adhesion,CP:WIKIPATHWAYS,C2,191,259
Cohort,-0.017925213029945417,0.01721339305070297,-1.0413526825969606,0.2980841771737838,LGP Offspring,Interactions between immune cells and microRNAs in tumor microenvironment,CP:WIKIPATHWAYS,C2,11,15
Cohort,-0.02254869533527067,0.0450572336292092,-0.5004456225793021,0.6168933655580034,LGP Proband,Interactions between immune cells and microRNAs in tumor microenvironment,CP:WIKIPATHWAYS,C2,11,24
Cohort,-0.02190930365171369,0.014139864612435684,-1.5494705396574282,0.121666120024645,LonGen OPEL,Interactions between immune cells and microRNAs in tumor microenvironment,CP:WIKIPATHWAYS,C2,18,13
Cohort,-0.028158008457648865,0.02332981009870028,-1.2069540359960995,0.22787201197972823,LGP Offspring,Interactome of polycomb repressive complex 2 (PRC2) ,CP:WIKIPATHWAYS,C2,23,30
Cohort,-0.09496308383119063,0.065894757208211,-1.4411326159246778,0.1499225592304137,LGP Proband,Interactome of polycomb repressive complex 2 (PRC2) ,CP:WIKIPATHWAYS,C2,23,46
Cohort,0.003974453790631025,0.022388482237437616,0.17752225222239565,0.8591433509746916,LonGen OPEL,Interactome of polycomb repressive complex 2 (PRC2) ,CP:WIKIPATHWAYS,C2,32,44
Cohort,-0.027368497748015745,0.028350022240090925,-0.965378351954618,0.33470056328658027,LGP Offspring,Interferon type I signaling pathways,CP:WIKIPATHWAYS,C2,33,52
Cohort,0.034310571925351994,0.08709408630797458,0.3939483537840436,0.6937198710307291,LGP Proband,Interferon type I signaling pathways,CP:WIKIPATHWAYS,C2,33,96
Cohort,0.026594002092049034,0.027016797321593337,0.9843506532431814,0.3252422288620289,LonGen OPEL,Interferon type I signaling pathways,CP:WIKIPATHWAYS,C2,44,62
Cohort,-0.001924262614629155,0.009920648307038425,-0.19396540982749524,0.8462612364263892,LGP Offspring,Interleukin-1 Induced Activation of NF-kappa-B,CP:WIKIPATHWAYS,C2,3,7
Cohort,0.008918518714482501,0.031012492843656918,0.28757825949185617,0.7737410301453443,LGP Proband,Interleukin-1 Induced Activation of NF-kappa-B,CP:WIKIPATHWAYS,C2,3,13
Cohort,-0.006402731194121498,0.009956126372997354,-0.6430946087111503,0.520347919070572,LonGen OPEL,Interleukin-1 Induced Activation of NF-kappa-B,CP:WIKIPATHWAYS,C2,8,7
Cohort,0.007577861699879962,0.030223629360506193,0.2507263972004005,0.8021018365634549,LGP Offspring,Interleukin-11 Signaling Pathway,CP:WIKIPATHWAYS,C2,28,60
Cohort,-0.0697228404455857,0.08071073836421985,-0.8638607682034881,0.3879127520282374,LGP Proband,Interleukin-11 Signaling Pathway,CP:WIKIPATHWAYS,C2,28,76
Cohort,-0.016748373042283063,0.02886977502491798,-0.5801352115777578,0.5619876162313856,LonGen OPEL,Interleukin-11 Signaling Pathway,CP:WIKIPATHWAYS,C2,58,59
Cohort,0.022693988235242792,0.02388545647074225,0.9501174182306749,0.3423921465027747,LGP Offspring,Intracellular trafficking proteins involved in CMT neuropathy,CP:WIKIPATHWAYS,C2,16,42
Cohort,-0.04863413972090499,0.060365350220275234,-0.8056631750406044,0.42066673143031375,LGP Proband,Intracellular trafficking proteins involved in CMT neuropathy,CP:WIKIPATHWAYS,C2,16,47
Cohort,-0.02277367577131668,0.021011814455932983,-1.083850983887125,0.27875905358337244,LonGen OPEL,Intracellular trafficking proteins involved in CMT neuropathy,CP:WIKIPATHWAYS,C2,37,31
Cohort,-0.03383174075583524,0.02667769150041626,-1.2681659788781707,0.20517526052022617,LGP Offspring,Intraflagellar transport proteins binding to dynein,CP:WIKIPATHWAYS,C2,30,44
Cohort,-0.16755167650487837,0.07395758164215677,-2.2655104829627337,0.02373704306319617,LGP Proband,Intraflagellar transport proteins binding to dynein,CP:WIKIPATHWAYS,C2,30,65
Cohort,-0.03915709407783012,0.027390517202668052,-1.4295857865004429,0.1532282823715601,LonGen OPEL,Intraflagellar transport proteins binding to dynein,CP:WIKIPATHWAYS,C2,59,52
Cohort,-0.029216912248685705,0.03121364882313057,-0.9360300173248184,0.3495919925107386,LGP Offspring,Irinotecan Pathway,CP:WIKIPATHWAYS,C2,31,57
Cohort,0.03497109222929689,0.083501235989813,0.4188092764706297,0.6754633581339105,LGP Proband,Irinotecan Pathway,CP:WIKIPATHWAYS,C2,31,73
Cohort,-0.0023481306533187103,0.02663980331767544,-0.08814369330424941,0.9297846391603142,LonGen OPEL,Irinotecan Pathway,CP:WIKIPATHWAYS,C2,51,55
Cohort,0.015322800584072545,0.028249284767578625,0.542413753485835,0.5877122705529468,LGP Offspring,Iron metabolism in placenta,CP:WIKIPATHWAYS,C2,23,56
Cohort,-0.08947547169982496,0.07914928228057626,-1.130464725916824,0.2586054461929862,LGP Proband,Iron metabolism in placenta,CP:WIKIPATHWAYS,C2,23,70
Cohort,0.00928443831488506,0.023837436696384856,0.3894897942736067,0.6970180388045948,LonGen OPEL,Iron metabolism in placenta,CP:WIKIPATHWAYS,C2,39,46
Cohort,0.008591916367288942,0.06851316565725578,0.1254053331920305,0.9002399508035067,LGP Offspring,Joubert Syndrome,CP:WIKIPATHWAYS,C2,147,298
Cohort,0.06865196118938188,0.19181361800067803,0.3579097350071318,0.7205014272535719,LGP Proband,Joubert Syndrome,CP:WIKIPATHWAYS,C2,147,443
Cohort,0.03200064377440044,0.05953647148601481,0.5374964786402807,0.5910749411668013,LonGen OPEL,Joubert Syndrome,CP:WIKIPATHWAYS,C2,240,289
Cohort,-0.011495211669480922,0.01880180955355627,-0.6113885813350693,0.5411478987698297,LGP Offspring,Kennedy pathway from Sphingolipids,CP:WIKIPATHWAYS,C2,12,20
Cohort,-0.029891552199808043,0.05418852304484311,-0.5516214600473909,0.5813554942522761,LGP Proband,Kennedy pathway from Sphingolipids,CP:WIKIPATHWAYS,C2,12,35
Cohort,0.008465575978170499,0.01747862817602058,0.484338695972986,0.6282787515804416,LonGen OPEL,Kennedy pathway from Sphingolipids,CP:WIKIPATHWAYS,C2,21,27
Cohort,-0.008920606232656138,0.01726086183430551,-0.5168111719037498,0.6054570145768416,LGP Offspring,Ketogenesis and Ketolysis,CP:WIKIPATHWAYS,C2,12,16
Cohort,-0.0661500353987591,0.049119580565586685,-1.3467141746137792,0.17843815142764463,LGP Proband,Ketogenesis and Ketolysis,CP:WIKIPATHWAYS,C2,12,29
Cohort,-0.003548836716670075,0.014847751650509427,-0.23901509132181062,0.8111554045164491,LonGen OPEL,Ketogenesis and Ketolysis,CP:WIKIPATHWAYS,C2,15,17
Cohort,-0.003346052723168347,0.03339469965495188,-0.10019711983461971,0.9202175400343392,LGP Offspring,Kisspeptin/Kisspeptin Receptor System in the Ovary,CP:WIKIPATHWAYS,C2,31,71
Cohort,0.12026429425247744,0.0915820902640151,1.3131857321205114,0.1894815501446094,LGP Proband,Kisspeptin/Kisspeptin Receptor System in the Ovary,CP:WIKIPATHWAYS,C2,31,110
Cohort,-0.0318836259999946,0.026780236321313183,-1.1905655206866064,0.23417911834944372,LonGen OPEL,Kisspeptin/Kisspeptin Receptor System in the Ovary,CP:WIKIPATHWAYS,C2,59,56
Cohort,-0.024226300356726117,0.033837501654526515,-0.7159600789701125,0.47426323592578135,LGP Offspring,Kit receptor signaling pathway,CP:WIKIPATHWAYS,C2,44,72
Cohort,0.016032156236669932,0.09628050001168748,0.16651509116304747,0.8677919685780078,LGP Proband,Kit receptor signaling pathway,CP:WIKIPATHWAYS,C2,44,114
Cohort,-0.02264537314492638,0.02943538777008854,-0.7693247774346634,0.4419287495565013,LonGen OPEL,Kit receptor signaling pathway,CP:WIKIPATHWAYS,C2,66,63
Cohort,0.0010108486277087658,0.02274161054688265,0.0444492981543618,0.9645593926168277,LGP Offspring,Kynurenine Pathway and links to Cellular Senescence,CP:WIKIPATHWAYS,C2,15,32
Cohort,0.04146735177617507,0.06108155926961776,0.6788849576209348,0.4973991006206594,LGP Proband,Kynurenine Pathway and links to Cellular Senescence,CP:WIKIPATHWAYS,C2,15,40
Cohort,0.032868656109616104,0.0206475730976654,1.5918895627173022,0.11180653771983258,LonGen OPEL,Kynurenine Pathway and links to Cellular Senescence,CP:WIKIPATHWAYS,C2,20,37
Cohort,-0.007962143910415734,0.012606004295678359,-0.6316151988894172,0.527851874592338,LGP Offspring,LDLRAD4 and what we know about it,CP:WIKIPATHWAYS,C2,7,9
Cohort,-0.02281345793946866,0.034495788163424274,-0.6613403883218899,0.5085767040043354,LGP Proband,LDLRAD4 and what we know about it,CP:WIKIPATHWAYS,C2,7,13
Cohort,-5.573335048505534e-4,0.009626270684903203,-0.05789713619050987,0.9538450948039752,LonGen OPEL,LDLRAD4 and what we know about it,CP:WIKIPATHWAYS,C2,6,8
Cohort,0.0036140479886412904,0.015169961148762168,0.23823712883643,0.8117693767313809,LGP Offspring,Leptin and adiponectin,CP:WIKIPATHWAYS,C2,7,16
Cohort,-0.007104232006706093,0.039794963947374945,-0.1785208805843062,0.8583572794054009,LGP Proband,Leptin and adiponectin,CP:WIKIPATHWAYS,C2,7,19
Cohort,0.010185448644392513,0.016857225197830967,0.6042185783757035,0.5458704975804198,LonGen OPEL,Leptin and adiponectin,CP:WIKIPATHWAYS,C2,15,25
Cohort,-0.0029933541564415135,0.02122410296251716,-0.14103560285812447,0.8878838324566865,LGP Offspring,Leptin Insulin Overlap,CP:WIKIPATHWAYS,C2,13,32
Cohort,0.06044726607617648,0.04773723463678563,1.2662498474429158,0.20577720554987852,LGP Proband,Leptin Insulin Overlap,CP:WIKIPATHWAYS,C2,13,26
Cohort,-0.013815274315198703,0.020174782887060486,-0.6847793303421081,0.493682518117312,LonGen OPEL,Leptin Insulin Overlap,CP:WIKIPATHWAYS,C2,29,29
Cohort,-0.038554684444757834,0.038099060434353516,-1.0119589303570722,0.3119197551066033,LGP Offspring,Leptin signaling pathway,CP:WIKIPATHWAYS,C2,54,99
Cohort,0.11282309087322294,0.10362110294188037,1.0888041882405346,0.2765547655110728,LGP Proband,Leptin signaling pathway,CP:WIKIPATHWAYS,C2,54,125
Cohort,-0.030870827398647455,0.03692054080645788,-0.8361423403973473,0.403325754542062,LonGen OPEL,Leptin signaling pathway,CP:WIKIPATHWAYS,C2,89,94
Cohort,0.023897686730085497,0.011840577971875656,2.0182871804778872,0.043955826372619515,LGP Offspring,let-7 inhibition of ES cell reprogramming,CP:WIKIPATHWAYS,C2,1,13
Cohort,0.05452433626857289,0.034068707378033414,1.6004228062884687,0.10988352652184333,LGP Proband,let-7 inhibition of ES cell reprogramming,CP:WIKIPATHWAYS,C2,1,18
Cohort,0.008322845904517144,0.0081085746949595,1.02642526185161,0.30500298227660816,LonGen OPEL,let-7 inhibition of ES cell reprogramming,CP:WIKIPATHWAYS,C2,4,6
Cohort,-0.01443072502108476,0.030473649095280317,-0.4735476534485578,0.6359753998312554,LGP Offspring,Lipid Metabolism Pathway,CP:WIKIPATHWAYS,C2,34,59
Cohort,-0.10571838941795603,0.08269282490493134,-1.2784469455420862,0.201447538901336,LGP Proband,Lipid Metabolism Pathway,CP:WIKIPATHWAYS,C2,34,81
Cohort,-0.028420277516355424,0.027292346276957417,-1.0413277491041621,0.2980396328151181,LonGen OPEL,Lipid Metabolism Pathway,CP:WIKIPATHWAYS,C2,60,58
Cohort,-0.03112775523903769,0.020780698214198465,-1.4979167166659286,0.13462167310981024,LGP Offspring,Liver X Receptor Pathway,CP:WIKIPATHWAYS,C2,17,21
Cohort,-0.11620918828993658,0.05730805366325914,-2.0277985529360185,0.04289828472833796,LGP Proband,Liver X Receptor Pathway,CP:WIKIPATHWAYS,C2,17,33
Cohort,-0.007380697672961653,0.019735673297382357,-0.37397749556082244,0.7085206496353917,LonGen OPEL,Liver X Receptor Pathway,CP:WIKIPATHWAYS,C2,29,29
Cohort,-0.013961412447934599,0.04350208529797775,-0.3209366252744581,0.7483576095064148,LGP Offspring,LncRNA involvement in canonical Wnt signaling and colorectal cancer,CP:WIKIPATHWAYS,C2,63,128
Cohort,-0.07100256372549973,0.11944150525470257,-0.5944546962472601,0.552369258164932,LGP Proband,LncRNA involvement in canonical Wnt signaling and colorectal cancer,CP:WIKIPATHWAYS,C2,63,172
Cohort,-0.06551550690257328,0.037538396263895026,-1.7452931777372451,0.08131971269696109,LonGen OPEL,LncRNA involvement in canonical Wnt signaling and colorectal cancer,CP:WIKIPATHWAYS,C2,108,105
Cohort,0.017956846066390444,0.014869871871254837,1.207599246440252,0.22762377979303872,LGP Offspring,LncRNA-mediated mechanisms of therapeutic resistance,CP:WIKIPATHWAYS,C2,4,18
Cohort,0.035312486622142585,0.04075612912935504,0.8664337702450841,0.3865015221890067,LGP Proband,LncRNA-mediated mechanisms of therapeutic resistance,CP:WIKIPATHWAYS,C2,4,19
Cohort,0.02181737146562426,0.011474949658601196,1.9013043294068632,0.05762303254548064,LonGen OPEL,LncRNA-mediated mechanisms of therapeutic resistance,CP:WIKIPATHWAYS,C2,5,15
Cohort,-0.018864840076048935,0.020329375730120267,-0.9279596346924979,0.35375971169661713,LGP Offspring,LTF danger signal response pathway,CP:WIKIPATHWAYS,C2,16,25
Cohort,-0.037824643469181074,0.057431787926160924,-0.6586011829861814,0.5103336755882975,LGP Proband,LTF danger signal response pathway,CP:WIKIPATHWAYS,C2,16,42
Cohort,0.03693727200370963,0.019454359615192082,1.8986629595797637,0.057970196598541524,LonGen OPEL,LTF danger signal response pathway,CP:WIKIPATHWAYS,C2,19,37
Cohort,0.059485627675666244,0.03898272722120291,1.5259483344539244,0.1274904393276017,LGP Offspring,Lung fibrosis,CP:WIKIPATHWAYS,C2,40,120
Cohort,-0.039266615828232126,0.10641575478648602,-0.3689925040424436,0.7122269670264599,LGP Proband,Lung fibrosis,CP:WIKIPATHWAYS,C2,40,143
Cohort,7.782970678084059e-4,0.03734567770889817,0.020840351964558534,0.983378231242733,LonGen OPEL,Lung fibrosis,CP:WIKIPATHWAYS,C2,98,112
Cohort,0.016979831512698083,0.012306084077593624,1.3797916059759587,0.16810701064770361,LGP Offspring,Macrophage markers,CP:WIKIPATHWAYS,C2,2,13
Cohort,-0.017557744642151072,0.03306962190798523,-0.5309327300748925,0.5956067503685185,LGP Proband,Macrophage markers,CP:WIKIPATHWAYS,C2,2,17
Cohort,-0.00974315121299609,0.012542147532402435,-0.7768327702911177,0.4374882216580417,LonGen OPEL,Macrophage markers,CP:WIKIPATHWAYS,C2,13,11
Cohort,0.005649608239739163,0.018590157669792072,0.3039031911450352,0.7612951637953134,LGP Offspring,Major receptors targeted by epinephrine and norepinephrine,CP:WIKIPATHWAYS,C2,11,24
Cohort,-0.017434951140226064,0.051972434766203675,-0.33546535232872254,0.7373584428986062,LGP Proband,Major receptors targeted by epinephrine and norepinephrine,CP:WIKIPATHWAYS,C2,11,28
Cohort,-0.02075881455799405,0.016125661196126788,-1.2873155590655778,0.19835849918228773,LonGen OPEL,Major receptors targeted by epinephrine and norepinephrine,CP:WIKIPATHWAYS,C2,21,17
Cohort,-0.003017871275365733,0.016589753234054747,-0.18191176401411288,0.8557065058858337,LGP Offspring,Mammalian disorder of sexual development,CP:WIKIPATHWAYS,C2,9,19
Cohort,0.08721725606585753,0.0427639054668835,2.0395063339899777,0.04171422826876142,LGP Proband,Mammalian disorder of sexual development,CP:WIKIPATHWAYS,C2,9,20
Cohort,0.014028086162138593,0.014403439202911036,0.9739400406052617,0.3303821818023166,LonGen OPEL,Mammalian disorder of sexual development,CP:WIKIPATHWAYS,C2,12,20
Cohort,0.005846094718666056,0.016728584370884026,0.3494673900106658,0.726847284746073,LGP Offspring,Mammary gland development pathway - Embryonic development (Stage 1 of 4),CP:WIKIPATHWAYS,C2,8,20
Cohort,0.013097212522270899,0.04884267471022001,0.2681510093371359,0.7886493914175903,LGP Proband,Mammary gland development pathway - Embryonic development (Stage 1 of 4),CP:WIKIPATHWAYS,C2,8,32
Cohort,0.014649269734046342,0.014855740091900037,0.986101644443398,0.3243828731562961,LonGen OPEL,Mammary gland development pathway - Embryonic development (Stage 1 of 4),CP:WIKIPATHWAYS,C2,13,21
Cohort,0.01620931767529868,0.017746152534753024,0.9133989828812359,0.36135838790440367,LGP Offspring,Mammary gland development pathway - Involution (Stage 4 of 4),CP:WIKIPATHWAYS,C2,7,25
Cohort,0.09229478710690354,0.04642205276089473,1.988166865051934,0.04711975753037606,LGP Proband,Mammary gland development pathway - Involution (Stage 4 of 4),CP:WIKIPATHWAYS,C2,7,27
Cohort,-0.023387723952861806,0.01585917820204339,-1.4747122237297512,0.14068531786713043,LonGen OPEL,Mammary gland development pathway - Involution (Stage 4 of 4),CP:WIKIPATHWAYS,C2,23,16
Cohort,0.01951833533302308,0.027508860592348867,0.7095290358355221,0.4782408896222048,LGP Offspring,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4),CP:WIKIPATHWAYS,C2,21,54
Cohort,0.06491122918207626,0.08387477570455039,0.7739064413206495,0.4392054356393025,LGP Proband,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4),CP:WIKIPATHWAYS,C2,21,81
Cohort,0.041604439256269686,0.02212198879064066,1.8806825936857736,0.06037996982247726,LonGen OPEL,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4),CP:WIKIPATHWAYS,C2,27,47
Cohort,0.010741178792801578,0.0254629830021281,0.4218350533362046,0.6732795299207426,LGP Offspring,Mammary gland development pathway - Puberty (Stage 2 of 4),CP:WIKIPATHWAYS,C2,18,40
Cohort,-0.05077796038793425,0.0653540423562954,-0.7769674002887892,0.4373983168538884,LGP Proband,Mammary gland development pathway - Puberty (Stage 2 of 4),CP:WIKIPATHWAYS,C2,18,47
Cohort,-0.01246971916798671,0.01701633374012957,-0.7328088034956324,0.46389078432132813,LonGen OPEL,Mammary gland development pathway - Puberty (Stage 2 of 4),CP:WIKIPATHWAYS,C2,23,22
Cohort,0.014551238750905778,0.01836416204758227,0.792371506698914,0.42842206391275905,LGP Offspring,MAP3K1 role in promoting and blocking gonadal determination,CP:WIKIPATHWAYS,C2,7,23
Cohort,0.03468282330233892,0.05132749269754372,0.6757162970479302,0.4994081017937956,LGP Proband,MAP3K1 role in promoting and blocking gonadal determination,CP:WIKIPATHWAYS,C2,7,33
Cohort,0.013602612483422061,0.0160455560431972,0.84774952309547,0.39683230935425506,LonGen OPEL,MAP3K1 role in promoting and blocking gonadal determination,CP:WIKIPATHWAYS,C2,15,23
Cohort,0.0037493792381526015,0.018115291773254223,0.20697316306482347,0.8360931448679458,LGP Offspring,MAPK  and NFkB Signalling Pathways Inhibited by Yersinia YopJ,CP:WIKIPATHWAYS,C2,8,21
Cohort,0.0018435542201324672,0.051018065149202096,0.03613532215972914,0.9711831046679171,LGP Proband,MAPK  and NFkB Signalling Pathways Inhibited by Yersinia YopJ,CP:WIKIPATHWAYS,C2,8,32
Cohort,-0.012791995932623396,0.01709619366746057,-0.7482364894456353,0.45453853422497603,LonGen OPEL,MAPK  and NFkB Signalling Pathways Inhibited by Yersinia YopJ,CP:WIKIPATHWAYS,C2,20,17
Cohort,0.01004421000933867,0.030344725119840037,0.33100349301801874,0.7407444214998693,LGP Offspring,MAPK Cascade,CP:WIKIPATHWAYS,C2,29,65
Cohort,0.15747506872963374,0.08564078145056973,1.8387859856291178,0.066302061488495,LGP Proband,MAPK Cascade,CP:WIKIPATHWAYS,C2,29,101
Cohort,-0.041723736643740565,0.027525554647919778,-1.5158181979411558,0.1299623211755811,LonGen OPEL,MAPK Cascade,CP:WIKIPATHWAYS,C2,58,53
Cohort,0.03646409362676198,0.022727793296205605,1.6043833711233921,0.10909663268302351,LGP Offspring,MAPK pathway in congenital thyroid cancer,CP:WIKIPATHWAYS,C2,13,42
Cohort,-0.037990713911353904,0.05970765108214303,-0.636278822275022,0.5247692827974388,LGP Proband,MAPK pathway in congenital thyroid cancer,CP:WIKIPATHWAYS,C2,13,46
Cohort,-4.301174532752678e-5,0.020960305340381364,-0.00205205719234738,0.9983632105465219,LonGen OPEL,MAPK pathway in congenital thyroid cancer,CP:WIKIPATHWAYS,C2,30,39
Cohort,-0.11611638995970275,0.08339685648203413,-1.3923353332234683,0.16427870217810517,LGP Offspring,MAPK Signaling Pathway,CP:WIKIPATHWAYS,C2,240,458
Cohort,0.07119190895218147,0.24481441704112986,0.2907994954407482,0.7712769699651169,LGP Proband,MAPK Signaling Pathway,CP:WIKIPATHWAYS,C2,240,652
Cohort,0.06477491519876002,0.07446160354428824,0.8699102908821085,0.3846116731117383,LonGen OPEL,MAPK Signaling Pathway,CP:WIKIPATHWAYS,C2,344,428
Cohort,-6.471080622582097e-4,0.038477105009793226,-0.016818002864131987,0.9865867700845941,LGP Offspring,Matrix Metalloproteinases,CP:WIKIPATHWAYS,C2,43,96
Cohort,0.044254727651691736,0.09864154816537449,0.4486418600962935,0.6538065712802674,LGP Proband,Matrix Metalloproteinases,CP:WIKIPATHWAYS,C2,43,110
Cohort,-0.03718240535138756,0.03139279206208565,-1.184424923971457,0.2365984310833806,LonGen OPEL,Matrix Metalloproteinases,CP:WIKIPATHWAYS,C2,74,72
Cohort,0.0047182924902277055,0.02369310372717132,0.19914201805552195,0.8422115352030192,LGP Offspring,mBDNF and proBDNF regulation of GABA neurotransmission,CP:WIKIPATHWAYS,C2,18,42
Cohort,-0.019176472652552085,0.06062222317302765,-0.3163274398205208,0.7518331390874444,LGP Proband,mBDNF and proBDNF regulation of GABA neurotransmission,CP:WIKIPATHWAYS,C2,18,43
Cohort,-0.015499268279996644,0.021999894815840693,-0.7045155629033567,0.481317827080905,LonGen OPEL,mBDNF and proBDNF regulation of GABA neurotransmission,CP:WIKIPATHWAYS,C2,36,38
Cohort,0.0566796936327535,0.03783574079220328,1.4980463563286,0.13458799579895941,LGP Offspring,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms,CP:WIKIPATHWAYS,C2,31,96
Cohort,0.22599102824150819,0.0978796752094759,2.3088657349736446,0.021194682047083215,LGP Proband,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms,CP:WIKIPATHWAYS,C2,31,120
Cohort,0.009484180716934526,0.031224900043824323,0.3037377446724705,0.7614070746068758,LonGen OPEL,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms,CP:WIKIPATHWAYS,C2,67,82
Cohort,-0.025371639715775638,0.03868123437257515,-0.6559159790868523,0.512101362375986,LGP Offspring,MECP2 and Associated Rett Syndrome,CP:WIKIPATHWAYS,C2,56,98
Cohort,-0.054762241538984215,0.12575785739568712,-0.4354578129196267,0.663342826641614,LGP Proband,MECP2 and Associated Rett Syndrome,CP:WIKIPATHWAYS,C2,56,192
Cohort,-0.0243764012579491,0.03157769059526236,-0.7719500950967682,0.4403731000483694,LonGen OPEL,MECP2 and Associated Rett Syndrome,CP:WIKIPATHWAYS,C2,74,77
Cohort,-0.03567607784995323,0.020683693395084878,-1.7248407800529009,0.08501325019020155,LGP Offspring,MED and Pseudoachondroplasia genes,CP:WIKIPATHWAYS,C2,17,25
Cohort,-0.017090951812609646,0.052978150562450185,-0.3226037834684882,0.747076183872327,LGP Proband,MED and Pseudoachondroplasia genes,CP:WIKIPATHWAYS,C2,17,28
Cohort,-0.023658163696705946,0.015071440472548056,-1.5697347403387365,0.11687423659227358,LonGen OPEL,MED and Pseudoachondroplasia genes,CP:WIKIPATHWAYS,C2,21,14
Cohort,0.0032933709753844584,0.036899398739427644,0.08925270025783469,0.9289075193532231,LGP Offspring,Melanoma,CP:WIKIPATHWAYS,C2,43,99
Cohort,0.08843793176617418,0.10574262286056237,0.8363508429594465,0.4031971185365095,LGP Proband,Melanoma,CP:WIKIPATHWAYS,C2,43,133
Cohort,-0.0019774312521804527,0.03278611753201859,-0.060313065438422624,0.9519214351678558,LonGen OPEL,Melanoma,CP:WIKIPATHWAYS,C2,75,85
Cohort,-0.0030940851237788516,0.030857654220195003,-0.10026961549636869,0.9201600084097604,LGP Offspring,Melatonin metabolism and effects,CP:WIKIPATHWAYS,C2,35,68
Cohort,0.017366282048923622,0.09374782393278144,0.18524464163963422,0.8530821955875116,LGP Proband,Melatonin metabolism and effects,CP:WIKIPATHWAYS,C2,35,106
Cohort,-0.04736504784829396,0.02837141018995599,-1.6694639967195595,0.09541864780699467,LonGen OPEL,Melatonin metabolism and effects,CP:WIKIPATHWAYS,C2,67,60
Cohort,-0.03413096108052109,0.06300407773942265,-0.5417262232086417,0.5881856225895277,LGP Offspring,Mesodermal Commitment Pathway,CP:WIKIPATHWAYS,C2,128,250
Cohort,0.09436051144094412,0.16437322287177536,0.574062549802002,0.566080260150293,LGP Proband,Mesodermal Commitment Pathway,CP:WIKIPATHWAYS,C2,128,366
Cohort,-0.0057861401798788405,0.05292225522768798,-0.10933283464555825,0.9129660602490286,LonGen OPEL,Mesodermal Commitment Pathway,CP:WIKIPATHWAYS,C2,194,219
Cohort,0.03334637884499706,0.04174425600650061,0.7988255639243925,0.4246721279679545,LGP Offspring,MET in type 1 papillary renal cell carcinoma,CP:WIKIPATHWAYS,C2,49,115
Cohort,0.05461898346336666,0.10615408020820552,0.5145255213576304,0.6070209395888484,LGP Proband,MET in type 1 papillary renal cell carcinoma,CP:WIKIPATHWAYS,C2,49,130
Cohort,0.019751808904510473,0.03292185690017717,0.5999603535244143,0.5487034068944201,LonGen OPEL,MET in type 1 papillary renal cell carcinoma,CP:WIKIPATHWAYS,C2,66,86
Cohort,0.021199387784179607,0.024385103641505545,0.8693581169815667,0.3849598458225608,LGP Offspring,"Metabolic pathway of LDL, HDL and TG, including diseases",CP:WIKIPATHWAYS,C2,16,43
Cohort,-0.03997174827698043,0.07378761039741313,-0.5417135486797358,0.588160541231558,LGP Proband,"Metabolic pathway of LDL, HDL and TG, including diseases",CP:WIKIPATHWAYS,C2,16,71
Cohort,0.029556548939582455,0.020820267272776798,1.4196046838567074,0.15611429214100225,LonGen OPEL,"Metabolic pathway of LDL, HDL and TG, including diseases",CP:WIKIPATHWAYS,C2,26,40
Cohort,0.03964104096116546,0.04107319650254312,0.9651316268679263,0.3348240195580988,LGP Offspring,Metabolic reprogramming in colon cancer,CP:WIKIPATHWAYS,C2,48,120
Cohort,-0.1069435429082842,0.1089950466580679,-0.9811780093436765,0.32678950408805174,LGP Proband,Metabolic reprogramming in colon cancer,CP:WIKIPATHWAYS,C2,48,147
Cohort,-0.00553637738871765,0.03682706682908686,-0.150334464985001,0.8805388278857705,LonGen OPEL,Metabolic reprogramming in colon cancer,CP:WIKIPATHWAYS,C2,86,102
Cohort,0.009275815354458379,0.01791045568439245,0.5178994615162985,0.6046978628488908,LGP Offspring,Metabolism of alpha-linolenic acid,CP:WIKIPATHWAYS,C2,10,23
Cohort,-0.004633746924683349,0.04413634943875949,-0.1049870907677313,0.916411295794277,LGP Proband,Metabolism of alpha-linolenic acid,CP:WIKIPATHWAYS,C2,10,23
Cohort,-0.007004343119542065,0.014427399112256798,-0.4854889689432328,0.6274631319859859,LonGen OPEL,Metabolism of alpha-linolenic acid,CP:WIKIPATHWAYS,C2,16,16
Cohort,-0.003480414272209338,0.0157871846887735,-0.22045819700103414,0.8255808884692624,LGP Offspring,Metabolism of Spingolipids in ER and Golgi apparatus,CP:WIKIPATHWAYS,C2,8,17
Cohort,-0.0436949351843802,0.049330407789306925,-0.885760672626179,0.3760018220219091,LGP Proband,Metabolism of Spingolipids in ER and Golgi apparatus,CP:WIKIPATHWAYS,C2,8,33
Cohort,0.0015450852896764706,0.013914966516025114,0.11103765775484113,0.9116144754347446,LonGen OPEL,Metabolism of Spingolipids in ER and Golgi apparatus,CP:WIKIPATHWAYS,C2,13,17
Cohort,-0.09967237897779722,0.08386363837411018,-1.1885053034923825,0.23505174775622797,LGP Offspring,Metapathway biotransformation Phase I and II,CP:WIKIPATHWAYS,C2,206,391
Cohort,0.08771679319313987,0.23388950459458202,0.3750351831527707,0.7077296514595353,LGP Proband,Metapathway biotransformation Phase I and II,CP:WIKIPATHWAYS,C2,206,519
Cohort,0.12671115925964052,0.07050449731171707,1.797206761143484,0.07268174348567596,LonGen OPEL,Metapathway biotransformation Phase I and II,CP:WIKIPATHWAYS,C2,266,384
Cohort,0.001853053798852149,0.012710477968031693,0.14578946625868763,0.8841310524397683,LGP Offspring,Metastatic brain tumor,CP:WIKIPATHWAYS,C2,5,13
Cohort,0.09251723854696503,0.035634314805875006,2.596296268104804,0.009589317464081645,LGP Proband,Metastatic brain tumor,CP:WIKIPATHWAYS,C2,5,15
Cohort,-0.0037029362457046155,0.007754359906231475,-0.4775295821295194,0.6331161535225107,LonGen OPEL,Metastatic brain tumor,CP:WIKIPATHWAYS,C2,5,4
Cohort,-0.05235195436694585,0.0211238373671099,-2.4783354206494006,0.013442725857094127,LGP Offspring,Methionine De Novo and Salvage Pathway,CP:WIKIPATHWAYS,C2,20,24
Cohort,0.02516446312326428,0.059178322696403156,0.4252310977511664,0.670777910465487,LGP Proband,Methionine De Novo and Salvage Pathway,CP:WIKIPATHWAYS,C2,20,36
Cohort,-0.022146812447520668,0.0194549025835519,-1.138366658604841,0.2553099065813807,LonGen OPEL,Methionine De Novo and Salvage Pathway,CP:WIKIPATHWAYS,C2,30,24
Cohort,-0.04620726707688195,0.018848472653672645,-2.451512540347847,0.014477741331899066,LGP Offspring,Methionine metabolism leading to Sulphur Amino Acids and related disorders,CP:WIKIPATHWAYS,C2,17,15
Cohort,-0.013862780895934106,0.0503411047343468,-0.27537697015369206,0.7830948458890402,LGP Proband,Methionine metabolism leading to Sulphur Amino Acids and related disorders,CP:WIKIPATHWAYS,C2,17,22
Cohort,0.005684189859635718,0.01637703104315712,0.3470830484876418,0.728620669551421,LonGen OPEL,Methionine metabolism leading to Sulphur Amino Acids and related disorders,CP:WIKIPATHWAYS,C2,17,23
Cohort,0.009718949230680196,0.009543239716385451,1.0184119355184023,0.3088465691449943,LGP Offspring,Methylation Pathways,CP:WIKIPATHWAYS,C2,2,7
Cohort,-0.020246477609734186,0.027222968978304982,-0.7437277552595153,0.45725066447009755,LGP Proband,Methylation Pathways,CP:WIKIPATHWAYS,C2,2,8
Cohort,-0.007750871753276294,0.010578227939788971,-0.732719298297794,0.46394535370822265,LonGen OPEL,Methylation Pathways,CP:WIKIPATHWAYS,C2,8,9
Cohort,-0.006511627375975608,0.01139159260588801,-0.5716169460457988,0.5677715185253176,LGP Offspring,Mevalonate pathway,CP:WIKIPATHWAYS,C2,5,8
Cohort,0.004579198298117972,0.037503952116542026,0.12209908662127919,0.9028499589652603,LGP Proband,Mevalonate pathway,CP:WIKIPATHWAYS,C2,5,18
Cohort,0.008291406704974098,0.012585904787473522,0.6587851127895353,0.5102242789014602,LonGen OPEL,Mevalonate pathway,CP:WIKIPATHWAYS,C2,10,14
Cohort,-0.01330978051691572,0.024688171749978043,-0.5391156806468489,0.5899845396744248,LGP Offspring,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,CP:WIKIPATHWAYS,C2,19,35
Cohort,0.05311132353918036,0.06356806016770046,0.835503292047391,0.4036736817091702,LGP Proband,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,CP:WIKIPATHWAYS,C2,19,47
Cohort,-0.010983511631532916,0.02149185914563051,-0.5110545140421676,0.6094545985771818,LonGen OPEL,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,CP:WIKIPATHWAYS,C2,33,35
Cohort,-0.02786725699977098,0.022163620689047862,-1.2573422632855997,0.20906393437568577,LGP Offspring,MFAP5-mediated ovarian cancer cell motility and invasiveness,CP:WIKIPATHWAYS,C2,19,26
Cohort,0.04359871743626508,0.06359726377074232,0.6855439188929777,0.49319126211115927,LGP Proband,MFAP5-mediated ovarian cancer cell motility and invasiveness,CP:WIKIPATHWAYS,C2,19,43
Cohort,0.00457299205854113,0.01899625028453465,0.24073130170663862,0.8098253653637434,LonGen OPEL,MFAP5-mediated ovarian cancer cell motility and invasiveness,CP:WIKIPATHWAYS,C2,23,30
Cohort,-0.050222042300514594,0.03369923313566532,-1.490302230271302,0.13661121277487806,LGP Offspring,Microglia Pathogen Phagocytosis Pathway,CP:WIKIPATHWAYS,C2,47,69
Cohort,-0.03050187015596158,0.09574405938736855,-0.31857715612991516,0.7501269411429823,LGP Proband,Microglia Pathogen Phagocytosis Pathway,CP:WIKIPATHWAYS,C2,47,96
Cohort,-0.015682317275031353,0.029454783386446564,-0.5324200510755572,0.5945836825891709,LonGen OPEL,Microglia Pathogen Phagocytosis Pathway,CP:WIKIPATHWAYS,C2,63,67
Cohort,0.015071101108924383,0.013468778731988353,1.11896567675661,0.2635522276250715,LGP Offspring,MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma,CP:WIKIPATHWAYS,C2,4,14
Cohort,-0.05106394227184345,0.02825895211208778,-1.8070005593024387,0.07112246310052579,LGP Proband,MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma,CP:WIKIPATHWAYS,C2,4,9
Cohort,0.020319085722893277,0.009650954576584565,2.1053964726133985,0.0355695478061795,LonGen OPEL,MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma,CP:WIKIPATHWAYS,C2,3,11
Cohort,0.005925221104627159,0.009586482301115225,0.6180808474384665,0.5367302209014555,LGP Offspring,MicroRNA network associated with chronic lymphocytic leukemia,CP:WIKIPATHWAYS,C2,2,7
Cohort,0.08470831328867214,0.028058157060119354,3.019026271296801,0.002613124842451442,LGP Proband,MicroRNA network associated with chronic lymphocytic leukemia,CP:WIKIPATHWAYS,C2,2,9
Cohort,-0.0036734641654529556,0.006327200191997841,-0.580582888794774,0.5616859314116007,LonGen OPEL,MicroRNA network associated with chronic lymphocytic leukemia,CP:WIKIPATHWAYS,C2,4,2
Cohort,0.0089543644118974,0.038339293231648815,0.23355580286246996,0.8154005498733903,LGP Offspring,MicroRNAs in cardiomyocyte hypertrophy,CP:WIKIPATHWAYS,C2,47,105
Cohort,-0.024123354481250813,0.1027793250417244,-0.2347101858419256,0.8144912923099035,LGP Proband,MicroRNAs in cardiomyocyte hypertrophy,CP:WIKIPATHWAYS,C2,47,124
Cohort,-0.041117494459574855,0.03447203734969549,-1.192778194177086,0.23331167349737672,LonGen OPEL,MicroRNAs in cardiomyocyte hypertrophy,CP:WIKIPATHWAYS,C2,88,86
Cohort,0,0,NA,NA,LGP Offspring,mir-124 predicted interactions with cell cycle and differentiation ,CP:WIKIPATHWAYS,C2,0,0
Cohort,0.03048273506844827,0.007824538488398772,3.8957869673264667,1.0571976121804771e-4,LGP Proband,mir-124 predicted interactions with cell cycle and differentiation ,CP:WIKIPATHWAYS,C2,0,1
Cohort,0,0,NA,NA,LonGen OPEL,mir-124 predicted interactions with cell cycle and differentiation ,CP:WIKIPATHWAYS,C2,0,0
Cohort,0.0072171171301507915,0.02874693839557956,0.25105689624536065,0.8018464127471091,LGP Offspring,miR-509-3p alteration of YAP1/ECM axis,CP:WIKIPATHWAYS,C2,27,57
Cohort,-0.17813686429519263,0.08081053982197729,-2.204376615817958,0.02777027980390321,LGP Proband,miR-509-3p alteration of YAP1/ECM axis,CP:WIKIPATHWAYS,C2,27,73
Cohort,-0.015674380548255637,0.022751633692606497,-0.6889342875342299,0.49106537369397807,LonGen OPEL,miR-509-3p alteration of YAP1/ECM axis,CP:WIKIPATHWAYS,C2,39,41
Cohort,-0.0024692019973913066,0.014225550473828234,-0.17357514578673597,0.86225132850498,LGP Offspring,miR-517 relationship with ARCN1 and USP1,CP:WIKIPATHWAYS,C2,6,14
Cohort,-0.06571903658282216,0.04123925163962174,-1.5936040051629063,0.1114036458665198,LGP Proband,miR-517 relationship with ARCN1 and USP1,CP:WIKIPATHWAYS,C2,6,20
Cohort,-0.020240276983310004,0.014382781890252794,-1.4072574511490599,0.15974140613119422,LonGen OPEL,miR-517 relationship with ARCN1 and USP1,CP:WIKIPATHWAYS,C2,18,14
Cohort,0.00247214880077445,0.006435097671968106,0.38416647684204763,0.7009758720430436,LGP Offspring,miRNA Biogenesis,CP:WIKIPATHWAYS,C2,1,3
Cohort,0.008598333382478326,0.025748554238041312,0.3339346086381431,0.7385128502041212,LGP Proband,miRNA Biogenesis,CP:WIKIPATHWAYS,C2,1,10
Cohort,-0.0070817649922945,0.006345199712229019,-1.1160822847933232,0.2647237137968984,LonGen OPEL,miRNA Biogenesis,CP:WIKIPATHWAYS,C2,4,2
Cohort,-0.04548723895688752,0.04410821589624426,-1.031264539556239,0.302785596929656,LGP Offspring,miRNA Regulation of DNA Damage Response,CP:WIKIPATHWAYS,C2,68,120
Cohort,0.13344816657566183,0.12277789517035774,1.086907104821261,0.2773918938045045,LGP Proband,miRNA Regulation of DNA Damage Response,CP:WIKIPATHWAYS,C2,68,162
Cohort,0.06736514335814871,0.03931888653475453,1.7133024176206946,0.08704628808997525,LonGen OPEL,miRNA Regulation of DNA Damage Response,CP:WIKIPATHWAYS,C2,94,140
Cohort,-0.0049205149178597,0.025471273442836048,-0.19317899157663138,0.8468768166547351,LGP Offspring,miRNA regulation of p53 pathway in prostate cancer,CP:WIKIPATHWAYS,C2,20,42
Cohort,0.17652155619245807,0.07005524616860764,2.519747853966701,0.011929646184271088,LGP Proband,miRNA regulation of p53 pathway in prostate cancer,CP:WIKIPATHWAYS,C2,20,61
Cohort,0.0016240329232106976,0.024067606558115868,0.06747795711589176,0.9462181548157627,LonGen OPEL,miRNA regulation of p53 pathway in prostate cancer,CP:WIKIPATHWAYS,C2,44,46
Cohort,0.007991446249114785,0.025966527964629456,0.30775952256691413,0.7583601204110156,LGP Offspring,miRNA regulation of prostate cancer signaling pathways,CP:WIKIPATHWAYS,C2,19,44
Cohort,0.05804199043530952,0.07215764872722552,0.8043775186567287,0.4214082069229579,LGP Proband,miRNA regulation of prostate cancer signaling pathways,CP:WIKIPATHWAYS,C2,19,58
Cohort,-0.043771472750957406,0.02250755683827812,-1.9447456276780872,0.05215746465969299,LonGen OPEL,miRNA regulation of prostate cancer signaling pathways,CP:WIKIPATHWAYS,C2,41,27
Cohort,0.03716701073977821,0.04593727053019966,0.8090818263863592,0.41875274884382163,LGP Offspring,miRNA targets in ECM and membrane receptors,CP:WIKIPATHWAYS,C2,57,137
Cohort,-0.05099536316434956,0.11429586112684764,-0.44616981456357346,0.6555903975858193,LGP Proband,miRNA targets in ECM and membrane receptors,CP:WIKIPATHWAYS,C2,57,170
Cohort,-0.023382227194559457,0.03630978321656303,-0.6439649351553673,0.5197836724533432,LonGen OPEL,miRNA targets in ECM and membrane receptors,CP:WIKIPATHWAYS,C2,96,104
Cohort,0.010110127194123481,0.01948138770302916,0.5189633997454637,0.6039561117195312,LGP Offspring,miRNAs involved in DNA damage response,CP:WIKIPATHWAYS,C2,11,28
Cohort,0.06592465890371792,0.05171606185239251,1.2747424405957175,0.20275544948854743,LGP Proband,miRNAs involved in DNA damage response,CP:WIKIPATHWAYS,C2,11,32
Cohort,0.007617199214641203,0.017753641261121236,0.42904996798161826,0.6680029539789345,LonGen OPEL,miRNAs involved in DNA damage response,CP:WIKIPATHWAYS,C2,20,25
Cohort,-0.01046618432242443,0.026779047664591698,-0.39083482181717866,0.696042474737788,LGP Offspring,miRNAs involvement in the immune response in sepsis,CP:WIKIPATHWAYS,C2,19,41
Cohort,-0.024707104912624442,0.06644837538067748,-0.371824062982419,0.7101182952358036,LGP Proband,miRNAs involvement in the immune response in sepsis,CP:WIKIPATHWAYS,C2,19,46
Cohort,0.02094393778554321,0.023615847601306878,0.886859457222454,0.37542243566274835,LonGen OPEL,miRNAs involvement in the immune response in sepsis,CP:WIKIPATHWAYS,C2,30,42
Cohort,0.009852739103286458,0.010114022546711256,0.9741662190075147,0.33032247049044494,LGP Offspring,Mitochondrial CII Assembly,CP:WIKIPATHWAYS,C2,1,9
Cohort,0.04041615703078158,0.03021644369326411,1.3375550558185378,0.18140616083025543,LGP Proband,Mitochondrial CII Assembly,CP:WIKIPATHWAYS,C2,1,14
Cohort,0.002781941985753316,0.013014672819106652,0.21375427753121748,0.8307934205479925,LonGen OPEL,Mitochondrial CII Assembly,CP:WIKIPATHWAYS,C2,11,15
Cohort,-0.011840842925181923,0.015826448296376822,-0.7481680477794042,0.4546190037267305,LGP Offspring,Mitochondrial CIII assembly,CP:WIKIPATHWAYS,C2,10,16
Cohort,-8.259690013877314e-4,0.04412878449693052,-0.01871723889075584,0.9850711528068751,LGP Proband,Mitochondrial CIII assembly,CP:WIKIPATHWAYS,C2,10,23
Cohort,-0.004487219856504359,0.01352059648120146,-0.3318803177613669,0.7400669977138391,LonGen OPEL,Mitochondrial CIII assembly,CP:WIKIPATHWAYS,C2,12,12
Cohort,-0.021601567692564737,0.021307130104461225,-1.0138187351679926,0.31103197475151156,LGP Offspring,Mitochondrial CIV Assembly,CP:WIKIPATHWAYS,C2,19,29
Cohort,-0.024892076326205805,0.059517224506595544,-0.4182331506982038,0.6758843270759888,LGP Proband,Mitochondrial CIV Assembly,CP:WIKIPATHWAYS,C2,19,38
Cohort,-0.006886630903862145,0.018404266861757824,-0.3741866468026421,0.708365109816363,LonGen OPEL,Mitochondrial CIV Assembly,CP:WIKIPATHWAYS,C2,24,27
Cohort,0.017212860153667527,0.027999639656876796,0.6147529169876298,0.5389247701849199,LGP Offspring,Mitochondrial complex I assembly model OXPHOS system,CP:WIKIPATHWAYS,C2,23,56
Cohort,0.11741766246913336,0.07887499688382796,1.4886550504981124,0.1369562442421338,LGP Proband,Mitochondrial complex I assembly model OXPHOS system,CP:WIKIPATHWAYS,C2,23,87
Cohort,0.024629741288733187,0.0264874227932212,0.9298655245174158,0.35272261731224186,LonGen OPEL,Mitochondrial complex I assembly model OXPHOS system,CP:WIKIPATHWAYS,C2,39,64
Cohort,-0.0022209361293172537,0.0100933847500577,-0.22003878622625153,0.8259073786649823,LGP Offspring,Mitochondrial fatty acid synthesis pathway,CP:WIKIPATHWAYS,C2,4,6
Cohort,-0.01014764413184473,0.027344269144342473,-0.3711067967579699,0.7106522363975478,LGP Proband,Mitochondrial fatty acid synthesis pathway,CP:WIKIPATHWAYS,C2,4,8
Cohort,-0.0026746120001159206,0.006337898934912346,-0.42200294254974746,0.6731368183948969,LonGen OPEL,Mitochondrial fatty acid synthesis pathway,CP:WIKIPATHWAYS,C2,3,3
Cohort,0.008951288558298302,0.0263366126324271,0.3398800249382481,0.7340524554055212,LGP Offspring,Mitochondrial Gene Expression,CP:WIKIPATHWAYS,C2,18,45
Cohort,0.08335267760430622,0.07415015361416927,1.1241066072232444,0.2612912436748055,LGP Proband,Mitochondrial Gene Expression,CP:WIKIPATHWAYS,C2,18,61
Cohort,-0.029387279924670127,0.02646622574184988,-1.1103691252130943,0.26717530037748766,LonGen OPEL,Mitochondrial Gene Expression,CP:WIKIPATHWAYS,C2,49,51
Cohort,0.005389264763275003,0.026437335140468254,0.20385052936086315,0.8385316559834232,LGP Offspring,Mitochondrial LC-Fatty Acid Beta-Oxidation,CP:WIKIPATHWAYS,C2,22,44
Cohort,-0.05057727631773291,0.07059243296365099,-0.7164688082613024,0.4739024955551361,LGP Proband,Mitochondrial LC-Fatty Acid Beta-Oxidation,CP:WIKIPATHWAYS,C2,22,60
Cohort,-0.0381760002097984,0.026569215277503826,-1.4368508746331718,0.15115329673373787,LonGen OPEL,Mitochondrial LC-Fatty Acid Beta-Oxidation,CP:WIKIPATHWAYS,C2,54,54
Cohort,-0.003932484933141876,0.021382626964256794,-0.1839102809825668,0.8541389909823814,LGP Offspring,Molybdenum cofactor (Moco) biosynthesis,CP:WIKIPATHWAYS,C2,17,32
Cohort,0.008644621322966253,0.059195069700103,0.14603617103184544,0.8839281233627689,LGP Proband,Molybdenum cofactor (Moco) biosynthesis,CP:WIKIPATHWAYS,C2,17,45
Cohort,2.3621061147153174e-4,0.01956807144825916,0.01207122593026641,0.9903718137977895,LonGen OPEL,Molybdenum cofactor (Moco) biosynthesis,CP:WIKIPATHWAYS,C2,27,32
Cohort,-0.023126208649176725,0.02381221023904179,-0.9711911837255528,0.3318004474138586,LGP Offspring,Monoamine GPCRs,CP:WIKIPATHWAYS,C2,21,32
Cohort,0.023153514004469196,0.06265071073805499,0.36956506529151634,0.7118004002147857,LGP Proband,Monoamine GPCRs,CP:WIKIPATHWAYS,C2,21,44
Cohort,-0.002772380818729235,0.018856969671607902,-0.1470215451904494,0.8831522427336576,LonGen OPEL,Monoamine GPCRs,CP:WIKIPATHWAYS,C2,25,27
Cohort,-0.016160783055869956,0.026357197524510028,-0.6131449688777327,0.5399867180297049,LGP Offspring,Monoamine Transport,CP:WIKIPATHWAYS,C2,25,41
Cohort,-0.1606135621948401,0.06563007411404402,-2.447255535865238,0.014600188156800125,LGP Proband,Monoamine Transport,CP:WIKIPATHWAYS,C2,25,44
Cohort,-0.0039033095170421007,0.022451529436620567,-0.17385494952853564,0.862023661568248,LonGen OPEL,Monoamine Transport,CP:WIKIPATHWAYS,C2,35,38
Cohort,-0.018839238220073266,0.05084365075487073,-0.3705327595554003,0.7111016448548759,LGP Offspring,mRNA Processing,CP:WIKIPATHWAYS,C2,81,158
Cohort,0.21741309842133316,0.142979737880949,1.5205867743467296,0.1287425838266966,LGP Proband,mRNA Processing,CP:WIKIPATHWAYS,C2,81,237
Cohort,0.019375985640178853,0.04351570523011764,0.4452641991601815,0.6562498976185016,LonGen OPEL,mRNA Processing,CP:WIKIPATHWAYS,C2,125,157
Cohort,-0.040989273724162924,0.030268749701956036,-1.3541779600336152,0.17613210107788754,LGP Offspring,MTHFR deficiency,CP:WIKIPATHWAYS,C2,37,57
Cohort,-0.08460459920118561,0.09484168939689136,-0.892061283800357,0.37261738571651815,LGP Proband,MTHFR deficiency,CP:WIKIPATHWAYS,C2,37,113
Cohort,0.01947369447952645,0.026189527735628024,0.7435679893163782,0.4573572877269315,LonGen OPEL,MTHFR deficiency,CP:WIKIPATHWAYS,C2,48,62
Cohort,-0.03504974648120813,0.058928176204939585,-0.5947875657870797,0.5521845067427176,LGP Offspring,Myometrial Relaxation and Contraction Pathways,CP:WIKIPATHWAYS,C2,128,247
Cohort,-0.062144777750700736,0.17505723443255336,-0.35499691259343,0.7226816570345778,LGP Proband,Myometrial Relaxation and Contraction Pathways,CP:WIKIPATHWAYS,C2,128,344
Cohort,0.10721441484904404,0.051212442721398195,2.0935227681347532,0.036618397129307596,LonGen OPEL,Myometrial Relaxation and Contraction Pathways,CP:WIKIPATHWAYS,C2,180,255
Cohort,0.022761944467048885,0.01631930464887641,1.3947864174847702,0.16353838655524214,LGP Offspring,"NAD Biosynthesis II (from tryptophan)",CP:WIKIPATHWAYS,C2,6,21
Cohort,-0.060504646427832494,0.03960798930001935,-1.527586921151863,0.12699427999265425,LGP Proband,"NAD Biosynthesis II (from tryptophan)",CP:WIKIPATHWAYS,C2,6,20
Cohort,0.0029506672259338364,0.016715222370877303,0.17652575361933218,0.8599258198537234,LonGen OPEL,"NAD Biosynthesis II (from tryptophan)",CP:WIKIPATHWAYS,C2,18,21
Cohort,-0.0029603555389691124,0.033147722635038644,-0.08930796156233921,0.9288636190867591,LGP Offspring,"NAD+ biosynthetic pathways",CP:WIKIPATHWAYS,C2,37,68
Cohort,-0.1381656090566582,0.08198062116562163,-1.6853447447968057,0.09229616011938889,LGP Proband,"NAD+ biosynthetic pathways",CP:WIKIPATHWAYS,C2,37,81
Cohort,-0.0077880819957134115,0.03402867621940064,-0.22886820355571819,0.8190301413778334,LonGen OPEL,"NAD+ biosynthetic pathways",CP:WIKIPATHWAYS,C2,75,81
Cohort,-0.00227523432976282,0.022048626766253934,-0.10319165696274257,0.9178414658052778,LGP Offspring,"NAD+ metabolism",CP:WIKIPATHWAYS,C2,16,29
Cohort,-0.07778730151505814,0.05758854414621689,-1.350742628908221,0.1771442537319184,LGP Proband,"NAD+ metabolism",CP:WIKIPATHWAYS,C2,16,40
Cohort,-0.006521590639816698,0.020308051529480856,-0.32113325251068103,0.7481937084750037,LonGen OPEL,"NAD+ metabolism",CP:WIKIPATHWAYS,C2,32,32
Cohort,-0.01054591638748102,0.027883656674439018,-0.37821138420300787,0.7053923041955008,LGP Offspring,"NAD Metabolism in Oncogene-Induced Senescence and Mitochondrial Dysfunction-Associated Senescence",CP:WIKIPATHWAYS,C2,25,50
Cohort,0.09398304906546735,0.07047808147437087,1.3335074834527665,0.1827294083124612,LGP Proband,"NAD Metabolism in Oncogene-Induced Senescence and Mitochondrial Dysfunction-Associated Senescence",CP:WIKIPATHWAYS,C2,25,60
Cohort,0.0211018604321469,0.02531853370045191,0.8334550761038052,0.40483814066506496,LonGen OPEL,"NAD Metabolism in Oncogene-Induced Senescence and Mitochondrial Dysfunction-Associated Senescence",CP:WIKIPATHWAYS,C2,44,56
Cohort,0.018226629881634662,0.024927328339406075,0.7311906688700894,0.4649160652513018,LGP Offspring,"NAD metabolism, sirtuins and aging",CP:WIKIPATHWAYS,C2,17,43
Cohort,-0.07141321527434515,0.07055702089741864,-1.0121347863903056,0.3117671548271817,LGP Proband,"NAD metabolism, sirtuins and aging",CP:WIKIPATHWAYS,C2,17,61
Cohort,-0.04740842609527819,0.023421943852500633,-2.0241029691571333,0.043293102036461084,LonGen OPEL,"NAD metabolism, sirtuins and aging",CP:WIKIPATHWAYS,C2,47,38
Cohort,-0.028385582158684343,0.025442581583106253,-1.1156722467790858,0.2649588914445996,LGP Offspring,Nanomaterial induced apoptosis,CP:WIKIPATHWAYS,C2,25,40
Cohort,-0.023613113300075303,0.06111130473038115,-0.38639517523402134,0.6993025794032005,LGP Proband,Nanomaterial induced apoptosis,CP:WIKIPATHWAYS,C2,25,37
Cohort,-0.009078901832591708,0.0216212444491524,-0.4199065347021513,0.6746670465975606,LonGen OPEL,Nanomaterial induced apoptosis,CP:WIKIPATHWAYS,C2,37,38
Cohort,0.013705736316388065,0.010998943849143981,1.2460956710361555,0.21316093741559689,LGP Offspring,Nanomaterial-induced Inflammasome Activation,CP:WIKIPATHWAYS,C2,2,10
Cohort,0.013354086739789656,0.03036585083120098,0.4397731785624232,0.6602153301237392,LGP Proband,Nanomaterial-induced Inflammasome Activation,CP:WIKIPATHWAYS,C2,2,13
Cohort,-0.0060972391680061055,0.010504648157742507,-0.5804324977331204,0.5617872695661326,LonGen OPEL,Nanomaterial-induced Inflammasome Activation,CP:WIKIPATHWAYS,C2,9,8
Cohort,-0.06601018597878243,0.03416968689529781,-1.9318346750161846,0.05379751728341721,LGP Offspring,Nanoparticle triggered autophagic cell death,CP:WIKIPATHWAYS,C2,47,64
Cohort,-0.20917743644676126,0.08651048991487309,-2.417943033874774,0.015821883931271184,LGP Proband,Nanoparticle triggered autophagic cell death,CP:WIKIPATHWAYS,C2,47,74
Cohort,0.014873185882654693,0.024098263592949993,0.6171891109617491,0.5372864966698212,LonGen OPEL,Nanoparticle triggered autophagic cell death,CP:WIKIPATHWAYS,C2,41,49
Cohort,-0.005625123611356048,0.01268003065479697,-0.44362066342702516,0.6574588143016358,LGP Offspring,Nanoparticle triggered regulated necrosis,CP:WIKIPATHWAYS,C2,7,10
Cohort,-0.010197427643112931,0.04261268339537082,-0.2393049869330857,0.8109278946259985,LGP Proband,Nanoparticle triggered regulated necrosis,CP:WIKIPATHWAYS,C2,7,24
Cohort,-0.02616387382176477,0.014365839673668113,-1.821256147645994,0.06894317233810232,LonGen OPEL,Nanoparticle triggered regulated necrosis,CP:WIKIPATHWAYS,C2,20,12
Cohort,0.021162414424858028,0.027307399021845948,0.7749699782073011,0.43862838734906495,LGP Offspring,Nanoparticle-mediated activation of receptor signaling,CP:WIKIPATHWAYS,C2,21,50
Cohort,-0.005851529684940049,0.07607159506484525,-0.07692134863153673,0.9387045631054931,LGP Proband,Nanoparticle-mediated activation of receptor signaling,CP:WIKIPATHWAYS,C2,21,72
Cohort,-0.0547391691002775,0.02164591469688108,-2.52884527481598,0.01163596966589428,LonGen OPEL,Nanoparticle-mediated activation of receptor signaling,CP:WIKIPATHWAYS,C2,38,27
Cohort,0.02520025865705703,0.025439607867097674,0.9905914740788828,0.32223953370657066,LGP Offspring,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,CP:WIKIPATHWAYS,C2,16,47
Cohort,0.04204133086757518,0.05674288227293716,0.7409093296557178,0.4589569682404965,LGP Proband,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,CP:WIKIPATHWAYS,C2,16,37
Cohort,-0.0021784568889017626,0.021399606307281174,-0.10179892366340156,0.9189419170841219,LonGen OPEL,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,CP:WIKIPATHWAYS,C2,32,36
Cohort,-0.0016149898394024111,0.042473551069712207,-0.03802342395981241,0.9696802317174444,LGP Offspring,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,CP:WIKIPATHWAYS,C2,58,124
Cohort,-0.02925807266914054,0.11614505502448638,-0.2519097576988722,0.8011728800137702,LGP Proband,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,CP:WIKIPATHWAYS,C2,58,164
Cohort,-0.0639390449717963,0.03397013013548473,-1.882213718840201,0.060171574966986725,LonGen OPEL,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,CP:WIKIPATHWAYS,C2,93,88
Cohort,-0.004185287590791678,0.035578982683703034,-0.11763370605615293,0.9063928387647315,LGP Offspring,Neovascularisation processes,CP:WIKIPATHWAYS,C2,40,86
Cohort,-0.06113543704202632,0.08815367005024805,-0.6935098335347673,0.4881827524797213,LGP Proband,Neovascularisation processes,CP:WIKIPATHWAYS,C2,40,95
Cohort,-0.006656986910817099,0.0327932198969019,-0.2029988800046442,0.8391877851914947,LonGen OPEL,Neovascularisation processes,CP:WIKIPATHWAYS,C2,75,91
Cohort,-0.0013844962219223566,0.01309821898276967,-0.10570110514594554,0.9158508602357243,LGP Offspring,Nephrogenesis,CP:WIKIPATHWAYS,C2,5,12
Cohort,-0.0018517300725563175,0.032257267496177425,-0.05740505059133582,0.9542362901434176,LGP Proband,Nephrogenesis,CP:WIKIPATHWAYS,C2,5,12
Cohort,-0.01640409203954926,0.01027482289469252,-1.5965328266653458,0.11076677833582647,LonGen OPEL,Nephrogenesis,CP:WIKIPATHWAYS,C2,10,6
Cohort,0.0029952018551426094,0.04466473922359247,0.06705965168963768,0.9465540431701654,LGP Offspring,Nephrotic syndrome,CP:WIKIPATHWAYS,C2,59,133
Cohort,0.2046187198272646,0.1237910070961811,1.6529368701902822,0.09872006959450037,LGP Proband,Nephrotic syndrome,CP:WIKIPATHWAYS,C2,59,194
Cohort,0.00559285680949406,0.039728814600626806,0.14077582897240082,0.8880826545590688,LonGen OPEL,Nephrotic syndrome,CP:WIKIPATHWAYS,C2,99,125
Cohort,-0.06504609865414326,0.036851399764904126,-1.7650916673208896,0.07799982394654005,LGP Offspring,Netrin-UNC5B signaling Pathway,CP:WIKIPATHWAYS,C2,50,84
Cohort,0.13241974879172283,0.11532771401575276,1.1482040541758718,0.25121356346958323,LGP Proband,Netrin-UNC5B signaling Pathway,CP:WIKIPATHWAYS,C2,50,156
Cohort,-0.06628999422009378,0.037910828723396545,-1.7485767642737688,0.08074967614992083,LonGen OPEL,Netrin-UNC5B signaling Pathway,CP:WIKIPATHWAYS,C2,118,118
Cohort,0.0052147584864570065,0.03503269201305028,0.14885406135829982,0.8817131844203361,LGP Offspring,Neural Crest Cell Migration during Development,CP:WIKIPATHWAYS,C2,35,78
Cohort,-0.05848764400381028,0.09408599125028873,-0.6216403018832072,0.5343482967286649,LGP Proband,Neural Crest Cell Migration during Development,CP:WIKIPATHWAYS,C2,35,100
Cohort,0.020029621957771512,0.031470233954975245,0.6364624421422503,0.5246580242518879,LonGen OPEL,Neural Crest Cell Migration during Development,CP:WIKIPATHWAYS,C2,63,79
Cohort,0.005757014674957651,0.037283055966766065,0.15441370149725456,0.8773296395847547,LGP Offspring,Neural Crest Cell Migration in Cancer,CP:WIKIPATHWAYS,C2,40,90
Cohort,-0.08420355134757875,0.09691246625529201,-0.8688619184013462,0.3851726242461512,LGP Proband,Neural Crest Cell Migration in Cancer,CP:WIKIPATHWAYS,C2,40,105
Cohort,0.03010496213506467,0.03339833015659974,0.9013912370440988,0.3676529854484982,LonGen OPEL,Neural Crest Cell Migration in Cancer,CP:WIKIPATHWAYS,C2,68,90
Cohort,-0.031753076704459024,0.04244284495230279,-0.748137330099881,0.45463751746268655,LGP Offspring,Neural Crest Differentiation,CP:WIKIPATHWAYS,C2,63,117
Cohort,-0.13631395893968817,0.12454350597731513,-1.0945087651901895,0.2740479019176565,LGP Proband,Neural Crest Differentiation,CP:WIKIPATHWAYS,C2,63,184
Cohort,-0.008331595570022499,0.0403256168139021,-0.20660801317613606,0.8363688374846115,LonGen OPEL,Neural Crest Differentiation,CP:WIKIPATHWAYS,C2,112,127
Cohort,-0.07749934491838158,0.03765660235712504,-2.0580546323164985,0.039967720323060174,LGP Offspring,Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway,CP:WIKIPATHWAYS,C2,57,81
Cohort,-0.13065483834117997,0.09852650581913422,-1.3260882161093173,0.1851735324104529,LGP Proband,Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway,CP:WIKIPATHWAYS,C2,57,98
Cohort,-2.7547883136985585e-5,0.029954122458299797,-9.19669176599514e-4,0.9992664406918661,LonGen OPEL,Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway,CP:WIKIPATHWAYS,C2,65,74
Cohort,-0.007640790092771485,0.018603178117152282,-0.4107249871314522,0.6814043578847777,LGP Offspring,Neuroinflammation,CP:WIKIPATHWAYS,C2,14,20
Cohort,-0.06497661582529266,0.047092177587568444,-1.379775137908369,0.1680256814035019,LGP Proband,Neuroinflammation,CP:WIKIPATHWAYS,C2,14,24
Cohort,0.016062050511727044,0.016301404626045284,0.9853169637948981,0.3247677973024137,LonGen OPEL,Neuroinflammation,CP:WIKIPATHWAYS,C2,16,26
Cohort,0.007182441354711498,0.02540038590904453,0.2827689854961607,0.7774404917412852,LGP Offspring,Nicotine Activity on Dopaminergic Neurons,CP:WIKIPATHWAYS,C2,20,42
Cohort,-0.0657989628060888,0.07046290044030398,-0.9338100247779828,0.35067217006023865,LGP Proband,Nicotine Activity on Dopaminergic Neurons,CP:WIKIPATHWAYS,C2,20,58
Cohort,-0.033371619294689986,0.021828548433737063,-1.5288061593281463,0.12670977079566964,LonGen OPEL,Nicotine Activity on Dopaminergic Neurons,CP:WIKIPATHWAYS,C2,37,31
Cohort,-0.012574108944025036,0.016814400302397677,-0.7478178655132892,0.4548300859872627,LGP Offspring,Nicotine Metabolism,CP:WIKIPATHWAYS,C2,10,16
Cohort,-0.016588070437657608,0.05032460694708142,-0.32962146043387297,0.741768772513729,LGP Proband,Nicotine Metabolism,CP:WIKIPATHWAYS,C2,10,24
Cohort,0.0026618416767550165,0.014471814938483422,0.18393281617198215,0.8541130050015724,LonGen OPEL,Nicotine Metabolism,CP:WIKIPATHWAYS,C2,12,16
Cohort,9.496799263934903e-4,0.022959631067540037,0.04136303077344011,0.9670186981138621,LGP Offspring,NLR Proteins,CP:WIKIPATHWAYS,C2,14,32
Cohort,-0.008771322924631305,0.05987767172342491,-0.14648737454499006,0.8835720565376253,LGP Proband,NLR Proteins,CP:WIKIPATHWAYS,C2,14,41
Cohort,0.004023497405426582,0.021507016009385812,0.18707836566777555,0.8516468620591104,LonGen OPEL,NLR Proteins,CP:WIKIPATHWAYS,C2,29,33
Cohort,-0.01270018702716862,0.02212957344604878,-0.5739011218689454,0.5662256054919865,LGP Offspring,NO metabolism in cystic fibrosis,CP:WIKIPATHWAYS,C2,19,30
Cohort,-0.08369429709801766,0.06452524170607711,-1.2970783973078117,0.194962918694517,LGP Proband,NO metabolism in cystic fibrosis,CP:WIKIPATHWAYS,C2,19,52
Cohort,-0.0159731039750316,0.01839820919940977,-0.8681879742700193,0.3855531047501777,LonGen OPEL,NO metabolism in cystic fibrosis,CP:WIKIPATHWAYS,C2,28,26
Cohort,-0.024866288134094798,0.042874607948977295,-0.5799770382434003,0.5621233534785454,LGP Offspring,NO/cGMP/PKG mediated Neuroprotection,CP:WIKIPATHWAYS,C2,55,100
Cohort,-0.21254437757433117,0.11948095253180792,-1.7788975821710842,0.0756207207390083,LGP Proband,NO/cGMP/PKG mediated Neuroprotection,CP:WIKIPATHWAYS,C2,55,158
Cohort,0.028100844999712993,0.03852415207657585,0.7294344842128109,0.46595050953950246,LonGen OPEL,NO/cGMP/PKG mediated Neuroprotection,CP:WIKIPATHWAYS,C2,93,127
Cohort,0.12621920429741176,0.05692406834084498,2.217325781102774,0.02693268421646258,LGP Offspring,Nonalcoholic fatty liver disease,CP:WIKIPATHWAYS,C2,74,214
Cohort,-0.1598823481440844,0.13933275994465288,-1.1474856897085395,0.25151000279649904,LGP Proband,Nonalcoholic fatty liver disease,CP:WIKIPATHWAYS,C2,74,274
Cohort,0.013007269770695678,0.04932709017868736,0.2636942443508597,0.7920837791680437,LonGen OPEL,Nonalcoholic fatty liver disease,CP:WIKIPATHWAYS,C2,160,203
Cohort,-0.006024472357893451,0.043830827920969685,-0.13744829024804261,0.8907173907887462,LGP Offspring,"Non-genomic actions of 1,25 dihydroxyvitamin D3",CP:WIKIPATHWAYS,C2,65,127
Cohort,-0.120716367086695,0.12751961058872782,-0.9466494332077721,0.34409163705763834,LGP Proband,"Non-genomic actions of 1,25 dihydroxyvitamin D3",CP:WIKIPATHWAYS,C2,65,208
Cohort,-0.05540541727242064,0.03734650642127236,-1.4835502054045415,0.13832411636068773,LonGen OPEL,"Non-genomic actions of 1,25 dihydroxyvitamin D3",CP:WIKIPATHWAYS,C2,106,106
Cohort,0.005106074576977808,0.021380805660382227,0.2388158172373812,0.8113207843429425,LGP Offspring,Non-homologous end joining,CP:WIKIPATHWAYS,C2,14,31
Cohort,-0.10236675169622457,0.06028120505725374,-1.6981537047741317,0.0898517699585003,LGP Proband,Non-homologous end joining,CP:WIKIPATHWAYS,C2,14,44
Cohort,-0.018204360477466736,0.020252120244978213,-0.8988866477810269,0.36898486558611043,LonGen OPEL,Non-homologous end joining,CP:WIKIPATHWAYS,C2,31,33
Cohort,-0.024457198530339834,0.040358866291288716,-0.6059931999531616,0.5447226866202115,LGP Offspring,Non-small cell lung cancer,CP:WIKIPATHWAYS,C2,52,105
Cohort,0.2223930474221777,0.10320619141191027,2.154842111502556,0.031459850898503026,LGP Proband,Non-small cell lung cancer,CP:WIKIPATHWAYS,C2,52,129
Cohort,-0.023612750728769158,0.030211218908077393,-0.7815888131033323,0.43468866815248897,LonGen OPEL,Non-small cell lung cancer,CP:WIKIPATHWAYS,C2,72,74
Cohort,-0.021103137140371618,0.038408050836723245,-0.5494456677867701,0.5828810981362906,LGP Offspring,Notch Signaling,CP:WIKIPATHWAYS,C2,51,96
Cohort,-0.056674193670577196,0.1048398901239443,-0.5405785298284419,0.5889424546668934,LGP Proband,Notch Signaling,CP:WIKIPATHWAYS,C2,51,145
Cohort,-0.07048676414683669,0.03819763957787403,-1.8453172742031452,0.06536264593039423,LonGen OPEL,Notch Signaling,CP:WIKIPATHWAYS,C2,110,105
Cohort,0.0011698742723427573,0.03901711089421218,0.029983621173660432,0.9760889654783116,LGP Offspring,Notch Signaling Pathway Netpath,CP:WIKIPATHWAYS,C2,47,99
Cohort,-0.035662426061856704,0.10963767935693959,-0.3252752727988074,0.7450543262107227,LGP Proband,Notch Signaling Pathway Netpath,CP:WIKIPATHWAYS,C2,47,140
Cohort,-0.036086128962056783,0.03576124008985149,-1.0090849442409995,0.3132405332221121,LonGen OPEL,Notch Signaling Pathway Netpath,CP:WIKIPATHWAYS,C2,93,94
Cohort,-0.0041390738942489996,0.022588956843178683,-0.18323439736434308,0.854669048645516,LGP Offspring,NOTCH1 regulation of human endothelial cell calcification,CP:WIKIPATHWAYS,C2,17,32
Cohort,0.012030737637922886,0.06291231312017885,0.19123025432145618,0.8483917451753836,LGP Proband,NOTCH1 regulation of human endothelial cell calcification,CP:WIKIPATHWAYS,C2,17,45
Cohort,-0.008949075418947915,0.020224414677265705,-0.44248872275189177,0.6582557959764119,LonGen OPEL,NOTCH1 regulation of human endothelial cell calcification,CP:WIKIPATHWAYS,C2,30,31
Cohort,0.002410152205385675,0.0402687163294292,0.05985172672674163,0.9522914164641911,LGP Offspring,Novel intracellular components of RIG-I-like receptor (RLR) pathway,CP:WIKIPATHWAYS,C2,54,115
Cohort,-0.05764173559676518,0.108838572650538,-0.5296076031963678,0.5965249678292803,LGP Proband,Novel intracellular components of RIG-I-like receptor (RLR) pathway,CP:WIKIPATHWAYS,C2,54,163
Cohort,0.027277273901012422,0.03834854539320405,0.7112987890760094,0.47710748322005136,LonGen OPEL,Novel intracellular components of RIG-I-like receptor (RLR) pathway,CP:WIKIPATHWAYS,C2,89,123
Cohort,-0.03680609027734439,0.07356160339639414,-0.5003437741699437,0.6169958797894153,LGP Offspring,NRF2 pathway,CP:WIKIPATHWAYS,C2,164,332
Cohort,-0.15325814414910913,0.20970587224056925,-0.7308242850409801,0.4650917462268782,LGP Proband,NRF2 pathway,CP:WIKIPATHWAYS,C2,164,443
Cohort,-0.10628452421479968,0.06098086832465601,-1.7429158871426946,0.08173445323681422,LonGen OPEL,NRF2 pathway,CP:WIKIPATHWAYS,C2,260,274
Cohort,0.05529010258340944,0.025402691124821613,2.1765450877519066,0.029859938267391434,LGP Offspring,NRF2-ARE regulation,CP:WIKIPATHWAYS,C2,13,53
Cohort,0.02200982819443168,0.07143841847602742,0.30809512114014,0.7580868842971789,LGP Proband,NRF2-ARE regulation,CP:WIKIPATHWAYS,C2,13,66
Cohort,-0.04794674577810435,0.020379991565797125,-2.352638156071239,0.018883304517022675,LonGen OPEL,NRF2-ARE regulation,CP:WIKIPATHWAYS,C2,38,27
Cohort,-0.0025919039241819363,0.01236958187112322,-0.20953852370974108,0.8340909960693046,LGP Offspring,nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell,CP:WIKIPATHWAYS,C2,5,10
Cohort,0.007733656732744015,0.029392139539752615,0.2631198971508798,0.7925231570676772,LGP Proband,nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell,CP:WIKIPATHWAYS,C2,5,9
Cohort,-0.002021532712133782,0.00992365683045155,-0.20370844605695593,0.8386334074199351,LonGen OPEL,nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell,CP:WIKIPATHWAYS,C2,8,7
Cohort,0.025732853546552963,0.026187317193323737,0.9826456584530684,0.32613341623637015,LGP Offspring,Nuclear Receptors,CP:WIKIPATHWAYS,C2,20,49
Cohort,-0.050385358525446455,0.07349088834911918,-0.6856000744757679,0.49315585845831345,LGP Proband,Nuclear Receptors,CP:WIKIPATHWAYS,C2,20,68
Cohort,0.028879210422164295,0.02302174051533725,1.2544321052930274,0.21005320842212036,LonGen OPEL,Nuclear Receptors,CP:WIKIPATHWAYS,C2,32,51
Cohort,0.031532756661576865,0.03733600516551899,0.8445669675099141,0.39865145007374025,LGP Offspring,Nuclear Receptors in Lipid Metabolism and Toxicity,CP:WIKIPATHWAYS,C2,39,88
Cohort,0.04414427122359518,0.10580478550279829,0.41722376746775475,0.6766221173498022,LGP Proband,Nuclear Receptors in Lipid Metabolism and Toxicity,CP:WIKIPATHWAYS,C2,39,133
Cohort,-5.721320043117061e-4,0.03180849755382607,-0.017986766062859434,0.9856539182139439,LonGen OPEL,Nuclear Receptors in Lipid Metabolism and Toxicity,CP:WIKIPATHWAYS,C2,71,80
Cohort,-0.09903838184880219,0.09381979852332012,-1.0556234761491725,0.29151738729631105,LGP Offspring,Nuclear Receptors Meta-Pathway,CP:WIKIPATHWAYS,C2,298,564
Cohort,-0.04281863836867966,0.2752394460711175,-0.1555686838492474,0.8764106553886218,LGP Proband,Nuclear Receptors Meta-Pathway,CP:WIKIPATHWAYS,C2,298,809
Cohort,-0.17456603294440018,0.0821100017738724,-2.1260020603232714,0.03381029047780796,LonGen OPEL,Nuclear Receptors Meta-Pathway,CP:WIKIPATHWAYS,C2,478,509
Cohort,0.025873218087223197,0.03316671968341234,0.7800957807763896,0.43560754733154283,LGP Offspring,Nucleotide Excision Repair,CP:WIKIPATHWAYS,C2,32,80
Cohort,0.005188643969693441,0.09777807304263146,0.05306551671795762,0.9576924142105998,LGP Proband,Nucleotide Excision Repair,CP:WIKIPATHWAYS,C2,32,119
Cohort,0.032502356218700984,0.028115107294335626,1.1560459605732774,0.24800921167636145,LonGen OPEL,Nucleotide Excision Repair,CP:WIKIPATHWAYS,C2,49,71
Cohort,0.004131144367158408,0.006133291342380347,0.6735607582526969,0.5008208299509704,LGP Offspring,Nucleotide GPCRs,CP:WIKIPATHWAYS,C2,1,3
Cohort,-0.05498651878489693,0.01346541915335723,-4.083535622519968,4.8627807847242084e-5,LGP Proband,Nucleotide GPCRs,CP:WIKIPATHWAYS,C2,1,2
Cohort,-0.004513874563388648,0.006365034412517976,-0.7091673462929452,0.4784282879833879,LonGen OPEL,Nucleotide GPCRs,CP:WIKIPATHWAYS,C2,4,2
Cohort,-0.007087394437162754,0.02026452879500761,-0.34974385582105477,0.7266398682006392,LGP Offspring,Nucleotide Metabolism,CP:WIKIPATHWAYS,C2,10,21
Cohort,0.009916458222144445,0.056286783646095406,0.1761773826782221,0.8601973581990756,LGP Proband,Nucleotide Metabolism,CP:WIKIPATHWAYS,C2,10,35
Cohort,2.9399108600305414e-4,0.017308164374265862,0.0169856883518027,0.9864522895869556,LonGen OPEL,Nucleotide Metabolism,CP:WIKIPATHWAYS,C2,19,26
Cohort,0.027339291572474198,0.0444042818923619,0.6156904336105681,0.5383060844029205,LGP Offspring,Nucleotide-binding Oligomerization Domain (NOD) pathway,CP:WIKIPATHWAYS,C2,55,129
Cohort,0.0780810968179354,0.11308343373756913,0.6904733455400455,0.4900886743241526,LGP Proband,Nucleotide-binding Oligomerization Domain (NOD) pathway,CP:WIKIPATHWAYS,C2,55,138
Cohort,0.09745314229885045,0.03639470932590782,2.6776733240586092,0.007566294732467084,LonGen OPEL,Nucleotide-binding Oligomerization Domain (NOD) pathway,CP:WIKIPATHWAYS,C2,66,120
Cohort,-0.04281267958682674,0.022183026737213115,-1.929974664593735,0.05402804061983771,LGP Offspring,"Oligodendrocyte specification and differentiation, leading to Myelin Components for CNS",CP:WIKIPATHWAYS,C2,21,27
Cohort,0.09871531326930891,0.07062763672957115,1.3976867673950883,0.16257880117170878,LGP Proband,"Oligodendrocyte specification and differentiation, leading to Myelin Components for CNS",CP:WIKIPATHWAYS,C2,21,60
Cohort,0.012433024118477999,0.01966564906697099,0.6322203796140963,0.5274244256913159,LonGen OPEL,"Oligodendrocyte specification and differentiation, leading to Myelin Components for CNS",CP:WIKIPATHWAYS,C2,30,33
Cohort,-6.208726774130501e-4,0.017151421911440482,-0.03619948716898571,0.9711339814999325,LGP Offspring,Omega-3/Omega-6 FA synthesis,CP:WIKIPATHWAYS,C2,11,19
Cohort,-0.004590232619853963,0.05274968058851076,-0.08701915478240349,0.9306771744702473,LGP Proband,Omega-3/Omega-6 FA synthesis,CP:WIKIPATHWAYS,C2,11,36
Cohort,-0.030075514813158122,0.01894103545247203,-1.5878495602114988,0.1127174720294083,LonGen OPEL,Omega-3/Omega-6 FA synthesis,CP:WIKIPATHWAYS,C2,30,26
Cohort,-0.02415859480015833,0.017357798679757855,-1.3918006105423588,0.16444054333485897,LGP Offspring,Omega-9 FA synthesis,CP:WIKIPATHWAYS,C2,14,17
Cohort,-0.04011490910529997,0.053873576371471964,-0.7446119564941726,0.4567160963567044,LGP Proband,Omega-9 FA synthesis,CP:WIKIPATHWAYS,C2,14,34
Cohort,-0.015638686476282165,0.019475815940485443,-0.8029797839572499,0.422226110441674,LonGen OPEL,Omega-9 FA synthesis,CP:WIKIPATHWAYS,C2,28,29
Cohort,0.015181798894387344,0.04277384366505205,0.354931836691391,0.7227513610095933,LGP Offspring,Oncostatin M Signaling Pathway,CP:WIKIPATHWAYS,C2,55,127
Cohort,0.07107880833256161,0.11966856109108305,0.5939639257336901,0.5526973090994088,LGP Proband,Oncostatin M Signaling Pathway,CP:WIKIPATHWAYS,C2,55,158
Cohort,-0.027539897440743866,0.03579856037602506,-0.7693018141362978,0.4419423705011619,LonGen OPEL,Oncostatin M Signaling Pathway,CP:WIKIPATHWAYS,C2,93,99
Cohort,-0.027609871836766962,0.03921308260796552,-0.704098479397752,0.4816139142206649,LGP Offspring,One Carbon Metabolism,CP:WIKIPATHWAYS,C2,56,102
Cohort,-0.22849218579914468,0.11624561430913202,-1.9655983338133969,0.0496764665401589,LGP Proband,One Carbon Metabolism,CP:WIKIPATHWAYS,C2,56,177
Cohort,-0.017005881159359505,0.03494592936204942,-0.4866341078863266,0.6266516054964006,LonGen OPEL,One Carbon Metabolism,CP:WIKIPATHWAYS,C2,88,100
Cohort,-0.06366526157576455,0.04469049774062547,-1.4245816178925714,0.15473965032470252,LGP Offspring,One carbon metabolism and related pathways,CP:WIKIPATHWAYS,C2,69,116
Cohort,-0.13138824819053843,0.12465321070295951,-1.0540301966519585,0.2921743527039811,LGP Proband,One carbon metabolism and related pathways,CP:WIKIPATHWAYS,C2,69,181
Cohort,-0.035576811721623615,0.03790524343125982,-0.938572305600444,0.3482350758718443,LonGen OPEL,One carbon metabolism and related pathways,CP:WIKIPATHWAYS,C2,108,115
Cohort,-0.05461486497455757,0.055423816910579994,-0.9854042543239565,0.32477809459884044,LGP Offspring,Osteoblast differentiation,CP:WIKIPATHWAYS,C2,106,200
Cohort,-0.023497990202572466,0.1510839260419292,-0.15552938567436514,0.8764416240225412,LGP Proband,Osteoblast differentiation,CP:WIKIPATHWAYS,C2,106,284
Cohort,-0.07653049158622885,0.04686934719567191,-1.632847397398698,0.10289656628864709,LonGen OPEL,Osteoblast differentiation,CP:WIKIPATHWAYS,C2,160,158
Cohort,-0.025170772516302984,0.009971991823760983,-2.5241469268282763,0.011825836858547491,LGP Offspring,Osteoblast Signaling,CP:WIKIPATHWAYS,C2,7,3
Cohort,-0.0234962331288728,0.03630835622351411,-0.6471301808385396,0.5177257634157382,LGP Proband,Osteoblast Signaling,CP:WIKIPATHWAYS,C2,7,15
Cohort,0.002062634185742765,0.01122876462731457,0.18369199588753488,0.8543018697530124,LonGen OPEL,Osteoblast Signaling,CP:WIKIPATHWAYS,C2,8,11
Cohort,0.005269079371010666,0.01919531836127552,0.2744981495925832,0.7837856893842698,LGP Offspring,Osteoclast Signaling,CP:WIKIPATHWAYS,C2,12,26
Cohort,0.01779285363249592,0.04696315463440188,0.3788683654454111,0.7048820465535797,LGP Proband,Osteoclast Signaling,CP:WIKIPATHWAYS,C2,12,25
Cohort,0.002785565222792323,0.017713855387669734,0.15725346977436094,0.875084967985071,LonGen OPEL,Osteoclast Signaling,CP:WIKIPATHWAYS,C2,21,26
Cohort,0.03246426657024001,0.02241234074983634,1.4484995981723625,0.1479410419667577,LGP Offspring,Osteopontin Signaling,CP:WIKIPATHWAYS,C2,10,38
Cohort,-0.016281977837089005,0.05401011824619532,-0.3014616217441066,0.7631376591735108,LGP Proband,Osteopontin Signaling,CP:WIKIPATHWAYS,C2,10,38
Cohort,-0.013180698153406925,0.02203711996411408,-0.5981134637770623,0.5499343614869443,LonGen OPEL,Osteopontin Signaling,CP:WIKIPATHWAYS,C2,36,37
Cohort,0.013038201859205468,0.03372478412263447,0.38660593976804275,0.6991696207900262,LGP Offspring,Ovarian Infertility Genes,CP:WIKIPATHWAYS,C2,35,76
Cohort,0.04887899067335067,0.09610791590579328,0.508584440861903,0.6111780417322952,LGP Proband,Ovarian Infertility Genes,CP:WIKIPATHWAYS,C2,35,114
Cohort,-0.008805137750437323,0.028911623065831886,-0.30455356070421874,0.7607857984215498,LonGen OPEL,Ovarian Infertility Genes,CP:WIKIPATHWAYS,C2,57,61
Cohort,-0.08281610792798483,0.024146557979026848,-3.42972725139198,6.409056602637248e-4,LGP Offspring,Overview of interferons-mediated signaling pathway,CP:WIKIPATHWAYS,C2,28,26
Cohort,-0.03298708669038981,0.07560738968451028,-0.436294478992546,0.6627360038423491,LGP Proband,Overview of interferons-mediated signaling pathway,CP:WIKIPATHWAYS,C2,28,54
Cohort,-0.021681105500619746,0.021472324706115126,-1.009723250619676,0.3129347272508405,LonGen OPEL,Overview of interferons-mediated signaling pathway,CP:WIKIPATHWAYS,C2,35,36
Cohort,-0.005008665124735604,0.02927648652506353,-0.17108149642368106,0.864210880071895,LGP Offspring,Overview of leukocyte-intrinsic Hippo pathway functions,CP:WIKIPATHWAYS,C2,26,54
Cohort,0.024651161034666483,0.07873144452841417,0.31310439154675845,0.7542796345758511,LGP Proband,Overview of leukocyte-intrinsic Hippo pathway functions,CP:WIKIPATHWAYS,C2,26,59
Cohort,0.008838035250076376,0.025082404198802536,0.3523599723545765,0.7246615874876718,LonGen OPEL,Overview of leukocyte-intrinsic Hippo pathway functions,CP:WIKIPATHWAYS,C2,44,53
Cohort,0.02776711752539559,0.026251872903011963,1.0577194864527086,0.29056116742815596,LGP Offspring,Overview of nanoparticle effects,CP:WIKIPATHWAYS,C2,18,47
Cohort,-0.11236452650818565,0.06798763739148199,-1.6527199770331118,0.09876423712730978,LGP Proband,Overview of nanoparticle effects,CP:WIKIPATHWAYS,C2,18,59
Cohort,-0.02963824028821303,0.023882104767803506,-1.241022957414106,0.21496288070252198,LonGen OPEL,Overview of nanoparticle effects,CP:WIKIPATHWAYS,C2,45,38
Cohort,-8.101682309991533e-4,0.04346546852960054,-0.01863935345474117,0.9851343087204937,LGP Offspring,Oxidation by Cytochrome P450,CP:WIKIPATHWAYS,C2,56,122
Cohort,0.08738476491599029,0.12815648984821404,0.681859849778088,0.49551688437047625,LGP Proband,Oxidation by Cytochrome P450,CP:WIKIPATHWAYS,C2,56,199
Cohort,-0.011854737666515562,0.03840218062508505,-0.30869959657373774,0.7576308240091812,LonGen OPEL,Oxidation by Cytochrome P450,CP:WIKIPATHWAYS,C2,102,116
Cohort,-0.033289635874997864,0.032280562150750675,-1.0312594842535519,0.3027879651949287,LGP Offspring,Oxidative Damage,CP:WIKIPATHWAYS,C2,41,69
Cohort,-0.052551660812672034,0.08419219584337803,-0.6241868416216796,0.5326755850303649,LGP Proband,Oxidative Damage,CP:WIKIPATHWAYS,C2,41,85
Cohort,-0.03233783443807957,0.029363952141426813,-1.101276636139765,0.2711091699422456,LonGen OPEL,Oxidative Damage,CP:WIKIPATHWAYS,C2,63,66
Cohort,0.028245037559722623,0.023310257416282176,1.2116999420175218,0.22605063091611535,LGP Offspring,Oxidative phosphorylation,CP:WIKIPATHWAYS,C2,15,40
Cohort,-0.03171343789509781,0.06549387738636485,-0.4842198868149502,0.6283569532820473,LGP Proband,Oxidative phosphorylation,CP:WIKIPATHWAYS,C2,15,60
Cohort,0.00430874112494875,0.022741431037882242,0.18946657832443925,0.84977544775152,LonGen OPEL,Oxidative phosphorylation,CP:WIKIPATHWAYS,C2,34,48
Cohort,-0.057732875176738016,0.03257919730700879,-1.7720778886199844,0.07683200738119152,LGP Offspring,Oxidative Stress,CP:WIKIPATHWAYS,C2,43,62
Cohort,0.019113618794043483,0.0866924029215851,0.22047628338704728,0.8255542004278534,LGP Proband,Oxidative Stress,CP:WIKIPATHWAYS,C2,43,89
Cohort,-0.01792445809835849,0.02524776876272552,-0.7099422632870916,0.4779478587686513,LonGen OPEL,Oxidative Stress,CP:WIKIPATHWAYS,C2,47,54
Cohort,0.0029083485618157366,0.03325731790132873,0.08744988307369006,0.9303398178692426,LGP Offspring,Oxysterols derived from cholesterol,CP:WIKIPATHWAYS,C2,33,73
Cohort,-0.1514693215802915,0.09046804455690508,-1.674285349287241,0.09444946063712387,LGP Proband,Oxysterols derived from cholesterol,CP:WIKIPATHWAYS,C2,33,104
Cohort,-0.035345499847784234,0.025694624487226043,-1.3755990038054877,0.1693327708133751,LonGen OPEL,Oxysterols derived from cholesterol,CP:WIKIPATHWAYS,C2,54,48
Cohort,-0.01906402595565824,0.025445054833085536,-0.7492232215931319,0.45398330247809293,LGP Offspring,p38 MAPK Signaling Pathway,CP:WIKIPATHWAYS,C2,22,41
Cohort,-0.022177700118205905,0.07278901697788642,-0.3046847043551031,0.7606823135840521,LGP Proband,p38 MAPK Signaling Pathway,CP:WIKIPATHWAYS,C2,22,67
Cohort,0.006952509174661832,0.021600606912744534,0.3218663810117203,0.747638428237247,LonGen OPEL,p38 MAPK Signaling Pathway,CP:WIKIPATHWAYS,C2,31,39
Cohort,-0.019971308360976315,0.045379549025660035,-0.4400949059604683,0.6600090461155567,LGP Offspring,p53 transcriptional gene network,CP:WIKIPATHWAYS,C2,62,128
Cohort,-0.058342703029499884,0.11068258541195357,-0.5271172769623337,0.5982523291650295,LGP Proband,p53 transcriptional gene network,CP:WIKIPATHWAYS,C2,62,147
Cohort,0.02476300295891383,0.035143544217755535,0.7046245195270557,0.48125003803604494,LonGen OPEL,p53 transcriptional gene network,CP:WIKIPATHWAYS,C2,88,111
Cohort,-0.012512926228185688,0.04360187254943146,-0.2869813954435048,0.7742145060641528,LGP Offspring,Pancreatic adenocarcinoma pathway,CP:WIKIPATHWAYS,C2,65,137
Cohort,0.12715671703226117,0.11757838862701378,1.0814633413256929,0.27980366285526925,LGP Proband,Pancreatic adenocarcinoma pathway,CP:WIKIPATHWAYS,C2,65,173
Cohort,-0.02039781252541083,0.04000691971885984,-0.5098571114385246,0.6102929015949976,LonGen OPEL,Pancreatic adenocarcinoma pathway,CP:WIKIPATHWAYS,C2,113,123
Cohort,0.01944306989082925,0.03989090950544398,0.48740603139609595,0.6261286384246427,LGP Offspring,Parkinsons Disease Pathway,CP:WIKIPATHWAYS,C2,46,98
Cohort,0.14137755281972988,0.10093261168091644,1.4007123214712225,0.16167206286598534,LGP Proband,Parkinsons Disease Pathway,CP:WIKIPATHWAYS,C2,46,114
Cohort,-0.032376041038522964,0.033184332603222726,-0.9756423739369927,0.32953811841265435,LonGen OPEL,Parkinsons Disease Pathway,CP:WIKIPATHWAYS,C2,72,78
Cohort,0.051473142309712165,0.04219131695397968,1.2199937339205758,0.2228926890635783,LGP Offspring,Parkin-Ubiquitin Proteasomal System pathway,CP:WIKIPATHWAYS,C2,46,122
Cohort,0.045095623801265555,0.10781278934906705,0.418277127171423,0.6758521903559536,LGP Proband,Parkin-Ubiquitin Proteasomal System pathway,CP:WIKIPATHWAYS,C2,46,136
Cohort,-0.026455853975333326,0.03449653172645327,-0.766913444665104,0.44336037348056245,LonGen OPEL,Parkin-Ubiquitin Proteasomal System pathway,CP:WIKIPATHWAYS,C2,84,88
Cohort,0.028164078985140433,0.02278240182482059,1.236220798917553,0.21680586203089214,LGP Offspring,Pathogenesis of SARS-CoV-2 Mediated by nsp9-nsp10 Complex,CP:WIKIPATHWAYS,C2,11,39
Cohort,0.03823306034496806,0.06092786051230542,0.627513587765752,0.5304943957739752,LGP Proband,Pathogenesis of SARS-CoV-2 Mediated by nsp9-nsp10 Complex,CP:WIKIPATHWAYS,C2,11,48
Cohort,0.02707224805959588,0.02223207910063988,1.2177110353487672,0.22369464596145028,LonGen OPEL,Pathogenesis of SARS-CoV-2 Mediated by nsp9-nsp10 Complex,CP:WIKIPATHWAYS,C2,24,38
Cohort,-0.010174016066653174,0.03111662002763984,-0.3269640487178858,0.7437962913746878,LGP Offspring,Pathogenic Escherichia coli infection,CP:WIKIPATHWAYS,C2,29,64
Cohort,0.09995402836444309,0.08363628244615744,1.1951036732029612,0.2323862551119004,LGP Proband,Pathogenic Escherichia coli infection,CP:WIKIPATHWAYS,C2,29,87
Cohort,-0.01777036823192303,0.02704195178348956,-0.6571407409568977,0.5112803783292609,LonGen OPEL,Pathogenic Escherichia coli infection,CP:WIKIPATHWAYS,C2,52,53
Cohort,-0.0091984196425944,0.04835910128355002,-0.19021072349256754,0.8492011121450815,LGP Offspring,Pathways Affected in Adenoid Cystic Carcinoma,CP:WIKIPATHWAYS,C2,64,137
Cohort,0.06196003908335988,0.1441738895001904,0.42975908674003044,0.6674819074414682,LGP Proband,Pathways Affected in Adenoid Cystic Carcinoma,CP:WIKIPATHWAYS,C2,64,237
Cohort,-0.10057317043290805,0.04683467044902078,-2.1474085216929466,0.032062133342447376,LonGen OPEL,Pathways Affected in Adenoid Cystic Carcinoma,CP:WIKIPATHWAYS,C2,165,146
Cohort,-0.10901216335505327,0.06370164178887995,-1.7112928378885666,0.08748579017788986,LGP Offspring,Pathways in clear cell renal cell carcinoma,CP:WIKIPATHWAYS,C2,149,262
Cohort,-0.4133606547989985,0.16683003133809887,-2.4777352823322256,0.0134189414312325,LGP Proband,Pathways in clear cell renal cell carcinoma,CP:WIKIPATHWAYS,C2,149,311
Cohort,-0.018331001456492208,0.05384033865828418,-0.34046965367056986,0.7335927042183432,LonGen OPEL,Pathways in clear cell renal cell carcinoma,CP:WIKIPATHWAYS,C2,202,236
Cohort,-0.017738285192955065,0.019534678767767433,-0.9080407926760254,0.36418026032795625,LGP Offspring,Pathways of nucleic acid metabolism and innate immune sensing,CP:WIKIPATHWAYS,C2,15,24
Cohort,-0.030139987384174546,0.0570951601478529,-0.5278904079807188,0.597715819994609,LGP Proband,Pathways of nucleic acid metabolism and innate immune sensing,CP:WIKIPATHWAYS,C2,15,42
Cohort,0.009157315436713729,0.018790195832944664,0.4873453964039214,0.6261477639107043,LonGen OPEL,Pathways of nucleic acid metabolism and innate immune sensing,CP:WIKIPATHWAYS,C2,20,32
Cohort,-0.07567955593299083,0.053976341267853084,-1.402087547161401,0.161348117671165,LGP Offspring,Pathways Regulating Hippo Signaling,CP:WIKIPATHWAYS,C2,110,184
Cohort,-0.09772838537280665,0.15510832398703525,-0.6300653817971451,0.5288243899174483,LGP Proband,Pathways Regulating Hippo Signaling,CP:WIKIPATHWAYS,C2,110,277
Cohort,-0.05173327538220129,0.046712054239097855,-1.1074930491688948,0.2684153607572162,LonGen OPEL,Pathways Regulating Hippo Signaling,CP:WIKIPATHWAYS,C2,153,165
Cohort,-0.013968553766980566,0.02675112111005972,-0.5221670415049525,0.6017250905435079,LGP Offspring,PDGF Pathway,CP:WIKIPATHWAYS,C2,26,44
Cohort,-0.028579474767229874,0.07954116541931175,-0.3593041994867614,0.719458483070125,LGP Proband,PDGF Pathway,CP:WIKIPATHWAYS,C2,26,78
Cohort,-0.010579592693477106,0.024614894400933365,-0.4298045127130808,0.6674541726242493,LonGen OPEL,PDGF Pathway,CP:WIKIPATHWAYS,C2,45,50
Cohort,-0.02435233781016355,0.02465312005285716,-0.9877994248984013,0.3236043110953276,LGP Offspring,PDGFR-beta pathway,CP:WIKIPATHWAYS,C2,24,38
Cohort,0.0085426086991658,0.0724217872825279,0.11795633634171225,0.9061306568421224,LGP Proband,PDGFR-beta pathway,CP:WIKIPATHWAYS,C2,24,60
Cohort,-0.031183006942288472,0.021582336738228073,-1.4448392368494118,0.14889657119136834,LonGen OPEL,PDGFR-beta pathway,CP:WIKIPATHWAYS,C2,36,33
Cohort,-0.005817155030668671,0.017536494975933604,-0.3317170870605503,0.7402057119970132,LGP Offspring,Pentose Phosphate Metabolism,CP:WIKIPATHWAYS,C2,11,16
Cohort,0.015341583371144394,0.049843140558244514,0.307797285630846,0.758313437690529,LGP Proband,Pentose Phosphate Metabolism,CP:WIKIPATHWAYS,C2,11,29
Cohort,-0.019216202971413833,0.016749696510568315,-1.1472567851775262,0.25162021455333045,LonGen OPEL,Pentose Phosphate Metabolism,CP:WIKIPATHWAYS,C2,22,20
Cohort,0.004581016807648921,0.042371020860305926,0.10811674381771895,0.9139351678194859,LGP Offspring,Peptide GPCRs,CP:WIKIPATHWAYS,C2,56,115
Cohort,-0.2600505538738863,0.11707012807614726,-2.2213228784095858,0.02659690629689899,LGP Proband,Peptide GPCRs,CP:WIKIPATHWAYS,C2,56,173
Cohort,0.014916640203520933,0.03592589563995546,0.41520579898726845,0.6781031438638494,LonGen OPEL,Peptide GPCRs,CP:WIKIPATHWAYS,C2,95,114
Cohort,0.015149411597088679,0.011326510771076742,1.3375179614691275,0.18150344771179244,LGP Offspring,Peroxiredoxin 2 induced ovarian failure,CP:WIKIPATHWAYS,C2,3,10
Cohort,0.024292982959668866,0.029728563596389715,0.8171596613103448,0.41407055913039714,LGP Proband,Peroxiredoxin 2 induced ovarian failure,CP:WIKIPATHWAYS,C2,3,12
Cohort,-0.0029070296672017225,0.010904248976911866,-0.26659604649131985,0.7898492453073536,LonGen OPEL,Peroxiredoxin 2 induced ovarian failure,CP:WIKIPATHWAYS,C2,10,8
Cohort,0.03295350010551862,0.019567146756803034,1.6841239305399223,0.09261934866051844,LGP Offspring,"Phase I biotransformations, non P450",CP:WIKIPATHWAYS,C2,6,31
Cohort,0.04448299741772241,0.05599055410234503,0.7944732487628541,0.4271459864004479,LGP Proband,"Phase I biotransformations, non P450",CP:WIKIPATHWAYS,C2,6,43
Cohort,0.002096533899136346,0.0201531971166027,0.1040298413698921,0.9171718718586146,LonGen OPEL,"Phase I biotransformations, non P450",CP:WIKIPATHWAYS,C2,29,36
Cohort,-0.03306613283895706,0.042780502782975724,-0.7729252974585319,0.43983675779294407,LGP Offspring,Phosphodiesterases in neuronal function,CP:WIKIPATHWAYS,C2,64,120
Cohort,0.0461658194827595,0.11806560203737167,0.3910183718721605,0.695883524054218,LGP Proband,Phosphodiesterases in neuronal function,CP:WIKIPATHWAYS,C2,64,164
Cohort,0.02534670110181423,0.03617052556599431,0.7007556762084738,0.48366028600313116,LonGen OPEL,Phosphodiesterases in neuronal function,CP:WIKIPATHWAYS,C2,84,116
Cohort,-0.0732102494696041,0.04015448615127045,-1.8232147011869504,0.06871237593925489,LGP Offspring,Phosphoinositides metabolism,CP:WIKIPATHWAYS,C2,60,97
Cohort,1.3535669758328229e-4,0.11867795424847781,0.0011405378399081934,0.9990902554100828,LGP Proband,Phosphoinositides metabolism,CP:WIKIPATHWAYS,C2,60,167
Cohort,0.008168365141494457,0.034154009862920894,0.2391626978582798,0.8110409899793434,LonGen OPEL,Phosphoinositides metabolism,CP:WIKIPATHWAYS,C2,77,94
Cohort,0.021294389380114687,0.032063004332282256,0.6641420485564007,0.5068258571954024,LGP Offspring,Photodynamic therapy-induced AP-1 survival signaling.,CP:WIKIPATHWAYS,C2,27,73
Cohort,0.17623085190463567,0.08098770200617897,2.1760199084447427,0.029833810263109398,LGP Proband,Photodynamic therapy-induced AP-1 survival signaling.,CP:WIKIPATHWAYS,C2,27,84
Cohort,-0.010172910247316806,0.024114998219915314,-0.4218499273582999,0.6732484628112385,LonGen OPEL,Photodynamic therapy-induced AP-1 survival signaling.,CP:WIKIPATHWAYS,C2,43,44
Cohort,0.005097266766387126,0.028904276010404115,0.1763499201485746,0.860071862908289,LGP Offspring,Photodynamic therapy-induced HIF-1 survival signaling,CP:WIKIPATHWAYS,C2,25,50
Cohort,-0.015853169780652966,0.07319707087243235,-0.21658202427637885,0.8285870610973378,LGP Proband,Photodynamic therapy-induced HIF-1 survival signaling,CP:WIKIPATHWAYS,C2,25,59
Cohort,-0.024839014468028327,0.021978517111419998,-1.130149697639156,0.25875357333868304,LonGen OPEL,Photodynamic therapy-induced HIF-1 survival signaling,CP:WIKIPATHWAYS,C2,37,32
Cohort,0.03281209537161238,0.02820738389377372,1.16324489698086,0.2451405950265085,LGP Offspring,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling,CP:WIKIPATHWAYS,C2,20,61
Cohort,-6.312796638136108e-4,0.07140259950305461,-0.008841129989764654,0.992948005113208,LGP Proband,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling,CP:WIKIPATHWAYS,C2,20,67
Cohort,-0.03591873121252127,0.023820979960217963,-1.5078611909546566,0.13198682621588576,LonGen OPEL,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling,CP:WIKIPATHWAYS,C2,44,36
Cohort,0.006150942405091602,0.03668235770541977,0.16768121761657673,0.8668842233392415,LGP Offspring,Photodynamic therapy-induced NF-kB survival signaling,CP:WIKIPATHWAYS,C2,40,95
Cohort,0.04810619131022105,0.09001972022675699,0.5343961433010789,0.5932099097404506,LGP Proband,Photodynamic therapy-induced NF-kB survival signaling,CP:WIKIPATHWAYS,C2,40,96
Cohort,-0.006311177769127185,0.03205076254969706,-0.19691193803396223,0.8439467169142771,LonGen OPEL,Photodynamic therapy-induced NF-kB survival signaling,CP:WIKIPATHWAYS,C2,69,80
Cohort,-0.011652279292199754,0.026784171085777048,-0.43504349098140865,0.6636697114597946,LGP Offspring,Photodynamic therapy-induced unfolded protein response,CP:WIKIPATHWAYS,C2,19,42
Cohort,-0.16707402205524496,0.07662539249829631,-2.180400212096267,0.029506675660626463,LGP Proband,Photodynamic therapy-induced unfolded protein response,CP:WIKIPATHWAYS,C2,19,66
Cohort,0.021978571881495625,0.018576047010235564,1.1831673266860943,0.23709608396600843,LonGen OPEL,Photodynamic therapy-induced unfolded protein response,CP:WIKIPATHWAYS,C2,21,31
Cohort,0.003531610654772512,0.017537591093694103,0.20137375970878657,0.840466909145366,LGP Offspring,Physiological and Pathological Hypertrophy  of the Heart,CP:WIKIPATHWAYS,C2,10,22
Cohort,0.04221890002496949,0.050006277112423135,0.8442720086931044,0.3987595300994057,LGP Proband,Physiological and Pathological Hypertrophy  of the Heart,CP:WIKIPATHWAYS,C2,10,33
Cohort,0.019379606312978873,0.017097569217090595,1.1334714348521058,0.25735759448817525,LonGen OPEL,Physiological and Pathological Hypertrophy  of the Heart,CP:WIKIPATHWAYS,C2,15,25
Cohort,0.051589449129458696,0.024639655710577624,2.0937568988560065,0.03665358540869825,LGP Offspring,Phytochemical activity on NRF2 transcriptional activation,CP:WIKIPATHWAYS,C2,12,49
Cohort,0.027246754462323896,0.06960586566338776,0.39144336763353427,0.6955695304721192,LGP Proband,Phytochemical activity on NRF2 transcriptional activation,CP:WIKIPATHWAYS,C2,12,62
Cohort,-0.04378436529657036,0.01965042339875143,-2.2281639641083952,0.02614823543619773,LonGen OPEL,Phytochemical activity on NRF2 transcriptional activation,CP:WIKIPATHWAYS,C2,36,26
Cohort,-0.20529896924011123,0.11042001647632829,-1.8592550136425943,0.06342528689847607,LGP Offspring,PI3K-Akt Signaling Pathway,CP:WIKIPATHWAYS,C2,407,766
Cohort,-0.5315322120378928,0.3051274663632399,-1.742000542832577,0.081877002086267,LGP Proband,PI3K-Akt Signaling Pathway,CP:WIKIPATHWAYS,C2,407,1020
Cohort,-0.112796472744533,0.09749109352993247,-1.1569925893784476,0.24762247075742497,LonGen OPEL,PI3K-Akt Signaling Pathway,CP:WIKIPATHWAYS,C2,613,695
Cohort,-0.020262737462803115,0.025441106543606453,-0.7964566096239748,0.42604629941537786,LGP Offspring,PI3K-AKT-mTOR signaling pathway and therapeutic opportunities,CP:WIKIPATHWAYS,C2,24,39
Cohort,-0.09267742937796651,0.0637925688873947,-1.4527934992171074,0.146657224880603,LGP Proband,PI3K-AKT-mTOR signaling pathway and therapeutic opportunities,CP:WIKIPATHWAYS,C2,24,44
Cohort,-0.045601941204888474,0.02175313176508976,-2.0963391247448873,0.03636725847481511,LonGen OPEL,PI3K-AKT-mTOR signaling pathway and therapeutic opportunities,CP:WIKIPATHWAYS,C2,43,32
Cohort,-0.002859151224113908,0.03501231519828895,-0.08166130139984672,0.9349402242522356,LGP Offspring,PI3K/AKT/mTOR - VitD3 Signalling,CP:WIKIPATHWAYS,C2,42,80
Cohort,-0.002585379247174329,0.08527076786778134,-0.030319643083115556,0.9758193847711839,LGP Proband,PI3K/AKT/mTOR - VitD3 Signalling,CP:WIKIPATHWAYS,C2,42,79
Cohort,-0.004143958669231924,0.029981732174442784,-0.1382161192395796,0.8901045724423401,LonGen OPEL,PI3K/AKT/mTOR - VitD3 Signalling,CP:WIKIPATHWAYS,C2,54,67
Cohort,-8.269686808205031e-4,0.013054867164180025,-0.06334562201364574,0.9495100132326477,LGP Offspring,Pilocytic astrocytoma,CP:WIKIPATHWAYS,C2,6,11
Cohort,0.06972467975658234,0.044913504227631754,1.552421280762284,0.12094082621796509,LGP Proband,Pilocytic astrocytoma,CP:WIKIPATHWAYS,C2,6,28
Cohort,0.008274309298599316,0.01151801319439447,0.7183799114439473,0.47273387026238134,LonGen OPEL,Pilocytic astrocytoma,CP:WIKIPATHWAYS,C2,8,12
Cohort,-0.036955213840140055,0.02528829341218819,-1.4613565746721668,0.1443822694704378,LGP Offspring,PKC-gamma calcium signaling pathway in ataxia,CP:WIKIPATHWAYS,C2,25,41
Cohort,0.1126654949496846,0.0771862545583646,1.4596574946448824,0.14476078112345234,LGP Proband,PKC-gamma calcium signaling pathway in ataxia,CP:WIKIPATHWAYS,C2,25,75
Cohort,0.004985215972519879,0.022571801780385925,0.22086034695076273,0.8252578112447604,LonGen OPEL,PKC-gamma calcium signaling pathway in ataxia,CP:WIKIPATHWAYS,C2,35,44
Cohort,0.004427141334516798,0.022875231993695223,0.1935342704168853,0.846598705397935,LGP Offspring,Platelet-mediated interactions with vascular and circulating cells,CP:WIKIPATHWAYS,C2,16,35
Cohort,-0.030235349008424374,0.06605114045065227,-0.45775665343755306,0.6472465121815336,LGP Proband,Platelet-mediated interactions with vascular and circulating cells,CP:WIKIPATHWAYS,C2,16,48
Cohort,0.0015964955244325931,0.02048811160921269,0.07792301969473421,0.9379088708120946,LonGen OPEL,Platelet-mediated interactions with vascular and circulating cells,CP:WIKIPATHWAYS,C2,31,34
Cohort,0.017923387234263656,0.024009504445787012,0.7465121687427706,0.45561761921546695,LGP Offspring,PPAR Alpha Pathway,CP:WIKIPATHWAYS,C2,19,37
Cohort,-0.09014816396356468,0.07106669718288532,-1.2685008243956308,0.2049731094082083,LGP Proband,PPAR Alpha Pathway,CP:WIKIPATHWAYS,C2,19,65
Cohort,-0.021945056195384748,0.022717617899066744,-0.9659928383726476,0.3343411525780692,LonGen OPEL,PPAR Alpha Pathway,CP:WIKIPATHWAYS,C2,39,39
Cohort,0.11587121029311881,0.04800860412241768,2.4135509126167785,0.016062793039020255,LGP Offspring,PPAR signaling pathway,CP:WIKIPATHWAYS,C2,69,188
Cohort,0.06276942002758222,0.13324126464976552,0.47109594908586516,0.6376954147220042,LGP Proband,PPAR signaling pathway,CP:WIKIPATHWAYS,C2,69,238
Cohort,-0.06847277866778435,0.04410075230196858,-1.552644231529988,0.12090563098265006,LonGen OPEL,PPAR signaling pathway,CP:WIKIPATHWAYS,C2,145,150
Cohort,0.03176920603254051,0.03858036196708345,0.8234553646657288,0.4105394951551701,LGP Offspring,Prader-Willi and Angelman Syndrome,CP:WIKIPATHWAYS,C2,41,97
Cohort,0.03928280315867569,0.10720584310231056,0.3664240868026814,0.7141415852249706,LGP Proband,Prader-Willi and Angelman Syndrome,CP:WIKIPATHWAYS,C2,41,141
Cohort,-0.009914383158353635,0.03311815851985818,-0.29936396229303663,0.7647405020687424,LonGen OPEL,Prader-Willi and Angelman Syndrome,CP:WIKIPATHWAYS,C2,70,86
Cohort,-0.04529489212259211,0.03555570182575839,-1.2739136002591336,0.20313184048924293,LGP Offspring,Pregnane X Receptor pathway,CP:WIKIPATHWAYS,C2,40,64
Cohort,0.07976129433695527,0.1015138762297993,0.7857181431669281,0.43225579403504877,LGP Proband,Pregnane X Receptor pathway,CP:WIKIPATHWAYS,C2,40,92
Cohort,-0.03556390430434207,0.029190889376499336,-1.2183220540369506,0.2234625851727159,LonGen OPEL,Pregnane X Receptor pathway,CP:WIKIPATHWAYS,C2,60,53
Cohort,0.04206108193956688,0.030955655507197016,1.358752746482397,0.17467814065910142,LGP Offspring,Preimplantation Embryo,CP:WIKIPATHWAYS,C2,22,67
Cohort,0.11480538644886706,0.08103446860858686,1.4167475695237872,0.1569301573799384,LGP Proband,Preimplantation Embryo,CP:WIKIPATHWAYS,C2,22,88
Cohort,-0.0051780187161364075,0.026062841798515115,-0.19867437158872736,0.8425682046487164,LonGen OPEL,Preimplantation Embryo,CP:WIKIPATHWAYS,C2,49,59
Cohort,-0.11379388774224768,0.059814527797057454,-1.9024456421077975,0.05753760712761015,LGP Offspring,Primary Focal Segmental Glomerulosclerosis FSGS,CP:WIKIPATHWAYS,C2,120,204
Cohort,-0.012447935797493008,0.16462787104802853,-0.07561256619701683,0.9397454720124432,LGP Proband,Primary Focal Segmental Glomerulosclerosis FSGS,CP:WIKIPATHWAYS,C2,120,303
Cohort,0.05603007114742807,0.04978526235952663,1.1254348875939282,0.260744011866348,LonGen OPEL,Primary Focal Segmental Glomerulosclerosis FSGS,CP:WIKIPATHWAYS,C2,147,216
Cohort,-0.007232908260936606,0.02010762667396387,-0.3597096951427915,0.7191765834480859,LGP Offspring,Prion disease pathway,CP:WIKIPATHWAYS,C2,15,28
Cohort,-0.04248711261455764,0.06151962681197082,-0.6906269562462669,0.4899921608155354,LGP Proband,Prion disease pathway,CP:WIKIPATHWAYS,C2,15,51
Cohort,-0.022640143720883146,0.022759225542338182,-0.9947677559926847,0.3201515258787848,LonGen OPEL,Prion disease pathway,CP:WIKIPATHWAYS,C2,44,35
Cohort,-0.007486694807988633,0.0382397715084441,-0.19578293783307316,0.8448389005476064,LGP Offspring,Prolactin Signaling Pathway,CP:WIKIPATHWAYS,C2,51,96
Cohort,0.016631347699311037,0.11085187078972468,0.15003217880606726,0.8807755029321687,LGP Proband,Prolactin Signaling Pathway,CP:WIKIPATHWAYS,C2,51,165
Cohort,-0.048702073465034385,0.03747001142887393,-1.299761372036977,0.1940590347228903,LonGen OPEL,Prolactin Signaling Pathway,CP:WIKIPATHWAYS,C2,98,97
Cohort,-0.04664354317321532,0.03619588540423497,-1.288642138527656,0.19796336658837815,LGP Offspring,Prostaglandin Synthesis and Regulation,CP:WIKIPATHWAYS,C2,47,71
Cohort,-0.04971532448498243,0.10314452915104813,-0.48199671755908374,0.6299347385035826,LGP Proband,Prostaglandin Synthesis and Regulation,CP:WIKIPATHWAYS,C2,47,109
Cohort,0.06093527207497385,0.03408526759407894,1.7877304881584415,0.0741998158880645,LonGen OPEL,Prostaglandin Synthesis and Regulation,CP:WIKIPATHWAYS,C2,60,97
Cohort,0.012757942059853727,0.03658347547842078,0.34873510220151605,0.7273967754973232,LGP Offspring,Proteasome Degradation,CP:WIKIPATHWAYS,C2,38,83
Cohort,-0.001894086822277211,0.09524035279818954,-0.019887440214450953,0.9841379212072331,LGP Proband,Proteasome Degradation,CP:WIKIPATHWAYS,C2,38,110
Cohort,0.01574712530752524,0.03161805654588197,0.49804216412460656,0.618591891621322,LonGen OPEL,Proteasome Degradation,CP:WIKIPATHWAYS,C2,57,75
Cohort,-0.047405281860947696,0.0286588999589156,-1.6541207767536874,0.09856719752740435,LGP Offspring,Proteoglycan biosynthesis,CP:WIKIPATHWAYS,C2,34,47
Cohort,-0.07121823560361278,0.08048920674386406,-0.8848172131978672,0.3765102422623786,LGP Proband,Proteoglycan biosynthesis,CP:WIKIPATHWAYS,C2,34,64
Cohort,-0.031033824935290284,0.020025580223053303,-1.5497091514763888,0.1216088132123981,LonGen OPEL,Proteoglycan biosynthesis,CP:WIKIPATHWAYS,C2,31,30
Cohort,0.017566949045015066,0.048613958033161396,0.36135607458730257,0.7179461881947131,LGP Offspring,Proximal tubule transport,CP:WIKIPATHWAYS,C2,79,177
Cohort,-5.057449490752144e-4,0.13046571978522398,-0.0038764585050217386,0.9969079683705245,LGP Proband,Proximal tubule transport,CP:WIKIPATHWAYS,C2,79,209
Cohort,-0.023987592983280365,0.046483590755747525,-0.5160443200123129,0.6059667658673072,LonGen OPEL,Proximal tubule transport,CP:WIKIPATHWAYS,C2,136,155
Cohort,-0.02849596874466494,0.014188214424366798,-2.0084252952736636,0.04499537868312927,LGP Offspring,PTF1A related regulatory pathway,CP:WIKIPATHWAYS,C2,10,10
Cohort,0.008744365671098776,0.04019600041934732,0.21754317792498326,0.8278382719261447,LGP Proband,PTF1A related regulatory pathway,CP:WIKIPATHWAYS,C2,10,17
Cohort,-0.011932848495183885,0.015970448608941135,-0.7471830496047068,0.4551737233587321,LonGen OPEL,PTF1A related regulatory pathway,CP:WIKIPATHWAYS,C2,20,20
Cohort,-8.437213836721948e-5,0.024432468459049395,-0.0034532793323209794,0.997245706008802,LGP Offspring,Purine metabolism,CP:WIKIPATHWAYS,C2,19,42
Cohort,-0.04208129115754563,0.06901740053547051,-0.6097200246757852,0.5422133629456218,LGP Proband,Purine metabolism,CP:WIKIPATHWAYS,C2,19,60
Cohort,0.020940414812607572,0.017999449140226456,1.1633919821361887,0.24501912143052204,LonGen OPEL,Purine metabolism,CP:WIKIPATHWAYS,C2,17,34
Cohort,0.014065687405524732,0.029255031724317863,0.48079549316751596,0.6308174198851841,LGP Offspring,Purine metabolism and related disorders,CP:WIKIPATHWAYS,C2,24,59
Cohort,-0.0522738532560684,0.08401448159532234,-0.6222005095247632,0.5339800928191961,LGP Proband,Purine metabolism and related disorders,CP:WIKIPATHWAYS,C2,24,84
Cohort,0.006470484814301225,0.0235040292256575,0.2752925786544677,0.7831629084386956,LonGen OPEL,Purine metabolism and related disorders,CP:WIKIPATHWAYS,C2,33,49
Cohort,0.031163858626510506,0.020552164443028896,1.5163297623905982,0.1299034487733841,LGP Offspring,Purinergic signaling,CP:WIKIPATHWAYS,C2,9,34
Cohort,-0.04988494293915712,0.058156066907646964,-0.8577771089364664,0.39126198274530566,LGP Proband,Purinergic signaling,CP:WIKIPATHWAYS,C2,9,47
Cohort,0.026101029838121844,0.019861772811780684,1.3141339439065804,0.18917969693595382,LonGen OPEL,Purinergic signaling,CP:WIKIPATHWAYS,C2,22,35
Cohort,-0.03595879523567738,0.04285021635628886,-0.8391741814484428,0.4016682277968273,LGP Offspring,Pyrimidine metabolism,CP:WIKIPATHWAYS,C2,62,114
Cohort,-0.020331154310920353,0.11770218304299267,-0.17273387617198283,0.862902524370246,LGP Proband,Pyrimidine metabolism,CP:WIKIPATHWAYS,C2,62,164
Cohort,-0.01034699344961355,0.040366719276941423,-0.2563248546067512,0.797766236989716,LonGen OPEL,Pyrimidine metabolism,CP:WIKIPATHWAYS,C2,96,114
Cohort,-0.018206584308687393,0.019377759593185474,-0.9395608517658591,0.347778456421709,LGP Offspring,Pyrimidine metabolism and related diseases,CP:WIKIPATHWAYS,C2,14,22
Cohort,0.042265353613321344,0.0624456537193076,0.6768341925493094,0.49869883872588605,LGP Proband,Pyrimidine metabolism and related diseases,CP:WIKIPATHWAYS,C2,14,46
Cohort,-0.03681088337787375,0.018243097424030724,-2.0177978838935875,0.04394739379041861,LonGen OPEL,Pyrimidine metabolism and related diseases,CP:WIKIPATHWAYS,C2,28,23
Cohort,0.018685282723618808,0.04544487559671272,0.41116368959695027,0.6810828222827146,LGP Offspring,RAC1/PAK1/p38/MMP2 Pathway,CP:WIKIPATHWAYS,C2,55,121
Cohort,0.07595525647497788,0.11799009948689083,0.6437426259091916,0.5199193222178911,LGP Proband,RAC1/PAK1/p38/MMP2 Pathway,CP:WIKIPATHWAYS,C2,55,153
Cohort,-0.08439148130478892,0.03509498787945666,-2.404659081081736,0.016414975720058796,LonGen OPEL,RAC1/PAK1/p38/MMP2 Pathway,CP:WIKIPATHWAYS,C2,98,82
Cohort,0.012003356218365062,0.01061502138166912,1.1307896410923326,0.25854466038169477,LGP Offspring,RalA downstream regulated genes,CP:WIKIPATHWAYS,C2,1,10
Cohort,-0.019922794482399888,0.026062710738964146,-0.764417588098962,0.4448346525125376,LGP Proband,RalA downstream regulated genes,CP:WIKIPATHWAYS,C2,1,10
Cohort,-0.0031051441757624,0.008908852990370683,-0.3485458991318702,0.7275224144102181,LonGen OPEL,RalA downstream regulated genes,CP:WIKIPATHWAYS,C2,6,6
Cohort,0.008372683865240973,0.03793363134258483,0.22071928177995656,0.8253776623614896,LGP Offspring,RANKL/RANK (Receptor activator of NFKB (ligand)) Signaling Pathway,CP:WIKIPATHWAYS,C2,40,89
Cohort,0.03169114391049756,0.10263192382229737,0.3087844671543853,0.7575626019659139,LGP Proband,RANKL/RANK (Receptor activator of NFKB (ligand)) Signaling Pathway,CP:WIKIPATHWAYS,C2,40,107
Cohort,-0.004996846782919493,0.03172689182576936,-0.15749562895603064,0.87489419367216,LonGen OPEL,RANKL/RANK (Receptor activator of NFKB (ligand)) Signaling Pathway,CP:WIKIPATHWAYS,C2,61,71
Cohort,-0.02865146871548138,0.028323953449801754,-1.0115631903667712,0.31210887791340036,LGP Offspring,RAS and Bradykinin pathways in COVID-19,CP:WIKIPATHWAYS,C2,31,48
Cohort,-0.01613495876381255,0.0807271498404965,-0.19987028893863537,0.8416307503615854,LGP Proband,RAS and Bradykinin pathways in COVID-19,CP:WIKIPATHWAYS,C2,31,70
Cohort,-0.01219975252373492,0.026902840551628435,-0.4534745132330075,0.6503306870961509,LonGen OPEL,RAS and Bradykinin pathways in COVID-19,CP:WIKIPATHWAYS,C2,52,58
Cohort,-0.061064118576991594,0.07796135394287963,-0.7832613915573063,0.433747949530516,LGP Offspring,Ras Signaling,CP:WIKIPATHWAYS,C2,173,338
Cohort,-0.2008582107864897,0.2134483653831815,-0.9410154555454664,0.34696941525660785,LGP Proband,Ras Signaling,CP:WIKIPATHWAYS,C2,173,466
Cohort,0.035209223942385084,0.06438455071923371,0.5468582687782423,0.5846293723181551,LonGen OPEL,Ras Signaling,CP:WIKIPATHWAYS,C2,278,345
Cohort,-0.02890119662030437,0.031873745557918096,-0.9067398924857364,0.3648674524026523,LGP Offspring,Regucalcin in proximal tubule epithelial kidney cells,CP:WIKIPATHWAYS,C2,29,56
Cohort,0.1394451570086527,0.07827490925263317,1.7814796381122826,0.07519795359095002,LGP Proband,Regucalcin in proximal tubule epithelial kidney cells,CP:WIKIPATHWAYS,C2,29,67
Cohort,0.0188349054879342,0.024127402493444163,0.7806437304244405,0.43524414638010456,LonGen OPEL,Regucalcin in proximal tubule epithelial kidney cells,CP:WIKIPATHWAYS,C2,41,52
Cohort,-0.07905833998275445,0.06552145173182479,-1.2066023858313657,0.2280073839128137,LGP Offspring,Regulation of Actin Cytoskeleton,CP:WIKIPATHWAYS,C2,138,252
Cohort,-0.33059622549953066,0.17806005309060663,-1.8566557729335582,0.06371257929007387,LGP Proband,Regulation of Actin Cytoskeleton,CP:WIKIPATHWAYS,C2,138,364
Cohort,-0.10863123376531592,0.053301998897425144,-2.038033019631531,0.04187674048242736,LonGen OPEL,Regulation of Actin Cytoskeleton,CP:WIKIPATHWAYS,C2,215,206
Cohort,-0.04821279083236558,0.024523703781501975,-1.965966938025572,0.04971128391330025,LGP Offspring,Regulation of Apoptosis by Parathyroid Hormone-related Protein,CP:WIKIPATHWAYS,C2,26,39
Cohort,0.0942995318108104,0.06909460309480665,1.3647886750491836,0.17268756413820174,LGP Proband,Regulation of Apoptosis by Parathyroid Hormone-related Protein,CP:WIKIPATHWAYS,C2,26,58
Cohort,-0.002960097334303162,0.022852788090006373,-0.12952893636630822,0.896971852476605,LonGen OPEL,Regulation of Apoptosis by Parathyroid Hormone-related Protein,CP:WIKIPATHWAYS,C2,37,44
Cohort,-0.011709479780161793,0.038654216759494,-0.3029289107839906,0.762037232841007,LGP Offspring,Regulation of Microtubule Cytoskeleton,CP:WIKIPATHWAYS,C2,51,97
Cohort,-0.04853572651985603,0.10827136708899791,-0.44827850450950874,0.6540686445478108,LGP Proband,Regulation of Microtubule Cytoskeleton,CP:WIKIPATHWAYS,C2,51,154
Cohort,0.04685774879936013,0.034927572887462094,1.3415689933662867,0.18011838574196504,LonGen OPEL,Regulation of Microtubule Cytoskeleton,CP:WIKIPATHWAYS,C2,80,112
Cohort,0.006531482524229033,0.02367259019281604,0.27590907758844035,0.7827022246639732,LGP Offspring,Regulation of sister chromatid separation at the metaphase-anaphase transition,CP:WIKIPATHWAYS,C2,17,39
Cohort,-0.11925218454402128,0.056100727062255606,-2.1256798403287323,0.033823201562957116,LGP Proband,Regulation of sister chromatid separation at the metaphase-anaphase transition,CP:WIKIPATHWAYS,C2,17,35
Cohort,0.01653410597945547,0.02126149849763156,0.7776547820134736,0.43700361840656765,LonGen OPEL,Regulation of sister chromatid separation at the metaphase-anaphase transition,CP:WIKIPATHWAYS,C2,27,40
Cohort,-0.1567236696192714,0.05936170191294665,-2.6401478490139163,0.008478224402118735,LGP Offspring,Regulation of toll-like receptor signaling pathway,CP:WIKIPATHWAYS,C2,135,215
Cohort,0.0903543538248773,0.17052855648623105,0.5298488164483628,0.5963577763568606,LGP Proband,Regulation of toll-like receptor signaling pathway,CP:WIKIPATHWAYS,C2,135,307
Cohort,0.018299242138776737,0.05190112633583715,0.35257890205248427,0.7244974909820663,LonGen OPEL,Regulation of toll-like receptor signaling pathway,CP:WIKIPATHWAYS,C2,182,223
Cohort,-0.021721287875195228,0.02394248152949678,-0.9072279265804142,0.36460955646340043,LGP Offspring,Regulation of Wnt/B-catenin Signaling by Small Molecule Compounds,CP:WIKIPATHWAYS,C2,23,36
Cohort,-0.015356289087148957,0.0672486426447327,-0.22835091509987154,0.8194294213617199,LGP Proband,Regulation of Wnt/B-catenin Signaling by Small Molecule Compounds,CP:WIKIPATHWAYS,C2,23,56
Cohort,-0.004563488997054558,0.02007753980945674,-0.22729323614166638,0.8202540956557707,LonGen OPEL,Regulation of Wnt/B-catenin Signaling by Small Molecule Compounds,CP:WIKIPATHWAYS,C2,30,33
Cohort,-0.0836247966876588,0.04549250020539077,-1.8382106129605387,0.06646996509734779,LGP Offspring,Regulatory circuits of the STAT3 signaling pathway,CP:WIKIPATHWAYS,C2,81,133
Cohort,-0.14243282319636802,0.12163839361497723,-1.1709528460825578,0.24195218194634224,LGP Proband,Regulatory circuits of the STAT3 signaling pathway,CP:WIKIPATHWAYS,C2,81,155
Cohort,-0.15856019202515348,0.037985206162000885,-4.174261720442411,3.319185080310989e-5,LonGen OPEL,Regulatory circuits of the STAT3 signaling pathway,CP:WIKIPATHWAYS,C2,136,92
Cohort,-0.012314785223178278,0.024762453091900838,-0.49731685215008553,0.6191273411842957,LGP Offspring,"Relationship between inflammation, COX-2 and EGFR",CP:WIKIPATHWAYS,C2,21,42
Cohort,0.07811081914579951,0.06392366851582565,1.221938930592845,0.22207597630641068,LGP Proband,"Relationship between inflammation, COX-2 and EGFR",CP:WIKIPATHWAYS,C2,21,47
Cohort,0.011083576309920557,0.021039949756611737,0.5267872042535453,0.5984881334296042,LonGen OPEL,"Relationship between inflammation, COX-2 and EGFR",CP:WIKIPATHWAYS,C2,28,36
Cohort,-0.053312908186828115,0.03421994252469308,-1.5579485017649453,0.11971347196901251,LGP Offspring,Renin Angiotensin Aldosterone System (RAAS),CP:WIKIPATHWAYS,C2,44,73
Cohort,-0.09856011198513594,0.10302331462589577,-0.9566777417619801,0.33900716254821717,LGP Proband,Renin Angiotensin Aldosterone System (RAAS),CP:WIKIPATHWAYS,C2,44,121
Cohort,0.03920113382313561,0.03168749631863989,1.2371167929754012,0.21640856052070231,LonGen OPEL,Renin Angiotensin Aldosterone System (RAAS),CP:WIKIPATHWAYS,C2,63,87
Cohort,-0.050848309910390355,0.03565225612428032,-1.426229794073566,0.15426366076454773,LGP Offspring,Resistin as a regulator of inflammation,CP:WIKIPATHWAYS,C2,44,78
Cohort,0.04396634388529293,0.094758595574383,0.4639826457830995,0.6427812575571789,LGP Proband,Resistin as a regulator of inflammation,CP:WIKIPATHWAYS,C2,44,101
Cohort,0.0430417202428675,0.030229590919467534,1.4238274132631115,0.15488829841364876,LonGen OPEL,Resistin as a regulator of inflammation,CP:WIKIPATHWAYS,C2,52,78
Cohort,-0.07294604253294136,0.05051692717725324,-1.443992075705418,0.14920448913750672,LGP Offspring,Retinoblastoma Gene in Cancer,CP:WIKIPATHWAYS,C2,100,179
Cohort,0.23870126487488397,0.15222050621311997,1.5681281767693278,0.11723053420059548,LGP Proband,Retinoblastoma Gene in Cancer,CP:WIKIPATHWAYS,C2,100,260
Cohort,-0.00947653132639469,0.04291447202698699,-0.22082367273294948,0.8252863582800923,LonGen OPEL,Retinoblastoma Gene in Cancer,CP:WIKIPATHWAYS,C2,139,157
Cohort,-0.04730783717827535,0.0404145603614311,-1.1705641915982024,0.24218647996088172,LGP Offspring,Rett syndrome causing genes,CP:WIKIPATHWAYS,C2,57,104
Cohort,-0.1316545900205974,0.1130957645987547,-1.164098323997246,0.24471706966253062,LGP Proband,Rett syndrome causing genes,CP:WIKIPATHWAYS,C2,57,153
Cohort,-0.0210029170657702,0.03338368731344715,-0.6291371252243337,0.5294397941608244,LonGen OPEL,Rett syndrome causing genes,CP:WIKIPATHWAYS,C2,86,94
Cohort,-0.0035148498576739284,0.0201613078175179,-0.1743364016604082,0.8616532894938638,LGP Offspring,Riboflavin and CoQ disorders,CP:WIKIPATHWAYS,C2,12,25
Cohort,0.014440660304208607,0.05254703198132697,0.27481400489641766,0.783527199750252,LGP Proband,Riboflavin and CoQ disorders,CP:WIKIPATHWAYS,C2,12,35
Cohort,-0.028422301948729838,0.015745992907814595,-1.805049838084463,0.07144465245823796,LonGen OPEL,Riboflavin and CoQ disorders,CP:WIKIPATHWAYS,C2,23,16
Cohort,-0.01745718039734374,0.012212503803114736,-1.429451378585559,0.15333649544054445,LGP Offspring,Robo4 and VEGF Signaling Pathways Crosstalk,CP:WIKIPATHWAYS,C2,8,7
Cohort,-0.08078527005787682,0.03413109121740159,-2.3669114340150013,0.018164722807375175,LGP Proband,Robo4 and VEGF Signaling Pathways Crosstalk,CP:WIKIPATHWAYS,C2,8,11
Cohort,-0.009419030237535778,0.010608366662316375,-0.8878869421995543,0.3748697725963166,LonGen OPEL,Robo4 and VEGF Signaling Pathways Crosstalk,CP:WIKIPATHWAYS,C2,9,8
Cohort,0.0012426814852509675,0.020362777087117707,0.0610271123596956,0.9513556544555096,LGP Offspring,Role of Altered Glycolysation of MUC1 in Tumour Microenvironment,CP:WIKIPATHWAYS,C2,10,26
Cohort,0.02048515915759372,0.04555884538000579,0.449641754235149,0.6530856100557677,LGP Proband,Role of Altered Glycolysation of MUC1 in Tumour Microenvironment,CP:WIKIPATHWAYS,C2,10,21
Cohort,0.013443779973578368,0.018242586117616005,0.7369448545782851,0.4613730329026351,LonGen OPEL,Role of Altered Glycolysation of MUC1 in Tumour Microenvironment,CP:WIKIPATHWAYS,C2,18,26
Cohort,-0.025334253413569978,0.014518250670181771,-1.7449935249845627,0.0814403997860278,LGP Offspring,Role of Osx and miRNAs in tooth development,CP:WIKIPATHWAYS,C2,10,11
Cohort,-0.02335724293241622,0.037356342843355324,-0.6252550746297383,0.5319747001800632,LGP Proband,Role of Osx and miRNAs in tooth development,CP:WIKIPATHWAYS,C2,10,13
Cohort,0.014174305977581776,0.014720758836612419,0.9628787574678864,0.3359007816084295,LonGen OPEL,Role of Osx and miRNAs in tooth development,CP:WIKIPATHWAYS,C2,11,20
Cohort,-0.13467438934577508,0.031424133857267084,-4.28569932770416,2.086397355785259e-5,LGP Offspring,SARS coronavirus and innate immunity,CP:WIKIPATHWAYS,C2,52,54
Cohort,-0.02395333928782222,0.09427396605644517,-0.2540822274675546,0.7994946616456978,LGP Proband,SARS coronavirus and innate immunity,CP:WIKIPATHWAYS,C2,52,96
Cohort,-0.01610274640750483,0.026861772561747974,-0.5994670072680035,0.5490320894289684,LonGen OPEL,SARS coronavirus and innate immunity,CP:WIKIPATHWAYS,C2,49,58
Cohort,-0.04775674625898168,0.01992642985617033,-2.396653419789272,0.016816196924005388,LGP Offspring,SARS-CoV-2 and Angiotensin-converting enzyme 2 receptor: molecular mechanisms,CP:WIKIPATHWAYS,C2,19,20
Cohort,-0.003436955460002178,0.054517180931502575,-0.06304352868723159,0.9497469483338298,LGP Proband,SARS-CoV-2 and Angiotensin-converting enzyme 2 receptor: molecular mechanisms,CP:WIKIPATHWAYS,C2,19,31
Cohort,0.009011476004310428,0.01651969374558703,0.5454989749260756,0.5855632077195234,LonGen OPEL,SARS-CoV-2 and Angiotensin-converting enzyme 2 receptor: molecular mechanisms,CP:WIKIPATHWAYS,C2,18,25
Cohort,0.012729734488955861,0.014830502545326954,0.8583481544235978,0.39100448099230767,LGP Offspring,SARS-CoV-2 and COVID-19 Pathway,CP:WIKIPATHWAYS,C2,5,15
Cohort,-0.016383669229496654,0.02782616393710016,-0.5887864840633884,0.5561639425049383,LGP Proband,SARS-CoV-2 and COVID-19 Pathway,CP:WIKIPATHWAYS,C2,5,8
Cohort,0.003443294400424313,0.008563670506817871,0.4020816071429853,0.6877319078410726,LonGen OPEL,SARS-CoV-2 and COVID-19 Pathway,CP:WIKIPATHWAYS,C2,4,7
Cohort,-0.03808246466170821,0.032749009060537744,-1.1628585338662119,0.245297234700513,LGP Offspring,SARS-CoV-2 Innate Immunity Evasion and Cell-specific immune response,CP:WIKIPATHWAYS,C2,38,67
Cohort,0.03995525074806904,0.08817281124982128,0.4531470663316299,0.6505607140297942,LGP Proband,SARS-CoV-2 Innate Immunity Evasion and Cell-specific immune response,CP:WIKIPATHWAYS,C2,38,92
Cohort,0.015578119277035372,0.027650763585301903,0.5633883935601731,0.5733291037147181,LonGen OPEL,SARS-CoV-2 Innate Immunity Evasion and Cell-specific immune response,CP:WIKIPATHWAYS,C2,54,69
Cohort,-0.01976020393720583,0.03604476137421764,-0.5482129214854521,0.5837266948182056,LGP Offspring,SARS-CoV-2 mitochondrial interactions,CP:WIKIPATHWAYS,C2,42,83
Cohort,0.08132527442451251,0.10588227243977075,0.768072620190249,0.4426614559278983,LGP Proband,SARS-CoV-2 mitochondrial interactions,CP:WIKIPATHWAYS,C2,42,130
Cohort,-0.017506927966304996,0.03040820766237031,-0.5757303475656524,0.5649601822137258,LonGen OPEL,SARS-CoV-2 mitochondrial interactions,CP:WIKIPATHWAYS,C2,67,76
Cohort,-0.002951532480882787,0.007190384790750437,-0.4104832448855279,0.6815815613931338,LGP Offspring,SCFA and skeletal muscle substrate metabolism,CP:WIKIPATHWAYS,C2,2,3
Cohort,0.01069863171420919,0.01928203988318375,0.5548495791433188,0.5791463216145041,LGP Proband,SCFA and skeletal muscle substrate metabolism,CP:WIKIPATHWAYS,C2,2,4
Cohort,0.007341989911599966,0.006351753583149879,1.155899676441639,0.24806901315325952,LonGen OPEL,SCFA and skeletal muscle substrate metabolism,CP:WIKIPATHWAYS,C2,2,4
Cohort,0.010387808848586371,0.007205458964800496,1.4416581787963854,0.1498619094478752,LGP Offspring,Secretion of Hydrochloric Acid in Parietal Cells,CP:WIKIPATHWAYS,C2,0,5
Cohort,-0.0016708730262032297,0.017699373289984496,-0.0944029485579991,0.9248117489049962,LGP Proband,Secretion of Hydrochloric Acid in Parietal Cells,CP:WIKIPATHWAYS,C2,0,5
Cohort,0.003754877161651835,0.003654278658320603,1.0275289633706983,0.3044835868930355,LonGen OPEL,Secretion of Hydrochloric Acid in Parietal Cells,CP:WIKIPATHWAYS,C2,0,2
Cohort,0.008700990157917999,0.016101239390968608,0.5403925714438167,0.5891043206235426,LGP Offspring,Selective expression of chemokine receptors during T-cell polarization,CP:WIKIPATHWAYS,C2,7,20
Cohort,0.0055352010330359976,0.04127437354486471,0.13410745112870837,0.8933499623834782,LGP Proband,Selective expression of chemokine receptors during T-cell polarization,CP:WIKIPATHWAYS,C2,7,20
Cohort,-0.015588581614848142,0.01598759095030966,-0.9750425604018979,0.3298353625313357,LonGen OPEL,Selective expression of chemokine receptors during T-cell polarization,CP:WIKIPATHWAYS,C2,21,19
Cohort,-0.014845318812554449,0.05070666351638301,-0.29276859850496806,0.769788872864751,LGP Offspring,Selenium Micronutrient Network,CP:WIKIPATHWAYS,C2,83,163
Cohort,-0.1520011057384758,0.1407716168436769,-1.0797709733437881,0.2805563389401027,LGP Proband,Selenium Micronutrient Network,CP:WIKIPATHWAYS,C2,83,230
Cohort,0.05097508069512063,0.046094877008143506,1.1058730167804753,0.26911560154428393,LonGen OPEL,Selenium Micronutrient Network,CP:WIKIPATHWAYS,C2,124,162
Cohort,-0.03212164577973895,0.04729133896682613,-0.679228934547013,0.49722530635814344,LGP Offspring,Senescence and Autophagy in Cancer,CP:WIKIPATHWAYS,C2,78,145
Cohort,-0.12929095633865986,0.13092862943274483,-0.9874918640699114,0.32368796571978975,LGP Proband,Senescence and Autophagy in Cancer,CP:WIKIPATHWAYS,C2,78,207
Cohort,0.02121068858555543,0.04100613141074346,0.517256513985572,0.6051208053946369,LonGen OPEL,Senescence and Autophagy in Cancer,CP:WIKIPATHWAYS,C2,103,130
Cohort,-0.005952164927767002,0.016355641816410967,-0.3639212080197735,0.7160306381166632,LGP Offspring,Serotonin and anxiety,CP:WIKIPATHWAYS,C2,10,17
Cohort,0.020362395793456244,0.054211024775797235,0.3756135560556149,0.7072997246401498,LGP Proband,Serotonin and anxiety,CP:WIKIPATHWAYS,C2,10,35
Cohort,0.004027485396138483,0.01683463373786686,0.23923807662528995,0.8109825630510679,LonGen OPEL,Serotonin and anxiety,CP:WIKIPATHWAYS,C2,20,22
Cohort,-0.027642176446169408,0.017631183204607596,-1.5678004207310157,0.11739566755884957,LGP Offspring,Serotonin and anxiety-related events,CP:WIKIPATHWAYS,C2,13,16
Cohort,-0.02763292752508853,0.0449585011440933,-0.6146318676533321,0.5389655064148056,LGP Proband,Serotonin and anxiety-related events,CP:WIKIPATHWAYS,C2,13,21
Cohort,0.021450865283848656,0.00995694944619674,2.1543611725418823,0.031511303600549836,LonGen OPEL,Serotonin and anxiety-related events,CP:WIKIPATHWAYS,C2,4,11
Cohort,-0.006380604284504494,0.014780524990499122,-0.43168996288061,0.6661044081618863,LGP Offspring,Serotonin Receptor 2 and ELK-SRF/GATA4 signaling,CP:WIKIPATHWAYS,C2,7,15
Cohort,0.020517534735995224,0.04135925987478347,0.4960808002394806,0.6199681116248179,LGP Proband,Serotonin Receptor 2 and ELK-SRF/GATA4 signaling,CP:WIKIPATHWAYS,C2,7,17
Cohort,-0.005532937290274941,0.012749648526717188,-0.4339678288919527,0.664429397205403,LonGen OPEL,Serotonin Receptor 2 and ELK-SRF/GATA4 signaling,CP:WIKIPATHWAYS,C2,12,11
Cohort,0.01798911664073755,0.01833304232172487,0.9812401196183481,0.3268253842675666,LGP Offspring,Serotonin Receptor 4/6/7 and NR3C Signaling,CP:WIKIPATHWAYS,C2,8,26
Cohort,0.04426813283883373,0.055378788207538866,0.7993698358464151,0.4243035964178482,LGP Proband,Serotonin Receptor 4/6/7 and NR3C Signaling,CP:WIKIPATHWAYS,C2,8,38
Cohort,-0.00989081861560832,0.011995245092645861,-0.8245616108062903,0.40986753545253896,LonGen OPEL,Serotonin Receptor 4/6/7 and NR3C Signaling,CP:WIKIPATHWAYS,C2,12,10
Cohort,-0.004892255992342716,0.007803486542321179,-0.6269320727100907,0.5309154315884252,LGP Offspring,Serotonin Transporter Activity,CP:WIKIPATHWAYS,C2,3,3
Cohort,-0.043037808059158675,0.015684069921498765,-2.7440459188571378,0.006199053594029548,LGP Proband,Serotonin Transporter Activity,CP:WIKIPATHWAYS,C2,3,1
Cohort,-0.005322540861364969,0.0063278007103175484,-0.8411359815245931,0.40052436528773827,LonGen OPEL,Serotonin Transporter Activity,CP:WIKIPATHWAYS,C2,4,2
Cohort,-0.025081602072046735,0.0268118410153451,-0.9354673577876244,0.34988154506310665,LGP Offspring,Signal Transduction of S1P Receptor,CP:WIKIPATHWAYS,C2,25,47
Cohort,-0.037650029132968665,0.07627135516900645,-0.49363262327700314,0.6216956231500562,LGP Proband,Signal Transduction of S1P Receptor,CP:WIKIPATHWAYS,C2,25,71
Cohort,-0.008304895763687842,0.024127285214370197,-0.3442117789009039,0.7307779361281969,LonGen OPEL,Signal Transduction of S1P Receptor,CP:WIKIPATHWAYS,C2,37,47
Cohort,-0.03236848965286939,0.031658332598435875,-1.0224319159016164,0.30694226547767156,LGP Offspring,Signal transduction through IL1R,CP:WIKIPATHWAYS,C2,35,57
Cohort,0.04426277506791884,0.08657958584650528,0.5112380087656133,0.6093197206072609,LGP Proband,Signal transduction through IL1R,CP:WIKIPATHWAYS,C2,35,76
Cohort,0.045987841595306396,0.02886364920961172,1.5932788422328887,0.11149463276293856,LonGen OPEL,Signal transduction through IL1R,CP:WIKIPATHWAYS,C2,46,79
Cohort,-0.007812111342440716,0.025909890461753272,-0.30151078230039285,0.7631177544509049,LGP Offspring,Signaling of Hepatocyte Growth Factor Receptor,CP:WIKIPATHWAYS,C2,22,42
Cohort,0.10134587672840788,0.07400871590001165,1.3693775860849915,0.1712498987893832,LGP Proband,Signaling of Hepatocyte Growth Factor Receptor,CP:WIKIPATHWAYS,C2,22,70
Cohort,0.007930992705490659,0.023867408749007907,0.3322938316804217,0.739754880318144,LonGen OPEL,Signaling of Hepatocyte Growth Factor Receptor,CP:WIKIPATHWAYS,C2,35,45
Cohort,-0.08859500131125703,0.05691180539578986,-1.5567069203854669,0.12000810326266836,LGP Offspring,Signaling Pathways in Glioblastoma,CP:WIKIPATHWAYS,C2,113,196
Cohort,0.1014487771109994,0.15448394596799928,0.6566946259387633,0.5115584470537587,LGP Proband,Signaling Pathways in Glioblastoma,CP:WIKIPATHWAYS,C2,113,273
Cohort,-0.017962947258198723,0.046409371009783255,-0.38705431397490975,0.6988194551402179,LonGen OPEL,Signaling Pathways in Glioblastoma,CP:WIKIPATHWAYS,C2,154,177
Cohort,-0.02880161684094397,0.02492268281973389,-1.1556387026736432,0.2482372549784989,LGP Offspring,Simplified Depiction of MYD88 Distinct Input-Output Pathway,CP:WIKIPATHWAYS,C2,26,40
Cohort,-0.0021267075198460944,0.07239388007955111,-0.029376896465683696,0.9765710269651737,LGP Proband,Simplified Depiction of MYD88 Distinct Input-Output Pathway,CP:WIKIPATHWAYS,C2,26,68
Cohort,0.05069495149153055,0.023980002725244944,2.1140511146882166,0.034821325591170633,LonGen OPEL,Simplified Depiction of MYD88 Distinct Input-Output Pathway,CP:WIKIPATHWAYS,C2,32,52
Cohort,0.00937138212078565,0.02753388761525832,0.340358116214303,0.7336925938509891,LGP Offspring,Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway,CP:WIKIPATHWAYS,C2,25,56
Cohort,-0.05226170627677208,0.07935129853911137,-0.6586118594015556,0.5103268213914107,LGP Proband,Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway,CP:WIKIPATHWAYS,C2,25,79
Cohort,0.012571159969104738,0.023148158759136804,0.5430738617231393,0.5872309824868942,LonGen OPEL,Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway,CP:WIKIPATHWAYS,C2,35,46
Cohort,-0.010995910390738087,0.024444440788288523,-0.44983276508441516,0.652975235490066,LGP Offspring,Sleep regulation,CP:WIKIPATHWAYS,C2,21,39
Cohort,-0.027254513146971696,0.07893558685984657,-0.3452753597102308,0.7299744321836462,LGP Proband,Sleep regulation,CP:WIKIPATHWAYS,C2,21,77
Cohort,0.029130596368849272,0.024149342637854215,1.2062687090781061,0.22807229460711753,LonGen OPEL,Sleep regulation,CP:WIKIPATHWAYS,C2,30,46
Cohort,-0.02400519073123366,0.06620320327455265,-0.3625986288258779,0.7170180702492175,LGP Offspring,Small cell lung cancer,CP:WIKIPATHWAYS,C2,143,292
Cohort,-0.18459472913752736,0.18062639299309302,-1.0219698576640794,0.30709151163125054,LGP Proband,Small cell lung cancer,CP:WIKIPATHWAYS,C2,143,364
Cohort,0.053799361825371074,0.05731816570285728,0.9386092727438625,0.34821610056959884,LonGen OPEL,Small cell lung cancer,CP:WIKIPATHWAYS,C2,210,275
Cohort,-0.01981103605343636,0.021392560267096947,-0.9260712979692727,0.354739414547401,LGP Offspring,Small Ligand GPCRs,CP:WIKIPATHWAYS,C2,20,26
Cohort,-0.11297200914137644,0.06158260376685616,-1.8344792560099272,0.06693896525984878,LGP Proband,Small Ligand GPCRs,CP:WIKIPATHWAYS,C2,20,45
Cohort,-0.005777116448106076,0.01582485963843947,-0.3650658887408477,0.71515919743253,LonGen OPEL,Small Ligand GPCRs,CP:WIKIPATHWAYS,C2,20,20
Cohort,-0.011608944637692142,0.012551759039677394,-0.9248858746407639,0.35535530967574436,LGP Offspring,Somatic Sex determination,CP:WIKIPATHWAYS,C2,7,9
Cohort,0.05385102796891479,0.03612851955897109,1.4905406760721536,0.13646022345321218,LGP Proband,Somatic Sex determination,CP:WIKIPATHWAYS,C2,7,15
Cohort,0.013275111671055792,0.012019743366493824,1.1044421886794544,0.26973510483338375,LonGen OPEL,Somatic Sex determination,CP:WIKIPATHWAYS,C2,8,14
Cohort,-0.004488013154101701,0.014224487910859035,-0.3155131616847544,0.7524694376249528,LGP Offspring,Somatroph axis (GH) and its relationship to dietary restriction and aging,CP:WIKIPATHWAYS,C2,7,13
Cohort,0.034334437040870504,0.03238940445174121,1.0600515082649113,0.28942806251409,LGP Proband,Somatroph axis (GH) and its relationship to dietary restriction and aging,CP:WIKIPATHWAYS,C2,7,11
Cohort,0.0022606079935924214,0.010628249756571532,0.21269804957252433,0.8316169449955383,LonGen OPEL,Somatroph axis (GH) and its relationship to dietary restriction and aging,CP:WIKIPATHWAYS,C2,7,10
Cohort,0.0014142468661548944,0.016941707552668012,0.08347723284434667,0.9334967926299651,LGP Offspring,Somitogenesis in the context of spondylocostal dysostosis,CP:WIKIPATHWAYS,C2,8,21
Cohort,-0.040242195084722175,0.04518116913691463,-0.8906851206699488,0.373354986949326,LGP Proband,Somitogenesis in the context of spondylocostal dysostosis,CP:WIKIPATHWAYS,C2,8,24
Cohort,0.003250881596655917,0.016988877751032305,0.19135352224536326,0.848297428826204,LonGen OPEL,Somitogenesis in the context of spondylocostal dysostosis,CP:WIKIPATHWAYS,C2,20,23
Cohort,0.03858609297050701,0.023360112952997475,1.6517939381605515,0.09904096070909764,LGP Offspring,Sphingolipid Metabolism (general overview),CP:WIKIPATHWAYS,C2,12,43
Cohort,-0.10129027253745143,0.06324660611046916,-1.6015131683197927,0.10964198153341256,LGP Proband,Sphingolipid Metabolism (general overview),CP:WIKIPATHWAYS,C2,12,56
Cohort,0.010511958847252303,0.021425940919212506,0.49061830642062004,0.6238316519552707,LonGen OPEL,Sphingolipid Metabolism (general overview),CP:WIKIPATHWAYS,C2,27,38
Cohort,0.045888208253501366,0.029281688123962195,1.5671298751368605,0.11755229502450018,LGP Offspring,Sphingolipid Metabolism (integrated pathway),CP:WIKIPATHWAYS,C2,19,64
Cohort,-0.0693473640497843,0.07858246102084991,-0.8824789036752704,0.37777216290216575,LGP Proband,Sphingolipid Metabolism (integrated pathway),CP:WIKIPATHWAYS,C2,19,87
Cohort,-0.003726663633749742,0.024123471191672918,-0.1544828936159127,0.8772681578380805,LonGen OPEL,Sphingolipid Metabolism (integrated pathway),CP:WIKIPATHWAYS,C2,38,44
Cohort,0.03770759967499708,0.030233873275940865,1.2471971199602654,0.21275714508283936,LGP Offspring,Sphingolipid pathway,CP:WIKIPATHWAYS,C2,23,68
Cohort,-0.09751916114902014,0.08151673346881799,-1.196308500098614,0.2319161768492601,LGP Proband,Sphingolipid pathway,CP:WIKIPATHWAYS,C2,23,92
Cohort,-0.0036842291129963495,0.02637520079618189,-0.1396853484250889,0.8889439380741806,LonGen OPEL,Sphingolipid pathway,CP:WIKIPATHWAYS,C2,50,55
Cohort,-0.07629222816844901,0.05885608353603758,-1.2962505077616195,0.19533154353931031,LGP Offspring,Spinal Cord Injury,CP:WIKIPATHWAYS,C2,118,220
Cohort,-0.04913792954859493,0.16324516791406096,-0.301006946646428,0.7634842236894772,LGP Proband,Spinal Cord Injury,CP:WIKIPATHWAYS,C2,118,320
Cohort,-0.08784113486485291,0.05365365793065405,-1.6371881853495485,0.10198639887411717,LonGen OPEL,Spinal Cord Injury,CP:WIKIPATHWAYS,C2,210,214
Cohort,-0.034757807208089714,0.03429424111387458,-1.013517316002878,0.31117574404736326,LGP Offspring,Splicing factor NOVA regulated synaptic proteins,CP:WIKIPATHWAYS,C2,45,79
Cohort,-0.05838947748913351,0.10066101390571254,-0.580060494362057,0.5620304971696125,LGP Proband,Splicing factor NOVA regulated synaptic proteins,CP:WIKIPATHWAYS,C2,45,136
Cohort,-0.012117968468204565,0.030609870982503676,-0.39588433662889616,0.6922964419706416,LonGen OPEL,Splicing factor NOVA regulated synaptic proteins,CP:WIKIPATHWAYS,C2,72,81
Cohort,-0.00904168565508553,0.02959959267564374,-0.3054665567248009,0.7601048728789332,LGP Offspring,SREBF and miR33 in cholesterol and lipid homeostasis,CP:WIKIPATHWAYS,C2,27,50
Cohort,-0.006879827210292331,0.07790670923721646,-0.08830853308595148,0.9296526568155368,LGP Proband,SREBF and miR33 in cholesterol and lipid homeostasis,CP:WIKIPATHWAYS,C2,27,77
Cohort,-0.005739430248770144,0.023386649971188465,-0.2454148095533529,0.8061985214874039,LonGen OPEL,SREBF and miR33 in cholesterol and lipid homeostasis,CP:WIKIPATHWAYS,C2,43,43
Cohort,-0.022467797820575133,0.016159543869610424,-1.3903732680739824,0.16487313750052696,LGP Offspring,SRF and miRs in Smooth Muscle Differentiation and Proliferation,CP:WIKIPATHWAYS,C2,10,14
Cohort,-0.01994941741499049,0.05150725914795837,-0.3873127350396248,0.6986235152355569,LGP Proband,SRF and miRs in Smooth Muscle Differentiation and Proliferation,CP:WIKIPATHWAYS,C2,10,31
Cohort,-0.006835002585973037,0.013040663539072558,-0.5241299697284527,0.6003340528134968,LonGen OPEL,SRF and miRs in Smooth Muscle Differentiation and Proliferation,CP:WIKIPATHWAYS,C2,14,12
Cohort,7.440468830096471e-4,0.0340445831020206,0.021855074000465196,0.9825700112044007,LGP Offspring,Statin Pathway,CP:WIKIPATHWAYS,C2,37,77
Cohort,-0.18337548807132012,0.098671139710141,-1.8584510993793006,0.06345711216679742,LGP Proband,Statin Pathway,CP:WIKIPATHWAYS,C2,37,127
Cohort,0.05871582116792049,0.028459201643626357,2.063157705657928,0.03942141830172697,LonGen OPEL,Statin Pathway,CP:WIKIPATHWAYS,C2,47,80
Cohort,-0.01521085639231533,0.01804739695224494,-0.8428282722746469,0.399622596477308,LGP Offspring,Steroid Biosynthesis,CP:WIKIPATHWAYS,C2,12,22
Cohort,7.085902100516843e-4,0.051959254100213265,0.013637420750594953,0.9891225113310153,LGP Proband,Steroid Biosynthesis,CP:WIKIPATHWAYS,C2,12,34
Cohort,-0.014114418774747294,0.013748480415318263,-1.0266166404122241,0.3049128784736456,LonGen OPEL,Steroid Biosynthesis,CP:WIKIPATHWAYS,C2,15,12
Cohort,-0.0025312492407308556,0.043059195056309285,-0.058785335801579554,0.9531404613845931,LGP Offspring,Sterol Regulatory Element-Binding Proteins (SREBP) signalling,CP:WIKIPATHWAYS,C2,63,126
Cohort,-0.19427610149780467,0.12170377690050713,-1.596302977980917,0.11079998612494657,LGP Proband,Sterol Regulatory Element-Binding Proteins (SREBP) signalling,CP:WIKIPATHWAYS,C2,63,182
Cohort,-0.01717683007332214,0.03819205528794604,-0.4497487748124253,0.6530140413824816,LonGen OPEL,Sterol Regulatory Element-Binding Proteins (SREBP) signalling,CP:WIKIPATHWAYS,C2,108,126
Cohort,-0.017553002719465832,0.028925466180831985,-0.6068356032615186,0.5441637665069677,LGP Offspring,STING pathway in Kawasaki-like disease and COVID-19,CP:WIKIPATHWAYS,C2,25,51
Cohort,0.008925139643283394,0.07530747107772373,0.11851599204641845,0.9056873631828393,LGP Proband,STING pathway in Kawasaki-like disease and COVID-19,CP:WIKIPATHWAYS,C2,25,59
Cohort,0.01275432477366357,0.026249765085133367,0.4858833872340831,0.6271835682337574,LonGen OPEL,STING pathway in Kawasaki-like disease and COVID-19,CP:WIKIPATHWAYS,C2,44,56
Cohort,-0.03850413222864891,0.041618948264800254,-0.9251587037631669,0.355213499491255,LGP Offspring,Striated Muscle Contraction Pathway,CP:WIKIPATHWAYS,C2,59,114
Cohort,-0.00586873754413695,0.1159794780499201,-0.05060151712021774,0.9596551701001423,LGP Proband,Striated Muscle Contraction Pathway,CP:WIKIPATHWAYS,C2,59,170
Cohort,0.03602645775361354,0.03591003292005404,1.0032421255034405,0.3160489236528786,LonGen OPEL,Striated Muscle Contraction Pathway,CP:WIKIPATHWAYS,C2,83,111
Cohort,-0.04924402542663979,0.033296150059030236,-1.4789705518306413,0.13961399729602111,LGP Offspring,Structural Pathway of Interleukin 1 (IL-1),CP:WIKIPATHWAYS,C2,43,70
Cohort,-0.023975241150875435,0.09259903524579675,-0.2589145889828665,0.7957650303098366,LGP Proband,Structural Pathway of Interleukin 1 (IL-1),CP:WIKIPATHWAYS,C2,43,102
Cohort,0.02135091466944601,0.031454773284154074,0.6787813880127991,0.4974736853741579,LonGen OPEL,Structural Pathway of Interleukin 1 (IL-1),CP:WIKIPATHWAYS,C2,58,83
Cohort,0.09634960355977441,0.06567922623152272,1.4669722694377823,0.1428486511950979,LGP Offspring,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways,CP:WIKIPATHWAYS,C2,121,303
Cohort,0.20848639264020094,0.18554308715299458,1.1236548655045706,0.2614828009045524,LGP Proband,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways,CP:WIKIPATHWAYS,C2,121,398
Cohort,0.04413629543157384,0.057702784662746705,0.7648902161227674,0.4445636230953428,LonGen OPEL,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways,CP:WIKIPATHWAYS,C2,230,302
Cohort,-0.04235565340753334,0.026489121834359863,-1.5989829210794186,0.110291652087809,LGP Offspring,Sulfation Biotransformation Reaction,CP:WIKIPATHWAYS,C2,28,36
Cohort,0.017621948604470444,0.07670779706751756,0.22972825811905084,0.8183592648433828,LGP Proband,Sulfation Biotransformation Reaction,CP:WIKIPATHWAYS,C2,28,59
Cohort,-0.002344251583721334,0.020150497498280837,-0.11633715663453653,0.9074146825690912,LonGen OPEL,Sulfation Biotransformation Reaction,CP:WIKIPATHWAYS,C2,28,35
Cohort,0.006884433893775391,0.011497636878083263,0.5987694660020498,0.5495272114767211,LGP Offspring,Sulindac Metabolic Pathway,CP:WIKIPATHWAYS,C2,3,10
Cohort,0.02841712536209586,0.03130831774617823,0.9076541765187849,0.3643231446400076,LGP Proband,Sulindac Metabolic Pathway,CP:WIKIPATHWAYS,C2,3,13
Cohort,-0.0161588566510211,0.010273258882497258,-1.572904648451062,0.11613826431291523,LonGen OPEL,Sulindac Metabolic Pathway,CP:WIKIPATHWAYS,C2,10,6
Cohort,0.007656218712513944,0.018671175913734607,0.4100555180823931,0.6818951396685033,LGP Offspring,Supression of HMGB1 mediated inflammation by THBD,CP:WIKIPATHWAYS,C2,8,23
Cohort,0.014090173843029559,0.04360815164029917,0.32310871506896305,0.7466939034063862,LGP Proband,Supression of HMGB1 mediated inflammation by THBD,CP:WIKIPATHWAYS,C2,8,20
Cohort,0.007850857853044332,0.01739486234408307,0.4513319908918297,0.6518732241253564,LonGen OPEL,Supression of HMGB1 mediated inflammation by THBD,CP:WIKIPATHWAYS,C2,17,22
Cohort,-0.053540818274009395,0.037661486896755324,-1.4216331506184408,0.155593948894728,LGP Offspring,Synaptic signaling pathways associated with autism spectrum disorder,CP:WIKIPATHWAYS,C2,54,87
Cohort,-0.20189503131596956,0.09886282189164002,-2.042173462712398,0.041448401224971704,LGP Proband,Synaptic signaling pathways associated with autism spectrum disorder,CP:WIKIPATHWAYS,C2,54,106
Cohort,0.006772162424340351,0.030552116742036017,0.22165935282064023,0.8246359264327588,LonGen OPEL,Synaptic signaling pathways associated with autism spectrum disorder,CP:WIKIPATHWAYS,C2,61,82
Cohort,-0.038873188696271675,0.03272043945183566,-1.1880399330666946,0.2352349095054834,LGP Offspring,Synaptic Vesicle Pathway,CP:WIKIPATHWAYS,C2,42,73
Cohort,-0.028582254098839042,0.08979552113363658,-0.3183037832844916,0.7503342035396976,LGP Proband,Synaptic Vesicle Pathway,CP:WIKIPATHWAYS,C2,42,105
Cohort,0.006761148003131266,0.0288148816783642,0.2346408386680244,0.8145478516284181,LonGen OPEL,Synaptic Vesicle Pathway,CP:WIKIPATHWAYS,C2,58,70
Cohort,0.006988599370537721,0.012622913095114738,0.5536439423988759,0.5800056159573621,LGP Offspring,Synthesis and Degradation of Ketone Bodies,CP:WIKIPATHWAYS,C2,4,12
Cohort,0.05259405847613499,0.03265202539809818,1.6107441371523108,0.1076138795225234,LGP Proband,Synthesis and Degradation of Ketone Bodies,CP:WIKIPATHWAYS,C2,4,14
Cohort,0.005411342409974484,0.008973329233203596,0.6030473494665886,0.546648967109602,LonGen OPEL,Synthesis and Degradation of Ketone Bodies,CP:WIKIPATHWAYS,C2,4,8
Cohort,-0.06529612048761373,0.025549026894660477,-2.5557184920127054,0.010814538362037232,LGP Offspring,Tamoxifen metabolism,CP:WIKIPATHWAYS,C2,30,31
Cohort,-0.08414966590046591,0.0762054853030209,-1.1042468342778218,0.26980456405981956,LGP Proband,Tamoxifen metabolism,CP:WIKIPATHWAYS,C2,30,51
Cohort,-0.014792624869364578,0.02331678250717973,-0.6344196445118282,0.5259892760344227,LonGen OPEL,Tamoxifen metabolism,CP:WIKIPATHWAYS,C2,35,38
Cohort,-0.07341390994455843,0.03454132228046269,-2.1253937341617903,0.03391576737917163,LGP Offspring,Target Of Rapamycin (TOR) Signaling,CP:WIKIPATHWAYS,C2,48,65
Cohort,-0.16837348478019684,0.0927217543056134,-1.8159005515063196,0.0697445831942396,LGP Proband,Target Of Rapamycin (TOR) Signaling,CP:WIKIPATHWAYS,C2,48,88
Cohort,-0.006253873870915066,0.024921925096022222,-0.2509386352306004,0.801926313774196,LonGen OPEL,Target Of Rapamycin (TOR) Signaling,CP:WIKIPATHWAYS,C2,44,49
Cohort,0.025377959590737378,0.02538082233448458,0.9998872083926409,0.3177228675746533,LGP Offspring,TCA Cycle (aka Krebs or citric acid cycle),CP:WIKIPATHWAYS,C2,16,46
Cohort,-0.011310450504493611,0.06629985304106022,-0.17059540837125126,0.8645832851105685,LGP Proband,TCA Cycle (aka Krebs or citric acid cycle),CP:WIKIPATHWAYS,C2,16,58
Cohort,0.006605331816213823,0.02243650467239908,0.29440110715371653,0.7685281768165083,LonGen OPEL,TCA Cycle (aka Krebs or citric acid cycle),CP:WIKIPATHWAYS,C2,31,42
Cohort,0.013059378568111934,0.02777221812312952,0.4702317441917144,0.6383411237073545,LGP Offspring,TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc),CP:WIKIPATHWAYS,C2,21,51
Cohort,0.024343423129263637,0.0703451453008939,0.3460569030760719,0.7293872297527952,LGP Proband,TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc),CP:WIKIPATHWAYS,C2,21,60
Cohort,-0.035418291613346406,0.023902028426640125,-1.481811124191902,0.138786304493409,LonGen OPEL,TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc),CP:WIKIPATHWAYS,C2,41,37
Cohort,0.035869328937935756,0.01990212569255893,1.8022863231813824,0.07194569797635166,LGP Offspring,TCA cycle in senescence,CP:WIKIPATHWAYS,C2,6,30
Cohort,0.11855009194942703,0.05064175171212739,2.340955593782064,0.019469173818957058,LGP Proband,TCA cycle in senescence,CP:WIKIPATHWAYS,C2,6,33
Cohort,-0.027115681189949906,0.01653603759591137,-1.6397931507276213,0.10144328504958006,LonGen OPEL,TCA cycle in senescence,CP:WIKIPATHWAYS,C2,22,15
Cohort,2.439538805582874e-4,0.008480785438214724,0.028765481963383067,0.9770601208125376,LGP Offspring,TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer,CP:WIKIPATHWAYS,C2,2,5
Cohort,0.017169723700020657,0.020797044946076624,0.8255847763246642,0.40927576412024347,LGP Proband,TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer,CP:WIKIPATHWAYS,C2,2,5
Cohort,-0.021279029497914256,0.008026454307526966,-2.65111202065393,0.00818219364649681,LonGen OPEL,TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer,CP:WIKIPATHWAYS,C2,8,2
Cohort,-0.02030206704124863,0.032874567328797705,-0.6175614978653811,0.5370724006370972,LGP Offspring,T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection,CP:WIKIPATHWAYS,C2,36,68
Cohort,0.11773905190562182,0.0969402224732324,1.214553143181949,0.22488033905179133,LGP Proband,T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection,CP:WIKIPATHWAYS,C2,36,107
Cohort,-0.05225034766549918,0.0299095840185339,-1.7469433086438617,0.08103283932480108,LonGen OPEL,T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection,CP:WIKIPATHWAYS,C2,62,54
Cohort,-0.0029961982415530816,0.04693247913960668,-0.06384061307821616,0.94911601221253,LGP Offspring,T-Cell antigen Receptor (TCR)  Signaling Pathway,CP:WIKIPATHWAYS,C2,70,142
Cohort,0.024594684909245233,0.1271559188851483,0.19342147125262818,0.8466759967650817,LGP Proband,T-Cell antigen Receptor (TCR)  Signaling Pathway,CP:WIKIPATHWAYS,C2,70,188
Cohort,0.0017320098763317616,0.04265003174322192,0.04060981447234253,0.9676171430622993,LonGen OPEL,T-Cell antigen Receptor (TCR)  Signaling Pathway,CP:WIKIPATHWAYS,C2,116,136
Cohort,-0.017670317935242066,0.022464584528262152,-0.7865855659610115,0.43180016544189537,LGP Offspring,T-Cell Receptor and Co-stimulatory Signaling,CP:WIKIPATHWAYS,C2,16,23
Cohort,-0.007034612016226266,0.05723450668267692,-0.12290858127297219,0.9022091018632482,LGP Proband,T-Cell Receptor and Co-stimulatory Signaling,CP:WIKIPATHWAYS,C2,16,32
Cohort,-0.004986216377075605,0.016237835881697048,-0.3070739483637696,0.7588674012348713,LonGen OPEL,T-Cell Receptor and Co-stimulatory Signaling,CP:WIKIPATHWAYS,C2,17,20
Cohort,0.010907965062697679,0.012277563033919369,0.8884470829074235,0.37461632343940476,LGP Offspring,TFs Regulate miRNAs related to cardiac hypertrophy,CP:WIKIPATHWAYS,C2,3,12
Cohort,0.014138287563971005,0.025996884147000833,0.5438454656344687,0.5866931664681367,LGP Proband,TFs Regulate miRNAs related to cardiac hypertrophy,CP:WIKIPATHWAYS,C2,3,8
Cohort,0.0048877567799927146,0.010869373011497433,0.44968157545265314,0.6530624812047978,LonGen OPEL,TFs Regulate miRNAs related to cardiac hypertrophy,CP:WIKIPATHWAYS,C2,7,11
Cohort,-0.016708462964068325,0.02587934114403996,-0.6456293794757716,0.5187384877544339,LGP Offspring,TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition,CP:WIKIPATHWAYS,C2,24,39
Cohort,-0.1890156294455949,0.07671476353947955,-2.4638755400493704,0.013945164045026817,LGP Proband,TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition,CP:WIKIPATHWAYS,C2,24,71
Cohort,-0.0858248816989272,0.021556564247718176,-3.9813803680710396,7.478415891767864e-5,LonGen OPEL,TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition,CP:WIKIPATHWAYS,C2,49,26
Cohort,0.08216439205456122,0.02989762913884877,2.748190890755193,0.006152361433034843,LGP Offspring,TGF-beta Receptor Signaling,CP:WIKIPATHWAYS,C2,17,72
Cohort,0.12380677367794776,0.07393076560473633,1.674631294093026,0.09438149814731393,LGP Proband,TGF-beta Receptor Signaling,CP:WIKIPATHWAYS,C2,17,68
Cohort,-0.003004543424605622,0.026303431844072845,-0.11422628964982982,0.9090872166997497,LonGen OPEL,TGF-beta Receptor Signaling,CP:WIKIPATHWAYS,C2,49,54
Cohort,0.07518557969714475,0.03114420951656782,2.4141110294402623,0.016038336769960942,LGP Offspring,TGF-beta Receptor Signalling in Skeletal Dysplasias,CP:WIKIPATHWAYS,C2,20,76
Cohort,0.12667489139471957,0.07705035092036878,1.6440533999077764,0.10054204456670977,LGP Proband,TGF-beta Receptor Signalling in Skeletal Dysplasias,CP:WIKIPATHWAYS,C2,20,75
Cohort,-0.002281525453485978,0.027597833074100485,-0.08267045631300317,0.934134360574107,LonGen OPEL,TGF-beta Receptor Signalling in Skeletal Dysplasias,CP:WIKIPATHWAYS,C2,54,60
Cohort,0.01038754775477594,0.06739114038785385,0.15413818040461777,0.8775467888730204,LGP Offspring,TGF-beta Signaling Pathway,CP:WIKIPATHWAYS,C2,134,271
Cohort,-0.0542633211251318,0.17840695144315558,-0.30415474669674686,0.761085870415611,LGP Proband,TGF-beta Signaling Pathway,CP:WIKIPATHWAYS,C2,134,368
Cohort,-0.07707658697423674,0.05361769232274656,-1.4375215276010316,0.1509628378789542,LonGen OPEL,TGF-beta Signaling Pathway,CP:WIKIPATHWAYS,C2,207,230
Cohort,-0.009725735944675871,0.01659818283036901,-0.5859518505170996,0.5581034489767722,LGP Offspring,Tgif disruption of Shh signaling,CP:WIKIPATHWAYS,C2,11,17
Cohort,-0.016814065869935665,0.04597753945749472,-0.36570173324477095,0.7146803869274823,LGP Proband,Tgif disruption of Shh signaling,CP:WIKIPATHWAYS,C2,11,25
Cohort,8.665333726365225e-4,0.015105067327375307,0.05736706456555023,0.9542671954958364,LonGen OPEL,Tgif disruption of Shh signaling,CP:WIKIPATHWAYS,C2,17,19
Cohort,-0.013106375830028983,0.02171411289270055,-0.6035879013245272,0.54632013233498955,LGP Offspring,The alternative pathway of fetal androgen synthesis,CP:WIKIPATHWAYS,C2,17,32
Cohort,0.005674301880987958,0.05388371176096645,0.10530644039816206,0.9161579739243995,LGP Proband,The alternative pathway of fetal androgen synthesis,CP:WIKIPATHWAYS,C2,17,33
Cohort,0.008462603542534081,0.016440027200928947,0.5147560547865699,0.6068663953412095,LonGen OPEL,The alternative pathway of fetal androgen synthesis,CP:WIKIPATHWAYS,C2,17,25
Cohort,0.017347185452480696,0.019137553181074102,0.9064474067476938,0.3650220678086331,LGP Offspring,The effect of progerin on the involved genes in Hutchinson-Gilford Progeria Syndrome,CP:WIKIPATHWAYS,C2,9,28
Cohort,-0.0015650727774961738,0.05888964591930876,-0.026576365896997474,0.9788039815475258,LGP Proband,The effect of progerin on the involved genes in Hutchinson-Gilford Progeria Syndrome,CP:WIKIPATHWAYS,C2,9,46
Cohort,-0.0104663872385755,0.01945737623826879,-0.5379135969006036,0.5907870606083696,LonGen OPEL,The effect of progerin on the involved genes in Hutchinson-Gilford Progeria Syndrome,CP:WIKIPATHWAYS,C2,28,30
Cohort,-0.03071561618211579,0.02331636629700245,-1.3173414669705454,0.18817051390503053,LGP Offspring,The human immune response to tuberculosis,CP:WIKIPATHWAYS,C2,20,31
Cohort,-0.009246801506099725,0.06476926738157089,-0.14276526321696148,0.8865100551199814,LGP Proband,The human immune response to tuberculosis,CP:WIKIPATHWAYS,C2,20,42
Cohort,-0.02029653066225738,0.021194266495735612,-0.9576425146084268,0.33853381467927246,LonGen OPEL,The human immune response to tuberculosis,CP:WIKIPATHWAYS,C2,36,31
Cohort,0.004025880159898163,0.02924618005853735,0.13765490576342654,0.8905541503182282,LGP Offspring,The influence of laminopathies on Wnt signaling,CP:WIKIPATHWAYS,C2,26,57
Cohort,0.02445616651928446,0.07774781597986533,0.3145576015359451,0.7531762496941179,LGP Proband,The influence of laminopathies on Wnt signaling,CP:WIKIPATHWAYS,C2,26,77
Cohort,-0.01309663575084877,0.02509298693947016,-0.5219241448792348,0.6018683447468756,LonGen OPEL,The influence of laminopathies on Wnt signaling,CP:WIKIPATHWAYS,C2,46,51
Cohort,-0.023780608741682495,0.03381107697996959,-0.703337807185812,0.48208741626564344,LGP Offspring,The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies,CP:WIKIPATHWAYS,C2,39,78
Cohort,0.042368974330728275,0.08985677677026639,0.47151673867683364,0.6373950917088549,LGP Proband,The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies,CP:WIKIPATHWAYS,C2,39,103
Cohort,-0.03572609419610958,0.03258005725716366,-1.0965632722531258,0.2731639805329226,LonGen OPEL,The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies,CP:WIKIPATHWAYS,C2,83,87
Cohort,-0.007858467879453341,0.05918158255821292,-0.13278570020873467,0.8944023790846984,LGP Offspring,Thermogenesis,CP:WIKIPATHWAYS,C2,125,239
Cohort,-0.10786449125256525,0.1634685819781071,-0.6598484549588327,0.509533260610598,LGP Proband,Thermogenesis,CP:WIKIPATHWAYS,C2,125,311
Cohort,-0.07505664334042597,0.049828228473510594,-1.5063076822072285,0.13238492763918147,LonGen OPEL,Thermogenesis,CP:WIKIPATHWAYS,C2,182,182
Cohort,0.014676833178369505,0.02099263977948302,0.6991418579341215,0.4847038577979932,LGP Offspring,Thiamine metabolic pathways,CP:WIKIPATHWAYS,C2,13,31
Cohort,-0.062953186336857,0.04994092734352338,-1.260553011036971,0.20782248788555652,LGP Proband,Thiamine metabolic pathways,CP:WIKIPATHWAYS,C2,13,30
Cohort,-0.002430724749438354,0.018842521236368488,-0.12900209685032715,0.8973885769837141,LonGen OPEL,Thiamine metabolic pathways,CP:WIKIPATHWAYS,C2,21,26
Cohort,-0.019370978423126083,0.03161869194033031,-0.6126432573391182,0.5403182814000262,LGP Offspring,Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway,CP:WIKIPATHWAYS,C2,34,65
Cohort,0.06836476283371415,0.08140403982876003,0.8398202715433405,0.4012498418407173,LGP Proband,Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway,CP:WIKIPATHWAYS,C2,34,79
Cohort,0.004401626728180648,0.02800363308956396,0.1571805598974581,0.8751424082055816,LonGen OPEL,Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway,CP:WIKIPATHWAYS,C2,49,62
Cohort,-0.061393833747523996,0.05804618592459207,-1.0576721410650627,0.2905827434711128,LGP Offspring,Thyroid hormones production and their peripheral downstream signalling effects,CP:WIKIPATHWAYS,C2,116,209
Cohort,-0.05905628727133518,0.15367546220111375,-0.38429223784633054,0.7008598217982702,LGP Proband,Thyroid hormones production and their peripheral downstream signalling effects,CP:WIKIPATHWAYS,C2,116,253
Cohort,-0.004415185905337319,0.0470950305885671,-0.0937505688001222,0.9253308910046114,LonGen OPEL,Thyroid hormones production and their peripheral downstream signalling effects,CP:WIKIPATHWAYS,C2,146,170
Cohort,-0.023459471415661935,0.017306404581622435,-1.3555369808338702,0.1756992354996656,LGP Offspring,Thyroxine (Thyroid Hormone) Production,CP:WIKIPATHWAYS,C2,14,17
Cohort,0.047635894613556516,0.05014277904102609,0.9500050759967157,0.3423848831139792,LGP Proband,Thyroxine (Thyroid Hormone) Production,CP:WIKIPATHWAYS,C2,14,29
Cohort,-0.013295901512832551,0.015776065051170043,-0.8427894706130444,0.3995993599486768,LonGen OPEL,Thyroxine (Thyroid Hormone) Production,CP:WIKIPATHWAYS,C2,19,15
Cohort,-0.047518238180983205,0.02398578320047972,-1.9811001285141623,0.04798485427830193,LGP Offspring,TLR4 Signaling and Tolerance,CP:WIKIPATHWAYS,C2,23,31
Cohort,-0.04989866401607908,0.06725664073546789,-0.7419143072033472,0.4583481348210843,LGP Proband,TLR4 Signaling and Tolerance,CP:WIKIPATHWAYS,C2,23,48
Cohort,0.008620965908707881,0.021886853980675018,0.39388785232997653,0.6937693289444049,LonGen OPEL,TLR4 Signaling and Tolerance,CP:WIKIPATHWAYS,C2,28,36
Cohort,-0.010837310567929382,0.047678491265640874,-0.227299779843059,0.8202593681217986,LGP Offspring,TNF alpha Signaling Pathway,CP:WIKIPATHWAYS,C2,73,151
Cohort,0.18026433244026432,0.12830614447227062,1.4049547913835323,0.16040707199928417,LGP Proband,TNF alpha Signaling Pathway,CP:WIKIPATHWAYS,C2,73,198
Cohort,-0.047583646743707915,0.04274254454337051,-1.1132619092301625,0.2659320232946702,LonGen OPEL,TNF alpha Signaling Pathway,CP:WIKIPATHWAYS,C2,129,132
Cohort,0.005190239260511978,0.031025669680468833,0.16728854893273482,0.8671930434624457,LGP Offspring,TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway,CP:WIKIPATHWAYS,C2,24,59
Cohort,0.04082531468408491,0.07412740518358137,0.55074522820512,0.5819558267104223,LGP Proband,TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway,CP:WIKIPATHWAYS,C2,24,63
Cohort,-0.036008360081540534,0.026117233871145732,-1.378720283288595,0.16836833150632563,LonGen OPEL,TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway,CP:WIKIPATHWAYS,C2,54,55
Cohort,-0.12835325864006336,0.05342645916892533,-2.402428696130363,0.01655527044664141,LGP Offspring,Toll-like Receptor Signaling Pathway,CP:WIKIPATHWAYS,C2,106,168
Cohort,0.09275658402959061,0.14580599635942304,0.6361643988971377,0.5248438150396297,LGP Proband,Toll-like Receptor Signaling Pathway,CP:WIKIPATHWAYS,C2,106,220
Cohort,0.041333902554240735,0.04530803932381554,0.9122862779125855,0.3618942430102817,LonGen OPEL,Toll-like Receptor Signaling Pathway,CP:WIKIPATHWAYS,C2,126,166
Cohort,-0.08427384130606994,0.040331310587405154,-2.089538873859144,0.03703249243113573,LGP Offspring,Toll-like Receptor Signaling related to MyD88,CP:WIKIPATHWAYS,C2,63,92
Cohort,-0.03554028050147629,0.10398802701578518,-0.34177281290356004,0.7326079692388172,LGP Proband,Toll-like Receptor Signaling related to MyD88,CP:WIKIPATHWAYS,C2,63,115
Cohort,0.07456683314460874,0.032644705741770336,2.2841937597617,0.022622625839047464,LonGen OPEL,Toll-like Receptor Signaling related to MyD88,CP:WIKIPATHWAYS,C2,61,99
Cohort,0.008635148691020144,0.018989829087731884,0.4547249293885832,0.6494531300301647,LGP Offspring,TP53 Network,CP:WIKIPATHWAYS,C2,11,26
Cohort,0.07814405176752093,0.056801195237525054,1.3757466095695106,0.16926944241342656,LGP Proband,TP53 Network,CP:WIKIPATHWAYS,C2,11,38
Cohort,1.0902382624400448e-4,0.01720766232855128,0.006335772062606673,0.9949464065865552,LonGen OPEL,TP53 Network,CP:WIKIPATHWAYS,C2,23,24
Cohort,0.014529178044749696,0.01585736451560543,0.9162416636416065,0.3598668937870928,LGP Offspring,Transcription co-factors SKI and SKIL protein partners,CP:WIKIPATHWAYS,C2,5,18
Cohort,0.0609019127214493,0.04975784549340677,1.223966032241472,0.22131069862354907,LGP Proband,Transcription co-factors SKI and SKIL protein partners,CP:WIKIPATHWAYS,C2,5,33
Cohort,0.02332936228381455,0.015985796147771365,1.4593806944715093,0.14485486220825225,LonGen OPEL,Transcription co-factors SKI and SKIL protein partners,CP:WIKIPATHWAYS,C2,14,26
Cohort,0.004681263487340348,0.024717711316609655,0.18938903474427513,0.8498447667845163,LGP Offspring,Transcription factor regulation in adipogenesis,CP:WIKIPATHWAYS,C2,19,39
Cohort,0.05876999580554007,0.06424757082288549,0.9147426907011672,0.3605911159084906,LGP Proband,Transcription factor regulation in adipogenesis,CP:WIKIPATHWAYS,C2,19,46
Cohort,4.492313665073971e-4,0.019310710308765144,0.02326332689603296,0.9814460549493277,LonGen OPEL,Transcription factor regulation in adipogenesis,CP:WIKIPATHWAYS,C2,26,31
Cohort,0.0026358243564998506,0.009003922530362009,0.2927417853287411,0.769809360443121,LGP Offspring,Transcriptional cascade regulating adipogenesis,CP:WIKIPATHWAYS,C2,2,6
Cohort,-0.02341075160736255,0.03406549860740792,-0.687227622209869,0.4921303532313762,LGP Proband,Transcriptional cascade regulating adipogenesis,CP:WIKIPATHWAYS,C2,2,17
Cohort,-0.004285398797474424,0.010249454202296783,-0.4181099513098089,0.6759794979742679,LonGen OPEL,Transcriptional cascade regulating adipogenesis,CP:WIKIPATHWAYS,C2,7,9
Cohort,0.019158908110959227,0.02576281618367488,0.7436651325059583,0.4573374779030197,LGP Offspring,Translation Factors,CP:WIKIPATHWAYS,C2,19,51
Cohort,0.07764745063504105,0.07360455878105387,1.0549271936540408,0.2917641289051476,LGP Proband,Translation Factors,CP:WIKIPATHWAYS,C2,19,78
Cohort,-0.011288222662406642,0.025512586388546452,-0.44245700888540035,0.6582787305731584,LonGen OPEL,Translation Factors,CP:WIKIPATHWAYS,C2,47,54
Cohort,-0.0028254524623878255,0.025733865176092368,-0.10979510629490538,0.9126044574849858,LGP Offspring,Translation inhibitors in chronically activated PDGFRA cells,CP:WIKIPATHWAYS,C2,21,48
Cohort,0.06487045705710125,0.07525451535277766,0.8620141496228089,0.3889275143085946,LGP Proband,Translation inhibitors in chronically activated PDGFRA cells,CP:WIKIPATHWAYS,C2,21,63
Cohort,-0.0035133291081418717,0.02329398403918248,-0.1508255995295674,0.8801515039350009,LonGen OPEL,Translation inhibitors in chronically activated PDGFRA cells,CP:WIKIPATHWAYS,C2,37,43
Cohort,-0.012327760779957382,0.03785248208869097,-0.32567905985854745,0.7447679714894015,LGP Offspring,Trans-sulfuration and one carbon metabolism,CP:WIKIPATHWAYS,C2,51,98
Cohort,-0.16580957340060157,0.10859367179553678,-1.5268806244326327,0.12716983531159218,LGP Proband,Trans-sulfuration and one carbon metabolism,CP:WIKIPATHWAYS,C2,51,157
Cohort,-0.0016442934425889254,0.03234150381856569,-0.050841588932083494,0.9594645054502667,LonGen OPEL,Trans-sulfuration and one carbon metabolism,CP:WIKIPATHWAYS,C2,75,87
Cohort,-0.03518140376509666,0.02160968028050285,-1.6280390689925561,0.1039825420506236,LGP Offspring,Trans-sulfuration pathway,CP:WIKIPATHWAYS,C2,18,24
Cohort,0.020787324704690645,0.05746466564363262,0.36174098416587563,0.7176372259933681,LGP Proband,Trans-sulfuration pathway,CP:WIKIPATHWAYS,C2,18,32
Cohort,0.005767427484410083,0.016154950211037723,0.3570068250949817,0.7211813179307558,LonGen OPEL,Trans-sulfuration pathway,CP:WIKIPATHWAYS,C2,18,23
Cohort,-0.023452359017233047,0.030949221130683113,-0.7577689570346678,0.4488533771701084,LGP Offspring,Triacylglyceride Synthesis,CP:WIKIPATHWAYS,C2,35,63
Cohort,-0.10794512384205178,0.08755914223745323,-1.2328252776770408,0.21798834951237364,LGP Proband,Triacylglyceride Synthesis,CP:WIKIPATHWAYS,C2,35,87
Cohort,-0.022349150113088013,0.027402458634481996,-0.8155892290980368,0.41497908454190613,LonGen OPEL,Triacylglyceride Synthesis,CP:WIKIPATHWAYS,C2,54,57
Cohort,0.042036218140789436,0.021488315710034518,1.9562360637301857,0.0508487545453802,LGP Offspring,Tryptophan catabolism leading to NAD+ production,CP:WIKIPATHWAYS,C2,9,37
Cohort,-0.039151364022468445,0.055929311091303946,-0.7000151308596364,0.4841130679910721,LGP Proband,Tryptophan catabolism leading to NAD+ production,CP:WIKIPATHWAYS,C2,9,45
Cohort,0.02764886054257758,0.02196513066796568,1.2587614870373227,0.20848553408856582,LonGen OPEL,Tryptophan catabolism leading to NAD+ production,CP:WIKIPATHWAYS,C2,30,42
Cohort,0.020027891126952142,0.0356076347244986,0.5624605869474573,0.5739887148574712,LGP Offspring,Tryptophan metabolism,CP:WIKIPATHWAYS,C2,36,86
Cohort,0.11690526009713402,0.09569043194589182,1.2217027107081944,0.22216527813548712,LGP Proband,Tryptophan metabolism,CP:WIKIPATHWAYS,C2,36,115
Cohort,-3.735222162040783e-4,0.03202490353315206,-0.011663492313643022,0.9906970130653272,LonGen OPEL,Tryptophan metabolism,CP:WIKIPATHWAYS,C2,70,81
Cohort,-0.03171862271512257,0.029260983595030658,-1.0839903112658622,0.27875555160275123,LGP Offspring,Tumor suppressor activity of SMARCB1,CP:WIKIPATHWAYS,C2,32,55
Cohort,0.028217842073884922,0.08264838210147553,0.3414203806099811,0.7328731356042704,LGP Proband,Tumor suppressor activity of SMARCB1,CP:WIKIPATHWAYS,C2,32,87
Cohort,0.012635120867403883,0.02816976017520987,0.448534910798535,0.6538892658274376,LonGen OPEL,Tumor suppressor activity of SMARCB1,CP:WIKIPATHWAYS,C2,55,68
Cohort,-0.00463494632941902,0.027583512566101847,-0.16803321615808406,0.8666074061606375,LGP Offspring,Type 2 papillary renal cell carcinoma,CP:WIKIPATHWAYS,C2,25,50
Cohort,-0.11157487934411815,0.07117624051144476,-1.567586016659274,0.11735709446083274,LGP Proband,Type 2 papillary renal cell carcinoma,CP:WIKIPATHWAYS,C2,25,59
Cohort,-0.01675750173353526,0.026650085462126792,-0.6287972981306132,0.5296621618663275,LonGen OPEL,Type 2 papillary renal cell carcinoma,CP:WIKIPATHWAYS,C2,50,50
Cohort,-0.025993310897016633,0.028483907059338714,-0.9125612874268414,0.3617986488749789,LGP Offspring,Type I collagen synthesis in the context of Osteogenesis imperfecta,CP:WIKIPATHWAYS,C2,31,51
Cohort,-0.002416309556592077,0.08226300344857285,-0.02937298001892972,0.9765741495518744,LGP Proband,Type I collagen synthesis in the context of Osteogenesis imperfecta,CP:WIKIPATHWAYS,C2,31,81
Cohort,-0.032347230555882955,0.027749836127658266,-1.1656728496368476,0.24409590495010663,LonGen OPEL,Type I collagen synthesis in the context of Osteogenesis imperfecta,CP:WIKIPATHWAYS,C2,60,60
Cohort,-0.053919239234482635,0.02314669496750114,-2.3294573722160914,0.020128505513560917,LGP Offspring,Type I Interferon Induction and Signaling During SARS-CoV-2 Infection,CP:WIKIPATHWAYS,C2,22,25
Cohort,-0.07968734093887155,0.06748779589511662,-1.1807666835454864,0.23803205162208368,LGP Proband,Type I Interferon Induction and Signaling During SARS-CoV-2 Infection,CP:WIKIPATHWAYS,C2,22,50
Cohort,-0.021107979190699618,0.020039766961206813,-1.0533046233302343,0.2925210216854297,LonGen OPEL,Type I Interferon Induction and Signaling During SARS-CoV-2 Infection,CP:WIKIPATHWAYS,C2,31,25
Cohort,-0.014385707725576612,0.021985179595712608,-0.6543366026621865,0.5131175158397877,LGP Offspring,Type II diabetes mellitus,CP:WIKIPATHWAYS,C2,18,33
Cohort,0.044549788667854376,0.06039540235089691,0.7376354314028803,0.4609434998555546,LGP Proband,Type II diabetes mellitus,CP:WIKIPATHWAYS,C2,18,43
Cohort,-0.01122347527879386,0.017652340229399082,-0.6358066484636257,0.5250852038382425,LonGen OPEL,Type II diabetes mellitus,CP:WIKIPATHWAYS,C2,24,25
Cohort,-3.6343240940937274e-4,0.027835741125896846,-0.013056322365035044,0.9895867101463409,LGP Offspring,Type II interferon signaling (IFNG),CP:WIKIPATHWAYS,C2,27,52
Cohort,-0.049837239373473716,0.07282537479960088,-0.6843389342054831,0.4939512810734984,LGP Proband,Type II interferon signaling (IFNG),CP:WIKIPATHWAYS,C2,27,64
Cohort,-0.007142880849940375,0.023173459226341127,-0.30823541622224043,0.7579838475388269,LonGen OPEL,Type II interferon signaling (IFNG),CP:WIKIPATHWAYS,C2,40,44
Cohort,-0.022825633724560822,0.011446832448084766,-1.9940567688120487,0.04654711863325815,LGP Offspring,Type III interferon signaling,CP:WIKIPATHWAYS,C2,8,5
Cohort,-0.03305706515568186,0.03652415986823567,-0.9050739366747468,0.36568759706612197,LGP Proband,Type III interferon signaling,CP:WIKIPATHWAYS,C2,8,14
Cohort,-0.008061299599403774,0.010603221219455209,-0.7602689251274494,0.44731897596741244,LonGen OPEL,Type III interferon signaling,CP:WIKIPATHWAYS,C2,10,7
Cohort,-0.025553867759037036,0.04265706567047849,-0.5990535766439744,0.5493378538573948,LGP Offspring,TYROBP Causal Network,CP:WIKIPATHWAYS,C2,62,122
Cohort,0.050361580569693,0.11635561785522139,0.43282465855973323,0.6652540614190019,LGP Proband,TYROBP Causal Network,CP:WIKIPATHWAYS,C2,62,157
Cohort,-0.01850301645759336,0.03640169301783838,-0.5083009861251808,0.6113831123687493,LonGen OPEL,TYROBP Causal Network,CP:WIKIPATHWAYS,C2,100,113
Cohort,-0.0087942256897391,0.010504307803382665,-0.8372018275118639,0.40277500234456354,LGP Offspring,Ultraconserved region 339 modulation of tumor suppressor microRNAs in cancer,CP:WIKIPATHWAYS,C2,5,6
Cohort,0.04346767162961135,0.03637753580135167,1.194904236146645,0.23246413327053556,LGP Proband,Ultraconserved region 339 modulation of tumor suppressor microRNAs in cancer,CP:WIKIPATHWAYS,C2,5,15
Cohort,0.0019036347306616327,0.008935190967747272,0.2130491376774205,0.8313431864839433,LonGen OPEL,Ultraconserved region 339 modulation of tumor suppressor microRNAs in cancer,CP:WIKIPATHWAYS,C2,5,7
Cohort,-0.0014030859819485098,0.021887972539447534,-0.06410305839975823,0.9489071170805898,LGP Offspring,Unfolded protein response,CP:WIKIPATHWAYS,C2,14,33
Cohort,0.017989893494464122,0.06583013681079204,0.27327747390485296,0.7847075865759641,LGP Proband,Unfolded protein response,CP:WIKIPATHWAYS,C2,14,56
Cohort,0.010455575348592995,0.017989939377811976,0.581190137943903,0.5612768382110512,LonGen OPEL,Unfolded protein response,CP:WIKIPATHWAYS,C2,22,29
Cohort,-0.008104918265998783,0.02838669170570674,-0.28551824037914936,0.7753345929419052,LGP Offspring,Urea cycle and associated pathways,CP:WIKIPATHWAYS,C2,27,51
Cohort,0.06339834666081984,0.08174167297061588,0.7755939456195127,0.4382086416668486,LGP Proband,Urea cycle and associated pathways,CP:WIKIPATHWAYS,C2,27,81
Cohort,0.01853982000731956,0.027515573682430575,0.6737936930298396,0.5006380868758633,LonGen OPEL,Urea cycle and associated pathways,CP:WIKIPATHWAYS,C2,43,62
Cohort,-0.00868892263869958,0.02374647421356801,-0.36590369418863006,0.714551413701052,LGP Offspring,Urea cycle and metabolism of amino groups,CP:WIKIPATHWAYS,C2,19,41
Cohort,0.18563684014100298,0.06750609385898058,2.7499271477445593,0.006089880513257814,LGP Proband,Urea cycle and metabolism of amino groups,CP:WIKIPATHWAYS,C2,19,56
Cohort,0.011796702001827194,0.020290606532409407,0.5813873519741647,0.5611440096200571,LonGen OPEL,Urea cycle and metabolism of amino groups,CP:WIKIPATHWAYS,C2,27,37
Cohort,-0.018040425870293822,0.01775088454990457,-1.016311374206465,0.30984473271005003,LGP Offspring,Urea cycle and related diseases,CP:WIKIPATHWAYS,C2,13,19
Cohort,-0.009963705908337376,0.05175719240437974,-0.1925086243181583,0.8473906785638503,LGP Proband,Urea cycle and related diseases,CP:WIKIPATHWAYS,C2,13,32
Cohort,-0.0035258345647410784,0.01683951964360296,-0.20937857132287507,0.8342062922501716,LonGen OPEL,Urea cycle and related diseases,CP:WIKIPATHWAYS,C2,18,24
Cohort,-0.015998652421595688,0.02114213523344117,-0.7567188576246606,0.4494819597042461,LGP Offspring,Valproic acid pathway,CP:WIKIPATHWAYS,C2,16,28
Cohort,0.062210054821278685,0.05487180804477952,1.133734371765381,0.2572317705475081,LGP Proband,Valproic acid pathway,CP:WIKIPATHWAYS,C2,16,34
Cohort,0.0019395601136250188,0.01652582165279068,0.11736542692855999,0.9066000866002044,LonGen OPEL,Valproic acid pathway,CP:WIKIPATHWAYS,C2,17,26
Cohort,-0.12663004879512524,0.1154881387022038,-1.0964766617431754,0.2732606805431426,LGP Offspring,VEGFA-VEGFR2 Signaling Pathway,CP:WIKIPATHWAYS,C2,444,885
Cohort,-0.11820511182928195,0.3158687646189782,-0.3742222247643535,0.7083341125045273,LGP Proband,VEGFA-VEGFR2 Signaling Pathway,CP:WIKIPATHWAYS,C2,444,1229
Cohort,-0.013020835459086038,0.10103717005369633,-0.12887173554213857,0.8974916957861823,LonGen OPEL,VEGFA-VEGFR2 Signaling Pathway,CP:WIKIPATHWAYS,C2,684,825
Cohort,0.07627842984583719,0.05049076077464541,1.510740354780738,0.13132189840926622,LGP Offspring,Viral Acute Myocarditis,CP:WIKIPATHWAYS,C2,70,178
Cohort,-0.013663739853429484,0.13892854663652676,-0.0983508442593687,0.9216773383038166,LGP Proband,Viral Acute Myocarditis,CP:WIKIPATHWAYS,C2,70,229
Cohort,-0.09756955613807233,0.04452082348682336,-2.1915487741809083,0.028701165609752145,LonGen OPEL,Viral Acute Myocarditis,CP:WIKIPATHWAYS,C2,147,136
Cohort,-0.022435047817961646,0.03623795284090915,-0.6191036209041765,0.5360566757027873,LGP Offspring,Vitamin A and Carotenoid Metabolism,CP:WIKIPATHWAYS,C2,49,89
Cohort,-0.20385484225403663,0.10266156553711585,-1.98569777489255,0.04739395833407708,LGP Proband,Vitamin A and Carotenoid Metabolism,CP:WIKIPATHWAYS,C2,49,130
Cohort,0.10112900934679177,0.02959971448274408,3.4165535416143133,6.66358915001041e-4,LonGen OPEL,Vitamin A and Carotenoid Metabolism,CP:WIKIPATHWAYS,C2,45,95
Cohort,-0.014657319585122333,0.020323871736570957,-0.7211873689769366,0.47104358179807426,LGP Offspring,Vitamin B12 Disorders,CP:WIKIPATHWAYS,C2,16,28
Cohort,0.05214833120558711,0.057532131187618796,0.9064209882217903,0.3649748667536816,LGP Proband,Vitamin B12 Disorders,CP:WIKIPATHWAYS,C2,16,42
Cohort,-0.0037161979146649125,0.016460119611112326,-0.22576980012685235,0.8214384208247576,LonGen OPEL,Vitamin B12 Disorders,CP:WIKIPATHWAYS,C2,20,23
Cohort,0.03464047575127406,0.04569616916450098,0.7580608262056348,0.4486787550623197,LGP Offspring,Vitamin B12 Metabolism,CP:WIKIPATHWAYS,C2,58,138
Cohort,0.03472783655431071,0.1296975194521832,0.26776022163719293,0.7889500970204173,LGP Proband,Vitamin B12 Metabolism,CP:WIKIPATHWAYS,C2,58,192
Cohort,0.03202002473456679,0.03974898333043616,0.8055558168213265,0.42073957695261566,LonGen OPEL,Vitamin B12 Metabolism,CP:WIKIPATHWAYS,C2,93,121
Cohort,0.005750234089218511,0.022734349239451456,0.2529315455064794,0.800398005865099,LGP Offspring,Vitamin B6-dependent and responsive disorders,CP:WIKIPATHWAYS,C2,17,37
Cohort,0.043428652920502915,0.06670541996594363,0.6510513379973525,0.5151926818268913,LGP Proband,Vitamin B6-dependent and responsive disorders,CP:WIKIPATHWAYS,C2,17,48
Cohort,-0.0029359688552736646,0.021302855350699042,-0.13782043800890392,0.8904171857883785,LonGen OPEL,Vitamin B6-dependent and responsive disorders,CP:WIKIPATHWAYS,C2,30,35
Cohort,-0.0038762466639100748,0.029796108569737623,-0.13009237950780522,0.8965320397241907,LGP Offspring,Vitamin D in inflammatory diseases,CP:WIKIPATHWAYS,C2,26,58
Cohort,0.06596981830334385,0.08511842974882478,0.7750356591165227,0.43853827227234576,LGP Proband,Vitamin D in inflammatory diseases,CP:WIKIPATHWAYS,C2,26,80
Cohort,0.01209968997676778,0.02772953050621907,0.4363467305749771,0.662703504048376,LonGen OPEL,Vitamin D in inflammatory diseases,CP:WIKIPATHWAYS,C2,46,61
Cohort,0.02058998456359516,0.014820852547494998,1.3892577702674231,0.1652118162025841,LGP Offspring,Vitamin D Metabolism,CP:WIKIPATHWAYS,C2,4,16
Cohort,0.0013588012435716162,0.0454137227199562,0.029920498963510796,0.9761376156907138,LGP Proband,Vitamin D Metabolism,CP:WIKIPATHWAYS,C2,4,27
Cohort,-0.01050340787603921,0.014623934840448015,-0.7182340451208842,0.47282374009399764,LonGen OPEL,Vitamin D Metabolism,CP:WIKIPATHWAYS,C2,16,17
Cohort,-0.056870797251014335,0.07114609097905022,-0.799352381394511,0.42436688747023443,LGP Offspring,Vitamin D Receptor Pathway,CP:WIKIPATHWAYS,C2,180,358
Cohort,0.21575516899664862,0.19766333008818793,1.0915285546408076,0.27535560172715756,LGP Proband,Vitamin D Receptor Pathway,CP:WIKIPATHWAYS,C2,180,465
Cohort,0.054331735147630886,0.06399785765636273,0.8489617799296625,0.3961577965435069,LonGen OPEL,Vitamin D Receptor Pathway,CP:WIKIPATHWAYS,C2,275,332
Cohort,-0.037184085408866294,0.03575524666803333,-1.0399616524561808,0.29872952402324704,LGP Offspring,Vitamin D-sensitive calcium signaling in depression,CP:WIKIPATHWAYS,C2,47,78
Cohort,-0.1030185503518667,0.0915398304559026,-1.1253959051354563,0.26074506252460194,LGP Proband,Vitamin D-sensitive calcium signaling in depression,CP:WIKIPATHWAYS,C2,47,99
Cohort,-0.02776453801879668,0.03168257619335008,-0.8763346089458544,0.38111253377581467,LonGen OPEL,Vitamin D-sensitive calcium signaling in depression,CP:WIKIPATHWAYS,C2,71,75
Cohort,0.002376036350318828,0.0223802046773239,0.1061668731173973,0.9154814502306166,LGP Offspring,White fat cell differentiation,CP:WIKIPATHWAYS,C2,18,35
Cohort,-0.03953651957655764,0.06434554898659474,-0.6144406287495406,0.5390917762690433,LGP Proband,White fat cell differentiation,CP:WIKIPATHWAYS,C2,18,53
Cohort,-0.012972037688078798,0.020126173234040867,-0.6445357265502536,0.5194137909937813,LonGen OPEL,White fat cell differentiation,CP:WIKIPATHWAYS,C2,31,32
Cohort,0.016639915327832964,0.04914927627284512,0.3385587050246452,0.7350473234552868,LGP Offspring,Wnt Signaling,CP:WIKIPATHWAYS,C2,78,171
Cohort,-0.0554634818089308,0.13640366021045164,-0.4066128557207223,0.6843966740428968,LGP Proband,Wnt Signaling,CP:WIKIPATHWAYS,C2,78,236
Cohort,-0.06986557480519816,0.04002361993363355,-1.7456085911531243,0.08126481468859025,LonGen OPEL,Wnt Signaling,CP:WIKIPATHWAYS,C2,126,127
Cohort,0.014952414232127122,0.02647184146003746,0.5648422401856574,0.572368458350186,LGP Offspring,Wnt Signaling in Kidney Disease,CP:WIKIPATHWAYS,C2,21,50
Cohort,-0.10579089614593117,0.06866960294524363,-1.5405782414423983,0.12379878063431482,LGP Proband,Wnt Signaling in Kidney Disease,CP:WIKIPATHWAYS,C2,21,63
Cohort,-0.0231333348310169,0.021188497110738298,-1.091787431176181,0.2752568860011997,LonGen OPEL,Wnt Signaling in Kidney Disease,CP:WIKIPATHWAYS,C2,36,35
Cohort,0.03248116491350399,0.048839275507930796,0.6650623821852049,0.5062374186326141,LGP Offspring,Wnt Signaling Pathway and Pluripotency,CP:WIKIPATHWAYS,C2,64,152
Cohort,-0.06413034881859166,0.1301886755926511,-0.49259544677487827,0.6224281188624414,LGP Proband,Wnt Signaling Pathway and Pluripotency,CP:WIKIPATHWAYS,C2,64,210
Cohort,-0.03808093700992709,0.041445097845375194,-0.9188284981736746,0.3584636178949614,LonGen OPEL,Wnt Signaling Pathway and Pluripotency,CP:WIKIPATHWAYS,C2,123,140
Cohort,-0.07544945365866951,0.044183209068738453,-1.7076499251398487,0.08816046097505177,LGP Offspring,Wnt Signaling Pathway (Netpath),CP:WIKIPATHWAYS,C2,74,111
Cohort,-0.08857170917013847,0.11839739289557161,-0.7480883404946267,0.45461776760925876,LGP Proband,Wnt Signaling Pathway (Netpath),CP:WIKIPATHWAYS,C2,74,151
Cohort,-0.021060001729822492,0.03440795633515555,-0.6120677881791228,0.540667694942595,LonGen OPEL,Wnt Signaling Pathway (Netpath),CP:WIKIPATHWAYS,C2,88,98
Cohort,-0.026000957418749374,0.029542196241407366,-0.8801294665528465,0.37910195348355047,LGP Offspring,Wnt/beta-catenin Signaling Pathway in Leukemia,CP:WIKIPATHWAYS,C2,36,56
Cohort,-0.10307118894611758,0.0823185693751044,-1.252101314788998,0.21088397036261694,LGP Proband,Wnt/beta-catenin Signaling Pathway in Leukemia,CP:WIKIPATHWAYS,C2,36,78
Cohort,0.03190553495371114,0.024273749686305617,1.3144048762977523,0.18908859639568265,LonGen OPEL,Wnt/beta-catenin Signaling Pathway in Leukemia,CP:WIKIPATHWAYS,C2,35,54
Cohort,-0.03979548333241221,0.02462623184894929,-1.615979398574132,0.10656533045881175,LGP Offspring,Zinc homeostasis,CP:WIKIPATHWAYS,C2,25,35
Cohort,-0.12496454474585182,0.07067935231168233,-1.768048809994498,0.07741830470444805,LGP Proband,Zinc homeostasis,CP:WIKIPATHWAYS,C2,25,57
Cohort,0.004835343050867356,0.020266022249628163,0.2385935923343849,0.8114821440727762,LonGen OPEL,Zinc homeostasis,CP:WIKIPATHWAYS,C2,26,38
Cohort,-0.05599387237225789,0.054968679713466695,-1.018650487225365,0.30873334687534704,LGP Offspring,,,C8,109,194
Cohort,-0.17907750140835968,0.14897857478488347,-1.2020352702859276,0.2296910534599721,LGP Proband,,,C8,109,262
Cohort,0.10029797513918841,0.04871066628336749,2.0590557015935476,0.03981372106689828,LonGen OPEL,,,C8,129,201
Cohort,0.022430642533530346,0.08980527518046341,0.24976976562296638,0.8028412817903744,LGP Offspring,,,C8,256,557
Cohort,-0.229043681488738,0.2448307990927913,-0.935518253166874,0.34979207707043214,LGP Proband,,,C8,256,746
Cohort,-0.043397169737158105,0.0813771743248187,-0.5332843035804782,0.5939856526567839,LonGen OPEL,,,C8,453,539
Cohort,0.08381596041390449,0.09369422253051886,0.8945691436481397,0.371335843198235,LGP Offspring,,,C8,284,641
Cohort,0.23416785278669966,0.26401257517993687,0.8869571937136076,0.3753576405679183,LGP Proband,,,C8,284,928
Cohort,-0.12638832555675028,0.08881184363020604,-1.4231021493372535,0.15509834311498202,LonGen OPEL,,,C8,544,603
Cohort,-0.02933844742983065,0.02535330033166967,-1.157184549783564,0.24760569392304313,LGP Offspring,,,C8,25,38
Cohort,-0.06912399486971063,0.07197330632686855,-0.9604115525245194,0.3371264765202564,LGP Proband,,,C8,25,61
Cohort,0.04861518205600828,0.020862159500846876,2.3303043989302643,0.020039121487783744,LonGen OPEL,,,C8,24,47
Cohort,-0.027970872805701086,0.0873250797294245,-0.32030744079900564,0.7488342640220937,LGP Offspring,,,C8,237,486
Cohort,-0.2873835189695069,0.22975597614926085,-1.2508206480026807,0.21135070649163354,LGP Proband,,,C8,237,700
Cohort,-0.031736785439498184,0.0769960310597183,-0.4121872907303892,0.6803131301449856,LonGen OPEL,,,C8,415,478
Cohort,-0.013828214742085634,0.08558133594908368,-0.16157979527583774,0.8716850486938927,LGP Offspring,,,C8,216,450
Cohort,0.0843833873911126,0.2387650345293339,0.3534160165346385,0.7238658944130352,LGP Proband,,,C8,216,646
Cohort,-0.08506562167629422,0.07653356619755125,-1.1114812219349575,0.2666968641501207,LonGen OPEL,,,C8,389,429
Cohort,0.0030932596439605265,0.05406356519749417,0.05721523604040635,0.9543906486862213,LGP Offspring,,,C8,103,213
Cohort,0.03463340523665638,0.15675814204699146,0.22093528785429412,0.8251968971966525,LGP Proband,,,C8,103,301
Cohort,-0.047146339744257276,0.051705418547378805,-0.9118258988863238,0.3621364315405394,LonGen OPEL,,,C8,188,199
Cohort,-0.053025008287413765,0.05475791616043893,-0.9683532903635741,0.3332142788957344,LGP Offspring,,,C8,104,198
Cohort,-0.15581428091724722,0.15667461085716594,-0.9945088107434137,0.3202636671511233,LGP Proband,,,C8,104,294
Cohort,0.051000104208500686,0.04652213447764994,1.0962546061381178,0.2732989160925126,LonGen OPEL,,,C8,142,184
Cohort,-0.027456567787250263,0.06661823911802167,-0.41214790650061883,0.6803616773450287,LGP Offspring,,,C8,141,290
Cohort,-0.09044898539588735,0.17661169665403867,-0.5121347402775149,0.6086922997808022,LGP Proband,,,C8,141,369
Cohort,0.058817480582487446,0.0556840436076601,1.05627172115777,0.2911645595707289,LonGen OPEL,,,C8,198,262
Cohort,-0.10127639151193416,0.10131441068683802,-0.9996247406993128,0.3178498236523764,LGP Offspring,,,C8,332,647
Cohort,-0.05334515231508441,0.283065880444801,-0.1884549004325759,0.8505659120065457,LGP Proband,,,C8,332,939
Cohort,-0.07978362894148136,0.0863674966236355,-0.9237691499749642,0.3558864549402474,LonGen OPEL,,,C8,568,625
Cohort,0.013536655268825979,0.08068004741571871,0.16778194488503315,0.8668050081614622,LGP Offspring,,,C8,191,414
Cohort,-0.03734659829135454,0.20824310140974336,-0.17934134690911374,0.8577132433772282,LGP Proband,,,C8,191,521
Cohort,-0.03825158001499356,0.06625332230352997,-0.577353386744132,0.5638640140501696,LonGen OPEL,,,C8,310,355
Cohort,0.022408620437214304,0.03389004608183753,0.6612154018056532,0.5086994745499117,LGP Offspring,,,C8,30,78
Cohort,-0.05512833812690636,0.09428060235114812,-0.5847261976708725,0.5588899814114202,LGP Proband,,,C8,30,114
Cohort,0.05528333933407231,0.029508659792609755,1.8734615439199869,0.06137089108919645,LonGen OPEL,,,C8,51,81
Cohort,-0.024599202616650943,0.0680271271810292,-0.36160872340219813,0.7177574399336185,LGP Offspring,,,C8,166,336
Cohort,0.11442818900965185,0.19965128707518998,0.5731402521164687,0.5667042304981014,LGP Proband,,,C8,166,503
Cohort,0.08442950689642709,0.06310156179960302,1.337993933724763,0.1812805149690582,LonGen OPEL,,,C8,254,333
Cohort,-0.03850128125201821,0.07793673212847789,-0.4940068719913641,0.6214618020416302,LGP Offspring,,,C8,196,396
Cohort,-0.22405472276544275,0.2103376071764027,-1.0652147553315845,0.2870870454886957,LGP Proband,,,C8,196,539
Cohort,0.18652426842568648,0.07154236300680243,2.607186296152271,0.009299866088336422,LonGen OPEL,,,C8,285,418
Cohort,-0.012406192014635838,0.07006204231734527,-0.1770743701481342,0.8595030137937227,LGP Offspring,,,C8,147,303
Cohort,-0.22128489931485107,0.19159787737817494,-1.1549444197551315,0.2484439874251563,LGP Proband,,,C8,147,416
Cohort,0.054363162332384314,0.05646931068861436,0.9627027790751004,0.335989056922425,LonGen OPEL,,,C8,209,264
Cohort,-0.05683717126725646,0.040893138570187317,-1.3898950595270023,0.16501826322301258,LGP Offspring,,,C8,66,101
Cohort,-0.19823624953287958,0.11386169201875805,-1.741026731802135,0.08204765419153438,LGP Proband,,,C8,66,165
Cohort,0.09023086356101388,0.03457647440128237,2.6096027753965396,0.009235001456491572,LonGen OPEL,,,C8,65,116
Cohort,0.05406250234822853,0.09232638049727449,0.5855585592876619,0.5583676273226512,LGP Offspring,,,C8,276,608
Cohort,-0.3381639290057923,0.258771210735101,-1.3068066113118126,0.19163861665945378,LGP Proband,,,C8,276,793
Cohort,-0.05553507186961922,0.08540429584318175,-0.6502608717902434,0.5157113535300306,LonGen OPEL,,,C8,489,564
Cohort,-0.04133938346958195,0.04684162217841953,-0.8825352655832547,0.37780113163379747,LGP Offspring,,,C8,73,137
Cohort,-0.06680468521246972,0.13752621008702223,-0.4857596611598461,0.6272651696344771,LGP Proband,,,C8,73,239
Cohort,0.05067441184581922,0.0384232245669254,1.3188484937685216,0.1875990587246577,LonGen OPEL,,,C8,85,128
Cohort,-0.10517558992595344,0.12205044529008531,-0.8617386825257024,0.38913690291812053,LGP Offspring,,,C8,481,978
Cohort,-0.14167592697473275,0.35546404571912954,-0.39856612414375714,0.690314944090516,LGP Proband,,,C8,481,1431
Cohort,-0.14395222988919604,0.10748286099114596,-1.3393040393766062,0.18085399899427032,LonGen OPEL,,,C8,831,936
Cohort,-0.0360025008142048,0.06280097293444621,-0.5732793479455396,0.5666462168322477,LGP Offspring,,,C8,118,239
Cohort,0.03716955169803698,0.17014898087566813,0.21845297871750197,0.8271296337076601,LGP Proband,,,C8,118,364
Cohort,-0.03624321248727529,0.05245317859456256,-0.6909631305171725,0.4897901549018926,LonGen OPEL,,,C8,204,223
Cohort,0.026175668286507803,0.055498078599452966,0.47164999126232476,0.6373288267816247,LGP Offspring,,,C8,95,212
Cohort,0.025219324636427627,0.15503171651832232,0.1626720338444237,0.8708160729511614,LGP Proband,,,C8,95,299
Cohort,-0.013787864779363303,0.0496409044104445,-0.2777520865728289,0.7812747968906658,LonGen OPEL,,,C8,162,191
Cohort,-6.13454011784108e-4,0.06951715321063048,-0.00882449846479472,0.9929617638122624,LGP Offspring,,,C8,157,319
Cohort,-0.33746003314097966,0.18361144919530537,-1.8379029990772926,0.06643223341323694,LGP Proband,,,C8,157,432
Cohort,-0.06628455773672395,0.0603674035010334,-1.0980190283583964,0.2725282018724683,LonGen OPEL,,,C8,242,258
Cohort,-0.005295558835648493,0.054362129428707794,-0.09741264537095176,0.9224275770618973,LGP Offspring,,,C8,89,190
Cohort,-0.1698616838861356,0.1419587781222644,-1.1965563956871996,0.23181954123946796,LGP Proband,,,C8,89,249
Cohort,0.005387706845206214,0.049152287391444616,0.1096125354716247,0.9127442958593712,LonGen OPEL,,,C8,161,188
Cohort,0.02824547594135039,0.025387740266090843,1.112563609258146,0.2662913768541661,LGP Offspring,,,C8,15,47
Cohort,-0.04979619793050949,0.06955241885336115,-0.7159520653838923,0.47422135392106535,LGP Proband,,,C8,15,62
Cohort,0.018606393893242323,0.022461042481473882,0.8283851432358531,0.4077007221637753,LonGen OPEL,,,C8,34,45
Cohort,-0.046939057855568615,0.08389890652150653,-0.5594716284357809,0.576025201312363,LGP Offspring,,,C8,226,458
Cohort,-0.0972088486147323,0.22278375361259223,-0.4363372420045168,0.6627049943491998,LGP Proband,,,C8,226,597
Cohort,0.16432650284032982,0.07233887168365954,2.271621038809334,0.023375536370569047,LonGen OPEL,,,C8,302,423
Cohort,-0.11665481332873177,0.08056922735447945,-1.4478829841012004,0.14811339202822768,LGP Offspring,,,C8,240,452
Cohort,-0.36728344816418595,0.21865649731890302,-1.6797280330916287,0.09338476386040165,LGP Proband,,,C8,240,624
Cohort,0.09497682044776522,0.0771758367030297,1.2306548850676302,0.21881549665548156,LonGen OPEL,,,C8,354,463
Cohort,-0.05753476197889106,0.047077412322520475,-1.2221309358451737,0.22208408095382856,LGP Offspring,,,C8,78,136
Cohort,-0.14308426988995618,0.1318914548836847,-1.0848638375863124,0.27829546115302145,LGP Proband,,,C8,78,201
Cohort,0.06369814288919166,0.038283261649880725,1.6638640529572046,0.09653319132112782,LonGen OPEL,,,C8,87,136
Cohort,-0.15122979776659107,0.07706179855795649,-1.9624483284393428,0.0501200912987727,LGP Offspring,,,C8,212,383
Cohort,-0.19921154591158172,0.22085695314875575,-0.9019935441081857,0.3673207128392687,LGP Proband,,,C8,212,540
Cohort,0.023294071629358724,0.06397890936165002,0.36408985182422576,0.71588760337453,LonGen OPEL,,,C8,281,343
Cohort,-0.10531509927129354,0.09369969041798246,-1.1239642180405955,0.26142717135331917,LGP Offspring,,,C8,290,563
Cohort,-0.31227579175025466,0.24057048016515786,-1.2980636341411018,0.19462433005092536,LGP Proband,,,C8,290,773
Cohort,0.17444150072658446,0.0850974394544725,2.049903050489685,0.04070103006390999,LonGen OPEL,,,C8,423,573
Cohort,0.017914028748134317,0.02793903464421608,0.6411828102243635,0.5216212321025575,LGP Offspring,,,C8,20,53
Cohort,-0.07703144807408228,0.08133771310812493,-0.9470569693996905,0.34388406538246796,LGP Proband,,,C8,20,78
Cohort,0.03742466541994415,0.02529969084011445,1.47925386347428,0.13946810008423247,LonGen OPEL,,,C8,40,57
Cohort,-0.10099800133307563,0.09787860278304192,-1.0318700764144353,0.30250200946796063,LGP Offspring,,,C8,319,616
Cohort,-0.2078382108254003,0.27757875682584204,-0.7487540228296424,0.45421658663316133,LGP Proband,,,C8,319,894
Cohort,-0.009629047481317226,0.08494966751274333,-0.11335003141563525,0.9097816342436297,LonGen OPEL,,,C8,532,620
Cohort,0.001777975951324544,0.03566938725186207,0.04984599087083357,0.9602598406396183,LGP Offspring,,,C8,47,92
Cohort,-0.024177714382366274,0.10769500690301848,-0.22450172090279721,0.8224219171208145,LGP Proband,,,C8,47,164
Cohort,0.023879011751987568,0.03439181243286385,0.6943225745546767,0.48768252559621983,LonGen OPEL,,,C8,75,99
Cohort,-0.12389784695588986,0.06529574849628507,-1.8974871995370248,0.05818950732063334,LGP Offspring,,,C8,163,288
Cohort,0.2610706763089428,0.20968723745069945,1.245048003316484,0.21346382172157383,LGP Proband,,,C8,163,477
Cohort,-0.03817394774654539,0.0632620532992021,-0.6034256834187653,0.5463974432750828,LonGen OPEL,,,C8,263,313
Cohort,-0.0043171441491956074,0.058081106046763975,-0.07432957880863461,0.9407701307345708,LGP Offspring,,,C8,95,206
Cohort,0.10046227895820434,0.15812201048918892,0.63534658234739,0.5253766762993473,LGP Proband,,,C8,95,292
Cohort,-0.06257023533384601,0.04628221897094312,-1.3519281643157348,0.17678229998895117,LonGen OPEL,,,C8,154,177
Cohort,-0.006714186454687027,0.023311749604551818,-0.2880172689130131,0.7734217999706857,LGP Offspring,,,C8,19,34
Cohort,-0.03740956975576592,0.07805987878329528,-0.479241965768611,0.6318921364982022,LGP Proband,,,C8,19,75
Cohort,0.030876955977549966,0.027649789253747482,1.1167157801524688,0.2644528329760858,LonGen OPEL,,,C8,40,65
Cohort,0.020974723452655452,0.014806691945527662,1.4165705297185462,0.1570691713029751,LGP Offspring,,,C8,4,18
Cohort,0.003261666164367892,0.05060677951528658,0.06445117028999353,0.9486264313257629,LGP Proband,,,C8,4,37
Cohort,0.024269490282504975,0.013246699809680532,1.832115970860087,0.06730761988170716,LonGen OPEL,,,C8,7,20
Cohort,-0.002803929666914976,0.010551424310970269,-0.2657394475170279,0.7905209028825997,LGP Offspring,,,C8,4,7
Cohort,0.004667553807386907,0.03584153136920096,0.13022752179048325,0.896417823790317,LGP Proband,,,C8,4,17
Cohort,0.003400840376924116,0.00960218902134984,0.35417344621758323,0.7233026997202223,LonGen OPEL,,,C8,5,9
Cohort,-0.08525089683113309,0.15386153313154144,-0.5540754410541926,0.5797104520315054,LGP Offspring,,,C8,713,1439
Cohort,-0.2747004677481545,0.40700776146416584,-0.6749268533846864,0.49990929752915814,LGP Proband,,,C8,713,1919
Cohort,-0.05622426376271692,0.1332227925666658,-0.42203186616570754,0.6731157156788041,LonGen OPEL,,,C8,1084,1292
Cohort,-0.008287904339458163,0.02405743146772338,-0.34450495476117715,0.730573716469648,LGP Offspring,,,C8,21,36
Cohort,-0.11272299572078087,0.0696527632455247,-1.6183564078202382,0.10596390422481232,LGP Proband,,,C8,21,59
Cohort,-0.015741052560802913,0.021092222488889673,-0.746296535089866,0.4557086498685752,LonGen OPEL,,,C8,36,34
Cohort,-0.024909358629264376,0.08174015977973112,-0.30473831585830935,0.760659258919405,LGP Offspring,,,C8,194,411
Cohort,0.17931415655781094,0.21966528244342567,0.8163063118724413,0.4145580566345849,LGP Proband,,,C8,194,596
Cohort,-0.015557525674703072,0.06826018487735509,-0.2279150826013099,0.8197707875976601,LonGen OPEL,,,C8,310,388
Cohort,0.009470752299712223,0.09610897591648507,0.09854180849811504,0.9215312870992967,LGP Offspring,,,C8,344,725
Cohort,-0.2853387713180104,0.2744036671806624,-1.0398504300241314,0.29871075489056853,LGP Proband,,,C8,344,970
Cohort,0.03439178367416172,0.08776047877639992,0.39188236155578243,0.6952500281616989,LonGen OPEL,,,C8,546,690
Cohort,-0.012369235646423699,0.015187194055676203,-0.8144516756076285,0.4156730588466241,LGP Offspring,,,C8,8,13
Cohort,0.027861979438933853,0.04624030389640449,0.6025474984194539,0.5469735484062326,LGP Proband,,,C8,8,23
Cohort,-0.005388302881572938,0.01147212511646611,-0.46968655125971626,0.6387076142424207,LonGen OPEL,,,C8,11,9
Cohort,-0.003305313824015281,0.014155712820479048,-0.2334968126248993,0.8154463324816739,LGP Offspring,,,C8,7,13
Cohort,0.08392740888919997,0.057253439458826924,1.4658928735548769,0.14305438541285495,LGP Proband,,,C8,7,48
Cohort,0.007235191369966889,0.017187424369224734,0.4209584411566632,0.673899060938239,LonGen OPEL,,,C8,18,29
Cohort,-0.03853421766571576,0.08350000475829283,-0.4614876104170368,0.6445972655740562,LGP Offspring,,,C8,217,440
Cohort,0.4142925399440176,0.2216350459631302,1.8692555509156106,0.06193753258514945,LGP Proband,,,C8,217,618
Cohort,0.0709591483001425,0.07281353662833384,0.9745323683746223,0.3300883306060449,LonGen OPEL,,,C8,340,416
Cohort,-0.07809116037733022,0.04582449813322478,-1.704135638328152,0.08881528837258008,LGP Offspring,,,C8,77,130
Cohort,0.010075624015383323,0.14161067673277497,0.07115017206221272,0.9432952954000569,LGP Proband,,,C8,77,230
Cohort,-0.04828296331178436,0.04339467855497535,-1.112647101432407,0.2661959243745864,LonGen OPEL,,,C8,131,144
Cohort,-0.06709057117118532,0.050076067196400204,-1.339773167650199,0.1807692990851767,LGP Offspring,,,C8,96,176
Cohort,-0.18783984195026446,0.14620126938446368,-1.2848030850970544,0.19921782395083812,LGP Proband,,,C8,96,268
Cohort,6.343488905809958e-4,0.04506723177641865,0.014075612492199217,0.9887731839698748,LonGen OPEL,,,C8,143,166
Cohort,-0.08131674056753041,0.06507377288581795,-1.249608512944428,0.21187505912243396,LGP Offspring,,,C8,152,279
Cohort,-0.536092744220433,0.18061067303681844,-2.968222947218339,0.0030809677451133074,LGP Proband,,,C8,152,374
Cohort,0.08148158724922241,0.05572402588013996,1.4622343946305296,0.14407167138276006,LonGen OPEL,,,C8,194,262
Cohort,-0.008833477305316598,0.03267018494853452,-0.27038344959577093,0.7869477984922243,LGP Offspring,,,C8,38,73
Cohort,-0.11869390473809124,0.09999279055006866,-1.187024625326948,0.23555590130440673,LGP Proband,,,C8,38,113
Cohort,-0.028956769047899806,0.02922685631018945,-0.990758935568603,0.32210437267706515,LonGen OPEL,,,C8,68,75
Cohort,0.0238808749582301,0.06031590150227694,0.3959300012672212,0.6922815970999626,LGP Offspring,,,C8,110,241
Cohort,-0.19206755757930735,0.16376447789237306,-1.172827954213216,0.24119967587160185,LGP Proband,,,C8,110,338
Cohort,0.08134596302141582,0.05591732407473346,1.4547542173637817,0.1461315254050546,LonGen OPEL,,,C8,189,260
Cohort,-0.022523035341013232,0.04060039642227603,-0.5547491484259406,0.5792497480104406,LGP Offspring,,,C8,56,109
Cohort,-0.05120344705200049,0.11121035607701733,-0.46041977436472004,0.6453349642503716,LGP Proband,,,C8,56,148
Cohort,-4.2622521328426933e-4,0.036109007279040414,-0.011803847444226833,0.9905850687561588,LonGen OPEL,,,C8,83,101
Cohort,-0.06895336376171131,0.05758733821173387,-1.1973702189218658,0.2315819794998439,LGP Offspring,,,C8,118,213
Cohort,-0.22419828836643174,0.1555485036645569,-1.4413400520388118,0.14986399063360245,LGP Proband,,,C8,118,291
Cohort,0.0020864822389620205,0.05046452235663218,0.041345526352491266,0.9670308073632436,LonGen OPEL,,,C8,175,210
Cohort,-0.01365024751022202,0.010497482776860342,-1.3003353089858203,0.1939292152281497,LGP Offspring,,,C8,6,5
Cohort,-0.013993763209819847,0.030640253151170176,-0.45671173605448534,0.647997176202781,LGP Proband,,,C8,6,10
Cohort,-0.008125838281902937,0.009266360814570112,-0.8769179664498001,0.3807957685644796,LonGen OPEL,,,C8,8,5
Cohort,0.0181554958287939,0.040244576310643564,0.45112900900368724,0.6520412475986137,LGP Offspring,,,C8,49,116
Cohort,0.0934711724520731,0.10691229579371603,0.8742789756607869,0.3822180296129303,LGP Proband,,,C8,49,133
Cohort,-0.04011811669269184,0.03213614417312582,-1.2483799075758761,0.21225901871446382,LonGen OPEL,,,C8,72,76
Cohort,0.014017056118171679,0.026496099297390323,0.5290233841912065,0.5969628877296168,LGP Offspring,,,C8,20,51
Cohort,0.004016909901933134,0.06937466476286139,0.057901683787069225,0.9538408115544874,LGP Proband,,,C8,20,66
Cohort,0.035507001632484554,0.0233785183046118,1.5187875112461773,0.12921305486785856,LonGen OPEL,,,C8,31,48
Cohort,0.04612373880076143,0.05787987923576751,0.7968872673849456,0.4257962923675117,LGP Offspring,,,C8,102,239
Cohort,0.12928870611654833,0.16596089409068468,0.7790311496267436,0.43618235088329826,LGP Proband,,,C8,102,315
Cohort,0.10467687688601754,0.051090782807065735,2.048840732805154,0.040805096534084095,LonGen OPEL,,,C8,160,231
Cohort,-0.04705616395970644,0.0710241474328395,-0.6625375405484845,0.5078526008733859,LGP Offspring,,,C8,169,331
Cohort,-0.17692619009762836,0.19826793104928975,-0.8923590878327379,0.37245788668406765,LGP Proband,,,C8,169,444
Cohort,0.06289103528385338,0.05937079842928348,1.0592923953812556,0.2897879636378125,LonGen OPEL,,,C8,241,328
Cohort,-0.13151759336999067,0.21085606675058816,-0.6237316070471746,0.5330142663408073,LGP Offspring,,,C8,1326,2689
Cohort,-0.48718400472964646,0.5848921285327169,-0.8329467622548028,0.4051132192996698,LGP Proband,,,C8,1326,3757
Cohort,-0.10974098535384252,0.181479309690645,-0.6047024618999833,0.5455490401910013,LonGen OPEL,,,C8,2096,2449
Cohort,-0.2269768752861182,0.11794418161750297,-1.9244431745027661,0.054718481992830574,LGP Offspring,,,C8,459,865
Cohort,0.015632363059093966,0.3294563828252049,0.0474489609976317,0.9621667673082657,LGP Proband,,,C8,459,1181
Cohort,-0.04466611237264453,0.10253737746443002,-0.4356081019152172,0.6632391876408639,LonGen OPEL,,,C8,674,805
Cohort,0.04414682400890488,0.04102540309457364,1.0760850760475307,0.2822731003751472,LGP Offspring,,,C8,50,121
Cohort,-0.008405182137661804,0.1158539468292199,-0.07254981265378786,0.9421817600081204,LGP Proband,,,C8,50,178
Cohort,0.05520477870949577,0.037455346038507885,1.4738824907061243,0.14090857851052044,LonGen OPEL,,,C8,85,128
Cohort,-0.1380639179808009,0.0832769054044253,-1.6578896311085094,0.09780367771569022,LGP Offspring,,,C8,246,458
Cohort,-0.025084196035606358,0.2209250962709301,-0.11354163225007498,0.9096284841321436,LGP Proband,,,C8,246,594
Cohort,0.14560498452455714,0.07031605035695858,2.0707218876116507,0.03870662218134063,LonGen OPEL,,,C8,308,438
Cohort,-0.014231672543339702,0.04700115936460807,-0.3027940743533269,0.7621399494650125,LGP Offspring,,,C8,73,145
Cohort,-0.08729566880087344,0.1311670671446384,-0.6655303857988392,0.505895329337533,LGP Proband,,,C8,73,199
Cohort,0.0010330231168462717,0.038719389885413166,0.02667973642930372,0.9787218624172145,LonGen OPEL,,,C8,102,127
Cohort,0.030947811355629493,0.04058480769982955,0.7625467042870693,0.4459997701648585,LGP Offspring,,,C8,46,112
Cohort,0.0012080391531019486,0.1067342897708753,0.011318191704795392,0.9909722891690514,LGP Proband,,,C8,46,137
Cohort,0.01548142933557074,0.03452956365566586,0.4483528807358802,0.6540205549403415,LonGen OPEL,,,C8,80,105
Cohort,0.01831824756015585,0.03969951609246321,0.46142243944463335,0.6446439888243614,LGP Offspring,,,C8,51,116
Cohort,-0.0041828238290059164,0.12086707427128743,-0.03460680962308663,0.9724015522178624,LGP Proband,,,C8,51,185
Cohort,0.01570036402564414,0.03666516853203659,0.4282092420201417,0.6686146245476314,LonGen OPEL,,,C8,100,130
Cohort,0.2170906527468669,0.0804397637998489,2.698797739971418,0.007132877866257417,LGP Offspring,,,C8,167,435
Cohort,0.021564518227238486,0.22058858308525137,0.09775899516478782,0.9221471572723656,LGP Proband,,,C8,167,565
Cohort,-0.056615556836957716,0.07319377282058243,-0.7735023712432154,0.43945477057401017,LonGen OPEL,,,C8,344,399
Cohort,0.035047952284143334,0.03912281338682379,0.8958443744218858,0.370654770801793,LGP Offspring,,,C8,44,107
Cohort,0.08027557923134977,0.10076272068885002,0.7966793540563135,0.4258640043619437,LGP Proband,,,C8,44,134
Cohort,-0.0032961095048670216,0.03374255396484205,-0.09768405522300988,0.9222077679811516,LonGen OPEL,,,C8,74,92
Cohort,-0.04800453197833218,0.05371845507630157,-0.8936320285113684,0.3718368312548238,LGP Offspring,,,C8,95,182
Cohort,0.12091944087574712,0.1490051169660247,0.8115120026604086,0.41730324206319047,LGP Proband,,,C8,95,260
Cohort,-0.07767231246431691,0.043406122860521666,-1.7894321663767099,0.07392531524274867,LonGen OPEL,,,C8,144,141
Cohort,0.057425778226952766,0.03516767960582857,1.6329134839318549,0.1029528513251473,LGP Offspring,,,C8,32,95
Cohort,0.14498705868687653,0.08634998458983277,1.6790629364391103,0.0935143502493279,LGP Proband,,,C8,32,88
Cohort,0.0722721540825837,0.026414998710887923,2.736027166747278,0.006357090699441487,LonGen OPEL,,,C8,35,71
Cohort,-0.02660551097573997,0.026677555748475967,-0.9972994237772285,0.31897603843931643,LGP Offspring,,,C8,22,41
Cohort,-0.0731477109103518,0.06881728980733516,-1.0629263534664084,0.2881230226908684,LGP Proband,,,C8,22,56
Cohort,-0.014210194131509485,0.020991370732517816,-0.6769540833032126,0.4986317636259452,LonGen OPEL,,,C8,33,34
Cohort,-0.02338130640086908,0.07758183817619867,-0.3013760301446715,0.7632204509282648,LGP Offspring,,,C8,212,432
Cohort,-0.3761725507635714,0.231761193743316,-1.6231041301081504,0.104945044837614,LGP Proband,,,C8,212,605
Cohort,0.013481339596755376,0.07245454460620535,0.1860661697623971,0.8524402766194498,LonGen OPEL,,,C8,330,398
Cohort,-0.0019138456901233775,0.0396235186258163,-0.04830075057686651,0.9614908227038567,LGP Offspring,,,C8,53,107
Cohort,-0.24213136723872286,0.09794277850562151,-2.472171720397186,0.013628027362519538,LGP Proband,,,C8,53,118
Cohort,0.0355555281640179,0.03009569961663587,1.1814155715577392,0.23779051806876123,LonGen OPEL,,,C8,58,92
Cohort,-0.021770767677207876,0.045118116102724225,-0.48252829589871465,0.6295869105889542,LGP Offspring,,,C8,72,144
Cohort,-0.2896412345245163,0.12539636628852133,-2.309805643475251,0.021142304489566402,LGP Proband,,,C8,72,201
Cohort,-0.08378373697069148,0.03980462330832338,-2.104874509719875,0.03561510928944188,LonGen OPEL,,,C8,120,115
Cohort,-0.017777507017342088,0.042802010125198894,-0.4153428066892566,0.6780227651552124,LGP Offspring,,,C8,60,119
Cohort,-0.2104173063275378,0.12105860715708641,-1.7381441210082567,0.08255450163507784,LGP Proband,,,C8,60,177
Cohort,-0.017803723883778894,0.03584176292850458,-0.4967312550806417,0.6195157305163665,LonGen OPEL,,,C8,99,106
Cohort,0.027369086188372284,0.05430691183684287,0.5039705861124764,0.614446249045999,LGP Offspring,,,C8,92,209
Cohort,0.09274523971323304,0.14839083193857835,0.6250065351181666,0.5321377291623146,LGP Proband,,,C8,92,280
Cohort,-0.020337002321843458,0.045852938610001795,-0.4435266950896664,0.6575053408381241,LonGen OPEL,,,C8,146,167
Cohort,0.012465070125398185,0.07372878129502065,0.1690665423523015,0.8657948770597241,LGP Offspring,,,C8,162,341
Cohort,0.274181303194578,0.19299101836446306,1.4206946287872697,0.15577930509397983,LGP Proband,,,C8,162,424
Cohort,-0.015314994278316037,0.061006454928867214,-0.2510389154094126,0.8018488100004747,LonGen OPEL,,,C8,238,288
Cohort,0.0038412687586916986,0.06103582523449935,0.06293465753815176,0.9498371405068646,LGP Offspring,,,C8,115,245
Cohort,0.11306345148124869,0.16737694516882584,0.675501941842746,0.4995441634826151,LGP Proband,,,C8,115,326
Cohort,0.009454241568627007,0.05304817306295454,0.1782199277137641,0.8585956058820868,LonGen OPEL,,,C8,192,231
Cohort,0.025304129869048994,0.06649297636724719,0.38055342460971847,0.7036541967319697,LGP Offspring,,,C8,155,341
Cohort,0.2347877890373866,0.19563593790700012,1.2001260686009447,0.23043117248939315,LGP Proband,,,C8,155,465
Cohort,0.07729672646769356,0.06290154519111259,1.228852585939572,0.2194902412850312,LonGen OPEL,,,C8,250,332
Cohort,-0.015669965348343844,0.08267163166424389,-0.18954464830190623,0.849722862077806,LGP Offspring,,,C8,218,437
Cohort,-0.39625330934100916,0.2273264147446252,-1.7431027968577857,0.08168418956026773,LGP Proband,,,C8,218,653
Cohort,-0.09568848335720534,0.07241916557430929,-1.3213143592357386,0.1867762330629266,LonGen OPEL,,,C8,391,448
Cohort,-0.10157433143733896,0.05579124370887427,-1.820614216226593,0.06910750755326314,LGP Offspring,,,C8,108,186
Cohort,-0.16784758168956315,0.14608429502384374,-1.148977593122979,0.250894629099663,LGP Proband,,,C8,108,258
Cohort,0.02362399012333181,0.046217502490615944,0.5111481332884323,0.6093890772530977,LonGen OPEL,,,C8,146,184
Cohort,0.052447373385094816,0.07496429835406977,0.6996313516785884,0.48439823047180075,LGP Offspring,,,C8,174,396
Cohort,0.012339106710037222,0.21359395703014655,0.05776898785715968,0.9539464787712315,LGP Proband,,,C8,174,526
Cohort,0.014947636729996912,0.06520470935105223,0.22924167408708337,0.8187399709300298,LonGen OPEL,,,C8,287,357
Cohort,0.005019392462738387,0.05313995045464523,0.09445609978546031,0.9247748437522312,LGP Offspring,,,C8,87,197
Cohort,0.03196341578840821,0.15092906402347464,0.2117777380732766,0.8323321788763867,LGP Proband,,,C8,87,286
Cohort,-0.007178049669316959,0.04508616561968702,-0.1592073659549048,0.8735458863769862,LonGen OPEL,,,C8,132,169
Cohort,0.023714614629095826,0.05907777952977675,0.40141343865408885,0.6882426171942335,LGP Offspring,,,C8,101,237
Cohort,0.17015121219226298,0.16092596419644997,1.0573260383548257,0.29066897074168146,LGP Proband,,,C8,101,305
Cohort,-0.006660079892944053,0.0474682289883977,-0.14030605385703196,0.8884536762429476,LonGen OPEL,,,C8,165,192
Cohort,0.023672918948535175,0.014821396245417222,1.5972124728704185,0.11068566733014293,LGP Offspring,,,C8,3,19
Cohort,-0.01443311257143806,0.02724171325518648,-0.5298166248295774,0.5963800880079073,LGP Proband,,,C8,3,9
Cohort,-0.002864394622833291,0.008873575591193972,-0.3228004983330374,0.7469311067416811,LonGen OPEL,,,C8,6,6
Cohort,0.013532964339228416,0.05246372230494175,0.2579489930312035,0.7965247803119299,LGP Offspring,,,C8,77,168
Cohort,-0.010073319949604606,0.13370386971256032,-0.07534052657758121,0.9399618452437939,LGP Proband,,,C8,77,213
Cohort,-0.04133480099786975,0.041110422647169347,-1.0054579431748034,0.3149819325265546,LonGen OPEL,,,C8,118,131
Cohort,-0.0018403647556455211,0.038522651897175644,-0.04777357385877296,0.9619108077662566,LGP Offspring,,,C8,47,100
Cohort,-0.05143604739071855,0.11358738230170656,-0.4528324039909296,0.650787203573028,LGP Proband,,,C8,47,150
Cohort,0.07613236196652556,0.03648390587633934,2.086738251780744,0.03722946748450402,LonGen OPEL,,,C8,71,122
Cohort,0.010467121882317944,0.033837511279546255,0.3093348620069763,0.7571621344820025,LGP Offspring,,,C8,36,79
Cohort,-0.05637491333600985,0.0932893121139475,-0.6043019511940569,0.5458072597867591,LGP Proband,,,C8,36,110
Cohort,0.01081650409875835,0.027771668533318,0.38947980693999934,0.6970254225053534,LonGen OPEL,,,C8,51,67
Cohort,-0.06499283345693697,0.026575414000246957,-2.445600036798411,0.014715143829321101,LGP Offspring,,,C8,31,36
Cohort,-0.21315055969677282,0.07910864755082625,-2.694402777646103,0.00719327584724661,LGP Proband,,,C8,31,70
Cohort,0.029293551013236004,0.020954762989348157,1.3979423689080457,0.16251978876277076,LonGen OPEL,,,C8,26,40
Cohort,-0.04267638023047879,0.025427796919914814,-1.6783357349002204,0.0937437550469221,LGP Offspring,,,C8,27,40
Cohort,-0.06188212999682072,0.06521378191858512,-0.9489118431143322,0.3429403288937698,LGP Proband,,,C8,27,47
Cohort,0.04021766563058719,0.019077275842527112,2.10814510219189,0.03533044445647607,LonGen OPEL,,,C8,16,36
Cohort,-0.031225864013577506,0.02890938307472776,-1.080129033983945,0.28046993166186773,LGP Offspring,,,C8,30,50
Cohort,-0.10885878081531034,0.07231734351580583,-1.5052928595409194,0.13262741811163767,LGP Proband,,,C8,30,58
Cohort,-0.00390905086511807,0.023322648547204755,-0.16760750208991912,0.8669346407535106,LonGen OPEL,,,C8,36,47
Cohort,-0.02159677446391046,0.03571695977436786,-0.6046644115384452,0.5456048954740167,LGP Offspring,,,C8,44,84
Cohort,0.04586887340454478,0.09703568476724327,0.4727010842925377,0.6365501290891673,LGP Proband,,,C8,44,107
Cohort,-0.043403833658149905,0.029532222276396396,-1.469711058379795,0.14203514471853507,LonGen OPEL,,,C8,64,60
Cohort,-0.046042069710589946,0.038231150545622455,-1.2043077190587417,0.22889215331070156,LGP Offspring,,,C8,52,91
Cohort,0.10699240053600619,0.11065451137860903,0.9669050019111035,0.33387182277183935,LGP Proband,,,C8,52,151
Cohort,-0.09788664687576173,0.03230472150463494,-3.0301034126456527,0.0025238107600216706,LonGen OPEL,,,C8,95,77
Cohort,-0.24980080792254944,0.08609511081078962,-2.9014517267018127,0.003835166911384773,LGP Offspring,,,C8,277,480
Cohort,-0.23532191594915078,0.2390504737805357,-0.9844026335843702,0.3252030718768484,LGP Proband,,,C8,277,675
Cohort,0.041282089830518225,0.07504651807034608,0.5500866781297139,0.5824142396587921,LonGen OPEL,,,C8,373,457
Cohort,-0.07050217497908025,0.04983220484873438,-1.4147914023288664,0.15759011568977707,LGP Offspring,,,C8,92,157
Cohort,-0.4928363661927109,0.14294028016480836,-3.4478480497203217,5.933693326447555e-4,LGP Proband,,,C8,92,229
Cohort,0.04356534135223926,0.04271841203178463,1.0198258615002935,0.3081209058093358,LonGen OPEL,,,C8,121,161
Cohort,0.027745288383114252,0.056626004423746136,0.489974326556568,0.624311039486136,LGP Offspring,,,C8,112,254
Cohort,0.09763531214014787,0.17178166239478027,0.5683686534350049,0.5699376681757108,LGP Proband,,,C8,112,345
Cohort,-0.006571841549024305,0.054493745737365436,-0.12059808809432061,0.9040398167145709,LonGen OPEL,,,C8,201,235
Cohort,-0.018388336682324886,0.07250775073388932,-0.2536051180212708,0.7998777524022411,LGP Offspring,,,C8,183,377
Cohort,0.15823677201107453,0.20793243873244432,0.7610008951738628,0.44687163970855914,LGP Proband,,,C8,183,513
Cohort,-0.02633601508312291,0.06350269115638972,-0.4147228188843922,0.6784565696411651,LonGen OPEL,,,C8,270,323
Cohort,0,0,NA,NA,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,0,0
Cohort,-0,0,NA,NA,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,0,0
Cohort,0,0,NA,NA,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,0,0
Cohort,-0.05526578397824927,0.047054090724743126,-1.174516033080798,0.24060196584248456,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,75,135
Cohort,-0.17119801825241998,0.13308260072753256,-1.2864042129964326,0.19865901253513565,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,75,197
Cohort,-0.014455430004317947,0.03898038983806819,-0.3708385181463936,0.7108564775057097,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,113,131
Cohort,-0.09373017854966917,0.0709269037596945,-1.3215038804912986,0.1867804784532495,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,172,332
Cohort,0.38902473366733215,0.20402690507415472,1.9067325141551255,0.05689862415111602,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,172,484
Cohort,-0.02363553247227503,0.0652867132003722,-0.3620266868043264,0.7174281736515649,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,293,359
Cohort,0.0882025666534149,0.05531651425257233,1.5945069541201848,0.1112899346229567,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,86,219
Cohort,-0.10550120003863392,0.15209691985952067,-0.693644553328737,0.48809828536607147,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,86,299
Cohort,-0.0013155886092861108,0.04770277145330842,-0.027578871608619472,0.9780049458492511,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,155,179
Cohort,0.025512513314792068,0.0481241613566637,0.5301393851980213,0.596189377189265,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,63,152
Cohort,0.07961522556983106,0.13440851505392618,0.5923376620736309,0.5537850535550316,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,63,242
Cohort,-0.02180027040470868,0.04007103082581801,-0.5440406686683645,0.5865658355401269,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,108,116
Cohort,0.10209655383914895,0.06057429903515144,1.6854764391066586,0.09235818276076202,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,109,274
Cohort,-0.03394437048625497,0.1586699907742261,-0.21393062620489414,0.8306534465136536,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,109,351
Cohort,-0.030152265711134402,0.05149133316882801,-0.5855794335771458,0.5583241484329768,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,193,219
Cohort,-0.009800067851720952,0.07713267531798955,-0.12705468611478715,0.898934898581123,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,162,350
Cohort,0.0025286036223110602,0.195711175363873,0.012920077852528312,0.9896946460942782,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,162,436
Cohort,0.10488408763521972,0.060356861036581104,1.7377326427173134,0.08264468015503593,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,226,306
Cohort,-0.04981708521635225,0.06618745240687059,-0.7526666068081054,0.4519122950810498,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,152,282
Cohort,-0.18910821546300832,0.18044484799534252,-1.0480111655384554,0.2949370756072013,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,152,395
Cohort,-0.03823204870996655,0.057085578588923935,-0.6697321750082874,0.5032227594520919,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,236,256
Cohort,0.0020433477400155007,0.03325171744751708,0.06145089327312561,0.9510182853669662,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,37,79
Cohort,0.050338112564139295,0.09462542985728249,0.5319723528871791,0.594886819058001,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,37,117
Cohort,-0.03001756063389079,0.03173635742409883,-0.9458413967539046,0.344516507515055,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,75,74
Cohort,-0.017229175495970868,0.07488705911533114,-0.23006879559039395,0.8181079127432691,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,173,347
Cohort,-0.009187015849469855,0.2065630164804698,-0.04447560848985991,0.9645359406537724,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,173,480
Cohort,-0.0474985499858931,0.05912123431156591,-0.8034093086686612,0.42197803356452124,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,254,278
Cohort,-0.031968433508901176,0.0532312114426347,-0.6005580681430174,0.5483356594130735,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,95,187
Cohort,-0.018873705843351248,0.1471998534206172,-0.12821823802650437,0.8980071781014027,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,95,262
Cohort,-0.0295453605265854,0.048263499701980024,-0.6121678019419154,0.5406015619958139,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,171,185
Cohort,0.011537240746366683,0.05814868040439394,0.19840933046341122,0.8427844710091272,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,106,213
Cohort,-0.26927084724209954,0.16152757365752377,-1.6670271282166147,0.09588445499272233,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,106,304
Cohort,-0.04242435808626171,0.04646001585010072,-0.9131369697147819,0.36144699287388093,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,159,174
Cohort,-0.08780829301778144,0.0768207834135174,-1.1430278254924782,0.25343167822196194,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,203,389
Cohort,-0.032953030573250455,0.20572848752664458,-0.16017728497120556,0.8727802087031751,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,203,543
Cohort,-0.16863286643479533,0.06961663634873444,-2.422307012795813,0.01564463014595629,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,341,343
Cohort,-0.022767496578711695,0.028979203943963864,-0.7856494823921477,0.43234814471169347,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,30,51
Cohort,-0.0796243621574581,0.08431280263074654,-0.9443923066604514,0.3452427166705695,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,30,87
Cohort,0.012655262817217494,0.024390676087817732,0.5188565815745609,0.6040049702415813,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,38,52
Cohort,0.014706101762054346,0.026122712527087002,0.5629622783930033,0.5736472294529644,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,18,51
Cohort,0.06451624378897117,0.0726422122277992,0.8881371011479421,0.37472307283873463,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,18,71
Cohort,0.007805728546879343,0.02269643998616401,0.3439186300423237,0.7309983076192277,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,35,45
Cohort,-0.3049020229459271,0.11797520652426373,-2.5844584801232666,0.009961703738795527,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,528,1006
Cohort,0.0037180983849891603,0.33714758229406205,0.011028103359632618,0.9912036623489379,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,528,1439
Cohort,-0.04505424248203983,0.11126968254939966,-0.4049103174356357,0.685652222195753,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,838,974
Cohort,0.028737607398054955,0.04674156792326147,0.6148190716502122,0.5388811017022959,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,65,154
Cohort,0.03509315066941303,0.1365719299158133,0.2569572729260355,0.79727513485498,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,65,226
Cohort,0.021722775089994626,0.042927434534474423,0.506034784644523,0.6129723415240826,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,124,152
Cohort,-0.026152334619527536,0.04340443217402023,-0.6025268229446172,0.547025571606642,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,57,115
Cohort,-0.04156275924919739,0.12017634826157227,-0.34584807951339247,0.7295441110681451,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,57,148
Cohort,-0.011614845290022057,0.034260721625400364,-0.33901344568910047,0.7346890140141632,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,88,106
Cohort,0.07541023161310667,0.040319863053853065,1.8702997952246339,0.06187412647833463,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,45,134
Cohort,-0.09266659713129002,0.1090475874018873,-0.8497812683353894,0.39569057856409695,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,45,147
Cohort,-0.012101018777475289,0.036734035745669705,-0.32942252414783435,0.7419230063690607,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,88,100
Cohort,-0.029783052113397775,0.020211498412970316,-1.4735697227814197,0.141062962092112,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,19,20
Cohort,-0.1062613249293515,0.05603634666561543,-1.896292875112694,0.05826669293600492,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,19,31
Cohort,0.005472492173187978,0.017154500637542845,0.3190120358975276,0.7498010794466214,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,18,25
Cohort,-0.14824315673661856,0.12945125507114114,-1.1451658514639365,0.252545725193609,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,573,1120
Cohort,-0.33301467470972224,0.354390795003306,-0.9396820668172706,0.3476527359256104,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,573,1584
Cohort,-0.15054700557724163,0.1159973357462525,-1.29784882220543,0.19471524018164355,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,909,1014
Cohort,-0.09825760910014816,0.08144551563366764,-1.2064213521846843,0.228077097364153,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,268,522
Cohort,-0.11724442419293392,0.23608666306100157,-0.4966160420618066,0.6195907072734268,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,268,662
Cohort,-0.18150217841810548,0.07875948271643964,-2.304512068363549,0.021450485852907507,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,441,450
Cohort,0.039619653784413233,0.022036214085243214,1.797933784412857,0.07263359343662257,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,10,37
Cohort,0.027704093746471342,0.06046865923098804,0.458156243230774,0.6469595435832634,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,10,54
Cohort,-0.01862023975186162,0.018348606926615836,-1.0148040026325793,0.31050761708317837,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,28,26
Cohort,-0.010905223965578588,0.027658068649061507,-0.3942872549760854,0.6934933236983196,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,25,48
Cohort,-0.030216602529207437,0.07928504512315773,-0.3811135187256356,0.7032160797220206,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,25,72
Cohort,-0.016087780662144877,0.02003272401503707,-0.8030750411211666,0.42217108619570753,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,33,28
Cohort,-0.00466255811700891,0.02676462604702421,-0.17420598773982537,0.8617557364204066,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,22,49
Cohort,0.04873312801916728,0.0759291802677184,0.6418234445221104,0.5211641858965229,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,22,80
Cohort,-0.024218499172395207,0.025935127770712232,-0.9338106751008352,0.3506847333505081,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,54,54
Cohort,-0.08509826525188978,0.09042907929129296,-0.9410497808760012,0.3470155010740482,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,303,594
Cohort,-0.32975993427800376,0.2568165338112888,-1.2840292226680172,0.1994883226466319,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,303,836
Cohort,-0.08842073001668299,0.08385988260740072,-1.0543865227028086,0.29202592023716434,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,484,549
Cohort,-0.12097136162555083,0.11396011232172003,-1.061523713525636,0.2888310510152581,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,425,861
Cohort,0.06037192455100553,0.31056666629873536,0.19439280226208672,0.845915665625413,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,425,1149
Cohort,-0.10096553375738723,0.09554619952543719,-1.0567195164105638,0.29096021053738835,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,680,761
Cohort,0.014957448164640355,0.03498441811951304,0.42754600386786573,0.6691178417248923,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,38,82
Cohort,-0.07790640280633405,0.10498883535783093,-0.7420446425642072,0.45826920857596276,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,38,119
Cohort,-0.01081446176903458,0.032273730208378974,-0.3350855850628294,0.7376488102490971,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,73,78
Cohort,-0.021794091806265056,0.04516938140484384,-0.48249701741383416,0.6296091131565198,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,67,131
Cohort,-0.025494160099360546,0.13279152204177028,-0.19198635355155597,0.8477996289090755,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,67,212
Cohort,0.007124343169662214,0.03848153272177787,0.1851366789668004,0.8531689941907042,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,107,131
Cohort,4.407084462909267e-4,0.12762538715890503,0.0034531409157819454,0.9972458164077265,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,524,1077
Cohort,-0.078561243551694665,0.3419733723273383,-0.22972912486442224,0.8183585915132882,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,524,1422
Cohort,-0.20150216599467097,0.10740722467470244,-1.8760578406615385,0.06101306744788667,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,846,917
Cohort,0.005027526366691425,0.009601589206309644,0.5236139829214529,0.6007186610339208,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,2,7
Cohort,-0.009994103549313963,0.02481686923810691,-0.4027141156857841,0.6872617515294236,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,2,8
Cohort,-0.007723661895092617,0.00725451762548367,-1.0646692576720658,0.2873484729890927,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,4,4
Cohort,-0.043961766881523597,0.029955377584944088,-1.467575120923172,0.14268476302621705,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,39,56
Cohort,-0.2881067991235153,0.0895479395214403,-3.21734705078875,0.0013437425345734306,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,39,108
Cohort,-0.028707515766326446,0.029612743909998532,-0.9694311291644122,0.3326245911543152,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,63,71
Cohort,0.046381397656111496,0.024930202708874354,1.8604500812823799,0.06325590951853674,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,13,48
Cohort,0.12247807132441806,0.07632071731032485,1.6047814491367332,0.1089204862606601,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,13,79
Cohort,-0.01791943763042737,0.02117837314487378,-0.8461196479940559,0.39774028290768915,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,33,33
Cohort,0.029064833369616454,0.08415154465505087,0.34538680767842506,0.7299110396087771,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,214,464
Cohort,-0.11099923647613583,0.22403596832551867,-0.49545274942127465,0.6204110844320765,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,214,648
Cohort,0.11351424688268393,0.07220142225702651,1.5721885156027784,0.11630421234021396,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,348,464
Cohort,-0.013221745169814298,0.02734660962159633,-0.48348754572386704,0.6289061643453079,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,27,50
Cohort,-0.08173210315517014,0.06904886479336315,-1.1836849657088941,0.23687506034219874,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,27,52
Cohort,-0.0067865191540509295,0.022620099536395072,-0.3000216309009437,0.7642389868450898,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,35,42
Cohort,0.0073659580796586735,0.013507349557083282,0.5453296406174629,0.5857067010075216,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,4,12
Cohort,0.05283726273209096,0.049553125762595227,1.0662750718336065,0.28660788701089923,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,4,29
Cohort,0.015788328571795962,0.011156561781433828,1.4151607709527572,0.15741245347710023,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,4,15
Cohort,-0.07573111647092744,0.04944651516799595,-1.5315764157216905,0.1260948152538047,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,85,144
Cohort,-0.090230466648905,0.1319016640817743,-0.6840737550738203,0.49411862152684694,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,85,198
Cohort,0.03227882657069753,0.040215909836464336,0.8026382270588308,0.42242344161870005,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,117,144
Cohort,-0.04049018574185053,0.06862553052514007,-0.5900163602672256,0.5553768435725415,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,147,291
Cohort,-0.021778525802488704,0.1874962058135592,-0.11615448807611947,0.9075580681976826,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,147,417
Cohort,0.030353952961005102,0.05843673151008993,0.5194327638903634,0.6036033862733112,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,227,283
Cohort,-0.08308822597853509,0.03495101564399245,-2.3772764381116542,0.017718268299472154,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,49,70
Cohort,0.06224784995076915,0.1081890045807526,0.575362072994277,0.5652016431020093,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,49,131
Cohort,-0.020136834748462788,0.02847603240160094,-0.7071502962375715,0.47968004747699744,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,62,71
Cohort,0.0015989258598448784,0.03529645600254355,0.0452998980897588,0.9638816467777633,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,41,83
Cohort,0.017214459860743145,0.0950149047142543,0.18117641555831188,0.8562731256755685,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,41,118
Cohort,0.004680332955615622,0.03149975712313939,0.14858314422295968,0.88192020627694645,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,67,83
Cohort,-0.10864333114424737,0.0541538441901597,-2.0061979489904607,0.045233020513961206,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,103,170
Cohort,-0.2269595613867588,0.1452650559599091,-1.5623823629641262,0.11857729129466443,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,103,249
Cohort,0.015252735742539075,0.043690552391460705,0.34910832909313855,0.727100311467701,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,125,152
Cohort,-0.028774239320976697,0.026731258278707655,-1.0764266695180729,0.28212048262405626,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,25,45
Cohort,0.008442512651408038,0.07076869956766535,0.11929726988039036,0.9050685757063615,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,25,58
Cohort,0.01684708690498948,0.019983960655692145,0.84303042801432,0.39946466959034954,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,26,36
Cohort,-0.09495358329091942,0.08164681969575632,-1.1629795703586325,0.2452481564117781,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,230,446
Cohort,-0.17214465965125197,0.2104709567076281,-0.8179022053403007,0.41364663863225415,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,230,550
Cohort,0.0691340086136162,0.06879393887073407,1.0049433096645495,0.31522953425943845,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,306,404
Cohort,0.01746250949844977,0.05154335159614056,0.3387926659343844,0.7348711335719584,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,75,177
Cohort,0.1305713457704463,0.14154691413848713,0.9224598541420512,0.3565555405419193,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,75,226
Cohort,-0.042487925655349076,0.04250127015470753,-0.9996860211633704,0.3177662715109789,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,139,146
Cohort,0.034434378450459664,0.058228568309596884,0.591365706733071,0.5544731019694643,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,102,234
Cohort,0.13333594172767482,0.15869703683851616,0.8401917539478208,0.401041676713043,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,102,311
Cohort,-0.02988181995920776,0.0499878472566069,-0.5977816929345418,0.5501556315631586,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,171,196
Cohort,-0.029207315223547196,0.04615488811256377,-0.6328108769826419,0.5270711484909152,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,73,137
Cohort,-0.11947690088274213,0.12723497899222377,-0.939025587374398,0.3479894762089175,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,73,202
Cohort,-0.011683229194802634,0.04104972669685146,-0.2846116194897528,0.7760157342427599,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,112,139
Cohort,-0.00497336875754681,0.0032119977308811194,-1.5483724380410782,0.12200065974606518,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,1,0
Cohort,0.007033343170730415,0.017668672957051757,0.3980685582797735,0.6906815256013115,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,1,4
Cohort,0.0036061088121343544,0.005789346243501073,0.6228870515703654,0.533537156300245,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,1,4
Cohort,-0.022791105168047568,0.02491315446706884,-0.9148221353571955,0.36061120512503786,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,22,36
Cohort,-0.14263776345863105,0.057336987339112265,-2.4877094189657765,0.013051201112667941,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,22,33
Cohort,0.011506536165310412,0.017332979163276016,0.6638521893391363,0.5069771465819761,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,19,29
Cohort,0.06253643308491293,0.05315976671547957,1.1763865221534724,0.23985453978765275,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,74,194
Cohort,0.11868265043019106,0.14392735272486187,0.8246010795256566,0.40983388094292017,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,74,253
Cohort,-0.019253089700318964,0.045081613036670874,-0.4270718903659872,0.6694424560860286,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,158,174
Cohort,-0.0580560882818936,0.03646594991234739,-1.5920629634341645,0.11183803114659512,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,52,89
Cohort,-0.030652411237394515,0.09640074342712365,-0.3179686187852577,0.7505883389945838,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,52,104
Cohort,0.03507487013289345,0.03206892277329664,1.0937339673317563,0.27440254000732234,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,61,95
Cohort,-0.04225560206989784,0.0576521948598106,-0.7329400410972776,0.4638490707193307,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,117,219
Cohort,-0.2097031709622167,0.1692725867208919,-1.238848977407012,0.21574997889493686,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,117,354
Cohort,-0.011674914466409161,0.053962331615473376,-0.21635303955364021,0.8287680005629124,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,193,228
Cohort,0.0020329077110137427,0.09277954208870164,0.02191116344452516,0.9825252855765545,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,262,539
Cohort,-0.21967234641099537,0.24939470529198485,-0.880822013257293,0.37866791902273544,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,262,734
Cohort,-0.039768849261879104,0.07566281988874941,-0.5256062266824459,0.5993082127346893,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,432,492
Cohort,0.047982711631456613,0.035106394280965,1.3667798306895125,0.17214870066600949,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,36,91
Cohort,-0.09242409786533189,0.09902940658043798,-0.933299522402562,0.3509354577260778,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,36,127
Cohort,-0.0031594106766229995,0.03405320777640499,-0.09277865090912558,0.9261027572524727,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,79,93
Cohort,0.017418949400937682,0.042060494558763345,0.4141403847879489,0.67890266691282,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,46,107
Cohort,0.11222318157355964,0.11057724569225169,1.0148849419336123,0.3104550063842999,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,46,148
Cohort,-0.014323079487079662,0.030794139383643192,-0.46512355187583515,0.6419701936198782,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,68,73
Cohort,0.06139026200317331,0.050684343420508184,1.2112273309696904,0.2262315410806051,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,73,191
Cohort,0.06018580228857332,0.14666383741825886,0.41036565896564026,0.6816431320746474,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,73,278
Cohort,0.008915865407947495,0.04596524675425913,0.19396970619158818,0.846249090446553,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,130,163
Cohort,-0.0010901099198891968,0.07263509999181061,-0.015008032204982211,0.9880302005147865,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,148,319
Cohort,0.09270615323612454,0.1907746221644284,0.48594594073535224,0.6271331426598941,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,148,410
Cohort,0.030380807602555786,0.05778514581516814,0.5257546238566567,0.5992051366565463,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,241,293
Cohort,-0.060841498841538943,0.060360130055976714,-1.0079749461294372,0.3138271437816694,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,119,228
Cohort,-0.21379617624856231,0.16406439612282514,-1.3031235374706527,0.19289224029365667,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,119,340
Cohort,0.021906886201955716,0.05118086862271711,0.42802880825340545,0.6687459279673926,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,159,205
Cohort,0.005190305899846044,0.0517089474772855,0.10037539252033743,0.9200760658756912,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,78,166
Cohort,-0.04793974700948735,0.1406846529284329,-0.3407603175726252,0.7333698460299647,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,78,236
Cohort,-0.06383712420302612,0.045556769913129236,-1.4012653733957678,0.16152448459548888,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,148,144
Cohort,-0.06300890361121454,0.04069468852403047,-1.5483323720246043,0.12201030070140262,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,69,112
Cohort,0.0048329696553478935,0.10950052809822655,0.044136496319109236,0.9648061662450542,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,69,162
Cohort,-0.044274404237183825,0.03694397374305137,-1.1984201955403133,0.23111015096817425,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,97,93
Cohort,-0.04755813538882172,0.03001394639833972,-1.5845345612882313,0.11353979289705404,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,33,43
Cohort,-0.18239496937349342,0.07888968095238677,-2.312025694254949,0.021019037745645137,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,33,60
Cohort,-0.02025671658591999,0.02534028467120453,-0.7993878856830184,0.42430400208263463,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,47,49
Cohort,9.01320980910052e-4,0.011832007296691184,0.07617650651399666,0.9393012120295483,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,4,10
Cohort,-0.044717573322479526,0.0340311271402798,-1.31401975427229,0.18920086019763255,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,4,15
Cohort,0.0018453991163573974,0.009327543963421305,0.19784405451148498,0.8432175889180459,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,6,7
Cohort,-0.07159857593497101,0.043399161548446176,-1.6497686448399707,0.09945480795162877,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,71,121
Cohort,0.14777246072825337,0.13283746464478796,1.1124306017387648,0.2662736006065706,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,71,199
Cohort,-0.03504003435687484,0.03656990508393444,-0.9581658545859423,0.3382700588304294,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,95,97
Cohort,-0.011798474078580116,0.055243375105143815,-0.21357265113009974,0.8309447250213435,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,100,199
Cohort,-0.283802430755505,0.15187561395795426,-1.8686504262236185,0.06202183481052128,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,100,259
Cohort,-0.015611119383117489,0.0461031182884957,-0.33861309088528607,0.7349905171918674,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,152,178
Cohort,-0.0799890444457019,0.04481168892190641,-1.7850040105629421,0.07470895511487535,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,79,131
Cohort,0.21371876760298503,0.1304571494863061,1.6382296289972116,0.10175098490874762,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,79,187
Cohort,-0.036623945155126694,0.0379204945102837,-0.9658087434802466,0.33443322276826193,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,110,116
Cohort,-0.09846326324628173,0.07386479379529912,-1.3330202141923275,0.18297423957263825,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,176,325
Cohort,0.09218167671157873,0.2035839402637984,0.4527944423913413,0.6508145299845751,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,176,493
Cohort,-0.01287964940355918,0.06189475439862651,-0.20808951467210265,0.8352123037086433,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,247,301
Cohort,0.044159372129244596,0.06481384192075842,0.6813262540929754,0.49589840417607234,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,149,324
Cohort,-0.2688237350721558,0.17686740142007398,-1.519916801591257,0.12891088881646823,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,149,457
Cohort,-0.08121767374260265,0.06111267741935387,-1.3289824169425393,0.18423457691939524,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,279,287
Cohort,0.17977282509725134,0.09312562336809765,1.930433521896152,0.05397109477582856,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,269,619
Cohort,0.005886351035847854,0.2691994209421056,0.021866135578032245,0.9825599684827302,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,269,859
Cohort,-0.016956324755406958,0.08359307892582037,-0.20284364415448586,0.8393090802769346,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,475,561
Cohort,0.05729373372848712,0.03340754286828168,1.7149939447622125,0.08680462339797451,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,30,86
Cohort,-0.1342006927442946,0.08701332151626832,-1.542300539799575,0.12337990547036963,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,30,98
Cohort,-0.013870809942477243,0.03191690808401453,-0.4345912801442189,0.663976910449811,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,76,87
Cohort,0.053754795263431285,0.052238851011463756,1.0290194792307905,0.30383855845359187,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,68,171
Cohort,0.0665885321666626,0.1467286190951477,0.4538210239917993,0.6500757175304659,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,68,259
Cohort,-0.001916456972205974,0.04359860024316446,-0.043956846355553414,0.9649498263334988,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,128,150
Cohort,-0.041127301024736225,0.057502485783618953,-0.7152264891555764,0.47471604487594954,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,114,219
Cohort,-0.026370312971030367,0.15945069058483655,-0.1653822437162786,0.868683207622245,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,114,290
Cohort,-0.029845806956066655,0.05007641491550269,-0.5960052652816201,0.5513411427953296,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,172,206
Cohort,0.002792638420315575,0.07653100272811623,0.03649028917387496,0.9709021942303249,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,176,386
Cohort,-0.039868892650057226,0.19955068061144732,-0.1997933183083823,0.8416909305362761,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,176,470
Cohort,0.07177845705772645,0.0637110503715469,1.1266249204672103,0.2602406206131998,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,268,332
Cohort,-0.03972374805578709,0.03743553255908167,-1.0611241603974542,0.28901243524164705,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,53,91
Cohort,-0.07080261686104818,0.10745247968402925,-0.6589202693995309,0.510128844778255,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,53,139
Cohort,-0.015188264457044123,0.03366843001471578,-0.45111294023527804,0.652031016782283,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,76,81
Cohort,-0.01533646132053114,0.032598478958960016,-0.47046554963006215,0.6381741946859774,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,34,66
Cohort,0.055037618608308796,0.09157542943087262,0.6010085778506226,0.5479975764378973,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,34,95
Cohort,-0.02219854043073832,0.02784706505337974,-0.7971590682244674,0.42559636561708214,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,56,58
Cohort,0.041103555763238285,0.03885050188846811,1.0579929155416894,0.2904365825963462,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,39,103
Cohort,-0.08810534781978233,0.0990605399654163,-0.8894091214376721,0.37403971043674134,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,39,115
Cohort,0.02503468321866056,0.03257047059850278,0.7686313018704547,0.44234019870108676,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,63,88
Cohort,0.0407028712242131,0.06439541592101804,0.6320771539721988,0.5275501678761796,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,142,310
Cohort,-0.2846458487977424,0.17768551967603768,-1.6019642417497975,0.10954217946796971,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,142,451
Cohort,-0.06715956692984358,0.06078868447435567,-1.1048037560045494,0.26957846515087075,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,261,272
Cohort,0.05763756745930334,0.06644746929584923,0.8674155399760842,0.3860221699538293,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,113,270
Cohort,-0.14953347878167586,0.17724797560141345,-0.8436399810734054,0.3991125188790555,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,113,376
Cohort,-0.02337109997432335,0.05358478844174003,-0.43615176347544116,0.6628448853548108,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,183,212
Cohort,-0.06923013412316646,0.07766234845765256,-0.8914246800161602,0.3730185536264853,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,198,383
Cohort,0.20781757789731034,0.20726632429547642,1.002659639011343,0.31631592593657526,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,198,549
Cohort,-0.03809881568018989,0.0633800066881467,-0.601117255598446,0.5479330248516201,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,304,356
Cohort,-0.008130355713580664,0.04722306534282628,-0.17216916467739968,0.8633560684221143,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,70,153
Cohort,-0.18623409776594207,0.1369831146606389,-1.359540540652162,0.17434282009561325,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,70,236
Cohort,-0.03277159009745141,0.04357571057340262,-0.7520609455638863,0.45223672579108043,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,129,147
Cohort,-0.15132854402991067,0.06496145944190776,-2.3295126884462514,0.020125559392328518,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,157,265
Cohort,-0.09931886709229448,0.18739829244689474,-0.529988111393489,0.5962612369778807,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,157,394
Cohort,-0.0871230269757823,0.054604564929366564,-1.5955264379174123,0.1109914857420148,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,225,245
Cohort,0.03673889819545906,0.07557099586627261,0.4861507748352388,0.6270178213313194,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,166,368
Cohort,-0.019233646739635978,0.19566027692486168,-0.09830123437381297,0.9217167183495065,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,166,481
Cohort,0.1128045269396778,0.06512769600607902,1.7320515519103978,0.08365177144621194,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,259,340
Cohort,0.007150031509934713,0.0650790906407166,0.1098668011421369,0.9125476187858454,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,130,275
Cohort,0.1489700425959969,0.1769436591735696,0.84190664583164,0.4000815566959608,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,130,379
Cohort,0.02972952992246583,0.059829031614737876,0.4969080916085304,0.6193910730723264,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,212,271
Cohort,-0.05556663735046807,0.09286487368759587,-0.5983601241670585,0.5498000914468217,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,289,596
Cohort,0.23868663447795127,0.25888373670687714,0.921983889425259,0.3568036110655429,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,289,806
Cohort,-0.003277681458289315,0.08254197705578974,-0.03970926763813696,0.9683348700875418,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,472,587
Cohort,0.031651656805396174,0.053160329825602474,0.5953999327926002,0.5517754365293219,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,88,186
Cohort,-0.2763877158817279,0.13309085936218543,-2.0766844335235906,0.03813637578758959,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,88,250
Cohort,0.005797756536856411,0.04577051994339873,0.12667010433847156,0.8992334974999521,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,143,170
Cohort,-0.06740522442202297,0.04698005111838456,-1.4347626879368272,0.1518171935322153,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,77,129
Cohort,-0.15970145267163036,0.12499395851220314,-1.2776733737578103,0.20172014528018556,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,77,176
Cohort,-0.00421359260303889,0.037465770162321624,-0.11246512709556931,0.9104829737267395,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,102,115
Cohort,-0.010780461633067019,0.03946449580041175,-0.27316861433092327,0.7848070365130069,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,50,96
Cohort,0.06376581744882813,0.10552628605776818,0.604264774502922,0.5458319605159467,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,50,135
Cohort,0.0010695409030894293,0.03293288479404696,0.03247638066868538,0.9741002929120249,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,72,89
Cohort,-0.05653935324953783,0.12549219474888157,-0.45054079548673864,0.6524650077981256,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,492,991
Cohort,-0.18240660352106253,0.35315469544340233,-0.5165062389784807,0.6056378061472026,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,492,1402
Cohort,-0.05166227693057498,0.11030883953573221,-0.4683421305854648,0.6396681611378441,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,786,927
Cohort,0.0178719780154663,0.04271097077935037,0.4184399860119061,0.6757583563444913,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,51,118
Cohort,0.04714159667670356,0.13240981937882698,0.3560279509318759,0.7219096721318227,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,51,200
Cohort,-0.03745535326318465,0.03622571146534749,-1.0339438964232186,0.30147640996923414,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,100,97
Cohort,0.10456954855712977,0.07289022864775761,1.434616827208248,0.15185876305500684,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,145,351
Cohort,-0.16349220000820136,0.19060265863681983,-0.8577645305552869,0.3912689256784314,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,145,463
Cohort,0.08775380786257547,0.061755274967639655,1.4209929096511884,0.15571043447557892,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,222,304
Cohort,-0.11742824976899804,0.11177296951343586,-1.0505961350063477,0.29381954037489594,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,405,811
Cohort,0.14926031099515838,0.309887812544942,0.48165918423626825,0.6301744344008735,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,405,1133
Cohort,0.02590466688150154,0.09211478610080265,0.28122159294984045,0.7786135284949894,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,612,779
Cohort,0.0037945719154725576,0.06904110197165428,0.05496105663305415,0.9561857282711063,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,141,317
Cohort,0.02158053702462429,0.1819860881304282,0.11858344363750302,0.9056339379224927,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,141,425
Cohort,0.060498011293897,0.05741930099932195,1.053618038551382,0.2923775377720114,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,217,286
Cohort,0.0031386903951656168,0.06768244554005778,0.04637377343742679,0.963026035702498,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,137,288
Cohort,0.08044101436409548,0.17788466627605312,0.452208816240866,0.6512361487285421,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,137,384
Cohort,-0.009457205642459205,0.053609598258092105,-0.17640881390174729,0.8600176521031901,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,211,244
Cohort,-0.13198407816645127,0.06771496321044361,-1.9491124547505552,0.051695237735481556,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,163,273
Cohort,-0.20394234156138724,0.1802994681427671,-1.1311311323442115,0.2583250565380442,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,163,374
Cohort,0.05295290575322902,0.0547995673579932,0.9663015294865313,0.3341868056292807,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,197,263
Cohort,-0.029466638487626717,0.04531040848818447,-0.6503282462198656,0.5157011661043269,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,71,137
Cohort,0.066160493103426,0.125330948324648,0.5278863200815234,0.5977186561892917,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,71,195
Cohort,-0.03243095356756861,0.036923530983207574,-0.8783275245890719,0.3800310423347506,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,105,118
Cohort,-0.24536023480513058,0.15032497523876037,-1.6321987375379654,0.10310332672486947,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,733,1484
Cohort,0.8127925708736772,0.4150429235769502,1.9583337642979546,0.05052384685493129,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,733,2032
Cohort,-0.08008683345429851,0.1300048193455975,-0.6160297276472512,0.5380510112463393,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,1153,1370
Cohort,0.16465230936214248,0.07233323895116933,2.2763021779419534,0.023139793807375898,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,150,390
Cohort,-0.46781724518652656,0.18643706627315554,-2.509250196530721,0.012287324731712243,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,150,496
Cohort,0.09719389177172097,0.06388677291108685,1.5213460837502097,0.1285701334961973,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,256,343
Cohort,0.054219352862027295,0.041962872820958716,1.292079145614334,0.19677126416436969,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,47,125
Cohort,-0.12019296849513351,0.11391987244476108,-1.0550658626607419,0.2917007460069674,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,47,163
Cohort,-0.04861804476029563,0.03778011943948941,-1.286868476902642,0.19851423409138236,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,110,118
Cohort,0.0013331941105048423,0.051004874822362656,0.026138562542267325,0.9791545331570122,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,77,163
Cohort,-0.037130207766276346,0.13929771172277966,-0.2665528909776367,0.7898793196854191,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,77,238
Cohort,-0.0010212553182446203,0.04091063265190463,-0.02496307810573726,0.9800906703362395,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,115,134
Cohort,0.04475832246688378,0.07191742618043719,0.6223571232177777,0.5339169289490007,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,159,361
Cohort,-0.282880922116746,0.1912650430833012,-1.4789995994905538,0.13951800996266908,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,159,479
Cohort,0.013395803439246465,0.06382274589746037,0.2098907411594071,0.833806657699295,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,252,312
Cohort,0.005717003782765069,0.04371310518934806,0.1307846641871184,0.8959845648978153,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,60,129
Cohort,-0.03138572605774251,0.12946287082239796,-0.24243032661309225,0.8085063415724455,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,60,205
Cohort,-0.06630542068265638,0.0411754825850161,-1.6103131407325668,0.10772596630553147,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,127,134
Cohort,-0.03442305018410609,0.0772241956591118,-0.44575472609722755,0.6559171526379133,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,182,382
Cohort,0.19453699108082034,0.20021922770372713,0.9716199253784206,0.33152136968523793,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,182,479
Cohort,0.08102579497651563,0.0628741714487716,1.2886976179484695,0.19787764409653338,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,252,329
Cohort,-0.057591812270742664,0.046555225323429796,-1.2370644083588722,0.21649273161364163,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,78,133
Cohort,-0.07328496922597587,0.1303882021361264,-0.562052149085281,0.5742315080174965,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,78,201
Cohort,-0.05064551170294974,0.04131460341386173,-1.2258501236383001,0.22061762345011007,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,129,141
Cohort,0.05368363669694154,0.07078052953043483,0.7584520355115199,0.4484447594782299,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,144,319
Cohort,-0.22852761254165818,0.18526717087040034,-1.2335030079426201,0.217735677345297,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,144,393
Cohort,-0.062058594368373014,0.06185112794735424,-1.0033542867835064,0.31599485714896813,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,258,290
Cohort,0.024540661451566876,0.043593997009665576,0.5629367145693424,0.5736646276008006,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,56,128
Cohort,-0.25259022074248655,0.12765328511504276,-1.9787208806639722,0.04817604084326469,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,56,182
Cohort,-0.03431512819108303,0.03899391398968124,-0.880012409120143,0.3791181853873471,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,101,105
Cohort,-0.027627246995131784,0.04191903689163399,-0.659062064487591,0.5100803449196529,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,62,108
Cohort,-0.08907970821041229,0.12607230826637225,-0.7065763246136493,0.4800271559784324,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,62,179
Cohort,-0.00587887155466921,0.03839490092737916,-0.15311594541651816,0.8783456468566818,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,91,113
Cohort,-0.22594068562628472,0.07602289699036127,-2.9720083628874483,0.0030636923830971944,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,207,336
Cohort,-0.03901552169621602,0.21986241679746277,-0.17745425645965274,0.8591946814363106,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,207,561
Cohort,-0.09267916003932969,0.06372509354975757,-1.4543589483625368,0.14624099752323463,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,282,297
Cohort,-0.014409924705365246,0.049283350008598494,-0.2923893100377945,0.7700786969215867,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,79,152
Cohort,-0.24030714526703437,0.12541651109032212,-1.9160726381071997,0.0556974349662951,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,79,180
Cohort,-0.03757410948170734,0.04119889239068464,-0.9120174670084847,0.3620356422171568,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,116,124
Cohort,-0.03526995331816841,0.04366817609893116,-0.8076809353856135,0.41955838887124286,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,67,128
Cohort,-0.06058655254877936,0.1231817835366065,-0.49184669038969203,0.6229571536112981,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,67,188
Cohort,-0.029238381073010536,0.042456602185782365,-0.6886651207995567,0.49123469122222974,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,128,144
Cohort,-0.08266616793679638,0.04994524507943913,-1.6551358954253568,0.09836108013335121,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,98,173
Cohort,0.03130597292876994,0.15690586506428245,0.19952073121004277,0.8419040626421258,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,98,306
Cohort,-0.07384872419610344,0.04374769101627433,-1.688059929120177,0.09179143609260963,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,151,157
Cohort,-0.08295169773068667,0.07505103646387987,-1.1052705150928754,0.2694356053536699,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,186,361
Cohort,0.022330959748230732,0.2158530947186679,0.10345443403225599,0.9176271829602058,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,186,522
Cohort,0.07512049098116719,0.06539335579547757,1.148748065722639,0.25100495265181016,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,265,355
Cohort,-0.11080223142811213,0.06404316618915316,-1.730117950459458,0.08406560957802672,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,141,260
Cohort,-0.05894834880137323,0.17328688565717015,-0.34017778424384826,0.7338083067476893,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,141,344
Cohort,0.062490239202710074,0.05293517978662292,1.1805049015532347,0.2381520956225081,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,186,237
Cohort,-0.08789147061847516,0.039603917092041696,-2.2192620597152173,0.026800097881004667,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,68,98
Cohort,-0.20214210537006183,0.10651434382894023,-1.8977923357881052,0.05806852738621461,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,68,119
Cohort,-0.015439383715144727,0.03366142906882696,-0.4586669117219022,0.646598583221665,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,84,90
Cohort,0.009253780184953991,0.0679716590187022,0.13614174375834848,0.8917497596163626,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,134,291
Cohort,0.07045105138670549,0.1870864736889314,0.3765694547423264,0.7065893733800996,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,134,381
Cohort,-0.03853593477535034,0.05724748636059382,-0.6731463200430834,0.5010495897577958,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,223,253
Cohort,-0.07365045417271072,0.09108591288559366,-0.8085822696339188,0.41903993479521273,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,251,496
Cohort,-0.17821442268055573,0.25001313399084624,-0.7128202420240879,0.47615638318381603,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,251,677
Cohort,0.005467401930793692,0.07994974827718933,0.0683854802373857,0.9454959539297021,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,392,487
Cohort,-0.034772873957398455,0.04842523796852905,-0.718073372814335,0.47296013387013913,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,75,143
Cohort,0.021041109620728294,0.12868918358732737,0.16350332665254635,0.8701617661089625,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,75,207
Cohort,-0.024476831111478883,0.04055464124065017,-0.6035519083064751,0.5463135392755538,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,118,128
Cohort,-0.048025009857198396,0.04652290113040765,-1.0322875119627688,0.3023066175078971,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,75,144
Cohort,0.03048697681380832,0.13702078260652986,0.22249892486277065,0.8239799866236578,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,75,234
Cohort,0.027782807869283752,0.04007687842832589,0.6932378208789628,0.4883625357742145,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,96,132
Cohort,-0.027580559830252236,0.041422465467710425,-0.6658357854568505,0.5057432023491065,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,65,113
Cohort,-0.12092567400736304,0.12557519860998098,-0.96297418077706,0.3358396003273495,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,65,187
Cohort,-0.00918363990707943,0.03715068678597489,-0.24719973442177204,0.8048173939940816,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,96,110
Cohort,-0.027308485250545012,0.0405241716356761,-0.6738813934571226,0.5006170718792438,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,58,101
Cohort,-0.24690144635033212,0.1253971680737013,-1.9689555206319933,0.04928891812362143,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,58,179
Cohort,-0.039958076136892826,0.04265006745915615,-0.9368818976701195,0.3491034687970238,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,115,122
Cohort,-0.024685616393277463,0.03987602075270831,-0.6190591720865443,0.5360859385062784,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,60,104
Cohort,-0.28792195532857445,0.12551028181926466,-2.2940109061597305,0.022037649075312724,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,60,178
Cohort,-0.043117671568130976,0.039901724899593656,-1.0805966828910214,0.28020384245347757,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,112,122
Cohort,0.06617067651720025,0.07137881785661986,0.9270351976144897,0.35423911185489265,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,151,330
Cohort,-0.15772681360714583,0.2032370452492664,-0.7760731485428598,0.4379258184562509,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,151,506
Cohort,-0.007343888598312943,0.06259043875280709,-0.11733243518737245,0.9066262211415868,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,270,310
Cohort,-0.07593114395889883,0.04741789539532713,-1.6013183066404415,0.10977360886994078,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,79,132
Cohort,-0.026244985307296957,0.12634221965713938,-0.207729335280947,0.8354910243229614,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,79,171
Cohort,-0.07599904612676296,0.04180806595583878,-1.8178082240646958,0.06946924121464391,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,132,128
Cohort,-0.12427868741970118,0.058183222693133745,-2.1359883771850168,0.03303896788043537,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,120,199
Cohort,0.05424305733489867,0.17159817898045804,0.3161050872286703,0.7520018387432166,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,120,328
Cohort,0.0309732442599755,0.051851379536139885,0.597346580497197,0.5504458904924322,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,165,214
Cohort,0.017500836492449764,0.05853001530891154,0.2990061834100556,0.7650272248660988,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,117,252
Cohort,-0.10312406885924791,0.16106724786118368,-0.6402547397353292,0.5221828559136584,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,117,360
Cohort,-0.01646394026811972,0.052627746119435145,-0.3128376470988499,0.7544859544239804,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,199,230
Cohort,0.01902843660201147,0.06731006002629282,0.28269825631679035,0.7774946912109639,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,139,300
Cohort,0.08031247956347927,0.18130734729265935,0.4429631824784351,0.6579072354854825,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,139,363
Cohort,-0.03327422534326338,0.0553356839546731,-0.6013158773011492,0.5478008163881685,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,225,257
Cohort,0.0551360998478769,0.035117390392785025,1.5700511692692514,0.11687113305716003,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,33,91
Cohort,-0.1671911605961188,0.09358740905241676,-1.786470661907926,0.07438623970415582,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,33,110
Cohort,-0.041408262145859916,0.030765260420005807,-1.3459421952083739,0.17870436019147096,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,74,77
Cohort,0.026690251370617597,0.04744018597637221,0.5626084894336374,0.5738880323102835,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,60,153
Cohort,0.012112483920491135,0.12956667570816507,0.09348456193916092,0.9255410665218344,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,60,211
Cohort,0.007544911751979832,0.04211340991664915,0.17915698982610812,0.8578600256700933,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,104,124
Cohort,-0.0025803499228058617,0.051537552416366976,-0.05006737421209802,0.9600834881244349,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,97,191
Cohort,-0.16209166950469855,0.14324693040901723,-1.1315542262711904,0.25814714992247473,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,97,250
Cohort,0.010157884170283168,0.04782517630503941,0.21239616777351678,0.8318523515993974,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,145,186
Cohort,0.03816391974576916,0.07808167560189577,0.4887692208393459,0.6251636161128662,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,160,370
Cohort,0.11401434494221793,0.20239372500565692,0.5633294458068363,0.5733619893352901,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,160,475
Cohort,0.04882358256232047,0.06381479412152295,0.7650825053097466,0.4444491851194404,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,276,353
Cohort,-0.035522009120982787,0.0356319083202344,-0.9969157082953876,0.31916213371793223,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,48,86
Cohort,0.02544218279270962,0.09673896614096963,0.2629982912535456,0.7926168529515538,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,48,126
Cohort,-0.031529594331417735,0.028920353071896842,-1.090221625338883,0.2759454459986323,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,63,57
Cohort,-0.022245435194432728,0.021025342079783547,-1.0580296439420283,0.29041985046638863,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,19,24
Cohort,-0.24089977875421326,0.05917443045835191,-4.071011362310671,5.126374842540065e-5,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,19,31
Cohort,0.01810182273839377,0.019904137756079292,0.9094502339276141,0.36338779819911227,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,22,32
Cohort,-0.021409088142973105,0.05217249575442719,-0.410352003165507,0.6816777724458584,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,88,167
Cohort,-0.2634560672582311,0.1442466676304542,-1.8264274078981129,0.06814325341673692,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,88,238
Cohort,0.03517775093795992,0.041841028803660446,0.8407477527149716,0.4007417374259672,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,118,153
Cohort,-0.06400571787043789,0.07225967321167157,-0.8857736968024307,0.3760544616042424,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,180,334
Cohort,-0.4447858084177475,0.21479707090984018,-2.0707256692734126,0.03869159254389138,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,180,548
Cohort,-0.0018739967100386975,0.06712817650363805,-0.02791669322251194,0.977735591685968,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,294,354
Cohort,-0.10200565340650226,0.04602481058021085,-2.216318809802149,0.02700186045572878,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,82,124
Cohort,-0.09512371738256144,0.1267749025751878,-0.7503355589340355,0.4532642582815015,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,82,190
Cohort,-0.06736392081142197,0.04003425766374046,-1.6826569229091595,0.09283368700603116,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,118,115
Cohort,-0.09752416155881519,0.051294980260458964,-1.9012418186656805,0.05769531510911418,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,93,148
Cohort,-0.11386279276356608,0.14230088639947214,-0.8001551897851596,0.4238487441918436,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,93,243
Cohort,-0.08048286879446513,0.04201365194847782,-1.9156361102139579,0.05576941626130706,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,142,137
Cohort,0.05683209035770367,0.059061323199039714,0.9622556231288043,0.3362652829390427,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,94,228
Cohort,0.19216168910435424,0.1695549525912305,1.1333298506922704,0.2574014463975507,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,94,324
Cohort,-0.05214349075349503,0.04927992054812459,-1.0581082553202172,0.2903270814592114,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,167,185
Cohort,-0.030602328237183233,0.07635311329911404,-0.4008000055911057,0.6886940187217477,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,209,429
Cohort,0.051061134573735664,0.21361924036930166,0.2390287245917641,0.8111420337909071,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,209,547
Cohort,-0.030550997901293453,0.06640961751757359,-0.46003875708528097,0.6456140323664339,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,321,374
Cohort,0.1284437447355564,0.0696582760434254,1.843912195809781,0.0656333856493507,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,120,325
Cohort,-0.08772655943852893,0.1792607762368113,-0.4893795579833835,0.624701687944681,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,120,403
Cohort,0.12160239068801933,0.05849970233725229,2.0786839219621736,0.03796617918235203,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,205,285
Cohort,-0.03541231221192327,0.07512544663559557,-0.4713757295007466,0.6375245327712207,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,187,388
Cohort,0.037784233229454504,0.20452359344864712,0.1847426626549155,0.8534757957749656,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,187,485
Cohort,-0.12278841468516162,0.06661352127703125,-1.843295660268598,0.06565744814726424,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,315,334
Cohort,0.003270682091403183,0.05047969512825351,0.06479203337289137,0.9483587395668978,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,86,182
Cohort,0.15240350581779763,0.14388782224239832,1.059182795615973,0.28982319926583633,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,86,247
Cohort,0.05032615531063446,0.044970780503937005,1.1190856539887852,0.26344117963413816,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,131,172
Cohort,-0.03147648137750359,0.047066241186215295,-0.6687698142914881,0.5038706307579243,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,80,150
Cohort,6.027080263857694e-4,0.13157694895971203,0.004580650571023003,0.9963462778317602,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,80,225
Cohort,-0.0063175855927007,0.04218486567001763,-0.1497595285029163,0.8809922770193306,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,113,145
Cohort,-0.05398291917240714,0.04963318825359382,-1.0876375480170442,0.2771427787022067,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,85,151
Cohort,-0.06820238520955109,0.13351533583157243,-0.5108206093687048,0.6096118628606522,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,85,201
Cohort,0.004841389544394164,0.03989356717952258,0.12135764953301181,0.9034383875177407,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,105,131
Cohort,-0.03561858472196127,0.04108521110484296,-0.8669441817170728,0.38628020873390856,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,62,124
Cohort,0.1993345275651106,0.132270784191719,1.5070185663690214,0.13218456852895216,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,62,212
Cohort,-0.06554985459182244,0.04230832460246097,-1.5493370443699765,0.12169819048664077,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,133,124
Cohort,-0.0045643858430729845,0.04801311927502161,-0.09506538862696981,0.9242910615345687,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,75,150
Cohort,0.032491516194724276,0.13178134713796566,0.24655626080911117,0.8053123307595942,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,75,213
Cohort,-0.08135766363736556,0.039841345211367354,-2.042041080835618,0.04147656725494443,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,125,116
Cohort,0.06290566097314633,0.07614018964160703,0.826182089501539,0.40899229791178404,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,160,364
Cohort,0.08378143268771335,0.209487435690418,0.3999353584695463,0.6893065369452076,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,160,551
Cohort,-0.0368634751974564,0.06858469384234983,-0.5374883685008718,0.5910805391441961,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,300,357
Cohort,0.017561358949052978,0.04213677418664102,0.41677036954149677,0.6769786821794916,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,50,112
Cohort,-0.0068971732843941215,0.11016892234046086,-0.06260543479838554,0.9500957021604375,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,50,142
Cohort,0.042147274969824726,0.035460203532156044,1.1885796123985783,0.23495961070943103,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,74,106
Cohort,-0.005470825385234934,0.04421462509967507,-0.12373338850893341,0.9015631546985161,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,56,127
Cohort,0.17182719229264654,0.12066709619127239,1.423977187785136,0.15482709883631232,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,56,171
Cohort,0.0013733300274876802,0.03487857634601322,0.03937460101190908,0.9686016026984987,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,85,101
Cohort,-0.04145469488778084,0.057572450140923076,-0.7200439582875148,0.47174681036766986,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,114,223
Cohort,0.040460183398269296,0.15668495923967307,0.2582263389836889,0.7962959405286778,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,114,328
Cohort,-0.013941834974511144,0.049748869379797354,-0.28024425777549067,0.7793629272008343,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,173,202
Cohort,-0.07166038073253793,0.08114628938526977,-0.8831011408581575,0.37749556225159797,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,211,423
Cohort,-0.23463955168519102,0.21999318570029933,-1.0665764529854334,0.2864717912607425,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,211,585
Cohort,0.046440113264519745,0.07088103363943703,0.6551839170511368,0.5125386392107987,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,319,418
Cohort,0.042013822981620694,0.05883727922252442,0.7140680795711696,0.47543155841947604,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,98,233
Cohort,0.22669910982864416,0.1552467032009622,1.4602507180792688,0.14459776806127697,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,98,286
Cohort,-0.015990180472030605,0.05056118786015285,-0.31625405076039415,0.7518925953887877,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,164,188
Cohort,-0.00438942855191878,0.007837954746583832,-0.5600221861234794,0.5756498295646122,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,3,3
Cohort,-0.01999541482221905,0.024945025991847558,-0.8015792338221607,0.42302471199562286,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,3,7
Cohort,0.006237098254852309,0.004493510660311619,1.3880234690307323,0.16551826126093402,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,0,3
Cohort,0.04012250581780667,0.027256686038592427,1.4720243598578961,0.14147968519263734,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,17,53
Cohort,-0.08648107497952967,0.07045608564450183,-1.2274464893761576,0.22000116540059664,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,17,65
Cohort,-0.002242434276811928,0.023380779672136913,-0.09590930278019161,0.9236167461446625,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,39,45
Cohort,0.041054638621282204,0.04984553532170156,0.8236372296198009,0.41043619306814794,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,63,135
Cohort,0.08806545891316908,0.12467011856295636,0.7063878652581651,0.48014425363739743,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,63,175
Cohort,0.010413016803192355,0.035707740237306114,0.2916179162834064,0.7706547533988547,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,90,106
Cohort,-0.16963272707054122,0.12903392085916715,-1.3146366935225138,0.18907786261812873,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,535,1078
Cohort,0.8766636576862401,0.34757835657230385,2.52220439250473,0.011847293674165264,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,535,1441
Cohort,-0.12307909605177778,0.11079856784040261,-1.110836524792129,0.2669741479564443,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,835,954
Cohort,-0.04091041528980867,0.039098370518163283,-1.0463457875003663,0.2957753964143824,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,55,97
Cohort,-0.01591845526303538,0.11092568035432876,-0.14350559051959133,0.8859255618761025,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,55,143
Cohort,-0.07898823301771442,0.03294060993300056,-2.397898313916235,0.016718818014074217,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,91,83
Cohort,0.020787301062356843,0.04512921437764598,0.460617392724955,0.6452212697139008,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,66,142
Cohort,0.04966508858222712,0.1380756285549582,0.3596948216133518,0.7191664236930917,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,66,213
Cohort,-0.005782248042887444,0.038632788927794905,-0.14967203257560635,0.8810612879905328,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,102,122
Cohort,0.12716100266914407,0.05812830859833463,2.1875916525943304,0.02904112414757481,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,88,234
Cohort,0.058735871566866556,0.15006515345011606,0.39140246897086106,0.6955997447772535,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,88,282
Cohort,3.12956559131879e-4,0.044706167728004786,0.007000299400206409,0.9944163687907743,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,146,167
Cohort,-0.0034714489199569403,0.01691540526243027,-0.20522410584316028,0.8374588167681487,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,9,20
Cohort,-0.026823244379199584,0.04103308217422562,-0.6536980153064945,0.5134865707464675,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,9,20
Cohort,-0.010281510402680652,0.01477407670092916,-0.6959155966771199,0.4866848209111069,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,18,16
Cohort,0.003923250487325682,0.028117762965107623,0.13952925388104984,0.8890734996127307,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,29,55
Cohort,-0.16364651167282993,0.0777603283544746,-2.1044987223669964,0.03563366908716951,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,29,68
Cohort,0.03489685313740755,0.02703726923150488,1.2906944424973352,0.19718440550143276,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,40,62
Cohort,-0.057873014803129535,0.03632455147463255,-1.5932203552064632,0.11157820563043165,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,53,88
Cohort,-0.21508253652601217,0.11346855725932317,-1.8955254364824476,0.05836833355529575,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,53,167
Cohort,-0.012671235295826047,0.03423802899299033,-0.37009242846369084,0.7114120714705139,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,71,86
Cohort,-0.023010588285311398,0.034401086970303855,-0.6688913145440692,0.5037931653709429,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,45,75
Cohort,-0.13835756201847993,0.09529664729966086,-1.4518618014274287,0.14691610317844073,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,45,106
Cohort,-0.04067381103280197,0.03033564086778311,-1.3407928716613382,0.18037020380534882,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,69,72
Cohort,0.022537846098160896,0.06169215181633809,0.3653276054506522,0.7149811496141747,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,125,270
Cohort,0.004013576498161563,0.17208047069788762,0.023323834958633872,0.9813975384704883,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,125,361
Cohort,-6.752105933991966e-4,0.054619226767028115,-0.012362141197626762,0.9901397872248938,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,202,248
Cohort,0.006205567857094691,0.04942866460375356,0.12554593385926607,0.9001286897883689,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,69,155
Cohort,-0.096137811004813,0.12365878728891755,-0.7774442327353229,0.4371171925537882,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,69,167
Cohort,0.012833562665619296,0.041395532965124396,0.3100228876490497,0.7566246983649456,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,108,135
Cohort,-0.06270558128144905,0.03532717090191514,-1.7749958369309922,0.07634849079963267,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,47,72
Cohort,-0.0765603910657885,0.09523073054025748,-0.8039462748153933,0.42165708973226634,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,47,108
Cohort,-0.03664408741199258,0.030418020598143542,-1.2046834965398445,0.22868356080093338,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,73,79
Cohort,0.052116117538134006,0.027466052416545123,1.8974738978776604,0.058191264364053585,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,16,55
Cohort,0.12987149908017334,0.07300842202927237,1.778856404102283,0.07562747864813134,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,16,74
Cohort,-0.020512510026918063,0.021982086515650635,-0.9331466333877689,0.35102722236914596,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,37,33
Cohort,-0.011096940661968415,0.02755055835695213,-0.4027846012481342,0.6872340345434977,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,30,53
Cohort,-0.057985989320716705,0.07901619842694724,-0.7338493938597468,0.46324677827541394,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,30,72
Cohort,-0.025982671544409496,0.026755098140742464,-0.971129741618973,0.3317786695923751,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,53,54
Cohort,-0.01446580597051152,0.03900140131451862,-0.37090477477604106,0.7108246600273862,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,51,101
Cohort,0.05008717374438683,0.10743390643735168,0.4662138370030726,0.6411841878537861,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,51,142
Cohort,-0.028117485138244976,0.035326738948719766,-0.7959264278273822,0.4263120907306972,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,86,93
Cohort,-0.04027152735443944,0.04314175276715889,-0.9334698933487845,0.35091069986921875,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,67,123
Cohort,-0.11941178105919889,0.12162246341781868,-0.9818234041928153,0.32647158397687337,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,67,161
Cohort,-0.04728672678007578,0.036005635841904096,-1.313314587408078,0.18945540136485728,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,93,98
Cohort,0.01786673449640147,0.028921209134791417,0.6177727360267341,0.5369332105659053,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,22,56
Cohort,-0.13597359254750072,0.07519745614177524,-1.808220643676294,0.07093225986040105,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,22,66
Cohort,-0.018892497723887573,0.024776053517766367,-0.7625305503291787,0.44596931306069787,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,48,49
Cohort,-0.012113099406140549,0.07570859830589467,-0.15999635017938804,0.8729317440815156,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,170,352
Cohort,-0.17496557700144902,0.20404937383647367,-0.8574668655521943,0.39143325074124113,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,170,462
Cohort,0.1024318215623574,0.06450326427313562,1.5880098893695573,0.11268120988222093,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,243,328
Cohort,-0.026154133238798314,0.08134666112517001,-0.3215145265588017,0.7479198907633084,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,198,408
Cohort,0.19415740434078577,0.21729505253346929,0.8935196732603026,0.3718367004062618,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,198,542
Cohort,-0.04096278115478524,0.06833917706084545,-0.5994040741566763,0.5490740244127864,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,300,345
Cohort,-0.17647643478477334,0.10684495953852635,-1.6517057570800908,0.09905895085165188,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,369,693
Cohort,0.012079829449613602,0.2756573692644797,0.04382189919988534,0.965056860345705,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,369,945
Cohort,-0.11644144018545807,0.08843100217857534,-1.316749073478995,0.18830171692802178,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,552,627
Cohort,-0.024482355512605247,0.03111093820269498,-0.7869372293788449,0.4315944074709718,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,35,63
Cohort,0.026287377270159628,0.10035923499202183,0.26193281836244936,0.7934379151718076,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,35,125
Cohort,-0.038523660631908076,0.030630561412730937,-1.2576870568195508,0.20887379163047165,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,68,73
Cohort,0.0242722342791975,0.07400247165466353,0.3279922107529755,0.7430191122819786,LGP Offspring,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,170,357
Cohort,-0.5057951377844461,0.20533713673985074,-2.4632423818456997,0.013969633624462106,LGP Proband,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,170,514
Cohort,-0.04037646188825126,0.06533227268902476,-0.6180171028251118,0.5367408414932376,LonGen OPEL,"descartes DE_gene_by_organ.csv, fold.change>5, qval<0.05, pval<0.05",,C8,293,342
Cohort,-0.012683963522045866,0.037625188138857006,-0.33711362386376054,0.7361358859389381,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,49,95
Cohort,-0.09543800180494418,0.11653136313535972,-0.8189898344713082,0.41302617286954235,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,49,143
Cohort,-0.04382395492335929,0.03732604764285917,-1.1740850609920719,0.24071210156274891,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,101,99
Cohort,-0.1267498568744047,0.04972093285178565,-2.5492252378336597,0.011016002818696647,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,101,156
Cohort,0.09939304963061364,0.1358677390524857,0.7315426776345937,0.464653239273938,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,101,224
Cohort,-0.07367702039678643,0.045240527203845256,-1.6285623742802935,0.10380137744494712,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,152,154
Cohort,0.061232697744052114,0.04173025995329179,1.4673452265236109,0.14274724388895876,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,43,123
Cohort,-0.07983780454329836,0.10873445359362714,-0.7342456958644946,0.46300538279064074,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,43,170
Cohort,0.055759874813027695,0.03977369060992093,1.4019286105453654,0.16132638542634026,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,88,125
Cohort,-0.03633378194032055,0.02867216789313126,-1.2672143269998333,0.2055150360982623,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,33,51
Cohort,0.07610033765053803,0.08084284277430885,0.9413367348175694,0.34680489763596145,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,33,79
Cohort,-0.001318357146480154,0.02477414527075839,-0.053215040602682166,0.9575739239220671,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,46,52
Cohort,-0.058198436811199974,0.05525995218245695,-1.0531756636169491,0.2926367834376699,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,109,203
Cohort,0.0048770614589877664,0.1578975887994262,0.03088749800469081,0.975366650212925,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,109,288
Cohort,-0.07677952942666848,0.04959002025566352,-1.5482859057291822,0.12195094394356006,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,177,176
Cohort,-0.021771624389005997,0.04046993759555254,-0.5379702980169309,0.590774620437875,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,52,101
Cohort,-0.006885071878229875,0.10673221006580265,-0.06450791072334287,0.948581266677581,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,52,133
Cohort,-0.003382013185175459,0.03164837368495414,-0.10686214776284987,0.9149252690070035,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,76,78
Cohort,0.050214094477871445,0.03514735787266741,1.4286733773784115,0.15356001263664884,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,36,94
Cohort,0.099119262763799,0.0968527182747557,1.0234019708420932,0.3064145781445179,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,36,131
Cohort,-0.016108339676418507,0.030164823267058383,-0.5340107427053844,0.5934831976866458,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,67,69
Cohort,0.0054342040630627145,0.03702812132893251,0.146758838094673,0.883366130845973,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,45,96
Cohort,0.005424555603421072,0.1022473980321076,0.05305323859407806,0.9577021940071923,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,45,142
Cohort,-0.030503649035083288,0.029986905104429598,-1.0172323195359483,0.3093520018090365,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,71,77
Cohort,0.029976600306954666,0.040026920491663835,0.7489109813780881,0.4541713627296362,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,42,110
Cohort,0.13469322939167674,0.11379516646318912,1.1836463144965637,0.23689035805548045,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,42,161
Cohort,0.0054479844785560215,0.03721055963886591,0.14640963563648415,0.8836350912328608,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,91,103
Cohort,-0.010920644447099767,0.07581533693339429,-0.1440426817161524,0.8855096954507252,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,172,342
Cohort,-0.24635671123036612,0.20520562844767756,-1.2005358385829124,0.23027217853376494,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,172,479
Cohort,0.0840400559010029,0.05929169498251585,1.4174001253596298,0.15675726976208934,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,242,326
Cohort,-0.010504650159664975,0.017002276519693573,-0.6178378611533308,0.5368903016685861,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,11,18
Cohort,-0.010391187961778785,0.046700571488992704,-0.22250665528210894,0.8239739714254235,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,11,26
Cohort,-0.016157758672124496,0.01167309632373578,-1.3841878987385476,0.1666888664684574,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,13,8
Cohort,-0.3282786827027355,0.1657846540497977,-1.9801512063000026,0.04809160568837234,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,849,1672
Cohort,0.8630718303958819,0.45508723198708007,1.8964975717455077,0.0582396075338284,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,849,2323
Cohort,0.05853321951134837,0.14139522806093283,0.4139688468561618,0.6790084382657811,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,1304,1599
Cohort,0.0417659630057526,0.05733418365041541,0.7284652949872426,0.4665810748956022,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,85,199
Cohort,-0.08592019811728158,0.1564780620050376,-0.5490878211062934,0.583092158388216,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,85,273
Cohort,-0.04610054748653348,0.05026175512668306,-0.9172092651826146,0.3593108010390754,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,189,211
Cohort,0.014418136057403325,0.0789571902004566,0.18260700540126296,0.8551611358617551,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,198,444
Cohort,0.1989237507743843,0.22103133609821232,0.8999798593534953,0.36839075447627545,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,198,570
Cohort,-0.04426573348519567,0.0691346440583107,-0.6402829447976954,0.5221729250104292,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,327,384
Cohort,-0.052770817900178964,0.04764092660550891,-1.107678243480614,0.26839476464435646,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,78,144
Cohort,-0.2138596130510699,0.13727712552128998,-1.557867796539074,0.11964395894903855,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,78,225
Cohort,0.022364674747208598,0.04059889704553489,0.5508690229225892,0.5818780351107403,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,106,140
Cohort,0.005376737545239503,0.042560924378998596,0.1263303751901737,0.8995079768385279,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,60,130
Cohort,0.09047814442741998,0.12373146181930071,0.7312460638310054,0.4648342644525162,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,60,207
Cohort,-0.02345265836706299,0.041289559408001206,-0.5680045683054266,0.5701920461269301,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,127,135
Cohort,-0.04926708111991567,0.04896349716842692,-1.0062002097285754,0.31467929479024975,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,82,161
Cohort,0.07166233973852228,0.1411908547026362,0.5075565261606442,0.6118985765582587,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,82,236
Cohort,0.0710757303326635,0.04234305625840804,1.6785687338889248,0.0936286154189801,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,118,163
Cohort,0.0028717227257642687,0.04240476924610101,0.06772169208368738,0.9460272061314423,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,49,105
Cohort,-0.00462044678155471,0.10808084958686973,-0.04274991174862145,0.9659111245494267,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,49,143
Cohort,0.06580486596820677,0.033719567469369056,1.9515335132333498,0.051344000378690566,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,69,105
Cohort,-0.01273665575518417,0.01510725907987705,-0.8430818381972057,0.3994808787345402,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,10,13
Cohort,0.03335902764002382,0.04394959824711378,0.7590291827574225,0.4480495637390388,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,10,23
Cohort,-0.010834100958033395,0.01377912398854391,-0.786269211819341,0.4319437867713458,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,13,14
Cohort,-0.07696833547995396,0.03748309605759296,-2.0534145675077573,0.04041660424332289,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,60,92
Cohort,-0.038961138851057814,0.10667231695255432,-0.3652413293730832,0.7150238753895898,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,60,136
Cohort,-0.024897958244050004,0.031481030412251,-0.7908876525960484,0.42924512947056803,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,78,78
Cohort,0.07393210713166103,0.028724807949349604,2.5738068383964605,0.010270515900143233,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,15,68
Cohort,0.12816091286808623,0.0804535437909403,1.5929803316198752,0.11154350759062194,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,15,98
Cohort,0.010857169394591911,0.02665887528586263,0.4072628450439369,0.6839244436204255,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,49,64
Cohort,0.004547568076641218,0.08587827718247269,0.0529536481848445,0.9577844835408458,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,224,460
Cohort,-0.7032333052386308,0.2216262590391232,-3.1730594934352547,0.0015636817107527803,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,224,628
Cohort,-0.04144745113489683,0.07044304676430677,-0.588382431463741,0.5564425315154828,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,352,404
Cohort,-0.0031350565648193317,0.004537193003992037,-0.6909683061886415,0.48982265364759947,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,1,1
Cohort,-0.012788131689896634,0.022262060730400046,-0.5744361155404517,0.565827622396611,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,1,7
Cohort,0.009457850846638041,0.008936622325648784,1.0583250026683226,0.2902283497359871,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,4,8
Cohort,-0.11884240327879579,0.060552968402439344,-1.9626189502215763,0.050100202759849555,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,132,221
Cohort,-0.05667614990613267,0.17552203088870386,-0.32290049071999544,0.7468515411621149,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,132,341
Cohort,0.0362485394416064,0.0513184588374248,0.7063450513282284,0.48018027326133395,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,176,226
Cohort,-0.04992088600399763,0.025714054638478836,-1.9413852348783374,0.05262677692133588,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,26,38
Cohort,0.0010856308260822497,0.06374770123014727,0.01703011724552725,0.9864166623062153,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,26,41
Cohort,-0.010369270891924246,0.023238376480012538,-0.4462132240969121,0.6555645845740006,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,36,42
Cohort,0.036072829434708166,0.03240191915742434,1.11329298920378,0.26597832141595246,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,29,79
Cohort,0.08386642241538968,0.07977672219409766,1.0512643301054878,0.2934417097069013,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,29,79
Cohort,0.014981801691013236,0.02645075754419034,0.5664035015248116,0.5712791692766899,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,47,64
Cohort,0.007073040288001352,0.02332185884662492,0.3032794398815661,0.7617702240339169,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,16,39
Cohort,0.06140509186239377,0.06371529301996283,0.9637418106694535,0.33545473664998726,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,16,51
Cohort,0.022276993080870645,0.020360557476059978,1.0941249082724782,0.2742311728341666,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,24,41
Cohort,-0.010188809746574724,0.036797125760320765,-0.2768914564941799,0.7819480960162479,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,48,98
Cohort,0.1047944874873191,0.10523856967389558,0.9957802335403021,0.3196457559069552,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,48,143
Cohort,0.037449749380027444,0.03583492432012894,1.0450628846170449,0.29631115870961944,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,85,112
Cohort,0.09310538767408662,0.060605407481705606,1.5362554521589757,0.12494363402469691,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,113,268
Cohort,-0.41217437631300696,0.17024860479542706,-2.4210147085098352,0.01568976836765351,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,113,366
Cohort,0.05402800997703349,0.052736531921361574,1.0244892488872366,0.3059154805137486,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,191,247
Cohort,-0.03128688789706436,0.02680459936665549,-1.1672208738916936,0.24353273629188096,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,26,43
Cohort,-0.07506264146756507,0.07695880910582094,-0.9753612658474409,0.32966390584852523,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,26,66
Cohort,0.030599037926718115,0.023475178638872767,1.3034634750786893,0.1927934481508356,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,29,50
Cohort,-0.10192853939456459,0.059170431522625556,-1.72262626402495,0.08541348936061191,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,126,216
Cohort,0.0139718684468589,0.16694658452029565,0.08369065163570534,0.9333224733164998,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,126,339
Cohort,-0.030703506849511862,0.05186892269444331,-0.5919441787982442,0.5540560539008692,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,205,228
Cohort,0.0014825581815007028,0.024088669589019344,0.06154587226255604,0.9509426744474908,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,18,37
Cohort,-0.00524623497519605,0.0660070713810635,-0.07947989306947377,0.9366699904285339,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,18,57
Cohort,0.005571399194469785,0.02398121104406505,0.23232351294654963,0.8163464683990348,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,37,47
Cohort,0.0017411861724797022,0.008486607366594328,0.20516869666122417,0.8375020885561655,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,2,5
Cohort,0.01583810204490548,0.024893526041232607,0.6362337749450159,0.5247986247415583,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,2,8
Cohort,0.0014763561531620994,0.006345553845129369,0.23265993626313647,0.8160852895088349,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,2,4
Cohort,0.038666829483516144,0.060900169700807284,0.63492153919242,0.5256944202316667,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,114,261
Cohort,0.1444754728748587,0.16969116724062946,0.851402434341124,0.39479023197539376,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,114,346
Cohort,0.019487549927014416,0.05108754762960282,0.3814540104430909,0.7029681871159079,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,174,219
Cohort,-0.08035395786270726,0.04174886202116793,-1.9246981587657497,0.054686493453943726,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,59,90
Cohort,-0.009879034031908972,0.11021137555080376,-0.08963715390118751,0.9285970799316888,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,59,132
Cohort,-0.00484766900951009,0.03428165194158809,-0.14140710073627577,0.8875841238263805,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,80,100
Cohort,0.04130571219878017,0.07912849066736921,0.5220080890006626,0.6018356974413734,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,174,384
Cohort,0.02506452987906342,0.19841325433331672,0.12632487664839784,0.899505212487477,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,174,495
Cohort,0.08296799146099437,0.061184006129122705,1.356040519574654,0.17547081772677028,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,256,334
Cohort,6.864344827108038e-4,0.00956911501551824,0.07173437476690504,0.9428345168849677,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,3,6
Cohort,-0.03766119708809068,0.030402833131456704,-1.2387397228820762,0.21579042900289916,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,3,12
Cohort,-0.0068355997788028785,0.010567522613350686,-0.6468497895776433,0.5179156387640242,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,9,8
Cohort,0.06400924930575483,0.04951434914152649,1.2927414055832114,0.1965421704765384,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,75,182
Cohort,-0.031686489471215225,0.1331895841907848,-0.2379051610058827,0.8120130870833309,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,75,231
Cohort,-0.027339961525314024,0.04527547212648985,-0.603858120991695,0.5461100206679788,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,139,157
Cohort,0.03240848549125816,0.04578955159279892,0.7077703179857056,0.479331844717405,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,62,140
Cohort,-0.03125946264460798,0.12442097333146983,-0.2512394961043237,0.8016908386092818,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,62,206
Cohort,0.03371114755785934,0.038744290907550875,0.8700932903456332,0.38451172703158565,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,91,121
Cohort,0.062497938270188985,0.07271514147841986,0.8594900181654312,0.39037490872687275,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,177,399
Cohort,-0.28828048340720963,0.20143910691201203,-1.431104852610023,0.1527747586982154,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,177,527
Cohort,-0.037348012878614355,0.06440856199857836,-0.5798609954906105,0.5621724462123171,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,290,337
Cohort,-0.01613611381526299,0.02651363246360198,-0.6085968732279409,0.5429961182549767,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,24,42
Cohort,-0.03432492985471985,0.07819125777905508,-0.4389867976252761,0.6607848070412159,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,24,70
Cohort,0.0031643011607090698,0.023853000954729687,0.1326584091752043,0.8944970631875129,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,40,51
Cohort,0.03763345565427264,0.03025535799229267,1.243860861400466,0.2139819240429828,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,27,67
Cohort,-0.04119839547432145,0.07870603199942273,-0.5234464808824769,0.6008026366448723,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,27,81
Cohort,-0.0166318161975088,0.026640324918427948,-0.624309810350851,0.532603028402928,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,48,54
Cohort,-0.005282165214427159,0.0333400137887327,-0.15843320425417082,0.8741627675982947,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,35,70
Cohort,-0.010531926002446339,0.09370829360070738,-0.11239054301130541,0.91054079837897,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,35,105
Cohort,0.03932092669767845,0.027264919428163614,1.4421801906027802,0.14964487694641415,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,43,73
Cohort,-0.10477741590078764,0.059703122918332636,-1.754973789965924,0.07971676802454633,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,123,223
Cohort,0.2305752192995115,0.1605035693512929,1.436573779831982,0.15121414525929733,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,123,336
Cohort,0.03054783404096423,0.05461378492565178,0.5593429219848135,0.5760850470963096,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,205,249
Cohort,-0.050995152850924784,0.039791905749584,-1.2815458795023384,0.2004413909694014,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,62,110
Cohort,-0.012893489828259464,0.11754087294234782,-0.10969367085255138,0.9126787083610485,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,62,173
Cohort,0.04107769709871184,0.035409774578067044,1.1600666083922355,0.24636951181503564,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,79,110
Cohort,0.053994250520159104,0.04680447908268183,1.1536128930048828,0.24906661520037984,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,55,147
Cohort,-0.13044340755981543,0.12035707334367086,-1.083803418743357,0.27876518644571474,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,55,180
Cohort,-0.022435860863209752,0.039342513988063085,-0.5702701375417193,0.5686554166983969,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,105,106
Cohort,0.03659544175868018,0.03259249119300623,1.1228181835493727,0.26191333906089015,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,31,82
Cohort,0.013854332333042544,0.08897579338487027,0.15570900585415154,0.8763000772252558,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,31,105
Cohort,0.008263602726414729,0.0286370951238372,0.2885628828859879,0.7729910286601507,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,50,73
Cohort,0.0036125213524516933,0.0394773691566721,0.09150866508137456,0.9271155306609988,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,53,108
Cohort,-0.11010086307116507,0.1105709104492747,-0.9957489056009422,0.3196609718849539,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,53,145
Cohort,0.001998248325990706,0.03646914085182572,0.054792854433001255,0.956317242231199,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,94,106
Cohort,-0.1310365018939457,0.06186964775044114,-2.1179448511247,0.03454409907495722,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,145,244
Cohort,-0.27245919880164987,0.17432546669129634,-1.5629339991048659,0.11844746863070088,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,145,345
Cohort,0.010452050109660415,0.053024337762106036,0.197117975457866,0.8437855370286884,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,190,232
Cohort,0.09562395023479096,0.0456868123224802,2.0930317825596947,0.036718486332675764,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,51,151
Cohort,0.1354087628958132,0.12688314588667413,1.0671926673125975,0.2861936613040364,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,51,219
Cohort,-0.03538866903678613,0.04277102038475948,-0.8273982878696087,0.4082593216992131,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,135,153
Cohort,-0.008958594265913453,0.04106794461500807,-0.2181407993483945,0.8273852424400903,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,56,114
Cohort,0.059128193665084844,0.12661304742030483,0.466999214297424,0.6406224159121433,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,56,200
Cohort,-0.012564657252337406,0.037597370647180405,-0.3341897860423834,0.738324377722961,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,101,125
Cohort,-0.04995769299646263,0.09361851635110637,-0.5336304712317975,0.5937726337883885,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,262,517
Cohort,-0.13588609316751366,0.2578278875336381,-0.5270418745907964,0.5983046658614976,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,262,725
Cohort,-0.028749760592351972,0.0773543758761722,-0.3716630153977868,0.7102426744053756,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,415,509
Cohort,-0.19149240585336555,0.05781754789355131,-3.312011886182459,9.755847294898003e-4,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,135,199
Cohort,0.046613771006933355,0.15999359013727338,0.29134774066222946,0.7708578232634352,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,135,298
Cohort,0.04074500738029123,0.05160957842621308,0.789485375055813,0.4300634716157893,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,179,228
Cohort,-0.05573336929435267,0.06589279438611258,-0.8458188761546728,0.39795308056145184,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,140,275
Cohort,-0.015193145831618536,0.18961549450543447,-0.08012607762485936,0.9361562048796924,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,140,417
Cohort,0.023872725039971038,0.05355034839787336,0.4457996213693933,0.6558632210740759,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,213,266
Cohort,-0.06882945463715553,0.037842278768762914,-1.8188506843824408,0.06937653102844209,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,56,81
Cohort,-0.16635793840307958,0.11083751232827556,-1.5009172879157113,0.13375543297736148,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,56,133
Cohort,-0.014002598803248134,0.03311762501518951,-0.4228140996471153,0.6725450947260081,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,81,91
Cohort,-0.06263376911447037,0.05019866817795635,-1.247717746065116,0.21256647579343568,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,100,186
Cohort,0.025276121801094495,0.1634027704035704,0.15468600525356946,0.8771062892764395,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,100,320
Cohort,-0.0629932435368697,0.049202603751681166,-1.2802827235482905,0.20081867675230916,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,168,190
Cohort,-0.05151668183993703,0.038885882950743196,-1.3248170783518864,0.18567948322041022,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,62,105
Cohort,-0.03404200721604598,0.10788568188165543,-0.315537767591701,0.7524323198146762,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,62,137
Cohort,0.04502163737484503,0.03453980912069935,1.3034709374773015,0.19279090323561765,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,72,101
Cohort,-0.0020376340208165967,0.037830002241577954,-0.053862910390660435,0.9570603006519198,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,52,103
Cohort,-0.057050505506112514,0.10805385163031055,-0.5279821556134986,0.5976521668692127,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,52,142
Cohort,-0.056901882434420695,0.03621812687672088,-1.5710884946674106,0.11655948148088474,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,97,89
Cohort,-0.17507841245696446,0.0924239864359163,-1.8942962666770273,0.05861227185921712,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,306,566
Cohort,-0.1786861860937122,0.2517457160961362,-0.709788388317503,0.4780337674638303,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,306,768
Cohort,0.11515498351511474,0.08237318961419506,1.3979667905838933,0.1625124571270384,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,441,580
Cohort,0.010077190874957499,0.015924883675060182,0.6327952580739599,0.5270813431546685,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,7,19
Cohort,-0.08025957839770169,0.03911246112437767,-2.052020662736516,0.04047936552067052,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,7,19
Cohort,-0.010620170273813043,0.015288542668404239,-0.6946489606076717,0.48747802101239857,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,18,16
Cohort,0.013226454752971947,0.08220948457757357,0.16088721174855866,0.8722303020467551,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,196,419
Cohort,0.27743329802712147,0.21669003072568105,1.280323312973906,0.20078742624268067,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,196,571
Cohort,-0.050946119337147495,0.07213546597320589,-0.7062561896539353,0.4802354924273766,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,366,402
Cohort,0.05558368200672596,0.03965043696630943,1.4018428612515632,0.16142115971884954,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,46,119
Cohort,0.03420765666894961,0.09801146396637209,0.3490168933777616,0.7271647233334816,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,46,135
Cohort,-0.02948795937667748,0.0333530576622114,-0.884115623680493,0.3769007569076738,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,81,74
Cohort,0.06371140566584764,0.05827533563228429,1.0932825178024679,0.2746592114215227,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,86,217
Cohort,0.048347598315244454,0.14927760304906623,0.323877107668677,0.7461122781323136,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,86,272
Cohort,0.028876605688412337,0.051570199754273016,0.5599475244619286,0.5756727688558267,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,165,208
Cohort,-0.01518141613254452,0.011504205305215856,-1.3196405774905169,0.1874017846274806,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,6,7
Cohort,0.022980397975882437,0.04233802137056646,0.5427839382182014,0.5874235915749624,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,6,24
Cohort,0.004501319815385436,0.008589877097551083,0.5240261023837853,0.6004062594116439,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,4,7
Cohort,-0.0091155822409231535,0.03412439148624251,-0.2671280525133515,0.7894520411475421,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,36,77
Cohort,0.07660461503477564,0.09733671044061798,0.7870064098941342,0.43150169553465256,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,36,110
Cohort,0.01674184070061501,0.03160699544998482,0.5296878258203138,0.5964760893885392,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,72,90
Cohort,-0.017286957247235175,0.020315143229059408,-0.8509394717191744,0.3951042885900551,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,14,26
Cohort,-0.013903482795294946,0.05637815032828773,-0.24661119093718964,0.8052698294981829,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,14,38
Cohort,0.008217905822158233,0.017884536383921144,0.45949783912466596,0.646002166123673,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,17,27
Cohort,0.03390998121576503,0.033253408956789104,1.019744509798352,0.30821445029953826,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,29,82
Cohort,0.042452071912707993,0.08402877670951162,0.5052087341395587,0.6135457131017079,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,29,91
Cohort,0.011932828546776932,0.028785614261844183,0.4145413899537346,0.6785893504876872,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,56,71
Cohort,0.0045734383617766425,0.05834571026640214,0.0783851690363296,0.9375448665936553,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,108,228
Cohort,0.012958838951897377,0.15879785399652807,0.08160588210581679,0.9349797033762157,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,108,300
Cohort,-0.038110670531905054,0.05021525797922765,-0.758946026876336,0.44810951516941,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,178,201
Cohort,0.08218740391274534,0.09180580376063073,0.8952310262108933,0.3709822493645645,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,216,488
Cohort,0.21612079994237401,0.22896428254247278,0.9439061741094211,0.34549095398643126,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,216,624
Cohort,0.03846658966921947,0.07168104772605094,0.5366354272084616,0.5916694133052012,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,369,462
Cohort,-0.04143179295622499,0.04386465184016973,-0.9445371436479336,0.3452326929245173,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,60,109
Cohort,-0.07472772292831326,0.12396598543867589,-0.6028082837713571,0.5468001107763928,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,60,178
Cohort,0.006070417620534894,0.03637947008513148,0.16686382749197637,0.867519573524914,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,86,105
Cohort,-0.11123878004937093,0.06566492085696324,-1.6940366119024257,0.09071895475112567,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,148,265
Cohort,0.2952368696183056,0.18246262280158126,1.6180676627637898,0.1060261214371188,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,148,393
Cohort,-0.0594734674892166,0.060823703114149995,-0.9778008316527628,0.32846991018055227,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,263,278
Cohort,0.07960152438497603,0.027790014380953076,2.8643930619745883,0.004307703169732091,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,14,63
Cohort,0.1294433244478375,0.06668150510892583,1.941217796994665,0.052568415967914485,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,14,62
Cohort,-0.004846039293630186,0.022649595266903643,-0.21395699289653017,0.8306353878054118,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,39,42
Cohort,0.0256451939687781,0.029504038842964053,0.8692096056839965,0.3850409979130839,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,26,64
Cohort,-0.014724966853379573,0.08055552535086506,-0.18279276051200682,0.8550050539002957,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,26,82
Cohort,-0.04029099931526579,0.02483914402568525,-1.6220768023890977,0.1051828857090709,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,47,43
Cohort,-7.478969908538756e-4,0.028064055593756132,-0.026649640439718642,0.978747044949148,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,26,52
Cohort,-0.04334487176901644,0.08440280482138837,-0.5135477649201593,0.6077042267120223,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,26,80
Cohort,0.03467534521910121,0.02633244258362534,1.3168298044885458,0.18827466102941018,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,42,59
Cohort,-0.030293229205984505,0.02763460101468227,-1.0962064981466424,0.27337878028102097,LGP Offspring,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,28,50
Cohort,-0.024495006285679223,0.0791365117474165,-0.30952850643532304,0.7569968480134603,LGP Proband,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,28,72
Cohort,-0.051279219624048314,0.021524161167366277,-2.3824026973833936,0.017433951824872115,LonGen OPEL,"descartes DE_gene_77_main_cell_type.csv, fold.change>=1.5, qval<0.05, pval<0.05",,C8,43,31
Cohort,0.0035827299698402188,0.03079987007878584,0.11632289229388378,0.9074311908033033,LGP Offspring,,,C8,26,60
Cohort,-0.047051942978360094,0.07817061415560715,-0.6019134362267905,0.5473953509018776,LGP Proband,,,C8,26,67
Cohort,-0.0053479976481770695,0.02560631894525312,-0.2088546057561498,0.8346151751452862,LonGen OPEL,,,C8,44,44
Cohort,0.01405346199843973,0.02904390800960069,0.48386952588454174,0.6286351742534645,LGP Offspring,,,C8,22,60
Cohort,0.026911496413050726,0.07954188981404803,0.33833111679850786,0.7351988292511893,LGP Proband,,,C8,22,81
Cohort,0.027801835302322195,0.025517339240887386,1.0895272050063227,0.2762511924076314,LonGen OPEL,,,C8,34,54
Cohort,-0.014147881175372006,0.01424316703666345,-0.9933100650265375,0.32091428542637335,LGP Offspring,,,C8,8,13
Cohort,-0.012161027493312562,0.0486154397419698,-0.2501474337753223,0.8025349394556013,LGP Proband,,,C8,8,30
Cohort,-0.01023575856384716,0.011499304842908065,-0.8901197684275525,0.37367051936656637,LonGen OPEL,,,C8,11,9
Cohort,-0.018733843151353315,0.02587202147899656,-0.7240966140416139,0.46925693377556177,LGP Offspring,,,C8,23,45
Cohort,-0.10053136827094208,0.07270125934542006,-1.3828009194901962,0.1670960365465279,LGP Proband,,,C8,23,67
Cohort,-0.0035448896479373937,0.02455796710680402,-0.14434784575288595,0.8852623360040571,LonGen OPEL,,,C8,42,52
Cohort,0.03563970607507716,0.04619234165618605,0.771550105434075,0.44065054788845537,LGP Offspring,,,C8,60,141
Cohort,-0.12326924929514754,0.12585490910993477,-0.9794552327511623,0.32763912641084914,LGP Proband,,,C8,60,186
Cohort,0.00569194503505297,0.03968603863397822,0.14342436864382999,0.8859913377148338,LonGen OPEL,,,C8,105,129
Cohort,-0.029901051126178482,0.05539212846721766,-0.5398068634223835,0.589508000475341,LGP Offspring,,,C8,97,190
Cohort,0.0027757733911931703,0.1482576502321004,0.01872263176198759,0.9850668519623769,LGP Proband,,,C8,97,242
Cohort,-0.002326488034958325,0.045003365433316525,-0.05169586791026963,0.9587839995657677,LonGen OPEL,,,C8,140,160
Cohort,-0.017456891194801306,0.01817215705193484,-0.9606394631584269,0.3370769488576446,LGP Offspring,,,C8,14,21
Cohort,-0.005568549349670435,0.05952962023118988,-0.09354249746671248,0.9254950563694759,LGP Proband,,,C8,14,42
Cohort,0.017311738354014408,0.01858861142764298,0.9313088511963973,0.3519761917284586,LonGen OPEL,,,C8,19,34
Cohort,-0.054236001224211954,0.05212125126138998,-1.0405736606785672,0.29844547722775877,LGP Offspring,,,C8,97,180
Cohort,-0.12633325489733574,0.14508102986013266,-0.8707772133898486,0.38412638133627175,LGP Proband,,,C8,97,263
Cohort,-0.06141631849982271,0.04841923762869218,-1.2684280362032951,0.20501596600689062,LonGen OPEL,,,C8,161,184
Cohort,-0.015600380060714713,0.032312565568623094,-0.48279608214902503,0.6293968402320016,LGP Offspring,,,C8,33,69
Cohort,-0.06604215474758002,0.08780573769647083,-0.752139398633336,0.4521794484363202,LGP Proband,,,C8,33,95
Cohort,0.03339129939361343,0.03165092258367751,1.0549866060091861,0.2917515519781803,LonGen OPEL,,,C8,55,82
Cohort,0.0290193374987163,0.028249716167661705,1.027243506677621,0.3046732370033439,LGP Offspring,,,C8,22,59
Cohort,-0.12979299063758118,0.07269618747920595,-1.7854167479512901,0.07455704271385427,LGP Proband,,,C8,22,67
Cohort,0.013446072368461954,0.025343689203943573,0.5305491343529297,0.5958792292325674,LonGen OPEL,,,C8,44,57
Cohort,-0.07911467941709657,0.0716927874577894,-1.1035235512871775,0.2701925387158957,LGP Offspring,,,C8,182,342
Cohort,-0.331392326617534,0.20096612849784273,-1.6489959233159597,0.09952506134462495,LGP Proband,,,C8,182,478
Cohort,-0.048404373208044485,0.06332290062911719,-0.76440549512331,0.44485217213486683,LonGen OPEL,,,C8,283,323
Cohort,0.013710449615693454,0.02464621810194992,0.556290200751276,0.578196572159734,LGP Offspring,,,C8,16,44
Cohort,-0.039606038232720006,0.06299057272757043,-0.6287613609105158,0.5296774633135519,LGP Proband,,,C8,16,48
Cohort,0.03508305452765674,0.024435932835635298,1.4357157864051164,0.1514760685179126,LonGen OPEL,,,C8,27,46
Cohort,0.0053075618727079,0.04188516668014531,0.126716981055344,0.8992020858809624,LGP Offspring,,,C8,54,118
Cohort,-0.12065542560361661,0.11224486180865166,-1.0749305015787964,0.282716725174332,LGP Proband,,,C8,54,151
Cohort,-0.036377462780626243,0.03369795257574484,-1.0795155194921269,0.280684964856512,LonGen OPEL,,,C8,83,91
Cohort,-0.02281858450891399,0.0567895657800975,-0.40180945558331777,0.6879512628400823,LGP Offspring,,,C8,102,207
Cohort,0.025196196867263168,0.15140335487901216,0.16641769191572858,0.8678685883724995,LGP Proband,,,C8,102,313
Cohort,-0.03862414887698181,0.048082753826242094,-0.8032848745843241,0.4220498930740957,LonGen OPEL,,,C8,167,182
Cohort,0.00836427585610103,0.01866151943165505,0.44820979806783184,0.6541454072870025,LGP Offspring,,,C8,10,26
Cohort,-0.021025483635154607,0.047910245756339676,-0.4388515087583835,0.6608827996212239,LGP Proband,,,C8,10,30
Cohort,-0.00910236161779172,0.016309067159289765,-0.5581166310058971,0.5769216830440369,LonGen OPEL,,,C8,21,21
Cohort,0.057777649919862874,0.04560378784901672,1.2669484848747852,0.20561002494335973,LGP Offspring,,,C8,57,141
Cohort,-0.14566274025232934,0.12192210736225603,-1.1947196731068217,0.23253621980366757,LGP Proband,,,C8,57,206
Cohort,0.03590972013848388,0.04082074998066705,0.8796928071015584,0.37929123924561026,LonGen OPEL,,,C8,117,147
Cohort,-0.019592635456928197,0.037775054912388625,-0.5186659689143864,0.6041634318077622,LGP Offspring,,,C8,49,93
Cohort,0.007910398381901476,0.10906590628331474,0.07252860817341995,0.9421986291709381,LGP Proband,,,C8,49,147
Cohort,0.00584306350640186,0.03312808631449727,0.17637793656209055,0.8600419002597451,LonGen OPEL,,,C8,76,95
Cohort,0.003077831618978725,0.012652542657085604,0.2432579523654161,0.8078793715490475,LGP Offspring,,,C8,4,10
Cohort,-0.04818371269097072,0.04079422943726174,-1.1811404052887777,0.23788366194786062,LGP Proband,,,C8,4,24
Cohort,-0.014259920736499778,0.014239309212446436,-1.0014475087060632,0.3169148326982805,LonGen OPEL,,,C8,18,14
Cohort,0.03500846521506229,0.06623861079746061,0.5285205229033035,0.5973115749947228,LGP Offspring,,,C8,143,329
Cohort,0.5938835882314203,0.18631389559363917,3.1875431853280176,0.0014883425866944232,LGP Proband,,,C8,143,471
Cohort,0.053294666176657554,0.06508003015226639,0.8189096724750301,0.41308304912941907,LonGen OPEL,,,C8,252,325
Cohort,0.03981688083803031,0.02314198331075174,1.7205474700835788,0.08579058675471576,LGP Offspring,,,C8,11,44
Cohort,0.04426706999075468,0.0725740824939595,0.6099570048913692,0.5420564403641416,LGP Proband,,,C8,11,75
Cohort,-0.00483778333926447,0.025021667383626996,-0.19334376343081308,0.8467390774717183,LonGen OPEL,,,C8,45,53
Cohort,-0.001531481908445031,0.021893922223837528,-0.06995009358248261,0.9442540688658501,LGP Offspring,,,C8,15,34
Cohort,0.09942187557043815,0.06011093249044585,1.6539732699412117,0.0985092380197501,LGP Proband,,,C8,15,48
Cohort,-0.012180445148372248,0.01839781724796825,-0.6620592532365429,0.5081248679562546,LonGen OPEL,,,C8,25,26
Cohort,0.015252998124926719,0.018161120448005504,0.8398709853059665,0.4012776581735602,LGP Offspring,,,C8,9,25
Cohort,0.03511770351381981,0.06754569136999657,0.5199103421927355,0.6032640328617813,LGP Proband,,,C8,9,63
Cohort,-0.005244526362323356,0.023252329988662546,-0.22554842309912598,0.8216105542049892,LonGen OPEL,,,C8,37,44
Cohort,-0.02951439991787809,0.019011637772746445,-1.5524385784473318,0.12102533769642061,LGP Offspring,,,C8,15,23
Cohort,0.009649324824161214,0.05651348904260612,0.17074374609726337,0.8644666769531228,LGP Proband,,,C8,15,36
Cohort,-0.006721891391613027,0.0173713335452622,-0.386953101447202,0.6988943544112456,LonGen OPEL,,,C8,22,26
Cohort,0.026006135368311444,0.028298150003606738,0.9190047888288398,0.3584208599668399,LGP Offspring,,,C8,22,62
Cohort,0.10189408878053327,0.08258460710136026,1.2338145370779994,0.21761960349222292,LGP Proband,,,C8,22,92
Cohort,-0.005256228962606341,0.02525381525182336,-0.20813603450380963,0.8351759937804425,LonGen OPEL,,,C8,45,51
Cohort,0.03099802332796073,0.02202826210673218,1.4071933218230255,0.15982967639194537,LGP Offspring,,,C8,11,37
Cohort,0.043317600805699324,0.05624544187170368,0.7701530891073295,0.4414271791907489,LGP Proband,,,C8,11,42
Cohort,-0.01864306802879901,0.020142767317985255,-0.9255465117820638,0.35496221050511345,LonGen OPEL,,,C8,32,31
Cohort,0.025246121322524497,0.051292223181830666,0.49220173656788335,0.6227365397731022,LGP Offspring,,,C8,79,166
Cohort,-0.29203005158015033,0.12952403037408416,-2.2546399362089433,0.024414609458816128,LGP Proband,,,C8,79,230
Cohort,-0.0412388134021108,0.04101122332665648,-1.0055494583431848,0.314937915938528,LonGen OPEL,,,C8,121,123
Cohort,-0.0630270180102812,0.04897886195690597,-1.2868207935442741,0.1985972300196208,LGP Offspring,,,C8,81,144
Cohort,-0.3574920615903103,0.14096403358160728,-2.536051590658762,0.011392461877480851,LGP Proband,,,C8,81,219
Cohort,-0.05027231663829074,0.03938192748666577,-1.2765326596904716,0.20213958149602868,LonGen OPEL,,,C8,111,114
Cohort,-0.08155790888018914,0.07427946262660354,-1.0979873304977141,0.2726009488375386,LGP Offspring,,,C8,179,340
Cohort,0.022604905915336034,0.20260731398361656,0.11157003896297611,0.9111911742381542,LGP Proband,,,C8,179,503
Cohort,0.05627237576699226,0.06269248665318247,0.8975936156160699,0.36967364420974647,LonGen OPEL,,,C8,271,336
Cohort,0.04165938376760273,0.10722904296163688,0.38850839862953107,0.6977621661354749,LGP Offspring,,,C8,389,813
Cohort,-0.30206693153915726,0.2988642232627621,-1.0107162652037456,0.31244538641186453,LGP Proband,,,C8,389,1092
Cohort,-0.06430101539823455,0.09407740954774853,-0.6834904968934001,0.4944958521587244,LonGen OPEL,,,C8,608,690
Cohort,0.07355843107956331,0.05696998288895494,1.2911787462345272,0.19708305101484508,LGP Offspring,,,C8,93,236
Cohort,-0.0562991690857876,0.15240629490472252,-0.3694018617865048,0.7119219800999602,LGP Proband,,,C8,93,284
Cohort,0.01156248380748426,0.048382564686933485,0.2389803823402297,0.8111823091427478,LonGen OPEL,,,C8,156,197
Cohort,-0.09412502821402391,0.10975024753496658,-0.8576293022394829,0.3914011405267628,LGP Offspring,,,C8,374,724
Cohort,-0.6350463115976598,0.30053435984482396,-2.113057262156499,0.034892388055756965,LGP Proband,,,C8,374,1010
Cohort,0.026427237773882065,0.09458068118933283,0.27941475406568156,0.7799991333203868,LonGen OPEL,,,C8,563,708
Cohort,0.04168504356517178,0.03785156333568982,1.1012766684293702,0.2711682263413623,LGP Offspring,,,C8,45,108
Cohort,0.034111527600023214,0.11360616586722189,0.30026123441126723,0.7640527266303558,LGP Proband,,,C8,45,171
Cohort,-0.006681077396724533,0.03576858010983379,-0.18678620667102513,0.8518758568673288,LonGen OPEL,,,C8,84,99
Cohort,-0.11429479605226209,0.0673729412077652,-1.6964495538319888,0.09026115066242983,LGP Offspring,,,C8,152,274
Cohort,-0.04749188771856031,0.18457641215480433,-0.25730204181631205,0.7970090841167786,LGP Proband,,,C8,152,400
Cohort,0.07495796626024187,0.05915759330926523,1.2670895157680797,0.20549387018710552,LonGen OPEL,,,C8,222,293
Cohort,0.0044440367316582905,0.014212296941196204,0.31268954976423746,0.7546129723656038,LGP Offspring,,,C8,6,14
Cohort,0.022585419815147067,0.0381103391443275,0.5926323491799409,0.5535878709361266,LGP Proband,,,C8,6,18
Cohort,-0.017474580073909143,0.015462948664692364,-1.1300936485555357,0.2587771732990619,LonGen OPEL,,,C8,17,16
Cohort,-0.16319528060466948,0.09534973354862558,-1.7115441704034196,0.08743939753977045,LGP Offspring,,,C8,314,604
Cohort,-0.10018300269013697,0.25810117330185467,-0.38815399948984686,0.6980011276727094,LGP Proband,,,C8,314,824
Cohort,0.12112931696948077,0.08448787593224218,1.4336887468519672,0.1520537821127645,LonGen OPEL,,,C8,444,601
Cohort,0.06383987525748215,0.04051431869790225,1.5757361177293512,0.11555447444737335,LGP Offspring,,,C8,41,126
Cohort,-0.1457091695791623,0.10849135475155684,-1.3430486688347985,0.17962158342953086,LGP Proband,,,C8,41,157
Cohort,0.02977823024573744,0.03244100109327722,0.9179195845441529,0.35893900667710144,LonGen OPEL,,,C8,74,92
Cohort,-0.007807589692544519,0.05083227393404224,-0.15359512939899778,0.8779748163038724,LGP Offspring,,,C8,84,175
Cohort,-0.10794813542088111,0.15392740230682014,-0.7012925171420125,0.4833161113692763,LGP Proband,,,C8,84,260
Cohort,0.05779327670655776,0.04021188819988442,1.4372186757130163,0.15104882213906815,LonGen OPEL,,,C8,107,162
Cohort,-0.07189108494332348,0.11927132227360596,-0.6027524770657511,0.5468755116160045,LGP Offspring,,,C8,497,1009
Cohort,-0.16851562103947962,0.32251653104228123,-0.522502274518721,0.6014594244450013,LGP Proband,,,C8,497,1397
Cohort,0.05031862350886282,0.11121877105818505,0.45242923501230026,0.6510830618715504,LonGen OPEL,,,C8,758,921
Cohort,-0.06551332311862262,0.11035414333875337,-0.5936643712372159,0.5529352049464689,LGP Offspring,,,C8,374,735
Cohort,-0.31456229068314795,0.29598274225636445,-1.0627724045163784,0.2881928071217702,LGP Proband,,,C8,374,993
Cohort,-0.040538723484468506,0.09101041981357393,-0.44542947464156496,0.6561305274737499,LonGen OPEL,,,C8,548,604
Cohort,0.012313976986675863,0.054023763339530656,0.22793630479395707,0.819764683657771,LGP Offspring,,,C8,87,196
Cohort,0.014904573973167216,0.1549911274228699,0.09616404642636307,0.9234133872964089,LGP Proband,,,C8,87,281
Cohort,-0.015258576842017015,0.04705235795118141,-0.3242893131487345,0.745804205152582,LonGen OPEL,,,C8,158,181
Cohort,0.09008584450241994,0.04918576386487424,1.831543060913084,0.06745942460635815,LGP Offspring,,,C8,59,177
Cohort,0.22437948530372193,0.14167821736124964,1.5837260623600413,0.11363517223181162,LGP Proband,,,C8,59,266
Cohort,0.026809094134443958,0.04073909845858164,0.6580679285698984,0.5106847505686445,LonGen OPEL,,,C8,103,139
Cohort,0.014465276239049757,0.007333180660548152,1.9725787361099165,0.04895067625107258,LGP Offspring,,,C8,0,6
Cohort,-0.027449320213747984,0.018916853670536787,-1.451051041141192,0.1471416629606749,LGP Proband,,,C8,0,6
Cohort,0.008192339180715089,0.00579273972711188,1.414242580651831,0.15768169510090307,LonGen OPEL,,,C8,1,4
Cohort,-0.015659113512870255,0.02145619474115935,-0.7298178312499852,0.46575435718004055,LGP Offspring,,,C8,17,30
Cohort,-0.015798745649131557,0.061129846266780724,-0.2584456957438307,0.7961267203145834,LGP Proband,,,C8,17,46
Cohort,-0.020356218235737876,0.01743349730592083,-1.1676497193035629,0.24329771850881965,LonGen OPEL,,,C8,25,19
Cohort,-0.14008393810251274,0.1015536008274292,-1.3794088733550516,0.16822486604762943,LGP Offspring,,,C8,338,653
Cohort,-0.095510479900339,0.27839030542583276,-0.34308119944853604,0.7316238328072122,LGP Proband,,,C8,338,901
Cohort,0.02456862151152788,0.09220693470178727,0.266450908394113,0.7899609680002557,LonGen OPEL,,,C8,545,666
Cohort,-0.004200869329146008,0.014203988743624075,-0.295752792048058,0.7675097011836522,LGP Offspring,,,C8,9,12
Cohort,-0.04171973068464243,0.04123549198123082,-1.011743250295935,0.3119542611146419,LGP Proband,,,C8,9,18
Cohort,-0.01608310310215339,0.01585872431742979,-1.0141486023864477,0.3108200050607458,LonGen OPEL,,,C8,17,18
Cohort,-0.01864814558851197,0.011779122239678867,-1.58315239531977,0.1138544348856407,LGP Offspring,,,C8,9,6
Cohort,-0.02799196362430912,0.03899414138875862,-0.7178504931096842,0.47305050127248904,LGP Proband,,,C8,9,15
Cohort,0.003925280741200905,0.012002789137967857,0.32703071728422267,0.7437306300067904,LonGen OPEL,,,C8,9,13
Cohort,-0.006195589439674233,0.016082185501306707,-0.385245490370126,0.7001767284989739,LGP Offspring,,,C8,9,17
Cohort,-0.019461577452989206,0.0403709233669957,-0.48206916834851393,0.6298832933906451,LGP Proband,,,C8,9,18
Cohort,-0.02546147155427754,0.017831696688742786,-1.4278771111192945,0.15371943626866363,LonGen OPEL,,,C8,24,21
Cohort,2.712097100264739e-4,0.011519914833341638,0.023542683600535158,0.9812243388289725,LGP Offspring,,,C8,5,9
Cohort,0.017157502016464814,0.03215788929040135,0.5335394329374121,0.593802380439291,LGP Proband,,,C8,5,13
Cohort,-0.015731929684512962,0.014521733925482182,-1.0833368635757177,0.2789869655780017,LonGen OPEL,,,C8,15,16
Cohort,-0.019826805986285386,0.01481295266262804,-1.3384776443866535,0.18119076670743456,LGP Offspring,,,C8,10,10
Cohort,-0.0031626593990117476,0.04393965911893811,-0.0719773312408023,0.9426372050284868,LGP Proband,,,C8,10,20
Cohort,0.0034123785592961634,0.011220240770757046,0.3041270351514859,0.7611105952542806,LonGen OPEL,,,C8,8,9
Cohort,-0.009182217331459911,0.00638139304737896,-1.438904838377153,0.1506403246733276,LGP Offspring,,,C8,3,1
Cohort,-0.011184246548508468,0.022261962982674077,-0.5023926487171362,0.6155239698128442,LGP Proband,,,C8,3,5
Cohort,-0.0025052259609396913,0.007733061592366439,-0.32396301659005056,0.7460511363695976,LonGen OPEL,,,C8,5,4
Cohort,-0.0027141576341575095,0.06987931567449701,-0.03884064415856983,0.9690289073525005,LGP Offspring,,,C8,153,294
Cohort,-0.4784955196848896,0.17940245938071053,-2.6671625424569725,0.007797746756640774,LGP Proband,,,C8,153,370
Cohort,0.03863039051870323,0.05274781295352057,0.732360042164078,0.4641644204478591,LonGen OPEL,,,C8,190,242
Cohort,0.008848990773181353,0.01412295494876299,0.6265679388828203,0.5311540150224903,LGP Offspring,,,C8,5,15
Cohort,-0.011408647442016279,0.02945312356591719,-0.38734932193128174,0.6985964431522651,LGP Proband,,,C8,5,9
Cohort,-0.0017931051701884874,0.009654586512560046,-0.1857257343808317,0.8527071621711099,LonGen OPEL,,,C8,6,8
Cohort,-0.006740274876403548,0.020419589364955068,-0.3300886592739951,0.7414352381127658,LGP Offspring,,,C8,15,28
Cohort,-0.041609941929575754,0.05923057583866677,-0.702507806827906,0.48255855939874537,LGP Proband,,,C8,15,41
Cohort,0.02650291813353314,0.019621797072590295,1.3506876070263252,0.1771793626314993,LonGen OPEL,,,C8,22,38
Cohort,-0.020203022991581002,0.02109790486479719,-0.9575843251284474,0.33861474218563226,LGP Offspring,,,C8,18,25
Cohort,0.12042110631547882,0.059102664939111794,2.037490296580331,0.04191612067815431,LGP Proband,,,C8,18,39
Cohort,0.00518413709065516,0.018838880202081475,0.2751828683576624,0.7832471605913641,LonGen OPEL,,,C8,25,29
Cohort,-0.12012005462881527,0.07376703132903092,-1.6283704585186711,0.1039122791930673,LGP Offspring,,,C8,193,339
Cohort,-0.22066574804374675,0.20483187984384993,-1.077301776520176,0.28165697674594103,LGP Proband,,,C8,193,532
Cohort,-0.08905736140570286,0.0640247385964169,-1.3909836003717304,0.16461908294150815,LonGen OPEL,,,C8,309,335
Cohort,-0.3058755023854626,0.1525322343358276,-2.0053171299649475,0.045327289720034615,LGP Offspring,,,C8,766,1495
Cohort,-0.2396580253835527,0.42112639620540454,-0.5690881111775749,0.5694495692246444,LGP Proband,,,C8,766,2053
Cohort,-0.1244659801751002,0.13498829819650643,-0.9220501468498508,0.3567817973516785,LonGen OPEL,,,C8,1198,1393
Cohort,0.06804097176099123,0.040736391217932516,1.670274899830572,0.09532789363431438,LGP Offspring,,,C8,47,121
Cohort,0.1463095755004261,0.10830639712349681,1.350885814561775,0.1770983931815316,LGP Proband,,,C8,47,144
Cohort,0.018789305327093185,0.03640123195638519,0.5161722369618132,0.60587747074091,LonGen OPEL,,,C8,85,109
Cohort,-0.027775517493444722,0.044273853841549866,-0.6273571212673182,0.5306370052796981,LGP Offspring,"Most stromal cells from selectable follicle C clustered in CL1 (Fig. 3a). Although stromal clusters (CL0, CL1) showed high expression of GNL3 and ARID5B (Fig. 8d), CL0 expressed high levels of XBP1 and SELK (Fig. 8e), both involved in endoplasmic reticulum (ER)-stress-induced apoptosis, whereas CL1 expressed high levels of GPRC5A and TNFRS12A (Fig. 8f).",,C8,58,117
Cohort,0.04732690216527476,0.11358450532093683,0.41666688631121834,0.6770292926776231,LGP Proband,"Most stromal cells from selectable follicle C clustered in CL1 (Fig. 3a). Although stromal clusters (CL0, CL1) showed high expression of GNL3 and ARID5B (Fig. 8d), CL0 expressed high levels of XBP1 and SELK (Fig. 8e), both involved in endoplasmic reticulum (ER)-stress-induced apoptosis, whereas CL1 expressed high levels of GPRC5A and TNFRS12A (Fig. 8f).",,C8,58,150
Cohort,-0.05939438515642893,0.03406713141236633,-1.743451317854982,0.081640892658939,LonGen OPEL,"Most stromal cells from selectable follicle C clustered in CL1 (Fig. 3a). Although stromal clusters (CL0, CL1) showed high expression of GNL3 and ARID5B (Fig. 8d), CL0 expressed high levels of XBP1 and SELK (Fig. 8e), both involved in endoplasmic reticulum (ER)-stress-induced apoptosis, whereas CL1 expressed high levels of GPRC5A and TNFRS12A (Fig. 8f).",,C8,95,93
Cohort,0.05403227070364593,0.08604341547147028,0.6279652011438528,0.5302388142480796,LGP Offspring,"Most stromal cells from selectable follicle C clustered in CL1 (Fig. 3a). Although stromal clusters (CL0, CL1) showed high expression of GNL3 and ARID5B (Fig. 8d), CL0 expressed high levels of XBP1 and SELK (Fig. 8e), both involved in endoplasmic reticulum (ER)-stress-induced apoptosis, whereas CL1 expressed high levels of GPRC5A and TNFRS12A (Fig. 8f).",,C8,230,492
Cohort,-0.21753668879430105,0.2397983193862839,-0.9071651934469054,0.3645814778562948,LGP Proband,"Most stromal cells from selectable follicle C clustered in CL1 (Fig. 3a). Although stromal clusters (CL0, CL1) showed high expression of GNL3 and ARID5B (Fig. 8d), CL0 expressed high levels of XBP1 and SELK (Fig. 8e), both involved in endoplasmic reticulum (ER)-stress-induced apoptosis, whereas CL1 expressed high levels of GPRC5A and TNFRS12A (Fig. 8f).",,C8,230,662
Cohort,-0.04908537213781514,0.07327222731681621,-0.6699041906502806,0.5031131489438311,LonGen OPEL,"Most stromal cells from selectable follicle C clustered in CL1 (Fig. 3a). Although stromal clusters (CL0, CL1) showed high expression of GNL3 and ARID5B (Fig. 8d), CL0 expressed high levels of XBP1 and SELK (Fig. 8e), both involved in endoplasmic reticulum (ER)-stress-induced apoptosis, whereas CL1 expressed high levels of GPRC5A and TNFRS12A (Fig. 8f).",,C8,379,444
Cohort,0.08534139261340414,0.05172102093772058,1.6500330246026511,0.09940070640645977,LGP Offspring,"The GC of CL10 were negative for several GC markers, such as VCAN and FST (Fig. 4b), but were also negative for KRT18 (Fig. 4b), similarly to pan-KRT-negative GC in atretic follicles (Fig. 4d). This suggested that CL10 could represent GC in the early stages of atresia. ",,C8,77,201
Cohort,-0.027164582063537775,0.14228022390696637,-0.19092310454403028,0.8486323047448776,LGP Proband,"The GC of CL10 were negative for several GC markers, such as VCAN and FST (Fig. 4b), but were also negative for KRT18 (Fig. 4b), similarly to pan-KRT-negative GC in atretic follicles (Fig. 4d). This suggested that CL10 could represent GC in the early stages of atresia. ",,C8,77,284
Cohort,-0.07607452104126364,0.05171727005009166,-1.4709693873551395,0.1416945839783801,LonGen OPEL,"The GC of CL10 were negative for several GC markers, such as VCAN and FST (Fig. 4b), but were also negative for KRT18 (Fig. 4b), similarly to pan-KRT-negative GC in atretic follicles (Fig. 4d). This suggested that CL10 could represent GC in the early stages of atresia. ",,C8,182,195
Cohort,-0.08597943053319508,0.10332986464395864,-0.8320869366223641,0.4056537152819857,LGP Offspring,"Pseudotime analysis using Monocle 3 alpha, that places the progenitor cell population in the middle of a longer trajectory segment, revealed that pGC (CL15) branched to mural GC (CL11) and mature cumulus GC (CL8 and CL3) (Fig. 6a).",,C8,388,753
Cohort,-0.12181960424904602,0.30065213246243083,-0.40518456746442155,0.6854457586801987,LGP Proband,"Pseudotime analysis using Monocle 3 alpha, that places the progenitor cell population in the middle of a longer trajectory segment, revealed that pGC (CL15) branched to mural GC (CL11) and mature cumulus GC (CL8 and CL3) (Fig. 6a).",,C8,388,1080
Cohort,0.016701464698702033,0.09323103842897329,0.17914060574822194,0.8578728858743017,LonGen OPEL,"Pseudotime analysis using Monocle 3 alpha, that places the progenitor cell population in the middle of a longer trajectory segment, revealed that pGC (CL15) branched to mural GC (CL11) and mature cumulus GC (CL8 and CL3) (Fig. 6a).",,C8,621,745
Cohort,0.040394347013891475,0.039634168788891935,1.0191798705063948,0.3084821873337288,LGP Offspring,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,46,110
Cohort,0.07008769560681351,0.11647788601142897,0.601725340378657,0.5475205104716572,LGP Proband,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,46,170
Cohort,-0.010945998073817144,0.03402048973841845,-0.32174722227634817,0.747728671559688,LonGen OPEL,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,81,94
Cohort,0.019870781445144536,0.09192536413073142,0.2161621183995024,0.8289265909242427,LGP Offspring,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,246,525
Cohort,-0.08969048326664891,0.2480532378449917,-0.3615775550678215,0.7177593230330792,LGP Proband,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,246,713
Cohort,0.05836739528404356,0.07892909491735689,0.7394915062076595,0.45982661402284086,LonGen OPEL,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,411,529
Cohort,0.09816639537469407,0.07272529838922802,1.3498245802898536,0.17752407318826177,LGP Offspring,"The clusters of smooth muscle cells (CL14, CL17) also showed features of growth and remodeling: many DEGs of CL17 (such as CRYAB, GJA4) were involved in regulation of immune response and apoptosis, whereas DEGs of CL14 (such as ACTA2, PLN, ADIRF, and MYH11) associated with mature smooth muscle cells (Fig. 3e-g).",,C8,148,356
Cohort,-0.09731203720406839,0.20406534656709294,-0.47686703715799184,0.6335817278416139,LGP Proband,"The clusters of smooth muscle cells (CL14, CL17) also showed features of growth and remodeling: many DEGs of CL17 (such as CRYAB, GJA4) were involved in regulation of immune response and apoptosis, whereas DEGs of CL14 (such as ACTA2, PLN, ADIRF, and MYH11) associated with mature smooth muscle cells (Fig. 3e-g).",,C8,148,503
Cohort,0.06722096208873593,0.06304859272858662,1.0661770418589775,0.28666688894877584,LonGen OPEL,"The clusters of smooth muscle cells (CL14, CL17) also showed features of growth and remodeling: many DEGs of CL17 (such as CRYAB, GJA4) were involved in regulation of immune response and apoptosis, whereas DEGs of CL14 (such as ACTA2, PLN, ADIRF, and MYH11) associated with mature smooth muscle cells (Fig. 3e-g).",,C8,244,319
Cohort,-0.12880376208179042,0.11198028830489103,-1.1502360284257689,0.2504534048292517,LGP Offspring,"The GC of small antral follicles (1-2_mm diameter) clustered pronouncedly in cluster (CL15) showing WT1high/EGR4high/VCANlow/FSTlow expression (Fig. 4b), suggesting that at that stage mural and cumulus GC still have a common progenitor (pGC) signature. ",,C8,449,872
Cohort,-0.7001009658919619,0.32475603647357215,-2.1557750657821395,0.0313866465296494,LGP Proband,"The GC of small antral follicles (1-2_mm diameter) clustered pronouncedly in cluster (CL15) showing WT1high/EGR4high/VCANlow/FSTlow expression (Fig. 4b), suggesting that at that stage mural and cumulus GC still have a common progenitor (pGC) signature. ",,C8,449,1231
Cohort,0.0037693438245560013,0.10603687336383556,0.03554748178610061,0.9716520974193712,LonGen OPEL,"The GC of small antral follicles (1-2_mm diameter) clustered pronouncedly in cluster (CL15) showing WT1high/EGR4high/VCANlow/FSTlow expression (Fig. 4b), suggesting that at that stage mural and cumulus GC still have a common progenitor (pGC) signature. ",,C8,690,832
Cohort,0.010353409519003239,0.06886071635320921,0.1503529162534006,0.8805310363571333,LGP Offspring,"We identified three separate clusters (CL) of endothelial cells (CL7, CL9, CL16) expressing markers associated with lymph and blood vascular system (such as PECAM1, CD34, CTGF), but also associated with remodeling and inflammatory response (such as TXNIP, ANGPT2) (Fig. 3a-d). The DEGs of CL7 (such as CCL14, SOCS3, EGFL7) and CL16 (such as CCL21, TFF3) are linked to angiogenesis and lymphatics, respectively, while DEGs of CL9 (TM4SF1, NMMT) were more related to regulation of apoptosis (Fig. 3c, d). ",,C8,155,328
Cohort,0.09192733917449669,0.19004198550749557,0.4837212099684726,0.62871071708079,LGP Proband,"We identified three separate clusters (CL) of endothelial cells (CL7, CL9, CL16) expressing markers associated with lymph and blood vascular system (such as PECAM1, CD34, CTGF), but also associated with remodeling and inflammatory response (such as TXNIP, ANGPT2) (Fig. 3a-d). The DEGs of CL7 (such as CCL14, SOCS3, EGFL7) and CL16 (such as CCL21, TFF3) are linked to angiogenesis and lymphatics, respectively, while DEGs of CL9 (TM4SF1, NMMT) were more related to regulation of apoptosis (Fig. 3c, d). ",,C8,155,432
Cohort,0.05060398667785372,0.06004725821172599,0.8427360080192938,0.3996292481766366,LonGen OPEL,"We identified three separate clusters (CL) of endothelial cells (CL7, CL9, CL16) expressing markers associated with lymph and blood vascular system (such as PECAM1, CD34, CTGF), but also associated with remodeling and inflammatory response (such as TXNIP, ANGPT2) (Fig. 3a-d). The DEGs of CL7 (such as CCL14, SOCS3, EGFL7) and CL16 (such as CCL21, TFF3) are linked to angiogenesis and lymphatics, respectively, while DEGs of CL9 (TM4SF1, NMMT) were more related to regulation of apoptosis (Fig. 3c, d). ",,C8,217,298
Cohort,0.003324628386208684,0.07160147816226842,0.04643239876520666,0.9629793271432876,LGP Offspring,"The clusters of smooth muscle cells (CL14, CL17) also showed features of growth and remodeling: many DEGs of CL17 (such as CRYAB, GJA4) were involved in regulation of immune response and apoptosis, whereas DEGs of CL14 (such as ACTA2, PLN, ADIRF, and MYH11) associated with mature smooth muscle cells (Fig. 3e-g).",,C8,161,339
Cohort,-0.41619643221753844,0.2037247715771858,-2.042934833086083,0.04137278125305715,LGP Proband,"The clusters of smooth muscle cells (CL14, CL17) also showed features of growth and remodeling: many DEGs of CL17 (such as CRYAB, GJA4) were involved in regulation of immune response and apoptosis, whereas DEGs of CL14 (such as ACTA2, PLN, ADIRF, and MYH11) associated with mature smooth muscle cells (Fig. 3e-g).",,C8,161,485
Cohort,0.026468860136822002,0.06247615873348046,0.42366337293137,0.6719257836874206,LonGen OPEL,"The clusters of smooth muscle cells (CL14, CL17) also showed features of growth and remodeling: many DEGs of CL17 (such as CRYAB, GJA4) were involved in regulation of immune response and apoptosis, whereas DEGs of CL14 (such as ACTA2, PLN, ADIRF, and MYH11) associated with mature smooth muscle cells (Fig. 3e-g).",,C8,252,308
Cohort,0.034704064645689654,0.09410475830110507,0.3687811888815204,0.7124062942390696,LGP Offspring,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,247,549
Cohort,-0.27214612102057867,0.2550999419156505,-1.0668215718785405,0.286361134306347,LGP Proband,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,247,729
Cohort,-0.02741504310427951,0.07736895784482846,-0.35434163607661934,0.7231767144559944,LonGen OPEL,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,405,474
Cohort,0.05041065854504483,0.042770515995284086,1.1786310586153124,0.2389598158296504,LGP Offspring,"TC from (early atretic) follicle D and present in stromal samples were mainly present in CL2 and CL6 (Fig. 4a, Supplementary Fig. 2c), suggesting that those may represent atretic TC. The TC in CL2 and CL6 expressed IFITM3, lower levels of COL3A1 and higher levels of FOS and IGFBP5 compared to the TC in CL5 (Fig. 8a).",,C8,51,128
Cohort,0.18778617258556768,0.11361138545839873,1.652881635303441,0.09873131597713526,LGP Proband,"TC from (early atretic) follicle D and present in stromal samples were mainly present in CL2 and CL6 (Fig. 4a, Supplementary Fig. 2c), suggesting that those may represent atretic TC. The TC in CL2 and CL6 expressed IFITM3, lower levels of COL3A1 and higher levels of FOS and IGFBP5 compared to the TC in CL5 (Fig. 8a).",,C8,51,153
Cohort,-0.029537735169650196,0.03385763885017211,-0.8724097773138143,0.3832479422952382,LonGen OPEL,"TC from (early atretic) follicle D and present in stromal samples were mainly present in CL2 and CL6 (Fig. 4a, Supplementary Fig. 2c), suggesting that those may represent atretic TC. The TC in CL2 and CL6 expressed IFITM3, lower levels of COL3A1 and higher levels of FOS and IGFBP5 compared to the TC in CL5 (Fig. 8a).",,C8,84,95
Cohort,-0.04148462886391476,0.07537552787049014,-0.5503726479394406,0.5822456178279257,LGP Offspring,"Pseudotime analysis using Monocle 3 alpha, that places the progenitor cell population in the middle of a longer trajectory segment, revealed that pGC (CL15) branched to mural GC (CL11) and mature cumulus GC (CL8 and CL3) (Fig. 6a).",,C8,215,423
Cohort,-0.3069033376954307,0.21813014801904598,-1.406973499457001,0.15980778521721434,LGP Proband,"Pseudotime analysis using Monocle 3 alpha, that places the progenitor cell population in the middle of a longer trajectory segment, revealed that pGC (CL15) branched to mural GC (CL11) and mature cumulus GC (CL8 and CL3) (Fig. 6a).",,C8,215,615
Cohort,-0.007764820517852934,0.0722549061428646,-0.10746426689005856,0.9144477515468459,LonGen OPEL,"Pseudotime analysis using Monocle 3 alpha, that places the progenitor cell population in the middle of a longer trajectory segment, revealed that pGC (CL15) branched to mural GC (CL11) and mature cumulus GC (CL8 and CL3) (Fig. 6a).",,C8,350,413
Cohort,0.12013773072437674,0.056608562540332606,2.122253689780247,0.03417943379350302,LGP Offspring,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,84,220
Cohort,-0.1804470403844522,0.1582589516540457,-1.1402011608095932,0.2545298380523165,LGP Proband,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,84,294
Cohort,0.0815333589251631,0.0510087482616122,1.59841912816596,0.11034657281071975,LonGen OPEL,"The ovaries analyzed showed a pronounced population of CD53high/CXCR4high immune cells (Fig. 2e), including separate clusters for adaptive T lymphocytes and Natural Killer (NK) cells (CL4 and CL12), B lymphocytes (CL18), and innate immune system, such as monocytes and macrophages (CL13)",,C8,150,210
Cohort,-0.16214102184414844,0.09099205594098159,-1.7819250281509722,0.07521025476169119,LGP Offspring,"TC from (healthy) follicles, such as follicles A, B, and C, were mainly clustered in CL5 (Fig. 4a), characterized by expression of known markers PTH1, APOD, APOC1, and several genes not earlier associated with TC, such as WFDC1, MATN2, COLEC11 (Fig. 7a). TC from the small antral follicles A and B did not overlap with TC from selectable follicle C in CL5 (Fig. 4a).",,C8,302,550
Cohort,-0.02376127523383423,0.26026532402690034,-0.09129635429796376,0.9272790375815929,LGP Proband,"TC from (healthy) follicles, such as follicles A, B, and C, were mainly clustered in CL5 (Fig. 4a), characterized by expression of known markers PTH1, APOD, APOC1, and several genes not earlier associated with TC, such as WFDC1, MATN2, COLEC11 (Fig. 7a). TC from the small antral follicles A and B did not overlap with TC from selectable follicle C in CL5 (Fig. 4a).",,C8,302,814
Cohort,-0.09584579399123298,0.08304470143111534,-1.1541470116637846,0.2487862950012502,LonGen OPEL,"TC from (healthy) follicles, such as follicles A, B, and C, were mainly clustered in CL5 (Fig. 4a), characterized by expression of known markers PTH1, APOD, APOC1, and several genes not earlier associated with TC, such as WFDC1, MATN2, COLEC11 (Fig. 7a). TC from the small antral follicles A and B did not overlap with TC from selectable follicle C in CL5 (Fig. 4a).",,C8,488,562
Cohort,0.05354702743755779,0.08420325968055255,0.6359258256830279,0.5250399988263652,LGP Offspring,"TC from (early atretic) follicle D and present in stromal samples were mainly present in CL2 and CL6 (Fig. 4a, Supplementary Fig. 2c), suggesting that those may represent atretic TC. The TC in CL2 and CL6 expressed IFITM3, lower levels of COL3A1 and higher levels of FOS and IGFBP5 compared to the TC in CL5 (Fig. 8a).",,C8,216,463
Cohort,-0.19185941157842326,0.2354437349093764,-0.8148843359636264,0.4153711513395202,LGP Proband,"TC from (early atretic) follicle D and present in stromal samples were mainly present in CL2 and CL6 (Fig. 4a, Supplementary Fig. 2c), suggesting that those may represent atretic TC. The TC in CL2 and CL6 expressed IFITM3, lower levels of COL3A1 and higher levels of FOS and IGFBP5 compared to the TC in CL5 (Fig. 8a).",,C8,216,657
Cohort,-0.0014836838064020007,0.07124226935711546,-0.020825891985062305,0.9833897625083297,LonGen OPEL,"TC from (early atretic) follicle D and present in stromal samples were mainly present in CL2 and CL6 (Fig. 4a, Supplementary Fig. 2c), suggesting that those may represent atretic TC. The TC in CL2 and CL6 expressed IFITM3, lower levels of COL3A1 and higher levels of FOS and IGFBP5 compared to the TC in CL5 (Fig. 8a).",,C8,347,427
Cohort,0.019351723203738284,0.0720704547145239,0.2685111850673318,0.7883877863615794,LGP Offspring,"We identified three separate clusters (CL) of endothelial cells (CL7, CL9, CL16) expressing markers associated with lymph and blood vascular system (such as PECAM1, CD34, CTGF), but also associated with remodeling and inflammatory response (such as TXNIP, ANGPT2) (Fig. 3a-d). The DEGs of CL7 (such as CCL14, SOCS3, EGFL7) and CL16 (such as CCL21, TFF3) are linked to angiogenesis and lymphatics, respectively, while DEGs of CL9 (TM4SF1, NMMT) were more related to regulation of apoptosis (Fig. 3c, d). ",,C8,148,321
Cohort,-0.1609979341203864,0.19158918356491783,-0.8403289325873351,0.4009648232587608,LGP Proband,"We identified three separate clusters (CL) of endothelial cells (CL7, CL9, CL16) expressing markers associated with lymph and blood vascular system (such as PECAM1, CD34, CTGF), but also associated with remodeling and inflammatory response (such as TXNIP, ANGPT2) (Fig. 3a-d). The DEGs of CL7 (such as CCL14, SOCS3, EGFL7) and CL16 (such as CCL21, TFF3) are linked to angiogenesis and lymphatics, respectively, while DEGs of CL9 (TM4SF1, NMMT) were more related to regulation of apoptosis (Fig. 3c, d). ",,C8,148,441
Cohort,0.059112047470673904,0.05834067905657963,1.013221793550709,0.3112621109241121,LonGen OPEL,"We identified three separate clusters (CL) of endothelial cells (CL7, CL9, CL16) expressing markers associated with lymph and blood vascular system (such as PECAM1, CD34, CTGF), but also associated with remodeling and inflammatory response (such as TXNIP, ANGPT2) (Fig. 3a-d). The DEGs of CL7 (such as CCL14, SOCS3, EGFL7) and CL16 (such as CCL21, TFF3) are linked to angiogenesis and lymphatics, respectively, while DEGs of CL9 (TM4SF1, NMMT) were more related to regulation of apoptosis (Fig. 3c, d). ",,C8,206,278
Cohort,-0.11828555914874217,0.10469800964955518,-1.129778489053108,0.2589702911345019,LGP Offspring,"Pseudotime analysis using Monocle 3 alpha, that places the progenitor cell population in the middle of a longer trajectory segment, revealed that pGC (CL15) branched to mural GC (CL11) and mature cumulus GC (CL8 and CL3) (Fig. 6a).",,C8,400,776
Cohort,-0.18218080832454592,0.2913698187127303,-0.6252562778444911,0.5319739109954735,LGP Proband,"Pseudotime analysis using Monocle 3 alpha, that places the progenitor cell population in the middle of a longer trajectory segment, revealed that pGC (CL15) branched to mural GC (CL11) and mature cumulus GC (CL8 and CL3) (Fig. 6a).",,C8,400,1124
Cohort,-0.16964351829263616,0.10107967387183661,-1.678314855939629,0.09367816060330407,LonGen OPEL,"Pseudotime analysis using Monocle 3 alpha, that places the progenitor cell population in the middle of a longer trajectory segment, revealed that pGC (CL15) branched to mural GC (CL11) and mature cumulus GC (CL8 and CL3) (Fig. 6a).",,C8,699,790
Cohort,0.005599049654037246,0.08654680160008549,0.06469389452321155,0.9484368499672002,LGP Offspring,"We identified three separate clusters (CL) of endothelial cells (CL7, CL9, CL16) expressing markers associated with lymph and blood vascular system (such as PECAM1, CD34, CTGF), but also associated with remodeling and inflammatory response (such as TXNIP, ANGPT2) (Fig. 3a-d). The DEGs of CL7 (such as CCL14, SOCS3, EGFL7) and CL16 (such as CCL21, TFF3) are linked to angiogenesis and lymphatics, respectively, while DEGs of CL9 (TM4SF1, NMMT) were more related to regulation of apoptosis (Fig. 3c, d). ",,C8,228,482
Cohort,0.13219462418423275,0.24050484670377958,0.5496547200441732,0.5827033712779077,LGP Proband,"We identified three separate clusters (CL) of endothelial cells (CL7, CL9, CL16) expressing markers associated with lymph and blood vascular system (such as PECAM1, CD34, CTGF), but also associated with remodeling and inflammatory response (such as TXNIP, ANGPT2) (Fig. 3a-d). The DEGs of CL7 (such as CCL14, SOCS3, EGFL7) and CL16 (such as CCL21, TFF3) are linked to angiogenesis and lymphatics, respectively, while DEGs of CL9 (TM4SF1, NMMT) were more related to regulation of apoptosis (Fig. 3c, d). ",,C8,228,644
Cohort,0.20299778847857625,0.07913568752460397,2.565186388447848,0.010494192910585287,LonGen OPEL,"We identified three separate clusters (CL) of endothelial cells (CL7, CL9, CL16) expressing markers associated with lymph and blood vascular system (such as PECAM1, CD34, CTGF), but also associated with remodeling and inflammatory response (such as TXNIP, ANGPT2) (Fig. 3a-d). The DEGs of CL7 (such as CCL14, SOCS3, EGFL7) and CL16 (such as CCL21, TFF3) are linked to angiogenesis and lymphatics, respectively, while DEGs of CL9 (TM4SF1, NMMT) were more related to regulation of apoptosis (Fig. 3c, d). ",,C8,335,484
Cohort,-0.28376544358869743,0.1461114156953581,-1.9421168581402812,0.05253797902867508,LGP Offspring,,,C8,696,1367
Cohort,0.11037210693265247,0.38007074880861813,0.29039884621120776,0.7715833182863262,LGP Proband,,,C8,696,1793
Cohort,0.012833921502989917,0.12295041054768303,0.10438290889653128,0.916891779994359,LonGen OPEL,,,C8,1040,1246
Cohort,0.010524304155414109,0.046756962471936656,0.22508528353891155,0.8219809528196244,LGP Offspring,,,C8,71,150
Cohort,0.12473917314991417,0.12910464970996427,0.9661865272098471,0.3342309352604892,LGP Proband,,,C8,71,195
Cohort,0.034222096711719906,0.041245537428813095,0.8297163486058302,0.40694793026682896,LonGen OPEL,,,C8,103,148
Cohort,0.025821050955779284,0.03362399357034869,0.7679352811484467,0.4427937942018205,LGP Offspring,,,C8,31,81
Cohort,-0.049773817619587116,0.09440053038994842,-0.5272620547149695,0.5981518449355864,LGP Proband,,,C8,31,114
Cohort,-0.015408379895351817,0.029537753455518914,-0.5216503658125318,0.6020588990760088,LonGen OPEL,,,C8,60,65
Cohort,-0.16683826258889214,0.0817488564922508,-2.0408635636965418,0.04165231869494582,LGP Offspring,,,C8,234,404
Cohort,-0.17842524895121034,0.23291873468987773,-0.7660407789385283,0.44386878957911857,LGP Proband,,,C8,234,619
Cohort,0.09958701805953762,0.07640438598715027,1.3034201737618338,0.1928082157649275,LonGen OPEL,,,C8,321,438
Cohort,-0.056811936051170096,0.06687733514375448,-0.849494614715904,0.395906866276024,LGP Offspring,,,C8,144,282
Cohort,0.20749966438666642,0.1879777619020221,1.1038521912757933,0.2699756459781009,LGP Proband,,,C8,144,418
Cohort,-0.06410788480356168,0.05988013185607898,-1.0706036011684816,0.2846722148160634,LonGen OPEL,,,C8,242,270
Cohort,-0.013514015704621855,0.04877698857969743,-0.27705719639786924,0.7818208850846642,LGP Offspring,,,C8,72,146
Cohort,0.15855886421441862,0.13890606843463496,1.1414826292418727,0.2539967757654281,LGP Proband,,,C8,72,218
Cohort,0.010640049984315548,0.04293263082148325,0.24783130641487094,0.8043288462359772,LonGen OPEL,,,C8,126,161
Cohort,0.05131862409668799,0.08963504406397914,0.5725285755430444,0.5671542917953076,LGP Offspring,,,C8,250,558
Cohort,0.09016792745242175,0.2468226100919443,0.3653146987580803,0.7149691336231137,LGP Proband,,,C8,250,737
Cohort,-0.0444189803547516,0.07823032637765778,-0.5677974567090321,0.5703326190914044,LonGen OPEL,,,C8,417,462
Cohort,-0.019587143324185725,0.059644101587848095,-0.328400341404026,0.7427106824419192,LGP Offspring,,,C8,120,233
Cohort,0.002789975989832531,0.17047869564248533,0.01636554045253521,0.9869466849498586,LGP Proband,,,C8,120,326
Cohort,-0.06862302276762622,0.05231959810851645,-1.3116121921520636,0.19002918697941587,LonGen OPEL,,,C8,200,216
Cohort,-0.003572003500064294,0.009622419217208317,-0.3712167823322723,0.7105923835538348,LGP Offspring,,,C8,3,6
Cohort,-0.001736523291884771,0.023631816944880753,-0.07348242819987422,0.9414398462255987,LGP Proband,,,C8,3,6
Cohort,0.010712341900403856,0.007329920603265007,1.4614540157000062,0.14428552059576724,LonGen OPEL,,,C8,2,6
Cohort,-0.031167564066467226,0.04964307383274103,-0.6278330824452559,0.5303253170534754,LGP Offspring,,,C8,83,154
Cohort,-0.04787841485429364,0.14062132117559561,-0.34047763492783045,0.7335826045034678,LGP Proband,,,C8,83,261
Cohort,0.009863692033518428,0.044476932654778326,0.22177095956860537,0.8245490690784771,LonGen OPEL,,,C8,139,166
Cohort,-0.0029439239416995462,0.030586012417438448,-0.09625066195360217,0.9233500216882901,LGP Offspring,,,C8,32,69
Cohort,-0.0847809780413208,0.09284360070752534,-0.9131590911515453,0.36142277280116164,LGP Proband,,,C8,32,99
Cohort,-0.03763828913659017,0.02689459839819064,-1.3994739233258944,0.16206048415098992,LonGen OPEL,,,C8,54,55
Cohort,-0.0019745621572979546,0.022255356583709057,-0.08872300697007642,0.9293283252594905,LGP Offspring,,,C8,16,32
Cohort,0.009465074295150625,0.05935115194787297,0.1594758312941192,0.8733326108718998,LGP Proband,,,C8,16,42
Cohort,0.023654715216727622,0.017955252747442255,1.3174259114841622,0.18807497282000185,LonGen OPEL,,,C8,19,33
Cohort,0.0207803989919498,0.04570895891056541,0.4546242025028163,0.6495255694059665,LGP Offspring,,,C8,69,147
Cohort,-0.1999841924156947,0.11913252594403148,-1.6786699587789096,0.09359098529733106,LGP Proband,,,C8,69,168
Cohort,0.07148423091795089,0.03862330203721988,1.85080578685541,0.06456779326529741,LonGen OPEL,,,C8,89,126
Cohort,-0.11248827027217725,0.09282847992400284,-1.2117861928178677,0.22601762625347838,LGP Offspring,,,C8,291,576
Cohort,-0.2022413512353486,0.2622278260168842,-0.7712429085322423,0.44078141255442826,LGP Proband,,,C8,291,833
Cohort,-0.023870787754205657,0.08651481502898939,-0.27591560758937106,0.7826845009680702,LonGen OPEL,,,C8,455,564
Cohort,-0.06507322407407802,0.10699522218473237,-0.6081881297627102,0.5432669865721151,LGP Offspring,,,C8,415,835
Cohort,-0.5013065532035059,0.3077702703003917,-1.6288335865391346,0.10372589628045831,LGP Proband,,,C8,415,1146
Cohort,-0.1377840320714523,0.09368675364930297,-1.470688509361936,0.14177054772696354,LonGen OPEL,,,C8,648,726
Cohort,-0.023573616189207877,0.02855114487515204,-0.8256627288429302,0.40928672492524065,LGP Offspring,,,C8,29,54
Cohort,0.12786401868527686,0.08493486895234698,1.5054361096031765,0.13259061363824173,LGP Proband,,,C8,29,90
Cohort,0.03134056238170338,0.025007984468944276,1.253222242705049,0.21049282549582943,LonGen OPEL,,,C8,35,54
Cohort,-0.007559162598942773,0.04095126143294841,-0.18458924913264946,0.8536065807236374,LGP Offspring,,,C8,58,122
Cohort,-0.115825374911943,0.11195622390310568,-1.0345594990072722,0.30117456312264906,LGP Proband,,,C8,58,175
Cohort,-0.038898296104438686,0.03708617198297846,-1.0488625281221244,0.29455974133289037,LonGen OPEL,,,C8,99,102
Cohort,-0.14773150411651248,0.05873277641430715,-2.5153162022241036,0.01212335214854315,LGP Offspring,,,C8,130,200
Cohort,-0.10499663399490053,0.15925593600846805,-0.6592949476578228,0.5098883829596705,LGP Proband,,,C8,130,323
Cohort,-0.02576907408692978,0.04742394463719549,-0.5433768591809338,0.5870224876849603,LonGen OPEL,,,C8,172,192
Cohort,-0.06249638799721012,0.09501746892058018,-0.6577357690873389,0.5109318351933964,LGP Offspring,,,C8,296,584
Cohort,0.11048053199199141,0.2541332535098794,0.434734653832685,0.6638675026777991,LGP Proband,,,C8,296,767
Cohort,0.045107558250225534,0.08401870966509317,0.5368751606639603,0.5915038730694905,LonGen OPEL,,,C8,461,573
Cohort,-0.4331081848823591,0.14468301957872978,-2.9934969987731126,0.0028586245006593115,LGP Offspring,,,C8,677,1237
Cohort,-0.3513453017743755,0.3850203441310517,-0.9125369792272223,0.3617498158524748,LGP Proband,,,C8,677,1711
Cohort,0.009188018845670392,0.12335064394551971,0.07448699537984144,0.9406416030523079,LonGen OPEL,,,C8,992,1185
Cohort,0.017907761498557804,0.017980616208947274,0.9959481527472225,0.3196316973141213,LGP Offspring,,,C8,7,26
Cohort,-0.006013295265507008,0.04505272814240444,-0.13347238920803967,0.8938519979020136,LGP Proband,,,C8,7,27
Cohort,0.008465931422221306,0.014119704831740729,0.5995827478765783,0.5489549707182426,LonGen OPEL,,,C8,14,17
Cohort,-0.04692509233224478,0.027384472441319897,-1.7135656870073723,0.08706697555539787,LGP Offspring,,,C8,27,40
Cohort,0.005756942026019053,0.07084721136603163,0.08125855506543302,0.935255829058417,LGP Proband,,,C8,27,52
Cohort,-0.04821978507382119,0.02473425896642274,-1.9495140379697866,0.05158489607274838,LonGen OPEL,,,C8,46,35
Cohort,-0.008601793194947452,0.0282344937498755,-0.30465547819448263,0.7607223283431299,LGP Offspring,,,C8,25,47
Cohort,-0.11128410775307922,0.07797567169600536,-1.4271644646669999,0.15390677597408753,LGP Proband,,,C8,25,72
Cohort,-0.009360952264643256,0.019656612462888457,-0.47622408399802696,0.6340454261280113,LonGen OPEL,,,C8,28,30
Cohort,0.023557173226314215,0.056621622304759846,0.4160455364475472,0.6775087289828239,LGP Offspring,,,C8,106,225
Cohort,0.20142820575527468,0.16225088513883493,1.2414613675784665,0.21478440324873735,LGP Proband,,,C8,106,334
Cohort,-0.05889815780161769,0.05346527084278209,-1.101615251792352,0.2709619586371029,LonGen OPEL,,,C8,210,228
Cohort,0.007045049603512402,0.0359586800927649,0.1959206952351376,0.8447311168721955,LGP Offspring,,,C8,37,75
Cohort,-0.293165673031324,0.09815174818085762,-2.9868614514244554,0.0029010975067789877,LGP Proband,,,C8,37,117
Cohort,0.006915243755015042,0.031255205719637615,0.22125094350827457,0.8249537871268923,LonGen OPEL,,,C8,65,83
Cohort,-0.014730919559138444,0.04833287381089884,-0.30478054370970775,0.7606271088645566,LGP Offspring,,,C8,72,146
Cohort,0.056623114661304375,0.13432417872288857,0.4215407471659896,0.6734688872365548,LGP Proband,,,C8,72,196
Cohort,-0.06674999830959966,0.04249767015826715,-1.5706742995795655,0.1166557131401994,LonGen OPEL,,,C8,137,133
Cohort,-0.02936074969286615,0.03626887695020786,-0.8095301581346008,0.4184951100630768,LGP Offspring,,,C8,50,86
Cohort,-0.055432713825598494,0.09769535501634884,-0.5674037810325998,0.5705925764675003,LGP Proband,,,C8,50,115
Cohort,0.034690482809403844,0.03111901779439457,1.114767922259185,0.26528634245590166,LonGen OPEL,,,C8,61,82
Cohort,0.003138016263754982,0.0298504922111249,0.10512443954225595,0.9163082506239402,LGP Offspring,,,C8,26,59
Cohort,-0.05745639637704366,0.08154612425781788,-0.7045877029714908,0.48126355539407106,LGP Proband,,,C8,26,86
Cohort,-0.02336208908442563,0.029337417675823256,-0.7963239758377967,0.4260811801014901,LonGen OPEL,,,C8,65,72
Cohort,0.003917525295613511,0.007177089498761282,0.5458375984150191,0.5853576496438793,LGP Offspring,,,C8,1,4
Cohort,-0.00310440442656691,0.024872902135781465,-0.12481070401917435,0.9007034897975044,LGP Proband,,,C8,1,9
Cohort,0.010496693064816622,0.0063439339722053114,1.654603139125628,0.09839924177227231,LonGen OPEL,,,C8,1,5
Cohort,-0.012198919923691215,0.01189685660486573,-1.0253901790076165,0.3055458962496929,LGP Offspring,,,C8,6,8
Cohort,0.0074650207787802045,0.042520841802328076,0.17556145321590233,0.8606811032615319,LGP Proband,,,C8,6,25
Cohort,0.006322457609302408,0.014427672790848526,0.43821742431757554,0.6613475742939179,LonGen OPEL,,,C8,13,19
Cohort,-0.0030744439516063884,0.04337762142661316,-0.07087626869554786,0.9435171929994757,LGP Offspring,,,C8,59,120
Cohort,-0.11119801068654203,0.11247028771475512,-0.988687883226192,0.32310262004750756,LGP Proband,,,C8,59,150
Cohort,-0.018505934430086652,0.03580431216152601,-0.5168632858131664,0.6053951715848908,LonGen OPEL,,,C8,95,99
Cohort,0.005619919371196143,0.018617079156458567,0.3018690162923061,0.7628447597042898,LGP Offspring,,,C8,10,23
Cohort,0.0712059515063484,0.04839700975026962,1.4712882443310809,0.14159038439049831,LGP Proband,,,C8,10,27
Cohort,0.018284181419593967,0.01641659524713885,1.1137620891750137,0.26571745842221645,LonGen OPEL,,,C8,15,25
Cohort,-0.020178182921357646,0.021727372823572642,-0.9286987011823981,0.35337673788736035,LGP Offspring,,,C8,19,30
Cohort,-0.07567995479771021,0.05657680702463585,-1.3376498034743471,0.1813752711371643,LGP Proband,,,C8,19,34
Cohort,0.01403157305699673,0.017280108942833192,0.8120072103374226,0.41703025178399944,LonGen OPEL,,,C8,17,30
Cohort,0.014164974000106193,0.020853187519319857,0.6792714057255164,0.4971984175090527,LGP Offspring,,,C8,12,31
Cohort,-0.05413021343856891,0.0639696689321629,-0.8461856117462745,0.39769192743110815,LGP Proband,,,C8,12,51
Cohort,-0.01152227115002374,0.01929725963562628,-0.5970936478851906,0.5506146538855208,LonGen OPEL,,,C8,28,27
Cohort,-0.006617029133160846,0.01730447609010003,-0.3823882964562261,0.7022935589519682,LGP Offspring,,,C8,11,18
Cohort,0.007973296091498057,0.05347494219705928,0.14910340738875127,0.8815080832504636,LGP Proband,,,C8,11,38
Cohort,0.01806743000925749,0.015215876467052494,1.1874064598499845,0.23542154371817223,LonGen OPEL,,,C8,14,22
Cohort,-9.194504524174865e-4,0.01812491311164492,-0.05072854400757137,0.9595568162966376,LGP Offspring,,,C8,11,23
Cohort,8.223659821126806e-4,0.05121672166696516,0.016056591584679803,0.9871930841815207,LGP Proband,,,C8,11,33
Cohort,-0.0029169595411285827,0.015109262854066115,-0.19305770038566691,0.84696302696014,LonGen OPEL,,,C8,15,18
Cohort,0.022463775302226114,0.03190064464560076,0.7041793528559295,0.48156358715660874,LGP Offspring,,,C8,28,72
Cohort,0.10920703902519119,0.09099696616807361,1.2001173624127548,0.230434551406449,LGP Proband,,,C8,28,100
Cohort,0.018006117787351818,0.028665910010063272,0.6281369676047509,0.53009438870831,LonGen OPEL,,,C8,57,71
Cohort,0.039333468698127864,0.04137683796583425,0.950615625355576,0.34213927276962275,LGP Offspring,,,C8,50,122
Cohort,0.00102295030073081,0.11824562807510962,0.008651062346939643,0.9930996058929242,LGP Proband,,,C8,50,176
Cohort,-0.04998137216637792,0.039082368616592124,-1.2788726460442499,0.20131461353010457,LonGen OPEL,,,C8,115,111
Cohort,-0.019048667421206606,0.016923956787018194,-1.1255445556217802,0.2607577908255242,LGP Offspring,,,C8,11,18
Cohort,0.009541428972195095,0.04326844620962844,0.22051702355958092,0.8255224855562286,LGP Proband,,,C8,11,18
Cohort,-0.004108847720293394,0.01605475071891228,-0.25592722006285823,0.798073157195037,LonGen OPEL,,,C8,19,21
Cohort,-0.007551962422084313,0.0169999051789833,-0.44423556146775917,0.6570144575153515,LGP Offspring,,,C8,10,20
Cohort,-0.010434528898290626,0.043215554392385946,-0.24145308431190837,0.8092633251179994,LGP Proband,,,C8,10,22
Cohort,0.011670660567292141,0.014359393907235497,0.8127543991540938,0.4166018962475244,LonGen OPEL,,,C8,12,20
Cohort,0.020121950562963477,0.0212121790819588,0.9486036528928529,0.3431612191911473,LGP Offspring,,,C8,13,34
Cohort,-0.04902607837869176,0.05467143134191224,-0.8967403482101146,0.37011625524707237,LGP Proband,,,C8,13,38
Cohort,-0.01731885302702558,0.01628836964345049,-1.0632649802363394,0.28798425214890067,LonGen OPEL,,,C8,22,18
Cohort,0.06239982629216431,0.04491321559078972,1.3893422118936534,0.16518616035209185,LGP Offspring,,,C8,52,139
Cohort,-0.09112999759292059,0.12533688362220885,-0.7270804487815825,0.4673807113352161,LGP Proband,,,C8,52,204
Cohort,0.06324284510079436,0.03842880512626766,1.645714585530147,0.10021729888039284,LonGen OPEL,,,C8,91,142
Cohort,-0.034440340824021025,0.024329263104045734,-1.4155932580750425,0.1573551629872422,LGP Offspring,,,C8,23,33
Cohort,-0.07259221395356973,0.06521974630058767,-1.1130404221292658,0.26601176926958,LGP Proband,,,C8,23,47
Cohort,-0.013836581781194962,0.020290973034452615,-0.6819082435180136,0.4954953331393285,LonGen OPEL,,,C8,29,33
Cohort,0.00809614624521293,0.06213279135647331,0.13030391953200784,0.8963647437017495,LGP Offspring,,,C8,122,256
Cohort,-0.25274155678885146,0.16888944067922182,-1.4964911706285604,0.13490402891193778,LGP Proband,,,C8,122,349
Cohort,0.07335957737881961,0.05413198127734215,1.3551984547353986,0.17573876910812591,LonGen OPEL,,,C8,186,252
Cohort,0.14770794956067862,0.059341188739104656,2.4891302769494748,0.0130450366250848,LGP Offspring,,,C8,80,241
Cohort,0.12985214408449341,0.1579409089076223,0.8221564949992933,0.41122281848162623,LGP Proband,,,C8,80,295
Cohort,0.0190354839760875,0.04731301613961882,0.4023308072331417,0.6875485989936521,LonGen OPEL,,,C8,145,185
Cohort,-0.02805830952512821,0.04057642333721183,-0.6914929216887505,0.48949323294593305,LGP Offspring,,,C8,56,103
Cohort,0.1381500261098835,0.11131779434408169,1.241041712368678,0.21493930290044672,LGP Proband,,,C8,56,146
Cohort,0.03808152579327456,0.037454141733048146,1.0167507258529125,0.30958096148615993,LonGen OPEL,,,C8,87,115
Cohort,-0.07269577222526838,0.07053906898932356,-1.0305745917382498,0.30310893196129657,LGP Offspring,,,C8,173,334
Cohort,0.1569143900258506,0.1943819060613071,0.8072479234582697,0.4197538176049995,LGP Proband,,,C8,173,444
Cohort,-0.018147488888728847,0.059539279052833606,-0.30479859980543667,0.7605992216098506,LonGen OPEL,,,C8,249,287
Cohort,0.014540845993573187,0.045963929823031685,0.31635341124133026,0.7518319335434435,LGP Offspring,,,C8,68,138
Cohort,-0.1305449234725451,0.12704593085639154,-1.0275411624171473,0.3044636316974264,LGP Proband,,,C8,68,202
Cohort,0.07585041095162569,0.040519980073686984,1.87192616614542,0.06158331605025561,LonGen OPEL,,,C8,99,152
Cohort,-0.02606754240947013,0.03200868539268319,-0.8143896598586604,0.41570854912900934,LGP Offspring,,,C8,38,68
Cohort,-0.022197689393090737,0.09030832166566408,-0.24579893617412304,0.8058983566291607,LGP Proband,,,C8,38,103
Cohort,0.031125290625095565,0.026639866096820317,1.1683726379094157,0.24300629025956916,LonGen OPEL,,,C8,42,65
Cohort,-0.36047763623064605,0.18982046595236893,-1.8990451552315735,0.0579840191506478,LGP Offspring,,,C8,1068,2065
Cohort,-0.503760233992264,0.5068099407061418,-0.9939825436146168,0.32051966165782625,LGP Proband,,,C8,1068,2907
Cohort,-0.12352607888377484,0.1522921374348194,-0.81111264812764,0.41754343702796337,LonGen OPEL,,,C8,1643,1930
Cohort,-0.0803325303978652,0.06154095423035243,-1.3053507441105718,0.19221754505180666,LGP Offspring,,,C8,145,272
Cohort,0.05010504454476083,0.1738809868741659,0.28815712083012746,0.7732980653426155,LGP Proband,,,C8,145,396
Cohort,-0.04062113502600303,0.05492103217541306,-0.7396280335056816,0.459743791892563,LonGen OPEL,,,C8,235,250
Cohort,-0.09532297597781886,0.060901624215209935,-1.5651959566952294,0.11800494454385264,LGP Offspring,,,C8,131,224
Cohort,-0.06033682801781288,0.1744484398629954,-0.3458719840956957,0.7295261518764695,LGP Proband,,,C8,131,362
Cohort,0.04634603536579097,0.055399162198398536,0.8365836869484414,0.40307769028367435,LonGen OPEL,,,C8,205,262
Cohort,0.03173174273444337,0.07482517832030901,0.42407841112796596,0.6716435438146393,LGP Offspring,,,C8,174,375
Cohort,0.09071345414930582,0.2015158819118845,0.4501553589159364,0.6527154078588868,LGP Proband,,,C8,174,493
Cohort,-0.023994218100107705,0.061178343436442226,-0.3922011736887766,0.6950145639137371,LonGen OPEL,,,C8,258,319
Cohort,-0.13508555403591935,0.0873831719732776,-1.5458989526865592,0.12259696627528491,LGP Offspring,,,C8,235,451
Cohort,0.06795583991966783,0.23006171754033442,0.29538091189706006,0.7677764340049578,LGP Proband,,,C8,235,674
Cohort,-0.15578401780787657,0.07584058154936045,-2.0540984078093514,0.0402922455350654,LonGen OPEL,,,C8,401,433
Cohort,0.024815622564562025,0.1049963101533822,0.23634756810320776,0.8132345723585257,LGP Offspring,,,C8,372,795
Cohort,-0.1413701502912546,0.3071544774021563,-0.46025749481802003,0.6454513790802728,LGP Proband,,,C8,372,1178
Cohort,0.0156031585003326,0.09392940882791874,0.1661157958410876,0.8681080066282517,LonGen OPEL,,,C8,632,770
Cohort,-0.08760591386908417,0.09949960363093857,-0.8804649533482548,0.37892038935729844,LGP Offspring,,,C8,353,706
Cohort,-0.32143336726303534,0.27964598091693604,-1.1494295974112767,0.2507083963480605,LGP Proband,,,C8,353,938
Cohort,-0.14061892047792945,0.09006071964143829,-1.5613790455792513,0.11883180591564531,LonGen OPEL,,,C8,543,583
Cohort,0.02937618864144657,0.059429292760642516,0.49430486678955005,0.6212514754950653,LGP Offspring,,,C8,101,240
Cohort,-0.12431332713246547,0.16715191851846292,-0.7437146293880816,0.4572586027264962,LGP Proband,,,C8,101,324
Cohort,-0.0063230285339897045,0.05068777613211077,-0.1247446429196182,0.9007572088592389,LonGen OPEL,,,C8,168,196
Cohort,0.07107275688191485,0.07184912662958495,0.9891944441903567,0.3229219426154215,LGP Offspring,,,C8,145,342
Cohort,-0.20633634436688364,0.1954120216684361,-1.0559040462565978,0.29131782601686096,LGP Proband,,,C8,145,485
Cohort,0.12464969565920492,0.06038368276711887,2.064294358128836,0.03931329594768029,LonGen OPEL,,,C8,227,319
Cohort,-0.031530847077245454,0.01400656481093962,-2.251147765554817,0.02469660743332836,LGP Offspring,,,C8,11,7
Cohort,-0.11153465521369915,0.03000382985972946,-3.7173472765021485,2.1477045270766663e-4,LGP Proband,,,C8,11,4
Cohort,-1.1467395771630031e-4,0.008520850905937169,-0.013458040632584904,0.989265733543651,LonGen OPEL,,,C8,5,6
Cohort,-0.10053870799055291,0.0820866733926869,-1.224787213748997,0.22108201857792129,LGP Offspring,,,C8,229,432
Cohort,-0.28364971864449273,0.24052348676175409,-1.179301541248055,0.23861443140482594,LGP Proband,,,C8,229,662
Cohort,-0.09598350373003385,0.0746597943077598,-1.2856116818963397,0.19895250107865603,LonGen OPEL,,,C8,389,435
Cohort,-0.38704181529323906,0.1613269494511325,-2.399114448082202,0.016704568721270206,LGP Offspring,,,C8,856,1623
Cohort,-0.2176173528141751,0.4597039751269287,-0.47338584086441465,0.6360618104756395,LGP Proband,,,C8,856,2200
Cohort,-0.153599150875772,0.1362120575390451,-1.1276472410068608,0.259808711113585,LonGen OPEL,,,C8,1308,1505
Cohort,0.021398426281808863,0.03764511484873586,0.568425049778469,0.5699351553308334,LGP Offspring,Amacrine Cells,,C8,45,104
Cohort,-0.2296534022321071,0.09920408137082051,-2.3149592139629087,0.020857118614961652,LGP Proband,Amacrine Cells,,C8,45,124
Cohort,-0.11145768762853064,0.033278766149637706,-3.349213343047697,8.485371758699682e-4,LonGen OPEL,Amacrine Cells,,C8,102,76
Cohort,0.08728433407224447,0.04929908297271969,1.7705062408674908,0.07709347098555941,LGP Offspring,Bipolar Cells,,C8,65,174
Cohort,0.05014244882396709,0.13025424186588946,0.38495827932877646,0.7003664759688506,LGP Proband,Bipolar Cells,,C8,65,204
Cohort,-0.008181213191795262,0.04096630422874146,-0.19970591308686866,0.8417615938154714,LonGen OPEL,Bipolar Cells,,C8,104,123
Cohort,-0.023610349255744303,0.07966581942620615,-0.2963673684121757,0.7670405691591916,LGP Offspring,Fetal Blood Cells,,C8,207,428
Cohort,-0.2852408756488874,0.2216599855378313,-1.2868397286807751,0.19850721151988693,LGP Proband,Fetal Blood Cells,,C8,207,622
Cohort,0.049547731323039676,0.06888852862847579,0.7192450224950603,0.47220105960389125,LonGen OPEL,Fetal Blood Cells,,C8,310,388
Cohort,-0.06587633150424874,0.10603016689808323,-0.6212980082127894,0.5346130073707935,LGP Offspring,Retinal Fibroblasts,,C8,379,778
Cohort,-0.24315067556335812,0.2989927630837235,-0.8132326450164662,0.4163167824330718,LGP Proband,Retinal Fibroblasts,,C8,379,961
Cohort,0.023869866963975174,0.09206817439942576,0.25926295508390196,0.7954993935407653,LonGen OPEL,Retinal Fibroblasts,,C8,556,667
Cohort,-0.04427517815382424,0.025179179423422335,-1.7584043311847688,0.07913120793864926,LGP Offspring,Horizontal Cells,,C8,27,36
Cohort,-0.0054951705051862225,0.07693763383331602,-0.07142370035828512,0.943077671137992,LGP Proband,Horizontal Cells,,C8,27,76
Cohort,-0.008170710170701152,0.024357323738074515,-0.3354518853780715,0.7373726230463173,LonGen OPEL,Horizontal Cells,,C8,39,46
Cohort,-0.027829389685361805,0.09263808331964063,-0.30040981730309146,0.7639569372968475,LGP Offspring,Retinal Microglia,,C8,276,576
Cohort,-0.238668588316493,0.247665047392103,-0.9636748940944954,0.3354882750337511,LGP Proband,Retinal Microglia,,C8,276,760
Cohort,0.011505812359953089,0.0788927638714161,0.14584116204505035,0.8840837038905927,LonGen OPEL,Retinal Microglia,,C8,421,525
Cohort,-0.05382465754867194,0.033538826092597236,-1.6048461982559443,0.10899469691517388,LGP Offspring,M�ller glia cells,,C8,41,67
Cohort,0.04503908644205217,0.09239717640464135,0.48745089617034815,0.6260669337827567,LGP Proband,M�ller glia cells,,C8,41,98
Cohort,-0.02001610511956211,0.029208841260625507,-0.6852755623190191,0.4933695562852951,LonGen OPEL,M�ller glia cells,,C8,57,60
Cohort,-0.0910171421503837,0.04661519008349823,-1.9525210985378725,0.051288732766945865,LGP Offspring,Rod Photoreceptor Cells,,C8,84,134
Cohort,0.006679521954105899,0.12911960842490663,0.05173127486667197,0.958755204291993,LGP Proband,Rod Photoreceptor Cells,,C8,84,194
Cohort,0.006128341037371538,0.03996403922500059,0.15334638730756195,0.8781639864883681,LonGen OPEL,Rod Photoreceptor Cells,,C8,102,133
Cohort,-0.041768007167935,0.09256356616004054,-0.4512359333230416,0.6519642293737569,LGP Offspring,Retinal Ganglion Cells,,C8,282,580
Cohort,-0.01783239707182113,0.264870700534042,-0.06732491376308061,0.9463391798768369,LGP Proband,Retinal Ganglion Cells,,C8,282,878
Cohort,0.11002648660651393,0.08331707326683485,1.3205755110256736,0.18702249588205477,LonGen OPEL,Retinal Ganglion Cells,,C8,474,611
Cohort,-0.129982692281563,0.05446322064247477,-2.3866141360761195,0.01727838980557816,LGP Offspring,Retinal Progenitor Cells,,C8,112,182
Cohort,-0.08674185446925814,0.14596703594198165,-0.5942564628340875,0.5525017538998542,LGP Proband,Retinal Progenitor Cells,,C8,112,253
Cohort,0.029989390529503387,0.04151157385563091,0.7224344380148194,0.47023960651242147,LonGen OPEL,Retinal Progenitor Cells,,C8,122,155
Cohort,-0.1808610010025489,0.10156419522980262,-1.7807555171714462,0.07540138669687572,LGP Offspring,Retinal Pigment Epithelium Cells,,C8,342,637
Cohort,-0.2029925017194781,0.2811776124841457,-0.7219369277876769,0.47053561439887626,LGP Proband,Retinal Pigment Epithelium Cells,,C8,342,957
Cohort,-0.013404895618323288,0.08694480193890332,-0.15417707924325363,0.8775091945397544,LonGen OPEL,Retinal Pigment Epithelium Cells,,C8,512,612
Cohort,-0.08524936339293393,0.04259217291604436,-2.0015265142957923,0.04573487459643039,LGP Offspring,,,C8,64,94
Cohort,-0.06710448280540696,0.11601466128730163,-0.5784138147783556,0.5631409240136764,LGP Proband,,,C8,64,152
Cohort,0.02945995057400922,0.032939001287772295,0.8943789860728237,0.3713894951853628,LonGen OPEL,,,C8,68,93
Cohort,-0.021597553402786643,0.08452100564301937,-0.25552882669197624,0.7983924103940776,LGP Offspring,,,C8,225,474
Cohort,-0.07049911800695094,0.23906530016303965,-0.29489481726905326,0.7681476221510681,LGP Proband,,,C8,225,637
Cohort,-0.12618706834068316,0.07567000537103907,-1.6675969259145622,0.09578909349525097,LonGen OPEL,,,C8,418,451
Cohort,0.067125954425673,0.09267490749827317,0.724316389815914,0.4691221161403035,LGP Offspring,,,C8,248,554
Cohort,-0.20633485310478566,0.2546742213024471,-0.8101913576079836,0.4180613150775164,LGP Proband,,,C8,248,755
Cohort,-0.049649726079362466,0.07882251451288264,-0.6298926948244944,0.5289455535834552,LonGen OPEL,,,C8,446,511
Cohort,0.2214543730803645,0.10448150746561059,2.1195556845622154,0.03440738313810246,LGP Offspring,,,C8,316,755
Cohort,0.023979882144938052,0.285303382587813,0.08405046560412696,0.9330364782136602,LGP Proband,,,C8,316,945
Cohort,0.07058622398213264,0.09094148168038067,0.7761719149267019,0.4378780424614843,LonGen OPEL,,,C8,542,675
Cohort,0.09851261286389605,0.08143765589376427,1.2096690625821318,0.22682876204108932,LGP Offspring,,,C8,184,436
Cohort,0.05301173315755802,0.21664688470865795,0.24469187834778724,0.8067552062057071,LGP Proband,,,C8,184,528
Cohort,-0.055424644638795074,0.06547467610613056,-0.8465050601999927,0.39752546364741537,LonGen OPEL,,,C8,316,352
Cohort,0.04289708117709659,0.09905158439313765,0.43307819294275246,0.6650961088868992,LGP Offspring,,,C8,308,676
Cohort,-0.05121508210876561,0.28284256920559514,-0.18107275100990167,0.8563544663892493,LGP Proband,,,C8,308,897
Cohort,-0.2030790505925667,0.08346324631076966,-2.4331554255200643,0.015187064228786231,LonGen OPEL,,,C8,554,567
Cohort,-0.12904637067675906,0.08984337088748894,-1.4363482736902662,0.15136587027816628,LGP Offspring,,,C8,240,464
Cohort,0.0015266047919000136,0.2296331032919442,0.006648017076001293,0.994697278716286,LGP Proband,,,C8,240,646
Cohort,-0.19927464125051333,0.07531429392245008,-2.6459073154918404,0.008308018961293344,LonGen OPEL,,,C8,424,410
Cohort,-0.10410710215663999,0.07756974216345423,-1.3421096841764213,0.18001101439714112,LGP Offspring,,,C8,192,366
Cohort,-0.17199982654188384,0.22138396914074246,-0.7769299069371044,0.4374204260872281,LGP Proband,,,C8,192,531
Cohort,-0.1551525146056045,0.06545857191803325,-2.3702398335222674,0.01801396306609114,LonGen OPEL,,,C8,358,348
Cohort,0.0025251969325541367,0.09109278540274358,0.027721151805706903,0.9778927349451778,LGP Offspring,,,C8,248,527
Cohort,-0.5644405130056244,0.25161394620197514,-2.2432799195976902,0.0251405656489792,LGP Proband,,,C8,248,764
Cohort,-0.15492391579276396,0.08174300669701431,-1.895255900813624,0.05842056789967148,LonGen OPEL,,,C8,470,490
Cohort,-0.0460815295577672,0.08194057007991912,-0.5623774585998423,0.5740453069971934,LGP Offspring,,,C8,212,439
Cohort,0.39945048203498074,0.23253384078135264,1.7178165581954017,0.08620127219362979,LGP Proband,,,C8,212,605
Cohort,-0.05660644350319748,0.07111929218336477,-0.7959365421867637,0.4263062150292164,LonGen OPEL,,,C8,383,435
Cohort,0.024280772911748648,0.07791289445722036,0.31163998053082853,0.7554102332106802,LGP Offspring,,,C8,188,416
Cohort,-0.023695049508814674,0.2122962464681485,-0.11161313449020269,0.9111570129068071,LGP Proband,,,C8,188,560
Cohort,0.021605191730617104,0.0677727439587564,0.31878880016670275,0.7499703017932389,LonGen OPEL,,,C8,325,410
Cohort,-0.055251288048732354,0.10533263872667854,-0.5245410037823193,0.6000742665820606,LGP Offspring,,,C8,327,654
Cohort,-0.10216816358830284,0.2848120062912954,-0.3587214068630553,0.7198943002786999,LGP Proband,,,C8,327,972
Cohort,-0.07268432155889927,0.08623862557716795,-0.84282792162382,0.3995778647691943,LonGen OPEL,,,C8,540,619
Cohort,0.08738357353180527,0.08176095893338417,1.0687689414577708,0.28555528789670415,LGP Offspring,,,C8,193,439
Cohort,-0.06149277824038392,0.2129524934982811,-0.2887628936868038,0.772834586114195,LGP Proband,,,C8,193,585
Cohort,-0.015742846019291042,0.06642865886476063,-0.23698876792532053,0.8127264799910272,LonGen OPEL,,,C8,337,391
Cohort,-0.05017257029078629,0.06088347708887047,-0.8240753105731844,0.4101874199153718,LGP Offspring,,,C8,128,245
Cohort,-0.07868860401748197,0.17411367411208167,-0.4519381054863502,0.6514310834247179,LGP Proband,,,C8,128,369
Cohort,-0.10500856635840349,0.053517906879491185,-1.9621202038946752,0.05009653907762276,LonGen OPEL,,,C8,224,229
Cohort,-0.035608475259554774,0.08825875063937279,-0.40345546477370603,0.6867407721661278,LGP Offspring,,,C8,217,452
Cohort,-0.01616940733742776,0.23216726423295544,-0.06964550920151887,0.9444925088863418,LGP Proband,,,C8,217,611
Cohort,-0.09801917868747695,0.07540693639025281,-1.299869526328443,0.19402197508619962,LonGen OPEL,,,C8,363,391
Cohort,0.04499337876524826,0.05822297072350028,0.7727771050865975,0.4399244112317007,LGP Offspring,,,C8,99,236
Cohort,0.017909683784550465,0.16013699982960322,0.11183976097721077,0.9109773713922559,LGP Proband,,,C8,99,307
Cohort,0.009164228694411714,0.049061111292466215,0.18679211401839904,0.8518712265525967,LonGen OPEL,,,C8,160,192
Cohort,0.04317162274799664,0.0758427298396979,0.5692255914211513,0.5693921355882761,LGP Offspring,,,C8,158,365
Cohort,0.22243076803274728,0.2096870746080267,1.060774816228147,0.2890993409988278,LGP Proband,,,C8,158,518
Cohort,-0.03593469566726208,0.06443551243176389,-0.5576846417620456,0.5772165439226955,LonGen OPEL,,,C8,295,334
Cohort,0.03232768129781365,0.04293325476434414,0.7529753212342437,0.45172688213254686,LGP Offspring,,,C8,61,129
Cohort,-0.07324108298268055,0.1216753796743342,-0.6019383968943536,0.5473787430607328,LGP Proband,,,C8,61,194
Cohort,-0.052729745142201606,0.03605114046191156,-1.462637366435361,0.14396133935642866,LonGen OPEL,,,C8,95,100
Cohort,0.10048268403092078,0.09112474937648922,1.1026936668518945,0.27055262680977604,LGP Offspring,,,C8,233,551
Cohort,-0.07033323315478492,0.23782210984132576,-0.29573883270025253,0.7675031551491602,LGP Proband,,,C8,233,725
Cohort,-0.10584768243183243,0.07825681058468166,-1.352568315026009,0.17657766827703972,LonGen OPEL,,,C8,426,477
Cohort,0.17736763578779172,0.09381992573196085,1.8905113642332523,0.059117042472592,LGP Offspring,,,C8,234,573
Cohort,-0.16313192435377977,0.24607404111335573,-0.6629383725958802,0.5075531996545175,LGP Proband,,,C8,234,775
Cohort,0.04681029056892632,0.07856058016577609,0.595849603836284,0.5514450844600665,LonGen OPEL,,,C8,410,505
Cohort,0.07810726639023227,0.07455290235143013,1.0476757299406998,0.29516246822105285,LGP Offspring,,,C8,164,377
Cohort,-0.062108766802872695,0.20336489526556062,-0.3054055456413409,0.7601335057242877,LGP Proband,,,C8,164,527
Cohort,-0.11273866657448375,0.06496836449721323,-1.7352855877928033,0.08307725775565131,LonGen OPEL,,,C8,300,313
Cohort,-0.07693358888912806,0.07063046606680438,-1.0892408499239123,0.2764358340844475,LGP Offspring,,,C8,187,349
Cohort,0.06097401542150316,0.19905282662993953,0.30632077149479703,0.7594368787159416,LGP Proband,,,C8,187,480
Cohort,-0.08510138734360981,0.05879562361149231,-1.447410234236817,0.14817576884146885,LonGen OPEL,,,C8,262,283
Cohort,-0.14870455148041958,0.10385899974707634,-1.4317926404312946,0.15266535446682672,LGP Offspring,,,C8,377,734
Cohort,-0.2188259021641635,0.2996188949970846,-0.7303474707971697,0.4653829209406922,LGP Proband,,,C8,377,1015
Cohort,-0.18430590951117456,0.08860658072823482,-2.08004764427666,0.03784057584796942,LonGen OPEL,,,C8,602,650
Cohort,0.0028764571201412995,0.018395751349199553,0.1563652968306979,0.8757917743615163,LGP Offspring,,,C8,9,18
Cohort,-0.057909045890947565,0.03883587344434042,-1.491122530665953,0.1363074452090794,LGP Proband,,,C8,9,18
Cohort,-0.02820353780505899,0.013161177053882311,-2.142934305160757,0.03242096270661885,LonGen OPEL,,,C8,17,8
Cohort,-0.03121360048191244,0.09914827624435593,-0.3148173792248788,0.7529974614850727,LGP Offspring,,,C8,317,637
Cohort,-0.38321457793134683,0.2767652218605978,-1.3846196980788499,0.16653909905655867,LGP Proband,,,C8,317,876
Cohort,0.03855656288574234,0.0871888404299172,0.44221901215367454,0.6584508535480936,LonGen OPEL,,,C8,490,607
Cohort,-0.3311418283512908,0.13568680111265885,-2.4404866621945667,0.014923225454934134,LGP Offspring,,,C8,644,1224
Cohort,0.14131194339639364,0.3794770747390757,0.3723859827199263,0.7097000953273631,LGP Proband,,,C8,644,1741
Cohort,-0.21115636779858923,0.11395915158617774,-1.852912774968401,0.06426478745152614,LonGen OPEL,,,C8,969,1081
Cohort,-0.0014078270663664553,0.08450514544336472,-0.016659660887868417,0.9867130442707484,LGP Offspring,,,C8,216,436
Cohort,0.0060117439746066904,0.22530082188724285,0.026683187057415222,0.9787188063802528,LGP Proband,,,C8,216,583
Cohort,-0.07114656636712487,0.06825561950690233,-1.0423547083904232,0.29756372511688156,LonGen OPEL,,,C8,336,368
Cohort,0.045701751764227444,0.052700734134248146,0.8671938354370601,0.3861435259983308,LGP Offspring,,,C8,76,184
Cohort,-0.11277732398709925,0.14080597681542303,-0.8009413132720535,0.42339373255291013,LGP Proband,,,C8,76,244
Cohort,-0.014921193217113077,0.04219824017442635,-0.3535975233904625,0.7237341606814381,LonGen OPEL,,,C8,123,150
Cohort,0.07107245048461418,0.06768561289495618,1.0500377767859495,0.2940759794187345,LGP Offspring,,,C8,149,352
Cohort,0.2135837598024281,0.19591869522882863,1.090165282863726,0.2759552176792252,LGP Proband,,,C8,149,486
Cohort,0.12488671997034909,0.06165045710767572,2.0257225303654756,0.04312637418569002,LonGen OPEL,,,C8,245,346
Cohort,-0.06231655971346168,0.06686204629952927,-0.9320169387920814,0.3516605134836849,LGP Offspring,,,C8,173,331
Cohort,0.13070364870042753,0.19376714200434234,0.6745397973486054,0.5001551262590844,LGP Proband,,,C8,173,461
Cohort,0.10540351911712464,0.06496952170994244,1.6223533180327305,0.10512368751261608,LonGen OPEL,,,C8,265,360
Cohort,-0.013724203553277328,0.028637455833367242,-0.4792396235592417,0.6319231592002486,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,28,53
Cohort,0.08374732531543574,0.08445767610510675,0.9915892690584218,0.32168552270846923,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,28,95
Cohort,0.00881571331527787,0.028126956690990614,0.3134257791246091,0.7540393104857495,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,48,65
Cohort,-0.0033720574115381893,0.1259398828947107,-0.026775135358489452,0.9786469872720402,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,474,996
Cohort,-0.11974004124026132,0.3437484114919261,-0.34833627512799065,0.7276755622530492,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,474,1432
Cohort,-0.13203539370735404,0.10909409447257995,-1.2102891026841074,0.22652724173268296,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,837,954
Cohort,-0.183128825789103,0.13631435424467764,-1.3434302411057581,0.1795834946657092,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,580,1145
Cohort,-0.1554823720618161,0.3795554968094749,-0.4096433153222476,0.6821728081884724,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,580,1692
Cohort,-0.1874295541221501,0.11477553051160629,-1.6330096954175866,0.10286241989493128,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,946,1047
Cohort,-0.3702352666418985,0.1267169167204084,-2.9217509092238685,0.003596822695347346,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,561,1023
Cohort,-0.22523640109507811,0.36711439966967113,-0.6135319162030839,0.5396919773533184,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,561,1487
Cohort,-0.09971371364662004,0.10912617717820555,-0.9137469691051787,0.3611265003071271,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,856,989
Cohort,-0.12612580541797339,0.15923540233070074,-0.7920713834479771,0.4285969100248648,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,810,1642
Cohort,-0.20993531086376868,0.43465464083856975,-0.4829933725284632,0.6292272018356322,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,810,2313
Cohort,0.15989769907721518,0.1374948778403039,1.1629356786871106,0.24520411160339692,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,1217,1531
Cohort,-0.5312552272541132,0.2023072257620565,-2.6259824643087573,0.008835490877203237,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,1370,2630
Cohort,-0.5945642190688786,0.5675104591836546,-1.0476709449974542,0.2950937579935751,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,1370,3708
Cohort,-0.28993957222607963,0.17702077575372788,-1.6378844290539372,0.1018410112384216,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,2199,2495
Cohort,-0.22881177078366324,0.12290989446436555,-1.8616220588327095,0.0630901687246304,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,545,1063
Cohort,-0.1660331880295147,0.34951625574698925,-0.4750370985597425,0.6348849054496548,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,545,1415
Cohort,0.07322178647287608,0.110055565819164,0.6653165237748109,0.5060407881522557,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,806,1007
Cohort,-0.37846564652709486,0.16727734207019312,-2.262503946100977,0.023982852815104747,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,897,1726
Cohort,-0.7599713603940714,0.4562338925351684,-1.665749460591619,0.09613885805017063,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,897,2395
Cohort,-0.18010393492167595,0.13587059594758405,-1.3255549051330884,0.18536747201518763,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,1351,1534
Cohort,-0.07533074253695417,0.09715011544220585,-0.7754055895257075,0.4383711960036192,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,288,580
Cohort,0.37164666336645524,0.2766753556803739,1.3432590063995289,0.1795535169228065,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,288,852
Cohort,-0.05708164500392345,0.08589159792870557,-0.6645777512639146,0.5065130771003515,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,501,580
Cohort,-0.013617132528489628,0.10071130020902004,-0.13520957926496943,0.8924864227067881,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,311,668
Cohort,-0.13668139540719765,0.2788470905491747,-0.4901661162682774,0.624145275162614,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,311,906
Cohort,-0.08390011613136245,0.08754663479120417,-0.9583477004166002,0.3381784420953651,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,546,620
Cohort,-0.264089761402185,0.12641114960239286,-2.0891334524908554,0.03706908706986126,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,548,1047
Cohort,0.009685914158186933,0.3611090362466284,0.026822685632191427,0.9786075758404928,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,548,1569
Cohort,-0.18263037165966803,0.11319705175156997,-1.6133845257779433,0.10705733230819178,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,909,1014
Cohort,-0.13997431257267534,0.08318259806651701,-1.682735521926651,0.09288806457820079,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,243,437
Cohort,-0.16152943135709538,0.22904661958866182,-0.7052251268636115,0.4808670564371913,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,243,668
Cohort,0.04056079429111437,0.06987915967622473,0.5804419297405281,0.561780913727217,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,347,438
Cohort,-0.3383638833184738,0.1084133125396794,-3.121054743112219,0.001878807868321056,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,441,792
Cohort,-0.2572153625275577,0.3086824598933321,-0.8332684747181318,0.4049318996855096,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,441,1190
Cohort,-0.057339637132955534,0.09975918310510548,-0.5747805399783893,0.5656021390874753,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,700,794
Cohort,-0.18616389369715178,0.1141413008838156,-1.63099502332331,0.10335714049931453,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,428,825
Cohort,-0.2763937964809845,0.31587875215196876,-0.8749996465353006,0.38182601019809403,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,428,1211
Cohort,-0.10535871014869334,0.10218624443507372,-1.0310459174926947,0.3028324554609972,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,688,793
Cohort,-0.02759324807855702,0.1611674945905187,-0.17120851911648627,0.8641110431648922,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,819,1680
Cohort,-0.2932529785263359,0.4327297295243933,-0.6776816070590893,0.4981615434361366,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,819,2285
Cohort,-0.12037154542515661,0.12985138557761852,-0.9269946938933867,0.3542102658897952,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,1277,1464
Cohort,-0.2906131119038495,0.0930788937989638,-3.122223525040268,0.0018714713174692967,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,327,541
Cohort,-0.35342356110659123,0.26267378322890594,-1.3454847178205134,0.17883443990744954,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,327,864
Cohort,-0.056579970608382546,0.08398291087536276,-0.6737081391755004,0.5006924589194773,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,469,540
Cohort,-0.10638574987548974,0.09405672185433507,-1.131080775282053,0.2584222015388158,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,326,595
Cohort,-0.7373002836594104,0.2724315200492998,-2.7063692318935297,0.0069413182739228,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,326,914
Cohort,0.0015148156324857884,0.08481494301149561,0.01786024465382797,0.9857548197634247,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,487,580
Cohort,-0.13537228333529136,0.09679137279070699,-1.3985986501917715,0.162391967452848,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,324,621
Cohort,-0.2962185280159791,0.28271484364298716,-1.0477643274721167,0.2950507468311743,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,324,889
Cohort,0.012901632282000053,0.08272033128797351,0.15596688360792127,0.8760986692455353,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,482,581
Cohort,-0.2938192221830847,0.10453153760910182,-2.8108189059825057,0.005084635007232005,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,392,688
Cohort,-0.23224227961217384,0.2982900053175489,-0.7785788174998924,0.4364486988799655,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,392,1006
Cohort,-0.0626979600196716,0.08953060677282515,-0.7002963822054878,0.4839468563932162,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,559,654
Cohort,-0.28316105913712075,0.11258090715088337,-2.5151783397661043,0.01212804909911487,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,456,822
Cohort,-0.3222176490691858,0.32305038999190894,-0.9974222568722361,0.3188488897441508,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,456,1156
Cohort,0.005797749327071997,0.09934026008126348,0.05836253420646628,0.9534745049641389,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,654,800
Cohort,-0.5288468450969047,0.14378423501823745,-3.6780586204727266,2.5369267376023074e-4,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,751,1365
Cohort,0.05302254923325949,0.40056894208976757,0.1323680986265209,0.8947250741072285,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,751,1936
Cohort,-0.0511779634059588,0.12293051959483953,-0.41631617253903797,0.6772908854584025,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,1089,1300
Cohort,-0.4015075680690886,0.13198113703384912,-3.0421587288349716,0.0024398481883285694,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,640,1168
Cohort,-0.33888315646678563,0.3659366501134499,-0.9260705544572346,0.3546772084629096,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,640,1643
Cohort,-0.13144312409665793,0.11400283366725893,-1.1529812011541936,0.24926420944130995,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,919,1054
Cohort,-0.1241842571438636,0.10786662739046247,-1.151275979866632,0.2500257494773717,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,396,792
Cohort,-0.23685257070211765,0.3056277098490122,-0.7749708651062065,0.43857653801900376,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,396,1102
Cohort,0.029769272828015978,0.0958147082699415,0.3106962737301893,0.7561128674760813,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,610,743
Cohort,-0.4892348722388042,0.15067792099138316,-3.2468915752214427,0.0012243578141478192,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,759,1377
Cohort,-0.4278169200046638,0.4159991753475601,-1.0284080963555522,0.3040560639903768,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,759,1987
Cohort,0.04869429279668943,0.12493838088679851,0.3897464690278747,0.6968282873544369,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,1089,1338
Cohort,-0.1915334743419061,0.09951661078762844,-1.9246382370340618,0.05469400940911821,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,352,637
Cohort,-0.5658762437562554,0.29665479916991044,-1.9075243189716515,0.05679596311531927,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,352,946
Cohort,-0.072942402390839,0.09036570104947711,-0.8071912411867587,0.4197974335925493,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,561,645
Cohort,-0.13709110665510976,0.10719204361432927,-1.2789298723360063,0.2013606059307785,LGP Offspring," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,407,793
Cohort,-0.628200295936733,0.3136461373265599,-2.0028950501075924,0.04551176990370536,LGP Proband," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,407,1161
Cohort,-0.08779006076555336,0.09548023442250526,-0.919457951653926,0.35813462768048876,LonGen OPEL," Cell types are named using anatomical and functional mnemonics prefixed by �m� or �h� to indicate mouse and human respectively: OMTN, oculomotor and trochlear nucleus; Sert, serotonergic; NbM, medial neuroblast; NbDA, neuroblast dopaminergic; DA0-2, dopaminergic neurons; RN, red nucleus; Gaba1-2, GABAergic neurons; mNbL1-2, lateral neuroblasts; NbML1-5, mediolateral neuroblasts; NProg, neuronal progenitor; Prog, progenitor medial floorplate (FPM), lateral floorplate (FPL), midline (M), basal plate (BP); Rgl1-3, radial glia-like cells; Mgl, microglia; Endo, endothelial cells; Peric, pericytes; Epend, ependymal; OPC, oligodendrocyte precursor cells.",,C8,667,755
Cohort,-0.02276441417768261,0.04371021635260874,-0.5208030542343443,0.6026745180577221,LGP Offspring,,,C8,77,144
Cohort,-0.022270793010917184,0.13737893117857364,-0.1621121435423619,0.8712568100514796,LGP Proband,,,C8,77,229
Cohort,0.040588819212071414,0.043570113570520326,0.9315747856928684,0.35183877141200504,LonGen OPEL,,,C8,120,160
Cohort,-0.021876458042524062,0.028177313539372497,-0.7763855135428658,0.43779295209651414,LGP Offspring,,,C8,26,48
Cohort,-0.009464813468435487,0.07897084093021602,-0.11985200305514332,0.9046292511057321,LGP Proband,,,C8,26,63
Cohort,-0.004368719614268161,0.021714147565576568,-0.20119231487557407,0.8405995990815528,LonGen OPEL,,,C8,36,37
Cohort,0.0013942525631321467,0.035572267545805954,0.039194930751512695,0.9687465474037792,LGP Offspring,,,C8,39,84
Cohort,-0.07625504324712294,0.09656724335844245,-0.7896574510683316,0.42995229068049623,LGP Proband,,,C8,39,113
Cohort,0.018950259057694745,0.02951402830207438,0.6420763327777536,0.521008485009747,LonGen OPEL,,,C8,55,77
Cohort,-0.013227288274977364,0.02969904989176413,-0.44537748928612814,0.6561895645033562,LGP Offspring,,,C8,30,59
Cohort,0.004310520006039089,0.08252046839451312,0.052235767560496554,0.9583533419997998,LGP Proband,,,C8,30,83
Cohort,0.012296847451766244,0.024401838397809815,0.5039311895807795,0.6144491725766228,LonGen OPEL,,,C8,36,52
Cohort,-0.07765560427989357,0.054545815314312796,-1.423676662130977,0.15500147453776555,LGP Offspring,,,C8,105,179
Cohort,-0.3701773205774445,0.1548843457958146,-2.3900241091210894,0.017068348995686954,LGP Proband,,,C8,105,258
Cohort,-0.11377258572459029,0.046423521593115046,-2.450753019595644,0.014469913498912846,LonGen OPEL,,,C8,168,142
Cohort,-0.01996626208775844,0.07831457284959528,-0.25494951145432476,0.7988396370215162,LGP Offspring,,,C8,192,383
Cohort,-0.2692263446822727,0.21958056775004672,-1.2260936723177565,0.22050950391390264,LGP Proband,,,C8,192,555
Cohort,-0.03986308584064056,0.06477335537125097,-0.6154241294458772,0.5384505690793533,LonGen OPEL,,,C8,294,347
Cohort,-4.1450312447967026e-4,0.06214805002328566,-0.00666960788511247,0.9946804300135333,LGP Offspring,,,C8,125,251
Cohort,-0.1896205905292073,0.1736909411997663,-1.0917126087256324,0.275274716423486,LGP Proband,,,C8,125,334
Cohort,0.0613798517471413,0.048527531049816316,1.2648459630911644,0.20629672459421078,LonGen OPEL,,,C8,161,204
Cohort,-0.05168147224208901,0.05558985902150298,-0.9296924502380525,0.3528622054616758,LGP Offspring,,,C8,102,191
Cohort,-0.020961439811922576,0.15894984354429556,-0.13187455454198746,0.8951153221976723,LGP Proband,,,C8,102,268
Cohort,0.018449039229339118,0.04540740868051811,0.4063002000212052,0.6846312440434679,LonGen OPEL,,,C8,133,163
Cohort,0.11933259306474439,0.07833636071565118,1.5233359320571855,0.1281423289716661,LGP Offspring,,,C8,185,428
Cohort,-0.1517697717953221,0.2111311627903835,-0.7188411686341305,0.47244013692082587,LGP Proband,,,C8,185,563
Cohort,-0.08594586417791868,0.07213782344142708,-1.1914119400580911,0.23384702256745377,LonGen OPEL,,,C8,340,378
Cohort,-0.08158193751346296,0.08381583971965662,-0.973347493580384,0.33072878102896475,LGP Offspring,,,C8,235,458
Cohort,-0.08009314866336734,0.2386700822838905,-0.33558101583967725,0.7372712395699386,LGP Proband,,,C8,235,657
Cohort,-0.10316271770325591,0.07664564932490271,-1.3459696487917627,0.17869550959244387,LonGen OPEL,,,C8,383,426
Cohort,-0.10030959975120918,0.04967852981058117,-2.0191740805067857,0.04386334135194551,LGP Offspring,,,C8,92,143
Cohort,-0.08853150664310111,0.13203834643623616,-0.6704984501290666,0.5027257173105566,LGP Proband,,,C8,92,225
Cohort,-0.07839209145181693,0.04064559780465916,-1.9286736002399485,0.05412668276121915,LonGen OPEL,,,C8,131,126
Cohort,0.096661702612084,0.13801086652362546,0.7003919694652226,0.4839235280719303,LGP Offspring,,,C8,595,1292
Cohort,0.2534255881190011,0.3689023577895203,0.6869719934498082,0.492291347035131,LGP Proband,,,C8,595,1700
Cohort,0.15692435377006053,0.11666201887818473,1.345119476578891,0.1789697432266029,LonGen OPEL,,,C8,903,1199
Cohort,-0.2937234054782092,0.12104889122523084,-2.4264857158558337,0.015506328571146498,LGP Offspring,,,C8,507,957
Cohort,-0.15036951688204242,0.34145418359033713,-0.4403797759949243,0.6597761824549282,LGP Proband,,,C8,507,1312
Cohort,-0.029769438734661997,0.10985496933955459,-0.27098854893533847,0.7864700941634577,LonGen OPEL,,,C8,743,894
Cohort,-0.4762444106258404,0.1622978793076177,-2.934384679932704,0.0034553818664612317,LGP Offspring,,,C8,953,1784
Cohort,-1.0234993810897204,0.47010163299643,-2.1771874617110574,0.0297463098627332,LGP Proband,,,C8,953,2550
Cohort,-0.2785897556460069,0.14361003233951028,-1.9399045533768098,0.05274419638456847,LonGen OPEL,,,C8,1503,1681
Cohort,0.042583611341593504,0.0899295196996545,0.47352205909487477,0.6359936458285008,LGP Offspring,,,C8,238,532
Cohort,0.08148292252298626,0.2460572080132716,0.33115438145827986,0.7406110625014379,LGP Proband,,,C8,238,710
Cohort,-0.1376290244210646,0.07503594483031666,-1.8341746043485354,0.06700121353542601,LonGen OPEL,,,C8,416,436
Cohort,0.16129246825320384,0.20568219028810253,0.784182957344429,0.4332074530678811,LGP Offspring,,,C8,1235,2647
Cohort,-0.6039449006657513,0.5318166588126161,-1.1356261423141116,0.2564393019688757,LGP Proband,,,C8,1235,3540
Cohort,0.21140316149236435,0.1836028281305828,1.151415605330487,0.24990702348886032,LonGen OPEL,,,C8,1966,2474
Cohort,0.12567353657010202,0.09879229525149524,1.2720985604208839,0.20377552057297516,LGP Offspring,,,C8,323,731
Cohort,0.15244346072423615,0.28440310786467715,0.5360119369608676,0.5920932227202864,LGP Proband,,,C8,323,944
Cohort,0.16249368550607862,0.09092731991324879,1.787072198554948,0.07430622935302524,LonGen OPEL,,,C8,541,709
Cohort,0.029906522439009476,0.03031431801990054,0.9865477567193378,0.32421736082505836,LGP Offspring,,,C8,23,64
Cohort,0.22943941250311123,0.09230137106043042,2.4857638610037056,0.013122223636549576,LGP Proband,,,C8,23,100
Cohort,0.033553455312443685,0.025776178621518347,1.3017234170014926,0.19338753875589537,LonGen OPEL,,,C8,41,62
Cohort,-0.10281629982224348,0.14910270674753262,-0.6895669573345616,0.4907031856071048,LGP Offspring,,,C8,745,1504
Cohort,-0.672016104435089,0.40773297195798236,-1.648176994879731,0.09969299511056164,LGP Proband,,,C8,745,1985
Cohort,0.08426861819176147,0.12583598996466958,0.6696702447004327,0.5032622253090882,LonGen OPEL,,,C8,1152,1384
Cohort,0.007101021450912922,0.06427253153257372,0.110482989880585,0.9120591312567761,LGP Offspring,,,C8,132,306
Cohort,0.25695760944999385,0.18482996224541784,1.3902378506619217,0.16482756510796256,LGP Proband,,,C8,132,446
Cohort,-0.01283975958774466,0.05956598383427211,-0.21555523406560653,0.8293896725896098,LonGen OPEL,,,C8,260,303
Cohort,0.010478560519733594,0.04239636203792602,0.24715706763613138,0.8048617124209201,LGP Offspring,,,C8,62,134
Cohort,-0.14469779753219106,0.1207131213708585,-1.1986915414741544,0.2309883961253061,LGP Proband,,,C8,62,185
Cohort,-0.03591902298294283,0.040511012471581835,-0.8866483652596872,0.3755360401030088,LonGen OPEL,,,C8,118,128
Cohort,0.001884448560136052,0.062408980764771506,0.03019515039412055,0.9759203284547786,LGP Offspring,,,C8,112,252
Cohort,-0.26366078235142354,0.16931876430293014,-1.5571858407831576,0.11980573891862867,LGP Proband,,,C8,112,334
Cohort,0.0750711747072825,0.05156453123840463,1.4558684604383723,0.14582326731002063,LonGen OPEL,,,C8,172,237
Cohort,0.047343900235096874,0.07906445842904933,0.5988012967619607,0.5495059949089756,LGP Offspring,,,C8,174,394
Cohort,-0.08470589973086687,0.21689068699454023,-0.3905465048068162,0.696232208090451,LGP Proband,,,C8,174,544
Cohort,-0.05161038866703481,0.06414638045248983,-0.8045721099612186,0.4213068742082212,LonGen OPEL,,,C8,314,352
Cohort,0.07049883369772274,0.09149604839639448,0.7705123328637746,0.4412652373992555,LGP Offspring,,,C8,227,510
Cohort,-0.3423484134156163,0.23963046113649847,-1.4286514819191019,0.15347882904352414,LGP Proband,,,C8,227,637
Cohort,-0.06958947096857733,0.07287932639556978,-0.9548588661599864,0.33993895571132327,LonGen OPEL,,,C8,404,454
Cohort,-0.08620092583791271,0.07074036853400385,-1.218553530668662,0.22343877811862914,LGP Offspring,,,C8,163,314
Cohort,-0.21245496251980847,0.19547260199954908,-1.0868784696501792,0.27740454291435857,LGP Proband,,,C8,163,431
Cohort,-0.007115634120437206,0.06193395420348392,-0.11489068011157176,0.908560746585036,LonGen OPEL,,,C8,264,320
Cohort,0.03303333478277702,0.061250638591417765,0.5393141286759668,0.5898477005499168,LGP Offspring,,,C8,104,228
Cohort,-0.32449904738197366,0.15781038915410273,-2.0562590911875804,0.040068235493508235,LGP Proband,,,C8,104,299
Cohort,0.02508868964080304,0.04885890696900443,0.5134926505154738,0.6077492439152705,LonGen OPEL,,,C8,149,197
Cohort,-0.0692755447694171,0.06312512113280382,-1.0974322666830834,0.27284322648827514,LGP Offspring,,,C8,141,266
Cohort,0.03528192709980334,0.18661739425575957,0.18906022796272343,0.8500916106620485,LGP Proband,,,C8,141,376
Cohort,0.021526726105404993,0.05618919506846387,0.3831114875231029,0.7017393897217252,LonGen OPEL,,,C8,207,258
Cohort,0.040286366701258326,0.058456976285695086,0.6891626844393719,0.490957367248151,LGP Offspring,,,C8,112,246
Cohort,0.10659829085068008,0.16665024922024446,0.6396527538929756,0.5225740395857497,LGP Proband,,,C8,112,350
Cohort,-0.04770940850852977,0.05497736126587454,-0.8678009895346482,0.3857648275247789,LonGen OPEL,,,C8,205,230
Cohort,0.06207533950729172,0.06437991354731167,0.9642035238471336,0.33528868698411096,LGP Offspring,,,C8,125,286
Cohort,-0.13414878773151376,0.16411054980724551,-0.8174293967638091,0.4139165366197567,LGP Proband,,,C8,125,346
Cohort,0.028458177758974516,0.054871826481093615,0.5186300435758219,0.6041628942085755,LonGen OPEL,,,C8,195,242
Cohort,-0.026325052536744855,0.08807715132334827,-0.29888628482204754,0.7651186698516952,LGP Offspring,,,C8,265,542
Cohort,-0.1319834932362647,0.24278957759784664,-0.5436126811624524,0.5868533067556596,LGP Proband,,,C8,265,780
Cohort,-0.004609008959504351,0.07704833953016506,-0.0598197052345286,0.9523142458862979,LonGen OPEL,,,C8,406,487
Cohort,-0.01646973965341936,0.03762093826864723,-0.4377812040680818,0.6616847367011724,LGP Offspring,,,C8,49,98
Cohort,-0.023901934776795437,0.1089044127903606,-0.2194762743251397,0.8263327635727425,LGP Proband,,,C8,49,133
Cohort,-0.006619197011532373,0.03352887118975584,-0.1974178305637308,0.8435509767350493,LonGen OPEL,,,C8,75,93
Cohort,0.1189753416249296,0.10207136841087866,1.165609352330867,0.24418352770258853,LGP Offspring,,,C8,270,625
Cohort,-0.2460959149793951,0.25745943956007933,-0.9558628551351581,0.33941850825195374,LGP Proband,,,C8,270,818
Cohort,-0.13128761311826484,0.07748804963532736,-1.6942949749816631,0.0906004130994531,LonGen OPEL,,,C8,469,512
Cohort,0.08693238842422703,0.06769239809757019,1.2842267502316107,0.19950257304139044,LGP Offspring,,,C8,127,301
Cohort,-0.12040202210488635,0.17898789661487866,-0.6726824795530769,0.5013356473735666,LGP Proband,,,C8,127,411
Cohort,-0.002411704632436239,0.05523309506355039,-0.0436641225638608,0.9651830885383872,LonGen OPEL,,,C8,220,256
Cohort,-0.16801724433864879,0.128404944384752,-1.308495129558272,0.191150120099089,LGP Offspring,,,C8,510,980
Cohort,-0.25713570307274536,0.33596916813275496,-0.7653550607094419,0.4442766726920647,LGP Proband,,,C8,510,1356
Cohort,-0.017476659618388086,0.11012417182349438,-0.1586995782034071,0.8739458242996522,LonGen OPEL,,,C8,778,917
Cohort,-0.06541031265083508,0.06773389735033648,-0.9656953934381887,0.3345419652735313,LGP Offspring,,,C8,143,277
Cohort,-0.18974655732255002,0.16927188120414047,-1.1209573378210245,0.26262868867586503,LGP Proband,,,C8,143,348
Cohort,0.08361381755627424,0.053311849697280846,1.5683908555237944,0.1171873580436139,LonGen OPEL,,,C8,184,248
Cohort,-0.027539319356298005,0.08083606255011065,-0.3406811080045648,0.7334495095894757,LGP Offspring,,,C8,205,412
Cohort,-0.2988125059471003,0.21902837830260302,-1.364263883350631,0.1728525511860233,LGP Proband,,,C8,205,544
Cohort,-0.011069482194385501,0.06751480573590729,-0.1639563659219458,0.8698071144780635,LonGen OPEL,,,C8,326,385
Cohort,-0.02437430629085205,0.05775273193194257,-0.42204594441654136,0.6731256698158399,LGP Offspring,,,C8,113,227
Cohort,-0.20694999296644817,0.15714839857729462,-1.3169080616794084,0.18823117406499112,LGP Proband,,,C8,113,300
Cohort,-0.02339955413975211,0.049194064632797734,-0.47565807611984967,0.6344484986311196,LonGen OPEL,,,C8,172,195
Cohort,-0.1089817902523751,0.05285965125480578,-2.061719812093292,0.03961615074809697,LGP Offspring,,,C8,114,189
Cohort,0.052668211419817125,0.14732189341959293,0.35750430704695635,0.7208047517348248,LGP Proband,,,C8,114,256
Cohort,-0.019903590351855644,0.05014693818928623,-0.3969053958334788,0.6915436153402879,LonGen OPEL,,,C8,172,190
Cohort,0.05056206647879466,0.06325132586719552,0.7993835035957407,0.4243488591439061,LGP Offspring,,,C8,110,268
Cohort,0.27467842561800715,0.1672553277699084,1.642270110497644,0.10091100824006062,LGP Proband,,,C8,110,328
Cohort,-0.06168116256553461,0.05634552330492373,-1.09469499877987,0.27398140758758704,LonGen OPEL,,,C8,219,242
Cohort,-0.0018356862704801305,0.08327090947373317,-0.022044748665308814,0.982418765169332,LGP Offspring,,,C8,214,458
Cohort,0.10251235468082569,0.21824824446065663,0.4697052887374106,0.6386883708381427,LGP Proband,,,C8,214,611
Cohort,0.09276935135465923,0.07005075158877352,1.3243162885568045,0.18577813906800902,LonGen OPEL,,,C8,323,424
Cohort,0.04851130240057292,0.10009619129968281,0.4846468359153906,0.6280838781786988,LGP Offspring,,,C8,340,734
Cohort,-0.12138296424126158,0.2789342417207338,-0.4351669536606732,0.6635538348681354,LGP Proband,,,C8,340,1000
Cohort,0.13773168831992785,0.0946063691674329,1.455839490850478,0.1458312754985916,LonGen OPEL,,,C8,523,682
Cohort,0.03298742086740442,0.055051594925060746,0.5992091766334602,0.5492341612971952,LGP Offspring,,,C8,88,209
Cohort,-0.004423359019715328,0.144788709874808,-0.030550441560947668,0.9756353747675932,LGP Proband,,,C8,88,264
Cohort,0.019032392111199472,0.04916328847988436,0.3871260995689245,0.6987663341621306,LonGen OPEL,,,C8,153,201
Cohort,0.07206926336743671,0.07069777272811496,1.019399347198619,0.3083780989759126,LGP Offspring,,,C8,149,346
Cohort,-0.19097761159020113,0.19209927201908852,-0.9941610375869829,0.3204328210140308,LGP Proband,,,C8,149,406
Cohort,0.02965319007298653,0.06433409797304221,0.46092493727683953,0.6449783658787622,LonGen OPEL,,,C8,257,317
Cohort,0.04605231952754231,0.027111153187235656,1.6986484938318465,0.08984557321218514,LGP Offspring,,,C8,15,56
Cohort,-0.05546435549913019,0.07305391305151425,-0.759224977586338,0.44793251465392436,LGP Proband,,,C8,15,69
Cohort,0.002560034245114162,0.024937238385408175,0.10265909181876955,0.9182593979711962,LonGen OPEL,,,C8,42,53
Cohort,-0.014331187272919023,0.02240679151034208,-0.6395912268967344,0.5226550713096012,LGP Offspring,,,C8,19,32
Cohort,-0.06473878363089634,0.06091156189592484,-1.0628324346945954,0.2881655943289879,LGP Proband,,,C8,19,43
Cohort,0.0042451598544920284,0.017823877640577128,0.23817263224628893,0.8118084987193425,LonGen OPEL,,,C8,21,27
Cohort,0.06560137017614107,0.062088049798248716,1.0565860965082439,0.2910779677910185,LGP Offspring,,,C8,123,288
Cohort,0.08983319207134745,0.1781798392922982,0.5041714732045472,0.6142740461060113,LGP Proband,,,C8,123,393
Cohort,0.0465450292152039,0.05712081844952275,0.8148522811579705,0.41540059337873414,LonGen OPEL,,,C8,213,276
Cohort,-0.022516077595575643,0.07519888199947397,-0.2994203769642898,0.7647113504677909,LGP Offspring,,,C8,171,353
Cohort,0.17217997553357722,0.21181664148053225,0.812872748477612,0.41652300023576705,LGP Proband,,,C8,171,535
Cohort,-0.10835575376091827,0.06650962519277456,-1.6291740247649114,0.10367183714857059,LonGen OPEL,,,C8,306,333
Cohort,0.011664890697418802,0.03618176851231793,0.3223969191402996,0.7472516988526813,LGP Offspring,,,C8,40,96
Cohort,0.052813884466921736,0.10148550145212658,0.5204081736920367,0.6029172331291456,LGP Proband,,,C8,40,134
Cohort,0.017440937683474277,0.03132211870287025,0.5568249660542934,0.5778035402655479,LonGen OPEL,,,C8,61,82
Cohort,-0.049463621630399114,0.033491765274395534,-1.4768890569113737,0.14017106683725442,LGP Offspring,,,C8,46,74
Cohort,-0.10499724587560313,0.1050814964624201,-0.9991982357536457,0.3179884835396919,LGP Proband,,,C8,46,147
Cohort,-0.03746541817501294,0.032833438763536796,-1.1410750620681314,0.2541818613250715,LonGen OPEL,,,C8,75,80
Cohort,-0.05981481455073403,0.025058518398435224,-2.3870052330974665,0.017260177389227634,LGP Offspring,,,C8,29,35
Cohort,-0.08441371099505106,0.0650484129739499,-1.2977059260286092,0.19474721079587062,LGP Proband,,,C8,29,46
Cohort,0.05176773068523991,0.017845483059837797,2.9008870486529963,0.003823644155269574,LonGen OPEL,,,C8,15,34
Cohort,-0.07556871189395839,0.05430350049856604,-1.3915992744510806,0.1645015116450924,LGP Offspring,,,C8,114,209
Cohort,-0.1596085569548114,0.1623660367384274,-0.9830168929475177,0.32588420457122713,LGP Proband,,,C8,114,316
Cohort,0.0884748643914007,0.04699887107675015,1.8824891399395398,0.060134152061005176,LonGen OPEL,,,C8,144,211
Cohort,-0.4049156509372177,0.21635939304159765,-1.8714955946440832,0.061708089049695304,LGP Offspring,,,C8,1381,2773
Cohort,-0.027647450602314407,0.5920201462076937,-0.04670018542344515,0.9627633625126422,LGP Proband,,,C8,1381,3798
Cohort,0.11770216419524901,0.1787976266444037,0.6582982470418213,0.5105368497391086,LonGen OPEL,,,C8,2127,2599
Cohort,-0.062093302231157145,0.08545913865671459,-0.7265846954131269,0.46773191857940866,LGP Offspring,,,C8,227,445
Cohort,-0.11538222650711688,0.2322757585453423,-0.4967467428788667,0.6194985640705755,LGP Proband,,,C8,227,689
Cohort,-0.03807442483733059,0.07209053376238993,-0.5281473565284414,0.5975442665218543,LonGen OPEL,,,C8,365,421
Cohort,0.022637674462997814,0.03977475176789964,0.5691468445886728,0.5694455398013779,LGP Offspring,,,C8,49,114
Cohort,-0.12377811277430342,0.11229145291038671,-1.1022932695784384,0.27065218373109734,LGP Proband,,,C8,49,163
Cohort,-0.043869783350168036,0.035710421832571254,-1.2284868421843922,0.21962735085782306,LonGen OPEL,,,C8,96,104
Cohort,0.05246906503939572,0.06333273277828777,0.82846677756788,0.4076986028198839,LGP Offspring,,,C8,118,272
Cohort,-0.16899304916057997,0.16465921438108116,-1.0263200258533285,0.3050383351847405,LGP Proband,,,C8,118,340
Cohort,-0.0580906936277081,0.05351190293356031,-1.085565835695149,0.27799976932817955,LonGen OPEL,,,C8,218,230
Cohort,-0.08247288722128088,0.11509861347617872,-0.7165411009781608,0.47390476843404794,LGP Offspring,,,C8,429,878
Cohort,-0.12233490308255067,0.32658134558540447,-0.3745924399425282,0.7080588226079184,LGP Proband,,,C8,429,1216
Cohort,0.2438447285194754,0.0973492675118619,2.504843998849433,0.012449353116489635,LonGen OPEL,,,C8,621,829
Cohort,0.01341467952334072,0.0317705657793256,0.42223609162384507,0.6729869556015674,LGP Offspring,,,C8,28,65
Cohort,0.02246624017189548,0.08290881971724295,0.2709752743859537,0.786477099861615,LGP Proband,,,C8,28,89
Cohort,-0.011114588749859919,0.023821906016984445,-0.46657008645468945,0.6409351566748205,LonGen OPEL,,,C8,41,47
Cohort,-0.004910200540651245,0.06496997391000715,-0.07557645855688022,0.9397784262665713,LGP Offspring,,,C8,126,265
Cohort,-0.2323879414598321,0.1785911967219484,-1.3012284240507148,0.1935396355344998,LGP Proband,,,C8,126,380
Cohort,0.10657165702273654,0.05763448858712959,1.8490952142591779,0.06481465854518945,LonGen OPEL,,,C8,201,289
Cohort,0.04245769148030458,0.031175755369217625,1.3618817243551549,0.17368887136550767,LGP Offspring,,,C8,27,81
Cohort,0.04654162291884814,0.09710474253124113,0.4792929954360827,0.6318558536354126,LGP Proband,,,C8,27,135
Cohort,-0.008712162939994954,0.02873594176099101,-0.3031800040679961,0.7618319048798963,LonGen OPEL,,,C8,61,72
Cohort,-0.01974658917728419,0.0631452945086358,-0.3127167167552545,0.7545923395853178,LGP Offspring,,,C8,127,254
Cohort,-0.20790174737238612,0.16435217553785358,-1.2649771546498465,0.20623285289153592,LGP Proband,,,C8,127,336
Cohort,-0.034259753667911695,0.05256576094279916,-0.6517503609467836,0.5147503586216737,LonGen OPEL,,,C8,200,231
Cohort,0.02644660206817206,0.09653375232551623,0.2739622301119396,0.7841973371779429,LGP Offspring,,,C8,269,571
Cohort,0.0754837063910076,0.26384510103813846,0.2860909908654947,0.7748794779490291,LGP Proband,,,C8,269,794
Cohort,-0.1799742696502371,0.08398561040241748,-2.142917921152082,0.03242228300218848,LonGen OPEL,,,C8,494,518
Cohort,0.034892982201996436,0.07206085934947339,0.48421546061192555,0.6283897993174743,LGP Offspring,,,C8,156,357
Cohort,-0.19705817288588828,0.18957690098587696,-1.0394629929126686,0.29889071257014743,LGP Proband,,,C8,156,449
Cohort,-0.036371301538994066,0.0583662863564727,-0.6231559999698449,0.5333605117100103,LonGen OPEL,,,C8,265,300
Cohort,-0.19916016265608577,0.11260441154782239,-1.7686710486605022,0.0773996978228308,LGP Offspring,,,C8,411,789
Cohort,0.058863566316834245,0.3191079750116248,0.1844628493370932,0.8536952124114239,LGP Proband,,,C8,411,1133
Cohort,0.04980487979960549,0.10087255254607896,0.49374065137148615,0.6216255557205548,LonGen OPEL,,,C8,643,798
Cohort,-0.0449248047341214,0.060961398936432515,-0.7369385466525584,0.46141540218240773,LGP Offspring,,,C8,109,218
Cohort,-0.041269399893496296,0.17328024202635495,-0.2381656408768142,0.8118111268042267,LGP Proband,,,C8,109,332
Cohort,0.0812028397422711,0.051230630435594574,1.5850447096167708,0.11335334588318492,LonGen OPEL,,,C8,158,221
Cohort,-0.007052086595558571,0.02457008451743259,-0.2870192241526513,0.7741855533445695,LGP Offspring,,,C8,19,39
Cohort,-0.011711323735736686,0.06172587111852535,-0.18973120222554216,0.8495659356566195,LGP Proband,,,C8,19,41
Cohort,-9.08357733860144e-4,0.018742116960177746,-0.04846612235907898,0.9613569206803665,LonGen OPEL,,,C8,23,29
Cohort,-0.07769641563067119,0.05348411025890063,-1.4527009097574215,0.14677081701683609,LGP Offspring,,,C8,100,174
Cohort,0.09503125191882177,0.1513870651266676,0.6277369327379974,0.5303481219920554,LGP Proband,,,C8,100,269
Cohort,-0.04614123630512001,0.04424231102251533,-1.0429210237602258,0.29730150421849666,LonGen OPEL,,,C8,141,151
Cohort,-0.07977438358705405,0.05777776974135795,-1.380710677206197,0.16782425347652963,LGP Offspring,,,C8,125,222
Cohort,-0.1358537145242158,0.16911562189065246,-0.8033185403300985,0.4220195270592144,LGP Proband,,,C8,125,317
Cohort,-0.013716643535092632,0.05134624059248678,-0.26714017183761873,0.7894304334598838,LonGen OPEL,,,C8,180,215
Cohort,-0.0013568845842379465,0.012271122534862428,-0.11057542456959571,0.9119858559391377,LGP Offspring,,,C8,5,10
Cohort,-0.025075313247029548,0.0454511712858562,-0.551697844909723,0.581303174468287,LGP Proband,,,C8,5,25
Cohort,-0.0029368994416351544,0.013997085357006125,-0.20982221417726182,0.8338601252649519,LonGen OPEL,,,C8,12,14
Cohort,0.02303512911586506,0.052597031662789895,0.43795492611727377,0.6615588599821565,LGP Offspring,,,C8,86,187
Cohort,-0.26925207818970864,0.14779146670849935,-1.8218377839146527,0.06883765723864357,LGP Proband,,,C8,86,260
Cohort,0.010089316152318496,0.04984671656387985,0.20240683535070514,0.8396504057182329,LonGen OPEL,,,C8,162,201
Cohort,-0.14504210178502458,0.09750104004154718,-1.4875954320407165,0.13732390755070048,LGP Offspring,,,C8,309,590
Cohort,0.05785945421878511,0.2828572135111571,0.20455357493120072,0.8379708381418935,LGP Proband,,,C8,309,842
Cohort,0.04808475597505922,0.0847576608718819,0.5673204696828908,0.5706564276771313,LonGen OPEL,,,C8,466,578
Cohort,-0.013601164975865573,0.07003682203182521,-0.19420020185503437,0.8460774677905301,LGP Offspring,,,C8,167,350
Cohort,0.1421279528046122,0.19446009206283166,0.730884940436465,0.465054713256536,LGP Proband,,,C8,167,476
Cohort,-0.01753036809436512,0.05856070273477523,-0.29935378633964077,0.7647482626743243,LonGen OPEL,,,C8,249,310
Cohort,-0.004186587222531146,0.14215562051674657,-0.029450732987641153,0.9765138036078882,LGP Offspring,,,C8,586,1228
Cohort,0.10885830347854537,0.3915887257264953,0.2779914137634732,0.7810878506008629,LGP Proband,,,C8,586,1703
Cohort,0.04640584876883582,0.11647477482732746,0.3984197336945443,0.6904276569726175,LonGen OPEL,,,C8,936,1131
Cohort,-0.1684899752981991,0.06646824958321257,-2.534894123957094,0.011472520742627307,LGP Offspring,,,C8,159,263
Cohort,0.030198239871395968,0.17874980495988343,0.16894138641534917,0.8658837098884442,LGP Proband,,,C8,159,364
Cohort,-0.04458930849435119,0.059562474194368414,-0.7486141080849706,0.4543109646698087,LonGen OPEL,,,C8,247,257
Cohort,0.009152231591903598,0.06050801681934642,0.15125651232676535,0.8798184981246522,LGP Offspring,,,C8,108,231
Cohort,0.1183008863291483,0.16545667585394083,0.7149961506151619,0.47481151631345186,LGP Proband,,,C8,108,294
Cohort,-0.05289763998419372,0.04851337835234606,-1.0903722185662967,0.2758791718128844,LonGen OPEL,,,C8,175,192
Cohort,-0.008412428548855117,0.11428018930417645,-0.07361230848562901,0.9413406527204402,LGP Offspring,,,C8,393,828
Cohort,-0.044364649669224265,0.31235827558599305,-0.14203129270705223,0.8870895906936749,LGP Proband,,,C8,393,1195
Cohort,0.14930129759284444,0.10011537254863315,1.49129243383995,0.13628090501192563,LonGen OPEL,,,C8,604,789
Cohort,-0.06751489856065808,0.14115796325169927,-0.4782932326692191,0.6325961527546591,LGP Offspring,,,C8,644,1321
Cohort,0.35899019394497655,0.4055794680304622,0.8851291109194255,0.3763421169020519,LGP Proband,,,C8,644,1912
Cohort,-0.3070219583530227,0.12960750010613656,-2.3688595035133004,0.018080845105836928,LonGen OPEL,,,C8,1168,1285
Cohort,-0.2710395213278859,0.1438901906760518,-1.8836553072480988,0.06004060290541656,LGP Offspring,,,C8,668,1282
Cohort,-1.134130042187233,0.4006683639990862,-2.830595435255826,0.004757857427882431,LGP Proband,,,C8,668,1764
Cohort,-0.14432589066833507,0.12526353265275633,-1.1521780330786422,0.24959383541201893,LonGen OPEL,,,C8,1039,1192
Cohort,-0.04857757406665018,0.057210383936442746,-0.8491041437620294,0.3961239312523529,LGP Offspring,,,C8,119,218
Cohort,-1.5113554968616708e-4,0.1606363373913904,-9.408553017361529e-4,0.9992495311860237,LGP Proband,,,C8,119,310
Cohort,0.02033450737594517,0.05039517577885569,0.40350107052264556,0.6866880123917555,LonGen OPEL,,,C8,162,206
Cohort,0.06553584019875724,0.11110320095588114,0.5898645550705726,0.5554785621013776,LGP Offspring,,,C8,414,916
Cohort,0.5634688692861741,0.3163035646000941,1.7814180184740367,0.07520802018010281,LGP Proband,,,C8,414,1263
Cohort,-0.15743896411160038,0.09944437517508327,-1.5831862167609878,0.11377623282451321,LonGen OPEL,,,C8,712,795
Cohort,-0.4934313864007924,0.2587620635778421,-1.9068922993511217,0.05695817957835544,LGP Offspring,,,C8,1923,3866
Cohort,-0.26075986709399696,0.6885727868678422,-0.3786961553914047,0.7050098899465309,LGP Proband,,,C8,1923,5320
Cohort,-0.013537939256389369,0.21482175189824398,-0.06301940626013502,0.9497668719961505,LonGen OPEL,,,C8,3039,3652
Cohort,-0.008507220265479802,0.05192874447109517,-0.16382487872810275,0.8699179731100355,LGP Offspring,,,C8,85,179
Cohort,-0.030462477713274115,0.14550012280537417,-0.2093639312869979,0.834215275768671,LGP Proband,,,C8,85,263
Cohort,0.020650726217838505,0.04798460816966462,0.43036146392654473,0.6670492155403956,LonGen OPEL,,,C8,136,176
Cohort,-0.14285121124047115,0.057733539542796475,-2.4743193016007448,0.013593400517709115,LGP Offspring,,,C8,129,210
Cohort,0.06580984084775182,0.15303619505326932,0.43002794747245593,0.6672864001566243,LGP Proband,,,C8,129,295
Cohort,-0.04609636415510324,0.049947766574768494,-0.9228913986794592,0.35634345400683964,LonGen OPEL,,,C8,183,200
Cohort,0.005501359294335736,0.11328268666065205,0.04856310753659584,0.9612818151735385,LGP Offspring,,,C8,421,871
Cohort,-0.596905666817177,0.3312708873103541,-1.8018657530203088,0.07192754229619791,LGP Proband,,,C8,421,1266
Cohort,-0.14964426490645708,0.10633416420080952,-1.407301839734758,0.1597282531785211,LonGen OPEL,,,C8,749,846
Cohort,-0.003298624135338537,0.029576104430307292,-0.11153004085143692,0.9112291514336179,LGP Offspring,,,C8,28,58
Cohort,-0.009891191584955532,0.07945610248156813,-0.12448624178677838,0.9009602904626315,LGP Proband,,,C8,28,76
Cohort,-0.006010765052208926,0.023779156801595,-0.2527745244442709,0.8005077159338158,LonGen OPEL,,,C8,39,45
Cohort,0.035601829472178464,0.03630096663337076,0.9807405359682738,0.3270715669195473,LGP Offspring,,,C8,37,92
Cohort,-0.09336878178337163,0.09398449058818077,-0.9934488254290057,0.3207794174217952,LGP Proband,,,C8,37,103
Cohort,0.0036014248946025598,0.030128455898744293,0.11953566112734844,0.904881150670496,LonGen OPEL,,,C8,63,79
Cohort,0.1309021318536707,0.056558541250472466,2.3144538200510465,0.02094164622578466,LGP Offspring,,,C8,82,228
Cohort,-0.006210994547749807,0.15679908513758056,-0.039611165730336254,0.968412605422329,LGP Proband,,,C8,82,300
Cohort,0.09094530724317945,0.04806399319133007,1.8921712742665844,0.05883082553997821,LonGen OPEL,,,C8,138,202
Cohort,-0.012505623917343986,0.048665471742513074,-0.2569711844880639,0.7972792102579378,LGP Offspring,,,C8,80,159
Cohort,-0.0931289165115061,0.12812941698760436,-0.7268347792491374,0.46753113104062105,LGP Proband,,,C8,80,196
Cohort,-0.056465963968923436,0.038918766978269445,-1.4508672384315666,0.14721078003412968,LonGen OPEL,,,C8,111,117
Cohort,-0.02695188978267935,0.04225273454052785,-0.637873266091872,0.5237721837550338,LGP Offspring,,,C8,61,115
Cohort,-0.13582044680582003,0.11508969073697269,-1.1801269595573565,0.23828621189246568,LGP Proband,,,C8,61,153
Cohort,0.032593390046220985,0.03695518377027422,0.8819707202332532,0.37805888817559163,LonGen OPEL,,,C8,85,111
Cohort,-0.038329782898221545,0.047305507414294554,-0.8102604748012752,0.4180756258357151,LGP Offspring,,,C8,82,146
Cohort,-0.017216148675721493,0.13440004238796893,-0.12809630391353677,0.8981036419024264,LGP Proband,,,C8,82,217
Cohort,0.050739027296179726,0.044801621381159985,1.1325265856899667,0.2577541388055485,LonGen OPEL,,,C8,115,158
Cohort,-0.0233962111340651,0.04630000626168441,-0.5053176667370485,0.6135004438698396,LGP Offspring,,,C8,72,133
Cohort,-0.1744176092080926,0.12696347225253754,-1.3737621231811155,0.1698846667540753,LGP Proband,,,C8,72,199
Cohort,0.026473846215874952,0.03969635971198493,0.6669086638662763,0.5050237406920863,LonGen OPEL,,,C8,102,129
Cohort,0.03174467388601646,0.039542126681176244,0.8028064383580131,0.42236877736714573,LGP Offspring,,,C8,38,104
Cohort,-0.143328169475401,0.1022704012360059,-1.4014628645549898,0.1614477233562632,LGP Proband,,,C8,38,124
Cohort,0.06249504626656173,0.03462315373976451,1.8050073293810465,0.07145131047629315,LonGen OPEL,,,C8,66,106
Cohort,0.07062988951882536,0.04362330517433562,1.6190861567357393,0.1058951399135339,LGP Offspring,,,C8,52,148
Cohort,0.06680305621058834,0.12283906009548147,0.5438258495193877,0.5867066602723899,LGP Proband,,,C8,52,179
Cohort,0.0058786910875105024,0.03523854623980584,0.16682558490082858,0.8675496549719173,LonGen OPEL,,,C8,86,102
Cohort,-0.04236465367301349,0.046056928370321916,-0.9198323720674423,0.35798847235074494,LGP Offspring,,,C8,75,137
Cohort,-0.08932836207633897,0.13226959261550325,-0.6753507008675012,0.4996401753586469,LGP Proband,,,C8,75,194
Cohort,0.01289579635216938,0.04086007008390184,0.31560876732930765,0.7523822098748898,LonGen OPEL,,,C8,107,128
Cohort,0.043433756723213465,0.03724286337035479,1.1662303269030223,0.2439326106385005,LGP Offspring,,,C8,36,89
Cohort,0.05628515253892137,0.09733600277188029,0.5782562560210431,0.5632472282008019,LGP Proband,,,C8,36,123
Cohort,0.016095935839859528,0.03014909351857985,0.5338779366596927,0.5935750408642464,LonGen OPEL,,,C8,56,80
Cohort,4.941769662059499e-4,0.0458796885354347,0.01077114910717577,0.9914092105002421,LGP Offspring,,,C8,65,133
Cohort,0.021789689326614785,0.12788976190422574,0.17037868397106468,0.8647536572837248,LGP Proband,,,C8,65,192
Cohort,-0.0514324492078544,0.03753363520659307,-1.3703029009782643,0.17097869368690852,LonGen OPEL,,,C8,107,106
Cohort,-0.013711923531081445,0.0312777683140832,-0.438392003975152,0.6612422015123319,LGP Offspring,,,C8,31,63
Cohort,-0.05469322027093739,0.08688110245260515,-0.6295180278216809,0.5291823763925253,LGP Proband,,,C8,31,91
Cohort,0.05646729956922884,0.02725578987260561,2.0717542890211114,0.03860992386300746,LonGen OPEL,,,C8,37,74
Cohort,-0.012638343750821956,0.01385959719865482,-0.9118839147827907,0.3621548965146171,LGP Offspring,,,C8,8,9
Cohort,-0.005782292821994497,0.04283212424009295,-0.13499897389123627,0.8926452591383399,LGP Proband,,,C8,8,21
Cohort,-0.006041737893159484,0.012782607273850131,-0.4726530170037609,0.6365903154629193,LonGen OPEL,,,C8,12,11
Cohort,-0.12278795598747037,0.07572140137165091,-1.6215753243235744,0.1053605972706488,LGP Offspring,,,C8,187,321
Cohort,-0.21994344782505773,0.2110424147995525,-1.0421765124037243,0.29763185455917873,LGP Proband,,,C8,187,507
Cohort,-0.0036714659429003408,0.06491838214078927,-0.05655510537736429,0.9549137906108502,LonGen OPEL,,,C8,268,321
Cohort,0.017846033663100103,0.026376809371704835,0.6765804541258905,0.498903613455835,LGP Offspring,,,C8,24,53
Cohort,-0.09376525184266848,0.08051478635193916,-1.1645718270034282,0.24452536282970885,LGP Proband,,,C8,24,81
Cohort,0.03866168368337315,0.021736487744451034,1.778653669254493,0.07567814517178288,LonGen OPEL,,,C8,29,46
Cohort,-0.07959059579623594,0.08473513390791358,-0.9392868356440139,0.3479189838440102,LGP Offspring,,,C8,245,471
Cohort,-0.337635886879801,0.23498165222050227,-1.4368606386466718,0.15113262431248448,LGP Proband,,,C8,245,676
Cohort,0.00593560382324917,0.07307294890105842,0.08122846980332,0.9352806774808309,LonGen OPEL,,,C8,372,437
Cohort,0,0,NA,NA,LGP Offspring,,,C8,0,0
Cohort,-0,0,NA,NA,LGP Proband,,,C8,0,0
Cohort,-0.004436753438658446,0.004507660267325742,-0.9842697043560998,0.32528199300635763,LonGen OPEL,,,C8,2,1
Cohort,0.01170390248048082,0.022890300154470532,0.5113040196720626,0.6093051485339311,LGP Offspring,,,C8,14,35
Cohort,0.01950794809192765,0.06125185463294808,0.3184874679930769,0.7501949377792254,LGP Proband,,,C8,14,45
Cohort,0.03406941939196585,0.019771625334512582,1.723147127034397,0.08525027702458557,LonGen OPEL,,,C8,21,42
Cohort,-0.010635584598270834,0.02988464212154528,-0.35588796931260985,0.7220354972991209,LGP Offspring,,,C8,33,58
Cohort,-0.052427513812343396,0.08118324148376059,-0.6457923193770315,0.5185915014097919,LGP Proband,,,C8,33,70
Cohort,0.04961225205046199,0.027983889850602045,1.7728861968556753,0.07662993598695247,LonGen OPEL,,,C8,44,71
Cohort,-0.025218425530169862,0.04452594625495354,-0.5663759594410482,0.57132621143932,LGP Offspring,,,C8,70,131
Cohort,-0.10288445512595466,0.12345249094624931,-0.8333931080479382,0.4048616684495596,LGP Proband,,,C8,70,199
Cohort,-0.052363439490161645,0.03792290249783858,-1.3807867025248426,0.1677321082788861,LonGen OPEL,,,C8,114,115
Cohort,-0.2138001556798185,0.12262321044551336,-1.7435537277407924,0.08169154194306316,LGP Offspring,,,C8,558,1051
Cohort,-0.32418509927927136,0.3494115798509937,-0.9278029635352093,0.35377821340557625,LGP Proband,,,C8,558,1495
Cohort,-0.18606915954606082,0.11144644955168541,-1.66958355599985,0.09539496525266612,LonGen OPEL,,,C8,886,984
Cohort,-0.019019689860209014,0.014221061016343201,-1.3374311409219823,0.18153175510512226,LGP Offspring,,,C8,8,10
Cohort,0.021160866860108117,0.03957710013954209,0.5346745159574228,0.5930174554297301,LGP Proband,,,C8,8,18
Cohort,0.012747008019990295,0.013259046386677674,0.9613819612847978,0.3366520907253394,LonGen OPEL,,,C8,9,18
Cohort,-0.32063906543525145,0.12853633822684815,-2.494540219975534,0.012849681806052731,LGP Offspring,,,C8,562,1064
Cohort,-0.20080314409436212,0.3432797858783913,-0.5849547580570261,0.558736355548727,LGP Proband,,,C8,562,1475
Cohort,-0.1954097602354264,0.11206474227044647,-1.743722033142618,0.0815936213110545,LonGen OPEL,,,C8,861,966
Cohort,-0.03087663278820724,0.015831965120726578,-1.9502716531243984,0.0515566929519832,LGP Offspring,,,C8,12,11
Cohort,0.010676761977040965,0.04984170335368478,0.21421342487589035,0.8304329892503919,LGP Proband,,,C8,12,26
Cohort,-0.007552549421006639,0.012773050980652843,-0.5912878162348508,0.5544954590168918,LonGen OPEL,,,C8,13,12
Cohort,-0.021957799703568117,0.024293952900399554,-0.9038380782901322,0.36640323978428246,LGP Offspring,,,C8,25,38
Cohort,0.03606239861697055,0.06586382574815405,0.547529667572966,0.584161385373227,LGP Proband,,,C8,25,54
Cohort,0.01544916904253123,0.020262320935534532,0.7624580171088714,0.4460125623812685,LonGen OPEL,,,C8,26,38
Cohort,-0.09900757075231484,0.0676298834306529,-1.4639618720300818,0.14366921026962867,LGP Offspring,,,C8,169,305
Cohort,-0.504784639484302,0.19242085093912384,-2.623336488850684,0.008866354520132125,LGP Proband,,,C8,169,453
Cohort,-0.02602747275581212,0.05878067515233038,-0.44278961900933955,0.6580382121031245,LonGen OPEL,,,C8,240,270
Cohort,0.026309394760738878,0.040279942887720015,0.653163656017986,0.5138728574002616,LGP Offspring,,,C8,47,115
Cohort,0.04556162893419492,0.11661088143521137,0.39071507198501726,0.6961076387466913,LGP Proband,,,C8,47,167
Cohort,0.06469165773217324,0.034302488212163286,1.8859173518856946,0.059669958907246516,LonGen OPEL,,,C8,67,103
Cohort,-0.015607790351179,0.02846904182204223,-0.5482372904835395,0.5837099734682927,LGP Offspring,,,C8,30,55
Cohort,-0.08240534635824828,0.07577351439960335,-1.08752176814277,0.2771204714185628,LGP Proband,,,C8,30,65
Cohort,-0.01732160776072023,0.025391821458442657,-0.68217271411858,0.4953281966323799,LonGen OPEL,,,C8,47,50
Cohort,0.001292941856732441,0.021951231626939658,0.058900652077566236,0.9530486456578454,LGP Offspring,,,C8,17,32
Cohort,-0.003911389734331175,0.06214383341167469,-0.06294091496448237,0.9498286352771322,LGP Proband,,,C8,17,43
Cohort,-0.016402170558329137,0.02194043911955149,-0.7475771322969051,0.45493604601747994,LonGen OPEL,,,C8,34,35
Cohort,0.006379384698983084,0.010979595649229436,0.5810218247363963,0.5614194018610295,LGP Offspring,,,C8,4,8
Cohort,-0.027567710385843477,0.03576993486815547,-0.7706950120948054,0.4411059978103251,LGP Proband,,,C8,4,17
Cohort,0.0025317113978201096,0.008579390953126738,0.2950922054551475,0.7680003930642846,LonGen OPEL,,,C8,5,6
Cohort,-0.008787584668691234,0.051147636945794606,-0.17180822406329674,0.8636397182992003,LGP Offspring,,,C8,84,174
Cohort,0.1662545779732657,0.13377188911950585,1.2428214856466686,0.21428292179298827,LGP Proband,,,C8,84,240
Cohort,-0.054643786719346304,0.04495032818250803,-1.2156482261370984,0.22447936239765565,LonGen OPEL,,,C8,137,143
Cohort,-0.019503725758247065,0.02066854884518152,-0.9436427252024512,0.345689378149427,LGP Offspring,,,C8,18,25
Cohort,-0.11032346924255629,0.057979224329549335,-1.9028103690295406,0.05740943098568437,LGP Proband,,,C8,18,34
Cohort,0.008400805864087679,0.018277059318914157,0.45963662520885074,0.645902571448498,LonGen OPEL,,,C8,23,28
Cohort,-0.039894421095403296,0.03884966004211001,-1.0268924117266622,0.30483842640472425,LGP Offspring,,,C8,55,89
Cohort,-0.15142581659924526,0.10540551796928298,-1.4366023669023988,0.15120601973983946,LGP Proband,,,C8,55,122
Cohort,-0.008929921440998382,0.033755683541067234,-0.264545715098147,0.7914279254824498,LonGen OPEL,,,C8,79,99
Cohort,0.042313000309240505,0.052740984596132794,0.8022793020125583,0.422673358556639,LGP Offspring,,,C8,82,186
Cohort,0.1856234398750867,0.14519013113270307,1.2784852415721546,0.20143405039185341,LGP Proband,,,C8,82,281
Cohort,-0.02902893080091792,0.047314863178290055,-0.6135266774740997,0.5397034229385835,LonGen OPEL,,,C8,150,166
Cohort,-0.13271143642046657,0.04789312159099519,-2.7709915748197718,0.0057422044562223115,LGP Offspring,,,C8,87,132
Cohort,-0.18289976299066346,0.13931513489930852,-1.3128491970585694,0.18959489794976844,LGP Proband,,,C8,87,205
Cohort,-0.057207973187061466,0.04107616262016004,-1.3927292506867228,0.16409054934180636,LonGen OPEL,,,C8,127,128
Cohort,0.006694864057375942,0.014198312545159353,0.471525333456505,0.6374177761767351,LGP Offspring,,,C8,6,14
Cohort,-0.01069873236704467,0.041682277565848115,-0.2566734111432181,0.7974942026018055,LGP Proband,,,C8,6,23
Cohort,0.004608764794766508,0.012336670138978061,0.37358255857105105,0.7088143862299054,LonGen OPEL,,,C8,11,13
Cohort,-0.18961947139696514,0.08987786526075871,-2.109746052009919,0.03524718390761447,LGP Offspring,,,C8,301,541
Cohort,-0.21872149233135918,0.2601676271707526,-0.8406944965055487,0.4007600616904292,LGP Proband,,,C8,301,820
Cohort,0.12839704816017616,0.0795265938121397,1.6145171320109577,0.10681159931989655,LonGen OPEL,,,C8,432,569
Cohort,0.0126976140668559,0.015486540620873417,0.8199128764587694,0.41255476874005037,LGP Offspring,,,C8,7,18
Cohort,-0.01270590127680356,0.04262284377245025,-0.29810074017201454,0.7657005245957632,LGP Proband,,,C8,7,24
Cohort,-0.015201838154382629,0.012377049652865816,-1.2282279364422484,0.21972444635062208,LonGen OPEL,,,C8,14,10
Cohort,0.01962368457123051,0.019606919261097994,1.0008550711057285,0.31725499862791523,LGP Offspring,,,C8,9,28
Cohort,0.020264086147823754,0.05396860589036317,0.375479147802893,0.7073996271292566,LGP Proband,,,C8,9,38
Cohort,-0.0366191838147762,0.018974862964591794,-1.9298786970482864,0.053976903626394464,LonGen OPEL,,,C8,29,22
Cohort,-0.16886072111101902,0.10539747281771392,-1.6021325426186024,0.10959344606080214,LGP Offspring,,,C8,396,770
Cohort,-0.29287804964024744,0.2865665012376734,-1.0220247250649137,0.30706555855915657,LGP Proband,,,C8,396,1024
Cohort,0.09186798929375042,0.0942283571453211,0.9749505571032034,0.3298809711493448,LonGen OPEL,,,C8,571,730
Cohort,-0.07589995026998973,0.05254705306273217,-1.444418779857706,0.14908453250322926,LGP Offspring,,,C8,111,183
Cohort,-0.10002533799199673,0.1556955034703131,-0.6424420472173035,0.5207627657322714,LGP Proband,,,C8,111,278
Cohort,0.02919726680279508,0.048011066299100215,0.6081361872052875,0.5432706267226934,LonGen OPEL,,,C8,156,195
Cohort,-0.03849888680048079,0.059204514866520355,-0.6502694412289084,0.5157391200960972,LGP Offspring,,,C8,116,224
Cohort,0.18069758827287757,0.15899011940836724,1.1365334458851153,0.2560598329369869,LGP Proband,,,C8,116,289
Cohort,0.04502418248227195,0.04844140966845321,0.9294564875471268,0.35293433572868405,LonGen OPEL,,,C8,172,214
Cohort,0.028947151524999902,0.08573343273661353,0.33764134481737207,0.7357382983389404,LGP Offspring,Genes up-regulated during adipocyte differentiation (adipogenesis).,,H,194,438
Cohort,0.1458095000271094,0.22869971266323152,0.6375587373029151,0.523935951549902,LGP Proband,Genes up-regulated during adipocyte differentiation (adipogenesis).,,H,194,618
Cohort,0.10420625785438821,0.07590888560411876,1.3727807624241297,0.17020713567160156,LonGen OPEL,Genes up-regulated during adipocyte differentiation (adipogenesis).,,H,340,468
Cohort,-0.09264401246289657,0.06574014097099554,-1.4092457225452404,0.15922235977817226,LGP Offspring,Genes up-regulated during transplant rejection.,,H,165,304
Cohort,-0.2141266874163671,0.18264129094918669,-1.1723892571255428,0.24137558280040025,LGP Proband,Genes up-regulated during transplant rejection.,,H,165,410
Cohort,0.003409919224580717,0.06098247450017087,0.05591638011624409,0.955422453632863,LonGen OPEL,Genes up-regulated during transplant rejection.,,H,254,296
Cohort,-0.04337688246374614,0.056248869817826015,-0.7711600713797706,0.440881513653926,LGP Offspring,Genes defining response to androgens.,,H,107,210
Cohort,0.07835551062505677,0.1468894175546102,0.5334319648719823,0.5938767207099657,LGP Proband,Genes defining response to androgens.,,H,107,264
Cohort,0.006124353712612344,0.04225020229974447,0.14495442339336168,0.8847835506830437,LonGen OPEL,Genes defining response to androgens.,,H,136,157
Cohort,-0.047602481378042176,0.03308931079301423,-1.4386060101346068,0.1507249938755111,LGP Offspring,Genes up-regulated during formation of blood vessels (angiogenesis).,,H,42,68
Cohort,-0.01908503579687791,0.0954681228204524,-0.19991003523523007,0.8415996747274843,LGP Proband,Genes up-regulated during formation of blood vessels (angiogenesis).,,H,42,108
Cohort,-0.015550752597454687,0.027452581117738243,-0.5664586703436314,0.5712416932577296,LonGen OPEL,Genes up-regulated during formation of blood vessels (angiogenesis).,,H,52,55
Cohort,-0.15650674159075334,0.0859738517000134,-1.8203993248650618,0.06914024280694823,LGP Offspring,Genes encoding components of apical junction complex.,,H,279,511
Cohort,-0.2907831019875852,0.24735148857066447,-1.1755866264152803,0.24009558704377745,LGP Proband,Genes encoding components of apical junction complex.,,H,279,745
Cohort,-0.04219366466426466,0.07650768596749731,-0.5514957632124667,0.5814486458047758,LonGen OPEL,Genes encoding components of apical junction complex.,,H,429,502
Cohort,-0.007602636756958576,0.03594692726865417,-0.21149615098223146,0.8325638800371727,LGP Offspring,"Genes encoding proteins over-represented on the apical surface of epithelial cells, e.g., important for cell polarity (apical area).",,H,41,87
Cohort,0.1118103714940002,0.10181332206378757,1.0981899934858164,0.2724384767660239,LGP Proband,"Genes encoding proteins over-represented on the apical surface of epithelial cells, e.g., important for cell polarity (apical area).",,H,41,123
Cohort,0.02232010743547503,0.03192042976709937,0.6992420715613464,0.48460502837593467,LonGen OPEL,"Genes encoding proteins over-represented on the apical surface of epithelial cells, e.g., important for cell polarity (apical area).",,H,67,92
Cohort,-0.18190642351594813,0.06867578459977108,-2.6487709543627767,0.00826713301325254,LGP Offspring,Genes mediating programmed cell death (apoptosis) by activation of caspases.,,H,166,271
Cohort,0.03411014368018582,0.1841138374002341,0.18526659463425235,0.8530649831470911,LGP Proband,Genes mediating programmed cell death (apoptosis) by activation of caspases.,,H,166,339
Cohort,0.03554502458499651,0.056061819177115974,0.6340326644181702,0.5262416582376445,LonGen OPEL,Genes mediating programmed cell death (apoptosis) by activation of caspases.,,H,198,257
Cohort,-0.03551226085955142,0.06585982211535095,-0.5392097901107759,0.5899196450047826,LGP Offspring,Genes involve in metabolism of bile acids and salts.,,H,149,295
Cohort,0.011120702898647142,0.18768240292126592,0.05925277343828742,0.9527649707196053,LGP Proband,Genes involve in metabolism of bile acids and salts.,,H,149,450
Cohort,-0.0478619301121269,0.061332087647659496,-0.7803734056320414,0.43540310690793993,LonGen OPEL,Genes involve in metabolism of bile acids and salts.,,H,266,307
Cohort,0.019009443870448096,0.04516054410668588,0.42093035516890076,0.6739397272789378,LGP Offspring,Genes involved in cholesterol homeostasis.,,H,63,142
Cohort,-0.07660766373880273,0.12031814933909665,-0.6367091262590551,0.5244890432251743,LGP Proband,Genes involved in cholesterol homeostasis.,,H,63,176
Cohort,0.03374204250199756,0.03916244722083258,0.8615917772382821,0.3891716646558365,LonGen OPEL,Genes involved in cholesterol homeostasis.,,H,100,133
Cohort,-0.03671069504787002,0.07241942904479753,-0.5069177640873329,0.6123778292147474,LGP Offspring,Genes encoding components of blood coagulation system; also up-regulated in platelets.,,H,157,319
Cohort,-0.26452938534980164,0.1907586974120048,-1.3867225397249663,0.1658969211751344,LGP Proband,Genes encoding components of blood coagulation system; also up-regulated in platelets.,,H,157,427
Cohort,-0.07733697109982525,0.061494608967426576,-1.2576219671677284,0.2088973293652267,LonGen OPEL,Genes encoding components of blood coagulation system; also up-regulated in platelets.,,H,268,291
Cohort,-0.16538028846345507,0.07042693997017534,-2.348253218633252,0.019148899601918967,LGP Offspring,"Genes encoding components of the complement system, which is part of the innate immune system.",,H,204,354
Cohort,-0.0922844912186286,0.20696379450603855,-0.44589678807776223,0.6557875342952502,LGP Proband,"Genes encoding components of the complement system, which is part of the innate immune system.",,H,204,532
Cohort,-0.0932849877761764,0.06852982511160188,-1.3612319544703397,0.17382560482852308,LonGen OPEL,"Genes encoding components of the complement system, which is part of the innate immune system.",,H,325,367
Cohort,-0.07181943724309187,0.05422269491147565,-1.3245272548762983,0.18577560089812326,LGP Offspring,Genes involved in DNA repair.,,H,111,210
Cohort,0.09768016963327261,0.15643210827818085,0.6244253223230198,0.5325190734280383,LGP Proband,Genes involved in DNA repair.,,H,111,316
Cohort,-0.026763355599513393,0.049456012210948704,-0.5411547434386238,0.5885523390586196,LonGen OPEL,Genes involved in DNA repair.,,H,159,184
Cohort,-0.13373633407412536,0.07585950499625607,-1.7629476237780053,0.07836111329416821,LGP Offspring,Genes encoding cell cycle related targets of E2F transcription factors.,,H,205,364
Cohort,-0.11244602334154188,0.20823393339784493,-0.5399985559832181,0.5893421835765706,LGP Proband,Genes encoding cell cycle related targets of E2F transcription factors.,,H,205,501
Cohort,0.08587938370605822,0.06349885653104327,1.3524555936542506,0.1766136881550931,LonGen OPEL,Genes encoding cell cycle related targets of E2F transcription factors.,,H,282,372
Cohort,-0.11849012537121456,0.09116159816021488,-1.2997811333119706,0.19411903043660697,LGP Offspring,"Genes defining epithelial-mesenchymal transition, as in wound healing, fibrosis and metastasis.",,H,250,462
Cohort,-0.2984597849762505,0.2467445634993935,-1.2095901151515507,0.22677896952565743,LGP Proband,"Genes defining epithelial-mesenchymal transition, as in wound healing, fibrosis and metastasis.",,H,250,676
Cohort,-0.015855242467585396,0.07269851434596664,-0.218095825069155,0.8274103482141419,LonGen OPEL,"Genes defining epithelial-mesenchymal transition, as in wound healing, fibrosis and metastasis.",,H,399,464
Cohort,-0.125699995516164,0.09322910854139471,-1.3482912953131143,0.1780162836718129,LGP Offspring,Genes defining early response to estrogen.,,H,271,503
Cohort,-0.2771124260167697,0.25383929394058224,-1.091684513122051,0.27528706240336076,LGP Proband,Genes defining early response to estrogen.,,H,271,725
Cohort,0.09135202469129883,0.077416995110517,1.1799996184415167,0.23835288375062638,LonGen OPEL,Genes defining early response to estrogen.,,H,382,489
Cohort,-0.09192315033406108,0.08397248316803552,-1.0946818155908962,0.2740459380339213,LGP Offspring,Genes defining late response to estrogen.,,H,240,461
Cohort,0.008837345395356138,0.23347740839800282,0.03785096577863049,0.9698155667311952,LGP Proband,Genes defining late response to estrogen.,,H,240,654
Cohort,0.06953453864378242,0.07068748776339606,0.9836894879688924,0.3255671027430481,LonGen OPEL,Genes defining late response to estrogen.,,H,331,433
Cohort,0.09854244788325127,0.07434282663546536,1.3255138705775473,0.18544854837087418,LGP Offspring,Genes encoding proteins involved in metabolism of fatty acids.,,H,176,398
Cohort,-0.12261589497813573,0.20824163298758028,-0.5888154698894849,0.5561445050715421,LGP Proband,Genes encoding proteins involved in metabolism of fatty acids.,,H,176,539
Cohort,-0.020786330240631843,0.06919391007661863,-0.30040693202068036,0.7639452156070268,LonGen OPEL,Genes encoding proteins involved in metabolism of fatty acids.,,H,342,413
Cohort,-0.03857868416566,0.0722951256716357,-0.533627735027176,0.5937745261962206,LGP Offspring,"Genes involved in the G2/M checkpoint, as in progression through the cell division cycle.",,H,182,351
Cohort,-0.33807978872081884,0.19478265141807913,-1.735677106043538,0.08299029169867655,LGP Proband,"Genes involved in the G2/M checkpoint, as in progression through the cell division cycle.",,H,182,471
Cohort,0.03838997052743682,0.05939257009817133,0.6463766505470493,0.5182217724366522,LonGen OPEL,"Genes involved in the G2/M checkpoint, as in progression through the cell division cycle.",,H,249,311
Cohort,-0.0822312734829323,0.07453640590775358,-1.1032363645854069,0.27031711216687726,LGP Offspring,Genes encoding proteins involved in glycolysis and gluconeogenesis.,,H,210,386
Cohort,-0.42351717289490454,0.2181603519412285,-1.9413113754464346,0.05255705202962483,LGP Proband,Genes encoding proteins involved in glycolysis and gluconeogenesis.,,H,210,586
Cohort,0.09046076836740358,0.07380262879319663,1.225712008455484,0.22066958365874276,LonGen OPEL,Genes encoding proteins involved in glycolysis and gluconeogenesis.,,H,322,425
Cohort,-0.058485248904414325,0.030997091416215237,-1.8867979617539035,0.05961578676233652,LGP Offspring,Genes up-regulated by activation of hedgehog signaling.,,H,41,57
Cohort,0.03667847165639534,0.09557019405208637,0.38378567732535246,0.7012351225951471,LGP Proband,Genes up-regulated by activation of hedgehog signaling.,,H,41,111
Cohort,-0.007067834354862451,0.030060835369438564,-0.2351176960986249,0.8141778548512698,LonGen OPEL,Genes up-regulated by activation of hedgehog signaling.,,H,69,72
Cohort,-0.008782567745906389,0.07559724328730551,-0.11617576731638812,0.9075477447649116,LGP Offspring,Genes involved in metabolism of heme (a cofactor consisting of iron and porphyrin) and erythroblast differentiation.,,H,181,369
Cohort,-0.5782821184206085,0.20989141872295022,-2.7551489333821784,0.005994405940360935,LGP Proband,Genes involved in metabolism of heme (a cofactor consisting of iron and porphyrin) and erythroblast differentiation.,,H,181,502
Cohort,-0.10314071577942299,0.06600925231808563,-1.5625190735748395,0.11856321330987095,LonGen OPEL,Genes involved in metabolism of heme (a cofactor consisting of iron and porphyrin) and erythroblast differentiation.,,H,310,333
Cohort,-0.018212367657341372,0.07269220368121916,-0.25054086593947544,0.8022452323584784,LGP Offspring,Genes up-regulated in response to low oxygen levels (hypoxia).,,H,182,383
Cohort,-0.2650726650287432,0.1890925169086575,-1.4018146744367916,0.16134264745982885,LGP Proband,Genes up-regulated in response to low oxygen levels (hypoxia).,,H,182,507
Cohort,-0.03559445873679767,0.06672147556400383,-0.5334782906989671,0.593851458823478,LonGen OPEL,Genes up-regulated in response to low oxygen levels (hypoxia).,,H,298,340
Cohort,-0.12574450621047256,0.0750551777020669,-1.6753608486494829,0.09432590664901745,LGP Offspring,Genes up-regulated by STAT5 in response to IL2 stimulation.,,H,180,336
Cohort,-0.17111242147100236,0.20726049021997608,-0.8255911258792838,0.40927216306636194,LGP Proband,Genes up-regulated by STAT5 in response to IL2 stimulation.,,H,180,468
Cohort,0.05229637349942742,0.06527493510781478,0.8011708232731196,0.4232718356072128,LonGen OPEL,Genes up-regulated by STAT5 in response to IL2 stimulation.,,H,259,343
Cohort,-0.004169693615881552,0.037752502374244205,-0.11044813863057278,0.9120867589193775,LGP Offspring,"Genes up-regulated by IL6 [GeneID=3569] via STAT3 [GeneID=6774], e.g., during acute phase response.",,H,45,89
Cohort,0.21090049547891285,0.11729071050524915,1.7981005875949088,0.07252261729686753,LGP Proband,"Genes up-regulated by IL6 [GeneID=3569] via STAT3 [GeneID=6774], e.g., during acute phase response.",,H,45,148
Cohort,0.0458964244205744,0.03071640813936773,1.494198937985564,0.1355199187545768,LonGen OPEL,"Genes up-regulated by IL6 [GeneID=3569] via STAT3 [GeneID=6774], e.g., during acute phase response.",,H,60,87
Cohort,0.005516792006173421,0.07161158949631805,0.07703769801754044,0.9386163502461592,LGP Offspring,Genes defining inflammatory response.,,H,163,355
Cohort,-0.17479611643454812,0.20037877737633963,-0.8723284906876956,0.38328026380539293,LGP Proband,Genes defining inflammatory response.,,H,163,451
Cohort,0.0207750468130155,0.06321422052840918,0.3286451472367513,0.7425103581467123,LonGen OPEL,Genes defining inflammatory response.,,H,258,308
Cohort,-0.003506811890307114,0.04947761617123458,-0.07087673501024314,0.9435168220061407,LGP Offspring,Genes up-regulated in response to alpha interferon proteins.,,H,75,159
Cohort,-0.008353363334573177,0.12702016158224247,-0.06576407422663037,0.947581419493803,LGP Proband,Genes up-regulated in response to alpha interferon proteins.,,H,75,197
Cohort,0.04524169431409449,0.040490753861710305,1.1173339589727143,0.26418868607815915,LonGen OPEL,Genes up-regulated in response to alpha interferon proteins.,,H,105,142
Cohort,-0.005525909511617914,0.07881039363581166,-0.07011650693122443,0.9441216648969742,LGP Offspring,Genes up-regulated in response to IFNG [GeneID=3458].,,H,193,398
Cohort,-0.10559346549178547,0.19838807777413658,-0.5322571128089808,0.5946896943449156,LGP Proband,Genes up-regulated in response to IFNG [GeneID=3458].,,H,193,481
Cohort,-0.01555738941705898,0.06749929437213595,-0.23048225261864588,0.8177762738125282,LonGen OPEL,Genes up-regulated in response to IFNG [GeneID=3458].,,H,290,342
Cohort,-0.0384127003191939,0.08249403143878782,-0.46564217615788206,0.6416216286187624,LGP Offspring,Genes down-regulated by KRAS activation.,,H,212,446
Cohort,0.4272806677084973,0.22838996594041036,1.8708381778032224,0.06171749984160311,LGP Proband,Genes down-regulated by KRAS activation.,,H,212,610
Cohort,-0.15292125746742224,0.06916485528284196,-2.2109676488451804,0.02732163806987466,LonGen OPEL,Genes down-regulated by KRAS activation.,,H,363,382
Cohort,-0.03694358512633387,0.07246963139521563,-0.5097802267664472,0.6103718242966492,LGP Offspring,Genes up-regulated by KRAS activation.,,H,173,343
Cohort,0.09297008526157283,0.20213982787107465,0.4599295756839637,0.6456866457004249,LGP Proband,Genes up-regulated by KRAS activation.,,H,173,514
Cohort,0.022874795796690498,0.06265507635773407,0.36509086137067426,0.7151405640310098,LonGen OPEL,Genes up-regulated by KRAS activation.,,H,257,328
Cohort,0.02490585374591538,0.09500609048652729,0.2621500749938474,0.7932856041208949,LGP Offspring,Genes important for mitotic spindle assembly.,,H,285,590
Cohort,-0.1605987451252931,0.2628237208655988,-0.6110511813635692,0.541332197531727,LGP Proband,Genes important for mitotic spindle assembly.,,H,285,838
Cohort,0.02152233863929245,0.07932584144930017,0.2713156046765429,0.7862186504945238,LonGen OPEL,Genes important for mitotic spindle assembly.,,H,442,529
Cohort,-0.12221186631921067,0.07164539359516735,-1.7057881907910148,0.08850687579658334,LGP Offspring,Genes up-regulated through activation of mTORC1 complex.,,H,179,332
Cohort,-0.31602536893772365,0.19734317686555775,-1.60140002789668,0.10966702566245239,LGP Proband,Genes up-regulated through activation of mTORC1 complex.,,H,179,442
Cohort,0.003744505154591734,0.060039392678454526,0.062367472213546736,0.9502858545475805,LonGen OPEL,Genes up-regulated through activation of mTORC1 complex.,,H,267,310
Cohort,0.031401765534465935,0.05730525763225582,0.5479735513271752,0.583890956056746,LGP Offspring,A subgroup of genes regulated by MYC - version 1 (v1).,,H,98,214
Cohort,0.05904940682655475,0.15655964557815552,0.3771687564090513,0.7061441484100744,LGP Proband,A subgroup of genes regulated by MYC - version 1 (v1).,,H,98,303
Cohort,0.011924024226179013,0.051429902353717964,0.2318500265501088,0.8167140894645235,LonGen OPEL,A subgroup of genes regulated by MYC - version 1 (v1).,,H,176,214
Cohort,-5.99637492946819e-4,0.04544324416564268,-0.013195305571959458,0.9894758681572299,LGP Offspring,A subgroup of genes regulated by MYC - version 2 (v2).,,H,56,114
Cohort,-0.010437795200928182,0.13110341059011305,-0.07961497838955024,0.9365625810193565,LGP Proband,A subgroup of genes regulated by MYC - version 2 (v2).,,H,56,205
Cohort,-0.008933524225138784,0.038030764610767126,-0.2349025668184846,0.8143447699198757,LonGen OPEL,A subgroup of genes regulated by MYC - version 2 (v2).,,H,98,116
Cohort,-0.09264884579876269,0.0974433009606283,-0.9507974882357199,0.342046994921126,LGP Offspring,Genes involved in development of skeletal muscle (myogenesis).,,H,305,606
Cohort,-0.05930384050887471,0.2552886018816483,-0.23230116844922025,0.8163610958277574,LGP Proband,Genes involved in development of skeletal muscle (myogenesis).,,H,305,831
Cohort,0.002761892271185451,0.0778877604618572,0.03545990094988019,0.9717219108033435,LonGen OPEL,Genes involved in development of skeletal muscle (myogenesis).,,H,454,546
Cohort,0.010764490233919883,0.024836280804364102,0.43341796296764384,0.6648494194817243,LGP Offspring,Genes up-regulated by activation of Notch signaling.,,H,16,45
Cohort,0.07585996628360189,0.06208873423988315,1.2217992074135842,0.22212879489262477,LGP Proband,Genes up-regulated by activation of Notch signaling.,,H,16,46
Cohort,-0.005722246378062491,0.0193059645206214,-0.29639785010224967,0.7670035816520336,LonGen OPEL,Genes up-regulated by activation of Notch signaling.,,H,26,29
Cohort,0.13262154694290754,0.06629714056088463,2.000411266925053,0.045855378827158955,LGP Offspring,Genes encoding proteins involved in oxidative phosphorylation.,,H,120,304
Cohort,-0.009786503424011871,0.19139873808315647,-0.051131493979651825,0.959232983680241,LGP Proband,Genes encoding proteins involved in oxidative phosphorylation.,,H,120,434
Cohort,-0.1393789647018438,0.06486238162013248,-2.1488413040106793,0.031947948368671514,LonGen OPEL,Genes encoding proteins involved in oxidative phosphorylation.,,H,293,307
Cohort,-0.04708077667796451,0.06543276341248926,-0.7195290894435634,0.4720636579531111,LGP Offspring,Genes involved in p53 pathways and networks.,,H,145,287
Cohort,0.08021163218766025,0.1776463578561785,0.4515242144879725,0.6517291661852272,LGP Proband,Genes involved in p53 pathways and networks.,,H,145,372
Cohort,0.006952668052913612,0.05586833486283286,0.12444738276133885,0.9009924780906278,LonGen OPEL,Genes involved in p53 pathways and networks.,,H,222,271
Cohort,-0.0051720981071259105,0.030486004780317152,-0.16965483487902622,0.8653323520189935,LGP Offspring,Genes specifically up-regulated in pancreatic beta cells.,,H,31,58
Cohort,-0.05861486646711997,0.08229840708660476,-0.7122235841750622,0.47652552538096993,LGP Proband,Genes specifically up-regulated in pancreatic beta cells.,,H,31,72
Cohort,-0.004339316690494886,0.026486072655641343,-0.1638339042149627,0.8699034893504656,LonGen OPEL,Genes specifically up-regulated in pancreatic beta cells.,,H,45,50
Cohort,-2.953621625629007e-5,0.059784313698019946,-4.940462544319265e-4,0.9996059538913338,LGP Offspring,Genes encoding components of peroxisome.,,H,127,256
Cohort,-0.009351709375089147,0.17166041826493197,-0.05447795985593017,0.9565674150378588,LGP Proband,Genes encoding components of peroxisome.,,H,127,374
Cohort,0.01045186966718383,0.055495727535545,0.18833647437975132,0.8506608973282087,LonGen OPEL,Genes encoding components of peroxisome.,,H,197,240
Cohort,-0.1512253801894857,0.048676627964197486,-3.106734926271282,0.0019708697528964376,LGP Offspring,Genes up-regulated by activation of the PI3K/AKT/mTOR pathway.,,H,90,124
Cohort,-0.16643396966053223,0.1385438851585383,-1.201308664543937,0.2299725287112007,LGP Proband,Genes up-regulated by activation of the PI3K/AKT/mTOR pathway.,,H,90,204
Cohort,-0.001463884619489449,0.041040922948119195,-0.03566890104640143,0.9715553107446957,LonGen OPEL,Genes up-regulated by activation of the PI3K/AKT/mTOR pathway.,,H,119,136
Cohort,-0.04149528111012801,0.04569712228463225,-0.9080502017537919,0.36417529299938356,LGP Offspring,Genes involved in protein secretion pathway.,,H,78,140
Cohort,-0.20819798419018365,0.12259771116369034,-1.698220808643004,0.08983910306341752,LGP Proband,Genes involved in protein secretion pathway.,,H,78,176
Cohort,-0.0022221333728568373,0.04083013468914718,-0.05442385605079793,0.9566111288153112,LonGen OPEL,Genes involved in protein secretion pathway.,,H,113,130
Cohort,0.016183955665393192,0.03798114716234763,0.4261049724542563,0.6701669970769915,LGP Offspring,Genes up-regulated by reactive oxigen species (ROS).,,H,51,110
Cohort,0.01045274114982473,0.11161295957415039,0.09365167978437505,0.9254083486796708,LGP Proband,Genes up-regulated by reactive oxigen species (ROS).,,H,51,150
Cohort,-0.0017494059936688175,0.03600143680798638,-0.04859267153695205,0.9612560996933842,LonGen OPEL,Genes up-regulated by reactive oxigen species (ROS).,,H,86,103
Cohort,0.015854342511073587,0.06820053975906928,0.23246652544220198,0.8162460450371991,LGP Offspring,"Genes up-regulated during production of male gametes (sperm), as in spermatogenesis.",,H,147,291
Cohort,0.017141149861286634,0.18899253855380851,0.09069749521569782,0.9277547388281877,LGP Proband,"Genes up-regulated during production of male gametes (sperm), as in spermatogenesis.",,H,147,432
Cohort,0.06237841496040151,0.056184249250457105,1.110247369904903,0.2672277167392783,LonGen OPEL,"Genes up-regulated during production of male gametes (sperm), as in spermatogenesis.",,H,216,275
Cohort,-0.0782075865570085,0.035775454722625215,-2.186068273998716,0.029152878792522288,LGP Offspring,Genes up-regulated in response to TGFB1 [GeneID=7040].,,H,51,76
Cohort,0.08645082414723214,0.1007773371875343,0.8578399326661879,0.39122730683289886,LGP Proband,Genes up-regulated in response to TGFB1 [GeneID=7040].,,H,51,129
Cohort,-0.02522656528945958,0.031697010326665324,-0.7958657624008647,0.4263473338902497,LonGen OPEL,Genes up-regulated in response to TGFB1 [GeneID=7040].,,H,79,84
Cohort,0.028516542249670488,0.06632394392775327,0.4299584819734722,0.6673628653263559,LGP Offspring,Genes regulated by NF-kB in response to TNF [GeneID=7124].,,H,146,317
Cohort,-0.12398636216757217,0.18766888065052365,-0.6606655388884594,0.5090092684620653,LGP Proband,Genes regulated by NF-kB in response to TNF [GeneID=7124].,,H,146,406
Cohort,-0.04916400745639264,0.05497037946496041,-0.8943727137217798,0.37139284796709793,LonGen OPEL,Genes regulated by NF-kB in response to TNF [GeneID=7124].,,H,224,256
Cohort,0.03757289705692794,0.054739617232200825,0.686393127258214,0.49270059745848727,LGP Offspring,"Genes up-regulated during unfolded protein response, a cellular stress response related to the endoplasmic reticulum.",,H,91,210
Cohort,0.007390969026830971,0.15477100552632114,0.047754222450755,0.9619235529460706,LGP Proband,"Genes up-regulated during unfolded protein response, a cellular stress response related to the endoplasmic reticulum.",,H,91,289
Cohort,0.049789325444521325,0.04774962675244771,1.0427165368778313,0.29739616988293405,LonGen OPEL,"Genes up-regulated during unfolded protein response, a cellular stress response related to the endoplasmic reticulum.",,H,144,183
Cohort,-0.05115889317382832,0.07321165493565691,-0.6987807230800892,0.484929408241491,LGP Offspring,Genes down-regulated in response to ultraviolet (UV) radiation.,,H,186,375
Cohort,0.09226763177375075,0.20053239920423974,0.4601133389910591,0.6455547997579975,LGP Proband,Genes down-regulated in response to ultraviolet (UV) radiation.,,H,186,524
Cohort,0.010058969634537061,0.06431735254037511,0.15639589064588066,0.8757606318773449,LonGen OPEL,Genes down-regulated in response to ultraviolet (UV) radiation.,,H,296,360
Cohort,-0.057858879332448744,0.06254252526380859,-0.9251126187885137,0.3552374508685162,LGP Offspring,Genes up-regulated in response to ultraviolet (UV) radiation.,,H,126,240
Cohort,-0.13355309184641062,0.16316792567503885,-0.8185008867024002,0.4133050372237379,LGP Proband,Genes up-regulated in response to ultraviolet (UV) radiation.,,H,126,284
Cohort,-0.05783006856176878,0.049015201834354996,-1.1798394456724526,0.23841655778548537,LonGen OPEL,Genes up-regulated in response to ultraviolet (UV) radiation.,,H,179,192
Cohort,-0.055764504897524304,0.03465072116890801,-1.6093317257581823,0.10801068496410968,LGP Offspring,Genes up-regulated by activation of WNT signaling through accumulation of beta catenin CTNNB1 [GeneID=1499].,,H,46,75
Cohort,-0.030267821237859194,0.09722038190662395,-0.3113320544958376,0.755626004617994,LGP Proband,Genes up-regulated by activation of WNT signaling through accumulation of beta catenin CTNNB1 [GeneID=1499].,,H,46,113
Cohort,-0.036140777366381535,0.02797887217673599,-1.2917167331866954,0.19683018646939024,LonGen OPEL,Genes up-regulated by activation of WNT signaling through accumulation of beta catenin CTNNB1 [GeneID=1499].,,H,64,63
Cohort,-0.1273472094950159,0.09090912456531997,-1.4008187858361179,0.16172713162488708,LGP Offspring,Genes encoding proteins involved in processing of drugs and other xenobiotics.,,H,307,588
Cohort,0.1343578304800573,0.25142291988834614,0.5343897467252547,0.5932143323815826,LGP Proband,Genes encoding proteins involved in processing of drugs and other xenobiotics.,,H,307,768
Cohort,0.07901723364282498,0.08403217724664508,0.9403211511573644,0.34733811159158334,LonGen OPEL,Genes encoding proteins involved in processing of drugs and other xenobiotics.,,H,452,574